1	Synergism	_	NN	NN	_	0	ROOT-FRAG	_	_
2	between	_	IN	IN	_	1	NMOD	_	_
3	two	_	CD	CD	_	5	NMOD	_	_
4	distinct	_	JJ	JJ	_	5	NMOD	_	_
5	elements	_	NNS	NNS	_	2	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	HTLV-I	_	NN	NN	_	9	NMOD	_	_
9	enhancer	_	NN	NN	_	6	PMOD	_	_
10	during	_	IN	IN	_	1	TMP	_	_
11	activation	_	NN	NN	_	10	PMOD	_	_
12	by	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	trans-activator	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	HTLV-I	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	conducted	_	VBN	VBN	_	2	VC	_	_
4	functional	_	JJ	JJ	_	5	NMOD	_	_
5	studies	_	NNS	NNS	_	3	IOBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	enhancer	_	NN	NN	_	9	NMOD	_	_
9	elements	_	NNS	NNS	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	human	_	JJ	JJ	_	15	NMOD	_	_
12	T-cell	_	NN	NN	_	15	NMOD	_	_
13	leukemia	_	NN	NN	_	15	NMOD	_	_
14	virus	_	NN	NN	_	15	NMOD	_	_
15	type	_	NN	NN	_	10	PMOD	_	_
16	I	_	CD	CD	_	15	NMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	HTLV-I	_	NN	NN	_	15	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	using	_	VBG	VBG	_	3	OBJ	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	human	_	JJ	JJ	_	24	NMOD	_	_
23	T-cell	_	NN	NN	_	24	NMOD	_	_
24	lines	_	NNS	NNS	_	20	OBJ	_	_
25	Jurkat	_	NN	NN	_	24	NMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	MOLT	_	NN	NN	_	25	COORD	_	_
28	4	_	CD	CD	_	27	NMOD	_	_
29	,	_	,	,	_	25	P	_	_
30	which	_	WDT	WDT	_	31	SBJ	_	_
31	are	_	VBP	VBP	_	25	NMOD	_	_
32	negative	_	JJ	JJ	_	31	PRD	_	_
33	for	_	IN	IN	_	32	AMOD	_	_
34	HTLV-I	_	NN	NN	_	33	PMOD	_	_
35	,	_	,	,	_	25	P	_	_
36	and	_	CC	CC	_	25	CC	_	_
37	MT-2	_	NN	NN	_	25	COORD	_	_
38	and	_	CC	CC	_	37	CC	_	_
39	TL-Mor	_	NN	NN	_	37	COORD	_	_
40	,	_	,	,	_	37	P	_	_
41	which	_	WDT	WDT	_	42	SBJ	_	_
42	carry	_	VBP	VBP	_	37	NMOD	_	_
43	the	_	DT	DT	_	45	NMOD	_	_
44	proviral	_	JJ	JJ	_	45	NMOD	_	_
45	genome	_	NN	NN	_	42	OBJ	_	_
46	of	_	IN	IN	_	45	NMOD	_	_
47	HTLV-I	_	NN	NN	_	46	PMOD	_	_
48	.	_	.	.	_	2	P	_	_

1	Two	_	CD	CD	_	3	NMOD	_	_
2	distinct	_	JJ	JJ	_	3	NMOD	_	_
3	elements	_	NNS	NNS	_	4	SBJ	_	_
4	have	_	VBP	VBP	_	0	ROOT-S	_	_
5	been	_	VBN	VBN	_	4	VC	_	_
6	implicated	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	function	_	NN	NN	_	7	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	HTLV-I	_	NN	NN	_	12	NMOD	_	_
12	enhancer	_	NN	NN	_	9	PMOD	_	_
13	.	_	.	.	_	4	P	_	_

1	One	_	CD	CD	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	9	NMOD	_	_
4	21-base-pair	_	JJ	JJ	_	9	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	bp	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	core	_	NN	NN	_	9	NMOD	_	_
9	element	_	NN	NN	_	2	PRD	_	_
10	that	_	WDT	WDT	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	9	NMOD	_	_
12	responsible	_	JJ	JJ	_	11	PRD	_	_
13	for	_	IN	IN	_	12	AMOD	_	_
14	trans-activation	_	NN	NN	_	13	PMOD	_	_
15	by	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	HTLV-I	_	NN	NN	_	19	NMOD	_	_
18	trans-activator	_	NN	NN	_	19	NMOD	_	_
19	p40tax	_	NN	NN	_	15	PMOD	_	_
20	and	_	CC	CC	_	11	CC	_	_
21	that	_	WDT	WDT	_	22	SBJ	_	_
22	has	_	VBZ	VBZ	_	11	COORD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	ability	_	NN	NN	_	22	OBJ	_	_
25	to	_	TO	TO	_	26	VMOD	_	_
26	bind	_	VB	VB	_	24	NMOD	_	_
27	to	_	TO	TO	_	26	ADV	_	_
28	cyclic-AMP	_	NN	NN	_	34	AMOD	_	_
29	responsive	_	JJ	JJ	_	34	AMOD	_	_
30	element	_	NN	NN	_	34	AMOD	_	_
31	binding	_	NN	NN	_	34	AMOD	_	_
32	factor	_	NN	NN	_	34	AMOD	_	_
33	(	_	(	(	_	34	P	_	_
34	CREB	_	NN	NN	_	39	NMOD	_	_
35	)	_	)	)	_	34	P	_	_
36	-like	_	JJ	JJ	_	34	AMOD	_	_
37	factor	_	NN	NN	_	39	NMOD	_	_
38	(	_	(	(	_	39	P	_	_
39	s	_	NNS	NNS	_	27	PMOD	_	_
40	)	_	)	)	_	39	P	_	_
41	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	other	_	JJ	JJ	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	region	_	NN	NN	_	3	PRD	_	_
6	interposed	_	VBN	VBN	_	5	NMOD	_	_
7	between	_	IN	IN	_	6	AMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	21-bp	_	JJ	JJ	_	10	NMOD	_	_
10	elements	_	NNS	NNS	_	7	PMOD	_	_
11	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	subfragment	_	NN	NN	_	19	SBJ	_	_
9	(	_	(	(	_	10	P	_	_
10	C26	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	in	_	IN	IN	_	8	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	region	_	NN	NN	_	12	PMOD	_	_
15	between	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	21-bp	_	JJ	JJ	_	18	NMOD	_	_
18	elements	_	NNS	NNS	_	15	PMOD	_	_
19	is	_	VBZ	VBZ	_	6	VMOD	_	_
20	involved	_	VBN	VBN	_	19	VC	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	trans-activation	_	NN	NN	_	21	PMOD	_	_
23	by	_	IN	IN	_	22	NMOD	_	_
24	p40tax	_	NN	NN	_	23	PMOD	_	_
25	,	_	,	,	_	20	P	_	_
26	possibly	_	RB	RB	_	27	DEP	_	_
27	through	_	IN	IN	_	20	ADV	_	_
28	binding	_	NN	NN	_	27	PMOD	_	_
29	to	_	TO	TO	_	28	NMOD	_	_
30	an	_	DT	DT	_	34	NMOD	_	_
31	NF-kappa	_	NN	NN	_	34	NMOD	_	_
32	B-like	_	JJ	JJ	_	31	AMOD	_	_
33	nuclear	_	JJ	JJ	_	34	NMOD	_	_
34	factor	_	NN	NN	_	29	PMOD	_	_
35	or	_	CC	CC	_	34	CC	_	_
36	factors	_	NNS	NNS	_	34	COORD	_	_
37	.	_	.	.	_	5	P	_	_

1	Formation	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	protein-DNA	_	JJ	JJ	_	5	NMOD	_	_
5	complex	_	NN	NN	_	2	PMOD	_	_
6	with	_	IN	IN	_	1	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	C26	_	NN	NN	_	9	NMOD	_	_
9	subfragment	_	NN	NN	_	6	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	positively	_	RB	RB	_	10	ADV	_	_
12	affected	_	VBN	VBN	_	10	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	p40tax	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	C26	_	NN	NN	_	3	NMOD	_	_
3	element	_	NN	NN	_	4	SBJ	_	_
4	conferred	_	VBD	VBD	_	0	ROOT-S	_	_
5	partial	_	JJ	JJ	_	6	NMOD	_	_
6	responsiveness	_	NN	NN	_	4	OBJ	_	_
7	to	_	TO	TO	_	6	NMOD	_	_
8	p40tax	_	NN	NN	_	7	PMOD	_	_
9	when	_	WRB	WRB	_	10	ADV	_	_
10	linked	_	VBN	VBN	_	4	TMP	_	_
11	to	_	TO	TO	_	10	ADV	_	_
12	one	_	CD	CD	_	13	NMOD	_	_
13	copy	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	21-bp	_	JJ	JJ	_	17	NMOD	_	_
17	element	_	NN	NN	_	14	PMOD	_	_
18	that	_	WDT	WDT	_	23	SBJ	_	_
19	,	_	,	,	_	23	P	_	_
20	by	_	IN	IN	_	23	ADV	_	_
21	itself	_	PRP	PRP	_	20	PMOD	_	_
22	,	_	,	,	_	23	P	_	_
23	showed	_	VBD	VBD	_	13	NMOD	_	_
24	little	_	JJ	JJ	_	25	NMOD	_	_
25	activation	_	NN	NN	_	23	OBJ	_	_
26	in	_	IN	IN	_	23	ADV	_	_
27	response	_	NN	NN	_	26	DEP	_	_
28	to	_	TO	TO	_	26	DEP	_	_
29	p40tax	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	4	P	_	_

1	However	_	RB	RB	_	12	ADV	_	_
2	,	_	,	,	_	12	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	C26	_	NN	NN	_	5	NMOD	_	_
5	element	_	NN	NN	_	12	SBJ	_	_
6	alone	_	RB	RB	_	5	NMOD	_	_
7	,	_	,	,	_	12	P	_	_
8	even	_	RB	RB	_	9	AMOD	_	_
9	when	_	WRB	WRB	_	10	ADV	_	_
10	repeated	_	VBN	VBN	_	12	TMP	_	_
11	,	_	,	,	_	12	P	_	_
12	could	_	MD	MD	_	0	ROOT-S	_	_
13	not	_	RB	RB	_	12	VMOD	_	_
14	be	_	VB	VB	_	12	VC	_	_
15	activated	_	VBN	VBN	_	14	VC	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	p40tax	_	NN	NN	_	16	PMOD	_	_
18	,	_	,	,	_	15	P	_	_
19	unlike	_	IN	IN	_	15	ADV	_	_
20	other	_	JJ	JJ	_	23	NMOD	_	_
21	NF-kappa	_	NN	NN	_	23	NMOD	_	_
22	B-binding	_	JJ	JJ	_	21	AMOD	_	_
23	elements	_	NNS	NNS	_	19	PMOD	_	_
24	.	_	.	.	_	12	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	8	P	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	C26	_	NN	NN	_	6	NMOD	_	_
6	element	_	NN	NN	_	8	SBJ	_	_
7	itself	_	PRP	PRP	_	6	NMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	profoundly	_	RB	RB	_	8	ADV	_	_
10	activated	_	VBN	VBN	_	8	VC	_	_
11	upon	_	IN	IN	_	10	TMP	_	_
12	stimulation	_	NN	NN	_	11	PMOD	_	_
13	with	_	IN	IN	_	12	NMOD	_	_
14	12-O-tetradecanoylphorbol-13-acetate	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	8	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	4	SBJ	_	_
3	therefore	_	RB	RB	_	4	ADV	_	_
4	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	HTLV-I	_	NN	NN	_	8	NMOD	_	_
8	enhancer	_	NN	NN	_	9	SBJ	_	_
9	contains	_	VBZ	VBZ	_	5	VMOD	_	_
10	multiple	_	JJ	JJ	_	11	AMOD	_	_
11	functional	_	JJ	JJ	_	12	NMOD	_	_
12	elements	_	NNS	NNS	_	9	OBJ	_	_
13	,	_	,	,	_	12	P	_	_
14	including	_	VBG	VBG	_	12	NMOD	_	_
15	binding	_	VBG	VBG	_	16	NMOD	_	_
16	sites	_	NNS	NNS	_	14	PMOD	_	_
17	for	_	IN	IN	_	16	NMOD	_	_
18	at	_	IN	IN	_	19	AMOD	_	_
19	least	_	JJS	JJS	_	24	NMOD	_	_
20	CREB-	_	NN	NN	_	24	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	NF-kappa	_	NN	NN	_	20	COORD	_	_
23	B-like	_	JJ	JJ	_	20	COORD	_	_
24	factors	_	NNS	NNS	_	17	PMOD	_	_
25	,	_	,	,	_	12	P	_	_
26	which	_	WDT	WDT	_	28	SBJ	_	_
27	synergistically	_	RB	RB	_	28	ADV	_	_
28	cooperate	_	VBP	VBP	_	12	NMOD	_	_
29	in	_	IN	IN	_	28	ADV	_	_
30	activation	_	NN	NN	_	29	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	HTLV-I	_	NN	NN	_	34	NMOD	_	_
34	enhancer	_	NN	NN	_	31	PMOD	_	_
35	in	_	IN	IN	_	30	NMOD	_	_
36	response	_	NN	NN	_	35	DEP	_	_
37	to	_	TO	TO	_	35	DEP	_	_
38	p40tax	_	NN	NN	_	35	PMOD	_	_
39	.	_	.	.	_	4	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	4	SBJ	_	_
3	also	_	RB	RB	_	4	ADV	_	_
4	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	TPA-dependent	_	JJ	JJ	_	7	NMOD	_	_
7	activation	_	NN	NN	_	12	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	HTLV-I	_	NN	NN	_	11	NMOD	_	_
11	enhancer	_	NN	NN	_	8	PMOD	_	_
12	may	_	MD	MD	_	5	VMOD	_	_
13	be	_	VB	VB	_	12	VC	_	_
14	mediated	_	VBN	VBN	_	13	VC	_	_
15	through	_	IN	IN	_	14	ADV	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	C26	_	NN	NN	_	18	NMOD	_	_
18	element	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	4	P	_	_

1	Inhibition	_	NN	NN	_	9	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	phorbol	_	NN	NN	_	6	NMOD	_	_
4	ester-induced	_	JJ	JJ	_	3	AMOD	_	_
5	monocytic	_	JJ	JJ	_	6	NMOD	_	_
6	differentiation	_	NN	NN	_	2	PMOD	_	_
7	by	_	IN	IN	_	1	NMOD	_	_
8	dexamethasone	_	NN	NN	_	7	PMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	associated	_	VBN	VBN	_	9	VC	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	down-regulation	_	NN	NN	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	c-fos	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	c-jun	_	NN	NN	_	14	COORD	_	_
17	(	_	(	(	_	18	P	_	_
18	AP-1	_	NN	NN	_	14	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	.	_	.	.	_	9	P	_	_

1	Previous	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	shown	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	treatment	_	NN	NN	_	17	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	human	_	JJ	JJ	_	11	NMOD	_	_
9	myeloid	_	JJ	JJ	_	11	NMOD	_	_
10	leukemia	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	7	PMOD	_	_
12	with	_	IN	IN	_	6	NMOD	_	_
13	12-O-tetradecanoylphorbol-13-acetate	_	NN	NN	_	12	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	TPA	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	is	_	VBZ	VBZ	_	5	VMOD	_	_
18	associated	_	VBN	VBN	_	17	VC	_	_
19	with	_	IN	IN	_	18	ADV	_	_
20	induction	_	NN	NN	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	monocytic	_	JJ	JJ	_	23	NMOD	_	_
23	differentiation	_	NN	NN	_	21	PMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	expression	_	NN	NN	_	23	COORD	_	_
26	of	_	IN	IN	_	23	NMOD	_	_
27	the	_	DT	DT	_	33	NMOD	_	_
28	c-jun	_	NN	NN	_	33	NMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	c-fos	_	NN	NN	_	28	COORD	_	_
31	early	_	JJ	JJ	_	33	NMOD	_	_
32	response	_	NN	NN	_	33	NMOD	_	_
33	genes	_	NNS	NNS	_	26	PMOD	_	_
34	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	present	_	JJ	JJ	_	3	NMOD	_	_
3	work	_	NN	NN	_	4	SBJ	_	_
4	demonstrates	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	glucocorticoid	_	NN	NN	_	8	NMOD	_	_
8	dexamethasone	_	NN	NN	_	9	SBJ	_	_
9	inhibits	_	VBZ	VBZ	_	5	VMOD	_	_
10	TPA-induced	_	JJ	JJ	_	11	NMOD	_	_
11	increases	_	NNS	NNS	_	9	OBJ	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	c-jun	_	NN	NN	_	17	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	c-fos	_	NN	NN	_	13	COORD	_	_
16	mRNA	_	NN	NN	_	17	NMOD	_	_
17	levels	_	NNS	NNS	_	12	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	U-937	_	NN	NN	_	21	NMOD	_	_
20	leukemia	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	18	PMOD	_	_
22	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	associated	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	block	_	NN	NN	_	5	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	appearance	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	monocytic	_	JJ	JJ	_	13	NMOD	_	_
13	phenotype	_	NN	NN	_	10	PMOD	_	_
14	,	_	,	,	_	7	P	_	_
15	including	_	VBG	VBG	_	7	NMOD	_	_
16	inhibition	_	NN	NN	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	TPA-induced	_	JJ	JJ	_	19	NMOD	_	_
19	increases	_	NNS	NNS	_	17	PMOD	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	lamin	_	NN	NN	_	22	NMOD	_	_
22	A	_	NN	NN	_	20	PMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	lamin	_	NN	NN	_	25	NMOD	_	_
25	C	_	NN	NN	_	22	COORD	_	_
26	,	_	,	,	_	22	P	_	_
27	and	_	CC	CC	_	22	CC	_	_
28	vimentin	_	NN	NN	_	29	NMOD	_	_
29	transcripts	_	NNS	NNS	_	22	COORD	_	_
30	.	_	.	.	_	3	P	_	_

1	Other	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	demonstrated	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	TPA-induced	_	JJ	JJ	_	8	NMOD	_	_
7	monocytic	_	JJ	JJ	_	8	NMOD	_	_
8	differentiation	_	NN	NN	_	21	SBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	expression	_	NN	NN	_	8	COORD	_	_
11	of	_	IN	IN	_	8	NMOD	_	_
12	the	_	DT	DT	_	16	NMOD	_	_
13	c-jun	_	NN	NN	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	c-fos	_	NN	NN	_	13	COORD	_	_
16	genes	_	NNS	NNS	_	11	PMOD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	myeloid	_	JJ	JJ	_	20	NMOD	_	_
19	leukemia	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	17	PMOD	_	_
21	are	_	VBP	VBP	_	5	VMOD	_	_
22	regulated	_	VBN	VBN	_	21	VC	_	_
23	by	_	IN	IN	_	22	LGS	_	_
24	protein	_	NN	NN	_	26	NMOD	_	_
25	kinase	_	NN	NN	_	26	NMOD	_	_
26	C	_	NN	NN	_	23	PMOD	_	_
27	(	_	(	(	_	28	P	_	_
28	PKC	_	NN	NN	_	26	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	finding	_	NN	NN	_	13	SBJ	_	_
3	that	_	IN	IN	_	2	NMOD	_	_
4	dexamethasone	_	NN	NN	_	5	SBJ	_	_
5	has	_	VBZ	VBZ	_	3	VMOD	_	_
6	no	_	DT	DT	_	7	NMOD	_	_
7	effect	_	NN	NN	_	5	OBJ	_	_
8	on	_	IN	IN	_	5	ADV	_	_
9	TPA-induced	_	JJ	JJ	_	10	NMOD	_	_
10	activation	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	PKC	_	NN	NN	_	11	PMOD	_	_
13	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	that	_	IN	IN	_	13	OBJ	_	_
15	this	_	DT	DT	_	16	NMOD	_	_
16	glucocorticoid	_	NN	NN	_	17	SBJ	_	_
17	inhibits	_	VBZ	VBZ	_	14	VMOD	_	_
18	signals	_	NNS	NNS	_	17	OBJ	_	_
19	downstream	_	JJ	JJ	_	18	NMOD	_	_
20	or	_	CC	CC	_	19	CC	_	_
21	parallel	_	JJ	JJ	_	19	COORD	_	_
22	to	_	TO	TO	_	19	AMOD	_	_
23	this	_	DT	DT	_	24	NMOD	_	_
24	enzyme	_	NN	NN	_	22	PMOD	_	_
25	.	_	.	.	_	13	P	_	_

1	Nuclear	_	JJ	JJ	_	3	NMOD	_	_
2	run-on	_	JJ	JJ	_	3	NMOD	_	_
3	assays	_	NNS	NNS	_	4	SBJ	_	_
4	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	:	_	:	:	_	5	P	_	_
7	(	_	(	(	_	8	P	_	_
8	1	_	LS	LS	_	18	VMOD	_	_
9	)	_	)	)	_	8	P	_	_
10	induction	_	NN	NN	_	18	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	c-jun	_	NN	NN	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	c-fos	_	NN	NN	_	12	COORD	_	_
15	expression	_	NN	NN	_	11	PMOD	_	_
16	by	_	IN	IN	_	10	NMOD	_	_
17	TPA	_	NN	NN	_	16	PMOD	_	_
18	is	_	VBZ	VBZ	_	5	VMOD	_	_
19	regulated	_	VBN	VBN	_	18	VC	_	_
20	by	_	IN	IN	_	19	LGS	_	_
21	transcriptional	_	JJ	JJ	_	22	NMOD	_	_
22	mechanisms	_	NNS	NNS	_	20	PMOD	_	_
23	,	_	,	,	_	18	P	_	_
24	(	_	(	(	_	25	P	_	_
25	2	_	LS	LS	_	33	VMOD	_	_
26	)	_	)	)	_	25	P	_	_
27	TPA-induced	_	JJ	JJ	_	28	NMOD	_	_
28	expression	_	NN	NN	_	33	SBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	c-jun	_	NN	NN	_	29	PMOD	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	c-fos	_	NN	NN	_	30	COORD	_	_
33	does	_	VBZ	VBZ	_	18	COORD	_	_
34	not	_	RB	RB	_	33	VMOD	_	_
35	require	_	VB	VB	_	33	VC	_	_
36	protein	_	NN	NN	_	37	NMOD	_	_
37	synthesis	_	NN	NN	_	35	OBJ	_	_
38	,	_	,	,	_	18	P	_	_
39	and	_	CC	CC	_	18	CC	_	_
40	(	_	(	(	_	41	P	_	_
41	3	_	LS	LS	_	48	VMOD	_	_
42	)	_	)	)	_	41	P	_	_
43	TPA-induced	_	JJ	JJ	_	44	NMOD	_	_
44	expression	_	NN	NN	_	48	SBJ	_	_
45	of	_	IN	IN	_	44	NMOD	_	_
46	both	_	DT	DT	_	47	NMOD	_	_
47	genes	_	NNS	NNS	_	45	PMOD	_	_
48	is	_	VBZ	VBZ	_	18	COORD	_	_
49	inhibited	_	VBN	VBN	_	48	VC	_	_
50	at	_	IN	IN	_	49	ADV	_	_
51	the	_	DT	DT	_	53	NMOD	_	_
52	transcriptional	_	JJ	JJ	_	53	NMOD	_	_
53	level	_	NN	NN	_	50	PMOD	_	_
54	by	_	IN	IN	_	49	LGS	_	_
55	dexamethasone	_	NN	NN	_	54	PMOD	_	_
56	.	_	.	.	_	4	P	_	_

1	To	_	TO	TO	_	3	VMOD	_	_
2	further	_	RB	RB	_	3	ADV	_	_
3	define	_	VB	VB	_	14	ADV	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	effects	_	NNS	NNS	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	dexamethasone	_	NN	NN	_	6	PMOD	_	_
8	at	_	IN	IN	_	5	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	molecular	_	JJ	JJ	_	11	NMOD	_	_
11	level	_	NN	NN	_	8	PMOD	_	_
12	,	_	,	,	_	14	P	_	_
13	we	_	PRP	PRP	_	14	SBJ	_	_
14	prepared	_	VBD	VBD	_	0	ROOT-S	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	series	_	NN	NN	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	deleted	_	VBN	VBN	_	21	NMOD	_	_
19	c-jun	_	NN	NN	_	21	NMOD	_	_
20	promoter	_	NN	NN	_	21	NMOD	_	_
21	fragments	_	NNS	NNS	_	17	PMOD	_	_
22	linked	_	VBN	VBN	_	21	NMOD	_	_
23	to	_	TO	TO	_	22	ADV	_	_
24	the	_	DT	DT	_	30	NMOD	_	_
25	chloramphenicol	_	NN	NN	_	26	NMOD	_	_
26	acetyltransferase	_	NN	NN	_	30	NMOD	_	_
27	(	_	(	(	_	28	P	_	_
28	CAT	_	NN	NN	_	26	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	gene	_	NN	NN	_	23	PMOD	_	_
31	.	_	.	.	_	14	P	_	_

1	Increases	_	NNS	NNS	_	15	SBJ	_	_
2	in	_	IN	IN	_	1	NMOD	_	_
3	CAT	_	NN	NN	_	4	NMOD	_	_
4	activity	_	NN	NN	_	2	PMOD	_	_
5	during	_	IN	IN	_	4	TMP	_	_
6	transient	_	JJ	JJ	_	7	NMOD	_	_
7	expression	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	these	_	DT	DT	_	10	NMOD	_	_
10	constructs	_	NNS	NNS	_	8	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	TPA-treated	_	JJ	JJ	_	14	NMOD	_	_
13	U-937	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	11	PMOD	_	_
15	could	_	MD	MD	_	0	ROOT-S	_	_
16	be	_	VB	VB	_	15	VC	_	_
17	assigned	_	VBN	VBN	_	16	VC	_	_
18	to	_	TO	TO	_	17	ADV	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	region	_	NN	NN	_	18	PMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	-97	_	CD	CD	_	20	PRN	_	_
23	to	_	TO	TO	_	22	NMOD	_	_
24	-20	_	CD	CD	_	22	NMOD	_	_
25	)	_	)	)	_	22	P	_	_
26	of	_	IN	IN	_	20	NMOD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	promoter	_	NN	NN	_	26	PMOD	_	_
29	that	_	WDT	WDT	_	30	SBJ	_	_
30	contains	_	VBZ	VBZ	_	20	NMOD	_	_
31	the	_	DT	DT	_	34	NMOD	_	_
32	AP-1	_	NN	NN	_	34	NMOD	_	_
33	binding	_	NN	NN	_	34	NMOD	_	_
34	site	_	NN	NN	_	30	OBJ	_	_
35	.	_	.	.	_	15	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	induction	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	CAT	_	NN	NN	_	5	NMOD	_	_
5	activity	_	NN	NN	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	sensitive	_	JJ	JJ	_	6	PRD	_	_
8	to	_	TO	TO	_	7	AMOD	_	_
9	dexamethasone	_	NN	NN	_	8	PMOD	_	_
10	.	_	.	.	_	6	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	dexamethasone	_	NN	NN	_	6	SBJ	_	_
6	down-regulates	_	VBZ	VBZ	_	4	VMOD	_	_
7	TPA-induced	_	JJ	JJ	_	8	NMOD	_	_
8	transcription	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	c-jun	_	NN	NN	_	12	NMOD	_	_
12	gene	_	NN	NN	_	9	PMOD	_	_
13	during	_	IN	IN	_	6	TMP	_	_
14	monocytic	_	JJ	JJ	_	15	NMOD	_	_
15	differentiation	_	NN	NN	_	13	PMOD	_	_
16	by	_	IN	IN	_	6	ADV	_	_
17	inhibiting	_	VBG	VBG	_	16	PMOD	_	_
18	activation	_	NN	NN	_	17	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	AP-1	_	NN	NN	_	22	NMOD	_	_
22	site	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	Charybdotoxin-sensitive	_	JJ	JJ	_	6	NMOD	_	_
2	,	_	,	,	_	1	P	_	_
3	Ca-LRB-2+-RRB--dependent	_	JJ	JJ	_	1	COORD	_	_
4	membrane	_	NN	NN	_	6	NMOD	_	_
5	potential	_	JJ	JJ	_	6	NMOD	_	_
6	changes	_	NNS	NNS	_	7	SBJ	_	_
7	are	_	VBP	VBP	_	0	ROOT-S	_	_
8	not	_	RB	RB	_	7	VMOD	_	_
9	involved	_	VBN	VBN	_	7	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	human	_	JJ	JJ	_	15	NMOD	_	_
12	T	_	NN	NN	_	15	NMOD	_	_
13	or	_	CC	CC	_	12	CC	_	_
14	B	_	NN	NN	_	12	COORD	_	_
15	cell	_	NN	NN	_	10	PMOD	_	_
16	activation	_	NN	NN	_	15	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	proliferation	_	NN	NN	_	16	COORD	_	_
19	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	involvement	_	NN	NN	_	12	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	ion	_	NN	NN	_	5	NMOD	_	_
5	channels	_	NNS	NNS	_	3	PMOD	_	_
6	in	_	IN	IN	_	2	NMOD	_	_
7	B	_	NN	NN	_	11	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	T	_	NN	NN	_	7	COORD	_	_
10	lymphocyte	_	NN	NN	_	11	NMOD	_	_
11	activation	_	NN	NN	_	6	PMOD	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	supported	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	many	_	JJ	JJ	_	16	NMOD	_	_
16	reports	_	NNS	NNS	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	changes	_	NNS	NNS	_	17	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	ion	_	NN	NN	_	21	NMOD	_	_
21	fluxes	_	NNS	NNS	_	19	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	membrane	_	NN	NN	_	24	NMOD	_	_
24	potential	_	NN	NN	_	21	COORD	_	_
25	after	_	IN	IN	_	18	TMP	_	_
26	mitogen	_	NN	NN	_	27	NMOD	_	_
27	binding	_	NN	NN	_	25	PMOD	_	_
28	.	_	.	.	_	12	P	_	_

1	Human	_	JJ	JJ	_	5	NMOD	_	_
2	T	_	NN	NN	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	B	_	NN	NN	_	2	COORD	_	_
5	lymphocytes	_	NNS	NNS	_	6	SBJ	_	_
6	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
7	an	_	DT	DT	_	11	NMOD	_	_
8	early	_	JJ	JJ	_	11	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	transient	_	JJ	JJ	_	8	COORD	_	_
11	hyperpolarization	_	NN	NN	_	6	OBJ	_	_
12	after	_	IN	IN	_	6	TMP	_	_
13	ligand	_	JJ	JJ	_	14	NMOD	_	_
14	binding	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	6	P	_	_

1	Inasmuch	_	RB	RB	_	2	VMOD	_	_
2	as	_	IN	IN	_	19	ADV	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	change	_	NN	NN	_	8	SBJ	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	membrane	_	NN	NN	_	7	NMOD	_	_
7	potential	_	NN	NN	_	5	PMOD	_	_
8	is	_	VBZ	VBZ	_	2	VMOD	_	_
9	dependent	_	JJ	JJ	_	8	PRD	_	_
10	on	_	IN	IN	_	9	AMOD	_	_
11	elevation	_	NN	NN	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	free	_	JJ	JJ	_	15	NMOD	_	_
14	cytosolic	_	JJ	JJ	_	15	NMOD	_	_
15	calcium	_	NN	NN	_	12	PMOD	_	_
16	,	_	,	,	_	19	P	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	hyperpolarization	_	NN	NN	_	19	SBJ	_	_
19	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
20	presumably	_	RB	RB	_	19	ADV	_	_
21	through	_	IN	IN	_	19	PRD	_	_
22	opening	_	NN	NN	_	21	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	Ca-LRB-2+-RRB--stimulated	_	JJ	JJ	_	26	NMOD	_	_
25	K+	_	NN	NN	_	26	NMOD	_	_
26	channels	_	NNS	NNS	_	23	PMOD	_	_
27	.	_	.	.	_	19	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	used	_	VBN	VBN	_	2	VC	_	_
4	charybdotoxin	_	NN	NN	_	3	IOBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	known	_	JJ	JJ	_	8	NMOD	_	_
8	inhibitor	_	NN	NN	_	4	NMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	Ca-LRB-2+-RRB--dependent	_	JJ	JJ	_	12	NMOD	_	_
11	K+	_	NN	NN	_	12	NMOD	_	_
12	channels	_	NNS	NNS	_	9	PMOD	_	_
13	,	_	,	,	_	4	P	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	study	_	VB	VB	_	3	OBJ	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	role	_	NN	NN	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	these	_	DT	DT	_	20	NMOD	_	_
20	channels	_	NNS	NNS	_	18	PMOD	_	_
21	in	_	IN	IN	_	17	NMOD	_	_
22	lymphocyte	_	NN	NN	_	21	PMOD	_	_
23	activation	_	NN	NN	_	22	NMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	mitogenesis	_	NN	NN	_	23	COORD	_	_
26	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	charybdotoxin	_	NN	NN	_	5	SBJ	_	_
5	inhibits	_	VBZ	VBZ	_	3	VMOD	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	ligand-induced	_	JJ	JJ	_	10	NMOD	_	_
8	transient	_	JJ	JJ	_	10	NMOD	_	_
9	membrane	_	NN	NN	_	10	NMOD	_	_
10	hyperpolarization	_	NN	NN	_	5	OBJ	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	B	_	NN	NN	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	T	_	NN	NN	_	12	COORD	_	_
15	cells	_	NNS	NNS	_	11	PMOD	_	_
16	in	_	IN	IN	_	5	ADV	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	dose-dependent	_	JJ	JJ	_	19	NMOD	_	_
19	fashion	_	NN	NN	_	16	PMOD	_	_
20	,	_	,	,	_	5	P	_	_
21	without	_	IN	IN	_	5	ADV	_	_
22	affecting	_	VBG	VBG	_	21	PMOD	_	_
23	changes	_	NNS	NNS	_	22	OBJ	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	cytosolic	_	JJ	JJ	_	26	NMOD	_	_
26	Ca2+	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	However	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	blockade	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	Ca-LRB-2+-RRB--activated	_	JJ	JJ	_	8	NMOD	_	_
7	K+	_	NN	NN	_	8	NMOD	_	_
8	channel	_	NN	NN	_	4	PMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	not	_	RB	RB	_	9	VMOD	_	_
11	associated	_	VBN	VBN	_	9	VC	_	_
12	with	_	IN	IN	_	11	ADV	_	_
13	changes	_	NNS	NNS	_	12	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	cell-cycle	_	JJ	JJ	_	17	NMOD	_	_
16	gene	_	NN	NN	_	17	NMOD	_	_
17	activation	_	NN	NN	_	14	PMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	IL-2	_	NN	NN	_	20	NMOD	_	_
20	production	_	NN	NN	_	17	COORD	_	_
21	,	_	,	,	_	17	P	_	_
22	IL-2R	_	NN	NN	_	23	NMOD	_	_
23	expression	_	NN	NN	_	17	COORD	_	_
24	or	_	CC	CC	_	17	CC	_	_
25	B	_	NN	NN	_	29	NMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	T	_	NN	NN	_	25	COORD	_	_
28	cell	_	NN	NN	_	29	NMOD	_	_
29	mitogenesis	_	NN	NN	_	17	COORD	_	_
30	.	_	.	.	_	9	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	imply	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	membrane	_	NN	NN	_	7	NMOD	_	_
6	potential	_	JJ	JJ	_	7	NMOD	_	_
7	changes	_	NNS	NNS	_	17	SBJ	_	_
8	secondary	_	JJ	JJ	_	7	NMOD	_	_
9	to	_	TO	TO	_	8	AMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	ligand-dependent	_	JJ	JJ	_	12	NMOD	_	_
12	opening	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	Ca-LRB-2+-RRB--activated	_	JJ	JJ	_	16	NMOD	_	_
15	K+	_	NN	NN	_	16	NMOD	_	_
16	channels	_	NNS	NNS	_	13	PMOD	_	_
17	are	_	VBP	VBP	_	4	VMOD	_	_
18	not	_	RB	RB	_	17	VMOD	_	_
19	involved	_	VBN	VBN	_	17	VC	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	B	_	NN	NN	_	24	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	T	_	NN	NN	_	21	COORD	_	_
24	lymphocyte	_	NN	NN	_	20	PMOD	_	_
25	activation	_	NN	NN	_	24	NMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	mitogenesis	_	NN	NN	_	25	COORD	_	_
28	.	_	.	.	_	3	P	_	_

1	One	_	CD	CD	_	4	NMOD	_	_
2	base	_	NN	NN	_	4	NMOD	_	_
3	pair	_	NN	NN	_	4	NMOD	_	_
4	change	_	NN	NN	_	5	SBJ	_	_
5	abolishes	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	T	_	NN	NN	_	9	NMOD	_	_
8	cell-restricted	_	JJ	JJ	_	7	AMOD	_	_
9	activity	_	NN	NN	_	5	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	a	_	DT	DT	_	14	NMOD	_	_
12	kB-like	_	JJ	JJ	_	14	NMOD	_	_
13	proto-enhancer	_	NN	NN	_	14	NMOD	_	_
14	element	_	NN	NN	_	10	PMOD	_	_
15	from	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	interleukin	_	NN	NN	_	19	NMOD	_	_
18	2	_	CD	CD	_	19	NMOD	_	_
19	promoter	_	NN	NN	_	15	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	inducible	_	JJ	JJ	_	6	NMOD	_	_
3	,	_	,	,	_	2	P	_	_
4	T	_	NN	NN	_	2	COORD	_	_
5	cell-specific	_	JJ	JJ	_	4	AMOD	_	_
6	enhancers	_	NNS	NNS	_	17	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	murine	_	JJ	JJ	_	16	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	human	_	JJ	JJ	_	8	COORD	_	_
11	Interleukin	_	NN	NN	_	16	NMOD	_	_
12	2	_	CD	CD	_	11	NMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	Il-2	_	NN	NN	_	11	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	genes	_	NNS	NNS	_	7	PMOD	_	_
17	contain	_	VBP	VBP	_	0	ROOT-S	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	kB-like	_	JJ	JJ	_	21	NMOD	_	_
20	sequence	_	NN	NN	_	21	NMOD	_	_
21	GGGATTTCACC	_	NN	NN	_	17	OBJ	_	_
22	as	_	IN	IN	_	17	ADV	_	_
23	an	_	DT	DT	_	27	NMOD	_	_
24	essential	_	JJ	JJ	_	27	NMOD	_	_
25	cis-acting	_	JJ	JJ	_	27	NMOD	_	_
26	enhancer	_	NN	NN	_	27	NMOD	_	_
27	motif	_	NN	NN	_	22	PMOD	_	_
28	.	_	.	.	_	17	P	_	_

1	When	_	WRB	WRB	_	2	ADV	_	_
2	cloned	_	VBN	VBN	_	15	TMP	_	_
3	in	_	IN	IN	_	2	ADV	_	_
4	multiple	_	JJ	JJ	_	5	NMOD	_	_
5	copies	_	NNS	NNS	_	3	PMOD	_	_
6	this	_	DT	DT	_	8	NMOD	_	_
7	so-called	_	JJ	JJ	_	8	NMOD	_	_
8	TCEd	_	NN	NN	_	15	SBJ	_	_
9	(	_	(	(	_	13	P	_	_
10	distal	_	JJ	JJ	_	13	NMOD	_	_
11	T	_	NN	NN	_	13	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	element	_	NN	NN	_	8	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	acts	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	as	_	IN	IN	_	15	ADV	_	_
17	an	_	DT	DT	_	20	NMOD	_	_
18	inducible	_	JJ	JJ	_	20	NMOD	_	_
19	proto-enhancer	_	NN	NN	_	20	NMOD	_	_
20	element	_	NN	NN	_	16	PMOD	_	_
21	in	_	IN	IN	_	15	ADV	_	_
22	E14	_	NN	NN	_	25	NMOD	_	_
23	T	_	NN	NN	_	25	NMOD	_	_
24	lymphoma	_	NN	NN	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	21	PMOD	_	_
26	,	_	,	,	_	21	P	_	_
27	but	_	CC	CC	_	21	CC	_	_
28	not	_	RB	RB	_	29	DEP	_	_
29	in	_	IN	IN	_	21	COORD	_	_
30	HeLa	_	NN	NN	_	31	NMOD	_	_
31	cells	_	NNS	NNS	_	29	PMOD	_	_
32	.	_	.	.	_	15	P	_	_

1	In	_	IN	IN	_	14	ADV	_	_
2	extracts	_	NNS	NNS	_	1	PMOD	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	induced	_	VBN	VBN	_	9	NMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	Il-2	_	NN	NN	_	7	AMOD	_	_
7	secreting	_	NN	NN	_	4	COORD	_	_
8	El4	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	3	PMOD	_	_
10	three	_	CD	CD	_	13	NMOD	_	_
11	individual	_	JJ	JJ	_	13	NMOD	_	_
12	protein	_	NN	NN	_	13	NMOD	_	_
13	factors	_	NNS	NNS	_	14	SBJ	_	_
14	bind	_	VBP	VBP	_	0	ROOT-S	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	TCEd	_	NN	NN	_	17	NMOD	_	_
17	DNA	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	14	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	binding	_	NN	NN	_	18	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	most	_	RBS	RBS	_	6	AMOD	_	_
6	prominent	_	JJ	JJ	_	7	NMOD	_	_
7	factor	_	NN	NN	_	3	PMOD	_	_
8	,	_	,	,	_	7	P	_	_
9	named	_	VBN	VBN	_	7	NMOD	_	_
10	TCF-1	_	NN	NN	_	9	OBJ	_	_
11	(	_	(	(	_	14	P	_	_
12	T	_	NN	NN	_	14	NMOD	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	factor	_	NN	NN	_	10	PRN	_	_
15	1	_	CD	CD	_	14	NMOD	_	_
16	)	_	)	)	_	14	P	_	_
17	,	_	,	,	_	7	P	_	_
18	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
19	correlated	_	VBN	VBN	_	18	VC	_	_
20	with	_	IN	IN	_	19	ADV	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	proto-enhancer	_	NN	NN	_	23	NMOD	_	_
23	activity	_	NN	NN	_	20	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	TCEd	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	18	P	_	_

1	TCF-1	_	NN	NN	_	2	SBJ	_	_
2	consists	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	of	_	IN	IN	_	2	ADV	_	_
4	two	_	CD	CD	_	5	NMOD	_	_
5	polypeptides	_	NNS	NNS	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	about	_	RB	RB	_	8	DEP	_	_
8	50	_	CD	CD	_	9	NMOD	_	_
9	kD	_	NN	NN	_	6	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	105	_	CD	CD	_	12	NMOD	_	_
12	kD	_	NN	NN	_	9	COORD	_	_
13	;	_	:	:	_	2	P	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	former	_	JJ	JJ	_	16	SBJ	_	_
16	seems	_	VBZ	VBZ	_	2	VMOD	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	be	_	VB	VB	_	16	OBJ	_	_
19	related	_	JJ	JJ	_	18	PRD	_	_
20	to	_	TO	TO	_	19	AMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	50	_	CD	CD	_	23	NMOD	_	_
23	kD	_	NN	NN	_	20	PMOD	_	_
24	polypeptide	_	NN	NN	_	23	NMOD	_	_
25	of	_	IN	IN	_	23	NMOD	_	_
26	NF-kB	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	16	P	_	_

1	Purified	_	VBN	VBN	_	2	NMOD	_	_
2	NF-kB	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	also	_	RB	RB	_	5	AMOD	_	_
5	able	_	JJ	JJ	_	3	PRD	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	bind	_	VB	VB	_	5	AMOD	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	TCEd	_	NN	NN	_	8	PMOD	_	_
11	,	_	,	,	_	3	P	_	_
12	but	_	CC	CC	_	3	CC	_	_
13	TCF-1	_	NN	NN	_	14	SBJ	_	_
14	binds	_	VBZ	VBZ	_	3	COORD	_	_
15	stronger	_	JJR	JJR	_	14	ADV	_	_
16	than	_	IN	IN	_	15	AMOD	_	_
17	NF-kB	_	NN	NN	_	16	PMOD	_	_
18	to	_	TO	TO	_	14	ADV	_	_
19	TCEd	_	NN	NN	_	20	NMOD	_	_
20	DNA	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	14	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	conversion	_	NN	NN	_	14	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	TCEd	_	NN	NN	_	3	PMOD	_	_
6	to	_	TO	TO	_	2	NMOD	_	_
7	a	_	DT	DT	_	13	NMOD	_	_
8	'	_	``	``	_	13	P	_	_
9	perfect	_	JJ	JJ	_	13	NMOD	_	_
10	'	_	''	''	_	13	P	_	_
11	NF-kB	_	NN	NN	_	13	NMOD	_	_
12	binding	_	NN	NN	_	13	NMOD	_	_
13	site	_	NN	NN	_	6	PMOD	_	_
14	leads	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	tighter	_	JJR	JJR	_	18	NMOD	_	_
18	binding	_	NN	NN	_	15	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	NF-kB	_	NN	NN	_	19	PMOD	_	_
21	to	_	TO	TO	_	18	NMOD	_	_
22	TCEd	_	NN	NN	_	23	NMOD	_	_
23	DNA	_	NN	NN	_	21	PMOD	_	_
24	and	_	CC	CC	_	14	CC	_	_
25	,	_	,	,	_	14	P	_	_
26	as	_	IN	IN	_	14	COORD	_	_
27	a	_	DT	DT	_	29	NMOD	_	_
28	functional	_	JJ	JJ	_	29	NMOD	_	_
29	consequence	_	NN	NN	_	26	PMOD	_	_
30	,	_	,	,	_	26	P	_	_
31	to	_	TO	TO	_	33	NMOD	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	activity	_	NN	NN	_	18	GAP	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	the	_	DT	DT	_	40	NMOD	_	_
36	'	_	``	``	_	40	P	_	_
37	converted	_	VBN	VBN	_	40	NMOD	_	_
38	'	_	''	''	_	40	P	_	_
39	TCEd	_	NN	NN	_	40	NMOD	_	_
40	motifs	_	NNS	NNS	_	34	PMOD	_	_
41	in	_	IN	IN	_	33	NMOD	_	_
42	HeLa	_	NN	NN	_	43	NMOD	_	_
43	cells	_	NNS	NNS	_	41	PMOD	_	_
44	.	_	.	.	_	14	P	_	_

1	Thus	_	RB	RB	_	17	ADV	_	_
2	,	_	,	,	_	17	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	substitution	_	NN	NN	_	17	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	underlined	_	VBN	VBN	_	9	NMOD	_	_
8	A	_	NN	NN	_	9	NMOD	_	_
9	residue	_	NN	NN	_	5	PMOD	_	_
10	to	_	TO	TO	_	4	NMOD	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	C	_	NN	NN	_	10	PMOD	_	_
13	within	_	IN	IN	_	4	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	GGGATTTCACC	_	NN	NN	_	16	NMOD	_	_
16	motif	_	NN	NN	_	13	PMOD	_	_
17	abolishes	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	its	_	PRP$	PRP$	_	21	NMOD	_	_
19	T	_	NN	NN	_	21	NMOD	_	_
20	cell-restricted	_	JJ	JJ	_	19	AMOD	_	_
21	activity	_	NN	NN	_	17	OBJ	_	_
22	and	_	CC	CC	_	17	CC	_	_
23	leads	_	VBZ	VBZ	_	17	COORD	_	_
24	to	_	TO	TO	_	23	ADV	_	_
25	its	_	PRP$	PRP$	_	26	SBJ	_	_
26	functioning	_	VBG	VBG	_	24	PMOD	_	_
27	in	_	IN	IN	_	26	ADV	_	_
28	both	_	CC	CC	_	30	CC	_	_
29	El4	_	NN	NN	_	30	NMOD	_	_
30	cells	_	NNS	NNS	_	27	PMOD	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	HeLa	_	NN	NN	_	33	NMOD	_	_
33	cells	_	NNS	NNS	_	30	COORD	_	_
34	.	_	.	.	_	17	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	lymphocyte-specific	_	JJ	JJ	_	6	NMOD	_	_
6	factors	_	NNS	NNS	_	11	SBJ	_	_
7	binding	_	VBG	VBG	_	6	NMOD	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	TCEd	_	NN	NN	_	8	PMOD	_	_
11	are	_	VBP	VBP	_	4	VMOD	_	_
12	involved	_	VBN	VBN	_	11	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	control	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	T	_	NN	NN	_	19	NMOD	_	_
18	cell	_	NN	NN	_	19	NMOD	_	_
19	specific-transcription	_	NN	NN	_	16	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	Il-2	_	NN	NN	_	23	NMOD	_	_
23	gene	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	Negative	_	JJ	JJ	_	2	NMOD	_	_
2	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	human	_	JJ	JJ	_	9	NMOD	_	_
5	immunodeficiency	_	NN	NN	_	9	NMOD	_	_
6	virus	_	NN	NN	_	9	NMOD	_	_
7	type	_	NN	NN	_	9	NMOD	_	_
8	1	_	CD	CD	_	9	NMOD	_	_
9	expression	_	NN	NN	_	3	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	monocytes	_	NNS	NNS	_	10	PMOD	_	_
12	:	_	:	:	_	2	P	_	_
13	role	_	NN	NN	_	2	NMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	21	NMOD	_	_
16	65-kDa	_	JJ	JJ	_	21	NMOD	_	_
17	plus	_	CC	CC	_	16	CC	_	_
18	50-kDa	_	JJ	JJ	_	16	COORD	_	_
19	NF-kappa	_	NN	NN	_	21	NMOD	_	_
20	B	_	NN	NN	_	21	NMOD	_	_
21	dimer	_	NN	NN	_	14	PMOD	_	_
22	.	_	.	.	_	13	P	_	_

1	Although	_	IN	IN	_	26	ADV	_	_
2	monocytic	_	JJ	JJ	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	4	SBJ	_	_
4	can	_	MD	MD	_	1	VMOD	_	_
5	provide	_	VB	VB	_	4	VC	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	reservoir	_	NN	NN	_	5	OBJ	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	viral	_	JJ	JJ	_	10	NMOD	_	_
10	production	_	NN	NN	_	8	PMOD	_	_
11	in	_	FW	FW	_	5	ADV	_	_
12	vivo	_	FW	FW	_	11	AMOD	_	_
13	,	_	,	,	_	26	P	_	_
14	their	_	PRP$	PRP$	_	15	NMOD	_	_
15	regulation	_	NN	NN	_	26	SBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	human	_	JJ	JJ	_	20	NMOD	_	_
18	immunodeficiency	_	NN	NN	_	20	NMOD	_	_
19	virus	_	NN	NN	_	20	NMOD	_	_
20	type	_	NN	NN	_	25	NMOD	_	_
21	1	_	CD	CD	_	20	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	HIV-1	_	NN	NN	_	20	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	transcription	_	NN	NN	_	16	PMOD	_	_
26	can	_	MD	MD	_	0	ROOT-S	_	_
27	be	_	VB	VB	_	26	VC	_	_
28	either	_	CC	CC	_	29	CC	_	_
29	latent	_	JJ	JJ	_	27	PRD	_	_
30	,	_	,	,	_	29	P	_	_
31	restricted	_	JJ	JJ	_	29	COORD	_	_
32	,	_	,	,	_	29	P	_	_
33	or	_	CC	CC	_	29	CC	_	_
34	productive	_	JJ	JJ	_	29	COORD	_	_
35	.	_	.	.	_	26	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	differences	_	NNS	NNS	_	6	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	gene	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	3	PMOD	_	_
6	have	_	VBP	VBP	_	0	ROOT-S	_	_
7	not	_	RB	RB	_	6	VMOD	_	_
8	been	_	VBN	VBN	_	6	VC	_	_
9	molecularly	_	RB	RB	_	10	AMOD	_	_
10	defined	_	VBN	VBN	_	8	PRD	_	_
11	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	THP-1	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	restricted	_	JJ	JJ	_	7	NMOD	_	_
6	HIV	_	NN	NN	_	7	NMOD	_	_
7	expression	_	NN	NN	_	4	PMOD	_	_
8	,	_	,	,	_	10	P	_	_
9	there	_	EX	EX	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	an	_	DT	DT	_	12	NMOD	_	_
12	absence	_	NN	NN	_	10	PRD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	DNA-protein	_	JJ	JJ	_	17	NMOD	_	_
15	binding	_	NN	NN	_	17	NMOD	_	_
16	complex	_	NN	NN	_	17	NMOD	_	_
17	formation	_	NN	NN	_	13	PMOD	_	_
18	with	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	HIV-1	_	NN	NN	_	21	NMOD	_	_
21	promoter-enhancer	_	NN	NN	_	18	PMOD	_	_
22	associated	_	VBN	VBN	_	21	NMOD	_	_
23	with	_	IN	IN	_	22	ADV	_	_
24	markedly	_	RB	RB	_	28	NMOD	_	_
25	less	_	JJR	JJR	_	24	AMOD	_	_
26	viral	_	JJ	JJ	_	24	AMOD	_	_
27	RNA	_	NN	NN	_	28	NMOD	_	_
28	production	_	NN	NN	_	23	PMOD	_	_
29	.	_	.	.	_	10	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	absence	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	binding	_	NN	NN	_	3	PMOD	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	localized	_	JJ	JJ	_	5	PRD	_	_
7	to	_	TO	TO	_	6	AMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	NF-kappa	_	NN	NN	_	11	NMOD	_	_
10	B	_	NN	NN	_	11	NMOD	_	_
11	region	_	NN	NN	_	7	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	HIV-1	_	NN	NN	_	15	NMOD	_	_
15	enhancer	_	NN	NN	_	12	PMOD	_	_
16	;	_	:	:	_	5	P	_	_
17	the	_	DT	DT	_	23	NMOD	_	_
18	65-kDa	_	JJ	JJ	_	23	NMOD	_	_
19	plus	_	CC	CC	_	18	CC	_	_
20	50-kDa	_	JJ	JJ	_	18	COORD	_	_
21	NF-kappa	_	NN	NN	_	23	NMOD	_	_
22	B	_	NN	NN	_	23	NMOD	_	_
23	heterodimer	_	NN	NN	_	24	SBJ	_	_
24	was	_	VBD	VBD	_	5	VC	_	_
25	preferentially	_	RB	RB	_	26	AMOD	_	_
26	lost	_	VBN	VBN	_	24	PRD	_	_
27	.	_	.	.	_	24	P	_	_

1	Adding	_	VBG	VBG	_	14	SBJ	_	_
2	purified	_	VBN	VBN	_	5	NMOD	_	_
3	NF-kappa	_	NN	NN	_	5	NMOD	_	_
4	B	_	NN	NN	_	5	NMOD	_	_
5	protein	_	NN	NN	_	1	OBJ	_	_
6	to	_	TO	TO	_	1	ADV	_	_
7	nuclear	_	JJ	JJ	_	8	NMOD	_	_
8	extracts	_	NNS	NNS	_	6	PMOD	_	_
9	from	_	IN	IN	_	8	NMOD	_	_
10	cells	_	NNS	NNS	_	9	PMOD	_	_
11	with	_	IN	IN	_	10	NMOD	_	_
12	restricted	_	JJ	JJ	_	13	NMOD	_	_
13	expression	_	NN	NN	_	11	PMOD	_	_
14	overcomes	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	this	_	DT	DT	_	16	NMOD	_	_
16	lack	_	NN	NN	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	binding	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	12	P	_	_
4	treatment	_	NN	NN	_	12	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	these	_	DT	DT	_	8	NMOD	_	_
7	nuclear	_	JJ	JJ	_	8	NMOD	_	_
8	extracts	_	NNS	NNS	_	5	PMOD	_	_
9	with	_	IN	IN	_	4	NMOD	_	_
10	sodium	_	NN	NN	_	11	NMOD	_	_
11	deoxycholate	_	NN	NN	_	9	PMOD	_	_
12	restored	_	VBD	VBD	_	0	ROOT-S	_	_
13	their	_	PRP$	PRP$	_	14	NMOD	_	_
14	ability	_	NN	NN	_	12	IOBJ	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	form	_	VB	VB	_	14	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	heterodimer	_	NN	NN	_	16	OBJ	_	_
19	,	_	,	,	_	12	P	_	_
20	suggesting	_	VBG	VBG	_	12	OBJ	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	presence	_	NN	NN	_	20	OBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	an	_	DT	DT	_	25	NMOD	_	_
25	inhibitor	_	NN	NN	_	23	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	NF-kappa	_	NN	NN	_	29	NMOD	_	_
28	B	_	NN	NN	_	29	NMOD	_	_
29	activity	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	12	P	_	_

1	Furthermore	_	RB	RB	_	16	ADV	_	_
2	,	_	,	,	_	16	P	_	_
3	treatment	_	NN	NN	_	16	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	nuclear	_	JJ	JJ	_	6	NMOD	_	_
6	extracts	_	NNS	NNS	_	4	PMOD	_	_
7	from	_	IN	IN	_	6	NMOD	_	_
8	these	_	DT	DT	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	7	PMOD	_	_
10	that	_	WDT	WDT	_	11	SBJ	_	_
11	had	_	VBD	VBD	_	6	NMOD	_	_
12	restricted	_	JJ	JJ	_	13	NMOD	_	_
13	expression	_	NN	NN	_	11	OBJ	_	_
14	with	_	IN	IN	_	3	NMOD	_	_
15	lipopolysaccharide	_	NN	NN	_	14	PMOD	_	_
16	increased	_	VBD	VBD	_	0	ROOT-S	_	_
17	viral	_	JJ	JJ	_	18	NMOD	_	_
18	production	_	NN	NN	_	16	OBJ	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	NF-kappa	_	NN	NN	_	22	NMOD	_	_
21	B	_	NN	NN	_	22	NMOD	_	_
22	activity	_	NN	NN	_	18	COORD	_	_
23	.	_	.	.	_	16	P	_	_

1	Antiserum	_	NN	NN	_	14	SBJ	_	_
2	specific	_	JJ	JJ	_	1	NMOD	_	_
3	for	_	IN	IN	_	2	AMOD	_	_
4	NF-kappa	_	NN	NN	_	7	NMOD	_	_
5	B	_	NN	NN	_	7	NMOD	_	_
6	binding	_	NN	NN	_	7	NMOD	_	_
7	proteins	_	NNS	NNS	_	3	PMOD	_	_
8	,	_	,	,	_	1	P	_	_
9	but	_	CC	CC	_	1	CC	_	_
10	not	_	RB	RB	_	9	COORD	_	_
11	c-rel-specific	_	JJ	JJ	_	12	NMOD	_	_
12	antiserum	_	NN	NN	_	1	COORD	_	_
13	,	_	,	,	_	1	P	_	_
14	disrupted	_	VBD	VBD	_	0	ROOT-S	_	_
15	heterodimer	_	NN	NN	_	17	NMOD	_	_
16	complex	_	NN	NN	_	17	NMOD	_	_
17	formation	_	NN	NN	_	14	OBJ	_	_
18	.	_	.	.	_	14	P	_	_

1	Thus	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	both	_	DT	DT	_	6	NMOD	_	_
4	NF-kappa	_	NN	NN	_	6	NMOD	_	_
5	B-binding	_	JJ	JJ	_	4	AMOD	_	_
6	complexes	_	NNS	NNS	_	7	SBJ	_	_
7	are	_	VBP	VBP	_	0	ROOT-S	_	_
8	needed	_	VBN	VBN	_	7	VC	_	_
9	for	_	IN	IN	_	8	ADV	_	_
10	optimal	_	JJ	JJ	_	12	NMOD	_	_
11	viral	_	JJ	JJ	_	12	NMOD	_	_
12	transcription	_	NN	NN	_	9	PMOD	_	_
13	.	_	.	.	_	7	P	_	_

1	Binding	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	65-kDa	_	JJ	JJ	_	7	NMOD	_	_
5	plus	_	CC	CC	_	4	CC	_	_
6	50-kDa	_	JJ	JJ	_	4	COORD	_	_
7	heterodimer	_	NN	NN	_	2	PMOD	_	_
8	to	_	TO	TO	_	1	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	HIV-1	_	NN	NN	_	11	NMOD	_	_
11	enhancer	_	NN	NN	_	8	PMOD	_	_
12	can	_	MD	MD	_	0	ROOT-S	_	_
13	be	_	VB	VB	_	12	VC	_	_
14	negatively	_	RB	RB	_	13	ADV	_	_
15	regulated	_	VBN	VBN	_	13	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	monocytes	_	NNS	NNS	_	16	PMOD	_	_
18	,	_	,	,	_	15	P	_	_
19	providing	_	VBG	VBG	_	15	OBJ	_	_
20	one	_	CD	CD	_	21	NMOD	_	_
21	mechanism	_	NN	NN	_	19	OBJ	_	_
22	restricting	_	VBG	VBG	_	21	NMOD	_	_
23	HIV-1	_	NN	NN	_	25	NMOD	_	_
24	gene	_	NN	NN	_	25	NMOD	_	_
25	expression	_	NN	NN	_	22	OBJ	_	_
26	.	_	.	.	_	12	P	_	_

1	Isolation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	candidate	_	NN	NN	_	2	PMOD	_	_
5	repressor\/activator	_	NN	NN	_	4	NMOD	_	_
6	,	_	,	,	_	4	P	_	_
7	NF-E1	_	NN	NN	_	4	NMOD	_	_
8	(	_	(	(	_	11	P	_	_
9	YY-1	_	NN	NN	_	11	NMOD	_	_
10	,	_	,	,	_	11	P	_	_
11	delta	_	NN	NN	_	7	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	,	_	,	,	_	4	P	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	binds	_	VBZ	VBZ	_	4	NMOD	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	immunoglobulin	_	NN	NN	_	21	NMOD	_	_
19	kappa	_	NN	NN	_	21	NMOD	_	_
20	3'	_	JJ	JJ	_	21	NMOD	_	_
21	enhancer	_	NN	NN	_	16	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	the	_	DT	DT	_	28	NMOD	_	_
24	immunoglobulin	_	NN	NN	_	28	NMOD	_	_
25	heavy-chain	_	NN	NN	_	28	NMOD	_	_
26	mu	_	NN	NN	_	28	NMOD	_	_
27	E1	_	NN	NN	_	28	NMOD	_	_
28	site	_	NN	NN	_	21	COORD	_	_
29	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	determined	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	developmental	_	JJ	JJ	_	7	NMOD	_	_
7	control	_	NN	NN	_	18	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	immunoglobulin	_	NN	NN	_	17	NMOD	_	_
10	kappa	_	NN	NN	_	17	NMOD	_	_
11	3'	_	JJ	JJ	_	17	NMOD	_	_
12	enhancer	_	NN	NN	_	17	NMOD	_	_
13	(	_	(	(	_	17	P	_	_
14	kappa	_	NN	NN	_	17	NMOD	_	_
15	E3'	_	NN	NN	_	17	NMOD	_	_
16	)	_	)	)	_	17	P	_	_
17	activity	_	NN	NN	_	8	PMOD	_	_
18	is	_	VBZ	VBZ	_	4	VMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	result	_	NN	NN	_	18	PRD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	combined	_	JJ	JJ	_	24	NMOD	_	_
24	influence	_	NN	NN	_	21	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	positive-	_	JJ	JJ	_	29	NMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	negative-acting	_	JJ	JJ	_	26	COORD	_	_
29	elements	_	NNS	NNS	_	25	PMOD	_	_
30	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	central	_	JJ	JJ	_	6	NMOD	_	_
6	core	_	NN	NN	_	12	SBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	kappa	_	NN	NN	_	11	NMOD	_	_
10	E3'	_	NN	NN	_	11	NMOD	_	_
11	enhancer	_	NN	NN	_	7	PMOD	_	_
12	is	_	VBZ	VBZ	_	3	VMOD	_	_
13	active	_	JJ	JJ	_	12	PRD	_	_
14	at	_	IN	IN	_	12	TMP	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	pre-B-cell	_	JJ	JJ	_	17	NMOD	_	_
17	stage	_	NN	NN	_	14	PMOD	_	_
18	but	_	CC	CC	_	12	CC	_	_
19	is	_	VBZ	VBZ	_	12	COORD	_	_
20	repressed	_	VBN	VBN	_	19	VC	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	flanking	_	VBG	VBG	_	24	NMOD	_	_
23	negative-acting	_	JJ	JJ	_	24	NMOD	_	_
24	elements	_	NNS	NNS	_	21	PMOD	_	_
25	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	negative-acting	_	JJ	JJ	_	3	NMOD	_	_
3	sequences	_	NNS	NNS	_	4	SBJ	_	_
4	repress	_	VBP	VBP	_	0	ROOT-S	_	_
5	enhancer	_	NN	NN	_	6	NMOD	_	_
6	activity	_	NN	NN	_	4	OBJ	_	_
7	in	_	IN	IN	_	4	ADV	_	_
8	a	_	DT	DT	_	12	NMOD	_	_
9	position-	_	NN	NN	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	orientation-independent	_	JJ	JJ	_	9	COORD	_	_
12	manner	_	NN	NN	_	7	PMOD	_	_
13	at	_	IN	IN	_	4	TMP	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	pre-B-cell	_	JJ	JJ	_	16	NMOD	_	_
16	stage	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	isolated	_	VBN	VBN	_	2	VC	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	human	_	JJ	JJ	_	7	NMOD	_	_
6	cDNA	_	NN	NN	_	7	NMOD	_	_
7	clone	_	NN	NN	_	3	OBJ	_	_
8	encoding	_	VBG	VBG	_	7	NMOD	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	zinc	_	NN	NN	_	12	NMOD	_	_
11	finger	_	NN	NN	_	12	NMOD	_	_
12	protein	_	NN	NN	_	8	OBJ	_	_
13	(	_	(	(	_	14	P	_	_
14	NF-E1	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	that	_	WDT	WDT	_	17	SBJ	_	_
17	binds	_	VBZ	VBZ	_	12	NMOD	_	_
18	to	_	TO	TO	_	17	ADV	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	negative-acting	_	JJ	JJ	_	21	NMOD	_	_
21	segment	_	NN	NN	_	18	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	26	NMOD	_	_
24	kappa	_	NN	NN	_	26	NMOD	_	_
25	E3'	_	NN	NN	_	26	NMOD	_	_
26	enhancer	_	NN	NN	_	22	PMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	protein	_	NN	NN	_	4	SBJ	_	_
3	also	_	RB	RB	_	4	ADV	_	_
4	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	the	_	DT	DT	_	12	NMOD	_	_
7	immunoglobulin	_	NN	NN	_	12	NMOD	_	_
8	heavy-chain	_	NN	NN	_	12	NMOD	_	_
9	enhancer	_	NN	NN	_	12	NMOD	_	_
10	mu	_	NN	NN	_	12	NMOD	_	_
11	E1	_	NN	NN	_	12	NMOD	_	_
12	site	_	NN	NN	_	5	PMOD	_	_
13	.	_	.	.	_	4	P	_	_

1	NF-E1	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	encoded	_	VBN	VBN	_	2	VC	_	_
4	by	_	IN	IN	_	3	LGS	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	same	_	JJ	JJ	_	7	NMOD	_	_
7	gene	_	NN	NN	_	4	PMOD	_	_
8	as	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	YY-1	_	NN	NN	_	11	NMOD	_	_
11	protein	_	NN	NN	_	8	PMOD	_	_
12	,	_	,	,	_	7	P	_	_
13	which	_	WDT	WDT	_	14	SBJ	_	_
14	binds	_	VBZ	VBZ	_	7	NMOD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	adeno-associated	_	JJ	JJ	_	20	NMOD	_	_
18	virus	_	NN	NN	_	20	NMOD	_	_
19	P5	_	NN	NN	_	20	NMOD	_	_
20	promoter	_	NN	NN	_	15	PMOD	_	_
21	.	_	.	.	_	2	P	_	_

1	NF-E1	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	also	_	RB	RB	_	2	ADV	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	human	_	JJ	JJ	_	6	NMOD	_	_
6	homologue	_	NN	NN	_	2	PRD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	mouse	_	NN	NN	_	11	NMOD	_	_
10	delta	_	NN	NN	_	11	NMOD	_	_
11	protein	_	NN	NN	_	7	PMOD	_	_
12	,	_	,	,	_	6	P	_	_
13	which	_	WDT	WDT	_	14	SBJ	_	_
14	binds	_	VBZ	VBZ	_	6	NMOD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	ribosomal	_	JJ	JJ	_	19	NMOD	_	_
17	protein	_	NN	NN	_	19	NMOD	_	_
18	gene	_	NN	NN	_	19	NMOD	_	_
19	promoters	_	NNS	NNS	_	15	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	predicted	_	VBN	VBN	_	5	NMOD	_	_
3	amino	_	NN	NN	_	5	NMOD	_	_
4	acid	_	NN	NN	_	5	NMOD	_	_
5	sequence	_	NN	NN	_	9	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	this	_	DT	DT	_	8	NMOD	_	_
8	protein	_	NN	NN	_	6	PMOD	_	_
9	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	features	_	NNS	NNS	_	9	OBJ	_	_
11	characteristic	_	JJ	JJ	_	10	NMOD	_	_
12	of	_	IN	IN	_	11	AMOD	_	_
13	transcriptional	_	JJ	JJ	_	14	NMOD	_	_
14	activators	_	NNS	NNS	_	12	PMOD	_	_
15	as	_	RB	RB	_	14	CC	_	_
16	well	_	RB	RB	_	15	DEP	_	_
17	as	_	IN	IN	_	15	DEP	_	_
18	transcriptional	_	JJ	JJ	_	19	NMOD	_	_
19	repressors	_	NNS	NNS	_	14	COORD	_	_
20	.	_	.	.	_	9	P	_	_

1	Cotransfection	_	NN	NN	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	6	SBJ	_	_
3	with	_	IN	IN	_	2	NMOD	_	_
4	this	_	DT	DT	_	5	NMOD	_	_
5	cDNA	_	NN	NN	_	3	PMOD	_	_
6	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	it	_	PRP	PRP	_	9	SBJ	_	_
9	can	_	MD	MD	_	7	VMOD	_	_
10	repress	_	VB	VB	_	9	VC	_	_
11	basal	_	JJ	JJ	_	13	NMOD	_	_
12	promoter	_	NN	NN	_	13	NMOD	_	_
13	activity	_	NN	NN	_	10	OBJ	_	_
14	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	apparent	_	JJ	JJ	_	4	NMOD	_	_
3	dual	_	JJ	JJ	_	4	NMOD	_	_
4	function	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	this	_	DT	DT	_	7	NMOD	_	_
7	protein	_	NN	NN	_	5	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	discussed	_	VBN	VBN	_	8	VC	_	_
10	.	_	.	.	_	8	P	_	_

1	cAMP-dependent	_	JJ	JJ	_	2	NMOD	_	_
2	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	proenkephalin	_	NN	NN	_	3	PMOD	_	_
5	by	_	IN	IN	_	2	NMOD	_	_
6	JunD	_	NN	NN	_	5	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	JunB	_	NN	NN	_	6	COORD	_	_
9	:	_	:	:	_	2	P	_	_
10	positive	_	JJ	JJ	_	13	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	negative	_	JJ	JJ	_	10	COORD	_	_
13	effects	_	NNS	NNS	_	2	NMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	AP-1	_	NN	NN	_	16	NMOD	_	_
16	proteins	_	NNS	NNS	_	14	PMOD	_	_
17	.	_	.	.	_	13	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	JunD	_	NN	NN	_	15	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	component	_	NN	NN	_	4	NMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	AP-1	_	NN	NN	_	13	NMOD	_	_
11	transcription	_	NN	NN	_	13	NMOD	_	_
12	factor	_	NN	NN	_	13	NMOD	_	_
13	complex	_	NN	NN	_	8	PMOD	_	_
14	,	_	,	,	_	4	P	_	_
15	activates	_	VBZ	VBZ	_	3	VMOD	_	_
16	transcription	_	NN	NN	_	15	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	human	_	JJ	JJ	_	21	NMOD	_	_
20	proenkephalin	_	NN	NN	_	21	NMOD	_	_
21	gene	_	NN	NN	_	17	PMOD	_	_
22	in	_	IN	IN	_	15	ADV	_	_
23	a	_	DT	DT	_	24	NMOD	_	_
24	fashion	_	NN	NN	_	22	PMOD	_	_
25	that	_	WDT	WDT	_	26	SBJ	_	_
26	is	_	VBZ	VBZ	_	24	NMOD	_	_
27	completely	_	RB	RB	_	28	AMOD	_	_
28	dependent	_	JJ	JJ	_	26	PRD	_	_
29	upon	_	IN	IN	_	28	AMOD	_	_
30	the	_	DT	DT	_	33	NMOD	_	_
31	cAMP-dependent	_	JJ	JJ	_	33	NMOD	_	_
32	protein	_	NN	NN	_	33	NMOD	_	_
33	kinase	_	NN	NN	_	29	PMOD	_	_
34	,	_	,	,	_	33	P	_	_
35	protein	_	NN	NN	_	37	NMOD	_	_
36	kinase	_	NN	NN	_	37	NMOD	_	_
37	A	_	NN	NN	_	33	NMOD	_	_
38	.	_	.	.	_	2	P	_	_

1	Activation	_	NN	NN	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	proenkephalin	_	NN	NN	_	4	NMOD	_	_
4	transcription	_	NN	NN	_	2	PMOD	_	_
5	by	_	IN	IN	_	1	NMOD	_	_
6	JunD	_	NN	NN	_	5	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	dependent	_	JJ	JJ	_	7	PRD	_	_
9	upon	_	IN	IN	_	8	AMOD	_	_
10	a	_	DT	DT	_	20	NMOD	_	_
11	previously	_	RB	RB	_	12	AMOD	_	_
12	characterized	_	VBN	VBN	_	20	NMOD	_	_
13	cAMP-	_	NN	NN	_	20	NMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	phorbol	_	NN	NN	_	16	NMOD	_	_
16	ester-	_	NN	NN	_	13	COORD	_	_
17	,	_	,	,	_	13	P	_	_
18	and	_	CC	CC	_	13	CC	_	_
19	Ca-LRB-2+-RRB--inducible	_	JJ	JJ	_	13	COORD	_	_
20	enhancer	_	NN	NN	_	9	PMOD	_	_
21	,	_	,	,	_	7	P	_	_
22	and	_	CC	CC	_	7	CC	_	_
23	JunD	_	NN	NN	_	24	SBJ	_	_
24	is	_	VBZ	VBZ	_	7	COORD	_	_
25	shown	_	VBN	VBN	_	24	VC	_	_
26	to	_	TO	TO	_	27	VMOD	_	_
27	bind	_	VB	VB	_	25	OBJ	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	enhancer	_	NN	NN	_	27	OBJ	_	_
30	as	_	IN	IN	_	27	ADV	_	_
31	a	_	DT	DT	_	32	NMOD	_	_
32	homodimer	_	NN	NN	_	30	PMOD	_	_
33	.	_	.	.	_	7	P	_	_

1	Another	_	DT	DT	_	2	NMOD	_	_
2	component	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	AP-1	_	NN	NN	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	complex	_	NN	NN	_	3	PMOD	_	_
8	,	_	,	,	_	2	P	_	_
9	JunB	_	NN	NN	_	2	NMOD	_	_
10	,	_	,	,	_	2	P	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	shown	_	VBN	VBN	_	11	VC	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	inhibit	_	VB	VB	_	12	OBJ	_	_
15	activation	_	NN	NN	_	14	OBJ	_	_
16	mediated	_	VBN	VBN	_	15	NMOD	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	JunD	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	11	P	_	_

1	As	_	IN	IN	_	5	ADV	_	_
2	a	_	DT	DT	_	3	NMOD	_	_
3	homodimer	_	NN	NN	_	1	PMOD	_	_
4	JunB	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	unable	_	JJ	JJ	_	5	PRD	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	bind	_	VB	VB	_	6	AMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	enhancer	_	NN	NN	_	8	OBJ	_	_
11	;	_	:	:	_	5	P	_	_
12	however	_	RB	RB	_	5	COORD	_	_
13	in	_	IN	IN	_	21	ADV	_	_
14	the	_	DT	DT	_	13	DEP	_	_
15	presence	_	NN	NN	_	13	DEP	_	_
16	of	_	IN	IN	_	13	DEP	_	_
17	c-Fos	_	NN	NN	_	13	PMOD	_	_
18	,	_	,	,	_	21	P	_	_
19	high-affinity	_	JJ	JJ	_	20	NMOD	_	_
20	binding	_	NN	NN	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	5	COORD	_	_
22	observed	_	VBN	VBN	_	21	VC	_	_
23	.	_	.	.	_	5	P	_	_

1	Furthermore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	JunD	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	shown	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	activate	_	VB	VB	_	5	OBJ	_	_
8	transcription	_	NN	NN	_	7	IOBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	genes	_	NNS	NNS	_	9	PMOD	_	_
11	linked	_	VBN	VBN	_	10	NMOD	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	both	_	CC	CC	_	14	CC	_	_
14	cAMP	_	NN	NN	_	19	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	phorbol	_	NN	NN	_	17	NMOD	_	_
17	ester	_	NN	NN	_	14	COORD	_	_
18	response	_	NN	NN	_	19	NMOD	_	_
19	elements	_	NNS	NNS	_	12	PMOD	_	_
20	in	_	IN	IN	_	7	ADV	_	_
21	a	_	DT	DT	_	25	NMOD	_	_
22	protein	_	NN	NN	_	23	AMOD	_	_
23	kinase	_	NN	NN	_	25	NMOD	_	_
24	A-dependent	_	JJ	JJ	_	23	AMOD	_	_
25	fashion	_	NN	NN	_	20	PMOD	_	_
26	,	_	,	,	_	7	P	_	_
27	further	_	RB	RB	_	28	ADV	_	_
28	blurring	_	VBG	VBG	_	7	OBJ	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	distinction	_	NN	NN	_	28	OBJ	_	_
31	between	_	IN	IN	_	30	NMOD	_	_
32	these	_	DT	DT	_	34	NMOD	_	_
33	response	_	NN	NN	_	34	NMOD	_	_
34	elements	_	NNS	NNS	_	31	PMOD	_	_
35	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	transcriptional	_	JJ	JJ	_	7	NMOD	_	_
7	activity	_	NN	NN	_	12	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	an	_	DT	DT	_	11	NMOD	_	_
10	AP-1-related	_	JJ	JJ	_	11	NMOD	_	_
11	protein	_	NN	NN	_	8	PMOD	_	_
12	is	_	VBZ	VBZ	_	4	VMOD	_	_
13	regulated	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	cAMP-dependent	_	JJ	JJ	_	18	NMOD	_	_
17	second-messenger	_	NN	NN	_	18	NMOD	_	_
18	pathway	_	NN	NN	_	14	PMOD	_	_
19	and	_	CC	CC	_	3	CC	_	_
20	suggest	_	VBP	VBP	_	3	COORD	_	_
21	that	_	IN	IN	_	20	OBJ	_	_
22	JunD	_	NN	NN	_	27	SBJ	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	other	_	JJ	JJ	_	26	NMOD	_	_
25	AP-1-related	_	JJ	JJ	_	26	NMOD	_	_
26	proteins	_	NNS	NNS	_	22	COORD	_	_
27	may	_	MD	MD	_	21	VMOD	_	_
28	play	_	VB	VB	_	27	VC	_	_
29	an	_	DT	DT	_	31	NMOD	_	_
30	important	_	JJ	JJ	_	31	NMOD	_	_
31	role	_	NN	NN	_	28	OBJ	_	_
32	in	_	IN	IN	_	28	ADV	_	_
33	the	_	DT	DT	_	34	NMOD	_	_
34	regulation	_	NN	NN	_	32	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	gene	_	NN	NN	_	37	NMOD	_	_
37	expression	_	NN	NN	_	35	PMOD	_	_
38	by	_	IN	IN	_	34	NMOD	_	_
39	cAMP-dependent	_	JJ	JJ	_	42	NMOD	_	_
40	intracellular	_	JJ	JJ	_	42	NMOD	_	_
41	signaling	_	NN	NN	_	42	NMOD	_	_
42	pathways	_	NNS	NNS	_	38	PMOD	_	_
43	.	_	.	.	_	3	P	_	_

1	Glucocorticoid	_	NN	NN	_	2	NMOD	_	_
2	resistance	_	NN	NN	_	0	ROOT-FRAG	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	chronic	_	JJ	JJ	_	5	NMOD	_	_
5	asthma	_	NN	NN	_	3	PMOD	_	_
6	.	_	.	.	_	2	P	_	_

1	Glucocorticoid	_	NN	NN	_	2	NMOD	_	_
2	pharmacokinetics	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	,	_	,	,	_	2	P	_	_
4	glucocorticoid	_	NN	NN	_	6	NMOD	_	_
5	receptor	_	NN	NN	_	6	NMOD	_	_
6	characteristics	_	NNS	NNS	_	2	COORD	_	_
7	,	_	,	,	_	2	P	_	_
8	and	_	CC	CC	_	2	CC	_	_
9	inhibition	_	NN	NN	_	2	COORD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	peripheral	_	JJ	JJ	_	15	NMOD	_	_
12	blood	_	NN	NN	_	15	NMOD	_	_
13	T	_	NN	NN	_	15	NMOD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	proliferation	_	NN	NN	_	10	PMOD	_	_
16	by	_	IN	IN	_	9	NMOD	_	_
17	glucocorticoids	_	NNS	NNS	_	16	PMOD	_	_
18	in	_	FW	FW	_	19	AMOD	_	_
19	vitro	_	FW	FW	_	9	NMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	total	_	NN	NN	_	17	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	37	_	CD	CD	_	11	NMOD	_	_
5	chronic	_	JJ	JJ	_	11	NMOD	_	_
6	,	_	,	,	_	5	P	_	_
7	severe	_	JJ	JJ	_	5	COORD	_	_
8	,	_	,	,	_	5	P	_	_
9	nonsmoking	_	JJ	JJ	_	5	COORD	_	_
10	asthmatic	_	JJ	JJ	_	11	NMOD	_	_
11	patients	_	NNS	NNS	_	3	PMOD	_	_
12	with	_	IN	IN	_	11	NMOD	_	_
13	documented	_	JJ	JJ	_	16	NMOD	_	_
14	reversible	_	JJ	JJ	_	16	NMOD	_	_
15	airways	_	NNS	NNS	_	16	NMOD	_	_
16	obstruction	_	NN	NN	_	12	PMOD	_	_
17	were	_	VBD	VBD	_	0	ROOT-S	_	_
18	classified	_	VBN	VBN	_	17	VC	_	_
19	as	_	IN	IN	_	18	ADV	_	_
20	glucocorticoid-sensitive	_	JJ	JJ	_	19	PMOD	_	_
21	or	_	CC	CC	_	20	CC	_	_
22	-resistant	_	JJ	JJ	_	20	COORD	_	_
23	on	_	IN	IN	_	18	ADV	_	_
24	the	_	DT	DT	_	23	DEP	_	_
25	basis	_	NN	NN	_	23	DEP	_	_
26	of	_	IN	IN	_	23	DEP	_	_
27	changes	_	NNS	NNS	_	23	PMOD	_	_
28	in	_	IN	IN	_	27	NMOD	_	_
29	FEV1	_	NN	NN	_	28	PMOD	_	_
30	,	_	,	,	_	29	P	_	_
31	FVC	_	NN	NN	_	29	COORD	_	_
32	,	_	,	,	_	29	P	_	_
33	and	_	CC	CC	_	29	CC	_	_
34	peak	_	JJ	JJ	_	36	NMOD	_	_
35	expiratory	_	NN	NN	_	36	NMOD	_	_
36	flow	_	NN	NN	_	29	COORD	_	_
37	(	_	(	(	_	38	P	_	_
38	PEF	_	NN	NN	_	36	PRN	_	_
39	)	_	)	)	_	38	P	_	_
40	after	_	IN	IN	_	27	TMP	_	_
41	oral	_	JJ	JJ	_	42	NMOD	_	_
42	prednisolone	_	NN	NN	_	40	PMOD	_	_
43	.	_	.	.	_	17	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	resistant	_	JJ	JJ	_	3	NMOD	_	_
3	patients	_	NNS	NNS	_	4	SBJ	_	_
4	showed	_	VBD	VBD	_	0	ROOT-S	_	_
5	no	_	DT	DT	_	7	NMOD	_	_
6	significant	_	JJ	JJ	_	7	NMOD	_	_
7	improvements	_	NNS	NNS	_	4	OBJ	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	airflow	_	NN	NN	_	10	NMOD	_	_
10	limitation	_	NN	NN	_	8	PMOD	_	_
11	.	_	.	.	_	4	P	_	_

1	Phytohemagglutinin	_	NN	NN	_	3	AMOD	_	_
2	(	_	(	(	_	3	P	_	_
3	PHA	_	NN	NN	_	6	NMOD	_	_
4	)	_	)	)	_	3	P	_	_
5	-induced	_	JJ	JJ	_	3	AMOD	_	_
6	proliferation	_	NN	NN	_	21	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	peripheral	_	JJ	JJ	_	11	NMOD	_	_
9	blood	_	NN	NN	_	11	NMOD	_	_
10	T	_	NN	NN	_	11	NMOD	_	_
11	lymphocytes	_	NNS	NNS	_	7	PMOD	_	_
12	from	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	20	NMOD	_	_
14	sensitive	_	JJ	JJ	_	20	NMOD	_	_
15	but	_	CC	CC	_	20	CC	_	_
16	not	_	RB	RB	_	15	COORD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	resistant	_	JJ	JJ	_	20	NMOD	_	_
19	asthmatic	_	JJ	JJ	_	20	NMOD	_	_
20	patients	_	NNS	NNS	_	12	PMOD	_	_
21	was	_	VBD	VBD	_	0	ROOT-S	_	_
22	significantly	_	RB	RB	_	21	ADV	_	_
23	(	_	(	(	_	25	P	_	_
24	p	_	NN	NN	_	25	SBJ	_	_
25	less	_	JJR	JJR	_	22	PRN	_	_
26	than	_	IN	IN	_	25	AMOD	_	_
27	0.01	_	CD	CD	_	26	PMOD	_	_
28	)	_	)	)	_	25	P	_	_
29	inhibited	_	VBN	VBN	_	21	VC	_	_
30	by	_	IN	IN	_	29	LGS	_	_
31	dexamethasone	_	NN	NN	_	30	PMOD	_	_
32	(	_	(	(	_	34	P	_	_
33	10-LRB--7-RRB-	_	CD	CD	_	34	NMOD	_	_
34	mol\/L	_	NN	NN	_	31	PRN	_	_
35	)	_	)	)	_	34	P	_	_
36	,	_	,	,	_	29	P	_	_
37	reflecting	_	VBG	VBG	_	29	OBJ	_	_
38	a	_	DT	DT	_	39	NMOD	_	_
39	shift	_	NN	NN	_	37	OBJ	_	_
40	of	_	IN	IN	_	39	NMOD	_	_
41	the	_	DT	DT	_	43	NMOD	_	_
42	dose-response	_	JJ	JJ	_	43	NMOD	_	_
43	curve	_	NN	NN	_	40	PMOD	_	_
44	.	_	.	.	_	21	P	_	_

1	When	_	WRB	WRB	_	7	ADV	_	_
2	all	_	PDT	PDT	_	5	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	asthmatic	_	JJ	JJ	_	5	NMOD	_	_
5	patients	_	NNS	NNS	_	6	SBJ	_	_
6	were	_	VBD	VBD	_	11	TMP	_	_
7	analyzed	_	VBN	VBN	_	6	VC	_	_
8	together	_	RB	RB	_	7	ADV	_	_
9	,	_	,	,	_	11	P	_	_
10	there	_	EX	EX	_	11	SBJ	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	significant	_	JJ	JJ	_	14	NMOD	_	_
14	correlation	_	NN	NN	_	11	PRD	_	_
15	between	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	degree	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	sensitivity	_	NN	NN	_	18	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	T	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	20	PMOD	_	_
23	to	_	TO	TO	_	19	NMOD	_	_
24	dexamethasone	_	NN	NN	_	23	PMOD	_	_
25	and	_	CC	CC	_	17	CC	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	clinical	_	JJ	JJ	_	28	NMOD	_	_
28	responsiveness	_	NN	NN	_	17	COORD	_	_
29	to	_	TO	TO	_	28	NMOD	_	_
30	prednisolone	_	JJ	JJ	_	29	PMOD	_	_
31	(	_	(	(	_	33	P	_	_
32	p	_	NN	NN	_	33	SBJ	_	_
33	less	_	RBR	RBR	_	11	PRN	_	_
34	than	_	IN	IN	_	33	AMOD	_	_
35	0.01	_	CD	CD	_	34	PMOD	_	_
36	)	_	)	)	_	33	P	_	_
37	.	_	.	.	_	11	P	_	_

1	No	_	DT	DT	_	2	NMOD	_	_
2	differences	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	observed	_	VBN	VBN	_	3	VC	_	_
5	between	_	IN	IN	_	4	ADV	_	_
6	six	_	CD	CD	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	sensitive	_	JJ	JJ	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	resistant	_	JJ	JJ	_	9	COORD	_	_
12	patients	_	NNS	NNS	_	7	PMOD	_	_
13	in	_	IN	IN	_	4	ADV	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	clearance	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	plasma	_	NN	NN	_	16	PMOD	_	_
18	prednisolone	_	JJ	JJ	_	17	NMOD	_	_
19	derived	_	VBN	VBN	_	17	NMOD	_	_
20	from	_	IN	IN	_	19	ADV	_	_
21	orally	_	RB	RB	_	22	AMOD	_	_
22	administered	_	VBN	VBN	_	23	NMOD	_	_
23	prednisone	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	Peripheral	_	JJ	JJ	_	6	NMOD	_	_
2	blood	_	NN	NN	_	6	NMOD	_	_
3	mononuclear	_	JJ	JJ	_	6	NMOD	_	_
4	cell	_	NN	NN	_	6	NMOD	_	_
5	glucocorticoid	_	NN	NN	_	6	NMOD	_	_
6	receptors	_	NNS	NNS	_	7	SBJ	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	also	_	RB	RB	_	7	ADV	_	_
9	characterized	_	VBN	VBN	_	7	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	five	_	CD	CD	_	16	NMOD	_	_
12	sensitive	_	JJ	JJ	_	16	NMOD	_	_
13	and	_	CC	CC	_	16	CC	_	_
14	seven	_	CD	CD	_	16	NMOD	_	_
15	resistant	_	JJ	JJ	_	16	NMOD	_	_
16	patients	_	NNS	NNS	_	10	PMOD	_	_
17	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	numbers	_	NNS	NNS	_	9	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	binding	_	NN	NN	_	5	NMOD	_	_
5	affinities	_	NNS	NNS	_	2	COORD	_	_
6	of	_	IN	IN	_	2	NMOD	_	_
7	these	_	DT	DT	_	8	NMOD	_	_
8	receptors	_	NNS	NNS	_	6	PMOD	_	_
9	could	_	MD	MD	_	0	ROOT-S	_	_
10	not	_	RB	RB	_	9	VMOD	_	_
11	account	_	VB	VB	_	9	VC	_	_
12	for	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	observed	_	VBN	VBN	_	15	NMOD	_	_
15	difference	_	NN	NN	_	12	PMOD	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	susceptibility	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	these	_	DT	DT	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	19	PMOD	_	_
22	to	_	TO	TO	_	18	NMOD	_	_
23	functional	_	JJ	JJ	_	24	NMOD	_	_
24	inhibition	_	NN	NN	_	22	PMOD	_	_
25	by	_	IN	IN	_	24	NMOD	_	_
26	dexamethasone	_	NN	NN	_	25	PMOD	_	_
27	in	_	FW	FW	_	28	AMOD	_	_
28	vitro	_	FW	FW	_	24	NMOD	_	_
29	.	_	.	.	_	9	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	clinical	_	JJ	JJ	_	7	NMOD	_	_
6	glucocorticoid	_	NN	NN	_	7	NMOD	_	_
7	resistance	_	NN	NN	_	11	SBJ	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	chronic	_	JJ	JJ	_	10	NMOD	_	_
10	asthma	_	NN	NN	_	8	PMOD	_	_
11	does	_	VBZ	VBZ	_	4	VMOD	_	_
12	not	_	RB	RB	_	11	VMOD	_	_
13	reflect	_	VB	VB	_	11	VC	_	_
14	abnormal	_	JJ	JJ	_	16	NMOD	_	_
15	glucocorticoid	_	NN	NN	_	16	NMOD	_	_
16	clearance	_	NN	NN	_	13	OBJ	_	_
17	but	_	CC	CC	_	11	CC	_	_
18	may	_	MD	MD	_	11	COORD	_	_
19	be	_	VB	VB	_	18	VC	_	_
20	due	_	JJ	JJ	_	24	PMOD	_	_
21	at	_	IN	IN	_	23	AMOD	_	_
22	least	_	JJS	JJS	_	21	AMOD	_	_
23	partly	_	RB	RB	_	24	PMOD	_	_
24	to	_	TO	TO	_	19	PRD	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	relative	_	JJ	JJ	_	27	NMOD	_	_
27	insensitivity	_	NN	NN	_	24	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	T	_	NN	NN	_	30	NMOD	_	_
30	lymphocytes	_	NNS	NNS	_	28	PMOD	_	_
31	to	_	TO	TO	_	27	NMOD	_	_
32	glucocorticoids	_	NNS	NNS	_	31	PMOD	_	_
33	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	lack	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	sensitivity	_	NN	NN	_	3	PMOD	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	unexplained	_	JJ	JJ	_	5	PRD	_	_
7	but	_	CC	CC	_	5	CC	_	_
8	is	_	VBZ	VBZ	_	5	COORD	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	attributable	_	JJ	JJ	_	8	PRD	_	_
11	to	_	TO	TO	_	10	AMOD	_	_
12	abnormalities	_	NNS	NNS	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	cellular	_	JJ	JJ	_	16	NMOD	_	_
15	glucocorticoid	_	NN	NN	_	16	NMOD	_	_
16	receptors	_	NNS	NNS	_	13	PMOD	_	_
17	.	_	.	.	_	5	P	_	_

1	Identification	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	transcriptional	_	JJ	JJ	_	5	NMOD	_	_
4	suppressor	_	NN	NN	_	5	NMOD	_	_
5	proteins	_	NNS	NNS	_	2	PMOD	_	_
6	that	_	WDT	WDT	_	7	SBJ	_	_
7	bind	_	VBP	VBP	_	5	NMOD	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	negative	_	JJ	JJ	_	12	NMOD	_	_
11	regulatory	_	JJ	JJ	_	12	NMOD	_	_
12	element	_	NN	NN	_	8	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	human	_	JJ	JJ	_	18	NMOD	_	_
16	immunodeficiency	_	NN	NN	_	18	NMOD	_	_
17	virus	_	NN	NN	_	18	NMOD	_	_
18	type	_	NN	NN	_	13	PMOD	_	_
19	1	_	CD	CD	_	18	NMOD	_	_
20	.	_	.	.	_	1	P	_	_

1	Two	_	CD	CD	_	3	NMOD	_	_
2	different	_	JJ	JJ	_	3	NMOD	_	_
3	proteins	_	NNS	NNS	_	27	SBJ	_	_
4	which	_	WDT	WDT	_	6	SBJ	_	_
5	independently	_	RB	RB	_	6	ADV	_	_
6	bound	_	VBD	VBD	_	3	NMOD	_	_
7	to	_	TO	TO	_	6	ADV	_	_
8	neighboring	_	VBG	VBG	_	9	NMOD	_	_
9	sequences	_	NNS	NNS	_	7	PMOD	_	_
10	within	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	negative	_	JJ	JJ	_	14	NMOD	_	_
13	regulatory	_	JJ	JJ	_	14	NMOD	_	_
14	element	_	NN	NN	_	10	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	NRE	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	of	_	IN	IN	_	14	NMOD	_	_
19	human	_	JJ	JJ	_	22	NMOD	_	_
20	immunodeficiency	_	NN	NN	_	22	NMOD	_	_
21	virus	_	NN	NN	_	22	NMOD	_	_
22	type	_	NN	NN	_	18	PMOD	_	_
23	1	_	CD	CD	_	22	NMOD	_	_
24	(	_	(	(	_	25	P	_	_
25	HIV-1	_	NN	NN	_	22	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	were	_	VBD	VBD	_	0	ROOT-S	_	_
28	detected	_	VBN	VBN	_	27	VC	_	_
29	in	_	IN	IN	_	28	ADV	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	nuclear	_	JJ	JJ	_	32	NMOD	_	_
32	extract	_	NN	NN	_	29	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	a	_	DT	DT	_	39	NMOD	_	_
35	virus-infected	_	JJ	JJ	_	39	NMOD	_	_
36	human	_	JJ	JJ	_	39	NMOD	_	_
37	T	_	NN	NN	_	39	NMOD	_	_
38	cell	_	NN	NN	_	39	NMOD	_	_
39	line	_	NN	NN	_	33	PMOD	_	_
40	.	_	.	.	_	27	P	_	_

1	One	_	CD	CD	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	factors	_	NNS	NNS	_	2	PMOD	_	_
5	bound	_	VBD	VBD	_	0	ROOT-S	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	a	_	DT	DT	_	11	NMOD	_	_
8	novel	_	JJ	JJ	_	11	NMOD	_	_
9	dyad	_	NN	NN	_	11	NMOD	_	_
10	symmetrical	_	JJ	JJ	_	11	NMOD	_	_
11	sequence	_	NN	NN	_	6	PMOD	_	_
12	.	_	.	.	_	5	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	sequence	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	well	_	RB	RB	_	3	ADV	_	_
5	conserved	_	VBN	VBN	_	3	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	various	_	JJ	JJ	_	9	NMOD	_	_
8	HIV-1	_	NN	NN	_	9	NMOD	_	_
9	isolates	_	NNS	NNS	_	6	PMOD	_	_
10	and	_	CC	CC	_	3	CC	_	_
11	partial	_	JJ	JJ	_	12	NMOD	_	_
12	homology	_	NN	NN	_	13	SBJ	_	_
13	was	_	VBD	VBD	_	3	COORD	_	_
14	found	_	VBN	VBN	_	13	VC	_	_
15	with	_	IN	IN	_	14	ADV	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	promoter	_	JJ	JJ	_	18	NMOD	_	_
18	region	_	NN	NN	_	15	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	human	_	JJ	JJ	_	23	NMOD	_	_
22	retinoblastoma	_	NN	NN	_	23	NMOD	_	_
23	gene	_	NN	NN	_	19	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	Similar	_	JJ	JJ	_	4	NMOD	_	_
2	DNA	_	NN	NN	_	4	NMOD	_	_
3	binding	_	NN	NN	_	4	NMOD	_	_
4	activity	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	detected	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	variety	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	virus-uninfected	_	JJ	JJ	_	15	NMOD	_	_
12	human	_	JJ	JJ	_	15	NMOD	_	_
13	T	_	NN	NN	_	15	NMOD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	lines	_	NNS	NNS	_	10	PMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	HeLa	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	15	COORD	_	_
19	by	_	IN	IN	_	6	ADV	_	_
20	means	_	NNS	NNS	_	19	DEP	_	_
21	of	_	IN	IN	_	19	DEP	_	_
22	a	_	DT	DT	_	26	NMOD	_	_
23	gel	_	NN	NN	_	26	NMOD	_	_
24	mobility	_	NN	NN	_	26	NMOD	_	_
25	shift	_	NN	NN	_	26	NMOD	_	_
26	assay	_	NN	NN	_	19	PMOD	_	_
27	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	other	_	JJ	JJ	_	3	NMOD	_	_
3	factor	_	NN	NN	_	4	SBJ	_	_
4	bound	_	VBN	VBN	_	0	ROOT-S	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	a	_	DT	DT	_	10	NMOD	_	_
7	putative	_	JJ	JJ	_	10	NMOD	_	_
8	AP-1	_	NN	NN	_	10	NMOD	_	_
9	recognition	_	NN	NN	_	10	NMOD	_	_
10	sequence	_	NN	NN	_	5	PMOD	_	_
11	predicted	_	VBD	VBD	_	10	NMOD	_	_
12	for	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	HIV-1	_	NN	NN	_	15	NMOD	_	_
15	NRE	_	NN	NN	_	12	PMOD	_	_
16	.	_	.	.	_	4	P	_	_

1	However	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	factor	_	NN	NN	_	5	SBJ	_	_
5	did	_	VBD	VBD	_	0	ROOT-S	_	_
6	not	_	RB	RB	_	5	VMOD	_	_
7	bind	_	VB	VB	_	5	VC	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	typical	_	JJ	JJ	_	12	NMOD	_	_
11	AP-1	_	NN	NN	_	12	NMOD	_	_
12	site	_	NN	NN	_	8	PMOD	_	_
13	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	insertion	_	NN	NN	_	20	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	multiple	_	JJ	JJ	_	5	NMOD	_	_
5	copies	_	NNS	NNS	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	binding	_	VBG	VBG	_	9	NMOD	_	_
9	site	_	NN	NN	_	6	PMOD	_	_
10	for	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	15	NMOD	_	_
12	former	_	JJ	JJ	_	15	NMOD	_	_
13	or	_	CC	CC	_	12	CC	_	_
14	latter	_	JJ	JJ	_	12	COORD	_	_
15	factor	_	NN	NN	_	10	PMOD	_	_
16	into	_	IN	IN	_	2	NMOD	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	heterologous	_	JJ	JJ	_	19	NMOD	_	_
19	promoter	_	NN	NN	_	16	PMOD	_	_
20	reduced	_	VBD	VBD	_	0	ROOT-S	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	promoter	_	NN	NN	_	23	NMOD	_	_
23	activity	_	NN	NN	_	20	OBJ	_	_
24	to	_	TO	TO	_	20	ADV	_	_
25	one-tenth	_	CD	CD	_	24	PMOD	_	_
26	or	_	CC	CC	_	25	CC	_	_
27	one-third	_	CD	CD	_	25	COORD	_	_
28	,	_	,	,	_	20	P	_	_
29	respectively	_	RB	RB	_	20	ADV	_	_
30	.	_	.	.	_	20	P	_	_

1	Thus	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	each	_	DT	DT	_	4	NMOD	_	_
4	factor	_	NN	NN	_	5	SBJ	_	_
5	may	_	MD	MD	_	0	ROOT-S	_	_
6	function	_	VB	VB	_	5	VC	_	_
7	as	_	IN	IN	_	6	ADV	_	_
8	a	_	DT	DT	_	11	NMOD	_	_
9	novel	_	JJ	JJ	_	11	NMOD	_	_
10	negative	_	JJ	JJ	_	11	NMOD	_	_
11	regulator	_	NN	NN	_	7	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	transcription	_	NN	NN	_	12	PMOD	_	_
14	.	_	.	.	_	5	P	_	_

1	Constitutive	_	JJ	JJ	_	2	NMOD	_	_
2	activation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NF-kB	_	NN	NN	_	3	PMOD	_	_
5	in	_	IN	IN	_	2	NMOD	_	_
6	human	_	JJ	JJ	_	7	NMOD	_	_
7	thymocytes	_	NNS	NNS	_	5	PMOD	_	_
8	.	_	.	.	_	2	P	_	_

1	NF-kB	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	7	NMOD	_	_
4	eukaryotic	_	JJ	JJ	_	7	NMOD	_	_
5	transcription	_	NN	NN	_	7	NMOD	_	_
6	regulatory	_	JJ	JJ	_	7	NMOD	_	_
7	factor	_	NN	NN	_	2	PRD	_	_
8	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	T	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	T	_	NN	NN	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	lines	_	NNS	NNS	_	3	COORD	_	_
8	,	_	,	,	_	10	P	_	_
9	NF-kB	_	NN	NN	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	bound	_	VBN	VBN	_	10	VC	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	a	_	DT	DT	_	16	NMOD	_	_
14	cytoplasmic	_	JJ	JJ	_	16	NMOD	_	_
15	proteic	_	JJ	JJ	_	16	NMOD	_	_
16	inhibitor	_	NN	NN	_	12	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	IkB	_	NN	NN	_	16	NMOD	_	_
20	.	_	.	.	_	10	P	_	_

1	Treatment	_	NN	NN	_	17	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	T	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	mitogens	_	NNS	NNS	_	5	PMOD	_	_
7	(	_	(	(	_	9	P	_	_
8	phorbol	_	NN	NN	_	9	NMOD	_	_
9	esters	_	NNS	NNS	_	6	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	or	_	CC	CC	_	6	CC	_	_
12	cytokines	_	NNS	NNS	_	6	COORD	_	_
13	(	_	(	(	_	15	P	_	_
14	TNF	_	NN	NN	_	15	NMOD	_	_
15	alpha	_	NN	NN	_	12	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	NF-kB	_	NN	NN	_	20	NMOD	_	_
19	nuclear	_	JJ	JJ	_	20	NMOD	_	_
20	translocation	_	NN	NN	_	17	OBJ	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	subsequent	_	JJ	JJ	_	24	NMOD	_	_
24	expression	_	NN	NN	_	20	COORD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	NF-kB	_	NN	NN	_	30	NMOD	_	_
27	dependent	_	JJ	JJ	_	26	AMOD	_	_
28	T	_	NN	NN	_	30	NMOD	_	_
29	cell	_	NN	NN	_	30	NMOD	_	_
30	genes	_	NNS	NNS	_	25	PMOD	_	_
31	.	_	.	.	_	17	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	examined	_	VBD	VBD	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	activation	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	NF-kB	_	NN	NN	_	6	PMOD	_	_
8	in	_	IN	IN	_	5	NMOD	_	_
9	human	_	JJ	JJ	_	13	NMOD	_	_
10	T	_	NN	NN	_	13	NMOD	_	_
11	cell	_	NN	NN	_	13	NMOD	_	_
12	thymic	_	JJ	JJ	_	13	NMOD	_	_
13	progenitors	_	NNS	NNS	_	8	PMOD	_	_
14	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	differences	_	NNS	NNS	_	2	OBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	-LRB-Ca2+-RRB-i	_	NN	NN	_	6	NMOD	_	_
6	requirement	_	NN	NN	_	4	PMOD	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	NF-kB	_	NN	NN	_	9	NMOD	_	_
9	activation	_	NN	NN	_	6	NMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	thymocytes	_	NNS	NNS	_	10	PMOD	_	_
12	as	_	IN	IN	_	3	NMOD	_	_
13	compared	_	VBN	VBN	_	12	VMOD	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	mature	_	JJ	JJ	_	17	NMOD	_	_
16	T	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	14	PMOD	_	_
18	.	_	.	.	_	2	P	_	_

1	Furthermore	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	our	_	PRP$	PRP$	_	4	NMOD	_	_
4	results	_	NNS	NNS	_	5	SBJ	_	_
5	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	thymocytes	_	NNS	NNS	_	8	SBJ	_	_
8	have	_	VBP	VBP	_	6	VMOD	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	constitutively	_	RB	RB	_	11	AMOD	_	_
11	active	_	JJ	JJ	_	12	NMOD	_	_
12	form	_	NN	NN	_	8	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	NF-kB	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	5	P	_	_
16	suggesting	_	VBG	VBG	_	5	ADV	_	_
17	that	_	IN	IN	_	16	OBJ	_	_
18	they	_	PRP	PRP	_	19	SBJ	_	_
19	are	_	VBP	VBP	_	17	VMOD	_	_
20	activated	_	VBN	VBN	_	19	VC	_	_
21	in	_	FW	FW	_	20	ADV	_	_
22	vivo	_	FW	FW	_	21	AMOD	_	_
23	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	role	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	jun	_	NN	NN	_	9	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	fos	_	NN	NN	_	4	COORD	_	_
7	gene	_	NN	NN	_	9	NMOD	_	_
8	family	_	NN	NN	_	9	NMOD	_	_
9	members	_	NNS	NNS	_	3	PMOD	_	_
10	in	_	IN	IN	_	2	NMOD	_	_
11	12-O-tetradecanoylphorbol-13-acetate	_	NN	NN	_	14	NMOD	_	_
12	induced	_	VBD	VBD	_	11	AMOD	_	_
13	hemopoietic	_	JJ	JJ	_	14	NMOD	_	_
14	differentiation	_	NN	NN	_	10	PMOD	_	_
15	.	_	.	.	_	2	P	_	_

1	Terminal	_	JJ	JJ	_	2	NMOD	_	_
2	differentiation	_	NN	NN	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	leukemic	_	JJ	JJ	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	lines	_	NNS	NNS	_	3	PMOD	_	_
8	U-937	_	NN	NN	_	7	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	HL-60	_	NN	NN	_	8	COORD	_	_
11	by	_	IN	IN	_	2	NMOD	_	_
12	12-O-tetradecanoylphorbol-13-acetate	_	NN	NN	_	11	PMOD	_	_
13	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	accompanied	_	VBN	VBN	_	13	VC	_	_
15	by	_	IN	IN	_	14	LGS	_	_
16	marked	_	JJ	JJ	_	17	NMOD	_	_
17	changes	_	NNS	NNS	_	15	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	gene	_	NN	NN	_	20	NMOD	_	_
20	expression	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	13	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	expression	_	NN	NN	_	17	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	jun	_	NN	NN	_	16	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	fos	_	NN	NN	_	11	COORD	_	_
14	gene	_	NN	NN	_	16	NMOD	_	_
15	family	_	NN	NN	_	16	NMOD	_	_
16	members	_	NNS	NNS	_	10	PMOD	_	_
17	is	_	VBZ	VBZ	_	7	VMOD	_	_
18	induced	_	VBN	VBN	_	17	VC	_	_
19	with	_	IN	IN	_	18	ADV	_	_
20	variable	_	JJ	JJ	_	21	NMOD	_	_
21	kinetics	_	NNS	NNS	_	19	PMOD	_	_
22	during	_	IN	IN	_	18	TMP	_	_
23	12-O-tetradecanoylphorbol-13-acetate	_	NN	NN	_	25	NMOD	_	_
24	induced	_	VBD	VBD	_	23	AMOD	_	_
25	differentiation	_	NN	NN	_	22	PMOD	_	_
26	,	_	,	,	_	18	P	_	_
27	with	_	IN	IN	_	18	ADV	_	_
28	c-jun	_	NN	NN	_	29	NMOD	_	_
29	expression	_	NN	NN	_	32	SBJ	_	_
30	best	_	RB	RB	_	32	ADV	_	_
31	paralleling	_	JJ	JJ	_	32	VMOD	_	_
32	differentiation	_	NN	NN	_	27	PMOD	_	_
33	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	generation	_	NN	NN	_	15	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	AP-1	_	NN	NN	_	5	NMOD	_	_
5	complexes	_	NNS	NNS	_	3	PMOD	_	_
6	,	_	,	,	_	2	P	_	_
7	as	_	IN	IN	_	2	NMOD	_	_
8	measured	_	VBN	VBN	_	7	VMOD	_	_
9	by	_	IN	IN	_	8	ADV	_	_
10	DNA	_	NN	NN	_	12	NMOD	_	_
11	binding	_	NN	NN	_	12	NMOD	_	_
12	activity	_	NN	NN	_	9	PMOD	_	_
13	,	_	,	,	_	2	P	_	_
14	closely	_	RB	RB	_	15	ADV	_	_
15	parallels	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	morphological	_	JJ	JJ	_	17	NMOD	_	_
17	differentiation	_	NN	NN	_	15	OBJ	_	_
18	.	_	.	.	_	15	P	_	_

1	Furthermore	_	RB	RB	_	12	ADV	_	_
2	,	_	,	,	_	12	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	ability	_	NN	NN	_	12	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	these	_	DT	DT	_	7	NMOD	_	_
7	complexes	_	NNS	NNS	_	5	PMOD	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	regulate	_	VB	VB	_	4	NMOD	_	_
10	gene	_	NN	NN	_	11	NMOD	_	_
11	expression	_	NN	NN	_	9	OBJ	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	demonstrated	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	increased	_	VBN	VBN	_	16	NMOD	_	_
16	transcription	_	NN	NN	_	14	PMOD	_	_
17	from	_	IN	IN	_	16	NMOD	_	_
18	an	_	DT	DT	_	22	NMOD	_	_
19	AP-1	_	NN	NN	_	22	NMOD	_	_
20	driven	_	VBN	VBN	_	19	AMOD	_	_
21	reporter	_	NN	NN	_	22	NMOD	_	_
22	construct	_	NN	NN	_	17	PMOD	_	_
23	and	_	CC	CC	_	16	CC	_	_
24	marked	_	JJ	JJ	_	25	NMOD	_	_
25	increases	_	NNS	NNS	_	16	COORD	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	expression	_	NN	NN	_	26	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	endogenous	_	JJ	JJ	_	33	NMOD	_	_
31	AP-1	_	NN	NN	_	33	NMOD	_	_
32	regulated	_	JJ	JJ	_	33	NMOD	_	_
33	genes	_	NNS	NNS	_	29	PMOD	_	_
34	.	_	.	.	_	12	P	_	_

1	Differentiation	_	NN	NN	_	2	NMOD	_	_
2	assays	_	NNS	NNS	_	8	SBJ	_	_
3	using	_	VBG	VBG	_	2	NMOD	_	_
4	water	_	NN	NN	_	7	NMOD	_	_
5	soluble	_	JJ	JJ	_	4	AMOD	_	_
6	phorbol	_	NN	NN	_	7	NMOD	_	_
7	esters	_	NNS	NNS	_	3	OBJ	_	_
8	reveal	_	VBP	VBP	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	differentiation	_	NN	NN	_	11	SBJ	_	_
11	becomes	_	VBZ	VBZ	_	9	VMOD	_	_
12	irreversible	_	JJ	JJ	_	11	PRD	_	_
13	soon	_	RB	RB	_	11	TMP	_	_
14	after	_	IN	IN	_	13	TMP	_	_
15	AP-1	_	NN	NN	_	16	SBJ	_	_
16	appears	_	VBZ	VBZ	_	14	VMOD	_	_
17	.	_	.	.	_	8	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	tight	_	JJ	JJ	_	3	NMOD	_	_
3	correlation	_	NN	NN	_	16	SBJ	_	_
4	between	_	IN	IN	_	3	NMOD	_	_
5	c-jun	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	4	PMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	generation	_	NN	NN	_	6	COORD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	AP-1	_	NN	NN	_	12	NMOD	_	_
12	activity	_	NN	NN	_	10	PMOD	_	_
13	,	_	,	,	_	6	P	_	_
14	and	_	CC	CC	_	6	CC	_	_
15	differentiation	_	NN	NN	_	6	COORD	_	_
16	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	critical	_	JJ	JJ	_	19	NMOD	_	_
19	role	_	NN	NN	_	16	OBJ	_	_
20	for	_	IN	IN	_	19	NMOD	_	_
21	this	_	DT	DT	_	25	NMOD	_	_
22	gene	_	NN	NN	_	25	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	transcriptional	_	JJ	JJ	_	22	COORD	_	_
25	complex	_	NN	NN	_	20	PMOD	_	_
26	during	_	IN	IN	_	19	TMP	_	_
27	this	_	DT	DT	_	28	NMOD	_	_
28	process	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	cellular	_	JJ	JJ	_	4	NMOD	_	_
3	oncogene	_	NN	NN	_	4	NMOD	_	_
4	c-myb	_	NN	NN	_	5	SBJ	_	_
5	can	_	MD	MD	_	0	ROOT-S	_	_
6	interact	_	VB	VB	_	5	VC	_	_
7	synergistically	_	RB	RB	_	6	ADV	_	_
8	with	_	IN	IN	_	6	ADV	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	Epstein-Barr	_	JJ	JJ	_	13	NMOD	_	_
11	virus	_	NN	NN	_	13	NMOD	_	_
12	BZLF1	_	NN	NN	_	13	NMOD	_	_
13	transactivator	_	NN	NN	_	8	PMOD	_	_
14	in	_	IN	IN	_	6	ADV	_	_
15	lymphoid	_	JJ	JJ	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	.	_	.	.	_	5	P	_	_

1	Regulation	_	NN	NN	_	13	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	replicative	_	JJ	JJ	_	4	NMOD	_	_
4	functions	_	NNS	NNS	_	2	PMOD	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	12	NMOD	_	_
7	Epstein-Barr	_	JJ	JJ	_	8	NMOD	_	_
8	virus	_	NN	NN	_	12	NMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	EBV	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	genome	_	NN	NN	_	5	PMOD	_	_
13	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	mediated	_	VBN	VBN	_	13	VC	_	_
15	through	_	IN	IN	_	14	ADV	_	_
16	activation	_	NN	NN	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	a	_	DT	DT	_	22	NMOD	_	_
19	virally	_	RB	RB	_	20	AMOD	_	_
20	encoded	_	VBN	VBN	_	22	NMOD	_	_
21	transcription	_	NN	NN	_	22	NMOD	_	_
22	factor	_	NN	NN	_	17	PMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	Z	_	NN	NN	_	22	NMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	BZLF1	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	.	_	.	.	_	13	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	shown	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	Z	_	NN	NN	_	8	NMOD	_	_
7	gene	_	NN	NN	_	8	NMOD	_	_
8	product	_	NN	NN	_	25	SBJ	_	_
9	,	_	,	,	_	8	P	_	_
10	which	_	WDT	WDT	_	11	SBJ	_	_
11	binds	_	VBZ	VBZ	_	8	NMOD	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	AP-1	_	NN	NN	_	14	NMOD	_	_
14	sites	_	NNS	NNS	_	12	PMOD	_	_
15	as	_	IN	IN	_	11	ADV	_	_
16	a	_	DT	DT	_	17	NMOD	_	_
17	homodimer	_	NN	NN	_	15	PMOD	_	_
18	and	_	CC	CC	_	11	CC	_	_
19	has	_	VBZ	VBZ	_	11	COORD	_	_
20	sequence	_	NN	NN	_	21	NMOD	_	_
21	similarity	_	NN	NN	_	19	OBJ	_	_
22	to	_	TO	TO	_	21	NMOD	_	_
23	c-Fos	_	NN	NN	_	22	PMOD	_	_
24	,	_	,	,	_	8	P	_	_
25	can	_	MD	MD	_	4	VMOD	_	_
26	efficiently	_	RB	RB	_	25	ADV	_	_
27	activate	_	VB	VB	_	25	VC	_	_
28	the	_	DT	DT	_	31	NMOD	_	_
29	EBV	_	NN	NN	_	31	NMOD	_	_
30	early	_	JJ	JJ	_	31	NMOD	_	_
31	promoter	_	NN	NN	_	27	OBJ	_	_
32	,	_	,	,	_	31	P	_	_
33	BMRF1	_	NN	NN	_	31	NMOD	_	_
34	,	_	,	,	_	31	P	_	_
35	in	_	IN	IN	_	27	ADV	_	_
36	certain	_	JJ	JJ	_	38	NMOD	_	_
37	cell	_	NN	NN	_	38	NMOD	_	_
38	types	_	NNS	NNS	_	35	PMOD	_	_
39	(	_	(	(	_	43	P	_	_
40	i.e.	_	FW	FW	_	43	NMOD	_	_
41	,	_	,	,	_	43	P	_	_
42	HeLa	_	NN	NN	_	43	NMOD	_	_
43	cells	_	NNS	NNS	_	38	PRN	_	_
44	)	_	)	)	_	43	P	_	_
45	but	_	CC	CC	_	38	CC	_	_
46	not	_	RB	RB	_	45	COORD	_	_
47	others	_	NNS	NNS	_	38	COORD	_	_
48	(	_	(	(	_	52	P	_	_
49	i.e.	_	FW	FW	_	52	NMOD	_	_
50	,	_	,	,	_	52	P	_	_
51	Jurkat	_	NN	NN	_	52	NMOD	_	_
52	cells	_	NNS	NNS	_	47	PRN	_	_
53	)	_	)	)	_	52	P	_	_
54	.	_	.	.	_	2	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	c-myb	_	NN	NN	_	8	NMOD	_	_
7	proto-oncogene	_	NN	NN	_	8	NMOD	_	_
8	product	_	NN	NN	_	20	SBJ	_	_
9	,	_	,	,	_	8	P	_	_
10	which	_	WDT	WDT	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	8	NMOD	_	_
12	itself	_	PRP	PRP	_	11	VMOD	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	DNA-binding	_	JJ	JJ	_	15	NMOD	_	_
15	protein	_	NN	NN	_	11	PRD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	transcriptional	_	JJ	JJ	_	18	NMOD	_	_
18	transactivator	_	NN	NN	_	15	COORD	_	_
19	,	_	,	,	_	8	P	_	_
20	can	_	MD	MD	_	4	VMOD	_	_
21	interact	_	VB	VB	_	20	VC	_	_
22	synergistically	_	RB	RB	_	21	ADV	_	_
23	with	_	IN	IN	_	21	ADV	_	_
24	Z	_	NN	NN	_	23	PMOD	_	_
25	in	_	IN	IN	_	21	ADV	_	_
26	activating	_	VBG	VBG	_	25	PMOD	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	BMRF1	_	NN	NN	_	29	NMOD	_	_
29	promoter	_	NN	NN	_	26	OBJ	_	_
30	in	_	IN	IN	_	26	ADV	_	_
31	Jurkat	_	NN	NN	_	32	NMOD	_	_
32	cells	_	NNS	NNS	_	30	PMOD	_	_
33	(	_	(	(	_	36	P	_	_
34	a	_	DT	DT	_	36	NMOD	_	_
35	T-cell	_	NN	NN	_	36	NMOD	_	_
36	line	_	NN	NN	_	32	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	or	_	CC	CC	_	32	CC	_	_
39	Raji	_	NN	NN	_	40	NMOD	_	_
40	cells	_	NNS	NNS	_	32	COORD	_	_
41	(	_	(	(	_	44	P	_	_
42	an	_	DT	DT	_	44	NMOD	_	_
43	EBV-positive	_	JJ	JJ	_	44	NMOD	_	_
44	B-cell	_	NN	NN	_	40	PRN	_	_
45	)	_	)	)	_	44	P	_	_
46	,	_	,	,	_	3	P	_	_
47	whereas	_	IN	IN	_	3	COORD	_	_
48	the	_	DT	DT	_	51	NMOD	_	_
49	c-myb	_	NN	NN	_	51	NMOD	_	_
50	gene	_	NN	NN	_	51	NMOD	_	_
51	product	_	NN	NN	_	54	SBJ	_	_
52	by	_	IN	IN	_	51	NMOD	_	_
53	itself	_	PRP	PRP	_	52	PMOD	_	_
54	has	_	VBZ	VBZ	_	3	COORD	_	_
55	little	_	JJ	JJ	_	56	NMOD	_	_
56	effect	_	NN	NN	_	54	OBJ	_	_
57	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	simian	_	JJ	JJ	_	6	NMOD	_	_
3	virus	_	NN	NN	_	6	NMOD	_	_
4	40	_	CD	CD	_	6	NMOD	_	_
5	early	_	JJ	JJ	_	6	NMOD	_	_
6	promoter	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	also	_	RB	RB	_	7	ADV	_	_
9	synergistically	_	RB	RB	_	7	ADV	_	_
10	activated	_	VBN	VBN	_	7	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	Z\/c-myb	_	NN	NN	_	14	NMOD	_	_
14	combination	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	7	P	_	_

1	Synergistic	_	JJ	JJ	_	2	NMOD	_	_
2	transactivation	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	BMRF1	_	NN	NN	_	6	NMOD	_	_
6	promoter	_	NN	NN	_	3	PMOD	_	_
7	by	_	IN	IN	_	2	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	Z\/c-myb	_	NN	NN	_	10	NMOD	_	_
10	combination	_	NN	NN	_	7	PMOD	_	_
11	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	involve	_	VB	VB	_	11	OBJ	_	_
14	direct	_	JJ	JJ	_	15	NMOD	_	_
15	binding	_	NN	NN	_	13	OBJ	_	_
16	by	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	Z	_	NN	NN	_	19	NMOD	_	_
19	protein	_	NN	NN	_	16	PMOD	_	_
20	but	_	CC	CC	_	19	CC	_	_
21	not	_	RB	RB	_	20	COORD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	c-myb	_	NN	NN	_	24	NMOD	_	_
24	protein	_	NN	NN	_	19	COORD	_	_
25	.	_	.	.	_	11	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	30-bp	_	JJ	JJ	_	3	NMOD	_	_
3	sequence	_	NN	NN	_	20	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	BMRF1	_	NN	NN	_	7	NMOD	_	_
7	promoter	_	NN	NN	_	4	PMOD	_	_
8	which	_	WDT	WDT	_	9	SBJ	_	_
9	contains	_	VBZ	VBZ	_	7	NMOD	_	_
10	a	_	DT	DT	_	13	NMOD	_	_
11	Z	_	NN	NN	_	13	NMOD	_	_
12	binding	_	NN	NN	_	13	NMOD	_	_
13	site	_	NN	NN	_	9	OBJ	_	_
14	(	_	(	(	_	18	P	_	_
15	a	_	DT	DT	_	18	NMOD	_	_
16	consensus	_	NN	NN	_	18	NMOD	_	_
17	AP-1	_	NN	NN	_	18	NMOD	_	_
18	site	_	NN	NN	_	13	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
21	sufficient	_	JJ	JJ	_	20	PRD	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	transfer	_	VB	VB	_	21	AMOD	_	_
24	high-level	_	JJ	JJ	_	26	NMOD	_	_
25	lymphoid-specific	_	JJ	JJ	_	26	NMOD	_	_
26	responsiveness	_	NN	NN	_	23	OBJ	_	_
27	to	_	TO	TO	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	Z\/c-myb	_	NN	NN	_	30	NMOD	_	_
30	combination	_	NN	NN	_	27	PMOD	_	_
31	to	_	TO	TO	_	23	ADV	_	_
32	a	_	DT	DT	_	34	NMOD	_	_
33	heterologous	_	JJ	JJ	_	34	NMOD	_	_
34	promoter	_	NN	NN	_	31	PMOD	_	_
35	.	_	.	.	_	20	P	_	_

1	That	_	IN	IN	_	19	SBJ	_	_
2	the	_	DT	DT	_	5	NMOD	_	_
3	c-myb	_	NN	NN	_	5	NMOD	_	_
4	oncogene	_	NN	NN	_	5	NMOD	_	_
5	product	_	NN	NN	_	6	SBJ	_	_
6	can	_	MD	MD	_	1	VMOD	_	_
7	interact	_	VB	VB	_	6	VC	_	_
8	synergistically	_	RB	RB	_	7	ADV	_	_
9	with	_	IN	IN	_	7	ADV	_	_
10	an	_	DT	DT	_	12	NMOD	_	_
11	EBV-encoded	_	JJ	JJ	_	12	NMOD	_	_
12	member	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	leucine	_	NN	NN	_	18	NMOD	_	_
16	zipper	_	NN	NN	_	18	NMOD	_	_
17	protein	_	NN	NN	_	18	NMOD	_	_
18	family	_	NN	NN	_	13	PMOD	_	_
19	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
20	c-myb	_	NN	NN	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	19	OBJ	_	_
22	likely	_	JJ	JJ	_	21	PRD	_	_
23	to	_	TO	TO	_	24	VMOD	_	_
24	engage	_	VB	VB	_	22	AMOD	_	_
25	in	_	IN	IN	_	24	ADV	_	_
26	similar	_	JJ	JJ	_	27	NMOD	_	_
27	interactions	_	NNS	NNS	_	25	PMOD	_	_
28	with	_	IN	IN	_	27	NMOD	_	_
29	cellularly	_	RB	RB	_	30	AMOD	_	_
30	encoded	_	VBN	VBN	_	32	NMOD	_	_
31	transcription	_	NN	NN	_	32	NMOD	_	_
32	factors	_	NNS	NNS	_	28	PMOD	_	_
33	.	_	.	.	_	19	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	29-kDa	_	JJ	JJ	_	3	NMOD	_	_
3	proteins	_	NNS	NNS	_	9	SBJ	_	_
4	phosphorylated	_	VBN	VBN	_	3	NMOD	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	thrombin-activated	_	JJ	JJ	_	8	NMOD	_	_
7	human	_	JJ	JJ	_	8	NMOD	_	_
8	platelets	_	NNS	NNS	_	5	PMOD	_	_
9	are	_	VBP	VBP	_	0	ROOT-S	_	_
10	forms	_	NNS	NNS	_	9	PRD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	18	NMOD	_	_
13	estrogen	_	NN	NN	_	18	NMOD	_	_
14	receptor-related	_	JJ	JJ	_	13	AMOD	_	_
15	27-kDa	_	JJ	JJ	_	18	NMOD	_	_
16	heat	_	NN	NN	_	18	NMOD	_	_
17	shock	_	NN	NN	_	18	NMOD	_	_
18	protein	_	NN	NN	_	11	PMOD	_	_
19	.	_	.	.	_	9	P	_	_

1	Thrombin	_	NN	NN	_	2	SBJ	_	_
2	plays	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	critical	_	JJ	JJ	_	5	NMOD	_	_
5	role	_	NN	NN	_	2	OBJ	_	_
6	in	_	IN	IN	_	2	ADV	_	_
7	platelet	_	NN	NN	_	8	NMOD	_	_
8	activation	_	NN	NN	_	6	PMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	hemostasis	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	8	P	_	_
12	and	_	CC	CC	_	8	CC	_	_
13	thrombosis	_	NN	NN	_	8	COORD	_	_
14	.	_	.	.	_	2	P	_	_

1	Cellular	_	JJ	JJ	_	2	NMOD	_	_
2	activation	_	NN	NN	_	5	SBJ	_	_
3	by	_	IN	IN	_	2	NMOD	_	_
4	thrombin	_	NN	NN	_	3	PMOD	_	_
5	leads	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	phosphorylation	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	multiple	_	JJ	JJ	_	11	NMOD	_	_
11	proteins	_	NNS	NNS	_	9	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	most	_	JJS	JJS	_	14	NMOD	_	_
14	of	_	IN	IN	_	16	SBJ	_	_
15	which	_	WDT	WDT	_	14	PMOD	_	_
16	are	_	VBP	VBP	_	11	NMOD	_	_
17	unidentified	_	JJ	JJ	_	16	PRD	_	_
18	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	characterized	_	VBN	VBN	_	2	VC	_	_
4	several	_	JJ	JJ	_	6	NMOD	_	_
5	29-kDa	_	JJ	JJ	_	6	NMOD	_	_
6	proteins	_	NNS	NNS	_	3	OBJ	_	_
7	that	_	WDT	WDT	_	8	SBJ	_	_
8	are	_	VBP	VBP	_	6	NMOD	_	_
9	rapidly	_	RB	RB	_	8	TMP	_	_
10	phosphorylated	_	VBN	VBN	_	8	VC	_	_
11	following	_	VBG	VBG	_	10	TMP	_	_
12	exposure	_	NN	NN	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	intact	_	JJ	JJ	_	16	NMOD	_	_
15	human	_	JJ	JJ	_	16	NMOD	_	_
16	platelets	_	NNS	NNS	_	13	PMOD	_	_
17	to	_	TO	TO	_	12	NMOD	_	_
18	thrombin	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	murine	_	JJ	JJ	_	4	NMOD	_	_
3	monoclonal	_	JJ	JJ	_	4	NMOD	_	_
4	antibody	_	NN	NN	_	14	SBJ	_	_
5	raised	_	VBN	VBN	_	4	NMOD	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	an	_	DT	DT	_	12	NMOD	_	_
8	unidentified	_	JJ	JJ	_	12	NMOD	_	_
9	estrogen	_	NN	NN	_	12	NMOD	_	_
10	receptor-related	_	JJ	JJ	_	9	AMOD	_	_
11	29-kDa	_	JJ	JJ	_	12	NMOD	_	_
12	protein	_	NN	NN	_	6	PMOD	_	_
13	selectively	_	RB	RB	_	14	ADV	_	_
14	recognized	_	VBD	VBD	_	0	ROOT-S	_	_
15	these	_	DT	DT	_	16	NMOD	_	_
16	proteins	_	NNS	NNS	_	14	OBJ	_	_
17	as	_	RB	RB	_	16	CC	_	_
18	well	_	RB	RB	_	17	DEP	_	_
19	as	_	IN	IN	_	17	DEP	_	_
20	a	_	DT	DT	_	26	NMOD	_	_
21	more	_	RBR	RBR	_	22	AMOD	_	_
22	basic	_	JJ	JJ	_	26	NMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	unphosphorylated	_	JJ	JJ	_	22	COORD	_	_
25	27-kDa	_	JJ	JJ	_	26	NMOD	_	_
26	protein	_	NN	NN	_	16	COORD	_	_
27	.	_	.	.	_	14	P	_	_

1	Cellular	_	JJ	JJ	_	2	NMOD	_	_
2	activation	_	NN	NN	_	5	SBJ	_	_
3	by	_	IN	IN	_	2	NMOD	_	_
4	thrombin	_	NN	NN	_	3	PMOD	_	_
5	led	_	VBN	VBN	_	0	ROOT-S	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	marked	_	JJ	JJ	_	9	NMOD	_	_
9	shift	_	NN	NN	_	6	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	proportion	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	protein	_	NN	NN	_	13	PMOD	_	_
15	from	_	IN	IN	_	9	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	27-kDa	_	JJ	JJ	_	19	NMOD	_	_
18	unphosphorylated	_	JJ	JJ	_	19	NMOD	_	_
19	form	_	NN	NN	_	15	PMOD	_	_
20	to	_	TO	TO	_	9	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	29-kDa	_	JJ	JJ	_	24	NMOD	_	_
23	phosphoprotein	_	NN	NN	_	24	NMOD	_	_
24	species	_	NNS	NNS	_	20	PMOD	_	_
25	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	29-kDa	_	JJ	JJ	_	3	NMOD	_	_
3	proteins	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	confirmed	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	be	_	VB	VB	_	5	OBJ	_	_
8	phosphorylated	_	VBN	VBN	_	9	NMOD	_	_
9	forms	_	NNS	NNS	_	7	PRD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	HSP27	_	NN	NN	_	10	PMOD	_	_
12	by	_	IN	IN	_	5	LGS	_	_
13	immunoprecipitation	_	NN	NN	_	14	NMOD	_	_
14	studies	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	Thus	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	"	_	``	``	_	7	P	_	_
5	estrogen	_	NN	NN	_	7	NMOD	_	_
6	receptor-related	_	JJ	JJ	_	5	AMOD	_	_
7	protein	_	NN	NN	_	9	SBJ	_	_
8	"	_	''	''	_	7	P	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	HSP27	_	NN	NN	_	9	PRD	_	_
11	,	_	,	,	_	9	P	_	_
12	and	_	CC	CC	_	9	CC	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	three	_	CD	CD	_	17	NMOD	_	_
15	major	_	JJ	JJ	_	17	NMOD	_	_
16	29-kDa	_	JJ	JJ	_	17	NMOD	_	_
17	proteins	_	NNS	NNS	_	22	SBJ	_	_
18	phosphorylated	_	VBN	VBN	_	17	NMOD	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	thrombin-activated	_	JJ	JJ	_	21	NMOD	_	_
21	platelets	_	NNS	NNS	_	19	PMOD	_	_
22	are	_	VBP	VBP	_	9	COORD	_	_
23	forms	_	NNS	NNS	_	22	PRD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	HSP27	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	9	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	role	_	NN	NN	_	3	OBJ	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	HSP27	_	NN	NN	_	6	PMOD	_	_
8	in	_	IN	IN	_	5	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	signal	_	NN	NN	_	12	NMOD	_	_
11	transduction	_	NN	NN	_	12	NMOD	_	_
12	events	_	NNS	NNS	_	8	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	platelet	_	NN	NN	_	15	NMOD	_	_
15	activation	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	High	_	JJ	JJ	_	3	NMOD	_	_
2	affinity	_	NN	NN	_	3	NMOD	_	_
3	aldosterone	_	NN	NN	_	0	ROOT-S	_	_
4	binding	_	VBG	VBG	_	3	NMOD	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	plasma	_	NN	NN	_	9	NMOD	_	_
7	membrane	_	NN	NN	_	9	NMOD	_	_
8	rich	_	JJ	JJ	_	9	NMOD	_	_
9	fractions	_	NNS	NNS	_	5	PMOD	_	_
10	from	_	IN	IN	_	9	NMOD	_	_
11	mononuclear	_	JJ	JJ	_	12	NMOD	_	_
12	leukocytes	_	NNS	NNS	_	10	PMOD	_	_
13	:	_	:	:	_	3	P	_	_
14	is	_	VBZ	VBZ	_	3	VMOD	_	_
15	there	_	EX	EX	_	14	SBJ	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	membrane	_	NN	NN	_	18	NMOD	_	_
18	receptor	_	NN	NN	_	14	PRD	_	_
19	for	_	IN	IN	_	18	NMOD	_	_
20	mineralocorticoids	_	NNS	NNS	_	19	PMOD	_	_
21	?	_	.	.	_	14	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	vitro	_	FW	FW	_	3	NMOD	_	_
3	effects	_	NNS	NNS	_	22	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	aldosterone	_	NN	NN	_	4	PMOD	_	_
6	on	_	IN	IN	_	3	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	intracellular	_	JJ	JJ	_	9	NMOD	_	_
9	concentrations	_	NNS	NNS	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	sodium	_	NN	NN	_	10	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	potassium	_	NN	NN	_	11	COORD	_	_
14	and	_	CC	CC	_	11	CC	_	_
15	calcium	_	NN	NN	_	11	COORD	_	_
16	,	_	,	,	_	3	P	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	volume	_	NN	NN	_	3	COORD	_	_
19	and	_	CC	CC	_	3	CC	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	sodium-proton-antiport	_	NN	NN	_	3	COORD	_	_
22	have	_	VBP	VBP	_	0	ROOT-S	_	_
23	been	_	VBN	VBN	_	22	VC	_	_
24	described	_	VBN	VBN	_	23	VC	_	_
25	in	_	IN	IN	_	24	ADV	_	_
26	intact	_	JJ	JJ	_	29	NMOD	_	_
27	human	_	JJ	JJ	_	29	NMOD	_	_
28	mononuclear	_	JJ	JJ	_	29	NMOD	_	_
29	leukocytes	_	NNS	NNS	_	25	PMOD	_	_
30	(	_	(	(	_	31	P	_	_
31	HML	_	NN	NN	_	29	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	.	_	.	.	_	22	P	_	_

1	In	_	IN	IN	_	20	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	present	_	JJ	JJ	_	4	NMOD	_	_
4	paper	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	20	P	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	binding	_	NN	NN	_	20	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	-LCB-125I-RCB--labeled	_	JJ	JJ	_	11	NMOD	_	_
11	aldosterone	_	NN	NN	_	8	PMOD	_	_
12	derivative	_	JJ	JJ	_	11	NMOD	_	_
13	to	_	TO	TO	_	7	NMOD	_	_
14	plasma	_	NN	NN	_	15	NMOD	_	_
15	membrane	_	NN	NN	_	16	AMOD	_	_
16	rich	_	JJ	JJ	_	17	NMOD	_	_
17	fractions	_	NNS	NNS	_	13	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	HML	_	NN	NN	_	18	PMOD	_	_
20	was	_	VBD	VBD	_	0	ROOT-S	_	_
21	studied	_	VBN	VBN	_	20	VC	_	_
22	.	_	.	.	_	20	P	_	_

1	High	_	JJ	JJ	_	3	NMOD	_	_
2	affinity	_	NN	NN	_	3	NMOD	_	_
3	binding	_	NN	NN	_	15	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	radioligand	_	NN	NN	_	4	PMOD	_	_
7	with	_	IN	IN	_	3	NMOD	_	_
8	an	_	DT	DT	_	10	NMOD	_	_
9	apparent	_	JJ	JJ	_	10	NMOD	_	_
10	Kd	_	NN	NN	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	approximately	_	RB	RB	_	14	NMOD	_	_
13	0.1	_	CD	CD	_	12	DEP	_	_
14	nM	_	NN	NN	_	11	PMOD	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	found	_	VBN	VBN	_	15	VC	_	_
17	.	_	.	.	_	15	P	_	_

1	Aldosterone	_	NN	NN	_	2	SBJ	_	_
2	displaced	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	tracer	_	NN	NN	_	2	OBJ	_	_
5	at	_	IN	IN	_	2	ADV	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	similar	_	JJ	JJ	_	8	NMOD	_	_
8	Kd	_	NN	NN	_	5	PMOD	_	_
9	.	_	.	.	_	2	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	canrenone	_	NN	NN	_	5	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	cortisol	_	NN	NN	_	2	COORD	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	inactive	_	JJ	JJ	_	5	PRD	_	_
7	as	_	IN	IN	_	5	ADV	_	_
8	ligands	_	NNS	NNS	_	7	PMOD	_	_
9	up	_	RB	RB	_	10	DEP	_	_
10	to	_	TO	TO	_	5	ADV	_	_
11	concentrations	_	NNS	NNS	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	0.1	_	CD	CD	_	14	NMOD	_	_
14	microM	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	first	_	JJ	JJ	_	3	PRD	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	demonstrate	_	VB	VB	_	5	NMOD	_	_
8	membrane	_	NN	NN	_	10	NMOD	_	_
9	binding	_	NN	NN	_	10	NMOD	_	_
10	sites	_	NNS	NNS	_	7	OBJ	_	_
11	with	_	IN	IN	_	10	NMOD	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	high	_	JJ	JJ	_	14	NMOD	_	_
14	affinity	_	NN	NN	_	11	PMOD	_	_
15	for	_	IN	IN	_	10	NMOD	_	_
16	aldosterone	_	NN	NN	_	15	PMOD	_	_
17	,	_	,	,	_	15	P	_	_
18	but	_	CC	CC	_	15	CC	_	_
19	not	_	RB	RB	_	20	DEP	_	_
20	for	_	IN	IN	_	15	COORD	_	_
21	cortisol	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	perfectly	_	RB	RB	_	5	AMOD	_	_
5	compatible	_	JJ	JJ	_	3	PRD	_	_
6	with	_	IN	IN	_	5	AMOD	_	_
7	major	_	JJ	JJ	_	8	NMOD	_	_
8	properties	_	NNS	NNS	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	steroidal	_	JJ	JJ	_	11	NMOD	_	_
11	effects	_	NNS	NNS	_	9	PMOD	_	_
12	on	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	sodium-proton-antiport	_	NN	NN	_	12	PMOD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	HML	_	NN	NN	_	15	PMOD	_	_
17	and	_	CC	CC	_	3	CC	_	_
18	thus	_	RB	RB	_	3	COORD	_	_
19	very	_	RB	RB	_	21	ADV	_	_
20	likely	_	RB	RB	_	19	AMOD	_	_
21	represent	_	VBP	VBP	_	3	COORD	_	_
22	membrane	_	NN	NN	_	23	NMOD	_	_
23	receptors	_	NNS	NNS	_	21	OBJ	_	_
24	for	_	IN	IN	_	23	NMOD	_	_
25	aldosterone	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	Transcription	_	NN	NN	_	3	NMOD	_	_
2	factor	_	NN	NN	_	3	NMOD	_	_
3	requirements	_	NNS	NNS	_	0	ROOT-FRAG	_	_
4	for	_	IN	IN	_	3	NMOD	_	_
5	U2	_	NN	NN	_	8	NMOD	_	_
6	snRNA-encoding	_	JJ	JJ	_	5	AMOD	_	_
7	gene	_	NN	NN	_	8	NMOD	_	_
8	activation	_	NN	NN	_	4	PMOD	_	_
9	in	_	IN	IN	_	3	NMOD	_	_
10	B	_	NN	NN	_	12	NMOD	_	_
11	lymphoid	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	PMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	Transcription	_	NN	NN	_	17	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	13	NMOD	_	_
4	human	_	JJ	JJ	_	13	NMOD	_	_
5	U2	_	NN	NN	_	10	AMOD	_	_
6	small	_	JJ	JJ	_	10	AMOD	_	_
7	nuclear	_	JJ	JJ	_	10	AMOD	_	_
8	RNA	_	NN	NN	_	10	AMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	snRNA	_	NN	NN	_	13	NMOD	_	_
11	)	_	)	)	_	10	P	_	_
12	-encoding	_	JJ	JJ	_	10	AMOD	_	_
13	gene	_	NN	NN	_	2	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	HeLa	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	a	_	DT	DT	_	21	NMOD	_	_
19	distal	_	JJ	JJ	_	21	NMOD	_	_
20	enhancer	_	NN	NN	_	21	NMOD	_	_
21	element	_	NN	NN	_	17	OBJ	_	_
22	,	_	,	,	_	21	P	_	_
23	which	_	WDT	WDT	_	24	SBJ	_	_
24	is	_	VBZ	VBZ	_	21	NMOD	_	_
25	composed	_	VBN	VBN	_	24	VC	_	_
26	of	_	IN	IN	_	25	ADV	_	_
27	one	_	CD	CD	_	29	NMOD	_	_
28	octamer	_	NN	NN	_	29	NMOD	_	_
29	motif	_	NN	NN	_	26	PMOD	_	_
30	(	_	(	(	_	31	P	_	_
31	Oct	_	NN	NN	_	29	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	and	_	CC	CC	_	29	CC	_	_
34	three	_	CD	CD	_	37	NMOD	_	_
35	Sp	_	NN	NN	_	37	NMOD	_	_
36	1-binding	_	JJ	JJ	_	35	AMOD	_	_
37	sites	_	NNS	NNS	_	29	COORD	_	_
38	.	_	.	.	_	17	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	study	_	VB	VB	_	14	ADV	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	transcription	_	NN	NN	_	6	NMOD	_	_
5	factor	_	NN	NN	_	6	NMOD	_	_
6	requirement	_	NN	NN	_	2	OBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	B-cells	_	NNS	NNS	_	7	PMOD	_	_
9	,	_	,	,	_	14	P	_	_
10	different	_	JJ	JJ	_	13	NMOD	_	_
11	U2	_	NN	NN	_	13	NMOD	_	_
12	enhancer	_	NN	NN	_	13	NMOD	_	_
13	constructions	_	NNS	NNS	_	14	SBJ	_	_
14	were	_	VBD	VBD	_	0	ROOT-S	_	_
15	transfected	_	VBN	VBN	_	14	VC	_	_
16	into	_	IN	IN	_	15	ADV	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	lymphoid	_	JJ	JJ	_	20	NMOD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	line	_	NN	NN	_	16	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	BJA-B	_	NN	NN	_	20	NMOD	_	_
23	.	_	.	.	_	14	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	showed	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	activation	_	NN	NN	_	14	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	U2	_	NN	NN	_	10	NMOD	_	_
9	snRNA	_	NN	NN	_	10	NMOD	_	_
10	transcription	_	NN	NN	_	7	PMOD	_	_
11	in	_	IN	IN	_	6	NMOD	_	_
12	B-cells	_	NNS	NNS	_	11	PMOD	_	_
13	also	_	RB	RB	_	14	ADV	_	_
14	requires	_	VBZ	VBZ	_	4	VMOD	_	_
15	an	_	DT	DT	_	16	NMOD	_	_
16	enhancer	_	NN	NN	_	14	OBJ	_	_
17	comprising	_	VBG	VBG	_	16	NMOD	_	_
18	both	_	CC	CC	_	20	CC	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	Oct	_	NN	NN	_	17	OBJ	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	at	_	IN	IN	_	24	DEP	_	_
23	least	_	JJS	JJS	_	24	DEP	_	_
24	one	_	CD	CD	_	27	NMOD	_	_
25	Sp	_	NN	NN	_	27	NMOD	_	_
26	1-binding	_	JJ	JJ	_	25	AMOD	_	_
27	site	_	NN	NN	_	20	COORD	_	_
28	.	_	.	.	_	3	P	_	_

1	Deletion	_	NN	NN	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	all	_	PDT	PDT	_	7	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	Sp	_	NN	NN	_	7	NMOD	_	_
6	1-binding	_	JJ	JJ	_	5	AMOD	_	_
7	sites	_	NNS	NNS	_	2	PMOD	_	_
8	from	_	IN	IN	_	1	NMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	enhancer	_	NN	NN	_	8	PMOD	_	_
11	reduces	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	transcription	_	NN	NN	_	11	OBJ	_	_
13	by	_	IN	IN	_	11	ADV	_	_
14	80-90	_	CD	CD	_	15	NMOD	_	_
15	%	_	NN	NN	_	13	PMOD	_	_
16	in	_	IN	IN	_	11	ADV	_	_
17	HeLa	_	NN	NN	_	16	PMOD	_	_
18	,	_	,	,	_	16	P	_	_
19	as	_	RB	RB	_	16	CC	_	_
20	well	_	RB	RB	_	19	DEP	_	_
21	as	_	IN	IN	_	19	DEP	_	_
22	in	_	IN	IN	_	16	COORD	_	_
23	BJA-B	_	NN	NN	_	22	PMOD	_	_
24	cells	_	NNS	NNS	_	17	NMOD	_	_
25	,	_	,	,	_	11	P	_	_
26	whereas	_	IN	IN	_	11	COORD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	removal	_	NN	NN	_	33	SBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	octamer-binding	_	JJ	JJ	_	32	NMOD	_	_
32	site	_	NN	NN	_	29	PMOD	_	_
33	reduces	_	VBZ	VBZ	_	11	COORD	_	_
34	transcription	_	NN	NN	_	33	OBJ	_	_
35	to	_	TO	TO	_	33	ADV	_	_
36	levels	_	NNS	NNS	_	35	PMOD	_	_
37	below	_	IN	IN	_	36	NMOD	_	_
38	detection	_	NN	NN	_	37	PMOD	_	_
39	in	_	IN	IN	_	33	ADV	_	_
40	both	_	DT	DT	_	42	NMOD	_	_
41	cell	_	NN	NN	_	42	NMOD	_	_
42	types	_	NNS	NNS	_	39	PMOD	_	_
43	.	_	.	.	_	11	P	_	_

1	Enhancers	_	NNS	NNS	_	6	SBJ	_	_
2	containing	_	VBG	VBG	_	1	NMOD	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	single	_	JJ	JJ	_	5	NMOD	_	_
5	Oct	_	NN	NN	_	2	OBJ	_	_
6	have	_	VBP	VBP	_	0	ROOT-S	_	_
7	,	_	,	,	_	6	P	_	_
8	nevertheless	_	RB	RB	_	6	ADV	_	_
9	,	_	,	,	_	6	P	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	capacity	_	NN	NN	_	6	OBJ	_	_
12	to	_	TO	TO	_	14	VMOD	_	_
13	partially	_	RB	RB	_	14	ADV	_	_
14	activate	_	VB	VB	_	11	NMOD	_	_
15	U2	_	NN	NN	_	17	NMOD	_	_
16	snRNA	_	NN	NN	_	17	NMOD	_	_
17	transcription	_	NN	NN	_	14	OBJ	_	_
18	in	_	IN	IN	_	6	ADV	_	_
19	both	_	DT	DT	_	21	NMOD	_	_
20	HeLa	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	18	PMOD	_	_
22	,	_	,	,	_	21	P	_	_
23	in	_	IN	IN	_	28	ADV	_	_
24	which	_	WDT	WDT	_	23	PMOD	_	_
25	only	_	RB	RB	_	26	NMOD	_	_
26	OTF-1	_	NN	NN	_	27	SBJ	_	_
27	is	_	VBZ	VBZ	_	21	NMOD	_	_
28	expressed	_	VBN	VBN	_	27	VC	_	_
29	,	_	,	,	_	18	P	_	_
30	and	_	CC	CC	_	18	CC	_	_
31	in	_	IN	IN	_	18	COORD	_	_
32	BJA-B	_	NN	NN	_	33	NMOD	_	_
33	cells	_	NNS	NNS	_	31	PMOD	_	_
34	in	_	IN	IN	_	37	ADV	_	_
35	which	_	WDT	WDT	_	34	PMOD	_	_
36	OTF-2	_	NN	NN	_	37	SBJ	_	_
37	is	_	VBZ	VBZ	_	33	NMOD	_	_
38	the	_	DT	DT	_	42	NMOD	_	_
39	predominantly	_	RB	RB	_	40	AMOD	_	_
40	expressed	_	VBN	VBN	_	42	NMOD	_	_
41	octamer-binding	_	JJ	JJ	_	42	NMOD	_	_
42	factor	_	NN	NN	_	37	PRD	_	_
43	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	most	_	RBS	RBS	_	3	AMOD	_	_
3	likely	_	JJ	JJ	_	4	NMOD	_	_
4	interpretation	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	our	_	PRP$	PRP$	_	7	NMOD	_	_
7	results	_	NNS	NNS	_	5	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	PRD	_	_
10	both	_	CC	CC	_	14	CC	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	ubiquitous	_	JJ	JJ	_	14	NMOD	_	_
13	transcription	_	NN	NN	_	14	NMOD	_	_
14	factor	_	NN	NN	_	26	SBJ	_	_
15	,	_	,	,	_	14	P	_	_
16	OTF-1	_	NN	NN	_	14	NMOD	_	_
17	,	_	,	,	_	14	P	_	_
18	and	_	CC	CC	_	14	CC	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	B-cell-specific	_	JJ	JJ	_	22	NMOD	_	_
21	transcription	_	NN	NN	_	22	NMOD	_	_
22	factor	_	NN	NN	_	14	COORD	_	_
23	,	_	,	,	_	22	P	_	_
24	OTF-2	_	NN	NN	_	22	NMOD	_	_
25	,	_	,	,	_	22	P	_	_
26	can	_	MD	MD	_	9	VMOD	_	_
27	activate	_	VB	VB	_	26	VC	_	_
28	U2	_	NN	NN	_	30	NMOD	_	_
29	snRNA	_	NN	NN	_	30	NMOD	_	_
30	transcription	_	NN	NN	_	27	OBJ	_	_
31	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	4	SBJ	_	_
3	also	_	RB	RB	_	4	ADV	_	_
4	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	similar	_	JJ	JJ	_	8	NMOD	_	_
7	functional	_	JJ	JJ	_	8	NMOD	_	_
8	cooperation	_	NN	NN	_	4	OBJ	_	_
9	between	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	transcription	_	NN	NN	_	12	NMOD	_	_
12	factors	_	NNS	NNS	_	9	PMOD	_	_
13	which	_	WDT	WDT	_	14	SBJ	_	_
14	bind	_	VBP	VBP	_	12	NMOD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	Oct	_	NN	NN	_	15	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	the	_	DT	DT	_	17	NMOD	_	_
20	adjacent	_	JJ	JJ	_	17	NMOD	_	_
21	Sp	_	NN	NN	_	17	NMOD	_	_
22	1-binding	_	JJ	JJ	_	21	AMOD	_	_
23	site	_	NN	NN	_	17	NMOD	_	_
24	in	_	IN	IN	_	14	ADV	_	_
25	BJA-B	_	NN	NN	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	24	PMOD	_	_
27	,	_	,	,	_	14	P	_	_
28	as	_	IN	IN	_	14	ADV	_	_
29	has	_	VBZ	VBZ	_	28	VMOD	_	_
30	been	_	VBN	VBN	_	29	VC	_	_
31	observed	_	VBN	VBN	_	30	VC	_	_
32	in	_	IN	IN	_	31	ADV	_	_
33	HeLa	_	NN	NN	_	34	NMOD	_	_
34	cells	_	NNS	NNS	_	32	PMOD	_	_
35	,	_	,	,	_	4	P	_	_
36	since	_	IN	IN	_	4	ADV	_	_
37	a	_	DT	DT	_	38	NMOD	_	_
38	template	_	NN	NN	_	47	SBJ	_	_
39	which	_	WDT	WDT	_	40	SBJ	_	_
40	contains	_	VBZ	VBZ	_	38	NMOD	_	_
41	a	_	DT	DT	_	44	NMOD	_	_
42	weak	_	JJ	JJ	_	44	NMOD	_	_
43	binding	_	VBG	VBG	_	44	NMOD	_	_
44	site	_	NN	NN	_	40	OBJ	_	_
45	for	_	IN	IN	_	44	NMOD	_	_
46	OTFs	_	NNS	NNS	_	45	PMOD	_	_
47	expresses	_	VBZ	VBZ	_	36	VMOD	_	_
48	wild-type	_	JJ	JJ	_	49	NMOD	_	_
49	levels	_	NNS	NNS	_	47	OBJ	_	_
50	of	_	IN	IN	_	49	NMOD	_	_
51	U2	_	NN	NN	_	52	NMOD	_	_
52	snRNA	_	NN	NN	_	50	PMOD	_	_
53	in	_	IN	IN	_	47	ADV	_	_
54	both	_	DT	DT	_	56	NMOD	_	_
55	cell	_	NN	NN	_	56	NMOD	_	_
56	types	_	NNS	NNS	_	53	PMOD	_	_
57	when	_	WRB	WRB	_	63	ADV	_	_
58	the	_	DT	DT	_	61	NMOD	_	_
59	weak	_	JJ	JJ	_	61	NMOD	_	_
60	octamer-binding	_	JJ	JJ	_	61	NMOD	_	_
61	site	_	NN	NN	_	62	SBJ	_	_
62	is	_	VBZ	VBZ	_	47	TMP	_	_
63	combined	_	VBN	VBN	_	62	VC	_	_
64	with	_	IN	IN	_	63	ADV	_	_
65	a	_	DT	DT	_	68	NMOD	_	_
66	Sp	_	NN	NN	_	68	NMOD	_	_
67	1-binding	_	JJ	JJ	_	66	AMOD	_	_
68	site	_	NN	NN	_	64	PMOD	_	_
69	.	_	.	.	_	4	P	_	_

1	Cortisol	_	NN	NN	_	3	NMOD	_	_
2	receptor	_	NN	NN	_	3	NMOD	_	_
3	resistance	_	NN	NN	_	0	ROOT-FRAG	_	_
4	:	_	:	:	_	3	P	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	variability	_	NN	NN	_	3	NMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	its	_	PRP$	PRP$	_	10	NMOD	_	_
9	clinical	_	JJ	JJ	_	10	NMOD	_	_
10	presentation	_	NN	NN	_	7	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	response	_	NN	NN	_	10	COORD	_	_
13	to	_	TO	TO	_	12	NMOD	_	_
14	treatment	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	6	P	_	_

1	Primary	_	JJ	JJ	_	7	NMOD	_	_
2	(	_	(	(	_	7	P	_	_
3	partial	_	JJ	JJ	_	7	NMOD	_	_
4	)	_	)	)	_	7	P	_	_
5	cortisol	_	NN	NN	_	7	NMOD	_	_
6	receptor	_	NN	NN	_	7	NMOD	_	_
7	resistance	_	NN	NN	_	8	SBJ	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	previously	_	RB	RB	_	8	TMP	_	_
10	reported	_	VBN	VBN	_	8	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	a	_	DT	DT	_	13	NMOD	_	_
13	total	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	7	_	CD	CD	_	16	NMOD	_	_
16	patients	_	NNS	NNS	_	14	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	14	_	CD	CD	_	21	NMOD	_	_
19	asymptomatic	_	JJ	JJ	_	21	NMOD	_	_
20	family	_	NN	NN	_	21	NMOD	_	_
21	members	_	NNS	NNS	_	16	COORD	_	_
22	.	_	.	.	_	8	P	_	_

1	Its	_	PRP$	PRP$	_	2	NMOD	_	_
2	occurrence	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	considered	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	be	_	VB	VB	_	4	OBJ	_	_
7	extremely	_	RB	RB	_	8	AMOD	_	_
8	rare	_	JJ	JJ	_	6	PRD	_	_
9	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	present	_	JJ	JJ	_	4	NMOD	_	_
4	study	_	NN	NN	_	1	PMOD	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	report	_	VBP	VBP	_	0	ROOT-S	_	_
7	on	_	IN	IN	_	6	ADV	_	_
8	6	_	CD	CD	_	9	NMOD	_	_
9	patients	_	NNS	NNS	_	7	PMOD	_	_
10	(	_	(	(	_	12	P	_	_
11	2	_	CD	CD	_	12	NMOD	_	_
12	males	_	NNS	NNS	_	9	PRN	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	4	_	CD	CD	_	15	NMOD	_	_
15	females	_	NNS	NNS	_	12	COORD	_	_
16	)	_	)	)	_	12	P	_	_
17	with	_	IN	IN	_	9	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	syndrome	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	first	_	JJ	JJ	_	4	NMOD	_	_
3	male	_	JJ	JJ	_	4	NMOD	_	_
4	patient	_	NN	NN	_	5	SBJ	_	_
5	presented	_	VBD	VBD	_	0	ROOT-S	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	mild	_	JJ	JJ	_	8	NMOD	_	_
8	hypertension	_	NN	NN	_	6	PMOD	_	_
9	.	_	.	.	_	5	P	_	_

1	Hydrochlorothiazide	_	NN	NN	_	2	NMOD	_	_
2	therapy	_	NN	NN	_	3	SBJ	_	_
3	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	life-threatening	_	JJ	JJ	_	6	NMOD	_	_
6	hypokalemia	_	NN	NN	_	4	PMOD	_	_
7	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	second	_	JJ	JJ	_	4	NMOD	_	_
3	male	_	JJ	JJ	_	4	NMOD	_	_
4	patient	_	NN	NN	_	5	SBJ	_	_
5	had	_	VBD	VBD	_	0	ROOT-S	_	_
6	slight	_	JJ	JJ	_	7	NMOD	_	_
7	hypertension	_	NN	NN	_	5	OBJ	_	_
8	without	_	IN	IN	_	7	NMOD	_	_
9	hypokalemia	_	NN	NN	_	8	PMOD	_	_
10	.	_	.	.	_	5	P	_	_

1	All	_	DT	DT	_	4	NMOD	_	_
2	four	_	CD	CD	_	4	NMOD	_	_
3	female	_	JJ	JJ	_	4	NMOD	_	_
4	patients	_	NNS	NNS	_	5	SBJ	_	_
5	presented	_	VBD	VBD	_	0	ROOT-S	_	_
6	between	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	age	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	20-30	_	CD	CD	_	11	NMOD	_	_
11	yr	_	NN	NN	_	9	PMOD	_	_
12	with	_	IN	IN	_	5	ADV	_	_
13	acne	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	hirsutism	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	13	P	_	_
17	and	_	CC	CC	_	13	CC	_	_
18	irregular	_	JJ	JJ	_	19	NMOD	_	_
19	menstruations	_	NNS	NNS	_	13	COORD	_	_
20	.	_	.	.	_	5	P	_	_

1	Low	_	JJ	JJ	_	4	NMOD	_	_
2	dose	_	NN	NN	_	4	NMOD	_	_
3	dexamethasone	_	NN	NN	_	4	NMOD	_	_
4	therapy	_	NN	NN	_	9	SBJ	_	_
5	(	_	(	(	_	7	P	_	_
6	1-1.5	_	CD	CD	_	7	NMOD	_	_
7	mg\/day	_	NN	NN	_	4	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	of	_	IN	IN	_	9	PRD	_	_
11	clinical	_	JJ	JJ	_	12	NMOD	_	_
12	benefit	_	NN	NN	_	10	PMOD	_	_
13	in	_	IN	IN	_	9	ADV	_	_
14	these	_	DT	DT	_	15	NMOD	_	_
15	patients	_	NNS	NNS	_	13	PMOD	_	_
16	.	_	.	.	_	9	P	_	_

1	All	_	DT	DT	_	2	NMOD	_	_
2	patients	_	NNS	NNS	_	3	SBJ	_	_
3	showed	_	VBD	VBD	_	0	ROOT-S	_	_
4	insufficient	_	JJ	JJ	_	5	NMOD	_	_
5	suppression	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	serum	_	NN	NN	_	9	NMOD	_	_
8	cortisol	_	NN	NN	_	9	NMOD	_	_
9	concentrations	_	NNS	NNS	_	6	PMOD	_	_
10	in	_	IN	IN	_	3	ADV	_	_
11	the	_	DT	DT	_	15	NMOD	_	_
12	overnight	_	JJ	JJ	_	15	NMOD	_	_
13	1-mg	_	JJ	JJ	_	15	NMOD	_	_
14	dexamethasone	_	NN	NN	_	15	NMOD	_	_
15	test	_	NN	NN	_	10	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	diurnal	_	JJ	JJ	_	3	NMOD	_	_
3	rhythm	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	ACTH	_	NN	NN	_	4	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	cortisol	_	NN	NN	_	5	COORD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	intact	_	JJ	JJ	_	8	PRD	_	_
10	,	_	,	,	_	8	P	_	_
11	albeit	_	IN	IN	_	8	ADV	_	_
12	at	_	IN	IN	_	11	PMOD	_	_
13	an	_	DT	DT	_	15	NMOD	_	_
14	elevated	_	JJ	JJ	_	15	NMOD	_	_
15	level	_	NN	NN	_	12	PMOD	_	_
16	.	_	.	.	_	8	P	_	_

1	There	_	EX	EX	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	normal	_	JJ	JJ	_	5	NMOD	_	_
5	increase	_	NN	NN	_	6	PRD	_	_
6	in	_	IN	IN	_	2	VMOD	_	_
7	ACTH	_	NN	NN	_	6	PMOD	_	_
8	,	_	,	,	_	7	P	_	_
9	cortisol	_	NN	NN	_	7	COORD	_	_
10	,	_	,	,	_	7	P	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	GH	_	NN	NN	_	7	COORD	_	_
13	(	_	(	(	_	2	P	_	_
14	except	_	IN	IN	_	2	ADV	_	_
15	in	_	IN	IN	_	14	PMOD	_	_
16	one	_	CD	CD	_	18	NMOD	_	_
17	obese	_	JJ	JJ	_	18	NMOD	_	_
18	patient	_	NN	NN	_	15	PMOD	_	_
19	)	_	)	)	_	2	P	_	_
20	in	_	IN	IN	_	2	ADV	_	_
21	response	_	NN	NN	_	20	DEP	_	_
22	to	_	TO	TO	_	20	DEP	_	_
23	insulin-induced	_	JJ	JJ	_	24	NMOD	_	_
24	hypoglycemia	_	NN	NN	_	20	PMOD	_	_
25	,	_	,	,	_	2	P	_	_
26	while	_	IN	IN	_	2	ADV	_	_
27	cortisol	_	NN	NN	_	28	NMOD	_	_
28	production	_	NN	NN	_	29	SBJ	_	_
29	was	_	VBD	VBD	_	26	VMOD	_	_
30	elevated	_	JJ	JJ	_	29	VC	_	_
31	in	_	IN	IN	_	30	ADV	_	_
32	three	_	CD	CD	_	33	NMOD	_	_
33	patients	_	NNS	NNS	_	31	PMOD	_	_
34	.	_	.	.	_	2	P	_	_

1	Circulating	_	VBG	VBG	_	4	NMOD	_	_
2	adrenal	_	JJ	JJ	_	4	NMOD	_	_
3	androgen	_	NN	NN	_	4	NMOD	_	_
4	levels	_	NNS	NNS	_	5	SBJ	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	increased	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	all	_	DT	DT	_	9	NMOD	_	_
9	patients	_	NNS	NNS	_	7	PMOD	_	_
10	.	_	.	.	_	5	P	_	_

1	Glucocorticoid	_	NN	NN	_	2	NMOD	_	_
2	receptors	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	investigated	_	VBN	VBN	_	3	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	a	_	DT	DT	_	11	NMOD	_	_
7	whole	_	JJ	JJ	_	11	NMOD	_	_
8	cell	_	NN	NN	_	11	NMOD	_	_
9	dexamethasone	_	NN	NN	_	11	NMOD	_	_
10	binding	_	NN	NN	_	11	NMOD	_	_
11	assay	_	NN	NN	_	5	PMOD	_	_
12	in	_	IN	IN	_	4	ADV	_	_
13	mononuclear	_	JJ	JJ	_	14	NMOD	_	_
14	leukocytes	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	the	_	DT	DT	_	5	NMOD	_	_
3	first	_	JJ	JJ	_	5	NMOD	_	_
4	male	_	JJ	JJ	_	5	NMOD	_	_
5	patient	_	NN	NN	_	1	PMOD	_	_
6	,	_	,	,	_	11	P	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	number	_	NN	NN	_	11	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	receptors	_	NNS	NNS	_	9	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	very	_	RB	RB	_	13	AMOD	_	_
13	low	_	JJ	JJ	_	11	PRD	_	_
14	,	_	,	,	_	11	P	_	_
15	while	_	IN	IN	_	11	ADV	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	affinity	_	NN	NN	_	18	SBJ	_	_
18	was	_	VBD	VBD	_	15	VMOD	_	_
19	lower	_	JJR	JJR	_	18	PRD	_	_
20	than	_	IN	IN	_	19	AMOD	_	_
21	that	_	DT	DT	_	20	PMOD	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	controls	_	NNS	NNS	_	22	PMOD	_	_
24	.	_	.	.	_	11	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	lowered	_	JJ	JJ	_	3	NMOD	_	_
3	affinity	_	NN	NN	_	6	SBJ	_	_
4	to	_	TO	TO	_	3	NMOD	_	_
5	dexamethasone	_	NN	NN	_	4	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	found	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	one	_	CD	CD	_	11	NMOD	_	_
10	female	_	JJ	JJ	_	11	NMOD	_	_
11	patient	_	NN	NN	_	8	PMOD	_	_
12	,	_	,	,	_	7	P	_	_
13	while	_	IN	IN	_	7	OBJ	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	lowered	_	JJ	JJ	_	16	NMOD	_	_
16	number	_	NN	NN	_	19	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	receptors	_	NNS	NNS	_	17	PMOD	_	_
19	was	_	VBD	VBD	_	13	VMOD	_	_
20	found	_	VBN	VBN	_	19	VC	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	three	_	CD	CD	_	23	NMOD	_	_
23	patients	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	the	_	DT	DT	_	5	NMOD	_	_
3	second	_	JJ	JJ	_	5	NMOD	_	_
4	male	_	JJ	JJ	_	5	NMOD	_	_
5	patient	_	NN	NN	_	1	PMOD	_	_
6	,	_	,	,	_	9	P	_	_
7	no	_	DT	DT	_	8	NMOD	_	_
8	abnormalities	_	NNS	NNS	_	9	SBJ	_	_
9	were	_	VBD	VBD	_	0	ROOT-S	_	_
10	found	_	VBN	VBN	_	9	VC	_	_
11	.	_	.	.	_	9	P	_	_

1	As	_	IN	IN	_	9	ADV	_	_
2	a	_	DT	DT	_	3	NMOD	_	_
3	bioassay	_	NN	NN	_	1	PMOD	_	_
4	for	_	IN	IN	_	3	NMOD	_	_
5	glucocorticoid	_	NN	NN	_	6	NMOD	_	_
6	action	_	NN	NN	_	4	PMOD	_	_
7	we	_	PRP	PRP	_	9	SBJ	_	_
8	also	_	RB	RB	_	9	ADV	_	_
9	measured	_	VBD	VBD	_	0	ROOT-S	_	_
10	dexamethasone	_	NN	NN	_	11	NMOD	_	_
11	suppressibility	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	mitogen-stimulated	_	JJ	JJ	_	14	NMOD	_	_
14	incorporation	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	-LCB-3H-RCB-thymidine	_	NN	NN	_	15	PMOD	_	_
17	in	_	IN	IN	_	14	NMOD	_	_
18	mononuclear	_	JJ	JJ	_	19	NMOD	_	_
19	leukocytes	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	9	P	_	_

1	In	_	IN	IN	_	15	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	male	_	JJ	JJ	_	4	NMOD	_	_
4	patient	_	NN	NN	_	1	PMOD	_	_
5	with	_	IN	IN	_	4	NMOD	_	_
6	normal	_	JJ	JJ	_	8	NMOD	_	_
7	receptor	_	NN	NN	_	8	NMOD	_	_
8	status	_	NN	NN	_	5	PMOD	_	_
9	,	_	,	,	_	15	P	_	_
10	dexamethasone	_	NN	NN	_	11	NMOD	_	_
11	suppressibility	_	NN	NN	_	15	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	-LCB-3H-RCB-thymidine	_	NN	NN	_	14	NMOD	_	_
14	incorporation	_	NN	NN	_	12	PMOD	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	significantly	_	RB	RB	_	17	AMOD	_	_
17	lower	_	JJR	JJR	_	15	PRD	_	_
18	than	_	IN	IN	_	17	AMOD	_	_
19	that	_	DT	DT	_	18	PMOD	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	healthy	_	JJ	JJ	_	22	NMOD	_	_
22	controls	_	NNS	NNS	_	20	PMOD	_	_
23	with	_	IN	IN	_	15	ADV	_	_
24	respect	_	NN	NN	_	23	DEP	_	_
25	to	_	TO	TO	_	23	DEP	_	_
26	both	_	CC	CC	_	28	CC	_	_
27	maximal	_	JJ	JJ	_	28	NMOD	_	_
28	suppression	_	NN	NN	_	23	PMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	IC50	_	NN	NN	_	28	COORD	_	_
31	.	_	.	.	_	15	P	_	_

1	Partial	_	JJ	JJ	_	4	NMOD	_	_
2	cortisol	_	NN	NN	_	4	NMOD	_	_
3	receptor	_	NN	NN	_	4	NMOD	_	_
4	resistance	_	NN	NN	_	5	SBJ	_	_
5	might	_	MD	MD	_	0	ROOT-S	_	_
6	be	_	VB	VB	_	5	VC	_	_
7	less	_	RBR	RBR	_	8	AMOD	_	_
8	rare	_	JJ	JJ	_	6	PRD	_	_
9	than	_	IN	IN	_	8	AMOD	_	_
10	previously	_	RB	RB	_	11	TMP	_	_
11	thought	_	VBN	VBN	_	9	VMOD	_	_
12	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	six	_	CD	CD	_	4	NMOD	_	_
4	patients	_	NNS	NNS	_	1	PMOD	_	_
5	presented	_	VBN	VBN	_	4	NMOD	_	_
6	,	_	,	,	_	12	P	_	_
7	at	_	IN	IN	_	9	DEP	_	_
8	least	_	JJS	JJS	_	9	DEP	_	_
9	three	_	CD	CD	_	11	NMOD	_	_
10	different	_	JJ	JJ	_	11	NMOD	_	_
11	forms	_	NNS	NNS	_	12	SBJ	_	_
12	can	_	MD	MD	_	0	ROOT-S	_	_
13	be	_	VB	VB	_	12	VC	_	_
14	recognized	_	VBN	VBN	_	13	VC	_	_
15	.	_	.	.	_	12	P	_	_

1	Therapy	_	NN	NN	_	4	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	dexamethasone	_	NN	NN	_	2	PMOD	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	successful	_	JJ	JJ	_	4	PRD	_	_
6	in	_	IN	IN	_	4	ADV	_	_
7	female	_	JJ	JJ	_	8	NMOD	_	_
8	patients	_	NNS	NNS	_	6	PMOD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	acne	_	NN	NN	_	9	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	hirsutism	_	NN	NN	_	10	COORD	_	_
13	,	_	,	,	_	4	P	_	_
14	as	_	IN	IN	_	4	ADV	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	secondary	_	JJ	JJ	_	17	NMOD	_	_
17	increase	_	NN	NN	_	24	SBJ	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	production	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	adrenal	_	JJ	JJ	_	23	NMOD	_	_
23	androgens	_	NNS	NNS	_	21	PMOD	_	_
24	was	_	VBD	VBD	_	14	VMOD	_	_
25	effectively	_	RB	RB	_	24	ADV	_	_
26	controlled	_	VBN	VBN	_	24	VC	_	_
27	.	_	.	.	_	4	P	_	_

1	A	_	DT	DT	_	5	NMOD	_	_
2	novel	_	JJ	JJ	_	5	NMOD	_	_
3	mitogen-inducible	_	JJ	JJ	_	5	NMOD	_	_
4	gene	_	NN	NN	_	5	NMOD	_	_
5	product	_	NN	NN	_	10	SBJ	_	_
6	related	_	JJ	JJ	_	5	NMOD	_	_
7	to	_	TO	TO	_	6	AMOD	_	_
8	p50\/p105-NF-kappa	_	NN	NN	_	9	NMOD	_	_
9	B	_	NN	NN	_	7	PMOD	_	_
10	participates	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	transactivation	_	NN	NN	_	11	PMOD	_	_
13	through	_	IN	IN	_	10	ADV	_	_
14	a	_	DT	DT	_	17	NMOD	_	_
15	kappa	_	NN	NN	_	17	NMOD	_	_
16	B	_	NN	NN	_	17	NMOD	_	_
17	site	_	NN	NN	_	13	PMOD	_	_
18	.	_	.	.	_	10	P	_	_

1	A	_	DT	DT	_	8	NMOD	_	_
2	Rel-related	_	JJ	JJ	_	8	NMOD	_	_
3	,	_	,	,	_	2	P	_	_
4	mitogen-inducible	_	JJ	JJ	_	2	COORD	_	_
5	,	_	,	,	_	2	P	_	_
6	kappa	_	NN	NN	_	2	COORD	_	_
7	B-binding	_	JJ	JJ	_	6	AMOD	_	_
8	protein	_	NN	NN	_	9	SBJ	_	_
9	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	been	_	VBN	VBN	_	9	VC	_	_
11	cloned	_	VBN	VBN	_	10	VC	_	_
12	as	_	IN	IN	_	11	ADV	_	_
13	an	_	DT	DT	_	16	NMOD	_	_
14	immediate-early	_	JJ	JJ	_	16	NMOD	_	_
15	activation	_	NN	NN	_	16	NMOD	_	_
16	gene	_	NN	NN	_	12	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	human	_	JJ	JJ	_	22	NMOD	_	_
19	peripheral	_	JJ	JJ	_	22	NMOD	_	_
20	blood	_	NN	NN	_	22	NMOD	_	_
21	T	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	17	PMOD	_	_
23	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	cDNA	_	NN	NN	_	3	SBJ	_	_
3	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	an	_	DT	DT	_	7	NMOD	_	_
5	open	_	JJ	JJ	_	7	NMOD	_	_
6	reading	_	NN	NN	_	7	NMOD	_	_
7	frame	_	NN	NN	_	3	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	900	_	CD	CD	_	11	NMOD	_	_
10	amino	_	NN	NN	_	11	NMOD	_	_
11	acids	_	NNS	NNS	_	8	PMOD	_	_
12	capable	_	JJ	JJ	_	7	NMOD	_	_
13	of	_	IN	IN	_	12	AMOD	_	_
14	encoding	_	VBG	VBG	_	13	PMOD	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	97-kDa	_	JJ	JJ	_	17	NMOD	_	_
17	protein	_	NN	NN	_	14	OBJ	_	_
18	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	protein	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	most	_	RBS	RBS	_	5	AMOD	_	_
5	similar	_	JJ	JJ	_	3	PRD	_	_
6	to	_	TO	TO	_	5	AMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	105-kDa	_	JJ	JJ	_	10	NMOD	_	_
9	precursor	_	NN	NN	_	10	NMOD	_	_
10	polypeptide	_	NN	NN	_	6	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	p50-NF-kappa	_	NN	NN	_	13	NMOD	_	_
13	B	_	NN	NN	_	11	PMOD	_	_
14	.	_	.	.	_	3	P	_	_

1	Like	_	IN	IN	_	7	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	105-kDa	_	JJ	JJ	_	4	NMOD	_	_
4	precursor	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	it	_	PRP	PRP	_	7	SBJ	_	_
7	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	an	_	DT	DT	_	11	NMOD	_	_
9	amino-terminal	_	JJ	JJ	_	11	NMOD	_	_
10	Rel-related	_	JJ	JJ	_	11	NMOD	_	_
11	domain	_	NN	NN	_	7	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	about	_	IN	IN	_	14	DEP	_	_
14	300	_	CD	CD	_	16	NMOD	_	_
15	amino	_	NN	NN	_	16	NMOD	_	_
16	acids	_	NNS	NNS	_	12	PMOD	_	_
17	and	_	CC	CC	_	11	CC	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	carboxy-terminal	_	JJ	JJ	_	20	NMOD	_	_
20	domain	_	NN	NN	_	11	COORD	_	_
21	containing	_	VBG	VBG	_	20	NMOD	_	_
22	six	_	CD	CD	_	28	NMOD	_	_
23	full	_	JJ	JJ	_	25	NMOD	_	_
24	cell	_	NN	NN	_	25	NMOD	_	_
25	cycle	_	NN	NN	_	28	NMOD	_	_
26	or	_	CC	CC	_	25	CC	_	_
27	ankyrin	_	NN	NN	_	25	COORD	_	_
28	repeats	_	NNS	NNS	_	21	OBJ	_	_
29	.	_	.	.	_	7	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	vitro-translated	_	JJ	JJ	_	3	NMOD	_	_
3	proteins	_	NNS	NNS	_	16	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	truncated	_	VBN	VBN	_	3	NMOD	_	_
6	downstream	_	RB	RB	_	5	ADV	_	_
7	of	_	IN	IN	_	6	AMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	Rel	_	NN	NN	_	10	NMOD	_	_
10	domain	_	NN	NN	_	7	PMOD	_	_
11	and	_	CC	CC	_	5	CC	_	_
12	excluding	_	VBG	VBG	_	5	COORD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	repeats	_	NNS	NNS	_	12	OBJ	_	_
15	,	_	,	,	_	3	P	_	_
16	bind	_	VBP	VBP	_	0	ROOT-S	_	_
17	kappa	_	NN	NN	_	19	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	sites	_	NNS	NNS	_	16	OBJ	_	_
20	.	_	.	.	_	16	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	refer	_	VBP	VBP	_	0	ROOT-S	_	_
3	to	_	TO	TO	_	2	ADV	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	kappa	_	NN	NN	_	3	PMOD	_	_
6	B-binding	_	JJ	JJ	_	5	AMOD	_	_
7	,	_	,	,	_	5	P	_	_
8	truncated	_	VBN	VBN	_	9	NMOD	_	_
9	protein	_	NN	NN	_	5	NMOD	_	_
10	as	_	IN	IN	_	9	NMOD	_	_
11	p50B	_	NN	NN	_	10	PMOD	_	_
12	by	_	IN	IN	_	9	NMOD	_	_
13	analogy	_	NN	NN	_	12	PMOD	_	_
14	with	_	IN	IN	_	13	NMOD	_	_
15	p50-NF-kappa	_	NN	NN	_	16	NMOD	_	_
16	B	_	NN	NN	_	14	PMOD	_	_
17	and	_	CC	CC	_	3	CC	_	_
18	to	_	TO	TO	_	3	COORD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	full-length	_	JJ	JJ	_	21	NMOD	_	_
21	protein	_	NN	NN	_	18	PMOD	_	_
22	as	_	IN	IN	_	21	NMOD	_	_
23	p97	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	2	P	_	_

1	p50B	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	able	_	JJ	JJ	_	2	PRD	_	_
4	to	_	TO	TO	_	5	VMOD	_	_
5	form	_	VB	VB	_	3	AMOD	_	_
6	heteromeric	_	JJ	JJ	_	9	NMOD	_	_
7	kappa	_	NN	NN	_	9	NMOD	_	_
8	B-binding	_	JJ	JJ	_	7	AMOD	_	_
9	complexes	_	NNS	NNS	_	5	OBJ	_	_
10	with	_	IN	IN	_	5	ADV	_	_
11	RelB	_	NN	NN	_	10	PMOD	_	_
12	,	_	,	,	_	10	P	_	_
13	as	_	RB	RB	_	10	CC	_	_
14	well	_	RB	RB	_	13	DEP	_	_
15	as	_	IN	IN	_	13	DEP	_	_
16	with	_	IN	IN	_	10	COORD	_	_
17	p65	_	NN	NN	_	16	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	p50	_	NN	NN	_	17	COORD	_	_
20	,	_	,	,	_	17	P	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	two	_	CD	CD	_	23	NMOD	_	_
23	subunits	_	NNS	NNS	_	17	NMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	NF-kappa	_	NN	NN	_	26	NMOD	_	_
26	B	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	Transient-transfection	_	NN	NN	_	2	NMOD	_	_
2	experiments	_	NNS	NNS	_	7	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	embryonal	_	JJ	JJ	_	6	NMOD	_	_
5	carcinoma	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	3	PMOD	_	_
7	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	functional	_	JJ	JJ	_	10	NMOD	_	_
10	cooperation	_	NN	NN	_	7	OBJ	_	_
11	between	_	IN	IN	_	10	NMOD	_	_
12	p50B	_	NN	NN	_	11	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	RelB	_	NN	NN	_	12	COORD	_	_
15	or	_	CC	CC	_	14	CC	_	_
16	p65	_	NN	NN	_	14	COORD	_	_
17	in	_	IN	IN	_	10	NMOD	_	_
18	transactivation	_	NN	NN	_	17	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	reporter	_	NN	NN	_	22	NMOD	_	_
22	plasmid	_	NN	NN	_	19	PMOD	_	_
23	dependent	_	JJ	JJ	_	18	NMOD	_	_
24	on	_	IN	IN	_	23	AMOD	_	_
25	a	_	DT	DT	_	28	NMOD	_	_
26	kappa	_	NN	NN	_	28	NMOD	_	_
27	B	_	NN	NN	_	28	NMOD	_	_
28	site	_	NN	NN	_	24	PMOD	_	_
29	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	imply	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	existence	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	complex	_	JJ	JJ	_	9	NMOD	_	_
9	family	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	NF-kappa	_	NN	NN	_	14	NMOD	_	_
12	B-like	_	JJ	JJ	_	11	AMOD	_	_
13	transcription	_	NN	NN	_	14	NMOD	_	_
14	factors	_	NNS	NNS	_	10	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	{	_	(	(	_	2	P	_	_
2	Changes	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	leucocytic	_	JJ	JJ	_	7	NMOD	_	_
5	estrogen	_	NN	NN	_	7	NMOD	_	_
6	receptor	_	NN	NN	_	7	NMOD	_	_
7	levels	_	NNS	NNS	_	3	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	patients	_	NNS	NNS	_	8	PMOD	_	_
10	with	_	IN	IN	_	9	NMOD	_	_
11	climacteric	_	JJ	JJ	_	12	NMOD	_	_
12	syndrome	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	2	CC	_	_
14	therapeutic	_	JJ	JJ	_	15	NMOD	_	_
15	effect	_	NN	NN	_	2	COORD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	liuwei	_	FW	FW	_	19	NMOD	_	_
18	dihuang	_	FW	FW	_	19	NMOD	_	_
19	pills	_	NNS	NNS	_	16	PMOD	_	_
20	}	_	)	)	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	numbers	_	NNS	NNS	_	19	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	estrogen	_	NN	NN	_	5	NMOD	_	_
5	receptor	_	NN	NN	_	3	PMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	ER	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	in	_	IN	IN	_	5	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	peripheral	_	JJ	JJ	_	12	NMOD	_	_
12	leucocytes	_	NNS	NNS	_	9	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	22	_	CD	CD	_	15	NMOD	_	_
15	women	_	NNS	NNS	_	13	PMOD	_	_
16	with	_	IN	IN	_	15	NMOD	_	_
17	climacteric	_	JJ	JJ	_	18	NMOD	_	_
18	syndrome	_	NN	NN	_	16	PMOD	_	_
19	were	_	VBD	VBD	_	0	ROOT-S	_	_
20	measured	_	VBN	VBN	_	19	VC	_	_
21	by	_	IN	IN	_	20	ADV	_	_
22	radioligand	_	NN	NN	_	23	NMOD	_	_
23	method	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	19	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	compared	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	those	_	DT	DT	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	12	_	CD	CD	_	11	NMOD	_	_
9	normal	_	JJ	JJ	_	11	NMOD	_	_
10	child-bearing-age	_	JJ	JJ	_	11	NMOD	_	_
11	women	_	NNS	NNS	_	7	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	wat	_	VBD	VBD	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	contents	_	NNS	NNS	_	14	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	leucocytic	_	JJ	JJ	_	9	NMOD	_	_
9	ER	_	NN	NN	_	7	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	climacteric	_	JJ	JJ	_	13	NMOD	_	_
12	syndrome	_	NN	NN	_	13	NMOD	_	_
13	patients	_	NNS	NNS	_	10	PMOD	_	_
14	were	_	VBD	VBD	_	4	VMOD	_	_
15	significantly	_	RB	RB	_	16	AMOD	_	_
16	lower	_	JJR	JJR	_	14	PRD	_	_
17	than	_	IN	IN	_	16	AMOD	_	_
18	normal	_	JJ	JJ	_	20	NMOD	_	_
19	child-bearing-age	_	JJ	JJ	_	20	NMOD	_	_
20	women	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	authors	_	NNS	NNS	_	3	SBJ	_	_
3	used	_	VBD	VBD	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	Chinese	_	JJ	JJ	_	6	NMOD	_	_
6	prescription	_	NN	NN	_	3	IOBJ	_	_
7	--	_	:	:	_	6	P	_	_
8	Liuwei	_	FW	FW	_	10	NMOD	_	_
9	Dihuang	_	FW	FW	_	10	NMOD	_	_
10	Pills	_	NNS	NNS	_	6	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	LDP	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	treat	_	VB	VB	_	3	OBJ	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	patients	_	NNS	NNS	_	15	OBJ	_	_
18	for	_	IN	IN	_	15	TMP	_	_
19	2	_	CD	CD	_	20	NMOD	_	_
20	months	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	numbers	_	NNS	NNS	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	leucocytic	_	JJ	JJ	_	5	NMOD	_	_
5	ER	_	NN	NN	_	3	PMOD	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	significantly	_	RB	RB	_	6	ADV	_	_
8	increased	_	VBN	VBN	_	6	VC	_	_
9	after	_	IN	IN	_	8	TMP	_	_
10	treatment	_	NN	NN	_	9	PMOD	_	_
11	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	decrease	_	NN	NN	_	11	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	ER	_	NN	NN	_	8	NMOD	_	_
8	levels	_	NNS	NNS	_	6	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	cell	_	NN	NN	_	9	PMOD	_	_
11	may	_	MD	MD	_	4	VMOD	_	_
12	involve	_	VB	VB	_	11	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	pathogenesis	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	climacteric	_	JJ	JJ	_	18	NMOD	_	_
18	syndrome	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	LDP	_	NN	NN	_	4	SBJ	_	_
2	not	_	RB	RB	_	4	CC	_	_
3	only	_	RB	RB	_	2	DEP	_	_
4	increases	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	plasma	_	NN	NN	_	7	NMOD	_	_
6	estradiol	_	NN	NN	_	7	NMOD	_	_
7	levels	_	NNS	NNS	_	4	OBJ	_	_
8	,	_	,	,	_	4	P	_	_
9	but	_	CC	CC	_	4	CC	_	_
10	also	_	RB	RB	_	9	COORD	_	_
11	increases	_	VBZ	VBZ	_	4	COORD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	leucocytic	_	JJ	JJ	_	15	NMOD	_	_
14	ER	_	NN	NN	_	15	NMOD	_	_
15	levels	_	NNS	NNS	_	11	OBJ	_	_
16	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	may	_	MD	MD	_	0	ROOT-S	_	_
3	be	_	VB	VB	_	2	VC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	basis	_	NN	NN	_	3	PRD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	therapeutic	_	JJ	JJ	_	9	NMOD	_	_
9	effect	_	NN	NN	_	6	PMOD	_	_
10	on	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	disease	_	NN	NN	_	10	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	Activity	_	NN	NN	_	17	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	kappa	_	NN	NN	_	6	NMOD	_	_
5	B	_	NN	NN	_	6	NMOD	_	_
6	enhancer	_	NN	NN	_	2	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	interleukin-2	_	NN	NN	_	12	NMOD	_	_
10	receptor	_	NN	NN	_	12	NMOD	_	_
11	alpha	_	NN	NN	_	12	NMOD	_	_
12	chain	_	NN	NN	_	7	PMOD	_	_
13	in	_	IN	IN	_	1	NMOD	_	_
14	somatic	_	JJ	JJ	_	16	NMOD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	hybrids	_	NNS	NNS	_	13	PMOD	_	_
17	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	accompanied	_	VBN	VBN	_	17	VC	_	_
19	by	_	IN	IN	_	18	LGS	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	nuclear	_	JJ	JJ	_	22	NMOD	_	_
22	localization	_	NN	NN	_	19	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	NF-kappa	_	NN	NN	_	25	NMOD	_	_
25	B	_	NN	NN	_	23	PMOD	_	_
26	.	_	.	.	_	17	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	two	_	CD	CD	_	6	NMOD	_	_
3	nuclear	_	JJ	JJ	_	6	NMOD	_	_
4	proteins	_	NNS	NNS	_	6	NMOD	_	_
5	NF-kappa	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	32	SBJ	_	_
7	(	_	(	(	_	6	P	_	_
8	consisting	_	VBG	VBG	_	6	NMOD	_	_
9	of	_	IN	IN	_	8	ADV	_	_
10	subunits	_	NNS	NNS	_	9	PMOD	_	_
11	p50	_	NN	NN	_	10	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	p65	_	NN	NN	_	11	COORD	_	_
14	)	_	)	)	_	6	P	_	_
15	and	_	CC	CC	_	6	CC	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	DNA-binding	_	JJ	JJ	_	18	NMOD	_	_
18	subunit	_	NN	NN	_	6	COORD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	NF-kappa	_	NN	NN	_	21	NMOD	_	_
21	B	_	NN	NN	_	19	PMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	p50	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	by	_	IN	IN	_	18	NMOD	_	_
26	itself	_	PRP	PRP	_	25	PMOD	_	_
27	,	_	,	,	_	18	P	_	_
28	also	_	RB	RB	_	29	ADV	_	_
29	called	_	VBN	VBN	_	18	NMOD	_	_
30	KBF1	_	NN	NN	_	29	OBJ	_	_
31	,	_	,	,	_	6	P	_	_
32	are	_	VBP	VBP	_	0	ROOT-S	_	_
33	constitutively	_	RB	RB	_	32	ADV	_	_
34	expressed	_	VBN	VBN	_	32	VC	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	localized	_	JJ	JJ	_	34	COORD	_	_
37	in	_	IN	IN	_	34	ADV	_	_
38	the	_	DT	DT	_	39	NMOD	_	_
39	nucleus	_	NN	NN	_	37	PMOD	_	_
40	of	_	IN	IN	_	37	PMOD	_	_
41	the	_	DT	DT	_	45	NMOD	_	_
42	human	_	JJ	JJ	_	45	NMOD	_	_
43	T-cell	_	NN	NN	_	45	NMOD	_	_
44	line	_	NN	NN	_	45	NMOD	_	_
45	IARC	_	NN	NN	_	40	PMOD	_	_
46	301.5	_	CD	CD	_	45	NMOD	_	_
47	.	_	.	.	_	32	P	_	_

1	In	_	IN	IN	_	25	ADV	_	_
2	order	_	NN	NN	_	1	VMOD	_	_
3	to	_	TO	TO	_	1	VMOD	_	_
4	define	_	VB	VB	_	1	VMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	roles	_	NNS	NNS	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	these	_	DT	DT	_	10	NMOD	_	_
9	two	_	CD	CD	_	10	NMOD	_	_
10	factors	_	NNS	NNS	_	7	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	which	_	WDT	WDT	_	13	SBJ	_	_
13	bind	_	VBP	VBP	_	10	NMOD	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	same	_	JJ	JJ	_	19	NMOD	_	_
17	kappa	_	NN	NN	_	19	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	enhancers	_	NNS	NNS	_	14	PMOD	_	_
20	,	_	,	,	_	25	P	_	_
21	in	_	IN	IN	_	25	ADV	_	_
22	transcription	_	NN	NN	_	23	NMOD	_	_
23	activation	_	NN	NN	_	21	PMOD	_	_
24	we	_	PRP	PRP	_	25	SBJ	_	_
25	have	_	VBP	VBP	_	0	ROOT-S	_	_
26	prepared	_	VBN	VBN	_	25	VC	_	_
27	somatic	_	JJ	JJ	_	29	NMOD	_	_
28	cell	_	NN	NN	_	29	NMOD	_	_
29	hybrids	_	NNS	NNS	_	26	OBJ	_	_
30	between	_	IN	IN	_	29	NMOD	_	_
31	IARC	_	NN	NN	_	30	PMOD	_	_
32	301.5	_	CD	CD	_	31	NMOD	_	_
33	and	_	CC	CC	_	31	CC	_	_
34	a	_	DT	DT	_	36	NMOD	_	_
35	murine	_	JJ	JJ	_	36	NMOD	_	_
36	myeloma	_	NN	NN	_	31	COORD	_	_
37	.	_	.	.	_	25	P	_	_

1	Most	_	JJS	JJS	_	2	NMOD	_	_
2	hybrids	_	NNS	NNS	_	3	SBJ	_	_
3	express	_	VBP	VBP	_	0	ROOT-S	_	_
4	both	_	CC	CC	_	5	CC	_	_
5	KBF1	_	NN	NN	_	3	OBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	NF-kappa	_	NN	NN	_	8	NMOD	_	_
8	B	_	NN	NN	_	5	COORD	_	_
9	in	_	IN	IN	_	3	ADV	_	_
10	their	_	PRP$	PRP$	_	11	NMOD	_	_
11	nuclei	_	NNS	NNS	_	9	PMOD	_	_
12	,	_	,	,	_	3	P	_	_
13	but	_	CC	CC	_	3	CC	_	_
14	one	_	CD	CD	_	15	NMOD	_	_
15	hybrid	_	NN	NN	_	16	SBJ	_	_
16	expresses	_	VBZ	VBZ	_	3	COORD	_	_
17	only	_	RB	RB	_	18	NMOD	_	_
18	KBF1	_	NN	NN	_	16	OBJ	_	_
19	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	kappa	_	NN	NN	_	4	NMOD	_	_
3	B	_	NN	NN	_	4	NMOD	_	_
4	enhancer	_	NN	NN	_	21	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	gene	_	NN	NN	_	5	PMOD	_	_
8	encoding	_	VBG	VBG	_	7	NMOD	_	_
9	the	_	DT	DT	_	16	NMOD	_	_
10	interleukin-2	_	NN	NN	_	16	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	IL-2	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	receptor	_	NN	NN	_	16	NMOD	_	_
15	alpha	_	NN	NN	_	16	NMOD	_	_
16	chain	_	NN	NN	_	8	OBJ	_	_
17	(	_	(	(	_	19	P	_	_
18	IL-2R	_	NN	NN	_	19	NMOD	_	_
19	alpha	_	NN	NN	_	16	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
22	functional	_	JJ	JJ	_	21	PRD	_	_
23	only	_	RB	RB	_	24	DEP	_	_
24	in	_	IN	IN	_	21	ADV	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	hybrids	_	NNS	NNS	_	24	PMOD	_	_
27	expressing	_	VBG	VBG	_	26	NMOD	_	_
28	nuclear	_	JJ	JJ	_	30	NMOD	_	_
29	NF-kappa	_	NN	NN	_	30	NMOD	_	_
30	B	_	NN	NN	_	27	OBJ	_	_
31	.	_	.	.	_	21	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	nuclear	_	JJ	JJ	_	7	NMOD	_	_
6	NF-kappa	_	NN	NN	_	7	NMOD	_	_
7	B	_	NN	NN	_	8	SBJ	_	_
8	is	_	VBZ	VBZ	_	4	VMOD	_	_
9	necessary	_	JJ	JJ	_	8	PRD	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	activate	_	VB	VB	_	9	AMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	kappa	_	NN	NN	_	15	NMOD	_	_
14	B	_	NN	NN	_	15	NMOD	_	_
15	enhancer	_	NN	NN	_	11	OBJ	_	_
16	,	_	,	,	_	8	P	_	_
17	while	_	IN	IN	_	8	ADV	_	_
18	KBF1	_	NN	NN	_	21	SBJ	_	_
19	by	_	IN	IN	_	18	NMOD	_	_
20	itself	_	PRP	PRP	_	19	PMOD	_	_
21	is	_	VBZ	VBZ	_	17	VMOD	_	_
22	not	_	RB	RB	_	21	VMOD	_	_
23	sufficient	_	JJ	JJ	_	21	PRD	_	_
24	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	propose	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	KBF1	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	3	VMOD	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	competitive	_	JJ	JJ	_	8	NMOD	_	_
8	inhibitor	_	NN	NN	_	5	PRD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	NF-kappa	_	NN	NN	_	11	NMOD	_	_
11	B	_	NN	NN	_	9	PMOD	_	_
12	and	_	CC	CC	_	2	CC	_	_
13	discuss	_	VB	VB	_	2	COORD	_	_
14	how	_	WRB	WRB	_	19	ADV	_	_
15	these	_	DT	DT	_	16	NMOD	_	_
16	factors	_	NNS	NNS	_	17	SBJ	_	_
17	may	_	MD	MD	_	13	OBJ	_	_
18	be	_	VB	VB	_	17	VC	_	_
19	involved	_	VBN	VBN	_	18	VC	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	transient	_	JJ	JJ	_	23	NMOD	_	_
23	expression	_	NN	NN	_	20	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	IL-2	_	NN	NN	_	29	NMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	IL-2	_	NN	NN	_	28	NMOD	_	_
28	alpha	_	NN	NN	_	25	COORD	_	_
29	genes	_	NNS	NNS	_	24	PMOD	_	_
30	during	_	IN	IN	_	23	TMP	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	immune	_	JJ	JJ	_	33	NMOD	_	_
33	response	_	NN	NN	_	30	PMOD	_	_
34	.	_	.	.	_	2	P	_	_

1	Influence	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	estradiol	_	NN	NN	_	2	PMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	tamoxifen	_	NN	NN	_	3	COORD	_	_
6	on	_	IN	IN	_	1	NMOD	_	_
7	susceptibility	_	NN	NN	_	6	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	human	_	JJ	JJ	_	13	NMOD	_	_
10	breast	_	NN	NN	_	13	NMOD	_	_
11	cancer	_	NN	NN	_	13	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	lines	_	NNS	NNS	_	8	PMOD	_	_
14	to	_	TO	TO	_	7	NMOD	_	_
15	lysis	_	NN	NN	_	14	PMOD	_	_
16	by	_	IN	IN	_	15	NMOD	_	_
17	lymphokine-activated	_	JJ	JJ	_	19	NMOD	_	_
18	killer	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	design	_	NN	NN	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	combination	_	NN	NN	_	8	NMOD	_	_
5	hormonal	_	JJ	JJ	_	8	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	immunotherapeutic	_	JJ	JJ	_	5	COORD	_	_
8	protocols	_	NNS	NNS	_	3	PMOD	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	breast	_	NN	NN	_	12	NMOD	_	_
11	cancer	_	NN	NN	_	12	NMOD	_	_
12	patients	_	NNS	NNS	_	9	PMOD	_	_
13	may	_	MD	MD	_	0	ROOT-S	_	_
14	be	_	VB	VB	_	13	VC	_	_
15	facilitated	_	VBN	VBN	_	14	VC	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	analysis	_	NN	NN	_	16	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	preclinical	_	JJ	JJ	_	23	NMOD	_	_
20	in	_	FW	FW	_	21	AMOD	_	_
21	vitro	_	FW	FW	_	23	NMOD	_	_
22	model	_	JJ	JJ	_	23	NMOD	_	_
23	systems	_	NNS	NNS	_	18	PMOD	_	_
24	.	_	.	.	_	13	P	_	_

1	Estrogen	_	NN	NN	_	20	NMOD	_	_
2	receptor	_	NN	NN	_	20	NMOD	_	_
3	positive	_	JJ	JJ	_	20	NMOD	_	_
4	(	_	(	(	_	3	PRN	_	_
5	ER+	_	JJ	JJ	_	7	DEP	_	_
6	:	_	:	:	_	7	P	_	_
7	MCF-7	_	NN	NN	_	4	DEP	_	_
8	)	_	)	)	_	4	P	_	_
9	and	_	CC	CC	_	3	CC	_	_
10	negative	_	JJ	JJ	_	3	COORD	_	_
11	(	_	(	(	_	10	PRN	_	_
12	ER-	_	JJ	JJ	_	14	DEP	_	_
13	:	_	:	:	_	14	P	_	_
14	MDA-MB-231	_	NN	NN	_	11	DEP	_	_
15	)	_	)	)	_	11	P	_	_
16	human	_	JJ	JJ	_	20	NMOD	_	_
17	breast	_	NN	NN	_	20	NMOD	_	_
18	cancer	_	NN	NN	_	20	NMOD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	lines	_	NNS	NNS	_	21	SBJ	_	_
21	were	_	VBD	VBD	_	0	ROOT-S	_	_
22	utilized	_	VBN	VBN	_	21	VC	_	_
23	to	_	TO	TO	_	24	VMOD	_	_
24	evaluate	_	VB	VB	_	22	OBJ	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	effects	_	NNS	NNS	_	24	OBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	tamoxifen	_	NN	NN	_	27	PMOD	_	_
29	(	_	(	(	_	30	P	_	_
30	TAM	_	NN	NN	_	28	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	and	_	CC	CC	_	28	CC	_	_
33	estradiol	_	NN	NN	_	28	COORD	_	_
34	(	_	(	(	_	35	P	_	_
35	E2	_	NN	NN	_	33	PRN	_	_
36	)	_	)	)	_	35	P	_	_
37	on	_	IN	IN	_	26	NMOD	_	_
38	modulation	_	NN	NN	_	37	PMOD	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	breast	_	NN	NN	_	43	NMOD	_	_
41	cancer	_	NN	NN	_	43	NMOD	_	_
42	target	_	NN	NN	_	43	NMOD	_	_
43	susceptibility	_	NN	NN	_	39	PMOD	_	_
44	to	_	TO	TO	_	43	NMOD	_	_
45	lysis	_	NN	NN	_	44	PMOD	_	_
46	by	_	IN	IN	_	45	NMOD	_	_
47	lymphokine-activated	_	JJ	JJ	_	48	NMOD	_	_
48	killer	_	NN	NN	_	52	NMOD	_	_
49	(	_	(	(	_	50	P	_	_
50	LAK	_	NN	NN	_	48	PRN	_	_
51	)	_	)	)	_	50	P	_	_
52	cells	_	NNS	NNS	_	46	PMOD	_	_
53	.	_	.	.	_	21	P	_	_

1	E2-stimulated	_	JJ	JJ	_	3	NMOD	_	_
2	ER+	_	JJ	JJ	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	more	_	RBR	RBR	_	6	AMOD	_	_
6	susceptible	_	JJ	JJ	_	4	PRD	_	_
7	to	_	TO	TO	_	6	AMOD	_	_
8	lysis	_	NN	NN	_	7	PMOD	_	_
9	by	_	IN	IN	_	8	NMOD	_	_
10	LAK	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	than	_	IN	IN	_	6	AMOD	_	_
13	corresponding	_	VBG	VBG	_	17	NMOD	_	_
14	TAM-treated	_	JJ	JJ	_	17	NMOD	_	_
15	or	_	CC	CC	_	14	CC	_	_
16	control	_	NN	NN	_	14	COORD	_	_
17	cells	_	NNS	NNS	_	12	PMOD	_	_
18	,	_	,	,	_	4	P	_	_
19	while	_	IN	IN	_	4	ADV	_	_
20	treatment	_	NN	NN	_	30	SBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	ER-	_	JJ	JJ	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	21	PMOD	_	_
24	with	_	IN	IN	_	20	NMOD	_	_
25	either	_	CC	CC	_	26	CC	_	_
26	E2	_	NN	NN	_	24	PMOD	_	_
27	or	_	CC	CC	_	26	CC	_	_
28	TAM	_	NN	NN	_	26	COORD	_	_
29	alone	_	RB	RB	_	26	NMOD	_	_
30	did	_	VBD	VBD	_	19	VMOD	_	_
31	not	_	RB	RB	_	30	VMOD	_	_
32	alter	_	VB	VB	_	30	VC	_	_
33	from	_	IN	IN	_	32	ADV	_	_
34	control	_	NN	NN	_	33	PMOD	_	_
35	their	_	PRP$	PRP$	_	36	NMOD	_	_
36	susceptibility	_	NN	NN	_	32	OBJ	_	_
37	to	_	TO	TO	_	36	NMOD	_	_
38	this	_	DT	DT	_	40	NMOD	_	_
39	immune-mediated	_	JJ	JJ	_	40	NMOD	_	_
40	lysis	_	NN	NN	_	37	PMOD	_	_
41	.	_	.	.	_	4	P	_	_

1	All	_	DT	DT	_	5	NMOD	_	_
2	ER+	_	JJ	JJ	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	ER-	_	JJ	JJ	_	2	COORD	_	_
5	cells	_	NNS	NNS	_	7	SBJ	_	_
6	tested	_	VBN	VBN	_	5	NMOD	_	_
7	remained	_	VBD	VBD	_	0	ROOT-S	_	_
8	sensitive	_	JJ	JJ	_	7	PRD	_	_
9	after	_	IN	IN	_	7	TMP	_	_
10	treatment	_	NN	NN	_	9	PMOD	_	_
11	with	_	IN	IN	_	10	NMOD	_	_
12	TAM	_	NN	NN	_	11	PMOD	_	_
13	to	_	TO	TO	_	8	AMOD	_	_
14	lysis	_	NN	NN	_	13	PMOD	_	_
15	by	_	IN	IN	_	14	NMOD	_	_
16	LAK	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	15	PMOD	_	_
18	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	14	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	14	P	_	_
4	an	_	DT	DT	_	10	NMOD	_	_
5	adenocarcinoma	_	NN	NN	_	6	AMOD	_	_
6	reactive	_	JJ	JJ	_	10	NMOD	_	_
7	human-mouse	_	JJ	JJ	_	8	AMOD	_	_
8	chimeric	_	JJ	JJ	_	10	NMOD	_	_
9	monoclonal	_	JJ	JJ	_	10	NMOD	_	_
10	antibody	_	NN	NN	_	14	SBJ	_	_
11	(	_	(	(	_	12	P	_	_
12	ING-1	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	able	_	JJ	JJ	_	14	PRD	_	_
16	to	_	TO	TO	_	18	VMOD	_	_
17	significantly	_	RB	RB	_	18	ADV	_	_
18	boost	_	VB	VB	_	15	AMOD	_	_
19	in	_	FW	FW	_	24	NMOD	_	_
20	vivo	_	FW	FW	_	19	AMOD	_	_
21	generated	_	VBN	VBN	_	19	AMOD	_	_
22	LAK	_	NN	NN	_	24	NMOD	_	_
23	cell-mediated	_	JJ	JJ	_	22	AMOD	_	_
24	lysis	_	NN	NN	_	18	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	control	_	NN	NN	_	35	NMOD	_	_
27	,	_	,	,	_	26	P	_	_
28	E2-treated	_	JJ	JJ	_	26	COORD	_	_
29	,	_	,	,	_	26	P	_	_
30	and	_	CC	CC	_	26	CC	_	_
31	TAM-treated	_	JJ	JJ	_	26	COORD	_	_
32	ER+	_	JJ	JJ	_	35	NMOD	_	_
33	and	_	CC	CC	_	32	CC	_	_
34	ER-	_	JJ	JJ	_	32	COORD	_	_
35	cells	_	NNS	NNS	_	25	PMOD	_	_
36	.	_	.	.	_	14	P	_	_

1	These	_	DT	DT	_	4	NMOD	_	_
2	in	_	FW	FW	_	3	AMOD	_	_
3	vitro	_	FW	FW	_	4	NMOD	_	_
4	results	_	NNS	NNS	_	5	SBJ	_	_
5	provide	_	VBP	VBP	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	preclinical	_	JJ	JJ	_	8	NMOD	_	_
8	rationale	_	NN	NN	_	5	OBJ	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	in	_	FW	FW	_	11	AMOD	_	_
11	vivo	_	FW	FW	_	12	NMOD	_	_
12	testing	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	TAM	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	interleukin-2	_	NN	NN	_	14	COORD	_	_
17	(	_	(	(	_	18	P	_	_
18	IL-2	_	NN	NN	_	16	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	,	_	,	,	_	14	P	_	_
21	and	_	CC	CC	_	14	CC	_	_
22	breast	_	NN	NN	_	27	NMOD	_	_
23	cancer	_	NN	NN	_	27	NMOD	_	_
24	reactive	_	JJ	JJ	_	27	NMOD	_	_
25	antibody-dependent	_	JJ	JJ	_	27	NMOD	_	_
26	cellular	_	JJ	JJ	_	27	NMOD	_	_
27	cytotoxicity	_	NN	NN	_	14	COORD	_	_
28	facilitating	_	VBG	VBG	_	14	NMOD	_	_
29	antibody	_	NN	NN	_	28	OBJ	_	_
30	in	_	IN	IN	_	28	ADV	_	_
31	patients	_	NNS	NNS	_	30	PMOD	_	_
32	with	_	IN	IN	_	31	NMOD	_	_
33	refractory	_	JJ	JJ	_	38	NMOD	_	_
34	or	_	CC	CC	_	33	CC	_	_
35	high	_	JJ	JJ	_	36	NMOD	_	_
36	risk	_	NN	NN	_	33	COORD	_	_
37	breast	_	NN	NN	_	38	NMOD	_	_
38	cancer	_	NN	NN	_	32	PMOD	_	_
39	.	_	.	.	_	5	P	_	_

1	Glucocorticoid	_	NN	NN	_	2	NMOD	_	_
2	receptor	_	NN	NN	_	0	ROOT-FRAG	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	inhibition	_	NN	NN	_	2	COORD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	3-O-methyl-D-glucose	_	NN	NN	_	7	NMOD	_	_
7	uptake	_	NN	NN	_	5	PMOD	_	_
8	by	_	IN	IN	_	4	NMOD	_	_
9	glucocorticoids	_	NNS	NNS	_	8	PMOD	_	_
10	in	_	IN	IN	_	2	NMOD	_	_
11	peripheral	_	JJ	JJ	_	13	NMOD	_	_
12	blood	_	NN	NN	_	13	NMOD	_	_
13	leukocytes	_	NNS	NNS	_	10	PMOD	_	_
14	from	_	IN	IN	_	13	NMOD	_	_
15	normal	_	JJ	JJ	_	16	NMOD	_	_
16	humans	_	NNS	NNS	_	14	PMOD	_	_
17	:	_	:	:	_	2	P	_	_
18	correlation	_	NN	NN	_	2	NMOD	_	_
19	between	_	IN	IN	_	18	NMOD	_	_
20	receptor	_	NN	NN	_	21	NMOD	_	_
21	level	_	NN	NN	_	19	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	hormone	_	NN	NN	_	24	NMOD	_	_
24	effect	_	NN	NN	_	21	COORD	_	_
25	in	_	FW	FW	_	21	NMOD	_	_
26	vitro	_	FW	FW	_	25	AMOD	_	_
27	.	_	.	.	_	18	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	measured	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	glucocorticoid	_	NN	NN	_	7	NMOD	_	_
6	receptor	_	NN	NN	_	7	NMOD	_	_
7	concentration	_	NN	NN	_	3	OBJ	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	mononuclear	_	JJ	JJ	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	polymorphonuclear	_	JJ	JJ	_	9	COORD	_	_
12	leukocytes	_	NNS	NNS	_	8	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	both	_	DT	DT	_	15	NMOD	_	_
15	of	_	IN	IN	_	17	SBJ	_	_
16	which	_	WDT	WDT	_	15	PMOD	_	_
17	were	_	VBD	VBD	_	12	NMOD	_	_
18	isolated	_	VBN	VBN	_	17	VC	_	_
19	from	_	IN	IN	_	18	ADV	_	_
20	peripheral	_	JJ	JJ	_	21	NMOD	_	_
21	blood	_	NN	NN	_	19	PMOD	_	_
22	from	_	IN	IN	_	21	NMOD	_	_
23	ten	_	CD	CD	_	26	NMOD	_	_
24	healthy	_	JJ	JJ	_	26	NMOD	_	_
25	male	_	JJ	JJ	_	26	NMOD	_	_
26	volunteers	_	NNS	NNS	_	22	PMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	parallel	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	12	P	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	inhibitory	_	JJ	JJ	_	6	NMOD	_	_
6	effect	_	NN	NN	_	12	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	dexamethasone	_	NN	NN	_	7	PMOD	_	_
9	on	_	IN	IN	_	6	NMOD	_	_
10	3-O-methyl-D-glucose	_	NN	NN	_	11	NMOD	_	_
11	uptake	_	NN	NN	_	9	PMOD	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	assayed	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	corresponding	_	JJ	JJ	_	18	NMOD	_	_
17	mononuclear	_	JJ	JJ	_	18	NMOD	_	_
18	leukocytes	_	NNS	NNS	_	14	PMOD	_	_
19	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	glucocorticoid	_	NN	NN	_	4	NMOD	_	_
3	receptor	_	NN	NN	_	4	NMOD	_	_
4	levels	_	NNS	NNS	_	8	SBJ	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	mononuclear	_	JJ	JJ	_	7	NMOD	_	_
7	leukocytes	_	NNS	NNS	_	5	PMOD	_	_
8	correlated	_	VBD	VBD	_	0	ROOT-S	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	those	_	DT	DT	_	9	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	polymorphonuclear	_	JJ	JJ	_	13	NMOD	_	_
13	leukocytes	_	NNS	NNS	_	11	PMOD	_	_
14	,	_	,	,	_	8	P	_	_
15	and	_	CC	CC	_	8	CC	_	_
16	there	_	EX	EX	_	17	SBJ	_	_
17	was	_	VBD	VBD	_	8	COORD	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	linear	_	JJ	JJ	_	20	NMOD	_	_
20	relationship	_	NN	NN	_	17	PRD	_	_
21	between	_	IN	IN	_	17	ADV	_	_
22	the	_	DT	DT	_	26	NMOD	_	_
23	cellular	_	JJ	JJ	_	26	NMOD	_	_
24	glucocorticoid	_	NN	NN	_	26	NMOD	_	_
25	receptor	_	NN	NN	_	26	NMOD	_	_
26	levels	_	NNS	NNS	_	21	PMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	glucocorticoid-mediated	_	JJ	JJ	_	29	NMOD	_	_
29	inhibition	_	NN	NN	_	26	COORD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	the	_	DT	DT	_	32	NMOD	_	_
32	uptake	_	NN	NN	_	30	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	3-O-methyl-D-glucose	_	NN	NN	_	33	PMOD	_	_
35	in	_	IN	IN	_	26	NMOD	_	_
36	mononuclear	_	JJ	JJ	_	37	NMOD	_	_
37	leukocytes	_	NNS	NNS	_	35	PMOD	_	_
38	.	_	.	.	_	8	P	_	_

1	When	_	WRB	WRB	_	5	ADV	_	_
2	mononuclear	_	JJ	JJ	_	3	NMOD	_	_
3	leukocytes	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	16	TMP	_	_
5	incubated	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	6	DEP	_	_
8	presence	_	NN	NN	_	6	DEP	_	_
9	of	_	IN	IN	_	6	DEP	_	_
10	8-bromo-cAMP	_	NN	NN	_	6	PMOD	_	_
11	,	_	,	,	_	16	P	_	_
12	cellular	_	JJ	JJ	_	15	NMOD	_	_
13	glucocorticoid	_	NN	NN	_	15	NMOD	_	_
14	receptor	_	NN	NN	_	15	NMOD	_	_
15	levels	_	NNS	NNS	_	16	SBJ	_	_
16	increased	_	VBD	VBD	_	0	ROOT-S	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	a	_	DT	DT	_	22	NMOD	_	_
19	more	_	RBR	RBR	_	20	AMOD	_	_
20	pronounced	_	JJ	JJ	_	22	NMOD	_	_
21	inhibitory	_	JJ	JJ	_	22	NMOD	_	_
22	effect	_	NN	NN	_	25	SBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	dexamethasone	_	NN	NN	_	23	PMOD	_	_
25	was	_	VBD	VBD	_	16	COORD	_	_
26	observed	_	VBN	VBN	_	25	VC	_	_
27	on	_	IN	IN	_	26	ADV	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	transport	_	NN	NN	_	27	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	3-O-methyl-D-glucose	_	NN	NN	_	30	PMOD	_	_
32	.	_	.	.	_	16	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	conclude	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	cellular	_	JJ	JJ	_	8	NMOD	_	_
6	glucocorticoid	_	NN	NN	_	8	NMOD	_	_
7	receptor	_	NN	NN	_	8	NMOD	_	_
8	levels	_	NNS	NNS	_	13	SBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	peripheral	_	JJ	JJ	_	12	NMOD	_	_
11	blood	_	NN	NN	_	12	NMOD	_	_
12	leukocytes	_	NNS	NNS	_	9	PMOD	_	_
13	reflect	_	VBP	VBP	_	3	VMOD	_	_
14	in	_	FW	FW	_	15	AMOD	_	_
15	vitro	_	FW	FW	_	16	NMOD	_	_
16	responsiveness	_	NN	NN	_	13	OBJ	_	_
17	to	_	TO	TO	_	16	NMOD	_	_
18	glucocorticoids	_	NNS	NNS	_	17	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	mononuclear	_	JJ	JJ	_	21	NMOD	_	_
21	leukocytes	_	NNS	NNS	_	19	PMOD	_	_
22	from	_	IN	IN	_	21	NMOD	_	_
23	healthy	_	JJ	JJ	_	24	NMOD	_	_
24	males	_	NNS	NNS	_	22	PMOD	_	_
25	,	_	,	,	_	3	P	_	_
26	and	_	CC	CC	_	3	CC	_	_
27	that	_	IN	IN	_	3	COORD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	individual	_	JJ	JJ	_	30	NMOD	_	_
30	responsiveness	_	NN	NN	_	31	SBJ	_	_
31	may	_	MD	MD	_	27	VMOD	_	_
32	alter	_	VB	VB	_	31	VC	_	_
33	upon	_	IN	IN	_	32	TMP	_	_
34	changes	_	NNS	NNS	_	33	PMOD	_	_
35	in	_	IN	IN	_	34	NMOD	_	_
36	the	_	DT	DT	_	38	NMOD	_	_
37	cellular	_	JJ	JJ	_	38	NMOD	_	_
38	levels	_	NNS	NNS	_	35	PMOD	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	glucocorticoid	_	NN	NN	_	41	NMOD	_	_
41	receptor	_	NN	NN	_	39	PMOD	_	_
42	.	_	.	.	_	2	P	_	_

1	Structure	_	NN	NN	_	3	NMOD	_	_
2	function	_	NN	NN	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	vitamin	_	NN	NN	_	7	NMOD	_	_
6	D	_	NN	NN	_	7	NMOD	_	_
7	analogs	_	NNS	NNS	_	4	PMOD	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	C-ring	_	NN	NN	_	10	NMOD	_	_
10	modifications	_	NNS	NNS	_	8	PMOD	_	_
11	.	_	.	.	_	3	P	_	_

1	Analogs	_	NNS	NNS	_	15	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	1	_	CD	CD	_	5	NMOD	_	_
4	alpha,25-dihydroxyvitamin	_	NN	NN	_	5	NMOD	_	_
5	D3	_	NN	NN	_	2	PMOD	_	_
6	(	_	(	(	_	9	P	_	_
7	1	_	CD	CD	_	9	NMOD	_	_
8	alpha,25--LRB-OH-RRB-	_	NN	NN	_	9	NMOD	_	_
9	2D3	_	NN	NN	_	5	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	with	_	IN	IN	_	1	NMOD	_	_
12	substitutions	_	NNS	NNS	_	11	PMOD	_	_
13	on	_	IN	IN	_	12	NMOD	_	_
14	C-11	_	NN	NN	_	13	PMOD	_	_
15	were	_	VBD	VBD	_	0	ROOT-S	_	_
16	synthesized	_	VBN	VBN	_	15	VC	_	_
17	.	_	.	.	_	15	P	_	_

1	Small	_	JJ	JJ	_	3	NMOD	_	_
2	apolar	_	JJ	JJ	_	3	NMOD	_	_
3	substitutions	_	NNS	NNS	_	11	SBJ	_	_
4	(	_	(	(	_	6	P	_	_
5	11	_	CD	CD	_	6	NMOD	_	_
6	alpha-methyl	_	NN	NN	_	3	PRN	_	_
7	,	_	,	,	_	6	P	_	_
8	11	_	CD	CD	_	9	NMOD	_	_
9	alpha-fluoromethyl	_	NN	NN	_	6	NMOD	_	_
10	)	_	)	)	_	6	P	_	_
11	did	_	VBD	VBD	_	0	ROOT-S	_	_
12	not	_	RB	RB	_	11	VMOD	_	_
13	markedly	_	RB	RB	_	11	ADV	_	_
14	decrease	_	VB	VB	_	11	VC	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	affinity	_	NN	NN	_	14	OBJ	_	_
17	for	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	vitamin	_	NN	NN	_	21	NMOD	_	_
20	D	_	NN	NN	_	21	NMOD	_	_
21	receptor	_	NN	NN	_	17	PMOD	_	_
22	,	_	,	,	_	11	P	_	_
23	but	_	CC	CC	_	11	CC	_	_
24	larger	_	JJR	JJR	_	38	NMOD	_	_
25	(	_	(	(	_	27	P	_	_
26	11	_	CD	CD	_	27	NMOD	_	_
27	alpha-chloromethyl	_	NN	NN	_	24	PRN	_	_
28	or	_	CC	CC	_	27	CC	_	_
29	11	_	CD	CD	_	30	NMOD	_	_
30	alpha-	_	NN	NN	_	27	COORD	_	_
31	or	_	CC	CC	_	30	CC	_	_
32	11	_	CD	CD	_	30	COORD	_	_
33	beta-phenyl	_	NN	NN	_	30	COORD	_	_
34	)	_	)	)	_	27	P	_	_
35	or	_	CC	CC	_	24	CC	_	_
36	more	_	RBR	RBR	_	37	AMOD	_	_
37	polar	_	JJ	JJ	_	24	COORD	_	_
38	substitutions	_	NNS	NNS	_	46	SBJ	_	_
39	(	_	(	(	_	41	P	_	_
40	11	_	CD	CD	_	41	NMOD	_	_
41	alpha-hydroxymethyl	_	NN	NN	_	38	PRN	_	_
42	,	_	,	,	_	41	P	_	_
43	11	_	CD	CD	_	44	NMOD	_	_
44	alpha--LRB-2-hydroxyethyl	_	NN	NN	_	41	NMOD	_	_
45	}	_	)	)	_	41	P	_	_
46	decreased	_	VBD	VBD	_	11	COORD	_	_
47	the	_	DT	DT	_	48	NMOD	_	_
48	affinity	_	NN	NN	_	46	OBJ	_	_
49	to	_	TO	TO	_	46	ADV	_	_
50	less	_	JJR	JJR	_	52	DEP	_	_
51	than	_	IN	IN	_	52	DEP	_	_
52	5	_	CD	CD	_	53	NMOD	_	_
53	%	_	NN	NN	_	49	PMOD	_	_
54	of	_	IN	IN	_	53	NMOD	_	_
55	that	_	DT	DT	_	54	PMOD	_	_
56	of	_	IN	IN	_	55	NMOD	_	_
57	1	_	CD	CD	_	58	NMOD	_	_
58	alpha,25-OH-RRB-2D3	_	NN	NN	_	56	PMOD	_	_
59	.	_	.	.	_	11	P	_	_

1	Their	_	PRP$	PRP$	_	2	NMOD	_	_
2	affinity	_	NN	NN	_	11	SBJ	_	_
3	for	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	vitamin	_	NN	NN	_	7	NMOD	_	_
6	D-binding	_	JJ	JJ	_	5	AMOD	_	_
7	protein	_	NN	NN	_	3	PMOD	_	_
8	,	_	,	,	_	11	P	_	_
9	however	_	RB	RB	_	11	ADV	_	_
10	,	_	,	,	_	11	P	_	_
11	increased	_	VBD	VBD	_	0	ROOT-S	_	_
12	up	_	RB	RB	_	11	ADV	_	_
13	to	_	TO	TO	_	12	AMOD	_	_
14	4-fold	_	RB	RB	_	12	AMOD	_	_
15	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	biological	_	JJ	JJ	_	3	NMOD	_	_
3	activity	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	11	_	CD	CD	_	7	NMOD	_	_
6	alpha-methyl-1	_	NN	NN	_	7	NMOD	_	_
7	alpha,25--LRB-OH-RRB-2D3	_	NN	NN	_	4	PMOD	_	_
8	closely	_	RB	RB	_	9	ADV	_	_
9	resembled	_	VBD	VBD	_	0	ROOT-S	_	_
10	that	_	DT	DT	_	9	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	natural	_	JJ	JJ	_	14	NMOD	_	_
14	hormone	_	NN	NN	_	11	PMOD	_	_
15	on	_	IN	IN	_	10	NMOD	_	_
16	normal	_	JJ	JJ	_	20	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	leukemic	_	JJ	JJ	_	16	COORD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	proliferation	_	NN	NN	_	15	PMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	bone	_	NN	NN	_	23	NMOD	_	_
23	resorption	_	NN	NN	_	20	COORD	_	_
24	,	_	,	,	_	9	P	_	_
25	whereas	_	IN	IN	_	9	COORD	_	_
26	its	_	PRP$	PRP$	_	29	NMOD	_	_
27	in	_	FW	FW	_	28	AMOD	_	_
28	vivo	_	FW	FW	_	29	NMOD	_	_
29	effect	_	NN	NN	_	37	SBJ	_	_
30	on	_	IN	IN	_	29	NMOD	_	_
31	calcium	_	NN	NN	_	32	NMOD	_	_
32	metabolism	_	NN	NN	_	30	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	the	_	DT	DT	_	36	NMOD	_	_
35	rachitic	_	JJ	JJ	_	36	NMOD	_	_
36	chick	_	NN	NN	_	33	PMOD	_	_
37	was	_	VBD	VBD	_	9	COORD	_	_
38	about	_	IN	IN	_	39	DEP	_	_
39	50	_	CD	CD	_	40	NMOD	_	_
40	%	_	NN	NN	_	37	PRD	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	that	_	DT	DT	_	41	PMOD	_	_
43	of	_	IN	IN	_	42	NMOD	_	_
44	1	_	CD	CD	_	45	NMOD	_	_
45	alpha,25--LRB-OH-RRB-2D3	_	NN	NN	_	43	PMOD	_	_
46	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	11	_	CD	CD	_	4	NMOD	_	_
3	beta-methyl	_	NN	NN	_	4	NMOD	_	_
4	analog	_	NN	NN	_	5	SBJ	_	_
5	had	_	VBD	VBD	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	11	NMOD	_	_
7	greater	_	JJR	JJR	_	9	AMOD	_	_
8	than	_	IN	IN	_	9	AMOD	_	_
9	10-fold	_	RB	RB	_	11	NMOD	_	_
10	lower	_	JJR	JJR	_	9	AMOD	_	_
11	activity	_	NN	NN	_	5	OBJ	_	_
12	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	differentiating	_	JJ	JJ	_	3	NMOD	_	_
3	effects	_	NNS	NNS	_	17	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	other	_	JJ	JJ	_	8	NMOD	_	_
7	C-11	_	NN	NN	_	8	NMOD	_	_
8	analogs	_	NNS	NNS	_	4	PMOD	_	_
9	on	_	IN	IN	_	3	NMOD	_	_
10	human	_	JJ	JJ	_	13	NMOD	_	_
11	promyeloid	_	JJ	JJ	_	13	NMOD	_	_
12	leukemia	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	9	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	HL-60	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	agreed	_	VBD	VBD	_	0	ROOT-S	_	_
18	well	_	RB	RB	_	17	ADV	_	_
19	with	_	IN	IN	_	17	ADV	_	_
20	their	_	PRP$	PRP$	_	22	NMOD	_	_
21	bone-resorbing	_	JJ	JJ	_	22	NMOD	_	_
22	activity	_	NN	NN	_	19	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	receptor	_	NN	NN	_	25	NMOD	_	_
25	affinity	_	NN	NN	_	22	COORD	_	_
26	,	_	,	,	_	17	P	_	_
27	but	_	CC	CC	_	17	CC	_	_
28	they	_	PRP	PRP	_	29	SBJ	_	_
29	demonstrated	_	VBD	VBD	_	17	COORD	_	_
30	lower	_	JJR	JJR	_	32	NMOD	_	_
31	calcemic	_	JJ	JJ	_	32	NMOD	_	_
32	effects	_	NNS	NNS	_	29	OBJ	_	_
33	in	_	FW	FW	_	29	ADV	_	_
34	vivo	_	FW	FW	_	33	AMOD	_	_
35	.	_	.	.	_	17	P	_	_

1	Large	_	JJ	JJ	_	4	NMOD	_	_
2	or	_	CC	CC	_	1	CC	_	_
3	polar	_	JJ	JJ	_	1	COORD	_	_
4	substitutions	_	NNS	NNS	_	11	SBJ	_	_
5	on	_	IN	IN	_	4	NMOD	_	_
6	C-11	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	1	_	CD	CD	_	9	NMOD	_	_
9	alpha,25--LRB-OH-RRB-2D3	_	NN	NN	_	7	PMOD	_	_
10	thus	_	RB	RB	_	11	ADV	_	_
11	impair	_	VBP	VBP	_	0	ROOT-S	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	binding	_	NN	NN	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	vitamin	_	NN	NN	_	18	NMOD	_	_
17	D	_	NN	NN	_	18	NMOD	_	_
18	receptor	_	NN	NN	_	14	PMOD	_	_
19	but	_	CC	CC	_	11	CC	_	_
20	increase	_	VBP	VBP	_	11	COORD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	affinity	_	NN	NN	_	20	OBJ	_	_
23	to	_	TO	TO	_	22	NMOD	_	_
24	vitamin	_	NN	NN	_	26	NMOD	_	_
25	D-binding	_	JJ	JJ	_	24	AMOD	_	_
26	protein	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effects	_	NNS	NNS	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	many	_	JJ	JJ	_	8	NMOD	_	_
5	C-11-substituted	_	JJ	JJ	_	8	NMOD	_	_
6	1	_	CD	CD	_	8	NMOD	_	_
7	alpha,25--LRB-OH-RRB-2D3	_	NN	NN	_	8	NMOD	_	_
8	analogs	_	NNS	NNS	_	3	PMOD	_	_
9	on	_	IN	IN	_	2	NMOD	_	_
10	HL-60	_	NN	NN	_	12	NMOD	_	_
11	cell	_	NN	NN	_	12	NMOD	_	_
12	differentiation	_	NN	NN	_	9	PMOD	_	_
13	exceeded	_	VBD	VBD	_	0	ROOT-S	_	_
14	their	_	PRP$	PRP$	_	15	NMOD	_	_
15	activity	_	NN	NN	_	13	OBJ	_	_
16	on	_	IN	IN	_	15	NMOD	_	_
17	calcium	_	NN	NN	_	18	NMOD	_	_
18	metabolism	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	13	P	_	_

1	Transcriptional	_	JJ	JJ	_	2	NMOD	_	_
2	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	during	_	IN	IN	_	2	TMP	_	_
4	T-cell	_	NN	NN	_	5	NMOD	_	_
5	development	_	NN	NN	_	3	PMOD	_	_
6	:	_	:	:	_	2	P	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	alpha	_	NN	NN	_	10	NMOD	_	_
9	TCR	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	2	NMOD	_	_
11	as	_	IN	IN	_	10	NMOD	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	molecular	_	JJ	JJ	_	14	NMOD	_	_
14	model	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	regulation	_	NN	NN	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	gene	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	3	PMOD	_	_
6	during	_	IN	IN	_	2	TMP	_	_
7	lymphocyte	_	NN	NN	_	8	NMOD	_	_
8	differentiation	_	NN	NN	_	6	PMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	complex	_	JJ	JJ	_	12	NMOD	_	_
12	process	_	NN	NN	_	9	PRD	_	_
13	involving	_	VBG	VBG	_	12	NMOD	_	_
14	interactions	_	NNS	NNS	_	13	OBJ	_	_
15	between	_	IN	IN	_	14	NMOD	_	_
16	multiple	_	JJ	JJ	_	22	NMOD	_	_
17	positive	_	JJ	JJ	_	22	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	negative	_	JJ	JJ	_	17	COORD	_	_
20	transcriptional	_	JJ	JJ	_	22	NMOD	_	_
21	regulatory	_	JJ	JJ	_	22	NMOD	_	_
22	elements	_	NNS	NNS	_	15	PMOD	_	_
23	.	_	.	.	_	9	P	_	_

1	In	_	IN	IN	_	16	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	article	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	16	P	_	_
5	transcriptional	_	JJ	JJ	_	6	NMOD	_	_
6	regulation	_	NN	NN	_	16	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	archetypal	_	JJ	JJ	_	11	NMOD	_	_
10	T-cell-specific	_	JJ	JJ	_	11	NMOD	_	_
11	gene	_	NN	NN	_	7	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	alpha	_	NN	NN	_	14	NMOD	_	_
14	TCR	_	NN	NN	_	11	NMOD	_	_
15	,	_	,	,	_	11	P	_	_
16	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	discussed	_	VBN	VBN	_	16	VC	_	_
18	.	_	.	.	_	16	P	_	_

1	Major	_	JJ	JJ	_	3	NMOD	_	_
2	recent	_	JJ	JJ	_	3	NMOD	_	_
3	developments	_	NNS	NNS	_	26	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	including	_	VBG	VBG	_	3	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	identification	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	novel	_	JJ	JJ	_	10	NMOD	_	_
10	families	_	NNS	NNS	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	transcription	_	NN	NN	_	13	NMOD	_	_
13	factors	_	NNS	NNS	_	11	PMOD	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	regulate	_	VBP	VBP	_	13	NMOD	_	_
16	multiple	_	JJ	JJ	_	18	NMOD	_	_
17	T-cell	_	NN	NN	_	18	NMOD	_	_
18	genes	_	NNS	NNS	_	15	OBJ	_	_
19	during	_	IN	IN	_	15	TMP	_	_
20	thymocyte	_	NN	NN	_	21	NMOD	_	_
21	ontogeny	_	NN	NN	_	19	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	T-cell	_	NN	NN	_	24	NMOD	_	_
24	activation	_	NN	NN	_	21	COORD	_	_
25	,	_	,	,	_	3	P	_	_
26	are	_	VBP	VBP	_	0	ROOT-S	_	_
27	described	_	VBN	VBN	_	26	VC	_	_
28	.	_	.	.	_	26	P	_	_

1	Induction	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	monocytic	_	JJ	JJ	_	4	NMOD	_	_
4	differentiation	_	NN	NN	_	2	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	NF-kappa	_	NN	NN	_	8	NMOD	_	_
7	B-like	_	JJ	JJ	_	6	AMOD	_	_
8	activities	_	NNS	NNS	_	4	COORD	_	_
9	by	_	IN	IN	_	1	NMOD	_	_
10	human	_	JJ	JJ	_	14	NMOD	_	_
11	immunodeficiency	_	NN	NN	_	14	NMOD	_	_
12	virus	_	NN	NN	_	14	NMOD	_	_
13	1	_	CD	CD	_	14	NMOD	_	_
14	infection	_	NN	NN	_	9	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	myelomonoblastic	_	JJ	JJ	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	15	PMOD	_	_
18	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effects	_	NNS	NNS	_	21	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	human	_	JJ	JJ	_	6	NMOD	_	_
5	immunodeficiency	_	NN	NN	_	6	NMOD	_	_
6	virus	_	NN	NN	_	11	NMOD	_	_
7	1	_	CD	CD	_	6	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	HIV-1	_	NN	NN	_	6	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	infection	_	NN	NN	_	3	PMOD	_	_
12	on	_	IN	IN	_	2	NMOD	_	_
13	cellular	_	JJ	JJ	_	14	NMOD	_	_
14	differentiation	_	NN	NN	_	12	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	NF-kappa	_	NN	NN	_	20	NMOD	_	_
17	B	_	NN	NN	_	20	NMOD	_	_
18	DNA	_	NN	NN	_	20	NMOD	_	_
19	binding	_	NN	NN	_	20	NMOD	_	_
20	activity	_	NN	NN	_	14	COORD	_	_
21	have	_	VBP	VBP	_	0	ROOT-S	_	_
22	been	_	VBN	VBN	_	21	VC	_	_
23	investigated	_	VBN	VBN	_	22	VC	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	new	_	JJ	JJ	_	27	NMOD	_	_
27	model	_	NN	NN	_	24	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	myeloid	_	JJ	JJ	_	30	NMOD	_	_
30	differentiation	_	NN	NN	_	28	PMOD	_	_
31	.	_	.	.	_	21	P	_	_

1	PLB-985	_	NN	NN	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	3	SBJ	_	_
3	represent	_	VBP	VBP	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	8	NMOD	_	_
5	bipotential	_	JJ	JJ	_	8	NMOD	_	_
6	myelomonoblastic	_	JJ	JJ	_	8	NMOD	_	_
7	cell	_	NN	NN	_	8	NMOD	_	_
8	population	_	NN	NN	_	3	OBJ	_	_
9	capable	_	JJ	JJ	_	8	NMOD	_	_
10	of	_	IN	IN	_	9	AMOD	_	_
11	either	_	CC	CC	_	12	CC	_	_
12	granulocytic	_	JJ	JJ	_	15	NMOD	_	_
13	or	_	CC	CC	_	12	CC	_	_
14	monocytic	_	JJ	JJ	_	12	COORD	_	_
15	differentiation	_	NN	NN	_	10	PMOD	_	_
16	after	_	IN	IN	_	15	TMP	_	_
17	induction	_	NN	NN	_	16	PMOD	_	_
18	with	_	IN	IN	_	17	NMOD	_	_
19	appropriate	_	JJ	JJ	_	20	NMOD	_	_
20	inducers	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	By	_	IN	IN	_	15	ADV	_	_
2	virtue	_	NN	NN	_	1	DEP	_	_
3	of	_	IN	IN	_	1	DEP	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	presence	_	NN	NN	_	1	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	CD4	_	NN	NN	_	6	PMOD	_	_
8	on	_	IN	IN	_	5	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	surface	_	NN	NN	_	8	PMOD	_	_
12	,	_	,	,	_	15	P	_	_
13	PLB-985	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	15	SBJ	_	_
15	were	_	VBD	VBD	_	0	ROOT-S	_	_
16	chronically	_	RB	RB	_	15	ADV	_	_
17	infected	_	VBN	VBN	_	15	VC	_	_
18	with	_	IN	IN	_	17	ADV	_	_
19	HIV-1	_	NN	NN	_	21	NMOD	_	_
20	strain	_	NN	NN	_	21	NMOD	_	_
21	IIIB	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	15	P	_	_

1	PLB-IIIB	_	NN	NN	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	4	SBJ	_	_
3	clearly	_	RB	RB	_	4	ADV	_	_
4	possessed	_	VBD	VBD	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	more	_	RBR	RBR	_	7	AMOD	_	_
7	monocytic	_	JJ	JJ	_	8	NMOD	_	_
8	phenotype	_	NN	NN	_	4	OBJ	_	_
9	than	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	parental	_	JJ	JJ	_	12	NMOD	_	_
12	myeloblasts	_	NNS	NNS	_	9	PMOD	_	_
13	,	_	,	,	_	4	P	_	_
14	as	_	IN	IN	_	4	ADV	_	_
15	determined	_	VBN	VBN	_	14	VMOD	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	differential	_	JJ	JJ	_	18	NMOD	_	_
18	staining	_	NN	NN	_	16	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	increased	_	VBN	VBN	_	21	NMOD	_	_
21	expression	_	NN	NN	_	18	COORD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	26	NMOD	_	_
24	myeloid-specific	_	JJ	JJ	_	26	NMOD	_	_
25	surface	_	NN	NN	_	26	NMOD	_	_
26	markers	_	NNS	NNS	_	22	PMOD	_	_
27	,	_	,	,	_	18	P	_	_
28	and	_	CC	CC	_	18	CC	_	_
29	transcription	_	NN	NN	_	18	COORD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	c-fms	_	NN	NN	_	33	NMOD	_	_
33	proto-oncogene	_	NN	NN	_	30	PMOD	_	_
34	.	_	.	.	_	4	P	_	_

1	NF-kappa	_	NN	NN	_	4	NMOD	_	_
2	B	_	NN	NN	_	4	NMOD	_	_
3	binding	_	NN	NN	_	4	NMOD	_	_
4	activity	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	inducible	_	JJ	JJ	_	5	PRD	_	_
7	by	_	IN	IN	_	5	ADV	_	_
8	tumor	_	NN	NN	_	10	NMOD	_	_
9	necrosis	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	7	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	phorbol	_	NN	NN	_	14	NMOD	_	_
13	myristate	_	NN	NN	_	14	NMOD	_	_
14	acetate	_	NN	NN	_	10	COORD	_	_
15	in	_	IN	IN	_	5	ADV	_	_
16	PLB-985	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	5	P	_	_

1	However	_	RB	RB	_	15	ADV	_	_
2	,	_	,	,	_	15	P	_	_
3	in	_	IN	IN	_	15	ADV	_	_
4	PLB-IIIB	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	3	PMOD	_	_
6	,	_	,	,	_	15	P	_	_
7	constitutive	_	JJ	JJ	_	8	NMOD	_	_
8	expression	_	NN	NN	_	15	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	a	_	DT	DT	_	14	NMOD	_	_
11	novel	_	JJ	JJ	_	14	NMOD	_	_
12	NF-kappa	_	NN	NN	_	14	NMOD	_	_
13	B	_	NN	NN	_	14	NMOD	_	_
14	complex	_	NN	NN	_	9	PMOD	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	detected	_	VBN	VBN	_	15	VC	_	_
17	,	_	,	,	_	16	P	_	_
18	composed	_	VBN	VBN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	ADV	_	_
20	proteins	_	NNS	NNS	_	19	PMOD	_	_
21	ranging	_	VBG	VBG	_	20	NMOD	_	_
22	between	_	IN	IN	_	21	ADV	_	_
23	70	_	CD	CD	_	26	NMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	110	_	CD	CD	_	23	COORD	_	_
26	kD	_	NN	NN	_	22	PMOD	_	_
27	.	_	.	.	_	15	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	proteins	_	NNS	NNS	_	3	SBJ	_	_
3	interacted	_	VBD	VBD	_	0	ROOT-S	_	_
4	specifically	_	RB	RB	_	5	DEP	_	_
5	with	_	IN	IN	_	3	ADV	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	symmetric	_	JJ	JJ	_	10	NMOD	_	_
8	NF-kappa	_	NN	NN	_	10	NMOD	_	_
9	B	_	NN	NN	_	10	NMOD	_	_
10	site	_	NN	NN	_	5	PMOD	_	_
11	from	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	18	NMOD	_	_
13	interferon	_	NN	NN	_	14	NMOD	_	_
14	beta	_	NN	NN	_	18	NMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	IFN-beta	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	promoter	_	NN	NN	_	11	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	Mutations	_	NNS	NNS	_	12	SBJ	_	_
2	affecting	_	VBG	VBG	_	1	NMOD	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	5'	_	JJ	JJ	_	6	NMOD	_	_
5	guanine	_	JJ	JJ	_	6	NMOD	_	_
6	residues	_	NNS	NNS	_	2	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	kappa	_	NN	NN	_	11	NMOD	_	_
10	B	_	NN	NN	_	11	NMOD	_	_
11	site	_	NN	NN	_	7	PMOD	_	_
12	were	_	VBD	VBD	_	0	ROOT-S	_	_
13	unable	_	JJ	JJ	_	12	PRD	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	compete	_	VB	VB	_	13	AMOD	_	_
16	for	_	IN	IN	_	15	ADV	_	_
17	these	_	DT	DT	_	20	NMOD	_	_
18	NF-kappa	_	NN	NN	_	20	NMOD	_	_
19	B-related	_	JJ	JJ	_	18	AMOD	_	_
20	proteins	_	NNS	NNS	_	16	PMOD	_	_
21	.	_	.	.	_	12	P	_	_

1	Inducibility	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	endogenous	_	JJ	JJ	_	7	NMOD	_	_
4	IFN-beta	_	NN	NN	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	IFN-alpha	_	NN	NN	_	4	COORD	_	_
7	RNA	_	NN	NN	_	2	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	also	_	RB	RB	_	8	ADV	_	_
10	increased	_	VBN	VBN	_	8	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	PLB-IIIB	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	.	_	.	.	_	8	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	HIV-1	_	NN	NN	_	6	NMOD	_	_
6	infection	_	NN	NN	_	10	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	myelomonoblastic	_	JJ	JJ	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	7	PMOD	_	_
10	may	_	MD	MD	_	4	VMOD	_	_
11	select	_	VB	VB	_	10	VC	_	_
12	for	_	IN	IN	_	11	ADV	_	_
13	a	_	DT	DT	_	17	NMOD	_	_
14	more	_	RBR	RBR	_	15	AMOD	_	_
15	mature	_	JJ	JJ	_	17	NMOD	_	_
16	monocytic	_	JJ	JJ	_	17	NMOD	_	_
17	phenotype	_	NN	NN	_	12	PMOD	_	_
18	and	_	CC	CC	_	4	CC	_	_
19	that	_	IN	IN	_	4	COORD	_	_
20	unique	_	JJ	JJ	_	22	NMOD	_	_
21	subunit	_	NN	NN	_	22	NMOD	_	_
22	associations	_	NNS	NNS	_	29	SBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	NF-kappa	_	NN	NN	_	28	NMOD	_	_
25	B	_	NN	NN	_	28	NMOD	_	_
26	DNA	_	NN	NN	_	28	NMOD	_	_
27	binding	_	NN	NN	_	28	NMOD	_	_
28	proteins	_	NNS	NNS	_	23	PMOD	_	_
29	may	_	MD	MD	_	19	VMOD	_	_
30	contribute	_	VB	VB	_	29	VC	_	_
31	to	_	TO	TO	_	30	ADV	_	_
32	differential	_	JJ	JJ	_	36	NMOD	_	_
33	NF-kappa	_	NN	NN	_	36	NMOD	_	_
34	B-mediated	_	JJ	JJ	_	33	AMOD	_	_
35	gene	_	NN	NN	_	36	NMOD	_	_
36	expression	_	NN	NN	_	31	PMOD	_	_
37	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	AP-1	_	NN	NN	_	3	NMOD	_	_
3	site	_	NN	NN	_	15	SBJ	_	_
4	at	_	IN	IN	_	3	NMOD	_	_
5	-150	_	CD	CD	_	6	NMOD	_	_
6	bp	_	NN	NN	_	4	PMOD	_	_
7	,	_	,	,	_	3	P	_	_
8	but	_	CC	CC	_	3	CC	_	_
9	not	_	RB	RB	_	8	COORD	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	NF-kappa	_	NN	NN	_	13	NMOD	_	_
12	B	_	NN	NN	_	13	NMOD	_	_
13	site	_	NN	NN	_	3	COORD	_	_
14	,	_	,	,	_	3	P	_	_
15	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	likely	_	JJ	JJ	_	15	PRD	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	represent	_	VB	VB	_	16	AMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	major	_	JJ	JJ	_	21	NMOD	_	_
21	target	_	NN	NN	_	18	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	protein	_	NN	NN	_	25	NMOD	_	_
24	kinase	_	NN	NN	_	25	NMOD	_	_
25	C	_	NN	NN	_	22	PMOD	_	_
26	in	_	IN	IN	_	18	ADV	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	interleukin	_	NN	NN	_	30	NMOD	_	_
29	2	_	CD	CD	_	30	NMOD	_	_
30	promoter	_	NN	NN	_	26	PMOD	_	_
31	.	_	.	.	_	15	P	_	_

1	Stimulation	_	NN	NN	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	T	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	antigen	_	NN	NN	_	5	PMOD	_	_
7	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	activation	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	several	_	JJ	JJ	_	12	NMOD	_	_
12	kinases	_	NNS	NNS	_	10	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	including	_	VBG	VBG	_	12	NMOD	_	_
15	protein	_	NN	NN	_	17	NMOD	_	_
16	kinase	_	NN	NN	_	17	NMOD	_	_
17	C	_	NN	NN	_	14	PMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	PKC	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	,	_	,	,	_	12	P	_	_
22	that	_	WDT	WDT	_	23	SBJ	_	_
23	may	_	MD	MD	_	12	NMOD	_	_
24	mediate	_	VB	VB	_	23	VC	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	later	_	JJ	JJ	_	27	NMOD	_	_
27	induction	_	NN	NN	_	24	OBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	activation-related	_	JJ	JJ	_	30	NMOD	_	_
30	genes	_	NNS	NNS	_	28	PMOD	_	_
31	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	examined	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	potential	_	JJ	JJ	_	6	NMOD	_	_
6	role	_	NN	NN	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	PKC	_	NN	NN	_	7	PMOD	_	_
9	in	_	IN	IN	_	6	NMOD	_	_
10	induction	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	18	NMOD	_	_
13	interleukin	_	NN	NN	_	18	NMOD	_	_
14	2	_	CD	CD	_	13	NMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	IL-2	_	NN	NN	_	13	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	gene	_	NN	NN	_	11	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	T	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	19	PMOD	_	_
22	stimulated	_	VBN	VBN	_	21	NMOD	_	_
23	through	_	IN	IN	_	22	ADV	_	_
24	the	_	DT	DT	_	28	NMOD	_	_
25	T	_	NN	NN	_	28	NMOD	_	_
26	cell	_	NN	NN	_	28	NMOD	_	_
27	receptor\/CD3	_	NN	NN	_	28	NMOD	_	_
28	complex	_	NN	NN	_	23	PMOD	_	_
29	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	previously	_	RB	RB	_	2	TMP	_	_
4	shown	_	VBN	VBN	_	2	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	prolonged	_	JJ	JJ	_	7	NMOD	_	_
7	treatment	_	NN	NN	_	18	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	14	NMOD	_	_
10	untransformed	_	JJ	JJ	_	14	NMOD	_	_
11	T	_	NN	NN	_	14	NMOD	_	_
12	cell	_	NN	NN	_	14	NMOD	_	_
13	clone	_	NN	NN	_	14	NMOD	_	_
14	Ar-5	_	NN	NN	_	8	PMOD	_	_
15	with	_	IN	IN	_	7	NMOD	_	_
16	phorbol	_	NN	NN	_	17	NMOD	_	_
17	esters	_	NNS	NNS	_	15	PMOD	_	_
18	results	_	VBZ	VBZ	_	5	VMOD	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	downmodulation	_	NN	NN	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	26	NMOD	_	_
23	alpha	_	NN	NN	_	26	NMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	beta	_	NN	NN	_	23	COORD	_	_
26	isozymes	_	NNS	NNS	_	21	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	PKC	_	NN	NN	_	27	PMOD	_	_
29	,	_	,	,	_	18	P	_	_
30	and	_	CC	CC	_	18	CC	_	_
31	abrogates	_	VBZ	VBZ	_	18	COORD	_	_
32	induction	_	NN	NN	_	31	OBJ	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	IL-2	_	NN	NN	_	35	NMOD	_	_
35	mRNA	_	NN	NN	_	33	PMOD	_	_
36	and	_	CC	CC	_	35	CC	_	_
37	protein	_	NN	NN	_	35	COORD	_	_
38	.	_	.	.	_	2	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	phorbol	_	NN	NN	_	7	NMOD	_	_
6	ester	_	NN	NN	_	7	NMOD	_	_
7	treatment	_	NN	NN	_	9	SBJ	_	_
8	also	_	RB	RB	_	9	ADV	_	_
9	abolishes	_	VBZ	VBZ	_	4	VMOD	_	_
10	induction	_	NN	NN	_	9	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	chloramphenicol	_	JJ	JJ	_	14	NMOD	_	_
13	acetyltransferase	_	NN	NN	_	14	NMOD	_	_
14	activity	_	NN	NN	_	11	PMOD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	Ar-5	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	15	PMOD	_	_
18	transfected	_	VBN	VBN	_	17	NMOD	_	_
19	with	_	IN	IN	_	18	ADV	_	_
20	a	_	DT	DT	_	21	NMOD	_	_
21	plasmid	_	NN	NN	_	19	PMOD	_	_
22	containing	_	VBG	VBG	_	21	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	IL-2	_	NN	NN	_	25	NMOD	_	_
25	promoter	_	NN	NN	_	22	OBJ	_	_
26	linked	_	VBN	VBN	_	25	NMOD	_	_
27	to	_	TO	TO	_	26	ADV	_	_
28	this	_	DT	DT	_	30	NMOD	_	_
29	reporter	_	NN	NN	_	30	NMOD	_	_
30	gene	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	IL-2	_	NN	NN	_	3	NMOD	_	_
3	promoter	_	NN	NN	_	4	SBJ	_	_
4	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	binding	_	VBG	VBG	_	6	NMOD	_	_
6	sites	_	NNS	NNS	_	4	OBJ	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	factors	_	NNS	NNS	_	7	PMOD	_	_
10	including	_	VBG	VBG	_	9	NMOD	_	_
11	NFAT-1	_	NN	NN	_	10	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	Oct	_	NN	NN	_	11	COORD	_	_
14	,	_	,	,	_	11	P	_	_
15	NF-kappa	_	NN	NN	_	16	NMOD	_	_
16	B	_	NN	NN	_	11	COORD	_	_
17	,	_	,	,	_	11	P	_	_
18	and	_	CC	CC	_	11	CC	_	_
19	AP-1	_	NN	NN	_	11	COORD	_	_
20	,	_	,	,	_	11	P	_	_
21	which	_	WDT	WDT	_	22	SBJ	_	_
22	are	_	VBP	VBP	_	11	NMOD	_	_
23	all	_	DT	DT	_	25	AMOD	_	_
24	potentially	_	RB	RB	_	25	AMOD	_	_
25	sensitive	_	JJ	JJ	_	22	PRD	_	_
26	to	_	TO	TO	_	25	AMOD	_	_
27	activation	_	NN	NN	_	26	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	PKC	_	NN	NN	_	28	PMOD	_	_
30	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	induction	_	NN	NN	_	14	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	trimer	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	NFAT	_	NN	NN	_	13	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	Oct	_	NN	NN	_	10	COORD	_	_
13	sites	_	NNS	NNS	_	8	PMOD	_	_
14	is	_	VBZ	VBZ	_	3	VMOD	_	_
15	not	_	RB	RB	_	14	VMOD	_	_
16	sensitive	_	JJ	JJ	_	14	PRD	_	_
17	to	_	TO	TO	_	16	AMOD	_	_
18	phorbol	_	NN	NN	_	20	NMOD	_	_
19	ester	_	NN	NN	_	20	NMOD	_	_
20	treatment	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	3	P	_	_
22	and	_	CC	CC	_	3	CC	_	_
23	that	_	IN	IN	_	3	COORD	_	_
24	mutations	_	NNS	NNS	_	30	SBJ	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	29	NMOD	_	_
27	NF-kappa	_	NN	NN	_	29	NMOD	_	_
28	B	_	NN	NN	_	29	NMOD	_	_
29	site	_	NN	NN	_	25	PMOD	_	_
30	have	_	VBP	VBP	_	23	VMOD	_	_
31	no	_	DT	DT	_	32	NMOD	_	_
32	effect	_	NN	NN	_	30	OBJ	_	_
33	on	_	IN	IN	_	30	ADV	_	_
34	inducibility	_	NN	NN	_	33	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	the	_	DT	DT	_	38	NMOD	_	_
37	IL-2	_	NN	NN	_	38	NMOD	_	_
38	promoter	_	NN	NN	_	35	PMOD	_	_
39	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	15	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	15	P	_	_
4	mutations	_	NNS	NNS	_	15	SBJ	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	AP-1	_	NN	NN	_	8	NMOD	_	_
8	site	_	NN	NN	_	5	PMOD	_	_
9	located	_	JJ	JJ	_	8	NMOD	_	_
10	at	_	IN	IN	_	9	AMOD	_	_
11	-150	_	CD	CD	_	12	NMOD	_	_
12	bp	_	NN	NN	_	10	PMOD	_	_
13	almost	_	RB	RB	_	15	ADV	_	_
14	completely	_	RB	RB	_	13	AMOD	_	_
15	abrogate	_	VBP	VBP	_	0	ROOT-S	_	_
16	induction	_	NN	NN	_	15	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	IL-2	_	NN	NN	_	20	NMOD	_	_
20	promoter	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	15	P	_	_
22	and	_	CC	CC	_	15	CC	_	_
23	appearance	_	NN	NN	_	33	SBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	an	_	DT	DT	_	28	NMOD	_	_
26	inducible	_	JJ	JJ	_	28	NMOD	_	_
27	nuclear	_	JJ	JJ	_	28	NMOD	_	_
28	factor	_	NN	NN	_	24	PMOD	_	_
29	binding	_	VBG	VBG	_	28	NMOD	_	_
30	to	_	TO	TO	_	29	ADV	_	_
31	this	_	DT	DT	_	32	NMOD	_	_
32	site	_	NN	NN	_	30	PMOD	_	_
33	is	_	VBZ	VBZ	_	15	COORD	_	_
34	sensitive	_	JJ	JJ	_	33	PRD	_	_
35	to	_	TO	TO	_	34	AMOD	_	_
36	PKC	_	NN	NN	_	37	NMOD	_	_
37	depletion	_	NN	NN	_	35	PMOD	_	_
38	.	_	.	.	_	15	P	_	_

1	Moreover	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	cotransfections	_	NNS	NNS	_	11	SBJ	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	c-fos	_	NN	NN	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	c-jun	_	NN	NN	_	5	COORD	_	_
8	expression	_	NN	NN	_	9	NMOD	_	_
9	plasmids	_	NNS	NNS	_	4	PMOD	_	_
10	markedly	_	RB	RB	_	11	ADV	_	_
11	enhance	_	VBP	VBP	_	0	ROOT-S	_	_
12	induction	_	NN	NN	_	11	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	IL-2	_	NN	NN	_	16	NMOD	_	_
16	promoter	_	NN	NN	_	13	PMOD	_	_
17	in	_	IN	IN	_	12	NMOD	_	_
18	minimally	_	RB	RB	_	19	AMOD	_	_
19	stimulated	_	VBN	VBN	_	21	NMOD	_	_
20	T	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	17	PMOD	_	_
22	.	_	.	.	_	11	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	AP-1	_	NN	NN	_	7	NMOD	_	_
7	site	_	NN	NN	_	11	SBJ	_	_
8	at	_	IN	IN	_	7	NMOD	_	_
9	-150	_	CD	CD	_	10	NMOD	_	_
10	bp	_	NN	NN	_	8	PMOD	_	_
11	represents	_	VBZ	VBZ	_	4	VMOD	_	_
12	a	_	DT	DT	_	20	NMOD	_	_
13	major	_	JJ	JJ	_	20	NMOD	_	_
14	,	_	,	,	_	15	P	_	_
15	if	_	IN	IN	_	20	PRN	_	_
16	not	_	RB	RB	_	15	VMOD	_	_
17	the	_	DT	DT	_	16	NMOD	_	_
18	only	_	JJ	JJ	_	16	NMOD	_	_
19	,	_	,	,	_	15	P	_	_
20	site	_	NN	NN	_	11	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	PKC	_	NN	NN	_	23	NMOD	_	_
23	responsiveness	_	NN	NN	_	21	PMOD	_	_
24	in	_	IN	IN	_	20	NMOD	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	IL-2	_	NN	NN	_	27	NMOD	_	_
27	promoter	_	NN	NN	_	24	PMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	Interleukin	_	NN	NN	_	3	NMOD	_	_
2	6-induced	_	JJ	JJ	_	1	AMOD	_	_
3	differentiation	_	NN	NN	_	14	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	a	_	DT	DT	_	9	NMOD	_	_
6	human	_	JJ	JJ	_	9	NMOD	_	_
7	B	_	NN	NN	_	9	NMOD	_	_
8	cell	_	NN	NN	_	9	NMOD	_	_
9	line	_	NN	NN	_	4	PMOD	_	_
10	into	_	IN	IN	_	3	NMOD	_	_
11	IgM-secreting	_	JJ	JJ	_	13	NMOD	_	_
12	plasma	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	10	PMOD	_	_
14	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	mediated	_	VBN	VBN	_	14	VC	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	c-fos	_	NN	NN	_	16	PMOD	_	_
18	.	_	.	.	_	14	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	role	_	NN	NN	_	16	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	protooncogene	_	NN	NN	_	6	NMOD	_	_
6	c-fos	_	NN	NN	_	3	PMOD	_	_
7	in	_	IN	IN	_	2	NMOD	_	_
8	interleukin	_	NN	NN	_	10	AMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	IL	_	NN	NN	_	15	NMOD	_	_
11	)	_	)	)	_	10	P	_	_
12	6-induced	_	JJ	JJ	_	10	AMOD	_	_
13	B	_	NN	NN	_	15	NMOD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	differentiation	_	NN	NN	_	7	PMOD	_	_
16	was	_	VBD	VBD	_	0	ROOT-S	_	_
17	assessed	_	VBN	VBN	_	16	VC	_	_
18	.	_	.	.	_	16	P	_	_

1	Treatment	_	NN	NN	_	9	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	SKW	_	NN	NN	_	5	NMOD	_	_
4	6.4	_	CD	CD	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	2	PMOD	_	_
6	with	_	IN	IN	_	1	NMOD	_	_
7	IL	_	NN	NN	_	6	PMOD	_	_
8	6	_	CD	CD	_	7	NMOD	_	_
9	induced	_	VBD	VBD	_	0	ROOT-S	_	_
10	a	_	DT	DT	_	14	NMOD	_	_
11	transient	_	JJ	JJ	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	early	_	JJ	JJ	_	11	COORD	_	_
14	stimulation	_	NN	NN	_	9	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	c-fos	_	NN	NN	_	19	NMOD	_	_
17	sense	_	NN	NN	_	19	NMOD	_	_
18	mRNA	_	NN	NN	_	19	NMOD	_	_
19	expression	_	NN	NN	_	15	PMOD	_	_
20	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	3	SBJ	_	_
3	appeared	_	VBD	VBD	_	0	ROOT-S	_	_
4	within	_	IN	IN	_	3	TMP	_	_
5	30	_	CD	CD	_	6	NMOD	_	_
6	min	_	NN	NN	_	4	PMOD	_	_
7	and	_	CC	CC	_	3	CC	_	_
8	returned	_	VBD	VBD	_	3	COORD	_	_
9	to	_	TO	TO	_	8	ADV	_	_
10	basal	_	JJ	JJ	_	11	NMOD	_	_
11	levels	_	NNS	NNS	_	9	PMOD	_	_
12	after	_	IN	IN	_	8	TMP	_	_
13	2	_	CD	CD	_	14	NMOD	_	_
14	h	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	addition	_	NN	NN	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	antisense	_	JJ	JJ	_	5	NMOD	_	_
5	oligonucleotides	_	NNS	NNS	_	3	PMOD	_	_
6	to	_	TO	TO	_	2	NMOD	_	_
7	c-fos	_	NN	NN	_	6	PMOD	_	_
8	significantly	_	RB	RB	_	9	ADV	_	_
9	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
10	IL	_	NN	NN	_	13	NMOD	_	_
11	6-induced	_	JJ	JJ	_	10	AMOD	_	_
12	IgM	_	NN	NN	_	13	NMOD	_	_
13	production	_	NN	NN	_	9	OBJ	_	_
14	by	_	IN	IN	_	9	ADV	_	_
15	SKW	_	NN	NN	_	17	NMOD	_	_
16	6.4	_	CD	CD	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	14	PMOD	_	_
18	(	_	(	(	_	22	P	_	_
19	p	_	NN	NN	_	22	SBJ	_	_
20	less	_	JJR	JJR	_	22	DEP	_	_
21	than	_	IN	IN	_	22	DEP	_	_
22	0.001	_	CD	CD	_	9	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	,	_	,	,	_	9	P	_	_
25	whereas	_	IN	IN	_	9	COORD	_	_
26	control	_	NN	NN	_	27	NMOD	_	_
27	oligonucleotides	_	NNS	NNS	_	28	SBJ	_	_
28	had	_	VBD	VBD	_	9	COORD	_	_
29	no	_	DT	DT	_	31	NMOD	_	_
30	inhibitory	_	JJ	JJ	_	31	NMOD	_	_
31	effect	_	NN	NN	_	28	OBJ	_	_
32	.	_	.	.	_	9	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	activation	_	NN	NN	_	8	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	c-fos	_	NN	NN	_	6	PMOD	_	_
8	is	_	VBZ	VBZ	_	4	VMOD	_	_
9	involved	_	VBN	VBN	_	8	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	IL	_	NN	NN	_	13	NMOD	_	_
12	6-induced	_	JJ	JJ	_	11	AMOD	_	_
13	differentiation	_	NN	NN	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	SKW	_	NN	NN	_	17	NMOD	_	_
16	6.4	_	CD	CD	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	14	PMOD	_	_
18	into	_	IN	IN	_	13	NMOD	_	_
19	IgM-secreting	_	JJ	JJ	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	Gangliosides	_	NN	NN	_	2	SBJ	_	_
2	suppress	_	VBP	VBP	_	0	ROOT-S	_	_
3	tumor	_	NN	NN	_	6	NMOD	_	_
4	necrosis	_	NN	NN	_	6	NMOD	_	_
5	factor	_	NN	NN	_	6	NMOD	_	_
6	production	_	NN	NN	_	2	OBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	human	_	JJ	JJ	_	9	NMOD	_	_
9	monocytes	_	NNS	NNS	_	7	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	normal	_	JJ	JJ	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	malignant	_	JJ	JJ	_	2	COORD	_	_
5	cells	_	NNS	NNS	_	6	SBJ	_	_
6	contain	_	VBP	VBP	_	0	ROOT-S	_	_
7	gangliosides	_	NNS	NNS	_	6	OBJ	_	_
8	as	_	IN	IN	_	6	ADV	_	_
9	important	_	JJ	JJ	_	12	NMOD	_	_
10	cell	_	NN	NN	_	12	NMOD	_	_
11	membrane	_	NN	NN	_	12	NMOD	_	_
12	constituents	_	NNS	NNS	_	8	PMOD	_	_
13	that	_	WDT	WDT	_	19	SBJ	_	_
14	,	_	,	,	_	19	P	_	_
15	after	_	IN	IN	_	19	TMP	_	_
16	being	_	VBG	VBG	_	15	PMOD	_	_
17	shed	_	VBN	VBN	_	16	VC	_	_
18	,	_	,	,	_	19	P	_	_
19	may	_	MD	MD	_	12	NMOD	_	_
20	influence	_	VB	VB	_	19	VC	_	_
21	cells	_	NNS	NNS	_	20	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	immune	_	JJ	JJ	_	25	NMOD	_	_
25	system	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	studied	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	impact	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	gangliosides	_	NNS	NNS	_	6	PMOD	_	_
8	on	_	IN	IN	_	5	NMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	expression	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	TNF	_	NN	NN	_	11	PMOD	_	_
13	in	_	IN	IN	_	10	NMOD	_	_
14	blood	_	NN	NN	_	15	NMOD	_	_
15	monocytes	_	NNS	NNS	_	13	PMOD	_	_
16	and	_	CC	CC	_	13	CC	_	_
17	in	_	IN	IN	_	13	COORD	_	_
18	the	_	DT	DT	_	23	NMOD	_	_
19	monocytic	_	JJ	JJ	_	23	NMOD	_	_
20	cell	_	NN	NN	_	23	NMOD	_	_
21	line	_	NN	NN	_	23	NMOD	_	_
22	Mono	_	NN	NN	_	23	NMOD	_	_
23	Mac	_	NN	NN	_	17	PMOD	_	_
24	6	_	CD	CD	_	23	NMOD	_	_
25	.	_	.	.	_	2	P	_	_

1	Although	_	IN	IN	_	30	ADV	_	_
2	under	_	IN	IN	_	14	ADV	_	_
3	standard	_	JJ	JJ	_	5	NMOD	_	_
4	culture	_	NN	NN	_	5	NMOD	_	_
5	conditions	_	NNS	NNS	_	2	PMOD	_	_
6	,	_	,	,	_	14	P	_	_
7	bovine	_	JJ	JJ	_	9	NMOD	_	_
8	brain	_	NN	NN	_	9	NMOD	_	_
9	gangliosides	_	NNS	NNS	_	14	SBJ	_	_
10	(	_	(	(	_	9	PRN	_	_
11	100	_	CD	CD	_	12	NMOD	_	_
12	micrograms\/ml	_	NNS	NNS	_	10	DEP	_	_
13	)	_	)	)	_	10	P	_	_
14	suppressed	_	VBD	VBD	_	1	VMOD	_	_
15	LPS-stimulated	_	JJ	JJ	_	17	NMOD	_	_
16	TNF	_	NN	NN	_	17	NMOD	_	_
17	production	_	NN	NN	_	14	OBJ	_	_
18	5-fold	_	RB	RB	_	14	VMOD	_	_
19	in	_	IN	IN	_	14	VMOD	_	_
20	PBMC	_	NN	NN	_	19	PMOD	_	_
21	and	_	CC	CC	_	14	CC	_	_
22	10-fold	_	RB	RB	_	18	GAP	_	_
23	in	_	IN	IN	_	19	GAP	_	_
24	Mono	_	NN	NN	_	27	NMOD	_	_
25	Mac	_	NN	NN	_	27	NMOD	_	_
26	6	_	CD	CD	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	23	PMOD	_	_
28	,	_	,	,	_	30	P	_	_
29	suppression	_	NN	NN	_	30	SBJ	_	_
30	was	_	VBD	VBD	_	0	ROOT-S	_	_
31	more	_	RBR	RBR	_	32	AMOD	_	_
32	efficient	_	JJ	JJ	_	30	PRD	_	_
33	under	_	IN	IN	_	30	ADV	_	_
34	serum-free	_	JJ	JJ	_	35	NMOD	_	_
35	conditions	_	NNS	NNS	_	33	PMOD	_	_
36	.	_	.	.	_	30	P	_	_

1	Looking	_	VBG	VBG	_	17	ADV	_	_
2	at	_	IN	IN	_	1	ADV	_	_
3	highly	_	RB	RB	_	4	AMOD	_	_
4	purified	_	VBN	VBN	_	5	NMOD	_	_
5	gangliosides	_	NNS	NNS	_	2	PMOD	_	_
6	,	_	,	,	_	17	P	_	_
7	GD3	_	NN	NN	_	17	SBJ	_	_
8	,	_	,	,	_	7	P	_	_
9	GD1a	_	NN	NN	_	7	COORD	_	_
10	,	_	,	,	_	7	P	_	_
11	GM3	_	NN	NN	_	7	COORD	_	_
12	,	_	,	,	_	7	P	_	_
13	GM2	_	NN	NN	_	7	COORD	_	_
14	,	_	,	,	_	7	P	_	_
15	and	_	CC	CC	_	7	CC	_	_
16	GM1	_	NN	NN	_	7	COORD	_	_
17	were	_	VBD	VBD	_	0	ROOT-S	_	_
18	all	_	DT	DT	_	19	AMOD	_	_
19	effective	_	JJ	JJ	_	17	PRD	_	_
20	in	_	IN	IN	_	17	ADV	_	_
21	reducing	_	VBG	VBG	_	20	PMOD	_	_
22	TNF	_	NN	NN	_	23	NMOD	_	_
23	production	_	NN	NN	_	21	OBJ	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	PBMC	_	NN	NN	_	24	PMOD	_	_
26	,	_	,	,	_	24	P	_	_
27	and	_	CC	CC	_	24	CC	_	_
28	in	_	IN	IN	_	24	COORD	_	_
29	Mono	_	NN	NN	_	30	NMOD	_	_
30	Mac	_	NN	NN	_	28	PMOD	_	_
31	6	_	CD	CD	_	30	NMOD	_	_
32	by	_	IN	IN	_	23	NMOD	_	_
33	factor	_	NN	NN	_	32	PMOD	_	_
34	10	_	CD	CD	_	33	NMOD	_	_
35	to	_	TO	TO	_	34	NMOD	_	_
36	50	_	CD	CD	_	34	NMOD	_	_
37	.	_	.	.	_	17	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	suppressive	_	JJ	JJ	_	3	NMOD	_	_
3	activity	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	lost	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	molecules	_	NNS	NNS	_	6	PMOD	_	_
8	,	_	,	,	_	5	P	_	_
9	lacking	_	VBG	VBG	_	5	OBJ	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	sugar	_	NN	NN	_	12	NMOD	_	_
12	moiety	_	NN	NN	_	9	OBJ	_	_
13	or	_	CC	CC	_	12	CC	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	lipid	_	NN	NN	_	16	NMOD	_	_
16	moiety	_	NN	NN	_	12	COORD	_	_
17	.	_	.	.	_	4	P	_	_

1	Gangliosides	_	NNS	NNS	_	2	SBJ	_	_
2	appear	_	VBP	VBP	_	0	ROOT-S	_	_
3	to	_	TO	TO	_	4	VMOD	_	_
4	act	_	VB	VB	_	2	OBJ	_	_
5	at	_	IN	IN	_	4	ADV	_	_
6	an	_	DT	DT	_	8	NMOD	_	_
7	early	_	JJ	JJ	_	8	NMOD	_	_
8	step	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	activation	_	NN	NN	_	9	PMOD	_	_
11	in	_	IN	IN	_	16	ADV	_	_
12	that	_	IN	IN	_	11	PMOD	_	_
13	TNF	_	NN	NN	_	14	NMOD	_	_
14	transcripts	_	NNS	NNS	_	15	SBJ	_	_
15	were	_	VBD	VBD	_	8	NMOD	_	_
16	reduced	_	VBN	VBN	_	15	VC	_	_
17	and	_	CC	CC	_	15	CC	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	mobilization	_	NN	NN	_	26	SBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	25	NMOD	_	_
22	nuclear	_	JJ	JJ	_	25	NMOD	_	_
23	factor	_	NN	NN	_	25	NMOD	_	_
24	kappa	_	NN	NN	_	25	NMOD	_	_
25	B	_	NN	NN	_	20	PMOD	_	_
26	was	_	VBD	VBD	_	15	COORD	_	_
27	blocked	_	VBN	VBN	_	26	VC	_	_
28	.	_	.	.	_	2	P	_	_

1	Furthermore	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	in	_	IN	IN	_	8	ADV	_	_
4	time	_	NN	NN	_	5	NMOD	_	_
5	kinetics	_	NNS	NNS	_	3	PMOD	_	_
6	,	_	,	,	_	8	P	_	_
7	gangliosides	_	NNS	NNS	_	8	SBJ	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	effective	_	JJ	JJ	_	8	PRD	_	_
10	for	_	IN	IN	_	8	TMP	_	_
11	up	_	RB	RB	_	14	NMOD	_	_
12	to	_	TO	TO	_	11	DEP	_	_
13	30	_	CD	CD	_	11	DEP	_	_
14	min	_	NN	NN	_	10	PMOD	_	_
15	after	_	IN	IN	_	14	TMP	_	_
16	addition	_	NN	NN	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	LPS	_	NN	NN	_	17	PMOD	_	_
19	,	_	,	,	_	10	P	_	_
20	but	_	CC	CC	_	10	CC	_	_
21	not	_	RB	RB	_	10	COORD	_	_
22	thereafter	_	RB	RB	_	21	AMOD	_	_
23	.	_	.	.	_	8	P	_	_

1	However	_	RB	RB	_	19	ADV	_	_
2	,	_	,	,	_	19	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	expression	_	NN	NN	_	19	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	CD14	_	NN	NN	_	8	NMOD	_	_
8	Ag	_	NN	NN	_	5	PMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	receptor	_	NN	NN	_	12	NMOD	_	_
12	molecule	_	NN	NN	_	8	NMOD	_	_
13	for	_	IN	IN	_	12	NMOD	_	_
14	LPS-LPS	_	NN	NN	_	17	NMOD	_	_
15	binding	_	NN	NN	_	17	NMOD	_	_
16	protein	_	NN	NN	_	17	NMOD	_	_
17	complexes	_	NNS	NNS	_	13	PMOD	_	_
18	,	_	,	,	_	8	P	_	_
19	was	_	VBD	VBD	_	0	ROOT-S	_	_
20	unaffected	_	JJ	JJ	_	19	VC	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	gangliosides	_	NNS	NNS	_	21	PMOD	_	_
23	.	_	.	.	_	19	P	_	_

1	Finally	_	RB	RB	_	16	ADV	_	_
2	,	_	,	,	_	16	P	_	_
3	when	_	WRB	WRB	_	4	ADV	_	_
4	using	_	VBG	VBG	_	16	TMP	_	_
5	Staphylococcus	_	FW	FW	_	6	NMOD	_	_
6	aureus	_	FW	FW	_	4	OBJ	_	_
7	or	_	CC	CC	_	6	CC	_	_
8	platelet	_	NN	NN	_	10	NMOD	_	_
9	activating	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	6	COORD	_	_
11	as	_	IN	IN	_	4	ADV	_	_
12	a	_	DT	DT	_	13	NMOD	_	_
13	stimulus	_	NN	NN	_	11	PMOD	_	_
14	,	_	,	,	_	16	P	_	_
15	gangliosides	_	NNS	NNS	_	16	SBJ	_	_
16	were	_	VBD	VBD	_	0	ROOT-S	_	_
17	able	_	JJ	JJ	_	16	PRD	_	_
18	to	_	TO	TO	_	19	VMOD	_	_
19	suppress	_	VB	VB	_	17	AMOD	_	_
20	TNF	_	NN	NN	_	21	NMOD	_	_
21	production	_	NN	NN	_	19	OBJ	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	Mono	_	NN	NN	_	26	NMOD	_	_
24	Mac	_	NN	NN	_	26	NMOD	_	_
25	6	_	CD	CD	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	22	PMOD	_	_
27	by	_	IN	IN	_	19	ADV	_	_
28	factor	_	NN	NN	_	27	PMOD	_	_
29	5	_	CD	CD	_	28	NMOD	_	_
30	to	_	TO	TO	_	29	NMOD	_	_
31	10	_	CD	CD	_	29	NMOD	_	_
32	,	_	,	,	_	19	P	_	_
33	as	_	RB	RB	_	19	ADV	_	_
34	well	_	RB	RB	_	33	PMOD	_	_
35	.	_	.	.	_	16	P	_	_

1	On	_	IN	IN	_	11	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	other	_	JJ	JJ	_	4	NMOD	_	_
4	hand	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	11	P	_	_
6	phorbol	_	NN	NN	_	8	NMOD	_	_
7	ester-induced	_	JJ	JJ	_	6	AMOD	_	_
8	production	_	NN	NN	_	11	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	O2-	_	NN	NN	_	9	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	similar	_	JJ	JJ	_	11	PRD	_	_
13	in	_	IN	IN	_	11	ADV	_	_
14	cells	_	NNS	NNS	_	13	PMOD	_	_
15	treated	_	VBN	VBN	_	14	NMOD	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	without	_	IN	IN	_	16	COORD	_	_
19	gangliosides	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	11	P	_	_

1	Taken	_	VBN	VBN	_	6	ADV	_	_
2	together	_	RB	RB	_	1	ADV	_	_
3	,	_	,	,	_	6	P	_	_
4	our	_	PRP$	PRP$	_	5	NMOD	_	_
5	data	_	NNS	NNS	_	6	SBJ	_	_
6	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	TNF	_	NN	NN	_	10	NMOD	_	_
9	gene	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	19	SBJ	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	monocytes	_	NNS	NNS	_	11	PMOD	_	_
13	induced	_	VBN	VBN	_	10	NMOD	_	_
14	by	_	IN	IN	_	13	ADV	_	_
15	different	_	JJ	JJ	_	16	NMOD	_	_
16	types	_	NNS	NNS	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	stimuli	_	NNS	NNS	_	17	PMOD	_	_
19	can	_	MD	MD	_	7	VMOD	_	_
20	be	_	VB	VB	_	19	VC	_	_
21	blocked	_	VBN	VBN	_	20	VC	_	_
22	by	_	IN	IN	_	21	LGS	_	_
23	gangliosides	_	NNS	NNS	_	22	PMOD	_	_
24	at	_	IN	IN	_	21	TMP	_	_
25	an	_	DT	DT	_	27	NMOD	_	_
26	early	_	JJ	JJ	_	27	NMOD	_	_
27	step	_	NN	NN	_	24	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	signal	_	JJ	JJ	_	30	NMOD	_	_
30	transduction	_	NN	NN	_	28	PMOD	_	_
31	.	_	.	.	_	6	P	_	_

1	T	_	NN	NN	_	4	NMOD	_	_
2	cell-specific	_	JJ	JJ	_	1	AMOD	_	_
3	negative	_	JJ	JJ	_	4	NMOD	_	_
4	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	transcription	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	human	_	JJ	JJ	_	11	NMOD	_	_
10	cytokine	_	NN	NN	_	11	NMOD	_	_
11	IL-4	_	NN	NN	_	7	PMOD	_	_
12	.	_	.	.	_	4	P	_	_

1	IL-4	_	NN	NN	_	7	SBJ	_	_
2	secreted	_	VBN	VBN	_	1	NMOD	_	_
3	by	_	IN	IN	_	2	LGS	_	_
4	activated	_	VBN	VBN	_	6	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	3	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	pleiotropic	_	JJ	JJ	_	10	NMOD	_	_
10	cytokine	_	NN	NN	_	7	PRD	_	_
11	affecting	_	VBG	VBG	_	10	NMOD	_	_
12	growth	_	NN	NN	_	11	OBJ	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	differentiation	_	NN	NN	_	12	COORD	_	_
15	of	_	IN	IN	_	12	NMOD	_	_
16	diverse	_	JJ	JJ	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	types	_	NNS	NNS	_	15	PMOD	_	_
19	such	_	JJ	JJ	_	20	DEP	_	_
20	as	_	IN	IN	_	18	NMOD	_	_
21	T	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	20	PMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	B	_	NN	NN	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	22	COORD	_	_
26	,	_	,	,	_	22	P	_	_
27	and	_	CC	CC	_	22	CC	_	_
28	mast	_	NN	NN	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	22	COORD	_	_
30	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	investigated	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	upstream	_	JJ	JJ	_	6	NMOD	_	_
5	regulatory	_	JJ	JJ	_	6	NMOD	_	_
6	elements	_	NNS	NNS	_	2	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	human	_	JJ	JJ	_	11	NMOD	_	_
10	IL-4	_	NN	NN	_	11	NMOD	_	_
11	promoter	_	NN	NN	_	7	PMOD	_	_
12	.	_	.	.	_	2	P	_	_

1	A	_	DT	DT	_	7	NMOD	_	_
2	novel	_	JJ	JJ	_	7	NMOD	_	_
3	T	_	NN	NN	_	7	NMOD	_	_
4	cell-specific	_	JJ	JJ	_	3	AMOD	_	_
5	negative	_	JJ	JJ	_	7	NMOD	_	_
6	regulatory	_	JJ	JJ	_	7	NMOD	_	_
7	element	_	NN	NN	_	16	SBJ	_	_
8	(	_	(	(	_	9	P	_	_
9	NRE	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	composed	_	VBN	VBN	_	7	NMOD	_	_
12	of	_	IN	IN	_	11	ADV	_	_
13	two	_	CD	CD	_	15	NMOD	_	_
14	protein-binding	_	JJ	JJ	_	15	NMOD	_	_
15	sites	_	NNS	NNS	_	12	PMOD	_	_
16	were	_	VBD	VBD	_	0	ROOT-S	_	_
17	mapped	_	VBN	VBN	_	16	VC	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	5'	_	JJ	JJ	_	22	NMOD	_	_
21	flanking	_	JJ	JJ	_	22	NMOD	_	_
22	region	_	NN	NN	_	18	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	IL-4	_	NN	NN	_	26	NMOD	_	_
26	gene	_	NN	NN	_	23	PMOD	_	_
27	:	_	:	:	_	17	P	_	_
28	-311CTCCCTTCT-303	_	NN	NN	_	7	NMOD	_	_
29	(	_	(	(	_	30	P	_	_
30	NRE-I	_	NN	NN	_	28	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	and	_	CC	CC	_	28	CC	_	_
33	-288CTTTTTGCTT-TGC-300	_	NN	NN	_	28	COORD	_	_
34	(	_	(	(	_	35	P	_	_
35	NRE-II	_	NN	NN	_	33	PRN	_	_
36	)	_	)	)	_	35	P	_	_
37	.	_	.	.	_	16	P	_	_

1	A	_	DT	DT	_	5	NMOD	_	_
2	T	_	NN	NN	_	5	NMOD	_	_
3	cell-specific	_	JJ	JJ	_	2	AMOD	_	_
4	protein	_	NN	NN	_	5	NMOD	_	_
5	Neg-1	_	NN	NN	_	19	SBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	a	_	DT	DT	_	10	NMOD	_	_
8	ubiquitous	_	JJ	JJ	_	10	NMOD	_	_
9	protein	_	NN	NN	_	10	NMOD	_	_
10	Neg-2	_	NN	NN	_	5	COORD	_	_
11	binding	_	VBG	VBG	_	5	NMOD	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	NRE-I	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	NRE-II	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	11	P	_	_
17	respectively	_	RB	RB	_	11	ADV	_	_
18	,	_	,	,	_	11	P	_	_
19	were	_	VBD	VBD	_	0	ROOT-S	_	_
20	identified	_	VBN	VBN	_	19	VC	_	_
21	.	_	.	.	_	19	P	_	_

1	Furthermore	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	positive	_	JJ	JJ	_	6	NMOD	_	_
5	regulatory	_	JJ	JJ	_	6	NMOD	_	_
6	element	_	NN	NN	_	7	SBJ	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	found	_	VBN	VBN	_	7	VC	_	_
9	45	_	CD	CD	_	10	NMOD	_	_
10	bp	_	NN	NN	_	11	AMOD	_	_
11	downstream	_	RB	RB	_	8	ADV	_	_
12	of	_	IN	IN	_	11	AMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	NRE	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	enhancer	_	NN	NN	_	3	NMOD	_	_
3	activity	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	PRE	_	NN	NN	_	4	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	completely	_	RB	RB	_	7	ADV	_	_
9	suppressed	_	VBN	VBN	_	7	VC	_	_
10	when	_	WRB	WRB	_	13	ADV	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	NRE	_	NN	NN	_	13	SBJ	_	_
13	was	_	VBD	VBD	_	9	TMP	_	_
14	present	_	JJ	JJ	_	13	PRD	_	_
15	.	_	.	.	_	7	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	IL-4	_	NN	NN	_	7	NMOD	_	_
6	promoter	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	8	SBJ	_	_
8	is	_	VBZ	VBZ	_	4	VMOD	_	_
9	normally	_	RB	RB	_	8	ADV	_	_
10	down-regulated	_	VBN	VBN	_	8	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	an	_	DT	DT	_	13	NMOD	_	_
13	NRE	_	NN	NN	_	11	PMOD	_	_
14	via	_	IN	IN	_	10	ADV	_	_
15	repression	_	NN	NN	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	enhancer	_	NN	NN	_	21	NMOD	_	_
19	positive	_	JJ	JJ	_	21	NMOD	_	_
20	regulatory	_	JJ	JJ	_	21	NMOD	_	_
21	element	_	NN	NN	_	16	PMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	may	_	MD	MD	_	0	ROOT-S	_	_
4	have	_	VB	VB	_	3	VC	_	_
5	implications	_	NNS	NNS	_	4	OBJ	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	stringent	_	JJ	JJ	_	9	NMOD	_	_
9	control	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	IL-4	_	NN	NN	_	12	NMOD	_	_
12	expression	_	NN	NN	_	10	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	T	_	NN	NN	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	13	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	Human	_	JJ	JJ	_	4	NMOD	_	_
2	T	_	NN	NN	_	4	NMOD	_	_
3	cell	_	NN	NN	_	4	NMOD	_	_
4	activation	_	NN	NN	_	9	SBJ	_	_
5	through	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	activation-inducer	_	JJ	JJ	_	8	NMOD	_	_
8	molecule\/CD69	_	NN	NN	_	5	PMOD	_	_
9	enhances	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	activity	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	transcription	_	NN	NN	_	15	NMOD	_	_
14	factor	_	NN	NN	_	15	NMOD	_	_
15	AP-1	_	NN	NN	_	12	PMOD	_	_
16	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	induction	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	AP-1	_	NN	NN	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factor	_	NN	NN	_	3	PMOD	_	_
8	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	been	_	VBN	VBN	_	8	VC	_	_
10	ascribed	_	VBN	VBN	_	9	VC	_	_
11	to	_	TO	TO	_	10	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	early	_	JJ	JJ	_	14	NMOD	_	_
14	events	_	NNS	NNS	_	11	PMOD	_	_
15	leading	_	VBG	VBG	_	14	NMOD	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	T	_	NN	NN	_	18	NMOD	_	_
18	cell	_	NN	NN	_	16	PMOD	_	_
19	differentiation	_	NN	NN	_	18	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	activation	_	NN	NN	_	19	COORD	_	_
22	.	_	.	.	_	8	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	studied	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	regulation	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	AP-1	_	NN	NN	_	8	NMOD	_	_
8	activity	_	NN	NN	_	6	PMOD	_	_
9	in	_	IN	IN	_	5	NMOD	_	_
10	human	_	JJ	JJ	_	14	NMOD	_	_
11	peripheral	_	JJ	JJ	_	14	NMOD	_	_
12	blood	_	NN	NN	_	14	NMOD	_	_
13	T	_	NN	NN	_	14	NMOD	_	_
14	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
15	stimulated	_	VBN	VBN	_	14	NMOD	_	_
16	through	_	IN	IN	_	15	ADV	_	_
17	the	_	DT	DT	_	26	NMOD	_	_
18	activation	_	NN	NN	_	26	NMOD	_	_
19	inducer	_	NN	NN	_	26	NMOD	_	_
20	molecule	_	NN	NN	_	26	NMOD	_	_
21	(	_	(	(	_	26	P	_	_
22	AIM	_	NN	NN	_	26	NMOD	_	_
23	)	_	)	)	_	26	P	_	_
24	\/CD69	_	NN	NN	_	26	NMOD	_	_
25	activation	_	NN	NN	_	26	NMOD	_	_
26	pathway	_	NN	NN	_	16	PMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	Phorbol	_	NN	NN	_	2	NMOD	_	_
2	esters	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	required	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	induce	_	VB	VB	_	4	VMOD	_	_
7	AIM\/CD69	_	NN	NN	_	9	NMOD	_	_
8	cell-surface	_	JJ	JJ	_	9	NMOD	_	_
9	expression	_	NN	NN	_	6	OBJ	_	_
10	as	_	RB	RB	_	6	CC	_	_
11	well	_	RB	RB	_	10	DEP	_	_
12	as	_	IN	IN	_	10	DEP	_	_
13	for	_	IN	IN	_	6	COORD	_	_
14	triggering	_	VBG	VBG	_	13	PMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	proliferation	_	NN	NN	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	17	PMOD	_	_
20	in	_	IN	IN	_	14	ADV	_	_
21	conjunction	_	NN	NN	_	20	DEP	_	_
22	with	_	IN	IN	_	20	DEP	_	_
23	anti-AIM	_	JJ	JJ	_	24	NMOD	_	_
24	mAb	_	NN	NN	_	20	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	Mobility	_	NN	NN	_	3	NMOD	_	_
2	shift	_	NN	NN	_	3	NMOD	_	_
3	assays	_	NNS	NNS	_	4	SBJ	_	_
4	showed	_	VBD	VBD	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	addition	_	NN	NN	_	15	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	anti-AIM	_	JJ	JJ	_	9	NMOD	_	_
9	mAb	_	NN	NN	_	7	PMOD	_	_
10	to	_	TO	TO	_	6	NMOD	_	_
11	PMA-treated	_	JJ	JJ	_	13	NMOD	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	lymphocytes	_	NNS	NNS	_	10	PMOD	_	_
14	markedly	_	RB	RB	_	15	ADV	_	_
15	enhanced	_	VBD	VBD	_	5	VMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	binding	_	NN	NN	_	18	NMOD	_	_
18	activity	_	NN	NN	_	15	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	AP-1	_	NN	NN	_	19	PMOD	_	_
21	to	_	TO	TO	_	18	NMOD	_	_
22	its	_	PRP$	PRP$	_	24	NMOD	_	_
23	cognate	_	JJ	JJ	_	24	NMOD	_	_
24	sequence	_	NN	NN	_	21	PMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	the	_	DT	DT	_	30	NMOD	_	_
27	phorbol	_	NN	NN	_	30	NMOD	_	_
28	ester	_	NN	NN	_	30	NMOD	_	_
29	response	_	NN	NN	_	30	NMOD	_	_
30	element	_	NN	NN	_	24	NMOD	_	_
31	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	6	P	_	_
4	anti-AIM	_	NN	NN	_	5	NMOD	_	_
5	mAb	_	NN	NN	_	6	SBJ	_	_
6	did	_	VBD	VBD	_	0	ROOT-S	_	_
7	not	_	RB	RB	_	6	VMOD	_	_
8	induce	_	VB	VB	_	6	VC	_	_
9	any	_	DT	DT	_	10	NMOD	_	_
10	change	_	NN	NN	_	8	OBJ	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	binding	_	NN	NN	_	14	NMOD	_	_
14	activity	_	NN	NN	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	NF-kappa	_	NN	NN	_	17	NMOD	_	_
17	B	_	NN	NN	_	15	PMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	transcription	_	NN	NN	_	21	NMOD	_	_
21	factor	_	NN	NN	_	17	NMOD	_	_
22	whose	_	WP$	WP$	_	23	NMOD	_	_
23	activity	_	NN	NN	_	24	SBJ	_	_
24	is	_	VBZ	VBZ	_	21	NMOD	_	_
25	also	_	RB	RB	_	24	ADV	_	_
26	regulated	_	VBN	VBN	_	24	VC	_	_
27	by	_	IN	IN	_	26	LGS	_	_
28	protein	_	NN	NN	_	30	NMOD	_	_
29	kinase	_	NN	NN	_	30	NMOD	_	_
30	C	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	increase	_	NN	NN	_	6	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	AP-1-binding	_	JJ	JJ	_	5	NMOD	_	_
5	activity	_	NN	NN	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	accompanied	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	marked	_	JJ	JJ	_	11	NMOD	_	_
11	stimulation	_	NN	NN	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	transcription	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	c-fos	_	NN	NN	_	15	PMOD	_	_
17	but	_	CC	CC	_	14	CC	_	_
18	not	_	RB	RB	_	17	COORD	_	_
19	that	_	DT	DT	_	20	NMOD	_	_
20	of	_	IN	IN	_	14	COORD	_	_
21	c-jun	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	Blockade	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	DNA-binding	_	JJ	JJ	_	5	NMOD	_	_
5	complexes	_	NNS	NNS	_	2	PMOD	_	_
6	with	_	IN	IN	_	1	NMOD	_	_
7	an	_	DT	DT	_	9	NMOD	_	_
8	anti-Fos	_	JJ	JJ	_	9	NMOD	_	_
9	mAb	_	NN	NN	_	6	PMOD	_	_
10	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	direct	_	JJ	JJ	_	13	NMOD	_	_
13	participation	_	NN	NN	_	10	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	c-Fos	_	NN	NN	_	14	PMOD	_	_
16	in	_	IN	IN	_	13	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	AP-1	_	NN	NN	_	19	NMOD	_	_
19	complexes	_	NNS	NNS	_	16	PMOD	_	_
20	induced	_	VBN	VBN	_	19	NMOD	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	anti-AIM	_	NN	NN	_	23	NMOD	_	_
23	mAb	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	10	P	_	_

1	Most	_	JJS	JJS	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	AP-1	_	NN	NN	_	5	NMOD	_	_
5	activity	_	NN	NN	_	2	PMOD	_	_
6	could	_	MD	MD	_	0	ROOT-S	_	_
7	be	_	VB	VB	_	6	VC	_	_
8	eliminated	_	VBN	VBN	_	7	VC	_	_
9	when	_	WRB	WRB	_	14	ADV	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	anti-AIM	_	NN	NN	_	12	NMOD	_	_
12	mAb	_	NN	NN	_	13	SBJ	_	_
13	was	_	VBD	VBD	_	8	TMP	_	_
14	added	_	VBN	VBN	_	13	VC	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	culture	_	NN	NN	_	18	NMOD	_	_
18	medium	_	NN	NN	_	15	PMOD	_	_
19	in	_	IN	IN	_	14	ADV	_	_
20	the	_	DT	DT	_	19	DEP	_	_
21	presence	_	NN	NN	_	19	DEP	_	_
22	of	_	IN	IN	_	19	DEP	_	_
23	cycloheximide	_	NN	NN	_	19	PMOD	_	_
24	,	_	,	,	_	8	P	_	_
25	suggesting	_	VBG	VBG	_	8	OBJ	_	_
26	that	_	IN	IN	_	25	OBJ	_	_
27	de	_	FW	FW	_	28	AMOD	_	_
28	novo	_	FW	FW	_	30	NMOD	_	_
29	protein	_	NN	NN	_	30	NMOD	_	_
30	synthesis	_	NN	NN	_	31	SBJ	_	_
31	is	_	VBZ	VBZ	_	26	VMOD	_	_
32	crucial	_	JJ	JJ	_	31	PRD	_	_
33	for	_	IN	IN	_	32	AMOD	_	_
34	the	_	DT	DT	_	35	NMOD	_	_
35	induction	_	NN	NN	_	33	PMOD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	AP-1-binding	_	JJ	JJ	_	38	NMOD	_	_
38	activity	_	NN	NN	_	36	PMOD	_	_
39	.	_	.	.	_	6	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	VMOD	_	_
3	provide	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	evidence	_	NN	NN	_	3	OBJ	_	_
6	that	_	IN	IN	_	5	NMOD	_	_
7	activation	_	NN	NN	_	6	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	human	_	JJ	JJ	_	13	NMOD	_	_
10	peripheral	_	JJ	JJ	_	13	NMOD	_	_
11	blood	_	NN	NN	_	13	NMOD	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	8	PMOD	_	_
14	through	_	IN	IN	_	7	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	AIM	_	NN	NN	_	18	NMOD	_	_
17	activation	_	NN	NN	_	18	NMOD	_	_
18	pathway	_	NN	NN	_	14	PMOD	_	_
19	regulate	_	VBP	VBP	_	6	VMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	activity	_	NN	NN	_	19	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	AP-1	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	Therefore	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	pathway	_	NN	NN	_	5	SBJ	_	_
5	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	as	_	IN	IN	_	5	ADV	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	crucial	_	JJ	JJ	_	9	NMOD	_	_
9	step	_	NN	NN	_	6	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	initiation	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	early	_	JJ	JJ	_	18	NMOD	_	_
15	T	_	NN	NN	_	18	NMOD	_	_
16	cell	_	NN	NN	_	18	NMOD	_	_
17	activation	_	NN	NN	_	18	NMOD	_	_
18	events	_	NNS	NNS	_	13	PMOD	_	_
19	.	_	.	.	_	5	P	_	_

1	cis-acting	_	JJ	JJ	_	2	NMOD	_	_
2	sequences	_	NNS	NNS	_	9	SBJ	_	_
3	required	_	VBN	VBN	_	2	NMOD	_	_
4	for	_	IN	IN	_	3	ADV	_	_
5	inducible	_	JJ	JJ	_	8	NMOD	_	_
6	interleukin-2	_	NN	NN	_	8	NMOD	_	_
7	enhancer	_	NN	NN	_	8	NMOD	_	_
8	function	_	NN	NN	_	4	PMOD	_	_
9	bind	_	VBP	VBP	_	0	ROOT-S	_	_
10	a	_	DT	DT	_	13	NMOD	_	_
11	novel	_	JJ	JJ	_	13	NMOD	_	_
12	Ets-related	_	JJ	JJ	_	13	NMOD	_	_
13	protein	_	NN	NN	_	9	OBJ	_	_
14	,	_	,	,	_	13	P	_	_
15	Elf-1	_	NN	NN	_	13	NMOD	_	_
16	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	recent	_	JJ	JJ	_	3	NMOD	_	_
3	definition	_	NN	NN	_	17	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	a	_	DT	DT	_	9	NMOD	_	_
6	consensus	_	NN	NN	_	9	NMOD	_	_
7	DNA	_	NN	NN	_	9	NMOD	_	_
8	binding	_	NN	NN	_	9	NMOD	_	_
9	sequence	_	NN	NN	_	4	PMOD	_	_
10	for	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	Ets	_	NN	NN	_	13	NMOD	_	_
13	family	_	NN	NN	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	transcription	_	NN	NN	_	16	NMOD	_	_
16	factors	_	NNS	NNS	_	14	PMOD	_	_
17	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	allowed	_	VBN	VBN	_	17	VC	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	identification	_	NN	NN	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	potential	_	JJ	JJ	_	25	NMOD	_	_
23	Ets	_	NN	NN	_	25	NMOD	_	_
24	binding	_	NN	NN	_	25	NMOD	_	_
25	sites	_	NNS	NNS	_	21	PMOD	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	promoters	_	NNS	NNS	_	26	PMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	enhancers	_	NNS	NNS	_	28	COORD	_	_
31	of	_	IN	IN	_	28	NMOD	_	_
32	many	_	JJ	JJ	_	35	NMOD	_	_
33	inducible	_	JJ	JJ	_	35	NMOD	_	_
34	T-cell	_	NN	NN	_	35	NMOD	_	_
35	genes	_	NNS	NNS	_	31	PMOD	_	_
36	.	_	.	.	_	17	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	1	PMOD	_	_
4	described	_	VBN	VBN	_	3	NMOD	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	this	_	DT	DT	_	7	NMOD	_	_
7	report	_	NN	NN	_	5	PMOD	_	_
8	,	_	,	,	_	10	P	_	_
9	we	_	PRP	PRP	_	10	SBJ	_	_
10	have	_	VBP	VBP	_	0	ROOT-S	_	_
11	identified	_	VBN	VBN	_	10	VC	_	_
12	two	_	CD	CD	_	16	NMOD	_	_
13	potential	_	JJ	JJ	_	16	NMOD	_	_
14	Ets	_	NNS	NNS	_	16	NMOD	_	_
15	binding	_	NN	NN	_	16	NMOD	_	_
16	sites	_	NNS	NNS	_	11	OBJ	_	_
17	,	_	,	,	_	16	P	_	_
18	EBS1	_	NN	NN	_	16	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	EBS2	_	NN	NN	_	18	COORD	_	_
21	,	_	,	,	_	16	P	_	_
22	which	_	WDT	WDT	_	23	SBJ	_	_
23	are	_	VBP	VBP	_	16	NMOD	_	_
24	conserved	_	VBN	VBN	_	23	VC	_	_
25	in	_	IN	IN	_	24	ADV	_	_
26	both	_	CC	CC	_	32	CC	_	_
27	the	_	DT	DT	_	32	NMOD	_	_
28	human	_	JJ	JJ	_	32	NMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	murine	_	JJ	JJ	_	28	COORD	_	_
31	interleukin-2	_	NN	NN	_	32	NMOD	_	_
32	enhancers	_	NNS	NNS	_	25	PMOD	_	_
33	.	_	.	.	_	10	P	_	_

1	Within	_	IN	IN	_	9	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	human	_	JJ	JJ	_	4	NMOD	_	_
4	enhancer	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	9	P	_	_
6	these	_	DT	DT	_	8	NMOD	_	_
7	two	_	CD	CD	_	8	NMOD	_	_
8	sites	_	NNS	NNS	_	9	SBJ	_	_
9	are	_	VBP	VBP	_	0	ROOT-S	_	_
10	located	_	JJ	JJ	_	23	AMOD	_	_
11	within	_	IN	IN	_	23	AMOD	_	_
12	the	_	DT	DT	_	17	NMOD	_	_
13	previously	_	RB	RB	_	14	AMOD	_	_
14	defined	_	VBN	VBN	_	17	NMOD	_	_
15	DNase	_	NN	NN	_	17	NMOD	_	_
16	I	_	CD	CD	_	17	NMOD	_	_
17	footprints	_	NNS	NNS	_	11	PMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	NFAT-1	_	NN	NN	_	17	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	NFIL-2B	_	NN	NN	_	19	COORD	_	_
22	,	_	,	,	_	17	P	_	_
23	respectively	_	RB	RB	_	9	PRD	_	_
24	.	_	.	.	_	9	P	_	_

1	Electrophoretic	_	JJ	JJ	_	3	NMOD	_	_
2	mobility	_	NN	NN	_	3	NMOD	_	_
3	shift	_	NN	NN	_	7	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	methylation	_	NN	NN	_	6	NMOD	_	_
6	interference	_	NN	NN	_	3	COORD	_	_
7	analyses	_	NNS	NNS	_	8	SBJ	_	_
8	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	EBS1	_	NN	NN	_	13	SBJ	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	EBS2	_	NN	NN	_	10	COORD	_	_
13	are	_	VBP	VBP	_	9	VMOD	_	_
14	essential	_	JJ	JJ	_	13	PRD	_	_
15	for	_	IN	IN	_	14	AMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	formation	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	25	NMOD	_	_
20	NFAT-1	_	NN	NN	_	25	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	NFIL-2B	_	NN	NN	_	20	COORD	_	_
23	nuclear	_	JJ	JJ	_	25	NMOD	_	_
24	protein	_	NN	NN	_	25	NMOD	_	_
25	complexes	_	NNS	NNS	_	18	PMOD	_	_
26	.	_	.	.	_	8	P	_	_

1	Furthermore	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	in	_	FW	FW	_	4	AMOD	_	_
4	vitro	_	FW	FW	_	6	NMOD	_	_
5	mutagenesis	_	NN	NN	_	6	NMOD	_	_
6	experiments	_	NNS	NNS	_	7	SBJ	_	_
7	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	inducible	_	JJ	JJ	_	12	NMOD	_	_
10	interleukin-2	_	NN	NN	_	12	NMOD	_	_
11	enhancer	_	NN	NN	_	12	NMOD	_	_
12	function	_	NN	NN	_	13	SBJ	_	_
13	requires	_	VBZ	VBZ	_	8	VMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	presence	_	NN	NN	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	either	_	CC	CC	_	18	CC	_	_
18	EBS1	_	NN	NN	_	16	PMOD	_	_
19	or	_	CC	CC	_	18	CC	_	_
20	EBS2	_	NN	NN	_	18	COORD	_	_
21	.	_	.	.	_	7	P	_	_

1	Two	_	CD	CD	_	5	NMOD	_	_
2	well-characterized	_	JJ	JJ	_	5	NMOD	_	_
3	Ets	_	NN	NN	_	5	NMOD	_	_
4	family	_	NN	NN	_	5	NMOD	_	_
5	members	_	NNS	NNS	_	11	SBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	Ets-1	_	NN	NN	_	5	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	Ets-2	_	NN	NN	_	7	COORD	_	_
10	,	_	,	,	_	5	P	_	_
11	are	_	VBP	VBP	_	0	ROOT-S	_	_
12	reciprocally	_	RB	RB	_	11	ADV	_	_
13	expressed	_	VBN	VBN	_	11	VC	_	_
14	during	_	IN	IN	_	13	TMP	_	_
15	T-cell	_	NN	NN	_	16	NMOD	_	_
16	activation	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	11	P	_	_

1	Surprisingly	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	however	_	RB	RB	_	9	ADV	_	_
4	,	_	,	,	_	9	P	_	_
5	neither	_	DT	DT	_	9	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	these	_	DT	DT	_	8	NMOD	_	_
8	proteins	_	NNS	NNS	_	6	PMOD	_	_
9	bound	_	VBD	VBD	_	0	ROOT-S	_	_
10	in	_	FW	FW	_	9	ADV	_	_
11	vitro	_	FW	FW	_	10	AMOD	_	_
12	to	_	TO	TO	_	9	ADV	_	_
13	EBS1	_	NN	NN	_	12	PMOD	_	_
14	or	_	CC	CC	_	13	CC	_	_
15	EBS2	_	NN	NN	_	13	COORD	_	_
16	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	therefore	_	RB	RB	_	3	ADV	_	_
3	screened	_	VBD	VBD	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	T-cell	_	NN	NN	_	7	NMOD	_	_
6	cDNA	_	NN	NN	_	7	NMOD	_	_
7	library	_	NN	NN	_	3	OBJ	_	_
8	under	_	IN	IN	_	3	ADV	_	_
9	low-stringency	_	NN	NN	_	10	NMOD	_	_
10	conditions	_	NNS	NNS	_	8	PMOD	_	_
11	with	_	IN	IN	_	3	ADV	_	_
12	a	_	DT	DT	_	13	NMOD	_	_
13	probe	_	NN	NN	_	11	PMOD	_	_
14	from	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	DNA	_	NN	NN	_	18	NMOD	_	_
17	binding	_	NN	NN	_	18	NMOD	_	_
18	domain	_	NN	NN	_	14	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	Ets-1	_	NN	NN	_	19	PMOD	_	_
21	and	_	CC	CC	_	3	CC	_	_
22	isolated	_	VBD	VBD	_	3	COORD	_	_
23	a	_	DT	DT	_	27	NMOD	_	_
24	novel	_	JJ	JJ	_	27	NMOD	_	_
25	Ets	_	NN	NN	_	27	NMOD	_	_
26	family	_	NN	NN	_	27	NMOD	_	_
27	member	_	NN	NN	_	22	OBJ	_	_
28	,	_	,	,	_	27	P	_	_
29	Elf-1	_	NN	NN	_	27	NMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	Elf-1	_	NN	NN	_	2	SBJ	_	_
2	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	DNA	_	NN	NN	_	6	NMOD	_	_
5	binding	_	NN	NN	_	6	NMOD	_	_
6	domain	_	NN	NN	_	2	OBJ	_	_
7	that	_	WDT	WDT	_	8	SBJ	_	_
8	is	_	VBZ	VBZ	_	6	NMOD	_	_
9	nearly	_	RB	RB	_	10	AMOD	_	_
10	identical	_	JJ	JJ	_	8	PRD	_	_
11	to	_	TO	TO	_	10	AMOD	_	_
12	that	_	DT	DT	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	E74	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	ecdysone-inducible	_	JJ	JJ	_	20	NMOD	_	_
18	Drosophila	_	NN	NN	_	20	NMOD	_	_
19	transcription	_	NN	NN	_	20	NMOD	_	_
20	factor	_	NN	NN	_	14	NMOD	_	_
21	required	_	VBN	VBN	_	20	NMOD	_	_
22	for	_	IN	IN	_	21	ADV	_	_
23	metamorphosis	_	NN	NN	_	22	PMOD	_	_
24	(	_	(	(	_	2	PRN	_	_
25	hence	_	RB	RB	_	28	ADV	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	name	_	NN	NN	_	28	NMOD	_	_
28	Elf-1	_	NN	NN	_	24	DEP	_	_
29	,	_	,	,	_	28	P	_	_
30	for	_	IN	IN	_	28	ADV	_	_
31	E74-like	_	JJ	JJ	_	32	NMOD	_	_
32	factor	_	NN	NN	_	30	PMOD	_	_
33	1	_	CD	CD	_	32	NMOD	_	_
34	)	_	)	)	_	24	P	_	_
35	.	_	.	.	_	2	P	_	_

1	Elf-1	_	NN	NN	_	2	SBJ	_	_
2	bound	_	VBD	VBD	_	0	ROOT-S	_	_
3	specifically	_	RB	RB	_	4	DEP	_	_
4	to	_	TO	TO	_	2	ADV	_	_
5	both	_	CC	CC	_	6	CC	_	_
6	EBS1	_	NN	NN	_	4	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	EBS2	_	NN	NN	_	6	COORD	_	_
9	in	_	IN	IN	_	2	ADV	_	_
10	electrophoretic	_	JJ	JJ	_	13	NMOD	_	_
11	mobility	_	NN	NN	_	13	NMOD	_	_
12	shift	_	NN	NN	_	13	NMOD	_	_
13	assays	_	NNS	NNS	_	9	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	It	_	PRP	PRP	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	bound	_	VBD	VBD	_	0	ROOT-S	_	_
4	to	_	TO	TO	_	3	ADV	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	purine-rich	_	JJ	JJ	_	8	NMOD	_	_
7	CD3R	_	NN	NN	_	8	NMOD	_	_
8	element	_	NN	NN	_	4	PMOD	_	_
9	from	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	18	NMOD	_	_
11	human	_	JJ	JJ	_	18	NMOD	_	_
12	immunodeficiency	_	NN	NN	_	18	NMOD	_	_
13	virus	_	NN	NN	_	18	NMOD	_	_
14	type	_	NN	NN	_	18	NMOD	_	_
15	2	_	CD	CD	_	18	NMOD	_	_
16	long	_	JJ	JJ	_	18	NMOD	_	_
17	terminal	_	JJ	JJ	_	18	NMOD	_	_
18	repeat	_	NN	NN	_	9	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	which	_	WDT	WDT	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	18	NMOD	_	_
22	required	_	VBN	VBN	_	21	VC	_	_
23	for	_	IN	IN	_	22	ADV	_	_
24	inducible	_	JJ	JJ	_	26	NMOD	_	_
25	virus	_	NN	NN	_	26	NMOD	_	_
26	expression	_	NN	NN	_	23	PMOD	_	_
27	in	_	IN	IN	_	26	NMOD	_	_
28	response	_	NN	NN	_	27	DEP	_	_
29	to	_	TO	TO	_	27	DEP	_	_
30	signalling	_	NN	NN	_	27	PMOD	_	_
31	through	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	T-cell	_	NN	NN	_	34	NMOD	_	_
34	receptor	_	NN	NN	_	31	PMOD	_	_
35	.	_	.	.	_	3	P	_	_

1	Taken	_	VBN	VBN	_	6	ADV	_	_
2	together	_	RB	RB	_	1	ADV	_	_
3	,	_	,	,	_	6	P	_	_
4	these	_	DT	DT	_	5	NMOD	_	_
5	results	_	NNS	NNS	_	6	SBJ	_	_
6	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	multiple	_	JJ	JJ	_	11	NMOD	_	_
9	Ets	_	NN	NN	_	11	NMOD	_	_
10	family	_	NN	NN	_	11	NMOD	_	_
11	members	_	NNS	NNS	_	18	SBJ	_	_
12	with	_	IN	IN	_	11	NMOD	_	_
13	apparently	_	RB	RB	_	14	AMOD	_	_
14	distinct	_	JJ	JJ	_	17	NMOD	_	_
15	DNA	_	NN	NN	_	17	NMOD	_	_
16	binding	_	NN	NN	_	17	NMOD	_	_
17	specificities	_	NNS	NNS	_	12	PMOD	_	_
18	regulate	_	VBP	VBP	_	7	VMOD	_	_
19	differential	_	JJ	JJ	_	21	NMOD	_	_
20	gene	_	NN	NN	_	21	NMOD	_	_
21	expression	_	NN	NN	_	18	OBJ	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	resting	_	VBG	VBG	_	27	NMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	activated	_	VBN	VBN	_	23	COORD	_	_
26	T	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	22	PMOD	_	_
28	.	_	.	.	_	6	P	_	_

1	Mineralocorticoids	_	NNPS	NNPS	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	mineralocorticoid	_	NN	NN	_	4	NMOD	_	_
4	receptors	_	NNS	NNS	_	1	COORD	_	_
5	in	_	IN	IN	_	1	NMOD	_	_
6	mononuclear	_	JJ	JJ	_	7	NMOD	_	_
7	leukocytes	_	NNS	NNS	_	5	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	patients	_	NNS	NNS	_	8	PMOD	_	_
10	with	_	IN	IN	_	9	NMOD	_	_
11	pregnancy-induced	_	JJ	JJ	_	12	NMOD	_	_
12	hypertension	_	NN	NN	_	10	PMOD	_	_
13	.	_	.	.	_	1	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	examine	_	VB	VB	_	18	PRP	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	role	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	mineralocorticoids	_	NNS	NNS	_	5	PMOD	_	_
7	in	_	IN	IN	_	4	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	pathophysiology	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	pregnancy-induced	_	JJ	JJ	_	12	NMOD	_	_
12	hypertension	_	NN	NN	_	10	PMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	PIH	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	,	_	,	,	_	18	P	_	_
17	we	_	PRP	PRP	_	18	SBJ	_	_
18	studied	_	VBD	VBD	_	0	ROOT-S	_	_
19	plasma	_	NN	NN	_	20	NMOD	_	_
20	aldosterone	_	NN	NN	_	23	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	18-hydroxycorticosterone	_	NN	NN	_	20	COORD	_	_
23	levels	_	NNS	NNS	_	18	OBJ	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	25	_	CD	CD	_	26	NMOD	_	_
26	women	_	NNS	NNS	_	24	PMOD	_	_
27	with	_	IN	IN	_	26	NMOD	_	_
28	PIH	_	NN	NN	_	27	PMOD	_	_
29	and	_	CC	CC	_	26	CC	_	_
30	25	_	CD	CD	_	33	NMOD	_	_
31	normal	_	JJ	JJ	_	33	NMOD	_	_
32	pregnant	_	JJ	JJ	_	33	NMOD	_	_
33	women	_	NNS	NNS	_	26	COORD	_	_
34	,	_	,	,	_	33	P	_	_
35	as	_	IN	IN	_	33	NMOD	_	_
36	controls	_	NNS	NNS	_	35	PMOD	_	_
37	.	_	.	.	_	18	P	_	_

1	Furthermore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	evaluated	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	11	NMOD	_	_
6	mineralocorticoid	_	NN	NN	_	7	NMOD	_	_
7	receptor	_	NN	NN	_	11	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	MR	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	status	_	NN	NN	_	4	OBJ	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	mononuclear	_	JJ	JJ	_	14	NMOD	_	_
14	leukocytes	_	NNS	NNS	_	12	PMOD	_	_
15	in	_	IN	IN	_	11	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	2	_	CD	CD	_	18	NMOD	_	_
18	groups	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	4	P	_	_

1	MR	_	NN	NN	_	2	NMOD	_	_
2	count	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	significantly	_	RB	RB	_	3	ADV	_	_
5	(	_	(	(	_	9	P	_	_
6	P	_	NN	NN	_	9	SBJ	_	_
7	less	_	JJR	JJR	_	9	DEP	_	_
8	than	_	IN	IN	_	9	DEP	_	_
9	0.0005	_	CD	CD	_	3	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	decreased	_	VBN	VBN	_	3	VC	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	PIH	_	NN	NN	_	15	NMOD	_	_
15	group	_	NN	NN	_	12	PMOD	_	_
16	(	_	(	(	_	15	PRN	_	_
17	148	_	CD	CD	_	21	NMOD	_	_
18	+\/-	_	CC	CC	_	17	CC	_	_
19	9	_	CD	CD	_	17	COORD	_	_
20	binding	_	VBG	VBG	_	21	NMOD	_	_
21	sites\/cell	_	NNS	NNS	_	16	DEP	_	_
22	)	_	)	)	_	16	P	_	_
23	compared	_	VBN	VBN	_	11	ADV	_	_
24	with	_	IN	IN	_	23	PMOD	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	control	_	NN	NN	_	27	NMOD	_	_
27	group	_	NN	NN	_	24	PMOD	_	_
28	(	_	(	(	_	27	PRN	_	_
29	300	_	CD	CD	_	33	NMOD	_	_
30	+\/-	_	CC	CC	_	29	CC	_	_
31	17	_	CD	CD	_	29	COORD	_	_
32	binding	_	VBG	VBG	_	33	NMOD	_	_
33	sites\/cell	_	NNS	NNS	_	28	DEP	_	_
34	;	_	:	:	_	33	P	_	_
35	mean	_	NN	NN	_	33	NMOD	_	_
36	+\/-	_	CC	CC	_	35	CC	_	_
37	SEM	_	NN	NN	_	35	COORD	_	_
38	)	_	)	)	_	28	P	_	_
39	.	_	.	.	_	3	P	_	_

1	Plasma	_	NN	NN	_	2	NMOD	_	_
2	aldosterone	_	NN	NN	_	7	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	women	_	NNS	NNS	_	3	PMOD	_	_
5	with	_	IN	IN	_	4	NMOD	_	_
6	PIH	_	NN	NN	_	5	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	281	_	CD	CD	_	11	NMOD	_	_
9	+\/-	_	CC	CC	_	8	CC	_	_
10	61	_	CD	CD	_	8	COORD	_	_
11	pmol\/L	_	NN	NN	_	7	PRD	_	_
12	;	_	:	:	_	7	P	_	_
13	in	_	IN	IN	_	18	ADV	_	_
14	normal	_	JJ	JJ	_	16	NMOD	_	_
15	pregnant	_	JJ	JJ	_	16	NMOD	_	_
16	women	_	NNS	NNS	_	13	PMOD	_	_
17	it	_	PRP	PRP	_	18	SBJ	_	_
18	was	_	VBD	VBD	_	7	VC	_	_
19	697	_	CD	CD	_	22	NMOD	_	_
20	+\/-	_	CC	CC	_	19	CC	_	_
21	172	_	CD	CD	_	19	COORD	_	_
22	pmol\/L	_	NN	NN	_	18	PRD	_	_
23	(	_	(	(	_	27	P	_	_
24	P	_	NN	NN	_	27	SBJ	_	_
25	less	_	JJR	JJR	_	27	DEP	_	_
26	than	_	IN	IN	_	27	DEP	_	_
27	0.025	_	CD	CD	_	18	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	.	_	.	.	_	18	P	_	_

1	Plasma	_	NN	NN	_	2	NMOD	_	_
2	18-hydroxycorticosterone	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	also	_	RB	RB	_	3	ADV	_	_
5	significantly	_	RB	RB	_	12	AMOD	_	_
6	(	_	(	(	_	10	P	_	_
7	P	_	NN	NN	_	10	SBJ	_	_
8	less	_	JJR	JJR	_	10	DEP	_	_
9	than	_	IN	IN	_	10	DEP	_	_
10	0.025	_	CD	CD	_	12	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	lower	_	JJR	JJR	_	3	PRD	_	_
13	(	_	(	(	_	12	PRN	_	_
14	PIH	_	NN	NN	_	13	DEP	_	_
15	,	_	,	,	_	14	P	_	_
16	1071	_	CD	CD	_	19	NMOD	_	_
17	+\/-	_	CC	CC	_	16	CC	_	_
18	149	_	CD	CD	_	16	COORD	_	_
19	pmol\/L	_	NN	NN	_	14	COORD	_	_
20	;	_	:	:	_	14	P	_	_
21	controls	_	NNS	NNS	_	14	COORD	_	_
22	,	_	,	,	_	21	P	_	_
23	1907	_	CD	CD	_	26	NMOD	_	_
24	+\/-	_	CC	CC	_	23	CC	_	_
25	318	_	CD	CD	_	23	COORD	_	_
26	pmol\/L	_	NN	NN	_	21	COORD	_	_
27	)	_	)	)	_	13	P	_	_
28	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	values	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	determined	_	VBN	VBN	_	3	VC	_	_
5	at	_	IN	IN	_	4	TMP	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	onset	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	clinical	_	JJ	JJ	_	10	NMOD	_	_
10	symptoms	_	NNS	NNS	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	PIH	_	NN	NN	_	11	PMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	can	_	MD	MD	_	0	ROOT-S	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	be	_	VB	VB	_	3	VC	_	_
6	explained	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	receptor	_	NN	NN	_	9	NMOD	_	_
9	down-regulation	_	NN	NN	_	7	PMOD	_	_
10	due	_	JJ	JJ	_	11	DEP	_	_
11	to	_	TO	TO	_	9	NMOD	_	_
12	higher	_	JJR	JJR	_	13	NMOD	_	_
13	levels	_	NNS	NNS	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	mineralocorticoids	_	NNS	NNS	_	14	PMOD	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	PIH	_	NN	NN	_	16	PMOD	_	_
18	;	_	:	:	_	3	P	_	_
19	a	_	DT	DT	_	22	NMOD	_	_
20	hitherto	_	RB	RB	_	21	AMOD	_	_
21	unknown	_	JJ	JJ	_	22	NMOD	_	_
22	mineralocorticoid	_	NN	NN	_	23	SBJ	_	_
23	may	_	MD	MD	_	3	VMOD	_	_
24	,	_	,	,	_	23	P	_	_
25	thus	_	RB	RB	_	23	ADV	_	_
26	,	_	,	,	_	23	P	_	_
27	be	_	VB	VB	_	23	VC	_	_
28	responsible	_	JJ	JJ	_	27	PRD	_	_
29	for	_	IN	IN	_	28	AMOD	_	_
30	the	_	DT	DT	_	35	NMOD	_	_
31	hypertension	_	NN	NN	_	35	NMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	altered	_	JJ	JJ	_	34	NMOD	_	_
34	MR	_	NN	NN	_	31	COORD	_	_
35	status	_	NN	NN	_	29	PMOD	_	_
36	.	_	.	.	_	23	P	_	_

1	A	_	DT	DT	_	5	NMOD	_	_
2	lymphoid	_	JJ	JJ	_	3	AMOD	_	_
3	cell-specific	_	JJ	JJ	_	5	NMOD	_	_
4	nuclear	_	JJ	JJ	_	5	NMOD	_	_
5	factor	_	NN	NN	_	10	SBJ	_	_
6	containing	_	VBG	VBG	_	5	NMOD	_	_
7	c-Rel-like	_	JJ	JJ	_	8	NMOD	_	_
8	proteins	_	NNS	NNS	_	6	OBJ	_	_
9	preferentially	_	RB	RB	_	10	ADV	_	_
10	interacts	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	interleukin-6	_	NN	NN	_	13	AMOD	_	_
13	kappa	_	NN	NN	_	15	NMOD	_	_
14	B-related	_	JJ	JJ	_	13	AMOD	_	_
15	motifs	_	NNS	NNS	_	11	PMOD	_	_
16	whose	_	WP$	WP$	_	17	NMOD	_	_
17	activities	_	NNS	NNS	_	18	SBJ	_	_
18	are	_	VBP	VBP	_	15	NMOD	_	_
19	repressed	_	VBN	VBN	_	18	VC	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	lymphoid	_	JJ	JJ	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	proto-oncoprotein	_	NN	NN	_	3	NMOD	_	_
3	c-Rel	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	6	NMOD	_	_
6	member	_	NN	NN	_	4	PRD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	15	NMOD	_	_
9	nuclear	_	JJ	JJ	_	15	NMOD	_	_
10	factor	_	NN	NN	_	15	NMOD	_	_
11	kappa	_	NN	NN	_	15	NMOD	_	_
12	B	_	NN	NN	_	15	NMOD	_	_
13	transcription	_	NN	NN	_	15	NMOD	_	_
14	factor	_	NN	NN	_	15	NMOD	_	_
15	family	_	NN	NN	_	7	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	which	_	WDT	WDT	_	18	SBJ	_	_
18	includes	_	VBZ	VBZ	_	15	NMOD	_	_
19	the	_	DT	DT	_	23	NMOD	_	_
20	p50	_	NN	NN	_	23	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	p65	_	NN	NN	_	20	COORD	_	_
23	subunits	_	NNS	NNS	_	18	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	nuclear	_	JJ	JJ	_	28	NMOD	_	_
26	factor	_	NN	NN	_	28	NMOD	_	_
27	kappa	_	NN	NN	_	28	NMOD	_	_
28	B	_	NN	NN	_	24	PMOD	_	_
29	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	that	_	IN	IN	_	2	OBJ	_	_
5	c-Rel	_	NN	NN	_	6	SBJ	_	_
6	binds	_	VBZ	VBZ	_	4	VMOD	_	_
7	to	_	TO	TO	_	6	ADV	_	_
8	kappa	_	NN	NN	_	10	NMOD	_	_
9	B	_	NN	NN	_	10	NMOD	_	_
10	sites	_	NNS	NNS	_	7	PMOD	_	_
11	as	_	IN	IN	_	6	ADV	_	_
12	homodimers	_	NNS	NNS	_	11	PMOD	_	_
13	as	_	RB	RB	_	12	CC	_	_
14	well	_	RB	RB	_	13	DEP	_	_
15	as	_	IN	IN	_	13	DEP	_	_
16	heterodimers	_	NNS	NNS	_	12	COORD	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	p50	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	homodimers	_	NNS	NNS	_	5	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	heterodimers	_	NNS	NNS	_	2	COORD	_	_
5	show	_	VBP	VBP	_	0	ROOT-S	_	_
6	distinct	_	JJ	JJ	_	8	NMOD	_	_
7	DNA-binding	_	JJ	JJ	_	8	NMOD	_	_
8	specificities	_	NNS	NNS	_	5	OBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	affinities	_	NNS	NNS	_	8	COORD	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	various	_	JJ	JJ	_	15	NMOD	_	_
13	kappa	_	NN	NN	_	15	NMOD	_	_
14	B	_	NN	NN	_	15	NMOD	_	_
15	motifs	_	NNS	NNS	_	11	PMOD	_	_
16	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	particular	_	JJ	JJ	_	1	PMOD	_	_
3	,	_	,	,	_	7	P	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	c-Rel	_	NN	NN	_	6	NMOD	_	_
6	homodimer	_	NN	NN	_	7	SBJ	_	_
7	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	high	_	JJ	JJ	_	10	NMOD	_	_
10	affinity	_	NN	NN	_	7	OBJ	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	interleukin-6	_	NN	NN	_	21	NMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	IL-6	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	and	_	CC	CC	_	12	CC	_	_
17	beta	_	NN	NN	_	20	NMOD	_	_
18	interferon	_	NN	NN	_	20	NMOD	_	_
19	kappa	_	NN	NN	_	20	NMOD	_	_
20	B	_	NN	NN	_	12	COORD	_	_
21	sites	_	NNS	NNS	_	11	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	14	ADV	_	_
2	spite	_	NN	NN	_	1	DEP	_	_
3	of	_	IN	IN	_	1	DEP	_	_
4	its	_	PRP$	PRP$	_	5	NMOD	_	_
5	association	_	NN	NN	_	1	PMOD	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	p50	_	NN	NN	_	6	PMOD	_	_
8	in	_	FW	FW	_	5	NMOD	_	_
9	vitro	_	FW	FW	_	8	AMOD	_	_
10	,	_	,	,	_	14	P	_	_
11	however	_	RB	RB	_	14	ADV	_	_
12	,	_	,	,	_	14	P	_	_
13	we	_	PRP	PRP	_	14	SBJ	_	_
14	found	_	VBD	VBD	_	0	ROOT-S	_	_
15	a	_	DT	DT	_	19	NMOD	_	_
16	lymphoid	_	JJ	JJ	_	17	AMOD	_	_
17	cell-specific	_	JJ	JJ	_	19	NMOD	_	_
18	nuclear	_	JJ	JJ	_	19	NMOD	_	_
19	factor	_	NN	NN	_	14	OBJ	_	_
20	in	_	FW	FW	_	14	ADV	_	_
21	vivo	_	FW	FW	_	20	AMOD	_	_
22	that	_	WDT	WDT	_	23	SBJ	_	_
23	contains	_	VBZ	VBZ	_	19	NMOD	_	_
24	c-Rel	_	NN	NN	_	28	NMOD	_	_
25	but	_	CC	CC	_	24	CC	_	_
26	not	_	RB	RB	_	25	COORD	_	_
27	p50	_	NN	NN	_	24	COORD	_	_
28	epitopes	_	NNS	NNS	_	23	OBJ	_	_
29	;	_	:	:	_	14	P	_	_
30	this	_	DT	DT	_	31	NMOD	_	_
31	factor	_	NN	NN	_	41	SBJ	_	_
32	,	_	,	,	_	31	P	_	_
33	termed	_	VBN	VBN	_	31	NMOD	_	_
34	IL-6	_	NN	NN	_	38	NMOD	_	_
35	kappa	_	NN	NN	_	38	NMOD	_	_
36	B	_	NN	NN	_	38	NMOD	_	_
37	binding	_	NN	NN	_	38	NMOD	_	_
38	factor	_	NN	NN	_	33	OBJ	_	_
39	II	_	CD	CD	_	38	NMOD	_	_
40	,	_	,	,	_	31	P	_	_
41	appears	_	VBZ	VBZ	_	14	VMOD	_	_
42	to	_	TO	TO	_	43	VMOD	_	_
43	contain	_	VB	VB	_	41	OBJ	_	_
44	the	_	DT	DT	_	46	NMOD	_	_
45	c-Rel	_	NN	NN	_	46	NMOD	_	_
46	homodimer	_	NN	NN	_	43	OBJ	_	_
47	and	_	CC	CC	_	41	CC	_	_
48	preferentially	_	RB	RB	_	49	ADV	_	_
49	recognizes	_	VBZ	VBZ	_	41	COORD	_	_
50	several	_	JJ	JJ	_	56	NMOD	_	_
51	IL-6	_	NN	NN	_	52	AMOD	_	_
52	kappa	_	NN	NN	_	56	NMOD	_	_
53	B-related	_	JJ	JJ	_	52	AMOD	_	_
54	kappa	_	NN	NN	_	56	NMOD	_	_
55	B	_	NN	NN	_	56	NMOD	_	_
56	motifs	_	NNS	NNS	_	49	OBJ	_	_
57	.	_	.	.	_	41	P	_	_

1	Although	_	IN	IN	_	27	ADV	_	_
2	it	_	PRP	PRP	_	3	SBJ	_	_
3	has	_	VBZ	VBZ	_	1	VMOD	_	_
4	been	_	VBN	VBN	_	3	VC	_	_
5	previously	_	RB	RB	_	4	TMP	_	_
6	shown	_	VBN	VBN	_	4	VC	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	IL-6	_	NN	NN	_	12	NMOD	_	_
10	kappa	_	NN	NN	_	12	NMOD	_	_
11	B	_	NN	NN	_	12	NMOD	_	_
12	motif	_	NN	NN	_	13	SBJ	_	_
13	functions	_	VBZ	VBZ	_	7	VMOD	_	_
14	as	_	IN	IN	_	13	ADV	_	_
15	a	_	DT	DT	_	20	NMOD	_	_
16	potent	_	JJ	JJ	_	20	NMOD	_	_
17	IL-1\/tumor	_	NN	NN	_	18	AMOD	_	_
18	necrosis	_	NN	NN	_	20	NMOD	_	_
19	factor-responsive	_	JJ	JJ	_	18	AMOD	_	_
20	element	_	NN	NN	_	14	PMOD	_	_
21	in	_	IN	IN	_	13	ADV	_	_
22	nonlymphoid	_	JJ	JJ	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	21	PMOD	_	_
24	,	_	,	,	_	27	P	_	_
25	its	_	PRP$	PRP$	_	26	NMOD	_	_
26	activity	_	NN	NN	_	27	SBJ	_	_
27	was	_	VBD	VBD	_	0	ROOT-S	_	_
28	found	_	VBN	VBN	_	27	VC	_	_
29	to	_	TO	TO	_	30	VMOD	_	_
30	be	_	VB	VB	_	28	OBJ	_	_
31	repressed	_	VBN	VBN	_	30	VC	_	_
32	in	_	IN	IN	_	31	ADV	_	_
33	lymphoid	_	JJ	JJ	_	34	NMOD	_	_
34	cells	_	NNS	NNS	_	32	PMOD	_	_
35	such	_	JJ	JJ	_	36	DEP	_	_
36	as	_	IN	IN	_	34	NMOD	_	_
37	a	_	DT	DT	_	40	NMOD	_	_
38	Jurkat	_	NN	NN	_	40	NMOD	_	_
39	T-cell	_	NN	NN	_	40	NMOD	_	_
40	line	_	NN	NN	_	36	PMOD	_	_
41	.	_	.	.	_	27	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	present	_	VBP	VBP	_	0	ROOT-S	_	_
4	evidence	_	NN	NN	_	3	OBJ	_	_
5	that	_	IN	IN	_	4	NMOD	_	_
6	IL-6	_	NN	NN	_	10	NMOD	_	_
7	kappa	_	NN	NN	_	10	NMOD	_	_
8	B	_	NN	NN	_	10	NMOD	_	_
9	binding	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	12	SBJ	_	_
11	II	_	CD	CD	_	10	NMOD	_	_
12	functions	_	VBZ	VBZ	_	5	VMOD	_	_
13	as	_	IN	IN	_	12	ADV	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	repressor	_	NN	NN	_	13	PMOD	_	_
16	specific	_	JJ	JJ	_	15	NMOD	_	_
17	for	_	IN	IN	_	16	AMOD	_	_
18	IL-6	_	NN	NN	_	19	AMOD	_	_
19	kappa	_	NN	NN	_	23	NMOD	_	_
20	B-related	_	JJ	JJ	_	19	AMOD	_	_
21	kappa	_	NN	NN	_	23	NMOD	_	_
22	B	_	NN	NN	_	23	NMOD	_	_
23	motifs	_	NNS	NNS	_	17	PMOD	_	_
24	in	_	IN	IN	_	12	ADV	_	_
25	lymphoid	_	JJ	JJ	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	24	PMOD	_	_
27	.	_	.	.	_	3	P	_	_

1	Modulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	normal	_	JJ	JJ	_	5	NMOD	_	_
4	erythroid	_	JJ	JJ	_	5	NMOD	_	_
5	differentiation	_	NN	NN	_	2	PMOD	_	_
6	by	_	IN	IN	_	1	NMOD	_	_
7	the	_	DT	DT	_	14	NMOD	_	_
8	endogenous	_	JJ	JJ	_	10	NMOD	_	_
9	thyroid	_	NN	NN	_	10	NMOD	_	_
10	hormone	_	NN	NN	_	14	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	retinoic	_	JJ	JJ	_	13	NMOD	_	_
13	acid	_	NN	NN	_	10	COORD	_	_
14	receptors	_	NNS	NNS	_	6	PMOD	_	_
15	:	_	:	:	_	1	P	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	possible	_	JJ	JJ	_	18	NMOD	_	_
18	target	_	NN	NN	_	1	NMOD	_	_
19	for	_	IN	IN	_	18	NMOD	_	_
20	v-erbA	_	NN	NN	_	22	NMOD	_	_
21	oncogene	_	NN	NN	_	22	NMOD	_	_
22	action	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	18	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	v-erbA	_	NN	NN	_	3	NMOD	_	_
3	oncogene	_	NN	NN	_	18	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	mutated	_	VBN	VBN	_	7	NMOD	_	_
7	version	_	NN	NN	_	3	NMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	thyroid	_	NN	NN	_	13	NMOD	_	_
11	hormone	_	NN	NN	_	13	NMOD	_	_
12	receptor	_	NN	NN	_	13	NMOD	_	_
13	alpha	_	NN	NN	_	8	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	c-erbA\/TR-alpha	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	,	_	,	,	_	3	P	_	_
18	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
19	erythroid	_	JJ	JJ	_	20	NMOD	_	_
20	differentiation	_	NN	NN	_	18	OBJ	_	_
21	and	_	CC	CC	_	18	CC	_	_
22	constitutively	_	RB	RB	_	23	ADV	_	_
23	represses	_	VBZ	VBZ	_	18	COORD	_	_
24	transcription	_	NN	NN	_	23	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	certain	_	JJ	JJ	_	28	NMOD	_	_
27	erythrocyte	_	NN	NN	_	28	NMOD	_	_
28	genes	_	NNS	NNS	_	25	PMOD	_	_
29	,	_	,	,	_	18	P	_	_
30	suggesting	_	VBG	VBG	_	18	OBJ	_	_
31	a	_	DT	DT	_	33	NMOD	_	_
32	normal	_	JJ	JJ	_	33	NMOD	_	_
33	function	_	NN	NN	_	30	OBJ	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	the	_	DT	DT	_	37	NMOD	_	_
36	proto-oncogene	_	NN	NN	_	37	NMOD	_	_
37	c-erbA	_	NN	NN	_	34	PMOD	_	_
38	in	_	IN	IN	_	33	NMOD	_	_
39	erythropoiesis	_	NN	NN	_	38	PMOD	_	_
40	.	_	.	.	_	18	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	10	NMOD	_	_
6	endogenous	_	JJ	JJ	_	10	NMOD	_	_
7	thyroid	_	NN	NN	_	10	NMOD	_	_
8	hormone	_	NN	NN	_	10	NMOD	_	_
9	receptor	_	NN	NN	_	10	NMOD	_	_
10	alpha	_	NN	NN	_	25	SBJ	_	_
11	(	_	(	(	_	12	P	_	_
12	c-erbA\/TR-alpha	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	and	_	CC	CC	_	10	CC	_	_
15	the	_	DT	DT	_	21	NMOD	_	_
16	closely	_	RB	RB	_	17	AMOD	_	_
17	related	_	JJ	JJ	_	21	NMOD	_	_
18	retinoic	_	JJ	JJ	_	21	NMOD	_	_
19	acid	_	NN	NN	_	21	NMOD	_	_
20	receptor	_	NN	NN	_	21	NMOD	_	_
21	alpha	_	NN	NN	_	10	COORD	_	_
22	(	_	(	(	_	23	P	_	_
23	RAR-alpha	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	play	_	VBP	VBP	_	4	VMOD	_	_
26	a	_	DT	DT	_	27	NMOD	_	_
27	role	_	NN	NN	_	25	OBJ	_	_
28	in	_	IN	IN	_	25	ADV	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	regulation	_	NN	NN	_	28	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	normal	_	JJ	JJ	_	34	NMOD	_	_
33	erythroid	_	JJ	JJ	_	34	NMOD	_	_
34	differentiation	_	NN	NN	_	31	PMOD	_	_
35	.	_	.	.	_	3	P	_	_

1	Retinoic	_	JJ	JJ	_	2	NMOD	_	_
2	acid	_	NN	NN	_	7	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	RA	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	distinctly	_	RB	RB	_	7	ADV	_	_
7	modulated	_	VBD	VBD	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	erythroid	_	JJ	JJ	_	11	NMOD	_	_
10	differentiation	_	NN	NN	_	11	NMOD	_	_
11	program	_	NN	NN	_	7	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	normal	_	JJ	JJ	_	15	NMOD	_	_
14	erythroid	_	JJ	JJ	_	15	NMOD	_	_
15	progenitors	_	NNS	NNS	_	12	PMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	erythroblasts	_	NNS	NNS	_	15	COORD	_	_
18	reversibly	_	RB	RB	_	19	ADV	_	_
19	transformed	_	VBN	VBN	_	15	NMOD	_	_
20	by	_	IN	IN	_	19	LGS	_	_
21	a	_	DT	DT	_	25	NMOD	_	_
22	conditional	_	JJ	JJ	_	25	NMOD	_	_
23	tyrosine	_	NN	NN	_	25	NMOD	_	_
24	kinase	_	NN	NN	_	25	NMOD	_	_
25	oncogene	_	NN	NN	_	20	PMOD	_	_
26	.	_	.	.	_	7	P	_	_

1	When	_	WRB	WRB	_	2	ADV	_	_
2	added	_	VBN	VBN	_	9	TMP	_	_
3	pulsewise	_	RB	RB	_	2	ADV	_	_
4	to	_	TO	TO	_	2	ADV	_	_
5	immature	_	JJ	JJ	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	,	_	,	,	_	9	P	_	_
8	differentiation	_	NN	NN	_	9	SBJ	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	accelerated	_	VBN	VBN	_	9	VC	_	_
11	while	_	IN	IN	_	10	OBJ	_	_
12	more	_	RBR	RBR	_	13	AMOD	_	_
13	mature	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	15	SBJ	_	_
15	underwent	_	VBD	VBD	_	11	VMOD	_	_
16	premature	_	JJ	JJ	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	death	_	NN	NN	_	15	OBJ	_	_
19	.	_	.	.	_	9	P	_	_

1	Thyroid	_	NN	NN	_	2	NMOD	_	_
2	hormone	_	NN	NN	_	7	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	T3	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	alone	_	RB	RB	_	2	NMOD	_	_
7	caused	_	VBD	VBD	_	0	ROOT-S	_	_
8	similar	_	JJ	JJ	_	11	NMOD	_	_
9	but	_	CC	CC	_	8	CC	_	_
10	weaker	_	JJR	JJR	_	8	COORD	_	_
11	effects	_	NNS	NNS	_	7	OBJ	_	_
12	.	_	.	.	_	7	P	_	_

1	Interestingly	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	T3	_	NN	NN	_	5	SBJ	_	_
4	strongly	_	RB	RB	_	5	ADV	_	_
5	enhanced	_	VBD	VBD	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	action	_	NN	NN	_	5	IOBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	RA	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	5	P	_	_
11	suggesting	_	VBG	VBG	_	5	OBJ	_	_
12	cooperative	_	JJ	JJ	_	13	NMOD	_	_
13	action	_	NN	NN	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	two	_	CD	CD	_	17	NMOD	_	_
17	receptors	_	NNS	NNS	_	14	PMOD	_	_
18	in	_	IN	IN	_	13	NMOD	_	_
19	modulating	_	VBG	VBG	_	18	PMOD	_	_
20	erythroid	_	JJ	JJ	_	21	NMOD	_	_
21	differentiation	_	NN	NN	_	19	OBJ	_	_
22	.	_	.	.	_	5	P	_	_

1	Expression	_	NN	NN	_	9	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	human	_	JJ	JJ	_	5	NMOD	_	_
5	RAR-alpha	_	NN	NN	_	2	PMOD	_	_
6	in	_	IN	IN	_	1	NMOD	_	_
7	receptor-negative	_	JJ	JJ	_	8	NMOD	_	_
8	erythroblasts	_	NNS	NNS	_	6	PMOD	_	_
9	conferred	_	VBD	VBD	_	0	ROOT-S	_	_
10	RA-induced	_	JJ	JJ	_	11	NMOD	_	_
11	regulation	_	NN	NN	_	9	IOBJ	_	_
12	of	_	IN	IN	_	9	ADV	_	_
13	differentiation	_	NN	NN	_	12	PMOD	_	_
14	to	_	TO	TO	_	9	ADV	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	otherwise	_	RB	RB	_	17	AMOD	_	_
17	unresponsive	_	JJ	JJ	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	14	PMOD	_	_
19	,	_	,	,	_	9	P	_	_
20	thus	_	RB	RB	_	9	VMOD	_	_
21	showing	_	VBG	VBG	_	9	OBJ	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	RAR-alpha	_	NN	NN	_	25	SBJ	_	_
25	is	_	VBZ	VBZ	_	22	VMOD	_	_
26	essential	_	JJ	JJ	_	25	PRD	_	_
27	for	_	IN	IN	_	26	AMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	RA	_	NN	NN	_	30	NMOD	_	_
30	effect	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	9	P	_	_

1	Likewise	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	enhanced	_	VBN	VBN	_	4	NMOD	_	_
4	expression	_	NN	NN	_	10	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	exogenous	_	JJ	JJ	_	7	NMOD	_	_
7	c-erbA\/TR-alpha	_	NN	NN	_	5	PMOD	_	_
8	in	_	IN	IN	_	4	NMOD	_	_
9	erythroblasts	_	NNS	NNS	_	8	PMOD	_	_
10	rendered	_	VBD	VBD	_	0	ROOT-S	_	_
11	them	_	PRP	PRP	_	12	SBJ	_	_
12	susceptible	_	JJ	JJ	_	10	OBJ	_	_
13	to	_	TO	TO	_	12	AMOD	_	_
14	modulation	_	NN	NN	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	differentiation	_	NN	NN	_	15	PMOD	_	_
17	by	_	IN	IN	_	14	NMOD	_	_
18	T3	_	NN	NN	_	17	PMOD	_	_
19	,	_	,	,	_	10	P	_	_
20	suggesting	_	VBG	VBG	_	10	ADV	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	similar	_	JJ	JJ	_	23	NMOD	_	_
23	function	_	NN	NN	_	20	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	both	_	DT	DT	_	26	NMOD	_	_
26	receptors	_	NNS	NNS	_	24	PMOD	_	_
27	.	_	.	.	_	10	P	_	_

1	An	_	DT	DT	_	5	NMOD	_	_
2	11-base-pair	_	JJ	JJ	_	5	NMOD	_	_
3	DNA	_	NN	NN	_	5	NMOD	_	_
4	sequence	_	NN	NN	_	5	NMOD	_	_
5	motif	_	NN	NN	_	14	SBJ	_	_
6	apparently	_	RB	RB	_	7	AMOD	_	_
7	unique	_	JJ	JJ	_	5	NMOD	_	_
8	to	_	TO	TO	_	7	AMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	human	_	JJ	JJ	_	13	NMOD	_	_
11	interleukin	_	NN	NN	_	13	NMOD	_	_
12	4	_	CD	CD	_	13	NMOD	_	_
13	gene	_	NN	NN	_	8	PMOD	_	_
14	confers	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	responsiveness	_	NN	NN	_	14	OBJ	_	_
16	to	_	TO	TO	_	15	NMOD	_	_
17	T-cell	_	NN	NN	_	19	NMOD	_	_
18	activation	_	NN	NN	_	19	NMOD	_	_
19	signals	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	14	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	identified	_	VBN	VBN	_	2	VC	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	DNA	_	NN	NN	_	6	NMOD	_	_
6	segment	_	NN	NN	_	3	OBJ	_	_
7	that	_	WDT	WDT	_	8	SBJ	_	_
8	confers	_	VBZ	VBZ	_	6	NMOD	_	_
9	responsiveness	_	NN	NN	_	8	OBJ	_	_
10	to	_	TO	TO	_	9	NMOD	_	_
11	antigen	_	NN	NN	_	13	NMOD	_	_
12	stimulation	_	NN	NN	_	13	NMOD	_	_
13	signals	_	NNS	NNS	_	10	PMOD	_	_
14	on	_	IN	IN	_	8	ADV	_	_
15	the	_	DT	DT	_	22	NMOD	_	_
16	human	_	JJ	JJ	_	22	NMOD	_	_
17	interleukin	_	NN	NN	_	22	NMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	IL	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	4	_	CD	CD	_	22	NMOD	_	_
22	gene	_	NN	NN	_	14	PMOD	_	_
23	in	_	IN	IN	_	22	NMOD	_	_
24	Jurkat	_	NN	NN	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	23	PMOD	_	_
26	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	human	_	JJ	JJ	_	4	NMOD	_	_
3	IL-4	_	NN	NN	_	4	NMOD	_	_
4	gene	_	NN	NN	_	10	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	of	_	IN	IN	_	4	NMOD	_	_
7	10	_	CD	CD	_	8	NMOD	_	_
8	kilobases	_	NNS	NNS	_	6	PMOD	_	_
9	,	_	,	,	_	4	P	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	composed	_	VBN	VBN	_	10	VC	_	_
12	of	_	IN	IN	_	11	ADV	_	_
13	four	_	CD	CD	_	14	NMOD	_	_
14	exons	_	NNS	NNS	_	12	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	three	_	CD	CD	_	17	NMOD	_	_
17	introns	_	NNS	NNS	_	14	COORD	_	_
18	.	_	.	.	_	10	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	cis-acting	_	JJ	JJ	_	3	NMOD	_	_
3	element	_	NN	NN	_	8	SBJ	_	_
4	(	_	(	(	_	6	P	_	_
5	P	_	NN	NN	_	6	NMOD	_	_
6	sequence	_	NN	NN	_	3	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	resides	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	5'	_	JJ	JJ	_	12	AMOD	_	_
12	upstream	_	JJ	JJ	_	13	NMOD	_	_
13	region	_	NN	NN	_	9	PMOD	_	_
14	;	_	:	:	_	8	P	_	_
15	no	_	DT	DT	_	18	NMOD	_	_
16	additional	_	JJ	JJ	_	18	NMOD	_	_
17	DNA	_	NN	NN	_	18	NMOD	_	_
18	segments	_	NNS	NNS	_	22	SBJ	_	_
19	with	_	IN	IN	_	18	NMOD	_	_
20	enhancer	_	NN	NN	_	21	NMOD	_	_
21	activity	_	NN	NN	_	19	PMOD	_	_
22	were	_	VBD	VBD	_	8	VMOD	_	_
23	identified	_	VBN	VBN	_	22	VC	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	the	_	DT	DT	_	28	NMOD	_	_
26	human	_	JJ	JJ	_	28	NMOD	_	_
27	IL-4	_	NN	NN	_	28	NMOD	_	_
28	gene	_	NN	NN	_	24	PMOD	_	_
29	.	_	.	.	_	22	P	_	_

1	For	_	IN	IN	_	9	ADV	_	_
2	further	_	JJ	JJ	_	4	NMOD	_	_
3	mapping	_	NN	NN	_	4	NMOD	_	_
4	purposes	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	9	P	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	fusion	_	NN	NN	_	8	NMOD	_	_
8	promoter	_	NN	NN	_	9	SBJ	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	constructed	_	VBN	VBN	_	9	VC	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	17	NMOD	_	_
13	granulocyte\/macrophage	_	JJ	JJ	_	14	AMOD	_	_
14	colony-stimulating	_	JJ	JJ	_	17	NMOD	_	_
15	factor	_	NN	NN	_	17	NMOD	_	_
16	basic	_	JJ	JJ	_	17	NMOD	_	_
17	promoter	_	NN	NN	_	11	PMOD	_	_
18	containing	_	VBG	VBG	_	17	NMOD	_	_
19	60	_	CD	CD	_	21	NMOD	_	_
20	base	_	NN	NN	_	21	NMOD	_	_
21	pairs	_	NNS	NNS	_	18	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	sequence	_	NN	NN	_	22	PMOD	_	_
24	upstream	_	JJ	JJ	_	21	NMOD	_	_
25	from	_	IN	IN	_	24	AMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	cap	_	NN	NN	_	28	NMOD	_	_
28	site	_	NN	NN	_	25	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	35	NMOD	_	_
31	mouse	_	NN	NN	_	35	NMOD	_	_
32	granulocyte\/macrophage	_	JJ	JJ	_	33	AMOD	_	_
33	colony-stimulating	_	JJ	JJ	_	35	NMOD	_	_
34	factor	_	NN	NN	_	35	NMOD	_	_
35	gene	_	NN	NN	_	29	PMOD	_	_
36	and	_	CC	CC	_	21	CC	_	_
37	various	_	JJ	JJ	_	38	NMOD	_	_
38	lengths	_	NNS	NNS	_	21	COORD	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	the	_	DT	DT	_	43	NMOD	_	_
41	5'	_	JJ	JJ	_	42	AMOD	_	_
42	upstream	_	JJ	JJ	_	43	NMOD	_	_
43	sequence	_	NN	NN	_	39	PMOD	_	_
44	of	_	IN	IN	_	43	NMOD	_	_
45	the	_	DT	DT	_	47	NMOD	_	_
46	IL-4	_	NN	NN	_	47	NMOD	_	_
47	gene	_	NN	NN	_	44	PMOD	_	_
48	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	P	_	NN	NN	_	3	NMOD	_	_
3	sequence	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	located	_	JJ	JJ	_	4	PRD	_	_
6	between	_	IN	IN	_	5	AMOD	_	_
7	positions	_	NNS	NNS	_	6	PMOD	_	_
8	-79	_	CD	CD	_	7	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	-69	_	CD	CD	_	8	COORD	_	_
11	relative	_	JJ	JJ	_	12	DEP	_	_
12	to	_	TO	TO	_	5	AMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	transcription	_	NN	NN	_	16	NMOD	_	_
15	start	_	NN	NN	_	16	NMOD	_	_
16	site	_	NN	NN	_	12	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	human	_	JJ	JJ	_	21	NMOD	_	_
20	IL-4	_	NN	NN	_	21	NMOD	_	_
21	gene	_	NN	NN	_	17	PMOD	_	_
22	,	_	,	,	_	4	P	_	_
23	and	_	CC	CC	_	4	CC	_	_
24	this	_	DT	DT	_	25	NMOD	_	_
25	location	_	NN	NN	_	26	SBJ	_	_
26	was	_	VBD	VBD	_	4	COORD	_	_
27	confirmed	_	VBN	VBN	_	26	VC	_	_
28	by	_	IN	IN	_	27	LGS	_	_
29	base-substitution	_	NN	NN	_	30	NMOD	_	_
30	mutations	_	NNS	NNS	_	28	PMOD	_	_
31	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	plasmids	_	NNS	NNS	_	10	SBJ	_	_
3	carrying	_	VBG	VBG	_	2	NMOD	_	_
4	multiple	_	JJ	JJ	_	5	NMOD	_	_
5	copies	_	NNS	NNS	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	P	_	NN	NN	_	9	NMOD	_	_
9	sequence	_	NN	NN	_	6	PMOD	_	_
10	showed	_	VBD	VBD	_	0	ROOT-S	_	_
11	higher	_	JJR	JJR	_	12	NMOD	_	_
12	responsiveness	_	NN	NN	_	10	OBJ	_	_
13	to	_	TO	TO	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	stimulation	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	binding	_	VBG	VBG	_	5	NMOD	_	_
3	protein	_	NN	NN	_	5	NMOD	_	_
4	(	_	(	(	_	5	P	_	_
5	s	_	NNS	NNS	_	16	SBJ	_	_
6	)	_	)	)	_	5	P	_	_
7	that	_	WDT	WDT	_	8	SBJ	_	_
8	recognize	_	VBP	VBP	_	5	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	P	_	NN	NN	_	11	NMOD	_	_
11	sequence	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	IL-4	_	NN	NN	_	15	NMOD	_	_
15	gene	_	NN	NN	_	12	PMOD	_	_
16	were	_	VBD	VBD	_	0	ROOT-S	_	_
17	identified	_	VBN	VBN	_	16	VC	_	_
18	by	_	IN	IN	_	17	LGS	_	_
19	DNA-mobility-shift	_	JJ	JJ	_	20	NMOD	_	_
20	assays	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	binding	_	NN	NN	_	21	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NF-LRB-P-RRB-	_	NN	NN	_	3	PMOD	_	_
5	(	_	(	(	_	9	P	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	DNA	_	NN	NN	_	9	NMOD	_	_
8	binding	_	NN	NN	_	9	NMOD	_	_
9	protein	_	NN	NN	_	4	PRN	_	_
10	that	_	WDT	WDT	_	12	SBJ	_	_
11	specifically	_	RB	RB	_	12	ADV	_	_
12	recognizes	_	VBZ	VBZ	_	9	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	P	_	NN	NN	_	15	NMOD	_	_
15	sequence	_	NN	NN	_	12	OBJ	_	_
16	)	_	)	)	_	9	P	_	_
17	to	_	TO	TO	_	2	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	P	_	NN	NN	_	20	NMOD	_	_
20	sequence	_	NN	NN	_	17	PMOD	_	_
21	was	_	VBD	VBD	_	0	ROOT-S	_	_
22	abolished	_	VBN	VBN	_	21	VC	_	_
23	when	_	WRB	WRB	_	29	ADV	_	_
24	oligonucleotides	_	NNS	NNS	_	28	SBJ	_	_
25	carrying	_	VBG	VBG	_	24	NMOD	_	_
26	base	_	NN	NN	_	27	NMOD	_	_
27	substitutions	_	NNS	NNS	_	25	OBJ	_	_
28	were	_	VBD	VBD	_	22	TMP	_	_
29	used	_	VBN	VBN	_	28	VC	_	_
30	,	_	,	,	_	22	P	_	_
31	indicating	_	VBG	VBG	_	22	OBJ	_	_
32	that	_	IN	IN	_	31	OBJ	_	_
33	the	_	DT	DT	_	35	NMOD	_	_
34	NF-LRB-P-RRB-	_	NN	NN	_	35	NMOD	_	_
35	interaction	_	NN	NN	_	36	SBJ	_	_
36	is	_	VBZ	VBZ	_	32	VMOD	_	_
37	sequence-specific	_	JJ	JJ	_	36	PRD	_	_
38	and	_	CC	CC	_	32	CC	_	_
39	that	_	IN	IN	_	32	COORD	_	_
40	binding	_	NN	NN	_	41	NMOD	_	_
41	specificity	_	NN	NN	_	39	SBJ	_	_
42	of	_	IN	IN	_	41	NMOD	_	_
43	the	_	DT	DT	_	44	NMOD	_	_
44	protein	_	NN	NN	_	42	PMOD	_	_
45	paralleled	_	VBD	VBD	_	39	VMOD	_	_
46	the	_	DT	DT	_	48	NMOD	_	_
47	sequence	_	NN	NN	_	48	NMOD	_	_
48	requirements	_	NNS	NNS	_	45	OBJ	_	_
49	for	_	IN	IN	_	48	NMOD	_	_
50	IL-4	_	NN	NN	_	51	NMOD	_	_
51	expression	_	NN	NN	_	49	PMOD	_	_
52	in	_	FW	FW	_	48	NMOD	_	_
53	vivo	_	FW	FW	_	52	AMOD	_	_
54	.	_	.	.	_	21	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	P	_	NN	NN	_	3	NMOD	_	_
3	sequence	_	NN	NN	_	4	SBJ	_	_
4	does	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	share	_	VB	VB	_	4	VC	_	_
7	homology	_	NN	NN	_	6	IOBJ	_	_
8	with	_	IN	IN	_	6	ADV	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	5'	_	JJ	JJ	_	11	AMOD	_	_
11	upstream	_	JJ	JJ	_	12	NMOD	_	_
12	sequence	_	NN	NN	_	8	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	IL-2	_	NN	NN	_	16	NMOD	_	_
16	gene	_	NN	NN	_	13	PMOD	_	_
17	,	_	,	,	_	6	P	_	_
18	even	_	RB	RB	_	19	VMOD	_	_
19	though	_	IN	IN	_	6	OBJ	_	_
20	surrounding	_	VBG	VBG	_	21	NMOD	_	_
21	sequences	_	NNS	NNS	_	26	SBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	IL-4	_	NN	NN	_	25	NMOD	_	_
25	gene	_	NN	NN	_	22	PMOD	_	_
26	share	_	NN	NN	_	19	VMOD	_	_
27	high	_	JJ	JJ	_	28	NMOD	_	_
28	homology	_	NN	NN	_	26	OBJ	_	_
29	with	_	IN	IN	_	26	ADV	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	IL-2	_	NN	NN	_	32	NMOD	_	_
32	gene	_	NN	NN	_	29	PMOD	_	_
33	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	conclude	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	different	_	JJ	JJ	_	6	NMOD	_	_
6	set	_	NN	NN	_	9	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	proteins	_	NNS	NNS	_	7	PMOD	_	_
9	recognize	_	VBP	VBP	_	3	VMOD	_	_
10	IL-2	_	NN	NN	_	13	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	IL-4	_	NN	NN	_	10	COORD	_	_
13	genes	_	NNS	NNS	_	9	OBJ	_	_
14	.	_	.	.	_	2	P	_	_

1	Glucocorticoid	_	NN	NN	_	3	NMOD	_	_
2	receptor	_	NN	NN	_	3	NMOD	_	_
3	binding	_	NN	NN	_	0	ROOT-FRAG	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	three	_	CD	CD	_	8	NMOD	_	_
6	different	_	JJ	JJ	_	8	NMOD	_	_
7	cell	_	NN	NN	_	8	NMOD	_	_
8	types	_	NNS	NNS	_	4	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	major	_	JJ	JJ	_	12	NMOD	_	_
11	depressive	_	JJ	JJ	_	12	NMOD	_	_
12	disorder	_	NN	NN	_	9	PMOD	_	_
13	:	_	:	:	_	3	P	_	_
14	lack	_	NN	NN	_	3	NMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	evidence	_	NN	NN	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	receptor	_	NN	NN	_	20	NMOD	_	_
19	binding	_	NN	NN	_	20	NMOD	_	_
20	defect	_	NN	NN	_	17	PMOD	_	_
21	.	_	.	.	_	14	P	_	_

1	1	_	LS	LS	_	39	VMOD	_	_
2	.	_	.	.	_	1	P	_	_
3	In	_	IN	IN	_	39	PRP	_	_
4	order	_	NN	NN	_	3	VMOD	_	_
5	to	_	TO	TO	_	3	VMOD	_	_
6	further	_	RB	RB	_	7	ADV	_	_
7	understand	_	VB	VB	_	3	VMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	apparent	_	JJ	JJ	_	11	NMOD	_	_
10	glucocorticoid	_	NN	NN	_	11	NMOD	_	_
11	resistance	_	NN	NN	_	7	OBJ	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	major	_	JJ	JJ	_	15	NMOD	_	_
14	depressive	_	JJ	JJ	_	15	NMOD	_	_
15	disorder	_	NN	NN	_	12	PMOD	_	_
16	,	_	,	,	_	39	P	_	_
17	circadian	_	JJ	JJ	_	18	NMOD	_	_
18	variation	_	NN	NN	_	39	SBJ	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	cortisol	_	NN	NN	_	21	NMOD	_	_
21	concentration	_	NN	NN	_	19	PMOD	_	_
22	,	_	,	,	_	18	P	_	_
23	dexamethasone	_	NN	NN	_	24	NMOD	_	_
24	suppression	_	NN	NN	_	18	COORD	_	_
25	and	_	CC	CC	_	18	CC	_	_
26	glucocorticoid	_	NN	NN	_	28	NMOD	_	_
27	receptor	_	NN	NN	_	28	NMOD	_	_
28	binding	_	NN	NN	_	18	COORD	_	_
29	in	_	IN	IN	_	28	NMOD	_	_
30	mononuclear	_	JJ	JJ	_	31	NMOD	_	_
31	leukocytes	_	NNS	NNS	_	29	PMOD	_	_
32	,	_	,	,	_	31	P	_	_
33	polymorphonuclear	_	JJ	JJ	_	34	NMOD	_	_
34	leukocytes	_	NNS	NNS	_	31	COORD	_	_
35	and	_	CC	CC	_	31	CC	_	_
36	cultured	_	VBN	VBN	_	38	NMOD	_	_
37	skin	_	NN	NN	_	38	NMOD	_	_
38	fibroblasts	_	NNS	NNS	_	31	COORD	_	_
39	were	_	VBD	VBD	_	0	ROOT-S	_	_
40	measured	_	VBN	VBN	_	39	VC	_	_
41	in	_	IN	IN	_	40	ADV	_	_
42	rigidly	_	RB	RB	_	43	AMOD	_	_
43	defined	_	VBN	VBN	_	47	NMOD	_	_
44	major	_	JJ	JJ	_	47	NMOD	_	_
45	depressive	_	JJ	JJ	_	47	NMOD	_	_
46	disorder	_	NN	NN	_	47	NMOD	_	_
47	patients	_	NNS	NNS	_	41	PMOD	_	_
48	and	_	CC	CC	_	47	CC	_	_
49	non-depressed	_	JJ	JJ	_	51	NMOD	_	_
50	psychiatric	_	JJ	JJ	_	51	NMOD	_	_
51	controls	_	NNS	NNS	_	47	COORD	_	_
52	.	_	.	.	_	39	P	_	_

1	2	_	LS	LS	_	8	VMOD	_	_
2	.	_	.	.	_	1	P	_	_
3	Mononuclear	_	JJ	JJ	_	4	NMOD	_	_
4	leukocytes	_	NNS	NNS	_	8	SBJ	_	_
5	binding	_	VBG	VBG	_	4	NMOD	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	glucocorticoid	_	NN	NN	_	6	PMOD	_	_
8	correlated	_	VBD	VBD	_	0	ROOT-S	_	_
9	significantly	_	RB	RB	_	8	ADV	_	_
10	with	_	IN	IN	_	8	ADV	_	_
11	polymorphonuclear	_	JJ	JJ	_	12	NMOD	_	_
12	leukocytes	_	NNS	NNS	_	10	PMOD	_	_
13	binding	_	VBG	VBG	_	12	NMOD	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	glucocorticoid	_	NN	NN	_	14	PMOD	_	_
16	,	_	,	,	_	8	P	_	_
17	but	_	CC	CC	_	8	CC	_	_
18	both	_	DT	DT	_	19	NMOD	_	_
19	determinations	_	NNS	NNS	_	20	SBJ	_	_
20	failed	_	VBD	VBD	_	8	COORD	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	differentiate	_	VB	VB	_	20	OBJ	_	_
23	major	_	JJ	JJ	_	25	NMOD	_	_
24	depressive	_	JJ	JJ	_	25	NMOD	_	_
25	disorder	_	NN	NN	_	22	OBJ	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	control	_	NN	NN	_	28	NMOD	_	_
28	subjects	_	NNS	NNS	_	25	COORD	_	_
29	.	_	.	.	_	8	P	_	_

1	3	_	LS	LS	_	12	VMOD	_	_
2	.	_	.	.	_	1	P	_	_
3	Initial	_	JJ	JJ	_	8	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	post-dexamethasone	_	JJ	JJ	_	3	COORD	_	_
6	in	_	FW	FW	_	7	AMOD	_	_
7	vitro	_	FW	FW	_	8	NMOD	_	_
8	fibroblast	_	NN	NN	_	12	SBJ	_	_
9	binding	_	VBG	VBG	_	8	NMOD	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	glucocorticoid	_	NN	NN	_	10	PMOD	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	not	_	RB	RB	_	12	VMOD	_	_
14	different	_	JJ	JJ	_	12	PRD	_	_
15	between	_	IN	IN	_	12	ADV	_	_
16	major	_	JJ	JJ	_	18	NMOD	_	_
17	depressive	_	JJ	JJ	_	18	NMOD	_	_
18	disorder	_	NN	NN	_	15	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	non-depressed	_	JJ	JJ	_	22	NMOD	_	_
21	control	_	NN	NN	_	22	NMOD	_	_
22	subjects	_	NNS	NNS	_	18	COORD	_	_
23	.	_	.	.	_	12	P	_	_

1	4	_	LS	LS	_	12	VMOD	_	_
2	.	_	.	.	_	1	P	_	_
3	The	_	DT	DT	_	4	NMOD	_	_
4	phenomenon	_	NN	NN	_	12	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	glucocorticoid	_	NN	NN	_	7	NMOD	_	_
7	resistance	_	NN	NN	_	5	PMOD	_	_
8	in	_	IN	IN	_	4	NMOD	_	_
9	major	_	JJ	JJ	_	11	NMOD	_	_
10	depressive	_	JJ	JJ	_	11	NMOD	_	_
11	disorder	_	NN	NN	_	8	PMOD	_	_
12	remains	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	unexplained	_	JJ	JJ	_	12	PRD	_	_
14	.	_	.	.	_	12	P	_	_

1	Kinetics	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	nuclear	_	JJ	JJ	_	4	NMOD	_	_
4	translocation	_	NN	NN	_	2	PMOD	_	_
5	and	_	CC	CC	_	1	CC	_	_
6	turnover	_	NN	NN	_	1	COORD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	vitamin	_	NN	NN	_	11	NMOD	_	_
10	D	_	NN	NN	_	11	NMOD	_	_
11	receptor	_	NN	NN	_	7	PMOD	_	_
12	in	_	IN	IN	_	1	NMOD	_	_
13	human	_	JJ	JJ	_	16	NMOD	_	_
14	HL60	_	NN	NN	_	16	NMOD	_	_
15	leukemia	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	12	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	peripheral	_	JJ	JJ	_	20	NMOD	_	_
19	blood	_	NN	NN	_	20	NMOD	_	_
20	lymphocytes	_	NNS	NNS	_	16	COORD	_	_
21	--	_	:	:	_	1	P	_	_
22	coincident	_	JJ	JJ	_	23	NMOD	_	_
23	rise	_	NN	NN	_	1	NMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	DNA-relaxing	_	JJ	JJ	_	26	NMOD	_	_
26	activity	_	NN	NN	_	24	PMOD	_	_
27	in	_	IN	IN	_	23	NMOD	_	_
28	nuclear	_	JJ	JJ	_	29	NMOD	_	_
29	extracts	_	NNS	NNS	_	27	PMOD	_	_
30	.	_	.	.	_	23	P	_	_

1	High	_	JJ	JJ	_	3	NMOD	_	_
2	affinity	_	NN	NN	_	3	NMOD	_	_
3	receptors	_	NNS	NNS	_	12	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	VDR	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	for	_	IN	IN	_	3	NMOD	_	_
8	1,25-dihydroxycholecalciferol	_	NN	NN	_	7	PMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	calcitriol	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	are	_	VBP	VBP	_	0	ROOT-S	_	_
13	expressed	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	HL60	_	NN	NN	_	18	NMOD	_	_
16	human	_	JJ	JJ	_	18	NMOD	_	_
17	leukemia	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	14	PMOD	_	_
19	and	_	CC	CC	_	14	CC	_	_
20	in	_	IN	IN	_	14	COORD	_	_
21	low	_	JJ	JJ	_	22	NMOD	_	_
22	numbers	_	NNS	NNS	_	20	PMOD	_	_
23	in	_	IN	IN	_	22	NMOD	_	_
24	peripheral	_	JJ	JJ	_	26	NMOD	_	_
25	blood	_	NN	NN	_	26	NMOD	_	_
26	lymphocytes	_	NNS	NNS	_	23	PMOD	_	_
27	(	_	(	(	_	28	P	_	_
28	PBL	_	NN	NN	_	26	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	.	_	.	.	_	12	P	_	_

1	HL60	_	NN	NN	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	10	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	expressing	_	VBG	VBG	_	2	NMOD	_	_
5	some	_	DT	DT	_	6	NMOD	_	_
6	characteristics	_	NNS	NNS	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	promyelocytes	_	NNS	NNS	_	7	PMOD	_	_
9	,	_	,	,	_	2	P	_	_
10	can	_	MD	MD	_	0	ROOT-S	_	_
11	be	_	VB	VB	_	10	VC	_	_
12	induced	_	VBN	VBN	_	11	VC	_	_
13	to	_	TO	TO	_	12	ADV	_	_
14	monocytoid	_	NN	NN	_	15	NMOD	_	_
15	differentiation	_	NN	NN	_	13	PMOD	_	_
16	by	_	IN	IN	_	12	LGS	_	_
17	calcitriol	_	NN	NN	_	16	PMOD	_	_
18	.	_	.	.	_	10	P	_	_

1	Specific	_	JJ	JJ	_	3	NMOD	_	_
2	nuclear	_	JJ	JJ	_	3	NMOD	_	_
3	translocation	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	-LCB-3H-RCB-calcitriol\/VDR	_	NN	NN	_	4	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	examined	_	VBN	VBN	_	6	VC	_	_
8	after	_	IN	IN	_	7	TMP	_	_
9	exposure	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	whole	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	to	_	TO	TO	_	9	NMOD	_	_
14	10-LRB--9-RRB-	_	CD	CD	_	15	AMOD	_	_
15	M\/l	_	NN	NN	_	16	NMOD	_	_
16	calcitriol	_	NN	NN	_	13	PMOD	_	_
17	in	_	IN	IN	_	9	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	presence	_	NN	NN	_	17	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	absence	_	NN	NN	_	19	COORD	_	_
22	of	_	IN	IN	_	19	NMOD	_	_
23	a	_	DT	DT	_	25	NMOD	_	_
24	500-fold	_	JJ	JJ	_	25	NMOD	_	_
25	excess	_	NN	NN	_	22	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	unlabeled	_	JJ	JJ	_	28	NMOD	_	_
28	ligand	_	NN	NN	_	26	PMOD	_	_
29	and	_	CC	CC	_	9	CC	_	_
30	subsequent	_	JJ	JJ	_	31	NMOD	_	_
31	isolation	_	NN	NN	_	9	COORD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	nuclei	_	NNS	NNS	_	32	PMOD	_	_
34	.	_	.	.	_	6	P	_	_

1	Specific	_	JJ	JJ	_	3	NMOD	_	_
2	nuclear	_	JJ	JJ	_	3	NMOD	_	_
3	translocation	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	-LCB-3H-RCB-calcitriol\/VDR	_	NN	NN	_	4	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	found	_	VBN	VBN	_	6	VC	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	be	_	VB	VB	_	7	OBJ	_	_
10	time	_	NN	NN	_	9	PRD	_	_
11	dependent	_	JJ	JJ	_	10	AMOD	_	_
12	reaching	_	VBG	VBG	_	9	VC	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	maximum	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	approximately	_	RB	RB	_	19	NMOD	_	_
17	2100	_	CD	CD	_	16	DEP	_	_
18	binding	_	VBG	VBG	_	19	NMOD	_	_
19	sites\/nucleus	_	NNS	NNS	_	15	PMOD	_	_
20	after	_	IN	IN	_	12	TMP	_	_
21	3	_	CD	CD	_	22	NMOD	_	_
22	h	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	incubation	_	NN	NN	_	23	PMOD	_	_
25	in	_	IN	IN	_	22	NMOD	_	_
26	HL60	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	,	_	,	,	_	6	P	_	_
29	whereas	_	IN	IN	_	6	VMOD	_	_
30	a	_	DT	DT	_	31	NMOD	_	_
31	maximum	_	NN	NN	_	14	GAP	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	approximately	_	RB	RB	_	36	NMOD	_	_
34	310	_	CD	CD	_	33	DEP	_	_
35	binding	_	VBG	VBG	_	36	NMOD	_	_
36	sites\/nucleus	_	NNS	NNS	_	32	PMOD	_	_
37	was	_	VBD	VBD	_	31	NMOD	_	_
38	found	_	VBN	VBN	_	37	VC	_	_
39	after	_	IN	IN	_	38	TMP	_	_
40	3	_	CD	CD	_	41	NMOD	_	_
41	h	_	NN	NN	_	39	PMOD	_	_
42	in	_	IN	IN	_	41	NMOD	_	_
43	PBL	_	NN	NN	_	42	PMOD	_	_
44	.	_	.	.	_	6	P	_	_

1	Pulse	_	NN	NN	_	2	NMOD	_	_
2	exposure	_	NN	NN	_	20	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	HL60	_	NN	NN	_	3	PMOD	_	_
5	to	_	TO	TO	_	2	NMOD	_	_
6	radiolabeled	_	VBN	VBN	_	7	NMOD	_	_
7	hormone	_	NN	NN	_	5	PMOD	_	_
8	for	_	IN	IN	_	2	TMP	_	_
9	3	_	CD	CD	_	10	NMOD	_	_
10	h	_	NN	NN	_	8	PMOD	_	_
11	followed	_	VBN	VBN	_	2	NMOD	_	_
12	by	_	IN	IN	_	11	ADV	_	_
13	culture	_	NN	NN	_	12	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	medium	_	NN	NN	_	14	PMOD	_	_
16	without	_	IN	IN	_	13	NMOD	_	_
17	serum	_	NN	NN	_	16	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	calcitriol	_	NN	NN	_	17	COORD	_	_
20	lead	_	VBD	VBD	_	0	ROOT-S	_	_
21	to	_	TO	TO	_	20	ADV	_	_
22	nuclear	_	JJ	JJ	_	23	NMOD	_	_
23	retention	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	approximately	_	RB	RB	_	28	NMOD	_	_
26	1600	_	CD	CD	_	25	DEP	_	_
27	radiolabeled	_	VBN	VBN	_	28	NMOD	_	_
28	VDR	_	NN	NN	_	24	PMOD	_	_
29	by	_	IN	IN	_	23	TMP	_	_
30	8	_	CD	CD	_	31	NMOD	_	_
31	h	_	NN	NN	_	29	PMOD	_	_
32	and	_	CC	CC	_	23	CC	_	_
33	approximately	_	RB	RB	_	35	NMOD	_	_
34	1000	_	CD	CD	_	33	DEP	_	_
35	VDR	_	NN	NN	_	28	GAP	_	_
36	by	_	IN	IN	_	29	GAP	_	_
37	24	_	CD	CD	_	38	NMOD	_	_
38	h	_	NN	NN	_	36	PMOD	_	_
39	.	_	.	.	_	20	P	_	_

1	Radiolabeled	_	VBN	VBN	_	2	NMOD	_	_
2	VDR	_	NN	NN	_	3	SBJ	_	_
3	disappeared	_	VBD	VBD	_	0	ROOT-S	_	_
4	from	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	compartment	_	NN	NN	_	4	PMOD	_	_
8	with	_	IN	IN	_	3	ADV	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	halflife	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	TMP	_	_
12	approximately	_	RB	RB	_	14	NMOD	_	_
13	30	_	CD	CD	_	12	DEP	_	_
14	min	_	NN	NN	_	11	PMOD	_	_
15	if	_	IN	IN	_	3	OBJ	_	_
16	cells	_	NNS	NNS	_	17	SBJ	_	_
17	were	_	VBD	VBD	_	15	VMOD	_	_
18	cultured	_	VBN	VBN	_	17	VC	_	_
19	with	_	IN	IN	_	18	ADV	_	_
20	identical	_	JJ	JJ	_	21	NMOD	_	_
21	concentrations	_	NNS	NNS	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	unlabeled	_	JJ	JJ	_	24	NMOD	_	_
24	hormone	_	NN	NN	_	22	PMOD	_	_
25	after	_	IN	IN	_	18	ADV	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	pulse	_	NN	NN	_	25	PMOD	_	_
28	(	_	(	(	_	29	P	_	_
29	pulse\/chase-experiments	_	NNS	NNS	_	18	PRN	_	_
30	)	_	)	)	_	29	P	_	_
31	.	_	.	.	_	3	P	_	_

1	No	_	DT	DT	_	2	NMOD	_	_
2	difference	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	VDR	_	NN	NN	_	5	NMOD	_	_
5	retention	_	NN	NN	_	3	PMOD	_	_
6	in	_	IN	IN	_	2	NMOD	_	_
7	pulse	_	NN	NN	_	6	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	pulse\/chase-experiments	_	NNS	NNS	_	7	COORD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	seen	_	VBN	VBN	_	10	VC	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	PBL	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	where	_	WRB	WRB	_	18	ADV	_	_
16	VDR	_	NN	NN	_	17	NMOD	_	_
17	halflife	_	NN	NN	_	18	SBJ	_	_
18	was	_	VBD	VBD	_	13	NMOD	_	_
19	approximately	_	RB	RB	_	21	NMOD	_	_
20	30	_	CD	CD	_	19	DEP	_	_
21	min	_	NN	NN	_	18	PRD-TMP	_	_
22	.	_	.	.	_	10	P	_	_

1	No	_	DT	DT	_	3	NMOD	_	_
2	specific	_	JJ	JJ	_	3	NMOD	_	_
3	translocation	_	NN	NN	_	8	SBJ	_	_
4	into	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	compartment	_	NN	NN	_	4	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	seen	_	VBN	VBN	_	8	VC	_	_
10	when	_	WRB	WRB	_	14	ADV	_	_
11	isolated	_	VBN	VBN	_	12	NMOD	_	_
12	nuclei	_	NNS	NNS	_	13	SBJ	_	_
13	were	_	VBD	VBD	_	9	TMP	_	_
14	incubated	_	VBN	VBN	_	13	VC	_	_
15	in	_	IN	IN	_	14	ADV	_	_
16	-LCB-3H-RCB-calcitriol	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	8	P	_	_

1	Radiolabeled	_	VBN	VBN	_	3	NMOD	_	_
2	hormone\/receptor	_	NN	NN	_	3	NMOD	_	_
3	complexes	_	NNS	NNS	_	26	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	nuclei	_	NNS	NNS	_	4	PMOD	_	_
6	isolated	_	VBN	VBN	_	3	NMOD	_	_
7	from	_	IN	IN	_	6	ADV	_	_
8	cells	_	NNS	NNS	_	7	PMOD	_	_
9	exposed	_	VBN	VBN	_	8	NMOD	_	_
10	for	_	IN	IN	_	9	TMP	_	_
11	3	_	CD	CD	_	12	NMOD	_	_
12	h	_	NN	NN	_	10	PMOD	_	_
13	to	_	TO	TO	_	9	ADV	_	_
14	radiolabeled	_	VBN	VBN	_	15	NMOD	_	_
15	hormone	_	NN	NN	_	13	PMOD	_	_
16	--	_	:	:	_	9	P	_	_
17	in	_	IN	IN	_	9	ADV	_	_
18	contrast	_	NN	NN	_	17	DEP	_	_
19	to	_	TO	TO	_	17	DEP	_	_
20	identical	_	JJ	JJ	_	21	NMOD	_	_
21	experiments	_	NNS	NNS	_	17	PMOD	_	_
22	with	_	IN	IN	_	21	NMOD	_	_
23	intact	_	JJ	JJ	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	--	_	:	:	_	9	P	_	_
26	did	_	VBD	VBD	_	0	ROOT-S	_	_
27	not	_	RB	RB	_	26	VMOD	_	_
28	disappear	_	VB	VB	_	26	VC	_	_
29	from	_	IN	IN	_	28	ADV	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	nuclear	_	JJ	JJ	_	32	NMOD	_	_
32	compartment	_	NN	NN	_	29	PMOD	_	_
33	upon	_	IN	IN	_	28	TMP	_	_
34	incubation	_	NN	NN	_	33	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	nuclei	_	NNS	NNS	_	35	PMOD	_	_
37	with	_	IN	IN	_	34	NMOD	_	_
38	identical	_	JJ	JJ	_	39	NMOD	_	_
39	concentrations	_	NNS	NNS	_	37	PMOD	_	_
40	of	_	IN	IN	_	39	NMOD	_	_
41	the	_	DT	DT	_	43	NMOD	_	_
42	unlabeled	_	JJ	JJ	_	43	NMOD	_	_
43	compound	_	NN	NN	_	40	PMOD	_	_
44	.	_	.	.	_	26	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	activity	_	NN	NN	_	17	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	DNA	_	NN	NN	_	6	NMOD	_	_
5	relaxing	_	NN	NN	_	6	NMOD	_	_
6	enzymes	_	NNS	NNS	_	3	PMOD	_	_
7	(	_	(	(	_	6	P	_	_
8	e.g.	_	FW	FW	_	6	NMOD	_	_
9	topoisomerases	_	NNS	NNS	_	8	AMOD	_	_
10	I	_	CD	CD	_	9	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	II	_	CD	CD	_	10	COORD	_	_
13	)	_	)	)	_	6	P	_	_
14	in	_	IN	IN	_	6	NMOD	_	_
15	nuclear	_	JJ	JJ	_	16	NMOD	_	_
16	extracts	_	NNS	NNS	_	14	PMOD	_	_
17	was	_	VBD	VBD	_	0	ROOT-S	_	_
18	measured	_	VBN	VBN	_	17	VC	_	_
19	using	_	VBG	VBG	_	18	OBJ	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	PBR	_	NN	NN	_	22	NMOD	_	_
22	322-relaxation-assay	_	NN	NN	_	19	OBJ	_	_
23	.	_	.	.	_	17	P	_	_

1	Enhanced	_	VBN	VBN	_	4	NMOD	_	_
2	overall	_	JJ	JJ	_	4	NMOD	_	_
3	enzyme	_	NN	NN	_	4	NMOD	_	_
4	activity	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	found	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	extracts	_	NNS	NNS	_	7	PMOD	_	_
10	by	_	IN	IN	_	6	TMP	_	_
11	1	_	CD	CD	_	12	NMOD	_	_
12	h	_	NN	NN	_	10	PMOD	_	_
13	after	_	IN	IN	_	12	NMOD	_	_
14	incubation	_	NN	NN	_	13	PMOD	_	_
15	with	_	IN	IN	_	14	NMOD	_	_
16	calcitriol	_	NN	NN	_	15	PMOD	_	_
17	(	_	(	(	_	16	PRN	_	_
18	final	_	JJ	JJ	_	20	NMOD	_	_
19	ethanol	_	NN	NN	_	20	NMOD	_	_
20	concentration	_	NN	NN	_	17	DEP	_	_
21	0.0001	_	CD	CD	_	22	AMOD	_	_
22	%	_	NN	NN	_	23	NMOD	_	_
23	v\/v	_	NN	NN	_	20	NMOD	_	_
24	)	_	)	)	_	17	P	_	_
25	in	_	IN	IN	_	14	NMOD	_	_
26	HL60	_	NN	NN	_	25	PMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	PBL	_	NN	NN	_	26	COORD	_	_
29	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	enhanced	_	VBN	VBN	_	3	NMOD	_	_
3	activity	_	NN	NN	_	4	SBJ	_	_
4	disappeared	_	VBD	VBD	_	0	ROOT-S	_	_
5	after	_	IN	IN	_	4	TMP	_	_
6	2	_	CD	CD	_	7	NMOD	_	_
7	h	_	NN	NN	_	5	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	PBL	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	4	P	_	_
11	whereas	_	IN	IN	_	4	COORD	_	_
12	it	_	PRP	PRP	_	13	SBJ	_	_
13	was	_	VBD	VBD	_	4	COORD	_	_
14	still	_	RB	RB	_	13	ADV	_	_
15	enhanced	_	VBN	VBN	_	13	VC	_	_
16	by	_	IN	IN	_	15	TMP	_	_
17	4	_	CD	CD	_	18	NMOD	_	_
18	h	_	NN	NN	_	16	PMOD	_	_
19	in	_	IN	IN	_	15	ADV	_	_
20	HL60	_	NN	NN	_	19	PMOD	_	_
21	.	_	.	.	_	4	P	_	_

1	No	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	seen	_	VBN	VBN	_	3	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	ethanol	_	NN	NN	_	8	NMOD	_	_
7	treated	_	JJ	JJ	_	6	AMOD	_	_
8	controls	_	NNS	NNS	_	5	PMOD	_	_
9	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	conclude	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	a	_	DT	DT	_	8	NMOD	_	_
5	specific	_	JJ	JJ	_	8	NMOD	_	_
6	nuclear	_	JJ	JJ	_	8	NMOD	_	_
7	translocation	_	NN	NN	_	8	NMOD	_	_
8	mechanism	_	NN	NN	_	9	SBJ	_	_
9	exists	_	VBZ	VBZ	_	3	VMOD	_	_
10	for	_	IN	IN	_	9	ADV	_	_
11	calcitriol	_	NN	NN	_	10	PMOD	_	_
12	in	_	IN	IN	_	9	ADV	_	_
13	both	_	DT	DT	_	15	NMOD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	types	_	NNS	NNS	_	12	PMOD	_	_
16	examined	_	VBN	VBN	_	15	NMOD	_	_
17	,	_	,	,	_	9	P	_	_
18	most	_	RBS	RBS	_	19	AMOD	_	_
19	likely	_	RB	RB	_	20	PMOD	_	_
20	due	_	IN	IN	_	9	ADV	_	_
21	to	_	TO	TO	_	20	DEP	_	_
22	translocation	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	receptor	_	NN	NN	_	25	NMOD	_	_
25	proteins	_	NNS	NNS	_	23	PMOD	_	_
26	after	_	IN	IN	_	22	TMP	_	_
27	hormone	_	NN	NN	_	28	NMOD	_	_
28	binding	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	2	P	_	_

1	Translocated	_	VBN	VBN	_	3	NMOD	_	_
2	hormone\/receptor	_	NN	NN	_	3	NMOD	_	_
3	complexes	_	NNS	NNS	_	4	SBJ	_	_
4	compete	_	VBP	VBP	_	0	ROOT-S	_	_
5	for	_	IN	IN	_	4	ADV	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	limited	_	JJ	JJ	_	8	NMOD	_	_
8	number	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	specific	_	JJ	JJ	_	13	NMOD	_	_
11	nuclear	_	JJ	JJ	_	13	NMOD	_	_
12	binding	_	VBG	VBG	_	13	NMOD	_	_
13	sites	_	NNS	NNS	_	9	PMOD	_	_
14	.	_	.	.	_	4	P	_	_

1	Enhanced	_	VBN	VBN	_	2	NMOD	_	_
2	activity	_	NN	NN	_	12	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	topoisomerases	_	NNS	NNS	_	3	PMOD	_	_
5	in	_	IN	IN	_	2	NMOD	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	extracts	_	NNS	NNS	_	5	PMOD	_	_
8	upon	_	IN	IN	_	2	TMP	_	_
9	translocation	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	VDR	_	NN	NN	_	10	PMOD	_	_
12	might	_	MD	MD	_	0	ROOT-S	_	_
13	reflect	_	VB	VB	_	12	VC	_	_
14	interaction	_	NN	NN	_	13	IOBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	both	_	DT	DT	_	15	PMOD	_	_
17	within	_	IN	IN	_	14	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	nuclear	_	JJ	JJ	_	20	NMOD	_	_
20	compartment	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	13	P	_	_
22	thus	_	RB	RB	_	23	ADV	_	_
23	initiating	_	VBG	VBG	_	13	OBJ	_	_
24	DNA-unwinding	_	NN	NN	_	23	OBJ	_	_
25	,	_	,	,	_	24	P	_	_
26	a	_	DT	DT	_	27	NMOD	_	_
27	prerequisite	_	NN	NN	_	24	NMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	transcription	_	NN	NN	_	30	NMOD	_	_
30	initiation	_	NN	NN	_	28	PMOD	_	_
31	.	_	.	.	_	12	P	_	_

1	{	_	(	(	_	2	P	_	_
2	Regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	intracellular	_	JJ	JJ	_	6	NMOD	_	_
5	cholesterol	_	NN	NN	_	6	NMOD	_	_
6	synthesis	_	NN	NN	_	3	PMOD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	hypercholesterolemia	_	NN	NN	_	7	PMOD	_	_
9	by	_	IN	IN	_	2	NMOD	_	_
10	glucocorticoids	_	NNS	NNS	_	9	PMOD	_	_
11	}	_	)	)	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	rate	_	NN	NN	_	19	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	endogenous	_	JJ	JJ	_	6	NMOD	_	_
5	cholesterol	_	NN	NN	_	6	NMOD	_	_
6	synthesis	_	NN	NN	_	3	PMOD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	blood	_	NN	NN	_	9	NMOD	_	_
9	lymphocytes	_	NNS	NNS	_	7	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	skin	_	NN	NN	_	12	NMOD	_	_
12	fibroblasts	_	NNS	NNS	_	9	COORD	_	_
13	from	_	IN	IN	_	9	NMOD	_	_
14	patients	_	NNS	NNS	_	13	PMOD	_	_
15	with	_	IN	IN	_	14	NMOD	_	_
16	type	_	NN	NN	_	18	NMOD	_	_
17	IIa	_	NN	NN	_	18	NMOD	_	_
18	hyperlipidemia	_	NN	NN	_	15	PMOD	_	_
19	was	_	VBD	VBD	_	0	ROOT-S	_	_
20	found	_	VBN	VBN	_	19	VC	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	be	_	VB	VB	_	20	OBJ	_	_
23	increased	_	VBN	VBN	_	22	VC	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	comparison	_	NN	NN	_	24	DEP	_	_
26	with	_	IN	IN	_	24	DEP	_	_
27	healthy	_	JJ	JJ	_	28	NMOD	_	_
28	donors	_	NNS	NNS	_	24	PMOD	_	_
29	.	_	.	.	_	19	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	hyperlipidemic	_	JJ	JJ	_	5	NMOD	_	_
5	patients	_	NNS	NNS	_	3	PMOD	_	_
6	had	_	VBD	VBD	_	0	ROOT-S	_	_
7	lowered	_	JJ	JJ	_	8	NMOD	_	_
8	levels	_	NNS	NNS	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	glucocorticoid	_	NN	NN	_	11	NMOD	_	_
11	receptors	_	NNS	NNS	_	9	PMOD	_	_
12	concomitantly	_	RB	RB	_	13	DEP	_	_
13	with	_	IN	IN	_	6	ADV	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	partial	_	JJ	JJ	_	16	NMOD	_	_
16	loss	_	NN	NN	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	their	_	PRP$	PRP$	_	19	NMOD	_	_
19	sensitivity	_	NN	NN	_	17	PMOD	_	_
20	to	_	TO	TO	_	19	NMOD	_	_
21	glucocorticoids	_	NNS	NNS	_	20	PMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	16	ADV	_	_
2	fibroblasts	_	NNS	NNS	_	1	PMOD	_	_
3	from	_	IN	IN	_	2	NMOD	_	_
4	patients	_	NNS	NNS	_	3	PMOD	_	_
5	with	_	IN	IN	_	4	NMOD	_	_
6	hereditary	_	JJ	JJ	_	7	NMOD	_	_
7	hypercholesteremia	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	homozygous	_	JJ	JJ	_	10	NMOD	_	_
10	type	_	NN	NN	_	8	PMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	number	_	NN	NN	_	16	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	glucocorticoid	_	NN	NN	_	15	NMOD	_	_
15	receptors	_	NNS	NNS	_	13	PMOD	_	_
16	did	_	VBD	VBD	_	0	ROOT-S	_	_
17	not	_	RB	RB	_	16	VMOD	_	_
18	exceed	_	VB	VB	_	16	VC	_	_
19	10	_	CD	CD	_	20	NMOD	_	_
20	%	_	NN	NN	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	their	_	PRP$	PRP$	_	23	NMOD	_	_
23	content	_	NN	NN	_	21	PMOD	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	normal	_	JJ	JJ	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	24	PMOD	_	_
27	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	decrease	_	NN	NN	_	15	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	number	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	glucocorticoid	_	NN	NN	_	8	NMOD	_	_
8	receptors	_	NNS	NNS	_	6	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	patients	_	NNS	NNS	_	9	PMOD	_	_
11	with	_	IN	IN	_	10	NMOD	_	_
12	type	_	NN	NN	_	14	NMOD	_	_
13	IIa	_	NN	NN	_	14	NMOD	_	_
14	hyperlipidemia	_	NN	NN	_	11	PMOD	_	_
15	seems	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	be	_	VB	VB	_	15	OBJ	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	compensatory	_	JJ	JJ	_	20	NMOD	_	_
20	response	_	NN	NN	_	17	PRD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	cells	_	NNS	NNS	_	21	PMOD	_	_
23	culminating	_	VBG	VBG	_	22	NMOD	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	activation	_	NN	NN	_	24	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	endogenous	_	JJ	JJ	_	29	NMOD	_	_
28	cholesterol	_	NN	NN	_	29	NMOD	_	_
29	synthesis	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	15	P	_	_

1	Transcription	_	NN	NN	_	3	NMOD	_	_
2	factor	_	NN	NN	_	3	NMOD	_	_
3	activation	_	NN	NN	_	0	ROOT-FRAG	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	functional	_	JJ	JJ	_	6	NMOD	_	_
6	stimulation	_	NN	NN	_	3	COORD	_	_
7	of	_	IN	IN	_	3	NMOD	_	_
8	human	_	JJ	JJ	_	9	NMOD	_	_
9	monocytes	_	NNS	NNS	_	7	PMOD	_	_
10	.	_	.	.	_	3	P	_	_

1	Activation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	expression	_	NN	NN	_	2	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	genes	_	NNS	NNS	_	4	PMOD	_	_
6	encoding	_	VBG	VBG	_	5	NMOD	_	_
7	transcription	_	NN	NN	_	8	NMOD	_	_
8	factors	_	NNS	NNS	_	6	OBJ	_	_
9	:	_	:	:	_	1	P	_	_
10	c-fos	_	NN	NN	_	22	SBJ	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	c-jun	_	NN	NN	_	10	COORD	_	_
13	and	_	CC	CC	_	10	CC	_	_
14	formation	_	NN	NN	_	10	COORD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	AP1	_	NN	NN	_	18	NMOD	_	_
17	transcriptional	_	JJ	JJ	_	18	NMOD	_	_
18	complex	_	NN	NN	_	15	PMOD	_	_
19	in	_	IN	IN	_	10	NMOD	_	_
20	human	_	JJ	JJ	_	21	NMOD	_	_
21	monocytes	_	NNS	NNS	_	19	PMOD	_	_
22	was	_	VBD	VBD	_	1	NMOD	_	_
23	investigated	_	VBN	VBN	_	22	VC	_	_
24	.	_	.	.	_	22	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	lipopolysaccharide	_	NN	NN	_	6	SBJ	_	_
6	induced	_	VBD	VBD	_	4	VMOD	_	_
7	strongly	_	RB	RB	_	6	ADV	_	_
8	both	_	CC	CC	_	9	CC	_	_
9	c-fos	_	NN	NN	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	c-jun	_	NN	NN	_	9	COORD	_	_
12	expression	_	NN	NN	_	6	OBJ	_	_
13	as	_	RB	RB	_	12	CC	_	_
14	well	_	RB	RB	_	13	DEP	_	_
15	as	_	IN	IN	_	13	DEP	_	_
16	AP1	_	NN	NN	_	17	NMOD	_	_
17	formation	_	NN	NN	_	12	COORD	_	_
18	.	_	.	.	_	2	P	_	_

1	Interferon	_	NN	NN	_	2	NMOD	_	_
2	gamma	_	NN	NN	_	3	SBJ	_	_
3	activated	_	VBD	VBD	_	0	ROOT-S	_	_
4	strongly	_	RB	RB	_	3	VMOD	_	_
5	c-fos	_	NN	NN	_	3	OBJ	_	_
6	and	_	CC	CC	_	3	CC	_	_
7	weakly	_	RB	RB	_	4	GAP	_	_
8	c-jun	_	NN	NN	_	5	GAP	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	AP1	_	NN	NN	_	8	COORD	_	_
11	.	_	.	.	_	3	P	_	_

1	Tumor	_	NN	NN	_	3	NMOD	_	_
2	necrosis	_	NN	NN	_	3	NMOD	_	_
3	factor	_	NN	NN	_	4	SBJ	_	_
4	induced	_	VBD	VBD	_	0	ROOT-S	_	_
5	slightly	_	RB	RB	_	4	ADV	_	_
6	c-fos	_	NN	NN	_	4	OBJ	_	_
7	and	_	CC	CC	_	4	CC	_	_
8	had	_	VBD	VBD	_	4	COORD	_	_
9	almost	_	RB	RB	_	11	NMOD	_	_
10	no	_	DT	DT	_	9	DEP	_	_
11	effect	_	NN	NN	_	8	OBJ	_	_
12	on	_	IN	IN	_	8	ADV	_	_
13	c-jun	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	AP1	_	NN	NN	_	13	COORD	_	_
16	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	differences	_	NNS	NNS	_	16	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	functional	_	JJ	JJ	_	8	NMOD	_	_
8	responses	_	NNS	NNS	_	6	PMOD	_	_
9	elicited	_	VBN	VBN	_	8	NMOD	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	monocytes	_	NNS	NNS	_	10	PMOD	_	_
12	by	_	IN	IN	_	9	LGS	_	_
13	all	_	DT	DT	_	15	NMOD	_	_
14	three	_	CD	CD	_	13	DEP	_	_
15	factors	_	NNS	NNS	_	12	PMOD	_	_
16	may	_	MD	MD	_	4	VMOD	_	_
17	be	_	VB	VB	_	16	VC	_	_
18	dependent	_	JJ	JJ	_	17	PRD	_	_
19	on	_	IN	IN	_	18	AMOD	_	_
20	different	_	JJ	JJ	_	21	NMOD	_	_
21	routes	_	NNS	NNS	_	19	PMOD	_	_
22	on	_	IN	IN	_	21	NMOD	_	_
23	nuclear	_	JJ	JJ	_	24	NMOD	_	_
24	signalling	_	NN	NN	_	22	PMOD	_	_
25	employed	_	VBN	VBN	_	24	NMOD	_	_
26	by	_	IN	IN	_	25	LGS	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	factors	_	NNS	NNS	_	26	PMOD	_	_
29	.	_	.	.	_	3	P	_	_

1	Stable	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	15	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	HB24	_	NN	NN	_	3	PMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	a	_	DT	DT	_	10	NMOD	_	_
7	diverged	_	JJ	JJ	_	10	NMOD	_	_
8	human	_	JJ	JJ	_	10	NMOD	_	_
9	homeobox	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	4	NMOD	_	_
11	,	_	,	,	_	4	P	_	_
12	in	_	IN	IN	_	2	NMOD	_	_
13	T	_	NN	NN	_	14	NMOD	_	_
14	lymphocytes	_	NNS	NNS	_	12	PMOD	_	_
15	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	genes	_	NNS	NNS	_	15	OBJ	_	_
17	involved	_	VBN	VBN	_	16	NMOD	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	T	_	NN	NN	_	20	NMOD	_	_
20	cell	_	NN	NN	_	18	PMOD	_	_
21	activation	_	NN	NN	_	20	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	growth	_	NN	NN	_	21	COORD	_	_
24	.	_	.	.	_	15	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	diverged	_	JJ	JJ	_	4	NMOD	_	_
3	homeobox	_	NN	NN	_	4	NMOD	_	_
4	gene	_	NN	NN	_	18	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	HB24	_	NN	NN	_	4	NMOD	_	_
7	,	_	,	,	_	4	P	_	_
8	which	_	WDT	WDT	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	4	NMOD	_	_
10	known	_	VBN	VBN	_	9	VC	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	be	_	VB	VB	_	10	OBJ	_	_
13	induced	_	VBN	VBN	_	12	VC	_	_
14	following	_	VBG	VBG	_	13	TMP	_	_
15	lymphocyte	_	NN	NN	_	16	NMOD	_	_
16	activation	_	NN	NN	_	14	PMOD	_	_
17	,	_	,	,	_	4	P	_	_
18	was	_	VBD	VBD	_	0	ROOT-S	_	_
19	introduced	_	VBN	VBN	_	18	VC	_	_
20	into	_	IN	IN	_	19	ADV	_	_
21	Jurkat	_	NN	NN	_	23	NMOD	_	_
22	T	_	NN	NN	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	20	PMOD	_	_
24	under	_	IN	IN	_	19	ADV	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	control	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	a	_	DT	DT	_	30	NMOD	_	_
29	constitutive	_	JJ	JJ	_	30	NMOD	_	_
30	promoter	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	18	P	_	_

1	Stable	_	JJ	JJ	_	2	NMOD	_	_
2	transfectants	_	NNS	NNS	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	HB24	_	NN	NN	_	3	PMOD	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	established	_	VBN	VBN	_	5	VC	_	_
7	that	_	WDT	WDT	_	8	SBJ	_	_
8	expressed	_	VBD	VBD	_	2	NMOD	_	_
9	high	_	JJ	JJ	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	HB24	_	NN	NN	_	13	NMOD	_	_
13	mRNA	_	NN	NN	_	11	PMOD	_	_
14	and	_	CC	CC	_	8	CC	_	_
15	possessed	_	VBD	VBD	_	8	COORD	_	_
16	an	_	DT	DT	_	18	NMOD	_	_
17	altered	_	JJ	JJ	_	18	NMOD	_	_
18	phenotype	_	NN	NN	_	15	OBJ	_	_
19	suggestive	_	JJ	JJ	_	18	NMOD	_	_
20	of	_	IN	IN	_	19	AMOD	_	_
21	activated	_	VBN	VBN	_	23	NMOD	_	_
22	T	_	NN	NN	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	20	PMOD	_	_
24	.	_	.	.	_	5	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	number	_	NN	NN	_	18	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	genes	_	NNS	NNS	_	3	PMOD	_	_
5	known	_	VBN	VBN	_	4	NMOD	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	be	_	VB	VB	_	5	OBJ	_	_
8	induced	_	VBN	VBN	_	7	VC	_	_
9	following	_	VBG	VBG	_	8	TMP	_	_
10	T	_	NN	NN	_	12	NMOD	_	_
11	cell	_	NN	NN	_	12	NMOD	_	_
12	activation	_	NN	NN	_	9	PMOD	_	_
13	and	_	CC	CC	_	5	CC	_	_
14	associated	_	VBN	VBN	_	5	COORD	_	_
15	with	_	IN	IN	_	14	ADV	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	growth	_	NN	NN	_	15	PMOD	_	_
18	were	_	VBD	VBD	_	0	ROOT-S	_	_
19	increased	_	VBN	VBN	_	18	VC	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	transfectants	_	NNS	NNS	_	20	PMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	including	_	VBG	VBG	_	22	NMOD	_	_
25	c-fos	_	NN	NN	_	24	PMOD	_	_
26	,	_	,	,	_	25	P	_	_
27	c-myc	_	NN	NN	_	25	COORD	_	_
28	,	_	,	,	_	25	P	_	_
29	c-myb	_	NN	NN	_	25	COORD	_	_
30	,	_	,	,	_	25	P	_	_
31	HLA-DR	_	NN	NN	_	25	COORD	_	_
32	,	_	,	,	_	25	P	_	_
33	lck	_	NN	NN	_	25	COORD	_	_
34	,	_	,	,	_	25	P	_	_
35	NF-kappa	_	NN	NN	_	36	NMOD	_	_
36	B	_	NN	NN	_	25	COORD	_	_
37	,	_	,	,	_	25	P	_	_
38	interleukin-2	_	NN	NN	_	25	COORD	_	_
39	and	_	CC	CC	_	25	CC	_	_
40	interleukin-2	_	NN	NN	_	42	NMOD	_	_
41	receptor	_	NN	NN	_	42	NMOD	_	_
42	alpha	_	NN	NN	_	25	COORD	_	_
43	(	_	(	(	_	45	P	_	_
44	IL-2R	_	NN	NN	_	45	NMOD	_	_
45	alpha	_	NN	NN	_	42	PRN	_	_
46	)	_	)	)	_	45	P	_	_
47	.	_	.	.	_	18	P	_	_

1	Analysis	_	NN	NN	_	18	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	IL-2R	_	NN	NN	_	5	NMOD	_	_
4	alpha	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	2	PMOD	_	_
6	by	_	IN	IN	_	5	NMOD	_	_
7	transient	_	JJ	JJ	_	8	NMOD	_	_
8	transfection	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	IL-2R	_	NN	NN	_	13	NMOD	_	_
11	alpha	_	NN	NN	_	13	NMOD	_	_
12	promoter	_	NN	NN	_	13	NMOD	_	_
13	constructs	_	NNS	NNS	_	9	PMOD	_	_
14	into	_	IN	IN	_	8	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	HB24	_	NN	NN	_	17	NMOD	_	_
17	transfectants	_	NNS	NNS	_	14	PMOD	_	_
18	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
19	constitutive	_	JJ	JJ	_	20	NMOD	_	_
20	expression	_	NN	NN	_	18	OBJ	_	_
21	(	_	(	(	_	20	PRN	_	_
22	about	_	RB	RB	_	24	NMOD	_	_
23	60	_	CD	CD	_	22	DEP	_	_
24	%	_	NN	NN	_	21	DEP	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	phytohemagglutinin-	_	NN	NN	_	31	NMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	phorbol	_	NN	NN	_	26	COORD	_	_
29	ester-activated	_	JJ	JJ	_	28	AMOD	_	_
30	Jurkat	_	NN	NN	_	31	NMOD	_	_
31	cells	_	NNS	NNS	_	25	PMOD	_	_
32	)	_	)	)	_	21	P	_	_
33	that	_	WDT	WDT	_	34	SBJ	_	_
34	was	_	VBD	VBD	_	20	NMOD	_	_
35	dependent	_	JJ	JJ	_	34	PRD	_	_
36	on	_	IN	IN	_	35	AMOD	_	_
37	the	_	DT	DT	_	40	NMOD	_	_
38	kappa	_	NN	NN	_	40	NMOD	_	_
39	B	_	NN	NN	_	40	NMOD	_	_
40	site	_	NN	NN	_	36	PMOD	_	_
41	in	_	IN	IN	_	40	NMOD	_	_
42	the	_	DT	DT	_	45	NMOD	_	_
43	IL-2R	_	NN	NN	_	45	NMOD	_	_
44	alpha	_	NN	NN	_	45	NMOD	_	_
45	promoter	_	NN	NN	_	41	PMOD	_	_
46	.	_	.	.	_	18	P	_	_

1	Furthermore	_	RB	RB	_	17	ADV	_	_
2	,	_	,	,	_	17	P	_	_
3	as	_	IN	IN	_	17	ADV	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	consequence	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	11	NMOD	_	_
8	increased	_	VBN	VBN	_	11	NMOD	_	_
9	HB24	_	NN	NN	_	11	NMOD	_	_
10	mRNA	_	NN	NN	_	11	NMOD	_	_
11	levels	_	NNS	NNS	_	6	PMOD	_	_
12	,	_	,	,	_	17	P	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	Jurkat	_	NN	NN	_	16	NMOD	_	_
15	HB24	_	NN	NN	_	16	NMOD	_	_
16	transfectants	_	NNS	NNS	_	17	SBJ	_	_
17	proliferated	_	VBD	VBD	_	0	ROOT-S	_	_
18	more	_	RBR	RBR	_	19	AMOD	_	_
19	rapidly	_	RB	RB	_	17	TMP	_	_
20	than	_	IN	IN	_	19	AMOD	_	_
21	control	_	NN	NN	_	23	NMOD	_	_
22	cell	_	NN	NN	_	23	NMOD	_	_
23	lines	_	NNS	NNS	_	20	PMOD	_	_
24	.	_	.	.	_	17	P	_	_

1	Thus	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	stable	_	JJ	JJ	_	4	NMOD	_	_
4	expression	_	NN	NN	_	7	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	HB24	_	NN	NN	_	5	PMOD	_	_
7	confers	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	an	_	DT	DT	_	10	NMOD	_	_
9	activation	_	NN	NN	_	10	NMOD	_	_
10	phenotype	_	NN	NN	_	7	IOBJ	_	_
11	on	_	IN	IN	_	7	ADV	_	_
12	a	_	DT	DT	_	16	NMOD	_	_
13	human	_	JJ	JJ	_	16	NMOD	_	_
14	T	_	NN	NN	_	16	NMOD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	line	_	NN	NN	_	11	PMOD	_	_
17	,	_	,	,	_	7	P	_	_
18	implicating	_	VBG	VBG	_	7	OBJ	_	_
19	this	_	DT	DT	_	20	NMOD	_	_
20	gene	_	NN	NN	_	18	OBJ	_	_
21	as	_	IN	IN	_	18	ADV	_	_
22	an	_	DT	DT	_	25	NMOD	_	_
23	important	_	JJ	JJ	_	25	NMOD	_	_
24	transcriptional	_	JJ	JJ	_	25	NMOD	_	_
25	factor	_	NN	NN	_	21	PMOD	_	_
26	during	_	IN	IN	_	25	TMP	_	_
27	T	_	NN	NN	_	28	NMOD	_	_
28	cell	_	NN	NN	_	26	PMOD	_	_
29	activation	_	NN	NN	_	28	NMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	growth	_	NN	NN	_	29	COORD	_	_
32	.	_	.	.	_	7	P	_	_

1	Studies	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	on	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	biological	_	JJ	JJ	_	5	NMOD	_	_
5	activity	_	NN	NN	_	2	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	triiodothyronine	_	NN	NN	_	8	NMOD	_	_
8	sulfate	_	NN	NN	_	6	PMOD	_	_
9	.	_	.	.	_	1	P	_	_

1	Hepatic	_	JJ	JJ	_	2	NMOD	_	_
2	microsomes	_	NNS	NNS	_	10	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	isolated	_	VBN	VBN	_	5	NMOD	_	_
5	hepatocytes	_	NNS	NNS	_	2	COORD	_	_
6	in	_	IN	IN	_	2	NMOD	_	_
7	short	_	JJ	JJ	_	9	NMOD	_	_
8	term	_	NN	NN	_	9	NMOD	_	_
9	culture	_	NN	NN	_	6	PMOD	_	_
10	desulfate	_	VBP	VBP	_	0	ROOT-S	_	_
11	T3	_	NN	NN	_	12	NMOD	_	_
12	sulfate	_	NN	NN	_	10	OBJ	_	_
13	(	_	(	(	_	14	P	_	_
14	T3SO4	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	.	_	.	.	_	10	P	_	_

1	We	_	PRP	PRP	_	5	SBJ	_	_
2	,	_	,	,	_	5	P	_	_
3	therefore	_	RB	RB	_	5	ADV	_	_
4	,	_	,	,	_	5	P	_	_
5	wished	_	VBD	VBD	_	0	ROOT-S	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	determine	_	VB	VB	_	5	OBJ	_	_
8	whether	_	IN	IN	_	7	OBJ	_	_
9	T3SO4	_	NN	NN	_	10	SBJ	_	_
10	could	_	MD	MD	_	8	VMOD	_	_
11	mimic	_	VB	VB	_	10	VC	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	action	_	NN	NN	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	thyroid	_	NN	NN	_	16	NMOD	_	_
16	hormone	_	NN	NN	_	14	PMOD	_	_
17	in	_	FW	FW	_	11	ADV	_	_
18	vitro	_	FW	FW	_	17	AMOD	_	_
19	.	_	.	.	_	5	P	_	_

1	T3SO4	_	NN	NN	_	2	SBJ	_	_
2	had	_	VBD	VBD	_	0	ROOT-S	_	_
3	no	_	DT	DT	_	5	NMOD	_	_
4	thyromimetic	_	JJ	JJ	_	5	NMOD	_	_
5	effect	_	NN	NN	_	2	OBJ	_	_
6	on	_	IN	IN	_	2	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	activity	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	Ca-LRB-2+-RRB--ATPase	_	NN	NN	_	9	PMOD	_	_
11	in	_	IN	IN	_	8	NMOD	_	_
12	human	_	JJ	JJ	_	14	NMOD	_	_
13	erythrocyte	_	NN	NN	_	14	NMOD	_	_
14	membranes	_	NNS	NNS	_	11	PMOD	_	_
15	at	_	IN	IN	_	2	ADV	_	_
16	doses	_	NNS	NNS	_	15	PMOD	_	_
17	up	_	RB	RB	_	20	DEP	_	_
18	to	_	TO	TO	_	20	DEP	_	_
19	10,000	_	CD	CD	_	20	DEP	_	_
20	times	_	NNS	NNS	_	24	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	maximally	_	RB	RB	_	23	AMOD	_	_
23	effective	_	JJ	JJ	_	24	NMOD	_	_
24	dose	_	NN	NN	_	16	NMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	T3	_	NN	NN	_	25	PMOD	_	_
27	(	_	(	(	_	29	P	_	_
28	10\/-LRB--10-RRB-	_	CD	CD	_	29	NMOD	_	_
29	mol\/L	_	NN	NN	_	24	PRN	_	_
30	)	_	)	)	_	29	P	_	_
31	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	GH4C1	_	NN	NN	_	4	NMOD	_	_
3	pituitary	_	JJ	JJ	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	T3SO4	_	NN	NN	_	7	SBJ	_	_
7	failed	_	VBD	VBD	_	0	ROOT-S	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	displace	_	VB	VB	_	7	OBJ	_	_
10	-LCB-125I-RCB-T3	_	NN	NN	_	9	OBJ	_	_
11	from	_	IN	IN	_	9	ADV	_	_
12	nuclear	_	JJ	JJ	_	13	NMOD	_	_
13	receptors	_	NNS	NNS	_	11	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	intact	_	JJ	JJ	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	or	_	CC	CC	_	16	CC	_	_
18	soluble	_	JJ	JJ	_	19	NMOD	_	_
19	preparations	_	NNS	NNS	_	16	COORD	_	_
20	.	_	.	.	_	7	P	_	_

1	Thus	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	T3SO4	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	directly	_	RB	RB	_	4	ADV	_	_
7	thyromimetic	_	JJ	JJ	_	4	PRD	_	_
8	in	_	IN	IN	_	4	ADV	_	_
9	either	_	CC	CC	_	14	CC	_	_
10	an	_	DT	DT	_	14	NMOD	_	_
11	isolated	_	VBN	VBN	_	14	NMOD	_	_
12	human	_	JJ	JJ	_	14	NMOD	_	_
13	membrane	_	NN	NN	_	14	NMOD	_	_
14	system	_	NN	NN	_	8	PMOD	_	_
15	or	_	CC	CC	_	14	CC	_	_
16	a	_	DT	DT	_	19	NMOD	_	_
17	pituitary	_	JJ	JJ	_	19	NMOD	_	_
18	cell	_	NN	NN	_	19	NMOD	_	_
19	system	_	NN	NN	_	14	COORD	_	_
20	in	_	IN	IN	_	25	ADV	_	_
21	which	_	WDT	WDT	_	20	PMOD	_	_
22	nuclear	_	JJ	JJ	_	24	NMOD	_	_
23	receptor	_	NN	NN	_	24	NMOD	_	_
24	occupancy	_	NN	NN	_	25	SBJ	_	_
25	correlates	_	VBZ	VBZ	_	14	NMOD	_	_
26	with	_	IN	IN	_	25	ADV	_	_
27	GH	_	NN	NN	_	28	NMOD	_	_
28	synthesis	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	4	P	_	_

1	Thyroid	_	NN	NN	_	2	NMOD	_	_
2	hormones	_	NNS	NNS	_	3	SBJ	_	_
3	inhibit	_	VBP	VBP	_	0	ROOT-S	_	_
4	-LCB-3H-RCB-glycosaminoglycan	_	NN	NN	_	5	NMOD	_	_
5	synthesis	_	NN	NN	_	3	OBJ	_	_
6	by	_	IN	IN	_	3	ADV	_	_
7	cultured	_	VBN	VBN	_	10	NMOD	_	_
8	human	_	JJ	JJ	_	10	NMOD	_	_
9	dermal	_	JJ	JJ	_	10	NMOD	_	_
10	fibroblasts	_	NNS	NNS	_	6	PMOD	_	_
11	,	_	,	,	_	3	P	_	_
12	and	_	CC	CC	_	3	CC	_	_
13	T3SO4	_	NN	NN	_	14	SBJ	_	_
14	displayed	_	VBN	VBN	_	3	COORD	_	_
15	about	_	IN	IN	_	16	DEP	_	_
16	0.5	_	CD	CD	_	17	NMOD	_	_
17	%	_	NN	NN	_	14	OBJ	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	activity	_	NN	NN	_	17	NMOD	_	_
20	of	_	IN	IN	_	17	NMOD	_	_
21	T3	_	NN	NN	_	20	PMOD	_	_
22	at	_	IN	IN	_	14	TMP	_	_
23	72	_	CD	CD	_	24	NMOD	_	_
24	h	_	NN	NN	_	22	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	Human	_	JJ	JJ	_	2	NMOD	_	_
2	fibroblasts	_	NNS	NNS	_	3	SBJ	_	_
3	contained	_	VBD	VBD	_	0	ROOT-S	_	_
4	roughly	_	RB	RB	_	7	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	same	_	JJ	JJ	_	7	NMOD	_	_
7	level	_	NN	NN	_	3	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	microsomal	_	JJ	JJ	_	12	NMOD	_	_
10	p-nitrophenyl	_	NN	NN	_	12	NMOD	_	_
11	sulfatase	_	NN	NN	_	12	NMOD	_	_
12	activity	_	NN	NN	_	8	PMOD	_	_
13	as	_	IN	IN	_	7	NMOD	_	_
14	that	_	DT	DT	_	13	PMOD	_	_
15	previously	_	RB	RB	_	16	TMP	_	_
16	observed	_	VBN	VBN	_	14	NMOD	_	_
17	in	_	IN	IN	_	16	ADV	_	_
18	hepatic	_	JJ	JJ	_	19	NMOD	_	_
19	microsomes	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Propylthiouracil	_	NN	NN	_	6	SBJ	_	_
2	(	_	(	(	_	1	PRN	_	_
3	50	_	CD	CD	_	4	NMOD	_	_
4	mumol\/L	_	NN	NN	_	2	DEP	_	_
5	)	_	)	)	_	2	P	_	_
6	did	_	VBD	VBD	_	0	ROOT-S	_	_
7	not	_	RB	RB	_	6	VMOD	_	_
8	affect	_	VB	VB	_	6	VC	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	action	_	NN	NN	_	8	IOBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	T3SO4	_	NN	NN	_	11	PMOD	_	_
13	,	_	,	,	_	8	P	_	_
14	suggesting	_	VBG	VBG	_	8	OBJ	_	_
15	that	_	IN	IN	_	14	OBJ	_	_
16	deiodination	_	NN	NN	_	17	SBJ	_	_
17	was	_	VBD	VBD	_	15	VMOD	_	_
18	not	_	RB	RB	_	17	VMOD	_	_
19	important	_	JJ	JJ	_	17	PRD	_	_
20	for	_	IN	IN	_	19	AMOD	_	_
21	this	_	DT	DT	_	22	NMOD	_	_
22	activity	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	T3SO4	_	NN	NN	_	23	PMOD	_	_
25	.	_	.	.	_	6	P	_	_

1	Thus	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	it	_	PRP	PRP	_	4	SBJ	_	_
4	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	T3SO4	_	NN	NN	_	6	SBJ	_	_
6	has	_	VBZ	VBZ	_	4	OBJ	_	_
7	no	_	DT	DT	_	10	NMOD	_	_
8	intrinsic	_	JJ	JJ	_	10	NMOD	_	_
9	biological	_	JJ	JJ	_	10	NMOD	_	_
10	activity	_	NN	NN	_	6	OBJ	_	_
11	,	_	,	,	_	6	P	_	_
12	but	_	CC	CC	_	6	CC	_	_
13	,	_	,	,	_	6	P	_	_
14	under	_	IN	IN	_	18	ADV	_	_
15	certain	_	JJ	JJ	_	16	NMOD	_	_
16	circumstances	_	NNS	NNS	_	14	PMOD	_	_
17	,	_	,	,	_	18	P	_	_
18	may	_	MD	MD	_	6	COORD	_	_
19	be	_	VB	VB	_	18	VC	_	_
20	reactivated	_	VBN	VBN	_	19	VC	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	desulfation	_	NN	NN	_	21	PMOD	_	_
23	.	_	.	.	_	4	P	_	_

1	Nuclear	_	JJ	JJ	_	2	NMOD	_	_
2	factor	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	activated	_	VBN	VBN	_	6	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	3	PMOD	_	_
7	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	Fos	_	NN	NN	_	7	OBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	Jun	_	NN	NN	_	8	COORD	_	_
11	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	nuclear	_	JJ	JJ	_	4	NMOD	_	_
3	factor	_	NN	NN	_	4	NMOD	_	_
4	NF-AT	_	NN	NN	_	9	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	ref.	_	NN	NN	_	4	PRN	_	_
7	1	_	CD	CD	_	6	NMOD	_	_
8	)	_	)	)	_	6	P	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	induced	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	stimulated	_	VBN	VBN	_	13	NMOD	_	_
15	through	_	IN	IN	_	14	ADV	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	T-cell	_	NN	NN	_	18	AMOD	_	_
18	receptor\/CD3	_	NN	NN	_	19	NMOD	_	_
19	complex	_	NN	NN	_	15	PMOD	_	_
20	,	_	,	,	_	9	P	_	_
21	and	_	CC	CC	_	9	CC	_	_
22	is	_	VBZ	VBZ	_	9	COORD	_	_
23	required	_	VBN	VBN	_	22	VC	_	_
24	for	_	IN	IN	_	23	ADV	_	_
25	interleukin-2	_	NN	NN	_	30	NMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	IL-2	_	NN	NN	_	25	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	gene	_	NN	NN	_	30	NMOD	_	_
30	induction	_	NN	NN	_	24	PMOD	_	_
31	.	_	.	.	_	9	P	_	_

1	Although	_	IN	IN	_	11	ADV	_	_
2	NF-AT	_	NN	NN	_	3	SBJ	_	_
3	has	_	VBZ	VBZ	_	1	VMOD	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	been	_	VBN	VBN	_	3	VC	_	_
6	cloned	_	VBN	VBN	_	5	VC	_	_
7	or	_	CC	CC	_	6	CC	_	_
8	purified	_	VBN	VBN	_	6	COORD	_	_
9	,	_	,	,	_	11	P	_	_
10	there	_	EX	EX	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	evidence	_	NN	NN	_	11	PRD	_	_
13	that	_	IN	IN	_	12	NMOD	_	_
14	it	_	PRP	PRP	_	15	SBJ	_	_
15	is	_	VBZ	VBZ	_	13	VMOD	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	major	_	JJ	JJ	_	18	NMOD	_	_
18	target	_	NN	NN	_	15	PRD	_	_
19	for	_	IN	IN	_	18	NMOD	_	_
20	immunosuppression	_	NN	NN	_	19	PMOD	_	_
21	by	_	IN	IN	_	20	NMOD	_	_
22	cyclosporin	_	NN	NN	_	23	NMOD	_	_
23	A	_	NN	NN	_	21	PMOD	_	_
24	(	_	(	(	_	25	P	_	_
25	CsA	_	NN	NN	_	23	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	and	_	CC	CC	_	23	CC	_	_
28	FK506	_	NN	NN	_	23	COORD	_	_
29	(	_	(	(	_	30	P	_	_
30	refs	_	NNS	NNS	_	28	PRN	_	_
31	2-7	_	CD	CD	_	30	NMOD	_	_
32	)	_	)	)	_	30	P	_	_
33	.	_	.	.	_	11	P	_	_

1	NF-AT	_	NN	NN	_	2	NMOD	_	_
2	induction	_	NN	NN	_	3	SBJ	_	_
3	may	_	MD	MD	_	0	ROOT-S	_	_
4	require	_	VB	VB	_	3	VC	_	_
5	two	_	CD	CD	_	7	NMOD	_	_
6	activation-dependent	_	JJ	JJ	_	7	NMOD	_	_
7	events	_	NNS	NNS	_	4	OBJ	_	_
8	:	_	:	:	_	7	P	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	CsA-sensitive	_	JJ	JJ	_	11	NMOD	_	_
11	translocation	_	NN	NN	_	7	NMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	pre-existing	_	JJ	JJ	_	15	NMOD	_	_
15	component	_	NN	NN	_	12	PMOD	_	_
16	and	_	CC	CC	_	11	CC	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	CsA-resistant	_	JJ	JJ	_	19	NMOD	_	_
19	synthesis	_	NN	NN	_	11	COORD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	nuclear	_	JJ	JJ	_	23	NMOD	_	_
23	component	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	report	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	newly	_	RB	RB	_	7	AMOD	_	_
7	synthesized	_	VBN	VBN	_	9	NMOD	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	component	_	NN	NN	_	12	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	NF-AT	_	NN	NN	_	10	PMOD	_	_
12	is	_	VBZ	VBZ	_	4	VMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	transcription	_	NN	NN	_	16	NMOD	_	_
15	factor	_	NN	NN	_	16	NMOD	_	_
16	AP-1	_	NN	NN	_	12	PRD	_	_
17	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	inducible	_	JJ	JJ	_	7	NMOD	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	form	_	NN	NN	_	10	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	NF-AT	_	NN	NN	_	8	PMOD	_	_
10	contains	_	VBZ	VBZ	_	3	VMOD	_	_
11	Fos	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	Jun	_	NN	NN	_	11	COORD	_	_
14	proteins	_	NNS	NNS	_	10	OBJ	_	_
15	.	_	.	.	_	2	P	_	_

1	Furthermore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	identify	_	VBP	VBP	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	pre-existing	_	JJ	JJ	_	8	NMOD	_	_
7	NF-AT-binding	_	JJ	JJ	_	8	NMOD	_	_
8	factor	_	NN	NN	_	4	OBJ	_	_
9	that	_	WDT	WDT	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	8	NMOD	_	_
11	present	_	JJ	JJ	_	10	PRD	_	_
12	in	_	IN	IN	_	11	AMOD	_	_
13	hypotonic	_	JJ	JJ	_	14	NMOD	_	_
14	extracts	_	NNS	NNS	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	unstimulated	_	JJ	JJ	_	18	NMOD	_	_
17	T	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	4	P	_	_

1	On	_	IN	IN	_	13	ADV	_	_
2	the	_	DT	DT	_	1	DEP	_	_
3	basis	_	NN	NN	_	1	DEP	_	_
4	of	_	IN	IN	_	1	DEP	_	_
5	binding	_	NN	NN	_	10	NMOD	_	_
6	,	_	,	,	_	5	P	_	_
7	reconstitution	_	NN	NN	_	5	COORD	_	_
8	and	_	CC	CC	_	5	CC	_	_
9	cotransfection	_	NN	NN	_	5	COORD	_	_
10	experiments	_	NNS	NNS	_	1	PMOD	_	_
11	,	_	,	,	_	13	P	_	_
12	we	_	PRP	PRP	_	13	SBJ	_	_
13	propose	_	VBP	VBP	_	0	ROOT-S	_	_
14	that	_	IN	IN	_	13	OBJ	_	_
15	activation	_	NN	NN	_	18	SBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	NF-AT	_	NN	NN	_	16	PMOD	_	_
18	occurs	_	VBZ	VBZ	_	14	VMOD	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	at	_	IN	IN	_	22	DEP	_	_
21	least	_	JJS	JJS	_	22	DEP	_	_
22	two	_	CD	CD	_	23	NMOD	_	_
23	stages	_	NNS	NNS	_	19	PMOD	_	_
24	:	_	:	:	_	23	P	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	CsA-sensitive	_	JJ	JJ	_	27	NMOD	_	_
27	stage	_	NN	NN	_	23	NMOD	_	_
28	involving	_	VBG	VBG	_	27	NMOD	_	_
29	modification	_	NN	NN	_	28	OBJ	_	_
30	and\/or	_	CC	CC	_	29	CC	_	_
31	translocation	_	NN	NN	_	29	COORD	_	_
32	of	_	IN	IN	_	29	NMOD	_	_
33	the	_	DT	DT	_	36	NMOD	_	_
34	pre-existing	_	JJ	JJ	_	36	NMOD	_	_
35	NF-AT	_	NN	NN	_	36	NMOD	_	_
36	complex	_	NN	NN	_	32	PMOD	_	_
37	,	_	,	,	_	27	P	_	_
38	and	_	CC	CC	_	27	CC	_	_
39	a	_	DT	DT	_	41	NMOD	_	_
40	CsA-insensitive	_	JJ	JJ	_	41	NMOD	_	_
41	stage	_	NN	NN	_	27	COORD	_	_
42	involving	_	VBG	VBG	_	41	NMOD	_	_
43	the	_	DT	DT	_	44	NMOD	_	_
44	addition	_	NN	NN	_	42	OBJ	_	_
45	of	_	IN	IN	_	44	NMOD	_	_
46	newly	_	RB	RB	_	47	AMOD	_	_
47	synthesized	_	VBN	VBN	_	51	NMOD	_	_
48	Fos	_	NN	NN	_	51	NMOD	_	_
49	or	_	CC	CC	_	48	CC	_	_
50	Fos\/Jun	_	NN	NN	_	48	COORD	_	_
51	proteins	_	NNS	NNS	_	45	PMOD	_	_
52	to	_	TO	TO	_	44	NMOD	_	_
53	the	_	DT	DT	_	55	NMOD	_	_
54	pre-existing	_	JJ	JJ	_	55	NMOD	_	_
55	complex	_	NN	NN	_	52	PMOD	_	_
56	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	mechanism	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	action	_	NN	NN	_	3	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	cyclosporin	_	NN	NN	_	7	NMOD	_	_
7	A	_	NN	NN	_	5	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	FK506	_	NN	NN	_	7	COORD	_	_
10	.	_	.	.	_	2	P	_	_

1	CsA	_	NN	NN	_	4	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	FK506	_	NN	NN	_	1	COORD	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	powerful	_	JJ	JJ	_	6	NMOD	_	_
6	suppressors	_	NNS	NNS	_	4	PRD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	immune	_	JJ	JJ	_	10	NMOD	_	_
10	system	_	NN	NN	_	7	PMOD	_	_
11	,	_	,	,	_	7	P	_	_
12	most	_	RBS	RBS	_	13	AMOD	_	_
13	notably	_	RB	RB	_	14	PMOD	_	_
14	of	_	IN	IN	_	7	COORD	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	.	_	.	.	_	4	P	_	_

1	They	_	PRP	PRP	_	2	SBJ	_	_
2	act	_	VBP	VBP	_	0	ROOT-S	_	_
3	at	_	IN	IN	_	2	ADV	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	point	_	NN	NN	_	3	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	activation	_	NN	NN	_	6	PMOD	_	_
8	that	_	WDT	WDT	_	9	SBJ	_	_
9	lies	_	VBZ	VBZ	_	5	NMOD	_	_
10	between	_	IN	IN	_	9	ADV	_	_
11	receptor	_	NN	NN	_	12	NMOD	_	_
12	ligation	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	transcription	_	NN	NN	_	12	COORD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	early	_	JJ	JJ	_	18	NMOD	_	_
18	genes	_	NNS	NNS	_	16	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	Here	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	Stuart	_	NNP	NNP	_	4	NMOD	_	_
4	Schreiber	_	NNP	NNP	_	8	SBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	Gerald	_	NNP	NNP	_	7	NMOD	_	_
7	Crabtree	_	NNP	NNP	_	4	COORD	_	_
8	review	_	VBP	VBP	_	0	ROOT-S	_	_
9	recent	_	JJ	JJ	_	10	NMOD	_	_
10	findings	_	NNS	NNS	_	8	OBJ	_	_
11	that	_	WDT	WDT	_	16	SBJ	_	_
12	indicate	_	VBP	VBP	_	16	VMOD	_	_
13	CsA	_	NN	NN	_	16	SBJ	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	FK506	_	NN	NN	_	13	COORD	_	_
16	operate	_	VBP	VBP	_	10	NMOD	_	_
17	as	_	IN	IN	_	16	ADV	_	_
18	prodrugs	_	NNS	NNS	_	17	PMOD	_	_
19	:	_	:	:	_	8	P	_	_
20	they	_	PRP	PRP	_	21	SBJ	_	_
21	bind	_	VBP	VBP	_	8	VMOD	_	_
22	endogenous	_	JJ	JJ	_	24	NMOD	_	_
23	intracellular	_	JJ	JJ	_	24	NMOD	_	_
24	receptors	_	NNS	NNS	_	21	OBJ	_	_
25	,	_	,	,	_	24	P	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	immunophilins	_	NNS	NNS	_	24	NMOD	_	_
28	,	_	,	,	_	21	P	_	_
29	and	_	CC	CC	_	21	CC	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	resulting	_	VBG	VBG	_	32	NMOD	_	_
32	complex	_	NN	NN	_	33	SBJ	_	_
33	targets	_	VBZ	VBZ	_	21	COORD	_	_
34	the	_	DT	DT	_	36	NMOD	_	_
35	protein	_	NN	NN	_	36	NMOD	_	_
36	phosphatase	_	NN	NN	_	33	IOBJ	_	_
37	,	_	,	,	_	36	P	_	_
38	calcineurin	_	NN	NN	_	36	NMOD	_	_
39	,	_	,	,	_	36	P	_	_
40	to	_	TO	TO	_	41	VMOD	_	_
41	exert	_	VB	VB	_	33	OBJ	_	_
42	the	_	DT	DT	_	44	NMOD	_	_
43	immunosuppressive	_	JJ	JJ	_	44	NMOD	_	_
44	effect	_	NN	NN	_	41	OBJ	_	_
45	.	_	.	.	_	21	P	_	_

1	{	_	(	(	_	4	P	_	_
2	Plasma	_	NN	NN	_	4	NMOD	_	_
3	cortisol	_	NN	NN	_	4	NMOD	_	_
4	concentration	_	NN	NN	_	0	ROOT-FRAG	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	blood	_	NN	NN	_	8	NMOD	_	_
7	leukocyte	_	NN	NN	_	8	NMOD	_	_
8	content	_	NN	NN	_	4	COORD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	glucocorticoid	_	NN	NN	_	11	NMOD	_	_
11	receptors	_	NNS	NNS	_	9	PMOD	_	_
12	in	_	IN	IN	_	4	NMOD	_	_
13	patients	_	NNS	NNS	_	12	PMOD	_	_
14	with	_	IN	IN	_	13	NMOD	_	_
15	deficiency-cold	_	JJ	JJ	_	18	NMOD	_	_
16	vs	_	CC	CC	_	15	CC	_	_
17	deficiency-heat	_	JJ	JJ	_	15	COORD	_	_
18	syndromes	_	NNS	NNS	_	14	PMOD	_	_
19	}	_	)	)	_	4	P	_	_

1	Plasma	_	NN	NN	_	3	NMOD	_	_
2	cortisol	_	NN	NN	_	3	NMOD	_	_
3	concentration	_	NN	NN	_	14	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	blood	_	NN	NN	_	7	NMOD	_	_
6	leukocyte	_	NN	NN	_	7	NMOD	_	_
7	content	_	NN	NN	_	3	COORD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	glucocorticoid	_	NN	NN	_	10	NMOD	_	_
10	receptors	_	NNS	NNS	_	8	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	GCR	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	were	_	VBD	VBD	_	0	ROOT-S	_	_
15	assayed	_	VBN	VBN	_	14	VC	_	_
16	in	_	IN	IN	_	15	VMOD	_	_
17	20	_	CD	CD	_	18	NMOD	_	_
18	patients	_	NNS	NNS	_	16	PMOD	_	_
19	with	_	IN	IN	_	18	NMOD	_	_
20	deficiency	_	NN	NN	_	21	NMOD	_	_
21	syndromes	_	NNS	NNS	_	19	PMOD	_	_
22	,	_	,	,	_	18	P	_	_
23	10	_	CD	CD	_	18	NMOD	_	_
24	cold	_	JJ	JJ	_	23	NMOD	_	_
25	in	_	IN	IN	_	24	AMOD	_	_
26	property	_	NN	NN	_	25	PMOD	_	_
27	(	_	(	(	_	28	P	_	_
28	deficiency-cold	_	JJ	JJ	_	24	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	,	_	,	,	_	23	P	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	other	_	JJ	JJ	_	33	NMOD	_	_
33	10	_	CD	CD	_	23	NMOD	_	_
34	hot	_	JJ	JJ	_	33	NMOD	_	_
35	in	_	IN	IN	_	34	AMOD	_	_
36	property	_	NN	NN	_	35	PMOD	_	_
37	(	_	(	(	_	38	P	_	_
38	deficiency-heat	_	JJ	JJ	_	34	PRN	_	_
39	)	_	)	)	_	38	P	_	_
40	,	_	,	,	_	15	P	_	_
41	and	_	CC	CC	_	15	CC	_	_
42	also	_	RB	RB	_	15	COORD	_	_
43	in	_	IN	IN	_	16	GAP	_	_
44	10	_	CD	CD	_	46	NMOD	_	_
45	healthy	_	JJ	JJ	_	46	NMOD	_	_
46	individuals	_	NNS	NNS	_	43	PMOD	_	_
47	as	_	IN	IN	_	43	ADV	_	_
48	normal	_	JJ	JJ	_	49	NMOD	_	_
49	control	_	NN	NN	_	47	PMOD	_	_
50	for	_	IN	IN	_	15	ADV	_	_
51	the	_	DT	DT	_	52	NMOD	_	_
52	purpose	_	NN	NN	_	50	PMOD	_	_
53	of	_	IN	IN	_	52	NMOD	_	_
54	investigating	_	VBG	VBG	_	53	PMOD	_	_
55	the	_	DT	DT	_	56	NMOD	_	_
56	nature	_	NN	NN	_	54	OBJ	_	_
57	of	_	IN	IN	_	56	NMOD	_	_
58	cold	_	NN	NN	_	61	NMOD	_	_
59	and	_	CC	CC	_	58	CC	_	_
60	heat	_	NN	NN	_	58	COORD	_	_
61	syndromes	_	NNS	NNS	_	57	PMOD	_	_
62	.	_	.	.	_	14	P	_	_

1	As	_	IN	IN	_	13	ADV	_	_
2	a	_	DT	DT	_	3	NMOD	_	_
3	result	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	13	P	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	cases	_	NNS	NNS	_	13	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	deficiency-cold	_	JJ	JJ	_	9	NMOD	_	_
9	syndrome	_	NN	NN	_	7	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	DCS	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	had	_	VBD	VBD	_	0	ROOT-S	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	normal	_	JJ	JJ	_	16	NMOD	_	_
16	concentration	_	NN	NN	_	13	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	plasma	_	NN	NN	_	19	NMOD	_	_
19	cortisol	_	NN	NN	_	17	PMOD	_	_
20	but	_	CC	CC	_	16	CC	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	lowered	_	JJ	JJ	_	23	NMOD	_	_
23	content	_	NN	NN	_	16	COORD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	GCR	_	NN	NN	_	24	PMOD	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	leukocytes	_	NNS	NNS	_	26	PMOD	_	_
28	when	_	WRB	WRB	_	29	ADV	_	_
29	compared	_	VBN	VBN	_	13	TMP	_	_
30	with	_	IN	IN	_	29	ADV	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	normal	_	JJ	JJ	_	33	NMOD	_	_
33	control	_	NN	NN	_	30	PMOD	_	_
34	(	_	(	(	_	38	P	_	_
35	P	_	NN	NN	_	38	SBJ	_	_
36	less	_	JJR	JJR	_	38	DEP	_	_
37	than	_	IN	IN	_	38	DEP	_	_
38	0.05	_	CD	CD	_	33	PRN	_	_
39	)	_	)	)	_	38	P	_	_
40	;	_	:	:	_	13	P	_	_
41	the	_	DT	DT	_	42	NMOD	_	_
42	cases	_	NNS	NNS	_	49	SBJ	_	_
43	of	_	IN	IN	_	42	NMOD	_	_
44	deficiency-heat	_	JJ	JJ	_	45	NMOD	_	_
45	syndrome	_	NN	NN	_	43	PMOD	_	_
46	(	_	(	(	_	47	P	_	_
47	DHS	_	NN	NN	_	45	PRN	_	_
48	)	_	)	)	_	47	P	_	_
49	had	_	VBD	VBD	_	13	VMOD	_	_
50	a	_	DT	DT	_	52	NMOD	_	_
51	higher	_	JJR	JJR	_	52	NMOD	_	_
52	concentration	_	NN	NN	_	49	OBJ	_	_
53	of	_	IN	IN	_	52	NMOD	_	_
54	plasma	_	NN	NN	_	55	NMOD	_	_
55	cortisol	_	NN	NN	_	53	PMOD	_	_
56	than	_	IN	IN	_	52	NMOD	_	_
57	the	_	DT	DT	_	59	NMOD	_	_
58	normal	_	JJ	JJ	_	59	NMOD	_	_
59	control	_	NN	NN	_	56	PMOD	_	_
60	(	_	(	(	_	64	P	_	_
61	P	_	NN	NN	_	64	SBJ	_	_
62	less	_	JJR	JJR	_	64	DEP	_	_
63	than	_	IN	IN	_	64	DEP	_	_
64	0.05	_	CD	CD	_	59	PRN	_	_
65	)	_	)	)	_	64	P	_	_
66	and	_	CC	CC	_	52	CC	_	_
67	a	_	DT	DT	_	70	NMOD	_	_
68	slightly	_	RB	RB	_	69	AMOD	_	_
69	higher	_	JJR	JJR	_	70	NMOD	_	_
70	content	_	NN	NN	_	52	NMOD	_	_
71	of	_	IN	IN	_	70	NMOD	_	_
72	GCR	_	NN	NN	_	71	PMOD	_	_
73	in	_	IN	IN	_	70	NMOD	_	_
74	leukocytes	_	NNS	NNS	_	73	PMOD	_	_
75	.	_	.	.	_	49	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	concluded	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	DCS	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	4	VMOD	_	_
8	characterized	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	diminished	_	VBN	VBN	_	12	NMOD	_	_
11	biological	_	JJ	JJ	_	12	NMOD	_	_
12	effects	_	NNS	NNS	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	adrenocortical	_	JJ	JJ	_	15	NMOD	_	_
15	activity	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	7	P	_	_
17	while	_	IN	IN	_	7	VMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	DHS	_	NN	NN	_	6	GAP	_	_
20	,	_	,	,	_	19	P	_	_
21	by	_	IN	IN	_	9	GAP	_	_
22	augmented	_	JJ	JJ	_	24	NMOD	_	_
23	biological	_	JJ	JJ	_	24	NMOD	_	_
24	effects	_	NNS	NNS	_	21	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	adrenocortical	_	JJ	JJ	_	27	NMOD	_	_
27	activity	_	NN	NN	_	25	PMOD	_	_
28	.	_	.	.	_	2	P	_	_

1	Activation	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	9	NMOD	_	_
4	human	_	JJ	JJ	_	9	NMOD	_	_
5	immunodeficiency	_	NN	NN	_	9	NMOD	_	_
6	virus	_	NN	NN	_	9	NMOD	_	_
7	type	_	NN	NN	_	9	NMOD	_	_
8	1	_	CD	CD	_	9	NMOD	_	_
9	enhancer	_	NN	NN	_	2	PMOD	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	not	_	RB	RB	_	10	VMOD	_	_
12	dependent	_	JJ	JJ	_	10	PRD	_	_
13	on	_	IN	IN	_	12	AMOD	_	_
14	NFAT-1	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	function	_	NN	NN	_	16	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	putative	_	JJ	JJ	_	7	NMOD	_	_
6	NFAT-1	_	NN	NN	_	7	NMOD	_	_
7	site	_	NN	NN	_	3	PMOD	_	_
8	in	_	IN	IN	_	2	NMOD	_	_
9	the	_	DT	DT	_	15	NMOD	_	_
10	human	_	JJ	JJ	_	15	NMOD	_	_
11	immunodeficiency	_	NN	NN	_	15	NMOD	_	_
12	virus	_	NN	NN	_	15	NMOD	_	_
13	type	_	NN	NN	_	15	NMOD	_	_
14	1	_	CD	CD	_	15	NMOD	_	_
15	enhancer	_	NN	NN	_	8	PMOD	_	_
16	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	been	_	VBN	VBN	_	16	VC	_	_
18	analyzed	_	VBN	VBN	_	17	VC	_	_
19	.	_	.	.	_	16	P	_	_

1	Activation	_	NN	NN	_	7	SBJ	_	_
2	by	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	T-cell	_	NN	NN	_	6	NMOD	_	_
5	antigen	_	NN	NN	_	6	NMOD	_	_
6	receptor	_	NN	NN	_	2	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	minimal	_	JJ	JJ	_	7	PRD	_	_
9	in	_	IN	IN	_	7	ADV	_	_
10	Jurkat	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	and	_	CC	CC	_	7	CC	_	_
13	is	_	VBZ	VBZ	_	7	COORD	_	_
14	mediated	_	VBN	VBN	_	13	VC	_	_
15	by	_	IN	IN	_	14	LGS	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	kappa	_	NN	NN	_	19	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	sites	_	NNS	NNS	_	15	PMOD	_	_
20	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	putative	_	JJ	JJ	_	4	NMOD	_	_
3	NFAT-1	_	NN	NN	_	4	NMOD	_	_
4	region	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	not	_	RB	RB	_	5	VMOD	_	_
7	required	_	VBN	VBN	_	5	VC	_	_
8	for	_	IN	IN	_	7	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	response	_	NN	NN	_	8	PMOD	_	_
11	to	_	TO	TO	_	10	NMOD	_	_
12	anti-CD3	_	NN	NN	_	11	PMOD	_	_
13	or	_	CC	CC	_	11	CC	_	_
14	to	_	TO	TO	_	11	COORD	_	_
15	mitogens	_	NNS	NNS	_	14	PMOD	_	_
16	in	_	IN	IN	_	10	NMOD	_	_
17	T-cell	_	NN	NN	_	24	NMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	B-cell	_	NN	NN	_	17	COORD	_	_
20	,	_	,	,	_	17	P	_	_
21	or	_	CC	CC	_	17	CC	_	_
22	monocyte\/macrophage	_	NN	NN	_	23	NMOD	_	_
23	leukemia	_	NN	NN	_	17	COORD	_	_
24	lines	_	NNS	NNS	_	16	PMOD	_	_
25	,	_	,	,	_	5	P	_	_
26	nor	_	CC	CC	_	5	CC	_	_
27	is	_	VBZ	VBZ	_	5	COORD	_	_
28	it	_	PRP	PRP	_	27	SBJ	_	_
29	a	_	DT	DT	_	33	NMOD	_	_
30	cis-acting	_	JJ	JJ	_	33	NMOD	_	_
31	negative	_	JJ	JJ	_	33	NMOD	_	_
32	regulatory	_	JJ	JJ	_	33	NMOD	_	_
33	element	_	NN	NN	_	27	PRD	_	_
34	.	_	.	.	_	5	P	_	_

1	Protein	_	NN	NN	_	4	NMOD	_	_
2	kinase	_	NN	NN	_	4	NMOD	_	_
3	C	_	NN	NN	_	4	NMOD	_	_
4	activation	_	NN	NN	_	0	ROOT-FRAG	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	protooncogene	_	NN	NN	_	7	NMOD	_	_
7	expression	_	NN	NN	_	4	COORD	_	_
8	in	_	IN	IN	_	4	NMOD	_	_
9	differentiation\/retrodifferentiation	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	human	_	JJ	JJ	_	14	NMOD	_	_
12	U-937	_	NN	NN	_	14	NMOD	_	_
13	leukemia	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	10	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	Human	_	JJ	JJ	_	4	NMOD	_	_
2	U-937	_	NN	NN	_	4	NMOD	_	_
3	leukemia	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	5	SBJ	_	_
5	differentiate	_	VBP	VBP	_	0	ROOT-S	_	_
6	along	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	monocytic	_	JJ	JJ	_	9	NMOD	_	_
9	lineage	_	NN	NN	_	6	PMOD	_	_
10	following	_	VBG	VBG	_	5	TMP	_	_
11	3-day	_	JJ	JJ	_	12	NMOD	_	_
12	exposures	_	NNS	NNS	_	10	PMOD	_	_
13	to	_	TO	TO	_	12	NMOD	_	_
14	12-O-tetradecanoylphorbol-13-acetate	_	NN	NN	_	13	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	TPA	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	.	_	.	.	_	5	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	induction	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	differentiation	_	NN	NN	_	3	PMOD	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	accompanied	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	adherence	_	NN	NN	_	7	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	loss	_	NN	NN	_	8	COORD	_	_
11	of	_	IN	IN	_	8	NMOD	_	_
12	proliferation	_	NN	NN	_	11	PMOD	_	_
13	,	_	,	,	_	8	P	_	_
14	as	_	RB	RB	_	8	CC	_	_
15	well	_	RB	RB	_	14	DEP	_	_
16	as	_	IN	IN	_	14	DEP	_	_
17	expression\/repression	_	NN	NN	_	8	COORD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	differentiation-associated	_	JJ	JJ	_	20	NMOD	_	_
20	genes	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	5	P	_	_

1	Long	_	JJ	JJ	_	2	AMOD	_	_
2	term	_	NN	NN	_	3	NMOD	_	_
3	culture	_	NN	NN	_	17	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	TPA-differentiated	_	JJ	JJ	_	7	NMOD	_	_
6	U-937	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	4	PMOD	_	_
8	in	_	IN	IN	_	3	NMOD	_	_
9	the	_	DT	DT	_	8	DEP	_	_
10	absence	_	NN	NN	_	8	DEP	_	_
11	of	_	IN	IN	_	8	DEP	_	_
12	phorbol	_	NN	NN	_	13	NMOD	_	_
13	ester	_	NN	NN	_	8	PMOD	_	_
14	for	_	IN	IN	_	3	TMP	_	_
15	32-36	_	CD	CD	_	16	NMOD	_	_
16	days	_	NNS	NNS	_	14	PMOD	_	_
17	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	a	_	DT	DT	_	20	NMOD	_	_
20	process	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	retrodifferentiation	_	NN	NN	_	21	PMOD	_	_
23	.	_	.	.	_	17	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	retrodifferentiated	_	VBN	VBN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	4	SBJ	_	_
4	detached	_	VBD	VBD	_	0	ROOT-S	_	_
5	from	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	substrate	_	NN	NN	_	5	PMOD	_	_
8	and	_	CC	CC	_	4	CC	_	_
9	reinitiated	_	VBD	VBD	_	4	COORD	_	_
10	proliferation	_	NN	NN	_	9	OBJ	_	_
11	.	_	.	.	_	4	P	_	_

1	Other	_	JJ	JJ	_	3	NMOD	_	_
2	cellular	_	JJ	JJ	_	3	NMOD	_	_
3	parameters	_	NNS	NNS	_	17	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	such	_	JJ	JJ	_	6	DEP	_	_
6	as	_	IN	IN	_	3	NMOD	_	_
7	glycosidase	_	NN	NN	_	8	NMOD	_	_
8	activities	_	NNS	NNS	_	6	PMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	cytokine	_	NN	NN	_	11	NMOD	_	_
11	release	_	NN	NN	_	8	COORD	_	_
12	,	_	,	,	_	8	P	_	_
13	and	_	CC	CC	_	8	CC	_	_
14	filament	_	NN	NN	_	15	NMOD	_	_
15	expression	_	NN	NN	_	8	COORD	_	_
16	,	_	,	,	_	3	P	_	_
17	returned	_	VBD	VBD	_	0	ROOT-S	_	_
18	to	_	TO	TO	_	17	ADV	_	_
19	levels	_	NNS	NNS	_	18	PMOD	_	_
20	similar	_	JJ	JJ	_	19	NMOD	_	_
21	to	_	TO	TO	_	20	AMOD	_	_
22	that	_	DT	DT	_	21	PMOD	_	_
23	observed	_	VBN	VBN	_	22	NMOD	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	uninduced	_	JJ	JJ	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	24	PMOD	_	_
27	.	_	.	.	_	17	P	_	_

1	Treatment	_	NN	NN	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	U-937	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	TPA	_	NN	NN	_	5	PMOD	_	_
7	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	rapid	_	JJ	JJ	_	11	NMOD	_	_
11	translocation	_	NN	NN	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	protein	_	NN	NN	_	15	NMOD	_	_
14	kinase	_	NN	NN	_	15	NMOD	_	_
15	C	_	NN	NN	_	12	PMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	PKC	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	from	_	IN	IN	_	11	NMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	cytosol	_	NN	NN	_	19	PMOD	_	_
22	to	_	TO	TO	_	11	NMOD	_	_
23	cell	_	NN	NN	_	25	NMOD	_	_
24	membrane	_	NN	NN	_	25	NMOD	_	_
25	fractions	_	NNS	NNS	_	22	PMOD	_	_
26	within	_	IN	IN	_	11	TMP	_	_
27	2-8	_	CD	CD	_	28	NMOD	_	_
28	min	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	7	P	_	_

1	Increased	_	VBN	VBN	_	2	NMOD	_	_
2	levels	_	NNS	NNS	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	membrane-associated	_	JJ	JJ	_	6	NMOD	_	_
5	PKC	_	NN	NN	_	6	NMOD	_	_
6	activity	_	NN	NN	_	3	PMOD	_	_
7	persisted	_	VBD	VBD	_	0	ROOT-S	_	_
8	until	_	IN	IN	_	7	TMP	_	_
9	17-29	_	CD	CD	_	10	NMOD	_	_
10	days	_	NNS	NNS	_	8	PMOD	_	_
11	.	_	.	.	_	7	P	_	_

1	However	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	longer	_	JJR	JJR	_	4	NMOD	_	_
4	periods	_	NNS	NNS	_	7	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	incubation	_	NN	NN	_	5	PMOD	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	associated	_	VBN	VBN	_	7	VC	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	a	_	DT	DT	_	11	NMOD	_	_
11	return	_	NN	NN	_	9	PMOD	_	_
12	to	_	TO	TO	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	distribution	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	PKC	_	NN	NN	_	15	PMOD	_	_
17	in	_	IN	IN	_	14	NMOD	_	_
18	control	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	7	P	_	_

1	Activation	_	NN	NN	_	4	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	PKC	_	NN	NN	_	2	PMOD	_	_
4	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	been	_	VBN	VBN	_	4	VC	_	_
6	implicated	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	regulation	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	certain	_	JJ	JJ	_	15	NMOD	_	_
12	immediate	_	JJ	JJ	_	15	NMOD	_	_
13	early	_	JJ	JJ	_	15	NMOD	_	_
14	response	_	NN	NN	_	15	NMOD	_	_
15	genes	_	NNS	NNS	_	10	PMOD	_	_
16	,	_	,	,	_	4	P	_	_
17	and	_	CC	CC	_	4	CC	_	_
18	in	_	IN	IN	_	25	ADV	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	present	_	JJ	JJ	_	21	NMOD	_	_
21	studies	_	NNS	NNS	_	18	PMOD	_	_
22	,	_	,	,	_	25	P	_	_
23	TPA	_	NN	NN	_	25	SBJ	_	_
24	rapidly	_	RB	RB	_	25	TMP	_	_
25	induced	_	VBD	VBD	_	4	COORD	_	_
26	c-fos	_	NN	NN	_	30	NMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	c-jun	_	NN	NN	_	26	COORD	_	_
29	gene	_	NN	NN	_	30	NMOD	_	_
30	expression	_	NN	NN	_	25	OBJ	_	_
31	.	_	.	.	_	4	P	_	_

1	Levels	_	NNS	NNS	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	c-fos	_	NN	NN	_	6	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	c-jun	_	NN	NN	_	3	COORD	_	_
6	transcripts	_	NNS	NNS	_	2	PMOD	_	_
7	remained	_	VBD	VBD	_	0	ROOT-S	_	_
8	elevated	_	JJ	JJ	_	7	PRD	_	_
9	during	_	IN	IN	_	7	TMP	_	_
10	periods	_	NNS	NNS	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	PKC	_	NN	NN	_	13	NMOD	_	_
13	activation	_	NN	NN	_	11	PMOD	_	_
14	and	_	CC	CC	_	7	CC	_	_
15	also	_	RB	RB	_	7	COORD	_	_
16	returned	_	VBD	VBD	_	7	COORD	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	levels	_	NNS	NNS	_	17	PMOD	_	_
19	observed	_	VBN	VBN	_	18	NMOD	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	control	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	20	PMOD	_	_
23	by	_	IN	IN	_	19	TMP	_	_
24	30-36	_	CD	CD	_	25	NMOD	_	_
25	days	_	NNS	NNS	_	23	PMOD	_	_
26	,	_	,	,	_	7	P	_	_
27	when	_	WRB	WRB	_	30	ADV	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	30	SBJ	_	_
30	entered	_	VBD	VBD	_	7	TMP	_	_
31	retrodifferentiation	_	NN	NN	_	30	OBJ	_	_
32	.	_	.	.	_	7	P	_	_

1	Staurosporine	_	NN	NN	_	10	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	nonspecific	_	JJ	JJ	_	5	NMOD	_	_
5	inhibitor	_	NN	NN	_	1	NMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	PKC	_	NN	NN	_	6	PMOD	_	_
8	,	_	,	,	_	1	P	_	_
9	partially	_	RB	RB	_	10	ADV	_	_
10	blocked	_	VBD	VBD	_	0	ROOT-S	_	_
11	TPA-induced	_	JJ	JJ	_	12	NMOD	_	_
12	adherence	_	NN	NN	_	10	OBJ	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	growth	_	NN	NN	_	15	NMOD	_	_
15	inhibition	_	NN	NN	_	12	COORD	_	_
16	and	_	CC	CC	_	10	CC	_	_
17	concomitantly	_	RB	RB	_	18	ADV	_	_
18	prevented	_	VBD	VBD	_	10	COORD	_	_
19	TPA-induced	_	JJ	JJ	_	24	NMOD	_	_
20	c-fos	_	NN	NN	_	24	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	c-jun	_	NN	NN	_	20	COORD	_	_
23	gene	_	NN	NN	_	24	NMOD	_	_
24	expression	_	NN	NN	_	18	OBJ	_	_
25	.	_	.	.	_	10	P	_	_

1	(	_	(	(	_	3	P	_	_
2	ABSTRACT	_	NN	NN	_	3	SBJ	_	_
3	TRUNCATED	_	VBN	VBN	_	0	ROOT-S	_	_
4	AT	_	IN	IN	_	3	ADV	_	_
5	250	_	CD	CD	_	6	NMOD	_	_
6	WORDS	_	NNS	NNS	_	4	PMOD	_	_
7	)	_	)	)	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	promoter	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	CD19	_	NN	NN	_	6	NMOD	_	_
6	gene	_	NN	NN	_	3	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	target	_	NN	NN	_	7	PRD	_	_
10	for	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	15	NMOD	_	_
12	B-cell-specific	_	JJ	JJ	_	15	NMOD	_	_
13	transcription	_	NN	NN	_	15	NMOD	_	_
14	factor	_	NN	NN	_	15	NMOD	_	_
15	BSAP	_	NN	NN	_	10	PMOD	_	_
16	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	CD19	_	NN	NN	_	3	NMOD	_	_
3	protein	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	expressed	_	VBN	VBN	_	4	VC	_	_
6	on	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	surface	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	all	_	DT	DT	_	12	NMOD	_	_
11	B-lymphoid	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	PMOD	_	_
13	with	_	IN	IN	_	5	ADV	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	exception	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	terminally	_	RB	RB	_	18	AMOD	_	_
18	differentiated	_	VBN	VBN	_	20	NMOD	_	_
19	plasma	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	16	PMOD	_	_
21	and	_	CC	CC	_	4	CC	_	_
22	has	_	VBZ	VBZ	_	4	COORD	_	_
23	been	_	VBN	VBN	_	22	VC	_	_
24	implicated	_	VBN	VBN	_	23	VC	_	_
25	as	_	IN	IN	_	24	ADV	_	_
26	a	_	DT	DT	_	28	NMOD	_	_
27	signal-transducing	_	JJ	JJ	_	28	NMOD	_	_
28	receptor	_	NN	NN	_	25	PMOD	_	_
29	in	_	IN	IN	_	24	ADV	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	control	_	NN	NN	_	29	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	proliferation	_	NN	NN	_	32	PMOD	_	_
34	and	_	CC	CC	_	33	CC	_	_
35	differentiation	_	NN	NN	_	33	COORD	_	_
36	.	_	.	.	_	4	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	complete	_	JJ	JJ	_	5	NMOD	_	_
5	correlation	_	NN	NN	_	3	OBJ	_	_
6	between	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	expression	_	NN	NN	_	9	NMOD	_	_
9	pattern	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	CD19	_	NN	NN	_	13	NMOD	_	_
13	gene	_	NN	NN	_	10	PMOD	_	_
14	and	_	CC	CC	_	9	CC	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	B-cell-specific	_	JJ	JJ	_	19	NMOD	_	_
17	transcription	_	NN	NN	_	19	NMOD	_	_
18	factor	_	NN	NN	_	19	NMOD	_	_
19	BSAP	_	NN	NN	_	9	COORD	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	large	_	JJ	JJ	_	23	NMOD	_	_
23	panel	_	NN	NN	_	20	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	B-lymphoid	_	JJ	JJ	_	27	NMOD	_	_
26	cell	_	NN	NN	_	27	NMOD	_	_
27	lines	_	NNS	NNS	_	24	PMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	human	_	JJ	JJ	_	4	NMOD	_	_
3	CD19	_	NN	NN	_	4	NMOD	_	_
4	gene	_	NN	NN	_	5	SBJ	_	_
5	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	been	_	VBN	VBN	_	5	VC	_	_
7	cloned	_	VBN	VBN	_	6	VC	_	_
8	,	_	,	,	_	5	P	_	_
9	and	_	CC	CC	_	5	CC	_	_
10	several	_	JJ	JJ	_	12	NMOD	_	_
11	BSAP-binding	_	JJ	JJ	_	12	NMOD	_	_
12	sites	_	NNS	NNS	_	13	SBJ	_	_
13	have	_	VBP	VBP	_	5	COORD	_	_
14	been	_	VBN	VBN	_	13	VC	_	_
15	mapped	_	VBN	VBN	_	14	VC	_	_
16	by	_	IN	IN	_	15	ADV	_	_
17	in	_	FW	FW	_	18	AMOD	_	_
18	vitro	_	FW	FW	_	21	NMOD	_	_
19	protein-DNA	_	JJ	JJ	_	21	NMOD	_	_
20	binding	_	NN	NN	_	21	NMOD	_	_
21	studies	_	NNS	NNS	_	16	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	13	ADV	_	_
2	particular	_	JJ	JJ	_	1	PMOD	_	_
3	,	_	,	,	_	13	P	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	high-affinity	_	JJ	JJ	_	7	NMOD	_	_
6	BSAP-binding	_	JJ	JJ	_	7	NMOD	_	_
7	site	_	NN	NN	_	13	SBJ	_	_
8	instead	_	RB	RB	_	7	CC	_	_
9	of	_	IN	IN	_	8	DEP	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	TATA	_	NN	NN	_	12	NMOD	_	_
12	sequence	_	NN	NN	_	7	COORD	_	_
13	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	located	_	JJ	JJ	_	13	PRD	_	_
15	in	_	IN	IN	_	14	AMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	-30	_	CD	CD	_	19	NMOD	_	_
18	promoter	_	NN	NN	_	19	NMOD	_	_
19	region	_	NN	NN	_	15	PMOD	_	_
20	upstream	_	JJ	JJ	_	19	NMOD	_	_
21	of	_	IN	IN	_	20	AMOD	_	_
22	a	_	DT	DT	_	23	NMOD	_	_
23	cluster	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	heterogeneous	_	JJ	JJ	_	28	NMOD	_	_
26	transcription	_	NN	NN	_	28	NMOD	_	_
27	start	_	NN	NN	_	28	NMOD	_	_
28	sites	_	NNS	NNS	_	24	PMOD	_	_
29	.	_	.	.	_	13	P	_	_

1	Moreover	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	site	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	occupied	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	BSAP	_	NN	NN	_	7	PMOD	_	_
9	in	_	FW	FW	_	8	NMOD	_	_
10	vivo	_	FW	FW	_	9	AMOD	_	_
11	in	_	IN	IN	_	6	ADV	_	_
12	a	_	DT	DT	_	15	NMOD	_	_
13	CD19-expressing	_	JJ	JJ	_	15	NMOD	_	_
14	B-cell	_	NN	NN	_	15	NMOD	_	_
15	line	_	NN	NN	_	11	PMOD	_	_
16	but	_	CC	CC	_	11	CC	_	_
17	not	_	RB	RB	_	18	DEP	_	_
18	in	_	IN	IN	_	11	COORD	_	_
19	plasma	_	NN	NN	_	22	NMOD	_	_
20	or	_	CC	CC	_	19	CC	_	_
21	HeLa	_	NN	NN	_	19	COORD	_	_
22	cells	_	NNS	NNS	_	18	PMOD	_	_
23	.	_	.	.	_	5	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	high-affinity	_	JJ	JJ	_	3	NMOD	_	_
3	site	_	NN	NN	_	4	SBJ	_	_
4	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	been	_	VBN	VBN	_	4	VC	_	_
6	conserved	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	promoters	_	NNS	NNS	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	both	_	CC	CC	_	16	NMOD	_	_
12	human	_	JJ	JJ	_	11	COORD	_	_
13	and	_	CC	CC	_	11	CC	_	_
14	mouse	_	NN	NN	_	11	COORD	_	_
15	CD19	_	NN	NN	_	16	NMOD	_	_
16	genes	_	NNS	NNS	_	10	PMOD	_	_
17	and	_	CC	CC	_	4	CC	_	_
18	was	_	VBD	VBD	_	4	COORD	_	_
19	furthermore	_	RB	RB	_	18	ADV	_	_
20	shown	_	VBN	VBN	_	18	VC	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	confer	_	VB	VB	_	20	OBJ	_	_
23	B-cell	_	NN	NN	_	24	NMOD	_	_
24	specificity	_	NN	NN	_	22	OBJ	_	_
25	to	_	TO	TO	_	22	ADV	_	_
26	a	_	DT	DT	_	29	NMOD	_	_
27	beta-globin	_	NN	NN	_	29	NMOD	_	_
28	reporter	_	NN	NN	_	29	NMOD	_	_
29	gene	_	NN	NN	_	25	PMOD	_	_
30	in	_	IN	IN	_	22	ADV	_	_
31	transient	_	JJ	JJ	_	33	NMOD	_	_
32	transfection	_	NN	NN	_	33	NMOD	_	_
33	experiments	_	NNS	NNS	_	30	PMOD	_	_
34	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	BSAP	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	found	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	be	_	VB	VB	_	6	OBJ	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	only	_	RB	RB	_	13	NMOD	_	_
11	abundant	_	JJ	JJ	_	13	NMOD	_	_
12	DNA-binding	_	JJ	JJ	_	13	NMOD	_	_
13	activity	_	NN	NN	_	8	PRD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	B-cell	_	NN	NN	_	17	NMOD	_	_
16	nuclear	_	JJ	JJ	_	17	NMOD	_	_
17	extracts	_	NNS	NNS	_	14	PMOD	_	_
18	that	_	WDT	WDT	_	19	SBJ	_	_
19	interacts	_	VBZ	VBZ	_	13	NMOD	_	_
20	with	_	IN	IN	_	19	ADV	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	CD19	_	NN	NN	_	23	NMOD	_	_
23	promoter	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	5	P	_	_

1	Together	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	evidence	_	NN	NN	_	6	SBJ	_	_
5	strongly	_	RB	RB	_	6	ADV	_	_
6	implicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	BSAP	_	NN	NN	_	6	OBJ	_	_
8	in	_	IN	IN	_	6	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	regulation	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	CD19	_	NN	NN	_	14	NMOD	_	_
14	gene	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	6	P	_	_

1	Eicosanoids	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	in	_	IN	IN	_	1	NMOD	_	_
3	breast	_	NN	NN	_	5	NMOD	_	_
4	cancer	_	NN	NN	_	5	NMOD	_	_
5	patients	_	NNS	NNS	_	2	PMOD	_	_
6	before	_	IN	IN	_	1	TMP	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	after	_	IN	IN	_	6	COORD	_	_
9	mastectomy	_	NN	NN	_	6	PMOD	_	_
10	.	_	.	.	_	1	P	_	_

1	In	_	IN	IN	_	14	ADV	_	_
2	19	_	CD	CD	_	3	NMOD	_	_
3	patients	_	NNS	NNS	_	1	PMOD	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	malignant	_	JJ	JJ	_	8	NMOD	_	_
7	breast	_	NN	NN	_	8	NMOD	_	_
8	tumor	_	NN	NN	_	4	PMOD	_	_
9	,	_	,	,	_	14	P	_	_
10	tumor	_	NN	NN	_	11	NMOD	_	_
11	tissue	_	NN	NN	_	14	SBJ	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	blood	_	NN	NN	_	11	COORD	_	_
14	were	_	VBD	VBD	_	0	ROOT-S	_	_
15	taken	_	VBN	VBN	_	14	VC	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	determine	_	VB	VB	_	15	OBJ	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	eicosanoid	_	NN	NN	_	20	NMOD	_	_
20	profile	_	NN	NN	_	17	OBJ	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	platelet	_	NN	NN	_	23	NMOD	_	_
23	aggregation	_	NN	NN	_	20	COORD	_	_
24	.	_	.	.	_	14	P	_	_

1	Values	_	NNS	NNS	_	2	SBJ	_	_
2	were	_	VBD	VBD	_	0	ROOT-S	_	_
3	compared	_	VBN	VBN	_	2	VC	_	_
4	with	_	IN	IN	_	3	ADV	_	_
5	those	_	DT	DT	_	4	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	patients	_	NNS	NNS	_	6	PMOD	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	benign	_	JJ	JJ	_	10	NMOD	_	_
10	tumors	_	NNS	NNS	_	8	PMOD	_	_
11	(	_	(	(	_	14	P	_	_
12	n	_	NN	NN	_	14	SBJ	_	_
13	=	_	JJ	JJ	_	14	VMOD	_	_
14	4	_	CD	CD	_	10	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	,	_	,	,	_	8	P	_	_
17	or	_	CC	CC	_	8	CC	_	_
18	undergoing	_	VBG	VBG	_	8	COORD	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	mammary	_	JJ	JJ	_	21	NMOD	_	_
21	reduction	_	NN	NN	_	18	OBJ	_	_
22	(	_	(	(	_	25	P	_	_
23	n	_	NN	NN	_	25	SBJ	_	_
24	=	_	JJ	JJ	_	25	VMOD	_	_
25	7	_	CD	CD	_	21	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	.	_	.	.	_	2	P	_	_

1	Postoperatively	_	RB	RB	_	4	TMP	_	_
2	,	_	,	,	_	4	P	_	_
3	blood	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	taken	_	VBN	VBN	_	4	VC	_	_
6	as	_	RB	RB	_	5	ADV	_	_
7	well	_	RB	RB	_	6	PMOD	_	_
8	in	_	IN	IN	_	5	OBJ	_	_
9	order	_	NN	NN	_	8	VMOD	_	_
10	to	_	TO	TO	_	8	VMOD	_	_
11	compare	_	VB	VB	_	8	VMOD	_	_
12	pre-	_	JJ	JJ	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	postoperative	_	JJ	JJ	_	12	COORD	_	_
15	values	_	NNS	NNS	_	11	OBJ	_	_
16	.	_	.	.	_	4	P	_	_

1	Eicosanoids	_	NNS	NNS	_	2	SBJ	_	_
2	were	_	VBD	VBD	_	0	ROOT-S	_	_
3	measured	_	VBN	VBN	_	2	VC	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	peripheral	_	JJ	JJ	_	7	NMOD	_	_
6	blood	_	NN	NN	_	7	NMOD	_	_
7	monocytes	_	NNS	NNS	_	4	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	mammary	_	JJ	JJ	_	10	NMOD	_	_
10	tissue	_	NN	NN	_	7	COORD	_	_
11	by	_	IN	IN	_	3	ADV	_	_
12	means	_	NNS	NNS	_	11	DEP	_	_
13	of	_	IN	IN	_	11	DEP	_	_
14	HPLC	_	NN	NN	_	11	PMOD	_	_
15	;	_	:	:	_	2	P	_	_
16	furthermore	_	RBR	RBR	_	25	ADV	_	_
17	,	_	,	,	_	25	P	_	_
18	TXA2	_	NN	NN	_	25	SBJ	_	_
19	,	_	,	,	_	18	P	_	_
20	6-keto-PGF1	_	NN	NN	_	21	NMOD	_	_
21	alpha	_	NN	NN	_	18	COORD	_	_
22	,	_	,	,	_	18	P	_	_
23	and	_	CC	CC	_	18	CC	_	_
24	PGE2	_	NN	NN	_	18	COORD	_	_
25	were	_	VBD	VBD	_	2	VC	_	_
26	determined	_	VBN	VBN	_	25	VC	_	_
27	by	_	IN	IN	_	26	LGS	_	_
28	RIA	_	NN	NN	_	27	PMOD	_	_
29	.	_	.	.	_	25	P	_	_

1	Differences	_	NNS	NNS	_	10	SBJ	_	_
2	in	_	IN	IN	_	1	NMOD	_	_
3	pre-	_	JJ	JJ	_	6	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	postoperative	_	JJ	JJ	_	3	COORD	_	_
6	values	_	NNS	NNS	_	2	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	cancer	_	NN	NN	_	9	NMOD	_	_
9	patients	_	NNS	NNS	_	7	PMOD	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	seen	_	VBN	VBN	_	10	VC	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	plasma	_	NN	NN	_	15	NMOD	_	_
14	RIA	_	NN	NN	_	15	NMOD	_	_
15	values	_	NNS	NNS	_	12	PMOD	_	_
16	:	_	:	:	_	10	P	_	_
17	PGE2	_	NN	NN	_	21	SBJ	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	6-k-PGF1	_	NN	NN	_	20	NMOD	_	_
20	alpha	_	NN	NN	_	17	COORD	_	_
21	were	_	VBD	VBD	_	10	VC	_	_
22	significantly	_	RB	RB	_	23	AMOD	_	_
23	higher	_	JJR	JJR	_	21	PRD	_	_
24	preoperatively	_	RB	RB	_	21	TMP	_	_
25	when	_	WRB	WRB	_	26	ADV	_	_
26	compared	_	VBN	VBN	_	21	TMP	_	_
27	with	_	IN	IN	_	26	ADV	_	_
28	postoperatively	_	RB	RB	_	27	PMOD	_	_
29	,	_	,	,	_	21	P	_	_
30	however	_	RB	RB	_	21	COORD	_	_
31	,	_	,	,	_	21	P	_	_
32	such	_	JJ	JJ	_	33	NMOD	_	_
33	differences	_	NNS	NNS	_	34	SBJ	_	_
34	were	_	VBD	VBD	_	21	COORD	_	_
35	seen	_	VBN	VBN	_	34	VC	_	_
36	in	_	IN	IN	_	35	ADV	_	_
37	the	_	DT	DT	_	39	NMOD	_	_
38	control	_	NN	NN	_	39	NMOD	_	_
39	groups	_	NNS	NNS	_	36	PMOD	_	_
40	as	_	RB	RB	_	35	ADV	_	_
41	well	_	RB	RB	_	40	PMOD	_	_
42	.	_	.	.	_	10	P	_	_

1	Compared	_	VBN	VBN	_	20	ADV	_	_
2	to	_	TO	TO	_	1	PMOD	_	_
3	benign	_	JJ	JJ	_	4	NMOD	_	_
4	tumor	_	NN	NN	_	9	NMOD	_	_
5	or	_	CC	CC	_	4	CC	_	_
6	mammary	_	JJ	JJ	_	7	NMOD	_	_
7	reduction	_	NN	NN	_	4	COORD	_	_
8	test	_	NN	NN	_	9	NMOD	_	_
9	material	_	NN	NN	_	2	PMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	eicosanoid	_	NN	NN	_	12	NMOD	_	_
12	profile	_	NN	NN	_	20	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	tissue	_	NN	NN	_	13	PMOD	_	_
15	obtained	_	VBN	VBN	_	14	NMOD	_	_
16	from	_	IN	IN	_	15	ADV	_	_
17	malignant	_	JJ	JJ	_	19	NMOD	_	_
18	mammary	_	JJ	JJ	_	19	NMOD	_	_
19	tumors	_	NNS	NNS	_	16	PMOD	_	_
20	showed	_	VBD	VBD	_	0	ROOT-S	_	_
21	important	_	JJ	JJ	_	22	NMOD	_	_
22	differences	_	NNS	NNS	_	20	OBJ	_	_
23	.	_	.	.	_	20	P	_	_

1	Except	_	IN	IN	_	14	ADV	_	_
2	for	_	IN	IN	_	1	DEP	_	_
3	PGF2	_	NN	NN	_	4	NMOD	_	_
4	alpha	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	HHT	_	NN	NN	_	4	COORD	_	_
7	and	_	CC	CC	_	4	CC	_	_
8	15-HETE	_	NN	NN	_	4	COORD	_	_
9	no	_	DT	DT	_	11	NMOD	_	_
10	detectable	_	JJ	JJ	_	11	NMOD	_	_
11	quantities	_	NNS	NNS	_	14	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	eicosanoids	_	NNS	NNS	_	12	PMOD	_	_
14	were	_	VBD	VBD	_	0	ROOT-S	_	_
15	found	_	VBN	VBN	_	14	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	non-tumor	_	JJ	JJ	_	19	NMOD	_	_
19	material	_	NN	NN	_	16	PMOD	_	_
20	,	_	,	,	_	14	P	_	_
21	whereas	_	IN	IN	_	14	COORD	_	_
22	in	_	IN	IN	_	35	ADV	_	_
23	the	_	DT	DT	_	26	NMOD	_	_
24	malignant	_	JJ	JJ	_	26	NMOD	_	_
25	tumor	_	NN	NN	_	26	NMOD	_	_
26	material	_	NN	NN	_	22	PMOD	_	_
27	substantial	_	JJ	JJ	_	28	NMOD	_	_
28	quantities	_	NNS	NNS	_	35	SBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	a	_	DT	DT	_	31	NMOD	_	_
31	number	_	NN	NN	_	29	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	eicosanoid	_	NN	NN	_	34	NMOD	_	_
34	metabolites	_	NNS	NNS	_	32	PMOD	_	_
35	were	_	VBD	VBD	_	14	COORD	_	_
36	present	_	JJ	JJ	_	35	PRD	_	_
37	.	_	.	.	_	14	P	_	_

1	Statistically	_	RB	RB	_	2	AMOD	_	_
2	significant	_	JJ	JJ	_	3	NMOD	_	_
3	correlations	_	NNS	NNS	_	4	SBJ	_	_
4	could	_	MD	MD	_	0	ROOT-S	_	_
5	be	_	VB	VB	_	4	VC	_	_
6	established	_	VBN	VBN	_	5	VC	_	_
7	between	_	IN	IN	_	19	PMOD	_	_
8	patient\/histopathology	_	NN	NN	_	9	NMOD	_	_
9	data	_	NNS	NNS	_	7	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	results	_	NNS	NNS	_	9	COORD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	platelet	_	NN	NN	_	17	NMOD	_	_
16	aggregation	_	NN	NN	_	17	NMOD	_	_
17	assays	_	NNS	NNS	_	13	PMOD	_	_
18	,	_	,	,	_	19	P	_	_
19	e.g.	_	FW	FW	_	6	ADV	_	_
20	between	_	IN	IN	_	19	PMOD	_	_
21	menopausal	_	JJ	JJ	_	22	NMOD	_	_
22	status	_	NN	NN	_	20	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	ADP	_	NN	NN	_	25	NMOD	_	_
25	aggregation	_	NN	NN	_	22	COORD	_	_
26	;	_	:	:	_	22	P	_	_
27	oestrogen	_	NN	NN	_	28	NMOD	_	_
28	receptor	_	NN	NN	_	22	COORD	_	_
29	(	_	(	(	_	30	P	_	_
30	+\/-	_	JJ	JJ	_	28	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	and	_	CC	CC	_	28	CC	_	_
33	collagen	_	NN	NN	_	28	COORD	_	_
34	and	_	CC	CC	_	28	CC	_	_
35	arachidonic	_	JJ	JJ	_	37	NMOD	_	_
36	acid	_	NN	NN	_	37	NMOD	_	_
37	aggregation	_	NN	NN	_	28	COORD	_	_
38	,	_	,	,	_	22	P	_	_
39	inflammatory	_	JJ	JJ	_	42	NMOD	_	_
40	cell	_	NN	NN	_	42	NMOD	_	_
41	infiltration	_	NN	NN	_	42	NMOD	_	_
42	score	_	NN	NN	_	22	COORD	_	_
43	and	_	CC	CC	_	42	CC	_	_
44	arachidonic	_	JJ	JJ	_	46	NMOD	_	_
45	acid	_	NN	NN	_	46	NMOD	_	_
46	aggregation	_	NN	NN	_	42	COORD	_	_
47	and	_	CC	CC	_	22	CC	_	_
48	fibrosis	_	NN	NN	_	49	NMOD	_	_
49	score	_	NN	NN	_	22	COORD	_	_
50	and	_	CC	CC	_	49	CC	_	_
51	ADP	_	NN	NN	_	52	NMOD	_	_
52	aggregation	_	NN	NN	_	49	COORD	_	_
53	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	eicosanoid	_	NN	NN	_	6	NMOD	_	_
6	synthesis	_	NN	NN	_	13	SBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	material	_	NN	NN	_	7	PMOD	_	_
9	from	_	IN	IN	_	8	NMOD	_	_
10	mammary	_	JJ	JJ	_	12	NMOD	_	_
11	cancer	_	NN	NN	_	12	NMOD	_	_
12	patients	_	NNS	NNS	_	9	PMOD	_	_
13	is	_	VBZ	VBZ	_	4	VMOD	_	_
14	different	_	JJ	JJ	_	13	PRD	_	_
15	from	_	IN	IN	_	14	AMOD	_	_
16	that	_	DT	DT	_	15	PMOD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	benign	_	JJ	JJ	_	20	NMOD	_	_
19	mammary	_	JJ	JJ	_	20	NMOD	_	_
20	tissue	_	NN	NN	_	17	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	implications	_	NNS	NNS	_	16	SBJ	_	_
3	,	_	,	,	_	7	P	_	_
4	in	_	IN	IN	_	7	PMOD	_	_
5	particular	_	JJ	JJ	_	4	PMOD	_	_
6	,	_	,	,	_	7	P	_	_
7	in	_	IN	IN	_	2	NMOD	_	_
8	relation	_	NN	NN	_	7	DEP	_	_
9	to	_	TO	TO	_	7	DEP	_	_
10	future	_	JJ	JJ	_	11	NMOD	_	_
11	prognosis	_	NN	NN	_	7	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	patient	_	NN	NN	_	12	PMOD	_	_
15	,	_	,	,	_	7	P	_	_
16	remain	_	VBP	VBP	_	0	ROOT-S	_	_
17	obscure	_	JJ	JJ	_	16	PRD	_	_
18	.	_	.	.	_	16	P	_	_

1	c-myc	_	NN	NN	_	3	NMOD	_	_
2	mRNA	_	NN	NN	_	3	NMOD	_	_
3	expression	_	NN	NN	_	0	ROOT-FRAG	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	minor	_	JJ	JJ	_	7	NMOD	_	_
6	salivary	_	JJ	JJ	_	7	NMOD	_	_
7	glands	_	NNS	NNS	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	patients	_	NNS	NNS	_	8	PMOD	_	_
10	with	_	IN	IN	_	9	NMOD	_	_
11	Sjogren	_	NN	NN	_	13	NMOD	_	_
12	's	_	POS	POS	_	11	NMOD	_	_
13	syndrome	_	NN	NN	_	10	PMOD	_	_
14	.	_	.	.	_	3	P	_	_

1	c-myc	_	NN	NN	_	2	NMOD	_	_
2	protooncogene	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	implicated	_	VBN	VBN	_	3	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	pathogenesis	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	B	_	NN	NN	_	12	NMOD	_	_
10	cell	_	NN	NN	_	12	NMOD	_	_
11	lymphoid	_	JJ	JJ	_	12	NMOD	_	_
12	malignancies	_	NNS	NNS	_	8	PMOD	_	_
13	and	_	CC	CC	_	3	CC	_	_
14	high	_	JJ	JJ	_	15	NMOD	_	_
15	levels	_	NNS	NNS	_	20	SBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	c-myc	_	NN	NN	_	19	NMOD	_	_
18	mRNA	_	NN	NN	_	19	NMOD	_	_
19	expression	_	NN	NN	_	16	PMOD	_	_
20	are	_	VBP	VBP	_	3	COORD	_	_
21	observed	_	VBN	VBN	_	20	VC	_	_
22	in	_	IN	IN	_	21	ADV	_	_
23	activated	_	VBN	VBN	_	26	NMOD	_	_
24	blood	_	NN	NN	_	26	NMOD	_	_
25	mononuclear	_	JJ	JJ	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	22	PMOD	_	_
27	.	_	.	.	_	3	P	_	_

1	Sjogren	_	NN	NN	_	3	NMOD	_	_
2	's	_	POS	POS	_	1	NMOD	_	_
3	syndrome	_	NN	NN	_	7	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	SS	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	characterized	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	lymphocytic	_	JJ	JJ	_	11	NMOD	_	_
11	infiltrates	_	NNS	NNS	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	exocrine	_	JJ	JJ	_	14	NMOD	_	_
14	glands	_	NNS	NNS	_	12	PMOD	_	_
15	,	_	,	,	_	11	P	_	_
16	remarkable	_	JJ	JJ	_	19	NMOD	_	_
17	B	_	NN	NN	_	19	NMOD	_	_
18	cell	_	NN	NN	_	19	NMOD	_	_
19	hyperreactivity	_	NN	NN	_	11	COORD	_	_
20	and	_	CC	CC	_	11	CC	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	strong	_	JJ	JJ	_	23	NMOD	_	_
23	predisposition	_	NN	NN	_	11	COORD	_	_
24	to	_	TO	TO	_	23	NMOD	_	_
25	B	_	NN	NN	_	27	NMOD	_	_
26	cell	_	NN	NN	_	27	NMOD	_	_
27	neoplasia	_	NN	NN	_	24	PMOD	_	_
28	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	24	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	24	P	_	_
5	c-myc	_	NN	NN	_	8	NMOD	_	_
6	protooncogene	_	NN	NN	_	8	NMOD	_	_
7	mRNA	_	NN	NN	_	8	NMOD	_	_
8	expression	_	NN	NN	_	24	SBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	29	_	CD	CD	_	15	NMOD	_	_
11	labial	_	JJ	JJ	_	15	NMOD	_	_
12	minor	_	JJ	JJ	_	15	NMOD	_	_
13	salivary	_	JJ	JJ	_	15	NMOD	_	_
14	gland	_	NN	NN	_	15	NMOD	_	_
15	biopsies	_	NNS	NNS	_	9	PMOD	_	_
16	from	_	IN	IN	_	15	NMOD	_	_
17	patients	_	NNS	NNS	_	16	PMOD	_	_
18	with	_	IN	IN	_	17	NMOD	_	_
19	primary	_	JJ	JJ	_	20	NMOD	_	_
20	SS	_	NNS	NNS	_	18	PMOD	_	_
21	and	_	CC	CC	_	17	CC	_	_
22	15	_	CD	CD	_	23	NMOD	_	_
23	controls	_	NNS	NNS	_	17	COORD	_	_
24	was	_	VBD	VBD	_	0	ROOT-S	_	_
25	examined	_	VBN	VBN	_	24	VC	_	_
26	using	_	VBG	VBG	_	25	OBJ	_	_
27	in	_	FW	FW	_	28	AMOD	_	_
28	situ	_	FW	FW	_	30	NMOD	_	_
29	hybridization	_	NN	NN	_	30	NMOD	_	_
30	histochemistry	_	NN	NN	_	26	OBJ	_	_
31	.	_	.	.	_	24	P	_	_

1	Two	_	CD	CD	_	3	NMOD	_	_
2	40mer	_	JJ	JJ	_	3	NMOD	_	_
3	oligonucleotides	_	NNS	NNS	_	20	SBJ	_	_
4	from	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	10	NMOD	_	_
6	1st	_	JJ	JJ	_	10	NMOD	_	_
7	and	_	CC	CC	_	10	CC	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	2nd	_	JJ	JJ	_	10	NMOD	_	_
10	exon	_	NN	NN	_	4	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	c-myc	_	NN	NN	_	14	NMOD	_	_
14	gene	_	NN	NN	_	11	PMOD	_	_
15	,	_	,	,	_	3	P	_	_
16	labeled	_	VBN	VBN	_	3	NMOD	_	_
17	with	_	IN	IN	_	16	ADV	_	_
18	35S	_	NN	NN	_	17	PMOD	_	_
19	,	_	,	,	_	3	P	_	_
20	were	_	VBD	VBD	_	0	ROOT-S	_	_
21	used	_	VBN	VBN	_	20	VC	_	_
22	as	_	IN	IN	_	21	ADV	_	_
23	probes	_	NNS	NNS	_	22	PMOD	_	_
24	.	_	.	.	_	20	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	detect	_	VB	VB	_	22	ADV	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	origin	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	cell	_	NN	NN	_	5	PMOD	_	_
8	hybridized	_	VBN	VBN	_	7	NMOD	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	c-myc	_	NN	NN	_	12	NMOD	_	_
12	probe	_	NN	NN	_	9	PMOD	_	_
13	,	_	,	,	_	22	P	_	_
14	a	_	DT	DT	_	21	NMOD	_	_
15	combined	_	JJ	JJ	_	21	NMOD	_	_
16	immunochemistry	_	NN	NN	_	21	NMOD	_	_
17	in	_	FW	FW	_	18	AMOD	_	_
18	situ	_	FW	FW	_	21	NMOD	_	_
19	hybridization	_	NN	NN	_	21	NMOD	_	_
20	histochemistry	_	NN	NN	_	21	NMOD	_	_
21	technique	_	NN	NN	_	22	SBJ	_	_
22	was	_	VBD	VBD	_	0	ROOT-S	_	_
23	used	_	VBN	VBN	_	22	VC	_	_
24	.	_	.	.	_	22	P	_	_

1	High	_	JJ	JJ	_	4	NMOD	_	_
2	c-myc	_	NN	NN	_	4	NMOD	_	_
3	mRNA	_	NN	NN	_	4	NMOD	_	_
4	expression	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	detected	_	VBN	VBN	_	5	VC	_	_
7	on	_	IN	IN	_	6	ADV	_	_
8	acinar	_	JJ	JJ	_	10	NMOD	_	_
9	epithelial	_	JJ	JJ	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	7	PMOD	_	_
11	.	_	.	.	_	5	P	_	_

1	c-myc	_	NN	NN	_	2	SBJ	_	_
2	did	_	VBD	VBD	_	0	ROOT-S	_	_
3	not	_	RB	RB	_	2	VMOD	_	_
4	correlate	_	VB	VB	_	2	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	c-fos	_	NN	NN	_	10	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	c-jun	_	NN	NN	_	6	COORD	_	_
9	protein	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	5	PMOD	_	_
11	.	_	.	.	_	2	P	_	_

1	Stronger	_	JJR	JJR	_	4	NMOD	_	_
2	c-myc	_	NN	NN	_	4	NMOD	_	_
3	mRNA	_	NN	NN	_	4	NMOD	_	_
4	expression	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	detected	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	labial	_	JJ	JJ	_	10	NMOD	_	_
9	salivary	_	JJ	JJ	_	10	NMOD	_	_
10	glands	_	NNS	NNS	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	patients	_	NNS	NNS	_	11	PMOD	_	_
13	with	_	IN	IN	_	12	NMOD	_	_
14	longer	_	JJR	JJR	_	16	NMOD	_	_
15	disease	_	NN	NN	_	16	NMOD	_	_
16	duration	_	NN	NN	_	13	PMOD	_	_
17	(	_	(	(	_	20	P	_	_
18	p	_	NN	NN	_	20	SBJ	_	_
19	less	_	JJR	JJR	_	20	DEP	_	_
20	than	_	IN	IN	_	16	PRN	_	_
21	or	_	CC	CC	_	20	CC	_	_
22	equal	_	JJ	JJ	_	20	COORD	_	_
23	to	_	TO	TO	_	20	COORD	_	_
24	0.002	_	CD	CD	_	20	COORD	_	_
25	)	_	)	)	_	20	P	_	_
26	and	_	CC	CC	_	16	CC	_	_
27	more	_	RBR	RBR	_	28	AMOD	_	_
28	intense	_	JJ	JJ	_	31	NMOD	_	_
29	T	_	NN	NN	_	31	NMOD	_	_
30	lymphocyte	_	NN	NN	_	31	NMOD	_	_
31	infiltrates	_	NNS	NNS	_	16	COORD	_	_
32	(	_	(	(	_	36	P	_	_
33	p	_	NN	NN	_	36	SBJ	_	_
34	less	_	JJR	JJR	_	36	DEP	_	_
35	than	_	IN	IN	_	36	DEP	_	_
36	0.05	_	CD	CD	_	31	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	although	_	IN	IN	_	6	OBJ	_	_
39	these	_	DT	DT	_	40	NMOD	_	_
40	patients	_	NNS	NNS	_	41	SBJ	_	_
41	revealed	_	VBD	VBD	_	38	VMOD	_	_
42	no	_	DT	DT	_	43	NMOD	_	_
43	hypergammaglobulinemia	_	NN	NN	_	41	PRD	_	_
44	.	_	.	.	_	5	P	_	_

1	No	_	DT	DT	_	2	NMOD	_	_
2	correlation	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	observed	_	VBN	VBN	_	3	VC	_	_
5	between	_	IN	IN	_	4	ADV	_	_
6	c-myc	_	NN	NN	_	7	NMOD	_	_
7	mRNA	_	NN	NN	_	5	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	B	_	NN	NN	_	10	NMOD	_	_
10	lymphocyte	_	NN	NN	_	7	COORD	_	_
11	monoclonicity	_	NN	NN	_	10	NMOD	_	_
12	or	_	CC	CC	_	11	CC	_	_
13	lymphoma	_	NN	NN	_	11	COORD	_	_
14	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	conclusion	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	8	P	_	_
4	strong	_	JJ	JJ	_	7	NMOD	_	_
5	c-myc	_	NN	NN	_	7	NMOD	_	_
6	mRNA	_	NN	NN	_	7	NMOD	_	_
7	expression	_	NN	NN	_	8	SBJ	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	observed	_	VBN	VBN	_	8	VC	_	_
10	on	_	IN	IN	_	9	ADV	_	_
11	epithelial	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	labial	_	JJ	JJ	_	16	NMOD	_	_
15	salivary	_	JJ	JJ	_	16	NMOD	_	_
16	glands	_	NNS	NNS	_	13	PMOD	_	_
17	from	_	IN	IN	_	16	NMOD	_	_
18	patients	_	NNS	NNS	_	17	PMOD	_	_
19	with	_	IN	IN	_	18	NMOD	_	_
20	primary	_	JJ	JJ	_	21	NMOD	_	_
21	SS	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	8	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	may	_	MD	MD	_	0	ROOT-S	_	_
4	indicate	_	VB	VB	_	3	VC	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	presence	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	reactivated	_	VBN	VBN	_	10	NMOD	_	_
10	virus	_	NN	NN	_	7	PMOD	_	_
11	hosted	_	VBN	VBN	_	10	NMOD	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	these	_	DT	DT	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	Every	_	DT	DT	_	2	NMOD	_	_
2	enhancer	_	NN	NN	_	3	SBJ	_	_
3	works	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	with	_	IN	IN	_	3	ADV	_	_
5	every	_	DT	DT	_	6	NMOD	_	_
6	promoter	_	NN	NN	_	4	PMOD	_	_
7	for	_	IN	IN	_	3	ADV	_	_
8	all	_	PDT	PDT	_	10	NMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	combinations	_	NNS	NNS	_	7	PMOD	_	_
11	tested	_	VBN	VBN	_	10	NMOD	_	_
12	:	_	:	:	_	3	P	_	_
13	could	_	MD	MD	_	3	VMOD	_	_
14	new	_	JJ	JJ	_	16	NMOD	_	_
15	regulatory	_	JJ	JJ	_	16	NMOD	_	_
16	pathways	_	NNS	NNS	_	13	SBJ	_	_
17	evolve	_	VBP	VBP	_	13	VC	_	_
18	by	_	IN	IN	_	17	ADV	_	_
19	enhancer	_	NN	NN	_	20	NMOD	_	_
20	shuffling	_	NN	NN	_	18	PMOD	_	_
21	?	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	promoters	_	NNS	NNS	_	9	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	enhancers	_	NNS	NNS	_	2	COORD	_	_
5	of	_	IN	IN	_	2	NMOD	_	_
6	cell	_	NN	NN	_	8	NMOD	_	_
7	type-specific	_	JJ	JJ	_	6	AMOD	_	_
8	genes	_	NNS	NNS	_	5	PMOD	_	_
9	are	_	VBP	VBP	_	0	ROOT-S	_	_
10	often	_	RB	RB	_	9	ADV	_	_
11	conserved	_	VBN	VBN	_	9	VC	_	_
12	in	_	IN	IN	_	9	ADV	_	_
13	evolution	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	9	P	_	_
15	and	_	CC	CC	_	9	CC	_	_
16	hence	_	RB	RB	_	9	COORD	_	_
17	one	_	NN	NN	_	18	SBJ	_	_
18	might	_	MD	MD	_	9	COORD	_	_
19	expect	_	VB	VB	_	18	VC	_	_
20	that	_	IN	IN	_	19	OBJ	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	given	_	JJ	JJ	_	23	NMOD	_	_
23	enhancer	_	NN	NN	_	24	SBJ	_	_
24	has	_	VBZ	VBZ	_	20	VMOD	_	_
25	evolved	_	VBN	VBN	_	24	VC	_	_
26	to	_	TO	TO	_	27	VMOD	_	_
27	work	_	VB	VB	_	25	OBJ	_	_
28	best	_	RBS	RBS	_	27	ADV	_	_
29	with	_	IN	IN	_	27	ADV	_	_
30	its	_	PRP$	PRP$	_	32	NMOD	_	_
31	own	_	JJ	JJ	_	32	NMOD	_	_
32	promoter	_	NN	NN	_	29	PMOD	_	_
33	.	_	.	.	_	9	P	_	_

1	While	_	IN	IN	_	12	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	expectation	_	NN	NN	_	4	SBJ	_	_
4	may	_	MD	MD	_	1	VMOD	_	_
5	be	_	VB	VB	_	4	VC	_	_
6	realized	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	some	_	DT	DT	_	9	NMOD	_	_
9	cases	_	NNS	NNS	_	7	PMOD	_	_
10	,	_	,	,	_	12	P	_	_
11	we	_	PRP	PRP	_	12	SBJ	_	_
12	have	_	VBP	VBP	_	0	ROOT-S	_	_
13	not	_	RB	RB	_	12	VMOD	_	_
14	found	_	VBN	VBN	_	12	VC	_	_
15	evidence	_	NN	NN	_	14	OBJ	_	_
16	for	_	IN	IN	_	15	NMOD	_	_
17	it	_	PRP	PRP	_	16	PMOD	_	_
18	.	_	.	.	_	12	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	total	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	27	_	CD	CD	_	5	NMOD	_	_
5	combinations	_	NNS	NNS	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	different	_	JJ	JJ	_	8	NMOD	_	_
8	promoters	_	NNS	NNS	_	6	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	enhancers	_	NNS	NNS	_	8	COORD	_	_
11	were	_	VBD	VBD	_	0	ROOT-S	_	_
12	tested	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	transfection	_	NN	NN	_	13	PMOD	_	_
15	into	_	IN	IN	_	14	NMOD	_	_
16	cultured	_	VBN	VBN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	15	PMOD	_	_
18	.	_	.	.	_	11	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	found	_	VBD	VBD	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	relative	_	JJ	JJ	_	6	NMOD	_	_
6	efficiency	_	NN	NN	_	10	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	enhancers	_	NNS	NNS	_	7	PMOD	_	_
10	is	_	VBZ	VBZ	_	3	VMOD	_	_
11	approximately	_	RB	RB	_	13	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	same	_	JJ	JJ	_	10	PRD	_	_
14	,	_	,	,	_	10	P	_	_
15	irrespective	_	JJ	JJ	_	10	VMOD	_	_
16	of	_	IN	IN	_	15	AMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	type	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	promoter	_	NN	NN	_	19	PMOD	_	_
21	used	_	VBN	VBN	_	20	NMOD	_	_
22	,	_	,	,	_	10	P	_	_
23	i.e.	_	FW	FW	_	10	VMOD	_	_
24	,	_	,	,	_	10	P	_	_
25	there	_	EX	EX	_	26	SBJ	_	_
26	was	_	VBD	VBD	_	10	VC	_	_
27	no	_	DT	DT	_	29	NMOD	_	_
28	strong	_	JJ	JJ	_	29	NMOD	_	_
29	preference	_	NN	NN	_	26	PRD	_	_
30	for	_	IN	IN	_	29	NMOD	_	_
31	any	_	DT	DT	_	34	NMOD	_	_
32	given	_	JJ	JJ	_	34	NMOD	_	_
33	enhancer\/promoter	_	JJ	JJ	_	34	NMOD	_	_
34	combination	_	NN	NN	_	30	PMOD	_	_
35	.	_	.	.	_	2	P	_	_

1	Notably	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	do	_	VBP	VBP	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	see	_	VB	VB	_	4	VC	_	_
7	particularly	_	RB	RB	_	8	AMOD	_	_
8	strong	_	JJ	JJ	_	9	NMOD	_	_
9	transcription	_	NN	NN	_	6	OBJ	_	_
10	when	_	WRB	WRB	_	26	ADV	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	immunoglobulin	_	NN	NN	_	14	NMOD	_	_
13	kappa	_	NN	NN	_	14	NMOD	_	_
14	enhancer	_	NN	NN	_	23	SBJ	_	_
15	(	_	(	(	_	14	P	_	_
16	or	_	CC	CC	_	14	CC	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	immunoglobulin	_	NN	NN	_	21	NMOD	_	_
19	heavy	_	JJ	JJ	_	21	NMOD	_	_
20	chain	_	NN	NN	_	21	NMOD	_	_
21	enhancer	_	NN	NN	_	14	COORD	_	_
22	)	_	)	)	_	14	P	_	_
23	is	_	VBZ	VBZ	_	6	TMP	_	_
24	used	_	VBN	VBN	_	23	VC	_	_
25	to	_	TO	TO	_	26	VMOD	_	_
26	activate	_	VB	VB	_	24	OBJ	_	_
27	a	_	DT	DT	_	30	NMOD	_	_
28	kappa	_	NN	NN	_	30	NMOD	_	_
29	gene	_	NN	NN	_	30	NMOD	_	_
30	promoter	_	NN	NN	_	26	OBJ	_	_
31	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	propose	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	a	_	DT	DT	_	8	NMOD	_	_
5	generally	_	RB	RB	_	6	AMOD	_	_
6	permissive	_	JJ	JJ	_	8	NMOD	_	_
7	enhancer\/promoter	_	JJ	JJ	_	8	NMOD	_	_
8	interaction	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	3	VMOD	_	_
10	of	_	IN	IN	_	9	PRD	_	_
11	evolutionary	_	JJ	JJ	_	12	NMOD	_	_
12	benefit	_	NN	NN	_	10	PMOD	_	_
13	for	_	IN	IN	_	12	NMOD	_	_
14	higher	_	JJR	JJR	_	15	NMOD	_	_
15	eukaryotes	_	NNS	NNS	_	13	PMOD	_	_
16	:	_	:	:	_	9	P	_	_
17	by	_	IN	IN	_	22	ADV	_	_
18	enhancer	_	NN	NN	_	19	NMOD	_	_
19	shuffling	_	NN	NN	_	17	PMOD	_	_
20	,	_	,	,	_	22	P	_	_
21	genes	_	NNS	NNS	_	22	SBJ	_	_
22	could	_	MD	MD	_	9	COORD	_	_
23	be	_	VB	VB	_	22	VC	_	_
24	easily	_	RB	RB	_	23	ADV	_	_
25	brought	_	VBN	VBN	_	23	VC	_	_
26	under	_	IN	IN	_	25	ADV	_	_
27	a	_	DT	DT	_	29	NMOD	_	_
28	new	_	JJ	JJ	_	29	NMOD	_	_
29	type	_	NN	NN	_	26	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	inducibility\/cell	_	NN	NN	_	33	NMOD	_	_
32	type	_	NN	NN	_	33	NMOD	_	_
33	specificity	_	NN	NN	_	30	PMOD	_	_
34	.	_	.	.	_	2	P	_	_

1	Oct2	_	NN	NN	_	2	NMOD	_	_
2	transactivation	_	NN	NN	_	8	SBJ	_	_
3	from	_	IN	IN	_	2	NMOD	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	remote	_	JJ	JJ	_	7	NMOD	_	_
6	enhancer	_	NN	NN	_	7	NMOD	_	_
7	position	_	NN	NN	_	3	PMOD	_	_
8	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	B-cell-restricted	_	JJ	JJ	_	11	NMOD	_	_
11	activity	_	NN	NN	_	8	OBJ	_	_
12	.	_	.	.	_	8	P	_	_

1	Previous	_	JJ	JJ	_	3	NMOD	_	_
2	cotransfection	_	NN	NN	_	3	NMOD	_	_
3	experiments	_	NNS	NNS	_	4	SBJ	_	_
4	had	_	VBD	VBD	_	0	ROOT-S	_	_
5	demonstrated	_	VBN	VBN	_	4	VC	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	ectopic	_	JJ	JJ	_	8	NMOD	_	_
8	expression	_	NN	NN	_	15	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	lymphocyte-specific	_	JJ	JJ	_	14	NMOD	_	_
12	transcription	_	NN	NN	_	14	NMOD	_	_
13	factor	_	NN	NN	_	14	NMOD	_	_
14	Oct2	_	NN	NN	_	9	PMOD	_	_
15	could	_	MD	MD	_	6	VMOD	_	_
16	efficiently	_	RB	RB	_	15	ADV	_	_
17	activate	_	VB	VB	_	15	VC	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	promoter	_	NN	NN	_	17	OBJ	_	_
20	containing	_	VBG	VBG	_	19	NMOD	_	_
21	an	_	DT	DT	_	23	NMOD	_	_
22	octamer	_	NN	NN	_	23	NMOD	_	_
23	motif	_	NN	NN	_	20	OBJ	_	_
24	.	_	.	.	_	4	P	_	_

1	Oct2	_	NN	NN	_	2	NMOD	_	_
2	expression	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	unable	_	JJ	JJ	_	3	PRD	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	stimulate	_	VB	VB	_	4	AMOD	_	_
7	a	_	DT	DT	_	11	NMOD	_	_
8	multimerized	_	JJ	JJ	_	11	NMOD	_	_
9	octamer	_	NN	NN	_	11	NMOD	_	_
10	enhancer	_	NN	NN	_	11	NMOD	_	_
11	element	_	NN	NN	_	6	OBJ	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	HeLa	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	,	_	,	,	_	3	P	_	_
16	however	_	RB	RB	_	3	ADV	_	_
17	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	tested	_	VBN	VBN	_	2	VC	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	variety	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	Oct2	_	NN	NN	_	6	PMOD	_	_
8	isoforms	_	VBZ	VBZ	_	7	NMOD	_	_
9	generated	_	VBN	VBN	_	7	NMOD	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	alternative	_	JJ	JJ	_	12	NMOD	_	_
12	splicing	_	NN	NN	_	10	PMOD	_	_
13	for	_	IN	IN	_	3	ADV	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	capability	_	NN	NN	_	13	PMOD	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	activate	_	VB	VB	_	15	NMOD	_	_
18	an	_	DT	DT	_	20	NMOD	_	_
19	octamer	_	NN	NN	_	20	NMOD	_	_
20	enhancer	_	NN	NN	_	17	OBJ	_	_
21	in	_	IN	IN	_	17	ADV	_	_
22	nonlymphoid	_	JJ	JJ	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	21	PMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	B-cell	_	NN	NN	_	27	NMOD	_	_
27	line	_	NN	NN	_	23	COORD	_	_
28	.	_	.	.	_	2	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	analyses	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	several	_	JJ	JJ	_	7	NMOD	_	_
6	Oct2	_	NN	NN	_	7	NMOD	_	_
7	isoforms	_	NNS	NNS	_	8	SBJ	_	_
8	can	_	MD	MD	_	4	VMOD	_	_
9	stimulate	_	VB	VB	_	8	VC	_	_
10	from	_	IN	IN	_	9	ADV	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	remote	_	JJ	JJ	_	13	NMOD	_	_
13	position	_	NN	NN	_	10	PMOD	_	_
14	but	_	CC	CC	_	4	CC	_	_
15	that	_	IN	IN	_	4	COORD	_	_
16	this	_	DT	DT	_	17	NMOD	_	_
17	stimulation	_	NN	NN	_	18	SBJ	_	_
18	is	_	VBZ	VBZ	_	15	VMOD	_	_
19	restricted	_	JJ	JJ	_	18	VC	_	_
20	to	_	TO	TO	_	19	ADV	_	_
21	B	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	result	_	NN	NN	_	3	SBJ	_	_
3	indicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	involvement	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	either	_	CC	CC	_	10	CC	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	B-cell-specific	_	JJ	JJ	_	10	NMOD	_	_
10	cofactor	_	NN	NN	_	6	PMOD	_	_
11	or	_	CC	CC	_	10	CC	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	specific	_	JJ	JJ	_	14	NMOD	_	_
14	modification	_	NN	NN	_	10	COORD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	a	_	DT	DT	_	17	NMOD	_	_
17	cofactor	_	NN	NN	_	15	PMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	Oct2	_	NN	NN	_	21	NMOD	_	_
21	protein	_	NN	NN	_	17	COORD	_	_
22	in	_	IN	IN	_	5	NMOD	_	_
23	Oct2-mediated	_	JJ	JJ	_	25	NMOD	_	_
24	enhancer	_	NN	NN	_	25	NMOD	_	_
25	activation	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	Mutational	_	JJ	JJ	_	2	NMOD	_	_
2	analyses	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	carboxy-terminal	_	JJ	JJ	_	7	NMOD	_	_
7	domain	_	NN	NN	_	10	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	Oct2	_	NN	NN	_	8	PMOD	_	_
10	is	_	VBZ	VBZ	_	4	VMOD	_	_
11	critical	_	JJ	JJ	_	10	PRD	_	_
12	for	_	IN	IN	_	11	AMOD	_	_
13	enhancer	_	NN	NN	_	14	NMOD	_	_
14	activation	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	Moreover	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	domain	_	NN	NN	_	5	SBJ	_	_
5	conferred	_	VBD	VBD	_	0	ROOT-S	_	_
6	enhancing	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	5	OBJ	_	_
8	when	_	WRB	WRB	_	9	ADV	_	_
9	fused	_	VBN	VBN	_	5	TMP	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	Oct1	_	NN	NN	_	13	NMOD	_	_
13	protein	_	NN	NN	_	10	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	which	_	WDT	WDT	_	18	SBJ	_	_
16	by	_	IN	IN	_	18	ADV	_	_
17	itself	_	PRP	PRP	_	16	PMOD	_	_
18	was	_	VBD	VBD	_	13	NMOD	_	_
19	unable	_	JJ	JJ	_	18	PRD	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	stimulate	_	VB	VB	_	19	AMOD	_	_
22	from	_	IN	IN	_	21	ADV	_	_
23	a	_	DT	DT	_	25	NMOD	_	_
24	remote	_	JJ	JJ	_	25	NMOD	_	_
25	position	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	glutamine-rich	_	JJ	JJ	_	4	NMOD	_	_
3	activation	_	NN	NN	_	4	NMOD	_	_
4	domain	_	NN	NN	_	16	SBJ	_	_
5	present	_	JJ	JJ	_	4	NMOD	_	_
6	in	_	IN	IN	_	5	AMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	amino-terminal	_	JJ	JJ	_	9	NMOD	_	_
9	portion	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	Oct2	_	NN	NN	_	10	PMOD	_	_
12	and	_	CC	CC	_	4	CC	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	POU	_	NN	NN	_	15	NMOD	_	_
15	domain	_	NN	NN	_	4	COORD	_	_
16	contribute	_	VBP	VBP	_	0	ROOT-S	_	_
17	only	_	RB	RB	_	16	ADV	_	_
18	marginally	_	RB	RB	_	17	AMOD	_	_
19	to	_	TO	TO	_	16	ADV	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	transactivation	_	NN	NN	_	22	NMOD	_	_
22	function	_	NN	NN	_	19	PMOD	_	_
23	from	_	IN	IN	_	16	ADV	_	_
24	a	_	DT	DT	_	26	NMOD	_	_
25	distal	_	JJ	JJ	_	26	NMOD	_	_
26	position	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	16	P	_	_

1	{	_	(	(	_	2	P	_	_
2	Changes	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	plasma	_	NN	NN	_	5	NMOD	_	_
5	interleukin-1	_	NN	NN	_	3	PMOD	_	_
6	and	_	CC	CC	_	2	CC	_	_
7	their	_	PRP$	PRP$	_	9	NMOD	_	_
8	possible	_	JJ	JJ	_	9	NMOD	_	_
9	relationship	_	NN	NN	_	2	COORD	_	_
10	with	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	changes	_	NNS	NNS	_	10	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	glucocorticoid	_	NN	NN	_	15	NMOD	_	_
15	receptor	_	NN	NN	_	13	PMOD	_	_
16	in	_	IN	IN	_	2	NMOD	_	_
17	aged	_	JJ	JJ	_	19	NMOD	_	_
18	long-distance	_	JJ	JJ	_	19	NMOD	_	_
19	runner	_	NN	NN	_	16	PMOD	_	_
20	}	_	)	)	_	2	P	_	_

1	For	_	IN	IN	_	39	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	changes	_	NNS	NNS	_	4	PMOD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	plasma	_	NN	NN	_	7	PMOD	_	_
9	interleukin-1	_	NN	NN	_	8	NMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	IL-1	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	and	_	CC	CC	_	6	CC	_	_
14	their	_	PRP$	PRP$	_	16	NMOD	_	_
15	possible	_	JJ	JJ	_	16	NMOD	_	_
16	relationship	_	NN	NN	_	6	COORD	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	changes	_	NNS	NNS	_	17	PMOD	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	glucocorticoid	_	NN	NN	_	22	NMOD	_	_
22	receptor	_	NN	NN	_	20	PMOD	_	_
23	(	_	(	(	_	24	P	_	_
24	GR	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	,	_	,	,	_	39	P	_	_
27	plasma	_	NN	NN	_	28	NMOD	_	_
28	IL-1	_	NN	NN	_	39	SBJ	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	GR	_	NN	NN	_	28	COORD	_	_
31	in	_	IN	IN	_	28	NMOD	_	_
32	peripheral	_	JJ	JJ	_	34	NMOD	_	_
33	blood	_	NN	NN	_	34	NMOD	_	_
34	leukocytes	_	NNS	NNS	_	31	PMOD	_	_
35	in	_	IN	IN	_	34	NMOD	_	_
36	aged	_	JJ	JJ	_	38	NMOD	_	_
37	long-distance	_	JJ	JJ	_	38	NMOD	_	_
38	runner	_	NN	NN	_	35	PMOD	_	_
39	were	_	VBD	VBD	_	0	ROOT-S	_	_
40	measured	_	VBN	VBN	_	39	VC	_	_
41	simultaneously	_	RB	RB	_	40	ADV	_	_
42	.	_	.	.	_	39	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	activity	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	IL-1	_	NN	NN	_	3	PMOD	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	expressed	_	VBN	VBN	_	5	VC	_	_
7	as	_	IN	IN	_	6	ADV	_	_
8	its	_	PRP$	PRP$	_	9	NMOD	_	_
9	ability	_	NN	NN	_	7	PMOD	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	stimulate	_	VB	VB	_	9	NMOD	_	_
12	3H-TdR	_	NN	NN	_	13	NMOD	_	_
13	incorporation	_	NN	NN	_	11	OBJ	_	_
14	in	_	IN	IN	_	11	ADV	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	thymocytes	_	NNS	NNS	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	C57	_	NN	NN	_	19	NMOD	_	_
19	mice	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	GR	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	determined	_	VBN	VBN	_	2	VC	_	_
4	by	_	IN	IN	_	3	ADV	_	_
5	whole	_	JJ	JJ	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	assay	_	NN	NN	_	4	PMOD	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	3H-Dex	_	NN	NN	_	8	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	showed	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	activity	_	NN	NN	_	14	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	plasma	_	NN	NN	_	9	NMOD	_	_
9	IL-1	_	NN	NN	_	7	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	aged	_	JJ	JJ	_	13	NMOD	_	_
12	long-distance	_	JJ	JJ	_	13	NMOD	_	_
13	runner	_	NN	NN	_	10	PMOD	_	_
14	was	_	VBD	VBD	_	4	VMOD	_	_
15	209	_	CD	CD	_	16	NMOD	_	_
16	%	_	NN	NN	_	14	PRD	_	_
17	,	_	,	,	_	16	P	_	_
18	223	_	CD	CD	_	19	NMOD	_	_
19	%	_	NN	NN	_	16	COORD	_	_
20	and	_	CC	CC	_	16	CC	_	_
21	145	_	CD	CD	_	22	NMOD	_	_
22	%	_	NN	NN	_	16	COORD	_	_
23	of	_	IN	IN	_	16	NMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	control	_	NN	NN	_	23	PMOD	_	_
26	at	_	IN	IN	_	14	ADV	_	_
27	14.7-18.7	_	CD	CD	_	33	NMOD	_	_
28	,	_	,	,	_	27	P	_	_
29	3.8-7.0	_	CD	CD	_	27	COORD	_	_
30	and	_	CC	CC	_	27	CC	_	_
31	1.5-2.6	_	CD	CD	_	27	COORD	_	_
32	KD	_	NN	NN	_	27	AMOD	_	_
33	fractions	_	NNS	NNS	_	26	PMOD	_	_
34	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	GR	_	NN	NN	_	10	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	peripheral	_	JJ	JJ	_	6	NMOD	_	_
5	blood	_	NN	NN	_	6	NMOD	_	_
6	leukocytes	_	NNS	NNS	_	3	PMOD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	aged	_	JJ	JJ	_	9	NMOD	_	_
9	runner	_	NN	NN	_	7	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	65	_	CD	CD	_	12	NMOD	_	_
12	%	_	NN	NN	_	10	PRD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	control	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	10	P	_	_

1	Possible	_	JJ	JJ	_	2	NMOD	_	_
2	relationship	_	NN	NN	_	18	SBJ	_	_
3	between	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	changes	_	NNS	NNS	_	3	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	IL-1	_	NN	NN	_	6	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	GR	_	NN	NN	_	7	COORD	_	_
10	in	_	IN	IN	_	7	NMOD	_	_
11	aged	_	JJ	JJ	_	13	NMOD	_	_
12	long-distance	_	JJ	JJ	_	13	NMOD	_	_
13	runner	_	NN	NN	_	10	PMOD	_	_
14	and	_	CC	CC	_	2	CC	_	_
15	its	_	PRP$	PRP$	_	17	NMOD	_	_
16	physiological	_	JJ	JJ	_	17	NMOD	_	_
17	significance	_	NN	NN	_	2	COORD	_	_
18	are	_	VBP	VBP	_	0	ROOT-S	_	_
19	discussed	_	VBN	VBN	_	18	VC	_	_
20	.	_	.	.	_	18	P	_	_

1	Transcription	_	NN	NN	_	3	NMOD	_	_
2	factor	_	NN	NN	_	3	NMOD	_	_
3	AP-2	_	NN	NN	_	4	SBJ	_	_
4	activates	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	gene	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	HTLV-I	_	NN	NN	_	7	PMOD	_	_
9	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	HTLV-I	_	NN	NN	_	3	NMOD	_	_
3	LTR	_	NN	NN	_	4	SBJ	_	_
4	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	three	_	CD	CD	_	8	NMOD	_	_
6	conserved	_	VBN	VBN	_	8	NMOD	_	_
7	regulatory	_	JJ	JJ	_	8	NMOD	_	_
8	elements	_	NNS	NNS	_	4	OBJ	_	_
9	known	_	VBN	VBN	_	8	NMOD	_	_
10	as	_	IN	IN	_	9	ADV	_	_
11	21	_	CD	CD	_	13	AMOD	_	_
12	base	_	NN	NN	_	13	AMOD	_	_
13	pair	_	NN	NN	_	14	NMOD	_	_
14	repeats	_	NNS	NNS	_	10	PMOD	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	are	_	VBP	VBP	_	14	NMOD	_	_
17	required	_	VBN	VBN	_	16	VC	_	_
18	for	_	IN	IN	_	17	ADV	_	_
19	stimulation	_	NN	NN	_	18	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	expression	_	NN	NN	_	20	PMOD	_	_
23	by	_	IN	IN	_	19	NMOD	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	transactivator	_	NN	NN	_	27	NMOD	_	_
26	protein	_	NN	NN	_	27	NMOD	_	_
27	tax	_	NN	NN	_	23	PMOD	_	_
28	.	_	.	.	_	4	P	_	_

1	Mutagenesis	_	NN	NN	_	2	SBJ	_	_
2	indicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	21	_	CD	CD	_	6	AMOD	_	_
6	bp	_	NN	NN	_	7	NMOD	_	_
7	repeats	_	NNS	NNS	_	8	SBJ	_	_
8	can	_	MD	MD	_	3	VMOD	_	_
9	be	_	VB	VB	_	8	VC	_	_
10	subdivided	_	VBN	VBN	_	9	VC	_	_
11	into	_	IN	IN	_	10	ADV	_	_
12	three	_	CD	CD	_	13	NMOD	_	_
13	motifs	_	NNS	NNS	_	11	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	A	_	NN	NN	_	13	NMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	B	_	NN	NN	_	15	COORD	_	_
18	and	_	CC	CC	_	15	CC	_	_
19	C	_	NN	NN	_	15	COORD	_	_
20	,	_	,	,	_	13	P	_	_
21	each	_	DT	DT	_	22	NMOD	_	_
22	of	_	IN	IN	_	24	SBJ	_	_
23	which	_	WDT	WDT	_	22	PMOD	_	_
24	influences	_	VBZ	VBZ	_	13	NMOD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	level	_	NN	NN	_	24	OBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	tax	_	NN	NN	_	29	NMOD	_	_
29	activation	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	A	_	NN	NN	_	3	NMOD	_	_
3	site	_	NN	NN	_	9	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	21	_	CD	CD	_	7	AMOD	_	_
7	bp	_	NN	NN	_	8	NMOD	_	_
8	repeat	_	NN	NN	_	4	PMOD	_	_
9	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	strong	_	JJ	JJ	_	11	NMOD	_	_
11	homology	_	NN	NN	_	9	OBJ	_	_
12	with	_	IN	IN	_	11	NMOD	_	_
13	previously	_	RB	RB	_	14	AMOD	_	_
14	described	_	VBN	VBN	_	16	NMOD	_	_
15	binding	_	VBG	VBG	_	16	NMOD	_	_
16	sites	_	NNS	NNS	_	12	PMOD	_	_
17	for	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	transcription	_	NN	NN	_	21	NMOD	_	_
20	factor	_	NN	NN	_	21	NMOD	_	_
21	AP-2	_	NN	NN	_	17	PMOD	_	_
22	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	AP-2	_	NN	NN	_	5	NMOD	_	_
5	mRNA	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	3	VMOD	_	_
7	present	_	JJ	JJ	_	6	PRD	_	_
8	in	_	IN	IN	_	7	AMOD	_	_
9	T-lymphocytes	_	NNS	NNS	_	8	PMOD	_	_
10	and	_	CC	CC	_	3	CC	_	_
11	that	_	IN	IN	_	3	COORD	_	_
12	cellular	_	JJ	JJ	_	13	NMOD	_	_
13	factors	_	NNS	NNS	_	21	SBJ	_	_
14	from	_	IN	IN	_	13	NMOD	_	_
15	both	_	CC	CC	_	16	CC	_	_
16	non-transformed	_	JJ	JJ	_	19	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	transformed	_	VBN	VBN	_	16	COORD	_	_
19	T-lymphocytes	_	NNS	NNS	_	14	PMOD	_	_
20	specifically	_	RB	RB	_	21	ADV	_	_
21	bound	_	VBD	VBD	_	11	VMOD	_	_
22	to	_	TO	TO	_	21	ADV	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	consensus	_	NN	NN	_	25	NMOD	_	_
25	motif	_	NN	NN	_	22	PMOD	_	_
26	for	_	IN	IN	_	25	NMOD	_	_
27	AP-2	_	NN	NN	_	26	PMOD	_	_
28	in	_	IN	IN	_	25	NMOD	_	_
29	each	_	DT	DT	_	31	NMOD	_	_
30	21	_	CD	CD	_	31	NMOD	_	_
31	bp	_	NN	NN	_	28	PMOD	_	_
32	.	_	.	.	_	2	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	determine	_	VB	VB	_	18	ADV	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	role	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	AP-2	_	NN	NN	_	5	PMOD	_	_
7	in	_	IN	IN	_	4	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	regulation	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	15	NMOD	_	_
12	HTLV-I	_	NN	NN	_	15	NMOD	_	_
13	LTR	_	NN	NN	_	15	NMOD	_	_
14	gene	_	NN	NN	_	15	NMOD	_	_
15	expression	_	NN	NN	_	10	PMOD	_	_
16	,	_	,	,	_	18	P	_	_
17	we	_	PRP	PRP	_	18	SBJ	_	_
18	used	_	VBD	VBD	_	0	ROOT-S	_	_
19	an	_	DT	DT	_	21	NMOD	_	_
20	AP-2	_	NN	NN	_	21	NMOD	_	_
21	cDNA	_	NN	NN	_	18	OBJ	_	_
22	in	_	IN	IN	_	18	ADV	_	_
23	DNA	_	NN	NN	_	24	NMOD	_	_
24	binding	_	NN	NN	_	28	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	transient	_	JJ	JJ	_	27	NMOD	_	_
27	expression	_	NN	NN	_	24	COORD	_	_
28	assays	_	NNS	NNS	_	22	PMOD	_	_
29	.	_	.	.	_	18	P	_	_

1	Gel	_	NN	NN	_	2	NMOD	_	_
2	retardation	_	NN	NN	_	6	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	methylation	_	NN	NN	_	5	NMOD	_	_
5	interference	_	NN	NN	_	2	COORD	_	_
6	studies	_	NNS	NNS	_	7	SBJ	_	_
7	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	bacterially	_	RB	RB	_	10	AMOD	_	_
10	produced	_	VBN	VBN	_	11	NMOD	_	_
11	AP-2	_	NN	NN	_	12	SBJ	_	_
12	bound	_	VBD	VBD	_	8	VMOD	_	_
13	specifically	_	RB	RB	_	12	VMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	with	_	IN	IN	_	13	COORD	_	_
16	high	_	JJ	JJ	_	17	NMOD	_	_
17	affinity	_	NN	NN	_	15	PMOD	_	_
18	to	_	TO	TO	_	12	ADV	_	_
19	all	_	DT	DT	_	23	NMOD	_	_
20	three	_	CD	CD	_	19	DEP	_	_
21	21	_	CD	CD	_	22	AMOD	_	_
22	bp	_	NN	NN	_	23	NMOD	_	_
23	repeats	_	NNS	NNS	_	18	PMOD	_	_
24	,	_	,	,	_	8	P	_	_
25	and	_	CC	CC	_	8	CC	_	_
26	that	_	IN	IN	_	8	COORD	_	_
27	it	_	PRP	PRP	_	28	SBJ	_	_
28	required	_	VBD	VBD	_	26	VMOD	_	_
29	the	_	DT	DT	_	32	NMOD	_	_
30	core	_	NN	NN	_	32	NMOD	_	_
31	sequence	_	NN	NN	_	32	NMOD	_	_
32	AGGC	_	NN	NN	_	28	OBJ	_	_
33	for	_	IN	IN	_	28	ADV	_	_
34	specific	_	JJ	JJ	_	35	NMOD	_	_
35	binding	_	NN	NN	_	33	PMOD	_	_
36	.	_	.	.	_	7	P	_	_

1	Binding	_	NN	NN	_	4	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	AP-2	_	NN	NN	_	2	PMOD	_	_
4	prevented	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	subsequent	_	JJ	JJ	_	7	NMOD	_	_
7	binding	_	NN	NN	_	4	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	members	_	NNS	NNS	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	CREB\/ATF	_	NN	NN	_	13	NMOD	_	_
13	family	_	NN	NN	_	10	PMOD	_	_
14	to	_	TO	TO	_	7	NMOD	_	_
15	an	_	DT	DT	_	18	NMOD	_	_
16	adjacent	_	JJ	JJ	_	18	NMOD	_	_
17	regulatory	_	JJ	JJ	_	18	NMOD	_	_
18	motif	_	NN	NN	_	14	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	21	_	CD	CD	_	22	AMOD	_	_
22	bp	_	NN	NN	_	23	NMOD	_	_
23	repeat	_	NN	NN	_	19	PMOD	_	_
24	.	_	.	.	_	4	P	_	_

1	Transfection	_	NN	NN	_	9	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	an	_	DT	DT	_	6	NMOD	_	_
4	AP-2	_	NN	NN	_	6	NMOD	_	_
5	expression	_	NN	NN	_	6	NMOD	_	_
6	construct	_	NN	NN	_	2	PMOD	_	_
7	into	_	IN	IN	_	1	NMOD	_	_
8	T-lymphocytes	_	NNS	NNS	_	7	PMOD	_	_
9	activated	_	VBD	VBD	_	0	ROOT-S	_	_
10	gene	_	NN	NN	_	11	NMOD	_	_
11	expression	_	NN	NN	_	9	OBJ	_	_
12	from	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	HTLV-I	_	NN	NN	_	15	NMOD	_	_
15	LTR	_	NN	NN	_	12	PMOD	_	_
16	.	_	.	.	_	9	P	_	_

1	At	_	IN	IN	_	3	DEP	_	_
2	least	_	JJS	JJS	_	3	DEP	_	_
3	two	_	CD	CD	_	6	NMOD	_	_
4	21	_	CD	CD	_	5	AMOD	_	_
5	bp	_	NN	NN	_	6	NMOD	_	_
6	repeats	_	NNS	NNS	_	7	SBJ	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	required	_	VBN	VBN	_	7	VC	_	_
9	for	_	IN	IN	_	8	ADV	_	_
10	high	_	JJ	JJ	_	11	NMOD	_	_
11	levels	_	NNS	NNS	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	AP-2	_	NN	NN	_	14	NMOD	_	_
14	activation	_	NN	NN	_	12	PMOD	_	_
15	and	_	CC	CC	_	7	CC	_	_
16	mutagenesis	_	NN	NN	_	28	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	22	NMOD	_	_
19	AP-2	_	NN	NN	_	22	NMOD	_	_
20	consensus	_	NN	NN	_	22	NMOD	_	_
21	binding	_	NN	NN	_	22	NMOD	_	_
22	sequences	_	NNS	NNS	_	17	PMOD	_	_
23	in	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	21	_	CD	CD	_	26	AMOD	_	_
26	bp	_	NN	NN	_	27	NMOD	_	_
27	repeats	_	NNS	NNS	_	23	PMOD	_	_
28	eliminate	_	VBP	VBP	_	7	COORD	_	_
29	this	_	DT	DT	_	30	NMOD	_	_
30	activation	_	NN	NN	_	28	OBJ	_	_
31	.	_	.	.	_	7	P	_	_

1	(	_	(	(	_	3	P	_	_
2	ABSTRACT	_	NN	NN	_	3	SBJ	_	_
3	TRUNCATED	_	VBN	VBN	_	0	ROOT-S	_	_
4	AT	_	IN	IN	_	3	ADV	_	_
5	250	_	CD	CD	_	6	NMOD	_	_
6	WORDS	_	NNS	NNS	_	4	PMOD	_	_
7	)	_	)	)	_	3	P	_	_

1	{	_	(	(	_	3	P	_	_
2	Age-related	_	JJ	JJ	_	3	NMOD	_	_
3	changes	_	NNS	NNS	_	0	ROOT-FRAG	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	glucocorticoid	_	NN	NN	_	8	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	mineralocorticoid	_	NN	NN	_	5	COORD	_	_
8	receptors	_	NNS	NNS	_	4	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	healthy	_	JJ	JJ	_	13	NMOD	_	_
13	persons	_	NNS	NNS	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	patients	_	NNS	NNS	_	13	COORD	_	_
16	with	_	IN	IN	_	15	NMOD	_	_
17	hypertension	_	NN	NN	_	16	PMOD	_	_
18	}	_	)	)	_	3	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	been	_	VBN	VBN	_	2	VC	_	_
4	found	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	number	_	NN	NN	_	21	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	glucocorticoid	_	NN	NN	_	10	NMOD	_	_
10	receptors	_	NNS	NNS	_	8	PMOD	_	_
11	in	_	IN	IN	_	7	NMOD	_	_
12	lymphocytes	_	NNS	NNS	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	peripheral	_	JJ	JJ	_	16	NMOD	_	_
16	blood	_	NN	NN	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	healthy	_	JJ	JJ	_	20	NMOD	_	_
19	elderly	_	JJ	JJ	_	20	NMOD	_	_
20	subjects	_	NNS	NNS	_	17	PMOD	_	_
21	increases	_	VBZ	VBZ	_	5	VMOD	_	_
22	,	_	,	,	_	21	P	_	_
23	while	_	IN	IN	_	21	OBJ	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	number	_	NN	NN	_	29	SBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	mineralocorticoid	_	NN	NN	_	28	NMOD	_	_
28	receptors	_	NNS	NNS	_	26	PMOD	_	_
29	decreases	_	VBZ	VBZ	_	23	VMOD	_	_
30	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	mechanisms	_	NNS	NNS	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	hormone-receptor	_	NN	NN	_	5	NMOD	_	_
5	interactions	_	NNS	NNS	_	3	PMOD	_	_
6	in	_	IN	IN	_	2	NMOD	_	_
7	hypertension	_	NN	NN	_	6	PMOD	_	_
8	are	_	VBP	VBP	_	0	ROOT-S	_	_
9	activated	_	VBN	VBN	_	8	VC	_	_
10	:	_	:	:	_	8	P	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	number	_	NN	NN	_	19	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	glucocorticoid	_	NN	NN	_	18	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	mineralocorticoid	_	NN	NN	_	14	COORD	_	_
17	binding	_	NN	NN	_	18	NMOD	_	_
18	sites	_	NNS	NNS	_	13	PMOD	_	_
19	grows	_	VBZ	VBZ	_	8	VC	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	hypertensive	_	JJ	JJ	_	22	NMOD	_	_
22	patients	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	19	P	_	_

1	Still	_	RB	RB	_	11	ADV	_	_
2	a	_	DT	DT	_	5	NMOD	_	_
3	more	_	RBR	RBR	_	4	AMOD	_	_
4	essential	_	JJ	JJ	_	5	NMOD	_	_
5	rise	_	NN	NN	_	11	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	number	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	receptors	_	NNS	NNS	_	9	PMOD	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	observed	_	VBN	VBN	_	11	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	mid-age	_	JJ	JJ	_	16	NMOD	_	_
15	hypertensive	_	NN	NN	_	16	NMOD	_	_
16	patients	_	NNS	NNS	_	13	PMOD	_	_
17	than	_	IN	IN	_	5	NMOD	_	_
18	in	_	IN	IN	_	17	PMOD	_	_
19	elderly	_	JJ	JJ	_	20	NMOD	_	_
20	ones	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	11	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	vivo	_	FW	FW	_	4	NMOD	_	_
3	footprint	_	NN	NN	_	4	NMOD	_	_
4	analysis	_	NN	NN	_	0	ROOT-FRAG	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	HLA-DRA	_	NN	NN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	promoter	_	NN	NN	_	5	PMOD	_	_
10	:	_	:	:	_	4	P	_	_
11	cell-specific	_	JJ	JJ	_	12	NMOD	_	_
12	interaction	_	NN	NN	_	4	NMOD	_	_
13	at	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	octamer	_	NN	NN	_	16	NMOD	_	_
16	site	_	NN	NN	_	13	PMOD	_	_
17	and	_	CC	CC	_	12	CC	_	_
18	up-regulation	_	NN	NN	_	12	COORD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	X	_	NN	NN	_	22	NMOD	_	_
21	box	_	NN	NN	_	22	NMOD	_	_
22	binding	_	NN	NN	_	19	PMOD	_	_
23	by	_	IN	IN	_	18	NMOD	_	_
24	interferon	_	NN	NN	_	25	NMOD	_	_
25	gamma	_	NN	NN	_	23	PMOD	_	_
26	.	_	.	.	_	12	P	_	_

1	Analysis	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	11	NMOD	_	_
4	major	_	JJ	JJ	_	11	NMOD	_	_
5	histocompatibility	_	NN	NN	_	11	NMOD	_	_
6	complex	_	NN	NN	_	11	NMOD	_	_
7	class	_	NN	NN	_	11	NMOD	_	_
8	II	_	CD	CD	_	11	NMOD	_	_
9	gene	_	NN	NN	_	11	NMOD	_	_
10	promoter	_	NN	NN	_	11	NMOD	_	_
11	DRA	_	NN	NN	_	2	PMOD	_	_
12	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	previously	_	RB	RB	_	12	TMP	_	_
14	identified	_	VBN	VBN	_	12	VC	_	_
15	at	_	IN	IN	_	17	DEP	_	_
16	least	_	JJS	JJS	_	17	DEP	_	_
17	five	_	CD	CD	_	19	NMOD	_	_
18	cis-acting	_	JJ	JJ	_	19	NMOD	_	_
19	regions	_	NNS	NNS	_	14	OBJ	_	_
20	required	_	VBN	VBN	_	19	NMOD	_	_
21	for	_	IN	IN	_	20	ADV	_	_
22	maximal	_	JJ	JJ	_	23	NMOD	_	_
23	expression	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	12	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	examined	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	DRA	_	NN	NN	_	6	NMOD	_	_
6	promoter	_	NN	NN	_	3	OBJ	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	protein-DNA	_	JJ	JJ	_	9	NMOD	_	_
9	interactions	_	NNS	NNS	_	7	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	intact	_	JJ	JJ	_	13	NMOD	_	_
13	cell	_	NN	NN	_	10	PMOD	_	_
14	,	_	,	,	_	6	P	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	may	_	MD	MD	_	6	NMOD	_	_
17	mediate	_	VB	VB	_	16	VC	_	_
18	transcriptional	_	JJ	JJ	_	19	NMOD	_	_
19	activation	_	NN	NN	_	17	OBJ	_	_
20	.	_	.	.	_	2	P	_	_

1	Using	_	VBG	VBG	_	7	ADV	_	_
2	in	_	FW	FW	_	3	AMOD	_	_
3	vivo	_	FW	FW	_	5	NMOD	_	_
4	genomic	_	JJ	JJ	_	5	NMOD	_	_
5	footprinting	_	NN	NN	_	1	OBJ	_	_
6	we	_	PRP	PRP	_	7	SBJ	_	_
7	identified	_	VBD	VBD	_	0	ROOT-S	_	_
8	interactions	_	NNS	NNS	_	7	OBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	B-cell	_	NN	NN	_	11	NMOD	_	_
11	lines	_	NNS	NNS	_	9	PMOD	_	_
12	at	_	IN	IN	_	7	ADV	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	octamer	_	NN	NN	_	15	NMOD	_	_
15	site	_	NN	NN	_	12	PMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	the	_	DT	DT	_	24	NMOD	_	_
18	Y	_	NN	NN	_	24	NMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	X1	_	NN	NN	_	18	COORD	_	_
21	,	_	,	,	_	18	P	_	_
22	and	_	CC	CC	_	18	CC	_	_
23	X2	_	NN	NN	_	18	COORD	_	_
24	boxes	_	NNS	NNS	_	15	COORD	_	_
25	.	_	.	.	_	7	P	_	_

1	Class	_	NN	NN	_	6	NMOD	_	_
2	II	_	CD	CD	_	6	NMOD	_	_
3	antigen	_	NN	NN	_	6	NMOD	_	_
4	expressing	_	VBG	VBG	_	6	NMOD	_	_
5	T-cell	_	NN	NN	_	6	NMOD	_	_
6	lines	_	NNS	NNS	_	7	SBJ	_	_
7	maintained	_	VBD	VBD	_	0	ROOT-S	_	_
8	contacts	_	NNS	NNS	_	7	IOBJ	_	_
9	identical	_	JJ	JJ	_	8	NMOD	_	_
10	to	_	TO	TO	_	9	AMOD	_	_
11	B-cell	_	NN	NN	_	12	NMOD	_	_
12	lines	_	NNS	NNS	_	10	PMOD	_	_
13	,	_	,	,	_	7	P	_	_
14	while	_	IN	IN	_	7	OBJ	_	_
15	class	_	NN	NN	_	18	NMOD	_	_
16	II-negative	_	JJ	JJ	_	15	AMOD	_	_
17	T-cell	_	NN	NN	_	18	NMOD	_	_
18	lines	_	NNS	NNS	_	19	SBJ	_	_
19	exhibited	_	VBD	VBD	_	14	VMOD	_	_
20	no	_	DT	DT	_	21	NMOD	_	_
21	interactions	_	NNS	NNS	_	19	OBJ	_	_
22	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	lymphoid	_	JJ	JJ	_	4	NMOD	_	_
3	cell	_	NN	NN	_	4	NMOD	_	_
4	lines	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	9	P	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	octamer	_	NN	NN	_	8	NMOD	_	_
8	site	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	occupied	_	VBN	VBN	_	9	VC	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	required	_	VBN	VBN	_	10	COORD	_	_
13	for	_	IN	IN	_	12	ADV	_	_
14	maximal	_	JJ	JJ	_	15	NMOD	_	_
15	expression	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	9	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	most	_	RBS	RBS	_	4	AMOD	_	_
4	likely	_	RB	RB	_	6	PMOD	_	_
5	due	_	JJ	JJ	_	6	DEP	_	_
6	to	_	TO	TO	_	2	PRD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	presence	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	lymphoid-specific	_	JJ	JJ	_	13	NMOD	_	_
12	OTF-2	_	NN	NN	_	13	NMOD	_	_
13	factor	_	NN	NN	_	9	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	11	P	_	_
4	the	_	DT	DT	_	10	NMOD	_	_
5	class	_	NN	NN	_	10	NMOD	_	_
6	II-positive	_	JJ	JJ	_	5	AMOD	_	_
7	nonlymphoid	_	JJ	JJ	_	10	NMOD	_	_
8	glioblastoma	_	NN	NN	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	line	_	NN	NN	_	11	SBJ	_	_
11	does	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	not	_	RB	RB	_	11	VMOD	_	_
13	exhibit	_	VB	VB	_	11	VC	_	_
14	interactions	_	NNS	NNS	_	13	OBJ	_	_
15	at	_	IN	IN	_	13	ADV	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	octamer	_	NN	NN	_	18	NMOD	_	_
18	site	_	NN	NN	_	15	PMOD	_	_
19	despite	_	IN	IN	_	13	ADV	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	presence	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	26	NMOD	_	_
24	ubiquitous	_	JJ	JJ	_	26	NMOD	_	_
25	OTF-1	_	NN	NN	_	26	NMOD	_	_
26	factor	_	NN	NN	_	22	PMOD	_	_
27	and	_	CC	CC	_	13	CC	_	_
28	an	_	DT	DT	_	31	NMOD	_	_
29	open	_	JJ	JJ	_	31	NMOD	_	_
30	binding	_	VBG	VBG	_	31	NMOD	_	_
31	site	_	NN	NN	_	18	GAP	_	_
32	.	_	.	.	_	11	P	_	_

1	Thus	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	DRA	_	NN	NN	_	5	NMOD	_	_
5	promoter	_	NN	NN	_	6	SBJ	_	_
6	discriminates	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	against	_	IN	IN	_	6	ADV	_	_
8	OTF-1	_	NN	NN	_	9	NMOD	_	_
9	activation	_	NN	NN	_	7	PMOD	_	_
10	at	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	level	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	DNA	_	NN	NN	_	15	NMOD	_	_
15	binding	_	NN	NN	_	13	PMOD	_	_
16	in	_	IN	IN	_	6	ADV	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	glioblastoma	_	NN	NN	_	19	NMOD	_	_
19	line	_	NN	NN	_	16	PMOD	_	_
20	.	_	.	.	_	6	P	_	_

1	Interferon	_	NN	NN	_	2	NMOD	_	_
2	gamma	_	NN	NN	_	3	SBJ	_	_
3	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	class	_	NN	NN	_	6	NMOD	_	_
5	II	_	CD	CD	_	6	NMOD	_	_
6	expression	_	NN	NN	_	3	OBJ	_	_
7	in	_	IN	IN	_	3	ADV	_	_
8	this	_	DT	DT	_	11	NMOD	_	_
9	glioblastoma	_	NN	NN	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	line	_	NN	NN	_	7	PMOD	_	_
12	and	_	CC	CC	_	3	CC	_	_
13	,	_	,	,	_	3	P	_	_
14	in	_	IN	IN	_	17	ADV	_	_
15	parallel	_	NN	NN	_	14	PMOD	_	_
16	,	_	,	,	_	17	P	_	_
17	up-regulates	_	VBZ	VBZ	_	3	COORD	_	_
18	X1	_	NN	NN	_	23	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	X2	_	NN	NN	_	18	COORD	_	_
21	box	_	NN	NN	_	23	NMOD	_	_
22	protein-DNA	_	JJ	JJ	_	23	NMOD	_	_
23	interactions	_	NNS	NNS	_	17	IOBJ	_	_
24	,	_	,	,	_	17	P	_	_
25	while	_	IN	IN	_	17	OBJ	_	_
26	all	_	DT	DT	_	28	NMOD	_	_
27	other	_	JJ	JJ	_	28	NMOD	_	_
28	interactions	_	NNS	NNS	_	29	SBJ	_	_
29	remain	_	VBP	VBP	_	25	VMOD	_	_
30	unchanged	_	JJ	JJ	_	29	PRD	_	_
31	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	interferon	_	NN	NN	_	6	NMOD	_	_
6	gamma	_	NN	NN	_	7	SBJ	_	_
7	functions	_	VBZ	VBZ	_	4	VMOD	_	_
8	on	_	IN	IN	_	7	ADV	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	poised	_	VBN	VBN	_	11	NMOD	_	_
11	promoter	_	NN	NN	_	8	PMOD	_	_
12	by	_	IN	IN	_	7	ADV	_	_
13	altering	_	VBG	VBG	_	12	PMOD	_	_
14	weak	_	JJ	JJ	_	17	NMOD	_	_
15	,	_	,	,	_	17	P	_	_
16	nonproductive	_	JJ	JJ	_	17	NMOD	_	_
17	interactions	_	NNS	NNS	_	13	OBJ	_	_
18	at	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	X	_	NN	NN	_	21	NMOD	_	_
21	boxes	_	NNS	NNS	_	18	PMOD	_	_
22	to	_	TO	TO	_	13	ADV	_	_
23	strong	_	JJ	JJ	_	24	NMOD	_	_
24	interactions	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	provide	_	VBP	VBP	_	0	ROOT-S	_	_
4	direct	_	JJ	JJ	_	7	NMOD	_	_
5	in	_	FW	FW	_	6	AMOD	_	_
6	vivo	_	FW	FW	_	7	NMOD	_	_
7	evidence	_	NN	NN	_	3	OBJ	_	_
8	to	_	TO	TO	_	10	VMOD	_	_
9	strongly	_	RB	RB	_	10	ADV	_	_
10	suggest	_	VB	VB	_	7	NMOD	_	_
11	that	_	IN	IN	_	10	OBJ	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	modulation	_	NN	NN	_	19	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	X1	_	NN	NN	_	18	NMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	X2	_	NN	NN	_	15	COORD	_	_
18	interactions	_	NNS	NNS	_	14	PMOD	_	_
19	is	_	VBZ	VBZ	_	11	VMOD	_	_
20	an	_	DT	DT	_	22	NMOD	_	_
21	important	_	JJ	JJ	_	22	NMOD	_	_
22	constituent	_	NN	NN	_	19	PRD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	28	NMOD	_	_
25	interferon	_	NN	NN	_	28	NMOD	_	_
26	gamma	_	NN	NN	_	28	NMOD	_	_
27	induction	_	NN	NN	_	28	NMOD	_	_
28	pathway	_	NN	NN	_	23	PMOD	_	_
29	.	_	.	.	_	3	P	_	_

1	Simple	_	JJ	JJ	_	2	NMOD	_	_
2	derivation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	TFIID-dependent	_	JJ	JJ	_	9	NMOD	_	_
5	RNA	_	NN	NN	_	9	NMOD	_	_
6	polymerase	_	NN	NN	_	9	NMOD	_	_
7	II	_	CD	CD	_	9	NMOD	_	_
8	transcription	_	NN	NN	_	9	NMOD	_	_
9	systems	_	NNS	NNS	_	3	PMOD	_	_
10	from	_	IN	IN	_	2	NMOD	_	_
11	Schizosaccharomyces	_	FW	FW	_	12	NMOD	_	_
12	pombe	_	FW	FW	_	10	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	other	_	JJ	JJ	_	15	NMOD	_	_
15	organisms	_	NNS	NNS	_	12	COORD	_	_
16	,	_	,	,	_	2	P	_	_
17	and	_	CC	CC	_	2	CC	_	_
18	factors	_	NNS	NNS	_	2	COORD	_	_
19	required	_	VBN	VBN	_	18	NMOD	_	_
20	for	_	IN	IN	_	19	ADV	_	_
21	transcriptional	_	JJ	JJ	_	22	NMOD	_	_
22	activation	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	2	P	_	_

1	Resolution	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	whole	_	JJ	JJ	_	5	NMOD	_	_
4	cell	_	NN	NN	_	5	NMOD	_	_
5	extract	_	NN	NN	_	2	PMOD	_	_
6	through	_	IN	IN	_	1	NMOD	_	_
7	two	_	CD	CD	_	9	NMOD	_	_
8	chromatographic	_	JJ	JJ	_	9	NMOD	_	_
9	steps	_	NNS	NNS	_	6	PMOD	_	_
10	yields	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	a	_	DT	DT	_	14	NMOD	_	_
12	single	_	JJ	JJ	_	14	NMOD	_	_
13	protein	_	NN	NN	_	14	NMOD	_	_
14	fraction	_	NN	NN	_	10	OBJ	_	_
15	requiring	_	VBG	VBG	_	14	NMOD	_	_
16	only	_	RB	RB	_	18	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	addition	_	NN	NN	_	15	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	TFIID	_	NN	NN	_	19	PMOD	_	_
21	for	_	IN	IN	_	15	ADV	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	initiation	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	transcription	_	NN	NN	_	24	PMOD	_	_
26	at	_	IN	IN	_	23	NMOD	_	_
27	RNA	_	NN	NN	_	30	NMOD	_	_
28	polymerase	_	NN	NN	_	30	NMOD	_	_
29	II	_	CD	CD	_	30	NMOD	_	_
30	promoters	_	NNS	NNS	_	26	PMOD	_	_
31	.	_	.	.	_	10	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	approach	_	NN	NN	_	3	SBJ	_	_
3	allows	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	convenient	_	JJ	JJ	_	6	NMOD	_	_
6	generation	_	NN	NN	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	RNA	_	NN	NN	_	12	NMOD	_	_
9	polymerase	_	NN	NN	_	12	NMOD	_	_
10	II	_	CD	CD	_	12	NMOD	_	_
11	transcription	_	NN	NN	_	12	NMOD	_	_
12	systems	_	NNS	NNS	_	7	PMOD	_	_
13	from	_	IN	IN	_	6	NMOD	_	_
14	Saccharomyces	_	FW	FW	_	15	NMOD	_	_
15	cerevisiae	_	FW	FW	_	13	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	human	_	JJ	JJ	_	18	NMOD	_	_
18	lymphocytes	_	NNS	NNS	_	15	COORD	_	_
19	,	_	,	,	_	15	P	_	_
20	and	_	CC	CC	_	15	CC	_	_
21	Schizosaccharomyces	_	FW	FW	_	22	NMOD	_	_
22	pombe	_	FW	FW	_	15	COORD	_	_
23	.	_	.	.	_	3	P	_	_

1	TFIIDs	_	NNS	NNS	_	6	SBJ	_	_
2	from	_	IN	IN	_	1	NMOD	_	_
3	all	_	DT	DT	_	5	NMOD	_	_
4	three	_	CD	CD	_	5	NMOD	_	_
5	organisms	_	NNS	NNS	_	2	PMOD	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	interchangeable	_	JJ	JJ	_	6	PRD	_	_
8	among	_	IN	IN	_	7	AMOD	_	_
9	all	_	DT	DT	_	11	NMOD	_	_
10	three	_	CD	CD	_	11	NMOD	_	_
11	systems	_	NNS	NNS	_	8	PMOD	_	_
12	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	7	NMOD	_	_
2	S.	_	FW	FW	_	3	NMOD	_	_
3	cerevisiae	_	FW	FW	_	7	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	Sch.	_	FW	FW	_	6	NMOD	_	_
6	pombe	_	FW	FW	_	3	COORD	_	_
7	systems	_	NNS	NNS	_	8	SBJ	_	_
8	support	_	VBP	VBP	_	0	ROOT-S	_	_
9	effects	_	NNS	NNS	_	8	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	acidic	_	JJ	JJ	_	13	NMOD	_	_
12	activator	_	NN	NN	_	13	NMOD	_	_
13	proteins	_	NNS	NNS	_	10	PMOD	_	_
14	,	_	,	,	_	8	P	_	_
15	provided	_	VBN	VBN	_	8	ADV	_	_
16	a	_	DT	DT	_	19	NMOD	_	_
17	further	_	JJ	JJ	_	19	NMOD	_	_
18	protein	_	NN	NN	_	19	NMOD	_	_
19	fraction	_	NN	NN	_	23	SBJ	_	_
20	from	_	IN	IN	_	19	NMOD	_	_
21	S.	_	FW	FW	_	22	NMOD	_	_
22	cerevisiae	_	FW	FW	_	20	PMOD	_	_
23	is	_	VBZ	VBZ	_	15	PMOD	_	_
24	supplied	_	VBN	VBN	_	23	VC	_	_
25	.	_	.	.	_	8	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	further	_	JJ	JJ	_	3	NMOD	_	_
3	fraction	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	distinct	_	JJ	JJ	_	4	PRD	_	_
6	from	_	IN	IN	_	5	AMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	mediator	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	transcriptional	_	JJ	JJ	_	11	NMOD	_	_
11	activation	_	NN	NN	_	9	PMOD	_	_
12	described	_	VBN	VBN	_	8	NMOD	_	_
13	previously	_	RB	RB	_	12	TMP	_	_
14	and	_	CC	CC	_	4	CC	_	_
15	represents	_	VBZ	VBZ	_	4	COORD	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	second	_	JJ	JJ	_	18	NMOD	_	_
18	component	_	NN	NN	_	15	OBJ	_	_
19	in	_	IN	IN	_	15	ADV	_	_
20	addition	_	NN	NN	_	19	DEP	_	_
21	to	_	TO	TO	_	19	DEP	_	_
22	general	_	JJ	JJ	_	24	NMOD	_	_
23	initiation	_	NN	NN	_	24	NMOD	_	_
24	factors	_	NNS	NNS	_	19	PMOD	_	_
25	that	_	WDT	WDT	_	26	SBJ	_	_
26	may	_	MD	MD	_	24	NMOD	_	_
27	facilitate	_	VB	VB	_	26	VC	_	_
28	a	_	DT	DT	_	29	NMOD	_	_
29	response	_	NN	NN	_	27	OBJ	_	_
30	to	_	TO	TO	_	29	NMOD	_	_
31	acidic	_	JJ	JJ	_	32	NMOD	_	_
32	activators	_	NNS	NNS	_	30	PMOD	_	_
33	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	development	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	functionally	_	RB	RB	_	5	AMOD	_	_
5	responsive	_	JJ	JJ	_	7	NMOD	_	_
6	T	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	3	PMOD	_	_
8	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	work	_	NN	NN	_	7	SBJ	_	_
3	reviewed	_	VBN	VBN	_	2	NMOD	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	this	_	DT	DT	_	6	NMOD	_	_
6	article	_	NN	NN	_	4	PMOD	_	_
7	separates	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	T	_	NN	NN	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	development	_	NN	NN	_	7	OBJ	_	_
11	into	_	IN	IN	_	7	ADV	_	_
12	four	_	CD	CD	_	13	NMOD	_	_
13	phases	_	NNS	NNS	_	11	PMOD	_	_
14	.	_	.	.	_	7	P	_	_

1	First	_	JJ	JJ	_	2	PRD	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	an	_	DT	DT	_	5	NMOD	_	_
4	expansion	_	NN	NN	_	5	NMOD	_	_
5	phase	_	NN	NN	_	2	SBJ	_	_
6	prior	_	RB	RB	_	7	DEP	_	_
7	to	_	TO	TO	_	5	NMOD	_	_
8	TCR	_	NN	NN	_	9	NMOD	_	_
9	rearrangement	_	NN	NN	_	7	PMOD	_	_
10	,	_	,	,	_	5	P	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	appears	_	VBZ	VBZ	_	5	NMOD	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	be	_	VB	VB	_	12	OBJ	_	_
15	correlated	_	VBN	VBN	_	14	VC	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	programming	_	NN	NN	_	16	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	at	_	IN	IN	_	21	DEP	_	_
20	least	_	JJS	JJS	_	21	DEP	_	_
21	some	_	DT	DT	_	23	NMOD	_	_
22	response	_	NN	NN	_	23	NMOD	_	_
23	genes	_	NNS	NNS	_	18	PMOD	_	_
24	for	_	IN	IN	_	17	NMOD	_	_
25	inducibility	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	phase	_	NN	NN	_	3	SBJ	_	_
3	can	_	MD	MD	_	0	ROOT-S	_	_
4	occur	_	VB	VB	_	3	VC	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	some	_	DT	DT	_	7	NMOD	_	_
7	extent	_	NN	NN	_	5	PMOD	_	_
8	outside	_	IN	IN	_	4	ADV	_	_
9	of	_	IN	IN	_	8	AMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	thymus	_	NN	NN	_	9	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	profound	_	JJ	JJ	_	7	NMOD	_	_
5	T	_	NN	NN	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	deficit	_	NN	NN	_	11	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	nude	_	JJ	JJ	_	10	NMOD	_	_
10	mice	_	NNS	NNS	_	8	PMOD	_	_
11	indicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	that	_	IN	IN	_	11	OBJ	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	thymus	_	NN	NN	_	15	SBJ	_	_
15	is	_	VBZ	VBZ	_	12	VMOD	_	_
16	by	_	IN	IN	_	15	ADV	_	_
17	far	_	RB	RB	_	16	PMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	most	_	RBS	RBS	_	20	AMOD	_	_
20	potent	_	JJ	JJ	_	21	NMOD	_	_
21	site	_	NN	NN	_	15	VMOD	_	_
22	for	_	IN	IN	_	21	NMOD	_	_
23	inducing	_	VBG	VBG	_	22	PMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	expansion	_	NN	NN	_	23	OBJ	_	_
26	per	_	FW	FW	_	23	ADV	_	_
27	se	_	FW	FW	_	26	AMOD	_	_
28	,	_	,	,	_	15	P	_	_
29	even	_	RB	RB	_	30	VMOD	_	_
30	if	_	IN	IN	_	15	ADV	_	_
31	other	_	JJ	JJ	_	32	NMOD	_	_
32	sites	_	NNS	NNS	_	33	SBJ	_	_
33	can	_	MD	MD	_	30	VMOD	_	_
34	induce	_	VB	VB	_	33	VC	_	_
35	some	_	DT	DT	_	37	NMOD	_	_
36	response	_	NN	NN	_	37	NMOD	_	_
37	acquisition	_	NN	NN	_	34	OBJ	_	_
38	.	_	.	.	_	11	P	_	_

1	Second	_	JJ	JJ	_	2	PRD	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	controlled	_	JJ	JJ	_	5	NMOD	_	_
5	phase	_	NN	NN	_	2	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	TCR	_	NN	NN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	rearrangement	_	NN	NN	_	6	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	details	_	NNS	NNS	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	regulatory	_	JJ	JJ	_	6	NMOD	_	_
6	mechanism	_	NN	NN	_	3	PMOD	_	_
7	that	_	WDT	WDT	_	8	SBJ	_	_
8	selects	_	VBZ	VBZ	_	6	NMOD	_	_
9	particular	_	JJ	JJ	_	10	NMOD	_	_
10	loci	_	NNS	NNS	_	8	OBJ	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	rearrangement	_	NN	NN	_	11	PMOD	_	_
13	are	_	VBP	VBP	_	0	ROOT-S	_	_
14	still	_	RB	RB	_	13	ADV	_	_
15	not	_	RB	RB	_	13	VMOD	_	_
16	known	_	VBN	VBN	_	13	VC	_	_
17	.	_	.	.	_	13	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	seems	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	rearrangement	_	NN	NN	_	16	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	TCR	_	NN	NN	_	10	NMOD	_	_
9	gamma	_	NN	NN	_	10	NMOD	_	_
10	loci	_	NNS	NNS	_	6	PMOD	_	_
11	in	_	IN	IN	_	5	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	gamma	_	NN	NN	_	15	NMOD	_	_
14	delta	_	NN	NN	_	15	NMOD	_	_
15	lineage	_	NN	NN	_	11	PMOD	_	_
16	may	_	MD	MD	_	3	VMOD	_	_
17	not	_	RB	RB	_	16	VMOD	_	_
18	always	_	RB	RB	_	16	TMP	_	_
19	take	_	VB	VB	_	16	VC	_	_
20	place	_	NN	NN	_	19	OBJ	_	_
21	at	_	IN	IN	_	19	ADV	_	_
22	a	_	DT	DT	_	24	NMOD	_	_
23	developmental	_	JJ	JJ	_	24	NMOD	_	_
24	stage	_	NN	NN	_	21	PMOD	_	_
25	strictly	_	RB	RB	_	26	AMOD	_	_
26	equivalent	_	JJ	JJ	_	24	NMOD	_	_
27	to	_	TO	TO	_	26	AMOD	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	rearrangement	_	NN	NN	_	27	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	TCR	_	NN	NN	_	32	NMOD	_	_
32	beta	_	NN	NN	_	30	PMOD	_	_
33	in	_	IN	IN	_	29	NMOD	_	_
34	the	_	DT	DT	_	37	NMOD	_	_
35	alpha	_	NN	NN	_	37	NMOD	_	_
36	beta	_	NN	NN	_	37	NMOD	_	_
37	lineage	_	NN	NN	_	33	PMOD	_	_
38	,	_	,	,	_	2	P	_	_
39	and	_	CC	CC	_	2	CC	_	_
40	it	_	PRP	PRP	_	41	SBJ	_	_
41	is	_	VBZ	VBZ	_	2	COORD	_	_
42	not	_	RB	RB	_	41	VMOD	_	_
43	clear	_	JJ	JJ	_	41	PRD	_	_
44	just	_	RB	RB	_	45	AMOD	_	_
45	how	_	WRB	WRB	_	50	ADV	_	_
46	early	_	RB	RB	_	45	AMOD	_	_
47	the	_	DT	DT	_	49	NMOD	_	_
48	two	_	CD	CD	_	49	NMOD	_	_
49	lineages	_	NNS	NNS	_	50	SBJ	_	_
50	diverge	_	VBP	VBP	_	41	EXP	_	_
51	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	15	ADV	_	_
2	the	_	DT	DT	_	6	NMOD	_	_
3	TCR	_	NN	NN	_	6	NMOD	_	_
4	alpha	_	NN	NN	_	6	NMOD	_	_
5	beta	_	NN	NN	_	6	NMOD	_	_
6	lineage	_	NN	NN	_	1	PMOD	_	_
7	,	_	,	,	_	15	P	_	_
8	however	_	RB	RB	_	15	ADV	_	_
9	,	_	,	,	_	15	P	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	final	_	JJ	JJ	_	14	NMOD	_	_
12	gene	_	NN	NN	_	14	NMOD	_	_
13	rearrangement	_	NN	NN	_	14	NMOD	_	_
14	events	_	NNS	NNS	_	15	SBJ	_	_
15	are	_	VBP	VBP	_	0	ROOT-S	_	_
16	accompanied	_	VBN	VBN	_	15	VC	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	rapid	_	JJ	JJ	_	19	NMOD	_	_
19	proliferation	_	NN	NN	_	17	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	an	_	DT	DT	_	22	NMOD	_	_
22	interruption	_	NN	NN	_	19	COORD	_	_
23	in	_	IN	IN	_	22	NMOD	_	_
24	cellular	_	JJ	JJ	_	27	NMOD	_	_
25	response	_	NN	NN	_	27	NMOD	_	_
26	gene	_	NN	NN	_	27	NMOD	_	_
27	inducibility	_	NN	NN	_	23	PMOD	_	_
28	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	loss	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	conventional	_	JJ	JJ	_	5	NMOD	_	_
5	responsiveness	_	NN	NN	_	3	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	probably	_	RB	RB	_	6	ADV	_	_
8	caused	_	VBN	VBN	_	6	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	alterations	_	NNS	NNS	_	9	PMOD	_	_
11	at	_	IN	IN	_	8	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	level	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	signaling	_	NN	NN	_	14	PMOD	_	_
16	,	_	,	,	_	6	P	_	_
17	and	_	CC	CC	_	6	CC	_	_
18	may	_	MD	MD	_	6	COORD	_	_
19	be	_	VB	VB	_	18	VC	_	_
20	a	_	DT	DT	_	21	NMOD	_	_
21	manifestation	_	NN	NN	_	19	PRD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	physiological	_	JJ	JJ	_	25	NMOD	_	_
25	state	_	NN	NN	_	22	PMOD	_	_
26	that	_	WDT	WDT	_	27	SBJ	_	_
27	is	_	VBZ	VBZ	_	25	NMOD	_	_
28	a	_	DT	DT	_	29	NMOD	_	_
29	precondition	_	NN	NN	_	27	PRD	_	_
30	for	_	IN	IN	_	29	NMOD	_	_
31	selection	_	NN	NN	_	30	PMOD	_	_
32	.	_	.	.	_	6	P	_	_

1	Third	_	JJ	JJ	_	2	PRD	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	complex	_	JJ	JJ	_	5	NMOD	_	_
5	process	_	NN	NN	_	2	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	selection	_	NN	NN	_	6	PMOD	_	_
8	.	_	.	.	_	2	P	_	_

1	Whereas	_	IN	IN	_	32	ADV	_	_
2	peripheral	_	JJ	JJ	_	4	NMOD	_	_
3	T	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	5	SBJ	_	_
5	can	_	MD	MD	_	1	VMOD	_	_
6	undergo	_	VB	VB	_	5	VC	_	_
7	forms	_	NNS	NNS	_	6	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	positive	_	JJ	JJ	_	10	NMOD	_	_
10	selection	_	NN	NN	_	8	PMOD	_	_
11	(	_	(	(	_	10	P	_	_
12	by	_	IN	IN	_	10	NMOD	_	_
13	antigen-driven	_	JJ	JJ	_	15	NMOD	_	_
14	clonal	_	JJ	JJ	_	15	NMOD	_	_
15	expansion	_	NN	NN	_	12	PMOD	_	_
16	)	_	)	)	_	10	P	_	_
17	and	_	CC	CC	_	10	CC	_	_
18	negative	_	JJ	JJ	_	19	NMOD	_	_
19	selection	_	NN	NN	_	10	COORD	_	_
20	(	_	(	(	_	19	P	_	_
21	by	_	IN	IN	_	19	NMOD	_	_
22	abortive	_	JJ	JJ	_	23	NMOD	_	_
23	stimulation	_	NN	NN	_	21	PMOD	_	_
24	leading	_	VBG	VBG	_	23	NMOD	_	_
25	to	_	TO	TO	_	24	ADV	_	_
26	anergy	_	NN	NN	_	25	PMOD	_	_
27	or	_	CC	CC	_	26	CC	_	_
28	death	_	NN	NN	_	26	COORD	_	_
29	)	_	)	)	_	19	P	_	_
30	,	_	,	,	_	32	P	_	_
31	neither	_	DT	DT	_	32	SBJ	_	_
32	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
33	exactly	_	RB	RB	_	35	AMOD	_	_
34	the	_	DT	DT	_	35	AMOD	_	_
35	same	_	JJ	JJ	_	36	NMOD	_	_
36	phenomenon	_	NN	NN	_	32	PRD	_	_
37	that	_	WDT	WDT	_	38	SBJ	_	_
38	occurs	_	VBZ	VBZ	_	36	NMOD	_	_
39	in	_	IN	IN	_	38	ADV	_	_
40	the	_	DT	DT	_	42	NMOD	_	_
41	thymic	_	JJ	JJ	_	42	NMOD	_	_
42	cortex	_	NN	NN	_	39	PMOD	_	_
43	.	_	.	.	_	32	P	_	_

1	Negative	_	JJ	JJ	_	2	NMOD	_	_
2	selection	_	NN	NN	_	6	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	cortex	_	NN	NN	_	3	PMOD	_	_
6	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	be	_	VB	VB	_	6	OBJ	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	suicidal	_	JJ	JJ	_	11	NMOD	_	_
11	inversion	_	NN	NN	_	8	PRD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	antigen	_	NN	NN	_	14	NMOD	_	_
14	responsiveness	_	NN	NN	_	12	PMOD	_	_
15	:	_	:	:	_	6	P	_	_
16	instead	_	RB	RB	_	17	DEP	_	_
17	of	_	IN	IN	_	26	ADV	_	_
18	turning	_	VBG	VBG	_	17	PMOD	_	_
19	on	_	IN	IN	_	18	PRT	_	_
20	IL-2	_	NN	NN	_	21	NMOD	_	_
21	expression	_	NN	NN	_	18	OBJ	_	_
22	,	_	,	,	_	26	P	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	activated	_	VBN	VBN	_	25	NMOD	_	_
25	cell	_	NN	NN	_	26	SBJ	_	_
26	destroys	_	VBZ	VBZ	_	6	VMOD	_	_
27	its	_	PRP$	PRP$	_	29	NMOD	_	_
28	own	_	JJ	JJ	_	29	NMOD	_	_
29	chromatin	_	NN	NN	_	26	OBJ	_	_
30	.	_	.	.	_	26	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	genes	_	NNS	NNS	_	11	SBJ	_	_
3	that	_	WDT	WDT	_	4	SBJ	_	_
4	need	_	VBP	VBP	_	2	NMOD	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	be	_	VB	VB	_	4	OBJ	_	_
7	induced	_	VBN	VBN	_	6	VC	_	_
8	for	_	IN	IN	_	7	ADV	_	_
9	this	_	DT	DT	_	10	NMOD	_	_
10	response	_	NN	NN	_	8	PMOD	_	_
11	are	_	VBP	VBP	_	0	ROOT-S	_	_
12	not	_	RB	RB	_	11	VMOD	_	_
13	yet	_	RB	RB	_	11	ADV	_	_
14	identified	_	VBN	VBN	_	11	VC	_	_
15	,	_	,	,	_	11	P	_	_
16	but	_	CC	CC	_	11	CC	_	_
17	it	_	PRP	PRP	_	18	SBJ	_	_
18	is	_	VBZ	VBZ	_	11	COORD	_	_
19	unquestionably	_	RB	RB	_	18	ADV	_	_
20	a	_	DT	DT	_	21	NMOD	_	_
21	form	_	NN	NN	_	18	PRD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	activation	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	11	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	interesting	_	JJ	JJ	_	2	PRD	_	_
4	that	_	IN	IN	_	2	EXP	_	_
5	in	_	IN	IN	_	15	ADV	_	_
6	humans	_	NNS	NNS	_	5	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	rats	_	NNS	NNS	_	6	COORD	_	_
9	,	_	,	,	_	15	P	_	_
10	cortical	_	JJ	JJ	_	11	NMOD	_	_
11	thymocytes	_	NNS	NNS	_	15	SBJ	_	_
12	undergoing	_	VBG	VBG	_	11	NMOD	_	_
13	negative	_	JJ	JJ	_	14	NMOD	_	_
14	selection	_	NN	NN	_	12	OBJ	_	_
15	can	_	MD	MD	_	4	VMOD	_	_
16	still	_	RB	RB	_	17	ADV	_	_
17	induce	_	VB	VB	_	15	VC	_	_
18	IL-2R	_	NN	NN	_	20	NMOD	_	_
19	alpha	_	NN	NN	_	20	NMOD	_	_
20	expression	_	NN	NN	_	17	OBJ	_	_
21	and	_	CC	CC	_	17	CC	_	_
22	even	_	RB	RB	_	23	ADV	_	_
23	be	_	VB	VB	_	17	COORD	_	_
24	rescued	_	VBN	VBN	_	23	VC	_	_
25	in	_	FW	FW	_	24	ADV	_	_
26	vitro	_	FW	FW	_	25	AMOD	_	_
27	,	_	,	,	_	17	P	_	_
28	if	_	IN	IN	_	17	ADV	_	_
29	exogenous	_	JJ	JJ	_	30	NMOD	_	_
30	IL-2	_	NN	NN	_	31	SBJ	_	_
31	is	_	VBZ	VBZ	_	28	VMOD	_	_
32	provided	_	VBN	VBN	_	31	VC	_	_
33	.	_	.	.	_	2	P	_	_

1	Perhaps	_	RB	RB	_	4	ADV	_	_
2	murine	_	JJ	JJ	_	3	NMOD	_	_
3	thymocytes	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	denied	_	VBN	VBN	_	4	VC	_	_
6	this	_	DT	DT	_	7	NMOD	_	_
7	form	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	rescue	_	NN	NN	_	8	PMOD	_	_
10	because	_	IN	IN	_	5	ADV	_	_
11	they	_	PRP	PRP	_	12	SBJ	_	_
12	shut	_	VBD	VBD	_	10	VMOD	_	_
13	off	_	RP	RP	_	12	PRT	_	_
14	IL-2R	_	NN	NN	_	17	NMOD	_	_
15	beta	_	NN	NN	_	17	NMOD	_	_
16	chain	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	12	OBJ	_	_
18	at	_	IN	IN	_	12	TMP	_	_
19	an	_	DT	DT	_	21	NMOD	_	_
20	earlier	_	JJR	JJR	_	21	NMOD	_	_
21	stage	_	NN	NN	_	18	PMOD	_	_
22	or	_	CC	CC	_	10	CC	_	_
23	because	_	IN	IN	_	10	COORD	_	_
24	they	_	PRP	PRP	_	25	SBJ	_	_
25	may	_	MD	MD	_	23	VMOD	_	_
26	be	_	VB	VB	_	25	VC	_	_
27	uncommonly	_	RB	RB	_	29	AMOD	_	_
28	Bcl-2	_	NN	NN	_	29	AMOD	_	_
29	deficient	_	JJ	JJ	_	26	PRD	_	_
30	(	_	(	(	_	31	P	_	_
31	cf.	_	VBP	VBP	_	5	PRN	_	_
32	Sentman	_	NNP	NNP	_	31	OBJ	_	_
33	et	_	FW	FW	_	32	NMOD	_	_
34	al.	_	FW	FW	_	32	NMOD	_	_
35	,	_	,	,	_	32	P	_	_
36	1991	_	CD	CD	_	32	NMOD	_	_
37	;	_	:	:	_	32	P	_	_
38	Strasser	_	NNP	NNP	_	32	NMOD	_	_
39	et	_	FW	FW	_	38	NMOD	_	_
40	al.	_	FW	FW	_	38	NMOD	_	_
41	,	_	,	,	_	38	P	_	_
42	1991	_	CD	CD	_	38	NMOD	_	_
43	)	_	)	)	_	31	P	_	_
44	.	_	.	.	_	4	P	_	_

1	Even	_	RB	RB	_	6	ADV	_	_
2	so	_	RB	RB	_	1	AMOD	_	_
3	,	_	,	,	_	6	P	_	_
4	medullary	_	JJ	JJ	_	5	NMOD	_	_
5	thymocytes	_	NNS	NNS	_	6	SBJ	_	_
6	remain	_	VBP	VBP	_	0	ROOT-S	_	_
7	at	_	IN	IN	_	9	AMOD	_	_
8	least	_	JJS	JJS	_	7	AMOD	_	_
9	partially	_	RB	RB	_	6	PRD	_	_
10	susceptible	_	JJ	JJ	_	9	AMOD	_	_
11	to	_	TO	TO	_	9	AMOD	_	_
12	negative	_	JJ	JJ	_	13	NMOD	_	_
13	selection	_	NN	NN	_	11	PMOD	_	_
14	even	_	RB	RB	_	15	VMOD	_	_
15	as	_	IN	IN	_	6	OBJ	_	_
16	they	_	PRP	PRP	_	17	SBJ	_	_
17	continue	_	VBP	VBP	_	15	VMOD	_	_
18	to	_	TO	TO	_	19	VMOD	_	_
19	mature	_	VB	VB	_	17	OBJ	_	_
20	.	_	.	.	_	6	P	_	_

1	SRC-related	_	JJ	JJ	_	2	NMOD	_	_
2	proto-oncogenes	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	transcription	_	NN	NN	_	5	NMOD	_	_
5	factors	_	NNS	NNS	_	2	COORD	_	_
6	in	_	IN	IN	_	2	NMOD	_	_
7	primary	_	JJ	JJ	_	10	NMOD	_	_
8	human	_	JJ	JJ	_	10	NMOD	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	6	PMOD	_	_
11	:	_	:	:	_	2	P	_	_
12	modulation	_	NN	NN	_	2	NMOD	_	_
13	by	_	IN	IN	_	12	NMOD	_	_
14	cyclosporin	_	NN	NN	_	15	NMOD	_	_
15	A	_	NN	NN	_	13	PMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	FK506	_	NN	NN	_	15	COORD	_	_
18	.	_	.	.	_	12	P	_	_

1	Activation	_	NN	NN	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	T	_	NN	NN	_	4	NMOD	_	_
4	lymphocytes	_	NNS	NNS	_	2	PMOD	_	_
5	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	transcription	_	NN	NN	_	5	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	genes	_	NNS	NNS	_	7	PMOD	_	_
9	encoding	_	VBG	VBG	_	8	NMOD	_	_
10	for	_	IN	IN	_	9	ADV	_	_
11	lymphokines	_	NNS	NNS	_	10	PMOD	_	_
12	.	_	.	.	_	5	P	_	_

1	Interleukin-2	_	NN	NN	_	6	NMOD	_	_
2	(	_	(	(	_	3	P	_	_
3	IL-2	_	NN	NN	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	gene	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	controlled	_	VBN	VBN	_	7	VC	_	_
9	transcriptionally	_	RB	RB	_	8	ADV	_	_
10	by	_	IN	IN	_	8	LGS	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	cooperative	_	JJ	JJ	_	13	NMOD	_	_
13	activity	_	NN	NN	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	specific	_	JJ	JJ	_	17	NMOD	_	_
16	trans-activating	_	JJ	JJ	_	17	NMOD	_	_
17	factors	_	NNS	NNS	_	14	PMOD	_	_
18	that	_	WDT	WDT	_	19	SBJ	_	_
19	bind	_	VBP	VBP	_	17	NMOD	_	_
20	to	_	TO	TO	_	19	ADV	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	IL-2	_	NN	NN	_	23	NMOD	_	_
23	enhancer	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	7	P	_	_

1	Cyclosporin	_	NN	NN	_	2	NMOD	_	_
2	A	_	NN	NN	_	8	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	CsA	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	and	_	CC	CC	_	2	CC	_	_
7	FK506	_	NN	NN	_	2	COORD	_	_
8	inhibit	_	VBP	VBP	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	production	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	IL-2	_	NN	NN	_	11	PMOD	_	_
13	in	_	IN	IN	_	10	NMOD	_	_
14	T	_	NN	NN	_	15	NMOD	_	_
15	lymphocytes	_	NNS	NNS	_	13	PMOD	_	_
16	at	_	IN	IN	_	10	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	level	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	gene	_	NN	NN	_	21	NMOD	_	_
21	transcription	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	8	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	member	_	NN	NN	_	17	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	src	_	NN	NN	_	7	NMOD	_	_
6	gene	_	NN	NN	_	7	NMOD	_	_
7	family	_	NN	NN	_	3	PMOD	_	_
8	,	_	,	,	_	2	P	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	lymphocyte-specific	_	JJ	JJ	_	13	NMOD	_	_
11	protein	_	NN	NN	_	13	NMOD	_	_
12	tyrosine	_	NN	NN	_	13	NMOD	_	_
13	kinase	_	NN	NN	_	2	NMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	p56lck	_	NN	NN	_	13	NMOD	_	_
16	,	_	,	,	_	13	P	_	_
17	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	been	_	VBN	VBN	_	17	VC	_	_
19	implicated	_	VBN	VBN	_	18	VC	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	IL-2	_	NN	NN	_	22	NMOD	_	_
22	production	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	17	P	_	_

1	CsA	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	not	_	RB	RB	_	6	VMOD	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	inhibit	_	VB	VB	_	3	OBJ	_	_
7	lck	_	NN	NN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	expression	_	NN	NN	_	6	OBJ	_	_
10	,	_	,	,	_	9	P	_	_
11	nor	_	CC	CC	_	9	CC	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	activity	_	NN	NN	_	9	COORD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	lck	_	NN	NN	_	18	NMOD	_	_
17	gene	_	NN	NN	_	18	NMOD	_	_
18	product	_	NN	NN	_	14	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	However	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	CsA	_	NN	NN	_	6	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	FK506	_	NN	NN	_	3	COORD	_	_
6	inhibit	_	VBP	VBP	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	appearance	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	DNA	_	NN	NN	_	12	NMOD	_	_
11	binding	_	NN	NN	_	12	NMOD	_	_
12	activity	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	factors	_	NNS	NNS	_	13	PMOD	_	_
15	that	_	WDT	WDT	_	16	SBJ	_	_
16	bind	_	VBP	VBP	_	14	NMOD	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	the	_	DT	DT	_	22	NMOD	_	_
19	NF-AT	_	NN	NN	_	22	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	AP-1	_	NN	NN	_	19	COORD	_	_
22	sites	_	NNS	NNS	_	17	PMOD	_	_
23	in	_	IN	IN	_	16	ADV	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	IL-2	_	NN	NN	_	26	NMOD	_	_
26	enhancer	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	6	P	_	_

1	Since	_	IN	IN	_	21	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	induction	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	NF-AT	_	NN	NN	_	4	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	AP-1	_	NN	NN	_	5	COORD	_	_
8	is	_	VBZ	VBZ	_	1	VMOD	_	_
9	induced	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	same	_	JJ	JJ	_	13	NMOD	_	_
13	stimuli	_	NNS	NNS	_	10	PMOD	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	stimulate	_	VBP	VBP	_	13	NMOD	_	_
16	IL-2	_	NN	NN	_	17	NMOD	_	_
17	production	_	NN	NN	_	15	OBJ	_	_
18	,	_	,	,	_	21	P	_	_
19	these	_	DT	DT	_	20	NMOD	_	_
20	results	_	NNS	NNS	_	21	SBJ	_	_
21	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	immunosuppressant	_	JJ	JJ	_	25	NMOD	_	_
25	action	_	NN	NN	_	30	SBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	CsA	_	NN	NN	_	26	PMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	FK506	_	NN	NN	_	27	COORD	_	_
30	is	_	VBZ	VBZ	_	22	VMOD	_	_
31	exerted	_	VBN	VBN	_	30	VC	_	_
32	at	_	IN	IN	_	31	ADV	_	_
33	the	_	DT	DT	_	34	NMOD	_	_
34	level	_	NN	NN	_	32	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	these	_	DT	DT	_	38	NMOD	_	_
37	trans-activating	_	JJ	JJ	_	38	NMOD	_	_
38	factors	_	NNS	NNS	_	35	PMOD	_	_
39	.	_	.	.	_	21	P	_	_

1	Bcl-2	_	NN	NN	_	0	ROOT-FRAG	_	_
2	:	_	:	:	_	1	P	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	repressor	_	NN	NN	_	1	NMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	lymphocyte	_	NN	NN	_	7	NMOD	_	_
7	death	_	NN	NN	_	5	PMOD	_	_
8	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	genes	_	NNS	NNS	_	10	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	mechanisms	_	NNS	NNS	_	2	COORD	_	_
5	that	_	WDT	WDT	_	6	SBJ	_	_
6	control	_	VBP	VBP	_	2	NMOD	_	_
7	programmed	_	VBN	VBN	_	9	NMOD	_	_
8	cell	_	NN	NN	_	9	NMOD	_	_
9	death	_	NN	NN	_	6	OBJ	_	_
10	are	_	VBP	VBP	_	0	ROOT-S	_	_
11	currently	_	RB	RB	_	10	TMP	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	subject	_	NN	NN	_	10	PRD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	intense	_	JJ	JJ	_	16	NMOD	_	_
16	study	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	bcl-2	_	NN	NN	_	3	NMOD	_	_
3	gene	_	NN	NN	_	11	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	a	_	DT	DT	_	6	NMOD	_	_
6	repressor	_	NN	NN	_	3	NMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	lymphocyte	_	NN	NN	_	9	NMOD	_	_
9	death	_	NN	NN	_	7	PMOD	_	_
10	,	_	,	,	_	3	P	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	perhaps	_	RB	RB	_	11	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	best	_	JJS	JJS	_	11	PRD	_	_
15	understood	_	VBN	VBN	_	14	NMOD	_	_
16	of	_	IN	IN	_	14	NMOD	_	_
17	the	_	DT	DT	_	22	NMOD	_	_
18	programmed	_	VBN	VBN	_	20	NMOD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	death	_	NN	NN	_	21	AMOD	_	_
21	associated	_	JJ	JJ	_	22	NMOD	_	_
22	genes	_	NNS	NNS	_	16	PMOD	_	_
23	.	_	.	.	_	11	P	_	_

1	Here	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	Stanley	_	NNP	NNP	_	4	NMOD	_	_
4	Korsmeyer	_	NNP	NNP	_	5	SBJ	_	_
5	provides	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	brief	_	JJ	JJ	_	8	NMOD	_	_
8	overview	_	NN	NN	_	5	IOBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	bcl-2	_	NN	NN	_	9	PMOD	_	_
11	,	_	,	,	_	5	P	_	_
12	concentrating	_	VBG	VBG	_	5	OBJ	_	_
13	on	_	IN	IN	_	12	ADV	_	_
14	its	_	PRP$	PRP$	_	15	NMOD	_	_
15	roles	_	NNS	NNS	_	13	PMOD	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	B-	_	NN	NN	_	20	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	T-cell	_	NN	NN	_	17	COORD	_	_
20	development	_	NN	NN	_	16	PMOD	_	_
21	and	_	CC	CC	_	16	CC	_	_
22	in	_	IN	IN	_	16	COORD	_	_
23	oncogenesis	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	5	P	_	_

1	Mitogen	_	NN	NN	_	2	NMOD	_	_
2	stimulation	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	T-cells	_	NNS	NNS	_	3	PMOD	_	_
5	increases	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	c-Fos	_	NN	NN	_	10	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	c-Jun	_	NN	NN	_	6	COORD	_	_
9	protein	_	NN	NN	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	5	OBJ	_	_
11	,	_	,	,	_	10	P	_	_
12	AP-1	_	NN	NN	_	13	NMOD	_	_
13	binding	_	NN	NN	_	10	COORD	_	_
14	and	_	CC	CC	_	10	CC	_	_
15	AP-1	_	NN	NN	_	17	NMOD	_	_
16	transcriptional	_	JJ	JJ	_	17	NMOD	_	_
17	activity	_	NN	NN	_	10	COORD	_	_
18	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	analysed	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	effect	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	mitogenic	_	JJ	JJ	_	8	NMOD	_	_
8	lectins	_	NNS	NNS	_	6	PMOD	_	_
9	on	_	IN	IN	_	5	NMOD	_	_
10	c-Fos	_	NN	NN	_	14	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	c-Jun	_	NN	NN	_	10	COORD	_	_
13	protein	_	NN	NN	_	14	NMOD	_	_
14	levels	_	NNS	NNS	_	9	PMOD	_	_
15	as	_	RB	RB	_	9	CC	_	_
16	well	_	RB	RB	_	15	DEP	_	_
17	as	_	IN	IN	_	15	DEP	_	_
18	on	_	IN	IN	_	9	COORD	_	_
19	activator	_	NN	NN	_	20	NMOD	_	_
20	protein-1	_	NN	NN	_	24	NMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	AP-1	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	binding	_	NN	NN	_	18	PMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	enhancer	_	NN	NN	_	27	NMOD	_	_
27	activity	_	NN	NN	_	24	COORD	_	_
28	in	_	IN	IN	_	5	NMOD	_	_
29	Jurkat	_	NN	NN	_	30	NMOD	_	_
30	T-cells	_	NNS	NNS	_	28	PMOD	_	_
31	.	_	.	.	_	2	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	c-Fos	_	NN	NN	_	6	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	c-Jun	_	NN	NN	_	2	COORD	_	_
5	protein	_	NN	NN	_	6	NMOD	_	_
6	levels	_	NNS	NNS	_	7	SBJ	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	increased	_	VBN	VBN	_	7	VC	_	_
9	after	_	IN	IN	_	8	TMP	_	_
10	Con	_	NN	NN	_	11	NMOD	_	_
11	A	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	PHA	_	NN	NN	_	11	COORD	_	_
14	stimulation	_	NN	NN	_	9	PMOD	_	_
15	.	_	.	.	_	7	P	_	_

1	Since	_	IN	IN	_	32	ADV	_	_
2	T-cell	_	NN	NN	_	3	NMOD	_	_
3	stimulation	_	NN	NN	_	4	SBJ	_	_
4	increases	_	VBZ	VBZ	_	1	VMOD	_	_
5	both	_	CC	CC	_	10	CC	_	_
6	intracellular	_	JJ	JJ	_	10	NMOD	_	_
7	Ca2+	_	NN	NN	_	10	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	cAMP	_	NN	NN	_	7	COORD	_	_
10	levels	_	NNS	NNS	_	4	OBJ	_	_
11	and	_	CC	CC	_	4	CC	_	_
12	activates	_	VBZ	VBZ	_	4	COORD	_	_
13	protein	_	NN	NN	_	15	NMOD	_	_
14	kinase	_	NN	NN	_	15	NMOD	_	_
15	C	_	NN	NN	_	12	OBJ	_	_
16	(	_	(	(	_	17	P	_	_
17	PKC	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	,	_	,	,	_	32	P	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	possible	_	JJ	JJ	_	22	NMOD	_	_
22	involvement	_	NN	NN	_	32	SBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	these	_	DT	DT	_	26	NMOD	_	_
25	intracellular	_	JJ	JJ	_	26	NMOD	_	_
26	messengers	_	NNS	NNS	_	23	PMOD	_	_
27	in	_	IN	IN	_	22	NMOD	_	_
28	c-Fos	_	NN	NN	_	31	NMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	c-Jun	_	NN	NN	_	28	COORD	_	_
31	induction	_	NN	NN	_	27	PMOD	_	_
32	was	_	VBD	VBD	_	0	ROOT-S	_	_
33	tested	_	VBN	VBN	_	32	VC	_	_
34	.	_	.	.	_	32	P	_	_

1	PMA	_	NN	NN	_	8	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	which	_	WDT	WDT	_	5	SBJ	_	_
4	directly	_	RB	RB	_	5	ADV	_	_
5	activates	_	VBZ	VBZ	_	1	NMOD	_	_
6	PKC	_	NN	NN	_	5	OBJ	_	_
7	,	_	,	,	_	1	P	_	_
8	mimicked	_	VBD	VBD	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	effect	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	lectins	_	NNS	NNS	_	11	PMOD	_	_
14	on	_	IN	IN	_	10	NMOD	_	_
15	c-Fos	_	NN	NN	_	14	PMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	c-Jun	_	NN	NN	_	15	COORD	_	_
18	,	_	,	,	_	8	P	_	_
19	but	_	CC	CC	_	8	CC	_	_
20	elevation	_	NN	NN	_	28	SBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	either	_	CC	CC	_	27	CC	_	_
23	intracellular	_	JJ	JJ	_	27	NMOD	_	_
24	Ca2+	_	NN	NN	_	27	NMOD	_	_
25	or	_	CC	CC	_	24	CC	_	_
26	cAMP	_	NN	NN	_	24	COORD	_	_
27	levels	_	NNS	NNS	_	21	PMOD	_	_
28	had	_	VBD	VBD	_	8	COORD	_	_
29	little	_	JJ	JJ	_	32	NMOD	_	_
30	or	_	CC	CC	_	29	CC	_	_
31	no	_	DT	DT	_	29	COORD	_	_
32	effect	_	NN	NN	_	28	OBJ	_	_
33	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	mitogen-induced	_	JJ	JJ	_	3	NMOD	_	_
3	increase	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	c-Fos	_	NN	NN	_	8	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	c-Jun	_	NN	NN	_	5	COORD	_	_
8	immunoreactivity	_	NN	NN	_	4	PMOD	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	inhibited	_	VBN	VBN	_	9	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	H-7	_	NN	NN	_	11	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	kinase	_	NN	NN	_	16	NMOD	_	_
16	inhibitor	_	NN	NN	_	12	NMOD	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	relatively	_	RB	RB	_	19	AMOD	_	_
19	high	_	JJ	JJ	_	20	NMOD	_	_
20	specificity	_	NN	NN	_	17	PMOD	_	_
21	for	_	IN	IN	_	20	NMOD	_	_
22	PKC	_	NN	NN	_	21	PMOD	_	_
23	,	_	,	,	_	12	P	_	_
24	and	_	CC	CC	_	10	CC	_	_
25	less	_	RBR	RBR	_	26	AMOD	_	_
26	efficiently	_	RB	RB	_	27	ADV	_	_
27	by	_	IN	IN	_	11	GAP	_	_
28	H-8	_	NN	NN	_	27	PMOD	_	_
29	,	_	,	,	_	27	P	_	_
30	a	_	DT	DT	_	34	NMOD	_	_
31	structurally	_	RB	RB	_	32	AMOD	_	_
32	related	_	JJ	JJ	_	34	NMOD	_	_
33	kinase	_	NN	NN	_	34	NMOD	_	_
34	inhibitor	_	NN	NN	_	27	PMOD	_	_
35	less	_	RBR	RBR	_	36	AMOD	_	_
36	active	_	JJ	JJ	_	34	NMOD	_	_
37	on	_	IN	IN	_	36	AMOD	_	_
38	PKC	_	NN	NN	_	37	PMOD	_	_
39	,	_	,	,	_	36	P	_	_
40	but	_	CC	CC	_	36	CC	_	_
41	more	_	RBR	RBR	_	42	AMOD	_	_
42	active	_	JJ	JJ	_	36	COORD	_	_
43	on	_	IN	IN	_	42	AMOD	_	_
44	cyclic	_	JJ	JJ	_	45	AMOD	_	_
45	nucleotide-dependent	_	JJ	JJ	_	46	NMOD	_	_
46	kinases	_	NNS	NNS	_	43	PMOD	_	_
47	.	_	.	.	_	9	P	_	_

1	Con	_	NN	NN	_	3	NMOD	_	_
2	A	_	NN	NN	_	3	NMOD	_	_
3	stimulation	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	found	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	increase	_	VB	VB	_	5	OBJ	_	_
8	both	_	CC	CC	_	9	CC	_	_
9	binding	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	AP-1	_	NN	NN	_	10	PMOD	_	_
12	to	_	TO	TO	_	9	NMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	AP-1	_	NN	NN	_	16	NMOD	_	_
15	consensus	_	NN	NN	_	16	NMOD	_	_
16	sequence	_	NN	NN	_	12	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	TRE	_	NN	NN	_	16	NMOD	_	_
19	,	_	,	,	_	16	P	_	_
20	and	_	CC	CC	_	9	CC	_	_
21	AP-1	_	NN	NN	_	23	NMOD	_	_
22	enhancer	_	NN	NN	_	23	NMOD	_	_
23	activity	_	NN	NN	_	9	COORD	_	_
24	,	_	,	,	_	9	P	_	_
25	in	_	IN	IN	_	9	NMOD	_	_
26	Jurkat	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	4	P	_	_

1	PMA	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	also	_	RB	RB	_	2	ADV	_	_
4	found	_	VBN	VBN	_	2	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	increase	_	VB	VB	_	4	OBJ	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	AP-1	_	NN	NN	_	10	NMOD	_	_
9	enhancer	_	NN	NN	_	10	NMOD	_	_
10	activity	_	NN	NN	_	6	OBJ	_	_
11	,	_	,	,	_	2	P	_	_
12	whereas	_	IN	IN	_	2	COORD	_	_
13	elevation	_	NN	NN	_	18	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	Ca2+	_	NN	NN	_	14	PMOD	_	_
16	or	_	CC	CC	_	15	CC	_	_
17	cAMP	_	NN	NN	_	15	COORD	_	_
18	had	_	VBD	VBD	_	2	COORD	_	_
19	only	_	RB	RB	_	20	AMOD	_	_
20	minor	_	JJ	JJ	_	21	NMOD	_	_
21	effects	_	NNS	NNS	_	18	OBJ	_	_
22	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	conclude	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	stimulation	_	NN	NN	_	8	SBJ	_	_
5	with	_	IN	IN	_	4	NMOD	_	_
6	mitogenic	_	JJ	JJ	_	7	NMOD	_	_
7	lectins	_	NNS	NNS	_	5	PMOD	_	_
8	is	_	VBZ	VBZ	_	3	VMOD	_	_
9	sufficient	_	JJ	JJ	_	8	PRD	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	increase	_	VB	VB	_	9	AMOD	_	_
12	both	_	CC	CC	_	13	CC	_	_
13	c-Fos	_	NN	NN	_	17	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	c-Jun	_	NN	NN	_	13	COORD	_	_
16	protein	_	NN	NN	_	17	NMOD	_	_
17	levels	_	NNS	NNS	_	11	OBJ	_	_
18	,	_	,	,	_	17	P	_	_
19	AP-1	_	NN	NN	_	20	NMOD	_	_
20	binding	_	NN	NN	_	17	COORD	_	_
21	and	_	CC	CC	_	17	CC	_	_
22	AP-1	_	NN	NN	_	24	NMOD	_	_
23	enhancer	_	NN	NN	_	24	NMOD	_	_
24	activity	_	NN	NN	_	17	COORD	_	_
25	in	_	IN	IN	_	17	NMOD	_	_
26	Jurkat	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	and	_	CC	CC	_	3	CC	_	_
29	that	_	IN	IN	_	3	COORD	_	_
30	they	_	PRP	PRP	_	31	SBJ	_	_
31	act	_	VBP	VBP	_	29	VMOD	_	_
32	via	_	IN	IN	_	31	ADV	_	_
33	mechanisms	_	NNS	NNS	_	32	PMOD	_	_
34	that	_	WDT	WDT	_	35	SBJ	_	_
35	could	_	MD	MD	_	33	NMOD	_	_
36	involve	_	VB	VB	_	35	VC	_	_
37	the	_	DT	DT	_	38	NMOD	_	_
38	activation	_	NN	NN	_	36	OBJ	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	PKC	_	NN	NN	_	39	PMOD	_	_
41	.	_	.	.	_	2	P	_	_

1	Functional	_	JJ	JJ	_	2	NMOD	_	_
2	interaction	_	NN	NN	_	0	ROOT-FRAG	_	_
3	between	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	two	_	CD	CD	_	8	NMOD	_	_
6	zinc	_	NN	NN	_	8	NMOD	_	_
7	finger	_	NN	NN	_	8	NMOD	_	_
8	domains	_	NNS	NNS	_	3	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	v-erb	_	NN	NN	_	13	NMOD	_	_
12	A	_	NN	NN	_	13	NMOD	_	_
13	oncoprotein	_	NN	NN	_	9	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	v-erb	_	NN	NN	_	4	NMOD	_	_
3	A	_	NN	NN	_	4	NMOD	_	_
4	oncogene	_	NN	NN	_	9	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	avian	_	JJ	JJ	_	8	NMOD	_	_
7	erythroblastosis	_	NN	NN	_	8	NMOD	_	_
8	virus	_	NN	NN	_	5	PMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	a	_	DT	DT	_	15	NMOD	_	_
11	mutated	_	VBN	VBN	_	15	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	virally	_	RB	RB	_	14	AMOD	_	_
14	transduced	_	VBN	VBN	_	11	COORD	_	_
15	copy	_	NN	NN	_	9	PRD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	a	_	DT	DT	_	20	NMOD	_	_
18	host	_	NN	NN	_	20	NMOD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	gene	_	NN	NN	_	16	PMOD	_	_
21	encoding	_	VBG	VBG	_	20	NMOD	_	_
22	a	_	DT	DT	_	25	NMOD	_	_
23	thyroid	_	NN	NN	_	25	NMOD	_	_
24	hormone	_	NN	NN	_	25	NMOD	_	_
25	receptor	_	NN	NN	_	21	OBJ	_	_
26	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	protein	_	NN	NN	_	9	SBJ	_	_
3	expressed	_	VBN	VBN	_	2	NMOD	_	_
4	by	_	IN	IN	_	3	LGS	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	v-erb	_	NN	NN	_	8	NMOD	_	_
7	A	_	NN	NN	_	8	NMOD	_	_
8	oncogene	_	NN	NN	_	4	PMOD	_	_
9	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	DNA	_	NN	NN	_	10	PMOD	_	_
12	and	_	CC	CC	_	9	CC	_	_
13	acts	_	VBZ	VBZ	_	9	COORD	_	_
14	as	_	IN	IN	_	13	ADV	_	_
15	a	_	DT	DT	_	18	NMOD	_	_
16	dominant	_	JJ	JJ	_	18	NMOD	_	_
17	negative	_	JJ	JJ	_	18	NMOD	_	_
18	inhibitor	_	NN	NN	_	14	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	both	_	CC	CC	_	24	CC	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	thyroid	_	NN	NN	_	24	NMOD	_	_
23	hormone	_	NN	NN	_	24	NMOD	_	_
24	receptor	_	NN	NN	_	19	PMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	the	_	DT	DT	_	31	NMOD	_	_
27	closely	_	RB	RB	_	28	AMOD	_	_
28	related	_	JJ	JJ	_	31	NMOD	_	_
29	retinoic	_	JJ	JJ	_	31	NMOD	_	_
30	acid	_	NN	NN	_	31	NMOD	_	_
31	receptor	_	NN	NN	_	24	COORD	_	_
32	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	v-erb	_	NN	NN	_	4	NMOD	_	_
3	A	_	NN	NN	_	4	NMOD	_	_
4	protein	_	NN	NN	_	5	SBJ	_	_
5	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	sustained	_	VBN	VBN	_	5	VC	_	_
7	two	_	CD	CD	_	10	NMOD	_	_
8	amino	_	NN	NN	_	10	NMOD	_	_
9	acid	_	NN	NN	_	10	NMOD	_	_
10	alterations	_	NNS	NNS	_	6	OBJ	_	_
11	within	_	IN	IN	_	6	ADV	_	_
12	its	_	PRP$	PRP$	_	14	NMOD	_	_
13	DNA-binding	_	JJ	JJ	_	14	NMOD	_	_
14	domain	_	NN	NN	_	11	PMOD	_	_
15	relative	_	JJ	JJ	_	16	DEP	_	_
16	to	_	TO	TO	_	6	ADV	_	_
17	that	_	DT	DT	_	16	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	c-erb	_	NN	NN	_	20	NMOD	_	_
20	A	_	NN	NN	_	18	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	one	_	CD	CD	_	23	NMOD	_	_
23	of	_	IN	IN	_	30	SBJ	_	_
24	which	_	WDT	WDT	_	23	PMOD	_	_
25	,	_	,	,	_	23	P	_	_
26	at	_	IN	IN	_	23	NMOD	_	_
27	serine	_	NN	NN	_	26	PMOD	_	_
28	61	_	CD	CD	_	27	NMOD	_	_
29	,	_	,	,	_	30	P	_	_
30	is	_	VBZ	VBZ	_	20	NMOD	_	_
31	known	_	VBN	VBN	_	30	VC	_	_
32	to	_	TO	TO	_	33	VMOD	_	_
33	be	_	VB	VB	_	31	OBJ	_	_
34	important	_	JJ	JJ	_	33	PRD	_	_
35	for	_	IN	IN	_	34	AMOD	_	_
36	v-erb	_	NN	NN	_	38	NMOD	_	_
37	A	_	NN	NN	_	38	NMOD	_	_
38	function	_	NN	NN	_	35	PMOD	_	_
39	in	_	IN	IN	_	38	NMOD	_	_
40	the	_	DT	DT	_	42	NMOD	_	_
41	neoplastic	_	JJ	JJ	_	42	NMOD	_	_
42	cell	_	NN	NN	_	39	PMOD	_	_
43	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	that	_	IN	IN	_	2	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	second	_	JJ	JJ	_	7	NMOD	_	_
7	alteration	_	NN	NN	_	14	SBJ	_	_
8	,	_	,	,	_	7	P	_	_
9	at	_	IN	IN	_	7	NMOD	_	_
10	threonine	_	NN	NN	_	9	PMOD	_	_
11	78	_	CD	CD	_	10	NMOD	_	_
12	,	_	,	,	_	7	P	_	_
13	also	_	RB	RB	_	14	ADV	_	_
14	plays	_	VBZ	VBZ	_	4	VMOD	_	_
15	an	_	DT	DT	_	22	NMOD	_	_
16	important	_	JJ	JJ	_	22	NMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	although	_	IN	IN	_	16	COORD	_	_
19	more	_	RBR	RBR	_	20	AMOD	_	_
20	indirect	_	JJ	JJ	_	16	COORD	_	_
21	,	_	,	,	_	16	P	_	_
22	role	_	NN	NN	_	14	OBJ	_	_
23	:	_	:	:	_	2	P	_	_
24	alteration	_	NN	NN	_	39	SBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	sequence	_	NN	NN	_	25	PMOD	_	_
28	at	_	IN	IN	_	24	NMOD	_	_
29	threonine	_	NN	NN	_	28	PMOD	_	_
30	78	_	CD	CD	_	29	NMOD	_	_
31	such	_	JJ	JJ	_	32	VMOD	_	_
32	that	_	IN	IN	_	24	NMOD	_	_
33	it	_	PRP	PRP	_	34	SBJ	_	_
34	resembles	_	VBZ	VBZ	_	32	VMOD	_	_
35	that	_	DT	DT	_	34	OBJ	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	c-erb	_	NN	NN	_	38	NMOD	_	_
38	A	_	NN	NN	_	36	PMOD	_	_
39	can	_	MD	MD	_	2	VMOD	_	_
40	act	_	VB	VB	_	39	VC	_	_
41	as	_	IN	IN	_	40	ADV	_	_
42	an	_	DT	DT	_	44	NMOD	_	_
43	intragenic	_	JJ	JJ	_	44	NMOD	_	_
44	suppressor	_	NN	NN	_	41	PMOD	_	_
45	and	_	CC	CC	_	39	CC	_	_
46	can	_	MD	MD	_	39	COORD	_	_
47	partially	_	RB	RB	_	46	ADV	_	_
48	restore	_	VB	VB	_	46	VC	_	_
49	function	_	NN	NN	_	48	OBJ	_	_
50	to	_	TO	TO	_	48	ADV	_	_
51	a	_	DT	DT	_	54	NMOD	_	_
52	v-erb	_	NN	NN	_	54	NMOD	_	_
53	A	_	NN	NN	_	54	NMOD	_	_
54	protein	_	NN	NN	_	50	PMOD	_	_
55	rendered	_	VBN	VBN	_	54	NMOD	_	_
56	defective	_	JJ	JJ	_	55	OBJ	_	_
57	due	_	JJ	JJ	_	58	DEP	_	_
58	to	_	TO	TO	_	55	ADV	_	_
59	a	_	DT	DT	_	60	NMOD	_	_
60	mutation	_	NN	NN	_	58	PMOD	_	_
61	at	_	IN	IN	_	60	NMOD	_	_
62	position	_	NN	NN	_	61	PMOD	_	_
63	61	_	CD	CD	_	62	NMOD	_	_
64	.	_	.	.	_	39	P	_	_

1	Threonine	_	NN	NN	_	3	SBJ	_	_
2	78	_	CD	CD	_	1	NMOD	_	_
3	lies	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	within	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	D-box	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	v-erb	_	NN	NN	_	11	NMOD	_	_
10	A	_	NN	NN	_	11	NMOD	_	_
11	protein	_	NN	NN	_	7	PMOD	_	_
12	,	_	,	,	_	4	P	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	region	_	NN	NN	_	4	PMOD	_	_
15	thought	_	VBN	VBN	_	14	NMOD	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	mediate	_	VB	VB	_	15	OBJ	_	_
18	receptor-receptor	_	JJ	JJ	_	19	NMOD	_	_
19	dimerizations	_	NNS	NNS	_	17	OBJ	_	_
20	,	_	,	,	_	3	P	_	_
21	and	_	CC	CC	_	3	CC	_	_
22	is	_	VBZ	VBZ	_	3	COORD	_	_
23	not	_	RB	RB	_	22	VMOD	_	_
24	in	_	IN	IN	_	22	PRD	_	_
25	physical	_	JJ	JJ	_	26	NMOD	_	_
26	proximity	_	NN	NN	_	24	PMOD	_	_
27	to	_	TO	TO	_	26	NMOD	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	serine	_	NN	NN	_	27	PMOD	_	_
30	at	_	IN	IN	_	29	NMOD	_	_
31	position	_	NN	NN	_	30	PMOD	_	_
32	61	_	CD	CD	_	31	NMOD	_	_
33	.	_	.	.	_	3	P	_	_

1	It	_	PRP	PRP	_	3	SBJ	_	_
2	therefore	_	RB	RB	_	3	ADV	_	_
3	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	an	_	DT	DT	_	7	NMOD	_	_
6	indirect	_	JJ	JJ	_	7	NMOD	_	_
7	interaction	_	NN	NN	_	8	SBJ	_	_
8	occurs	_	VBZ	VBZ	_	4	VMOD	_	_
9	between	_	IN	IN	_	8	ADV	_	_
10	these	_	DT	DT	_	12	NMOD	_	_
11	two	_	CD	CD	_	12	NMOD	_	_
12	sites	_	NNS	NNS	_	9	PMOD	_	_
13	and	_	CC	CC	_	4	CC	_	_
14	that	_	IN	IN	_	4	COORD	_	_
15	this	_	DT	DT	_	16	NMOD	_	_
16	interaction	_	NN	NN	_	17	SBJ	_	_
17	is	_	VBZ	VBZ	_	14	VMOD	_	_
18	crucial	_	JJ	JJ	_	17	PRD	_	_
19	for	_	IN	IN	_	18	AMOD	_	_
20	v-erb	_	NN	NN	_	22	NMOD	_	_
21	A	_	NN	NN	_	22	NMOD	_	_
22	function	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	Okadaic	_	JJ	JJ	_	2	NMOD	_	_
2	acid	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	potent	_	JJ	JJ	_	6	NMOD	_	_
6	inducer	_	NN	NN	_	3	PRD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	AP-1	_	NN	NN	_	7	PMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	NF-kappa	_	NN	NN	_	11	NMOD	_	_
11	B	_	NN	NN	_	8	COORD	_	_
12	,	_	,	,	_	8	P	_	_
13	and	_	CC	CC	_	8	CC	_	_
14	tumor	_	NN	NN	_	16	NMOD	_	_
15	necrosis	_	NN	NN	_	16	NMOD	_	_
16	factor-alpha	_	NN	NN	_	8	COORD	_	_
17	in	_	IN	IN	_	8	NMOD	_	_
18	human	_	JJ	JJ	_	20	NMOD	_	_
19	B	_	NN	NN	_	20	NMOD	_	_
20	lymphocytes	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	Treatment	_	NN	NN	_	22	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	human	_	JJ	JJ	_	5	NMOD	_	_
4	B	_	NN	NN	_	5	NMOD	_	_
5	lymphocytes	_	NNS	NNS	_	2	PMOD	_	_
6	with	_	IN	IN	_	1	NMOD	_	_
7	an	_	DT	DT	_	9	NMOD	_	_
8	optimal	_	JJ	JJ	_	9	NMOD	_	_
9	concentration	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	okadaic	_	JJ	JJ	_	12	NMOD	_	_
12	acid	_	NN	NN	_	10	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	an	_	DT	DT	_	15	NMOD	_	_
15	inhibitor	_	NN	NN	_	12	NMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	phosphatases	_	NNS	NNS	_	16	PMOD	_	_
18	1	_	CD	CD	_	17	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	2A	_	NN	NN	_	18	COORD	_	_
21	,	_	,	,	_	12	P	_	_
22	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
23	in	_	IN	IN	_	22	ADV	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	induction	_	NN	NN	_	23	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	transcription	_	NN	NN	_	29	NMOD	_	_
29	factor	_	NN	NN	_	26	PMOD	_	_
30	,	_	,	,	_	29	P	_	_
31	AP-1	_	NN	NN	_	29	NMOD	_	_
32	and	_	CC	CC	_	25	CC	_	_
33	a	_	DT	DT	_	35	NMOD	_	_
34	marked	_	JJ	JJ	_	35	NMOD	_	_
35	increase	_	NN	NN	_	25	COORD	_	_
36	in	_	IN	IN	_	35	NMOD	_	_
37	NF-kappa	_	NN	NN	_	39	NMOD	_	_
38	B	_	NN	NN	_	39	NMOD	_	_
39	levels	_	NNS	NNS	_	36	PMOD	_	_
40	.	_	.	.	_	22	P	_	_

1	In	_	IN	IN	_	19	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	19	P	_	_
4	no	_	DT	DT	_	5	NMOD	_	_
5	effect	_	NN	NN	_	19	SBJ	_	_
6	on	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	levels	_	NNS	NNS	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	octamer	_	NN	NN	_	13	NMOD	_	_
12	binding	_	NN	NN	_	13	NMOD	_	_
13	proteins	_	NNS	NNS	_	9	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	Oct-1	_	NN	NN	_	13	NMOD	_	_
16	or	_	CC	CC	_	15	CC	_	_
17	Oct-2	_	NN	NN	_	15	COORD	_	_
18	,	_	,	,	_	13	P	_	_
19	were	_	VBD	VBD	_	0	ROOT-S	_	_
20	found	_	VBN	VBN	_	19	VC	_	_
21	.	_	.	.	_	19	P	_	_

1	Since	_	IN	IN	_	26	ADV	_	_
2	both	_	CC	CC	_	3	CC	_	_
3	AP-1	_	NN	NN	_	7	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	NF-kappa	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	3	COORD	_	_
7	have	_	VBP	VBP	_	1	VMOD	_	_
8	been	_	VBN	VBN	_	7	VC	_	_
9	reported	_	VBN	VBN	_	8	VC	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	be	_	VB	VB	_	9	OBJ	_	_
12	important	_	JJ	JJ	_	11	PRD	_	_
13	in	_	IN	IN	_	12	AMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	induction	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	24	NMOD	_	_
18	tumor	_	NN	NN	_	20	NMOD	_	_
19	necrosis	_	NN	NN	_	20	NMOD	_	_
20	factor-alpha	_	NN	NN	_	24	NMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	TNF-alpha	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	gene	_	NN	NN	_	16	PMOD	_	_
25	we	_	PRP	PRP	_	26	SBJ	_	_
26	examined	_	VBD	VBD	_	0	ROOT-S	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	effects	_	NNS	NNS	_	26	OBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	okadaic	_	JJ	JJ	_	31	NMOD	_	_
31	acid	_	NN	NN	_	29	PMOD	_	_
32	on	_	IN	IN	_	28	NMOD	_	_
33	TNF-alpha	_	NN	NN	_	35	NMOD	_	_
34	mRNA	_	NN	NN	_	35	NMOD	_	_
35	levels	_	NNS	NNS	_	32	PMOD	_	_
36	.	_	.	.	_	26	P	_	_

1	Treatment	_	NN	NN	_	5	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	okadaic	_	JJ	JJ	_	4	NMOD	_	_
4	acid	_	NN	NN	_	2	PMOD	_	_
5	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	striking	_	JJ	JJ	_	9	NMOD	_	_
9	increase	_	NN	NN	_	6	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	TNF-alpha	_	NN	NN	_	13	NMOD	_	_
12	mRNA	_	NN	NN	_	13	NMOD	_	_
13	transcripts	_	NNS	NNS	_	10	PMOD	_	_
14	within	_	IN	IN	_	5	TMP	_	_
15	1	_	CD	CD	_	16	NMOD	_	_
16	h	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	stimulation	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	5	CC	_	_
20	large	_	JJ	JJ	_	21	NMOD	_	_
21	amounts	_	NNS	NNS	_	24	SBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	TNF-alpha	_	NN	NN	_	22	PMOD	_	_
24	were	_	VBD	VBD	_	5	COORD	_	_
25	released	_	VBN	VBN	_	24	VC	_	_
26	into	_	IN	IN	_	25	ADV	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	culture	_	NN	NN	_	29	NMOD	_	_
29	media	_	NNS	NNS	_	26	PMOD	_	_
30	.	_	.	.	_	5	P	_	_

1	Although	_	IN	IN	_	15	ADV	_	_
2	okadaic	_	JJ	JJ	_	3	NMOD	_	_
3	acid	_	NN	NN	_	4	SBJ	_	_
4	provides	_	VBZ	VBZ	_	1	VMOD	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	potent	_	JJ	JJ	_	8	NMOD	_	_
7	inductive	_	JJ	JJ	_	8	NMOD	_	_
8	signal	_	NN	NN	_	4	OBJ	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	AP-1	_	NN	NN	_	9	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	NF-kappa	_	NN	NN	_	13	NMOD	_	_
13	B	_	NN	NN	_	10	COORD	_	_
14	it	_	PRP	PRP	_	15	SBJ	_	_
15	did	_	VBD	VBD	_	0	ROOT-S	_	_
16	not	_	RB	RB	_	15	VMOD	_	_
17	induce	_	VB	VB	_	15	VC	_	_
18	either	_	CC	CC	_	21	CC	_	_
19	B	_	NN	NN	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	proliferation	_	NN	NN	_	17	OBJ	_	_
22	or	_	CC	CC	_	21	CC	_	_
23	immunoglobulin	_	NN	NN	_	24	NMOD	_	_
24	secretion	_	NN	NN	_	21	COORD	_	_
25	.	_	.	.	_	15	P	_	_

1	A	_	DT	DT	_	5	NMOD	_	_
2	novel	_	JJ	JJ	_	5	NMOD	_	_
3	Ets-related	_	JJ	JJ	_	5	NMOD	_	_
4	transcription	_	NN	NN	_	5	NMOD	_	_
5	factor	_	NN	NN	_	9	SBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	Elf-1	_	NN	NN	_	5	NMOD	_	_
8	,	_	,	,	_	5	P	_	_
9	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	human	_	JJ	JJ	_	17	NMOD	_	_
12	immunodeficiency	_	NN	NN	_	17	NMOD	_	_
13	virus	_	NN	NN	_	17	NMOD	_	_
14	type	_	NN	NN	_	17	NMOD	_	_
15	2	_	CD	CD	_	17	NMOD	_	_
16	regulatory	_	JJ	JJ	_	17	NMOD	_	_
17	elements	_	NNS	NNS	_	10	PMOD	_	_
18	that	_	WDT	WDT	_	19	SBJ	_	_
19	are	_	VBP	VBP	_	17	NMOD	_	_
20	required	_	VBN	VBN	_	19	VC	_	_
21	for	_	IN	IN	_	20	ADV	_	_
22	inducible	_	JJ	JJ	_	24	NMOD	_	_
23	trans	_	JJ	JJ	_	24	NMOD	_	_
24	activation	_	NN	NN	_	21	PMOD	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	T	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	9	P	_	_

1	Human	_	JJ	JJ	_	4	NMOD	_	_
2	immunodeficiency	_	NN	NN	_	4	NMOD	_	_
3	virus	_	NN	NN	_	4	NMOD	_	_
4	type	_	NN	NN	_	11	SBJ	_	_
5	1	_	CD	CD	_	4	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	HIV-1	_	NN	NN	_	4	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	and	_	CC	CC	_	4	CC	_	_
10	HIV-2	_	NN	NN	_	4	COORD	_	_
11	are	_	VBP	VBP	_	0	ROOT-S	_	_
12	structurally	_	RB	RB	_	13	AMOD	_	_
13	related	_	JJ	JJ	_	14	NMOD	_	_
14	retroviruses	_	NNS	NNS	_	11	PRD	_	_
15	which	_	WDT	WDT	_	17	SBJ	_	_
16	both	_	DT	DT	_	17	VMOD	_	_
17	cause	_	VBP	VBP	_	14	NMOD	_	_
18	AIDS	_	NN	NN	_	17	OBJ	_	_
19	in	_	IN	IN	_	17	ADV	_	_
20	humans	_	NNS	NNS	_	19	PMOD	_	_
21	.	_	.	.	_	11	P	_	_

1	Although	_	IN	IN	_	18	ADV	_	_
2	both	_	DT	DT	_	3	NMOD	_	_
3	viruses	_	NNS	NNS	_	4	SBJ	_	_
4	establish	_	VBP	VBP	_	1	VMOD	_	_
5	latency	_	NN	NN	_	4	OBJ	_	_
6	in	_	IN	IN	_	4	ADV	_	_
7	quiescent	_	JJ	JJ	_	10	NMOD	_	_
8	human-peripheral-blood	_	JJ	JJ	_	10	NMOD	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	6	PMOD	_	_
11	,	_	,	,	_	18	P	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	asymptomatic	_	JJ	JJ	_	14	NMOD	_	_
14	phase	_	NN	NN	_	18	SBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	HIV-2	_	NN	NN	_	17	NMOD	_	_
17	infection	_	NN	NN	_	15	PMOD	_	_
18	may	_	MD	MD	_	0	ROOT-S	_	_
19	be	_	VB	VB	_	18	VC	_	_
20	more	_	JJR	JJR	_	21	AMOD	_	_
21	prolonged	_	JJ	JJ	_	19	PRD	_	_
22	than	_	IN	IN	_	21	AMOD	_	_
23	that	_	DT	DT	_	22	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	HIV-1	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	18	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	latent	_	JJ	JJ	_	3	NMOD	_	_
3	phases	_	NNS	NNS	_	10	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	both	_	CC	CC	_	6	CC	_	_
6	HIV-1	_	NN	NN	_	9	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	HIV-2	_	NN	NN	_	6	COORD	_	_
9	infection	_	NN	NN	_	4	PMOD	_	_
10	have	_	VBP	VBP	_	0	ROOT-S	_	_
11	been	_	VBN	VBN	_	10	VC	_	_
12	shown	_	VBN	VBN	_	11	VC	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	be	_	VB	VB	_	12	OBJ	_	_
15	disrupted	_	VBN	VBN	_	14	VC	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	T-cell	_	NN	NN	_	18	NMOD	_	_
18	activation	_	NN	NN	_	16	PMOD	_	_
19	,	_	,	,	_	15	P	_	_
20	a	_	DT	DT	_	21	NMOD	_	_
21	process	_	NN	NN	_	15	OBJ	_	_
22	that	_	WDT	WDT	_	23	SBJ	_	_
23	requires	_	VBZ	VBZ	_	21	NMOD	_	_
24	host	_	NN	NN	_	27	NMOD	_	_
25	cell	_	NN	NN	_	27	NMOD	_	_
26	transcription	_	NN	NN	_	27	NMOD	_	_
27	factors	_	NNS	NNS	_	23	OBJ	_	_
28	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	case	_	NN	NN	_	1	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	HIV-1	_	NN	NN	_	4	PMOD	_	_
6	,	_	,	,	_	12	P	_	_
7	the	_	DT	DT	_	11	NMOD	_	_
8	transcription	_	NN	NN	_	11	NMOD	_	_
9	factor	_	NN	NN	_	11	NMOD	_	_
10	NF-kappa	_	NN	NN	_	11	NMOD	_	_
11	B	_	NN	NN	_	12	SBJ	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	sufficient	_	JJ	JJ	_	12	PRD	_	_
14	for	_	IN	IN	_	13	AMOD	_	_
15	inducible	_	JJ	JJ	_	17	NMOD	_	_
16	transcriptional	_	JJ	JJ	_	17	NMOD	_	_
17	activation	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	12	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	10	P	_	_
4	factors	_	NNS	NNS	_	10	SBJ	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	addition	_	NN	NN	_	5	DEP	_	_
7	to	_	TO	TO	_	5	DEP	_	_
8	NF-kappa	_	NN	NN	_	9	NMOD	_	_
9	B	_	NN	NN	_	5	PMOD	_	_
10	are	_	VBP	VBP	_	0	ROOT-S	_	_
11	required	_	VBN	VBN	_	10	VC	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	activate	_	VB	VB	_	11	OBJ	_	_
14	HIV-2	_	NN	NN	_	15	NMOD	_	_
15	transcription	_	NN	NN	_	13	OBJ	_	_
16	in	_	IN	IN	_	13	ADV	_	_
17	infected	_	JJ	JJ	_	19	NMOD	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	a	_	DT	DT	_	12	NMOD	_	_
9	novel	_	JJ	JJ	_	12	NMOD	_	_
10	Ets-related	_	JJ	JJ	_	12	NMOD	_	_
11	transcription	_	NN	NN	_	12	NMOD	_	_
12	factor	_	NN	NN	_	16	SBJ	_	_
13	,	_	,	,	_	12	P	_	_
14	Elf-1	_	NN	NN	_	12	NMOD	_	_
15	,	_	,	,	_	12	P	_	_
16	binds	_	VBZ	VBZ	_	7	VMOD	_	_
17	specifically	_	RB	RB	_	16	ADV	_	_
18	to	_	TO	TO	_	16	ADV	_	_
19	two	_	CD	CD	_	21	NMOD	_	_
20	purine-rich	_	JJ	JJ	_	21	NMOD	_	_
21	motifs	_	NNS	NNS	_	18	PMOD	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	HIV-2	_	NN	NN	_	25	NMOD	_	_
25	enhancer	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	6	P	_	_

1	Mutagenesis	_	NN	NN	_	2	NMOD	_	_
2	experiments	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	these	_	DT	DT	_	8	NMOD	_	_
6	Elf-1	_	NN	NN	_	8	NMOD	_	_
7	binding	_	NN	NN	_	8	NMOD	_	_
8	sites	_	NNS	NNS	_	9	SBJ	_	_
9	are	_	VBP	VBP	_	4	VMOD	_	_
10	required	_	VBN	VBN	_	9	VC	_	_
11	for	_	IN	IN	_	10	ADV	_	_
12	induction	_	NN	NN	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	HIV-2	_	NN	NN	_	15	NMOD	_	_
15	transcription	_	NN	NN	_	13	PMOD	_	_
16	following	_	VBG	VBG	_	12	TMP	_	_
17	T-cell-receptor-mediated	_	JJ	JJ	_	19	NMOD	_	_
18	T-cell	_	NN	NN	_	19	NMOD	_	_
19	activation	_	NN	NN	_	16	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Moreover	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	Elf-1	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	only	_	JJ	JJ	_	7	NMOD	_	_
7	factor	_	NN	NN	_	4	PRD	_	_
8	present	_	JJ	JJ	_	7	NMOD	_	_
9	in	_	IN	IN	_	8	AMOD	_	_
10	activated	_	VBN	VBN	_	13	NMOD	_	_
11	T-cell	_	NN	NN	_	13	NMOD	_	_
12	nuclear	_	JJ	JJ	_	13	NMOD	_	_
13	extracts	_	NNS	NNS	_	9	PMOD	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	binds	_	VBZ	VBZ	_	13	NMOD	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	these	_	DT	DT	_	18	NMOD	_	_
18	sites	_	NNS	NNS	_	16	PMOD	_	_
19	in	_	IN	IN	_	15	ADV	_	_
20	electrophoretic	_	JJ	JJ	_	23	NMOD	_	_
21	mobility	_	NN	NN	_	23	NMOD	_	_
22	shift	_	NN	NN	_	23	NMOD	_	_
23	assays	_	NNS	NNS	_	19	PMOD	_	_
24	.	_	.	.	_	4	P	_	_

1	Thus	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	Elf-1	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	novel	_	JJ	JJ	_	8	NMOD	_	_
7	transcription	_	NN	NN	_	8	NMOD	_	_
8	factor	_	NN	NN	_	4	PRD	_	_
9	that	_	WDT	WDT	_	10	SBJ	_	_
10	appears	_	VBZ	VBZ	_	8	NMOD	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	be	_	VB	VB	_	10	OBJ	_	_
13	required	_	VBN	VBN	_	12	VC	_	_
14	for	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	T-cell-receptor-mediated	_	JJ	JJ	_	18	NMOD	_	_
17	trans	_	JJ	JJ	_	18	NMOD	_	_
18	activation	_	NN	NN	_	14	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	HIV-2	_	NN	NN	_	22	NMOD	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	expression	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	may	_	MD	MD	_	0	ROOT-S	_	_
4	explain	_	VB	VB	_	3	VC	_	_
5	differences	_	NNS	NNS	_	4	OBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	clinical	_	JJ	JJ	_	9	NMOD	_	_
9	spectra	_	NNS	NNS	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	diseases	_	NNS	NNS	_	10	PMOD	_	_
12	caused	_	VBN	VBN	_	11	NMOD	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	HIV-1	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	HIV-2	_	NN	NN	_	14	COORD	_	_
17	and	_	CC	CC	_	3	CC	_	_
18	may	_	MD	MD	_	3	COORD	_	_
19	also	_	RB	RB	_	18	ADV	_	_
20	have	_	VB	VB	_	18	VC	_	_
21	implications	_	NNS	NNS	_	20	OBJ	_	_
22	for	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	design	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	therapeutic	_	JJ	JJ	_	27	NMOD	_	_
27	approaches	_	NNS	NNS	_	25	PMOD	_	_
28	to	_	TO	TO	_	27	NMOD	_	_
29	HIV-2	_	NN	NN	_	30	NMOD	_	_
30	infection	_	NN	NN	_	28	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	{	_	(	(	_	2	P	_	_
2	Effect	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	antihypertensive	_	JJ	JJ	_	5	NMOD	_	_
5	therapy	_	NN	NN	_	3	PMOD	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	captopril	_	NN	NN	_	6	PMOD	_	_
8	on	_	IN	IN	_	2	NMOD	_	_
9	gluco-	_	JJ	JJ	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	mineralocorticoid	_	NN	NN	_	9	COORD	_	_
12	receptors	_	NNS	NNS	_	8	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	peripheral	_	JJ	JJ	_	16	NMOD	_	_
15	blood	_	NN	NN	_	16	NMOD	_	_
16	lymphocytes	_	NNS	NNS	_	13	PMOD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	hypertensive	_	JJ	JJ	_	19	NMOD	_	_
19	patients	_	NNS	NNS	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	various	_	JJ	JJ	_	22	NMOD	_	_
22	age	_	NN	NN	_	20	PMOD	_	_
23	}	_	)	)	_	2	P	_	_

1	Binding	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	3H-dexamethasone	_	NN	NN	_	2	PMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	3H-aldosterone	_	NN	NN	_	3	COORD	_	_
6	by	_	IN	IN	_	1	NMOD	_	_
7	peripheral	_	JJ	JJ	_	9	NMOD	_	_
8	lymphocyte	_	NN	NN	_	9	NMOD	_	_
9	receptors	_	NNS	NNS	_	6	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	investigated	_	VBN	VBN	_	10	VC	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	healthy	_	JJ	JJ	_	14	NMOD	_	_
14	persons	_	NNS	NNS	_	12	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	hypertensive	_	JJ	JJ	_	17	NMOD	_	_
17	patients	_	NNS	NNS	_	14	COORD	_	_
18	before	_	IN	IN	_	11	TMP	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	after	_	IN	IN	_	18	COORD	_	_
21	2-week	_	JJ	JJ	_	23	NMOD	_	_
22	captopril	_	NN	NN	_	23	NMOD	_	_
23	treatment	_	NN	NN	_	18	PMOD	_	_
24	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	number	_	NN	NN	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	glucocorticoid	_	NN	NN	_	8	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	mineralocorticoid	_	NN	NN	_	4	COORD	_	_
7	binding	_	NN	NN	_	8	NMOD	_	_
8	sites	_	NNS	NNS	_	3	PMOD	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	increased	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	hypertensives	_	NNS	NNS	_	11	PMOD	_	_
13	vs	_	CC	CC	_	12	CC	_	_
14	normotensives	_	NNS	NNS	_	12	COORD	_	_
15	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	treatment	_	NN	NN	_	8	SBJ	_	_
3	with	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	ACE	_	NN	NN	_	7	NMOD	_	_
6	inhibitor	_	NN	NN	_	7	NMOD	_	_
7	captopril	_	NN	NN	_	3	PMOD	_	_
8	led	_	VBD	VBD	_	0	ROOT-S	_	_
9	to	_	TO	TO	_	8	ADV	_	_
10	activation	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	hormone-receptor	_	NN	NN	_	13	NMOD	_	_
13	interactions	_	NNS	NNS	_	11	PMOD	_	_
14	.	_	.	.	_	8	P	_	_

1	There	_	EX	EX	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	more	_	RBR	RBR	_	5	AMOD	_	_
5	marked	_	JJ	JJ	_	6	NMOD	_	_
6	rise	_	NN	NN	_	2	PRD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	number	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	receptors	_	NNS	NNS	_	10	PMOD	_	_
12	in	_	IN	IN	_	6	NMOD	_	_
13	middle-aged	_	JJ	JJ	_	18	NMOD	_	_
14	(	_	(	(	_	16	P	_	_
15	44-55	_	CD	CD	_	16	NMOD	_	_
16	years	_	NNS	NNS	_	13	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	hypertensives	_	NNS	NNS	_	12	PMOD	_	_
19	vs	_	CC	CC	_	18	CC	_	_
20	elderly	_	JJ	JJ	_	25	NMOD	_	_
21	(	_	(	(	_	23	P	_	_
22	61-80	_	CD	CD	_	23	NMOD	_	_
23	years	_	NNS	NNS	_	20	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	subjects	_	NNS	NNS	_	18	COORD	_	_
26	after	_	IN	IN	_	2	TMP	_	_
27	captopril	_	NN	NN	_	28	NMOD	_	_
28	treatment	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	2	P	_	_

1	Leukotriene	_	NN	NN	_	2	NMOD	_	_
2	B4	_	NN	NN	_	4	SBJ	_	_
3	transcriptionally	_	RB	RB	_	4	ADV	_	_
4	activates	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	interleukin-6	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	4	OBJ	_	_
7	involving	_	VBG	VBG	_	6	NMOD	_	_
8	NK-chi	_	NN	NN	_	9	NMOD	_	_
9	B	_	NN	NN	_	7	OBJ	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	NF-IL6	_	NN	NN	_	9	COORD	_	_
12	.	_	.	.	_	4	P	_	_

1	Leukotriene	_	NN	NN	_	2	NMOD	_	_
2	B4	_	NN	NN	_	6	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	LTB4	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	notable	_	JJ	JJ	_	9	NMOD	_	_
9	participant	_	NN	NN	_	6	PRD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	inflammation	_	NN	NN	_	10	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	chemotaxis	_	NN	NN	_	11	COORD	_	_
14	.	_	.	.	_	6	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	,	_	,	,	_	2	P	_	_
4	however	_	RB	RB	_	2	ADV	_	_
5	,	_	,	,	_	2	P	_	_
6	still	_	RB	RB	_	7	AMOD	_	_
7	unclear	_	JJ	JJ	_	2	PRD	_	_
8	whether	_	IN	IN	_	2	EXP	_	_
9	LTB4	_	NN	NN	_	10	SBJ	_	_
10	acts	_	VBZ	VBZ	_	8	VMOD	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	this	_	DT	DT	_	13	NMOD	_	_
13	regard	_	NN	NN	_	11	PMOD	_	_
14	directly	_	RB	RB	_	10	ADV	_	_
15	or	_	CC	CC	_	14	CC	_	_
16	indirectly	_	RB	RB	_	14	COORD	_	_
17	by	_	IN	IN	_	10	ADV	_	_
18	stimulating	_	VBG	VBG	_	17	PMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	release	_	NN	NN	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	chemotactic	_	JJ	JJ	_	25	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	inflammatory	_	JJ	JJ	_	22	COORD	_	_
25	cytokines	_	NNS	NNS	_	21	PMOD	_	_
26	.	_	.	.	_	2	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	report	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	LTB4	_	NN	NN	_	6	SBJ	_	_
6	induces	_	VBZ	VBZ	_	4	VMOD	_	_
7	synthesis	_	NN	NN	_	6	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	interleukin	_	NN	NN	_	8	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	IL	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	-6	_	CD	CD	_	9	NMOD	_	_
14	by	_	IN	IN	_	7	NMOD	_	_
15	human	_	JJ	JJ	_	17	NMOD	_	_
16	blood	_	NN	NN	_	17	NMOD	_	_
17	monocytes	_	NNS	NNS	_	14	PMOD	_	_
18	through	_	IN	IN	_	6	ADV	_	_
19	transcriptional	_	JJ	JJ	_	20	NMOD	_	_
20	activation	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	IL-6	_	NN	NN	_	24	NMOD	_	_
24	gene	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	furthermore	_	RB	RB	_	3	ADV	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	this	_	DT	DT	_	6	NMOD	_	_
6	process	_	NN	NN	_	7	SBJ	_	_
7	involves	_	VBZ	VBZ	_	4	VMOD	_	_
8	activation	_	NN	NN	_	7	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	transcription	_	NN	NN	_	14	NMOD	_	_
12	factor	_	NN	NN	_	14	NMOD	_	_
13	NF-chi	_	NN	NN	_	14	NMOD	_	_
14	B	_	NN	NN	_	9	PMOD	_	_
15	and	_	CC	CC	_	7	CC	_	_
16	,	_	,	,	_	7	P	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	lesser	_	JJR	JJR	_	20	NMOD	_	_
20	extent	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	16	P	_	_
22	of	_	IN	IN	_	9	GAP	_	_
23	NF-IL6	_	NN	NN	_	22	PMOD	_	_
24	,	_	,	,	_	7	P	_	_
25	while	_	IN	IN	_	7	OBJ	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	activity	_	NN	NN	_	25	SBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	32	NMOD	_	_
30	transcription	_	NN	NN	_	32	NMOD	_	_
31	factor	_	NN	NN	_	32	NMOD	_	_
32	AP-1	_	NN	NN	_	28	PMOD	_	_
33	,	_	,	,	_	27	P	_	_
34	shown	_	VBN	VBN	_	27	NMOD	_	_
35	to	_	TO	TO	_	37	VMOD	_	_
36	otherwise	_	RB	RB	_	37	ADV	_	_
37	confer	_	VB	VB	_	34	OBJ	_	_
38	IL-6	_	NN	NN	_	39	NMOD	_	_
39	inducibility	_	NN	NN	_	37	OBJ	_	_
40	,	_	,	,	_	27	P	_	_
41	appeared	_	VBD	VBD	_	25	VMOD	_	_
42	to	_	TO	TO	_	43	VMOD	_	_
43	be	_	VB	VB	_	41	OBJ	_	_
44	unaffected	_	JJ	JJ	_	43	VC	_	_
45	by	_	IN	IN	_	44	LGS	_	_
46	LTB4	_	NN	NN	_	45	PMOD	_	_
47	.	_	.	.	_	3	P	_	_

1	Involvement	_	NN	NN	_	14	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	NF-chi	_	NN	NN	_	4	NMOD	_	_
4	B	_	NN	NN	_	2	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	NF-IL6	_	NN	NN	_	4	COORD	_	_
7	in	_	IN	IN	_	1	NMOD	_	_
8	induction	_	NN	NN	_	7	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	IL-6	_	NN	NN	_	11	NMOD	_	_
11	transcription	_	NN	NN	_	9	PMOD	_	_
12	by	_	IN	IN	_	8	NMOD	_	_
13	monocytes	_	NNS	NNS	_	12	PMOD	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	demonstrated	_	VBN	VBN	_	14	VC	_	_
16	using	_	VBG	VBG	_	15	OBJ	_	_
17	deleted	_	JJ	JJ	_	18	NMOD	_	_
18	forms	_	NNS	NNS	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	IL-6	_	NN	NN	_	22	NMOD	_	_
22	promoter	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	14	P	_	_

1	Activation	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	IL-6	_	NN	NN	_	5	NMOD	_	_
5	promoter	_	NN	NN	_	2	PMOD	_	_
6	by	_	IN	IN	_	1	NMOD	_	_
7	LTB4	_	NN	NN	_	6	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	CC	_	_
10	only	_	RB	RB	_	9	DEP	_	_
11	associated	_	VBN	VBN	_	8	COORD	_	_
12	with	_	IN	IN	_	11	ADV	_	_
13	accumulation	_	NN	NN	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	respective	_	JJ	JJ	_	17	NMOD	_	_
17	transcripts	_	NNS	NNS	_	14	PMOD	_	_
18	but	_	CC	CC	_	8	CC	_	_
19	resulted	_	VBD	VBD	_	8	COORD	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	synthesis	_	NN	NN	_	20	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	functional	_	JJ	JJ	_	25	NMOD	_	_
24	IL-6	_	NN	NN	_	25	NMOD	_	_
25	protein	_	NN	NN	_	22	PMOD	_	_
26	as	_	RB	RB	_	19	ADV	_	_
27	well	_	RB	RB	_	26	PMOD	_	_
28	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	LTB4	_	NN	NN	_	5	SBJ	_	_
5	mediated	_	VBD	VBD	_	0	ROOT-S	_	_
6	transactivation	_	NN	NN	_	5	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	11	NMOD	_	_
9	heterologous	_	JJ	JJ	_	11	NMOD	_	_
10	promoter	_	NN	NN	_	11	NMOD	_	_
11	construct	_	NN	NN	_	7	PMOD	_	_
12	containing	_	VBG	VBG	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	NF-chi	_	NN	NN	_	15	NMOD	_	_
15	B	_	NN	NN	_	12	OBJ	_	_
16	or	_	CC	CC	_	15	CC	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	NF-IL6	_	NN	NN	_	15	COORD	_	_
19	enhancer	_	NN	NN	_	15	NMOD	_	_
20	,	_	,	,	_	15	P	_	_
21	but	_	CC	CC	_	15	CC	_	_
22	not	_	RB	RB	_	21	COORD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	AP-1	_	NN	NN	_	25	NMOD	_	_
25	enhancer	_	NN	NN	_	15	COORD	_	_
26	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	signaling	_	NN	NN	_	3	NMOD	_	_
3	events	_	NNS	NNS	_	7	SBJ	_	_
4	mediating	_	VBG	VBG	_	3	NMOD	_	_
5	this	_	DT	DT	_	6	NMOD	_	_
6	effect	_	NN	NN	_	4	OBJ	_	_
7	appeared	_	VBD	VBD	_	0	ROOT-S	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	involve	_	VB	VB	_	7	OBJ	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	release	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	H2O2	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	9	P	_	_
15	since	_	IN	IN	_	9	ADV	_	_
16	LTB4	_	NN	NN	_	17	SBJ	_	_
17	failed	_	VBD	VBD	_	15	VMOD	_	_
18	to	_	TO	TO	_	19	VMOD	_	_
19	induce	_	VB	VB	_	17	OBJ	_	_
20	NF-chi	_	NN	NN	_	21	NMOD	_	_
21	B	_	NN	NN	_	19	OBJ	_	_
22	or	_	CC	CC	_	21	CC	_	_
23	NF-IL6	_	NN	NN	_	21	COORD	_	_
24	in	_	IN	IN	_	19	ADV	_	_
25	the	_	DT	DT	_	24	DEP	_	_
26	presence	_	NN	NN	_	24	DEP	_	_
27	of	_	IN	IN	_	24	DEP	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	scavenger	_	NN	NN	_	24	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	H2O2	_	NN	NN	_	30	PMOD	_	_
32	,	_	,	,	_	29	P	_	_
33	N-acetyl-L-cysteine	_	NN	NN	_	29	NMOD	_	_
34	.	_	.	.	_	7	P	_	_

1	Estrogen	_	NN	NN	_	3	NMOD	_	_
2	binding	_	NN	NN	_	3	NMOD	_	_
3	sites	_	NNS	NNS	_	0	ROOT-FRAG	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	peripheral	_	JJ	JJ	_	7	NMOD	_	_
6	blood	_	NN	NN	_	7	NMOD	_	_
7	monocytes	_	NNS	NNS	_	4	PMOD	_	_
8	and	_	CC	CC	_	3	CC	_	_
9	effects	_	NNS	NNS	_	3	COORD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	danazol	_	NN	NN	_	10	PMOD	_	_
12	on	_	IN	IN	_	9	NMOD	_	_
13	their	_	PRP$	PRP$	_	14	NMOD	_	_
14	sites	_	NNS	NNS	_	12	PMOD	_	_
15	in	_	FW	FW	_	14	NMOD	_	_
16	vitro	_	FW	FW	_	15	AMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	1	_	LS	LS	_	5	VMOD	_	_
2	.	_	.	.	_	1	P	_	_
3	This	_	DT	DT	_	4	NMOD	_	_
4	study	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	designed	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	investigate	_	VB	VB	_	6	OBJ	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	presence	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	estrogen	_	NN	NN	_	33	NMOD	_	_
13	type	_	NN	NN	_	33	NMOD	_	_
14	I	_	CD	CD	_	13	NMOD	_	_
15	(	_	(	(	_	13	PRN	_	_
16	high	_	JJ	JJ	_	17	NMOD	_	_
17	affinity	_	NN	NN	_	15	DEP	_	_
18	,	_	,	,	_	17	P	_	_
19	low	_	JJ	JJ	_	20	NMOD	_	_
20	capacity	_	NN	NN	_	17	NMOD	_	_
21	)	_	)	)	_	15	P	_	_
22	and	_	CC	CC	_	13	CC	_	_
23	type	_	NN	NN	_	13	COORD	_	_
24	II	_	CD	CD	_	23	NMOD	_	_
25	(	_	(	(	_	23	PRN	_	_
26	low	_	JJ	JJ	_	27	NMOD	_	_
27	affinity	_	NN	NN	_	25	DEP	_	_
28	,	_	,	,	_	27	P	_	_
29	high	_	JJ	JJ	_	30	NMOD	_	_
30	capacity	_	NN	NN	_	27	NMOD	_	_
31	)	_	)	)	_	25	P	_	_
32	binding	_	NN	NN	_	33	NMOD	_	_
33	sites	_	NNS	NNS	_	11	PMOD	_	_
34	in	_	IN	IN	_	10	NMOD	_	_
35	human	_	JJ	JJ	_	38	NMOD	_	_
36	peripheral	_	JJ	JJ	_	38	NMOD	_	_
37	blood	_	NN	NN	_	38	NMOD	_	_
38	monocytes	_	NNS	NNS	_	34	PMOD	_	_
39	and	_	CC	CC	_	10	CC	_	_
40	the	_	DT	DT	_	41	NMOD	_	_
41	effects	_	NNS	NNS	_	10	COORD	_	_
42	of	_	IN	IN	_	41	NMOD	_	_
43	danazol	_	NN	NN	_	42	PMOD	_	_
44	on	_	IN	IN	_	41	NMOD	_	_
45	these	_	DT	DT	_	46	NMOD	_	_
46	sites	_	NNS	NNS	_	44	PMOD	_	_
47	.	_	.	.	_	5	P	_	_

1	2	_	LS	LS	_	10	VMOD	_	_
2	.	_	.	.	_	1	P	_	_
3	These	_	DT	DT	_	5	NMOD	_	_
4	two	_	CD	CD	_	5	NMOD	_	_
5	types	_	NNS	NNS	_	10	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	estrogen	_	NN	NN	_	9	NMOD	_	_
8	binding	_	NN	NN	_	9	NMOD	_	_
9	sites	_	NNS	NNS	_	6	PMOD	_	_
10	existed	_	VBD	VBD	_	0	ROOT-S	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	human	_	JJ	JJ	_	15	NMOD	_	_
13	peripheral	_	JJ	JJ	_	15	NMOD	_	_
14	blood	_	NN	NN	_	15	NMOD	_	_
15	monocytes	_	NNS	NNS	_	11	PMOD	_	_
16	.	_	.	.	_	10	P	_	_

1	3	_	LS	LS	_	4	VMOD	_	_
2	.	_	.	.	_	1	P	_	_
3	Danazol	_	NN	NN	_	4	SBJ	_	_
4	bound	_	VBD	VBD	_	0	ROOT-S	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	these	_	DT	DT	_	7	NMOD	_	_
7	sites	_	NNS	NNS	_	5	PMOD	_	_
8	in	_	IN	IN	_	4	ADV	_	_
9	high	_	JJ	JJ	_	10	NMOD	_	_
10	concentration	_	NN	NN	_	8	PMOD	_	_
11	(	_	(	(	_	17	P	_	_
12	10-LRB--6-RRB-	_	CD	CD	_	13	NMOD	_	_
13	M	_	NN	NN	_	17	NMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	clinical	_	JJ	JJ	_	13	COORD	_	_
16	serum	_	NN	NN	_	17	NMOD	_	_
17	concentration	_	NN	NN	_	10	PRN	_	_
18	during	_	IN	IN	_	17	TMP	_	_
19	danazol	_	NN	NN	_	20	NMOD	_	_
20	therapy	_	NN	NN	_	18	PMOD	_	_
21	)	_	)	)	_	17	P	_	_
22	and	_	CC	CC	_	4	CC	_	_
23	decreased	_	VBD	VBD	_	4	COORD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	number	_	NN	NN	_	23	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	both	_	DT	DT	_	28	NMOD	_	_
28	sites	_	NNS	NNS	_	26	PMOD	_	_
29	.	_	.	.	_	4	P	_	_

1	4	_	LS	LS	_	4	VMOD	_	_
2	.	_	.	.	_	1	P	_	_
3	It	_	PRP	PRP	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	suggested	_	VBN	VBN	_	4	VC	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	danazol	_	NN	NN	_	8	SBJ	_	_
8	has	_	VBZ	VBZ	_	6	VMOD	_	_
9	an	_	DT	DT	_	11	NMOD	_	_
10	anti-estrogenic	_	JJ	JJ	_	11	NMOD	_	_
11	action	_	NN	NN	_	8	OBJ	_	_
12	to	_	TO	TO	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	monocytes	_	NNS	NNS	_	12	PMOD	_	_
15	through	_	IN	IN	_	8	ADV	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	competition	_	NN	NN	_	15	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	suppression	_	NN	NN	_	17	COORD	_	_
20	of	_	IN	IN	_	17	NMOD	_	_
21	estrogen	_	NN	NN	_	23	NMOD	_	_
22	binding	_	NN	NN	_	23	NMOD	_	_
23	sites	_	NNS	NNS	_	20	PMOD	_	_
24	as	_	IN	IN	_	8	ADV	_	_
25	seen	_	VBN	VBN	_	24	VMOD	_	_
26	in	_	IN	IN	_	25	ADV	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	estrogen	_	NN	NN	_	30	NMOD	_	_
29	target	_	NN	NN	_	30	NMOD	_	_
30	organ	_	NN	NN	_	26	PMOD	_	_
31	.	_	.	.	_	4	P	_	_

1	Stable	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	transdominant	_	JJ	JJ	_	6	NMOD	_	_
5	Rev	_	NN	NN	_	6	NMOD	_	_
6	protein	_	NN	NN	_	3	PMOD	_	_
7	in	_	IN	IN	_	2	NMOD	_	_
8	human	_	JJ	JJ	_	10	NMOD	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	7	PMOD	_	_
11	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	human	_	JJ	JJ	_	15	NMOD	_	_
13	immunodeficiency	_	NN	NN	_	15	NMOD	_	_
14	virus	_	NN	NN	_	15	NMOD	_	_
15	replication	_	NN	NN	_	11	OBJ	_	_
16	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	9	NMOD	_	_
2	human	_	JJ	JJ	_	4	NMOD	_	_
3	immunodeficiency	_	NN	NN	_	4	NMOD	_	_
4	virus	_	NN	NN	_	9	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	HIV	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	Rev	_	NN	NN	_	9	NMOD	_	_
9	protein	_	NN	NN	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	essential	_	JJ	JJ	_	10	PRD	_	_
12	for	_	IN	IN	_	11	AMOD	_	_
13	viral	_	JJ	JJ	_	16	NMOD	_	_
14	structural	_	JJ	JJ	_	16	NMOD	_	_
15	protein	_	NN	NN	_	16	NMOD	_	_
16	expression	_	NN	NN	_	12	PMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	Gag	_	NN	NN	_	16	PRN	_	_
19	,	_	,	,	_	18	P	_	_
20	Pol	_	NN	NN	_	18	COORD	_	_
21	,	_	,	,	_	18	P	_	_
22	and	_	CC	CC	_	18	CC	_	_
23	Env	_	NN	NN	_	18	COORD	_	_
24	)	_	)	)	_	18	P	_	_
25	and	_	CC	CC	_	12	CC	_	_
26	,	_	,	,	_	12	P	_	_
27	hence	_	RB	RB	_	12	COORD	_	_
28	,	_	,	,	_	12	P	_	_
29	for	_	IN	IN	_	12	COORD	_	_
30	viral	_	JJ	JJ	_	31	NMOD	_	_
31	replication	_	NN	NN	_	29	PMOD	_	_
32	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	transient	_	JJ	JJ	_	4	NMOD	_	_
3	transfection	_	NN	NN	_	4	NMOD	_	_
4	assays	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	10	P	_	_
6	mutant	_	JJ	JJ	_	7	NMOD	_	_
7	forms	_	NNS	NNS	_	10	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	Rev	_	NN	NN	_	8	PMOD	_	_
10	have	_	VBP	VBP	_	0	ROOT-S	_	_
11	been	_	VBN	VBN	_	10	VC	_	_
12	identified	_	VBN	VBN	_	11	VC	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	inhibit	_	VBP	VBP	_	7	NMOD	_	_
15	wild-type	_	JJ	JJ	_	17	NMOD	_	_
16	Rev	_	NN	NN	_	17	NMOD	_	_
17	activity	_	NN	NN	_	14	OBJ	_	_
18	and	_	CC	CC	_	14	CC	_	_
19	therefore	_	RB	RB	_	14	COORD	_	_
20	suppress	_	VBP	VBP	_	14	COORD	_	_
21	viral	_	JJ	JJ	_	22	NMOD	_	_
22	replication	_	NN	NN	_	20	OBJ	_	_
23	.	_	.	.	_	10	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	determine	_	VB	VB	_	25	ADV	_	_
3	whether	_	IN	IN	_	2	OBJ	_	_
4	such	_	JJ	JJ	_	7	NMOD	_	_
5	transdominant	_	JJ	JJ	_	7	NMOD	_	_
6	Rev	_	NN	NN	_	7	NMOD	_	_
7	proteins	_	NNS	NNS	_	8	SBJ	_	_
8	could	_	MD	MD	_	3	VMOD	_	_
9	provide	_	VB	VB	_	8	VC	_	_
10	long-term	_	JJ	JJ	_	11	NMOD	_	_
11	protection	_	NN	NN	_	9	OBJ	_	_
12	against	_	IN	IN	_	11	NMOD	_	_
13	HIV	_	NN	NN	_	14	NMOD	_	_
14	infection	_	NN	NN	_	12	PMOD	_	_
15	without	_	IN	IN	_	9	ADV	_	_
16	affecting	_	VBG	VBG	_	15	PMOD	_	_
17	T	_	NN	NN	_	19	NMOD	_	_
18	cell	_	NN	NN	_	19	NMOD	_	_
19	function	_	NN	NN	_	16	OBJ	_	_
20	,	_	,	,	_	25	P	_	_
21	T	_	NN	NN	_	24	NMOD	_	_
22	leukemia	_	NN	NN	_	24	NMOD	_	_
23	cell	_	NN	NN	_	24	NMOD	_	_
24	lines	_	NNS	NNS	_	25	SBJ	_	_
25	were	_	VBD	VBD	_	0	ROOT-S	_	_
26	stably	_	RB	RB	_	25	ADV	_	_
27	transduced	_	VBN	VBN	_	25	VC	_	_
28	with	_	IN	IN	_	27	ADV	_	_
29	a	_	DT	DT	_	31	NMOD	_	_
30	retroviral	_	JJ	JJ	_	31	NMOD	_	_
31	vector	_	NN	NN	_	28	PMOD	_	_
32	encoding	_	VBG	VBG	_	31	NMOD	_	_
33	a	_	DT	DT	_	35	NMOD	_	_
34	transdominant	_	JJ	JJ	_	35	NMOD	_	_
35	mutant	_	NN	NN	_	32	OBJ	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	the	_	DT	DT	_	39	NMOD	_	_
38	Rev	_	NN	NN	_	39	NMOD	_	_
39	protein	_	NN	NN	_	36	PMOD	_	_
40	,	_	,	,	_	35	P	_	_
41	M10	_	NN	NN	_	35	NMOD	_	_
42	.	_	.	.	_	25	P	_	_

1	While	_	IN	IN	_	15	ADV	_	_
2	all	_	PDT	PDT	_	6	NMOD	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	M10-expressing	_	JJ	JJ	_	6	NMOD	_	_
5	cell	_	NN	NN	_	6	NMOD	_	_
6	lines	_	NNS	NNS	_	7	SBJ	_	_
7	remained	_	VBD	VBD	_	1	VMOD	_	_
8	infectable	_	JJ	JJ	_	7	PRD	_	_
9	by	_	IN	IN	_	8	AMOD	_	_
10	HIV-1	_	NN	NN	_	9	PMOD	_	_
11	,	_	,	,	_	15	P	_	_
12	these	_	DT	DT	_	14	NMOD	_	_
13	same	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	15	SBJ	_	_
15	failed	_	VBD	VBD	_	0	ROOT-S	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	support	_	VB	VB	_	15	OBJ	_	_
18	a	_	DT	DT	_	21	NMOD	_	_
19	productive	_	JJ	JJ	_	21	NMOD	_	_
20	replication	_	NN	NN	_	21	NMOD	_	_
21	cycle	_	NN	NN	_	17	OBJ	_	_
22	when	_	WRB	WRB	_	23	ADV	_	_
23	infected	_	VBN	VBN	_	17	TMP	_	_
24	with	_	IN	IN	_	23	ADV	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	cloned	_	VBN	VBN	_	27	NMOD	_	_
27	isolate	_	NN	NN	_	24	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	HIV-1	_	NN	NN	_	28	PMOD	_	_
30	.	_	.	.	_	15	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	11	P	_	_
4	two	_	CD	CD	_	7	DEP	_	_
5	out	_	IN	IN	_	7	DEP	_	_
6	of	_	IN	IN	_	7	DEP	_	_
7	three	_	CD	CD	_	10	NMOD	_	_
8	M10-expressing	_	JJ	JJ	_	10	NMOD	_	_
9	CEM	_	NN	NN	_	10	NMOD	_	_
10	clones	_	NNS	NNS	_	11	SBJ	_	_
11	were	_	VBD	VBD	_	0	ROOT-S	_	_
12	also	_	RB	RB	_	13	AMOD	_	_
13	resistant	_	JJ	JJ	_	11	PRD	_	_
14	to	_	TO	TO	_	13	AMOD	_	_
15	highly	_	RB	RB	_	16	AMOD	_	_
16	productive	_	JJ	JJ	_	17	NMOD	_	_
17	infection	_	NN	NN	_	14	PMOD	_	_
18	by	_	IN	IN	_	17	NMOD	_	_
19	a	_	DT	DT	_	22	NMOD	_	_
20	heterogeneous	_	JJ	JJ	_	22	NMOD	_	_
21	HIV-1	_	NN	NN	_	22	NMOD	_	_
22	pool	_	NN	NN	_	18	PMOD	_	_
23	.	_	.	.	_	11	P	_	_

1	Expression	_	NN	NN	_	4	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	M10	_	NN	NN	_	2	PMOD	_	_
4	did	_	VBD	VBD	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	affect	_	VB	VB	_	4	VC	_	_
7	induction	_	NN	NN	_	6	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	HIV	_	NN	NN	_	10	NMOD	_	_
10	transcription	_	NN	NN	_	8	PMOD	_	_
11	mediated	_	VBN	VBN	_	7	NMOD	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	kappa	_	NN	NN	_	17	NMOD	_	_
15	B	_	NN	NN	_	17	NMOD	_	_
16	regulatory	_	JJ	JJ	_	17	NMOD	_	_
17	element	_	NN	NN	_	12	PMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	Tat	_	NN	NN	_	17	COORD	_	_
20	.	_	.	.	_	4	P	_	_

1	Importantly	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	constitutive	_	JJ	JJ	_	4	NMOD	_	_
4	expression	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	Rev	_	NN	NN	_	7	NMOD	_	_
7	M10	_	NN	NN	_	5	PMOD	_	_
8	did	_	VBD	VBD	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	alter	_	VB	VB	_	8	VC	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	secretion	_	NN	NN	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	interleukin	_	NN	NN	_	13	PMOD	_	_
15	2	_	CD	CD	_	14	NMOD	_	_
16	in	_	IN	IN	_	10	ADV	_	_
17	response	_	NN	NN	_	16	DEP	_	_
18	to	_	TO	TO	_	16	DEP	_	_
19	mitogen	_	NN	NN	_	20	NMOD	_	_
20	stimulation	_	NN	NN	_	16	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	EL-4	_	NN	NN	_	25	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	Jurkat	_	NN	NN	_	22	COORD	_	_
25	cells	_	NNS	NNS	_	21	PMOD	_	_
26	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	inhibition	_	NN	NN	_	27	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	HIV	_	NN	NN	_	5	NMOD	_	_
5	infection	_	NN	NN	_	3	PMOD	_	_
6	in	_	IN	IN	_	2	NMOD	_	_
7	cells	_	NNS	NNS	_	6	PMOD	_	_
8	stably	_	RB	RB	_	9	ADV	_	_
9	expressing	_	VBG	VBG	_	7	NMOD	_	_
10	a	_	DT	DT	_	13	NMOD	_	_
11	transdominant	_	JJ	JJ	_	13	NMOD	_	_
12	Rev	_	NN	NN	_	13	NMOD	_	_
13	protein	_	NN	NN	_	9	OBJ	_	_
14	,	_	,	,	_	2	P	_	_
15	in	_	IN	IN	_	2	NMOD	_	_
16	the	_	DT	DT	_	15	DEP	_	_
17	absence	_	NN	NN	_	15	DEP	_	_
18	of	_	IN	IN	_	15	DEP	_	_
19	any	_	DT	DT	_	21	NMOD	_	_
20	deleterious	_	JJ	JJ	_	21	NMOD	_	_
21	effect	_	NN	NN	_	15	PMOD	_	_
22	on	_	IN	IN	_	21	NMOD	_	_
23	T	_	NN	NN	_	25	NMOD	_	_
24	cell	_	NN	NN	_	25	NMOD	_	_
25	function	_	NN	NN	_	22	PMOD	_	_
26	,	_	,	,	_	2	P	_	_
27	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
28	that	_	IN	IN	_	27	OBJ	_	_
29	such	_	PDT	PDT	_	31	NMOD	_	_
30	a	_	DT	DT	_	31	NMOD	_	_
31	strategy	_	NN	NN	_	32	SBJ	_	_
32	could	_	MD	MD	_	28	VMOD	_	_
33	provide	_	VB	VB	_	32	VC	_	_
34	a	_	DT	DT	_	36	NMOD	_	_
35	therapeutic	_	JJ	JJ	_	36	NMOD	_	_
36	effect	_	NN	NN	_	33	OBJ	_	_
37	in	_	IN	IN	_	33	ADV	_	_
38	the	_	DT	DT	_	40	NMOD	_	_
39	T	_	NN	NN	_	40	NMOD	_	_
40	lymphocytes	_	NNS	NNS	_	37	PMOD	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	acquired	_	VBN	VBN	_	45	NMOD	_	_
43	immunodeficiency	_	NN	NN	_	45	NMOD	_	_
44	syndrome	_	NN	NN	_	45	NMOD	_	_
45	patients	_	NNS	NNS	_	41	PMOD	_	_
46	.	_	.	.	_	27	P	_	_

1	Glucocorticoid	_	NN	NN	_	2	NMOD	_	_
2	receptor	_	NN	NN	_	0	ROOT-FRAG	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	patients	_	NNS	NNS	_	3	PMOD	_	_
5	with	_	IN	IN	_	4	NMOD	_	_
6	lupus	_	NN	NN	_	7	NMOD	_	_
7	nephritis	_	NN	NN	_	5	PMOD	_	_
8	:	_	:	:	_	2	P	_	_
9	relationship	_	NN	NN	_	2	NMOD	_	_
10	between	_	IN	IN	_	9	NMOD	_	_
11	receptor	_	NN	NN	_	12	NMOD	_	_
12	levels	_	NNS	NNS	_	10	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	mononuclear	_	JJ	JJ	_	15	NMOD	_	_
15	leukocytes	_	NNS	NNS	_	13	PMOD	_	_
16	and	_	CC	CC	_	12	CC	_	_
17	effect	_	NN	NN	_	12	COORD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	glucocorticoid	_	NN	NN	_	20	NMOD	_	_
20	therapy	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	investigated	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	clinical	_	JJ	JJ	_	5	NMOD	_	_
5	significance	_	NN	NN	_	2	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	glucocorticoid	_	NN	NN	_	9	NMOD	_	_
8	receptor	_	NN	NN	_	9	NMOD	_	_
9	determination	_	NN	NN	_	6	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	20	_	CD	CD	_	12	NMOD	_	_
12	patients	_	NNS	NNS	_	10	PMOD	_	_
13	with	_	IN	IN	_	12	NMOD	_	_
14	systemic	_	JJ	JJ	_	16	NMOD	_	_
15	lupus	_	NN	NN	_	16	NMOD	_	_
16	erythematosus	_	NN	NN	_	13	PMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	SLE	_	NN	NN	_	16	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	who	_	WP	WP	_	22	SBJ	_	_
21	afterwards	_	RB	RB	_	22	TMP	_	_
22	developed	_	VBD	VBD	_	12	NMOD	_	_
23	nephrotic	_	JJ	JJ	_	24	NMOD	_	_
24	syndrome	_	NN	NN	_	22	OBJ	_	_
25	.	_	.	.	_	2	P	_	_

1	Glucocorticoid	_	NN	NN	_	3	NMOD	_	_
2	receptor	_	NN	NN	_	3	NMOD	_	_
3	concentrations	_	NNS	NNS	_	13	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	mononuclear	_	JJ	JJ	_	6	NMOD	_	_
6	leukocytes	_	NNS	NNS	_	4	PMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	MNL	_	NNS	NNS	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	in	_	IN	IN	_	3	NMOD	_	_
11	these	_	DT	DT	_	12	NMOD	_	_
12	patients	_	NNS	NNS	_	10	PMOD	_	_
13	were	_	VBD	VBD	_	0	ROOT-S	_	_
14	comparable	_	JJ	JJ	_	13	PRD	_	_
15	with	_	IN	IN	_	14	AMOD	_	_
16	those	_	DT	DT	_	15	PMOD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	both	_	CC	CC	_	20	CC	_	_
19	other	_	JJ	JJ	_	20	NMOD	_	_
20	patients	_	NNS	NNS	_	17	PMOD	_	_
21	with	_	IN	IN	_	20	NMOD	_	_
22	SLE	_	NN	NN	_	21	PMOD	_	_
23	and	_	CC	CC	_	20	CC	_	_
24	healthy	_	JJ	JJ	_	25	NMOD	_	_
25	persons	_	NNS	NNS	_	20	COORD	_	_
26	.	_	.	.	_	13	P	_	_

1	Improvement	_	NN	NN	_	29	SBJ	_	_
2	in	_	IN	IN	_	1	NMOD	_	_
3	urinary	_	JJ	JJ	_	5	NMOD	_	_
4	protein	_	NN	NN	_	5	NMOD	_	_
5	excretion	_	NN	NN	_	2	PMOD	_	_
6	and	_	CC	CC	_	2	CC	_	_
7	in	_	IN	IN	_	2	COORD	_	_
8	disease	_	NN	NN	_	9	NMOD	_	_
9	activity	_	NN	NN	_	7	PMOD	_	_
10	,	_	,	,	_	1	P	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	was	_	VBD	VBD	_	1	NMOD	_	_
13	scored	_	VBN	VBN	_	12	VC	_	_
14	according	_	VBG	VBG	_	13	ADV	_	_
15	to	_	TO	TO	_	14	PMOD	_	_
16	the	_	DT	DT	_	21	NMOD	_	_
17	SLE	_	NNP	NNP	_	21	NMOD	_	_
18	Disease	_	NNP	NNP	_	21	NMOD	_	_
19	Activity	_	NNP	NNP	_	21	NMOD	_	_
20	Index	_	NNP	NNP	_	21	NMOD	_	_
21	system	_	NN	NN	_	15	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	University	_	NNP	NNP	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	Toronto	_	NNP	NNP	_	25	PMOD	_	_
27	,	_	,	,	_	1	P	_	_
28	closely	_	RB	RB	_	29	ADV	_	_
29	related	_	JJ	JJ	_	0	ROOT-S	_	_
30	to	_	TO	TO	_	29	ADV	_	_
31	the	_	DT	DT	_	34	NMOD	_	_
32	glucocorticoid	_	NN	NN	_	34	NMOD	_	_
33	receptor	_	NN	NN	_	34	NMOD	_	_
34	concentrations	_	NNS	NNS	_	30	PMOD	_	_
35	in	_	IN	IN	_	34	NMOD	_	_
36	MNL	_	NN	NN	_	35	PMOD	_	_
37	isolated	_	VBN	VBN	_	36	NMOD	_	_
38	from	_	IN	IN	_	37	ADV	_	_
39	the	_	DT	DT	_	41	NMOD	_	_
40	corresponding	_	JJ	JJ	_	41	NMOD	_	_
41	patients	_	NNS	NNS	_	38	PMOD	_	_
42	.	_	.	.	_	29	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	summary	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	12	P	_	_
4	glucocorticoid	_	NN	NN	_	6	NMOD	_	_
5	receptor	_	NN	NN	_	6	NMOD	_	_
6	determination	_	NN	NN	_	12	SBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	patients	_	NNS	NNS	_	7	PMOD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	lupus	_	NN	NN	_	11	NMOD	_	_
11	nephritis	_	NN	NN	_	9	PMOD	_	_
12	may	_	MD	MD	_	0	ROOT-S	_	_
13	be	_	VB	VB	_	12	VC	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	predictive	_	JJ	JJ	_	16	NMOD	_	_
16	clue	_	NN	NN	_	13	PRD	_	_
17	for	_	IN	IN	_	16	NMOD	_	_
18	assessing	_	VBG	VBG	_	17	PMOD	_	_
19	responsiveness	_	NN	NN	_	18	OBJ	_	_
20	to	_	TO	TO	_	19	NMOD	_	_
21	glucocorticoid	_	NN	NN	_	22	NMOD	_	_
22	therapy	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	12	P	_	_

1	Characterization	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	7	NMOD	_	_
4	new	_	JJ	JJ	_	7	NMOD	_	_
5	tissue-specific	_	JJ	JJ	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factor	_	NN	NN	_	2	PMOD	_	_
8	binding	_	VBG	VBG	_	7	NMOD	_	_
9	to	_	TO	TO	_	8	ADV	_	_
10	the	_	DT	DT	_	20	NMOD	_	_
11	simian	_	JJ	JJ	_	20	NMOD	_	_
12	virus	_	NN	NN	_	20	NMOD	_	_
13	40	_	CD	CD	_	20	NMOD	_	_
14	enhancer	_	NN	NN	_	20	NMOD	_	_
15	TC-II	_	NN	NN	_	20	NMOD	_	_
16	(	_	(	(	_	20	P	_	_
17	NF-kappa	_	NN	NN	_	20	NMOD	_	_
18	B	_	NN	NN	_	20	NMOD	_	_
19	)	_	)	)	_	20	P	_	_
20	element	_	NN	NN	_	9	PMOD	_	_
21	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	biochemically	_	RB	RB	_	2	ADV	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	functionally	_	RB	RB	_	3	COORD	_	_
6	characterized	_	VBN	VBN	_	2	VC	_	_
7	a	_	DT	DT	_	10	NMOD	_	_
8	new	_	JJ	JJ	_	10	NMOD	_	_
9	transcription	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	6	OBJ	_	_
11	,	_	,	,	_	10	P	_	_
12	NP-TCII	_	NN	NN	_	10	NMOD	_	_
13	,	_	,	,	_	10	P	_	_
14	which	_	WDT	WDT	_	15	SBJ	_	_
15	is	_	VBZ	VBZ	_	10	NMOD	_	_
16	present	_	JJ	JJ	_	15	PRD	_	_
17	in	_	IN	IN	_	16	AMOD	_	_
18	nuclei	_	NNS	NNS	_	17	PMOD	_	_
19	from	_	IN	IN	_	18	NMOD	_	_
20	unstimulated	_	JJ	JJ	_	24	NMOD	_	_
21	T	_	NN	NN	_	24	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	B	_	NN	NN	_	21	COORD	_	_
24	lymphocytes	_	NNS	NNS	_	19	PMOD	_	_
25	but	_	CC	CC	_	15	CC	_	_
26	is	_	VBZ	VBZ	_	15	COORD	_	_
27	not	_	RB	RB	_	26	VMOD	_	_
28	found	_	VBN	VBN	_	26	VC	_	_
29	in	_	IN	IN	_	28	ADV	_	_
30	nonhematopoietic	_	JJ	JJ	_	31	NMOD	_	_
31	cells	_	NNS	NNS	_	29	PMOD	_	_
32	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	factor	_	NN	NN	_	3	SBJ	_	_
3	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	DNA-binding	_	JJ	JJ	_	6	NMOD	_	_
6	specificity	_	NN	NN	_	3	OBJ	_	_
7	similar	_	JJ	JJ	_	6	NMOD	_	_
8	to	_	TO	TO	_	7	AMOD	_	_
9	that	_	DT	DT	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	NF-kappa	_	NN	NN	_	12	NMOD	_	_
12	B	_	NN	NN	_	10	PMOD	_	_
13	but	_	CC	CC	_	3	CC	_	_
14	is	_	VBZ	VBZ	_	3	COORD	_	_
15	unrelated	_	JJ	JJ	_	14	PRD	_	_
16	to	_	TO	TO	_	15	AMOD	_	_
17	this	_	DT	DT	_	21	NMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	other	_	JJ	JJ	_	17	COORD	_	_
20	Rel	_	NN	NN	_	21	NMOD	_	_
21	proteins	_	NNS	NNS	_	16	PMOD	_	_
22	by	_	IN	IN	_	15	AMOD	_	_
23	functional	_	JJ	JJ	_	26	NMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	biochemical	_	JJ	JJ	_	23	COORD	_	_
26	criteria	_	NNS	NNS	_	22	PMOD	_	_
27	.	_	.	.	_	3	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	can	_	MD	MD	_	0	ROOT-S	_	_
3	also	_	RB	RB	_	2	ADV	_	_
4	be	_	VB	VB	_	2	VC	_	_
5	distinguished	_	VBN	VBN	_	4	VC	_	_
6	from	_	IN	IN	_	5	ADV	_	_
7	other	_	JJ	JJ	_	12	NMOD	_	_
8	previously	_	RB	RB	_	9	AMOD	_	_
9	described	_	VBN	VBN	_	12	NMOD	_	_
10	lymphocyte-specific	_	JJ	JJ	_	12	NMOD	_	_
11	DNA-binding	_	JJ	JJ	_	12	NMOD	_	_
12	proteins	_	NNS	NNS	_	6	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	candidate	_	NN	NN	_	4	NMOD	_	_
3	oncoprotein	_	NN	NN	_	4	NMOD	_	_
4	Bcl-3	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	an	_	DT	DT	_	7	NMOD	_	_
7	antagonist	_	NN	NN	_	5	PRD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	p50\/NF-kappa	_	NN	NN	_	11	NMOD	_	_
10	B-mediated	_	JJ	JJ	_	9	AMOD	_	_
11	inhibition	_	NN	NN	_	8	PMOD	_	_
12	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	candidate	_	NN	NN	_	4	NMOD	_	_
3	oncogene	_	NN	NN	_	4	NMOD	_	_
4	bcl-3	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	discovered	_	VBN	VBN	_	5	VC	_	_
7	as	_	IN	IN	_	6	ADV	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	translocation	_	NN	NN	_	7	PMOD	_	_
10	into	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	immunoglobulin	_	NN	NN	_	13	NMOD	_	_
13	alpha-locus	_	NN	NN	_	10	PMOD	_	_
14	in	_	IN	IN	_	6	ADV	_	_
15	some	_	DT	DT	_	16	NMOD	_	_
16	cases	_	NNS	NNS	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	B-cell	_	NN	NN	_	21	NMOD	_	_
19	chronic	_	JJ	JJ	_	21	NMOD	_	_
20	lymphocytic	_	JJ	JJ	_	21	NMOD	_	_
21	leukaemias	_	NNS	NNS	_	17	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	protein	_	NN	NN	_	3	NMOD	_	_
3	Bcl-3	_	NN	NN	_	4	SBJ	_	_
4	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	seven	_	CD	CD	_	8	NMOD	_	_
6	so-called	_	JJ	JJ	_	8	NMOD	_	_
7	ankyrin	_	NN	NN	_	8	NMOD	_	_
8	repeats	_	NNS	NNS	_	4	OBJ	_	_
9	.	_	.	.	_	4	P	_	_

1	Similar	_	JJ	JJ	_	3	NMOD	_	_
2	repeat	_	NN	NN	_	3	NMOD	_	_
3	motifs	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	found	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	number	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	diverse	_	JJ	JJ	_	12	NMOD	_	_
11	regulatory	_	JJ	JJ	_	12	NMOD	_	_
12	proteins	_	NNS	NNS	_	9	PMOD	_	_
13	but	_	CC	CC	_	4	CC	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	motifs	_	NNS	NNS	_	18	SBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	Bcl-3	_	NN	NN	_	16	PMOD	_	_
18	are	_	VBP	VBP	_	4	COORD	_	_
19	most	_	RBS	RBS	_	20	AMOD	_	_
20	closely	_	RB	RB	_	18	PRD	_	_
21	related	_	JJ	JJ	_	20	AMOD	_	_
22	to	_	TO	TO	_	20	AMOD	_	_
23	those	_	DT	DT	_	22	PMOD	_	_
24	found	_	VBN	VBN	_	23	NMOD	_	_
25	in	_	IN	IN	_	24	ADV	_	_
26	I	_	NN	NN	_	29	NMOD	_	_
27	kappa	_	NN	NN	_	29	NMOD	_	_
28	B	_	NN	NN	_	29	NMOD	_	_
29	proteins	_	NNS	NNS	_	25	PMOD	_	_
30	in	_	IN	IN	_	41	ADV	_	_
31	which	_	WDT	WDT	_	30	PMOD	_	_
32	the	_	DT	DT	_	35	NMOD	_	_
33	ankyrin	_	NN	NN	_	35	NMOD	_	_
34	repeat	_	NN	NN	_	35	NMOD	_	_
35	domain	_	NN	NN	_	36	SBJ	_	_
36	is	_	VBZ	VBZ	_	29	NMOD	_	_
37	thought	_	VBN	VBN	_	36	VC	_	_
38	to	_	TO	TO	_	39	VMOD	_	_
39	be	_	VB	VB	_	37	OBJ	_	_
40	directly	_	RB	RB	_	39	ADV	_	_
41	involved	_	VBN	VBN	_	39	VC	_	_
42	in	_	IN	IN	_	41	ADV	_	_
43	inhibition	_	NN	NN	_	42	PMOD	_	_
44	of	_	IN	IN	_	43	NMOD	_	_
45	NF-kappa	_	NN	NN	_	47	NMOD	_	_
46	B	_	NN	NN	_	47	NMOD	_	_
47	activity	_	NN	NN	_	44	PMOD	_	_
48	.	_	.	.	_	4	P	_	_

1	No	_	DT	DT	_	3	NMOD	_	_
2	biological	_	JJ	JJ	_	3	NMOD	_	_
3	function	_	NN	NN	_	4	SBJ	_	_
4	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	yet	_	RB	RB	_	4	ADV	_	_
6	been	_	VBN	VBN	_	4	VC	_	_
7	described	_	VBN	VBN	_	6	VC	_	_
8	for	_	IN	IN	_	7	ADV	_	_
9	Bcl-3	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	4	P	_	_
11	but	_	CC	CC	_	4	CC	_	_
12	it	_	PRP	PRP	_	13	SBJ	_	_
13	was	_	VBD	VBD	_	4	COORD	_	_
14	noted	_	VBN	VBN	_	13	VC	_	_
15	recently	_	RB	RB	_	14	TMP	_	_
16	that	_	IN	IN	_	14	OBJ	_	_
17	Bcl-3	_	NN	NN	_	18	SBJ	_	_
18	interferes	_	VBZ	VBZ	_	16	VMOD	_	_
19	with	_	IN	IN	_	18	ADV	_	_
20	DNA-binding	_	NN	NN	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	p50	_	NN	NN	_	24	NMOD	_	_
24	subunit	_	NN	NN	_	21	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	NF-kappa	_	NN	NN	_	27	NMOD	_	_
27	B	_	NN	NN	_	25	PMOD	_	_
28	in	_	FW	FW	_	18	ADV	_	_
29	vitro	_	FW	FW	_	28	AMOD	_	_
30	.	_	.	.	_	4	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	Bcl-3	_	NN	NN	_	6	SBJ	_	_
6	can	_	MD	MD	_	4	VMOD	_	_
7	aid	_	VB	VB	_	6	VC	_	_
8	kappa	_	NN	NN	_	9	AMOD	_	_
9	B	_	NN	NN	_	11	NMOD	_	_
10	site-dependent	_	JJ	JJ	_	9	AMOD	_	_
11	transcription	_	NN	NN	_	7	OBJ	_	_
12	in	_	FW	FW	_	7	ADV	_	_
13	vivo	_	FW	FW	_	12	AMOD	_	_
14	by	_	IN	IN	_	7	ADV	_	_
15	counteracting	_	VBG	VBG	_	14	PMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	inhibitory	_	JJ	JJ	_	18	NMOD	_	_
18	effects	_	NNS	NNS	_	15	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	p50\/NF-kappa	_	NN	NN	_	22	NMOD	_	_
21	B	_	NN	NN	_	22	NMOD	_	_
22	homodimers	_	NNS	NNS	_	19	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	Bcl-3	_	NN	NN	_	2	SBJ	_	_
2	may	_	MD	MD	_	0	ROOT-S	_	_
3	therefore	_	RB	RB	_	2	ADV	_	_
4	aid	_	VB	VB	_	2	VC	_	_
5	activation	_	NN	NN	_	4	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	select	_	JJ	JJ	_	10	NMOD	_	_
8	NF-kappa	_	NN	NN	_	10	NMOD	_	_
9	B-regulated	_	JJ	JJ	_	8	AMOD	_	_
10	genes	_	NNS	NNS	_	6	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	including	_	VBG	VBG	_	10	NMOD	_	_
13	those	_	DT	DT	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	human	_	JJ	JJ	_	18	NMOD	_	_
17	immunodeficiency	_	NN	NN	_	18	NMOD	_	_
18	virus	_	NN	NN	_	14	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	microtitre	_	NN	NN	_	4	NMOD	_	_
3	assay	_	NN	NN	_	4	NMOD	_	_
4	system	_	NN	NN	_	0	ROOT-FRAG	_	_
5	for	_	IN	IN	_	4	NMOD	_	_
6	glucocorticoid	_	NN	NN	_	7	NMOD	_	_
7	receptors	_	NNS	NNS	_	5	PMOD	_	_
8	:	_	:	:	_	4	P	_	_
9	decreased	_	VBN	VBN	_	11	NMOD	_	_
10	receptor	_	NN	NN	_	11	NMOD	_	_
11	concentration	_	NN	NN	_	4	NMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	myocardial	_	JJ	JJ	_	14	NMOD	_	_
14	infarction	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	11	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	major	_	JJ	JJ	_	3	NMOD	_	_
3	difficulty	_	NN	NN	_	10	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	determination	_	NN	NN	_	4	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	glucocorticoid	_	NN	NN	_	9	NMOD	_	_
8	receptor	_	NN	NN	_	9	NMOD	_	_
9	sites	_	NNS	NNS	_	6	PMOD	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	the	_	DT	DT	_	15	NMOD	_	_
12	very	_	RB	RB	_	13	AMOD	_	_
13	complicated	_	JJ	JJ	_	15	NMOD	_	_
14	assay	_	NN	NN	_	15	NMOD	_	_
15	procedure	_	NN	NN	_	10	PRD	_	_
16	.	_	.	.	_	10	P	_	_

1	Therefore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	describe	_	VBP	VBP	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	microtitre	_	NN	NN	_	8	NMOD	_	_
7	assay	_	NN	NN	_	8	NMOD	_	_
8	system	_	NN	NN	_	4	IOBJ	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	glucocorticoid	_	NN	NN	_	11	NMOD	_	_
11	receptors	_	NNS	NNS	_	9	PMOD	_	_
12	which	_	WDT	WDT	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	8	NMOD	_	_
14	a	_	DT	DT	_	18	NMOD	_	_
15	whole-cell	_	JJ	JJ	_	18	NMOD	_	_
16	competitive	_	JJ	JJ	_	18	NMOD	_	_
17	binding	_	NN	NN	_	18	NMOD	_	_
18	radioassay	_	NN	NN	_	13	PRD	_	_
19	using	_	VBG	VBG	_	4	OBJ	_	_
20	-LCB-3H-RCB--dexamethasone	_	NN	NN	_	19	OBJ	_	_
21	as	_	IN	IN	_	19	ADV	_	_
22	radioligand	_	NN	NN	_	21	PMOD	_	_
23	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	modification	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	previously	_	RB	RB	_	6	AMOD	_	_
6	described	_	VBN	VBN	_	7	NMOD	_	_
7	protocol	_	NN	NN	_	3	PMOD	_	_
8	simplifies	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	reduces	_	VBZ	VBZ	_	8	COORD	_	_
11	laboratory	_	NN	NN	_	12	NMOD	_	_
12	work	_	NN	NN	_	8	OBJ	_	_
13	and	_	CC	CC	_	8	CC	_	_
14	allows	_	VBZ	VBZ	_	8	COORD	_	_
15	assay	_	NN	NN	_	16	NMOD	_	_
16	reproducibility	_	NN	NN	_	18	SBJ	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	be	_	VB	VB	_	14	OBJ	_	_
19	controlled	_	VBN	VBN	_	18	VC	_	_
20	more	_	RBR	RBR	_	21	AMOD	_	_
21	reliably	_	RB	RB	_	19	ADV	_	_
22	.	_	.	.	_	8	P	_	_

1	Thus	_	RB	RB	_	2	ADV	_	_
2	enabled	_	VBN	VBN	_	15	ADV	_	_
3	to	_	TO	TO	_	4	VMOD	_	_
4	perform	_	VB	VB	_	2	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	test	_	NN	NN	_	4	OBJ	_	_
7	on	_	IN	IN	_	4	ADV	_	_
8	multiple	_	JJ	JJ	_	10	NMOD	_	_
9	blood	_	NN	NN	_	10	NMOD	_	_
10	samples	_	NNS	NNS	_	7	PMOD	_	_
11	in	_	IN	IN	_	4	ADV	_	_
12	parallel	_	NN	NN	_	11	PMOD	_	_
13	,	_	,	,	_	15	P	_	_
14	we	_	PRP	PRP	_	15	SBJ	_	_
15	investigated	_	VBD	VBD	_	0	ROOT-S	_	_
16	cardiac	_	JJ	JJ	_	18	NMOD	_	_
17	infarction	_	NN	NN	_	18	NMOD	_	_
18	patients	_	NNS	NNS	_	15	IOBJ	_	_
19	over	_	IN	IN	_	15	TMP	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	12-day	_	JJ	JJ	_	22	NMOD	_	_
22	period	_	NN	NN	_	19	PMOD	_	_
23	to	_	TO	TO	_	24	VMOD	_	_
24	test	_	VB	VB	_	15	OBJ	_	_
25	if	_	IN	IN	_	24	OBJ	_	_
26	glucocorticoid	_	NN	NN	_	28	NMOD	_	_
27	receptor	_	NN	NN	_	28	NMOD	_	_
28	binding	_	NN	NN	_	29	SBJ	_	_
29	is	_	VBZ	VBZ	_	25	VMOD	_	_
30	altered	_	VBN	VBN	_	29	VC	_	_
31	in	_	IN	IN	_	30	ADV	_	_
32	this	_	DT	DT	_	36	NMOD	_	_
33	'	_	``	``	_	36	P	_	_
34	stressful	_	JJ	JJ	_	36	NMOD	_	_
35	'	_	''	''	_	36	P	_	_
36	disease	_	NN	NN	_	31	PMOD	_	_
37	.	_	.	.	_	15	P	_	_

1	On	_	IN	IN	_	12	TMP	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	first	_	JJ	JJ	_	4	NMOD	_	_
4	day	_	NN	NN	_	1	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	disease	_	NN	NN	_	5	PMOD	_	_
8	,	_	,	,	_	12	P	_	_
9	glucocorticoid	_	NN	NN	_	11	NMOD	_	_
10	receptor	_	NN	NN	_	11	NMOD	_	_
11	capacity	_	NN	NN	_	12	SBJ	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	significantly	_	RB	RB	_	12	ADV	_	_
14	decreased	_	VBN	VBN	_	12	VC	_	_
15	without	_	IN	IN	_	14	ADV	_	_
16	alteration	_	NN	NN	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	receptor-ligand	_	JJ	JJ	_	20	NMOD	_	_
20	affinity	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	12	P	_	_
22	whereas	_	IN	IN	_	12	COORD	_	_
23	on	_	IN	IN	_	33	TMP	_	_
24	days	_	NNS	NNS	_	23	PMOD	_	_
25	4	_	CD	CD	_	24	NMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	12	_	CD	CD	_	25	COORD	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	number	_	NN	NN	_	33	SBJ	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	receptor	_	NN	NN	_	32	NMOD	_	_
32	sites	_	NNS	NNS	_	30	PMOD	_	_
33	was	_	VBD	VBD	_	12	COORD	_	_
34	normal	_	JJ	JJ	_	33	PRD	_	_
35	again	_	RB	RB	_	33	ADV	_	_
36	.	_	.	.	_	12	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	result	_	NN	NN	_	3	SBJ	_	_
3	fits	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	well	_	RB	RB	_	3	ADV	_	_
5	into	_	IN	IN	_	3	ADV	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	general	_	JJ	JJ	_	8	NMOD	_	_
8	observation	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	stress-induced	_	JJ	JJ	_	11	NMOD	_	_
11	down-regulation	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	immune	_	JJ	JJ	_	14	NMOD	_	_
14	responses	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	Activation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	NF-kappa	_	NN	NN	_	4	NMOD	_	_
4	B	_	NN	NN	_	2	PMOD	_	_
5	by	_	IN	IN	_	1	NMOD	_	_
6	interleukin	_	NN	NN	_	5	PMOD	_	_
7	2	_	CD	CD	_	6	NMOD	_	_
8	in	_	IN	IN	_	1	NMOD	_	_
9	human	_	JJ	JJ	_	11	NMOD	_	_
10	blood	_	NN	NN	_	11	NMOD	_	_
11	monocytes	_	NNS	NNS	_	8	PMOD	_	_
12	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	that	_	IN	IN	_	2	OBJ	_	_
5	interleukin	_	NN	NN	_	10	SBJ	_	_
6	2	_	CD	CD	_	5	NMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	IL-2	_	NN	NN	_	5	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	acts	_	VBZ	VBZ	_	4	VMOD	_	_
11	on	_	IN	IN	_	10	ADV	_	_
12	human	_	JJ	JJ	_	14	NMOD	_	_
13	blood	_	NN	NN	_	14	NMOD	_	_
14	monocytes	_	NNS	NNS	_	11	PMOD	_	_
15	by	_	IN	IN	_	10	ADV	_	_
16	enhancing	_	VBG	VBG	_	15	PMOD	_	_
17	binding	_	NN	NN	_	18	NMOD	_	_
18	activity	_	NN	NN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	24	NMOD	_	_
21	transcription	_	NN	NN	_	24	NMOD	_	_
22	factor	_	NN	NN	_	24	NMOD	_	_
23	NF-kappa	_	NN	NN	_	24	NMOD	_	_
24	B	_	NN	NN	_	19	PMOD	_	_
25	to	_	TO	TO	_	18	NMOD	_	_
26	its	_	PRP$	PRP$	_	28	NMOD	_	_
27	consensus	_	NN	NN	_	28	NMOD	_	_
28	sequence	_	NN	NN	_	25	PMOD	_	_
29	in	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	34	NMOD	_	_
31	5'	_	JJ	JJ	_	34	NMOD	_	_
32	regulatory	_	JJ	JJ	_	34	NMOD	_	_
33	enhancer	_	NN	NN	_	34	NMOD	_	_
34	region	_	NN	NN	_	29	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	the	_	DT	DT	_	40	NMOD	_	_
37	IL-2	_	NN	NN	_	40	NMOD	_	_
38	receptor	_	NN	NN	_	40	NMOD	_	_
39	alpha	_	NN	NN	_	40	NMOD	_	_
40	chain	_	NN	NN	_	35	PMOD	_	_
41	(	_	(	(	_	42	P	_	_
42	p55	_	NN	NN	_	34	PRN	_	_
43	)	_	)	)	_	42	P	_	_
44	.	_	.	.	_	2	P	_	_

1	Similarly	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	IL-2	_	NN	NN	_	4	SBJ	_	_
4	activates	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	NF-kappa	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	4	OBJ	_	_
7	in	_	IN	IN	_	4	ADV	_	_
8	the	_	DT	DT	_	13	NMOD	_	_
9	human	_	JJ	JJ	_	13	NMOD	_	_
10	monocytic	_	JJ	JJ	_	13	NMOD	_	_
11	cell	_	NN	NN	_	13	NMOD	_	_
12	line	_	NN	NN	_	13	NMOD	_	_
13	U	_	NN	NN	_	7	PMOD	_	_
14	937	_	CD	CD	_	13	NMOD	_	_
15	,	_	,	,	_	7	P	_	_
16	but	_	CC	CC	_	7	CC	_	_
17	not	_	RB	RB	_	18	DEP	_	_
18	in	_	IN	IN	_	7	COORD	_	_
19	resting	_	VBG	VBG	_	21	NMOD	_	_
20	human	_	JJ	JJ	_	21	NMOD	_	_
21	T-cells	_	NNS	NNS	_	18	PMOD	_	_
22	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	detectable	_	JJ	JJ	_	3	PRD	_	_
5	within	_	IN	IN	_	3	TMP	_	_
6	15	_	CD	CD	_	7	NMOD	_	_
7	min	_	NN	NN	_	5	PMOD	_	_
8	and	_	CC	CC	_	3	CC	_	_
9	peaks	_	VBZ	VBZ	_	3	COORD	_	_
10	1	_	CD	CD	_	11	NMOD	_	_
11	h	_	NN	NN	_	12	PMOD	_	_
12	after	_	IN	IN	_	9	TMP	_	_
13	exposure	_	NN	NN	_	12	PMOD	_	_
14	to	_	TO	TO	_	13	NMOD	_	_
15	IL-2	_	NN	NN	_	14	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	Enhanced	_	VBN	VBN	_	5	NMOD	_	_
2	NF-kappa	_	NN	NN	_	5	NMOD	_	_
3	B	_	NN	NN	_	5	NMOD	_	_
4	binding	_	NN	NN	_	5	NMOD	_	_
5	activity	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	followed	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	functional	_	JJ	JJ	_	10	NMOD	_	_
10	activation	_	NN	NN	_	8	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	that	_	IN	IN	_	20	VMOD	_	_
13	inducibility	_	NN	NN	_	20	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	IL-2	_	NN	NN	_	19	NMOD	_	_
17	receptor	_	NN	NN	_	19	NMOD	_	_
18	alpha	_	NN	NN	_	19	NMOD	_	_
19	chain	_	NN	NN	_	14	PMOD	_	_
20	is	_	VBZ	VBZ	_	11	PMOD	_	_
21	mediated	_	VBN	VBN	_	20	VC	_	_
22	by	_	IN	IN	_	21	LGS	_	_
23	enhanced	_	VBN	VBN	_	26	NMOD	_	_
24	NF-kappa	_	NN	NN	_	26	NMOD	_	_
25	B	_	NN	NN	_	26	NMOD	_	_
26	binding	_	NN	NN	_	22	PMOD	_	_
27	and	_	CC	CC	_	20	CC	_	_
28	that	_	IN	IN	_	50	VMOD	_	_
29	a	_	DT	DT	_	31	NMOD	_	_
30	heterologous	_	JJ	JJ	_	31	NMOD	_	_
31	promoter	_	NN	NN	_	50	SBJ	_	_
32	containing	_	VBG	VBG	_	31	NMOD	_	_
33	the	_	DT	DT	_	37	NMOD	_	_
34	NF-kappa	_	NN	NN	_	37	NMOD	_	_
35	B	_	NN	NN	_	37	NMOD	_	_
36	consensus	_	NN	NN	_	37	NMOD	_	_
37	sequence	_	NN	NN	_	32	OBJ	_	_
38	(	_	(	(	_	39	P	_	_
39	-291	_	CD	CD	_	37	PRN	_	_
40	to	_	TO	TO	_	39	NMOD	_	_
41	-245	_	CD	CD	_	39	NMOD	_	_
42	)	_	)	)	_	39	P	_	_
43	of	_	IN	IN	_	37	NMOD	_	_
44	the	_	DT	DT	_	49	NMOD	_	_
45	IL-2	_	NN	NN	_	49	NMOD	_	_
46	receptor	_	NN	NN	_	49	NMOD	_	_
47	alpha	_	NN	NN	_	49	NMOD	_	_
48	chain	_	NN	NN	_	49	NMOD	_	_
49	gene	_	NN	NN	_	43	PMOD	_	_
50	is	_	VBZ	VBZ	_	20	COORD	_	_
51	activated	_	VBN	VBN	_	50	VC	_	_
52	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	IL-2	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	capable	_	JJ	JJ	_	5	PRD	_	_
7	of	_	IN	IN	_	6	AMOD	_	_
8	increasing	_	VBG	VBG	_	7	PMOD	_	_
9	transcript	_	NN	NN	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	p50	_	NN	NN	_	14	NMOD	_	_
14	gene	_	NN	NN	_	11	PMOD	_	_
15	coding	_	VBG	VBG	_	14	NMOD	_	_
16	for	_	IN	IN	_	15	ADV	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	p50	_	NN	NN	_	19	NMOD	_	_
19	subunit	_	NN	NN	_	16	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	25	NMOD	_	_
22	NF-kappa	_	NN	NN	_	25	NMOD	_	_
23	B	_	NN	NN	_	25	NMOD	_	_
24	transcription	_	NN	NN	_	25	NMOD	_	_
25	factor	_	NN	NN	_	20	PMOD	_	_
26	,	_	,	,	_	5	P	_	_
27	whereas	_	IN	IN	_	5	COORD	_	_
28	mRNA	_	NN	NN	_	29	NMOD	_	_
29	levels	_	NNS	NNS	_	36	SBJ	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	the	_	DT	DT	_	35	NMOD	_	_
32	p65	_	NN	NN	_	35	NMOD	_	_
33	NF-kappa	_	NN	NN	_	35	NMOD	_	_
34	B	_	NN	NN	_	35	NMOD	_	_
35	gene	_	NN	NN	_	30	PMOD	_	_
36	remained	_	VBD	VBD	_	5	COORD	_	_
37	unchanged	_	JJ	JJ	_	36	PRD	_	_
38	.	_	.	.	_	5	P	_	_

1	Single	_	JJ	JJ	_	3	NMOD	_	_
2	point	_	NN	NN	_	3	NMOD	_	_
3	estimation	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	glucocorticoid	_	NN	NN	_	6	NMOD	_	_
6	receptors	_	NNS	NNS	_	4	PMOD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	lymphocytes	_	NNS	NNS	_	7	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	normal	_	JJ	JJ	_	11	NMOD	_	_
11	subjects	_	NNS	NNS	_	9	PMOD	_	_
12	and	_	CC	CC	_	9	CC	_	_
13	of	_	IN	IN	_	9	COORD	_	_
14	children	_	NNS	NNS	_	13	PMOD	_	_
15	under	_	IN	IN	_	14	NMOD	_	_
16	long	_	JJ	JJ	_	19	NMOD	_	_
17	term	_	NN	NN	_	19	NMOD	_	_
18	glucocorticoid	_	NN	NN	_	19	NMOD	_	_
19	treatment	_	NN	NN	_	15	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	single	_	JJ	JJ	_	4	NMOD	_	_
3	point	_	NN	NN	_	4	NMOD	_	_
4	assay	_	NN	NN	_	22	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	glucocorticoid	_	NN	NN	_	7	NMOD	_	_
7	receptors	_	NNS	NNS	_	5	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	GR	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	in	_	IN	IN	_	7	NMOD	_	_
12	human	_	JJ	JJ	_	13	NMOD	_	_
13	lymphocytes	_	NNS	NNS	_	11	PMOD	_	_
14	based	_	VBN	VBN	_	4	NMOD	_	_
15	on	_	IN	IN	_	14	PMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	measurement	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	specific	_	JJ	JJ	_	21	NMOD	_	_
20	dexamethasone	_	NN	NN	_	21	NMOD	_	_
21	binding	_	NN	NN	_	18	PMOD	_	_
22	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
23	been	_	VBN	VBN	_	22	VC	_	_
24	developed	_	VBN	VBN	_	23	VC	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	compared	_	VBN	VBN	_	24	COORD	_	_
27	with	_	IN	IN	_	26	ADV	_	_
28	a	_	DT	DT	_	32	NMOD	_	_
29	common	_	JJ	JJ	_	32	NMOD	_	_
30	multi-point	_	JJ	JJ	_	32	NMOD	_	_
31	Scatchard	_	NN	NN	_	32	NMOD	_	_
32	analysis	_	NN	NN	_	27	PMOD	_	_
33	.	_	.	.	_	22	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	assay	_	NN	NN	_	3	NMOD	_	_
3	conditions	_	NN	NN	_	29	SBJ	_	_
4	-	_	:	:	_	3	P	_	_
5	concentration	_	NN	NN	_	3	NMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	ligand	_	NN	NN	_	6	PMOD	_	_
9	20	_	CD	CD	_	10	NMOD	_	_
10	nmol\/l	_	NN	NN	_	5	NMOD	_	_
11	,	_	,	,	_	5	P	_	_
12	incubation	_	NN	NN	_	15	NMOD	_	_
13	time	_	NN	NN	_	15	NMOD	_	_
14	2	_	CD	CD	_	15	NMOD	_	_
15	h	_	NN	NN	_	5	COORD	_	_
16	and	_	CC	CC	_	5	CC	_	_
17	the	_	DT	DT	_	22	NMOD	_	_
18	cell	_	NN	NN	_	22	NMOD	_	_
19	count	_	NN	NN	_	22	NMOD	_	_
20	2-6	_	CD	CD	_	22	NMOD	_	_
21	mil.	_	CD	CD	_	22	NMOD	_	_
22	cells\/tube	_	NNS	NNS	_	5	COORD	_	_
23	in	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	28	NMOD	_	_
25	assay	_	NN	NN	_	28	NMOD	_	_
26	volume	_	NN	NN	_	28	NMOD	_	_
27	0.25	_	CD	CD	_	28	NMOD	_	_
28	ml	_	NN	NN	_	23	PMOD	_	_
29	were	_	VBD	VBD	_	0	ROOT-S	_	_
30	found	_	VBN	VBN	_	29	VC	_	_
31	to	_	TO	TO	_	32	VMOD	_	_
32	be	_	VB	VB	_	30	OBJ	_	_
33	optimal	_	JJ	JJ	_	32	PRD	_	_
34	.	_	.	.	_	29	P	_	_

1	An	_	DT	DT	_	2	NMOD	_	_
2	attempt	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	also	_	RB	RB	_	3	ADV	_	_
5	undertaken	_	VBN	VBN	_	3	VC	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	use	_	VB	VB	_	2	NMOD	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	harvester	_	NN	NN	_	7	OBJ	_	_
11	for	_	IN	IN	_	7	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	separation	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	cells	_	NNS	NNS	_	14	PMOD	_	_
16	from	_	IN	IN	_	13	NMOD	_	_
17	unbound	_	JJ	JJ	_	18	NMOD	_	_
18	ligand	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	Though	_	IN	IN	_	28	ADV	_	_
2	specifically	_	RB	RB	_	3	AMOD	_	_
3	bound	_	VBN	VBN	_	4	NMOD	_	_
4	dexamethasone	_	NN	NN	_	14	SBJ	_	_
5	measured	_	VBN	VBN	_	4	NMOD	_	_
6	by	_	IN	IN	_	5	ADV	_	_
7	whole-cell	_	JJ	JJ	_	8	NMOD	_	_
8	assay	_	NN	NN	_	6	PMOD	_	_
9	and	_	CC	CC	_	4	CC	_	_
10	that	_	DT	DT	_	4	COORD	_	_
11	using	_	VBG	VBG	_	10	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	harvester	_	NN	NN	_	11	OBJ	_	_
14	correlated	_	VBD	VBD	_	1	VMOD	_	_
15	well	_	RB	RB	_	14	ADV	_	_
16	,	_	,	,	_	28	P	_	_
17	almost	_	RB	RB	_	18	DEP	_	_
18	by	_	IN	IN	_	21	AMOD	_	_
19	one	_	CD	CD	_	20	NMOD	_	_
20	order	_	NN	NN	_	18	PMOD	_	_
21	lower	_	JJR	JJR	_	22	NMOD	_	_
22	values	_	NNS	NNS	_	28	SBJ	_	_
23	obtained	_	VBN	VBN	_	22	NMOD	_	_
24	with	_	IN	IN	_	23	ADV	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	latter	_	JJ	JJ	_	27	NMOD	_	_
27	method	_	NN	NN	_	24	PMOD	_	_
28	render	_	VBP	VBP	_	0	ROOT-S	_	_
29	it	_	PRP	PRP	_	30	SBJ	_	_
30	non-applicable	_	JJ	JJ	_	28	OBJ	_	_
31	for	_	IN	IN	_	30	AMOD	_	_
32	receptor	_	NN	NN	_	33	NMOD	_	_
33	quantitation	_	NN	NN	_	31	PMOD	_	_
34	.	_	.	.	_	28	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	16	SBJ	_	_
3	from	_	IN	IN	_	2	NMOD	_	_
4	9	_	CD	CD	_	6	NMOD	_	_
5	healthy	_	JJ	JJ	_	6	NMOD	_	_
6	volunteers	_	NNS	NNS	_	3	PMOD	_	_
7	(	_	(	(	_	2	PRN	_	_
8	average	_	JJ	JJ	_	10	NMOD	_	_
9	GR	_	NN	NN	_	10	NMOD	_	_
10	concentration	_	NN	NN	_	7	DEP	_	_
11	7131	_	CD	CD	_	14	NMOD	_	_
12	+\/-	_	CC	CC	_	11	CC	_	_
13	1256	_	CD	CD	_	11	COORD	_	_
14	sites\/cell	_	NNS	NNS	_	10	NMOD	_	_
15	)	_	)	)	_	7	P	_	_
16	correlated	_	VBD	VBD	_	0	ROOT-S	_	_
17	excellently	_	RB	RB	_	16	ADV	_	_
18	with	_	IN	IN	_	16	ADV	_	_
19	those	_	DT	DT	_	18	PMOD	_	_
20	obtained	_	VBN	VBN	_	19	NMOD	_	_
21	by	_	IN	IN	_	20	ADV	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	Scatchard	_	NN	NN	_	24	NMOD	_	_
24	analysis	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	single	_	JJ	JJ	_	4	NMOD	_	_
3	point	_	NN	NN	_	4	NMOD	_	_
4	assay	_	NN	NN	_	5	SBJ	_	_
5	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	been	_	VBN	VBN	_	5	VC	_	_
7	also	_	RB	RB	_	6	ADV	_	_
8	applied	_	VBN	VBN	_	6	VC	_	_
9	for	_	IN	IN	_	8	ADV	_	_
10	determination	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	GH	_	NN	NN	_	11	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	10	_	CD	CD	_	15	NMOD	_	_
15	children	_	NNS	NNS	_	13	PMOD	_	_
16	treated	_	VBN	VBN	_	15	NMOD	_	_
17	with	_	IN	IN	_	16	ADV	_	_
18	large	_	JJ	JJ	_	19	NMOD	_	_
19	doses	_	NNS	NNS	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	prednisone	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	average	_	JJ	JJ	_	3	NMOD	_	_
3	values	_	NNS	NNS	_	7	SBJ	_	_
4	from	_	IN	IN	_	3	NMOD	_	_
5	healthy	_	JJ	JJ	_	6	NMOD	_	_
6	volunteers	_	NNS	NNS	_	4	PMOD	_	_
7	did	_	VBD	VBD	_	0	ROOT-S	_	_
8	not	_	RB	RB	_	7	VMOD	_	_
9	differ	_	VB	VB	_	7	VC	_	_
10	significantly	_	RB	RB	_	9	ADV	_	_
11	from	_	IN	IN	_	9	ADV	_	_
12	those	_	DT	DT	_	11	PMOD	_	_
13	found	_	VBN	VBN	_	12	NMOD	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	these	_	DT	DT	_	16	NMOD	_	_
16	children	_	NNS	NNS	_	14	PMOD	_	_
17	,	_	,	,	_	9	P	_	_
18	though	_	RB	RB	_	22	VMOD	_	_
19	much	_	RB	RB	_	20	AMOD	_	_
20	broader	_	JJR	JJR	_	21	NMOD	_	_
21	range	_	NN	NN	_	22	SBJ	_	_
22	was	_	VBD	VBD	_	9	OBJ	_	_
23	found	_	VBN	VBN	_	22	VC	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	patients	_	NNS	NNS	_	24	PMOD	_	_
26	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	11	NMOD	_	_
5	human	_	JJ	JJ	_	11	NMOD	_	_
6	tumor	_	NN	NN	_	11	NMOD	_	_
7	necrosis	_	NN	NN	_	11	NMOD	_	_
8	factor	_	NN	NN	_	11	NMOD	_	_
9	alpha	_	NN	NN	_	11	NMOD	_	_
10	promoter	_	NN	NN	_	11	NMOD	_	_
11	region	_	NN	NN	_	3	PMOD	_	_
12	in	_	IN	IN	_	2	NMOD	_	_
13	macrophage	_	NN	NN	_	21	NMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	cell	_	NN	NN	_	13	COORD	_	_
17	,	_	,	,	_	13	P	_	_
18	and	_	CC	CC	_	13	CC	_	_
19	B	_	NN	NN	_	20	NMOD	_	_
20	cell	_	NN	NN	_	13	COORD	_	_
21	lines	_	NNS	NNS	_	12	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	13	NMOD	_	_
2	1311-base	_	JJ	JJ	_	3	AMOD	_	_
3	pair	_	NN	NN	_	13	NMOD	_	_
4	human	_	JJ	JJ	_	13	NMOD	_	_
5	tumor	_	NN	NN	_	13	NMOD	_	_
6	necrosis	_	NN	NN	_	13	NMOD	_	_
7	factor	_	NN	NN	_	13	NMOD	_	_
8	(	_	(	(	_	13	P	_	_
9	TNF	_	NN	NN	_	13	NMOD	_	_
10	)	_	)	)	_	13	P	_	_
11	alpha	_	NN	NN	_	13	NMOD	_	_
12	promoter	_	NN	NN	_	13	NMOD	_	_
13	region	_	NN	NN	_	14	SBJ	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	fused	_	VBN	VBN	_	14	VC	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	the	_	DT	DT	_	23	NMOD	_	_
18	luciferase	_	NN	NN	_	23	NMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	Luc	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	reporter	_	NN	NN	_	23	NMOD	_	_
23	gene	_	NN	NN	_	16	PMOD	_	_
24	and	_	CC	CC	_	15	CC	_	_
25	studied	_	VBN	VBN	_	15	COORD	_	_
26	in	_	IN	IN	_	25	ADV	_	_
27	a	_	DT	DT	_	30	NMOD	_	_
28	transient	_	JJ	JJ	_	30	NMOD	_	_
29	transfection	_	NN	NN	_	30	NMOD	_	_
30	system	_	NN	NN	_	26	PMOD	_	_
31	in	_	IN	IN	_	25	ADV	_	_
32	three	_	CD	CD	_	36	NMOD	_	_
33	TNF	_	NN	NN	_	36	NMOD	_	_
34	producing	_	NN	NN	_	36	NMOD	_	_
35	cell	_	NN	NN	_	36	NMOD	_	_
36	lines	_	NNS	NNS	_	31	PMOD	_	_
37	,	_	,	,	_	36	P	_	_
38	the	_	DT	DT	_	42	NMOD	_	_
39	U937	_	NN	NN	_	42	NMOD	_	_
40	macrophage	_	NN	NN	_	42	NMOD	_	_
41	cell	_	NN	NN	_	42	NMOD	_	_
42	line	_	NN	NN	_	36	NMOD	_	_
43	,	_	,	,	_	42	P	_	_
44	the	_	DT	DT	_	49	NMOD	_	_
45	MLA	_	NN	NN	_	49	NMOD	_	_
46	144	_	CD	CD	_	49	NMOD	_	_
47	T	_	NN	NN	_	49	NMOD	_	_
48	cell	_	NN	NN	_	49	NMOD	_	_
49	line	_	NN	NN	_	42	COORD	_	_
50	,	_	,	,	_	42	P	_	_
51	and	_	CC	CC	_	42	CC	_	_
52	the	_	DT	DT	_	56	NMOD	_	_
53	729-6	_	CD	CD	_	56	NMOD	_	_
54	B	_	NN	NN	_	56	NMOD	_	_
55	cell	_	NN	NN	_	56	NMOD	_	_
56	line	_	NN	NN	_	42	COORD	_	_
57	.	_	.	.	_	14	P	_	_

1	This	_	DT	DT	_	5	NMOD	_	_
2	full	_	JJ	JJ	_	5	NMOD	_	_
3	length	_	NN	NN	_	5	NMOD	_	_
4	promoter	_	NN	NN	_	5	NMOD	_	_
5	construct	_	NN	NN	_	6	SBJ	_	_
6	can	_	MD	MD	_	0	ROOT-S	_	_
7	be	_	VB	VB	_	6	VC	_	_
8	induced	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	phorbol	_	NN	NN	_	12	NMOD	_	_
11	13-myristate	_	NN	NN	_	12	NMOD	_	_
12	acetate	_	NN	NN	_	9	PMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	PMA	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	in	_	IN	IN	_	8	ADV	_	_
17	each	_	DT	DT	_	16	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	these	_	DT	DT	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	types	_	NNS	NNS	_	18	PMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	Analysis	_	NN	NN	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	series	_	NN	NN	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	5'-truncations	_	NNS	NNS	_	5	PMOD	_	_
7	showed	_	VBD	VBD	_	0	ROOT-S	_	_
8	several	_	JJ	JJ	_	9	NMOD	_	_
9	peaks	_	NNS	NNS	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	basal	_	JJ	JJ	_	15	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	PMA	_	NN	NN	_	11	COORD	_	_
14	induced	_	JJ	JJ	_	13	AMOD	_	_
15	activity	_	NN	NN	_	10	PMOD	_	_
16	suggesting	_	VBG	VBG	_	9	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	presence	_	NN	NN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	several	_	JJ	JJ	_	25	NMOD	_	_
21	positive	_	JJ	JJ	_	25	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	negative	_	JJ	JJ	_	21	COORD	_	_
24	regulatory	_	JJ	JJ	_	25	NMOD	_	_
25	elements	_	NNS	NNS	_	19	PMOD	_	_
26	.	_	.	.	_	7	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	PMA	_	NN	NN	_	4	NMOD	_	_
3	responsive	_	JJ	JJ	_	4	NMOD	_	_
4	element	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	localized	_	JJ	JJ	_	5	VC	_	_
7	to	_	TO	TO	_	6	ADV	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	region	_	NN	NN	_	7	PMOD	_	_
10	between	_	IN	IN	_	9	NMOD	_	_
11	-95	_	CD	CD	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	-36	_	CD	CD	_	11	COORD	_	_
14	bp	_	NN	NN	_	10	PMOD	_	_
15	relative	_	JJ	JJ	_	9	NMOD	_	_
16	to	_	TO	TO	_	15	AMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	transcription	_	NN	NN	_	20	NMOD	_	_
19	start	_	NN	NN	_	20	NMOD	_	_
20	site	_	NN	NN	_	16	PMOD	_	_
21	.	_	.	.	_	5	P	_	_

1	Within	_	IN	IN	_	11	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	region	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	11	P	_	_
5	single	_	JJ	JJ	_	10	NMOD	_	_
6	AP-2-	_	NN	NN	_	10	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	AP-1-like	_	JJ	JJ	_	6	COORD	_	_
9	consensus	_	NN	NN	_	10	NMOD	_	_
10	sequences	_	NNS	NNS	_	11	SBJ	_	_
11	were	_	VBD	VBD	_	0	ROOT-S	_	_
12	noted	_	VBN	VBN	_	11	VC	_	_
13	.	_	.	.	_	11	P	_	_

1	These	_	DT	DT	_	5	NMOD	_	_
2	AP-2	_	NN	NN	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	AP-1	_	NN	NN	_	2	COORD	_	_
5	sites	_	NNS	NNS	_	6	SBJ	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	each	_	DT	DT	_	6	VMOD	_	_
8	modified	_	VBN	VBN	_	6	VC	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	a	_	DT	DT	_	13	NMOD	_	_
11	double	_	JJ	JJ	_	13	NMOD	_	_
12	point	_	NN	NN	_	13	NMOD	_	_
13	mutation	_	NN	NN	_	9	PMOD	_	_
14	.	_	.	.	_	6	P	_	_

1	A	_	DT	DT	_	7	NMOD	_	_
2	modest	_	JJ	JJ	_	7	NMOD	_	_
3	(	_	(	(	_	5	P	_	_
4	20-50	_	CD	CD	_	5	NMOD	_	_
5	%	_	NN	NN	_	2	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	reduction	_	NN	NN	_	12	SBJ	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	TNF	_	NN	NN	_	11	NMOD	_	_
10	promoter	_	NN	NN	_	11	NMOD	_	_
11	activity	_	NN	NN	_	8	PMOD	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	observed	_	VBN	VBN	_	12	VC	_	_
14	with	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	AP-2	_	NN	NN	_	18	NMOD	_	_
17	site	_	NN	NN	_	18	NMOD	_	_
18	mutation	_	NN	NN	_	14	PMOD	_	_
19	.	_	.	.	_	12	P	_	_

1	However	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	mutation	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	AP-1	_	NN	NN	_	7	NMOD	_	_
7	site	_	NN	NN	_	4	PMOD	_	_
8	markedly	_	RB	RB	_	9	ADV	_	_
9	diminished	_	VBD	VBD	_	0	ROOT-S	_	_
10	both	_	CC	CC	_	16	CC	_	_
11	the	_	DT	DT	_	16	NMOD	_	_
12	basal	_	JJ	JJ	_	16	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	PMA-activated	_	JJ	JJ	_	12	COORD	_	_
15	promoter	_	NN	NN	_	16	NMOD	_	_
16	activity	_	NN	NN	_	9	OBJ	_	_
17	.	_	.	.	_	9	P	_	_

1	Also	_	RB	RB	_	13	ADV	_	_
2	co-transfections	_	NNS	NNS	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	wild-type	_	JJ	JJ	_	7	NMOD	_	_
6	promoter	_	NN	NN	_	7	NMOD	_	_
7	construct	_	NN	NN	_	3	PMOD	_	_
8	with	_	IN	IN	_	2	NMOD	_	_
9	an	_	DT	DT	_	12	NMOD	_	_
10	AP-1\/c-jun	_	NN	NN	_	12	NMOD	_	_
11	expression	_	NN	NN	_	12	NMOD	_	_
12	vector	_	NN	NN	_	8	PMOD	_	_
13	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	augmented	_	JJ	JJ	_	20	NMOD	_	_
16	basal	_	JJ	JJ	_	20	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	PMA-induced	_	JJ	JJ	_	16	COORD	_	_
19	promoter	_	NN	NN	_	20	NMOD	_	_
20	activity	_	NN	NN	_	14	PMOD	_	_
21	.	_	.	.	_	13	P	_	_

1	Redox	_	NN	NN	_	2	NMOD	_	_
2	status	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	cells	_	NNS	NNS	_	3	PMOD	_	_
5	influences	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	constitutive	_	JJ	JJ	_	11	NMOD	_	_
7	or	_	CC	CC	_	6	CC	_	_
8	induced	_	VBN	VBN	_	6	COORD	_	_
9	NF-kappa	_	NN	NN	_	11	NMOD	_	_
10	B	_	NN	NN	_	11	NMOD	_	_
11	translocation	_	NN	NN	_	5	OBJ	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	HIV	_	NN	NN	_	17	NMOD	_	_
14	long	_	JJ	JJ	_	17	NMOD	_	_
15	terminal	_	JJ	JJ	_	17	NMOD	_	_
16	repeat	_	NN	NN	_	17	NMOD	_	_
17	activity	_	NN	NN	_	11	COORD	_	_
18	in	_	IN	IN	_	11	NMOD	_	_
19	human	_	JJ	JJ	_	24	NMOD	_	_
20	T	_	NN	NN	_	24	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	monocytic	_	JJ	JJ	_	20	COORD	_	_
23	cell	_	NN	NN	_	24	NMOD	_	_
24	lines	_	NNS	NNS	_	18	PMOD	_	_
25	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	tested	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	hypothesis	_	NN	NN	_	3	OBJ	_	_
6	that	_	IN	IN	_	5	NMOD	_	_
7	cellular	_	JJ	JJ	_	9	NMOD	_	_
8	activation	_	NN	NN	_	9	NMOD	_	_
9	events	_	NNS	NNS	_	26	SBJ	_	_
10	occurring	_	VBG	VBG	_	9	NMOD	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	lymphocytes	_	NNS	NNS	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	monocytes	_	NNS	NNS	_	13	COORD	_	_
16	and	_	CC	CC	_	10	CC	_	_
17	mediated	_	VBN	VBN	_	10	COORD	_	_
18	through	_	IN	IN	_	17	ADV	_	_
19	translocation	_	NN	NN	_	18	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	25	NMOD	_	_
22	transcription	_	NN	NN	_	25	NMOD	_	_
23	factor	_	NN	NN	_	25	NMOD	_	_
24	NF-kappa	_	NN	NN	_	25	NMOD	_	_
25	B	_	NN	NN	_	20	PMOD	_	_
26	are	_	VBP	VBP	_	6	VMOD	_	_
27	dependent	_	JJ	JJ	_	26	PRD	_	_
28	upon	_	IN	IN	_	27	AMOD	_	_
29	the	_	DT	DT	_	32	NMOD	_	_
30	constitutive	_	JJ	JJ	_	32	NMOD	_	_
31	redox	_	NN	NN	_	32	NMOD	_	_
32	status	_	NN	NN	_	28	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	these	_	DT	DT	_	35	NMOD	_	_
35	cells	_	NNS	NNS	_	33	PMOD	_	_
36	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	used	_	VBD	VBD	_	0	ROOT-S	_	_
3	phenolic	_	JJ	JJ	_	8	NMOD	_	_
4	,	_	,	,	_	3	P	_	_
5	lipid-soluble	_	JJ	JJ	_	3	COORD	_	_
6	,	_	,	,	_	3	P	_	_
7	chain-breaking	_	JJ	JJ	_	3	COORD	_	_
8	antioxidants	_	NNS	NNS	_	2	IOBJ	_	_
9	(	_	(	(	_	11	P	_	_
10	butylated	_	VBN	VBN	_	11	NMOD	_	_
11	hydroxyanisole	_	NN	NN	_	8	PRN	_	_
12	(	_	(	(	_	13	P	_	_
13	BHA	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	,	_	,	,	_	11	P	_	_
16	nordihydroquairetic	_	JJ	JJ	_	17	NMOD	_	_
17	acid	_	NN	NN	_	11	COORD	_	_
18	,	_	,	,	_	11	P	_	_
19	or	_	CC	CC	_	11	CC	_	_
20	alpha-tocopherol	_	NN	NN	_	11	COORD	_	_
21	(	_	(	(	_	23	P	_	_
22	vitamin	_	NN	NN	_	23	NMOD	_	_
23	E	_	NN	NN	_	20	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	to	_	TO	TO	_	26	VMOD	_	_
26	show	_	VB	VB	_	2	OBJ	_	_
27	that	_	IN	IN	_	26	OBJ	_	_
28	peroxyl	_	JJ	JJ	_	30	NMOD	_	_
29	radical	_	JJ	JJ	_	30	NMOD	_	_
30	scavenging	_	NN	NN	_	38	SBJ	_	_
31	in	_	IN	IN	_	30	NMOD	_	_
32	unstimulated	_	JJ	JJ	_	37	NMOD	_	_
33	and	_	CC	CC	_	32	CC	_	_
34	PMA-	_	NN	NN	_	32	COORD	_	_
35	or	_	CC	CC	_	34	CC	_	_
36	TNF-stimulated	_	JJ	JJ	_	34	COORD	_	_
37	cells	_	NNS	NNS	_	31	PMOD	_	_
38	blocks	_	VBZ	VBZ	_	27	VMOD	_	_
39	the	_	DT	DT	_	40	NMOD	_	_
40	functions	_	NNS	NNS	_	38	OBJ	_	_
41	depending	_	VBG	VBG	_	38	ADV	_	_
42	on	_	IN	IN	_	41	PMOD	_	_
43	NF-kappa	_	NN	NN	_	45	NMOD	_	_
44	B	_	NN	NN	_	45	NMOD	_	_
45	activation	_	NN	NN	_	42	PMOD	_	_
46	.	_	.	.	_	2	P	_	_

1	BHA	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	to	_	TO	TO	_	5	VMOD	_	_
5	suppress	_	VB	VB	_	3	OBJ	_	_
6	not	_	RB	RB	_	8	CC	_	_
7	only	_	RB	RB	_	6	DEP	_	_
8	PMA-	_	NN	NN	_	17	NMOD	_	_
9	or	_	CC	CC	_	8	CC	_	_
10	TNF-induced	_	JJ	JJ	_	8	COORD	_	_
11	,	_	,	,	_	8	P	_	_
12	but	_	CC	CC	_	8	CC	_	_
13	also	_	RB	RB	_	12	COORD	_	_
14	constitutive	_	JJ	JJ	_	8	COORD	_	_
15	,	_	,	,	_	8	P	_	_
16	HIV-enhancer	_	JJ	JJ	_	17	NMOD	_	_
17	activity	_	NN	NN	_	5	OBJ	_	_
18	concomitant	_	JJ	JJ	_	17	NMOD	_	_
19	to	_	TO	TO	_	18	AMOD	_	_
20	an	_	DT	DT	_	21	NMOD	_	_
21	inhibition	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	NF-kappa	_	NN	NN	_	26	NMOD	_	_
24	B	_	NN	NN	_	26	NMOD	_	_
25	binding	_	NN	NN	_	26	NMOD	_	_
26	activity	_	NN	NN	_	22	PMOD	_	_
27	in	_	IN	IN	_	26	NMOD	_	_
28	both	_	CC	CC	_	30	CC	_	_
29	lymphoblastoid	_	JJ	JJ	_	30	AMOD	_	_
30	T	_	NN	NN	_	40	NMOD	_	_
31	(	_	(	(	_	32	P	_	_
32	J.Jhan	_	NN	NN	_	30	PRN	_	_
33	)	_	)	)	_	32	P	_	_
34	and	_	CC	CC	_	30	CC	_	_
35	monocytic	_	JJ	JJ	_	30	COORD	_	_
36	(	_	(	(	_	37	P	_	_
37	U937	_	NN	NN	_	35	PRN	_	_
38	)	_	)	)	_	37	P	_	_
39	cell	_	NN	NN	_	40	NMOD	_	_
40	lines	_	NNS	NNS	_	27	PMOD	_	_
41	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	also	_	RB	RB	_	2	ADV	_	_
4	true	_	JJ	JJ	_	2	PRD	_	_
5	for	_	IN	IN	_	2	ADV	_	_
6	KBF	_	NN	NN	_	12	NMOD	_	_
7	(	_	(	(	_	9	P	_	_
8	p50	_	NN	NN	_	9	NMOD	_	_
9	homodimer	_	NN	NN	_	6	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	binding	_	NN	NN	_	12	NMOD	_	_
12	activity	_	NN	NN	_	5	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	U937	_	NN	NN	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	13	PMOD	_	_
16	.	_	.	.	_	2	P	_	_

1	Secretion	_	NN	NN	_	13	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	TNF	_	NN	NN	_	2	PMOD	_	_
4	,	_	,	,	_	3	P	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	product	_	NN	NN	_	3	NMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	another	_	DT	DT	_	11	NMOD	_	_
9	NF-kappa	_	NN	NN	_	11	NMOD	_	_
10	B-dependent	_	JJ	JJ	_	9	AMOD	_	_
11	gene	_	NN	NN	_	7	PMOD	_	_
12	,	_	,	,	_	3	P	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	abolished	_	VBN	VBN	_	13	VC	_	_
15	by	_	IN	IN	_	14	ADV	_	_
16	BHA	_	NN	NN	_	15	PMOD	_	_
17	in	_	IN	IN	_	14	ADV	_	_
18	PMA-stimulated	_	JJ	JJ	_	20	NMOD	_	_
19	U937	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	anti-oxidative	_	JJ	JJ	_	3	NMOD	_	_
3	effect	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	BHA	_	NN	NN	_	4	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	accompanied	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	an	_	DT	DT	_	10	NMOD	_	_
10	increase	_	NN	NN	_	8	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	thiol	_	NN	NN	_	18	NMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	but	_	CC	CC	_	12	CC	_	_
15	not	_	RB	RB	_	14	COORD	_	_
16	glutathione	_	NN	NN	_	12	COORD	_	_
17	,	_	,	,	_	12	P	_	_
18	content	_	NN	NN	_	11	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	stimulated	_	VBN	VBN	_	24	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	unstimulated	_	JJ	JJ	_	20	COORD	_	_
23	T	_	NN	NN	_	24	NMOD	_	_
24	cell	_	NN	NN	_	19	PMOD	_	_
25	,	_	,	,	_	6	P	_	_
26	whereas	_	IN	IN	_	6	COORD	_	_
27	TNF	_	NN	NN	_	28	NMOD	_	_
28	stimulation	_	NN	NN	_	31	SBJ	_	_
29	itself	_	PRP	PRP	_	28	NMOD	_	_
30	barely	_	RB	RB	_	31	ADV	_	_
31	modified	_	VBD	VBD	_	6	COORD	_	_
32	the	_	DT	DT	_	35	NMOD	_	_
33	cellular	_	JJ	JJ	_	35	NMOD	_	_
34	thiol	_	NN	NN	_	35	NMOD	_	_
35	level	_	NN	NN	_	31	OBJ	_	_
36	.	_	.	.	_	6	P	_	_

1	Oxidative	_	JJ	JJ	_	2	NMOD	_	_
2	stress	_	NN	NN	_	18	SBJ	_	_
3	obtained	_	VBN	VBN	_	2	NMOD	_	_
4	by	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	addition	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	H2O2	_	NN	NN	_	7	PMOD	_	_
9	to	_	TO	TO	_	6	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	culture	_	NN	NN	_	12	NMOD	_	_
12	medium	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	J.Jhan	_	NN	NN	_	17	NMOD	_	_
15	or	_	CC	CC	_	14	CC	_	_
16	U937	_	NN	NN	_	14	COORD	_	_
17	cells	_	NNS	NNS	_	13	PMOD	_	_
18	could	_	MD	MD	_	0	ROOT-S	_	_
19	not	_	RB	RB	_	18	VMOD	_	_
20	by	_	IN	IN	_	18	ADV	_	_
21	itself	_	PRP	PRP	_	20	PMOD	_	_
22	induce	_	VB	VB	_	18	VC	_	_
23	NF-kappa	_	NN	NN	_	25	NMOD	_	_
24	B	_	NN	NN	_	25	NMOD	_	_
25	activation	_	NN	NN	_	22	OBJ	_	_
26	.	_	.	.	_	18	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	observations	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	TNF	_	NN	NN	_	8	SBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	PMA	_	NN	NN	_	5	COORD	_	_
8	do	_	VBP	VBP	_	4	VMOD	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	lead	_	VB	VB	_	8	VC	_	_
11	to	_	TO	TO	_	10	ADV	_	_
12	NF-kappa	_	NN	NN	_	14	NMOD	_	_
13	B	_	NN	NN	_	14	NMOD	_	_
14	activation	_	NN	NN	_	11	PMOD	_	_
15	through	_	IN	IN	_	14	NMOD	_	_
16	induction	_	NN	NN	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	changes	_	NNS	NNS	_	17	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	cell	_	NN	NN	_	23	NMOD	_	_
22	redox	_	NN	NN	_	23	NMOD	_	_
23	status	_	NN	NN	_	19	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	Rather	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	TNF	_	NN	NN	_	6	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	PMA	_	NN	NN	_	3	COORD	_	_
6	can	_	MD	MD	_	0	ROOT-S	_	_
7	exert	_	VB	VB	_	6	VC	_	_
8	their	_	PRP$	PRP$	_	9	NMOD	_	_
9	effect	_	NN	NN	_	7	IOBJ	_	_
10	only	_	RB	RB	_	11	VMOD	_	_
11	if	_	IN	IN	_	7	OBJ	_	_
12	cells	_	NNS	NNS	_	13	SBJ	_	_
13	are	_	VBP	VBP	_	11	VMOD	_	_
14	in	_	IN	IN	_	13	PRD	_	_
15	an	_	DT	DT	_	18	NMOD	_	_
16	appropriate	_	JJ	JJ	_	18	NMOD	_	_
17	redox	_	NN	NN	_	18	NMOD	_	_
18	status	_	NN	NN	_	14	PMOD	_	_
19	,	_	,	,	_	13	P	_	_
20	because	_	IN	IN	_	13	ADV	_	_
21	prior	_	JJ	JJ	_	22	NMOD	_	_
22	modification	_	NN	NN	_	28	SBJ	_	_
23	toward	_	IN	IN	_	22	NMOD	_	_
24	reduction	_	NN	NN	_	23	PMOD	_	_
25	with	_	IN	IN	_	22	NMOD	_	_
26	BHA	_	NN	NN	_	27	NMOD	_	_
27	treatment	_	NN	NN	_	25	PMOD	_	_
28	prevents	_	VBZ	VBZ	_	20	VMOD	_	_
29	this	_	DT	DT	_	30	VMOD	_	_
30	activation	_	NN	NN	_	28	VC	_	_
31	.	_	.	.	_	6	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	basal	_	JJ	JJ	_	7	NMOD	_	_
6	redox	_	NN	NN	_	7	NMOD	_	_
7	equilibrium	_	NN	NN	_	11	SBJ	_	_
8	tending	_	VBG	VBG	_	7	NMOD	_	_
9	toward	_	IN	IN	_	8	ADV	_	_
10	oxidation	_	NN	NN	_	9	PMOD	_	_
11	is	_	VBZ	VBZ	_	3	VMOD	_	_
12	a	_	DT	DT	_	13	NMOD	_	_
13	prerequisite	_	NN	NN	_	11	PRD	_	_
14	for	_	IN	IN	_	13	NMOD	_	_
15	full	_	JJ	JJ	_	16	NMOD	_	_
16	activation	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	transduction	_	NN	NN	_	19	NMOD	_	_
19	pathways	_	NNS	NNS	_	17	PMOD	_	_
20	regulating	_	VBG	VBG	_	16	NMOD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	activity	_	NN	NN	_	20	OBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	NF-kappa	_	NN	NN	_	26	NMOD	_	_
25	B-dependent	_	JJ	JJ	_	24	AMOD	_	_
26	genes	_	NNS	NNS	_	23	PMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	Expression	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	c-fos	_	NN	NN	_	2	PMOD	_	_
4	,	_	,	,	_	3	P	_	_
5	c-jun	_	NN	NN	_	3	COORD	_	_
6	and	_	CC	CC	_	3	CC	_	_
7	jun	_	NN	NN	_	8	NMOD	_	_
8	B	_	NN	NN	_	3	COORD	_	_
9	in	_	IN	IN	_	1	NMOD	_	_
10	peripheral	_	JJ	JJ	_	12	NMOD	_	_
11	blood	_	NN	NN	_	12	NMOD	_	_
12	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
13	from	_	IN	IN	_	12	NMOD	_	_
14	young	_	JJ	JJ	_	17	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	elderly	_	JJ	JJ	_	14	COORD	_	_
17	adults	_	NNS	NNS	_	13	PMOD	_	_
18	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	expression	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	c-fos	_	NN	NN	_	10	NMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	c-jun	_	NN	NN	_	4	COORD	_	_
7	and	_	CC	CC	_	4	CC	_	_
8	jun	_	NN	NN	_	9	NMOD	_	_
9	B	_	NN	NN	_	4	COORD	_	_
10	proto-oncogenes	_	NNS	NNS	_	3	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	studied	_	VBN	VBN	_	11	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	phytohemagglutinin	_	NN	NN	_	18	AMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	PHA	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	activated	_	VBN	VBN	_	21	NMOD	_	_
19	peripheral	_	JJ	JJ	_	21	NMOD	_	_
20	blood	_	NN	NN	_	21	NMOD	_	_
21	lymphocytes	_	NNS	NNS	_	13	PMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	PBL	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	from	_	IN	IN	_	21	NMOD	_	_
26	young	_	JJ	JJ	_	29	NMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	aged	_	JJ	JJ	_	26	COORD	_	_
29	humans	_	NNS	NNS	_	25	PMOD	_	_
30	.	_	.	.	_	11	P	_	_

1	Specific	_	JJ	JJ	_	2	NMOD	_	_
2	mRNAs	_	NNS	NNS	_	7	SBJ	_	_
3	for	_	IN	IN	_	2	NMOD	_	_
4	c-fos	_	NN	NN	_	3	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	c-jun	_	NN	NN	_	4	COORD	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	detectable	_	JJ	JJ	_	7	PRD	_	_
9	within	_	IN	IN	_	7	TMP	_	_
10	30	_	CD	CD	_	11	NMOD	_	_
11	min	_	NN	NN	_	9	PMOD	_	_
12	after	_	IN	IN	_	11	TMP	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	activation	_	NN	NN	_	12	PMOD	_	_
15	and	_	CC	CC	_	7	CC	_	_
16	reached	_	VBD	VBD	_	7	COORD	_	_
17	maximal	_	JJ	JJ	_	18	NMOD	_	_
18	levels	_	NNS	NNS	_	16	OBJ	_	_
19	within	_	IN	IN	_	16	TMP	_	_
20	2	_	CD	CD	_	21	NMOD	_	_
21	h	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	c-fos	_	NN	NN	_	6	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	jun	_	NN	NN	_	5	NMOD	_	_
5	B	_	NN	NN	_	2	COORD	_	_
6	mRNAs	_	NNS	NNS	_	7	SBJ	_	_
7	decreased	_	VBD	VBD	_	0	ROOT-S	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	pre-activation	_	NN	NN	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	8	PMOD	_	_
11	within	_	IN	IN	_	7	TMP	_	_
12	6	_	CD	CD	_	13	NMOD	_	_
13	h	_	NN	NN	_	11	PMOD	_	_
14	,	_	,	,	_	7	P	_	_
15	while	_	IN	IN	_	7	OBJ	_	_
16	c-jun	_	NN	NN	_	17	NMOD	_	_
17	mRNA	_	NN	NN	_	18	SBJ	_	_
18	remained	_	VBD	VBD	_	15	VMOD	_	_
19	elevated	_	JJ	JJ	_	18	PRD	_	_
20	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	PHA-activated	_	JJ	JJ	_	3	NMOD	_	_
3	PBL	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	8	P	_	_
5	no	_	DT	DT	_	7	NMOD	_	_
6	age-related	_	JJ	JJ	_	7	NMOD	_	_
7	differences	_	NNS	NNS	_	8	SBJ	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	observed	_	VBN	VBN	_	8	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	c-fos	_	NN	NN	_	16	NMOD	_	_
12	or	_	CC	CC	_	11	CC	_	_
13	jun	_	NN	NN	_	14	NMOD	_	_
14	B	_	NN	NN	_	11	COORD	_	_
15	mRNA	_	NN	NN	_	16	NMOD	_	_
16	expression	_	NN	NN	_	10	PMOD	_	_
17	.	_	.	.	_	8	P	_	_

1	However	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	c-jun	_	NN	NN	_	5	NMOD	_	_
4	mRNA	_	NN	NN	_	5	NMOD	_	_
5	levels	_	NNS	NNS	_	6	SBJ	_	_
6	decreased	_	VBD	VBD	_	0	ROOT-S	_	_
7	significantly	_	RB	RB	_	6	ADV	_	_
8	(	_	(	(	_	20	P	_	_
9	1.73	_	CD	CD	_	17	NMOD	_	_
10	+\/-	_	CC	CC	_	9	CC	_	_
11	0.08	_	CD	CD	_	9	COORD	_	_
12	vs.	_	CC	CC	_	17	CC	_	_
13	1.16	_	CD	CD	_	17	NMOD	_	_
14	+\/-	_	CC	CC	_	13	CC	_	_
15	0.09	_	CD	CD	_	13	COORD	_	_
16	arbitrary	_	JJ	JJ	_	17	NMOD	_	_
17	units	_	NNS	NNS	_	20	DEP	_	_
18	,	_	,	,	_	20	P	_	_
19	P	_	NN	NN	_	20	SBJ	_	_
20	&lt;	_	VBG	VBG	_	7	PRN	_	_
21	0.01	_	CD	CD	_	20	OBJ	_	_
22	,	_	,	,	_	20	P	_	_
23	young	_	JJ	JJ	_	20	DEP	_	_
24	vs.	_	CC	CC	_	23	CC	_	_
25	old	_	JJ	JJ	_	23	COORD	_	_
26	)	_	)	)	_	20	P	_	_
27	in	_	IN	IN	_	6	ADV	_	_
28	PBL	_	NN	NN	_	27	PMOD	_	_
29	from	_	IN	IN	_	27	PMOD	_	_
30	elderly	_	JJ	JJ	_	31	NMOD	_	_
31	individuals	_	NNS	NNS	_	29	PMOD	_	_
32	activated	_	VBN	VBN	_	27	PMOD	_	_
33	with	_	IN	IN	_	32	ADV	_	_
34	PHA	_	NN	NN	_	33	PMOD	_	_
35	.	_	.	.	_	6	P	_	_

1	Because	_	IN	IN	_	30	PRP	_	_
2	previous	_	JJ	JJ	_	3	NMOD	_	_
3	work	_	NN	NN	_	4	SBJ	_	_
4	has	_	VBZ	VBZ	_	1	VMOD	_	_
5	demonstrated	_	VBN	VBN	_	4	VC	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	T	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	12	SBJ	_	_
9	from	_	IN	IN	_	8	NMOD	_	_
10	elderly	_	JJ	JJ	_	11	NMOD	_	_
11	individuals	_	NNS	NNS	_	9	PMOD	_	_
12	may	_	MD	MD	_	6	VMOD	_	_
13	display	_	VB	VB	_	12	VC	_	_
14	normal	_	JJ	JJ	_	16	NMOD	_	_
15	proliferative	_	JJ	JJ	_	16	NMOD	_	_
16	responses	_	NNS	NNS	_	13	OBJ	_	_
17	when	_	WRB	WRB	_	18	ADV	_	_
18	activated	_	VBN	VBN	_	13	TMP	_	_
19	via	_	IN	IN	_	18	ADV	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	anti-CD2	_	JJ	JJ	_	22	NMOD	_	_
22	pathway	_	NN	NN	_	19	PMOD	_	_
23	,	_	,	,	_	30	P	_	_
24	c-jun	_	NN	NN	_	29	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	jun	_	NN	NN	_	27	NMOD	_	_
27	B	_	NN	NN	_	24	COORD	_	_
28	mRNA	_	NN	NN	_	29	NMOD	_	_
29	expression	_	NN	NN	_	30	SBJ	_	_
30	was	_	VBD	VBD	_	0	ROOT-S	_	_
31	also	_	RB	RB	_	30	ADV	_	_
32	studied	_	VBN	VBN	_	30	VC	_	_
33	in	_	IN	IN	_	32	ADV	_	_
34	anti-CD2-activated	_	JJ	JJ	_	37	NMOD	_	_
35	purified	_	VBN	VBN	_	37	NMOD	_	_
36	T	_	NN	NN	_	37	NMOD	_	_
37	cells	_	NNS	NNS	_	33	PMOD	_	_
38	.	_	.	.	_	30	P	_	_

1	No	_	DT	DT	_	3	NMOD	_	_
2	age-related	_	JJ	JJ	_	3	NMOD	_	_
3	differences	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	found	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	expression	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	either	_	DT	DT	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	these	_	DT	DT	_	14	NMOD	_	_
13	two	_	CD	CD	_	14	NMOD	_	_
14	proto-oncogenes	_	NNS	NNS	_	11	PMOD	_	_
15	by	_	IN	IN	_	8	NMOD	_	_
16	anti-CD2	_	NN	NN	_	19	NMOD	_	_
17	activated	_	JJ	JJ	_	19	NMOD	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	15	PMOD	_	_
20	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	decreased	_	VBN	VBN	_	8	NMOD	_	_
7	IL-2	_	NN	NN	_	8	NMOD	_	_
8	production	_	NN	NN	_	19	SBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	proliferative	_	JJ	JJ	_	11	NMOD	_	_
11	response	_	NN	NN	_	8	COORD	_	_
12	displayed	_	VBN	VBN	_	8	NMOD	_	_
13	by	_	IN	IN	_	12	ADV	_	_
14	PHA-activated	_	JJ	JJ	_	15	NMOD	_	_
15	PBL	_	NN	NN	_	13	PMOD	_	_
16	from	_	IN	IN	_	15	NMOD	_	_
17	elderly	_	JJ	JJ	_	18	NMOD	_	_
18	adults	_	NNS	NNS	_	16	PMOD	_	_
19	may	_	MD	MD	_	4	VMOD	_	_
20	be	_	VB	VB	_	19	VC	_	_
21	related	_	JJ	JJ	_	20	PRD	_	_
22	to	_	TO	TO	_	21	AMOD	_	_
23	age-related	_	JJ	JJ	_	24	NMOD	_	_
24	changes	_	NNS	NNS	_	22	PMOD	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	c-jun	_	NN	NN	_	28	NMOD	_	_
27	mRNA	_	NN	NN	_	28	NMOD	_	_
28	expression	_	NN	NN	_	25	PMOD	_	_
29	and	_	CC	CC	_	25	CC	_	_
30	in	_	IN	IN	_	25	COORD	_	_
31	the	_	DT	DT	_	32	NMOD	_	_
32	ratio	_	NN	NN	_	30	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	c-fos	_	NN	NN	_	33	PMOD	_	_
35	to	_	TO	TO	_	32	NMOD	_	_
36	c-jun	_	NN	NN	_	35	PMOD	_	_
37	mRNA	_	NN	NN	_	34	NMOD	_	_
38	.	_	.	.	_	3	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	mechanism	_	NN	NN	_	0	ROOT-FRAG	_	_
3	for	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	antiinflammatory	_	JJ	JJ	_	6	NMOD	_	_
6	effects	_	NNS	NNS	_	3	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	corticosteroids	_	NNS	NNS	_	7	PMOD	_	_
9	:	_	:	:	_	2	P	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	glucocorticoid	_	NN	NN	_	12	NMOD	_	_
12	receptor	_	NN	NN	_	13	SBJ	_	_
13	regulates	_	VBZ	VBZ	_	2	NMOD	_	_
14	leukocyte	_	NN	NN	_	15	NMOD	_	_
15	adhesion	_	NN	NN	_	13	OBJ	_	_
16	to	_	TO	TO	_	15	NMOD	_	_
17	endothelial	_	JJ	JJ	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	16	PMOD	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	expression	_	NN	NN	_	15	COORD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	endothelial-leukocyte	_	JJ	JJ	_	24	NMOD	_	_
23	adhesion	_	NN	NN	_	24	NMOD	_	_
24	molecule	_	NN	NN	_	21	PMOD	_	_
25	1	_	CD	CD	_	24	NMOD	_	_
26	and	_	CC	CC	_	24	CC	_	_
27	intercellular	_	JJ	JJ	_	29	NMOD	_	_
28	adhesion	_	NN	NN	_	29	NMOD	_	_
29	molecule	_	NN	NN	_	24	COORD	_	_
30	1	_	CD	CD	_	29	NMOD	_	_
31	.	_	.	.	_	13	P	_	_

1	Corticosteroids	_	NNS	NNS	_	2	SBJ	_	_
2	are	_	VBP	VBP	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	preeminent	_	JJ	JJ	_	6	NMOD	_	_
5	antiinflammatory	_	JJ	JJ	_	6	NMOD	_	_
6	agents	_	NNS	NNS	_	2	PRD	_	_
7	although	_	IN	IN	_	2	ADV	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	molecular	_	JJ	JJ	_	10	NMOD	_	_
10	mechanisms	_	NNS	NNS	_	15	SBJ	_	_
11	that	_	WDT	WDT	_	12	SBJ	_	_
12	impart	_	VBP	VBP	_	10	NMOD	_	_
13	their	_	PRP$	PRP$	_	14	NMOD	_	_
14	efficacy	_	NN	NN	_	12	OBJ	_	_
15	have	_	VBP	VBP	_	7	VMOD	_	_
16	not	_	RB	RB	_	15	VMOD	_	_
17	been	_	VBN	VBN	_	15	VC	_	_
18	defined	_	VBN	VBN	_	17	VC	_	_
19	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	endothelium	_	NN	NN	_	3	SBJ	_	_
3	plays	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	critical	_	JJ	JJ	_	6	NMOD	_	_
6	role	_	NN	NN	_	3	OBJ	_	_
7	in	_	IN	IN	_	3	ADV	_	_
8	inflammation	_	NN	NN	_	7	PMOD	_	_
9	by	_	IN	IN	_	3	ADV	_	_
10	directing	_	VBG	VBG	_	9	PMOD	_	_
11	circulating	_	VBG	VBG	_	12	NMOD	_	_
12	leukocytes	_	NNS	NNS	_	10	OBJ	_	_
13	into	_	IN	IN	_	10	ADV	_	_
14	extravascular	_	JJ	JJ	_	15	NMOD	_	_
15	tissues	_	NNS	NNS	_	13	PMOD	_	_
16	by	_	IN	IN	_	10	ADV	_	_
17	expressing	_	VBG	VBG	_	16	PMOD	_	_
18	adhesive	_	JJ	JJ	_	19	NMOD	_	_
19	molecules	_	NNS	NNS	_	17	OBJ	_	_
20	for	_	IN	IN	_	19	NMOD	_	_
21	leukocytes	_	NNS	NNS	_	20	PMOD	_	_
22	{	_	(	(	_	23	P	_	_
23	e.g.	_	FW	FW	_	19	PRN	_	_
24	,	_	,	,	_	23	P	_	_
25	endothelial-leukocyte	_	JJ	JJ	_	27	NMOD	_	_
26	adhesion	_	NN	NN	_	27	NMOD	_	_
27	molecule	_	NN	NN	_	23	PMOD	_	_
28	1	_	CD	CD	_	27	NMOD	_	_
29	(	_	(	(	_	30	P	_	_
30	ELAM-1	_	NN	NN	_	27	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	and	_	CC	CC	_	27	CC	_	_
33	intercellular	_	JJ	JJ	_	35	NMOD	_	_
34	adhesion	_	NN	NN	_	35	NMOD	_	_
35	molecule	_	NN	NN	_	27	COORD	_	_
36	1	_	CD	CD	_	35	NMOD	_	_
37	(	_	(	(	_	38	P	_	_
38	ICAM-1	_	NN	NN	_	35	PRN	_	_
39	)	_	)	)	_	38	P	_	_
40	}	_	)	)	_	23	P	_	_
41	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	therefore	_	RB	RB	_	3	ADV	_	_
3	determined	_	VBD	VBD	_	0	ROOT-S	_	_
4	whether	_	IN	IN	_	3	OBJ	_	_
5	corticosteroids	_	NNS	NNS	_	6	SBJ	_	_
6	suppress	_	VBP	VBP	_	4	VMOD	_	_
7	inflammation	_	NN	NN	_	6	OBJ	_	_
8	by	_	IN	IN	_	6	ADV	_	_
9	inhibiting	_	VBG	VBG	_	8	PMOD	_	_
10	endothelial	_	JJ	JJ	_	11	NMOD	_	_
11	expression	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	adhesion	_	NN	NN	_	14	NMOD	_	_
14	molecules	_	NNS	NNS	_	12	PMOD	_	_
15	for	_	IN	IN	_	14	NMOD	_	_
16	neutrophils	_	NNS	NNS	_	15	PMOD	_	_
17	(	_	(	(	_	19	P	_	_
18	polymorphonuclear	_	JJ	JJ	_	19	NMOD	_	_
19	leukocytes	_	NNS	NNS	_	14	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	.	_	.	.	_	3	P	_	_

1	Preincubation	_	NN	NN	_	16	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	endothelial	_	JJ	JJ	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	endotoxin	_	NN	NN	_	5	PMOD	_	_
7	{	_	(	(	_	6	PRN	_	_
8	lipopolysaccharide	_	NN	NN	_	7	DEP	_	_
9	(	_	(	(	_	10	P	_	_
10	LPS	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	,	_	,	,	_	8	P	_	_
13	1	_	CD	CD	_	14	NMOD	_	_
14	microgram\/ml	_	NN	NN	_	8	COORD	_	_
15	}	_	)	)	_	7	P	_	_
16	led	_	VBD	VBD	_	0	ROOT-S	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	4-fold	_	JJ	JJ	_	20	NMOD	_	_
20	increase	_	NN	NN	_	17	PMOD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	subsequent	_	JJ	JJ	_	23	NMOD	_	_
23	adherence	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	polymorphonuclear	_	JJ	JJ	_	26	NMOD	_	_
26	leukocytes	_	NNS	NNS	_	24	PMOD	_	_
27	(	_	(	(	_	29	P	_	_
28	P	_	NN	NN	_	29	SBJ	_	_
29	&lt;	_	VBG	VBG	_	26	PRN	_	_
30	0.0001	_	CD	CD	_	29	OBJ	_	_
31	,	_	,	,	_	29	P	_	_
32	n	_	NN	NN	_	34	SBJ	_	_
33	=	_	JJ	JJ	_	34	VMOD	_	_
34	10	_	CD	CD	_	29	COORD	_	_
35	)	_	)	)	_	29	P	_	_
36	to	_	TO	TO	_	23	NMOD	_	_
37	endothelial	_	JJ	JJ	_	38	NMOD	_	_
38	cells	_	NNS	NNS	_	36	PMOD	_	_
39	,	_	,	,	_	20	P	_	_
40	an	_	DT	DT	_	41	NMOD	_	_
41	increase	_	NN	NN	_	20	NMOD	_	_
42	that	_	WDT	WDT	_	43	SBJ	_	_
43	was	_	VBD	VBD	_	41	NMOD	_	_
44	markedly	_	RB	RB	_	43	ADV	_	_
45	attenuated	_	VBN	VBN	_	43	VC	_	_
46	when	_	WRB	WRB	_	50	ADV	_	_
47	endothelial	_	JJ	JJ	_	48	NMOD	_	_
48	cells	_	NNS	NNS	_	49	SBJ	_	_
49	were	_	VBD	VBD	_	45	TMP	_	_
50	treated	_	VBN	VBN	_	49	VC	_	_
51	with	_	IN	IN	_	50	ADV	_	_
52	dexamethasone	_	NN	NN	_	51	PMOD	_	_
53	(	_	(	(	_	55	P	_	_
54	IC50	_	NN	NN	_	55	SBJ	_	_
55	&lt;	_	VBG	VBG	_	52	PRN	_	_
56	1	_	CD	CD	_	57	NMOD	_	_
57	nM	_	NN	NN	_	55	OBJ	_	_
58	,	_	,	,	_	55	P	_	_
59	P	_	NN	NN	_	60	SBJ	_	_
60	&lt;	_	VBG	VBG	_	55	COORD	_	_
61	0.0001	_	CD	CD	_	60	OBJ	_	_
62	,	_	,	,	_	55	P	_	_
63	n	_	NN	NN	_	64	SBJ	_	_
64	=	_	VBG	VBG	_	55	COORD	_	_
65	6	_	CD	CD	_	64	PRD	_	_
66	or	_	CC	CC	_	65	CC	_	_
67	7	_	CD	CD	_	65	COORD	_	_
68	)	_	)	)	_	55	P	_	_
69	during	_	IN	IN	_	50	TMP	_	_
70	preincubation	_	NN	NN	_	69	PMOD	_	_
71	with	_	IN	IN	_	70	NMOD	_	_
72	LPS	_	NN	NN	_	71	PMOD	_	_
73	.	_	.	.	_	16	P	_	_

1	Moreover	_	RB	RB	_	24	ADV	_	_
2	,	_	,	,	_	24	P	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	steroid	_	NN	NN	_	7	NMOD	_	_
5	receptor	_	NN	NN	_	7	NMOD	_	_
6	agonist	_	NN	NN	_	7	NMOD	_	_
7	cortisol	_	NN	NN	_	24	SBJ	_	_
8	(	_	(	(	_	7	PRN	_	_
9	10	_	CD	CD	_	10	NMOD	_	_
10	microM	_	NN	NN	_	8	DEP	_	_
11	)	_	)	)	_	8	P	_	_
12	,	_	,	,	_	7	P	_	_
13	but	_	CC	CC	_	7	CC	_	_
14	not	_	RB	RB	_	13	COORD	_	_
15	its	_	PRP$	PRP$	_	18	NMOD	_	_
16	inactive	_	JJ	JJ	_	18	NMOD	_	_
17	metabolite	_	NN	NN	_	18	NMOD	_	_
18	tetrahydrocortisol	_	NN	NN	_	7	COORD	_	_
19	(	_	(	(	_	18	PRN	_	_
20	10	_	CD	CD	_	21	NMOD	_	_
21	microM	_	NN	NN	_	19	DEP	_	_
22	)	_	)	)	_	19	P	_	_
23	,	_	,	,	_	7	P	_	_
24	diminished	_	VBD	VBD	_	0	ROOT-S	_	_
25	LPS-induced	_	JJ	JJ	_	28	NMOD	_	_
26	endothelial	_	JJ	JJ	_	28	NMOD	_	_
27	cell	_	NN	NN	_	28	NMOD	_	_
28	adhesiveness	_	NN	NN	_	24	OBJ	_	_
29	.	_	.	.	_	24	P	_	_

1	Further	_	JJ	JJ	_	2	NMOD	_	_
2	evidence	_	NN	NN	_	23	SBJ	_	_
3	that	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	action	_	NN	NN	_	8	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	dexamethasone	_	NN	NN	_	6	PMOD	_	_
8	was	_	VBD	VBD	_	3	VMOD	_	_
9	mediated	_	VBN	VBN	_	8	VC	_	_
10	through	_	IN	IN	_	9	ADV	_	_
11	ligation	_	NN	NN	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	corticosteroid	_	NN	NN	_	14	NMOD	_	_
14	receptors	_	NNS	NNS	_	12	PMOD	_	_
15	{	_	(	(	_	18	P	_	_
16	human	_	JJ	JJ	_	18	NMOD	_	_
17	glucocorticoid	_	NN	NN	_	18	NMOD	_	_
18	receptors	_	NNS	NNS	_	14	PRN	_	_
19	(	_	(	(	_	20	P	_	_
20	hGRs	_	NNS	NNS	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	}	_	)	)	_	18	P	_	_
23	was	_	VBD	VBD	_	0	ROOT-S	_	_
24	provided	_	VBN	VBN	_	23	VC	_	_
25	by	_	IN	IN	_	24	LGS	_	_
26	experiments	_	NNS	NNS	_	25	PMOD	_	_
27	utilizing	_	VBG	VBG	_	26	NMOD	_	_
28	the	_	DT	DT	_	31	NMOD	_	_
29	steroid	_	NN	NN	_	31	NMOD	_	_
30	antagonist	_	NN	NN	_	31	NMOD	_	_
31	RU-486	_	NN	NN	_	27	OBJ	_	_
32	.	_	.	.	_	23	P	_	_

1	RU-486	_	NN	NN	_	28	SBJ	_	_
2	(	_	(	(	_	1	PRN	_	_
3	10	_	CD	CD	_	4	NMOD	_	_
4	microM	_	NN	NN	_	2	DEP	_	_
5	)	_	)	)	_	2	P	_	_
6	,	_	,	,	_	1	P	_	_
7	which	_	WDT	WDT	_	8	SBJ	_	_
8	prevents	_	VBZ	VBZ	_	1	NMOD	_	_
9	translocation	_	NN	NN	_	8	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	ligated	_	VBN	VBN	_	12	NMOD	_	_
12	hGR	_	NN	NN	_	10	PMOD	_	_
13	to	_	TO	TO	_	9	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	nucleus	_	NN	NN	_	13	PMOD	_	_
16	by	_	IN	IN	_	8	ADV	_	_
17	inhibiting	_	VBG	VBG	_	16	PMOD	_	_
18	dissociation	_	NN	NN	_	17	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	hGR	_	NN	NN	_	19	PMOD	_	_
21	from	_	IN	IN	_	18	NMOD	_	_
22	heat	_	NN	NN	_	24	NMOD	_	_
23	shock	_	NN	NN	_	24	NMOD	_	_
24	protein	_	NN	NN	_	21	PMOD	_	_
25	90	_	CD	CD	_	24	NMOD	_	_
26	,	_	,	,	_	1	P	_	_
27	completely	_	RB	RB	_	28	ADV	_	_
28	aborted	_	VBD	VBD	_	0	ROOT-S	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	effect	_	NN	NN	_	28	OBJ	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	dexamethasone	_	NN	NN	_	31	PMOD	_	_
33	on	_	IN	IN	_	30	NMOD	_	_
34	adhesiveness	_	NN	NN	_	33	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	endothelial	_	JJ	JJ	_	37	NMOD	_	_
37	cells	_	NNS	NNS	_	35	PMOD	_	_
38	(	_	(	(	_	40	P	_	_
39	P	_	NN	NN	_	40	SBJ	_	_
40	&lt;	_	VBG	VBG	_	37	PRN	_	_
41	0.0005	_	CD	CD	_	40	OBJ	_	_
42	,	_	,	,	_	40	P	_	_
43	n	_	NN	NN	_	45	SBJ	_	_
44	=	_	JJ	JJ	_	45	VMOD	_	_
45	3	_	CD	CD	_	40	COORD	_	_
46	)	_	)	)	_	40	P	_	_
47	.	_	.	.	_	28	P	_	_

1	Treatment	_	NN	NN	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	endothelial	_	JJ	JJ	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	LPS	_	NN	NN	_	5	PMOD	_	_
7	(	_	(	(	_	6	PRN	_	_
8	1	_	CD	CD	_	9	NMOD	_	_
9	microgram\/ml	_	NN	NN	_	7	DEP	_	_
10	)	_	)	)	_	7	P	_	_
11	stimulated	_	VBD	VBD	_	0	ROOT-S	_	_
12	transcription	_	NN	NN	_	11	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	ELAM-1	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	11	P	_	_
16	as	_	IN	IN	_	11	VMOD	_	_
17	shown	_	VBN	VBN	_	16	VMOD	_	_
18	by	_	IN	IN	_	17	ADV	_	_
19	Northern	_	NN	NN	_	21	NMOD	_	_
20	blot	_	NN	NN	_	21	NMOD	_	_
21	analysis	_	NN	NN	_	18	PMOD	_	_
22	,	_	,	,	_	11	P	_	_
23	and	_	CC	CC	_	11	CC	_	_
24	expression	_	NN	NN	_	12	GAP	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	membrane-associated	_	JJ	JJ	_	27	NMOD	_	_
27	ELAM-1	_	NN	NN	_	25	PMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	ICAM-1	_	NN	NN	_	27	COORD	_	_
30	,	_	,	,	_	24	P	_	_
31	as	_	IN	IN	_	16	GAP	_	_
32	shown	_	VBN	VBN	_	31	VMOD	_	_
33	by	_	IN	IN	_	32	ADV	_	_
34	quantitative	_	JJ	JJ	_	35	NMOD	_	_
35	immunofluorescence	_	NN	NN	_	33	PMOD	_	_
36	(	_	(	(	_	39	P	_	_
37	both	_	DT	DT	_	38	NMOD	_	_
38	P	_	NN	NN	_	39	SBJ	_	_
39	&lt;	_	VBG	VBG	_	35	PRN	_	_
40	0.001	_	CD	CD	_	39	OBJ	_	_
41	,	_	,	,	_	39	P	_	_
42	n	_	NN	NN	_	43	SBJ	_	_
43	=	_	VBG	VBG	_	39	COORD	_	_
44	9	_	CD	CD	_	43	PRD	_	_
45	)	_	)	)	_	39	P	_	_
46	.	_	.	.	_	11	P	_	_

1	Dexamethasone	_	NN	NN	_	3	SBJ	_	_
2	markedly	_	RB	RB	_	3	ADV	_	_
3	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
4	LPS-stimulated	_	JJ	JJ	_	5	NMOD	_	_
5	accumulation	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	mRNA	_	NN	NN	_	6	PMOD	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	ELAM-1	_	NN	NN	_	8	PMOD	_	_
10	and	_	CC	CC	_	5	CC	_	_
11	expression	_	NN	NN	_	5	COORD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	ELAM-1	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	ICAM-1	_	NN	NN	_	13	COORD	_	_
16	(	_	(	(	_	18	P	_	_
17	IC50	_	NN	NN	_	18	SBJ	_	_
18	&lt;	_	VBG	VBG	_	13	PRN	_	_
19	10	_	CD	CD	_	20	NMOD	_	_
20	nM	_	NN	NN	_	18	OBJ	_	_
21	,	_	,	,	_	18	P	_	_
22	both	_	DT	DT	_	23	NMOD	_	_
23	P	_	NN	NN	_	24	SBJ	_	_
24	&lt;	_	VBG	VBG	_	18	COORD	_	_
25	0.001	_	CD	CD	_	24	OBJ	_	_
26	,	_	,	,	_	18	P	_	_
27	n	_	NN	NN	_	28	SBJ	_	_
28	=	_	VBG	VBG	_	18	COORD	_	_
29	4-9	_	CD	CD	_	28	PRD	_	_
30	)	_	)	)	_	18	P	_	_
31	;	_	:	:	_	3	P	_	_
32	inhibition	_	NN	NN	_	37	SBJ	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	expression	_	NN	NN	_	33	PMOD	_	_
35	by	_	IN	IN	_	32	NMOD	_	_
36	dexamethasone	_	NN	NN	_	35	PMOD	_	_
37	was	_	VBD	VBD	_	3	VMOD	_	_
38	reversed	_	VBN	VBN	_	37	VC	_	_
39	by	_	IN	IN	_	38	LGS	_	_
40	RU-486	_	NN	NN	_	39	PMOD	_	_
41	(	_	(	(	_	44	P	_	_
42	both	_	DT	DT	_	43	NMOD	_	_
43	P	_	NN	NN	_	44	SBJ	_	_
44	&lt;	_	VBG	VBG	_	40	PRN	_	_
45	0.005	_	CD	CD	_	44	OBJ	_	_
46	,	_	,	,	_	44	P	_	_
47	n	_	NN	NN	_	48	SBJ	_	_
48	=	_	VBG	VBG	_	44	COORD	_	_
49	4-6	_	CD	CD	_	48	PRD	_	_
50	)	_	)	)	_	44	P	_	_
51	.	_	.	.	_	37	P	_	_

1	As	_	IN	IN	_	11	ADV	_	_
2	in	_	IN	IN	_	1	VMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	adhesion	_	NN	NN	_	5	NMOD	_	_
5	studies	_	NNS	NNS	_	2	PMOD	_	_
6	,	_	,	,	_	11	P	_	_
7	cortisol	_	NN	NN	_	11	SBJ	_	_
8	but	_	CC	CC	_	7	CC	_	_
9	not	_	RB	RB	_	8	COORD	_	_
10	tetrahydrocortisol	_	NN	NN	_	7	COORD	_	_
11	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
12	expression	_	NN	NN	_	11	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	ELAM-1	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	ICAM-1	_	NN	NN	_	14	COORD	_	_
17	(	_	(	(	_	20	P	_	_
18	both	_	DT	DT	_	19	NMOD	_	_
19	P	_	NN	NN	_	20	SBJ	_	_
20	&lt;	_	VBG	VBG	_	14	PRN	_	_
21	0.005	_	CD	CD	_	20	OBJ	_	_
22	,	_	,	,	_	20	P	_	_
23	n	_	NN	NN	_	25	SBJ	_	_
24	=	_	JJ	JJ	_	25	VMOD	_	_
25	3	_	CD	CD	_	20	COORD	_	_
26	or	_	CC	CC	_	25	CC	_	_
27	4	_	CD	CD	_	25	COORD	_	_
28	)	_	)	)	_	20	P	_	_
29	.	_	.	.	_	11	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	10	P	_	_
4	sodium	_	NN	NN	_	5	NMOD	_	_
5	salicylate	_	NN	NN	_	10	SBJ	_	_
6	(	_	(	(	_	5	PRN	_	_
7	1	_	CD	CD	_	8	NMOD	_	_
8	mM	_	NN	NN	_	6	DEP	_	_
9	)	_	)	)	_	6	P	_	_
10	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
11	neither	_	CC	CC	_	12	CC	_	_
12	adhesion	_	NN	NN	_	10	OBJ	_	_
13	nor	_	CC	CC	_	12	CC	_	_
14	expression	_	NN	NN	_	12	COORD	_	_
15	of	_	IN	IN	_	12	NMOD	_	_
16	these	_	DT	DT	_	18	NMOD	_	_
17	adhesion	_	NN	NN	_	18	NMOD	_	_
18	molecules	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	10	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	antagonism	_	NN	NN	_	11	SBJ	_	_
6	by	_	IN	IN	_	5	NMOD	_	_
7	dexamethasone	_	NN	NN	_	6	PMOD	_	_
8	of	_	IN	IN	_	5	NMOD	_	_
9	endotoxin-induced	_	JJ	JJ	_	10	NMOD	_	_
10	inflammation	_	NN	NN	_	8	PMOD	_	_
11	is	_	VBZ	VBZ	_	4	VMOD	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	specific	_	JJ	JJ	_	14	NMOD	_	_
14	instance	_	NN	NN	_	11	PRD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	general	_	JJ	JJ	_	19	NMOD	_	_
18	biological	_	JJ	JJ	_	19	NMOD	_	_
19	principle	_	NN	NN	_	15	PMOD	_	_
20	that	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	glucocorticoid	_	NN	NN	_	23	NMOD	_	_
23	receptor	_	NN	NN	_	24	SBJ	_	_
24	is	_	VBZ	VBZ	_	20	VMOD	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	hormone-dependent	_	JJ	JJ	_	27	NMOD	_	_
27	regulator	_	NN	NN	_	24	PRD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	transcription	_	NN	NN	_	28	PMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	Membrane	_	NN	NN	_	2	NMOD	_	_
2	receptors	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	for	_	IN	IN	_	2	NMOD	_	_
4	aldosterone	_	NN	NN	_	3	PMOD	_	_
5	:	_	:	:	_	2	P	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	novel	_	JJ	JJ	_	8	NMOD	_	_
8	pathway	_	NN	NN	_	2	NMOD	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	mineralocorticoid	_	NN	NN	_	11	NMOD	_	_
11	action	_	NN	NN	_	9	PMOD	_	_
12	.	_	.	.	_	8	P	_	_

1	Rapid	_	JJ	JJ	_	5	NMOD	_	_
2	nongenomic	_	JJ	JJ	_	5	NMOD	_	_
3	in	_	FW	FW	_	4	AMOD	_	_
4	vitro	_	FW	FW	_	5	NMOD	_	_
5	effects	_	NNS	NNS	_	18	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	aldosterone	_	NN	NN	_	6	PMOD	_	_
8	on	_	IN	IN	_	5	NMOD	_	_
9	intracellular	_	JJ	JJ	_	10	NMOD	_	_
10	electrolytes	_	NNS	NNS	_	8	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	volume	_	NN	NN	_	10	COORD	_	_
14	,	_	,	,	_	10	P	_	_
15	and	_	CC	CC	_	10	CC	_	_
16	Na-LRB-+-RRB--H+	_	JJ	JJ	_	17	NMOD	_	_
17	antiport	_	NN	NN	_	10	COORD	_	_
18	have	_	VBP	VBP	_	0	ROOT-S	_	_
19	been	_	VBN	VBN	_	18	VC	_	_
20	found	_	VBN	VBN	_	19	VC	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	human	_	JJ	JJ	_	24	NMOD	_	_
23	mononuclear	_	JJ	JJ	_	24	NMOD	_	_
24	leukocytes	_	NNS	NNS	_	21	PMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	HML	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	.	_	.	.	_	18	P	_	_

1	Binding	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	125I-labeled	_	JJ	JJ	_	4	NMOD	_	_
4	aldosterone	_	NN	NN	_	2	PMOD	_	_
5	to	_	TO	TO	_	1	NMOD	_	_
6	plasma	_	NN	NN	_	7	NMOD	_	_
7	membranes	_	NNS	NNS	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	HML	_	NN	NN	_	8	PMOD	_	_
10	shares	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	important	_	JJ	JJ	_	12	NMOD	_	_
12	features	_	NNS	NNS	_	10	OBJ	_	_
13	with	_	IN	IN	_	10	ADV	_	_
14	these	_	DT	DT	_	16	NMOD	_	_
15	functional	_	JJ	JJ	_	16	NMOD	_	_
16	data	_	NNS	NNS	_	13	PMOD	_	_
17	.	_	.	.	_	10	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	includes	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	8	NMOD	_	_
4	very	_	RB	RB	_	5	AMOD	_	_
5	low	_	JJ	JJ	_	8	NMOD	_	_
6	apparent	_	JJ	JJ	_	8	NMOD	_	_
7	dissociation	_	NN	NN	_	8	NMOD	_	_
8	constant	_	NN	NN	_	2	OBJ	_	_
9	(	_	(	(	_	10	P	_	_
10	Kd	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	of	_	IN	IN	_	8	NMOD	_	_
13	0.1	_	CD	CD	_	14	NMOD	_	_
14	nM	_	NN	NN	_	12	PMOD	_	_
15	for	_	IN	IN	_	8	NMOD	_	_
16	both	_	CC	CC	_	17	CC	_	_
17	aldosterone	_	NN	NN	_	15	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	effect	_	NN	NN	_	17	COORD	_	_
21	on	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	Na-LRB-+-RRB--H-LRB-+-RRB--antiport	_	NN	NN	_	21	PMOD	_	_
24	,	_	,	,	_	8	P	_	_
25	a	_	DT	DT	_	28	NMOD	_	_
26	high	_	JJ	JJ	_	28	NMOD	_	_
27	turnover	_	NN	NN	_	28	NMOD	_	_
28	rate	_	NN	NN	_	8	COORD	_	_
29	,	_	,	,	_	8	P	_	_
30	and	_	CC	CC	_	8	CC	_	_
31	the	_	DT	DT	_	35	NMOD	_	_
32	almost	_	RB	RB	_	33	AMOD	_	_
33	exclusive	_	JJ	JJ	_	35	NMOD	_	_
34	binding	_	NN	NN	_	35	NMOD	_	_
35	selectivity	_	NN	NN	_	8	COORD	_	_
36	for	_	IN	IN	_	35	NMOD	_	_
37	aldosterone	_	NN	NN	_	36	PMOD	_	_
38	.	_	.	.	_	2	P	_	_

1	Dexamethasone	_	NN	NN	_	14	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	RU	_	NN	NN	_	1	COORD	_	_
4	26988	_	CD	CD	_	3	NMOD	_	_
5	,	_	,	,	_	1	P	_	_
6	corticosterone	_	NN	NN	_	1	COORD	_	_
7	,	_	,	,	_	1	P	_	_
8	ouabain	_	NN	NN	_	1	COORD	_	_
9	,	_	,	,	_	1	P	_	_
10	amiloride	_	NN	NN	_	1	COORD	_	_
11	,	_	,	,	_	1	P	_	_
12	and	_	CC	CC	_	1	CC	_	_
13	18-hydroxyprogesterone	_	NN	NN	_	1	COORD	_	_
14	were	_	VBD	VBD	_	0	ROOT-S	_	_
15	inactive	_	JJ	JJ	_	14	PRD	_	_
16	as	_	IN	IN	_	14	ADV	_	_
17	ligands	_	NNS	NNS	_	16	PMOD	_	_
18	.	_	.	.	_	14	P	_	_

1	Deoxycorticosterone	_	NN	NN	_	2	NMOD	_	_
2	acetate	_	NN	NN	_	3	SBJ	_	_
3	had	_	VBD	VBD	_	0	ROOT-S	_	_
4	an	_	DT	DT	_	6	NMOD	_	_
5	intermediate	_	JJ	JJ	_	6	NMOD	_	_
6	activity	_	NN	NN	_	3	OBJ	_	_
7	with	_	IN	IN	_	3	ADV	_	_
8	an	_	DT	DT	_	10	NMOD	_	_
9	apparent	_	JJ	JJ	_	10	NMOD	_	_
10	Kd	_	NN	NN	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	100	_	CD	CD	_	13	NMOD	_	_
13	nM	_	NN	NN	_	11	PMOD	_	_
14	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	first	_	JJ	JJ	_	3	PRD	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	demonstrate	_	VB	VB	_	5	NMOD	_	_
8	membrane	_	NN	NN	_	9	NMOD	_	_
9	binding	_	NN	NN	_	12	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	aldosterone	_	NN	NN	_	10	PMOD	_	_
12	being	_	VBG	VBG	_	7	OBJ	_	_
13	compatible	_	JJ	JJ	_	12	PRD	_	_
14	with	_	IN	IN	_	13	AMOD	_	_
15	major	_	JJ	JJ	_	16	NMOD	_	_
16	aspects	_	NNS	NNS	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	its	_	PRP$	PRP$	_	20	NMOD	_	_
19	nongenomic	_	JJ	JJ	_	20	NMOD	_	_
20	effects	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	Natural	_	JJ	JJ	_	2	NMOD	_	_
2	variants	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	HIV-1	_	NN	NN	_	8	NMOD	_	_
6	long	_	JJ	JJ	_	8	NMOD	_	_
7	terminal	_	JJ	JJ	_	8	NMOD	_	_
8	repeat	_	NN	NN	_	3	PMOD	_	_
9	:	_	:	:	_	2	P	_	_
10	analysis	_	NN	NN	_	2	NMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	promoters	_	NNS	NNS	_	11	PMOD	_	_
13	with	_	IN	IN	_	12	NMOD	_	_
14	duplicated	_	JJ	JJ	_	17	NMOD	_	_
15	DNA	_	NN	NN	_	17	NMOD	_	_
16	regulatory	_	JJ	JJ	_	17	NMOD	_	_
17	motifs	_	NNS	NNS	_	13	PMOD	_	_
18	.	_	.	.	_	10	P	_	_

1	Sequence	_	NN	NN	_	2	NMOD	_	_
2	variation	_	NN	NN	_	14	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	11	NMOD	_	_
5	long	_	JJ	JJ	_	7	NMOD	_	_
6	terminal	_	JJ	JJ	_	7	NMOD	_	_
7	repeat	_	NN	NN	_	11	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	LTR	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	region	_	NN	NN	_	3	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	HIV-1	_	NN	NN	_	12	PMOD	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	analyzed	_	VBN	VBN	_	14	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	viral	_	JJ	JJ	_	18	NMOD	_	_
18	isolates	_	NNS	NNS	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	17	_	CD	CD	_	22	NMOD	_	_
21	infected	_	JJ	JJ	_	22	NMOD	_	_
22	individuals	_	NNS	NNS	_	19	PMOD	_	_
23	.	_	.	.	_	14	P	_	_

1	Two	_	CD	CD	_	2	NMOD	_	_
2	classes	_	NNS	NNS	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	LTR	_	NN	NN	_	6	NMOD	_	_
5	size	_	NN	NN	_	6	NMOD	_	_
6	variants	_	NNS	NNS	_	3	PMOD	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	found	_	VBN	VBN	_	7	VC	_	_
9	.	_	.	.	_	7	P	_	_

1	One	_	CD	CD	_	3	NMOD	_	_
2	HIV-1	_	NN	NN	_	3	NMOD	_	_
3	variant	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	detected	_	VBN	VBN	_	4	VC	_	_
6	containing	_	VBG	VBG	_	5	ADV	_	_
7	an	_	DT	DT	_	10	NMOD	_	_
8	additional	_	JJ	JJ	_	10	NMOD	_	_
9	binding	_	VBG	VBG	_	10	NMOD	_	_
10	site	_	NN	NN	_	6	OBJ	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	transcription	_	NN	NN	_	15	NMOD	_	_
14	factor	_	NN	NN	_	15	NMOD	_	_
15	Sp1	_	NN	NN	_	11	PMOD	_	_
16	.	_	.	.	_	4	P	_	_

1	Another	_	DT	DT	_	4	NMOD	_	_
2	LTR	_	NN	NN	_	4	NMOD	_	_
3	size	_	NN	NN	_	4	NMOD	_	_
4	variation	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	observed	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	four	_	CD	CD	_	9	NMOD	_	_
9	patients	_	NNS	NNS	_	7	PMOD	_	_
10	in	_	IN	IN	_	6	ADV	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	region	_	NN	NN	_	10	PMOD	_	_
13	just	_	RB	RB	_	14	AMOD	_	_
14	upstream	_	JJ	JJ	_	12	NMOD	_	_
15	of	_	IN	IN	_	14	AMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	NF-kappa	_	NN	NN	_	19	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	enhancer	_	NN	NN	_	15	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	variation	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	result	_	NN	NN	_	3	PRD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	duplication	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	a	_	DT	DT	_	13	NMOD	_	_
11	short	_	JJ	JJ	_	13	NMOD	_	_
12	DNA	_	NN	NN	_	13	NMOD	_	_
13	sequence	_	NN	NN	_	9	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	CTG-motif	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	.	_	.	.	_	3	P	_	_

1	Cell	_	NN	NN	_	3	NMOD	_	_
2	culture	_	NN	NN	_	3	NMOD	_	_
3	experiments	_	NNS	NNS	_	4	SBJ	_	_
4	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	natural	_	JJ	JJ	_	8	NMOD	_	_
8	variant	_	NN	NN	_	13	SBJ	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	four	_	CD	CD	_	12	NMOD	_	_
11	Sp1	_	NN	NN	_	12	NMOD	_	_
12	sites	_	NNS	NNS	_	9	PMOD	_	_
13	had	_	VBD	VBD	_	5	VMOD	_	_
14	a	_	DT	DT	_	18	NMOD	_	_
15	slightly	_	RB	RB	_	16	AMOD	_	_
16	higher	_	JJR	JJR	_	18	NMOD	_	_
17	promoter	_	NN	NN	_	18	NMOD	_	_
18	activity	_	NN	NN	_	13	OBJ	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	viral	_	JJ	JJ	_	22	NMOD	_	_
21	replication	_	NN	NN	_	22	NMOD	_	_
22	rate	_	NN	NN	_	18	COORD	_	_
23	than	_	IN	IN	_	18	NMOD	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	isogenic	_	JJ	JJ	_	27	NMOD	_	_
26	control	_	NN	NN	_	27	NMOD	_	_
27	LTR	_	NN	NN	_	23	PMOD	_	_
28	with	_	IN	IN	_	27	NMOD	_	_
29	three	_	CD	CD	_	31	NMOD	_	_
30	Sp1	_	NN	NN	_	31	NMOD	_	_
31	sites	_	NNS	NNS	_	28	PMOD	_	_
32	.	_	.	.	_	4	P	_	_

1	No	_	DT	DT	_	3	NMOD	_	_
2	positive	_	JJ	JJ	_	3	NMOD	_	_
3	effect	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	duplicated	_	JJ	JJ	_	7	NMOD	_	_
7	CTG-motif	_	NN	NN	_	4	PMOD	_	_
8	could	_	MD	MD	_	0	ROOT-S	_	_
9	be	_	VB	VB	_	8	VC	_	_
10	detected	_	VBN	VBN	_	9	VC	_	_
11	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	23	ADV	_	_
2	order	_	NN	NN	_	1	VMOD	_	_
3	to	_	TO	TO	_	1	VMOD	_	_
4	measure	_	VB	VB	_	1	VMOD	_	_
5	small	_	JJ	JJ	_	6	NMOD	_	_
6	differences	_	NNS	NNS	_	4	OBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	virus	_	NN	NN	_	9	NMOD	_	_
9	production	_	NN	NN	_	7	PMOD	_	_
10	more	_	RBR	RBR	_	11	AMOD	_	_
11	accurately	_	RB	RB	_	4	ADV	_	_
12	,	_	,	,	_	23	P	_	_
13	equal	_	JJ	JJ	_	14	NMOD	_	_
14	amounts	_	NNS	NNS	_	23	SBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	size	_	NN	NN	_	18	NMOD	_	_
18	variant	_	NN	NN	_	15	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	wild-type	_	JJ	JJ	_	22	NMOD	_	_
22	plasmid	_	NN	NN	_	18	COORD	_	_
23	were	_	VBD	VBD	_	0	ROOT-S	_	_
24	cotransfected	_	VBN	VBN	_	23	VC	_	_
25	into	_	IN	IN	_	24	ADV	_	_
26	T-cells	_	NNS	NNS	_	25	PMOD	_	_
27	.	_	.	.	_	23	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	virus	_	NN	NN	_	7	SBJ	_	_
3	with	_	IN	IN	_	2	NMOD	_	_
4	four	_	CD	CD	_	6	NMOD	_	_
5	Sp1	_	NN	NN	_	6	NMOD	_	_
6	sites	_	NNS	NNS	_	3	PMOD	_	_
7	did	_	VBD	VBD	_	0	ROOT-S	_	_
8	outgrow	_	VB	VB	_	7	VC	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	three	_	CD	CD	_	12	NMOD	_	_
11	Sp1	_	NN	NN	_	12	NMOD	_	_
12	virus	_	NN	NN	_	8	OBJ	_	_
13	in	_	IN	IN	_	8	TMP	_	_
14	35	_	CD	CD	_	15	NMOD	_	_
15	days	_	NNS	NNS	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	culture	_	NN	NN	_	16	PMOD	_	_
18	and	_	CC	CC	_	7	CC	_	_
19	CTG-monomer	_	NN	NN	_	20	NMOD	_	_
20	virus	_	NN	NN	_	21	SBJ	_	_
21	outcompeted	_	VBD	VBD	_	7	COORD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	CTG-dimer	_	NN	NN	_	24	NMOD	_	_
24	virus	_	NN	NN	_	21	OBJ	_	_
25	in	_	IN	IN	_	21	TMP	_	_
26	42	_	CD	CD	_	27	NMOD	_	_
27	days	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	7	P	_	_

1	Based	_	VBN	VBN	_	6	ADV	_	_
2	on	_	IN	IN	_	1	PMOD	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	results	_	NNS	NNS	_	2	PMOD	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	estimate	_	VBP	VBP	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	10	NMOD	_	_
8	5-10	_	CD	CD	_	10	NMOD	_	_
9	%	_	NN	NN	_	8	AMOD	_	_
10	difference	_	NN	NN	_	6	OBJ	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	virus	_	NN	NN	_	13	NMOD	_	_
13	production	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	LTR	_	NN	NN	_	17	NMOD	_	_
17	variants	_	NNS	NNS	_	14	PMOD	_	_
18	when	_	WRB	WRB	_	19	ADV	_	_
19	compared	_	VBN	VBN	_	6	TMP	_	_
20	to	_	TO	TO	_	19	ADV	_	_
21	that	_	DT	DT	_	20	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	wild-type	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	6	P	_	_

1	SCL	_	NN	NN	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	related	_	JJ	JJ	_	7	NMOD	_	_
4	hemopoietic	_	JJ	JJ	_	7	NMOD	_	_
5	helix-loop-helix	_	JJ	JJ	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factors	_	NNS	NNS	_	1	COORD	_	_
8	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	helix-loop-helix	_	JJ	JJ	_	6	NMOD	_	_
3	(	_	(	(	_	4	P	_	_
4	HLH	_	JJ	JJ	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	proteins	_	NNS	NNS	_	7	SBJ	_	_
7	are	_	VBP	VBP	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	family	_	NN	NN	_	7	PRD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	transcription	_	NN	NN	_	12	NMOD	_	_
12	factors	_	NNS	NNS	_	10	PMOD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	include	_	VBP	VBP	_	12	NMOD	_	_
15	proteins	_	NNS	NNS	_	14	OBJ	_	_
16	critical	_	JJ	JJ	_	15	NMOD	_	_
17	to	_	TO	TO	_	16	AMOD	_	_
18	differentiation	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	development	_	NN	NN	_	18	COORD	_	_
21	in	_	IN	IN	_	18	NMOD	_	_
22	species	_	NNS	NNS	_	21	PMOD	_	_
23	ranging	_	VBG	VBG	_	22	NMOD	_	_
24	from	_	IN	IN	_	23	ADV	_	_
25	plants	_	NNS	NNS	_	24	PMOD	_	_
26	to	_	TO	TO	_	24	PMOD	_	_
27	mammals	_	NNS	NNS	_	26	PMOD	_	_
28	.	_	.	.	_	7	P	_	_

1	Five	_	CD	CD	_	2	NMOD	_	_
2	members	_	NNS	NNS	_	17	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	this	_	DT	DT	_	5	NMOD	_	_
5	family	_	NN	NN	_	3	PMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	MYC	_	NN	NN	_	2	PRN	_	_
8	,	_	,	,	_	7	P	_	_
9	SCL	_	NN	NN	_	7	COORD	_	_
10	,	_	,	,	_	7	P	_	_
11	TAL-2	_	NN	NN	_	7	COORD	_	_
12	,	_	,	,	_	7	P	_	_
13	LYL-1	_	NN	NN	_	7	COORD	_	_
14	and	_	CC	CC	_	7	CC	_	_
15	E2A	_	NN	NN	_	7	COORD	_	_
16	)	_	)	)	_	7	P	_	_
17	are	_	VBP	VBP	_	0	ROOT-S	_	_
18	implicated	_	VBN	VBN	_	17	VC	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	oncogenic	_	JJ	JJ	_	21	NMOD	_	_
21	events	_	NNS	NNS	_	19	PMOD	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	human	_	JJ	JJ	_	25	NMOD	_	_
24	lymphoid	_	JJ	JJ	_	25	NMOD	_	_
25	tumors	_	NNS	NNS	_	22	PMOD	_	_
26	because	_	IN	IN	_	18	ADV	_	_
27	of	_	IN	IN	_	26	DEP	_	_
28	their	_	PRP$	PRP$	_	30	NMOD	_	_
29	consistent	_	JJ	JJ	_	30	NMOD	_	_
30	involvement	_	NN	NN	_	26	PMOD	_	_
31	in	_	IN	IN	_	30	NMOD	_	_
32	chromosomal	_	JJ	JJ	_	33	NMOD	_	_
33	translocations	_	NNS	NNS	_	31	PMOD	_	_
34	.	_	.	.	_	17	P	_	_

1	Although	_	IN	IN	_	13	ADV	_	_
2	activated	_	VBN	VBN	_	1	VMOD	_	_
3	in	_	IN	IN	_	2	ADV	_	_
4	T	_	NN	NN	_	6	NMOD	_	_
5	cell	_	NN	NN	_	6	NMOD	_	_
6	leukemias	_	NNS	NNS	_	3	PMOD	_	_
7	,	_	,	,	_	13	P	_	_
8	expression	_	NN	NN	_	13	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	SCL	_	NN	NN	_	9	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	LYL-1	_	NN	NN	_	10	COORD	_	_
13	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	low	_	JJ	JJ	_	13	PRD	_	_
15	or	_	CC	CC	_	14	CC	_	_
16	undetectable	_	JJ	JJ	_	14	COORD	_	_
17	in	_	IN	IN	_	14	AMOD	_	_
18	normal	_	JJ	JJ	_	21	NMOD	_	_
19	T	_	NN	NN	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	populations	_	NNS	NNS	_	17	PMOD	_	_
22	.	_	.	.	_	13	P	_	_

1	SCL	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	expressed	_	VBN	VBN	_	2	VC	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	erythroid	_	JJ	JJ	_	11	NMOD	_	_
6	,	_	,	,	_	5	P	_	_
7	megakaryocyte	_	NN	NN	_	5	COORD	_	_
8	and	_	CC	CC	_	5	CC	_	_
9	mast	_	NN	NN	_	10	NMOD	_	_
10	cell	_	NN	NN	_	5	COORD	_	_
11	populations	_	NNS	NNS	_	4	PMOD	_	_
12	(	_	(	(	_	16	P	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	same	_	JJ	JJ	_	16	NMOD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	lineages	_	NNS	NNS	_	11	PRN	_	_
17	as	_	IN	IN	_	16	NMOD	_	_
18	GATA-1	_	NN	NN	_	17	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	a	_	DT	DT	_	23	NMOD	_	_
21	zinc-finger	_	NN	NN	_	23	NMOD	_	_
22	transcription	_	NN	NN	_	23	NMOD	_	_
23	factor	_	NN	NN	_	18	NMOD	_	_
24	)	_	)	)	_	16	P	_	_
25	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	8	P	_	_
4	both	_	CC	CC	_	5	CC	_	_
5	SCL	_	NN	NN	_	8	SBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	GATA-1	_	NN	NN	_	5	COORD	_	_
8	undergo	_	VBP	VBP	_	0	ROOT-S	_	_
9	coordinate	_	JJ	JJ	_	10	NMOD	_	_
10	modulation	_	NN	NN	_	8	OBJ	_	_
11	during	_	IN	IN	_	8	TMP	_	_
12	chemically	_	RB	RB	_	13	AMOD	_	_
13	induced	_	VBN	VBN	_	15	NMOD	_	_
14	erythroid	_	JJ	JJ	_	15	NMOD	_	_
15	differentiation	_	NN	NN	_	11	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	mouse	_	NN	NN	_	19	NMOD	_	_
18	erythroleukemia	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	PMOD	_	_
20	and	_	CC	CC	_	8	CC	_	_
21	are	_	VBP	VBP	_	8	COORD	_	_
22	down-modulated	_	VBN	VBN	_	21	VC	_	_
23	during	_	IN	IN	_	22	TMP	_	_
24	myeloid	_	JJ	JJ	_	25	NMOD	_	_
25	differentiation	_	NN	NN	_	23	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	human	_	JJ	JJ	_	29	NMOD	_	_
28	K562	_	NN	NN	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	26	PMOD	_	_
30	,	_	,	,	_	8	P	_	_
31	thus	_	RB	RB	_	32	ADV	_	_
32	implying	_	VBG	VBG	_	8	OBJ	_	_
33	a	_	DT	DT	_	34	NMOD	_	_
34	role	_	NN	NN	_	32	OBJ	_	_
35	for	_	IN	IN	_	34	NMOD	_	_
36	SCL	_	NN	NN	_	35	PMOD	_	_
37	in	_	IN	IN	_	34	NMOD	_	_
38	erythroid	_	JJ	JJ	_	40	NMOD	_	_
39	differentiation	_	NN	NN	_	40	NMOD	_	_
40	events	_	NNS	NNS	_	37	PMOD	_	_
41	.	_	.	.	_	8	P	_	_

1	However	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	in	_	IN	IN	_	9	ADV	_	_
4	contrast	_	NN	NN	_	3	DEP	_	_
5	to	_	TO	TO	_	3	DEP	_	_
6	GATA-1	_	NN	NN	_	3	PMOD	_	_
7	,	_	,	,	_	9	P	_	_
8	SCL	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	expressed	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	developing	_	VBG	VBG	_	14	NMOD	_	_
14	brain	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	9	P	_	_

1	Studies	_	NNS	NNS	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	function	_	NN	NN	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	SCL	_	NN	NN	_	5	PMOD	_	_
7	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
8	it	_	PRP	PRP	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	7	OBJ	_	_
10	also	_	RB	RB	_	11	AMOD	_	_
11	important	_	JJ	JJ	_	9	PRD	_	_
12	in	_	IN	IN	_	9	ADV	_	_
13	proliferation	_	NN	NN	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	self-renewal	_	JJ	JJ	_	13	COORD	_	_
16	events	_	NNS	NNS	_	12	PMOD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	erythroid	_	JJ	JJ	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	7	P	_	_

1	Transcription	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	hypersensitive	_	JJ	JJ	_	7	NMOD	_	_
5	site	_	NN	NN	_	7	NMOD	_	_
6	HS2	_	NN	NN	_	7	NMOD	_	_
7	enhancer	_	NN	NN	_	2	PMOD	_	_
8	in	_	IN	IN	_	1	NMOD	_	_
9	erythroid	_	JJ	JJ	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	.	_	.	.	_	1	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	human	_	JJ	JJ	_	4	NMOD	_	_
4	genome	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	12	P	_	_
6	the	_	DT	DT	_	11	NMOD	_	_
7	erythroid-specific	_	JJ	JJ	_	11	NMOD	_	_
8	hypersensitive	_	JJ	JJ	_	11	NMOD	_	_
9	site	_	NN	NN	_	11	NMOD	_	_
10	HS2	_	NN	NN	_	11	NMOD	_	_
11	enhancer	_	NN	NN	_	12	SBJ	_	_
12	regulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	transcription	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	downstream	_	JJ	JJ	_	20	NMOD	_	_
18	beta-like	_	JJ	JJ	_	20	NMOD	_	_
19	globin	_	NN	NN	_	20	NMOD	_	_
20	genes	_	NNS	NNS	_	15	PMOD	_	_
21	10-50	_	CD	CD	_	22	NMOD	_	_
22	kilobases	_	NNS	NNS	_	23	AMOD	_	_
23	away	_	RB	RB	_	20	NMOD	_	_
24	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	mechanism	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	HS2	_	NN	NN	_	6	NMOD	_	_
5	enhancer	_	NN	NN	_	6	NMOD	_	_
6	function	_	NN	NN	_	3	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	not	_	RB	RB	_	7	VMOD	_	_
9	known	_	VBN	VBN	_	7	VC	_	_
10	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	present	_	JJ	JJ	_	3	NMOD	_	_
3	study	_	NN	NN	_	4	SBJ	_	_
4	employs	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	RNA	_	NN	NN	_	7	NMOD	_	_
6	protection	_	NN	NN	_	7	NMOD	_	_
7	assays	_	NNS	NNS	_	4	IOBJ	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	analyze	_	VB	VB	_	4	OBJ	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	transcriptional	_	JJ	JJ	_	12	NMOD	_	_
12	status	_	NN	NN	_	9	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	HS2	_	NN	NN	_	16	NMOD	_	_
16	enhancer	_	NN	NN	_	13	PMOD	_	_
17	in	_	IN	IN	_	12	NMOD	_	_
18	transfected	_	VBN	VBN	_	25	NMOD	_	_
19	recombinant	_	JJ	JJ	_	25	NMOD	_	_
20	chloramphenicol	_	NN	NN	_	21	NMOD	_	_
21	acetyltransferase	_	NN	NN	_	25	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	CAT	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	plasmids	_	NNS	NNS	_	17	PMOD	_	_
26	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	16	ADV	_	_
2	erythroid	_	JJ	JJ	_	4	NMOD	_	_
3	K562	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	1	PMOD	_	_
5	in	_	IN	IN	_	10	ADV	_	_
6	which	_	WDT	WDT	_	5	PMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	HS2	_	NN	NN	_	9	NMOD	_	_
9	enhancer	_	NN	NN	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	4	NMOD	_	_
11	active	_	JJ	JJ	_	10	PRD	_	_
12	,	_	,	,	_	16	P	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	HS2	_	NN	NN	_	15	NMOD	_	_
15	sequence	_	NN	NN	_	16	SBJ	_	_
16	directs	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	synthesis	_	NN	NN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	long	_	JJ	JJ	_	22	NMOD	_	_
21	enhancer	_	NN	NN	_	22	NMOD	_	_
22	transcripts	_	NNS	NNS	_	19	PMOD	_	_
23	that	_	WDT	WDT	_	24	SBJ	_	_
24	are	_	VBP	VBP	_	22	NMOD	_	_
25	initiated	_	VBN	VBN	_	24	VC	_	_
26	apparently	_	RB	RB	_	25	ADV	_	_
27	from	_	IN	IN	_	25	ADV	_	_
28	within	_	IN	IN	_	27	PMOD	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	enhancer	_	NN	NN	_	28	PMOD	_	_
31	and	_	CC	CC	_	25	CC	_	_
32	elongated	_	VBN	VBN	_	25	COORD	_	_
33	through	_	IN	IN	_	32	ADV	_	_
34	the	_	DT	DT	_	36	NMOD	_	_
35	intervening	_	VBG	VBG	_	36	NMOD	_	_
36	DNA	_	NN	NN	_	33	PMOD	_	_
37	into	_	IN	IN	_	32	ADV	_	_
38	the	_	DT	DT	_	41	NMOD	_	_
39	cis-linked	_	JJ	JJ	_	41	NMOD	_	_
40	CAT	_	NN	NN	_	41	NMOD	_	_
41	gene	_	NN	NN	_	37	PMOD	_	_
42	.	_	.	.	_	16	P	_	_

1	In	_	IN	IN	_	16	ADV	_	_
2	nonerythroid	_	JJ	JJ	_	4	NMOD	_	_
3	HL-60	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	1	PMOD	_	_
5	in	_	IN	IN	_	10	ADV	_	_
6	which	_	WDT	WDT	_	5	PMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	HS2	_	NN	NN	_	9	NMOD	_	_
9	enhancer	_	NN	NN	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	4	NMOD	_	_
11	inactive	_	JJ	JJ	_	10	PRD	_	_
12	,	_	,	,	_	16	P	_	_
13	long	_	JJ	JJ	_	15	NMOD	_	_
14	enhancer	_	NN	NN	_	15	NMOD	_	_
15	transcripts	_	NNS	NNS	_	16	SBJ	_	_
16	are	_	VBP	VBP	_	0	ROOT-S	_	_
17	not	_	RB	RB	_	16	VMOD	_	_
18	detectable	_	JJ	JJ	_	16	PRD	_	_
19	.	_	.	.	_	16	P	_	_

1	Splitting	_	VBG	VBG	_	10	SBJ	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	HS2	_	NN	NN	_	4	NMOD	_	_
4	enhancer	_	NN	NN	_	1	OBJ	_	_
5	between	_	IN	IN	_	1	ADV	_	_
6	two	_	CD	CD	_	9	NMOD	_	_
7	tandem	_	JJ	JJ	_	9	NMOD	_	_
8	Ap1	_	NN	NN	_	9	NMOD	_	_
9	sites	_	NNS	NNS	_	5	PMOD	_	_
10	abolishes	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	synthesis	_	NN	NN	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	group	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	long	_	JJ	JJ	_	19	NMOD	_	_
18	enhancer	_	NN	NN	_	19	NMOD	_	_
19	transcripts	_	NNS	NNS	_	16	PMOD	_	_
20	and	_	CC	CC	_	10	CC	_	_
21	results	_	VBZ	VBZ	_	10	COORD	_	_
22	in	_	IN	IN	_	21	ADV	_	_
23	loss	_	NN	NN	_	22	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	enhancer	_	NN	NN	_	26	NMOD	_	_
26	function	_	NN	NN	_	24	PMOD	_	_
27	and	_	CC	CC	_	23	CC	_	_
28	transcriptional	_	JJ	JJ	_	29	NMOD	_	_
29	silencing	_	NN	NN	_	23	COORD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	the	_	DT	DT	_	34	NMOD	_	_
32	cis-linked	_	JJ	JJ	_	34	NMOD	_	_
33	CAT	_	NN	NN	_	34	NMOD	_	_
34	gene	_	NN	NN	_	30	PMOD	_	_
35	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	24	ADV	_	_
2	directing	_	VBG	VBG	_	1	PMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	synthesis	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	RNA	_	NN	NN	_	5	PMOD	_	_
7	through	_	IN	IN	_	2	ADV	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	intervening	_	VBG	VBG	_	10	NMOD	_	_
10	DNA	_	NN	NN	_	7	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	gene	_	NN	NN	_	10	COORD	_	_
14	by	_	IN	IN	_	2	ADV	_	_
15	a	_	DT	DT	_	19	NMOD	_	_
16	tracking	_	NN	NN	_	19	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	transcription	_	NN	NN	_	16	COORD	_	_
19	mechanism	_	NN	NN	_	14	PMOD	_	_
20	,	_	,	,	_	24	P	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	HS2	_	NN	NN	_	23	NMOD	_	_
23	enhancer	_	NN	NN	_	24	SBJ	_	_
24	may	_	MD	MD	_	0	ROOT-S	_	_
25	(	_	(	(	_	26	P	_	_
26	i	_	LS	LS	_	28	VMOD	_	_
27	)	_	)	)	_	26	P	_	_
28	open	_	VB	VB	_	24	VC	_	_
29	up	_	RP	RP	_	28	PRT	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	chromatin	_	NN	NN	_	32	NMOD	_	_
32	structure	_	NN	NN	_	28	OBJ	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	a	_	DT	DT	_	36	NMOD	_	_
35	gene	_	NN	NN	_	36	NMOD	_	_
36	domain	_	NN	NN	_	33	PMOD	_	_
37	and	_	CC	CC	_	28	CC	_	_
38	(	_	(	(	_	39	P	_	_
39	ii	_	LS	LS	_	41	VMOD	_	_
40	)	_	)	)	_	39	P	_	_
41	deliver	_	VB	VB	_	28	COORD	_	_
42	enhancer	_	NN	NN	_	44	NMOD	_	_
43	binding	_	NN	NN	_	44	NMOD	_	_
44	proteins	_	NNS	NNS	_	41	OBJ	_	_
45	to	_	TO	TO	_	41	ADV	_	_
46	the	_	DT	DT	_	48	NMOD	_	_
47	promoter	_	NN	NN	_	48	NMOD	_	_
48	sequence	_	NN	NN	_	45	PMOD	_	_
49	where	_	WRB	WRB	_	52	ADV	_	_
50	they	_	PRP	PRP	_	51	SBJ	_	_
51	may	_	MD	MD	_	48	NMOD	_	_
52	stimulate	_	VB	VB	_	51	VC	_	_
53	the	_	DT	DT	_	54	NMOD	_	_
54	transcription	_	NN	NN	_	52	OBJ	_	_
55	of	_	IN	IN	_	54	NMOD	_	_
56	the	_	DT	DT	_	57	NMOD	_	_
57	gene	_	NN	NN	_	55	PMOD	_	_
58	at	_	IN	IN	_	52	ADV	_	_
59	the	_	DT	DT	_	61	NMOD	_	_
60	cap	_	NN	NN	_	61	NMOD	_	_
61	site	_	NN	NN	_	58	PMOD	_	_
62	.	_	.	.	_	24	P	_	_

1	Ablation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	transplanted	_	VBN	VBN	_	6	NMOD	_	_
4	HTLV-I	_	NN	NN	_	6	NMOD	_	_
5	Tax-transformed	_	JJ	JJ	_	4	AMOD	_	_
6	tumors	_	NNS	NNS	_	2	PMOD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	mice	_	NNS	NNS	_	7	PMOD	_	_
9	by	_	IN	IN	_	1	NMOD	_	_
10	antisense	_	JJ	JJ	_	11	NMOD	_	_
11	inhibition	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	NF-kappa	_	NN	NN	_	14	NMOD	_	_
14	B	_	NN	NN	_	12	PMOD	_	_
15	{	_	(	(	_	18	P	_	_
16	published	_	VBN	VBN	_	17	NMOD	_	_
17	erratum	_	NN	NN	_	18	SBJ	_	_
18	appears	_	VBZ	VBZ	_	1	NMOD	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	Science	_	NNP	NNP	_	19	PMOD	_	_
21	1993	_	CD	CD	_	20	NMOD	_	_
22	Mar	_	NNP	NNP	_	20	TMP	_	_
23	12	_	CD	CD	_	22	NMOD	_	_
24	;	_	:	:	_	20	P	_	_
25	259	_	CD	CD	_	20	NMOD	_	_
26	(	_	(	(	_	20	P	_	_
27	5101	_	CD	CD	_	20	NMOD	_	_
28	)	_	)	)	_	20	P	_	_
29	:	_	:	:	_	20	P	_	_
30	1523	_	CD	CD	_	20	NMOD	_	_
31	}	_	)	)	_	18	P	_	_

1	Mice	_	NNS	NNS	_	15	SBJ	_	_
2	transgenic	_	JJ	JJ	_	1	NMOD	_	_
3	for	_	IN	IN	_	2	AMOD	_	_
4	the	_	DT	DT	_	14	NMOD	_	_
5	human	_	JJ	JJ	_	9	NMOD	_	_
6	T	_	NN	NN	_	9	NMOD	_	_
7	cell	_	NN	NN	_	9	NMOD	_	_
8	leukemia	_	NN	NN	_	9	NMOD	_	_
9	virus	_	NN	NN	_	14	NMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	HTLV-I	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	Tax	_	NN	NN	_	14	NMOD	_	_
14	gene	_	NN	NN	_	3	PMOD	_	_
15	develop	_	VBP	VBP	_	0	ROOT-S	_	_
16	fibroblastic	_	JJ	JJ	_	17	NMOD	_	_
17	tumors	_	NNS	NNS	_	15	OBJ	_	_
18	that	_	WDT	WDT	_	19	SBJ	_	_
19	express	_	VBP	VBP	_	17	NMOD	_	_
20	NF-kappa	_	NN	NN	_	23	NMOD	_	_
21	B-inducible	_	JJ	JJ	_	20	AMOD	_	_
22	early	_	JJ	JJ	_	23	NMOD	_	_
23	genes	_	NNS	NNS	_	19	OBJ	_	_
24	.	_	.	.	_	15	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	vitro	_	FW	FW	_	3	NMOD	_	_
3	inhibition	_	NN	NN	_	14	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	NF-kappa	_	NN	NN	_	7	NMOD	_	_
6	B	_	NN	NN	_	7	NMOD	_	_
7	expression	_	NN	NN	_	4	PMOD	_	_
8	by	_	IN	IN	_	3	NMOD	_	_
9	antisense	_	JJ	JJ	_	10	NMOD	_	_
10	oligodeoxynucleotides	_	NNS	NNS	_	8	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	ODNs	_	NNS	NNS	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
15	growth	_	NN	NN	_	14	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	these	_	DT	DT	_	20	NMOD	_	_
18	culture-adapted	_	JJ	JJ	_	20	NMOD	_	_
19	Tax-transformed	_	JJ	JJ	_	20	NMOD	_	_
20	fibroblasts	_	NNS	NNS	_	16	PMOD	_	_
21	as	_	RB	RB	_	20	CC	_	_
22	well	_	RB	RB	_	21	DEP	_	_
23	as	_	IN	IN	_	21	DEP	_	_
24	an	_	DT	DT	_	28	NMOD	_	_
25	HTLV-I-transformed	_	JJ	JJ	_	28	NMOD	_	_
26	human	_	JJ	JJ	_	28	NMOD	_	_
27	lymphocyte	_	NN	NN	_	28	NMOD	_	_
28	line	_	NN	NN	_	20	COORD	_	_
29	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	9	P	_	_
4	antisense	_	JJ	JJ	_	5	NMOD	_	_
5	inhibition	_	NN	NN	_	9	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	Tax	_	NN	NN	_	6	PMOD	_	_
8	itself	_	PRP	PRP	_	7	NMOD	_	_
9	had	_	VBD	VBD	_	0	ROOT-S	_	_
10	no	_	DT	DT	_	12	NMOD	_	_
11	apparent	_	JJ	JJ	_	12	NMOD	_	_
12	effect	_	NN	NN	_	9	OBJ	_	_
13	on	_	IN	IN	_	9	ADV	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	growth	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	9	P	_	_

1	Mice	_	NNS	NNS	_	9	SBJ	_	_
2	treated	_	VBN	VBN	_	1	NMOD	_	_
3	with	_	IN	IN	_	2	ADV	_	_
4	antisense	_	NN	NN	_	3	PMOD	_	_
5	to	_	TO	TO	_	4	NMOD	_	_
6	NF-kappa	_	NN	NN	_	8	NMOD	_	_
7	B	_	NN	NN	_	8	NMOD	_	_
8	ODNs	_	NNS	NNS	_	5	PMOD	_	_
9	showed	_	VBD	VBD	_	0	ROOT-S	_	_
10	rapid	_	JJ	JJ	_	11	NMOD	_	_
11	regression	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	transplanted	_	VBN	VBN	_	14	NMOD	_	_
14	fibrosarcomas	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	9	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	NF-kappa	_	NN	NN	_	6	NMOD	_	_
5	B	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	7	SBJ	_	_
7	may	_	MD	MD	_	3	VMOD	_	_
8	be	_	VB	VB	_	7	VC	_	_
9	necessary	_	JJ	JJ	_	8	PRD	_	_
10	for	_	IN	IN	_	9	AMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	maintenance	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	malignant	_	JJ	JJ	_	16	NMOD	_	_
16	phenotype	_	NN	NN	_	13	PMOD	_	_
17	and	_	CC	CC	_	2	CC	_	_
18	provides	_	VBZ	VBZ	_	2	COORD	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	therapeutic	_	JJ	JJ	_	21	NMOD	_	_
21	approach	_	NN	NN	_	18	OBJ	_	_
22	for	_	IN	IN	_	21	NMOD	_	_
23	HTLV-I-associated	_	JJ	JJ	_	24	NMOD	_	_
24	disease	_	NN	NN	_	22	PMOD	_	_
25	.	_	.	.	_	2	P	_	_

1	Inhibition	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	anti-CD3	_	JJ	JJ	_	5	AMOD	_	_
4	monoclonal	_	JJ	JJ	_	5	AMOD	_	_
5	antibody-induced	_	JJ	JJ	_	7	NMOD	_	_
6	T-cell	_	NN	NN	_	7	NMOD	_	_
7	proliferation	_	NN	NN	_	2	PMOD	_	_
8	by	_	IN	IN	_	1	NMOD	_	_
9	dexamethasone	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	isoproterenol	_	NN	NN	_	9	COORD	_	_
12	,	_	,	,	_	9	P	_	_
13	or	_	CC	CC	_	9	CC	_	_
14	prostaglandin	_	NN	NN	_	15	NMOD	_	_
15	E2	_	NN	NN	_	9	COORD	_	_
16	either	_	CC	CC	_	9	NMOD	_	_
17	alone	_	RB	RB	_	16	COORD	_	_
18	or	_	CC	CC	_	16	CC	_	_
19	in	_	IN	IN	_	16	COORD	_	_
20	combination	_	NN	NN	_	19	PMOD	_	_
21	.	_	.	.	_	1	P	_	_

1	1	_	LS	LS	_	8	VMOD	_	_
2	.	_	.	.	_	1	P	_	_
3	The	_	DT	DT	_	4	NMOD	_	_
4	purpose	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	these	_	DT	DT	_	7	NMOD	_	_
7	studies	_	NNS	NNS	_	5	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	investigate	_	VB	VB	_	8	PRD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	modulation	_	NN	NN	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	proliferation	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	human	_	JJ	JJ	_	19	NMOD	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	PMOD	_	_
20	obtained	_	VBN	VBN	_	19	NMOD	_	_
21	from	_	IN	IN	_	20	ADV	_	_
22	peripheral	_	JJ	JJ	_	23	NMOD	_	_
23	blood	_	NN	NN	_	21	PMOD	_	_
24	by	_	IN	IN	_	12	NMOD	_	_
25	dexamethasone	_	NN	NN	_	24	PMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	DEX	_	NN	NN	_	25	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	,	_	,	,	_	25	P	_	_
30	isoproterenol	_	NN	NN	_	25	COORD	_	_
31	(	_	(	(	_	32	P	_	_
32	ISO	_	NN	NN	_	30	PRN	_	_
33	)	_	)	)	_	32	P	_	_
34	,	_	,	,	_	25	P	_	_
35	and	_	CC	CC	_	25	CC	_	_
36	prostaglandin	_	NN	NN	_	37	NMOD	_	_
37	E2	_	NN	NN	_	25	COORD	_	_
38	(	_	(	(	_	39	P	_	_
39	PGE2	_	NN	NN	_	37	PRN	_	_
40	)	_	)	)	_	39	P	_	_
41	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	former	_	JJ	JJ	_	4	NMOD	_	_
3	two	_	CD	CD	_	4	NMOD	_	_
4	substances	_	NNS	NNS	_	5	SBJ	_	_
5	interact	_	VBP	VBP	_	0	ROOT-S	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	T	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	via	_	IN	IN	_	5	ADV	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	glucocorticoid	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	beta-adrenergic	_	JJ	JJ	_	11	COORD	_	_
14	receptors	_	NNS	NNS	_	9	PMOD	_	_
15	respectively	_	RB	RB	_	5	ADV	_	_
16	.	_	.	.	_	5	P	_	_

1	When	_	WRB	WRB	_	3	PMOD	_	_
2	occupied	_	VBN	VBN	_	14	TMP	_	_
3	by	_	IN	IN	_	2	LGS	_	_
4	their	_	PRP$	PRP$	_	6	NMOD	_	_
5	natural	_	JJ	JJ	_	6	NMOD	_	_
6	ligands	_	NNS	NNS	_	3	PMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	glucocorticosteroids	_	NNS	NNS	_	6	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	catecholamines	_	NNS	NNS	_	8	COORD	_	_
11	,	_	,	,	_	14	P	_	_
12	these	_	DT	DT	_	13	NMOD	_	_
13	receptors	_	NNS	NNS	_	14	SBJ	_	_
14	have	_	VBP	VBP	_	0	ROOT-S	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	role	_	NN	NN	_	14	OBJ	_	_
17	in	_	IN	IN	_	14	ADV	_	_
18	modulating	_	VBG	VBG	_	17	PMOD	_	_
19	T-cell	_	NN	NN	_	20	NMOD	_	_
20	function	_	NN	NN	_	18	OBJ	_	_
21	during	_	IN	IN	_	18	TMP	_	_
22	stress	_	NN	NN	_	21	PMOD	_	_
23	.	_	.	.	_	14	P	_	_

1	During	_	IN	IN	_	9	TMP	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	inflammatory	_	JJ	JJ	_	4	NMOD	_	_
4	response	_	NN	NN	_	1	PMOD	_	_
5	increased	_	VBN	VBN	_	6	NMOD	_	_
6	levels	_	NNS	NNS	_	9	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	PGE2	_	NN	NN	_	7	PMOD	_	_
9	bind	_	VBP	VBP	_	0	ROOT-S	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	their	_	PRP$	PRP$	_	12	NMOD	_	_
12	receptors	_	NNS	NNS	_	10	PMOD	_	_
13	on	_	IN	IN	_	12	NMOD	_	_
14	T	_	NN	NN	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	13	PMOD	_	_
16	and	_	CC	CC	_	9	CC	_	_
17	thus	_	RB	RB	_	9	COORD	_	_
18	alter	_	VBP	VBP	_	9	COORD	_	_
19	responsiveness	_	NN	NN	_	18	OBJ	_	_
20	.	_	.	.	_	9	P	_	_

1	Proliferation	_	NN	NN	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	T	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	induced	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	immobilized	_	VBN	VBN	_	11	NMOD	_	_
9	anti-CD3	_	JJ	JJ	_	11	NMOD	_	_
10	monoclonal	_	JJ	JJ	_	11	NMOD	_	_
11	antibody	_	NN	NN	_	7	PMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	mAb	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	in	_	IN	IN	_	6	ADV	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	presence	_	NN	NN	_	15	PMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	absence	_	NN	NN	_	17	COORD	_	_
20	of	_	IN	IN	_	17	NMOD	_	_
21	an	_	DT	DT	_	24	NMOD	_	_
22	additional	_	JJ	JJ	_	24	NMOD	_	_
23	costimulatory	_	JJ	JJ	_	24	NMOD	_	_
24	signal	_	NN	NN	_	20	PMOD	_	_
25	delivered	_	VBN	VBN	_	24	NMOD	_	_
26	by	_	IN	IN	_	25	LGS	_	_
27	anti-CD28	_	JJ	JJ	_	28	NMOD	_	_
28	mAb	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	5	P	_	_

1	2	_	LS	LS	_	13	VMOD	_	_
2	.	_	.	.	_	1	P	_	_
3	Various	_	JJ	JJ	_	5	NMOD	_	_
4	physiologic	_	JJ	JJ	_	5	NMOD	_	_
5	concentrations	_	NNS	NNS	_	13	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	DEX	_	NN	NN	_	6	PMOD	_	_
8	,	_	,	,	_	7	P	_	_
9	ISO	_	NN	NN	_	7	COORD	_	_
10	,	_	,	,	_	7	P	_	_
11	or	_	CC	CC	_	7	CC	_	_
12	PGE2	_	NN	NN	_	7	COORD	_	_
13	were	_	VBD	VBD	_	0	ROOT-S	_	_
14	added	_	VBN	VBN	_	13	VC	_	_
15	at	_	IN	IN	_	14	TMP	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	time	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	initiation	_	NN	NN	_	18	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	cultures	_	NNS	NNS	_	20	PMOD	_	_
23	and	_	CC	CC	_	13	CC	_	_
24	subsequent	_	JJ	JJ	_	25	NMOD	_	_
25	proliferation	_	NN	NN	_	31	SBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	unstimulated	_	JJ	JJ	_	30	NMOD	_	_
29	T	_	NN	NN	_	30	NMOD	_	_
30	cells	_	NNS	NNS	_	26	PMOD	_	_
31	was	_	VBD	VBD	_	13	COORD	_	_
32	determined	_	VBN	VBN	_	31	VC	_	_
33	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	physiologic	_	JJ	JJ	_	6	NMOD	_	_
6	concentrations	_	NNS	NNS	_	13	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	all	_	DT	DT	_	9	NMOD	_	_
9	three	_	CD	CD	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	these	_	DT	DT	_	12	NMOD	_	_
12	agents	_	NNS	NNS	_	10	PMOD	_	_
13	inhibit	_	VBP	VBP	_	4	VMOD	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	anti-CD3	_	JJ	JJ	_	16	AMOD	_	_
16	mAb-induced	_	JJ	JJ	_	17	NMOD	_	_
17	proliferation	_	NN	NN	_	13	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	T	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	3	_	LS	LS	_	15	VMOD	_	_
2	.	_	.	.	_	1	P	_	_
3	Although	_	IN	IN	_	15	ADV	_	_
4	DEX	_	NN	NN	_	7	SBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	PGE2	_	NN	NN	_	4	COORD	_	_
7	were	_	VBD	VBD	_	3	VMOD	_	_
8	equipotent	_	JJ	JJ	_	7	PRD	_	_
9	in	_	IN	IN	_	7	ADV	_	_
10	suppressing	_	JJ	JJ	_	12	VMOD	_	_
11	T-cell	_	NN	NN	_	12	NMOD	_	_
12	proliferation	_	NN	NN	_	9	PMOD	_	_
13	,	_	,	,	_	15	P	_	_
14	ISO	_	NN	NN	_	15	SBJ	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	much	_	RB	RB	_	15	PRD	_	_
17	less	_	RBR	RBR	_	16	AMOD	_	_
18	effective	_	JJ	JJ	_	16	AMOD	_	_
19	.	_	.	.	_	15	P	_	_

1	4	_	LS	LS	_	17	VMOD	_	_
2	.	_	.	.	_	1	P	_	_
3	Because	_	IN	IN	_	17	ADV	_	_
4	concomitant	_	JJ	JJ	_	5	NMOD	_	_
5	elevations	_	NNS	NNS	_	13	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	peripheral	_	JJ	JJ	_	9	NMOD	_	_
9	levels	_	NNS	NNS	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	these	_	DT	DT	_	12	NMOD	_	_
12	substances	_	NNS	NNS	_	10	PMOD	_	_
13	may	_	MD	MD	_	3	VMOD	_	_
14	occur	_	VB	VB	_	13	VC	_	_
15	,	_	,	,	_	17	P	_	_
16	experiments	_	NNS	NNS	_	17	SBJ	_	_
17	were	_	VBD	VBD	_	0	ROOT-S	_	_
18	performed	_	VBN	VBN	_	17	VC	_	_
19	to	_	TO	TO	_	20	VMOD	_	_
20	determine	_	VB	VB	_	18	OBJ	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	T-cell	_	NN	NN	_	24	NMOD	_	_
23	inhibitory	_	JJ	JJ	_	24	NMOD	_	_
24	effects	_	NNS	NNS	_	20	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	DEX	_	NN	NN	_	25	PMOD	_	_
27	together	_	RB	RB	_	28	DEP	_	_
28	with	_	IN	IN	_	24	NMOD	_	_
29	either	_	CC	CC	_	30	CC	_	_
30	PGE2	_	NN	NN	_	28	PMOD	_	_
31	or	_	CC	CC	_	30	CC	_	_
32	ISO	_	NN	NN	_	30	COORD	_	_
33	.	_	.	.	_	17	P	_	_

1	Synergistic	_	JJ	JJ	_	2	NMOD	_	_
2	suppression	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	T-cell	_	NN	NN	_	5	NMOD	_	_
5	proliferation	_	NN	NN	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	observed	_	VBN	VBN	_	6	VC	_	_
8	when	_	WRB	WRB	_	23	ADV	_	_
9	various	_	JJ	JJ	_	10	NMOD	_	_
10	concentrations	_	NNS	NNS	_	22	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	DEX	_	NN	NN	_	11	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	PGE2	_	NN	NN	_	12	COORD	_	_
15	,	_	,	,	_	12	P	_	_
16	but	_	CC	CC	_	12	CC	_	_
17	not	_	RB	RB	_	16	COORD	_	_
18	DEX	_	NN	NN	_	12	COORD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	ISO	_	NN	NN	_	18	COORD	_	_
21	,	_	,	,	_	12	P	_	_
22	were	_	VBD	VBD	_	7	TMP	_	_
23	added	_	VBN	VBN	_	22	VC	_	_
24	to	_	TO	TO	_	23	ADV	_	_
25	cultures	_	NNS	NNS	_	24	PMOD	_	_
26	.	_	.	.	_	6	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	synergistic	_	JJ	JJ	_	3	NMOD	_	_
3	suppression	_	NN	NN	_	4	SBJ	_	_
4	could	_	MD	MD	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	be	_	VB	VB	_	4	VC	_	_
7	explained	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	an	_	DT	DT	_	10	NMOD	_	_
10	increase	_	NN	NN	_	8	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	cAMP	_	NN	NN	_	13	NMOD	_	_
13	accumulation	_	NN	NN	_	11	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	stimulated	_	VBN	VBN	_	16	NMOD	_	_
18	with	_	IN	IN	_	17	ADV	_	_
19	DEX	_	NN	NN	_	18	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	PGE2	_	NN	NN	_	19	COORD	_	_
22	.	_	.	.	_	4	P	_	_

1	5	_	LS	LS	_	15	VMOD	_	_
2	.	_	.	.	_	1	P	_	_
3	Finally	_	RB	RB	_	15	ADV	_	_
4	,	_	,	,	_	15	P	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	addition	_	NN	NN	_	15	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	anti-CD28	_	JJ	JJ	_	9	NMOD	_	_
9	mAb	_	NN	NN	_	7	PMOD	_	_
10	to	_	TO	TO	_	6	NMOD	_	_
11	anti-CD3	_	JJ	JJ	_	12	AMOD	_	_
12	mAb-stimulated	_	JJ	JJ	_	14	NMOD	_	_
13	T	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	10	PMOD	_	_
15	overcame	_	VBD	VBD	_	0	ROOT-S	_	_
16	much	_	JJ	JJ	_	15	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	suppression	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	proliferation	_	NN	NN	_	20	PMOD	_	_
22	induced	_	VBN	VBN	_	19	NMOD	_	_
23	by	_	IN	IN	_	22	LGS	_	_
24	PGE2	_	NN	NN	_	23	PMOD	_	_
25	or	_	CC	CC	_	24	CC	_	_
26	ISO	_	NN	NN	_	24	COORD	_	_
27	but	_	CC	CC	_	15	CC	_	_
28	less	_	RBR	RBR	_	29	AMOD	_	_
29	so	_	RB	RB	_	15	ADV	_	_
30	than	_	IN	IN	_	29	AMOD	_	_
31	that	_	DT	DT	_	30	PMOD	_	_
32	induced	_	VBN	VBN	_	31	NMOD	_	_
33	by	_	IN	IN	_	32	LGS	_	_
34	DEX	_	NN	NN	_	33	PMOD	_	_
35	.	_	.	.	_	15	P	_	_

1	Mutations	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	in	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	Pit-1	_	NN	NN	_	5	NMOD	_	_
5	gene	_	NN	NN	_	2	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	children	_	NNS	NNS	_	6	PMOD	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	combined	_	JJ	JJ	_	12	NMOD	_	_
10	pituitary	_	JJ	JJ	_	12	NMOD	_	_
11	hormone	_	NN	NN	_	12	NMOD	_	_
12	deficiency	_	NN	NN	_	8	PMOD	_	_
13	.	_	.	.	_	1	P	_	_

1	Pit-1	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	pituitary-specific	_	JJ	JJ	_	6	NMOD	_	_
5	transcription	_	NN	NN	_	6	NMOD	_	_
6	factor	_	NN	NN	_	2	PRD	_	_
7	that	_	WDT	WDT	_	8	SBJ	_	_
8	binds	_	VBZ	VBZ	_	6	NMOD	_	_
9	to	_	TO	TO	_	8	ADV	_	_
10	and	_	CC	CC	_	8	CC	_	_
11	transactivates	_	VBZ	VBZ	_	8	COORD	_	_
12	promoters	_	NNS	NNS	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	growth	_	NN	NN	_	15	NMOD	_	_
15	hormone	_	NN	NN	_	13	PMOD	_	_
16	and	_	CC	CC	_	12	CC	_	_
17	prolactin	_	NN	NN	_	18	NMOD	_	_
18	genes	_	NNS	NNS	_	12	COORD	_	_
19	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	13	ADV	_	_
2	three	_	CD	CD	_	5	NMOD	_	_
3	unrelated	_	JJ	JJ	_	5	NMOD	_	_
4	Japanese	_	JJ	JJ	_	5	NMOD	_	_
5	children	_	NNS	NNS	_	1	PMOD	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	combined	_	JJ	JJ	_	10	NMOD	_	_
8	pituitary	_	JJ	JJ	_	10	NMOD	_	_
9	hormone	_	NN	NN	_	10	NMOD	_	_
10	deficiency	_	NN	NN	_	6	PMOD	_	_
11	,	_	,	,	_	13	P	_	_
12	we	_	PRP	PRP	_	13	SBJ	_	_
13	identified	_	VBD	VBD	_	0	ROOT-S	_	_
14	three	_	CD	CD	_	16	NMOD	_	_
15	point	_	NN	NN	_	16	NMOD	_	_
16	mutations	_	NNS	NNS	_	13	OBJ	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	Pit-1	_	NN	NN	_	20	NMOD	_	_
20	gene	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	16	P	_	_
22	Pro24Leu	_	NN	NN	_	16	NMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	Arg143Gln	_	NN	NN	_	22	COORD	_	_
25	,	_	,	,	_	22	P	_	_
26	and	_	CC	CC	_	22	CC	_	_
27	Arg271Trp	_	NN	NN	_	22	COORD	_	_
28	,	_	,	,	_	16	P	_	_
29	located	_	JJ	JJ	_	42	AMOD	_	_
30	on	_	IN	IN	_	42	AMOD	_	_
31	the	_	DT	DT	_	34	NMOD	_	_
32	major	_	JJ	JJ	_	34	NMOD	_	_
33	transactivation	_	NN	NN	_	34	NMOD	_	_
34	region	_	NN	NN	_	30	PMOD	_	_
35	,	_	,	,	_	34	P	_	_
36	POU-specific	_	JJ	JJ	_	37	NMOD	_	_
37	domain	_	NN	NN	_	34	NMOD	_	_
38	,	_	,	,	_	37	P	_	_
39	and	_	CC	CC	_	37	CC	_	_
40	POU-homeodomain	_	NN	NN	_	37	COORD	_	_
41	,	_	,	,	_	34	P	_	_
42	respectively	_	RB	RB	_	16	NMOD	_	_
43	.	_	.	.	_	13	P	_	_

1	Calcitriol	_	NN	NN	_	0	ROOT-FRAG	_	_
2	:	_	:	:	_	1	P	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	hematolymphopoietrope	_	NN	NN	_	1	NMOD	_	_
5	?	_	.	.	_	4	P	_	_
6	{	_	(	(	_	7	P	_	_
7	editorial	_	NN	NN	_	1	NMOD	_	_
8	}	_	)	)	_	7	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	MEDLINE	_	NN	NN	_	3	NMOD	_	_
3	search	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	English-language	_	JJ	JJ	_	7	NMOD	_	_
7	literature	_	NN	NN	_	4	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	conducted	_	VBN	VBN	_	8	VC	_	_
10	using	_	VBG	VBG	_	9	OBJ	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	indexing	_	NN	NN	_	13	NMOD	_	_
13	terms	_	NNS	NNS	_	10	OBJ	_	_
14	'	_	``	``	_	15	P	_	_
15	immunology	_	NN	NN	_	13	PRN	_	_
16	,	_	,	,	_	15	P	_	_
17	calcitriol	_	NN	NN	_	15	COORD	_	_
18	and	_	CC	CC	_	15	CC	_	_
19	vitamin	_	NN	NN	_	20	NMOD	_	_
20	D	_	NN	NN	_	15	COORD	_	_
21	'	_	''	''	_	15	P	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	identify	_	VB	VB	_	9	OBJ	_	_
24	studies	_	NNS	NNS	_	23	OBJ	_	_
25	indicating	_	VBG	VBG	_	24	NMOD	_	_
26	a	_	DT	DT	_	27	NMOD	_	_
27	role	_	NN	NN	_	25	OBJ	_	_
28	for	_	IN	IN	_	27	NMOD	_	_
29	calcitriol	_	NN	NN	_	28	PMOD	_	_
30	as	_	IN	IN	_	27	NMOD	_	_
31	a	_	DT	DT	_	33	NMOD	_	_
32	primary	_	JJ	JJ	_	33	NMOD	_	_
33	immunomodulator	_	NN	NN	_	30	PMOD	_	_
34	.	_	.	.	_	8	P	_	_

1	Sixty-six	_	CD	CD	_	2	NMOD	_	_
2	papers	_	NNS	NNS	_	10	SBJ	_	_
3	published	_	VBN	VBN	_	2	NMOD	_	_
4	between	_	IN	IN	_	3	TMP	_	_
5	January	_	NNP	NNP	_	4	PMOD	_	_
6	1956	_	CD	CD	_	5	NMOD	_	_
7	and	_	CC	CC	_	5	CC	_	_
8	June	_	NNP	NNP	_	5	COORD	_	_
9	1991	_	CD	CD	_	8	NMOD	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	identified	_	VBN	VBN	_	10	VC	_	_
12	.	_	.	.	_	10	P	_	_

1	Forty-five	_	CD	CD	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	reports	_	NNS	NNS	_	2	PMOD	_	_
5	are	_	VBP	VBP	_	0	ROOT-S	_	_
6	cited	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	this	_	DT	DT	_	9	NMOD	_	_
9	review	_	NN	NN	_	7	PMOD	_	_
10	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	4	SBJ	_	_
3	strongly	_	RB	RB	_	4	ADV	_	_
4	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
5	an	_	DT	DT	_	11	NMOD	_	_
6	endocrine	_	NN	NN	_	11	NMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	autocrine	_	NN	NN	_	6	COORD	_	_
9	and\/or	_	CC	CC	_	6	CC	_	_
10	paracrine	_	NN	NN	_	6	COORD	_	_
11	role	_	NN	NN	_	4	OBJ	_	_
12	for	_	IN	IN	_	11	NMOD	_	_
13	calcitriol	_	NN	NN	_	12	PMOD	_	_
14	in	_	IN	IN	_	11	NMOD	_	_
15	immune	_	JJ	JJ	_	16	NMOD	_	_
16	regulation	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	4	P	_	_

1	No	_	DT	DT	_	3	NMOD	_	_
2	unifying	_	JJ	JJ	_	3	NMOD	_	_
3	hypothesis	_	NN	NN	_	4	SBJ	_	_
4	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	yet	_	RB	RB	_	4	ADV	_	_
6	emerged	_	VBN	VBN	_	4	VC	_	_
7	explaining	_	VBG	VBG	_	3	NMOD	_	_
8	this	_	DT	DT	_	9	NMOD	_	_
9	collection	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	data	_	NNS	NNS	_	10	PMOD	_	_
12	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	paper	_	NN	NN	_	3	SBJ	_	_
3	provides	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	brief	_	JJ	JJ	_	6	NMOD	_	_
6	review	_	NN	NN	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	immune	_	JJ	JJ	_	9	NMOD	_	_
9	properties	_	NNS	NNS	_	7	PMOD	_	_
10	currently	_	RB	RB	_	11	TMP	_	_
11	attributed	_	VBN	VBN	_	9	NMOD	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	calcitriol	_	NN	NN	_	12	PMOD	_	_
14	.	_	.	.	_	3	P	_	_

1	Activation	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	protein	_	NN	NN	_	5	NMOD	_	_
4	kinase	_	NN	NN	_	5	NMOD	_	_
5	C	_	NN	NN	_	2	PMOD	_	_
6	and	_	CC	CC	_	1	CC	_	_
7	elevation	_	NN	NN	_	1	COORD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	cAMP	_	NN	NN	_	8	PMOD	_	_
10	interact	_	VBP	VBP	_	0	ROOT-S	_	_
11	synergistically	_	RB	RB	_	10	ADV	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	raise	_	VB	VB	_	10	OBJ	_	_
14	c-Fos	_	NN	NN	_	17	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	AP-1	_	NN	NN	_	14	COORD	_	_
17	activity	_	NN	NN	_	13	OBJ	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	Jurkat	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	10	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	earlier	_	RBR	RBR	_	2	TMP	_	_
4	found	_	VBN	VBN	_	2	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	in	_	IN	IN	_	17	ADV	_	_
7	Jurkat	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	activation	_	NN	NN	_	17	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	protein	_	NN	NN	_	13	NMOD	_	_
12	kinase	_	NN	NN	_	13	NMOD	_	_
13	C	_	NN	NN	_	10	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	PKC	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	enhances	_	VBZ	VBZ	_	5	VMOD	_	_
18	the	_	DT	DT	_	25	NMOD	_	_
19	cyclic	_	JJ	JJ	_	21	NMOD	_	_
20	adenosine	_	NN	NN	_	21	NMOD	_	_
21	monophosphate	_	NN	NN	_	25	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	cAMP	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	accumulation	_	NN	NN	_	17	OBJ	_	_
26	induced	_	VBN	VBN	_	25	NMOD	_	_
27	by	_	IN	IN	_	26	LGS	_	_
28	adenosine	_	NN	NN	_	30	NMOD	_	_
29	receptor	_	NN	NN	_	30	NMOD	_	_
30	stimulation	_	NN	NN	_	27	PMOD	_	_
31	or	_	CC	CC	_	30	CC	_	_
32	activation	_	NN	NN	_	30	COORD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	Gs	_	NN	NN	_	33	PMOD	_	_
35	.	_	.	.	_	2	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	therefore	_	RB	RB	_	3	ADV	_	_
5	examined	_	VBN	VBN	_	3	VC	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	effect	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	phorbol	_	NN	NN	_	11	NMOD	_	_
11	ester	_	NN	NN	_	8	PMOD	_	_
12	PMA	_	NN	NN	_	11	NMOD	_	_
13	(	_	(	(	_	16	P	_	_
14	phorbol	_	NN	NN	_	16	NMOD	_	_
15	12-myristate	_	NN	NN	_	16	NMOD	_	_
16	13-acetate	_	NN	NN	_	12	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	which	_	WDT	WDT	_	19	SBJ	_	_
19	stimulates	_	VBZ	VBZ	_	11	NMOD	_	_
20	PKC	_	NN	NN	_	37	SBJ	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	a	_	DT	DT	_	23	NMOD	_	_
23	combination	_	NN	NN	_	20	COORD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	28	NMOD	_	_
26	adenosine	_	NN	NN	_	28	NMOD	_	_
27	receptor	_	NN	NN	_	28	NMOD	_	_
28	agonist	_	NN	NN	_	24	PMOD	_	_
29	NECA	_	NN	NN	_	28	NMOD	_	_
30	(	_	(	(	_	32	P	_	_
31	5'--LRB-N-ethyl-RRB--carboxamido	_	JJ	JJ	_	32	NMOD	_	_
32	adenosine	_	NN	NN	_	29	PRN	_	_
33	)	_	)	)	_	32	P	_	_
34	and	_	CC	CC	_	28	CC	_	_
35	forskolin	_	NN	NN	_	28	COORD	_	_
36	to	_	TO	TO	_	37	VMOD	_	_
37	raise	_	VB	VB	_	19	OBJ	_	_
38	cAMP	_	NN	NN	_	37	OBJ	_	_
39	,	_	,	,	_	7	P	_	_
40	on	_	IN	IN	_	7	NMOD	_	_
41	the	_	DT	DT	_	42	NMOD	_	_
42	levels	_	NNS	NNS	_	40	PMOD	_	_
43	of	_	IN	IN	_	42	NMOD	_	_
44	c-Fos	_	NN	NN	_	43	PMOD	_	_
45	and	_	CC	CC	_	44	CC	_	_
46	Jun	_	NN	NN	_	44	COORD	_	_
47	and	_	CC	CC	_	40	CC	_	_
48	on	_	IN	IN	_	40	COORD	_	_
49	the	_	DT	DT	_	50	NMOD	_	_
50	binding	_	VBG	VBG	_	48	PMOD	_	_
51	and	_	CC	CC	_	50	CC	_	_
52	transcriptional	_	JJ	JJ	_	53	NMOD	_	_
53	activity	_	NN	NN	_	50	COORD	_	_
54	of	_	IN	IN	_	50	NMOD	_	_
55	the	_	DT	DT	_	57	NMOD	_	_
56	transcription	_	NN	NN	_	57	NMOD	_	_
57	factor	_	NN	NN	_	54	PMOD	_	_
58	,	_	,	,	_	57	P	_	_
59	activator	_	NN	NN	_	60	NMOD	_	_
60	protein-1	_	NN	NN	_	57	NMOD	_	_
61	(	_	(	(	_	62	P	_	_
62	AP-1	_	NN	NN	_	60	PRN	_	_
63	)	_	)	)	_	62	P	_	_
64	.	_	.	.	_	3	P	_	_

1	PMA	_	NN	NN	_	2	NMOD	_	_
2	treatment	_	NN	NN	_	3	SBJ	_	_
3	caused	_	VBD	VBD	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	8	NMOD	_	_
5	concentration-	_	NN	NN	_	8	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	time-dependent	_	JJ	JJ	_	5	COORD	_	_
8	increase	_	NN	NN	_	3	OBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	both	_	CC	CC	_	11	CC	_	_
11	c-Fos	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	Jun	_	NN	NN	_	11	COORD	_	_
14	immunoreactivity	_	NN	NN	_	9	PMOD	_	_
15	in	_	IN	IN	_	3	ADV	_	_
16	contrast	_	NN	NN	_	15	DEP	_	_
17	to	_	TO	TO	_	15	DEP	_	_
18	cAMP	_	NN	NN	_	19	NMOD	_	_
19	elevation	_	NN	NN	_	15	PMOD	_	_
20	that	_	WDT	WDT	_	21	SBJ	_	_
21	had	_	VBD	VBD	_	19	NMOD	_	_
22	only	_	RB	RB	_	25	NMOD	_	_
23	a	_	DT	DT	_	25	NMOD	_	_
24	slight	_	JJ	JJ	_	25	NMOD	_	_
25	effect	_	NN	NN	_	21	OBJ	_	_
26	.	_	.	.	_	3	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	PMA	_	NN	NN	_	10	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	combination	_	NN	NN	_	2	COORD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	NECA	_	NN	NN	_	6	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	forskolin	_	NN	NN	_	7	COORD	_	_
10	acted	_	VBD	VBD	_	0	ROOT-S	_	_
11	together	_	RB	RB	_	10	ADV	_	_
12	either	_	CC	CC	_	14	CC	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	increase	_	VB	VB	_	10	OBJ	_	_
15	(	_	(	(	_	16	P	_	_
16	c-Fos	_	NN	NN	_	14	OBJ	_	_
17	)	_	)	)	_	16	P	_	_
18	or	_	CC	CC	_	14	CC	_	_
19	decrease	_	VB	VB	_	14	COORD	_	_
20	(	_	(	(	_	21	P	_	_
21	Jun	_	NN	NN	_	19	OBJ	_	_
22	)	_	)	)	_	21	P	_	_
23	protein	_	NN	NN	_	24	NMOD	_	_
24	levels	_	NNS	NNS	_	16	NMOD	_	_
25	as	_	RB	RB	_	27	DEP	_	_
26	well	_	RB	RB	_	27	DEP	_	_
27	as	_	IN	IN	_	14	ADV	_	_
28	increasing	_	VBG	VBG	_	27	PMOD	_	_
29	AP-1	_	NN	NN	_	30	NMOD	_	_
30	binding	_	NN	NN	_	28	OBJ	_	_
31	,	_	,	,	_	28	P	_	_
32	as	_	IN	IN	_	28	ADV	_	_
33	judged	_	VBN	VBN	_	32	VMOD	_	_
34	by	_	IN	IN	_	33	LGS	_	_
35	gel-shift	_	NN	NN	_	36	NMOD	_	_
36	assay	_	NN	NN	_	34	PMOD	_	_
37	,	_	,	,	_	28	P	_	_
38	and	_	CC	CC	_	28	CC	_	_
39	AP-1	_	NN	NN	_	41	NMOD	_	_
40	transcriptional	_	JJ	JJ	_	41	NMOD	_	_
41	activity	_	NN	NN	_	30	GAP	_	_
42	.	_	.	.	_	10	P	_	_

1	Furthermore	_	RB	RB	_	3	ADV	_	_
2	there	_	EX	EX	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	clear-cut	_	JJ	JJ	_	6	NMOD	_	_
6	synergy	_	NN	NN	_	3	PRD	_	_
7	between	_	IN	IN	_	3	ADV	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	PKC	_	NN	NN	_	10	NMOD	_	_
10	stimulator	_	NN	NN	_	7	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	cAMP	_	NN	NN	_	15	NMOD	_	_
14	elevating	_	NN	NN	_	15	NMOD	_	_
15	agents	_	NNS	NNS	_	10	COORD	_	_
16	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	simultaneous	_	JJ	JJ	_	7	NMOD	_	_
7	activation	_	NN	NN	_	14	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	PKC	_	NN	NN	_	8	PMOD	_	_
10	and	_	CC	CC	_	7	CC	_	_
11	elevation	_	NN	NN	_	7	COORD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	cAMP	_	NN	NN	_	12	PMOD	_	_
14	leads	_	VBZ	VBZ	_	4	VMOD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	an	_	DT	DT	_	20	NMOD	_	_
17	enhanced	_	VBN	VBN	_	20	NMOD	_	_
18	AP-1	_	NN	NN	_	20	NMOD	_	_
19	transcriptional	_	JJ	JJ	_	20	NMOD	_	_
20	activity	_	NN	NN	_	15	PMOD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	a	_	DT	DT	_	25	NMOD	_	_
23	T-leukemia	_	NN	NN	_	25	NMOD	_	_
24	cell	_	NN	NN	_	25	NMOD	_	_
25	line	_	NN	NN	_	21	PMOD	_	_
26	,	_	,	,	_	14	P	_	_
27	suggesting	_	VBG	VBG	_	14	OBJ	_	_
28	that	_	IN	IN	_	27	OBJ	_	_
29	the	_	DT	DT	_	32	NMOD	_	_
30	previously	_	RB	RB	_	31	AMOD	_	_
31	observed	_	VBN	VBN	_	32	NMOD	_	_
32	interaction	_	NN	NN	_	39	SBJ	_	_
33	between	_	IN	IN	_	32	NMOD	_	_
34	the	_	DT	DT	_	38	NMOD	_	_
35	parallel	_	JJ	JJ	_	38	NMOD	_	_
36	signal	_	NN	NN	_	38	NMOD	_	_
37	transduction	_	NN	NN	_	38	NMOD	_	_
38	pathways	_	NNS	NNS	_	33	PMOD	_	_
39	may	_	MD	MD	_	28	VMOD	_	_
40	have	_	VB	VB	_	39	VC	_	_
41	functional	_	JJ	JJ	_	42	NMOD	_	_
42	consequences	_	NNS	NNS	_	40	OBJ	_	_
43	at	_	IN	IN	_	40	ADV	_	_
44	the	_	DT	DT	_	45	NMOD	_	_
45	level	_	NN	NN	_	43	PMOD	_	_
46	of	_	IN	IN	_	45	NMOD	_	_
47	gene	_	NN	NN	_	48	NMOD	_	_
48	transcription	_	NN	NN	_	46	PMOD	_	_
49	.	_	.	.	_	3	P	_	_

1	Involvement	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	Alu	_	NN	NN	_	4	NMOD	_	_
4	sequences	_	NNS	NNS	_	2	PMOD	_	_
5	in	_	IN	IN	_	1	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	cell-specific	_	JJ	JJ	_	8	NMOD	_	_
8	regulation	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	transcription	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	gamma	_	NN	NN	_	14	NMOD	_	_
14	chain	_	NN	NN	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	Fc	_	NN	NN	_	20	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	cell	_	NN	NN	_	16	COORD	_	_
20	receptors	_	NNS	NNS	_	15	PMOD	_	_
21	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	Fc	_	NN	NN	_	5	NMOD	_	_
3	epsilon	_	NN	NN	_	5	NMOD	_	_
4	RI-gamma	_	NN	NN	_	5	NMOD	_	_
5	chains	_	NNS	NNS	_	6	SBJ	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	expressed	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	variety	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	hematopoietic	_	JJ	JJ	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	where	_	WRB	WRB	_	16	ADV	_	_
15	they	_	PRP	PRP	_	16	SBJ	_	_
16	play	_	VBP	VBP	_	13	NMOD	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	critical	_	JJ	JJ	_	19	NMOD	_	_
19	role	_	NN	NN	_	16	OBJ	_	_
20	in	_	IN	IN	_	16	ADV	_	_
21	signal	_	NN	NN	_	22	NMOD	_	_
22	transduction	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	6	P	_	_

1	They	_	PRP	PRP	_	2	SBJ	_	_
2	are	_	VBP	VBP	_	0	ROOT-S	_	_
3	part	_	NN	NN	_	2	PRD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	high	_	JJ	JJ	_	9	NMOD	_	_
7	affinity	_	NN	NN	_	9	NMOD	_	_
8	IgE	_	NN	NN	_	9	NMOD	_	_
9	receptor	_	NN	NN	_	4	PMOD	_	_
10	in	_	IN	IN	_	3	NMOD	_	_
11	mast	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	basophils	_	NNS	NNS	_	12	COORD	_	_
15	,	_	,	,	_	12	P	_	_
16	Langerhans	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	12	COORD	_	_
18	,	_	,	,	_	12	P	_	_
19	and	_	CC	CC	_	12	CC	_	_
20	possibly	_	RB	RB	_	21	AMOD	_	_
21	other	_	JJ	JJ	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	12	COORD	_	_
23	;	_	:	:	_	3	P	_	_
24	a	_	DT	DT	_	25	NMOD	_	_
25	component	_	NN	NN	_	3	COORD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	low	_	JJ	JJ	_	30	NMOD	_	_
29	affinity	_	NN	NN	_	30	NMOD	_	_
30	receptor	_	NN	NN	_	26	PMOD	_	_
31	for	_	IN	IN	_	30	NMOD	_	_
32	IgG	_	NN	NN	_	31	PMOD	_	_
33	(	_	(	(	_	36	P	_	_
34	Fc	_	NN	NN	_	36	NMOD	_	_
35	gamma	_	NN	NN	_	36	NMOD	_	_
36	RIIIA	_	NN	NN	_	32	PRN	_	_
37	or	_	CC	CC	_	36	CC	_	_
38	CD16	_	NN	NN	_	36	COORD	_	_
39	)	_	)	)	_	36	P	_	_
40	in	_	IN	IN	_	25	NMOD	_	_
41	natural	_	JJ	JJ	_	43	NMOD	_	_
42	killer	_	NN	NN	_	43	NMOD	_	_
43	cells	_	NNS	NNS	_	40	PMOD	_	_
44	and	_	CC	CC	_	43	CC	_	_
45	macrophages	_	NNS	NNS	_	43	COORD	_	_
46	;	_	:	:	_	3	P	_	_
47	and	_	CC	CC	_	3	CC	_	_
48	part	_	NN	NN	_	3	COORD	_	_
49	of	_	IN	IN	_	48	NMOD	_	_
50	the	_	DT	DT	_	54	NMOD	_	_
51	T	_	NN	NN	_	54	NMOD	_	_
52	cell	_	NN	NN	_	54	NMOD	_	_
53	antigen	_	NN	NN	_	54	NMOD	_	_
54	receptor	_	NN	NN	_	49	PMOD	_	_
55	in	_	IN	IN	_	48	NMOD	_	_
56	subsets	_	NNS	NNS	_	55	PMOD	_	_
57	of	_	IN	IN	_	56	NMOD	_	_
58	T	_	NN	NN	_	59	NMOD	_	_
59	cells	_	NNS	NNS	_	57	PMOD	_	_
60	.	_	.	.	_	2	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	investigated	_	VBN	VBN	_	3	VC	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	transcriptional	_	JJ	JJ	_	7	NMOD	_	_
7	regulation	_	NN	NN	_	4	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	gamma	_	NN	NN	_	12	NMOD	_	_
11	chain	_	NN	NN	_	12	NMOD	_	_
12	gene	_	NN	NN	_	8	PMOD	_	_
13	by	_	IN	IN	_	4	ADV	_	_
14	analyzing	_	VBG	VBG	_	13	PMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	2.5-kilobase	_	JJ	JJ	_	17	NMOD	_	_
17	sequence	_	NN	NN	_	14	OBJ	_	_
18	upstream	_	JJ	JJ	_	17	NMOD	_	_
19	of	_	IN	IN	_	18	AMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	transcription	_	NN	NN	_	23	NMOD	_	_
22	start	_	NN	NN	_	23	NMOD	_	_
23	site	_	NN	NN	_	19	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	sequence	_	NN	NN	_	3	SBJ	_	_
3	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	promoter	_	NN	NN	_	3	OBJ	_	_
6	specific	_	JJ	JJ	_	5	NMOD	_	_
7	to	_	TO	TO	_	6	AMOD	_	_
8	cells	_	NNS	NNS	_	7	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	hematopoietic	_	JJ	JJ	_	11	NMOD	_	_
11	lineage	_	NN	NN	_	9	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	tissue	_	NN	NN	_	5	NMOD	_	_
5	specificity	_	NN	NN	_	9	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	this	_	DT	DT	_	8	NMOD	_	_
8	promoter	_	NN	NN	_	6	PMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	only	_	RB	RB	_	11	AMOD	_	_
11	partial	_	JJ	JJ	_	9	PRD	_	_
12	because	_	IN	IN	_	9	ADV	_	_
13	it	_	PRP	PRP	_	14	SBJ	_	_
14	is	_	VBZ	VBZ	_	12	VMOD	_	_
15	active	_	JJ	JJ	_	14	PRD	_	_
16	in	_	IN	IN	_	14	ADV	_	_
17	all	_	DT	DT	_	16	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	hematopoietic	_	JJ	JJ	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	18	PMOD	_	_
22	tested	_	VBN	VBN	_	21	NMOD	_	_
23	here	_	RB	RB	_	22	ADV	_	_
24	,	_	,	,	_	14	P	_	_
25	regardless	_	RB	RB	_	14	ADV	_	_
26	of	_	IN	IN	_	25	AMOD	_	_
27	whether	_	IN	IN	_	26	PMOD	_	_
28	they	_	PRP	PRP	_	30	SBJ	_	_
29	constitutively	_	RB	RB	_	30	ADV	_	_
30	express	_	VBP	VBP	_	27	VMOD	_	_
31	Fc	_	NN	NN	_	35	NMOD	_	_
32	epsilon	_	NN	NN	_	35	NMOD	_	_
33	RI-gamma	_	NN	NN	_	35	NMOD	_	_
34	chain	_	NN	NN	_	35	NMOD	_	_
35	transcripts	_	NNS	NNS	_	30	OBJ	_	_
36	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	identified	_	VBN	VBN	_	2	VC	_	_
4	two	_	CD	CD	_	8	NMOD	_	_
5	adjacent	_	JJ	JJ	_	8	NMOD	_	_
6	cis-acting	_	JJ	JJ	_	8	NMOD	_	_
7	regulatory	_	JJ	JJ	_	8	NMOD	_	_
8	elements	_	NNS	NNS	_	3	OBJ	_	_
9	,	_	,	,	_	8	P	_	_
10	both	_	DT	DT	_	11	NMOD	_	_
11	of	_	IN	IN	_	13	SBJ	_	_
12	which	_	WDT	WDT	_	11	PMOD	_	_
13	are	_	VBP	VBP	_	8	NMOD	_	_
14	part	_	NN	NN	_	13	PRD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	an	_	DT	DT	_	18	NMOD	_	_
17	Alu	_	NN	NN	_	18	NMOD	_	_
18	repeat	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	first	_	JJ	JJ	_	6	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	-445\/-366	_	CD	CD	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	positive	_	JJ	JJ	_	9	NMOD	_	_
9	element	_	NN	NN	_	6	PRD	_	_
10	active	_	JJ	JJ	_	9	NMOD	_	_
11	in	_	IN	IN	_	10	AMOD	_	_
12	both	_	CC	CC	_	13	CC	_	_
13	basophils	_	NNS	NNS	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	13	COORD	_	_
17	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	second	_	JJ	JJ	_	6	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	-365\/-264	_	CD	CD	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	to	_	TO	TO	_	6	ADV	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	factors	_	NNS	NNS	_	7	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	appear	_	VBP	VBP	_	9	NMOD	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	be	_	VB	VB	_	12	OBJ	_	_
15	different	_	JJ	JJ	_	14	PRD	_	_
16	in	_	IN	IN	_	14	ADV	_	_
17	basophils	_	NNS	NNS	_	16	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	T	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	17	COORD	_	_
21	,	_	,	,	_	6	P	_	_
22	and	_	CC	CC	_	6	CC	_	_
23	acts	_	VBZ	VBZ	_	6	COORD	_	_
24	as	_	IN	IN	_	23	VMOD	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	negative	_	JJ	JJ	_	27	NMOD	_	_
27	element	_	NN	NN	_	24	PMOD	_	_
28	in	_	IN	IN	_	23	VMOD	_	_
29	basophils	_	NNS	NNS	_	28	PMOD	_	_
30	and	_	CC	CC	_	23	CC	_	_
31	as	_	IN	IN	_	24	GAP	_	_
32	a	_	DT	DT	_	34	NMOD	_	_
33	positive	_	JJ	JJ	_	34	NMOD	_	_
34	one	_	NN	NN	_	31	PMOD	_	_
35	in	_	IN	IN	_	28	GAP	_	_
36	T	_	NN	NN	_	37	NMOD	_	_
37	cells	_	NNS	NNS	_	35	PMOD	_	_
38	.	_	.	.	_	6	P	_	_

1	Thus	_	RB	RB	_	15	ADV	_	_
2	,	_	,	,	_	15	P	_	_
3	this	_	DT	DT	_	5	NMOD	_	_
4	Alu	_	NN	NN	_	5	NMOD	_	_
5	repeat	_	NN	NN	_	13	NMOD	_	_
6	(	_	(	(	_	13	P	_	_
7	90	_	CD	CD	_	8	AMOD	_	_
8	%	_	NN	NN	_	13	NMOD	_	_
9	identical	_	JJ	JJ	_	8	AMOD	_	_
10	to	_	TO	TO	_	12	NMOD	_	_
11	Alu	_	NN	NN	_	12	NMOD	_	_
12	consensus	_	NN	NN	_	9	PMOD	_	_
13	sequences	_	NNS	NNS	_	15	SBJ	_	_
14	)	_	)	)	_	15	P	_	_
15	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	evolved	_	VBN	VBN	_	15	OBJ	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	become	_	VB	VB	_	16	VC	_	_
19	both	_	CC	CC	_	18	CC	_	_
20	a	_	DT	DT	_	21	AMOD	_	_
21	positive	_	JJ	JJ	_	18	COORD	_	_
22	and	_	CC	CC	_	21	AMOD	_	_
23	negative	_	JJ	JJ	_	18	COORD	_	_
24	regulator	_	NN	NN	_	15	VMOD	_	_

1	Human	_	JJ	JJ	_	3	NMOD	_	_
2	immunodeficiency	_	NN	NN	_	3	NMOD	_	_
3	viruses	_	NNS	NNS	_	7	SBJ	_	_
4	containing	_	VBG	VBG	_	3	NMOD	_	_
5	heterologous	_	JJ	JJ	_	6	NMOD	_	_
6	enhancer\/promoters	_	NNS	NNS	_	4	OBJ	_	_
7	are	_	VBP	VBP	_	0	ROOT-S	_	_
8	replication	_	NN	NN	_	7	PRD	_	_
9	competent	_	JJ	JJ	_	8	AMOD	_	_
10	and	_	CC	CC	_	7	CC	_	_
11	exhibit	_	VBP	VBP	_	7	COORD	_	_
12	different	_	JJ	JJ	_	14	NMOD	_	_
13	lymphocyte	_	NN	NN	_	14	NMOD	_	_
14	tropisms	_	NNS	NNS	_	11	OBJ	_	_
15	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	8	NMOD	_	_
2	human	_	JJ	JJ	_	4	NMOD	_	_
3	immunodeficiency	_	NN	NN	_	4	NMOD	_	_
4	virus	_	NN	NN	_	8	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	HIV	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	type	_	NN	NN	_	16	SBJ	_	_
9	1	_	CD	CD	_	8	NMOD	_	_
10	long	_	JJ	JJ	_	12	NMOD	_	_
11	terminal	_	JJ	JJ	_	12	NMOD	_	_
12	repeat	_	NN	NN	_	8	NMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	LTR	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	binding	_	VBG	VBG	_	18	NMOD	_	_
18	sites	_	NNS	NNS	_	16	OBJ	_	_
19	for	_	IN	IN	_	18	NMOD	_	_
20	nuclear	_	JJ	JJ	_	23	NMOD	_	_
21	factor	_	NN	NN	_	23	NMOD	_	_
22	kappa	_	NN	NN	_	23	NMOD	_	_
23	B	_	NN	NN	_	19	PMOD	_	_
24	(	_	(	(	_	26	P	_	_
25	NF-kappa	_	NN	NN	_	26	NMOD	_	_
26	B	_	NN	NN	_	23	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	and	_	CC	CC	_	23	CC	_	_
29	the	_	DT	DT	_	34	NMOD	_	_
30	constitutively	_	RB	RB	_	31	AMOD	_	_
31	expressed	_	VBN	VBN	_	34	NMOD	_	_
32	transcription	_	NN	NN	_	34	NMOD	_	_
33	factor	_	NN	NN	_	34	NMOD	_	_
34	Sp1	_	NN	NN	_	23	COORD	_	_
35	,	_	,	,	_	23	P	_	_
36	both	_	DT	DT	_	37	NMOD	_	_
37	of	_	IN	IN	_	39	SBJ	_	_
38	which	_	WDT	WDT	_	37	PMOD	_	_
39	are	_	VBP	VBP	_	23	NMOD	_	_
40	highly	_	RB	RB	_	41	ADV	_	_
41	conserved	_	VBN	VBN	_	39	VC	_	_
42	in	_	IN	IN	_	41	ADV	_	_
43	HIV	_	NN	NN	_	48	NMOD	_	_
44	and	_	CC	CC	_	43	CC	_	_
45	simian	_	JJ	JJ	_	47	NMOD	_	_
46	immunodeficiency	_	NN	NN	_	47	NMOD	_	_
47	virus	_	NN	NN	_	43	COORD	_	_
48	isolates	_	NNS	NNS	_	42	PMOD	_	_
49	.	_	.	.	_	16	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	delineate	_	VB	VB	_	29	VC	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	effects	_	NNS	NNS	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	these	_	DT	DT	_	7	NMOD	_	_
7	motifs	_	NNS	NNS	_	5	PMOD	_	_
8	on	_	IN	IN	_	4	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	replicative	_	JJ	JJ	_	11	NMOD	_	_
11	capacity	_	NN	NN	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	HIV	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	2	CC	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	explore	_	VB	VB	_	2	COORD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	possibility	_	NN	NN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	extending	_	VBG	VBG	_	19	PMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	virus	_	NN	NN	_	24	NMOD	_	_
23	host	_	NN	NN	_	24	NMOD	_	_
24	range	_	NN	NN	_	20	OBJ	_	_
25	,	_	,	,	_	29	P	_	_
26	known	_	VBN	VBN	_	28	NMOD	_	_
27	heterologous	_	JJ	JJ	_	28	NMOD	_	_
28	enhancer\/promoters	_	NNS	NNS	_	29	SBJ	_	_
29	were	_	VBD	VBD	_	0	ROOT-S	_	_
30	inserted	_	VBN	VBN	_	29	VC	_	_
31	into	_	IN	IN	_	30	ADV	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	HIV-1	_	NN	NN	_	34	NMOD	_	_
34	LTR	_	NN	NN	_	31	PMOD	_	_
35	in	_	IN	IN	_	30	ADV	_	_
36	place	_	NN	NN	_	35	DEP	_	_
37	of	_	IN	IN	_	35	DEP	_	_
38	the	_	DT	DT	_	44	NMOD	_	_
39	NF-kappa	_	NN	NN	_	40	NMOD	_	_
40	B	_	NN	NN	_	44	NMOD	_	_
41	and	_	CC	CC	_	40	CC	_	_
42	Sp1	_	NN	NN	_	40	COORD	_	_
43	binding	_	NN	NN	_	44	NMOD	_	_
44	sites	_	NNS	NNS	_	35	PMOD	_	_
45	.	_	.	.	_	29	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effects	_	NNS	NNS	_	27	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	these	_	DT	DT	_	5	NMOD	_	_
5	substitutions	_	NNS	NNS	_	3	PMOD	_	_
6	on	_	IN	IN	_	2	NMOD	_	_
7	viral	_	JJ	JJ	_	8	NMOD	_	_
8	replication	_	NN	NN	_	6	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	transfected	_	VBN	VBN	_	12	NMOD	_	_
11	HeLa	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	PMOD	_	_
13	and	_	CC	CC	_	6	CC	_	_
14	on	_	IN	IN	_	6	COORD	_	_
15	HIV	_	NN	NN	_	16	NMOD	_	_
16	infection	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	human	_	JJ	JJ	_	21	NMOD	_	_
19	peripheral	_	JJ	JJ	_	21	NMOD	_	_
20	blood	_	NN	NN	_	21	NMOD	_	_
21	lymphocytes	_	NNS	NNS	_	17	PMOD	_	_
22	or	_	CC	CC	_	21	CC	_	_
23	continuous	_	JJ	JJ	_	26	NMOD	_	_
24	T-leukemia	_	NN	NN	_	26	NMOD	_	_
25	cell	_	NN	NN	_	26	NMOD	_	_
26	lines	_	NNS	NNS	_	21	COORD	_	_
27	were	_	VBD	VBD	_	0	ROOT-S	_	_
28	evaluated	_	VBN	VBN	_	27	VC	_	_
29	.	_	.	.	_	27	P	_	_

1	HIVs	_	NN	NN	_	19	SBJ	_	_
2	in	_	IN	IN	_	15	ADV	_	_
3	which	_	WDT	WDT	_	2	PMOD	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	NF-	_	NN	NN	_	8	NMOD	_	_
6	kappa	_	NN	NN	_	8	NMOD	_	_
7	B\/Sp1	_	NN	NN	_	8	NMOD	_	_
8	enhancer	_	NN	NN	_	14	SBJ	_	_
9	plus	_	CC	CC	_	8	CC	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	downstream	_	JJ	JJ	_	13	NMOD	_	_
12	TATA	_	NN	NN	_	13	NMOD	_	_
13	element	_	NN	NN	_	8	COORD	_	_
14	were	_	VBD	VBD	_	1	NMOD	_	_
15	replaced	_	VBN	VBN	_	14	VC	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	heterologous	_	JJ	JJ	_	18	NMOD	_	_
18	enhancer\/promoters	_	NNS	NNS	_	16	PMOD	_	_
19	were	_	VBD	VBD	_	0	ROOT-S	_	_
20	also	_	RB	RB	_	21	ADV	_	_
21	constructed	_	VBN	VBN	_	19	VC	_	_
22	.	_	.	.	_	19	P	_	_

1	Viruses	_	NNS	NNS	_	8	SBJ	_	_
2	containing	_	VBG	VBG	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	human	_	JJ	JJ	_	7	NMOD	_	_
5	cytomegalovirus	_	NN	NN	_	7	NMOD	_	_
6	immediate-early	_	JJ	JJ	_	7	NMOD	_	_
7	enhancer	_	NN	NN	_	2	OBJ	_	_
8	exhibited	_	VBD	VBD	_	0	ROOT-S	_	_
9	infectious	_	JJ	JJ	_	10	NMOD	_	_
10	kinetics	_	NNS	NNS	_	8	OBJ	_	_
11	similar	_	JJ	JJ	_	10	NMOD	_	_
12	to	_	TO	TO	_	11	AMOD	_	_
13	that	_	DT	DT	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	wild-type	_	JJ	JJ	_	16	NMOD	_	_
16	HIV	_	NN	NN	_	14	PMOD	_	_
17	in	_	IN	IN	_	8	ADV	_	_
18	activated	_	VBN	VBN	_	22	NMOD	_	_
19	human	_	JJ	JJ	_	22	NMOD	_	_
20	peripheral	_	JJ	JJ	_	22	NMOD	_	_
21	blood	_	NN	NN	_	22	NMOD	_	_
22	lymphocytes	_	NNS	NNS	_	17	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	AA2	_	NN	NN	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	22	COORD	_	_
26	but	_	CC	CC	_	8	CC	_	_
27	replicated	_	VBD	VBD	_	8	COORD	_	_
28	less	_	RBR	RBR	_	29	AMOD	_	_
29	efficiently	_	RB	RB	_	27	ADV	_	_
30	in	_	IN	IN	_	27	ADV	_	_
31	H9	_	NN	NN	_	34	NMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	CEM	_	NN	NN	_	31	COORD	_	_
34	cells	_	NNS	NNS	_	30	PMOD	_	_
35	.	_	.	.	_	8	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	heterologous	_	JJ	JJ	_	7	NMOD	_	_
6	enhancer	_	NN	NN	_	7	NMOD	_	_
7	elements	_	NNS	NNS	_	8	SBJ	_	_
8	are	_	VBP	VBP	_	4	VMOD	_	_
9	capable	_	JJ	JJ	_	8	PRD	_	_
10	of	_	IN	IN	_	9	AMOD	_	_
11	restoring	_	VBG	VBG	_	10	PMOD	_	_
12	Tat	_	NN	NN	_	13	NMOD	_	_
13	responsiveness	_	NN	NN	_	11	OBJ	_	_
14	to	_	TO	TO	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	HIV	_	NN	NN	_	17	NMOD	_	_
17	LTR	_	NN	NN	_	14	PMOD	_	_
18	in	_	IN	IN	_	11	ADV	_	_
19	the	_	DT	DT	_	18	DEP	_	_
20	context	_	NN	NN	_	18	DEP	_	_
21	of	_	IN	IN	_	18	DEP	_	_
22	directing	_	VBG	VBG	_	18	PMOD	_	_
23	reporter	_	NN	NN	_	25	NMOD	_	_
24	gene	_	NN	NN	_	25	NMOD	_	_
25	expression	_	NN	NN	_	22	OBJ	_	_
26	as	_	RB	RB	_	18	CC	_	_
27	well	_	RB	RB	_	26	DEP	_	_
28	as	_	IN	IN	_	26	DEP	_	_
29	in	_	IN	IN	_	18	COORD	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	production	_	NN	NN	_	29	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	infectious	_	JJ	JJ	_	35	NMOD	_	_
34	progeny	_	NN	NN	_	35	NMOD	_	_
35	virions	_	NNS	NNS	_	32	PMOD	_	_
36	.	_	.	.	_	3	P	_	_

1	Photoaffinity	_	NN	NN	_	2	NMOD	_	_
2	labeling	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	plasma	_	NN	NN	_	6	NMOD	_	_
5	membrane	_	NN	NN	_	6	NMOD	_	_
6	receptors	_	NNS	NNS	_	3	PMOD	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	aldosterone	_	NN	NN	_	7	PMOD	_	_
9	from	_	IN	IN	_	6	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	mononuclear	_	JJ	JJ	_	12	NMOD	_	_
12	leukocytes	_	NNS	NNS	_	9	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	Non-genomic	_	JJ	JJ	_	2	NMOD	_	_
2	effects	_	NNS	NNS	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	aldosterone	_	NN	NN	_	3	PMOD	_	_
5	on	_	IN	IN	_	2	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	sodium-proton-antiport	_	NN	NN	_	5	PMOD	_	_
8	have	_	VBP	VBP	_	0	ROOT-S	_	_
9	been	_	VBN	VBN	_	8	VC	_	_
10	shown	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	human	_	JJ	JJ	_	14	NMOD	_	_
13	mononuclear	_	JJ	JJ	_	14	NMOD	_	_
14	leukocytes	_	NNS	NNS	_	11	PMOD	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	could	_	MD	MD	_	14	NMOD	_	_
17	be	_	VB	VB	_	16	VC	_	_
18	related	_	JJ	JJ	_	17	PRD	_	_
19	to	_	TO	TO	_	18	AMOD	_	_
20	a	_	DT	DT	_	24	NMOD	_	_
21	new	_	JJ	JJ	_	24	NMOD	_	_
22	aldosterone	_	NN	NN	_	24	NMOD	_	_
23	membrane	_	NN	NN	_	24	NMOD	_	_
24	receptor	_	NN	NN	_	19	PMOD	_	_
25	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	present	_	JJ	JJ	_	4	NMOD	_	_
4	paper	_	NN	NN	_	1	PMOD	_	_
5	plasma	_	NN	NN	_	6	NMOD	_	_
6	membranes	_	NNS	NNS	_	11	SBJ	_	_
7	from	_	IN	IN	_	6	NMOD	_	_
8	human	_	JJ	JJ	_	10	NMOD	_	_
9	mononuclear	_	JJ	JJ	_	10	NMOD	_	_
10	leukocytes	_	NNS	NNS	_	7	PMOD	_	_
11	were	_	VBD	VBD	_	0	ROOT-S	_	_
12	covalently	_	RB	RB	_	11	ADV	_	_
13	photolabeled	_	VBN	VBN	_	11	VC	_	_
14	with	_	IN	IN	_	13	ADV	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	-LCB-125I-RCB--aldosterone	_	NN	NN	_	17	NMOD	_	_
17	derivative	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	11	P	_	_

1	Sodium	_	NN	NN	_	2	AMOD	_	_
2	dodecyl	_	NN	NN	_	5	NMOD	_	_
3	sulfate-polyacrylamide	_	JJ	JJ	_	2	AMOD	_	_
4	gel	_	NN	NN	_	5	NMOD	_	_
5	electrophoresis	_	NN	NN	_	6	SBJ	_	_
6	showed	_	VBD	VBD	_	0	ROOT-S	_	_
7	significant	_	JJ	JJ	_	9	NMOD	_	_
8	aldosterone	_	NN	NN	_	9	NMOD	_	_
9	binding	_	NN	NN	_	6	IOBJ	_	_
10	at	_	IN	IN	_	9	NMOD	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	molecular	_	JJ	JJ	_	13	NMOD	_	_
13	weight	_	NN	NN	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	approximately	_	RB	RB	_	17	NMOD	_	_
16	50000	_	CD	CD	_	15	DEP	_	_
17	Dalton	_	NN	NN	_	14	PMOD	_	_
18	which	_	WDT	WDT	_	19	SBJ	_	_
19	was	_	VBD	VBD	_	6	OBJ	_	_
20	absent	_	JJ	JJ	_	19	PRD	_	_
21	with	_	IN	IN	_	19	ADV	_	_
22	1	_	CD	CD	_	23	NMOD	_	_
23	microM	_	NN	NN	_	21	PMOD	_	_
24	cold	_	JJ	JJ	_	25	NMOD	_	_
25	aldosterone	_	NN	NN	_	23	NMOD	_	_
26	,	_	,	,	_	23	P	_	_
27	but	_	CC	CC	_	23	CC	_	_
28	not	_	RB	RB	_	27	COORD	_	_
29	cortisol	_	NN	NN	_	23	COORD	_	_
30	in	_	IN	IN	_	23	NMOD	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	binding	_	VBG	VBG	_	33	NMOD	_	_
33	media	_	NNS	NNS	_	30	PMOD	_	_
34	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	presence	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	sulfhydryl	_	NN	NN	_	7	NMOD	_	_
6	agent	_	NN	NN	_	7	NMOD	_	_
7	dithiothreitol	_	NN	NN	_	3	PMOD	_	_
8	did	_	VBD	VBD	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	affect	_	VB	VB	_	8	VC	_	_
11	results	_	NNS	NNS	_	10	OBJ	_	_
12	suggesting	_	VBG	VBG	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	absence	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	disulfide	_	NN	NN	_	17	NMOD	_	_
17	bridges	_	NNS	NNS	_	15	PMOD	_	_
18	in	_	IN	IN	_	14	NMOD	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	steroid	_	NN	NN	_	22	NMOD	_	_
21	binding	_	NN	NN	_	22	NMOD	_	_
22	domain	_	NN	NN	_	18	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	receptor	_	NN	NN	_	23	PMOD	_	_
26	.	_	.	.	_	8	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	first	_	JJ	JJ	_	3	PRD	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	define	_	VB	VB	_	5	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	molecular	_	JJ	JJ	_	10	NMOD	_	_
10	weight	_	NN	NN	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	membrane	_	NN	NN	_	14	NMOD	_	_
14	receptor	_	NN	NN	_	11	PMOD	_	_
15	for	_	IN	IN	_	14	NMOD	_	_
16	aldosterone	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	Alpha-lipoic	_	JJ	JJ	_	2	NMOD	_	_
2	acid	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	potent	_	JJ	JJ	_	6	NMOD	_	_
6	inhibitor	_	NN	NN	_	3	PRD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	NF-kappa	_	NN	NN	_	10	NMOD	_	_
9	B	_	NN	NN	_	10	NMOD	_	_
10	activation	_	NN	NN	_	7	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	human	_	JJ	JJ	_	14	NMOD	_	_
13	T	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	11	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	Acquired	_	VBN	VBN	_	3	NMOD	_	_
2	immunodeficiency	_	NN	NN	_	3	NMOD	_	_
3	syndrome	_	NN	NN	_	7	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	AIDS	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	from	_	IN	IN	_	7	ADV	_	_
9	infection	_	NN	NN	_	8	PMOD	_	_
10	with	_	IN	IN	_	9	NMOD	_	_
11	a	_	DT	DT	_	14	NMOD	_	_
12	human	_	JJ	JJ	_	14	NMOD	_	_
13	immunodeficiency	_	NN	NN	_	14	NMOD	_	_
14	virus	_	NN	NN	_	10	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	HIV	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	8	NMOD	_	_
2	long	_	JJ	JJ	_	4	NMOD	_	_
3	terminal	_	JJ	JJ	_	4	NMOD	_	_
4	repeat	_	NN	NN	_	8	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	LTR	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	region	_	NN	NN	_	13	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	HIV	_	NN	NN	_	12	NMOD	_	_
11	proviral	_	JJ	JJ	_	12	NMOD	_	_
12	DNA	_	NN	NN	_	9	PMOD	_	_
13	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	binding	_	VBG	VBG	_	15	NMOD	_	_
15	sites	_	NNS	NNS	_	13	OBJ	_	_
16	for	_	IN	IN	_	15	NMOD	_	_
17	nuclear	_	JJ	JJ	_	20	NMOD	_	_
18	factor	_	NN	NN	_	20	NMOD	_	_
19	kappa	_	NN	NN	_	20	NMOD	_	_
20	B	_	NN	NN	_	16	PMOD	_	_
21	(	_	(	(	_	23	P	_	_
22	NF-kappa	_	NN	NN	_	23	NMOD	_	_
23	B	_	NN	NN	_	20	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	,	_	,	,	_	13	P	_	_
26	and	_	CC	CC	_	13	CC	_	_
27	this	_	DT	DT	_	29	NMOD	_	_
28	transcriptional	_	JJ	JJ	_	29	NMOD	_	_
29	activator	_	NN	NN	_	30	SBJ	_	_
30	appears	_	VBZ	VBZ	_	13	COORD	_	_
31	to	_	TO	TO	_	32	VMOD	_	_
32	regulate	_	VB	VB	_	30	OBJ	_	_
33	HIV	_	NN	NN	_	34	NMOD	_	_
34	activation	_	NN	NN	_	32	OBJ	_	_
35	.	_	.	.	_	13	P	_	_

1	Recent	_	JJ	JJ	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	an	_	DT	DT	_	5	NMOD	_	_
5	involvement	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	reactive	_	JJ	JJ	_	9	NMOD	_	_
8	oxygen	_	NN	NN	_	9	NMOD	_	_
9	species	_	NNS	NNS	_	6	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	ROS	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	in	_	IN	IN	_	5	NMOD	_	_
14	signal	_	NN	NN	_	16	NMOD	_	_
15	transduction	_	NN	NN	_	16	NMOD	_	_
16	pathways	_	NNS	NNS	_	13	PMOD	_	_
17	leading	_	VBG	VBG	_	16	NMOD	_	_
18	to	_	TO	TO	_	17	ADV	_	_
19	NF-kappa	_	NN	NN	_	21	NMOD	_	_
20	B	_	NN	NN	_	21	NMOD	_	_
21	activation	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	present	_	JJ	JJ	_	3	NMOD	_	_
3	study	_	NN	NN	_	4	VMOD	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	based	_	VBN	VBN	_	4	VC	_	_
6	on	_	IN	IN	_	5	ADV	_	_
7	reports	_	NNS	NNS	_	6	PMOD	_	_
8	that	_	IN	IN	_	7	NMOD	_	_
9	antioxidants	_	NNS	NNS	_	13	SBJ	_	_
10	which	_	WDT	WDT	_	11	SBJ	_	_
11	eliminate	_	VBP	VBP	_	9	NMOD	_	_
12	ROS	_	NN	NN	_	11	OBJ	_	_
13	should	_	MD	MD	_	8	VMOD	_	_
14	block	_	VB	VB	_	13	VC	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	activation	_	NN	NN	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	NF-kappa	_	NN	NN	_	19	NMOD	_	_
19	B	_	NN	NN	_	17	PMOD	_	_
20	and	_	CC	CC	_	14	CC	_	_
21	subsequently	_	RB	RB	_	23	ADV	_	_
22	HIV	_	NN	NN	_	23	NMOD	_	_
23	transcription	_	NN	NN	_	16	GAP	_	_
24	,	_	,	,	_	13	P	_	_
25	and	_	CC	CC	_	13	CC	_	_
26	thus	_	RB	RB	_	13	COORD	_	_
27	antioxidants	_	NNS	NNS	_	28	SBJ	_	_
28	can	_	MD	MD	_	13	COORD	_	_
29	be	_	VB	VB	_	28	VC	_	_
30	used	_	VBN	VBN	_	29	VC	_	_
31	as	_	IN	IN	_	30	ADV	_	_
32	therapeutic	_	JJ	JJ	_	33	NMOD	_	_
33	agents	_	NNS	NNS	_	31	PMOD	_	_
34	for	_	IN	IN	_	33	NMOD	_	_
35	AIDS	_	NN	NN	_	34	PMOD	_	_
36	.	_	.	.	_	4	P	_	_

1	Incubation	_	NN	NN	_	27	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	Jurkat	_	NN	NN	_	5	NMOD	_	_
4	T	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	2	PMOD	_	_
6	(	_	(	(	_	10	P	_	_
7	1	_	CD	CD	_	10	NMOD	_	_
8	x	_	CC	CC	_	7	CC	_	_
9	10-LRB-6-RRB-	_	CD	CD	_	7	COORD	_	_
10	cells\/ml	_	NNS	NNS	_	5	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	with	_	IN	IN	_	1	NMOD	_	_
13	a	_	DT	DT	_	19	NMOD	_	_
14	natural	_	JJ	JJ	_	19	NMOD	_	_
15	thiol	_	NN	NN	_	19	NMOD	_	_
16	antioxidant	_	NN	NN	_	19	NMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	alpha-lipoic	_	JJ	JJ	_	16	COORD	_	_
19	acid	_	NN	NN	_	12	PMOD	_	_
20	,	_	,	,	_	1	P	_	_
21	prior	_	JJ	JJ	_	22	DEP	_	_
22	to	_	TO	TO	_	1	NMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	stimulation	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	cells	_	NNS	NNS	_	25	PMOD	_	_
27	was	_	VBD	VBD	_	0	ROOT-S	_	_
28	found	_	VBN	VBN	_	27	VC	_	_
29	to	_	TO	TO	_	30	VMOD	_	_
30	inhibit	_	VB	VB	_	28	OBJ	_	_
31	NF-kappa	_	NN	NN	_	33	NMOD	_	_
32	B	_	NN	NN	_	33	NMOD	_	_
33	activation	_	NN	NN	_	30	OBJ	_	_
34	induced	_	VBN	VBN	_	33	NMOD	_	_
35	by	_	IN	IN	_	34	ADV	_	_
36	tumor	_	NN	NN	_	38	NMOD	_	_
37	necrosis	_	NN	NN	_	38	NMOD	_	_
38	factor-alpha	_	NN	NN	_	35	PMOD	_	_
39	(	_	(	(	_	41	P	_	_
40	25	_	CD	CD	_	41	NMOD	_	_
41	ng\/ml	_	NN	NN	_	38	PRN	_	_
42	)	_	)	)	_	41	P	_	_
43	or	_	CC	CC	_	35	CC	_	_
44	by	_	IN	IN	_	35	COORD	_	_
45	phorbol	_	NN	NN	_	47	NMOD	_	_
46	12-myristate	_	NN	NN	_	47	NMOD	_	_
47	13-acetate	_	NN	NN	_	44	PMOD	_	_
48	(	_	(	(	_	50	P	_	_
49	50	_	CD	CD	_	50	NMOD	_	_
50	ng\/ml	_	NN	NN	_	47	PRN	_	_
51	)	_	)	)	_	50	P	_	_
52	.	_	.	.	_	27	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	inhibitory	_	JJ	JJ	_	3	NMOD	_	_
3	action	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	alpha-lipoic	_	JJ	JJ	_	6	NMOD	_	_
6	acid	_	NN	NN	_	4	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	found	_	VBN	VBN	_	7	VC	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	be	_	VB	VB	_	8	OBJ	_	_
11	very	_	RB	RB	_	12	AMOD	_	_
12	potent	_	JJ	JJ	_	10	PRD	_	_
13	as	_	IN	IN	_	10	ADV	_	_
14	only	_	RB	RB	_	16	NMOD	_	_
15	4	_	CD	CD	_	14	DEP	_	_
16	mM	_	NN	NN	_	17	SBJ	_	_
17	was	_	VBD	VBD	_	13	VMOD	_	_
18	needed	_	VBN	VBN	_	17	VC	_	_
19	for	_	IN	IN	_	18	ADV	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	complete	_	JJ	JJ	_	22	NMOD	_	_
22	inhibition	_	NN	NN	_	19	PMOD	_	_
23	,	_	,	,	_	7	P	_	_
24	whereas	_	IN	IN	_	7	COORD	_	_
25	20	_	CD	CD	_	26	NMOD	_	_
26	mM	_	NN	NN	_	27	SBJ	_	_
27	was	_	VBD	VBD	_	7	COORD	_	_
28	required	_	VBN	VBN	_	27	VC	_	_
29	for	_	IN	IN	_	28	ADV	_	_
30	N-acetylcysteine	_	NN	NN	_	29	PMOD	_	_
31	.	_	.	.	_	7	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	alpha-lipoic	_	JJ	JJ	_	6	NMOD	_	_
6	acid	_	NN	NN	_	7	SBJ	_	_
7	may	_	MD	MD	_	4	VMOD	_	_
8	be	_	VB	VB	_	7	VC	_	_
9	effective	_	JJ	JJ	_	8	PRD	_	_
10	in	_	IN	IN	_	8	ADV	_	_
11	AIDS	_	NN	NN	_	12	NMOD	_	_
12	therapeutics	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	A	_	DT	DT	_	7	NMOD	_	_
2	human	_	JJ	JJ	_	7	NMOD	_	_
3	putative	_	JJ	JJ	_	7	NMOD	_	_
4	lymphocyte	_	NN	NN	_	7	NMOD	_	_
5	G0\/G1	_	NN	NN	_	7	NMOD	_	_
6	switch	_	VBP	VBP	_	7	NMOD	_	_
7	gene	_	NN	NN	_	0	ROOT-FRAG	_	_
8	homologous	_	JJ	JJ	_	7	NMOD	_	_
9	to	_	TO	TO	_	8	AMOD	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	rodent	_	JJ	JJ	_	12	NMOD	_	_
12	gene	_	NN	NN	_	9	PMOD	_	_
13	encoding	_	VBG	VBG	_	12	NMOD	_	_
14	a	_	DT	DT	_	18	NMOD	_	_
15	zinc-binding	_	JJ	JJ	_	18	NMOD	_	_
16	potential	_	JJ	JJ	_	18	NMOD	_	_
17	transcription	_	NN	NN	_	18	NMOD	_	_
18	factor	_	NN	NN	_	13	OBJ	_	_
19	.	_	.	.	_	7	P	_	_

1	G0S24	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	member	_	NN	NN	_	2	PRD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	set	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	genes	_	NNS	NNS	_	8	PMOD	_	_
10	(	_	(	(	_	15	P	_	_
11	putative	_	JJ	JJ	_	15	NMOD	_	_
12	G0\/G1	_	NN	NN	_	15	NMOD	_	_
13	switch	_	NN	NN	_	15	NMOD	_	_
14	regulatory	_	JJ	JJ	_	15	NMOD	_	_
15	genes	_	NNS	NNS	_	9	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	that	_	WDT	WDT	_	18	SBJ	_	_
18	are	_	VBP	VBP	_	9	NMOD	_	_
19	expressed	_	VBN	VBN	_	18	VC	_	_
20	transiently	_	RB	RB	_	19	TMP	_	_
21	within	_	IN	IN	_	19	TMP	_	_
22	1-2	_	CD	CD	_	23	NMOD	_	_
23	hr	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	addition	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	lectin	_	NN	NN	_	27	PMOD	_	_
29	or	_	CC	CC	_	28	CC	_	_
30	cycloheximide	_	NN	NN	_	28	COORD	_	_
31	to	_	TO	TO	_	26	NMOD	_	_
32	human	_	JJ	JJ	_	35	NMOD	_	_
33	blood	_	NN	NN	_	35	NMOD	_	_
34	mononuclear	_	JJ	JJ	_	35	NMOD	_	_
35	cells	_	NNS	NNS	_	31	PMOD	_	_
36	.	_	.	.	_	2	P	_	_

1	Comparison	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	full-length	_	JJ	JJ	_	6	NMOD	_	_
5	cDNA	_	NN	NN	_	6	NMOD	_	_
6	sequence	_	NN	NN	_	2	PMOD	_	_
7	with	_	IN	IN	_	1	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	corresponding	_	JJ	JJ	_	11	NMOD	_	_
10	genomic	_	JJ	JJ	_	11	NMOD	_	_
11	sequence	_	NN	NN	_	7	PMOD	_	_
12	reveals	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	an	_	DT	DT	_	16	NMOD	_	_
14	open	_	JJ	JJ	_	16	NMOD	_	_
15	reading	_	NN	NN	_	16	NMOD	_	_
16	frame	_	NN	NN	_	12	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	326	_	CD	CD	_	20	NMOD	_	_
19	amino	_	NN	NN	_	20	NMOD	_	_
20	acids	_	NNS	NNS	_	17	PMOD	_	_
21	,	_	,	,	_	16	P	_	_
22	distributed	_	VBN	VBN	_	16	NMOD	_	_
23	across	_	IN	IN	_	22	ADV	_	_
24	two	_	CD	CD	_	25	NMOD	_	_
25	exons	_	NNS	NNS	_	23	PMOD	_	_
26	.	_	.	.	_	12	P	_	_

1	Potential	_	JJ	JJ	_	3	NMOD	_	_
2	phosphorylation	_	NN	NN	_	3	NMOD	_	_
3	sites	_	NNS	NNS	_	4	SBJ	_	_
4	include	_	VBP	VBP	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	sequence	_	NN	NN	_	7	NMOD	_	_
7	PSPTSPT	_	NN	NN	_	4	OBJ	_	_
8	,	_	,	,	_	7	P	_	_
9	which	_	WDT	WDT	_	10	SBJ	_	_
10	resembles	_	VBZ	VBZ	_	7	NMOD	_	_
11	an	_	DT	DT	_	15	NMOD	_	_
12	RNA	_	NN	NN	_	15	NMOD	_	_
13	polymerase	_	NN	NN	_	15	NMOD	_	_
14	II	_	CD	CD	_	15	NMOD	_	_
15	repeat	_	NN	NN	_	10	OBJ	_	_
16	reported	_	VBN	VBN	_	15	NMOD	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	be	_	VB	VB	_	16	OBJ	_	_
19	a	_	DT	DT	_	20	NMOD	_	_
20	target	_	NN	NN	_	18	PRD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	27	NMOD	_	_
23	cell	_	NN	NN	_	27	NMOD	_	_
24	cycle	_	NN	NN	_	27	NMOD	_	_
25	control	_	NN	NN	_	27	NMOD	_	_
26	kinase	_	NN	NN	_	27	NMOD	_	_
27	cdc2	_	NN	NN	_	21	PMOD	_	_
28	.	_	.	.	_	4	P	_	_

1	Comparison	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	derived	_	VBN	VBN	_	6	NMOD	_	_
5	protein	_	NN	NN	_	6	NMOD	_	_
6	sequence	_	NN	NN	_	2	PMOD	_	_
7	with	_	IN	IN	_	1	NMOD	_	_
8	those	_	DT	DT	_	7	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	rodent	_	JJ	JJ	_	11	NMOD	_	_
11	homologs	_	NNS	NNS	_	9	PMOD	_	_
12	allows	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	classification	_	NN	NN	_	12	OBJ	_	_
14	into	_	IN	IN	_	13	NMOD	_	_
15	three	_	CD	CD	_	16	NMOD	_	_
16	groups	_	NNS	NNS	_	14	PMOD	_	_
17	.	_	.	.	_	12	P	_	_

1	Group	_	NN	NN	_	3	SBJ	_	_
2	1	_	CD	CD	_	1	NMOD	_	_
3	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	G0S24	_	NN	NN	_	3	OBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	the	_	DT	DT	_	11	NMOD	_	_
7	rat	_	NN	NN	_	11	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	mouse	_	NN	NN	_	7	COORD	_	_
10	TIS11	_	NN	NN	_	11	NMOD	_	_
11	genes	_	NNS	NNS	_	4	COORD	_	_
12	(	_	(	(	_	11	P	_	_
13	also	_	RB	RB	_	14	ADV	_	_
14	known	_	VBN	VBN	_	11	NMOD	_	_
15	as	_	IN	IN	_	14	ADV	_	_
16	TTP	_	NN	NN	_	15	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	Nup475	_	NN	NN	_	16	COORD	_	_
19	,	_	,	,	_	16	P	_	_
20	and	_	CC	CC	_	16	CC	_	_
21	Zfp36	_	NN	NN	_	16	COORD	_	_
22	)	_	)	)	_	11	P	_	_
23	.	_	.	.	_	3	P	_	_

1	Members	_	NNS	NNS	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	group	_	NN	NN	_	2	PMOD	_	_
5	have	_	VBP	VBP	_	0	ROOT-S	_	_
6	three	_	CD	CD	_	8	NMOD	_	_
7	tetraproline	_	JJ	JJ	_	8	NMOD	_	_
8	repeats	_	NNS	NNS	_	5	OBJ	_	_
9	.	_	.	.	_	5	P	_	_

1	Groups	_	NNS	NNS	_	5	SBJ	_	_
2	1	_	CD	CD	_	1	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	2	_	CD	CD	_	2	COORD	_	_
5	have	_	VBP	VBP	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	serine-rich	_	JJ	JJ	_	8	NMOD	_	_
8	region	_	NN	NN	_	5	OBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	an	_	DT	DT	_	13	NMOD	_	_
11	"	_	``	``	_	13	P	_	_
12	arginine	_	NN	NN	_	13	NMOD	_	_
13	element	_	NN	NN	_	8	COORD	_	_
14	"	_	''	''	_	13	P	_	_
15	(	_	(	(	_	16	P	_	_
16	RRLPIF	_	NN	NN	_	13	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	at	_	IN	IN	_	5	ADV	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	carboxyl	_	NN	NN	_	21	NMOD	_	_
21	terminus	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	All	_	DT	DT	_	2	NMOD	_	_
2	groups	_	NNS	NNS	_	3	SBJ	_	_
3	contain	_	VBP	VBP	_	0	ROOT-S	_	_
4	cysteine-	_	NN	NN	_	10	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	histidine-rich	_	JJ	JJ	_	4	COORD	_	_
7	putative	_	JJ	JJ	_	10	NMOD	_	_
8	zinc	_	NN	NN	_	10	NMOD	_	_
9	finger	_	NN	NN	_	10	NMOD	_	_
10	domains	_	NNS	NNS	_	3	OBJ	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	a	_	DT	DT	_	17	NMOD	_	_
13	serine-phenylalanine	_	JJ	JJ	_	17	NMOD	_	_
14	"	_	``	``	_	17	P	_	_
15	SFS	_	NNS	NNS	_	17	NMOD	_	_
16	"	_	''	''	_	17	P	_	_
17	domain	_	NN	NN	_	10	COORD	_	_
18	similar	_	JJ	JJ	_	17	NMOD	_	_
19	to	_	TO	TO	_	18	AMOD	_	_
20	part	_	NN	NN	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	large	_	JJ	JJ	_	24	NMOD	_	_
24	subunit	_	NN	NN	_	21	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	eukaryotic	_	JJ	JJ	_	28	NMOD	_	_
27	RNA	_	NN	NN	_	28	NMOD	_	_
28	polymerase	_	NN	NN	_	25	PMOD	_	_
29	II	_	CD	CD	_	28	NMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	Comparison	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	group	_	NN	NN	_	9	NMOD	_	_
4	1	_	CD	CD	_	9	NMOD	_	_
5	human	_	JJ	JJ	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	mouse	_	NN	NN	_	5	COORD	_	_
8	genomic	_	JJ	JJ	_	9	NMOD	_	_
9	sequences	_	NNS	NNS	_	2	PMOD	_	_
10	shows	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	high	_	JJ	JJ	_	12	NMOD	_	_
12	conservation	_	NN	NN	_	10	OBJ	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	5'	_	JJ	JJ	_	16	NMOD	_	_
16	flank	_	NN	NN	_	13	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	exons	_	NNS	NNS	_	16	COORD	_	_
19	.	_	.	.	_	10	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	CpG	_	NN	NN	_	3	NMOD	_	_
3	island	_	NN	NN	_	4	SBJ	_	_
4	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	expression	_	NN	NN	_	4	OBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	germ	_	NN	NN	_	9	NMOD	_	_
9	line	_	NN	NN	_	6	PMOD	_	_
10	.	_	.	.	_	4	P	_	_

1	G0S24	_	NN	NN	_	2	SBJ	_	_
2	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	potential	_	JJ	JJ	_	4	NMOD	_	_
4	sites	_	NNS	NNS	_	2	OBJ	_	_
5	for	_	IN	IN	_	4	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factors	_	NNS	NNS	_	5	PMOD	_	_
8	in	_	IN	IN	_	2	ADV	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	5'	_	JJ	JJ	_	11	NMOD	_	_
11	flank	_	NN	NN	_	8	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	intron	_	NN	NN	_	11	COORD	_	_
14	;	_	:	:	_	2	P	_	_
15	these	_	DT	DT	_	16	SBJ	_	_
16	include	_	VBP	VBP	_	2	VMOD	_	_
17	a	_	DT	DT	_	20	NMOD	_	_
18	serum	_	NN	NN	_	20	NMOD	_	_
19	response	_	NN	NN	_	20	NMOD	_	_
20	element	_	NN	NN	_	16	OBJ	_	_
21	.	_	.	.	_	16	P	_	_

1	Protein	_	NN	NN	_	4	NMOD	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	genomic	_	JJ	JJ	_	1	COORD	_	_
4	sequences	_	NNS	NNS	_	5	SBJ	_	_
5	show	_	VBP	VBP	_	0	ROOT-S	_	_
6	similarities	_	NNS	NNS	_	5	IOBJ	_	_
7	with	_	IN	IN	_	6	NMOD	_	_
8	those	_	DT	DT	_	7	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	a	_	DT	DT	_	11	NMOD	_	_
11	variety	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	proteins	_	NNS	NNS	_	12	PMOD	_	_
14	involved	_	VBN	VBN	_	13	NMOD	_	_
15	in	_	IN	IN	_	14	ADV	_	_
16	transcription	_	NN	NN	_	15	PMOD	_	_
17	,	_	,	,	_	5	P	_	_
18	suggesting	_	VBG	VBG	_	5	OBJ	_	_
19	that	_	IN	IN	_	18	OBJ	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	G0S24	_	NN	NN	_	22	NMOD	_	_
22	product	_	NN	NN	_	23	SBJ	_	_
23	has	_	VBZ	VBZ	_	19	VMOD	_	_
24	a	_	DT	DT	_	26	NMOD	_	_
25	similar	_	JJ	JJ	_	26	NMOD	_	_
26	role	_	NN	NN	_	23	OBJ	_	_
27	.	_	.	.	_	5	P	_	_

1	Ras	_	NN	NN	_	3	NMOD	_	_
2	oncogene	_	NN	NN	_	3	NMOD	_	_
3	transformation	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	human	_	JJ	JJ	_	7	NMOD	_	_
6	B	_	NN	NN	_	7	NMOD	_	_
7	lymphoblasts	_	NNS	NNS	_	4	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	associated	_	VBN	VBN	_	8	VC	_	_
10	with	_	IN	IN	_	9	ADV	_	_
11	lymphocyte	_	NN	NN	_	12	NMOD	_	_
12	activation	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	10	CC	_	_
14	with	_	IN	IN	_	10	COORD	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	block	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	differentiation	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	p21ras	_	NN	NN	_	6	NMOD	_	_
3	small	_	JJ	JJ	_	6	NMOD	_	_
4	GTP	_	NN	NN	_	6	NMOD	_	_
5	binding	_	NN	NN	_	6	NMOD	_	_
6	proteins	_	NNS	NNS	_	7	SBJ	_	_
7	participate	_	VBP	VBP	_	0	ROOT-S	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	signal	_	JJ	JJ	_	10	NMOD	_	_
10	transduction	_	NN	NN	_	8	PMOD	_	_
11	from	_	IN	IN	_	10	NMOD	_	_
12	cell	_	NN	NN	_	14	NMOD	_	_
13	surface	_	NN	NN	_	14	NMOD	_	_
14	receptors	_	NNS	NNS	_	11	PMOD	_	_
15	and	_	CC	CC	_	7	CC	_	_
16	affect	_	VB	VB	_	7	COORD	_	_
17	neoplastic	_	JJ	JJ	_	18	NMOD	_	_
18	transformation	_	NN	NN	_	16	OBJ	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	development	_	NN	NN	_	18	COORD	_	_
21	in	_	IN	IN	_	18	NMOD	_	_
22	many	_	JJ	JJ	_	25	NMOD	_	_
23	different	_	JJ	JJ	_	25	NMOD	_	_
24	cell	_	NN	NN	_	25	NMOD	_	_
25	types	_	NNS	NNS	_	21	PMOD	_	_
26	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	present	_	JJ	JJ	_	4	NMOD	_	_
4	study	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	we	_	PRP	PRP	_	7	SBJ	_	_
7	examined	_	VBD	VBD	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	relationship	_	NN	NN	_	7	OBJ	_	_
10	between	_	IN	IN	_	9	NMOD	_	_
11	ras	_	NN	NN	_	10	PMOD	_	_
12	transformation	_	NN	NN	_	11	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	differentiation	_	NN	NN	_	12	COORD	_	_
15	of	_	IN	IN	_	11	NMOD	_	_
16	human	_	JJ	JJ	_	18	NMOD	_	_
17	B	_	NN	NN	_	18	NMOD	_	_
18	lymphocytes	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	constitutive	_	JJ	JJ	_	6	NMOD	_	_
6	expression	_	NN	NN	_	16	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	T24	_	NN	NN	_	11	NMOD	_	_
10	Ha-ras	_	NN	NN	_	11	NMOD	_	_
11	oncogene	_	NN	NN	_	7	PMOD	_	_
12	in	_	IN	IN	_	6	NMOD	_	_
13	EBV-immortalized	_	JJ	JJ	_	15	NMOD	_	_
14	B	_	NN	NN	_	15	NMOD	_	_
15	lymphoblasts	_	NNS	NNS	_	12	PMOD	_	_
16	was	_	VBD	VBD	_	3	VMOD	_	_
17	associated	_	VBN	VBN	_	16	VC	_	_
18	with	_	IN	IN	_	17	ADV	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	induction	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	27	NMOD	_	_
23	interleukin	_	NN	NN	_	27	NMOD	_	_
24	2	_	CD	CD	_	27	NMOD	_	_
25	receptor	_	NN	NN	_	27	NMOD	_	_
26	alpha	_	NN	NN	_	27	NMOD	_	_
27	subunit	_	NN	NN	_	21	PMOD	_	_
28	,	_	,	,	_	17	P	_	_
29	with	_	IN	IN	_	17	ADV	_	_
30	an	_	DT	DT	_	34	NMOD	_	_
31	impaired	_	JJ	JJ	_	34	NMOD	_	_
32	immunoglobulin	_	NN	NN	_	34	NMOD	_	_
33	gene	_	NN	NN	_	34	NMOD	_	_
34	expression	_	NN	NN	_	29	PMOD	_	_
35	,	_	,	,	_	34	P	_	_
36	altered	_	JJ	JJ	_	38	NMOD	_	_
37	adhesion	_	NN	NN	_	38	NMOD	_	_
38	properties	_	NNS	NNS	_	34	COORD	_	_
39	and	_	CC	CC	_	34	CC	_	_
40	increased	_	VBN	VBN	_	41	NMOD	_	_
41	survival	_	NN	NN	_	34	COORD	_	_
42	in	_	IN	IN	_	41	NMOD	_	_
43	serum-free	_	JJ	JJ	_	44	NMOD	_	_
44	medium	_	NN	NN	_	42	PMOD	_	_
45	.	_	.	.	_	2	P	_	_

1	Since	_	IN	IN	_	17	ADV	_	_
2	induction	_	NN	NN	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	IL-2	_	NN	NN	_	8	NMOD	_	_
6	receptor	_	NN	NN	_	8	NMOD	_	_
7	alpha	_	NN	NN	_	8	NMOD	_	_
8	subunit	_	NN	NN	_	3	PMOD	_	_
9	is	_	VBZ	VBZ	_	1	VMOD	_	_
10	a	_	DT	DT	_	11	NMOD	_	_
11	hallmark	_	NN	NN	_	9	PRD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	lymphocyte	_	NN	NN	_	14	NMOD	_	_
14	activation	_	NN	NN	_	12	PMOD	_	_
15	,	_	,	,	_	17	P	_	_
16	we	_	PRP	PRP	_	17	SBJ	_	_
17	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
18	that	_	IN	IN	_	17	OBJ	_	_
19	p21ras	_	NN	NN	_	21	SBJ	_	_
20	naturally	_	RB	RB	_	21	ADV	_	_
21	triggers	_	VBZ	VBZ	_	18	VMOD	_	_
22	B	_	NN	NN	_	24	NMOD	_	_
23	cell	_	NN	NN	_	24	NMOD	_	_
24	activation	_	NN	NN	_	21	OBJ	_	_
25	.	_	.	.	_	17	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	ras-transformed	_	JJ	JJ	_	3	NMOD	_	_
3	lymphocytes	_	NNS	NNS	_	4	SBJ	_	_
4	displayed	_	VBD	VBD	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	fully	_	RB	RB	_	7	AMOD	_	_
7	functional	_	JJ	JJ	_	8	NMOD	_	_
8	IL-2r	_	NN	NN	_	4	OBJ	_	_
9	,	_	,	,	_	4	P	_	_
10	as	_	IN	IN	_	4	ADV	_	_
11	assessed	_	VBN	VBN	_	10	VMOD	_	_
12	by	_	IN	IN	_	11	ADV	_	_
13	c-fos	_	NN	NN	_	14	NMOD	_	_
14	induction	_	NN	NN	_	12	PMOD	_	_
15	following	_	VBG	VBG	_	14	TMP	_	_
16	treatment	_	NN	NN	_	15	PMOD	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	IL-2	_	NN	NN	_	17	PMOD	_	_
19	;	_	:	:	_	4	P	_	_
20	nevertheless	_	RB	RB	_	23	ADV	_	_
21	,	_	,	,	_	23	P	_	_
22	they	_	PRP	PRP	_	23	SBJ	_	_
23	were	_	VBD	VBD	_	4	COORD	_	_
24	not	_	RB	RB	_	23	VMOD	_	_
25	growth	_	NN	NN	_	23	PRD	_	_
26	stimulated	_	VBN	VBN	_	25	NMOD	_	_
27	by	_	IN	IN	_	26	ADV	_	_
28	this	_	DT	DT	_	29	NMOD	_	_
29	lymphokine	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	decreased	_	VBN	VBN	_	3	NMOD	_	_
3	expression	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	immunoglobulin	_	NN	NN	_	6	NMOD	_	_
6	genes	_	NNS	NNS	_	4	PMOD	_	_
7	indicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	ras	_	NN	NN	_	11	NMOD	_	_
11	oncogene	_	NN	NN	_	12	SBJ	_	_
12	blocks	_	VBZ	VBZ	_	8	VMOD	_	_
13	terminal	_	JJ	JJ	_	14	NMOD	_	_
14	differentiation	_	NN	NN	_	12	OBJ	_	_
15	to	_	TO	TO	_	14	NMOD	_	_
16	plasma	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	15	PMOD	_	_
18	,	_	,	,	_	12	P	_	_
19	possibly	_	RB	RB	_	20	PMOD	_	_
20	by	_	IN	IN	_	12	ADV	_	_
21	inhibiting	_	VBG	VBG	_	20	PMOD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	activity	_	NN	NN	_	21	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	lymphocyte-specific	_	JJ	JJ	_	27	NMOD	_	_
26	transcription	_	NN	NN	_	27	NMOD	_	_
27	factors	_	NNS	NNS	_	24	PMOD	_	_
28	.	_	.	.	_	7	P	_	_

1	Somewhat	_	RB	RB	_	8	ADV	_	_
2	unexpectedly	_	RB	RB	_	1	AMOD	_	_
3	,	_	,	,	_	8	P	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	constitutive	_	JJ	JJ	_	7	NMOD	_	_
6	p21ras	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	8	SBJ	_	_
8	did	_	VBD	VBD	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	cause	_	VB	VB	_	8	VC	_	_
11	an	_	DT	DT	_	14	NMOD	_	_
12	increased	_	VBN	VBN	_	14	NMOD	_	_
13	DNA	_	NN	NN	_	14	NMOD	_	_
14	binding	_	NN	NN	_	10	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	transcription	_	NN	NN	_	17	NMOD	_	_
17	factors	_	NNS	NNS	_	15	PMOD	_	_
18	PEA1	_	NN	NN	_	17	NMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	AP1	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	,	_	,	,	_	18	P	_	_
23	PEA3	_	NN	NN	_	18	COORD	_	_
24	,	_	,	,	_	18	P	_	_
25	Oct-2	_	NN	NN	_	18	COORD	_	_
26	or	_	CC	CC	_	18	CC	_	_
27	NF-kB	_	NN	NN	_	18	COORD	_	_
28	.	_	.	.	_	8	P	_	_

1	Transcription	_	NN	NN	_	3	NMOD	_	_
2	factor	_	NN	NN	_	3	NMOD	_	_
3	GATA-1	_	NN	NN	_	0	ROOT-FRAG	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	erythroid	_	JJ	JJ	_	6	NMOD	_	_
6	development	_	NN	NN	_	3	COORD	_	_
7	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	summary	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	derived	_	VBD	VBD	_	0	ROOT-S	_	_
6	an	_	DT	DT	_	8	NMOD	_	_
7	experimental	_	JJ	JJ	_	8	NMOD	_	_
8	system	_	NN	NN	_	5	OBJ	_	_
9	that	_	WDT	WDT	_	10	SBJ	_	_
10	allows	_	VBZ	VBZ	_	8	NMOD	_	_
11	us	_	PRP	PRP	_	13	SBJ	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	dissect	_	VB	VB	_	10	OBJ	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	function	_	NN	NN	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	GATA-1	_	NN	NN	_	16	PMOD	_	_
18	in	_	IN	IN	_	15	NMOD	_	_
19	red	_	JJ	JJ	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	development	_	NN	NN	_	18	PMOD	_	_
22	at	_	IN	IN	_	15	NMOD	_	_
23	a	_	DT	DT	_	25	NMOD	_	_
24	genetic	_	JJ	JJ	_	25	NMOD	_	_
25	level	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	established	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	essential	_	JJ	JJ	_	6	NMOD	_	_
6	nature	_	NN	NN	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	GATA-1	_	NN	NN	_	7	PMOD	_	_
9	during	_	IN	IN	_	6	TMP	_	_
10	both	_	CC	CC	_	11	CC	_	_
11	primitive	_	JJ	JJ	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	definitive	_	JJ	JJ	_	11	COORD	_	_
14	erythropoiesis	_	NN	NN	_	9	PMOD	_	_
15	.	_	.	.	_	2	P	_	_

1	By	_	IN	IN	_	12	ADV	_	_
2	ablating	_	VBG	VBG	_	1	PMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	expression	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	endogenous	_	JJ	JJ	_	9	NMOD	_	_
8	GATA-1	_	NN	NN	_	9	NMOD	_	_
9	gene	_	NN	NN	_	5	PMOD	_	_
10	,	_	,	,	_	12	P	_	_
11	we	_	PRP	PRP	_	12	SBJ	_	_
12	are	_	VBP	VBP	_	0	ROOT-S	_	_
13	in	_	IN	IN	_	12	PRD	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	position	_	NN	NN	_	13	PMOD	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	introduce	_	VB	VB	_	15	NMOD	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	variety	_	NN	NN	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	constructs	_	NNS	NNS	_	20	PMOD	_	_
22	that	_	WDT	WDT	_	23	SBJ	_	_
23	harbor	_	VBP	VBP	_	21	NMOD	_	_
24	subtle	_	JJ	JJ	_	25	NMOD	_	_
25	modifications	_	NNS	NNS	_	23	OBJ	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	flanking	_	JJ	JJ	_	30	NMOD	_	_
28	or	_	CC	CC	_	27	CC	_	_
29	protein-coding	_	JJ	JJ	_	27	COORD	_	_
30	sequences	_	NNS	NNS	_	26	PMOD	_	_
31	.	_	.	.	_	12	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	can	_	MD	MD	_	0	ROOT-S	_	_
3	now	_	RB	RB	_	2	TMP	_	_
4	study	_	VB	VB	_	2	VC	_	_
5	regulatory	_	JJ	JJ	_	6	NMOD	_	_
6	regions	_	NNS	NNS	_	4	OBJ	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	functional	_	JJ	JJ	_	9	NMOD	_	_
9	domains	_	NNS	NNS	_	6	COORD	_	_
10	of	_	IN	IN	_	6	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	protein	_	NN	NN	_	10	PMOD	_	_
13	in	_	IN	IN	_	6	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	context	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	a	_	DT	DT	_	20	NMOD	_	_
18	true	_	JJ	JJ	_	20	NMOD	_	_
19	erythroid	_	JJ	JJ	_	20	NMOD	_	_
20	environment	_	NN	NN	_	16	PMOD	_	_
21	,	_	,	,	_	4	P	_	_
22	experiments	_	NNS	NNS	_	4	OBJ	_	_
23	that	_	WDT	WDT	_	24	SBJ	_	_
24	have	_	VBP	VBP	_	22	NMOD	_	_
25	not	_	RB	RB	_	24	VMOD	_	_
26	been	_	VBN	VBN	_	24	VC	_	_
27	possible	_	JJ	JJ	_	26	PRD	_	_
28	heretofore	_	RB	RB	_	26	TMP	_	_
29	.	_	.	.	_	2	P	_	_

1	Although	_	IN	IN	_	14	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	assay	_	NN	NN	_	4	SBJ	_	_
4	involves	_	VBZ	VBZ	_	1	VMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	dramatic	_	JJ	JJ	_	7	NMOD	_	_
7	loss	_	NN	NN	_	4	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	red	_	JJ	JJ	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	production	_	NN	NN	_	8	PMOD	_	_
12	,	_	,	,	_	14	P	_	_
13	it	_	PRP	PRP	_	14	SBJ	_	_
14	should	_	MD	MD	_	0	ROOT-S	_	_
15	be	_	VB	VB	_	14	VC	_	_
16	possible	_	JJ	JJ	_	15	PRD	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	define	_	VB	VB	_	15	EXP	_	_
19	important	_	JJ	JJ	_	21	NMOD	_	_
20	regulatory	_	JJ	JJ	_	21	NMOD	_	_
21	domains	_	NNS	NNS	_	18	OBJ	_	_
22	that	_	WDT	WDT	_	23	SBJ	_	_
23	can	_	MD	MD	_	21	NMOD	_	_
24	then	_	RB	RB	_	23	ADV	_	_
25	be	_	VB	VB	_	23	VC	_	_
26	assayed	_	VBN	VBN	_	25	VC	_	_
27	using	_	VBG	VBG	_	26	OBJ	_	_
28	less	_	RBR	RBR	_	29	AMOD	_	_
29	stringent	_	JJ	JJ	_	30	NMOD	_	_
30	systems	_	NNS	NNS	_	27	OBJ	_	_
31	,	_	,	,	_	30	P	_	_
32	such	_	JJ	JJ	_	33	DEP	_	_
33	as	_	IN	IN	_	30	NMOD	_	_
34	cell-free	_	JJ	JJ	_	35	NMOD	_	_
35	extracts	_	NNS	NNS	_	33	PMOD	_	_
36	for	_	IN	IN	_	35	NMOD	_	_
37	in	_	FW	FW	_	38	AMOD	_	_
38	vitro	_	FW	FW	_	39	NMOD	_	_
39	transcription	_	NN	NN	_	36	PMOD	_	_
40	.	_	.	.	_	14	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	ideal	_	JJ	JJ	_	3	NMOD	_	_
3	situation	_	NN	NN	_	4	SBJ	_	_
4	would	_	MD	MD	_	0	ROOT-S	_	_
5	be	_	VB	VB	_	4	VC	_	_
6	analyses	_	NNS	NNS	_	5	PRD	_	_
7	conducted	_	VBN	VBN	_	6	NMOD	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	GATA-1-	_	JJ	JJ	_	11	NMOD	_	_
10	erythroid	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	8	PMOD	_	_
12	.	_	.	.	_	4	P	_	_

1	However	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	5	SBJ	_	_
5	have	_	VBP	VBP	_	0	ROOT-S	_	_
6	been	_	VBN	VBN	_	5	VC	_	_
7	impossible	_	JJ	JJ	_	6	PRD	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	generate	_	VB	VB	_	7	AMOD	_	_
10	given	_	VBN	VBN	_	6	ADV	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	requirement	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	GATA-1	_	NN	NN	_	13	PMOD	_	_
15	for	_	IN	IN	_	12	NMOD	_	_
16	Epo	_	NN	NN	_	18	NMOD	_	_
17	receptor	_	NN	NN	_	18	NMOD	_	_
18	expression	_	NN	NN	_	15	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	red	_	JJ	JJ	_	22	NMOD	_	_
21	cell	_	NN	NN	_	22	NMOD	_	_
22	viability	_	NN	NN	_	18	COORD	_	_
23	(	_	(	(	_	6	PRN	_	_
24	C.	_	NNP	NNP	_	25	NMOD	_	_
25	Simon	_	NNP	NNP	_	23	DEP	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	S.	_	NNP	NNP	_	28	NMOD	_	_
28	Orkin	_	NNP	NNP	_	25	COORD	_	_
29	,	_	,	,	_	25	P	_	_
30	unpublished	_	JJ	JJ	_	31	NMOD	_	_
31	observations	_	NNS	NNS	_	25	COORD	_	_
32	)	_	)	)	_	23	P	_	_
33	.	_	.	.	_	5	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	may	_	MD	MD	_	0	ROOT-S	_	_
3	be	_	VB	VB	_	2	VC	_	_
4	possible	_	JJ	JJ	_	3	PRD	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	produce	_	VB	VB	_	3	EXP	_	_
7	such	_	JJ	JJ	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	OBJ	_	_
9	by	_	IN	IN	_	6	ADV	_	_
10	first	_	RB	RB	_	11	TMP	_	_
11	expressing	_	VBG	VBG	_	9	PMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	Epo	_	NN	NN	_	14	NMOD	_	_
14	receptor	_	NN	NN	_	11	OBJ	_	_
15	under	_	IN	IN	_	11	ADV	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	influence	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	constitutive	_	JJ	JJ	_	21	NMOD	_	_
21	promoter	_	NN	NN	_	18	PMOD	_	_
22	and	_	CC	CC	_	11	CC	_	_
23	then	_	RB	RB	_	24	TMP	_	_
24	targeting	_	VBG	VBG	_	11	COORD	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	GATA-1	_	NN	NN	_	27	NMOD	_	_
27	gene	_	NN	NN	_	24	OBJ	_	_
28	.	_	.	.	_	2	P	_	_

1	If	_	IN	IN	_	10	ADV	_	_
2	GATA-1-	_	JJ	JJ	_	4	NMOD	_	_
3	-red	_	JJ	JJ	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	5	SBJ	_	_
5	were	_	VBD	VBD	_	1	VMOD	_	_
6	available	_	JJ	JJ	_	5	PRD	_	_
7	,	_	,	,	_	10	P	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	analyses	_	NNS	NNS	_	10	SBJ	_	_
10	would	_	MD	MD	_	0	ROOT-S	_	_
11	involve	_	VB	VB	_	10	VC	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	actual	_	JJ	JJ	_	14	NMOD	_	_
14	transcription	_	NN	NN	_	11	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	or	_	CC	CC	_	14	CC	_	_
17	chromatin	_	NN	NN	_	18	NMOD	_	_
18	structure	_	NN	NN	_	14	COORD	_	_
19	surrounding	_	VBG	VBG	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	globin	_	NN	NN	_	22	NMOD	_	_
22	genes	_	NNS	NNS	_	15	PMOD	_	_
23	.	_	.	.	_	10	P	_	_

1	Structure-function	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	GATA-1	_	NN	NN	_	6	NMOD	_	_
6	protein	_	NN	NN	_	3	PMOD	_	_
7	could	_	MD	MD	_	0	ROOT-S	_	_
8	be	_	VB	VB	_	7	VC	_	_
9	greatly	_	RB	RB	_	10	ADV	_	_
10	simplified	_	VBN	VBN	_	8	VC	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	larger	_	JJR	JJR	_	14	NMOD	_	_
14	number	_	NN	NN	_	2	GAP	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	mutants	_	NNS	NNS	_	15	PMOD	_	_
17	studied	_	VBN	VBN	_	10	GAP	_	_
18	.	_	.	.	_	7	P	_	_

1	However	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	ES	_	NN	NN	_	6	NMOD	_	_
5	cell	_	NN	NN	_	6	NMOD	_	_
6	system	_	NN	NN	_	7	SBJ	_	_
7	can	_	MD	MD	_	0	ROOT-S	_	_
8	be	_	VB	VB	_	7	VC	_	_
9	used	_	VBN	VBN	_	8	VC	_	_
10	as	_	IN	IN	_	9	ADV	_	_
11	an	_	DT	DT	_	12	NMOD	_	_
12	alternative	_	NN	NN	_	10	PMOD	_	_
13	until	_	IN	IN	_	9	TMP	_	_
14	targeted	_	VBN	VBN	_	16	NMOD	_	_
15	erythroleukemia	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	17	SBJ	_	_
17	become	_	VBP	VBP	_	13	VMOD	_	_
18	available	_	JJ	JJ	_	17	PRD	_	_
19	.	_	.	.	_	7	P	_	_

1	Other	_	JJ	JJ	_	2	NMOD	_	_
2	applications	_	NNS	NNS	_	3	SBJ	_	_
3	involve	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	introduction	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	other	_	JJ	JJ	_	11	NMOD	_	_
8	GATA-binding	_	JJ	JJ	_	11	NMOD	_	_
9	protein	_	NN	NN	_	11	NMOD	_	_
10	family	_	NN	NN	_	11	NMOD	_	_
11	members	_	NNS	NNS	_	6	PMOD	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	determine	_	VB	VB	_	5	NMOD	_	_
14	whether	_	IN	IN	_	13	OBJ	_	_
15	they	_	PRP	PRP	_	16	SBJ	_	_
16	rescue	_	VBP	VBP	_	14	VMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	mutation	_	NN	NN	_	16	OBJ	_	_
19	.	_	.	.	_	3	P	_	_

1	If	_	IN	IN	_	8	ADV	_	_
2	they	_	PRP	PRP	_	3	SBJ	_	_
3	can	_	MD	MD	_	1	VMOD	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	,	_	,	,	_	8	P	_	_
6	chimeric	_	JJ	JJ	_	7	NMOD	_	_
7	proteins	_	NNS	NNS	_	8	SBJ	_	_
8	can	_	MD	MD	_	0	ROOT-S	_	_
9	be	_	VB	VB	_	8	VC	_	_
10	tested	_	VBN	VBN	_	9	VC	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	identify	_	VB	VB	_	10	OBJ	_	_
13	which	_	WDT	WDT	_	15	NMOD	_	_
14	amino	_	NN	NN	_	15	NMOD	_	_
15	acids	_	NNS	NNS	_	16	SBJ	_	_
16	distinguish	_	VBP	VBP	_	12	OBJ	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	different	_	JJ	JJ	_	20	NMOD	_	_
19	family	_	NN	NN	_	20	NMOD	_	_
20	members	_	NNS	NNS	_	16	OBJ	_	_
21	.	_	.	.	_	8	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	feel	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	these	_	DT	DT	_	5	NMOD	_	_
5	experiments	_	NNS	NNS	_	6	SBJ	_	_
6	are	_	VBP	VBP	_	3	VMOD	_	_
7	vital	_	JJ	JJ	_	6	PRD	_	_
8	to	_	TO	TO	_	7	AMOD	_	_
9	understanding	_	VBG	VBG	_	8	PMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	function	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	GATA-1	_	NN	NN	_	12	PMOD	_	_
14	during	_	IN	IN	_	11	TMP	_	_
15	erythroid	_	JJ	JJ	_	16	NMOD	_	_
16	ontogeny	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	2	P	_	_

1	How	_	WRB	WRB	_	4	ADV	_	_
2	does	_	VBZ	VBZ	_	0	ROOT-SBARQ	_	_
3	GATA-1	_	NN	NN	_	2	SBJ	_	_
4	regulate	_	VB	VB	_	2	VC	_	_
5	red	_	JJ	JJ	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	genes	_	NNS	NNS	_	4	OBJ	_	_
8	like	_	IN	IN	_	7	NMOD	_	_
9	globin	_	NN	NN	_	8	PMOD	_	_
10	or	_	CC	CC	_	9	CC	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	Epo	_	NN	NN	_	13	NMOD	_	_
13	receptor	_	NN	NN	_	9	COORD	_	_
14	?	_	.	.	_	2	P	_	_

1	Once	_	IN	IN	_	13	TMP	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	identify	_	VB	VB	_	1	VMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	functional	_	JJ	JJ	_	6	NMOD	_	_
6	domains	_	NNS	NNS	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	GATA-binding	_	JJ	JJ	_	10	NMOD	_	_
10	proteins	_	NNS	NNS	_	7	PMOD	_	_
11	,	_	,	,	_	13	P	_	_
12	we	_	PRP	PRP	_	13	SBJ	_	_
13	hope	_	VBP	VBP	_	0	ROOT-S	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	learn	_	VB	VB	_	13	OBJ	_	_
16	what	_	WP	WP	_	17	NMOD	_	_
17	proteins	_	NNS	NNS	_	20	PMOD	_	_
18	GATA-1	_	NN	NN	_	19	SBJ	_	_
19	binds	_	VBZ	VBZ	_	15	OBJ	_	_
20	to	_	TO	TO	_	19	ADV	_	_
21	in	_	IN	IN	_	19	ADV	_	_
22	the	_	DT	DT	_	25	NMOD	_	_
23	basic	_	JJ	JJ	_	25	NMOD	_	_
24	transcription	_	NN	NN	_	25	NMOD	_	_
25	machinery	_	NN	NN	_	21	PMOD	_	_
26	or	_	CC	CC	_	21	CC	_	_
27	in	_	IN	IN	_	21	COORD	_	_
28	chromatin	_	NN	NN	_	27	PMOD	_	_
29	.	_	.	.	_	13	P	_	_

1	Is	_	VBZ	VBZ	_	0	ROOT-SQ	_	_
2	GATA-1	_	NN	NN	_	1	SBJ	_	_
3	necessary	_	JJ	JJ	_	1	PRD	_	_
4	for	_	IN	IN	_	3	AMOD	_	_
5	globin	_	NN	NN	_	7	NMOD	_	_
6	gene	_	NN	NN	_	7	NMOD	_	_
7	switching	_	NN	NN	_	4	PMOD	_	_
8	?	_	.	.	_	1	P	_	_

1	GATA-1	_	NN	NN	_	2	SBJ	_	_
2	may	_	MD	MD	_	0	ROOT-S	_	_
3	be	_	VB	VB	_	2	VC	_	_
4	modified	_	VBN	VBN	_	3	VC	_	_
5	differently	_	RB	RB	_	4	ADV	_	_
6	during	_	IN	IN	_	4	TMP	_	_
7	development	_	NN	NN	_	6	PMOD	_	_
8	so	_	IN	IN	_	9	VMOD	_	_
9	that	_	IN	IN	_	4	OBJ	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	locus	_	NN	NN	_	13	NMOD	_	_
12	control	_	NN	NN	_	13	NMOD	_	_
13	region	_	NN	NN	_	14	SBJ	_	_
14	can	_	MD	MD	_	9	VMOD	_	_
15	interact	_	VB	VB	_	14	VC	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	different	_	JJ	JJ	_	19	NMOD	_	_
18	globin	_	NN	NN	_	19	NMOD	_	_
19	promoters	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	may	_	MD	MD	_	0	ROOT-S	_	_
3	find	_	VB	VB	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	one	_	CD	CD	_	6	NMOD	_	_
6	region	_	NN	NN	_	10	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	protein	_	NN	NN	_	7	PMOD	_	_
10	is	_	VBZ	VBZ	_	4	VMOD	_	_
11	required	_	VBN	VBN	_	10	VC	_	_
12	for	_	IN	IN	_	11	VMOD	_	_
13	embryonic	_	JJ	JJ	_	14	NMOD	_	_
14	expression	_	NN	NN	_	12	PMOD	_	_
15	and	_	CC	CC	_	10	CC	_	_
16	another	_	DT	DT	_	6	GAP	_	_
17	for	_	IN	IN	_	12	GAP	_	_
18	adult	_	JJ	JJ	_	21	NMOD	_	_
19	globin	_	NN	NN	_	21	NMOD	_	_
20	gene	_	NN	NN	_	21	NMOD	_	_
21	expression	_	NN	NN	_	17	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	Activation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	lymphokine	_	NN	NN	_	4	NMOD	_	_
4	genes	_	NNS	NNS	_	2	PMOD	_	_
5	in	_	IN	IN	_	1	NMOD	_	_
6	T	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	5	PMOD	_	_
8	:	_	:	:	_	1	P	_	_
9	role	_	NN	NN	_	1	NMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	cis-acting	_	JJ	JJ	_	13	NMOD	_	_
12	DNA	_	NN	NN	_	13	NMOD	_	_
13	elements	_	NNS	NNS	_	10	PMOD	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	respond	_	VBP	VBP	_	13	NMOD	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	T	_	NN	NN	_	20	NMOD	_	_
18	cell	_	NN	NN	_	20	NMOD	_	_
19	activation	_	NN	NN	_	20	NMOD	_	_
20	signals	_	NNS	NNS	_	16	PMOD	_	_
21	.	_	.	.	_	9	P	_	_

1	Activation	_	NN	NN	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	T	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	initiated	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	recognition	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	antigen	_	NN	NN	_	10	PMOD	_	_
12	on	_	IN	IN	_	9	NMOD	_	_
13	antigen	_	NN	NN	_	15	NMOD	_	_
14	presenting	_	NN	NN	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	12	PMOD	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	exert	_	VB	VB	_	9	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	effector	_	NN	NN	_	20	NMOD	_	_
20	functions	_	NNS	NNS	_	17	OBJ	_	_
21	in	_	IN	IN	_	17	ADV	_	_
22	immune	_	JJ	JJ	_	25	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	inflammatory	_	JJ	JJ	_	22	COORD	_	_
25	responses	_	NNS	NNS	_	21	PMOD	_	_
26	.	_	.	.	_	5	P	_	_

1	Two	_	CD	CD	_	2	NMOD	_	_
2	types	_	NNS	NNS	_	16	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	helper	_	NN	NN	_	6	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cell	_	NN	NN	_	10	NMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	Th	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	clones	_	NNS	NNS	_	3	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	Th1	_	NN	NN	_	2	PRN	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	Th2	_	NN	NN	_	12	COORD	_	_
15	)	_	)	)	_	12	P	_	_
16	are	_	VBP	VBP	_	0	ROOT-S	_	_
17	defined	_	VBN	VBN	_	16	VC	_	_
18	on	_	IN	IN	_	17	ADV	_	_
19	the	_	DT	DT	_	18	DEP	_	_
20	basis	_	NN	NN	_	18	DEP	_	_
21	of	_	IN	IN	_	18	DEP	_	_
22	different	_	JJ	JJ	_	23	NMOD	_	_
23	patterns	_	NNS	NNS	_	18	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	cytokine	_	NN	NN	_	29	NMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	lymphokine	_	NN	NN	_	25	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	secretion	_	NN	NN	_	24	PMOD	_	_
30	.	_	.	.	_	16	P	_	_

1	They	_	PRP	PRP	_	2	SBJ	_	_
2	determine	_	VBP	VBP	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	outcome	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	an	_	DT	DT	_	8	NMOD	_	_
7	antigenic	_	JJ	JJ	_	8	NMOD	_	_
8	response	_	NN	NN	_	5	PMOD	_	_
9	toward	_	IN	IN	_	8	NMOD	_	_
10	humoral	_	JJ	JJ	_	13	NMOD	_	_
11	or	_	CC	CC	_	10	CC	_	_
12	cell-mediated	_	JJ	JJ	_	10	COORD	_	_
13	immunity	_	NN	NN	_	9	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	Although	_	IN	IN	_	12	ADV	_	_
2	lymphokine	_	NN	NN	_	3	NMOD	_	_
3	genes	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	1	VMOD	_	_
5	coordinately	_	RB	RB	_	4	ADV	_	_
6	regulated	_	VBN	VBN	_	4	VC	_	_
7	upon	_	IN	IN	_	6	ADV	_	_
8	antigen	_	NN	NN	_	9	NMOD	_	_
9	stimulation	_	NN	NN	_	7	PMOD	_	_
10	,	_	,	,	_	12	P	_	_
11	they	_	PRP	PRP	_	12	SBJ	_	_
12	are	_	VBP	VBP	_	0	ROOT-S	_	_
13	regulated	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	mechanisms	_	NNS	NNS	_	14	PMOD	_	_
17	common	_	JJ	JJ	_	16	NMOD	_	_
18	to	_	TO	TO	_	17	AMOD	_	_
19	all	_	DT	DT	_	18	PMOD	_	_
20	as	_	RB	RB	_	16	CC	_	_
21	well	_	RB	RB	_	20	DEP	_	_
22	as	_	IN	IN	_	20	DEP	_	_
23	those	_	DT	DT	_	16	COORD	_	_
24	which	_	WDT	WDT	_	25	SBJ	_	_
25	are	_	VBP	VBP	_	23	NMOD	_	_
26	unique	_	JJ	JJ	_	25	PRD	_	_
27	to	_	TO	TO	_	26	AMOD	_	_
28	each	_	DT	DT	_	29	NMOD	_	_
29	gene	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	12	P	_	_

1	For	_	IN	IN	_	25	ADV	_	_
2	most	_	JJS	JJS	_	4	NMOD	_	_
3	lymphokine	_	NN	NN	_	4	NMOD	_	_
4	genes	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	25	P	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	combination	_	NN	NN	_	25	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	phorbol	_	NN	NN	_	10	NMOD	_	_
10	esters	_	NNS	NNS	_	8	PMOD	_	_
11	(	_	(	(	_	15	P	_	_
12	phorbol	_	NN	NN	_	15	NMOD	_	_
13	12-myristate	_	NN	NN	_	15	NMOD	_	_
14	13	_	CD	CD	_	15	NMOD	_	_
15	acetate	_	NN	NN	_	10	PRN	_	_
16	,	_	,	,	_	15	P	_	_
17	PMA	_	NN	NN	_	15	NMOD	_	_
18	)	_	)	)	_	15	P	_	_
19	and	_	CC	CC	_	10	CC	_	_
20	calcium	_	NN	NN	_	21	NMOD	_	_
21	ionophores	_	NNS	NNS	_	10	COORD	_	_
22	(	_	(	(	_	23	P	_	_
23	A23187	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
26	required	_	VBN	VBN	_	25	VC	_	_
27	for	_	IN	IN	_	26	ADV	_	_
28	their	_	PRP$	PRP$	_	30	NMOD	_	_
29	maximal	_	JJ	JJ	_	30	NMOD	_	_
30	induction	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	25	P	_	_

1	Yet	_	RB	RB	_	9	VMOD	_	_
2	phorbol	_	NN	NN	_	3	NMOD	_	_
3	ester	_	NN	NN	_	9	SBJ	_	_
4	alone	_	RB	RB	_	3	NMOD	_	_
5	or	_	CC	CC	_	3	CC	_	_
6	calcium	_	NN	NN	_	7	NMOD	_	_
7	ionophore	_	NN	NN	_	3	COORD	_	_
8	alone	_	RB	RB	_	7	NMOD	_	_
9	produce	_	VBP	VBP	_	0	ROOT-S	_	_
10	several	_	JJ	JJ	_	11	NMOD	_	_
11	lymphokines	_	NNS	NNS	_	9	OBJ	_	_
12	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	production	_	NN	NN	_	12	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	granulocyte-macrophage	_	JJ	JJ	_	8	NMOD	_	_
6	colony	_	NN	NN	_	8	NMOD	_	_
7	stimulating	_	NN	NN	_	8	NMOD	_	_
8	factor	_	NN	NN	_	3	PMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	GM-CSF	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	completely	_	RB	RB	_	14	AMOD	_	_
14	dependent	_	JJ	JJ	_	12	PRD	_	_
15	on	_	IN	IN	_	14	AMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	two	_	CD	CD	_	18	NMOD	_	_
18	signals	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	12	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	previously	_	RB	RB	_	2	TMP	_	_
4	found	_	VBN	VBN	_	2	VC	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	cis-acting	_	JJ	JJ	_	7	NMOD	_	_
7	region	_	NN	NN	_	4	OBJ	_	_
8	spanning	_	VBG	VBG	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	GM-CSF	_	NN	NN	_	12	NMOD	_	_
11	promoter	_	NN	NN	_	12	NMOD	_	_
12	region	_	NN	NN	_	8	OBJ	_	_
13	(	_	(	(	_	14	P	_	_
14	positions	_	NNS	NNS	_	12	PRN	_	_
15	-95	_	CD	CD	_	14	NMOD	_	_
16	to	_	TO	TO	_	15	NMOD	_	_
17	+27	_	CD	CD	_	15	NMOD	_	_
18	)	_	)	)	_	14	P	_	_
19	that	_	WDT	WDT	_	20	SBJ	_	_
20	confers	_	VBZ	VBZ	_	12	NMOD	_	_
21	inducibility	_	NN	NN	_	20	OBJ	_	_
22	to	_	TO	TO	_	20	ADV	_	_
23	reporter	_	NN	NN	_	24	NMOD	_	_
24	genes	_	NNS	NNS	_	22	PMOD	_	_
25	in	_	IN	IN	_	20	ADV	_	_
26	transient	_	JJ	JJ	_	28	NMOD	_	_
27	transfection	_	NN	NN	_	28	NMOD	_	_
28	assays	_	NNS	NNS	_	25	PMOD	_	_
29	.	_	.	.	_	2	P	_	_

1	Further	_	JJ	JJ	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	3	SBJ	_	_
3	identified	_	VBD	VBD	_	0	ROOT-S	_	_
4	three	_	CD	CD	_	5	NMOD	_	_
5	elements	_	NNS	NNS	_	3	OBJ	_	_
6	required	_	VBN	VBN	_	5	NMOD	_	_
7	for	_	IN	IN	_	6	ADV	_	_
8	efficient	_	JJ	JJ	_	9	NMOD	_	_
9	induction	_	NN	NN	_	7	PMOD	_	_
10	,	_	,	,	_	5	P	_	_
11	referred	_	VBN	VBN	_	5	NMOD	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	as	_	IN	IN	_	11	ADV	_	_
14	GM2	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	GC-box	_	NN	NN	_	14	COORD	_	_
17	and	_	CC	CC	_	14	CC	_	_
18	conserved	_	VBN	VBN	_	20	NMOD	_	_
19	lymphokine	_	NN	NN	_	20	NMOD	_	_
20	element	_	NN	NN	_	14	COORD	_	_
21	(	_	(	(	_	22	P	_	_
22	CLE0	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	.	_	.	.	_	3	P	_	_

1	GM2	_	NN	NN	_	2	SBJ	_	_
2	defines	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	binding	_	VBG	VBG	_	5	NMOD	_	_
5	site	_	NN	NN	_	2	OBJ	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	protein	_	NN	NN	_	9	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	s	_	NNS	NNS	_	6	PMOD	_	_
10	)	_	)	)	_	9	P	_	_
11	whose	_	WP$	WP$	_	12	NMOD	_	_
12	binding	_	NN	NN	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	9	NMOD	_	_
14	inducible	_	JJ	JJ	_	13	PRD	_	_
15	by	_	IN	IN	_	14	AMOD	_	_
16	PMA	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	2	P	_	_

1	One	_	CD	CD	_	2	NMOD	_	_
2	protein	_	NN	NN	_	5	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	NF-GM2	_	NN	NN	_	2	NMOD	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	similar	_	JJ	JJ	_	5	PRD	_	_
7	to	_	TO	TO	_	6	AMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	transcription	_	NN	NN	_	11	NMOD	_	_
10	factor	_	NN	NN	_	11	NMOD	_	_
11	NF-kB	_	NN	NN	_	7	PMOD	_	_
12	.	_	.	.	_	5	P	_	_

1	GC-box	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	binding	_	VBG	VBG	_	5	NMOD	_	_
5	site	_	NN	NN	_	2	PRD	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	constitutively	_	RB	RB	_	8	AMOD	_	_
8	bound	_	VBN	VBN	_	9	NMOD	_	_
9	proteins	_	NNS	NNS	_	6	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	CLEO	_	NN	NN	_	2	SBJ	_	_
2	defines	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	binding	_	VBG	VBG	_	5	NMOD	_	_
5	site	_	NN	NN	_	2	OBJ	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	protein	_	NN	NN	_	9	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	s	_	NNS	NNS	_	6	PMOD	_	_
10	)	_	)	)	_	9	P	_	_
11	whose	_	WP$	WP$	_	13	NMOD	_	_
12	optimum	_	NN	NN	_	13	NMOD	_	_
13	binding	_	NN	NN	_	14	SBJ	_	_
14	is	_	VBZ	VBZ	_	9	NMOD	_	_
15	stimulated	_	VBN	VBN	_	14	VC	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	PMA	_	NN	NN	_	16	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	A23187	_	NN	NN	_	17	COORD	_	_
20	.	_	.	.	_	2	P	_	_

1	Viral	_	JJ	JJ	_	2	NMOD	_	_
2	trans-activators	_	NNS	NNS	_	25	SBJ	_	_
3	such	_	JJ	JJ	_	4	DEP	_	_
4	as	_	IN	IN	_	2	NMOD	_	_
5	Tax	_	NN	NN	_	24	NMOD	_	_
6	(	_	(	(	_	11	P	_	_
7	human	_	JJ	JJ	_	11	NMOD	_	_
8	T	_	NN	NN	_	11	NMOD	_	_
9	cell	_	NN	NN	_	11	NMOD	_	_
10	leukemia	_	NN	NN	_	11	NMOD	_	_
11	virus-1	_	NN	NN	_	5	PRN	_	_
12	,	_	,	,	_	11	P	_	_
13	HTLV-1	_	NN	NN	_	11	NMOD	_	_
14	)	_	)	)	_	11	P	_	_
15	and	_	CC	CC	_	5	CC	_	_
16	E2	_	NN	NN	_	5	COORD	_	_
17	(	_	(	(	_	20	P	_	_
18	bovine	_	JJ	JJ	_	20	NMOD	_	_
19	papilloma	_	NN	NN	_	20	NMOD	_	_
20	virus	_	NN	NN	_	16	PRN	_	_
21	,	_	,	,	_	20	P	_	_
22	BPV	_	NN	NN	_	20	NMOD	_	_
23	)	_	)	)	_	20	P	_	_
24	proteins	_	NNS	NNS	_	4	PMOD	_	_
25	are	_	VBP	VBP	_	0	ROOT-S	_	_
26	other	_	JJ	JJ	_	27	NMOD	_	_
27	agents	_	NNS	NNS	_	25	PRD	_	_
28	which	_	WDT	WDT	_	29	SBJ	_	_
29	activate	_	VBP	VBP	_	27	NMOD	_	_
30	lymphokine	_	NN	NN	_	32	NMOD	_	_
31	gene	_	NN	NN	_	32	NMOD	_	_
32	expression	_	NN	NN	_	29	OBJ	_	_
33	by	_	IN	IN	_	29	ADV	_	_
34	bypassing	_	VBG	VBG	_	33	PMOD	_	_
35	T	_	NN	NN	_	37	NMOD	_	_
36	cell	_	NN	NN	_	37	NMOD	_	_
37	receptor	_	NN	NN	_	41	AMOD	_	_
38	(	_	(	(	_	39	P	_	_
39	TCR	_	NN	NN	_	37	PRN	_	_
40	)	_	)	)	_	39	P	_	_
41	mediated	_	JJ	JJ	_	42	NMOD	_	_
42	signaling	_	NN	NN	_	34	OBJ	_	_
43	.	_	.	.	_	25	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	trans-activation	_	NN	NN	_	3	NMOD	_	_
3	domain	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	E2	_	NN	NN	_	4	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	Tax	_	NN	NN	_	5	COORD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	interchangeable	_	JJ	JJ	_	8	PRD	_	_
10	although	_	IN	IN	_	8	ADV	_	_
11	they	_	PRP	PRP	_	12	SBJ	_	_
12	have	_	VBP	VBP	_	10	VMOD	_	_
13	no	_	DT	DT	_	16	NMOD	_	_
14	obvious	_	JJ	JJ	_	16	NMOD	_	_
15	sequence	_	NN	NN	_	16	NMOD	_	_
16	homology	_	NN	NN	_	12	OBJ	_	_
17	between	_	IN	IN	_	16	NMOD	_	_
18	them	_	PRP	PRP	_	17	PMOD	_	_
19	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	viral	_	JJ	JJ	_	3	NMOD	_	_
3	trans-activators	_	NNS	NNS	_	4	SBJ	_	_
4	appear	_	VBP	VBP	_	0	ROOT-S	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	target	_	VB	VB	_	4	OBJ	_	_
7	specific	_	JJ	JJ	_	10	NMOD	_	_
8	DNA	_	NN	NN	_	10	NMOD	_	_
9	binding	_	NN	NN	_	10	NMOD	_	_
10	protein	_	NN	NN	_	6	OBJ	_	_
11	such	_	JJ	JJ	_	12	DEP	_	_
12	as	_	IN	IN	_	10	NMOD	_	_
13	NF-kB	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	Sp1	_	NN	NN	_	13	COORD	_	_
16	to	_	TO	TO	_	6	ADV	_	_
17	cis-acting	_	JJ	JJ	_	19	NMOD	_	_
18	DNA	_	NN	NN	_	19	NMOD	_	_
19	site	_	NN	NN	_	16	PMOD	_	_
20	and	_	CC	CC	_	6	CC	_	_
21	promote	_	VB	VB	_	6	COORD	_	_
22	lymphokine	_	NN	NN	_	24	NMOD	_	_
23	gene	_	NN	NN	_	24	NMOD	_	_
24	expression	_	NN	NN	_	21	OBJ	_	_
25	without	_	IN	IN	_	21	ADV	_	_
26	TCR-mediated	_	JJ	JJ	_	27	NMOD	_	_
27	stimulation	_	NN	NN	_	25	PMOD	_	_
28	.	_	.	.	_	4	P	_	_

1	Expression	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	tal-1	_	NN	NN	_	6	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	GATA-binding	_	JJ	JJ	_	3	COORD	_	_
6	proteins	_	NNS	NNS	_	2	PMOD	_	_
7	during	_	IN	IN	_	1	TMP	_	_
8	human	_	JJ	JJ	_	9	NMOD	_	_
9	hematopoiesis	_	NN	NN	_	7	PMOD	_	_
10	.	_	.	.	_	1	P	_	_

1	Tal-1	_	NN	NN	_	2	NMOD	_	_
2	rearrangements	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	associated	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	nearly	_	RB	RB	_	8	NMOD	_	_
7	30	_	CD	CD	_	6	DEP	_	_
8	%	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	human	_	JJ	JJ	_	14	NMOD	_	_
11	T	_	NN	NN	_	14	NMOD	_	_
12	acute	_	JJ	JJ	_	14	NMOD	_	_
13	lymphoblastic	_	JJ	JJ	_	14	NMOD	_	_
14	leukemia	_	NN	NN	_	9	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	Tal-1	_	NN	NN	_	2	NMOD	_	_
2	gene	_	NN	NN	_	3	SBJ	_	_
3	encodes	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	putative	_	JJ	JJ	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factor	_	NN	NN	_	3	OBJ	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	basic	_	JJ	JJ	_	12	NMOD	_	_
11	helix-loop-helix	_	JJ	JJ	_	12	NMOD	_	_
12	domain	_	NN	NN	_	8	PMOD	_	_
13	and	_	CC	CC	_	3	CC	_	_
14	is	_	VBZ	VBZ	_	3	COORD	_	_
15	known	_	VBN	VBN	_	14	VC	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	be	_	VB	VB	_	15	OBJ	_	_
18	predominantly	_	RB	RB	_	17	ADV	_	_
19	expressed	_	VBN	VBN	_	17	VC	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	hematopoietic	_	JJ	JJ	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	investigated	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	pattern	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	tal-1	_	NN	NN	_	7	NMOD	_	_
7	expression	_	NN	NN	_	5	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	purified	_	VBN	VBN	_	12	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	hematopoietic	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	8	PMOD	_	_
13	by	_	IN	IN	_	2	ADV	_	_
14	in	_	FW	FW	_	15	AMOD	_	_
15	situ	_	FW	FW	_	16	NMOD	_	_
16	hybridization	_	NN	NN	_	13	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	reverse	_	JJ	JJ	_	23	NMOD	_	_
19	transcriptase	_	NN	NN	_	23	NMOD	_	_
20	polymerase	_	NN	NN	_	23	NMOD	_	_
21	chain	_	NN	NN	_	23	NMOD	_	_
22	reaction	_	NN	NN	_	23	NMOD	_	_
23	analysis	_	NN	NN	_	16	COORD	_	_
24	.	_	.	.	_	2	P	_	_

1	Both	_	DT	DT	_	2	NMOD	_	_
2	methods	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	tal-1	_	NN	NN	_	7	NMOD	_	_
7	gene	_	NN	NN	_	8	SBJ	_	_
8	is	_	VBZ	VBZ	_	4	VMOD	_	_
9	expressed	_	VBN	VBN	_	8	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	megakaryocytes	_	NNS	NNS	_	10	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	erythroblasts	_	NNS	NNS	_	11	COORD	_	_
14	as	_	RB	RB	_	10	CC	_	_
15	well	_	RB	RB	_	14	DEP	_	_
16	as	_	IN	IN	_	14	DEP	_	_
17	in	_	IN	IN	_	10	COORD	_	_
18	basophilic	_	JJ	JJ	_	19	NMOD	_	_
19	granulocytes	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	6	P	_	_
4	our	_	PRP$	PRP$	_	5	NMOD	_	_
5	results	_	NNS	NNS	_	6	SBJ	_	_
6	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	tal-1	_	NN	NN	_	11	NMOD	_	_
10	1A	_	NN	NN	_	11	NMOD	_	_
11	promoter	_	NN	NN	_	20	SBJ	_	_
12	,	_	,	,	_	11	P	_	_
13	which	_	WDT	WDT	_	14	SBJ	_	_
14	contains	_	VBZ	VBZ	_	11	NMOD	_	_
15	two	_	CD	CD	_	18	NMOD	_	_
16	consensus	_	NN	NN	_	18	NMOD	_	_
17	GATA-binding	_	JJ	JJ	_	18	NMOD	_	_
18	sites	_	NNS	NNS	_	14	OBJ	_	_
19	,	_	,	,	_	11	P	_	_
20	is	_	VBZ	VBZ	_	7	VMOD	_	_
21	active	_	JJ	JJ	_	20	PRD	_	_
22	mainly	_	RB	RB	_	23	DEP	_	_
23	in	_	IN	IN	_	20	ADV	_	_
24	these	_	DT	DT	_	25	NMOD	_	_
25	lineages	_	NNS	NNS	_	23	PMOD	_	_
26	.	_	.	.	_	6	P	_	_

1	Because	_	IN	IN	_	23	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	GATA-1	_	NN	NN	_	4	NMOD	_	_
4	gene	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	1	VMOD	_	_
6	known	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	transactivate	_	VB	VB	_	6	OBJ	_	_
9	several	_	JJ	JJ	_	10	NMOD	_	_
10	genes	_	NNS	NNS	_	8	OBJ	_	_
11	specific	_	JJ	JJ	_	10	NMOD	_	_
12	for	_	IN	IN	_	11	AMOD	_	_
13	the	_	DT	DT	_	20	NMOD	_	_
14	erythroid	_	JJ	JJ	_	20	NMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	megakaryocytic	_	JJ	JJ	_	14	COORD	_	_
17	,	_	,	,	_	14	P	_	_
18	and	_	CC	CC	_	14	CC	_	_
19	mastocytic\/basophilic	_	JJ	JJ	_	14	COORD	_	_
20	lineages	_	NNS	NNS	_	12	PMOD	_	_
21	,	_	,	,	_	23	P	_	_
22	we	_	PRP	PRP	_	23	SBJ	_	_
23	studied	_	VBD	VBD	_	0	ROOT-S	_	_
24	GATA-1	_	NN	NN	_	25	NMOD	_	_
25	expression	_	NN	NN	_	23	OBJ	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	these	_	DT	DT	_	30	NMOD	_	_
28	purified	_	VBN	VBN	_	30	NMOD	_	_
29	hematopoietic	_	JJ	JJ	_	30	NMOD	_	_
30	cells	_	NNS	NNS	_	26	PMOD	_	_
31	.	_	.	.	_	23	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	found	_	VBD	VBD	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	GATA-1	_	NN	NN	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	tal-1	_	NN	NN	_	4	COORD	_	_
7	genes	_	NNS	NNS	_	8	SBJ	_	_
8	are	_	VBP	VBP	_	3	VMOD	_	_
9	coexpressed	_	VBN	VBN	_	8	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	these	_	DT	DT	_	13	NMOD	_	_
12	three	_	CD	CD	_	13	NMOD	_	_
13	lineages	_	NNS	NNS	_	10	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	Remarkably	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	expression	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	both	_	DT	DT	_	7	NMOD	_	_
7	genes	_	NNS	NNS	_	5	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	downmodulated	_	VBN	VBN	_	8	VC	_	_
10	during	_	IN	IN	_	9	TMP	_	_
11	erythroid	_	JJ	JJ	_	15	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	megakaryocytic	_	JJ	JJ	_	11	COORD	_	_
14	terminal	_	JJ	JJ	_	15	NMOD	_	_
15	maturation	_	NN	NN	_	10	PMOD	_	_
16	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	immature	_	JJ	JJ	_	4	NMOD	_	_
3	hematopoietic	_	JJ	JJ	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	10	P	_	_
6	tal-1	_	NN	NN	_	9	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	GATA-1	_	NN	NN	_	6	COORD	_	_
9	genes	_	NNS	NNS	_	10	SBJ	_	_
10	are	_	VBP	VBP	_	0	ROOT-S	_	_
11	coexpressed	_	VBN	VBN	_	10	VC	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	committed	_	VBN	VBN	_	15	NMOD	_	_
14	progenitors	_	NNS	NNS	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	12	PMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	CD34+\/CD38-LRB-2+-RRB-	_	JJ	JJ	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	,	_	,	,	_	11	P	_	_
20	whereas	_	IN	IN	_	11	OBJ	_	_
21	they	_	PRP	PRP	_	22	SBJ	_	_
22	are	_	VBP	VBP	_	20	VMOD	_	_
23	not	_	RB	RB	_	22	VMOD	_	_
24	detectable	_	JJ	JJ	_	22	PRD	_	_
25	in	_	IN	IN	_	22	ADV	_	_
26	the	_	DT	DT	_	29	NMOD	_	_
27	most	_	RBS	RBS	_	28	AMOD	_	_
28	primitive	_	JJ	JJ	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	25	PMOD	_	_
30	(	_	(	(	_	31	P	_	_
31	CD34-LRB-2+-RRB-\/CD38-	_	JJ	JJ	_	29	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	GATA-2	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	strongly	_	RB	RB	_	5	ADV	_	_
7	expressed	_	VBN	VBN	_	5	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	both	_	CC	CC	_	15	CC	_	_
10	most	_	RBS	RBS	_	11	AMOD	_	_
11	primitive	_	JJ	JJ	_	15	NMOD	_	_
12	and	_	CC	CC	_	15	CC	_	_
13	committed	_	VBN	VBN	_	14	NMOD	_	_
14	progenitors	_	NNS	NNS	_	15	COORD	_	_
15	cells	_	NNS	NNS	_	8	PMOD	_	_
16	,	_	,	,	_	5	P	_	_
17	whereas	_	IN	IN	_	5	COORD	_	_
18	GATA-3	_	NN	NN	_	19	SBJ	_	_
19	is	_	VBZ	VBZ	_	5	COORD	_	_
20	mostly	_	RB	RB	_	19	ADV	_	_
21	detected	_	VBN	VBN	_	19	VC	_	_
22	in	_	IN	IN	_	21	ADV	_	_
23	most	_	RBS	RBS	_	24	AMOD	_	_
24	primitive	_	JJ	JJ	_	25	NMOD	_	_
25	ones	_	NNS	NNS	_	22	PMOD	_	_
26	.	_	.	.	_	5	P	_	_

1	Altogether	_	RB	RB	_	5	ADV	_	_
2	our	_	PRP$	PRP$	_	3	NMOD	_	_
3	results	_	NNS	NNS	_	5	SBJ	_	_
4	strongly	_	RB	RB	_	5	ADV	_	_
5	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	GATA-1	_	NN	NN	_	8	SBJ	_	_
8	modulates	_	VBZ	VBZ	_	6	VMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	transcription	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	tal-1	_	NN	NN	_	11	PMOD	_	_
13	during	_	IN	IN	_	8	TMP	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	differentiation	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	24	NMOD	_	_
18	erythroid	_	JJ	JJ	_	24	NMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	megakaryocytic	_	JJ	JJ	_	18	COORD	_	_
21	,	_	,	,	_	18	P	_	_
22	and	_	CC	CC	_	18	CC	_	_
23	basosophilic	_	JJ	JJ	_	18	COORD	_	_
24	lineages	_	NNS	NNS	_	16	PMOD	_	_
25	.	_	.	.	_	5	P	_	_

1	Cell-type-specific	_	JJ	JJ	_	2	NMOD	_	_
2	transactivation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	9	NMOD	_	_
5	parathyroid	_	JJ	JJ	_	6	AMOD	_	_
6	hormone-related	_	JJ	JJ	_	9	NMOD	_	_
7	protein	_	NN	NN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	promoter	_	NN	NN	_	3	PMOD	_	_
10	by	_	IN	IN	_	2	NMOD	_	_
11	the	_	DT	DT	_	25	NMOD	_	_
12	human	_	JJ	JJ	_	16	NMOD	_	_
13	T-cell	_	NN	NN	_	16	NMOD	_	_
14	leukemia	_	NN	NN	_	16	NMOD	_	_
15	virus	_	NN	NN	_	16	NMOD	_	_
16	type	_	NN	NN	_	21	NMOD	_	_
17	I	_	CD	CD	_	16	NMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	HTLV-I	_	NN	NN	_	21	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	tax	_	NN	NN	_	25	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	HTLV-II	_	NN	NN	_	24	NMOD	_	_
24	tax	_	NN	NN	_	21	COORD	_	_
25	proteins	_	NNS	NNS	_	10	PMOD	_	_
26	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	14	NMOD	_	_
2	human	_	JJ	JJ	_	6	NMOD	_	_
3	T-cell	_	NN	NN	_	6	NMOD	_	_
4	leukemia	_	NN	NN	_	6	NMOD	_	_
5	virus	_	NN	NN	_	6	NMOD	_	_
6	type	_	NN	NN	_	14	NMOD	_	_
7	I	_	CD	CD	_	6	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	HTLV-I	_	NN	NN	_	6	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	and	_	CC	CC	_	6	CC	_	_
12	HTLV-II	_	NN	NN	_	6	COORD	_	_
13	Tax	_	NN	NN	_	14	NMOD	_	_
14	proteins	_	NNS	NNS	_	15	SBJ	_	_
15	are	_	VBP	VBP	_	0	ROOT-S	_	_
16	potent	_	JJ	JJ	_	17	NMOD	_	_
17	transactivators	_	NNS	NNS	_	15	PRD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	viral	_	JJ	JJ	_	23	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	cellular	_	JJ	JJ	_	19	COORD	_	_
22	gene	_	NN	NN	_	23	NMOD	_	_
23	expression	_	NN	NN	_	18	PMOD	_	_
24	.	_	.	.	_	15	P	_	_

1	Using	_	VBG	VBG	_	14	VC	_	_
2	deletion	_	NN	NN	_	3	NMOD	_	_
3	mutants	_	NNS	NNS	_	1	OBJ	_	_
4	,	_	,	,	_	14	P	_	_
5	the	_	DT	DT	_	13	NMOD	_	_
6	downstream	_	JJ	JJ	_	13	NMOD	_	_
7	parathyroid	_	JJ	JJ	_	8	AMOD	_	_
8	hormone-related	_	JJ	JJ	_	9	NMOD	_	_
9	protein	_	NN	NN	_	13	NMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	PTHrP	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	promoter	_	NN	NN	_	14	SBJ	_	_
14	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	shown	_	VBN	VBN	_	14	VC	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	be	_	VB	VB	_	15	OBJ	_	_
18	responsive	_	JJ	JJ	_	17	PRD	_	_
19	to	_	TO	TO	_	18	AMOD	_	_
20	both	_	CC	CC	_	21	CC	_	_
21	HTLV-I	_	NN	NN	_	24	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	HTLV-II	_	NN	NN	_	21	COORD	_	_
24	Tax	_	NN	NN	_	19	PMOD	_	_
25	as	_	RB	RB	_	24	CC	_	_
26	well	_	RB	RB	_	25	DEP	_	_
27	as	_	IN	IN	_	25	DEP	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	AP1\/c-jun	_	NN	NN	_	30	NMOD	_	_
30	proto-oncogene	_	NN	NN	_	24	COORD	_	_
31	.	_	.	.	_	14	P	_	_

1	Transactivation	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	PTHrP	_	NN	NN	_	2	PMOD	_	_
4	by	_	IN	IN	_	1	NMOD	_	_
5	Tax	_	NN	NN	_	4	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	seen	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	but	_	CC	CC	_	8	CC	_	_
12	not	_	RB	RB	_	13	DEP	_	_
13	in	_	IN	IN	_	8	COORD	_	_
14	B-cell	_	NN	NN	_	15	NMOD	_	_
15	lines	_	NNS	NNS	_	13	PMOD	_	_
16	or	_	CC	CC	_	15	CC	_	_
17	fibroblasts	_	NNS	NNS	_	15	COORD	_	_
18	.	_	.	.	_	6	P	_	_

1	A	_	DT	DT	_	6	NMOD	_	_
2	carboxy	_	NN	NN	_	6	NMOD	_	_
3	terminal	_	JJ	JJ	_	6	NMOD	_	_
4	Tax	_	NN	NN	_	6	NMOD	_	_
5	deletion	_	NN	NN	_	6	NMOD	_	_
6	mutant	_	NN	NN	_	7	SBJ	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	deficient	_	JJ	JJ	_	7	PRD	_	_
9	in	_	IN	IN	_	7	ADV	_	_
10	transactivation	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	both	_	CC	CC	_	18	CC	_	_
13	the	_	DT	DT	_	18	NMOD	_	_
14	PTHrP	_	NN	NN	_	18	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	IL2R	_	NN	NN	_	17	NMOD	_	_
17	alpha	_	NN	NN	_	14	COORD	_	_
18	promoters	_	NNS	NNS	_	11	PMOD	_	_
19	but	_	CC	CC	_	18	CC	_	_
20	not	_	RB	RB	_	19	COORD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	HTLV-I	_	NN	NN	_	18	COORD	_	_
23	long	_	JJ	JJ	_	25	NMOD	_	_
24	terminal	_	JJ	JJ	_	25	NMOD	_	_
25	repeat	_	NN	NN	_	22	NMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	LTR	_	NN	NN	_	25	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	.	_	.	.	_	7	P	_	_

1	Exogenous	_	JJ	JJ	_	2	NMOD	_	_
2	provision	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NFkB	_	NN	NN	_	3	PMOD	_	_
5	rescued	_	VBD	VBD	_	0	ROOT-S	_	_
6	IL2R	_	NN	NN	_	8	NMOD	_	_
7	alpha	_	NN	NN	_	8	NMOD	_	_
8	expression	_	NN	NN	_	5	OBJ	_	_
9	but	_	CC	CC	_	8	CC	_	_
10	not	_	RB	RB	_	9	COORD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	PTHrP	_	NN	NN	_	13	NMOD	_	_
13	promoter	_	NN	NN	_	8	COORD	_	_
14	.	_	.	.	_	5	P	_	_

1	Thus	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	HTLV-I	_	NN	NN	_	4	NMOD	_	_
4	Tax	_	NN	NN	_	11	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	HTLV-II	_	NN	NN	_	7	NMOD	_	_
7	Tax	_	NN	NN	_	4	COORD	_	_
8	,	_	,	,	_	4	P	_	_
9	and	_	CC	CC	_	4	CC	_	_
10	c-jun	_	NN	NN	_	4	COORD	_	_
11	transactivate	_	VBP	VBP	_	0	ROOT-S	_	_
12	PTHrP	_	NN	NN	_	11	OBJ	_	_
13	and	_	CC	CC	_	11	CC	_	_
14	may	_	MD	MD	_	11	COORD	_	_
15	contribute	_	VB	VB	_	14	VC	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	pathogenesis	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	hypercalcemia	_	NN	NN	_	19	PMOD	_	_
21	in	_	IN	IN	_	18	NMOD	_	_
22	adult	_	JJ	JJ	_	24	NMOD	_	_
23	T-cell	_	NN	NN	_	24	NMOD	_	_
24	leukemia	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	11	P	_	_

1	I	_	NN	NN	_	3	NMOD	_	_
2	kappa	_	NN	NN	_	3	NMOD	_	_
3	B\/MAD-3	_	NN	NN	_	4	SBJ	_	_
4	masks	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	nuclear	_	JJ	JJ	_	8	NMOD	_	_
7	localization	_	NN	NN	_	8	NMOD	_	_
8	signal	_	NN	NN	_	4	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	NF-kappa	_	NN	NN	_	12	NMOD	_	_
11	B	_	NN	NN	_	12	NMOD	_	_
12	p65	_	NN	NN	_	9	PMOD	_	_
13	and	_	CC	CC	_	4	CC	_	_
14	requires	_	VBZ	VBZ	_	4	COORD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	transactivation	_	NN	NN	_	17	NMOD	_	_
17	domain	_	NN	NN	_	19	SBJ	_	_
18	to	_	TO	TO	_	19	VMOD	_	_
19	inhibit	_	VB	VB	_	14	OBJ	_	_
20	NF-kappa	_	NN	NN	_	24	NMOD	_	_
21	B	_	NN	NN	_	24	NMOD	_	_
22	p65	_	NN	NN	_	24	NMOD	_	_
23	DNA	_	NN	NN	_	24	NMOD	_	_
24	binding	_	NN	NN	_	19	OBJ	_	_
25	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	active	_	JJ	JJ	_	4	NMOD	_	_
3	nuclear	_	JJ	JJ	_	4	NMOD	_	_
4	form	_	NN	NN	_	12	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	11	NMOD	_	_
7	NF-kappa	_	NN	NN	_	11	NMOD	_	_
8	B	_	NN	NN	_	11	NMOD	_	_
9	transcription	_	NN	NN	_	11	NMOD	_	_
10	factor	_	NN	NN	_	11	NMOD	_	_
11	complex	_	NN	NN	_	5	PMOD	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	composed	_	VBN	VBN	_	12	VC	_	_
14	of	_	IN	IN	_	13	ADV	_	_
15	two	_	CD	CD	_	18	NMOD	_	_
16	DNA	_	NN	NN	_	18	NMOD	_	_
17	binding	_	NN	NN	_	18	NMOD	_	_
18	subunits	_	NNS	NNS	_	14	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	NF-kappa	_	NN	NN	_	22	NMOD	_	_
21	B	_	NN	NN	_	22	NMOD	_	_
22	p65	_	NN	NN	_	18	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	NF-kappa	_	NN	NN	_	26	NMOD	_	_
25	B	_	NN	NN	_	26	NMOD	_	_
26	p50	_	NN	NN	_	22	COORD	_	_
27	,	_	,	,	_	18	P	_	_
28	both	_	DT	DT	_	29	NMOD	_	_
29	of	_	IN	IN	_	31	SBJ	_	_
30	which	_	WDT	WDT	_	29	PMOD	_	_
31	share	_	VBP	VBP	_	18	NMOD	_	_
32	extensive	_	JJ	JJ	_	35	NMOD	_	_
33	N-terminal	_	JJ	JJ	_	35	NMOD	_	_
34	sequence	_	NN	NN	_	35	NMOD	_	_
35	homology	_	NN	NN	_	31	OBJ	_	_
36	with	_	IN	IN	_	31	ADV	_	_
37	the	_	DT	DT	_	40	NMOD	_	_
38	v-rel	_	NN	NN	_	40	NMOD	_	_
39	oncogene	_	NN	NN	_	40	NMOD	_	_
40	product	_	NN	NN	_	36	PMOD	_	_
41	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	NF-kappa	_	NN	NN	_	5	NMOD	_	_
3	B	_	NN	NN	_	5	NMOD	_	_
4	p65	_	NN	NN	_	5	NMOD	_	_
5	subunit	_	NN	NN	_	6	SBJ	_	_
6	provides	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	transactivation	_	NN	NN	_	9	NMOD	_	_
9	activity	_	NN	NN	_	6	OBJ	_	_
10	in	_	IN	IN	_	6	ADV	_	_
11	this	_	DT	DT	_	12	NMOD	_	_
12	complex	_	JJ	JJ	_	10	PMOD	_	_
13	and	_	CC	CC	_	6	CC	_	_
14	serves	_	VBZ	VBZ	_	6	COORD	_	_
15	as	_	IN	IN	_	14	ADV	_	_
16	an	_	DT	DT	_	18	NMOD	_	_
17	intracellular	_	JJ	JJ	_	18	NMOD	_	_
18	receptor	_	NN	NN	_	15	PMOD	_	_
19	for	_	IN	IN	_	18	NMOD	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	cytoplasmic	_	JJ	JJ	_	22	NMOD	_	_
22	inhibitor	_	NN	NN	_	19	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	NF-kappa	_	NN	NN	_	25	NMOD	_	_
25	B	_	NN	NN	_	23	PMOD	_	_
26	,	_	,	,	_	22	P	_	_
27	termed	_	VBN	VBN	_	22	NMOD	_	_
28	I	_	NN	NN	_	30	NMOD	_	_
29	kappa	_	NN	NN	_	30	NMOD	_	_
30	B	_	NN	NN	_	27	OBJ	_	_
31	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	8	P	_	_
4	NF-kappa	_	NN	NN	_	6	NMOD	_	_
5	B	_	NN	NN	_	6	NMOD	_	_
6	p50	_	NN	NN	_	8	SBJ	_	_
7	alone	_	RB	RB	_	6	NMOD	_	_
8	fails	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	stimulate	_	VB	VB	_	8	OBJ	_	_
11	kappa	_	NN	NN	_	13	NMOD	_	_
12	B-directed	_	JJ	JJ	_	11	AMOD	_	_
13	transcription	_	NN	NN	_	10	OBJ	_	_
14	,	_	,	,	_	8	P	_	_
15	and	_	CC	CC	_	8	CC	_	_
16	based	_	VBN	VBN	_	23	ADV	_	_
17	on	_	IN	IN	_	16	PMOD	_	_
18	prior	_	JJ	JJ	_	21	NMOD	_	_
19	in	_	FW	FW	_	20	AMOD	_	_
20	vitro	_	FW	FW	_	21	NMOD	_	_
21	studies	_	NNS	NNS	_	17	PMOD	_	_
22	,	_	,	,	_	23	P	_	_
23	is	_	VBZ	VBZ	_	8	COORD	_	_
24	not	_	RB	RB	_	23	VMOD	_	_
25	directly	_	RB	RB	_	23	ADV	_	_
26	regulated	_	VBN	VBN	_	23	VC	_	_
27	by	_	IN	IN	_	26	LGS	_	_
28	I	_	NN	NN	_	30	NMOD	_	_
29	kappa	_	NN	NN	_	30	NMOD	_	_
30	B	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	8	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	investigate	_	VB	VB	_	27	ADV	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	molecular	_	JJ	JJ	_	5	NMOD	_	_
5	basis	_	NN	NN	_	2	OBJ	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	critical	_	JJ	JJ	_	10	NMOD	_	_
9	regulatory	_	JJ	JJ	_	10	NMOD	_	_
10	interaction	_	NN	NN	_	6	PMOD	_	_
11	between	_	IN	IN	_	10	NMOD	_	_
12	NF-kappa	_	NN	NN	_	13	NMOD	_	_
13	B	_	NN	NN	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	I	_	NN	NN	_	17	NMOD	_	_
16	kappa	_	NN	NN	_	17	NMOD	_	_
17	B\/MAD-3	_	NN	NN	_	13	COORD	_	_
18	,	_	,	,	_	27	P	_	_
19	a	_	DT	DT	_	20	NMOD	_	_
20	series	_	NN	NN	_	27	SBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	human	_	JJ	JJ	_	26	NMOD	_	_
23	NF-kappa	_	NN	NN	_	26	NMOD	_	_
24	B	_	NN	NN	_	26	NMOD	_	_
25	p65	_	NN	NN	_	26	NMOD	_	_
26	mutants	_	NNS	NNS	_	21	PMOD	_	_
27	was	_	VBD	VBD	_	0	ROOT-S	_	_
28	identified	_	VBN	VBN	_	27	VC	_	_
29	that	_	WDT	WDT	_	31	SBJ	_	_
30	functionally	_	RB	RB	_	31	ADV	_	_
31	segregated	_	VBD	VBD	_	26	NMOD	_	_
32	DNA	_	NN	NN	_	33	NMOD	_	_
33	binding	_	NN	NN	_	31	OBJ	_	_
34	,	_	,	,	_	33	P	_	_
35	I	_	NN	NN	_	36	AMOD	_	_
36	kappa	_	NN	NN	_	38	NMOD	_	_
37	B-mediated	_	JJ	JJ	_	36	AMOD	_	_
38	inhibition	_	NN	NN	_	33	COORD	_	_
39	,	_	,	,	_	33	P	_	_
40	and	_	CC	CC	_	33	CC	_	_
41	I	_	NN	NN	_	42	AMOD	_	_
42	kappa	_	NN	NN	_	45	NMOD	_	_
43	B-induced	_	JJ	JJ	_	42	AMOD	_	_
44	nuclear	_	JJ	JJ	_	45	NMOD	_	_
45	exclusion	_	NN	NN	_	33	COORD	_	_
46	of	_	IN	IN	_	33	NMOD	_	_
47	this	_	DT	DT	_	49	NMOD	_	_
48	transcription	_	NN	NN	_	49	NMOD	_	_
49	factor	_	NN	NN	_	46	PMOD	_	_
50	.	_	.	.	_	27	P	_	_

1	Results	_	NNS	NNS	_	14	SBJ	_	_
2	from	_	IN	IN	_	1	NMOD	_	_
3	in	_	FW	FW	_	4	AMOD	_	_
4	vivo	_	FW	FW	_	6	NMOD	_	_
5	expression	_	NN	NN	_	6	NMOD	_	_
6	studies	_	NNS	NNS	_	2	PMOD	_	_
7	performed	_	VBN	VBN	_	6	NMOD	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	these	_	DT	DT	_	13	NMOD	_	_
10	NF-kappa	_	NN	NN	_	13	NMOD	_	_
11	B	_	NN	NN	_	13	NMOD	_	_
12	p65	_	NN	NN	_	13	NMOD	_	_
13	mutants	_	NNS	NNS	_	8	PMOD	_	_
14	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	following	_	NN	NN	_	14	OBJ	_	_
17	:	_	:	:	_	14	P	_	_
18	1	_	LS	LS	_	24	VMOD	_	_
19	)	_	)	)	_	18	P	_	_
20	I	_	NN	NN	_	22	NMOD	_	_
21	kappa	_	NN	NN	_	22	NMOD	_	_
22	B\/MAD-3	_	NN	NN	_	24	SBJ	_	_
23	completely	_	RB	RB	_	24	ADV	_	_
24	inhibits	_	VBZ	VBZ	_	14	VMOD	_	_
25	NF-kappa	_	NN	NN	_	26	AMOD	_	_
26	B	_	NN	NN	_	29	NMOD	_	_
27	p65-dependent	_	JJ	JJ	_	26	AMOD	_	_
28	transcriptional	_	JJ	JJ	_	29	NMOD	_	_
29	activation	_	NN	NN	_	24	OBJ	_	_
30	mediated	_	VBN	VBN	_	29	NMOD	_	_
31	through	_	IN	IN	_	30	ADV	_	_
32	the	_	DT	DT	_	40	NMOD	_	_
33	human	_	JJ	JJ	_	40	NMOD	_	_
34	immunodeficiency	_	NN	NN	_	40	NMOD	_	_
35	virus	_	NN	NN	_	40	NMOD	_	_
36	type	_	NN	NN	_	40	NMOD	_	_
37	1	_	CD	CD	_	40	NMOD	_	_
38	kappa	_	NN	NN	_	40	NMOD	_	_
39	B	_	NN	NN	_	40	NMOD	_	_
40	enhancer	_	NN	NN	_	31	PMOD	_	_
41	in	_	IN	IN	_	40	NMOD	_	_
42	human	_	JJ	JJ	_	44	NMOD	_	_
43	T	_	NN	NN	_	44	NMOD	_	_
44	lymphocytes	_	NNS	NNS	_	41	PMOD	_	_
45	,	_	,	,	_	24	P	_	_
46	2	_	LS	LS	_	58	VMOD	_	_
47	)	_	)	)	_	46	P	_	_
48	the	_	DT	DT	_	49	NMOD	_	_
49	binding	_	NN	NN	_	58	SBJ	_	_
50	of	_	IN	IN	_	49	NMOD	_	_
51	I	_	NN	NN	_	53	NMOD	_	_
52	kappa	_	NN	NN	_	53	NMOD	_	_
53	B\/MAD-3	_	NN	NN	_	50	PMOD	_	_
54	to	_	TO	TO	_	49	NMOD	_	_
55	NF-kappa	_	NN	NN	_	57	NMOD	_	_
56	B	_	NN	NN	_	57	NMOD	_	_
57	p65	_	NN	NN	_	54	PMOD	_	_
58	is	_	VBZ	VBZ	_	24	COORD	_	_
59	sufficient	_	JJ	JJ	_	58	PRD	_	_
60	to	_	TO	TO	_	61	VMOD	_	_
61	retarget	_	VB	VB	_	59	AMOD	_	_
62	NF-kappa	_	NN	NN	_	64	NMOD	_	_
63	B	_	NN	NN	_	64	NMOD	_	_
64	p65	_	NN	NN	_	61	OBJ	_	_
65	from	_	IN	IN	_	61	ADV	_	_
66	the	_	DT	DT	_	67	NMOD	_	_
67	nucleus	_	NN	NN	_	65	PMOD	_	_
68	to	_	TO	TO	_	61	ADV	_	_
69	the	_	DT	DT	_	70	NMOD	_	_
70	cytoplasm	_	NN	NN	_	68	PMOD	_	_
71	,	_	,	,	_	24	P	_	_
72	3	_	LS	LS	_	92	VMOD	_	_
73	)	_	)	)	_	72	P	_	_
74	selective	_	JJ	JJ	_	75	NMOD	_	_
75	deletion	_	NN	NN	_	92	SBJ	_	_
76	of	_	IN	IN	_	75	NMOD	_	_
77	the	_	DT	DT	_	81	NMOD	_	_
78	functional	_	JJ	JJ	_	81	NMOD	_	_
79	nuclear	_	JJ	JJ	_	81	NMOD	_	_
80	localization	_	NN	NN	_	81	NMOD	_	_
81	signal	_	NN	NN	_	76	PMOD	_	_
82	present	_	JJ	JJ	_	81	NMOD	_	_
83	in	_	IN	IN	_	82	AMOD	_	_
84	the	_	DT	DT	_	87	NMOD	_	_
85	Rel	_	NN	NN	_	87	NMOD	_	_
86	homology	_	NN	NN	_	87	NMOD	_	_
87	domain	_	NN	NN	_	83	PMOD	_	_
88	of	_	IN	IN	_	87	NMOD	_	_
89	NF-kappa	_	NN	NN	_	91	NMOD	_	_
90	B	_	NN	NN	_	91	NMOD	_	_
91	p65	_	NN	NN	_	88	PMOD	_	_
92	disrupts	_	VBZ	VBZ	_	24	COORD	_	_
93	its	_	PRP$	PRP$	_	94	NMOD	_	_
94	ability	_	NN	NN	_	92	OBJ	_	_
95	to	_	TO	TO	_	96	VMOD	_	_
96	engage	_	VB	VB	_	94	NMOD	_	_
97	I	_	NN	NN	_	99	NMOD	_	_
98	kappa	_	NN	NN	_	99	NMOD	_	_
99	B\/MAD-3	_	NN	NN	_	96	OBJ	_	_
100	,	_	,	,	_	24	P	_	_
101	and	_	CC	CC	_	24	CC	_	_
102	4	_	LS	LS	_	111	VMOD	_	_
103	)	_	)	)	_	102	P	_	_
104	the	_	DT	DT	_	106	NMOD	_	_
105	unique	_	JJ	JJ	_	106	NMOD	_	_
106	C-terminus	_	NN	NN	_	111	SBJ	_	_
107	of	_	IN	IN	_	106	NMOD	_	_
108	NF-kappa	_	NN	NN	_	110	NMOD	_	_
109	B	_	NN	NN	_	110	NMOD	_	_
110	p65	_	NN	NN	_	107	PMOD	_	_
111	attenuates	_	VBZ	VBZ	_	24	COORD	_	_
112	its	_	PRP$	PRP$	_	115	NMOD	_	_
113	own	_	JJ	JJ	_	115	NMOD	_	_
114	nuclear	_	JJ	JJ	_	115	NMOD	_	_
115	localization	_	NN	NN	_	111	OBJ	_	_
116	and	_	CC	CC	_	111	CC	_	_
117	contains	_	VBZ	VBZ	_	111	COORD	_	_
118	sequences	_	NNS	NNS	_	117	OBJ	_	_
119	that	_	WDT	WDT	_	120	SBJ	_	_
120	are	_	VBP	VBP	_	118	NMOD	_	_
121	required	_	VBN	VBN	_	120	VC	_	_
122	for	_	IN	IN	_	121	ADV	_	_
123	I	_	NN	NN	_	124	AMOD	_	_
124	kappa	_	NN	NN	_	126	NMOD	_	_
125	B-mediated	_	JJ	JJ	_	124	AMOD	_	_
126	inhibition	_	NN	NN	_	122	PMOD	_	_
127	of	_	IN	IN	_	126	NMOD	_	_
128	NF-kappa	_	NN	NN	_	133	NMOD	_	_
129	B	_	NN	NN	_	133	NMOD	_	_
130	p65	_	NN	NN	_	133	NMOD	_	_
131	DNA	_	NN	NN	_	133	NMOD	_	_
132	binding	_	NN	NN	_	133	NMOD	_	_
133	activity	_	NN	NN	_	127	PMOD	_	_
134	.	_	.	.	_	24	P	_	_

1	Together	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	findings	_	NNS	NNS	_	5	SBJ	_	_
5	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	nuclear	_	JJ	JJ	_	10	NMOD	_	_
9	localization	_	NN	NN	_	10	NMOD	_	_
10	signal	_	NN	NN	_	18	SBJ	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	transactivation	_	NN	NN	_	13	NMOD	_	_
13	domain	_	NN	NN	_	10	COORD	_	_
14	of	_	IN	IN	_	10	NMOD	_	_
15	NF-kappa	_	NN	NN	_	17	NMOD	_	_
16	B	_	NN	NN	_	17	NMOD	_	_
17	p65	_	NN	NN	_	14	PMOD	_	_
18	constitute	_	VBP	VBP	_	6	VMOD	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	bipartite	_	JJ	JJ	_	21	NMOD	_	_
21	system	_	NN	NN	_	18	OBJ	_	_
22	that	_	WDT	WDT	_	23	SBJ	_	_
23	is	_	VBZ	VBZ	_	21	NMOD	_	_
24	critically	_	RB	RB	_	23	ADV	_	_
25	involved	_	VBN	VBN	_	23	VC	_	_
26	in	_	IN	IN	_	25	ADV	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	inhibitory	_	JJ	JJ	_	29	NMOD	_	_
29	function	_	NN	NN	_	26	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	I	_	NN	NN	_	33	NMOD	_	_
32	kappa	_	NN	NN	_	33	NMOD	_	_
33	B\/MAD-3	_	NN	NN	_	30	PMOD	_	_
34	.	_	.	.	_	5	P	_	_

1	Unexpectedly	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	our	_	PRP$	PRP$	_	6	NMOD	_	_
4	in	_	FW	FW	_	5	AMOD	_	_
5	vivo	_	FW	FW	_	6	NMOD	_	_
6	studies	_	NNS	NNS	_	8	SBJ	_	_
7	also	_	RB	RB	_	8	ADV	_	_
8	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	I	_	NN	NN	_	12	NMOD	_	_
11	kappa	_	NN	NN	_	12	NMOD	_	_
12	B\/MAD-3	_	NN	NN	_	13	SBJ	_	_
13	binds	_	VBZ	VBZ	_	9	VMOD	_	_
14	directly	_	RB	RB	_	13	ADV	_	_
15	to	_	TO	TO	_	13	ADV	_	_
16	NF-kappa	_	NN	NN	_	18	NMOD	_	_
17	B	_	NN	NN	_	18	NMOD	_	_
18	p50	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	8	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	interaction	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	functional	_	JJ	JJ	_	3	PRD	_	_
5	as	_	IN	IN	_	3	ADV	_	_
6	it	_	PRP	PRP	_	7	SBJ	_	_
7	leads	_	VBZ	VBZ	_	5	VMOD	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	retargeting	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	NF-kappa	_	NN	NN	_	13	NMOD	_	_
12	B	_	NN	NN	_	13	NMOD	_	_
13	p50	_	NN	NN	_	10	PMOD	_	_
14	from	_	IN	IN	_	9	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	nucleus	_	NN	NN	_	14	PMOD	_	_
17	to	_	TO	TO	_	9	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	cytoplasm	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	no	_	DT	DT	_	4	NMOD	_	_
4	loss	_	NN	NN	_	9	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	DNA	_	NN	NN	_	8	NMOD	_	_
7	binding	_	NN	NN	_	8	NMOD	_	_
8	activity	_	NN	NN	_	5	PMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	observed	_	VBN	VBN	_	9	VC	_	_
11	,	_	,	,	_	10	P	_	_
12	presumably	_	RB	RB	_	13	ADV	_	_
13	reflecting	_	VBG	VBG	_	10	OBJ	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	unique	_	JJ	JJ	_	17	NMOD	_	_
16	C-terminal	_	JJ	JJ	_	17	NMOD	_	_
17	domain	_	NN	NN	_	13	OBJ	_	_
18	that	_	WDT	WDT	_	19	SBJ	_	_
19	is	_	VBZ	VBZ	_	17	NMOD	_	_
20	distinct	_	JJ	JJ	_	19	PRD	_	_
21	from	_	IN	IN	_	20	AMOD	_	_
22	that	_	DT	DT	_	21	PMOD	_	_
23	present	_	JJ	JJ	_	22	NMOD	_	_
24	in	_	IN	IN	_	23	AMOD	_	_
25	NF-kappa	_	NN	NN	_	27	NMOD	_	_
26	B	_	NN	NN	_	27	NMOD	_	_
27	p65	_	NN	NN	_	24	PMOD	_	_
28	.	_	.	.	_	9	P	_	_

1	Surrogate	_	NN	NN	_	3	NMOD	_	_
2	thyroglobulin	_	NN	NN	_	3	NMOD	_	_
3	receptors	_	NNS	NNS	_	0	ROOT-FRAG	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	T	_	NN	NN	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	proliferation	_	NN	NN	_	3	COORD	_	_
8	in	_	IN	IN	_	3	NMOD	_	_
9	Hashimoto	_	NN	NN	_	11	NMOD	_	_
10	's	_	POS	POS	_	9	NMOD	_	_
11	thyroiditis	_	NN	NN	_	8	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	Immunoglobulin	_	NN	NN	_	2	NMOD	_	_
2	molecules	_	NNS	NNS	_	10	SBJ	_	_
3	on	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	surface	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	lymphocyte	_	NN	NN	_	6	PMOD	_	_
10	are	_	VBP	VBP	_	0	ROOT-S	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	endogenous	_	JJ	JJ	_	14	NMOD	_	_
13	"	_	``	``	_	14	P	_	_
14	receptors	_	NNS	NNS	_	10	PRD	_	_
15	"	_	''	''	_	14	P	_	_
16	to	_	TO	TO	_	20	ADV	_	_
17	which	_	WDT	WDT	_	16	PMOD	_	_
18	specific	_	JJ	JJ	_	19	NMOD	_	_
19	antigens	_	NNS	NNS	_	20	SBJ	_	_
20	bind	_	VBP	VBP	_	14	NMOD	_	_
21	.	_	.	.	_	10	P	_	_

1	Studies	_	NNS	NNS	_	4	SBJ	_	_
2	in	_	IN	IN	_	1	NMOD	_	_
3	mice	_	NNS	NNS	_	2	PMOD	_	_
4	have	_	VBP	VBP	_	0	ROOT-S	_	_
5	shown	_	VBN	VBN	_	4	VC	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	monoclonal	_	JJ	JJ	_	9	NMOD	_	_
9	antibody	_	NN	NN	_	20	SBJ	_	_
10	,	_	,	,	_	9	P	_	_
11	conjugated	_	VBN	VBN	_	9	NMOD	_	_
12	with	_	IN	IN	_	11	ADV	_	_
13	palmitate	_	NN	NN	_	12	PMOD	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	provide	_	VB	VB	_	11	OBJ	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	lipid	_	NN	NN	_	18	NMOD	_	_
18	tail	_	NN	NN	_	15	OBJ	_	_
19	,	_	,	,	_	9	P	_	_
20	can	_	MD	MD	_	6	VMOD	_	_
21	be	_	VB	VB	_	20	VC	_	_
22	inserted	_	VBN	VBN	_	21	VC	_	_
23	into	_	IN	IN	_	22	ADV	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	cell	_	NN	NN	_	26	NMOD	_	_
26	membrane	_	NN	NN	_	23	PMOD	_	_
27	to	_	TO	TO	_	28	VMOD	_	_
28	provide	_	VB	VB	_	22	OBJ	_	_
29	a	_	DT	DT	_	34	NMOD	_	_
30	"	_	``	``	_	34	P	_	_
31	surrogate	_	JJ	JJ	_	34	NMOD	_	_
32	"	_	''	''	_	34	P	_	_
33	antigen	_	NN	NN	_	34	NMOD	_	_
34	receptor	_	NN	NN	_	28	OBJ	_	_
35	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	investigated	_	VBN	VBN	_	2	VC	_	_
4	whether	_	IN	IN	_	3	OBJ	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	palmitate	_	JJ	JJ	_	7	NMOD	_	_
7	conjugate	_	NN	NN	_	19	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	monoclonal	_	JJ	JJ	_	12	NMOD	_	_
12	antibody	_	NN	NN	_	8	PMOD	_	_
13	specific	_	JJ	JJ	_	7	NMOD	_	_
14	for	_	IN	IN	_	13	AMOD	_	_
15	thyroglobulin	_	NN	NN	_	14	PMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	TG	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	could	_	MD	MD	_	4	VMOD	_	_
20	function	_	VB	VB	_	19	VC	_	_
21	as	_	IN	IN	_	20	ADV	_	_
22	a	_	DT	DT	_	25	NMOD	_	_
23	surrogate	_	JJ	JJ	_	25	NMOD	_	_
24	TG	_	NN	NN	_	25	NMOD	_	_
25	receptor	_	NN	NN	_	21	PMOD	_	_
26	on	_	IN	IN	_	20	ADV	_	_
27	blood	_	NN	NN	_	29	NMOD	_	_
28	mononuclear	_	JJ	JJ	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	26	PMOD	_	_
30	separated	_	VBN	VBN	_	29	NMOD	_	_
31	into	_	IN	IN	_	30	ADV	_	_
32	fractions	_	NNS	NNS	_	31	PMOD	_	_
33	enriched	_	VBN	VBN	_	32	NMOD	_	_
34	for	_	IN	IN	_	33	ADV	_	_
35	T	_	NN	NN	_	36	NMOD	_	_
36	cells	_	NNS	NNS	_	34	PMOD	_	_
37	or	_	CC	CC	_	33	CC	_	_
38	depleted	_	VBN	VBN	_	33	COORD	_	_
39	of	_	IN	IN	_	38	ADV	_	_
40	T	_	NN	NN	_	41	NMOD	_	_
41	cells	_	NNS	NNS	_	39	PMOD	_	_
42	(	_	(	(	_	44	P	_	_
43	non-T	_	JJ	JJ	_	44	NMOD	_	_
44	cells	_	NNS	NNS	_	41	PRN	_	_
45	)	_	)	)	_	44	P	_	_
46	.	_	.	.	_	2	P	_	_

1	Using	_	VBG	VBG	_	6	ADV	_	_
2	flow	_	NN	NN	_	3	NMOD	_	_
3	cytometry	_	NN	NN	_	1	OBJ	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	detected	_	VBD	VBD	_	0	ROOT-S	_	_
7	surrogate	_	JJ	JJ	_	9	NMOD	_	_
8	TG	_	NN	NN	_	9	NMOD	_	_
9	receptors	_	NNS	NNS	_	6	OBJ	_	_
10	on	_	IN	IN	_	6	ADV	_	_
11	non-T	_	JJ	JJ	_	18	NMOD	_	_
12	(	_	(	(	_	10	P	_	_
13	but	_	CC	CC	_	10	CC	_	_
14	not	_	RB	RB	_	15	DEP	_	_
15	on	_	IN	IN	_	10	COORD	_	_
16	T	_	NN	NN	_	15	PMOD	_	_
17	)	_	)	)	_	10	P	_	_
18	cells	_	NNS	NNS	_	10	PMOD	_	_
19	from	_	IN	IN	_	18	NMOD	_	_
20	11	_	CD	CD	_	22	DEP	_	_
21	of	_	IN	IN	_	22	DEP	_	_
22	11	_	CD	CD	_	23	NMOD	_	_
23	individuals	_	NNS	NNS	_	19	PMOD	_	_
24	studied	_	VBN	VBN	_	23	NMOD	_	_
25	(	_	(	(	_	28	P	_	_
26	5	_	CD	CD	_	28	NMOD	_	_
27	Hashimoto	_	NN	NN	_	28	NMOD	_	_
28	patients	_	NNS	NNS	_	23	PRN	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	6	_	CD	CD	_	32	NMOD	_	_
31	control	_	NN	NN	_	32	NMOD	_	_
32	donors	_	NNS	NNS	_	28	COORD	_	_
33	)	_	)	)	_	28	P	_	_
34	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	7	P	_	_
4	endogenous	_	JJ	JJ	_	6	NMOD	_	_
5	TG	_	NN	NN	_	6	NMOD	_	_
6	receptors	_	NNS	NNS	_	7	SBJ	_	_
7	could	_	MD	MD	_	0	ROOT-S	_	_
8	only	_	RB	RB	_	7	ADV	_	_
9	be	_	VB	VB	_	7	VC	_	_
10	detected	_	VBN	VBN	_	9	VC	_	_
11	on	_	IN	IN	_	10	ADV	_	_
12	non-T	_	JJ	JJ	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	from	_	IN	IN	_	13	NMOD	_	_
15	1	_	CD	CD	_	17	DEP	_	_
16	of	_	IN	IN	_	17	DEP	_	_
17	3	_	CD	CD	_	19	NMOD	_	_
18	Hashimoto	_	NN	NN	_	19	NMOD	_	_
19	patients	_	NNS	NNS	_	14	PMOD	_	_
20	and	_	CC	CC	_	14	CC	_	_
21	from	_	IN	IN	_	14	COORD	_	_
22	0	_	CD	CD	_	24	DEP	_	_
23	of	_	IN	IN	_	24	DEP	_	_
24	4	_	CD	CD	_	26	NMOD	_	_
25	control	_	NN	NN	_	26	NMOD	_	_
26	donors	_	NNS	NNS	_	21	PMOD	_	_
27	.	_	.	.	_	7	P	_	_

1	Because	_	IN	IN	_	16	ADV	_	_
2	of	_	IN	IN	_	1	DEP	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	efficient	_	JJ	JJ	_	5	NMOD	_	_
5	binding	_	NN	NN	_	1	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	TG	_	NN	NN	_	6	PMOD	_	_
8	by	_	IN	IN	_	5	NMOD	_	_
9	surrogate	_	JJ	JJ	_	10	NMOD	_	_
10	receptors	_	NNS	NNS	_	8	PMOD	_	_
11	on	_	IN	IN	_	5	NMOD	_	_
12	non-T	_	JJ	JJ	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	,	_	,	,	_	16	P	_	_
15	we	_	PRP	PRP	_	16	SBJ	_	_
16	assessed	_	VBD	VBD	_	0	ROOT-S	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	ability	_	NN	NN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	such	_	JJ	JJ	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	19	PMOD	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	present	_	VB	VB	_	18	NMOD	_	_
24	TG	_	NN	NN	_	23	OBJ	_	_
25	to	_	TO	TO	_	23	ADV	_	_
26	T	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	16	P	_	_

1	Proliferation	_	NN	NN	_	6	SBJ	_	_
2	in	_	IN	IN	_	1	NMOD	_	_
3	response	_	NN	NN	_	2	DEP	_	_
4	to	_	TO	TO	_	2	DEP	_	_
5	TG	_	NN	NN	_	2	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	observed	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	from	_	IN	IN	_	10	NMOD	_	_
12	only	_	RB	RB	_	17	NMOD	_	_
13	1	_	CD	CD	_	12	DEP	_	_
14	of	_	IN	IN	_	12	DEP	_	_
15	5	_	CD	CD	_	12	DEP	_	_
16	Hashimoto	_	NN	NN	_	17	NMOD	_	_
17	patients	_	NNS	NNS	_	11	PMOD	_	_
18	.	_	.	.	_	6	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	low	_	JJ	JJ	_	3	NMOD	_	_
3	frequency	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	response	_	NN	NN	_	4	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	no	_	RB	RB	_	8	AMOD	_	_
8	different	_	JJ	JJ	_	6	PRD	_	_
9	from	_	IN	IN	_	8	AMOD	_	_
10	that	_	DT	DT	_	9	PMOD	_	_
11	previously	_	RB	RB	_	12	ADV	_	_
12	detected	_	VBN	VBN	_	10	NMOD	_	_
13	using	_	VBG	VBG	_	12	OBJ	_	_
14	cultures	_	NNS	NNS	_	13	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	T	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	15	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	autologous	_	JJ	JJ	_	21	NMOD	_	_
20	dendritic	_	JJ	JJ	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	17	COORD	_	_
22	.	_	.	.	_	6	P	_	_

1	Therefore	_	RB	RB	_	12	ADV	_	_
2	,	_	,	,	_	12	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	successful	_	JJ	JJ	_	5	NMOD	_	_
5	generation	_	NN	NN	_	12	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	surrogate	_	JJ	JJ	_	8	NMOD	_	_
8	receptors	_	NNS	NNS	_	6	PMOD	_	_
9	on	_	IN	IN	_	5	NMOD	_	_
10	non-T	_	JJ	JJ	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	not	_	RB	RB	_	12	VMOD	_	_
14	associated	_	VBN	VBN	_	12	VC	_	_
15	with	_	IN	IN	_	14	ADV	_	_
16	more	_	RBR	RBR	_	17	AMOD	_	_
17	efficient	_	JJ	JJ	_	19	NMOD	_	_
18	TG	_	NN	NN	_	19	NMOD	_	_
19	presentation	_	NN	NN	_	15	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	T	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	12	P	_	_

1	Furthermore	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	significance	_	NN	NN	_	9	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	present	_	JJ	JJ	_	8	NMOD	_	_
8	study	_	NN	NN	_	5	PMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	that	_	IN	IN	_	9	PRD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	20	SBJ	_	_
14	,	_	,	,	_	13	P	_	_
15	not	_	RB	RB	_	13	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	antigen-presenting	_	JJ	JJ	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	13	NMOD	_	_
19	,	_	,	,	_	13	P	_	_
20	are	_	VBP	VBP	_	10	VMOD	_	_
21	likely	_	JJ	JJ	_	20	PRD	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	be	_	VB	VB	_	21	AMOD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	limiting	_	VBG	VBG	_	26	NMOD	_	_
26	element	_	NN	NN	_	23	PRD	_	_
27	in	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	32	NMOD	_	_
29	T	_	NN	NN	_	32	NMOD	_	_
30	cell	_	NN	NN	_	32	NMOD	_	_
31	proliferative	_	JJ	JJ	_	32	NMOD	_	_
32	response	_	NN	NN	_	27	PMOD	_	_
33	to	_	TO	TO	_	32	NMOD	_	_
34	TG	_	NN	NN	_	33	PMOD	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	other	_	JJ	JJ	_	38	NMOD	_	_
37	thyroid	_	NN	NN	_	38	NMOD	_	_
38	autoantigens	_	NNS	NNS	_	34	COORD	_	_
39	.	_	.	.	_	9	P	_	_

1	ras	_	NN	NN	_	3	NMOD	_	_
2	protein	_	NN	NN	_	3	NMOD	_	_
3	activity	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	essential	_	JJ	JJ	_	4	PRD	_	_
6	for	_	IN	IN	_	5	AMOD	_	_
7	T-cell	_	NN	NN	_	11	NMOD	_	_
8	antigen	_	NN	NN	_	11	NMOD	_	_
9	receptor	_	NN	NN	_	11	NMOD	_	_
10	signal	_	NN	NN	_	11	NMOD	_	_
11	transduction	_	NN	NN	_	6	PMOD	_	_
12	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	14	ADV	_	_
2	a	_	DT	DT	_	5	NMOD	_	_
3	Jurkat	_	NN	NN	_	5	NMOD	_	_
4	cell	_	NN	NN	_	5	NMOD	_	_
5	model	_	NN	NN	_	1	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	T-cell	_	NN	NN	_	8	NMOD	_	_
8	activation	_	NN	NN	_	6	PMOD	_	_
9	an	_	DT	DT	_	13	NMOD	_	_
10	interleukin-2	_	NN	NN	_	13	NMOD	_	_
11	promoter\/reporter	_	NN	NN	_	13	NMOD	_	_
12	gene	_	NN	NN	_	13	NMOD	_	_
13	construct	_	NN	NN	_	14	SBJ	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	activated	_	VBN	VBN	_	14	VC	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	antigen	_	NN	NN	_	19	NMOD	_	_
18	receptor	_	NN	NN	_	19	NMOD	_	_
19	agonism	_	NN	NN	_	16	PMOD	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	combination	_	NN	NN	_	20	PMOD	_	_
22	with	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	lymphokine	_	NN	NN	_	25	NMOD	_	_
25	interleukin-1	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	14	P	_	_

1	Antigen	_	NN	NN	_	3	NMOD	_	_
2	receptor	_	NN	NN	_	3	NMOD	_	_
3	signals	_	NNS	NNS	_	4	SBJ	_	_
4	could	_	MD	MD	_	0	ROOT-S	_	_
5	be	_	VB	VB	_	4	VC	_	_
6	mimicked	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	suboptimal	_	JJ	JJ	_	9	NMOD	_	_
9	activation	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	protein	_	NN	NN	_	13	NMOD	_	_
12	kinase	_	NN	NN	_	13	NMOD	_	_
13	C	_	NN	NN	_	10	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	PKC	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	with	_	IN	IN	_	9	NMOD	_	_
18	phorbol	_	NN	NN	_	19	NMOD	_	_
19	esters	_	NNS	NNS	_	17	PMOD	_	_
20	in	_	IN	IN	_	6	ADV	_	_
21	combination	_	NN	NN	_	20	PMOD	_	_
22	with	_	IN	IN	_	21	NMOD	_	_
23	calcium	_	NN	NN	_	24	NMOD	_	_
24	mobilization	_	NN	NN	_	22	PMOD	_	_
25	by	_	IN	IN	_	24	NMOD	_	_
26	an	_	DT	DT	_	27	NMOD	_	_
27	ionophore	_	NN	NN	_	25	PMOD	_	_
28	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	cotransfection	_	NN	NN	_	3	NMOD	_	_
3	experiments	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	7	P	_	_
5	oncogenic	_	JJ	JJ	_	6	NMOD	_	_
6	rats	_	NNS	NNS	_	7	SBJ	_	_
7	obviated	_	VBD	VBD	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	need	_	NN	NN	_	7	OBJ	_	_
10	for	_	IN	IN	_	9	NMOD	_	_
11	PKC	_	NN	NN	_	12	NMOD	_	_
12	stimulation	_	NN	NN	_	10	PMOD	_	_
13	but	_	CC	CC	_	7	CC	_	_
14	did	_	VBD	VBD	_	7	COORD	_	_
15	not	_	RB	RB	_	14	VMOD	_	_
16	replace	_	VB	VB	_	14	VC	_	_
17	either	_	CC	CC	_	20	CC	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	calcium	_	NN	NN	_	20	NMOD	_	_
20	signal	_	NN	NN	_	16	OBJ	_	_
21	or	_	CC	CC	_	20	CC	_	_
22	interleukin-1	_	NN	NN	_	20	COORD	_	_
23	.	_	.	.	_	7	P	_	_

1	Activated	_	VBN	VBN	_	3	NMOD	_	_
2	ras	_	NN	NN	_	3	NMOD	_	_
3	expression	_	NN	NN	_	5	SBJ	_	_
4	also	_	RB	RB	_	5	ADV	_	_
5	replaced	_	VBD	VBD	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	requirement	_	NN	NN	_	5	OBJ	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	PKC	_	NN	NN	_	10	NMOD	_	_
10	stimulation	_	NN	NN	_	8	PMOD	_	_
11	in	_	IN	IN	_	7	NMOD	_	_
12	activation	_	NN	NN	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	T-cell	_	NN	NN	_	18	NMOD	_	_
16	transcription	_	NN	NN	_	18	NMOD	_	_
17	factor	_	NN	NN	_	18	NMOD	_	_
18	NF-AT	_	NN	NN	_	13	PMOD	_	_
19	.	_	.	.	_	5	P	_	_

1	A	_	DT	DT	_	5	NMOD	_	_
2	dominant	_	JJ	JJ	_	5	NMOD	_	_
3	inhibitory	_	JJ	JJ	_	5	NMOD	_	_
4	ras	_	NN	NN	_	5	NMOD	_	_
5	mutant	_	NN	NN	_	7	SBJ	_	_
6	specifically	_	RB	RB	_	7	ADV	_	_
7	blocked	_	VBD	VBD	_	0	ROOT-S	_	_
8	antigen	_	NN	NN	_	10	NMOD	_	_
9	receptor	_	NN	NN	_	10	NMOD	_	_
10	agonism	_	NN	NN	_	7	IOBJ	_	_
11	,	_	,	,	_	7	P	_	_
12	indicating	_	VBG	VBG	_	7	OBJ	_	_
13	that	_	IN	IN	_	12	OBJ	_	_
14	ras	_	NN	NN	_	15	NMOD	_	_
15	activity	_	NN	NN	_	16	SBJ	_	_
16	is	_	VBZ	VBZ	_	13	VMOD	_	_
17	required	_	VBN	VBN	_	16	VC	_	_
18	for	_	IN	IN	_	17	ADV	_	_
19	antigen	_	NN	NN	_	21	NMOD	_	_
20	receptor	_	NN	NN	_	21	NMOD	_	_
21	signaling	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	8	P	_	_
4	an	_	DT	DT	_	5	NMOD	_	_
5	inhibitor	_	NN	NN	_	8	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	PKC	_	NN	NN	_	6	PMOD	_	_
8	blocked	_	VBD	VBD	_	0	ROOT-S	_	_
9	both	_	CC	CC	_	11	CC	_	_
10	activated	_	VBD	VBD	_	11	NMOD	_	_
11	ras	_	NN	NN	_	8	IOBJ	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	phorbol	_	NN	NN	_	15	NMOD	_	_
14	ester	_	NN	NN	_	15	NMOD	_	_
15	stimulation	_	NN	NN	_	11	COORD	_	_
16	,	_	,	,	_	8	P	_	_
17	suggesting	_	VBG	VBG	_	8	OBJ	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	role	_	NN	NN	_	17	OBJ	_	_
20	for	_	IN	IN	_	19	NMOD	_	_
21	ras	_	NN	NN	_	20	PMOD	_	_
22	upstream	_	JJ	JJ	_	21	NMOD	_	_
23	of	_	IN	IN	_	22	AMOD	_	_
24	PKC	_	NN	NN	_	23	PMOD	_	_
25	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	c-rel	_	NN	NN	_	4	NMOD	_	_
3	protooncogene	_	NN	NN	_	4	NMOD	_	_
4	product	_	NN	NN	_	5	SBJ	_	_
5	represses	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	NF-kappa	_	NN	NN	_	7	AMOD	_	_
7	B	_	NN	NN	_	10	NMOD	_	_
8	p65-mediated	_	JJ	JJ	_	7	AMOD	_	_
9	transcriptional	_	JJ	JJ	_	10	NMOD	_	_
10	activation	_	NN	NN	_	5	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	long	_	JJ	JJ	_	15	NMOD	_	_
14	terminal	_	JJ	JJ	_	15	NMOD	_	_
15	repeat	_	NN	NN	_	11	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	type	_	NN	NN	_	21	NMOD	_	_
18	1	_	CD	CD	_	21	NMOD	_	_
19	human	_	JJ	JJ	_	21	NMOD	_	_
20	immunodeficiency	_	NN	NN	_	21	NMOD	_	_
21	virus	_	NN	NN	_	16	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	long	_	JJ	JJ	_	4	NMOD	_	_
3	terminal	_	JJ	JJ	_	4	NMOD	_	_
4	repeat	_	NN	NN	_	37	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	LTR	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	of	_	IN	IN	_	4	NMOD	_	_
9	the	_	DT	DT	_	14	NMOD	_	_
10	type	_	NN	NN	_	14	NMOD	_	_
11	1	_	CD	CD	_	14	NMOD	_	_
12	human	_	JJ	JJ	_	14	NMOD	_	_
13	immunodeficiency	_	NN	NN	_	14	NMOD	_	_
14	virus	_	NN	NN	_	8	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	HIV-1	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	and	_	CC	CC	_	4	CC	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	5'	_	JJ	JJ	_	22	NMOD	_	_
21	regulatory	_	JJ	JJ	_	22	NMOD	_	_
22	region	_	NN	NN	_	4	COORD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	gene	_	NN	NN	_	23	PMOD	_	_
26	encoding	_	VBG	VBG	_	25	NMOD	_	_
27	the	_	DT	DT	_	32	NMOD	_	_
28	interleukin	_	NN	NN	_	32	NMOD	_	_
29	2	_	CD	CD	_	32	NMOD	_	_
30	receptor	_	NN	NN	_	32	NMOD	_	_
31	alpha	_	NN	NN	_	32	NMOD	_	_
32	subunit	_	NN	NN	_	26	OBJ	_	_
33	(	_	(	(	_	35	P	_	_
34	IL-2R	_	NN	NN	_	35	NMOD	_	_
35	alpha	_	NN	NN	_	32	PRN	_	_
36	)	_	)	)	_	35	P	_	_
37	share	_	NN	NN	_	0	ROOT-S	_	_
38	functional	_	JJ	JJ	_	42	NMOD	_	_
39	kappa	_	NN	NN	_	42	NMOD	_	_
40	B	_	NN	NN	_	42	NMOD	_	_
41	enhancer	_	NN	NN	_	42	NMOD	_	_
42	elements	_	NNS	NNS	_	37	OBJ	_	_
43	involved	_	VBN	VBN	_	42	NMOD	_	_
44	in	_	IN	IN	_	43	ADV	_	_
45	the	_	DT	DT	_	46	NMOD	_	_
46	regulation	_	NN	NN	_	44	PMOD	_	_
47	of	_	IN	IN	_	46	NMOD	_	_
48	these	_	DT	DT	_	51	NMOD	_	_
49	inducible	_	JJ	JJ	_	51	NMOD	_	_
50	transcription	_	NN	NN	_	51	NMOD	_	_
51	units	_	NNS	NNS	_	47	PMOD	_	_
52	during	_	IN	IN	_	46	TMP	_	_
53	T-cell	_	NN	NN	_	54	NMOD	_	_
54	activation	_	NN	NN	_	52	PMOD	_	_
55	.	_	.	.	_	37	P	_	_

1	These	_	DT	DT	_	5	NMOD	_	_
2	kappa	_	NN	NN	_	5	NMOD	_	_
3	B	_	NN	NN	_	5	NMOD	_	_
4	enhancer	_	NN	NN	_	5	NMOD	_	_
5	elements	_	NNS	NNS	_	6	SBJ	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	recognized	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	ADV	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	structurally	_	RB	RB	_	11	AMOD	_	_
11	related	_	JJ	JJ	_	12	NMOD	_	_
12	family	_	NN	NN	_	8	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	interactive	_	JJ	JJ	_	15	NMOD	_	_
15	proteins	_	NNS	NNS	_	13	PMOD	_	_
16	that	_	WDT	WDT	_	17	SBJ	_	_
17	includes	_	VBZ	VBZ	_	12	NMOD	_	_
18	p50	_	NN	NN	_	17	OBJ	_	_
19	,	_	,	,	_	18	P	_	_
20	p65	_	NN	NN	_	18	COORD	_	_
21	,	_	,	,	_	18	P	_	_
22	and	_	CC	CC	_	18	CC	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	product	_	NN	NN	_	18	COORD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	c-rel	_	NN	NN	_	28	NMOD	_	_
28	protooncogene	_	NN	NN	_	25	PMOD	_	_
29	(	_	(	(	_	30	P	_	_
30	c-Rel	_	NN	NN	_	24	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	.	_	.	.	_	6	P	_	_

1	Recent	_	JJ	JJ	_	3	NMOD	_	_
2	biochemical	_	JJ	JJ	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	4	SBJ	_	_
4	have	_	VBP	VBP	_	0	ROOT-S	_	_
5	shown	_	VBN	VBN	_	4	VC	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	p65	_	NN	NN	_	10	SBJ	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	p50	_	NN	NN	_	7	COORD	_	_
10	form	_	VBP	VBP	_	6	VMOD	_	_
11	the	_	DT	DT	_	15	NMOD	_	_
12	prototypical	_	JJ	JJ	_	15	NMOD	_	_
13	NF-kappa	_	NN	NN	_	15	NMOD	_	_
14	B	_	NN	NN	_	15	NMOD	_	_
15	complex	_	NN	NN	_	10	OBJ	_	_
16	,	_	,	,	_	15	P	_	_
17	which	_	WDT	WDT	_	18	SBJ	_	_
18	is	_	VBZ	VBZ	_	15	NMOD	_	_
19	rapidly	_	RB	RB	_	20	TMP	_	_
20	translocated	_	VBN	VBN	_	18	VC	_	_
21	from	_	IN	IN	_	20	ADV	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	cytoplasm	_	NN	NN	_	21	PMOD	_	_
24	to	_	TO	TO	_	20	ADV	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	nucleus	_	NN	NN	_	24	PMOD	_	_
27	during	_	IN	IN	_	20	TMP	_	_
28	T-cell	_	NN	NN	_	29	NMOD	_	_
29	activation	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	4	NMOD	_	_
2	intracellular	_	JJ	JJ	_	4	NMOD	_	_
3	signaling	_	NN	NN	_	4	NMOD	_	_
4	complex	_	NN	NN	_	6	SBJ	_	_
5	potently	_	RB	RB	_	6	ADV	_	_
6	stimulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	kappa	_	NN	NN	_	9	NMOD	_	_
8	B-directed	_	JJ	JJ	_	7	AMOD	_	_
9	transcription	_	NN	NN	_	6	OBJ	_	_
10	from	_	IN	IN	_	9	NMOD	_	_
11	either	_	CC	CC	_	14	CC	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	HIV-1	_	NN	NN	_	14	NMOD	_	_
14	LTR	_	NN	NN	_	10	PMOD	_	_
15	or	_	CC	CC	_	14	CC	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	IL-2R	_	NN	NN	_	19	NMOD	_	_
18	alpha	_	NN	NN	_	19	NMOD	_	_
19	promoter	_	NN	NN	_	14	COORD	_	_
20	via	_	IN	IN	_	6	ADV	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	strong	_	JJ	JJ	_	24	NMOD	_	_
23	transactivation	_	NN	NN	_	24	NMOD	_	_
24	domain	_	NN	NN	_	20	PMOD	_	_
25	present	_	JJ	JJ	_	24	NMOD	_	_
26	in	_	IN	IN	_	25	AMOD	_	_
27	p65	_	NN	NN	_	26	PMOD	_	_
28	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	now	_	RB	RB	_	3	TMP	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	nuclear	_	JJ	JJ	_	6	NMOD	_	_
6	expression	_	NN	NN	_	31	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	human	_	JJ	JJ	_	9	NMOD	_	_
9	c-Rel	_	NN	NN	_	7	PMOD	_	_
10	,	_	,	,	_	6	P	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	is	_	VBZ	VBZ	_	6	NMOD	_	_
13	induced	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	ADV	_	_
15	either	_	DT	DT	_	17	NMOD	_	_
16	phorbol	_	NN	NN	_	17	NMOD	_	_
17	ester	_	NN	NN	_	14	PMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	tumor	_	NN	NN	_	22	NMOD	_	_
20	necrosis	_	NN	NN	_	22	NMOD	_	_
21	factor	_	NN	NN	_	22	NMOD	_	_
22	alpha	_	NN	NN	_	17	COORD	_	_
23	with	_	IN	IN	_	13	ADV	_	_
24	delayed	_	VBN	VBN	_	25	NMOD	_	_
25	kinetics	_	NNS	NNS	_	23	PMOD	_	_
26	relative	_	JJ	JJ	_	25	NMOD	_	_
27	to	_	TO	TO	_	26	AMOD	_	_
28	p65	_	NN	NN	_	27	PMOD	_	_
29	,	_	,	,	_	6	P	_	_
30	markedly	_	RB	RB	_	31	ADV	_	_
31	represses	_	VBZ	VBZ	_	4	VMOD	_	_
32	p65-mediated	_	JJ	JJ	_	33	NMOD	_	_
33	activation	_	NN	NN	_	31	OBJ	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	these	_	DT	DT	_	37	NMOD	_	_
36	transcription	_	NN	NN	_	37	NMOD	_	_
37	units	_	NNS	NNS	_	34	PMOD	_	_
38	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	3	NMOD	_	_
2	inhibitory	_	JJ	JJ	_	3	NMOD	_	_
3	effects	_	NNS	NNS	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	c-Rel	_	NN	NN	_	4	PMOD	_	_
6	correlate	_	VBP	VBP	_	0	ROOT-S	_	_
7	with	_	IN	IN	_	6	ADV	_	_
8	its	_	PRP$	PRP$	_	10	NMOD	_	_
9	DNA-binding	_	JJ	JJ	_	10	NMOD	_	_
10	activity	_	NN	NN	_	7	PMOD	_	_
11	but	_	CC	CC	_	7	CC	_	_
12	not	_	RB	RB	_	13	DEP	_	_
13	with	_	IN	IN	_	7	COORD	_	_
14	its	_	PRP$	PRP$	_	15	NMOD	_	_
15	ability	_	NN	NN	_	13	PMOD	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	heterodimerize	_	VB	VB	_	15	NMOD	_	_
18	with	_	IN	IN	_	17	ADV	_	_
19	p50	_	NN	NN	_	18	PMOD	_	_
20	,	_	,	,	_	6	P	_	_
21	suggesting	_	VBG	VBG	_	6	OBJ	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	c-Rel	_	NN	NN	_	24	NMOD	_	_
24	inhibition	_	NN	NN	_	25	SBJ	_	_
25	involves	_	VBZ	VBZ	_	22	VMOD	_	_
26	competition	_	NN	NN	_	25	OBJ	_	_
27	with	_	IN	IN	_	26	NMOD	_	_
28	p50\/p65	_	NN	NN	_	27	PMOD	_	_
29	for	_	IN	IN	_	26	NMOD	_	_
30	occupancy	_	NN	NN	_	29	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	36	NMOD	_	_
33	kappa	_	NN	NN	_	36	NMOD	_	_
34	B	_	NN	NN	_	36	NMOD	_	_
35	enhancer	_	NN	NN	_	36	NMOD	_	_
36	element	_	NN	NN	_	31	PMOD	_	_
37	.	_	.	.	_	6	P	_	_

1	Together	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	findings	_	NNS	NNS	_	5	SBJ	_	_
5	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	one	_	CD	CD	_	8	NMOD	_	_
8	function	_	NN	NN	_	11	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	c-Rel	_	NN	NN	_	9	PMOD	_	_
11	is	_	VBZ	VBZ	_	6	VMOD	_	_
12	as	_	IN	IN	_	25	ADV	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	physiologic	_	JJ	JJ	_	15	NMOD	_	_
15	repressor	_	NN	NN	_	12	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	23	NMOD	_	_
18	HIV-1	_	NN	NN	_	19	NMOD	_	_
19	LTR	_	NN	NN	_	23	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	IL-2R	_	NN	NN	_	22	NMOD	_	_
22	alpha	_	NN	NN	_	19	COORD	_	_
23	promoters	_	NNS	NNS	_	16	PMOD	_	_
24	,	_	,	,	_	25	P	_	_
25	serving	_	VBG	VBG	_	11	PRD	_	_
26	to	_	TO	TO	_	28	VMOD	_	_
27	efficiently	_	RB	RB	_	28	ADV	_	_
28	counter	_	VB	VB	_	25	OBJ	_	_
29	the	_	DT	DT	_	33	NMOD	_	_
30	strong	_	JJ	JJ	_	33	NMOD	_	_
31	transcriptional	_	JJ	JJ	_	33	NMOD	_	_
32	activating	_	JJ	JJ	_	33	NMOD	_	_
33	effects	_	NNS	NNS	_	28	OBJ	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	p65	_	NN	NN	_	34	PMOD	_	_
36	.	_	.	.	_	5	P	_	_

1	Replication	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	type	_	NN	NN	_	7	NMOD	_	_
4	1	_	CD	CD	_	7	NMOD	_	_
5	human	_	JJ	JJ	_	7	NMOD	_	_
6	immunodeficiency	_	NN	NN	_	7	NMOD	_	_
7	viruses	_	NNS	NNS	_	2	PMOD	_	_
8	containing	_	VBG	VBG	_	7	NMOD	_	_
9	linker	_	NN	NN	_	11	NMOD	_	_
10	substitution	_	NN	NN	_	11	NMOD	_	_
11	mutations	_	NNS	NNS	_	8	OBJ	_	_
12	in	_	IN	IN	_	8	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	-201	_	CD	CD	_	12	PMOD	_	_
15	to	_	TO	TO	_	14	NMOD	_	_
16	-130	_	CD	CD	_	14	NMOD	_	_
17	region	_	NN	NN	_	14	NMOD	_	_
18	of	_	IN	IN	_	14	NMOD	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	long	_	JJ	JJ	_	22	NMOD	_	_
21	terminal	_	JJ	JJ	_	22	NMOD	_	_
22	repeat	_	NN	NN	_	18	PMOD	_	_
23	.	_	.	.	_	1	P	_	_

1	In	_	IN	IN	_	14	ADV	_	_
2	previous	_	JJ	JJ	_	4	NMOD	_	_
3	transfection	_	NN	NN	_	4	NMOD	_	_
4	analyses	_	NNS	NNS	_	1	PMOD	_	_
5	using	_	VBG	VBG	_	4	NMOD	_	_
6	the	_	DT	DT	_	11	NMOD	_	_
7	chloramphenicol	_	JJ	JJ	_	11	NMOD	_	_
8	acetyltransferase	_	NN	NN	_	11	NMOD	_	_
9	reporter	_	NN	NN	_	11	NMOD	_	_
10	gene	_	NN	NN	_	11	NMOD	_	_
11	system	_	NN	NN	_	5	OBJ	_	_
12	,	_	,	,	_	14	P	_	_
13	we	_	PRP	PRP	_	14	SBJ	_	_
14	determined	_	VBD	VBD	_	0	ROOT-S	_	_
15	that	_	IN	IN	_	14	OBJ	_	_
16	linker	_	NN	NN	_	17	NMOD	_	_
17	substitution	_	NN	NN	_	21	NMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	LS	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	mutations	_	NNS	NNS	_	47	SBJ	_	_
22	between	_	IN	IN	_	21	NMOD	_	_
23	-201	_	CD	CD	_	22	PMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	-130	_	CD	CD	_	23	COORD	_	_
26	(	_	(	(	_	23	P	_	_
27	relative	_	JJ	JJ	_	23	NMOD	_	_
28	to	_	TO	TO	_	27	AMOD	_	_
29	the	_	DT	DT	_	32	NMOD	_	_
30	transcription	_	NN	NN	_	32	NMOD	_	_
31	start	_	NN	NN	_	32	NMOD	_	_
32	site	_	NN	NN	_	28	PMOD	_	_
33	)	_	)	)	_	23	P	_	_
34	of	_	IN	IN	_	23	NMOD	_	_
35	the	_	DT	DT	_	39	NMOD	_	_
36	human	_	JJ	JJ	_	39	NMOD	_	_
37	immunodeficiency	_	NN	NN	_	39	NMOD	_	_
38	virus	_	NN	NN	_	39	NMOD	_	_
39	type	_	NN	NN	_	34	PMOD	_	_
40	1	_	CD	CD	_	39	NMOD	_	_
41	long	_	JJ	JJ	_	43	NMOD	_	_
42	terminal	_	JJ	JJ	_	43	NMOD	_	_
43	repeat	_	NN	NN	_	39	NMOD	_	_
44	(	_	(	(	_	45	P	_	_
45	LTR	_	NN	NN	_	43	PRN	_	_
46	)	_	)	)	_	45	P	_	_
47	caused	_	VBD	VBD	_	15	VMOD	_	_
48	moderate	_	JJ	JJ	_	49	NMOD	_	_
49	decreases	_	NNS	NNS	_	47	OBJ	_	_
50	in	_	IN	IN	_	49	NMOD	_	_
51	LTR	_	NN	NN	_	53	NMOD	_	_
52	transcriptional	_	JJ	JJ	_	53	NMOD	_	_
53	activity	_	NN	NN	_	50	PMOD	_	_
54	in	_	IN	IN	_	53	NMOD	_	_
55	a	_	DT	DT	_	57	NMOD	_	_
56	T-cell	_	NN	NN	_	57	NMOD	_	_
57	line	_	NN	NN	_	54	PMOD	_	_
58	(	_	(	(	_	14	PRN	_	_
59	S.L.Zeichner	_	NNP	NNP	_	58	DEP	_	_
60	,	_	,	,	_	59	P	_	_
61	J.Y.H.	_	NNP	NNP	_	62	NMOD	_	_
62	Kim	_	NNP	NNP	_	59	COORD	_	_
63	,	_	,	,	_	59	P	_	_
64	and	_	CC	CC	_	59	CC	_	_
65	J.C.Alwine	_	NNP	NNP	_	59	COORD	_	_
66	,	_	,	,	_	59	P	_	_
67	J.Virol.65	_	NNP	NNP	_	59	COORD	_	_
68	:	_	:	:	_	59	P	_	_
69	2436-2444	_	CD	CD	_	59	COORD	_	_
70	,	_	,	,	_	59	P	_	_
71	1991	_	CD	CD	_	59	COORD	_	_
72	)	_	)	)	_	58	P	_	_
73	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	15	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	15	P	_	_
4	two	_	CD	CD	_	5	NMOD	_	_
5	mutations	_	NNS	NNS	_	15	SBJ	_	_
6	between	_	IN	IN	_	5	NMOD	_	_
7	-93	_	CD	CD	_	6	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	-76	_	CD	CD	_	7	COORD	_	_
10	and	_	CC	CC	_	6	CC	_	_
11	between	_	IN	IN	_	6	COORD	_	_
12	-75	_	CD	CD	_	11	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	-58	_	CD	CD	_	12	COORD	_	_
15	were	_	VBD	VBD	_	0	ROOT-S	_	_
16	utilized	_	VBN	VBN	_	15	VC	_	_
17	,	_	,	,	_	16	P	_	_
18	since	_	IN	IN	_	16	ADV	_	_
19	they	_	PRP	PRP	_	20	SBJ	_	_
20	affect	_	VBP	VBP	_	18	VMOD	_	_
21	the	_	DT	DT	_	33	NMOD	_	_
22	nuclear	_	JJ	JJ	_	25	NMOD	_	_
23	factor	_	NN	NN	_	25	NMOD	_	_
24	kappa	_	NN	NN	_	25	NMOD	_	_
25	B	_	NN	NN	_	33	NMOD	_	_
26	(	_	(	(	_	28	P	_	_
27	NF-kappa	_	NN	NN	_	28	NMOD	_	_
28	B	_	NN	NN	_	25	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	-	_	:	:	_	25	P	_	_
31	and	_	CC	CC	_	25	CC	_	_
32	Sp1-binding	_	JJ	JJ	_	25	COORD	_	_
33	sites	_	NNS	NNS	_	20	OBJ	_	_
34	and	_	CC	CC	_	20	CC	_	_
35	were	_	VBD	VBD	_	20	COORD	_	_
36	expected	_	VBN	VBN	_	35	VC	_	_
37	to	_	TO	TO	_	38	VMOD	_	_
38	diminish	_	VB	VB	_	36	OBJ	_	_
39	viral	_	JJ	JJ	_	40	NMOD	_	_
40	replication	_	NN	NN	_	38	OBJ	_	_
41	.	_	.	.	_	15	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	while	_	IN	IN	_	30	ADV	_	_
6	transfection	_	NN	NN	_	7	NMOD	_	_
7	analyses	_	NNS	NNS	_	8	SBJ	_	_
8	offer	_	VBP	VBP	_	5	VMOD	_	_
9	an	_	DT	DT	_	11	NMOD	_	_
10	adequate	_	JJ	JJ	_	11	NMOD	_	_
11	approximation	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	effects	_	NNS	NNS	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	LS	_	NN	NN	_	18	NMOD	_	_
18	mutations	_	NNS	NNS	_	15	PMOD	_	_
19	,	_	,	,	_	30	P	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	analysis	_	NN	NN	_	30	SBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	viral	_	JJ	JJ	_	24	NMOD	_	_
24	replication	_	NN	NN	_	22	PMOD	_	_
25	using	_	VBG	VBG	_	24	NMOD	_	_
26	a	_	DT	DT	_	29	NMOD	_	_
27	mutant	_	JJ	JJ	_	29	NMOD	_	_
28	viral	_	JJ	JJ	_	29	NMOD	_	_
29	stock	_	NN	NN	_	25	OBJ	_	_
30	presents	_	VBZ	VBZ	_	4	VMOD	_	_
31	a	_	DT	DT	_	34	NMOD	_	_
32	more	_	RBR	RBR	_	33	AMOD	_	_
33	accurate	_	JJ	JJ	_	34	NMOD	_	_
34	picture	_	NN	NN	_	30	OBJ	_	_
35	,	_	,	,	_	34	P	_	_
36	which	_	WDT	WDT	_	37	SBJ	_	_
37	is	_	VBZ	VBZ	_	34	NMOD	_	_
38	sometimes	_	RB	RB	_	37	TMP	_	_
39	at	_	IN	IN	_	37	PRD	_	_
40	variance	_	NN	NN	_	39	DEP	_	_
41	with	_	IN	IN	_	39	DEP	_	_
42	the	_	DT	DT	_	44	NMOD	_	_
43	transfection	_	NN	NN	_	44	NMOD	_	_
44	results	_	NNS	NNS	_	39	PMOD	_	_
45	.	_	.	.	_	3	P	_	_

1	Three	_	CD	CD	_	2	NMOD	_	_
2	mutants	_	NNS	NNS	_	14	SBJ	_	_
3	(	_	(	(	_	5	P	_	_
4	-201\/-184	_	CD	CD	_	5	NMOD	_	_
5	NXS	_	NN	NN	_	2	PRN	_	_
6	,	_	,	,	_	5	P	_	_
7	-165\/-148	_	CD	CD	_	8	NMOD	_	_
8	NXS	_	NN	NN	_	5	COORD	_	_
9	,	_	,	,	_	5	P	_	_
10	and	_	CC	CC	_	5	CC	_	_
11	-147\/-130	_	CD	CD	_	12	NMOD	_	_
12	NXS	_	NN	NN	_	5	COORD	_	_
13	)	_	)	)	_	5	P	_	_
14	had	_	VBD	VBD	_	0	ROOT-S	_	_
15	effects	_	NNS	NNS	_	14	OBJ	_	_
16	on	_	IN	IN	_	14	ADV	_	_
17	viral	_	JJ	JJ	_	18	NMOD	_	_
18	replication	_	NN	NN	_	16	PMOD	_	_
19	that	_	WDT	WDT	_	20	SBJ	_	_
20	were	_	VBD	VBD	_	15	NMOD	_	_
21	much	_	RB	RB	_	20	PRD	_	_
22	more	_	RBR	RBR	_	21	AMOD	_	_
23	severe	_	JJ	JJ	_	21	AMOD	_	_
24	than	_	IN	IN	_	21	AMOD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	effects	_	NNS	NNS	_	24	PMOD	_	_
27	predicted	_	VBN	VBN	_	26	NMOD	_	_
28	from	_	IN	IN	_	27	ADV	_	_
29	their	_	PRP$	PRP$	_	30	NMOD	_	_
30	performance	_	NN	NN	_	28	PMOD	_	_
31	in	_	IN	IN	_	30	NMOD	_	_
32	transfection	_	NN	NN	_	33	NMOD	_	_
33	analyses	_	NNS	NNS	_	31	PMOD	_	_
34	,	_	,	,	_	14	P	_	_
35	and	_	CC	CC	_	14	CC	_	_
36	the	_	DT	DT	_	37	NMOD	_	_
37	effects	_	NNS	NNS	_	49	SBJ	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	two	_	CD	CD	_	41	NMOD	_	_
40	LS	_	NN	NN	_	41	NMOD	_	_
41	mutations	_	NNS	NNS	_	38	PMOD	_	_
42	(	_	(	(	_	44	P	_	_
43	-201\/-184	_	CD	CD	_	44	NMOD	_	_
44	NXS	_	NN	NN	_	41	PRN	_	_
45	and	_	CC	CC	_	44	CC	_	_
46	-183\/-166	_	CD	CD	_	47	NMOD	_	_
47	NXS	_	NN	NN	_	44	COORD	_	_
48	)	_	)	)	_	44	P	_	_
49	were	_	VBD	VBD	_	14	COORD	_	_
50	not	_	RB	RB	_	49	VMOD	_	_
51	predicted	_	VBN	VBN	_	49	VC	_	_
52	by	_	IN	IN	_	51	ADV	_	_
53	their	_	PRP$	PRP$	_	54	NMOD	_	_
54	effects	_	NNS	NNS	_	52	PMOD	_	_
55	in	_	IN	IN	_	54	NMOD	_	_
56	transfection	_	NN	NN	_	55	PMOD	_	_
57	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	observed	_	VBD	VBD	_	0	ROOT-S	_	_
6	cell	_	NN	NN	_	8	NMOD	_	_
7	type-specific	_	JJ	JJ	_	6	AMOD	_	_
8	permissiveness	_	NN	NN	_	5	OBJ	_	_
9	to	_	TO	TO	_	8	NMOD	_	_
10	replication	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	some	_	DT	DT	_	14	NMOD	_	_
13	mutant	_	JJ	JJ	_	14	NMOD	_	_
14	viruses	_	NNS	NNS	_	11	PMOD	_	_
15	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	cell	_	NN	NN	_	4	NMOD	_	_
4	types	_	NNS	NNS	_	1	PMOD	_	_
5	tested	_	VBN	VBN	_	4	NMOD	_	_
6	,	_	,	,	_	10	P	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	LS	_	NN	NN	_	9	NMOD	_	_
9	mutations	_	NNS	NNS	_	10	SBJ	_	_
10	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
11	an	_	DT	DT	_	13	NMOD	_	_
12	apparent	_	JJ	JJ	_	13	NMOD	_	_
13	requirement	_	NN	NN	_	10	OBJ	_	_
14	not	_	RB	RB	_	13	NMOD	_	_
15	only	_	RB	RB	_	14	DEP	_	_
16	for	_	IN	IN	_	14	COORD	_	_
17	the	_	DT	DT	_	23	NMOD	_	_
18	intact	_	JJ	JJ	_	23	NMOD	_	_
19	NF-kappa	_	NN	NN	_	20	NMOD	_	_
20	B	_	NN	NN	_	23	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	SP1-binding	_	JJ	JJ	_	20	COORD	_	_
23	sites	_	NNS	NNS	_	16	PMOD	_	_
24	but	_	CC	CC	_	14	CC	_	_
25	also	_	RB	RB	_	24	COORD	_	_
26	for	_	IN	IN	_	14	COORD	_	_
27	several	_	JJ	JJ	_	28	NMOD	_	_
28	regions	_	NNS	NNS	_	26	PMOD	_	_
29	between	_	IN	IN	_	28	NMOD	_	_
30	-201	_	CD	CD	_	29	PMOD	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	-130	_	CD	CD	_	30	COORD	_	_
33	not	_	RB	RB	_	35	VMOD	_	_
34	previously	_	RB	RB	_	35	TMP	_	_
35	associated	_	VBN	VBN	_	28	NMOD	_	_
36	with	_	IN	IN	_	35	ADV	_	_
37	viral	_	JJ	JJ	_	38	NMOD	_	_
38	infectivity	_	NN	NN	_	36	PMOD	_	_
39	.	_	.	.	_	10	P	_	_

1	Expression	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	PILOT	_	NN	NN	_	2	PMOD	_	_
4	,	_	,	,	_	3	P	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	putative	_	JJ	JJ	_	8	NMOD	_	_
7	transcription	_	NN	NN	_	8	NMOD	_	_
8	factor	_	NN	NN	_	3	NMOD	_	_
9	,	_	,	,	_	3	P	_	_
10	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	two	_	CD	CD	_	12	NMOD	_	_
12	signals	_	NNS	NNS	_	10	OBJ	_	_
13	and	_	CC	CC	_	10	CC	_	_
14	is	_	VBZ	VBZ	_	10	COORD	_	_
15	cyclosporin	_	NN	NN	_	16	NMOD	_	_
16	A	_	NN	NN	_	17	AMOD	_	_
17	sensitive	_	JJ	JJ	_	14	PRD	_	_
18	in	_	IN	IN	_	10	ADV	_	_
19	T	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	10	P	_	_

1	Few	_	JJ	JJ	_	3	NMOD	_	_
2	known	_	JJ	JJ	_	3	NMOD	_	_
3	genes	_	NNS	NNS	_	15	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	IL-2	_	NN	NN	_	3	PRN	_	_
6	,	_	,	,	_	5	P	_	_
7	members	_	NNS	NNS	_	5	NMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	IL-8	_	NN	NN	_	11	NMOD	_	_
11	family	_	NN	NN	_	8	PMOD	_	_
12	,	_	,	,	_	5	P	_	_
13	interferon-gamma	_	NN	NN	_	5	NMOD	_	_
14	)	_	)	)	_	5	P	_	_
15	are	_	VBP	VBP	_	0	ROOT-S	_	_
16	induced	_	VBN	VBN	_	15	VC	_	_
17	in	_	IN	IN	_	16	ADV	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	17	PMOD	_	_
20	only	_	RB	RB	_	21	DEP	_	_
21	through	_	IN	IN	_	16	ADV	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	combined	_	JJ	JJ	_	24	NMOD	_	_
24	effect	_	NN	NN	_	21	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	phorbol	_	NN	NN	_	28	NMOD	_	_
27	myristic	_	JJ	JJ	_	28	NMOD	_	_
28	acetate	_	NN	NN	_	25	PMOD	_	_
29	(	_	(	(	_	30	P	_	_
30	PMA	_	NN	NN	_	28	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	and	_	CC	CC	_	28	CC	_	_
33	a	_	DT	DT	_	34	NMOD	_	_
34	Ca-LRB-2+-RRB--ionophore	_	NN	NN	_	28	COORD	_	_
35	,	_	,	,	_	15	P	_	_
36	and	_	CC	CC	_	15	CC	_	_
37	expression	_	NN	NN	_	42	SBJ	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	only	_	RB	RB	_	41	NMOD	_	_
40	these	_	DT	DT	_	41	NMOD	_	_
41	genes	_	NNS	NNS	_	38	PMOD	_	_
42	can	_	MD	MD	_	15	COORD	_	_
43	be	_	VB	VB	_	42	VC	_	_
44	fully	_	RB	RB	_	45	ADV	_	_
45	suppressed	_	VBN	VBN	_	43	VC	_	_
46	by	_	IN	IN	_	45	LGS	_	_
47	Cyclosporin	_	NN	NN	_	48	NMOD	_	_
48	A	_	NN	NN	_	46	PMOD	_	_
49	(	_	(	(	_	50	P	_	_
50	CyA	_	NN	NN	_	48	PRN	_	_
51	)	_	)	)	_	50	P	_	_
52	.	_	.	.	_	15	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	identified	_	VBN	VBN	_	2	VC	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	putative	_	JJ	JJ	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factor	_	NN	NN	_	3	OBJ	_	_
8	,	_	,	,	_	7	P	_	_
9	designated	_	VBN	VBN	_	7	NMOD	_	_
10	PILOT	_	NN	NN	_	9	OBJ	_	_
11	,	_	,	,	_	7	P	_	_
12	with	_	IN	IN	_	7	NMOD	_	_
13	an	_	DT	DT	_	17	NMOD	_	_
14	identical	_	JJ	JJ	_	17	NMOD	_	_
15	dual	_	JJ	JJ	_	17	NMOD	_	_
16	signal	_	NN	NN	_	17	NMOD	_	_
17	requirement	_	NN	NN	_	12	PMOD	_	_
18	for	_	IN	IN	_	17	NMOD	_	_
19	expression	_	NN	NN	_	18	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	Induction	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	PILOT	_	NN	NN	_	5	NMOD	_	_
5	gene	_	NN	NN	_	2	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	detectable	_	JJ	JJ	_	6	PRD	_	_
8	in	_	IN	IN	_	6	ADV	_	_
9	human	_	JJ	JJ	_	11	NMOD	_	_
10	T	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	8	PMOD	_	_
12	20	_	CD	CD	_	13	NMOD	_	_
13	min	_	NN	NN	_	14	PMOD	_	_
14	following	_	VBG	VBG	_	6	TMP	_	_
15	activation	_	NN	NN	_	14	PMOD	_	_
16	in	_	IN	IN	_	6	ADV	_	_
17	the	_	DT	DT	_	16	DEP	_	_
18	presence	_	NN	NN	_	16	DEP	_	_
19	of	_	IN	IN	_	16	DEP	_	_
20	cycloheximide	_	NN	NN	_	16	PMOD	_	_
21	and	_	CC	CC	_	6	CC	_	_
22	is	_	VBZ	VBZ	_	6	COORD	_	_
23	fully	_	RB	RB	_	24	ADV	_	_
24	suppressed	_	VBN	VBN	_	22	VC	_	_
25	by	_	IN	IN	_	24	LGS	_	_
26	CyA	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	PILOT	_	NN	NN	_	3	NMOD	_	_
3	protein	_	NN	NN	_	4	SBJ	_	_
4	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	calculated	_	VBN	VBN	_	7	NMOD	_	_
7	M-LRB-r-RRB-	_	NN	NN	_	4	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	42.6	_	CD	CD	_	10	NMOD	_	_
10	kDa	_	NN	NN	_	8	PMOD	_	_
11	and	_	CC	CC	_	4	CC	_	_
12	contains	_	VBZ	VBZ	_	4	COORD	_	_
13	three	_	CD	CD	_	15	NMOD	_	_
14	zinc	_	NN	NN	_	15	NMOD	_	_
15	fingers	_	NNS	NNS	_	12	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	C2H2-type	_	NN	NN	_	16	PMOD	_	_
19	at	_	IN	IN	_	12	ADV	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	carboxyl-terminus	_	NN	NN	_	19	PMOD	_	_
22	which	_	WDT	WDT	_	23	SBJ	_	_
23	are	_	VBP	VBP	_	15	NMOD	_	_
24	highly	_	RB	RB	_	25	AMOD	_	_
25	homologous	_	JJ	JJ	_	23	PRD	_	_
26	to	_	TO	TO	_	25	AMOD	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	zinc	_	NN	NN	_	30	NMOD	_	_
29	finger	_	NN	NN	_	30	NMOD	_	_
30	regions	_	NNS	NNS	_	26	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	transcription	_	NN	NN	_	34	NMOD	_	_
34	factors	_	NNS	NNS	_	31	PMOD	_	_
35	EGR1	_	NNS	NNS	_	34	NMOD	_	_
36	,	_	,	,	_	35	P	_	_
37	EGR2	_	NNS	NNS	_	35	COORD	_	_
38	,	_	,	,	_	35	P	_	_
39	and	_	CC	CC	_	35	CC	_	_
40	pAT	_	NN	NN	_	35	COORD	_	_
41	133	_	CD	CD	_	40	NMOD	_	_
42	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	contrast	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	T	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	1	PMOD	_	_
6	,	_	,	,	_	12	P	_	_
7	in	_	IN	IN	_	12	ADV	_	_
8	fibroblasts	_	NNS	NNS	_	7	PMOD	_	_
9	PILOT	_	NN	NN	_	11	NMOD	_	_
10	gene	_	NN	NN	_	11	NMOD	_	_
11	expression	_	NN	NN	_	12	SBJ	_	_
12	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	only	_	RB	RB	_	15	NMOD	_	_
14	one	_	CD	CD	_	13	DEP	_	_
15	signal	_	NN	NN	_	12	OBJ	_	_
16	(	_	(	(	_	17	P	_	_
17	PMA	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	and	_	CC	CC	_	12	CC	_	_
20	is	_	VBZ	VBZ	_	12	COORD	_	_
21	not	_	RB	RB	_	20	VMOD	_	_
22	affected	_	VBN	VBN	_	20	VC	_	_
23	by	_	IN	IN	_	22	LGS	_	_
24	CyA	_	NN	NN	_	23	PMOD	_	_
25	.	_	.	.	_	12	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	observation	_	NN	NN	_	4	SBJ	_	_
3	directly	_	RB	RB	_	4	ADV	_	_
4	demonstrates	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	existence	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	12	NMOD	_	_
9	Ca2+	_	NN	NN	_	12	NMOD	_	_
10	signal-dependent	_	JJ	JJ	_	9	AMOD	_	_
11	regulatory	_	JJ	JJ	_	12	NMOD	_	_
12	element	_	NN	NN	_	7	PMOD	_	_
13	obligatory	_	JJ	JJ	_	12	NMOD	_	_
14	for	_	IN	IN	_	13	AMOD	_	_
15	expression	_	NN	NN	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	some	_	DT	DT	_	18	NMOD	_	_
18	genes	_	NNS	NNS	_	16	PMOD	_	_
19	in	_	IN	IN	_	15	NMOD	_	_
20	T	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	19	PMOD	_	_
22	but	_	CC	CC	_	19	CC	_	_
23	not	_	RB	RB	_	24	DEP	_	_
24	in	_	IN	IN	_	19	COORD	_	_
25	fibroblasts	_	NNS	NNS	_	24	PMOD	_	_
26	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	4	NMOD	_	_
2	differential	_	JJ	JJ	_	4	NMOD	_	_
3	expression	_	NN	NN	_	4	NMOD	_	_
4	model	_	NN	NN	_	5	SBJ	_	_
5	will	_	MD	MD	_	0	ROOT-S	_	_
6	be	_	VB	VB	_	5	VC	_	_
7	valuable	_	JJ	JJ	_	6	PRD	_	_
8	in	_	IN	IN	_	6	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	dissection	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	dual	_	JJ	JJ	_	15	NMOD	_	_
14	signal	_	NN	NN	_	15	NMOD	_	_
15	pathway	_	NN	NN	_	11	PMOD	_	_
16	in	_	IN	IN	_	10	NMOD	_	_
17	T	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	16	PMOD	_	_
19	and	_	CC	CC	_	10	CC	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	effects	_	NNS	NNS	_	10	COORD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	CyA	_	NN	NN	_	22	PMOD	_	_
24	upon	_	IN	IN	_	21	NMOD	_	_
25	it	_	PRP	PRP	_	24	PMOD	_	_
26	.	_	.	.	_	5	P	_	_

1	Human	_	JJ	JJ	_	3	NMOD	_	_
2	CD4	_	NN	NN	_	3	NMOD	_	_
3	lymphocytes	_	NNS	NNS	_	5	SBJ	_	_
4	specifically	_	RB	RB	_	5	ADV	_	_
5	recognize	_	VBP	VBP	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	peptide	_	NN	NN	_	5	OBJ	_	_
8	representing	_	VBG	VBG	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	fusion	_	NN	NN	_	11	NMOD	_	_
11	region	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	hybrid	_	NN	NN	_	17	NMOD	_	_
15	protein	_	NN	NN	_	17	NMOD	_	_
16	pml\/RAR	_	NN	NN	_	17	NMOD	_	_
17	alpha	_	NN	NN	_	12	PMOD	_	_
18	present	_	JJ	JJ	_	17	NMOD	_	_
19	in	_	IN	IN	_	18	AMOD	_	_
20	acute	_	JJ	JJ	_	23	NMOD	_	_
21	promyelocytic	_	JJ	JJ	_	23	NMOD	_	_
22	leukemia	_	NN	NN	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	19	PMOD	_	_
24	.	_	.	.	_	5	P	_	_

1	Fusion	_	NN	NN	_	2	NMOD	_	_
2	proteins	_	NNS	NNS	_	8	SBJ	_	_
3	present	_	JJ	JJ	_	2	NMOD	_	_
4	in	_	IN	IN	_	3	AMOD	_	_
5	leukemic	_	JJ	JJ	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	frequently	_	RB	RB	_	8	TMP	_	_
8	contain	_	VBP	VBP	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	new	_	JJ	JJ	_	12	NMOD	_	_
11	amino	_	NN	NN	_	12	NMOD	_	_
12	acid	_	NN	NN	_	8	OBJ	_	_
13	at	_	IN	IN	_	8	ADV	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	fusion	_	NN	NN	_	16	NMOD	_	_
16	point	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	8	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	tested	_	VBD	VBD	_	0	ROOT-S	_	_
3	whether	_	IN	IN	_	2	OBJ	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	peptide	_	NN	NN	_	33	SBJ	_	_
6	(	_	(	(	_	7	P	_	_
7	BCR1\/25	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	encompassing	_	VBG	VBG	_	5	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	fusion	_	NN	NN	_	12	NMOD	_	_
12	region	_	NN	NN	_	9	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	hybrid	_	NN	NN	_	18	NMOD	_	_
16	molecule	_	NN	NN	_	18	NMOD	_	_
17	pml\/RAR	_	NN	NN	_	18	NMOD	_	_
18	alpha	_	NN	NN	_	13	PMOD	_	_
19	,	_	,	,	_	5	P	_	_
20	which	_	WDT	WDT	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	5	NMOD	_	_
22	selectively	_	RB	RB	_	23	ADV	_	_
23	expressed	_	VBN	VBN	_	21	VC	_	_
24	by	_	IN	IN	_	23	LGS	_	_
25	acute	_	JJ	JJ	_	27	NMOD	_	_
26	promyelocytic	_	JJ	JJ	_	27	NMOD	_	_
27	leukemia	_	NN	NN	_	31	NMOD	_	_
28	(	_	(	(	_	29	P	_	_
29	APL	_	NN	NN	_	27	PRN	_	_
30	)	_	)	)	_	29	P	_	_
31	cells	_	NNS	NNS	_	24	PMOD	_	_
32	,	_	,	,	_	5	P	_	_
33	can	_	MD	MD	_	3	VMOD	_	_
34	be	_	VB	VB	_	33	VC	_	_
35	recognized	_	VBN	VBN	_	34	VC	_	_
36	by	_	IN	IN	_	35	LGS	_	_
37	human	_	JJ	JJ	_	39	NMOD	_	_
38	T	_	NN	NN	_	39	NMOD	_	_
39	lymphocytes	_	NNS	NNS	_	36	PMOD	_	_
40	in	_	FW	FW	_	35	ADV	_	_
41	vitro	_	FW	FW	_	40	AMOD	_	_
42	.	_	.	.	_	2	P	_	_

1	CD4+	_	JJ	JJ	_	2	NMOD	_	_
2	lymphocytes	_	NNS	NNS	_	11	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	at	_	IN	IN	_	2	NMOD	_	_
5	both	_	CC	CC	_	6	CC	_	_
6	polyclonal	_	JJ	JJ	_	9	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	clonal	_	JJ	JJ	_	6	COORD	_	_
9	level	_	NN	NN	_	4	PMOD	_	_
10	,	_	,	,	_	2	P	_	_
11	recognized	_	VBD	VBD	_	0	ROOT-S	_	_
12	peptide	_	NN	NN	_	13	NMOD	_	_
13	BCR1\/25	_	NN	NN	_	11	OBJ	_	_
14	in	_	IN	IN	_	11	ADV	_	_
15	an	_	DT	DT	_	17	NMOD	_	_
16	HLA-DR--restricted	_	JJ	JJ	_	17	NMOD	_	_
17	fashion	_	NN	NN	_	14	PMOD	_	_
18	on	_	IN	IN	_	11	ADV	_	_
19	presentation	_	NN	NN	_	18	PMOD	_	_
20	by	_	IN	IN	_	19	NMOD	_	_
21	autologous	_	JJ	JJ	_	23	NMOD	_	_
22	antigen-presenting	_	JJ	JJ	_	23	NMOD	_	_
23	cell	_	NN	NN	_	20	PMOD	_	_
24	(	_	(	(	_	25	P	_	_
25	APC	_	NN	NN	_	23	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	or	_	CC	CC	_	20	CC	_	_
28	by	_	IN	IN	_	20	COORD	_	_
29	APC	_	NN	NN	_	28	PMOD	_	_
30	expressing	_	VBG	VBG	_	29	NMOD	_	_
31	the	_	DT	DT	_	34	NMOD	_	_
32	HLA-DR11	_	NN	NN	_	34	NMOD	_	_
33	restricting	_	NN	NN	_	34	NMOD	_	_
34	molecule	_	NN	NN	_	30	OBJ	_	_
35	.	_	.	.	_	11	P	_	_

1	Control	_	NN	NN	_	2	NMOD	_	_
2	peptides	_	NNS	NNS	_	12	SBJ	_	_
3	corresponding	_	VBG	VBG	_	2	NMOD	_	_
4	to	_	TO	TO	_	3	ADV	_	_
5	the	_	DT	DT	_	11	NMOD	_	_
6	normal	_	JJ	JJ	_	7	NMOD	_	_
7	pml	_	NN	NN	_	11	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	RAR	_	NN	NN	_	10	NMOD	_	_
10	alpha	_	NN	NN	_	7	COORD	_	_
11	proteins	_	NNS	NNS	_	4	PMOD	_	_
12	were	_	VBD	VBD	_	0	ROOT-S	_	_
13	not	_	RB	RB	_	12	VMOD	_	_
14	recognized	_	VBN	VBN	_	12	VC	_	_
15	.	_	.	.	_	12	P	_	_

1	One	_	CD	CD	_	2	NMOD	_	_
2	clone	_	NN	NN	_	7	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	DEG5	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	also	_	RB	RB	_	7	ADV	_	_
7	exerted	_	VBD	VBD	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	12	NMOD	_	_
9	high	_	JJ	JJ	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	specific	_	JJ	JJ	_	9	COORD	_	_
12	cytotoxicity	_	NN	NN	_	7	OBJ	_	_
13	against	_	IN	IN	_	12	NMOD	_	_
14	autologous	_	JJ	JJ	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	13	PMOD	_	_
16	pulsed	_	VBN	VBN	_	15	NMOD	_	_
17	with	_	IN	IN	_	16	ADV	_	_
18	BCR1\/25	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	autologous	_	JJ	JJ	_	4	NMOD	_	_
3	DE	_	NN	NN	_	4	NMOD	_	_
4	LCL	_	NN	NN	_	23	SBJ	_	_
5	containing	_	VBG	VBG	_	4	NMOD	_	_
6	a	_	DT	DT	_	11	NMOD	_	_
7	transduced	_	VBN	VBN	_	11	NMOD	_	_
8	pml\/RAR	_	NN	NN	_	11	NMOD	_	_
9	alpha	_	NN	NN	_	11	NMOD	_	_
10	fusion	_	NN	NN	_	11	NMOD	_	_
11	gene	_	NN	NN	_	5	OBJ	_	_
12	and	_	CC	CC	_	5	CC	_	_
13	expressing	_	VBG	VBG	_	5	COORD	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	bcr1	_	NN	NN	_	16	NMOD	_	_
16	type	_	NN	NN	_	13	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	22	NMOD	_	_
19	pml\/RAR	_	NN	NN	_	22	NMOD	_	_
20	alpha	_	NN	NN	_	22	NMOD	_	_
21	hybrid	_	NN	NN	_	22	NMOD	_	_
22	protein	_	NN	NN	_	17	PMOD	_	_
23	induced	_	VBD	VBD	_	0	ROOT-S	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	proliferation	_	NN	NN	_	23	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	DE	_	NN	NN	_	31	NMOD	_	_
28	anti-BCR1\/25	_	CD	CD	_	31	NMOD	_	_
29	T	_	NN	NN	_	31	NMOD	_	_
30	cell	_	NN	NN	_	31	NMOD	_	_
31	clones	_	NNS	NNS	_	26	PMOD	_	_
32	.	_	.	.	_	23	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	concluded	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	10	NMOD	_	_
6	bcr1	_	NN	NN	_	10	NMOD	_	_
7	type-pml\/RAR	_	NN	NN	_	10	NMOD	_	_
8	alpha	_	NN	NN	_	10	NMOD	_	_
9	fusion	_	NN	NN	_	10	NMOD	_	_
10	protein	_	NN	NN	_	13	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	APL	_	NN	NN	_	11	PMOD	_	_
13	contains	_	VBZ	VBZ	_	4	VMOD	_	_
14	an	_	DT	DT	_	16	NMOD	_	_
15	antigenic	_	JJ	JJ	_	16	NMOD	_	_
16	site	_	NN	NN	_	13	OBJ	_	_
17	,	_	,	,	_	16	P	_	_
18	absent	_	JJ	JJ	_	16	NMOD	_	_
19	from	_	IN	IN	_	18	AMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	normal	_	JJ	JJ	_	23	NMOD	_	_
22	parent	_	NN	NN	_	23	NMOD	_	_
23	molecules	_	NNS	NNS	_	19	PMOD	_	_
24	and	_	CC	CC	_	18	CC	_	_
25	recognized	_	VBN	VBN	_	18	COORD	_	_
26	by	_	IN	IN	_	25	LGS	_	_
27	human	_	JJ	JJ	_	29	NMOD	_	_
28	CD4+	_	JJ	JJ	_	29	NMOD	_	_
29	lymphocytes	_	NNS	NNS	_	26	PMOD	_	_
30	.	_	.	.	_	2	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	serum	_	NN	NN	_	4	NMOD	_	_
3	response	_	NN	NN	_	4	NMOD	_	_
4	element	_	NN	NN	_	11	SBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	binding	_	VBG	VBG	_	8	NMOD	_	_
8	site	_	NN	NN	_	4	COORD	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	NF-Y	_	NN	NN	_	9	PMOD	_	_
11	mediate	_	VB	VB	_	0	ROOT-S	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	serum	_	NN	NN	_	14	NMOD	_	_
14	response	_	NN	NN	_	11	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	human	_	JJ	JJ	_	20	NMOD	_	_
18	thrombospondin	_	NN	NN	_	20	NMOD	_	_
19	1	_	CD	CD	_	20	NMOD	_	_
20	gene	_	NN	NN	_	15	PMOD	_	_
21	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	expression	_	NN	NN	_	19	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	thrombospondin	_	NN	NN	_	3	PMOD	_	_
5	1	_	CD	CD	_	4	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	TSP	_	NN	NN	_	4	PRN	_	_
8	1	_	CD	CD	_	7	NMOD	_	_
9	)	_	)	)	_	7	P	_	_
10	,	_	,	,	_	4	P	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	member	_	NN	NN	_	4	NMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	TSP	_	NN	NN	_	17	NMOD	_	_
16	gene	_	NN	NN	_	17	NMOD	_	_
17	family	_	NN	NN	_	13	PMOD	_	_
18	,	_	,	,	_	4	P	_	_
19	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
20	rapidly	_	RB	RB	_	21	TMP	_	_
21	induced	_	VBN	VBN	_	19	VC	_	_
22	by	_	IN	IN	_	21	LGS	_	_
23	growth	_	NN	NN	_	24	NMOD	_	_
24	factors	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	19	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	tested	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	ability	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	human	_	JJ	JJ	_	10	NMOD	_	_
7	TSP	_	NN	NN	_	10	NMOD	_	_
8	1-chloramphenicol	_	JJ	JJ	_	10	NMOD	_	_
9	acetyltransferase	_	NN	NN	_	10	NMOD	_	_
10	constructs	_	NNS	NNS	_	5	PMOD	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	respond	_	VB	VB	_	4	NMOD	_	_
13	to	_	TO	TO	_	12	ADV	_	_
14	serum	_	NN	NN	_	13	PMOD	_	_
15	in	_	IN	IN	_	12	ADV	_	_
16	stably	_	RB	RB	_	17	AMOD	_	_
17	transfected	_	VBN	VBN	_	19	NMOD	_	_
18	NIH-3T3	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	15	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	Two	_	CD	CD	_	3	NMOD	_	_
2	transcriptional	_	JJ	JJ	_	3	NMOD	_	_
3	elements	_	NNS	NNS	_	22	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	TSP	_	NN	NN	_	8	NMOD	_	_
7	1	_	CD	CD	_	8	NMOD	_	_
8	promoter	_	NN	NN	_	4	PMOD	_	_
9	,	_	,	,	_	3	P	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	distal	_	JJ	JJ	_	12	NMOD	_	_
12	element	_	NN	NN	_	3	NMOD	_	_
13	at	_	IN	IN	_	12	NMOD	_	_
14	-1280	_	CD	CD	_	13	PMOD	_	_
15	and	_	CC	CC	_	12	CC	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	proximal	_	JJ	JJ	_	18	NMOD	_	_
18	element	_	NN	NN	_	12	COORD	_	_
19	at	_	IN	IN	_	18	NMOD	_	_
20	-65	_	CD	CD	_	19	PMOD	_	_
21	,	_	,	,	_	3	P	_	_
22	were	_	VBD	VBD	_	0	ROOT-S	_	_
23	required	_	VBN	VBN	_	22	VC	_	_
24	for	_	IN	IN	_	23	ADV	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	response	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	32	NMOD	_	_
29	human	_	JJ	JJ	_	32	NMOD	_	_
30	TSP	_	NN	NN	_	32	NMOD	_	_
31	1	_	CD	CD	_	32	NMOD	_	_
32	gene	_	NN	NN	_	27	PMOD	_	_
33	to	_	TO	TO	_	26	NMOD	_	_
34	serum	_	NN	NN	_	33	PMOD	_	_
35	.	_	.	.	_	22	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	distal	_	JJ	JJ	_	3	NMOD	_	_
3	element	_	NN	NN	_	4	SBJ	_	_
4	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	5'-CC-LRB-A-SP-+-SP-T-RRB-6GG-3'	_	NN	NN	_	8	NMOD	_	_
7	consensus	_	NN	NN	_	8	NMOD	_	_
8	sequence	_	NN	NN	_	4	OBJ	_	_
9	characteristic	_	JJ	JJ	_	8	NMOD	_	_
10	of	_	IN	IN	_	9	AMOD	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	serum-response	_	JJ	JJ	_	13	NMOD	_	_
13	element	_	NN	NN	_	10	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	SRE	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	.	_	.	.	_	4	P	_	_

1	Deletions	_	NNS	NNS	_	7	SBJ	_	_
2	or	_	CC	CC	_	1	CC	_	_
3	mutations	_	NNS	NNS	_	1	COORD	_	_
4	in	_	IN	IN	_	1	NMOD	_	_
5	this	_	DT	DT	_	6	NMOD	_	_
6	element	_	NN	NN	_	4	PMOD	_	_
7	reduced	_	VBD	VBD	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	serum	_	NN	NN	_	10	NMOD	_	_
10	response	_	NN	NN	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	TSP	_	NN	NN	_	15	NMOD	_	_
14	1	_	CD	CD	_	15	NMOD	_	_
15	gene	_	NN	NN	_	11	PMOD	_	_
16	by	_	IN	IN	_	7	ADV	_	_
17	80-90	_	CD	CD	_	18	NMOD	_	_
18	%	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	gel-shift	_	JJ	JJ	_	3	NMOD	_	_
3	assays	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	12	P	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	-1280	_	CD	CD	_	7	NMOD	_	_
7	element	_	NN	NN	_	12	SBJ	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	c-fos	_	NN	NN	_	11	NMOD	_	_
11	SRE	_	NN	NN	_	7	COORD	_	_
12	cross-competed	_	VBD	VBD	_	0	ROOT-S	_	_
13	,	_	,	,	_	12	P	_	_
14	whereas	_	IN	IN	_	12	COORD	_	_
15	their	_	PRP$	PRP$	_	19	NMOD	_	_
16	functional	_	JJ	JJ	_	19	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	binding	_	VBG	VBG	_	16	COORD	_	_
19	mutants	_	NNS	NNS	_	20	SBJ	_	_
20	did	_	VBD	VBD	_	12	COORD	_	_
21	not	_	RB	RB	_	20	VMOD	_	_
22	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	proximal	_	JJ	JJ	_	3	NMOD	_	_
3	element	_	NN	NN	_	4	SBJ	_	_
4	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	sequence	_	NN	NN	_	7	NMOD	_	_
7	5'-GGCCAATGGG-3'	_	NN	NN	_	4	OBJ	_	_
8	,	_	,	,	_	7	P	_	_
9	which	_	WDT	WDT	_	11	SBJ	_	_
10	closely	_	RB	RB	_	11	ADV	_	_
11	resembles	_	VBZ	VBZ	_	7	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	consensus	_	NN	NN	_	15	NMOD	_	_
14	binding	_	NN	NN	_	15	NMOD	_	_
15	motif	_	NN	NN	_	11	OBJ	_	_
16	for	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	CCAAT-binding	_	JJ	JJ	_	20	NMOD	_	_
19	factor	_	NN	NN	_	20	NMOD	_	_
20	NF-Y	_	NN	NN	_	16	PMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	CBF	_	NN	NN	_	20	PRN	_	_
23	,	_	,	,	_	22	P	_	_
24	CP1	_	NN	NN	_	22	NMOD	_	_
25	,	_	,	,	_	22	P	_	_
26	alpha	_	NN	NN	_	27	NMOD	_	_
27	CP1	_	NN	NN	_	22	NMOD	_	_
28	)	_	)	)	_	22	P	_	_
29	.	_	.	.	_	4	P	_	_

1	Deletions	_	NNS	NNS	_	8	SBJ	_	_
2	or	_	CC	CC	_	1	CC	_	_
3	mutations	_	NNS	NNS	_	1	COORD	_	_
4	in	_	IN	IN	_	1	NMOD	_	_
5	this	_	DT	DT	_	6	NMOD	_	_
6	element	_	NN	NN	_	4	PMOD	_	_
7	also	_	RB	RB	_	8	ADV	_	_
8	reduced	_	VBD	VBD	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	serum	_	NN	NN	_	11	NMOD	_	_
11	response	_	NN	NN	_	8	OBJ	_	_
12	by	_	IN	IN	_	8	ADV	_	_
13	80-90	_	CD	CD	_	14	NMOD	_	_
14	%	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	8	P	_	_

1	Methylation	_	NN	NN	_	3	NMOD	_	_
2	interference	_	NN	NN	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	-65	_	CD	CD	_	7	NMOD	_	_
7	region	_	NN	NN	_	4	PMOD	_	_
8	identified	_	VBD	VBD	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	pattern	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	contacts	_	NNS	NNS	_	11	PMOD	_	_
13	with	_	IN	IN	_	12	NMOD	_	_
14	nuclear	_	JJ	JJ	_	15	NMOD	_	_
15	factors	_	NNS	NNS	_	13	PMOD	_	_
16	resembling	_	VBG	VBG	_	10	NMOD	_	_
17	that	_	DT	DT	_	16	OBJ	_	_
18	for	_	IN	IN	_	17	NMOD	_	_
19	NF-Y	_	NN	NN	_	18	PMOD	_	_
20	,	_	,	,	_	10	P	_	_
21	and	_	CC	CC	_	10	CC	_	_
22	an	_	DT	DT	_	24	NMOD	_	_
23	NF-Y-binding	_	JJ	JJ	_	24	NMOD	_	_
24	site	_	NN	NN	_	10	COORD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	the	_	DT	DT	_	30	NMOD	_	_
27	proximal	_	JJ	JJ	_	30	NMOD	_	_
28	TSP	_	NN	NN	_	30	NMOD	_	_
29	1	_	CD	CD	_	30	NMOD	_	_
30	element	_	NN	NN	_	24	COORD	_	_
31	cross-competed	_	VBD	VBD	_	24	NMOD	_	_
32	in	_	IN	IN	_	31	ADV	_	_
33	gel-shift	_	JJ	JJ	_	34	NMOD	_	_
34	assays	_	NNS	NNS	_	32	PMOD	_	_
35	,	_	,	,	_	8	P	_	_
36	whereas	_	IN	IN	_	8	COORD	_	_
37	their	_	PRP$	PRP$	_	39	NMOD	_	_
38	binding	_	VBG	VBG	_	39	NMOD	_	_
39	mutants	_	NNS	NNS	_	40	SBJ	_	_
40	did	_	VBD	VBD	_	8	COORD	_	_
41	not	_	RB	RB	_	40	VMOD	_	_
42	.	_	.	.	_	8	P	_	_

1	Finally	_	RB	RB	_	16	TMP	_	_
2	,	_	,	,	_	16	P	_	_
3	an	_	DT	DT	_	7	NMOD	_	_
4	abbreviated	_	VBN	VBN	_	7	NMOD	_	_
5	TSP	_	NN	NN	_	7	NMOD	_	_
6	1	_	CD	CD	_	7	NMOD	_	_
7	promoter\/5'-flank	_	NN	NN	_	16	SBJ	_	_
8	,	_	,	,	_	7	P	_	_
9	containing	_	VBG	VBG	_	7	NMOD	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	SRE-	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	NF-Y-binding	_	JJ	JJ	_	11	COORD	_	_
14	sites	_	NNS	NNS	_	9	OBJ	_	_
15	,	_	,	,	_	7	P	_	_
16	mediated	_	VBD	VBD	_	0	ROOT-S	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	serum	_	NN	NN	_	19	NMOD	_	_
19	response	_	NN	NN	_	16	OBJ	_	_
20	that	_	WDT	WDT	_	21	SBJ	_	_
21	was	_	VBD	VBD	_	19	NMOD	_	_
22	close	_	JJ	JJ	_	21	PRD	_	_
23	in	_	IN	IN	_	21	ADV	_	_
24	magnitude	_	NN	NN	_	23	PMOD	_	_
25	to	_	TO	TO	_	22	AMOD	_	_
26	that	_	DT	DT	_	25	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	parent	_	NN	NN	_	30	NMOD	_	_
30	promoter	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	16	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	conclude	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	serum	_	NN	NN	_	6	NMOD	_	_
6	response	_	NN	NN	_	13	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	human	_	JJ	JJ	_	12	NMOD	_	_
10	TSP	_	NN	NN	_	12	NMOD	_	_
11	1	_	CD	CD	_	12	NMOD	_	_
12	gene	_	NN	NN	_	7	PMOD	_	_
13	requires	_	VBZ	VBZ	_	3	VMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	coordinated	_	VBN	VBN	_	16	NMOD	_	_
16	function	_	NN	NN	_	13	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	an	_	DT	DT	_	22	NMOD	_	_
19	SRE-	_	NN	NN	_	22	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	NF-Y-binding	_	JJ	JJ	_	19	COORD	_	_
22	site	_	NN	NN	_	17	PMOD	_	_
23	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	interleukin	_	NN	NN	_	5	NMOD	_	_
3	2	_	CD	CD	_	5	NMOD	_	_
4	CD28-responsive	_	JJ	JJ	_	5	NMOD	_	_
5	complex	_	NN	NN	_	6	SBJ	_	_
6	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	at	_	IN	IN	_	9	DEP	_	_
8	least	_	JJS	JJS	_	9	DEP	_	_
9	three	_	CD	CD	_	10	NMOD	_	_
10	members	_	NNS	NNS	_	6	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	16	NMOD	_	_
13	NF	_	NN	NN	_	16	NMOD	_	_
14	kappa	_	NN	NN	_	16	NMOD	_	_
15	B	_	NN	NN	_	16	NMOD	_	_
16	family	_	NN	NN	_	11	PMOD	_	_
17	:	_	:	:	_	10	P	_	_
18	c-Rel	_	NN	NN	_	10	NMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	p50	_	NN	NN	_	18	COORD	_	_
21	,	_	,	,	_	18	P	_	_
22	and	_	CC	CC	_	18	CC	_	_
23	p65	_	NN	NN	_	18	COORD	_	_
24	.	_	.	.	_	6	P	_	_

1	Optimal	_	JJ	JJ	_	2	NMOD	_	_
2	activation	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	T	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	3	PMOD	_	_
6	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	at	_	IN	IN	_	9	DEP	_	_
8	least	_	JJS	JJS	_	9	DEP	_	_
9	two	_	CD	CD	_	10	NMOD	_	_
10	signals	_	NNS	NNS	_	6	OBJ	_	_
11	.	_	.	.	_	6	P	_	_

1	One	_	CD	CD	_	2	NMOD	_	_
2	signal	_	NN	NN	_	3	SBJ	_	_
3	can	_	MD	MD	_	0	ROOT-S	_	_
4	be	_	VB	VB	_	3	VC	_	_
5	delivered	_	VBN	VBN	_	4	VC	_	_
6	by	_	IN	IN	_	5	LGS	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	antigen-specific	_	JJ	JJ	_	10	NMOD	_	_
9	T-cell	_	NN	NN	_	10	NMOD	_	_
10	receptor	_	NN	NN	_	6	PMOD	_	_
11	,	_	,	,	_	3	P	_	_
12	and	_	CC	CC	_	3	CC	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	second	_	JJ	JJ	_	15	NMOD	_	_
15	signal	_	NN	NN	_	16	SBJ	_	_
16	is	_	VBZ	VBZ	_	3	COORD	_	_
17	provided	_	VBN	VBN	_	16	VC	_	_
18	by	_	IN	IN	_	17	LGS	_	_
19	the	_	DT	DT	_	23	NMOD	_	_
20	costimulatory	_	JJ	JJ	_	23	NMOD	_	_
21	molecule	_	NN	NN	_	23	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	s	_	NNS	NNS	_	18	PMOD	_	_
24	)	_	)	)	_	23	P	_	_
25	delivered	_	VBN	VBN	_	23	NMOD	_	_
26	by	_	IN	IN	_	25	LGS	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	antigen-presenting	_	JJ	JJ	_	29	NMOD	_	_
29	cell	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	CD28	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	T-cell	_	NN	NN	_	6	NMOD	_	_
5	surface	_	NN	NN	_	6	NMOD	_	_
6	molecule	_	NN	NN	_	2	PRD	_	_
7	and	_	CC	CC	_	2	CC	_	_
8	stimulation	_	NN	NN	_	12	SBJ	_	_
9	through	_	IN	IN	_	8	NMOD	_	_
10	this	_	DT	DT	_	11	NMOD	_	_
11	protein	_	NN	NN	_	9	PMOD	_	_
12	plays	_	VBZ	VBZ	_	2	COORD	_	_
13	an	_	DT	DT	_	15	NMOD	_	_
14	important	_	JJ	JJ	_	15	NMOD	_	_
15	role	_	NN	NN	_	12	OBJ	_	_
16	in	_	IN	IN	_	12	ADV	_	_
17	delivering	_	VBG	VBG	_	16	PMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	second	_	JJ	JJ	_	21	NMOD	_	_
20	activation	_	NN	NN	_	21	NMOD	_	_
21	signal	_	NN	NN	_	17	OBJ	_	_
22	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	show	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	in	_	IN	IN	_	18	ADV	_	_
9	human	_	JJ	JJ	_	13	NMOD	_	_
10	peripheral	_	JJ	JJ	_	13	NMOD	_	_
11	blood	_	NN	NN	_	13	NMOD	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	8	PMOD	_	_
14	,	_	,	,	_	18	P	_	_
15	CD28-mediated	_	JJ	JJ	_	17	NMOD	_	_
16	signal	_	NN	NN	_	17	NMOD	_	_
17	transduction	_	NN	NN	_	18	SBJ	_	_
18	involves	_	VBZ	VBZ	_	7	VMOD	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	rel	_	NN	NN	_	22	NMOD	_	_
21	family	_	NN	NN	_	22	NMOD	_	_
22	proteins	_	NNS	NNS	_	18	OBJ	_	_
23	--	_	:	:	_	22	P	_	_
24	c-Rel	_	NN	NN	_	22	NMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	p50	_	NN	NN	_	24	COORD	_	_
27	,	_	,	,	_	24	P	_	_
28	and	_	CC	CC	_	24	CC	_	_
29	p65	_	NN	NN	_	24	COORD	_	_
30	.	_	.	.	_	6	P	_	_

1	Treatment	_	NN	NN	_	21	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	peripheral	_	JJ	JJ	_	6	NMOD	_	_
4	blood	_	NN	NN	_	6	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	2	PMOD	_	_
7	with	_	IN	IN	_	1	NMOD	_	_
8	phorbol	_	NN	NN	_	10	NMOD	_	_
9	12-myristate	_	NN	NN	_	10	NMOD	_	_
10	13-acetate	_	NN	NN	_	7	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	PMA	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	and	_	CC	CC	_	10	CC	_	_
15	anti-CD28	_	JJ	JJ	_	17	NMOD	_	_
16	monoclonal	_	JJ	JJ	_	17	NMOD	_	_
17	antibody	_	NN	NN	_	10	COORD	_	_
18	(	_	(	(	_	19	P	_	_
19	mAb	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
22	in	_	IN	IN	_	21	ADV	_	_
23	augmentation	_	NN	NN	_	22	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	nuclear	_	JJ	JJ	_	26	NMOD	_	_
26	c-Rel	_	NN	NN	_	24	PMOD	_	_
27	,	_	,	,	_	26	P	_	_
28	p50	_	NN	NN	_	26	COORD	_	_
29	,	_	,	,	_	26	P	_	_
30	and	_	CC	CC	_	26	CC	_	_
31	p65	_	NN	NN	_	26	COORD	_	_
32	,	_	,	,	_	21	P	_	_
33	and	_	CC	CC	_	21	CC	_	_
34	this	_	DT	DT	_	35	NMOD	_	_
35	augmentation	_	NN	NN	_	36	SBJ	_	_
36	can	_	MD	MD	_	21	COORD	_	_
37	occur	_	VB	VB	_	36	VC	_	_
38	in	_	IN	IN	_	37	ADV	_	_
39	the	_	DT	DT	_	38	DEP	_	_
40	presence	_	NN	NN	_	38	DEP	_	_
41	of	_	IN	IN	_	38	DEP	_	_
42	the	_	DT	DT	_	45	NMOD	_	_
43	immunosuppressant	_	JJ	JJ	_	45	NMOD	_	_
44	cyclosporin	_	NN	NN	_	45	NMOD	_	_
45	A	_	NN	NN	_	38	PMOD	_	_
46	.	_	.	.	_	21	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	also	_	RB	RB	_	2	ADV	_	_
4	shown	_	VBN	VBN	_	2	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	this	_	DT	DT	_	7	NMOD	_	_
7	report	_	NN	NN	_	5	PMOD	_	_
8	that	_	IN	IN	_	4	OBJ	_	_
9	,	_	,	,	_	8	P	_	_
10	in	_	IN	IN	_	25	ADV	_	_
11	response	_	NN	NN	_	10	DEP	_	_
12	to	_	TO	TO	_	10	DEP	_	_
13	PMA\/anti-CD28	_	JJ	JJ	_	14	NMOD	_	_
14	mAb	_	NN	NN	_	10	PMOD	_	_
15	or	_	CC	CC	_	14	CC	_	_
16	anti-CD3\/anti-CD28	_	JJ	JJ	_	17	NMOD	_	_
17	mAb	_	NN	NN	_	14	COORD	_	_
18	,	_	,	,	_	25	P	_	_
19	c-Rel	_	NN	NN	_	25	SBJ	_	_
20	,	_	,	,	_	19	P	_	_
21	p50	_	NN	NN	_	19	COORD	_	_
22	,	_	,	,	_	19	P	_	_
23	and	_	CC	CC	_	19	CC	_	_
24	p65	_	NN	NN	_	19	COORD	_	_
25	are	_	VBP	VBP	_	8	VMOD	_	_
26	associated	_	VBN	VBN	_	25	VC	_	_
27	with	_	IN	IN	_	26	ADV	_	_
28	CD28-responsive	_	JJ	JJ	_	29	NMOD	_	_
29	element	_	NN	NN	_	27	PMOD	_	_
30	present	_	JJ	JJ	_	29	NMOD	_	_
31	in	_	IN	IN	_	30	AMOD	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	promoter	_	NN	NN	_	31	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	the	_	DT	DT	_	39	NMOD	_	_
36	human	_	JJ	JJ	_	39	NMOD	_	_
37	interleukin	_	NN	NN	_	39	NMOD	_	_
38	2	_	CD	CD	_	39	NMOD	_	_
39	gene	_	NN	NN	_	34	PMOD	_	_
40	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	functional	_	JJ	JJ	_	3	NMOD	_	_
3	significance	_	NN	NN	_	11	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	c-Rel	_	NN	NN	_	6	NMOD	_	_
6	involvement	_	NN	NN	_	4	PMOD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	CD28-responsive	_	JJ	JJ	_	10	NMOD	_	_
10	complex	_	NN	NN	_	7	PMOD	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	demonstrated	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	transient	_	JJ	JJ	_	16	NMOD	_	_
15	transfection	_	NN	NN	_	16	NMOD	_	_
16	analysis	_	NN	NN	_	13	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	where	_	WRB	WRB	_	22	ADV	_	_
19	cotransfection	_	NN	NN	_	22	SBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	c-Rel	_	NN	NN	_	20	PMOD	_	_
22	augments	_	VBZ	VBZ	_	16	NMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	level	_	NN	NN	_	22	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	expression	_	NN	NN	_	25	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	a	_	DT	DT	_	32	NMOD	_	_
29	chloramphenicol	_	JJ	JJ	_	32	NMOD	_	_
30	acetyltransferase	_	NN	NN	_	32	NMOD	_	_
31	reporter	_	NN	NN	_	32	NMOD	_	_
32	gene	_	NN	NN	_	27	PMOD	_	_
33	linked	_	VBN	VBN	_	32	NMOD	_	_
34	to	_	TO	TO	_	33	ADV	_	_
35	the	_	DT	DT	_	37	NMOD	_	_
36	CD28-responsive	_	JJ	JJ	_	37	NMOD	_	_
37	element	_	NN	NN	_	34	PMOD	_	_
38	.	_	.	.	_	11	P	_	_

1	Expression	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	Tat	_	NN	NN	_	5	NMOD	_	_
5	protein	_	NN	NN	_	2	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	HIV1	_	NN	NN	_	6	PMOD	_	_
8	in	_	IN	IN	_	1	NMOD	_	_
9	human	_	JJ	JJ	_	12	NMOD	_	_
10	promonocytic	_	JJ	JJ	_	12	NMOD	_	_
11	U937	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	8	PMOD	_	_
13	.	_	.	.	_	1	P	_	_

1	Numerous	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	shown	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	upon	_	IN	IN	_	15	TMP	_	_
8	HIV1	_	NN	NN	_	9	NMOD	_	_
9	infection	_	NN	NN	_	7	PMOD	_	_
10	,	_	,	,	_	15	P	_	_
11	human	_	JJ	JJ	_	14	NMOD	_	_
12	promonocytic	_	JJ	JJ	_	14	NMOD	_	_
13	U937	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	15	SBJ	_	_
15	were	_	VBD	VBD	_	5	VMOD	_	_
16	induced	_	VBN	VBN	_	15	VC	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	differentiate	_	VB	VB	_	16	OBJ	_	_
19	,	_	,	,	_	18	P	_	_
20	as	_	IN	IN	_	18	ADV	_	_
21	indicated	_	VBN	VBN	_	20	VMOD	_	_
22	,	_	,	,	_	21	P	_	_
23	for	_	IN	IN	_	21	ADV	_	_
24	example	_	NN	NN	_	23	PMOD	_	_
25	,	_	,	,	_	21	P	_	_
26	by	_	IN	IN	_	21	LGS	_	_
27	increased	_	VBN	VBN	_	28	NMOD	_	_
28	expression	_	NN	NN	_	26	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	adhesion	_	NN	NN	_	31	NMOD	_	_
31	molecules	_	NNS	NNS	_	29	PMOD	_	_
32	.	_	.	.	_	3	P	_	_

1	One	_	CD	CD	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	viral	_	JJ	JJ	_	5	NMOD	_	_
5	proteins	_	NNS	NNS	_	2	PMOD	_	_
6	involved	_	VBN	VBN	_	5	NMOD	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	this	_	DT	DT	_	9	NMOD	_	_
9	process	_	NN	NN	_	7	PMOD	_	_
10	might	_	MD	MD	_	0	ROOT-S	_	_
11	be	_	VB	VB	_	10	VC	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	Tat	_	NN	NN	_	14	NMOD	_	_
14	protein	_	NN	NN	_	11	PRD	_	_
15	.	_	.	.	_	10	P	_	_

1	Indeed	_	RB	RB	_	14	ADV	_	_
2	,	_	,	,	_	14	P	_	_
3	this	_	DT	DT	_	5	NMOD	_	_
4	viral	_	JJ	JJ	_	5	NMOD	_	_
5	protein	_	NN	NN	_	14	SBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	which	_	WDT	WDT	_	8	SBJ	_	_
8	is	_	VBZ	VBZ	_	5	NMOD	_	_
9	essential	_	JJ	JJ	_	8	PRD	_	_
10	for	_	IN	IN	_	9	AMOD	_	_
11	productive	_	JJ	JJ	_	12	NMOD	_	_
12	infection	_	NN	NN	_	10	PMOD	_	_
13	,	_	,	,	_	5	P	_	_
14	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	also	_	RB	RB	_	14	ADV	_	_
16	been	_	VBN	VBN	_	14	VC	_	_
17	shown	_	VBN	VBN	_	16	VC	_	_
18	to	_	TO	TO	_	19	VMOD	_	_
19	display	_	VB	VB	_	17	OBJ	_	_
20	growth-stimulating	_	JJ	JJ	_	21	NMOD	_	_
21	properties	_	NNS	NNS	_	19	OBJ	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	immunomodulatory	_	JJ	JJ	_	24	NMOD	_	_
24	activities	_	NNS	NNS	_	21	COORD	_	_
25	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	22	ADV	_	_
2	order	_	NN	NN	_	1	VMOD	_	_
3	to	_	TO	TO	_	1	VMOD	_	_
4	apprehend	_	VB	VB	_	1	VMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	role	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	HIV1	_	NN	NN	_	11	NMOD	_	_
10	tat	_	NN	NN	_	11	NMOD	_	_
11	gene	_	NN	NN	_	7	PMOD	_	_
12	in	_	IN	IN	_	6	NMOD	_	_
13	inducing	_	VBG	VBG	_	12	PMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	differentiation	_	NN	NN	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	HIV1-infected	_	JJ	JJ	_	19	NMOD	_	_
18	U937	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	PMOD	_	_
20	,	_	,	,	_	22	P	_	_
21	we	_	PRP	PRP	_	22	SBJ	_	_
22	have	_	VBP	VBP	_	0	ROOT-S	_	_
23	successfully	_	RB	RB	_	22	ADV	_	_
24	introduced	_	VBN	VBN	_	22	VC	_	_
25	this	_	DT	DT	_	26	NMOD	_	_
26	gene	_	NN	NN	_	24	OBJ	_	_
27	into	_	IN	IN	_	24	ADV	_	_
28	U937	_	NN	NN	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	27	PMOD	_	_
30	by	_	IN	IN	_	24	ADV	_	_
31	infecting	_	VBG	VBG	_	30	PMOD	_	_
32	them	_	PRP	PRP	_	31	OBJ	_	_
33	with	_	IN	IN	_	31	ADV	_	_
34	retroviral	_	JJ	JJ	_	37	NMOD	_	_
35	particles	_	NNS	NNS	_	37	NMOD	_	_
36	transducing	_	VBG	VBG	_	37	NMOD	_	_
37	tat	_	NN	NN	_	33	PMOD	_	_
38	.	_	.	.	_	22	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	15	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	Tat	_	NN	NN	_	6	NMOD	_	_
6	protein	_	NN	NN	_	3	PMOD	_	_
7	constitutively	_	RB	RB	_	8	ADV	_	_
8	expressed	_	VBN	VBN	_	6	NMOD	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	these	_	DT	DT	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	upon	_	IN	IN	_	8	TMP	_	_
13	their	_	PRP$	PRP$	_	14	NMOD	_	_
14	differentiation	_	NN	NN	_	12	PMOD	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	then	_	RB	RB	_	15	TMP	_	_
17	evaluated	_	VBN	VBN	_	15	VC	_	_
18	by	_	IN	IN	_	17	ADV	_	_
19	looking	_	VBG	VBG	_	18	PMOD	_	_
20	for	_	IN	IN	_	19	ADV	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	expression	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	c-fos	_	NN	NN	_	23	PMOD	_	_
26	and	_	CC	CC	_	23	CC	_	_
27	of	_	IN	IN	_	23	COORD	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	c-fms	_	NN	NN	_	27	PMOD	_	_
30	proto-oncogenes	_	NNS	NNS	_	25	NMOD	_	_
31	which	_	WDT	WDT	_	32	SBJ	_	_
32	are	_	VBP	VBP	_	25	NMOD	_	_
33	linked	_	VBN	VBN	_	32	VC	_	_
34	to	_	TO	TO	_	33	ADV	_	_
35	the	_	DT	DT	_	36	NMOD	_	_
36	differentiation	_	NN	NN	_	34	PMOD	_	_
37	of	_	IN	IN	_	36	NMOD	_	_
38	myelomonoblastic	_	JJ	JJ	_	39	NMOD	_	_
39	cells	_	NNS	NNS	_	37	PMOD	_	_
40	.	_	.	.	_	15	P	_	_

1	Northern	_	NN	NN	_	3	NMOD	_	_
2	blot	_	NN	NN	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	4	SBJ	_	_
4	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	these	_	DT	DT	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	5	PMOD	_	_
8	,	_	,	,	_	4	P	_	_
9	an	_	DT	DT	_	10	NMOD	_	_
10	increase	_	NN	NN	_	4	OBJ	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	transcription	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	these	_	DT	DT	_	17	NMOD	_	_
16	two	_	CD	CD	_	17	NMOD	_	_
17	proto-oncogenes	_	NNS	NNS	_	14	PMOD	_	_
18	,	_	,	,	_	4	P	_	_
19	and	_	CC	CC	_	4	CC	_	_
20	this	_	DT	DT	_	21	NMOD	_	_
21	increase	_	NN	NN	_	22	SBJ	_	_
22	was	_	VBD	VBD	_	4	COORD	_	_
23	amplified	_	VBN	VBN	_	22	VC	_	_
24	after	_	IN	IN	_	23	TMP	_	_
25	treatment	_	NN	NN	_	24	PMOD	_	_
26	with	_	IN	IN	_	25	NMOD	_	_
27	phorbol	_	NN	NN	_	29	NMOD	_	_
28	myristate	_	NN	NN	_	29	NMOD	_	_
29	acetate	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	4	P	_	_

1	No	_	DT	DT	_	3	NMOD	_	_
2	such	_	JJ	JJ	_	3	NMOD	_	_
3	increase	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	observed	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	control	_	NN	NN	_	9	NMOD	_	_
8	U937	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	6	PMOD	_	_
10	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	among	_	IN	IN	_	14	ADV	_	_
7	HIV1	_	NN	NN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	products	_	NNS	NNS	_	6	PMOD	_	_
10	,	_	,	,	_	14	P	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	Tat	_	NN	NN	_	13	NMOD	_	_
13	protein	_	NN	NN	_	14	SBJ	_	_
14	appears	_	VBZ	VBZ	_	4	VMOD	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	trigger	_	VB	VB	_	14	OBJ	_	_
17	monocytic	_	JJ	JJ	_	18	NMOD	_	_
18	differentiation	_	NN	NN	_	16	OBJ	_	_
19	,	_	,	,	_	3	P	_	_
20	and	_	CC	CC	_	3	CC	_	_
21	suggests	_	VBZ	VBZ	_	3	COORD	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	this	_	DT	DT	_	25	NMOD	_	_
24	viral	_	JJ	JJ	_	25	NMOD	_	_
25	protein	_	NN	NN	_	26	SBJ	_	_
26	directs	_	VBZ	VBZ	_	22	VMOD	_	_
27	progenitors	_	NNS	NNS	_	26	OBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	monocyte\/macrophage	_	NN	NN	_	31	NMOD	_	_
31	lineage	_	NN	NN	_	28	PMOD	_	_
32	towards	_	IN	IN	_	26	ADV	_	_
33	a	_	DT	DT	_	35	NMOD	_	_
34	differentiation	_	NN	NN	_	35	NMOD	_	_
35	stage	_	NN	NN	_	32	PMOD	_	_
36	in	_	IN	IN	_	45	ADV	_	_
37	which	_	WDT	WDT	_	36	PMOD	_	_
38	production	_	NN	NN	_	44	SBJ	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	viral	_	JJ	JJ	_	41	NMOD	_	_
41	antigens	_	NNS	NNS	_	39	PMOD	_	_
42	and	_	CC	CC	_	41	CC	_	_
43	virions	_	NNS	NNS	_	41	COORD	_	_
44	might	_	MD	MD	_	35	NMOD	_	_
45	be	_	VB	VB	_	44	VC	_	_
46	more	_	RBR	RBR	_	47	AMOD	_	_
47	efficient	_	JJ	JJ	_	45	PRD	_	_
48	.	_	.	.	_	3	P	_	_

1	Stimulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	interleukin-1	_	NN	NN	_	4	NMOD	_	_
4	alpha	_	NN	NN	_	8	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	interleukin-1	_	NN	NN	_	7	NMOD	_	_
7	beta	_	NN	NN	_	4	COORD	_	_
8	production	_	NN	NN	_	2	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	human	_	JJ	JJ	_	11	NMOD	_	_
11	monocytes	_	NNS	NNS	_	9	PMOD	_	_
12	by	_	IN	IN	_	1	NMOD	_	_
13	protein	_	NN	NN	_	18	NMOD	_	_
14	phosphatase	_	NN	NN	_	18	NMOD	_	_
15	1	_	CD	CD	_	18	NMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	2A	_	NN	NN	_	15	COORD	_	_
18	inhibitors	_	NNS	NNS	_	12	PMOD	_	_
19	.	_	.	.	_	1	P	_	_

1	Protein	_	NN	NN	_	2	NMOD	_	_
2	phosphatases	_	NNS	NNS	_	6	SBJ	_	_
3	1	_	CD	CD	_	2	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	2A	_	NN	NN	_	3	COORD	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	important	_	JJ	JJ	_	6	PRD	_	_
8	in	_	IN	IN	_	6	ADV	_	_
9	regulating	_	VBG	VBG	_	8	PMOD	_	_
10	cellular	_	JJ	JJ	_	11	NMOD	_	_
11	functions	_	NNS	NNS	_	9	OBJ	_	_
12	by	_	IN	IN	_	9	ADV	_	_
13	controlling	_	VBG	VBG	_	12	PMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	phosphorylation	_	NN	NN	_	16	NMOD	_	_
16	state	_	NN	NN	_	13	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	their	_	PRP$	PRP$	_	19	NMOD	_	_
19	substrates	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	17	ADV	_	_
2	human	_	JJ	JJ	_	3	NMOD	_	_
3	monocytes	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	17	P	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	inhibitors	_	NNS	NNS	_	17	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	these	_	DT	DT	_	9	NMOD	_	_
9	phosphatases	_	NNS	NNS	_	7	PMOD	_	_
10	,	_	,	,	_	6	P	_	_
11	okadaic	_	JJ	JJ	_	12	NMOD	_	_
12	acid	_	NN	NN	_	6	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	calyculin	_	NN	NN	_	15	NMOD	_	_
15	A	_	NN	NN	_	12	COORD	_	_
16	,	_	,	,	_	6	P	_	_
17	were	_	VBD	VBD	_	0	ROOT-S	_	_
18	found	_	VBN	VBN	_	17	VC	_	_
19	to	_	TO	TO	_	20	VMOD	_	_
20	increase	_	VB	VB	_	18	OBJ	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	mRNA	_	NN	NN	_	23	NMOD	_	_
23	accumulation	_	NN	NN	_	20	OBJ	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	cytokine	_	NN	NN	_	26	NMOD	_	_
26	production	_	NN	NN	_	23	COORD	_	_
27	of	_	IN	IN	_	23	NMOD	_	_
28	interleukin-1	_	NN	NN	_	29	NMOD	_	_
29	beta	_	NN	NN	_	27	PMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	interleukin-1	_	NN	NN	_	32	NMOD	_	_
32	alpha	_	NN	NN	_	29	COORD	_	_
33	.	_	.	.	_	17	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	increased	_	VBN	VBN	_	4	NMOD	_	_
3	mRNA	_	NN	NN	_	4	NMOD	_	_
4	accumulation	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	found	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	be	_	VB	VB	_	6	OBJ	_	_
9	primarily	_	RB	RB	_	10	DEP	_	_
10	because	_	IN	IN	_	8	PRD	_	_
11	of	_	IN	IN	_	10	DEP	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	increase	_	NN	NN	_	10	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	transcription	_	NN	NN	_	17	NMOD	_	_
17	rate	_	NN	NN	_	14	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	interleukin-1	_	NN	NN	_	21	NMOD	_	_
21	genes	_	NNS	NNS	_	18	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	Stimulation	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	interleukin-1	_	NN	NN	_	5	NMOD	_	_
4	gene	_	NN	NN	_	5	NMOD	_	_
5	transcription	_	NN	NN	_	2	PMOD	_	_
6	may	_	MD	MD	_	0	ROOT-S	_	_
7	be	_	VB	VB	_	6	VC	_	_
8	caused	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	stimulation	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	transcription	_	NN	NN	_	15	NMOD	_	_
14	factor	_	NN	NN	_	15	NMOD	_	_
15	activities	_	NNS	NNS	_	12	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	including	_	VBG	VBG	_	15	NMOD	_	_
18	those	_	DT	DT	_	17	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	AP-1	_	NN	NN	_	19	PMOD	_	_
21	,	_	,	,	_	15	P	_	_
22	by	_	IN	IN	_	11	NMOD	_	_
23	these	_	DT	DT	_	26	NMOD	_	_
24	protein	_	NN	NN	_	26	NMOD	_	_
25	phosphatase	_	NN	NN	_	26	NMOD	_	_
26	inhibitors	_	NNS	NNS	_	22	PMOD	_	_
27	.	_	.	.	_	6	P	_	_

1	Okadaic	_	JJ	JJ	_	2	NMOD	_	_
2	acid	_	NN	NN	_	3	SBJ	_	_
3	increased	_	VBD	VBD	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	synthesis	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	13	NMOD	_	_
8	interleukin-1	_	NN	NN	_	13	NMOD	_	_
9	beta	_	NN	NN	_	13	NMOD	_	_
10	precursor	_	NN	NN	_	13	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	mature	_	JJ	JJ	_	10	COORD	_	_
13	forms	_	NNS	NNS	_	6	PMOD	_	_
14	and	_	CC	CC	_	5	CC	_	_
15	their	_	PRP$	PRP$	_	16	NMOD	_	_
16	secretion	_	NN	NN	_	5	COORD	_	_
17	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	increased	_	VBD	VBD	_	3	NMOD	_	_
3	processing	_	NN	NN	_	6	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	secretion	_	NN	NN	_	3	COORD	_	_
6	correlated	_	VBN	VBN	_	0	ROOT-S	_	_
7	with	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	stimulation	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	IL-1	_	NN	NN	_	15	NMOD	_	_
12	beta	_	NN	NN	_	15	NMOD	_	_
13	convertase	_	NN	NN	_	15	NMOD	_	_
14	mRNA	_	NN	NN	_	15	NMOD	_	_
15	accumulation	_	NN	NN	_	10	PMOD	_	_
16	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	stimulation	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	interleukin-1	_	NN	NN	_	6	NMOD	_	_
5	alpha	_	NN	NN	_	6	NMOD	_	_
6	production	_	NN	NN	_	3	PMOD	_	_
7	by	_	IN	IN	_	2	NMOD	_	_
8	okadaic	_	JJ	JJ	_	9	NMOD	_	_
9	acid	_	NN	NN	_	7	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	more	_	RBR	RBR	_	12	AMOD	_	_
12	modest	_	JJ	JJ	_	10	PRD	_	_
13	than	_	IN	IN	_	12	AMOD	_	_
14	that	_	DT	DT	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	interleukin-1	_	NN	NN	_	17	NMOD	_	_
17	beta	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	10	P	_	_

1	However	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	phosphorylation	_	NN	NN	_	11	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	precursor	_	NN	NN	_	10	NMOD	_	_
8	interleukin-1	_	NN	NN	_	10	NMOD	_	_
9	alpha	_	NN	NN	_	10	NMOD	_	_
10	cytokine	_	NN	NN	_	5	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	increased	_	VBN	VBN	_	11	VC	_	_
13	.	_	.	.	_	11	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	protein	_	NN	NN	_	10	NMOD	_	_
6	phosphatase	_	NN	NN	_	10	NMOD	_	_
7	1	_	CD	CD	_	10	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	2A	_	NN	NN	_	7	COORD	_	_
10	inhibitors	_	NNS	NNS	_	11	SBJ	_	_
11	exert	_	VBP	VBP	_	4	VMOD	_	_
12	multiple	_	JJ	JJ	_	13	NMOD	_	_
13	effects	_	NNS	NNS	_	11	OBJ	_	_
14	on	_	IN	IN	_	11	ADV	_	_
15	cytokine	_	NN	NN	_	16	NMOD	_	_
16	production	_	NN	NN	_	14	PMOD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	human	_	JJ	JJ	_	19	NMOD	_	_
19	monocytes	_	NNS	NNS	_	17	PMOD	_	_
20	and	_	CC	CC	_	3	CC	_	_
21	suggest	_	VBP	VBP	_	3	COORD	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	these	_	DT	DT	_	25	NMOD	_	_
24	two	_	CD	CD	_	25	NMOD	_	_
25	phosphatases	_	NNS	NNS	_	26	SBJ	_	_
26	play	_	VBP	VBP	_	22	VMOD	_	_
27	important	_	JJ	JJ	_	28	NMOD	_	_
28	roles	_	NNS	NNS	_	26	OBJ	_	_
29	in	_	IN	IN	_	26	ADV	_	_
30	regulating	_	VBG	VBG	_	29	PMOD	_	_
31	interleukin-1	_	NN	NN	_	32	NMOD	_	_
32	production	_	NN	NN	_	30	OBJ	_	_
33	.	_	.	.	_	3	P	_	_

1	Cell	_	NN	NN	_	2	NMOD	_	_
2	type-	_	NN	NN	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	stage-specific	_	JJ	JJ	_	2	COORD	_	_
5	expression	_	NN	NN	_	10	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	CD20\/B1	_	NN	NN	_	9	NMOD	_	_
9	antigen	_	NN	NN	_	6	PMOD	_	_
10	correlates	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	activity	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	a	_	DT	DT	_	19	NMOD	_	_
16	diverged	_	JJ	JJ	_	19	NMOD	_	_
17	octamer	_	NN	NN	_	19	NMOD	_	_
18	DNA	_	NN	NN	_	19	NMOD	_	_
19	motif	_	NN	NN	_	14	PMOD	_	_
20	present	_	JJ	JJ	_	19	NMOD	_	_
21	in	_	IN	IN	_	20	AMOD	_	_
22	its	_	PRP$	PRP$	_	23	NMOD	_	_
23	promoter	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	CD20	_	NN	NN	_	6	NMOD	_	_
3	(	_	(	(	_	6	P	_	_
4	B1	_	NN	NN	_	6	NMOD	_	_
5	)	_	)	)	_	6	P	_	_
6	gene	_	NN	NN	_	7	SBJ	_	_
7	encodes	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	11	NMOD	_	_
9	B	_	NN	NN	_	11	NMOD	_	_
10	cell-specific	_	JJ	JJ	_	9	AMOD	_	_
11	protein	_	NN	NN	_	7	OBJ	_	_
12	involved	_	VBN	VBN	_	11	NMOD	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	regulation	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	human	_	JJ	JJ	_	19	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	cell	_	NN	NN	_	16	PMOD	_	_
20	proliferation	_	NN	NN	_	19	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	differentiation	_	NN	NN	_	20	COORD	_	_
23	.	_	.	.	_	7	P	_	_

1	Studies	_	NNS	NNS	_	8	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	5'	_	JJ	JJ	_	7	NMOD	_	_
4	deletion	_	NN	NN	_	7	NMOD	_	_
5	CD20	_	NN	NN	_	7	NMOD	_	_
6	promoter-CAT	_	NN	NN	_	7	NMOD	_	_
7	constructs	_	NNS	NNS	_	2	PMOD	_	_
8	have	_	VBP	VBP	_	0	ROOT-S	_	_
9	previously	_	RB	RB	_	10	TMP	_	_
10	revealed	_	VBN	VBN	_	8	VC	_	_
11	two	_	CD	CD	_	12	NMOD	_	_
12	regions	_	NNS	NNS	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	promoter	_	NN	NN	_	13	PMOD	_	_
16	between	_	IN	IN	_	12	NMOD	_	_
17	bases	_	NNS	NNS	_	16	PMOD	_	_
18	-186	_	CD	CD	_	17	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	-280	_	CD	CD	_	18	COORD	_	_
21	and	_	CC	CC	_	16	CC	_	_
22	between	_	IN	IN	_	16	COORD	_	_
23	bases	_	NNS	NNS	_	22	PMOD	_	_
24	-280	_	CD	CD	_	23	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	-454	_	CD	CD	_	24	COORD	_	_
27	which	_	WDT	WDT	_	28	SBJ	_	_
28	contained	_	VBD	VBD	_	12	NMOD	_	_
29	positive	_	JJ	JJ	_	31	NMOD	_	_
30	regulatory	_	JJ	JJ	_	31	NMOD	_	_
31	elements	_	NNS	NNS	_	28	OBJ	_	_
32	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	identified	_	VBD	VBD	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	sequence	_	NN	NN	_	8	NMOD	_	_
8	element	_	NN	NN	_	5	OBJ	_	_
9	present	_	JJ	JJ	_	8	NMOD	_	_
10	in	_	IN	IN	_	9	AMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	most	_	RBS	RBS	_	13	AMOD	_	_
13	proximal	_	JJ	JJ	_	14	NMOD	_	_
14	region	_	NN	NN	_	10	PMOD	_	_
15	located	_	JJ	JJ	_	14	NMOD	_	_
16	between	_	IN	IN	_	15	AMOD	_	_
17	bases	_	NNS	NNS	_	16	PMOD	_	_
18	-214	_	CD	CD	_	17	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	-201	_	CD	CD	_	18	COORD	_	_
21	,	_	,	,	_	14	P	_	_
22	TTCTTCTAATTAA	_	NN	NN	_	14	NMOD	_	_
23	,	_	,	,	_	8	P	_	_
24	which	_	WDT	WDT	_	25	SBJ	_	_
25	is	_	VBZ	VBZ	_	8	NMOD	_	_
26	important	_	JJ	JJ	_	25	PRD	_	_
27	in	_	IN	IN	_	25	ADV	_	_
28	the	_	DT	DT	_	31	NMOD	_	_
29	high	_	JJ	JJ	_	31	NMOD	_	_
30	constitutive	_	JJ	JJ	_	31	NMOD	_	_
31	expression	_	NN	NN	_	27	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	CD20	_	NN	NN	_	32	PMOD	_	_
34	in	_	IN	IN	_	31	NMOD	_	_
35	mature	_	JJ	JJ	_	37	NMOD	_	_
36	B	_	NN	NN	_	37	NMOD	_	_
37	cells	_	NNS	NNS	_	34	PMOD	_	_
38	and	_	CC	CC	_	31	CC	_	_
39	the	_	DT	DT	_	40	NMOD	_	_
40	induction	_	NN	NN	_	31	COORD	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	CD20	_	NN	NN	_	41	PMOD	_	_
43	in	_	IN	IN	_	40	NMOD	_	_
44	pre-B	_	JJ	JJ	_	45	NMOD	_	_
45	cells	_	NNS	NNS	_	43	PMOD	_	_
46	.	_	.	.	_	5	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	sequence	_	NN	NN	_	3	NMOD	_	_
3	element	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	referred	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	as	_	IN	IN	_	5	ADV	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	BAT	_	NN	NN	_	10	NMOD	_	_
10	box	_	NN	NN	_	7	PMOD	_	_
11	and	_	CC	CC	_	4	CC	_	_
12	its	_	PRP$	PRP$	_	13	NMOD	_	_
13	deletion	_	NN	NN	_	15	SBJ	_	_
14	significantly	_	RB	RB	_	15	ADV	_	_
15	reduced	_	VBD	VBD	_	4	COORD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	activity	_	NN	NN	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	a	_	DT	DT	_	22	NMOD	_	_
20	CD20	_	NN	NN	_	22	NMOD	_	_
21	promoter-CAT	_	JJ	JJ	_	22	NMOD	_	_
22	construct	_	NN	NN	_	18	PMOD	_	_
23	in	_	IN	IN	_	17	NMOD	_	_
24	B	_	NN	NN	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	23	PMOD	_	_
26	.	_	.	.	_	4	P	_	_

1	Mobility	_	NN	NN	_	3	NMOD	_	_
2	shift	_	NN	NN	_	3	NMOD	_	_
3	assays	_	NNS	NNS	_	13	SBJ	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	various	_	JJ	JJ	_	7	NMOD	_	_
6	mutant	_	JJ	JJ	_	7	NMOD	_	_
7	probes	_	NNS	NNS	_	4	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	B	_	NN	NN	_	12	NMOD	_	_
10	cell	_	NN	NN	_	12	NMOD	_	_
11	nuclear	_	JJ	JJ	_	12	NMOD	_	_
12	extracts	_	NNS	NNS	_	7	COORD	_	_
13	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
14	that	_	IN	IN	_	13	OBJ	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	core	_	NN	NN	_	18	NMOD	_	_
17	sequence	_	NN	NN	_	18	NMOD	_	_
18	TAAT	_	NN	NN	_	19	SBJ	_	_
19	was	_	VBD	VBD	_	14	VMOD	_	_
20	essential	_	JJ	JJ	_	19	PRD	_	_
21	for	_	IN	IN	_	20	AMOD	_	_
22	binding	_	VBG	VBG	_	21	PMOD	_	_
23	to	_	TO	TO	_	22	ADV	_	_
24	this	_	DT	DT	_	25	NMOD	_	_
25	site	_	NN	NN	_	23	PMOD	_	_
26	.	_	.	.	_	13	P	_	_

1	Cross	_	NN	NN	_	3	NMOD	_	_
2	competition	_	NN	NN	_	3	NMOD	_	_
3	experiments	_	NNS	NNS	_	28	SBJ	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	an	_	DT	DT	_	7	NMOD	_	_
6	octamer	_	NN	NN	_	7	NMOD	_	_
7	sequence	_	NN	NN	_	4	PMOD	_	_
8	from	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	Ig	_	NN	NN	_	13	NMOD	_	_
11	heavy	_	JJ	JJ	_	13	NMOD	_	_
12	chain	_	NN	NN	_	13	NMOD	_	_
13	promoter	_	NN	NN	_	8	PMOD	_	_
14	,	_	,	,	_	7	P	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	BAT	_	NN	NN	_	17	NMOD	_	_
17	box	_	NN	NN	_	7	COORD	_	_
18	,	_	,	,	_	7	P	_	_
19	and	_	CC	CC	_	7	CC	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	TA-rich	_	JJ	JJ	_	22	NMOD	_	_
22	sequence	_	NN	NN	_	7	COORD	_	_
23	present	_	JJ	JJ	_	22	NMOD	_	_
24	in	_	IN	IN	_	23	AMOD	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	CD21	_	NN	NN	_	27	NMOD	_	_
27	promoter	_	NN	NN	_	24	PMOD	_	_
28	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
29	that	_	IN	IN	_	28	OBJ	_	_
30	all	_	DT	DT	_	32	NMOD	_	_
31	three	_	CD	CD	_	32	NMOD	_	_
32	sequences	_	NNS	NNS	_	33	SBJ	_	_
33	bound	_	VBD	VBD	_	29	VMOD	_	_
34	the	_	DT	DT	_	37	NMOD	_	_
35	same	_	JJ	JJ	_	37	NMOD	_	_
36	nuclear	_	JJ	JJ	_	37	NMOD	_	_
37	proteins	_	NNS	NNS	_	33	IOBJ	_	_
38	suggesting	_	VBG	VBG	_	33	OBJ	_	_
39	that	_	IN	IN	_	38	OBJ	_	_
40	the	_	DT	DT	_	44	NMOD	_	_
41	BAT	_	NN	NN	_	44	NMOD	_	_
42	box	_	NN	NN	_	44	NMOD	_	_
43	binding	_	NN	NN	_	44	NMOD	_	_
44	proteins	_	NNS	NNS	_	45	SBJ	_	_
45	were	_	VBD	VBD	_	39	VMOD	_	_
46	Oct-1	_	NN	NN	_	45	PRD	_	_
47	and	_	CC	CC	_	46	CC	_	_
48	Oct-2	_	NN	NN	_	46	COORD	_	_
49	.	_	.	.	_	28	P	_	_

1	Southwestern	_	NN	NN	_	2	NMOD	_	_
2	blotting	_	NN	NN	_	7	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	UV	_	NN	NN	_	6	NMOD	_	_
5	cross-linking	_	NN	NN	_	6	NMOD	_	_
6	studies	_	NNS	NNS	_	2	COORD	_	_
7	confirmed	_	VBD	VBD	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	BAT	_	NN	NN	_	13	NMOD	_	_
11	box	_	NN	NN	_	13	NMOD	_	_
12	binding	_	NN	NN	_	13	NMOD	_	_
13	proteins	_	NNS	NNS	_	14	SBJ	_	_
14	were	_	VBD	VBD	_	8	VMOD	_	_
15	Oct-1	_	NN	NN	_	14	PRD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	Oct-2	_	NN	NN	_	15	COORD	_	_
18	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	affinity	_	NN	NN	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	BAT	_	NN	NN	_	8	NMOD	_	_
6	box	_	NN	NN	_	8	NMOD	_	_
7	binding	_	NN	NN	_	8	NMOD	_	_
8	proteins	_	NNS	NNS	_	3	PMOD	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	BAT	_	NN	NN	_	12	NMOD	_	_
12	box	_	NN	NN	_	9	PMOD	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	approximately	_	RB	RB	_	13	PRD	_	_
15	25-fold	_	RB	RB	_	14	AMOD	_	_
16	less	_	JJR	JJR	_	14	AMOD	_	_
17	than	_	IN	IN	_	14	AMOD	_	_
18	for	_	IN	IN	_	17	PMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	octamer	_	NN	NN	_	21	NMOD	_	_
21	sequence	_	NN	NN	_	18	PMOD	_	_
22	and	_	CC	CC	_	13	CC	_	_
23	the	_	DT	DT	_	27	NMOD	_	_
24	BAT	_	NN	NN	_	27	NMOD	_	_
25	box	_	NN	NN	_	27	NMOD	_	_
26	binding	_	NN	NN	_	27	NMOD	_	_
27	proteins	_	NNS	NNS	_	28	SBJ	_	_
28	dissociated	_	VBD	VBD	_	13	COORD	_	_
29	from	_	IN	IN	_	28	ADV	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	BAT	_	NN	NN	_	32	NMOD	_	_
32	box	_	NN	NN	_	29	PMOD	_	_
33	10-fold	_	RB	RB	_	35	AMOD	_	_
34	more	_	RBR	RBR	_	33	AMOD	_	_
35	rapidly	_	RB	RB	_	28	ADV	_	_
36	than	_	IN	IN	_	35	AMOD	_	_
37	from	_	IN	IN	_	36	PMOD	_	_
38	the	_	DT	DT	_	40	NMOD	_	_
39	octamer	_	NN	NN	_	40	NMOD	_	_
40	sequence	_	NN	NN	_	37	PMOD	_	_
41	.	_	.	.	_	13	P	_	_

1	Despite	_	IN	IN	_	13	ADV	_	_
2	this	_	DT	DT	_	4	NMOD	_	_
3	lower	_	JJR	JJR	_	4	NMOD	_	_
4	affinity	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	13	P	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	trimer	_	NN	NN	_	13	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	BAT	_	NN	NN	_	12	NMOD	_	_
11	box	_	NN	NN	_	12	NMOD	_	_
12	sequence	_	NN	NN	_	8	PMOD	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	as	_	IN	IN	_	15	AMOD	_	_
15	efficiently	_	RB	RB	_	13	ADV	_	_
16	transactivated	_	VBN	VBN	_	13	VC	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	an	_	DT	DT	_	21	NMOD	_	_
19	Oct-2	_	NN	NN	_	21	NMOD	_	_
20	expression	_	NN	NN	_	21	NMOD	_	_
21	vector	_	NN	NN	_	17	PMOD	_	_
22	as	_	IN	IN	_	15	AMOD	_	_
23	was	_	VBD	VBD	_	22	VMOD	_	_
24	a	_	DT	DT	_	25	NMOD	_	_
25	trimer	_	NN	NN	_	23	SBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	octamer	_	NN	NN	_	29	NMOD	_	_
29	sequence	_	NN	NN	_	26	PMOD	_	_
30	in	_	IN	IN	_	25	NMOD	_	_
31	HeLa	_	NN	NN	_	32	NMOD	_	_
32	cells	_	NNS	NNS	_	30	PMOD	_	_
33	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	BAT	_	NN	NN	_	3	NMOD	_	_
3	box	_	NN	NN	_	6	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	Oct-2	_	NN	NN	_	3	COORD	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	also	_	RB	RB	_	6	ADV	_	_
8	implicated	_	VBN	VBN	_	6	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	induction	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	CD20	_	NN	NN	_	12	PMOD	_	_
14	in	_	IN	IN	_	11	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	pre-B	_	JJ	JJ	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	line	_	NN	NN	_	14	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	PB-697	_	NN	NN	_	18	NMOD	_	_
21	,	_	,	,	_	8	P	_	_
22	via	_	IN	IN	_	8	ADV	_	_
23	phorbol	_	NN	NN	_	24	NMOD	_	_
24	esters	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	induction	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	CD20	_	NN	NN	_	5	NMOD	_	_
5	mRNA	_	NN	NN	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	temporally	_	RB	RB	_	8	TMP	_	_
8	associated	_	VBN	VBN	_	6	VC	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	induction	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	Oct-2	_	NN	NN	_	13	NMOD	_	_
13	mRNA	_	NN	NN	_	11	PMOD	_	_
14	and	_	CC	CC	_	6	CC	_	_
15	a	_	DT	DT	_	19	NMOD	_	_
16	BAT	_	NN	NN	_	19	NMOD	_	_
17	box-deleted	_	JJ	JJ	_	16	AMOD	_	_
18	CD20-CAT	_	NN	NN	_	19	NMOD	_	_
19	construct	_	NN	NN	_	28	SBJ	_	_
20	,	_	,	,	_	28	P	_	_
21	in	_	IN	IN	_	28	ADV	_	_
22	contrast	_	NN	NN	_	21	DEP	_	_
23	to	_	TO	TO	_	21	DEP	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	wild	_	JJ	JJ	_	26	NMOD	_	_
26	type	_	NN	NN	_	21	PMOD	_	_
27	,	_	,	,	_	28	P	_	_
28	was	_	VBD	VBD	_	6	COORD	_	_
29	poorly	_	RB	RB	_	30	ADV	_	_
30	induced	_	VBN	VBN	_	28	VC	_	_
31	by	_	IN	IN	_	30	LGS	_	_
32	phorbol	_	NN	NN	_	33	NMOD	_	_
33	esters	_	NNS	NNS	_	31	PMOD	_	_
34	.	_	.	.	_	6	P	_	_

1	Together	_	RB	RB	_	4	ADV	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	results	_	NNS	NNS	_	4	SBJ	_	_
4	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	BAT	_	NN	NN	_	10	NMOD	_	_
8	box	_	NN	NN	_	10	NMOD	_	_
9	binding	_	NN	NN	_	10	NMOD	_	_
10	proteins	_	NNS	NNS	_	11	SBJ	_	_
11	are	_	VBP	VBP	_	5	VMOD	_	_
12	important	_	JJ	JJ	_	11	PRD	_	_
13	in	_	IN	IN	_	11	ADV	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	B	_	NN	NN	_	16	NMOD	_	_
16	cell	_	NN	NN	_	17	AMOD	_	_
17	specific	_	JJ	JJ	_	18	NMOD	_	_
18	expression	_	NN	NN	_	13	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	CD20	_	NN	NN	_	19	PMOD	_	_
21	and	_	CC	CC	_	11	CC	_	_
22	perhaps	_	RB	RB	_	23	ADV	_	_
23	CD21	_	NN	NN	_	20	GAP	_	_
24	.	_	.	.	_	4	P	_	_

1	Transcription	_	NN	NN	_	3	NMOD	_	_
2	factor	_	NN	NN	_	3	NMOD	_	_
3	jun-B	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	target	_	NN	NN	_	4	PRD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	autoreactive	_	JJ	JJ	_	8	NMOD	_	_
8	T-cells	_	NNS	NNS	_	6	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	IDDM	_	NN	NN	_	9	PMOD	_	_
11	.	_	.	.	_	4	P	_	_

1	Target	_	NN	NN	_	2	NMOD	_	_
2	antigens	_	NNS	NNS	_	8	SBJ	_	_
3	defined	_	VBN	VBN	_	2	NMOD	_	_
4	by	_	IN	IN	_	3	ADV	_	_
5	autoantibodies	_	NNS	NNS	_	4	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	IDDM	_	NN	NN	_	6	PMOD	_	_
8	include	_	VBP	VBP	_	0	ROOT-S	_	_
9	insulin	_	NN	NN	_	8	OBJ	_	_
10	,	_	,	,	_	9	P	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	putative	_	JJ	JJ	_	13	NMOD	_	_
13	glycolipid	_	NN	NN	_	9	COORD	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	reacts	_	VBZ	VBZ	_	13	NMOD	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	islet	_	NN	NN	_	19	NMOD	_	_
18	cell	_	NN	NN	_	19	NMOD	_	_
19	antibodies	_	NNS	NNS	_	16	PMOD	_	_
20	,	_	,	,	_	9	P	_	_
21	and	_	CC	CC	_	9	CC	_	_
22	a	_	DT	DT	_	24	NMOD	_	_
23	64,000-M-LRB-r-RRB-	_	JJ	JJ	_	24	NMOD	_	_
24	protein	_	NN	NN	_	9	COORD	_	_
25	recently	_	RB	RB	_	26	TMP	_	_
26	identified	_	VBN	VBN	_	24	NMOD	_	_
27	as	_	IN	IN	_	26	ADV	_	_
28	glutamic	_	JJ	JJ	_	30	NMOD	_	_
29	acid	_	NN	NN	_	30	NMOD	_	_
30	decarboxylase	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	15	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	15	P	_	_
4	some	_	DT	DT	_	6	NMOD	_	_
5	IDDM	_	NN	NN	_	6	NMOD	_	_
6	sera	_	NN	NN	_	15	SBJ	_	_
7	that	_	WDT	WDT	_	8	SBJ	_	_
8	contain	_	VBP	VBP	_	6	NMOD	_	_
9	antibodies	_	NNS	NNS	_	8	OBJ	_	_
10	to	_	TO	TO	_	9	NMOD	_	_
11	glutamic	_	JJ	JJ	_	13	NMOD	_	_
12	acid	_	NN	NN	_	13	NMOD	_	_
13	decarboxylase	_	NN	NN	_	10	PMOD	_	_
14	also	_	RB	RB	_	15	ADV	_	_
15	coprecipitate	_	VBP	VBP	_	0	ROOT-S	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	38,000-M-LRB-r-RRB-	_	JJ	JJ	_	18	NMOD	_	_
18	protein	_	NN	NN	_	15	OBJ	_	_
19	from	_	IN	IN	_	18	NMOD	_	_
20	islets	_	NNS	NNS	_	19	PMOD	_	_
21	.	_	.	.	_	15	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	study	_	NN	NN	_	3	SBJ	_	_
3	used	_	VBD	VBD	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	8	NMOD	_	_
5	high	_	JJ	JJ	_	8	NMOD	_	_
6	titer	_	NN	NN	_	8	NMOD	_	_
7	anti-38,000-M-LRB-r-RRB-	_	JJ	JJ	_	8	NMOD	_	_
8	serum	_	NN	NN	_	3	IOBJ	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	screen	_	VB	VB	_	3	OBJ	_	_
11	bacteriophage	_	NN	NN	_	15	NMOD	_	_
12	lambda	_	NN	NN	_	15	NMOD	_	_
13	cDNA	_	NN	NN	_	15	NMOD	_	_
14	expression	_	NN	NN	_	15	NMOD	_	_
15	libraries	_	NNS	NNS	_	10	OBJ	_	_
16	and	_	CC	CC	_	3	CC	_	_
17	identified	_	VBD	VBD	_	3	COORD	_	_
18	human	_	JJ	JJ	_	19	NMOD	_	_
19	islet	_	NN	NN	_	17	OBJ	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	placental	_	JJ	JJ	_	22	NMOD	_	_
22	clones	_	NNS	NNS	_	19	COORD	_	_
23	encoding	_	VBG	VBG	_	19	NMOD	_	_
24	jun-B	_	NN	NN	_	23	OBJ	_	_
25	,	_	,	,	_	24	P	_	_
26	the	_	DT	DT	_	29	NMOD	_	_
27	nuclear	_	JJ	JJ	_	29	NMOD	_	_
28	transcription	_	NN	NN	_	29	NMOD	_	_
29	protein	_	NN	NN	_	24	NMOD	_	_
30	,	_	,	,	_	24	P	_	_
31	of	_	IN	IN	_	24	NMOD	_	_
32	predicted	_	VBN	VBN	_	34	NMOD	_	_
33	38,000	_	CD	CD	_	34	NMOD	_	_
34	M-LRB-r-RRB-	_	NN	NN	_	31	PMOD	_	_
35	.	_	.	.	_	3	P	_	_

1	Peripheral	_	JJ	JJ	_	3	NMOD	_	_
2	blood	_	NN	NN	_	3	NMOD	_	_
3	T-cells	_	NNS	NNS	_	4	SBJ	_	_
4	exhibited	_	VBD	VBD	_	0	ROOT-S	_	_
5	significant	_	JJ	JJ	_	6	NMOD	_	_
6	proliferation	_	NN	NN	_	4	OBJ	_	_
7	in	_	IN	IN	_	4	ADV	_	_
8	response	_	NN	NN	_	7	DEP	_	_
9	to	_	TO	TO	_	7	DEP	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	recombinant	_	JJ	JJ	_	12	NMOD	_	_
12	fragment	_	NN	NN	_	7	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	jun-B	_	NN	NN	_	13	PMOD	_	_
15	(	_	(	(	_	17	P	_	_
16	amino	_	NN	NN	_	17	NMOD	_	_
17	acids	_	NNS	NNS	_	14	PRN	_	_
18	1-180	_	CD	CD	_	17	NMOD	_	_
19	)	_	)	)	_	17	P	_	_
20	in	_	IN	IN	_	14	NMOD	_	_
21	12	_	CD	CD	_	23	DEP	_	_
22	of	_	IN	IN	_	23	DEP	_	_
23	17	_	CD	CD	_	30	NMOD	_	_
24	(	_	(	(	_	26	P	_	_
25	71	_	CD	CD	_	26	NMOD	_	_
26	%	_	NN	NN	_	23	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	recent-onset	_	JJ	JJ	_	30	NMOD	_	_
29	IDDM	_	NN	NN	_	30	NMOD	_	_
30	subjects	_	NNS	NNS	_	20	PMOD	_	_
31	,	_	,	,	_	30	P	_	_
32	8	_	CD	CD	_	34	DEP	_	_
33	of	_	IN	IN	_	34	DEP	_	_
34	16	_	CD	CD	_	41	NMOD	_	_
35	(	_	(	(	_	37	P	_	_
36	50	_	CD	CD	_	37	NMOD	_	_
37	%	_	NN	NN	_	34	PRN	_	_
38	)	_	)	)	_	37	P	_	_
39	ICA-positive	_	JJ	JJ	_	41	NMOD	_	_
40	first-degree	_	JJ	JJ	_	41	NMOD	_	_
41	relatives	_	NNS	NNS	_	30	COORD	_	_
42	of	_	IN	IN	_	41	NMOD	_	_
43	IDDM	_	NN	NN	_	44	NMOD	_	_
44	subjects	_	NNS	NNS	_	42	PMOD	_	_
45	who	_	WP	WP	_	46	SBJ	_	_
46	were	_	VBD	VBD	_	44	NMOD	_	_
47	at	_	IN	IN	_	46	PRD	_	_
48	risk	_	NN	NN	_	47	PMOD	_	_
49	,	_	,	,	_	30	P	_	_
50	3	_	CD	CD	_	52	DEP	_	_
51	of	_	IN	IN	_	52	DEP	_	_
52	12	_	CD	CD	_	60	NMOD	_	_
53	(	_	(	(	_	55	P	_	_
54	25	_	CD	CD	_	55	NMOD	_	_
55	%	_	NN	NN	_	52	PRN	_	_
56	)	_	)	)	_	55	P	_	_
57	other	_	JJ	JJ	_	60	NMOD	_	_
58	autoimmune	_	JJ	JJ	_	60	NMOD	_	_
59	disease	_	NN	NN	_	60	NMOD	_	_
60	subjects	_	NNS	NNS	_	30	COORD	_	_
61	,	_	,	,	_	30	P	_	_
62	and	_	CC	CC	_	30	CC	_	_
63	0	_	CD	CD	_	65	DEP	_	_
64	of	_	IN	IN	_	65	DEP	_	_
65	10	_	CD	CD	_	68	NMOD	_	_
66	healthy	_	JJ	JJ	_	68	NMOD	_	_
67	control	_	NN	NN	_	68	NMOD	_	_
68	subjects	_	NNS	NNS	_	30	COORD	_	_
69	.	_	.	.	_	4	P	_	_

1	Proliferation	_	NN	NN	_	5	SBJ	_	_
2	to	_	TO	TO	_	1	NMOD	_	_
3	tetanus	_	NN	NN	_	4	NMOD	_	_
4	toxoid	_	NN	NN	_	2	PMOD	_	_
5	did	_	VBD	VBD	_	0	ROOT-S	_	_
6	not	_	RB	RB	_	5	VMOD	_	_
7	differ	_	VB	VB	_	5	VC	_	_
8	significantly	_	RB	RB	_	7	ADV	_	_
9	between	_	IN	IN	_	7	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	groups	_	NNS	NNS	_	9	PMOD	_	_
12	.	_	.	.	_	5	P	_	_

1	Responses	_	NNS	NNS	_	4	SBJ	_	_
2	to	_	TO	TO	_	1	NMOD	_	_
3	jun-B	_	NN	NN	_	2	PMOD	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	related	_	JJ	JJ	_	4	PRD	_	_
7	to	_	TO	TO	_	6	AMOD	_	_
8	age	_	NN	NN	_	7	PMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	sex	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	8	P	_	_
12	or	_	CC	CC	_	8	CC	_	_
13	human	_	JJ	JJ	_	16	NMOD	_	_
14	leukocyte	_	NN	NN	_	16	NMOD	_	_
15	antigen	_	NN	NN	_	16	NMOD	_	_
16	status	_	NN	NN	_	8	COORD	_	_
17	.	_	.	.	_	4	P	_	_

1	Thus	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	autoreactive	_	JJ	JJ	_	4	NMOD	_	_
4	T-cells	_	NNS	NNS	_	5	SBJ	_	_
5	identify	_	VBP	VBP	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	novel	_	JJ	JJ	_	8	NMOD	_	_
8	antigen	_	NN	NN	_	5	OBJ	_	_
9	,	_	,	,	_	8	P	_	_
10	p38	_	NN	NN	_	11	NMOD	_	_
11	jun-B	_	NN	NN	_	8	NMOD	_	_
12	,	_	,	,	_	8	P	_	_
13	in	_	IN	IN	_	8	NMOD	_	_
14	IDDM	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	5	CC	_	_
16	appear	_	VBP	VBP	_	5	COORD	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	indicate	_	VB	VB	_	16	OBJ	_	_
19	subjects	_	NNS	NNS	_	18	OBJ	_	_
20	at	_	IN	IN	_	19	NMOD	_	_
21	risk	_	NN	NN	_	20	PMOD	_	_
22	for	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	development	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	clinical	_	JJ	JJ	_	27	NMOD	_	_
27	disease	_	NN	NN	_	25	PMOD	_	_
28	.	_	.	.	_	5	P	_	_

1	Transcriptional	_	JJ	JJ	_	2	NMOD	_	_
2	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	interleukin	_	NN	NN	_	3	PMOD	_	_
5	3	_	CD	CD	_	4	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	IL3	_	NN	NN	_	4	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	in	_	IN	IN	_	4	NMOD	_	_
10	primary	_	JJ	JJ	_	13	NMOD	_	_
11	human	_	JJ	JJ	_	13	NMOD	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	Role	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	AP-1-	_	NN	NN	_	6	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	octamer-binding	_	JJ	JJ	_	3	COORD	_	_
6	proteins	_	NNS	NNS	_	2	PMOD	_	_
7	in	_	IN	IN	_	1	NMOD	_	_
8	control	_	NN	NN	_	7	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	IL3	_	NN	NN	_	12	NMOD	_	_
11	gene	_	NN	NN	_	12	NMOD	_	_
12	expression	_	NN	NN	_	9	PMOD	_	_
13	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	investigated	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	molecular	_	JJ	JJ	_	8	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	biochemical	_	JJ	JJ	_	5	COORD	_	_
8	basis	_	NN	NN	_	3	OBJ	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	activation	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	interleukin	_	NN	NN	_	18	NMOD	_	_
13	3	_	CD	CD	_	12	NMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	IL3	_	NN	NN	_	12	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	gene	_	NN	NN	_	18	NMOD	_	_
18	expression	_	NN	NN	_	11	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	primary	_	JJ	JJ	_	23	NMOD	_	_
21	human	_	JJ	JJ	_	23	NMOD	_	_
22	T	_	NN	NN	_	23	NMOD	_	_
23	lymphocytes	_	NNS	NNS	_	19	PMOD	_	_
24	following	_	VBG	VBG	_	10	TMP	_	_
25	CD3	_	NN	NN	_	28	NMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	CD2	_	NN	NN	_	25	COORD	_	_
28	receptor	_	NN	NN	_	24	PMOD	_	_
29	stimulation	_	NN	NN	_	28	NMOD	_	_
30	or	_	CC	CC	_	29	CC	_	_
31	activation	_	NN	NN	_	29	COORD	_	_
32	by	_	IN	IN	_	28	NMOD	_	_
33	phytohemagglutinin	_	NN	NN	_	32	PMOD	_	_
34	plus	_	CC	CC	_	33	CC	_	_
35	phorbol	_	NN	NN	_	37	NMOD	_	_
36	12-myristate	_	NN	NN	_	37	NMOD	_	_
37	13-acetate	_	NN	NN	_	33	COORD	_	_
38	.	_	.	.	_	2	P	_	_

1	Using	_	VBG	VBG	_	29	VMOD	_	_
2	transfection	_	NN	NN	_	6	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	reporter	_	NN	NN	_	5	NMOD	_	_
5	gene	_	NN	NN	_	2	COORD	_	_
6	assays	_	NNS	NNS	_	1	OBJ	_	_
7	specifically	_	RB	RB	_	8	ADV	_	_
8	designed	_	VBN	VBN	_	6	NMOD	_	_
9	for	_	IN	IN	_	8	ADV	_	_
10	primary	_	JJ	JJ	_	12	NMOD	_	_
11	T	_	NN	NN	_	12	NMOD	_	_
12	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
13	in	_	IN	IN	_	8	ADV	_	_
14	conjunction	_	NN	NN	_	13	DEP	_	_
15	with	_	IN	IN	_	13	DEP	_	_
16	gel	_	NN	NN	_	18	NMOD	_	_
17	retardation	_	NN	NN	_	18	NMOD	_	_
18	assays	_	NNS	NNS	_	13	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	Western	_	NN	NN	_	22	NMOD	_	_
21	blot	_	NN	NN	_	22	NMOD	_	_
22	analyses	_	NNS	NNS	_	18	COORD	_	_
23	and	_	CC	CC	_	18	CC	_	_
24	UV	_	NN	NN	_	26	NMOD	_	_
25	cross-linking	_	JJ	JJ	_	26	NMOD	_	_
26	studies	_	NNS	NNS	_	18	COORD	_	_
27	,	_	,	,	_	29	P	_	_
28	we	_	PRP	PRP	_	29	SBJ	_	_
29	found	_	VBD	VBD	_	0	ROOT-S	_	_
30	that	_	IN	IN	_	29	OBJ	_	_
31	c-Jun	_	NN	NN	_	37	NMOD	_	_
32	,	_	,	,	_	31	P	_	_
33	c-Fos	_	NN	NN	_	31	COORD	_	_
34	,	_	,	,	_	31	P	_	_
35	and	_	CC	CC	_	31	CC	_	_
36	octamer-binding	_	NN	NN	_	31	COORD	_	_
37	proteins	_	NNS	NNS	_	38	SBJ	_	_
38	play	_	VBP	VBP	_	30	VMOD	_	_
39	a	_	DT	DT	_	41	NMOD	_	_
40	major	_	JJ	JJ	_	41	NMOD	_	_
41	role	_	NN	NN	_	38	OBJ	_	_
42	in	_	IN	IN	_	38	ADV	_	_
43	transcriptional	_	JJ	JJ	_	44	NMOD	_	_
44	activation	_	NN	NN	_	42	PMOD	_	_
45	of	_	IN	IN	_	44	NMOD	_	_
46	the	_	DT	DT	_	48	NMOD	_	_
47	IL3	_	NN	NN	_	48	NMOD	_	_
48	gene	_	NN	NN	_	45	PMOD	_	_
49	via	_	IN	IN	_	38	ADV	_	_
50	their	_	PRP$	PRP$	_	51	NMOD	_	_
51	interaction	_	NN	NN	_	49	PMOD	_	_
52	with	_	IN	IN	_	51	NMOD	_	_
53	two	_	CD	CD	_	55	NMOD	_	_
54	specific	_	JJ	JJ	_	55	NMOD	_	_
55	regions	_	NNS	NNS	_	52	PMOD	_	_
56	contained	_	VBN	VBN	_	55	NMOD	_	_
57	within	_	IN	IN	_	56	ADV	_	_
58	the	_	DT	DT	_	61	NMOD	_	_
59	IL3	_	NN	NN	_	61	NMOD	_	_
60	5'-flanking	_	JJ	JJ	_	61	NMOD	_	_
61	sequence	_	NN	NN	_	57	PMOD	_	_
62	.	_	.	.	_	29	P	_	_

1	Additionally	_	RB	RB	_	21	ADV	_	_
2	,	_	,	,	_	21	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	region	_	NN	NN	_	21	SBJ	_	_
5	between	_	IN	IN	_	4	NMOD	_	_
6	bases	_	NNS	NNS	_	5	PMOD	_	_
7	-107	_	CD	CD	_	6	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	-59	_	CD	CD	_	7	COORD	_	_
10	of	_	IN	IN	_	6	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	IL3	_	NN	NN	_	13	NMOD	_	_
13	promoter	_	NN	NN	_	10	PMOD	_	_
14	containing	_	VBG	VBG	_	13	NMOD	_	_
15	putative	_	JJ	JJ	_	20	NMOD	_	_
16	AP-2	_	NN	NN	_	20	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	Sp1	_	NN	NN	_	16	COORD	_	_
19	binding	_	NN	NN	_	20	NMOD	_	_
20	motifs	_	NNS	NNS	_	14	OBJ	_	_
21	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
22	necessary	_	JJ	JJ	_	21	PRD	_	_
23	for	_	IN	IN	_	22	AMOD	_	_
24	basal	_	JJ	JJ	_	26	NMOD	_	_
25	level	_	NN	NN	_	26	NMOD	_	_
26	expression	_	NN	NN	_	23	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	IL3	_	NN	NN	_	30	NMOD	_	_
30	gene	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	21	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	4	SBJ	_	_
3	also	_	RB	RB	_	4	ADV	_	_
4	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	CD2	_	NN	NN	_	8	NMOD	_	_
7	receptor	_	NN	NN	_	8	NMOD	_	_
8	activation	_	NN	NN	_	16	SBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	phytohemagglutinin	_	NN	NN	_	15	NMOD	_	_
11	plus	_	CC	CC	_	10	CC	_	_
12	phorbol	_	NN	NN	_	14	NMOD	_	_
13	12-myristate	_	NN	NN	_	14	NMOD	_	_
14	13-acetate	_	NN	NN	_	10	COORD	_	_
15	stimulation	_	NN	NN	_	8	COORD	_	_
16	augment	_	VBP	VBP	_	5	VMOD	_	_
17	T	_	NN	NN	_	21	NMOD	_	_
18	cell	_	NN	NN	_	21	NMOD	_	_
19	IL3	_	NN	NN	_	21	NMOD	_	_
20	gene	_	NN	NN	_	21	NMOD	_	_
21	expression	_	NN	NN	_	16	OBJ	_	_
22	through	_	IN	IN	_	16	ADV	_	_
23	the	_	DT	DT	_	28	NMOD	_	_
24	same	_	JJ	JJ	_	28	NMOD	_	_
25	cis-	_	JJ	JJ	_	28	NMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	trans-activating	_	JJ	JJ	_	25	COORD	_	_
28	signals	_	NNS	NNS	_	22	PMOD	_	_
29	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	should	_	MD	MD	_	0	ROOT-S	_	_
4	contribute	_	VB	VB	_	3	VC	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	better	_	JJR	JJR	_	8	NMOD	_	_
8	understanding	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	regulation	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	IL3	_	NN	NN	_	15	NMOD	_	_
14	gene	_	NN	NN	_	15	NMOD	_	_
15	expression	_	NN	NN	_	12	PMOD	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	human	_	JJ	JJ	_	19	NMOD	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	lymphocytes	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Interaction	_	NN	NN	_	10	SBJ	_	_
2	between	_	IN	IN	_	1	NMOD	_	_
3	NF-kappa	_	NN	NN	_	4	NMOD	_	_
4	B-	_	NN	NN	_	9	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	serum	_	NN	NN	_	7	AMOD	_	_
7	response	_	NN	NN	_	4	COORD	_	_
8	factor-binding	_	JJ	JJ	_	7	AMOD	_	_
9	elements	_	NNS	NNS	_	2	PMOD	_	_
10	activates	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	an	_	DT	DT	_	15	NMOD	_	_
12	interleukin-2	_	NN	NN	_	15	NMOD	_	_
13	receptor	_	NN	NN	_	15	NMOD	_	_
14	alpha-chain	_	JJ	JJ	_	15	NMOD	_	_
15	enhancer	_	NN	NN	_	10	OBJ	_	_
16	specifically	_	RB	RB	_	10	ADV	_	_
17	in	_	IN	IN	_	10	ADV	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	lymphocytes	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	10	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	find	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	short	_	JJ	JJ	_	7	NMOD	_	_
6	enhancer	_	NN	NN	_	7	NMOD	_	_
7	element	_	NN	NN	_	24	SBJ	_	_
8	containing	_	VBG	VBG	_	7	NMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	NF-kappa	_	NN	NN	_	13	NMOD	_	_
11	B	_	NN	NN	_	13	NMOD	_	_
12	binding	_	NN	NN	_	13	NMOD	_	_
13	site	_	NN	NN	_	8	OBJ	_	_
14	from	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	interleukin-2	_	NN	NN	_	19	NMOD	_	_
17	receptor	_	NN	NN	_	19	NMOD	_	_
18	alpha-chain	_	JJ	JJ	_	19	NMOD	_	_
19	gene	_	NN	NN	_	14	PMOD	_	_
20	(	_	(	(	_	22	P	_	_
21	IL-2R	_	NN	NN	_	22	NMOD	_	_
22	alpha	_	NN	NN	_	19	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	is	_	VBZ	VBZ	_	3	VMOD	_	_
25	preferentially	_	RB	RB	_	26	ADV	_	_
26	activated	_	VBN	VBN	_	24	VC	_	_
27	in	_	IN	IN	_	26	ADV	_	_
28	T	_	NN	NN	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	27	PMOD	_	_
30	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	IL-2R	_	NN	NN	_	4	NMOD	_	_
3	alpha	_	NN	NN	_	4	NMOD	_	_
4	enhancer	_	NN	NN	_	5	SBJ	_	_
5	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	NF-kappa	_	NN	NN	_	7	NMOD	_	_
7	B	_	NN	NN	_	5	OBJ	_	_
8	poorly	_	RB	RB	_	5	ADV	_	_
9	and	_	CC	CC	_	5	CC	_	_
10	is	_	VBZ	VBZ	_	5	COORD	_	_
11	only	_	RB	RB	_	13	ADV	_	_
12	weakly	_	RB	RB	_	11	AMOD	_	_
13	activated	_	VBN	VBN	_	10	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	NF-kappa	_	NN	NN	_	18	NMOD	_	_
17	B	_	NN	NN	_	18	NMOD	_	_
18	site	_	NN	NN	_	14	PMOD	_	_
19	alone	_	RB	RB	_	18	NMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	Serum	_	NN	NN	_	3	NMOD	_	_
2	response	_	NN	NN	_	3	NMOD	_	_
3	factor	_	NN	NN	_	7	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	SRF	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	site	_	NN	NN	_	8	PMOD	_	_
11	adjacent	_	JJ	JJ	_	10	NMOD	_	_
12	to	_	TO	TO	_	11	AMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	NF-kappa	_	NN	NN	_	16	NMOD	_	_
15	B	_	NN	NN	_	16	NMOD	_	_
16	site	_	NN	NN	_	12	PMOD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	IL-2R	_	NN	NN	_	20	NMOD	_	_
20	enhancer	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	7	P	_	_
22	and	_	CC	CC	_	7	CC	_	_
23	both	_	DT	DT	_	24	NMOD	_	_
24	sites	_	NNS	NNS	_	26	SBJ	_	_
25	together	_	RB	RB	_	24	NMOD	_	_
26	have	_	VBP	VBP	_	7	COORD	_	_
27	strong	_	JJ	JJ	_	29	NMOD	_	_
28	transcriptional	_	JJ	JJ	_	29	NMOD	_	_
29	activity	_	NN	NN	_	26	OBJ	_	_
30	specifically	_	RB	RB	_	26	ADV	_	_
31	in	_	IN	IN	_	26	ADV	_	_
32	T	_	NN	NN	_	33	NMOD	_	_
33	cells	_	NNS	NNS	_	31	PMOD	_	_
34	.	_	.	.	_	7	P	_	_

1	Surprisingly	_	RB	RB	_	12	ADV	_	_
2	,	_	,	,	_	12	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	levels	_	NNS	NNS	_	12	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	SRF	_	NN	NN	_	5	PMOD	_	_
7	constitutively	_	RB	RB	_	8	ADV	_	_
8	expressed	_	VBN	VBN	_	6	NMOD	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	T	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	are	_	VBP	VBP	_	0	ROOT-S	_	_
13	consistently	_	RB	RB	_	12	TMP	_	_
14	higher	_	JJR	JJR	_	12	PRD	_	_
15	than	_	IN	IN	_	14	AMOD	_	_
16	in	_	IN	IN	_	15	PMOD	_	_
17	other	_	JJ	JJ	_	19	NMOD	_	_
18	cell	_	NN	NN	_	19	NMOD	_	_
19	types	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	12	P	_	_

1	Overexpression	_	NN	NN	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	SRF	_	NN	NN	_	2	PMOD	_	_
4	in	_	IN	IN	_	1	NMOD	_	_
5	B	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	causes	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	IL-2R	_	NN	NN	_	10	NMOD	_	_
10	enhancer	_	NN	NN	_	12	SBJ	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	function	_	VB	VB	_	7	OBJ	_	_
13	as	_	RB	RB	_	15	VMOD	_	_
14	well	_	RB	RB	_	15	VMOD	_	_
15	as	_	IN	IN	_	7	ADV	_	_
16	it	_	PRP	PRP	_	17	SBJ	_	_
17	does	_	VBZ	VBZ	_	15	VMOD	_	_
18	in	_	IN	IN	_	17	VC	_	_
19	T	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	18	PMOD	_	_
21	,	_	,	,	_	7	P	_	_
22	suggesting	_	VBG	VBG	_	7	ADV	_	_
23	that	_	IN	IN	_	22	OBJ	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	high	_	JJ	JJ	_	26	NMOD	_	_
26	level	_	NN	NN	_	33	SBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	SRF	_	NN	NN	_	29	NMOD	_	_
29	binding	_	NN	NN	_	27	PMOD	_	_
30	in	_	IN	IN	_	29	NMOD	_	_
31	T	_	NN	NN	_	32	NMOD	_	_
32	cells	_	NNS	NNS	_	30	PMOD	_	_
33	is	_	VBZ	VBZ	_	23	VMOD	_	_
34	functionally	_	RB	RB	_	33	ADV	_	_
35	important	_	JJ	JJ	_	33	PRD	_	_
36	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	transcriptionally	_	RB	RB	_	3	AMOD	_	_
3	active	_	JJ	JJ	_	4	NMOD	_	_
4	factors	_	NNS	NNS	_	20	SBJ	_	_
5	mediating	_	VBG	VBG	_	4	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	effect	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	HTLV-I	_	NN	NN	_	12	NMOD	_	_
11	Tax	_	NN	NN	_	12	NMOD	_	_
12	transactivator	_	NN	NN	_	8	PMOD	_	_
13	on	_	IN	IN	_	7	NMOD	_	_
14	the	_	DT	DT	_	19	NMOD	_	_
15	IL-2R	_	NN	NN	_	19	NMOD	_	_
16	alpha	_	NN	NN	_	19	NMOD	_	_
17	kappa	_	NN	NN	_	19	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	enhancer	_	NN	NN	_	13	PMOD	_	_
20	include	_	VBP	VBP	_	0	ROOT-S	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	product	_	NN	NN	_	20	OBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	c-rel	_	NN	NN	_	26	NMOD	_	_
26	proto-oncogene	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	20	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	transactivator	_	NN	NN	_	4	NMOD	_	_
3	HTLV-I	_	NN	NN	_	4	NMOD	_	_
4	Tax	_	NN	NN	_	5	SBJ	_	_
5	activates	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	promoter	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	gene	_	NN	NN	_	8	PMOD	_	_
11	coding	_	VBG	VBG	_	10	NMOD	_	_
12	for	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	interleukin	_	NN	NN	_	17	NMOD	_	_
15	2	_	CD	CD	_	17	NMOD	_	_
16	alpha-chain	_	JJ	JJ	_	17	NMOD	_	_
17	receptor	_	NN	NN	_	12	PMOD	_	_
18	(	_	(	(	_	20	P	_	_
19	IL-2R	_	NN	NN	_	20	NMOD	_	_
20	alpha	_	NN	NN	_	17	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	via	_	IN	IN	_	11	ADV	_	_
23	a	_	DT	DT	_	26	NMOD	_	_
24	kappa	_	NN	NN	_	26	NMOD	_	_
25	B	_	NN	NN	_	26	NMOD	_	_
26	site	_	NN	NN	_	22	PMOD	_	_
27	that	_	WDT	WDT	_	28	SBJ	_	_
28	can	_	MD	MD	_	26	NMOD	_	_
29	bind	_	VB	VB	_	28	VC	_	_
30	several	_	JJ	JJ	_	32	NMOD	_	_
31	protein	_	NN	NN	_	32	NMOD	_	_
32	species	_	NNS	NNS	_	29	OBJ	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	the	_	DT	DT	_	36	NMOD	_	_
35	rel	_	NN	NN	_	36	NMOD	_	_
36	family	_	NN	NN	_	33	PMOD	_	_
37	.	_	.	.	_	5	P	_	_

1	Tax1	_	NN	NN	_	3	SBJ	_	_
2	strongly	_	RB	RB	_	3	ADV	_	_
3	activates	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	enhancer	_	NN	NN	_	6	NMOD	_	_
6	activity	_	NN	NN	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	this	_	DT	DT	_	9	NMOD	_	_
9	motif	_	NN	NN	_	7	PMOD	_	_
10	,	_	,	,	_	3	P	_	_
11	in	_	IN	IN	_	3	ADV	_	_
12	both	_	CC	CC	_	14	CC	_	_
13	epithelial	_	JJ	JJ	_	14	NMOD	_	_
14	HeLa	_	NN	NN	_	18	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	lymphoid	_	JJ	JJ	_	17	NMOD	_	_
17	Jurkat	_	NN	NN	_	14	COORD	_	_
18	cells	_	NNS	NNS	_	11	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	activation	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	observed	_	VBN	VBN	_	3	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	undifferentiated	_	JJ	JJ	_	10	NMOD	_	_
8	embryocarcinoma	_	NN	NN	_	10	NMOD	_	_
9	F9	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	6	PMOD	_	_
11	.	_	.	.	_	3	P	_	_

1	Overexpression	_	NN	NN	_	13	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	9	NMOD	_	_
4	p50	_	NN	NN	_	9	NMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	p65	_	NN	NN	_	4	COORD	_	_
7	and	_	CC	CC	_	4	CC	_	_
8	Rel	_	NN	NN	_	4	COORD	_	_
9	proteins	_	NNS	NNS	_	2	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	these	_	DT	DT	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	showed	_	VBD	VBD	_	0	ROOT-S	_	_
14	that	_	IN	IN	_	13	OBJ	_	_
15	significant	_	JJ	JJ	_	16	NMOD	_	_
16	activation	_	NN	NN	_	24	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	23	NMOD	_	_
19	IL-2R	_	NN	NN	_	23	NMOD	_	_
20	alpha	_	NN	NN	_	23	NMOD	_	_
21	kappa	_	NN	NN	_	23	NMOD	_	_
22	B	_	NN	NN	_	23	NMOD	_	_
23	site	_	NN	NN	_	17	PMOD	_	_
24	was	_	VBD	VBD	_	14	VMOD	_	_
25	observed	_	VBN	VBN	_	24	VC	_	_
26	only	_	RB	RB	_	27	DEP	_	_
27	with	_	IN	IN	_	25	ADV	_	_
28	Rel	_	NN	NN	_	27	PMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	Rel	_	NN	NN	_	28	COORD	_	_
31	plus	_	CC	CC	_	30	CC	_	_
32	p65	_	NN	NN	_	30	COORD	_	_
33	.	_	.	.	_	13	P	_	_

1	Moreover	_	RB	RB	_	32	ADV	_	_
2	,	_	,	,	_	32	P	_	_
3	whereas	_	IN	IN	_	32	ADV	_	_
4	both	_	CC	CC	_	5	CC	_	_
5	Tax	_	NN	NN	_	13	SBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	phorbol	_	NN	NN	_	9	NMOD	_	_
8	12-myristate	_	NN	NN	_	9	NMOD	_	_
9	13-acetate	_	NN	NN	_	5	COORD	_	_
10	(	_	(	(	_	11	P	_	_
11	PMA	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	are	_	VBP	VBP	_	3	VMOD	_	_
14	able	_	JJ	JJ	_	13	PRD	_	_
15	to	_	TO	TO	_	17	VMOD	_	_
16	efficiently	_	RB	RB	_	17	ADV	_	_
17	induce	_	VB	VB	_	14	AMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	binding	_	NN	NN	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	NF-kappa	_	NN	NN	_	22	NMOD	_	_
22	B	_	NN	NN	_	20	PMOD	_	_
23	to	_	TO	TO	_	19	NMOD	_	_
24	the	_	DT	DT	_	29	NMOD	_	_
25	IL-2R	_	NN	NN	_	29	NMOD	_	_
26	alpha	_	NN	NN	_	29	NMOD	_	_
27	kappa	_	NN	NN	_	29	NMOD	_	_
28	B	_	NN	NN	_	29	NMOD	_	_
29	site	_	NN	NN	_	23	PMOD	_	_
30	,	_	,	,	_	32	P	_	_
31	PMA	_	NN	NN	_	32	SBJ	_	_
32	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
33	functionally	_	RB	RB	_	32	ADV	_	_
34	inactive	_	JJ	JJ	_	32	PRD	_	_
35	.	_	.	.	_	32	P	_	_

1	Using	_	VBG	VBG	_	9	VMOD	_	_
2	the	_	DT	DT	_	6	NMOD	_	_
3	DNA	_	NN	NN	_	6	NMOD	_	_
4	affinity	_	NN	NN	_	6	NMOD	_	_
5	precipitation	_	NN	NN	_	6	NMOD	_	_
6	assay	_	NN	NN	_	1	OBJ	_	_
7	,	_	,	,	_	9	P	_	_
8	we	_	PRP	PRP	_	9	SBJ	_	_
9	observed	_	VBD	VBD	_	0	ROOT-S	_	_
10	that	_	IN	IN	_	9	OBJ	_	_
11	Tax1	_	NN	NN	_	12	SBJ	_	_
12	is	_	VBZ	VBZ	_	10	VMOD	_	_
13	able	_	JJ	JJ	_	12	PRD	_	_
14	to	_	TO	TO	_	16	VMOD	_	_
15	efficiently	_	RB	RB	_	16	ADV	_	_
16	induce	_	VB	VB	_	13	AMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	binding	_	NN	NN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	Rel	_	NN	NN	_	19	PMOD	_	_
21	,	_	,	,	_	12	P	_	_
22	whereas	_	IN	IN	_	12	COORD	_	_
23	PMA	_	NN	NN	_	24	SBJ	_	_
24	is	_	VBZ	VBZ	_	12	COORD	_	_
25	not	_	RB	RB	_	24	VMOD	_	_
26	.	_	.	.	_	9	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	established	_	VBD	VBD	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	clear	_	JJ	JJ	_	5	NMOD	_	_
5	difference	_	NN	NN	_	2	IOBJ	_	_
6	between	_	IN	IN	_	5	NMOD	_	_
7	both	_	DT	DT	_	8	NMOD	_	_
8	stimuli	_	NNS	NNS	_	6	PMOD	_	_
9	,	_	,	,	_	2	P	_	_
10	indicating	_	VBG	VBG	_	2	OBJ	_	_
11	that	_	IN	IN	_	10	OBJ	_	_
12	Rel	_	NN	NN	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	11	VMOD	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	functionally	_	RB	RB	_	16	AMOD	_	_
16	active	_	JJ	JJ	_	17	NMOD	_	_
17	factor	_	NN	NN	_	13	PRD	_	_
18	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	conclude	_	VBP	VBP	_	0	ROOT-S	_	_
3	from	_	IN	IN	_	2	ADV	_	_
4	these	_	DT	DT	_	5	NMOD	_	_
5	results	_	NNS	NNS	_	3	PMOD	_	_
6	that	_	IN	IN	_	2	OBJ	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	functional	_	JJ	JJ	_	9	NMOD	_	_
9	activity	_	NN	NN	_	16	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	members	_	NNS	NNS	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	rel	_	NN	NN	_	15	NMOD	_	_
15	family	_	NN	NN	_	12	PMOD	_	_
16	is	_	VBZ	VBZ	_	6	VMOD	_	_
17	regulated	_	VBN	VBN	_	16	VC	_	_
18	by	_	IN	IN	_	17	LGS	_	_
19	their	_	PRP$	PRP$	_	20	NMOD	_	_
20	interaction	_	NN	NN	_	18	PMOD	_	_
21	with	_	IN	IN	_	20	NMOD	_	_
22	DNA	_	NN	NN	_	21	PMOD	_	_
23	and	_	CC	CC	_	6	CC	_	_
24	that	_	IN	IN	_	6	COORD	_	_
25	Rel	_	NN	NN	_	26	SBJ	_	_
26	can	_	MD	MD	_	24	VMOD	_	_
27	be	_	VB	VB	_	26	VC	_	_
28	a	_	DT	DT	_	31	NMOD	_	_
29	potent	_	JJ	JJ	_	31	NMOD	_	_
30	transcriptional	_	JJ	JJ	_	31	NMOD	_	_
31	activator	_	NN	NN	_	27	PRD	_	_
32	on	_	IN	IN	_	27	ADV	_	_
33	specific	_	JJ	JJ	_	36	NMOD	_	_
34	kappa	_	NN	NN	_	36	NMOD	_	_
35	B	_	NN	NN	_	36	NMOD	_	_
36	sites	_	NNS	NNS	_	32	PMOD	_	_
37	.	_	.	.	_	2	P	_	_

1	p105	_	NN	NN	_	5	NMOD	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	p98	_	NN	NN	_	1	COORD	_	_
4	precursor	_	NN	NN	_	5	NMOD	_	_
5	proteins	_	NNS	NNS	_	6	SBJ	_	_
6	play	_	VBP	VBP	_	0	ROOT-S	_	_
7	an	_	DT	DT	_	9	NMOD	_	_
8	active	_	JJ	JJ	_	9	NMOD	_	_
9	role	_	NN	NN	_	6	OBJ	_	_
10	in	_	IN	IN	_	6	ADV	_	_
11	NF-kappa	_	NN	NN	_	14	NMOD	_	_
12	B-mediated	_	JJ	JJ	_	11	AMOD	_	_
13	signal	_	NN	NN	_	14	NMOD	_	_
14	transduction	_	NN	NN	_	10	PMOD	_	_
15	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	Rel\/NF-kappa	_	NN	NN	_	4	NMOD	_	_
3	B	_	NN	NN	_	4	NMOD	_	_
4	family	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factors	_	NNS	NNS	_	5	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	composed	_	VBN	VBN	_	8	VC	_	_
10	of	_	IN	IN	_	9	ADV	_	_
11	two	_	CD	CD	_	13	NMOD	_	_
12	distinct	_	JJ	JJ	_	13	NMOD	_	_
13	subgroups	_	NNS	NNS	_	10	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	proteins	_	NNS	NNS	_	13	NMOD	_	_
16	that	_	WDT	WDT	_	17	SBJ	_	_
17	undergo	_	VBP	VBP	_	15	NMOD	_	_
18	proteolytic	_	JJ	JJ	_	19	NMOD	_	_
19	processing	_	NN	NN	_	17	OBJ	_	_
20	and	_	CC	CC	_	17	CC	_	_
21	contain	_	VBP	VBP	_	17	COORD	_	_
22	SWI6\/ankyrin	_	NN	NN	_	23	NMOD	_	_
23	repeats	_	NNS	NNS	_	21	OBJ	_	_
24	in	_	IN	IN	_	21	ADV	_	_
25	their	_	PRP$	PRP$	_	27	NMOD	_	_
26	carboxyl	_	NN	NN	_	27	NMOD	_	_
27	termini	_	NNS	NNS	_	24	PMOD	_	_
28	(	_	(	(	_	29	P	_	_
29	p105	_	NN	NN	_	15	PRN	_	_
30	,	_	,	,	_	29	P	_	_
31	p98	_	NN	NN	_	29	NMOD	_	_
32	)	_	)	)	_	29	P	_	_
33	,	_	,	,	_	15	P	_	_
34	and	_	CC	CC	_	15	CC	_	_
35	those	_	DT	DT	_	15	COORD	_	_
36	without	_	IN	IN	_	35	NMOD	_	_
37	such	_	JJ	JJ	_	38	NMOD	_	_
38	repeats	_	NNS	NNS	_	36	PMOD	_	_
39	that	_	WDT	WDT	_	40	SBJ	_	_
40	do	_	VBP	VBP	_	35	NMOD	_	_
41	not	_	RB	RB	_	40	VMOD	_	_
42	require	_	VB	VB	_	40	VC	_	_
43	processing	_	NN	NN	_	42	OBJ	_	_
44	(	_	(	(	_	45	P	_	_
45	p65	_	NN	NN	_	35	PRN	_	_
46	,	_	,	,	_	45	P	_	_
47	c-Rel	_	NN	NN	_	45	COORD	_	_
48	,	_	,	,	_	45	P	_	_
49	RelB	_	NN	NN	_	45	COORD	_	_
50	,	_	,	,	_	45	P	_	_
51	and	_	CC	CC	_	45	CC	_	_
52	Dorsal	_	NN	NN	_	45	COORD	_	_
53	)	_	)	)	_	45	P	_	_
54	.	_	.	.	_	8	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	p105	_	NN	NN	_	8	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	p98	_	NN	NN	_	5	COORD	_	_
8	precursors	_	NNS	NNS	_	9	SBJ	_	_
9	share	_	VBP	VBP	_	3	VMOD	_	_
10	functional	_	JJ	JJ	_	11	NMOD	_	_
11	properties	_	NNS	NNS	_	9	OBJ	_	_
12	with	_	IN	IN	_	9	ADV	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	I	_	NN	NN	_	17	NMOD	_	_
15	kappa	_	NN	NN	_	17	NMOD	_	_
16	B	_	NN	NN	_	17	NMOD	_	_
17	proteins	_	NNS	NNS	_	12	PMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	which	_	WDT	WDT	_	21	SBJ	_	_
20	also	_	RB	RB	_	21	ADV	_	_
21	contain	_	VBP	VBP	_	17	NMOD	_	_
22	SWI6\/ankyrin	_	NN	NN	_	23	NMOD	_	_
23	repeats	_	NNS	NNS	_	21	OBJ	_	_
24	.	_	.	.	_	2	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	p105	_	NN	NN	_	5	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	p98	_	NN	NN	_	2	COORD	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	found	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	form	_	VB	VB	_	6	OBJ	_	_
9	stable	_	JJ	JJ	_	10	NMOD	_	_
10	complexes	_	NNS	NNS	_	8	OBJ	_	_
11	with	_	IN	IN	_	8	ADV	_	_
12	other	_	JJ	JJ	_	16	NMOD	_	_
13	Rel\/NF-kappa	_	NN	NN	_	16	NMOD	_	_
14	B	_	NN	NN	_	16	NMOD	_	_
15	family	_	NN	NN	_	16	NMOD	_	_
16	members	_	NNS	NNS	_	11	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	including	_	VBG	VBG	_	16	NMOD	_	_
19	p65	_	NN	NN	_	18	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	c-Rel	_	NN	NN	_	19	COORD	_	_
22	.	_	.	.	_	5	P	_	_

1	Association	_	NN	NN	_	5	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	precursors	_	NNS	NNS	_	2	PMOD	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	sufficient	_	JJ	JJ	_	5	PRD	_	_
7	for	_	IN	IN	_	6	AMOD	_	_
8	cytoplasmic	_	JJ	JJ	_	9	NMOD	_	_
9	retention	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	either	_	CC	CC	_	12	CC	_	_
12	p65	_	NN	NN	_	10	PMOD	_	_
13	or	_	CC	CC	_	12	CC	_	_
14	c-Rel	_	NN	NN	_	12	COORD	_	_
15	,	_	,	,	_	12	P	_	_
16	both	_	DT	DT	_	17	NMOD	_	_
17	of	_	IN	IN	_	19	SBJ	_	_
18	which	_	WDT	WDT	_	17	PMOD	_	_
19	are	_	VBP	VBP	_	12	NMOD	_	_
20	otherwise	_	RB	RB	_	19	ADV	_	_
21	nuclear	_	JJ	JJ	_	19	PRD	_	_
22	.	_	.	.	_	5	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	complexes	_	NNS	NNS	_	3	SBJ	_	_
3	undergo	_	VBP	VBP	_	0	ROOT-S	_	_
4	stimulus-responsive	_	JJ	JJ	_	5	NMOD	_	_
5	processing	_	NN	NN	_	3	IOBJ	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	produce	_	VB	VB	_	3	OBJ	_	_
8	active	_	JJ	JJ	_	12	NMOD	_	_
9	p50\/c-Rel	_	NN	NN	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	p55\/c-Rel	_	NN	NN	_	9	COORD	_	_
12	complexes	_	NNS	NNS	_	7	OBJ	_	_
13	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	observations	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	second	_	JJ	JJ	_	6	NMOD	_	_
6	pathway	_	NN	NN	_	3	OBJ	_	_
7	leading	_	VBG	VBG	_	6	NMOD	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	NF-kappa	_	NN	NN	_	11	NMOD	_	_
10	B	_	NN	NN	_	11	NMOD	_	_
11	induction	_	NN	NN	_	8	PMOD	_	_
12	,	_	,	,	_	6	P	_	_
13	in	_	IN	IN	_	26	ADV	_	_
14	which	_	WDT	WDT	_	13	PMOD	_	_
15	processing	_	NN	NN	_	26	SBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	precursors	_	NNS	NNS	_	16	PMOD	_	_
19	rather	_	RB	RB	_	15	CC	_	_
20	than	_	IN	IN	_	19	DEP	_	_
21	phosphorylation	_	NN	NN	_	15	COORD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	I	_	NN	NN	_	25	NMOD	_	_
24	kappa	_	NN	NN	_	25	NMOD	_	_
25	B	_	NN	NN	_	22	PMOD	_	_
26	plays	_	VBZ	VBZ	_	6	NMOD	_	_
27	a	_	DT	DT	_	29	NMOD	_	_
28	major	_	JJ	JJ	_	29	NMOD	_	_
29	role	_	NN	NN	_	26	OBJ	_	_
30	.	_	.	.	_	3	P	_	_

1	Mutual	_	JJ	JJ	_	2	NMOD	_	_
2	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	transcriptional	_	JJ	JJ	_	8	NMOD	_	_
6	activator	_	NN	NN	_	8	NMOD	_	_
7	NF-kappa	_	NN	NN	_	8	NMOD	_	_
8	B	_	NN	NN	_	3	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	its	_	PRP$	PRP$	_	11	NMOD	_	_
11	inhibitor	_	NN	NN	_	8	COORD	_	_
12	,	_	,	,	_	11	P	_	_
13	I	_	NN	NN	_	15	NMOD	_	_
14	kappa	_	NN	NN	_	15	NMOD	_	_
15	B-alpha	_	NN	NN	_	11	NMOD	_	_
16	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	NK-kappa	_	NN	NN	_	6	NMOD	_	_
3	B	_	NN	NN	_	6	NMOD	_	_
4	transcription	_	NN	NN	_	6	NMOD	_	_
5	factor	_	NN	NN	_	6	NMOD	_	_
6	complex	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	sequestered	_	VBN	VBN	_	7	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	cytoplasm	_	NN	NN	_	9	PMOD	_	_
12	by	_	IN	IN	_	8	LGS	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	inhibitory	_	JJ	JJ	_	15	NMOD	_	_
15	protein	_	NN	NN	_	12	PMOD	_	_
16	I	_	NN	NN	_	18	NMOD	_	_
17	kappa	_	NN	NN	_	18	NMOD	_	_
18	B-alpha	_	NN	NN	_	15	NMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	MAD-3	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	.	_	.	.	_	7	P	_	_

1	Various	_	JJ	JJ	_	3	NMOD	_	_
2	cellular	_	JJ	JJ	_	3	NMOD	_	_
3	stimuli	_	NNS	NNS	_	4	SBJ	_	_
4	relieve	_	VBP	VBP	_	0	ROOT-S	_	_
5	this	_	DT	DT	_	6	NMOD	_	_
6	inhibition	_	NN	NN	_	4	IOBJ	_	_
7	by	_	IN	IN	_	4	ADV	_	_
8	mechanisms	_	NNS	NNS	_	7	PMOD	_	_
9	largely	_	RB	RB	_	10	AMOD	_	_
10	unknown	_	JJ	JJ	_	8	NMOD	_	_
11	,	_	,	,	_	4	P	_	_
12	leading	_	VBG	VBG	_	4	OBJ	_	_
13	to	_	TO	TO	_	12	ADV	_	_
14	NF-kappa	_	NN	NN	_	17	NMOD	_	_
15	B	_	NN	NN	_	17	NMOD	_	_
16	nuclear	_	JJ	JJ	_	17	NMOD	_	_
17	localization	_	NN	NN	_	13	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	transactivation	_	NN	NN	_	17	COORD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	its	_	PRP$	PRP$	_	23	NMOD	_	_
22	target	_	NN	NN	_	23	NMOD	_	_
23	genes	_	NNS	NNS	_	20	PMOD	_	_
24	.	_	.	.	_	4	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	demonstrated	_	VBN	VBN	_	2	VC	_	_
4	here	_	RB	RB	_	3	ADV	_	_
5	with	_	IN	IN	_	3	ADV	_	_
6	human	_	JJ	JJ	_	8	NMOD	_	_
7	T	_	NN	NN	_	8	NMOD	_	_
8	lymphocytes	_	NNS	NNS	_	5	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	monocytes	_	NNS	NNS	_	8	COORD	_	_
11	that	_	IN	IN	_	3	OBJ	_	_
12	different	_	JJ	JJ	_	13	NMOD	_	_
13	stimuli	_	NNS	NNS	_	25	SBJ	_	_
14	,	_	,	,	_	13	P	_	_
15	including	_	VBG	VBG	_	13	NMOD	_	_
16	tumor	_	NN	NN	_	19	NMOD	_	_
17	necrosis	_	NN	NN	_	19	NMOD	_	_
18	factor	_	NN	NN	_	19	NMOD	_	_
19	alpha	_	NN	NN	_	15	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	phorbol	_	NN	NN	_	23	NMOD	_	_
22	12-myristate	_	NN	NN	_	23	NMOD	_	_
23	13-acetate	_	NN	NN	_	19	COORD	_	_
24	,	_	,	,	_	13	P	_	_
25	cause	_	VB	VB	_	11	VMOD	_	_
26	rapid	_	JJ	JJ	_	27	NMOD	_	_
27	degradation	_	NN	NN	_	25	IOBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	I	_	NN	NN	_	31	NMOD	_	_
30	kappa	_	NN	NN	_	31	NMOD	_	_
31	B-alpha	_	NN	NN	_	28	PMOD	_	_
32	,	_	,	,	_	25	P	_	_
33	with	_	IN	IN	_	25	ADV	_	_
34	concomitant	_	JJ	JJ	_	35	NMOD	_	_
35	activation	_	NN	NN	_	33	PMOD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	NF-kappa	_	NN	NN	_	38	NMOD	_	_
38	B	_	NN	NN	_	36	PMOD	_	_
39	,	_	,	,	_	25	P	_	_
40	followed	_	VBN	VBN	_	25	OBJ	_	_
41	by	_	IN	IN	_	40	LGS	_	_
42	a	_	DT	DT	_	44	NMOD	_	_
43	dramatic	_	JJ	JJ	_	44	NMOD	_	_
44	increase	_	NN	NN	_	41	PMOD	_	_
45	in	_	IN	IN	_	44	NMOD	_	_
46	I	_	NN	NN	_	52	NMOD	_	_
47	kappa	_	NN	NN	_	52	NMOD	_	_
48	B-alpha	_	NN	NN	_	52	NMOD	_	_
49	mRNA	_	NN	NN	_	52	NMOD	_	_
50	and	_	CC	CC	_	49	CC	_	_
51	protein	_	NN	NN	_	49	COORD	_	_
52	synthesis	_	NN	NN	_	45	PMOD	_	_
53	.	_	.	.	_	2	P	_	_

1	Transfection	_	NN	NN	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	reveal	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	I	_	NN	NN	_	9	NMOD	_	_
7	kappa	_	NN	NN	_	9	NMOD	_	_
8	B-alpha	_	NN	NN	_	9	NMOD	_	_
9	mRNA	_	NN	NN	_	14	SBJ	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	encoded	_	VBN	VBN	_	13	NMOD	_	_
13	protein	_	NN	NN	_	9	COORD	_	_
14	are	_	VBP	VBP	_	4	VMOD	_	_
15	potently	_	RB	RB	_	14	ADV	_	_
16	induced	_	VBN	VBN	_	14	VC	_	_
17	by	_	IN	IN	_	16	ADV	_	_
18	NF-kappa	_	NN	NN	_	19	NMOD	_	_
19	B	_	NN	NN	_	17	PMOD	_	_
20	and	_	CC	CC	_	17	CC	_	_
21	by	_	IN	IN	_	17	LGS	_	_
22	homodimers	_	NNS	NNS	_	21	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	p65	_	NN	NN	_	23	PMOD	_	_
25	and	_	CC	CC	_	23	CC	_	_
26	of	_	IN	IN	_	23	COORD	_	_
27	c-Rel	_	NN	NN	_	26	PMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	propose	_	VBP	VBP	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	model	_	NN	NN	_	2	OBJ	_	_
5	in	_	IN	IN	_	14	ADV	_	_
6	which	_	WDT	WDT	_	5	PMOD	_	_
7	NF-kappa	_	NN	NN	_	8	NMOD	_	_
8	B	_	NN	NN	_	14	SBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	I	_	NN	NN	_	12	NMOD	_	_
11	kappa	_	NN	NN	_	12	NMOD	_	_
12	B-alpha	_	NN	NN	_	8	COORD	_	_
13	mutually	_	RB	RB	_	14	ADV	_	_
14	regulate	_	VBP	VBP	_	4	NMOD	_	_
15	each	_	DT	DT	_	16	NMOD	_	_
16	other	_	JJ	JJ	_	14	OBJ	_	_
17	in	_	IN	IN	_	14	ADV	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	cycle	_	NN	NN	_	17	PMOD	_	_
20	:	_	:	:	_	2	P	_	_
21	saturating	_	JJ	JJ	_	22	NMOD	_	_
22	amounts	_	NNS	NNS	_	30	SBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	29	NMOD	_	_
25	inhibitory	_	JJ	JJ	_	29	NMOD	_	_
26	I	_	NN	NN	_	29	NMOD	_	_
27	kappa	_	NN	NN	_	29	NMOD	_	_
28	B-alpha	_	NN	NN	_	29	NMOD	_	_
29	protein	_	NN	NN	_	23	PMOD	_	_
30	are	_	VBP	VBP	_	2	VMOD	_	_
31	destroyed	_	VBN	VBN	_	30	VC	_	_
32	upon	_	IN	IN	_	31	ADV	_	_
33	stimulation	_	NN	NN	_	32	PMOD	_	_
34	,	_	,	,	_	31	P	_	_
35	allowing	_	VBG	VBG	_	31	OBJ	_	_
36	rapid	_	JJ	JJ	_	37	VMOD	_	_
37	activation	_	NN	NN	_	35	OBJ	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	NF-kappa	_	NN	NN	_	40	NMOD	_	_
40	B	_	NN	NN	_	38	PMOD	_	_
41	.	_	.	.	_	30	P	_	_

1	Subsequently	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	I	_	NN	NN	_	9	NMOD	_	_
4	kappa	_	NN	NN	_	9	NMOD	_	_
5	B-alpha	_	NN	NN	_	9	NMOD	_	_
6	mRNA	_	NN	NN	_	9	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	protein	_	NN	NN	_	6	COORD	_	_
9	levels	_	NNS	NNS	_	10	SBJ	_	_
10	are	_	VBP	VBP	_	0	ROOT-S	_	_
11	quickly	_	RB	RB	_	12	TMP	_	_
12	induced	_	VBN	VBN	_	10	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	activated	_	VBN	VBN	_	17	NMOD	_	_
16	NF-kappa	_	NN	NN	_	17	NMOD	_	_
17	B	_	NN	NN	_	13	PMOD	_	_
18	.	_	.	.	_	10	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	resurgence	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	I	_	NN	NN	_	7	NMOD	_	_
5	kappa	_	NN	NN	_	7	NMOD	_	_
6	B-alpha	_	NN	NN	_	7	NMOD	_	_
7	protein	_	NN	NN	_	3	PMOD	_	_
8	acts	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	restore	_	VB	VB	_	8	OBJ	_	_
11	an	_	DT	DT	_	12	NMOD	_	_
12	equilibrium	_	NN	NN	_	10	OBJ	_	_
13	in	_	IN	IN	_	19	ADV	_	_
14	which	_	WDT	WDT	_	13	PMOD	_	_
15	NF-kappa	_	NN	NN	_	16	NMOD	_	_
16	B	_	NN	NN	_	17	SBJ	_	_
17	is	_	VBZ	VBZ	_	12	NMOD	_	_
18	again	_	RB	RB	_	17	TMP	_	_
19	inhibited	_	VBN	VBN	_	17	VC	_	_
20	.	_	.	.	_	8	P	_	_

1	Induced	_	VBN	VBN	_	3	NMOD	_	_
2	myeloid	_	JJ	JJ	_	3	NMOD	_	_
3	differentiation	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	K562	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	with	_	IN	IN	_	3	NMOD	_	_
8	downregulation	_	NN	NN	_	7	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	erythroid	_	JJ	JJ	_	14	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	megakaryocytic	_	JJ	JJ	_	10	COORD	_	_
13	transcription	_	NN	NN	_	14	NMOD	_	_
14	factors	_	NNS	NNS	_	9	PMOD	_	_
15	:	_	:	:	_	3	P	_	_
16	a	_	DT	DT	_	19	NMOD	_	_
17	novel	_	JJ	JJ	_	19	NMOD	_	_
18	experimental	_	JJ	JJ	_	19	NMOD	_	_
19	model	_	NN	NN	_	3	NMOD	_	_
20	for	_	IN	IN	_	19	NMOD	_	_
21	hemopoietic	_	JJ	JJ	_	23	NMOD	_	_
22	lineage	_	NN	NN	_	23	NMOD	_	_
23	restriction	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	19	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	human	_	JJ	JJ	_	6	NMOD	_	_
3	erythroleukemia	_	NN	NN	_	6	NMOD	_	_
4	cell	_	NN	NN	_	6	NMOD	_	_
5	line	_	NN	NN	_	6	NMOD	_	_
6	K562	_	NN	NN	_	7	SBJ	_	_
7	can	_	MD	MD	_	0	ROOT-S	_	_
8	be	_	VB	VB	_	7	VC	_	_
9	induced	_	VBN	VBN	_	8	VC	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	differentiate	_	VB	VB	_	9	OBJ	_	_
12	along	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	erythroid	_	JJ	JJ	_	17	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	megakaryocytic	_	JJ	JJ	_	14	COORD	_	_
17	lineages	_	NNS	NNS	_	12	PMOD	_	_
18	.	_	.	.	_	7	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	hexamethylene	_	NN	NN	_	6	NMOD	_	_
6	bisacetamide	_	NN	NN	_	10	SBJ	_	_
7	(	_	(	(	_	8	P	_	_
8	HMBA	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	induced	_	VBD	VBD	_	4	VMOD	_	_
11	K562	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	14	SBJ	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	differentiate	_	VB	VB	_	10	OBJ	_	_
15	along	_	IN	IN	_	14	ADV	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	third	_	JJ	JJ	_	18	NMOD	_	_
18	pathway	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	accompanied	_	VBN	VBN	_	2	VC	_	_
4	by	_	IN	IN	_	3	LGS	_	_
5	downregulation	_	NN	NN	_	4	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	two	_	CD	CD	_	9	NMOD	_	_
8	transcription	_	NN	NN	_	9	NMOD	_	_
9	factors	_	NNS	NNS	_	6	PMOD	_	_
10	normally	_	RB	RB	_	11	ADV	_	_
11	expressed	_	VBN	VBN	_	9	NMOD	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	erythroid	_	JJ	JJ	_	18	NMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	mast	_	NN	NN	_	13	COORD	_	_
16	and	_	CC	CC	_	13	CC	_	_
17	megakaryocyte	_	NN	NN	_	13	COORD	_	_
18	lineages	_	NNS	NNS	_	12	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	Northern	_	NN	NN	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	3	SBJ	_	_
3	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
4	coordinate	_	JJ	JJ	_	5	NMOD	_	_
5	downregulation	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	alpha	_	NN	NN	_	8	NMOD	_	_
8	globin	_	NN	NN	_	6	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	gamma	_	NN	NN	_	11	NMOD	_	_
11	globin	_	NN	NN	_	8	COORD	_	_
12	in	_	IN	IN	_	8	CC	_	_
13	addition	_	NN	NN	_	12	DEP	_	_
14	to	_	TO	TO	_	12	DEP	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	two	_	CD	CD	_	19	NMOD	_	_
17	lineage-restricted	_	JJ	JJ	_	19	NMOD	_	_
18	transcription	_	NN	NN	_	19	NMOD	_	_
19	factors	_	NNS	NNS	_	8	COORD	_	_
20	,	_	,	,	_	19	P	_	_
21	SCL	_	NN	NN	_	19	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	GATA-1	_	NN	NN	_	21	COORD	_	_
24	.	_	.	.	_	3	P	_	_

1	Proliferation	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	K562	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	2	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	also	_	RB	RB	_	6	ADV	_	_
8	suppressed	_	VBN	VBN	_	6	VC	_	_
9	.	_	.	.	_	6	P	_	_

1	Clonal	_	JJ	JJ	_	2	NMOD	_	_
2	assay	_	NN	NN	_	3	SBJ	_	_
3	showed	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	suppression	_	NN	NN	_	7	SBJ	_	_
7	was	_	VBD	VBD	_	4	VMOD	_	_
8	irreversible	_	JJ	JJ	_	7	PRD	_	_
9	and	_	CC	CC	_	7	CC	_	_
10	appeared	_	VBD	VBD	_	7	COORD	_	_
11	analogous	_	JJ	JJ	_	10	PRD	_	_
12	to	_	TO	TO	_	11	AMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	commitment	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	murine	_	JJ	JJ	_	17	NMOD	_	_
17	erythroleukemia	_	NN	NN	_	21	NMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	MEL	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	cells	_	NNS	NNS	_	15	PMOD	_	_
22	to	_	TO	TO	_	14	NMOD	_	_
23	terminal	_	JJ	JJ	_	24	NMOD	_	_
24	differentiation	_	NN	NN	_	22	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	contrast	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	MEL	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	1	PMOD	_	_
6	,	_	,	,	_	11	P	_	_
7	however	_	RB	RB	_	11	ADV	_	_
8	,	_	,	,	_	11	P	_	_
9	K562	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	11	SBJ	_	_
11	acquired	_	VBD	VBD	_	0	ROOT-S	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	macrophage-like	_	JJ	JJ	_	14	NMOD	_	_
14	morphology	_	NN	NN	_	11	OBJ	_	_
15	and	_	CC	CC	_	11	CC	_	_
16	exhibited	_	VBD	VBD	_	11	COORD	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	complete	_	JJ	JJ	_	19	NMOD	_	_
19	failure	_	NN	NN	_	16	OBJ	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	generate	_	VB	VB	_	19	NMOD	_	_
22	benzidine-positive	_	JJ	JJ	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	21	OBJ	_	_
24	.	_	.	.	_	11	P	_	_

1	Electron	_	NN	NN	_	2	NMOD	_	_
2	microscopy	_	NN	NN	_	3	SBJ	_	_
3	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	marked	_	JJ	JJ	_	6	NMOD	_	_
6	increase	_	NN	NN	_	3	OBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	granules	_	NNS	NNS	_	7	PMOD	_	_
9	resembling	_	VBG	VBG	_	8	NMOD	_	_
10	those	_	DT	DT	_	9	OBJ	_	_
11	specific	_	JJ	JJ	_	10	NMOD	_	_
12	for	_	IN	IN	_	11	AMOD	_	_
13	eosinophils	_	NNS	NNS	_	12	PMOD	_	_
14	.	_	.	.	_	3	P	_	_

1	Surface	_	NN	NN	_	3	NMOD	_	_
2	marker	_	NN	NN	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	4	SBJ	_	_
4	showed	_	VBD	VBD	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	HMBA-induced	_	JJ	JJ	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	8	SBJ	_	_
8	expressed	_	VBD	VBD	_	5	VMOD	_	_
9	reduced	_	VBN	VBN	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	glycophorin	_	NN	NN	_	13	NMOD	_	_
13	A	_	NN	NN	_	11	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	CD5	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	13	P	_	_
17	CD7	_	NN	NN	_	13	COORD	_	_
18	and	_	CC	CC	_	13	CC	_	_
19	CD11b	_	NN	NN	_	13	COORD	_	_
20	.	_	.	.	_	4	P	_	_

1	No	_	DT	DT	_	2	NMOD	_	_
2	upregulation	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	megakaryocyte	_	NN	NN	_	7	NMOD	_	_
5	or	_	CC	CC	_	4	CC	_	_
6	lymphoid	_	JJ	JJ	_	4	COORD	_	_
7	markers	_	NNS	NNS	_	3	PMOD	_	_
8	occurred	_	VBD	VBD	_	0	ROOT-S	_	_
9	.	_	.	.	_	8	P	_	_

1	Thus	_	RB	RB	_	9	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	response	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	K562	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	to	_	TO	TO	_	3	NMOD	_	_
8	HMBA	_	NN	NN	_	7	PMOD	_	_
9	may	_	MD	MD	_	0	ROOT-S	_	_
10	provide	_	VB	VB	_	9	VC	_	_
11	a	_	DT	DT	_	14	NMOD	_	_
12	useful	_	JJ	JJ	_	14	NMOD	_	_
13	experimental	_	JJ	JJ	_	14	NMOD	_	_
14	system	_	NN	NN	_	10	OBJ	_	_
15	for	_	IN	IN	_	14	NMOD	_	_
16	studying	_	VBG	VBG	_	15	PMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	molecular	_	JJ	JJ	_	19	NMOD	_	_
19	mechanisms	_	NNS	NNS	_	16	OBJ	_	_
20	responsible	_	JJ	JJ	_	19	NMOD	_	_
21	for	_	IN	IN	_	20	AMOD	_	_
22	downmodulation	_	NN	NN	_	21	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	lineage-restricted	_	JJ	JJ	_	26	NMOD	_	_
25	transcription	_	NN	NN	_	26	NMOD	_	_
26	factors	_	NNS	NNS	_	23	PMOD	_	_
27	during	_	IN	IN	_	22	TMP	_	_
28	hemopoietic	_	JJ	JJ	_	30	NMOD	_	_
29	lineage	_	NN	NN	_	30	NMOD	_	_
30	commitment	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	9	P	_	_

1	Costimulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	peripheral	_	JJ	JJ	_	7	NMOD	_	_
4	blood	_	NN	NN	_	7	NMOD	_	_
5	T	_	NN	NN	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	activation	_	NN	NN	_	2	PMOD	_	_
8	by	_	IN	IN	_	1	NMOD	_	_
9	human	_	JJ	JJ	_	11	NMOD	_	_
10	endothelial	_	JJ	JJ	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	8	PMOD	_	_
12	.	_	.	.	_	1	P	_	_

1	Enhanced	_	VBD	VBD	_	3	NMOD	_	_
2	IL-2	_	NN	NN	_	3	NMOD	_	_
3	transcription	_	NN	NN	_	4	SBJ	_	_
4	correlates	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	increased	_	VBN	VBN	_	8	NMOD	_	_
7	c-fos	_	NN	NN	_	8	NMOD	_	_
8	synthesis	_	NN	NN	_	5	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	increased	_	VBN	VBN	_	12	NMOD	_	_
11	Fos	_	NN	NN	_	12	NMOD	_	_
12	content	_	NN	NN	_	8	COORD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	AP-1	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	Endothelial	_	JJ	JJ	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	6	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	EC	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	act	_	VBP	VBP	_	0	ROOT-S	_	_
7	as	_	IN	IN	_	6	ADV	_	_
8	APC	_	NN	NN	_	7	PMOD	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	resting	_	VBG	VBG	_	11	NMOD	_	_
11	PBL	_	NN	NN	_	9	PMOD	_	_
12	in	_	FW	FW	_	6	ADV	_	_
13	vitro	_	FW	FW	_	12	AMOD	_	_
14	,	_	,	,	_	6	P	_	_
15	and	_	CC	CC	_	6	CC	_	_
16	may	_	MD	MD	_	6	COORD	_	_
17	have	_	VB	VB	_	16	VC	_	_
18	important	_	JJ	JJ	_	19	NMOD	_	_
19	roles	_	NNS	NNS	_	17	OBJ	_	_
20	in	_	FW	FW	_	17	ADV	_	_
21	vivo	_	FW	FW	_	20	AMOD	_	_
22	in	_	IN	IN	_	17	ADV	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	pathogenesis	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	allograft	_	NN	NN	_	27	NMOD	_	_
27	rejection	_	NN	NN	_	25	PMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	delayed	_	VBN	VBN	_	30	NMOD	_	_
30	hypersensitivity	_	NN	NN	_	27	COORD	_	_
31	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	previously	_	RB	RB	_	3	TMP	_	_
3	reported	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	human	_	JJ	JJ	_	8	NMOD	_	_
6	umbilical	_	JJ	JJ	_	8	NMOD	_	_
7	vein	_	NN	NN	_	8	NMOD	_	_
8	EC	_	NN	NN	_	9	SBJ	_	_
9	provide	_	VBP	VBP	_	4	VMOD	_	_
10	costimulatory	_	JJ	JJ	_	11	NMOD	_	_
11	signals	_	NNS	NNS	_	9	IOBJ	_	_
12	to	_	TO	TO	_	9	DTV	_	_
13	PHA-stimulated	_	JJ	JJ	_	14	NMOD	_	_
14	PBL	_	NN	NN	_	12	PMOD	_	_
15	via	_	IN	IN	_	9	ADV	_	_
16	CD2:lymphocyte	_	NN	NN	_	18	NMOD	_	_
17	function-associated	_	JJ	JJ	_	16	AMOD	_	_
18	Ag-3	_	NN	NN	_	15	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	an	_	DT	DT	_	23	NMOD	_	_
21	unidentified	_	JJ	JJ	_	23	NMOD	_	_
22	ligand	_	NN	NN	_	23	NMOD	_	_
23	pair	_	NN	NN	_	18	COORD	_	_
24	,	_	,	,	_	9	P	_	_
25	resulting	_	VBG	VBG	_	9	OBJ	_	_
26	in	_	IN	IN	_	25	ADV	_	_
27	a	_	DT	DT	_	31	NMOD	_	_
28	three-	_	CD	CD	_	30	DEP	_	_
29	to	_	TO	TO	_	30	DEP	_	_
30	eight-fold	_	JJ	JJ	_	31	NMOD	_	_
31	enhancement	_	NN	NN	_	26	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	IL-2	_	NN	NN	_	34	NMOD	_	_
34	production	_	NN	NN	_	32	PMOD	_	_
35	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	physiologic	_	JJ	JJ	_	3	NMOD	_	_
3	relevance	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	this	_	DT	DT	_	6	NMOD	_	_
6	increase	_	NN	NN	_	4	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	demonstrated	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	proliferative	_	JJ	JJ	_	12	NMOD	_	_
12	advantage	_	NN	NN	_	9	PMOD	_	_
13	provided	_	VBN	VBN	_	12	NMOD	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	EC	_	NN	NN	_	14	PMOD	_	_
16	to	_	TO	TO	_	13	DTV	_	_
17	PBL	_	NN	NN	_	16	PMOD	_	_
18	suboptimally	_	RB	RB	_	19	ADV	_	_
19	stimulated	_	VBN	VBN	_	17	NMOD	_	_
20	with	_	IN	IN	_	19	ADV	_	_
21	mAb	_	NN	NN	_	22	NMOD	_	_
22	OKT3	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	now	_	RB	RB	_	3	TMP	_	_
3	report	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	EC	_	NN	NN	_	6	NMOD	_	_
6	costimulation	_	NN	NN	_	7	SBJ	_	_
7	causes	_	VBZ	VBZ	_	4	VMOD	_	_
8	increased	_	VBN	VBN	_	9	NMOD	_	_
9	levels	_	NNS	NNS	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	IL-2	_	NN	NN	_	12	NMOD	_	_
12	mRNA	_	NN	NN	_	10	PMOD	_	_
13	as	_	IN	IN	_	7	ADV	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	result	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	increased	_	VBN	VBN	_	19	NMOD	_	_
18	IL-2	_	NN	NN	_	19	NMOD	_	_
19	transcription	_	NN	NN	_	16	PMOD	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	PBL	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	therefore	_	RB	RB	_	3	ADV	_	_
3	examined	_	VBD	VBD	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	effects	_	NNS	NNS	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	EC	_	NN	NN	_	6	PMOD	_	_
8	on	_	IN	IN	_	5	NMOD	_	_
9	T	_	NN	NN	_	12	NMOD	_	_
10	cell	_	NN	NN	_	12	NMOD	_	_
11	nuclear	_	JJ	JJ	_	12	NMOD	_	_
12	factors	_	NNS	NNS	_	8	PMOD	_	_
13	known	_	VBN	VBN	_	12	NMOD	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	regulate	_	VB	VB	_	13	OBJ	_	_
16	IL-2	_	NN	NN	_	17	NMOD	_	_
17	transcription	_	NN	NN	_	15	OBJ	_	_
18	,	_	,	,	_	12	P	_	_
19	including	_	VBG	VBG	_	12	NMOD	_	_
20	c-jun	_	NN	NN	_	23	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	c-fos-two	_	NN	NN	_	20	COORD	_	_
23	components	_	NNS	NNS	_	19	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	28	NMOD	_	_
26	transcription	_	NN	NN	_	28	NMOD	_	_
27	factor	_	NN	NN	_	28	NMOD	_	_
28	AP-1	_	NN	NN	_	24	PMOD	_	_
29	,	_	,	,	_	28	P	_	_
30	NFAT	_	NN	NN	_	28	COORD	_	_
31	,	_	,	,	_	28	P	_	_
32	and	_	CC	CC	_	28	CC	_	_
33	others	_	NNS	NNS	_	28	COORD	_	_
34	.	_	.	.	_	3	P	_	_

1	PBL	_	NN	NN	_	3	SBJ	_	_
2	constitutively	_	RB	RB	_	3	ADV	_	_
3	express	_	VBP	VBP	_	0	ROOT-S	_	_
4	c-jun	_	NN	NN	_	5	NMOD	_	_
5	transcripts	_	NNS	NNS	_	3	OBJ	_	_
6	,	_	,	,	_	3	P	_	_
7	and	_	CC	CC	_	3	CC	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	level	_	NN	NN	_	13	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	c-jun	_	NN	NN	_	12	NMOD	_	_
12	mRNA	_	NN	NN	_	10	PMOD	_	_
13	is	_	VBZ	VBZ	_	3	COORD	_	_
14	not	_	RB	RB	_	13	VMOD	_	_
15	altered	_	VBN	VBN	_	13	VC	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	PHA	_	NN	NN	_	18	NMOD	_	_
18	activation	_	NN	NN	_	16	PMOD	_	_
19	in	_	IN	IN	_	15	ADV	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	absence	_	NN	NN	_	19	PMOD	_	_
22	or	_	CC	CC	_	21	CC	_	_
23	presence	_	NN	NN	_	21	COORD	_	_
24	of	_	IN	IN	_	21	NMOD	_	_
25	EC	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	6	P	_	_
4	c-fos	_	NN	NN	_	5	NMOD	_	_
5	mRNA	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	absent	_	JJ	JJ	_	6	PRD	_	_
8	from	_	IN	IN	_	7	AMOD	_	_
9	resting	_	VBG	VBG	_	11	NMOD	_	_
10	T	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	8	PMOD	_	_
12	and	_	CC	CC	_	6	CC	_	_
13	is	_	VBZ	VBZ	_	6	COORD	_	_
14	induced	_	VBN	VBN	_	13	VC	_	_
15	on	_	IN	IN	_	14	TMP	_	_
16	PHA	_	NN	NN	_	17	NMOD	_	_
17	activation	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	6	P	_	_

1	EC	_	NN	NN	_	3	SBJ	_	_
2	alone	_	RB	RB	_	1	NMOD	_	_
3	do	_	VBP	VBP	_	0	ROOT-S	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	induce	_	VB	VB	_	3	VC	_	_
6	c-fos	_	NN	NN	_	7	NMOD	_	_
7	mRNA	_	NN	NN	_	5	OBJ	_	_
8	but	_	CC	CC	_	3	CC	_	_
9	augment	_	VBP	VBP	_	3	COORD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	level	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	c-fos	_	NN	NN	_	14	NMOD	_	_
14	mRNA	_	NN	NN	_	12	PMOD	_	_
15	in	_	IN	IN	_	11	NMOD	_	_
16	PHA-activated	_	JJ	JJ	_	18	NMOD	_	_
17	T	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	15	PMOD	_	_
19	by	_	IN	IN	_	9	ADV	_	_
20	3-	_	CD	CD	_	19	PMOD	_	_
21	to	_	TO	TO	_	20	NMOD	_	_
22	10-fold	_	RB	RB	_	20	NMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	largely	_	RB	RB	_	5	AMOD	_	_
5	independent	_	JJ	JJ	_	3	PRD	_	_
6	of	_	IN	IN	_	5	AMOD	_	_
7	the	_	DT	DT	_	11	NMOD	_	_
8	CD2:lymphocyte	_	NN	NN	_	11	NMOD	_	_
9	function-associated	_	JJ	JJ	_	8	AMOD	_	_
10	Ag-3	_	NN	NN	_	11	NMOD	_	_
11	pathway	_	NN	NN	_	6	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	Gel-shift	_	NN	NN	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	3	SBJ	_	_
3	reveals	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	constitutive	_	JJ	JJ	_	6	NMOD	_	_
6	presence	_	NN	NN	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	factors	_	NNS	NNS	_	7	PMOD	_	_
10	in	_	IN	IN	_	6	NMOD	_	_
11	resting	_	VBG	VBG	_	12	NMOD	_	_
12	PBL	_	NN	NN	_	10	PMOD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	bind	_	VBP	VBP	_	9	NMOD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	proximal	_	JJ	JJ	_	19	NMOD	_	_
18	AP-1	_	NN	NN	_	19	NMOD	_	_
19	site	_	NN	NN	_	15	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	IL-2	_	NN	NN	_	23	NMOD	_	_
23	promoter	_	NN	NN	_	20	PMOD	_	_
24	and	_	CC	CC	_	14	CC	_	_
25	that	_	IN	IN	_	26	SBJ	_	_
26	contain	_	VBP	VBP	_	14	COORD	_	_
27	immunoreactive	_	JJ	JJ	_	32	NMOD	_	_
28	c-Jun	_	NN	NN	_	32	NMOD	_	_
29	but	_	CC	CC	_	28	CC	_	_
30	not	_	RB	RB	_	29	COORD	_	_
31	c-Fos	_	NN	NN	_	28	COORD	_	_
32	protein	_	NN	NN	_	26	OBJ	_	_
33	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	8	P	_	_
4	AP-1	_	NN	NN	_	8	SBJ	_	_
5	from	_	IN	IN	_	4	NMOD	_	_
6	PHA-activated	_	JJ	JJ	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	5	PMOD	_	_
8	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	c-Jun	_	NN	NN	_	8	OBJ	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	low	_	JJ	JJ	_	12	NMOD	_	_
12	levels	_	NNS	NNS	_	9	COORD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	c-Fos	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	8	P	_	_

1	Strikingly	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	costimulation	_	NN	NN	_	6	SBJ	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	EC	_	NN	NN	_	4	PMOD	_	_
6	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	dramatic	_	JJ	JJ	_	10	NMOD	_	_
10	increase	_	NN	NN	_	7	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	up	_	NN	NN	_	10	PRN	_	_
13	to	_	TO	TO	_	12	DEP	_	_
14	15-fold	_	JJ	JJ	_	12	DEP	_	_
15	)	_	)	)	_	12	P	_	_
16	in	_	IN	IN	_	10	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	c-Fos	_	NN	NN	_	19	NMOD	_	_
19	content	_	NN	NN	_	16	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	AP-1	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	Levels	_	NNS	NNS	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	other	_	JJ	JJ	_	5	NMOD	_	_
4	nuclear	_	JJ	JJ	_	5	NMOD	_	_
5	factors	_	NNS	NNS	_	2	PMOD	_	_
6	involved	_	VBN	VBN	_	5	NMOD	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	IL-2	_	NN	NN	_	9	NMOD	_	_
9	regulation	_	NN	NN	_	7	PMOD	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	not	_	RB	RB	_	10	VMOD	_	_
12	altered	_	VBN	VBN	_	10	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	EC	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	12	P	_	_
16	although	_	IN	IN	_	12	OBJ	_	_
17	NFAT-DNA	_	NN	NN	_	18	NMOD	_	_
18	complexes	_	NNS	NNS	_	19	SBJ	_	_
19	migrated	_	VBD	VBD	_	16	VMOD	_	_
20	at	_	IN	IN	_	19	ADV	_	_
21	a	_	DT	DT	_	24	NMOD	_	_
22	slightly	_	RB	RB	_	23	AMOD	_	_
23	different	_	JJ	JJ	_	24	NMOD	_	_
24	mobility	_	NN	NN	_	20	PMOD	_	_
25	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	summary	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	6	P	_	_
4	our	_	PRP$	PRP$	_	5	NMOD	_	_
5	data	_	NNS	NNS	_	6	SBJ	_	_
6	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	changes	_	NNS	NNS	_	16	SBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	composition	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	transcription	_	NN	NN	_	15	NMOD	_	_
14	factor	_	NN	NN	_	15	NMOD	_	_
15	AP-1	_	NN	NN	_	12	PMOD	_	_
16	is	_	VBZ	VBZ	_	7	VMOD	_	_
17	a	_	DT	DT	_	20	NMOD	_	_
18	key	_	JJ	JJ	_	20	NMOD	_	_
19	molecular	_	JJ	JJ	_	20	NMOD	_	_
20	mechanism	_	NN	NN	_	16	PRD	_	_
21	for	_	IN	IN	_	20	NMOD	_	_
22	increasing	_	VBG	VBG	_	24	NMOD	_	_
23	IL-2	_	NN	NN	_	24	NMOD	_	_
24	transcription	_	NN	NN	_	21	PMOD	_	_
25	and	_	CC	CC	_	16	CC	_	_
26	may	_	MD	MD	_	16	COORD	_	_
27	underlie	_	VB	VB	_	26	VC	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	phenomenon	_	NN	NN	_	27	OBJ	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	costimulation	_	NN	NN	_	30	PMOD	_	_
32	by	_	IN	IN	_	31	NMOD	_	_
33	EC	_	NN	NN	_	32	PMOD	_	_
34	.	_	.	.	_	6	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	protein	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	AP-1	_	NN	NN	_	6	NMOD	_	_
6	family	_	NN	NN	_	3	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	component	_	NN	NN	_	7	PRD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	nuclear	_	JJ	JJ	_	12	NMOD	_	_
12	factor	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	activated	_	VBN	VBN	_	16	NMOD	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	13	PMOD	_	_
17	.	_	.	.	_	7	P	_	_

1	Nuclear	_	JJ	JJ	_	2	NMOD	_	_
2	factor	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	activated	_	VBN	VBN	_	6	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	3	PMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	NF-AT	_	NN	NN	_	2	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	transcriptional	_	JJ	JJ	_	13	NMOD	_	_
13	activator	_	NN	NN	_	10	PRD	_	_
14	involved	_	VBN	VBN	_	13	NMOD	_	_
15	in	_	IN	IN	_	14	ADV	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	induction	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	IL-2	_	NN	NN	_	21	NMOD	_	_
20	gene	_	NN	NN	_	21	NMOD	_	_
21	expression	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	response	_	NN	NN	_	3	NMOD	_	_
3	element	_	NN	NN	_	6	SBJ	_	_
4	for	_	IN	IN	_	3	NMOD	_	_
5	NF-AT	_	NN	NN	_	4	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	sequence	_	NN	NN	_	6	PRD	_	_
9	localized	_	JJ	JJ	_	8	NMOD	_	_
10	between	_	IN	IN	_	9	ADV	_	_
11	-285\/-254	_	CD	CD	_	10	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	IL-2	_	NN	NN	_	16	NMOD	_	_
15	regulatory	_	JJ	JJ	_	16	NMOD	_	_
16	region	_	NN	NN	_	12	PMOD	_	_
17	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	composition	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NF-AT	_	NN	NN	_	5	NMOD	_	_
5	protein	_	NN	NN	_	3	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	still	_	RB	RB	_	6	ADV	_	_
8	not	_	RB	RB	_	6	ADV	_	_
9	fully	_	RB	RB	_	8	AMOD	_	_
10	elucidated	_	VBN	VBN	_	6	VC	_	_
11	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	in	_	IN	IN	_	14	ADV	_	_
6	normal	_	JJ	JJ	_	9	NMOD	_	_
7	human	_	JJ	JJ	_	9	NMOD	_	_
8	T	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	5	PMOD	_	_
10	,	_	,	,	_	14	P	_	_
11	an	_	DT	DT	_	13	NMOD	_	_
12	AP-1	_	NN	NN	_	13	NMOD	_	_
13	protein	_	NN	NN	_	14	SBJ	_	_
14	is	_	VBZ	VBZ	_	3	VMOD	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	component	_	NN	NN	_	14	PRD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	NF-AT	_	NN	NN	_	21	NMOD	_	_
20	protein	_	NN	NN	_	21	NMOD	_	_
21	complex	_	NN	NN	_	17	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	evidenced	_	VBN	VBN	_	2	VC	_	_
4	by	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	ability	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	AP-1	_	NN	NN	_	10	NMOD	_	_
10	site	_	NN	NN	_	7	PMOD	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	compete	_	VB	VB	_	6	NMOD	_	_
13	with	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	NF-AT	_	NN	NN	_	16	NMOD	_	_
16	site	_	NN	NN	_	13	PMOD	_	_
17	for	_	IN	IN	_	12	ADV	_	_
18	binding	_	NN	NN	_	17	PMOD	_	_
19	to	_	TO	TO	_	18	ADV	_	_
20	NF-AT	_	NN	NN	_	19	PMOD	_	_
21	and	_	CC	CC	_	4	CC	_	_
22	by	_	IN	IN	_	4	COORD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	capacity	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	immobilized	_	VBN	VBN	_	30	NMOD	_	_
27	anti-Jun	_	JJ	JJ	_	30	NMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	anti-Fos	_	JJ	JJ	_	27	COORD	_	_
30	antibodies	_	NNS	NNS	_	25	PMOD	_	_
31	to	_	TO	TO	_	32	VMOD	_	_
32	deplete	_	VB	VB	_	24	NMOD	_	_
33	NF-AT-binding	_	NN	NN	_	34	NMOD	_	_
34	activity	_	NN	NN	_	32	OBJ	_	_
35	from	_	IN	IN	_	32	ADV	_	_
36	nuclear	_	JJ	JJ	_	37	NMOD	_	_
37	extracts	_	NNS	NNS	_	35	PMOD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	activated	_	VBN	VBN	_	41	NMOD	_	_
40	T	_	NN	NN	_	41	NMOD	_	_
41	cells	_	NNS	NNS	_	38	PMOD	_	_
42	.	_	.	.	_	2	P	_	_

1	There	_	EX	EX	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	no	_	DT	DT	_	5	NMOD	_	_
4	detectable	_	JJ	JJ	_	5	NMOD	_	_
5	binding	_	NN	NN	_	2	PRD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	in	_	FW	FW	_	11	NMOD	_	_
8	vitro	_	FW	FW	_	7	AMOD	_	_
9	translated	_	VBN	VBN	_	7	AMOD	_	_
10	Jun\/Fos	_	NN	NN	_	11	NMOD	_	_
11	heterodimer	_	NN	NN	_	6	PMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	AP-1	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	to	_	TO	TO	_	5	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	NF-AT	_	NN	NN	_	18	NMOD	_	_
18	sequence	_	NN	NN	_	15	PMOD	_	_
19	,	_	,	,	_	2	P	_	_
20	and	_	CC	CC	_	2	CC	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	NF-AT	_	NN	NN	_	23	NMOD	_	_
23	sequence	_	NN	NN	_	24	SBJ	_	_
24	was	_	VBD	VBD	_	2	COORD	_	_
25	unable	_	JJ	JJ	_	24	PRD	_	_
26	to	_	TO	TO	_	27	VMOD	_	_
27	inhibit	_	VB	VB	_	25	AMOD	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	binding	_	NN	NN	_	27	OBJ	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	Jun\/Fos	_	NN	NN	_	30	PMOD	_	_
32	to	_	TO	TO	_	29	NMOD	_	_
33	the	_	DT	DT	_	35	NMOD	_	_
34	AP-1	_	NN	NN	_	35	NMOD	_	_
35	sequence	_	NN	NN	_	32	PMOD	_	_
36	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	presence	_	NN	NN	_	12	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	an	_	DT	DT	_	6	NMOD	_	_
5	AP-1	_	NN	NN	_	6	NMOD	_	_
6	protein	_	NN	NN	_	3	PMOD	_	_
7	in	_	IN	IN	_	2	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	NF-AT	_	NN	NN	_	11	NMOD	_	_
10	protein	_	NN	NN	_	11	NMOD	_	_
11	complex	_	NN	NN	_	7	PMOD	_	_
12	may	_	MD	MD	_	0	ROOT-S	_	_
13	regulate	_	VB	VB	_	12	VC	_	_
14	NF-AT-binding	_	JJ	JJ	_	15	NMOD	_	_
15	activity	_	NN	NN	_	13	OBJ	_	_
16	through	_	IN	IN	_	13	ADV	_	_
17	protein-protein	_	JJ	JJ	_	18	NMOD	_	_
18	interaction	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	lytic	_	JJ	JJ	_	3	NMOD	_	_
3	transition	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	Epstein-Barr	_	JJ	JJ	_	6	NMOD	_	_
6	virus	_	NN	NN	_	4	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	imitated	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	recombinant	_	JJ	JJ	_	11	NMOD	_	_
11	B-cells	_	NNS	NNS	_	9	PMOD	_	_
12	.	_	.	.	_	7	P	_	_

1	Lytic	_	JJ	JJ	_	2	NMOD	_	_
2	transition	_	NN	NN	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	Epstein-Barr	_	JJ	JJ	_	5	NMOD	_	_
5	virus	_	NN	NN	_	3	PMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	EBV	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	initiated	_	VBN	VBN	_	9	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	distinct	_	JJ	JJ	_	15	NMOD	_	_
13	immediate	_	JJ	JJ	_	15	NMOD	_	_
14	early	_	JJ	JJ	_	15	NMOD	_	_
15	regulators	_	NNS	NNS	_	11	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	viral	_	JJ	JJ	_	19	NMOD	_	_
19	cycle	_	NN	NN	_	16	PMOD	_	_
20	,	_	,	,	_	10	P	_	_
21	in	_	IN	IN	_	10	TMP	_	_
22	synchronization	_	NN	NN	_	21	PMOD	_	_
23	to	_	TO	TO	_	22	NMOD	_	_
24	temporary	_	JJ	JJ	_	27	NMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	permissive	_	JJ	JJ	_	24	COORD	_	_
27	conditions	_	NNS	NNS	_	23	PMOD	_	_
28	during	_	IN	IN	_	27	TMP	_	_
29	host	_	NN	NN	_	31	NMOD	_	_
30	cell	_	NN	NN	_	31	NMOD	_	_
31	differentiation	_	NN	NN	_	28	PMOD	_	_
32	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	developed	_	VBD	VBD	_	0	ROOT-S	_	_
3	eukaryotic	_	JJ	JJ	_	4	NMOD	_	_
4	vectors	_	NNS	NNS	_	2	OBJ	_	_
5	suitable	_	JJ	JJ	_	4	NMOD	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	imitate	_	VB	VB	_	5	AMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	processes	_	NNS	NNS	_	7	OBJ	_	_
10	involved	_	VBN	VBN	_	9	NMOD	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	lytic	_	JJ	JJ	_	13	NMOD	_	_
13	transition	_	NN	NN	_	11	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	cell	_	NN	NN	_	17	NMOD	_	_
16	culture	_	NN	NN	_	17	NMOD	_	_
17	systems	_	NNS	NNS	_	14	PMOD	_	_
18	.	_	.	.	_	2	P	_	_

1	Two	_	CD	CD	_	5	NMOD	_	_
2	stable	_	JJ	JJ	_	5	NMOD	_	_
3	B	_	NN	NN	_	5	NMOD	_	_
4	cell	_	NN	NN	_	5	NMOD	_	_
5	lines	_	NNS	NNS	_	6	SBJ	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	established	_	VBN	VBN	_	6	VC	_	_
8	:	_	:	:	_	6	P	_	_
9	R59Z	_	NN	NN	_	11	NMOD	_	_
10	activator	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	12	SBJ	_	_
12	were	_	VBD	VBD	_	6	VC	_	_
13	used	_	VBN	VBN	_	12	VC	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	induce	_	VB	VB	_	13	OBJ	_	_
16	lytic	_	JJ	JJ	_	18	NMOD	_	_
17	EBV	_	NN	NN	_	18	NMOD	_	_
18	expression	_	NN	NN	_	15	OBJ	_	_
19	in	_	IN	IN	_	15	ADV	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	constitutive	_	JJ	JJ	_	22	NMOD	_	_
22	manner	_	NN	NN	_	19	PMOD	_	_
23	by	_	IN	IN	_	15	ADV	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	production	_	NN	NN	_	23	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	BZLF	_	NN	NN	_	30	NMOD	_	_
29	1	_	CD	CD	_	30	NMOD	_	_
30	trans-activator	_	NN	NN	_	26	PMOD	_	_
31	(	_	(	(	_	32	P	_	_
32	Zta	_	NN	NN	_	30	PRN	_	_
33	)	_	)	)	_	32	P	_	_
34	.	_	.	.	_	12	P	_	_

1	R7-57	_	NN	NN	_	3	NMOD	_	_
2	reporter	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	10	SBJ	_	_
4	,	_	,	,	_	10	P	_	_
5	on	_	IN	IN	_	10	ADV	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	other	_	JJ	JJ	_	8	NMOD	_	_
8	hand	_	NN	NN	_	5	PMOD	_	_
9	,	_	,	,	_	10	P	_	_
10	signaled	_	VBD	VBD	_	0	ROOT-S	_	_
11	induced	_	VBN	VBN	_	12	NMOD	_	_
12	activity	_	NN	NN	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	lytic	_	JJ	JJ	_	16	NMOD	_	_
16	origin	_	NN	NN	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	EBV	_	NN	NN	_	19	NMOD	_	_
19	replication	_	NN	NN	_	17	PMOD	_	_
20	(	_	(	(	_	22	P	_	_
21	ori	_	NN	NN	_	22	NMOD	_	_
22	Lyt	_	NN	NN	_	16	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	.	_	.	.	_	10	P	_	_

1	Different	_	JJ	JJ	_	2	NMOD	_	_
2	modes	_	NNS	NNS	_	16	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	like	_	IN	IN	_	2	NMOD	_	_
5	chemical	_	JJ	JJ	_	6	NMOD	_	_
6	induction	_	NN	NN	_	4	PMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	lytic	_	JJ	JJ	_	9	NMOD	_	_
9	superinfection	_	NN	NN	_	6	COORD	_	_
10	with	_	IN	IN	_	9	NMOD	_	_
11	EBV	_	NN	NN	_	10	PMOD	_	_
12	and	_	CC	CC	_	6	CC	_	_
13	single	_	JJ	JJ	_	15	NMOD	_	_
14	gene	_	NN	NN	_	15	NMOD	_	_
15	trans-activation	_	NN	NN	_	6	COORD	_	_
16	converted	_	VBD	VBD	_	0	ROOT-S	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	recombinant	_	JJ	JJ	_	21	NMOD	_	_
19	ori	_	NN	NN	_	21	NMOD	_	_
20	Lyt	_	NN	NN	_	21	NMOD	_	_
21	element	_	NN	NN	_	16	OBJ	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	R7-57	_	NN	NN	_	25	NMOD	_	_
24	reporter	_	NN	NN	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	22	PMOD	_	_
26	.	_	.	.	_	16	P	_	_

1	BZLF	_	NN	NN	_	11	SBJ	_	_
2	1	_	CD	CD	_	1	NMOD	_	_
3	,	_	,	,	_	1	P	_	_
4	transiently	_	RB	RB	_	5	TMP	_	_
5	expressed	_	VBN	VBN	_	1	NMOD	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	R7-57	_	NN	NN	_	9	NMOD	_	_
8	reporter	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	6	PMOD	_	_
10	,	_	,	,	_	1	P	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	only	_	JJ	JJ	_	15	NMOD	_	_
14	EBV	_	NN	NN	_	15	NMOD	_	_
15	trans-activator	_	NN	NN	_	11	PRD	_	_
16	found	_	VBN	VBN	_	15	NMOD	_	_
17	,	_	,	,	_	15	P	_	_
18	sufficient	_	JJ	JJ	_	15	NMOD	_	_
19	in	_	NN	NN	_	18	AMOD	_	_
20	inducing	_	VBG	VBG	_	19	PMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	viral	_	JJ	JJ	_	24	NMOD	_	_
23	lytic	_	JJ	JJ	_	24	NMOD	_	_
24	cycle	_	NN	NN	_	20	OBJ	_	_
25	.	_	.	.	_	11	P	_	_

1	Basing	_	VBG	VBG	_	10	ADV	_	_
2	on	_	IN	IN	_	1	PMOD	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	experiments	_	NNS	NNS	_	2	PMOD	_	_
5	,	_	,	,	_	10	P	_	_
6	trans-cellular	_	JJ	JJ	_	7	NMOD	_	_
7	activation	_	NN	NN	_	10	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	EBV	_	NN	NN	_	8	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	tested	_	VBN	VBN	_	10	VC	_	_
12	by	_	IN	IN	_	11	ADV	_	_
13	cocultivation	_	NN	NN	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	BZLF	_	NN	NN	_	19	NMOD	_	_
16	1-expressing	_	JJ	JJ	_	15	AMOD	_	_
17	R59Z	_	NN	NN	_	19	NMOD	_	_
18	activator	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	14	PMOD	_	_
20	with	_	IN	IN	_	13	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	R7-57	_	NN	NN	_	24	NMOD	_	_
23	reporter	_	NN	NN	_	24	NMOD	_	_
24	line	_	NN	NN	_	20	PMOD	_	_
25	.	_	.	.	_	10	P	_	_

1	No	_	DT	DT	_	3	NMOD	_	_
2	lytic	_	JJ	JJ	_	3	NMOD	_	_
3	effect	_	NN	NN	_	8	SBJ	_	_
4	on	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	reporter	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	4	PMOD	_	_
8	could	_	MD	MD	_	0	ROOT-S	_	_
9	be	_	VB	VB	_	8	VC	_	_
10	measured	_	VBN	VBN	_	9	VC	_	_
11	,	_	,	,	_	10	P	_	_
12	neither	_	CC	CC	_	10	ADV	_	_
13	by	_	IN	IN	_	12	COORD	_	_
14	cocultivation	_	NN	NN	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	activator	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	15	PMOD	_	_
18	nor	_	CC	CC	_	12	CC	_	_
19	by	_	IN	IN	_	12	COORD	_	_
20	coincubation	_	NN	NN	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	BZLF	_	NN	NN	_	25	NMOD	_	_
23	1-containing	_	JJ	JJ	_	22	AMOD	_	_
24	cell	_	NN	NN	_	25	NMOD	_	_
25	lysates	_	NNS	NNS	_	21	PMOD	_	_
26	.	_	.	.	_	8	P	_	_

1	Latency	_	NN	NN	_	3	NMOD	_	_
2	breaking	_	NN	NN	_	3	NMOD	_	_
3	activity	_	NN	NN	_	7	SBJ	_	_
4	,	_	,	,	_	7	P	_	_
5	however	_	RB	RB	_	7	ADV	_	_
6	,	_	,	,	_	7	P	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	transferred	_	VBN	VBN	_	7	VC	_	_
9	from	_	IN	IN	_	8	ADV	_	_
10	activator	_	NN	NN	_	9	PMOD	_	_
11	to	_	TO	TO	_	8	ADV	_	_
12	reporter	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	when	_	WRB	WRB	_	20	ADV	_	_
15	active	_	JJ	JJ	_	18	NMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	exogenous	_	JJ	JJ	_	15	COORD	_	_
18	virus	_	NN	NN	_	19	SBJ	_	_
19	was	_	VBD	VBD	_	8	TMP	_	_
20	added	_	VBN	VBN	_	19	VC	_	_
21	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	cell	_	NN	NN	_	3	NMOD	_	_
3	system	_	NN	NN	_	8	SBJ	_	_
4	described	_	VBN	VBN	_	3	NMOD	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	these	_	DT	DT	_	7	NMOD	_	_
7	experiments	_	NNS	NNS	_	5	PMOD	_	_
8	provides	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	tool	_	NN	NN	_	8	OBJ	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	detection	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	EBV	_	NN	NN	_	16	NMOD	_	_
16	reactivation	_	NN	NN	_	14	PMOD	_	_
17	and	_	CC	CC	_	8	CC	_	_
18	demonstrates	_	VBZ	VBZ	_	8	COORD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	potential	_	NN	NN	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	26	NMOD	_	_
23	lytic	_	JJ	JJ	_	26	NMOD	_	_
24	regulatory	_	JJ	JJ	_	26	NMOD	_	_
25	gene	_	NN	NN	_	26	NMOD	_	_
26	BZLF	_	NN	NN	_	21	PMOD	_	_
27	1	_	CD	CD	_	26	NMOD	_	_
28	.	_	.	.	_	8	P	_	_

1	Immobilization	_	NN	NN	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	recovery	_	NN	NN	_	1	COORD	_	_
4	of	_	IN	IN	_	1	NMOD	_	_
5	fusion	_	NN	NN	_	6	NMOD	_	_
6	proteins	_	NNS	NNS	_	4	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	B-lymphocyte	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	6	COORD	_	_
10	using	_	VBG	VBG	_	1	NMOD	_	_
11	magnetic	_	JJ	JJ	_	12	NMOD	_	_
12	separation	_	NN	NN	_	10	OBJ	_	_
13	.	_	.	.	_	1	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	new	_	JJ	JJ	_	3	NMOD	_	_
3	approach	_	NN	NN	_	18	SBJ	_	_
4	to	_	TO	TO	_	5	VMOD	_	_
5	facilitate	_	VB	VB	_	3	NMOD	_	_
6	immobilization	_	NN	NN	_	5	OBJ	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	affinity	_	NN	NN	_	9	NMOD	_	_
9	purification	_	NN	NN	_	6	COORD	_	_
10	of	_	IN	IN	_	6	NMOD	_	_
11	recombinant	_	JJ	JJ	_	12	NMOD	_	_
12	proteins	_	NNS	NNS	_	10	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	selected	_	VBN	VBN	_	17	NMOD	_	_
15	human	_	JJ	JJ	_	17	NMOD	_	_
16	B	_	NN	NN	_	17	NMOD	_	_
17	lymphocytes	_	NNS	NNS	_	12	COORD	_	_
18	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
19	been	_	VBN	VBN	_	18	VC	_	_
20	developed	_	VBN	VBN	_	19	VC	_	_
21	.	_	.	.	_	18	P	_	_

1	Using	_	VBG	VBG	_	21	VMOD	_	_
2	magnetic	_	JJ	JJ	_	3	NMOD	_	_
3	beads	_	NNS	NNS	_	1	OBJ	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	attached	_	VBN	VBN	_	6	NMOD	_	_
6	DNA	_	NN	NN	_	4	PMOD	_	_
7	containing	_	VBG	VBG	_	6	NMOD	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	Escherichia	_	FW	FW	_	12	NMOD	_	_
10	coli	_	FW	FW	_	12	NMOD	_	_
11	lac	_	NN	NN	_	12	NMOD	_	_
12	operator	_	NN	NN	_	7	OBJ	_	_
13	,	_	,	,	_	21	P	_	_
14	fusion	_	NN	NN	_	15	NMOD	_	_
15	proteins	_	NNS	NNS	_	21	SBJ	_	_
16	comprising	_	VBG	VBG	_	15	NMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	DNA-binding	_	JJ	JJ	_	20	NMOD	_	_
19	lac	_	NN	NN	_	20	NMOD	_	_
20	repressor	_	NN	NN	_	16	OBJ	_	_
21	could	_	MD	MD	_	0	ROOT-S	_	_
22	be	_	VB	VB	_	21	VC	_	_
23	affinity-purified	_	JJ	JJ	_	22	VC	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	recovered	_	VBN	VBN	_	23	COORD	_	_
26	by	_	IN	IN	_	23	ADV	_	_
27	gentle	_	JJ	JJ	_	29	NMOD	_	_
28	elution	_	NN	NN	_	29	NMOD	_	_
29	conditions	_	NNS	NNS	_	26	PMOD	_	_
30	,	_	,	,	_	29	P	_	_
31	such	_	JJ	JJ	_	32	DEP	_	_
32	as	_	IN	IN	_	29	NMOD	_	_
33	with	_	IN	IN	_	32	PMOD	_	_
34	a	_	DT	DT	_	36	NMOD	_	_
35	lactose	_	NN	NN	_	36	NMOD	_	_
36	analogue	_	NN	NN	_	33	PMOD	_	_
37	or	_	CC	CC	_	26	CC	_	_
38	by	_	IN	IN	_	26	COORD	_	_
39	enzymatic	_	JJ	JJ	_	40	NMOD	_	_
40	means	_	NNS	NNS	_	38	PMOD	_	_
41	using	_	VBG	VBG	_	40	NMOD	_	_
42	either	_	CC	CC	_	43	CC	_	_
43	deoxyribonuclease	_	NN	NN	_	41	OBJ	_	_
44	(	_	(	(	_	45	P	_	_
45	DNase	_	NN	NN	_	43	PRN	_	_
46	)	_	)	)	_	45	P	_	_
47	or	_	CC	CC	_	43	CC	_	_
48	restriction	_	NN	NN	_	49	NMOD	_	_
49	endonucleases	_	NNS	NNS	_	43	COORD	_	_
50	.	_	.	.	_	21	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	for	_	IN	IN	_	3	TMP	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	first	_	JJ	JJ	_	7	NMOD	_	_
7	time	_	NN	NN	_	4	PMOD	_	_
8	that	_	IN	IN	_	3	OBJ	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	DNA-binding	_	JJ	JJ	_	11	NMOD	_	_
11	protein	_	NN	NN	_	12	SBJ	_	_
12	can	_	MD	MD	_	8	VMOD	_	_
13	be	_	VB	VB	_	12	VC	_	_
14	used	_	VBN	VBN	_	13	VC	_	_
15	for	_	IN	IN	_	14	ADV	_	_
16	affinity	_	NN	NN	_	17	NMOD	_	_
17	purification	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	fusion	_	NN	NN	_	20	NMOD	_	_
20	proteins	_	NNS	NNS	_	18	PMOD	_	_
21	as	_	IN	IN	_	14	ADV	_	_
22	exemplified	_	VBN	VBN	_	21	VMOD	_	_
23	by	_	IN	IN	_	22	LGS	_	_
24	the	_	DT	DT	_	28	NMOD	_	_
25	specific	_	JJ	JJ	_	28	NMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	gentle	_	JJ	JJ	_	25	COORD	_	_
28	recovery	_	NN	NN	_	23	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	beta-galactosidase	_	NN	NN	_	29	PMOD	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	alkaline	_	NN	NN	_	33	NMOD	_	_
33	phosphatase	_	NN	NN	_	30	COORD	_	_
34	from	_	IN	IN	_	28	NMOD	_	_
35	bacterial	_	JJ	JJ	_	36	NMOD	_	_
36	lysates	_	NNS	NNS	_	34	PMOD	_	_
37	using	_	VBG	VBG	_	22	OBJ	_	_
38	immunomagnetic	_	JJ	JJ	_	39	NMOD	_	_
39	separation	_	NN	NN	_	37	OBJ	_	_
40	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	approach	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	further	_	RB	RB	_	3	ADV	_	_
5	extended	_	VBN	VBN	_	3	VC	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	cell	_	NN	NN	_	8	NMOD	_	_
8	separation	_	NN	NN	_	6	PMOD	_	_
9	by	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	efficient	_	JJ	JJ	_	12	NMOD	_	_
12	recovery	_	NN	NN	_	9	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	elution	_	NN	NN	_	12	COORD	_	_
15	of	_	IN	IN	_	12	NMOD	_	_
16	human	_	JJ	JJ	_	19	NMOD	_	_
17	CD37	_	NN	NN	_	19	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	lymphocytes	_	NNS	NNS	_	15	PMOD	_	_
20	from	_	IN	IN	_	19	NMOD	_	_
21	peripheral	_	JJ	JJ	_	22	NMOD	_	_
22	blood	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	Negative	_	JJ	JJ	_	3	NMOD	_	_
2	transcriptional	_	JJ	JJ	_	3	NMOD	_	_
3	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	human	_	JJ	JJ	_	11	NMOD	_	_
6	interleukin	_	NN	NN	_	11	NMOD	_	_
7	2	_	CD	CD	_	6	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	IL-2	_	NN	NN	_	6	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	gene	_	NN	NN	_	4	PMOD	_	_
12	by	_	IN	IN	_	3	NMOD	_	_
13	glucocorticoids	_	NNS	NNS	_	12	PMOD	_	_
14	through	_	IN	IN	_	3	NMOD	_	_
15	interference	_	NN	NN	_	14	PMOD	_	_
16	with	_	IN	IN	_	15	NMOD	_	_
17	nuclear	_	JJ	JJ	_	19	NMOD	_	_
18	transcription	_	NN	NN	_	19	NMOD	_	_
19	factors	_	NNS	NNS	_	16	PMOD	_	_
20	AP-1	_	NN	NN	_	19	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	NF-AT	_	NN	NN	_	20	COORD	_	_
23	.	_	.	.	_	3	P	_	_

1	IL-2	_	NN	NN	_	3	NMOD	_	_
2	gene	_	NN	NN	_	3	NMOD	_	_
3	transcription	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	affected	_	VBN	VBN	_	4	VC	_	_
6	by	_	IN	IN	_	5	LGS	_	_
7	several	_	JJ	JJ	_	9	NMOD	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	proteins	_	NNS	NNS	_	6	PMOD	_	_
10	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	asked	_	VBD	VBD	_	0	ROOT-S	_	_
3	whether	_	IN	IN	_	2	OBJ	_	_
4	dexamethasone	_	NN	NN	_	14	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	Dex	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	and	_	CC	CC	_	4	CC	_	_
9	cyclosporin	_	NN	NN	_	10	NMOD	_	_
10	A	_	NN	NN	_	4	COORD	_	_
11	(	_	(	(	_	12	P	_	_
12	CsA	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	inhibit	_	VBP	VBP	_	3	VMOD	_	_
15	IL-2	_	NN	NN	_	17	NMOD	_	_
16	gene	_	NN	NN	_	17	NMOD	_	_
17	transcription	_	NN	NN	_	14	OBJ	_	_
18	by	_	IN	IN	_	14	ADV	_	_
19	interfering	_	VBG	VBG	_	18	PMOD	_	_
20	with	_	IN	IN	_	19	ADV	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	activity	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	nuclear	_	JJ	JJ	_	25	NMOD	_	_
25	proteins	_	NNS	NNS	_	23	PMOD	_	_
26	that	_	WDT	WDT	_	27	SBJ	_	_
27	bind	_	VBP	VBP	_	25	NMOD	_	_
28	to	_	TO	TO	_	27	ADV	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	IL-2	_	NN	NN	_	31	NMOD	_	_
31	promoter	_	NN	NN	_	28	PMOD	_	_
32	.	_	.	.	_	2	P	_	_

1	Nuclear	_	JJ	JJ	_	2	NMOD	_	_
2	extracts	_	NNS	NNS	_	8	SBJ	_	_
3	from	_	IN	IN	_	2	NMOD	_	_
4	primary	_	JJ	JJ	_	3	PMOD	_	_
5	human	_	JJ	JJ	_	4	PMOD	_	_
6	T	_	NN	NN	_	4	PMOD	_	_
7	lymphocytes	_	NNS	NNS	_	4	PMOD	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	analyzed	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	ADV	_	_
11	electrophoretic	_	JJ	JJ	_	15	NMOD	_	_
12	DNA	_	NN	NN	_	15	NMOD	_	_
13	mobility	_	NN	NN	_	15	NMOD	_	_
14	shift	_	NN	NN	_	15	NMOD	_	_
15	assays	_	NNS	NNS	_	10	PMOD	_	_
16	.	_	.	.	_	8	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	Dex	_	NN	NN	_	5	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	CsA	_	NN	NN	_	2	COORD	_	_
5	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	binding	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	transcription	_	NN	NN	_	10	NMOD	_	_
10	factors	_	NNS	NNS	_	8	PMOD	_	_
11	AP-1	_	NN	NN	_	10	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	NF-AT	_	NN	NN	_	11	COORD	_	_
14	,	_	,	,	_	8	P	_	_
15	but	_	CC	CC	_	8	CC	_	_
16	not	_	RB	RB	_	17	DEP	_	_
17	of	_	IN	IN	_	8	COORD	_	_
18	NF-kB	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	OCT-1\/OAF	_	NN	NN	_	18	COORD	_	_
21	,	_	,	,	_	7	P	_	_
22	to	_	TO	TO	_	7	NMOD	_	_
23	their	_	PRP$	PRP$	_	25	NMOD	_	_
24	corresponding	_	JJ	JJ	_	25	NMOD	_	_
25	sites	_	NNS	NNS	_	22	PMOD	_	_
26	on	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	IL-2	_	NN	NN	_	30	NMOD	_	_
29	gene	_	NN	NN	_	30	NMOD	_	_
30	promoter	_	NN	NN	_	26	PMOD	_	_
31	.	_	.	.	_	5	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	correlate	_	VB	VB	_	26	VMOD	_	_
3	changes	_	NNS	NNS	_	2	OBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	nuclear	_	JJ	JJ	_	7	NMOD	_	_
6	factor	_	NN	NN	_	7	NMOD	_	_
7	binding	_	NN	NN	_	4	PMOD	_	_
8	in	_	FW	FW	_	3	NMOD	_	_
9	vitro	_	FW	FW	_	8	AMOD	_	_
10	with	_	IN	IN	_	2	ADV	_	_
11	transcriptional	_	JJ	JJ	_	12	NMOD	_	_
12	activity	_	NN	NN	_	10	PMOD	_	_
13	in	_	FW	FW	_	12	NMOD	_	_
14	vivo	_	FW	FW	_	13	AMOD	_	_
15	and	_	CC	CC	_	2	CC	_	_
16	define	_	VB	VB	_	2	COORD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	structural	_	JJ	JJ	_	19	NMOD	_	_
19	requirements	_	NNS	NNS	_	16	OBJ	_	_
20	for	_	IN	IN	_	19	NMOD	_	_
21	IL-2	_	NN	NN	_	23	NMOD	_	_
22	promoter	_	NN	NN	_	23	NMOD	_	_
23	repression	_	NN	NN	_	20	PMOD	_	_
24	,	_	,	,	_	26	P	_	_
25	we	_	PRP	PRP	_	26	SBJ	_	_
26	used	_	VBD	VBD	_	0	ROOT-S	_	_
27	transient	_	JJ	JJ	_	29	NMOD	_	_
28	DNA	_	NN	NN	_	29	NMOD	_	_
29	transfections	_	NNS	NNS	_	26	OBJ	_	_
30	.	_	.	.	_	26	P	_	_

1	Jurkat	_	NN	NN	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	transfected	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	plasmids	_	NNS	NNS	_	5	PMOD	_	_
7	containing	_	VBG	VBG	_	6	NMOD	_	_
8	either	_	CC	CC	_	12	CC	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	intact	_	JJ	JJ	_	12	NMOD	_	_
11	IL-2	_	NN	NN	_	12	NMOD	_	_
12	promoter	_	NN	NN	_	7	OBJ	_	_
13	or	_	CC	CC	_	12	CC	_	_
14	its	_	PRP$	PRP$	_	21	NMOD	_	_
15	AP-1	_	NN	NN	_	21	NMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	NF-AT	_	NN	NN	_	15	COORD	_	_
18	,	_	,	,	_	15	P	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	NF-kB	_	NN	NN	_	15	COORD	_	_
21	motifs	_	NNS	NNS	_	12	COORD	_	_
22	.	_	.	.	_	3	P	_	_

1	Dex	_	NN	NN	_	2	SBJ	_	_
2	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	IL-2	_	NN	NN	_	5	NMOD	_	_
5	promoter	_	NN	NN	_	2	OBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	AP-1	_	NN	NN	_	5	COORD	_	_
9	,	_	,	,	_	5	P	_	_
10	but	_	CC	CC	_	5	CC	_	_
11	not	_	RB	RB	_	10	COORD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	NF-AT	_	NN	NN	_	5	COORD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	NF-kB	_	NN	NN	_	13	COORD	_	_
16	plasmids	_	NNS	NNS	_	5	NMOD	_	_
17	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	CsA	_	NN	NN	_	5	SBJ	_	_
5	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	IL-2	_	NN	NN	_	8	NMOD	_	_
8	promoter	_	NN	NN	_	5	OBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	NF-AT	_	NN	NN	_	8	COORD	_	_
12	,	_	,	,	_	8	P	_	_
13	but	_	CC	CC	_	8	CC	_	_
14	not	_	RB	RB	_	13	COORD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	AP-1	_	NN	NN	_	8	COORD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	NF-kB	_	NN	NN	_	16	COORD	_	_
19	plasmids	_	NNS	NNS	_	8	NMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	in	_	IN	IN	_	13	ADV	_	_
6	human	_	JJ	JJ	_	8	NMOD	_	_
7	T	_	NN	NN	_	8	NMOD	_	_
8	lymphocytes	_	NNS	NNS	_	5	PMOD	_	_
9	both	_	CC	CC	_	10	CC	_	_
10	Dex	_	NN	NN	_	13	SBJ	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	CsA	_	NN	NN	_	10	COORD	_	_
13	inhibited	_	VBD	VBD	_	4	VMOD	_	_
14	IL-2	_	NN	NN	_	16	NMOD	_	_
15	gene	_	NN	NN	_	16	NMOD	_	_
16	transcription	_	NN	NN	_	13	OBJ	_	_
17	through	_	IN	IN	_	13	ADV	_	_
18	interference	_	NN	NN	_	17	PMOD	_	_
19	with	_	IN	IN	_	18	NMOD	_	_
20	transcription	_	NN	NN	_	21	NMOD	_	_
21	factors	_	NNS	NNS	_	19	PMOD	_	_
22	AP-1	_	NN	NN	_	21	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	NF-AT	_	NN	NN	_	22	COORD	_	_
25	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	propose	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	,	_	,	,	_	8	P	_	_
5	while	_	IN	IN	_	6	NMOD	_	_
6	maximum	_	NN	NN	_	8	SBJ	_	_
7	inhibition	_	NN	NN	_	8	VMOD	_	_
8	may	_	MD	MD	_	19	ADV	_	_
9	involve	_	VB	VB	_	8	OBJ	_	_
10	interaction	_	NN	NN	_	9	NMOD	_	_
11	with	_	IN	IN	_	13	NMOD	_	_
12	both	_	DT	DT	_	13	NMOD	_	_
13	transcription	_	NN	NN	_	10	PMOD	_	_
14	factors	_	NNS	NNS	_	19	VMOD	_	_
15	,	_	,	,	_	19	SBJ	_	_
16	AP-1	_	NN	NN	_	19	VMOD	_	_
17	is	_	VBZ	VBZ	_	19	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	primary	_	JJ	JJ	_	3	VMOD	_	_
20	target	_	NN	NN	_	19	NMOD	_	_
21	of	_	IN	IN	_	20	PMOD	_	_
22	Dex	_	NN	NN	_	2	VMOD	_	_

1	Human	_	JJ	JJ	_	5	NMOD	_	_
2	CD3-CD16+	_	JJ	JJ	_	5	NMOD	_	_
3	natural	_	JJ	JJ	_	5	NMOD	_	_
4	killer	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	6	SBJ	_	_
6	express	_	VBP	VBP	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	12	NMOD	_	_
8	hGATA-3	_	NN	NN	_	12	NMOD	_	_
9	T	_	NN	NN	_	12	NMOD	_	_
10	cell	_	NN	NN	_	12	NMOD	_	_
11	transcription	_	NN	NN	_	12	NMOD	_	_
12	factor	_	NN	NN	_	6	OBJ	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	an	_	DT	DT	_	19	NMOD	_	_
15	unrearranged	_	JJ	JJ	_	19	NMOD	_	_
16	2.3-kb	_	JJ	JJ	_	19	NMOD	_	_
17	TcR	_	NN	NN	_	19	NMOD	_	_
18	delta	_	NN	NN	_	19	NMOD	_	_
19	transcript	_	NN	NN	_	12	COORD	_	_
20	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	analyzed	_	VBD	VBD	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	14	NMOD	_	_
7	T	_	NN	NN	_	9	NMOD	_	_
8	cell	_	NN	NN	_	9	NMOD	_	_
9	receptor	_	NN	NN	_	14	NMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	TcR	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	delta	_	NN	NN	_	14	NMOD	_	_
14	transcripts	_	NNS	NNS	_	5	OBJ	_	_
15	expressed	_	VBN	VBN	_	14	NMOD	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	CD3-CD16+	_	JJ	JJ	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	16	PMOD	_	_
19	and	_	CC	CC	_	5	CC	_	_
20	we	_	PRP	PRP	_	21	SBJ	_	_
21	investigated	_	VBD	VBD	_	5	COORD	_	_
22	whether	_	IN	IN	_	21	OBJ	_	_
23	these	_	DT	DT	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	25	SBJ	_	_
25	expressed	_	VBD	VBD	_	22	VMOD	_	_
26	the	_	DT	DT	_	31	NMOD	_	_
27	hGATA-3	_	NN	NN	_	31	NMOD	_	_
28	T	_	NN	NN	_	31	NMOD	_	_
29	cell	_	NN	NN	_	31	NMOD	_	_
30	transcription	_	NN	NN	_	31	NMOD	_	_
31	factor	_	NN	NN	_	25	OBJ	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	the	_	DT	DT	_	37	NMOD	_	_
34	recombination-activating	_	JJ	JJ	_	37	NMOD	_	_
35	gene	_	NN	NN	_	37	NMOD	_	_
36	(	_	(	(	_	37	P	_	_
37	RAG	_	NN	NN	_	31	COORD	_	_
38	)	_	)	)	_	37	P	_	_
39	-1	_	CD	CD	_	37	NMOD	_	_
40	.	_	.	.	_	5	P	_	_

1	Multiple	_	JJ	JJ	_	4	NMOD	_	_
2	TcR	_	NN	NN	_	4	NMOD	_	_
3	delta	_	NN	NN	_	4	NMOD	_	_
4	transcripts	_	NNS	NNS	_	12	SBJ	_	_
5	deriving	_	VBG	VBG	_	4	NMOD	_	_
6	from	_	IN	IN	_	5	ADV	_	_
7	an	_	DT	DT	_	11	NMOD	_	_
8	unrearranged	_	JJ	JJ	_	11	NMOD	_	_
9	TcR	_	NN	NN	_	11	NMOD	_	_
10	delta	_	NN	NN	_	11	NMOD	_	_
11	gene	_	NN	NN	_	6	PMOD	_	_
12	were	_	VBD	VBD	_	0	ROOT-S	_	_
13	detected	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	both	_	CC	CC	_	16	CC	_	_
16	polyclonal	_	JJ	JJ	_	26	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	clonal	_	JJ	JJ	_	16	COORD	_	_
19	CD3-CD16+	_	JJ	JJ	_	26	NMOD	_	_
20	natural	_	JJ	JJ	_	21	NMOD	_	_
21	killer	_	NN	NN	_	26	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	NK	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	cell	_	NN	NN	_	26	NMOD	_	_
26	lines	_	NNS	NNS	_	14	PMOD	_	_
27	.	_	.	.	_	12	P	_	_

1	Two	_	CD	CD	_	5	NMOD	_	_
2	unrearranged	_	JJ	JJ	_	5	NMOD	_	_
3	TcR	_	NN	NN	_	5	NMOD	_	_
4	delta	_	NN	NN	_	5	NMOD	_	_
5	transcripts	_	NNS	NNS	_	6	SBJ	_	_
6	had	_	VBD	VBD	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	size	_	NN	NN	_	6	OBJ	_	_
9	similar	_	JJ	JJ	_	8	NMOD	_	_
10	to	_	TO	TO	_	9	AMOD	_	_
11	that	_	DT	DT	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	functional	_	JJ	JJ	_	17	NMOD	_	_
15	TcR	_	NN	NN	_	17	NMOD	_	_
16	delta	_	NN	NN	_	17	NMOD	_	_
17	mRNA	_	NN	NN	_	12	PMOD	_	_
18	(	_	(	(	_	22	P	_	_
19	2.3	_	CD	CD	_	22	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	1.3	_	CD	CD	_	19	COORD	_	_
22	kb	_	NN	NN	_	17	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	found	_	VBN	VBN	_	17	NMOD	_	_
25	in	_	IN	IN	_	24	ADV	_	_
26	TcR	_	NN	NN	_	29	NMOD	_	_
27	gamma\/delta+	_	JJ	JJ	_	26	AMOD	_	_
28	T	_	NN	NN	_	29	NMOD	_	_
29	lymphocytes	_	NNS	NNS	_	25	PMOD	_	_
30	.	_	.	.	_	6	P	_	_

1	Sequence	_	NN	NN	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	14	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	nine	_	CD	CD	_	8	NMOD	_	_
5	different	_	JJ	JJ	_	8	NMOD	_	_
6	2.3-kb	_	JJ	JJ	_	8	NMOD	_	_
7	cDNA	_	NN	NN	_	8	NMOD	_	_
8	clones	_	NNS	NNS	_	3	PMOD	_	_
9	obtained	_	VBN	VBN	_	8	NMOD	_	_
10	from	_	IN	IN	_	9	ADV	_	_
11	NK-derived	_	JJ	JJ	_	13	NMOD	_	_
12	polyA+	_	JJ	JJ	_	13	NMOD	_	_
13	RNA	_	NN	NN	_	10	PMOD	_	_
14	confirmed	_	VBD	VBD	_	0	ROOT-S	_	_
15	that	_	IN	IN	_	14	OBJ	_	_
16	they	_	PRP	PRP	_	17	SBJ	_	_
17	corresponded	_	VBD	VBD	_	15	VMOD	_	_
18	to	_	TO	TO	_	17	ADV	_	_
19	an	_	DT	DT	_	23	NMOD	_	_
20	unrearranged	_	JJ	JJ	_	23	NMOD	_	_
21	TcR	_	NN	NN	_	23	NMOD	_	_
22	delta	_	NN	NN	_	23	NMOD	_	_
23	gene	_	NN	NN	_	18	PMOD	_	_
24	.	_	.	.	_	14	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	cDNA	_	NN	NN	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	2343	_	CD	CD	_	5	NMOD	_	_
5	bp	_	NN	NN	_	6	AMOD	_	_
6	long	_	JJ	JJ	_	3	PRD	_	_
7	and	_	CC	CC	_	3	CC	_	_
8	their	_	PRP$	PRP$	_	11	NMOD	_	_
9	transcription	_	NN	NN	_	11	NMOD	_	_
10	initiation	_	NN	NN	_	11	NMOD	_	_
11	site	_	NN	NN	_	12	SBJ	_	_
12	was	_	VBD	VBD	_	3	COORD	_	_
13	located	_	JJ	JJ	_	16	AMOD	_	_
14	814	_	CD	CD	_	15	NMOD	_	_
15	bp	_	NN	NN	_	16	AMOD	_	_
16	upstream	_	RB	RB	_	12	PRD	_	_
17	from	_	IN	IN	_	16	AMOD	_	_
18	the	_	DT	DT	_	22	NMOD	_	_
19	J	_	NN	NN	_	22	NMOD	_	_
20	delta	_	NN	NN	_	22	NMOD	_	_
21	1	_	CD	CD	_	22	NMOD	_	_
22	segment	_	NN	NN	_	17	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	sequence	_	NN	NN	_	11	SBJ	_	_
3	located	_	JJ	JJ	_	4	AMOD	_	_
4	upstream	_	RB	RB	_	2	NMOD	_	_
5	of	_	IN	IN	_	4	AMOD	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	J	_	NN	NN	_	10	NMOD	_	_
8	delta	_	NN	NN	_	10	NMOD	_	_
9	1	_	CD	CD	_	10	NMOD	_	_
10	segment	_	NN	NN	_	5	PMOD	_	_
11	corresponded	_	VBD	VBD	_	0	ROOT-S	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	previously	_	RB	RB	_	15	AMOD	_	_
15	reported	_	VBN	VBN	_	17	NMOD	_	_
16	germ-line	_	JJ	JJ	_	17	NMOD	_	_
17	sequence	_	NN	NN	_	12	PMOD	_	_
18	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	J	_	NN	NN	_	5	NMOD	_	_
3	delta	_	NN	NN	_	5	NMOD	_	_
4	1	_	CD	CD	_	5	NMOD	_	_
5	segment	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	correctly	_	RB	RB	_	8	ADV	_	_
8	spliced	_	VBN	VBN	_	6	VC	_	_
9	to	_	TO	TO	_	8	ADV	_	_
10	C	_	NN	NN	_	11	NMOD	_	_
11	delta	_	NN	NN	_	9	PMOD	_	_
12	;	_	:	:	_	6	P	_	_
13	in	_	IN	IN	_	20	ADV	_	_
14	addition	_	NN	NN	_	13	PMOD	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	four	_	CD	CD	_	19	NMOD	_	_
17	C	_	NN	NN	_	19	NMOD	_	_
18	delta	_	NN	NN	_	19	NMOD	_	_
19	exons	_	NNS	NNS	_	20	SBJ	_	_
20	were	_	VBD	VBD	_	6	COORD	_	_
21	found	_	VBN	VBN	_	20	VC	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	be	_	VB	VB	_	21	OBJ	_	_
24	already	_	RB	RB	_	25	TMP	_	_
25	assembled	_	VBN	VBN	_	23	VC	_	_
26	.	_	.	.	_	6	P	_	_

1	Two	_	CD	CD	_	3	NMOD	_	_
2	polyadenylation	_	NN	NN	_	3	NMOD	_	_
3	sites	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	present	_	JJ	JJ	_	4	PRD	_	_
6	in	_	IN	IN	_	5	AMOD	_	_
7	the	_	DT	DT	_	11	NMOD	_	_
8	fourth	_	JJ	JJ	_	11	NMOD	_	_
9	C	_	NN	NN	_	11	NMOD	_	_
10	delta	_	NN	NN	_	11	NMOD	_	_
11	exon	_	NN	NN	_	6	PMOD	_	_
12	.	_	.	.	_	4	P	_	_

1	However	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	only	_	JJ	JJ	_	10	SBJ	_	_
4	that	_	WDT	WDT	_	3	NMOD	_	_
5	located	_	JJ	JJ	_	3	NMOD	_	_
6	at	_	IN	IN	_	5	AMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	3'	_	JJ	JJ	_	9	NMOD	_	_
9	end	_	NN	NN	_	6	PMOD	_	_
10	appeared	_	VBD	VBD	_	0	ROOT-S	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	be	_	VB	VB	_	10	OBJ	_	_
13	utilized	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	2.3-kb	_	JJ	JJ	_	17	NMOD	_	_
17	cDNA	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	expression	_	NN	NN	_	25	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	hGATA-3	_	NN	NN	_	3	PMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	T	_	NN	NN	_	9	NMOD	_	_
8	cell-specific	_	JJ	JJ	_	7	AMOD	_	_
9	factor	_	NN	NN	_	4	NMOD	_	_
10	known	_	VBN	VBN	_	9	NMOD	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	be	_	VB	VB	_	10	OBJ	_	_
13	involved	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	regulation	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	transcription	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	TcR	_	NN	NN	_	23	NMOD	_	_
22	delta	_	NN	NN	_	23	NMOD	_	_
23	locus	_	NN	NN	_	20	PMOD	_	_
24	,	_	,	,	_	4	P	_	_
25	was	_	VBD	VBD	_	0	ROOT-S	_	_
26	analyzed	_	VBN	VBN	_	25	VC	_	_
27	by	_	IN	IN	_	26	ADV	_	_
28	Northern	_	NN	NN	_	29	NMOD	_	_
29	blot	_	NN	NN	_	27	PMOD	_	_
30	,	_	,	,	_	26	P	_	_
31	in	_	IN	IN	_	26	ADV	_	_
32	cultured	_	VBN	VBN	_	33	NMOD	_	_
33	NK	_	NN	NN	_	31	PMOD	_	_
34	cell	_	NN	NN	_	35	NMOD	_	_
35	population	_	NN	NN	_	33	NMOD	_	_
36	and	_	CC	CC	_	35	CC	_	_
37	clones	_	NNS	NNS	_	35	COORD	_	_
38	(	_	(	(	_	31	P	_	_
39	but	_	CC	CC	_	31	CC	_	_
40	not	_	RB	RB	_	41	DEP	_	_
41	in	_	IN	IN	_	31	COORD	_	_
42	freshly	_	RB	RB	_	43	AMOD	_	_
43	derived	_	VBN	VBN	_	45	NMOD	_	_
44	cell	_	NN	NN	_	45	NMOD	_	_
45	populations	_	NNS	NNS	_	41	PMOD	_	_
46	)	_	)	)	_	31	P	_	_
47	.	_	.	.	_	25	P	_	_

1	All	_	DT	DT	_	2	NMOD	_	_
2	NK	_	NN	NN	_	8	SBJ	_	_
3	clones	_	NNS	NNS	_	2	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	cell	_	NN	NN	_	6	NMOD	_	_
6	lines	_	NNS	NNS	_	3	COORD	_	_
7	studied	_	VBN	VBN	_	2	NMOD	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	found	_	VBN	VBN	_	8	VC	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	express	_	VB	VB	_	9	OBJ	_	_
12	hGATA-3-specific	_	JJ	JJ	_	13	NMOD	_	_
13	mRNA	_	NN	NN	_	11	IOBJ	_	_
14	,	_	,	,	_	11	P	_	_
15	suggesting	_	VBG	VBG	_	11	OBJ	_	_
16	that	_	IN	IN	_	15	OBJ	_	_
17	hGATA-3	_	NN	NN	_	18	SBJ	_	_
18	may	_	MD	MD	_	16	VMOD	_	_
19	be	_	VB	VB	_	18	VC	_	_
20	involved	_	VBN	VBN	_	19	VC	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	regulation	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	30	NMOD	_	_
26	unrearranged	_	JJ	JJ	_	30	NMOD	_	_
27	TcR	_	NN	NN	_	30	NMOD	_	_
28	delta	_	NN	NN	_	30	NMOD	_	_
29	gene	_	NN	NN	_	30	NMOD	_	_
30	expression	_	NN	NN	_	24	PMOD	_	_
31	in	_	IN	IN	_	30	NMOD	_	_
32	NK	_	NN	NN	_	33	NMOD	_	_
33	cells	_	NNS	NNS	_	31	PMOD	_	_
34	.	_	.	.	_	8	P	_	_

1	Finally	_	RB	RB	_	9	TMP	_	_
2	,	_	,	,	_	9	P	_	_
3	no	_	DT	DT	_	4	NMOD	_	_
4	transcription	_	NN	NN	_	9	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	RAG-1	_	NN	NN	_	8	NMOD	_	_
8	gene	_	NN	NN	_	5	PMOD	_	_
9	could	_	MD	MD	_	0	ROOT-S	_	_
10	be	_	VB	VB	_	9	VC	_	_
11	detected	_	VBN	VBN	_	10	VC	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	all	_	DT	DT	_	14	NMOD	_	_
14	NK	_	NN	NN	_	12	PMOD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	lines	_	NNS	NNS	_	14	NMOD	_	_
17	or	_	CC	CC	_	16	CC	_	_
18	clones	_	NNS	NNS	_	16	COORD	_	_
19	analyzed	_	VBN	VBN	_	14	NMOD	_	_
20	.	_	.	.	_	9	P	_	_

1	Cell-specific	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	helix-loop-helix	_	JJ	JJ	_	6	NMOD	_	_
5	transcription	_	NN	NN	_	6	NMOD	_	_
6	factors	_	NNS	NNS	_	3	PMOD	_	_
7	encoded	_	VBN	VBN	_	6	NMOD	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	E2A	_	NN	NN	_	11	NMOD	_	_
11	gene	_	NN	NN	_	8	PMOD	_	_
12	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	E2A	_	NN	NN	_	3	NMOD	_	_
3	gene	_	NN	NN	_	4	SBJ	_	_
4	encodes	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	transcription	_	NN	NN	_	6	NMOD	_	_
6	factors	_	NNS	NNS	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	helix-loop-helix	_	JJ	JJ	_	10	NMOD	_	_
10	family	_	NN	NN	_	7	PMOD	_	_
11	that	_	WDT	WDT	_	12	SBJ	_	_
12	are	_	VBP	VBP	_	6	NMOD	_	_
13	implicated	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	cell-specific	_	JJ	JJ	_	17	NMOD	_	_
16	gene	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	14	PMOD	_	_
18	as	_	IN	IN	_	13	ADV	_	_
19	part	_	NN	NN	_	18	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	dimeric	_	JJ	JJ	_	22	NMOD	_	_
22	complexes	_	NNS	NNS	_	20	PMOD	_	_
23	that	_	WDT	WDT	_	24	SBJ	_	_
24	interact	_	VBP	VBP	_	22	NMOD	_	_
25	with	_	IN	IN	_	24	ADV	_	_
26	E	_	NN	NN	_	29	NMOD	_	_
27	box	_	NN	NN	_	29	NMOD	_	_
28	enhancer	_	NN	NN	_	29	NMOD	_	_
29	elements	_	NNS	NNS	_	25	PMOD	_	_
30	.	_	.	.	_	4	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	previously	_	RB	RB	_	2	TMP	_	_
4	been	_	VBN	VBN	_	2	VC	_	_
5	shown	_	VBN	VBN	_	4	VC	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	transcripts	_	NNS	NNS	_	12	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	E2A	_	NN	NN	_	11	NMOD	_	_
11	gene	_	NN	NN	_	8	PMOD	_	_
12	can	_	MD	MD	_	6	VMOD	_	_
13	be	_	VB	VB	_	12	VC	_	_
14	detected	_	VBN	VBN	_	13	VC	_	_
15	in	_	IN	IN	_	14	ADV	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	wide	_	JJ	JJ	_	18	NMOD	_	_
18	range	_	NN	NN	_	15	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	types	_	NNS	NNS	_	19	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	now	_	RB	RB	_	2	TMP	_	_
4	examined	_	VBN	VBN	_	2	VC	_	_
5	expression	_	NN	NN	_	4	IOBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	mouse	_	NN	NN	_	10	NMOD	_	_
9	E2A	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	6	PMOD	_	_
11	at	_	IN	IN	_	5	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	protein	_	NN	NN	_	14	NMOD	_	_
14	level	_	NN	NN	_	11	PMOD	_	_
15	using	_	VBG	VBG	_	4	OBJ	_	_
16	polyclonal	_	JJ	JJ	_	17	NMOD	_	_
17	antisera	_	NNS	NNS	_	15	IOBJ	_	_
18	directed	_	VBN	VBN	_	17	NMOD	_	_
19	against	_	IN	IN	_	18	ADV	_	_
20	distinct	_	JJ	JJ	_	21	NMOD	_	_
21	portions	_	NNS	NNS	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	E2A	_	NN	NN	_	25	NMOD	_	_
25	protein	_	NN	NN	_	22	PMOD	_	_
26	to	_	TO	TO	_	27	VMOD	_	_
27	probe	_	NN	NN	_	15	OBJ	_	_
28	blots	_	NNS	NNS	_	27	OBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	cellular	_	JJ	JJ	_	31	NMOD	_	_
31	extracts	_	NNS	NNS	_	29	PMOD	_	_
32	.	_	.	.	_	2	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	73	_	CD	CD	_	4	NMOD	_	_
3	kDa	_	NN	NN	_	4	NMOD	_	_
4	protein	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	identified	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	this	_	DT	DT	_	9	NMOD	_	_
9	analysis	_	NN	NN	_	7	PMOD	_	_
10	:	_	:	:	_	5	P	_	_
11	this	_	DT	DT	_	12	NMOD	_	_
12	protein	_	NN	NN	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	5	VC	_	_
14	highly	_	RB	RB	_	15	AMOD	_	_
15	enriched	_	VBN	VBN	_	13	PRD	_	_
16	in	_	IN	IN	_	13	ADV	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	lines	_	NNS	NNS	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	B	_	NN	NN	_	22	NMOD	_	_
21	lymphoid	_	JJ	JJ	_	22	NMOD	_	_
22	origin	_	NN	NN	_	19	PMOD	_	_
23	as	_	IN	IN	_	13	ADV	_	_
24	compared	_	VBN	VBN	_	23	VMOD	_	_
25	to	_	TO	TO	_	24	ADV	_	_
26	pancreatic	_	JJ	JJ	_	27	NMOD	_	_
27	beta-cells	_	NNS	NNS	_	25	PMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	fibroblast	_	NN	NN	_	30	NMOD	_	_
30	cells	_	NNS	NNS	_	27	COORD	_	_
31	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	detection	_	NN	NN	_	12	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	this	_	DT	DT	_	5	NMOD	_	_
5	protein	_	NN	NN	_	3	PMOD	_	_
6	selectively	_	RB	RB	_	7	DEP	_	_
7	in	_	IN	IN	_	2	NMOD	_	_
8	extracts	_	NNS	NNS	_	7	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	lymphoid	_	JJ	JJ	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	correlates	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	with	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	presence	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	E	_	NN	NN	_	21	NMOD	_	_
19	box-binding	_	JJ	JJ	_	18	AMOD	_	_
20	activity	_	NN	NN	_	21	NMOD	_	_
21	LEF1\/BCF1	_	NN	NN	_	16	PMOD	_	_
22	in	_	IN	IN	_	15	NMOD	_	_
23	these	_	DT	DT	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	;	_	:	:	_	12	P	_	_
26	this	_	DT	DT	_	28	NMOD	_	_
27	binding	_	NN	NN	_	28	NMOD	_	_
28	activity	_	NN	NN	_	29	SBJ	_	_
29	was	_	VBD	VBD	_	12	VMOD	_	_
30	previously	_	RB	RB	_	29	TMP	_	_
31	shown	_	VBN	VBN	_	29	VC	_	_
32	to	_	TO	TO	_	33	VMOD	_	_
33	be	_	VB	VB	_	31	OBJ	_	_
34	efficiently	_	RB	RB	_	33	ADV	_	_
35	recognized	_	VBN	VBN	_	33	VC	_	_
36	by	_	IN	IN	_	35	LGS	_	_
37	antiserum	_	NN	NN	_	36	PMOD	_	_
38	directed	_	VBN	VBN	_	37	NMOD	_	_
39	against	_	IN	IN	_	38	ADV	_	_
40	E2A	_	NN	NN	_	42	NMOD	_	_
41	gene	_	NN	NN	_	42	NMOD	_	_
42	products	_	NNS	NNS	_	39	PMOD	_	_
43	.	_	.	.	_	29	P	_	_

1	Transfection	_	NN	NN	_	9	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	cells	_	NNS	NNS	_	2	PMOD	_	_
4	with	_	IN	IN	_	1	NMOD	_	_
5	full	_	JJ	JJ	_	8	NMOD	_	_
6	length	_	NN	NN	_	8	NMOD	_	_
7	E2A	_	NN	NN	_	8	NMOD	_	_
8	cDNA	_	NN	NN	_	4	PMOD	_	_
9	leads	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	appearance	_	NN	NN	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	protein	_	NN	NN	_	12	PMOD	_	_
14	co-migrating	_	VBG	VBG	_	13	NMOD	_	_
15	with	_	IN	IN	_	14	ADV	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	73	_	CD	CD	_	19	NMOD	_	_
18	kDa	_	NN	NN	_	19	NMOD	_	_
19	protein	_	NN	NN	_	15	PMOD	_	_
20	on	_	IN	IN	_	14	ADV	_	_
21	SDS	_	NN	NN	_	23	NMOD	_	_
22	gel	_	NN	NN	_	23	NMOD	_	_
23	electrophoresis	_	NN	NN	_	20	PMOD	_	_
24	and	_	CC	CC	_	14	CC	_	_
25	co-migrating	_	VBG	VBG	_	14	COORD	_	_
26	with	_	IN	IN	_	25	ADV	_	_
27	LEF1\/BCF1	_	NN	NN	_	26	PMOD	_	_
28	on	_	IN	IN	_	25	ADV	_	_
29	mobility	_	NN	NN	_	31	NMOD	_	_
30	shift	_	NN	NN	_	31	NMOD	_	_
31	analysis	_	NN	NN	_	28	PMOD	_	_
32	.	_	.	.	_	9	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	consistent	_	JJ	JJ	_	3	PRD	_	_
5	with	_	IN	IN	_	4	AMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	view	_	NN	NN	_	5	PMOD	_	_
8	that	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	DNA-binding	_	JJ	JJ	_	12	NMOD	_	_
11	activity	_	NN	NN	_	12	NMOD	_	_
12	LEF1\/BCF1	_	NN	NN	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	8	VMOD	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	homodimer	_	NN	NN	_	13	PRD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	E2A	_	NN	NN	_	18	NMOD	_	_
18	proteins	_	NNS	NNS	_	16	PMOD	_	_
19	;	_	:	:	_	3	P	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	selective	_	JJ	JJ	_	22	NMOD	_	_
22	appearance	_	NN	NN	_	33	SBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	this	_	DT	DT	_	28	NMOD	_	_
25	putative	_	JJ	JJ	_	28	NMOD	_	_
26	cell-specific	_	JJ	JJ	_	28	NMOD	_	_
27	transcription	_	NN	NN	_	28	NMOD	_	_
28	factor	_	NN	NN	_	23	PMOD	_	_
29	in	_	IN	IN	_	22	NMOD	_	_
30	B	_	NN	NN	_	32	NMOD	_	_
31	lymphoid	_	JJ	JJ	_	32	NMOD	_	_
32	cells	_	NNS	NNS	_	29	PMOD	_	_
33	seems	_	VBZ	VBZ	_	3	VC	_	_
34	to	_	TO	TO	_	35	VMOD	_	_
35	be	_	VB	VB	_	33	OBJ	_	_
36	attributable	_	JJ	JJ	_	35	PRD	_	_
37	,	_	,	,	_	43	P	_	_
38	at	_	IN	IN	_	40	PMOD	_	_
39	least	_	JJS	JJS	_	38	AMOD	_	_
40	in	_	IN	IN	_	43	PMOD	_	_
41	part	_	NN	NN	_	40	PMOD	_	_
42	,	_	,	,	_	43	P	_	_
43	to	_	TO	TO	_	36	AMOD	_	_
44	the	_	DT	DT	_	48	NMOD	_	_
45	elevated	_	JJ	JJ	_	48	NMOD	_	_
46	E2A	_	NN	NN	_	48	NMOD	_	_
47	protein	_	NN	NN	_	48	NMOD	_	_
48	concentrations	_	NNS	NNS	_	43	PMOD	_	_
49	in	_	IN	IN	_	48	NMOD	_	_
50	these	_	DT	DT	_	51	NMOD	_	_
51	cells	_	NNS	NNS	_	49	PMOD	_	_
52	.	_	.	.	_	33	P	_	_

1	Hypertension	_	NN	NN	_	0	ROOT-FRAG	_	_
2	in	_	IN	IN	_	1	NMOD	_	_
3	pregnancy	_	NN	NN	_	2	PMOD	_	_
4	.	_	.	.	_	1	P	_	_

1	Pregnancy-induced	_	JJ	JJ	_	2	NMOD	_	_
2	hypertension	_	NN	NN	_	6	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	PIH	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	frequent	_	JJ	JJ	_	9	NMOD	_	_
9	cause	_	NN	NN	_	6	PRD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	maternal	_	JJ	JJ	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	neonatal	_	JJ	JJ	_	11	COORD	_	_
14	morbidity	_	NN	NN	_	10	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	mortality	_	NN	NN	_	14	COORD	_	_
17	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	present	_	JJ	JJ	_	4	NMOD	_	_
4	study	_	NN	NN	_	1	PMOD	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	focused	_	VBD	VBD	_	0	ROOT-S	_	_
7	on	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	pathophysiology	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	PIH	_	NN	NN	_	10	PMOD	_	_
12	,	_	,	,	_	7	P	_	_
13	mainly	_	RB	RB	_	14	DEP	_	_
14	on	_	IN	IN	_	7	COORD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	role	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	mineralocorticoids	_	NNS	NNS	_	17	PMOD	_	_
19	,	_	,	,	_	16	P	_	_
20	reversed	_	VBN	VBN	_	23	NMOD	_	_
21	blood	_	NN	NN	_	23	NMOD	_	_
22	pressure	_	NN	NN	_	23	NMOD	_	_
23	patterns	_	NNS	NNS	_	16	COORD	_	_
24	,	_	,	,	_	16	P	_	_
25	and	_	CC	CC	_	16	CC	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	resulting	_	VBG	VBG	_	28	NMOD	_	_
28	necessity	_	NN	NN	_	16	COORD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	continuous	_	JJ	JJ	_	31	NMOD	_	_
31	monitoring	_	NN	NN	_	29	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	the	_	DT	DT	_	35	NMOD	_	_
34	preeclamptic	_	JJ	JJ	_	35	NMOD	_	_
35	mother	_	NN	NN	_	32	PMOD	_	_
36	.	_	.	.	_	6	P	_	_

1	Problems	_	NNS	NNS	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	antihypertensive	_	JJ	JJ	_	4	NMOD	_	_
4	therapy	_	NN	NN	_	2	PMOD	_	_
5	are	_	VBP	VBP	_	0	ROOT-S	_	_
6	discussed	_	VBN	VBN	_	5	VC	_	_
7	and	_	CC	CC	_	5	CC	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	first	_	JJ	JJ	_	10	NMOD	_	_
10	results	_	NNS	NNS	_	17	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	pilot	_	NN	NN	_	14	NMOD	_	_
14	study	_	NN	NN	_	11	PMOD	_	_
15	with	_	IN	IN	_	14	NMOD	_	_
16	Urapidil	_	NN	NN	_	15	PMOD	_	_
17	are	_	VBP	VBP	_	5	COORD	_	_
18	presented	_	VBN	VBN	_	17	VC	_	_
19	.	_	.	.	_	5	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	examine	_	VB	VB	_	14	VMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	role	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	mineralocorticoids	_	NNS	NNS	_	5	PMOD	_	_
7	in	_	IN	IN	_	4	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	pathophysiology	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	PIH	_	NN	NN	_	10	PMOD	_	_
12	,	_	,	,	_	14	P	_	_
13	we	_	PRP	PRP	_	14	SBJ	_	_
14	studied	_	VBD	VBD	_	0	ROOT-S	_	_
15	plasma	_	NN	NN	_	16	NMOD	_	_
16	aldosterone	_	NN	NN	_	22	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	18-hydroxy-corticosterone	_	NN	NN	_	16	COORD	_	_
19	(	_	(	(	_	20	P	_	_
20	18-OH-B	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	levels	_	NNS	NNS	_	14	OBJ	_	_
23	in	_	IN	IN	_	22	NMOD	_	_
24	25	_	CD	CD	_	25	NMOD	_	_
25	women	_	NNS	NNS	_	23	PMOD	_	_
26	with	_	IN	IN	_	25	NMOD	_	_
27	PIH	_	NN	NN	_	26	PMOD	_	_
28	and	_	CC	CC	_	23	CC	_	_
29	in	_	IN	IN	_	23	COORD	_	_
30	25	_	CD	CD	_	33	NMOD	_	_
31	healthy	_	JJ	JJ	_	33	NMOD	_	_
32	pregnant	_	JJ	JJ	_	33	NMOD	_	_
33	women	_	NNS	NNS	_	29	PMOD	_	_
34	.	_	.	.	_	14	P	_	_

1	Furthermore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	evaluated	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	mineralocorticoid	_	NN	NN	_	7	NMOD	_	_
7	receptor	_	NN	NN	_	11	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	MR	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	count	_	NN	NN	_	4	OBJ	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	mononuclear	_	JJ	JJ	_	14	NMOD	_	_
14	leukocytes	_	NNS	NNS	_	12	PMOD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	2	_	CD	CD	_	18	NMOD	_	_
18	groups	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	MR-count	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	significantly	_	RB	RB	_	3	ADV	_	_
5	decreased	_	VBN	VBN	_	3	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	PIH-group	_	NN	NN	_	6	PMOD	_	_
9	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	values	_	NNS	NNS	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	plasma	_	NN	NN	_	5	NMOD	_	_
5	aldosterone	_	NN	NN	_	3	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	18-OH-B	_	NN	NN	_	5	COORD	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	also	_	RB	RB	_	8	ADV	_	_
10	low	_	JJ	JJ	_	8	PRD	_	_
11	.	_	.	.	_	8	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	can	_	MD	MD	_	0	ROOT-S	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	be	_	VB	VB	_	3	VC	_	_
6	explained	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	receptor	_	NN	NN	_	9	NMOD	_	_
9	down-regulation	_	NN	NN	_	7	PMOD	_	_
10	due	_	JJ	JJ	_	11	DEP	_	_
11	to	_	TO	TO	_	9	NMOD	_	_
12	higher	_	JJR	JJR	_	13	NMOD	_	_
13	level	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	mineralocorticoids	_	NNS	NNS	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	zona	_	NN	NN	_	19	NMOD	_	_
19	glomerulosa	_	NN	NN	_	16	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Perhaps	_	RB	RB	_	8	ADV	_	_
2	deoxycorticosterone	_	NN	NN	_	8	SBJ	_	_
3	or	_	CC	CC	_	2	CC	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	hitherto	_	RB	RB	_	7	NMOD	_	_
6	unknown	_	JJ	JJ	_	7	NMOD	_	_
7	mineralocorticoid	_	NN	NN	_	2	COORD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	responsible	_	JJ	JJ	_	8	PRD	_	_
10	for	_	IN	IN	_	9	AMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	hypertension	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	altered	_	JJ	JJ	_	15	NMOD	_	_
15	MR-status	_	NN	NN	_	12	COORD	_	_
16	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	first	_	JJ	JJ	_	3	NMOD	_	_
3	results	_	NNS	NNS	_	20	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	continuous	_	JJ	JJ	_	8	NMOD	_	_
6	blood	_	NN	NN	_	8	NMOD	_	_
7	pressure	_	NN	NN	_	8	NMOD	_	_
8	measurements	_	NNS	NNS	_	4	PMOD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	a	_	DT	DT	_	16	NMOD	_	_
11	noninvasive	_	JJ	JJ	_	16	NMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	real-time	_	JJ	JJ	_	11	COORD	_	_
14	blood	_	NN	NN	_	16	NMOD	_	_
15	pressure	_	NN	NN	_	16	NMOD	_	_
16	monitor	_	NN	NN	_	9	PMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	Finapres	_	NN	NN	_	16	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	are	_	VBP	VBP	_	0	ROOT-S	_	_
21	presented	_	VBN	VBN	_	20	VC	_	_
22	.	_	.	.	_	20	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	comparison	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	obtained	_	VBN	VBN	_	6	NMOD	_	_
6	values	_	NNS	NNS	_	3	PMOD	_	_
7	with	_	IN	IN	_	2	NMOD	_	_
8	intraarterial	_	JJ	JJ	_	9	NMOD	_	_
9	measurements	_	NNS	NNS	_	7	PMOD	_	_
10	demonstrates	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	good	_	JJ	JJ	_	13	NMOD	_	_
13	correlation	_	NN	NN	_	10	OBJ	_	_
14	between	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	two	_	CD	CD	_	17	NMOD	_	_
17	methods	_	NNS	NNS	_	14	PMOD	_	_
18	.	_	.	.	_	10	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	report	_	VBP	VBP	_	0	ROOT-S	_	_
4	on	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	first	_	JJ	JJ	_	7	NMOD	_	_
7	experiences	_	NNS	NNS	_	4	PMOD	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	Urapidil	_	NN	NN	_	8	PMOD	_	_
10	in	_	IN	IN	_	7	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	treatment	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	hypertension	_	NN	NN	_	13	PMOD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	severe	_	JJ	JJ	_	17	NMOD	_	_
17	preeclampsia	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	hypertension	_	NN	NN	_	9	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	preeclamptic	_	JJ	JJ	_	8	NMOD	_	_
8	women	_	NNS	NNS	_	6	PMOD	_	_
9	can	_	MD	MD	_	4	VMOD	_	_
10	be	_	VB	VB	_	9	VC	_	_
11	treated	_	VBN	VBN	_	10	VC	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	Urapidil	_	NN	NN	_	12	PMOD	_	_
14	without	_	IN	IN	_	11	ADV	_	_
15	side	_	JJ	JJ	_	16	NMOD	_	_
16	effects	_	NNS	NNS	_	14	PMOD	_	_
17	or	_	CC	CC	_	16	CC	_	_
18	reflex-tachycardia	_	NN	NN	_	16	COORD	_	_
19	.	_	.	.	_	3	P	_	_

1	Further	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	will	_	MD	MD	_	0	ROOT-S	_	_
4	have	_	VB	VB	_	3	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	prove	_	VB	VB	_	4	OBJ	_	_
7	if	_	IN	IN	_	6	OBJ	_	_
8	Urapidil	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	7	VMOD	_	_
10	suited	_	VBN	VBN	_	16	AMOD	_	_
11	for	_	IN	IN	_	16	AMOD	_	_
12	prepartal	_	JJ	JJ	_	13	NMOD	_	_
13	treatment	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	PIH	_	NN	NN	_	14	PMOD	_	_
16	as	_	RB	RB	_	9	PRD	_	_
17	well	_	RB	RB	_	16	AMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	Aldosterone-specific	_	JJ	JJ	_	3	NMOD	_	_
2	membrane	_	NN	NN	_	3	NMOD	_	_
3	receptors	_	NNS	NNS	_	0	ROOT-FRAG	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	rapid	_	JJ	JJ	_	7	NMOD	_	_
6	non-genomic	_	JJ	JJ	_	7	NMOD	_	_
7	actions	_	NNS	NNS	_	3	COORD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	mineralocorticoids	_	NNS	NNS	_	8	PMOD	_	_
10	.	_	.	.	_	3	P	_	_

1	Functional	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	19	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	extrarenal	_	JJ	JJ	_	7	NMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	non-epithelial	_	JJ	JJ	_	4	COORD	_	_
7	cells	_	NNS	NNS	_	3	PMOD	_	_
8	such	_	JJ	JJ	_	9	DEP	_	_
9	as	_	IN	IN	_	7	NMOD	_	_
10	smooth	_	JJ	JJ	_	12	NMOD	_	_
11	muscle	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	more	_	RBR	RBR	_	15	AMOD	_	_
15	recently	_	RB	RB	_	18	TMP	_	_
16	circulating	_	VBG	VBG	_	18	NMOD	_	_
17	human	_	JJ	JJ	_	18	NMOD	_	_
18	lymphocytes	_	NNS	NNS	_	12	COORD	_	_
19	have	_	VBP	VBP	_	0	ROOT-S	_	_
20	provided	_	VBN	VBN	_	19	VC	_	_
21	increasing	_	VBG	VBG	_	22	NMOD	_	_
22	evidence	_	NN	NN	_	20	OBJ	_	_
23	that	_	IN	IN	_	22	NMOD	_	_
24	aldosterone	_	NN	NN	_	25	SBJ	_	_
25	produces	_	VBZ	VBZ	_	23	VMOD	_	_
26	not	_	RB	RB	_	30	CC	_	_
27	only	_	RB	RB	_	26	DEP	_	_
28	classical	_	JJ	JJ	_	30	NMOD	_	_
29	genomic	_	JJ	JJ	_	30	NMOD	_	_
30	effects	_	NNS	NNS	_	25	OBJ	_	_
31	,	_	,	,	_	30	P	_	_
32	but	_	CC	CC	_	30	CC	_	_
33	also	_	RB	RB	_	32	COORD	_	_
34	rapid	_	JJ	JJ	_	37	NMOD	_	_
35	,	_	,	,	_	34	P	_	_
36	non-genomic	_	JJ	JJ	_	34	COORD	_	_
37	effects	_	NNS	NNS	_	30	COORD	_	_
38	on	_	IN	IN	_	30	NMOD	_	_
39	transmembrane	_	NN	NN	_	41	NMOD	_	_
40	electrolyte	_	NN	NN	_	41	NMOD	_	_
41	movements	_	NNS	NNS	_	38	PMOD	_	_
42	.	_	.	.	_	19	P	_	_

1	These	_	DT	DT	_	2	SBJ	_	_
2	involve	_	VBP	VBP	_	0	ROOT-S	_	_
3	activation	_	NN	NN	_	2	OBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	sodium\/proton	_	NN	NN	_	7	NMOD	_	_
7	exchanger	_	NN	NN	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	membrane	_	NN	NN	_	8	PMOD	_	_
12	at	_	IN	IN	_	3	NMOD	_	_
13	very	_	RB	RB	_	14	AMOD	_	_
14	low	_	JJ	JJ	_	17	NMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	physiological	_	JJ	JJ	_	14	COORD	_	_
17	concentrations	_	NNS	NNS	_	12	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	aldosterone	_	NN	NN	_	18	PMOD	_	_
20	with	_	IN	IN	_	3	NMOD	_	_
21	an	_	DT	DT	_	23	NMOD	_	_
22	acute	_	JJ	JJ	_	23	NMOD	_	_
23	onset	_	NN	NN	_	20	PMOD	_	_
24	within	_	IN	IN	_	23	TMP	_	_
25	1-2	_	CD	CD	_	26	NMOD	_	_
26	min	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	second	_	JJ	JJ	_	4	NMOD	_	_
3	messenger	_	NN	NN	_	4	NMOD	_	_
4	cascade	_	NN	NN	_	6	SBJ	_	_
5	involved	_	VBN	VBN	_	4	NMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	inositol	_	NN	NN	_	10	NMOD	_	_
9	1,4,5-trisphosphate\/calcium	_	NN	NN	_	10	NMOD	_	_
10	pathway	_	NN	NN	_	6	PRD	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	responds	_	VBZ	VBZ	_	10	NMOD	_	_
13	over	_	IN	IN	_	12	TMP	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	same	_	JJ	JJ	_	18	NMOD	_	_
16	rapid	_	JJ	JJ	_	18	NMOD	_	_
17	time	_	NN	NN	_	18	NMOD	_	_
18	course	_	NN	NN	_	13	PMOD	_	_
19	.	_	.	.	_	6	P	_	_

1	Such	_	JJ	JJ	_	2	NMOD	_	_
2	changes	_	NNS	NNS	_	4	SBJ	_	_
3	clearly	_	RB	RB	_	4	ADV	_	_
4	can	_	MD	MD	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	be	_	VB	VB	_	4	VC	_	_
7	explained	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	genomic	_	JJ	JJ	_	10	NMOD	_	_
10	mechanisms	_	NNS	NNS	_	8	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	which	_	WDT	WDT	_	13	SBJ	_	_
13	are	_	VBP	VBP	_	10	NMOD	_	_
14	responsible	_	JJ	JJ	_	13	PRD	_	_
15	for	_	IN	IN	_	14	AMOD	_	_
16	later	_	JJ	JJ	_	17	NMOD	_	_
17	effects	_	NNS	NNS	_	15	PMOD	_	_
18	than	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	23	NMOD	_	_
20	membrane	_	NN	NN	_	21	AMOD	_	_
21	related	_	JJ	JJ	_	23	NMOD	_	_
22	rapid	_	JJ	JJ	_	23	NMOD	_	_
23	responses	_	NNS	NNS	_	18	PMOD	_	_
24	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	mechanisms	_	NNS	NNS	_	11	SBJ	_	_
3	underlying	_	VBG	VBG	_	2	NMOD	_	_
4	these	_	DT	DT	_	6	NMOD	_	_
5	rapid	_	JJ	JJ	_	6	NMOD	_	_
6	effects	_	NNS	NNS	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	aldosterone	_	NN	NN	_	7	PMOD	_	_
9	on	_	IN	IN	_	6	NMOD	_	_
10	electrolytes	_	NNS	NNS	_	9	PMOD	_	_
11	have	_	VBP	VBP	_	0	ROOT-S	_	_
12	been	_	VBN	VBN	_	11	VC	_	_
13	extensively	_	RB	RB	_	12	ADV	_	_
14	studied	_	VBN	VBN	_	12	VC	_	_
15	in	_	IN	IN	_	14	ADV	_	_
16	human	_	JJ	JJ	_	17	NMOD	_	_
17	lymphocytes	_	NNS	NNS	_	15	PMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	which	_	WDT	WDT	_	21	SBJ	_	_
20	thus	_	RB	RB	_	21	ADV	_	_
21	may	_	MD	MD	_	17	NMOD	_	_
22	represent	_	VB	VB	_	21	VC	_	_
23	valuable	_	JJ	JJ	_	24	NMOD	_	_
24	tools	_	NNS	NNS	_	22	OBJ	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	delineation	_	NN	NN	_	25	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	receptor-effector	_	JJ	JJ	_	31	NMOD	_	_
31	mechanisms	_	NNS	NNS	_	28	PMOD	_	_
32	involved	_	VBN	VBN	_	31	NMOD	_	_
33	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	unique	_	JJ	JJ	_	3	NMOD	_	_
3	characteristics	_	NNS	NNS	_	11	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	this	_	DT	DT	_	7	NMOD	_	_
6	new	_	JJ	JJ	_	7	NMOD	_	_
7	pathway	_	NN	NN	_	4	PMOD	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	steroid	_	NN	NN	_	10	NMOD	_	_
10	action	_	NN	NN	_	8	PMOD	_	_
11	include	_	VBP	VBP	_	0	ROOT-S	_	_
12	its	_	PRP$	PRP$	_	15	NMOD	_	_
13	rapid	_	JJ	JJ	_	15	NMOD	_	_
14	time	_	NN	NN	_	15	NMOD	_	_
15	course	_	NN	NN	_	11	OBJ	_	_
16	,	_	,	,	_	15	P	_	_
17	10,000-fold	_	JJ	JJ	_	18	NMOD	_	_
18	selectivity	_	NN	NN	_	15	COORD	_	_
19	for	_	IN	IN	_	18	NMOD	_	_
20	aldosterone	_	NN	NN	_	19	PMOD	_	_
21	over	_	IN	IN	_	18	NMOD	_	_
22	cortisol	_	NN	NN	_	21	PMOD	_	_
23	and	_	CC	CC	_	15	CC	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	ineffectiveness	_	NN	NN	_	15	COORD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	spironolactones	_	NNS	NNS	_	26	PMOD	_	_
28	,	_	,	,	_	27	P	_	_
29	classical	_	JJ	JJ	_	31	NMOD	_	_
30	mineralocorticoid	_	NN	NN	_	31	NMOD	_	_
31	antagonists	_	NNS	NNS	_	27	NMOD	_	_
32	,	_	,	,	_	27	P	_	_
33	as	_	IN	IN	_	25	NMOD	_	_
34	antagonists	_	NNS	NNS	_	33	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	the	_	DT	DT	_	37	NMOD	_	_
37	response	_	NN	NN	_	35	PMOD	_	_
38	.	_	.	.	_	11	P	_	_

1	Adenovirus	_	NN	NN	_	2	NMOD	_	_
2	E1A	_	NN	NN	_	3	SBJ	_	_
3	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	IFN-induced	_	JJ	JJ	_	5	NMOD	_	_
5	resistance	_	NN	NN	_	3	OBJ	_	_
6	to	_	TO	TO	_	5	NMOD	_	_
7	cytolysis	_	NN	NN	_	6	PMOD	_	_
8	by	_	IN	IN	_	7	NMOD	_	_
9	natural	_	JJ	JJ	_	11	NMOD	_	_
10	killer	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	8	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	Infection	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	target	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	cytopathic	_	JJ	JJ	_	7	NMOD	_	_
7	viruses	_	NNS	NNS	_	5	PMOD	_	_
8	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	IFN	_	NN	NN	_	10	NMOD	_	_
10	induction	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	cytolytic	_	JJ	JJ	_	13	NMOD	_	_
13	resistance	_	NN	NN	_	11	PMOD	_	_
14	to	_	TO	TO	_	13	NMOD	_	_
15	NK	_	NN	NN	_	17	NMOD	_	_
16	cell-mediated	_	JJ	JJ	_	15	AMOD	_	_
17	cytolysis	_	NN	NN	_	14	PMOD	_	_
18	{	_	(	(	_	20	P	_	_
19	IFN-mediated	_	JJ	JJ	_	20	NMOD	_	_
20	cytoprotection	_	NN	NN	_	10	PRN	_	_
21	(	_	(	(	_	22	P	_	_
22	IFN-MCP	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	}	_	)	)	_	20	P	_	_
25	.	_	.	.	_	8	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	been	_	VBN	VBN	_	2	VC	_	_
4	thought	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	virally	_	RB	RB	_	8	AMOD	_	_
8	induced	_	VBN	VBN	_	9	NMOD	_	_
9	inhibition	_	NN	NN	_	12	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	IFN-MCP	_	NN	NN	_	10	PMOD	_	_
12	is	_	VBZ	VBZ	_	5	VMOD	_	_
13	secondary	_	JJ	JJ	_	12	PRD	_	_
14	to	_	TO	TO	_	13	AMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	shutdown	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	cellular	_	JJ	JJ	_	20	NMOD	_	_
19	macromolecular	_	JJ	JJ	_	20	NMOD	_	_
20	synthesis	_	NN	NN	_	17	PMOD	_	_
21	that	_	WDT	WDT	_	22	SBJ	_	_
22	accompanies	_	VBZ	VBZ	_	20	NMOD	_	_
23	cytopathic	_	JJ	JJ	_	25	NMOD	_	_
24	virus	_	NN	NN	_	25	NMOD	_	_
25	infections	_	NNS	NNS	_	22	OBJ	_	_
26	.	_	.	.	_	2	P	_	_

1	Group	_	NN	NN	_	10	NMOD	_	_
2	C	_	NN	NN	_	10	NMOD	_	_
3	,	_	,	,	_	10	P	_	_
4	adenovirus	_	NN	NN	_	5	NMOD	_	_
5	serotype	_	NN	NN	_	10	NMOD	_	_
6	5	_	CD	CD	_	5	NMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	Ad5	_	NN	NN	_	5	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	infection	_	NN	NN	_	11	SBJ	_	_
11	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	both	_	CC	CC	_	13	CC	_	_
13	IFN-MCP	_	NN	NN	_	11	OBJ	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	cellular	_	JJ	JJ	_	17	NMOD	_	_
16	protein	_	NN	NN	_	17	NMOD	_	_
17	synthesis	_	NN	NN	_	13	COORD	_	_
18	.	_	.	.	_	11	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	study	_	NN	NN	_	3	SBJ	_	_
3	determined	_	VBD	VBD	_	0	ROOT-S	_	_
4	if	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	Ad5-induced	_	JJ	JJ	_	7	NMOD	_	_
7	inhibition	_	NN	NN	_	10	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	IFN-MCP	_	NN	NN	_	8	PMOD	_	_
10	was	_	VBD	VBD	_	4	VMOD	_	_
11	independent	_	JJ	JJ	_	10	PRD	_	_
12	of	_	IN	IN	_	11	AMOD	_	_
13	adenovirus	_	NN	NN	_	17	NMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	Ad	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	infection	_	NN	NN	_	12	PMOD	_	_
18	and	_	CC	CC	_	11	CC	_	_
19	secondary	_	JJ	JJ	_	11	COORD	_	_
20	only	_	RB	RB	_	21	DEP	_	_
21	to	_	TO	TO	_	19	AMOD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	expression	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	Ad	_	NN	NN	_	24	PMOD	_	_
27	early	_	JJ	JJ	_	30	NMOD	_	_
28	region	_	NN	NN	_	30	NMOD	_	_
29	1A	_	NN	NN	_	30	NMOD	_	_
30	gene	_	NN	NN	_	26	NMOD	_	_
31	(	_	(	(	_	32	P	_	_
32	E1A	_	NN	NN	_	30	PRN	_	_
33	)	_	)	)	_	32	P	_	_
34	.	_	.	.	_	3	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	test	_	VB	VB	_	10	VC	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	hypothesis	_	NN	NN	_	2	OBJ	_	_
5	,	_	,	,	_	10	P	_	_
6	4-h	_	JJ	JJ	_	9	NMOD	_	_
7	NK	_	NN	NN	_	9	NMOD	_	_
8	cytolysis	_	NN	NN	_	9	NMOD	_	_
9	assays	_	NNS	NNS	_	10	SBJ	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	performed	_	VBN	VBN	_	10	VC	_	_
12	on	_	IN	IN	_	11	ADV	_	_
13	IFN-gamma-treated	_	JJ	JJ	_	15	NMOD	_	_
14	human	_	JJ	JJ	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	12	PMOD	_	_
16	infected	_	VBN	VBN	_	15	NMOD	_	_
17	with	_	IN	IN	_	16	AMOD	_	_
18	an	_	DT	DT	_	22	NMOD	_	_
19	Ad5	_	NN	NN	_	22	NMOD	_	_
20	E1A	_	NN	NN	_	22	NMOD	_	_
21	deletion	_	NN	NN	_	22	NMOD	_	_
22	mutant	_	NN	NN	_	17	PMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	dl343	_	NN	NN	_	22	NMOD	_	_
25	,	_	,	,	_	16	P	_	_
26	or	_	CC	CC	_	16	CC	_	_
27	transfected	_	VBN	VBN	_	16	COORD	_	_
28	with	_	IN	IN	_	27	AMOD	_	_
29	the	_	DT	DT	_	32	NMOD	_	_
30	Ad5	_	NN	NN	_	32	NMOD	_	_
31	E1A	_	NN	NN	_	32	NMOD	_	_
32	gene	_	NN	NN	_	28	PMOD	_	_
33	.	_	.	.	_	10	P	_	_

1	IFN-MCP	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	not	_	RB	RB	_	2	VMOD	_	_
4	inhibited	_	VBN	VBN	_	2	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	infection	_	NN	NN	_	5	PMOD	_	_
7	with	_	IN	IN	_	6	NMOD	_	_
8	dl343	_	NN	NN	_	7	PMOD	_	_
9	,	_	,	,	_	4	P	_	_
10	despite	_	IN	IN	_	4	ADV	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	production	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	large	_	JJ	JJ	_	15	NMOD	_	_
15	amounts	_	NNS	NNS	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	both	_	CC	CC	_	30	CC	_	_
18	early	_	JJ	JJ	_	30	NMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	E1B	_	NN	NN	_	30	PRN	_	_
21	,	_	,	,	_	20	P	_	_
22	p55	_	NN	NN	_	20	NMOD	_	_
23	)	_	)	)	_	20	P	_	_
24	and	_	CC	CC	_	30	CC	_	_
25	late	_	JJ	JJ	_	30	NMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	hexon	_	NN	NN	_	30	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	Ad	_	NN	NN	_	30	NMOD	_	_
30	proteins	_	NNS	NNS	_	16	PMOD	_	_
31	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	contrast	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	E1A-negative	_	JJ	JJ	_	8	NMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	parental	_	JJ	JJ	_	4	COORD	_	_
7	cell	_	NN	NN	_	8	NMOD	_	_
8	lines	_	NNS	NNS	_	1	PMOD	_	_
9	,	_	,	,	_	11	P	_	_
10	IFN-MCP	_	NN	NN	_	11	SBJ	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	blocked	_	VBN	VBN	_	11	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	Ad5	_	NN	NN	_	20	NMOD	_	_
15	E1A-transfected	_	JJ	JJ	_	14	AMOD	_	_
16	epithelial	_	JJ	JJ	_	20	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	fibroblastic	_	JJ	JJ	_	16	COORD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	lines	_	NNS	NNS	_	13	PMOD	_	_
21	.	_	.	.	_	11	P	_	_

1	Genetic	_	JJ	JJ	_	3	NMOD	_	_
2	mapping	_	NN	NN	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	8	SBJ	_	_
4	within	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	E1A	_	NN	NN	_	7	NMOD	_	_
7	gene	_	NN	NN	_	4	PMOD	_	_
8	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	expression	_	NN	NN	_	18	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	only	_	RB	RB	_	15	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	first	_	JJ	JJ	_	15	NMOD	_	_
15	exon	_	NN	NN	_	11	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	E1A	_	NN	NN	_	16	PMOD	_	_
18	was	_	VBD	VBD	_	9	VMOD	_	_
19	sufficient	_	JJ	JJ	_	18	PRD	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	inhibit	_	VB	VB	_	19	AMOD	_	_
22	IFN-MCP	_	NN	NN	_	21	OBJ	_	_
23	.	_	.	.	_	8	P	_	_

1	DNA	_	NN	NN	_	3	NMOD	_	_
2	sequence	_	NN	NN	_	3	NMOD	_	_
3	homology	_	NN	NN	_	22	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	E1A	_	NN	NN	_	6	NMOD	_	_
6	genes	_	NNS	NNS	_	4	PMOD	_	_
7	between	_	IN	IN	_	3	NMOD	_	_
8	different	_	JJ	JJ	_	10	NMOD	_	_
9	Ad	_	NN	NN	_	10	NMOD	_	_
10	groups	_	NNS	NNS	_	7	PMOD	_	_
11	(	_	(	(	_	10	PRN	_	_
12	group	_	NN	NN	_	13	NMOD	_	_
13	A	_	NN	NN	_	11	DEP	_	_
14	,	_	,	,	_	13	P	_	_
15	Ad12	_	NN	NN	_	13	COORD	_	_
16	;	_	:	:	_	13	P	_	_
17	group	_	NN	NN	_	18	NMOD	_	_
18	C	_	NN	NN	_	13	COORD	_	_
19	,	_	,	,	_	18	P	_	_
20	Ad5	_	NN	NN	_	18	COORD	_	_
21	)	_	)	)	_	11	P	_	_
22	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
23	limited	_	VBN	VBN	_	22	VC	_	_
24	almost	_	RB	RB	_	26	PMOD	_	_
25	entirely	_	RB	RB	_	24	AMOD	_	_
26	to	_	TO	TO	_	23	ADV	_	_
27	three	_	CD	CD	_	29	NMOD	_	_
28	conserved	_	VBN	VBN	_	29	NMOD	_	_
29	regions	_	NNS	NNS	_	26	PMOD	_	_
30	located	_	JJ	JJ	_	29	NMOD	_	_
31	within	_	IN	IN	_	30	AMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	first	_	JJ	JJ	_	34	NMOD	_	_
34	exon	_	NN	NN	_	31	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	E1A	_	NN	NN	_	35	PMOD	_	_
37	.	_	.	.	_	22	P	_	_

1	Because	_	IN	IN	_	21	ADV	_	_
2	IFN-MCP	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	1	VMOD	_	_
4	also	_	RB	RB	_	3	ADV	_	_
5	blocked	_	VBN	VBN	_	3	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	Ad12	_	NN	NN	_	10	NMOD	_	_
8	E1A-transfected	_	JJ	JJ	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	lines	_	NNS	NNS	_	6	PMOD	_	_
11	,	_	,	,	_	21	P	_	_
12	expression	_	NN	NN	_	21	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	one	_	CD	CD	_	13	PMOD	_	_
15	or	_	CC	CC	_	14	CC	_	_
16	more	_	JJR	JJR	_	14	COORD	_	_
17	of	_	IN	IN	_	14	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	E1A-conserved	_	JJ	JJ	_	20	NMOD	_	_
20	regions	_	NNS	NNS	_	17	PMOD	_	_
21	may	_	MD	MD	_	0	ROOT-S	_	_
22	be	_	VB	VB	_	21	VC	_	_
23	necessary	_	JJ	JJ	_	22	PRD	_	_
24	to	_	TO	TO	_	25	VMOD	_	_
25	inhibit	_	VB	VB	_	23	AMOD	_	_
26	IFN-MCP	_	NN	NN	_	25	OBJ	_	_
27	.	_	.	.	_	21	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	summary	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	10	P	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	expression	_	NN	NN	_	10	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	E1A	_	NN	NN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	products	_	NNS	NNS	_	6	PMOD	_	_
10	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
11	IFN-MCP	_	NN	NN	_	10	OBJ	_	_
12	independently	_	RB	RB	_	10	ADV	_	_
13	of	_	IN	IN	_	10	ADV	_	_
14	virus	_	NN	NN	_	15	NMOD	_	_
15	infection	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	10	P	_	_

1	E1A	_	NN	NN	_	5	SBJ	_	_
2	's	_	POS	POS	_	1	NMOD	_	_
3	inhibition	_	NN	NN	_	1	NMOD	_	_
4	of	_	IN	IN	_	3	PMOD	_	_
5	IFN-MCP	_	NN	NN	_	0	ROOT-S	_	_
6	has	_	VBZ	VBZ	_	8	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	net	_	JJ	JJ	_	5	OBJ	_	_
9	effect	_	NN	NN	_	8	NMOD	_	_
10	of	_	IN	IN	_	15	VMOD	_	_
11	promoting	_	VBG	VBG	_	15	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	selective	_	JJ	JJ	_	14	AMOD	_	_
14	NK	_	NN	NN	_	15	NMOD	_	_
15	cell-mediated	_	JJ	JJ	_	9	PMOD	_	_
16	clearance	_	NN	NN	_	15	NMOD	_	_
17	of	_	IN	IN	_	18	AMOD	_	_
18	Ad-infected	_	JJ	JJ	_	21	NMOD	_	_
19	or	_	CC	CC	_	18	AMOD	_	_
20	Ad-transformed	_	JJ	JJ	_	21	NMOD	_	_
21	human	_	JJ	JJ	_	16	PMOD	_	_
22	cells	_	NNS	NNS	_	5	VMOD	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	mutation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	glucocorticoid	_	NN	NN	_	6	NMOD	_	_
6	receptor	_	NN	NN	_	3	PMOD	_	_
7	in	_	IN	IN	_	2	NMOD	_	_
8	primary	_	JJ	JJ	_	10	NMOD	_	_
9	cortisol	_	NN	NN	_	10	NMOD	_	_
10	resistance	_	NN	NN	_	7	PMOD	_	_
11	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	precise	_	JJ	JJ	_	4	NMOD	_	_
3	molecular	_	JJ	JJ	_	4	NMOD	_	_
4	abnormalities	_	NNS	NNS	_	10	SBJ	_	_
5	that	_	WDT	WDT	_	6	SBJ	_	_
6	cause	_	VBP	VBP	_	4	NMOD	_	_
7	primary	_	JJ	JJ	_	9	NMOD	_	_
8	cortisol	_	NN	NN	_	9	NMOD	_	_
9	resistance	_	NN	NN	_	6	OBJ	_	_
10	have	_	VBP	VBP	_	0	ROOT-S	_	_
11	not	_	RB	RB	_	10	VMOD	_	_
12	been	_	VBN	VBN	_	10	VC	_	_
13	completely	_	RB	RB	_	14	ADV	_	_
14	described	_	VBN	VBN	_	12	VC	_	_
15	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	a	_	DT	DT	_	3	NMOD	_	_
3	subject	_	NN	NN	_	1	PMOD	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	primary	_	JJ	JJ	_	7	NMOD	_	_
6	cortisol	_	NN	NN	_	7	NMOD	_	_
7	resistance	_	NN	NN	_	4	PMOD	_	_
8	we	_	PRP	PRP	_	9	SBJ	_	_
9	have	_	VBP	VBP	_	0	ROOT-S	_	_
10	observed	_	VBN	VBN	_	9	VC	_	_
11	glucocorticoid	_	NN	NN	_	12	NMOD	_	_
12	receptors	_	NNS	NNS	_	10	OBJ	_	_
13	(	_	(	(	_	14	P	_	_
14	hGR	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	with	_	IN	IN	_	12	NMOD	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	decreased	_	VBN	VBN	_	19	NMOD	_	_
19	affinity	_	NN	NN	_	16	PMOD	_	_
20	for	_	IN	IN	_	19	NMOD	_	_
21	dexamethasone	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	hypothesize	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	mutation	_	NN	NN	_	11	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	hGR	_	NN	NN	_	10	NMOD	_	_
9	glucocorticoid-binding	_	JJ	JJ	_	10	NMOD	_	_
10	domain	_	NN	NN	_	6	PMOD	_	_
11	is	_	VBZ	VBZ	_	3	VMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	cause	_	NN	NN	_	11	PRD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	cortisol	_	NN	NN	_	16	NMOD	_	_
16	resistance	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	2	P	_	_

1	Total	_	JJ	JJ	_	2	NMOD	_	_
2	RNA	_	NN	NN	_	11	SBJ	_	_
3	isolated	_	VBN	VBN	_	2	NMOD	_	_
4	from	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	index	_	NN	NN	_	7	NMOD	_	_
7	subject	_	NN	NN	_	10	NMOD	_	_
8	's	_	POS	POS	_	7	NMOD	_	_
9	mononuclear	_	JJ	JJ	_	10	NMOD	_	_
10	leukocytes	_	NNS	NNS	_	4	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	used	_	VBN	VBN	_	11	VC	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	produce	_	VB	VB	_	12	OBJ	_	_
15	first	_	JJ	JJ	_	18	NMOD	_	_
16	strand	_	NN	NN	_	18	NMOD	_	_
17	hGR	_	NN	NN	_	18	NMOD	_	_
18	cDNAs	_	NNS	NNS	_	14	OBJ	_	_
19	,	_	,	,	_	11	P	_	_
20	and	_	CC	CC	_	11	CC	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	entire	_	JJ	JJ	_	24	NMOD	_	_
23	hGR	_	NN	NN	_	24	NMOD	_	_
24	cDNA	_	NN	NN	_	25	SBJ	_	_
25	was	_	VBD	VBD	_	11	COORD	_	_
26	amplified	_	VBN	VBN	_	25	VC	_	_
27	in	_	IN	IN	_	26	ADV	_	_
28	segments	_	NNS	NNS	_	27	PMOD	_	_
29	and	_	CC	CC	_	26	CC	_	_
30	sequenced	_	VBN	VBN	_	26	COORD	_	_
31	.	_	.	.	_	11	P	_	_

1	At	_	IN	IN	_	5	ADV	_	_
2	nucleotide	_	NN	NN	_	1	PMOD	_	_
3	2,317	_	CD	CD	_	2	NMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	identified	_	VBD	VBD	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	homozygous	_	JJ	JJ	_	8	NMOD	_	_
8	A	_	NN	NN	_	5	OBJ	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	G	_	NN	NN	_	12	NMOD	_	_
11	point	_	NN	NN	_	12	NMOD	_	_
12	mutation	_	NN	NN	_	9	PMOD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	predicts	_	VBZ	VBZ	_	12	NMOD	_	_
15	an	_	DT	DT	_	16	NMOD	_	_
16	isoleucine	_	NN	NN	_	14	OBJ	_	_
17	(	_	(	(	_	18	P	_	_
18	ATT	_	NN	NN	_	16	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	for	_	IN	IN	_	16	NMOD	_	_
21	valine	_	NN	NN	_	25	NMOD	_	_
22	(	_	(	(	_	25	P	_	_
23	GTT	_	NN	NN	_	25	NMOD	_	_
24	)	_	)	)	_	25	P	_	_
25	substitution	_	NN	NN	_	20	PMOD	_	_
26	at	_	IN	IN	_	25	NMOD	_	_
27	amino	_	NN	NN	_	28	NMOD	_	_
28	acid	_	NN	NN	_	26	PMOD	_	_
29	729	_	CD	CD	_	28	NMOD	_	_
30	.	_	.	.	_	5	P	_	_

1	When	_	WRB	WRB	_	9	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	wild-type	_	JJ	JJ	_	4	NMOD	_	_
4	hGR	_	NN	NN	_	8	SBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	hGR-Ile	_	NN	NN	_	4	COORD	_	_
7	729	_	CD	CD	_	6	NMOD	_	_
8	were	_	VBD	VBD	_	22	TMP	_	_
9	expressed	_	VBN	VBN	_	8	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	COS-1	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	and	_	CC	CC	_	9	CC	_	_
14	assayed	_	VBN	VBN	_	9	COORD	_	_
15	for	_	IN	IN	_	14	ADV	_	_
16	-LCB-3H-RCB--Dexamethasone	_	NN	NN	_	17	NMOD	_	_
17	binding	_	NN	NN	_	15	PMOD	_	_
18	,	_	,	,	_	22	P	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	dissociation	_	NN	NN	_	21	NMOD	_	_
21	constants	_	NNS	NNS	_	22	SBJ	_	_
22	were	_	VBD	VBD	_	0	ROOT-S	_	_
23	0.799	_	CD	CD	_	30	NMOD	_	_
24	+\/-	_	CC	CC	_	23	CC	_	_
25	0.068	_	CD	CD	_	23	COORD	_	_
26	and	_	CC	CC	_	23	CC	_	_
27	1.54	_	CD	CD	_	23	COORD	_	_
28	+\/-	_	CC	CC	_	27	CC	_	_
29	0.06	_	CD	CD	_	27	COORD	_	_
30	nM	_	NN	NN	_	22	PRD	_	_
31	(	_	(	(	_	32	P	_	_
32	mean	_	NN	NN	_	30	PRN	_	_
33	+\/-	_	CC	CC	_	32	CC	_	_
34	SEM	_	NN	NN	_	32	COORD	_	_
35	)	_	)	)	_	32	P	_	_
36	(	_	(	(	_	39	P	_	_
37	P	_	NN	NN	_	39	SBJ	_	_
38	&lt;	_	JJR	JJR	_	39	DEP	_	_
39	0.01	_	CD	CD	_	30	PRN	_	_
40	)	_	)	)	_	39	P	_	_
41	,	_	,	,	_	30	P	_	_
42	respectively	_	RB	RB	_	30	NMOD	_	_
43	.	_	.	.	_	22	P	_	_

1	When	_	WRB	WRB	_	9	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	wild-type	_	JJ	JJ	_	4	NMOD	_	_
4	hGR	_	NN	NN	_	8	SBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	hGR-Ile	_	NN	NN	_	4	COORD	_	_
7	729	_	CD	CD	_	6	NMOD	_	_
8	were	_	VBD	VBD	_	39	TMP	_	_
9	expressed	_	VBN	VBN	_	8	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	CV-1	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	were	_	VBD	VBD	_	12	NMOD	_	_
15	cotransfected	_	VBN	VBN	_	14	VC	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	the	_	DT	DT	_	24	NMOD	_	_
18	mouse	_	NN	NN	_	24	NMOD	_	_
19	mammary	_	JJ	JJ	_	24	NMOD	_	_
20	tumor	_	NN	NN	_	24	NMOD	_	_
21	virus	_	NN	NN	_	24	NMOD	_	_
22	long	_	JJ	JJ	_	24	NMOD	_	_
23	terminal	_	JJ	JJ	_	24	NMOD	_	_
24	repeat	_	NN	NN	_	16	PMOD	_	_
25	fused	_	VBN	VBN	_	24	NMOD	_	_
26	to	_	TO	TO	_	25	ADV	_	_
27	the	_	DT	DT	_	34	NMOD	_	_
28	chloramphenicol	_	NN	NN	_	30	NMOD	_	_
29	acetyl	_	NN	NN	_	30	NMOD	_	_
30	transferase	_	NN	NN	_	34	NMOD	_	_
31	(	_	(	(	_	32	P	_	_
32	CAT	_	NN	NN	_	30	PRN	_	_
33	)	_	)	)	_	32	P	_	_
34	gene	_	NN	NN	_	26	PMOD	_	_
35	,	_	,	,	_	39	P	_	_
36	the	_	DT	DT	_	37	NMOD	_	_
37	hGR-Ile	_	NN	NN	_	39	SBJ	_	_
38	729	_	CD	CD	_	37	NMOD	_	_
39	conferred	_	VBD	VBD	_	0	ROOT-S	_	_
40	a	_	DT	DT	_	42	NMOD	_	_
41	fourfold	_	JJ	JJ	_	42	NMOD	_	_
42	decrease	_	NN	NN	_	39	OBJ	_	_
43	in	_	IN	IN	_	42	NMOD	_	_
44	apparent	_	JJ	JJ	_	45	NMOD	_	_
45	potency	_	NN	NN	_	43	PMOD	_	_
46	on	_	IN	IN	_	39	ADV	_	_
47	dexamethasone	_	NN	NN	_	48	NMOD	_	_
48	stimulation	_	NN	NN	_	46	PMOD	_	_
49	of	_	IN	IN	_	48	NMOD	_	_
50	CAT	_	NN	NN	_	51	NMOD	_	_
51	activity	_	NN	NN	_	49	PMOD	_	_
52	.	_	.	.	_	39	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	isoleucine	_	NN	NN	_	10	SBJ	_	_
3	for	_	IN	IN	_	2	NMOD	_	_
4	valine	_	NN	NN	_	5	NMOD	_	_
5	substitution	_	NN	NN	_	3	PMOD	_	_
6	at	_	IN	IN	_	5	NMOD	_	_
7	amino	_	NN	NN	_	8	NMOD	_	_
8	acid	_	NN	NN	_	6	PMOD	_	_
9	729	_	CD	CD	_	8	NMOD	_	_
10	impairs	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	function	_	NN	NN	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	hGR	_	NN	NN	_	13	PMOD	_	_
16	and	_	CC	CC	_	10	CC	_	_
17	is	_	VBZ	VBZ	_	10	COORD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	likely	_	JJ	JJ	_	20	NMOD	_	_
20	cause	_	NN	NN	_	17	PRD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	primary	_	JJ	JJ	_	24	NMOD	_	_
23	cortisol	_	NN	NN	_	24	NMOD	_	_
24	resistance	_	NN	NN	_	21	PMOD	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	this	_	DT	DT	_	27	NMOD	_	_
27	subject	_	NN	NN	_	25	PMOD	_	_
28	.	_	.	.	_	10	P	_	_

1	Mice	_	NNS	NNS	_	11	SBJ	_	_
2	deficient	_	NN	NN	_	1	NMOD	_	_
3	for	_	IN	IN	_	2	AMOD	_	_
4	the	_	DT	DT	_	10	NMOD	_	_
5	55	_	CD	CD	_	6	AMOD	_	_
6	kd	_	JJ	JJ	_	10	NMOD	_	_
7	tumor	_	NN	NN	_	10	NMOD	_	_
8	necrosis	_	NN	NN	_	10	NMOD	_	_
9	factor	_	NN	NN	_	10	NMOD	_	_
10	receptor	_	NN	NN	_	3	PMOD	_	_
11	are	_	VBP	VBP	_	0	ROOT-S	_	_
12	resistant	_	JJ	JJ	_	11	PRD	_	_
13	to	_	TO	TO	_	12	AMOD	_	_
14	endotoxic	_	JJ	JJ	_	15	NMOD	_	_
15	shock	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	11	P	_	_
17	yet	_	RB	RB	_	11	COORD	_	_
18	succumb	_	VBP	VBP	_	11	COORD	_	_
19	to	_	TO	TO	_	18	ADV	_	_
20	L.	_	FW	FW	_	22	NMOD	_	_
21	monocytogenes	_	NNS	NNS	_	22	NMOD	_	_
22	infection	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	multiple	_	JJ	JJ	_	4	NMOD	_	_
3	biological	_	JJ	JJ	_	4	NMOD	_	_
4	activities	_	NNS	NNS	_	12	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	tumor	_	NN	NN	_	8	NMOD	_	_
7	necrosis	_	NN	NN	_	8	NMOD	_	_
8	factor	_	NN	NN	_	5	PMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	TNF	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	are	_	VBP	VBP	_	0	ROOT-S	_	_
13	mediated	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	two	_	CD	CD	_	19	NMOD	_	_
16	distinct	_	JJ	JJ	_	19	NMOD	_	_
17	cell	_	NN	NN	_	19	NMOD	_	_
18	surface	_	NN	NN	_	19	NMOD	_	_
19	receptors	_	NNS	NNS	_	14	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	55	_	CD	CD	_	22	NMOD	_	_
22	kd	_	NNS	NNS	_	20	PMOD	_	_
23	(	_	(	(	_	24	P	_	_
24	TNFRp55	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	and	_	CC	CC	_	22	CC	_	_
27	75	_	CD	CD	_	28	NMOD	_	_
28	kd	_	NN	NN	_	22	COORD	_	_
29	(	_	(	(	_	30	P	_	_
30	TNFRp75	_	NN	NN	_	28	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	.	_	.	.	_	12	P	_	_

1	Using	_	VBG	VBG	_	6	VMOD	_	_
2	gene	_	NN	NN	_	3	NMOD	_	_
3	targeting	_	NN	NN	_	1	OBJ	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	generated	_	VBD	VBD	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	10	NMOD	_	_
8	TNFRp55-deficient	_	JJ	JJ	_	10	NMOD	_	_
9	mouse	_	NN	NN	_	10	NMOD	_	_
10	strain	_	NN	NN	_	6	OBJ	_	_
11	.	_	.	.	_	6	P	_	_

1	Cells	_	NNS	NNS	_	5	SBJ	_	_
2	from	_	IN	IN	_	1	NMOD	_	_
3	TNFRp55-\/-mutant	_	JJ	JJ	_	4	NMOD	_	_
4	mice	_	NNS	NNS	_	2	PMOD	_	_
5	lack	_	VBP	VBP	_	0	ROOT-S	_	_
6	expression	_	NN	NN	_	5	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	TNFRp55	_	NN	NN	_	7	PMOD	_	_
9	but	_	CC	CC	_	5	CC	_	_
10	display	_	VBP	VBP	_	5	COORD	_	_
11	normal	_	JJ	JJ	_	12	NMOD	_	_
12	numbers	_	NNS	NNS	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	high	_	JJ	JJ	_	17	NMOD	_	_
15	affinity	_	NN	NN	_	17	NMOD	_	_
16	TNFRp75	_	NN	NN	_	17	NMOD	_	_
17	molecules	_	NNS	NNS	_	13	PMOD	_	_
18	.	_	.	.	_	5	P	_	_

1	Thymocyte	_	NN	NN	_	2	NMOD	_	_
2	development	_	NN	NN	_	6	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	lymphocyte	_	NN	NN	_	5	NMOD	_	_
5	populations	_	NNS	NNS	_	2	COORD	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	unaltered	_	JJ	JJ	_	6	PRD	_	_
8	,	_	,	,	_	6	P	_	_
9	and	_	CC	CC	_	6	CC	_	_
10	clonal	_	JJ	JJ	_	11	NMOD	_	_
11	deletion	_	NN	NN	_	17	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	potentially	_	RB	RB	_	14	AMOD	_	_
14	self-reactive	_	JJ	JJ	_	16	NMOD	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	12	PMOD	_	_
17	is	_	VBZ	VBZ	_	6	COORD	_	_
18	not	_	RB	RB	_	17	VMOD	_	_
19	impaired	_	JJ	JJ	_	17	PRD	_	_
20	.	_	.	.	_	6	P	_	_

1	However	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	TNF	_	NN	NN	_	4	NMOD	_	_
4	signaling	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	largely	_	RB	RB	_	7	ADV	_	_
7	abolished	_	VBN	VBN	_	5	VC	_	_
8	,	_	,	,	_	7	P	_	_
9	as	_	IN	IN	_	7	ADV	_	_
10	judged	_	VBN	VBN	_	9	VMOD	_	_
11	by	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	failure	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	TNF	_	NN	NN	_	14	PMOD	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	induce	_	VB	VB	_	13	NMOD	_	_
18	NF-kappa	_	NN	NN	_	19	NMOD	_	_
19	B	_	NN	NN	_	17	OBJ	_	_
20	in	_	IN	IN	_	17	ADV	_	_
21	T	_	NN	NN	_	22	NMOD	_	_
22	lymphocytes	_	NNS	NNS	_	20	PMOD	_	_
23	from	_	IN	IN	_	22	NMOD	_	_
24	TNFRp55-deficient	_	JJ	JJ	_	25	NMOD	_	_
25	mice	_	NNS	NNS	_	23	PMOD	_	_
26	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	loss	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	TNFRp55	_	NN	NN	_	5	NMOD	_	_
5	function	_	NN	NN	_	3	PMOD	_	_
6	renders	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	mice	_	NNS	NNS	_	8	SBJ	_	_
8	resistant	_	JJ	JJ	_	6	OBJ	_	_
9	to	_	TO	TO	_	8	AMOD	_	_
10	lethal	_	JJ	JJ	_	11	NMOD	_	_
11	dosages	_	NNS	NNS	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	either	_	CC	CC	_	14	CC	_	_
14	lipopolysaccharides	_	NNS	NNS	_	12	PMOD	_	_
15	or	_	CC	CC	_	14	CC	_	_
16	S.	_	FW	FW	_	19	NMOD	_	_
17	aureus	_	FW	FW	_	19	NMOD	_	_
18	enterotoxin	_	NN	NN	_	19	NMOD	_	_
19	B	_	NN	NN	_	14	COORD	_	_
20	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	6	P	_	_
4	TNFRp55-deficient	_	JJ	JJ	_	5	NMOD	_	_
5	mice	_	NNS	NNS	_	6	SBJ	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	severely	_	RB	RB	_	8	AMOD	_	_
8	impaired	_	JJ	JJ	_	6	PRD	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	clear	_	VB	VB	_	8	AMOD	_	_
11	L.	_	FW	FW	_	12	NMOD	_	_
12	monocytogenes	_	FW	FW	_	10	OBJ	_	_
13	and	_	CC	CC	_	6	CC	_	_
14	readily	_	RB	RB	_	15	ADV	_	_
15	succumb	_	VBP	VBP	_	6	COORD	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	infection	_	NN	NN	_	16	PMOD	_	_
18	.	_	.	.	_	6	P	_	_

1	Thus	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	55	_	CD	CD	_	6	NMOD	_	_
5	kd	_	NN	NN	_	6	NMOD	_	_
6	TNFR	_	NN	NN	_	7	SBJ	_	_
7	plays	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	decisive	_	JJ	JJ	_	10	NMOD	_	_
10	role	_	NN	NN	_	7	OBJ	_	_
11	in	_	IN	IN	_	7	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	host	_	NN	NN	_	11	PMOD	_	_
14	's	_	POS	POS	_	13	NMOD	_	_
15	defense	_	NN	NN	_	13	NMOD	_	_
16	against	_	IN	IN	_	17	NMOD	_	_
17	microorganisms	_	NNS	NNS	_	15	PMOD	_	_
18	and	_	CC	CC	_	20	CC	_	_
19	their	_	PRP$	PRP$	_	20	NMOD	_	_
20	pathogenic	_	JJ	JJ	_	17	NMOD	_	_
21	factors	_	NNS	NNS	_	7	VMOD	_	_

1	{	_	(	(	_	3	P	_	_
2	The	_	DT	DT	_	3	NMOD	_	_
3	trend	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	molecular	_	JJ	JJ	_	7	NMOD	_	_
6	biology	_	NN	NN	_	7	NMOD	_	_
7	study	_	NN	NN	_	4	PMOD	_	_
8	on	_	IN	IN	_	7	NMOD	_	_
9	eosinophils	_	NNS	NNS	_	8	PMOD	_	_
10	}	_	)	)	_	3	P	_	_

1	Recently	_	RB	RB	_	5	TMP	_	_
2	,	_	,	,	_	5	P	_	_
3	many	_	JJ	JJ	_	4	NMOD	_	_
4	investigators	_	NNS	NNS	_	5	SBJ	_	_
5	have	_	VBP	VBP	_	0	ROOT-S	_	_
6	been	_	VBN	VBN	_	5	VC	_	_
7	interested	_	JJ	JJ	_	6	PRD	_	_
8	in	_	IN	IN	_	7	AMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	study	_	NN	NN	_	8	PMOD	_	_
11	on	_	IN	IN	_	10	NMOD	_	_
12	eosinophil	_	NN	NN	_	13	NMOD	_	_
13	biology	_	NN	NN	_	11	PMOD	_	_
14	since	_	IN	IN	_	6	ADV	_	_
15	genes	_	NNS	NNS	_	16	NMOD	_	_
16	association	_	NN	NN	_	39	SBJ	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	eosinophils	_	NNS	NNS	_	17	PMOD	_	_
19	such	_	JJ	JJ	_	20	DEP	_	_
20	as	_	IN	IN	_	18	NMOD	_	_
21	interleukin-5	_	NN	NN	_	20	PMOD	_	_
22	or	_	CC	CC	_	21	CC	_	_
23	eosinophil	_	NN	NN	_	25	NMOD	_	_
24	granule	_	NN	NN	_	25	NMOD	_	_
25	proteins	_	NNS	NNS	_	21	COORD	_	_
26	(	_	(	(	_	27	P	_	_
27	EPO	_	NN	NN	_	25	PRN	_	_
28	,	_	,	,	_	27	P	_	_
29	ECP	_	NN	NN	_	27	COORD	_	_
30	,	_	,	,	_	27	P	_	_
31	EDN	_	NN	NN	_	27	COORD	_	_
32	,	_	,	,	_	27	P	_	_
33	MBP	_	NN	NN	_	27	COORD	_	_
34	,	_	,	,	_	27	P	_	_
35	and	_	CC	CC	_	27	CC	_	_
36	CLC	_	NN	NN	_	27	COORD	_	_
37	)	_	)	)	_	27	P	_	_
38	,	_	,	,	_	39	P	_	_
39	were	_	VBD	VBD	_	14	VMOD	_	_
40	isolated	_	VBN	VBN	_	39	VC	_	_
41	.	_	.	.	_	5	P	_	_

1	However	_	RB	RB	_	15	ADV	_	_
2	,	_	,	,	_	15	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	molecular	_	JJ	JJ	_	5	NMOD	_	_
5	basis	_	NN	NN	_	15	SBJ	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	commitment	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	progenitors	_	NNS	NNS	_	9	PMOD	_	_
11	to	_	TO	TO	_	8	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	eosinophil	_	NN	NN	_	14	NMOD	_	_
14	lineage	_	NN	NN	_	11	PMOD	_	_
15	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	not	_	RB	RB	_	15	VMOD	_	_
17	been	_	VBN	VBN	_	15	VC	_	_
18	determined	_	VBN	VBN	_	17	VC	_	_
19	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	mechanism	_	NN	NN	_	32	SBJ	_	_
3	by	_	IN	IN	_	27	ADV	_	_
4	which	_	WDT	WDT	_	3	PMOD	_	_
5	eosinophil-specific	_	JJ	JJ	_	6	NMOD	_	_
6	genes	_	NNS	NNS	_	26	SBJ	_	_
7	encoding	_	VBG	VBG	_	6	NMOD	_	_
8	primary	_	JJ	JJ	_	12	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	secondary	_	JJ	JJ	_	8	COORD	_	_
11	granule	_	NN	NN	_	12	NMOD	_	_
12	proteins	_	NNS	NNS	_	7	OBJ	_	_
13	(	_	(	(	_	15	P	_	_
14	e.g.	_	FW	FW	_	15	NMOD	_	_
15	ECP	_	NN	NN	_	12	PRN	_	_
16	,	_	,	,	_	15	P	_	_
17	EDN	_	NN	NN	_	15	COORD	_	_
18	,	_	,	,	_	15	P	_	_
19	EPO	_	NN	NN	_	15	COORD	_	_
20	,	_	,	,	_	15	P	_	_
21	MBP	_	NN	NN	_	15	COORD	_	_
22	,	_	,	,	_	15	P	_	_
23	and	_	CC	CC	_	15	CC	_	_
24	CLC	_	NN	NN	_	15	COORD	_	_
25	)	_	)	)	_	15	P	_	_
26	are	_	VBP	VBP	_	2	NMOD	_	_
27	expressed	_	VBN	VBN	_	26	VC	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	regulated	_	VBN	VBN	_	27	COORD	_	_
30	during	_	IN	IN	_	27	TMP	_	_
31	eosinophilopoiesis	_	NN	NN	_	30	PMOD	_	_
32	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
33	also	_	RB	RB	_	32	ADV	_	_
34	unknown	_	JJ	JJ	_	32	PRD	_	_
35	.	_	.	.	_	32	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	paper	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	I	_	PRP	PRP	_	6	SBJ	_	_
6	described	_	VBD	VBD	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	characterization	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	genes	_	NNS	NNS	_	9	PMOD	_	_
11	encoding	_	VBG	VBG	_	10	NMOD	_	_
12	eosinophil	_	NN	NN	_	14	NMOD	_	_
13	granule	_	NN	NN	_	14	NMOD	_	_
14	proteins	_	NNS	NNS	_	11	OBJ	_	_
15	and	_	CC	CC	_	8	CC	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	mRNA	_	NN	NN	_	18	NMOD	_	_
18	expression	_	NN	NN	_	8	COORD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	GATA-1	_	NN	NN	_	23	NMOD	_	_
21	binding	_	NN	NN	_	23	NMOD	_	_
22	transcription	_	NN	NN	_	23	NMOD	_	_
23	factor	_	NN	NN	_	19	PMOD	_	_
24	during	_	IN	IN	_	18	TMP	_	_
25	eosinophil	_	NN	NN	_	26	NMOD	_	_
26	differentiation	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	6	P	_	_

1	Regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	Ets-related	_	JJ	JJ	_	7	NMOD	_	_
5	transcription	_	NN	NN	_	7	NMOD	_	_
6	factor	_	NN	NN	_	7	NMOD	_	_
7	Elf-1	_	NN	NN	_	2	PMOD	_	_
8	by	_	IN	IN	_	1	NMOD	_	_
9	binding	_	VBG	VBG	_	8	PMOD	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	retinoblastoma	_	NN	NN	_	13	NMOD	_	_
13	protein	_	NN	NN	_	10	PMOD	_	_
14	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	retinoblastoma	_	NN	NN	_	4	NMOD	_	_
3	gene	_	NN	NN	_	4	NMOD	_	_
4	product	_	NN	NN	_	8	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	Rb	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	nuclear	_	JJ	JJ	_	11	NMOD	_	_
11	phosphoprotein	_	NN	NN	_	8	PRD	_	_
12	that	_	WDT	WDT	_	13	SBJ	_	_
13	regulates	_	VBZ	VBZ	_	11	NMOD	_	_
14	cell	_	NN	NN	_	16	NMOD	_	_
15	cycle	_	NN	NN	_	16	NMOD	_	_
16	progression	_	NN	NN	_	13	OBJ	_	_
17	.	_	.	.	_	8	P	_	_

1	Elf-1	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	7	NMOD	_	_
4	lymphoid-specific	_	JJ	JJ	_	7	NMOD	_	_
5	Ets	_	NN	NN	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factor	_	NN	NN	_	2	PRD	_	_
8	that	_	WDT	WDT	_	9	SBJ	_	_
9	regulates	_	VBZ	VBZ	_	7	NMOD	_	_
10	inducible	_	JJ	JJ	_	12	NMOD	_	_
11	gene	_	NN	NN	_	12	NMOD	_	_
12	expression	_	NN	NN	_	9	OBJ	_	_
13	during	_	IN	IN	_	9	TMP	_	_
14	T	_	NN	NN	_	16	NMOD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	activation	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	it	_	PRP	PRP	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	demonstrated	_	VBN	VBN	_	6	VC	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	Elf-1	_	NN	NN	_	10	SBJ	_	_
10	contains	_	VBZ	VBZ	_	8	VMOD	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	sequence	_	NN	NN	_	13	NMOD	_	_
13	motif	_	NN	NN	_	10	OBJ	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	is	_	VBZ	VBZ	_	13	NMOD	_	_
16	highly	_	RB	RB	_	17	AMOD	_	_
17	related	_	JJ	JJ	_	15	PRD	_	_
18	to	_	TO	TO	_	17	AMOD	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	Rb	_	NN	NN	_	22	NMOD	_	_
21	binding	_	NN	NN	_	22	NMOD	_	_
22	sites	_	NNS	NNS	_	18	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	several	_	JJ	JJ	_	26	NMOD	_	_
25	viral	_	JJ	JJ	_	26	NMOD	_	_
26	oncoproteins	_	NNS	NNS	_	23	PMOD	_	_
27	and	_	CC	CC	_	15	CC	_	_
28	binds	_	VBZ	VBZ	_	15	COORD	_	_
29	to	_	TO	TO	_	28	ADV	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	pocket	_	NN	NN	_	32	NMOD	_	_
32	region	_	NN	NN	_	29	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	Rb	_	NN	NN	_	33	PMOD	_	_
35	both	_	CC	CC	_	36	CC	_	_
36	in	_	FW	FW	_	28	ADV	_	_
37	vitro	_	FW	FW	_	36	AMOD	_	_
38	and	_	CC	CC	_	36	CC	_	_
39	in	_	FW	FW	_	36	COORD	_	_
40	vivo	_	FW	FW	_	39	AMOD	_	_
41	.	_	.	.	_	6	P	_	_

1	Elf-1	_	NN	NN	_	2	SBJ	_	_
2	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	exclusively	_	RB	RB	_	2	ADV	_	_
4	to	_	TO	TO	_	2	ADV	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	underphosphorylated	_	JJ	JJ	_	7	NMOD	_	_
7	form	_	NN	NN	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	Rb	_	NN	NN	_	8	PMOD	_	_
10	and	_	CC	CC	_	2	CC	_	_
11	fails	_	VBZ	VBZ	_	2	COORD	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	bind	_	VB	VB	_	11	OBJ	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	Rb	_	NN	NN	_	16	NMOD	_	_
16	mutants	_	NNS	NNS	_	14	PMOD	_	_
17	derived	_	VBN	VBN	_	16	NMOD	_	_
18	from	_	IN	IN	_	17	ADV	_	_
19	patients	_	NNS	NNS	_	18	PMOD	_	_
20	with	_	IN	IN	_	19	NMOD	_	_
21	retinoblastoma	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	Co-immunoprecipitation	_	NN	NN	_	2	NMOD	_	_
2	experiments	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
4	an	_	DT	DT	_	5	NMOD	_	_
5	association	_	NN	NN	_	3	OBJ	_	_
6	between	_	IN	IN	_	5	NMOD	_	_
7	Elf-1	_	NN	NN	_	6	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	Rb	_	NN	NN	_	7	COORD	_	_
10	in	_	IN	IN	_	7	NMOD	_	_
11	resting	_	VBG	VBG	_	15	NMOD	_	_
12	normal	_	JJ	JJ	_	15	NMOD	_	_
13	human	_	JJ	JJ	_	15	NMOD	_	_
14	T	_	NN	NN	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	10	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	After	_	IN	IN	_	10	TMP	_	_
2	T	_	NN	NN	_	4	NMOD	_	_
3	cell	_	NN	NN	_	4	NMOD	_	_
4	activation	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	10	P	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	phosphorylation	_	NN	NN	_	10	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	Rb	_	NN	NN	_	8	PMOD	_	_
10	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	release	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	Elf-1	_	NN	NN	_	14	PMOD	_	_
16	,	_	,	,	_	13	P	_	_
17	which	_	WDT	WDT	_	18	SBJ	_	_
18	is	_	VBZ	VBZ	_	13	NMOD	_	_
19	correlated	_	VBN	VBN	_	18	VC	_	_
20	temporally	_	RB	RB	_	19	TMP	_	_
21	with	_	IN	IN	_	19	ADV	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	activation	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	Elf-1-mediated	_	JJ	JJ	_	26	NMOD	_	_
26	transcription	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	10	P	_	_

1	Overexpression	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	phosphorylation-defective	_	JJ	JJ	_	5	NMOD	_	_
5	form	_	NN	NN	_	2	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	Rb	_	NN	NN	_	6	PMOD	_	_
8	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
9	Elf-1-dependent	_	JJ	JJ	_	10	NMOD	_	_
10	transcription	_	NN	NN	_	8	OBJ	_	_
11	during	_	IN	IN	_	8	TMP	_	_
12	T	_	NN	NN	_	14	NMOD	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	activation	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	8	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	Rb	_	NN	NN	_	6	SBJ	_	_
6	interacts	_	VBZ	VBZ	_	4	VMOD	_	_
7	specifically	_	RB	RB	_	6	ADV	_	_
8	with	_	IN	IN	_	6	ADV	_	_
9	a	_	DT	DT	_	13	NMOD	_	_
10	lineage-restricted	_	JJ	JJ	_	13	NMOD	_	_
11	Ets	_	NN	NN	_	13	NMOD	_	_
12	transcription	_	NN	NN	_	13	NMOD	_	_
13	factor	_	NN	NN	_	8	PMOD	_	_
14	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	regulated	_	JJ	JJ	_	3	NMOD	_	_
3	interaction	_	NN	NN	_	4	SBJ	_	_
4	may	_	MD	MD	_	0	ROOT-S	_	_
5	be	_	VB	VB	_	4	VC	_	_
6	important	_	JJ	JJ	_	5	PRD	_	_
7	for	_	IN	IN	_	5	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	coordination	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	lineage-specific	_	JJ	JJ	_	13	NMOD	_	_
12	effector	_	NN	NN	_	13	NMOD	_	_
13	functions	_	NNS	NNS	_	10	PMOD	_	_
14	such	_	JJ	JJ	_	15	DEP	_	_
15	as	_	IN	IN	_	13	NMOD	_	_
16	lymphokine	_	NN	NN	_	17	NMOD	_	_
17	production	_	NN	NN	_	15	PMOD	_	_
18	with	_	IN	IN	_	9	NMOD	_	_
19	cell	_	NN	NN	_	21	NMOD	_	_
20	cycle	_	NN	NN	_	21	NMOD	_	_
21	progression	_	NN	NN	_	18	PMOD	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	activated	_	VBN	VBN	_	25	NMOD	_	_
24	T	_	NN	NN	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	22	PMOD	_	_
26	.	_	.	.	_	4	P	_	_

1	Activation	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	primary	_	JJ	JJ	_	5	NMOD	_	_
4	human	_	JJ	JJ	_	5	NMOD	_	_
5	T-lymphocytes	_	NNS	NNS	_	2	PMOD	_	_
6	through	_	IN	IN	_	1	NMOD	_	_
7	CD2	_	NN	NN	_	11	NMOD	_	_
8	plus	_	CC	CC	_	7	CC	_	_
9	CD28	_	NN	NN	_	7	COORD	_	_
10	adhesion	_	NN	NN	_	11	NMOD	_	_
11	molecules	_	NNS	NNS	_	6	PMOD	_	_
12	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	long-term	_	JJ	JJ	_	15	NMOD	_	_
14	nuclear	_	JJ	JJ	_	15	NMOD	_	_
15	expression	_	NN	NN	_	12	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	NF-kappa	_	NN	NN	_	18	NMOD	_	_
18	B	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	12	P	_	_

1	Stimulation	_	NN	NN	_	13	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	highly	_	RB	RB	_	4	AMOD	_	_
4	purified	_	VBN	VBN	_	6	NMOD	_	_
5	human	_	JJ	JJ	_	6	NMOD	_	_
6	T-cells	_	NNS	NNS	_	2	PMOD	_	_
7	via	_	IN	IN	_	1	NMOD	_	_
8	CD2	_	NN	NN	_	12	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	CD28	_	NN	NN	_	8	COORD	_	_
11	adhesion	_	NN	NN	_	12	NMOD	_	_
12	molecules	_	NNS	NNS	_	7	PMOD	_	_
13	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	maintains	_	VBZ	VBZ	_	13	COORD	_	_
16	proliferation	_	NN	NN	_	13	OBJ	_	_
17	for	_	IN	IN	_	15	ADV	_	_
18	more	_	JJR	JJR	_	20	DEP	_	_
19	than	_	IN	IN	_	20	DEP	_	_
20	3	_	CD	CD	_	21	NMOD	_	_
21	weeks	_	NNS	NNS	_	17	PMOD	_	_
22	.	_	.	.	_	13	P	_	_

1	This	_	DT	DT	_	9	NMOD	_	_
2	potent	_	JJ	JJ	_	9	NMOD	_	_
3	interleukin	_	NN	NN	_	6	AMOD	_	_
4	2	_	CD	CD	_	6	AMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	IL-2	_	NN	NN	_	9	NMOD	_	_
7	)	_	)	)	_	6	P	_	_
8	-dependent	_	JJ	JJ	_	6	AMOD	_	_
9	activation	_	NN	NN	_	10	SBJ	_	_
10	does	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	not	_	RB	RB	_	10	VMOD	_	_
12	require	_	VB	VB	_	10	VC	_	_
13	monocytes	_	NNS	NNS	_	12	OBJ	_	_
14	or	_	CC	CC	_	13	CC	_	_
15	accessory	_	JJ	JJ	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	13	COORD	_	_
17	.	_	.	.	_	10	P	_	_

1	Long-lasting	_	JJ	JJ	_	3	NMOD	_	_
2	IL-2	_	NN	NN	_	3	NMOD	_	_
3	receptivity	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	associated	_	VBN	VBN	_	4	VC	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	high-level	_	JJ	JJ	_	8	NMOD	_	_
8	expression	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	20	NMOD	_	_
11	inducible	_	JJ	JJ	_	20	NMOD	_	_
12	IL-2	_	NN	NN	_	15	NMOD	_	_
13	receptor	_	NN	NN	_	15	NMOD	_	_
14	alpha	_	NN	NN	_	15	NMOD	_	_
15	chain	_	NN	NN	_	20	NMOD	_	_
16	(	_	(	(	_	18	P	_	_
17	IL-2R	_	NN	NN	_	18	NMOD	_	_
18	alpha	_	NN	NN	_	15	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	gene	_	NN	NN	_	9	PMOD	_	_
21	that	_	WDT	WDT	_	22	SBJ	_	_
22	is	_	VBZ	VBZ	_	8	NMOD	_	_
23	regulated	_	VBN	VBN	_	22	VC	_	_
24	at	_	IN	IN	_	23	ADV	_	_
25	both	_	CC	CC	_	26	CC	_	_
26	transcriptional	_	JJ	JJ	_	29	NMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	posttranscriptional	_	JJ	JJ	_	26	COORD	_	_
29	levels	_	NNS	NNS	_	24	PMOD	_	_
30	.	_	.	.	_	4	P	_	_

1	Increase	_	NN	NN	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	IL-2R	_	NN	NN	_	6	NMOD	_	_
4	alpha	_	NN	NN	_	6	NMOD	_	_
5	gene	_	NN	NN	_	6	NMOD	_	_
6	transcription	_	NN	NN	_	2	PMOD	_	_
7	involves	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	enhanced	_	VBN	VBN	_	10	NMOD	_	_
10	binding	_	NN	NN	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	16	NMOD	_	_
13	transcription	_	NN	NN	_	16	NMOD	_	_
14	factor	_	NN	NN	_	16	NMOD	_	_
15	NF-kappa	_	NN	NN	_	16	NMOD	_	_
16	B	_	NN	NN	_	11	PMOD	_	_
17	to	_	TO	TO	_	10	NMOD	_	_
18	its	_	PRP$	PRP$	_	20	NMOD	_	_
19	consensus	_	NN	NN	_	20	NMOD	_	_
20	sequence	_	NN	NN	_	17	PMOD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	5'-regulatory	_	JJ	JJ	_	24	NMOD	_	_
24	region	_	NN	NN	_	21	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	29	NMOD	_	_
27	IL-2R	_	NN	NN	_	29	NMOD	_	_
28	alpha	_	NN	NN	_	29	NMOD	_	_
29	gene	_	NN	NN	_	25	PMOD	_	_
30	.	_	.	.	_	7	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	dissect	_	VB	VB	_	18	VMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	molecular	_	JJ	JJ	_	5	NMOD	_	_
5	basis	_	NN	NN	_	2	OBJ	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	unusually	_	RB	RB	_	9	AMOD	_	_
9	persistent	_	JJ	JJ	_	10	NMOD	_	_
10	transcription	_	NN	NN	_	6	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	IL-2R	_	NN	NN	_	15	NMOD	_	_
14	alpha	_	NN	NN	_	15	NMOD	_	_
15	gene	_	NN	NN	_	11	PMOD	_	_
16	,	_	,	,	_	18	P	_	_
17	we	_	PRP	PRP	_	18	SBJ	_	_
18	analyzed	_	VBD	VBD	_	0	ROOT-S	_	_
19	nuclear	_	JJ	JJ	_	21	NMOD	_	_
20	NF-kappa	_	NN	NN	_	21	NMOD	_	_
21	B	_	NN	NN	_	18	OBJ	_	_
22	binding	_	VBG	VBG	_	21	NMOD	_	_
23	to	_	TO	TO	_	21	NMOD	_	_
24	a	_	DT	DT	_	31	NMOD	_	_
25	radiolabeled	_	VBN	VBN	_	31	NMOD	_	_
26	IL-2R	_	NN	NN	_	31	NMOD	_	_
27	alpha	_	NN	NN	_	31	NMOD	_	_
28	kappa	_	NN	NN	_	31	NMOD	_	_
29	B-specific	_	JJ	JJ	_	28	AMOD	_	_
30	oligonucleotide	_	NN	NN	_	31	NMOD	_	_
31	probe	_	NN	NN	_	23	PMOD	_	_
32	during	_	IN	IN	_	21	TMP	_	_
33	the	_	DT	DT	_	35	NMOD	_	_
34	time	_	NN	NN	_	35	NMOD	_	_
35	course	_	NN	NN	_	32	PMOD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	CD2	_	NN	NN	_	40	NMOD	_	_
38	+	_	CC	CC	_	37	CC	_	_
39	CD28	_	NN	NN	_	37	COORD	_	_
40	activation	_	NN	NN	_	36	PMOD	_	_
41	.	_	.	.	_	18	P	_	_

1	Resting	_	VBG	VBG	_	4	NMOD	_	_
2	T-cell	_	NN	NN	_	4	NMOD	_	_
3	nuclear	_	JJ	JJ	_	4	NMOD	_	_
4	extracts	_	NNS	NNS	_	5	SBJ	_	_
5	contained	_	VBD	VBD	_	0	ROOT-S	_	_
6	KBF1\/p50	_	NN	NN	_	7	NMOD	_	_
7	homodimer	_	NN	NN	_	5	OBJ	_	_
8	.	_	.	.	_	5	P	_	_

1	After	_	IN	IN	_	9	TMP	_	_
2	stimulation	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	9	P	_	_
4	two	_	CD	CD	_	8	NMOD	_	_
5	new	_	JJ	JJ	_	8	NMOD	_	_
6	kappa	_	NN	NN	_	8	NMOD	_	_
7	B-specific	_	JJ	JJ	_	6	AMOD	_	_
8	complexes	_	NNS	NNS	_	9	SBJ	_	_
9	were	_	VBD	VBD	_	0	ROOT-S	_	_
10	identified	_	VBN	VBN	_	9	VC	_	_
11	as	_	IN	IN	_	10	ADV	_	_
12	NF-kappa	_	NN	NN	_	15	NMOD	_	_
13	B	_	NN	NN	_	15	NMOD	_	_
14	p50-p65	_	NN	NN	_	15	NMOD	_	_
15	heterodimer	_	NN	NN	_	11	PMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	putative	_	JJ	JJ	_	19	NMOD	_	_
18	c-Rel	_	NN	NN	_	19	NMOD	_	_
19	homodimer	_	NN	NN	_	15	COORD	_	_
20	or	_	CC	CC	_	19	CC	_	_
21	c-Rel-p65	_	NN	NN	_	22	NMOD	_	_
22	heterodimer	_	NN	NN	_	19	COORD	_	_
23	.	_	.	.	_	9	P	_	_

1	Both	_	DT	DT	_	3	NMOD	_	_
2	inducible	_	JJ	JJ	_	3	NMOD	_	_
3	complexes	_	NNS	NNS	_	4	SBJ	_	_
4	persisted	_	VBD	VBD	_	0	ROOT-S	_	_
5	for	_	IN	IN	_	4	TMP	_	_
6	at	_	IN	IN	_	8	DEP	_	_
7	least	_	JJS	JJS	_	8	DEP	_	_
8	3	_	CD	CD	_	9	NMOD	_	_
9	weeks	_	NNS	NNS	_	5	PMOD	_	_
10	.	_	.	.	_	4	P	_	_

1	Their	_	PRP$	PRP$	_	3	NMOD	_	_
2	relative	_	JJ	JJ	_	3	NMOD	_	_
3	levels	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	very	_	RB	RB	_	6	AMOD	_	_
6	similar	_	JJ	JJ	_	4	PRD	_	_
7	for	_	IN	IN	_	4	TMP	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	duration	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	proliferation	_	NN	NN	_	10	PMOD	_	_
12	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	parallel	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	8	P	_	_
4	CD2	_	NN	NN	_	7	NMOD	_	_
5	+	_	CC	CC	_	4	CC	_	_
6	CD28	_	NN	NN	_	4	COORD	_	_
7	activation	_	NN	NN	_	8	SBJ	_	_
8	triggered	_	VBD	VBD	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	13	NMOD	_	_
10	significant	_	JJ	JJ	_	13	NMOD	_	_
11	intracellular	_	JJ	JJ	_	13	NMOD	_	_
12	thiol	_	NN	NN	_	13	NMOD	_	_
13	decrease	_	NN	NN	_	8	IOBJ	_	_
14	,	_	,	,	_	8	P	_	_
15	suggesting	_	VBG	VBG	_	8	OBJ	_	_
16	that	_	IN	IN	_	15	OBJ	_	_
17	oxygen	_	NN	NN	_	18	NMOD	_	_
18	radicals	_	NNS	NNS	_	19	SBJ	_	_
19	are	_	VBP	VBP	_	16	VMOD	_	_
20	involved	_	VBN	VBN	_	19	VC	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	signaling	_	NN	NN	_	24	NMOD	_	_
24	pathway	_	NN	NN	_	21	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	adhesion	_	NN	NN	_	27	NMOD	_	_
27	molecules	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	8	P	_	_

1	Finally	_	RB	RB	_	26	TMP	_	_
2	,	_	,	,	_	26	P	_	_
3	micromolar	_	JJ	JJ	_	4	NMOD	_	_
4	amounts	_	NNS	NNS	_	26	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	pyrrolidine	_	NN	NN	_	7	NMOD	_	_
7	dithiocarbamate	_	NN	NN	_	5	PMOD	_	_
8	,	_	,	,	_	7	P	_	_
9	an	_	DT	DT	_	12	NMOD	_	_
10	oxygen	_	NN	NN	_	11	AMOD	_	_
11	radical	_	NN	NN	_	12	NMOD	_	_
12	scavenger	_	NN	NN	_	7	NMOD	_	_
13	that	_	WDT	WDT	_	15	SBJ	_	_
14	efficiently	_	RB	RB	_	15	ADV	_	_
15	blocked	_	VBD	VBD	_	12	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	nuclear	_	JJ	JJ	_	18	NMOD	_	_
18	appearance	_	NN	NN	_	15	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	NF-kappa	_	NN	NN	_	21	NMOD	_	_
21	B	_	NN	NN	_	19	PMOD	_	_
22	in	_	IN	IN	_	18	NMOD	_	_
23	T-lymphocytes	_	NNS	NNS	_	22	PMOD	_	_
24	,	_	,	,	_	7	P	_	_
25	also	_	RB	RB	_	26	ADV	_	_
26	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
27	IL-2	_	NN	NN	_	28	NMOD	_	_
28	secretion	_	NN	NN	_	26	OBJ	_	_
29	,	_	,	,	_	28	P	_	_
30	IL-2R	_	NN	NN	_	34	NMOD	_	_
31	alpha	_	NN	NN	_	34	NMOD	_	_
32	cell	_	NN	NN	_	34	NMOD	_	_
33	surface	_	NN	NN	_	34	NMOD	_	_
34	expression	_	NN	NN	_	28	COORD	_	_
35	,	_	,	,	_	28	P	_	_
36	and	_	CC	CC	_	28	CC	_	_
37	T-cell	_	NN	NN	_	38	NMOD	_	_
38	proliferation	_	NN	NN	_	28	COORD	_	_
39	.	_	.	.	_	26	P	_	_

1	Together	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	results	_	NNS	NNS	_	5	SBJ	_	_
5	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	NF-kappa	_	NN	NN	_	8	NMOD	_	_
8	B	_	NN	NN	_	9	SBJ	_	_
9	plays	_	VBZ	VBZ	_	6	VMOD	_	_
10	an	_	DT	DT	_	12	NMOD	_	_
11	important	_	JJ	JJ	_	12	NMOD	_	_
12	role	_	NN	NN	_	9	OBJ	_	_
13	in	_	IN	IN	_	9	ADV	_	_
14	long-term	_	JJ	JJ	_	15	NMOD	_	_
15	activation	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	human	_	JJ	JJ	_	19	NMOD	_	_
18	primary	_	JJ	JJ	_	19	NMOD	_	_
19	T-lymphocytes	_	NNS	NNS	_	16	PMOD	_	_
20	via	_	IN	IN	_	15	NMOD	_	_
21	CD2	_	NN	NN	_	20	PMOD	_	_
22	+	_	CC	CC	_	21	CC	_	_
23	CD28	_	NN	NN	_	21	COORD	_	_
24	.	_	.	.	_	5	P	_	_

1	Expression	_	NN	NN	_	2	NMOD	_	_
2	levels	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	thyrotropin	_	NN	NN	_	7	NMOD	_	_
6	receptor	_	NN	NN	_	7	NMOD	_	_
7	gene	_	NN	NN	_	3	PMOD	_	_
8	in	_	IN	IN	_	2	NMOD	_	_
9	autoimmune	_	JJ	JJ	_	11	NMOD	_	_
10	thyroid	_	NN	NN	_	11	NMOD	_	_
11	disease	_	NN	NN	_	8	PMOD	_	_
12	:	_	:	:	_	2	P	_	_
13	coregulation	_	NN	NN	_	2	NMOD	_	_
14	with	_	IN	IN	_	13	NMOD	_	_
15	parameters	_	NNS	NNS	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	thyroid	_	NN	NN	_	18	NMOD	_	_
18	function	_	NN	NN	_	16	PMOD	_	_
19	and	_	CC	CC	_	13	CC	_	_
20	inverse	_	JJ	JJ	_	21	NMOD	_	_
21	relation	_	NN	NN	_	13	COORD	_	_
22	to	_	TO	TO	_	21	NMOD	_	_
23	major	_	JJ	JJ	_	26	NMOD	_	_
24	histocompatibility	_	NN	NN	_	26	NMOD	_	_
25	complex	_	NN	NN	_	26	NMOD	_	_
26	classes	_	NNS	NNS	_	22	PMOD	_	_
27	I	_	CD	CD	_	26	NMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	II	_	CD	CD	_	27	COORD	_	_
30	.	_	.	.	_	13	P	_	_

1	Using	_	VBG	VBG	_	13	VMOD	_	_
2	a	_	DT	DT	_	10	NMOD	_	_
3	human	_	JJ	JJ	_	10	NMOD	_	_
4	TSH	_	NN	NN	_	5	NMOD	_	_
5	receptor	_	NN	NN	_	10	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	TSH-R	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	cDNA	_	NN	NN	_	10	NMOD	_	_
10	probe	_	NN	NN	_	1	OBJ	_	_
11	,	_	,	,	_	13	P	_	_
12	we	_	PRP	PRP	_	13	SBJ	_	_
13	investigated	_	VBD	VBD	_	0	ROOT-S	_	_
14	TSH-R	_	NN	NN	_	16	NMOD	_	_
15	transcript	_	NN	NN	_	16	NMOD	_	_
16	levels	_	NNS	NNS	_	13	OBJ	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	13	_	CD	CD	_	21	NMOD	_	_
19	human	_	JJ	JJ	_	21	NMOD	_	_
20	thyroid	_	NN	NN	_	21	NMOD	_	_
21	fragments	_	NNS	NNS	_	17	PMOD	_	_
22	by	_	IN	IN	_	13	ADV	_	_
23	Northern	_	NN	NN	_	25	NMOD	_	_
24	blot	_	NN	NN	_	25	NMOD	_	_
25	analysis	_	NN	NN	_	22	PMOD	_	_
26	;	_	:	:	_	13	P	_	_
27	7	_	CD	CD	_	30	NMOD	_	_
28	Graves	_	NN	NN	_	30	NMOD	_	_
29	'	_	POS	POS	_	28	NMOD	_	_
30	disease	_	NN	NN	_	46	SBJ	_	_
31	,	_	,	,	_	30	P	_	_
32	2	_	CD	CD	_	35	NMOD	_	_
33	Hashimoto	_	NN	NN	_	35	NMOD	_	_
34	's	_	POS	POS	_	33	NMOD	_	_
35	disease	_	NN	NN	_	30	COORD	_	_
36	,	_	,	,	_	30	P	_	_
37	3	_	CD	CD	_	39	NMOD	_	_
38	endemic	_	JJ	JJ	_	39	NMOD	_	_
39	goiter	_	NN	NN	_	30	COORD	_	_
40	,	_	,	,	_	30	P	_	_
41	and	_	CC	CC	_	30	CC	_	_
42	1	_	CD	CD	_	45	NMOD	_	_
43	healthy	_	JJ	JJ	_	45	NMOD	_	_
44	thyroid	_	NN	NN	_	45	NMOD	_	_
45	gland	_	NN	NN	_	30	COORD	_	_
46	were	_	VBD	VBD	_	13	VMOD	_	_
47	studied	_	VBN	VBN	_	46	VC	_	_
48	.	_	.	.	_	46	P	_	_

1	TSH-R	_	NN	NN	_	3	NMOD	_	_
2	expression	_	NN	NN	_	3	NMOD	_	_
3	levels	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	variable	_	JJ	JJ	_	4	PRD	_	_
6	,	_	,	,	_	4	P	_	_
7	but	_	CC	CC	_	4	CC	_	_
8	displayed	_	VBD	VBD	_	4	COORD	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	close	_	JJ	JJ	_	11	NMOD	_	_
11	correlation	_	NN	NN	_	8	OBJ	_	_
12	to	_	TO	TO	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	expression	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	thyroid	_	NN	NN	_	17	NMOD	_	_
17	peroxidase	_	NN	NN	_	15	PMOD	_	_
18	(	_	(	(	_	21	P	_	_
19	r	_	NN	NN	_	21	SBJ	_	_
20	=	_	JJ	JJ	_	21	VMOD	_	_
21	0.703	_	CD	CD	_	17	PRN	_	_
22	;	_	:	:	_	21	P	_	_
23	P	_	NN	NN	_	25	SBJ	_	_
24	&lt;	_	JJR	JJR	_	25	DEP	_	_
25	0.05	_	CD	CD	_	21	COORD	_	_
26	)	_	)	)	_	21	P	_	_
27	,	_	,	,	_	17	P	_	_
28	thyroglobulin	_	NN	NN	_	17	COORD	_	_
29	(	_	(	(	_	32	P	_	_
30	r	_	NN	NN	_	32	SBJ	_	_
31	=	_	JJ	JJ	_	32	VMOD	_	_
32	0.817	_	CD	CD	_	28	PRN	_	_
33	;	_	:	:	_	32	P	_	_
34	P	_	NN	NN	_	36	SBJ	_	_
35	&lt;	_	JJR	JJR	_	36	DEP	_	_
36	0.01	_	CD	CD	_	32	COORD	_	_
37	)	_	)	)	_	32	P	_	_
38	,	_	,	,	_	17	P	_	_
39	and	_	CC	CC	_	17	CC	_	_
40	the	_	DT	DT	_	43	NMOD	_	_
41	nuclear	_	JJ	JJ	_	43	NMOD	_	_
42	oncogene	_	NN	NN	_	43	NMOD	_	_
43	c-fos	_	NN	NN	_	17	COORD	_	_
44	(	_	(	(	_	47	P	_	_
45	r	_	NN	NN	_	47	SBJ	_	_
46	=	_	JJ	JJ	_	47	VMOD	_	_
47	0.935	_	CD	CD	_	43	PRN	_	_
48	;	_	:	:	_	47	P	_	_
49	P	_	NN	NN	_	51	SBJ	_	_
50	&lt;	_	JJR	JJR	_	51	DEP	_	_
51	0.001	_	CD	CD	_	47	COORD	_	_
52	)	_	)	)	_	47	P	_	_
53	,	_	,	,	_	17	P	_	_
54	but	_	CC	CC	_	17	CC	_	_
55	not	_	RB	RB	_	54	COORD	_	_
56	c-myc	_	NN	NN	_	17	COORD	_	_
57	.	_	.	.	_	4	P	_	_

1	Overall	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	TSH-R	_	NN	NN	_	5	NMOD	_	_
4	transcript	_	NN	NN	_	5	NMOD	_	_
5	levels	_	NNS	NNS	_	6	SBJ	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	low	_	JJ	JJ	_	6	PRD	_	_
8	or	_	CC	CC	_	7	CC	_	_
9	absent	_	JJ	JJ	_	7	COORD	_	_
10	in	_	IN	IN	_	6	ADV	_	_
11	those	_	DT	DT	_	12	NMOD	_	_
12	thyroids	_	NNS	NNS	_	10	PMOD	_	_
13	in	_	IN	IN	_	31	ADV	_	_
14	which	_	WDT	WDT	_	13	PMOD	_	_
15	expression	_	NN	NN	_	31	SBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	major	_	JJ	JJ	_	21	NMOD	_	_
19	histocompatibility	_	NN	NN	_	21	NMOD	_	_
20	complex	_	NN	NN	_	21	NMOD	_	_
21	class	_	NN	NN	_	16	PMOD	_	_
22	I	_	CD	CD	_	21	NMOD	_	_
23	or	_	CC	CC	_	22	CC	_	_
24	II	_	CD	CD	_	22	COORD	_	_
25	(	_	(	(	_	26	P	_	_
26	MHC	_	NN	NN	_	21	PRN	_	_
27	I	_	CD	CD	_	26	NMOD	_	_
28	or	_	CC	CC	_	27	CC	_	_
29	II	_	CD	CD	_	27	COORD	_	_
30	)	_	)	)	_	26	P	_	_
31	was	_	VBD	VBD	_	12	NMOD	_	_
32	high	_	JJ	JJ	_	31	PRD	_	_
33	,	_	,	,	_	6	P	_	_
34	thus	_	RB	RB	_	35	ADV	_	_
35	establishing	_	VBG	VBG	_	6	VC	_	_
36	an	_	DT	DT	_	38	NMOD	_	_
37	inverse	_	JJ	JJ	_	38	NMOD	_	_
38	relation	_	NN	NN	_	35	OBJ	_	_
39	(	_	(	(	_	45	P	_	_
40	MHC	_	NN	NN	_	45	VMOD	_	_
41	I	_	NN	NN	_	40	DEP	_	_
42	,	_	,	,	_	45	P	_	_
43	r	_	NN	NN	_	45	SBJ	_	_
44	=	_	JJ	JJ	_	45	VMOD	_	_
45	-0.791	_	CD	CD	_	6	PRN	_	_
46	;	_	:	:	_	45	P	_	_
47	P	_	NN	NN	_	49	SBJ	_	_
48	&lt;	_	JJR	JJR	_	49	DEP	_	_
49	0.01	_	CD	CD	_	45	COORD	_	_
50	;	_	:	:	_	45	P	_	_
51	MHC	_	NN	NN	_	56	VMOD	_	_
52	II	_	CD	CD	_	51	DEP	_	_
53	,	_	,	,	_	56	P	_	_
54	r	_	NN	NN	_	56	SBJ	_	_
55	=	_	JJ	JJ	_	56	VMOD	_	_
56	-0.784	_	NN	NN	_	45	NMOD	_	_
57	;	_	:	:	_	56	P	_	_
58	P	_	NN	NN	_	60	SBJ	_	_
59	&lt;	_	JJR	JJR	_	60	DEP	_	_
60	0.01	_	CD	CD	_	56	COORD	_	_
61	)	_	)	)	_	45	P	_	_
62	.	_	.	.	_	6	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	situ	_	FW	FW	_	3	NMOD	_	_
3	hybridization	_	NN	NN	_	4	SBJ	_	_
4	showed	_	VBD	VBD	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	apart	_	RB	RB	_	7	DEP	_	_
7	from	_	IN	IN	_	13	ADV	_	_
8	lymphocytes	_	NNS	NNS	_	7	PMOD	_	_
9	,	_	,	,	_	13	P	_	_
10	thyroid	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	13	SBJ	_	_
12	themselves	_	PRP	PRP	_	11	NMOD	_	_
13	were	_	VBD	VBD	_	5	VMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	source	_	NN	NN	_	13	PRD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	MHC	_	NN	NN	_	19	NMOD	_	_
18	II	_	CD	CD	_	19	NMOD	_	_
19	transcripts	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	4	P	_	_

1	gamma-Interferon	_	NN	NN	_	2	NMOD	_	_
2	expression	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	only	_	RB	RB	_	5	AMOD	_	_
5	detectable	_	JJ	JJ	_	3	PRD	_	_
6	in	_	IN	IN	_	3	ADV	_	_
7	1	_	CD	CD	_	10	NMOD	_	_
8	Hashimoto	_	NN	NN	_	10	NMOD	_	_
9	's	_	POS	POS	_	8	NMOD	_	_
10	goiter	_	NN	NN	_	6	PMOD	_	_
11	.	_	.	.	_	3	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	next	_	JJ	JJ	_	16	ADV	_	_
6	to	_	TO	TO	_	5	AMOD	_	_
7	lymphocyte	_	NN	NN	_	8	NMOD	_	_
8	infiltration	_	NN	NN	_	6	PMOD	_	_
9	,	_	,	,	_	16	P	_	_
10	active	_	JJ	JJ	_	12	NMOD	_	_
11	regulatory	_	JJ	JJ	_	12	NMOD	_	_
12	events	_	NNS	NNS	_	16	SBJ	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	thyrocyte	_	NN	NN	_	13	PMOD	_	_
16	are	_	VBP	VBP	_	4	VMOD	_	_
17	responsible	_	JJ	JJ	_	16	PRD	_	_
18	for	_	IN	IN	_	17	AMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	inverse	_	JJ	JJ	_	21	NMOD	_	_
21	relation	_	NN	NN	_	18	PMOD	_	_
22	between	_	IN	IN	_	21	NMOD	_	_
23	functional	_	JJ	JJ	_	24	NMOD	_	_
24	parameters	_	NNS	NNS	_	22	PMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	TSH-R	_	NN	NN	_	24	PRN	_	_
27	,	_	,	,	_	26	P	_	_
28	thyroid	_	NN	NN	_	29	NMOD	_	_
29	peroxidase	_	NN	NN	_	26	COORD	_	_
30	,	_	,	,	_	26	P	_	_
31	thyroglobulin	_	NN	NN	_	26	COORD	_	_
32	,	_	,	,	_	26	P	_	_
33	and	_	CC	CC	_	26	CC	_	_
34	c-fos	_	NN	NN	_	26	COORD	_	_
35	)	_	)	)	_	26	P	_	_
36	and	_	CC	CC	_	24	CC	_	_
37	immunological	_	JJ	JJ	_	38	NMOD	_	_
38	markers	_	NNS	NNS	_	24	COORD	_	_
39	(	_	(	(	_	40	P	_	_
40	MHC	_	NN	NN	_	38	PRN	_	_
41	I	_	CD	CD	_	40	NMOD	_	_
42	and	_	CC	CC	_	41	CC	_	_
43	II	_	CD	CD	_	41	COORD	_	_
44	)	_	)	)	_	40	P	_	_
45	.	_	.	.	_	3	P	_	_

1	Calcium	_	NN	NN	_	3	NMOD	_	_
2	dependent	_	JJ	JJ	_	1	AMOD	_	_
3	activation	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	NF-AT	_	NN	NN	_	8	NMOD	_	_
7	transcription	_	NN	NN	_	8	NMOD	_	_
8	factor	_	NN	NN	_	4	PMOD	_	_
9	by	_	IN	IN	_	3	NMOD	_	_
10	p59fyn	_	NN	NN	_	9	PMOD	_	_
11	.	_	.	.	_	3	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	reporter	_	NN	NN	_	3	NMOD	_	_
3	gene	_	NN	NN	_	13	SBJ	_	_
4	under	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	control	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	12	NMOD	_	_
9	T-cell	_	NN	NN	_	12	NMOD	_	_
10	antigen	_	NN	NN	_	12	NMOD	_	_
11	receptor	_	NN	NN	_	12	NMOD	_	_
12	element	_	NN	NN	_	7	PMOD	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	activated	_	VBN	VBN	_	13	VC	_	_
15	in	_	IN	IN	_	14	ADV	_	_
16	Jurkat	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	15	PMOD	_	_
18	by	_	IN	IN	_	14	ADV	_	_
19	antigen	_	NN	NN	_	21	NMOD	_	_
20	receptor	_	NN	NN	_	21	NMOD	_	_
21	triggering	_	NN	NN	_	18	PMOD	_	_
22	or	_	CC	CC	_	18	CC	_	_
23	by	_	IN	IN	_	18	LGS	_	_
24	a	_	DT	DT	_	25	NMOD	_	_
25	combination	_	NN	NN	_	23	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	phorbol	_	NN	NN	_	29	NMOD	_	_
28	myristate	_	NN	NN	_	29	NMOD	_	_
29	acetate	_	NN	NN	_	26	PMOD	_	_
30	,	_	,	,	_	29	P	_	_
31	which	_	WDT	WDT	_	32	SBJ	_	_
32	activates	_	VBZ	VBZ	_	29	NMOD	_	_
33	protein	_	NN	NN	_	35	NMOD	_	_
34	kinase	_	NN	NN	_	35	NMOD	_	_
35	C	_	NN	NN	_	32	OBJ	_	_
36	,	_	,	,	_	29	P	_	_
37	and	_	CC	CC	_	29	CC	_	_
38	a	_	DT	DT	_	40	NMOD	_	_
39	calcium	_	NN	NN	_	40	NMOD	_	_
40	ionophore	_	NN	NN	_	29	COORD	_	_
41	.	_	.	.	_	13	P	_	_

1	Both	_	DT	DT	_	3	NMOD	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	signals	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	necessary	_	JJ	JJ	_	4	PRD	_	_
6	for	_	IN	IN	_	5	AMOD	_	_
7	expression	_	NN	NN	_	6	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	reporter	_	NN	NN	_	11	NMOD	_	_
11	gene	_	NN	NN	_	8	PMOD	_	_
12	.	_	.	.	_	4	P	_	_

1	When	_	WRB	WRB	_	2	ADV	_	_
2	co-transfected	_	VBN	VBN	_	17	TMP	_	_
3	with	_	IN	IN	_	2	ADV	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	construct	_	NN	NN	_	3	PMOD	_	_
6	capable	_	JJ	JJ	_	5	NMOD	_	_
7	of	_	IN	IN	_	6	AMOD	_	_
8	overexpressing	_	VBG	VBG	_	7	PMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	tyrosine	_	NN	NN	_	12	NMOD	_	_
11	kinase	_	NN	NN	_	12	NMOD	_	_
12	p59fyn	_	NN	NN	_	8	OBJ	_	_
13	,	_	,	,	_	17	P	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	reporter	_	NN	NN	_	16	NMOD	_	_
16	gene	_	NN	NN	_	17	SBJ	_	_
17	was	_	VBD	VBD	_	0	ROOT-S	_	_
18	activated	_	VBN	VBN	_	17	VC	_	_
19	by	_	IN	IN	_	18	LGS	_	_
20	PMA	_	NN	NN	_	19	PMOD	_	_
21	alone	_	RB	RB	_	20	NMOD	_	_
22	.	_	.	.	_	17	P	_	_

1	Thus	_	RB	RB	_	3	ADV	_	_
2	p59fyn	_	NN	NN	_	3	SBJ	_	_
3	could	_	MD	MD	_	0	ROOT-S	_	_
4	replace	_	VB	VB	_	3	VC	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	calcium	_	NN	NN	_	7	NMOD	_	_
7	ionophore	_	NN	NN	_	4	OBJ	_	_
8	but	_	CC	CC	_	7	CC	_	_
9	not	_	RB	RB	_	8	COORD	_	_
10	activation	_	NN	NN	_	7	COORD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	protein	_	NN	NN	_	14	NMOD	_	_
13	kinase	_	NN	NN	_	14	NMOD	_	_
14	C	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	activation	_	NN	NN	_	7	SBJ	_	_
3	by	_	IN	IN	_	2	NMOD	_	_
4	p59fyn	_	NN	NN	_	3	PMOD	_	_
5	plus	_	CC	CC	_	4	CC	_	_
6	PMA	_	NN	NN	_	4	COORD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	blocked	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	ADV	_	_
10	EGTA	_	NN	NN	_	9	PMOD	_	_
11	and	_	CC	CC	_	9	CC	_	_
12	by	_	IN	IN	_	9	LGS	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	immunosuppressant	_	JJ	JJ	_	17	NMOD	_	_
15	drug	_	NN	NN	_	17	NMOD	_	_
16	cyclosporin	_	NN	NN	_	17	NMOD	_	_
17	A	_	NN	NN	_	12	PMOD	_	_
18	.	_	.	.	_	7	P	_	_

1	Cell-specific	_	JJ	JJ	_	3	NMOD	_	_
2	bifunctional	_	JJ	JJ	_	3	NMOD	_	_
3	role	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	Jun	_	NN	NN	_	8	NMOD	_	_
6	oncogene	_	NN	NN	_	8	NMOD	_	_
7	family	_	NN	NN	_	8	NMOD	_	_
8	members	_	NNS	NNS	_	4	PMOD	_	_
9	on	_	IN	IN	_	3	NMOD	_	_
10	glucocorticoid	_	NN	NN	_	12	NMOD	_	_
11	receptor-dependent	_	JJ	JJ	_	10	AMOD	_	_
12	transcription	_	NN	NN	_	9	PMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	Interaction	_	NN	NN	_	18	SBJ	_	_
2	between	_	IN	IN	_	1	NMOD	_	_
3	protein	_	NN	NN	_	7	NMOD	_	_
4	kinase	_	NN	NN	_	7	NMOD	_	_
5	C	_	NN	NN	_	7	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	PKC	_	NN	NN	_	17	NMOD	_	_
8	)	_	)	)	_	7	P	_	_
9	-	_	:	:	_	7	P	_	_
10	and	_	CC	CC	_	7	CC	_	_
11	glucocorticoid	_	NN	NN	_	14	AMOD	_	_
12	receptor	_	NN	NN	_	14	AMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	GR	_	NN	NN	_	7	COORD	_	_
15	)	_	)	)	_	14	P	_	_
16	-mediated	_	JJ	JJ	_	14	AMOD	_	_
17	signaling	_	NN	NN	_	2	PMOD	_	_
18	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
19	suggested	_	VBN	VBN	_	18	VC	_	_
20	by	_	IN	IN	_	19	LGS	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	ability	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	28	NMOD	_	_
25	PKC	_	NN	NN	_	28	NMOD	_	_
26	activating	_	NN	NN	_	28	NMOD	_	_
27	phorbol	_	NN	NN	_	28	NMOD	_	_
28	ester	_	NN	NN	_	23	PMOD	_	_
29	12-O-tetradecanoylphorbol-13-acetate	_	NN	NN	_	28	NMOD	_	_
30	(	_	(	(	_	31	P	_	_
31	TPA	_	NN	NN	_	29	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	to	_	TO	TO	_	34	VMOD	_	_
34	inhibit	_	VB	VB	_	22	NMOD	_	_
35	GR-dependent	_	JJ	JJ	_	36	NMOD	_	_
36	transcription	_	NN	NN	_	34	OBJ	_	_
37	of	_	IN	IN	_	36	NMOD	_	_
38	the	_	DT	DT	_	42	NMOD	_	_
39	mouse	_	NN	NN	_	42	NMOD	_	_
40	mammary	_	JJ	JJ	_	42	NMOD	_	_
41	tumor	_	NN	NN	_	42	NMOD	_	_
42	virus	_	NN	NN	_	37	PMOD	_	_
43	(	_	(	(	_	44	P	_	_
44	MMTV	_	NN	NN	_	42	PRN	_	_
45	)	_	)	)	_	44	P	_	_
46	long	_	JJ	JJ	_	48	NMOD	_	_
47	terminal	_	JJ	JJ	_	48	NMOD	_	_
48	repeat	_	NN	NN	_	42	NMOD	_	_
49	(	_	(	(	_	50	P	_	_
50	LTR	_	NN	NN	_	48	PRN	_	_
51	)	_	)	)	_	50	P	_	_
52	.	_	.	.	_	18	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	report	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	this	_	DT	DT	_	6	NMOD	_	_
6	interference	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	4	VMOD	_	_
8	cell	_	NN	NN	_	7	PRD	_	_
9	specific	_	JJ	JJ	_	8	AMOD	_	_
10	,	_	,	,	_	7	P	_	_
11	as	_	IN	IN	_	7	ADV	_	_
12	TPA	_	NN	NN	_	13	SBJ	_	_
13	augmented	_	VBD	VBD	_	11	VMOD	_	_
14	dexamethasone-induced	_	JJ	JJ	_	16	NMOD	_	_
15	transcriptional	_	JJ	JJ	_	16	NMOD	_	_
16	activation	_	NN	NN	_	13	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	MMTV	_	NN	NN	_	20	NMOD	_	_
20	LTR	_	NN	NN	_	17	PMOD	_	_
21	in	_	IN	IN	_	13	ADV	_	_
22	several	_	JJ	JJ	_	25	NMOD	_	_
23	T	_	NN	NN	_	25	NMOD	_	_
24	cell	_	NN	NN	_	25	NMOD	_	_
25	lines	_	NNS	NNS	_	21	PMOD	_	_
26	but	_	CC	CC	_	13	CC	_	_
27	was	_	VBD	VBD	_	13	COORD	_	_
28	inhibitory	_	JJ	JJ	_	27	PRD	_	_
29	in	_	IN	IN	_	27	ADV	_	_
30	NIH-3T3	_	NN	NN	_	31	NMOD	_	_
31	fibroblasts	_	NNS	NNS	_	29	PMOD	_	_
32	.	_	.	.	_	3	P	_	_

1	TPA-GR	_	NN	NN	_	2	NMOD	_	_
2	synergism	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	determined	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	have	_	VB	VB	_	4	OBJ	_	_
7	occurred	_	VBN	VBN	_	6	VC	_	_
8	at	_	IN	IN	_	7	ADV	_	_
9	the	_	DT	DT	_	15	NMOD	_	_
10	GR-responsive	_	JJ	JJ	_	11	NMOD	_	_
11	element	_	NN	NN	_	15	NMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	GRE	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	level	_	NN	NN	_	8	PMOD	_	_
16	by	_	IN	IN	_	4	LGS	_	_
17	functional	_	JJ	JJ	_	18	NMOD	_	_
18	analysis	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	deletion	_	NN	NN	_	21	NMOD	_	_
21	mutants	_	NNS	NNS	_	19	PMOD	_	_
22	or	_	CC	CC	_	21	CC	_	_
23	synthetic	_	JJ	JJ	_	25	NMOD	_	_
24	GRE	_	NN	NN	_	25	NMOD	_	_
25	oligonucleotides	_	NNS	NNS	_	21	COORD	_	_
26	driving	_	VBG	VBG	_	21	NMOD	_	_
27	chloramphenicol	_	NN	NN	_	29	NMOD	_	_
28	acetyl-transferase	_	NN	NN	_	29	NMOD	_	_
29	expression	_	NN	NN	_	26	OBJ	_	_
30	.	_	.	.	_	3	P	_	_

1	Synergism	_	NN	NN	_	2	SBJ	_	_
2	required	_	VBD	VBD	_	0	ROOT-S	_	_
3	an	_	DT	DT	_	7	NMOD	_	_
4	intact	_	JJ	JJ	_	7	NMOD	_	_
5	GR	_	NN	NN	_	7	NMOD	_	_
6	DNA-binding	_	JJ	JJ	_	7	NMOD	_	_
7	domain	_	NN	NN	_	2	OBJ	_	_
8	,	_	,	,	_	2	P	_	_
9	whereas	_	IN	IN	_	2	COORD	_	_
10	amino-	_	NN	NN	_	13	NMOD	_	_
11	or	_	CC	CC	_	10	CC	_	_
12	carboxyl-terminal	_	JJ	JJ	_	10	COORD	_	_
13	domains	_	NNS	NNS	_	14	SBJ	_	_
14	were	_	VBD	VBD	_	2	COORD	_	_
15	dispensable	_	JJ	JJ	_	14	PRD	_	_
16	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	abrogated	_	VBN	VBN	_	3	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	PKC	_	NN	NN	_	9	NMOD	_	_
8	inhibitor	_	NN	NN	_	9	NMOD	_	_
9	staurosporine	_	NN	NN	_	5	PMOD	_	_
10	,	_	,	,	_	4	P	_	_
11	suggesting	_	VBG	VBG	_	4	OBJ	_	_
12	a	_	DT	DT	_	13	NMOD	_	_
13	role	_	NN	NN	_	11	OBJ	_	_
14	for	_	IN	IN	_	13	NMOD	_	_
15	PKC	_	NN	NN	_	14	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	Increased	_	VBN	VBN	_	8	NMOD	_	_
2	c-jun	_	NN	NN	_	8	NMOD	_	_
3	,	_	,	,	_	2	P	_	_
4	jun-B	_	NN	NN	_	2	COORD	_	_
5	,	_	,	,	_	2	P	_	_
6	and	_	CC	CC	_	2	CC	_	_
7	jun-D	_	NN	NN	_	2	COORD	_	_
8	expression	_	NN	NN	_	25	SBJ	_	_
9	above	_	IN	IN	_	8	NMOD	_	_
10	basal	_	JJ	JJ	_	11	NMOD	_	_
11	levels	_	NNS	NNS	_	9	PMOD	_	_
12	and	_	CC	CC	_	8	CC	_	_
13	increased	_	VBN	VBN	_	15	NMOD	_	_
14	transcriptional	_	JJ	JJ	_	15	NMOD	_	_
15	activity	_	NN	NN	_	8	COORD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	AP-1\/TPA	_	NN	NN	_	19	NMOD	_	_
18	responsive	_	JJ	JJ	_	19	NMOD	_	_
19	elements	_	NNS	NNS	_	16	PMOD	_	_
20	fused	_	VBN	VBN	_	19	NMOD	_	_
21	to	_	TO	TO	_	20	ADV	_	_
22	chloramphenicol	_	NN	NN	_	24	NMOD	_	_
23	acetyl-transferase	_	NN	NN	_	24	NMOD	_	_
24	vectors	_	NNS	NNS	_	21	PMOD	_	_
25	were	_	VBD	VBD	_	0	ROOT-S	_	_
26	observed	_	VBN	VBN	_	25	VC	_	_
27	in	_	IN	IN	_	26	ADV	_	_
28	T	_	NN	NN	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	27	PMOD	_	_
30	treated	_	VBN	VBN	_	29	NMOD	_	_
31	with	_	IN	IN	_	30	ADV	_	_
32	TPA	_	NN	NN	_	31	PMOD	_	_
33	alone	_	RB	RB	_	32	NMOD	_	_
34	or	_	CC	CC	_	33	CC	_	_
35	in	_	IN	IN	_	33	COORD	_	_
36	combination	_	NN	NN	_	35	PMOD	_	_
37	with	_	IN	IN	_	36	NMOD	_	_
38	dexamethasone	_	NN	NN	_	37	PMOD	_	_
39	.	_	.	.	_	25	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	ability	_	NN	NN	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	Jun	_	NN	NN	_	5	NMOD	_	_
5	proteins	_	NNS	NNS	_	3	PMOD	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	cooperate	_	VB	VB	_	2	NMOD	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	GR	_	NN	NN	_	8	PMOD	_	_
10	in	_	IN	IN	_	7	ADV	_	_
11	T	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	been	_	VBN	VBN	_	13	VC	_	_
15	investigated	_	VBN	VBN	_	14	VC	_	_
16	after	_	IN	IN	_	15	TMP	_	_
17	transfection	_	NN	NN	_	16	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	c-jun	_	NN	NN	_	26	NMOD	_	_
20	,	_	,	,	_	19	P	_	_
21	jun-B	_	NN	NN	_	19	COORD	_	_
22	,	_	,	,	_	19	P	_	_
23	or	_	CC	CC	_	19	CC	_	_
24	jun-D	_	NN	NN	_	19	COORD	_	_
25	expression	_	NN	NN	_	26	NMOD	_	_
26	vectors	_	NNS	NNS	_	18	PMOD	_	_
27	,	_	,	,	_	17	P	_	_
28	which	_	WDT	WDT	_	29	SBJ	_	_
29	augmented	_	VBD	VBD	_	17	NMOD	_	_
30	GR-dependent	_	JJ	JJ	_	31	NMOD	_	_
31	transcription	_	NN	NN	_	29	OBJ	_	_
32	from	_	IN	IN	_	31	NMOD	_	_
33	either	_	CC	CC	_	35	CC	_	_
34	MMTV	_	NN	NN	_	35	NMOD	_	_
35	LTR	_	NN	NN	_	32	PMOD	_	_
36	or	_	CC	CC	_	35	CC	_	_
37	GRE	_	NN	NN	_	35	COORD	_	_
38	.	_	.	.	_	13	P	_	_

1	Conversely	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	c-jun	_	NN	NN	_	6	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	jun-B	_	NN	NN	_	3	COORD	_	_
6	transfection	_	NN	NN	_	7	SBJ	_	_
7	blunted	_	VBD	VBD	_	0	ROOT-S	_	_
8	GR-dependent	_	JJ	JJ	_	9	NMOD	_	_
9	transcription	_	NN	NN	_	7	OBJ	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	HeLa	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	presence	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	c-fos	_	NN	NN	_	3	PMOD	_	_
5	had	_	VBD	VBD	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	negative	_	JJ	JJ	_	8	NMOD	_	_
8	influence	_	NN	NN	_	5	OBJ	_	_
9	on	_	IN	IN	_	5	ADV	_	_
10	GR	_	NN	NN	_	11	NMOD	_	_
11	function	_	NN	NN	_	9	PMOD	_	_
12	and	_	CC	CC	_	5	CC	_	_
13	correlated	_	VBD	VBD	_	5	COORD	_	_
14	with	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	20	NMOD	_	_
16	cell-specific	_	JJ	JJ	_	20	NMOD	_	_
17	synergistic	_	JJ	JJ	_	20	NMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	antagonistic	_	JJ	JJ	_	17	COORD	_	_
20	activity	_	NN	NN	_	14	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	Jun	_	NN	NN	_	21	PMOD	_	_
23	with	_	IN	IN	_	13	ADV	_	_
24	respect	_	NN	NN	_	23	DEP	_	_
25	to	_	TO	TO	_	23	DEP	_	_
26	GR	_	NN	NN	_	23	PMOD	_	_
27	;	_	:	:	_	5	P	_	_
28	high	_	JJ	JJ	_	30	NMOD	_	_
29	basal	_	JJ	JJ	_	30	NMOD	_	_
30	expression	_	NN	NN	_	42	SBJ	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	c-fos	_	NN	NN	_	31	PMOD	_	_
33	as	_	RB	RB	_	30	CC	_	_
34	well	_	RB	RB	_	33	DEP	_	_
35	as	_	IN	IN	_	33	DEP	_	_
36	AP-1	_	NN	NN	_	38	NMOD	_	_
37	DNA	_	NN	NN	_	38	NMOD	_	_
38	binding	_	NN	NN	_	30	COORD	_	_
39	and	_	CC	CC	_	38	CC	_	_
40	transcriptional	_	JJ	JJ	_	41	NMOD	_	_
41	activity	_	NN	NN	_	38	COORD	_	_
42	were	_	VBD	VBD	_	5	VMOD	_	_
43	observed	_	VBN	VBN	_	42	VC	_	_
44	in	_	IN	IN	_	43	ADV	_	_
45	HeLa	_	NN	NN	_	46	NMOD	_	_
46	cells	_	NNS	NNS	_	44	PMOD	_	_
47	,	_	,	,	_	44	P	_	_
48	but	_	CC	CC	_	44	CC	_	_
49	not	_	RB	RB	_	50	DEP	_	_
50	in	_	IN	IN	_	44	COORD	_	_
51	T	_	NN	NN	_	52	NMOD	_	_
52	cells	_	NNS	NNS	_	50	PMOD	_	_
53	.	_	.	.	_	42	P	_	_

1	Furthermore	_	RB	RB	_	6	ADV	_	_
2	overexpression	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	exogenous	_	JJ	JJ	_	5	NMOD	_	_
5	c-fos	_	NN	NN	_	3	PMOD	_	_
6	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	an	_	DT	DT	_	9	NMOD	_	_
8	inhibitory	_	JJ	JJ	_	9	NMOD	_	_
9	effect	_	NN	NN	_	6	OBJ	_	_
10	on	_	IN	IN	_	6	ADV	_	_
11	GR-dependent	_	JJ	JJ	_	12	NMOD	_	_
12	transcription	_	NN	NN	_	10	PMOD	_	_
13	from	_	IN	IN	_	12	NMOD	_	_
14	GRE	_	NN	NN	_	13	PMOD	_	_
15	in	_	IN	IN	_	12	NMOD	_	_
16	T	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	15	PMOD	_	_
18	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	propose	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	Jun	_	NN	NN	_	5	SBJ	_	_
5	plays	_	VBZ	VBZ	_	3	VMOD	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	bifunctional	_	JJ	JJ	_	8	NMOD	_	_
8	role	_	NN	NN	_	5	IOBJ	_	_
9	on	_	IN	IN	_	5	ADV	_	_
10	GR-dependent	_	JJ	JJ	_	12	NMOD	_	_
11	transcriptional	_	JJ	JJ	_	12	NMOD	_	_
12	activation	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	GRE	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	5	P	_	_
16	selecting	_	VBG	VBG	_	5	OBJ	_	_
17	either	_	CC	CC	_	18	CC	_	_
18	synergistic	_	JJ	JJ	_	21	NMOD	_	_
19	or	_	CC	CC	_	18	CC	_	_
20	antagonistic	_	JJ	JJ	_	18	COORD	_	_
21	activity	_	NN	NN	_	16	OBJ	_	_
22	depending	_	VBG	VBG	_	16	ADV	_	_
23	on	_	IN	IN	_	22	PMOD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	cell-specific	_	JJ	JJ	_	26	NMOD	_	_
26	microenvironment	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	regard	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	9	P	_	_
5	intracellular	_	JJ	JJ	_	6	NMOD	_	_
6	levels	_	NNS	NNS	_	9	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	c-fos	_	NN	NN	_	7	PMOD	_	_
9	appear	_	VBP	VBP	_	0	ROOT-S	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	be	_	VB	VB	_	9	OBJ	_	_
12	influential	_	JJ	JJ	_	11	PRD	_	_
13	.	_	.	.	_	9	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	concatenated	_	JJ	JJ	_	3	NMOD	_	_
3	form	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	Epstein-Barr	_	JJ	JJ	_	7	NMOD	_	_
6	viral	_	JJ	JJ	_	7	NMOD	_	_
7	DNA	_	NN	NN	_	4	PMOD	_	_
8	in	_	IN	IN	_	3	NMOD	_	_
9	lymphoblastoid	_	JJ	JJ	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	lines	_	NNS	NNS	_	8	PMOD	_	_
12	induced	_	VBN	VBN	_	11	NMOD	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	transfection	_	NN	NN	_	13	PMOD	_	_
15	with	_	IN	IN	_	14	NMOD	_	_
16	BZLF1	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	replicative	_	JJ	JJ	_	3	NMOD	_	_
3	form	_	NN	NN	_	11	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	Epstein-Barr	_	JJ	JJ	_	6	NMOD	_	_
6	virus	_	NN	NN	_	10	NMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	EBV	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	DNA	_	NN	NN	_	4	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	studied	_	VBN	VBN	_	11	VC	_	_
13	using	_	VBG	VBG	_	12	OBJ	_	_
14	two	_	CD	CD	_	17	NMOD	_	_
15	lymphoblastoid	_	JJ	JJ	_	17	NMOD	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	lines	_	NNS	NNS	_	13	OBJ	_	_
18	,	_	,	,	_	17	P	_	_
19	X50-7	_	NN	NN	_	17	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	6F11	_	NN	NN	_	19	COORD	_	_
22	,	_	,	,	_	17	P	_	_
23	which	_	WDT	WDT	_	24	SBJ	_	_
24	are	_	VBP	VBP	_	17	NMOD	_	_
25	latently	_	RB	RB	_	26	ADV	_	_
26	infected	_	VBN	VBN	_	24	VC	_	_
27	by	_	IN	IN	_	26	LGS	_	_
28	Epstein-Barr	_	JJ	JJ	_	29	NMOD	_	_
29	virus	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	lytic	_	JJ	JJ	_	3	NMOD	_	_
3	cycle	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	EBV	_	NN	NN	_	6	NMOD	_	_
6	infection	_	NN	NN	_	4	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	induced	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	transfection	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	with	_	IN	IN	_	10	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	BRLF1\/BZLF1	_	NN	NN	_	18	NMOD	_	_
17	coding	_	NN	NN	_	18	NMOD	_	_
18	region	_	NN	NN	_	14	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	P3HR-1	_	NN	NN	_	23	NMOD	_	_
22	defective	_	JJ	JJ	_	23	NMOD	_	_
23	genome	_	NN	NN	_	19	PMOD	_	_
24	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	combined	_	VBD	VBD	_	0	ROOT-S	_	_
3	two	_	CD	CD	_	4	NMOD	_	_
4	techniques	_	NNS	NNS	_	2	IOBJ	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	identify	_	VB	VB	_	2	OBJ	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	productive	_	JJ	JJ	_	10	NMOD	_	_
9	replicative	_	JJ	JJ	_	10	NMOD	_	_
10	form	_	NN	NN	_	6	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	Epstein-Barr	_	JJ	JJ	_	14	NMOD	_	_
13	viral	_	JJ	JJ	_	14	NMOD	_	_
14	DNA	_	NN	NN	_	11	PMOD	_	_
15	in	_	IN	IN	_	10	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	lytic	_	JJ	JJ	_	18	AMOD	_	_
18	cycle-induced	_	JJ	JJ	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	15	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	Restriction	_	NN	NN	_	3	NMOD	_	_
2	enzyme	_	NN	NN	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	9	SBJ	_	_
4	followed	_	VBN	VBN	_	3	NMOD	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	Southern	_	NN	NN	_	8	NMOD	_	_
7	blot	_	NN	NN	_	8	NMOD	_	_
8	hybridization	_	NN	NN	_	5	PMOD	_	_
9	identified	_	VBD	VBD	_	0	ROOT-S	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	significant	_	JJ	JJ	_	12	NMOD	_	_
12	increase	_	NN	NN	_	9	OBJ	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	fused	_	VBN	VBN	_	16	NMOD	_	_
16	fragment	_	NN	NN	_	13	PMOD	_	_
17	encompassing	_	VBG	VBG	_	16	NMOD	_	_
18	both	_	DT	DT	_	19	NMOD	_	_
19	ends	_	NNS	NNS	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	EBV	_	NN	NN	_	22	NMOD	_	_
22	DNA	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	9	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	indicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	an	_	DT	DT	_	4	NMOD	_	_
4	increase	_	NN	NN	_	2	OBJ	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	either	_	CC	CC	_	8	CC	_	_
7	episomal	_	JJ	JJ	_	8	NMOD	_	_
8	DNA	_	NN	NN	_	5	PMOD	_	_
9	or	_	CC	CC	_	8	CC	_	_
10	concatameric	_	JJ	JJ	_	12	NMOD	_	_
11	linear	_	JJ	JJ	_	12	NMOD	_	_
12	DNA	_	NN	NN	_	8	COORD	_	_
13	.	_	.	.	_	2	P	_	_

1	Southern	_	NN	NN	_	3	NMOD	_	_
2	blot	_	NN	NN	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	in	_	FW	FW	_	6	AMOD	_	_
6	situ	_	FW	FW	_	8	NMOD	_	_
7	lysing	_	VBG	VBG	_	8	NMOD	_	_
8	gels	_	NNS	NNS	_	4	PMOD	_	_
9	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
10	that	_	IN	IN	_	9	OBJ	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	cellular	_	JJ	JJ	_	13	NMOD	_	_
13	content	_	NN	NN	_	18	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	linear	_	JJ	JJ	_	17	NMOD	_	_
16	EBV	_	NN	NN	_	17	NMOD	_	_
17	DNA	_	NN	NN	_	14	PMOD	_	_
18	was	_	VBD	VBD	_	10	VMOD	_	_
19	also	_	RB	RB	_	20	ADV	_	_
20	increased	_	VBN	VBN	_	18	VC	_	_
21	significantly	_	RB	RB	_	20	ADV	_	_
22	after	_	IN	IN	_	20	TMP	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	initiation	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	29	NMOD	_	_
27	viral	_	JJ	JJ	_	29	NMOD	_	_
28	lytic	_	JJ	JJ	_	29	NMOD	_	_
29	cycle	_	NN	NN	_	25	PMOD	_	_
30	,	_	,	,	_	20	P	_	_
31	while	_	IN	IN	_	20	OBJ	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	amount	_	NN	NN	_	37	SBJ	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	circular	_	JJ	JJ	_	36	NMOD	_	_
36	DNA	_	NN	NN	_	34	PMOD	_	_
37	remained	_	VBD	VBD	_	31	VMOD	_	_
38	approximately	_	RB	RB	_	39	AMOD	_	_
39	constant	_	JJ	JJ	_	37	PRD	_	_
40	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	propose	_	VBP	VBP	_	0	ROOT-S	_	_
3	from	_	IN	IN	_	2	ADV	_	_
4	these	_	DT	DT	_	5	NMOD	_	_
5	results	_	NNS	NNS	_	3	PMOD	_	_
6	that	_	IN	IN	_	2	OBJ	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	source	_	NN	NN	_	19	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	fused	_	VBN	VBN	_	12	NMOD	_	_
12	fragment	_	NN	NN	_	9	PMOD	_	_
13	encompassing	_	VBG	VBG	_	12	NMOD	_	_
14	both	_	DT	DT	_	15	NMOD	_	_
15	ends	_	NNS	NNS	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	EBV	_	NN	NN	_	18	NMOD	_	_
18	DNA	_	NN	NN	_	16	PMOD	_	_
19	is	_	VBZ	VBZ	_	6	VMOD	_	_
20	a	_	DT	DT	_	25	NMOD	_	_
21	concatenated	_	VBN	VBN	_	25	NMOD	_	_
22	linear	_	JJ	JJ	_	25	NMOD	_	_
23	EBV	_	NN	NN	_	25	NMOD	_	_
24	DNA	_	NN	NN	_	25	NMOD	_	_
25	molecule	_	NN	NN	_	19	PRD	_	_
26	,	_	,	,	_	6	P	_	_
27	and	_	CC	CC	_	6	CC	_	_
28	that	_	IN	IN	_	6	COORD	_	_
29	such	_	PDT	PDT	_	32	NMOD	_	_
30	a	_	DT	DT	_	32	NMOD	_	_
31	concatenated	_	VBN	VBN	_	32	NMOD	_	_
32	molecule	_	NN	NN	_	35	SBJ	_	_
33	most	_	RBS	RBS	_	34	AMOD	_	_
34	likely	_	RB	RB	_	35	ADV	_	_
35	represents	_	VBZ	VBZ	_	28	VMOD	_	_
36	a	_	DT	DT	_	38	NMOD	_	_
37	replicative	_	JJ	JJ	_	38	NMOD	_	_
38	form	_	NN	NN	_	35	OBJ	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	EBV	_	NN	NN	_	41	NMOD	_	_
41	DNA	_	NN	NN	_	39	PMOD	_	_
42	in	_	IN	IN	_	41	NMOD	_	_
43	productively	_	RB	RB	_	44	AMOD	_	_
44	infected	_	JJ	JJ	_	45	NMOD	_	_
45	cells	_	NNS	NNS	_	42	PMOD	_	_
46	.	_	.	.	_	2	P	_	_

1	Ectopic	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	a	_	DT	DT	_	8	NMOD	_	_
5	conditional	_	JJ	JJ	_	8	NMOD	_	_
6	GATA-2\/estrogen	_	NN	NN	_	8	NMOD	_	_
7	receptor	_	NN	NN	_	8	NMOD	_	_
8	chimera	_	NN	NN	_	3	PMOD	_	_
9	arrests	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	erythroid	_	JJ	JJ	_	11	NMOD	_	_
11	differentiation	_	NN	NN	_	9	OBJ	_	_
12	in	_	IN	IN	_	9	ADV	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	hormone-dependent	_	JJ	JJ	_	15	NMOD	_	_
15	manner	_	NN	NN	_	12	PMOD	_	_
16	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	GATA	_	NN	NN	_	3	NMOD	_	_
3	factors	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	6	NMOD	_	_
6	family	_	NN	NN	_	4	PRD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	transcriptional	_	JJ	JJ	_	10	NMOD	_	_
9	regulatory	_	JJ	JJ	_	10	NMOD	_	_
10	proteins	_	NNS	NNS	_	7	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	eukaryotes	_	NNS	NNS	_	11	PMOD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	share	_	VBP	VBP	_	12	NMOD	_	_
15	extensive	_	JJ	JJ	_	16	NMOD	_	_
16	homology	_	NN	NN	_	14	OBJ	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	their	_	PRP$	PRP$	_	20	NMOD	_	_
19	DNA-binding	_	JJ	JJ	_	20	NMOD	_	_
20	domains	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	4	P	_	_

1	One	_	CD	CD	_	3	NMOD	_	_
2	enigmatic	_	JJ	JJ	_	3	NMOD	_	_
3	aspect	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	GATA	_	NN	NN	_	7	NMOD	_	_
6	factor	_	NN	NN	_	7	NMOD	_	_
7	expression	_	NN	NN	_	4	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	PRD	_	_
10	several	_	JJ	JJ	_	12	NMOD	_	_
11	GATA	_	NN	NN	_	12	NMOD	_	_
12	proteins	_	NNS	NNS	_	23	SBJ	_	_
13	,	_	,	,	_	12	P	_	_
14	which	_	WDT	WDT	_	16	SBJ	_	_
15	ostensibly	_	RB	RB	_	16	ADV	_	_
16	share	_	VBP	VBP	_	12	NMOD	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	same	_	JJ	JJ	_	21	NMOD	_	_
19	DNA-binding	_	JJ	JJ	_	21	NMOD	_	_
20	site	_	NN	NN	_	21	NMOD	_	_
21	specificity	_	NN	NN	_	16	OBJ	_	_
22	,	_	,	,	_	12	P	_	_
23	are	_	VBP	VBP	_	9	VMOD	_	_
24	coexpressed	_	VBN	VBN	_	23	VC	_	_
25	in	_	IN	IN	_	24	ADV	_	_
26	erythroid	_	JJ	JJ	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	8	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	elucidate	_	VB	VB	_	21	VC	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	roles	_	NNS	NNS	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	individual	_	JJ	JJ	_	8	NMOD	_	_
7	GATA	_	NN	NN	_	8	NMOD	_	_
8	factors	_	NNS	NNS	_	5	PMOD	_	_
9	in	_	IN	IN	_	4	NMOD	_	_
10	erythropoiesis	_	NN	NN	_	9	PMOD	_	_
11	,	_	,	,	_	21	P	_	_
12	conditional	_	JJ	JJ	_	13	NMOD	_	_
13	alleles	_	NNS	NNS	_	21	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	GATA-1	_	NN	NN	_	14	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	GATA-2	_	NN	NN	_	15	COORD	_	_
18	,	_	,	,	_	15	P	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	GATA-3	_	NN	NN	_	15	COORD	_	_
21	were	_	VBD	VBD	_	0	ROOT-S	_	_
22	prepared	_	VBN	VBN	_	21	VC	_	_
23	by	_	IN	IN	_	22	ADV	_	_
24	fusing	_	VBG	VBG	_	23	PMOD	_	_
25	each	_	DT	DT	_	24	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	factors	_	NNS	NNS	_	26	PMOD	_	_
29	to	_	TO	TO	_	24	ADV	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	hormone-binding	_	JJ	JJ	_	32	NMOD	_	_
32	domain	_	NN	NN	_	29	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	the	_	DT	DT	_	37	NMOD	_	_
35	human	_	JJ	JJ	_	37	NMOD	_	_
36	estrogen	_	NN	NN	_	37	NMOD	_	_
37	receptor	_	NN	NN	_	33	PMOD	_	_
38	(	_	(	(	_	39	P	_	_
39	ER	_	NN	NN	_	37	PRN	_	_
40	)	_	)	)	_	39	P	_	_
41	.	_	.	.	_	21	P	_	_

1	These	_	DT	DT	_	4	NMOD	_	_
2	GATA\/ER	_	NN	NN	_	4	NMOD	_	_
3	chimeric	_	JJ	JJ	_	4	NMOD	_	_
4	factors	_	NNS	NNS	_	5	SBJ	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	shown	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	be	_	VB	VB	_	6	OBJ	_	_
9	hormone-inducible	_	JJ	JJ	_	11	NMOD	_	_
10	trans-activating	_	JJ	JJ	_	11	NMOD	_	_
11	proteins	_	NNS	NNS	_	8	PRD	_	_
12	in	_	IN	IN	_	6	ADV	_	_
13	transient	_	JJ	JJ	_	15	NMOD	_	_
14	transfection	_	NN	NN	_	15	NMOD	_	_
15	assays	_	NNS	NNS	_	12	PMOD	_	_
16	.	_	.	.	_	5	P	_	_

1	When	_	WRB	WRB	_	3	ADV	_	_
2	stably	_	RB	RB	_	3	ADV	_	_
3	introduced	_	VBN	VBN	_	16	TMP	_	_
4	into	_	IN	IN	_	3	ADV	_	_
5	primary	_	JJ	JJ	_	6	NMOD	_	_
6	erythroblasts	_	NNS	NNS	_	4	PMOD	_	_
7	or	_	CC	CC	_	6	CC	_	_
8	conditionally	_	RB	RB	_	9	AMOD	_	_
9	transformed	_	VBN	VBN	_	12	NMOD	_	_
10	erythroid	_	JJ	JJ	_	12	NMOD	_	_
11	progenitors	_	NNS	NNS	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	6	COORD	_	_
13	,	_	,	,	_	16	P	_	_
14	exogenous	_	JJ	JJ	_	15	NMOD	_	_
15	GATA-2\/ER	_	NN	NN	_	16	SBJ	_	_
16	promoted	_	VBD	VBD	_	0	ROOT-S	_	_
17	proliferation	_	NN	NN	_	16	OBJ	_	_
18	and	_	CC	CC	_	16	CC	_	_
19	inhibited	_	VBD	VBD	_	16	COORD	_	_
20	terminal	_	JJ	JJ	_	21	NMOD	_	_
21	differentiation	_	NN	NN	_	19	OBJ	_	_
22	in	_	IN	IN	_	16	ADV	_	_
23	an	_	DT	DT	_	25	NMOD	_	_
24	estrogen-dependent	_	JJ	JJ	_	25	NMOD	_	_
25	manner	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	16	P	_	_

1	These	_	DT	DT	_	3	NMOD	_	_
2	phenotypic	_	JJ	JJ	_	3	NMOD	_	_
3	effects	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	specifically	_	RB	RB	_	4	ADV	_	_
6	attributable	_	JJ	JJ	_	4	PRD	_	_
7	to	_	TO	TO	_	6	AMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	action	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	ectopically	_	RB	RB	_	12	AMOD	_	_
12	expressed	_	VBN	VBN	_	13	NMOD	_	_
13	GATA-2\/ER	_	NN	NN	_	10	PMOD	_	_
14	because	_	IN	IN	_	4	ADV	_	_
15	erythroblasts	_	NNS	NNS	_	19	SBJ	_	_
16	expressing	_	VBG	VBG	_	15	NMOD	_	_
17	exogenous	_	JJ	JJ	_	18	NMOD	_	_
18	GATA-2	_	NN	NN	_	16	OBJ	_	_
19	are	_	VBP	VBP	_	14	VMOD	_	_
20	constitutively	_	RB	RB	_	21	ADV	_	_
21	arrested	_	VBN	VBN	_	19	VC	_	_
22	in	_	IN	IN	_	21	ADV	_	_
23	differentiation	_	NN	NN	_	22	PMOD	_	_
24	and	_	CC	CC	_	14	CC	_	_
25	because	_	IN	IN	_	14	COORD	_	_
26	erythroid	_	JJ	JJ	_	27	NMOD	_	_
27	progenitors	_	NNS	NNS	_	33	SBJ	_	_
28	expressing	_	VBG	VBG	_	27	NMOD	_	_
29	either	_	CC	CC	_	30	CC	_	_
30	Gal\/ER	_	NN	NN	_	28	OBJ	_	_
31	or	_	CC	CC	_	30	CC	_	_
32	GATA-3\/ER	_	NN	NN	_	30	COORD	_	_
33	do	_	VBP	VBP	_	25	VMOD	_	_
34	not	_	RB	RB	_	33	VMOD	_	_
35	display	_	VB	VB	_	33	VC	_	_
36	a	_	DT	DT	_	38	NMOD	_	_
37	hormone-responsive	_	JJ	JJ	_	38	NMOD	_	_
38	block	_	NN	NN	_	35	OBJ	_	_
39	in	_	IN	IN	_	35	ADV	_	_
40	differentiation	_	NN	NN	_	39	PMOD	_	_
41	.	_	.	.	_	4	P	_	_

1	Thus	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	GATA-2	_	NN	NN	_	6	NMOD	_	_
5	transcription	_	NN	NN	_	6	NMOD	_	_
6	factor	_	NN	NN	_	7	SBJ	_	_
7	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	play	_	VB	VB	_	7	OBJ	_	_
10	a	_	DT	DT	_	11	NMOD	_	_
11	role	_	NN	NN	_	9	OBJ	_	_
12	in	_	IN	IN	_	9	ADV	_	_
13	regulating	_	VBG	VBG	_	12	PMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	self-renewal	_	JJ	JJ	_	16	NMOD	_	_
16	capacity	_	NN	NN	_	13	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	early	_	JJ	JJ	_	21	NMOD	_	_
19	erythroid	_	JJ	JJ	_	21	NMOD	_	_
20	progenitor	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	17	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	Lipopolysaccharide	_	NN	NN	_	2	SBJ	_	_
2	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	phosphorylation	_	NN	NN	_	2	OBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	MAD3	_	NN	NN	_	4	PMOD	_	_
6	and	_	CC	CC	_	3	CC	_	_
7	activation	_	NN	NN	_	3	COORD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	c-Rel	_	NN	NN	_	14	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	related	_	JJ	JJ	_	13	NMOD	_	_
12	NF-kappa	_	NN	NN	_	13	NMOD	_	_
13	B	_	NN	NN	_	9	COORD	_	_
14	proteins	_	NNS	NNS	_	8	PMOD	_	_
15	in	_	IN	IN	_	3	NMOD	_	_
16	human	_	JJ	JJ	_	19	NMOD	_	_
17	monocytic	_	JJ	JJ	_	19	NMOD	_	_
18	THP-1	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	15	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	Many	_	JJ	JJ	_	2	NMOD	_	_
2	effects	_	NNS	NNS	_	25	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	lipopolysaccharide	_	NN	NN	_	3	PMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	LPS	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	on	_	IN	IN	_	2	NMOD	_	_
9	gene	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	8	PMOD	_	_
11	,	_	,	,	_	2	P	_	_
12	including	_	VBG	VBG	_	2	NMOD	_	_
13	that	_	DT	DT	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	human	_	JJ	JJ	_	17	NMOD	_	_
16	immunodeficiency	_	NN	NN	_	17	NMOD	_	_
17	virus	_	NN	NN	_	14	PMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	HIV	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	,	_	,	,	_	2	P	_	_
22	in	_	IN	IN	_	2	NMOD	_	_
23	monocytic	_	JJ	JJ	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	are	_	VBP	VBP	_	0	ROOT-S	_	_
26	mediated	_	VBN	VBN	_	25	VC	_	_
27	by	_	IN	IN	_	26	LGS	_	_
28	activation	_	NN	NN	_	27	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	kappa	_	NN	NN	_	33	NMOD	_	_
31	B	_	NN	NN	_	33	NMOD	_	_
32	DNA-binding	_	JJ	JJ	_	33	NMOD	_	_
33	proteins	_	NNS	NNS	_	29	PMOD	_	_
34	.	_	.	.	_	25	P	_	_

1	However	_	RB	RB	_	28	ADV	_	_
2	,	_	,	,	_	28	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	specific	_	JJ	JJ	_	5	NMOD	_	_
5	members	_	NNS	NNS	_	28	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	12	NMOD	_	_
8	NF-kappa	_	NN	NN	_	12	NMOD	_	_
9	B\/Rel	_	NN	NN	_	12	NMOD	_	_
10	transcription	_	NN	NN	_	12	NMOD	_	_
11	factor	_	NN	NN	_	12	NMOD	_	_
12	family	_	NN	NN	_	6	PMOD	_	_
13	involved	_	VBN	VBN	_	12	NMOD	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	LPS	_	NN	NN	_	17	NMOD	_	_
17	response	_	NN	NN	_	14	PMOD	_	_
18	,	_	,	,	_	5	P	_	_
19	and	_	CC	CC	_	5	CC	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	mechanisms	_	NNS	NNS	_	5	COORD	_	_
22	through	_	IN	IN	_	27	ADV	_	_
23	which	_	WDT	WDT	_	22	PMOD	_	_
24	LPS-generated	_	JJ	JJ	_	25	NMOD	_	_
25	signals	_	NNS	NNS	_	26	SBJ	_	_
26	are	_	VBP	VBP	_	21	NMOD	_	_
27	transduced	_	VBN	VBN	_	26	VC	_	_
28	remain	_	VBP	VBP	_	0	ROOT-S	_	_
29	unclear	_	JJ	JJ	_	28	PRD	_	_
30	.	_	.	.	_	28	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	LPS	_	NN	NN	_	6	SBJ	_	_
6	induces	_	VBZ	VBZ	_	4	VMOD	_	_
7	nuclear	_	JJ	JJ	_	8	NMOD	_	_
8	expression	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	c-Rel\/p50	_	NN	NN	_	11	NMOD	_	_
11	heterodimers	_	NNS	NNS	_	9	PMOD	_	_
12	as	_	RB	RB	_	11	CC	_	_
13	well	_	RB	RB	_	12	DEP	_	_
14	as	_	IN	IN	_	12	DEP	_	_
15	p50\/p65	_	NN	NN	_	23	NMOD	_	_
16	(	_	(	(	_	18	P	_	_
17	NF-kappa	_	NN	NN	_	18	NMOD	_	_
18	B	_	NN	NN	_	15	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	kappa	_	NN	NN	_	23	NMOD	_	_
21	B	_	NN	NN	_	23	NMOD	_	_
22	DNA-binding	_	JJ	JJ	_	23	NMOD	_	_
23	complexes	_	NNS	NNS	_	11	COORD	_	_
24	in	_	IN	IN	_	6	ADV	_	_
25	human	_	JJ	JJ	_	28	NMOD	_	_
26	monocytic	_	JJ	JJ	_	28	NMOD	_	_
27	THP-1	_	NN	NN	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	24	PMOD	_	_
29	.	_	.	.	_	3	P	_	_

1	Nuclear	_	JJ	JJ	_	2	NMOD	_	_
2	localization	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	these	_	DT	DT	_	5	NMOD	_	_
5	proteins	_	NNS	NNS	_	3	PMOD	_	_
6	occurred	_	VBD	VBD	_	0	ROOT-S	_	_
7	concomitantly	_	RB	RB	_	8	DEP	_	_
8	with	_	IN	IN	_	6	ADV	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	rapid	_	JJ	JJ	_	11	NMOD	_	_
11	decrease	_	NN	NN	_	8	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	their	_	PRP$	PRP$	_	15	NMOD	_	_
14	cytosolic	_	JJ	JJ	_	15	NMOD	_	_
15	levels	_	NNS	NNS	_	12	PMOD	_	_
16	and	_	CC	CC	_	6	CC	_	_
17	was	_	VBD	VBD	_	6	COORD	_	_
18	independent	_	JJ	JJ	_	17	PRD	_	_
19	of	_	IN	IN	_	18	AMOD	_	_
20	phorbol	_	NN	NN	_	24	NMOD	_	_
21	ester-sensitive	_	JJ	JJ	_	20	AMOD	_	_
22	protein	_	NN	NN	_	24	NMOD	_	_
23	kinase	_	NN	NN	_	24	NMOD	_	_
24	C	_	NN	NN	_	19	PMOD	_	_
25	.	_	.	.	_	6	P	_	_

1	Within	_	IN	IN	_	8	TMP	_	_
2	24	_	CD	CD	_	3	NMOD	_	_
3	h	_	NN	NN	_	1	PMOD	_	_
4	following	_	VBG	VBG	_	3	TMP	_	_
5	LPS	_	NN	NN	_	6	NMOD	_	_
6	stimulation	_	NN	NN	_	4	PMOD	_	_
7	there	_	EX	EX	_	8	SBJ	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	striking	_	JJ	JJ	_	11	NMOD	_	_
11	increase	_	NN	NN	_	8	PRD	_	_
12	in	_	IN	IN	_	8	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	levels	_	NNS	NNS	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	c-Rel	_	NN	NN	_	15	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	p105	_	NN	NN	_	16	COORD	_	_
19	,	_	,	,	_	16	P	_	_
20	and	_	CC	CC	_	16	CC	_	_
21	p50	_	NN	NN	_	16	COORD	_	_
22	in	_	IN	IN	_	16	NMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	cytosol	_	NN	NN	_	22	PMOD	_	_
25	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	increased	_	VBN	VBN	_	3	NMOD	_	_
3	levels	_	NNS	NNS	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	these	_	DT	DT	_	6	NMOD	_	_
6	proteins	_	NNS	NNS	_	4	PMOD	_	_
7	correlated	_	VBD	VBD	_	0	ROOT-S	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	increases	_	NNS	NNS	_	8	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	amounts	_	NNS	NNS	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	their	_	PRP$	PRP$	_	15	NMOD	_	_
15	mRNAs	_	NNS	NNS	_	13	PMOD	_	_
16	during	_	IN	IN	_	9	TMP	_	_
17	LPS	_	NN	NN	_	18	NMOD	_	_
18	activation	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	THP-1	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	19	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	LPS	_	NN	NN	_	2	NMOD	_	_
2	activation	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	THP-1	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	3	PMOD	_	_
6	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	phosphorylation	_	NN	NN	_	7	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	MAD3	_	NN	NN	_	9	PMOD	_	_
11	(	_	(	(	_	16	P	_	_
12	an	_	DT	DT	_	16	NMOD	_	_
13	I	_	NN	NN	_	14	AMOD	_	_
14	kappa	_	NN	NN	_	16	NMOD	_	_
15	B-like	_	JJ	JJ	_	14	AMOD	_	_
16	protein	_	NN	NN	_	10	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	,	_	,	,	_	8	P	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	rapid	_	JJ	JJ	_	21	NMOD	_	_
21	increase	_	NN	NN	_	8	COORD	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	MAD3	_	NN	NN	_	24	NMOD	_	_
24	mRNA	_	NN	NN	_	22	PMOD	_	_
25	,	_	,	,	_	8	P	_	_
26	and	_	CC	CC	_	8	CC	_	_
27	an	_	DT	DT	_	28	NMOD	_	_
28	increase	_	NN	NN	_	8	COORD	_	_
29	in	_	IN	IN	_	28	NMOD	_	_
30	MAD3	_	NN	NN	_	31	NMOD	_	_
31	protein	_	NN	NN	_	29	PMOD	_	_
32	by	_	IN	IN	_	28	TMP	_	_
33	2	_	CD	CD	_	34	NMOD	_	_
34	h	_	NN	NN	_	32	PMOD	_	_
35	.	_	.	.	_	6	P	_	_

1	Thus	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	LPS	_	NN	NN	_	4	NMOD	_	_
4	activation	_	NN	NN	_	9	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	human	_	JJ	JJ	_	8	NMOD	_	_
7	monocytic	_	JJ	JJ	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	5	PMOD	_	_
9	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	nuclear	_	JJ	JJ	_	12	NMOD	_	_
12	expression	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	c-Rel\/p50	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	p50\/p65	_	NN	NN	_	14	COORD	_	_
17	(	_	(	(	_	19	P	_	_
18	NF-kappa	_	NN	NN	_	19	NMOD	_	_
19	B	_	NN	NN	_	16	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	and	_	CC	CC	_	9	CC	_	_
22	induces	_	VBZ	VBZ	_	9	COORD	_	_
23	phosphorylation	_	NN	NN	_	22	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	MAD3	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	9	P	_	_

1	Molecular	_	JJ	JJ	_	2	NMOD	_	_
2	basis	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	multiple	_	JJ	JJ	_	7	NMOD	_	_
6	lymphokine	_	NN	NN	_	7	NMOD	_	_
7	deficiency	_	NN	NN	_	3	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	patient	_	NN	NN	_	8	PMOD	_	_
11	with	_	IN	IN	_	10	NMOD	_	_
12	severe	_	JJ	JJ	_	14	NMOD	_	_
13	combined	_	JJ	JJ	_	14	NMOD	_	_
14	immunodeficiency	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	previously	_	RB	RB	_	2	TMP	_	_
4	reported	_	VBN	VBN	_	2	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	T	_	NN	NN	_	8	NMOD	_	_
8	lymphocytes	_	NNS	NNS	_	16	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	a	_	DT	DT	_	11	NMOD	_	_
11	child	_	NN	NN	_	9	PMOD	_	_
12	with	_	IN	IN	_	11	NMOD	_	_
13	severe	_	JJ	JJ	_	15	NMOD	_	_
14	combined	_	JJ	JJ	_	15	NMOD	_	_
15	immunodeficiency	_	NN	NN	_	12	PMOD	_	_
16	are	_	VBP	VBP	_	5	VMOD	_	_
17	defective	_	JJ	JJ	_	16	PRD	_	_
18	in	_	IN	IN	_	16	ADV	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	transcription	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	several	_	JJ	JJ	_	24	NMOD	_	_
23	lymphokine	_	NN	NN	_	24	NMOD	_	_
24	genes	_	NNS	NNS	_	21	PMOD	_	_
25	that	_	WDT	WDT	_	26	SBJ	_	_
26	include	_	VBP	VBP	_	24	NMOD	_	_
27	IL2	_	NN	NN	_	26	OBJ	_	_
28	,	_	,	,	_	27	P	_	_
29	IL3	_	NN	NN	_	27	COORD	_	_
30	,	_	,	,	_	27	P	_	_
31	IL4	_	NN	NN	_	27	COORD	_	_
32	,	_	,	,	_	27	P	_	_
33	and	_	CC	CC	_	27	CC	_	_
34	IL5	_	NN	NN	_	27	COORD	_	_
35	,	_	,	,	_	27	P	_	_
36	which	_	WDT	WDT	_	37	SBJ	_	_
37	encode	_	VBP	VBP	_	27	NMOD	_	_
38	interleukins	_	NNS	NNS	_	37	OBJ	_	_
39	2	_	CD	CD	_	38	NMOD	_	_
40	,	_	,	,	_	39	P	_	_
41	3	_	CD	CD	_	39	COORD	_	_
42	,	_	,	,	_	39	P	_	_
43	4	_	CD	CD	_	39	COORD	_	_
44	,	_	,	,	_	39	P	_	_
45	and	_	CC	CC	_	39	CC	_	_
46	5	_	CD	CD	_	39	COORD	_	_
47	(	_	(	(	_	48	P	_	_
48	IL-2	_	NN	NN	_	38	PRN	_	_
49	,	_	,	,	_	48	P	_	_
50	-3	_	CD	CD	_	48	COORD	_	_
51	,	_	,	,	_	48	P	_	_
52	-4	_	CD	CD	_	48	COORD	_	_
53	,	_	,	,	_	48	P	_	_
54	and	_	CC	CC	_	48	CC	_	_
55	-5	_	CD	CD	_	48	COORD	_	_
56	)	_	)	)	_	48	P	_	_
57	.	_	.	.	_	2	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	determine	_	VB	VB	_	24	VMOD	_	_
3	whether	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	defect	_	NN	NN	_	12	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	patient	_	NN	NN	_	11	NMOD	_	_
9	's	_	POS	POS	_	8	NMOD	_	_
10	T	_	NN	NN	_	11	NMOD	_	_
11	lymphocytes	_	NNS	NNS	_	6	PMOD	_	_
12	involved	_	VBD	VBD	_	3	VMOD	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	trans-acting	_	JJ	JJ	_	15	NMOD	_	_
15	factor	_	NN	NN	_	12	OBJ	_	_
16	common	_	JJ	JJ	_	15	NMOD	_	_
17	to	_	TO	TO	_	16	AMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	affected	_	VBN	VBN	_	21	NMOD	_	_
20	lymphokine	_	NN	NN	_	21	NMOD	_	_
21	genes	_	NNS	NNS	_	17	PMOD	_	_
22	,	_	,	,	_	24	P	_	_
23	we	_	PRP	PRP	_	24	SBJ	_	_
24	examined	_	VBD	VBD	_	0	ROOT-S	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	ability	_	NN	NN	_	24	OBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	nuclear	_	JJ	JJ	_	29	NMOD	_	_
29	factors	_	NNS	NNS	_	27	PMOD	_	_
30	from	_	IN	IN	_	29	NMOD	_	_
31	the	_	DT	DT	_	32	NMOD	_	_
32	patient	_	NN	NN	_	35	NMOD	_	_
33	's	_	POS	POS	_	32	NMOD	_	_
34	T	_	NN	NN	_	35	NMOD	_	_
35	lymphocytes	_	NNS	NNS	_	30	PMOD	_	_
36	to	_	TO	TO	_	37	VMOD	_	_
37	bind	_	VB	VB	_	26	NMOD	_	_
38	response	_	NN	NN	_	39	NMOD	_	_
39	elements	_	NNS	NNS	_	37	OBJ	_	_
40	present	_	JJ	JJ	_	39	NMOD	_	_
41	in	_	IN	IN	_	40	AMOD	_	_
42	the	_	DT	DT	_	44	NMOD	_	_
43	regulatory	_	JJ	JJ	_	44	NMOD	_	_
44	region	_	NN	NN	_	41	PMOD	_	_
45	of	_	IN	IN	_	44	NMOD	_	_
46	IL2	_	NN	NN	_	45	PMOD	_	_
47	.	_	.	.	_	24	P	_	_

1	Nuclear	_	JJ	JJ	_	3	NMOD	_	_
2	factor	_	NN	NN	_	3	NMOD	_	_
3	NF-kB	_	NN	NN	_	18	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	activation	_	NN	NN	_	6	NMOD	_	_
6	protein	_	NN	NN	_	3	COORD	_	_
7	1	_	CD	CD	_	6	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	AP-1	_	NN	NN	_	6	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	,	_	,	,	_	3	P	_	_
12	OCT-1	_	NN	NN	_	3	COORD	_	_
13	,	_	,	,	_	3	P	_	_
14	and	_	CC	CC	_	3	CC	_	_
15	NF-IL-2B	_	NN	NN	_	17	NMOD	_	_
16	binding	_	NN	NN	_	17	NMOD	_	_
17	activity	_	NN	NN	_	3	COORD	_	_
18	were	_	VBD	VBD	_	0	ROOT-S	_	_
19	normal	_	JJ	JJ	_	18	PRD	_	_
20	.	_	.	.	_	18	P	_	_

1	In	_	IN	IN	_	36	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	36	P	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	binding	_	NN	NN	_	36	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	factor	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	activated	_	VBN	VBN	_	13	NMOD	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	10	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	NF-AT	_	NN	NN	_	9	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	to	_	TO	TO	_	5	NMOD	_	_
18	its	_	PRP$	PRP$	_	20	NMOD	_	_
19	response	_	NN	NN	_	20	NMOD	_	_
20	element	_	NN	NN	_	17	PMOD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	IL2	_	NN	NN	_	24	NMOD	_	_
24	enhancer	_	NN	NN	_	21	PMOD	_	_
25	and	_	CC	CC	_	17	CC	_	_
26	to	_	TO	TO	_	17	COORD	_	_
27	an	_	DT	DT	_	30	NMOD	_	_
28	NF-AT-like	_	JJ	JJ	_	30	NMOD	_	_
29	response	_	NN	NN	_	30	NMOD	_	_
30	element	_	NN	NN	_	26	PMOD	_	_
31	present	_	JJ	JJ	_	30	NMOD	_	_
32	in	_	IN	IN	_	31	AMOD	_	_
33	the	_	DT	DT	_	35	NMOD	_	_
34	IL4	_	NN	NN	_	35	NMOD	_	_
35	enhancer	_	NN	NN	_	32	PMOD	_	_
36	was	_	VBD	VBD	_	0	ROOT-S	_	_
37	abnormal	_	JJ	JJ	_	36	PRD	_	_
38	.	_	.	.	_	36	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	ascertain	_	VB	VB	_	17	VMOD	_	_
3	whether	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	abnormal	_	JJ	JJ	_	8	NMOD	_	_
6	NF-AT	_	NN	NN	_	8	NMOD	_	_
7	binding	_	NN	NN	_	8	NMOD	_	_
8	activity	_	NN	NN	_	9	SBJ	_	_
9	was	_	VBD	VBD	_	3	VMOD	_	_
10	related	_	JJ	JJ	_	9	PRD	_	_
11	to	_	TO	TO	_	10	AMOD	_	_
12	an	_	DT	DT	_	14	NMOD	_	_
13	impaired	_	JJ	JJ	_	14	NMOD	_	_
14	function	_	NN	NN	_	11	PMOD	_	_
15	,	_	,	,	_	17	P	_	_
16	we	_	PRP	PRP	_	17	SBJ	_	_
17	transfected	_	VBD	VBD	_	0	ROOT-S	_	_
18	patient	_	NN	NN	_	22	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	control	_	NN	NN	_	18	COORD	_	_
21	T	_	NN	NN	_	22	NMOD	_	_
22	lymphocytes	_	NNS	NNS	_	17	OBJ	_	_
23	with	_	IN	IN	_	17	ADV	_	_
24	constructs	_	NNS	NNS	_	23	PMOD	_	_
25	containing	_	VBG	VBG	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	reporter	_	NN	NN	_	28	NMOD	_	_
28	gene	_	NN	NN	_	25	OBJ	_	_
29	encoding	_	JJ	JJ	_	32	VMOD	_	_
30	chloramphenicol	_	NN	NN	_	32	NMOD	_	_
31	acetyl	_	NN	NN	_	32	NMOD	_	_
32	transferase	_	NN	NN	_	28	NMOD	_	_
33	(	_	(	(	_	34	P	_	_
34	CAT	_	NN	NN	_	32	PRN	_	_
35	)	_	)	)	_	34	P	_	_
36	under	_	IN	IN	_	32	NMOD	_	_
37	the	_	DT	DT	_	38	NMOD	_	_
38	control	_	NN	NN	_	36	PMOD	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	the	_	DT	DT	_	44	NMOD	_	_
41	entire	_	JJ	JJ	_	44	NMOD	_	_
42	IL2	_	NN	NN	_	44	NMOD	_	_
43	regulatory	_	JJ	JJ	_	44	NMOD	_	_
44	region	_	NN	NN	_	39	PMOD	_	_
45	or	_	CC	CC	_	39	CC	_	_
46	of	_	IN	IN	_	39	COORD	_	_
47	multimers	_	NNS	NNS	_	46	PMOD	_	_
48	of	_	IN	IN	_	47	NMOD	_	_
49	individual	_	JJ	JJ	_	51	NMOD	_	_
50	enhancer	_	NN	NN	_	51	NMOD	_	_
51	sequences	_	NNS	NNS	_	48	PMOD	_	_
52	.	_	.	.	_	17	P	_	_

1	CAT	_	NN	NN	_	2	NMOD	_	_
2	expression	_	NN	NN	_	17	SBJ	_	_
3	directed	_	VBN	VBN	_	2	NMOD	_	_
4	by	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	IL2	_	NN	NN	_	8	NMOD	_	_
7	regulatory	_	JJ	JJ	_	8	NMOD	_	_
8	region	_	NN	NN	_	4	PMOD	_	_
9	or	_	CC	CC	_	4	CC	_	_
10	by	_	IN	IN	_	4	LGS	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	multimer	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	NF-AT-binding	_	JJ	JJ	_	16	NMOD	_	_
16	site	_	NN	NN	_	13	PMOD	_	_
17	was	_	VBD	VBD	_	0	ROOT-S	_	_
18	markedly	_	RB	RB	_	19	AMOD	_	_
19	lower	_	JJR	JJR	_	17	PRD	_	_
20	in	_	IN	IN	_	17	ADV	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	patient	_	NN	NN	_	20	PMOD	_	_
23	relative	_	JJ	JJ	_	24	DEP	_	_
24	to	_	TO	TO	_	17	ADV	_	_
25	controls	_	NNS	NNS	_	24	PMOD	_	_
26	.	_	.	.	_	17	P	_	_

1	In	_	IN	IN	_	20	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	20	P	_	_
4	CAT	_	NN	NN	_	6	NMOD	_	_
5	gene	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	20	SBJ	_	_
7	directed	_	VBN	VBN	_	6	NMOD	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	multimer	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	19	NMOD	_	_
13	OCT-1	_	NN	NN	_	16	AMOD	_	_
14	proximal	_	NN	NN	_	16	AMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	OCT-1p	_	NN	NN	_	19	NMOD	_	_
17	)	_	)	)	_	16	P	_	_
18	-binding	_	JJ	JJ	_	16	AMOD	_	_
19	site	_	NN	NN	_	11	PMOD	_	_
20	was	_	VBD	VBD	_	0	ROOT-S	_	_
21	equivalent	_	JJ	JJ	_	20	PRD	_	_
22	in	_	IN	IN	_	20	ADV	_	_
23	patient	_	NN	NN	_	22	PMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	controls	_	NNS	NNS	_	23	COORD	_	_
26	.	_	.	.	_	20	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	an	_	DT	DT	_	6	NMOD	_	_
6	abnormality	_	NN	NN	_	12	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	\/	_	CC	CC	_	7	CC	_	_
9	or	_	CC	CC	_	7	COORD	_	_
10	influencing	_	JJ	JJ	_	7	PMOD	_	_
11	NF-AT	_	NN	NN	_	12	VMOD	_	_
12	may	_	MD	MD	_	4	VMOD	_	_
13	underlie	_	VB	VB	_	16	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	multiple	_	JJ	JJ	_	16	NMOD	_	_
16	lymphokine	_	NN	NN	_	12	OBJ	_	_
17	deficiency	_	NN	NN	_	16	NMOD	_	_
18	in	_	IN	IN	_	19	NMOD	_	_
19	this	_	DT	DT	_	17	PMOD	_	_
20	patient	_	NN	NN	_	3	VMOD	_	_

1	Expression	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	mRNA	_	NN	NN	_	2	PMOD	_	_
4	for	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	GATA-binding	_	JJ	JJ	_	7	NMOD	_	_
7	proteins	_	NNS	NNS	_	4	PMOD	_	_
8	in	_	IN	IN	_	1	NMOD	_	_
9	human	_	JJ	JJ	_	10	NMOD	_	_
10	eosinophils	_	NNS	NNS	_	8	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	basophils	_	NNS	NNS	_	10	COORD	_	_
13	:	_	:	:	_	1	P	_	_
14	potential	_	JJ	JJ	_	15	NMOD	_	_
15	role	_	NN	NN	_	1	NMOD	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	gene	_	NN	NN	_	18	NMOD	_	_
18	transcription	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	expression	_	NN	NN	_	14	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	hematopoietic	_	JJ	JJ	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factors	_	NNS	NNS	_	3	PMOD	_	_
8	GATA-1	_	NN	NN	_	7	NMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	GATA-2	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	8	P	_	_
12	and	_	CC	CC	_	8	CC	_	_
13	GATA-3	_	NN	NN	_	8	COORD	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	studied	_	VBN	VBN	_	14	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	eosinophils	_	NNS	NNS	_	16	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	basophils	_	NNS	NNS	_	17	COORD	_	_
20	.	_	.	.	_	14	P	_	_

1	Eosinophils	_	NNS	NNS	_	2	SBJ	_	_
2	express	_	VBP	VBP	_	0	ROOT-S	_	_
3	mRNA	_	NN	NN	_	2	OBJ	_	_
4	for	_	IN	IN	_	3	NMOD	_	_
5	GATA-1	_	NN	NN	_	4	PMOD	_	_
6	,	_	,	,	_	5	P	_	_
7	GATA-2	_	NN	NN	_	5	COORD	_	_
8	,	_	,	,	_	5	P	_	_
9	and	_	CC	CC	_	5	CC	_	_
10	GATA-3	_	NN	NN	_	5	COORD	_	_
11	.	_	.	.	_	2	P	_	_

1	Basophils	_	NNS	NNS	_	2	SBJ	_	_
2	express	_	VBP	VBP	_	0	ROOT-S	_	_
3	GATA-2	_	NN	NN	_	2	OBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	GATA-3	_	NN	NN	_	3	COORD	_	_
6	.	_	.	.	_	2	P	_	_

1	Treatment	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	HL-60	_	NN	NN	_	5	NMOD	_	_
4	eosinophilic	_	JJ	JJ	_	5	NMOD	_	_
5	sublines	_	NNS	NNS	_	2	PMOD	_	_
6	with	_	IN	IN	_	1	NMOD	_	_
7	either	_	CC	CC	_	8	CC	_	_
8	interleukin-5	_	NN	NN	_	6	PMOD	_	_
9	or	_	CC	CC	_	8	CC	_	_
10	butyric	_	JJ	JJ	_	11	NMOD	_	_
11	acid	_	NN	NN	_	8	COORD	_	_
12	increased	_	VBD	VBD	_	0	ROOT-S	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	expression	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	GATA-1	_	NN	NN	_	17	NMOD	_	_
17	mRNA	_	NN	NN	_	15	PMOD	_	_
18	concomitant	_	JJ	JJ	_	12	VMOD	_	_
19	with	_	IN	IN	_	18	AMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	expression	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	eosinophil-specific	_	JJ	JJ	_	24	NMOD	_	_
24	genes	_	NNS	NNS	_	22	PMOD	_	_
25	,	_	,	,	_	12	P	_	_
26	whereas	_	IN	IN	_	12	COORD	_	_
27	levels	_	NNS	NNS	_	31	SBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	GATA-2	_	NN	NN	_	30	NMOD	_	_
30	mRNA	_	NN	NN	_	28	PMOD	_	_
31	remained	_	VBD	VBD	_	12	COORD	_	_
32	relatively	_	RB	RB	_	33	AMOD	_	_
33	constant	_	JJ	JJ	_	31	PRD	_	_
34	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	presence	_	NN	NN	_	12	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	mRNA	_	NN	NN	_	3	PMOD	_	_
5	for	_	IN	IN	_	4	NMOD	_	_
6	these	_	DT	DT	_	7	NMOD	_	_
7	proteins	_	NNS	NNS	_	5	PMOD	_	_
8	in	_	IN	IN	_	2	NMOD	_	_
9	eosinophils	_	NNS	NNS	_	8	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	basophils	_	NNS	NNS	_	9	COORD	_	_
12	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	that	_	IN	IN	_	12	OBJ	_	_
14	gene	_	NN	NN	_	15	NMOD	_	_
15	transcription	_	NN	NN	_	19	SBJ	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	these	_	DT	DT	_	18	NMOD	_	_
18	lineages	_	NNS	NNS	_	16	PMOD	_	_
19	may	_	MD	MD	_	13	VMOD	_	_
20	be	_	VB	VB	_	19	VC	_	_
21	regulated	_	VBN	VBN	_	20	VC	_	_
22	by	_	IN	IN	_	21	LGS	_	_
23	GATA-binding	_	JJ	JJ	_	24	NMOD	_	_
24	proteins	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	12	P	_	_

1	Proliferation	_	NN	NN	_	2	NMOD	_	_
2	index	_	NN	NN	_	0	ROOT-FRAG	_	_
3	as	_	IN	IN	_	2	NMOD	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	prognostic	_	JJ	JJ	_	6	NMOD	_	_
6	marker	_	NN	NN	_	3	PMOD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	breast	_	NN	NN	_	9	NMOD	_	_
9	cancer	_	NN	NN	_	7	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	BACKGROUND	_	NN	NN	_	0	ROOT-FRAG	_	_
2	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	proliferative	_	JJ	JJ	_	3	NMOD	_	_
3	activity	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	tumors	_	NNS	NNS	_	4	PMOD	_	_
6	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	been	_	VBN	VBN	_	6	VC	_	_
8	extensively	_	RB	RB	_	9	ADV	_	_
9	investigated	_	VBN	VBN	_	7	VC	_	_
10	with	_	IN	IN	_	9	ADV	_	_
11	different	_	JJ	JJ	_	12	NMOD	_	_
12	approaches	_	NNS	NNS	_	10	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	among	_	IN	IN	_	23	ADV	_	_
15	which	_	WDT	WDT	_	14	PMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	use	_	NN	NN	_	23	SBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	monoclonal	_	JJ	JJ	_	22	NMOD	_	_
21	antibody	_	NN	NN	_	22	NMOD	_	_
22	Ki-67	_	NN	NN	_	18	PMOD	_	_
23	represents	_	VBZ	VBZ	_	12	NMOD	_	_
24	an	_	DT	DT	_	28	NMOD	_	_
25	easy	_	JJ	JJ	_	28	NMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	reliable	_	JJ	JJ	_	25	COORD	_	_
28	means	_	NN	NN	_	23	OBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	assessing	_	VBG	VBG	_	29	PMOD	_	_
31	cell	_	NN	NN	_	32	NMOD	_	_
32	proliferation	_	NN	NN	_	30	OBJ	_	_
33	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	13	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	13	P	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	proliferative	_	JJ	JJ	_	7	NMOD	_	_
7	activity	_	NN	NN	_	13	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	129	_	CD	CD	_	12	NMOD	_	_
10	primary	_	JJ	JJ	_	12	NMOD	_	_
11	breast	_	NN	NN	_	12	NMOD	_	_
12	cancers	_	NNS	NNS	_	8	PMOD	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	investigated	_	VBN	VBN	_	13	VC	_	_
15	,	_	,	,	_	13	P	_	_
16	and	_	CC	CC	_	13	CC	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	results	_	NNS	NNS	_	19	SBJ	_	_
19	were	_	VBD	VBD	_	13	COORD	_	_
20	related	_	JJ	JJ	_	19	VC	_	_
21	to	_	TO	TO	_	20	ADV	_	_
22	prognosis	_	NN	NN	_	21	PMOD	_	_
23	.	_	.	.	_	13	P	_	_

1	METHODS	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	.	_	.	.	_	1	P	_	_

1	Tumor	_	NN	NN	_	2	NMOD	_	_
2	samples	_	NNS	NNS	_	18	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	obtained	_	VBN	VBN	_	2	NMOD	_	_
5	from	_	IN	IN	_	4	ADV	_	_
6	129	_	CD	CD	_	7	NMOD	_	_
7	patients	_	NNS	NNS	_	5	PMOD	_	_
8	who	_	WP	WP	_	9	SBJ	_	_
9	underwent	_	VBD	VBD	_	7	NMOD	_	_
10	surgery	_	NN	NN	_	9	OBJ	_	_
11	between	_	IN	IN	_	9	TMP	_	_
12	January	_	NNP	NNP	_	11	PMOD	_	_
13	1987	_	CD	CD	_	12	NMOD	_	_
14	and	_	CC	CC	_	12	CC	_	_
15	December	_	NNP	NNP	_	12	COORD	_	_
16	1988	_	CD	CD	_	15	NMOD	_	_
17	,	_	,	,	_	2	P	_	_
18	were	_	VBD	VBD	_	0	ROOT-S	_	_
19	processed	_	VBN	VBN	_	18	VC	_	_
20	for	_	IN	IN	_	19	ADV	_	_
21	staining	_	VBG	VBG	_	20	PMOD	_	_
22	by	_	IN	IN	_	19	ADV	_	_
23	an	_	DT	DT	_	25	NMOD	_	_
24	immunohistochemical	_	JJ	JJ	_	25	NMOD	_	_
25	procedure	_	NN	NN	_	22	PMOD	_	_
26	(	_	(	(	_	28	P	_	_
27	avidin-biotin	_	NN	NN	_	28	NMOD	_	_
28	complex	_	NN	NN	_	25	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	.	_	.	.	_	18	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	median	_	JJ	JJ	_	3	NMOD	_	_
3	time	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	observation	_	NN	NN	_	4	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	42	_	CD	CD	_	8	NMOD	_	_
8	months	_	NNS	NNS	_	6	PRD	_	_
9	(	_	(	(	_	10	P	_	_
10	range	_	NN	NN	_	6	PRN	_	_
11	,	_	,	,	_	10	P	_	_
12	31-55	_	CD	CD	_	13	NMOD	_	_
13	months	_	NNS	NNS	_	10	PRD	_	_
14	)	_	)	)	_	10	P	_	_
15	.	_	.	.	_	6	P	_	_

1	Life-table	_	JJ	JJ	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	6	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	Mantel-Cox	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	used	_	VBN	VBN	_	6	VC	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	assess	_	VB	VB	_	7	OBJ	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	probability	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	disease-free	_	JJ	JJ	_	14	NMOD	_	_
14	survival	_	NN	NN	_	12	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	DFS	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	and	_	CC	CC	_	14	CC	_	_
19	overall	_	JJ	JJ	_	20	NMOD	_	_
20	survival	_	NN	NN	_	14	COORD	_	_
21	(	_	(	(	_	22	P	_	_
22	OS	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	.	_	.	.	_	6	P	_	_

1	RESULTS	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	.	_	.	.	_	1	P	_	_

1	Tumors	_	NNS	NNS	_	12	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	high	_	JJ	JJ	_	6	NMOD	_	_
4	Ki-67	_	NN	NN	_	6	NMOD	_	_
5	proliferation	_	NN	NN	_	6	NMOD	_	_
6	indices	_	NNS	NNS	_	2	PMOD	_	_
7	(	_	(	(	_	10	P	_	_
8	&gt;	_	JJR	JJR	_	9	DEP	_	_
9	20	_	CD	CD	_	10	NMOD	_	_
10	%	_	NN	NN	_	6	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	were	_	VBD	VBD	_	0	ROOT-S	_	_
13	associated	_	VBN	VBN	_	12	VC	_	_
14	with	_	IN	IN	_	13	ADV	_	_
15	a	_	DT	DT	_	18	NMOD	_	_
16	higher	_	JJR	JJR	_	18	NMOD	_	_
17	4-year	_	JJ	JJ	_	18	NMOD	_	_
18	probability	_	NN	NN	_	14	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	relapse	_	NN	NN	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	disease	_	NN	NN	_	21	PMOD	_	_
23	(	_	(	(	_	32	P	_	_
24	55.3	_	CD	CD	_	25	NMOD	_	_
25	%	_	NN	NN	_	32	DEP	_	_
26	versus	_	CC	CC	_	25	CC	_	_
27	79.1	_	CD	CD	_	28	NMOD	_	_
28	%	_	NN	NN	_	25	COORD	_	_
29	;	_	:	:	_	32	P	_	_
30	P	_	NN	NN	_	32	SBJ	_	_
31	=	_	JJ	JJ	_	32	VMOD	_	_
32	0.003	_	CD	CD	_	20	PRN	_	_
33	)	_	)	)	_	32	P	_	_
34	and	_	CC	CC	_	20	CC	_	_
35	death	_	NN	NN	_	20	COORD	_	_
36	(	_	(	(	_	45	P	_	_
37	71	_	CD	CD	_	38	NMOD	_	_
38	%	_	NN	NN	_	45	DEP	_	_
39	versus	_	CC	CC	_	38	CC	_	_
40	95.6	_	CD	CD	_	41	NMOD	_	_
41	%	_	NN	NN	_	38	COORD	_	_
42	;	_	:	:	_	45	P	_	_
43	P	_	NN	NN	_	45	SBJ	_	_
44	=	_	JJ	JJ	_	45	VMOD	_	_
45	0.00005	_	CD	CD	_	35	PRN	_	_
46	)	_	)	)	_	45	P	_	_
47	when	_	WRB	WRB	_	48	ADV	_	_
48	compared	_	VBN	VBN	_	13	TMP	_	_
49	with	_	IN	IN	_	48	ADV	_	_
50	tumors	_	NNS	NNS	_	49	PMOD	_	_
51	with	_	IN	IN	_	50	NMOD	_	_
52	low	_	JJ	JJ	_	54	NMOD	_	_
53	Ki-67	_	NN	NN	_	54	NMOD	_	_
54	values	_	NNS	NNS	_	51	PMOD	_	_
55	.	_	.	.	_	12	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	7	P	_	_
4	this	_	DT	DT	_	6	NMOD	_	_
5	proliferative	_	JJ	JJ	_	6	NMOD	_	_
6	parameter	_	NN	NN	_	7	SBJ	_	_
7	maintained	_	VBD	VBD	_	0	ROOT-S	_	_
8	its	_	PRP$	PRP$	_	10	NMOD	_	_
9	prognostic	_	JJ	JJ	_	10	NMOD	_	_
10	significance	_	NN	NN	_	7	OBJ	_	_
11	when	_	WRB	WRB	_	15	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	patients	_	NNS	NNS	_	14	SBJ	_	_
14	were	_	VBD	VBD	_	7	TMP	_	_
15	stratified	_	VBN	VBN	_	14	VC	_	_
16	according	_	VBG	VBG	_	15	ADV	_	_
17	to	_	TO	TO	_	16	PMOD	_	_
18	lymph	_	NN	NN	_	20	NMOD	_	_
19	node	_	NN	NN	_	20	NMOD	_	_
20	involvement	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	menopausal	_	JJ	JJ	_	23	NMOD	_	_
23	status	_	NN	NN	_	20	COORD	_	_
24	,	_	,	,	_	20	P	_	_
25	and	_	CC	CC	_	20	CC	_	_
26	nuclear	_	JJ	JJ	_	29	NMOD	_	_
27	estrogen	_	NN	NN	_	29	NMOD	_	_
28	receptor	_	NN	NN	_	29	NMOD	_	_
29	content	_	NN	NN	_	20	COORD	_	_
30	.	_	.	.	_	7	P	_	_

1	CONCLUSIONS	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	.	_	.	.	_	1	P	_	_

1	Tumor	_	NN	NN	_	3	NMOD	_	_
2	proliferative	_	JJ	JJ	_	3	NMOD	_	_
3	activity	_	NN	NN	_	11	SBJ	_	_
4	as	_	IN	IN	_	3	NMOD	_	_
5	evaluated	_	VBN	VBN	_	4	VMOD	_	_
6	by	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	monoclonal	_	JJ	JJ	_	10	NMOD	_	_
9	antibody	_	NN	NN	_	10	NMOD	_	_
10	Ki-67	_	NN	NN	_	6	PMOD	_	_
11	seems	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	be	_	VB	VB	_	11	OBJ	_	_
14	an	_	DT	DT	_	16	NMOD	_	_
15	effective	_	JJ	JJ	_	16	NMOD	_	_
16	indicator	_	NN	NN	_	13	PRD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	prognosis	_	NN	NN	_	17	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	breast	_	NN	NN	_	21	NMOD	_	_
21	cancer	_	NN	NN	_	19	PMOD	_	_
22	for	_	IN	IN	_	16	NMOD	_	_
23	DFS	_	NN	NN	_	22	PMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	OS	_	NN	NN	_	23	COORD	_	_
26	.	_	.	.	_	11	P	_	_

1	Differential	_	JJ	JJ	_	2	NMOD	_	_
2	contribution	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	herpes	_	NN	NN	_	7	NMOD	_	_
5	simplex	_	NN	NN	_	7	NMOD	_	_
6	virus	_	NN	NN	_	7	NMOD	_	_
7	type	_	NN	NN	_	3	PMOD	_	_
8	1	_	CD	CD	_	7	NMOD	_	_
9	gene	_	NN	NN	_	10	NMOD	_	_
10	products	_	NNS	NNS	_	7	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	cellular	_	JJ	JJ	_	13	NMOD	_	_
13	factors	_	NNS	NNS	_	10	COORD	_	_
14	to	_	TO	TO	_	2	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	activation	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	human	_	JJ	JJ	_	23	NMOD	_	_
19	immunodeficiency	_	NN	NN	_	23	NMOD	_	_
20	virus	_	NN	NN	_	23	NMOD	_	_
21	type	_	NN	NN	_	23	NMOD	_	_
22	1	_	CD	CD	_	23	NMOD	_	_
23	provirus	_	NN	NN	_	17	PMOD	_	_
24	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	previously	_	RB	RB	_	2	TMP	_	_
4	reported	_	VBN	VBN	_	2	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	infection	_	NN	NN	_	16	SBJ	_	_
7	with	_	IN	IN	_	6	NMOD	_	_
8	herpes	_	NN	NN	_	11	NMOD	_	_
9	simplex	_	NN	NN	_	11	NMOD	_	_
10	virus	_	NN	NN	_	11	NMOD	_	_
11	type	_	NN	NN	_	7	PMOD	_	_
12	1	_	CD	CD	_	11	NMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	HSV-1	_	NN	NN	_	11	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	activates	_	VBZ	VBZ	_	5	VMOD	_	_
17	expression	_	NN	NN	_	16	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	28	NMOD	_	_
20	human	_	JJ	JJ	_	23	NMOD	_	_
21	immunodeficiency	_	NN	NN	_	23	NMOD	_	_
22	virus	_	NN	NN	_	23	NMOD	_	_
23	type	_	NN	NN	_	28	NMOD	_	_
24	1	_	CD	CD	_	23	NMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	HIV-1	_	NN	NN	_	23	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	provirus	_	NN	NN	_	18	PMOD	_	_
29	in	_	IN	IN	_	17	NMOD	_	_
30	T	_	NN	NN	_	31	NMOD	_	_
31	cells	_	NNS	NNS	_	29	PMOD	_	_
32	.	_	.	.	_	2	P	_	_

1	Activation	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	HIV-1	_	NN	NN	_	5	NMOD	_	_
5	provirus	_	NN	NN	_	2	PMOD	_	_
6	correlated	_	VBD	VBD	_	0	ROOT-S	_	_
7	with	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	activation	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	binding	_	NN	NN	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	55-	_	CD	CD	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	85-kDa	_	JJ	JJ	_	13	COORD	_	_
16	proteins	_	NNS	NNS	_	12	PMOD	_	_
17	to	_	TO	TO	_	11	NMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	kappa	_	NN	NN	_	21	NMOD	_	_
20	B	_	NN	NN	_	21	NMOD	_	_
21	enhancer	_	NN	NN	_	17	PMOD	_	_
22	and	_	CC	CC	_	11	CC	_	_
23	binding	_	NN	NN	_	11	COORD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	28	NMOD	_	_
26	50-kDa	_	JJ	JJ	_	28	NMOD	_	_
27	HLP-1	_	NN	NN	_	28	NMOD	_	_
28	protein	_	NN	NN	_	24	PMOD	_	_
29	to	_	TO	TO	_	23	NMOD	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	LBP-1	_	NN	NN	_	32	NMOD	_	_
32	sequences	_	NNS	NNS	_	29	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	the	_	DT	DT	_	38	NMOD	_	_
35	HIV-1	_	NN	NN	_	38	NMOD	_	_
36	long	_	JJ	JJ	_	38	NMOD	_	_
37	terminal	_	JJ	JJ	_	38	NMOD	_	_
38	repeat	_	NN	NN	_	33	PMOD	_	_
39	.	_	.	.	_	6	P	_	_

1	Further	_	RB	RB	_	2	NMOD	_	_
2	examination	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	this	_	DT	DT	_	5	NMOD	_	_
5	system	_	NN	NN	_	3	PMOD	_	_
6	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	shown	_	VBN	VBN	_	6	VC	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	inhibition	_	NN	NN	_	19	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	HSV-1	_	NN	NN	_	13	NMOD	_	_
13	replication	_	NN	NN	_	11	PMOD	_	_
14	by	_	IN	IN	_	10	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	antiviral	_	JJ	JJ	_	18	NMOD	_	_
17	drug	_	NN	NN	_	18	NMOD	_	_
18	acyclovir	_	NN	NN	_	14	PMOD	_	_
19	does	_	VBZ	VBZ	_	8	VMOD	_	_
20	not	_	RB	RB	_	19	VMOD	_	_
21	inhibit	_	VB	VB	_	19	VC	_	_
22	HSV-1-mediated	_	JJ	JJ	_	23	NMOD	_	_
23	induction	_	NN	NN	_	21	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	HIV-1	_	NN	NN	_	26	NMOD	_	_
26	provirus	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	6	P	_	_

1	Surprisingly	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	the	_	DT	DT	_	9	NMOD	_	_
4	NF-kappa	_	NN	NN	_	5	NMOD	_	_
5	B	_	NN	NN	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	HLP-1	_	NN	NN	_	5	COORD	_	_
8	binding	_	NN	NN	_	9	NMOD	_	_
9	activities	_	NNS	NNS	_	10	SBJ	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	substantially	_	RB	RB	_	12	ADV	_	_
12	inhibited	_	VBN	VBN	_	10	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	acyclovir-treated	_	JJ	JJ	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	13	PMOD	_	_
16	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	transient-transfection	_	JJ	JJ	_	4	NMOD	_	_
4	assay	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	12	P	_	_
6	ICP0	_	NN	NN	_	12	SBJ	_	_
7	,	_	,	,	_	6	P	_	_
8	but	_	CC	CC	_	6	CC	_	_
9	not	_	RB	RB	_	8	COORD	_	_
10	ICP4	_	NN	NN	_	6	COORD	_	_
11	,	_	,	,	_	6	P	_	_
12	activated	_	VBD	VBD	_	0	ROOT-S	_	_
13	the	_	DT	DT	_	19	NMOD	_	_
14	HIV-1	_	NN	NN	_	19	NMOD	_	_
15	long	_	JJ	JJ	_	19	NMOD	_	_
16	terminal	_	JJ	JJ	_	19	NMOD	_	_
17	repeat	_	NN	NN	_	19	NMOD	_	_
18	promoter	_	NN	NN	_	19	NMOD	_	_
19	region	_	NN	NN	_	12	OBJ	_	_
20	and	_	CC	CC	_	12	CC	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	effect	_	NN	NN	_	25	SBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	ICP0	_	NN	NN	_	23	PMOD	_	_
25	was	_	VBD	VBD	_	12	COORD	_	_
26	greatly	_	RB	RB	_	27	ADV	_	_
27	enhanced	_	VBN	VBN	_	25	VC	_	_
28	in	_	IN	IN	_	27	ADV	_	_
29	the	_	DT	DT	_	28	DEP	_	_
30	presence	_	NN	NN	_	28	DEP	_	_
31	of	_	IN	IN	_	28	DEP	_	_
32	the	_	DT	DT	_	36	NMOD	_	_
33	NF-kappa	_	NN	NN	_	36	NMOD	_	_
34	B	_	NN	NN	_	36	NMOD	_	_
35	binding	_	NN	NN	_	36	NMOD	_	_
36	proteins	_	NNS	NNS	_	28	PMOD	_	_
37	,	_	,	,	_	27	P	_	_
38	suggesting	_	VBG	VBG	_	27	OBJ	_	_
39	that	_	IN	IN	_	38	OBJ	_	_
40	induction	_	NN	NN	_	45	SBJ	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	the	_	DT	DT	_	44	NMOD	_	_
43	HIV-1	_	NN	NN	_	44	NMOD	_	_
44	provirus	_	NN	NN	_	41	PMOD	_	_
45	involves	_	VBZ	VBZ	_	39	VMOD	_	_
46	cooperation	_	NN	NN	_	45	OBJ	_	_
47	between	_	IN	IN	_	46	NMOD	_	_
48	the	_	DT	DT	_	51	NMOD	_	_
49	HSV-1-activated	_	JJ	JJ	_	51	NMOD	_	_
50	cellular	_	JJ	JJ	_	51	NMOD	_	_
51	factor	_	NN	NN	_	47	PMOD	_	_
52	,	_	,	,	_	51	P	_	_
53	NF-kappa	_	NN	NN	_	54	NMOD	_	_
54	B	_	NN	NN	_	51	NMOD	_	_
55	,	_	,	,	_	51	P	_	_
56	and	_	CC	CC	_	51	CC	_	_
57	the	_	DT	DT	_	59	NMOD	_	_
58	virus-encoded	_	JJ	JJ	_	59	NMOD	_	_
59	transactivator	_	NN	NN	_	51	COORD	_	_
60	,	_	,	,	_	59	P	_	_
61	ICP0	_	NN	NN	_	59	NMOD	_	_
62	.	_	.	.	_	12	P	_	_

1	Glucocorticoid	_	NN	NN	_	2	NMOD	_	_
2	receptors	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	mononuclear	_	JJ	JJ	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	patients	_	NNS	NNS	_	6	PMOD	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	sepsis	_	NN	NN	_	8	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	Glucocorticoid	_	NN	NN	_	2	NMOD	_	_
2	receptor	_	NN	NN	_	7	NMOD	_	_
3	(	_	(	(	_	4	P	_	_
4	GR	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	hormone-binding	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	8	SBJ	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	studied	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	ADV	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	whole-cell	_	JJ	JJ	_	13	NMOD	_	_
13	method	_	NN	NN	_	10	PMOD	_	_
14	in	_	IN	IN	_	9	ADV	_	_
15	mononuclear	_	JJ	JJ	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	MNC	_	NN	NN	_	16	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	from	_	IN	IN	_	16	NMOD	_	_
21	peripheral	_	JJ	JJ	_	22	NMOD	_	_
22	blood	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	7	_	CD	CD	_	25	NMOD	_	_
25	patients	_	NNS	NNS	_	23	PMOD	_	_
26	during	_	IN	IN	_	9	TMP	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	hemodynamic	_	JJ	JJ	_	30	NMOD	_	_
29	compensatory	_	JJ	JJ	_	30	NMOD	_	_
30	phase	_	NN	NN	_	26	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	sepsis	_	NN	NN	_	31	PMOD	_	_
33	.	_	.	.	_	8	P	_	_

1	4	_	CD	CD	_	2	NMOD	_	_
2	patients	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	receiving	_	VBG	VBG	_	3	VC	_	_
5	dopamine	_	NN	NN	_	4	OBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	which	_	WDT	WDT	_	8	SBJ	_	_
8	did	_	VBD	VBD	_	5	NMOD	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	affect	_	VB	VB	_	8	VC	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	GR	_	NN	NN	_	13	NMOD	_	_
13	count	_	NN	NN	_	10	OBJ	_	_
14	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	patients	_	NNS	NNS	_	6	NMOD	_	_
3	'	_	POS	POS	_	2	NMOD	_	_
4	plasma	_	NN	NN	_	6	NMOD	_	_
5	cortisol	_	NN	NN	_	6	NMOD	_	_
6	concentrations	_	NNS	NNS	_	7	SBJ	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	normal	_	JJ	JJ	_	7	PRD	_	_
9	or	_	CC	CC	_	8	CC	_	_
10	slightly	_	RB	RB	_	11	AMOD	_	_
11	elevated	_	JJ	JJ	_	8	COORD	_	_
12	.	_	.	.	_	7	P	_	_

1	Despite	_	IN	IN	_	17	ADV	_	_
2	a	_	DT	DT	_	4	NMOD	_	_
3	wide	_	JJ	JJ	_	4	NMOD	_	_
4	range	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	17	P	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	mean	_	NN	NN	_	8	NMOD	_	_
8	GR	_	NN	NN	_	17	SBJ	_	_
9	count	_	NN	NN	_	8	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	affinity	_	NN	NN	_	9	COORD	_	_
12	in	_	IN	IN	_	8	NMOD	_	_
13	MNC	_	NN	NN	_	12	PMOD	_	_
14	from	_	IN	IN	_	13	NMOD	_	_
15	septic	_	JJ	JJ	_	16	NMOD	_	_
16	patients	_	NNS	NNS	_	14	PMOD	_	_
17	did	_	VBD	VBD	_	0	ROOT-S	_	_
18	not	_	RB	RB	_	17	VMOD	_	_
19	differ	_	VB	VB	_	17	VC	_	_
20	from	_	IN	IN	_	19	ADV	_	_
21	those	_	DT	DT	_	20	PMOD	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	normal	_	JJ	JJ	_	24	NMOD	_	_
24	controls	_	NNS	NNS	_	22	PMOD	_	_
25	,	_	,	,	_	19	P	_	_
26	suggesting	_	VBG	VBG	_	19	OBJ	_	_
27	that	_	IN	IN	_	26	OBJ	_	_
28	glucocorticoids	_	NNS	NNS	_	29	SBJ	_	_
29	could	_	MD	MD	_	27	VMOD	_	_
30	still	_	RB	RB	_	31	ADV	_	_
31	be	_	VB	VB	_	29	VC	_	_
32	effective	_	JJ	JJ	_	31	PRD	_	_
33	in	_	IN	IN	_	31	ADV	_	_
34	the	_	DT	DT	_	37	NMOD	_	_
35	hemodynamic	_	JJ	JJ	_	37	NMOD	_	_
36	compensatory	_	JJ	JJ	_	37	NMOD	_	_
37	phase	_	NN	NN	_	33	PMOD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	sepsis	_	NN	NN	_	38	PMOD	_	_
40	.	_	.	.	_	17	P	_	_

1	Transcriptional	_	JJ	JJ	_	2	NMOD	_	_
2	activation	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	macrophage	_	NN	NN	_	8	NMOD	_	_
6	colony-stimulating	_	JJ	JJ	_	8	NMOD	_	_
7	factor	_	NN	NN	_	8	NMOD	_	_
8	gene	_	NN	NN	_	3	PMOD	_	_
9	by	_	IN	IN	_	2	NMOD	_	_
10	IL-2	_	NN	NN	_	9	PMOD	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	associated	_	VBN	VBN	_	11	VC	_	_
13	with	_	IN	IN	_	12	ADV	_	_
14	secretion	_	NN	NN	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	bioactive	_	JJ	JJ	_	20	NMOD	_	_
17	macrophage	_	NN	NN	_	20	NMOD	_	_
18	colony-stimulating	_	JJ	JJ	_	20	NMOD	_	_
19	factor	_	NN	NN	_	20	NMOD	_	_
20	protein	_	NN	NN	_	15	PMOD	_	_
21	by	_	IN	IN	_	14	NMOD	_	_
22	monocytes	_	NNS	NNS	_	21	PMOD	_	_
23	and	_	CC	CC	_	11	CC	_	_
24	involves	_	VBZ	VBZ	_	11	COORD	_	_
25	activation	_	NN	NN	_	24	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	31	NMOD	_	_
28	transcription	_	NN	NN	_	31	NMOD	_	_
29	factor	_	NN	NN	_	31	NMOD	_	_
30	NF-kappa	_	NN	NN	_	31	NMOD	_	_
31	B	_	NN	NN	_	26	PMOD	_	_
32	.	_	.	.	_	11	P	_	_

1	Human	_	JJ	JJ	_	3	NMOD	_	_
2	peripheral	_	JJ	JJ	_	3	NMOD	_	_
3	blood	_	NN	NN	_	9	SBJ	_	_
4	monocytes	_	NNS	NNS	_	3	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	Mo	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	constitutively	_	RB	RB	_	9	ADV	_	_
9	display	_	VBP	VBP	_	0	ROOT-S	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	beta-chain	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	receptor	_	NN	NN	_	12	PMOD	_	_
15	for	_	IN	IN	_	14	NMOD	_	_
16	IL-2	_	NN	NN	_	15	PMOD	_	_
17	,	_	,	,	_	9	P	_	_
18	whereas	_	IN	IN	_	9	COORD	_	_
19	expression	_	NN	NN	_	24	SBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	IL-2R	_	NN	NN	_	23	NMOD	_	_
23	alpha-chain	_	NN	NN	_	20	PMOD	_	_
24	is	_	VBZ	VBZ	_	9	COORD	_	_
25	not	_	RB	RB	_	26	AMOD	_	_
26	constitutive	_	JJ	JJ	_	24	PRD	_	_
27	but	_	CC	CC	_	26	CC	_	_
28	inducible	_	JJ	JJ	_	26	COORD	_	_
29	with	_	IN	IN	_	26	AMOD	_	_
30	IL-2	_	NN	NN	_	29	PMOD	_	_
31	.	_	.	.	_	9	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	report	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	binding	_	NN	NN	_	13	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	human	_	JJ	JJ	_	8	NMOD	_	_
8	IL-2	_	NN	NN	_	6	PMOD	_	_
9	to	_	TO	TO	_	5	NMOD	_	_
10	its	_	PRP$	PRP$	_	12	NMOD	_	_
11	binding	_	VBG	VBG	_	12	NMOD	_	_
12	site	_	NN	NN	_	9	PMOD	_	_
13	leads	_	VBZ	VBZ	_	4	VMOD	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	transcriptional	_	JJ	JJ	_	16	NMOD	_	_
16	activation	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	24	NMOD	_	_
19	macrophage	_	NN	NN	_	20	NMOD	_	_
20	CSF	_	NN	NN	_	24	NMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	M-CSF	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	gene	_	NN	NN	_	17	PMOD	_	_
25	in	_	IN	IN	_	16	NMOD	_	_
26	Mo	_	NN	NN	_	25	PMOD	_	_
27	resulting	_	VBG	VBG	_	16	NMOD	_	_
28	in	_	IN	IN	_	27	ADV	_	_
29	accumulation	_	NN	NN	_	28	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	M-CSF	_	NN	NN	_	32	NMOD	_	_
32	mRNA	_	NN	NN	_	30	PMOD	_	_
33	and	_	CC	CC	_	29	CC	_	_
34	subsequent	_	JJ	JJ	_	35	NMOD	_	_
35	release	_	NN	NN	_	29	COORD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	bioactive	_	JJ	JJ	_	39	NMOD	_	_
38	M-CSF	_	NN	NN	_	39	NMOD	_	_
39	protein	_	NN	NN	_	36	PMOD	_	_
40	as	_	IN	IN	_	29	NMOD	_	_
41	demonstrated	_	VBN	VBN	_	40	VMOD	_	_
42	by	_	IN	IN	_	41	LGS	_	_
43	ELISA	_	NN	NN	_	42	PMOD	_	_
44	and	_	CC	CC	_	16	CC	_	_
45	inhibition	_	NN	NN	_	16	COORD	_	_
46	of	_	IN	IN	_	45	NMOD	_	_
47	IL-2	_	NN	NN	_	49	NMOD	_	_
48	induced	_	JJ	JJ	_	47	AMOD	_	_
49	release	_	NN	NN	_	46	PMOD	_	_
50	of	_	IN	IN	_	49	NMOD	_	_
51	an	_	DT	DT	_	53	NMOD	_	_
52	activity-stimulating	_	JJ	JJ	_	53	NMOD	_	_
53	growth	_	NN	NN	_	50	PMOD	_	_
54	of	_	IN	IN	_	53	NMOD	_	_
55	monocyte-type	_	JJ	JJ	_	56	NMOD	_	_
56	colonies	_	NNS	NNS	_	54	PMOD	_	_
57	by	_	IN	IN	_	45	NMOD	_	_
58	a	_	DT	DT	_	61	NMOD	_	_
59	neutralizing	_	VBG	VBG	_	61	NMOD	_	_
60	anti-M-CSF	_	JJ	JJ	_	61	NMOD	_	_
61	antibody	_	NN	NN	_	57	PMOD	_	_
62	.	_	.	.	_	3	P	_	_

1	Transcriptional	_	JJ	JJ	_	2	NMOD	_	_
2	activation	_	NN	NN	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	M-CSF	_	NN	NN	_	6	NMOD	_	_
6	gene	_	NN	NN	_	3	PMOD	_	_
7	by	_	IN	IN	_	2	NMOD	_	_
8	IL-2	_	NN	NN	_	7	PMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	preceded	_	VBN	VBN	_	9	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	enhanced	_	VBN	VBN	_	14	NMOD	_	_
13	binding	_	NN	NN	_	14	NMOD	_	_
14	activity	_	NN	NN	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	transcription	_	NN	NN	_	20	NMOD	_	_
18	factor	_	NN	NN	_	20	NMOD	_	_
19	NF-kappa	_	NN	NN	_	20	NMOD	_	_
20	B	_	NN	NN	_	15	PMOD	_	_
21	to	_	TO	TO	_	14	NMOD	_	_
22	its	_	PRP$	PRP$	_	24	NMOD	_	_
23	recognition	_	NN	NN	_	24	NMOD	_	_
24	sequence	_	NN	NN	_	21	PMOD	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	30	NMOD	_	_
27	5'	_	JJ	JJ	_	30	NMOD	_	_
28	regulatory	_	JJ	JJ	_	30	NMOD	_	_
29	enhancer	_	NN	NN	_	30	NMOD	_	_
30	region	_	NN	NN	_	25	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	M-CSF	_	NN	NN	_	34	NMOD	_	_
34	gene	_	NN	NN	_	31	PMOD	_	_
35	.	_	.	.	_	9	P	_	_

1	Moreover	_	RB	RB	_	21	ADV	_	_
2	,	_	,	,	_	21	P	_	_
3	using	_	VBG	VBG	_	21	VC	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	heterologous	_	JJ	JJ	_	6	NMOD	_	_
6	promoter	_	NN	NN	_	12	NMOD	_	_
7	(	_	(	(	_	10	P	_	_
8	herpes	_	NN	NN	_	10	NMOD	_	_
9	thymidine	_	NN	NN	_	10	NMOD	_	_
10	kinase	_	NN	NN	_	6	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	construct	_	NN	NN	_	3	OBJ	_	_
13	containing	_	VBG	VBG	_	12	NMOD	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	NF-kappa	_	NN	NN	_	18	NMOD	_	_
16	B	_	NN	NN	_	18	NMOD	_	_
17	consensus	_	NN	NN	_	18	NMOD	_	_
18	sequence	_	NN	NN	_	13	OBJ	_	_
19	,	_	,	,	_	21	P	_	_
20	it	_	PRP	PRP	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
22	shown	_	VBN	VBN	_	21	VC	_	_
23	that	_	IN	IN	_	22	OBJ	_	_
24	NF-kappa	_	NN	NN	_	26	NMOD	_	_
25	B	_	NN	NN	_	26	NMOD	_	_
26	binding	_	NN	NN	_	33	SBJ	_	_
27	by	_	IN	IN	_	26	NMOD	_	_
28	an	_	DT	DT	_	32	NMOD	_	_
29	IL-2-induced	_	JJ	JJ	_	32	NMOD	_	_
30	monocyte-derived	_	JJ	JJ	_	32	NMOD	_	_
31	nuclear	_	JJ	JJ	_	32	NMOD	_	_
32	protein	_	NN	NN	_	27	PMOD	_	_
33	confers	_	VBZ	VBZ	_	23	VMOD	_	_
34	reporter	_	NN	NN	_	35	NMOD	_	_
35	gene	_	NN	NN	_	41	NMOD	_	_
36	(	_	(	(	_	39	P	_	_
37	human	_	JJ	JJ	_	39	NMOD	_	_
38	growth	_	NN	NN	_	39	NMOD	_	_
39	hormone	_	NN	NN	_	35	PRN	_	_
40	)	_	)	)	_	39	P	_	_
41	activity	_	NN	NN	_	33	OBJ	_	_
42	.	_	.	.	_	21	P	_	_

1	Taken	_	VBN	VBN	_	6	VMOD	_	_
2	together	_	RB	RB	_	1	ADV	_	_
3	,	_	,	,	_	6	P	_	_
4	our	_	PRP$	PRP$	_	5	NMOD	_	_
5	findings	_	NNS	NNS	_	6	SBJ	_	_
6	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	IL-2	_	NN	NN	_	9	SBJ	_	_
9	induces	_	VBZ	VBZ	_	7	VMOD	_	_
10	gene	_	NN	NN	_	11	NMOD	_	_
11	expression	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	M-CSF	_	NN	NN	_	12	PMOD	_	_
14	in	_	IN	IN	_	11	NMOD	_	_
15	human	_	JJ	JJ	_	17	NMOD	_	_
16	blood-derived	_	JJ	JJ	_	17	NMOD	_	_
17	Mo	_	NN	NN	_	14	PMOD	_	_
18	and	_	CC	CC	_	6	CC	_	_
19	provide	_	VBP	VBP	_	6	COORD	_	_
20	evidence	_	NN	NN	_	19	OBJ	_	_
21	for	_	IN	IN	_	20	NMOD	_	_
22	involvement	_	NN	NN	_	21	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	NF-kappa	_	NN	NN	_	25	NMOD	_	_
25	B	_	NN	NN	_	23	PMOD	_	_
26	in	_	IN	IN	_	22	NMOD	_	_
27	transcriptional	_	JJ	JJ	_	28	NMOD	_	_
28	regulation	_	NN	NN	_	26	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	this	_	DT	DT	_	31	NMOD	_	_
31	gene	_	NN	NN	_	29	PMOD	_	_
32	.	_	.	.	_	6	P	_	_

1	Comparative	_	JJ	JJ	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NFAT	_	NN	NN	_	3	PMOD	_	_
5	(	_	(	(	_	7	P	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	factor	_	NN	NN	_	4	PRN	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	activated	_	VBN	VBN	_	11	NMOD	_	_
10	T	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	8	PMOD	_	_
12	)	_	)	)	_	7	P	_	_
13	complex	_	JJ	JJ	_	4	NMOD	_	_
14	in	_	IN	IN	_	4	NMOD	_	_
15	human	_	JJ	JJ	_	19	NMOD	_	_
16	T	_	NN	NN	_	19	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	B	_	NN	NN	_	16	COORD	_	_
19	lymphocytes	_	NNS	NNS	_	14	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	Nuclear	_	JJ	JJ	_	2	NMOD	_	_
2	factor	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	activated	_	VBN	VBN	_	6	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	3	PMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	NFAT	_	NN	NN	_	2	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	transcriptional	_	JJ	JJ	_	13	NMOD	_	_
13	activator	_	NN	NN	_	10	PRD	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	binds	_	VBZ	VBZ	_	13	NMOD	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	sequences	_	NNS	NNS	_	16	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	24	NMOD	_	_
20	interleukin-2	_	NN	NN	_	24	NMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	IL-2	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	promoter	_	NN	NN	_	18	PMOD	_	_
25	and	_	CC	CC	_	10	CC	_	_
26	is	_	VBZ	VBZ	_	10	COORD	_	_
27	thought	_	VBN	VBN	_	26	VC	_	_
28	to	_	TO	TO	_	29	VMOD	_	_
29	be	_	VB	VB	_	27	OBJ	_	_
30	largely	_	RB	RB	_	31	AMOD	_	_
31	responsible	_	JJ	JJ	_	29	PRD	_	_
32	for	_	IN	IN	_	31	AMOD	_	_
33	the	_	DT	DT	_	36	NMOD	_	_
34	T	_	NN	NN	_	36	NMOD	_	_
35	cell-specific	_	JJ	JJ	_	34	AMOD	_	_
36	inducibility	_	NN	NN	_	32	PMOD	_	_
37	of	_	IN	IN	_	36	NMOD	_	_
38	IL-2	_	NN	NN	_	39	NMOD	_	_
39	expression	_	NN	NN	_	37	PMOD	_	_
40	.	_	.	.	_	10	P	_	_

1	Electrophoretic	_	JJ	JJ	_	4	NMOD	_	_
2	mobility	_	NN	NN	_	4	NMOD	_	_
3	shift	_	NN	NN	_	4	NMOD	_	_
4	assays	_	NNS	NNS	_	8	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	EMSA	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	showed	_	VBD	VBD	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	specific	_	JJ	JJ	_	13	NMOD	_	_
11	NFAT	_	NN	NN	_	13	NMOD	_	_
12	binding	_	NN	NN	_	13	NMOD	_	_
13	activity	_	NN	NN	_	14	SBJ	_	_
14	could	_	MD	MD	_	9	VMOD	_	_
15	also	_	RB	RB	_	14	ADV	_	_
16	be	_	VB	VB	_	14	VC	_	_
17	induced	_	VBN	VBN	_	16	VC	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	human	_	JJ	JJ	_	21	NMOD	_	_
20	B	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	18	PMOD	_	_
22	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	B	_	NN	NN	_	5	NMOD	_	_
3	cell	_	NN	NN	_	5	NMOD	_	_
4	NFAT	_	NN	NN	_	5	NMOD	_	_
5	complex	_	NN	NN	_	9	SBJ	_	_
6	,	_	,	,	_	9	P	_	_
7	however	_	RB	RB	_	9	ADV	_	_
8	,	_	,	,	_	9	P	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	not	_	RB	RB	_	9	VMOD	_	_
11	functional	_	JJ	JJ	_	9	PRD	_	_
12	,	_	,	,	_	9	P	_	_
13	since	_	IN	IN	_	9	ADV	_	_
14	it	_	PRP	PRP	_	15	SBJ	_	_
15	failed	_	VBD	VBD	_	13	VMOD	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	activate	_	VB	VB	_	15	OBJ	_	_
18	transcription	_	NN	NN	_	17	OBJ	_	_
19	from	_	IN	IN	_	18	NMOD	_	_
20	an	_	DT	DT	_	27	NMOD	_	_
21	NFAT-driven	_	JJ	JJ	_	27	NMOD	_	_
22	chloramphenicol	_	NN	NN	_	23	NMOD	_	_
23	acetyltransferase	_	NN	NN	_	27	NMOD	_	_
24	(	_	(	(	_	25	P	_	_
25	CAT	_	NN	NN	_	23	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	construct	_	NN	NN	_	19	PMOD	_	_
28	.	_	.	.	_	9	P	_	_

1	Competition	_	NN	NN	_	12	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	an	_	DT	DT	_	5	NMOD	_	_
4	AP-1	_	NN	NN	_	5	NMOD	_	_
5	motif	_	NN	NN	_	2	PMOD	_	_
6	or	_	CC	CC	_	2	CC	_	_
7	with	_	IN	IN	_	2	COORD	_	_
8	anti-Jun	_	JJ	JJ	_	11	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	anti-Fos	_	JJ	JJ	_	8	COORD	_	_
11	antibodies	_	NNS	NNS	_	7	PMOD	_	_
12	abolished	_	VBD	VBD	_	0	ROOT-S	_	_
13	binding	_	NN	NN	_	12	IOBJ	_	_
14	to	_	TO	TO	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	NFAT	_	NN	NN	_	17	NMOD	_	_
17	motif	_	NN	NN	_	14	PMOD	_	_
18	in	_	IN	IN	_	13	NMOD	_	_
19	both	_	CC	CC	_	20	CC	_	_
20	T	_	NN	NN	_	23	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	B	_	NN	NN	_	20	COORD	_	_
23	cells	_	NNS	NNS	_	18	PMOD	_	_
24	,	_	,	,	_	12	P	_	_
25	indicating	_	VBG	VBG	_	12	OBJ	_	_
26	that	_	IN	IN	_	25	OBJ	_	_
27	Jun	_	NN	NN	_	30	SBJ	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	Fos	_	NN	NN	_	27	COORD	_	_
30	are	_	VBP	VBP	_	26	VMOD	_	_
31	critical	_	JJ	JJ	_	30	PRD	_	_
32	for	_	IN	IN	_	31	AMOD	_	_
33	NFAT	_	NN	NN	_	35	NMOD	_	_
34	complex	_	NN	NN	_	35	NMOD	_	_
35	formation	_	NN	NN	_	32	PMOD	_	_
36	in	_	IN	IN	_	35	NMOD	_	_
37	both	_	DT	DT	_	39	NMOD	_	_
38	cell	_	NN	NN	_	39	NMOD	_	_
39	types	_	NNS	NNS	_	36	PMOD	_	_
40	.	_	.	.	_	12	P	_	_

1	Purified	_	VBN	VBN	_	6	NMOD	_	_
2	recombinant	_	JJ	JJ	_	6	NMOD	_	_
3	Jun	_	NN	NN	_	6	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	Fos	_	NN	NN	_	3	COORD	_	_
6	proteins	_	NNS	NNS	_	7	SBJ	_	_
7	failed	_	VBD	VBD	_	0	ROOT-S	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	bind	_	VB	VB	_	7	OBJ	_	_
10	directly	_	RB	RB	_	9	ADV	_	_
11	to	_	TO	TO	_	9	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	NFAT	_	NN	NN	_	14	NMOD	_	_
14	motif	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	7	P	_	_

1	However	_	RB	RB	_	21	ADV	_	_
2	,	_	,	,	_	21	P	_	_
3	when	_	WRB	WRB	_	4	ADV	_	_
4	combined	_	VBN	VBN	_	21	TMP	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	unstimulated	_	JJ	JJ	_	11	NMOD	_	_
7	B	_	NN	NN	_	11	NMOD	_	_
8	or	_	CC	CC	_	7	CC	_	_
9	T	_	NN	NN	_	7	COORD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	extracts	_	NNS	NNS	_	5	PMOD	_	_
12	,	_	,	,	_	21	P	_	_
13	full-length	_	JJ	JJ	_	20	NMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	but	_	CC	CC	_	13	CC	_	_
16	not	_	RB	RB	_	17	AMOD	_	_
17	truncated	_	VBN	VBN	_	13	COORD	_	_
18	,	_	,	,	_	13	P	_	_
19	Jun\/Fos	_	NN	NN	_	20	NMOD	_	_
20	heterodimers	_	NNS	NNS	_	21	SBJ	_	_
21	were	_	VBD	VBD	_	0	ROOT-S	_	_
22	able	_	JJ	JJ	_	21	PRD	_	_
23	to	_	TO	TO	_	24	VMOD	_	_
24	form	_	VB	VB	_	22	AMOD	_	_
25	an	_	DT	DT	_	27	NMOD	_	_
26	NFAT	_	NN	NN	_	27	NMOD	_	_
27	complex	_	NN	NN	_	24	IOBJ	_	_
28	,	_	,	,	_	24	P	_	_
29	indicating	_	VBG	VBG	_	24	OBJ	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	presence	_	NN	NN	_	29	OBJ	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	a	_	DT	DT	_	39	NMOD	_	_
34	constitutively	_	RB	RB	_	35	AMOD	_	_
35	expressed	_	VBN	VBN	_	39	NMOD	_	_
36	nuclear	_	JJ	JJ	_	39	NMOD	_	_
37	factor	_	NN	NN	_	39	NMOD	_	_
38	(	_	(	(	_	39	P	_	_
39	s	_	NNS	NNS	_	32	PMOD	_	_
40	)	_	)	)	_	39	P	_	_
41	in	_	IN	IN	_	31	NMOD	_	_
42	B	_	NN	NN	_	45	NMOD	_	_
43	and	_	CC	CC	_	42	CC	_	_
44	T	_	NN	NN	_	42	COORD	_	_
45	cells	_	NNS	NNS	_	41	PMOD	_	_
46	necessary	_	JJ	JJ	_	31	NMOD	_	_
47	for	_	IN	IN	_	46	AMOD	_	_
48	the	_	DT	DT	_	49	NMOD	_	_
49	formation	_	NN	NN	_	47	PMOD	_	_
50	of	_	IN	IN	_	49	NMOD	_	_
51	the	_	DT	DT	_	53	NMOD	_	_
52	NFAT	_	NN	NN	_	53	NMOD	_	_
53	complex	_	NN	NN	_	50	PMOD	_	_
54	in	_	IN	IN	_	46	AMOD	_	_
55	both	_	DT	DT	_	57	NMOD	_	_
56	cell	_	NN	NN	_	57	NMOD	_	_
57	types	_	NNS	NNS	_	54	PMOD	_	_
58	.	_	.	.	_	21	P	_	_

1	An	_	DT	DT	_	3	NMOD	_	_
2	NFAT	_	NN	NN	_	3	NMOD	_	_
3	oligonucleotide	_	NN	NN	_	15	SBJ	_	_
4	carrying	_	VBG	VBG	_	3	NMOD	_	_
5	mutations	_	NNS	NNS	_	4	OBJ	_	_
6	in	_	IN	IN	_	4	ADV	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	5'	_	JJ	JJ	_	10	NMOD	_	_
9	purine-rich	_	JJ	JJ	_	10	NMOD	_	_
10	part	_	NN	NN	_	6	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	NFAT	_	NN	NN	_	14	NMOD	_	_
14	sequence	_	NN	NN	_	11	PMOD	_	_
15	failed	_	VBD	VBD	_	0	ROOT-S	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	form	_	VB	VB	_	15	OBJ	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	complex	_	NN	NN	_	17	OBJ	_	_
20	and	_	CC	CC	_	17	CC	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	compete	_	VB	VB	_	17	COORD	_	_
23	with	_	IN	IN	_	22	ADV	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	wild	_	JJ	JJ	_	27	NMOD	_	_
26	type	_	NN	NN	_	27	NMOD	_	_
27	motif	_	NN	NN	_	23	PMOD	_	_
28	for	_	IN	IN	_	22	ADV	_	_
29	NFAT	_	NN	NN	_	31	NMOD	_	_
30	complex	_	NN	NN	_	31	NMOD	_	_
31	formation	_	NN	NN	_	28	PMOD	_	_
32	in	_	IN	IN	_	17	ADV	_	_
33	both	_	CC	CC	_	34	CC	_	_
34	T	_	NN	NN	_	37	NMOD	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	B	_	NN	NN	_	34	COORD	_	_
37	cells	_	NNS	NNS	_	32	PMOD	_	_
38	.	_	.	.	_	15	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	therefore	_	RB	RB	_	3	ADV	_	_
3	propose	_	VBP	VBP	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	model	_	NN	NN	_	3	OBJ	_	_
6	whereby	_	WRB	WRB	_	22	ADV	_	_
7	a	_	DT	DT	_	10	NMOD	_	_
8	core	_	NN	NN	_	10	NMOD	_	_
9	NFAT	_	NN	NN	_	10	NMOD	_	_
10	complex	_	NN	NN	_	22	SBJ	_	_
11	consisting	_	VBG	VBG	_	10	NMOD	_	_
12	of	_	IN	IN	_	11	ADV	_	_
13	Jun	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	Fos	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	13	P	_	_
17	and	_	CC	CC	_	13	CC	_	_
18	a	_	DT	DT	_	21	NMOD	_	_
19	constitutive	_	JJ	JJ	_	21	NMOD	_	_
20	nuclear	_	JJ	JJ	_	21	NMOD	_	_
21	factor	_	NN	NN	_	13	COORD	_	_
22	is	_	VBZ	VBZ	_	5	NMOD	_	_
23	formed	_	VBN	VBN	_	22	VC	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	both	_	DT	DT	_	26	NMOD	_	_
26	T	_	NN	NN	_	29	NMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	B	_	NN	NN	_	26	COORD	_	_
29	cells	_	NNS	NNS	_	24	PMOD	_	_
30	,	_	,	,	_	22	P	_	_
31	but	_	CC	CC	_	22	CC	_	_
32	an	_	DT	DT	_	34	NMOD	_	_
33	additional	_	JJ	JJ	_	34	NMOD	_	_
34	factor	_	NN	NN	_	47	SBJ	_	_
35	and\/or	_	CC	CC	_	34	CC	_	_
36	post-translational	_	JJ	JJ	_	37	NMOD	_	_
37	modification	_	NN	NN	_	34	COORD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	a	_	DT	DT	_	40	NMOD	_	_
40	factor	_	NN	NN	_	38	PMOD	_	_
41	,	_	,	,	_	34	P	_	_
42	missing	_	VBG	VBG	_	34	NMOD	_	_
43	in	_	IN	IN	_	42	AMOD	_	_
44	B	_	NN	NN	_	45	NMOD	_	_
45	cells	_	NNS	NNS	_	43	PMOD	_	_
46	,	_	,	,	_	34	P	_	_
47	might	_	MD	MD	_	22	COORD	_	_
48	be	_	VB	VB	_	47	VC	_	_
49	required	_	VBN	VBN	_	48	VC	_	_
50	for	_	IN	IN	_	49	ADV	_	_
51	transactivation	_	NN	NN	_	50	PMOD	_	_
52	by	_	IN	IN	_	51	NMOD	_	_
53	NFAT	_	NN	NN	_	52	PMOD	_	_
54	.	_	.	.	_	3	P	_	_

1	1,25-Dihydroxy	_	NN	NN	_	3	NMOD	_	_
2	vitamin	_	NN	NN	_	3	NMOD	_	_
3	D3	_	NN	NN	_	8	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	12-O-tetradecanoyl	_	NN	NN	_	6	NMOD	_	_
6	phorbol-13-acetate	_	NN	NN	_	3	COORD	_	_
7	synergistically	_	RB	RB	_	8	ADV	_	_
8	induce	_	VBP	VBP	_	0	ROOT-S	_	_
9	monocytic	_	JJ	JJ	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	differentiation	_	NN	NN	_	8	OBJ	_	_
12	:	_	:	:	_	11	P	_	_
13	FOS	_	NN	NN	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	RB	_	NN	NN	_	13	COORD	_	_
16	expression	_	NN	NN	_	11	NMOD	_	_
17	.	_	.	.	_	8	P	_	_

1	1,25-dihydroxy	_	NN	NN	_	3	NMOD	_	_
2	vitamin	_	NN	NN	_	3	NMOD	_	_
3	D3	_	NN	NN	_	10	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	12-O-tetradecanoyl	_	NN	NN	_	6	NMOD	_	_
6	phorbol-13-acetate	_	NN	NN	_	3	COORD	_	_
7	(	_	(	(	_	8	P	_	_
8	TPA	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	interact	_	VBP	VBP	_	0	ROOT-S	_	_
11	synergistically	_	RB	RB	_	10	ADV	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	induce	_	VB	VB	_	10	OBJ	_	_
14	monocytic	_	JJ	JJ	_	15	NMOD	_	_
15	differentiation	_	NN	NN	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	U937	_	NN	NN	_	20	NMOD	_	_
18	histiocytic	_	JJ	JJ	_	20	NMOD	_	_
19	lymphoma	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	16	PMOD	_	_
21	.	_	.	.	_	10	P	_	_

1	Addition	_	NN	NN	_	4	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	TPA	_	NN	NN	_	2	PMOD	_	_
4	causes	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	an	_	DT	DT	_	8	NMOD	_	_
6	otherwise	_	JJ	JJ	_	7	AMOD	_	_
7	ineffective	_	JJ	JJ	_	8	NMOD	_	_
8	dose	_	NN	NN	_	14	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	1,25-dihydroxy	_	NN	NN	_	12	NMOD	_	_
11	vitamin	_	NN	NN	_	12	NMOD	_	_
12	D3	_	NN	NN	_	9	PMOD	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	induce	_	VB	VB	_	4	OBJ	_	_
15	differentiation	_	NN	NN	_	14	OBJ	_	_
16	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	induced	_	VBD	VBD	_	3	NMOD	_	_
3	differentiation	_	NN	NN	_	4	SBJ	_	_
4	depends	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	on	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	12	NMOD	_	_
7	simultaneous	_	JJ	JJ	_	12	TMP	_	_
8	(	_	(	(	_	7	P	_	_
9	vs.	_	CC	CC	_	7	CC	_	_
10	sequential	_	JJ	JJ	_	7	COORD	_	_
11	)	_	)	)	_	7	P	_	_
12	presence	_	NN	NN	_	5	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	both	_	DT	DT	_	15	NMOD	_	_
15	agents	_	NNS	NNS	_	13	PMOD	_	_
16	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	kinetics	_	NNS	NNS	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	induced	_	JJ	JJ	_	5	NMOD	_	_
5	differentiation	_	NN	NN	_	3	PMOD	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	consistent	_	JJ	JJ	_	6	PRD	_	_
8	with	_	IN	IN	_	7	AMOD	_	_
9	a	_	DT	DT	_	13	NMOD	_	_
10	G1	_	NN	NN	_	13	NMOD	_	_
11	specific	_	JJ	JJ	_	10	AMOD	_	_
12	cellular	_	JJ	JJ	_	13	NMOD	_	_
13	response	_	NN	NN	_	8	PMOD	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	initiate	_	VB	VB	_	13	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	metabolic	_	JJ	JJ	_	18	NMOD	_	_
18	cascade	_	NN	NN	_	15	OBJ	_	_
19	culminating	_	VBG	VBG	_	18	NMOD	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	cell	_	NN	NN	_	22	NMOD	_	_
22	differentiation	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	induced	_	VBD	VBD	_	3	NMOD	_	_
3	differentiation	_	NN	NN	_	4	SBJ	_	_
4	occurs	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	down-regulation	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	c-fos	_	NN	NN	_	9	NMOD	_	_
9	protein	_	NN	NN	_	7	PMOD	_	_
10	and	_	CC	CC	_	6	CC	_	_
11	an	_	DT	DT	_	13	NMOD	_	_
12	accompanying	_	VBG	VBG	_	13	NMOD	_	_
13	up-regulation	_	NN	NN	_	6	COORD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	RB	_	NN	NN	_	17	NMOD	_	_
16	protein	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	14	PMOD	_	_
18	,	_	,	,	_	4	P	_	_
19	consistent	_	JJ	JJ	_	4	VMOD	_	_
20	with	_	IN	IN	_	19	AMOD	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	possible	_	JJ	JJ	_	23	NMOD	_	_
23	need	_	NN	NN	_	20	PMOD	_	_
24	for	_	IN	IN	_	23	NMOD	_	_
25	up-regulated	_	JJ	JJ	_	27	NMOD	_	_
26	RB	_	NN	NN	_	27	NMOD	_	_
27	expression	_	NN	NN	_	29	SBJ	_	_
28	to	_	TO	TO	_	29	VMOD	_	_
29	maintain	_	VB	VB	_	24	VMOD	_	_
30	a	_	DT	DT	_	33	NMOD	_	_
31	given	_	JJ	JJ	_	33	NMOD	_	_
32	differentiated	_	VBN	VBN	_	33	NMOD	_	_
33	phenotype	_	NN	NN	_	29	OBJ	_	_
34	and	_	CC	CC	_	29	CC	_	_
35	suppress	_	VB	VB	_	29	COORD	_	_
36	transcriptional	_	JJ	JJ	_	37	NMOD	_	_
37	activators	_	NNS	NNS	_	35	OBJ	_	_
38	that	_	WDT	WDT	_	39	SBJ	_	_
39	might	_	MD	MD	_	37	NMOD	_	_
40	typically	_	RB	RB	_	41	ADV	_	_
41	be	_	VB	VB	_	39	VC	_	_
42	associated	_	VBN	VBN	_	41	VC	_	_
43	with	_	IN	IN	_	42	ADV	_	_
44	proliferation	_	NN	NN	_	43	PMOD	_	_
45	.	_	.	.	_	4	P	_	_

1	Differential	_	JJ	JJ	_	2	NMOD	_	_
2	autoregulation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	glucocorticoid	_	NN	NN	_	6	NMOD	_	_
5	receptor	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	3	PMOD	_	_
7	in	_	IN	IN	_	2	NMOD	_	_
8	human	_	JJ	JJ	_	12	NMOD	_	_
9	T-	_	NN	NN	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	B-cell	_	NN	NN	_	9	COORD	_	_
12	lines	_	NNS	NNS	_	7	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	Regulation	_	NN	NN	_	13	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	glucocorticoid	_	NN	NN	_	4	NMOD	_	_
4	receptor	_	NN	NN	_	8	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	GR	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	expression	_	NN	NN	_	2	PMOD	_	_
9	by	_	IN	IN	_	1	NMOD	_	_
10	its	_	PRP$	PRP$	_	12	NMOD	_	_
11	cognate	_	JJ	JJ	_	12	NMOD	_	_
12	ligand	_	NN	NN	_	9	PMOD	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	examined	_	VBN	VBN	_	13	VC	_	_
15	in	_	IN	IN	_	14	ADV	_	_
16	the	_	DT	DT	_	22	NMOD	_	_
17	glucocorticoid-sensitive	_	JJ	JJ	_	22	NMOD	_	_
18	human	_	JJ	JJ	_	22	NMOD	_	_
19	leukemic	_	JJ	JJ	_	22	NMOD	_	_
20	T-cell	_	NN	NN	_	22	NMOD	_	_
21	line	_	NN	NN	_	22	NMOD	_	_
22	6TG1.1	_	NN	NN	_	15	PMOD	_	_
23	and	_	CC	CC	_	15	CC	_	_
24	in	_	IN	IN	_	15	COORD	_	_
25	the	_	DT	DT	_	29	NMOD	_	_
26	human	_	JJ	JJ	_	29	NMOD	_	_
27	B-cell	_	NN	NN	_	29	NMOD	_	_
28	line	_	NN	NN	_	29	NMOD	_	_
29	IM-9	_	NN	NN	_	24	PMOD	_	_
30	.	_	.	.	_	13	P	_	_

1	In	_	IN	IN	_	27	ADV	_	_
2	contrast	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	decrease	_	NN	NN	_	1	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	GR	_	NN	NN	_	8	NMOD	_	_
8	mRNA	_	NN	NN	_	6	PMOD	_	_
9	seen	_	VBN	VBN	_	5	NMOD	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	IM-9	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	after	_	IN	IN	_	9	TMP	_	_
14	treatment	_	NN	NN	_	13	PMOD	_	_
15	with	_	IN	IN	_	14	NMOD	_	_
16	1	_	CD	CD	_	17	AMOD	_	_
17	microM	_	NN	NN	_	18	NMOD	_	_
18	dexamethasone	_	NN	NN	_	15	PMOD	_	_
19	for	_	IN	IN	_	14	TMP	_	_
20	16-18	_	CD	CD	_	21	NMOD	_	_
21	h	_	NN	NN	_	19	PMOD	_	_
22	,	_	,	,	_	27	P	_	_
23	treatment	_	NN	NN	_	27	SBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	6TG1.1	_	NN	NN	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	24	PMOD	_	_
27	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
28	in	_	IN	IN	_	27	ADV	_	_
29	an	_	DT	DT	_	31	NMOD	_	_
30	8-fold	_	JJ	JJ	_	31	NMOD	_	_
31	increase	_	NN	NN	_	28	PMOD	_	_
32	in	_	IN	IN	_	31	NMOD	_	_
33	GR	_	NN	NN	_	34	NMOD	_	_
34	mRNA	_	NN	NN	_	32	PMOD	_	_
35	,	_	,	,	_	27	P	_	_
36	as	_	IN	IN	_	27	ADV	_	_
37	determined	_	VBN	VBN	_	36	VMOD	_	_
38	by	_	IN	IN	_	37	ADV	_	_
39	Northern	_	NN	NN	_	40	NMOD	_	_
40	blot	_	NN	NN	_	44	NMOD	_	_
41	and	_	CC	CC	_	40	CC	_	_
42	RNase	_	NN	NN	_	43	NMOD	_	_
43	protection	_	NN	NN	_	40	COORD	_	_
44	analysis	_	NN	NN	_	38	PMOD	_	_
45	,	_	,	,	_	27	P	_	_
46	with	_	IN	IN	_	27	ADV	_	_
47	a	_	DT	DT	_	52	NMOD	_	_
48	corresponding	_	JJ	JJ	_	52	NMOD	_	_
49	3-	_	CD	CD	_	51	AMOD	_	_
50	to	_	TO	TO	_	51	AMOD	_	_
51	4-fold	_	JJ	JJ	_	52	NMOD	_	_
52	increase	_	NN	NN	_	46	PMOD	_	_
53	in	_	IN	IN	_	52	NMOD	_	_
54	GR	_	NN	NN	_	55	NMOD	_	_
55	protein	_	NN	NN	_	53	PMOD	_	_
56	.	_	.	.	_	27	P	_	_

1	Half-maximal	_	JJ	JJ	_	2	NMOD	_	_
2	induction	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	GR	_	NN	NN	_	3	PMOD	_	_
5	mRNA	_	NN	NN	_	4	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	protein	_	NN	NN	_	5	COORD	_	_
8	in	_	IN	IN	_	2	NMOD	_	_
9	6TG1.1	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	observed	_	VBN	VBN	_	11	VC	_	_
13	between	_	IN	IN	_	12	ADV	_	_
14	10-100	_	CD	CD	_	16	NMOD	_	_
15	nM	_	NN	NN	_	14	AMOD	_	_
16	dexamethasone	_	NN	NN	_	13	PMOD	_	_
17	,	_	,	,	_	11	P	_	_
18	and	_	CC	CC	_	11	CC	_	_
19	inclusion	_	NN	NN	_	26	SBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	1	_	CD	CD	_	22	AMOD	_	_
22	microM	_	NN	NN	_	23	NMOD	_	_
23	RU	_	NN	NN	_	20	PMOD	_	_
24	38486	_	CD	CD	_	23	NMOD	_	_
25	completely	_	RB	RB	_	26	ADV	_	_
26	blocked	_	VBD	VBD	_	11	COORD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	effects	_	NNS	NNS	_	26	IOBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	100	_	CD	CD	_	31	AMOD	_	_
31	nM	_	NN	NN	_	32	NMOD	_	_
32	dexamethasone	_	NN	NN	_	29	PMOD	_	_
33	,	_	,	,	_	26	P	_	_
34	demonstrating	_	VBG	VBG	_	26	OBJ	_	_
35	that	_	IN	IN	_	34	OBJ	_	_
36	positive	_	JJ	JJ	_	37	NMOD	_	_
37	autoregulation	_	NN	NN	_	44	SBJ	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	GR	_	NN	NN	_	40	NMOD	_	_
40	expression	_	NN	NN	_	38	PMOD	_	_
41	in	_	IN	IN	_	37	NMOD	_	_
42	6TG1.1	_	NN	NN	_	43	NMOD	_	_
43	cells	_	NNS	NNS	_	41	PMOD	_	_
44	is	_	VBZ	VBZ	_	35	VMOD	_	_
45	a	_	DT	DT	_	47	NMOD	_	_
46	receptor-mediated	_	JJ	JJ	_	47	NMOD	_	_
47	response	_	NN	NN	_	44	PRD	_	_
48	.	_	.	.	_	11	P	_	_

1	Positive	_	JJ	JJ	_	2	NMOD	_	_
2	autoregulation	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	GR	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	also	_	RB	RB	_	8	ADV	_	_
8	observed	_	VBN	VBN	_	6	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	glucocorticoid-resistant	_	JJ	JJ	_	12	NMOD	_	_
11	CEM-C1	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	which	_	WDT	WDT	_	15	SBJ	_	_
15	contain	_	VBP	VBP	_	12	NMOD	_	_
16	functional	_	JJ	JJ	_	17	NMOD	_	_
17	GR	_	NN	NN	_	15	OBJ	_	_
18	,	_	,	,	_	15	P	_	_
19	but	_	CC	CC	_	15	CC	_	_
20	whose	_	WP$	WP$	_	21	NMOD	_	_
21	growth	_	NN	NN	_	22	SBJ	_	_
22	is	_	VBZ	VBZ	_	15	COORD	_	_
23	unaffected	_	VBN	VBN	_	22	VC	_	_
24	by	_	IN	IN	_	23	LGS	_	_
25	glucocorticoids	_	NNS	NNS	_	24	PMOD	_	_
26	.	_	.	.	_	6	P	_	_

1	Thus	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	positive	_	JJ	JJ	_	4	NMOD	_	_
4	autoregulation	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	neither	_	CC	CC	_	8	CC	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	consequence	_	NN	NN	_	5	PRD	_	_
9	nor	_	CC	CC	_	8	CC	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	sole	_	JJ	JJ	_	12	NMOD	_	_
12	cause	_	NN	NN	_	8	COORD	_	_
13	of	_	IN	IN	_	8	NMOD	_	_
14	growth	_	NN	NN	_	15	NMOD	_	_
15	arrest	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	degree	_	NN	NN	_	15	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	negative	_	JJ	JJ	_	5	NMOD	_	_
5	autoregulation	_	NN	NN	_	3	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	IM-9	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	and	_	CC	CC	_	5	CC	_	_
10	positive	_	JJ	JJ	_	11	NMOD	_	_
11	autoregulation	_	NN	NN	_	5	COORD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	6TG1.1	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	unaffected	_	VBN	VBN	_	15	VC	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	inhibition	_	NN	NN	_	17	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	protein	_	NN	NN	_	21	NMOD	_	_
21	synthesis	_	NN	NN	_	19	PMOD	_	_
22	with	_	IN	IN	_	21	NMOD	_	_
23	cycloheximide	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	15	P	_	_

1	Measurement	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	GR	_	NN	NN	_	5	NMOD	_	_
4	mRNA	_	NN	NN	_	5	NMOD	_	_
5	turnover	_	NN	NN	_	2	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	6TG1.1	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	treated	_	VBN	VBN	_	8	NMOD	_	_
10	with	_	IN	IN	_	9	ADV	_	_
11	actinomycin-D	_	NN	NN	_	10	PMOD	_	_
12	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	half-life	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	2.5	_	CD	CD	_	17	NMOD	_	_
17	h	_	NN	NN	_	15	PMOD	_	_
18	,	_	,	,	_	14	P	_	_
19	which	_	WDT	WDT	_	20	SBJ	_	_
20	was	_	VBD	VBD	_	14	NMOD	_	_
21	unaffected	_	JJ	JJ	_	20	VC	_	_
22	by	_	IN	IN	_	21	LGS	_	_
23	dexamethasone	_	NN	NN	_	24	NMOD	_	_
24	treatment	_	NN	NN	_	22	PMOD	_	_
25	.	_	.	.	_	12	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	similar	_	JJ	JJ	_	3	NMOD	_	_
3	half-life	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	determined	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	IM-9	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	and	_	CC	CC	_	4	CC	_	_
10	was	_	VBD	VBD	_	4	COORD	_	_
11	also	_	RB	RB	_	10	ADV	_	_
12	unaffected	_	JJ	JJ	_	10	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	steroid	_	NN	NN	_	15	NMOD	_	_
15	treatment	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	consistent	_	JJ	JJ	_	3	PRD	_	_
5	with	_	IN	IN	_	4	AMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	interpretation	_	NN	NN	_	5	PMOD	_	_
8	that	_	IN	IN	_	7	NMOD	_	_
9	glucocorticoid-mediated	_	JJ	JJ	_	10	NMOD	_	_
10	autoregulation	_	NN	NN	_	14	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	GR	_	NN	NN	_	13	NMOD	_	_
13	expression	_	NN	NN	_	11	PMOD	_	_
14	is	_	VBZ	VBZ	_	8	VMOD	_	_
15	a	_	DT	DT	_	19	NMOD	_	_
16	tissue-specific	_	JJ	JJ	_	19	NMOD	_	_
17	primary	_	JJ	JJ	_	19	NMOD	_	_
18	transcriptional	_	JJ	JJ	_	19	NMOD	_	_
19	response	_	NN	NN	_	14	PRD	_	_
20	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	p65	_	NN	NN	_	3	NMOD	_	_
3	subunit	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	NF-kappa	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	4	PMOD	_	_
7	regulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	I	_	NN	NN	_	10	NMOD	_	_
9	kappa	_	NN	NN	_	10	NMOD	_	_
10	B	_	NN	NN	_	7	OBJ	_	_
11	by	_	IN	IN	_	7	ADV	_	_
12	two	_	CD	CD	_	14	NMOD	_	_
13	distinct	_	JJ	JJ	_	14	NMOD	_	_
14	mechanisms	_	NNS	NNS	_	11	PMOD	_	_
15	.	_	.	.	_	7	P	_	_

1	Transcription	_	NN	NN	_	4	NMOD	_	_
2	factor	_	NN	NN	_	4	NMOD	_	_
3	NF-kappa	_	NN	NN	_	4	NMOD	_	_
4	B	_	NN	NN	_	8	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	p50\/p65	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	generally	_	RB	RB	_	8	VC	_	_
10	localized	_	JJ	JJ	_	9	VMOD	_	_
11	to	_	TO	TO	_	9	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	cytoplasm	_	NN	NN	_	11	PMOD	_	_
14	by	_	IN	IN	_	9	LGS	_	_
15	its	_	PRP$	PRP$	_	19	NMOD	_	_
16	inhibitor	_	NN	NN	_	19	NMOD	_	_
17	I	_	NN	NN	_	19	NMOD	_	_
18	kappa	_	NN	NN	_	19	NMOD	_	_
19	B	_	NN	NN	_	14	PMOD	_	_
20	.	_	.	.	_	8	P	_	_

1	Overproduced	_	JJ	JJ	_	4	NMOD	_	_
2	I	_	NN	NN	_	4	NMOD	_	_
3	kappa	_	NN	NN	_	4	NMOD	_	_
4	B	_	NN	NN	_	11	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	free	_	JJ	JJ	_	4	NMOD	_	_
7	from	_	IN	IN	_	6	AMOD	_	_
8	NF-kappa	_	NN	NN	_	9	NMOD	_	_
9	B	_	NN	NN	_	7	PMOD	_	_
10	,	_	,	,	_	4	P	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	rapidly	_	RB	RB	_	13	TMP	_	_
13	degraded	_	VBN	VBN	_	11	VC	_	_
14	.	_	.	.	_	11	P	_	_

1	Overexpression	_	NN	NN	_	4	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	p65	_	NN	NN	_	2	PMOD	_	_
4	increases	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	endogenous	_	JJ	JJ	_	9	NMOD	_	_
6	I	_	NN	NN	_	9	NMOD	_	_
7	kappa	_	NN	NN	_	9	NMOD	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	protein	_	NN	NN	_	4	OBJ	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	both	_	CC	CC	_	12	CC	_	_
12	carcinoma	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	lymphoid	_	JJ	JJ	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	12	COORD	_	_
16	by	_	IN	IN	_	4	ADV	_	_
17	two	_	CD	CD	_	18	NMOD	_	_
18	mechanisms	_	NNS	NNS	_	16	PMOD	_	_
19	:	_	:	:	_	18	P	_	_
20	protein	_	NN	NN	_	21	NMOD	_	_
21	stabilization	_	NN	NN	_	18	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	increased	_	VBN	VBN	_	24	NMOD	_	_
24	transcription	_	NN	NN	_	21	COORD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	I	_	NN	NN	_	29	NMOD	_	_
27	kappa	_	NN	NN	_	29	NMOD	_	_
28	B	_	NN	NN	_	29	NMOD	_	_
29	mRNA	_	NN	NN	_	25	PMOD	_	_
30	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	13	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	13	P	_	_
4	p65	_	NN	NN	_	5	NMOD	_	_
5	delta	_	NN	NN	_	13	SBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	a	_	DT	DT	_	11	NMOD	_	_
8	naturally	_	RB	RB	_	9	AMOD	_	_
9	occurring	_	VBG	VBG	_	11	NMOD	_	_
10	splice	_	NN	NN	_	11	NMOD	_	_
11	variant	_	NN	NN	_	5	NMOD	_	_
12	,	_	,	,	_	5	P	_	_
13	fails	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	to	_	TO	TO	_	16	VMOD	_	_
15	markedly	_	RB	RB	_	16	ADV	_	_
16	augment	_	VB	VB	_	13	OBJ	_	_
17	I	_	NN	NN	_	21	NMOD	_	_
18	kappa	_	NN	NN	_	21	NMOD	_	_
19	B	_	NN	NN	_	21	NMOD	_	_
20	protein	_	NN	NN	_	21	NMOD	_	_
21	levels	_	NNS	NNS	_	16	OBJ	_	_
22	.	_	.	.	_	13	P	_	_

1	Both	_	CC	CC	_	3	CC	_	_
2	overexpressed	_	JJ	JJ	_	3	NMOD	_	_
3	p65	_	NN	NN	_	7	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	coexpressed	_	JJ	JJ	_	6	NMOD	_	_
6	p50	_	NN	NN	_	3	COORD	_	_
7	are	_	VBP	VBP	_	0	ROOT-S	_	_
8	cytoplasmic	_	JJ	JJ	_	7	PRD	_	_
9	,	_	,	,	_	7	P	_	_
10	whereas	_	IN	IN	_	7	COORD	_	_
11	p65	_	NN	NN	_	12	NMOD	_	_
12	delta	_	NN	NN	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	7	COORD	_	_
14	partly	_	RB	RB	_	15	AMOD	_	_
15	nuclear	_	JJ	JJ	_	13	PRD	_	_
16	,	_	,	,	_	7	P	_	_
17	indicating	_	VBG	VBG	_	7	COORD	_	_
18	that	_	IN	IN	_	17	OBJ	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	I	_	NN	NN	_	22	NMOD	_	_
21	kappa	_	NN	NN	_	22	NMOD	_	_
22	B	_	NN	NN	_	26	SBJ	_	_
23	induced	_	VBN	VBN	_	22	NMOD	_	_
24	by	_	IN	IN	_	23	LGS	_	_
25	p65	_	NN	NN	_	24	PMOD	_	_
26	can	_	MD	MD	_	18	VMOD	_	_
27	maintain	_	VB	VB	_	26	VC	_	_
28	NF-kappa	_	NN	NN	_	29	NMOD	_	_
29	B	_	NN	NN	_	27	OBJ	_	_
30	in	_	IN	IN	_	27	ADV	_	_
31	the	_	DT	DT	_	32	NMOD	_	_
32	cytoplasm	_	NN	NN	_	30	PMOD	_	_
33	.	_	.	.	_	7	P	_	_

1	Thus	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	p65	_	NN	NN	_	8	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	I	_	NN	NN	_	7	NMOD	_	_
6	kappa	_	NN	NN	_	7	NMOD	_	_
7	B	_	NN	NN	_	3	COORD	_	_
8	are	_	VBP	VBP	_	0	ROOT-S	_	_
9	linked	_	VBN	VBN	_	8	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	an	_	DT	DT	_	13	NMOD	_	_
12	autoregulatory	_	JJ	JJ	_	13	NMOD	_	_
13	loop	_	NN	NN	_	10	PMOD	_	_
14	,	_	,	,	_	9	P	_	_
15	ensuring	_	VBG	VBG	_	9	OBJ	_	_
16	that	_	IN	IN	_	15	OBJ	_	_
17	NF-kappa	_	NN	NN	_	18	NMOD	_	_
18	B	_	NN	NN	_	19	SBJ	_	_
19	is	_	VBZ	VBZ	_	16	VMOD	_	_
20	held	_	VBN	VBN	_	19	VC	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	cytoplasm	_	NN	NN	_	21	PMOD	_	_
24	until	_	IN	IN	_	20	TMP	_	_
25	cells	_	NNS	NNS	_	26	SBJ	_	_
26	are	_	VBP	VBP	_	24	VMOD	_	_
27	specifically	_	RB	RB	_	28	ADV	_	_
28	induced	_	VBN	VBN	_	26	VC	_	_
29	to	_	TO	TO	_	30	VMOD	_	_
30	translocate	_	VB	VB	_	28	OBJ	_	_
31	it	_	PRP	PRP	_	30	OBJ	_	_
32	to	_	TO	TO	_	30	ADV	_	_
33	the	_	DT	DT	_	34	NMOD	_	_
34	nucleus	_	NN	NN	_	32	PMOD	_	_
35	.	_	.	.	_	8	P	_	_

1	Single	_	JJ	JJ	_	5	NMOD	_	_
2	strand	_	NN	NN	_	5	NMOD	_	_
3	conformation	_	NN	NN	_	5	NMOD	_	_
4	polymorphism	_	NN	NN	_	5	NMOD	_	_
5	analysis	_	NN	NN	_	0	ROOT-FRAG	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	androgen	_	NN	NN	_	10	NMOD	_	_
8	receptor	_	NN	NN	_	10	NMOD	_	_
9	gene	_	NN	NN	_	10	NMOD	_	_
10	mutations	_	NNS	NNS	_	6	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	patients	_	NNS	NNS	_	11	PMOD	_	_
13	with	_	IN	IN	_	12	NMOD	_	_
14	androgen	_	NN	NN	_	16	NMOD	_	_
15	insensitivity	_	NN	NN	_	16	NMOD	_	_
16	syndromes	_	NNS	NNS	_	13	PMOD	_	_
17	:	_	:	:	_	5	P	_	_
18	application	_	NN	NN	_	5	NMOD	_	_
19	for	_	IN	IN	_	18	NMOD	_	_
20	diagnosis	_	NN	NN	_	19	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	genetic	_	JJ	JJ	_	23	NMOD	_	_
23	counseling	_	NN	NN	_	20	COORD	_	_
24	,	_	,	,	_	20	P	_	_
25	and	_	CC	CC	_	20	CC	_	_
26	therapy	_	NN	NN	_	20	COORD	_	_
27	.	_	.	.	_	18	P	_	_

1	Recent	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	mutations	_	NNS	NNS	_	11	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	androgen	_	NN	NN	_	10	NMOD	_	_
9	receptor	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	6	PMOD	_	_
11	are	_	VBP	VBP	_	4	VMOD	_	_
12	associated	_	VBN	VBN	_	11	VC	_	_
13	with	_	IN	IN	_	12	ADV	_	_
14	androgen	_	NN	NN	_	16	NMOD	_	_
15	insensitivity	_	NN	NN	_	16	NMOD	_	_
16	syndromes	_	NNS	NNS	_	13	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	heterogeneous	_	JJ	JJ	_	20	NMOD	_	_
20	group	_	NN	NN	_	16	NMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	related	_	JJ	JJ	_	23	NMOD	_	_
23	disorders	_	NNS	NNS	_	21	PMOD	_	_
24	involving	_	VBG	VBG	_	23	NMOD	_	_
25	defective	_	JJ	JJ	_	27	NMOD	_	_
26	sexual	_	JJ	JJ	_	27	NMOD	_	_
27	differentiation	_	NN	NN	_	24	OBJ	_	_
28	in	_	IN	IN	_	27	NMOD	_	_
29	karyotypic	_	JJ	JJ	_	30	NMOD	_	_
30	males	_	NNS	NNS	_	28	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	address	_	VBP	VBP	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	possibility	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	rapid	_	JJ	JJ	_	12	NMOD	_	_
11	mutational	_	JJ	JJ	_	12	NMOD	_	_
12	analysis	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	androgen	_	NN	NN	_	17	NMOD	_	_
16	receptor	_	NN	NN	_	17	NMOD	_	_
17	gene	_	NN	NN	_	13	PMOD	_	_
18	for	_	IN	IN	_	12	NMOD	_	_
19	initial	_	JJ	JJ	_	20	NMOD	_	_
20	diagnosis	_	NN	NN	_	18	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	genetic	_	JJ	JJ	_	23	NMOD	_	_
23	counseling	_	NN	NN	_	20	COORD	_	_
24	,	_	,	,	_	20	P	_	_
25	and	_	CC	CC	_	20	CC	_	_
26	molecular	_	JJ	JJ	_	27	NMOD	_	_
27	subclassification	_	NN	NN	_	20	COORD	_	_
28	of	_	IN	IN	_	20	NMOD	_	_
29	affected	_	VBN	VBN	_	30	NMOD	_	_
30	patients	_	NNS	NNS	_	28	PMOD	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	their	_	PRP$	PRP$	_	33	NMOD	_	_
33	families	_	NNS	NNS	_	30	COORD	_	_
34	.	_	.	.	_	6	P	_	_

1	DNA	_	NN	NN	_	18	SBJ	_	_
2	from	_	IN	IN	_	1	NMOD	_	_
3	peripheral	_	JJ	JJ	_	5	NMOD	_	_
4	blood	_	NN	NN	_	5	NMOD	_	_
5	leukocytes	_	NNS	NNS	_	2	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	six	_	CD	CD	_	8	NMOD	_	_
8	patients	_	NNS	NNS	_	6	PMOD	_	_
9	from	_	IN	IN	_	8	NMOD	_	_
10	five	_	CD	CD	_	11	NMOD	_	_
11	families	_	NNS	NNS	_	9	PMOD	_	_
12	with	_	IN	IN	_	8	NMOD	_	_
13	various	_	JJ	JJ	_	14	NMOD	_	_
14	degrees	_	NNS	NNS	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	androgen	_	NN	NN	_	17	NMOD	_	_
17	insensitivity	_	NN	NN	_	15	PMOD	_	_
18	was	_	VBD	VBD	_	0	ROOT-S	_	_
19	studied	_	VBN	VBN	_	18	VC	_	_
20	.	_	.	.	_	18	P	_	_

1	Exons	_	NNS	NNS	_	10	SBJ	_	_
2	2	_	CD	CD	_	1	NMOD	_	_
3	to	_	TO	TO	_	2	NMOD	_	_
4	8	_	CD	CD	_	2	NMOD	_	_
5	of	_	IN	IN	_	1	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	androgen	_	NN	NN	_	9	NMOD	_	_
8	receptor	_	NN	NN	_	9	NMOD	_	_
9	gene	_	NN	NN	_	5	PMOD	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	analyzed	_	VBN	VBN	_	10	VC	_	_
12	using	_	VBG	VBG	_	11	OBJ	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	combination	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	single	_	JJ	JJ	_	20	NMOD	_	_
17	strand	_	NN	NN	_	20	NMOD	_	_
18	conformation	_	NN	NN	_	20	NMOD	_	_
19	polymorphism	_	NN	NN	_	20	NMOD	_	_
20	analysis	_	NN	NN	_	15	PMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	direct	_	JJ	JJ	_	24	NMOD	_	_
23	DNA	_	NN	NN	_	24	NMOD	_	_
24	sequencing	_	NN	NN	_	20	COORD	_	_
25	.	_	.	.	_	10	P	_	_

1	Female	_	JJ	JJ	_	3	NMOD	_	_
2	family	_	NN	NN	_	3	NMOD	_	_
3	members	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	also	_	RB	RB	_	6	ADV	_	_
6	studied	_	VBN	VBN	_	4	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	identify	_	VB	VB	_	6	OBJ	_	_
9	heterozygote	_	NN	NN	_	10	NMOD	_	_
10	carriers	_	NNS	NNS	_	8	OBJ	_	_
11	.	_	.	.	_	4	P	_	_

1	Point	_	NN	NN	_	2	NMOD	_	_
2	mutations	_	NNS	NNS	_	7	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	AR	_	NN	NN	_	6	NMOD	_	_
6	gene	_	NN	NN	_	3	PMOD	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	identified	_	VBN	VBN	_	7	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	all	_	DT	DT	_	12	NMOD	_	_
11	six	_	CD	CD	_	10	DEP	_	_
12	patients	_	NNS	NNS	_	9	PMOD	_	_
13	,	_	,	,	_	7	P	_	_
14	and	_	CC	CC	_	7	CC	_	_
15	all	_	DT	DT	_	16	NMOD	_	_
16	mutations	_	NNS	NNS	_	17	SBJ	_	_
17	caused	_	VBD	VBD	_	7	COORD	_	_
18	amino	_	NN	NN	_	20	NMOD	_	_
19	acid	_	NN	NN	_	20	NMOD	_	_
20	substitutions	_	NNS	NNS	_	17	OBJ	_	_
21	.	_	.	.	_	7	P	_	_

1	One	_	CD	CD	_	2	NMOD	_	_
2	patient	_	NN	NN	_	7	SBJ	_	_
3	with	_	IN	IN	_	2	NMOD	_	_
4	incomplete	_	JJ	JJ	_	6	NMOD	_	_
5	androgen	_	NN	NN	_	6	NMOD	_	_
6	insensitivity	_	NN	NN	_	3	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	mosaic	_	NN	NN	_	7	PRD	_	_
10	for	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	mutation	_	NN	NN	_	10	PMOD	_	_
13	.	_	.	.	_	7	P	_	_

1	Four	_	CD	CD	_	17	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	five	_	CD	CD	_	5	NMOD	_	_
5	mothers	_	NNS	NNS	_	2	PMOD	_	_
6	,	_	,	,	_	1	P	_	_
7	as	_	RB	RB	_	1	CC	_	_
8	well	_	RB	RB	_	7	DEP	_	_
9	as	_	IN	IN	_	7	DEP	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	young	_	JJ	JJ	_	12	NMOD	_	_
12	sister	_	NN	NN	_	1	COORD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	one	_	CD	CD	_	15	NMOD	_	_
15	patient	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	1	P	_	_
17	were	_	VBD	VBD	_	0	ROOT-S	_	_
18	carriers	_	NNS	NNS	_	17	PRD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	mutation	_	NN	NN	_	19	PMOD	_	_
22	present	_	JJ	JJ	_	21	NMOD	_	_
23	in	_	IN	IN	_	22	AMOD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	affected	_	VBN	VBN	_	26	NMOD	_	_
26	child	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	17	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	new	_	JJ	JJ	_	6	NMOD	_	_
6	mutations	_	NNS	NNS	_	7	SBJ	_	_
7	may	_	MD	MD	_	4	VMOD	_	_
8	occur	_	VB	VB	_	7	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	androgen	_	NN	NN	_	13	NMOD	_	_
12	receptor	_	NN	NN	_	13	NMOD	_	_
13	gene	_	NN	NN	_	9	PMOD	_	_
14	leading	_	VBG	VBG	_	8	OBJ	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	sporadic	_	JJ	JJ	_	19	NMOD	_	_
17	androgen	_	NN	NN	_	19	NMOD	_	_
18	insensitivity	_	NN	NN	_	19	NMOD	_	_
19	syndrome	_	NN	NN	_	15	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Molecular	_	JJ	JJ	_	3	NMOD	_	_
2	genetic	_	JJ	JJ	_	3	NMOD	_	_
3	characterization	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	variant	_	JJ	JJ	_	7	NMOD	_	_
7	allele	_	NN	NN	_	4	PMOD	_	_
8	can	_	MD	MD	_	0	ROOT-S	_	_
9	serve	_	VB	VB	_	8	VC	_	_
10	as	_	IN	IN	_	9	ADV	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	primary	_	JJ	JJ	_	13	NMOD	_	_
13	tool	_	NN	NN	_	10	PMOD	_	_
14	for	_	IN	IN	_	13	NMOD	_	_
15	diagnosis	_	NN	NN	_	14	PMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	subsequent	_	JJ	JJ	_	18	NMOD	_	_
18	therapy	_	NN	NN	_	15	COORD	_	_
19	,	_	,	,	_	8	P	_	_
20	and	_	CC	CC	_	8	CC	_	_
21	can	_	MD	MD	_	8	COORD	_	_
22	provide	_	VB	VB	_	21	VC	_	_
23	a	_	DT	DT	_	24	NMOD	_	_
24	basis	_	NN	NN	_	22	OBJ	_	_
25	for	_	IN	IN	_	24	NMOD	_	_
26	distinguishing	_	VBG	VBG	_	25	PMOD	_	_
27	heterozygous	_	JJ	JJ	_	28	NMOD	_	_
28	carriers	_	NNS	NNS	_	26	OBJ	_	_
29	in	_	IN	IN	_	28	NMOD	_	_
30	familial	_	JJ	JJ	_	32	NMOD	_	_
31	androgen	_	NN	NN	_	32	NMOD	_	_
32	resistance	_	NN	NN	_	29	PMOD	_	_
33	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	identification	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	carriers	_	NNS	NNS	_	3	PMOD	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	of	_	IN	IN	_	5	PRD	_	_
7	substantial	_	JJ	JJ	_	9	NMOD	_	_
8	clinical	_	JJ	JJ	_	9	NMOD	_	_
9	importance	_	NN	NN	_	6	PMOD	_	_
10	for	_	IN	IN	_	5	ADV	_	_
11	genetic	_	JJ	JJ	_	12	NMOD	_	_
12	counseling	_	NN	NN	_	10	PMOD	_	_
13	.	_	.	.	_	5	P	_	_

1	Minimally	_	RB	RB	_	4	AMOD	_	_
2	modified	_	VBN	VBN	_	4	AMOD	_	_
3	low	_	JJ	JJ	_	4	AMOD	_	_
4	density	_	NN	NN	_	7	NMOD	_	_
5	lipoprotein-induced	_	JJ	JJ	_	4	AMOD	_	_
6	inflammatory	_	JJ	JJ	_	7	NMOD	_	_
7	responses	_	NNS	NNS	_	11	SBJ	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	endothelial	_	JJ	JJ	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	are	_	VBP	VBP	_	0	ROOT-S	_	_
12	mediated	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	cyclic	_	JJ	JJ	_	16	NMOD	_	_
15	adenosine	_	NN	NN	_	16	NMOD	_	_
16	monophosphate	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	11	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	previously	_	RB	RB	_	2	TMP	_	_
4	shown	_	VBN	VBN	_	2	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	minimally	_	RB	RB	_	7	AMOD	_	_
7	oxidized	_	VBN	VBN	_	8	NMOD	_	_
8	LDL	_	NN	NN	_	12	SBJ	_	_
9	(	_	(	(	_	10	P	_	_
10	MM-LDL	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	activated	_	VBD	VBD	_	5	VMOD	_	_
13	endothelial	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	IOBJ	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	increase	_	VB	VB	_	12	OBJ	_	_
17	their	_	PRP$	PRP$	_	18	NMOD	_	_
18	interaction	_	NN	NN	_	16	OBJ	_	_
19	with	_	IN	IN	_	18	NMOD	_	_
20	monocytes	_	NNS	NNS	_	19	PMOD	_	_
21	but	_	CC	CC	_	20	CC	_	_
22	not	_	RB	RB	_	21	COORD	_	_
23	neutrophils	_	NNS	NNS	_	20	COORD	_	_
24	,	_	,	,	_	12	P	_	_
25	inducing	_	VBG	VBG	_	12	OBJ	_	_
26	monocyte	_	NN	NN	_	25	OBJ	_	_
27	but	_	CC	CC	_	26	CC	_	_
28	not	_	RB	RB	_	27	COORD	_	_
29	neutrophil	_	NN	NN	_	26	COORD	_	_
30	binding	_	NN	NN	_	26	NMOD	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	synthesis	_	NN	NN	_	30	COORD	_	_
33	of	_	IN	IN	_	26	NMOD	_	_
34	monocyte	_	NN	NN	_	36	NMOD	_	_
35	chemotactic	_	JJ	JJ	_	36	NMOD	_	_
36	protein-1	_	NN	NN	_	33	PMOD	_	_
37	and	_	CC	CC	_	36	CC	_	_
38	monocyte	_	NN	NN	_	40	NMOD	_	_
39	colony-stimulating	_	JJ	JJ	_	40	NMOD	_	_
40	factor	_	NN	NN	_	36	COORD	_	_
41	(	_	(	(	_	42	P	_	_
42	M-CSF	_	NN	NN	_	40	PRN	_	_
43	)	_	)	)	_	42	P	_	_
44	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	present	_	JJ	JJ	_	4	NMOD	_	_
4	studies	_	NNS	NNS	_	1	PMOD	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	have	_	VBP	VBP	_	0	ROOT-S	_	_
7	examined	_	VBN	VBN	_	6	VC	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	signaling	_	NN	NN	_	10	NMOD	_	_
10	pathways	_	NNS	NNS	_	7	OBJ	_	_
11	by	_	IN	IN	_	17	ADV	_	_
12	which	_	WDT	WDT	_	11	PMOD	_	_
13	this	_	DT	DT	_	15	NMOD	_	_
14	monocyte-specific	_	JJ	JJ	_	15	NMOD	_	_
15	response	_	NN	NN	_	16	SBJ	_	_
16	is	_	VBZ	VBZ	_	10	NMOD	_	_
17	induced	_	VBN	VBN	_	16	VC	_	_
18	.	_	.	.	_	6	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	induction	_	NN	NN	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	monocyte	_	NN	NN	_	5	NMOD	_	_
5	binding	_	NN	NN	_	3	PMOD	_	_
6	and	_	CC	CC	_	2	CC	_	_
7	mRNA	_	NN	NN	_	8	NMOD	_	_
8	levels	_	NNS	NNS	_	2	COORD	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	M-CSF	_	NN	NN	_	9	PMOD	_	_
11	by	_	IN	IN	_	2	NMOD	_	_
12	MM-LDL	_	NN	NN	_	11	PMOD	_	_
13	were	_	VBD	VBD	_	0	ROOT-S	_	_
14	not	_	RB	RB	_	13	VMOD	_	_
15	inhibited	_	VBN	VBN	_	13	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	protein	_	NN	NN	_	18	AMOD	_	_
18	kinase	_	NN	NN	_	21	NMOD	_	_
19	C-depleted	_	JJ	JJ	_	18	AMOD	_	_
20	endothelial	_	JJ	JJ	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	16	PMOD	_	_
22	.	_	.	.	_	13	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	number	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	our	_	PRP$	PRP$	_	5	NMOD	_	_
5	studies	_	NNS	NNS	_	3	PMOD	_	_
6	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	cAMP	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	7	VMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	second	_	JJ	JJ	_	12	NMOD	_	_
12	messenger	_	NN	NN	_	9	PRD	_	_
13	for	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	effects	_	NNS	NNS	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	MM-LDL	_	NN	NN	_	16	PMOD	_	_
18	cited	_	VBN	VBN	_	15	NMOD	_	_
19	above	_	RB	RB	_	18	ADV	_	_
20	.	_	.	.	_	6	P	_	_

1	Incubation	_	NN	NN	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	endothelial	_	JJ	JJ	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	MM-LDL	_	NN	NN	_	5	PMOD	_	_
7	caused	_	VBD	VBD	_	6	NMOD	_	_
8	a	_	DT	DT	_	11	VMOD	_	_
9	173	_	CD	CD	_	11	NMOD	_	_
10	%	_	NN	NN	_	11	NMOD	_	_
11	increase	_	NN	NN	_	0	ROOT-S	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	intracellular	_	JJ	JJ	_	15	NMOD	_	_
14	cAMP	_	NN	NN	_	15	NMOD	_	_
15	levels	_	NNS	NNS	_	12	PMOD	_	_
16	.	_	.	.	_	11	P	_	_

1	Agents	_	NNS	NNS	_	19	SBJ	_	_
2	which	_	WDT	WDT	_	3	SBJ	_	_
3	increased	_	VBD	VBD	_	1	NMOD	_	_
4	cAMP	_	NN	NN	_	5	NMOD	_	_
5	levels	_	NNS	NNS	_	3	OBJ	_	_
6	,	_	,	,	_	1	P	_	_
7	including	_	VBG	VBG	_	1	NMOD	_	_
8	cholera	_	NN	NN	_	9	NMOD	_	_
9	toxin	_	NN	NN	_	7	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	pertussis	_	NN	NN	_	12	NMOD	_	_
12	toxin	_	NN	NN	_	9	COORD	_	_
13	,	_	,	,	_	9	P	_	_
14	dibutyryl	_	NN	NN	_	15	NMOD	_	_
15	cAMP	_	NN	NN	_	9	COORD	_	_
16	,	_	,	,	_	9	P	_	_
17	and	_	CC	CC	_	9	CC	_	_
18	isoproterenol	_	NN	NN	_	9	COORD	_	_
19	mimicked	_	VBD	VBD	_	0	ROOT-S	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	actions	_	NNS	NNS	_	19	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	MM-LDL	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	19	P	_	_

1	Agents	_	NNS	NNS	_	5	SBJ	_	_
2	which	_	WDT	WDT	_	3	SBJ	_	_
3	elevated	_	VBD	VBD	_	1	NMOD	_	_
4	cAMP	_	NN	NN	_	3	OBJ	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	also	_	RB	RB	_	5	ADV	_	_
7	shown	_	VBN	VBN	_	5	VC	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	activate	_	VB	VB	_	7	OBJ	_	_
10	NF	_	NN	NN	_	12	NMOD	_	_
11	kappa	_	NN	NN	_	12	NMOD	_	_
12	B	_	NN	NN	_	9	IOBJ	_	_
13	,	_	,	,	_	9	P	_	_
14	suggesting	_	VBG	VBG	_	9	OBJ	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	role	_	NN	NN	_	14	OBJ	_	_
17	for	_	IN	IN	_	16	NMOD	_	_
18	this	_	DT	DT	_	20	NMOD	_	_
19	transcription	_	NN	NN	_	20	NMOD	_	_
20	factor	_	NN	NN	_	17	PMOD	_	_
21	in	_	IN	IN	_	16	NMOD	_	_
22	activation	_	NN	NN	_	21	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	monocyte-endothelial	_	JJ	JJ	_	25	NMOD	_	_
25	interactions	_	NNS	NNS	_	23	PMOD	_	_
26	.	_	.	.	_	5	P	_	_

1	Although	_	IN	IN	_	20	ADV	_	_
2	endothelial	_	JJ	JJ	_	5	NMOD	_	_
3	leukocyte	_	NN	NN	_	5	NMOD	_	_
4	adhesion	_	NN	NN	_	5	NMOD	_	_
5	molecule	_	NN	NN	_	10	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	ELAM	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	mRNA	_	NN	NN	_	10	NMOD	_	_
10	synthesis	_	NN	NN	_	11	SBJ	_	_
11	can	_	MD	MD	_	1	VMOD	_	_
12	be	_	VB	VB	_	11	VC	_	_
13	regulated	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	NF	_	NN	NN	_	17	NMOD	_	_
16	kappa	_	NN	NN	_	17	NMOD	_	_
17	B	_	NN	NN	_	14	PMOD	_	_
18	,	_	,	,	_	20	P	_	_
19	ELAM	_	NN	NN	_	20	SBJ	_	_
20	was	_	VBD	VBD	_	0	ROOT-S	_	_
21	not	_	RB	RB	_	20	VMOD	_	_
22	expressed	_	VBN	VBN	_	20	VC	_	_
23	and	_	CC	CC	_	20	CC	_	_
24	ELAM	_	NN	NN	_	25	NMOD	_	_
25	mRNA	_	NN	NN	_	26	SBJ	_	_
26	was	_	VBD	VBD	_	20	COORD	_	_
27	only	_	RB	RB	_	26	ADV	_	_
28	slightly	_	RB	RB	_	27	AMOD	_	_
29	elevated	_	JJ	JJ	_	26	VC	_	_
30	in	_	IN	IN	_	29	ADV	_	_
31	response	_	NN	NN	_	30	DEP	_	_
32	to	_	TO	TO	_	30	DEP	_	_
33	MM-LDL	_	NN	NN	_	30	PMOD	_	_
34	.	_	.	.	_	20	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	present	_	VBP	VBP	_	0	ROOT-S	_	_
3	evidence	_	NN	NN	_	2	OBJ	_	_
4	that	_	IN	IN	_	3	NMOD	_	_
5	induction	_	NN	NN	_	11	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	neutrophil	_	NN	NN	_	8	NMOD	_	_
8	binding	_	NN	NN	_	6	PMOD	_	_
9	by	_	IN	IN	_	5	NMOD	_	_
10	LPS	_	NN	NN	_	9	PMOD	_	_
11	is	_	VBZ	VBZ	_	4	VMOD	_	_
12	actually	_	RB	RB	_	11	ADV	_	_
13	suppressed	_	VBN	VBN	_	11	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	agents	_	NNS	NNS	_	14	PMOD	_	_
16	that	_	WDT	WDT	_	17	SBJ	_	_
17	elevated	_	VBD	VBD	_	15	NMOD	_	_
18	cAMP	_	NN	NN	_	19	NMOD	_	_
19	levels	_	NNS	NNS	_	17	OBJ	_	_
20	.	_	.	.	_	2	P	_	_

1	Costimulation	_	NN	NN	_	9	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	cAMP	_	NN	NN	_	8	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	protein	_	NN	NN	_	7	NMOD	_	_
6	kinase	_	NN	NN	_	7	NMOD	_	_
7	C	_	NN	NN	_	3	COORD	_	_
8	pathways	_	NNS	NNS	_	2	PMOD	_	_
9	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	CD3-dependent	_	JJ	JJ	_	14	NMOD	_	_
12	T	_	NN	NN	_	14	NMOD	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	activation	_	NN	NN	_	9	OBJ	_	_
15	and	_	CC	CC	_	9	CC	_	_
16	leads	_	VBZ	VBZ	_	9	COORD	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	persistent	_	JJ	JJ	_	20	NMOD	_	_
20	expression	_	NN	NN	_	17	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	25	NMOD	_	_
23	AP-1	_	NN	NN	_	25	NMOD	_	_
24	transcription	_	NN	NN	_	25	NMOD	_	_
25	factor	_	NN	NN	_	21	PMOD	_	_
26	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effects	_	NNS	NNS	_	19	SBJ	_	_
3	mediated	_	VBN	VBN	_	2	NMOD	_	_
4	by	_	IN	IN	_	3	LGS	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	combined	_	JJ	JJ	_	7	NMOD	_	_
7	stimulation	_	NN	NN	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	cAMP-	_	NN	NN	_	18	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	protein	_	NN	NN	_	15	AMOD	_	_
12	kinase	_	NN	NN	_	15	AMOD	_	_
13	C	_	NN	NN	_	15	AMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	PKC	_	NN	NN	_	9	COORD	_	_
16	)	_	)	)	_	15	P	_	_
17	-dependent	_	JJ	JJ	_	15	AMOD	_	_
18	pathways	_	NNS	NNS	_	8	PMOD	_	_
19	have	_	VBP	VBP	_	0	ROOT-S	_	_
20	been	_	VBN	VBN	_	19	VC	_	_
21	investigated	_	VBN	VBN	_	20	VC	_	_
22	in	_	IN	IN	_	21	ADV	_	_
23	different	_	JJ	JJ	_	25	NMOD	_	_
24	cellular	_	JJ	JJ	_	25	NMOD	_	_
25	systems	_	NNS	NNS	_	22	PMOD	_	_
26	,	_	,	,	_	19	P	_	_
27	and	_	CC	CC	_	19	CC	_	_
28	it	_	PRP	PRP	_	29	SBJ	_	_
29	has	_	VBZ	VBZ	_	19	COORD	_	_
30	been	_	VBN	VBN	_	29	VC	_	_
31	shown	_	VBN	VBN	_	30	VC	_	_
32	that	_	IN	IN	_	31	OBJ	_	_
33	they	_	PRP	PRP	_	34	SBJ	_	_
34	may	_	MD	MD	_	32	VMOD	_	_
35	complement	_	VB	VB	_	34	VC	_	_
36	each	_	DT	DT	_	37	NMOD	_	_
37	other	_	JJ	JJ	_	35	OBJ	_	_
38	in	_	IN	IN	_	35	ADV	_	_
39	activating	_	VBG	VBG	_	38	PMOD	_	_
40	cell	_	NN	NN	_	39	OBJ	_	_
41	proliferation	_	NN	NN	_	40	NMOD	_	_
42	and	_	CC	CC	_	41	CC	_	_
43	differentiation	_	NN	NN	_	41	COORD	_	_
44	.	_	.	.	_	19	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	show	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	upon	_	IN	IN	_	16	TMP	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	stimulation	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	both	_	DT	DT	_	13	NMOD	_	_
13	pathways	_	NNS	NNS	_	11	PMOD	_	_
14	T	_	NN	NN	_	15	NMOD	_	_
15	lymphocytes	_	NNS	NNS	_	16	SBJ	_	_
16	became	_	VBD	VBD	_	7	VMOD	_	_
17	refractory	_	JJ	JJ	_	16	PRD	_	_
18	to	_	TO	TO	_	17	AMOD	_	_
19	activation	_	NN	NN	_	18	PMOD	_	_
20	via	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	28	NMOD	_	_
22	CD3\/T	_	NN	NN	_	28	NMOD	_	_
23	cell	_	NN	NN	_	28	NMOD	_	_
24	receptor	_	NN	NN	_	28	NMOD	_	_
25	(	_	(	(	_	28	P	_	_
26	TcR	_	NN	NN	_	28	NMOD	_	_
27	)	_	)	)	_	28	P	_	_
28	complex	_	NN	NN	_	20	PMOD	_	_
29	.	_	.	.	_	6	P	_	_

1	T	_	NN	NN	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	17	SBJ	_	_
3	preincubated	_	VBN	VBN	_	2	NMOD	_	_
4	with	_	IN	IN	_	3	ADV	_	_
5	phorbol	_	NN	NN	_	7	NMOD	_	_
6	12-myristate	_	NN	NN	_	7	NMOD	_	_
7	13-acetate	_	NN	NN	_	4	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	PMA	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	dibutyryl	_	NN	NN	_	13	NMOD	_	_
13	cAMP	_	NN	NN	_	7	COORD	_	_
14	(	_	(	(	_	15	P	_	_
15	Bt2cAMP	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	displayed	_	VBD	VBD	_	0	ROOT-S	_	_
18	a	_	DT	DT	_	21	NMOD	_	_
19	deficient	_	JJ	JJ	_	21	NMOD	_	_
20	proliferative	_	JJ	JJ	_	21	NMOD	_	_
21	ability	_	NN	NN	_	17	OBJ	_	_
22	in	_	IN	IN	_	17	ADV	_	_
23	response	_	NN	NN	_	22	DEP	_	_
24	to	_	TO	TO	_	22	DEP	_	_
25	anti-CD3	_	JJ	JJ	_	27	NMOD	_	_
26	mAb	_	NN	NN	_	27	NMOD	_	_
27	stimulation	_	NN	NN	_	22	PMOD	_	_
28	,	_	,	,	_	17	P	_	_
29	whereas	_	IN	IN	_	17	COORD	_	_
30	lymphocytes	_	NNS	NNS	_	38	SBJ	_	_
31	treated	_	VBN	VBN	_	30	NMOD	_	_
32	individually	_	RB	RB	_	31	ADV	_	_
33	with	_	IN	IN	_	31	ADV	_	_
34	either	_	CC	CC	_	35	CC	_	_
35	Bt2cAMP	_	NN	NN	_	33	PMOD	_	_
36	or	_	CC	CC	_	35	CC	_	_
37	PMA	_	NN	NN	_	35	COORD	_	_
38	responded	_	VBD	VBD	_	17	COORD	_	_
39	comparably	_	RB	RB	_	38	ADV	_	_
40	to	_	TO	TO	_	38	ADV	_	_
41	untreated	_	JJ	JJ	_	42	NMOD	_	_
42	samples	_	NNS	NNS	_	40	PMOD	_	_
43	.	_	.	.	_	17	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	detected	_	VBD	VBD	_	0	ROOT-S	_	_
3	an	_	DT	DT	_	4	NMOD	_	_
4	association	_	NN	NN	_	2	OBJ	_	_
5	between	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	reduced	_	VBN	VBN	_	9	NMOD	_	_
8	mitogenic	_	JJ	JJ	_	9	NMOD	_	_
9	response	_	NN	NN	_	5	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	low	_	JJ	JJ	_	12	NMOD	_	_
12	expression	_	NN	NN	_	9	COORD	_	_
13	of	_	IN	IN	_	9	NMOD	_	_
14	both	_	CC	CC	_	15	CC	_	_
15	interleukin-2	_	NN	NN	_	13	PMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	IL-2	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	alpha	_	NN	NN	_	22	NMOD	_	_
22	chain	_	NN	NN	_	15	COORD	_	_
23	(	_	(	(	_	24	P	_	_
24	CD25	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	of	_	IN	IN	_	22	NMOD	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	IL-2	_	NN	NN	_	29	NMOD	_	_
29	receptor	_	NN	NN	_	26	PMOD	_	_
30	(	_	(	(	_	31	P	_	_
31	IL-2R	_	NN	NN	_	29	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	.	_	.	.	_	2	P	_	_

1	Analysis	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	intracellular	_	JJ	JJ	_	5	NMOD	_	_
4	Ca2+	_	NN	NN	_	5	NMOD	_	_
5	mobilization	_	NN	NN	_	2	PMOD	_	_
6	suggested	_	VBD	VBD	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	CD3\/TcR-dependent	_	JJ	JJ	_	11	NMOD	_	_
10	signal	_	NN	NN	_	11	NMOD	_	_
11	transduction	_	NN	NN	_	12	SBJ	_	_
12	was	_	VBD	VBD	_	7	VMOD	_	_
13	impaired	_	JJ	JJ	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	PMA\/Bt2cAMP-treated	_	JJ	JJ	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	.	_	.	.	_	6	P	_	_

1	Remarkably	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	observed	_	VBD	VBD	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	these	_	DT	DT	_	7	NMOD	_	_
7	samples	_	NNS	NNS	_	8	SBJ	_	_
8	displayed	_	VBD	VBD	_	5	VMOD	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	persistent	_	JJ	JJ	_	11	NMOD	_	_
11	expression	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	c-fos	_	NN	NN	_	15	NMOD	_	_
15	protooncogene	_	NN	NN	_	12	PMOD	_	_
16	,	_	,	,	_	11	P	_	_
17	associated	_	VBN	VBN	_	11	NMOD	_	_
18	to	_	TO	TO	_	17	ADV	_	_
19	an	_	DT	DT	_	23	NMOD	_	_
20	increased	_	VBN	VBN	_	23	NMOD	_	_
21	AP-1	_	NN	NN	_	23	NMOD	_	_
22	DNA-binding	_	JJ	JJ	_	23	NMOD	_	_
23	activity	_	NN	NN	_	18	PMOD	_	_
24	,	_	,	,	_	4	P	_	_
25	whereas	_	IN	IN	_	4	COORD	_	_
26	no	_	DT	DT	_	27	NMOD	_	_
27	variations	_	NNS	NNS	_	32	SBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	CREB	_	NN	NN	_	28	PMOD	_	_
30	or	_	CC	CC	_	29	CC	_	_
31	NF-kB	_	NN	NN	_	29	COORD	_	_
32	were	_	VBD	VBD	_	4	COORD	_	_
33	detected	_	VBN	VBN	_	32	VC	_	_
34	.	_	.	.	_	4	P	_	_

1	Neither	_	CC	CC	_	2	CC	_	_
2	Bt2cAMP	_	NN	NN	_	6	SBJ	_	_
3	nor	_	CC	CC	_	2	CC	_	_
4	PMA	_	NN	NN	_	2	COORD	_	_
5	individually	_	RB	RB	_	6	ADV	_	_
6	mediated	_	VBD	VBD	_	0	ROOT-S	_	_
7	these	_	DT	DT	_	9	NMOD	_	_
8	sustained	_	JJ	JJ	_	9	NMOD	_	_
9	effects	_	NNS	NNS	_	6	OBJ	_	_
10	,	_	,	,	_	9	P	_	_
11	which	_	WDT	WDT	_	13	SBJ	_	_
12	therefore	_	RB	RB	_	13	ADV	_	_
13	appear	_	VBP	VBP	_	9	NMOD	_	_
14	as	_	IN	IN	_	13	ADV	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	consequence	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	interplay	_	NN	NN	_	17	PMOD	_	_
20	between	_	IN	IN	_	19	NMOD	_	_
21	both	_	DT	DT	_	23	NMOD	_	_
22	metabolic	_	JJ	JJ	_	23	NMOD	_	_
23	stimuli	_	NNS	NNS	_	20	PMOD	_	_
24	.	_	.	.	_	6	P	_	_

1	Altogether	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	data	_	NNS	NNS	_	5	SBJ	_	_
5	provide	_	VBP	VBP	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	evidence	_	NN	NN	_	5	OBJ	_	_
8	that	_	IN	IN	_	7	NMOD	_	_
9	both	_	DT	DT	_	10	NMOD	_	_
10	pathways	_	NNS	NNS	_	11	SBJ	_	_
11	complement	_	VBP	VBP	_	8	VMOD	_	_
12	each	_	DT	DT	_	13	NMOD	_	_
13	other	_	JJ	JJ	_	11	OBJ	_	_
14	in	_	IN	IN	_	11	ADV	_	_
15	regulating	_	VBG	VBG	_	14	PMOD	_	_
16	gene	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	15	OBJ	_	_
18	and	_	CC	CC	_	11	CC	_	_
19	,	_	,	,	_	25	ADV	_	_
20	conversely	_	RB	RB	_	25	VMOD	_	_
21	,	_	,	,	_	25	P	_	_
22	downregulate	_	VBP	VBP	_	25	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	TcR	_	NN	NN	_	25	NMOD	_	_
25	transduction	_	NN	NN	_	11	COORD	_	_
26	mechanisms	_	NNS	NNS	_	5	VMOD	_	_

1	Nuclear	_	JJ	JJ	_	4	NMOD	_	_
2	factor	_	NN	NN	_	4	NMOD	_	_
3	kappa	_	NN	NN	_	4	NMOD	_	_
4	B	_	NN	NN	_	0	ROOT-FRAG	_	_
5	,	_	,	,	_	4	P	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	mediator	_	NN	NN	_	4	NMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	lipopolysaccharide	_	NN	NN	_	10	NMOD	_	_
10	effects	_	NNS	NNS	_	8	PMOD	_	_
11	.	_	.	.	_	4	P	_	_

1	Exposure	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	certain	_	JJ	JJ	_	5	NMOD	_	_
4	cell	_	NN	NN	_	5	NMOD	_	_
5	types	_	NNS	NNS	_	2	PMOD	_	_
6	to	_	TO	TO	_	1	NMOD	_	_
7	bacterial	_	JJ	JJ	_	8	NMOD	_	_
8	lipopolysaccharide	_	NN	NN	_	6	PMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	LPS	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	leads	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	to	_	TO	TO	_	12	ADV	_	_
14	activation	_	NN	NN	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	nuclear	_	JJ	JJ	_	19	NMOD	_	_
17	factor	_	NN	NN	_	19	NMOD	_	_
18	kappa	_	NN	NN	_	19	NMOD	_	_
19	B	_	NN	NN	_	15	PMOD	_	_
20	(	_	(	(	_	22	P	_	_
21	NF-kappa	_	NN	NN	_	22	NMOD	_	_
22	B	_	NN	NN	_	19	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	,	_	,	,	_	19	P	_	_
25	an	_	DT	DT	_	28	NMOD	_	_
26	inducible	_	JJ	JJ	_	28	NMOD	_	_
27	transcription	_	NN	NN	_	28	NMOD	_	_
28	factor	_	NN	NN	_	19	NMOD	_	_
29	.	_	.	.	_	12	P	_	_

1	One	_	CD	CD	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	NF-kappa	_	NN	NN	_	4	NMOD	_	_
4	B	_	NN	NN	_	7	NMOD	_	_
5	's	_	POS	POS	_	4	NMOD	_	_
6	unique	_	JJ	JJ	_	7	NMOD	_	_
7	properties	_	NNS	NNS	_	2	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	its	_	PRP$	PRP$	_	11	NMOD	_	_
10	posttranslational	_	JJ	JJ	_	11	NMOD	_	_
11	activation	_	NN	NN	_	8	PRD	_	_
12	via	_	IN	IN	_	11	NMOD	_	_
13	release	_	NN	NN	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	an	_	DT	DT	_	17	NMOD	_	_
16	inhibitory	_	JJ	JJ	_	17	NMOD	_	_
17	subunit	_	NN	NN	_	14	PMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	called	_	VBN	VBN	_	17	NMOD	_	_
20	inhibitor	_	NN	NN	_	19	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	NF-kappa	_	NN	NN	_	23	NMOD	_	_
23	B	_	NN	NN	_	21	PMOD	_	_
24	(	_	(	(	_	27	P	_	_
25	I	_	NN	NN	_	27	NMOD	_	_
26	kappa	_	NN	NN	_	27	NMOD	_	_
27	B	_	NN	NN	_	20	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	,	_	,	,	_	17	P	_	_
30	from	_	IN	IN	_	13	NMOD	_	_
31	a	_	DT	DT	_	34	NMOD	_	_
32	sequestered	_	JJ	JJ	_	34	NMOD	_	_
33	cytoplasmic	_	JJ	JJ	_	34	NMOD	_	_
34	form	_	NN	NN	_	30	PMOD	_	_
35	.	_	.	.	_	8	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	event	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	also	_	RB	RB	_	5	ADV	_	_
5	triggered	_	VBN	VBN	_	3	VC	_	_
6	under	_	IN	IN	_	5	ADV	_	_
7	various	_	JJ	JJ	_	9	NMOD	_	_
8	other	_	JJ	JJ	_	9	NMOD	_	_
9	conditions	_	NNS	NNS	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	biomedical	_	JJ	JJ	_	12	NMOD	_	_
12	importance	_	NN	NN	_	10	PMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	Other	_	JJ	JJ	_	3	NMOD	_	_
2	bacterial	_	JJ	JJ	_	3	NMOD	_	_
3	toxins	_	NNS	NNS	_	29	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	tumor	_	NN	NN	_	7	NMOD	_	_
6	necrosis	_	NN	NN	_	7	NMOD	_	_
7	factor-alpha	_	NN	NN	_	3	COORD	_	_
8	(	_	(	(	_	9	P	_	_
9	TNF	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	,	_	,	,	_	3	P	_	_
12	interleukin-1	_	NN	NN	_	3	COORD	_	_
13	(	_	(	(	_	14	P	_	_
14	IL-1	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	,	_	,	,	_	3	P	_	_
17	T	_	NN	NN	_	19	NMOD	_	_
18	cell	_	NN	NN	_	19	NMOD	_	_
19	mitogens	_	NNS	NNS	_	3	COORD	_	_
20	,	_	,	,	_	3	P	_	_
21	UV	_	NN	NN	_	22	NMOD	_	_
22	light	_	NN	NN	_	3	COORD	_	_
23	,	_	,	,	_	3	P	_	_
24	gamma	_	NN	NN	_	25	NMOD	_	_
25	rays	_	NNS	NNS	_	3	COORD	_	_
26	and	_	CC	CC	_	3	CC	_	_
27	oxidative	_	JJ	JJ	_	28	NMOD	_	_
28	stress	_	NN	NN	_	3	COORD	_	_
29	were	_	VBD	VBD	_	0	ROOT-S	_	_
30	reported	_	VBN	VBN	_	29	VC	_	_
31	to	_	TO	TO	_	32	VMOD	_	_
32	induce	_	VB	VB	_	30	OBJ	_	_
33	NF-kappa	_	NN	NN	_	34	NMOD	_	_
34	B	_	NN	NN	_	32	OBJ	_	_
35	.	_	.	.	_	29	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	activated	_	JJ	JJ	_	3	NMOD	_	_
3	form	_	NN	NN	_	16	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	NF-kappa	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	4	PMOD	_	_
7	,	_	,	,	_	3	P	_	_
8	which	_	WDT	WDT	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	3	NMOD	_	_
10	rapidly	_	RB	RB	_	11	TMP	_	_
11	taken	_	VBN	VBN	_	9	VC	_	_
12	up	_	RP	RP	_	11	PRT	_	_
13	into	_	IN	IN	_	11	ADV	_	_
14	nuclei	_	NNS	NNS	_	13	PMOD	_	_
15	,	_	,	,	_	3	P	_	_
16	initiates	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	transcription	_	NN	NN	_	16	OBJ	_	_
18	from	_	IN	IN	_	17	NMOD	_	_
19	immediate	_	JJ	JJ	_	21	NMOD	_	_
20	early	_	JJ	JJ	_	21	NMOD	_	_
21	genes	_	NNS	NNS	_	18	PMOD	_	_
22	in	_	IN	IN	_	17	NMOD	_	_
23	a	_	DT	DT	_	25	NMOD	_	_
24	wide	_	JJ	JJ	_	25	NMOD	_	_
25	variety	_	NN	NN	_	22	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	cell	_	NN	NN	_	28	NMOD	_	_
28	types	_	NNS	NNS	_	26	PMOD	_	_
29	.	_	.	.	_	16	P	_	_

1	Most	_	JJS	JJS	_	9	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	target	_	NN	NN	_	5	NMOD	_	_
5	genes	_	NNS	NNS	_	2	PMOD	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	NF-kappa	_	NN	NN	_	8	NMOD	_	_
8	B	_	NN	NN	_	6	PMOD	_	_
9	are	_	VBP	VBP	_	0	ROOT-S	_	_
10	of	_	IN	IN	_	9	PRD	_	_
11	relevance	_	NN	NN	_	10	PMOD	_	_
12	for	_	IN	IN	_	9	ADV	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	immune	_	JJ	JJ	_	15	NMOD	_	_
15	response	_	NN	NN	_	12	PMOD	_	_
16	and	_	CC	CC	_	9	CC	_	_
17	can	_	MD	MD	_	9	COORD	_	_
18	be	_	VB	VB	_	17	VC	_	_
19	grouped	_	VBN	VBN	_	18	VC	_	_
20	into	_	IN	IN	_	19	ADV	_	_
21	those	_	DT	DT	_	20	PMOD	_	_
22	encoding	_	JJ	JJ	_	23	VMOD	_	_
23	cytokines	_	NNS	NNS	_	21	NMOD	_	_
24	,	_	,	,	_	23	P	_	_
25	cell	_	NN	NN	_	27	NMOD	_	_
26	surface	_	NN	NN	_	27	NMOD	_	_
27	receptors	_	NNS	NNS	_	23	COORD	_	_
28	,	_	,	,	_	23	P	_	_
29	acute	_	JJ	JJ	_	31	NMOD	_	_
30	phase	_	NN	NN	_	31	NMOD	_	_
31	proteins	_	NNS	NNS	_	23	COORD	_	_
32	and	_	CC	CC	_	23	CC	_	_
33	viral	_	JJ	JJ	_	34	NMOD	_	_
34	genomes	_	NNS	NNS	_	23	COORD	_	_
35	,	_	,	,	_	21	P	_	_
36	such	_	JJ	JJ	_	37	DEP	_	_
37	as	_	IN	IN	_	21	NMOD	_	_
38	that	_	DT	DT	_	37	PMOD	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	human	_	JJ	JJ	_	43	NMOD	_	_
41	immunodeficiency	_	NN	NN	_	43	NMOD	_	_
42	virus	_	NN	NN	_	43	NMOD	_	_
43	type	_	NN	NN	_	39	PMOD	_	_
44	1	_	CD	CD	_	43	NMOD	_	_
45	(	_	(	(	_	46	P	_	_
46	HIV-1	_	NN	NN	_	43	PRN	_	_
47	)	_	)	)	_	46	P	_	_
48	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	will	_	MD	MD	_	0	ROOT-S	_	_
3	discuss	_	VB	VB	_	2	VC	_	_
4	recent	_	JJ	JJ	_	6	NMOD	_	_
5	experimental	_	JJ	JJ	_	6	NMOD	_	_
6	evidences	_	NNS	NNS	_	3	OBJ	_	_
7	suggesting	_	VBG	VBG	_	6	NMOD	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	LPS	_	NN	NN	_	10	SBJ	_	_
10	might	_	MD	MD	_	8	VMOD	_	_
11	share	_	VB	VB	_	10	VC	_	_
12	a	_	DT	DT	_	13	NMOD	_	_
13	pathway	_	NN	NN	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	NF-kappa	_	NN	NN	_	17	NMOD	_	_
16	B	_	NN	NN	_	17	NMOD	_	_
17	activation	_	NN	NN	_	14	PMOD	_	_
18	with	_	IN	IN	_	11	ADV	_	_
19	other	_	JJ	JJ	_	20	NMOD	_	_
20	inducers	_	NNS	NNS	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	factor	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	common	_	JJ	JJ	_	3	NMOD	_	_
3	pathway	_	NN	NN	_	4	SBJ	_	_
4	may	_	MD	MD	_	0	ROOT-S	_	_
5	involve	_	VB	VB	_	4	VC	_	_
6	reactive	_	JJ	JJ	_	8	NMOD	_	_
7	oxygen	_	NN	NN	_	8	NMOD	_	_
8	intermediates	_	NNS	NNS	_	5	OBJ	_	_
9	(	_	(	(	_	10	P	_	_
10	ROI	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	as	_	IN	IN	_	5	ADV	_	_
13	messenger	_	NN	NN	_	14	NMOD	_	_
14	molecules	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	Analysis	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	preexisting	_	JJ	JJ	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	nuclear	_	JJ	JJ	_	4	COORD	_	_
7	forms	_	NNS	NNS	_	2	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	nuclear	_	JJ	JJ	_	10	NMOD	_	_
10	factor	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	activated	_	VBN	VBN	_	14	NMOD	_	_
13	T	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	11	PMOD	_	_
15	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	nuclear	_	JJ	JJ	_	3	NMOD	_	_
3	factor	_	NN	NN	_	12	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	activated	_	VBN	VBN	_	7	NMOD	_	_
6	T	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	4	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	NF-AT	_	NN	NN	_	3	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	3	_	CD	CD	_	3	NMOD	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	an	_	DT	DT	_	16	NMOD	_	_
14	inducible	_	JJ	JJ	_	16	NMOD	_	_
15	DNA-binding	_	JJ	JJ	_	16	NMOD	_	_
16	protein	_	NN	NN	_	12	PRD	_	_
17	that	_	WDT	WDT	_	18	SBJ	_	_
18	is	_	VBZ	VBZ	_	16	NMOD	_	_
19	essential	_	JJ	JJ	_	18	PRD	_	_
20	for	_	IN	IN	_	19	AMOD	_	_
21	transcriptional	_	JJ	JJ	_	22	NMOD	_	_
22	induction	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	IL-2	_	NN	NN	_	26	NMOD	_	_
26	gene	_	NN	NN	_	23	PMOD	_	_
27	during	_	IN	IN	_	22	TMP	_	_
28	T	_	NN	NN	_	30	NMOD	_	_
29	cell	_	NN	NN	_	30	NMOD	_	_
30	activation	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	12	P	_	_

1	NF-AT	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	thought	_	VBN	VBN	_	2	VC	_	_
4	to	_	TO	TO	_	5	VMOD	_	_
5	consist	_	VB	VB	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	ADV	_	_
7	two	_	CD	CD	_	8	NMOD	_	_
8	components	_	NNS	NNS	_	6	PMOD	_	_
9	:	_	:	:	_	8	P	_	_
10	a	_	DT	DT	_	15	NMOD	_	_
11	ubiquitous	_	JJ	JJ	_	15	NMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	inducible	_	JJ	JJ	_	11	COORD	_	_
14	nuclear	_	JJ	JJ	_	15	NMOD	_	_
15	component	_	NN	NN	_	8	NMOD	_	_
16	that	_	WDT	WDT	_	19	OBJ	_	_
17	we	_	PRP	PRP	_	18	SBJ	_	_
18	have	_	VBP	VBP	_	15	NMOD	_	_
19	identified	_	VBN	VBN	_	18	VC	_	_
20	as	_	IN	IN	_	19	ADV	_	_
21	Fos	_	NN	NN	_	24	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	Jun	_	NN	NN	_	21	COORD	_	_
24	proteins	_	NNS	NNS	_	20	PMOD	_	_
25	,	_	,	,	_	15	P	_	_
26	and	_	CC	CC	_	15	CC	_	_
27	a	_	DT	DT	_	32	NMOD	_	_
28	preexisting	_	VBG	VBG	_	32	NMOD	_	_
29	,	_	,	,	_	28	P	_	_
30	T	_	NN	NN	_	28	COORD	_	_
31	cell-specific	_	JJ	JJ	_	30	AMOD	_	_
32	component	_	NN	NN	_	15	COORD	_	_
33	(	_	(	(	_	34	P	_	_
34	NF-ATp	_	NN	NN	_	32	PRN	_	_
35	)	_	)	)	_	34	P	_	_
36	which	_	WDT	WDT	_	37	SBJ	_	_
37	is	_	VBZ	VBZ	_	32	NMOD	_	_
38	the	_	DT	DT	_	39	NMOD	_	_
39	target	_	NN	NN	_	37	PRD	_	_
40	for	_	IN	IN	_	39	NMOD	_	_
41	the	_	DT	DT	_	43	NMOD	_	_
42	immunosuppressive	_	JJ	JJ	_	43	NMOD	_	_
43	agents	_	NNS	NNS	_	40	PMOD	_	_
44	cyclosporin	_	NN	NN	_	45	NMOD	_	_
45	A	_	NN	NN	_	43	NMOD	_	_
46	(	_	(	(	_	47	P	_	_
47	CsA	_	NN	NN	_	45	PRN	_	_
48	)	_	)	)	_	47	P	_	_
49	and	_	CC	CC	_	45	CC	_	_
50	FK506	_	NN	NN	_	45	COORD	_	_
51	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	previously	_	RB	RB	_	2	TMP	_	_
4	shown	_	VBN	VBN	_	2	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	extracts	_	NNS	NNS	_	12	SBJ	_	_
8	from	_	IN	IN	_	7	NMOD	_	_
9	activated	_	VBN	VBN	_	11	NMOD	_	_
10	T	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	8	PMOD	_	_
12	form	_	VBP	VBP	_	5	VMOD	_	_
13	two	_	CD	CD	_	16	NMOD	_	_
14	inducible	_	JJ	JJ	_	16	NMOD	_	_
15	NF-AT	_	NN	NN	_	16	NMOD	_	_
16	complexes	_	NNS	NNS	_	12	IOBJ	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	an	_	DT	DT	_	19	NMOD	_	_
19	oligonucleotide	_	NN	NN	_	17	PMOD	_	_
20	corresponding	_	VBG	VBG	_	19	NMOD	_	_
21	to	_	TO	TO	_	20	ADV	_	_
22	the	_	DT	DT	_	25	NMOD	_	_
23	distal	_	JJ	JJ	_	25	NMOD	_	_
24	NF-AT	_	NN	NN	_	25	NMOD	_	_
25	site	_	NN	NN	_	21	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	murine	_	JJ	JJ	_	30	NMOD	_	_
29	IL-2	_	NN	NN	_	30	NMOD	_	_
30	promoter	_	NN	NN	_	26	PMOD	_	_
31	,	_	,	,	_	12	P	_	_
32	although	_	IN	IN	_	12	OBJ	_	_
33	hypotonic	_	JJ	JJ	_	34	NMOD	_	_
34	extracts	_	NNS	NNS	_	39	SBJ	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	unstimulated	_	JJ	JJ	_	38	NMOD	_	_
37	T	_	NN	NN	_	38	NMOD	_	_
38	cells	_	NNS	NNS	_	35	PMOD	_	_
39	form	_	VBP	VBP	_	32	VMOD	_	_
40	a	_	DT	DT	_	42	NMOD	_	_
41	single	_	JJ	JJ	_	42	NMOD	_	_
42	complex	_	NN	NN	_	39	OBJ	_	_
43	containing	_	VBG	VBG	_	42	NMOD	_	_
44	NF-ATp	_	NN	NN	_	43	OBJ	_	_
45	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	ability	_	NN	NN	_	27	SBJ	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	detect	_	VB	VB	_	5	NMOD	_	_
8	NF-ATp	_	NN	NN	_	7	OBJ	_	_
9	in	_	IN	IN	_	7	ADV	_	_
10	a	_	DT	DT	_	13	NMOD	_	_
11	gel	_	NN	NN	_	13	NMOD	_	_
12	shift	_	NN	NN	_	13	NMOD	_	_
13	assay	_	NN	NN	_	9	PMOD	_	_
14	,	_	,	,	_	5	P	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	is	_	VBZ	VBZ	_	5	NMOD	_	_
17	essential	_	JJ	JJ	_	16	PRD	_	_
18	for	_	IN	IN	_	17	AMOD	_	_
19	purification	_	NN	NN	_	18	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	biochemical	_	JJ	JJ	_	22	NMOD	_	_
22	studies	_	NNS	NNS	_	19	COORD	_	_
23	of	_	IN	IN	_	19	NMOD	_	_
24	this	_	DT	DT	_	25	NMOD	_	_
25	protein	_	NN	NN	_	23	PMOD	_	_
26	,	_	,	,	_	5	P	_	_
27	is	_	VBZ	VBZ	_	3	VMOD	_	_
28	strikingly	_	RB	RB	_	29	AMOD	_	_
29	dependent	_	JJ	JJ	_	27	PRD	_	_
30	on	_	IN	IN	_	29	AMOD	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	precise	_	JJ	JJ	_	33	NMOD	_	_
33	sequence	_	NN	NN	_	30	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	the	_	DT	DT	_	37	NMOD	_	_
36	NF-AT	_	NN	NN	_	37	NMOD	_	_
37	oligonucleotide	_	NN	NN	_	34	PMOD	_	_
38	used	_	VBN	VBN	_	37	NMOD	_	_
39	as	_	IN	IN	_	38	ADV	_	_
40	the	_	DT	DT	_	42	NMOD	_	_
41	labeled	_	JJ	JJ	_	42	NMOD	_	_
42	probe	_	NN	NN	_	39	PMOD	_	_
43	.	_	.	.	_	2	P	_	_

1	Moreover	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	present	_	VBP	VBP	_	0	ROOT-S	_	_
4	evidence	_	NN	NN	_	3	OBJ	_	_
5	that	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	component	_	NN	NN	_	20	SBJ	_	_
8	that	_	WDT	WDT	_	9	SBJ	_	_
9	forms	_	VBZ	VBZ	_	7	NMOD	_	_
10	the	_	DT	DT	_	19	NMOD	_	_
11	faster-migrating	_	JJ	JJ	_	19	NMOD	_	_
12	(	_	(	(	_	14	P	_	_
13	"	_	``	``	_	14	P	_	_
14	lower	_	JJR	JJR	_	11	PRN	_	_
15	"	_	''	''	_	14	P	_	_
16	)	_	)	)	_	14	P	_	_
17	nuclear	_	JJ	JJ	_	19	NMOD	_	_
18	NF-AT	_	NN	NN	_	19	NMOD	_	_
19	complex	_	NN	NN	_	9	OBJ	_	_
20	is	_	VBZ	VBZ	_	5	VMOD	_	_
21	derived	_	VBN	VBN	_	20	VC	_	_
22	by	_	IN	IN	_	21	LGS	_	_
23	a	_	DT	DT	_	29	NMOD	_	_
24	calcium-dependent	_	JJ	JJ	_	29	NMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	cyclosporin-sensitive	_	JJ	JJ	_	24	COORD	_	_
27	,	_	,	,	_	24	P	_	_
28	posttranslational	_	JJ	JJ	_	24	TMP	_	_
29	modification	_	NN	NN	_	22	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	NF-ATp	_	NN	NN	_	30	PMOD	_	_
32	,	_	,	,	_	5	P	_	_
33	and	_	CC	CC	_	5	CC	_	_
34	that	_	IN	IN	_	5	COORD	_	_
35	Fos	_	NN	NN	_	38	NMOD	_	_
36	and	_	CC	CC	_	35	CC	_	_
37	Jun	_	NN	NN	_	35	COORD	_	_
38	proteins	_	NNS	NNS	_	39	SBJ	_	_
39	stabilize	_	VBP	VBP	_	34	VMOD	_	_
40	its	_	PRP$	PRP$	_	41	NMOD	_	_
41	interaction	_	NN	NN	_	39	OBJ	_	_
42	with	_	IN	IN	_	41	NMOD	_	_
43	DNA	_	NN	NN	_	42	PMOD	_	_
44	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	discussed	_	VBN	VBN	_	3	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	context	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	model	_	NN	NN	_	8	PMOD	_	_
11	relating	_	VBG	VBG	_	10	NMOD	_	_
12	the	_	DT	DT	_	16	NMOD	_	_
13	two	_	CD	CD	_	16	NMOD	_	_
14	nuclear	_	JJ	JJ	_	16	NMOD	_	_
15	NF-AT	_	NN	NN	_	16	NMOD	_	_
16	complexes	_	NNS	NNS	_	11	OBJ	_	_
17	to	_	TO	TO	_	11	ADV	_	_
18	NF-ATp	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	Enhancing	_	NN	NN	_	2	NMOD	_	_
2	effect	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	17	_	CD	CD	_	5	NMOD	_	_
5	beta-estradiol	_	NN	NN	_	3	PMOD	_	_
6	on	_	IN	IN	_	2	NMOD	_	_
7	human	_	JJ	JJ	_	10	NMOD	_	_
8	NK	_	NN	NN	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	activity	_	NN	NN	_	6	PMOD	_	_
11	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	in	_	FW	FW	_	3	AMOD	_	_
3	vitro	_	FW	FW	_	4	NMOD	_	_
4	effect	_	NN	NN	_	11	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	17	_	CD	CD	_	7	NMOD	_	_
7	beta-estradiol	_	NN	NN	_	5	PMOD	_	_
8	on	_	IN	IN	_	4	NMOD	_	_
9	NK	_	NN	NN	_	10	NMOD	_	_
10	activity	_	NN	NN	_	8	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	studied	_	VBN	VBN	_	11	VC	_	_
13	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	proliferation	_	NN	NN	_	15	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	NK	_	NN	NN	_	5	NMOD	_	_
5	activity	_	NN	NN	_	2	COORD	_	_
6	of	_	IN	IN	_	2	NMOD	_	_
7	YT-N17	_	NN	NN	_	6	PMOD	_	_
8	(	_	(	(	_	13	P	_	_
9	a	_	DT	DT	_	13	NMOD	_	_
10	human	_	JJ	JJ	_	13	NMOD	_	_
11	NK-like	_	JJ	JJ	_	13	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	line	_	NN	NN	_	7	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	were	_	VBD	VBD	_	0	ROOT-S	_	_
16	enhanced	_	VBN	VBN	_	15	VC	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	17	_	CD	CD	_	19	NMOD	_	_
19	beta-estradiol	_	NN	NN	_	17	PMOD	_	_
20	(	_	(	(	_	21	P	_	_
21	E2	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	,	_	,	,	_	15	P	_	_
24	and	_	CC	CC	_	15	CC	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	enhancement	_	NN	NN	_	27	SBJ	_	_
27	was	_	VBD	VBD	_	15	COORD	_	_
28	blocked	_	VBN	VBN	_	27	VC	_	_
29	by	_	IN	IN	_	28	LGS	_	_
30	tamoxifen	_	NN	NN	_	29	PMOD	_	_
31	(	_	(	(	_	32	P	_	_
32	Tx	_	NN	NN	_	30	PRN	_	_
33	)	_	)	)	_	32	P	_	_
34	,	_	,	,	_	30	P	_	_
35	an	_	DT	DT	_	36	NMOD	_	_
36	antagonist	_	NN	NN	_	30	NMOD	_	_
37	of	_	IN	IN	_	36	NMOD	_	_
38	E2	_	NN	NN	_	37	PMOD	_	_
39	.	_	.	.	_	15	P	_	_

1	On	_	IN	IN	_	16	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	contrary	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	16	P	_	_
5	other	_	JJ	JJ	_	7	NMOD	_	_
6	steroid	_	NN	NN	_	7	NMOD	_	_
7	hormones	_	NNS	NNS	_	16	SBJ	_	_
8	such	_	JJ	JJ	_	9	DEP	_	_
9	as	_	IN	IN	_	7	NMOD	_	_
10	Tx	_	NN	NN	_	9	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	progesterone	_	NN	NN	_	10	COORD	_	_
13	,	_	,	,	_	10	P	_	_
14	and	_	CC	CC	_	10	CC	_	_
15	testosterone	_	NN	NN	_	10	COORD	_	_
16	had	_	VBD	VBD	_	0	ROOT-S	_	_
17	no	_	DT	DT	_	18	NMOD	_	_
18	effect	_	NN	NN	_	16	OBJ	_	_
19	.	_	.	.	_	16	P	_	_

1	YT-N17	_	NN	NN	_	2	SBJ	_	_
2	contained	_	VBD	VBD	_	0	ROOT-S	_	_
3	11.8	_	CD	CD	_	4	AMOD	_	_
4	fmol\/mg	_	NN	NN	_	5	NMOD	_	_
5	protein	_	NN	NN	_	2	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	estrogen	_	NN	NN	_	8	NMOD	_	_
8	receptor	_	NN	NN	_	6	PMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	mean	_	NN	NN	_	5	PRN	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	two	_	CD	CD	_	14	NMOD	_	_
13	independent	_	JJ	JJ	_	14	NMOD	_	_
14	assays	_	NNS	NNS	_	11	PMOD	_	_
15	)	_	)	)	_	10	P	_	_
16	,	_	,	,	_	5	P	_	_
17	a	_	DT	DT	_	18	NMOD	_	_
18	value	_	NN	NN	_	5	NMOD	_	_
19	which	_	WDT	WDT	_	20	SBJ	_	_
20	was	_	VBD	VBD	_	18	NMOD	_	_
21	5-10-fold	_	RB	RB	_	22	AMOD	_	_
22	higher	_	JJR	JJR	_	20	PRD	_	_
23	than	_	IN	IN	_	22	AMOD	_	_
24	that	_	DT	DT	_	23	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	other	_	JJ	JJ	_	29	NMOD	_	_
27	hematopoietic	_	JJ	JJ	_	29	NMOD	_	_
28	cell	_	NN	NN	_	29	NMOD	_	_
29	lines	_	NNS	NNS	_	25	PMOD	_	_
30	.	_	.	.	_	2	P	_	_

1	An	_	DT	DT	_	2	NMOD	_	_
2	enhancement	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NK	_	NN	NN	_	5	NMOD	_	_
5	activity	_	NN	NN	_	3	PMOD	_	_
6	by	_	IN	IN	_	2	NMOD	_	_
7	E2	_	NN	NN	_	6	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	also	_	RB	RB	_	10	ADV	_	_
10	seen	_	VBN	VBN	_	8	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	large	_	JJ	JJ	_	14	NMOD	_	_
13	granular	_	JJ	JJ	_	14	NMOD	_	_
14	lymphocytes	_	NNS	NNS	_	11	PMOD	_	_
15	obtained	_	VBN	VBN	_	14	NMOD	_	_
16	from	_	IN	IN	_	15	ADV	_	_
17	normal	_	JJ	JJ	_	18	NMOD	_	_
18	subjects	_	NNS	NNS	_	16	PMOD	_	_
19	,	_	,	,	_	8	P	_	_
20	and	_	CC	CC	_	8	CC	_	_
21	it	_	PRP	PRP	_	22	SBJ	_	_
22	was	_	VBD	VBD	_	8	COORD	_	_
23	again	_	RB	RB	_	24	TMP	_	_
24	suppressed	_	VBN	VBN	_	22	VC	_	_
25	by	_	IN	IN	_	24	LGS	_	_
26	Tx	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	8	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	E2	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	4	VMOD	_	_
7	one	_	CD	CD	_	6	PRD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	activating	_	VBG	VBG	_	11	NMOD	_	_
11	factors	_	NNS	NNS	_	8	PMOD	_	_
12	for	_	IN	IN	_	11	NMOD	_	_
13	NK\/LGL	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	Cytokine	_	NN	NN	_	2	NMOD	_	_
2	modulation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	HIV	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	3	PMOD	_	_
6	.	_	.	.	_	2	P	_	_

1	Cytokines	_	NNS	NNS	_	27	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	peptide	_	NN	NN	_	5	NMOD	_	_
5	hormones	_	NNS	NNS	_	1	NMOD	_	_
6	which	_	WDT	WDT	_	7	SBJ	_	_
7	control	_	VBP	VBP	_	5	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	homeostasis	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	immune	_	JJ	JJ	_	13	NMOD	_	_
13	system	_	NN	NN	_	10	PMOD	_	_
14	and	_	CC	CC	_	7	CC	_	_
15	also	_	RB	RB	_	7	COORD	_	_
16	play	_	VBP	VBP	_	7	COORD	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	fundamental	_	JJ	JJ	_	19	NMOD	_	_
19	role	_	NN	NN	_	16	OBJ	_	_
20	in	_	IN	IN	_	16	ADV	_	_
21	inflammatory	_	JJ	JJ	_	25	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	immune	_	JJ	JJ	_	24	AMOD	_	_
24	mediated	_	JJ	JJ	_	21	COORD	_	_
25	reactions	_	NNS	NNS	_	20	PMOD	_	_
26	,	_	,	,	_	1	P	_	_
27	have	_	VBP	VBP	_	0	ROOT-S	_	_
28	been	_	VBN	VBN	_	27	VC	_	_
29	involved	_	VBN	VBN	_	28	VC	_	_
30	at	_	IN	IN	_	29	ADV	_	_
31	multiple	_	JJ	JJ	_	32	NMOD	_	_
32	levels	_	NNS	NNS	_	30	PMOD	_	_
33	in	_	IN	IN	_	32	NMOD	_	_
34	the	_	DT	DT	_	35	NMOD	_	_
35	pathogenesis	_	NN	NN	_	33	PMOD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	the	_	DT	DT	_	41	NMOD	_	_
38	acquired	_	VBN	VBN	_	41	NMOD	_	_
39	immune	_	JJ	JJ	_	41	NMOD	_	_
40	deficiency	_	NN	NN	_	41	NMOD	_	_
41	syndrome	_	NN	NN	_	36	PMOD	_	_
42	(	_	(	(	_	43	P	_	_
43	AIDS	_	NN	NN	_	41	PRN	_	_
44	)	_	)	)	_	43	P	_	_
45	.	_	.	.	_	27	P	_	_

1	Infection	_	NN	NN	_	10	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	human	_	JJ	JJ	_	6	NMOD	_	_
5	immunodeficiency	_	NN	NN	_	6	NMOD	_	_
6	virus	_	NN	NN	_	2	PMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	HIV	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	been	_	VBN	VBN	_	10	VC	_	_
12	shown	_	VBN	VBN	_	11	VC	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	induce	_	VB	VB	_	12	OBJ	_	_
15	production	_	NN	NN	_	14	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	several	_	JJ	JJ	_	18	NMOD	_	_
18	cytokines	_	NNS	NNS	_	16	PMOD	_	_
19	both	_	CC	CC	_	20	CC	_	_
20	in	_	FW	FW	_	14	ADV	_	_
21	vitro	_	FW	FW	_	20	AMOD	_	_
22	and	_	CC	CC	_	20	CC	_	_
23	in	_	FW	FW	_	20	COORD	_	_
24	vivo	_	FW	FW	_	23	AMOD	_	_
25	.	_	.	.	_	10	P	_	_

1	Conversely	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	several	_	JJ	JJ	_	4	NMOD	_	_
4	cytokines	_	NNS	NNS	_	5	SBJ	_	_
5	modulate	_	VBP	VBP	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	levels	_	NNS	NNS	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	HIV	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	8	PMOD	_	_
11	in	_	IN	IN	_	7	NMOD	_	_
12	infected	_	JJ	JJ	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	both	_	CC	CC	_	16	CC	_	_
16	T	_	NN	NN	_	21	NMOD	_	_
17	lymphocytic	_	JJ	JJ	_	16	AMOD	_	_
18	and	_	CC	CC	_	16	CC	_	_
19	mononuclear	_	JJ	JJ	_	20	AMOD	_	_
20	phagocytic	_	JJ	JJ	_	16	COORD	_	_
21	lineage	_	NN	NN	_	14	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	Activated	_	VBN	VBN	_	3	NMOD	_	_
2	mononuclear	_	JJ	JJ	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	21	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	particularly	_	RB	RB	_	7	NMOD	_	_
6	B	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	3	NMOD	_	_
8	which	_	WDT	WDT	_	9	SBJ	_	_
9	are	_	VBP	VBP	_	7	NMOD	_	_
10	in	_	IN	IN	_	9	PRD	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	state	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	chronic	_	JJ	JJ	_	15	NMOD	_	_
15	activation	_	NN	NN	_	13	PMOD	_	_
16	in	_	IN	IN	_	9	ADV	_	_
17	HIV	_	NN	NN	_	19	NMOD	_	_
18	infected	_	JJ	JJ	_	17	AMOD	_	_
19	individuals	_	NNS	NNS	_	16	PMOD	_	_
20	,	_	,	,	_	3	P	_	_
21	release	_	VBP	VBP	_	0	ROOT-S	_	_
22	HIV-inductive	_	JJ	JJ	_	23	NMOD	_	_
23	cytokines	_	NNS	NNS	_	21	OBJ	_	_
24	and	_	CC	CC	_	21	CC	_	_
25	thus	_	RB	RB	_	21	COORD	_	_
26	play	_	VBP	VBP	_	21	COORD	_	_
27	a	_	DT	DT	_	30	NMOD	_	_
28	potentially	_	RB	RB	_	29	AMOD	_	_
29	important	_	JJ	JJ	_	30	NMOD	_	_
30	role	_	NN	NN	_	26	OBJ	_	_
31	in	_	IN	IN	_	26	ADV	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	pathogenesis	_	NN	NN	_	31	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	HIV	_	NN	NN	_	36	NMOD	_	_
36	infection	_	NN	NN	_	34	PMOD	_	_
37	.	_	.	.	_	21	P	_	_

1	FK506	_	NN	NN	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	ciclosporin	_	NN	NN	_	1	COORD	_	_
4	:	_	:	:	_	1	P	_	_
5	molecular	_	JJ	JJ	_	6	NMOD	_	_
6	probes	_	NNS	NNS	_	1	NMOD	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	studying	_	VBG	VBG	_	7	PMOD	_	_
9	intracellular	_	JJ	JJ	_	11	NMOD	_	_
10	signal	_	NN	NN	_	11	NMOD	_	_
11	transduction	_	NN	NN	_	8	OBJ	_	_
12	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	immunosuppressants	_	NNS	NNS	_	6	SBJ	_	_
3	ciclosporin	_	NN	NN	_	2	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	FK506	_	NN	NN	_	3	COORD	_	_
6	block	_	VBP	VBP	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	Ca-LRB-2+-RRB--dependent	_	JJ	JJ	_	10	NMOD	_	_
9	signal-transduction	_	NN	NN	_	10	NMOD	_	_
10	pathway	_	NN	NN	_	6	IOBJ	_	_
11	emanating	_	VBG	VBG	_	10	NMOD	_	_
12	from	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	T-cell	_	NN	NN	_	15	NMOD	_	_
15	receptor	_	NN	NN	_	12	PMOD	_	_
16	,	_	,	,	_	6	P	_	_
17	thereby	_	RB	RB	_	18	ADV	_	_
18	inhibiting	_	VBG	VBG	_	6	OBJ	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	activation	_	NN	NN	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	helper	_	NN	NN	_	24	NMOD	_	_
23	T	_	NN	NN	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	21	PMOD	_	_
25	.	_	.	.	_	6	P	_	_

1	Using	_	VBG	VBG	_	10	VMOD	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	drugs	_	NNS	NNS	_	1	OBJ	_	_
4	as	_	IN	IN	_	1	ADV	_	_
5	probes	_	NNS	NNS	_	4	PMOD	_	_
6	,	_	,	,	_	10	P	_	_
7	chemists	_	NNS	NNS	_	10	SBJ	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	biologists	_	NNS	NNS	_	7	COORD	_	_
10	have	_	VBP	VBP	_	0	ROOT-S	_	_
11	uncovered	_	VBN	VBN	_	10	VC	_	_
12	several	_	JJ	JJ	_	15	NMOD	_	_
13	intracellular	_	JJ	JJ	_	15	NMOD	_	_
14	signalling	_	NN	NN	_	15	NMOD	_	_
15	molecules	_	NNS	NNS	_	11	OBJ	_	_
16	bridging	_	VBG	VBG	_	15	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	generation	_	NN	NN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	second-messenger	_	NN	NN	_	22	NMOD	_	_
21	Ca2+	_	NN	NN	_	22	NMOD	_	_
22	ions	_	NNS	NNS	_	19	PMOD	_	_
23	and	_	CC	CC	_	18	CC	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	transcriptional	_	JJ	JJ	_	26	NMOD	_	_
26	activation	_	NN	NN	_	18	COORD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	IL-2	_	NN	NN	_	27	PMOD	_	_
29	,	_	,	,	_	15	P	_	_
30	among	_	IN	IN	_	32	PRD	_	_
31	which	_	WDT	WDT	_	30	PMOD	_	_
32	are	_	VBP	VBP	_	15	NMOD	_	_
33	calmodulin	_	NN	NN	_	32	SBJ	_	_
34	,	_	,	,	_	33	P	_	_
35	calcineurin	_	NN	NN	_	33	COORD	_	_
36	and	_	CC	CC	_	33	CC	_	_
37	the	_	DT	DT	_	39	NMOD	_	_
38	nuclear	_	JJ	JJ	_	39	NMOD	_	_
39	factor	_	NN	NN	_	33	COORD	_	_
40	of	_	IN	IN	_	39	NMOD	_	_
41	activated	_	VBN	VBN	_	43	NMOD	_	_
42	T	_	NN	NN	_	43	NMOD	_	_
43	cells	_	NNS	NNS	_	40	PMOD	_	_
44	(	_	(	(	_	45	P	_	_
45	NF-AT	_	NN	NN	_	39	PRN	_	_
46	)	_	)	)	_	45	P	_	_
47	.	_	.	.	_	10	P	_	_

1	Hence	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	Ca2+	_	NN	NN	_	4	SBJ	_	_
4	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	calmodulin	_	NN	NN	_	5	PMOD	_	_
7	,	_	,	,	_	4	P	_	_
8	leading	_	VBG	VBG	_	4	OBJ	_	_
9	to	_	TO	TO	_	8	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	binding	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	calmodulin	_	NN	NN	_	12	PMOD	_	_
14	to	_	TO	TO	_	11	NMOD	_	_
15	calcineurin	_	NN	NN	_	14	PMOD	_	_
16	;	_	:	:	_	4	P	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	activated	_	VBN	VBN	_	19	NMOD	_	_
19	calcineurin	_	NN	NN	_	24	SBJ	_	_
20	,	_	,	,	_	24	P	_	_
21	in	_	IN	IN	_	24	ADV	_	_
22	turn	_	NN	NN	_	21	PMOD	_	_
23	,	_	,	,	_	24	P	_	_
24	may	_	MD	MD	_	4	COORD	_	_
25	dephosphorylate	_	VB	VB	_	24	VC	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	cytoplasmic	_	JJ	JJ	_	28	NMOD	_	_
28	subunit	_	NN	NN	_	25	IOBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	NF-AT	_	NN	NN	_	29	PMOD	_	_
31	,	_	,	,	_	25	P	_	_
32	resulting	_	VBG	VBG	_	25	OBJ	_	_
33	in	_	IN	IN	_	32	ADV	_	_
34	its	_	PRP$	PRP$	_	35	NMOD	_	_
35	translocation	_	NN	NN	_	33	PMOD	_	_
36	from	_	IN	IN	_	35	NMOD	_	_
37	the	_	DT	DT	_	38	NMOD	_	_
38	cytoplasm	_	NN	NN	_	36	PMOD	_	_
39	into	_	IN	IN	_	35	NMOD	_	_
40	the	_	DT	DT	_	41	NMOD	_	_
41	nucleus	_	NN	NN	_	39	PMOD	_	_
42	to	_	TO	TO	_	43	VMOD	_	_
43	form	_	VB	VB	_	35	NMOD	_	_
44	a	_	DT	DT	_	47	NMOD	_	_
45	competent	_	JJ	JJ	_	47	NMOD	_	_
46	transcriptional	_	JJ	JJ	_	47	NMOD	_	_
47	activator	_	NN	NN	_	43	OBJ	_	_
48	.	_	.	.	_	4	P	_	_

1	As	_	IN	IN	_	9	ADV	_	_
2	described	_	VBN	VBN	_	1	VMOD	_	_
3	by	_	IN	IN	_	2	LGS	_	_
4	Jun	_	NNP	NNP	_	5	NMOD	_	_
5	Liu	_	NNP	NNP	_	3	PMOD	_	_
6	,	_	,	,	_	9	P	_	_
7	these	_	DT	DT	_	8	NMOD	_	_
8	drugs	_	NNS	NNS	_	9	SBJ	_	_
9	manifest	_	VBP	VBP	_	0	ROOT-S	_	_
10	their	_	PRP$	PRP$	_	11	NMOD	_	_
11	effects	_	NNS	NNS	_	9	OBJ	_	_
12	in	_	IN	IN	_	9	ADV	_	_
13	an	_	DT	DT	_	15	NMOD	_	_
14	unprecedented	_	JJ	JJ	_	15	NMOD	_	_
15	fashion	_	NN	NN	_	12	PMOD	_	_
16	.	_	.	.	_	9	P	_	_

1	They	_	PRP	PRP	_	2	SBJ	_	_
2	do	_	VBP	VBP	_	0	ROOT-S	_	_
3	not	_	RB	RB	_	2	VMOD	_	_
4	directly	_	RB	RB	_	2	ADV	_	_
5	intercept	_	VB	VB	_	2	VC	_	_
6	intracellular	_	JJ	JJ	_	8	NMOD	_	_
7	signalling	_	NN	NN	_	8	NMOD	_	_
8	molecules	_	NNS	NNS	_	5	OBJ	_	_
9	.	_	.	.	_	2	P	_	_

1	Instead	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	they	_	PRP	PRP	_	4	SBJ	_	_
4	form	_	VBP	VBP	_	0	ROOT-S	_	_
5	tight	_	JJ	JJ	_	6	NMOD	_	_
6	complexes	_	NNS	NNS	_	4	OBJ	_	_
7	with	_	IN	IN	_	4	ADV	_	_
8	two	_	CD	CD	_	10	NMOD	_	_
9	different	_	JJ	JJ	_	10	NMOD	_	_
10	classes	_	NNS	NNS	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	abundant	_	JJ	JJ	_	14	NMOD	_	_
13	cytosolic	_	JJ	JJ	_	14	NMOD	_	_
14	receptors	_	NNS	NNS	_	11	PMOD	_	_
15	called	_	VBN	VBN	_	14	NMOD	_	_
16	immunophilins	_	NNS	NNS	_	15	OBJ	_	_
17	upon	_	IN	IN	_	4	TMP	_	_
18	entering	_	VBG	VBG	_	17	PMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	cell	_	NN	NN	_	18	OBJ	_	_
21	,	_	,	,	_	4	P	_	_
22	and	_	CC	CC	_	4	CC	_	_
23	consequently	_	RB	RB	_	24	ADV	_	_
24	inhibit	_	VBP	VBP	_	4	COORD	_	_
25	their	_	PRP$	PRP$	_	30	NMOD	_	_
26	peptidyl	_	JJ	JJ	_	30	NMOD	_	_
27	prolyl	_	JJ	JJ	_	30	NMOD	_	_
28	cis-trans	_	JJ	JJ	_	30	NMOD	_	_
29	isomerase	_	NN	NN	_	30	NMOD	_	_
30	activities	_	NNS	NNS	_	24	OBJ	_	_
31	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	two	_	CD	CD	_	6	NMOD	_	_
3	structurally	_	RB	RB	_	4	AMOD	_	_
4	distinct	_	JJ	JJ	_	6	NMOD	_	_
5	immunophilin-drug	_	JJ	JJ	_	6	NMOD	_	_
6	complexes	_	NNS	NNS	_	7	SBJ	_	_
7	bind	_	VBP	VBP	_	0	ROOT-S	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	,	_	,	,	_	7	P	_	_
10	and	_	CC	CC	_	7	CC	_	_
11	inhibit	_	VBP	VBP	_	7	COORD	_	_
12	,	_	,	,	_	7	P	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	phosphatase	_	JJ	JJ	_	15	NMOD	_	_
15	activity	_	NN	NN	_	8	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	calcineurin	_	NN	NN	_	16	PMOD	_	_
18	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	8	NMOD	_	_
2	impaired	_	JJ	JJ	_	8	NMOD	_	_
3	transcription	_	NN	NN	_	8	NMOD	_	_
4	factor	_	NN	NN	_	8	NMOD	_	_
5	AP-1	_	NN	NN	_	8	NMOD	_	_
6	DNA	_	NN	NN	_	8	NMOD	_	_
7	binding	_	NN	NN	_	8	NMOD	_	_
8	activity	_	NN	NN	_	0	ROOT-FRAG	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
11	derived	_	VBN	VBN	_	10	NMOD	_	_
12	from	_	IN	IN	_	11	ADV	_	_
13	subjects	_	NNS	NNS	_	12	PMOD	_	_
14	with	_	IN	IN	_	13	NMOD	_	_
15	some	_	DT	DT	_	16	NMOD	_	_
16	symptoms	_	NNS	NNS	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	premature	_	JJ	JJ	_	19	NMOD	_	_
19	aging	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	study	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	human	_	JJ	JJ	_	5	NMOD	_	_
5	disorders	_	NNS	NNS	_	3	PMOD	_	_
6	known	_	VBN	VBN	_	5	NMOD	_	_
7	as	_	IN	IN	_	6	ADV	_	_
8	premature	_	JJ	JJ	_	10	NMOD	_	_
9	aging	_	NN	NN	_	10	NMOD	_	_
10	syndromes	_	NNS	NNS	_	7	PMOD	_	_
11	may	_	MD	MD	_	0	ROOT-S	_	_
12	provide	_	VB	VB	_	11	VC	_	_
13	insight	_	NN	NN	_	12	OBJ	_	_
14	into	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	mechanisms	_	NNS	NNS	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	cellular	_	JJ	JJ	_	19	NMOD	_	_
19	senescence	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	main	_	JJ	JJ	_	3	NMOD	_	_
3	feature	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	cellular	_	JJ	JJ	_	6	NMOD	_	_
6	senescence	_	NN	NN	_	4	PMOD	_	_
7	in	_	FW	FW	_	6	NMOD	_	_
8	vitro	_	FW	FW	_	7	AMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	cessation	_	NN	NN	_	9	PRD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	proliferation	_	NN	NN	_	11	PMOD	_	_
14	.	_	.	.	_	9	P	_	_

1	Down	_	NN	NN	_	2	NMOD	_	_
2	syndrome	_	NN	NN	_	12	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	DS	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	and	_	CC	CC	_	2	CC	_	_
7	neuronal	_	JJ	JJ	_	8	NMOD	_	_
8	ceroid-lypofuscinosis	_	NN	NN	_	2	COORD	_	_
9	(	_	(	(	_	10	P	_	_
10	NCL	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	are	_	VBP	VBP	_	0	ROOT-S	_	_
13	clinically	_	RB	RB	_	14	ADV	_	_
14	characterized	_	VBN	VBN	_	12	VC	_	_
15	by	_	IN	IN	_	14	LGS	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	premature	_	JJ	JJ	_	18	NMOD	_	_
18	onset	_	NN	NN	_	15	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	numerous	_	JJ	JJ	_	21	NMOD	_	_
21	features	_	NNS	NNS	_	19	PMOD	_	_
22	normally	_	RB	RB	_	23	ADV	_	_
23	associated	_	VBN	VBN	_	21	NMOD	_	_
24	with	_	IN	IN	_	23	ADV	_	_
25	human	_	JJ	JJ	_	26	NMOD	_	_
26	aging	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	12	P	_	_

1	Phytohemagglutinin	_	NN	NN	_	2	AMOD	_	_
2	stimulated	_	JJ	JJ	_	3	NMOD	_	_
3	lymphocytes	_	NNS	NNS	_	8	SBJ	_	_
4	derived	_	VBN	VBN	_	3	NMOD	_	_
5	from	_	IN	IN	_	4	ADV	_	_
6	DS	_	NN	NN	_	7	NMOD	_	_
7	subjects	_	NNS	NNS	_	5	PMOD	_	_
8	showed	_	VBD	VBD	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	14	NMOD	_	_
10	statistically	_	RB	RB	_	11	AMOD	_	_
11	significant	_	JJ	JJ	_	14	NMOD	_	_
12	diminished	_	VBN	VBN	_	14	NMOD	_	_
13	proliferation	_	NN	NN	_	14	NMOD	_	_
14	capacity	_	NN	NN	_	8	OBJ	_	_
15	in	_	IN	IN	_	8	ADV	_	_
16	comparison	_	NN	NN	_	15	DEP	_	_
17	with	_	IN	IN	_	15	DEP	_	_
18	lymphocytes	_	NNS	NNS	_	15	PMOD	_	_
19	derived	_	VBN	VBN	_	18	NMOD	_	_
20	from	_	IN	IN	_	19	ADV	_	_
21	NCL	_	NN	NN	_	24	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	healthy	_	JJ	JJ	_	21	COORD	_	_
24	individuals	_	NNS	NNS	_	20	PMOD	_	_
25	.	_	.	.	_	8	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
3	,	_	,	,	_	2	P	_	_
4	by	_	IN	IN	_	2	ADV	_	_
5	applying	_	VBG	VBG	_	4	PMOD	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	electrophoretic	_	JJ	JJ	_	10	NMOD	_	_
8	mobility	_	NN	NN	_	10	NMOD	_	_
9	shift	_	NN	NN	_	10	NMOD	_	_
10	assay	_	NN	NN	_	5	OBJ	_	_
11	,	_	,	,	_	2	P	_	_
12	slightly	_	RB	RB	_	13	AMOD	_	_
13	impaired	_	JJ	JJ	_	17	NMOD	_	_
14	AP-1	_	NN	NN	_	17	NMOD	_	_
15	DNA	_	NN	NN	_	17	NMOD	_	_
16	binding	_	NN	NN	_	17	NMOD	_	_
17	activity	_	NN	NN	_	2	OBJ	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	NCL	_	NN	NN	_	20	NMOD	_	_
20	lymphocytes	_	NNS	NNS	_	18	PMOD	_	_
21	and	_	CC	CC	_	17	CC	_	_
22	strong	_	JJ	JJ	_	13	GAP	_	_
23	in	_	IN	IN	_	18	GAP	_	_
24	DS	_	NN	NN	_	25	NMOD	_	_
25	ones	_	NNS	NNS	_	23	PMOD	_	_
26	.	_	.	.	_	2	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	showed	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	same	_	JJ	JJ	_	8	NMOD	_	_
7	molecular	_	JJ	JJ	_	8	NMOD	_	_
8	mechanisms	_	NNS	NNS	_	12	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	proliferation	_	NN	NN	_	11	NMOD	_	_
11	cessation	_	NN	NN	_	9	PMOD	_	_
12	could	_	MD	MD	_	4	VMOD	_	_
13	exist	_	VB	VB	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	fibroblasts	_	NNS	NNS	_	14	PMOD	_	_
16	characterized	_	VBN	VBN	_	15	NMOD	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	replicative	_	JJ	JJ	_	19	NMOD	_	_
19	senescence	_	NN	NN	_	17	PMOD	_	_
20	and	_	CC	CC	_	14	CC	_	_
21	in	_	IN	IN	_	14	COORD	_	_
22	lymphocytes	_	NNS	NNS	_	21	PMOD	_	_
23	derived	_	VBN	VBN	_	22	NMOD	_	_
24	from	_	IN	IN	_	23	ADV	_	_
25	individuals	_	NNS	NNS	_	24	PMOD	_	_
26	with	_	IN	IN	_	25	NMOD	_	_
27	premature	_	JJ	JJ	_	29	NMOD	_	_
28	aging	_	NN	NN	_	29	NMOD	_	_
29	syndromes	_	NNS	NNS	_	26	PMOD	_	_
30	(	_	(	(	_	31	P	_	_
31	Down	_	NN	NN	_	29	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	.	_	.	.	_	3	P	_	_

1	Cellular	_	JJ	JJ	_	2	AMOD	_	_
2	immune	_	JJ	JJ	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	cytokine	_	NN	NN	_	2	COORD	_	_
5	pathways	_	NNS	NNS	_	0	ROOT-FRAG	_	_
6	resulting	_	VBG	VBG	_	5	NMOD	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	tissue	_	NN	NN	_	10	NMOD	_	_
9	factor	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	7	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	relevance	_	NN	NN	_	10	COORD	_	_
13	to	_	TO	TO	_	12	NMOD	_	_
14	septic	_	JJ	JJ	_	15	NMOD	_	_
15	shock	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	5	P	_	_

1	Cells	_	NNS	NNS	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	monocyte	_	NN	NN	_	4	NMOD	_	_
4	lineage	_	NN	NN	_	2	PMOD	_	_
5	serve	_	VBP	VBP	_	0	ROOT-S	_	_
6	as	_	IN	IN	_	5	ADV	_	_
7	effector	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	in	_	IN	IN	_	5	ADV	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	cellular	_	JJ	JJ	_	13	NMOD	_	_
12	immune	_	JJ	JJ	_	13	NMOD	_	_
13	response	_	NN	NN	_	9	PMOD	_	_
14	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	they	_	PRP	PRP	_	5	SBJ	_	_
5	respond	_	VBP	VBP	_	0	ROOT-S	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	LPS	_	NN	NN	_	6	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	cytokines	_	NNS	NNS	_	7	COORD	_	_
10	with	_	IN	IN	_	5	ADV	_	_
11	activation	_	NN	NN	_	10	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	expression	_	NN	NN	_	11	COORD	_	_
14	of	_	IN	IN	_	11	NMOD	_	_
15	inflammatory	_	JJ	JJ	_	18	NMOD	_	_
16	effector	_	NN	NN	_	18	NMOD	_	_
17	gene	_	NN	NN	_	18	NMOD	_	_
18	products	_	NNS	NNS	_	14	PMOD	_	_
19	similar	_	JJ	JJ	_	18	NMOD	_	_
20	to	_	TO	TO	_	19	AMOD	_	_
21	those	_	DT	DT	_	20	PMOD	_	_
22	elicited	_	VBN	VBN	_	21	NMOD	_	_
23	by	_	IN	IN	_	22	LGS	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	antigen	_	NN	NN	_	26	AMOD	_	_
26	driven	_	JJ	JJ	_	27	NMOD	_	_
27	response	_	NN	NN	_	23	PMOD	_	_
28	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	response	_	NN	NN	_	5	SBJ	_	_
3	to	_	TO	TO	_	2	NMOD	_	_
4	antigen	_	NN	NN	_	3	PMOD	_	_
5	proceeds	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	at	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	11	NMOD	_	_
8	T	_	NN	NN	_	11	NMOD	_	_
9	helper	_	NN	NN	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	level	_	NN	NN	_	6	PMOD	_	_
12	through	_	IN	IN	_	5	ADV	_	_
13	two	_	CD	CD	_	15	NMOD	_	_
14	independent	_	JJ	JJ	_	15	NMOD	_	_
15	forms	_	NNS	NNS	_	12	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	cellular	_	JJ	JJ	_	18	NMOD	_	_
18	collaboration	_	NN	NN	_	16	PMOD	_	_
19	,	_	,	,	_	15	P	_	_
20	contact	_	NN	NN	_	15	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	lymphokine	_	NN	NN	_	20	COORD	_	_
23	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	review	_	VBP	VBP	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	control	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	expression	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	14	NMOD	_	_
9	Tissue	_	NN	NN	_	10	NMOD	_	_
10	Factor	_	NN	NN	_	14	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	TF	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	gene	_	NN	NN	_	7	PMOD	_	_
15	and	_	CC	CC	_	4	CC	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	function	_	NN	NN	_	4	COORD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	TF	_	NN	NN	_	21	NMOD	_	_
21	protein	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	enhanced	_	VBN	VBN	_	3	NMOD	_	_
3	initiation	_	NN	NN	_	10	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	transcription	_	NN	NN	_	4	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	TF	_	NN	NN	_	9	NMOD	_	_
9	gene	_	NN	NN	_	6	PMOD	_	_
10	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	require	_	VB	VB	_	10	OBJ	_	_
13	engagement	_	NN	NN	_	12	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	a	_	DT	DT	_	20	NMOD	_	_
16	56	_	CD	CD	_	17	AMOD	_	_
17	bp	_	NN	NN	_	20	NMOD	_	_
18	LPS	_	NN	NN	_	20	NMOD	_	_
19	Response	_	NN	NN	_	20	NMOD	_	_
20	Element	_	NN	NN	_	14	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	an	_	DT	DT	_	23	NMOD	_	_
23	enhancer	_	NN	NN	_	20	NMOD	_	_
24	that	_	WDT	WDT	_	25	SBJ	_	_
25	is	_	VBZ	VBZ	_	23	NMOD	_	_
26	engaged	_	VBN	VBN	_	25	VC	_	_
27	by	_	IN	IN	_	26	LGS	_	_
28	both	_	DT	DT	_	32	NMOD	_	_
29	AP-1	_	NN	NN	_	32	NMOD	_	_
30	type	_	NN	NN	_	32	NMOD	_	_
31	heterodimeric	_	JJ	JJ	_	32	NMOD	_	_
32	complexes	_	NNS	NNS	_	27	PMOD	_	_
33	as	_	RB	RB	_	32	CC	_	_
34	well	_	RB	RB	_	33	DEP	_	_
35	as	_	IN	IN	_	33	DEP	_	_
36	NF	_	NN	NN	_	38	NMOD	_	_
37	kappa	_	NN	NN	_	38	NMOD	_	_
38	B	_	NN	NN	_	41	NMOD	_	_
39	like	_	IN	IN	_	38	AMOD	_	_
40	heterodimeric	_	JJ	JJ	_	41	NMOD	_	_
41	complexes	_	NNS	NNS	_	32	COORD	_	_
42	.	_	.	.	_	10	P	_	_

1	Dissociation	_	NN	NN	_	22	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	NF	_	NN	NN	_	5	NMOD	_	_
4	kappa	_	NN	NN	_	5	NMOD	_	_
5	B	_	NN	NN	_	2	PMOD	_	_
6	from	_	IN	IN	_	1	NMOD	_	_
7	Ig	_	NN	NN	_	9	NMOD	_	_
8	kappa	_	NN	NN	_	9	NMOD	_	_
9	B	_	NN	NN	_	6	PMOD	_	_
10	by	_	IN	IN	_	1	NMOD	_	_
11	cytokine	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	LPS	_	NN	NN	_	11	COORD	_	_
14	stimulation	_	NN	NN	_	10	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	and	_	CC	CC	_	14	CC	_	_
17	possibly	_	RB	RB	_	20	NMOD	_	_
18	activated	_	VBN	VBN	_	20	NMOD	_	_
19	T	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	14	COORD	_	_
21	,	_	,	,	_	14	P	_	_
22	may	_	MD	MD	_	0	ROOT-S	_	_
23	represent	_	VB	VB	_	22	VC	_	_
24	a	_	DT	DT	_	26	NMOD	_	_
25	common	_	JJ	JJ	_	26	NMOD	_	_
26	pathway	_	NN	NN	_	23	OBJ	_	_
27	to	_	TO	TO	_	26	NMOD	_	_
28	induction	_	NN	NN	_	27	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	TF	_	NN	NN	_	29	PMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	other	_	JJ	JJ	_	31	NMOD	_	_
34	inflammatory	_	JJ	JJ	_	31	NMOD	_	_
35	genes	_	NNS	NNS	_	31	NMOD	_	_
36	.	_	.	.	_	22	P	_	_

1	Enhancement	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	expression	_	NN	NN	_	2	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	TF	_	NN	NN	_	4	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	observed	_	VBN	VBN	_	6	VC	_	_
8	upon	_	IN	IN	_	7	TMP	_	_
9	adhesion	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	Mo	_	NN	NN	_	10	PMOD	_	_
12	to	_	TO	TO	_	9	NMOD	_	_
13	endothelial	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	extracellular	_	JJ	JJ	_	18	NMOD	_	_
17	matrix	_	JJ	JJ	_	18	NMOD	_	_
18	proteins	_	NNS	NNS	_	14	COORD	_	_
19	,	_	,	,	_	8	P	_	_
20	as	_	RB	RB	_	8	CC	_	_
21	well	_	RB	RB	_	20	DEP	_	_
22	as	_	IN	IN	_	20	DEP	_	_
23	upon	_	IN	IN	_	8	COORD	_	_
24	engagement	_	NN	NN	_	23	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	leukocyte	_	NN	NN	_	27	NMOD	_	_
27	integrins	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	biological	_	JJ	JJ	_	3	NMOD	_	_
3	effects	_	NNS	NNS	_	13	SBJ	_	_
4	that	_	WDT	WDT	_	5	SBJ	_	_
5	follow	_	VBP	VBP	_	3	NMOD	_	_
6	from	_	IN	IN	_	5	ADV	_	_
7	expression	_	NN	NN	_	6	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	TF	_	NN	NN	_	8	PMOD	_	_
10	by	_	IN	IN	_	7	NMOD	_	_
11	vascular	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	have	_	VBP	VBP	_	0	ROOT-S	_	_
14	been	_	VBN	VBN	_	13	VC	_	_
15	resolved	_	VBN	VBN	_	14	VC	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	analysis	_	NN	NN	_	16	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	function	_	NN	NN	_	18	PMOD	_	_
20	aided	_	VBN	VBN	_	17	NMOD	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	use	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	recombinant	_	JJ	JJ	_	28	NMOD	_	_
26	full	_	JJ	JJ	_	28	NMOD	_	_
27	length	_	NN	NN	_	28	NMOD	_	_
28	TF	_	NN	NN	_	24	PMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	truncated	_	VBN	VBN	_	32	NMOD	_	_
31	surface	_	NN	NN	_	32	NMOD	_	_
32	domain	_	NN	NN	_	28	COORD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	TF	_	NN	NN	_	33	PMOD	_	_
35	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	rules	_	NNS	NNS	_	51	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	assembly	_	NN	NN	_	3	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	cognate	_	JJ	JJ	_	8	NMOD	_	_
8	ligands	_	NNS	NNS	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	TF	_	NN	NN	_	9	PMOD	_	_
11	,	_	,	,	_	8	P	_	_
12	namely	_	RB	RB	_	8	NMOD	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	zymogen	_	NN	NN	_	17	NMOD	_	_
15	plasma	_	NN	NN	_	17	NMOD	_	_
16	factors	_	NNS	NNS	_	17	NMOD	_	_
17	VII	_	NN	NN	_	8	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	the	_	DT	DT	_	23	NMOD	_	_
20	serine	_	NN	NN	_	23	NMOD	_	_
21	protease	_	NN	NN	_	23	NMOD	_	_
22	factor	_	NN	NN	_	23	NMOD	_	_
23	VIIa	_	NN	NN	_	17	COORD	_	_
24	,	_	,	,	_	8	P	_	_
25	with	_	IN	IN	_	4	NMOD	_	_
26	the	_	DT	DT	_	29	NMOD	_	_
27	soluble	_	JJ	JJ	_	29	NMOD	_	_
28	surface	_	NN	NN	_	29	NMOD	_	_
29	domain	_	NN	NN	_	25	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	TF	_	NN	NN	_	30	PMOD	_	_
32	in	_	IN	IN	_	29	NMOD	_	_
33	free	_	JJ	JJ	_	34	NMOD	_	_
34	solution	_	NN	NN	_	32	PMOD	_	_
35	,	_	,	,	_	2	P	_	_
36	in	_	IN	IN	_	2	NMOD	_	_
37	the	_	DT	DT	_	38	NMOD	_	_
38	presence	_	NN	NN	_	36	PMOD	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	phospholipid	_	JJ	JJ	_	41	NMOD	_	_
41	surfaces	_	NNS	NNS	_	39	PMOD	_	_
42	and	_	CC	CC	_	41	CC	_	_
43	cell	_	NN	NN	_	44	NMOD	_	_
44	surface	_	NN	NN	_	41	COORD	_	_
45	and	_	CC	CC	_	39	CC	_	_
46	of	_	IN	IN	_	39	COORD	_	_
47	the	_	DT	DT	_	50	NMOD	_	_
48	anchored	_	VBN	VBN	_	50	NMOD	_	_
49	TF	_	NN	NN	_	50	NMOD	_	_
50	molecule	_	NN	NN	_	46	PMOD	_	_
51	have	_	VBP	VBP	_	0	ROOT-S	_	_
52	been	_	VBN	VBN	_	51	VC	_	_
53	described	_	VBN	VBN	_	52	VC	_	_
54	.	_	.	.	_	51	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	evident	_	JJ	JJ	_	2	PRD	_	_
4	that	_	IN	IN	_	2	EXP	_	_
5	assembly	_	NN	NN	_	20	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	surface	_	NN	NN	_	9	NMOD	_	_
9	domain	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	TF	_	NN	NN	_	10	PMOD	_	_
12	with	_	IN	IN	_	5	NMOD	_	_
13	VIIa	_	NN	NN	_	12	PMOD	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	form	_	VB	VB	_	5	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	binary	_	JJ	JJ	_	19	NMOD	_	_
18	TF.VIIa	_	NN	NN	_	19	NMOD	_	_
19	complex	_	NN	NN	_	15	OBJ	_	_
20	induces	_	VBZ	VBZ	_	4	VMOD	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	significant	_	JJ	JJ	_	23	NMOD	_	_
23	increase	_	NN	NN	_	20	OBJ	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	Kcat	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	catalytic	_	JJ	JJ	_	30	NMOD	_	_
30	domain	_	NN	NN	_	27	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	VIIa	_	NN	NN	_	31	PMOD	_	_
33	for	_	IN	IN	_	30	NMOD	_	_
34	small	_	JJ	JJ	_	36	NMOD	_	_
35	peptidyl	_	JJ	JJ	_	36	NMOD	_	_
36	substrates	_	NNS	NNS	_	33	PMOD	_	_
37	and	_	CC	CC	_	33	CC	_	_
38	more	_	JJR	JJR	_	39	AMOD	_	_
39	profoundly	_	RB	RB	_	40	PMOD	_	_
40	for	_	IN	IN	_	33	COORD	_	_
41	protein	_	NN	NN	_	42	NMOD	_	_
42	substrate	_	NN	NN	_	40	PMOD	_	_
43	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	provides	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	substantial	_	JJ	JJ	_	4	NMOD	_	_
4	evidence	_	NN	NN	_	2	OBJ	_	_
5	for	_	IN	IN	_	4	NMOD	_	_
6	an	_	DT	DT	_	8	NMOD	_	_
7	allosteric	_	JJ	JJ	_	8	NMOD	_	_
8	effect	_	NN	NN	_	5	PMOD	_	_
9	on	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	catalytic	_	JJ	JJ	_	12	NMOD	_	_
12	cleft	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	VIIa	_	NN	NN	_	13	PMOD	_	_
15	that	_	WDT	WDT	_	16	SBJ	_	_
16	is	_	VBZ	VBZ	_	14	NMOD	_	_
17	imparted	_	VBN	VBN	_	16	VC	_	_
18	by	_	IN	IN	_	17	ADV	_	_
19	binding	_	VBG	VBG	_	18	PMOD	_	_
20	to	_	TO	TO	_	19	ADV	_	_
21	TF	_	NN	NN	_	20	PMOD	_	_
22	,	_	,	,	_	21	P	_	_
23	its	_	PRP$	PRP$	_	26	NMOD	_	_
24	cognate	_	JJ	JJ	_	26	NMOD	_	_
25	catalytic	_	JJ	JJ	_	26	NMOD	_	_
26	cofactor	_	NN	NN	_	21	NMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	also	_	RB	RB	_	4	AMOD	_	_
4	evident	_	JJ	JJ	_	2	PRD	_	_
5	that	_	IN	IN	_	2	EXP	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	TF.VIIa	_	NN	NN	_	8	NMOD	_	_
8	complex	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	5	VMOD	_	_
10	proteolytically	_	RB	RB	_	11	AMOD	_	_
11	active	_	JJ	JJ	_	9	PRD	_	_
12	and	_	CC	CC	_	9	CC	_	_
13	can	_	MD	MD	_	9	COORD	_	_
14	activate	_	VB	VB	_	13	VC	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	zymogen	_	NN	NN	_	19	NMOD	_	_
17	plasma	_	NN	NN	_	19	NMOD	_	_
18	factor	_	NN	NN	_	19	NMOD	_	_
19	X	_	NN	NN	_	14	OBJ	_	_
20	to	_	TO	TO	_	14	ADV	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	serine	_	NN	NN	_	24	NMOD	_	_
23	protease	_	NN	NN	_	24	NMOD	_	_
24	Xa	_	NN	NN	_	20	PMOD	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	free	_	JJ	JJ	_	27	NMOD	_	_
27	solution	_	NN	NN	_	25	PMOD	_	_
28	,	_	,	,	_	2	P	_	_
29	inferring	_	VBG	VBG	_	2	VC	_	_
30	that	_	IN	IN	_	29	OBJ	_	_
31	extended	_	VBN	VBN	_	33	NMOD	_	_
32	substrate	_	NN	NN	_	33	NMOD	_	_
33	recognition	_	NN	NN	_	42	SBJ	_	_
34	by	_	IN	IN	_	33	NMOD	_	_
35	induced	_	VBN	VBN	_	37	NMOD	_	_
36	structural	_	JJ	JJ	_	37	NMOD	_	_
37	loci	_	NNS	NNS	_	34	PMOD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	the	_	DT	DT	_	41	NMOD	_	_
40	TF.VIIa	_	NN	NN	_	41	NMOD	_	_
41	complex	_	NN	NN	_	38	PMOD	_	_
42	are	_	VBP	VBP	_	30	VMOD	_	_
43	created	_	VBN	VBN	_	42	VC	_	_
44	from	_	IN	IN	_	43	ADV	_	_
45	either	_	DT	DT	_	48	NMOD	_	_
46	or	_	CC	CC	_	48	CC	_	_
47	both	_	DT	DT	_	48	NMOD	_	_
48	proteins	_	NNS	NNS	_	44	PMOD	_	_
49	to	_	TO	TO	_	50	VMOD	_	_
50	constitute	_	VB	VB	_	43	OBJ	_	_
51	a	_	DT	DT	_	54	NMOD	_	_
52	new	_	JJ	JJ	_	54	NMOD	_	_
53	recognition	_	NN	NN	_	54	NMOD	_	_
54	structure	_	NN	NN	_	50	OBJ	_	_
55	.	_	.	.	_	2	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	also	_	RB	RB	_	4	AMOD	_	_
4	evident	_	JJ	JJ	_	2	PRD	_	_
5	that	_	IN	IN	_	2	EXP	_	_
6	association	_	NN	NN	_	13	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	X	_	NN	NN	_	7	PMOD	_	_
9	with	_	IN	IN	_	6	NMOD	_	_
10	charged	_	JJ	JJ	_	12	NMOD	_	_
11	phospholipid	_	JJ	JJ	_	12	NMOD	_	_
12	surfaces	_	NNS	NNS	_	9	PMOD	_	_
13	enhances	_	VBZ	VBZ	_	5	VMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	proteolytic	_	JJ	JJ	_	16	NMOD	_	_
16	activation	_	NN	NN	_	13	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	this	_	DT	DT	_	19	NMOD	_	_
19	zymogen	_	NN	NN	_	17	PMOD	_	_
20	by	_	IN	IN	_	13	ADV	_	_
21	increasing	_	VBG	VBG	_	20	PMOD	_	_
22	recognition	_	NN	NN	_	21	OBJ	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	susceptibility	_	NN	NN	_	22	COORD	_	_
25	of	_	IN	IN	_	22	NMOD	_	_
26	the	_	DT	DT	_	29	NMOD	_	_
27	sessile	_	NN	NN	_	29	NMOD	_	_
28	peptide	_	NN	NN	_	29	NMOD	_	_
29	bond	_	NN	NN	_	25	PMOD	_	_
30	deduced	_	VBN	VBN	_	29	NMOD	_	_
31	from	_	IN	IN	_	30	ADV	_	_
32	the	_	DT	DT	_	35	NMOD	_	_
33	markedly	_	RB	RB	_	34	AMOD	_	_
34	decreased	_	VBN	VBN	_	35	NMOD	_	_
35	Km	_	NN	NN	_	31	PMOD	_	_
36	and	_	CC	CC	_	35	CC	_	_
37	increased	_	VBN	VBN	_	38	NMOD	_	_
38	Kcat	_	NN	NN	_	35	COORD	_	_
39	.	_	.	.	_	2	P	_	_

1	Visualization	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	8	NMOD	_	_
4	endogenous	_	JJ	JJ	_	8	NMOD	_	_
5	NF-kappa	_	NN	NN	_	8	NMOD	_	_
6	B	_	NN	NN	_	8	NMOD	_	_
7	p50	_	NN	NN	_	8	NMOD	_	_
8	subunit	_	NN	NN	_	2	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	nucleus	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	follicular	_	JJ	JJ	_	15	NMOD	_	_
14	dendritic	_	JJ	JJ	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	12	PMOD	_	_
16	in	_	IN	IN	_	1	NMOD	_	_
17	germinal	_	JJ	JJ	_	18	NMOD	_	_
18	centers	_	NNS	NNS	_	16	PMOD	_	_
19	.	_	.	.	_	1	P	_	_

1	NF-kappa	_	NN	NN	_	2	NMOD	_	_
2	B	_	NN	NN	_	13	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	a	_	DT	DT	_	11	NMOD	_	_
5	50	_	CD	CD	_	7	AMOD	_	_
6	kDa\/65	_	CD	CD	_	7	AMOD	_	_
7	kDa	_	NN	NN	_	11	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	p50\/p65	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	heterodimer	_	NN	NN	_	2	NMOD	_	_
12	,	_	,	,	_	2	P	_	_
13	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	a	_	DT	DT	_	17	NMOD	_	_
15	ubiquitous	_	JJ	JJ	_	17	NMOD	_	_
16	transcription	_	NN	NN	_	17	NMOD	_	_
17	factor	_	NN	NN	_	13	PRD	_	_
18	involved	_	VBN	VBN	_	17	NMOD	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	positive	_	JJ	JJ	_	22	NMOD	_	_
22	regulation	_	NN	NN	_	19	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	various	_	JJ	JJ	_	26	NMOD	_	_
25	immune	_	JJ	JJ	_	26	NMOD	_	_
26	genes	_	NNS	NNS	_	23	PMOD	_	_
27	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	aim	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	this	_	DT	DT	_	5	NMOD	_	_
5	study	_	NN	NN	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	determine	_	VB	VB	_	6	PRD	_	_
9	whether	_	IN	IN	_	8	OBJ	_	_
10	NF-kappa	_	NN	NN	_	11	NMOD	_	_
11	B	_	NN	NN	_	12	SBJ	_	_
12	is	_	VBZ	VBZ	_	9	VMOD	_	_
13	related	_	JJ	JJ	_	12	PRD	_	_
14	to	_	TO	TO	_	13	AMOD	_	_
15	a	_	DT	DT	_	18	NMOD	_	_
16	particular	_	JJ	JJ	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	type	_	NN	NN	_	14	PMOD	_	_
19	and\/or	_	CC	CC	_	18	CC	_	_
20	differentiation	_	NN	NN	_	21	NMOD	_	_
21	step	_	NN	NN	_	18	COORD	_	_
22	during	_	IN	IN	_	18	TMP	_	_
23	immunopoiesis	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	6	P	_	_

1	Using	_	VBG	VBG	_	15	VMOD	_	_
2	in	_	FW	FW	_	3	AMOD	_	_
3	situ	_	FW	FW	_	4	NMOD	_	_
4	hybridization	_	NN	NN	_	1	OBJ	_	_
5	on	_	IN	IN	_	1	ADV	_	_
6	sections	_	NNS	NNS	_	5	PMOD	_	_
7	from	_	IN	IN	_	6	NMOD	_	_
8	non	_	JJ	JJ	_	9	AMOD	_	_
9	HIV	_	NN	NN	_	12	NMOD	_	_
10	hyperplastic	_	JJ	JJ	_	12	NMOD	_	_
11	lymph	_	NN	NN	_	12	NMOD	_	_
12	nodes	_	NNS	NNS	_	7	PMOD	_	_
13	,	_	,	,	_	15	P	_	_
14	we	_	PRP	PRP	_	15	SBJ	_	_
15	found	_	VBD	VBD	_	0	ROOT-S	_	_
16	that	_	IN	IN	_	15	OBJ	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	gene	_	NN	NN	_	26	SBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	105	_	CD	CD	_	22	AMOD	_	_
22	kDa	_	NN	NN	_	23	NMOD	_	_
23	precursor	_	NN	NN	_	19	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	p50	_	NN	NN	_	24	PMOD	_	_
26	was	_	VBD	VBD	_	16	VMOD	_	_
27	overexpressed	_	VBN	VBN	_	26	VC	_	_
28	in	_	IN	IN	_	27	ADV	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	light	_	JJ	JJ	_	31	NMOD	_	_
31	zone	_	NN	NN	_	28	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	germinal	_	JJ	JJ	_	34	NMOD	_	_
34	centers	_	NNS	NNS	_	32	PMOD	_	_
35	,	_	,	,	_	27	P	_	_
36	with	_	IN	IN	_	27	ADV	_	_
37	a	_	DT	DT	_	39	NMOD	_	_
38	network	_	NN	NN	_	39	NMOD	_	_
39	aspect	_	NN	NN	_	36	PMOD	_	_
40	,	_	,	,	_	39	P	_	_
41	which	_	WDT	WDT	_	42	SBJ	_	_
42	suggested	_	VBD	VBD	_	39	NMOD	_	_
43	the	_	DT	DT	_	44	NMOD	_	_
44	involvement	_	NN	NN	_	42	OBJ	_	_
45	of	_	IN	IN	_	44	NMOD	_	_
46	follicular	_	JJ	JJ	_	48	NMOD	_	_
47	dendritic	_	JJ	JJ	_	48	NMOD	_	_
48	cells	_	NNS	NNS	_	45	PMOD	_	_
49	(	_	(	(	_	50	P	_	_
50	FDC	_	NN	NN	_	48	PRN	_	_
51	)	_	)	)	_	50	P	_	_
52	.	_	.	.	_	15	P	_	_

1	By	_	IN	IN	_	7	ADV	_	_
2	immunohistochemistry	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	6	P	_	_
4	p50	_	NN	NN	_	5	NMOD	_	_
5	protein	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	detected	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	cytoplasm	_	NN	NN	_	8	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	nucleus	_	NN	NN	_	10	COORD	_	_
13	of	_	IN	IN	_	10	NMOD	_	_
14	FDC	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	7	P	_	_
16	confirming	_	VBG	VBG	_	7	OBJ	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	involvement	_	NN	NN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	FDC	_	NN	NN	_	19	PMOD	_	_
21	.	_	.	.	_	6	P	_	_

1	Furthermore	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	p50	_	NN	NN	_	4	NMOD	_	_
4	protein	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	detected	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	cytoplasm	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	all	_	DT	DT	_	12	NMOD	_	_
12	lymphocytes	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	5	P	_	_

1	Thus	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	focused	_	VBD	VBD	_	0	ROOT-S	_	_
5	our	_	PRP$	PRP$	_	6	NMOD	_	_
6	study	_	NN	NN	_	4	OBJ	_	_
7	on	_	IN	IN	_	4	ADV	_	_
8	isolated	_	VBN	VBN	_	10	NMOD	_	_
9	FDC	_	NN	NN	_	10	NMOD	_	_
10	clusters	_	NNS	NNS	_	7	PMOD	_	_
11	from	_	IN	IN	_	10	NMOD	_	_
12	normal	_	JJ	JJ	_	13	NMOD	_	_
13	tonsils	_	NNS	NNS	_	11	PMOD	_	_
14	.	_	.	.	_	4	P	_	_

1	As	_	IN	IN	_	8	ADV	_	_
2	showed	_	VBN	VBN	_	1	VMOD	_	_
3	on	_	IN	IN	_	2	ADV	_	_
4	tissue	_	NN	NN	_	5	NMOD	_	_
5	sections	_	NNS	NNS	_	3	PMOD	_	_
6	,	_	,	,	_	8	P	_	_
7	we	_	PRP	PRP	_	8	SBJ	_	_
8	detected	_	VBD	VBD	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	p50	_	NN	NN	_	8	OBJ	_	_
11	in	_	IN	IN	_	8	ADV	_	_
12	both	_	CC	CC	_	13	CC	_	_
13	cytoplasm	_	NN	NN	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	nucleus	_	NN	NN	_	13	COORD	_	_
16	of	_	IN	IN	_	13	NMOD	_	_
17	FDC	_	NN	NN	_	16	PMOD	_	_
18	.	_	.	.	_	8	P	_	_

1	Nuclei	_	NNS	NNS	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	lymphocytes	_	NNS	NNS	_	2	PMOD	_	_
4	from	_	IN	IN	_	3	NMOD	_	_
5	FDC	_	NN	NN	_	6	NMOD	_	_
6	clusters	_	NNS	NNS	_	4	PMOD	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	negative	_	JJ	JJ	_	7	PRD	_	_
9	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	next	_	RB	RB	_	3	TMP	_	_
3	studied	_	VBD	VBD	_	0	ROOT-S	_	_
4	p65	_	NN	NN	_	8	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	c-Rel	_	NN	NN	_	7	NMOD	_	_
7	protein	_	NN	NN	_	4	COORD	_	_
8	expression	_	NN	NN	_	3	OBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	FDC	_	NN	NN	_	11	NMOD	_	_
11	clusters	_	NNS	NNS	_	9	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	p65	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	detected	_	VBN	VBN	_	2	VC	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	cytoplasm	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	FDC	_	NN	NN	_	7	PMOD	_	_
9	,	_	,	,	_	2	P	_	_
10	whereas	_	IN	IN	_	2	COORD	_	_
11	nuclei	_	NNS	NNS	_	12	SBJ	_	_
12	were	_	VBD	VBD	_	2	COORD	_	_
13	negative	_	JJ	JJ	_	12	PRD	_	_
14	.	_	.	.	_	2	P	_	_

1	Furthermore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	p65	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	detected	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	nuclei	_	NNS	NNS	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	some	_	DT	DT	_	11	NMOD	_	_
11	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
12	.	_	.	.	_	4	P	_	_

1	c-Rel	_	NN	NN	_	2	NMOD	_	_
2	protein	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	detected	_	VBN	VBN	_	3	VC	_	_
5	only	_	RB	RB	_	6	DEP	_	_
6	in	_	IN	IN	_	4	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	cytoplasm	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
11	and	_	CC	CC	_	6	CC	_	_
12	not	_	RB	RB	_	13	DEP	_	_
13	in	_	IN	IN	_	6	COORD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	nucleus	_	NN	NN	_	13	PMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	cytoplasm	_	NN	NN	_	15	COORD	_	_
18	of	_	IN	IN	_	15	NMOD	_	_
19	FDC	_	NN	NN	_	18	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	in	_	IN	IN	_	21	ADV	_	_
7	the	_	DT	DT	_	6	DEP	_	_
8	context	_	NN	NN	_	6	DEP	_	_
9	of	_	IN	IN	_	6	DEP	_	_
10	T	_	NN	NN	_	14	NMOD	_	_
11	cell-dependent	_	JJ	JJ	_	10	AMOD	_	_
12	B	_	NN	NN	_	14	NMOD	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	immunopoiesis	_	NN	NN	_	6	PMOD	_	_
15	occurring	_	VBG	VBG	_	14	NMOD	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	FDC	_	NN	NN	_	18	NMOD	_	_
18	clusters	_	NNS	NNS	_	16	PMOD	_	_
19	,	_	,	,	_	21	P	_	_
20	p50	_	NN	NN	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	4	VMOD	_	_
22	mainly	_	RB	RB	_	21	ADV	_	_
23	related	_	JJ	JJ	_	21	PRD	_	_
24	to	_	TO	TO	_	23	AMOD	_	_
25	FDC	_	NN	NN	_	24	PMOD	_	_
26	with	_	IN	IN	_	25	NMOD	_	_
27	a	_	DT	DT	_	29	NMOD	_	_
28	massive	_	JJ	JJ	_	29	NMOD	_	_
29	overexpression	_	NN	NN	_	26	PMOD	_	_
30	in	_	IN	IN	_	29	NMOD	_	_
31	the	_	DT	DT	_	32	NMOD	_	_
32	nuclei	_	NNS	NNS	_	30	PMOD	_	_
33	,	_	,	,	_	21	P	_	_
34	whereas	_	IN	IN	_	21	COORD	_	_
35	p65	_	NN	NN	_	36	SBJ	_	_
36	is	_	VBZ	VBZ	_	21	COORD	_	_
37	expressed	_	VBN	VBN	_	36	VC	_	_
38	in	_	IN	IN	_	37	VMOD	_	_
39	a	_	DT	DT	_	41	NMOD	_	_
40	scattered	_	VBN	VBN	_	41	NMOD	_	_
41	manner	_	NN	NN	_	38	PMOD	_	_
42	in	_	IN	IN	_	37	VMOD	_	_
43	the	_	DT	DT	_	44	NMOD	_	_
44	nuclei	_	NNS	NNS	_	42	PMOD	_	_
45	of	_	IN	IN	_	44	NMOD	_	_
46	lymphocytes	_	NNS	NNS	_	45	PMOD	_	_
47	and	_	CC	CC	_	36	CC	_	_
48	c-Rel	_	NN	NN	_	49	NMOD	_	_
49	protein	_	NN	NN	_	35	GAP	_	_
50	exclusively	_	RB	RB	_	38	GAP	_	_
51	in	_	IN	IN	_	42	GAP	_	_
52	the	_	DT	DT	_	53	NMOD	_	_
53	cytoplasm	_	NN	NN	_	51	PMOD	_	_
54	of	_	IN	IN	_	53	NMOD	_	_
55	lymphocytes	_	NNS	NNS	_	54	PMOD	_	_
56	from	_	IN	IN	_	55	NMOD	_	_
57	FDC	_	NN	NN	_	58	NMOD	_	_
58	clusters	_	NNS	NNS	_	56	PMOD	_	_
59	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggested	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	two	_	CD	CD	_	7	NMOD	_	_
7	subunits	_	NNS	NNS	_	15	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	NF-kappa	_	NN	NN	_	10	NMOD	_	_
10	B	_	NN	NN	_	8	PMOD	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	c-Rel	_	NN	NN	_	14	NMOD	_	_
14	protein	_	NN	NN	_	7	COORD	_	_
15	have	_	VBP	VBP	_	4	VMOD	_	_
16	different	_	JJ	JJ	_	17	NMOD	_	_
17	roles	_	NNS	NNS	_	15	OBJ	_	_
18	in	_	IN	IN	_	15	ADV	_	_
19	different	_	JJ	JJ	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	types	_	NNS	NNS	_	18	PMOD	_	_
22	during	_	IN	IN	_	15	TMP	_	_
23	B	_	NN	NN	_	25	NMOD	_	_
24	cell	_	NN	NN	_	25	NMOD	_	_
25	immunopoiesis	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	Involvement	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	transcription	_	NN	NN	_	5	NMOD	_	_
4	factor	_	NN	NN	_	5	NMOD	_	_
5	YB-1	_	NN	NN	_	2	PMOD	_	_
6	in	_	IN	IN	_	1	NMOD	_	_
7	human	_	JJ	JJ	_	15	NMOD	_	_
8	T-cell	_	NN	NN	_	15	NMOD	_	_
9	lymphotropic	_	JJ	JJ	_	15	NMOD	_	_
10	virus	_	NN	NN	_	15	NMOD	_	_
11	type	_	NN	NN	_	15	NMOD	_	_
12	I	_	CD	CD	_	15	NMOD	_	_
13	basal	_	JJ	JJ	_	15	NMOD	_	_
14	gene	_	NN	NN	_	15	NMOD	_	_
15	expression	_	NN	NN	_	6	PMOD	_	_
16	.	_	.	.	_	1	P	_	_

1	Sequences	_	NNS	NNS	_	16	SBJ	_	_
2	which	_	WDT	WDT	_	3	SBJ	_	_
3	control	_	VBP	VBP	_	1	NMOD	_	_
4	basal	_	JJ	JJ	_	14	NMOD	_	_
5	human	_	JJ	JJ	_	9	NMOD	_	_
6	T-cell	_	NN	NN	_	9	NMOD	_	_
7	lymphotropic	_	NN	NN	_	9	NMOD	_	_
8	virus	_	NN	NN	_	9	NMOD	_	_
9	type	_	NN	NN	_	14	NMOD	_	_
10	I	_	CD	CD	_	9	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	HTLV-I	_	NN	NN	_	9	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	transcription	_	NN	NN	_	3	OBJ	_	_
15	likely	_	RB	RB	_	16	ADV	_	_
16	play	_	VB	VB	_	0	ROOT-S	_	_
17	an	_	DT	DT	_	19	NMOD	_	_
18	important	_	JJ	JJ	_	19	NMOD	_	_
19	role	_	NN	NN	_	16	OBJ	_	_
20	in	_	IN	IN	_	16	ADV	_	_
21	initiation	_	NN	NN	_	20	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	maintenance	_	NN	NN	_	21	COORD	_	_
24	of	_	IN	IN	_	21	NMOD	_	_
25	virus	_	NN	NN	_	26	NMOD	_	_
26	replication	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	16	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	previously	_	RB	RB	_	3	TMP	_	_
3	identified	_	VBD	VBD	_	0	ROOT-S	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	analyzed	_	VBD	VBD	_	3	COORD	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	45-nucleotide	_	JJ	JJ	_	8	NMOD	_	_
8	sequence	_	NN	NN	_	3	OBJ	_	_
9	(	_	(	(	_	12	P	_	_
10	downstream	_	JJ	JJ	_	12	NMOD	_	_
11	regulatory	_	JJ	JJ	_	12	NMOD	_	_
12	element	_	NN	NN	_	8	PRN	_	_
13	1	_	CD	CD	_	12	NMOD	_	_
14	{	_	(	(	_	15	P	_	_
15	DRE	_	NN	NN	_	12	PRN	_	_
16	1	_	CD	CD	_	15	NMOD	_	_
17	}	_	)	)	_	15	P	_	_
18	)	_	)	)	_	12	P	_	_
19	,	_	,	,	_	8	P	_	_
20	+195	_	CD	CD	_	8	NMOD	_	_
21	to	_	TO	TO	_	20	NMOD	_	_
22	+240	_	CD	CD	_	20	NMOD	_	_
23	,	_	,	,	_	8	P	_	_
24	at	_	IN	IN	_	8	NMOD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	boundary	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	R\/U5	_	NN	NN	_	30	NMOD	_	_
30	region	_	NN	NN	_	27	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	35	NMOD	_	_
33	long	_	JJ	JJ	_	35	NMOD	_	_
34	terminal	_	JJ	JJ	_	35	NMOD	_	_
35	repeat	_	NN	NN	_	31	PMOD	_	_
36	which	_	WDT	WDT	_	37	SBJ	_	_
37	is	_	VBZ	VBZ	_	30	NMOD	_	_
38	required	_	VBN	VBN	_	37	VC	_	_
39	for	_	IN	IN	_	38	ADV	_	_
40	HTLV-I	_	NN	NN	_	42	NMOD	_	_
41	basal	_	JJ	JJ	_	42	NMOD	_	_
42	transcription	_	NN	NN	_	39	PMOD	_	_
43	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	identified	_	VBD	VBD	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	protein	_	NN	NN	_	2	OBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	p37	_	NN	NN	_	4	NMOD	_	_
7	,	_	,	,	_	4	P	_	_
8	which	_	WDT	WDT	_	10	SBJ	_	_
9	specifically	_	RB	RB	_	10	ADV	_	_
10	bound	_	VBD	VBD	_	4	NMOD	_	_
11	to	_	TO	TO	_	10	ADV	_	_
12	DRE	_	NN	NN	_	11	PMOD	_	_
13	1	_	CD	CD	_	12	NMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	An	_	DT	DT	_	4	NMOD	_	_
2	affinity	_	NN	NN	_	4	NMOD	_	_
3	column	_	NN	NN	_	4	NMOD	_	_
4	fraction	_	NN	NN	_	9	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	containing	_	VBG	VBG	_	4	NMOD	_	_
7	p37	_	NN	NN	_	6	OBJ	_	_
8	,	_	,	,	_	4	P	_	_
9	stimulated	_	VBD	VBD	_	0	ROOT-S	_	_
10	HTLV-I	_	NN	NN	_	11	NMOD	_	_
11	transcription	_	NN	NN	_	9	OBJ	_	_
12	approximately	_	RB	RB	_	9	ADV	_	_
13	12-fold	_	RB	RB	_	12	AMOD	_	_
14	in	_	FW	FW	_	9	ADV	_	_
15	vitro	_	FW	FW	_	14	AMOD	_	_
16	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	now	_	RB	RB	_	3	TMP	_	_
3	report	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	identification	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	cDNA	_	NN	NN	_	9	NMOD	_	_
9	clone	_	NN	NN	_	6	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	15B-7	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	,	_	,	,	_	9	P	_	_
14	from	_	IN	IN	_	9	NMOD	_	_
15	a	_	DT	DT	_	18	NMOD	_	_
16	Jurkat	_	NN	NN	_	18	NMOD	_	_
17	expression	_	NN	NN	_	18	NMOD	_	_
18	library	_	NN	NN	_	14	PMOD	_	_
19	,	_	,	,	_	9	P	_	_
20	that	_	WDT	WDT	_	21	SBJ	_	_
21	binds	_	VBZ	VBZ	_	9	NMOD	_	_
22	specifically	_	RB	RB	_	21	ADV	_	_
23	to	_	TO	TO	_	21	ADV	_	_
24	the	_	DT	DT	_	28	NMOD	_	_
25	DRE	_	NN	NN	_	28	NMOD	_	_
26	1	_	CD	CD	_	28	NMOD	_	_
27	regulatory	_	JJ	JJ	_	28	NMOD	_	_
28	sequence	_	NN	NN	_	23	PMOD	_	_
29	.	_	.	.	_	3	P	_	_

1	Binding	_	NN	NN	_	18	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	cDNA	_	NN	NN	_	6	NMOD	_	_
5	fusion	_	NN	NN	_	6	NMOD	_	_
6	protein	_	NN	NN	_	2	PMOD	_	_
7	,	_	,	,	_	1	P	_	_
8	similarly	_	RB	RB	_	9	PMOD	_	_
9	to	_	TO	TO	_	1	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	results	_	NNS	NNS	_	9	PMOD	_	_
12	obtained	_	VBN	VBN	_	11	NMOD	_	_
13	with	_	IN	IN	_	12	ADV	_	_
14	purified	_	VBN	VBN	_	16	NMOD	_	_
15	Jurkat	_	NN	NN	_	16	NMOD	_	_
16	protein	_	NN	NN	_	13	PMOD	_	_
17	,	_	,	,	_	1	P	_	_
18	was	_	VBD	VBD	_	0	ROOT-S	_	_
19	decreased	_	VBN	VBN	_	18	VC	_	_
20	by	_	IN	IN	_	19	LGS	_	_
21	introduction	_	NN	NN	_	20	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	site-specific	_	JJ	JJ	_	24	NMOD	_	_
24	mutations	_	NNS	NNS	_	22	PMOD	_	_
25	in	_	IN	IN	_	21	NMOD	_	_
26	the	_	DT	DT	_	30	NMOD	_	_
27	DRE	_	NN	NN	_	30	NMOD	_	_
28	1	_	CD	CD	_	30	NMOD	_	_
29	regulatory	_	JJ	JJ	_	30	NMOD	_	_
30	sequence	_	NN	NN	_	25	PMOD	_	_
31	.	_	.	.	_	18	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	vitro	_	FW	FW	_	3	NMOD	_	_
3	transcription	_	NN	NN	_	9	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	translation	_	NN	NN	_	3	COORD	_	_
6	of	_	IN	IN	_	3	NMOD	_	_
7	15B-7	_	NN	NN	_	8	NMOD	_	_
8	cDNA	_	NN	NN	_	6	PMOD	_	_
9	produced	_	VBD	VBD	_	0	ROOT-S	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	fusion	_	NN	NN	_	12	NMOD	_	_
12	protein	_	NN	NN	_	9	OBJ	_	_
13	which	_	WDT	WDT	_	14	SBJ	_	_
14	bound	_	VBD	VBD	_	12	NMOD	_	_
15	specifically	_	RB	RB	_	14	ADV	_	_
16	to	_	TO	TO	_	14	ADV	_	_
17	the	_	DT	DT	_	22	NMOD	_	_
18	HTLV-I	_	NN	NN	_	22	NMOD	_	_
19	+195	_	CD	CD	_	22	NMOD	_	_
20	to	_	TO	TO	_	19	NMOD	_	_
21	+240	_	CD	CD	_	19	NMOD	_	_
22	oligonucleotide	_	NN	NN	_	16	PMOD	_	_
23	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	partial	_	JJ	JJ	_	3	NMOD	_	_
3	cDNA	_	NN	NN	_	4	SBJ	_	_
4	encodes	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	6	NMOD	_	_
6	protein	_	NN	NN	_	4	OBJ	_	_
7	which	_	WDT	WDT	_	8	SBJ	_	_
8	is	_	VBZ	VBZ	_	6	NMOD	_	_
9	homologous	_	JJ	JJ	_	8	PRD	_	_
10	to	_	TO	TO	_	9	AMOD	_	_
11	the	_	DT	DT	_	15	NMOD	_	_
12	C-terminal	_	JJ	JJ	_	15	NMOD	_	_
13	196	_	CD	CD	_	15	NMOD	_	_
14	amino	_	NN	NN	_	15	NMOD	_	_
15	acids	_	NNS	NNS	_	10	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	36-kDa	_	JJ	JJ	_	20	NMOD	_	_
19	transcription	_	NN	NN	_	20	NMOD	_	_
20	factor	_	NN	NN	_	16	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	YB-1	_	NN	NN	_	20	NMOD	_	_
23	.	_	.	.	_	4	P	_	_

1	Cotransfection	_	NN	NN	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	YB-1	_	NN	NN	_	6	NMOD	_	_
5	expression	_	NN	NN	_	6	NMOD	_	_
6	plasmid	_	NN	NN	_	2	PMOD	_	_
7	increases	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	HTLV-I	_	NN	NN	_	10	NMOD	_	_
9	basal	_	JJ	JJ	_	10	NMOD	_	_
10	transcription	_	NN	NN	_	7	OBJ	_	_
11	approximately	_	RB	RB	_	7	ADV	_	_
12	14-fold	_	RB	RB	_	11	AMOD	_	_
13	in	_	IN	IN	_	7	ADV	_	_
14	Jurkat	_	NN	NN	_	16	NMOD	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	lymphocytes	_	NNS	NNS	_	13	PMOD	_	_
17	.	_	.	.	_	7	P	_	_

1	On	_	IN	IN	_	19	ADV	_	_
2	the	_	DT	DT	_	1	DEP	_	_
3	basis	_	NN	NN	_	1	DEP	_	_
4	of	_	IN	IN	_	1	DEP	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	molecular	_	JJ	JJ	_	7	NMOD	_	_
7	weight	_	NN	NN	_	1	PMOD	_	_
8	,	_	,	,	_	7	P	_	_
9	DNA-binding	_	JJ	JJ	_	10	NMOD	_	_
10	characteristics	_	NNS	NNS	_	7	COORD	_	_
11	,	_	,	,	_	7	P	_	_
12	and	_	CC	CC	_	7	CC	_	_
13	in	_	FW	FW	_	14	AMOD	_	_
14	vivo	_	FW	FW	_	16	NMOD	_	_
15	transactivation	_	NN	NN	_	16	NMOD	_	_
16	activity	_	NN	NN	_	7	COORD	_	_
17	,	_	,	,	_	19	P	_	_
18	we	_	PRP	PRP	_	19	SBJ	_	_
19	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
20	that	_	IN	IN	_	19	OBJ	_	_
21	the	_	DT	DT	_	26	NMOD	_	_
22	previously	_	RB	RB	_	23	AMOD	_	_
23	identified	_	VBN	VBN	_	26	NMOD	_	_
24	DRE	_	NN	NN	_	26	NMOD	_	_
25	1-binding	_	JJ	JJ	_	24	AMOD	_	_
26	protein	_	NN	NN	_	30	SBJ	_	_
27	,	_	,	,	_	26	P	_	_
28	p37	_	NN	NN	_	26	NMOD	_	_
29	,	_	,	,	_	26	P	_	_
30	is	_	VBZ	VBZ	_	20	VMOD	_	_
31	YB-1	_	NN	NN	_	30	PRD	_	_
32	.	_	.	.	_	19	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	lymphotoxin	_	NN	NN	_	3	NMOD	_	_
3	promoter	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	stimulated	_	VBN	VBN	_	4	VC	_	_
6	by	_	IN	IN	_	5	LGS	_	_
7	HTLV-I	_	NN	NN	_	9	NMOD	_	_
8	tax	_	NN	NN	_	9	NMOD	_	_
9	activation	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	NF-kappa	_	NN	NN	_	12	NMOD	_	_
12	B	_	NN	NN	_	10	PMOD	_	_
13	in	_	IN	IN	_	9	NMOD	_	_
14	human	_	JJ	JJ	_	16	NMOD	_	_
15	T-cell	_	NN	NN	_	16	NMOD	_	_
16	lines	_	NNS	NNS	_	13	PMOD	_	_
17	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	HTLV-I	_	NN	NN	_	5	NMOD	_	_
3	transcriptional	_	JJ	JJ	_	5	NMOD	_	_
4	activator	_	NN	NN	_	5	NMOD	_	_
5	tax	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	used	_	VBN	VBN	_	6	VC	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	gain	_	VB	VB	_	7	OBJ	_	_
10	insight	_	NN	NN	_	9	OBJ	_	_
11	into	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	mechanism	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	lymphotoxin	_	NN	NN	_	22	NMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	LT	_	NN	NN	_	15	PRN	_	_
18	;	_	:	:	_	17	P	_	_
19	TNF-beta	_	NN	NN	_	17	NMOD	_	_
20	)	_	)	)	_	17	P	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	induction	_	NN	NN	_	14	PMOD	_	_
23	.	_	.	.	_	6	P	_	_

1	Tax-expressing	_	JJ	JJ	_	3	NMOD	_	_
2	cell	_	NN	NN	_	3	NMOD	_	_
3	lines	_	NNS	NNS	_	4	SBJ	_	_
4	produce	_	VBP	VBP	_	0	ROOT-S	_	_
5	LT	_	NN	NN	_	7	NMOD	_	_
6	biologic	_	JJ	JJ	_	7	NMOD	_	_
7	activity	_	NN	NN	_	4	OBJ	_	_
8	.	_	.	.	_	4	P	_	_

1	An	_	DT	DT	_	8	NMOD	_	_
2	LT	_	NN	NN	_	3	NMOD	_	_
3	promoter	_	NN	NN	_	8	NMOD	_	_
4	(	_	(	(	_	5	P	_	_
5	LT-293	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	CAT	_	NN	NN	_	8	NMOD	_	_
8	construct	_	NN	NN	_	15	SBJ	_	_
9	that	_	WDT	WDT	_	10	SBJ	_	_
10	contained	_	VBD	VBD	_	8	NMOD	_	_
11	an	_	DT	DT	_	14	NMOD	_	_
12	NF-kappa	_	NN	NN	_	14	NMOD	_	_
13	B	_	NN	NN	_	14	NMOD	_	_
14	site	_	NN	NN	_	10	OBJ	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	active	_	JJ	JJ	_	15	PRD	_	_
17	in	_	IN	IN	_	15	ADV	_	_
18	the	_	DT	DT	_	22	NMOD	_	_
19	LT-producing	_	JJ	JJ	_	22	NMOD	_	_
20	C81-66-45	_	NN	NN	_	22	NMOD	_	_
21	cell	_	NN	NN	_	22	NMOD	_	_
22	line	_	NN	NN	_	17	PMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	which	_	WDT	WDT	_	25	SBJ	_	_
25	contains	_	VBZ	VBZ	_	22	NMOD	_	_
26	defective	_	JJ	JJ	_	27	NMOD	_	_
27	HTLV-I	_	NN	NN	_	25	OBJ	_	_
28	but	_	CC	CC	_	25	CC	_	_
29	expresses	_	VBZ	VBZ	_	25	COORD	_	_
30	tax	_	NN	NN	_	29	OBJ	_	_
31	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	observation	_	NN	NN	_	17	SBJ	_	_
3	that	_	IN	IN	_	2	NMOD	_	_
4	a	_	DT	DT	_	8	NMOD	_	_
5	mutated	_	VBN	VBN	_	8	NMOD	_	_
6	LT-kappa	_	NN	NN	_	8	NMOD	_	_
7	B	_	NN	NN	_	8	NMOD	_	_
8	construct	_	NN	NN	_	12	SBJ	_	_
9	(	_	(	(	_	10	P	_	_
10	M1-CAT	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	was	_	VBD	VBD	_	3	VMOD	_	_
13	inactive	_	JJ	JJ	_	12	PRD	_	_
14	in	_	IN	IN	_	12	ADV	_	_
15	C81-66-45	_	NN	NN	_	14	PMOD	_	_
16	,	_	,	,	_	17	P	_	_
17	confirmed	_	VBD	VBD	_	0	ROOT-S	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	importance	_	NN	NN	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	NF-kappa	_	NN	NN	_	22	NMOD	_	_
22	B	_	NN	NN	_	20	PMOD	_	_
23	in	_	IN	IN	_	19	NMOD	_	_
24	LT	_	NN	NN	_	26	NMOD	_	_
25	gene	_	NN	NN	_	26	NMOD	_	_
26	expression	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	17	P	_	_

1	Tax	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	transfected	_	VBN	VBN	_	2	VC	_	_
4	into	_	IN	IN	_	3	ADV	_	_
5	HTLV-I-negative	_	JJ	JJ	_	8	NMOD	_	_
6	human	_	JJ	JJ	_	8	NMOD	_	_
7	T-cell	_	NN	NN	_	8	NMOD	_	_
8	lines	_	NNS	NNS	_	4	PMOD	_	_
9	.	_	.	.	_	2	P	_	_

1	Jurkat	_	NN	NN	_	3	NMOD	_	_
2	T	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	7	SBJ	_	_
4	stably	_	RB	RB	_	5	ADV	_	_
5	expressing	_	VBG	VBG	_	3	NMOD	_	_
6	tax	_	NN	NN	_	5	OBJ	_	_
7	contained	_	VBD	VBD	_	0	ROOT-S	_	_
8	elevated	_	JJ	JJ	_	9	NMOD	_	_
9	levels	_	NNS	NNS	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	NF-kappa	_	NN	NN	_	12	NMOD	_	_
12	B	_	NN	NN	_	10	PMOD	_	_
13	that	_	WDT	WDT	_	15	SBJ	_	_
14	directly	_	RB	RB	_	15	ADV	_	_
15	bound	_	VBD	VBD	_	12	NMOD	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	LT-kappa	_	NN	NN	_	20	NMOD	_	_
19	B	_	NN	NN	_	20	NMOD	_	_
20	site	_	NN	NN	_	16	PMOD	_	_
21	.	_	.	.	_	7	P	_	_

1	Tax	_	NN	NN	_	10	SBJ	_	_
2	co-transfected	_	VBN	VBN	_	1	NMOD	_	_
3	with	_	IN	IN	_	2	ADV	_	_
4	reporter	_	NN	NN	_	5	NMOD	_	_
5	constructs	_	NNS	NNS	_	3	PMOD	_	_
6	into	_	IN	IN	_	2	ADV	_	_
7	Jurkat	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	maximally	_	RB	RB	_	10	ADV	_	_
10	activated	_	VBD	VBD	_	0	ROOT-S	_	_
11	HTLV-I-LTR-CAT	_	NN	NN	_	10	OBJ	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	kappa	_	NN	NN	_	14	NMOD	_	_
14	B-fos-CAT	_	NN	NN	_	11	COORD	_	_
15	and	_	CC	CC	_	10	CC	_	_
16	also	_	RB	RB	_	10	COORD	_	_
17	activated	_	VBD	VBD	_	10	COORD	_	_
18	LT-293	_	NN	NN	_	17	OBJ	_	_
19	to	_	TO	TO	_	17	ADV	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	lesser	_	JJR	JJR	_	22	NMOD	_	_
22	extent	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	JM	_	NN	NN	_	4	NMOD	_	_
3	T	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	9	P	_	_
6	tax	_	NN	NN	_	9	SBJ	_	_
7	induced	_	JJ	JJ	_	9	VMOD	_	_
8	LT-293	_	NN	NN	_	9	NMOD	_	_
9	activity	_	NN	NN	_	0	ROOT-S	_	_
10	by	_	IN	IN	_	9	ADV	_	_
11	two-	_	CD	CD	_	10	NMOD	_	_
12	to	_	TO	TO	_	10	NMOD	_	_
13	four-fold	_	JJ	JJ	_	10	NMOD	_	_
14	,	_	,	,	_	9	P	_	_
15	though	_	IN	IN	_	9	OBJ	_	_
16	there	_	EX	EX	_	17	SBJ	_	_
17	was	_	VBD	VBD	_	15	VMOD	_	_
18	no	_	DT	DT	_	19	NMOD	_	_
19	induction	_	NN	NN	_	17	PRD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	M1-CAT	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	increase	_	NN	NN	_	7	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	LT-293	_	NN	NN	_	6	NMOD	_	_
5	CAT	_	NN	NN	_	6	NMOD	_	_
6	activity	_	NN	NN	_	3	PMOD	_	_
7	mirrored	_	VBD	VBD	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	increase	_	NN	NN	_	7	OBJ	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	LT	_	NN	NN	_	13	NMOD	_	_
12	biologic	_	JJ	JJ	_	13	NMOD	_	_
13	activity	_	NN	NN	_	10	PMOD	_	_
14	seen	_	VBN	VBN	_	9	NMOD	_	_
15	under	_	IN	IN	_	14	ADV	_	_
16	these	_	DT	DT	_	17	NMOD	_	_
17	conditions	_	NNS	NNS	_	15	PMOD	_	_
18	.	_	.	.	_	7	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	17	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	first	_	JJ	JJ	_	2	NMOD	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	demonstrate	_	VB	VB	_	5	NMOD	_	_
8	induction	_	NN	NN	_	7	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	LT	_	NN	NN	_	12	NMOD	_	_
11	promoter	_	NN	NN	_	12	NMOD	_	_
12	activity	_	NN	NN	_	9	PMOD	_	_
13	over	_	IN	IN	_	8	NMOD	_	_
14	basal	_	JJ	JJ	_	15	NMOD	_	_
15	levels	_	NNS	NNS	_	13	PMOD	_	_
16	,	_	,	,	_	2	P	_	_
17	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
18	that	_	IN	IN	_	17	OBJ	_	_
19	HTLV-I	_	NN	NN	_	20	NMOD	_	_
20	tax	_	NN	NN	_	21	SBJ	_	_
21	causes	_	VBZ	VBZ	_	18	VMOD	_	_
22	low-level	_	JJ	JJ	_	23	NMOD	_	_
23	activation	_	NN	NN	_	21	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	both	_	CC	CC	_	27	CC	_	_
26	endogenous	_	JJ	JJ	_	27	NMOD	_	_
27	LT	_	NN	NN	_	24	PMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	LT	_	NN	NN	_	31	NMOD	_	_
31	promoter	_	NN	NN	_	27	COORD	_	_
32	,	_	,	,	_	21	P	_	_
33	at	_	IN	IN	_	35	PMOD	_	_
34	least	_	JJS	JJS	_	33	AMOD	_	_
35	in	_	IN	IN	_	37	PMOD	_	_
36	part	_	NN	NN	_	35	PMOD	_	_
37	through	_	IN	IN	_	21	ADV	_	_
38	activation	_	NN	NN	_	37	PMOD	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	NF-kappa	_	NN	NN	_	41	NMOD	_	_
41	B	_	NN	NN	_	39	PMOD	_	_
42	.	_	.	.	_	17	P	_	_

1	Transient	_	JJ	JJ	_	2	NMOD	_	_
2	pseudohypoaldosteronism	_	NN	NN	_	0	ROOT-FRAG	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	obstructive	_	JJ	JJ	_	6	NMOD	_	_
5	renal	_	JJ	JJ	_	6	NMOD	_	_
6	disease	_	NN	NN	_	3	PMOD	_	_
7	with	_	IN	IN	_	2	NMOD	_	_
8	transient	_	JJ	JJ	_	9	NMOD	_	_
9	reduction	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	lymphocytic	_	JJ	JJ	_	13	NMOD	_	_
12	aldosterone	_	NN	NN	_	13	NMOD	_	_
13	receptors	_	NNS	NNS	_	10	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	Results	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	in	_	IN	IN	_	1	NMOD	_	_
3	two	_	CD	CD	_	5	NMOD	_	_
4	affected	_	JJ	JJ	_	5	NMOD	_	_
5	infants	_	NNS	NNS	_	2	PMOD	_	_
6	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	two	_	CD	CD	_	4	NMOD	_	_
4	patients	_	NNS	NNS	_	2	OBJ	_	_
5	with	_	IN	IN	_	4	NMOD	_	_
6	transient	_	JJ	JJ	_	7	NMOD	_	_
7	pseudohypoaldosteronism	_	NN	NN	_	5	PMOD	_	_
8	due	_	JJ	JJ	_	9	DEP	_	_
9	to	_	TO	TO	_	7	NMOD	_	_
10	obstructive	_	JJ	JJ	_	12	NMOD	_	_
11	renal	_	JJ	JJ	_	12	NMOD	_	_
12	disease	_	NN	NN	_	9	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	Both	_	DT	DT	_	2	NMOD	_	_
2	patients	_	NNS	NNS	_	3	SBJ	_	_
3	presented	_	VBD	VBD	_	0	ROOT-S	_	_
4	with	_	IN	IN	_	3	ADV	_	_
5	a	_	DT	DT	_	10	NMOD	_	_
6	salt-losing	_	JJ	JJ	_	10	NMOD	_	_
7	episode	_	NN	NN	_	10	NMOD	_	_
8	simulating	_	VBG	VBG	_	10	NMOD	_	_
9	adrenal	_	JJ	JJ	_	10	NMOD	_	_
10	insufficiency	_	NN	NN	_	4	PMOD	_	_
11	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	one	_	CD	CD	_	3	NMOD	_	_
3	patient	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	10	P	_	_
5	transient	_	JJ	JJ	_	6	NMOD	_	_
6	reduction	_	NN	NN	_	10	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	aldosterone	_	NN	NN	_	9	NMOD	_	_
9	receptors	_	NNS	NNS	_	7	PMOD	_	_
10	could	_	MD	MD	_	0	ROOT-S	_	_
11	be	_	VB	VB	_	10	VC	_	_
12	documented	_	VBN	VBN	_	11	VC	_	_
13	,	_	,	,	_	12	P	_	_
14	while	_	IN	IN	_	12	OBJ	_	_
15	in	_	IN	IN	_	24	ADV	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	second	_	JJ	JJ	_	18	NMOD	_	_
18	patient	_	NN	NN	_	15	PMOD	_	_
19	the	_	DT	DT	_	23	NMOD	_	_
20	clinical	_	JJ	JJ	_	23	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	biochemical	_	JJ	JJ	_	20	COORD	_	_
23	parameters	_	NNS	NNS	_	24	SBJ	_	_
24	were	_	VBD	VBD	_	14	VMOD	_	_
25	consistent	_	JJ	JJ	_	24	PRD	_	_
26	with	_	IN	IN	_	25	AMOD	_	_
27	transient	_	JJ	JJ	_	28	NMOD	_	_
28	pseudohypoaldosteronism	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	10	P	_	_

1	Aldosterone	_	NN	NN	_	2	NMOD	_	_
2	receptors	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	normal	_	JJ	JJ	_	3	PRD	_	_
5	in	_	IN	IN	_	3	ADV	_	_
6	both	_	DT	DT	_	7	NMOD	_	_
7	patients	_	NNS	NNS	_	5	PMOD	_	_
8	when	_	IN	IN	_	9	ADV	_	_
9	studied	_	VBN	VBN	_	3	TMP	_	_
10	after	_	IN	IN	_	9	TMP	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	surgical	_	JJ	JJ	_	13	NMOD	_	_
13	correction	_	NN	NN	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	obstruction	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	Increased	_	VBN	VBN	_	5	NMOD	_	_
2	natural	_	JJ	JJ	_	5	NMOD	_	_
3	killer	_	NN	NN	_	5	NMOD	_	_
4	cell	_	NN	NN	_	5	NMOD	_	_
5	activity	_	NN	NN	_	6	SBJ	_	_
6	correlates	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	with	_	IN	IN	_	6	ADV	_	_
8	low	_	JJ	JJ	_	11	NMOD	_	_
9	or	_	CC	CC	_	8	CC	_	_
10	negative	_	JJ	JJ	_	8	COORD	_	_
11	expression	_	NN	NN	_	7	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	HER-2\/neu	_	NN	NN	_	15	NMOD	_	_
15	oncogene	_	NN	NN	_	12	PMOD	_	_
16	in	_	IN	IN	_	11	NMOD	_	_
17	patients	_	NNS	NNS	_	16	PMOD	_	_
18	with	_	IN	IN	_	17	NMOD	_	_
19	breast	_	NN	NN	_	20	NMOD	_	_
20	cancer	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	6	P	_	_

1	BACKGROUND	_	NN	NN	_	0	ROOT-FRAG	_	_
2	.	_	.	.	_	1	P	_	_

1	Increased	_	VBN	VBN	_	2	NMOD	_	_
2	expression	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	HER-2\/neu	_	NN	NN	_	6	NMOD	_	_
6	oncogene	_	NN	NN	_	3	PMOD	_	_
7	in	_	IN	IN	_	2	NMOD	_	_
8	breast	_	NN	NN	_	9	NMOD	_	_
9	cancer	_	NN	NN	_	7	PMOD	_	_
10	correlates	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	decreased	_	VBN	VBN	_	15	NMOD	_	_
13	estrogen	_	NN	NN	_	15	NMOD	_	_
14	receptor	_	NN	NN	_	15	NMOD	_	_
15	concentration	_	NN	NN	_	11	PMOD	_	_
16	and	_	CC	CC	_	10	CC	_	_
17	seems	_	VBZ	VBZ	_	10	COORD	_	_
18	to	_	TO	TO	_	19	VMOD	_	_
19	be	_	VB	VB	_	17	OBJ	_	_
20	an	_	DT	DT	_	23	NMOD	_	_
21	important	_	JJ	JJ	_	23	NMOD	_	_
22	prognostic	_	JJ	JJ	_	23	NMOD	_	_
23	factor	_	NN	NN	_	19	PRD	_	_
24	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	authors	_	NNS	NNS	_	3	SBJ	_	_
3	investigated	_	VBD	VBD	_	0	ROOT-S	_	_
4	whether	_	IN	IN	_	3	OBJ	_	_
5	there	_	EX	EX	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	4	VMOD	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	correlation	_	NN	NN	_	6	PRD	_	_
9	between	_	IN	IN	_	8	NMOD	_	_
10	HER-2\/neu	_	NN	NN	_	11	NMOD	_	_
11	expression	_	NN	NN	_	9	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	immunologic	_	JJ	JJ	_	14	NMOD	_	_
14	parameters	_	NNS	NNS	_	11	COORD	_	_
15	representing	_	VBG	VBG	_	14	NMOD	_	_
16	tumor	_	NN	NN	_	17	NMOD	_	_
17	defense	_	NN	NN	_	15	OBJ	_	_
18	in	_	IN	IN	_	11	NMOD	_	_
19	patients	_	NNS	NNS	_	18	PMOD	_	_
20	with	_	IN	IN	_	19	NMOD	_	_
21	breast	_	NN	NN	_	22	NMOD	_	_
22	cancer	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	METHOD	_	NN	NN	_	0	ROOT-FRAG	_	_
2	.	_	.	.	_	1	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	Western	_	JJ	JJ	_	4	NMOD	_	_
3	blot	_	NN	NN	_	4	NMOD	_	_
4	analysis	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	used	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	investigate	_	VB	VB	_	6	OBJ	_	_
9	HER-2\/neu	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	8	OBJ	_	_
11	,	_	,	,	_	5	P	_	_
12	whereas	_	IN	IN	_	5	COORD	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	chromium-release	_	NN	NN	_	15	NMOD	_	_
15	assay	_	NN	NN	_	23	SBJ	_	_
16	using	_	VBG	VBG	_	15	NMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	K562	_	NN	NN	_	20	NMOD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	line	_	NN	NN	_	16	OBJ	_	_
21	as	_	IN	IN	_	16	ADV	_	_
22	target	_	NN	NN	_	21	PMOD	_	_
23	was	_	VBD	VBD	_	5	COORD	_	_
24	used	_	VBN	VBN	_	23	VC	_	_
25	to	_	TO	TO	_	26	VMOD	_	_
26	measure	_	VB	VB	_	24	OBJ	_	_
27	natural	_	JJ	JJ	_	28	NMOD	_	_
28	killer	_	NN	NN	_	33	NMOD	_	_
29	(	_	(	(	_	30	P	_	_
30	NK	_	NN	NN	_	28	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	cell	_	NN	NN	_	33	NMOD	_	_
33	activity	_	NN	NN	_	26	OBJ	_	_
34	.	_	.	.	_	5	P	_	_

1	RESULTS	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	.	_	.	.	_	1	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	patients	_	NNS	NNS	_	1	PMOD	_	_
3	with	_	IN	IN	_	2	NMOD	_	_
4	breast	_	NN	NN	_	5	NMOD	_	_
5	cancer	_	NN	NN	_	3	PMOD	_	_
6	,	_	,	,	_	10	P	_	_
7	NK	_	NN	NN	_	9	NMOD	_	_
8	cell	_	NN	NN	_	9	NMOD	_	_
9	activity	_	NN	NN	_	10	SBJ	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	significantly	_	RB	RB	_	12	AMOD	_	_
12	higher	_	JJR	JJR	_	10	PRD	_	_
13	compared	_	VBN	VBN	_	10	ADV	_	_
14	with	_	IN	IN	_	13	PMOD	_	_
15	patients	_	NNS	NNS	_	14	PMOD	_	_
16	with	_	IN	IN	_	15	NMOD	_	_
17	benign	_	JJ	JJ	_	18	NMOD	_	_
18	tumors	_	NNS	NNS	_	16	PMOD	_	_
19	(	_	(	(	_	22	P	_	_
20	P	_	NN	NN	_	22	SBJ	_	_
21	=	_	JJ	JJ	_	22	VMOD	_	_
22	0.006	_	CD	CD	_	15	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	or	_	CC	CC	_	15	CC	_	_
25	healthy	_	JJ	JJ	_	27	NMOD	_	_
26	control	_	NN	NN	_	27	NMOD	_	_
27	subjects	_	NNS	NNS	_	15	COORD	_	_
28	(	_	(	(	_	31	P	_	_
29	P	_	NN	NN	_	31	SBJ	_	_
30	=	_	JJ	JJ	_	31	VMOD	_	_
31	0.002	_	CD	CD	_	27	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	.	_	.	.	_	10	P	_	_

1	Moreover	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	23.3	_	CD	CD	_	4	NMOD	_	_
4	%	_	NN	NN	_	10	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	patients	_	NNS	NNS	_	5	PMOD	_	_
7	with	_	IN	IN	_	6	NMOD	_	_
8	breast	_	NN	NN	_	9	NMOD	_	_
9	cancer	_	NN	NN	_	7	PMOD	_	_
10	showed	_	VBD	VBD	_	0	ROOT-S	_	_
11	an	_	DT	DT	_	12	NMOD	_	_
12	overexpression	_	NN	NN	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	HER-2\/neu	_	NN	NN	_	15	NMOD	_	_
15	protein	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	10	P	_	_

1	Within	_	IN	IN	_	10	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	group	_	NN	NN	_	1	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	patients	_	NNS	NNS	_	4	PMOD	_	_
6	,	_	,	,	_	10	P	_	_
7	NK	_	NN	NN	_	9	NMOD	_	_
8	cell	_	NN	NN	_	9	NMOD	_	_
9	activity	_	NN	NN	_	10	SBJ	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	significantly	_	RB	RB	_	12	AMOD	_	_
12	lower	_	JJR	JJR	_	10	PRD	_	_
13	(	_	(	(	_	17	P	_	_
14	45.6	_	CD	CD	_	17	NMOD	_	_
15	+\/-	_	CC	CC	_	14	CC	_	_
16	16.1	_	CD	CD	_	14	COORD	_	_
17	%	_	NN	NN	_	12	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	compared	_	VBN	VBN	_	10	ADV	_	_
20	with	_	IN	IN	_	19	PMOD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	group	_	NN	NN	_	20	PMOD	_	_
23	with	_	IN	IN	_	22	NMOD	_	_
24	no	_	DT	DT	_	26	NMOD	_	_
25	HER-2\/neu	_	NN	NN	_	26	NMOD	_	_
26	overexpression	_	NN	NN	_	23	PMOD	_	_
27	(	_	(	(	_	31	P	_	_
28	57.3	_	CD	CD	_	31	NMOD	_	_
29	+\/-	_	CC	CC	_	28	CC	_	_
30	11.0	_	CD	CD	_	28	COORD	_	_
31	%	_	NN	NN	_	22	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	.	_	.	.	_	10	P	_	_

1	NK	_	NN	NN	_	3	NMOD	_	_
2	cell	_	NN	NN	_	3	NMOD	_	_
3	activity	_	NN	NN	_	4	SBJ	_	_
4	did	_	VBD	VBD	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	increase	_	VB	VB	_	4	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	patients	_	NNS	NNS	_	7	PMOD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	HER-2\/neu	_	NN	NN	_	11	NMOD	_	_
11	overexpression	_	NN	NN	_	9	PMOD	_	_
12	.	_	.	.	_	4	P	_	_

1	Thus	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	there	_	EX	EX	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	statistically	_	RB	RB	_	7	AMOD	_	_
7	significant	_	JJ	JJ	_	8	NMOD	_	_
8	correlation	_	NN	NN	_	4	PRD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	cytolytic	_	JJ	JJ	_	13	NMOD	_	_
11	effector	_	NN	NN	_	13	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	function	_	NN	NN	_	9	PMOD	_	_
14	with	_	IN	IN	_	8	NMOD	_	_
15	HER-2\/neu	_	NN	NN	_	16	NMOD	_	_
16	expression	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	tumor	_	NN	NN	_	17	PMOD	_	_
20	(	_	(	(	_	23	P	_	_
21	P	_	NN	NN	_	23	SBJ	_	_
22	=	_	JJ	JJ	_	23	VMOD	_	_
23	0.003	_	CD	CD	_	16	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	,	_	,	,	_	16	P	_	_
26	and	_	CC	CC	_	16	CC	_	_
27	HER-2\/neu	_	NN	NN	_	28	NMOD	_	_
28	overexpression	_	NN	NN	_	16	COORD	_	_
29	correlated	_	VBD	VBD	_	28	NMOD	_	_
30	with	_	IN	IN	_	29	ADV	_	_
31	a	_	DT	DT	_	35	NMOD	_	_
32	negative	_	JJ	JJ	_	35	NMOD	_	_
33	estrogen	_	NN	NN	_	35	NMOD	_	_
34	receptor	_	NN	NN	_	35	NMOD	_	_
35	status	_	NN	NN	_	30	PMOD	_	_
36	(	_	(	(	_	39	P	_	_
37	P	_	NN	NN	_	39	SBJ	_	_
38	=	_	JJ	JJ	_	39	VMOD	_	_
39	0.005	_	CD	CD	_	28	PRN	_	_
40	)	_	)	)	_	39	P	_	_
41	.	_	.	.	_	4	P	_	_

1	CONCLUSION	_	NN	NN	_	0	ROOT-FRAG	_	_
2	.	_	.	.	_	1	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	add	_	VBP	VBP	_	0	ROOT-S	_	_
4	further	_	JJ	JJ	_	5	NMOD	_	_
5	evidence	_	NN	NN	_	3	OBJ	_	_
6	to	_	TO	TO	_	3	ADV	_	_
7	previous	_	JJ	JJ	_	8	NMOD	_	_
8	observations	_	NNS	NNS	_	6	PMOD	_	_
9	from	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	authors	_	NNS	NNS	_	9	PMOD	_	_
12	'	_	POS	POS	_	11	NMOD	_	_
13	laboratory	_	NN	NN	_	18	VMOD	_	_
14	that	_	IN	IN	_	16	NMOD	_	_
15	certain	_	JJ	JJ	_	16	NMOD	_	_
16	tumor	_	NN	NN	_	18	SBJ	_	_
17	characteristics	_	NNS	NNS	_	18	VMOD	_	_
18	may	_	MD	MD	_	8	NMOD	_	_
19	be	_	VB	VB	_	18	VC	_	_
20	associated	_	VBN	VBN	_	19	ADV	_	_
21	with	_	IN	IN	_	20	PMOD	_	_
22	reactions	_	NNS	NNS	_	21	NMOD	_	_
23	of	_	IN	IN	_	24	NMOD	_	_
24	the	_	DT	DT	_	22	PMOD	_	_
25	host	_	NN	NN	_	24	NMOD	_	_
26	with	_	IN	IN	_	27	NMOD	_	_
27	breast	_	NN	NN	_	25	PMOD	_	_
28	cancer	_	NN	NN	_	3	VMOD	_	_

1	Induction	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	tyrosine	_	NN	NN	_	4	NMOD	_	_
4	phosphorylation	_	NN	NN	_	2	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	T-cell	_	NN	NN	_	7	NMOD	_	_
7	activation	_	NN	NN	_	4	COORD	_	_
8	by	_	IN	IN	_	1	NMOD	_	_
9	vanadate	_	NN	NN	_	10	NMOD	_	_
10	peroxide	_	NN	NN	_	8	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	an	_	DT	DT	_	13	NMOD	_	_
13	inhibitor	_	NN	NN	_	10	NMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	protein	_	NN	NN	_	17	NMOD	_	_
16	tyrosine	_	NN	NN	_	17	NMOD	_	_
17	phosphatases	_	NNS	NNS	_	14	PMOD	_	_
18	.	_	.	.	_	1	P	_	_

1	Rapid	_	JJ	JJ	_	3	NMOD	_	_
2	tyrosine	_	NN	NN	_	3	NMOD	_	_
3	phosphorylation	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	key	_	JJ	JJ	_	7	NMOD	_	_
6	cellular	_	JJ	JJ	_	7	NMOD	_	_
7	proteins	_	NNS	NNS	_	4	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	crucial	_	JJ	JJ	_	11	NMOD	_	_
11	event	_	NN	NN	_	8	PRD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	transduction	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	activation	_	NN	NN	_	17	NMOD	_	_
17	signals	_	NNS	NNS	_	15	PMOD	_	_
18	to	_	TO	TO	_	14	NMOD	_	_
19	T-lymphocytes	_	NNS	NNS	_	18	PMOD	_	_
20	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	regulatory	_	JJ	JJ	_	3	NMOD	_	_
3	role	_	NN	NN	_	14	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	protein	_	NN	NN	_	7	NMOD	_	_
6	tyrosine	_	NN	NN	_	7	NMOD	_	_
7	phosphatases	_	NNS	NNS	_	4	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	PTPases	_	NNS	NNS	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	in	_	IN	IN	_	3	NMOD	_	_
12	this	_	DT	DT	_	13	NMOD	_	_
13	process	_	NN	NN	_	11	PMOD	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	explored	_	VBN	VBN	_	14	VC	_	_
16	by	_	IN	IN	_	15	ADV	_	_
17	studying	_	VBG	VBG	_	16	PMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	effects	_	NNS	NNS	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	a	_	DT	DT	_	24	NMOD	_	_
22	powerful	_	JJ	JJ	_	24	NMOD	_	_
23	PTPase	_	NN	NN	_	24	NMOD	_	_
24	inhibitor	_	NN	NN	_	20	PMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	vanadate	_	NN	NN	_	27	NMOD	_	_
27	peroxide	_	NN	NN	_	24	NMOD	_	_
28	(	_	(	(	_	29	P	_	_
29	pervanadate	_	NN	NN	_	27	PRN	_	_
30	)	_	)	)	_	29	P	_	_
31	,	_	,	,	_	24	P	_	_
32	on	_	IN	IN	_	19	NMOD	_	_
33	the	_	DT	DT	_	35	NMOD	_	_
34	activation	_	NN	NN	_	35	NMOD	_	_
35	cascade	_	NN	NN	_	32	PMOD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	Jurkat	_	NN	NN	_	40	NMOD	_	_
38	human	_	JJ	JJ	_	40	NMOD	_	_
39	leukaemic	_	JJ	JJ	_	40	NMOD	_	_
40	T-cells	_	NNS	NNS	_	36	PMOD	_	_
41	.	_	.	.	_	14	P	_	_

1	Pervanadate	_	NN	NN	_	2	SBJ	_	_
2	induced	_	VBD	VBD	_	0	ROOT-S	_	_
3	activation	_	NN	NN	_	2	OBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	tyrosine	_	NN	NN	_	7	NMOD	_	_
7	kinases	_	NNS	NNS	_	4	PMOD	_	_
8	lck	_	NN	NN	_	7	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	fyn	_	NN	NN	_	8	COORD	_	_
11	(	_	(	(	_	12	P	_	_
12	4-	_	CD	CD	_	3	PRN	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	3-fold	_	JJ	JJ	_	12	COORD	_	_
15	respectively	_	RB	RB	_	12	NMOD	_	_
16	)	_	)	)	_	12	P	_	_
17	and	_	CC	CC	_	3	CC	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	dramatic	_	JJ	JJ	_	20	NMOD	_	_
20	increase	_	NN	NN	_	3	COORD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	tyrosine	_	NN	NN	_	23	NMOD	_	_
23	phosphorylation	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	cellular	_	JJ	JJ	_	26	NMOD	_	_
26	proteins	_	NNS	NNS	_	24	PMOD	_	_
27	,	_	,	,	_	26	P	_	_
28	notably	_	RB	RB	_	31	NMOD	_	_
29	phospholipase	_	NN	NN	_	31	NMOD	_	_
30	C	_	NN	NN	_	31	NMOD	_	_
31	gamma	_	NN	NN	_	26	NMOD	_	_
32	1	_	CD	CD	_	31	NMOD	_	_
33	.	_	.	.	_	2	P	_	_

1	After	_	IN	IN	_	6	TMP	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	event	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	observed	_	VBD	VBD	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	rise	_	NN	NN	_	6	OBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	intracellular	_	JJ	JJ	_	12	NMOD	_	_
11	Ca2+	_	NN	NN	_	12	NMOD	_	_
12	concentration	_	NN	NN	_	9	PMOD	_	_
13	,	_	,	,	_	8	P	_	_
14	corresponding	_	VBG	VBG	_	8	NMOD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	an	_	DT	DT	_	17	NMOD	_	_
17	influx	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	6	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	3	SBJ	_	_
3	required	_	VBD	VBD	_	0	ROOT-S	_	_
4	surface	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	CD45	_	NN	NN	_	9	NMOD	_	_
9	PTPase	_	NN	NN	_	6	PMOD	_	_
10	and	_	CC	CC	_	3	CC	_	_
11	was	_	VBD	VBD	_	3	COORD	_	_
12	not	_	RB	RB	_	11	VMOD	_	_
13	observed	_	VBN	VBN	_	11	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	CD45-deficient	_	JJ	JJ	_	16	NMOD	_	_
16	variants	_	NNS	NNS	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	Jurkat	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	13	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	CD45-negative	_	JJ	JJ	_	4	NMOD	_	_
4	variant	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	13	P	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	effect	_	NN	NN	_	13	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	pervanadate	_	NN	NN	_	8	PMOD	_	_
10	on	_	IN	IN	_	7	NMOD	_	_
11	tyrosine	_	NN	NN	_	12	NMOD	_	_
12	phosphorylation	_	NN	NN	_	10	PMOD	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	globally	_	RB	RB	_	13	ADV	_	_
15	decreased	_	VBN	VBN	_	13	VC	_	_
16	and	_	CC	CC	_	13	CC	_	_
17	some	_	DT	DT	_	19	NMOD	_	_
18	phosphorylated	_	VBN	VBN	_	19	NMOD	_	_
19	substrates	_	NNS	NNS	_	20	SBJ	_	_
20	were	_	VBD	VBD	_	13	COORD	_	_
21	specifically	_	RB	RB	_	20	ADV	_	_
22	missing	_	JJ	JJ	_	20	PRD	_	_
23	.	_	.	.	_	13	P	_	_

1	Pervanadate	_	NN	NN	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	stimulated	_	VBD	VBD	_	0	ROOT-S	_	_
4	transcription	_	NN	NN	_	3	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	c-fos	_	NN	NN	_	8	NMOD	_	_
8	gene	_	NN	NN	_	5	PMOD	_	_
9	and	_	CC	CC	_	4	CC	_	_
10	accumulation	_	NN	NN	_	4	COORD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	its	_	PRP$	PRP$	_	13	NMOD	_	_
13	mRNA	_	NN	NN	_	11	PMOD	_	_
14	as	_	RB	RB	_	4	CC	_	_
15	well	_	RB	RB	_	14	DEP	_	_
16	as	_	IN	IN	_	14	DEP	_	_
17	several	_	JJ	JJ	_	19	NMOD	_	_
18	other	_	JJ	JJ	_	19	NMOD	_	_
19	hallmarks	_	NNS	NNS	_	4	COORD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	T-lymphocyte	_	NN	NN	_	22	NMOD	_	_
22	activation	_	NN	NN	_	20	PMOD	_	_
23	such	_	JJ	JJ	_	24	DEP	_	_
24	as	_	IN	IN	_	19	NMOD	_	_
25	surface	_	NN	NN	_	26	NMOD	_	_
26	expression	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	CD69	_	NN	NN	_	30	NMOD	_	_
30	antigen	_	NN	NN	_	27	PMOD	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	the	_	DT	DT	_	36	NMOD	_	_
33	interleukin	_	NN	NN	_	36	NMOD	_	_
34	2	_	CD	CD	_	36	NMOD	_	_
35	receptor	_	NN	NN	_	36	NMOD	_	_
36	alpha-chain	_	NN	NN	_	30	COORD	_	_
37	(	_	(	(	_	38	P	_	_
38	CD25	_	NN	NN	_	36	PRN	_	_
39	)	_	)	)	_	38	P	_	_
40	.	_	.	.	_	3	P	_	_

1	Pervanadate	_	NN	NN	_	2	SBJ	_	_
2	synergized	_	VBD	VBD	_	0	ROOT-S	_	_
3	with	_	IN	IN	_	2	ADV	_	_
4	signals	_	NNS	NNS	_	3	PMOD	_	_
5	delivered	_	VBN	VBN	_	4	NMOD	_	_
6	by	_	IN	IN	_	5	ADV	_	_
7	T-cell	_	NN	NN	_	10	NMOD	_	_
8	antigen	_	NN	NN	_	10	NMOD	_	_
9	receptor	_	NN	NN	_	10	NMOD	_	_
10	engagement	_	NN	NN	_	6	PMOD	_	_
11	or	_	CC	CC	_	6	CC	_	_
12	by	_	IN	IN	_	6	LGS	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	phorbol	_	NN	NN	_	15	NMOD	_	_
15	ester	_	NN	NN	_	12	PMOD	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	induce	_	VB	VB	_	2	OBJ	_	_
18	interleukin	_	NN	NN	_	20	NMOD	_	_
19	2	_	CD	CD	_	20	NMOD	_	_
20	production	_	NN	NN	_	17	OBJ	_	_
21	.	_	.	.	_	2	P	_	_

1	Pervanadate	_	NN	NN	_	2	SBJ	_	_
2	activated	_	VBD	VBD	_	0	ROOT-S	_	_
3	NF-kappa	_	NN	NN	_	4	NMOD	_	_
4	B	_	NN	NN	_	2	OBJ	_	_
5	,	_	,	,	_	2	P	_	_
6	as	_	IN	IN	_	2	ADV	_	_
7	shown	_	VBN	VBN	_	6	VMOD	_	_
8	by	_	IN	IN	_	7	ADV	_	_
9	an	_	DT	DT	_	10	NMOD	_	_
10	increase	_	NN	NN	_	8	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	DNA-binding	_	JJ	JJ	_	13	NMOD	_	_
13	activity	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	this	_	DT	DT	_	17	NMOD	_	_
16	transcription	_	NN	NN	_	17	NMOD	_	_
17	factor	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	thus	_	RB	RB	_	3	ADV	_	_
3	conclude	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	PTPases	_	NNS	NNS	_	6	SBJ	_	_
6	play	_	VBP	VBP	_	4	VMOD	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	crucial	_	JJ	JJ	_	9	NMOD	_	_
9	role	_	NN	NN	_	6	OBJ	_	_
10	in	_	IN	IN	_	6	ADV	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	negative	_	JJ	JJ	_	13	NMOD	_	_
13	regulation	_	NN	NN	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	signal	_	NN	NN	_	16	NMOD	_	_
16	transduction	_	NN	NN	_	14	PMOD	_	_
17	culminating	_	VBG	VBG	_	16	NMOD	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	T-lymphocyte	_	NN	NN	_	20	NMOD	_	_
20	activation	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	Moreover	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	induction	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	tyrosine	_	NN	NN	_	6	NMOD	_	_
6	phosphorylation	_	NN	NN	_	4	PMOD	_	_
7	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	sufficient	_	JJ	JJ	_	9	AMOD	_	_
9	per	_	FW	FW	_	7	PRD	_	_
10	se	_	FW	FW	_	9	AMOD	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	initiate	_	VB	VB	_	9	AMOD	_	_
13	a	_	DT	DT	_	16	NMOD	_	_
14	complete	_	JJ	JJ	_	16	NMOD	_	_
15	activation	_	NN	NN	_	16	NMOD	_	_
16	programme	_	NN	NN	_	12	OBJ	_	_
17	.	_	.	.	_	7	P	_	_

1	Steroid-resistant	_	JJ	JJ	_	2	NMOD	_	_
2	asthma	_	NN	NN	_	0	ROOT-FRAG	_	_
3	.	_	.	.	_	2	P	_	_

1	Cellular	_	JJ	JJ	_	2	NMOD	_	_
2	mechanisms	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	contributing	_	VBG	VBG	_	2	NMOD	_	_
4	to	_	TO	TO	_	3	ADV	_	_
5	inadequate	_	JJ	JJ	_	6	NMOD	_	_
6	response	_	NN	NN	_	4	PMOD	_	_
7	to	_	TO	TO	_	6	NMOD	_	_
8	glucocorticoid	_	NN	NN	_	9	NMOD	_	_
9	therapy	_	NN	NN	_	7	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	current	_	JJ	JJ	_	3	NMOD	_	_
3	study	_	NN	NN	_	4	SBJ	_	_
4	examined	_	VBD	VBD	_	0	ROOT-S	_	_
5	whether	_	IN	IN	_	4	OBJ	_	_
6	alterations	_	NNS	NNS	_	14	SBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	glucocorticoid	_	NN	NN	_	9	NMOD	_	_
9	receptor	_	NN	NN	_	13	NMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	GR	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	binding	_	NN	NN	_	7	PMOD	_	_
14	contribute	_	VBP	VBP	_	5	VMOD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	poor	_	JJ	JJ	_	17	NMOD	_	_
17	response	_	NN	NN	_	15	PMOD	_	_
18	to	_	TO	TO	_	17	NMOD	_	_
19	glucocorticoid	_	NN	NN	_	20	NMOD	_	_
20	therapy	_	NN	NN	_	18	PMOD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	asthma	_	NN	NN	_	21	PMOD	_	_
23	.	_	.	.	_	4	P	_	_

1	29	_	CD	CD	_	3	NMOD	_	_
2	asthma	_	NN	NN	_	3	NMOD	_	_
3	patients	_	NNS	NNS	_	18	SBJ	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	forced	_	VBN	VBN	_	7	NMOD	_	_
6	expiratory	_	JJ	JJ	_	7	NMOD	_	_
7	volume	_	NN	NN	_	4	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	1	_	CD	CD	_	10	NMOD	_	_
10	s	_	NN	NN	_	8	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	FEV1	_	NN	NN	_	7	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	&lt;	_	JJR	JJR	_	15	DEP	_	_
15	70	_	CD	CD	_	16	NMOD	_	_
16	%	_	NN	NN	_	7	NMOD	_	_
17	predicted	_	VBN	VBN	_	7	NMOD	_	_
18	were	_	VBD	VBD	_	0	ROOT-S	_	_
19	studied	_	VBN	VBN	_	18	VC	_	_
20	.	_	.	.	_	18	P	_	_

1	Patients	_	NNS	NNS	_	2	SBJ	_	_
2	were	_	VBD	VBD	_	0	ROOT-S	_	_
3	classified	_	VBN	VBN	_	2	VC	_	_
4	as	_	IN	IN	_	3	ADV	_	_
5	steroid	_	NN	NN	_	4	PMOD	_	_
6	sensitive	_	JJ	JJ	_	5	AMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	SS	_	JJ	JJ	_	5	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	if	_	IN	IN	_	3	OBJ	_	_
11	their	_	PRP$	PRP$	_	13	NMOD	_	_
12	morning	_	NN	NN	_	13	NMOD	_	_
13	FEV1	_	NN	NN	_	14	SBJ	_	_
14	increased	_	VBD	VBD	_	10	VMOD	_	_
15	&gt;	_	RBR	RBR	_	16	DEP	_	_
16	30	_	CD	CD	_	17	NMOD	_	_
17	%	_	NN	NN	_	14	OBJ	_	_
18	after	_	IN	IN	_	14	TMP	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	1-wk	_	JJ	JJ	_	21	NMOD	_	_
21	course	_	NN	NN	_	18	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	oral	_	JJ	JJ	_	24	NMOD	_	_
24	prednisone	_	NN	NN	_	22	PMOD	_	_
25	20	_	CD	CD	_	26	NMOD	_	_
26	mg	_	NN	NN	_	24	NMOD	_	_
27	twice	_	RB	RB	_	24	NMOD	_	_
28	daily	_	RB	RB	_	27	AMOD	_	_
29	and	_	CC	CC	_	3	CC	_	_
30	steroid	_	NN	NN	_	5	GAP	_	_
31	resistant	_	JJ	JJ	_	30	AMOD	_	_
32	(	_	(	(	_	33	P	_	_
33	SR	_	JJ	JJ	_	30	PRN	_	_
34	)	_	)	)	_	33	P	_	_
35	if	_	IN	IN	_	10	GAP	_	_
36	they	_	PRP	PRP	_	37	SBJ	_	_
37	failed	_	VBD	VBD	_	35	VMOD	_	_
38	to	_	TO	TO	_	39	VMOD	_	_
39	increase	_	VB	VB	_	37	OBJ	_	_
40	&gt;	_	RBR	RBR	_	41	DEP	_	_
41	15	_	CD	CD	_	42	NMOD	_	_
42	%	_	NN	NN	_	39	OBJ	_	_
43	.	_	.	.	_	2	P	_	_

1	PBMC	_	NN	NN	_	20	SBJ	_	_
2	obtained	_	VBN	VBN	_	1	NMOD	_	_
3	from	_	IN	IN	_	2	ADV	_	_
4	these	_	DT	DT	_	6	NMOD	_	_
5	two	_	CD	CD	_	6	NMOD	_	_
6	groups	_	NNS	NNS	_	3	PMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	17	_	CD	CD	_	6	NMOD	_	_
9	SR	_	JJ	JJ	_	8	NMOD	_	_
10	and	_	CC	CC	_	8	CC	_	_
11	12	_	CD	CD	_	8	COORD	_	_
12	SS	_	JJ	JJ	_	11	NMOD	_	_
13	,	_	,	,	_	6	P	_	_
14	as	_	RB	RB	_	6	CC	_	_
15	well	_	RB	RB	_	14	DEP	_	_
16	as	_	IN	IN	_	14	DEP	_	_
17	12	_	CD	CD	_	19	NMOD	_	_
18	normal	_	JJ	JJ	_	19	NMOD	_	_
19	controls	_	NNS	NNS	_	6	COORD	_	_
20	were	_	VBD	VBD	_	0	ROOT-S	_	_
21	analyzed	_	VBN	VBN	_	20	VC	_	_
22	.	_	.	.	_	20	P	_	_

1	SR	_	JJ	JJ	_	2	NMOD	_	_
2	patients	_	NNS	NNS	_	3	SBJ	_	_
3	had	_	VBD	VBD	_	0	ROOT-S	_	_
4	two	_	CD	CD	_	8	NMOD	_	_
5	distinguishable	_	JJ	JJ	_	8	NMOD	_	_
6	GR	_	NN	NN	_	8	NMOD	_	_
7	binding	_	NN	NN	_	8	NMOD	_	_
8	abnormalities	_	NNS	NNS	_	3	OBJ	_	_
9	:	_	:	:	_	3	P	_	_
10	15	_	CD	CD	_	16	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	17	_	CD	CD	_	15	NMOD	_	_
14	SR	_	JJ	JJ	_	15	NMOD	_	_
15	patients	_	NNS	NNS	_	11	PMOD	_	_
16	demonstrated	_	VBD	VBD	_	3	VMOD	_	_
17	a	_	DT	DT	_	22	NMOD	_	_
18	significantly	_	RB	RB	_	19	AMOD	_	_
19	reduced	_	VBN	VBN	_	22	NMOD	_	_
20	GR	_	NN	NN	_	22	NMOD	_	_
21	binding	_	NN	NN	_	22	NMOD	_	_
22	affinity	_	NN	NN	_	16	OBJ	_	_
23	,	_	,	,	_	16	P	_	_
24	as	_	IN	IN	_	16	ADV	_	_
25	compared	_	VBN	VBN	_	24	VMOD	_	_
26	with	_	IN	IN	_	25	ADV	_	_
27	SS	_	JJ	JJ	_	28	NMOD	_	_
28	patients	_	NNS	NNS	_	26	PMOD	_	_
29	(	_	(	(	_	32	P	_	_
30	P	_	NN	NN	_	32	SBJ	_	_
31	=	_	JJ	JJ	_	32	VMOD	_	_
32	0.0001	_	CD	CD	_	28	PRN	_	_
33	)	_	)	)	_	32	P	_	_
34	and	_	CC	CC	_	28	CC	_	_
35	normal	_	JJ	JJ	_	36	NMOD	_	_
36	controls	_	NNS	NNS	_	28	COORD	_	_
37	(	_	(	(	_	40	P	_	_
38	P	_	NN	NN	_	40	SBJ	_	_
39	=	_	JJ	JJ	_	40	VMOD	_	_
40	0.0001	_	CD	CD	_	36	PRN	_	_
41	)	_	)	)	_	40	P	_	_
42	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	defect	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	localized	_	JJ	JJ	_	3	VC	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	T	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	5	PMOD	_	_
8	and	_	CC	CC	_	3	CC	_	_
9	reverted	_	VBD	VBD	_	3	COORD	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	normal	_	JJ	JJ	_	10	PMOD	_	_
12	after	_	IN	IN	_	9	TMP	_	_
13	48	_	CD	CD	_	14	NMOD	_	_
14	h	_	NN	NN	_	12	PMOD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	culture	_	NN	NN	_	17	NMOD	_	_
17	media	_	NNS	NNS	_	15	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	incubation	_	NN	NN	_	11	SBJ	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	a	_	DT	DT	_	6	NMOD	_	_
6	combination	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	IL-2	_	NN	NN	_	7	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	IL-4	_	NN	NN	_	8	COORD	_	_
11	sustained	_	VBD	VBD	_	0	ROOT-S	_	_
12	this	_	DT	DT	_	13	NMOD	_	_
13	abnormality	_	NN	NN	_	11	OBJ	_	_
14	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	other	_	JJ	JJ	_	5	NMOD	_	_
3	two	_	CD	CD	_	5	NMOD	_	_
4	SR	_	JJ	JJ	_	5	NMOD	_	_
5	patients	_	NNS	NNS	_	6	SBJ	_	_
6	had	_	VBD	VBD	_	0	ROOT-S	_	_
7	an	_	DT	DT	_	11	NMOD	_	_
8	abnormally	_	RB	RB	_	9	AMOD	_	_
9	low	_	JJ	JJ	_	11	NMOD	_	_
10	GR	_	NN	NN	_	11	NMOD	_	_
11	number	_	NN	NN	_	6	OBJ	_	_
12	with	_	IN	IN	_	11	NMOD	_	_
13	normal	_	JJ	JJ	_	15	NMOD	_	_
14	binding	_	NN	NN	_	15	NMOD	_	_
15	affinity	_	NN	NN	_	12	PMOD	_	_
16	that	_	WDT	WDT	_	17	SBJ	_	_
17	was	_	VBD	VBD	_	15	NMOD	_	_
18	not	_	RB	RB	_	17	VMOD	_	_
19	limited	_	VBN	VBN	_	17	PRD	_	_
20	to	_	TO	TO	_	19	AMOD	_	_
21	T	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	6	P	_	_

1	Furthermore	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	GR	_	NN	NN	_	4	NMOD	_	_
4	number	_	NN	NN	_	5	SBJ	_	_
5	failed	_	VBD	VBD	_	0	ROOT-S	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	normalize	_	VB	VB	_	5	OBJ	_	_
8	after	_	IN	IN	_	7	TMP	_	_
9	incubation	_	NN	NN	_	8	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	media	_	NNS	NNS	_	10	PMOD	_	_
12	alone	_	RB	RB	_	11	NMOD	_	_
13	or	_	CC	CC	_	11	CC	_	_
14	IL-2	_	NN	NN	_	11	COORD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	IL-4	_	NN	NN	_	14	COORD	_	_
17	.	_	.	.	_	5	P	_	_

1	Therefore	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	SR	_	JJ	JJ	_	4	NMOD	_	_
4	asthma	_	NN	NN	_	5	SBJ	_	_
5	may	_	MD	MD	_	0	ROOT-S	_	_
6	be	_	VB	VB	_	5	VC	_	_
7	due	_	JJ	JJ	_	8	DEP	_	_
8	to	_	TO	TO	_	6	PRD	_	_
9	more	_	JJR	JJR	_	11	DEP	_	_
10	than	_	IN	IN	_	11	DEP	_	_
11	one	_	CD	CD	_	12	NMOD	_	_
12	abnormality	_	NN	NN	_	8	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	majority	_	NN	NN	_	12	NMOD	_	_
16	related	_	JJ	JJ	_	15	NMOD	_	_
17	to	_	TO	TO	_	16	AMOD	_	_
18	a	_	DT	DT	_	21	NMOD	_	_
19	reversible	_	JJ	JJ	_	21	NMOD	_	_
20	cytokine-induced	_	JJ	JJ	_	21	NMOD	_	_
21	reduction	_	NN	NN	_	17	PMOD	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	GR	_	NN	NN	_	25	NMOD	_	_
24	binding	_	NN	NN	_	25	NMOD	_	_
25	affinity	_	NN	NN	_	22	PMOD	_	_
26	and	_	CC	CC	_	15	CC	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	second	_	JJ	JJ	_	15	COORD	_	_
29	related	_	JJ	JJ	_	28	NMOD	_	_
30	to	_	TO	TO	_	29	AMOD	_	_
31	an	_	DT	DT	_	33	NMOD	_	_
32	irreversible	_	JJ	JJ	_	33	NMOD	_	_
33	reduction	_	NN	NN	_	30	PMOD	_	_
34	in	_	IN	IN	_	33	NMOD	_	_
35	GR	_	NN	NN	_	36	NMOD	_	_
36	number	_	NN	NN	_	34	PMOD	_	_
37	.	_	.	.	_	5	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	may	_	MD	MD	_	0	ROOT-S	_	_
4	have	_	VB	VB	_	3	VC	_	_
5	important	_	JJ	JJ	_	6	NMOD	_	_
6	implications	_	NNS	NNS	_	4	OBJ	_	_
7	for	_	IN	IN	_	4	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	design	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	alternative	_	JJ	JJ	_	13	NMOD	_	_
12	treatment	_	NN	NN	_	13	NMOD	_	_
13	approaches	_	NNS	NNS	_	10	PMOD	_	_
14	for	_	IN	IN	_	13	NMOD	_	_
15	recalcitrant	_	JJ	JJ	_	16	NMOD	_	_
16	asthma	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	Increased	_	VBN	VBN	_	2	NMOD	_	_
2	proliferation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	,	_	,	,	_	2	P	_	_
4	cytotoxicity	_	NN	NN	_	2	COORD	_	_
5	,	_	,	,	_	2	P	_	_
6	and	_	CC	CC	_	2	CC	_	_
7	gene	_	NN	NN	_	8	NMOD	_	_
8	expression	_	NN	NN	_	2	COORD	_	_
9	after	_	IN	IN	_	2	TMP	_	_
10	stimulation	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	human	_	JJ	JJ	_	16	NMOD	_	_
13	peripheral	_	JJ	JJ	_	16	NMOD	_	_
14	blood	_	NN	NN	_	16	NMOD	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	lymphocytes	_	NNS	NNS	_	11	PMOD	_	_
17	through	_	IN	IN	_	10	NMOD	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	surface	_	NN	NN	_	20	NMOD	_	_
20	ganglioside	_	NN	NN	_	17	PMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	GD3	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	{	_	(	(	_	27	P	_	_
25	published	_	VBN	VBN	_	26	NMOD	_	_
26	erratum	_	NN	NN	_	27	SBJ	_	_
27	appears	_	VBZ	VBZ	_	2	PRN	_	_
28	in	_	IN	IN	_	27	ADV	_	_
29	J	_	NNP	NNP	_	30	NMOD	_	_
30	Immunol	_	NNP	NNP	_	28	PMOD	_	_
31	1994	_	CD	CD	_	32	NMOD	_	_
32	Jul	_	NNP	NNP	_	30	TMP	_	_
33	15	_	CD	CD	_	32	NMOD	_	_
34	;	_	:	:	_	30	P	_	_
35	153	_	CD	CD	_	37	NMOD	_	_
36	(	_	(	(	_	37	P	_	_
37	2	_	CD	CD	_	30	NMOD	_	_
38	)	_	)	)	_	37	P	_	_
39	:	_	:	:	_	30	P	_	_
40	910	_	CD	CD	_	30	NMOD	_	_
41	}	_	)	)	_	27	P	_	_

1	Previous	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	suggested	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	gangliosides	_	NNS	NNS	_	7	SBJ	_	_
7	have	_	VBP	VBP	_	5	VMOD	_	_
8	an	_	DT	DT	_	10	NMOD	_	_
9	important	_	JJ	JJ	_	10	NMOD	_	_
10	role	_	NN	NN	_	7	OBJ	_	_
11	in	_	IN	IN	_	7	ADV	_	_
12	cell	_	NN	NN	_	11	PMOD	_	_
13	signaling	_	NN	NN	_	12	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	recognition	_	NN	NN	_	13	COORD	_	_
16	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	their	_	PRP$	PRP$	_	5	NMOD	_	_
4	specific	_	JJ	JJ	_	5	NMOD	_	_
5	function	_	NN	NN	_	9	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	these	_	DT	DT	_	8	NMOD	_	_
8	processes	_	NNS	NNS	_	6	PMOD	_	_
9	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	not	_	RB	RB	_	9	VMOD	_	_
11	been	_	VBN	VBN	_	9	VC	_	_
12	clearly	_	RB	RB	_	11	ADV	_	_
13	defined	_	VBN	VBN	_	11	VC	_	_
14	.	_	.	.	_	9	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	mAb	_	NN	NN	_	17	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	R24	_	NN	NN	_	2	NMOD	_	_
5	,	_	,	,	_	2	P	_	_
6	that	_	WDT	WDT	_	7	SBJ	_	_
7	reacts	_	VBZ	VBZ	_	2	NMOD	_	_
8	specifically	_	RB	RB	_	7	ADV	_	_
9	with	_	IN	IN	_	7	ADV	_	_
10	a	_	DT	DT	_	13	NMOD	_	_
11	cell	_	NN	NN	_	13	NMOD	_	_
12	surface	_	NN	NN	_	13	NMOD	_	_
13	ganglioside	_	NN	NN	_	9	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	GD3	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	been	_	VBN	VBN	_	17	VC	_	_
19	demonstrated	_	VBN	VBN	_	18	VC	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	stimulate	_	VB	VB	_	19	OBJ	_	_
22	proliferation	_	NN	NN	_	21	OBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	T	_	NN	NN	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	23	PMOD	_	_
26	derived	_	VBN	VBN	_	25	NMOD	_	_
27	from	_	IN	IN	_	26	ADV	_	_
28	human	_	JJ	JJ	_	30	NMOD	_	_
29	peripheral	_	JJ	JJ	_	30	NMOD	_	_
30	blood	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	17	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	have	_	VBP	VBP	_	0	ROOT-S	_	_
7	investigated	_	VBN	VBN	_	6	VC	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	mechanisms	_	NNS	NNS	_	7	OBJ	_	_
10	by	_	IN	IN	_	15	ADV	_	_
11	which	_	WDT	WDT	_	10	PMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	R24	_	NN	NN	_	14	NMOD	_	_
14	mAb	_	NN	NN	_	15	SBJ	_	_
15	affects	_	VBZ	VBZ	_	9	NMOD	_	_
16	T	_	NN	NN	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	functions	_	NNS	NNS	_	15	OBJ	_	_
19	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	observed	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	R24	_	NN	NN	_	7	NMOD	_	_
7	mAb	_	NN	NN	_	8	SBJ	_	_
8	stimulates	_	VBZ	VBZ	_	4	VMOD	_	_
9	GD3+	_	JJ	JJ	_	11	NMOD	_	_
10	T	_	NN	NN	_	11	NMOD	_	_
11	cell	_	NN	NN	_	8	OBJ	_	_
12	proliferation	_	NN	NN	_	11	NMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	cytotoxicity	_	NN	NN	_	12	COORD	_	_
15	,	_	,	,	_	12	P	_	_
16	and	_	CC	CC	_	12	CC	_	_
17	surface	_	NN	NN	_	19	NMOD	_	_
18	marker	_	NN	NN	_	19	NMOD	_	_
19	expression	_	NN	NN	_	12	COORD	_	_
20	of	_	IN	IN	_	11	NMOD	_	_
21	IL-2R	_	NN	NN	_	22	NMOD	_	_
22	alpha-chain	_	NN	NN	_	20	PMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	IL-2R	_	NN	NN	_	25	NMOD	_	_
25	beta-chain	_	NN	NN	_	22	COORD	_	_
26	,	_	,	,	_	22	P	_	_
27	HLA-DR	_	NN	NN	_	22	COORD	_	_
28	,	_	,	,	_	22	P	_	_
29	CD11a	_	NN	NN	_	22	COORD	_	_
30	,	_	,	,	_	22	P	_	_
31	and	_	CC	CC	_	22	CC	_	_
32	CD11c	_	NN	NN	_	22	COORD	_	_
33	.	_	.	.	_	2	P	_	_

1	Additionally	_	RB	RB	_	14	ADV	_	_
2	,	_	,	,	_	14	P	_	_
3	IFN-gamma	_	NN	NN	_	4	NMOD	_	_
4	activity	_	NN	NN	_	14	SBJ	_	_
5	but	_	CC	CC	_	4	CC	_	_
6	not	_	RB	RB	_	5	COORD	_	_
7	IL-1	_	NN	NN	_	13	NMOD	_	_
8	,	_	,	,	_	7	P	_	_
9	IL-2	_	NN	NN	_	7	COORD	_	_
10	,	_	,	,	_	7	P	_	_
11	or	_	CC	CC	_	7	CC	_	_
12	IL-4	_	NN	NN	_	7	COORD	_	_
13	activity	_	NN	NN	_	4	COORD	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	present	_	JJ	JJ	_	14	PRD	_	_
16	in	_	IN	IN	_	15	AMOD	_	_
17	culture	_	NN	NN	_	18	NMOD	_	_
18	supernatants	_	NNS	NNS	_	16	PMOD	_	_
19	72	_	CD	CD	_	20	NMOD	_	_
20	h	_	NN	NN	_	21	PMOD	_	_
21	after	_	IN	IN	_	14	TMP	_	_
22	R24	_	NN	NN	_	23	NMOD	_	_
23	stimulation	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	some	_	DT	DT	_	3	NMOD	_	_
3	donors	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	11	P	_	_
5	increased	_	VBN	VBN	_	9	NMOD	_	_
6	IL-6	_	NN	NN	_	9	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	TNF-alpha	_	NN	NN	_	6	COORD	_	_
9	activity	_	NN	NN	_	11	SBJ	_	_
10	also	_	RB	RB	_	11	ADV	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	detected	_	VBN	VBN	_	11	VC	_	_
13	after	_	IN	IN	_	12	TMP	_	_
14	R24	_	NN	NN	_	15	NMOD	_	_
15	treatment	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	11	P	_	_

1	Furthermore	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	R24	_	NN	NN	_	4	NMOD	_	_
4	treatment	_	NN	NN	_	5	SBJ	_	_
5	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	translocation	_	NN	NN	_	6	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	c-rel	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	but	_	CC	CC	_	9	CC	_	_
12	little	_	JJ	JJ	_	17	NMOD	_	_
13	or	_	CC	CC	_	12	CC	_	_
14	no	_	DT	DT	_	12	COORD	_	_
15	NF	_	NN	NN	_	17	NMOD	_	_
16	kappa	_	NN	NN	_	17	NMOD	_	_
17	B	_	NN	NN	_	9	COORD	_	_
18	p50	_	NN	NN	_	17	NMOD	_	_
19	or	_	CC	CC	_	18	CC	_	_
20	p65	_	NN	NN	_	18	COORD	_	_
21	,	_	,	,	_	9	P	_	_
22	from	_	IN	IN	_	7	NMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	cytoplasm	_	NN	NN	_	22	PMOD	_	_
25	to	_	TO	TO	_	7	NMOD	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	nucleus	_	NN	NN	_	25	PMOD	_	_
28	and	_	CC	CC	_	7	CC	_	_
29	an	_	DT	DT	_	30	NMOD	_	_
30	increase	_	NN	NN	_	7	COORD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	NF	_	NN	NN	_	35	AMOD	_	_
33	kappa	_	NN	NN	_	35	AMOD	_	_
34	B	_	NN	NN	_	35	AMOD	_	_
35	binding	_	NN	NN	_	36	NMOD	_	_
36	complexes	_	NNS	NNS	_	31	PMOD	_	_
37	containing	_	VBG	VBG	_	36	NMOD	_	_
38	c-rel	_	NN	NN	_	37	OBJ	_	_
39	and	_	CC	CC	_	38	CC	_	_
40	p50	_	NN	NN	_	38	COORD	_	_
41	.	_	.	.	_	5	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	treatment	_	NN	NN	_	4	SBJ	_	_
3	also	_	RB	RB	_	4	ADV	_	_
4	caused	_	VBD	VBD	_	0	ROOT-S	_	_
5	increased	_	VBN	VBN	_	7	NMOD	_	_
6	tyrosine	_	NN	NN	_	7	NMOD	_	_
7	phosphorylation	_	NN	NN	_	4	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	specific	_	JJ	JJ	_	11	NMOD	_	_
10	protein	_	NN	NN	_	11	NMOD	_	_
11	substrates	_	NNS	NNS	_	8	PMOD	_	_
12	.	_	.	.	_	4	P	_	_

1	R24-stimulated	_	JJ	JJ	_	2	NMOD	_	_
2	increases	_	NNS	NNS	_	13	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	proliferation	_	NN	NN	_	3	PMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	cytotoxicity	_	NN	NN	_	4	COORD	_	_
7	,	_	,	,	_	4	P	_	_
8	and	_	CC	CC	_	4	CC	_	_
9	cell	_	NN	NN	_	12	NMOD	_	_
10	surface	_	NN	NN	_	12	NMOD	_	_
11	protein	_	NN	NN	_	12	NMOD	_	_
12	expression	_	NN	NN	_	4	COORD	_	_
13	could	_	MD	MD	_	0	ROOT-S	_	_
14	be	_	VB	VB	_	13	VC	_	_
15	blocked	_	VBN	VBN	_	14	VC	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	cyclosporin	_	NN	NN	_	16	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	staurosporin	_	NN	NN	_	17	COORD	_	_
20	,	_	,	,	_	15	P	_	_
21	indicating	_	VBG	VBG	_	15	OBJ	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	cyclophilin\/calcineurin	_	NN	NN	_	28	SBJ	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	protein	_	NN	NN	_	27	NMOD	_	_
26	kinase	_	NN	NN	_	27	NMOD	_	_
27	C	_	NN	NN	_	23	COORD	_	_
28	may	_	MD	MD	_	22	VMOD	_	_
29	be	_	VB	VB	_	28	VC	_	_
30	involved	_	VBN	VBN	_	29	VC	_	_
31	in	_	IN	IN	_	30	ADV	_	_
32	the	_	DT	DT	_	35	NMOD	_	_
33	R24	_	NN	NN	_	35	NMOD	_	_
34	signaling	_	NN	NN	_	35	NMOD	_	_
35	pathway	_	NN	NN	_	31	PMOD	_	_
36	.	_	.	.	_	13	P	_	_

1	Additionally	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	herbimycin	_	NN	NN	_	4	NMOD	_	_
4	A	_	NN	NN	_	11	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	tyrosine	_	NN	NN	_	9	NMOD	_	_
8	kinase	_	NN	NN	_	9	NMOD	_	_
9	inhibitor	_	NN	NN	_	4	NMOD	_	_
10	,	_	,	,	_	4	P	_	_
11	blocked	_	VBD	VBD	_	0	ROOT-S	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	R24-stimulated	_	JJ	JJ	_	14	NMOD	_	_
14	increase	_	NN	NN	_	11	OBJ	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	proliferation	_	NN	NN	_	15	PMOD	_	_
17	but	_	CC	CC	_	16	CC	_	_
18	not	_	RB	RB	_	17	COORD	_	_
19	cytotoxicity	_	NN	NN	_	16	COORD	_	_
20	at	_	IN	IN	_	11	ADV	_	_
21	concentrations	_	NNS	NNS	_	20	PMOD	_	_
22	consistent	_	JJ	JJ	_	21	NMOD	_	_
23	with	_	IN	IN	_	22	AMOD	_	_
24	specificity	_	NN	NN	_	23	PMOD	_	_
25	for	_	IN	IN	_	24	NMOD	_	_
26	tyrosine	_	NN	NN	_	27	NMOD	_	_
27	kinases	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	11	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	multiple	_	JJ	JJ	_	7	NMOD	_	_
6	biochemical	_	JJ	JJ	_	7	NMOD	_	_
7	pathways	_	NNS	NNS	_	8	SBJ	_	_
8	are	_	VBP	VBP	_	4	VMOD	_	_
9	involved	_	VBN	VBN	_	8	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	activation	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	human	_	JJ	JJ	_	16	NMOD	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	13	PMOD	_	_
17	by	_	IN	IN	_	12	NMOD	_	_
18	R24	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	SCL	_	NN	NN	_	3	NMOD	_	_
3	protein	_	NN	NN	_	4	SBJ	_	_
4	displays	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	cell-specific	_	JJ	JJ	_	6	NMOD	_	_
6	heterogeneity	_	NN	NN	_	4	OBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	size	_	NN	NN	_	7	PMOD	_	_
9	.	_	.	.	_	4	P	_	_

1	SCL	_	NN	NN	_	3	NMOD	_	_
2	protein	_	NN	NN	_	3	NMOD	_	_
3	production	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	examined	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	variety	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	hemopoietic	_	JJ	JJ	_	12	NMOD	_	_
11	cell	_	NN	NN	_	12	NMOD	_	_
12	lines	_	NNS	NNS	_	9	PMOD	_	_
13	by	_	IN	IN	_	5	ADV	_	_
14	immunoblotting	_	VBG	VBG	_	13	PMOD	_	_
15	using	_	VBG	VBG	_	14	NMOD	_	_
16	specific	_	JJ	JJ	_	18	NMOD	_	_
17	polyclonal	_	JJ	JJ	_	18	NMOD	_	_
18	antisera	_	NNS	NNS	_	15	OBJ	_	_
19	.	_	.	.	_	4	P	_	_

1	SCL	_	NN	NN	_	2	NMOD	_	_
2	protein	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	detected	_	VBN	VBN	_	3	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	erythroid	_	JJ	JJ	_	15	NMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	megakaryocyte	_	NN	NN	_	6	COORD	_	_
9	,	_	,	,	_	6	P	_	_
10	mast	_	NN	NN	_	6	COORD	_	_
11	and	_	CC	CC	_	6	CC	_	_
12	early	_	JJ	JJ	_	13	AMOD	_	_
13	myeloid	_	JJ	JJ	_	6	COORD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	lines	_	NNS	NNS	_	5	PMOD	_	_
16	,	_	,	,	_	5	P	_	_
17	as	_	RB	RB	_	5	CC	_	_
18	well	_	RB	RB	_	17	DEP	_	_
19	as	_	IN	IN	_	17	DEP	_	_
20	in	_	IN	IN	_	5	COORD	_	_
21	several	_	JJ	JJ	_	25	NMOD	_	_
22	lymphoid	_	JJ	JJ	_	25	NMOD	_	_
23	leukemia	_	NN	NN	_	25	NMOD	_	_
24	cell	_	NN	NN	_	25	NMOD	_	_
25	lines	_	NNS	NNS	_	20	PMOD	_	_
26	which	_	WDT	WDT	_	27	SBJ	_	_
27	are	_	VBP	VBP	_	25	NMOD	_	_
28	known	_	VBN	VBN	_	27	VC	_	_
29	to	_	TO	TO	_	30	VMOD	_	_
30	harbor	_	VB	VB	_	28	OBJ	_	_
31	SCL	_	NN	NN	_	33	NMOD	_	_
32	gene	_	NN	NN	_	33	NMOD	_	_
33	rearrangements	_	NNS	NNS	_	30	OBJ	_	_
34	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	14	ADV	_	_
2	most	_	JJS	JJS	_	4	NMOD	_	_
3	cell	_	NN	NN	_	4	NMOD	_	_
4	lines	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	14	P	_	_
6	proteins	_	NNS	NNS	_	14	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	molecular	_	JJ	JJ	_	9	NMOD	_	_
9	weight	_	NN	NN	_	7	PMOD	_	_
10	49	_	CD	CD	_	13	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	44	_	CD	CD	_	10	COORD	_	_
13	kDa	_	NN	NN	_	9	NMOD	_	_
14	were	_	VBD	VBD	_	0	ROOT-S	_	_
15	found	_	VBN	VBN	_	14	VC	_	_
16	,	_	,	,	_	14	P	_	_
17	however	_	RB	RB	_	22	ADV	_	_
18	two	_	CD	CD	_	21	NMOD	_	_
19	myeloid	_	JJ	JJ	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	lines	_	NNS	NNS	_	22	SBJ	_	_
22	expressed	_	VBD	VBD	_	14	COORD	_	_
23	only	_	RB	RB	_	27	NMOD	_	_
24	lower	_	JJR	JJR	_	27	NMOD	_	_
25	molecular	_	JJ	JJ	_	27	NMOD	_	_
26	weight	_	NN	NN	_	27	NMOD	_	_
27	species	_	NNS	NNS	_	22	OBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	24	_	CD	CD	_	32	NMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	22	_	CD	CD	_	29	COORD	_	_
32	kDa	_	NN	NN	_	28	PMOD	_	_
33	.	_	.	.	_	14	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	size	_	NN	NN	_	3	NMOD	_	_
3	discrepancy	_	NN	NN	_	4	SBJ	_	_
4	appeared	_	VBD	VBD	_	0	ROOT-S	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	be	_	VB	VB	_	4	OBJ	_	_
7	due	_	JJ	JJ	_	8	DEP	_	_
8	to	_	TO	TO	_	6	PRD	_	_
9	cell-specific	_	JJ	JJ	_	11	NMOD	_	_
10	translational	_	JJ	JJ	_	11	NMOD	_	_
11	regulation	_	NN	NN	_	8	PMOD	_	_
12	,	_	,	,	_	4	P	_	_
13	since	_	IN	IN	_	4	ADV	_	_
14	overexpression	_	NN	NN	_	21	SBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	a	_	DT	DT	_	20	NMOD	_	_
17	retrovirally	_	RB	RB	_	18	AMOD	_	_
18	transfected	_	VBN	VBN	_	20	NMOD	_	_
19	SCL	_	NN	NN	_	20	NMOD	_	_
20	gene	_	NN	NN	_	15	PMOD	_	_
21	yielded	_	VBD	VBD	_	13	VMOD	_	_
22	the	_	DT	DT	_	26	NMOD	_	_
23	higher	_	JJR	JJR	_	26	NMOD	_	_
24	molecular	_	JJ	JJ	_	26	NMOD	_	_
25	weight	_	NN	NN	_	26	NMOD	_	_
26	forms	_	NNS	NNS	_	21	OBJ	_	_
27	in	_	IN	IN	_	21	VMOD	_	_
28	most	_	JJS	JJS	_	30	NMOD	_	_
29	cell	_	NN	NN	_	30	NMOD	_	_
30	lines	_	NNS	NNS	_	27	PMOD	_	_
31	(	_	(	(	_	32	P	_	_
32	GP+E-86	_	NN	NN	_	30	PRN	_	_
33	,	_	,	,	_	32	P	_	_
34	AT2.5	_	NN	NN	_	32	NMOD	_	_
35	,	_	,	,	_	32	P	_	_
36	M1	_	NN	NN	_	32	NMOD	_	_
37	)	_	)	)	_	32	P	_	_
38	but	_	CC	CC	_	21	CC	_	_
39	only	_	RB	RB	_	43	NMOD	_	_
40	the	_	DT	DT	_	43	NMOD	_	_
41	22	_	CD	CD	_	42	AMOD	_	_
42	kDa	_	NN	NN	_	43	NMOD	_	_
43	form	_	NN	NN	_	26	GAP	_	_
44	in	_	IN	IN	_	27	GAP	_	_
45	the	_	DT	DT	_	48	NMOD	_	_
46	myeloid	_	JJ	JJ	_	48	NMOD	_	_
47	cell	_	NN	NN	_	48	NMOD	_	_
48	line	_	NN	NN	_	44	PMOD	_	_
49	,	_	,	,	_	48	P	_	_
50	WEHI-3B\/D+	_	NN	NN	_	48	NMOD	_	_
51	.	_	.	.	_	4	P	_	_

1	Overexpression	_	NN	NN	_	16	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	full-length	_	JJ	JJ	_	5	NMOD	_	_
4	SCL	_	NN	NN	_	5	NMOD	_	_
5	protein	_	NN	NN	_	2	PMOD	_	_
6	in	_	IN	IN	_	1	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	lymphoid	_	JJ	JJ	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	lines	_	NNS	NNS	_	6	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	SupT1	_	NN	NN	_	10	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	Raji	_	NN	NN	_	12	COORD	_	_
15	,	_	,	,	_	10	P	_	_
16	did	_	VBD	VBD	_	0	ROOT-S	_	_
17	not	_	RB	RB	_	16	VMOD	_	_
18	alter	_	VB	VB	_	16	VC	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	phenotype	_	NN	NN	_	18	OBJ	_	_
21	and	_	CC	CC	_	16	CC	_	_
22	there	_	EX	EX	_	23	SBJ	_	_
23	was	_	VBD	VBD	_	16	COORD	_	_
24	no	_	DT	DT	_	25	NMOD	_	_
25	evidence	_	NN	NN	_	23	PRD	_	_
26	for	_	IN	IN	_	25	NMOD	_	_
27	autoregulation	_	NN	NN	_	26	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	SCL	_	NN	NN	_	30	NMOD	_	_
30	transcription	_	NN	NN	_	28	PMOD	_	_
31	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	restricted	_	JJ	JJ	_	3	NMOD	_	_
3	pattern	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	SCL	_	NN	NN	_	7	NMOD	_	_
6	protein	_	NN	NN	_	7	NMOD	_	_
7	synthesis	_	NN	NN	_	4	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	consistent	_	JJ	JJ	_	8	PRD	_	_
10	with	_	IN	IN	_	9	AMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	restricted	_	JJ	JJ	_	13	NMOD	_	_
13	expression	_	NN	NN	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	SCL	_	NN	NN	_	16	NMOD	_	_
16	mRNA	_	NN	NN	_	14	PMOD	_	_
17	documented	_	VBN	VBN	_	13	NMOD	_	_
18	previously	_	RB	RB	_	17	TMP	_	_
19	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	7	P	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	present	_	JJ	JJ	_	6	NMOD	_	_
6	results	_	NNS	NNS	_	7	SBJ	_	_
7	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	SCL	_	NN	NN	_	11	NMOD	_	_
10	protein	_	NN	NN	_	11	NMOD	_	_
11	size	_	NN	NN	_	12	SBJ	_	_
12	was	_	VBD	VBD	_	8	VMOD	_	_
13	determined	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	regulation	_	NN	NN	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	translation	_	NN	NN	_	16	PMOD	_	_
18	in	_	IN	IN	_	13	ADV	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	cell-specific	_	JJ	JJ	_	21	NMOD	_	_
21	manner	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	Human	_	JJ	JJ	_	7	NMOD	_	_
2	T-cell	_	NN	NN	_	7	NMOD	_	_
3	leukemia	_	NN	NN	_	7	NMOD	_	_
4	virus	_	NN	NN	_	7	NMOD	_	_
5	type	_	NN	NN	_	7	NMOD	_	_
6	I	_	CD	CD	_	7	NMOD	_	_
7	Tax	_	NN	NN	_	8	SBJ	_	_
8	associates	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	and	_	CC	CC	_	8	CC	_	_
11	is	_	VBZ	VBZ	_	8	COORD	_	_
12	negatively	_	RB	RB	_	13	ADV	_	_
13	regulated	_	VBN	VBN	_	11	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	the	_	DT	DT	_	20	NMOD	_	_
16	NF-kappa	_	NN	NN	_	20	NMOD	_	_
17	B2	_	NN	NN	_	20	NMOD	_	_
18	p100	_	NN	NN	_	20	NMOD	_	_
19	gene	_	NN	NN	_	20	NMOD	_	_
20	product	_	NN	NN	_	9	PMOD	_	_
21	:	_	:	:	_	8	P	_	_
22	implications	_	NNS	NNS	_	8	VMOD	_	_
23	for	_	IN	IN	_	22	NMOD	_	_
24	viral	_	JJ	JJ	_	25	NMOD	_	_
25	latency	_	NN	NN	_	23	PMOD	_	_
26	.	_	.	.	_	22	P	_	_

1	Human	_	JJ	JJ	_	5	NMOD	_	_
2	T-cell	_	NN	NN	_	5	NMOD	_	_
3	leukemia	_	NN	NN	_	5	NMOD	_	_
4	virus	_	NN	NN	_	5	NMOD	_	_
5	type	_	NN	NN	_	10	SBJ	_	_
6	I	_	CD	CD	_	5	NMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	HTLV-I	_	NN	NN	_	5	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	etiologic	_	JJ	JJ	_	13	NMOD	_	_
13	agent	_	NN	NN	_	10	PRD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	adult	_	JJ	JJ	_	18	NMOD	_	_
17	T-cell	_	NN	NN	_	18	NMOD	_	_
18	leukemia	_	NN	NN	_	14	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	an	_	DT	DT	_	25	NMOD	_	_
21	aggressive	_	JJ	JJ	_	25	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	often	_	RB	RB	_	21	COORD	_	_
24	fatal	_	JJ	JJ	_	23	AMOD	_	_
25	malignancy	_	NN	NN	_	18	NMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	activated	_	VBN	VBN	_	31	NMOD	_	_
28	human	_	JJ	JJ	_	31	NMOD	_	_
29	CD4	_	NN	NN	_	31	NMOD	_	_
30	T	_	NN	NN	_	31	NMOD	_	_
31	cells	_	NNS	NNS	_	26	PMOD	_	_
32	.	_	.	.	_	10	P	_	_

1	HTLV-I	_	NN	NN	_	2	SBJ	_	_
2	encodes	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	an	_	DT	DT	_	6	NMOD	_	_
4	essential	_	JJ	JJ	_	6	NMOD	_	_
5	40-kDa	_	JJ	JJ	_	6	NMOD	_	_
6	protein	_	NN	NN	_	2	OBJ	_	_
7	termed	_	VBN	VBN	_	6	NMOD	_	_
8	Tax	_	NN	NN	_	7	OBJ	_	_
9	that	_	WDT	WDT	_	12	SBJ	_	_
10	not	_	RB	RB	_	12	CC	_	_
11	only	_	RB	RB	_	10	DEP	_	_
12	transactivates	_	VBZ	VBZ	_	6	NMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	long	_	JJ	JJ	_	16	NMOD	_	_
15	terminal	_	JJ	JJ	_	16	NMOD	_	_
16	repeat	_	NN	NN	_	12	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	this	_	DT	DT	_	19	NMOD	_	_
19	retrovirus	_	NN	NN	_	17	PMOD	_	_
20	but	_	CC	CC	_	12	CC	_	_
21	also	_	RB	RB	_	20	COORD	_	_
22	induces	_	VBZ	VBZ	_	12	COORD	_	_
23	an	_	DT	DT	_	24	NMOD	_	_
24	array	_	NN	NN	_	22	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	cellular	_	JJ	JJ	_	27	NMOD	_	_
27	genes	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	2	P	_	_

1	Tax-mediated	_	JJ	JJ	_	2	NMOD	_	_
2	transformation	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	T	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	3	PMOD	_	_
6	likely	_	RB	RB	_	7	ADV	_	_
7	involves	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	deregulated	_	VBN	VBN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	various	_	JJ	JJ	_	14	NMOD	_	_
13	cellular	_	JJ	JJ	_	14	NMOD	_	_
14	genes	_	NNS	NNS	_	11	PMOD	_	_
15	that	_	WDT	WDT	_	17	SBJ	_	_
16	normally	_	RB	RB	_	17	ADV	_	_
17	regulate	_	VBP	VBP	_	14	NMOD	_	_
18	lymphocyte	_	NN	NN	_	19	NMOD	_	_
19	growth	_	NN	NN	_	17	OBJ	_	_
20	produced	_	VBN	VBN	_	19	NMOD	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	altered	_	JJ	JJ	_	23	NMOD	_	_
23	activity	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	various	_	JJ	JJ	_	29	NMOD	_	_
26	endogenous	_	JJ	JJ	_	29	NMOD	_	_
27	host	_	NN	NN	_	29	NMOD	_	_
28	transcription	_	NN	NN	_	29	NMOD	_	_
29	factors	_	NNS	NNS	_	24	PMOD	_	_
30	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	particular	_	JJ	JJ	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	Tax	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	capable	_	JJ	JJ	_	5	PRD	_	_
7	of	_	IN	IN	_	6	AMOD	_	_
8	modulating	_	VBG	VBG	_	7	PMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	expression	_	NN	NN	_	8	OBJ	_	_
11	or	_	CC	CC	_	10	CC	_	_
12	activity	_	NN	NN	_	10	COORD	_	_
13	of	_	IN	IN	_	10	NMOD	_	_
14	various	_	JJ	JJ	_	17	NMOD	_	_
15	host	_	NN	NN	_	17	NMOD	_	_
16	transcription	_	NN	NN	_	17	NMOD	_	_
17	factors	_	NNS	NNS	_	13	PMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	including	_	VBG	VBG	_	17	NMOD	_	_
20	members	_	NNS	NNS	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	27	NMOD	_	_
23	NF-kappa	_	NN	NN	_	24	NMOD	_	_
24	B\/Rel	_	NN	NN	_	27	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	CREB\/ATF	_	NN	NN	_	24	COORD	_	_
27	families	_	NNS	NNS	_	21	PMOD	_	_
28	,	_	,	,	_	20	P	_	_
29	as	_	RB	RB	_	20	CC	_	_
30	well	_	RB	RB	_	29	DEP	_	_
31	as	_	IN	IN	_	29	DEP	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	cellular	_	JJ	JJ	_	34	NMOD	_	_
34	factors	_	NNS	NNS	_	20	COORD	_	_
35	HEB-1	_	NN	NN	_	34	NMOD	_	_
36	and	_	CC	CC	_	35	CC	_	_
37	p67SRF	_	NN	NN	_	35	COORD	_	_
38	.	_	.	.	_	5	P	_	_

1	An	_	DT	DT	_	4	NMOD	_	_
2	additional	_	JJ	JJ	_	4	NMOD	_	_
3	distinguishing	_	JJ	JJ	_	4	NMOD	_	_
4	characteristic	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	HTLV-I	_	NN	NN	_	7	NMOD	_	_
7	infection	_	NN	NN	_	5	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	profound	_	JJ	JJ	_	11	NMOD	_	_
11	state	_	NN	NN	_	8	PRD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	viral	_	JJ	JJ	_	14	NMOD	_	_
14	latency	_	NN	NN	_	12	PMOD	_	_
15	that	_	WDT	WDT	_	16	SBJ	_	_
16	is	_	VBZ	VBZ	_	14	NMOD	_	_
17	present	_	JJ	JJ	_	16	PRD	_	_
18	in	_	IN	IN	_	17	AMOD	_	_
19	circulating	_	VBG	VBG	_	23	NMOD	_	_
20	primary	_	JJ	JJ	_	23	NMOD	_	_
21	leukemic	_	JJ	JJ	_	23	NMOD	_	_
22	T	_	NN	NN	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	18	PMOD	_	_
24	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	HTLV-I	_	NN	NN	_	9	NMOD	_	_
9	Tax	_	NN	NN	_	10	SBJ	_	_
10	can	_	MD	MD	_	7	VMOD	_	_
11	physically	_	RB	RB	_	12	ADV	_	_
12	associate	_	VB	VB	_	10	VC	_	_
13	with	_	IN	IN	_	12	ADV	_	_
14	p100	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	product	_	NN	NN	_	14	NMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	23	NMOD	_	_
20	Rel-related	_	JJ	JJ	_	23	NMOD	_	_
21	NF-kappa	_	NN	NN	_	23	NMOD	_	_
22	B2	_	NN	NN	_	23	NMOD	_	_
23	gene	_	NN	NN	_	18	PMOD	_	_
24	,	_	,	,	_	14	P	_	_
25	both	_	CC	CC	_	12	ADV	_	_
26	in	_	IN	IN	_	25	COORD	_	_
27	transfected	_	VBN	VBN	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	26	PMOD	_	_
29	and	_	CC	CC	_	25	CC	_	_
30	in	_	IN	IN	_	25	COORD	_	_
31	HTLV-I-infected	_	JJ	JJ	_	34	NMOD	_	_
32	leukemic	_	JJ	JJ	_	34	NMOD	_	_
33	T-cell	_	NN	NN	_	34	NMOD	_	_
34	lines	_	NNS	NNS	_	30	PMOD	_	_
35	.	_	.	.	_	6	P	_	_

1	Furthermore	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	physical	_	JJ	JJ	_	5	NMOD	_	_
5	interaction	_	NN	NN	_	10	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	Tax	_	NN	NN	_	6	PMOD	_	_
8	with	_	IN	IN	_	5	NMOD	_	_
9	p100	_	NN	NN	_	8	PMOD	_	_
10	leads	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	to	_	TO	TO	_	10	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	inhibition	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	Tax-induced	_	JJ	JJ	_	16	NMOD	_	_
16	activation	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	28	NMOD	_	_
19	HTLV-I	_	NN	NN	_	28	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	human	_	JJ	JJ	_	24	NMOD	_	_
22	immunodeficiency	_	NN	NN	_	24	NMOD	_	_
23	virus	_	NN	NN	_	24	NMOD	_	_
24	type	_	NN	NN	_	19	COORD	_	_
25	1	_	CD	CD	_	24	NMOD	_	_
26	long	_	JJ	JJ	_	28	NMOD	_	_
27	terminal	_	JJ	JJ	_	28	NMOD	_	_
28	repeats	_	NNS	NNS	_	17	PMOD	_	_
29	,	_	,	,	_	10	P	_	_
30	reflecting	_	VBG	VBG	_	10	OBJ	_	_
31	p100-mediated	_	JJ	JJ	_	33	NMOD	_	_
32	cytoplasmic	_	JJ	JJ	_	33	NMOD	_	_
33	sequestration	_	NN	NN	_	30	OBJ	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	the	_	DT	DT	_	40	NMOD	_	_
36	normally	_	RB	RB	_	40	NMOD	_	_
37	nuclearly	_	RB	RB	_	36	AMOD	_	_
38	expressed	_	VBN	VBN	_	36	AMOD	_	_
39	Tax	_	NN	NN	_	40	NMOD	_	_
40	protein	_	NN	NN	_	34	PMOD	_	_
41	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	17	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	17	P	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	mutant	_	NN	NN	_	17	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	Tax	_	NN	NN	_	6	PMOD	_	_
8	that	_	WDT	WDT	_	10	SBJ	_	_
9	selectively	_	RB	RB	_	10	ADV	_	_
10	fails	_	VBZ	VBZ	_	5	NMOD	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	activate	_	VB	VB	_	10	OBJ	_	_
13	nuclear	_	JJ	JJ	_	16	NMOD	_	_
14	NF-kappa	_	NN	NN	_	16	NMOD	_	_
15	B	_	NN	NN	_	16	NMOD	_	_
16	expression	_	NN	NN	_	12	OBJ	_	_
17	does	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	not	_	RB	RB	_	17	VMOD	_	_
19	associate	_	VB	VB	_	17	VC	_	_
20	with	_	IN	IN	_	19	ADV	_	_
21	p100	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	17	P	_	_

1	(	_	(	(	_	3	P	_	_
2	ABSTRACT	_	NN	NN	_	3	SBJ	_	_
3	TRUNCATED	_	VBN	VBN	_	0	ROOT-S	_	_
4	AT	_	IN	IN	_	3	ADV	_	_
5	250	_	CD	CD	_	6	NMOD	_	_
6	WORDS	_	NNS	NNS	_	4	PMOD	_	_
7	)	_	)	)	_	3	P	_	_

1	Regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	BZLF1	_	NN	NN	_	5	NMOD	_	_
5	promoter	_	NN	NN	_	2	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	Epstein-Barr	_	JJ	JJ	_	8	NMOD	_	_
8	virus	_	NN	NN	_	6	PMOD	_	_
9	by	_	IN	IN	_	1	NMOD	_	_
10	second	_	JJ	JJ	_	11	NMOD	_	_
11	messengers	_	NNS	NNS	_	9	PMOD	_	_
12	in	_	IN	IN	_	1	NMOD	_	_
13	anti-immunoglobulin-treated	_	JJ	JJ	_	15	NMOD	_	_
14	B	_	NN	NN	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	12	PMOD	_	_
16	.	_	.	.	_	1	P	_	_

1	Initiation	_	NN	NN	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	10	NMOD	_	_
4	Epstein-Barr	_	JJ	JJ	_	5	NMOD	_	_
5	virus	_	NN	NN	_	10	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	EBV	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	lytic	_	JJ	JJ	_	10	NMOD	_	_
10	cycle	_	NN	NN	_	2	PMOD	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	dependent	_	JJ	JJ	_	11	PRD	_	_
13	on	_	IN	IN	_	12	AMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	transcription	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	BZLF1	_	NN	NN	_	19	NMOD	_	_
19	gene	_	NN	NN	_	16	PMOD	_	_
20	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	BZLF1	_	NN	NN	_	4	NMOD	_	_
3	gene	_	NN	NN	_	4	NMOD	_	_
4	promoter	_	NN	NN	_	8	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	Zp	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	activated	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	crosslinking	_	NN	NN	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	surface	_	NN	NN	_	12	PMOD	_	_
15	immunoglobulin	_	NN	NN	_	14	NMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	Ig	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	with	_	IN	IN	_	11	NMOD	_	_
20	anti-Ig	_	JJ	JJ	_	21	NMOD	_	_
21	antibody	_	NN	NN	_	19	PMOD	_	_
22	in	_	IN	IN	_	9	ADV	_	_
23	B	_	NN	NN	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	,	_	,	,	_	9	P	_	_
26	even	_	RB	RB	_	27	DEP	_	_
27	in	_	IN	IN	_	9	ADV	_	_
28	the	_	DT	DT	_	27	DEP	_	_
29	absence	_	NN	NN	_	27	DEP	_	_
30	of	_	IN	IN	_	27	DEP	_	_
31	other	_	JJ	JJ	_	33	NMOD	_	_
32	viral	_	JJ	JJ	_	33	NMOD	_	_
33	genes	_	NNS	NNS	_	27	PMOD	_	_
34	.	_	.	.	_	8	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	identified	_	VBD	VBD	_	0	ROOT-S	_	_
3	several	_	JJ	JJ	_	6	NMOD	_	_
4	anti-Ig	_	JJ	JJ	_	6	NMOD	_	_
5	response	_	NN	NN	_	6	NMOD	_	_
6	elements	_	NNS	NNS	_	2	OBJ	_	_
7	within	_	IN	IN	_	6	NMOD	_	_
8	Zp	_	NN	NN	_	7	PMOD	_	_
9	,	_	,	,	_	6	P	_	_
10	which	_	WDT	WDT	_	11	SBJ	_	_
11	were	_	VBD	VBD	_	6	NMOD	_	_
12	originally	_	RB	RB	_	13	ADV	_	_
13	defined	_	VBN	VBN	_	11	VC	_	_
14	as	_	IN	IN	_	13	ADV	_	_
15	12-O-tetradecanoylphorbol-13-acetate	_	NN	NN	_	20	NMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	TPA	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	response	_	NN	NN	_	20	NMOD	_	_
20	elements	_	NNS	NNS	_	14	PMOD	_	_
21	(	_	(	(	_	23	P	_	_
22	ZI	_	NN	NN	_	23	NMOD	_	_
23	repeats	_	NNS	NNS	_	20	PRN	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	ZII	_	NN	NN	_	23	COORD	_	_
26	,	_	,	,	_	25	P	_	_
27	an	_	DT	DT	_	29	NMOD	_	_
28	AP-1-like	_	JJ	JJ	_	29	NMOD	_	_
29	domain	_	NN	NN	_	25	NMOD	_	_
30	)	_	)	)	_	23	P	_	_
31	.	_	.	.	_	2	P	_	_

1	Since	_	IN	IN	_	23	ADV	_	_
2	anti-Ig	_	JJ	JJ	_	3	NMOD	_	_
3	crosslinking	_	NN	NN	_	4	SBJ	_	_
4	leads	_	VBZ	VBZ	_	1	VMOD	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	activation	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	protein	_	NN	NN	_	10	NMOD	_	_
9	kinase	_	NN	NN	_	10	NMOD	_	_
10	C	_	NN	NN	_	7	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	PKC	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	and	_	CC	CC	_	6	CC	_	_
15	an	_	DT	DT	_	16	NMOD	_	_
16	increase	_	NN	NN	_	6	COORD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	intracellular	_	JJ	JJ	_	20	NMOD	_	_
19	calcium	_	NN	NN	_	20	NMOD	_	_
20	level	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	23	P	_	_
22	Zp	_	NN	NN	_	23	SBJ	_	_
23	was	_	VBD	VBD	_	0	ROOT-S	_	_
24	tested	_	VBN	VBN	_	23	VC	_	_
25	for	_	IN	IN	_	24	ADV	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	response	_	NN	NN	_	25	PMOD	_	_
28	to	_	TO	TO	_	27	NMOD	_	_
29	these	_	DT	DT	_	31	NMOD	_	_
30	cellular	_	JJ	JJ	_	31	NMOD	_	_
31	factors	_	NNS	NNS	_	28	PMOD	_	_
32	.	_	.	.	_	23	P	_	_

1	Treatment	_	NN	NN	_	6	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	calcium	_	NN	NN	_	5	NMOD	_	_
4	ionophore	_	NN	NN	_	5	NMOD	_	_
5	A23187	_	NN	NN	_	2	PMOD	_	_
6	increased	_	VBD	VBD	_	0	ROOT-S	_	_
7	Zp	_	NN	NN	_	8	NMOD	_	_
8	activity	_	NN	NN	_	6	OBJ	_	_
9	.	_	.	.	_	6	P	_	_

1	When	_	WRB	WRB	_	6	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	calcium	_	NN	NN	_	4	NMOD	_	_
4	ionophore	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	19	TMP	_	_
6	used	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	conjunction	_	NN	NN	_	7	DEP	_	_
9	with	_	IN	IN	_	7	DEP	_	_
10	TPA	_	NN	NN	_	7	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	PKC	_	NN	NN	_	14	NMOD	_	_
14	activator	_	NN	NN	_	10	NMOD	_	_
15	,	_	,	,	_	19	P	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	Zp	_	NN	NN	_	18	NMOD	_	_
18	induction	_	NN	NN	_	19	SBJ	_	_
19	was	_	VBD	VBD	_	0	ROOT-S	_	_
20	synergistically	_	RB	RB	_	19	ADV	_	_
21	enhanced	_	VBN	VBN	_	19	VC	_	_
22	.	_	.	.	_	19	P	_	_

1	Retinoic	_	JJ	JJ	_	2	NMOD	_	_
2	acid	_	NN	NN	_	3	SBJ	_	_
3	downmodulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	erythroid	_	JJ	JJ	_	5	NMOD	_	_
5	differentiation	_	NN	NN	_	3	OBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	GATA1	_	NN	NN	_	8	NMOD	_	_
8	expression	_	NN	NN	_	5	COORD	_	_
9	in	_	IN	IN	_	5	NMOD	_	_
10	purified	_	VBN	VBN	_	12	NMOD	_	_
11	adult-progenitor	_	JJ	JJ	_	12	NMOD	_	_
12	culture	_	NN	NN	_	9	PMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	All-trans	_	JJ	JJ	_	3	NMOD	_	_
2	retinoic	_	JJ	JJ	_	3	NMOD	_	_
3	acid	_	NN	NN	_	7	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	RA	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	an	_	DT	DT	_	10	NMOD	_	_
9	important	_	JJ	JJ	_	10	NMOD	_	_
10	morphogen	_	NN	NN	_	7	PRD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	vertebrate	_	NN	NN	_	13	NMOD	_	_
13	development	_	NN	NN	_	11	PMOD	_	_
14	,	_	,	,	_	10	P	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	normal	_	JJ	JJ	_	17	NMOD	_	_
17	constituent	_	NN	NN	_	10	NMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	human	_	JJ	JJ	_	21	NMOD	_	_
20	adult	_	JJ	JJ	_	21	NMOD	_	_
21	blood	_	NN	NN	_	18	PMOD	_	_
22	and	_	CC	CC	_	7	CC	_	_
23	is	_	VBZ	VBZ	_	7	COORD	_	_
24	also	_	RB	RB	_	25	ADV	_	_
25	involved	_	VBN	VBN	_	23	VC	_	_
26	in	_	IN	IN	_	25	ADV	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	control	_	NN	NN	_	26	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	cell	_	NN	NN	_	29	PMOD	_	_
31	growth	_	NN	NN	_	30	NMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	differentiation	_	NN	NN	_	31	COORD	_	_
34	in	_	IN	IN	_	30	NMOD	_	_
35	acute	_	JJ	JJ	_	37	NMOD	_	_
36	promyelocytic	_	JJ	JJ	_	37	NMOD	_	_
37	leukemia	_	NN	NN	_	34	PMOD	_	_
38	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	examined	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	effects	_	NNS	NNS	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	RA	_	NN	NN	_	6	PMOD	_	_
8	on	_	IN	IN	_	5	NMOD	_	_
9	normal	_	JJ	JJ	_	10	NMOD	_	_
10	hematopoiesis	_	NN	NN	_	8	PMOD	_	_
11	by	_	IN	IN	_	3	ADV	_	_
12	using	_	VBG	VBG	_	11	PMOD	_	_
13	early	_	JJ	JJ	_	16	NMOD	_	_
14	hematopoietic	_	JJ	JJ	_	16	NMOD	_	_
15	progenitor	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	12	OBJ	_	_
17	(	_	(	(	_	18	P	_	_
18	HPC	_	NN	NN	_	16	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	stringently	_	RB	RB	_	21	ADV	_	_
21	purified	_	VBN	VBN	_	16	NMOD	_	_
22	from	_	IN	IN	_	21	ADV	_	_
23	adult	_	JJ	JJ	_	25	NMOD	_	_
24	peripheral	_	JJ	JJ	_	25	NMOD	_	_
25	blood	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	46	ADV	_	_
2	clonogenetic	_	JJ	JJ	_	14	NMOD	_	_
3	fetal	_	JJ	JJ	_	4	AMOD	_	_
4	calf	_	NN	NN	_	14	NMOD	_	_
5	serum-supplemented	_	JJ	JJ	_	4	AMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	FCS+	_	JJ	JJ	_	4	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	or	_	CC	CC	_	4	CC	_	_
10	-nonsupplemented	_	JJ	JJ	_	4	COORD	_	_
11	(	_	(	(	_	12	P	_	_
12	FCS-	_	JJ	JJ	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	culture	_	NN	NN	_	1	PMOD	_	_
15	treated	_	VBN	VBN	_	14	NMOD	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	saturating	_	JJ	JJ	_	18	NMOD	_	_
18	levels	_	NNS	NNS	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	interleukin-3	_	NN	NN	_	19	PMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	IL-3	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	granulocyte-macrophage	_	JJ	JJ	_	26	NMOD	_	_
25	colony-stimulating	_	JJ	JJ	_	26	NMOD	_	_
26	factor	_	NN	NN	_	20	NMOD	_	_
27	(	_	(	(	_	28	P	_	_
28	GM-CSF	_	NN	NN	_	26	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	and	_	CC	CC	_	20	CC	_	_
31	erythropoietin	_	NN	NN	_	20	COORD	_	_
32	(	_	(	(	_	33	P	_	_
33	Ep	_	NN	NN	_	31	PRN	_	_
34	)	_	)	)	_	33	P	_	_
35	(	_	(	(	_	31	P	_	_
36	combined	_	VBN	VBN	_	31	NMOD	_	_
37	with	_	IN	IN	_	36	PMOD	_	_
38	c-kit	_	NN	NN	_	39	NMOD	_	_
39	ligand	_	NN	NN	_	37	PMOD	_	_
40	in	_	IN	IN	_	39	NMOD	_	_
41	FCS-LRB---RRB--culture	_	JJ	JJ	_	42	NMOD	_	_
42	conditions	_	NNS	NNS	_	40	PMOD	_	_
43	)	_	)	)	_	31	P	_	_
44	,	_	,	,	_	46	P	_	_
45	RA	_	NN	NN	_	46	SBJ	_	_
46	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
47	a	_	DT	DT	_	50	NMOD	_	_
48	dramatic	_	JJ	JJ	_	50	NMOD	_	_
49	dose-dependent	_	JJ	JJ	_	50	NMOD	_	_
50	shift	_	NN	NN	_	46	IOBJ	_	_
51	from	_	IN	IN	_	50	NMOD	_	_
52	erythroid	_	JJ	JJ	_	56	NMOD	_	_
53	to	_	TO	TO	_	50	NMOD	_	_
54	granulomonocytic	_	JJ	JJ	_	53	NMOD	_	_
55	colony	_	NN	NN	_	56	NMOD	_	_
56	formation	_	NN	NN	_	51	PMOD	_	_
57	,	_	,	,	_	46	P	_	_
58	the	_	DT	DT	_	60	NMOD	_	_
59	latter	_	JJ	JJ	_	60	NMOD	_	_
60	colonies	_	NNS	NNS	_	61	SBJ	_	_
61	being	_	VBG	VBG	_	46	OBJ	_	_
62	essentially	_	RB	RB	_	63	ADV	_	_
63	represented	_	VBN	VBN	_	61	VC	_	_
64	by	_	IN	IN	_	63	LGS	_	_
65	granulocytic	_	JJ	JJ	_	66	NMOD	_	_
66	clones	_	NNS	NNS	_	64	PMOD	_	_
67	.	_	.	.	_	46	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	shift	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	apparently	_	RB	RB	_	3	ADV	_	_
5	not	_	RB	RB	_	3	VMOD	_	_
6	caused	_	VBN	VBN	_	3	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	recruitment	_	NN	NN	_	10	NMOD	_	_
10	phenomenon	_	NN	NN	_	7	PMOD	_	_
11	,	_	,	,	_	6	P	_	_
12	because	_	IN	IN	_	6	ADV	_	_
13	in	_	IN	IN	_	22	ADV	_	_
14	FCS+	_	JJ	JJ	_	15	NMOD	_	_
15	culture	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	22	P	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	total	_	JJ	JJ	_	19	NMOD	_	_
19	number	_	NN	NN	_	22	SBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	colonies	_	NNS	NNS	_	20	PMOD	_	_
22	is	_	VBZ	VBZ	_	12	VMOD	_	_
23	not	_	RB	RB	_	22	VMOD	_	_
24	significantly	_	RB	RB	_	25	ADV	_	_
25	modified	_	VBN	VBN	_	22	VC	_	_
26	by	_	IN	IN	_	25	LGS	_	_
27	RA	_	NN	NN	_	28	NMOD	_	_
28	addition	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	16	ADV	_	_
2	FCS-	_	JJ	JJ	_	4	NMOD	_	_
3	liquid-suspension	_	NN	NN	_	4	NMOD	_	_
4	culture	_	NN	NN	_	1	PMOD	_	_
5	supplemented	_	VBN	VBN	_	4	NMOD	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	saturating	_	JJ	JJ	_	9	NMOD	_	_
8	Ep	_	NN	NN	_	9	NMOD	_	_
9	level	_	NN	NN	_	6	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	low-dose	_	JJ	JJ	_	12	NMOD	_	_
12	IL-3\/GM-CSF	_	NN	NN	_	9	COORD	_	_
13	,	_	,	,	_	16	P	_	_
14	adult	_	JJ	JJ	_	15	NMOD	_	_
15	HPC	_	NN	NN	_	16	SBJ	_	_
16	undergo	_	VBP	VBP	_	0	ROOT-S	_	_
17	unilineage	_	JJ	JJ	_	19	NMOD	_	_
18	erythropoietic	_	JJ	JJ	_	19	NMOD	_	_
19	differentiation	_	NN	NN	_	16	OBJ	_	_
20	:	_	:	:	_	16	P	_	_
21	Here	_	RB	RB	_	28	ADV	_	_
22	again	_	RB	RB	_	28	TMP	_	_
23	,	_	,	,	_	28	P	_	_
24	treatment	_	NN	NN	_	28	SBJ	_	_
25	with	_	IN	IN	_	24	NMOD	_	_
26	high-dose	_	JJ	JJ	_	27	NMOD	_	_
27	RA	_	NN	NN	_	25	PMOD	_	_
28	induces	_	VBZ	VBZ	_	16	VMOD	_	_
29	a	_	DT	DT	_	30	NMOD	_	_
30	shift	_	NN	NN	_	28	OBJ	_	_
31	from	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	37	NMOD	_	_
33	erythroid	_	JJ	JJ	_	35	AMOD	_	_
34	to	_	TO	TO	_	35	AMOD	_	_
35	granulocytic	_	JJ	JJ	_	37	NMOD	_	_
36	differentiation	_	NN	NN	_	37	NMOD	_	_
37	pathway	_	NN	NN	_	31	PMOD	_	_
38	.	_	.	.	_	28	P	_	_

1	Studies	_	NNS	NNS	_	13	SBJ	_	_
2	on	_	IN	IN	_	1	NMOD	_	_
3	RA	_	NN	NN	_	7	NMOD	_	_
4	time-response	_	JJ	JJ	_	7	NMOD	_	_
5	or	_	CC	CC	_	4	CC	_	_
6	pulse	_	NN	NN	_	4	COORD	_	_
7	treatment	_	NN	NN	_	2	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	semisolid	_	JJ	JJ	_	12	NMOD	_	_
10	or	_	CC	CC	_	9	CC	_	_
11	liquid	_	JJ	JJ	_	9	COORD	_	_
12	culture	_	NN	NN	_	8	PMOD	_	_
13	show	_	VBP	VBP	_	0	ROOT-S	_	_
14	that	_	IN	IN	_	13	OBJ	_	_
15	early	_	JJ	JJ	_	17	NMOD	_	_
16	RA	_	NN	NN	_	17	NMOD	_	_
17	addition	_	NN	NN	_	18	SBJ	_	_
18	is	_	VBZ	VBZ	_	14	VMOD	_	_
19	most	_	RBS	RBS	_	20	AMOD	_	_
20	effective	_	JJ	JJ	_	18	PRD	_	_
21	,	_	,	,	_	13	P	_	_
22	thus	_	RB	RB	_	23	ADV	_	_
23	indicating	_	VBG	VBG	_	13	ADV	_	_
24	that	_	IN	IN	_	23	OBJ	_	_
25	early	_	JJ	JJ	_	29	NMOD	_	_
26	but	_	CC	CC	_	25	CC	_	_
27	not	_	RB	RB	_	28	AMOD	_	_
28	late	_	JJ	JJ	_	25	COORD	_	_
29	HPC	_	NN	NN	_	30	SBJ	_	_
30	are	_	VBP	VBP	_	24	VMOD	_	_
31	sensitive	_	JJ	JJ	_	30	PRD	_	_
32	to	_	TO	TO	_	31	AMOD	_	_
33	its	_	PRP$	PRP$	_	34	NMOD	_	_
34	action	_	NN	NN	_	32	PMOD	_	_
35	.	_	.	.	_	13	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	then	_	RB	RB	_	3	TMP	_	_
3	analyzed	_	VBD	VBD	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	expression	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	master	_	NN	NN	_	10	NMOD	_	_
9	GATA1	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	6	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	which	_	WDT	WDT	_	13	SBJ	_	_
13	encodes	_	VBZ	VBZ	_	10	NMOD	_	_
14	a	_	DT	DT	_	17	NMOD	_	_
15	finger	_	NN	NN	_	17	NMOD	_	_
16	transcription	_	NN	NN	_	17	NMOD	_	_
17	factor	_	NN	NN	_	13	OBJ	_	_
18	required	_	VBN	VBN	_	17	NMOD	_	_
19	for	_	IN	IN	_	18	ADV	_	_
20	normal	_	JJ	JJ	_	22	NMOD	_	_
21	erythroid	_	JJ	JJ	_	22	NMOD	_	_
22	development	_	NN	NN	_	19	PMOD	_	_
23	;	_	:	:	_	3	P	_	_
24	addition	_	NN	NN	_	37	SBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	RA	_	NN	NN	_	25	PMOD	_	_
27	to	_	TO	TO	_	24	NMOD	_	_
28	HPC	_	NN	NN	_	27	PMOD	_	_
29	stimulated	_	VBN	VBN	_	28	NMOD	_	_
30	into	_	IN	IN	_	29	ADV	_	_
31	unilineage	_	JJ	JJ	_	33	NMOD	_	_
32	erythropoietic	_	JJ	JJ	_	33	NMOD	_	_
33	differentiation	_	NN	NN	_	30	PMOD	_	_
34	in	_	IN	IN	_	29	ADV	_	_
35	liquid	_	JJ	JJ	_	36	NMOD	_	_
36	culture	_	NN	NN	_	34	PMOD	_	_
37	caused	_	VBD	VBD	_	3	VMOD	_	_
38	a	_	DT	DT	_	41	NMOD	_	_
39	virtually	_	RB	RB	_	40	AMOD	_	_
40	complete	_	JJ	JJ	_	41	NMOD	_	_
41	inhibition	_	NN	NN	_	37	OBJ	_	_
42	of	_	IN	IN	_	41	NMOD	_	_
43	GATA1	_	NN	NN	_	45	NMOD	_	_
44	mRNA	_	NN	NN	_	45	NMOD	_	_
45	induction	_	NN	NN	_	42	PMOD	_	_
46	.	_	.	.	_	37	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	RA	_	NN	NN	_	7	SBJ	_	_
6	directly	_	RB	RB	_	7	ADV	_	_
7	inhibits	_	VBZ	VBZ	_	4	VMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	erythroid	_	JJ	JJ	_	11	NMOD	_	_
10	differentiation	_	NN	NN	_	11	NMOD	_	_
11	program	_	NN	NN	_	7	OBJ	_	_
12	at	_	IN	IN	_	7	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	level	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	early	_	JJ	JJ	_	18	NMOD	_	_
17	adult	_	JJ	JJ	_	18	NMOD	_	_
18	HPC	_	NN	NN	_	15	PMOD	_	_
19	,	_	,	,	_	7	P	_	_
20	and	_	CC	CC	_	7	CC	_	_
21	may	_	MD	MD	_	7	COORD	_	_
22	lead	_	VB	VB	_	21	VC	_	_
23	to	_	TO	TO	_	22	ADV	_	_
24	a	_	DT	DT	_	25	NMOD	_	_
25	shift	_	NN	NN	_	23	PMOD	_	_
26	from	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	32	NMOD	_	_
28	erythroid	_	JJ	JJ	_	30	AMOD	_	_
29	to	_	TO	TO	_	30	AMOD	_	_
30	granulocytic	_	JJ	JJ	_	32	NMOD	_	_
31	differentiation	_	NN	NN	_	32	NMOD	_	_
32	pathway	_	NN	NN	_	26	PMOD	_	_
33	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	phenomenon	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	correlated	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	inhibition	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	GATA1	_	NN	NN	_	9	NMOD	_	_
9	induction	_	NN	NN	_	7	PMOD	_	_
10	in	_	IN	IN	_	6	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	early	_	JJ	JJ	_	13	NMOD	_	_
13	stages	_	NNS	NNS	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	erythropoietic	_	JJ	JJ	_	16	NMOD	_	_
16	differentiation	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	Induction	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	phosphatidylinositol	_	NN	NN	_	4	NMOD	_	_
4	turnover	_	NN	NN	_	2	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	EGR-1	_	NN	NN	_	8	NMOD	_	_
7	mRNA	_	NN	NN	_	8	NMOD	_	_
8	expression	_	NN	NN	_	4	COORD	_	_
9	by	_	IN	IN	_	1	NMOD	_	_
10	crosslinking	_	VBG	VBG	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	surface	_	NN	NN	_	11	PMOD	_	_
13	IgM	_	NN	NN	_	12	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	IgD	_	NN	NN	_	13	COORD	_	_
16	in	_	IN	IN	_	12	NMOD	_	_
17	the	_	DT	DT	_	22	NMOD	_	_
18	human	_	JJ	JJ	_	22	NMOD	_	_
19	B	_	NN	NN	_	22	NMOD	_	_
20	cell	_	NN	NN	_	22	NMOD	_	_
21	line	_	NN	NN	_	22	NMOD	_	_
22	B104	_	NN	NN	_	16	PMOD	_	_
23	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	previously	_	RB	RB	_	2	TMP	_	_
4	shown	_	VBN	VBN	_	2	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	a	_	DT	DT	_	11	NMOD	_	_
7	human	_	JJ	JJ	_	11	NMOD	_	_
8	B	_	NN	NN	_	11	NMOD	_	_
9	lymphoma	_	NN	NN	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	line	_	NN	NN	_	15	SBJ	_	_
12	,	_	,	,	_	11	P	_	_
13	B104	_	NN	NN	_	11	NMOD	_	_
14	,	_	,	,	_	11	P	_	_
15	expressed	_	VBD	VBD	_	5	VMOD	_	_
16	surface	_	NN	NN	_	17	NMOD	_	_
17	IgM	_	NN	NN	_	15	OBJ	_	_
18	(	_	(	(	_	19	P	_	_
19	sIgM	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	and	_	CC	CC	_	17	CC	_	_
22	surface	_	NN	NN	_	23	NMOD	_	_
23	IgD	_	NN	NN	_	17	COORD	_	_
24	(	_	(	(	_	25	P	_	_
25	sIgD	_	NN	NN	_	23	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	,	_	,	,	_	5	P	_	_
28	and	_	CC	CC	_	5	CC	_	_
29	that	_	IN	IN	_	5	COORD	_	_
30	crosslinking	_	VBG	VBG	_	47	SBJ	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	sIgM	_	NN	NN	_	31	PMOD	_	_
33	and	_	CC	CC	_	32	CC	_	_
34	sIgD	_	NN	NN	_	32	COORD	_	_
35	by	_	IN	IN	_	30	NMOD	_	_
36	anti-IgM	_	JJ	JJ	_	37	NMOD	_	_
37	antibody	_	NN	NN	_	35	PMOD	_	_
38	(	_	(	(	_	39	P	_	_
39	Ab	_	NN	NN	_	37	PRN	_	_
40	)	_	)	)	_	39	P	_	_
41	and	_	CC	CC	_	37	CC	_	_
42	anti-IgD	_	JJ	JJ	_	43	NMOD	_	_
43	Ab	_	NN	NN	_	37	COORD	_	_
44	,	_	,	,	_	47	P	_	_
45	respectively	_	RB	RB	_	47	ADV	_	_
46	,	_	,	,	_	47	P	_	_
47	induced	_	VBD	VBD	_	29	VMOD	_	_
48	Ca2+	_	NN	NN	_	49	NMOD	_	_
49	influx	_	NN	NN	_	47	OBJ	_	_
50	to	_	TO	TO	_	47	ADV	_	_
51	almost	_	RB	RB	_	53	AMOD	_	_
52	the	_	DT	DT	_	53	AMOD	_	_
53	same	_	JJ	JJ	_	54	NMOD	_	_
54	degree	_	NN	NN	_	50	PMOD	_	_
55	,	_	,	,	_	47	P	_	_
56	whereas	_	IN	IN	_	47	COORD	_	_
57	only	_	RB	RB	_	58	NMOD	_	_
58	sIgM-crosslinking	_	NN	NN	_	59	SBJ	_	_
59	caused	_	VBD	VBD	_	47	COORD	_	_
60	B104	_	NN	NN	_	62	NMOD	_	_
61	cell	_	NN	NN	_	62	NMOD	_	_
62	death	_	NN	NN	_	59	OBJ	_	_
63	.	_	.	.	_	2	P	_	_

1	Here	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	investigated	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	accumulation	_	NN	NN	_	4	IOBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	cyclic	_	JJ	JJ	_	9	NMOD	_	_
9	AMP	_	NN	NN	_	7	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	cAMP	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	,	_	,	,	_	6	P	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	hydrolysis	_	NN	NN	_	6	COORD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	inositol	_	NN	NN	_	18	NMOD	_	_
18	phosphates	_	NNS	NNS	_	16	PMOD	_	_
19	,	_	,	,	_	6	P	_	_
20	protein	_	NN	NN	_	22	NMOD	_	_
21	kinase	_	NN	NN	_	22	NMOD	_	_
22	C	_	NN	NN	_	26	NMOD	_	_
23	(	_	(	(	_	24	P	_	_
24	PKC	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	activity	_	NN	NN	_	6	COORD	_	_
27	and	_	CC	CC	_	6	CC	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	induction	_	NN	NN	_	6	COORD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	Egr-1	_	NN	NN	_	35	NMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	c-fos	_	NN	NN	_	31	COORD	_	_
34	mRNA	_	NN	NN	_	35	NMOD	_	_
35	expression	_	NN	NN	_	30	PMOD	_	_
36	by	_	IN	IN	_	6	NMOD	_	_
37	sIgM-	_	NN	NN	_	36	PMOD	_	_
38	and	_	CC	CC	_	37	CC	_	_
39	sIgD-crosslinking	_	NN	NN	_	37	COORD	_	_
40	to	_	TO	TO	_	41	VMOD	_	_
41	examine	_	VB	VB	_	4	OBJ	_	_
42	differences	_	NNS	NNS	_	41	OBJ	_	_
43	in	_	IN	IN	_	42	NMOD	_	_
44	the	_	DT	DT	_	45	NMOD	_	_
45	signals	_	NNS	NNS	_	43	PMOD	_	_
46	mediated	_	VBN	VBN	_	45	NMOD	_	_
47	through	_	IN	IN	_	46	ADV	_	_
48	sIgM	_	NN	NN	_	47	PMOD	_	_
49	and	_	CC	CC	_	48	CC	_	_
50	sIgD	_	NN	NN	_	48	COORD	_	_
51	in	_	IN	IN	_	46	ADV	_	_
52	B104	_	NN	NN	_	53	NMOD	_	_
53	cells	_	NNS	NNS	_	51	PMOD	_	_
54	.	_	.	.	_	4	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	sIgM-	_	NN	NN	_	7	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	sIgD-crosslinking	_	NN	NN	_	2	COORD	_	_
5	with	_	IN	IN	_	2	NMOD	_	_
6	antibodies	_	NNS	NNS	_	5	PMOD	_	_
7	induced	_	VBD	VBD	_	0	ROOT-S	_	_
8	elevation	_	NN	NN	_	7	IOBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	cAMP	_	NN	NN	_	11	NMOD	_	_
11	levels	_	NNS	NNS	_	9	PMOD	_	_
12	,	_	,	,	_	8	P	_	_
13	phosphatidylinositol	_	NN	NN	_	14	NMOD	_	_
14	turnover	_	NN	NN	_	8	COORD	_	_
15	,	_	,	,	_	8	P	_	_
16	PKC	_	NN	NN	_	17	NMOD	_	_
17	activation	_	NN	NN	_	8	COORD	_	_
18	and	_	CC	CC	_	8	CC	_	_
19	expression	_	NN	NN	_	8	COORD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	Egr-1	_	NN	NN	_	24	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	c-fos	_	NN	NN	_	21	COORD	_	_
24	mRNA	_	NN	NN	_	20	PMOD	_	_
25	,	_	,	,	_	7	P	_	_
26	although	_	IN	IN	_	7	OBJ	_	_
27	sIgM-crosslinking	_	NN	NN	_	28	SBJ	_	_
28	was	_	VBD	VBD	_	26	VMOD	_	_
29	more	_	RBR	RBR	_	30	AMOD	_	_
30	effective	_	JJ	JJ	_	28	PRD	_	_
31	than	_	IN	IN	_	30	AMOD	_	_
32	sIgD-crosslinking	_	NN	NN	_	31	PMOD	_	_
33	,	_	,	,	_	28	P	_	_
34	presumably	_	RB	RB	_	36	PMOD	_	_
35	due	_	JJ	JJ	_	36	DEP	_	_
36	to	_	TO	TO	_	28	ADV	_	_
37	the	_	DT	DT	_	39	NMOD	_	_
38	higher	_	JJR	JJR	_	39	NMOD	_	_
39	expression	_	NN	NN	_	36	PMOD	_	_
40	of	_	IN	IN	_	39	NMOD	_	_
41	sIgM	_	NN	NN	_	40	PMOD	_	_
42	than	_	IN	IN	_	39	NMOD	_	_
43	of	_	IN	IN	_	42	PMOD	_	_
44	sIgD	_	NN	NN	_	43	PMOD	_	_
45	.	_	.	.	_	7	P	_	_

1	Egr-1	_	NN	NN	_	3	NMOD	_	_
2	mRNA	_	NN	NN	_	3	NMOD	_	_
3	expression	_	NN	NN	_	9	SBJ	_	_
4	induced	_	VBN	VBN	_	3	NMOD	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	sIgM-	_	NN	NN	_	5	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	sIgD-crosslinking	_	NN	NN	_	6	COORD	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	inhibited	_	VBN	VBN	_	9	VC	_	_
11	by	_	IN	IN	_	10	ADV	_	_
12	H7	_	NN	NN	_	11	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	erbstatin	_	NN	NN	_	12	COORD	_	_
15	and	_	CC	CC	_	12	CC	_	_
16	genistein	_	NN	NN	_	12	COORD	_	_
17	,	_	,	,	_	11	P	_	_
18	but	_	CC	CC	_	11	CC	_	_
19	not	_	RB	RB	_	20	DEP	_	_
20	by	_	IN	IN	_	11	LGS	_	_
21	HA1004	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	9	P	_	_

1	Erbstatin	_	NN	NN	_	4	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	genistein	_	NN	NN	_	1	COORD	_	_
4	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	sIg-crosslinking-induced	_	JJ	JJ	_	9	NMOD	_	_
7	Egr-1	_	NN	NN	_	9	NMOD	_	_
8	mRNA	_	NN	NN	_	9	NMOD	_	_
9	expression	_	NN	NN	_	4	OBJ	_	_
10	in	_	IN	IN	_	4	ADV	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	dose-dependent	_	JJ	JJ	_	13	NMOD	_	_
13	manner	_	NN	NN	_	10	PMOD	_	_
14	parallel	_	JJ	JJ	_	9	NMOD	_	_
15	to	_	TO	TO	_	14	AMOD	_	_
16	that	_	WDT	WDT	_	15	PMOD	_	_
17	observed	_	VBN	VBN	_	16	NMOD	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	inhibition	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	sIg-crosslinking-induced	_	JJ	JJ	_	25	NMOD	_	_
23	protein	_	NN	NN	_	25	NMOD	_	_
24	tyrosine	_	NN	NN	_	25	NMOD	_	_
25	phosphorylation	_	NN	NN	_	21	PMOD	_	_
26	.	_	.	.	_	4	P	_	_

1	Phorbol	_	NN	NN	_	3	NMOD	_	_
2	myristate	_	NN	NN	_	3	NMOD	_	_
3	acetate	_	NN	NN	_	4	SBJ	_	_
4	induced	_	VBD	VBD	_	0	ROOT-S	_	_
5	Egr-1	_	NN	NN	_	7	NMOD	_	_
6	mRNA	_	NN	NN	_	7	NMOD	_	_
7	expression	_	NN	NN	_	4	OBJ	_	_
8	but	_	CC	CC	_	4	CC	_	_
9	forskolin	_	NN	NN	_	14	SBJ	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	dibutyryl	_	NN	NN	_	13	NMOD	_	_
12	cyclic	_	JJ	JJ	_	13	NMOD	_	_
13	AMP	_	NN	NN	_	9	COORD	_	_
14	did	_	VBD	VBD	_	4	COORD	_	_
15	not	_	RB	RB	_	14	VMOD	_	_
16	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	Egr-1	_	NN	NN	_	9	NMOD	_	_
7	mRNA	_	NN	NN	_	9	NMOD	_	_
8	activating	_	NN	NN	_	9	NMOD	_	_
9	signals	_	NNS	NNS	_	14	SBJ	_	_
10	through	_	IN	IN	_	9	NMOD	_	_
11	sIgM	_	NN	NN	_	10	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	sIgD	_	NN	NN	_	11	COORD	_	_
14	are	_	VBP	VBP	_	4	VMOD	_	_
15	protein	_	NN	NN	_	17	NMOD	_	_
16	tyrosine	_	NN	NN	_	17	NMOD	_	_
17	kinase-	_	NN	NN	_	14	PRD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	PKC-dependent	_	JJ	JJ	_	17	COORD	_	_
20	,	_	,	,	_	17	P	_	_
21	but	_	CC	CC	_	17	CC	_	_
22	protein	_	NN	NN	_	23	AMOD	_	_
23	kinase	_	NN	NN	_	17	COORD	_	_
24	A-independent	_	JJ	JJ	_	23	AMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	Cyclosporin	_	NN	NN	_	2	NMOD	_	_
2	A	_	NN	NN	_	8	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	CsA	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	and	_	CC	CC	_	2	CC	_	_
7	FK506	_	NN	NN	_	2	COORD	_	_
8	rescued	_	VBD	VBD	_	0	ROOT-S	_	_
9	B104	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	OBJ	_	_
11	from	_	IN	IN	_	8	ADV	_	_
12	death	_	NN	NN	_	11	PMOD	_	_
13	induced	_	VBN	VBN	_	12	NMOD	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	anti-IgM	_	JJ	JJ	_	16	NMOD	_	_
16	Ab	_	NN	NN	_	14	PMOD	_	_
17	,	_	,	,	_	8	P	_	_
18	but	_	CC	CC	_	8	CC	_	_
19	did	_	VBD	VBD	_	8	COORD	_	_
20	not	_	RB	RB	_	19	VMOD	_	_
21	affect	_	VB	VB	_	19	VC	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	expression	_	NN	NN	_	21	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	Egr-1	_	NN	NN	_	28	NMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	c-fos	_	NN	NN	_	25	COORD	_	_
28	mRNA	_	NN	NN	_	24	PMOD	_	_
29	,	_	,	,	_	8	P	_	_
30	showing	_	VBG	VBG	_	8	OBJ	_	_
31	that	_	IN	IN	_	30	OBJ	_	_
32	CsA	_	NN	NN	_	35	SBJ	_	_
33	and	_	CC	CC	_	32	CC	_	_
34	FK506	_	NN	NN	_	32	COORD	_	_
35	affect	_	VBP	VBP	_	31	VMOD	_	_
36	signal	_	NN	NN	_	37	NMOD	_	_
37	transducers	_	NNS	NNS	_	35	OBJ	_	_
38	differently	_	RB	RB	_	35	ADV	_	_
39	from	_	IN	IN	_	35	VMOD	_	_
40	or	_	CC	CC	_	39	CC	_	_
41	downstream	_	RB	RB	_	39	COORD	_	_
42	to	_	TO	TO	_	41	AMOD	_	_
43	these	_	DT	DT	_	44	NMOD	_	_
44	molecules	_	NNS	NNS	_	39	PMOD	_	_
45	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	difference	_	NN	NN	_	13	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	signals	_	NNS	NNS	_	3	PMOD	_	_
5	transduced	_	VBN	VBN	_	4	NMOD	_	_
6	through	_	IN	IN	_	5	ADV	_	_
7	sIgM	_	NN	NN	_	6	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	sIgD	_	NN	NN	_	7	COORD	_	_
10	in	_	IN	IN	_	5	ADV	_	_
11	B104	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	discussed	_	VBN	VBN	_	13	VC	_	_
15	.	_	.	.	_	13	P	_	_

1	G-LRB-Anh-RRB-MTetra	_	NN	NN	_	11	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	a	_	DT	DT	_	9	NMOD	_	_
4	natural	_	JJ	JJ	_	9	NMOD	_	_
5	bacterial	_	JJ	JJ	_	9	NMOD	_	_
6	cell	_	NN	NN	_	9	NMOD	_	_
7	wall	_	NN	NN	_	9	NMOD	_	_
8	breakdown	_	NN	NN	_	9	NMOD	_	_
9	product	_	NN	NN	_	1	NMOD	_	_
10	,	_	,	,	_	1	P	_	_
11	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	interleukin-1	_	NN	NN	_	13	NMOD	_	_
13	beta	_	NN	NN	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	interleukin-6	_	NN	NN	_	13	COORD	_	_
16	expression	_	NN	NN	_	11	OBJ	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	human	_	JJ	JJ	_	19	NMOD	_	_
19	monocytes	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	11	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	study	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	molecular	_	JJ	JJ	_	6	NMOD	_	_
6	mechanisms	_	NNS	NNS	_	3	PMOD	_	_
7	involved	_	VBN	VBN	_	6	NMOD	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	inflammatory	_	JJ	JJ	_	11	NMOD	_	_
10	cytokine	_	NN	NN	_	11	NMOD	_	_
11	expression	_	NN	NN	_	8	PMOD	_	_
12	{	_	(	(	_	15	P	_	_
13	published	_	VBN	VBN	_	14	NMOD	_	_
14	erratum	_	NN	NN	_	15	SBJ	_	_
15	appears	_	VBZ	VBZ	_	2	PRN	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	J	_	NNP	NNP	_	19	NMOD	_	_
18	Biol	_	NNP	NNP	_	19	NMOD	_	_
19	Chem	_	NNP	NNP	_	16	PMOD	_	_
20	1994	_	CD	CD	_	21	NMOD	_	_
21	Jun	_	NNP	NNP	_	19	TMP	_	_
22	17	_	CD	CD	_	21	NMOD	_	_
23	;	_	:	:	_	19	P	_	_
24	269	_	CD	CD	_	26	NMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	24	_	CD	CD	_	19	NMOD	_	_
27	)	_	)	)	_	26	P	_	_
28	:	_	:	:	_	19	P	_	_
29	16983	_	CD	CD	_	19	NMOD	_	_
30	}	_	)	)	_	15	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	believed	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	induction	_	NN	NN	_	14	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	cytokine	_	NN	NN	_	8	NMOD	_	_
8	expression	_	NN	NN	_	6	PMOD	_	_
9	by	_	IN	IN	_	5	NMOD	_	_
10	bacterial	_	JJ	JJ	_	13	NMOD	_	_
11	cell	_	NN	NN	_	13	NMOD	_	_
12	wall	_	NN	NN	_	13	NMOD	_	_
13	components	_	NNS	NNS	_	9	PMOD	_	_
14	plays	_	VBZ	VBZ	_	4	VMOD	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	role	_	NN	NN	_	14	OBJ	_	_
17	in	_	IN	IN	_	14	ADV	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	development	_	NN	NN	_	17	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	course	_	NN	NN	_	19	COORD	_	_
22	of	_	IN	IN	_	19	NMOD	_	_
23	sepsis	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	2	P	_	_

1	However	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	most	_	JJS	JJS	_	4	NMOD	_	_
4	attention	_	NN	NN	_	5	SBJ	_	_
5	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	been	_	VBN	VBN	_	5	VC	_	_
7	focused	_	VBN	VBN	_	6	VC	_	_
8	on	_	IN	IN	_	7	ADV	_	_
9	lipopolysaccharide	_	NN	NN	_	8	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	LPS	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	studied	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	ability	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	N-acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl-L-alanyl-D-isoglutamyl-m-diaminopimelyl-D-alanine	_	NN	NN	_	5	PMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	G-LRB-Anh-RRB-MTetra	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	,	_	,	,	_	6	P	_	_
11	a	_	DT	DT	_	15	NMOD	_	_
12	naturally	_	RB	RB	_	13	AMOD	_	_
13	occurring	_	VBG	VBG	_	15	NMOD	_	_
14	breakdown	_	NN	NN	_	15	NMOD	_	_
15	product	_	NN	NN	_	6	NMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	peptidoglycan	_	NN	NN	_	16	PMOD	_	_
18	that	_	WDT	WDT	_	19	SBJ	_	_
19	is	_	VBZ	VBZ	_	15	NMOD	_	_
20	produced	_	VBN	VBN	_	19	VC	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	soluble	_	JJ	JJ	_	24	NMOD	_	_
23	lytic	_	JJ	JJ	_	24	NMOD	_	_
24	transglycosylase	_	NN	NN	_	21	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	Escherichia	_	FW	FW	_	27	NMOD	_	_
27	coli	_	FW	FW	_	25	PMOD	_	_
28	,	_	,	,	_	6	P	_	_
29	to	_	TO	TO	_	30	VMOD	_	_
30	induce	_	VB	VB	_	4	NMOD	_	_
31	cytokine	_	NN	NN	_	32	NMOD	_	_
32	expression	_	NN	NN	_	30	OBJ	_	_
33	in	_	IN	IN	_	32	NMOD	_	_
34	human	_	JJ	JJ	_	35	NMOD	_	_
35	monocytes	_	NNS	NNS	_	33	PMOD	_	_
36	.	_	.	.	_	2	P	_	_

1	G-LRB-Anh-RRB-MTetra	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	to	_	TO	TO	_	6	VMOD	_	_
5	strongly	_	RB	RB	_	6	ADV	_	_
6	induce	_	VB	VB	_	3	OBJ	_	_
7	interleukin	_	NN	NN	_	12	NMOD	_	_
8	(	_	(	(	_	12	P	_	_
9	IL	_	NN	NN	_	12	NMOD	_	_
10	)	_	)	)	_	12	P	_	_
11	-1	_	CD	CD	_	12	NMOD	_	_
12	beta	_	NN	NN	_	16	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	IL-6	_	NN	NN	_	12	COORD	_	_
15	mRNA	_	NN	NN	_	16	NMOD	_	_
16	expression	_	NN	NN	_	6	OBJ	_	_
17	after	_	IN	IN	_	6	TMP	_	_
18	2	_	CD	CD	_	19	NMOD	_	_
19	h	_	NN	NN	_	17	PMOD	_	_
20	and	_	CC	CC	_	6	CC	_	_
21	IL-1	_	NN	NN	_	22	NMOD	_	_
22	beta	_	NN	NN	_	26	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	IL-6	_	NN	NN	_	22	COORD	_	_
25	protein	_	NN	NN	_	26	NMOD	_	_
26	secretion	_	NN	NN	_	16	GAP	_	_
27	after	_	IN	IN	_	17	GAP	_	_
28	48	_	CD	CD	_	29	NMOD	_	_
29	h	_	NN	NN	_	27	PMOD	_	_
30	of	_	IN	IN	_	19	NMOD	_	_
31	activation	_	NN	NN	_	30	PMOD	_	_
32	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	increase	_	NN	NN	_	6	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	mRNA	_	NN	NN	_	5	NMOD	_	_
5	accumulation	_	NN	NN	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	at	_	IN	IN	_	9	AMOD	_	_
8	least	_	JJS	JJS	_	7	AMOD	_	_
9	partly	_	RB	RB	_	11	PMOD	_	_
10	due	_	JJ	JJ	_	11	DEP	_	_
11	to	_	TO	TO	_	6	PRD	_	_
12	an	_	DT	DT	_	13	NMOD	_	_
13	increase	_	NN	NN	_	11	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	transcription	_	NN	NN	_	17	NMOD	_	_
17	rates	_	NNS	NNS	_	14	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	respective	_	JJ	JJ	_	21	NMOD	_	_
21	genes	_	NNS	NNS	_	18	PMOD	_	_
22	and	_	CC	CC	_	6	CC	_	_
23	was	_	VBD	VBD	_	6	COORD	_	_
24	accompanied	_	VBN	VBN	_	23	VC	_	_
25	by	_	IN	IN	_	24	LGS	_	_
26	a	_	DT	DT	_	28	NMOD	_	_
27	strong	_	JJ	JJ	_	28	NMOD	_	_
28	induction	_	NN	NN	_	25	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	nuclear	_	JJ	JJ	_	32	NMOD	_	_
31	factor-kappa	_	NN	NN	_	32	NMOD	_	_
32	B	_	NN	NN	_	38	NMOD	_	_
33	and	_	CC	CC	_	32	CC	_	_
34	activator	_	NN	NN	_	37	NMOD	_	_
35	protein-1	_	NN	NN	_	37	NMOD	_	_
36	transcription	_	NN	NN	_	37	NMOD	_	_
37	factor	_	NN	NN	_	32	COORD	_	_
38	expression	_	NN	NN	_	29	PMOD	_	_
39	.	_	.	.	_	6	P	_	_

1	Experiments	_	NNS	NNS	_	17	SBJ	_	_
2	using	_	VBG	VBG	_	1	NMOD	_	_
3	inhibitors	_	NNS	NNS	_	2	OBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	protein	_	NN	NN	_	7	NMOD	_	_
6	kinase	_	NN	NN	_	7	NMOD	_	_
7	C	_	NN	NN	_	4	PMOD	_	_
8	,	_	,	,	_	7	P	_	_
9	protein	_	NN	NN	_	11	NMOD	_	_
10	kinase	_	NN	NN	_	11	NMOD	_	_
11	A	_	NN	NN	_	7	COORD	_	_
12	,	_	,	,	_	7	P	_	_
13	and	_	CC	CC	_	7	CC	_	_
14	tyrosine	_	NN	NN	_	16	NMOD	_	_
15	kinase-dependent	_	JJ	JJ	_	14	AMOD	_	_
16	pathways	_	NNS	NNS	_	7	COORD	_	_
17	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
18	that	_	IN	IN	_	17	OBJ	_	_
19	G-LRB-Anh-RRB-MTetra-induced	_	JJ	JJ	_	25	NMOD	_	_
20	IL-1	_	NN	NN	_	21	NMOD	_	_
21	beta	_	NN	NN	_	25	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	IL-6	_	NN	NN	_	21	COORD	_	_
24	mRNA	_	NN	NN	_	25	NMOD	_	_
25	expression	_	NN	NN	_	26	SBJ	_	_
26	involves	_	VBZ	VBZ	_	18	VMOD	_	_
27	activation	_	NN	NN	_	26	OBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	an	_	DT	DT	_	31	NMOD	_	_
30	H7-inhibitable	_	JJ	JJ	_	31	NMOD	_	_
31	pathway	_	NN	NN	_	28	PMOD	_	_
32	.	_	.	.	_	17	P	_	_

1	By	_	IN	IN	_	10	ADV	_	_
2	using	_	VBG	VBG	_	1	PMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	protein	_	NN	NN	_	7	NMOD	_	_
5	synthesis	_	NN	NN	_	7	NMOD	_	_
6	inhibitor	_	NN	NN	_	7	NMOD	_	_
7	cycloheximide	_	NN	NN	_	2	OBJ	_	_
8	,	_	,	,	_	10	P	_	_
9	it	_	PRP	PRP	_	10	SBJ	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	shown	_	VBN	VBN	_	10	VC	_	_
12	that	_	IN	IN	_	11	OBJ	_	_
13	G-LRB-Anh-RRB-MTetra-induced	_	JJ	JJ	_	16	NMOD	_	_
14	IL-6	_	NN	NN	_	16	NMOD	_	_
15	mRNA	_	NN	NN	_	16	NMOD	_	_
16	expression	_	NN	NN	_	17	SBJ	_	_
17	depends	_	VBZ	VBZ	_	12	VMOD	_	_
18	on	_	IN	IN	_	17	ADV	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	synthesis	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	new	_	JJ	JJ	_	23	NMOD	_	_
23	protein	_	NN	NN	_	21	PMOD	_	_
24	,	_	,	,	_	17	P	_	_
25	whereas	_	IN	IN	_	17	COORD	_	_
26	G-LRB-Anh-RRB-MTetra-induced	_	JJ	JJ	_	30	NMOD	_	_
27	IL-1	_	NN	NN	_	30	NMOD	_	_
28	beta	_	NN	NN	_	30	NMOD	_	_
29	mRNA	_	NN	NN	_	30	NMOD	_	_
30	accumulation	_	NN	NN	_	31	SBJ	_	_
31	does	_	VBZ	VBZ	_	17	COORD	_	_
32	not	_	RB	RB	_	31	VMOD	_	_
33	.	_	.	.	_	10	P	_	_

1	When	_	WRB	WRB	_	6	ADV	_	_
2	responses	_	NNS	NNS	_	5	SBJ	_	_
3	to	_	TO	TO	_	2	NMOD	_	_
4	G-LRB-Anh-RRB-MTetra	_	NN	NN	_	3	PMOD	_	_
5	were	_	VBD	VBD	_	18	TMP	_	_
6	compared	_	VBN	VBN	_	5	VC	_	_
7	with	_	IN	IN	_	6	ADV	_	_
8	those	_	DT	DT	_	7	PMOD	_	_
9	to	_	TO	TO	_	8	NMOD	_	_
10	LPS	_	NN	NN	_	9	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	muramyldipeptide	_	NN	NN	_	10	COORD	_	_
13	(	_	(	(	_	14	P	_	_
14	MDP	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	,	_	,	,	_	18	P	_	_
17	it	_	PRP	PRP	_	18	SBJ	_	_
18	was	_	VBD	VBD	_	0	ROOT-S	_	_
19	found	_	VBN	VBN	_	18	VC	_	_
20	that	_	IN	IN	_	19	OBJ	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	optimal	_	JJ	JJ	_	23	NMOD	_	_
23	response	_	NN	NN	_	27	SBJ	_	_
24	to	_	TO	TO	_	23	NMOD	_	_
25	G-LRB-Anh-RRB-MTetra	_	NN	NN	_	26	NMOD	_	_
26	induction	_	NN	NN	_	24	PMOD	_	_
27	was	_	VBD	VBD	_	20	VMOD	_	_
28	similar	_	JJ	JJ	_	27	PRD	_	_
29	to	_	TO	TO	_	28	AMOD	_	_
30	that	_	DT	DT	_	29	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	LPS	_	NN	NN	_	31	PMOD	_	_
33	but	_	CC	CC	_	28	CC	_	_
34	significantly	_	RB	RB	_	35	AMOD	_	_
35	higher	_	JJR	JJR	_	28	COORD	_	_
36	than	_	IN	IN	_	35	AMOD	_	_
37	the	_	DT	DT	_	38	NMOD	_	_
38	response	_	NN	NN	_	36	PMOD	_	_
39	to	_	TO	TO	_	38	NMOD	_	_
40	MDP	_	NN	NN	_	39	PMOD	_	_
41	.	_	.	.	_	18	P	_	_

1	Furthermore	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	maximal	_	JJ	JJ	_	10	NMOD	_	_
4	G-LRB-Anh-RRB-MTetra-induced	_	JJ	JJ	_	10	NMOD	_	_
5	IL-1	_	NN	NN	_	6	NMOD	_	_
6	beta	_	NN	NN	_	10	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	IL-6	_	NN	NN	_	6	COORD	_	_
9	mRNA	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	11	SBJ	_	_
11	could	_	MD	MD	_	0	ROOT-S	_	_
12	be	_	VB	VB	_	11	VC	_	_
13	enhanced	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	co-stimulation	_	NN	NN	_	14	PMOD	_	_
16	with	_	IN	IN	_	15	NMOD	_	_
17	LPS	_	NN	NN	_	16	PMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	MDP	_	NN	NN	_	17	COORD	_	_
20	,	_	,	,	_	13	P	_	_
21	suggesting	_	VBG	VBG	_	13	OBJ	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	different	_	JJ	JJ	_	24	NMOD	_	_
24	receptors	_	NNS	NNS	_	28	SBJ	_	_
25	and\/or	_	CC	CC	_	24	CC	_	_
26	transduction	_	NN	NN	_	27	NMOD	_	_
27	pathways	_	NNS	NNS	_	24	COORD	_	_
28	were	_	VBD	VBD	_	22	VMOD	_	_
29	involved	_	VBN	VBN	_	28	VC	_	_
30	.	_	.	.	_	11	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	G-LRB-Anh-RRB-MTetra	_	NN	NN	_	6	SBJ	_	_
6	induces	_	VBZ	VBZ	_	4	VMOD	_	_
7	IL-1	_	NN	NN	_	8	NMOD	_	_
8	beta	_	NN	NN	_	11	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	IL-6	_	NN	NN	_	8	COORD	_	_
11	expression	_	NN	NN	_	6	IOBJ	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	human	_	JJ	JJ	_	14	NMOD	_	_
14	monocytes	_	NNS	NNS	_	12	PMOD	_	_
15	suggesting	_	VBG	VBG	_	6	OBJ	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	possible	_	JJ	JJ	_	18	NMOD	_	_
18	role	_	NN	NN	_	15	OBJ	_	_
19	for	_	IN	IN	_	18	NMOD	_	_
20	G-LRB-Anh-RRB-MTetra	_	NN	NN	_	19	PMOD	_	_
21	in	_	IN	IN	_	18	NMOD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	release	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	cytokines	_	NNS	NNS	_	24	PMOD	_	_
26	during	_	IN	IN	_	23	TMP	_	_
27	sepsis	_	NN	NN	_	26	PMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	rel	_	NN	NN	_	2	SBJ	_	_
2	Is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	rapidly	_	RB	RB	_	2	VC	_	_
4	tyrosine-phosphorylated	_	JJ	JJ	_	3	VMOD	_	_
5	following	_	VBG	VBG	_	3	TMP	_	_
6	granulocyte-colony	_	JJ	JJ	_	9	NMOD	_	_
7	stimulating	_	NN	NN	_	9	NMOD	_	_
8	factor	_	NN	NN	_	9	NMOD	_	_
9	treatment	_	NN	NN	_	5	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	human	_	JJ	JJ	_	12	NMOD	_	_
12	neutrophils	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	Stimulation	_	NN	NN	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	neutrophils	_	NNS	NNS	_	2	PMOD	_	_
4	with	_	IN	IN	_	1	NMOD	_	_
5	granulocyte-colony	_	JJ	JJ	_	7	NMOD	_	_
6	stimulating	_	NN	NN	_	7	NMOD	_	_
7	factor	_	NN	NN	_	4	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	G-CSF	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	an	_	DT	DT	_	16	NMOD	_	_
14	enhanced	_	VBN	VBN	_	16	NMOD	_	_
15	respiratory	_	JJ	JJ	_	16	NMOD	_	_
16	burst	_	NN	NN	_	12	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	prolonged	_	JJ	JJ	_	19	NMOD	_	_
19	survival	_	NN	NN	_	16	COORD	_	_
20	,	_	,	,	_	16	P	_	_
21	and	_	CC	CC	_	16	CC	_	_
22	increased	_	VBN	VBN	_	25	NMOD	_	_
23	tumor	_	NN	NN	_	25	NMOD	_	_
24	cell	_	NN	NN	_	25	NMOD	_	_
25	killing	_	NN	NN	_	16	COORD	_	_
26	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effects	_	NNS	NNS	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	G-CSF	_	NN	NN	_	3	PMOD	_	_
5	are	_	VBP	VBP	_	0	ROOT-S	_	_
6	mediated	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	binding	_	VBG	VBG	_	7	PMOD	_	_
9	to	_	TO	TO	_	8	NMOD	_	_
10	specific	_	JJ	JJ	_	14	NMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	high	_	JJ	JJ	_	13	NMOD	_	_
13	affinity	_	NN	NN	_	10	COORD	_	_
14	receptors	_	NNS	NNS	_	9	PMOD	_	_
15	.	_	.	.	_	5	P	_	_

1	G-CSF	_	NN	NN	_	2	NMOD	_	_
2	receptors	_	NNS	NNS	_	3	SBJ	_	_
3	lack	_	VBP	VBP	_	0	ROOT-S	_	_
4	intrinsic	_	JJ	JJ	_	7	NMOD	_	_
5	tyrosine	_	NN	NN	_	7	NMOD	_	_
6	kinase	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	3	OBJ	_	_
8	,	_	,	,	_	3	P	_	_
9	but	_	CC	CC	_	3	CC	_	_
10	activation	_	NN	NN	_	14	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	receptor	_	NN	NN	_	11	PMOD	_	_
14	results	_	VBZ	VBZ	_	3	COORD	_	_
15	in	_	IN	IN	_	14	ADV	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	rapid	_	JJ	JJ	_	18	NMOD	_	_
18	induction	_	NN	NN	_	15	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	tyrosine	_	NN	NN	_	22	NMOD	_	_
21	kinase	_	NN	NN	_	22	NMOD	_	_
22	activity	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	Antiphosphotyrosine	_	JJ	JJ	_	2	NMOD	_	_
2	immunoblots	_	NNS	NNS	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	whole	_	JJ	JJ	_	6	NMOD	_	_
5	cell	_	NN	NN	_	6	NMOD	_	_
6	lysates	_	NNS	NNS	_	3	PMOD	_	_
7	prepared	_	VBN	VBN	_	6	NMOD	_	_
8	from	_	IN	IN	_	7	ADV	_	_
9	neutrophils	_	NNS	NNS	_	8	PMOD	_	_
10	show	_	VBP	VBP	_	0	ROOT-S	_	_
11	that	_	IN	IN	_	10	OBJ	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	G-CSF	_	NN	NN	_	15	SBJ	_	_
14	rapidly	_	RB	RB	_	15	TMP	_	_
15	induces	_	VBZ	VBZ	_	11	VMOD	_	_
16	prominent	_	JJ	JJ	_	18	NMOD	_	_
17	tyrosine	_	NN	NN	_	18	NMOD	_	_
18	phosphorylation	_	NN	NN	_	15	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	a	_	DT	DT	_	21	NMOD	_	_
21	protein	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	a	_	DT	DT	_	26	NMOD	_	_
24	relative	_	JJ	JJ	_	26	NMOD	_	_
25	molecular	_	JJ	JJ	_	26	NMOD	_	_
26	mass	_	NN	NN	_	22	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	80	_	CD	CD	_	29	NMOD	_	_
29	kDa	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	10	P	_	_

1	Using	_	VBG	VBG	_	9	VMOD	_	_
2	monospecific	_	JJ	JJ	_	3	NMOD	_	_
3	antibodies	_	NNS	NNS	_	1	OBJ	_	_
4	,	_	,	,	_	9	P	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	80-kDa	_	JJ	JJ	_	8	NMOD	_	_
7	tyrosine-phosphorylated	_	JJ	JJ	_	8	NMOD	_	_
8	protein	_	NN	NN	_	9	SBJ	_	_
9	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	been	_	VBN	VBN	_	9	VC	_	_
11	shown	_	VBN	VBN	_	10	VC	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	be	_	VB	VB	_	11	OBJ	_	_
14	p80c-rel	_	NN	NN	_	13	PRD	_	_
15	,	_	,	,	_	14	P	_	_
16	a	_	DT	DT	_	17	NMOD	_	_
17	proto-oncogene	_	NN	NN	_	14	NMOD	_	_
18	belonging	_	VBG	VBG	_	17	NMOD	_	_
19	to	_	TO	TO	_	18	ADV	_	_
20	a	_	DT	DT	_	21	NMOD	_	_
21	family	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	transcriptional	_	JJ	JJ	_	24	NMOD	_	_
24	regulators	_	NNS	NNS	_	22	PMOD	_	_
25	which	_	WDT	WDT	_	26	SBJ	_	_
26	include	_	VBP	VBP	_	24	NMOD	_	_
27	NF-kB	_	NN	NN	_	26	OBJ	_	_
28	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	induction	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	tyrosine	_	NN	NN	_	5	NMOD	_	_
5	phosphorylation	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	p80c-rel	_	NN	NN	_	6	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	unique	_	JJ	JJ	_	8	PRD	_	_
10	to	_	TO	TO	_	9	AMOD	_	_
11	G-CSF	_	NN	NN	_	10	PMOD	_	_
12	in	_	IN	IN	_	13	VMOD	_	_
13	that	_	IN	IN	_	8	ADV	_	_
14	granulocyte-macrophage	_	JJ	JJ	_	17	NMOD	_	_
15	colony	_	NN	NN	_	17	NMOD	_	_
16	stimulating	_	NN	NN	_	17	NMOD	_	_
17	factor	_	NN	NN	_	26	SBJ	_	_
18	which	_	WDT	WDT	_	20	SBJ	_	_
19	also	_	RB	RB	_	20	ADV	_	_
20	stimulates	_	VBZ	VBZ	_	17	NMOD	_	_
21	neutrophils	_	NNS	NNS	_	20	OBJ	_	_
22	and	_	CC	CC	_	20	CC	_	_
23	induces	_	VBZ	VBZ	_	20	COORD	_	_
24	tyrosine	_	NN	NN	_	25	NMOD	_	_
25	phosphorylation	_	NN	NN	_	23	OBJ	_	_
26	does	_	VBZ	VBZ	_	13	VMOD	_	_
27	not	_	RB	RB	_	26	VMOD	_	_
28	result	_	VB	VB	_	26	VC	_	_
29	in	_	IN	IN	_	28	ADV	_	_
30	tyrosine	_	NN	NN	_	31	NMOD	_	_
31	phosphorylation	_	NN	NN	_	29	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	p80c-rel	_	NN	NN	_	32	PMOD	_	_
34	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	consequences	_	NNS	NNS	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	p80c-rel	_	NN	NN	_	6	NMOD	_	_
5	tyrosine	_	NN	NN	_	6	NMOD	_	_
6	phosphorylation	_	NN	NN	_	3	PMOD	_	_
7	are	_	VBP	VBP	_	0	ROOT-S	_	_
8	not	_	RB	RB	_	7	VMOD	_	_
9	yet	_	RB	RB	_	7	TMP	_	_
10	known	_	VBN	VBN	_	7	VC	_	_
11	;	_	:	:	_	7	P	_	_
12	however	_	RB	RB	_	16	ADV	_	_
13	,	_	,	,	_	16	P	_	_
14	tyrosine-phosphorylated	_	JJ	JJ	_	15	NMOD	_	_
15	p80c-rel	_	NN	NN	_	16	SBJ	_	_
16	is	_	VBZ	VBZ	_	7	VC	_	_
17	capable	_	JJ	JJ	_	16	PRD	_	_
18	of	_	IN	IN	_	17	AMOD	_	_
19	binding	_	VBG	VBG	_	18	PMOD	_	_
20	to	_	TO	TO	_	19	ADV	_	_
21	DNA	_	NN	NN	_	20	PMOD	_	_
22	,	_	,	,	_	16	P	_	_
23	and	_	CC	CC	_	16	CC	_	_
24	G-CSF	_	NN	NN	_	25	NMOD	_	_
25	stimulation	_	NN	NN	_	26	SBJ	_	_
26	results	_	VBZ	VBZ	_	16	COORD	_	_
27	in	_	IN	IN	_	26	ADV	_	_
28	an	_	DT	DT	_	29	NMOD	_	_
29	increase	_	NN	NN	_	27	PMOD	_	_
30	in	_	IN	IN	_	29	NMOD	_	_
31	the	_	DT	DT	_	32	NMOD	_	_
32	amount	_	NN	NN	_	30	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	p80c-rel	_	NN	NN	_	33	PMOD	_	_
35	which	_	WDT	WDT	_	36	SBJ	_	_
36	binds	_	VBZ	VBZ	_	34	NMOD	_	_
37	to	_	TO	TO	_	36	ADV	_	_
38	DNA	_	NN	NN	_	37	PMOD	_	_
39	.	_	.	.	_	16	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	one	_	CD	CD	_	25	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	first	_	JJ	JJ	_	10	NMOD	_	_
9	biochemical	_	JJ	JJ	_	10	NMOD	_	_
10	events	_	NNS	NNS	_	6	PMOD	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	occurs	_	VBZ	VBZ	_	5	NMOD	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	neutrophils	_	NNS	NNS	_	13	PMOD	_	_
15	following	_	VBG	VBG	_	12	TMP	_	_
16	G-CSF	_	NN	NN	_	17	NMOD	_	_
17	stimulation	_	NN	NN	_	15	PMOD	_	_
18	,	_	,	,	_	5	P	_	_
19	activation	_	NN	NN	_	5	NMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	tyrosine	_	NN	NN	_	23	NMOD	_	_
23	kinase	_	NN	NN	_	20	PMOD	_	_
24	,	_	,	,	_	5	P	_	_
25	leads	_	VBZ	VBZ	_	4	VMOD	_	_
26	directly	_	RB	RB	_	25	ADV	_	_
27	to	_	TO	TO	_	25	ADV	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	tyrosine	_	NN	NN	_	30	NMOD	_	_
30	phosphorylation	_	NN	NN	_	27	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	p80c-rel	_	NN	NN	_	31	PMOD	_	_
33	.	_	.	.	_	3	P	_	_

1	Thus	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	tyrosine	_	NN	NN	_	5	NMOD	_	_
5	kinase	_	NN	NN	_	9	SBJ	_	_
6	activated	_	VBN	VBN	_	5	NMOD	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	G-CSF	_	NN	NN	_	7	PMOD	_	_
9	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	to	_	TO	TO	_	12	VMOD	_	_
11	directly	_	RB	RB	_	12	ADV	_	_
12	transduce	_	VB	VB	_	9	OBJ	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	signal	_	NN	NN	_	12	OBJ	_	_
15	to	_	TO	TO	_	12	ADV	_	_
16	a	_	DT	DT	_	17	NMOD	_	_
17	protein	_	NN	NN	_	15	PMOD	_	_
18	which	_	WDT	WDT	_	19	SBJ	_	_
19	functions	_	VBZ	VBZ	_	17	NMOD	_	_
20	as	_	IN	IN	_	19	ADV	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	transcriptional	_	JJ	JJ	_	23	NMOD	_	_
23	regulator	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	9	P	_	_

1	Autoregulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	NF-kappa	_	NN	NN	_	6	NMOD	_	_
5	B	_	NN	NN	_	6	NMOD	_	_
6	transactivator	_	NN	NN	_	2	PMOD	_	_
7	RelA	_	NN	NN	_	6	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	p65	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	by	_	IN	IN	_	1	NMOD	_	_
12	multiple	_	JJ	JJ	_	14	NMOD	_	_
13	cytoplasmic	_	JJ	JJ	_	14	NMOD	_	_
14	inhibitors	_	NNS	NNS	_	11	PMOD	_	_
15	containing	_	VBG	VBG	_	14	NMOD	_	_
16	ankyrin	_	NN	NN	_	17	NMOD	_	_
17	motifs	_	NNS	NNS	_	15	OBJ	_	_
18	.	_	.	.	_	1	P	_	_

1	RelA	_	NN	NN	_	5	SBJ	_	_
2	(	_	(	(	_	3	P	_	_
3	p65	_	NN	NN	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	functions	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	as	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	critical	_	JJ	JJ	_	10	NMOD	_	_
9	transactivating	_	VBG	VBG	_	10	NMOD	_	_
10	component	_	NN	NN	_	6	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	17	NMOD	_	_
13	heterodimeric	_	JJ	JJ	_	17	NMOD	_	_
14	p50-p65	_	NN	NN	_	17	NMOD	_	_
15	NF-kappa	_	NN	NN	_	17	NMOD	_	_
16	B	_	NN	NN	_	17	NMOD	_	_
17	complex	_	NN	NN	_	11	PMOD	_	_
18	and	_	CC	CC	_	5	CC	_	_
19	contains	_	VBZ	VBZ	_	5	COORD	_	_
20	a	_	DT	DT	_	23	NMOD	_	_
21	high-affinity	_	JJ	JJ	_	23	NMOD	_	_
22	binding	_	VBG	VBG	_	23	NMOD	_	_
23	site	_	NN	NN	_	19	OBJ	_	_
24	for	_	IN	IN	_	23	NMOD	_	_
25	its	_	PRP$	PRP$	_	27	NMOD	_	_
26	cytoplasmic	_	JJ	JJ	_	27	NMOD	_	_
27	inhibitor	_	NN	NN	_	24	PMOD	_	_
28	,	_	,	,	_	27	P	_	_
29	I	_	NN	NN	_	32	NMOD	_	_
30	kappa	_	NN	NN	_	32	NMOD	_	_
31	B	_	NN	NN	_	32	NMOD	_	_
32	alpha	_	NN	NN	_	27	NMOD	_	_
33	.	_	.	.	_	5	P	_	_

1	After	_	IN	IN	_	9	TMP	_	_
2	cellular	_	JJ	JJ	_	3	NMOD	_	_
3	activation	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	9	P	_	_
5	I	_	NN	NN	_	8	NMOD	_	_
6	kappa	_	NN	NN	_	8	NMOD	_	_
7	B	_	NN	NN	_	8	NMOD	_	_
8	alpha	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	rapidly	_	RB	RB	_	11	TMP	_	_
11	degraded	_	VBN	VBN	_	9	VC	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	concert	_	NN	NN	_	12	DEP	_	_
14	with	_	IN	IN	_	12	DEP	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	induced	_	VBN	VBN	_	18	NMOD	_	_
17	nuclear	_	JJ	JJ	_	18	NMOD	_	_
18	translocation	_	NN	NN	_	12	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	NF-kappa	_	NN	NN	_	21	NMOD	_	_
21	B	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	present	_	JJ	JJ	_	3	NMOD	_	_
3	study	_	NN	NN	_	4	SBJ	_	_
4	demonstrates	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	tumor	_	NN	NN	_	8	AMOD	_	_
7	necrosis	_	NN	NN	_	8	AMOD	_	_
8	factor	_	NN	NN	_	10	NMOD	_	_
9	alpha-induced	_	JJ	JJ	_	8	AMOD	_	_
10	degradation	_	NN	NN	_	20	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	I	_	NN	NN	_	15	NMOD	_	_
13	kappa	_	NN	NN	_	15	NMOD	_	_
14	B	_	NN	NN	_	15	NMOD	_	_
15	alpha	_	NN	NN	_	11	PMOD	_	_
16	in	_	IN	IN	_	10	NMOD	_	_
17	human	_	JJ	JJ	_	19	NMOD	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	PMOD	_	_
20	is	_	VBZ	VBZ	_	5	VMOD	_	_
21	preceded	_	VBN	VBN	_	20	VC	_	_
22	by	_	IN	IN	_	21	LGS	_	_
23	its	_	PRP$	PRP$	_	25	NMOD	_	_
24	rapid	_	JJ	JJ	_	25	NMOD	_	_
25	phosphorylation	_	NN	NN	_	22	PMOD	_	_
26	in	_	FW	FW	_	25	NMOD	_	_
27	vivo	_	FW	FW	_	26	AMOD	_	_
28	.	_	.	.	_	4	P	_	_

1	However	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	effects	_	NNS	NNS	_	10	SBJ	_	_
5	on	_	IN	IN	_	4	NMOD	_	_
6	I	_	NN	NN	_	9	NMOD	_	_
7	kappa	_	NN	NN	_	9	NMOD	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	alpha	_	NN	NN	_	5	PMOD	_	_
10	result	_	VBP	VBP	_	0	ROOT-S	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	nuclear	_	JJ	JJ	_	13	NMOD	_	_
13	mobilization	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	only	_	RB	RB	_	17	NMOD	_	_
16	a	_	DT	DT	_	17	NMOD	_	_
17	fraction	_	NN	NN	_	14	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	entire	_	JJ	JJ	_	22	NMOD	_	_
21	cytoplasmic	_	JJ	JJ	_	22	NMOD	_	_
22	pool	_	NN	NN	_	18	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	RelA	_	NN	NN	_	23	PMOD	_	_
25	.	_	.	.	_	10	P	_	_

1	Subsequent	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	revealed	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	(	_	(	(	_	7	P	_	_
7	i	_	LS	LS	_	11	VMOD	_	_
8	)	_	)	)	_	7	P	_	_
9	cytoplasmic	_	JJ	JJ	_	10	NMOD	_	_
10	RelA	_	NN	NN	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	5	VMOD	_	_
12	stably	_	RB	RB	_	13	ADV	_	_
13	associated	_	VBN	VBN	_	11	VC	_	_
14	not	_	RB	RB	_	13	ADV	_	_
15	only	_	RB	RB	_	14	DEP	_	_
16	with	_	IN	IN	_	14	COORD	_	_
17	I	_	NN	NN	_	20	NMOD	_	_
18	kappa	_	NN	NN	_	20	NMOD	_	_
19	B	_	NN	NN	_	20	NMOD	_	_
20	alpha	_	NN	NN	_	16	PMOD	_	_
21	but	_	CC	CC	_	14	CC	_	_
22	also	_	RB	RB	_	21	COORD	_	_
23	with	_	IN	IN	_	14	COORD	_	_
24	other	_	JJ	JJ	_	27	NMOD	_	_
25	ankyrin	_	NN	NN	_	27	NMOD	_	_
26	motif-rich	_	JJ	JJ	_	27	NMOD	_	_
27	proteins	_	NNS	NNS	_	23	PMOD	_	_
28	including	_	VBG	VBG	_	27	NMOD	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	products	_	NNS	NNS	_	28	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	44	NMOD	_	_
33	NF-kappa	_	NN	NN	_	34	NMOD	_	_
34	B2	_	NN	NN	_	44	NMOD	_	_
35	(	_	(	(	_	36	P	_	_
36	p100	_	NN	NN	_	34	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	and	_	CC	CC	_	34	CC	_	_
39	NF-kappa	_	NN	NN	_	40	NMOD	_	_
40	B1	_	NN	NN	_	34	COORD	_	_
41	(	_	(	(	_	42	P	_	_
42	p105	_	NN	NN	_	40	PRN	_	_
43	)	_	)	)	_	42	P	_	_
44	genes	_	NNS	NNS	_	31	PMOD	_	_
45	;	_	:	:	_	11	P	_	_
46	(	_	(	(	_	47	P	_	_
47	ii	_	LS	LS	_	60	VMOD	_	_
48	)	_	)	)	_	47	P	_	_
49	in	_	IN	IN	_	60	ADV	_	_
50	contrast	_	NN	NN	_	49	DEP	_	_
51	to	_	TO	TO	_	49	DEP	_	_
52	RelA-I	_	NN	NN	_	55	NMOD	_	_
53	kappa	_	NN	NN	_	55	NMOD	_	_
54	B	_	NN	NN	_	55	NMOD	_	_
55	alpha	_	NN	NN	_	49	PMOD	_	_
56	,	_	,	,	_	60	P	_	_
57	RelA-p100	_	NN	NN	_	59	NMOD	_	_
58	cytoplasmic	_	JJ	JJ	_	59	NMOD	_	_
59	complexes	_	NNS	NNS	_	60	SBJ	_	_
60	are	_	VBP	VBP	_	11	COORD	_	_
61	not	_	RB	RB	_	60	VMOD	_	_
62	dissociated	_	VBN	VBN	_	60	VC	_	_
63	following	_	VBG	VBG	_	62	TMP	_	_
64	tumor	_	NN	NN	_	68	NMOD	_	_
65	necrosis	_	NN	NN	_	68	NMOD	_	_
66	factor	_	NN	NN	_	68	NMOD	_	_
67	alpha	_	NN	NN	_	68	NMOD	_	_
68	activation	_	NN	NN	_	63	PMOD	_	_
69	;	_	:	:	_	11	P	_	_
70	(	_	(	(	_	71	P	_	_
71	iii	_	LS	LS	_	74	VMOD	_	_
72	)	_	)	)	_	71	P	_	_
73	p100	_	NN	NN	_	74	SBJ	_	_
74	functions	_	VBZ	VBZ	_	11	COORD	_	_
75	as	_	IN	IN	_	74	ADV	_	_
76	a	_	DT	DT	_	78	NMOD	_	_
77	potent	_	JJ	JJ	_	78	NMOD	_	_
78	inhibitor	_	NN	NN	_	75	PMOD	_	_
79	of	_	IN	IN	_	78	NMOD	_	_
80	RelA-mediated	_	JJ	JJ	_	81	NMOD	_	_
81	transcription	_	NN	NN	_	79	PMOD	_	_
82	in	_	FW	FW	_	81	NMOD	_	_
83	vivo	_	FW	FW	_	82	AMOD	_	_
84	;	_	:	:	_	11	P	_	_
85	(	_	(	(	_	86	P	_	_
86	iv	_	LS	LS	_	94	VMOD	_	_
87	)	_	)	)	_	86	P	_	_
88	the	_	DT	DT	_	89	NMOD	_	_
89	interaction	_	NN	NN	_	94	SBJ	_	_
90	of	_	IN	IN	_	89	NMOD	_	_
91	RelA	_	NN	NN	_	90	PMOD	_	_
92	and	_	CC	CC	_	91	CC	_	_
93	p100	_	NN	NN	_	91	COORD	_	_
94	involves	_	VBZ	VBZ	_	11	COORD	_	_
95	the	_	DT	DT	_	99	NMOD	_	_
96	conserved	_	VBN	VBN	_	99	NMOD	_	_
97	Rel	_	NN	NN	_	99	NMOD	_	_
98	homology	_	NN	NN	_	99	NMOD	_	_
99	domain	_	NN	NN	_	94	OBJ	_	_
100	of	_	IN	IN	_	99	NMOD	_	_
101	both	_	DT	DT	_	102	NMOD	_	_
102	proteins	_	NNS	NNS	_	100	PMOD	_	_
103	but	_	CC	CC	_	99	CC	_	_
104	not	_	RB	RB	_	103	COORD	_	_
105	the	_	DT	DT	_	108	NMOD	_	_
106	nuclear	_	JJ	JJ	_	108	NMOD	_	_
107	localization	_	NN	NN	_	108	NMOD	_	_
108	signal	_	NN	NN	_	99	COORD	_	_
109	of	_	IN	IN	_	108	NMOD	_	_
110	RelA	_	NN	NN	_	109	PMOD	_	_
111	,	_	,	,	_	108	P	_	_
112	which	_	WDT	WDT	_	113	SBJ	_	_
113	is	_	VBZ	VBZ	_	108	NMOD	_	_
114	required	_	VBN	VBN	_	113	VC	_	_
115	for	_	IN	IN	_	114	ADV	_	_
116	I	_	NN	NN	_	120	NMOD	_	_
117	kappa	_	NN	NN	_	120	NMOD	_	_
118	B	_	NN	NN	_	120	NMOD	_	_
119	alpha	_	NN	NN	_	120	NMOD	_	_
120	binding	_	NN	NN	_	115	PMOD	_	_
121	;	_	:	:	_	11	P	_	_
122	(	_	(	(	_	123	P	_	_
123	v	_	LS	LS	_	130	VMOD	_	_
124	)	_	)	)	_	123	P	_	_
125	p100	_	NN	NN	_	126	NMOD	_	_
126	inhibition	_	NN	NN	_	130	SBJ	_	_
127	of	_	IN	IN	_	126	NMOD	_	_
128	RelA	_	NN	NN	_	129	NMOD	_	_
129	function	_	NN	NN	_	127	PMOD	_	_
130	requires	_	VBZ	VBZ	_	11	COORD	_	_
131	the	_	DT	DT	_	135	NMOD	_	_
132	C-terminal	_	JJ	JJ	_	135	NMOD	_	_
133	ankyrin	_	NN	NN	_	135	NMOD	_	_
134	motif	_	NN	NN	_	135	NMOD	_	_
135	domain	_	NN	NN	_	130	OBJ	_	_
136	,	_	,	,	_	135	P	_	_
137	which	_	WDT	WDT	_	138	SBJ	_	_
138	mediates	_	VBZ	VBZ	_	135	NMOD	_	_
139	cytoplasmic	_	JJ	JJ	_	140	NMOD	_	_
140	retention	_	NN	NN	_	138	OBJ	_	_
141	of	_	IN	IN	_	140	NMOD	_	_
142	RelA	_	NN	NN	_	141	PMOD	_	_
143	;	_	:	:	_	11	P	_	_
144	and	_	CC	CC	_	11	CC	_	_
145	(	_	(	(	_	146	P	_	_
146	vi	_	LS	LS	_	158	VMOD	_	_
147	)	_	)	)	_	146	P	_	_
148	as	_	IN	IN	_	158	ADV	_	_
149	observed	_	VBN	VBN	_	148	VMOD	_	_
150	with	_	IN	IN	_	149	ADV	_	_
151	I	_	PRP	PRP	_	154	NMOD	_	_
152	kappa	_	NN	NN	_	154	NMOD	_	_
153	B	_	NN	NN	_	154	NMOD	_	_
154	alpha	_	NN	NN	_	150	PMOD	_	_
155	,	_	,	,	_	158	P	_	_
156	nuclear	_	JJ	JJ	_	157	NMOD	_	_
157	RelA	_	NN	NN	_	158	SBJ	_	_
158	stimulates	_	VBZ	VBZ	_	11	COORD	_	_
159	p100	_	NN	NN	_	163	NMOD	_	_
160	mRNA	_	NN	NN	_	163	NMOD	_	_
161	and	_	CC	CC	_	160	CC	_	_
162	protein	_	NN	NN	_	160	COORD	_	_
163	expression	_	NN	NN	_	158	OBJ	_	_
164	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	4	SBJ	_	_
3	thus	_	RB	RB	_	4	ADV	_	_
4	reveal	_	VBP	VBP	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	presence	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	13	NMOD	_	_
9	second	_	JJ	JJ	_	13	NMOD	_	_
10	inducible	_	JJ	JJ	_	13	NMOD	_	_
11	autoregulated	_	JJ	JJ	_	13	NMOD	_	_
12	inhibitory	_	JJ	JJ	_	13	NMOD	_	_
13	pathway	_	NN	NN	_	7	PMOD	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	helps	_	VBZ	VBZ	_	13	NMOD	_	_
16	ensure	_	VB	VB	_	15	OBJ	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	rapid	_	JJ	JJ	_	21	TMP	_	_
19	but	_	CC	CC	_	18	CC	_	_
20	transient	_	JJ	JJ	_	18	COORD	_	_
21	action	_	NN	NN	_	16	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	nuclear	_	JJ	JJ	_	25	NMOD	_	_
24	NF-kappa	_	NN	NN	_	25	NMOD	_	_
25	B	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	4	P	_	_

1	Comparative	_	JJ	JJ	_	2	NMOD	_	_
2	mapping	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	SRY	_	NN	NN	_	3	PMOD	_	_
5	in	_	IN	IN	_	2	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	great	_	JJ	JJ	_	8	NMOD	_	_
8	apes	_	NNS	NNS	_	5	PMOD	_	_
9	.	_	.	.	_	2	P	_	_

1	Cytogenetic	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	primate	_	JJ	JJ	_	7	NMOD	_	_
6	Y	_	NN	NN	_	7	NMOD	_	_
7	chromosomes	_	NNS	NNS	_	3	PMOD	_	_
8	have	_	VBP	VBP	_	0	ROOT-S	_	_
9	suggested	_	VBN	VBN	_	8	VC	_	_
10	that	_	IN	IN	_	9	OBJ	_	_
11	extensive	_	JJ	JJ	_	12	NMOD	_	_
12	rearrangements	_	NNS	NNS	_	13	SBJ	_	_
13	have	_	VBP	VBP	_	10	VMOD	_	_
14	occurred	_	VBN	VBN	_	13	VC	_	_
15	during	_	IN	IN	_	14	TMP	_	_
16	evolution	_	NN	NN	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	great	_	JJ	JJ	_	20	NMOD	_	_
20	apes	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	8	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	used	_	VBN	VBN	_	2	VC	_	_
4	in	_	FW	FW	_	5	AMOD	_	_
5	situ	_	FW	FW	_	6	NMOD	_	_
6	hybridization	_	NN	NN	_	3	IOBJ	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	define	_	VB	VB	_	3	OBJ	_	_
9	these	_	DT	DT	_	10	NMOD	_	_
10	rearrangements	_	NNS	NNS	_	8	OBJ	_	_
11	at	_	IN	IN	_	8	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	molecular	_	JJ	JJ	_	14	NMOD	_	_
14	level	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	2	P	_	_

1	pHU-14	_	NN	NN	_	14	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	probe	_	NN	NN	_	1	NMOD	_	_
5	including	_	VBG	VBG	_	4	NMOD	_	_
6	sequences	_	NNS	NNS	_	5	PMOD	_	_
7	from	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	sex	_	NN	NN	_	12	NMOD	_	_
10	determining	_	JJ	JJ	_	12	NMOD	_	_
11	gene	_	NN	NN	_	12	NMOD	_	_
12	SRY	_	NN	NN	_	7	PMOD	_	_
13	,	_	,	,	_	1	P	_	_
14	hybridizes	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	close	_	RB	RB	_	14	ADV	_	_
16	to	_	TO	TO	_	15	AMOD	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	early	_	JJ	JJ	_	21	NMOD	_	_
19	replicating	_	VBG	VBG	_	21	NMOD	_	_
20	pseudoautosomal	_	JJ	JJ	_	21	NMOD	_	_
21	segment	_	NN	NN	_	16	PMOD	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	a	_	DT	DT	_	27	NMOD	_	_
24	telomeric	_	JJ	JJ	_	27	NMOD	_	_
25	or	_	CC	CC	_	24	CC	_	_
26	subtelomeric	_	JJ	JJ	_	24	COORD	_	_
27	position	_	NN	NN	_	22	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	Y	_	NN	NN	_	31	NMOD	_	_
31	chromosomes	_	NNS	NNS	_	28	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	all	_	DT	DT	_	35	NMOD	_	_
34	great	_	JJ	JJ	_	35	NMOD	_	_
35	apes	_	NNS	NNS	_	32	PMOD	_	_
36	.	_	.	.	_	14	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	low	_	JJ	JJ	_	4	NMOD	_	_
3	copy	_	NN	NN	_	4	NMOD	_	_
4	repeat	_	NN	NN	_	10	SBJ	_	_
5	detected	_	VBN	VBN	_	4	NMOD	_	_
6	by	_	IN	IN	_	5	LGS	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	probe	_	NN	NN	_	9	NMOD	_	_
9	Fr35-II	_	NN	NN	_	6	PMOD	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	obviously	_	RB	RB	_	10	ADV	_	_
12	included	_	VBN	VBN	_	10	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	Y	_	NN	NN	_	16	NMOD	_	_
15	chromosomal	_	NN	NN	_	16	NMOD	_	_
16	rearrangements	_	NNS	NNS	_	13	PMOD	_	_
17	during	_	IN	IN	_	16	TMP	_	_
18	hominid	_	NN	NN	_	19	NMOD	_	_
19	evolution	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	10	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	9	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	combined	_	VBN	VBN	_	2	NMOD	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	previous	_	JJ	JJ	_	7	NMOD	_	_
7	studies	_	NNS	NNS	_	5	PMOD	_	_
8	,	_	,	,	_	2	P	_	_
9	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
10	that	_	IN	IN	_	9	OBJ	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	Y	_	NN	NN	_	13	NMOD	_	_
13	chromosome	_	NN	NN	_	17	SBJ	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	great	_	JJ	JJ	_	16	NMOD	_	_
16	apes	_	NNS	NNS	_	14	PMOD	_	_
17	has	_	VBZ	VBZ	_	10	VMOD	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	conserved	_	VBN	VBN	_	20	NMOD	_	_
20	region	_	NN	NN	_	17	OBJ	_	_
21	including	_	VBG	VBG	_	20	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	pseudoautosomal	_	JJ	JJ	_	24	NMOD	_	_
24	region	_	NN	NN	_	21	PMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	testis-determining	_	JJ	JJ	_	28	NMOD	_	_
28	region	_	NN	NN	_	24	COORD	_	_
29	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	rest	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	Y	_	NN	NN	_	6	NMOD	_	_
6	chromosome	_	NN	NN	_	3	PMOD	_	_
7	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	undergone	_	VBN	VBN	_	7	VC	_	_
9	several	_	JJ	JJ	_	10	NMOD	_	_
10	rearrangements	_	NNS	NNS	_	8	OBJ	_	_
11	in	_	IN	IN	_	8	ADV	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	different	_	JJ	JJ	_	15	NMOD	_	_
14	great	_	JJ	JJ	_	15	NMOD	_	_
15	apes	_	NNS	NNS	_	11	PMOD	_	_
16	.	_	.	.	_	7	P	_	_

1	Detection	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	minimal	_	JJ	JJ	_	5	NMOD	_	_
4	residual	_	JJ	JJ	_	5	NMOD	_	_
5	disease	_	NN	NN	_	2	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	patient	_	NN	NN	_	6	PMOD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	acute	_	JJ	JJ	_	12	NMOD	_	_
11	promyelocytic	_	JJ	JJ	_	12	NMOD	_	_
12	leukemia	_	NN	NN	_	9	PMOD	_	_
13	by	_	IN	IN	_	1	NMOD	_	_
14	RT-PCR	_	NN	NN	_	13	PMOD	_	_
15	:	_	:	:	_	1	P	_	_
16	necessity	_	NN	NN	_	1	NMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	chemotherapy	_	NN	NN	_	17	PMOD	_	_
19	following	_	VBG	VBG	_	18	TMP	_	_
20	ATRA	_	NN	NN	_	21	NMOD	_	_
21	therapy	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	PML\/RAR	_	NN	NN	_	5	NMOD	_	_
3	alpha	_	NN	NN	_	5	NMOD	_	_
4	fusion	_	NN	NN	_	5	NMOD	_	_
5	gene	_	NN	NN	_	12	SBJ	_	_
6	resulting	_	VBG	VBG	_	5	NMOD	_	_
7	from	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	t	_	NN	NN	_	11	NMOD	_	_
10	-LRB-15;17-RRB-	_	NN	NN	_	11	NMOD	_	_
11	translocation	_	NN	NN	_	7	PMOD	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	specific	_	JJ	JJ	_	15	NMOD	_	_
15	marker	_	NN	NN	_	12	PRD	_	_
16	for	_	IN	IN	_	15	NMOD	_	_
17	acute	_	JJ	JJ	_	19	NMOD	_	_
18	promyelocytic	_	JJ	JJ	_	19	NMOD	_	_
19	leukemia	_	NN	NN	_	16	PMOD	_	_
20	(	_	(	(	_	21	P	_	_
21	APL	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	.	_	.	.	_	12	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	examined	_	VBD	VBD	_	0	ROOT-S	_	_
3	bone	_	NN	NN	_	5	NMOD	_	_
4	marrow	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	2	IOBJ	_	_
6	by	_	IN	IN	_	2	ADV	_	_
7	reverse	_	JJ	JJ	_	10	NMOD	_	_
8	transcriptase-polymerase	_	NN	NN	_	10	NMOD	_	_
9	chain	_	NN	NN	_	10	NMOD	_	_
10	reaction	_	NN	NN	_	6	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	RT-PCR	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	detect	_	VB	VB	_	2	OBJ	_	_
16	residual	_	JJ	JJ	_	20	NMOD	_	_
17	PML\/RAR	_	NN	NN	_	18	AMOD	_	_
18	alpha	_	NN	NN	_	20	NMOD	_	_
19	mRNA-containing	_	JJ	JJ	_	18	AMOD	_	_
20	cells	_	NNS	NNS	_	15	OBJ	_	_
21	following	_	VBG	VBG	_	20	TMP	_	_
22	treatment	_	NN	NN	_	21	PMOD	_	_
23	with	_	IN	IN	_	22	NMOD	_	_
24	all-trans	_	JJ	JJ	_	26	NMOD	_	_
25	retinoic	_	JJ	JJ	_	26	NMOD	_	_
26	acid	_	NN	NN	_	23	PMOD	_	_
27	(	_	(	(	_	28	P	_	_
28	ATRA	_	NN	NN	_	26	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	and	_	CC	CC	_	22	CC	_	_
31	cytotoxic	_	JJ	JJ	_	32	NMOD	_	_
32	chemotherapy	_	NN	NN	_	22	COORD	_	_
33	in	_	IN	IN	_	15	ADV	_	_
34	a	_	DT	DT	_	35	NMOD	_	_
35	patient	_	NN	NN	_	33	PMOD	_	_
36	with	_	IN	IN	_	35	NMOD	_	_
37	APL	_	NN	NN	_	36	PMOD	_	_
38	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	RT-PCR	_	NN	NN	_	3	NMOD	_	_
3	assay	_	NN	NN	_	4	SBJ	_	_
4	can	_	MD	MD	_	0	ROOT-S	_	_
5	detect	_	VB	VB	_	4	VC	_	_
6	one	_	CD	CD	_	8	NMOD	_	_
7	leukemic	_	JJ	JJ	_	8	NMOD	_	_
8	cell	_	NN	NN	_	5	OBJ	_	_
9	in	_	IN	IN	_	5	ADV	_	_
10	10-LRB-2-RRB-	_	CD	CD	_	12	NMOD	_	_
11	normal	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	PMOD	_	_
13	in	_	FW	FW	_	5	ADV	_	_
14	vitro	_	FW	FW	_	13	AMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	PML\/RAR	_	NN	NN	_	6	NMOD	_	_
5	alpha	_	NN	NN	_	6	NMOD	_	_
6	mRNA	_	NN	NN	_	7	SBJ	_	_
7	was	_	VBD	VBD	_	3	VMOD	_	_
8	still	_	RB	RB	_	7	ADV	_	_
9	detectable	_	JJ	JJ	_	7	PRD	_	_
10	despite	_	IN	IN	_	7	ADV	_	_
11	clinical	_	JJ	JJ	_	12	NMOD	_	_
12	remission	_	NN	NN	_	10	PMOD	_	_
13	following	_	VBG	VBG	_	12	TMP	_	_
14	ATRA	_	NN	NN	_	15	NMOD	_	_
15	treatment	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	7	P	_	_
17	but	_	CC	CC	_	7	CC	_	_
18	undetectable	_	JJ	JJ	_	9	GAP	_	_
19	following	_	VBG	VBG	_	18	TMP	_	_
20	consolidation	_	NN	NN	_	19	PMOD	_	_
21	with	_	IN	IN	_	20	NMOD	_	_
22	chemotherapy	_	NN	NN	_	21	PMOD	_	_
23	.	_	.	.	_	2	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	this	_	DT	DT	_	6	NMOD	_	_
6	technique	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	4	VMOD	_	_
8	useful	_	JJ	JJ	_	7	PRD	_	_
9	for	_	IN	IN	_	8	AMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	identification	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	minimal	_	JJ	JJ	_	15	NMOD	_	_
14	residual	_	JJ	JJ	_	15	NMOD	_	_
15	disease	_	NN	NN	_	12	PMOD	_	_
16	in	_	NN	NN	_	15	NMOD	_	_
17	patients	_	NNS	NNS	_	16	PMOD	_	_
18	with	_	IN	IN	_	17	NMOD	_	_
19	APL	_	NN	NN	_	18	PMOD	_	_
20	and	_	CC	CC	_	4	CC	_	_
21	that	_	IN	IN	_	4	COORD	_	_
22	cytotoxic	_	JJ	JJ	_	23	NMOD	_	_
23	chemotherapy	_	NN	NN	_	27	SBJ	_	_
24	following	_	VBG	VBG	_	23	TMP	_	_
25	ATRA	_	NN	NN	_	26	NMOD	_	_
26	therapy	_	NN	NN	_	24	PMOD	_	_
27	is	_	VBZ	VBZ	_	21	VMOD	_	_
28	required	_	VBN	VBN	_	27	VC	_	_
29	for	_	IN	IN	_	28	ADV	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	elimination	_	NN	NN	_	29	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	APL	_	NN	NN	_	34	NMOD	_	_
34	cells	_	NNS	NNS	_	32	PMOD	_	_
35	.	_	.	.	_	3	P	_	_

1	Patterns	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	Pan	_	NN	NN	_	4	NMOD	_	_
4	expression	_	NN	NN	_	2	PMOD	_	_
5	and	_	CC	CC	_	1	CC	_	_
6	role	_	NN	NN	_	1	COORD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	Pan	_	NN	NN	_	9	NMOD	_	_
9	proteins	_	NNS	NNS	_	7	PMOD	_	_
10	in	_	IN	IN	_	1	NMOD	_	_
11	endocrine	_	NN	NN	_	12	AMOD	_	_
12	cell	_	NN	NN	_	15	NMOD	_	_
13	type-specific	_	JJ	JJ	_	12	AMOD	_	_
14	complex	_	JJ	JJ	_	15	NMOD	_	_
15	formation	_	NN	NN	_	10	PMOD	_	_
16	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	Pan	_	NN	NN	_	3	NMOD	_	_
3	gene	_	NN	NN	_	4	SBJ	_	_
4	encodes	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	at	_	IN	IN	_	7	DEP	_	_
6	least	_	JJS	JJS	_	7	DEP	_	_
7	two	_	CD	CD	_	9	NMOD	_	_
8	distinct	_	JJ	JJ	_	9	NMOD	_	_
9	transcripts	_	NNS	NNS	_	4	OBJ	_	_
10	,	_	,	,	_	9	P	_	_
11	Pan-1	_	NN	NN	_	9	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	Pan-2	_	NN	NN	_	11	COORD	_	_
14	(	_	(	(	_	11	P	_	_
15	also	_	RB	RB	_	16	ADV	_	_
16	known	_	VBN	VBN	_	11	NMOD	_	_
17	as	_	IN	IN	_	16	ADV	_	_
18	E47	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	E12	_	NN	NN	_	18	COORD	_	_
21	,	_	,	,	_	18	P	_	_
22	respectively	_	RB	RB	_	18	NMOD	_	_
23	)	_	)	)	_	11	P	_	_
24	,	_	,	,	_	11	P	_	_
25	by	_	IN	IN	_	4	ADV	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	mechanism	_	NN	NN	_	25	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	alternative	_	JJ	JJ	_	31	NMOD	_	_
30	RNA	_	NN	NN	_	31	NMOD	_	_
31	splicing	_	NN	NN	_	28	PMOD	_	_
32	.	_	.	.	_	4	P	_	_

1	Northern	_	JJ	JJ	_	3	NMOD	_	_
2	blot	_	NN	NN	_	3	NMOD	_	_
3	analyses	_	NNS	NNS	_	10	SBJ	_	_
4	performed	_	VBN	VBN	_	3	NMOD	_	_
5	on	_	IN	IN	_	4	ADV	_	_
6	rat	_	NN	NN	_	9	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	mouse	_	NN	NN	_	6	COORD	_	_
9	tissues	_	NNS	NNS	_	5	PMOD	_	_
10	have	_	VBP	VBP	_	0	ROOT-S	_	_
11	detected	_	VBN	VBN	_	10	VC	_	_
12	ubiquitously	_	RB	RB	_	13	AMOD	_	_
13	expressed	_	VBN	VBN	_	15	NMOD	_	_
14	Pan	_	NN	NN	_	15	NMOD	_	_
15	transcripts	_	NNS	NNS	_	11	OBJ	_	_
16	,	_	,	,	_	10	P	_	_
17	but	_	CC	CC	_	10	CC	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	abundance	_	NN	NN	_	28	SBJ	_	_
20	,	_	,	,	_	19	P	_	_
21	distribution	_	NN	NN	_	19	COORD	_	_
22	,	_	,	,	_	19	P	_	_
23	and	_	CC	CC	_	19	CC	_	_
24	form	_	NN	NN	_	19	COORD	_	_
25	of	_	IN	IN	_	19	NMOD	_	_
26	Pan	_	NN	NN	_	27	NMOD	_	_
27	proteins	_	NNS	NNS	_	25	PMOD	_	_
28	have	_	VBP	VBP	_	10	COORD	_	_
29	not	_	RB	RB	_	28	VMOD	_	_
30	been	_	VBN	VBN	_	28	VC	_	_
31	clearly	_	RB	RB	_	30	ADV	_	_
32	defined	_	VBN	VBN	_	30	VC	_	_
33	.	_	.	.	_	10	P	_	_

1	Studies	_	NNS	NNS	_	20	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	cell	_	NN	NN	_	4	NMOD	_	_
4	lines	_	NNS	NNS	_	2	PMOD	_	_
5	representing	_	VBG	VBG	_	4	NMOD	_	_
6	endocrine	_	NN	NN	_	12	NMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	fibroblast	_	NN	NN	_	6	COORD	_	_
9	,	_	,	,	_	6	P	_	_
10	and	_	CC	CC	_	6	CC	_	_
11	lymphoid	_	JJ	JJ	_	6	COORD	_	_
12	lineages	_	NNS	NNS	_	5	OBJ	_	_
13	using	_	VBG	VBG	_	1	NMOD	_	_
14	polyclonal	_	JJ	JJ	_	15	NMOD	_	_
15	antisera	_	NNS	NNS	_	13	IOBJ	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	detect	_	VB	VB	_	13	OBJ	_	_
18	E2A	_	NN	NN	_	19	NMOD	_	_
19	proteins	_	NNS	NNS	_	17	OBJ	_	_
20	have	_	VBP	VBP	_	0	ROOT-S	_	_
21	suggested	_	VBN	VBN	_	20	VC	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	significant	_	JJ	JJ	_	26	NMOD	_	_
24	E2A	_	NN	NN	_	26	NMOD	_	_
25	protein	_	NN	NN	_	26	NMOD	_	_
26	expression	_	NN	NN	_	27	SBJ	_	_
27	is	_	VBZ	VBZ	_	22	VMOD	_	_
28	restricted	_	JJ	JJ	_	27	VC	_	_
29	to	_	TO	TO	_	28	ADV	_	_
30	B-lymphocytes	_	NNS	NNS	_	29	PMOD	_	_
31	.	_	.	.	_	20	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	developed	_	VBN	VBN	_	2	VC	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	monoclonal	_	JJ	JJ	_	6	NMOD	_	_
6	antibody	_	NN	NN	_	3	OBJ	_	_
7	,	_	,	,	_	6	P	_	_
8	Yae	_	NN	NN	_	6	NMOD	_	_
9	,	_	,	,	_	6	P	_	_
10	which	_	WDT	WDT	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	6	NMOD	_	_
12	specific	_	JJ	JJ	_	11	PRD	_	_
13	for	_	IN	IN	_	12	AMOD	_	_
14	Pan\/E2A	_	NN	NN	_	15	NMOD	_	_
15	proteins	_	NNS	NNS	_	13	PMOD	_	_
16	,	_	,	,	_	2	P	_	_
17	and	_	CC	CC	_	2	CC	_	_
18	have	_	VBP	VBP	_	2	COORD	_	_
19	used	_	VBN	VBN	_	18	VC	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	Yae	_	NN	NN	_	22	NMOD	_	_
22	antibody	_	NN	NN	_	19	IOBJ	_	_
23	to	_	TO	TO	_	24	VMOD	_	_
24	examine	_	VB	VB	_	19	OBJ	_	_
25	a	_	DT	DT	_	26	NMOD	_	_
26	variety	_	NN	NN	_	24	OBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	endocrine	_	JJ	JJ	_	32	NMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	nonendocrine	_	JJ	JJ	_	28	COORD	_	_
31	cell	_	NN	NN	_	32	NMOD	_	_
32	lineages	_	NNS	NNS	_	27	PMOD	_	_
33	for	_	IN	IN	_	24	ADV	_	_
34	differences	_	NNS	NNS	_	33	PMOD	_	_
35	in	_	IN	IN	_	34	NMOD	_	_
36	Pan\/E2A	_	NN	NN	_	38	NMOD	_	_
37	protein	_	NN	NN	_	38	NMOD	_	_
38	expression	_	NN	NN	_	35	PMOD	_	_
39	,	_	,	,	_	38	P	_	_
40	subcellular	_	JJ	JJ	_	41	NMOD	_	_
41	localization	_	NN	NN	_	38	COORD	_	_
42	,	_	,	,	_	38	P	_	_
43	and	_	CC	CC	_	38	CC	_	_
44	heteromeric	_	JJ	JJ	_	46	NMOD	_	_
45	complex	_	JJ	JJ	_	46	NMOD	_	_
46	formation	_	NN	NN	_	38	COORD	_	_
47	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	16	ADV	_	_
2	contrast	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	previous	_	JJ	JJ	_	5	NMOD	_	_
5	results	_	NNS	NNS	_	1	PMOD	_	_
6	obtained	_	VBN	VBN	_	5	NMOD	_	_
7	using	_	VBG	VBG	_	6	OBJ	_	_
8	polyclonal	_	JJ	JJ	_	9	NMOD	_	_
9	antiseras	_	NN	NN	_	7	IOBJ	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	detect	_	VB	VB	_	7	OBJ	_	_
12	Pan\/E2A	_	NN	NN	_	13	NMOD	_	_
13	proteins	_	NNS	NNS	_	11	OBJ	_	_
14	,	_	,	,	_	16	P	_	_
15	we	_	PRP	PRP	_	16	SBJ	_	_
16	report	_	VBP	VBP	_	0	ROOT-S	_	_
17	comparable	_	JJ	JJ	_	18	NMOD	_	_
18	levels	_	NNS	NNS	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	Pan	_	NN	NN	_	21	NMOD	_	_
21	proteins	_	NNS	NNS	_	19	PMOD	_	_
22	in	_	IN	IN	_	18	NMOD	_	_
23	GH\/PRL-	_	NN	NN	_	30	NMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	insulin-producing	_	JJ	JJ	_	23	COORD	_	_
26	,	_	,	,	_	30	P	_	_
27	B-	_	NN	NN	_	30	NMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	T-lymphocyte	_	NN	NN	_	27	COORD	_	_
30	cells	_	NNS	NNS	_	22	PMOD	_	_
31	.	_	.	.	_	16	P	_	_

1	IEF-1	_	NN	NN	_	14	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	a	_	DT	DT	_	7	NMOD	_	_
4	pancreatic	_	JJ	JJ	_	5	AMOD	_	_
5	beta-cell	_	NN	NN	_	7	NMOD	_	_
6	type-specific	_	JJ	JJ	_	5	AMOD	_	_
7	complex	_	NN	NN	_	1	NMOD	_	_
8	believed	_	VBN	VBN	_	7	NMOD	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	regulate	_	VB	VB	_	8	OBJ	_	_
11	insulin	_	NN	NN	_	12	NMOD	_	_
12	expression	_	NN	NN	_	10	OBJ	_	_
13	,	_	,	,	_	1	P	_	_
14	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	demonstrated	_	VBN	VBN	_	14	VC	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	consist	_	VB	VB	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	ADV	_	_
19	at	_	IN	IN	_	21	DEP	_	_
20	least	_	JJS	JJS	_	21	DEP	_	_
21	two	_	CD	CD	_	23	NMOD	_	_
22	distinct	_	JJ	JJ	_	23	NMOD	_	_
23	species	_	NNS	NNS	_	18	PMOD	_	_
24	,	_	,	,	_	23	P	_	_
25	one	_	CD	CD	_	26	NMOD	_	_
26	of	_	IN	IN	_	28	SBJ	_	_
27	which	_	WDT	WDT	_	26	PMOD	_	_
28	does	_	VBZ	VBZ	_	23	NMOD	_	_
29	not	_	RB	RB	_	28	VMOD	_	_
30	contain	_	VB	VB	_	28	VC	_	_
31	Pan	_	NN	NN	_	32	NMOD	_	_
32	molecules	_	NNS	NNS	_	30	OBJ	_	_
33	.	_	.	.	_	14	P	_	_

1	Although	_	IN	IN	_	26	ADV	_	_
2	it	_	PRP	PRP	_	3	SBJ	_	_
3	has	_	VBZ	VBZ	_	1	VMOD	_	_
4	been	_	VBN	VBN	_	3	VC	_	_
5	postulated	_	VBN	VBN	_	4	VC	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	pituitary	_	JJ	JJ	_	9	NMOD	_	_
8	endocrine	_	JJ	JJ	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	14	SBJ	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	pancreatic	_	JJ	JJ	_	13	NMOD	_	_
12	endocrine	_	NN	NN	_	13	NMOD	_	_
13	beta-cells	_	NNS	NNS	_	9	COORD	_	_
14	share	_	VBP	VBP	_	6	VMOD	_	_
15	identical	_	JJ	JJ	_	17	NMOD	_	_
16	Pan\/E2A	_	NN	NN	_	17	NMOD	_	_
17	complexes	_	NNS	NNS	_	14	OBJ	_	_
18	,	_	,	,	_	26	P	_	_
19	native-Western	_	JJ	JJ	_	20	NMOD	_	_
20	analyses	_	NNS	NNS	_	26	SBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	pituitary	_	JJ	JJ	_	25	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	endocrine	_	JJ	JJ	_	22	COORD	_	_
25	beta-cells	_	NNS	NNS	_	21	PMOD	_	_
26	detect	_	VBP	VBP	_	0	ROOT-S	_	_
27	Pan	_	NN	NN	_	28	NMOD	_	_
28	proteins	_	NNS	NNS	_	26	OBJ	_	_
29	in	_	IN	IN	_	26	ADV	_	_
30	distinct	_	JJ	JJ	_	33	NMOD	_	_
31	cell	_	NN	NN	_	33	NMOD	_	_
32	type-specific	_	JJ	JJ	_	31	AMOD	_	_
33	complexes	_	NNS	NNS	_	29	PMOD	_	_
34	.	_	.	.	_	26	P	_	_

1	Interferon	_	NN	NN	_	2	NMOD	_	_
2	alpha	_	NN	NN	_	4	SBJ	_	_
3	selectively	_	RB	RB	_	4	ADV	_	_
4	affects	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	expression	_	NN	NN	_	4	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	13	NMOD	_	_
8	human	_	JJ	JJ	_	13	NMOD	_	_
9	myeloid	_	JJ	JJ	_	13	NMOD	_	_
10	cell	_	NN	NN	_	13	NMOD	_	_
11	nuclear	_	JJ	JJ	_	13	NMOD	_	_
12	differentiation	_	NN	NN	_	13	NMOD	_	_
13	antigen	_	NN	NN	_	6	PMOD	_	_
14	in	_	IN	IN	_	5	NMOD	_	_
15	late	_	JJ	JJ	_	17	NMOD	_	_
16	stage	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	14	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	25	NMOD	_	_
20	monocytic	_	JJ	JJ	_	25	NMOD	_	_
21	but	_	CC	CC	_	25	CC	_	_
22	not	_	RB	RB	_	21	COORD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	granulocytic	_	JJ	JJ	_	25	NMOD	_	_
25	lineage	_	NN	NN	_	18	PMOD	_	_
26	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	7	NMOD	_	_
2	human	_	JJ	JJ	_	7	NMOD	_	_
3	myeloid	_	JJ	JJ	_	7	NMOD	_	_
4	cell	_	NN	NN	_	7	NMOD	_	_
5	nuclear	_	JJ	JJ	_	7	NMOD	_	_
6	differentiation	_	NN	NN	_	7	NMOD	_	_
7	antigen	_	NN	NN	_	11	SBJ	_	_
8	(	_	(	(	_	9	P	_	_
9	MNDA	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	expressed	_	VBN	VBN	_	11	VC	_	_
13	constitutively	_	RB	RB	_	12	ADV	_	_
14	in	_	IN	IN	_	12	ADV	_	_
15	cells	_	NNS	NNS	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	myeloid	_	JJ	JJ	_	19	NMOD	_	_
19	lineage	_	NN	NN	_	16	PMOD	_	_
20	,	_	,	,	_	12	P	_	_
21	appearing	_	VBG	VBG	_	12	OBJ	_	_
22	in	_	IN	IN	_	21	ADV	_	_
23	myeloblast	_	JJ	JJ	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	some	_	DT	DT	_	27	NMOD	_	_
27	cases	_	NNS	NNS	_	25	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	acute	_	JJ	JJ	_	31	NMOD	_	_
30	myeloid	_	JJ	JJ	_	31	NMOD	_	_
31	leukemia	_	NN	NN	_	28	PMOD	_	_
32	and	_	CC	CC	_	21	CC	_	_
33	consistently	_	RB	RB	_	34	TMP	_	_
34	being	_	VBG	VBG	_	21	COORD	_	_
35	detected	_	VBN	VBN	_	34	VC	_	_
36	in	_	IN	IN	_	35	ADV	_	_
37	promyelocyte	_	JJ	JJ	_	39	NMOD	_	_
38	stage	_	NN	NN	_	39	NMOD	_	_
39	cells	_	NNS	NNS	_	36	PMOD	_	_
40	as	_	RB	RB	_	36	CC	_	_
41	well	_	RB	RB	_	40	DEP	_	_
42	as	_	IN	IN	_	40	DEP	_	_
43	in	_	IN	IN	_	36	COORD	_	_
44	all	_	DT	DT	_	47	NMOD	_	_
45	later	_	JJR	JJR	_	47	NMOD	_	_
46	stage	_	NN	NN	_	47	NMOD	_	_
47	cells	_	NNS	NNS	_	43	PMOD	_	_
48	including	_	VBG	VBG	_	47	NMOD	_	_
49	peripheral	_	JJ	JJ	_	51	NMOD	_	_
50	blood	_	NN	NN	_	51	NMOD	_	_
51	monocytes	_	NNS	NNS	_	48	PMOD	_	_
52	and	_	CC	CC	_	51	CC	_	_
53	granulocytes	_	NNS	NNS	_	51	COORD	_	_
54	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	human	_	JJ	JJ	_	6	NMOD	_	_
3	myeloid	_	JJ	JJ	_	6	NMOD	_	_
4	leukemia	_	NN	NN	_	6	NMOD	_	_
5	cell	_	NN	NN	_	6	NMOD	_	_
6	lines	_	NNS	NNS	_	15	SBJ	_	_
7	,	_	,	,	_	6	P	_	_
8	HL-60	_	NN	NN	_	6	NMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	U937	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	8	P	_	_
12	and	_	CC	CC	_	8	CC	_	_
13	THP-1	_	NN	NN	_	8	COORD	_	_
14	,	_	,	,	_	6	P	_	_
15	express	_	VBP	VBP	_	0	ROOT-S	_	_
16	similar	_	JJ	JJ	_	17	NMOD	_	_
17	levels	_	NNS	NNS	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	immunochemically	_	RB	RB	_	20	AMOD	_	_
20	detectable	_	JJ	JJ	_	21	NMOD	_	_
21	MNDA	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	15	P	_	_

1	Although	_	IN	IN	_	15	ADV	_	_
2	,	_	,	,	_	1	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	level	_	NN	NN	_	11	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	MNDA	_	NN	NN	_	7	NMOD	_	_
7	mRNA	_	NN	NN	_	5	PMOD	_	_
8	in	_	IN	IN	_	4	NMOD	_	_
9	primary	_	JJ	JJ	_	10	NMOD	_	_
10	monocytes	_	NNS	NNS	_	8	PMOD	_	_
11	is	_	VBZ	VBZ	_	1	VMOD	_	_
12	very	_	RB	RB	_	13	AMOD	_	_
13	low	_	JJ	JJ	_	11	PRD	_	_
14	it	_	PRP	PRP	_	15	SBJ	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	up-regulated	_	VBN	VBN	_	15	VC	_	_
17	at	_	IN	IN	_	16	TMP	_	_
18	6	_	CD	CD	_	19	NMOD	_	_
19	h	_	NN	NN	_	17	PMOD	_	_
20	following	_	VBG	VBG	_	19	TMP	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	addition	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	interferon	_	NN	NN	_	25	NMOD	_	_
25	alpha	_	NN	NN	_	23	PMOD	_	_
26	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	interferon	_	NN	NN	_	5	NMOD	_	_
5	alpha	_	NN	NN	_	3	PMOD	_	_
6	on	_	IN	IN	_	2	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	MNDA	_	NN	NN	_	9	NMOD	_	_
9	mRNA	_	NN	NN	_	6	PMOD	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	also	_	RB	RB	_	12	ADV	_	_
12	observed	_	VBN	VBN	_	10	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	lines	_	NNS	NNS	_	13	PMOD	_	_
17	HL-60	_	NN	NN	_	16	NMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	U937	_	NN	NN	_	17	COORD	_	_
20	,	_	,	,	_	17	P	_	_
21	and	_	CC	CC	_	17	CC	_	_
22	THP-1	_	NN	NN	_	17	COORD	_	_
23	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	MNDA	_	NN	NN	_	4	NMOD	_	_
3	mRNA	_	NN	NN	_	4	NMOD	_	_
4	level	_	NN	NN	_	8	SBJ	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	primary	_	JJ	JJ	_	7	NMOD	_	_
7	granulocytes	_	NNS	NNS	_	5	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	unaffected	_	JJ	JJ	_	8	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	addition	_	NN	NN	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	interferon	_	NN	NN	_	14	NMOD	_	_
14	alpha	_	NN	NN	_	12	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	other	_	JJ	JJ	_	17	NMOD	_	_
17	agents	_	NNS	NNS	_	14	COORD	_	_
18	including	_	VBG	VBG	_	17	NMOD	_	_
19	interferon	_	NN	NN	_	20	NMOD	_	_
20	gamma	_	NN	NN	_	18	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	endotoxin	_	NN	NN	_	20	COORD	_	_
23	,	_	,	,	_	20	P	_	_
24	poly-LRB-I-RRB-.poly-LRB-C-RRB-	_	NN	NN	_	20	COORD	_	_
25	,	_	,	,	_	20	P	_	_
26	and	_	CC	CC	_	20	CC	_	_
27	FMLP	_	NN	NN	_	20	COORD	_	_
28	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	MNDA	_	NN	NN	_	4	NMOD	_	_
3	mRNA	_	NN	NN	_	4	NMOD	_	_
4	level	_	NN	NN	_	10	SBJ	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	myeloid	_	JJ	JJ	_	9	NMOD	_	_
8	cell	_	NN	NN	_	9	NMOD	_	_
9	lines	_	NNS	NNS	_	5	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	also	_	RB	RB	_	10	VC	_	_
12	unaffected	_	JJ	JJ	_	11	VMOD	_	_
13	by	_	IN	IN	_	11	LGS	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	latter	_	JJ	JJ	_	17	NMOD	_	_
16	four	_	CD	CD	_	17	NMOD	_	_
17	agents	_	NNS	NNS	_	13	PMOD	_	_
18	.	_	.	.	_	10	P	_	_

1	Induction	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	differentiation	_	NN	NN	_	2	PMOD	_	_
4	in	_	IN	IN	_	1	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	myeloid	_	JJ	JJ	_	8	NMOD	_	_
7	cell	_	NN	NN	_	8	NMOD	_	_
8	lines	_	NNS	NNS	_	4	PMOD	_	_
9	with	_	IN	IN	_	1	NMOD	_	_
10	phorbol	_	NN	NN	_	11	NMOD	_	_
11	ester	_	NN	NN	_	9	PMOD	_	_
12	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	monocyte	_	NN	NN	_	14	NMOD	_	_
14	differentiation	_	NN	NN	_	12	OBJ	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	was	_	VBD	VBD	_	14	NMOD	_	_
17	accompanied	_	VBN	VBN	_	16	VC	_	_
18	by	_	IN	IN	_	17	LGS	_	_
19	a	_	DT	DT	_	20	NMOD	_	_
20	decrease	_	NN	NN	_	18	PMOD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	MNDA	_	NN	NN	_	24	NMOD	_	_
23	mRNA	_	NN	NN	_	24	NMOD	_	_
24	level	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	12	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	reduced	_	JJ	JJ	_	3	NMOD	_	_
3	level	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	mRNA	_	NN	NN	_	4	PMOD	_	_
6	could	_	MD	MD	_	0	ROOT-S	_	_
7	then	_	RB	RB	_	6	TMP	_	_
8	be	_	VB	VB	_	6	VC	_	_
9	elevated	_	JJ	JJ	_	8	VC	_	_
10	with	_	IN	IN	_	9	ADV	_	_
11	subsequent	_	JJ	JJ	_	14	NMOD	_	_
12	interferon	_	NN	NN	_	14	NMOD	_	_
13	alpha	_	NN	NN	_	14	NMOD	_	_
14	treatment	_	NN	NN	_	10	PMOD	_	_
15	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effects	_	NNS	NNS	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	phorbol	_	NN	NN	_	5	NMOD	_	_
5	ester	_	NN	NN	_	3	PMOD	_	_
6	on	_	IN	IN	_	2	NMOD	_	_
7	MNDA	_	NN	NN	_	8	NMOD	_	_
8	mRNA	_	NN	NN	_	6	PMOD	_	_
9	appeared	_	VBD	VBD	_	0	ROOT-S	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	be	_	VB	VB	_	9	OBJ	_	_
12	associated	_	VBN	VBN	_	11	VC	_	_
13	with	_	IN	IN	_	12	ADV	_	_
14	induced	_	VBN	VBN	_	15	NMOD	_	_
15	differentiation	_	NN	NN	_	13	PMOD	_	_
16	since	_	IN	IN	_	9	ADV	_	_
17	inhibiting	_	VBG	VBG	_	20	SBJ	_	_
18	cell	_	NN	NN	_	19	NMOD	_	_
19	proliferation	_	NN	NN	_	17	OBJ	_	_
20	did	_	VBD	VBD	_	16	VMOD	_	_
21	not	_	RB	RB	_	20	VMOD	_	_
22	alter	_	VB	VB	_	20	VC	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	level	_	NN	NN	_	22	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	MNDA	_	NN	NN	_	27	NMOD	_	_
27	mRNA	_	NN	NN	_	25	PMOD	_	_
28	and	_	CC	CC	_	20	CC	_	_
29	cell	_	NN	NN	_	31	NMOD	_	_
30	cycle	_	NN	NN	_	31	NMOD	_	_
31	variation	_	NN	NN	_	36	SBJ	_	_
32	in	_	IN	IN	_	31	NMOD	_	_
33	MNDA	_	NN	NN	_	35	NMOD	_	_
34	mRNA	_	NN	NN	_	35	NMOD	_	_
35	levels	_	NNS	NNS	_	32	PMOD	_	_
36	were	_	VBD	VBD	_	20	COORD	_	_
37	not	_	RB	RB	_	36	VMOD	_	_
38	observed	_	VBN	VBN	_	36	VC	_	_
39	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	ability	_	NN	NN	_	17	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	interferon	_	NN	NN	_	5	NMOD	_	_
5	alpha	_	NN	NN	_	3	PMOD	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	up-regulate	_	VB	VB	_	2	NMOD	_	_
8	MNDA	_	NN	NN	_	9	NMOD	_	_
9	mRNA	_	NN	NN	_	7	OBJ	_	_
10	in	_	IN	IN	_	7	ADV	_	_
11	phorbol	_	NN	NN	_	12	NMOD	_	_
12	ester	_	NN	NN	_	13	AMOD	_	_
13	treated	_	JJ	JJ	_	16	NMOD	_	_
14	myeloid	_	JJ	JJ	_	16	NMOD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	lines	_	NNS	NNS	_	10	PMOD	_	_
17	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	consistent	_	JJ	JJ	_	17	PRD	_	_
19	with	_	IN	IN	_	18	AMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	observations	_	NNS	NNS	_	19	PMOD	_	_
22	made	_	VBN	VBN	_	21	NMOD	_	_
23	in	_	IN	IN	_	22	ADV	_	_
24	primary	_	JJ	JJ	_	25	NMOD	_	_
25	monocytes	_	NNS	NNS	_	23	PMOD	_	_
26	.	_	.	.	_	17	P	_	_

1	(	_	(	(	_	3	P	_	_
2	ABSTRACT	_	NN	NN	_	3	SBJ	_	_
3	TRUNCATED	_	VBN	VBN	_	0	ROOT-S	_	_
4	AT	_	IN	IN	_	3	ADV	_	_
5	250	_	CD	CD	_	6	NMOD	_	_
6	WORDS	_	NNS	NNS	_	4	PMOD	_	_
7	)	_	)	)	_	3	P	_	_

1	Calcineurin	_	NN	NN	_	2	SBJ	_	_
2	potentiates	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	activation	_	NN	NN	_	2	OBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	granulocyte-macrophage	_	JJ	JJ	_	9	NMOD	_	_
7	colony-stimulating	_	JJ	JJ	_	9	NMOD	_	_
8	factor	_	NN	NN	_	9	NMOD	_	_
9	gene	_	NN	NN	_	4	PMOD	_	_
10	in	_	IN	IN	_	3	NMOD	_	_
11	T	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	:	_	:	:	_	2	P	_	_
14	involvement	_	NN	NN	_	2	VMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	conserved	_	VBN	VBN	_	19	NMOD	_	_
18	lymphokine	_	NN	NN	_	19	NMOD	_	_
19	element	_	NN	NN	_	15	PMOD	_	_
20	0	_	CD	CD	_	19	NMOD	_	_
21	.	_	.	.	_	14	P	_	_

1	Granulocyte-macrophage	_	JJ	JJ	_	3	NMOD	_	_
2	colony-stimulating	_	JJ	JJ	_	3	NMOD	_	_
3	factor	_	NN	NN	_	12	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	GM-CSF	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	and	_	CC	CC	_	3	CC	_	_
8	interleukin-2	_	NN	NN	_	3	COORD	_	_
9	(	_	(	(	_	10	P	_	_
10	IL-2	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	are	_	VBP	VBP	_	0	ROOT-S	_	_
13	produced	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	ADV	_	_
15	stimulation	_	NN	NN	_	14	PMOD	_	_
16	with	_	IN	IN	_	15	NMOD	_	_
17	phorbol-12-myristate	_	NN	NN	_	18	NMOD	_	_
18	acetate	_	NN	NN	_	16	PMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	PMA	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	and	_	CC	CC	_	18	CC	_	_
23	calcium	_	NN	NN	_	24	NMOD	_	_
24	ionophore	_	NN	NN	_	18	COORD	_	_
25	(	_	(	(	_	26	P	_	_
26	A23187	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	in	_	IN	IN	_	15	NMOD	_	_
29	human	_	JJ	JJ	_	34	NMOD	_	_
30	T	_	NN	NN	_	34	NMOD	_	_
31	cell	_	NN	NN	_	34	NMOD	_	_
32	leukemia	_	NN	NN	_	34	NMOD	_	_
33	Jurkat	_	NN	NN	_	34	NMOD	_	_
34	cells	_	NNS	NNS	_	28	PMOD	_	_
35	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	expression	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	GM-CSF	_	NN	NN	_	3	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	IL-2	_	NN	NN	_	4	COORD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	inhibited	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	immunosuppressive	_	JJ	JJ	_	11	NMOD	_	_
11	drugs	_	NNS	NNS	_	9	PMOD	_	_
12	such	_	JJ	JJ	_	13	DEP	_	_
13	as	_	IN	IN	_	11	NMOD	_	_
14	cyclosporin	_	NN	NN	_	15	NMOD	_	_
15	A	_	NN	NN	_	13	PMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	CsA	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	FK506	_	NN	NN	_	15	COORD	_	_
21	.	_	.	.	_	7	P	_	_

1	Earlier	_	JJR	JJR	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	8	SBJ	_	_
3	on	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	IL-2	_	NN	NN	_	7	NMOD	_	_
6	gene	_	NN	NN	_	7	NMOD	_	_
7	expression	_	NN	NN	_	3	PMOD	_	_
8	showed	_	VBD	VBD	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	overexpression	_	NN	NN	_	22	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	calcineurin	_	NN	NN	_	11	PMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	CN	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	,	_	,	,	_	12	P	_	_
17	a	_	DT	DT	_	20	NMOD	_	_
18	Ca2+\/calmodulin-dependent	_	JJ	JJ	_	20	NMOD	_	_
19	protein	_	NN	NN	_	20	NMOD	_	_
20	phosphatase	_	NN	NN	_	12	NMOD	_	_
21	,	_	,	,	_	12	P	_	_
22	can	_	MD	MD	_	9	VMOD	_	_
23	stimulate	_	VB	VB	_	22	VC	_	_
24	transcription	_	NN	NN	_	23	OBJ	_	_
25	from	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	IL-2	_	NN	NN	_	28	NMOD	_	_
28	promoter	_	NN	NN	_	25	PMOD	_	_
29	through	_	IN	IN	_	23	ADV	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	NF-AT-binding	_	JJ	JJ	_	32	NMOD	_	_
32	site	_	NN	NN	_	29	PMOD	_	_
33	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	obtained	_	VBD	VBD	_	0	ROOT-S	_	_
7	evidence	_	NN	NN	_	6	OBJ	_	_
8	that	_	IN	IN	_	7	NMOD	_	_
9	transfection	_	NN	NN	_	27	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	cDNAs	_	NNS	NNS	_	10	PMOD	_	_
13	for	_	IN	IN	_	12	NMOD	_	_
14	CN	_	NN	NN	_	15	NMOD	_	_
15	A	_	NN	NN	_	25	NMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	catalytic	_	JJ	JJ	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	CN	_	NN	NN	_	21	NMOD	_	_
21	B	_	NN	NN	_	15	COORD	_	_
22	(	_	(	(	_	23	P	_	_
23	regulatory	_	JJ	JJ	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	subunits	_	NNS	NNS	_	13	PMOD	_	_
26	also	_	RB	RB	_	27	ADV	_	_
27	augments	_	VBZ	VBZ	_	8	VMOD	_	_
28	transcription	_	NN	NN	_	27	OBJ	_	_
29	from	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	GM-CSF	_	NN	NN	_	32	NMOD	_	_
32	promoter	_	NN	NN	_	29	PMOD	_	_
33	and	_	CC	CC	_	27	CC	_	_
34	recovers	_	VBZ	VBZ	_	27	COORD	_	_
35	the	_	DT	DT	_	36	NMOD	_	_
36	transcription	_	NN	NN	_	34	OBJ	_	_
37	inhibited	_	VBN	VBN	_	36	NMOD	_	_
38	by	_	IN	IN	_	37	LGS	_	_
39	CsA	_	NN	NN	_	38	PMOD	_	_
40	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	constitutively	_	RB	RB	_	3	AMOD	_	_
3	active	_	JJ	JJ	_	4	NMOD	_	_
4	type	_	NN	NN	_	19	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	CN	_	NN	NN	_	9	NMOD	_	_
8	A	_	NN	NN	_	9	NMOD	_	_
9	subunit	_	NN	NN	_	5	PMOD	_	_
10	,	_	,	,	_	4	P	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	lacks	_	VBZ	VBZ	_	4	NMOD	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	auto-inhibitory	_	JJ	JJ	_	17	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	calmodulin-binding	_	JJ	JJ	_	14	COORD	_	_
17	domains	_	NNS	NNS	_	12	OBJ	_	_
18	,	_	,	,	_	4	P	_	_
19	acts	_	VBZ	VBZ	_	0	ROOT-S	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	synergy	_	NN	NN	_	20	PMOD	_	_
22	with	_	IN	IN	_	21	NMOD	_	_
23	PMA	_	NN	NN	_	22	PMOD	_	_
24	to	_	TO	TO	_	25	VMOD	_	_
25	activate	_	VB	VB	_	19	OBJ	_	_
26	transcription	_	NN	NN	_	25	OBJ	_	_
27	from	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	GM-CSF	_	NN	NN	_	30	NMOD	_	_
30	promoter	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	19	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	found	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	active	_	JJ	JJ	_	7	NMOD	_	_
7	CN	_	NN	NN	_	9	SBJ	_	_
8	partially	_	RB	RB	_	9	ADV	_	_
9	replaces	_	VBZ	VBZ	_	4	VMOD	_	_
10	calcium	_	NN	NN	_	11	NMOD	_	_
11	ionophore	_	NN	NN	_	9	IOBJ	_	_
12	in	_	IN	IN	_	9	ADV	_	_
13	synergy	_	NN	NN	_	12	PMOD	_	_
14	with	_	IN	IN	_	13	NMOD	_	_
15	PMA	_	NN	NN	_	14	PMOD	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	induce	_	VB	VB	_	9	OBJ	_	_
18	expression	_	NN	NN	_	17	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	endogenous	_	JJ	JJ	_	21	NMOD	_	_
21	GM-CSF	_	NN	NN	_	19	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	IL-2	_	NN	NN	_	21	COORD	_	_
24	.	_	.	.	_	3	P	_	_

1	By	_	IN	IN	_	12	ADV	_	_
2	multimerizing	_	VBG	VBG	_	1	PMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	regulatory	_	JJ	JJ	_	5	NMOD	_	_
5	elements	_	NNS	NNS	_	2	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	GM-CSF	_	NN	NN	_	9	NMOD	_	_
9	promoter	_	NN	NN	_	6	PMOD	_	_
10	,	_	,	,	_	12	P	_	_
11	we	_	PRP	PRP	_	12	SBJ	_	_
12	found	_	VBD	VBD	_	0	ROOT-S	_	_
13	that	_	IN	IN	_	12	OBJ	_	_
14	one	_	CD	CD	_	23	SBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	target	_	NN	NN	_	18	NMOD	_	_
18	sites	_	NNS	NNS	_	15	PMOD	_	_
19	for	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	CN	_	NN	NN	_	22	NMOD	_	_
22	action	_	NN	NN	_	19	PMOD	_	_
23	is	_	VBZ	VBZ	_	13	VMOD	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	conserved	_	VBN	VBN	_	27	NMOD	_	_
26	lymphokine	_	NN	NN	_	27	NMOD	_	_
27	element	_	NN	NN	_	23	PRD	_	_
28	0	_	CD	CD	_	27	NMOD	_	_
29	(	_	(	(	_	30	P	_	_
30	CLE0	_	NN	NN	_	27	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	,	_	,	,	_	27	P	_	_
33	located	_	JJ	JJ	_	27	NMOD	_	_
34	at	_	IN	IN	_	33	AMOD	_	_
35	positions	_	NNS	NNS	_	34	PMOD	_	_
36	between	_	IN	IN	_	35	NMOD	_	_
37	-54	_	CD	CD	_	36	PMOD	_	_
38	and	_	CC	CC	_	37	CC	_	_
39	-40	_	CD	CD	_	37	COORD	_	_
40	.	_	.	.	_	12	P	_	_

1	Mobility	_	NN	NN	_	3	NMOD	_	_
2	shift	_	NN	NN	_	3	NMOD	_	_
3	assays	_	NNS	NNS	_	4	SBJ	_	_
4	showed	_	VBD	VBD	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	CLE0	_	NN	NN	_	8	NMOD	_	_
8	sequence	_	NN	NN	_	9	SBJ	_	_
9	has	_	VBZ	VBZ	_	5	VMOD	_	_
10	an	_	DT	DT	_	12	NMOD	_	_
11	AP1-binding	_	JJ	JJ	_	12	NMOD	_	_
12	site	_	NN	NN	_	9	OBJ	_	_
13	and	_	CC	CC	_	9	CC	_	_
14	is	_	VBZ	VBZ	_	9	COORD	_	_
15	associated	_	VBN	VBN	_	14	VC	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	an	_	DT	DT	_	19	NMOD	_	_
18	NF-AT-like	_	JJ	JJ	_	19	NMOD	_	_
19	factor	_	NN	NN	_	16	PMOD	_	_
20	,	_	,	,	_	19	P	_	_
21	termed	_	VBN	VBN	_	19	NMOD	_	_
22	NF-CLE0	_	NN	NN	_	23	NMOD	_	_
23	gamma	_	NN	NN	_	21	OBJ	_	_
24	.	_	.	.	_	4	P	_	_

1	NF-CLE0	_	NN	NN	_	3	NMOD	_	_
2	gamma	_	NN	NN	_	3	NMOD	_	_
3	binding	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	induced	_	VBN	VBN	_	4	VC	_	_
6	by	_	IN	IN	_	5	LGS	_	_
7	PMA\/A23187	_	NN	NN	_	6	PMOD	_	_
8	and	_	CC	CC	_	4	CC	_	_
9	is	_	VBZ	VBZ	_	4	COORD	_	_
10	inhibited	_	VBN	VBN	_	9	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	treatment	_	NN	NN	_	11	PMOD	_	_
13	with	_	IN	IN	_	12	NMOD	_	_
14	CsA	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	CN	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	4	VMOD	_	_
7	involved	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	coordinated	_	VBN	VBN	_	11	NMOD	_	_
11	induction	_	NN	NN	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	GM-CSF	_	NN	NN	_	17	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	IL-2	_	NN	NN	_	14	COORD	_	_
17	genes	_	NNS	NNS	_	12	PMOD	_	_
18	and	_	CC	CC	_	4	CC	_	_
19	that	_	IN	IN	_	4	COORD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	CLE0	_	NN	NN	_	22	NMOD	_	_
22	sequence	_	NN	NN	_	27	SBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	GM-CSF	_	NN	NN	_	26	NMOD	_	_
26	gene	_	NN	NN	_	23	PMOD	_	_
27	is	_	VBZ	VBZ	_	19	VMOD	_	_
28	a	_	DT	DT	_	30	NMOD	_	_
29	functional	_	JJ	JJ	_	30	NMOD	_	_
30	analogue	_	NN	NN	_	27	PRD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	NF-AT-binding	_	JJ	JJ	_	34	NMOD	_	_
34	site	_	NN	NN	_	31	PMOD	_	_
35	in	_	IN	IN	_	34	NMOD	_	_
36	the	_	DT	DT	_	38	NMOD	_	_
37	IL-2	_	NN	NN	_	38	NMOD	_	_
38	promoter	_	NN	NN	_	35	PMOD	_	_
39	,	_	,	,	_	30	P	_	_
40	which	_	WDT	WDT	_	41	SBJ	_	_
41	mediates	_	VBZ	VBZ	_	30	NMOD	_	_
42	signals	_	NNS	NNS	_	41	OBJ	_	_
43	downstream	_	RB	RB	_	42	NMOD	_	_
44	of	_	IN	IN	_	43	AMOD	_	_
45	T	_	NN	NN	_	47	NMOD	_	_
46	cell	_	NN	NN	_	47	NMOD	_	_
47	activation	_	NN	NN	_	44	PMOD	_	_
48	.	_	.	.	_	3	P	_	_

1	Glucocorticoid-mediated	_	JJ	JJ	_	2	NMOD	_	_
2	inhibition	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	interleukin-2	_	NN	NN	_	10	NMOD	_	_
5	receptor	_	NN	NN	_	10	NMOD	_	_
6	alpha	_	NN	NN	_	10	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	-beta	_	NN	NN	_	6	COORD	_	_
9	subunit	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	3	PMOD	_	_
11	by	_	IN	IN	_	10	NMOD	_	_
12	human	_	JJ	JJ	_	14	NMOD	_	_
13	T	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	11	PMOD	_	_
15	.	_	.	.	_	2	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	determine	_	VB	VB	_	35	VC	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	mechanism	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	glucocorticoid	_	NN	NN	_	8	AMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	GC	_	NN	NN	_	11	NMOD	_	_
9	)	_	)	)	_	8	P	_	_
10	-mediated	_	JJ	JJ	_	8	AMOD	_	_
11	inhibition	_	NN	NN	_	5	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	T	_	NN	NN	_	15	NMOD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	functions	_	NNS	NNS	_	12	PMOD	_	_
16	,	_	,	,	_	35	P	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	effect	_	NN	NN	_	35	SBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	dexamethasone	_	NN	NN	_	19	PMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	DM	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	on	_	IN	IN	_	18	NMOD	_	_
25	T	_	NN	NN	_	27	NMOD	_	_
26	cell	_	NN	NN	_	27	NMOD	_	_
27	proliferation	_	NN	NN	_	24	PMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	interleukin-2	_	NN	NN	_	30	NMOD	_	_
30	receptor	_	NN	NN	_	34	NMOD	_	_
31	(	_	(	(	_	32	P	_	_
32	IL-2R	_	NN	NN	_	30	PRN	_	_
33	)	_	)	)	_	32	P	_	_
34	generation	_	NN	NN	_	27	COORD	_	_
35	were	_	VBD	VBD	_	0	ROOT-S	_	_
36	studied	_	VBN	VBN	_	35	VC	_	_
37	.	_	.	.	_	35	P	_	_

1	Dexamethasone	_	NN	NN	_	2	SBJ	_	_
2	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
3	IL-2-induced	_	JJ	JJ	_	6	NMOD	_	_
4	T	_	NN	NN	_	6	NMOD	_	_
5	cell	_	NN	NN	_	6	NMOD	_	_
6	proliferation	_	NN	NN	_	2	OBJ	_	_
7	by	_	IN	IN	_	2	ADV	_	_
8	30	_	CD	CD	_	12	NMOD	_	_
9	%	_	NN	NN	_	12	NMOD	_	_
10	-	_	TO	TO	_	12	NMOD	_	_
11	88	_	CD	CD	_	12	NMOD	_	_
12	%	_	NN	NN	_	7	PMOD	_	_
13	,	_	,	,	_	2	P	_	_
14	relative	_	JJ	JJ	_	15	DEP	_	_
15	to	_	TO	TO	_	2	ADV	_	_
16	its	_	PRP$	PRP$	_	17	NMOD	_	_
17	concentration	_	NN	NN	_	15	PMOD	_	_
18	within	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	cultures	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	27	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	DM	_	NN	NN	_	3	PMOD	_	_
5	on	_	IN	IN	_	2	NMOD	_	_
6	expression	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	IL-2R	_	NN	NN	_	9	NMOD	_	_
9	alpha	_	NN	NN	_	22	NMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	Tac	_	NN	NN	_	9	PRN	_	_
12	,	_	,	,	_	11	P	_	_
13	p55	_	NN	NN	_	11	NMOD	_	_
14	,	_	,	,	_	11	P	_	_
15	CD25	_	NN	NN	_	11	NMOD	_	_
16	)	_	)	)	_	11	P	_	_
17	and	_	CC	CC	_	9	CC	_	_
18	beta	_	NN	NN	_	9	COORD	_	_
19	(	_	(	(	_	20	P	_	_
20	p75	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	genes	_	NNS	NNS	_	7	PMOD	_	_
23	in	_	IN	IN	_	6	NMOD	_	_
24	activated	_	VBN	VBN	_	26	NMOD	_	_
25	T	_	NN	NN	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	23	PMOD	_	_
27	was	_	VBD	VBD	_	0	ROOT-S	_	_
28	examined	_	VBN	VBN	_	27	VC	_	_
29	next	_	RB	RB	_	28	TMP	_	_
30	.	_	.	.	_	27	P	_	_

1	In	_	IN	IN	_	25	ADV	_	_
2	T	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	stimulated	_	VBN	VBN	_	3	NMOD	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	purified	_	VBN	VBN	_	7	NMOD	_	_
7	phytohemagglutinin	_	NN	NN	_	5	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	PHA-p	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	4	_	CD	CD	_	15	NMOD	_	_
13	beta-phorbol	_	NN	NN	_	15	NMOD	_	_
14	12-myristate	_	NN	NN	_	15	NMOD	_	_
15	13-acetate	_	NN	NN	_	7	COORD	_	_
16	(	_	(	(	_	17	P	_	_
17	PMA	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	addition	_	NN	NN	_	25	SBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	DM	_	NN	NN	_	20	PMOD	_	_
22	to	_	TO	TO	_	19	NMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	cultures	_	NNS	NNS	_	22	PMOD	_	_
25	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
26	in	_	IN	IN	_	25	ADV	_	_
27	a	_	DT	DT	_	30	NMOD	_	_
28	60	_	CD	CD	_	30	NMOD	_	_
29	%	_	NN	NN	_	30	NMOD	_	_
30	reduction	_	NN	NN	_	26	PMOD	_	_
31	in	_	IN	IN	_	30	NMOD	_	_
32	IL-2R	_	NN	NN	_	33	NMOD	_	_
33	alpha	_	NN	NN	_	31	PMOD	_	_
34	and	_	CC	CC	_	30	CC	_	_
35	a	_	DT	DT	_	38	NMOD	_	_
36	30	_	CD	CD	_	38	NMOD	_	_
37	%	_	NN	NN	_	38	NMOD	_	_
38	reduction	_	NN	NN	_	30	COORD	_	_
39	in	_	IN	IN	_	38	NMOD	_	_
40	IL-2R	_	NN	NN	_	43	NMOD	_	_
41	beta	_	NN	NN	_	43	NMOD	_	_
42	membrane	_	NN	NN	_	43	NMOD	_	_
43	expression	_	NN	NN	_	39	PMOD	_	_
44	compared	_	VBN	VBN	_	25	OBJ	_	_
45	to	_	TO	TO	_	44	ADV	_	_
46	T	_	NN	NN	_	47	NMOD	_	_
47	cells	_	NNS	NNS	_	45	PMOD	_	_
48	cultured	_	VBN	VBN	_	47	NMOD	_	_
49	in	_	IN	IN	_	48	ADV	_	_
50	the	_	DT	DT	_	49	DEP	_	_
51	absence	_	NN	NN	_	49	DEP	_	_
52	of	_	IN	IN	_	49	DEP	_	_
53	DM	_	NN	NN	_	49	PMOD	_	_
54	(	_	(	(	_	57	P	_	_
55	p	_	NN	NN	_	57	SBJ	_	_
56	&lt;	_	JJR	JJR	_	57	DEP	_	_
57	0.01	_	CD	CD	_	48	PRN	_	_
58	)	_	)	)	_	57	P	_	_
59	.	_	.	.	_	25	P	_	_

1	Inhibition	_	NN	NN	_	14	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	membrane	_	NN	NN	_	9	NMOD	_	_
4	IL-2R	_	NN	NN	_	5	NMOD	_	_
5	alpha	_	NN	NN	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	IL-2R	_	NN	NN	_	8	NMOD	_	_
8	beta	_	NN	NN	_	5	COORD	_	_
9	expression	_	NN	NN	_	2	PMOD	_	_
10	by	_	IN	IN	_	1	NMOD	_	_
11	10-LRB--6-RRB-	_	CD	CD	_	12	AMOD	_	_
12	M	_	NN	NN	_	13	NMOD	_	_
13	DM	_	NN	NN	_	10	PMOD	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	partially	_	RB	RB	_	16	AMOD	_	_
16	reversible	_	JJ	JJ	_	14	PRD	_	_
17	by	_	IN	IN	_	16	AMOD	_	_
18	recombinant	_	JJ	JJ	_	20	NMOD	_	_
19	human	_	JJ	JJ	_	20	NMOD	_	_
20	IL-2	_	NN	NN	_	17	PMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	rhIL-2	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	.	_	.	.	_	14	P	_	_

1	By	_	IN	IN	_	7	ADV	_	_
2	Northern	_	JJ	JJ	_	4	NMOD	_	_
3	blot	_	NN	NN	_	4	NMOD	_	_
4	analysis	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	DM	_	NN	NN	_	7	SBJ	_	_
7	caused	_	VBD	VBD	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	comparable	_	JJ	JJ	_	10	NMOD	_	_
10	decrease	_	NN	NN	_	7	OBJ	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	IL-2R	_	NN	NN	_	13	NMOD	_	_
13	alpha	_	NN	NN	_	11	PMOD	_	_
14	and	_	CC	CC	_	11	CC	_	_
15	in	_	IN	IN	_	11	COORD	_	_
16	IL-2R	_	NN	NN	_	17	NMOD	_	_
17	beta	_	NN	NN	_	15	PMOD	_	_
18	mRNA	_	NN	NN	_	19	NMOD	_	_
19	levels	_	NNS	NNS	_	13	NMOD	_	_
20	to	_	TO	TO	_	7	ADV	_	_
21	membrane	_	NN	NN	_	23	NMOD	_	_
22	receptor	_	NN	NN	_	23	NMOD	_	_
23	expression	_	NN	NN	_	20	PMOD	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	mitogen-stimulated	_	JJ	JJ	_	27	NMOD	_	_
26	T	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	24	PMOD	_	_
28	.	_	.	.	_	7	P	_	_

1	By	_	IN	IN	_	8	ADV	_	_
2	in	_	FW	FW	_	3	AMOD	_	_
3	vitro	_	FW	FW	_	5	NMOD	_	_
4	transcription	_	NN	NN	_	5	NMOD	_	_
5	assays	_	NNS	NNS	_	1	PMOD	_	_
6	,	_	,	,	_	8	P	_	_
7	DM	_	NN	NN	_	8	SBJ	_	_
8	regulated	_	VBD	VBD	_	0	ROOT-S	_	_
9	IL-2R	_	NN	NN	_	12	NMOD	_	_
10	alpha	_	NN	NN	_	12	NMOD	_	_
11	gene	_	NN	NN	_	12	NMOD	_	_
12	expression	_	NN	NN	_	8	IOBJ	_	_
13	at	_	IN	IN	_	12	NMOD	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	transcriptional	_	JJ	JJ	_	16	NMOD	_	_
16	level	_	NN	NN	_	13	PMOD	_	_
17	while	_	IN	IN	_	8	OBJ	_	_
18	transcription	_	NN	NN	_	23	SBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	IL-2R	_	NN	NN	_	22	NMOD	_	_
21	beta	_	NN	NN	_	22	NMOD	_	_
22	gene	_	NN	NN	_	19	PMOD	_	_
23	was	_	VBD	VBD	_	17	VMOD	_	_
24	unaffected	_	VBN	VBN	_	23	VC	_	_
25	by	_	IN	IN	_	24	LGS	_	_
26	DM	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	mechanism	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	action	_	NN	NN	_	3	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	DM	_	NN	NN	_	5	PMOD	_	_
7	on	_	IN	IN	_	4	NMOD	_	_
8	IL-2R	_	NN	NN	_	10	NMOD	_	_
9	alpha	_	NN	NN	_	10	NMOD	_	_
10	transcription	_	NN	NN	_	7	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	examined	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	ADV	_	_
14	determining	_	VBG	VBG	_	13	PMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	mRNA	_	NN	NN	_	17	NMOD	_	_
17	levels	_	NNS	NNS	_	14	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	p50	_	NN	NN	_	21	NMOD	_	_
21	subunit	_	NN	NN	_	18	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	nuclear	_	JJ	JJ	_	26	NMOD	_	_
24	factor	_	NN	NN	_	26	NMOD	_	_
25	kappa	_	NN	NN	_	26	NMOD	_	_
26	B	_	NN	NN	_	22	PMOD	_	_
27	(	_	(	(	_	29	P	_	_
28	NF-kappa	_	NN	NN	_	29	NMOD	_	_
29	B	_	NN	NN	_	26	PRN	_	_
30	)	_	)	)	_	29	P	_	_
31	,	_	,	,	_	26	P	_	_
32	a	_	DT	DT	_	34	NMOD	_	_
33	transcription	_	NN	NN	_	34	NMOD	_	_
34	factor	_	NN	NN	_	26	NMOD	_	_
35	that	_	WDT	WDT	_	36	SBJ	_	_
36	stimulates	_	VBZ	VBZ	_	34	NMOD	_	_
37	IL-2R	_	NN	NN	_	40	NMOD	_	_
38	alpha	_	NN	NN	_	40	NMOD	_	_
39	gene	_	NN	NN	_	40	NMOD	_	_
40	expression	_	NN	NN	_	36	OBJ	_	_
41	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	10-LRB--6-RRB-	_	CD	CD	_	6	AMOD	_	_
6	M	_	NN	NN	_	7	NMOD	_	_
7	DM	_	NN	NN	_	8	SBJ	_	_
8	increased	_	VBD	VBD	_	4	VMOD	_	_
9	T	_	NN	NN	_	15	NMOD	_	_
10	cell	_	NN	NN	_	15	NMOD	_	_
11	p50	_	NN	NN	_	15	NMOD	_	_
12	NF-kappa	_	NN	NN	_	15	NMOD	_	_
13	B	_	NN	NN	_	15	NMOD	_	_
14	mRNA	_	NN	NN	_	15	NMOD	_	_
15	levels	_	NNS	NNS	_	8	IOBJ	_	_
16	by	_	IN	IN	_	8	ADV	_	_
17	four-fold	_	JJ	JJ	_	16	PMOD	_	_
18	compared	_	VBN	VBN	_	8	OBJ	_	_
19	to	_	TO	TO	_	18	ADV	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	levels	_	NNS	NNS	_	19	PMOD	_	_
22	obtained	_	VBN	VBN	_	21	NMOD	_	_
23	in	_	IN	IN	_	22	ADV	_	_
24	the	_	DT	DT	_	23	DEP	_	_
25	absence	_	NN	NN	_	23	DEP	_	_
26	of	_	IN	IN	_	23	DEP	_	_
27	DM	_	NN	NN	_	23	PMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	Further	_	RB	RB	_	20	ADV	_	_
2	,	_	,	,	_	20	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	level	_	NN	NN	_	20	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	proteins	_	NNS	NNS	_	5	PMOD	_	_
8	capable	_	JJ	JJ	_	7	NMOD	_	_
9	of	_	IN	IN	_	8	AMOD	_	_
10	binding	_	VBG	VBG	_	9	PMOD	_	_
11	to	_	TO	TO	_	10	ADV	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	NF-kappa	_	NN	NN	_	15	NMOD	_	_
14	B	_	NN	NN	_	15	NMOD	_	_
15	sites	_	NNS	NNS	_	11	PMOD	_	_
16	in	_	IN	IN	_	10	ADV	_	_
17	activated	_	VBN	VBN	_	19	NMOD	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	PMOD	_	_
20	increased	_	VBD	VBD	_	0	ROOT-S	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	response	_	NN	NN	_	21	DEP	_	_
23	to	_	TO	TO	_	21	DEP	_	_
24	DM	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	20	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	sum	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	DM	_	NN	NN	_	5	SBJ	_	_
5	regulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	T	_	NN	NN	_	9	NMOD	_	_
7	cell	_	NN	NN	_	9	NMOD	_	_
8	membrane	_	NN	NN	_	9	NMOD	_	_
9	expression	_	NN	NN	_	5	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	IL-2R	_	NN	NN	_	10	PMOD	_	_
12	by	_	IN	IN	_	5	ADV	_	_
13	more	_	JJR	JJR	_	15	DEP	_	_
14	than	_	IN	IN	_	15	DEP	_	_
15	one	_	CD	CD	_	17	NMOD	_	_
16	molecular	_	JJ	JJ	_	17	NMOD	_	_
17	mechanism	_	NN	NN	_	12	PMOD	_	_
18	.	_	.	.	_	5	P	_	_

1	Increased	_	VBN	VBN	_	4	NMOD	_	_
2	interleukin	_	NN	NN	_	4	NMOD	_	_
3	2	_	CD	CD	_	4	NMOD	_	_
4	transcription	_	NN	NN	_	0	ROOT-FRAG	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	murine	_	JJ	JJ	_	7	NMOD	_	_
7	lymphocytes	_	NNS	NNS	_	5	PMOD	_	_
8	by	_	IN	IN	_	4	NMOD	_	_
9	ciprofloxacin	_	NN	NN	_	8	PMOD	_	_
10	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	fluoroquinolone	_	JJ	JJ	_	3	NMOD	_	_
3	antibiotic	_	JJ	JJ	_	10	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	ciprofloxacin	_	NN	NN	_	3	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	cipro	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	,	_	,	,	_	3	P	_	_
10	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	hyperproduction	_	NN	NN	_	10	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	interleukin	_	NN	NN	_	12	PMOD	_	_
14	2	_	CD	CD	_	13	NMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	IL-2	_	NN	NN	_	13	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	and	_	CC	CC	_	13	CC	_	_
19	interferon-gamma	_	NN	NN	_	13	COORD	_	_
20	(	_	(	(	_	21	P	_	_
21	IFN-gamma	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	in	_	IN	IN	_	11	NMOD	_	_
24	stimulated	_	VBN	VBN	_	28	NMOD	_	_
25	human	_	JJ	JJ	_	28	NMOD	_	_
26	peripheral	_	JJ	JJ	_	28	NMOD	_	_
27	blood	_	NN	NN	_	28	NMOD	_	_
28	lymphocytes	_	NNS	NNS	_	23	PMOD	_	_
29	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	13	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	investigation	_	NN	NN	_	1	PMOD	_	_
4	an	_	DT	DT	_	12	NMOD	_	_
5	enhanced	_	VBN	VBN	_	12	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	prolonged	_	JJ	JJ	_	5	COORD	_	_
8	IL-2	_	NN	NN	_	12	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	IL-2	_	NN	NN	_	11	NMOD	_	_
11	mRNA	_	NN	NN	_	8	COORD	_	_
12	response	_	NN	NN	_	13	SBJ	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	also	_	RB	RB	_	15	ADV	_	_
15	detected	_	VBN	VBN	_	13	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	both	_	CC	CC	_	16	CC	_	_
18	stimulated	_	VBN	VBN	_	27	NMOD	_	_
19	(	_	(	(	_	18	P	_	_
20	T	_	NN	NN	_	21	NMOD	_	_
21	cell	_	NN	NN	_	18	AMOD	_	_
22	mitogens	_	NNS	NNS	_	21	NMOD	_	_
23	or	_	CC	CC	_	22	CC	_	_
24	alloantigens	_	NNS	NNS	_	22	COORD	_	_
25	)	_	)	)	_	18	P	_	_
26	murine	_	JJ	JJ	_	27	NMOD	_	_
27	splenocytes	_	NNS	NNS	_	16	PMOD	_	_
28	and	_	CC	CC	_	16	CC	_	_
29	in	_	IN	IN	_	16	COORD	_	_
30	the	_	DT	DT	_	36	NMOD	_	_
31	stimulated	_	VBN	VBN	_	36	NMOD	_	_
32	murine	_	JJ	JJ	_	36	NMOD	_	_
33	T	_	NN	NN	_	36	NMOD	_	_
34	cell	_	NN	NN	_	36	NMOD	_	_
35	line	_	NN	NN	_	36	NMOD	_	_
36	EL-4	_	NN	NN	_	29	PMOD	_	_
37	in	_	IN	IN	_	15	ADV	_	_
38	the	_	DT	DT	_	37	DEP	_	_
39	presence	_	NN	NN	_	37	DEP	_	_
40	of	_	IN	IN	_	37	DEP	_	_
41	ciprofloxacin	_	NN	NN	_	37	PMOD	_	_
42	(	_	(	(	_	44	P	_	_
43	5-80	_	CD	CD	_	44	NMOD	_	_
44	micrograms\/ml	_	NN	NN	_	41	PRN	_	_
45	)	_	)	)	_	44	P	_	_
46	as	_	IN	IN	_	15	ADV	_	_
47	compared	_	VBN	VBN	_	46	VMOD	_	_
48	to	_	TO	TO	_	47	ADV	_	_
49	control	_	NN	NN	_	50	NMOD	_	_
50	cells	_	NNS	NNS	_	48	PMOD	_	_
51	without	_	IN	IN	_	50	NMOD	_	_
52	antibiotics	_	NNS	NNS	_	51	PMOD	_	_
53	.	_	.	.	_	13	P	_	_

1	However	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	in	_	IN	IN	_	11	ADV	_	_
4	contrast	_	NN	NN	_	3	DEP	_	_
5	to	_	TO	TO	_	3	DEP	_	_
6	human	_	JJ	JJ	_	7	NMOD	_	_
7	lymphocytes	_	NNS	NNS	_	3	PMOD	_	_
8	,	_	,	,	_	11	P	_	_
9	IFN-gamma	_	NN	NN	_	10	NMOD	_	_
10	production	_	NN	NN	_	11	SBJ	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	inhibited	_	VBN	VBN	_	11	VC	_	_
13	and	_	CC	CC	_	11	CC	_	_
14	IFN-gamma	_	NN	NN	_	16	NMOD	_	_
15	mRNA	_	NN	NN	_	16	NMOD	_	_
16	levels	_	NNS	NNS	_	17	SBJ	_	_
17	were	_	VBD	VBD	_	11	COORD	_	_
18	unaffected	_	JJ	JJ	_	17	VC	_	_
19	at	_	IN	IN	_	18	TMP	_	_
20	24	_	CD	CD	_	21	NMOD	_	_
21	h	_	NN	NN	_	19	PMOD	_	_
22	and	_	CC	CC	_	18	CC	_	_
23	only	_	RB	RB	_	25	ADV	_	_
24	slightly	_	RB	RB	_	23	AMOD	_	_
25	upregulated	_	VBN	VBN	_	18	COORD	_	_
26	at	_	IN	IN	_	25	TMP	_	_
27	48	_	CD	CD	_	30	NMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	72	_	CD	CD	_	27	COORD	_	_
30	h	_	NN	NN	_	26	PMOD	_	_
31	of	_	IN	IN	_	21	NMOD	_	_
32	culture	_	NN	NN	_	31	PMOD	_	_
33	in	_	IN	IN	_	18	ADV	_	_
34	murine	_	JJ	JJ	_	35	NMOD	_	_
35	splenocytes	_	NNS	NNS	_	33	PMOD	_	_
36	incubated	_	VBN	VBN	_	35	NMOD	_	_
37	with	_	IN	IN	_	36	ADV	_	_
38	cipro	_	NN	NN	_	37	PMOD	_	_
39	(	_	(	(	_	41	P	_	_
40	20	_	CD	CD	_	41	NMOD	_	_
41	micrograms\/ml	_	NNS	NNS	_	38	PRN	_	_
42	)	_	)	)	_	41	P	_	_
43	.	_	.	.	_	11	P	_	_

1	EL-4	_	NN	NN	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	transfected	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	plasmid	_	NN	NN	_	5	PMOD	_	_
8	containing	_	VBG	VBG	_	7	NMOD	_	_
9	the	_	DT	DT	_	14	NMOD	_	_
10	IL-2	_	NN	NN	_	14	NMOD	_	_
11	promoter	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	enhancer	_	NN	NN	_	11	COORD	_	_
14	region	_	NN	NN	_	8	OBJ	_	_
15	linked	_	VBN	VBN	_	14	NMOD	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	the	_	DT	DT	_	24	NMOD	_	_
18	chloramphenicol	_	NN	NN	_	19	NMOD	_	_
19	acetyltransferase	_	NN	NN	_	24	NMOD	_	_
20	(	_	(	(	_	21	P	_	_
21	CAT	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	reporter	_	NN	NN	_	24	NMOD	_	_
24	gene	_	NN	NN	_	16	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	Analysis	_	NN	NN	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	CAT	_	NN	NN	_	4	NMOD	_	_
4	activity	_	NN	NN	_	2	PMOD	_	_
5	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	cipro	_	NN	NN	_	8	SBJ	_	_
8	enhanced	_	VBD	VBD	_	6	VMOD	_	_
9	IL-2	_	NN	NN	_	11	NMOD	_	_
10	gene	_	NN	NN	_	11	NMOD	_	_
11	induction	_	NN	NN	_	8	OBJ	_	_
12	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	9	P	_	_
4	EL-4	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	9	SBJ	_	_
6	incubated	_	VBN	VBN	_	5	NMOD	_	_
7	with	_	IN	IN	_	6	ADV	_	_
8	ciprofloxacin	_	NN	NN	_	7	PMOD	_	_
9	showed	_	VBD	VBD	_	0	ROOT-S	_	_
10	an	_	DT	DT	_	12	NMOD	_	_
11	early	_	JJ	JJ	_	12	NMOD	_	_
12	peak	_	NN	NN	_	9	OBJ	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	more	_	RBR	RBR	_	15	AMOD	_	_
15	activated	_	VBN	VBN	_	17	NMOD	_	_
16	nuclear	_	JJ	JJ	_	17	NMOD	_	_
17	factor	_	NN	NN	_	12	COORD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	activated	_	VBN	VBN	_	21	NMOD	_	_
20	T	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	18	PMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	NFAT-1	_	NN	NN	_	17	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	as	_	IN	IN	_	9	ADV	_	_
26	compared	_	VBN	VBN	_	25	VMOD	_	_
27	to	_	TO	TO	_	26	ADV	_	_
28	control	_	NN	NN	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	27	PMOD	_	_
30	without	_	IN	IN	_	29	NMOD	_	_
31	antibiotics	_	NNS	NNS	_	30	PMOD	_	_
32	.	_	.	.	_	9	P	_	_

1	Cipro	_	NN	NN	_	2	SBJ	_	_
2	did	_	VBD	VBD	_	0	ROOT-S	_	_
3	not	_	RB	RB	_	2	VMOD	_	_
4	affect	_	VB	VB	_	2	VC	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	nuclear	_	JJ	JJ	_	8	NMOD	_	_
7	transcription	_	NN	NN	_	8	NMOD	_	_
8	factors	_	NNS	NNS	_	4	OBJ	_	_
9	AP-1	_	NN	NN	_	8	NMOD	_	_
10	or	_	CC	CC	_	9	CC	_	_
11	NFIL-2A	_	NN	NN	_	9	COORD	_	_
12	.	_	.	.	_	2	P	_	_

1	Taken	_	VBN	VBN	_	5	VMOD	_	_
2	together	_	RB	RB	_	1	ADV	_	_
3	,	_	,	,	_	5	P	_	_
4	cipro	_	NN	NN	_	5	SBJ	_	_
5	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
6	IFN-gamma	_	NN	NN	_	7	NMOD	_	_
7	synthesis	_	NN	NN	_	5	OBJ	_	_
8	,	_	,	,	_	5	P	_	_
9	but	_	CC	CC	_	5	CC	_	_
10	enhanced	_	VBD	VBD	_	5	COORD	_	_
11	IL-2	_	NN	NN	_	12	NMOD	_	_
12	production	_	NN	NN	_	10	OBJ	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	murine	_	JJ	JJ	_	15	NMOD	_	_
15	lymphocytes	_	NNS	NNS	_	13	PMOD	_	_
16	by	_	IN	IN	_	10	ADV	_	_
17	means	_	NNS	NNS	_	16	DEP	_	_
18	of	_	IN	IN	_	16	DEP	_	_
19	influencing	_	VBG	VBG	_	16	PMOD	_	_
20	NFAT-1	_	NN	NN	_	19	OBJ	_	_
21	and	_	CC	CC	_	19	CC	_	_
22	causing	_	VBG	VBG	_	19	COORD	_	_
23	an	_	DT	DT	_	26	NMOD	_	_
24	increased	_	VBN	VBN	_	26	NMOD	_	_
25	IL-2	_	NN	NN	_	26	NMOD	_	_
26	transcription	_	NN	NN	_	22	OBJ	_	_
27	.	_	.	.	_	5	P	_	_

1	Multiple	_	JJ	JJ	_	3	NMOD	_	_
2	prolactin-responsive	_	JJ	JJ	_	3	NMOD	_	_
3	elements	_	NNS	NNS	_	4	SBJ	_	_
4	mediate	_	VBP	VBP	_	0	ROOT-S	_	_
5	G1	_	NN	NN	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	S	_	NN	NN	_	5	COORD	_	_
8	phase	_	NN	NN	_	9	NMOD	_	_
9	expression	_	NN	NN	_	4	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	15	NMOD	_	_
12	interferon	_	NN	NN	_	15	NMOD	_	_
13	regulatory	_	JJ	JJ	_	15	NMOD	_	_
14	factor-1	_	NN	NN	_	15	NMOD	_	_
15	gene	_	NN	NN	_	10	PMOD	_	_
16	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	8	NMOD	_	_
2	interferon	_	NN	NN	_	4	NMOD	_	_
3	regulatory	_	JJ	JJ	_	4	NMOD	_	_
4	factor-1	_	NN	NN	_	8	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	IRF-1	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	gene	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	both	_	CC	CC	_	15	CC	_	_
11	an	_	DT	DT	_	15	NMOD	_	_
12	immediate-early	_	JJ	JJ	_	15	NMOD	_	_
13	G1	_	NN	NN	_	15	NMOD	_	_
14	phase	_	NN	NN	_	15	NMOD	_	_
15	gene	_	NN	NN	_	9	PRD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	an	_	DT	DT	_	20	NMOD	_	_
18	S	_	NN	NN	_	20	NMOD	_	_
19	phase	_	NN	NN	_	20	NMOD	_	_
20	gene	_	NN	NN	_	15	COORD	_	_
21	inducible	_	JJ	JJ	_	15	NMOD	_	_
22	by	_	IN	IN	_	21	AMOD	_	_
23	PRL	_	NN	NN	_	22	PMOD	_	_
24	in	_	IN	IN	_	21	AMOD	_	_
25	rat	_	NN	NN	_	28	NMOD	_	_
26	Nb2	_	NN	NN	_	28	NMOD	_	_
27	T	_	NN	NN	_	28	NMOD	_	_
28	lymphocytes	_	NNS	NNS	_	24	PMOD	_	_
29	.	_	.	.	_	9	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	understand	_	VB	VB	_	16	VMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	mechanism	_	NN	NN	_	2	OBJ	_	_
5	by	_	IN	IN	_	8	ADV	_	_
6	which	_	WDT	WDT	_	5	PMOD	_	_
7	PRL	_	NN	NN	_	8	SBJ	_	_
8	regulates	_	VBZ	VBZ	_	4	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	biphasic	_	JJ	JJ	_	11	NMOD	_	_
11	expression	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	IRF-1	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	16	P	_	_
15	we	_	PRP	PRP	_	16	SBJ	_	_
16	cloned	_	VBD	VBD	_	0	ROOT-S	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	rat	_	NN	NN	_	20	NMOD	_	_
19	IRF-1	_	NN	NN	_	20	NMOD	_	_
20	gene	_	NN	NN	_	16	OBJ	_	_
21	and	_	CC	CC	_	16	CC	_	_
22	functionally	_	RB	RB	_	23	ADV	_	_
23	characterized	_	VBD	VBD	_	16	COORD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	IRF-1	_	NN	NN	_	26	NMOD	_	_
26	promoter	_	NN	NN	_	23	OBJ	_	_
27	.	_	.	.	_	16	P	_	_

1	Upon	_	IN	IN	_	28	TMP	_	_
2	transfection	_	NN	NN	_	1	PMOD	_	_
3	into	_	IN	IN	_	2	NMOD	_	_
4	Nb2	_	NN	NN	_	6	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	3	PMOD	_	_
7	,	_	,	,	_	28	P	_	_
8	1.7	_	CD	CD	_	9	NMOD	_	_
9	kilobases	_	NNS	NNS	_	28	SBJ	_	_
10	(	_	(	(	_	11	P	_	_
11	kb	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	of	_	IN	IN	_	9	NMOD	_	_
14	IRF-1	_	NN	NN	_	16	NMOD	_	_
15	5'-flanking	_	JJ	JJ	_	16	NMOD	_	_
16	DNA	_	NN	NN	_	13	PMOD	_	_
17	linked	_	VBN	VBN	_	16	NMOD	_	_
18	to	_	TO	TO	_	17	ADV	_	_
19	a	_	DT	DT	_	27	NMOD	_	_
20	chloramphenicol	_	NN	NN	_	22	NMOD	_	_
21	acetyl	_	JJ	JJ	_	22	NMOD	_	_
22	transferase	_	NN	NN	_	27	NMOD	_	_
23	(	_	(	(	_	24	P	_	_
24	CAT	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	reporter	_	NN	NN	_	27	NMOD	_	_
27	gene	_	NN	NN	_	18	PMOD	_	_
28	mediated	_	VBD	VBD	_	0	ROOT-S	_	_
29	a	_	DT	DT	_	31	NMOD	_	_
30	30-fold	_	JJ	JJ	_	31	NMOD	_	_
31	induction	_	NN	NN	_	28	OBJ	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	CAT	_	NN	NN	_	35	NMOD	_	_
34	enzyme	_	NN	NN	_	35	NMOD	_	_
35	activity	_	NN	NN	_	32	PMOD	_	_
36	in	_	IN	IN	_	28	ADV	_	_
37	response	_	NN	NN	_	36	DEP	_	_
38	to	_	TO	TO	_	36	DEP	_	_
39	24	_	CD	CD	_	40	NMOD	_	_
40	h	_	NN	NN	_	36	PMOD	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	PRL	_	NN	NN	_	43	NMOD	_	_
43	stimulation	_	NN	NN	_	41	PMOD	_	_
44	.	_	.	.	_	28	P	_	_

1	Deletion	_	NN	NN	_	2	NMOD	_	_
2	mutants	_	NNS	NNS	_	13	SBJ	_	_
3	containing	_	VBG	VBG	_	2	NMOD	_	_
4	1.3	_	CD	CD	_	12	NMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	0.6	_	CD	CD	_	4	COORD	_	_
7	,	_	,	,	_	4	P	_	_
8	and	_	CC	CC	_	4	CC	_	_
9	0.2	_	CD	CD	_	4	COORD	_	_
10	kb	_	NN	NN	_	4	AMOD	_	_
11	5'-flanking	_	JJ	JJ	_	12	NMOD	_	_
12	DNA	_	NN	NN	_	3	OBJ	_	_
13	were	_	VBD	VBD	_	0	ROOT-S	_	_
14	incrementally	_	RB	RB	_	13	PRD	_	_
15	less	_	RBR	RBR	_	16	AMOD	_	_
16	transcriptionally	_	RB	RB	_	14	AMOD	_	_
17	active	_	JJ	JJ	_	14	AMOD	_	_
18	,	_	,	,	_	13	P	_	_
19	although	_	IN	IN	_	13	ADV	_	_
20	0.2	_	CD	CD	_	21	NMOD	_	_
21	kb	_	NN	NN	_	23	SBJ	_	_
22	still	_	RB	RB	_	23	ADV	_	_
23	mediated	_	VBD	VBD	_	19	VMOD	_	_
24	a	_	DT	DT	_	26	NMOD	_	_
25	12-fold	_	JJ	JJ	_	26	NMOD	_	_
26	induction	_	NN	NN	_	23	OBJ	_	_
27	by	_	IN	IN	_	26	NMOD	_	_
28	PRL	_	NN	NN	_	27	PMOD	_	_
29	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	sequence	_	NN	NN	_	15	SBJ	_	_
3	between	_	IN	IN	_	2	NMOD	_	_
4	-1.7	_	CD	CD	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	-0.2	_	CD	CD	_	4	COORD	_	_
7	kb	_	NN	NN	_	3	PMOD	_	_
8	linked	_	VBN	VBN	_	2	NMOD	_	_
9	to	_	TO	TO	_	8	ADV	_	_
10	a	_	DT	DT	_	14	NMOD	_	_
11	heterologous	_	JJ	JJ	_	14	NMOD	_	_
12	thymidine	_	NN	NN	_	14	NMOD	_	_
13	kinase	_	NN	NN	_	14	NMOD	_	_
14	promoter	_	NN	NN	_	9	PMOD	_	_
15	failed	_	VBD	VBD	_	0	ROOT-S	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	respond	_	VB	VB	_	15	OBJ	_	_
18	to	_	TO	TO	_	17	ADV	_	_
19	PRL	_	NN	NN	_	20	NMOD	_	_
20	stimulation	_	NN	NN	_	18	PMOD	_	_
21	,	_	,	,	_	15	P	_	_
22	suggesting	_	VBG	VBG	_	15	ADV	_	_
23	that	_	IN	IN	_	22	OBJ	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	activity	_	NN	NN	_	31	SBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	upstream	_	JJ	JJ	_	30	NMOD	_	_
28	PRL	_	NN	NN	_	30	NMOD	_	_
29	response	_	NN	NN	_	30	NMOD	_	_
30	elements	_	NNS	NNS	_	26	PMOD	_	_
31	may	_	MD	MD	_	23	VMOD	_	_
32	require	_	VB	VB	_	31	VC	_	_
33	an	_	DT	DT	_	34	NMOD	_	_
34	interaction	_	NN	NN	_	32	OBJ	_	_
35	with	_	IN	IN	_	34	NMOD	_	_
36	promoter-proximal	_	JJ	JJ	_	37	NMOD	_	_
37	elements	_	NNS	NNS	_	35	PMOD	_	_
38	.	_	.	.	_	15	P	_	_

1	By	_	IN	IN	_	15	ADV	_	_
2	assaying	_	VBG	VBG	_	1	PMOD	_	_
3	CAT	_	NN	NN	_	5	NMOD	_	_
4	enzyme	_	NN	NN	_	5	NMOD	_	_
5	activity	_	NN	NN	_	2	OBJ	_	_
6	across	_	IN	IN	_	5	NMOD	_	_
7	a	_	DT	DT	_	12	NMOD	_	_
8	24-h	_	JJ	JJ	_	12	NMOD	_	_
9	PRL	_	NN	NN	_	12	NMOD	_	_
10	induction	_	NN	NN	_	12	NMOD	_	_
11	time	_	NN	NN	_	12	NMOD	_	_
12	course	_	NN	NN	_	6	PMOD	_	_
13	,	_	,	,	_	15	P	_	_
14	we	_	PRP	PRP	_	15	SBJ	_	_
15	were	_	VBD	VBD	_	0	ROOT-S	_	_
16	able	_	JJ	JJ	_	15	PRD	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	assign	_	VB	VB	_	16	AMOD	_	_
19	G1	_	NN	NN	_	24	NMOD	_	_
20	vs.	_	CC	CC	_	19	CC	_	_
21	S	_	NN	NN	_	19	COORD	_	_
22	phase	_	NN	NN	_	24	NMOD	_	_
23	PRL	_	NN	NN	_	24	NMOD	_	_
24	responses	_	NNS	NNS	_	18	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	IRF-1	_	NN	NN	_	28	NMOD	_	_
28	gene	_	NN	NN	_	25	PMOD	_	_
29	to	_	TO	TO	_	18	ADV	_	_
30	different	_	JJ	JJ	_	31	NMOD	_	_
31	regions	_	NNS	NNS	_	29	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	the	_	DT	DT	_	38	NMOD	_	_
34	IRF-1	_	NN	NN	_	38	NMOD	_	_
35	5'-flanking	_	JJ	JJ	_	38	NMOD	_	_
36	and	_	CC	CC	_	35	CC	_	_
37	promoter	_	NN	NN	_	35	COORD	_	_
38	DNA	_	NN	NN	_	32	PMOD	_	_
39	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	0.2-kb	_	JJ	JJ	_	4	NMOD	_	_
3	IRF-CAT	_	NN	NN	_	4	NMOD	_	_
4	construct	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	induced	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	PRL	_	NN	NN	_	9	NMOD	_	_
9	stimulation	_	NN	NN	_	7	PMOD	_	_
10	during	_	IN	IN	_	6	TMP	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	G1	_	NN	NN	_	13	NMOD	_	_
13	phase	_	NN	NN	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	cycle	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	8	P	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	1.7-kb	_	JJ	JJ	_	7	NMOD	_	_
6	IRF-CAT	_	NN	NN	_	7	NMOD	_	_
7	construct	_	NN	NN	_	8	SBJ	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	inducible	_	JJ	JJ	_	8	PRD	_	_
10	by	_	IN	IN	_	9	AMOD	_	_
11	PRL	_	NN	NN	_	10	PMOD	_	_
12	during	_	IN	IN	_	8	TMP	_	_
13	both	_	CC	CC	_	14	CC	_	_
14	G1	_	NN	NN	_	17	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	S	_	NN	NN	_	14	COORD	_	_
17	phase	_	NN	NN	_	18	NMOD	_	_
18	of	_	IN	IN	_	12	LGS	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	cycle	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	8	P	_	_

1	Hence	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	PRL-induced	_	JJ	JJ	_	6	NMOD	_	_
5	biphasic	_	JJ	JJ	_	6	NMOD	_	_
6	expression	_	NN	NN	_	11	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	IRF-1	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	7	PMOD	_	_
11	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	be	_	VB	VB	_	11	OBJ	_	_
14	controlled	_	VBN	VBN	_	13	VC	_	_
15	by	_	IN	IN	_	14	LGS	_	_
16	separate	_	JJ	JJ	_	18	NMOD	_	_
17	PRL-responsive	_	JJ	JJ	_	18	NMOD	_	_
18	elements	_	NNS	NNS	_	15	PMOD	_	_
19	:	_	:	:	_	11	P	_	_
20	elements	_	NNS	NNS	_	31	SBJ	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	25	NMOD	_	_
23	first	_	JJ	JJ	_	25	NMOD	_	_
24	0.2	_	CD	CD	_	25	NMOD	_	_
25	kb	_	NN	NN	_	21	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	IRF-1	_	NN	NN	_	30	NMOD	_	_
29	promoter	_	NN	NN	_	30	NMOD	_	_
30	region	_	NN	NN	_	26	PMOD	_	_
31	act	_	VBP	VBP	_	11	VMOD	_	_
32	during	_	IN	IN	_	31	TMP	_	_
33	early	_	JJ	JJ	_	34	NMOD	_	_
34	activation	_	NN	NN	_	32	PMOD	_	_
35	,	_	,	,	_	31	P	_	_
36	and	_	CC	CC	_	31	CC	_	_
37	elements	_	NNS	NNS	_	43	SBJ	_	_
38	between	_	IN	IN	_	37	NMOD	_	_
39	0.2	_	CD	CD	_	42	NMOD	_	_
40	and	_	CC	CC	_	39	CC	_	_
41	1.7	_	CD	CD	_	39	COORD	_	_
42	kb	_	NN	NN	_	38	PMOD	_	_
43	act	_	VBP	VBP	_	31	COORD	_	_
44	in	_	IN	IN	_	43	ADV	_	_
45	concert	_	NN	NN	_	44	DEP	_	_
46	with	_	IN	IN	_	44	DEP	_	_
47	the	_	DT	DT	_	50	NMOD	_	_
48	proximal	_	JJ	JJ	_	50	NMOD	_	_
49	0.2-kb	_	JJ	JJ	_	50	NMOD	_	_
50	region	_	NN	NN	_	44	PMOD	_	_
51	during	_	IN	IN	_	43	TMP	_	_
52	S	_	NN	NN	_	54	NMOD	_	_
53	phase	_	NN	NN	_	54	NMOD	_	_
54	progression	_	NN	NN	_	51	PMOD	_	_
55	.	_	.	.	_	11	P	_	_

1	Description	_	NN	NN	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	functional	_	JJ	JJ	_	4	NMOD	_	_
4	implications	_	NNS	NNS	_	1	COORD	_	_
5	of	_	IN	IN	_	1	NMOD	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	novel	_	JJ	JJ	_	8	NMOD	_	_
8	mutation	_	NN	NN	_	5	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	sex-determining	_	JJ	JJ	_	13	NMOD	_	_
12	gene	_	NN	NN	_	13	NMOD	_	_
13	SRY	_	NN	NN	_	9	PMOD	_	_
14	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	sex-determining	_	JJ	JJ	_	4	NMOD	_	_
3	gene	_	NN	NN	_	4	NMOD	_	_
4	SRY	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	screened	_	VBN	VBN	_	5	VC	_	_
7	for	_	IN	IN	_	6	ADV	_	_
8	molecular	_	JJ	JJ	_	9	NMOD	_	_
9	alteration	_	NN	NN	_	7	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	an	_	DT	DT	_	14	NMOD	_	_
12	XY	_	NN	NN	_	14	NMOD	_	_
13	sex-reversed	_	JJ	JJ	_	12	AMOD	_	_
14	female	_	NN	NN	_	10	PMOD	_	_
15	by	_	IN	IN	_	6	ADV	_	_
16	single-strand	_	JJ	JJ	_	18	NMOD	_	_
17	conformation	_	NN	NN	_	18	NMOD	_	_
18	polymorphism	_	NN	NN	_	22	NMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	SSCP	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	technique	_	NN	NN	_	15	PMOD	_	_
23	.	_	.	.	_	5	P	_	_

1	An	_	DT	DT	_	3	NMOD	_	_
2	A-to-G	_	JJ	JJ	_	3	NMOD	_	_
3	transition	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	detected	_	VBN	VBN	_	4	VC	_	_
6	which	_	WDT	WDT	_	7	SBJ	_	_
7	leads	_	VBZ	VBZ	_	3	NMOD	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	an	_	DT	DT	_	10	NMOD	_	_
10	exchange	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	a	_	DT	DT	_	13	NMOD	_	_
13	tyrosine	_	NN	NN	_	11	PMOD	_	_
14	by	_	IN	IN	_	10	NMOD	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	cysteine	_	NN	NN	_	14	PMOD	_	_
17	in	_	IN	IN	_	10	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	SRY	_	NN	NN	_	20	NMOD	_	_
20	protein	_	NN	NN	_	17	PMOD	_	_
21	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	affected	_	VBN	VBN	_	4	NMOD	_	_
3	tyrosine	_	NN	NN	_	4	NMOD	_	_
4	residue	_	NN	NN	_	15	SBJ	_	_
5	located	_	JJ	JJ	_	4	NMOD	_	_
6	at	_	IN	IN	_	5	AMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	C	_	NN	NN	_	9	NMOD	_	_
9	terminus	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	DNA	_	NN	NN	_	14	NMOD	_	_
13	binding	_	NN	NN	_	14	NMOD	_	_
14	protein	_	NN	NN	_	10	PMOD	_	_
15	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	evolutionarily	_	RB	RB	_	18	ADV	_	_
17	strongly	_	RB	RB	_	16	AMOD	_	_
18	conserved	_	VBN	VBN	_	15	VC	_	_
19	among	_	IN	IN	_	18	ADV	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	members	_	NNS	NNS	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	27	NMOD	_	_
24	HMG	_	NN	NN	_	25	AMOD	_	_
25	box	_	NN	NN	_	27	NMOD	_	_
26	containing	_	VBG	VBG	_	25	AMOD	_	_
27	proteins	_	NNS	NNS	_	22	PMOD	_	_
28	.	_	.	.	_	15	P	_	_

1	Using	_	VBG	VBG	_	11	VC	_	_
2	gel	_	NN	NN	_	4	NMOD	_	_
3	shift	_	NN	NN	_	4	NMOD	_	_
4	assay	_	NN	NN	_	1	OBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	peptide	_	NN	NN	_	7	NMOD	_	_
7	synthesis	_	NN	NN	_	4	COORD	_	_
8	such	_	PDT	PDT	_	10	NMOD	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	mutation	_	NN	NN	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	shown	_	VBN	VBN	_	11	VC	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	abolish	_	VB	VB	_	12	OBJ	_	_
15	the	_	DT	DT	_	20	NMOD	_	_
16	SRY	_	NN	NN	_	20	NMOD	_	_
17	protein	_	NN	NN	_	20	NMOD	_	_
18	DNA	_	NN	NN	_	20	NMOD	_	_
19	binding	_	NN	NN	_	20	NMOD	_	_
20	ability	_	NN	NN	_	14	OBJ	_	_
21	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	involvement	_	NN	NN	_	12	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	this	_	DT	DT	_	7	NMOD	_	_
5	particular	_	JJ	JJ	_	7	NMOD	_	_
6	amino	_	NN	NN	_	7	NMOD	_	_
7	acid	_	NN	NN	_	3	PMOD	_	_
8	in	_	IN	IN	_	2	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	binding	_	NN	NN	_	11	NMOD	_	_
11	specificity	_	NN	NN	_	8	PMOD	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	also	_	RB	RB	_	14	ADV	_	_
14	discussed	_	VBN	VBN	_	12	VC	_	_
15	.	_	.	.	_	12	P	_	_

1	Prevalence	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	aneuploidy	_	NN	NN	_	2	PMOD	_	_
4	,	_	,	,	_	3	P	_	_
5	overexpressed	_	JJ	JJ	_	6	NMOD	_	_
6	ER	_	NN	NN	_	3	COORD	_	_
7	,	_	,	,	_	3	P	_	_
8	and	_	CC	CC	_	3	CC	_	_
9	overexpressed	_	JJ	JJ	_	10	NMOD	_	_
10	EGFR	_	NN	NN	_	3	COORD	_	_
11	in	_	IN	IN	_	3	NMOD	_	_
12	random	_	JJ	JJ	_	14	NMOD	_	_
13	breast	_	NN	NN	_	14	NMOD	_	_
14	aspirates	_	NNS	NNS	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	women	_	NNS	NNS	_	15	PMOD	_	_
17	at	_	IN	IN	_	16	NMOD	_	_
18	high	_	JJ	JJ	_	21	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	low	_	JJ	JJ	_	18	COORD	_	_
21	risk	_	NN	NN	_	17	PMOD	_	_
22	for	_	IN	IN	_	21	NMOD	_	_
23	breast	_	NN	NN	_	24	NMOD	_	_
24	cancer	_	NN	NN	_	22	PMOD	_	_
25	.	_	.	.	_	1	P	_	_

1	Breast	_	NN	NN	_	3	NMOD	_	_
2	tissue	_	NN	NN	_	3	NMOD	_	_
3	biomarkers	_	NNS	NNS	_	19	SBJ	_	_
4	which	_	WDT	WDT	_	6	SBJ	_	_
5	accurately	_	RB	RB	_	6	ADV	_	_
6	predict	_	VBP	VBP	_	3	NMOD	_	_
7	breast	_	NN	NN	_	9	NMOD	_	_
8	cancer	_	NN	NN	_	9	NMOD	_	_
9	development	_	NN	NN	_	6	OBJ	_	_
10	within	_	IN	IN	_	9	TMP	_	_
11	a	_	DT	DT	_	14	NMOD	_	_
12	10	_	CD	CD	_	13	AMOD	_	_
13	year	_	NN	NN	_	14	NMOD	_	_
14	period	_	NN	NN	_	10	PMOD	_	_
15	in	_	IN	IN	_	9	NMOD	_	_
16	high	_	JJ	JJ	_	17	AMOD	_	_
17	risk	_	NN	NN	_	18	NMOD	_	_
18	women	_	NNS	NNS	_	15	PMOD	_	_
19	are	_	VBP	VBP	_	0	ROOT-S	_	_
20	needed	_	VBN	VBN	_	19	VMOD	_	_
21	but	_	CC	CC	_	20	CC	_	_
22	currently	_	RB	RB	_	20	PRD	_	_
23	not	_	RB	RB	_	22	AMOD	_	_
24	available	_	JJ	JJ	_	22	AMOD	_	_
25	.	_	.	.	_	19	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	initiated	_	VBD	VBD	_	0	ROOT-S	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	study	_	NN	NN	_	2	IOBJ	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	determine	_	VB	VB	_	2	OBJ	_	_
7	1	_	LS	LS	_	10	NMOD	_	_
8	)	_	)	)	_	7	P	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	prevalence	_	NN	NN	_	6	VMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	one	_	CD	CD	_	17	NMOD	_	_
13	or	_	CC	CC	_	12	CC	_	_
14	more	_	JJR	JJR	_	12	COORD	_	_
15	breast	_	NN	NN	_	17	NMOD	_	_
16	tissue	_	NN	NN	_	17	NMOD	_	_
17	abnormalities	_	NNS	NNS	_	11	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	a	_	DT	DT	_	20	NMOD	_	_
20	group	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	women	_	NNS	NNS	_	21	PMOD	_	_
23	at	_	IN	IN	_	22	NMOD	_	_
24	high	_	JJ	JJ	_	25	NMOD	_	_
25	risk	_	NN	NN	_	23	PMOD	_	_
26	for	_	IN	IN	_	25	NMOD	_	_
27	breast	_	NN	NN	_	28	NMOD	_	_
28	cancer	_	NN	NN	_	26	PMOD	_	_
29	,	_	,	,	_	10	P	_	_
30	and	_	CC	CC	_	10	CC	_	_
31	2	_	LS	LS	_	33	VMOD	_	_
32	)	_	)	)	_	31	P	_	_
33	if	_	IN	IN	_	10	COORD	_	_
34	the	_	DT	DT	_	35	NMOD	_	_
35	prevalence	_	NN	NN	_	39	SBJ	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	biomarker	_	NN	NN	_	38	NMOD	_	_
38	abnormalities	_	NNS	NNS	_	36	PMOD	_	_
39	is	_	VBZ	VBZ	_	33	VMOD	_	_
40	greater	_	JJR	JJR	_	39	PRD	_	_
41	in	_	IN	IN	_	39	ADV	_	_
42	high	_	JJ	JJ	_	43	NMOD	_	_
43	risk	_	NN	NN	_	41	PMOD	_	_
44	than	_	IN	IN	_	40	AMOD	_	_
45	in	_	IN	IN	_	44	PMOD	_	_
46	low	_	JJ	JJ	_	48	NMOD	_	_
47	risk	_	NN	NN	_	48	NMOD	_	_
48	women	_	NNS	NNS	_	45	PMOD	_	_
49	.	_	.	.	_	2	P	_	_

1	Eligible	_	JJ	JJ	_	4	NMOD	_	_
2	high	_	JJ	JJ	_	4	NMOD	_	_
3	risk	_	NN	NN	_	4	NMOD	_	_
4	women	_	NNS	NNS	_	5	SBJ	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	those	_	DT	DT	_	5	PRD	_	_
7	with	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	11	NMOD	_	_
9	first	_	JJ	JJ	_	10	AMOD	_	_
10	degree	_	NN	NN	_	11	NMOD	_	_
11	relative	_	NN	NN	_	7	PMOD	_	_
12	with	_	IN	IN	_	11	NMOD	_	_
13	breast	_	NN	NN	_	14	NMOD	_	_
14	cancer	_	NN	NN	_	12	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	prior	_	JJ	JJ	_	18	NMOD	_	_
17	breast	_	NN	NN	_	18	NMOD	_	_
18	cancer	_	NN	NN	_	14	COORD	_	_
19	,	_	,	,	_	14	P	_	_
20	or	_	CC	CC	_	14	CC	_	_
21	precancerous	_	JJ	JJ	_	22	NMOD	_	_
22	mastopathy	_	NN	NN	_	14	COORD	_	_
23	.	_	.	.	_	5	P	_	_

1	Low	_	JJ	JJ	_	3	NMOD	_	_
2	risk	_	NN	NN	_	3	NMOD	_	_
3	women	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	those	_	DT	DT	_	4	PRD	_	_
6	without	_	IN	IN	_	5	NMOD	_	_
7	these	_	DT	DT	_	6	PMOD	_	_
8	or	_	CC	CC	_	7	CC	_	_
9	other	_	JJ	JJ	_	13	NMOD	_	_
10	major	_	JJ	JJ	_	13	NMOD	_	_
11	identifiable	_	JJ	JJ	_	13	NMOD	_	_
12	risk	_	NN	NN	_	13	NMOD	_	_
13	factors	_	NNS	NNS	_	7	COORD	_	_
14	.	_	.	.	_	4	P	_	_

1	Ductal	_	JJ	JJ	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	obtained	_	VBN	VBN	_	3	VC	_	_
5	via	_	IN	IN	_	4	ADV	_	_
6	random	_	JJ	JJ	_	9	NMOD	_	_
7	fine	_	JJ	JJ	_	9	NMOD	_	_
8	needle	_	NN	NN	_	9	NMOD	_	_
9	aspirations	_	NNS	NNS	_	5	PMOD	_	_
10	and	_	CC	CC	_	4	CC	_	_
11	cytologically	_	RB	RB	_	12	ADV	_	_
12	classified	_	VBN	VBN	_	4	COORD	_	_
13	.	_	.	.	_	3	P	_	_

1	Biomarkers	_	NNS	NNS	_	2	SBJ	_	_
2	included	_	VBD	VBD	_	0	ROOT-S	_	_
3	DNA	_	NN	NN	_	4	NMOD	_	_
4	ploidy	_	NN	NN	_	2	OBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	estrogen	_	NN	NN	_	7	NMOD	_	_
7	receptor	_	NN	NN	_	4	COORD	_	_
8	(	_	(	(	_	9	P	_	_
9	ER	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	,	_	,	,	_	4	P	_	_
12	and	_	CC	CC	_	4	CC	_	_
13	epidermal	_	JJ	JJ	_	16	NMOD	_	_
14	growth	_	NN	NN	_	16	NMOD	_	_
15	factor	_	NN	NN	_	16	NMOD	_	_
16	receptor	_	NN	NN	_	4	COORD	_	_
17	(	_	(	(	_	18	P	_	_
18	EGFR	_	NN	NN	_	16	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	prevalence	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	DNA	_	NN	NN	_	5	NMOD	_	_
5	aneuploidy	_	NN	NN	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	30	_	CD	CD	_	8	NMOD	_	_
8	%	_	NN	NN	_	6	PRD	_	_
9	,	_	,	,	_	6	P	_	_
10	overexpression	_	NN	NN	_	2	GAP	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	ER	_	NN	NN	_	11	PMOD	_	_
13	10	_	CD	CD	_	14	NMOD	_	_
14	%	_	NN	NN	_	8	GAP	_	_
15	,	_	,	,	_	6	P	_	_
16	and	_	CC	CC	_	6	CC	_	_
17	overexpression	_	NN	NN	_	2	GAP	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	EGFR	_	NN	NN	_	18	PMOD	_	_
20	35	_	CD	CD	_	21	NMOD	_	_
21	%	_	NN	NN	_	8	GAP	_	_
22	,	_	,	,	_	6	P	_	_
23	in	_	IN	IN	_	6	ADV	_	_
24	the	_	DT	DT	_	28	NMOD	_	_
25	206	_	CD	CD	_	28	NMOD	_	_
26	high	_	JJ	JJ	_	28	NMOD	_	_
27	risk	_	NN	NN	_	28	NMOD	_	_
28	women	_	NNS	NNS	_	23	PMOD	_	_
29	whose	_	WP$	WP$	_	33	NMOD	_	_
30	median	_	JJ	JJ	_	33	NMOD	_	_
31	10	_	CD	CD	_	32	AMOD	_	_
32	year	_	NN	NN	_	33	NMOD	_	_
33	Gail	_	NN	NN	_	39	NMOD	_	_
34	risk	_	NN	NN	_	33	NMOD	_	_
35	(	_	(	(	_	37	P	_	_
36	projected	_	VBN	VBN	_	37	NMOD	_	_
37	probability	_	NN	NN	_	34	PRN	_	_
38	)	_	)	)	_	37	P	_	_
39	of	_	IN	IN	_	43	SBJ	_	_
40	developing	_	VBG	VBG	_	39	PMOD	_	_
41	breast	_	NN	NN	_	42	NMOD	_	_
42	cancer	_	NN	NN	_	40	OBJ	_	_
43	was	_	VBD	VBD	_	28	NMOD	_	_
44	4.5	_	CD	CD	_	45	NMOD	_	_
45	%	_	NN	NN	_	43	PRD	_	_
46	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	prevalence	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	aneuploidy	_	NN	NN	_	3	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	overexpressed	_	JJ	JJ	_	7	NMOD	_	_
7	EGFR	_	NN	NN	_	4	COORD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	significantly	_	RB	RB	_	10	AMOD	_	_
10	higher	_	JJR	JJR	_	8	PRD	_	_
11	in	_	IN	IN	_	8	ADV	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	high	_	JJ	JJ	_	15	NMOD	_	_
14	risk	_	NN	NN	_	15	NMOD	_	_
15	women	_	NNS	NNS	_	11	PMOD	_	_
16	than	_	IN	IN	_	10	AMOD	_	_
17	in	_	IN	IN	_	16	PMOD	_	_
18	the	_	DT	DT	_	22	NMOD	_	_
19	25	_	CD	CD	_	22	NMOD	_	_
20	low	_	JJ	JJ	_	22	NMOD	_	_
21	risk	_	NN	NN	_	22	NMOD	_	_
22	controls	_	NNS	NNS	_	17	PMOD	_	_
23	(	_	(	(	_	26	P	_	_
24	p	_	NN	NN	_	26	SBJ	_	_
25	&lt;	_	JJR	JJR	_	26	DEP	_	_
26	0.002	_	CD	CD	_	22	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	,	_	,	,	_	22	P	_	_
29	whose	_	WP$	WP$	_	34	NMOD	_	_
30	median	_	JJ	JJ	_	34	NMOD	_	_
31	10	_	CD	CD	_	32	AMOD	_	_
32	year	_	NN	NN	_	34	NMOD	_	_
33	Gail	_	NN	NN	_	34	NMOD	_	_
34	risk	_	NN	NN	_	35	SBJ	_	_
35	was	_	VBD	VBD	_	22	NMOD	_	_
36	0.7	_	CD	CD	_	37	NMOD	_	_
37	%	_	NN	NN	_	35	PRD	_	_
38	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	difference	_	NN	NN	_	15	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	prevalence	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	ER	_	NN	NN	_	8	NMOD	_	_
8	overexpression	_	NN	NN	_	6	PMOD	_	_
9	between	_	IN	IN	_	2	NMOD	_	_
10	high	_	JJ	JJ	_	14	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	low	_	JJ	JJ	_	10	COORD	_	_
13	risk	_	NN	NN	_	14	NMOD	_	_
14	groups	_	NNS	NNS	_	9	PMOD	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	not	_	RB	RB	_	15	VMOD	_	_
17	statistically	_	RB	RB	_	15	ADV	_	_
18	significant	_	JJ	JJ	_	15	PRD	_	_
19	(	_	(	(	_	22	P	_	_
20	p	_	NN	NN	_	22	SBJ	_	_
21	=	_	JJ	JJ	_	22	VMOD	_	_
22	0.095	_	CD	CD	_	15	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	.	_	.	.	_	15	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	may	_	MD	MD	_	0	ROOT-S	_	_
3	be	_	VB	VB	_	2	VC	_	_
4	due	_	JJ	JJ	_	5	DEP	_	_
5	to	_	TO	TO	_	3	PRD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	low	_	JJ	JJ	_	8	NMOD	_	_
8	prevalence	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	overexpressed	_	JJ	JJ	_	11	NMOD	_	_
11	ER	_	NN	NN	_	9	PMOD	_	_
12	and	_	CC	CC	_	8	CC	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	small	_	JJ	JJ	_	15	NMOD	_	_
15	number	_	NN	NN	_	8	COORD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	controls	_	NNS	NNS	_	16	PMOD	_	_
18	.	_	.	.	_	2	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	significant	_	JJ	JJ	_	3	NMOD	_	_
3	difference	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	noted	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	prevalence	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	one	_	CD	CD	_	14	NMOD	_	_
11	or	_	CC	CC	_	10	CC	_	_
12	more	_	JJR	JJR	_	10	COORD	_	_
13	abnormal	_	JJ	JJ	_	14	NMOD	_	_
14	biomarkers	_	NNS	NNS	_	9	PMOD	_	_
15	between	_	IN	IN	_	5	ADV	_	_
16	the	_	DT	DT	_	22	NMOD	_	_
17	high	_	JJ	JJ	_	18	NMOD	_	_
18	risk	_	NN	NN	_	22	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	low	_	JJ	JJ	_	21	NMOD	_	_
21	risk	_	NN	NN	_	18	COORD	_	_
22	women	_	NNS	NNS	_	15	PMOD	_	_
23	(	_	(	(	_	26	P	_	_
24	p	_	NN	NN	_	26	SBJ	_	_
25	&lt;	_	JJR	JJR	_	26	DEP	_	_
26	0.001	_	CD	CD	_	5	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	.	_	.	.	_	4	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	large	_	JJ	JJ	_	4	NMOD	_	_
3	prospective	_	JJ	JJ	_	4	NMOD	_	_
4	trial	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	needed	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	determine	_	VB	VB	_	6	OBJ	_	_
9	if	_	IN	IN	_	8	OBJ	_	_
10	one	_	CD	CD	_	17	SBJ	_	_
11	or	_	CC	CC	_	10	CC	_	_
12	more	_	JJR	JJR	_	10	COORD	_	_
13	of	_	IN	IN	_	10	NMOD	_	_
14	these	_	DT	DT	_	15	NMOD	_	_
15	biomarkers	_	NNS	NNS	_	13	PMOD	_	_
16	,	_	,	,	_	17	P	_	_
17	is	_	VBZ	VBZ	_	9	VMOD	_	_
18	predictive	_	JJ	JJ	_	17	PRD	_	_
19	of	_	IN	IN	_	18	AMOD	_	_
20	breast	_	NN	NN	_	22	NMOD	_	_
21	cancer	_	NN	NN	_	22	NMOD	_	_
22	development	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	5	P	_	_

1	{	_	(	(	_	3	P	_	_
2	The	_	DT	DT	_	3	NMOD	_	_
3	changes	_	NNS	NNS	_	0	ROOT-FRAG	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	glucocorticoid	_	NN	NN	_	6	NMOD	_	_
6	receptors	_	NNS	NNS	_	4	PMOD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	peripheral	_	JJ	JJ	_	9	NMOD	_	_
9	leukocytes	_	NNS	NNS	_	7	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	asthmatic	_	JJ	JJ	_	12	NMOD	_	_
12	subjects	_	NNS	NNS	_	10	PMOD	_	_
13	}	_	)	)	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	number	_	NN	NN	_	12	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	glucocorticoid	_	NN	NN	_	5	NMOD	_	_
5	receptors	_	NNS	NNS	_	3	PMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	GCR	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	in	_	IN	IN	_	5	NMOD	_	_
10	peripheral	_	JJ	JJ	_	11	NMOD	_	_
11	leukocytes	_	NNS	NNS	_	9	PMOD	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	determined	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	ADV	_	_
15	radioligand-binding	_	JJ	JJ	_	16	NMOD	_	_
16	assay	_	NN	NN	_	14	PMOD	_	_
17	in	_	IN	IN	_	13	ADV	_	_
18	extrinsic	_	JJ	JJ	_	21	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	intrinsic	_	JJ	JJ	_	18	COORD	_	_
21	asthmatics	_	NNS	NNS	_	17	PMOD	_	_
22	.	_	.	.	_	12	P	_	_

1	Their	_	PRP$	PRP$	_	5	NMOD	_	_
2	corresponding	_	JJ	JJ	_	5	NMOD	_	_
3	plasma	_	NN	NN	_	5	NMOD	_	_
4	cortisol	_	NN	NN	_	5	NMOD	_	_
5	levels	_	NNS	NNS	_	6	SBJ	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	assessed	_	VBN	VBN	_	6	VC	_	_
8	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	showed	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	average	_	JJ	JJ	_	7	NMOD	_	_
7	number	_	NN	NN	_	12	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	GCR	_	NN	NN	_	8	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	asthmatics	_	NNS	NNS	_	10	PMOD	_	_
12	was	_	VBD	VBD	_	4	VMOD	_	_
13	significantly	_	RB	RB	_	14	AMOD	_	_
14	lower	_	JJR	JJR	_	12	PRD	_	_
15	than	_	IN	IN	_	14	AMOD	_	_
16	that	_	DT	DT	_	15	PMOD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	healthy	_	JJ	JJ	_	19	NMOD	_	_
19	subjects	_	NNS	NNS	_	17	PMOD	_	_
20	(	_	(	(	_	23	P	_	_
21	P	_	NN	NN	_	23	SBJ	_	_
22	&lt;	_	JJR	JJR	_	23	DEP	_	_
23	0.01	_	CD	CD	_	12	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	,	_	,	,	_	12	P	_	_
26	and	_	CC	CC	_	12	CC	_	_
27	there	_	EX	EX	_	28	SBJ	_	_
28	was	_	VBD	VBD	_	12	COORD	_	_
29	a	_	DT	DT	_	31	NMOD	_	_
30	linear	_	JJ	JJ	_	31	NMOD	_	_
31	correlation	_	NN	NN	_	28	PRD	_	_
32	between	_	IN	IN	_	31	NMOD	_	_
33	the	_	DT	DT	_	34	NMOD	_	_
34	number	_	NN	NN	_	32	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	GCR	_	NN	NN	_	35	PMOD	_	_
37	and	_	CC	CC	_	34	CC	_	_
38	the	_	DT	DT	_	39	NMOD	_	_
39	course	_	NN	NN	_	34	COORD	_	_
40	of	_	IN	IN	_	39	NMOD	_	_
41	asthma	_	NN	NN	_	40	PMOD	_	_
42	.	_	.	.	_	3	P	_	_

1	Besides	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	there	_	EX	EX	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	also	_	RB	RB	_	4	ADV	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	linear	_	JJ	JJ	_	8	NMOD	_	_
8	correlation	_	NN	NN	_	4	PRD	_	_
9	between	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	number	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	GCR	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	11	CC	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	age	_	NN	NN	_	11	COORD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	initial	_	JJ	JJ	_	20	NMOD	_	_
20	attack	_	NN	NN	_	17	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	asthma	_	NN	NN	_	21	PMOD	_	_
23	.	_	.	.	_	4	P	_	_

1	No	_	DT	DT	_	2	NMOD	_	_
2	difference	_	NN	NN	_	7	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	plasma	_	NN	NN	_	6	NMOD	_	_
5	cortisol	_	NN	NN	_	6	NMOD	_	_
6	level	_	NN	NN	_	3	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	found	_	VBN	VBN	_	7	VC	_	_
9	between	_	IN	IN	_	8	ADV	_	_
10	asthmatics	_	NNS	NNS	_	9	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	healthy	_	JJ	JJ	_	13	NMOD	_	_
13	subjects	_	NNS	NNS	_	10	COORD	_	_
14	.	_	.	.	_	7	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	there	_	EX	EX	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	4	VMOD	_	_
7	no	_	DT	DT	_	11	NMOD	_	_
8	primary	_	JJ	JJ	_	11	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	general	_	JJ	JJ	_	8	COORD	_	_
11	impairment	_	NN	NN	_	6	PRD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	glucocorticoid	_	NN	NN	_	14	NMOD	_	_
14	metabolism	_	NN	NN	_	12	PMOD	_	_
15	in	_	IN	IN	_	6	ADV	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	asthmatics	_	NNS	NNS	_	15	PMOD	_	_
18	,	_	,	,	_	6	P	_	_
19	but	_	CC	CC	_	6	CC	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	number	_	NN	NN	_	27	SBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	GCR	_	NN	NN	_	22	PMOD	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	asthmatics	_	NNS	NNS	_	24	PMOD	_	_
27	is	_	VBZ	VBZ	_	6	COORD	_	_
28	lower	_	JJR	JJR	_	27	PRD	_	_
29	than	_	IN	IN	_	28	AMOD	_	_
30	that	_	DT	DT	_	29	PMOD	_	_
31	in	_	IN	IN	_	30	NMOD	_	_
32	healthy	_	JJ	JJ	_	33	NMOD	_	_
33	controls	_	NNS	NNS	_	31	PMOD	_	_
34	.	_	.	.	_	3	P	_	_

1	Alteration	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	structural	_	JJ	JJ	_	4	NMOD	_	_
4	order	_	NN	NN	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	human	_	JJ	JJ	_	9	NMOD	_	_
7	erythrocyte	_	NN	NN	_	9	NMOD	_	_
8	ghost	_	NN	NN	_	9	NMOD	_	_
9	membrane	_	NN	NN	_	5	PMOD	_	_
10	by	_	IN	IN	_	1	NMOD	_	_
11	glucocorticoids	_	NNS	NNS	_	10	PMOD	_	_
12	and	_	CC	CC	_	1	CC	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	influence	_	NN	NN	_	1	COORD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	glucocorticoid	_	NN	NN	_	20	NMOD	_	_
18	receptor	_	NN	NN	_	20	NMOD	_	_
19	antagonist	_	NN	NN	_	20	NMOD	_	_
20	RU	_	NN	NN	_	15	PMOD	_	_
21	486	_	CD	CD	_	20	NMOD	_	_
22	.	_	.	.	_	1	P	_	_

1	High-dose	_	JJ	JJ	_	4	NMOD	_	_
2	pulse	_	NN	NN	_	4	NMOD	_	_
3	glucocorticoid	_	NN	NN	_	4	NMOD	_	_
4	therapy	_	NN	NN	_	5	SBJ	_	_
5	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	been	_	VBN	VBN	_	5	VC	_	_
7	used	_	VBN	VBN	_	6	VC	_	_
8	successfully	_	RB	RB	_	7	ADV	_	_
9	in	_	IN	IN	_	7	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	clinic	_	NN	NN	_	9	PMOD	_	_
12	in	_	IN	IN	_	7	ADV	_	_
13	severe	_	JJ	JJ	_	15	NMOD	_	_
14	pathological	_	JJ	JJ	_	15	NMOD	_	_
15	conditions	_	NNS	NNS	_	12	PMOD	_	_
16	for	_	IN	IN	_	7	TMP	_	_
17	about	_	RB	RB	_	19	NMOD	_	_
18	20	_	CD	CD	_	17	DEP	_	_
19	years	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	mode	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	glucocorticoid	_	NN	NN	_	5	NMOD	_	_
5	action	_	NN	NN	_	3	PMOD	_	_
6	after	_	IN	IN	_	2	TMP	_	_
7	administration	_	NN	NN	_	6	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	such	_	JJ	JJ	_	10	NMOD	_	_
10	megadoses	_	NNS	NNS	_	8	PMOD	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	inexplicable	_	JJ	JJ	_	11	PRD	_	_
13	up	_	RP	RP	_	14	DEP	_	_
14	to	_	TO	TO	_	11	TMP	_	_
15	now	_	RB	RB	_	14	PMOD	_	_
16	.	_	.	.	_	11	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	supposed	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	some	_	DT	DT	_	6	NMOD	_	_
6	effects	_	NNS	NNS	_	7	SBJ	_	_
7	may	_	MD	MD	_	4	VMOD	_	_
8	be	_	VB	VB	_	7	VC	_	_
9	due	_	JJ	JJ	_	10	DEP	_	_
10	to	_	TO	TO	_	8	PRD	_	_
11	membrane	_	NN	NN	_	12	NMOD	_	_
12	alterations	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	32	ADV	_	_
2	the	_	DT	DT	_	5	NMOD	_	_
3	present	_	JJ	JJ	_	5	NMOD	_	_
4	in-vitro	_	FW	FW	_	5	NMOD	_	_
5	experiments	_	NNS	NNS	_	1	PMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	effect	_	NN	NN	_	32	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	dexamethasone	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	8	P	_	_
11	of	_	IN	IN	_	8	COORD	_	_
12	further	_	JJ	JJ	_	13	NMOD	_	_
13	glucocorticoids	_	NNS	NNS	_	11	PMOD	_	_
14	,	_	,	,	_	8	P	_	_
15	and	_	CC	CC	_	8	CC	_	_
16	of	_	IN	IN	_	8	COORD	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	glucocorticoid	_	NN	NN	_	21	NMOD	_	_
19	receptor	_	NN	NN	_	21	NMOD	_	_
20	antagonist	_	NN	NN	_	21	NMOD	_	_
21	RU	_	NN	NN	_	16	PMOD	_	_
22	486	_	CD	CD	_	21	NMOD	_	_
23	,	_	,	,	_	7	P	_	_
24	on	_	IN	IN	_	7	NMOD	_	_
25	structural	_	JJ	JJ	_	26	NMOD	_	_
26	order	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	human	_	JJ	JJ	_	31	NMOD	_	_
29	erythrocyte	_	NN	NN	_	31	NMOD	_	_
30	ghost	_	NN	NN	_	31	NMOD	_	_
31	membranes	_	NNS	NNS	_	27	PMOD	_	_
32	was	_	VBD	VBD	_	0	ROOT-S	_	_
33	investigated	_	VBN	VBN	_	32	VC	_	_
34	by	_	IN	IN	_	33	ADV	_	_
35	determining	_	VBG	VBG	_	34	PMOD	_	_
36	the	_	DT	DT	_	39	NMOD	_	_
37	steady-state	_	JJ	JJ	_	39	NMOD	_	_
38	fluorescence	_	NN	NN	_	39	NMOD	_	_
39	anisotropy	_	NN	NN	_	35	OBJ	_	_
40	of	_	IN	IN	_	39	NMOD	_	_
41	diphenylhexatriene	_	NN	NN	_	40	PMOD	_	_
42	(	_	(	(	_	43	P	_	_
43	DPH	_	NN	NN	_	41	PRN	_	_
44	)	_	)	)	_	43	P	_	_
45	.	_	.	.	_	32	P	_	_

1	Dexamethasone	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	to	_	TO	TO	_	5	VMOD	_	_
5	induce	_	VB	VB	_	3	OBJ	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	significant	_	JJ	JJ	_	8	NMOD	_	_
8	decrease	_	NN	NN	_	5	OBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	membrane	_	NN	NN	_	12	NMOD	_	_
11	structural	_	JJ	JJ	_	12	NMOD	_	_
12	order	_	NN	NN	_	9	PMOD	_	_
13	at	_	IN	IN	_	5	ADV	_	_
14	concentrations	_	NNS	NNS	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	about	_	RB	RB	_	18	NMOD	_	_
17	10-LRB--6-RRB-	_	CD	CD	_	16	DEP	_	_
18	M	_	NN	NN	_	15	PMOD	_	_
19	in	_	IN	IN	_	5	ADV	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	concentration-dependent	_	JJ	JJ	_	22	NMOD	_	_
22	manner	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	found	_	VBD	VBD	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	correlation	_	NN	NN	_	2	OBJ	_	_
5	between	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	uptake	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	dexamethasone	_	NN	NN	_	8	PMOD	_	_
10	by	_	IN	IN	_	7	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	ghost	_	NN	NN	_	13	NMOD	_	_
13	membranes	_	NNS	NNS	_	10	PMOD	_	_
14	and	_	CC	CC	_	7	CC	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	decrease	_	NN	NN	_	7	COORD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	structural	_	JJ	JJ	_	20	NMOD	_	_
20	order	_	NN	NN	_	17	PMOD	_	_
21	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	other	_	JJ	JJ	_	3	NMOD	_	_
3	glucocorticoids	_	NNS	NNS	_	10	SBJ	_	_
4	tested	_	VBN	VBN	_	3	NMOD	_	_
5	,	_	,	,	_	3	P	_	_
6	methylprednisolone	_	NN	NN	_	3	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	corticosterone	_	NN	NN	_	6	COORD	_	_
9	,	_	,	,	_	3	P	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	also	_	RB	RB	_	10	ADV	_	_
12	effective	_	JJ	JJ	_	10	PRD	_	_
13	at	_	IN	IN	_	10	ADV	_	_
14	concentrations	_	NNS	NNS	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	10-LRB--5-RRB-	_	CD	CD	_	17	NMOD	_	_
17	M	_	NN	NN	_	15	PMOD	_	_
18	or	_	CC	CC	_	19	CC	_	_
19	greater	_	JJR	JJR	_	17	NMOD	_	_
20	.	_	.	.	_	10	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	observed	_	VBD	VBD	_	0	ROOT-S	_	_
3	no	_	DT	DT	_	4	NMOD	_	_
4	change	_	NN	NN	_	2	OBJ	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	membrane	_	NN	NN	_	8	NMOD	_	_
7	structural	_	JJ	JJ	_	8	NMOD	_	_
8	order	_	NN	NN	_	5	PMOD	_	_
9	with	_	IN	IN	_	4	NMOD	_	_
10	RU	_	NN	NN	_	9	PMOD	_	_
11	486	_	CD	CD	_	10	NMOD	_	_
12	up	_	IN	IN	_	10	NMOD	_	_
13	to	_	TO	TO	_	12	DEP	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	concentration	_	NN	NN	_	12	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	10-LRB--4-RRB-	_	CD	CD	_	18	NMOD	_	_
18	M	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	However	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	simultaneous	_	JJ	JJ	_	4	NMOD	_	_
4	incubation	_	NN	NN	_	10	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	RU	_	NN	NN	_	5	PMOD	_	_
7	486	_	CD	CD	_	6	NMOD	_	_
8	with	_	IN	IN	_	4	NMOD	_	_
9	dexamethasone	_	NN	NN	_	8	PMOD	_	_
10	caused	_	VBD	VBD	_	0	ROOT-S	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	distinct	_	JJ	JJ	_	13	NMOD	_	_
13	interference	_	NN	NN	_	10	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	RU	_	NN	NN	_	14	PMOD	_	_
16	486	_	CD	CD	_	15	NMOD	_	_
17	with	_	IN	IN	_	13	NMOD	_	_
18	dexamethasone	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	10	P	_	_

1	Thus	_	RB	RB	_	26	ADV	_	_
2	,	_	,	,	_	26	P	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	glucocorticoid-induced	_	JJ	JJ	_	6	NMOD	_	_
5	membrane	_	NN	NN	_	6	NMOD	_	_
6	perturbation	_	NN	NN	_	26	SBJ	_	_
7	,	_	,	,	_	6	P	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	possibility	_	NN	NN	_	6	COORD	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	inhibit	_	VB	VB	_	9	NMOD	_	_
12	it	_	PRP	PRP	_	11	OBJ	_	_
13	by	_	IN	IN	_	11	ADV	_	_
14	RU	_	NN	NN	_	13	PMOD	_	_
15	486	_	CD	CD	_	14	NMOD	_	_
16	,	_	,	,	_	6	P	_	_
17	and	_	CC	CC	_	6	CC	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	inactivity	_	NN	NN	_	6	COORD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	structurally	_	RB	RB	_	23	AMOD	_	_
23	related	_	JJ	JJ	_	24	NMOD	_	_
24	progesterone	_	NN	NN	_	20	PMOD	_	_
25	,	_	,	,	_	6	P	_	_
26	refer	_	VBP	VBP	_	0	ROOT-S	_	_
27	to	_	TO	TO	_	26	ADV	_	_
28	relatively	_	RB	RB	_	29	AMOD	_	_
29	specific	_	JJ	JJ	_	31	NMOD	_	_
30	binding	_	VBG	VBG	_	31	NMOD	_	_
31	sites	_	NNS	NNS	_	27	PMOD	_	_
32	for	_	IN	IN	_	31	NMOD	_	_
33	the	_	DT	DT	_	34	NMOD	_	_
34	glucocorticoids	_	NNS	NNS	_	32	PMOD	_	_
35	in	_	IN	IN	_	31	NMOD	_	_
36	the	_	DT	DT	_	37	NMOD	_	_
37	membrane	_	NN	NN	_	35	PMOD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	erythrocyte	_	NN	NN	_	40	NMOD	_	_
40	ghosts	_	NNS	NNS	_	38	PMOD	_	_
41	.	_	.	.	_	26	P	_	_

1	Cloning	_	NN	NN	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	characterization	_	NN	NN	_	1	COORD	_	_
4	of	_	IN	IN	_	1	NMOD	_	_
5	NF-ATc	_	NN	NN	_	4	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	NF-ATp	_	NN	NN	_	5	COORD	_	_
8	:	_	:	:	_	1	P	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	cytoplasmic	_	JJ	JJ	_	11	NMOD	_	_
11	components	_	NNS	NNS	_	1	NMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	NF-AT	_	NN	NN	_	12	PMOD	_	_
14	.	_	.	.	_	11	P	_	_

1	Present	_	JJ	JJ	_	2	NMOD	_	_
2	evidence	_	NN	NN	_	3	SBJ	_	_
3	indicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	pathway	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	signal	_	NN	NN	_	8	NMOD	_	_
8	transmission	_	NN	NN	_	6	PMOD	_	_
9	in	_	IN	IN	_	5	NMOD	_	_
10	T	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	that	_	WDT	WDT	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	5	NMOD	_	_
14	outlined	_	VBN	VBN	_	13	VC	_	_
15	in	_	IN	IN	_	14	ADV	_	_
16	figure	_	NN	NN	_	15	PMOD	_	_
17	1	_	CD	CD	_	16	NMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	elevation	_	NN	NN	_	15	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	intracellular	_	JJ	JJ	_	5	NMOD	_	_
5	calcium	_	NN	NN	_	3	PMOD	_	_
6	that	_	WDT	WDT	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	2	NMOD	_	_
8	induced	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	interactions	_	NNS	NNS	_	9	PMOD	_	_
11	at	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	antigen	_	NN	NN	_	14	NMOD	_	_
14	receptor	_	NN	NN	_	11	PMOD	_	_
15	leads	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	activation	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	calcium-dependent	_	JJ	JJ	_	23	NMOD	_	_
22	phosphatase	_	NN	NN	_	23	NMOD	_	_
23	calcineurin	_	NN	NN	_	19	PMOD	_	_
24	.	_	.	.	_	15	P	_	_

1	This	_	DT	DT	_	4	SBJ	_	_
2	in	_	IN	IN	_	4	ADV	_	_
3	turn	_	NN	NN	_	2	PMOD	_	_
4	leads	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	nuclear	_	JJ	JJ	_	8	NMOD	_	_
8	association	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	cytosolic	_	JJ	JJ	_	12	NMOD	_	_
12	component	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	NF-ATc	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	activation	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	calcineurin	_	NN	NN	_	3	PMOD	_	_
5	and	_	CC	CC	_	2	CC	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	nuclear	_	JJ	JJ	_	8	NMOD	_	_
8	import	_	NN	NN	_	2	COORD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	NF-ATc	_	NN	NN	_	9	PMOD	_	_
11	can	_	MD	MD	_	0	ROOT-S	_	_
12	both	_	DT	DT	_	11	ADV	_	_
13	be	_	VB	VB	_	11	VC	_	_
14	blocked	_	VBN	VBN	_	13	VC	_	_
15	by	_	IN	IN	_	14	ADV	_	_
16	cyclosporin	_	NN	NN	_	17	NMOD	_	_
17	A	_	NN	NN	_	20	NMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	FK506	_	NN	NN	_	17	COORD	_	_
20	in	_	IN	IN	_	15	LGS	_	_
21	complex	_	NN	NN	_	20	PMOD	_	_
22	with	_	IN	IN	_	21	NMOD	_	_
23	their	_	PRP$	PRP$	_	25	NMOD	_	_
24	respective	_	JJ	JJ	_	25	NMOD	_	_
25	immunophilins	_	NNS	NNS	_	22	PMOD	_	_
26	.	_	.	.	_	11	P	_	_

1	Once	_	RB	RB	_	2	VMOD	_	_
2	in	_	IN	IN	_	7	ADV	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	nucleus	_	NN	NN	_	2	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	NF-ATc	_	NN	NN	_	7	SBJ	_	_
7	interacts	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	NF-ATn	_	NN	NN	_	8	PMOD	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	form	_	VB	VB	_	7	OBJ	_	_
12	an	_	DT	DT	_	15	NMOD	_	_
13	active	_	JJ	JJ	_	15	NMOD	_	_
14	transcriptional	_	JJ	JJ	_	15	NMOD	_	_
15	complex	_	NN	NN	_	11	OBJ	_	_
16	.	_	.	.	_	7	P	_	_

1	NF-ATn	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	ubiquitous	_	JJ	JJ	_	5	NMOD	_	_
5	protein	_	NN	NN	_	2	PRD	_	_
6	,	_	,	,	_	2	P	_	_
7	can	_	MD	MD	_	2	COORD	_	_
8	be	_	VB	VB	_	7	VC	_	_
9	synthesized	_	VBN	VBN	_	8	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	response	_	NN	NN	_	10	DEP	_	_
12	to	_	TO	TO	_	10	DEP	_	_
13	PMA	_	NN	NN	_	10	PMOD	_	_
14	,	_	,	,	_	2	P	_	_
15	and	_	CC	CC	_	2	CC	_	_
16	has	_	VBZ	VBZ	_	2	COORD	_	_
17	many	_	JJ	JJ	_	18	NMOD	_	_
18	similarities	_	NNS	NNS	_	16	OBJ	_	_
19	to	_	TO	TO	_	18	NMOD	_	_
20	AP-1	_	NN	NN	_	19	PMOD	_	_
21	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	mechanism	_	NN	NN	_	9	SBJ	_	_
3	by	_	IN	IN	_	6	ADV	_	_
4	which	_	WDT	WDT	_	3	PMOD	_	_
5	NF-ATc	_	NN	NN	_	6	SBJ	_	_
6	enters	_	VBZ	VBZ	_	2	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	nucleus	_	NN	NN	_	6	OBJ	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	unknown	_	JJ	JJ	_	9	PRD	_	_
11	,	_	,	,	_	9	P	_	_
12	and	_	CC	CC	_	9	CC	_	_
13	although	_	IN	IN	_	21	ADV	_	_
14	it	_	PRP	PRP	_	15	SBJ	_	_
15	appears	_	VBZ	VBZ	_	13	VMOD	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	require	_	VB	VB	_	15	OBJ	_	_
18	calcineurin	_	NN	NN	_	17	OBJ	_	_
19	,	_	,	,	_	21	P	_	_
20	NF-ATc	_	NN	NN	_	21	SBJ	_	_
21	has	_	VBZ	VBZ	_	9	COORD	_	_
22	not	_	RB	RB	_	21	VMOD	_	_
23	yet	_	RB	RB	_	21	TMP	_	_
24	been	_	VBN	VBN	_	21	VC	_	_
25	shown	_	VBN	VBN	_	24	VC	_	_
26	to	_	TO	TO	_	27	VMOD	_	_
27	be	_	VB	VB	_	25	OBJ	_	_
28	an	_	DT	DT	_	31	NMOD	_	_
29	in	_	FW	FW	_	30	AMOD	_	_
30	vivo	_	FW	FW	_	31	NMOD	_	_
31	substrate	_	NN	NN	_	27	PRD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	calcineurin	_	NN	NN	_	32	PMOD	_	_
34	.	_	.	.	_	9	P	_	_

1	Alternative	_	JJ	JJ	_	2	NMOD	_	_
2	mechanisms	_	NNS	NNS	_	3	SBJ	_	_
3	include	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	possibility	_	NN	NN	_	3	OBJ	_	_
6	that	_	IN	IN	_	5	NMOD	_	_
7	NF-ATc	_	NN	NN	_	8	SBJ	_	_
8	operates	_	VBZ	VBZ	_	6	VMOD	_	_
9	on	_	IN	IN	_	8	ADV	_	_
10	some	_	DT	DT	_	12	NMOD	_	_
11	cytoplasmic	_	JJ	JJ	_	12	NMOD	_	_
12	anchor	_	NN	NN	_	9	PMOD	_	_
13	or	_	CC	CC	_	6	CC	_	_
14	that	_	IN	IN	_	6	COORD	_	_
15	other	_	JJ	JJ	_	16	NMOD	_	_
16	proteins	_	NNS	NNS	_	22	SBJ	_	_
17	that	_	WDT	WDT	_	18	SBJ	_	_
18	are	_	VBP	VBP	_	16	NMOD	_	_
19	controlled	_	VBN	VBN	_	18	VC	_	_
20	by	_	IN	IN	_	19	LGS	_	_
21	calcineurin	_	NN	NN	_	20	PMOD	_	_
22	carry	_	VBP	VBP	_	14	VMOD	_	_
23	out	_	RP	RP	_	22	PRT	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	nuclear	_	JJ	JJ	_	26	NMOD	_	_
26	import	_	NN	NN	_	22	OBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	NF-ATc	_	NN	NN	_	27	PMOD	_	_
29	.	_	.	.	_	3	P	_	_

1	Although	_	IN	IN	_	8	ADV	_	_
2	NF-ATp	_	NN	NN	_	3	SBJ	_	_
3	copurifies	_	VBZ	VBZ	_	1	VMOD	_	_
4	with	_	IN	IN	_	3	ADV	_	_
5	NF-ATc	_	NN	NN	_	4	PMOD	_	_
6	,	_	,	,	_	8	P	_	_
7	there	_	EX	EX	_	8	SBJ	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	as	_	RB	RB	_	8	TMP	_	_
10	yet	_	RB	RB	_	9	AMOD	_	_
11	no	_	DT	DT	_	12	NMOD	_	_
12	understanding	_	NN	NN	_	8	PRD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	how	_	WRB	WRB	_	17	ADV	_	_
15	NF-ATp	_	NN	NN	_	16	SBJ	_	_
16	is	_	VBZ	VBZ	_	13	PMOD	_	_
17	functioning	_	VBG	VBG	_	16	VC	_	_
18	in	_	FW	FW	_	17	ADV	_	_
19	vivo	_	FW	FW	_	18	AMOD	_	_
20	.	_	.	.	_	8	P	_	_

1	Now	_	RB	RB	_	13	TMP	_	_
2	that	_	IN	IN	_	1	AMOD	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	proteins	_	NNS	NNS	_	5	SBJ	_	_
5	are	_	VBP	VBP	_	2	VMOD	_	_
6	purified	_	VBN	VBN	_	5	VC	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	cloned	_	VBN	VBN	_	6	COORD	_	_
9	,	_	,	,	_	13	P	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	major	_	JJ	JJ	_	12	NMOD	_	_
12	goals	_	NNS	NNS	_	13	SBJ	_	_
13	will	_	MD	MD	_	0	ROOT-S	_	_
14	be	_	VB	VB	_	13	VC	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	understand	_	VB	VB	_	14	PRD	_	_
17	their	_	PRP$	PRP$	_	18	NMOD	_	_
18	role	_	NN	NN	_	16	OBJ	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	roles	_	NNS	NNS	_	18	COORD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	other	_	JJ	JJ	_	25	NMOD	_	_
24	family	_	NN	NN	_	25	NMOD	_	_
25	members	_	NNS	NNS	_	22	PMOD	_	_
26	in	_	IN	IN	_	18	NMOD	_	_
27	thymic	_	JJ	JJ	_	28	NMOD	_	_
28	development	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	13	P	_	_

1	Changes	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	in	_	IN	IN	_	1	NMOD	_	_
3	triiodothyronine	_	NN	NN	_	10	NMOD	_	_
4	(	_	(	(	_	5	P	_	_
5	T3	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	mononuclear	_	JJ	JJ	_	10	NMOD	_	_
8	leukocyte	_	NN	NN	_	10	NMOD	_	_
9	receptor	_	NN	NN	_	10	NMOD	_	_
10	kinetics	_	NNS	NNS	_	2	PMOD	_	_
11	after	_	IN	IN	_	1	TMP	_	_
12	T3	_	NN	NN	_	13	NMOD	_	_
13	administration	_	NN	NN	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	multiple	_	JJ	JJ	_	17	NMOD	_	_
16	cold-air	_	JJ	JJ	_	17	NMOD	_	_
17	exposures	_	NNS	NNS	_	13	COORD	_	_
18	.	_	.	.	_	1	P	_	_

1	Repeated	_	VBN	VBN	_	3	NMOD	_	_
2	cold-air	_	JJ	JJ	_	3	NMOD	_	_
3	exposures	_	NNS	NNS	_	4	SBJ	_	_
4	increase	_	VBP	VBP	_	0	ROOT-S	_	_
5	human	_	JJ	JJ	_	12	NMOD	_	_
6	triiodothyronine	_	NN	NN	_	12	NMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	T3	_	CD	CD	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	plasma	_	NN	NN	_	12	NMOD	_	_
11	clearance	_	NN	NN	_	12	NMOD	_	_
12	rates	_	NNS	NNS	_	4	OBJ	_	_
13	.	_	.	.	_	4	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	study	_	VB	VB	_	19	VC	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	response	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	nuclear	_	JJ	JJ	_	9	NMOD	_	_
8	T3	_	NN	NN	_	9	NMOD	_	_
9	receptor	_	NN	NN	_	5	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	NT3R	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	in	_	IN	IN	_	4	NMOD	_	_
14	this	_	DT	DT	_	15	NMOD	_	_
15	condition	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	19	P	_	_
17	binding	_	VBG	VBG	_	18	NMOD	_	_
18	characteristics	_	NNS	NNS	_	19	SBJ	_	_
19	were	_	VBD	VBD	_	0	ROOT-S	_	_
20	analyzed	_	VBN	VBN	_	19	VC	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	human	_	JJ	JJ	_	24	NMOD	_	_
23	mononuclear	_	JJ	JJ	_	24	NMOD	_	_
24	leukocytes	_	NNS	NNS	_	21	PMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	MNL	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	.	_	.	.	_	19	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	supplemented	_	VBD	VBD	_	0	ROOT-S	_	_
6	one	_	CD	CD	_	7	NMOD	_	_
7	group	_	NN	NN	_	5	IOBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	individuals	_	NNS	NNS	_	8	PMOD	_	_
10	with	_	IN	IN	_	5	ADV	_	_
11	a	_	DT	DT	_	15	NMOD	_	_
12	daily	_	RB	RB	_	13	AMOD	_	_
13	oral	_	JJ	JJ	_	15	NMOD	_	_
14	replacement	_	NN	NN	_	15	NMOD	_	_
15	dose	_	NN	NN	_	10	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	T3	_	NN	NN	_	16	PMOD	_	_
18	to	_	TO	TO	_	19	VMOD	_	_
19	isolate	_	VB	VB	_	5	OBJ	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	influence	_	NN	NN	_	19	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	serum	_	NN	NN	_	24	NMOD	_	_
24	thyroxine	_	NN	NN	_	33	NMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	T4	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	and	_	CC	CC	_	24	CC	_	_
29	thyrotropin	_	NN	NN	_	24	COORD	_	_
30	(	_	(	(	_	31	P	_	_
31	TSH	_	NN	NN	_	29	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	levels	_	NNS	NNS	_	22	PMOD	_	_
34	on	_	IN	IN	_	21	NMOD	_	_
35	receptor	_	NN	NN	_	36	NMOD	_	_
36	kinetics	_	NNS	NNS	_	34	PMOD	_	_
37	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	subjects	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	exposed	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	cold	_	JJ	JJ	_	7	NMOD	_	_
7	air	_	NN	NN	_	5	PMOD	_	_
8	(	_	(	(	_	11	P	_	_
9	4	_	CD	CD	_	11	NMOD	_	_
10	degrees	_	NNS	NNS	_	11	NMOD	_	_
11	C	_	NN	NN	_	7	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	twice\/d	_	RB	RB	_	4	ADV	_	_
14	,	_	,	,	_	4	P	_	_
15	30	_	CD	CD	_	16	NMOD	_	_
16	min\/exposure	_	NN	NN	_	4	TMP	_	_
17	,	_	,	,	_	4	P	_	_
18	for	_	IN	IN	_	4	ADV	_	_
19	a	_	DT	DT	_	20	NMOD	_	_
20	total	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	80	_	CD	CD	_	23	NMOD	_	_
23	exposures	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	T3-	_	JJ	JJ	_	3	NMOD	_	_
3	subjects	_	NNS	NNS	_	4	SBJ	_	_
4	received	_	VBD	VBD	_	0	ROOT-S	_	_
5	placebo	_	NN	NN	_	4	OBJ	_	_
6	{	_	(	(	_	9	P	_	_
7	n	_	NN	NN	_	9	SBJ	_	_
8	=	_	JJ	JJ	_	9	VMOD	_	_
9	8	_	CD	CD	_	5	PRN	_	_
10	}	_	)	)	_	9	P	_	_
11	and	_	CC	CC	_	4	CC	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	T3+	_	JJ	JJ	_	14	NMOD	_	_
14	subjects	_	NNS	NNS	_	15	SBJ	_	_
15	received	_	VBD	VBD	_	4	COORD	_	_
16	T3	_	CD	CD	_	15	OBJ	_	_
17	(	_	(	(	_	19	P	_	_
18	30	_	CD	CD	_	19	NMOD	_	_
19	micrograms\/d	_	NN	NN	_	16	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	{	_	(	(	_	24	P	_	_
22	n	_	NN	NN	_	24	SBJ	_	_
23	=	_	JJ	JJ	_	24	VMOD	_	_
24	8	_	CD	CD	_	16	PRN	_	_
25	}	_	)	)	_	24	P	_	_
26	in	_	IN	IN	_	4	ADV	_	_
27	a	_	DT	DT	_	29	NMOD	_	_
28	double-blind	_	JJ	JJ	_	29	NMOD	_	_
29	fashion	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	4	P	_	_

1	Mononuclear	_	JJ	JJ	_	2	NMOD	_	_
2	leukocytes	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	isolated	_	VBN	VBN	_	3	VC	_	_
5	from	_	IN	IN	_	4	ADV	_	_
6	peripheral	_	JJ	JJ	_	7	NMOD	_	_
7	blood	_	NN	NN	_	5	PMOD	_	_
8	before	_	IN	IN	_	4	TMP	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	cold	_	JJ	JJ	_	11	NMOD	_	_
11	exposure	_	NN	NN	_	15	SBJ	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	drug	_	NN	NN	_	14	NMOD	_	_
14	regimen	_	NNS	NNS	_	11	COORD	_	_
15	began	_	VBD	VBD	_	8	VMOD	_	_
16	,	_	,	,	_	4	P	_	_
17	and	_	CC	CC	_	4	CC	_	_
18	then	_	RB	RB	_	4	COORD	_	_
19	after	_	IN	IN	_	8	GAP	_	_
20	every	_	DT	DT	_	22	NMOD	_	_
21	20	_	CD	CD	_	20	DEP	_	_
22	exposures	_	NNS	NNS	_	19	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	dissociation	_	NN	NN	_	3	NMOD	_	_
3	constant	_	NN	NN	_	18	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	Kd	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	and	_	CC	CC	_	3	CC	_	_
8	maximum	_	NN	NN	_	10	NMOD	_	_
9	binding	_	NN	NN	_	10	NMOD	_	_
10	capacity	_	NN	NN	_	3	COORD	_	_
11	(	_	(	(	_	12	P	_	_
12	MBC	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	of	_	IN	IN	_	3	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	NT3R	_	NN	NN	_	17	NMOD	_	_
17	values	_	NNS	NNS	_	14	PMOD	_	_
18	were	_	VBD	VBD	_	0	ROOT-S	_	_
19	log	_	NN	NN	_	20	VMOD	_	_
20	transformed	_	VBN	VBN	_	18	VC	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	minimize	_	VB	VB	_	20	OBJ	_	_
23	between-subject	_	JJ	JJ	_	24	NMOD	_	_
24	variability	_	NN	NN	_	22	OBJ	_	_
25	.	_	.	.	_	18	P	_	_

1	In	_	IN	IN	_	21	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	T3+	_	JJ	JJ	_	4	NMOD	_	_
4	group	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	21	P	_	_
6	serum	_	NN	NN	_	8	NMOD	_	_
7	total	_	VBP	VBP	_	8	NMOD	_	_
8	thyroxine	_	NN	NN	_	21	SBJ	_	_
9	(	_	(	(	_	10	P	_	_
10	TT4	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	,	_	,	,	_	8	P	_	_
13	free	_	JJ	JJ	_	14	NMOD	_	_
14	T4	_	NN	NN	_	8	COORD	_	_
15	(	_	(	(	_	16	P	_	_
16	FT4	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	,	_	,	,	_	8	P	_	_
19	and	_	CC	CC	_	8	CC	_	_
20	TSH	_	NN	NN	_	8	COORD	_	_
21	were	_	VBD	VBD	_	0	ROOT-S	_	_
22	approx	_	RB	RB	_	24	NMOD	_	_
23	50	_	CD	CD	_	22	DEP	_	_
24	%	_	NN	NN	_	25	AMOD	_	_
25	lower	_	JJR	JJR	_	21	PRD	_	_
26	than	_	IN	IN	_	25	AMOD	_	_
27	both	_	CC	CC	_	26	CC	_	_
28	basal	_	JJ	JJ	_	26	NMOD	_	_
29	and	_	CC	CC	_	26	CC	_	_
30	T3-values	_	NNS	NNS	_	26	COORD	_	_
31	.	_	.	.	_	21	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	log10Kd	_	NN	NN	_	3	SBJ	_	_
3	increased	_	VBD	VBD	_	0	ROOT-S	_	_
4	0.304	_	CD	CD	_	3	OBJ	_	_
5	+\/-	_	CC	CC	_	4	CC	_	_
6	0.139	_	CD	CD	_	4	COORD	_	_
7	(	_	(	(	_	10	P	_	_
8	p	_	NN	NN	_	10	SBJ	_	_
9	&lt;	_	JJR	JJR	_	10	DEP	_	_
10	0.04	_	CD	CD	_	3	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	and	_	CC	CC	_	3	CC	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	log10MBC	_	NN	NN	_	15	SBJ	_	_
15	increased	_	VBD	VBD	_	3	COORD	_	_
16	0.49	_	CD	CD	_	15	OBJ	_	_
17	+\/-	_	CC	CC	_	16	CC	_	_
18	0.10	_	CD	CD	_	16	COORD	_	_
19	(	_	(	(	_	22	P	_	_
20	p	_	NN	NN	_	22	SBJ	_	_
21	&lt;	_	JJR	JJR	_	22	DEP	_	_
22	0.001	_	CD	CD	_	15	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	in	_	IN	IN	_	3	ADV	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	T3+	_	JJ	JJ	_	27	NMOD	_	_
27	subjects	_	NNS	NNS	_	24	PMOD	_	_
28	compared	_	VBN	VBN	_	3	ADV	_	_
29	to	_	TO	TO	_	28	PMOD	_	_
30	baseline	_	NN	NN	_	29	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	change	_	NN	NN	_	5	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	MBC	_	NN	NN	_	3	PMOD	_	_
5	represents	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	311	_	CD	CD	_	9	NMOD	_	_
8	%	_	NN	NN	_	9	NMOD	_	_
9	increase	_	NN	NN	_	5	OBJ	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	MBC	_	NN	NN	_	10	PMOD	_	_
13	over	_	IN	IN	_	9	NMOD	_	_
14	baseline	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	9	CC	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	fivefold	_	JJ	JJ	_	18	NMOD	_	_
18	increase	_	NN	NN	_	9	COORD	_	_
19	over	_	IN	IN	_	18	NMOD	_	_
20	placebo-treated	_	JJ	JJ	_	21	NMOD	_	_
21	subjects	_	NNS	NNS	_	19	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	T3-	_	JJ	JJ	_	3	NMOD	_	_
3	group	_	NN	NN	_	4	SBJ	_	_
4	showed	_	VBD	VBD	_	0	ROOT-S	_	_
5	no	_	DT	DT	_	6	NMOD	_	_
6	change	_	NN	NN	_	4	OBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	MBC	_	NN	NN	_	7	PMOD	_	_
9	over	_	IN	IN	_	4	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	study	_	NN	NN	_	9	PMOD	_	_
12	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	describe	_	VBP	VBP	_	0	ROOT-S	_	_
4	for	_	IN	IN	_	3	TMP	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	first	_	JJ	JJ	_	7	NMOD	_	_
7	time	_	NN	NN	_	4	PMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	rapid	_	JJ	JJ	_	10	NMOD	_	_
10	modulation	_	NN	NN	_	3	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	NT3R	_	NN	NN	_	11	PMOD	_	_
14	in	_	IN	IN	_	10	NMOD	_	_
15	response	_	NN	NN	_	14	DEP	_	_
16	to	_	TO	TO	_	14	DEP	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	combined	_	JJ	JJ	_	19	NMOD	_	_
19	influence	_	NN	NN	_	14	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	cold	_	JJ	JJ	_	22	NMOD	_	_
22	exposure	_	NN	NN	_	20	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	reduced	_	VBN	VBN	_	26	NMOD	_	_
25	circulating	_	VBG	VBG	_	26	NMOD	_	_
26	T4	_	NN	NN	_	22	COORD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	TSH	_	NN	NN	_	26	COORD	_	_
29	.	_	.	.	_	3	P	_	_

1	Selective	_	JJ	JJ	_	2	NMOD	_	_
2	effects	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	DNA	_	NN	NN	_	6	NMOD	_	_
5	damaging	_	NN	NN	_	6	NMOD	_	_
6	agents	_	NNS	NNS	_	3	PMOD	_	_
7	on	_	IN	IN	_	2	NMOD	_	_
8	HIV	_	NN	NN	_	12	NMOD	_	_
9	long	_	JJ	JJ	_	12	NMOD	_	_
10	terminal	_	JJ	JJ	_	12	NMOD	_	_
11	repeat	_	NN	NN	_	12	NMOD	_	_
12	activation	_	NN	NN	_	7	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	virus	_	NN	NN	_	15	NMOD	_	_
15	replication	_	NN	NN	_	12	COORD	_	_
16	in	_	FW	FW	_	15	NMOD	_	_
17	vitro	_	FW	FW	_	16	AMOD	_	_
18	.	_	.	.	_	2	P	_	_

1	Much	_	JJ	JJ	_	2	NMOD	_	_
2	attention	_	NN	NN	_	3	SBJ	_	_
3	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	recently	_	RB	RB	_	3	TMP	_	_
5	focused	_	VBN	VBN	_	3	VC	_	_
6	on	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	observation	_	NN	NN	_	6	PMOD	_	_
9	that	_	IN	IN	_	8	NMOD	_	_
10	UV	_	NN	NN	_	11	NMOD	_	_
11	light	_	NN	NN	_	12	SBJ	_	_
12	can	_	MD	MD	_	9	VMOD	_	_
13	activate	_	VB	VB	_	12	VC	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	long	_	JJ	JJ	_	17	NMOD	_	_
16	terminal	_	JJ	JJ	_	17	NMOD	_	_
17	repeat	_	NN	NN	_	13	OBJ	_	_
18	(	_	(	(	_	19	P	_	_
19	LTR	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	of	_	IN	IN	_	17	NMOD	_	_
22	the	_	DT	DT	_	25	NMOD	_	_
23	human	_	JJ	JJ	_	25	NMOD	_	_
24	immunodeficiency	_	NN	NN	_	25	NMOD	_	_
25	virus	_	NN	NN	_	21	PMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	HIV	_	NN	NN	_	25	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	.	_	.	.	_	3	P	_	_

1	Although	_	IN	IN	_	14	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	mechanism	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	LTR	_	NN	NN	_	6	NMOD	_	_
6	activation	_	NN	NN	_	4	PMOD	_	_
7	remains	_	VBZ	VBZ	_	1	VMOD	_	_
8	obscure	_	JJ	JJ	_	7	PRD	_	_
9	,	_	,	,	_	14	P	_	_
10	several	_	JJ	JJ	_	11	NMOD	_	_
11	lines	_	NNS	NNS	_	14	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	investigation	_	NN	NN	_	12	PMOD	_	_
14	have	_	VBP	VBP	_	0	ROOT-S	_	_
15	suggested	_	VBN	VBN	_	14	VC	_	_
16	that	_	IN	IN	_	15	OBJ	_	_
17	it	_	PRP	PRP	_	18	SBJ	_	_
18	is	_	VBZ	VBZ	_	16	VMOD	_	_
19	a	_	DT	DT	_	20	NMOD	_	_
20	result	_	NN	NN	_	18	PRD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	activation	_	NN	NN	_	21	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	30	NMOD	_	_
25	NF-kappa	_	NN	NN	_	30	NMOD	_	_
26	B	_	NN	NN	_	30	NMOD	_	_
27	transcription	_	NN	NN	_	30	NMOD	_	_
28	factor	_	NN	NN	_	30	NMOD	_	_
29	(	_	(	(	_	30	P	_	_
30	s	_	NNS	NNS	_	23	PMOD	_	_
31	)	_	)	)	_	30	P	_	_
32	following	_	VBG	VBG	_	22	TMP	_	_
33	signaling	_	NN	NN	_	34	NMOD	_	_
34	events	_	NNS	NNS	_	32	PMOD	_	_
35	related	_	JJ	JJ	_	34	NMOD	_	_
36	to	_	TO	TO	_	35	AMOD	_	_
37	generalized	_	VBN	VBN	_	39	NMOD	_	_
38	DNA	_	NN	NN	_	39	NMOD	_	_
39	damage	_	NN	NN	_	36	PMOD	_	_
40	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	present	_	VBP	VBP	_	0	ROOT-S	_	_
7	data	_	NNS	NNS	_	6	OBJ	_	_
8	demonstrating	_	NN	NN	_	7	NMOD	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	HIV	_	NN	NN	_	12	NMOD	_	_
11	LTR	_	NN	NN	_	12	NMOD	_	_
12	activation	_	NN	NN	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	9	VMOD	_	_
14	not	_	RB	RB	_	17	NMOD	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	general	_	JJ	JJ	_	17	NMOD	_	_
17	consequence	_	NN	NN	_	13	PRD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	cellular	_	JJ	JJ	_	21	NMOD	_	_
20	DNA	_	NN	NN	_	21	NMOD	_	_
21	damage	_	NN	NN	_	18	PMOD	_	_
22	,	_	,	,	_	17	P	_	_
23	but	_	CC	CC	_	17	CC	_	_
24	rather	_	RB	RB	_	23	COORD	_	_
25	a	_	DT	DT	_	26	NMOD	_	_
26	process	_	NN	NN	_	17	COORD	_	_
27	unique	_	JJ	JJ	_	26	NMOD	_	_
28	to	_	TO	TO	_	27	AMOD	_	_
29	specific	_	JJ	JJ	_	31	NMOD	_	_
30	genotoxic	_	JJ	JJ	_	31	NMOD	_	_
31	stimuli	_	NNS	NNS	_	28	PMOD	_	_
32	,	_	,	,	_	9	P	_	_
33	and	_	CC	CC	_	9	CC	_	_
34	that	_	IN	IN	_	9	COORD	_	_
35	it	_	PRP	PRP	_	36	SBJ	_	_
36	does	_	VBZ	VBZ	_	34	VMOD	_	_
37	not	_	RB	RB	_	36	ADV	_	_
38	necessarily	_	RB	RB	_	37	AMOD	_	_
39	depend	_	VB	VB	_	36	VC	_	_
40	on	_	IN	IN	_	39	ADV	_	_
41	activation	_	NN	NN	_	40	PMOD	_	_
42	of	_	IN	IN	_	41	NMOD	_	_
43	NF-kappa	_	NN	NN	_	44	NMOD	_	_
44	B	_	NN	NN	_	42	PMOD	_	_
45	.	_	.	.	_	6	P	_	_

1	Furthermore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	several	_	JJ	JJ	_	10	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	these	_	DT	DT	_	9	NMOD	_	_
9	agents	_	NNS	NNS	_	7	PMOD	_	_
10	can	_	MD	MD	_	5	VMOD	_	_
11	significantly	_	RB	RB	_	10	ADV	_	_
12	increase	_	VB	VB	_	10	VC	_	_
13	HIV	_	NN	NN	_	14	NMOD	_	_
14	replication	_	NN	NN	_	12	OBJ	_	_
15	and	_	CC	CC	_	12	CC	_	_
16	accelerate	_	VB	VB	_	12	COORD	_	_
17	CD4-positive	_	JJ	JJ	_	19	NMOD	_	_
18	lymphocyte	_	NN	NN	_	19	NMOD	_	_
19	cytotoxicity	_	NN	NN	_	16	OBJ	_	_
20	in	_	FW	FW	_	12	ADV	_	_
21	vitro	_	FW	FW	_	20	AMOD	_	_
22	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	6	SBJ	_	_
3	,	_	,	,	_	6	P	_	_
4	therefore	_	RB	RB	_	6	ADV	_	_
5	,	_	,	,	_	6	P	_	_
6	could	_	MD	MD	_	0	ROOT-S	_	_
7	have	_	VB	VB	_	6	VC	_	_
8	clinical	_	JJ	JJ	_	9	NMOD	_	_
9	significance	_	NN	NN	_	7	OBJ	_	_
10	to	_	TO	TO	_	7	ADV	_	_
11	AIDS	_	NN	NN	_	12	NMOD	_	_
12	patients	_	NNS	NNS	_	10	PMOD	_	_
13	with	_	IN	IN	_	12	NMOD	_	_
14	malignancies	_	NNS	NNS	_	13	PMOD	_	_
15	who	_	WP	WP	_	16	SBJ	_	_
16	are	_	VBP	VBP	_	12	NMOD	_	_
17	undergoing	_	VBG	VBG	_	16	VC	_	_
18	radiotherapy	_	NN	NN	_	17	OBJ	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	chemotherapy	_	NN	NN	_	18	COORD	_	_
21	.	_	.	.	_	6	P	_	_

1	Characterization	_	NN	NN	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	purification	_	NN	NN	_	1	COORD	_	_
4	of	_	IN	IN	_	1	NMOD	_	_
5	a	_	DT	DT	_	9	NMOD	_	_
6	protein	_	NN	NN	_	9	NMOD	_	_
7	kinase	_	NN	NN	_	9	NMOD	_	_
8	C	_	NN	NN	_	9	NMOD	_	_
9	substrate	_	NN	NN	_	4	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	human	_	JJ	JJ	_	13	NMOD	_	_
12	B	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	10	PMOD	_	_
14	.	_	.	.	_	1	P	_	_

1	Identification	_	NN	NN	_	0	ROOT-FRAG	_	_
2	as	_	IN	IN	_	1	NMOD	_	_
3	lymphocyte-specific	_	JJ	JJ	_	4	NMOD	_	_
4	protein	_	NN	NN	_	2	PMOD	_	_
5	1	_	CD	CD	_	4	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	LSP1	_	NN	NN	_	4	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	.	_	.	.	_	1	P	_	_

1	Incubation	_	NN	NN	_	13	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	B-chronic	_	JJ	JJ	_	5	NMOD	_	_
4	lymphocytic	_	JJ	JJ	_	5	NMOD	_	_
5	leukemia	_	NN	NN	_	9	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	B-CLL	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	cells	_	NNS	NNS	_	2	PMOD	_	_
10	with	_	IN	IN	_	1	NMOD	_	_
11	phorbol	_	NN	NN	_	12	NMOD	_	_
12	esters	_	NNS	NNS	_	10	PMOD	_	_
13	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	phosphorylation	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	two	_	CD	CD	_	21	NMOD	_	_
19	major	_	JJ	JJ	_	21	NMOD	_	_
20	PKC	_	NN	NN	_	21	NMOD	_	_
21	substrates	_	NNS	NNS	_	17	PMOD	_	_
22	,	_	,	,	_	21	P	_	_
23	MARCKS	_	NN	NN	_	21	NMOD	_	_
24	(	_	(	(	_	30	P	_	_
25	myristoylated	_	VBN	VBN	_	30	NMOD	_	_
26	,	_	,	,	_	25	P	_	_
27	alanine-rich	_	JJ	JJ	_	25	COORD	_	_
28	C	_	NN	NN	_	30	NMOD	_	_
29	kinase	_	NN	NN	_	30	NMOD	_	_
30	substrate	_	NN	NN	_	23	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	and	_	CC	CC	_	23	CC	_	_
33	MRP	_	NN	NN	_	23	COORD	_	_
34	(	_	(	(	_	36	P	_	_
35	MARCKS-related	_	JJ	JJ	_	36	NMOD	_	_
36	protein	_	NN	NN	_	33	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	,	_	,	,	_	21	P	_	_
39	and	_	CC	CC	_	17	CC	_	_
40	of	_	IN	IN	_	17	COORD	_	_
41	a	_	DT	DT	_	43	NMOD	_	_
42	third	_	JJ	JJ	_	43	NMOD	_	_
43	protein	_	NN	NN	_	40	PMOD	_	_
44	,	_	,	,	_	43	P	_	_
45	with	_	IN	IN	_	43	NMOD	_	_
46	an	_	DT	DT	_	48	NMOD	_	_
47	apparent	_	JJ	JJ	_	48	NMOD	_	_
48	m.w.	_	NN	NN	_	45	PMOD	_	_
49	of	_	IN	IN	_	48	NMOD	_	_
50	60,000	_	CD	CD	_	49	PMOD	_	_
51	that	_	WDT	WDT	_	52	SBJ	_	_
52	was	_	VBD	VBD	_	43	NMOD	_	_
53	the	_	DT	DT	_	59	NMOD	_	_
54	most	_	RBS	RBS	_	55	AMOD	_	_
55	prominent	_	JJ	JJ	_	59	NMOD	_	_
56	protein	_	NN	NN	_	59	NMOD	_	_
57	kinase	_	NN	NN	_	59	NMOD	_	_
58	C	_	NN	NN	_	59	NMOD	_	_
59	substrate	_	NN	NN	_	52	PRD	_	_
60	in	_	IN	IN	_	52	ADV	_	_
61	these	_	DT	DT	_	62	NMOD	_	_
62	cells	_	NNS	NNS	_	60	PMOD	_	_
63	.	_	.	.	_	13	P	_	_

1	p60	_	NN	NN	_	2	NMOD	_	_
2	phosphorylation	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	time	_	NN	NN	_	8	AMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	PMA	_	NN	NN	_	7	NMOD	_	_
7	dose	_	NN	NN	_	4	COORD	_	_
8	dependent	_	JJ	JJ	_	3	PRD	_	_
9	,	_	,	,	_	3	P	_	_
10	and	_	CC	CC	_	3	CC	_	_
11	was	_	VBD	VBD	_	3	COORD	_	_
12	induced	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	ADV	_	_
14	cell-permeable	_	JJ	JJ	_	15	NMOD	_	_
15	diacylglycerol	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	13	P	_	_
17	but	_	CC	CC	_	13	CC	_	_
18	not	_	RB	RB	_	19	DEP	_	_
19	by	_	IN	IN	_	13	LGS	_	_
20	inactive	_	JJ	JJ	_	22	NMOD	_	_
21	phorbol	_	NN	NN	_	22	NMOD	_	_
22	esters	_	NNS	NNS	_	19	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	Two-dimensional	_	JJ	JJ	_	3	NMOD	_	_
2	electrophoretic	_	JJ	JJ	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	15	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	protein	_	NN	NN	_	8	NMOD	_	_
7	phosphorylation	_	NN	NN	_	8	NMOD	_	_
8	pattern	_	NN	NN	_	4	PMOD	_	_
9	from	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	B	_	NN	NN	_	14	NMOD	_	_
12	cell	_	NN	NN	_	14	NMOD	_	_
13	line	_	NN	NN	_	14	NMOD	_	_
14	CESS	_	NN	NN	_	9	PMOD	_	_
15	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	identity	_	NN	NN	_	15	OBJ	_	_
18	between	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	p60	_	NN	NN	_	21	NMOD	_	_
21	protein	_	NN	NN	_	18	PMOD	_	_
22	expressed	_	VBN	VBN	_	21	NMOD	_	_
23	in	_	IN	IN	_	22	ADV	_	_
24	this	_	DT	DT	_	26	NMOD	_	_
25	cell	_	NN	NN	_	26	NMOD	_	_
26	line	_	NN	NN	_	23	PMOD	_	_
27	and	_	CC	CC	_	21	CC	_	_
28	that	_	DT	DT	_	21	COORD	_	_
29	expressed	_	VBN	VBN	_	28	NMOD	_	_
30	in	_	IN	IN	_	29	ADV	_	_
31	B-CLL	_	NN	NN	_	32	NMOD	_	_
32	cells	_	NNS	NNS	_	30	PMOD	_	_
33	.	_	.	.	_	15	P	_	_

1	p60	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	purified	_	VBN	VBN	_	2	VC	_	_
4	from	_	IN	IN	_	3	ADV	_	_
5	CESS	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	and	_	CC	CC	_	2	CC	_	_
8	peptide	_	NN	NN	_	9	NMOD	_	_
9	microsequencing	_	NN	NN	_	13	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	this	_	DT	DT	_	12	NMOD	_	_
12	protein	_	NN	NN	_	10	PMOD	_	_
13	revealed	_	VBD	VBD	_	2	COORD	_	_
14	that	_	IN	IN	_	13	OBJ	_	_
15	it	_	PRP	PRP	_	16	SBJ	_	_
16	was	_	VBD	VBD	_	14	VMOD	_	_
17	lymphocyte-specific	_	JJ	JJ	_	18	NMOD	_	_
18	protein	_	NN	NN	_	16	PRD	_	_
19	1	_	CD	CD	_	18	NMOD	_	_
20	(	_	(	(	_	21	P	_	_
21	LSP1	_	NN	NN	_	18	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	,	_	,	,	_	16	P	_	_
24	that	_	WDT	WDT	_	25	SBJ	_	_
25	is	_	VBZ	VBZ	_	16	CLF	_	_
26	here	_	RB	RB	_	25	ADV	_	_
27	characterized	_	VBN	VBN	_	25	VC	_	_
28	as	_	IN	IN	_	27	ADV	_	_
29	the	_	DT	DT	_	34	NMOD	_	_
30	most	_	RBS	RBS	_	31	AMOD	_	_
31	prominent	_	JJ	JJ	_	34	NMOD	_	_
32	protein	_	NN	NN	_	34	NMOD	_	_
33	kinase	_	NN	NN	_	34	NMOD	_	_
34	C	_	NN	NN	_	28	PMOD	_	_
35	substrate	_	JJ	JJ	_	34	NMOD	_	_
36	in	_	IN	IN	_	34	NMOD	_	_
37	B	_	NN	NN	_	38	NMOD	_	_
38	cells	_	NNS	NNS	_	36	PMOD	_	_
39	.	_	.	.	_	2	P	_	_

1	IL-13	_	NN	NN	_	2	SBJ	_	_
2	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	phosphorylation	_	NN	NN	_	2	OBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	activation	_	NN	NN	_	3	COORD	_	_
6	of	_	IN	IN	_	3	NMOD	_	_
7	JAK2	_	NN	NN	_	9	NMOD	_	_
8	Janus	_	NN	NN	_	9	NMOD	_	_
9	kinase	_	NN	NN	_	6	PMOD	_	_
10	in	_	IN	IN	_	2	ADV	_	_
11	human	_	JJ	JJ	_	15	NMOD	_	_
12	colon	_	NN	NN	_	15	NMOD	_	_
13	carcinoma	_	NN	NN	_	15	NMOD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	lines	_	NNS	NNS	_	10	PMOD	_	_
16	:	_	:	:	_	2	P	_	_
17	similarities	_	NNS	NNS	_	2	VMOD	_	_
18	between	_	IN	IN	_	17	NMOD	_	_
19	IL-4	_	NN	NN	_	22	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	IL-13	_	NN	NN	_	19	COORD	_	_
22	signaling	_	NN	NN	_	18	PMOD	_	_
23	.	_	.	.	_	17	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	recently	_	RB	RB	_	2	TMP	_	_
4	reported	_	VBN	VBN	_	2	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	IL-13R	_	NN	NN	_	7	SBJ	_	_
7	may	_	MD	MD	_	5	VMOD	_	_
8	share	_	VB	VB	_	7	VC	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	component	_	NN	NN	_	8	OBJ	_	_
11	with	_	IN	IN	_	8	ADV	_	_
12	IL-4R	_	NN	NN	_	11	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	report	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	both	_	CC	CC	_	6	CC	_	_
6	IL-4	_	NN	NN	_	9	SBJ	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	IL-13	_	NN	NN	_	6	COORD	_	_
9	share	_	VBP	VBP	_	4	VMOD	_	_
10	signaling	_	NN	NN	_	11	NMOD	_	_
11	events	_	NNS	NNS	_	9	OBJ	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	human	_	JJ	JJ	_	17	NMOD	_	_
14	colon	_	NN	NN	_	17	NMOD	_	_
15	carcinoma	_	NN	NN	_	17	NMOD	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	lines	_	NNS	NNS	_	12	PMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	HT-29	_	NN	NN	_	17	PRN	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	WiDr	_	NN	NN	_	19	COORD	_	_
22	)	_	)	)	_	19	P	_	_
23	.	_	.	.	_	3	P	_	_

1	IL-13	_	NN	NN	_	2	SBJ	_	_
2	caused	_	VBD	VBD	_	0	ROOT-S	_	_
3	rapid	_	JJ	JJ	_	4	NMOD	_	_
4	phosphorylation	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	11	NMOD	_	_
7	three	_	CD	CD	_	10	DEP	_	_
8	out	_	IN	IN	_	10	DEP	_	_
9	of	_	IN	IN	_	10	DEP	_	_
10	four	_	CD	CD	_	11	NMOD	_	_
11	members	_	NNS	NNS	_	5	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	known	_	JJ	JJ	_	16	NMOD	_	_
15	Janus	_	NN	NN	_	16	NMOD	_	_
16	family	_	NN	NN	_	12	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	kinases	_	NNS	NNS	_	17	PMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	JAKs	_	NNS	NNS	_	16	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	JAK2	_	NN	NN	_	5	NMOD	_	_
5	kinase	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	3	VMOD	_	_
7	rapidly	_	RB	RB	_	6	TMP	_	_
8	phosphorylated	_	VBN	VBN	_	6	VC	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	activated	_	VBN	VBN	_	8	COORD	_	_
11	in	_	IN	IN	_	8	ADV	_	_
12	response	_	NN	NN	_	11	DEP	_	_
13	to	_	TO	TO	_	11	DEP	_	_
14	IL-13	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	2	P	_	_

1	Within	_	IN	IN	_	9	ADV	_	_
2	1	_	CD	CD	_	3	NMOD	_	_
3	min	_	NN	NN	_	1	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	activation	_	NN	NN	_	4	PMOD	_	_
6	,	_	,	,	_	8	P	_	_
7	JAK2	_	NN	NN	_	8	SBJ	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	phosphorylated	_	VBN	VBN	_	8	VC	_	_
10	,	_	,	,	_	8	P	_	_
11	and	_	CC	CC	_	8	CC	_	_
12	peaked	_	VBD	VBD	_	8	COORD	_	_
13	in	_	IN	IN	_	12	TMP	_	_
14	10	_	CD	CD	_	15	NMOD	_	_
15	min	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	IL-13	_	NN	NN	_	5	SBJ	_	_
5	phosphorylated	_	VBD	VBD	_	0	ROOT-S	_	_
6	insulin	_	NN	NN	_	8	NMOD	_	_
7	response	_	NN	NN	_	8	NMOD	_	_
8	substrate-1	_	NN	NN	_	5	OBJ	_	_
9	,	_	,	,	_	8	P	_	_
10	IL-4R	_	NN	NN	_	11	NMOD	_	_
11	p140	_	NN	NN	_	8	COORD	_	_
12	,	_	,	,	_	8	P	_	_
13	JAK1	_	NN	NN	_	8	COORD	_	_
14	,	_	,	,	_	8	P	_	_
15	and	_	CC	CC	_	8	CC	_	_
16	Tyk2	_	NN	NN	_	8	COORD	_	_
17	,	_	,	,	_	8	P	_	_
18	but	_	CC	CC	_	8	CC	_	_
19	not	_	RB	RB	_	18	COORD	_	_
20	JAK3	_	NN	NN	_	21	NMOD	_	_
21	kinase	_	NN	NN	_	8	COORD	_	_
22	.	_	.	.	_	5	P	_	_

1	IL-4	_	NN	NN	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	stimulated	_	VBD	VBD	_	0	ROOT-S	_	_
4	all	_	DT	DT	_	6	NMOD	_	_
5	three	_	CD	CD	_	4	DEP	_	_
6	kinases	_	NNS	NNS	_	3	OBJ	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	substrates	_	NNS	NNS	_	6	COORD	_	_
9	,	_	,	,	_	3	P	_	_
10	but	_	CC	CC	_	3	CC	_	_
11	unlike	_	IN	IN	_	17	ADV	_	_
12	in	_	IN	IN	_	11	PMOD	_	_
13	immune	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	,	_	,	,	_	17	P	_	_
16	IL-4	_	NN	NN	_	17	SBJ	_	_
17	did	_	VBD	VBD	_	3	COORD	_	_
18	not	_	RB	RB	_	17	VMOD	_	_
19	involve	_	VB	VB	_	17	VC	_	_
20	JAK3	_	NN	NN	_	21	NMOD	_	_
21	activation	_	NN	NN	_	19	OBJ	_	_
22	for	_	IN	IN	_	19	ADV	_	_
23	its	_	PRP$	PRP$	_	24	NMOD	_	_
24	signaling	_	NN	NN	_	22	PMOD	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	colon	_	NN	NN	_	29	NMOD	_	_
27	cancer	_	NN	NN	_	29	NMOD	_	_
28	cell	_	NN	NN	_	29	NMOD	_	_
29	lines	_	NNS	NNS	_	25	PMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	Furthermore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	JAK2	_	NN	NN	_	4	SBJ	_	_
4	associated	_	VBN	VBN	_	0	ROOT-S	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	IL-4R	_	NN	NN	_	8	NMOD	_	_
8	p140	_	NN	NN	_	5	PMOD	_	_
9	before	_	IN	IN	_	4	TMP	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	after	_	IN	IN	_	9	COORD	_	_
12	stimulation	_	NN	NN	_	9	PMOD	_	_
13	with	_	IN	IN	_	12	NMOD	_	_
14	IL-13	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	IL-13	_	NN	NN	_	5	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	IL-4	_	NN	NN	_	2	COORD	_	_
5	induced	_	VBD	VBD	_	0	ROOT-S	_	_
6	phosphorylation	_	NN	NN	_	5	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	IL-4	_	NN	NN	_	9	NMOD	_	_
9	STAT	_	NN	NN	_	7	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	STAT6	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	but	_	CC	CC	_	9	CC	_	_
14	not	_	RB	RB	_	13	COORD	_	_
15	STAT1	_	NN	NN	_	9	COORD	_	_
16	,	_	,	,	_	15	P	_	_
17	STAT3	_	NN	NN	_	15	COORD	_	_
18	,	_	,	,	_	15	P	_	_
19	or	_	CC	CC	_	15	CC	_	_
20	STAT5	_	NN	NN	_	15	COORD	_	_
21	.	_	.	.	_	5	P	_	_

1	125I-IL-13	_	NN	NN	_	2	SBJ	_	_
2	did	_	VBD	VBD	_	0	ROOT-S	_	_
3	not	_	RB	RB	_	2	VMOD	_	_
4	bind	_	VB	VB	_	2	VC	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	colon	_	NN	NN	_	9	NMOD	_	_
7	cancer	_	NN	NN	_	9	NMOD	_	_
8	cell	_	NN	NN	_	9	NMOD	_	_
9	lines	_	NNS	NNS	_	5	PMOD	_	_
10	,	_	,	,	_	2	P	_	_
11	but	_	CC	CC	_	2	CC	_	_
12	unlabeled	_	JJ	JJ	_	13	NMOD	_	_
13	IL-13	_	NN	NN	_	14	SBJ	_	_
14	competed	_	VBD	VBD	_	2	COORD	_	_
15	for	_	IN	IN	_	14	ADV	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	binding	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	125I-IL-4	_	NN	NN	_	18	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	IL-13	_	NN	NN	_	6	SBJ	_	_
6	utilizes	_	VBZ	VBZ	_	4	VMOD	_	_
7	IL-4R	_	NN	NN	_	6	OBJ	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	its	_	PRP$	PRP$	_	11	NMOD	_	_
10	signaling	_	NN	NN	_	11	NMOD	_	_
11	pathway	_	NN	NN	_	7	COORD	_	_
12	,	_	,	,	_	6	P	_	_
13	and	_	CC	CC	_	6	CC	_	_
14	JAK2	_	NN	NN	_	15	SBJ	_	_
15	may	_	MD	MD	_	6	COORD	_	_
16	play	_	VB	VB	_	15	VC	_	_
17	an	_	DT	DT	_	19	NMOD	_	_
18	important	_	JJ	JJ	_	19	NMOD	_	_
19	role	_	NN	NN	_	16	OBJ	_	_
20	in	_	IN	IN	_	16	ADV	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	function	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	IL-4R	_	NN	NN	_	23	PMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	IL-13R	_	NN	NN	_	24	COORD	_	_
27	in	_	IN	IN	_	22	NMOD	_	_
28	colon	_	NN	NN	_	30	NMOD	_	_
29	cancer	_	NN	NN	_	30	NMOD	_	_
30	cells	_	NNS	NNS	_	27	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	Effects	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	interleukin-10	_	NN	NN	_	2	PMOD	_	_
4	on	_	IN	IN	_	1	NMOD	_	_
5	human	_	JJ	JJ	_	10	NMOD	_	_
6	peripheral	_	JJ	JJ	_	10	NMOD	_	_
7	blood	_	NN	NN	_	10	NMOD	_	_
8	mononuclear	_	JJ	JJ	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	responses	_	NNS	NNS	_	4	PMOD	_	_
11	to	_	TO	TO	_	10	NMOD	_	_
12	Cryptococcus	_	NN	NN	_	13	NMOD	_	_
13	neoformans	_	NNS	NNS	_	11	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	Candida	_	NN	NN	_	16	NMOD	_	_
16	albicans	_	NNS	NNS	_	13	COORD	_	_
17	,	_	,	,	_	13	P	_	_
18	and	_	CC	CC	_	13	CC	_	_
19	lipopolysaccharide	_	NN	NN	_	13	COORD	_	_
20	.	_	.	.	_	1	P	_	_

1	Deactivation	_	NN	NN	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	mononuclear	_	JJ	JJ	_	4	NMOD	_	_
4	phagocytes	_	NNS	NNS	_	2	PMOD	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	critical	_	JJ	JJ	_	5	PRD	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	limit	_	VB	VB	_	5	VC	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	inflammatory	_	JJ	JJ	_	11	NMOD	_	_
11	response	_	NN	NN	_	8	OBJ	_	_
12	but	_	CC	CC	_	5	CC	_	_
13	can	_	MD	MD	_	5	COORD	_	_
14	be	_	VB	VB	_	13	VC	_	_
15	detrimental	_	JJ	JJ	_	14	PRD	_	_
16	in	_	IN	IN	_	14	ADV	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	face	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	progressive	_	JJ	JJ	_	21	NMOD	_	_
21	infection	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	compared	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	effects	_	NNS	NNS	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	deactivating	_	VBG	VBG	_	8	NMOD	_	_
8	cytokine	_	NN	NN	_	5	PMOD	_	_
9	interleukin	_	NN	NN	_	8	NMOD	_	_
10	10	_	CD	CD	_	9	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	IL-10	_	NN	NN	_	9	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	on	_	IN	IN	_	4	NMOD	_	_
15	human	_	JJ	JJ	_	23	NMOD	_	_
16	peripheral	_	JJ	JJ	_	19	NMOD	_	_
17	blood	_	NN	NN	_	19	NMOD	_	_
18	mononuclear	_	JJ	JJ	_	19	NMOD	_	_
19	cell	_	NN	NN	_	23	NMOD	_	_
20	(	_	(	(	_	21	P	_	_
21	PBMC	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	responses	_	NNS	NNS	_	14	PMOD	_	_
24	to	_	TO	TO	_	23	NMOD	_	_
25	lipopolysaccharide	_	NN	NN	_	24	PMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	LPS	_	NN	NN	_	25	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	,	_	,	,	_	25	P	_	_
30	Cryptococcus	_	NN	NN	_	31	NMOD	_	_
31	neoformans	_	NNS	NNS	_	25	COORD	_	_
32	,	_	,	,	_	25	P	_	_
33	and	_	CC	CC	_	25	CC	_	_
34	Candida	_	NN	NN	_	35	NMOD	_	_
35	albicans	_	NNS	NNS	_	25	COORD	_	_
36	.	_	.	.	_	2	P	_	_

1	IL-10	_	NN	NN	_	2	SBJ	_	_
2	effected	_	VBD	VBD	_	0	ROOT-S	_	_
3	dose-dependent	_	JJ	JJ	_	4	NMOD	_	_
4	inhibition	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	tumor	_	NN	NN	_	9	NMOD	_	_
7	necrosis	_	NN	NN	_	9	NMOD	_	_
8	factor	_	NN	NN	_	9	NMOD	_	_
9	alpha	_	NN	NN	_	13	NMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	TNF-alpha	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	release	_	NN	NN	_	5	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	PBMC	_	NN	NN	_	14	PMOD	_	_
16	stimulated	_	VBN	VBN	_	15	NMOD	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	LPS	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	C.	_	FW	FW	_	21	NMOD	_	_
21	neoformans	_	FW	FW	_	18	COORD	_	_
22	,	_	,	,	_	2	P	_	_
23	with	_	IN	IN	_	2	ADV	_	_
24	significant	_	JJ	JJ	_	25	NMOD	_	_
25	inhibition	_	NN	NN	_	26	SBJ	_	_
26	seen	_	VBN	VBN	_	23	VMOD	_	_
27	with	_	IN	IN	_	26	ADV	_	_
28	0.1	_	CD	CD	_	29	NMOD	_	_
29	U\/ml	_	NN	NN	_	27	PMOD	_	_
30	and	_	CC	CC	_	26	CC	_	_
31	greater	_	JJR	JJR	_	33	DEP	_	_
32	than	_	IN	IN	_	33	DEP	_	_
33	90	_	CD	CD	_	34	NMOD	_	_
34	%	_	NN	NN	_	36	SBJ	_	_
35	inhibition	_	NN	NN	_	34	NMOD	_	_
36	noted	_	VBN	VBN	_	26	COORD	_	_
37	with	_	IN	IN	_	36	ADV	_	_
38	10	_	CD	CD	_	39	NMOD	_	_
39	U\/ml	_	NN	NN	_	37	PMOD	_	_
40	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	14	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	14	P	_	_
4	even	_	RB	RB	_	5	DEP	_	_
5	at	_	IN	IN	_	14	ADV	_	_
6	doses	_	NNS	NNS	_	5	PMOD	_	_
7	as	_	RB	RB	_	8	DEP	_	_
8	high	_	JJ	JJ	_	11	NMOD	_	_
9	as	_	IN	IN	_	8	DEP	_	_
10	100	_	CD	CD	_	8	DEP	_	_
11	U\/ml	_	NN	NN	_	6	NMOD	_	_
12	,	_	,	,	_	14	P	_	_
13	IL-10	_	NN	NN	_	14	SBJ	_	_
14	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
15	TNF-alpha	_	NN	NN	_	16	NMOD	_	_
16	release	_	NN	NN	_	14	IOBJ	_	_
17	in	_	IN	IN	_	14	ADV	_	_
18	response	_	NN	NN	_	17	DEP	_	_
19	to	_	TO	TO	_	17	DEP	_	_
20	C.	_	FW	FW	_	21	NMOD	_	_
21	albicans	_	FW	FW	_	17	PMOD	_	_
22	by	_	IN	IN	_	25	NMOD	_	_
23	only	_	RB	RB	_	25	NMOD	_	_
24	50	_	CD	CD	_	23	DEP	_	_
25	%	_	NN	NN	_	14	OBJ	_	_
26	.	_	.	.	_	14	P	_	_

1	IL-10	_	NN	NN	_	3	SBJ	_	_
2	profoundly	_	RB	RB	_	3	ADV	_	_
3	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
4	release	_	NN	NN	_	3	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	IL-1beta	_	NN	NN	_	5	PMOD	_	_
7	from	_	IN	IN	_	4	NMOD	_	_
8	PBMC	_	NN	NN	_	7	PMOD	_	_
9	stimulated	_	VBN	VBN	_	8	NMOD	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	all	_	DT	DT	_	13	NMOD	_	_
12	three	_	CD	CD	_	11	DEP	_	_
13	stimuli	_	NNS	NNS	_	10	PMOD	_	_
14	.	_	.	.	_	3	P	_	_

1	TNF-alpha	_	NN	NN	_	2	NMOD	_	_
2	mRNA	_	NN	NN	_	5	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	release	_	NN	NN	_	2	COORD	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	inhibited	_	VBN	VBN	_	5	VC	_	_
7	even	_	RB	RB	_	8	VMOD	_	_
8	if	_	IN	IN	_	6	OBJ	_	_
9	IL-10	_	NN	NN	_	10	SBJ	_	_
10	was	_	VBD	VBD	_	8	VMOD	_	_
11	added	_	VBN	VBN	_	10	VC	_	_
12	up	_	RP	RP	_	14	DEP	_	_
13	to	_	TO	TO	_	14	DEP	_	_
14	8	_	CD	CD	_	15	NMOD	_	_
15	h	_	NN	NN	_	16	PMOD	_	_
16	after	_	IN	IN	_	11	TMP	_	_
17	cryptococcal	_	JJ	JJ	_	18	NMOD	_	_
18	stimulation	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	9	P	_	_
4	inhibition	_	NN	NN	_	9	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	IL-1	_	NN	NN	_	8	NMOD	_	_
7	beta	_	NN	NN	_	8	NMOD	_	_
8	mRNA	_	NN	NN	_	5	PMOD	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	of	_	IN	IN	_	9	PRD	_	_
11	lesser	_	JJR	JJR	_	12	NMOD	_	_
12	magnitude	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	9	CC	_	_
14	occurred	_	VBD	VBD	_	9	COORD	_	_
15	only	_	RB	RB	_	16	AMOD	_	_
16	when	_	WRB	WRB	_	19	ADV	_	_
17	IL-10	_	NN	NN	_	18	SBJ	_	_
18	was	_	VBD	VBD	_	14	TMP	_	_
19	added	_	VBN	VBN	_	18	VC	_	_
20	within	_	IN	IN	_	19	TMP	_	_
21	2	_	CD	CD	_	22	NMOD	_	_
22	h	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	cryptococcal	_	JJ	JJ	_	25	NMOD	_	_
25	stimulation	_	NN	NN	_	23	PMOD	_	_
26	.	_	.	.	_	9	P	_	_

1	IL-10	_	NN	NN	_	2	SBJ	_	_
2	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
3	translocation	_	NN	NN	_	2	OBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	NF-kappaB	_	NN	NN	_	4	PMOD	_	_
6	in	_	IN	IN	_	2	ADV	_	_
7	response	_	NN	NN	_	6	DEP	_	_
8	to	_	TO	TO	_	6	DEP	_	_
9	LPS	_	NN	NN	_	6	PMOD	_	_
10	but	_	CC	CC	_	9	CC	_	_
11	not	_	RB	RB	_	10	COORD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	fungal	_	JJ	JJ	_	14	NMOD	_	_
14	stimuli	_	NNS	NNS	_	9	COORD	_	_
15	.	_	.	.	_	2	P	_	_

1	All	_	DT	DT	_	3	NMOD	_	_
2	three	_	CD	CD	_	3	NMOD	_	_
3	stimuli	_	NNS	NNS	_	4	SBJ	_	_
4	induced	_	VBD	VBD	_	0	ROOT-S	_	_
5	IL-10	_	NN	NN	_	6	NMOD	_	_
6	production	_	NN	NN	_	4	IOBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	PBMC	_	NN	NN	_	7	PMOD	_	_
9	,	_	,	,	_	4	P	_	_
10	although	_	IN	IN	_	4	OBJ	_	_
11	over	_	IN	IN	_	12	DEP	_	_
12	10-fold	_	RB	RB	_	14	NMOD	_	_
13	less	_	JJR	JJR	_	12	DEP	_	_
14	IL-10	_	NN	NN	_	15	SBJ	_	_
15	was	_	VBD	VBD	_	10	VMOD	_	_
16	released	_	VBN	VBN	_	15	VC	_	_
17	in	_	IN	IN	_	16	ADV	_	_
18	response	_	NN	NN	_	17	DEP	_	_
19	to	_	TO	TO	_	17	DEP	_	_
20	C.	_	FW	FW	_	21	NMOD	_	_
21	neoformans	_	FW	FW	_	17	PMOD	_	_
22	compared	_	VBN	VBN	_	16	ADV	_	_
23	with	_	IN	IN	_	22	PMOD	_	_
24	LPS	_	NN	NN	_	23	PMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	C.	_	NN	NN	_	27	NMOD	_	_
27	albicans	_	NNS	NNS	_	24	COORD	_	_
28	.	_	.	.	_	4	P	_	_

1	Thus	_	RB	RB	_	23	ADV	_	_
2	,	_	,	,	_	23	P	_	_
3	while	_	IN	IN	_	23	ADV	_	_
4	IL-10	_	NN	NN	_	5	SBJ	_	_
5	has	_	VBZ	VBZ	_	3	VMOD	_	_
6	deactivating	_	VBG	VBG	_	7	NMOD	_	_
7	effects	_	NNS	NNS	_	5	OBJ	_	_
8	on	_	IN	IN	_	5	ADV	_	_
9	PBMC	_	NN	NN	_	10	NMOD	_	_
10	responses	_	NNS	NNS	_	8	PMOD	_	_
11	to	_	TO	TO	_	10	NMOD	_	_
12	all	_	DT	DT	_	14	NMOD	_	_
13	three	_	CD	CD	_	12	DEP	_	_
14	stimuli	_	NNS	NNS	_	11	PMOD	_	_
15	,	_	,	,	_	23	P	_	_
16	disparate	_	JJ	JJ	_	20	NMOD	_	_
17	stimulus-	_	NN	NN	_	20	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	response-specific	_	JJ	JJ	_	17	COORD	_	_
20	patterns	_	NNS	NNS	_	23	SBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	deactivation	_	NN	NN	_	21	PMOD	_	_
23	are	_	VBP	VBP	_	0	ROOT-S	_	_
24	seen	_	VBN	VBN	_	23	VC	_	_
25	.	_	.	.	_	23	P	_	_

1	Inhibition	_	NN	NN	_	8	SBJ	_	_
2	by	_	IN	IN	_	1	NMOD	_	_
3	IL-10	_	NN	NN	_	2	PMOD	_	_
4	of	_	IN	IN	_	1	NMOD	_	_
5	proinflammatory	_	JJ	JJ	_	7	NMOD	_	_
6	cytokine	_	NN	NN	_	7	NMOD	_	_
7	release	_	NN	NN	_	4	PMOD	_	_
8	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	occur	_	VB	VB	_	8	OBJ	_	_
11	at	_	IN	IN	_	10	TMP	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	level	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	gene	_	NN	NN	_	16	NMOD	_	_
16	transcription	_	NN	NN	_	14	PMOD	_	_
17	for	_	IN	IN	_	10	VMOD	_	_
18	TNF-alpha	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	10	CC	_	_
20	both	_	CC	CC	_	21	CC	_	_
21	transcriptionally	_	RB	RB	_	11	GAP	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	posttranscriptionally	_	RB	RB	_	21	COORD	_	_
24	for	_	IN	IN	_	17	GAP	_	_
25	IL-1beta	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	8	P	_	_

1	Activation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	nuclear	_	JJ	JJ	_	4	NMOD	_	_
4	factor	_	NN	NN	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	activated	_	VBN	VBN	_	8	NMOD	_	_
7	T	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	5	PMOD	_	_
9	in	_	IN	IN	_	1	NMOD	_	_
10	a	_	DT	DT	_	13	NMOD	_	_
11	cyclosporin	_	NN	NN	_	13	NMOD	_	_
12	A-resistant	_	JJ	JJ	_	11	AMOD	_	_
13	pathway	_	NN	NN	_	9	PMOD	_	_
14	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	mechanism	_	NN	NN	_	14	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	action	_	NN	NN	_	3	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	immunosuppressive	_	JJ	JJ	_	8	NMOD	_	_
8	drug	_	NN	NN	_	5	PMOD	_	_
9	cyclosporin	_	NN	NN	_	10	NMOD	_	_
10	A	_	NN	NN	_	8	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	CsA	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	inactivation	_	NN	NN	_	14	PRD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	22	NMOD	_	_
19	Ca2+\/calmodulin-dependent	_	JJ	JJ	_	22	NMOD	_	_
20	serine-threonine	_	NN	NN	_	22	NMOD	_	_
21	phosphatase	_	NN	NN	_	22	NMOD	_	_
22	calcineurin	_	NN	NN	_	17	PMOD	_	_
23	by	_	IN	IN	_	16	NMOD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	drug-immunophilin	_	JJ	JJ	_	26	NMOD	_	_
26	complex	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	14	P	_	_

1	Inactive	_	JJ	JJ	_	2	NMOD	_	_
2	calcineurin	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	unable	_	JJ	JJ	_	3	PRD	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	activate	_	VB	VB	_	4	AMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	factor	_	NN	NN	_	6	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	activated	_	VBN	VBN	_	13	NMOD	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	10	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	NFAT	_	NN	NN	_	9	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	,	_	,	,	_	9	P	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	transcription	_	NN	NN	_	20	NMOD	_	_
20	factor	_	NN	NN	_	9	NMOD	_	_
21	required	_	VBN	VBN	_	20	NMOD	_	_
22	for	_	IN	IN	_	21	ADV	_	_
23	expression	_	NN	NN	_	22	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	31	NMOD	_	_
26	interleukin	_	NN	NN	_	31	NMOD	_	_
27	2	_	CD	CD	_	26	NMOD	_	_
28	(	_	(	(	_	29	P	_	_
29	IL-2	_	NN	NN	_	26	PRN	_	_
30	)	_	)	)	_	29	P	_	_
31	gene	_	NN	NN	_	24	PMOD	_	_
32	.	_	.	.	_	3	P	_	_

1	IL-2	_	NN	NN	_	2	NMOD	_	_
2	production	_	NN	NN	_	6	SBJ	_	_
3	by	_	IN	IN	_	2	NMOD	_	_
4	CsA-treated	_	JJ	JJ	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	3	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	therefore	_	RB	RB	_	6	ADV	_	_
8	dramatically	_	RB	RB	_	9	ADV	_	_
9	reduced	_	VBN	VBN	_	6	VC	_	_
10	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	,	_	,	,	_	2	P	_	_
5	however	_	RB	RB	_	2	ADV	_	_
6	,	_	,	,	_	2	P	_	_
7	that	_	IN	IN	_	2	OBJ	_	_
8	NFAT	_	NN	NN	_	9	SBJ	_	_
9	can	_	MD	MD	_	7	VMOD	_	_
10	be	_	VB	VB	_	9	VC	_	_
11	activated	_	VBN	VBN	_	10	VC	_	_
12	,	_	,	,	_	9	P	_	_
13	and	_	CC	CC	_	9	CC	_	_
14	significant	_	JJ	JJ	_	15	NMOD	_	_
15	levels	_	NNS	NNS	_	18	SBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	IL-2	_	NN	NN	_	16	PMOD	_	_
18	can	_	MD	MD	_	9	COORD	_	_
19	be	_	VB	VB	_	18	VC	_	_
20	produced	_	VBN	VBN	_	19	VC	_	_
21	by	_	IN	IN	_	9	LGS	_	_
22	the	_	DT	DT	_	25	NMOD	_	_
23	CsA-resistant	_	JJ	JJ	_	25	NMOD	_	_
24	CD28-signaling	_	JJ	JJ	_	25	NMOD	_	_
25	pathway	_	NN	NN	_	21	PMOD	_	_
26	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	15	ADV	_	_
2	transient	_	JJ	JJ	_	4	NMOD	_	_
3	transfection	_	NN	NN	_	4	NMOD	_	_
4	assays	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	15	P	_	_
6	both	_	CC	CC	_	8	CC	_	_
7	multicopy	_	JJ	JJ	_	8	NMOD	_	_
8	NFAT-	_	NN	NN	_	15	SBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	IL-2	_	NN	NN	_	13	NMOD	_	_
11	promoter-beta-galactosidase	_	NN	NN	_	13	NMOD	_	_
12	reporter	_	NN	NN	_	13	NMOD	_	_
13	gene	_	NN	NN	_	8	COORD	_	_
14	constructs	_	NNS	NNS	_	8	NMOD	_	_
15	could	_	MD	MD	_	0	ROOT-S	_	_
16	be	_	VB	VB	_	15	VC	_	_
17	activated	_	VBN	VBN	_	16	VC	_	_
18	by	_	IN	IN	_	17	LGS	_	_
19	phorbol	_	NN	NN	_	26	NMOD	_	_
20	12-myristate	_	NN	NN	_	26	NMOD	_	_
21	13-acetate	_	NN	NN	_	26	NMOD	_	_
22	(	_	(	(	_	26	P	_	_
23	PMA	_	NN	NN	_	26	NMOD	_	_
24	)	_	)	)	_	26	P	_	_
25	\/alpha-CD28	_	NN	NN	_	26	NMOD	_	_
26	stimulation	_	NN	NN	_	18	PMOD	_	_
27	,	_	,	,	_	15	P	_	_
28	and	_	CC	CC	_	15	CC	_	_
29	this	_	DT	DT	_	30	NMOD	_	_
30	activation	_	NN	NN	_	31	SBJ	_	_
31	was	_	VBD	VBD	_	15	COORD	_	_
32	resistant	_	JJ	JJ	_	31	PRD	_	_
33	to	_	TO	TO	_	32	AMOD	_	_
34	CsA	_	NN	NN	_	33	PMOD	_	_
35	.	_	.	.	_	15	P	_	_

1	Electrophoretic	_	JJ	JJ	_	4	NMOD	_	_
2	mobility	_	NN	NN	_	4	NMOD	_	_
3	shift	_	NN	NN	_	4	NMOD	_	_
4	assay	_	NN	NN	_	5	SBJ	_	_
5	showed	_	VBD	VBD	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	induction	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	CsA-resistant	_	JJ	JJ	_	12	NMOD	_	_
11	NFAT	_	NN	NN	_	12	NMOD	_	_
12	complex	_	NN	NN	_	8	PMOD	_	_
13	in	_	IN	IN	_	7	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	nuclear	_	JJ	JJ	_	16	NMOD	_	_
16	extracts	_	NNS	NNS	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	peripheral	_	JJ	JJ	_	21	NMOD	_	_
19	blood	_	NN	NN	_	21	NMOD	_	_
20	T	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	17	PMOD	_	_
22	stimulated	_	VBN	VBN	_	21	NMOD	_	_
23	with	_	IN	IN	_	22	ADV	_	_
24	PMA	_	NN	NN	_	23	PMOD	_	_
25	plus	_	CC	CC	_	24	CC	_	_
26	alphaCD28	_	NN	NN	_	24	COORD	_	_
27	.	_	.	.	_	5	P	_	_

1	Peripheral	_	JJ	JJ	_	4	NMOD	_	_
2	blood	_	NN	NN	_	4	NMOD	_	_
3	T	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	8	SBJ	_	_
5	stimulated	_	VBN	VBN	_	4	NMOD	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	PMA\/alphaCD28	_	NN	NN	_	6	PMOD	_	_
8	produced	_	VBD	VBD	_	0	ROOT-S	_	_
9	IL-2	_	NN	NN	_	8	OBJ	_	_
10	in	_	IN	IN	_	8	ADV	_	_
11	the	_	DT	DT	_	10	DEP	_	_
12	presence	_	NN	NN	_	10	DEP	_	_
13	of	_	IN	IN	_	10	DEP	_	_
14	CsA	_	NN	NN	_	10	PMOD	_	_
15	.	_	.	.	_	8	P	_	_

1	Collectively	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	data	_	NNS	NNS	_	5	SBJ	_	_
5	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	NFAT	_	NN	NN	_	8	SBJ	_	_
8	can	_	MD	MD	_	6	VMOD	_	_
9	be	_	VB	VB	_	8	VC	_	_
10	activated	_	VBN	VBN	_	9	VC	_	_
11	and	_	CC	CC	_	8	CC	_	_
12	IL-2	_	NN	NN	_	13	SBJ	_	_
13	can	_	MD	MD	_	8	COORD	_	_
14	be	_	VB	VB	_	13	VC	_	_
15	produced	_	VBN	VBN	_	14	VC	_	_
16	in	_	IN	IN	_	8	ADV	_	_
17	a	_	DT	DT	_	20	NMOD	_	_
18	calcineurin	_	NN	NN	_	20	NMOD	_	_
19	independent	_	JJ	JJ	_	18	AMOD	_	_
20	manner	_	NN	NN	_	16	PMOD	_	_
21	.	_	.	.	_	5	P	_	_

1	Transcription	_	NN	NN	_	2	NMOD	_	_
2	factors	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	T	_	NN	NN	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	B	_	NN	NN	_	4	COORD	_	_
7	lymphocytes	_	NNS	NNS	_	3	PMOD	_	_
8	--	_	:	:	_	2	P	_	_
9	basic	_	JJ	JJ	_	10	NMOD	_	_
10	research	_	NN	NN	_	2	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	clinical	_	JJ	JJ	_	13	NMOD	_	_
13	perspectives	_	NNS	NNS	_	10	COORD	_	_
14	for	_	IN	IN	_	10	NMOD	_	_
15	gastroenterology	_	NN	NN	_	14	PMOD	_	_
16	.	_	.	.	_	2	P	_	_

1	Tissue	_	NN	NN	_	3	NMOD	_	_
2	specific	_	JJ	JJ	_	1	AMOD	_	_
3	regulation	_	NN	NN	_	10	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	gene	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	4	PMOD	_	_
7	by	_	IN	IN	_	3	NMOD	_	_
8	transcription	_	NN	NN	_	9	NMOD	_	_
9	factors	_	NNS	NNS	_	7	PMOD	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	a	_	DT	DT	_	14	NMOD	_	_
12	fascinating	_	JJ	JJ	_	14	NMOD	_	_
13	new	_	JJ	JJ	_	14	NMOD	_	_
14	field	_	NN	NN	_	10	PRD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	molecular	_	JJ	JJ	_	17	NMOD	_	_
17	immunology	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	10	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	review	_	NN	NN	_	3	SBJ	_	_
3	summarizes	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	data	_	NNS	NNS	_	3	OBJ	_	_
5	on	_	IN	IN	_	4	NMOD	_	_
6	specific	_	JJ	JJ	_	7	NMOD	_	_
7	regulation	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	promoters	_	NNS	NNS	_	8	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	enhancers	_	NNS	NNS	_	9	COORD	_	_
12	by	_	IN	IN	_	7	NMOD	_	_
13	nuclear	_	JJ	JJ	_	15	NMOD	_	_
14	trans-acting	_	JJ	JJ	_	15	NMOD	_	_
15	factors	_	NNS	NNS	_	12	PMOD	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	lymphocytes	_	NNS	NNS	_	16	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	structural	_	JJ	JJ	_	3	NMOD	_	_
3	classes	_	NNS	NNS	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	transcription	_	NN	NN	_	6	NMOD	_	_
6	factors	_	NNS	NNS	_	4	PMOD	_	_
7	are	_	VBP	VBP	_	0	ROOT-S	_	_
8	described	_	VBN	VBN	_	7	VC	_	_
9	and	_	CC	CC	_	7	CC	_	_
10	basic	_	JJ	JJ	_	11	NMOD	_	_
11	methods	_	NNS	NNS	_	19	SBJ	_	_
12	for	_	IN	IN	_	11	NMOD	_	_
13	detection	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	analysis	_	NN	NN	_	13	COORD	_	_
16	of	_	IN	IN	_	13	NMOD	_	_
17	transcription	_	NN	NN	_	18	NMOD	_	_
18	factors	_	NNS	NNS	_	16	PMOD	_	_
19	are	_	VBP	VBP	_	7	COORD	_	_
20	detailed	_	VBN	VBN	_	19	VC	_	_
21	.	_	.	.	_	7	P	_	_

1	Furthermore	_	RB	RB	_	26	ADV	_	_
2	,	_	,	,	_	26	P	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	most	_	RBS	RBS	_	5	AMOD	_	_
5	important	_	JJ	JJ	_	7	NMOD	_	_
6	trans-acting	_	JJ	JJ	_	7	NMOD	_	_
7	factors	_	NNS	NNS	_	26	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	T	_	NN	NN	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	B	_	NN	NN	_	9	COORD	_	_
12	lymphocytes	_	NNS	NNS	_	8	PMOD	_	_
13	(	_	(	(	_	20	P	_	_
14	e.g.	_	FW	FW	_	20	NMOD	_	_
15	NF-kB	_	NN	NN	_	20	NMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	NF-AT	_	NN	NN	_	15	COORD	_	_
18	and	_	CC	CC	_	15	CC	_	_
19	STAT	_	NN	NN	_	15	COORD	_	_
20	families	_	NNS	NNS	_	12	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	and	_	CC	CC	_	7	CC	_	_
23	their	_	PRP$	PRP$	_	25	NMOD	_	_
24	functional	_	JJ	JJ	_	25	NMOD	_	_
25	importance	_	NN	NN	_	7	COORD	_	_
26	are	_	VBP	VBP	_	0	ROOT-S	_	_
27	described	_	VBN	VBN	_	26	VC	_	_
28	.	_	.	.	_	26	P	_	_

1	Several	_	JJ	JJ	_	2	NMOD	_	_
2	methods	_	NNS	NNS	_	9	SBJ	_	_
3	for	_	IN	IN	_	2	NMOD	_	_
4	specific	_	JJ	JJ	_	5	NMOD	_	_
5	down-regulation	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	transcription	_	NN	NN	_	8	NMOD	_	_
8	factors	_	NNS	NNS	_	6	PMOD	_	_
9	are	_	VBP	VBP	_	0	ROOT-S	_	_
10	shown	_	VBN	VBN	_	9	VC	_	_
11	that	_	IN	IN	_	12	SBJ	_	_
12	may	_	MD	MD	_	10	NMOD	_	_
13	be	_	VB	VB	_	12	VC	_	_
14	relevant	_	JJ	JJ	_	13	PRD	_	_
15	to	_	TO	TO	_	14	AMOD	_	_
16	treatment	_	NN	NN	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	human	_	JJ	JJ	_	19	NMOD	_	_
19	disease	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	discussed	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	regard	_	NN	NN	_	5	DEP	_	_
7	to	_	TO	TO	_	5	DEP	_	_
8	their	_	PRP$	PRP$	_	11	NMOD	_	_
9	potential	_	JJ	JJ	_	11	NMOD	_	_
10	clinical	_	JJ	JJ	_	11	NMOD	_	_
11	relevance	_	NN	NN	_	5	PMOD	_	_
12	for	_	IN	IN	_	11	NMOD	_	_
13	gastroenterology	_	NN	NN	_	12	PMOD	_	_
14	.	_	.	.	_	3	P	_	_

1	Modulation	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	expression	_	NN	NN	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	IFN-gamma	_	NN	NN	_	9	NMOD	_	_
8	receptor	_	NN	NN	_	9	NMOD	_	_
9	beta-chain	_	NN	NN	_	5	PMOD	_	_
10	controls	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	responsiveness	_	NN	NN	_	10	OBJ	_	_
12	to	_	TO	TO	_	11	NMOD	_	_
13	IFN-gamma	_	NN	NN	_	12	PMOD	_	_
14	in	_	IN	IN	_	11	NMOD	_	_
15	human	_	JJ	JJ	_	19	NMOD	_	_
16	peripheral	_	JJ	JJ	_	19	NMOD	_	_
17	blood	_	NN	NN	_	19	NMOD	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	14	PMOD	_	_
20	.	_	.	.	_	10	P	_	_

1	IFN-gamma	_	NN	NN	_	2	SBJ	_	_
2	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	potent	_	JJ	JJ	_	7	NMOD	_	_
4	antiproliferative	_	JJ	JJ	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	apoptotic	_	JJ	JJ	_	4	COORD	_	_
7	effects	_	NNS	NNS	_	2	OBJ	_	_
8	in	_	IN	IN	_	2	ADV	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	that	_	WDT	WDT	_	12	SBJ	_	_
12	are	_	VBP	VBP	_	7	NMOD	_	_
13	important	_	JJ	JJ	_	12	PRD	_	_
14	in	_	IN	IN	_	12	ADV	_	_
15	determining	_	VBG	VBG	_	14	PMOD	_	_
16	T	_	NN	NN	_	17	NMOD	_	_
17	cell	_	NN	NN	_	15	OBJ	_	_
18	development	_	NN	NN	_	17	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	polarized	_	VBN	VBN	_	21	NMOD	_	_
21	differentiation	_	NN	NN	_	18	COORD	_	_
22	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	work	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	show	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	human	_	JJ	JJ	_	12	NMOD	_	_
9	peripheral	_	JJ	JJ	_	12	NMOD	_	_
10	blood	_	NN	NN	_	12	NMOD	_	_
11	T	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	23	SBJ	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	are	_	VBP	VBP	_	12	NMOD	_	_
15	stimulated	_	VBN	VBN	_	14	VC	_	_
16	through	_	IN	IN	_	15	ADV	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	TCR	_	NN	NN	_	16	PMOD	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	expanded	_	VBN	VBN	_	15	COORD	_	_
21	with	_	IN	IN	_	20	ADV	_	_
22	IL-2	_	NN	NN	_	21	PMOD	_	_
23	are	_	VBP	VBP	_	7	VMOD	_	_
24	unresponsive	_	JJ	JJ	_	23	PRD	_	_
25	to	_	TO	TO	_	24	AMOD	_	_
26	IFN-gamma	_	NN	NN	_	25	PMOD	_	_
27	,	_	,	,	_	23	P	_	_
28	as	_	IN	IN	_	23	ADV	_	_
29	determined	_	VBN	VBN	_	28	VMOD	_	_
30	by	_	IN	IN	_	29	ADV	_	_
31	a	_	DT	DT	_	32	NMOD	_	_
32	lack	_	NN	NN	_	30	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	activation	_	NN	NN	_	33	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	jak	_	NN	NN	_	37	NMOD	_	_
37	kinases	_	NNS	NNS	_	35	PMOD	_	_
38	and	_	CC	CC	_	37	CC	_	_
39	the	_	DT	DT	_	41	NMOD	_	_
40	transcription	_	NN	NN	_	41	NMOD	_	_
41	factor	_	NN	NN	_	37	COORD	_	_
42	,	_	,	,	_	41	P	_	_
43	STAT1-LRB-alpha-RRB-	_	NN	NN	_	41	NMOD	_	_
44	,	_	,	,	_	34	P	_	_
45	a	_	DT	DT	_	47	NMOD	_	_
46	signal	_	NN	NN	_	47	NMOD	_	_
47	transducer	_	NN	NN	_	34	COORD	_	_
48	and	_	CC	CC	_	34	CC	_	_
49	activator	_	NN	NN	_	34	COORD	_	_
50	of	_	IN	IN	_	49	NMOD	_	_
51	transcription	_	NN	NN	_	50	PMOD	_	_
52	.	_	.	.	_	6	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	nonresponsiveness	_	NN	NN	_	3	SBJ	_	_
3	occurs	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	because	_	IN	IN	_	3	ADV	_	_
5	of	_	IN	IN	_	4	DEP	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	lack	_	NN	NN	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	expression	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	beta-chain	_	NN	NN	_	10	PMOD	_	_
13	(	_	(	(	_	15	P	_	_
14	accessory	_	JJ	JJ	_	15	NMOD	_	_
15	factor	_	NN	NN	_	12	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	of	_	IN	IN	_	12	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	IFN-gamma	_	NN	NN	_	20	NMOD	_	_
20	receptor	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	3	P	_	_
22	while	_	IN	IN	_	3	OBJ	_	_
23	at	_	IN	IN	_	27	TMP	_	_
24	the	_	DT	DT	_	26	VMOD	_	_
25	same	_	JJ	JJ	_	26	VMOD	_	_
26	time	_	NN	NN	_	23	PMOD	_	_
27	maintaining	_	VBG	VBG	_	22	VMOD	_	_
28	IFN-gamma	_	NN	NN	_	31	NMOD	_	_
29	receptor	_	NN	NN	_	31	NMOD	_	_
30	alpha-chain	_	NN	NN	_	31	NMOD	_	_
31	expression	_	NN	NN	_	27	OBJ	_	_
32	.	_	.	.	_	3	P	_	_

1	Expression	_	NN	NN	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	beta-chain	_	NN	NN	_	2	PMOD	_	_
5	can	_	MD	MD	_	0	ROOT-S	_	_
6	be	_	VB	VB	_	5	VC	_	_
7	restored	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	secondary	_	JJ	JJ	_	11	NMOD	_	_
10	TCR	_	NN	NN	_	11	NMOD	_	_
11	ligation	_	NN	NN	_	8	PMOD	_	_
12	or	_	CC	CC	_	11	CC	_	_
13	PMA	_	NN	NN	_	14	NMOD	_	_
14	treatment	_	NN	NN	_	11	COORD	_	_
15	.	_	.	.	_	5	P	_	_

1	T	_	NN	NN	_	3	NMOD	_	_
2	cell	_	NN	NN	_	3	NMOD	_	_
3	blasts	_	NNS	NNS	_	7	SBJ	_	_
4	treated	_	VBN	VBN	_	3	NMOD	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	PMA	_	NNS	NNS	_	5	PMOD	_	_
7	are	_	VBP	VBP	_	0	ROOT-S	_	_
8	now	_	RB	RB	_	7	TMP	_	_
9	responsive	_	JJ	JJ	_	7	PRD	_	_
10	to	_	TO	TO	_	9	AMOD	_	_
11	IFN-gamma	_	NN	NN	_	10	PMOD	_	_
12	.	_	.	.	_	7	P	_	_

1	When	_	WRB	WRB	_	3	ADV	_	_
2	freshly	_	RB	RB	_	3	ADV	_	_
3	isolated	_	VBN	VBN	_	14	TMP	_	_
4	,	_	,	,	_	14	P	_	_
5	highly	_	RB	RB	_	6	AMOD	_	_
6	enriched	_	VBN	VBN	_	13	NMOD	_	_
7	(	_	(	(	_	10	P	_	_
8	&gt;	_	JJR	JJR	_	9	DEP	_	_
9	98	_	CD	CD	_	10	NMOD	_	_
10	%	_	NN	NN	_	6	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	14	SBJ	_	_
14	are	_	VBP	VBP	_	0	ROOT-S	_	_
15	examined	_	VBN	VBN	_	14	VC	_	_
16	for	_	IN	IN	_	15	ADV	_	_
17	IFN-gamma	_	NN	NN	_	18	NMOD	_	_
18	responsiveness	_	NN	NN	_	16	PMOD	_	_
19	;	_	:	:	_	14	P	_	_
20	these	_	DT	DT	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	22	SBJ	_	_
22	can	_	MD	MD	_	14	VC	_	_
23	respond	_	VB	VB	_	22	VC	_	_
24	to	_	TO	TO	_	23	ADV	_	_
25	IFN-gamma	_	NN	NN	_	24	PMOD	_	_
26	and	_	CC	CC	_	23	CC	_	_
27	express	_	VB	VB	_	23	COORD	_	_
28	beta-chain	_	NN	NN	_	27	OBJ	_	_
29	.	_	.	.	_	22	P	_	_

1	Therefore	_	RB	RB	_	25	ADV	_	_
2	,	_	,	,	_	25	P	_	_
3	as	_	IN	IN	_	25	ADV	_	_
4	T	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	6	SBJ	_	_
6	progress	_	VBP	VBP	_	3	VMOD	_	_
7	from	_	IN	IN	_	6	ADV	_	_
8	primary	_	JJ	JJ	_	10	NMOD	_	_
9	TCR	_	NN	NN	_	10	NMOD	_	_
10	activation	_	NN	NN	_	7	PMOD	_	_
11	through	_	IN	IN	_	6	ADV	_	_
12	IL-2-dependent	_	JJ	JJ	_	13	NMOD	_	_
13	proliferation	_	NN	NN	_	11	PMOD	_	_
14	,	_	,	,	_	6	P	_	_
15	followed	_	VBN	VBN	_	6	OBJ	_	_
16	by	_	IN	IN	_	15	ADV	_	_
17	secondary	_	JJ	JJ	_	19	NMOD	_	_
18	TCR	_	NN	NN	_	19	NMOD	_	_
19	stimulation	_	NN	NN	_	16	PMOD	_	_
20	,	_	,	,	_	25	P	_	_
21	their	_	PRP$	PRP$	_	22	NMOD	_	_
22	responsiveness	_	NN	NN	_	25	SBJ	_	_
23	to	_	TO	TO	_	22	NMOD	_	_
24	IFN-gamma	_	NN	NN	_	23	PMOD	_	_
25	varies	_	VBZ	VBZ	_	0	ROOT-S	_	_
26	,	_	,	,	_	25	P	_	_
27	and	_	CC	CC	_	25	CC	_	_
28	this	_	DT	DT	_	29	SBJ	_	_
29	may	_	MD	MD	_	25	COORD	_	_
30	affect	_	VB	VB	_	29	VC	_	_
31	their	_	PRP$	PRP$	_	32	NMOD	_	_
32	ability	_	NN	NN	_	30	OBJ	_	_
33	to	_	TO	TO	_	34	VMOD	_	_
34	participate	_	VB	VB	_	32	NMOD	_	_
35	in	_	IN	IN	_	34	ADV	_	_
36	an	_	DT	DT	_	39	NMOD	_	_
37	ongoing	_	JJ	JJ	_	39	NMOD	_	_
38	immune	_	JJ	JJ	_	39	NMOD	_	_
39	response	_	NN	NN	_	35	PMOD	_	_
40	.	_	.	.	_	25	P	_	_

1	Differential	_	JJ	JJ	_	2	NMOD	_	_
2	utilization	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	Janus	_	NN	NN	_	6	AMOD	_	_
5	kinase-signal	_	JJ	JJ	_	6	AMOD	_	_
6	transducer	_	NN	NN	_	7	NMOD	_	_
7	activator	_	NN	NN	_	3	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	transcription	_	NN	NN	_	11	NMOD	_	_
10	signaling	_	NN	NN	_	11	NMOD	_	_
11	pathways	_	NNS	NNS	_	8	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	stimulation	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	human	_	JJ	JJ	_	19	NMOD	_	_
17	natural	_	JJ	JJ	_	19	NMOD	_	_
18	killer	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	15	PMOD	_	_
20	by	_	IN	IN	_	14	NMOD	_	_
21	IL-2	_	NN	NN	_	20	PMOD	_	_
22	,	_	,	,	_	21	P	_	_
23	IL-12	_	NN	NN	_	21	COORD	_	_
24	,	_	,	,	_	21	P	_	_
25	and	_	CC	CC	_	21	CC	_	_
26	IFN-alpha	_	NN	NN	_	21	COORD	_	_
27	.	_	.	.	_	2	P	_	_

1	IL-2-	_	NN	NN	_	8	NMOD	_	_
2	,	_	,	,	_	1	P	_	_
3	IL-12-	_	NN	NN	_	1	COORD	_	_
4	,	_	,	,	_	1	P	_	_
5	and	_	CC	CC	_	1	CC	_	_
6	IFN-alpha-mediated	_	JJ	JJ	_	1	COORD	_	_
7	signaling	_	NN	NN	_	8	NMOD	_	_
8	pathways	_	NNS	NNS	_	9	SBJ	_	_
9	were	_	VBD	VBD	_	0	ROOT-S	_	_
10	analyzed	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	primary	_	JJ	JJ	_	14	NMOD	_	_
13	NK	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	11	PMOD	_	_
15	and	_	CC	CC	_	11	CC	_	_
16	in	_	IN	IN	_	11	COORD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	NK3.3	_	NN	NN	_	20	NMOD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	line	_	NN	NN	_	16	PMOD	_	_
21	.	_	.	.	_	9	P	_	_

1	Gel	_	NN	NN	_	3	NMOD	_	_
2	mobility	_	NN	NN	_	3	NMOD	_	_
3	shift	_	NN	NN	_	6	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	immunoprecipitation	_	NN	NN	_	3	COORD	_	_
6	analyses	_	NNS	NNS	_	7	SBJ	_	_
7	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	in	_	IN	IN	_	26	ADV	_	_
10	addition	_	NN	NN	_	9	DEP	_	_
11	to	_	TO	TO	_	9	DEP	_	_
12	activating	_	VBG	VBG	_	9	PMOD	_	_
13	STAT3	_	NN	NN	_	12	OBJ	_	_
14	(	_	(	(	_	16	P	_	_
15	signal	_	NN	NN	_	16	NMOD	_	_
16	transducer	_	NN	NN	_	13	PRN	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	activator	_	NN	NN	_	16	COORD	_	_
19	of	_	IN	IN	_	16	NMOD	_	_
20	transcription-3	_	NN	NN	_	19	PMOD	_	_
21	)	_	)	)	_	16	P	_	_
22	and	_	CC	CC	_	13	CC	_	_
23	STAT5	_	NN	NN	_	13	COORD	_	_
24	,	_	,	,	_	26	P	_	_
25	IL-2	_	NN	NN	_	26	SBJ	_	_
26	induced	_	VBD	VBD	_	8	VMOD	_	_
27	tyrosine	_	NN	NN	_	30	NMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	serine	_	NN	NN	_	27	COORD	_	_
30	phosphorylation	_	NN	NN	_	26	OBJ	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	STAT1	_	NN	NN	_	33	NMOD	_	_
33	alpha	_	NN	NN	_	31	PMOD	_	_
34	,	_	,	,	_	30	P	_	_
35	which	_	WDT	WDT	_	36	SBJ	_	_
36	formed	_	VBD	VBD	_	30	NMOD	_	_
37	IFN-gamma-activated	_	JJ	JJ	_	39	NMOD	_	_
38	sequence-binding	_	NN	NN	_	39	NMOD	_	_
39	complexes	_	NNS	NNS	_	36	OBJ	_	_
40	by	_	IN	IN	_	36	ADV	_	_
41	itself	_	PRP	PRP	_	40	PMOD	_	_
42	and	_	CC	CC	_	40	CC	_	_
43	with	_	IN	IN	_	40	COORD	_	_
44	STAT3	_	NN	NN	_	43	PMOD	_	_
45	.	_	.	.	_	7	P	_	_

1	Although	_	IN	IN	_	13	ADV	_	_
2	IL-2	_	NN	NN	_	5	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	IFN-alpha	_	NN	NN	_	2	COORD	_	_
5	activated	_	VBD	VBD	_	1	VMOD	_	_
6	STAT1	_	NN	NN	_	7	NMOD	_	_
7	alpha	_	NN	NN	_	5	OBJ	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	STAT5	_	NN	NN	_	7	COORD	_	_
10	,	_	,	,	_	13	P	_	_
11	IL-2	_	NN	NN	_	13	SBJ	_	_
12	predominantly	_	RB	RB	_	13	ADV	_	_
13	activated	_	VBN	VBN	_	0	ROOT-S	_	_
14	STAT5	_	NN	NN	_	13	IOBJ	_	_
15	,	_	,	,	_	13	P	_	_
16	while	_	IN	IN	_	13	OBJ	_	_
17	IFN-alpha	_	NN	NN	_	19	SBJ	_	_
18	predominantly	_	RB	RB	_	19	ADV	_	_
19	activated	_	VBD	VBD	_	16	VMOD	_	_
20	STAT1	_	NN	NN	_	21	NMOD	_	_
21	alpha	_	NN	NN	_	19	OBJ	_	_
22	.	_	.	.	_	13	P	_	_

1	IL-2	_	NN	NN	_	2	SBJ	_	_
2	induced	_	VBD	VBD	_	0	ROOT-S	_	_
3	less	_	RBR	RBR	_	6	NMOD	_	_
4	STAT1	_	NN	NN	_	6	NMOD	_	_
5	alpha	_	NN	NN	_	6	NMOD	_	_
6	activation	_	NN	NN	_	2	OBJ	_	_
7	and	_	CC	CC	_	2	CC	_	_
8	IFN-alpha	_	NN	NN	_	9	SBJ	_	_
9	induced	_	VBD	VBD	_	2	COORD	_	_
10	greater	_	JJR	JJR	_	12	NMOD	_	_
11	STAT5	_	NN	NN	_	12	NMOD	_	_
12	activation	_	NN	NN	_	9	OBJ	_	_
13	in	_	IN	IN	_	2	ADV	_	_
14	NK3.3	_	NN	NN	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	13	PMOD	_	_
16	compared	_	VBN	VBN	_	2	ADV	_	_
17	with	_	IN	IN	_	16	PMOD	_	_
18	preactivated	_	JJ	JJ	_	21	NMOD	_	_
19	primary	_	JJ	JJ	_	21	NMOD	_	_
20	NK	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	17	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	NK3.3	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	IL-2	_	NN	NN	_	6	SBJ	_	_
6	induced	_	VBD	VBD	_	0	ROOT-S	_	_
7	comparable	_	JJ	JJ	_	8	NMOD	_	_
8	formation	_	NN	NN	_	6	IOBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	c-fos	_	NN	NN	_	15	AMOD	_	_
11	promoter	_	NN	NN	_	15	AMOD	_	_
12	sis-inducible	_	JJ	JJ	_	15	AMOD	_	_
13	element	_	NN	NN	_	15	AMOD	_	_
14	IFN-gamma-activated	_	JJ	JJ	_	15	AMOD	_	_
15	sequence-binding	_	NN	NN	_	16	NMOD	_	_
16	complexes	_	NNS	NNS	_	9	PMOD	_	_
17	containing	_	VBG	VBG	_	16	NMOD	_	_
18	STAT3	_	NN	NN	_	17	OBJ	_	_
19	alone	_	RB	RB	_	18	NMOD	_	_
20	with	_	IN	IN	_	8	NMOD	_	_
21	complexes	_	NNS	NNS	_	20	PMOD	_	_
22	containing	_	VBG	VBG	_	21	NMOD	_	_
23	STAT3	_	NN	NN	_	22	OBJ	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	STAT1	_	NN	NN	_	26	NMOD	_	_
26	alpha	_	NN	NN	_	23	COORD	_	_
27	,	_	,	,	_	6	P	_	_
28	while	_	IN	IN	_	6	OBJ	_	_
29	in	_	IN	IN	_	37	ADV	_	_
30	preactivated	_	JJ	JJ	_	33	NMOD	_	_
31	primary	_	JJ	JJ	_	33	NMOD	_	_
32	NK	_	NN	NN	_	33	NMOD	_	_
33	cells	_	NNS	NNS	_	29	PMOD	_	_
34	,	_	,	,	_	37	P	_	_
35	it	_	PRP	PRP	_	37	SBJ	_	_
36	preferentially	_	RB	RB	_	37	ADV	_	_
37	induced	_	VBD	VBD	_	28	VMOD	_	_
38	complexes	_	NNS	NNS	_	37	OBJ	_	_
39	containing	_	VBG	VBG	_	38	NMOD	_	_
40	STAT3	_	NN	NN	_	39	OBJ	_	_
41	and	_	CC	CC	_	40	CC	_	_
42	STAT1	_	NN	NN	_	43	NMOD	_	_
43	alpha	_	NN	NN	_	40	COORD	_	_
44	.	_	.	.	_	6	P	_	_

1	Thus	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	signaling	_	NN	NN	_	7	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	NK3.3	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	not	_	RB	RB	_	7	VMOD	_	_
9	always	_	RB	RB	_	7	TMP	_	_
10	identical	_	JJ	JJ	_	7	PRD	_	_
11	with	_	IN	IN	_	10	AMOD	_	_
12	that	_	DT	DT	_	11	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	primary	_	JJ	JJ	_	16	NMOD	_	_
15	NK	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	13	PMOD	_	_
17	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	contrast	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	IL-2	_	NN	NN	_	1	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	IFN-alpha	_	NN	NN	_	4	COORD	_	_
7	,	_	,	,	_	9	P	_	_
8	IL-12	_	NN	NN	_	9	SBJ	_	_
9	induced	_	VBD	VBD	_	0	ROOT-S	_	_
10	strong	_	JJ	JJ	_	12	NMOD	_	_
11	tyrosine	_	NN	NN	_	12	NMOD	_	_
12	phosphorylation	_	NN	NN	_	9	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	STAT4	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	12	CC	_	_
16	variable	_	JJ	JJ	_	18	NMOD	_	_
17	weak	_	JJ	JJ	_	18	NMOD	_	_
18	phosphorylation	_	NN	NN	_	12	COORD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	STAT3	_	NN	NN	_	19	PMOD	_	_
21	.	_	.	.	_	9	P	_	_

1	However	_	RB	RB	_	12	ADV	_	_
2	,	_	,	,	_	12	P	_	_
3	supershift	_	NN	NN	_	4	NMOD	_	_
4	analyses	_	NNS	NNS	_	12	SBJ	_	_
5	using	_	VBG	VBG	_	4	NMOD	_	_
6	the	_	DT	DT	_	11	NMOD	_	_
7	c-fos	_	NN	NN	_	11	NMOD	_	_
8	promoter	_	NN	NN	_	11	NMOD	_	_
9	sis-inducible	_	JJ	JJ	_	11	NMOD	_	_
10	element	_	NN	NN	_	11	NMOD	_	_
11	probe	_	NN	NN	_	5	OBJ	_	_
12	showed	_	VBD	VBD	_	0	ROOT-S	_	_
13	that	_	IN	IN	_	12	OBJ	_	_
14	IL-12	_	NN	NN	_	15	SBJ	_	_
15	activated	_	VBD	VBD	_	13	VMOD	_	_
16	STAT4	_	NN	NN	_	15	OBJ	_	_
17	,	_	,	,	_	16	P	_	_
18	STAT1	_	NN	NN	_	19	NMOD	_	_
19	alpha	_	NN	NN	_	16	COORD	_	_
20	,	_	,	,	_	16	P	_	_
21	and	_	CC	CC	_	16	CC	_	_
22	STAT3	_	NN	NN	_	16	COORD	_	_
23	,	_	,	,	_	15	P	_	_
24	and	_	CC	CC	_	15	CC	_	_
25	induced	_	VBD	VBD	_	15	COORD	_	_
26	complexes	_	NNS	NNS	_	25	OBJ	_	_
27	containing	_	VBG	VBG	_	26	NMOD	_	_
28	STAT4	_	NN	NN	_	27	OBJ	_	_
29	only	_	RB	RB	_	28	NMOD	_	_
30	,	_	,	,	_	28	P	_	_
31	STAT4	_	NN	NN	_	28	COORD	_	_
32	with	_	IN	IN	_	31	NMOD	_	_
33	STAT1	_	NN	NN	_	34	NMOD	_	_
34	alpha	_	NN	NN	_	32	PMOD	_	_
35	,	_	,	,	_	28	P	_	_
36	STAT3	_	NN	NN	_	28	COORD	_	_
37	with	_	IN	IN	_	36	NMOD	_	_
38	STAT1	_	NN	NN	_	39	NMOD	_	_
39	alpha	_	NN	NN	_	37	PMOD	_	_
40	,	_	,	,	_	28	P	_	_
41	or	_	CC	CC	_	28	CC	_	_
42	STAT1	_	NN	NN	_	43	NMOD	_	_
43	alpha	_	NN	NN	_	28	COORD	_	_
44	only	_	RB	RB	_	43	NMOD	_	_
45	in	_	IN	IN	_	15	ADV	_	_
46	preactivated	_	JJ	JJ	_	49	NMOD	_	_
47	primary	_	JJ	JJ	_	49	NMOD	_	_
48	NK	_	NN	NN	_	49	NMOD	_	_
49	cells	_	NNS	NNS	_	45	PMOD	_	_
50	.	_	.	.	_	12	P	_	_

1	STAT1	_	NN	NN	_	3	NMOD	_	_
2	alpha	_	NN	NN	_	3	NMOD	_	_
3	activation	_	NN	NN	_	6	SBJ	_	_
4	by	_	IN	IN	_	3	NMOD	_	_
5	IL-12	_	NN	NN	_	4	PMOD	_	_
6	correlated	_	VBD	VBD	_	0	ROOT-S	_	_
7	with	_	IN	IN	_	6	ADV	_	_
8	increased	_	VBN	VBN	_	9	NMOD	_	_
9	phosphorylation	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	serine	_	NN	NN	_	10	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	but	_	CC	CC	_	11	CC	_	_
14	not	_	RB	RB	_	13	COORD	_	_
15	tyrosine	_	NN	NN	_	11	COORD	_	_
16	.	_	.	.	_	6	P	_	_

1	Finally	_	RB	RB	_	4	TMP	_	_
2	,	_	,	,	_	4	P	_	_
3	IL-2	_	NN	NN	_	4	SBJ	_	_
4	induced	_	VBD	VBD	_	0	ROOT-S	_	_
5	tyrosine	_	NN	NN	_	6	NMOD	_	_
6	phosphorylation	_	NN	NN	_	4	IOBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	JAK1	_	NN	NN	_	7	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	JAK3	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	4	P	_	_
12	while	_	IN	IN	_	4	OBJ	_	_
13	IL-12	_	NN	NN	_	14	SBJ	_	_
14	induced	_	VBD	VBD	_	12	VMOD	_	_
15	phosphorylation	_	NN	NN	_	14	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	JAK2	_	NN	NN	_	16	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	TYK2	_	NN	NN	_	17	COORD	_	_
20	in	_	IN	IN	_	4	ADV	_	_
21	both	_	CC	CC	_	24	CC	_	_
22	preactivated	_	JJ	JJ	_	24	NMOD	_	_
23	primary	_	JJ	JJ	_	24	NMOD	_	_
24	NK	_	NN	NN	_	27	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	NK3.3	_	NN	NN	_	24	COORD	_	_
27	cells	_	NNS	NNS	_	20	PMOD	_	_
28	.	_	.	.	_	4	P	_	_

1	Differential	_	JJ	JJ	_	2	NMOD	_	_
2	phosphorylation	_	NN	NN	_	21	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	consequent	_	JJ	JJ	_	6	NMOD	_	_
5	differential	_	JJ	JJ	_	6	NMOD	_	_
6	activation	_	NN	NN	_	2	COORD	_	_
7	of	_	IN	IN	_	2	NMOD	_	_
8	both	_	CC	CC	_	9	CC	_	_
9	separate	_	JJ	JJ	_	13	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	overlapping	_	JJ	JJ	_	9	COORD	_	_
12	STAT	_	NN	NN	_	13	NMOD	_	_
13	proteins	_	NNS	NNS	_	7	PMOD	_	_
14	by	_	IN	IN	_	2	NMOD	_	_
15	IL-2	_	NN	NN	_	14	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	IL-12	_	NN	NN	_	15	COORD	_	_
18	,	_	,	,	_	15	P	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	IFN-alpha	_	NN	NN	_	15	COORD	_	_
21	may	_	MD	MD	_	0	ROOT-S	_	_
22	provide	_	VB	VB	_	21	VC	_	_
23	a	_	DT	DT	_	25	NMOD	_	_
24	molecular	_	JJ	JJ	_	25	NMOD	_	_
25	basis	_	NN	NN	_	22	OBJ	_	_
26	for	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	similarities	_	NNS	NNS	_	26	PMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	differences	_	NNS	NNS	_	28	COORD	_	_
31	in	_	IN	IN	_	28	NMOD	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	actions	_	NNS	NNS	_	31	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	these	_	DT	DT	_	36	NMOD	_	_
36	cytokines	_	NNS	NNS	_	34	PMOD	_	_
37	on	_	IN	IN	_	33	NMOD	_	_
38	NK	_	NN	NN	_	39	NMOD	_	_
39	cells	_	NNS	NNS	_	37	PMOD	_	_
40	.	_	.	.	_	21	P	_	_

1	Sublethal	_	JJ	JJ	_	2	NMOD	_	_
2	levels	_	NNS	NNS	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	oxidative	_	JJ	JJ	_	5	NMOD	_	_
5	stress	_	NN	NN	_	3	PMOD	_	_
6	stimulate	_	VBP	VBP	_	0	ROOT-S	_	_
7	transcriptional	_	JJ	JJ	_	8	NMOD	_	_
8	activation	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	c-jun	_	NN	NN	_	9	PMOD	_	_
11	and	_	CC	CC	_	6	CC	_	_
12	suppress	_	VBP	VBP	_	6	COORD	_	_
13	IL-2	_	NN	NN	_	15	NMOD	_	_
14	promoter	_	NN	NN	_	15	NMOD	_	_
15	activation	_	NN	NN	_	12	OBJ	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	Jurkat	_	NN	NN	_	19	NMOD	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	6	P	_	_

1	Sublethal	_	JJ	JJ	_	2	NMOD	_	_
2	levels	_	NNS	NNS	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	oxidative	_	JJ	JJ	_	5	NMOD	_	_
5	stress	_	NN	NN	_	3	PMOD	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	well	_	RB	RB	_	8	ADV	_	_
8	known	_	VBN	VBN	_	6	VC	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	alter	_	VB	VB	_	8	OBJ	_	_
11	T	_	NN	NN	_	14	NMOD	_	_
12	cell	_	NN	NN	_	14	NMOD	_	_
13	functional	_	JJ	JJ	_	14	NMOD	_	_
14	responses	_	NNS	NNS	_	10	OBJ	_	_
15	,	_	,	,	_	6	P	_	_
16	but	_	CC	CC	_	6	CC	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	underlying	_	JJ	JJ	_	19	NMOD	_	_
19	mechanisms	_	NNS	NNS	_	20	SBJ	_	_
20	are	_	VBP	VBP	_	6	COORD	_	_
21	unknown	_	JJ	JJ	_	20	PRD	_	_
22	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	current	_	JJ	JJ	_	3	NMOD	_	_
3	study	_	NN	NN	_	4	SBJ	_	_
4	examined	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	effects	_	NNS	NNS	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	oxidative	_	JJ	JJ	_	9	NMOD	_	_
9	stress	_	NN	NN	_	7	PMOD	_	_
10	on	_	IN	IN	_	6	NMOD	_	_
11	transcriptional	_	JJ	JJ	_	12	NMOD	_	_
12	activities	_	NNS	NNS	_	10	PMOD	_	_
13	mediated	_	VBN	VBN	_	12	NMOD	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	c-Fos\/c-Jun	_	NN	NN	_	16	NMOD	_	_
16	AP-1	_	NN	NN	_	14	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	nuclear	_	JJ	JJ	_	20	NMOD	_	_
20	factor	_	NN	NN	_	16	COORD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	activated	_	VBN	VBN	_	24	NMOD	_	_
23	T	_	NN	NN	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	21	PMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	NF-AT	_	NN	NN	_	20	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	present	_	JJ	JJ	_	3	NMOD	_	_
3	results	_	NNS	NNS	_	4	SBJ	_	_
4	show	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	Jurkat	_	NN	NN	_	8	NMOD	_	_
7	T	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	16	SBJ	_	_
9	acutely	_	RB	RB	_	10	ADV	_	_
10	exposed	_	VBN	VBN	_	8	NMOD	_	_
11	to	_	TO	TO	_	10	ADV	_	_
12	micromolar	_	JJ	JJ	_	13	NMOD	_	_
13	concentrations	_	NNS	NNS	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	H2O2	_	NN	NN	_	14	PMOD	_	_
16	exhibit	_	VBP	VBP	_	5	VMOD	_	_
17	substantial	_	JJ	JJ	_	18	NMOD	_	_
18	increases	_	NNS	NNS	_	16	OBJ	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	AP-1	_	NN	NN	_	22	NMOD	_	_
21	binding	_	NN	NN	_	22	NMOD	_	_
22	activity	_	NN	NN	_	19	PMOD	_	_
23	and	_	CC	CC	_	18	CC	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	expression	_	NN	NN	_	18	COORD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	c-jun	_	NN	NN	_	31	NMOD	_	_
28	but	_	CC	CC	_	27	CC	_	_
29	not	_	RB	RB	_	28	COORD	_	_
30	c-fos	_	NN	NN	_	27	COORD	_	_
31	mRNA	_	NN	NN	_	26	PMOD	_	_
32	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	preferential	_	JJ	JJ	_	3	NMOD	_	_
3	induction	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	c-jun	_	NN	NN	_	4	PMOD	_	_
6	by	_	IN	IN	_	3	NMOD	_	_
7	H2O2	_	NN	NN	_	6	PMOD	_	_
8	did	_	VBD	VBD	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	represent	_	VB	VB	_	8	VC	_	_
11	redox	_	NN	NN	_	12	NMOD	_	_
12	stabilization	_	NN	NN	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	mRNA	_	NN	NN	_	15	NMOD	_	_
15	transcripts	_	NNS	NNS	_	13	PMOD	_	_
16	,	_	,	,	_	8	P	_	_
17	and	_	CC	CC	_	8	CC	_	_
18	oxidative	_	JJ	JJ	_	19	NMOD	_	_
19	signals	_	NNS	NNS	_	21	SBJ	_	_
20	closely	_	RB	RB	_	21	ADV	_	_
21	resembled	_	VBD	VBD	_	8	COORD	_	_
22	PHA\/PMA	_	NN	NN	_	23	NMOD	_	_
23	stimulation	_	NN	NN	_	21	OBJ	_	_
24	by	_	IN	IN	_	21	ADV	_	_
25	effectively	_	RB	RB	_	26	ADV	_	_
26	transactivating	_	VBG	VBG	_	24	PMOD	_	_
27	the	_	DT	DT	_	31	NMOD	_	_
28	full	_	JJ	JJ	_	31	NMOD	_	_
29	length	_	NN	NN	_	31	NMOD	_	_
30	c-jun	_	NN	NN	_	31	NMOD	_	_
31	promoter	_	NN	NN	_	26	OBJ	_	_
32	via	_	IN	IN	_	26	ADV	_	_
33	the	_	DT	DT	_	44	NMOD	_	_
34	proximal	_	JJ	JJ	_	44	NMOD	_	_
35	jun1	_	NN	NN	_	44	NMOD	_	_
36	tumor	_	NN	NN	_	38	NMOD	_	_
37	promoter-responsive	_	JJ	JJ	_	36	AMOD	_	_
38	element	_	NN	NN	_	40	AMOD	_	_
39	(	_	(	(	_	40	P	_	_
40	TRE	_	NN	NN	_	44	NMOD	_	_
41	)	_	)	)	_	40	P	_	_
42	-like	_	JJ	JJ	_	40	AMOD	_	_
43	promoter	_	NN	NN	_	44	NMOD	_	_
44	element	_	NN	NN	_	32	PMOD	_	_
45	.	_	.	.	_	8	P	_	_

1	Similarly	_	RB	RB	_	22	ADV	_	_
2	,	_	,	,	_	22	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	complexes	_	NNS	NNS	_	22	SBJ	_	_
5	binding	_	VBG	VBG	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	consensus	_	NN	NN	_	9	NMOD	_	_
8	AP-1	_	NN	NN	_	9	NMOD	_	_
9	TRE	_	NN	NN	_	5	OBJ	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	jun	_	NN	NN	_	13	NMOD	_	_
12	TRE-like	_	JJ	JJ	_	13	NMOD	_	_
13	motifs	_	NNS	NNS	_	9	COORD	_	_
14	in	_	IN	IN	_	9	NMOD	_	_
15	cells	_	NNS	NNS	_	14	PMOD	_	_
16	exposed	_	VBN	VBN	_	15	NMOD	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	oxidative	_	JJ	JJ	_	19	NMOD	_	_
19	signals	_	NNS	NNS	_	17	PMOD	_	_
20	or	_	CC	CC	_	19	CC	_	_
21	PHA\/PMA	_	NN	NN	_	19	COORD	_	_
22	were	_	VBD	VBD	_	0	ROOT-S	_	_
23	indistinguishable	_	JJ	JJ	_	22	PRD	_	_
24	,	_	,	,	_	22	P	_	_
25	being	_	VBG	VBG	_	22	VC	_	_
26	composed	_	VBN	VBN	_	25	VC	_	_
27	of	_	IN	IN	_	26	ADV	_	_
28	c-Fos	_	NN	NN	_	27	PMOD	_	_
29	,	_	,	,	_	28	P	_	_
30	c-Jun	_	NN	NN	_	28	COORD	_	_
31	,	_	,	,	_	28	P	_	_
32	and	_	CC	CC	_	28	CC	_	_
33	JunD	_	NN	NN	_	28	COORD	_	_
34	.	_	.	.	_	22	P	_	_

1	However	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	PHA\/PMA	_	NN	NN	_	7	NMOD	_	_
4	but	_	CC	CC	_	3	CC	_	_
5	not	_	RB	RB	_	6	AMOD	_	_
6	oxidative	_	JJ	JJ	_	3	COORD	_	_
7	signals	_	NNS	NNS	_	8	SBJ	_	_
8	induced	_	VBD	VBD	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	coordinate	_	JJ	JJ	_	11	NMOD	_	_
11	activation	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	reporter	_	NN	NN	_	14	NMOD	_	_
14	constructs	_	NNS	NNS	_	12	PMOD	_	_
15	containing	_	VBG	VBG	_	14	NMOD	_	_
16	the	_	DT	DT	_	24	NMOD	_	_
17	AP-1-TRE	_	NN	NN	_	24	NMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	NF-AT	_	NN	NN	_	17	COORD	_	_
20	,	_	,	,	_	17	P	_	_
21	and	_	CC	CC	_	17	CC	_	_
22	IL-2	_	NN	NN	_	17	COORD	_	_
23	promoter	_	NN	NN	_	24	NMOD	_	_
24	regions	_	NNS	NNS	_	15	OBJ	_	_
25	along	_	IN	IN	_	11	CC	_	_
26	with	_	IN	IN	_	25	DEP	_	_
27	IL-2	_	NN	NN	_	29	NMOD	_	_
28	mRNA	_	NN	NN	_	29	NMOD	_	_
29	expression	_	NN	NN	_	11	COORD	_	_
30	.	_	.	.	_	8	P	_	_

1	Furthermore	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	sublethal	_	JJ	JJ	_	4	NMOD	_	_
4	levels	_	NNS	NNS	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	H2O2	_	NN	NN	_	5	PMOD	_	_
7	actively	_	RB	RB	_	8	ADV	_	_
8	suppressed	_	VBD	VBD	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	transcriptional	_	JJ	JJ	_	11	NMOD	_	_
11	activation	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	NF-AT	_	NN	NN	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	IL-2	_	NN	NN	_	13	COORD	_	_
16	reporters	_	NNS	NNS	_	12	PMOD	_	_
17	as	_	RB	RB	_	11	CC	_	_
18	well	_	RB	RB	_	17	DEP	_	_
19	as	_	IN	IN	_	17	DEP	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	expression	_	NN	NN	_	11	COORD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	IL-2	_	NN	NN	_	24	NMOD	_	_
24	mRNA	_	NN	NN	_	22	PMOD	_	_
25	in	_	IN	IN	_	21	NMOD	_	_
26	cells	_	NNS	NNS	_	25	PMOD	_	_
27	stimulated	_	VBN	VBN	_	26	NMOD	_	_
28	with	_	IN	IN	_	27	ADV	_	_
29	PHA\/PMA	_	NN	NN	_	28	PMOD	_	_
30	.	_	.	.	_	8	P	_	_

1	Gel	_	NN	NN	_	3	NMOD	_	_
2	shift	_	NN	NN	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	4	SBJ	_	_
4	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	oxidative	_	JJ	JJ	_	7	NMOD	_	_
7	suppression	_	NN	NN	_	10	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	NF-AT	_	NN	NN	_	8	PMOD	_	_
10	represented	_	VBD	VBD	_	5	VMOD	_	_
11	inhibition	_	NN	NN	_	10	OBJ	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	early	_	JJ	JJ	_	15	NMOD	_	_
15	generation	_	NN	NN	_	12	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	NFAT	_	NN	NN	_	18	NMOD	_	_
18	complexes	_	NNS	NNS	_	16	PMOD	_	_
19	rather	_	RB	RB	_	15	CC	_	_
20	than	_	IN	IN	_	19	DEP	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	binding	_	NN	NN	_	15	COORD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	preformed	_	JJ	JJ	_	26	NMOD	_	_
25	NF-AT	_	NN	NN	_	26	NMOD	_	_
26	complexes	_	NNS	NNS	_	23	PMOD	_	_
27	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	oxidative	_	JJ	JJ	_	6	NMOD	_	_
6	signals	_	NNS	NNS	_	7	SBJ	_	_
7	can	_	MD	MD	_	4	VMOD	_	_
8	positively	_	RB	RB	_	7	ADV	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	negatively	_	RB	RB	_	8	COORD	_	_
11	regulate	_	VB	VB	_	7	VC	_	_
12	T	_	NN	NN	_	15	NMOD	_	_
13	cell	_	NN	NN	_	15	NMOD	_	_
14	transcriptional	_	JJ	JJ	_	15	NMOD	_	_
15	events	_	NNS	NNS	_	11	OBJ	_	_
16	and	_	CC	CC	_	4	CC	_	_
17	that	_	IN	IN	_	4	COORD	_	_
18	changes	_	NNS	NNS	_	22	SBJ	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	cellular	_	JJ	JJ	_	21	NMOD	_	_
21	redox	_	NN	NN	_	19	PMOD	_	_
22	can	_	MD	MD	_	17	VMOD	_	_
23	uncouple	_	VB	VB	_	22	VC	_	_
24	AP-1	_	NN	NN	_	25	NMOD	_	_
25	regulation	_	NN	NN	_	23	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	c-jun	_	NN	NN	_	26	PMOD	_	_
28	from	_	IN	IN	_	23	ADV	_	_
29	transcriptional	_	JJ	JJ	_	30	NMOD	_	_
30	up-regulation	_	NN	NN	_	28	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	IL-2	_	NN	NN	_	31	PMOD	_	_
33	via	_	IN	IN	_	30	NMOD	_	_
34	NF-AT	_	NN	NN	_	33	PMOD	_	_
35	.	_	.	.	_	3	P	_	_

1	Cooperation	_	NN	NN	_	10	SBJ	_	_
2	between	_	IN	IN	_	1	NMOD	_	_
3	core	_	NN	NN	_	5	NMOD	_	_
4	binding	_	NN	NN	_	5	NMOD	_	_
5	factor	_	NN	NN	_	2	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	adjacent	_	JJ	JJ	_	9	NMOD	_	_
8	promoter	_	NN	NN	_	9	NMOD	_	_
9	elements	_	NNS	NNS	_	5	COORD	_	_
10	contributes	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	to	_	TO	TO	_	10	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	tissue-specific	_	JJ	JJ	_	14	NMOD	_	_
14	expression	_	NN	NN	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	interleukin-3	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	10	P	_	_

1	Tissue-specific	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	interleukin-3	_	NN	NN	_	3	PMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	IL-3	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	mediated	_	VBN	VBN	_	8	VC	_	_
10	via	_	IN	IN	_	9	ADV	_	_
11	cis-acting	_	JJ	JJ	_	12	NMOD	_	_
12	elements	_	NNS	NNS	_	10	PMOD	_	_
13	located	_	JJ	JJ	_	12	NMOD	_	_
14	within	_	IN	IN	_	13	AMOD	_	_
15	315	_	CD	CD	_	17	NMOD	_	_
16	base	_	NN	NN	_	17	NMOD	_	_
17	pairs	_	NNS	NNS	_	14	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	transcription	_	NN	NN	_	21	NMOD	_	_
21	start	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	8	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	achieved	_	VBN	VBN	_	2	VC	_	_
4	in	_	IN	IN	_	6	PMOD	_	_
5	part	_	NN	NN	_	4	PMOD	_	_
6	through	_	IN	IN	_	3	ADV	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	positive	_	JJ	JJ	_	9	NMOD	_	_
9	activities	_	NNS	NNS	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	15	NMOD	_	_
12	AP-1	_	NN	NN	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	Elf-1	_	NN	NN	_	12	COORD	_	_
15	sites	_	NNS	NNS	_	10	PMOD	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	IL-3	_	NN	NN	_	19	NMOD	_	_
19	promoter	_	NN	NN	_	16	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	contribution	_	NN	NN	_	11	SBJ	_	_
3	to	_	TO	TO	_	2	NMOD	_	_
4	T	_	NN	NN	_	6	NMOD	_	_
5	cell-specific	_	JJ	JJ	_	4	AMOD	_	_
6	expression	_	NN	NN	_	3	PMOD	_	_
7	by	_	IN	IN	_	2	NMOD	_	_
8	other	_	JJ	JJ	_	10	NMOD	_	_
9	promoter	_	NN	NN	_	10	NMOD	_	_
10	sites	_	NNS	NNS	_	7	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	assessed	_	VBN	VBN	_	11	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	a	_	DT	DT	_	17	NMOD	_	_
15	transient	_	JJ	JJ	_	17	NMOD	_	_
16	expression	_	NN	NN	_	17	NMOD	_	_
17	assay	_	NN	NN	_	13	PMOD	_	_
18	with	_	IN	IN	_	17	NMOD	_	_
19	IL-3	_	NN	NN	_	21	NMOD	_	_
20	promoter	_	NN	NN	_	21	NMOD	_	_
21	constructs	_	NNS	NNS	_	18	PMOD	_	_
22	linked	_	VBN	VBN	_	21	NMOD	_	_
23	to	_	TO	TO	_	22	ADV	_	_
24	a	_	DT	DT	_	26	NMOD	_	_
25	luciferase	_	NN	NN	_	26	NMOD	_	_
26	gene	_	NN	NN	_	23	PMOD	_	_
27	,	_	,	,	_	12	P	_	_
28	focusing	_	VBG	VBG	_	12	OBJ	_	_
29	initially	_	RB	RB	_	28	TMP	_	_
30	on	_	IN	IN	_	28	ADV	_	_
31	the	_	DT	DT	_	38	NMOD	_	_
32	core	_	NN	NN	_	34	NMOD	_	_
33	binding	_	NN	NN	_	34	NMOD	_	_
34	factor	_	NN	NN	_	38	NMOD	_	_
35	(	_	(	(	_	36	P	_	_
36	CBF	_	NN	NN	_	34	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	site	_	NN	NN	_	30	PMOD	_	_
39	,	_	,	,	_	38	P	_	_
40	which	_	WDT	WDT	_	41	SBJ	_	_
41	is	_	VBZ	VBZ	_	38	NMOD	_	_
42	footprinted	_	JJ	JJ	_	41	VC	_	_
43	in	_	FW	FW	_	42	ADV	_	_
44	vivo	_	FW	FW	_	43	AMOD	_	_
45	upon	_	IN	IN	_	42	TMP	_	_
46	T	_	NN	NN	_	48	NMOD	_	_
47	cell	_	NN	NN	_	48	NMOD	_	_
48	activation	_	NN	NN	_	45	PMOD	_	_
49	.	_	.	.	_	11	P	_	_

1	Activity	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	CBF	_	NN	NN	_	5	NMOD	_	_
5	site	_	NN	NN	_	2	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	shown	_	VBN	VBN	_	6	VC	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	be	_	VB	VB	_	7	OBJ	_	_
10	critically	_	RB	RB	_	11	AMOD	_	_
11	dependent	_	JJ	JJ	_	9	PRD	_	_
12	on	_	IN	IN	_	11	AMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	adjacent	_	JJ	JJ	_	16	NMOD	_	_
15	activator	_	NN	NN	_	16	NMOD	_	_
16	site	_	NN	NN	_	12	PMOD	_	_
17	Act-1	_	CD	CD	_	16	NMOD	_	_
18	.	_	.	.	_	6	P	_	_

1	Together	_	RB	RB	_	7	ADV	_	_
2	the	_	DT	DT	_	6	NMOD	_	_
3	Act-1	_	NN	NN	_	6	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	CBF	_	NN	NN	_	3	COORD	_	_
6	sites	_	NNS	NNS	_	7	SBJ	_	_
7	form	_	VBP	VBP	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	functional	_	JJ	JJ	_	10	NMOD	_	_
10	unit	_	NN	NN	_	7	OBJ	_	_
11	(	_	(	(	_	13	P	_	_
12	AC	_	NN	NN	_	13	NMOD	_	_
13	unit	_	NN	NN	_	10	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	with	_	IN	IN	_	10	NMOD	_	_
16	dual	_	JJ	JJ	_	17	NMOD	_	_
17	activity	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	AC	_	NN	NN	_	3	NMOD	_	_
3	unit	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	demonstrated	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	9	VMOD	_	_
7	enhance	_	VB	VB	_	9	NMOD	_	_
8	basal	_	JJ	JJ	_	9	NMOD	_	_
9	activity	_	NN	NN	_	5	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	promoters	_	NNS	NNS	_	10	PMOD	_	_
12	both	_	CC	CC	_	13	PMOD	_	_
13	in	_	IN	IN	_	9	NMOD	_	_
14	fibroblasts	_	NNS	NNS	_	13	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	T	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	14	COORD	_	_
18	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	activity	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	further	_	RB	RB	_	5	AMOD	_	_
5	inducible	_	JJ	JJ	_	3	PRD	_	_
6	in	_	IN	IN	_	3	ADV	_	_
7	activated	_	VBN	VBN	_	9	NMOD	_	_
8	T	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	6	PMOD	_	_
10	,	_	,	,	_	6	P	_	_
11	but	_	CC	CC	_	6	CC	_	_
12	not	_	RB	RB	_	13	DEP	_	_
13	in	_	IN	IN	_	6	COORD	_	_
14	fibroblasts	_	NNS	NNS	_	13	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	addition	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	the	_	DT	DT	_	9	NMOD	_	_
5	already	_	RB	RB	_	6	AMOD	_	_
6	identified	_	VBN	VBN	_	9	NMOD	_	_
7	NIP	_	NN	NN	_	9	NMOD	_	_
8	repressor	_	NN	NN	_	9	NMOD	_	_
9	site	_	NN	NN	_	1	PMOD	_	_
10	,	_	,	,	_	12	P	_	_
11	evidence	_	NN	NN	_	12	SBJ	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	presented	_	VBN	VBN	_	12	VC	_	_
14	for	_	IN	IN	_	13	ADV	_	_
15	a	_	DT	DT	_	18	NMOD	_	_
16	second	_	JJ	JJ	_	18	NMOD	_	_
17	repressor	_	NN	NN	_	18	NMOD	_	_
18	region	_	NN	NN	_	14	PMOD	_	_
19	that	_	WDT	WDT	_	20	SBJ	_	_
20	restricts	_	VBZ	VBZ	_	18	NMOD	_	_
21	promoter	_	NN	NN	_	22	NMOD	_	_
22	activity	_	NN	NN	_	20	OBJ	_	_
23	in	_	IN	IN	_	22	NMOD	_	_
24	fibroblasts	_	NNS	NNS	_	23	PMOD	_	_
25	.	_	.	.	_	12	P	_	_

1	Finally	_	RB	RB	_	8	TMP	_	_
2	,	_	,	,	_	8	P	_	_
3	a	_	DT	DT	_	7	NMOD	_	_
4	novel	_	JJ	JJ	_	7	NMOD	_	_
5	positive	_	JJ	JJ	_	7	NMOD	_	_
6	regulatory	_	JJ	JJ	_	7	NMOD	_	_
7	element	_	NN	NN	_	8	SBJ	_	_
8	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	been	_	VBN	VBN	_	8	VC	_	_
10	mapped	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	IL-3	_	NN	NN	_	14	NMOD	_	_
14	promoter	_	NN	NN	_	11	PMOD	_	_
15	between	_	IN	IN	_	14	NMOD	_	_
16	nucleotide	_	NN	NN	_	15	PMOD	_	_
17	-180	_	CD	CD	_	16	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	-210	_	CD	CD	_	17	COORD	_	_
20	that	_	WDT	WDT	_	21	SBJ	_	_
21	leads	_	VBZ	VBZ	_	14	NMOD	_	_
22	to	_	TO	TO	_	21	ADV	_	_
23	increased	_	VBN	VBN	_	24	NMOD	_	_
24	expression	_	NN	NN	_	22	PMOD	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	T	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	8	P	_	_

1	Together	_	RB	RB	_	4	ADV	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	results	_	NNS	NNS	_	4	SBJ	_	_
4	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	T	_	NN	NN	_	8	NMOD	_	_
7	cell	_	NN	NN	_	8	NMOD	_	_
8	expression	_	NN	NN	_	11	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	IL-3	_	NN	NN	_	9	PMOD	_	_
11	is	_	VBZ	VBZ	_	5	VMOD	_	_
12	not	_	RB	RB	_	11	VMOD	_	_
13	specified	_	VBN	VBN	_	11	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	activity	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	a	_	DT	DT	_	21	NMOD	_	_
19	single	_	JJ	JJ	_	21	NMOD	_	_
20	tissue-specific	_	JJ	JJ	_	21	NMOD	_	_
21	element	_	NN	NN	_	17	PMOD	_	_
22	,	_	,	,	_	11	P	_	_
23	but	_	CC	CC	_	11	CC	_	_
24	instead	_	RB	RB	_	11	COORD	_	_
25	involves	_	VBZ	VBZ	_	11	COORD	_	_
26	multiple	_	JJ	JJ	_	28	NMOD	_	_
27	interacting	_	VBG	VBG	_	28	NMOD	_	_
28	elements	_	NNS	NNS	_	25	OBJ	_	_
29	that	_	WDT	WDT	_	30	SBJ	_	_
30	provide	_	VBP	VBP	_	28	NMOD	_	_
31	both	_	CC	CC	_	34	CC	_	_
32	specific	_	JJ	JJ	_	34	NMOD	_	_
33	positive	_	JJ	JJ	_	34	NMOD	_	_
34	regulation	_	NN	NN	_	30	OBJ	_	_
35	in	_	IN	IN	_	34	NMOD	_	_
36	T	_	NN	NN	_	37	NMOD	_	_
37	cells	_	NNS	NNS	_	35	PMOD	_	_
38	and	_	CC	CC	_	34	CC	_	_
39	specific	_	JJ	JJ	_	41	NMOD	_	_
40	negative	_	JJ	JJ	_	41	NMOD	_	_
41	regulation	_	NN	NN	_	34	COORD	_	_
42	in	_	IN	IN	_	41	NMOD	_	_
43	fibroblasts	_	NNS	NNS	_	42	PMOD	_	_
44	.	_	.	.	_	4	P	_	_

1	A	_	DT	DT	_	7	NMOD	_	_
2	3'	_	JJ	JJ	_	7	NMOD	_	_
3	--&gt;	_	TO	TO	_	2	NMOD	_	_
4	5'	_	JJ	JJ	_	2	NMOD	_	_
5	XPB	_	NN	NN	_	7	NMOD	_	_
6	helicase	_	NN	NN	_	7	NMOD	_	_
7	defect	_	NN	NN	_	17	SBJ	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	repair\/transcription	_	NN	NN	_	11	NMOD	_	_
10	factor	_	NN	NN	_	11	NMOD	_	_
11	TFIIH	_	NN	NN	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	xeroderma	_	NN	NN	_	16	NMOD	_	_
14	pigmentosum	_	NN	NN	_	16	NMOD	_	_
15	group	_	NN	NN	_	16	NMOD	_	_
16	B	_	NN	NN	_	12	PMOD	_	_
17	affects	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	both	_	CC	CC	_	19	CC	_	_
19	DNA	_	NN	NN	_	17	OBJ	_	_
20	repair	_	NN	NN	_	19	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	transcription	_	NN	NN	_	20	COORD	_	_
23	.	_	.	.	_	17	P	_	_

1	XPB	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	subunit	_	NN	NN	_	2	PRD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	basal	_	JJ	JJ	_	10	NMOD	_	_
8	transcription	_	NN	NN	_	10	NMOD	_	_
9	factor	_	NN	NN	_	10	NMOD	_	_
10	TFIIH	_	NN	NN	_	5	PMOD	_	_
11	,	_	,	,	_	4	P	_	_
12	which	_	WDT	WDT	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	4	NMOD	_	_
14	also	_	RB	RB	_	13	ADV	_	_
15	involved	_	VBN	VBN	_	13	VC	_	_
16	in	_	IN	IN	_	15	VMOD	_	_
17	nucleotide	_	NN	NN	_	19	NMOD	_	_
18	excision	_	NN	NN	_	19	NMOD	_	_
19	repair	_	NN	NN	_	16	PMOD	_	_
20	(	_	(	(	_	21	P	_	_
21	NER	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	and	_	CC	CC	_	15	CC	_	_
24	potentially	_	RB	RB	_	25	ADV	_	_
25	in	_	IN	IN	_	16	GAP	_	_
26	cell	_	NN	NN	_	28	NMOD	_	_
27	cycle	_	NN	NN	_	28	NMOD	_	_
28	regulation	_	NN	NN	_	25	PMOD	_	_
29	.	_	.	.	_	2	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	frameshift	_	NN	NN	_	3	NMOD	_	_
3	mutation	_	NN	NN	_	11	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	3'-end	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	XPB	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	7	PMOD	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	responsible	_	JJ	JJ	_	11	PRD	_	_
13	for	_	IN	IN	_	12	AMOD	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	concurrence	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	two	_	CD	CD	_	18	NMOD	_	_
18	disorders	_	NNS	NNS	_	16	PMOD	_	_
19	:	_	:	:	_	18	P	_	_
20	xeroderma	_	NN	NN	_	21	NMOD	_	_
21	pigmentosum	_	NN	NN	_	18	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	XP	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	and	_	CC	CC	_	21	CC	_	_
26	Cockayne	_	NN	NN	_	28	NMOD	_	_
27	's	_	POS	POS	_	26	NMOD	_	_
28	syndrome	_	NN	NN	_	21	COORD	_	_
29	(	_	(	(	_	30	P	_	_
30	CS	_	NN	NN	_	28	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	.	_	.	.	_	11	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	isolated	_	VBN	VBN	_	2	VC	_	_
4	TFIIH	_	NN	NN	_	3	IOBJ	_	_
5	from	_	IN	IN	_	3	ADV	_	_
6	cells	_	NNS	NNS	_	5	PMOD	_	_
7	derived	_	VBN	VBN	_	6	NMOD	_	_
8	from	_	IN	IN	_	7	VMOD	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	patient	_	NN	NN	_	8	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	XP11BE	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	who	_	WP	WP	_	15	SBJ	_	_
15	carries	_	VBZ	VBZ	_	10	NMOD	_	_
16	this	_	DT	DT	_	18	NMOD	_	_
17	frameshift	_	NN	NN	_	18	NMOD	_	_
18	mutation	_	NN	NN	_	15	OBJ	_	_
19	(	_	(	(	_	20	P	_	_
20	TFIIHmut	_	NN	NN	_	6	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	and	_	CC	CC	_	6	CC	_	_
23	from	_	IN	IN	_	8	GAP	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	mother	_	NN	NN	_	23	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	this	_	DT	DT	_	28	NMOD	_	_
28	patient	_	NN	NN	_	26	PMOD	_	_
29	(	_	(	(	_	30	P	_	_
30	TFIIHwt	_	NN	NN	_	20	GAP	_	_
31	)	_	)	)	_	30	P	_	_
32	to	_	TO	TO	_	33	VMOD	_	_
33	determine	_	VB	VB	_	3	OBJ	_	_
34	the	_	DT	DT	_	36	NMOD	_	_
35	biochemical	_	JJ	JJ	_	36	NMOD	_	_
36	consequences	_	NNS	NNS	_	33	OBJ	_	_
37	of	_	IN	IN	_	36	NMOD	_	_
38	the	_	DT	DT	_	39	NMOD	_	_
39	mutation	_	NN	NN	_	37	PMOD	_	_
40	.	_	.	.	_	2	P	_	_

1	Although	_	IN	IN	_	11	ADV	_	_
2	identical	_	JJ	JJ	_	1	VMOD	_	_
3	in	_	IN	IN	_	2	AMOD	_	_
4	composition	_	NN	NN	_	3	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	stoichiometry	_	NN	NN	_	4	COORD	_	_
7	to	_	TO	TO	_	2	AMOD	_	_
8	TFIIHwt	_	NN	NN	_	7	PMOD	_	_
9	,	_	,	,	_	11	P	_	_
10	TFIIHmut	_	NN	NN	_	11	SBJ	_	_
11	shows	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	a	_	DT	DT	_	19	NMOD	_	_
13	reduced	_	VBN	VBN	_	19	NMOD	_	_
14	3'	_	JJ	JJ	_	19	NMOD	_	_
15	--&gt;	_	TO	TO	_	14	NMOD	_	_
16	5'	_	JJ	JJ	_	14	NMOD	_	_
17	XPB	_	NN	NN	_	19	NMOD	_	_
18	helicase	_	NN	NN	_	19	NMOD	_	_
19	activity	_	NN	NN	_	11	OBJ	_	_
20	.	_	.	.	_	11	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	decrease	_	NN	NN	_	9	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	helicase	_	NN	NN	_	8	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	DNA-dependent	_	JJ	JJ	_	7	NMOD	_	_
7	ATPase	_	NN	NN	_	4	COORD	_	_
8	activities	_	NNS	NNS	_	3	PMOD	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	also	_	RB	RB	_	9	ADV	_	_
11	observed	_	VBN	VBN	_	9	VC	_	_
12	with	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	mutated	_	VBN	VBN	_	17	NMOD	_	_
15	recombinant	_	JJ	JJ	_	17	NMOD	_	_
16	XPB	_	NN	NN	_	17	NMOD	_	_
17	protein	_	NN	NN	_	12	PMOD	_	_
18	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	XPB	_	NN	NN	_	3	NMOD	_	_
3	mutation	_	NN	NN	_	4	SBJ	_	_
4	causes	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	VMOD	_	_
6	severe	_	JJ	JJ	_	7	VMOD	_	_
7	NER	_	NN	NN	_	4	VC	_	_
8	defect	_	NN	NN	_	7	VMOD	_	_
9	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	provide	_	VBP	VBP	_	0	ROOT-S	_	_
6	evidence	_	NN	NN	_	5	OBJ	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	decrease	_	NN	NN	_	7	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	basal	_	JJ	JJ	_	13	NMOD	_	_
12	transcription	_	NN	NN	_	13	NMOD	_	_
13	activity	_	NN	NN	_	10	PMOD	_	_
14	in	_	FW	FW	_	13	NMOD	_	_
15	vitro	_	FW	FW	_	14	AMOD	_	_
16	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	latter	_	JJ	JJ	_	3	NMOD	_	_
3	defect	_	NN	NN	_	4	SBJ	_	_
4	may	_	MD	MD	_	0	ROOT-S	_	_
5	provide	_	VB	VB	_	4	VC	_	_
6	an	_	DT	DT	_	7	NMOD	_	_
7	explanation	_	NN	NN	_	5	OBJ	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	many	_	JJ	JJ	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	15	NMOD	_	_
12	XP	_	NN	NN	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	CS	_	NN	NN	_	12	COORD	_	_
15	symptoms	_	NNS	NNS	_	10	PMOD	_	_
16	that	_	WDT	WDT	_	17	SBJ	_	_
17	are	_	VBP	VBP	_	15	NMOD	_	_
18	difficult	_	JJ	JJ	_	17	PRD	_	_
19	to	_	TO	TO	_	20	VMOD	_	_
20	rationalize	_	VB	VB	_	18	AMOD	_	_
21	based	_	VBN	VBN	_	20	ADV	_	_
22	solely	_	RB	RB	_	23	DEP	_	_
23	on	_	IN	IN	_	21	PMOD	_	_
24	an	_	DT	DT	_	26	NMOD	_	_
25	NER	_	NN	NN	_	26	NMOD	_	_
26	defect	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	4	P	_	_

1	Thus	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	work	_	NN	NN	_	5	SBJ	_	_
5	presents	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	first	_	JJ	JJ	_	9	NMOD	_	_
8	detailed	_	JJ	JJ	_	9	NMOD	_	_
9	analysis	_	NN	NN	_	5	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	a	_	DT	DT	_	14	NMOD	_	_
12	naturally	_	RB	RB	_	13	AMOD	_	_
13	occurring	_	VBG	VBG	_	14	NMOD	_	_
14	mutation	_	NN	NN	_	10	PMOD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	a	_	DT	DT	_	19	NMOD	_	_
17	basal	_	JJ	JJ	_	19	NMOD	_	_
18	transcription	_	NN	NN	_	19	NMOD	_	_
19	factor	_	NN	NN	_	15	PMOD	_	_
20	and	_	CC	CC	_	5	CC	_	_
21	supports	_	VBZ	VBZ	_	5	COORD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	concept	_	NN	NN	_	21	OBJ	_	_
24	that	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	29	NMOD	_	_
26	combined	_	JJ	JJ	_	29	NMOD	_	_
27	XP\/CS	_	NN	NN	_	29	NMOD	_	_
28	clinical	_	JJ	JJ	_	29	NMOD	_	_
29	entity	_	NN	NN	_	30	SBJ	_	_
30	is	_	VBZ	VBZ	_	24	VMOD	_	_
31	actually	_	RB	RB	_	30	ADV	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	result	_	NN	NN	_	30	PRD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	a	_	DT	DT	_	38	NMOD	_	_
36	combined	_	JJ	JJ	_	38	NMOD	_	_
37	transcription\/repair	_	NN	NN	_	38	NMOD	_	_
38	deficiency	_	NN	NN	_	34	PMOD	_	_
39	.	_	.	.	_	5	P	_	_

1	Characterization	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	Grb2-binding	_	JJ	JJ	_	4	NMOD	_	_
4	proteins	_	NNS	NNS	_	2	PMOD	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	human	_	JJ	JJ	_	7	NMOD	_	_
7	platelets	_	NNS	NNS	_	5	PMOD	_	_
8	activated	_	VBN	VBN	_	7	NMOD	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	Fc	_	NN	NN	_	13	NMOD	_	_
11	gamma	_	NN	NN	_	13	NMOD	_	_
12	RIIA	_	NN	NN	_	13	NMOD	_	_
13	cross-linking	_	NN	NN	_	9	PMOD	_	_
14	.	_	.	.	_	1	P	_	_

1	Glutathione-S-transferase	_	NN	NN	_	5	AMOD	_	_
2	(	_	(	(	_	5	P	_	_
3	GST	_	NN	NN	_	5	AMOD	_	_
4	)	_	)	)	_	5	P	_	_
5	-Grb2	_	NN	NN	_	7	NMOD	_	_
6	fusion	_	NN	NN	_	7	NMOD	_	_
7	proteins	_	NNS	NNS	_	8	SBJ	_	_
8	have	_	VBP	VBP	_	0	ROOT-S	_	_
9	been	_	VBN	VBN	_	8	VC	_	_
10	used	_	VBN	VBN	_	9	VC	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	identify	_	VB	VB	_	10	OBJ	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	potential	_	JJ	JJ	_	15	NMOD	_	_
15	role	_	NN	NN	_	12	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	Grb2-binding	_	JJ	JJ	_	18	NMOD	_	_
18	proteins	_	NNS	NNS	_	16	PMOD	_	_
19	in	_	IN	IN	_	15	NMOD	_	_
20	platelet	_	NN	NN	_	21	NMOD	_	_
21	activation	_	NN	NN	_	19	PMOD	_	_
22	by	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	27	NMOD	_	_
24	platelet	_	NN	NN	_	27	NMOD	_	_
25	low-affinity	_	NN	NN	_	27	NMOD	_	_
26	IgG	_	NN	NN	_	27	NMOD	_	_
27	receptor	_	NN	NN	_	22	PMOD	_	_
28	,	_	,	,	_	27	P	_	_
29	Fc	_	NN	NN	_	31	NMOD	_	_
30	gamma	_	NN	NN	_	31	NMOD	_	_
31	RIIA	_	NN	NN	_	27	NMOD	_	_
32	.	_	.	.	_	8	P	_	_

1	Two	_	CD	CD	_	3	NMOD	_	_
2	tyrosine	_	NN	NN	_	3	NMOD	_	_
3	phosphoproteins	_	NNS	NNS	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	38	_	CD	CD	_	8	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	63	_	CD	CD	_	5	COORD	_	_
8	kD	_	NN	NN	_	4	PMOD	_	_
9	bind	_	VBP	VBP	_	0	ROOT-S	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	SH2	_	NN	NN	_	13	NMOD	_	_
13	domain	_	NN	NN	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	Grb2	_	NN	NN	_	14	PMOD	_	_
16	following	_	VBG	VBG	_	9	TMP	_	_
17	Fc	_	NN	NN	_	20	NMOD	_	_
18	gamma	_	NN	NN	_	20	NMOD	_	_
19	RIIA	_	NN	NN	_	20	NMOD	_	_
20	stimulation	_	NN	NN	_	16	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	platelets	_	NNS	NNS	_	21	PMOD	_	_
23	.	_	.	.	_	9	P	_	_

1	Both	_	DT	DT	_	2	SBJ	_	_
2	are	_	VBP	VBP	_	0	ROOT-S	_	_
3	located	_	JJ	JJ	_	2	PRD	_	_
4	in	_	IN	IN	_	3	AMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	particulate	_	JJ	JJ	_	7	NMOD	_	_
7	fraction	_	NN	NN	_	4	PMOD	_	_
8	following	_	VBG	VBG	_	2	TMP	_	_
9	platelet	_	NN	NN	_	10	NMOD	_	_
10	activation	_	NN	NN	_	8	PMOD	_	_
11	and	_	CC	CC	_	2	CC	_	_
12	are	_	VBP	VBP	_	2	COORD	_	_
13	also	_	RB	RB	_	12	ADV	_	_
14	able	_	JJ	JJ	_	12	PRD	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	bind	_	VB	VB	_	14	AMOD	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	GST-construct	_	NN	NN	_	17	PMOD	_	_
20	containing	_	VBG	VBG	_	19	NMOD	_	_
21	the	_	DT	DT	_	25	NMOD	_	_
22	SH2	_	NN	NN	_	25	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	SH3	_	NN	NN	_	22	COORD	_	_
25	domains	_	NNS	NNS	_	20	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	phospholipase	_	NN	NN	_	29	NMOD	_	_
28	C	_	NN	NN	_	29	NMOD	_	_
29	gamma	_	NN	NN	_	26	PMOD	_	_
30	1	_	CD	CD	_	29	NMOD	_	_
31	.	_	.	.	_	2	P	_	_

1	p38	_	NN	NN	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	forms	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	complex	_	NN	NN	_	3	OBJ	_	_
6	with	_	IN	IN	_	3	ADV	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	tyrosine	_	NN	NN	_	10	NMOD	_	_
9	kinase	_	NN	NN	_	10	NMOD	_	_
10	csk	_	NN	NN	_	6	PMOD	_	_
11	in	_	IN	IN	_	3	ADV	_	_
12	stimulated	_	VBN	VBN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	and	_	CC	CC	_	3	CC	_	_
15	is	_	VBZ	VBZ	_	3	COORD	_	_
16	a	_	DT	DT	_	17	NMOD	_	_
17	substrate	_	NN	NN	_	15	PRD	_	_
18	for	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	kinase	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	SH3	_	NN	NN	_	3	NMOD	_	_
3	domains	_	NNS	NNS	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	Grb2	_	NN	NN	_	4	PMOD	_	_
6	form	_	VBP	VBP	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	stable	_	JJ	JJ	_	9	NMOD	_	_
9	complex	_	NN	NN	_	6	OBJ	_	_
10	with	_	IN	IN	_	6	ADV	_	_
11	SOS1	_	NN	NN	_	10	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	two	_	CD	CD	_	14	NMOD	_	_
14	proteins	_	NNS	NNS	_	11	COORD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	75	_	CD	CD	_	17	NMOD	_	_
17	kD	_	NN	NN	_	15	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	120	_	CD	CD	_	20	NMOD	_	_
20	kD	_	NN	NN	_	17	COORD	_	_
21	,	_	,	,	_	14	P	_	_
22	which	_	WDT	WDT	_	23	SBJ	_	_
23	undergo	_	VBP	VBP	_	14	NMOD	_	_
24	tyrosine	_	NN	NN	_	25	NMOD	_	_
25	phosphorylation	_	NN	NN	_	23	OBJ	_	_
26	in	_	IN	IN	_	23	ADV	_	_
27	Fc	_	NN	NN	_	29	NMOD	_	_
28	gamma	_	NN	NN	_	29	NMOD	_	_
29	RIIA	_	NN	NN	_	30	AMOD	_	_
30	stimulated	_	JJ	JJ	_	31	NMOD	_	_
31	cells	_	NNS	NNS	_	26	PMOD	_	_
32	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	75-kD	_	JJ	JJ	_	3	NMOD	_	_
3	protein	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	recognized	_	VBN	VBN	_	4	VC	_	_
6	by	_	IN	IN	_	5	LGS	_	_
7	antibodies	_	NNS	NNS	_	6	PMOD	_	_
8	to	_	TO	TO	_	7	NMOD	_	_
9	SLP-76	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	has	_	VBZ	VBZ	_	9	NMOD	_	_
13	recently	_	RB	RB	_	12	TMP	_	_
14	been	_	VBN	VBN	_	12	VC	_	_
15	isolated	_	VBN	VBN	_	14	VC	_	_
16	from	_	IN	IN	_	15	ADV	_	_
17	T	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	16	PMOD	_	_
19	and	_	CC	CC	_	5	CC	_	_
20	sequenced	_	VBN	VBN	_	5	COORD	_	_
21	.	_	.	.	_	4	P	_	_

1	Tyrosine	_	NN	NN	_	2	NMOD	_	_
2	phosphorylation	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	p38	_	NN	NN	_	3	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	p63	_	NN	NN	_	4	COORD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	also	_	RB	RB	_	7	ADV	_	_
9	observed	_	VBN	VBN	_	7	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	platelets	_	NNS	NNS	_	10	PMOD	_	_
12	stimulated	_	VBN	VBN	_	11	NMOD	_	_
13	by	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	19	NMOD	_	_
15	tyrosine	_	NN	NN	_	19	NMOD	_	_
16	kinase-linked	_	JJ	JJ	_	15	AMOD	_	_
17	receptor	_	NN	NN	_	19	NMOD	_	_
18	agonist	_	NN	NN	_	19	NMOD	_	_
19	collagen	_	NN	NN	_	13	PMOD	_	_
20	and	_	CC	CC	_	13	CC	_	_
21	by	_	IN	IN	_	13	LGS	_	_
22	the	_	DT	DT	_	27	NMOD	_	_
23	G	_	NN	NN	_	27	NMOD	_	_
24	protein-coupled	_	JJ	JJ	_	23	AMOD	_	_
25	receptor	_	NN	NN	_	27	NMOD	_	_
26	agonist	_	NN	NN	_	27	NMOD	_	_
27	thrombin	_	NN	NN	_	21	PMOD	_	_
28	,	_	,	,	_	9	P	_	_
29	although	_	IN	IN	_	9	OBJ	_	_
30	phosphorylation	_	NN	NN	_	33	SBJ	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	SLP-76	_	NN	NN	_	31	PMOD	_	_
33	is	_	VBZ	VBZ	_	29	VMOD	_	_
34	only	_	RB	RB	_	33	ADV	_	_
35	observed	_	VBN	VBN	_	33	VC	_	_
36	in	_	IN	IN	_	35	ADV	_	_
37	collagen-stimulated	_	JJ	JJ	_	38	NMOD	_	_
38	platelets	_	NNS	NNS	_	36	PMOD	_	_
39	.	_	.	.	_	7	P	_	_

1	p38	_	NN	NN	_	4	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	p63	_	NN	NN	_	1	COORD	_	_
4	may	_	MD	MD	_	0	ROOT-S	_	_
5	provide	_	VB	VB	_	4	VC	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	docking	_	NN	NN	_	8	NMOD	_	_
8	site	_	NN	NN	_	5	IOBJ	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	Grb2	_	NN	NN	_	9	PMOD	_	_
11	,	_	,	,	_	5	P	_	_
12	thereby	_	RB	RB	_	13	ADV	_	_
13	linking	_	VBG	VBG	_	5	OBJ	_	_
14	Grb2	_	NN	NN	_	16	NMOD	_	_
15	SH3-binding	_	JJ	JJ	_	16	NMOD	_	_
16	proteins	_	NNS	NNS	_	13	OBJ	_	_
17	SOS1	_	NN	NN	_	16	NMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	SLP-76	_	NN	NN	_	17	COORD	_	_
20	,	_	,	,	_	17	P	_	_
21	and	_	CC	CC	_	17	CC	_	_
22	p120	_	NN	NN	_	17	COORD	_	_
23	to	_	TO	TO	_	13	ADV	_	_
24	downstream	_	JJ	JJ	_	26	NMOD	_	_
25	signalling	_	NN	NN	_	26	NMOD	_	_
26	events	_	NNS	NNS	_	23	PMOD	_	_
27	.	_	.	.	_	4	P	_	_

1	Retinoic	_	JJ	JJ	_	2	NMOD	_	_
2	acid	_	NN	NN	_	3	SBJ	_	_
3	activates	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	interferon	_	NN	NN	_	8	NMOD	_	_
5	regulatory	_	JJ	JJ	_	8	NMOD	_	_
6	factor-1	_	JJ	JJ	_	8	NMOD	_	_
7	gene	_	NN	NN	_	8	NMOD	_	_
8	expression	_	NN	NN	_	3	OBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	myeloid	_	JJ	JJ	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	All-trans-retinoic	_	JJ	JJ	_	2	NMOD	_	_
2	acid	_	NN	NN	_	6	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	ATRA	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	drug	_	NN	NN	_	6	PRD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	choice	_	NN	NN	_	9	PMOD	_	_
11	in	_	IN	IN	_	6	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	treatment	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	acute	_	JJ	JJ	_	17	NMOD	_	_
16	promyelocytic	_	JJ	JJ	_	17	NMOD	_	_
17	leukemia	_	NN	NN	_	14	PMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	APL	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	.	_	.	.	_	6	P	_	_

1	ATRA	_	NN	NN	_	2	SBJ	_	_
2	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	both	_	CC	CC	_	5	CC	_	_
4	in	_	FW	FW	_	5	AMOD	_	_
5	vitro	_	FW	FW	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	in	_	FW	FW	_	8	AMOD	_	_
8	vivo	_	FW	FW	_	5	COORD	_	_
9	differentiation	_	NN	NN	_	2	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	APL	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	into	_	IN	IN	_	9	NMOD	_	_
14	mature	_	JJ	JJ	_	15	NMOD	_	_
15	granulocytes	_	NNS	NNS	_	13	PMOD	_	_
16	.	_	.	.	_	2	P	_	_

1	However	_	RB	RB	_	14	ADV	_	_
2	,	_	,	,	_	14	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	molecular	_	JJ	JJ	_	5	NMOD	_	_
5	mechanisms	_	NNS	NNS	_	14	SBJ	_	_
6	involved	_	VBN	VBN	_	5	NMOD	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	ATRA-dependent	_	JJ	JJ	_	10	NMOD	_	_
9	growth	_	NN	NN	_	10	NMOD	_	_
10	inhibition	_	NN	NN	_	7	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	cellular	_	JJ	JJ	_	13	NMOD	_	_
13	differentiation	_	NN	NN	_	10	COORD	_	_
14	are	_	VBP	VBP	_	0	ROOT-S	_	_
15	not	_	RB	RB	_	14	VMOD	_	_
16	presently	_	RB	RB	_	14	TMP	_	_
17	understood	_	VBN	VBN	_	14	VC	_	_
18	.	_	.	.	_	14	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	NB4	_	NN	NN	_	4	NMOD	_	_
3	cell	_	NN	NN	_	4	NMOD	_	_
4	line	_	NN	NN	_	21	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	which	_	WDT	WDT	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	4	NMOD	_	_
8	derived	_	VBN	VBN	_	7	VC	_	_
9	from	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	bone	_	NN	NN	_	12	NMOD	_	_
12	marrow	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	patient	_	NN	NN	_	13	PMOD	_	_
16	with	_	IN	IN	_	15	NMOD	_	_
17	APL	_	NN	NN	_	16	PMOD	_	_
18	during	_	IN	IN	_	8	TMP	_	_
19	relapse	_	NN	NN	_	18	PMOD	_	_
20	,	_	,	,	_	4	P	_	_
21	can	_	MD	MD	_	0	ROOT-S	_	_
22	be	_	VB	VB	_	21	VC	_	_
23	used	_	VBN	VBN	_	22	VC	_	_
24	as	_	IN	IN	_	23	ADV	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	model	_	JJ	JJ	_	27	NMOD	_	_
27	system	_	NN	NN	_	24	PMOD	_	_
28	to	_	TO	TO	_	29	VMOD	_	_
29	study	_	VB	VB	_	27	NMOD	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	growth	_	NN	NN	_	29	OBJ	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	differentiation	_	NN	NN	_	31	COORD	_	_
34	of	_	IN	IN	_	31	NMOD	_	_
35	APL	_	NN	NN	_	36	NMOD	_	_
36	cells	_	NNS	NNS	_	34	PMOD	_	_
37	.	_	.	.	_	21	P	_	_

1	Because	_	IN	IN	_	23	ADV	_	_
2	interferon	_	NN	NN	_	7	NMOD	_	_
3	(	_	(	(	_	4	P	_	_
4	IFN	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	regulatory	_	JJ	JJ	_	7	NMOD	_	_
7	factors	_	NNS	NNS	_	18	SBJ	_	_
8	(	_	(	(	_	9	P	_	_
9	IRF-1	_	NN	NN	_	7	PRN	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	IRF-2	_	NN	NN	_	9	COORD	_	_
12	)	_	)	)	_	9	P	_	_
13	and	_	CC	CC	_	7	CC	_	_
14	other	_	JJ	JJ	_	17	NMOD	_	_
15	IFN-inducible	_	JJ	JJ	_	17	NMOD	_	_
16	gene	_	NN	NN	_	17	NMOD	_	_
17	products	_	NNS	NNS	_	7	COORD	_	_
18	regulate	_	VBP	VBP	_	1	VMOD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	growth	_	NN	NN	_	18	OBJ	_	_
21	,	_	,	,	_	23	P	_	_
22	we	_	PRP	PRP	_	23	SBJ	_	_
23	analyzed	_	VBD	VBD	_	0	ROOT-S	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	effects	_	NNS	NNS	_	23	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	ATRA	_	NN	NN	_	26	PMOD	_	_
28	on	_	IN	IN	_	25	NMOD	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	expression	_	NN	NN	_	28	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	these	_	DT	DT	_	33	NMOD	_	_
33	genes	_	NNS	NNS	_	31	PMOD	_	_
34	.	_	.	.	_	23	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	ATRA	_	NN	NN	_	6	SBJ	_	_
5	directly	_	RB	RB	_	6	ADV	_	_
6	activates	_	VBZ	VBZ	_	3	VMOD	_	_
7	IRF-1	_	NN	NN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	expression	_	NN	NN	_	6	IOBJ	_	_
10	,	_	,	,	_	6	P	_	_
11	followed	_	VBN	VBN	_	6	OBJ	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	activation	_	NN	NN	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	IRF-2	_	NN	NN	_	24	NMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	2'-5'	_	JJ	JJ	_	19	NMOD	_	_
18	oligoadenylate	_	NN	NN	_	19	NMOD	_	_
19	synthetase	_	NN	NN	_	15	COORD	_	_
20	(	_	(	(	_	21	P	_	_
21	OAS	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	gene	_	NN	NN	_	24	NMOD	_	_
24	expression	_	NN	NN	_	14	PMOD	_	_
25	with	_	IN	IN	_	13	NMOD	_	_
26	slower	_	JJR	JJR	_	27	NMOD	_	_
27	kinetics	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	addition	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	NB4	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	1	PMOD	_	_
6	,	_	,	,	_	9	P	_	_
7	ATRA	_	NN	NN	_	9	SBJ	_	_
8	also	_	RB	RB	_	9	ADV	_	_
9	activated	_	VBD	VBD	_	0	ROOT-S	_	_
10	IRF-1	_	NN	NN	_	12	NMOD	_	_
11	gene	_	NN	NN	_	12	NMOD	_	_
12	expression	_	NN	NN	_	9	OBJ	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	HL-60	_	NN	NN	_	20	NMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	U937	_	NN	NN	_	14	COORD	_	_
17	,	_	,	,	_	14	P	_	_
18	and	_	CC	CC	_	14	CC	_	_
19	THP-1	_	NN	NN	_	14	COORD	_	_
20	cells	_	NNS	NNS	_	13	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	which	_	WDT	WDT	_	24	SBJ	_	_
23	all	_	DT	DT	_	22	NMOD	_	_
24	respond	_	VBP	VBP	_	20	NMOD	_	_
25	to	_	TO	TO	_	24	ADV	_	_
26	ATRA	_	NN	NN	_	25	PMOD	_	_
27	by	_	IN	IN	_	24	ADV	_	_
28	growth	_	NN	NN	_	29	NMOD	_	_
29	inhibition	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	9	P	_	_

1	A	_	DT	DT	_	5	NMOD	_	_
2	more	_	JJR	JJR	_	5	NMOD	_	_
3	than	_	IN	IN	_	2	AMOD	_	_
4	additive	_	JJ	JJ	_	3	PMOD	_	_
5	increase	_	NN	NN	_	10	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	IRF-1	_	NN	NN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	expression	_	NN	NN	_	6	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	seen	_	VBN	VBN	_	10	VC	_	_
12	with	_	IN	IN	_	11	ADV	_	_
13	ATRA	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	IFN-gamma	_	NN	NN	_	13	COORD	_	_
16	in	_	IN	IN	_	11	ADV	_	_
17	NB4	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	16	PMOD	_	_
19	.	_	.	.	_	10	P	_	_

1	ATRA	_	NN	NN	_	2	SBJ	_	_
2	did	_	VBD	VBD	_	0	ROOT-S	_	_
3	not	_	RB	RB	_	2	VMOD	_	_
4	activate	_	VB	VB	_	2	VC	_	_
5	nuclear	_	JJ	JJ	_	8	NMOD	_	_
6	factor	_	NN	NN	_	8	NMOD	_	_
7	kappa	_	NN	NN	_	8	NMOD	_	_
8	B	_	NN	NN	_	4	IOBJ	_	_
9	or	_	CC	CC	_	8	CC	_	_
10	signal	_	NN	NN	_	11	NMOD	_	_
11	transducer	_	NN	NN	_	20	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	activator	_	NN	NN	_	11	COORD	_	_
14	of	_	IN	IN	_	11	NMOD	_	_
15	transcription	_	NN	NN	_	14	PMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	STAT	_	NN	NN	_	11	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	activation	_	NN	NN	_	20	NMOD	_	_
20	pathways	_	NNS	NNS	_	8	COORD	_	_
21	,	_	,	,	_	4	P	_	_
22	suggesting	_	VBG	VBG	_	4	OBJ	_	_
23	that	_	IN	IN	_	22	OBJ	_	_
24	an	_	DT	DT	_	26	NMOD	_	_
25	alternate	_	JJ	JJ	_	26	NMOD	_	_
26	mechanism	_	NN	NN	_	27	SBJ	_	_
27	is	_	VBZ	VBZ	_	23	VMOD	_	_
28	involved	_	VBN	VBN	_	27	VC	_	_
29	in	_	IN	IN	_	28	ADV	_	_
30	IRF-1	_	NN	NN	_	32	NMOD	_	_
31	gene	_	NN	NN	_	32	NMOD	_	_
32	activation	_	NN	NN	_	29	PMOD	_	_
33	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	ATRA-induced	_	JJ	JJ	_	3	NMOD	_	_
3	expression	_	NN	NN	_	16	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	IRF-1	_	NN	NN	_	4	PMOD	_	_
6	,	_	,	,	_	5	P	_	_
7	an	_	DT	DT	_	8	NMOD	_	_
8	activator	_	NN	NN	_	5	NMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	transcription	_	NN	NN	_	9	PMOD	_	_
11	and	_	CC	CC	_	8	CC	_	_
12	repressor	_	NN	NN	_	8	COORD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	transformation	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	5	P	_	_
16	may	_	MD	MD	_	0	ROOT-S	_	_
17	be	_	VB	VB	_	16	VC	_	_
18	one	_	CD	CD	_	17	PRD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	molecular	_	JJ	JJ	_	22	NMOD	_	_
22	mechanisms	_	NNS	NNS	_	19	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	ATRA-induced	_	JJ	JJ	_	26	NMOD	_	_
25	growth	_	NN	NN	_	26	NMOD	_	_
26	inhibition	_	NN	NN	_	23	PMOD	_	_
27	,	_	,	,	_	18	P	_	_
28	and	_	CC	CC	_	18	CC	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	basis	_	NN	NN	_	18	COORD	_	_
31	for	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	synergistic	_	JJ	JJ	_	34	NMOD	_	_
34	actions	_	NNS	NNS	_	31	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	ATRA	_	NN	NN	_	35	PMOD	_	_
37	and	_	CC	CC	_	36	CC	_	_
38	IFNs	_	NN	NN	_	36	COORD	_	_
39	in	_	IN	IN	_	34	NMOD	_	_
40	myeloid	_	JJ	JJ	_	42	NMOD	_	_
41	leukemia	_	NN	NN	_	42	NMOD	_	_
42	cells	_	NNS	NNS	_	39	PMOD	_	_
43	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	c-Jun	_	NN	NN	_	3	NMOD	_	_
3	delta-domain	_	NN	NN	_	4	SBJ	_	_
4	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	neuroendocrine	_	NN	NN	_	7	NMOD	_	_
6	promoter	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	4	OBJ	_	_
8	in	_	IN	IN	_	4	ADV	_	_
9	a	_	DT	DT	_	14	NMOD	_	_
10	DNA	_	NN	NN	_	11	NMOD	_	_
11	sequence-	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	pituitary-specific	_	JJ	JJ	_	11	COORD	_	_
14	manner	_	NN	NN	_	8	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	transcription	_	NN	NN	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	transformation	_	NN	NN	_	2	COORD	_	_
5	activity	_	NN	NN	_	8	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	c-Jun	_	NN	NN	_	6	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	governed	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	a	_	DT	DT	_	15	NMOD	_	_
12	27-amino	_	JJ	JJ	_	15	NMOD	_	_
13	acid	_	NN	NN	_	15	NMOD	_	_
14	regulatory	_	JJ	JJ	_	15	NMOD	_	_
15	motif	_	NN	NN	_	10	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	labeled	_	VBN	VBN	_	15	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	delta-domain	_	NN	NN	_	17	OBJ	_	_
20	,	_	,	,	_	15	P	_	_
21	which	_	WDT	WDT	_	22	SBJ	_	_
22	is	_	VBZ	VBZ	_	15	NMOD	_	_
23	deleted	_	VBN	VBN	_	22	VC	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	v-Jun	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	8	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	previously	_	RB	RB	_	2	TMP	_	_
4	shown	_	VBN	VBN	_	2	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	c-Jun	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	5	VMOD	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	potent	_	JJ	JJ	_	10	NMOD	_	_
10	inhibitor	_	NN	NN	_	7	PRD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	19	NMOD	_	_
13	rat	_	NN	NN	_	14	NMOD	_	_
14	prolactin	_	NN	NN	_	19	NMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	rPRL	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	promoter	_	NN	NN	_	19	NMOD	_	_
19	activity	_	NN	NN	_	11	PMOD	_	_
20	induced	_	VBN	VBN	_	19	NMOD	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	either	_	DT	DT	_	24	NMOD	_	_
23	oncogenic	_	JJ	JJ	_	24	NMOD	_	_
24	Ras	_	NN	NN	_	21	PMOD	_	_
25	or	_	CC	CC	_	24	CC	_	_
26	phorbol	_	NN	NN	_	27	NMOD	_	_
27	esters	_	NNS	NNS	_	24	COORD	_	_
28	.	_	.	.	_	2	P	_	_

1	Here	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	have	_	VBP	VBP	_	0	ROOT-S	_	_
5	characterized	_	VBN	VBN	_	4	VC	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	structural	_	JJ	JJ	_	10	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	cell-specific	_	JJ	JJ	_	7	COORD	_	_
10	requirements	_	NNS	NNS	_	5	OBJ	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	this	_	DT	DT	_	15	NMOD	_	_
13	c-Jun	_	NN	NN	_	15	NMOD	_	_
14	inhibitory	_	JJ	JJ	_	15	NMOD	_	_
15	response	_	NN	NN	_	11	PMOD	_	_
16	,	_	,	,	_	4	P	_	_
17	and	_	CC	CC	_	4	CC	_	_
18	we	_	PRP	PRP	_	19	SBJ	_	_
19	show	_	VBP	VBP	_	4	COORD	_	_
20	that	_	IN	IN	_	19	OBJ	_	_
21	this	_	DT	DT	_	24	NMOD	_	_
22	c-Jun	_	NN	NN	_	24	NMOD	_	_
23	inhibitory	_	JJ	JJ	_	24	NMOD	_	_
24	response	_	NN	NN	_	34	SBJ	_	_
25	mapped	_	VBD	VBD	_	24	NMOD	_	_
26	to	_	TO	TO	_	25	ADV	_	_
27	the	_	DT	DT	_	32	NMOD	_	_
28	rPRL	_	NN	NN	_	32	NMOD	_	_
29	footprint	_	NN	NN	_	32	NMOD	_	_
30	II	_	CD	CD	_	32	NMOD	_	_
31	repressor	_	NN	NN	_	32	NMOD	_	_
32	site	_	NN	NN	_	26	PMOD	_	_
33	,	_	,	,	_	34	P	_	_
34	was	_	VBD	VBD	_	20	VMOD	_	_
35	pituitary-specific	_	JJ	JJ	_	34	PRD	_	_
36	and	_	CC	CC	_	34	CC	_	_
37	required	_	VBD	VBD	_	34	COORD	_	_
38	the	_	DT	DT	_	40	NMOD	_	_
39	c-Jun	_	NN	NN	_	40	NMOD	_	_
40	delta-domain	_	NN	NN	_	37	OBJ	_	_
41	.	_	.	.	_	4	P	_	_

1	Moreover	_	RB	RB	_	21	ADV	_	_
2	,	_	,	,	_	21	P	_	_
3	alteration	_	NN	NN	_	21	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	any	_	DT	DT	_	6	NMOD	_	_
6	one	_	CD	CD	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	these	_	DT	DT	_	9	NMOD	_	_
9	features	_	NNS	NNS	_	7	PMOD	_	_
10	(	_	(	(	_	13	P	_	_
11	e.g.	_	FW	FW	_	13	NMOD	_	_
12	,	_	,	,	_	13	P	_	_
13	cis-element	_	NN	NN	_	9	PRN	_	_
14	,	_	,	,	_	13	P	_	_
15	trans-factor	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	13	P	_	_
17	or	_	CC	CC	_	13	CC	_	_
18	cell-specific	_	JJ	JJ	_	19	NMOD	_	_
19	background	_	NN	NN	_	13	COORD	_	_
20	)	_	)	)	_	13	P	_	_
21	switched	_	VBD	VBD	_	0	ROOT-S	_	_
22	c-Jun	_	NN	NN	_	21	OBJ	_	_
23	to	_	TO	TO	_	21	ADV	_	_
24	a	_	DT	DT	_	26	NMOD	_	_
25	transcriptional	_	JJ	JJ	_	26	NMOD	_	_
26	activator	_	NN	NN	_	23	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	rPRL	_	NN	NN	_	30	NMOD	_	_
30	promoter	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	21	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	HeLa	_	NN	NN	_	4	NMOD	_	_
3	nonpituitary	_	JJ	JJ	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	8	P	_	_
6	c-Jun	_	NN	NN	_	8	SBJ	_	_
7	alone	_	RB	RB	_	6	NMOD	_	_
8	activated	_	VBD	VBD	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	rPRL	_	NN	NN	_	11	NMOD	_	_
11	promoter	_	NN	NN	_	8	OBJ	_	_
12	via	_	IN	IN	_	8	ADV	_	_
13	the	_	DT	DT	_	18	NMOD	_	_
14	most	_	RBS	RBS	_	15	AMOD	_	_
15	proximal	_	JJ	JJ	_	18	NMOD	_	_
16	GHF-1\/Pit-1	_	NN	NN	_	18	NMOD	_	_
17	binding	_	NN	NN	_	18	NMOD	_	_
18	site	_	NN	NN	_	12	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	footprint	_	NN	NN	_	21	NMOD	_	_
21	I	_	NN	NN	_	18	NMOD	_	_
22	,	_	,	,	_	8	P	_	_
23	and	_	CC	CC	_	8	CC	_	_
24	synergized	_	VBD	VBD	_	8	COORD	_	_
25	with	_	IN	IN	_	24	ADV	_	_
26	GHF-1	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	8	P	_	_

1	Finally	_	RB	RB	_	5	TMP	_	_
2	,	_	,	,	_	5	P	_	_
3	recombinant	_	JJ	JJ	_	4	NMOD	_	_
4	GHF-1	_	NN	NN	_	5	SBJ	_	_
5	interacted	_	VBD	VBD	_	0	ROOT-S	_	_
6	directly	_	RB	RB	_	5	ADV	_	_
7	with	_	IN	IN	_	5	ADV	_	_
8	c-Jun	_	NN	NN	_	12	NMOD	_	_
9	but	_	CC	CC	_	8	CC	_	_
10	not	_	RB	RB	_	9	COORD	_	_
11	c-Fos	_	NN	NN	_	8	COORD	_	_
12	proteins	_	NNS	NNS	_	7	PMOD	_	_
13	.	_	.	.	_	5	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	provide	_	VBP	VBP	_	0	ROOT-S	_	_
4	important	_	JJ	JJ	_	6	NMOD	_	_
5	fundamental	_	JJ	JJ	_	6	NMOD	_	_
6	insights	_	NNS	NNS	_	3	OBJ	_	_
7	into	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	molecular	_	NN	NN	_	10	NMOD	_	_
10	mechanisms	_	NNS	NNS	_	7	PMOD	_	_
11	by	_	IN	IN	_	16	ADV	_	_
12	which	_	WDT	WDT	_	11	PMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	c-Jun	_	NN	NN	_	15	NMOD	_	_
15	delta-domain	_	NN	NN	_	16	SBJ	_	_
16	functions	_	VBZ	VBZ	_	10	NMOD	_	_
17	as	_	IN	IN	_	16	ADV	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	modulatory	_	JJ	JJ	_	20	NMOD	_	_
20	switch	_	NN	NN	_	17	PMOD	_	_
21	and	_	CC	CC	_	3	CC	_	_
22	further	_	RB	RB	_	23	ADV	_	_
23	imply	_	VBP	VBP	_	3	COORD	_	_
24	that	_	IN	IN	_	23	OBJ	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	functional	_	JJ	JJ	_	27	NMOD	_	_
27	role	_	NN	NN	_	30	SBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	c-Jun	_	NN	NN	_	28	PMOD	_	_
30	is	_	VBZ	VBZ	_	24	VMOD	_	_
31	dictated	_	VBN	VBN	_	30	VC	_	_
32	by	_	IN	IN	_	31	LGS	_	_
33	cell-specific	_	JJ	JJ	_	34	NMOD	_	_
34	influences	_	NNS	NNS	_	32	PMOD	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	the	_	DT	DT	_	38	NMOD	_	_
37	delta-domain	_	JJ	JJ	_	38	NMOD	_	_
38	motif	_	NN	NN	_	34	COORD	_	_
39	.	_	.	.	_	3	P	_	_

1	Constitutive	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	specific	_	JJ	JJ	_	6	NMOD	_	_
5	interferon	_	NN	NN	_	6	NMOD	_	_
6	isotypes	_	NNS	NNS	_	3	PMOD	_	_
7	in	_	IN	IN	_	2	NMOD	_	_
8	peripheral	_	JJ	JJ	_	10	NMOD	_	_
9	blood	_	NN	NN	_	10	NMOD	_	_
10	leukocytes	_	NNS	NNS	_	7	PMOD	_	_
11	from	_	IN	IN	_	10	NMOD	_	_
12	normal	_	JJ	JJ	_	13	NMOD	_	_
13	individuals	_	NNS	NNS	_	11	PMOD	_	_
14	and	_	CC	CC	_	7	CC	_	_
15	in	_	IN	IN	_	7	COORD	_	_
16	promonocytic	_	JJ	JJ	_	18	NMOD	_	_
17	U937	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	Constitutive	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	IFN-alpha5	_	NN	NN	_	3	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	IFN-beta	_	NN	NN	_	4	COORD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	detected	_	VBN	VBN	_	7	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	different	_	JJ	JJ	_	12	NMOD	_	_
11	lymphoid	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	PMOD	_	_
13	including	_	VBG	VBG	_	12	NMOD	_	_
14	peripheral	_	JJ	JJ	_	17	NMOD	_	_
15	blood	_	NN	NN	_	17	NMOD	_	_
16	mononuclear	_	JJ	JJ	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	13	PMOD	_	_
18	from	_	IN	IN	_	17	NMOD	_	_
19	normal	_	JJ	JJ	_	20	NMOD	_	_
20	individuals	_	NNS	NNS	_	18	PMOD	_	_
21	following	_	VBG	VBG	_	8	TMP	_	_
22	amplification	_	NN	NN	_	21	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	IFN	_	NN	NN	_	25	NMOD	_	_
25	mRNA	_	NN	NN	_	23	PMOD	_	_
26	by	_	IN	IN	_	22	NMOD	_	_
27	reverse	_	JJ	JJ	_	30	NMOD	_	_
28	transcriptase-polymerase	_	NN	NN	_	30	NMOD	_	_
29	chain	_	NN	NN	_	30	NMOD	_	_
30	reaction	_	NN	NN	_	26	PMOD	_	_
31	and	_	CC	CC	_	22	CC	_	_
32	direct	_	JJ	JJ	_	33	NMOD	_	_
33	sequencing	_	NN	NN	_	22	COORD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	the	_	DT	DT	_	37	NMOD	_	_
36	amplified	_	VBN	VBN	_	37	NMOD	_	_
37	product	_	NN	NN	_	34	PMOD	_	_
38	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	activated	_	JJ	JJ	_	3	NMOD	_	_
3	form	_	NN	NN	_	11	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	10	NMOD	_	_
6	interferon-induced	_	JJ	JJ	_	10	NMOD	_	_
7	transcription	_	NN	NN	_	10	NMOD	_	_
8	factor	_	NN	NN	_	10	NMOD	_	_
9	complex	_	NN	NN	_	10	NMOD	_	_
10	ISGF3	_	NN	NN	_	4	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	also	_	RB	RB	_	11	ADV	_	_
13	detected	_	VBN	VBN	_	11	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	nuclear	_	JJ	JJ	_	16	NMOD	_	_
16	extracts	_	NNS	NNS	_	14	PMOD	_	_
17	from	_	IN	IN	_	16	NMOD	_	_
18	uninduced	_	JJ	JJ	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	11	P	_	_

1	Culture	_	NN	NN	_	2	NMOD	_	_
2	supernatants	_	NNS	NNS	_	7	SBJ	_	_
3	from	_	IN	IN	_	2	NMOD	_	_
4	uninduced	_	JJ	JJ	_	6	NMOD	_	_
5	U937	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	3	PMOD	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	also	_	RB	RB	_	7	ADV	_	_
9	found	_	VBN	VBN	_	7	VC	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	activate	_	VB	VB	_	9	OBJ	_	_
12	an	_	DT	DT	_	13	NMOD	_	_
13	ISRE	_	NN	NN	_	11	IOBJ	_	_
14	cloned	_	VBN	VBN	_	13	NMOD	_	_
15	upstream	_	RB	RB	_	14	ADV	_	_
16	of	_	IN	IN	_	15	AMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	luciferase	_	NN	NN	_	20	NMOD	_	_
19	reporter	_	NN	NN	_	20	NMOD	_	_
20	gene	_	NN	NN	_	16	PMOD	_	_
21	,	_	,	,	_	11	P	_	_
22	indicating	_	VBG	VBG	_	11	OBJ	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	presence	_	NN	NN	_	22	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	endogenous	_	JJ	JJ	_	28	NMOD	_	_
27	IFN	_	NN	NN	_	28	NMOD	_	_
28	activity	_	NN	NN	_	25	PMOD	_	_
29	equivalent	_	JJ	JJ	_	28	NMOD	_	_
30	to	_	TO	TO	_	29	AMOD	_	_
31	approximately	_	RB	RB	_	35	NMOD	_	_
32	0.3	_	CD	CD	_	31	DEP	_	_
33	to	_	TO	TO	_	31	DEP	_	_
34	0.5	_	CD	CD	_	31	DEP	_	_
35	IU\/mL	_	NN	NN	_	30	PMOD	_	_
36	.	_	.	.	_	7	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	endogenous	_	JJ	JJ	_	3	NMOD	_	_
3	IFN	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	also	_	RB	RB	_	4	ADV	_	_
6	shown	_	VBN	VBN	_	4	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	play	_	VB	VB	_	6	OBJ	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	role	_	NN	NN	_	8	OBJ	_	_
11	in	_	IN	IN	_	8	ADV	_	_
12	maintaining	_	VBG	VBG	_	11	PMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	basal	_	JJ	JJ	_	15	NMOD	_	_
15	level	_	NN	NN	_	12	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	expression	_	NN	NN	_	16	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	24	NMOD	_	_
20	major	_	JJ	JJ	_	24	NMOD	_	_
21	histocompatibility	_	NN	NN	_	24	NMOD	_	_
22	class	_	NN	NN	_	24	NMOD	_	_
23	I	_	CD	CD	_	24	NMOD	_	_
24	genes	_	NNS	NNS	_	18	PMOD	_	_
25	in	_	IN	IN	_	17	NMOD	_	_
26	lymphoid	_	JJ	JJ	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	IFN-alpha5	_	NN	NN	_	8	SBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	IFN-beta	_	NN	NN	_	5	COORD	_	_
8	are	_	VBP	VBP	_	4	VMOD	_	_
9	produced	_	VBN	VBN	_	8	VC	_	_
10	at	_	IN	IN	_	9	ADV	_	_
11	low	_	JJ	JJ	_	12	NMOD	_	_
12	levels	_	NNS	NNS	_	10	PMOD	_	_
13	in	_	IN	IN	_	9	ADV	_	_
14	normal	_	JJ	JJ	_	15	NMOD	_	_
15	tissues	_	NNS	NNS	_	13	PMOD	_	_
16	and	_	CC	CC	_	8	CC	_	_
17	play	_	VBP	VBP	_	8	COORD	_	_
18	an	_	DT	DT	_	20	NMOD	_	_
19	important	_	JJ	JJ	_	20	NMOD	_	_
20	role	_	NN	NN	_	17	OBJ	_	_
21	in	_	IN	IN	_	17	ADV	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	regulation	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	cell	_	NN	NN	_	26	NMOD	_	_
26	function	_	NN	NN	_	24	PMOD	_	_
27	and	_	CC	CC	_	21	CC	_	_
28	in	_	IN	IN	_	21	COORD	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	maintenance	_	NN	NN	_	28	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	homeostasis	_	NN	NN	_	31	PMOD	_	_
33	.	_	.	.	_	3	P	_	_

1	Mechanisms	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	transactivation	_	NN	NN	_	2	PMOD	_	_
4	by	_	IN	IN	_	3	NMOD	_	_
5	nuclear	_	JJ	JJ	_	6	NMOD	_	_
6	factor	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	activated	_	VBN	VBN	_	10	NMOD	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells-1	_	NNS	NNS	_	7	PMOD	_	_
11	.	_	.	.	_	1	P	_	_

1	Nuclear	_	JJ	JJ	_	2	NMOD	_	_
2	factor	_	NN	NN	_	7	NMOD	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	activated	_	VBN	VBN	_	6	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cells-family	_	NN	NN	_	3	PMOD	_	_
7	proteins	_	NNS	NNS	_	18	SBJ	_	_
8	(	_	(	(	_	9	P	_	_
9	NFAT1\/NFATp	_	NN	NN	_	7	PRN	_	_
10	,	_	,	,	_	9	P	_	_
11	NFATc	_	NN	NN	_	9	COORD	_	_
12	,	_	,	,	_	9	P	_	_
13	NFAT3	_	NN	NN	_	9	COORD	_	_
14	,	_	,	,	_	9	P	_	_
15	and	_	CC	CC	_	9	CC	_	_
16	NFAT4\/NFATx/NFATc3	_	NN	NN	_	9	COORD	_	_
17	)	_	)	)	_	9	P	_	_
18	play	_	VBP	VBP	_	0	ROOT-S	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	key	_	JJ	JJ	_	21	NMOD	_	_
21	role	_	NN	NN	_	18	OBJ	_	_
22	in	_	IN	IN	_	18	ADV	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	transcription	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	cytokine	_	NN	NN	_	27	NMOD	_	_
27	genes	_	NNS	NNS	_	25	PMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	other	_	JJ	JJ	_	30	NMOD	_	_
30	genes	_	NNS	NNS	_	27	COORD	_	_
31	during	_	IN	IN	_	18	TMP	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	immune	_	JJ	JJ	_	34	NMOD	_	_
34	response	_	NN	NN	_	31	PMOD	_	_
35	.	_	.	.	_	18	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	defined	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	mechanisms	_	NNS	NNS	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	transactivation	_	NN	NN	_	6	PMOD	_	_
8	by	_	IN	IN	_	7	NMOD	_	_
9	NFAT1	_	NN	NN	_	8	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	NFAT1	_	NNP	NNP	_	2	VMOD	_	_
2	possesses	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	two	_	CD	CD	_	5	NMOD	_	_
4	transactivation	_	NN	NN	_	5	NMOD	_	_
5	domains	_	NNS	NNS	_	2	OBJ	_	_
6	whose	_	WP$	WP$	_	7	NMOD	_	_
7	sequences	_	NNS	NNS	_	8	SBJ	_	_
8	are	_	VBP	VBP	_	5	NMOD	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	conserved	_	VBN	VBN	_	8	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	other	_	JJ	JJ	_	15	NMOD	_	_
14	NFAT-family	_	NN	NN	_	15	NMOD	_	_
15	proteins	_	NNS	NNS	_	11	PMOD	_	_
16	,	_	,	,	_	5	P	_	_
17	and	_	CC	CC	_	5	CC	_	_
18	a	_	DT	DT	_	21	NMOD	_	_
19	conserved	_	VBN	VBN	_	21	NMOD	_	_
20	DNA-binding	_	JJ	JJ	_	21	NMOD	_	_
21	domain	_	NN	NN	_	5	COORD	_	_
22	that	_	WDT	WDT	_	23	SBJ	_	_
23	mediates	_	VBZ	VBZ	_	21	NMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	recruitment	_	NN	NN	_	23	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	cooperating	_	VBG	VBG	_	30	NMOD	_	_
28	nuclear	_	JJ	JJ	_	30	NMOD	_	_
29	transcription	_	NN	NN	_	30	NMOD	_	_
30	factors	_	NNS	NNS	_	26	PMOD	_	_
31	even	_	RB	RB	_	32	AMOD	_	_
32	when	_	WRB	WRB	_	35	ADV	_	_
33	it	_	PRP	PRP	_	34	SBJ	_	_
34	is	_	VBZ	VBZ	_	2	TMP	_	_
35	expressed	_	VBN	VBN	_	34	VC	_	_
36	in	_	IN	IN	_	35	ADV	_	_
37	the	_	DT	DT	_	36	DEP	_	_
38	absence	_	NN	NN	_	36	DEP	_	_
39	of	_	IN	IN	_	36	DEP	_	_
40	other	_	JJ	JJ	_	41	NMOD	_	_
41	regions	_	NNS	NNS	_	36	PMOD	_	_
42	of	_	IN	IN	_	41	NMOD	_	_
43	the	_	DT	DT	_	44	NMOD	_	_
44	protein	_	NN	NN	_	42	PMOD	_	_
45	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	activity	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	NH2-terminal	_	JJ	JJ	_	7	NMOD	_	_
6	transactivation	_	NN	NN	_	7	NMOD	_	_
7	domain	_	NN	NN	_	3	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	modulated	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	an	_	DT	DT	_	14	NMOD	_	_
12	adjacent	_	JJ	JJ	_	14	NMOD	_	_
13	regulatory	_	JJ	JJ	_	14	NMOD	_	_
14	region	_	NN	NN	_	10	PMOD	_	_
15	that	_	WDT	WDT	_	16	SBJ	_	_
16	contains	_	VBZ	VBZ	_	14	NMOD	_	_
17	several	_	JJ	JJ	_	20	NMOD	_	_
18	conserved	_	VBN	VBN	_	20	NMOD	_	_
19	sequence	_	NN	NN	_	20	NMOD	_	_
20	motifs	_	NNS	NNS	_	16	OBJ	_	_
21	represented	_	VBN	VBN	_	20	NMOD	_	_
22	only	_	RB	RB	_	23	DEP	_	_
23	in	_	IN	IN	_	21	ADV	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	NFAT	_	NN	NN	_	26	NMOD	_	_
26	family	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	8	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	emphasize	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	multiple	_	JJ	JJ	_	6	NMOD	_	_
6	levels	_	NNS	NNS	_	3	OBJ	_	_
7	at	_	IN	IN	_	12	ADV	_	_
8	which	_	WDT	WDT	_	7	PMOD	_	_
9	NFAT-dependent	_	JJ	JJ	_	10	NMOD	_	_
10	transactivation	_	NN	NN	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	6	NMOD	_	_
12	regulated	_	VBN	VBN	_	11	VC	_	_
13	,	_	,	,	_	3	P	_	_
14	and	_	CC	CC	_	3	CC	_	_
15	predict	_	VBP	VBP	_	3	COORD	_	_
16	significant	_	JJ	JJ	_	17	NMOD	_	_
17	differences	_	NNS	NNS	_	15	OBJ	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	architecture	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	cooperative	_	JJ	JJ	_	24	NMOD	_	_
23	transcription	_	NN	NN	_	24	NMOD	_	_
24	complexes	_	NNS	NNS	_	21	PMOD	_	_
25	containing	_	VBG	VBG	_	24	NMOD	_	_
26	different	_	JJ	JJ	_	28	NMOD	_	_
27	NFAT-family	_	NN	NN	_	28	NMOD	_	_
28	proteins	_	NNS	NNS	_	25	OBJ	_	_
29	.	_	.	.	_	3	P	_	_

1	Precise	_	JJ	JJ	_	2	NMOD	_	_
2	alignment	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	sites	_	NNS	NNS	_	3	PMOD	_	_
5	required	_	VBN	VBN	_	2	NMOD	_	_
6	for	_	IN	IN	_	5	ADV	_	_
7	mu	_	NN	NN	_	9	NMOD	_	_
8	enhancer	_	NN	NN	_	9	NMOD	_	_
9	activation	_	NN	NN	_	6	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	B	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	8	NMOD	_	_
2	lymphocyte-specific	_	JJ	JJ	_	8	NMOD	_	_
3	immunoglobulin	_	NN	NN	_	8	NMOD	_	_
4	mu	_	NN	NN	_	8	NMOD	_	_
5	heavy-chain	_	JJ	JJ	_	8	NMOD	_	_
6	gene	_	NN	NN	_	8	NMOD	_	_
7	intronic	_	JJ	JJ	_	8	NMOD	_	_
8	enhancer	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	regulated	_	VBN	VBN	_	9	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	multiple	_	JJ	JJ	_	14	NMOD	_	_
13	nuclear	_	JJ	JJ	_	14	NMOD	_	_
14	factors	_	NNS	NNS	_	11	PMOD	_	_
15	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	previously	_	RB	RB	_	3	AMOD	_	_
3	defined	_	VBN	VBN	_	5	NMOD	_	_
4	minimal	_	JJ	JJ	_	5	NMOD	_	_
5	enhancer	_	NN	NN	_	15	SBJ	_	_
6	containing	_	VBG	VBG	_	5	NMOD	_	_
7	the	_	DT	DT	_	14	NMOD	_	_
8	muA	_	NN	NN	_	14	NMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	muE3	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	8	P	_	_
12	and	_	CC	CC	_	8	CC	_	_
13	muB	_	NN	NN	_	8	COORD	_	_
14	sites	_	NNS	NNS	_	6	OBJ	_	_
15	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	transactivated	_	VBN	VBN	_	15	VC	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	combination	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	ETS-domain	_	NN	NN	_	23	NMOD	_	_
23	proteins	_	NNS	NNS	_	20	PMOD	_	_
24	PU.1	_	NN	NN	_	23	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	Ets-1	_	NN	NN	_	24	COORD	_	_
27	in	_	IN	IN	_	23	NMOD	_	_
28	nonlymphoid	_	JJ	JJ	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	27	PMOD	_	_
30	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	core	_	NN	NN	_	3	NMOD	_	_
3	GGAAs	_	NNS	NNS	_	10	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	muA	_	NN	NN	_	9	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	muB	_	NN	NN	_	6	COORD	_	_
9	sites	_	NNS	NNS	_	4	PMOD	_	_
10	are	_	VBP	VBP	_	0	ROOT-S	_	_
11	separated	_	VBN	VBN	_	10	VC	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	30	_	CD	CD	_	14	NMOD	_	_
14	nucleotides	_	NNS	NNS	_	12	PMOD	_	_
15	,	_	,	,	_	11	P	_	_
16	suggesting	_	VBG	VBG	_	11	OBJ	_	_
17	that	_	IN	IN	_	16	OBJ	_	_
18	ETS	_	NNS	NNS	_	19	NMOD	_	_
19	proteins	_	NNS	NNS	_	20	SBJ	_	_
20	bind	_	VBP	VBP	_	17	VMOD	_	_
21	to	_	TO	TO	_	20	ADV	_	_
22	these	_	DT	DT	_	23	NMOD	_	_
23	sites	_	NNS	NNS	_	21	PMOD	_	_
24	from	_	IN	IN	_	23	NMOD	_	_
25	these	_	DT	DT	_	27	NMOD	_	_
26	same	_	JJ	JJ	_	27	NMOD	_	_
27	side	_	NN	NN	_	24	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	DNA	_	NN	NN	_	31	NMOD	_	_
31	helix	_	NN	NN	_	28	PMOD	_	_
32	.	_	.	.	_	10	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	tested	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	necessity	_	NN	NN	_	2	OBJ	_	_
5	for	_	IN	IN	_	4	NMOD	_	_
6	appropriate	_	JJ	JJ	_	8	NMOD	_	_
7	spatial	_	JJ	JJ	_	8	NMOD	_	_
8	alignment	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	these	_	DT	DT	_	11	NMOD	_	_
11	elements	_	NNS	NNS	_	9	PMOD	_	_
12	by	_	IN	IN	_	2	ADV	_	_
13	using	_	VBG	VBG	_	12	PMOD	_	_
14	mutated	_	VBN	VBN	_	15	NMOD	_	_
15	enhancers	_	NNS	NNS	_	13	OBJ	_	_
16	with	_	IN	IN	_	15	NMOD	_	_
17	altered	_	JJ	JJ	_	18	NMOD	_	_
18	spacings	_	NNS	NNS	_	16	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	A	_	DT	DT	_	5	NMOD	_	_
2	4-	_	CD	CD	_	5	NMOD	_	_
3	or	_	CC	CC	_	2	CC	_	_
4	10-bp	_	JJ	JJ	_	2	COORD	_	_
5	insertion	_	NN	NN	_	10	SBJ	_	_
6	between	_	IN	IN	_	5	NMOD	_	_
7	muE3	_	NN	NN	_	6	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	muB	_	NN	NN	_	7	COORD	_	_
10	inactivated	_	VBD	VBD	_	0	ROOT-S	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	mu	_	NN	NN	_	13	NMOD	_	_
13	enhancer	_	NN	NN	_	10	OBJ	_	_
14	in	_	IN	IN	_	10	ADV	_	_
15	S194	_	NN	NN	_	17	NMOD	_	_
16	plasma	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	14	PMOD	_	_
18	but	_	CC	CC	_	10	CC	_	_
19	did	_	VBD	VBD	_	10	COORD	_	_
20	not	_	RB	RB	_	19	VMOD	_	_
21	affect	_	VB	VB	_	19	VC	_	_
22	in	_	FW	FW	_	23	AMOD	_	_
23	vitro	_	FW	FW	_	24	NMOD	_	_
24	binding	_	NN	NN	_	21	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	Ets-1	_	NN	NN	_	25	PMOD	_	_
27	,	_	,	,	_	26	P	_	_
28	PU.1	_	NN	NN	_	26	COORD	_	_
29	,	_	,	,	_	26	P	_	_
30	or	_	CC	CC	_	26	CC	_	_
31	the	_	DT	DT	_	34	NMOD	_	_
32	muE3-binding	_	JJ	JJ	_	34	NMOD	_	_
33	protein	_	NN	NN	_	34	NMOD	_	_
34	TFE3	_	NN	NN	_	26	COORD	_	_
35	,	_	,	,	_	21	P	_	_
36	alone	_	RB	RB	_	21	VMOD	_	_
37	or	_	CC	CC	_	36	CC	_	_
38	in	_	IN	IN	_	36	COORD	_	_
39	pairwise	_	JJ	JJ	_	40	NMOD	_	_
40	combinations	_	NNS	NNS	_	38	PMOD	_	_
41	.	_	.	.	_	10	P	_	_

1	Circular	_	JJ	JJ	_	2	NMOD	_	_
2	permutation	_	NN	NN	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	phasing	_	NN	NN	_	2	COORD	_	_
5	analyses	_	NNS	NNS	_	6	SBJ	_	_
6	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	PU.1	_	NN	NN	_	9	NMOD	_	_
9	binding	_	NN	NN	_	15	SBJ	_	_
10	but	_	CC	CC	_	9	CC	_	_
11	not	_	RB	RB	_	10	COORD	_	_
12	TFE3	_	NN	NN	_	9	COORD	_	_
13	or	_	CC	CC	_	12	CC	_	_
14	Ets-1	_	NN	NN	_	12	COORD	_	_
15	bends	_	VBZ	VBZ	_	7	VMOD	_	_
16	mu	_	NN	NN	_	18	NMOD	_	_
17	enhancer	_	NN	NN	_	18	NMOD	_	_
18	DNA	_	NN	NN	_	15	OBJ	_	_
19	toward	_	IN	IN	_	15	ADV	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	major	_	JJ	JJ	_	22	NMOD	_	_
22	groove	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	propose	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	requirement	_	NN	NN	_	15	SBJ	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	precise	_	JJ	JJ	_	8	NMOD	_	_
8	spacing	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	muA	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	muB	_	NN	NN	_	11	COORD	_	_
14	elements	_	NNS	NNS	_	9	PMOD	_	_
15	is	_	VBZ	VBZ	_	3	VMOD	_	_
16	due	_	JJ	JJ	_	19	PMOD	_	_
17	in	_	IN	IN	_	19	PMOD	_	_
18	part	_	NN	NN	_	17	PMOD	_	_
19	to	_	TO	TO	_	15	PRD	_	_
20	a	_	DT	DT	_	23	NMOD	_	_
21	directed	_	JJ	JJ	_	23	NMOD	_	_
22	DNA	_	NN	NN	_	23	NMOD	_	_
23	bend	_	NN	NN	_	19	PMOD	_	_
24	induced	_	VBN	VBN	_	23	NMOD	_	_
25	by	_	IN	IN	_	24	LGS	_	_
26	PU.1	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	C\/EBP	_	NN	NN	_	2	NMOD	_	_
2	activators	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	required	_	VBN	VBN	_	3	VC	_	_
5	for	_	IN	IN	_	4	ADV	_	_
6	HIV-1	_	NN	NN	_	7	NMOD	_	_
7	replication	_	NN	NN	_	5	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	proviral	_	JJ	JJ	_	10	NMOD	_	_
10	induction	_	NN	NN	_	7	COORD	_	_
11	in	_	IN	IN	_	7	NMOD	_	_
12	monocytic	_	JJ	JJ	_	14	NMOD	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	lines	_	NNS	NNS	_	11	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	Previous	_	JJ	JJ	_	2	NMOD	_	_
2	work	_	NN	NN	_	3	SBJ	_	_
3	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	shown	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	C\/EBP	_	NN	NN	_	7	NMOD	_	_
7	sites	_	NNS	NNS	_	12	SBJ	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	C\/EBP	_	NN	NN	_	11	NMOD	_	_
10	transcriptional	_	JJ	JJ	_	11	NMOD	_	_
11	activators	_	NNS	NNS	_	7	COORD	_	_
12	are	_	VBP	VBP	_	5	VMOD	_	_
13	necessary	_	JJ	JJ	_	12	PRD	_	_
14	for	_	IN	IN	_	13	AMOD	_	_
15	HIV-1	_	NN	NN	_	17	NMOD	_	_
16	LTR	_	NN	NN	_	17	NMOD	_	_
17	activity	_	NN	NN	_	14	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	monocytes\/macrophages	_	NNS	NNS	_	18	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	investigated	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	role	_	NN	NN	_	3	OBJ	_	_
6	that	_	WDT	WDT	_	9	OBJ	_	_
7	C\/EBP	_	NN	NN	_	8	NMOD	_	_
8	proteins	_	NNS	NNS	_	9	SBJ	_	_
9	play	_	VBP	VBP	_	5	NMOD	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	induction	_	NN	NN	_	10	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	replication	_	NN	NN	_	11	COORD	_	_
14	of	_	IN	IN	_	11	NMOD	_	_
15	HIV-1	_	NN	NN	_	14	PMOD	_	_
16	.	_	.	.	_	2	P	_	_

1	Ectopic	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	9	NMOD	_	_
5	dominant	_	JJ	JJ	_	9	NMOD	_	_
6	negative	_	JJ	JJ	_	9	NMOD	_	_
7	C\/EBP	_	NN	NN	_	9	NMOD	_	_
8	protein	_	NN	NN	_	9	NMOD	_	_
9	LIP	_	NN	NN	_	3	PMOD	_	_
10	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
11	HIV-1	_	NN	NN	_	12	NMOD	_	_
12	mRNA	_	NN	NN	_	10	IOBJ	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	virus	_	NN	NN	_	15	NMOD	_	_
15	production	_	NN	NN	_	12	COORD	_	_
16	in	_	IN	IN	_	12	NMOD	_	_
17	activated	_	VBN	VBN	_	19	NMOD	_	_
18	U1	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	PMOD	_	_
20	,	_	,	,	_	10	P	_	_
21	demonstrating	_	VBG	VBG	_	10	OBJ	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	C\/EBP	_	NN	NN	_	24	NMOD	_	_
24	proteins	_	NNS	NNS	_	25	SBJ	_	_
25	are	_	VBP	VBP	_	22	VMOD	_	_
26	required	_	VBN	VBN	_	25	VC	_	_
27	for	_	IN	IN	_	26	ADV	_	_
28	provirus	_	NN	NN	_	29	NMOD	_	_
29	induction	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	10	P	_	_

1	U1	_	NN	NN	_	2	NMOD	_	_
2	lines	_	NNS	NNS	_	7	SBJ	_	_
3	overexpressing	_	VBG	VBG	_	2	NMOD	_	_
4	C\/EBP	_	NN	NN	_	6	NMOD	_	_
5	activator	_	NN	NN	_	6	NMOD	_	_
6	NF-IL-6	_	NN	NN	_	3	OBJ	_	_
7	produced	_	VBD	VBD	_	0	ROOT-S	_	_
8	more	_	JJR	JJR	_	10	NMOD	_	_
9	viral	_	JJ	JJ	_	10	NMOD	_	_
10	mRNA	_	NN	NN	_	7	IOBJ	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	virus	_	NN	NN	_	13	NMOD	_	_
13	particles	_	NNS	NNS	_	10	COORD	_	_
14	following	_	VBG	VBG	_	7	TMP	_	_
15	cellular	_	JJ	JJ	_	16	NMOD	_	_
16	activation	_	NN	NN	_	14	PMOD	_	_
17	than	_	IN	IN	_	10	NMOD	_	_
18	control	_	NN	NN	_	19	NMOD	_	_
19	lines	_	NNS	NNS	_	17	PMOD	_	_
20	,	_	,	,	_	7	P	_	_
21	demonstrating	_	VBG	VBG	_	7	OBJ	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	C\/EBP	_	NN	NN	_	24	NMOD	_	_
24	proteins	_	NNS	NNS	_	25	VMOD	_	_
25	are	_	VBP	VBP	_	22	VMOD	_	_
26	limiting	_	VBG	VBG	_	25	PRD	_	_
27	for	_	IN	IN	_	25	ADV	_	_
28	virus	_	NN	NN	_	29	NMOD	_	_
29	transcription	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	7	P	_	_

1	HIV-1	_	NN	NN	_	3	NMOD	_	_
2	harboring	_	NN	NN	_	3	NMOD	_	_
3	mutations	_	NNS	NNS	_	8	SBJ	_	_
4	within	_	IN	IN	_	3	NMOD	_	_
5	two	_	CD	CD	_	7	NMOD	_	_
6	C\/EBP	_	NN	NN	_	7	NMOD	_	_
7	sites	_	NNS	NNS	_	4	PMOD	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	crippled	_	VBN	VBN	_	8	PRD	_	_
10	in	_	IN	IN	_	8	ADV	_	_
11	their	_	PRP$	PRP$	_	12	NMOD	_	_
12	ability	_	NN	NN	_	10	PMOD	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	replicate	_	VB	VB	_	12	NMOD	_	_
15	in	_	IN	IN	_	14	ADV	_	_
16	U937	_	NN	NN	_	18	NMOD	_	_
17	promonocytic	_	JJ	JJ	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	15	PMOD	_	_
19	,	_	,	,	_	8	P	_	_
20	indicating	_	VBG	VBG	_	8	VC	_	_
21	that	_	IN	IN	_	20	OBJ	_	_
22	these	_	DT	DT	_	23	NMOD	_	_
23	sites	_	NNS	NNS	_	24	SBJ	_	_
24	are	_	VBP	VBP	_	21	VMOD	_	_
25	required	_	VBN	VBN	_	24	VC	_	_
26	for	_	IN	IN	_	25	ADV	_	_
27	replication	_	NN	NN	_	26	PMOD	_	_
28	.	_	.	.	_	8	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	identify	_	VBP	VBP	_	0	ROOT-S	_	_
4	C\/EBP	_	NN	NN	_	5	NMOD	_	_
5	proteins	_	NNS	NNS	_	3	OBJ	_	_
6	as	_	IN	IN	_	3	ADV	_	_
7	regulators	_	NNS	NNS	_	6	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	HIV-1	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	8	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	monocytes\/macrophages	_	NNS	NNS	_	11	PMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	Reversal	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	apoptosis	_	NN	NN	_	2	PMOD	_	_
4	by	_	IN	IN	_	1	NMOD	_	_
5	the	_	DT	DT	_	10	NMOD	_	_
6	leukaemia-associated	_	JJ	JJ	_	10	NMOD	_	_
7	E2A-HLF	_	NN	NN	_	10	NMOD	_	_
8	chimaeric	_	JJ	JJ	_	10	NMOD	_	_
9	transcription	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	4	PMOD	_	_
11	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	E2A-HLF	_	NN	NN	_	10	NMOD	_	_
3	(	_	(	(	_	2	P	_	_
4	for	_	IN	IN	_	2	NMOD	_	_
5	hepatic	_	JJ	JJ	_	7	NMOD	_	_
6	leukaemia	_	NN	NN	_	7	NMOD	_	_
7	factor	_	NN	NN	_	4	PMOD	_	_
8	)	_	)	)	_	2	P	_	_
9	fusion	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	22	SBJ	_	_
11	,	_	,	,	_	10	P	_	_
12	formed	_	VBN	VBN	_	10	NMOD	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	action	_	NN	NN	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	t-LRB-17;19-RRB-	_	NN	NN	_	20	NMOD	_	_
18	-LRB-q22;p13-RRB-	_	NN	NN	_	20	NMOD	_	_
19	chromosomal	_	JJ	JJ	_	20	NMOD	_	_
20	translocation	_	NN	NN	_	15	PMOD	_	_
21	,	_	,	,	_	10	P	_	_
22	drives	_	VBZ	VBZ	_	0	ROOT-S	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	leukaemic	_	JJ	JJ	_	25	NMOD	_	_
25	transformation	_	NN	NN	_	22	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	early	_	JJ	JJ	_	29	NMOD	_	_
28	B-cell	_	NN	NN	_	29	NMOD	_	_
29	precursors	_	NNS	NNS	_	26	PMOD	_	_
30	,	_	,	,	_	22	P	_	_
31	but	_	CC	CC	_	22	CC	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	mechanism	_	NN	NN	_	37	SBJ	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	this	_	DT	DT	_	36	NMOD	_	_
36	activity	_	NN	NN	_	34	PMOD	_	_
37	remains	_	VBZ	VBZ	_	22	COORD	_	_
38	unknown	_	JJ	JJ	_	37	PRD	_	_
39	.	_	.	.	_	22	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	report	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	human	_	JJ	JJ	_	7	NMOD	_	_
6	leukaemia	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	13	SBJ	_	_
8	carrying	_	VBG	VBG	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	translocation	_	NN	NN	_	11	NMOD	_	_
11	t-LRB-17;19-RRB-	_	NN	NN	_	8	OBJ	_	_
12	rapidly	_	RB	RB	_	13	TMP	_	_
13	died	_	VBD	VBD	_	4	VMOD	_	_
14	by	_	IN	IN	_	13	ADV	_	_
15	apoptosis	_	NN	NN	_	14	PMOD	_	_
16	when	_	WRB	WRB	_	17	ADV	_	_
17	programmed	_	VBN	VBN	_	13	TMP	_	_
18	to	_	TO	TO	_	19	VMOD	_	_
19	express	_	VB	VB	_	17	OBJ	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	dominant-negative	_	JJ	JJ	_	22	NMOD	_	_
22	suppressor	_	NN	NN	_	19	OBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	fusion	_	NN	NN	_	27	NMOD	_	_
26	protein	_	NN	NN	_	27	NMOD	_	_
27	E2A-HLF	_	NN	NN	_	23	PMOD	_	_
28	,	_	,	,	_	13	P	_	_
29	indicating	_	VBG	VBG	_	13	OBJ	_	_
30	that	_	IN	IN	_	29	OBJ	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	chimaeric	_	JJ	JJ	_	33	NMOD	_	_
33	oncoprotein	_	NN	NN	_	35	SBJ	_	_
34	probably	_	RB	RB	_	35	ADV	_	_
35	affects	_	VBZ	VBZ	_	30	VMOD	_	_
36	cell	_	NN	NN	_	37	NMOD	_	_
37	survival	_	NN	NN	_	35	OBJ	_	_
38	rather	_	RB	RB	_	37	CC	_	_
39	than	_	IN	IN	_	38	DEP	_	_
40	cell	_	NN	NN	_	41	NMOD	_	_
41	growth	_	NN	NN	_	37	COORD	_	_
42	.	_	.	.	_	3	P	_	_

1	Moreover	_	RB	RB	_	15	ADV	_	_
2	,	_	,	,	_	15	P	_	_
3	when	_	WRB	WRB	_	4	ADV	_	_
4	introduced	_	VBN	VBN	_	15	TMP	_	_
5	into	_	IN	IN	_	4	ADV	_	_
6	murine	_	JJ	JJ	_	8	NMOD	_	_
7	pro-B	_	JJ	JJ	_	8	NMOD	_	_
8	lymphocytes	_	NNS	NNS	_	5	PMOD	_	_
9	,	_	,	,	_	15	P	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	oncogenic	_	JJ	JJ	_	14	NMOD	_	_
12	E2A-HLF	_	NN	NN	_	14	NMOD	_	_
13	fusion	_	NN	NN	_	14	NMOD	_	_
14	protein	_	NN	NN	_	15	SBJ	_	_
15	reversed	_	VBD	VBD	_	0	ROOT-S	_	_
16	both	_	CC	CC	_	17	CC	_	_
17	interleukin-3-dependent	_	JJ	JJ	_	20	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	p53-mediated	_	JJ	JJ	_	17	COORD	_	_
20	apoptosis	_	NN	NN	_	15	OBJ	_	_
21	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	close	_	JJ	JJ	_	3	NMOD	_	_
3	homology	_	NN	NN	_	29	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	15	NMOD	_	_
6	basic	_	JJ	JJ	_	8	NMOD	_	_
7	region\/leucine	_	NN	NN	_	8	NMOD	_	_
8	zipper	_	NN	NN	_	15	NMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	bZIP	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	DNA-binding	_	JJ	JJ	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	dimerization	_	NN	NN	_	12	COORD	_	_
15	domain	_	NN	NN	_	4	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	HLF	_	NN	NN	_	16	PMOD	_	_
18	to	_	TO	TO	_	3	NMOD	_	_
19	that	_	DT	DT	_	18	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	25	NMOD	_	_
22	CES-2	_	NN	NN	_	25	NMOD	_	_
23	cell-death	_	NN	NN	_	25	NMOD	_	_
24	specification	_	NN	NN	_	25	NMOD	_	_
25	protein	_	NN	NN	_	20	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	Caenorhabditis	_	NN	NN	_	28	NMOD	_	_
28	elegans	_	NNS	NNS	_	26	PMOD	_	_
29	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
30	a	_	DT	DT	_	31	NMOD	_	_
31	model	_	NN	NN	_	29	OBJ	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	leukaemogenesis	_	NN	NN	_	32	PMOD	_	_
34	in	_	IN	IN	_	37	ADV	_	_
35	which	_	WDT	WDT	_	34	PMOD	_	_
36	E2A-HLF	_	NN	NN	_	37	SBJ	_	_
37	blocks	_	VBZ	VBZ	_	31	NMOD	_	_
38	an	_	DT	DT	_	40	NMOD	_	_
39	early	_	JJ	JJ	_	40	NMOD	_	_
40	step	_	NN	NN	_	37	OBJ	_	_
41	within	_	IN	IN	_	40	NMOD	_	_
42	an	_	DT	DT	_	46	NMOD	_	_
43	evolutionarily	_	RB	RB	_	44	AMOD	_	_
44	conserved	_	VBN	VBN	_	46	NMOD	_	_
45	cell-death	_	NN	NN	_	46	NMOD	_	_
46	pathway	_	NN	NN	_	41	PMOD	_	_
47	.	_	.	.	_	29	P	_	_

1	Inhibition	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	transcription	_	NN	NN	_	6	NMOD	_	_
4	factor	_	NN	NN	_	6	NMOD	_	_
5	Stat1	_	NN	NN	_	6	NMOD	_	_
6	activity	_	NN	NN	_	2	PMOD	_	_
7	in	_	IN	IN	_	1	NMOD	_	_
8	mononuclear	_	JJ	JJ	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	cultures	_	NNS	NNS	_	7	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	10	COORD	_	_
14	by	_	IN	IN	_	1	NMOD	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	cyclic	_	JJ	JJ	_	19	NMOD	_	_
17	AMP	_	NN	NN	_	19	NMOD	_	_
18	signaling	_	NN	NN	_	19	NMOD	_	_
19	pathway	_	NN	NN	_	14	PMOD	_	_
20	.	_	.	.	_	1	P	_	_

1	Activation	_	NN	NN	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	T	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	cascade	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	gene	_	NN	NN	_	11	NMOD	_	_
11	activation	_	NN	NN	_	9	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	subsequent	_	JJ	JJ	_	14	NMOD	_	_
14	proliferation	_	NN	NN	_	11	COORD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	differentiation	_	NN	NN	_	14	COORD	_	_
17	into	_	IN	IN	_	16	NMOD	_	_
18	effector	_	NN	NN	_	19	NMOD	_	_
19	phenotypes	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	regulation	_	NN	NN	_	19	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	transcription	_	NN	NN	_	5	NMOD	_	_
5	factors	_	NNS	NNS	_	3	PMOD	_	_
6	belonging	_	VBG	VBG	_	5	NMOD	_	_
7	to	_	TO	TO	_	6	ADV	_	_
8	the	_	DT	DT	_	18	NMOD	_	_
9	signal	_	NN	NN	_	10	NMOD	_	_
10	transducer	_	NN	NN	_	18	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	activator	_	NN	NN	_	10	COORD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	transcription	_	NN	NN	_	13	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	STAT	_	NN	NN	_	10	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	family	_	NN	NN	_	7	PMOD	_	_
19	was	_	VBD	VBD	_	0	ROOT-S	_	_
20	analyzed	_	VBN	VBN	_	19	VC	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	PHA-activated	_	JJ	JJ	_	24	NMOD	_	_
23	mononuclear	_	JJ	JJ	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	21	PMOD	_	_
25	and	_	CC	CC	_	21	CC	_	_
26	in	_	IN	IN	_	21	COORD	_	_
27	purified	_	VBN	VBN	_	29	NMOD	_	_
28	T	_	NN	NN	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	26	PMOD	_	_
30	activated	_	VBN	VBN	_	29	NMOD	_	_
31	by	_	IN	IN	_	30	ADV	_	_
32	cross-linking	_	JJ	JJ	_	35	NMOD	_	_
33	cell	_	NN	NN	_	35	NMOD	_	_
34	surface	_	NN	NN	_	35	NMOD	_	_
35	CD3	_	NN	NN	_	31	PMOD	_	_
36	.	_	.	.	_	19	P	_	_

1	Cell	_	NN	NN	_	2	NMOD	_	_
2	activation	_	NN	NN	_	3	SBJ	_	_
3	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	delayed	_	VBN	VBN	_	7	NMOD	_	_
7	induction	_	NN	NN	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	STAT	_	NN	NN	_	11	NMOD	_	_
10	DNA-binding	_	JJ	JJ	_	11	NMOD	_	_
11	activity	_	NN	NN	_	8	PMOD	_	_
12	,	_	,	,	_	7	P	_	_
13	which	_	WDT	WDT	_	14	SBJ	_	_
14	was	_	VBD	VBD	_	7	NMOD	_	_
15	sustained	_	JJ	JJ	_	14	VC	_	_
16	for	_	IN	IN	_	15	TMP	_	_
17	several	_	JJ	JJ	_	18	NMOD	_	_
18	days	_	NNS	NNS	_	16	PMOD	_	_
19	,	_	,	,	_	14	P	_	_
20	was	_	VBD	VBD	_	14	COORD	_	_
21	composed	_	VBN	VBN	_	20	VC	_	_
22	predominantly	_	RB	RB	_	21	ADV	_	_
23	of	_	IN	IN	_	21	ADV	_	_
24	Stat1	_	NN	NN	_	23	PMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	Stat3	_	NN	NN	_	24	COORD	_	_
27	,	_	,	,	_	14	P	_	_
28	and	_	CC	CC	_	14	CC	_	_
29	was	_	VBD	VBD	_	14	COORD	_	_
30	blocked	_	VBN	VBN	_	29	VC	_	_
31	by	_	IN	IN	_	30	LGS	_	_
32	cycloheximide	_	NN	NN	_	31	PMOD	_	_
33	and	_	CC	CC	_	32	CC	_	_
34	actinomycin	_	NN	NN	_	35	NMOD	_	_
35	D	_	NN	NN	_	32	COORD	_	_
36	.	_	.	.	_	3	P	_	_

1	Increased	_	VBN	VBN	_	8	NMOD	_	_
2	Stat1	_	NN	NN	_	8	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	Stat3	_	NN	NN	_	2	COORD	_	_
5	mRNA	_	NN	NN	_	8	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	protein	_	NN	NN	_	5	COORD	_	_
8	levels	_	NNS	NNS	_	9	SBJ	_	_
9	were	_	VBD	VBD	_	0	ROOT-S	_	_
10	detected	_	VBN	VBN	_	9	VC	_	_
11	,	_	,	,	_	10	P	_	_
12	respectively	_	RB	RB	_	17	PMOD	_	_
13	4	_	CD	CD	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	24	_	CD	CD	_	13	COORD	_	_
16	h	_	NN	NN	_	17	PMOD	_	_
17	after	_	IN	IN	_	10	TMP	_	_
18	activation	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	9	P	_	_

1	Stimulation	_	NN	NN	_	18	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	cAMP	_	NN	NN	_	7	NMOD	_	_
5	signal	_	NN	NN	_	7	NMOD	_	_
6	transduction	_	NN	NN	_	7	NMOD	_	_
7	pathway	_	NN	NN	_	2	PMOD	_	_
8	,	_	,	,	_	1	P	_	_
9	which	_	WDT	WDT	_	10	SBJ	_	_
10	skews	_	VBZ	VBZ	_	1	NMOD	_	_
11	cytokine	_	NN	NN	_	12	NMOD	_	_
12	production	_	NN	NN	_	10	OBJ	_	_
13	toward	_	IN	IN	_	10	ADV	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	Th2	_	NN	NN	_	16	NMOD	_	_
16	pattern	_	NN	NN	_	13	PMOD	_	_
17	,	_	,	,	_	1	P	_	_
18	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	preferential	_	JJ	JJ	_	22	NMOD	_	_
22	suppression	_	NN	NN	_	19	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	Stat1	_	NN	NN	_	25	NMOD	_	_
25	activity	_	NN	NN	_	23	PMOD	_	_
26	.	_	.	.	_	18	P	_	_

1	cAMP	_	NN	NN	_	2	SBJ	_	_
2	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	induction	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	expression	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	IL-2	_	NN	NN	_	10	NMOD	_	_
9	receptor	_	NN	NN	_	10	NMOD	_	_
10	components	_	NNS	NNS	_	7	PMOD	_	_
11	,	_	,	,	_	2	P	_	_
12	but	_	CC	CC	_	2	CC	_	_
13	did	_	VBD	VBD	_	2	COORD	_	_
14	not	_	RB	RB	_	13	VMOD	_	_
15	inhibit	_	VB	VB	_	13	VC	_	_
16	IL-4	_	NN	NN	_	18	NMOD	_	_
17	receptor	_	NN	NN	_	18	NMOD	_	_
18	alpha-chain	_	NN	NN	_	21	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	CD69	_	NN	NN	_	18	COORD	_	_
21	expression	_	NN	NN	_	15	OBJ	_	_
22	or	_	CC	CC	_	21	CC	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	induction	_	NN	NN	_	21	COORD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	activator	_	NN	NN	_	30	NMOD	_	_
27	protein	_	NN	NN	_	30	NMOD	_	_
28	1	_	CD	CD	_	30	NMOD	_	_
29	transcription	_	NN	NN	_	30	NMOD	_	_
30	factors	_	NNS	NNS	_	25	PMOD	_	_
31	.	_	.	.	_	2	P	_	_

1	cAMP	_	NN	NN	_	2	NMOD	_	_
2	signaling	_	NN	NN	_	3	SBJ	_	_
3	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
4	Stat1	_	NN	NN	_	3	OBJ	_	_
5	at	_	IN	IN	_	3	ADV	_	_
6	several	_	JJ	JJ	_	8	NMOD	_	_
7	different	_	JJ	JJ	_	8	NMOD	_	_
8	levels	_	NNS	NNS	_	5	PMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	including	_	VBG	VBG	_	8	NMOD	_	_
11	suppression	_	NN	NN	_	22	NMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	DNA	_	NN	NN	_	14	NMOD	_	_
14	binding	_	NN	NN	_	12	PMOD	_	_
15	and	_	CC	CC	_	11	CC	_	_
16	down-regulation	_	NN	NN	_	11	COORD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	Stat1	_	NN	NN	_	17	PMOD	_	_
19	protein	_	NN	NN	_	18	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	mRNA	_	NN	NN	_	19	COORD	_	_
22	levels	_	NNS	NNS	_	10	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	regulation	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	STAT	_	NN	NN	_	8	NMOD	_	_
8	activity	_	NN	NN	_	6	PMOD	_	_
9	by	_	IN	IN	_	5	NMOD	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	signaling	_	NN	NN	_	12	NMOD	_	_
12	pathway	_	NN	NN	_	9	PMOD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	regulates	_	VBZ	VBZ	_	12	NMOD	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	T	_	NN	NN	_	19	NMOD	_	_
17	cell	_	NN	NN	_	19	NMOD	_	_
18	functional	_	JJ	JJ	_	19	NMOD	_	_
19	phenotype	_	NN	NN	_	14	OBJ	_	_
20	and	_	CC	CC	_	14	CC	_	_
21	is	_	VBZ	VBZ	_	14	COORD	_	_
22	distinct	_	JJ	JJ	_	21	PRD	_	_
23	from	_	IN	IN	_	22	AMOD	_	_
24	the	_	DT	DT	_	29	NMOD	_	_
25	cytokine-activated	_	JJ	JJ	_	29	NMOD	_	_
26	Janus	_	NN	NN	_	29	NMOD	_	_
27	kinase-STAT	_	NN	NN	_	29	NMOD	_	_
28	signaling	_	NN	NN	_	29	NMOD	_	_
29	pathway	_	NN	NN	_	23	PMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	oriP	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	essential	_	JJ	JJ	_	2	PRD	_	_
4	for	_	IN	IN	_	3	AMOD	_	_
5	EBNA	_	NN	NN	_	8	NMOD	_	_
6	gene	_	NN	NN	_	8	NMOD	_	_
7	promoter	_	NN	NN	_	8	NMOD	_	_
8	activity	_	NN	NN	_	4	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	Epstein-Barr	_	JJ	JJ	_	11	AMOD	_	_
11	virus-immortalized	_	JJ	JJ	_	14	NMOD	_	_
12	lymphoblastoid	_	JJ	JJ	_	14	NMOD	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	lines	_	NNS	NNS	_	9	PMOD	_	_
15	.	_	.	.	_	2	P	_	_

1	During	_	IN	IN	_	19	TMP	_	_
2	Epstein-Barr	_	JJ	JJ	_	5	NMOD	_	_
3	virus	_	NN	NN	_	5	NMOD	_	_
4	latent	_	JJ	JJ	_	5	NMOD	_	_
5	infection	_	NN	NN	_	1	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	B	_	NN	NN	_	8	NMOD	_	_
8	lymphocytes	_	NNS	NNS	_	6	PMOD	_	_
9	in	_	FW	FW	_	5	NMOD	_	_
10	vitro	_	FW	FW	_	9	AMOD	_	_
11	,	_	,	,	_	19	P	_	_
12	six	_	CD	CD	_	15	NMOD	_	_
13	viral	_	JJ	JJ	_	15	NMOD	_	_
14	nuclear	_	JJ	JJ	_	15	NMOD	_	_
15	antigens	_	NNS	NNS	_	19	SBJ	_	_
16	(	_	(	(	_	17	P	_	_
17	EBNAs	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	are	_	VBP	VBP	_	0	ROOT-S	_	_
20	expressed	_	VBN	VBN	_	19	VC	_	_
21	from	_	IN	IN	_	20	ADV	_	_
22	one	_	CD	CD	_	21	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	two	_	CD	CD	_	25	NMOD	_	_
25	promoters	_	NNS	NNS	_	23	PMOD	_	_
26	,	_	,	,	_	25	P	_	_
27	Cp	_	NN	NN	_	25	NMOD	_	_
28	or	_	CC	CC	_	27	CC	_	_
29	Wp	_	NN	NN	_	27	COORD	_	_
30	,	_	,	,	_	25	P	_	_
31	whose	_	WP$	WP$	_	32	NMOD	_	_
32	activities	_	NNS	NNS	_	33	SBJ	_	_
33	are	_	VBP	VBP	_	25	NMOD	_	_
34	mutually	_	RB	RB	_	35	AMOD	_	_
35	exclusive	_	JJ	JJ	_	33	PRD	_	_
36	.	_	.	.	_	19	P	_	_

1	Upon	_	IN	IN	_	5	TMP	_	_
2	infection	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	Wp	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	initially	_	RB	RB	_	5	TMP	_	_
7	active	_	JJ	JJ	_	5	PRD	_	_
8	,	_	,	,	_	5	P	_	_
9	followed	_	VBN	VBN	_	5	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	switch	_	NN	NN	_	10	PMOD	_	_
13	to	_	TO	TO	_	12	NMOD	_	_
14	Cp	_	NN	NN	_	13	PMOD	_	_
15	for	_	IN	IN	_	12	TMP	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	duration	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	latency	_	NN	NN	_	18	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	10	P	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	region	_	NN	NN	_	10	SBJ	_	_
7	upstream	_	JJ	JJ	_	6	NMOD	_	_
8	of	_	IN	IN	_	7	AMOD	_	_
9	Cp	_	NN	NN	_	8	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	analyzed	_	VBN	VBN	_	10	VC	_	_
12	for	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	presence	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	cis	_	NN	NN	_	17	NMOD	_	_
17	elements	_	NNS	NNS	_	15	PMOD	_	_
18	involved	_	VBN	VBN	_	17	NMOD	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	regulating	_	VBG	VBG	_	19	PMOD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	activities	_	NNS	NNS	_	20	OBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	EBNA	_	NN	NN	_	27	NMOD	_	_
26	gene	_	NN	NN	_	27	NMOD	_	_
27	promoters	_	NNS	NNS	_	23	PMOD	_	_
28	in	_	IN	IN	_	14	NMOD	_	_
29	established	_	JJ	JJ	_	35	NMOD	_	_
30	in	_	FW	FW	_	31	AMOD	_	_
31	vitro	_	FW	FW	_	35	NMOD	_	_
32	immortalized	_	VBN	VBN	_	35	NMOD	_	_
33	lymphoblastoid	_	JJ	JJ	_	35	NMOD	_	_
34	cell	_	NN	NN	_	35	NMOD	_	_
35	lines	_	NNS	NNS	_	28	PMOD	_	_
36	(	_	(	(	_	37	P	_	_
37	LCLs	_	NNS	NNS	_	35	PRN	_	_
38	)	_	)	)	_	37	P	_	_
39	.	_	.	.	_	10	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	determined	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	oriP	_	NN	NN	_	15	SBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	origin	_	NN	NN	_	5	NMOD	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	episomal	_	JJ	JJ	_	11	NMOD	_	_
11	maintenance	_	NN	NN	_	9	PMOD	_	_
12	during	_	IN	IN	_	11	TMP	_	_
13	latency	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	5	P	_	_
15	is	_	VBZ	VBZ	_	4	VMOD	_	_
16	essential	_	JJ	JJ	_	15	PRD	_	_
17	for	_	IN	IN	_	16	AMOD	_	_
18	efficient	_	JJ	JJ	_	20	NMOD	_	_
19	transcription	_	NN	NN	_	20	NMOD	_	_
20	initiation	_	NN	NN	_	17	PMOD	_	_
21	from	_	IN	IN	_	20	NMOD	_	_
22	either	_	CC	CC	_	23	CC	_	_
23	Cp	_	NN	NN	_	21	PMOD	_	_
24	or	_	CC	CC	_	23	CC	_	_
25	Wp	_	NN	NN	_	23	COORD	_	_
26	in	_	IN	IN	_	20	NMOD	_	_
27	LCLs	_	NN	NN	_	26	PMOD	_	_
28	,	_	,	,	_	26	P	_	_
29	as	_	RB	RB	_	26	CC	_	_
30	well	_	RB	RB	_	29	DEP	_	_
31	as	_	IN	IN	_	29	DEP	_	_
32	in	_	IN	IN	_	26	COORD	_	_
33	some	_	DT	DT	_	38	NMOD	_	_
34	Burkitt	_	NN	NN	_	38	NMOD	_	_
35	's	_	POS	POS	_	34	NMOD	_	_
36	lymphoma	_	NN	NN	_	38	NMOD	_	_
37	cell	_	NN	NN	_	38	NMOD	_	_
38	lines	_	NNS	NNS	_	32	PMOD	_	_
39	.	_	.	.	_	2	P	_	_

1	Deletion	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	EBNA2-dependent	_	JJ	JJ	_	5	NMOD	_	_
5	enhancer	_	NN	NN	_	2	PMOD	_	_
6	located	_	JJ	JJ	_	7	AMOD	_	_
7	upstream	_	RB	RB	_	5	NMOD	_	_
8	of	_	IN	IN	_	7	AMOD	_	_
9	Cp	_	NN	NN	_	8	PMOD	_	_
10	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	a	_	DT	DT	_	17	NMOD	_	_
13	ca.	_	FW	FW	_	16	DEP	_	_
14	two-	_	CD	CD	_	16	DEP	_	_
15	to	_	TO	TO	_	16	DEP	_	_
16	fivefold	_	JJ	JJ	_	17	NMOD	_	_
17	reduction	_	NN	NN	_	11	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	Cp	_	NN	NN	_	20	NMOD	_	_
20	activity	_	NN	NN	_	18	PMOD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	LCLs	_	NNS	NNS	_	21	PMOD	_	_
24	assayed	_	VBN	VBN	_	23	NMOD	_	_
25	.	_	.	.	_	10	P	_	_

1	More	_	RBR	RBR	_	2	AMOD	_	_
2	extensive	_	JJ	JJ	_	3	NMOD	_	_
3	deletion	_	NN	NN	_	15	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	sequences	_	NNS	NNS	_	4	PMOD	_	_
6	upstream	_	JJ	JJ	_	5	NMOD	_	_
7	of	_	IN	IN	_	6	AMOD	_	_
8	Cp	_	NN	NN	_	7	PMOD	_	_
9	,	_	,	,	_	5	P	_	_
10	including	_	VBG	VBG	_	5	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	EBNA2-dependent	_	JJ	JJ	_	13	NMOD	_	_
13	enhancer	_	NN	NN	_	10	PMOD	_	_
14	,	_	,	,	_	5	P	_	_
15	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	nearly	_	RB	RB	_	18	AMOD	_	_
18	complete	_	JJ	JJ	_	19	NMOD	_	_
19	loss	_	NN	NN	_	16	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	Cp	_	NN	NN	_	22	NMOD	_	_
22	activity	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	15	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	loss	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	activity	_	NN	NN	_	3	PMOD	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	shown	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	correlate	_	VB	VB	_	6	OBJ	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	deletion	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	two	_	CD	CD	_	14	NMOD	_	_
13	CCAAT	_	NN	NN	_	14	NMOD	_	_
14	boxes	_	NNS	NNS	_	11	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	a	_	DT	DT	_	19	NMOD	_	_
17	proximal	_	JJ	JJ	_	19	NMOD	_	_
18	CCAAT	_	NN	NN	_	19	NMOD	_	_
19	box	_	NN	NN	_	14	NMOD	_	_
20	located	_	JJ	JJ	_	19	NMOD	_	_
21	at	_	IN	IN	_	20	AMOD	_	_
22	bp	_	NN	NN	_	21	PMOD	_	_
23	-61	_	CD	CD	_	22	NMOD	_	_
24	to	_	TO	TO	_	23	NMOD	_	_
25	-65	_	CD	CD	_	23	NMOD	_	_
26	and	_	CC	CC	_	19	CC	_	_
27	a	_	DT	DT	_	30	NMOD	_	_
28	distal	_	JJ	JJ	_	30	NMOD	_	_
29	CCAAT	_	NN	NN	_	30	NMOD	_	_
30	box	_	NN	NN	_	19	COORD	_	_
31	located	_	JJ	JJ	_	30	NMOD	_	_
32	at	_	IN	IN	_	31	AMOD	_	_
33	bp	_	NN	NN	_	32	PMOD	_	_
34	-253	_	CD	CD	_	33	NMOD	_	_
35	to	_	TO	TO	_	34	NMOD	_	_
36	-257	_	CD	CD	_	34	NMOD	_	_
37	,	_	,	,	_	32	P	_	_
38	upstream	_	RB	RB	_	32	COORD	_	_
39	of	_	IN	IN	_	38	AMOD	_	_
40	Cp	_	NN	NN	_	39	PMOD	_	_
41	.	_	.	.	_	5	P	_	_

1	Site-directed	_	JJ	JJ	_	2	NMOD	_	_
2	mutagenesis	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	these	_	DT	DT	_	6	NMOD	_	_
5	cis	_	NN	NN	_	6	NMOD	_	_
6	elements	_	NNS	NNS	_	3	PMOD	_	_
7	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	Cp	_	NN	NN	_	10	NMOD	_	_
10	activity	_	NN	NN	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	8	VMOD	_	_
12	highly	_	RB	RB	_	13	AMOD	_	_
13	dependent	_	JJ	JJ	_	11	PRD	_	_
14	on	_	IN	IN	_	13	AMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	presence	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	a	_	DT	DT	_	22	NMOD	_	_
19	properly	_	RB	RB	_	20	AMOD	_	_
20	positioned	_	VBN	VBN	_	22	NMOD	_	_
21	CCAAT	_	NN	NN	_	22	NMOD	_	_
22	box	_	NN	NN	_	17	PMOD	_	_
23	,	_	,	,	_	11	P	_	_
24	with	_	IN	IN	_	11	ADV	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	dependence	_	NN	NN	_	24	PMOD	_	_
27	on	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	31	NMOD	_	_
29	distal	_	JJ	JJ	_	31	NMOD	_	_
30	CCAAT	_	NN	NN	_	31	NMOD	_	_
31	box	_	NN	NN	_	27	PMOD	_	_
32	apparent	_	JJ	JJ	_	31	NMOD	_	_
33	only	_	RB	RB	_	34	AMOD	_	_
34	when	_	WRB	WRB	_	39	ADV	_	_
35	the	_	DT	DT	_	38	NMOD	_	_
36	proximal	_	JJ	JJ	_	38	NMOD	_	_
37	CCAAT	_	NN	NN	_	38	NMOD	_	_
38	box	_	NN	NN	_	39	SBJ	_	_
39	was	_	VBD	VBD	_	32	TMP	_	_
40	deleted	_	VBN	VBN	_	39	VC	_	_
41	or	_	CC	CC	_	40	CC	_	_
42	mutated	_	VBN	VBN	_	40	COORD	_	_
43	.	_	.	.	_	7	P	_	_

1	Deletion	_	NN	NN	_	15	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	glucocorticoid	_	NN	NN	_	6	NMOD	_	_
5	response	_	NN	NN	_	6	NMOD	_	_
6	elements	_	NNS	NNS	_	2	PMOD	_	_
7	located	_	JJ	JJ	_	6	NMOD	_	_
8	at	_	IN	IN	_	7	AMOD	_	_
9	ca.	_	FW	FW	_	10	NMOD	_	_
10	bp	_	NN	NN	_	12	AMOD	_	_
11	-850	_	CD	CD	_	10	NMOD	_	_
12	upstream	_	RB	RB	_	8	PMOD	_	_
13	of	_	IN	IN	_	12	AMOD	_	_
14	Cp	_	NN	NN	_	13	PMOD	_	_
15	did	_	VBD	VBD	_	0	ROOT-S	_	_
16	not	_	RB	RB	_	15	VMOD	_	_
17	result	_	VB	VB	_	15	VC	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	significant	_	JJ	JJ	_	21	NMOD	_	_
21	loss	_	NN	NN	_	18	PMOD	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	activity	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	15	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	general	_	JJ	JJ	_	1	PMOD	_	_
3	,	_	,	,	_	9	P	_	_
4	deletions	_	NNS	NNS	_	9	SBJ	_	_
5	which	_	WDT	WDT	_	6	SBJ	_	_
6	diminished	_	VBD	VBD	_	4	NMOD	_	_
7	Cp	_	JJ	JJ	_	8	NMOD	_	_
8	activity	_	NN	NN	_	6	OBJ	_	_
9	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	induction	_	NN	NN	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	Wp	_	JJ	JJ	_	14	NMOD	_	_
14	activity	_	NN	NN	_	12	PMOD	_	_
15	,	_	,	,	_	9	P	_	_
16	consistent	_	JJ	JJ	_	9	VMOD	_	_
17	with	_	IN	IN	_	16	AMOD	_	_
18	suppression	_	NN	NN	_	17	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	Wp	_	JJ	JJ	_	21	NMOD	_	_
21	activity	_	NN	NN	_	19	PMOD	_	_
22	by	_	IN	IN	_	18	NMOD	_	_
23	transcriptional	_	JJ	JJ	_	24	NMOD	_	_
24	interference	_	NN	NN	_	22	PMOD	_	_
25	from	_	IN	IN	_	24	NMOD	_	_
26	Cp	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	identification	_	NN	NN	_	22	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	oriP	_	NN	NN	_	3	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	EBNA2-dependent	_	JJ	JJ	_	8	NMOD	_	_
8	enhancer	_	NN	NN	_	4	COORD	_	_
9	as	_	IN	IN	_	2	NMOD	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	major	_	JJ	JJ	_	14	NMOD	_	_
12	positive	_	JJ	JJ	_	14	NMOD	_	_
13	cis	_	NN	NN	_	14	NMOD	_	_
14	elements	_	NNS	NNS	_	9	PMOD	_	_
15	involved	_	VBN	VBN	_	14	NMOD	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	regulating	_	VBG	VBG	_	16	PMOD	_	_
18	Cp	_	JJ	JJ	_	19	NMOD	_	_
19	activity	_	NN	NN	_	17	OBJ	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	LCL	_	NN	NN	_	20	PMOD	_	_
22	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
23	that	_	IN	IN	_	22	OBJ	_	_
24	EBNA	_	NN	NN	_	26	NMOD	_	_
25	gene	_	NN	NN	_	26	NMOD	_	_
26	transcription	_	NN	NN	_	27	SBJ	_	_
27	is	_	VBZ	VBZ	_	23	VMOD	_	_
28	largely	_	RB	RB	_	27	ADV	_	_
29	autoregulated	_	VBN	VBN	_	27	VC	_	_
30	by	_	IN	IN	_	29	LGS	_	_
31	EBNA	_	NN	NN	_	30	PMOD	_	_
32	1	_	CD	CD	_	31	NMOD	_	_
33	and	_	CC	CC	_	31	CC	_	_
34	EBNA	_	NN	NN	_	31	COORD	_	_
35	2	_	CD	CD	_	34	NMOD	_	_
36	.	_	.	.	_	22	P	_	_

1	The	_	DT	DT	_	10	NMOD	_	_
2	human	_	JJ	JJ	_	10	NMOD	_	_
3	T-cell	_	NN	NN	_	10	NMOD	_	_
4	leukemia	_	NN	NN	_	10	NMOD	_	_
5	virus	_	NN	NN	_	10	NMOD	_	_
6	type	_	NN	NN	_	10	NMOD	_	_
7	1	_	CD	CD	_	10	NMOD	_	_
8	posttranscriptional	_	JJ	JJ	_	10	NMOD	_	_
9	trans-activator	_	NN	NN	_	10	NMOD	_	_
10	Rex	_	NN	NN	_	11	SBJ	_	_
11	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	a	_	DT	DT	_	15	NMOD	_	_
13	nuclear	_	JJ	JJ	_	15	NMOD	_	_
14	export	_	NN	NN	_	15	NMOD	_	_
15	signal	_	NN	NN	_	11	OBJ	_	_
16	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	Rex	_	NN	NN	_	3	NMOD	_	_
3	protein	_	NN	NN	_	11	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	human	_	JJ	JJ	_	9	NMOD	_	_
6	T-cell	_	NN	NN	_	9	NMOD	_	_
7	leukemia	_	NN	NN	_	9	NMOD	_	_
8	virus	_	NN	NN	_	9	NMOD	_	_
9	type	_	NN	NN	_	4	PMOD	_	_
10	1	_	CD	CD	_	9	NMOD	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	required	_	VBN	VBN	_	11	VC	_	_
13	for	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	nuclear	_	JJ	JJ	_	16	NMOD	_	_
16	export	_	NN	NN	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	unspliced	_	JJ	JJ	_	20	NMOD	_	_
19	viral	_	JJ	JJ	_	20	NMOD	_	_
20	mRNA	_	NN	NN	_	17	PMOD	_	_
21	and	_	CC	CC	_	13	CC	_	_
22	,	_	,	,	_	13	P	_	_
23	therefore	_	RB	RB	_	13	COORD	_	_
24	,	_	,	,	_	13	P	_	_
25	for	_	IN	IN	_	13	COORD	_	_
26	virus	_	NN	NN	_	27	NMOD	_	_
27	replication	_	NN	NN	_	25	PMOD	_	_
28	.	_	.	.	_	11	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	manuscript	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	Rex	_	NN	NN	_	9	SBJ	_	_
9	shuttles	_	VBZ	VBZ	_	7	VMOD	_	_
10	between	_	IN	IN	_	9	ADV	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	nucleus	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	cytoplasm	_	NN	NN	_	12	COORD	_	_
16	and	_	CC	CC	_	7	CC	_	_
17	that	_	IN	IN	_	7	COORD	_	_
18	its	_	PRP$	PRP$	_	20	NMOD	_	_
19	activation	_	NN	NN	_	20	NMOD	_	_
20	domain	_	NN	NN	_	21	SBJ	_	_
21	constitutes	_	VBZ	VBZ	_	17	VMOD	_	_
22	a	_	DT	DT	_	25	NMOD	_	_
23	nuclear	_	JJ	JJ	_	25	NMOD	_	_
24	export	_	NN	NN	_	25	NMOD	_	_
25	signal	_	NN	NN	_	21	OBJ	_	_
26	that	_	WDT	WDT	_	27	SBJ	_	_
27	specifies	_	VBZ	VBZ	_	25	NMOD	_	_
28	efficient	_	JJ	JJ	_	29	NMOD	_	_
29	transport	_	NN	NN	_	27	OBJ	_	_
30	to	_	TO	TO	_	29	NMOD	_	_
31	the	_	DT	DT	_	32	NMOD	_	_
32	cytoplasm	_	NN	NN	_	30	PMOD	_	_
33	.	_	.	.	_	6	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	consistent	_	JJ	JJ	_	3	PRD	_	_
5	with	_	IN	IN	_	4	AMOD	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	model	_	NN	NN	_	5	PMOD	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	Rex-mediated	_	JJ	JJ	_	10	NMOD	_	_
10	trans-activation	_	NN	NN	_	8	PMOD	_	_
11	in	_	IN	IN	_	17	ADV	_	_
12	which	_	WDT	WDT	_	11	PMOD	_	_
13	Rex-viral	_	JJ	JJ	_	15	NMOD	_	_
14	mRNA	_	NN	NN	_	15	NMOD	_	_
15	complexes	_	NNS	NNS	_	16	SBJ	_	_
16	are	_	VBP	VBP	_	7	NMOD	_	_
17	targeted	_	VBN	VBN	_	16	VC	_	_
18	for	_	IN	IN	_	17	ADV	_	_
19	nuclear	_	JJ	JJ	_	20	NMOD	_	_
20	export	_	NN	NN	_	18	PMOD	_	_
21	by	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	direct	_	JJ	JJ	_	24	NMOD	_	_
24	action	_	NN	NN	_	21	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	activation	_	NN	NN	_	28	NMOD	_	_
28	domain	_	NN	NN	_	25	PMOD	_	_
29	.	_	.	.	_	3	P	_	_

1	Multiple	_	JJ	JJ	_	4	NMOD	_	_
2	p21ras	_	NN	NN	_	4	NMOD	_	_
3	effector	_	NN	NN	_	4	NMOD	_	_
4	pathways	_	NNS	NNS	_	5	SBJ	_	_
5	regulate	_	VBP	VBP	_	0	ROOT-S	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	factor	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	activated	_	VBN	VBN	_	11	NMOD	_	_
10	T	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	8	PMOD	_	_
12	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	transcription	_	NN	NN	_	3	NMOD	_	_
3	factor	_	NN	NN	_	14	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	Nuclear	_	JJ	JJ	_	10	NMOD	_	_
6	Factor	_	NN	NN	_	10	NMOD	_	_
7	of	_	IN	IN	_	10	NMOD	_	_
8	Activated	_	VBN	VBN	_	10	NMOD	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	3	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	NFAT	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	major	_	JJ	JJ	_	17	NMOD	_	_
17	target	_	NN	NN	_	14	PRD	_	_
18	for	_	IN	IN	_	17	NMOD	_	_
19	p21ras	_	NN	NN	_	23	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	calcium	_	NN	NN	_	19	COORD	_	_
22	signalling	_	NN	NN	_	23	NMOD	_	_
23	pathways	_	NNS	NNS	_	18	PMOD	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	IL-2	_	NN	NN	_	27	NMOD	_	_
27	gene	_	NN	NN	_	24	PMOD	_	_
28	and	_	CC	CC	_	14	CC	_	_
29	is	_	VBZ	VBZ	_	14	COORD	_	_
30	induced	_	VBN	VBN	_	29	VC	_	_
31	by	_	IN	IN	_	30	LGS	_	_
32	p21ras	_	NN	NN	_	33	NMOD	_	_
33	signals	_	NNS	NNS	_	31	PMOD	_	_
34	acting	_	VBG	VBG	_	33	NMOD	_	_
35	in	_	IN	IN	_	34	ADV	_	_
36	synergy	_	NN	NN	_	35	PMOD	_	_
37	with	_	IN	IN	_	36	NMOD	_	_
38	calcium\/calcineurin	_	NN	NN	_	39	NMOD	_	_
39	signals	_	NNS	NNS	_	37	PMOD	_	_
40	.	_	.	.	_	14	P	_	_

1	One	_	CD	CD	_	4	NMOD	_	_
2	p21ras	_	NN	NN	_	4	NMOD	_	_
3	effector	_	NN	NN	_	4	NMOD	_	_
4	pathway	_	NN	NN	_	5	SBJ	_	_
5	involves	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	MAP	_	NN	NN	_	9	NMOD	_	_
8	kinase	_	NN	NN	_	9	NMOD	_	_
9	ERK-2	_	NN	NN	_	5	OBJ	_	_
10	,	_	,	,	_	5	P	_	_
11	and	_	CC	CC	_	5	CC	_	_
12	we	_	PRP	PRP	_	13	SBJ	_	_
13	have	_	VBP	VBP	_	5	COORD	_	_
14	examined	_	VBN	VBN	_	13	VC	_	_
15	its	_	PRP$	PRP$	_	16	NMOD	_	_
16	role	_	NN	NN	_	14	OBJ	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	NFAT	_	NN	NN	_	19	NMOD	_	_
19	regulation	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	Expression	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	dominant	_	JJ	JJ	_	5	NMOD	_	_
4	negative	_	JJ	JJ	_	5	NMOD	_	_
5	MAPKK-1	_	NN	NN	_	2	PMOD	_	_
6	prevents	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	NFAT	_	NN	NN	_	8	NMOD	_	_
8	induction	_	NN	NN	_	6	OBJ	_	_
9	.	_	.	.	_	6	P	_	_

1	Constitutively	_	RB	RB	_	2	AMOD	_	_
2	active	_	JJ	JJ	_	3	NMOD	_	_
3	MAPKK-1	_	NN	NN	_	5	SBJ	_	_
4	fully	_	RB	RB	_	5	ADV	_	_
5	activates	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	ERK-2	_	NN	NN	_	5	OBJ	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	transcription	_	NN	NN	_	11	NMOD	_	_
10	factor	_	NN	NN	_	11	NMOD	_	_
11	Elk-1	_	NN	NN	_	6	COORD	_	_
12	,	_	,	,	_	5	P	_	_
13	but	_	CC	CC	_	5	CC	_	_
14	does	_	VBZ	VBZ	_	5	COORD	_	_
15	not	_	RB	RB	_	14	VMOD	_	_
16	substitute	_	VB	VB	_	14	VC	_	_
17	for	_	IN	IN	_	16	ADV	_	_
18	activated	_	VBN	VBN	_	19	NMOD	_	_
19	p21ras	_	NN	NN	_	17	PMOD	_	_
20	and	_	CC	CC	_	16	CC	_	_
21	synergize	_	VBP	VBP	_	16	COORD	_	_
22	with	_	IN	IN	_	21	ADV	_	_
23	calcium\/calcineurin	_	NN	NN	_	24	NMOD	_	_
24	signals	_	NNS	NNS	_	22	PMOD	_	_
25	to	_	TO	TO	_	26	VMOD	_	_
26	induce	_	VB	VB	_	21	OBJ	_	_
27	NFAT	_	NN	NN	_	26	OBJ	_	_
28	.	_	.	.	_	5	P	_	_

1	Expression	_	NN	NN	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	dominant	_	JJ	JJ	_	5	NMOD	_	_
4	negative	_	JJ	JJ	_	5	NMOD	_	_
5	N17Rac	_	NN	NN	_	2	PMOD	_	_
6	also	_	RB	RB	_	7	ADV	_	_
7	prevents	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	TCR	_	NN	NN	_	11	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	p21ras	_	NN	NN	_	8	COORD	_	_
11	activation	_	NN	NN	_	7	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	NFAT	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	7	P	_	_
15	but	_	CC	CC	_	7	CC	_	_
16	without	_	IN	IN	_	7	ADV	_	_
17	interfering	_	VBG	VBG	_	16	PMOD	_	_
18	with	_	IN	IN	_	17	ADV	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	ERK-2	_	NN	NN	_	21	NMOD	_	_
21	pathway	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	transcriptional	_	JJ	JJ	_	3	NMOD	_	_
3	activity	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	NFAT	_	NN	NN	_	8	NMOD	_	_
7	binding	_	NN	NN	_	8	NMOD	_	_
8	site	_	NN	NN	_	4	PMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	mediated	_	VBN	VBN	_	9	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	a	_	DT	DT	_	13	NMOD	_	_
13	complex	_	NN	NN	_	11	PMOD	_	_
14	comprising	_	VBG	VBG	_	13	NMOD	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	member	_	NN	NN	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	NFAT	_	NN	NN	_	20	NMOD	_	_
20	group	_	NN	NN	_	17	PMOD	_	_
21	and	_	CC	CC	_	16	CC	_	_
22	AP-1	_	NN	NN	_	24	NMOD	_	_
23	family	_	NN	NN	_	24	NMOD	_	_
24	proteins	_	NNS	NNS	_	16	COORD	_	_
25	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	induction	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	AP-1	_	NN	NN	_	3	PMOD	_	_
5	by	_	IN	IN	_	2	NMOD	_	_
6	p21ras	_	NN	NN	_	5	PMOD	_	_
7	also	_	RB	RB	_	8	ADV	_	_
8	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	Rac-1	_	NN	NN	_	10	NMOD	_	_
10	function	_	NN	NN	_	8	OBJ	_	_
11	.	_	.	.	_	8	P	_	_

1	Activated	_	VBN	VBN	_	2	NMOD	_	_
2	Rac-1	_	NN	NN	_	3	SBJ	_	_
3	could	_	MD	MD	_	0	ROOT-S	_	_
4	mimic	_	VB	VB	_	3	VC	_	_
5	activated	_	VBN	VBN	_	6	NMOD	_	_
6	p21ras	_	NN	NN	_	4	IOBJ	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	induce	_	VB	VB	_	4	OBJ	_	_
9	AP-1	_	NN	NN	_	8	OBJ	_	_
10	but	_	CC	CC	_	8	CC	_	_
11	not	_	RB	RB	_	13	VMOD	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	induce	_	VB	VB	_	8	COORD	_	_
14	NFAT	_	NN	NN	_	13	OBJ	_	_
15	.	_	.	.	_	3	P	_	_

1	Moreover	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	combination	_	NN	NN	_	10	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	activated	_	VBN	VBN	_	7	NMOD	_	_
7	MAPKK-1	_	NN	NN	_	5	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	Rac-1	_	NN	NN	_	7	COORD	_	_
10	could	_	MD	MD	_	0	ROOT-S	_	_
11	not	_	RB	RB	_	10	VMOD	_	_
12	substitute	_	VB	VB	_	10	VC	_	_
13	for	_	IN	IN	_	12	ADV	_	_
14	activated	_	VBN	VBN	_	15	NMOD	_	_
15	p21ras	_	NN	NN	_	13	PMOD	_	_
16	and	_	CC	CC	_	12	CC	_	_
17	synergize	_	VB	VB	_	12	COORD	_	_
18	with	_	IN	IN	_	17	ADV	_	_
19	calcium	_	NN	NN	_	20	NMOD	_	_
20	signals	_	NNS	NNS	_	18	PMOD	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	induce	_	VB	VB	_	17	OBJ	_	_
23	NFAT	_	NN	NN	_	22	OBJ	_	_
24	.	_	.	.	_	10	P	_	_

1	Thus	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	p21ras	_	NN	NN	_	4	NMOD	_	_
4	regulation	_	NN	NN	_	10	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	NFAT	_	NN	NN	_	5	PMOD	_	_
7	in	_	IN	IN	_	4	NMOD	_	_
8	T	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	7	PMOD	_	_
10	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	activity	_	NN	NN	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	multiple	_	JJ	JJ	_	16	NMOD	_	_
15	effector	_	NN	NN	_	16	NMOD	_	_
16	pathways	_	NNS	NNS	_	13	PMOD	_	_
17	including	_	VBG	VBG	_	16	NMOD	_	_
18	those	_	DT	DT	_	17	PMOD	_	_
19	regulated	_	VBN	VBN	_	18	NMOD	_	_
20	by	_	IN	IN	_	19	LGS	_	_
21	MAPKK-1\/ERK-2	_	NN	NN	_	20	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	Rac-1	_	NN	NN	_	21	COORD	_	_
24	.	_	.	.	_	10	P	_	_

1	Protein-tyrosine	_	JJ	JJ	_	3	NMOD	_	_
2	kinase	_	NN	NN	_	3	NMOD	_	_
3	activation	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	required	_	VBN	VBN	_	4	VC	_	_
6	for	_	IN	IN	_	5	ADV	_	_
7	lipopolysaccharide	_	NN	NN	_	8	NMOD	_	_
8	induction	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	interleukin	_	NN	NN	_	11	NMOD	_	_
11	1beta	_	NN	NN	_	9	PMOD	_	_
12	and	_	CC	CC	_	8	CC	_	_
13	NFkappaB	_	NN	NN	_	14	NMOD	_	_
14	activation	_	NN	NN	_	8	COORD	_	_
15	,	_	,	,	_	8	P	_	_
16	but	_	CC	CC	_	8	CC	_	_
17	not	_	RB	RB	_	16	COORD	_	_
18	NFkappaB	_	NN	NN	_	20	NMOD	_	_
19	nuclear	_	JJ	JJ	_	20	NMOD	_	_
20	translocation	_	NN	NN	_	8	COORD	_	_
21	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	14	ADV	_	_
2	human	_	JJ	JJ	_	3	NMOD	_	_
3	monocytes	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	14	P	_	_
5	interleukin	_	NN	NN	_	8	NMOD	_	_
6	1beta	_	NN	NN	_	8	NMOD	_	_
7	protein	_	NN	NN	_	8	NMOD	_	_
8	production	_	NN	NN	_	14	SBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	steady	_	JJ	JJ	_	13	NMOD	_	_
11	state	_	NN	NN	_	13	NMOD	_	_
12	mRNA	_	NN	NN	_	13	NMOD	_	_
13	levels	_	NNS	NNS	_	8	COORD	_	_
14	are	_	VBP	VBP	_	0	ROOT-S	_	_
15	increased	_	VBN	VBN	_	14	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	response	_	NN	NN	_	16	DEP	_	_
18	to	_	TO	TO	_	16	DEP	_	_
19	lipopolysaccharide	_	NN	NN	_	16	PMOD	_	_
20	,	_	,	,	_	15	P	_	_
21	predominantly	_	RB	RB	_	22	PMOD	_	_
22	as	_	IN	IN	_	15	ADV	_	_
23	a	_	DT	DT	_	24	NMOD	_	_
24	result	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	increased	_	VBN	VBN	_	27	NMOD	_	_
27	transcription	_	NN	NN	_	25	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	32	NMOD	_	_
30	interleukin	_	NN	NN	_	32	NMOD	_	_
31	1beta	_	NN	NN	_	32	NMOD	_	_
32	gene	_	NN	NN	_	28	PMOD	_	_
33	.	_	.	.	_	14	P	_	_

1	Expression	_	NN	NN	_	19	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	interleukin	_	NN	NN	_	4	NMOD	_	_
4	1beta	_	NN	NN	_	2	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	other	_	JJ	JJ	_	7	NMOD	_	_
7	cytokines	_	NNS	NNS	_	4	COORD	_	_
8	,	_	,	,	_	7	P	_	_
9	such	_	JJ	JJ	_	10	DEP	_	_
10	as	_	IN	IN	_	7	NMOD	_	_
11	interleukin	_	NN	NN	_	10	PMOD	_	_
12	6	_	CD	CD	_	11	NMOD	_	_
13	and	_	CC	CC	_	11	CC	_	_
14	tumor	_	NN	NN	_	17	NMOD	_	_
15	necrosis	_	NN	NN	_	17	NMOD	_	_
16	factor	_	NN	NN	_	17	NMOD	_	_
17	alpha	_	NN	NN	_	11	COORD	_	_
18	,	_	,	,	_	7	P	_	_
19	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
20	been	_	VBN	VBN	_	19	VC	_	_
21	shown	_	VBN	VBN	_	20	VC	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	be	_	VB	VB	_	21	OBJ	_	_
24	dependent	_	JJ	JJ	_	23	PRD	_	_
25	on	_	IN	IN	_	24	AMOD	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	activation	_	NN	NN	_	25	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	transcription	_	NN	NN	_	31	NMOD	_	_
31	factor	_	NN	NN	_	28	PMOD	_	_
32	,	_	,	,	_	31	P	_	_
33	NFkappaB	_	NN	NN	_	31	NMOD	_	_
34	.	_	.	.	_	19	P	_	_

1	Since	_	IN	IN	_	20	ADV	_	_
2	recent	_	JJ	JJ	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	4	SBJ	_	_
4	have	_	VBP	VBP	_	1	VMOD	_	_
5	shown	_	VBN	VBN	_	4	VC	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	lipopolysaccharide-induced	_	JJ	JJ	_	10	NMOD	_	_
8	tyrosine	_	NN	NN	_	10	NMOD	_	_
9	kinase	_	NN	NN	_	10	NMOD	_	_
10	activation	_	NN	NN	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	6	VMOD	_	_
12	not	_	RB	RB	_	11	VMOD	_	_
13	required	_	VBN	VBN	_	11	VC	_	_
14	for	_	IN	IN	_	13	ADV	_	_
15	NFkappaB	_	NN	NN	_	17	NMOD	_	_
16	nuclear	_	JJ	JJ	_	17	NMOD	_	_
17	translocation	_	NN	NN	_	14	PMOD	_	_
18	,	_	,	,	_	20	P	_	_
19	we	_	PRP	PRP	_	20	SBJ	_	_
20	sought	_	VBD	VBD	_	0	ROOT-S	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	determine	_	VB	VB	_	20	OBJ	_	_
23	whether	_	IN	IN	_	22	OBJ	_	_
24	NFkappaB	_	NN	NN	_	33	SBJ	_	_
25	translocated	_	VBN	VBN	_	24	NMOD	_	_
26	in	_	IN	IN	_	25	ADV	_	_
27	the	_	DT	DT	_	26	DEP	_	_
28	absence	_	NN	NN	_	26	DEP	_	_
29	of	_	IN	IN	_	26	DEP	_	_
30	tyrosine	_	NN	NN	_	32	NMOD	_	_
31	kinase	_	NN	NN	_	32	NMOD	_	_
32	activity	_	NN	NN	_	26	PMOD	_	_
33	was	_	VBD	VBD	_	23	VMOD	_	_
34	active	_	JJ	JJ	_	33	PRD	_	_
35	in	_	IN	IN	_	33	ADV	_	_
36	stimulating	_	VBG	VBG	_	35	PMOD	_	_
37	transcription	_	NN	NN	_	36	OBJ	_	_
38	.	_	.	.	_	20	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	in	_	IN	IN	_	21	ADV	_	_
7	the	_	DT	DT	_	11	NMOD	_	_
8	human	_	JJ	JJ	_	11	NMOD	_	_
9	pro-monocytic	_	JJ	JJ	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	line	_	NN	NN	_	6	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	THP-1	_	NN	NN	_	11	NMOD	_	_
14	,	_	,	,	_	21	P	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	lipopolysaccharide-induced	_	JJ	JJ	_	17	NMOD	_	_
17	expression	_	NN	NN	_	21	SBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	interleukin	_	NN	NN	_	20	NMOD	_	_
20	1beta	_	NN	NN	_	18	PMOD	_	_
21	is	_	VBZ	VBZ	_	4	VMOD	_	_
22	dependent	_	JJ	JJ	_	21	PRD	_	_
23	on	_	IN	IN	_	22	AMOD	_	_
24	tyrosine	_	NN	NN	_	26	NMOD	_	_
25	kinase	_	NN	NN	_	26	NMOD	_	_
26	activation	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	Tyrosine	_	NN	NN	_	2	NMOD	_	_
2	kinases	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	required	_	VBN	VBN	_	3	VC	_	_
6	for	_	IN	IN	_	5	ADV	_	_
7	lipopolysaccharide-mediated	_	JJ	JJ	_	9	NMOD	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	translocation	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	NFkappaB	_	NN	NN	_	10	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	18	ADV	_	_
2	,	_	,	,	_	18	P	_	_
3	in	_	IN	IN	_	18	ADV	_	_
4	the	_	DT	DT	_	3	DEP	_	_
5	absence	_	NN	NN	_	3	DEP	_	_
6	of	_	IN	IN	_	3	DEP	_	_
7	tyrosine	_	NN	NN	_	9	NMOD	_	_
8	kinase	_	NN	NN	_	9	NMOD	_	_
9	activity	_	NN	NN	_	3	PMOD	_	_
10	,	_	,	,	_	18	P	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	ability	_	NN	NN	_	18	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	NFkappaB	_	NN	NN	_	13	PMOD	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	stimulate	_	VB	VB	_	12	NMOD	_	_
17	transcription	_	NN	NN	_	16	OBJ	_	_
18	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
19	impaired	_	JJ	JJ	_	18	PRD	_	_
20	.	_	.	.	_	18	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	inhibition	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	transcription	_	NN	NN	_	3	PMOD	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	specific	_	JJ	JJ	_	5	PRD	_	_
7	for	_	IN	IN	_	6	AMOD	_	_
8	NFkappaB	_	NN	NN	_	7	PMOD	_	_
9	;	_	:	:	_	5	P	_	_
10	in	_	IN	IN	_	20	ADV	_	_
11	the	_	DT	DT	_	10	DEP	_	_
12	absence	_	NN	NN	_	10	DEP	_	_
13	of	_	IN	IN	_	10	DEP	_	_
14	tyrosine	_	NN	NN	_	16	NMOD	_	_
15	kinase	_	NN	NN	_	16	NMOD	_	_
16	activity	_	NN	NN	_	10	PMOD	_	_
17	,	_	,	,	_	20	P	_	_
18	AP-1-dependent	_	JJ	JJ	_	19	NMOD	_	_
19	transcription	_	NN	NN	_	20	SBJ	_	_
20	is	_	VBZ	VBZ	_	5	VC	_	_
21	enhanced	_	VBN	VBN	_	20	VC	_	_
22	.	_	.	.	_	20	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	,	_	,	,	_	11	P	_	_
6	while	_	IN	IN	_	7	NMOD	_	_
7	lipopolysaccharide-induced	_	JJ	JJ	_	11	SBJ	_	_
8	expression	_	NN	NN	_	7	NMOD	_	_
9	of	_	IN	IN	_	10	NMOD	_	_
10	inflammatory	_	JJ	JJ	_	8	PMOD	_	_
11	mediators	_	NNS	NNS	_	20	ADV	_	_
12	requires	_	VBZ	VBZ	_	14	NMOD	_	_
13	tyrosine	_	NN	NN	_	14	NMOD	_	_
14	kinase	_	NN	NN	_	11	OBJ	_	_
15	activity	_	NN	NN	_	20	VMOD	_	_
16	,	_	,	,	_	18	P	_	_
17	tyrosine	_	NN	NN	_	18	NMOD	_	_
18	kinase	_	NN	NN	_	20	SBJ	_	_
19	activity	_	NN	NN	_	20	VMOD	_	_
20	is	_	VBZ	VBZ	_	4	VMOD	_	_
21	not	_	RB	RB	_	20	PRD	_	_
22	obligatory	_	JJ	JJ	_	21	AMOD	_	_
23	for	_	IN	IN	_	25	NMOD	_	_
24	lipopolysaccharide	_	NN	NN	_	25	NMOD	_	_
25	signal	_	NN	NN	_	22	PMOD	_	_
26	transduction	_	NN	NN	_	3	VMOD	_	_

1	LYSP100-associated	_	JJ	JJ	_	3	NMOD	_	_
2	nuclear	_	JJ	JJ	_	3	NMOD	_	_
3	domains	_	NNS	NNS	_	0	ROOT-FRAG	_	_
4	(	_	(	(	_	5	P	_	_
5	LANDs	_	NNS	NNS	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	:	_	:	:	_	3	P	_	_
8	description	_	NN	NN	_	3	NMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	new	_	JJ	JJ	_	12	NMOD	_	_
12	class	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	subnuclear	_	JJ	JJ	_	15	NMOD	_	_
15	structures	_	NNS	NNS	_	13	PMOD	_	_
16	and	_	CC	CC	_	8	CC	_	_
17	their	_	PRP$	PRP$	_	18	NMOD	_	_
18	relationship	_	NN	NN	_	8	COORD	_	_
19	to	_	TO	TO	_	18	NMOD	_	_
20	PML	_	NN	NN	_	22	NMOD	_	_
21	nuclear	_	JJ	JJ	_	22	NMOD	_	_
22	bodies	_	NNS	NNS	_	19	PMOD	_	_
23	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	PML	_	NN	NN	_	3	NMOD	_	_
3	gene	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	fused	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	the	_	DT	DT	_	16	NMOD	_	_
8	retinoic	_	JJ	JJ	_	11	NMOD	_	_
9	acid	_	NN	NN	_	11	NMOD	_	_
10	receptor	_	NN	NN	_	11	NMOD	_	_
11	alpha	_	NN	NN	_	16	NMOD	_	_
12	(	_	(	(	_	14	P	_	_
13	RAR	_	NN	NN	_	14	NMOD	_	_
14	alpha	_	NN	NN	_	11	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	gene	_	NN	NN	_	6	PMOD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	t-LRB-15;17-RRB-	_	NN	NN	_	17	PMOD	_	_
19	acute	_	JJ	JJ	_	21	NMOD	_	_
20	promyelocytic	_	JJ	JJ	_	21	NMOD	_	_
21	leukemia	_	NN	NN	_	18	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	APL	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	,	_	,	,	_	5	P	_	_
26	creating	_	VBG	VBG	_	5	OBJ	_	_
27	a	_	DT	DT	_	31	NMOD	_	_
28	PML-RAR	_	NN	NN	_	31	NMOD	_	_
29	alpha	_	NN	NN	_	31	NMOD	_	_
30	fusion	_	NN	NN	_	31	NMOD	_	_
31	oncoprotein	_	NN	NN	_	26	OBJ	_	_
32	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	PML	_	NN	NN	_	4	NMOD	_	_
3	gene	_	NN	NN	_	4	NMOD	_	_
4	product	_	NN	NN	_	5	SBJ	_	_
5	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	been	_	VBN	VBN	_	5	VC	_	_
7	localized	_	JJ	JJ	_	6	VC	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	subnuclear	_	JJ	JJ	_	11	NMOD	_	_
10	dot-like	_	JJ	JJ	_	11	NMOD	_	_
11	structures	_	NNS	NNS	_	8	PMOD	_	_
12	variously	_	RB	RB	_	13	ADV	_	_
13	termed	_	VBN	VBN	_	11	NMOD	_	_
14	PODs	_	NNS	NNS	_	13	OBJ	_	_
15	,	_	,	,	_	14	P	_	_
16	ND10s	_	NNS	NNS	_	14	COORD	_	_
17	,	_	,	,	_	14	P	_	_
18	Kr	_	NN	NN	_	19	NMOD	_	_
19	bodies	_	NNS	NNS	_	14	COORD	_	_
20	,	_	,	,	_	14	P	_	_
21	or	_	CC	CC	_	14	CC	_	_
22	PML	_	NN	NN	_	24	NMOD	_	_
23	nuclear	_	JJ	JJ	_	24	NMOD	_	_
24	bodies	_	NNS	NNS	_	14	COORD	_	_
25	(	_	(	(	_	27	P	_	_
26	PML	_	NN	NN	_	27	NMOD	_	_
27	NBs	_	NNS	NNS	_	24	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	present	_	JJ	JJ	_	3	NMOD	_	_
3	study	_	NN	NN	_	4	SBJ	_	_
4	describes	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	cloning	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	lymphoid-restricted	_	JJ	JJ	_	10	NMOD	_	_
10	gene	_	NN	NN	_	7	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	LYSP100	_	NN	NN	_	10	NMOD	_	_
13	,	_	,	,	_	10	P	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	is	_	VBZ	VBZ	_	10	NMOD	_	_
16	homologous	_	JJ	JJ	_	15	PRD	_	_
17	to	_	TO	TO	_	16	AMOD	_	_
18	another	_	DT	DT	_	19	NMOD	_	_
19	protein	_	NN	NN	_	17	PMOD	_	_
20	that	_	WDT	WDT	_	21	SBJ	_	_
21	localizes	_	VBZ	VBZ	_	19	NMOD	_	_
22	to	_	TO	TO	_	21	ADV	_	_
23	PML	_	NN	NN	_	24	NMOD	_	_
24	NBs	_	NNS	NNS	_	22	PMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	SP100	_	NN	NN	_	24	NMOD	_	_
27	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	addition	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	SP100	_	NN	NN	_	6	NMOD	_	_
5	homology	_	NN	NN	_	6	NMOD	_	_
6	regions	_	NNS	NNS	_	1	PMOD	_	_
7	,	_	,	,	_	12	P	_	_
8	one	_	CD	CD	_	11	NMOD	_	_
9	LYSP100	_	NN	NN	_	11	NMOD	_	_
10	cDNA	_	NN	NN	_	11	NMOD	_	_
11	isoform	_	NN	NN	_	12	SBJ	_	_
12	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	bromodomain	_	NN	NN	_	12	OBJ	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	PHD\/TTC	_	NN	NN	_	18	NMOD	_	_
18	domain	_	NN	NN	_	14	COORD	_	_
19	,	_	,	,	_	14	P	_	_
20	which	_	WDT	WDT	_	21	SBJ	_	_
21	are	_	VBP	VBP	_	14	NMOD	_	_
22	present	_	JJ	JJ	_	21	PRD	_	_
23	in	_	IN	IN	_	22	AMOD	_	_
24	a	_	DT	DT	_	25	NMOD	_	_
25	variety	_	NN	NN	_	23	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	transcriptional	_	JJ	JJ	_	29	NMOD	_	_
28	regulatory	_	JJ	JJ	_	29	NMOD	_	_
29	proteins	_	NNS	NNS	_	26	PMOD	_	_
30	.	_	.	.	_	12	P	_	_

1	By	_	IN	IN	_	5	ADV	_	_
2	immunofluorescence	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	LYSP100	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	localized	_	JJ	JJ	_	5	VC	_	_
7	to	_	TO	TO	_	6	ADV	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	dots	_	NNS	NNS	_	7	PMOD	_	_
10	that	_	WDT	WDT	_	11	SBJ	_	_
11	were	_	VBD	VBD	_	9	NMOD	_	_
12	surprisingly	_	RB	RB	_	11	ADV	_	_
13	largely	_	RB	RB	_	14	AMOD	_	_
14	nonoverlapping	_	JJ	JJ	_	11	PRD	_	_
15	with	_	IN	IN	_	14	AMOD	_	_
16	PML	_	NN	NN	_	17	NMOD	_	_
17	NBs	_	NNS	NNS	_	15	PMOD	_	_
18	.	_	.	.	_	5	P	_	_

1	However	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	minority	_	NN	NN	_	10	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	LYSP100	_	NN	NN	_	8	NMOD	_	_
7	nuclear	_	JJ	JJ	_	8	NMOD	_	_
8	dots	_	NNS	NNS	_	5	PMOD	_	_
9	exactly	_	RB	RB	_	10	ADV	_	_
10	colocalized	_	VBD	VBD	_	0	ROOT-S	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	PML	_	NN	NN	_	11	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	SP100	_	NN	NN	_	12	COORD	_	_
15	.	_	.	.	_	10	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	term	_	VBP	VBP	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	LYSP100	_	NN	NN	_	5	NMOD	_	_
5	structures	_	NNS	NNS	_	7	SBJ	_	_
6	"	_	``	``	_	7	P	_	_
7	LANDs	_	NNS	NNS	_	2	OBJ	_	_
8	,	_	,	,	_	2	P	_	_
9	"	_	''	''	_	2	P	_	_
10	for	_	IN	IN	_	2	ADV	_	_
11	LYSP100-associated	_	JJ	JJ	_	13	NMOD	_	_
12	nuclear	_	JJ	JJ	_	13	NMOD	_	_
13	domains	_	NNS	NNS	_	10	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	Although	_	IN	IN	_	11	ADV	_	_
2	LYSP100	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	1	VMOD	_	_
4	expressed	_	VBN	VBN	_	3	VC	_	_
5	only	_	RB	RB	_	6	DEP	_	_
6	in	_	IN	IN	_	4	ADV	_	_
7	lymphoid	_	JJ	JJ	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	,	_	,	,	_	11	P	_	_
10	LANDs	_	NNS	NNS	_	11	SBJ	_	_
11	could	_	MD	MD	_	0	ROOT-S	_	_
12	be	_	VB	VB	_	11	VC	_	_
13	visualized	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	HeLa	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	by	_	IN	IN	_	13	LGS	_	_
18	transfection	_	NN	NN	_	17	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	LYSP100	_	NN	NN	_	22	NMOD	_	_
22	cDNA	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	11	P	_	_

1	Immunoelectron	_	NN	NN	_	2	NMOD	_	_
2	microscopy	_	NN	NN	_	3	SBJ	_	_
3	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
4	LANDs	_	NNS	NNS	_	6	SBJ	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	be	_	VB	VB	_	3	OBJ	_	_
7	globular	_	JJ	JJ	_	10	NMOD	_	_
8	,	_	,	,	_	7	P	_	_
9	electron-dense	_	JJ	JJ	_	7	COORD	_	_
10	structures	_	NNS	NNS	_	6	PRD	_	_
11	morphologically	_	RB	RB	_	12	AMOD	_	_
12	distinct	_	JJ	JJ	_	10	NMOD	_	_
13	from	_	IN	IN	_	12	AMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	annular	_	JJ	JJ	_	16	NMOD	_	_
16	structures	_	NNS	NNS	_	13	PMOD	_	_
17	characteristic	_	JJ	JJ	_	16	NMOD	_	_
18	of	_	IN	IN	_	17	AMOD	_	_
19	PML	_	NN	NN	_	20	NMOD	_	_
20	NBs	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	LANDs	_	NNS	NNS	_	2	SBJ	_	_
2	were	_	VBD	VBD	_	0	ROOT-S	_	_
3	most	_	RBS	RBS	_	4	AMOD	_	_
4	often	_	RB	RB	_	2	TMP	_	_
5	found	_	VBN	VBN	_	2	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	nucleoplasm	_	NN	NN	_	6	PMOD	_	_
9	,	_	,	,	_	2	P	_	_
10	but	_	CC	CC	_	2	CC	_	_
11	were	_	VBD	VBD	_	2	COORD	_	_
12	also	_	RB	RB	_	11	ADV	_	_
13	found	_	VBN	VBN	_	11	VC	_	_
14	at	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	nuclear	_	JJ	JJ	_	17	NMOD	_	_
17	membrane	_	NN	NN	_	14	PMOD	_	_
18	and	_	CC	CC	_	14	CC	_	_
19	in	_	IN	IN	_	14	COORD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	cytoplasm	_	NN	NN	_	19	PMOD	_	_
22	,	_	,	,	_	2	P	_	_
23	suggesting	_	VBG	VBG	_	2	VC	_	_
24	that	_	IN	IN	_	23	OBJ	_	_
25	these	_	DT	DT	_	26	NMOD	_	_
26	structures	_	NNS	NNS	_	27	SBJ	_	_
27	may	_	MD	MD	_	24	VMOD	_	_
28	traffic	_	VBP	VBP	_	27	VC	_	_
29	between	_	IN	IN	_	28	ADV	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	cytoplasm	_	NN	NN	_	29	PMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	the	_	DT	DT	_	34	NMOD	_	_
34	nucleus	_	NN	NN	_	31	COORD	_	_
35	.	_	.	.	_	2	P	_	_

1	By	_	IN	IN	_	11	ADV	_	_
2	double-immunogold	_	JJ	JJ	_	3	NMOD	_	_
3	labeling	_	NN	NN	_	1	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	PML	_	NN	NN	_	4	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	LYSP100	_	NN	NN	_	5	COORD	_	_
8	,	_	,	,	_	11	P	_	_
9	some	_	DT	DT	_	10	NMOD	_	_
10	LANDs	_	NNS	NNS	_	11	SBJ	_	_
11	were	_	VBD	VBD	_	0	ROOT-S	_	_
12	shown	_	VBN	VBN	_	11	VC	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	contain	_	VB	VB	_	12	OBJ	_	_
15	both	_	CC	CC	_	16	CC	_	_
16	PML	_	NN	NN	_	14	OBJ	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	LYSP100	_	NN	NN	_	16	COORD	_	_
19	.	_	.	.	_	11	P	_	_

1	Thus	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	PML	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	localized	_	JJ	JJ	_	10	VMOD	_	_
6	to	_	TO	TO	_	10	NMOD	_	_
7	a	_	DT	DT	_	10	NMOD	_	_
8	second	_	JJ	JJ	_	10	NMOD	_	_
9	subnuclear	_	JJ	JJ	_	10	NMOD	_	_
10	domain	_	NN	NN	_	4	VC	_	_
11	that	_	WDT	WDT	_	12	SBJ	_	_
12	is	_	VBZ	VBZ	_	10	NMOD	_	_
13	morphologically	_	RB	RB	_	12	PRD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	biochemically	_	RB	RB	_	13	COORD	_	_
16	distinct	_	JJ	JJ	_	13	AMOD	_	_
17	from	_	IN	IN	_	13	AMOD	_	_
18	PML	_	NN	NN	_	19	NMOD	_	_
19	NBs	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	4	P	_	_

1	Abnormalities	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	p16	_	NN	NN	_	8	NMOD	_	_
4	,	_	,	,	_	3	P	_	_
5	p15	_	NN	NN	_	3	COORD	_	_
6	and	_	CC	CC	_	3	CC	_	_
7	CDK4	_	NN	NN	_	3	COORD	_	_
8	genes	_	NNS	NNS	_	2	PMOD	_	_
9	in	_	IN	IN	_	1	NMOD	_	_
10	recurrent	_	JJ	JJ	_	12	NMOD	_	_
11	malignant	_	JJ	JJ	_	12	NMOD	_	_
12	astrocytomas	_	NNS	NNS	_	9	PMOD	_	_
13	.	_	.	.	_	1	P	_	_

1	Abnormalities	_	NNS	NNS	_	21	SBJ	_	_
2	in	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	9	NMOD	_	_
4	p16	_	NN	NN	_	9	NMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	p15	_	NN	NN	_	4	COORD	_	_
7	and	_	CC	CC	_	4	CC	_	_
8	CDK4	_	NN	NN	_	4	COORD	_	_
9	genes	_	NNS	NNS	_	2	PMOD	_	_
10	that	_	WDT	WDT	_	11	SBJ	_	_
11	regulate	_	VBP	VBP	_	9	NMOD	_	_
12	transition	_	NN	NN	_	11	OBJ	_	_
13	through	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	G1	_	NN	NN	_	16	NMOD	_	_
16	phase	_	NN	NN	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	cycle	_	NN	NN	_	17	PMOD	_	_
21	have	_	VBP	VBP	_	0	ROOT-S	_	_
22	been	_	VBN	VBN	_	21	VC	_	_
23	implicated	_	VBN	VBN	_	22	VC	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	malignant	_	JJ	JJ	_	27	NMOD	_	_
27	progression	_	NN	NN	_	24	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	astrocytomas	_	NNS	NNS	_	28	PMOD	_	_
30	.	_	.	.	_	21	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	present	_	JJ	JJ	_	6	NMOD	_	_
6	study	_	NN	NN	_	3	PMOD	_	_
7	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	dysfunction	_	NN	NN	_	14	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	these	_	DT	DT	_	12	NMOD	_	_
12	genes	_	NNS	NNS	_	10	PMOD	_	_
13	also	_	RB	RB	_	14	ADV	_	_
14	occurs	_	VBZ	VBZ	_	8	VMOD	_	_
15	during	_	IN	IN	_	14	TMP	_	_
16	recurrence	_	NN	NN	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	glial	_	JJ	JJ	_	19	NMOD	_	_
19	tumors	_	NNS	NNS	_	17	PMOD	_	_
20	that	_	WDT	WDT	_	21	SBJ	_	_
21	were	_	VBD	VBD	_	19	NMOD	_	_
22	highly	_	RB	RB	_	23	AMOD	_	_
23	malignant	_	JJ	JJ	_	21	PRD	_	_
24	at	_	IN	IN	_	21	ADV	_	_
25	first	_	JJ	JJ	_	26	NMOD	_	_
26	presentation	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	7	P	_	_

1	Analysis	_	NN	NN	_	15	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	10	_	CD	CD	_	5	NMOD	_	_
4	matched	_	VBN	VBN	_	5	NMOD	_	_
5	pairs	_	NNS	NNS	_	2	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	high	_	JJ	JJ	_	10	NMOD	_	_
8	grade	_	NN	NN	_	10	NMOD	_	_
9	malignant	_	JJ	JJ	_	10	NMOD	_	_
10	astrocytomas	_	NNS	NNS	_	6	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	their	_	PRP$	PRP$	_	14	NMOD	_	_
13	subsequent	_	JJ	JJ	_	14	NMOD	_	_
14	recurrences	_	NNS	NNS	_	10	COORD	_	_
15	identified	_	VBD	VBD	_	0	ROOT-S	_	_
16	three	_	CD	CD	_	18	NMOD	_	_
17	distinct	_	JJ	JJ	_	18	NMOD	_	_
18	groups	_	NNS	NNS	_	15	OBJ	_	_
19	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	primary	_	JJ	JJ	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	recurrent	_	JJ	JJ	_	2	COORD	_	_
5	tumors	_	NNS	NNS	_	9	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	Group	_	NN	NN	_	8	NMOD	_	_
8	A	_	NN	NN	_	6	PMOD	_	_
9	did	_	VBD	VBD	_	0	ROOT-S	_	_
10	not	_	RB	RB	_	9	VMOD	_	_
11	show	_	VB	VB	_	9	VC	_	_
12	structural	_	JJ	JJ	_	13	NMOD	_	_
13	alterations	_	NNS	NNS	_	11	OBJ	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	21	NMOD	_	_
16	p16	_	NN	NN	_	21	NMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	p15	_	NN	NN	_	16	COORD	_	_
19	or	_	CC	CC	_	16	CC	_	_
20	CDK4	_	NN	NN	_	16	COORD	_	_
21	genes	_	NNS	NNS	_	14	PMOD	_	_
22	,	_	,	,	_	9	P	_	_
23	whereas	_	IN	IN	_	9	COORD	_	_
24	homozygous	_	JJ	JJ	_	25	NMOD	_	_
25	codeletion	_	NN	NN	_	30	SBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	p16	_	NN	NN	_	26	PMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	p15	_	NN	NN	_	27	COORD	_	_
30	was	_	VBD	VBD	_	9	COORD	_	_
31	observed	_	VBN	VBN	_	30	VC	_	_
32	in	_	IN	IN	_	31	ADV	_	_
33	both	_	CC	CC	_	34	CC	_	_
34	primary	_	JJ	JJ	_	37	NMOD	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	recurrent	_	JJ	JJ	_	34	COORD	_	_
37	tumors	_	NNS	NNS	_	32	PMOD	_	_
38	in	_	IN	IN	_	37	NMOD	_	_
39	Group	_	NN	NN	_	40	NMOD	_	_
40	B	_	NN	NN	_	38	PMOD	_	_
41	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	primary	_	JJ	JJ	_	3	NMOD	_	_
3	tumors	_	NNS	NNS	_	7	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	Group	_	NN	NN	_	6	NMOD	_	_
6	C	_	NN	NN	_	4	PMOD	_	_
7	had	_	VBD	VBD	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	normal	_	JJ	JJ	_	10	NMOD	_	_
10	profile	_	NN	NN	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	p16	_	NN	NN	_	11	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	p15	_	NN	NN	_	12	COORD	_	_
15	and	_	CC	CC	_	12	CC	_	_
16	CDK4	_	NN	NN	_	12	COORD	_	_
17	at	_	IN	IN	_	7	ADV	_	_
18	presentation	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	7	P	_	_

1	Upon	_	IN	IN	_	8	TMP	_	_
2	recurrence	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	8	P	_	_
4	however	_	RB	RB	_	8	ADV	_	_
5	,	_	,	,	_	8	P	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	tumors	_	NNS	NNS	_	8	SBJ	_	_
8	sustained	_	VBD	VBD	_	0	ROOT-S	_	_
9	either	_	CC	CC	_	10	CC	_	_
10	deletion	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	p16	_	NN	NN	_	11	PMOD	_	_
13	alone	_	RB	RB	_	12	NMOD	_	_
14	or	_	CC	CC	_	10	CC	_	_
15	codeletion	_	NN	NN	_	10	COORD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	both	_	CC	CC	_	18	CC	_	_
18	p16	_	NN	NN	_	16	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	p15	_	NN	NN	_	18	COORD	_	_
21	or	_	CC	CC	_	10	CC	_	_
22	amplification	_	NN	NN	_	10	COORD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	CDK4	_	NN	NN	_	23	PMOD	_	_
25	.	_	.	.	_	8	P	_	_

1	Analysis	_	NN	NN	_	20	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	molecular	_	JJ	JJ	_	5	NMOD	_	_
5	differences	_	NNS	NNS	_	2	PMOD	_	_
6	between	_	IN	IN	_	5	NMOD	_	_
7	primary	_	JJ	JJ	_	9	NMOD	_	_
8	anaplastic	_	JJ	JJ	_	9	NMOD	_	_
9	astrocytomas\/glioblastomas	_	NNS	NNS	_	6	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	their	_	PRP$	PRP$	_	13	NMOD	_	_
12	subsequent	_	JJ	JJ	_	13	NMOD	_	_
13	recurrences	_	NNS	NNS	_	9	COORD	_	_
14	,	_	,	,	_	5	P	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	are	_	VBP	VBP	_	5	NMOD	_	_
17	clinically	_	RB	RB	_	16	ADV	_	_
18	indistinguishable	_	JJ	JJ	_	16	PRD	_	_
19	,	_	,	,	_	5	P	_	_
20	may	_	MD	MD	_	0	ROOT-S	_	_
21	provide	_	VB	VB	_	20	VC	_	_
22	better	_	JJR	JJR	_	24	NMOD	_	_
23	therapeutic	_	JJ	JJ	_	24	NMOD	_	_
24	options	_	NNS	NNS	_	21	OBJ	_	_
25	for	_	IN	IN	_	24	NMOD	_	_
26	treatment	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	20	P	_	_

1	{	_	(	(	_	3	P	_	_
2	NGFI-B\/nur77	_	NN	NN	_	3	NMOD	_	_
3	family	_	NN	NN	_	0	ROOT-FRAG	_	_
4	involved	_	VBN	VBN	_	3	NMOD	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	T-cell	_	NN	NN	_	7	NMOD	_	_
7	apoptosis	_	NN	NN	_	5	PMOD	_	_
8	}	_	)	)	_	3	P	_	_

1	NGFI-B\/nur77	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	member	_	NN	NN	_	2	PRD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	steroid	_	NN	NN	_	9	NMOD	_	_
8	receptor	_	NN	NN	_	9	NMOD	_	_
9	superfamily	_	NN	NN	_	5	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	NGFI-B\/nur77	_	NN	NN	_	6	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	its	_	PRP$	PRP$	_	5	NMOD	_	_
4	related	_	JJ	JJ	_	5	NMOD	_	_
5	genes	_	NNS	NNS	_	1	COORD	_	_
6	constitute	_	VBP	VBP	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	family	_	NN	NN	_	6	OBJ	_	_
9	and	_	CC	CC	_	6	CC	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	NGFI-B\/nur77	_	NN	NN	_	12	NMOD	_	_
12	family	_	NN	NN	_	13	SBJ	_	_
13	consists	_	VBZ	VBZ	_	6	COORD	_	_
14	of	_	IN	IN	_	13	ADV	_	_
15	three	_	CD	CD	_	16	NMOD	_	_
16	subtypes	_	NNS	NNS	_	14	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	named	_	VBN	VBN	_	16	NMOD	_	_
19	nur77	_	NN	NN	_	20	NMOD	_	_
20	alpha	_	NN	NN	_	18	OBJ	_	_
21	,	_	,	,	_	20	P	_	_
22	nur77	_	NN	NN	_	23	NMOD	_	_
23	beta	_	NN	NN	_	20	NMOD	_	_
24	,	_	,	,	_	20	P	_	_
25	nur77	_	NN	NN	_	26	NMOD	_	_
26	gamma	_	NN	NN	_	20	NMOD	_	_
27	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	cloned	_	VBD	VBD	_	0	ROOT-S	_	_
3	human	_	JJ	JJ	_	6	NMOD	_	_
4	nur77	_	NN	NN	_	6	NMOD	_	_
5	beta	_	NN	NN	_	6	NMOD	_	_
6	cDNA	_	NN	NN	_	2	OBJ	_	_
7	,	_	,	,	_	6	P	_	_
8	called	_	VBN	VBN	_	6	NMOD	_	_
9	TINUR	_	NN	NN	_	8	OBJ	_	_
10	.	_	.	.	_	2	P	_	_

1	Although	_	IN	IN	_	24	ADV	_	_
2	NGFI-B\/nur77	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	1	VMOD	_	_
4	essential	_	JJ	JJ	_	3	PRD	_	_
5	for	_	IN	IN	_	4	AMOD	_	_
6	TCR-mediated	_	JJ	JJ	_	7	NMOD	_	_
7	apoptosis	_	NN	NN	_	5	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	T-cell	_	NN	NN	_	10	NMOD	_	_
10	hybridomas	_	NNS	NNS	_	8	PMOD	_	_
11	,	_	,	,	_	24	P	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	reports	_	NNS	NNS	_	24	SBJ	_	_
14	on	_	IN	IN	_	13	NMOD	_	_
15	nur77	_	NN	NN	_	17	NMOD	_	_
16	knock-out	_	JJ	JJ	_	17	NMOD	_	_
17	mice	_	NNS	NNS	_	14	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	nur77	_	NN	NN	_	23	NMOD	_	_
20	dominant	_	JJ	JJ	_	23	NMOD	_	_
21	negative	_	JJ	JJ	_	23	NMOD	_	_
22	transgenic	_	JJ	JJ	_	23	NMOD	_	_
23	mice	_	NNS	NNS	_	17	COORD	_	_
24	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
25	that	_	IN	IN	_	24	OBJ	_	_
26	there	_	EX	EX	_	27	SBJ	_	_
27	is	_	VBZ	VBZ	_	25	VMOD	_	_
28	a	_	DT	DT	_	30	NMOD	_	_
29	functional	_	JJ	JJ	_	30	NMOD	_	_
30	redundancy	_	NN	NN	_	27	PRD	_	_
31	among	_	IN	IN	_	27	ADV	_	_
32	NGFI-B\/nur77	_	NN	NN	_	33	NMOD	_	_
33	family	_	NN	NN	_	31	PMOD	_	_
34	.	_	.	.	_	24	P	_	_

1	NGFI-B\/nur77	_	NN	NN	_	2	SBJ	_	_
2	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	to	_	TO	TO	_	2	ADV	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	response	_	NN	NN	_	6	NMOD	_	_
6	element	_	NN	NN	_	3	PMOD	_	_
7	by	_	IN	IN	_	2	ADV	_	_
8	monomer	_	NN	NN	_	7	PMOD	_	_
9	or	_	CC	CC	_	8	CC	_	_
10	heterodimer	_	NN	NN	_	8	COORD	_	_
11	with	_	IN	IN	_	10	NMOD	_	_
12	retinoid	_	NN	NN	_	14	NMOD	_	_
13	X	_	NN	NN	_	14	NMOD	_	_
14	receptor	_	NN	NN	_	11	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	RXR	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	.	_	.	.	_	2	P	_	_

1	Assuming	_	VBG	VBG	_	13	ADV	_	_
2	that	_	IN	IN	_	1	PMOD	_	_
3	9-cis-retinoic	_	JJ	JJ	_	4	NMOD	_	_
4	acid	_	NN	NN	_	8	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	9-cis-RA	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	inhibits	_	VBZ	VBZ	_	2	VMOD	_	_
9	TCR-mediated	_	JJ	JJ	_	10	NMOD	_	_
10	apoptosis	_	NN	NN	_	8	OBJ	_	_
11	,	_	,	,	_	13	P	_	_
12	nur77	_	NNS	NNS	_	13	SBJ	_	_
13	may	_	MD	MD	_	0	ROOT-S	_	_
14	cause	_	VB	VB	_	13	VC	_	_
15	apoptosis	_	NN	NN	_	14	OBJ	_	_
16	by	_	IN	IN	_	14	ADV	_	_
17	monomer	_	NN	NN	_	16	PMOD	_	_
18	in	_	IN	IN	_	14	ADV	_	_
19	the	_	DT	DT	_	18	DEP	_	_
20	absence	_	NN	NN	_	18	DEP	_	_
21	of	_	IN	IN	_	18	DEP	_	_
22	9-cis-RA	_	NN	NN	_	18	PMOD	_	_
23	and	_	CC	CC	_	13	CC	_	_
24	may	_	MD	MD	_	13	COORD	_	_
25	inhibit	_	VB	VB	_	24	VC	_	_
26	apoptosis	_	NN	NN	_	25	OBJ	_	_
27	by	_	IN	IN	_	25	ADV	_	_
28	heterodimer	_	NN	NN	_	27	PMOD	_	_
29	with	_	IN	IN	_	28	NMOD	_	_
30	RXR	_	NN	NN	_	29	PMOD	_	_
31	in	_	IN	IN	_	25	ADV	_	_
32	the	_	DT	DT	_	31	DEP	_	_
33	presence	_	NN	NN	_	31	DEP	_	_
34	of	_	IN	IN	_	31	DEP	_	_
35	9-cis-RA	_	NN	NN	_	31	PMOD	_	_
36	.	_	.	.	_	13	P	_	_

1	Interaction	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	11	NMOD	_	_
4	human	_	JJ	JJ	_	11	NMOD	_	_
5	T-cell	_	NN	NN	_	11	NMOD	_	_
6	lymphotropic	_	JJ	JJ	_	11	NMOD	_	_
7	virus	_	NN	NN	_	11	NMOD	_	_
8	type	_	NN	NN	_	11	NMOD	_	_
9	1	_	CD	CD	_	11	NMOD	_	_
10	tax	_	NN	NN	_	11	NMOD	_	_
11	transactivator	_	NN	NN	_	2	PMOD	_	_
12	with	_	IN	IN	_	1	NMOD	_	_
13	transcription	_	NN	NN	_	15	NMOD	_	_
14	factor	_	NN	NN	_	15	NMOD	_	_
15	IIA	_	NN	NN	_	12	PMOD	_	_
16	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	Tax	_	NN	NN	_	3	NMOD	_	_
3	protein	_	NN	NN	_	14	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	human	_	JJ	JJ	_	9	NMOD	_	_
6	T-cell	_	NN	NN	_	9	NMOD	_	_
7	lymphotropic	_	NN	NN	_	9	NMOD	_	_
8	virus	_	NN	NN	_	9	NMOD	_	_
9	type	_	NN	NN	_	4	PMOD	_	_
10	1	_	CD	CD	_	9	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	HTLV-1	_	NN	NN	_	9	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	a	_	DT	DT	_	18	NMOD	_	_
16	40-kDa	_	JJ	JJ	_	18	NMOD	_	_
17	transcriptional	_	JJ	JJ	_	18	NMOD	_	_
18	activator	_	NN	NN	_	14	PRD	_	_
19	which	_	WDT	WDT	_	20	SBJ	_	_
20	is	_	VBZ	VBZ	_	18	NMOD	_	_
21	critical	_	JJ	JJ	_	20	PRD	_	_
22	for	_	IN	IN	_	21	AMOD	_	_
23	HTLV-1	_	NN	NN	_	25	NMOD	_	_
24	gene	_	NN	NN	_	25	NMOD	_	_
25	regulation	_	NN	NN	_	22	PMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	virus-induced	_	JJ	JJ	_	29	NMOD	_	_
28	cellular	_	JJ	JJ	_	29	NMOD	_	_
29	transformation	_	NN	NN	_	25	COORD	_	_
30	.	_	.	.	_	14	P	_	_

1	Tax	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	localized	_	JJ	JJ	_	2	VC	_	_
4	to	_	TO	TO	_	3	ADV	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	DNA	_	NN	NN	_	4	PMOD	_	_
7	through	_	IN	IN	_	3	ADV	_	_
8	its	_	PRP$	PRP$	_	9	NMOD	_	_
9	interaction	_	NN	NN	_	7	PMOD	_	_
10	with	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	site-specific	_	JJ	JJ	_	13	NMOD	_	_
13	activators	_	NNS	NNS	_	10	PMOD	_	_
14	cyclic	_	JJ	JJ	_	16	AMOD	_	_
15	AMP-responsive	_	JJ	JJ	_	16	AMOD	_	_
16	element-binding	_	JJ	JJ	_	17	NMOD	_	_
17	protein	_	NN	NN	_	13	NMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	NF-kappaB	_	NN	NN	_	17	COORD	_	_
20	,	_	,	,	_	17	P	_	_
21	and	_	CC	CC	_	17	CC	_	_
22	serum	_	NN	NN	_	24	NMOD	_	_
23	response	_	NN	NN	_	24	NMOD	_	_
24	factor	_	NN	NN	_	17	COORD	_	_
25	.	_	.	.	_	2	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	been	_	VBN	VBN	_	2	VC	_	_
4	suggested	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	recruitment	_	NN	NN	_	13	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	Tax	_	NN	NN	_	8	PMOD	_	_
10	to	_	TO	TO	_	7	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	DNA	_	NN	NN	_	10	PMOD	_	_
13	positions	_	VBZ	VBZ	_	5	VMOD	_	_
14	Tax	_	NN	NN	_	13	OBJ	_	_
15	for	_	IN	IN	_	13	ADV	_	_
16	interaction	_	NN	NN	_	15	PMOD	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	basal	_	JJ	JJ	_	21	NMOD	_	_
20	transcriptional	_	JJ	JJ	_	21	NMOD	_	_
21	machinery	_	NN	NN	_	17	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	On	_	IN	IN	_	11	ADV	_	_
2	the	_	DT	DT	_	1	DEP	_	_
3	basis	_	NN	NN	_	1	DEP	_	_
4	of	_	IN	IN	_	1	DEP	_	_
5	several	_	JJ	JJ	_	7	NMOD	_	_
6	independent	_	JJ	JJ	_	7	NMOD	_	_
7	assays	_	NNS	NNS	_	1	PMOD	_	_
8	,	_	,	,	_	11	P	_	_
9	we	_	PRP	PRP	_	11	SBJ	_	_
10	now	_	RB	RB	_	11	TMP	_	_
11	report	_	VBP	VBP	_	0	ROOT-S	_	_
12	a	_	DT	DT	_	16	NMOD	_	_
13	physical	_	JJ	JJ	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	functional	_	JJ	JJ	_	13	COORD	_	_
16	interaction	_	NN	NN	_	11	OBJ	_	_
17	between	_	IN	IN	_	16	NMOD	_	_
18	Tax	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	transcription	_	NN	NN	_	22	NMOD	_	_
22	factor	_	NN	NN	_	18	COORD	_	_
23	,	_	,	,	_	22	P	_	_
24	TFIIA	_	NN	NN	_	22	NMOD	_	_
25	.	_	.	.	_	11	P	_	_

1	First	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	Tax	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	found	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	interact	_	VB	VB	_	5	OBJ	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	the	_	DT	DT	_	14	NMOD	_	_
10	35-kDa	_	JJ	JJ	_	14	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	alpha	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	subunit	_	NN	NN	_	8	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	TFIIA	_	NN	NN	_	15	PMOD	_	_
17	in	_	IN	IN	_	7	ADV	_	_
18	the	_	DT	DT	_	22	NMOD	_	_
19	yeast	_	NN	NN	_	22	NMOD	_	_
20	two-hybrid	_	JJ	JJ	_	22	NMOD	_	_
21	interaction	_	NN	NN	_	22	NMOD	_	_
22	system	_	NN	NN	_	17	PMOD	_	_
23	.	_	.	.	_	4	P	_	_

1	Importantly	_	RB	RB	_	36	ADV	_	_
2	,	_	,	,	_	36	P	_	_
3	two	_	CD	CD	_	6	NMOD	_	_
4	previously	_	RB	RB	_	5	AMOD	_	_
5	characterized	_	VBN	VBN	_	6	NMOD	_	_
6	mutants	_	NNS	NNS	_	36	SBJ	_	_
7	with	_	IN	IN	_	6	NMOD	_	_
8	point	_	NN	NN	_	9	NMOD	_	_
9	mutations	_	NNS	NNS	_	7	PMOD	_	_
10	in	_	IN	IN	_	6	NMOD	_	_
11	Tax	_	NN	NN	_	10	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	M32	_	NN	NN	_	11	COORD	_	_
14	(	_	(	(	_	15	P	_	_
15	Y196A	_	NN	NN	_	13	PRN	_	_
16	,	_	,	,	_	15	P	_	_
17	K197S	_	NN	NN	_	15	NMOD	_	_
18	)	_	)	)	_	15	P	_	_
19	and	_	CC	CC	_	11	CC	_	_
20	M41	_	NN	NN	_	11	COORD	_	_
21	(	_	(	(	_	22	P	_	_
22	H287A	_	NN	NN	_	20	PRN	_	_
23	,	_	,	,	_	22	P	_	_
24	P288S	_	NN	NN	_	22	NMOD	_	_
25	)	_	)	)	_	22	P	_	_
26	,	_	,	,	_	6	P	_	_
27	which	_	WDT	WDT	_	28	SBJ	_	_
28	were	_	VBD	VBD	_	6	NMOD	_	_
29	shown	_	VBN	VBN	_	28	VC	_	_
30	to	_	TO	TO	_	31	VMOD	_	_
31	be	_	VB	VB	_	29	OBJ	_	_
32	defective	_	JJ	JJ	_	31	PRD	_	_
33	in	_	IN	IN	_	31	ADV	_	_
34	Tax-activated	_	JJ	JJ	_	35	NMOD	_	_
35	transcription	_	NN	NN	_	33	PMOD	_	_
36	were	_	VBD	VBD	_	0	ROOT-S	_	_
37	unable	_	JJ	JJ	_	36	PRD	_	_
38	to	_	TO	TO	_	39	VMOD	_	_
39	interact	_	VB	VB	_	37	AMOD	_	_
40	with	_	IN	IN	_	39	ADV	_	_
41	TFIIA	_	NN	NN	_	40	PMOD	_	_
42	in	_	IN	IN	_	39	ADV	_	_
43	this	_	DT	DT	_	44	NMOD	_	_
44	assay	_	NN	NN	_	42	PMOD	_	_
45	.	_	.	.	_	36	P	_	_

1	Second	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	a	_	DT	DT	_	9	NMOD	_	_
4	glutathione-S-transferase	_	NN	NN	_	9	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	GST	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	affinity-binding	_	JJ	JJ	_	9	NMOD	_	_
9	assay	_	NN	NN	_	10	SBJ	_	_
10	showed	_	VBD	VBD	_	0	ROOT-S	_	_
11	that	_	IN	IN	_	10	OBJ	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	interaction	_	NN	NN	_	18	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	holo-TFIIA	_	NN	NN	_	14	PMOD	_	_
16	with	_	IN	IN	_	13	NMOD	_	_
17	GST-Tax	_	NN	NN	_	16	PMOD	_	_
18	was	_	VBD	VBD	_	11	VMOD	_	_
19	20-fold	_	RB	RB	_	20	AMOD	_	_
20	higher	_	JJR	JJR	_	18	PRD	_	_
21	than	_	IN	IN	_	20	AMOD	_	_
22	that	_	DT	DT	_	21	PMOD	_	_
23	observed	_	VBN	VBN	_	22	NMOD	_	_
24	with	_	IN	IN	_	23	ADV	_	_
25	either	_	CC	CC	_	30	CC	_	_
26	the	_	DT	DT	_	30	NMOD	_	_
27	GST-Tax	_	NN	NN	_	30	NMOD	_	_
28	M32	_	NN	NN	_	30	NMOD	_	_
29	activation	_	NN	NN	_	30	NMOD	_	_
30	mutant	_	NN	NN	_	24	PMOD	_	_
31	or	_	CC	CC	_	30	CC	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	GST	_	NN	NN	_	34	NMOD	_	_
34	control	_	NN	NN	_	30	COORD	_	_
35	.	_	.	.	_	10	P	_	_

1	Third	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	coimmunoprecipitation	_	NN	NN	_	5	NMOD	_	_
5	assay	_	NN	NN	_	6	SBJ	_	_
6	showed	_	VBD	VBD	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	in	_	IN	IN	_	17	ADV	_	_
9	HTLV-1-infected	_	JJ	JJ	_	12	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	T	_	NN	NN	_	12	NMOD	_	_
12	lymphocytes	_	NNS	NNS	_	8	PMOD	_	_
13	,	_	,	,	_	17	P	_	_
14	Tax	_	NN	NN	_	17	SBJ	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	TFIIA	_	NN	NN	_	14	COORD	_	_
17	were	_	VBD	VBD	_	7	VMOD	_	_
18	associated	_	VBN	VBN	_	17	VC	_	_
19	.	_	.	.	_	6	P	_	_

1	Finally	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	TFIIA	_	NN	NN	_	4	SBJ	_	_
4	facilitates	_	NNS	NNS	_	0	ROOT-S	_	_
5	Tax	_	NN	NN	_	6	NMOD	_	_
6	transactivation	_	NN	NN	_	4	OBJ	_	_
7	in	_	FW	FW	_	4	ADV	_	_
8	vitro	_	FW	FW	_	7	AMOD	_	_
9	and	_	CC	CC	_	7	CC	_	_
10	in	_	FW	FW	_	7	COORD	_	_
11	vivo	_	FW	FW	_	10	AMOD	_	_
12	.	_	.	.	_	4	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	vitro	_	FW	FW	_	4	NMOD	_	_
3	transcription	_	NN	NN	_	4	NMOD	_	_
4	studies	_	NNS	NNS	_	5	SBJ	_	_
5	showed	_	VBD	VBD	_	0	ROOT-S	_	_
6	reduced	_	VBN	VBN	_	7	NMOD	_	_
7	levels	_	NNS	NNS	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	Tax-activated	_	JJ	JJ	_	10	NMOD	_	_
10	transcription	_	NN	NN	_	8	PMOD	_	_
11	in	_	IN	IN	_	7	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	extracts	_	NNS	NNS	_	11	PMOD	_	_
14	depleted	_	VBN	VBN	_	13	NMOD	_	_
15	of	_	IN	IN	_	14	ADV	_	_
16	TFIIA	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	13	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	13	P	_	_
4	transfection	_	NN	NN	_	13	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	human	_	JJ	JJ	_	8	NMOD	_	_
7	T	_	NN	NN	_	8	NMOD	_	_
8	lymphocytes	_	NNS	NNS	_	5	PMOD	_	_
9	with	_	IN	IN	_	4	NMOD	_	_
10	TFIIA	_	NN	NN	_	12	NMOD	_	_
11	expression	_	NN	NN	_	12	NMOD	_	_
12	vectors	_	NNS	NNS	_	9	PMOD	_	_
13	enhanced	_	VBD	VBD	_	0	ROOT-S	_	_
14	Tax-activated	_	JJ	JJ	_	15	NMOD	_	_
15	transcription	_	NN	NN	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	an	_	DT	DT	_	24	NMOD	_	_
18	HTLV-1	_	NN	NN	_	23	AMOD	_	_
19	long	_	JJ	JJ	_	23	AMOD	_	_
20	terminal	_	JJ	JJ	_	23	AMOD	_	_
21	repeat-chloramphenicol	_	NN	NN	_	23	AMOD	_	_
22	acetyltransferase	_	NN	NN	_	23	AMOD	_	_
23	reporter	_	NN	NN	_	24	NMOD	_	_
24	construct	_	NN	NN	_	16	PMOD	_	_
25	.	_	.	.	_	13	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	study	_	NN	NN	_	3	SBJ	_	_
3	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	interaction	_	NN	NN	_	14	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	Tax	_	NN	NN	_	7	PMOD	_	_
9	with	_	IN	IN	_	6	NMOD	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	transcription	_	NN	NN	_	13	NMOD	_	_
12	factor	_	NN	NN	_	13	NMOD	_	_
13	TFIIA	_	NN	NN	_	9	PMOD	_	_
14	may	_	MD	MD	_	4	VMOD	_	_
15	play	_	VB	VB	_	14	VC	_	_
16	a	_	DT	DT	_	17	NMOD	_	_
17	role	_	NN	NN	_	15	OBJ	_	_
18	in	_	IN	IN	_	15	ADV	_	_
19	Tax-mediated	_	JJ	JJ	_	21	NMOD	_	_
20	transcriptional	_	JJ	JJ	_	21	NMOD	_	_
21	activation	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	Peptide	_	NN	NN	_	2	NMOD	_	_
2	vaccination	_	NN	NN	_	3	SBJ	_	_
3	can	_	MD	MD	_	0	ROOT-S	_	_
4	lead	_	VB	VB	_	3	VC	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	enhanced	_	VBN	VBN	_	8	NMOD	_	_
7	tumor	_	NN	NN	_	8	NMOD	_	_
8	growth	_	NN	NN	_	5	PMOD	_	_
9	through	_	IN	IN	_	4	ADV	_	_
10	specific	_	JJ	JJ	_	13	NMOD	_	_
11	T-cell	_	NN	NN	_	13	NMOD	_	_
12	tolerance	_	NN	NN	_	13	NMOD	_	_
13	induction	_	NN	NN	_	9	PMOD	_	_
14	.	_	.	.	_	3	P	_	_

1	Vaccination	_	NN	NN	_	13	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	synthetic	_	JJ	JJ	_	4	NMOD	_	_
4	peptides	_	NNS	NNS	_	2	PMOD	_	_
5	representing	_	VBG	VBG	_	4	NMOD	_	_
6	cytotoxic	_	JJ	JJ	_	8	NMOD	_	_
7	T	_	NN	NN	_	8	NMOD	_	_
8	lymphocyte	_	NN	NN	_	12	NMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	CTL	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	epitopes	_	NNS	NNS	_	5	OBJ	_	_
13	can	_	MD	MD	_	0	ROOT-S	_	_
14	lead	_	VB	VB	_	13	VC	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	a	_	DT	DT	_	19	NMOD	_	_
17	protective	_	JJ	JJ	_	19	NMOD	_	_
18	CTL-mediated	_	JJ	JJ	_	19	NMOD	_	_
19	immunity	_	NN	NN	_	15	PMOD	_	_
20	against	_	IN	IN	_	19	NMOD	_	_
21	tumors	_	NNS	NNS	_	20	PMOD	_	_
22	or	_	CC	CC	_	21	CC	_	_
23	viruses	_	NNS	NNS	_	21	COORD	_	_
24	.	_	.	.	_	13	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	now	_	RB	RB	_	3	TMP	_	_
3	report	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	vaccination	_	NN	NN	_	32	SBJ	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	CTL	_	NN	NN	_	9	NMOD	_	_
9	epitope	_	NN	NN	_	6	PMOD	_	_
10	derived	_	VBN	VBN	_	9	NMOD	_	_
11	from	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	17	NMOD	_	_
13	human	_	JJ	JJ	_	17	NMOD	_	_
14	adenovirus	_	NN	NN	_	17	NMOD	_	_
15	type	_	NN	NN	_	17	NMOD	_	_
16	5	_	CD	CD	_	17	NMOD	_	_
17	E1A-region	_	NN	NN	_	11	PMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	Ad5E1A234-243	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	,	_	,	,	_	9	P	_	_
22	which	_	WDT	WDT	_	23	SBJ	_	_
23	can	_	MD	MD	_	9	NMOD	_	_
24	serve	_	VB	VB	_	23	VC	_	_
25	as	_	IN	IN	_	24	ADV	_	_
26	a	_	DT	DT	_	27	NMOD	_	_
27	target	_	NN	NN	_	25	PMOD	_	_
28	for	_	IN	IN	_	27	NMOD	_	_
29	tumor-eradicating	_	JJ	JJ	_	30	NMOD	_	_
30	CTL	_	NN	NN	_	28	PMOD	_	_
31	,	_	,	,	_	9	P	_	_
32	enhances	_	VBZ	VBZ	_	4	VMOD	_	_
33	rather	_	RB	RB	_	32	CC	_	_
34	than	_	IN	IN	_	33	DEP	_	_
35	inhibits	_	VBZ	VBZ	_	32	COORD	_	_
36	the	_	DT	DT	_	37	NMOD	_	_
37	growth	_	NN	NN	_	32	OBJ	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	Ad5E1A-expressing	_	JJ	JJ	_	40	NMOD	_	_
40	tumors	_	NNS	NNS	_	38	PMOD	_	_
41	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	adverse	_	JJ	JJ	_	3	NMOD	_	_
3	effect	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	peptide	_	NN	NN	_	6	NMOD	_	_
6	vaccination	_	NN	NN	_	4	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	rapidly	_	RB	RB	_	7	TMP	_	_
9	evoked	_	VBN	VBN	_	7	VC	_	_
10	,	_	,	,	_	7	P	_	_
11	required	_	VBD	VBD	_	7	COORD	_	_
12	low	_	JJ	JJ	_	13	NMOD	_	_
13	doses	_	NNS	NNS	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	peptide	_	NN	NN	_	14	PMOD	_	_
16	(	_	(	(	_	18	P	_	_
17	10	_	CD	CD	_	18	NMOD	_	_
18	micrograms	_	NNS	NNS	_	13	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	,	_	,	,	_	7	P	_	_
21	and	_	CC	CC	_	7	CC	_	_
22	was	_	VBD	VBD	_	7	COORD	_	_
23	achieved	_	VBN	VBN	_	22	VC	_	_
24	by	_	IN	IN	_	23	LGS	_	_
25	a	_	DT	DT	_	26	NMOD	_	_
26	mode	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	peptide	_	NN	NN	_	29	NMOD	_	_
29	delivery	_	NN	NN	_	27	PMOD	_	_
30	that	_	WDT	WDT	_	31	SBJ	_	_
31	induces	_	VBZ	VBZ	_	26	NMOD	_	_
32	protective	_	JJ	JJ	_	34	NMOD	_	_
33	T-cell-mediated	_	JJ	JJ	_	34	NMOD	_	_
34	immunity	_	NN	NN	_	31	OBJ	_	_
35	in	_	IN	IN	_	31	ADV	_	_
36	other	_	JJ	JJ	_	37	NMOD	_	_
37	models	_	NNS	NNS	_	35	PMOD	_	_
38	.	_	.	.	_	7	P	_	_

1	Ad5E1A-specific	_	JJ	JJ	_	3	NMOD	_	_
2	CTL	_	NN	NN	_	3	NMOD	_	_
3	activity	_	NN	NN	_	4	SBJ	_	_
4	could	_	MD	MD	_	0	ROOT-S	_	_
5	no	_	RB	RB	_	4	TMP	_	_
6	longer	_	RB	RB	_	5	AMOD	_	_
7	be	_	VB	VB	_	4	VC	_	_
8	isolated	_	VBN	VBN	_	7	VC	_	_
9	from	_	IN	IN	_	8	ADV	_	_
10	mice	_	NNS	NNS	_	9	PMOD	_	_
11	after	_	IN	IN	_	8	TMP	_	_
12	injection	_	NN	NN	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	Ad5E1A-peptide	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	8	P	_	_
16	indicating	_	VBG	VBG	_	8	OBJ	_	_
17	that	_	IN	IN	_	16	OBJ	_	_
18	tolerization	_	NN	NN	_	23	SBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	Ad5E1A-specific	_	JJ	JJ	_	22	NMOD	_	_
21	CTL	_	NN	NN	_	22	NMOD	_	_
22	activity	_	NN	NN	_	19	PMOD	_	_
23	causes	_	VBZ	VBZ	_	17	VMOD	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	enhanced	_	VBN	VBN	_	27	NMOD	_	_
26	tumor	_	NN	NN	_	27	NMOD	_	_
27	outgrowth	_	NN	NN	_	23	OBJ	_	_
28	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	14	ADV	_	_
2	contrast	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	peptide	_	NN	NN	_	5	NMOD	_	_
5	vaccination	_	NN	NN	_	1	PMOD	_	_
6	,	_	,	,	_	14	P	_	_
7	immunization	_	NN	NN	_	14	SBJ	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	adenovirus	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	expressing	_	VBG	VBG	_	9	NMOD	_	_
12	Ad5E1A	_	NN	NN	_	11	OBJ	_	_
13	,	_	,	,	_	9	P	_	_
14	induced	_	VBD	VBD	_	0	ROOT-S	_	_
15	Ad5E1A-specific	_	JJ	JJ	_	16	NMOD	_	_
16	immunity	_	NN	NN	_	14	OBJ	_	_
17	and	_	CC	CC	_	14	CC	_	_
18	prevented	_	VBD	VBD	_	14	COORD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	outgrowth	_	NN	NN	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	Ad5E1A-expressing	_	JJ	JJ	_	23	NMOD	_	_
23	tumors	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	14	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	immunization	_	NN	NN	_	9	SBJ	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	synthetic	_	JJ	JJ	_	8	NMOD	_	_
8	peptides	_	NNS	NNS	_	6	PMOD	_	_
9	can	_	MD	MD	_	4	VMOD	_	_
10	lead	_	VB	VB	_	9	VC	_	_
11	to	_	TO	TO	_	10	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	elimination	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	anti-tumor	_	JJ	JJ	_	17	NMOD	_	_
16	CTL	_	NN	NN	_	17	NMOD	_	_
17	responses	_	NNS	NNS	_	14	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	important	_	JJ	JJ	_	3	PRD	_	_
5	for	_	IN	IN	_	4	AMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	design	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	safe	_	JJ	JJ	_	11	NMOD	_	_
10	peptide-based	_	JJ	JJ	_	11	NMOD	_	_
11	vaccines	_	NNS	NNS	_	8	PMOD	_	_
12	against	_	IN	IN	_	11	NMOD	_	_
13	tumors	_	NNS	NNS	_	12	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	allogeneic	_	JJ	JJ	_	17	NMOD	_	_
16	organ	_	NN	NN	_	17	NMOD	_	_
17	transplants	_	NNS	NNS	_	13	COORD	_	_
18	,	_	,	,	_	13	P	_	_
19	and	_	CC	CC	_	13	CC	_	_
20	T-cell-mediated	_	JJ	JJ	_	22	NMOD	_	_
21	autoimmune	_	JJ	JJ	_	22	NMOD	_	_
22	diseases	_	NNS	NNS	_	13	COORD	_	_
23	.	_	.	.	_	3	P	_	_

1	Defective	_	JJ	JJ	_	2	NMOD	_	_
2	transcription	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	IL-2	_	NN	NN	_	6	NMOD	_	_
6	gene	_	NN	NN	_	3	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	associated	_	VBN	VBN	_	7	VC	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	impaired	_	JJ	JJ	_	11	NMOD	_	_
11	expression	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	c-Fos	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	FosB	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	13	P	_	_
17	and	_	CC	CC	_	13	CC	_	_
18	JunB	_	NN	NN	_	13	COORD	_	_
19	in	_	IN	IN	_	11	NMOD	_	_
20	anergic	_	JJ	JJ	_	24	NMOD	_	_
21	T	_	NN	NN	_	24	NMOD	_	_
22	helper	_	NN	NN	_	24	NMOD	_	_
23	1	_	CD	CD	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	19	PMOD	_	_
25	.	_	.	.	_	7	P	_	_

1	Anergic	_	JJ	JJ	_	4	NMOD	_	_
2	CD4+	_	JJ	JJ	_	4	NMOD	_	_
3	Th	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	5	SBJ	_	_
5	do	_	VBP	VBP	_	0	ROOT-S	_	_
6	not	_	RB	RB	_	5	VMOD	_	_
7	produce	_	VB	VB	_	5	VC	_	_
8	IL-2	_	NN	NN	_	7	OBJ	_	_
9	when	_	WRB	WRB	_	10	ADV	_	_
10	challenged	_	VBN	VBN	_	7	TMP	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	Ag-pulsed	_	JJ	JJ	_	14	NMOD	_	_
13	accessory	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	11	PMOD	_	_
15	because	_	IN	IN	_	10	ADV	_	_
16	of	_	IN	IN	_	15	DEP	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	transcriptional	_	JJ	JJ	_	19	NMOD	_	_
19	defect	_	NN	NN	_	15	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	work	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	report	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	these	_	DT	DT	_	11	NMOD	_	_
9	anergic	_	JJ	JJ	_	11	NMOD	_	_
10	T	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	12	SBJ	_	_
12	are	_	VBP	VBP	_	7	VMOD	_	_
13	defective	_	JJ	JJ	_	12	PRD	_	_
14	in	_	IN	IN	_	12	ADV	_	_
15	their	_	PRP$	PRP$	_	16	NMOD	_	_
16	ability	_	NN	NN	_	14	PMOD	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	up-regulate	_	VB	VB	_	16	NMOD	_	_
19	protein	_	NN	NN	_	20	NMOD	_	_
20	binding	_	NN	NN	_	18	OBJ	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	transactivation	_	NN	NN	_	20	COORD	_	_
23	at	_	IN	IN	_	20	NMOD	_	_
24	two	_	CD	CD	_	29	NMOD	_	_
25	critical	_	JJ	JJ	_	29	NMOD	_	_
26	IL-2	_	NN	NN	_	29	NMOD	_	_
27	DNA	_	NN	NN	_	29	NMOD	_	_
28	enhancer	_	NN	NN	_	29	NMOD	_	_
29	elements	_	NNS	NNS	_	23	PMOD	_	_
30	:	_	:	:	_	29	P	_	_
31	NF-AT	_	NN	NN	_	29	NMOD	_	_
32	(	_	(	(	_	34	P	_	_
33	nuclear	_	JJ	JJ	_	34	NMOD	_	_
34	factor	_	NN	NN	_	31	PRN	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	activated	_	VBN	VBN	_	38	NMOD	_	_
37	T	_	NN	NN	_	38	NMOD	_	_
38	cells	_	NNS	NNS	_	35	PMOD	_	_
39	;	_	:	:	_	34	P	_	_
40	a	_	DT	DT	_	41	NMOD	_	_
41	sequence	_	NN	NN	_	34	NMOD	_	_
42	that	_	WDT	WDT	_	43	SBJ	_	_
43	binds	_	VBZ	VBZ	_	41	NMOD	_	_
44	a	_	DT	DT	_	53	NMOD	_	_
45	heterotrimeric	_	JJ	JJ	_	53	NMOD	_	_
46	NFATp	_	NN	NN	_	53	NMOD	_	_
47	,	_	,	,	_	46	P	_	_
48	Fos	_	NN	NN	_	46	COORD	_	_
49	,	_	,	,	_	46	P	_	_
50	and	_	CC	CC	_	46	CC	_	_
51	Jun	_	NN	NN	_	46	COORD	_	_
52	protein	_	NN	NN	_	53	NMOD	_	_
53	complex	_	NN	NN	_	43	OBJ	_	_
54	)	_	)	)	_	34	P	_	_
55	and	_	CC	CC	_	31	CC	_	_
56	Activator	_	NN	NN	_	57	NMOD	_	_
57	Protein-1	_	NN	NN	_	31	COORD	_	_
58	(	_	(	(	_	59	P	_	_
59	AP-1	_	NN	NN	_	57	PRN	_	_
60	)	_	)	)	_	59	P	_	_
61	(	_	(	(	_	57	P	_	_
62	that	_	WDT	WDT	_	63	SBJ	_	_
63	binds	_	VBZ	VBZ	_	57	NMOD	_	_
64	Fos	_	NN	NN	_	67	NMOD	_	_
65	and	_	CC	CC	_	64	CC	_	_
66	Jun	_	NN	NN	_	64	COORD	_	_
67	heterodimers	_	NNS	NNS	_	63	OBJ	_	_
68	)	_	)	)	_	57	P	_	_
69	.	_	.	.	_	6	P	_	_

1	Western	_	NN	NN	_	3	NMOD	_	_
2	blot	_	NN	NN	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	nuclear	_	JJ	JJ	_	6	NMOD	_	_
6	extracts	_	NNS	NNS	_	4	PMOD	_	_
7	showed	_	VBD	VBD	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	impaired	_	JJ	JJ	_	12	NMOD	_	_
11	DNA-protein	_	NN	NN	_	12	NMOD	_	_
12	interactions	_	NNS	NNS	_	17	SBJ	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	anergic	_	JJ	JJ	_	16	NMOD	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	13	PMOD	_	_
17	were	_	VBD	VBD	_	8	VMOD	_	_
18	associated	_	VBN	VBN	_	17	VC	_	_
19	with	_	IN	IN	_	18	ADV	_	_
20	poor	_	JJ	JJ	_	21	NMOD	_	_
21	expression	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	27	NMOD	_	_
24	inducible	_	JJ	JJ	_	27	NMOD	_	_
25	AP-1	_	NN	NN	_	27	NMOD	_	_
26	family	_	NN	NN	_	27	NMOD	_	_
27	members	_	NNS	NNS	_	22	PMOD	_	_
28	c-Fos	_	NN	NN	_	27	NMOD	_	_
29	,	_	,	,	_	28	P	_	_
30	FosB	_	NN	NN	_	28	COORD	_	_
31	,	_	,	,	_	28	P	_	_
32	and	_	CC	CC	_	28	CC	_	_
33	JunB	_	NN	NN	_	28	COORD	_	_
34	.	_	.	.	_	7	P	_	_

1	However	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	reduced	_	VBN	VBN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	9	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	these	_	DT	DT	_	8	NMOD	_	_
8	proteins	_	NNS	NNS	_	6	PMOD	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	not	_	RB	RB	_	9	VMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	result	_	NN	NN	_	9	PRD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	a	_	DT	DT	_	17	NMOD	_	_
15	global	_	JJ	JJ	_	17	NMOD	_	_
16	TCR\/CD3-signaling	_	JJ	JJ	_	17	NMOD	_	_
17	defect	_	NN	NN	_	13	PMOD	_	_
18	because	_	IN	IN	_	9	ADV	_	_
19	CD3	_	NN	NN	_	20	NMOD	_	_
20	cross-linking	_	NN	NN	_	21	SBJ	_	_
21	induced	_	VBD	VBD	_	18	VMOD	_	_
22	an	_	DT	DT	_	24	NMOD	_	_
23	equivalent	_	JJ	JJ	_	24	NMOD	_	_
24	increase	_	NN	NN	_	21	OBJ	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	intracellular-free	_	JJ	JJ	_	28	NMOD	_	_
27	calcium	_	NN	NN	_	28	NMOD	_	_
28	ions	_	NNS	NNS	_	25	PMOD	_	_
29	,	_	,	,	_	24	P	_	_
30	as	_	RB	RB	_	24	CC	_	_
31	well	_	RB	RB	_	30	DEP	_	_
32	as	_	IN	IN	_	30	DEP	_	_
33	NFATp	_	NN	NN	_	34	NMOD	_	_
34	dephosphorylation	_	NN	NN	_	24	COORD	_	_
35	,	_	,	,	_	34	P	_	_
36	translocation	_	NN	NN	_	34	COORD	_	_
37	to	_	TO	TO	_	36	NMOD	_	_
38	the	_	DT	DT	_	39	NMOD	_	_
39	nucleus	_	NN	NN	_	37	PMOD	_	_
40	,	_	,	,	_	34	P	_	_
41	and	_	CC	CC	_	34	CC	_	_
42	DNA	_	NN	NN	_	43	NMOD	_	_
43	binding	_	NN	NN	_	34	COORD	_	_
44	in	_	IN	IN	_	21	ADV	_	_
45	both	_	CC	CC	_	46	CC	_	_
46	normal	_	JJ	JJ	_	50	NMOD	_	_
47	and	_	CC	CC	_	46	CC	_	_
48	anergic	_	JJ	JJ	_	46	COORD	_	_
49	T	_	NN	NN	_	50	NMOD	_	_
50	cells	_	NNS	NNS	_	44	PMOD	_	_
51	.	_	.	.	_	9	P	_	_

1	Thus	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	defective	_	JJ	JJ	_	6	NMOD	_	_
4	IL-2	_	NN	NN	_	6	NMOD	_	_
5	gene	_	NN	NN	_	6	NMOD	_	_
6	transcription	_	NN	NN	_	7	SBJ	_	_
7	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	be	_	VB	VB	_	7	OBJ	_	_
10	due	_	JJ	JJ	_	9	PRD	_	_
11	,	_	,	,	_	12	P	_	_
12	at	_	IN	IN	_	10	PMOD	_	_
13	least	_	JJS	JJS	_	12	PMOD	_	_
14	in	_	IN	IN	_	12	PMOD	_	_
15	part	_	NN	NN	_	10	PMOD	_	_
16	,	_	,	,	_	10	P	_	_
17	to	_	TO	TO	_	19	NMOD	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	selective	_	JJ	JJ	_	10	PMOD	_	_
20	block	_	NN	NN	_	19	NMOD	_	_
21	in	_	IN	IN	_	22	NMOD	_	_
22	the	_	DT	DT	_	20	PMOD	_	_
23	expression	_	NN	NN	_	22	NMOD	_	_
24	of	_	IN	IN	_	30	NMOD	_	_
25	the	_	DT	DT	_	30	NMOD	_	_
26	AP-1	_	NN	NN	_	27	NMOD	_	_
27	Fos	_	NN	NN	_	30	NMOD	_	_
28	and	_	CC	CC	_	27	NMOD	_	_
29	Jun	_	NN	NN	_	30	NMOD	_	_
30	family	_	NN	NN	_	23	PMOD	_	_
31	members	_	NNS	NNS	_	22	NMOD	_	_
32	in	_	IN	IN	_	34	NMOD	_	_
33	anergic	_	JJ	JJ	_	34	NMOD	_	_
34	T	_	NN	NN	_	31	PMOD	_	_
35	cells	_	NNS	NNS	_	7	VMOD	_	_

1	Elevated	_	JJ	JJ	_	3	NMOD	_	_
2	cyclic	_	JJ	JJ	_	3	NMOD	_	_
3	AMP	_	NN	NN	_	4	SBJ	_	_
4	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	NF-kappaB-mediated	_	JJ	JJ	_	6	NMOD	_	_
6	transcription	_	NN	NN	_	4	OBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	human	_	JJ	JJ	_	10	NMOD	_	_
9	monocytic	_	JJ	JJ	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	7	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	endothelial	_	JJ	JJ	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	10	COORD	_	_
14	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	NF-kappaB\/Rel	_	NN	NN	_	3	NMOD	_	_
3	family	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	transcription	_	NN	NN	_	6	NMOD	_	_
6	factors	_	NNS	NNS	_	4	PMOD	_	_
7	regulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	inducible	_	JJ	JJ	_	10	NMOD	_	_
10	expression	_	NN	NN	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	many	_	JJ	JJ	_	13	NMOD	_	_
13	genes	_	NNS	NNS	_	11	PMOD	_	_
14	in	_	IN	IN	_	10	NMOD	_	_
15	activated	_	VBN	VBN	_	17	NMOD	_	_
16	human	_	JJ	JJ	_	17	NMOD	_	_
17	monocytes	_	NNS	NNS	_	14	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	endothelial	_	JJ	JJ	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	17	COORD	_	_
21	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	examined	_	VBD	VBD	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	molecular	_	JJ	JJ	_	9	NMOD	_	_
9	mechanism	_	NN	NN	_	6	OBJ	_	_
10	by	_	IN	IN	_	17	ADV	_	_
11	which	_	WDT	WDT	_	10	PMOD	_	_
12	agents	_	NNS	NNS	_	17	SBJ	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	elevate	_	VBP	VBP	_	12	NMOD	_	_
15	intracellular	_	JJ	JJ	_	16	NMOD	_	_
16	cAMP	_	NN	NN	_	14	OBJ	_	_
17	inhibit	_	VBP	VBP	_	9	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	expression	_	NN	NN	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	43	NMOD	_	_
22	tumor	_	NN	NN	_	25	NMOD	_	_
23	necrosis	_	NN	NN	_	25	NMOD	_	_
24	factor	_	NN	NN	_	25	NMOD	_	_
25	alpha	_	NN	NN	_	43	NMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	TNFalpha	_	NN	NN	_	25	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	,	_	,	,	_	25	P	_	_
30	tissue	_	NN	NN	_	31	NMOD	_	_
31	factor	_	NN	NN	_	25	COORD	_	_
32	,	_	,	,	_	25	P	_	_
33	endothelial	_	JJ	JJ	_	36	NMOD	_	_
34	leukocyte	_	NN	NN	_	36	NMOD	_	_
35	adhesion	_	NN	NN	_	36	NMOD	_	_
36	molecule-1	_	NN	NN	_	25	COORD	_	_
37	,	_	,	,	_	25	P	_	_
38	and	_	CC	CC	_	25	CC	_	_
39	vascular	_	JJ	JJ	_	42	NMOD	_	_
40	cell	_	NN	NN	_	42	NMOD	_	_
41	adhesion	_	NN	NN	_	42	NMOD	_	_
42	molecule-1	_	NN	NN	_	25	COORD	_	_
43	genes	_	NNS	NNS	_	20	PMOD	_	_
44	.	_	.	.	_	6	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	forskolin	_	NN	NN	_	15	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	dibutyryl	_	NN	NN	_	5	NMOD	_	_
5	cAMP	_	NN	NN	_	2	COORD	_	_
6	,	_	,	,	_	2	P	_	_
7	which	_	WDT	WDT	_	8	SBJ	_	_
8	elevate	_	VBP	VBP	_	2	NMOD	_	_
9	intracellular	_	JJ	JJ	_	10	NMOD	_	_
10	cAMP	_	NN	NN	_	8	OBJ	_	_
11	by	_	IN	IN	_	8	ADV	_	_
12	independent	_	JJ	JJ	_	13	NMOD	_	_
13	mechanisms	_	NNS	NNS	_	11	PMOD	_	_
14	,	_	,	,	_	2	P	_	_
15	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
16	TNFalpha	_	NN	NN	_	20	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	tissue	_	NN	NN	_	19	NMOD	_	_
19	factor	_	NN	NN	_	16	COORD	_	_
20	expression	_	NN	NN	_	15	OBJ	_	_
21	at	_	IN	IN	_	15	ADV	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	level	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	transcription	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	15	P	_	_

1	Induction	_	NN	NN	_	19	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	NF-kappaB-dependent	_	JJ	JJ	_	5	NMOD	_	_
4	gene	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	2	PMOD	_	_
6	in	_	IN	IN	_	1	NMOD	_	_
7	transiently	_	RB	RB	_	8	AMOD	_	_
8	transfected	_	VBN	VBN	_	12	NMOD	_	_
9	human	_	JJ	JJ	_	12	NMOD	_	_
10	monocytic	_	JJ	JJ	_	12	NMOD	_	_
11	THP-1	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	6	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	human	_	JJ	JJ	_	18	NMOD	_	_
15	umbilical	_	JJ	JJ	_	18	NMOD	_	_
16	vein	_	NN	NN	_	18	NMOD	_	_
17	endothelial	_	JJ	JJ	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	12	COORD	_	_
19	was	_	VBD	VBD	_	0	ROOT-S	_	_
20	inhibited	_	VBN	VBN	_	19	VC	_	_
21	by	_	IN	IN	_	20	ADV	_	_
22	elevated	_	JJ	JJ	_	23	NMOD	_	_
23	cAMP	_	NN	NN	_	21	PMOD	_	_
24	and	_	CC	CC	_	21	CC	_	_
25	by	_	IN	IN	_	21	LGS	_	_
26	overexpression	_	NN	NN	_	25	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	catalytic	_	JJ	JJ	_	30	NMOD	_	_
30	subunit	_	NN	NN	_	27	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	protein	_	NN	NN	_	34	NMOD	_	_
33	kinase	_	NN	NN	_	34	NMOD	_	_
34	A	_	NN	NN	_	31	PMOD	_	_
35	(	_	(	(	_	36	P	_	_
36	PKA	_	NN	NN	_	34	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	.	_	.	.	_	19	P	_	_

1	Elevated	_	JJ	JJ	_	2	NMOD	_	_
2	cAMP	_	NN	NN	_	3	SBJ	_	_
3	did	_	VBD	VBD	_	0	ROOT-S	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	prevent	_	VB	VB	_	3	VC	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	translocation	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	p50\/p65	_	NN	NN	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	c-Rel\/p65	_	NN	NN	_	9	COORD	_	_
12	heterodimers	_	NNS	NNS	_	8	PMOD	_	_
13	,	_	,	,	_	5	P	_	_
14	decrease	_	VB	VB	_	5	COORD	_	_
15	nuclear	_	JJ	JJ	_	16	NMOD	_	_
16	translocation	_	NN	NN	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	p65	_	NN	NN	_	17	PMOD	_	_
19	,	_	,	,	_	5	P	_	_
20	or	_	CC	CC	_	5	CC	_	_
21	significantly	_	RB	RB	_	22	ADV	_	_
22	modify	_	VB	VB	_	5	COORD	_	_
23	TNFalpha-induced	_	JJ	JJ	_	24	NMOD	_	_
24	phosphorylation	_	NN	NN	_	22	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	p65	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	3	P	_	_

1	Functional	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	transcriptional	_	JJ	JJ	_	6	NMOD	_	_
6	activation	_	NN	NN	_	16	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	plasmid	_	NN	NN	_	7	PMOD	_	_
10	containing	_	VBG	VBG	_	9	NMOD	_	_
11	multimerized	_	JJ	JJ	_	13	NMOD	_	_
12	kappaB	_	NN	NN	_	13	NMOD	_	_
13	sites	_	NNS	NNS	_	10	OBJ	_	_
14	by	_	IN	IN	_	6	NMOD	_	_
15	p65	_	NN	NN	_	14	PMOD	_	_
16	was	_	VBD	VBD	_	4	VMOD	_	_
17	inhibited	_	VBN	VBN	_	16	VC	_	_
18	by	_	IN	IN	_	17	ADV	_	_
19	agents	_	NNS	NNS	_	18	PMOD	_	_
20	that	_	IN	IN	_	21	SBJ	_	_
21	elevate	_	VBP	VBP	_	19	NMOD	_	_
22	cAMP	_	NN	NN	_	21	OBJ	_	_
23	and	_	CC	CC	_	18	CC	_	_
24	by	_	IN	IN	_	18	LGS	_	_
25	overexpression	_	NN	NN	_	24	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	catalytic	_	JJ	JJ	_	29	NMOD	_	_
29	subunit	_	NN	NN	_	26	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	PKA	_	NN	NN	_	30	PMOD	_	_
32	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	study	_	NN	NN	_	3	SBJ	_	_
3	indicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	activation	_	NN	NN	_	8	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	PKA	_	NN	NN	_	6	PMOD	_	_
8	reduces	_	VBZ	VBZ	_	4	VMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	induction	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	distinct	_	JJ	JJ	_	14	NMOD	_	_
14	set	_	NN	NN	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	genes	_	NNS	NNS	_	15	PMOD	_	_
17	in	_	IN	IN	_	10	NMOD	_	_
18	monocytes	_	NNS	NNS	_	17	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	endothelial	_	JJ	JJ	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	18	COORD	_	_
22	by	_	IN	IN	_	8	ADV	_	_
23	inhibiting	_	VBG	VBG	_	22	PMOD	_	_
24	NF-kappaB-mediated	_	JJ	JJ	_	25	NMOD	_	_
25	transcription	_	NN	NN	_	23	OBJ	_	_
26	.	_	.	.	_	3	P	_	_

1	Activation	_	NN	NN	_	16	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	human	_	JJ	JJ	_	5	NMOD	_	_
4	monocytic	_	JJ	JJ	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	2	PMOD	_	_
6	by	_	IN	IN	_	1	NMOD	_	_
7	Treponema	_	FW	FW	_	8	NMOD	_	_
8	pallidum	_	FW	FW	_	12	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	Borrelia	_	FW	FW	_	11	NMOD	_	_
11	burgdorferi	_	FW	FW	_	8	COORD	_	_
12	lipoproteins	_	NNS	NNS	_	6	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	synthetic	_	JJ	JJ	_	15	NMOD	_	_
15	lipopeptides	_	NNS	NNS	_	12	COORD	_	_
16	proceeds	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	via	_	IN	IN	_	16	ADV	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	pathway	_	NN	NN	_	17	PMOD	_	_
20	distinct	_	JJ	JJ	_	19	NMOD	_	_
21	from	_	IN	IN	_	20	AMOD	_	_
22	that	_	DT	DT	_	21	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	lipopolysaccharide	_	NN	NN	_	23	PMOD	_	_
25	but	_	CC	CC	_	16	CC	_	_
26	involves	_	VBZ	VBZ	_	16	COORD	_	_
27	the	_	DT	DT	_	31	NMOD	_	_
28	transcriptional	_	JJ	JJ	_	31	NMOD	_	_
29	activator	_	NN	NN	_	31	NMOD	_	_
30	NF-kappa	_	NN	NN	_	31	NMOD	_	_
31	B	_	NN	NN	_	26	OBJ	_	_
32	.	_	.	.	_	16	P	_	_

1	There	_	EX	EX	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	increasing	_	VBG	VBG	_	4	NMOD	_	_
4	evidence	_	NN	NN	_	2	PRD	_	_
5	that	_	IN	IN	_	4	NMOD	_	_
6	lipoproteins	_	NNS	NNS	_	13	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	Treponema	_	FW	FW	_	9	NMOD	_	_
9	pallidum	_	FW	FW	_	7	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	Borrelia	_	FW	FW	_	12	NMOD	_	_
12	burgdorferi	_	FW	FW	_	9	COORD	_	_
13	are	_	VBP	VBP	_	5	VMOD	_	_
14	key	_	JJ	JJ	_	16	NMOD	_	_
15	inflammatory	_	JJ	JJ	_	16	NMOD	_	_
16	mediators	_	NNS	NNS	_	13	PRD	_	_
17	during	_	IN	IN	_	13	TMP	_	_
18	syphilis	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	Lyme	_	NN	NN	_	21	NMOD	_	_
21	disease	_	NN	NN	_	18	COORD	_	_
22	.	_	.	.	_	2	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	principal	_	JJ	JJ	_	3	NMOD	_	_
3	objective	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	present	_	JJ	JJ	_	7	NMOD	_	_
7	study	_	NN	NN	_	4	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	identify	_	VB	VB	_	8	PRD	_	_
11	more	_	RBR	RBR	_	12	AMOD	_	_
12	precisely	_	RB	RB	_	10	ADV	_	_
13	similarities	_	NNS	NNS	_	10	OBJ	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	divergences	_	NNS	NNS	_	13	COORD	_	_
16	among	_	IN	IN	_	13	NMOD	_	_
17	lipopolysaccharide	_	NN	NN	_	27	NMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	LPS	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	-	_	:	:	_	17	P	_	_
22	and	_	CC	CC	_	17	CC	_	_
23	lipoprotein-lipopeptide-induced	_	JJ	JJ	_	17	COORD	_	_
24	immune	_	JJ	JJ	_	27	NMOD	_	_
25	cell	_	NN	NN	_	27	NMOD	_	_
26	signaling	_	NN	NN	_	27	NMOD	_	_
27	events	_	NNS	NNS	_	16	PMOD	_	_
28	.	_	.	.	_	8	P	_	_

1	Like	_	IN	IN	_	28	ADV	_	_
2	LPS	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	28	P	_	_
4	purified	_	VBN	VBN	_	8	NMOD	_	_
5	native	_	JJ	JJ	_	8	NMOD	_	_
6	B.	_	FW	FW	_	8	NMOD	_	_
7	burgdorferi	_	FW	FW	_	8	NMOD	_	_
8	OspA	_	NN	NN	_	28	SBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	synthetic	_	JJ	JJ	_	11	NMOD	_	_
11	analogs	_	NNS	NNS	_	8	COORD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	OspA	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	OspB	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	13	P	_	_
17	and	_	CC	CC	_	13	CC	_	_
18	two	_	CD	CD	_	21	NMOD	_	_
19	T.	_	FW	FW	_	21	NMOD	_	_
20	pallidum	_	FW	FW	_	21	NMOD	_	_
21	lipoproteins	_	NNS	NNS	_	13	COORD	_	_
22	(	_	(	(	_	23	P	_	_
23	Tpp47	_	NN	NN	_	21	PRN	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	Tpp17	_	NN	NN	_	23	COORD	_	_
26	)	_	)	)	_	23	P	_	_
27	all	_	DT	DT	_	8	NMOD	_	_
28	induced	_	VBD	VBD	_	0	ROOT-S	_	_
29	NF-kappa	_	NN	NN	_	31	NMOD	_	_
30	B	_	NN	NN	_	31	NMOD	_	_
31	translocation	_	NN	NN	_	28	OBJ	_	_
32	in	_	IN	IN	_	31	NMOD	_	_
33	THP-1	_	NN	NN	_	36	NMOD	_	_
34	human	_	JJ	JJ	_	36	NMOD	_	_
35	monocytoid	_	NN	NN	_	36	NMOD	_	_
36	cells	_	NNS	NNS	_	32	PMOD	_	_
37	.	_	.	.	_	28	P	_	_

1	Acylation	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	OspA	_	NN	NN	_	2	PMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	synthetic	_	JJ	JJ	_	7	NMOD	_	_
7	peptides	_	NNS	NNS	_	3	COORD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	requisite	_	JJ	JJ	_	8	PRD	_	_
10	for	_	IN	IN	_	9	AMOD	_	_
11	cell	_	NN	NN	_	12	NMOD	_	_
12	activation	_	NN	NN	_	10	PMOD	_	_
13	.	_	.	.	_	8	P	_	_

1	Polymyxin	_	NN	NN	_	2	NMOD	_	_
2	B	_	NN	NN	_	3	SBJ	_	_
3	abrogated	_	VBD	VBD	_	0	ROOT-S	_	_
4	only	_	RB	RB	_	6	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	response	_	NN	NN	_	3	OBJ	_	_
7	to	_	TO	TO	_	6	NMOD	_	_
8	LPS	_	NN	NN	_	7	PMOD	_	_
9	.	_	.	.	_	3	P	_	_

1	By	_	IN	IN	_	19	ADV	_	_
2	using	_	VBG	VBG	_	1	PMOD	_	_
3	70Z\/3-derived	_	JJ	JJ	_	5	NMOD	_	_
4	pre-B-cell	_	NN	NN	_	5	NMOD	_	_
5	lines	_	NNS	NNS	_	2	OBJ	_	_
6	either	_	CC	CC	_	7	CC	_	_
7	lacking	_	VBG	VBG	_	5	NMOD	_	_
8	or	_	CC	CC	_	7	CC	_	_
9	expressing	_	VBG	VBG	_	7	COORD	_	_
10	human	_	JJ	JJ	_	11	NMOD	_	_
11	CD14	_	NN	NN	_	7	OBJ	_	_
12	(	_	(	(	_	15	P	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	LPS	_	NN	NN	_	15	NMOD	_	_
15	receptor	_	NN	NN	_	11	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	,	_	,	,	_	19	P	_	_
18	it	_	PRP	PRP	_	19	SBJ	_	_
19	was	_	VBD	VBD	_	0	ROOT-S	_	_
20	observed	_	VBN	VBN	_	19	VC	_	_
21	that	_	IN	IN	_	20	OBJ	_	_
22	expression	_	NN	NN	_	26	SBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	human	_	JJ	JJ	_	25	NMOD	_	_
25	CD14	_	NN	NN	_	23	PMOD	_	_
26	imparted	_	VBD	VBD	_	21	VMOD	_	_
27	responsiveness	_	NN	NN	_	26	OBJ	_	_
28	to	_	TO	TO	_	27	NMOD	_	_
29	LPS	_	NN	NN	_	28	PMOD	_	_
30	but	_	CC	CC	_	28	CC	_	_
31	not	_	RB	RB	_	32	DEP	_	_
32	to	_	TO	TO	_	28	COORD	_	_
33	OspA	_	NN	NN	_	32	PMOD	_	_
34	or	_	CC	CC	_	33	CC	_	_
35	spirochetal	_	JJ	JJ	_	36	NMOD	_	_
36	lipopeptides	_	NNS	NNS	_	33	COORD	_	_
37	(	_	(	(	_	38	P	_	_
38	assessed	_	VBN	VBN	_	26	PRN	_	_
39	by	_	IN	IN	_	38	ADV	_	_
40	induction	_	NN	NN	_	39	PMOD	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	NF-kappa	_	NN	NN	_	43	NMOD	_	_
43	B	_	NN	NN	_	41	PMOD	_	_
44	and	_	CC	CC	_	40	CC	_	_
45	expression	_	NN	NN	_	40	COORD	_	_
46	of	_	IN	IN	_	45	NMOD	_	_
47	surface	_	NN	NN	_	49	NMOD	_	_
48	immunoglobulin	_	NN	NN	_	49	NMOD	_	_
49	M	_	NN	NN	_	46	PMOD	_	_
50	)	_	)	)	_	38	P	_	_
51	.	_	.	.	_	19	P	_	_

1	Finally	_	RB	RB	_	22	TMP	_	_
2	,	_	,	,	_	22	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	biological	_	JJ	JJ	_	5	NMOD	_	_
5	relevance	_	NN	NN	_	22	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	observation	_	NN	NN	_	6	PMOD	_	_
9	that	_	IN	IN	_	8	NMOD	_	_
10	T.	_	FW	FW	_	12	NMOD	_	_
11	pallidum	_	FW	FW	_	12	NMOD	_	_
12	lipoproteins-lipopeptides	_	NNS	NNS	_	13	SBJ	_	_
13	induce	_	VBP	VBP	_	9	VMOD	_	_
14	both	_	CC	CC	_	16	CC	_	_
15	NF-kappa	_	NN	NN	_	16	NMOD	_	_
16	B	_	NN	NN	_	19	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	cytokine	_	NN	NN	_	16	COORD	_	_
19	production	_	NN	NN	_	13	OBJ	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	monocytes	_	NNS	NNS	_	20	PMOD	_	_
22	was	_	VBD	VBD	_	0	ROOT-S	_	_
23	supported	_	VBN	VBN	_	22	VC	_	_
24	by	_	IN	IN	_	23	LGS	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	ability	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	synthetic	_	JJ	JJ	_	30	NMOD	_	_
30	analogs	_	NNS	NNS	_	27	PMOD	_	_
31	to	_	TO	TO	_	32	VMOD	_	_
32	promote	_	VB	VB	_	26	NMOD	_	_
33	human	_	JJ	JJ	_	36	NMOD	_	_
34	immunodeficiency	_	NN	NN	_	36	NMOD	_	_
35	virus	_	NN	NN	_	36	NMOD	_	_
36	replication	_	NN	NN	_	32	OBJ	_	_
37	in	_	IN	IN	_	32	ADV	_	_
38	chronically	_	RB	RB	_	39	AMOD	_	_
39	infected	_	JJ	JJ	_	42	NMOD	_	_
40	U1	_	NN	NN	_	42	NMOD	_	_
41	monocytoid	_	NN	NN	_	42	NMOD	_	_
42	cells	_	NNS	NNS	_	37	PMOD	_	_
43	;	_	:	:	_	22	P	_	_
44	these	_	DT	DT	_	45	NMOD	_	_
45	observations	_	NNS	NNS	_	47	SBJ	_	_
46	also	_	RB	RB	_	47	ADV	_	_
47	suggest	_	VBP	VBP	_	22	VC	_	_
48	a	_	DT	DT	_	50	NMOD	_	_
49	potential	_	JJ	JJ	_	50	NMOD	_	_
50	mechanism	_	NN	NN	_	47	OBJ	_	_
51	whereby	_	WRB	WRB	_	56	ADV	_	_
52	a	_	DT	DT	_	54	NMOD	_	_
53	syphilitic	_	JJ	JJ	_	54	NMOD	_	_
54	chancre	_	NN	NN	_	55	SBJ	_	_
55	can	_	MD	MD	_	50	NMOD	_	_
56	serve	_	VB	VB	_	55	VC	_	_
57	as	_	IN	IN	_	56	ADV	_	_
58	a	_	DT	DT	_	59	NMOD	_	_
59	cofactor	_	NN	NN	_	57	PMOD	_	_
60	for	_	IN	IN	_	59	NMOD	_	_
61	human	_	JJ	JJ	_	64	NMOD	_	_
62	immunodeficiency	_	NN	NN	_	64	NMOD	_	_
63	virus	_	NN	NN	_	64	NMOD	_	_
64	transmission	_	NN	NN	_	60	PMOD	_	_
65	.	_	.	.	_	47	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	combined	_	JJ	JJ	_	3	NMOD	_	_
3	data	_	NNS	NNS	_	4	SBJ	_	_
4	lend	_	VBP	VBP	_	0	ROOT-S	_	_
5	additional	_	JJ	JJ	_	6	NMOD	_	_
6	support	_	NN	NN	_	4	OBJ	_	_
7	to	_	TO	TO	_	4	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	proposal	_	NN	NN	_	7	PMOD	_	_
10	that	_	IN	IN	_	9	NMOD	_	_
11	spirochetal	_	JJ	JJ	_	12	NMOD	_	_
12	lipoproteins	_	NNS	NNS	_	15	SBJ	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	LPS	_	NN	NN	_	12	COORD	_	_
15	initiate	_	VBP	VBP	_	10	VMOD	_	_
16	monocyte	_	NN	NN	_	17	NMOD	_	_
17	activation	_	NN	NN	_	15	OBJ	_	_
18	via	_	IN	IN	_	15	ADV	_	_
19	different	_	JJ	JJ	_	22	NMOD	_	_
20	cell	_	NN	NN	_	22	NMOD	_	_
21	surface	_	NN	NN	_	22	NMOD	_	_
22	events	_	NNS	NNS	_	18	PMOD	_	_
23	but	_	CC	CC	_	10	CC	_	_
24	that	_	IN	IN	_	10	COORD	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	signaling	_	NN	NN	_	27	NMOD	_	_
27	pathways	_	NNS	NNS	_	29	SBJ	_	_
28	ultimately	_	RB	RB	_	29	ADV	_	_
29	converge	_	VBP	VBP	_	24	VMOD	_	_
30	to	_	TO	TO	_	31	VMOD	_	_
31	produce	_	VB	VB	_	29	OBJ	_	_
32	qualitatively	_	RB	RB	_	33	AMOD	_	_
33	similar	_	JJ	JJ	_	35	NMOD	_	_
34	cellular	_	JJ	JJ	_	35	NMOD	_	_
35	responses	_	NNS	NNS	_	31	OBJ	_	_
36	.	_	.	.	_	4	P	_	_

1	Chronic	_	JJ	JJ	_	7	NMOD	_	_
2	human	_	JJ	JJ	_	7	NMOD	_	_
3	immunodeficiency	_	NN	NN	_	7	NMOD	_	_
4	virus	_	NN	NN	_	7	NMOD	_	_
5	type	_	NN	NN	_	7	NMOD	_	_
6	1	_	CD	CD	_	7	NMOD	_	_
7	infection	_	NN	NN	_	11	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	myeloid	_	JJ	JJ	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	disrupts	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	autoregulatory	_	JJ	JJ	_	14	NMOD	_	_
14	control	_	NN	NN	_	11	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	NF-kappaB\/Rel	_	NN	NN	_	18	NMOD	_	_
18	pathway	_	NN	NN	_	15	PMOD	_	_
19	via	_	IN	IN	_	11	ADV	_	_
20	enhanced	_	VBN	VBN	_	22	NMOD	_	_
21	IkappaBalpha	_	NN	NN	_	22	NMOD	_	_
22	degradation	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	11	P	_	_

1	Productive	_	JJ	JJ	_	10	NMOD	_	_
2	human	_	JJ	JJ	_	5	NMOD	_	_
3	immunodeficiency	_	NN	NN	_	5	NMOD	_	_
4	virus	_	NN	NN	_	5	NMOD	_	_
5	type	_	NN	NN	_	10	NMOD	_	_
6	1	_	CD	CD	_	5	NMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	HIV-1	_	NN	NN	_	5	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	infection	_	NN	NN	_	11	SBJ	_	_
11	causes	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	sustained	_	JJ	JJ	_	15	NMOD	_	_
13	NF-kappaB	_	NN	NN	_	15	NMOD	_	_
14	DNA-binding	_	JJ	JJ	_	15	NMOD	_	_
15	activity	_	NN	NN	_	11	OBJ	_	_
16	in	_	IN	IN	_	11	ADV	_	_
17	chronically	_	RB	RB	_	18	AMOD	_	_
18	infected	_	VBN	VBN	_	20	NMOD	_	_
19	monocytic	_	JJ	JJ	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	16	PMOD	_	_
21	.	_	.	.	_	11	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	direct	_	JJ	JJ	_	4	NMOD	_	_
3	temporal	_	JJ	JJ	_	4	NMOD	_	_
4	correlation	_	NN	NN	_	5	SBJ	_	_
5	exists	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	between	_	IN	IN	_	5	ADV	_	_
7	HIV	_	NN	NN	_	8	NMOD	_	_
8	infection	_	NN	NN	_	6	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	appearance	_	NN	NN	_	8	COORD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	NF-kappaB	_	NN	NN	_	15	NMOD	_	_
14	DNA-binding	_	JJ	JJ	_	15	NMOD	_	_
15	activity	_	NN	NN	_	12	PMOD	_	_
16	in	_	IN	IN	_	11	NMOD	_	_
17	myelomonoblastic	_	JJ	JJ	_	19	NMOD	_	_
18	PLB-985	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	examine	_	VB	VB	_	17	VMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	molecular	_	JJ	JJ	_	5	NMOD	_	_
5	basis	_	NN	NN	_	2	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	constitutive	_	JJ	JJ	_	10	NMOD	_	_
8	NF-kappaB	_	NN	NN	_	10	NMOD	_	_
9	DNA-binding	_	JJ	JJ	_	10	NMOD	_	_
10	activity	_	NN	NN	_	6	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	HIV1	_	NN	NN	_	14	NMOD	_	_
13	-infected	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	11	PMOD	_	_
15	,	_	,	,	_	17	P	_	_
16	we	_	PRP	PRP	_	17	SBJ	_	_
17	analyzed	_	VBD	VBD	_	0	ROOT-S	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	phosphorylation	_	NN	NN	_	17	OBJ	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	turnover	_	NN	NN	_	19	COORD	_	_
22	of	_	IN	IN	_	19	NMOD	_	_
23	IkappaBalpha	_	NN	NN	_	24	NMOD	_	_
24	protein	_	NN	NN	_	22	PMOD	_	_
25	,	_	,	,	_	19	P	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	activity	_	NN	NN	_	19	COORD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	33	NMOD	_	_
30	double-stranded	_	JJ	JJ	_	33	NMOD	_	_
31	RNA-dependent	_	JJ	JJ	_	33	NMOD	_	_
32	protein	_	NN	NN	_	33	NMOD	_	_
33	kinase	_	NN	NN	_	28	PMOD	_	_
34	(	_	(	(	_	35	P	_	_
35	PKR	_	NN	NN	_	33	PRN	_	_
36	)	_	)	)	_	35	P	_	_
37	and	_	CC	CC	_	19	CC	_	_
38	the	_	DT	DT	_	40	NMOD	_	_
39	intracellular	_	JJ	JJ	_	40	NMOD	_	_
40	levels	_	NNS	NNS	_	19	COORD	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	NF-kappaB	_	NN	NN	_	43	NMOD	_	_
43	subunits	_	NNS	NNS	_	41	PMOD	_	_
44	in	_	IN	IN	_	19	NMOD	_	_
45	the	_	DT	DT	_	51	NMOD	_	_
46	PLB-985	_	NN	NN	_	51	NMOD	_	_
47	and	_	CC	CC	_	46	CC	_	_
48	U937	_	NN	NN	_	46	COORD	_	_
49	myeloid	_	JJ	JJ	_	51	NMOD	_	_
50	cell	_	NN	NN	_	51	NMOD	_	_
51	models	_	NNS	NNS	_	44	PMOD	_	_
52	.	_	.	.	_	17	P	_	_

1	HIV-1	_	NN	NN	_	2	NMOD	_	_
2	infection	_	NN	NN	_	3	SBJ	_	_
3	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	constitutive	_	JJ	JJ	_	8	NMOD	_	_
6	,	_	,	,	_	5	P	_	_
7	low-level	_	JJ	JJ	_	5	COORD	_	_
8	expression	_	NN	NN	_	4	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	type	_	NN	NN	_	9	PMOD	_	_
11	1	_	CD	CD	_	10	NMOD	_	_
12	interferon	_	NN	NN	_	10	NMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	IFN	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	at	_	IN	IN	_	8	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	mRNA	_	NN	NN	_	19	NMOD	_	_
19	level	_	NN	NN	_	16	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Constitutive	_	JJ	JJ	_	3	NMOD	_	_
2	PKR	_	NN	NN	_	3	NMOD	_	_
3	activity	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	also	_	RB	RB	_	4	ADV	_	_
6	detected	_	VBN	VBN	_	4	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	HIV-1-infected	_	JJ	JJ	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	7	PMOD	_	_
10	as	_	IN	IN	_	6	ADV	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	result	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	low-level	_	JJ	JJ	_	16	NMOD	_	_
15	IFN	_	NN	NN	_	16	NMOD	_	_
16	production	_	NN	NN	_	13	PMOD	_	_
17	,	_	,	,	_	6	P	_	_
18	since	_	IN	IN	_	6	ADV	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	addition	_	NN	NN	_	27	SBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	anti-IFN-alpha\/beta	_	JJ	JJ	_	23	NMOD	_	_
23	antibody	_	NN	NN	_	21	PMOD	_	_
24	to	_	TO	TO	_	20	NMOD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	24	PMOD	_	_
27	decreased	_	VBD	VBD	_	18	VMOD	_	_
28	PKR	_	NN	NN	_	29	NMOD	_	_
29	expression	_	NN	NN	_	27	OBJ	_	_
30	.	_	.	.	_	4	P	_	_

1	Furthermore	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	analysis	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	IkappaBalpha	_	NN	NN	_	7	NMOD	_	_
7	turnover	_	NN	NN	_	5	PMOD	_	_
8	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
9	an	_	DT	DT	_	11	NMOD	_	_
10	increased	_	VBN	VBN	_	11	NMOD	_	_
11	degradation	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	IkappaBalpha	_	NN	NN	_	12	PMOD	_	_
14	in	_	IN	IN	_	11	NMOD	_	_
15	HIV-1-infected	_	JJ	JJ	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	that	_	WDT	WDT	_	18	SBJ	_	_
18	may	_	MD	MD	_	11	NMOD	_	_
19	account	_	VB	VB	_	18	VC	_	_
20	for	_	IN	IN	_	19	ADV	_	_
21	the	_	DT	DT	_	25	NMOD	_	_
22	constitutive	_	JJ	JJ	_	25	NMOD	_	_
23	DNA	_	NN	NN	_	25	NMOD	_	_
24	binding	_	NN	NN	_	25	NMOD	_	_
25	activity	_	NN	NN	_	20	PMOD	_	_
26	.	_	.	.	_	8	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	dramatic	_	JJ	JJ	_	3	NMOD	_	_
3	increase	_	NN	NN	_	24	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	intracellular	_	JJ	JJ	_	7	NMOD	_	_
7	levels	_	NNS	NNS	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	NF-kappaB	_	NN	NN	_	10	NMOD	_	_
10	subunits	_	NNS	NNS	_	8	PMOD	_	_
11	c-Rel	_	NN	NN	_	10	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	NF-kappaB2	_	NN	NN	_	14	NMOD	_	_
14	p100	_	NN	NN	_	11	COORD	_	_
15	and	_	CC	CC	_	3	CC	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	moderate	_	JJ	JJ	_	18	NMOD	_	_
18	increase	_	NN	NN	_	3	COORD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	NF-kappaB2	_	NN	NN	_	21	NMOD	_	_
21	p52	_	NN	NN	_	19	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	RelA-LRB-p65-RRB-	_	NN	NN	_	21	COORD	_	_
24	were	_	VBD	VBD	_	0	ROOT-S	_	_
25	detected	_	VBN	VBN	_	24	VC	_	_
26	in	_	IN	IN	_	25	ADV	_	_
27	HIV-1-infected	_	JJ	JJ	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	26	PMOD	_	_
29	,	_	,	,	_	24	P	_	_
30	whereas	_	IN	IN	_	24	COORD	_	_
31	NF-kappaB1	_	NN	NN	_	33	NMOD	_	_
32	p105\/p50	_	NN	NN	_	33	NMOD	_	_
33	levels	_	NNS	NNS	_	34	SBJ	_	_
34	were	_	VBD	VBD	_	24	COORD	_	_
35	not	_	RB	RB	_	34	VMOD	_	_
36	altered	_	VBN	VBN	_	34	VC	_	_
37	relative	_	JJ	JJ	_	38	DEP	_	_
38	to	_	TO	TO	_	36	ADV	_	_
39	the	_	DT	DT	_	40	NMOD	_	_
40	levels	_	NNS	NNS	_	38	PMOD	_	_
41	in	_	IN	IN	_	40	NMOD	_	_
42	uninfected	_	JJ	JJ	_	43	NMOD	_	_
43	cells	_	NNS	NNS	_	41	PMOD	_	_
44	.	_	.	.	_	24	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	HIV-1	_	NN	NN	_	5	NMOD	_	_
5	infection	_	NN	NN	_	9	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	myeloid	_	JJ	JJ	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	induces	_	VBZ	VBZ	_	3	VMOD	_	_
10	IFN	_	NN	NN	_	11	NMOD	_	_
11	production	_	NN	NN	_	9	OBJ	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	PKR	_	NN	NN	_	14	NMOD	_	_
14	activity	_	NN	NN	_	11	COORD	_	_
15	,	_	,	,	_	11	P	_	_
16	which	_	WDT	WDT	_	19	SBJ	_	_
17	in	_	IN	IN	_	19	ADV	_	_
18	turn	_	NN	NN	_	17	PMOD	_	_
19	contribute	_	VBP	VBP	_	11	NMOD	_	_
20	to	_	TO	TO	_	19	ADV	_	_
21	enhanced	_	VBN	VBN	_	23	NMOD	_	_
22	IkappaBalpha	_	NN	NN	_	23	NMOD	_	_
23	phosphorylation	_	NN	NN	_	20	PMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	subsequent	_	JJ	JJ	_	26	NMOD	_	_
26	degradation	_	NN	NN	_	23	COORD	_	_
27	.	_	.	.	_	2	P	_	_

1	Nuclear	_	JJ	JJ	_	2	NMOD	_	_
2	translocation	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NF-kappaB	_	NN	NN	_	5	NMOD	_	_
5	subunits	_	NNS	NNS	_	3	PMOD	_	_
6	may	_	MD	MD	_	0	ROOT-S	_	_
7	ultimately	_	RB	RB	_	6	ADV	_	_
8	increase	_	VB	VB	_	6	VC	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	intracellular	_	JJ	JJ	_	11	NMOD	_	_
11	pool	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	NF-kappaB\/IkappaBalpha	_	NN	NN	_	12	PMOD	_	_
14	by	_	IN	IN	_	8	ADV	_	_
15	an	_	DT	DT	_	17	NMOD	_	_
16	autoregulatory	_	JJ	JJ	_	17	NMOD	_	_
17	mechanism	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	6	P	_	_

1	Enhanced	_	VBN	VBN	_	2	NMOD	_	_
2	turnover	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	IkappaBalpha	_	NN	NN	_	3	PMOD	_	_
5	and	_	CC	CC	_	2	CC	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	accumulation	_	NN	NN	_	2	COORD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	NF-kappaB\/Rel	_	NN	NN	_	10	NMOD	_	_
10	proteins	_	NNS	NNS	_	8	PMOD	_	_
11	may	_	MD	MD	_	0	ROOT-S	_	_
12	contribute	_	VB	VB	_	11	VC	_	_
13	to	_	TO	TO	_	12	ADV	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	chronically	_	RB	RB	_	16	AMOD	_	_
16	activated	_	JJ	JJ	_	17	NMOD	_	_
17	state	_	NN	NN	_	13	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	HIV-1-infected	_	JJ	JJ	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	role	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	early	_	JJ	JJ	_	7	NMOD	_	_
5	growth	_	NN	NN	_	7	NMOD	_	_
6	response	_	NN	NN	_	7	NMOD	_	_
7	gene	_	NN	NN	_	3	PMOD	_	_
8	1	_	CD	CD	_	7	NMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	egr-1	_	NN	NN	_	7	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	in	_	IN	IN	_	2	NMOD	_	_
13	regulation	_	NN	NN	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	immune	_	JJ	JJ	_	17	NMOD	_	_
17	response	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	induction	_	NN	NN	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	immediate	_	JJ	JJ	_	6	NMOD	_	_
5	early	_	JJ	JJ	_	6	NMOD	_	_
6	genes	_	NNS	NNS	_	3	PMOD	_	_
7	in	_	IN	IN	_	2	NMOD	_	_
8	cells	_	NNS	NNS	_	7	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	immune	_	JJ	JJ	_	12	NMOD	_	_
12	system	_	NN	NN	_	9	PMOD	_	_
13	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	critical	_	JJ	JJ	_	13	PRD	_	_
15	to	_	TO	TO	_	14	AMOD	_	_
16	determining	_	VBG	VBG	_	15	PMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	ultimate	_	JJ	JJ	_	19	NMOD	_	_
19	outcome	_	NN	NN	_	16	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	exposure	_	NN	NN	_	20	PMOD	_	_
22	to	_	TO	TO	_	21	NMOD	_	_
23	antigen	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	importance	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	many	_	JJ	JJ	_	3	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	these	_	DT	DT	_	7	NMOD	_	_
7	genes	_	NNS	NNS	_	5	PMOD	_	_
8	relates	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	to	_	TO	TO	_	8	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	role	_	NN	NN	_	9	PMOD	_	_
12	their	_	PRP$	PRP$	_	15	NMOD	_	_
13	transcription	_	NN	NN	_	15	NMOD	_	_
14	factor	_	NN	NN	_	15	NMOD	_	_
15	products	_	NNS	NNS	_	16	SBJ	_	_
16	play	_	VBP	VBP	_	11	NMOD	_	_
17	in	_	IN	IN	_	16	ADV	_	_
18	dictating	_	VBG	VBG	_	17	PMOD	_	_
19	patterns	_	NNS	NNS	_	18	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	expression	_	NN	NN	_	20	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	downstream	_	JJ	JJ	_	26	NMOD	_	_
24	,	_	,	,	_	23	P	_	_
25	function-related	_	JJ	JJ	_	23	COORD	_	_
26	genes	_	NNS	NNS	_	22	PMOD	_	_
27	.	_	.	.	_	8	P	_	_

1	Evidence	_	NN	NN	_	5	SBJ	_	_
2	from	_	IN	IN	_	1	NMOD	_	_
3	several	_	JJ	JJ	_	4	NMOD	_	_
4	systems	_	NNS	NNS	_	2	PMOD	_	_
5	indicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	immediate	_	JJ	JJ	_	10	NMOD	_	_
9	early	_	JJ	JJ	_	10	NMOD	_	_
10	gene	_	NN	NN	_	13	SBJ	_	_
11	,	_	,	,	_	10	P	_	_
12	egr-1	_	NN	NN	_	10	NMOD	_	_
13	may	_	MD	MD	_	6	VMOD	_	_
14	be	_	VB	VB	_	13	VC	_	_
15	of	_	IN	IN	_	14	PRD	_	_
16	particular	_	JJ	JJ	_	17	NMOD	_	_
17	importance	_	NN	NN	_	15	PMOD	_	_
18	in	_	IN	IN	_	14	ADV	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	immune	_	JJ	JJ	_	21	NMOD	_	_
21	system	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	Recently	_	RB	RB	_	6	TMP	_	_
2	,	_	,	,	_	6	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	egr-1	_	NN	NN	_	5	NMOD	_	_
5	promoter	_	NN	NN	_	6	SBJ	_	_
6	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	been	_	VBN	VBN	_	6	VC	_	_
8	shown	_	VBN	VBN	_	7	VC	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	be	_	VB	VB	_	8	OBJ	_	_
11	highly	_	RB	RB	_	12	AMOD	_	_
12	responsive	_	JJ	JJ	_	10	PRD	_	_
13	to	_	TO	TO	_	12	AMOD	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	diverse	_	JJ	JJ	_	17	NMOD	_	_
16	biochemical	_	JJ	JJ	_	17	NMOD	_	_
17	signals	_	NNS	NNS	_	13	PMOD	_	_
18	generated	_	VBN	VBN	_	17	NMOD	_	_
19	by	_	IN	IN	_	18	LGS	_	_
20	antigen	_	NN	NN	_	19	PMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	cytokines	_	NNS	NNS	_	20	COORD	_	_
23	in	_	IN	IN	_	20	NMOD	_	_
24	cells	_	NNS	NNS	_	23	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	immune	_	JJ	JJ	_	28	NMOD	_	_
28	system	_	NN	NN	_	25	PMOD	_	_
29	.	_	.	.	_	6	P	_	_

1	Furthermore	_	RB	RB	_	17	ADV	_	_
2	,	_	,	,	_	17	P	_	_
3	an	_	DT	DT	_	5	NMOD	_	_
4	important	_	JJ	JJ	_	5	NMOD	_	_
5	role	_	NN	NN	_	17	SBJ	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	egr-1	_	NN	NN	_	6	PMOD	_	_
8	in	_	IN	IN	_	5	NMOD	_	_
9	determining	_	VBG	VBG	_	8	PMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	differentiation	_	NN	NN	_	12	NMOD	_	_
12	pathway	_	NN	NN	_	9	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	myeloid	_	JJ	JJ	_	16	NMOD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	precursors	_	NNS	NNS	_	13	PMOD	_	_
17	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	been	_	VBN	VBN	_	17	VC	_	_
19	recently	_	RB	RB	_	18	TMP	_	_
20	elaborated	_	VBN	VBN	_	18	VC	_	_
21	.	_	.	.	_	17	P	_	_

1	Finally	_	RB	RB	_	15	TMP	_	_
2	,	_	,	,	_	15	P	_	_
3	potential	_	JJ	JJ	_	4	NMOD	_	_
4	targets	_	NNS	NNS	_	15	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	regulation	_	NN	NN	_	5	PMOD	_	_
7	by	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	zinc-finger	_	NN	NN	_	11	NMOD	_	_
10	transcription	_	NN	NN	_	11	NMOD	_	_
11	factor	_	NN	NN	_	7	PMOD	_	_
12	encoded	_	VBN	VBN	_	11	NMOD	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	egr-1	_	NN	NN	_	13	PMOD	_	_
15	include	_	VBP	VBP	_	0	ROOT-S	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	interleukin-2	_	NN	NN	_	15	OBJ	_	_
18	,	_	,	,	_	17	P	_	_
19	CD44	_	NN	NN	_	17	COORD	_	_
20	,	_	,	,	_	17	P	_	_
21	ICAM-1	_	NN	NN	_	17	COORD	_	_
22	,	_	,	,	_	17	P	_	_
23	and	_	CC	CC	_	17	CC	_	_
24	tumor	_	NN	NN	_	27	NMOD	_	_
25	necrosis	_	NN	NN	_	27	NMOD	_	_
26	factor	_	NN	NN	_	27	NMOD	_	_
27	genes	_	NNS	NNS	_	17	COORD	_	_
28	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	role	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	egr-1	_	NN	NN	_	3	PMOD	_	_
5	in	_	IN	IN	_	2	NMOD	_	_
6	regulation	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	immune	_	JJ	JJ	_	10	NMOD	_	_
10	response	_	NN	NN	_	7	PMOD	_	_
11	will	_	MD	MD	_	0	ROOT-S	_	_
12	be	_	VB	VB	_	11	VC	_	_
13	discussed	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	context	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	these	_	DT	DT	_	20	NMOD	_	_
19	recent	_	JJ	JJ	_	20	NMOD	_	_
20	studies	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	11	P	_	_

1	Activation	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	Stat	_	NN	NN	_	4	NMOD	_	_
4	5b	_	NN	NN	_	2	PMOD	_	_
5	in	_	IN	IN	_	1	NMOD	_	_
6	erythroid	_	JJ	JJ	_	7	NMOD	_	_
7	progenitors	_	NNS	NNS	_	5	PMOD	_	_
8	correlates	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	ability	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	ErbB	_	NN	NN	_	12	PMOD	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	induce	_	VB	VB	_	11	NMOD	_	_
16	sustained	_	JJ	JJ	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	proliferation	_	NN	NN	_	15	OBJ	_	_
19	.	_	.	.	_	8	P	_	_

1	Self	_	NN	NN	_	2	NMOD	_	_
2	renewal	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	normal	_	JJ	JJ	_	6	NMOD	_	_
5	erythroid	_	JJ	JJ	_	6	NMOD	_	_
6	progenitors	_	NNS	NNS	_	3	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	induced	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	receptor	_	NN	NN	_	14	NMOD	_	_
12	tyrosine	_	NN	NN	_	14	NMOD	_	_
13	kinase	_	NN	NN	_	14	NMOD	_	_
14	c-ErbB	_	NN	NN	_	9	PMOD	_	_
15	,	_	,	,	_	7	P	_	_
16	whereas	_	IN	IN	_	7	COORD	_	_
17	other	_	JJ	JJ	_	18	NMOD	_	_
18	receptors	_	NNS	NNS	_	22	SBJ	_	_
19	(	_	(	(	_	20	P	_	_
20	c-Kit\/Epo-R	_	NNS	NNS	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	regulate	_	VBP	VBP	_	7	COORD	_	_
23	erythroid	_	JJ	JJ	_	24	NMOD	_	_
24	differentiation	_	NN	NN	_	22	OBJ	_	_
25	.	_	.	.	_	7	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	address	_	VB	VB	_	15	VMOD	_	_
3	possible	_	JJ	JJ	_	4	NMOD	_	_
4	mechanisms	_	NNS	NNS	_	2	OBJ	_	_
5	that	_	WDT	WDT	_	6	SBJ	_	_
6	could	_	MD	MD	_	4	NMOD	_	_
7	explain	_	VB	VB	_	6	VC	_	_
8	this	_	DT	DT	_	10	NMOD	_	_
9	selective	_	JJ	JJ	_	10	NMOD	_	_
10	activity	_	NN	NN	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	c-ErbB	_	NN	NN	_	11	PMOD	_	_
13	,	_	,	,	_	15	P	_	_
14	we	_	PRP	PRP	_	15	SBJ	_	_
15	analyzed	_	VBD	VBD	_	0	ROOT-S	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	ability	_	NN	NN	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	these	_	DT	DT	_	20	NMOD	_	_
20	receptors	_	NNS	NNS	_	18	PMOD	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	activate	_	VB	VB	_	17	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	different	_	JJ	JJ	_	25	NMOD	_	_
25	members	_	NNS	NNS	_	22	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	31	NMOD	_	_
28	Stat	_	NN	NN	_	31	NMOD	_	_
29	transcription	_	NN	NN	_	31	NMOD	_	_
30	factor	_	NN	NN	_	31	NMOD	_	_
31	family	_	NN	NN	_	26	PMOD	_	_
32	.	_	.	.	_	15	P	_	_

1	Ligand	_	NN	NN	_	2	NMOD	_	_
2	activation	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	c-ErbB	_	NN	NN	_	3	PMOD	_	_
5	induced	_	VBD	VBD	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	tyrosine	_	NN	NN	_	8	NMOD	_	_
8	phosphorylation	_	NN	NN	_	5	OBJ	_	_
9	,	_	,	,	_	8	P	_	_
10	DNA-binding	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	8	P	_	_
12	and	_	CC	CC	_	8	CC	_	_
13	reporter	_	NN	NN	_	15	NMOD	_	_
14	gene	_	NN	NN	_	15	NMOD	_	_
15	transcription	_	NN	NN	_	8	COORD	_	_
16	of	_	IN	IN	_	8	NMOD	_	_
17	Stat	_	NN	NN	_	18	NMOD	_	_
18	5b	_	NN	NN	_	16	PMOD	_	_
19	in	_	IN	IN	_	5	ADV	_	_
20	erythroblasts	_	NNS	NNS	_	19	PMOD	_	_
21	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	8	P	_	_
4	ligand	_	NN	NN	_	5	NMOD	_	_
5	activation	_	NN	NN	_	8	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	c-Kit	_	NN	NN	_	6	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	unable	_	JJ	JJ	_	8	PRD	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	induce	_	VB	VB	_	9	AMOD	_	_
12	any	_	DT	DT	_	11	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	these	_	DT	DT	_	15	NMOD	_	_
15	effects	_	NNS	NNS	_	13	PMOD	_	_
16	in	_	IN	IN	_	11	ADV	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	same	_	JJ	JJ	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	8	P	_	_

1	Activation	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	erythropoietin	_	NN	NN	_	5	NMOD	_	_
5	receptor	_	NN	NN	_	2	PMOD	_	_
6	caused	_	VBD	VBD	_	0	ROOT-S	_	_
7	specific	_	JJ	JJ	_	8	NMOD	_	_
8	DNA-binding	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	Stat	_	NN	NN	_	11	NMOD	_	_
11	5b	_	NN	NN	_	9	PMOD	_	_
12	,	_	,	,	_	6	P	_	_
13	but	_	CC	CC	_	6	CC	_	_
14	failed	_	VBD	VBD	_	6	COORD	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	induce	_	VB	VB	_	14	OBJ	_	_
17	reporter	_	NN	NN	_	19	NMOD	_	_
18	gene	_	NN	NN	_	19	NMOD	_	_
19	transcription	_	NN	NN	_	16	OBJ	_	_
20	.	_	.	.	_	6	P	_	_

1	These	_	DT	DT	_	3	NMOD	_	_
2	biochemical	_	JJ	JJ	_	3	NMOD	_	_
3	findings	_	NNS	NNS	_	4	SBJ	_	_
4	correlate	_	VBP	VBP	_	0	ROOT-S	_	_
5	perfectly	_	RB	RB	_	4	ADV	_	_
6	with	_	IN	IN	_	4	ADV	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	selective	_	JJ	JJ	_	9	NMOD	_	_
9	ability	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	c-ErbB	_	NN	NN	_	10	PMOD	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	cause	_	VB	VB	_	9	NMOD	_	_
14	sustained	_	JJ	JJ	_	16	NMOD	_	_
15	self	_	NN	NN	_	16	NMOD	_	_
16	renewal	_	NN	NN	_	13	OBJ	_	_
17	in	_	IN	IN	_	13	ADV	_	_
18	erythroid	_	JJ	JJ	_	19	NMOD	_	_
19	progenitors	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	4	P	_	_

1	Calcineurin	_	NN	NN	_	2	NMOD	_	_
2	mutants	_	NNS	NNS	_	3	SBJ	_	_
3	render	_	VBP	VBP	_	0	ROOT-S	_	_
4	T	_	NN	NN	_	5	NMOD	_	_
5	lymphocytes	_	NNS	NNS	_	6	SBJ	_	_
6	resistant	_	JJ	JJ	_	3	OBJ	_	_
7	to	_	TO	TO	_	6	AMOD	_	_
8	cyclosporin	_	NN	NN	_	9	NMOD	_	_
9	A	_	NN	NN	_	7	PMOD	_	_
10	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	immunosuppressants	_	NNS	NNS	_	10	SBJ	_	_
3	cyclosporin	_	NN	NN	_	4	NMOD	_	_
4	A	_	NN	NN	_	2	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	CsA	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	and	_	CC	CC	_	4	CC	_	_
9	FK506	_	NN	NN	_	4	COORD	_	_
10	have	_	VBP	VBP	_	0	ROOT-S	_	_
11	been	_	VBN	VBN	_	10	VC	_	_
12	widely	_	RB	RB	_	11	ADV	_	_
13	used	_	VBN	VBN	_	11	VC	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	prevent	_	VB	VB	_	13	OBJ	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	treat	_	VB	VB	_	15	COORD	_	_
18	graft	_	NN	NN	_	19	NMOD	_	_
19	rejection	_	NN	NN	_	15	OBJ	_	_
20	after	_	IN	IN	_	19	TMP	_	_
21	human	_	JJ	JJ	_	25	NMOD	_	_
22	organ	_	NN	NN	_	25	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	tissue	_	NN	NN	_	22	COORD	_	_
25	transplantations	_	NNS	NNS	_	20	PMOD	_	_
26	.	_	.	.	_	10	P	_	_

1	CsA	_	NN	NN	_	4	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	FK506	_	NN	NN	_	1	COORD	_	_
4	associate	_	VBP	VBP	_	0	ROOT-S	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	intracellular	_	JJ	JJ	_	8	NMOD	_	_
7	binding	_	VBG	VBG	_	8	NMOD	_	_
8	proteins	_	NNS	NNS	_	5	PMOD	_	_
9	(	_	(	(	_	12	P	_	_
10	i.e.	_	FW	FW	_	12	NMOD	_	_
11	,	_	,	,	_	12	P	_	_
12	CsA	_	NN	NN	_	8	PRN	_	_
13	with	_	IN	IN	_	12	NMOD	_	_
14	cyclophilin	_	NN	NN	_	15	NMOD	_	_
15	A	_	NN	NN	_	13	PMOD	_	_
16	and	_	CC	CC	_	12	CC	_	_
17	FK506	_	NN	NN	_	12	COORD	_	_
18	with	_	IN	IN	_	17	NMOD	_	_
19	FKBP12	_	NN	NN	_	18	PMOD	_	_
20	)	_	)	)	_	12	P	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	form	_	VB	VB	_	4	OBJ	_	_
23	protein\/drug	_	NN	NN	_	24	NMOD	_	_
24	complexes	_	NNS	NNS	_	22	OBJ	_	_
25	that	_	WDT	WDT	_	26	SBJ	_	_
26	suppress	_	VBP	VBP	_	24	NMOD	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	immune	_	JJ	JJ	_	29	NMOD	_	_
29	system	_	NN	NN	_	26	OBJ	_	_
30	by	_	IN	IN	_	26	ADV	_	_
31	preventing	_	VBG	VBG	_	30	PMOD	_	_
32	activation	_	NN	NN	_	31	OBJ	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	T	_	NN	NN	_	35	NMOD	_	_
35	cells	_	NNS	NNS	_	33	PMOD	_	_
36	in	_	IN	IN	_	32	NMOD	_	_
37	response	_	NN	NN	_	36	DEP	_	_
38	to	_	TO	TO	_	36	DEP	_	_
39	antigen	_	NN	NN	_	40	NMOD	_	_
40	presentation	_	NN	NN	_	36	PMOD	_	_
41	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	common	_	JJ	JJ	_	3	NMOD	_	_
3	target	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	CsA	_	NN	NN	_	4	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	FK506	_	NN	NN	_	5	COORD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	calcineurin	_	NN	NN	_	8	PRD	_	_
10	,	_	,	,	_	9	P	_	_
11	a	_	DT	DT	_	16	NMOD	_	_
12	Ca2+\/calmodulin-regulated	_	JJ	JJ	_	16	NMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	serine\/threonine-specific	_	JJ	JJ	_	12	COORD	_	_
15	protein	_	NN	NN	_	16	NMOD	_	_
16	phosphatase	_	NN	NN	_	9	NMOD	_	_
17	that	_	WDT	WDT	_	18	SBJ	_	_
18	regulates	_	VBZ	VBZ	_	16	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	nuclear	_	JJ	JJ	_	21	NMOD	_	_
21	import	_	NN	NN	_	18	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	a	_	DT	DT	_	25	NMOD	_	_
24	transcription	_	NN	NN	_	25	NMOD	_	_
25	factor	_	NN	NN	_	22	PMOD	_	_
26	,	_	,	,	_	25	P	_	_
27	NF-AT	_	NN	NN	_	25	NMOD	_	_
28	,	_	,	,	_	25	P	_	_
29	required	_	VBN	VBN	_	25	NMOD	_	_
30	for	_	IN	IN	_	29	ADV	_	_
31	expression	_	NN	NN	_	30	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	T	_	NN	NN	_	36	NMOD	_	_
34	cell	_	NN	NN	_	36	NMOD	_	_
35	activation	_	NN	NN	_	36	NMOD	_	_
36	genes	_	NNS	NNS	_	32	PMOD	_	_
37	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	previous	_	JJ	JJ	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	identified	_	VBD	VBD	_	0	ROOT-S	_	_
7	calcineurin	_	NN	NN	_	8	NMOD	_	_
8	mutations	_	NNS	NNS	_	6	OBJ	_	_
9	that	_	WDT	WDT	_	10	SBJ	_	_
10	block	_	VBP	VBP	_	8	NMOD	_	_
11	binding	_	NN	NN	_	10	OBJ	_	_
12	by	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	18	NMOD	_	_
14	cyclophilin	_	NN	NN	_	15	AMOD	_	_
15	A\/CsA	_	NN	NN	_	18	NMOD	_	_
16	or	_	CC	CC	_	15	CC	_	_
17	FKBP12\/FK506	_	NN	NN	_	15	COORD	_	_
18	complexes	_	NNS	NNS	_	12	PMOD	_	_
19	and	_	CC	CC	_	10	CC	_	_
20	thereby	_	RB	RB	_	10	COORD	_	_
21	render	_	VBP	VBP	_	10	COORD	_	_
22	yeast	_	NN	NN	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	24	SBJ	_	_
24	resistant	_	JJ	JJ	_	21	OBJ	_	_
25	to	_	TO	TO	_	24	AMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	antifungal	_	JJ	JJ	_	28	NMOD	_	_
28	effects	_	NNS	NNS	_	25	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	CsA	_	NN	NN	_	29	PMOD	_	_
31	or	_	CC	CC	_	30	CC	_	_
32	FK506	_	NN	NN	_	30	COORD	_	_
33	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	corresponding	_	JJ	JJ	_	10	NMOD	_	_
10	mutations	_	NNS	NNS	_	14	SBJ	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	murine	_	JJ	JJ	_	13	NMOD	_	_
13	calcineurin	_	NN	NN	_	11	PMOD	_	_
14	render	_	VBP	VBP	_	7	VMOD	_	_
15	the	_	DT	DT	_	22	NMOD	_	_
16	T	_	NN	NN	_	22	NMOD	_	_
17	cell	_	NN	NN	_	22	NMOD	_	_
18	receptor	_	NN	NN	_	22	NMOD	_	_
19	signal	_	NN	NN	_	22	NMOD	_	_
20	transduction	_	NN	NN	_	22	NMOD	_	_
21	cascade	_	NN	NN	_	22	NMOD	_	_
22	CsA	_	NN	NN	_	23	SBJ	_	_
23	resistant	_	JJ	JJ	_	14	OBJ	_	_
24	in	_	IN	IN	_	23	AMOD	_	_
25	human	_	JJ	JJ	_	28	NMOD	_	_
26	Jurkat	_	NN	NN	_	28	NMOD	_	_
27	T	_	NN	NN	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	24	PMOD	_	_
29	.	_	.	.	_	6	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	support	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	10	NMOD	_	_
5	recently	_	RB	RB	_	6	AMOD	_	_
6	determined	_	VBN	VBN	_	10	NMOD	_	_
7	calcineurin	_	NN	NN	_	10	NMOD	_	_
8	X-ray	_	NN	NN	_	10	NMOD	_	_
9	crystal	_	NN	NN	_	10	NMOD	_	_
10	structure	_	NN	NN	_	3	OBJ	_	_
11	,	_	,	,	_	3	P	_	_
12	provide	_	VBP	VBP	_	3	COORD	_	_
13	evidence	_	NN	NN	_	12	OBJ	_	_
14	that	_	IN	IN	_	13	NMOD	_	_
15	calcineurin	_	NN	NN	_	16	SBJ	_	_
16	is	_	VBZ	VBZ	_	14	VMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	only	_	RB	RB	_	20	NMOD	_	_
19	CsA-sensitive	_	JJ	JJ	_	20	NMOD	_	_
20	component	_	NN	NN	_	16	PRD	_	_
21	limiting	_	VBG	VBG	_	20	NMOD	_	_
22	signaling	_	NN	NN	_	21	OBJ	_	_
23	from	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	T	_	NN	NN	_	27	NMOD	_	_
26	cell	_	NN	NN	_	27	NMOD	_	_
27	receptor	_	NN	NN	_	23	PMOD	_	_
28	to	_	TO	TO	_	22	NMOD	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	nucleus	_	NN	NN	_	28	PMOD	_	_
31	,	_	,	,	_	3	P	_	_
32	and	_	CC	CC	_	3	CC	_	_
33	suggest	_	VBP	VBP	_	3	COORD	_	_
34	a	_	DT	DT	_	35	NMOD	_	_
35	means	_	NN	NN	_	33	OBJ	_	_
36	to	_	TO	TO	_	37	VMOD	_	_
37	render	_	VB	VB	_	35	NMOD	_	_
38	cells	_	NNS	NNS	_	41	SBJ	_	_
39	and	_	CC	CC	_	38	CC	_	_
40	tissues	_	NNS	NNS	_	38	COORD	_	_
41	resistant	_	JJ	JJ	_	37	OBJ	_	_
42	to	_	TO	TO	_	41	AMOD	_	_
43	the	_	DT	DT	_	46	NMOD	_	_
44	toxic	_	JJ	JJ	_	46	NMOD	_	_
45	side	_	JJ	JJ	_	46	NMOD	_	_
46	effects	_	NNS	NNS	_	42	PMOD	_	_
47	of	_	IN	IN	_	46	NMOD	_	_
48	CsA	_	NN	NN	_	47	PMOD	_	_
49	and	_	CC	CC	_	48	CC	_	_
50	FK506	_	NN	NN	_	48	COORD	_	_
51	.	_	.	.	_	3	P	_	_

1	Retinoid	_	NN	NN	_	3	NMOD	_	_
2	differentiation	_	NN	NN	_	3	NMOD	_	_
3	therapy	_	NN	NN	_	0	ROOT-FRAG	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	promyelocytic	_	JJ	JJ	_	6	NMOD	_	_
6	leukemia	_	NN	NN	_	4	PMOD	_	_
7	.	_	.	.	_	3	P	_	_

1	Acute	_	JJ	JJ	_	3	NMOD	_	_
2	promyelocytic	_	JJ	JJ	_	3	NMOD	_	_
3	leukemia	_	NN	NN	_	7	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	APL	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	specific	_	JJ	JJ	_	10	NMOD	_	_
10	type	_	NN	NN	_	7	PRD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	acute	_	JJ	JJ	_	14	NMOD	_	_
13	myeloid	_	JJ	JJ	_	14	NMOD	_	_
14	leukemia	_	NN	NN	_	11	PMOD	_	_
15	characterized	_	VBN	VBN	_	10	NMOD	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	morphology	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	blast	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	19	PMOD	_	_
23	,	_	,	,	_	18	P	_	_
24	a	_	DT	DT	_	27	NMOD	_	_
25	specific	_	JJ	JJ	_	27	NMOD	_	_
26	t-LRB-15;17-RRB-	_	NN	NN	_	27	NMOD	_	_
27	translocation	_	NN	NN	_	18	COORD	_	_
28	,	_	,	,	_	18	P	_	_
29	and	_	CC	CC	_	18	CC	_	_
30	risks	_	NNS	NNS	_	18	COORD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	definite	_	JJ	JJ	_	33	NMOD	_	_
33	coagulopathy	_	NN	NN	_	31	PMOD	_	_
34	.	_	.	.	_	7	P	_	_

1	Recently	_	RB	RB	_	4	TMP	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	leukemia	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	further	_	RB	RB	_	6	ADV	_	_
6	characterized	_	VBN	VBN	_	4	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	an	_	DT	DT	_	10	NMOD	_	_
9	exquisite	_	JJ	JJ	_	10	NMOD	_	_
10	sensitivity	_	NN	NN	_	7	PMOD	_	_
11	to	_	TO	TO	_	10	NMOD	_	_
12	all-trans	_	JJ	JJ	_	14	NMOD	_	_
13	retinoic	_	JJ	JJ	_	14	NMOD	_	_
14	acid	_	NN	NN	_	17	NMOD	_	_
15	's	_	POS	POS	_	14	NMOD	_	_
16	differentiation	_	NN	NN	_	17	NMOD	_	_
17	effect	_	NN	NN	_	11	PMOD	_	_
18	and	_	CC	CC	_	10	CC	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	production	_	NN	NN	_	10	COORD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	a	_	DT	DT	_	24	NMOD	_	_
23	fusion	_	NN	NN	_	24	NMOD	_	_
24	gene	_	NN	NN	_	21	PMOD	_	_
25	altering	_	VBG	VBG	_	24	NMOD	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	gene	_	NN	NN	_	25	OBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	RARalpha	_	NN	NN	_	28	PMOD	_	_
30	and	_	CC	CC	_	27	CC	_	_
31	a	_	DT	DT	_	34	NMOD	_	_
32	novel	_	JJ	JJ	_	34	NMOD	_	_
33	gene	_	NN	NN	_	34	NMOD	_	_
34	PML	_	NN	NN	_	27	COORD	_	_
35	.	_	.	.	_	4	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	vivo	_	FW	FW	_	4	NMOD	_	_
3	differentiation	_	NN	NN	_	4	NMOD	_	_
4	therapy	_	NN	NN	_	10	SBJ	_	_
5	with	_	IN	IN	_	4	NMOD	_	_
6	retinoids	_	NNS	NNS	_	5	PMOD	_	_
7	in	_	IN	IN	_	4	NMOD	_	_
8	APL	_	NN	NN	_	9	NMOD	_	_
9	patients	_	NNS	NNS	_	7	PMOD	_	_
10	follows	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	strict	_	JJ	JJ	_	12	NMOD	_	_
12	guidelines	_	NNS	NNS	_	10	OBJ	_	_
13	related	_	JJ	JJ	_	12	NMOD	_	_
14	both	_	CC	CC	_	15	CC	_	_
15	to	_	TO	TO	_	13	AMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	APL	_	NN	NN	_	18	NMOD	_	_
18	cell	_	NN	NN	_	15	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	biodisposal	_	NN	NN	_	18	COORD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	all-trans	_	JJ	JJ	_	25	NMOD	_	_
24	retinoic	_	JJ	JJ	_	25	NMOD	_	_
25	acid	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	10	P	_	_

1	IL4	_	NN	NN	_	4	NMOD	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	IL13	_	NN	NN	_	1	COORD	_	_
4	receptors	_	NNS	NNS	_	5	SBJ	_	_
5	share	_	VBP	VBP	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	gamma	_	NN	NN	_	9	NMOD	_	_
8	c	_	NN	NN	_	9	NMOD	_	_
9	chain	_	NN	NN	_	5	OBJ	_	_
10	and	_	CC	CC	_	5	CC	_	_
11	activate	_	VBP	VBP	_	5	COORD	_	_
12	STAT6	_	NN	NN	_	17	NMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	STAT3	_	NN	NN	_	12	COORD	_	_
15	and	_	CC	CC	_	12	CC	_	_
16	STAT5	_	NN	NN	_	12	COORD	_	_
17	proteins	_	NNS	NNS	_	11	OBJ	_	_
18	in	_	IN	IN	_	5	ADV	_	_
19	normal	_	JJ	JJ	_	22	NMOD	_	_
20	human	_	JJ	JJ	_	22	NMOD	_	_
21	B	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	18	PMOD	_	_
23	.	_	.	.	_	5	P	_	_

1	IL13	_	NN	NN	_	2	SBJ	_	_
2	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	same	_	JJ	JJ	_	6	NMOD	_	_
5	biological	_	JJ	JJ	_	6	NMOD	_	_
6	effects	_	NNS	NNS	_	2	OBJ	_	_
7	as	_	IN	IN	_	6	NMOD	_	_
8	IL4	_	NN	NN	_	7	PMOD	_	_
9	in	_	IN	IN	_	2	ADV	_	_
10	normal	_	JJ	JJ	_	13	NMOD	_	_
11	human	_	JJ	JJ	_	13	NMOD	_	_
12	B	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	9	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	as	_	IN	IN	_	17	ADV	_	_
5	in	_	IN	IN	_	4	PMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	IL4R	_	NN	NN	_	8	NMOD	_	_
8	complex	_	NN	NN	_	5	PMOD	_	_
9	,	_	,	,	_	17	P	_	_
10	both	_	CC	CC	_	12	CC	_	_
11	IL4R	_	NN	NN	_	12	NMOD	_	_
12	alpha	_	NN	NN	_	17	SBJ	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	IL2R	_	NN	NN	_	16	NMOD	_	_
15	gamma	_	NN	NN	_	16	NMOD	_	_
16	c	_	NN	NN	_	12	COORD	_	_
17	are	_	VBP	VBP	_	3	VMOD	_	_
18	components	_	NNS	NNS	_	17	PRD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	IL13R	_	NN	NN	_	19	PMOD	_	_
22	and	_	CC	CC	_	3	CC	_	_
23	that	_	IN	IN	_	3	COORD	_	_
24	both	_	DT	DT	_	25	NMOD	_	_
25	cytokines	_	NNS	NNS	_	26	SBJ	_	_
26	induced	_	VBD	VBD	_	23	VMOD	_	_
27	STAT6	_	NN	NN	_	32	NMOD	_	_
28	,	_	,	,	_	27	P	_	_
29	STAT3	_	NN	NN	_	27	COORD	_	_
30	and	_	CC	CC	_	27	CC	_	_
31	STAT5	_	NN	NN	_	27	COORD	_	_
32	activation	_	NN	NN	_	26	OBJ	_	_
33	in	_	IN	IN	_	32	NMOD	_	_
34	B	_	NN	NN	_	35	NMOD	_	_
35	cells	_	NNS	NNS	_	33	PMOD	_	_
36	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	spite	_	NN	NN	_	1	DEP	_	_
3	of	_	IN	IN	_	1	DEP	_	_
4	this	_	DT	DT	_	7	NMOD	_	_
5	similar	_	JJ	JJ	_	7	NMOD	_	_
6	downstream	_	JJ	JJ	_	7	NMOD	_	_
7	signalling	_	NN	NN	_	1	PMOD	_	_
8	,	_	,	,	_	12	P	_	_
9	IL4	_	NN	NN	_	12	SBJ	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	IL13	_	NN	NN	_	9	COORD	_	_
12	used	_	VBD	VBD	_	0	ROOT-S	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	different	_	JJ	JJ	_	15	NMOD	_	_
15	set	_	NN	NN	_	12	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	Janus	_	NN	NN	_	18	NMOD	_	_
18	kinases	_	NNS	NNS	_	16	PMOD	_	_
19	:	_	:	:	_	12	P	_	_
20	IL13	_	NN	NN	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	12	VMOD	_	_
22	unable	_	JJ	JJ	_	21	PRD	_	_
23	to	_	TO	TO	_	24	VMOD	_	_
24	activate	_	VB	VB	_	22	AMOD	_	_
25	JAK1	_	NN	NN	_	24	OBJ	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	JAK3	_	NN	NN	_	25	COORD	_	_
28	.	_	.	.	_	21	P	_	_

1	Attenuated	_	VBN	VBN	_	2	NMOD	_	_
2	function	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	variant	_	JJ	JJ	_	6	NMOD	_	_
6	form	_	NN	NN	_	3	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	helix-loop-helix	_	JJ	JJ	_	10	NMOD	_	_
10	protein	_	NN	NN	_	7	PMOD	_	_
11	,	_	,	,	_	6	P	_	_
12	Id-3	_	NN	NN	_	6	NMOD	_	_
13	,	_	,	,	_	6	P	_	_
14	generated	_	VBN	VBN	_	6	NMOD	_	_
15	by	_	IN	IN	_	14	ADV	_	_
16	an	_	DT	DT	_	19	NMOD	_	_
17	alternative	_	JJ	JJ	_	19	NMOD	_	_
18	splicing	_	NN	NN	_	19	NMOD	_	_
19	mechanism	_	NN	NN	_	15	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	Id	_	NN	NN	_	3	NMOD	_	_
3	family	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	helix-loop-helix	_	JJ	JJ	_	6	NMOD	_	_
6	proteins	_	NNS	NNS	_	4	PMOD	_	_
7	function	_	VBP	VBP	_	0	ROOT-S	_	_
8	as	_	IN	IN	_	7	ADV	_	_
9	negative	_	JJ	JJ	_	10	NMOD	_	_
10	regulators	_	NNS	NNS	_	8	PMOD	_	_
11	of	_	IN	IN	_	17	NMOD	_	_
12	DNA	_	NN	NN	_	13	AMOD	_	_
13	binding	_	NN	NN	_	17	NMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	basic	_	JJ	JJ	_	16	AMOD	_	_
16	helix-loop-helix	_	JJ	JJ	_	13	COORD	_	_
17	proteins	_	NNS	NNS	_	10	NMOD	_	_
18	in	_	IN	IN	_	7	ADV	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	regulation	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	cell	_	NN	NN	_	21	PMOD	_	_
23	growth	_	NN	NN	_	22	NMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	differentiation	_	NN	NN	_	23	COORD	_	_
26	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	on	_	IN	IN	_	2	ADV	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	identification	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	11	NMOD	_	_
9	17	_	CD	CD	_	10	AMOD	_	_
10	kDa	_	NN	NN	_	11	NMOD	_	_
11	variant	_	NN	NN	_	7	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	14	_	CD	CD	_	15	AMOD	_	_
15	kDa	_	NN	NN	_	17	NMOD	_	_
16	Id-3	_	NN	NN	_	17	NMOD	_	_
17	protein	_	NN	NN	_	12	PMOD	_	_
18	termed	_	VBN	VBN	_	11	NMOD	_	_
19	Id-3L	_	NN	NN	_	18	OBJ	_	_
20	(	_	(	(	_	22	P	_	_
21	long	_	JJ	JJ	_	22	NMOD	_	_
22	version	_	NN	NN	_	19	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	which	_	WDT	WDT	_	25	SBJ	_	_
25	possesses	_	VBZ	VBZ	_	11	NMOD	_	_
26	a	_	DT	DT	_	31	NMOD	_	_
27	unique	_	JJ	JJ	_	31	NMOD	_	_
28	60	_	CD	CD	_	31	NMOD	_	_
29	amino	_	NN	NN	_	31	NMOD	_	_
30	acid	_	NN	NN	_	31	NMOD	_	_
31	carboxy-terminus	_	NN	NN	_	25	OBJ	_	_
32	generated	_	VBN	VBN	_	31	NMOD	_	_
33	by	_	IN	IN	_	32	ADV	_	_
34	read	_	VBN	VBN	_	35	NMOD	_	_
35	through	_	IN	IN	_	33	PMOD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	a	_	DT	DT	_	40	NMOD	_	_
38	'	_	``	``	_	40	P	_	_
39	coding	_	VBG	VBG	_	40	NMOD	_	_
40	intron	_	NN	NN	_	36	PMOD	_	_
41	'	_	''	''	_	40	P	_	_
42	and	_	CC	CC	_	35	CC	_	_
43	alternative	_	JJ	JJ	_	44	NMOD	_	_
44	splicing	_	NN	NN	_	35	COORD	_	_
45	.	_	.	.	_	2	P	_	_

1	Northern	_	NN	NN	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	3	SBJ	_	_
3	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
4	expression	_	NN	NN	_	3	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	a	_	DT	DT	_	11	NMOD	_	_
7	minor	_	JJ	JJ	_	11	NMOD	_	_
8	1.1	_	CD	CD	_	9	AMOD	_	_
9	kb	_	NN	NN	_	11	NMOD	_	_
10	Id-3L	_	NN	NN	_	11	NMOD	_	_
11	transcript	_	NN	NN	_	5	PMOD	_	_
12	together	_	RB	RB	_	11	CC	_	_
13	with	_	IN	IN	_	12	DEP	_	_
14	the	_	DT	DT	_	19	NMOD	_	_
15	predominant	_	JJ	JJ	_	19	NMOD	_	_
16	0.95	_	CD	CD	_	17	AMOD	_	_
17	kb	_	NN	NN	_	19	NMOD	_	_
18	Id-3	_	NN	NN	_	19	NMOD	_	_
19	transcript	_	NN	NN	_	11	COORD	_	_
20	in	_	IN	IN	_	4	NMOD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	majority	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	adult	_	JJ	JJ	_	26	NMOD	_	_
25	human	_	JJ	JJ	_	26	NMOD	_	_
26	tissues	_	NNS	NNS	_	23	PMOD	_	_
27	analysed	_	VBN	VBN	_	26	NMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	variant	_	JJ	JJ	_	4	NMOD	_	_
3	Id-3L	_	NN	NN	_	4	NMOD	_	_
4	protein	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	functionally	_	RB	RB	_	7	AMOD	_	_
7	distinguishable	_	JJ	JJ	_	5	PRD	_	_
8	from	_	IN	IN	_	7	AMOD	_	_
9	conventional	_	JJ	JJ	_	10	NMOD	_	_
10	Id-3	_	NN	NN	_	8	PMOD	_	_
11	since	_	IN	IN	_	5	ADV	_	_
12	in	_	IN	IN	_	21	ADV	_	_
13	in	_	FW	FW	_	14	AMOD	_	_
14	vitro	_	FW	FW	_	18	NMOD	_	_
15	DNA	_	NN	NN	_	18	NMOD	_	_
16	mobility	_	NN	NN	_	18	NMOD	_	_
17	shift	_	NN	NN	_	18	NMOD	_	_
18	assays	_	NNS	NNS	_	12	PMOD	_	_
19	,	_	,	,	_	21	P	_	_
20	it	_	PRP	PRP	_	21	SBJ	_	_
21	was	_	VBD	VBD	_	11	VMOD	_	_
22	greatly	_	RB	RB	_	23	AMOD	_	_
23	impaired	_	JJ	JJ	_	21	PRD	_	_
24	in	_	IN	IN	_	21	ADV	_	_
25	its	_	PRP$	PRP$	_	26	NMOD	_	_
26	ability	_	NN	NN	_	24	PMOD	_	_
27	to	_	TO	TO	_	28	VMOD	_	_
28	abrogate	_	VB	VB	_	26	NMOD	_	_
29	binding	_	NN	NN	_	28	OBJ	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	the	_	DT	DT	_	34	NMOD	_	_
32	basic	_	JJ	JJ	_	33	AMOD	_	_
33	helix-loop-helix	_	JJ	JJ	_	34	NMOD	_	_
34	protein	_	NN	NN	_	30	PMOD	_	_
35	,	_	,	,	_	34	P	_	_
36	E47	_	NN	NN	_	34	NMOD	_	_
37	,	_	,	,	_	34	P	_	_
38	to	_	TO	TO	_	29	NMOD	_	_
39	an	_	DT	DT	_	43	NMOD	_	_
40	E	_	NN	NN	_	43	NMOD	_	_
41	box	_	NN	NN	_	43	NMOD	_	_
42	recognition	_	NN	NN	_	43	NMOD	_	_
43	sequence	_	NN	NN	_	38	PMOD	_	_
44	.	_	.	.	_	5	P	_	_

1	Characterization	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	11	NMOD	_	_
4	human	_	JJ	JJ	_	11	NMOD	_	_
5	myeloid	_	JJ	JJ	_	11	NMOD	_	_
6	cell	_	NN	NN	_	11	NMOD	_	_
7	nuclear	_	JJ	JJ	_	11	NMOD	_	_
8	differentiation	_	NN	NN	_	11	NMOD	_	_
9	antigen	_	NN	NN	_	11	NMOD	_	_
10	gene	_	NN	NN	_	11	NMOD	_	_
11	promoter	_	NN	NN	_	2	PMOD	_	_
12	.	_	.	.	_	1	P	_	_

1	MNDA	_	NN	NN	_	9	SBJ	_	_
2	(	_	(	(	_	7	P	_	_
3	myeloid	_	JJ	JJ	_	7	NMOD	_	_
4	cell	_	NN	NN	_	7	NMOD	_	_
5	nuclear	_	JJ	JJ	_	7	NMOD	_	_
6	differentiation	_	NN	NN	_	7	NMOD	_	_
7	antigen	_	NN	NN	_	1	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	an	_	DT	DT	_	15	NMOD	_	_
11	interferon	_	NN	NN	_	12	NMOD	_	_
12	alpha	_	NN	NN	_	13	AMOD	_	_
13	regulated	_	VBN	VBN	_	15	NMOD	_	_
14	nuclear	_	JJ	JJ	_	15	NMOD	_	_
15	protein	_	NN	NN	_	9	PRD	_	_
16	expressed	_	VBN	VBN	_	15	NMOD	_	_
17	only	_	RB	RB	_	18	DEP	_	_
18	in	_	IN	IN	_	16	ADV	_	_
19	cells	_	NNS	NNS	_	18	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	human	_	JJ	JJ	_	24	NMOD	_	_
23	myelomonocytic	_	JJ	JJ	_	24	NMOD	_	_
24	lineage	_	NN	NN	_	20	PMOD	_	_
25	.	_	.	.	_	9	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	identify	_	VB	VB	_	19	VMOD	_	_
3	mechanisms	_	NNS	NNS	_	2	OBJ	_	_
4	responsible	_	JJ	JJ	_	3	NMOD	_	_
5	for	_	IN	IN	_	4	AMOD	_	_
6	this	_	DT	DT	_	10	NMOD	_	_
7	lineage-specific	_	JJ	JJ	_	10	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	interferon-regulated	_	JJ	JJ	_	7	COORD	_	_
10	expression	_	NN	NN	_	5	PMOD	_	_
11	,	_	,	,	_	19	P	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	5'	_	JJ	JJ	_	15	NMOD	_	_
14	flanking	_	JJ	JJ	_	15	NMOD	_	_
15	sequence	_	NN	NN	_	19	SBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	gene	_	NN	NN	_	16	PMOD	_	_
19	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
20	been	_	VBN	VBN	_	19	VC	_	_
21	characterized	_	VBN	VBN	_	20	VC	_	_
22	.	_	.	.	_	19	P	_	_

1	Two	_	CD	CD	_	4	NMOD	_	_
2	interferon-stimulated	_	JJ	JJ	_	4	NMOD	_	_
3	response	_	NN	NN	_	4	NMOD	_	_
4	elements	_	NNS	NNS	_	8	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	ISRE	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	flank	_	VBP	VBP	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	14	NMOD	_	_
10	multiple	_	JJ	JJ	_	14	NMOD	_	_
11	transcription	_	NN	NN	_	14	NMOD	_	_
12	start	_	NN	NN	_	14	NMOD	_	_
13	site	_	NN	NN	_	14	NMOD	_	_
14	region	_	NN	NN	_	8	OBJ	_	_
15	identifying	_	VBG	VBG	_	14	NMOD	_	_
16	MNDA	_	NN	NN	_	15	OBJ	_	_
17	as	_	IN	IN	_	15	ADV	_	_
18	a	_	DT	DT	_	21	NMOD	_	_
19	TATA-less	_	JJ	JJ	_	21	NMOD	_	_
20	interferon-regulated	_	JJ	JJ	_	21	NMOD	_	_
21	gene	_	NN	NN	_	17	PMOD	_	_
22	.	_	.	.	_	8	P	_	_

1	Other	_	JJ	JJ	_	3	NMOD	_	_
2	DNA	_	NN	NN	_	3	NMOD	_	_
3	elements	_	NNS	NNS	_	5	SBJ	_	_
4	present	_	JJ	JJ	_	3	NMOD	_	_
5	include	_	VBP	VBP	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	cluster	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	Myb	_	NN	NN	_	10	NMOD	_	_
10	sites	_	NNS	NNS	_	8	PMOD	_	_
11	,	_	,	,	_	7	P	_	_
12	several	_	JJ	JJ	_	13	NMOD	_	_
13	Ets	_	NNS	NNS	_	7	COORD	_	_
14	,	_	,	,	_	7	P	_	_
15	an	_	DT	DT	_	19	NMOD	_	_
16	Ets	_	NN	NN	_	19	NMOD	_	_
17	related	_	JJ	JJ	_	16	AMOD	_	_
18	PU.1	_	NN	NN	_	19	NMOD	_	_
19	site	_	NN	NN	_	7	COORD	_	_
20	and	_	CC	CC	_	7	CC	_	_
21	an	_	DT	DT	_	23	NMOD	_	_
22	Sp1	_	NN	NN	_	23	NMOD	_	_
23	site	_	NN	NN	_	7	COORD	_	_
24	located	_	JJ	JJ	_	7	NMOD	_	_
25	within	_	IN	IN	_	24	AMOD	_	_
26	600	_	CD	CD	_	27	NMOD	_	_
27	bp	_	NN	NN	_	25	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	32	NMOD	_	_
30	transcription	_	NN	NN	_	32	NMOD	_	_
31	start	_	NN	NN	_	32	NMOD	_	_
32	sites	_	NNS	NNS	_	28	PMOD	_	_
33	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	6	P	_	_
4	DNA	_	NN	NN	_	5	NMOD	_	_
5	methylation	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	revealed	_	VBN	VBN	_	6	VC	_	_
8	as	_	IN	IN	_	7	ADV	_	_
9	one	_	CD	CD	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	possible	_	JJ	JJ	_	13	NMOD	_	_
13	factors	_	NNS	NNS	_	10	PMOD	_	_
14	in	_	IN	IN	_	9	NMOD	_	_
15	establishing	_	VBG	VBG	_	14	PMOD	_	_
16	MNDA	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	15	OBJ	_	_
18	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	5'	_	JJ	JJ	_	4	NMOD	_	_
3	flanking	_	JJ	JJ	_	4	NMOD	_	_
4	sequence	_	NN	NN	_	5	SBJ	_	_
5	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	promoter	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	5	OBJ	_	_
8	which	_	WDT	WDT	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	7	NMOD	_	_
10	elevated	_	VBN	VBN	_	9	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	interferon	_	NN	NN	_	13	NMOD	_	_
13	alpha	_	NN	NN	_	11	PMOD	_	_
14	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	MNDA	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	4	VMOD	_	_
8	regulated	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	mechanisms	_	NNS	NNS	_	9	PMOD	_	_
11	similar	_	JJ	JJ	_	10	NMOD	_	_
12	to	_	TO	TO	_	11	AMOD	_	_
13	other	_	JJ	JJ	_	17	NMOD	_	_
14	myelomonocytic	_	JJ	JJ	_	15	NMOD	_	_
15	cell	_	NN	NN	_	16	AMOD	_	_
16	specific	_	JJ	JJ	_	17	NMOD	_	_
17	genes	_	NNS	NNS	_	12	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	genes	_	NNS	NNS	_	17	COORD	_	_
20	up-regulated	_	VBN	VBN	_	19	NMOD	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	interferon	_	NN	NN	_	23	NMOD	_	_
23	alpha	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	Regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	GM-CSF	_	NN	NN	_	5	NMOD	_	_
4	gene	_	NN	NN	_	5	NMOD	_	_
5	transcription	_	NN	NN	_	2	PMOD	_	_
6	by	_	IN	IN	_	1	NMOD	_	_
7	core-binding	_	JJ	JJ	_	8	NMOD	_	_
8	factor	_	NN	NN	_	6	PMOD	_	_
9	.	_	.	.	_	1	P	_	_

1	GM-CSF	_	NN	NN	_	3	NMOD	_	_
2	gene	_	NN	NN	_	3	NMOD	_	_
3	activation	_	NN	NN	_	7	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	known	_	VBN	VBN	_	7	VC	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	involve	_	VB	VB	_	8	OBJ	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	transcription	_	NN	NN	_	13	NMOD	_	_
13	factors	_	NNS	NNS	_	10	OBJ	_	_
14	nuclear	_	JJ	JJ	_	16	NMOD	_	_
15	factor-kappa	_	NN	NN	_	16	NMOD	_	_
16	B	_	NN	NN	_	13	NMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	AP-1	_	NN	NN	_	16	COORD	_	_
19	,	_	,	,	_	16	P	_	_
20	NFAT	_	NN	NN	_	16	COORD	_	_
21	,	_	,	,	_	16	P	_	_
22	and	_	CC	CC	_	16	CC	_	_
23	Sp1	_	NN	NN	_	16	COORD	_	_
24	.	_	.	.	_	7	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	human	_	JJ	JJ	_	7	NMOD	_	_
7	GM-CSF	_	NN	NN	_	12	SBJ	_	_
8	promoter	_	NN	NN	_	7	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	enhancer	_	NN	NN	_	8	COORD	_	_
11	also	_	RB	RB	_	12	ADV	_	_
12	encompass	_	VBP	VBP	_	4	VMOD	_	_
13	binding	_	VBG	VBG	_	14	NMOD	_	_
14	sites	_	NNS	NNS	_	12	OBJ	_	_
15	for	_	IN	IN	_	14	NMOD	_	_
16	core-binding	_	JJ	JJ	_	17	NMOD	_	_
17	factor	_	NN	NN	_	15	PMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	CBF	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	.	_	.	.	_	3	P	_	_

1	Significantly	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	CBF	_	NN	NN	_	5	NMOD	_	_
5	sites	_	NNS	NNS	_	6	SBJ	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	each	_	DT	DT	_	9	NMOD	_	_
9	case	_	NN	NN	_	7	PMOD	_	_
10	contained	_	VBN	VBN	_	6	VC	_	_
11	within	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	16	NMOD	_	_
13	minimum	_	JJ	JJ	_	16	NMOD	_	_
14	essential	_	JJ	JJ	_	16	NMOD	_	_
15	core	_	NN	NN	_	16	NMOD	_	_
16	regions	_	NNS	NNS	_	11	PMOD	_	_
17	required	_	VBN	VBN	_	16	NMOD	_	_
18	for	_	IN	IN	_	17	ADV	_	_
19	inducible	_	JJ	JJ	_	20	NMOD	_	_
20	activation	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	transcription	_	NN	NN	_	21	PMOD	_	_
23	.	_	.	.	_	6	P	_	_

1	Furthermore	_	RB	RB	_	12	ADV	_	_
2	,	_	,	,	_	12	P	_	_
3	these	_	DT	DT	_	5	NMOD	_	_
4	core	_	NN	NN	_	5	NMOD	_	_
5	regions	_	NNS	NNS	_	12	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	enhancer	_	NN	NN	_	6	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	promoter	_	NN	NN	_	8	COORD	_	_
11	each	_	DT	DT	_	8	NMOD	_	_
12	encompass	_	VBP	VBP	_	0	ROOT-S	_	_
13	closely	_	RB	RB	_	14	AMOD	_	_
14	linked	_	VBN	VBN	_	16	NMOD	_	_
15	binding	_	VBG	VBG	_	16	NMOD	_	_
16	sites	_	NNS	NNS	_	12	OBJ	_	_
17	for	_	IN	IN	_	16	NMOD	_	_
18	CBF	_	NN	NN	_	17	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	AP-1	_	NN	NN	_	18	COORD	_	_
21	,	_	,	,	_	18	P	_	_
22	and	_	CC	CC	_	18	CC	_	_
23	NFATp	_	NN	NN	_	18	COORD	_	_
24	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	GM-CSF	_	NN	NN	_	6	NMOD	_	_
3	promoter	_	NN	NN	_	6	NMOD	_	_
4	CBF	_	NN	NN	_	6	NMOD	_	_
5	site	_	NN	NN	_	6	NMOD	_	_
6	TGTGGTCA	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	located	_	JJ	JJ	_	11	AMOD	_	_
9	51	_	CD	CD	_	10	AMOD	_	_
10	bp	_	NN	NN	_	11	AMOD	_	_
11	upstream	_	RB	RB	_	7	PRD	_	_
12	of	_	IN	IN	_	11	AMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	transcription	_	NN	NN	_	16	NMOD	_	_
15	start	_	NN	NN	_	16	NMOD	_	_
16	site	_	NN	NN	_	12	PMOD	_	_
17	and	_	CC	CC	_	7	CC	_	_
18	also	_	RB	RB	_	7	COORD	_	_
19	overlaps	_	VBZ	VBZ	_	7	COORD	_	_
20	a	_	DT	DT	_	23	NMOD	_	_
21	YY-1	_	NN	NN	_	23	NMOD	_	_
22	binding	_	NN	NN	_	23	NMOD	_	_
23	site	_	NN	NN	_	19	OBJ	_	_
24	.	_	.	.	_	7	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	2-bp	_	JJ	JJ	_	3	NMOD	_	_
3	mutation	_	NN	NN	_	8	SBJ	_	_
4	within	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	CBF	_	NN	NN	_	7	NMOD	_	_
7	site	_	NN	NN	_	4	PMOD	_	_
8	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	2-3-fold	_	JJ	JJ	_	12	NMOD	_	_
12	decrease	_	NN	NN	_	9	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	activities	_	NNS	NNS	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	both	_	CC	CC	_	22	CC	_	_
18	a	_	DT	DT	_	22	NMOD	_	_
19	69-bp	_	JJ	JJ	_	22	NMOD	_	_
20	proximal	_	JJ	JJ	_	22	NMOD	_	_
21	promoter	_	NN	NN	_	22	NMOD	_	_
22	fragment	_	NN	NN	_	16	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	a	_	DT	DT	_	28	NMOD	_	_
25	627-bp	_	JJ	JJ	_	28	NMOD	_	_
26	full-length	_	NN	NN	_	28	NMOD	_	_
27	promoter	_	NN	NN	_	28	NMOD	_	_
28	fragment	_	NN	NN	_	22	COORD	_	_
29	.	_	.	.	_	8	P	_	_

1	Stepwise	_	JJ	JJ	_	2	NMOD	_	_
2	deletions	_	NNS	NNS	_	8	SBJ	_	_
3	into	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	proximal	_	JJ	JJ	_	6	NMOD	_	_
6	promoter	_	NN	NN	_	3	PMOD	_	_
7	also	_	RB	RB	_	8	ADV	_	_
8	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	CBF	_	NN	NN	_	12	NMOD	_	_
12	site	_	NN	NN	_	20	SBJ	_	_
13	,	_	,	,	_	12	P	_	_
14	but	_	CC	CC	_	12	CC	_	_
15	not	_	RB	RB	_	14	COORD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	YY-1	_	NN	NN	_	18	NMOD	_	_
18	site	_	NN	NN	_	12	COORD	_	_
19	,	_	,	,	_	12	P	_	_
20	was	_	VBD	VBD	_	9	VMOD	_	_
21	required	_	VBN	VBN	_	20	VC	_	_
22	for	_	IN	IN	_	21	ADV	_	_
23	efficient	_	JJ	JJ	_	24	NMOD	_	_
24	induction	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	transcriptional	_	JJ	JJ	_	27	NMOD	_	_
27	activation	_	NN	NN	_	25	PMOD	_	_
28	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	AML1	_	NN	NN	_	6	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	CBF	_	NN	NN	_	5	NMOD	_	_
5	beta	_	NN	NN	_	2	COORD	_	_
6	genes	_	NNS	NNS	_	11	SBJ	_	_
7	that	_	WDT	WDT	_	8	SBJ	_	_
8	encode	_	VBP	VBP	_	6	NMOD	_	_
9	CBF	_	NN	NN	_	8	OBJ	_	_
10	each	_	DT	DT	_	6	NMOD	_	_
11	have	_	VBP	VBP	_	0	ROOT-S	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	ability	_	NN	NN	_	11	OBJ	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	influence	_	VB	VB	_	13	NMOD	_	_
16	cell	_	NN	NN	_	15	OBJ	_	_
17	growth	_	NN	NN	_	16	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	differentiation	_	NN	NN	_	17	COORD	_	_
20	and	_	CC	CC	_	11	CC	_	_
21	have	_	VBP	VBP	_	11	COORD	_	_
22	been	_	VBN	VBN	_	23	NMOD	_	_
23	implicated	_	VBN	VBN	_	21	OBJ	_	_
24	as	_	IN	IN	_	23	ADV	_	_
25	proto-oncogenes	_	NNS	NNS	_	24	PMOD	_	_
26	in	_	IN	IN	_	23	ADV	_	_
27	acute	_	JJ	JJ	_	29	NMOD	_	_
28	myeloid	_	JJ	JJ	_	29	NMOD	_	_
29	leukemia	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	11	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	study	_	NN	NN	_	3	SBJ	_	_
3	adds	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	GM-CSF	_	NN	NN	_	3	OBJ	_	_
5	to	_	TO	TO	_	3	ADV	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	growing	_	VBG	VBG	_	8	NMOD	_	_
8	list	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	cytokines	_	NNS	NNS	_	9	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	receptors	_	NNS	NNS	_	10	COORD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	are	_	VBP	VBP	_	10	NMOD	_	_
15	regulated	_	VBN	VBN	_	14	VC	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	CBF	_	NN	NN	_	16	PMOD	_	_
18	and	_	CC	CC	_	14	CC	_	_
19	which	_	WDT	WDT	_	20	SBJ	_	_
20	control	_	VBP	VBP	_	14	COORD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	growth	_	NN	NN	_	20	OBJ	_	_
23	,	_	,	,	_	22	P	_	_
24	differentiation	_	NN	NN	_	22	COORD	_	_
25	,	_	,	,	_	22	P	_	_
26	and	_	CC	CC	_	22	CC	_	_
27	activation	_	NN	NN	_	22	COORD	_	_
28	of	_	IN	IN	_	22	NMOD	_	_
29	hemopoietic	_	JJ	JJ	_	30	NMOD	_	_
30	cells	_	NNS	NNS	_	28	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	GM-CSF	_	NN	NN	_	3	NMOD	_	_
3	locus	_	NN	NN	_	4	SBJ	_	_
4	may	_	MD	MD	_	0	ROOT-S	_	_
5	represent	_	VB	VB	_	4	VC	_	_
6	one	_	CD	CD	_	5	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	several	_	JJ	JJ	_	10	NMOD	_	_
9	target	_	NN	NN	_	10	NMOD	_	_
10	genes	_	NNS	NNS	_	7	PMOD	_	_
11	that	_	WDT	WDT	_	12	SBJ	_	_
12	are	_	VBP	VBP	_	10	NMOD	_	_
13	dysregulated	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	acute	_	JJ	JJ	_	17	NMOD	_	_
16	myeloid	_	JJ	JJ	_	17	NMOD	_	_
17	leukemia	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	4	P	_	_

1	Tyloxapol	_	NN	NN	_	2	SBJ	_	_
2	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	NF-kappa	_	NN	NN	_	4	NMOD	_	_
4	B	_	NN	NN	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	cytokine	_	NN	NN	_	4	COORD	_	_
7	release	_	NN	NN	_	2	OBJ	_	_
8	,	_	,	,	_	2	P	_	_
9	scavenges	_	VBZ	VBZ	_	2	COORD	_	_
10	HOCI	_	NN	NN	_	9	OBJ	_	_
11	,	_	,	,	_	2	P	_	_
12	and	_	CC	CC	_	2	CC	_	_
13	reduces	_	VBZ	VBZ	_	2	COORD	_	_
14	viscosity	_	NN	NN	_	13	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	cystic	_	JJ	JJ	_	18	NMOD	_	_
17	fibrosis	_	NN	NN	_	18	NMOD	_	_
18	sputum	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	Cystic	_	JJ	JJ	_	2	NMOD	_	_
2	fibrosis	_	NN	NN	_	6	NMOD	_	_
3	(	_	(	(	_	4	P	_	_
4	CF	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	patients	_	NNS	NNS	_	7	SBJ	_	_
7	develop	_	VB	VB	_	0	ROOT-S	_	_
8	progressive	_	JJ	JJ	_	12	NMOD	_	_
9	cytokine-mediated	_	JJ	JJ	_	12	NMOD	_	_
10	inflammatory	_	JJ	JJ	_	12	NMOD	_	_
11	lung	_	NN	NN	_	12	NMOD	_	_
12	disease	_	NN	NN	_	7	OBJ	_	_
13	,	_	,	,	_	12	P	_	_
14	with	_	IN	IN	_	12	NMOD	_	_
15	abundant	_	JJ	JJ	_	16	NMOD	_	_
16	production	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	thick	_	JJ	JJ	_	27	NMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	tenacious	_	JJ	JJ	_	18	COORD	_	_
21	,	_	,	,	_	18	P	_	_
22	protease-	_	NN	NN	_	18	COORD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	oxidant-rich	_	JJ	JJ	_	22	COORD	_	_
25	purulent	_	JJ	JJ	_	27	NMOD	_	_
26	airway	_	NN	NN	_	27	NMOD	_	_
27	secretions	_	NNS	NNS	_	17	PMOD	_	_
28	that	_	WDT	WDT	_	29	SBJ	_	_
29	are	_	VBP	VBP	_	27	NMOD	_	_
30	difficult	_	JJ	JJ	_	29	PRD	_	_
31	to	_	TO	TO	_	32	VMOD	_	_
32	clear	_	VB	VB	_	30	AMOD	_	_
33	even	_	RB	RB	_	34	DEP	_	_
34	with	_	IN	IN	_	32	ADV	_	_
35	physiotherapy	_	NN	NN	_	34	PMOD	_	_
36	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	search	_	NN	NN	_	1	PMOD	_	_
4	for	_	IN	IN	_	3	NMOD	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	potential	_	JJ	JJ	_	7	NMOD	_	_
7	treatment	_	NN	NN	_	4	PMOD	_	_
8	,	_	,	,	_	10	P	_	_
9	we	_	PRP	PRP	_	10	SBJ	_	_
10	have	_	VBP	VBP	_	0	ROOT-S	_	_
11	tested	_	VBN	VBN	_	10	VC	_	_
12	tyloxapol	_	NN	NN	_	11	OBJ	_	_
13	,	_	,	,	_	12	P	_	_
14	an	_	DT	DT	_	19	NMOD	_	_
15	alkylaryl	_	NN	NN	_	19	NMOD	_	_
16	polyether	_	JJ	JJ	_	19	NMOD	_	_
17	alcohol	_	NN	NN	_	19	NMOD	_	_
18	polymer	_	NN	NN	_	19	NMOD	_	_
19	detergent	_	NN	NN	_	12	NMOD	_	_
20	previously	_	RB	RB	_	21	TMP	_	_
21	used	_	VBN	VBN	_	19	NMOD	_	_
22	as	_	IN	IN	_	21	ADV	_	_
23	a	_	DT	DT	_	25	NMOD	_	_
24	mucolytic	_	JJ	JJ	_	25	NMOD	_	_
25	agent	_	NN	NN	_	22	PMOD	_	_
26	in	_	IN	IN	_	21	ADV	_	_
27	adult	_	JJ	JJ	_	29	NMOD	_	_
28	chronic	_	JJ	JJ	_	29	NMOD	_	_
29	bronchitis	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	10	P	_	_

1	Tyloxapol	_	NN	NN	_	2	SBJ	_	_
2	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	activation	_	NN	NN	_	2	OBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factor	_	NN	NN	_	4	PMOD	_	_
8	nuclear	_	JJ	JJ	_	10	NMOD	_	_
9	factor-kappa	_	NN	NN	_	10	NMOD	_	_
10	B	_	NN	NN	_	7	NMOD	_	_
11	(	_	(	(	_	13	P	_	_
12	NK-kappa	_	NN	NN	_	13	NMOD	_	_
13	B	_	NN	NN	_	10	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	,	_	,	,	_	2	P	_	_
16	reduces	_	VBZ	VBZ	_	2	COORD	_	_
17	resting	_	VBG	VBG	_	18	NMOD	_	_
18	secretion	_	NN	NN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	cytokine	_	NN	NN	_	19	PMOD	_	_
22	interleukin-8	_	NN	NN	_	21	NMOD	_	_
23	(	_	(	(	_	24	P	_	_
24	IL-8	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	in	_	IN	IN	_	21	NMOD	_	_
27	cultured	_	VBN	VBN	_	29	NMOD	_	_
28	human	_	JJ	JJ	_	29	NMOD	_	_
29	monocytes	_	NNS	NNS	_	26	PMOD	_	_
30	,	_	,	,	_	2	P	_	_
31	and	_	CC	CC	_	2	CC	_	_
32	inhibits	_	VBZ	VBZ	_	2	COORD	_	_
33	lipopolysaccharide	_	NN	NN	_	35	AMOD	_	_
34	(	_	(	(	_	35	P	_	_
35	LPS	_	NN	NN	_	38	NMOD	_	_
36	)	_	)	)	_	35	P	_	_
37	-stimulated	_	JJ	JJ	_	35	AMOD	_	_
38	release	_	NN	NN	_	32	OBJ	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	tumor	_	NN	NN	_	42	NMOD	_	_
41	necrosis	_	NN	NN	_	42	NMOD	_	_
42	factor-alpha	_	NN	NN	_	39	PMOD	_	_
43	(	_	(	(	_	44	P	_	_
44	TNF-alpha	_	NN	NN	_	42	PRN	_	_
45	)	_	)	)	_	44	P	_	_
46	,	_	,	,	_	42	P	_	_
47	IL-1	_	NN	NN	_	48	NMOD	_	_
48	beta	_	NN	NN	_	42	COORD	_	_
49	,	_	,	,	_	42	P	_	_
50	IL-6	_	NN	NN	_	42	COORD	_	_
51	,	_	,	,	_	42	P	_	_
52	IL-8	_	NN	NN	_	42	COORD	_	_
53	,	_	,	,	_	42	P	_	_
54	granulocyte-macrophage	_	JJ	JJ	_	56	NMOD	_	_
55	colony-stimulating	_	JJ	JJ	_	56	NMOD	_	_
56	factor	_	NN	NN	_	42	COORD	_	_
57	(	_	(	(	_	58	P	_	_
58	GM-CSF	_	NN	NN	_	56	PRN	_	_
59	)	_	)	)	_	58	P	_	_
60	,	_	,	,	_	42	P	_	_
61	and	_	CC	CC	_	42	CC	_	_
62	the	_	DT	DT	_	63	NMOD	_	_
63	eiconsanoids	_	NNS	NNS	_	42	COORD	_	_
64	thromboxane	_	NN	NN	_	65	NMOD	_	_
65	A2	_	NN	NN	_	63	NMOD	_	_
66	and	_	CC	CC	_	65	CC	_	_
67	leukotriene	_	NN	NN	_	68	NMOD	_	_
68	B4	_	NN	NN	_	65	COORD	_	_
69	(	_	(	(	_	70	P	_	_
70	LTB4	_	NN	NN	_	68	PRN	_	_
71	)	_	)	)	_	70	P	_	_
72	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	previously	_	RB	RB	_	2	TMP	_	_
4	shown	_	VBN	VBN	_	2	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	tyloxapol	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	5	VMOD	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	potent	_	JJ	JJ	_	10	NMOD	_	_
10	antioxidant	_	NN	NN	_	7	PRD	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	hydroxyl	_	NN	NN	_	13	NMOD	_	_
13	radicals	_	NNS	NNS	_	11	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	OH	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	.	_	.	.	_	2	P	_	_

1	Tyloxapol	_	NN	NN	_	10	SBJ	_	_
2	(	_	(	(	_	7	P	_	_
3	0.05	_	CD	CD	_	5	DEP	_	_
4	to	_	TO	TO	_	5	DEP	_	_
5	0.1	_	CD	CD	_	7	NMOD	_	_
6	%	_	NN	NN	_	5	AMOD	_	_
7	wt\/vol	_	NN	NN	_	1	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	effectively	_	RB	RB	_	10	ADV	_	_
10	scavenges	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	oxidant	_	JJ	JJ	_	14	NMOD	_	_
13	hypochlorous	_	JJ	JJ	_	14	NMOD	_	_
14	acid	_	NN	NN	_	10	OBJ	_	_
15	(	_	(	(	_	16	P	_	_
16	HOCl	_	NN	NN	_	14	PRN	_	_
17	;	_	:	:	_	16	P	_	_
18	1	_	CD	CD	_	20	DEP	_	_
19	to	_	TO	TO	_	20	DEP	_	_
20	7.5	_	CD	CD	_	21	NMOD	_	_
21	mM	_	NN	NN	_	16	NMOD	_	_
22	)	_	)	)	_	16	P	_	_
23	in	_	FW	FW	_	10	ADV	_	_
24	vitro	_	FW	FW	_	23	AMOD	_	_
25	,	_	,	,	_	10	P	_	_
26	and	_	CC	CC	_	10	CC	_	_
27	protects	_	VBZ	VBZ	_	10	COORD	_	_
28	from	_	IN	IN	_	27	ADV	_	_
29	HOCl-mediated	_	JJ	JJ	_	31	NMOD	_	_
30	lung	_	NN	NN	_	31	NMOD	_	_
31	injury	_	NN	NN	_	28	PMOD	_	_
32	in	_	IN	IN	_	27	ADV	_	_
33	rats	_	NNS	NNS	_	32	PMOD	_	_
34	.	_	.	.	_	10	P	_	_

1	Tyloxapol	_	NN	NN	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	reduces	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	viscosity	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	CF	_	NN	NN	_	8	NMOD	_	_
8	sputum	_	NN	NN	_	6	PMOD	_	_
9	(	_	(	(	_	3	P	_	_
10	from	_	IN	IN	_	3	ADV	_	_
11	463	_	CD	CD	_	18	NMOD	_	_
12	+\/-	_	CC	CC	_	11	CC	_	_
13	133	_	CD	CD	_	11	COORD	_	_
14	to	_	TO	TO	_	3	ADV	_	_
15	128	_	CD	CD	_	14	NMOD	_	_
16	+\/-	_	CC	CC	_	15	CC	_	_
17	52	_	CD	CD	_	15	COORD	_	_
18	centipoise	_	NN	NN	_	10	PMOD	_	_
19	)	_	)	)	_	3	P	_	_
20	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	conclude	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	tyloxapol	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	3	VMOD	_	_
6	potentially	_	RB	RB	_	5	ADV	_	_
7	useful	_	JJ	JJ	_	5	PRD	_	_
8	as	_	IN	IN	_	7	AMOD	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	new	_	JJ	JJ	_	12	NMOD	_	_
11	antiinflammatory	_	JJ	JJ	_	12	NMOD	_	_
12	therapy	_	NN	NN	_	8	PMOD	_	_
13	for	_	IN	IN	_	12	NMOD	_	_
14	CF	_	NN	NN	_	16	NMOD	_	_
15	lung	_	NN	NN	_	16	NMOD	_	_
16	disease	_	NN	NN	_	13	PMOD	_	_
17	,	_	,	,	_	5	P	_	_
18	and	_	CC	CC	_	5	CC	_	_
19	could	_	MD	MD	_	5	COORD	_	_
20	possibly	_	RB	RB	_	19	ADV	_	_
21	promote	_	VB	VB	_	19	VC	_	_
22	clearance	_	NN	NN	_	21	OBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	secretions	_	NNS	NNS	_	23	PMOD	_	_
25	in	_	IN	IN	_	22	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	CF	_	NN	NN	_	28	NMOD	_	_
28	airway	_	NN	NN	_	25	PMOD	_	_
29	.	_	.	.	_	2	P	_	_

1	Severe	_	JJ	JJ	_	3	NMOD	_	_
2	combined	_	JJ	JJ	_	3	NMOD	_	_
3	immunodeficiency	_	NN	NN	_	0	ROOT-FRAG	_	_
4	due	_	IN	IN	_	3	NMOD	_	_
5	to	_	TO	TO	_	4	DEP	_	_
6	defective	_	JJ	JJ	_	7	NMOD	_	_
7	binding	_	NN	NN	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	nuclear	_	JJ	JJ	_	11	NMOD	_	_
11	factor	_	NN	NN	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	activated	_	VBN	VBN	_	15	NMOD	_	_
14	T	_	NN	NN	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	12	PMOD	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	T	_	NN	NN	_	18	NMOD	_	_
18	lymphocytes	_	NNS	NNS	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	two	_	CD	CD	_	22	NMOD	_	_
21	male	_	JJ	JJ	_	22	NMOD	_	_
22	siblings	_	NNS	NNS	_	19	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	Peripheral	_	JJ	JJ	_	3	NMOD	_	_
2	blood	_	NN	NN	_	3	NMOD	_	_
3	lymphocytes	_	NNS	NNS	_	29	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	PBL	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	and	_	CC	CC	_	3	CC	_	_
8	alloreactive	_	JJ	JJ	_	11	NMOD	_	_
9	T	_	NN	NN	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	lines	_	NNS	NNS	_	3	COORD	_	_
12	of	_	IN	IN	_	3	NMOD	_	_
13	two	_	CD	CD	_	15	NMOD	_	_
14	male	_	JJ	JJ	_	15	NMOD	_	_
15	infants	_	NNS	NNS	_	12	PMOD	_	_
16	born	_	VBN	VBN	_	15	NMOD	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	consanguinous	_	JJ	JJ	_	19	NMOD	_	_
19	parents	_	NNS	NNS	_	17	PMOD	_	_
20	and	_	CC	CC	_	16	CC	_	_
21	presenting	_	VBG	VBG	_	16	COORD	_	_
22	with	_	IN	IN	_	21	ADV	_	_
23	severe	_	JJ	JJ	_	25	NMOD	_	_
24	combined	_	JJ	JJ	_	25	NMOD	_	_
25	immunodeficiency	_	NN	NN	_	22	PMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	SCID	_	NN	NN	_	25	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	showed	_	VBD	VBD	_	0	ROOT-S	_	_
30	a	_	DT	DT	_	32	NMOD	_	_
31	pronounced	_	JJ	JJ	_	32	NMOD	_	_
32	deficiency	_	NN	NN	_	29	OBJ	_	_
33	in	_	IN	IN	_	32	NMOD	_	_
34	T	_	NN	NN	_	36	NMOD	_	_
35	cell	_	NN	NN	_	36	NMOD	_	_
36	activation	_	NN	NN	_	33	PMOD	_	_
37	.	_	.	.	_	29	P	_	_

1	Although	_	IN	IN	_	14	ADV	_	_
2	phenotypically	_	RB	RB	_	3	AMOD	_	_
3	normal	_	JJ	JJ	_	1	VMOD	_	_
4	,	_	,	,	_	14	P	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	proliferative	_	JJ	JJ	_	7	NMOD	_	_
7	response	_	NN	NN	_	14	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	childrens	_	NNS	NNS	_	13	NMOD	_	_
11	'	_	POS	POS	_	10	NMOD	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	8	PMOD	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	strongly	_	RB	RB	_	14	ADV	_	_
16	reduced	_	VBN	VBN	_	14	VC	_	_
17	but	_	CC	CC	_	14	CC	_	_
18	could	_	MD	MD	_	14	COORD	_	_
19	be	_	VB	VB	_	18	VC	_	_
20	improved	_	VBN	VBN	_	19	VC	_	_
21	by	_	IN	IN	_	14	LGS	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	addition	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	interleukin-2	_	NN	NN	_	24	PMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	IL-2	_	NN	NN	_	25	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	.	_	.	.	_	14	P	_	_

1	Furthermore	_	RB	RB	_	7	ADV	_	_
2	both	_	DT	DT	_	3	NMOD	_	_
3	childrens	_	NNS	NNS	_	6	NMOD	_	_
4	'	_	POS	POS	_	3	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	7	SBJ	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	unable	_	JJ	JJ	_	7	PRD	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	produce	_	VB	VB	_	8	AMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	cytokines	_	NNS	NNS	_	10	OBJ	_	_
13	IL-2	_	NN	NN	_	12	NMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	interferon-gamma	_	NN	NN	_	13	COORD	_	_
16	(	_	(	(	_	17	P	_	_
17	IFN-gamma	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	,	_	,	,	_	13	P	_	_
20	IL-4	_	NN	NN	_	13	COORD	_	_
21	and	_	CC	CC	_	13	CC	_	_
22	tumor	_	NN	NN	_	24	NMOD	_	_
23	necrosis	_	NN	NN	_	24	NMOD	_	_
24	factor-alpha	_	NN	NN	_	13	COORD	_	_
25	(	_	(	(	_	26	P	_	_
26	TNF-alpha	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	.	_	.	.	_	7	P	_	_

1	This	_	DT	DT	_	5	NMOD	_	_
2	multiple	_	JJ	JJ	_	5	NMOD	_	_
3	cytokine	_	NN	NN	_	5	NMOD	_	_
4	production	_	NN	NN	_	5	NMOD	_	_
5	deficiency	_	NN	NN	_	6	SBJ	_	_
6	could	_	MD	MD	_	0	ROOT-S	_	_
7	not	_	RB	RB	_	6	VMOD	_	_
8	be	_	VB	VB	_	6	VC	_	_
9	restored	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	IL-2	_	NN	NN	_	14	NMOD	_	_
12	or	_	CC	CC	_	11	CC	_	_
13	co-stimulatory	_	JJ	JJ	_	11	COORD	_	_
14	signals	_	NNS	NNS	_	10	PMOD	_	_
15	provided	_	VBN	VBN	_	14	NMOD	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	antigen-presenting	_	JJ	JJ	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	16	PMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	APC	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	.	_	.	.	_	6	P	_	_

1	Moreover	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	mRNA	_	NN	NN	_	8	SBJ	_	_
4	for	_	IN	IN	_	3	NMOD	_	_
5	IL-2	_	NN	NN	_	4	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	IFN-gamma	_	NN	NN	_	5	COORD	_	_
8	could	_	MD	MD	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	be	_	VB	VB	_	8	VC	_	_
11	detected	_	VBN	VBN	_	10	VC	_	_
12	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	14	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	14	P	_	_
4	expression	_	NN	NN	_	14	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	activation-dependent	_	JJ	JJ	_	10	NMOD	_	_
8	cell	_	NN	NN	_	10	NMOD	_	_
9	surface	_	NN	NN	_	10	NMOD	_	_
10	markers	_	NNS	NNS	_	5	PMOD	_	_
11	CD25	_	NN	NN	_	10	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	CD69	_	NN	NN	_	11	COORD	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	within	_	IN	IN	_	14	PRD	_	_
16	normal	_	JJ	JJ	_	17	NMOD	_	_
17	limits	_	NNS	NNS	_	15	PMOD	_	_
18	.	_	.	.	_	14	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	determine	_	VB	VB	_	34	VC	_	_
3	whether	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	functional	_	JJ	JJ	_	6	NMOD	_	_
6	defect	_	NN	NN	_	13	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	patients	_	NNS	NNS	_	12	NMOD	_	_
10	'	_	POS	POS	_	9	NMOD	_	_
11	T	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	7	PMOD	_	_
13	was	_	VBD	VBD	_	3	VMOD	_	_
14	due	_	JJ	JJ	_	15	DEP	_	_
15	to	_	TO	TO	_	13	PRD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	absence	_	NN	NN	_	15	PMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	abnormal	_	JJ	JJ	_	20	NMOD	_	_
20	binding	_	NN	NN	_	17	COORD	_	_
21	of	_	IN	IN	_	17	NMOD	_	_
22	transcription	_	NN	NN	_	23	NMOD	_	_
23	factors	_	NNS	NNS	_	21	PMOD	_	_
24	involved	_	VBN	VBN	_	23	NMOD	_	_
25	in	_	IN	IN	_	24	ADV	_	_
26	cytokine	_	NN	NN	_	28	NMOD	_	_
27	gene	_	NN	NN	_	28	NMOD	_	_
28	expression	_	NN	NN	_	25	PMOD	_	_
29	,	_	,	,	_	34	P	_	_
30	electrophoretic	_	JJ	JJ	_	33	NMOD	_	_
31	mobility	_	NN	NN	_	33	NMOD	_	_
32	shift	_	NN	NN	_	33	NMOD	_	_
33	assays	_	NNS	NNS	_	34	SBJ	_	_
34	were	_	VBD	VBD	_	0	ROOT-S	_	_
35	used	_	VBN	VBN	_	34	VC	_	_
36	to	_	TO	TO	_	37	VMOD	_	_
37	examine	_	VB	VB	_	35	OBJ	_	_
38	the	_	DT	DT	_	40	NMOD	_	_
39	DNA	_	NN	NN	_	40	NMOD	_	_
40	binding	_	NN	NN	_	37	OBJ	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	AP-1	_	NN	NN	_	41	PMOD	_	_
43	,	_	,	,	_	42	P	_	_
44	Oct	_	NN	NN	_	42	COORD	_	_
45	,	_	,	,	_	42	P	_	_
46	CREB	_	NN	NN	_	42	COORD	_	_
47	,	_	,	,	_	42	P	_	_
48	SP1	_	NN	NN	_	42	COORD	_	_
49	,	_	,	,	_	42	P	_	_
50	NF-kappa	_	NN	NN	_	51	NMOD	_	_
51	B	_	NN	NN	_	42	COORD	_	_
52	and	_	CC	CC	_	42	CC	_	_
53	the	_	DT	DT	_	55	NMOD	_	_
54	nuclear	_	JJ	JJ	_	55	NMOD	_	_
55	factor	_	NN	NN	_	42	COORD	_	_
56	of	_	IN	IN	_	55	NMOD	_	_
57	activated	_	VBN	VBN	_	59	NMOD	_	_
58	T	_	NN	NN	_	59	NMOD	_	_
59	cells	_	NNS	NNS	_	56	PMOD	_	_
60	(	_	(	(	_	61	P	_	_
61	NF-AT	_	NN	NN	_	55	PRN	_	_
62	)	_	)	)	_	61	P	_	_
63	to	_	TO	TO	_	40	NMOD	_	_
64	their	_	PRP$	PRP$	_	67	NMOD	_	_
65	respective	_	JJ	JJ	_	67	NMOD	_	_
66	response	_	NN	NN	_	67	NMOD	_	_
67	elements	_	NNS	NNS	_	63	PMOD	_	_
68	in	_	IN	IN	_	67	NMOD	_	_
69	the	_	DT	DT	_	70	NMOD	_	_
70	promoter	_	NN	NN	_	68	PMOD	_	_
71	of	_	IN	IN	_	70	NMOD	_	_
72	the	_	DT	DT	_	74	NMOD	_	_
73	IL-2	_	NN	NN	_	74	NMOD	_	_
74	gene	_	NN	NN	_	71	PMOD	_	_
75	.	_	.	.	_	34	P	_	_

1	Whereas	_	IN	IN	_	30	ADV	_	_
2	AP-1	_	NN	NN	_	12	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	NF-kappa	_	NN	NN	_	5	NMOD	_	_
5	B	_	NN	NN	_	2	COORD	_	_
6	,	_	,	,	_	2	P	_	_
7	Oct	_	NN	NN	_	2	COORD	_	_
8	,	_	,	,	_	2	P	_	_
9	CREB	_	NN	NN	_	2	COORD	_	_
10	and	_	CC	CC	_	2	CC	_	_
11	SP1	_	NN	NN	_	2	COORD	_	_
12	displayed	_	VBD	VBD	_	1	VMOD	_	_
13	normal	_	JJ	JJ	_	15	NMOD	_	_
14	binding	_	NN	NN	_	15	NMOD	_	_
15	activities	_	NNS	NNS	_	12	OBJ	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	nuclear	_	JJ	JJ	_	18	NMOD	_	_
18	extracts	_	NNS	NNS	_	16	PMOD	_	_
19	,	_	,	,	_	30	P	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	binding	_	NN	NN	_	30	SBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	NF-AT	_	NN	NN	_	22	PMOD	_	_
24	to	_	TO	TO	_	21	NMOD	_	_
25	its	_	PRP$	PRP$	_	29	NMOD	_	_
26	IL-2	_	NN	NN	_	29	NMOD	_	_
27	promoter	_	NN	NN	_	29	NMOD	_	_
28	response	_	NN	NN	_	29	NMOD	_	_
29	element	_	NN	NN	_	24	PMOD	_	_
30	was	_	VBD	VBD	_	0	ROOT-S	_	_
31	barely	_	RB	RB	_	32	AMOD	_	_
32	detectable	_	JJ	JJ	_	30	PRD	_	_
33	both	_	CC	CC	_	30	TMP	_	_
34	before	_	IN	IN	_	33	COORD	_	_
35	and	_	CC	CC	_	33	CC	_	_
36	after	_	IN	IN	_	33	COORD	_	_
37	T	_	NN	NN	_	39	NMOD	_	_
38	cell	_	NN	NN	_	39	NMOD	_	_
39	stimulation	_	NN	NN	_	34	PMOD	_	_
40	.	_	.	.	_	30	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	4	SBJ	_	_
3	strongly	_	RB	RB	_	4	ADV	_	_
4	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	this	_	DT	DT	_	9	NMOD	_	_
7	NF-AT\/DNA	_	NN	NN	_	9	NMOD	_	_
8	binding	_	NN	NN	_	9	NMOD	_	_
9	defect	_	NN	NN	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	5	VMOD	_	_
11	responsible	_	JJ	JJ	_	10	PRD	_	_
12	for	_	IN	IN	_	11	AMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	multiple	_	JJ	JJ	_	16	NMOD	_	_
15	cytokine	_	NN	NN	_	16	NMOD	_	_
16	deficiency	_	NN	NN	_	12	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	SCID	_	NN	NN	_	20	NMOD	_	_
20	phenotype	_	NN	NN	_	16	COORD	_	_
21	observed	_	VBN	VBN	_	16	NMOD	_	_
22	in	_	IN	IN	_	21	ADV	_	_
23	the	_	DT	DT	_	26	NMOD	_	_
24	two	_	CD	CD	_	26	NMOD	_	_
25	infant	_	JJ	JJ	_	26	NMOD	_	_
26	brothers	_	NNS	NNS	_	22	PMOD	_	_
27	.	_	.	.	_	4	P	_	_

1	Requirements	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	for	_	IN	IN	_	1	NMOD	_	_
3	induction	_	NN	NN	_	2	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	vitamin	_	NN	NN	_	8	NMOD	_	_
6	D-mediated	_	JJ	JJ	_	5	AMOD	_	_
7	gene	_	NN	NN	_	8	NMOD	_	_
8	regulation	_	NN	NN	_	4	PMOD	_	_
9	in	_	IN	IN	_	3	NMOD	_	_
10	normal	_	JJ	JJ	_	13	NMOD	_	_
11	human	_	JJ	JJ	_	13	NMOD	_	_
12	B	_	NN	NN	_	13	NMOD	_	_
13	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
14	.	_	.	.	_	1	P	_	_

1	Mature	_	JJ	JJ	_	3	NMOD	_	_
2	human	_	JJ	JJ	_	3	NMOD	_	_
3	lymphocytes	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	unique	_	JJ	JJ	_	6	NMOD	_	_
6	targets	_	NNS	NNS	_	4	PRD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	1	_	CD	CD	_	10	NMOD	_	_
9	alpha,25-dihydroxyvitamin	_	NN	NN	_	10	NMOD	_	_
10	D3	_	NN	NN	_	7	PMOD	_	_
11	(	_	(	(	_	13	P	_	_
12	1	_	CD	CD	_	13	NMOD	_	_
13	alpha,25-LRB-OH-RRB-2D3	_	NN	NN	_	10	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	in	_	IN	IN	_	4	ADV	_	_
16	that	_	IN	IN	_	15	PMOD	_	_
17	vitamin	_	NN	NN	_	19	NMOD	_	_
18	D	_	NN	NN	_	19	NMOD	_	_
19	receptors	_	NNS	NNS	_	23	SBJ	_	_
20	(	_	(	(	_	21	P	_	_
21	VDR	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	are	_	VBP	VBP	_	16	VMOD	_	_
24	not	_	RB	RB	_	23	VMOD	_	_
25	constitutively	_	RB	RB	_	26	ADV	_	_
26	expressed	_	VBN	VBN	_	23	VC	_	_
27	,	_	,	,	_	23	P	_	_
28	and	_	CC	CC	_	23	CC	_	_
29	specific	_	JJ	JJ	_	32	NMOD	_	_
30	cellular	_	JJ	JJ	_	32	NMOD	_	_
31	activation	_	NN	NN	_	32	NMOD	_	_
32	signals	_	NNS	NNS	_	33	SBJ	_	_
33	are	_	VBP	VBP	_	23	COORD	_	_
34	required	_	VBN	VBN	_	33	VC	_	_
35	for	_	IN	IN	_	34	ADV	_	_
36	both	_	DT	DT	_	38	NMOD	_	_
37	the	_	DT	DT	_	38	NMOD	_	_
38	up-regulation	_	NN	NN	_	35	PMOD	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	VDR	_	NN	NN	_	39	PMOD	_	_
41	and	_	CC	CC	_	38	CC	_	_
42	establishment	_	NN	NN	_	38	COORD	_	_
43	of	_	IN	IN	_	42	NMOD	_	_
44	reactivity	_	NN	NN	_	43	PMOD	_	_
45	to	_	TO	TO	_	44	NMOD	_	_
46	the	_	DT	DT	_	48	NMOD	_	_
47	lipophilic	_	JJ	JJ	_	48	NMOD	_	_
48	ligand	_	NN	NN	_	45	PMOD	_	_
49	.	_	.	.	_	4	P	_	_

1	Treatment	_	NN	NN	_	20	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	B	_	NN	NN	_	4	NMOD	_	_
4	lymphocytes	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	cytokine	_	NN	NN	_	8	NMOD	_	_
8	IL-4	_	NN	NN	_	5	PMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	IL-4	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	,	_	,	,	_	20	P	_	_
13	in	_	IN	IN	_	20	ADV	_	_
14	the	_	DT	DT	_	13	DEP	_	_
15	absence	_	NN	NN	_	13	DEP	_	_
16	of	_	IN	IN	_	13	DEP	_	_
17	prior	_	JJ	JJ	_	18	NMOD	_	_
18	activation	_	NN	NN	_	13	PMOD	_	_
19	,	_	,	,	_	20	P	_	_
20	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	weak	_	JJ	JJ	_	23	NMOD	_	_
23	up-regulation	_	NN	NN	_	20	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	VDR	_	NN	NN	_	26	NMOD	_	_
26	expression	_	NN	NN	_	24	PMOD	_	_
27	but	_	CC	CC	_	20	CC	_	_
28	fails	_	VBZ	VBZ	_	20	COORD	_	_
29	to	_	TO	TO	_	30	VMOD	_	_
30	generate	_	VB	VB	_	28	OBJ	_	_
31	vitamin	_	NN	NN	_	33	NMOD	_	_
32	D-responsive	_	JJ	JJ	_	31	AMOD	_	_
33	element	_	NN	NN	_	35	AMOD	_	_
34	(	_	(	(	_	35	P	_	_
35	VDRE	_	NN	NN	_	40	NMOD	_	_
36	)	_	)	)	_	35	P	_	_
37	-reactive	_	JJ	JJ	_	35	AMOD	_	_
38	nuclear	_	JJ	JJ	_	40	NMOD	_	_
39	protein	_	NN	NN	_	40	NMOD	_	_
40	complexes	_	NNS	NNS	_	30	OBJ	_	_
41	or	_	CC	CC	_	30	CC	_	_
42	to	_	TO	TO	_	43	VMOD	_	_
43	initiate	_	VB	VB	_	30	COORD	_	_
44	the	_	DT	DT	_	46	NMOD	_	_
45	genomic	_	JJ	JJ	_	46	NMOD	_	_
46	transcription	_	NN	NN	_	43	OBJ	_	_
47	of	_	IN	IN	_	46	NMOD	_	_
48	25-hydroxyvitamin	_	NN	NN	_	50	NMOD	_	_
49	D3	_	NN	NN	_	50	NMOD	_	_
50	24-hydroxylase	_	NN	NN	_	47	PMOD	_	_
51	.	_	.	.	_	20	P	_	_

1	Stimulation	_	NN	NN	_	16	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	B	_	NN	NN	_	4	NMOD	_	_
4	lymphocytes	_	NNS	NNS	_	2	PMOD	_	_
5	by	_	IN	IN	_	1	NMOD	_	_
6	either	_	CC	CC	_	5	PMOD	_	_
7	ligation	_	NN	NN	_	6	COORD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	CD40	_	NN	NN	_	10	NMOD	_	_
10	Ag	_	NN	NN	_	8	PMOD	_	_
11	or	_	CC	CC	_	6	CC	_	_
12	cross-linking	_	VBG	VBG	_	6	COORD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	Ig	_	NN	NN	_	15	NMOD	_	_
15	receptor	_	NN	NN	_	12	OBJ	_	_
16	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	also	_	RB	RB	_	16	ADV	_	_
18	insufficient	_	JJ	JJ	_	16	PRD	_	_
19	to	_	TO	TO	_	20	VMOD	_	_
20	render	_	VB	VB	_	18	AMOD	_	_
21	B	_	NN	NN	_	22	NMOD	_	_
22	lymphocytes	_	NNS	NNS	_	23	SBJ	_	_
23	responsive	_	JJ	JJ	_	20	OBJ	_	_
24	to	_	TO	TO	_	23	AMOD	_	_
25	1	_	CD	CD	_	26	NMOD	_	_
26	alpha,25-LRB-OH-RRB-2D3	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	16	P	_	_

1	However	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	this	_	DT	DT	_	5	NMOD	_	_
4	apparent	_	JJ	JJ	_	5	NMOD	_	_
5	lack	_	NN	NN	_	11	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	response	_	NN	NN	_	6	PMOD	_	_
8	to	_	TO	TO	_	7	NMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	secosterol	_	NN	NN	_	8	PMOD	_	_
11	can	_	MD	MD	_	0	ROOT-S	_	_
12	be	_	VB	VB	_	11	VC	_	_
13	overcome	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	stimulation	_	NN	NN	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	B	_	NN	NN	_	18	NMOD	_	_
18	lymphocytes	_	NNS	NNS	_	16	PMOD	_	_
19	with	_	IN	IN	_	15	NMOD	_	_
20	a	_	DT	DT	_	21	NMOD	_	_
21	combination	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	these	_	DT	DT	_	26	NMOD	_	_
24	cellular	_	JJ	JJ	_	26	NMOD	_	_
25	activation	_	NN	NN	_	26	NMOD	_	_
26	signals	_	NNS	NNS	_	22	PMOD	_	_
27	,	_	,	,	_	26	P	_	_
28	which	_	WDT	WDT	_	29	SBJ	_	_
29	are	_	VBP	VBP	_	26	NMOD	_	_
30	sufficient	_	JJ	JJ	_	29	PRD	_	_
31	to	_	TO	TO	_	32	VMOD	_	_
32	lead	_	VB	VB	_	30	AMOD	_	_
33	to	_	TO	TO	_	32	ADV	_	_
34	G1	_	NN	NN	_	37	NMOD	_	_
35	cell	_	NN	NN	_	37	NMOD	_	_
36	cycle	_	NN	NN	_	37	NMOD	_	_
37	progression	_	NN	NN	_	33	PMOD	_	_
38	.	_	.	.	_	11	P	_	_

1	In	_	IN	IN	_	17	ADV	_	_
2	the	_	DT	DT	_	1	DEP	_	_
3	presence	_	NN	NN	_	1	DEP	_	_
4	of	_	IN	IN	_	1	DEP	_	_
5	1	_	CD	CD	_	6	NMOD	_	_
6	alpha,25-LRB-OH-RRB-2D3	_	NN	NN	_	1	PMOD	_	_
7	,	_	,	,	_	17	P	_	_
8	cellular	_	JJ	JJ	_	9	NMOD	_	_
9	activation	_	NN	NN	_	17	SBJ	_	_
10	associated	_	VBN	VBN	_	9	NMOD	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	stimulation	_	NN	NN	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	such	_	PDT	PDT	_	16	NMOD	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	progression	_	NN	NN	_	13	PMOD	_	_
17	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	to	_	TO	TO	_	19	VMOD	_	_
19	be	_	VB	VB	_	17	OBJ	_	_
20	sufficient	_	JJ	JJ	_	19	PRD	_	_
21	for	_	IN	IN	_	20	AMOD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	up-regulation	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	VDR	_	NN	NN	_	26	NMOD	_	_
26	message	_	NN	NN	_	24	PMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	protein	_	NN	NN	_	26	COORD	_	_
29	and	_	CC	CC	_	20	CC	_	_
30	necessary	_	JJ	JJ	_	20	COORD	_	_
31	for	_	IN	IN	_	30	AMOD	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	establishment	_	NN	NN	_	31	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	VDRE	_	NN	NN	_	37	NMOD	_	_
36	binding	_	NN	NN	_	37	NMOD	_	_
37	complexes	_	NNS	NNS	_	34	PMOD	_	_
38	and	_	CC	CC	_	33	CC	_	_
39	the	_	DT	DT	_	40	NMOD	_	_
40	induction	_	NN	NN	_	33	COORD	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	24-hydroxylase	_	NN	NN	_	43	NMOD	_	_
43	message	_	NN	NN	_	41	PMOD	_	_
44	.	_	.	.	_	17	P	_	_

1	Furthermore	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	biologic	_	JJ	JJ	_	4	NMOD	_	_
4	functions	_	NNS	NNS	_	5	SBJ	_	_
5	are	_	VBP	VBP	_	0	ROOT-S	_	_
6	modulated	_	VBN	VBN	_	5	VC	_	_
7	,	_	,	,	_	6	P	_	_
8	in	_	IN	IN	_	12	ADV	_	_
9	that	_	IN	IN	_	8	PMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	hormone	_	NN	NN	_	12	SBJ	_	_
12	inhibits	_	VBZ	VBZ	_	6	OBJ	_	_
13	proliferation	_	NN	NN	_	12	OBJ	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	subset	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	activated	_	VBN	VBN	_	21	NMOD	_	_
20	B	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	17	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	observations	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	reactivity	_	NN	NN	_	9	SBJ	_	_
6	to	_	TO	TO	_	5	NMOD	_	_
7	1	_	CD	CD	_	8	NMOD	_	_
8	alpha,25-LRB-OH-RRB-2D3	_	NN	NN	_	6	PMOD	_	_
9	is	_	VBZ	VBZ	_	4	VMOD	_	_
10	tightly	_	RB	RB	_	11	ADV	_	_
11	regulated	_	VBN	VBN	_	9	VC	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	B	_	NN	NN	_	14	NMOD	_	_
14	lymphocytes	_	NNS	NNS	_	12	PMOD	_	_
15	,	_	,	,	_	11	P	_	_
16	requiring	_	VBG	VBG	_	11	OBJ	_	_
17	specific	_	JJ	JJ	_	18	NMOD	_	_
18	signals	_	NNS	NNS	_	16	OBJ	_	_
19	for	_	IN	IN	_	16	ADV	_	_
20	its	_	PRP$	PRP$	_	21	NMOD	_	_
21	initiation	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	Analysis	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	ligand-binding	_	JJ	JJ	_	5	NMOD	_	_
5	domain	_	NN	NN	_	2	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	human	_	JJ	JJ	_	11	NMOD	_	_
8	retinoic	_	JJ	JJ	_	11	NMOD	_	_
9	acid	_	NN	NN	_	11	NMOD	_	_
10	receptor	_	NN	NN	_	11	NMOD	_	_
11	alpha	_	NN	NN	_	6	PMOD	_	_
12	by	_	IN	IN	_	1	NMOD	_	_
13	site-directed	_	JJ	JJ	_	14	NMOD	_	_
14	mutagenesis	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	1	P	_	_

1	Three	_	CD	CD	_	2	NMOD	_	_
2	subtypes	_	NNS	NNS	_	22	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	retinoic	_	JJ	JJ	_	6	NMOD	_	_
5	acid	_	NN	NN	_	6	NMOD	_	_
6	receptors	_	NNS	NNS	_	3	PMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	RAR	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	,	_	,	,	_	2	P	_	_
11	termed	_	VBN	VBN	_	2	NMOD	_	_
12	RAR	_	NN	NN	_	13	NMOD	_	_
13	alpha	_	NN	NN	_	11	OBJ	_	_
14	,	_	,	,	_	13	P	_	_
15	RAR	_	NN	NN	_	16	NMOD	_	_
16	beta	_	NN	NN	_	13	COORD	_	_
17	,	_	,	,	_	13	P	_	_
18	and	_	CC	CC	_	13	CC	_	_
19	RAR	_	NN	NN	_	20	NMOD	_	_
20	gamma	_	NN	NN	_	13	COORD	_	_
21	,	_	,	,	_	2	P	_	_
22	have	_	VBP	VBP	_	0	ROOT-S	_	_
23	been	_	VBN	VBN	_	22	VC	_	_
24	described	_	VBN	VBN	_	23	VC	_	_
25	.	_	.	.	_	22	P	_	_

1	They	_	PRP	PRP	_	2	SBJ	_	_
2	are	_	VBP	VBP	_	0	ROOT-S	_	_
3	composed	_	VBN	VBN	_	2	VC	_	_
4	of	_	IN	IN	_	3	ADV	_	_
5	different	_	JJ	JJ	_	7	NMOD	_	_
6	structural	_	JJ	JJ	_	7	NMOD	_	_
7	domains	_	NNS	NNS	_	4	PMOD	_	_
8	,	_	,	,	_	7	P	_	_
9	including	_	VBG	VBG	_	7	NMOD	_	_
10	distinct	_	JJ	JJ	_	11	NMOD	_	_
11	domains	_	NNS	NNS	_	9	PMOD	_	_
12	for	_	IN	IN	_	11	NMOD	_	_
13	DNA	_	NN	NN	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	ligand	_	NN	NN	_	13	COORD	_	_
16	binding	_	NN	NN	_	12	PMOD	_	_
17	.	_	.	.	_	2	P	_	_

1	RARs	_	NNS	NNS	_	3	SBJ	_	_
2	specifically	_	RB	RB	_	3	ADV	_	_
3	bind	_	VBP	VBP	_	0	ROOT-S	_	_
4	all-trans-retinoic	_	JJ	JJ	_	5	NMOD	_	_
5	acid	_	NN	NN	_	3	OBJ	_	_
6	(	_	(	(	_	7	P	_	_
7	RA	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	,	_	,	,	_	5	P	_	_
10	9-cis-RA	_	NN	NN	_	5	COORD	_	_
11	,	_	,	,	_	5	P	_	_
12	and	_	CC	CC	_	5	CC	_	_
13	retinoid	_	JJ	JJ	_	14	NMOD	_	_
14	analogs	_	NNS	NNS	_	5	COORD	_	_
15	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	examined	_	VBD	VBD	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	functional	_	JJ	JJ	_	9	NMOD	_	_
9	role	_	NN	NN	_	6	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	cysteine	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	arginine	_	NN	NN	_	11	COORD	_	_
14	residues	_	NNS	NNS	_	10	PMOD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	ligand-binding	_	JJ	JJ	_	18	NMOD	_	_
18	domain	_	NN	NN	_	15	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	hRAR	_	NN	NN	_	21	NMOD	_	_
21	alpha	_	NN	NN	_	19	PMOD	_	_
22	(	_	(	(	_	24	P	_	_
23	hRAR	_	NN	NN	_	24	NMOD	_	_
24	alpha-LBD	_	NN	NN	_	18	PRN	_	_
25	,	_	,	,	_	24	P	_	_
26	amino	_	NN	NN	_	27	NMOD	_	_
27	acids	_	NNS	NNS	_	24	NMOD	_	_
28	154	_	CD	CD	_	27	NMOD	_	_
29	to	_	TO	TO	_	28	NMOD	_	_
30	462	_	CD	CD	_	28	NMOD	_	_
31	)	_	)	)	_	24	P	_	_
32	.	_	.	.	_	6	P	_	_

1	All	_	DT	DT	_	6	NMOD	_	_
2	conserved	_	VBN	VBN	_	6	NMOD	_	_
3	cysteine	_	NN	NN	_	6	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	arginine	_	NN	NN	_	3	COORD	_	_
6	residues	_	NNS	NNS	_	10	SBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	this	_	DT	DT	_	9	NMOD	_	_
9	domain	_	NN	NN	_	7	PMOD	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	mutated	_	VBN	VBN	_	10	VC	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	site-directed	_	JJ	JJ	_	14	NMOD	_	_
14	mutagenesis	_	NN	NN	_	12	PMOD	_	_
15	,	_	,	,	_	10	P	_	_
16	and	_	CC	CC	_	10	CC	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	mutant	_	JJ	JJ	_	19	NMOD	_	_
19	proteins	_	NNS	NNS	_	20	SBJ	_	_
20	were	_	VBD	VBD	_	10	COORD	_	_
21	characterized	_	VBN	VBN	_	20	VC	_	_
22	by	_	IN	IN	_	21	LGS	_	_
23	blocking	_	VBG	VBG	_	24	NMOD	_	_
24	reactions	_	NNS	NNS	_	22	PMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	ligand-binding	_	JJ	JJ	_	27	NMOD	_	_
27	experiments	_	NNS	NNS	_	24	COORD	_	_
28	,	_	,	,	_	24	P	_	_
29	transactivation	_	NN	NN	_	30	NMOD	_	_
30	assays	_	NNS	NNS	_	24	COORD	_	_
31	,	_	,	,	_	24	P	_	_
32	and	_	CC	CC	_	24	CC	_	_
33	protease	_	NN	NN	_	34	NMOD	_	_
34	mapping	_	NN	NN	_	24	COORD	_	_
35	.	_	.	.	_	10	P	_	_

1	Changes	_	NNS	NNS	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	any	_	DT	DT	_	5	NMOD	_	_
4	cysteine	_	JJ	JJ	_	5	NMOD	_	_
5	residue	_	NN	NN	_	2	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	hRAR	_	NN	NN	_	9	NMOD	_	_
9	alpha-LBD	_	NN	NN	_	6	PMOD	_	_
10	had	_	VBD	VBD	_	0	ROOT-S	_	_
11	no	_	DT	DT	_	13	NMOD	_	_
12	significant	_	JJ	JJ	_	13	NMOD	_	_
13	influence	_	NN	NN	_	10	OBJ	_	_
14	on	_	IN	IN	_	10	ADV	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	binding	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	all-trans	_	JJ	JJ	_	19	NMOD	_	_
19	RA	_	NN	NN	_	17	PMOD	_	_
20	or	_	CC	CC	_	19	CC	_	_
21	9-cis	_	JJ	JJ	_	22	NMOD	_	_
22	RA	_	NN	NN	_	19	COORD	_	_
23	.	_	.	.	_	10	P	_	_

1	Interestingly	_	RB	RB	_	5	VMOD	_	_
2	,	_	,	,	_	5	P	_	_
3	residue	_	JJ	JJ	_	4	NMOD	_	_
4	C-235	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	specifically	_	RB	RB	_	5	ADV	_	_
7	important	_	JJ	JJ	_	5	PRD	_	_
8	in	_	IN	IN	_	5	ADV	_	_
9	antagonist	_	NN	NN	_	10	NMOD	_	_
10	binding	_	NN	NN	_	8	PMOD	_	_
11	.	_	.	.	_	5	P	_	_

1	With	_	IN	IN	_	18	ADV	_	_
2	respect	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	arginine	_	NN	NN	_	5	NMOD	_	_
5	residues	_	NNS	NNS	_	1	PMOD	_	_
6	,	_	,	,	_	18	P	_	_
7	only	_	RB	RB	_	11	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	two	_	CD	CD	_	11	NMOD	_	_
10	single	_	JJ	JJ	_	11	NMOD	_	_
11	mutations	_	NNS	NNS	_	18	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	R-276	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	R-394	_	NN	NN	_	13	COORD	_	_
16	to	_	TO	TO	_	11	NMOD	_	_
17	alanine	_	NN	NN	_	16	PMOD	_	_
18	showed	_	VBD	VBD	_	0	ROOT-S	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	dramatic	_	JJ	JJ	_	21	NMOD	_	_
21	decrease	_	NN	NN	_	18	IOBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	agonist	_	NN	NN	_	26	NMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	antagonist	_	NN	NN	_	23	COORD	_	_
26	binding	_	NN	NN	_	22	PMOD	_	_
27	whereas	_	IN	IN	_	18	OBJ	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	R272A	_	NN	NN	_	30	NMOD	_	_
30	mutation	_	NN	NN	_	31	SBJ	_	_
31	showed	_	VBD	VBD	_	27	VMOD	_	_
32	only	_	RB	RB	_	35	NMOD	_	_
33	a	_	DT	DT	_	35	NMOD	_	_
34	slight	_	JJ	JJ	_	35	NMOD	_	_
35	effect	_	NN	NN	_	31	OBJ	_	_
36	.	_	.	.	_	18	P	_	_

1	For	_	IN	IN	_	11	ADV	_	_
2	all	_	DT	DT	_	5	NMOD	_	_
3	other	_	JJ	JJ	_	5	NMOD	_	_
4	arginine	_	NN	NN	_	5	NMOD	_	_
5	mutations	_	NNS	NNS	_	1	PMOD	_	_
6	,	_	,	,	_	11	P	_	_
7	no	_	DT	DT	_	8	NMOD	_	_
8	differences	_	NNS	NNS	_	11	SBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	affinity	_	NN	NN	_	9	PMOD	_	_
11	were	_	VBD	VBD	_	0	ROOT-S	_	_
12	detectable	_	JJ	JJ	_	11	PRD	_	_
13	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	two	_	CD	CD	_	3	NMOD	_	_
3	mutations	_	NNS	NNS	_	7	SBJ	_	_
4	R217A	_	NN	NN	_	3	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	R294A	_	NN	NN	_	4	COORD	_	_
7	caused	_	VBD	VBD	_	0	ROOT-S	_	_
8	an	_	DT	DT	_	11	NMOD	_	_
9	increased	_	VBN	VBN	_	11	NMOD	_	_
10	binding	_	NN	NN	_	11	NMOD	_	_
11	efficiency	_	NN	NN	_	7	OBJ	_	_
12	for	_	IN	IN	_	11	NMOD	_	_
13	antagonists	_	NNS	NNS	_	12	PMOD	_	_
14	but	_	CC	CC	_	11	CC	_	_
15	no	_	DT	DT	_	16	NMOD	_	_
16	change	_	NN	NN	_	11	COORD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	agonist	_	NN	NN	_	19	NMOD	_	_
19	binding	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	7	P	_	_

1	From	_	IN	IN	_	6	ADV	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	results	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	can	_	MD	MD	_	0	ROOT-S	_	_
7	conclude	_	VB	VB	_	6	VC	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	electrostatic	_	JJ	JJ	_	10	NMOD	_	_
10	interactions	_	NNS	NNS	_	17	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	retinoids	_	NNS	NNS	_	11	PMOD	_	_
13	with	_	IN	IN	_	10	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	RAR	_	NN	NN	_	16	NMOD	_	_
16	alpha-LBD	_	NN	NN	_	13	PMOD	_	_
17	play	_	VBP	VBP	_	8	VMOD	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	significant	_	JJ	JJ	_	20	NMOD	_	_
20	role	_	NN	NN	_	17	OBJ	_	_
21	in	_	IN	IN	_	17	ADV	_	_
22	ligand	_	NN	NN	_	23	NMOD	_	_
23	binding	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	antagonists	_	NNS	NNS	_	5	SBJ	_	_
5	show	_	VBP	VBP	_	0	ROOT-S	_	_
6	distinctly	_	RB	RB	_	7	AMOD	_	_
7	different	_	JJ	JJ	_	8	NMOD	_	_
8	requirements	_	NNS	NNS	_	5	OBJ	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	efficient	_	JJ	JJ	_	11	NMOD	_	_
11	binding	_	NN	NN	_	9	PMOD	_	_
12	,	_	,	,	_	8	P	_	_
13	which	_	WDT	WDT	_	14	SBJ	_	_
14	may	_	MD	MD	_	8	NMOD	_	_
15	contribute	_	VB	VB	_	14	VC	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	their	_	PRP$	PRP$	_	18	NMOD	_	_
18	interference	_	NN	NN	_	16	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	ligand-inducible	_	JJ	JJ	_	23	NMOD	_	_
22	transactivation	_	NN	NN	_	23	NMOD	_	_
23	function	_	NN	NN	_	19	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	RAR	_	NN	NN	_	26	NMOD	_	_
26	alpha	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	5	P	_	_

1	Cloning	_	NN	NN	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	characterization	_	NN	NN	_	1	COORD	_	_
4	of	_	IN	IN	_	1	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	beta	_	NN	NN	_	7	NMOD	_	_
7	subunit	_	NN	NN	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	human	_	JJ	JJ	_	11	AMOD	_	_
10	proximal	_	JJ	JJ	_	11	AMOD	_	_
11	sequence	_	NN	NN	_	14	NMOD	_	_
12	element-binding	_	JJ	JJ	_	11	AMOD	_	_
13	transcription	_	NN	NN	_	14	NMOD	_	_
14	factor	_	NN	NN	_	8	PMOD	_	_
15	and	_	CC	CC	_	1	CC	_	_
16	its	_	PRP$	PRP$	_	17	NMOD	_	_
17	involvement	_	NN	NN	_	1	COORD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	transcription	_	NN	NN	_	18	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	small	_	JJ	JJ	_	24	NMOD	_	_
22	nuclear	_	JJ	JJ	_	24	NMOD	_	_
23	RNA	_	NN	NN	_	24	NMOD	_	_
24	genes	_	NNS	NNS	_	20	PMOD	_	_
25	by	_	IN	IN	_	19	NMOD	_	_
26	RNA	_	NN	NN	_	27	NMOD	_	_
27	polymerases	_	NNS	NNS	_	25	PMOD	_	_
28	II	_	CD	CD	_	27	NMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	III	_	CD	CD	_	28	COORD	_	_
31	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	10	NMOD	_	_
2	proximal	_	JJ	JJ	_	4	NMOD	_	_
3	sequence	_	NN	NN	_	4	NMOD	_	_
4	element	_	NN	NN	_	6	AMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	PSE	_	NN	NN	_	10	NMOD	_	_
7	)	_	)	)	_	6	P	_	_
8	-binding	_	JJ	JJ	_	6	AMOD	_	_
9	transcription	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	37	SBJ	_	_
11	(	_	(	(	_	12	P	_	_
12	PTF	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	,	_	,	,	_	10	P	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	binds	_	VBZ	VBZ	_	10	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	PSE	_	NN	NN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	both	_	CC	CC	_	23	CC	_	_
21	RNA	_	NN	NN	_	23	NMOD	_	_
22	polymerase	_	NN	NN	_	23	NMOD	_	_
23	II-	_	NN	NN	_	35	NMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	RNA	_	NN	NN	_	26	AMOD	_	_
26	polymerase	_	NN	NN	_	23	COORD	_	_
27	III-transcribed	_	JJ	JJ	_	26	AMOD	_	_
28	mammalian	_	JJ	JJ	_	35	NMOD	_	_
29	small	_	JJ	JJ	_	31	NMOD	_	_
30	nuclear	_	JJ	JJ	_	31	NMOD	_	_
31	RNA	_	NN	NN	_	35	NMOD	_	_
32	(	_	(	(	_	33	P	_	_
33	snRNA	_	NN	NN	_	31	PRN	_	_
34	)	_	)	)	_	33	P	_	_
35	genes	_	NNS	NNS	_	19	PMOD	_	_
36	,	_	,	,	_	10	P	_	_
37	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
38	essential	_	JJ	JJ	_	37	PRD	_	_
39	for	_	IN	IN	_	38	AMOD	_	_
40	their	_	PRP$	PRP$	_	41	NMOD	_	_
41	transcription	_	NN	NN	_	39	PMOD	_	_
42	.	_	.	.	_	37	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	previously	_	RB	RB	_	3	TMP	_	_
3	reported	_	VBD	VBD	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	purification	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	human	_	JJ	JJ	_	8	NMOD	_	_
8	PTF	_	NN	NN	_	6	PMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	a	_	DT	DT	_	11	NMOD	_	_
11	complex	_	NN	NN	_	8	NMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	four	_	CD	CD	_	14	NMOD	_	_
14	subunits	_	NNS	NNS	_	12	PMOD	_	_
15	,	_	,	,	_	5	P	_	_
16	and	_	CC	CC	_	5	CC	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	molecular	_	JJ	JJ	_	19	NMOD	_	_
19	cloning	_	NN	NN	_	5	COORD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	characterization	_	NN	NN	_	19	COORD	_	_
22	of	_	IN	IN	_	19	NMOD	_	_
23	PTF	_	NN	NN	_	27	NMOD	_	_
24	gamma	_	NN	NN	_	27	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	delta	_	NN	NN	_	24	COORD	_	_
27	subunits	_	NNS	NNS	_	22	PMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	describe	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	isolation	_	NN	NN	_	3	OBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	expression	_	NN	NN	_	5	COORD	_	_
8	of	_	IN	IN	_	5	NMOD	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	cDNA	_	NN	NN	_	8	PMOD	_	_
11	encoding	_	VBG	VBG	_	10	NMOD	_	_
12	PTF	_	NN	NN	_	13	NMOD	_	_
13	beta	_	NN	NN	_	11	OBJ	_	_
14	,	_	,	,	_	5	P	_	_
15	as	_	RB	RB	_	5	CC	_	_
16	well	_	RB	RB	_	15	DEP	_	_
17	as	_	IN	IN	_	15	DEP	_	_
18	functional	_	JJ	JJ	_	19	NMOD	_	_
19	studies	_	NNS	NNS	_	5	COORD	_	_
20	using	_	VBG	VBG	_	19	NMOD	_	_
21	anti-PTF	_	JJ	JJ	_	22	AMOD	_	_
22	beta	_	NN	NN	_	23	NMOD	_	_
23	antibodies	_	NNS	NNS	_	20	OBJ	_	_
24	.	_	.	.	_	3	P	_	_

1	Native	_	JJ	JJ	_	3	NMOD	_	_
2	PTF	_	NN	NN	_	3	NMOD	_	_
3	beta	_	NN	NN	_	14	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	in	_	IN	IN	_	3	NMOD	_	_
6	either	_	CC	CC	_	8	CC	_	_
7	protein	_	NN	NN	_	8	NMOD	_	_
8	fractions	_	NNS	NNS	_	5	PMOD	_	_
9	or	_	CC	CC	_	8	CC	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	PTF-Oct-1-DNA	_	NN	NN	_	12	NMOD	_	_
12	complex	_	NN	NN	_	8	COORD	_	_
13	,	_	,	,	_	3	P	_	_
14	can	_	MD	MD	_	0	ROOT-S	_	_
15	be	_	VB	VB	_	14	VC	_	_
16	recognized	_	VBN	VBN	_	15	VC	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	polyclonal	_	JJ	JJ	_	19	NMOD	_	_
19	antibodies	_	NNS	NNS	_	17	PMOD	_	_
20	raised	_	VBN	VBN	_	19	NMOD	_	_
21	against	_	IN	IN	_	20	ADV	_	_
22	recombinant	_	JJ	JJ	_	24	NMOD	_	_
23	PTF	_	NN	NN	_	24	NMOD	_	_
24	beta	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	14	P	_	_

1	Immunodepletion	_	NN	NN	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	PTF	_	NN	NN	_	6	NMOD	_	_
6	beta	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	4	VMOD	_	_
8	required	_	VBN	VBN	_	7	VC	_	_
9	for	_	IN	IN	_	8	ADV	_	_
10	transcription	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	both	_	DT	DT	_	13	NMOD	_	_
13	classes	_	NNS	NNS	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	snRNA	_	NN	NN	_	16	NMOD	_	_
16	genes	_	NNS	NNS	_	14	PMOD	_	_
17	in	_	FW	FW	_	10	NMOD	_	_
18	vitro	_	FW	FW	_	17	AMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	6	P	_	_
4	immunoprecipitation	_	NN	NN	_	5	NMOD	_	_
5	analyses	_	NNS	NNS	_	6	SBJ	_	_
6	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	substantial	_	JJ	JJ	_	12	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	similar	_	JJ	JJ	_	8	COORD	_	_
11	molar	_	JJ	JJ	_	12	NMOD	_	_
12	amounts	_	NNS	NNS	_	21	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	TATA-binding	_	JJ	JJ	_	15	NMOD	_	_
15	protein	_	NN	NN	_	13	PMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	TBP	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	TFIIIB90	_	NN	NN	_	15	COORD	_	_
21	can	_	MD	MD	_	7	VMOD	_	_
22	weakly	_	RB	RB	_	21	ADV	_	_
23	associate	_	VBP	VBP	_	21	VC	_	_
24	with	_	IN	IN	_	23	ADV	_	_
25	PTF	_	NN	NN	_	24	PMOD	_	_
26	at	_	IN	IN	_	23	ADV	_	_
27	low	_	JJ	JJ	_	29	NMOD	_	_
28	salt	_	NN	NN	_	29	NMOD	_	_
29	conditions	_	NNS	NNS	_	26	PMOD	_	_
30	,	_	,	,	_	21	P	_	_
31	but	_	CC	CC	_	21	CC	_	_
32	this	_	DT	DT	_	33	NMOD	_	_
33	association	_	NN	NN	_	34	SBJ	_	_
34	is	_	VBZ	VBZ	_	21	COORD	_	_
35	dramatically	_	RB	RB	_	34	ADV	_	_
36	reduced	_	VBN	VBN	_	34	VC	_	_
37	at	_	IN	IN	_	36	ADV	_	_
38	high	_	JJ	JJ	_	40	NMOD	_	_
39	salt	_	NN	NN	_	40	NMOD	_	_
40	concentrations	_	NNS	NNS	_	37	PMOD	_	_
41	.	_	.	.	_	6	P	_	_

1	Along	_	IN	IN	_	34	ADV	_	_
2	with	_	IN	IN	_	1	DEP	_	_
3	our	_	PRP$	PRP$	_	5	NMOD	_	_
4	previous	_	JJ	JJ	_	5	NMOD	_	_
5	demonstration	_	NN	NN	_	1	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	both	_	DT	DT	_	9	NMOD	_	_
8	physical	_	JJ	JJ	_	9	NMOD	_	_
9	interactions	_	NNS	NNS	_	6	PMOD	_	_
10	between	_	IN	IN	_	9	NMOD	_	_
11	PTF	_	NN	NN	_	12	NMOD	_	_
12	gamma	_	NN	NN	_	10	PMOD	_	_
13	\/	_	:	:	_	12	P	_	_
14	PTF	_	NN	NN	_	15	NMOD	_	_
15	delta	_	NN	NN	_	12	NMOD	_	_
16	and	_	CC	CC	_	12	CC	_	_
17	TBP	_	NN	NN	_	12	COORD	_	_
18	and	_	CC	CC	_	9	CC	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	involvement	_	NN	NN	_	9	COORD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	TFIIIB90	_	NN	NN	_	21	PMOD	_	_
23	in	_	IN	IN	_	20	NMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	transcription	_	NN	NN	_	23	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	class	_	NN	NN	_	30	NMOD	_	_
28	III	_	CD	CD	_	30	NMOD	_	_
29	snRNA	_	NN	NN	_	30	NMOD	_	_
30	genes	_	NNS	NNS	_	26	PMOD	_	_
31	,	_	,	,	_	34	P	_	_
32	these	_	DT	DT	_	33	NMOD	_	_
33	results	_	NNS	NNS	_	34	SBJ	_	_
34	are	_	VBP	VBP	_	0	ROOT-S	_	_
35	consistent	_	JJ	JJ	_	34	PRD	_	_
36	with	_	IN	IN	_	35	AMOD	_	_
37	the	_	DT	DT	_	38	NMOD	_	_
38	notion	_	NN	NN	_	36	PMOD	_	_
39	that	_	IN	IN	_	38	NMOD	_	_
40	a	_	DT	DT	_	42	NMOD	_	_
41	TBP-containing	_	JJ	JJ	_	42	NMOD	_	_
42	complex	_	NN	NN	_	46	SBJ	_	_
43	related	_	JJ	JJ	_	42	NMOD	_	_
44	to	_	TO	TO	_	43	AMOD	_	_
45	TFIIIB	_	NN	NN	_	44	PMOD	_	_
46	is	_	VBZ	VBZ	_	39	VMOD	_	_
47	required	_	VBN	VBN	_	46	VC	_	_
48	for	_	IN	IN	_	47	ADV	_	_
49	the	_	DT	DT	_	50	NMOD	_	_
50	transcription	_	NN	NN	_	48	PMOD	_	_
51	of	_	IN	IN	_	50	NMOD	_	_
52	class	_	NN	NN	_	55	NMOD	_	_
53	III	_	CD	CD	_	55	NMOD	_	_
54	snRNA	_	NN	NN	_	55	NMOD	_	_
55	genes	_	NNS	NNS	_	51	PMOD	_	_
56	,	_	,	,	_	46	P	_	_
57	and	_	CC	CC	_	46	CC	_	_
58	acts	_	VBZ	VBZ	_	46	COORD	_	_
59	through	_	IN	IN	_	58	ADV	_	_
60	weak	_	JJ	JJ	_	61	NMOD	_	_
61	interaction	_	NN	NN	_	59	PMOD	_	_
62	with	_	IN	IN	_	61	NMOD	_	_
63	the	_	DT	DT	_	65	NMOD	_	_
64	four-subunit	_	JJ	JJ	_	65	NMOD	_	_
65	PTF	_	NN	NN	_	62	PMOD	_	_
66	.	_	.	.	_	34	P	_	_

1	Induction	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	bcl-2	_	NN	NN	_	4	NMOD	_	_
4	expression	_	NN	NN	_	2	PMOD	_	_
5	by	_	IN	IN	_	1	NMOD	_	_
6	phosphorylated	_	VBN	VBN	_	8	NMOD	_	_
7	CREB	_	NN	NN	_	8	NMOD	_	_
8	proteins	_	NNS	NNS	_	5	PMOD	_	_
9	during	_	IN	IN	_	1	TMP	_	_
10	B-cell	_	NN	NN	_	11	NMOD	_	_
11	activation	_	NN	NN	_	9	PMOD	_	_
12	and	_	CC	CC	_	1	CC	_	_
13	rescue	_	NN	NN	_	1	COORD	_	_
14	from	_	IN	IN	_	13	NMOD	_	_
15	apoptosis	_	NN	NN	_	14	PMOD	_	_
16	.	_	.	.	_	1	P	_	_

1	Engagement	_	NN	NN	_	9	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	surface	_	NN	NN	_	4	NMOD	_	_
4	immunoglobulin	_	NN	NN	_	2	PMOD	_	_
5	on	_	IN	IN	_	4	NMOD	_	_
6	mature	_	JJ	JJ	_	8	NMOD	_	_
7	B	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	5	PMOD	_	_
9	leads	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	rescue	_	NN	NN	_	10	PMOD	_	_
12	from	_	IN	IN	_	11	NMOD	_	_
13	apoptosis	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	10	CC	_	_
15	to	_	TO	TO	_	10	COORD	_	_
16	proliferation	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	9	P	_	_

1	Levels	_	NNS	NNS	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	bcl-2	_	NN	NN	_	2	PMOD	_	_
4	mRNA	_	NN	NN	_	3	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	protein	_	NN	NN	_	4	COORD	_	_
7	increase	_	VBP	VBP	_	0	ROOT-S	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	cross-linking	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	surface	_	NN	NN	_	12	NMOD	_	_
12	immunoglobulin	_	NN	NN	_	10	PMOD	_	_
13	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	located	_	JJ	JJ	_	8	VMOD	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	major	_	JJ	JJ	_	8	NMOD	_	_
6	positive	_	JJ	JJ	_	8	NMOD	_	_
7	regulatory	_	JJ	JJ	_	8	NMOD	_	_
8	region	_	NN	NN	_	2	VC	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	control	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	bcl-2	_	NN	NN	_	13	NMOD	_	_
13	expression	_	NN	NN	_	11	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	B	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	in	_	IN	IN	_	8	ADV	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	5'-flanking	_	JJ	JJ	_	20	NMOD	_	_
20	region	_	NN	NN	_	17	PMOD	_	_
21	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	positive	_	JJ	JJ	_	3	NMOD	_	_
3	region	_	NN	NN	_	4	SBJ	_	_
4	can	_	MD	MD	_	0	ROOT-S	_	_
5	be	_	VB	VB	_	4	VC	_	_
6	divided	_	VBN	VBN	_	5	VC	_	_
7	into	_	IN	IN	_	6	ADV	_	_
8	an	_	DT	DT	_	14	NMOD	_	_
9	upstream	_	JJ	JJ	_	14	NMOD	_	_
10	and	_	CC	CC	_	14	CC	_	_
11	a	_	DT	DT	_	14	NMOD	_	_
12	downstream	_	JJ	JJ	_	14	NMOD	_	_
13	regulatory	_	JJ	JJ	_	14	NMOD	_	_
14	region	_	NN	NN	_	7	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	downstream	_	JJ	JJ	_	4	NMOD	_	_
3	regulatory	_	JJ	JJ	_	4	NMOD	_	_
4	region	_	NN	NN	_	5	SBJ	_	_
5	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	cyclic	_	JJ	JJ	_	8	AMOD	_	_
8	AMP-responsive	_	JJ	JJ	_	9	NMOD	_	_
9	element	_	NN	NN	_	5	OBJ	_	_
10	(	_	(	(	_	11	P	_	_
11	CRE	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	by	_	IN	IN	_	2	ADV	_	_
4	antibody	_	NN	NN	_	6	NMOD	_	_
5	supershift	_	NN	NN	_	6	NMOD	_	_
6	experiments	_	NNS	NNS	_	3	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	UV	_	NN	NN	_	9	NMOD	_	_
9	cross-linking	_	NN	NN	_	6	COORD	_	_
10	followed	_	VBN	VBN	_	6	NMOD	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	denaturing	_	VBG	VBG	_	15	NMOD	_	_
13	polyacrylamide	_	NN	NN	_	15	NMOD	_	_
14	gel	_	NN	NN	_	15	NMOD	_	_
15	electrophoresis	_	NN	NN	_	11	PMOD	_	_
16	that	_	IN	IN	_	2	OBJ	_	_
17	both	_	CC	CC	_	18	CC	_	_
18	CREB	_	NN	NN	_	22	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	ATF	_	NN	NN	_	18	COORD	_	_
21	family	_	NN	NN	_	22	NMOD	_	_
22	members	_	NNS	NNS	_	23	SBJ	_	_
23	bind	_	VBP	VBP	_	16	VMOD	_	_
24	to	_	TO	TO	_	23	ADV	_	_
25	this	_	DT	DT	_	26	NMOD	_	_
26	region	_	NN	NN	_	24	PMOD	_	_
27	in	_	FW	FW	_	23	ADV	_	_
28	vitro	_	FW	FW	_	27	AMOD	_	_
29	.	_	.	.	_	2	P	_	_

1	Mutations	_	NNS	NNS	_	14	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	CRE	_	NN	NN	_	5	NMOD	_	_
5	site	_	NN	NN	_	2	PMOD	_	_
6	that	_	WDT	WDT	_	7	SBJ	_	_
7	result	_	VBP	VBP	_	1	NMOD	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	loss	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	CREB	_	NN	NN	_	12	NMOD	_	_
12	binding	_	NN	NN	_	10	PMOD	_	_
13	also	_	RB	RB	_	14	ADV	_	_
14	lead	_	VBP	VBP	_	0	ROOT-S	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	loss	_	NN	NN	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	functional	_	JJ	JJ	_	19	NMOD	_	_
19	activity	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	bcl-2	_	NN	NN	_	23	NMOD	_	_
23	promoter	_	NN	NN	_	20	PMOD	_	_
24	in	_	IN	IN	_	14	ADV	_	_
25	transient-transfection	_	NN	NN	_	26	NMOD	_	_
26	assays	_	NNS	NNS	_	24	PMOD	_	_
27	.	_	.	.	_	14	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	presence	_	NN	NN	_	12	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	an	_	DT	DT	_	7	NMOD	_	_
5	active	_	JJ	JJ	_	7	NMOD	_	_
6	CRE	_	NN	NN	_	7	NMOD	_	_
7	site	_	NN	NN	_	3	PMOD	_	_
8	in	_	IN	IN	_	2	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	bcl-2	_	NN	NN	_	11	NMOD	_	_
11	promoter	_	NN	NN	_	8	PMOD	_	_
12	implies	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	that	_	IN	IN	_	12	OBJ	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	regulation	_	NN	NN	_	19	SBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	bcl-2	_	NN	NN	_	18	NMOD	_	_
18	expression	_	NN	NN	_	16	PMOD	_	_
19	is	_	VBZ	VBZ	_	13	VMOD	_	_
20	linked	_	VBN	VBN	_	19	VC	_	_
21	to	_	TO	TO	_	20	ADV	_	_
22	a	_	DT	DT	_	25	NMOD	_	_
23	signal	_	NN	NN	_	25	NMOD	_	_
24	transduction	_	NN	NN	_	25	NMOD	_	_
25	pathway	_	NN	NN	_	21	PMOD	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	B	_	NN	NN	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	26	PMOD	_	_
29	.	_	.	.	_	12	P	_	_

1	Treatment	_	NN	NN	_	16	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	mature	_	JJ	JJ	_	7	NMOD	_	_
5	B-cell	_	NN	NN	_	7	NMOD	_	_
6	line	_	NN	NN	_	7	NMOD	_	_
7	BAL-17	_	NN	NN	_	2	PMOD	_	_
8	with	_	IN	IN	_	1	NMOD	_	_
9	either	_	CC	CC	_	11	CC	_	_
10	anti-immunoglobulin	_	JJ	JJ	_	11	NMOD	_	_
11	M	_	NN	NN	_	8	PMOD	_	_
12	or	_	CC	CC	_	11	CC	_	_
13	phorbol	_	NN	NN	_	15	NMOD	_	_
14	12-myristate	_	NN	NN	_	15	NMOD	_	_
15	13-acetate	_	NN	NN	_	11	COORD	_	_
16	leads	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	an	_	DT	DT	_	19	NMOD	_	_
19	increase	_	NN	NN	_	17	PMOD	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	bcl-2	_	NN	NN	_	22	NMOD	_	_
22	expression	_	NN	NN	_	20	PMOD	_	_
23	that	_	WDT	WDT	_	24	SBJ	_	_
24	is	_	VBZ	VBZ	_	22	NMOD	_	_
25	mediated	_	VBN	VBN	_	24	VC	_	_
26	by	_	IN	IN	_	25	LGS	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	CRE	_	NN	NN	_	29	NMOD	_	_
29	site	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	16	P	_	_

1	Treatment	_	NN	NN	_	14	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	more	_	RBR	RBR	_	5	AMOD	_	_
5	immature	_	JJ	JJ	_	7	NMOD	_	_
6	B-cell	_	NN	NN	_	7	NMOD	_	_
7	line	_	NN	NN	_	2	PMOD	_	_
8	,	_	,	,	_	7	P	_	_
9	Ramos	_	NN	NN	_	7	NMOD	_	_
10	,	_	,	,	_	7	P	_	_
11	with	_	IN	IN	_	1	NMOD	_	_
12	phorbol	_	NN	NN	_	13	NMOD	_	_
13	esters	_	NNS	NNS	_	11	PMOD	_	_
14	rescues	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	OBJ	_	_
17	from	_	IN	IN	_	14	ADV	_	_
18	calcium-dependent	_	JJ	JJ	_	19	NMOD	_	_
19	apoptosis	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	14	P	_	_

1	bcl-2	_	NN	NN	_	2	NMOD	_	_
2	expression	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	increased	_	VBN	VBN	_	3	VC	_	_
5	following	_	VBG	VBG	_	4	TMP	_	_
6	phorbol	_	NN	NN	_	8	NMOD	_	_
7	ester	_	NN	NN	_	8	NMOD	_	_
8	treatment	_	NN	NN	_	5	PMOD	_	_
9	,	_	,	,	_	3	P	_	_
10	and	_	CC	CC	_	3	CC	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	increased	_	VBN	VBN	_	13	NMOD	_	_
13	expression	_	NN	NN	_	14	SBJ	_	_
14	is	_	VBZ	VBZ	_	3	COORD	_	_
15	dependent	_	JJ	JJ	_	14	PRD	_	_
16	on	_	IN	IN	_	15	AMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	CRE	_	NN	NN	_	19	NMOD	_	_
19	site	_	NN	NN	_	16	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	stimuli	_	NNS	NNS	_	3	SBJ	_	_
3	result	_	VBP	VBP	_	0	ROOT-S	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	phosphorylation	_	NN	NN	_	4	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	CREB	_	NN	NN	_	6	PMOD	_	_
8	at	_	IN	IN	_	5	NMOD	_	_
9	serine	_	NN	NN	_	8	PMOD	_	_
10	133	_	CD	CD	_	9	NMOD	_	_
11	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	phosphorylation	_	NN	NN	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	CREB	_	NN	NN	_	3	PMOD	_	_
5	that	_	WDT	WDT	_	6	SBJ	_	_
6	results	_	VBZ	VBZ	_	2	NMOD	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	activation	_	NN	NN	_	7	PMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	mediated	_	VBN	VBN	_	9	VC	_	_
11	by	_	IN	IN	_	10	ADV	_	_
12	protein	_	NN	NN	_	14	NMOD	_	_
13	kinase	_	NN	NN	_	14	NMOD	_	_
14	C	_	NN	NN	_	11	PMOD	_	_
15	rather	_	RB	RB	_	11	CC	_	_
16	than	_	IN	IN	_	15	DEP	_	_
17	by	_	IN	IN	_	11	LGS	_	_
18	protein	_	NN	NN	_	20	NMOD	_	_
19	kinase	_	NN	NN	_	20	NMOD	_	_
20	A	_	NN	NN	_	17	PMOD	_	_
21	.	_	.	.	_	9	P	_	_

1	Although	_	IN	IN	_	13	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	CRE	_	NN	NN	_	4	NMOD	_	_
4	site	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	1	VMOD	_	_
6	necessary	_	JJ	JJ	_	5	PRD	_	_
7	,	_	,	,	_	13	P	_	_
8	optimal	_	JJ	JJ	_	9	NMOD	_	_
9	induction	_	NN	NN	_	13	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	bcl-2	_	NN	NN	_	12	NMOD	_	_
12	expression	_	NN	NN	_	10	PMOD	_	_
13	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	participation	_	NN	NN	_	13	IOBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	upstream	_	JJ	JJ	_	19	NMOD	_	_
18	regulatory	_	JJ	JJ	_	19	NMOD	_	_
19	element	_	NN	NN	_	15	PMOD	_	_
20	,	_	,	,	_	13	P	_	_
21	suggesting	_	VBG	VBG	_	13	OBJ	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	phosphorylation	_	NN	NN	_	26	SBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	CREB	_	NN	NN	_	24	PMOD	_	_
26	alters	_	VBZ	VBZ	_	22	VMOD	_	_
27	its	_	PRP$	PRP$	_	28	NMOD	_	_
28	interaction	_	NN	NN	_	26	OBJ	_	_
29	with	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	33	NMOD	_	_
31	upstream	_	JJ	JJ	_	33	NMOD	_	_
32	regulatory	_	JJ	JJ	_	33	NMOD	_	_
33	element	_	NN	NN	_	29	PMOD	_	_
34	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	CRE	_	NN	NN	_	3	NMOD	_	_
3	site	_	NN	NN	_	8	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	bcl-2	_	NN	NN	_	7	NMOD	_	_
7	promoter	_	NN	NN	_	4	PMOD	_	_
8	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	play	_	VB	VB	_	8	OBJ	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	major	_	JJ	JJ	_	13	NMOD	_	_
13	role	_	NN	NN	_	10	OBJ	_	_
14	in	_	IN	IN	_	10	ADV	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	induction	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	bcl-2	_	NN	NN	_	19	NMOD	_	_
19	expression	_	NN	NN	_	17	PMOD	_	_
20	during	_	IN	IN	_	10	TMP	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	activation	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	mature	_	JJ	JJ	_	26	NMOD	_	_
25	B	_	NN	NN	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	23	PMOD	_	_
27	and	_	CC	CC	_	20	CC	_	_
28	during	_	IN	IN	_	20	COORD	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	rescue	_	NN	NN	_	28	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	immature	_	JJ	JJ	_	34	NMOD	_	_
33	B	_	NN	NN	_	34	NMOD	_	_
34	cells	_	NNS	NNS	_	31	PMOD	_	_
35	from	_	IN	IN	_	30	NMOD	_	_
36	apoptosis	_	NN	NN	_	35	PMOD	_	_
37	.	_	.	.	_	8	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	possible	_	JJ	JJ	_	2	PRD	_	_
4	that	_	IN	IN	_	2	EXP	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	CRE	_	NN	NN	_	7	NMOD	_	_
7	site	_	NN	NN	_	8	SBJ	_	_
8	is	_	VBZ	VBZ	_	4	VMOD	_	_
9	responsible	_	JJ	JJ	_	8	PRD	_	_
10	for	_	IN	IN	_	9	AMOD	_	_
11	induction	_	NN	NN	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	bcl-2	_	NN	NN	_	14	NMOD	_	_
14	expression	_	NN	NN	_	12	PMOD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	other	_	JJ	JJ	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	types	_	NNS	NNS	_	15	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	particularly	_	RB	RB	_	18	NMOD	_	_
21	those	_	DT	DT	_	20	NMOD	_	_
22	in	_	IN	IN	_	28	ADV	_	_
23	which	_	WDT	WDT	_	22	PMOD	_	_
24	protein	_	NN	NN	_	26	NMOD	_	_
25	kinase	_	NN	NN	_	26	NMOD	_	_
26	C	_	NN	NN	_	27	SBJ	_	_
27	is	_	VBZ	VBZ	_	20	NMOD	_	_
28	involved	_	VBN	VBN	_	27	VC	_	_
29	.	_	.	.	_	2	P	_	_

1	JNK	_	NN	NN	_	7	SBJ	_	_
2	(	_	(	(	_	5	P	_	_
3	c-Jun	_	NN	NN	_	5	NMOD	_	_
4	NH2-terminal	_	JJ	JJ	_	5	NMOD	_	_
5	kinase	_	NN	NN	_	1	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	target	_	NN	NN	_	7	PRD	_	_
10	for	_	IN	IN	_	9	NMOD	_	_
11	antioxidants	_	NNS	NNS	_	10	PMOD	_	_
12	in	_	IN	IN	_	7	ADV	_	_
13	T	_	NN	NN	_	14	NMOD	_	_
14	lymphocytes	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	7	P	_	_

1	AP-1	_	NN	NN	_	2	SBJ	_	_
2	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	been	_	VBN	VBN	_	2	VC	_	_
4	shown	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	behave	_	VB	VB	_	4	OBJ	_	_
7	as	_	IN	IN	_	6	ADV	_	_
8	a	_	DT	DT	_	11	NMOD	_	_
9	redox-sensitive	_	JJ	JJ	_	11	NMOD	_	_
10	transcription	_	NN	NN	_	11	NMOD	_	_
11	factor	_	NN	NN	_	7	PMOD	_	_
12	that	_	WDT	WDT	_	13	SBJ	_	_
13	can	_	MD	MD	_	11	NMOD	_	_
14	be	_	VB	VB	_	13	VC	_	_
15	activated	_	VBN	VBN	_	14	VC	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	both	_	CC	CC	_	18	CC	_	_
18	oxidant	_	JJ	JJ	_	21	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	antioxidant	_	JJ	JJ	_	18	COORD	_	_
21	stimuli	_	NNS	NNS	_	16	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	However	_	RB	RB	_	13	ADV	_	_
2	,	_	,	,	_	13	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	mechanisms	_	NNS	NNS	_	13	SBJ	_	_
5	involved	_	VBN	VBN	_	4	NMOD	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	activation	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	AP-1	_	NN	NN	_	9	PMOD	_	_
11	by	_	IN	IN	_	8	NMOD	_	_
12	antioxidants	_	NNS	NNS	_	11	PMOD	_	_
13	are	_	VBP	VBP	_	0	ROOT-S	_	_
14	largely	_	RB	RB	_	15	AMOD	_	_
15	unknown	_	JJ	JJ	_	13	PRD	_	_
16	.	_	.	.	_	13	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	show	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	the	_	DT	DT	_	11	NMOD	_	_
8	structurally	_	RB	RB	_	9	AMOD	_	_
9	unrelated	_	JJ	JJ	_	11	NMOD	_	_
10	antioxidant	_	JJ	JJ	_	11	NMOD	_	_
11	agents	_	NNS	NNS	_	23	SBJ	_	_
12	pyrrolidine	_	NN	NN	_	13	NMOD	_	_
13	dithiocarbamate	_	NN	NN	_	11	NMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	PDTC	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	,	_	,	,	_	13	P	_	_
18	butylated	_	VBN	VBN	_	19	NMOD	_	_
19	hydroxyanisole	_	NN	NN	_	13	COORD	_	_
20	,	_	,	,	_	13	P	_	_
21	and	_	CC	CC	_	13	CC	_	_
22	Nacetylcysteine	_	NN	NN	_	13	COORD	_	_
23	activated	_	VBD	VBD	_	6	VMOD	_	_
24	JNK	_	NN	NN	_	23	OBJ	_	_
25	(	_	(	(	_	28	P	_	_
26	c-Jun	_	NN	NN	_	28	NMOD	_	_
27	NH2-terminal	_	JJ	JJ	_	28	NMOD	_	_
28	kinase	_	NN	NN	_	24	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	in	_	IN	IN	_	23	ADV	_	_
31	Jurkat	_	NN	NN	_	33	NMOD	_	_
32	T	_	NN	NN	_	33	NMOD	_	_
33	cells	_	NNS	NNS	_	30	PMOD	_	_
34	.	_	.	.	_	5	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	activation	_	NN	NN	_	3	SBJ	_	_
3	differed	_	VBD	VBD	_	0	ROOT-S	_	_
4	substantially	_	RB	RB	_	3	ADV	_	_
5	from	_	IN	IN	_	3	ADV	_	_
6	that	_	DT	DT	_	5	PMOD	_	_
7	mediated	_	VBN	VBN	_	6	NMOD	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	phorbol	_	NN	NN	_	11	NMOD	_	_
10	12-myristate	_	NN	NN	_	11	NMOD	_	_
11	13-acetate	_	NN	NN	_	8	PMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	PMA	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	and	_	CC	CC	_	11	CC	_	_
16	Ca2+	_	NN	NN	_	17	NMOD	_	_
17	ionophore	_	NN	NN	_	11	COORD	_	_
18	or	_	CC	CC	_	7	CC	_	_
19	produced	_	VBN	VBN	_	7	COORD	_	_
20	by	_	IN	IN	_	19	ADV	_	_
21	costimulation	_	NN	NN	_	20	PMOD	_	_
22	with	_	IN	IN	_	21	NMOD	_	_
23	antibodies	_	NNS	NNS	_	22	PMOD	_	_
24	against	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	29	NMOD	_	_
26	T	_	NN	NN	_	28	AMOD	_	_
27	cell	_	NN	NN	_	28	AMOD	_	_
28	receptor-CD3	_	NN	NN	_	29	NMOD	_	_
29	complex	_	NN	NN	_	24	PMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	to	_	TO	TO	_	29	COORD	_	_
32	CD28	_	NN	NN	_	29	COORD	_	_
33	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	activation	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	JNK	_	NN	NN	_	3	PMOD	_	_
5	by	_	IN	IN	_	2	NMOD	_	_
6	classical	_	JJ	JJ	_	9	NMOD	_	_
7	T	_	NN	NN	_	9	NMOD	_	_
8	cell	_	NN	NN	_	9	NMOD	_	_
9	stimuli	_	NNS	NNS	_	5	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	transient	_	JJ	JJ	_	10	PRD	_	_
12	,	_	,	,	_	10	P	_	_
13	whereas	_	IN	IN	_	10	COORD	_	_
14	that	_	DT	DT	_	26	SBJ	_	_
15	mediated	_	VBN	VBN	_	14	NMOD	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	PDTC	_	NN	NN	_	16	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	butylated	_	VBN	VBN	_	20	NMOD	_	_
20	hydroxyanisole	_	NN	NN	_	17	COORD	_	_
21	(	_	(	(	_	17	P	_	_
22	but	_	CC	CC	_	17	CC	_	_
23	not	_	RB	RB	_	22	COORD	_	_
24	N-acetylcysteine	_	NN	NN	_	17	COORD	_	_
25	)	_	)	)	_	17	P	_	_
26	was	_	VBD	VBD	_	10	COORD	_	_
27	sustained	_	JJ	JJ	_	26	PRD	_	_
28	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	kinetics	_	NNS	NNS	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	JNK	_	NN	NN	_	5	NMOD	_	_
5	activation	_	NN	NN	_	3	PMOD	_	_
6	correlated	_	VBD	VBD	_	0	ROOT-S	_	_
7	with	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	expression	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	c-jun	_	NN	NN	_	10	PMOD	_	_
12	which	_	WDT	WDT	_	13	SBJ	_	_
13	was	_	VBD	VBD	_	9	NMOD	_	_
14	transient	_	JJ	JJ	_	13	PRD	_	_
15	after	_	IN	IN	_	13	TMP	_	_
16	stimulation	_	NN	NN	_	15	PMOD	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	PMA	_	NN	NN	_	17	PMOD	_	_
19	plus	_	CC	CC	_	18	CC	_	_
20	ionophore	_	NN	NN	_	18	COORD	_	_
21	and	_	CC	CC	_	13	CC	_	_
22	prolonged	_	VBD	VBD	_	23	PMOD	_	_
23	in	_	IN	IN	_	15	GAP	_	_
24	response	_	NN	NN	_	23	DEP	_	_
25	to	_	TO	TO	_	23	DEP	_	_
26	PDTC	_	NN	NN	_	23	PMOD	_	_
27	,	_	,	,	_	9	P	_	_
28	which	_	WDT	WDT	_	31	SBJ	_	_
29	also	_	RB	RB	_	31	ADV	_	_
30	transiently	_	RB	RB	_	31	TMP	_	_
31	induced	_	VBD	VBD	_	9	NMOD	_	_
32	c-fos	_	NN	NN	_	31	OBJ	_	_
33	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	10	P	_	_
4	JNK	_	NN	NN	_	5	NMOD	_	_
5	activation	_	NN	NN	_	10	SBJ	_	_
6	by	_	IN	IN	_	5	NMOD	_	_
7	PMA	_	NN	NN	_	6	PMOD	_	_
8	plus	_	CC	CC	_	7	CC	_	_
9	ionophore	_	NN	NN	_	7	COORD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	sensitive	_	JJ	JJ	_	10	PRD	_	_
12	to	_	TO	TO	_	11	AMOD	_	_
13	inhibitors	_	NNS	NNS	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	signaling	_	NN	NN	_	16	NMOD	_	_
16	pathways	_	NNS	NNS	_	14	PMOD	_	_
17	involving	_	VBG	VBG	_	16	NMOD	_	_
18	Ca2+	_	NN	NN	_	26	NMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	protein	_	NN	NN	_	22	NMOD	_	_
21	kinase	_	NN	NN	_	22	NMOD	_	_
22	C	_	NN	NN	_	18	COORD	_	_
23	,	_	,	,	_	18	P	_	_
24	and	_	CC	CC	_	18	CC	_	_
25	tyrosine	_	NN	NN	_	18	COORD	_	_
26	phosphorylation	_	NN	NN	_	17	OBJ	_	_
27	,	_	,	,	_	13	P	_	_
28	which	_	WDT	WDT	_	29	SBJ	_	_
29	failed	_	VBD	VBD	_	13	NMOD	_	_
30	to	_	TO	TO	_	31	VMOD	_	_
31	inhibit	_	VB	VB	_	29	OBJ	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	activation	_	NN	NN	_	31	OBJ	_	_
34	mediated	_	VBN	VBN	_	33	NMOD	_	_
35	by	_	IN	IN	_	34	LGS	_	_
36	PDTC	_	NN	NN	_	35	PMOD	_	_
37	.	_	.	.	_	10	P	_	_

1	Transfection	_	NN	NN	_	33	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	trans-dominant	_	JJ	JJ	_	6	NMOD	_	_
4	negative	_	JJ	JJ	_	6	NMOD	_	_
5	expression	_	NN	NN	_	6	NMOD	_	_
6	vectors	_	NNS	NNS	_	2	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	ras	_	NN	NN	_	7	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	raf	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	6	P	_	_
12	together	_	RB	RB	_	6	CC	_	_
13	with	_	IN	IN	_	12	DEP	_	_
14	AP-1-dependent	_	JJ	JJ	_	16	NMOD	_	_
15	reporter	_	NN	NN	_	16	NMOD	_	_
16	constructs	_	NNS	NNS	_	6	COORD	_	_
17	,	_	,	,	_	1	P	_	_
18	as	_	RB	RB	_	1	CC	_	_
19	well	_	RB	RB	_	18	DEP	_	_
20	as	_	IN	IN	_	18	DEP	_	_
21	Western	_	NN	NN	_	23	NMOD	_	_
22	blot	_	NN	NN	_	23	NMOD	_	_
23	analysis	_	NN	NN	_	1	COORD	_	_
24	using	_	VBG	VBG	_	23	NMOD	_	_
25	anti-ERK	_	JJ	JJ	_	31	NMOD	_	_
26	(	_	(	(	_	29	P	_	_
27	extracellular	_	JJ	JJ	_	29	NMOD	_	_
28	signal-regulated	_	JJ	JJ	_	29	NMOD	_	_
29	kinase	_	NN	NN	_	25	PRN	_	_
30	)	_	)	)	_	29	P	_	_
31	antibodies	_	NNS	NNS	_	24	OBJ	_	_
32	,	_	,	,	_	1	P	_	_
33	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
34	that	_	IN	IN	_	33	OBJ	_	_
35	the	_	DT	DT	_	37	NMOD	_	_
36	Ras\/Raf/ERK	_	NN	NN	_	37	NMOD	_	_
37	pathway	_	NN	NN	_	38	SBJ	_	_
38	did	_	VBD	VBD	_	34	VMOD	_	_
39	not	_	RB	RB	_	38	VMOD	_	_
40	appear	_	VB	VB	_	38	VC	_	_
41	to	_	TO	TO	_	42	VMOD	_	_
42	mediate	_	VB	VB	_	40	OBJ	_	_
43	the	_	DT	DT	_	44	NMOD	_	_
44	effect	_	NN	NN	_	42	OBJ	_	_
45	of	_	IN	IN	_	44	NMOD	_	_
46	the	_	DT	DT	_	47	NMOD	_	_
47	antioxidant	_	NN	NN	_	45	PMOD	_	_
48	.	_	.	.	_	33	P	_	_

1	However	_	RB	RB	_	19	ADV	_	_
2	,	_	,	,	_	19	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	combined	_	JJ	JJ	_	5	NMOD	_	_
5	treatment	_	NN	NN	_	19	SBJ	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	PDTC	_	NN	NN	_	6	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	PMA	_	NN	NN	_	7	COORD	_	_
10	,	_	,	,	_	7	P	_	_
11	two	_	CD	CD	_	12	NMOD	_	_
12	agents	_	NNS	NNS	_	7	NMOD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	synergize	_	VBP	VBP	_	12	NMOD	_	_
15	on	_	IN	IN	_	14	TMP	_	_
16	AP-1	_	NN	NN	_	17	NMOD	_	_
17	activation	_	NN	NN	_	15	PMOD	_	_
18	,	_	,	,	_	7	P	_	_
19	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	persistent	_	JJ	JJ	_	23	NMOD	_	_
23	phosphorylation	_	NN	NN	_	20	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	ERK-2	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	19	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	conclusion	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	6	P	_	_
4	our	_	PRP$	PRP$	_	5	NMOD	_	_
5	results	_	NNS	NNS	_	6	SBJ	_	_
6	identify	_	VBP	VBP	_	0	ROOT-S	_	_
7	JNK	_	NN	NN	_	6	OBJ	_	_
8	as	_	IN	IN	_	6	ADV	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	target	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	antioxidant	_	JJ	JJ	_	13	NMOD	_	_
13	agents	_	NNS	NNS	_	11	PMOD	_	_
14	which	_	WDT	WDT	_	15	SBJ	_	_
15	can	_	MD	MD	_	10	NMOD	_	_
16	be	_	VB	VB	_	15	VC	_	_
17	regulated	_	VBN	VBN	_	16	VC	_	_
18	differentially	_	RB	RB	_	17	ADV	_	_
19	under	_	IN	IN	_	17	ADV	_	_
20	oxidant	_	JJ	JJ	_	23	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	antioxidant	_	JJ	JJ	_	20	COORD	_	_
23	conditions	_	NNS	NNS	_	19	PMOD	_	_
24	.	_	.	.	_	6	P	_	_

1	Cytomegalovirus	_	NN	NN	_	2	SBJ	_	_
2	modulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	interleukin-6	_	NN	NN	_	5	NMOD	_	_
4	gene	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	2	OBJ	_	_
6	.	_	.	.	_	2	P	_	_

1	Complications	_	NNS	NNS	_	5	SBJ	_	_
2	after	_	IN	IN	_	1	TMP	_	_
3	lung	_	NN	NN	_	4	NMOD	_	_
4	transplantation	_	NN	NN	_	2	PMOD	_	_
5	include	_	VBP	VBP	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	development	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	rejection	_	NN	NN	_	8	PMOD	_	_
10	and	_	CC	CC	_	7	CC	_	_
11	an	_	DT	DT	_	13	NMOD	_	_
12	increased	_	VBN	VBN	_	13	NMOD	_	_
13	incidence	_	NN	NN	_	7	COORD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	infection	_	NN	NN	_	14	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	particularly	_	RB	RB	_	18	DEP	_	_
18	with	_	IN	IN	_	15	NMOD	_	_
19	cytomegalovirus	_	NN	NN	_	18	PMOD	_	_
20	(	_	(	(	_	21	P	_	_
21	CMV	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	.	_	.	.	_	5	P	_	_

1	Several	_	JJ	JJ	_	3	NMOD	_	_
2	recent	_	JJ	JJ	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	4	SBJ	_	_
4	have	_	VBP	VBP	_	0	ROOT-S	_	_
5	suggested	_	VBN	VBN	_	4	VC	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	interleukin	_	NN	NN	_	9	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	IL	_	NN	NN	_	12	SBJ	_	_
10	)	_	)	)	_	9	P	_	_
11	-6	_	CD	CD	_	9	NMOD	_	_
12	may	_	MD	MD	_	6	VMOD	_	_
13	be	_	VB	VB	_	12	VC	_	_
14	used	_	VBN	VBN	_	13	VC	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	detect	_	VB	VB	_	14	OBJ	_	_
17	both	_	CC	CC	_	18	CC	_	_
18	infection	_	NN	NN	_	16	OBJ	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	rejection	_	NN	NN	_	18	COORD	_	_
21	after	_	IN	IN	_	18	TMP	_	_
22	lung	_	NN	NN	_	23	NMOD	_	_
23	transplantation	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	5	VMOD	_	_
2	addition	_	NN	NN	_	5	VMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	IL-6	_	NN	NN	_	5	SBJ	_	_
5	may	_	MD	MD	_	0	ROOT-S	_	_
6	play	_	VB	VB	_	5	VC	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	role	_	NN	NN	_	6	OBJ	_	_
9	in	_	IN	IN	_	6	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	development	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	bronchiolitis	_	NN	NN	_	14	NMOD	_	_
14	obliterans	_	NNS	NNS	_	12	PMOD	_	_
15	after	_	IN	IN	_	11	TMP	_	_
16	transplantation	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	5	P	_	_

1	Because	_	IN	IN	_	16	ADV	_	_
2	CMV	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	1	VMOD	_	_
4	also	_	RB	RB	_	3	ADV	_	_
5	associated	_	VBN	VBN	_	3	VC	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	development	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	bronchiolitis	_	NN	NN	_	11	NMOD	_	_
11	obliterans	_	NNS	NNS	_	9	PMOD	_	_
12	after	_	IN	IN	_	8	TMP	_	_
13	transplantation	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	16	P	_	_
15	we	_	PRP	PRP	_	16	SBJ	_	_
16	determined	_	VBD	VBD	_	0	ROOT-S	_	_
17	whether	_	IN	IN	_	16	OBJ	_	_
18	CMV	_	NN	NN	_	19	SBJ	_	_
19	induces	_	VBZ	VBZ	_	17	VMOD	_	_
20	IL-6	_	NN	NN	_	22	NMOD	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	expression	_	NN	NN	_	19	OBJ	_	_
23	.	_	.	.	_	16	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	CMV	_	NN	NN	_	5	NMOD	_	_
5	infection	_	NN	NN	_	6	SBJ	_	_
6	increased	_	VBD	VBD	_	3	VMOD	_	_
7	both	_	CC	CC	_	9	CC	_	_
8	IL-6	_	NN	NN	_	9	NMOD	_	_
9	protein	_	NN	NN	_	6	OBJ	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	mRNA	_	NN	NN	_	9	COORD	_	_
12	in	_	IN	IN	_	9	NMOD	_	_
13	peripheral	_	JJ	JJ	_	16	NMOD	_	_
14	blood	_	NN	NN	_	16	NMOD	_	_
15	mononuclear	_	JJ	JJ	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	12	PMOD	_	_
17	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	11	NMOD	_	_
6	CMV	_	NN	NN	_	11	NMOD	_	_
7	immediate	_	JJ	JJ	_	11	NMOD	_	_
8	early	_	JJ	JJ	_	11	NMOD	_	_
9	1	_	CD	CD	_	11	NMOD	_	_
10	gene	_	NN	NN	_	11	NMOD	_	_
11	product	_	NN	NN	_	12	SBJ	_	_
12	increased	_	VBD	VBD	_	4	VMOD	_	_
13	expression	_	NN	NN	_	12	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	IL-6	_	NN	NN	_	17	NMOD	_	_
17	promoter	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	10	NMOD	_	_
5	CMV	_	NN	NN	_	10	NMOD	_	_
6	immediate	_	JJ	JJ	_	10	NMOD	_	_
7	early	_	JJ	JJ	_	10	NMOD	_	_
8	1	_	CD	CD	_	10	NMOD	_	_
9	gene	_	NN	NN	_	10	NMOD	_	_
10	product	_	NN	NN	_	3	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	dependent	_	JJ	JJ	_	11	PRD	_	_
13	upon	_	IN	IN	_	12	AMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	presence	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	specific	_	JJ	JJ	_	21	NMOD	_	_
18	transcription	_	NN	NN	_	21	NMOD	_	_
19	factor	_	NN	NN	_	21	NMOD	_	_
20	binding	_	NN	NN	_	21	NMOD	_	_
21	sites	_	NNS	NNS	_	16	PMOD	_	_
22	in	_	IN	IN	_	15	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	IL-6	_	NN	NN	_	25	NMOD	_	_
25	promoter	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	11	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	CMV	_	NN	NN	_	6	SBJ	_	_
6	may	_	MD	MD	_	4	VMOD	_	_
7	be	_	VB	VB	_	6	VC	_	_
8	an	_	DT	DT	_	10	NMOD	_	_
9	important	_	JJ	JJ	_	10	NMOD	_	_
10	cofactor	_	NN	NN	_	7	PRD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	development	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	rejection	_	NN	NN	_	14	PMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	infection	_	NN	NN	_	15	COORD	_	_
18	after	_	IN	IN	_	13	TMP	_	_
19	transplantation	_	NN	NN	_	18	PMOD	_	_
20	through	_	IN	IN	_	13	NMOD	_	_
21	its	_	PRP$	PRP$	_	22	NMOD	_	_
22	effects	_	NNS	NNS	_	20	PMOD	_	_
23	on	_	IN	IN	_	22	NMOD	_	_
24	IL-6	_	NN	NN	_	23	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	Interstitial	_	JJ	JJ	_	2	NMOD	_	_
2	deletion	_	NN	NN	_	3	SBJ	_	_
3	constitutes	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	major	_	JJ	JJ	_	6	NMOD	_	_
6	mechanism	_	NN	NN	_	3	OBJ	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	loss	_	NN	NN	_	7	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	heterozygosity	_	NN	NN	_	9	PMOD	_	_
11	on	_	IN	IN	_	10	NMOD	_	_
12	chromosome	_	NN	NN	_	13	NMOD	_	_
13	20q	_	NN	NN	_	11	PMOD	_	_
14	in	_	IN	IN	_	8	NMOD	_	_
15	polycythemia	_	NN	NN	_	16	NMOD	_	_
16	vera	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	An	_	DT	DT	_	3	NMOD	_	_
2	acquired	_	VBN	VBN	_	3	NMOD	_	_
3	deletion	_	NN	NN	_	11	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	long	_	JJ	JJ	_	7	NMOD	_	_
7	arm	_	NN	NN	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	chromosome	_	NN	NN	_	8	PMOD	_	_
10	20	_	CD	CD	_	9	NMOD	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	recurrent	_	JJ	JJ	_	14	NMOD	_	_
14	abnormality	_	NN	NN	_	11	PRD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	myeloproliferative	_	JJ	JJ	_	17	NMOD	_	_
17	disorders	_	NNS	NNS	_	15	PMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	particularly	_	RB	RB	_	24	NMOD	_	_
20	polycythemia	_	NN	NN	_	21	NMOD	_	_
21	vera	_	NN	NN	_	24	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	myelodysplastic	_	JJ	JJ	_	21	COORD	_	_
24	syndromes	_	NNS	NNS	_	17	NMOD	_	_
25	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	association	_	NN	NN	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	20q	_	NN	NN	_	5	NMOD	_	_
5	deletions	_	NNS	NNS	_	3	PMOD	_	_
6	with	_	IN	IN	_	2	NMOD	_	_
7	myeloid	_	JJ	JJ	_	12	NMOD	_	_
8	"	_	``	``	_	12	P	_	_
9	stem	_	NN	NN	_	12	NMOD	_	_
10	cell	_	NN	NN	_	12	NMOD	_	_
11	"	_	''	''	_	12	P	_	_
12	disorders	_	NNS	NNS	_	6	PMOD	_	_
13	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	that	_	IN	IN	_	13	OBJ	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	deletions	_	NNS	NNS	_	17	SBJ	_	_
17	mark	_	VBP	VBP	_	14	VMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	site	_	NN	NN	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	one	_	CD	CD	_	24	NMOD	_	_
22	or	_	CC	CC	_	21	CC	_	_
23	more	_	JJR	JJR	_	21	COORD	_	_
24	genes	_	NNS	NNS	_	20	PMOD	_	_
25	,	_	,	,	_	19	P	_	_
26	loss	_	NN	NN	_	29	NMOD	_	_
27	or	_	CC	CC	_	26	CC	_	_
28	inactivation	_	NN	NN	_	26	COORD	_	_
29	of	_	IN	IN	_	31	SBJ	_	_
30	which	_	WDT	WDT	_	29	PMOD	_	_
31	plays	_	VBZ	VBZ	_	19	NMOD	_	_
32	a	_	DT	DT	_	33	NMOD	_	_
33	role	_	NN	NN	_	31	OBJ	_	_
34	in	_	IN	IN	_	31	ADV	_	_
35	the	_	DT	DT	_	36	NMOD	_	_
36	regulation	_	NN	NN	_	34	PMOD	_	_
37	of	_	IN	IN	_	36	NMOD	_	_
38	normal	_	JJ	JJ	_	40	NMOD	_	_
39	hematopoietic	_	JJ	JJ	_	40	NMOD	_	_
40	progenitors	_	NNS	NNS	_	37	PMOD	_	_
41	.	_	.	.	_	13	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	recently	_	RB	RB	_	2	TMP	_	_
4	performed	_	VBN	VBN	_	2	VC	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	detailed	_	JJ	JJ	_	8	NMOD	_	_
7	molecular	_	JJ	JJ	_	8	NMOD	_	_
8	analysis	_	NN	NN	_	4	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	20q	_	JJ	JJ	_	11	NMOD	_	_
11	deletions	_	NNS	NNS	_	9	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	peripheral	_	JJ	JJ	_	14	NMOD	_	_
14	blood	_	NN	NN	_	18	NMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	PB	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	granulocytes	_	NNS	NNS	_	12	PMOD	_	_
19	and	_	CC	CC	_	4	CC	_	_
20	defined	_	VBN	VBN	_	4	COORD	_	_
21	a	_	DT	DT	_	24	NMOD	_	_
22	commonly	_	RB	RB	_	23	AMOD	_	_
23	deleted	_	VBN	VBN	_	24	NMOD	_	_
24	region	_	NN	NN	_	20	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	16	_	CD	CD	_	28	DEP	_	_
27	to	_	TO	TO	_	28	DEP	_	_
28	21	_	CD	CD	_	29	NMOD	_	_
29	centimorgan	_	NN	NN	_	25	PMOD	_	_
30	(	_	(	(	_	31	P	_	_
31	cM	_	NN	NN	_	29	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	.	_	.	.	_	2	P	_	_

1	To	_	TO	TO	_	3	VMOD	_	_
2	further	_	RBR	RBR	_	3	ADV	_	_
3	reduce	_	VB	VB	_	12	VMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	size	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	common	_	JJ	JJ	_	10	NMOD	_	_
9	deleted	_	VBN	VBN	_	10	NMOD	_	_
10	region	_	NN	NN	_	6	PMOD	_	_
11	we	_	PRP	PRP	_	12	SBJ	_	_
12	have	_	VBP	VBP	_	0	ROOT-S	_	_
13	searched	_	VBN	VBN	_	12	VC	_	_
14	for	_	IN	IN	_	13	ADV	_	_
15	small	_	JJ	JJ	_	16	NMOD	_	_
16	deletions	_	NNS	NNS	_	14	PMOD	_	_
17	or	_	CC	CC	_	16	CC	_	_
18	mitotic	_	JJ	JJ	_	20	NMOD	_	_
19	recombination	_	NN	NN	_	20	NMOD	_	_
20	events	_	NNS	NNS	_	16	COORD	_	_
21	,	_	,	,	_	16	P	_	_
22	neither	_	DT	DT	_	23	NMOD	_	_
23	of	_	IN	IN	_	25	SBJ	_	_
24	which	_	WDT	WDT	_	23	PMOD	_	_
25	would	_	MD	MD	_	16	NMOD	_	_
26	be	_	VB	VB	_	25	VC	_	_
27	detected	_	VBN	VBN	_	26	VC	_	_
28	by	_	IN	IN	_	27	ADV	_	_
29	conventional	_	JJ	JJ	_	30	NMOD	_	_
30	cytogenetics	_	NNS	NNS	_	28	PMOD	_	_
31	.	_	.	.	_	12	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	studied	_	VBN	VBN	_	2	VC	_	_
4	48	_	CD	CD	_	5	NMOD	_	_
5	patients	_	NNS	NNS	_	3	OBJ	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	polycythemia	_	NN	NN	_	8	NMOD	_	_
8	vera	_	NN	NN	_	6	PMOD	_	_
9	and	_	CC	CC	_	5	CC	_	_
10	four	_	CD	CD	_	11	NMOD	_	_
11	patients	_	NNS	NNS	_	5	COORD	_	_
12	with	_	IN	IN	_	11	NMOD	_	_
13	idiopathic	_	JJ	JJ	_	14	NMOD	_	_
14	myelofibrosis	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	each	_	DT	DT	_	3	NMOD	_	_
3	case	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	7	P	_	_
5	cytogenetic	_	JJ	JJ	_	6	NMOD	_	_
6	analysis	_	NN	NN	_	7	SBJ	_	_
7	had	_	VBD	VBD	_	0	ROOT-S	_	_
8	either	_	RB	RB	_	7	VMOD	_	_
9	failed	_	VBN	VBN	_	7	VC	_	_
10	or	_	CC	CC	_	7	CC	_	_
11	had	_	VBD	VBD	_	7	COORD	_	_
12	shown	_	VBN	VBN	_	11	VC	_	_
13	no	_	DT	DT	_	14	NMOD	_	_
14	abnormalities	_	NNS	NNS	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	chromosome	_	NN	NN	_	15	PMOD	_	_
17	20	_	CD	CD	_	16	NMOD	_	_
18	.	_	.	.	_	7	P	_	_

1	Seventeen	_	CD	CD	_	3	NMOD	_	_
2	microsatellite	_	NN	NN	_	3	NMOD	_	_
3	markers	_	NNS	NNS	_	10	SBJ	_	_
4	that	_	WDT	WDT	_	5	SBJ	_	_
5	span	_	VBP	VBP	_	3	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	common	_	JJ	JJ	_	9	NMOD	_	_
8	deleted	_	VBN	VBN	_	9	NMOD	_	_
9	region	_	NN	NN	_	5	OBJ	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	used	_	VBN	VBN	_	10	VC	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	search	_	VB	VB	_	11	OBJ	_	_
14	for	_	IN	IN	_	13	ADV	_	_
15	loss	_	NN	NN	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	heterozygosity	_	NN	NN	_	16	PMOD	_	_
18	in	_	IN	IN	_	15	NMOD	_	_
19	granulocyte	_	NN	NN	_	20	NMOD	_	_
20	DNA	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	10	P	_	_

1	No	_	DT	DT	_	2	NMOD	_	_
2	instance	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	microsatellite	_	NN	NN	_	5	NMOD	_	_
5	instability	_	NN	NN	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	observed	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	total	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	880	_	CD	CD	_	13	NMOD	_	_
13	comparisons	_	NNS	NNS	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	granulocyte	_	NN	NN	_	18	NMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	T-cell	_	NN	NN	_	15	COORD	_	_
18	DNA	_	NN	NN	_	14	PMOD	_	_
19	.	_	.	.	_	6	P	_	_

1	Granulocyte	_	NN	NN	_	2	NMOD	_	_
2	DNA	_	NN	NN	_	6	SBJ	_	_
3	from	_	IN	IN	_	2	NMOD	_	_
4	four	_	CD	CD	_	5	NMOD	_	_
5	patients	_	NNS	NNS	_	3	PMOD	_	_
6	exhibited	_	VBD	VBD	_	0	ROOT-S	_	_
7	allele	_	NN	NN	_	8	NMOD	_	_
8	loss	_	NN	NN	_	6	OBJ	_	_
9	on	_	IN	IN	_	8	NMOD	_	_
10	20q	_	NN	NN	_	9	PMOD	_	_
11	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	each	_	DT	DT	_	3	NMOD	_	_
3	case	_	NN	NN	_	1	PMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	allele	_	NN	NN	_	6	NMOD	_	_
6	loss	_	NN	NN	_	7	SBJ	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	caused	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	an	_	DT	DT	_	12	NMOD	_	_
11	interstitial	_	JJ	JJ	_	12	NMOD	_	_
12	deletion	_	NN	NN	_	9	PMOD	_	_
13	because	_	IN	IN	_	8	ADV	_	_
14	heterozygosity	_	NN	NN	_	18	SBJ	_	_
15	at	_	IN	IN	_	14	NMOD	_	_
16	distal	_	JJ	JJ	_	17	NMOD	_	_
17	markers	_	NNS	NNS	_	15	PMOD	_	_
18	was	_	VBD	VBD	_	13	VMOD	_	_
19	retained	_	VBN	VBN	_	18	VC	_	_
20	and	_	CC	CC	_	13	CC	_	_
21	because	_	IN	IN	_	13	COORD	_	_
22	quantitative	_	JJ	JJ	_	24	NMOD	_	_
23	Southern	_	NN	NN	_	24	NMOD	_	_
24	blotting	_	NN	NN	_	25	SBJ	_	_
25	demonstrated	_	VBD	VBD	_	21	VMOD	_	_
26	hemizygosity	_	NN	NN	_	25	OBJ	_	_
27	.	_	.	.	_	7	P	_	_

1	Loss	_	NN	NN	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	heterozygosity	_	NN	NN	_	2	PMOD	_	_
4	in	_	IN	IN	_	1	NMOD	_	_
5	PB	_	NN	NN	_	6	NMOD	_	_
6	granulocytes	_	NNS	NNS	_	4	PMOD	_	_
7	would	_	MD	MD	_	0	ROOT-S	_	_
8	be	_	VB	VB	_	7	VC	_	_
9	masked	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	presence	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	significant	_	JJ	JJ	_	15	NMOD	_	_
15	numbers	_	NNS	NNS	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	normal	_	JJ	JJ	_	18	NMOD	_	_
18	granulocytes	_	NNS	NNS	_	16	PMOD	_	_
19	not	_	RB	RB	_	20	VMOD	_	_
20	derived	_	VBN	VBN	_	18	NMOD	_	_
21	from	_	IN	IN	_	20	ADV	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	malignant	_	JJ	JJ	_	24	NMOD	_	_
24	clone	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	7	P	_	_

1	Therefore	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	human	_	JJ	JJ	_	7	NMOD	_	_
5	androgen	_	NN	NN	_	7	NMOD	_	_
6	receptor	_	NN	NN	_	7	NMOD	_	_
7	assay	_	NN	NN	_	11	SBJ	_	_
8	(	_	(	(	_	9	P	_	_
9	HUMARA	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	used	_	VBN	VBN	_	11	VC	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	determine	_	VB	VB	_	12	OBJ	_	_
15	granulocyte	_	NN	NN	_	16	NMOD	_	_
16	clonality	_	NN	NN	_	14	OBJ	_	_
17	.	_	.	.	_	11	P	_	_

1	In	_	IN	IN	_	13	ADV	_	_
2	21	_	CD	CD	_	4	DEP	_	_
3	of	_	IN	IN	_	4	DEP	_	_
4	27	_	CD	CD	_	7	NMOD	_	_
5	informative	_	JJ	JJ	_	7	NMOD	_	_
6	female	_	NN	NN	_	7	NMOD	_	_
7	patients	_	NNS	NNS	_	1	PMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	majority	_	NN	NN	_	13	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	granulocytes	_	NNS	NNS	_	10	PMOD	_	_
13	were	_	VBD	VBD	_	0	ROOT-S	_	_
14	clonally	_	RB	RB	_	15	AMOD	_	_
15	derived	_	VBN	VBN	_	13	PRD	_	_
16	.	_	.	.	_	13	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	5	_	CD	CD	_	3	NMOD	_	_
3	patients	_	NNS	NNS	_	1	PMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	granulocytes	_	NNS	NNS	_	6	SBJ	_	_
6	appeared	_	VBD	VBD	_	0	ROOT-S	_	_
7	polyclonal	_	JJ	JJ	_	6	PRD	_	_
8	and	_	CC	CC	_	6	CC	_	_
9	in	_	IN	IN	_	15	ADV	_	_
10	1	_	CD	CD	_	11	NMOD	_	_
11	patient	_	NN	NN	_	9	PMOD	_	_
12	unilateral	_	JJ	JJ	_	14	NMOD	_	_
13	X	_	NN	NN	_	14	NMOD	_	_
14	inactivation	_	NN	NN	_	15	SBJ	_	_
15	was	_	VBD	VBD	_	6	COORD	_	_
16	observed	_	VBN	VBN	_	15	VC	_	_
17	in	_	IN	IN	_	16	ADV	_	_
18	both	_	CC	CC	_	19	CC	_	_
19	granulocytes	_	NNS	NNS	_	17	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	T	_	JJ	JJ	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	19	COORD	_	_
23	.	_	.	.	_	6	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	in	_	IN	IN	_	22	ADV	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	vast	_	JJ	JJ	_	9	NMOD	_	_
9	majority	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	patients	_	NNS	NNS	_	10	PMOD	_	_
12	presented	_	VBN	VBN	_	11	NMOD	_	_
13	here	_	RB	RB	_	12	ADV	_	_
14	,	_	,	,	_	22	P	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	failure	_	NN	NN	_	22	SBJ	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	detect	_	VB	VB	_	16	NMOD	_	_
19	loss	_	NN	NN	_	18	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	heterozygosity	_	NN	NN	_	20	PMOD	_	_
22	can	_	MD	MD	_	4	VMOD	_	_
23	not	_	RB	RB	_	22	VMOD	_	_
24	be	_	VB	VB	_	22	VC	_	_
25	attributed	_	VBN	VBN	_	24	VC	_	_
26	to	_	TO	TO	_	25	ADV	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	presence	_	NN	NN	_	26	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	normal	_	JJ	JJ	_	32	NMOD	_	_
31	polyclonal	_	JJ	JJ	_	32	NMOD	_	_
32	granulocytes	_	NNS	NNS	_	29	PMOD	_	_
33	.	_	.	.	_	3	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	4	SBJ	_	_
3	therefore	_	RB	RB	_	4	ADV	_	_
4	show	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	allele	_	NN	NN	_	7	NMOD	_	_
7	loss	_	NN	NN	_	14	SBJ	_	_
8	on	_	IN	IN	_	7	NMOD	_	_
9	chromosome	_	NN	NN	_	10	NMOD	_	_
10	20q	_	NN	NN	_	8	PMOD	_	_
11	in	_	IN	IN	_	7	NMOD	_	_
12	polycythemia	_	NN	NN	_	13	NMOD	_	_
13	vera	_	NN	NN	_	11	PMOD	_	_
14	does	_	VBZ	VBZ	_	5	VMOD	_	_
15	not	_	RB	RB	_	14	VMOD	_	_
16	commonly	_	RB	RB	_	14	ADV	_	_
17	involve	_	VB	VB	_	14	VC	_	_
18	mitotic	_	JJ	JJ	_	19	NMOD	_	_
19	recombination	_	NN	NN	_	17	OBJ	_	_
20	or	_	CC	CC	_	19	CC	_	_
21	chromosome	_	NN	NN	_	22	NMOD	_	_
22	loss	_	NN	NN	_	19	COORD	_	_
23	and	_	CC	CC	_	5	CC	_	_
24	that	_	IN	IN	_	5	COORD	_	_
25	microsatellite	_	NN	NN	_	26	NMOD	_	_
26	instability	_	NN	NN	_	27	SBJ	_	_
27	is	_	VBZ	VBZ	_	24	VMOD	_	_
28	a	_	DT	DT	_	30	NMOD	_	_
29	rare	_	JJ	JJ	_	30	NMOD	_	_
30	event	_	NN	NN	_	27	PRD	_	_
31	in	_	IN	IN	_	27	ADV	_	_
32	this	_	DT	DT	_	33	NMOD	_	_
33	disorder	_	NN	NN	_	31	PMOD	_	_
34	.	_	.	.	_	4	P	_	_

1	Transcriptional	_	JJ	JJ	_	2	NMOD	_	_
2	control	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	steroid-regulated	_	JJ	JJ	_	5	NMOD	_	_
5	apoptosis	_	NN	NN	_	3	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	murine	_	JJ	JJ	_	9	NMOD	_	_
8	thymoma	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	6	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	Early	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	8	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	murine	_	JJ	JJ	_	7	NMOD	_	_
5	T	_	NN	NN	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	lines	_	NNS	NNS	_	3	PMOD	_	_
8	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	transcriptional	_	JJ	JJ	_	12	NMOD	_	_
11	transactivation	_	NN	NN	_	12	NMOD	_	_
12	functions	_	NNS	NNS	_	23	SBJ	_	_
13	encoded	_	VBN	VBN	_	12	NMOD	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	22	NMOD	_	_
16	glucocorticoid	_	NN	NN	_	17	NMOD	_	_
17	receptor	_	NN	NN	_	22	NMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	GR	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	N-terminal	_	JJ	JJ	_	22	NMOD	_	_
22	domain	_	NN	NN	_	14	PMOD	_	_
23	are	_	VBP	VBP	_	9	VMOD	_	_
24	required	_	VBN	VBN	_	23	VC	_	_
25	for	_	IN	IN	_	24	ADV	_	_
26	glucocorticoid-mediated	_	JJ	JJ	_	27	NMOD	_	_
27	apoptosis	_	NN	NN	_	25	PMOD	_	_
28	.	_	.	.	_	8	P	_	_

1	However	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	more	_	RBR	RBR	_	4	AMOD	_	_
4	recent	_	JJ	JJ	_	5	TMP	_	_
5	studies	_	NNS	NNS	_	11	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	human	_	JJ	JJ	_	10	NMOD	_	_
8	T	_	NN	NN	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	lines	_	NNS	NNS	_	6	PMOD	_	_
11	have	_	VBP	VBP	_	0	ROOT-S	_	_
12	suggested	_	VBN	VBN	_	11	VC	_	_
13	that	_	IN	IN	_	12	OBJ	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	N-terminal	_	JJ	JJ	_	16	NMOD	_	_
16	domain	_	NN	NN	_	17	SBJ	_	_
17	is	_	VBZ	VBZ	_	13	VMOD	_	_
18	not	_	RB	RB	_	17	VMOD	_	_
19	necessary	_	JJ	JJ	_	17	PRD	_	_
20	for	_	IN	IN	_	19	AMOD	_	_
21	steroid-regulated	_	JJ	JJ	_	22	NMOD	_	_
22	apoptosis	_	NN	NN	_	20	PMOD	_	_
23	and	_	CC	CC	_	13	CC	_	_
24	that	_	IN	IN	_	13	COORD	_	_
25	GR-mediated	_	JJ	JJ	_	26	NMOD	_	_
26	transrepression	_	NN	NN	_	27	SBJ	_	_
27	may	_	MD	MD	_	24	VMOD	_	_
28	be	_	VB	VB	_	27	VC	_	_
29	the	_	DT	DT	_	32	NMOD	_	_
30	more	_	RBR	RBR	_	31	AMOD	_	_
31	critical	_	JJ	JJ	_	32	NMOD	_	_
32	mechanism	_	NN	NN	_	28	PRD	_	_
33	.	_	.	.	_	11	P	_	_

1	To	_	TO	TO	_	3	VMOD	_	_
2	better	_	RBR	RBR	_	3	ADV	_	_
3	understand	_	VB	VB	_	20	VMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	contribution	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	11	NMOD	_	_
8	GR	_	NN	NN	_	11	NMOD	_	_
9	N-terminal	_	JJ	JJ	_	11	NMOD	_	_
10	transactivation	_	NN	NN	_	11	NMOD	_	_
11	domain	_	NN	NN	_	6	PMOD	_	_
12	in	_	IN	IN	_	5	NMOD	_	_
13	mediating	_	VBG	VBG	_	12	PMOD	_	_
14	murine	_	JJ	JJ	_	16	NMOD	_	_
15	thymocyte	_	NN	NN	_	16	NMOD	_	_
16	apoptosis	_	NN	NN	_	13	OBJ	_	_
17	,	_	,	,	_	20	P	_	_
18	we	_	PRP	PRP	_	20	SBJ	_	_
19	stably	_	RB	RB	_	20	ADV	_	_
20	transfected	_	VBD	VBD	_	0	ROOT-S	_	_
21	GR	_	NN	NN	_	20	OBJ	_	_
22	,	_	,	,	_	21	P	_	_
23	GR	_	NN	NN	_	24	NMOD	_	_
24	variants	_	NNS	NNS	_	21	COORD	_	_
25	,	_	,	,	_	21	P	_	_
26	and	_	CC	CC	_	21	CC	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	androgen	_	NN	NN	_	29	NMOD	_	_
29	receptor	_	NN	NN	_	21	COORD	_	_
30	(	_	(	(	_	31	P	_	_
31	AR	_	NN	NN	_	29	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	into	_	IN	IN	_	20	ADV	_	_
34	receptor-negative	_	JJ	JJ	_	38	NMOD	_	_
35	S49	_	NN	NN	_	38	NMOD	_	_
36	murine	_	JJ	JJ	_	38	NMOD	_	_
37	thymoma	_	NN	NN	_	38	NMOD	_	_
38	cells	_	NNS	NNS	_	33	PMOD	_	_
39	.	_	.	.	_	20	P	_	_

1	GR	_	NN	NN	_	3	NMOD	_	_
2	expression	_	NN	NN	_	3	NMOD	_	_
3	levels	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	shown	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	be	_	VB	VB	_	5	OBJ	_	_
8	rate-limiting	_	JJ	JJ	_	7	PRD	_	_
9	for	_	IN	IN	_	7	ADV	_	_
10	initiating	_	VBG	VBG	_	9	PMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	apoptotic	_	JJ	JJ	_	13	NMOD	_	_
13	pathway	_	NN	NN	_	10	OBJ	_	_
14	,	_	,	,	_	4	P	_	_
15	and	_	CC	CC	_	4	CC	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	positive	_	JJ	JJ	_	18	NMOD	_	_
18	correlation	_	NN	NN	_	38	SBJ	_	_
19	between	_	IN	IN	_	18	NMOD	_	_
20	steroid	_	NN	NN	_	21	NMOD	_	_
21	sensitivity	_	NN	NN	_	19	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	GR-mediated	_	JJ	JJ	_	24	NMOD	_	_
24	induction	_	NN	NN	_	21	COORD	_	_
25	of	_	IN	IN	_	21	NMOD	_	_
26	an	_	DT	DT	_	37	NMOD	_	_
27	integrated	_	VBN	VBN	_	37	NMOD	_	_
28	mouse	_	NN	NN	_	31	NMOD	_	_
29	mammary	_	JJ	JJ	_	31	NMOD	_	_
30	tumor	_	NN	NN	_	31	NMOD	_	_
31	virus	_	NN	NN	_	37	NMOD	_	_
32	(	_	(	(	_	33	P	_	_
33	MMTV	_	NN	NN	_	31	PRN	_	_
34	)	_	)	)	_	33	P	_	_
35	LTR	_	NN	NN	_	37	NMOD	_	_
36	reporter	_	NN	NN	_	37	NMOD	_	_
37	gene	_	NN	NN	_	25	PMOD	_	_
38	was	_	VBD	VBD	_	4	COORD	_	_
39	observed	_	VBN	VBN	_	38	VC	_	_
40	.	_	.	.	_	4	P	_	_

1	Analysis	_	NN	NN	_	22	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	GR	_	NN	NN	_	5	NMOD	_	_
4	chimeric	_	JJ	JJ	_	5	NMOD	_	_
5	receptors	_	NNS	NNS	_	2	PMOD	_	_
6	containing	_	VBG	VBG	_	5	NMOD	_	_
7	the	_	DT	DT	_	14	NMOD	_	_
8	potent	_	JJ	JJ	_	14	NMOD	_	_
9	VP16	_	NN	NN	_	14	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	E1A	_	NN	NN	_	9	COORD	_	_
12	viral	_	JJ	JJ	_	14	NMOD	_	_
13	transactivation	_	NN	NN	_	14	NMOD	_	_
14	domains	_	NNS	NNS	_	6	OBJ	_	_
15	in	_	IN	IN	_	6	ADV	_	_
16	place	_	NN	NN	_	15	DEP	_	_
17	of	_	IN	IN	_	15	DEP	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	GR	_	NN	NN	_	21	NMOD	_	_
20	N	_	NN	NN	_	21	NMOD	_	_
21	terminus	_	NN	NN	_	15	PMOD	_	_
22	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
23	that	_	IN	IN	_	22	OBJ	_	_
24	even	_	RB	RB	_	27	NMOD	_	_
25	low	_	JJ	JJ	_	27	NMOD	_	_
26	level	_	NN	NN	_	27	NMOD	_	_
27	expression	_	NN	NN	_	31	SBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	these	_	DT	DT	_	30	NMOD	_	_
30	receptors	_	NNS	NNS	_	28	PMOD	_	_
31	resulted	_	VBD	VBD	_	23	VMOD	_	_
32	in	_	IN	IN	_	31	ADV	_	_
33	both	_	CC	CC	_	36	CC	_	_
34	enhanced	_	VBN	VBN	_	36	NMOD	_	_
35	steroid	_	NN	NN	_	36	NMOD	_	_
36	sensitivity	_	NN	NN	_	32	PMOD	_	_
37	and	_	CC	CC	_	36	CC	_	_
38	MMTV	_	NN	NN	_	39	NMOD	_	_
39	induction	_	NN	NN	_	36	COORD	_	_
40	,	_	,	,	_	31	P	_	_
41	thus	_	RB	RB	_	42	ADV	_	_
42	supporting	_	VBG	VBG	_	31	OBJ	_	_
43	a	_	DT	DT	_	44	NMOD	_	_
44	role	_	NN	NN	_	42	OBJ	_	_
45	for	_	IN	IN	_	44	NMOD	_	_
46	transactivation	_	NN	NN	_	45	PMOD	_	_
47	in	_	IN	IN	_	46	NMOD	_	_
48	apoptosis	_	NN	NN	_	47	PMOD	_	_
49	.	_	.	.	_	22	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	found	_	VBD	VBD	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	AR	_	NN	NN	_	8	SBJ	_	_
8	can	_	MD	MD	_	6	VMOD	_	_
9	initiate	_	VB	VB	_	8	VC	_	_
10	apoptosis	_	NN	NN	_	9	OBJ	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	S49	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	after	_	IN	IN	_	9	TMP	_	_
15	treatment	_	NN	NN	_	14	PMOD	_	_
16	with	_	IN	IN	_	15	NMOD	_	_
17	5	_	CD	CD	_	18	NMOD	_	_
18	alpha-dihydrotestosterone	_	NN	NN	_	16	PMOD	_	_
19	,	_	,	,	_	9	P	_	_
20	despite	_	IN	IN	_	9	ADV	_	_
21	its	_	PRP$	PRP$	_	23	NMOD	_	_
22	relative	_	JJ	JJ	_	23	NMOD	_	_
23	inability	_	NN	NN	_	20	PMOD	_	_
24	to	_	TO	TO	_	25	VMOD	_	_
25	induce	_	VB	VB	_	23	NMOD	_	_
26	high	_	JJ	JJ	_	28	NMOD	_	_
27	level	_	NN	NN	_	28	NMOD	_	_
28	expression	_	NN	NN	_	25	OBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	MMTV	_	NN	NN	_	29	PMOD	_	_
31	.	_	.	.	_	5	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	investigate	_	VB	VB	_	7	VMOD	_	_
3	this	_	DT	DT	_	2	OBJ	_	_
4	further	_	RBR	RBR	_	2	ADV	_	_
5	,	_	,	,	_	7	P	_	_
6	we	_	PRP	PRP	_	7	SBJ	_	_
7	examined	_	VBD	VBD	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	steroid-regulated	_	JJ	JJ	_	10	NMOD	_	_
10	expression	_	NN	NN	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	an	_	DT	DT	_	15	NMOD	_	_
13	endogenous	_	JJ	JJ	_	15	NMOD	_	_
14	thymocyte-specific	_	JJ	JJ	_	15	NMOD	_	_
15	gene	_	NN	NN	_	11	PMOD	_	_
16	called	_	VBN	VBN	_	15	NMOD	_	_
17	GIG18	_	NN	NN	_	16	OBJ	_	_
18	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	found	_	VBD	VBD	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	GIG18	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	3	VMOD	_	_
6	rapidly	_	RB	RB	_	7	TMP	_	_
7	induced	_	VBN	VBN	_	5	VC	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	comparable	_	JJ	JJ	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	8	PMOD	_	_
11	by	_	IN	IN	_	7	LGS	_	_
12	both	_	CC	CC	_	13	CC	_	_
13	AR	_	NN	NN	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	GR	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	7	P	_	_
17	demonstrating	_	VBG	VBG	_	7	OBJ	_	_
18	that	_	IN	IN	_	17	OBJ	_	_
19	AR	_	NN	NN	_	20	SBJ	_	_
20	can	_	MD	MD	_	18	VMOD	_	_
21	indeed	_	RB	RB	_	22	ADV	_	_
22	function	_	VB	VB	_	20	VC	_	_
23	as	_	IN	IN	_	22	ADV	_	_
24	a	_	DT	DT	_	26	NMOD	_	_
25	transcriptional	_	JJ	JJ	_	26	NMOD	_	_
26	activator	_	NN	NN	_	23	PMOD	_	_
27	in	_	IN	IN	_	26	NMOD	_	_
28	S49	_	NN	NN	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	27	PMOD	_	_
30	and	_	CC	CC	_	18	CC	_	_
31	,	_	,	,	_	18	P	_	_
32	moreover	_	RB	RB	_	18	COORD	_	_
33	,	_	,	,	_	18	P	_	_
34	that	_	IN	IN	_	18	COORD	_	_
35	GIG18	_	NN	NN	_	36	NMOD	_	_
36	induction	_	NN	NN	_	37	SBJ	_	_
37	may	_	MD	MD	_	34	VMOD	_	_
38	be	_	VB	VB	_	37	VC	_	_
39	a	_	DT	DT	_	40	NMOD	_	_
40	marker	_	NN	NN	_	38	PRD	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	early	_	JJ	JJ	_	44	NMOD	_	_
43	apoptotic	_	JJ	JJ	_	44	NMOD	_	_
44	events	_	NNS	NNS	_	41	PMOD	_	_
45	in	_	IN	IN	_	40	NMOD	_	_
46	steroid-treated	_	JJ	JJ	_	47	NMOD	_	_
47	cells	_	NNS	NNS	_	45	PMOD	_	_
48	.	_	.	.	_	2	P	_	_

1	Taken	_	VBN	VBN	_	6	VMOD	_	_
2	together	_	RB	RB	_	1	ADV	_	_
3	,	_	,	,	_	6	P	_	_
4	these	_	DT	DT	_	5	NMOD	_	_
5	results	_	NNS	NNS	_	6	SBJ	_	_
6	support	_	VBP	VBP	_	0	ROOT-S	_	_
7	our	_	PRP$	PRP$	_	8	NMOD	_	_
8	conclusion	_	NN	NN	_	6	IOBJ	_	_
9	that	_	IN	IN	_	8	NMOD	_	_
10	transcriptional	_	JJ	JJ	_	11	NMOD	_	_
11	transactivation	_	NN	NN	_	12	SBJ	_	_
12	is	_	VBZ	VBZ	_	9	VMOD	_	_
13	a	_	DT	DT	_	16	NMOD	_	_
14	necessary	_	JJ	JJ	_	16	NMOD	_	_
15	signaling	_	NN	NN	_	16	NMOD	_	_
16	component	_	NN	NN	_	12	PRD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	S49	_	NN	NN	_	20	NMOD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	apoptosis	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	6	P	_	_
22	although	_	IN	IN	_	6	OBJ	_	_
23	an	_	DT	DT	_	25	NMOD	_	_
24	additional	_	JJ	JJ	_	25	NMOD	_	_
25	role	_	NN	NN	_	29	SBJ	_	_
26	for	_	IN	IN	_	25	NMOD	_	_
27	GR-mediated	_	JJ	JJ	_	28	NMOD	_	_
28	transrepression	_	NN	NN	_	26	PMOD	_	_
29	can	_	MD	MD	_	22	VMOD	_	_
30	not	_	RB	RB	_	31	VMOD	_	_
31	be	_	VB	VB	_	29	VC	_	_
32	excluded	_	VBN	VBN	_	6	VMOD	_	_

1	Suppression	_	NN	NN	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	c-jun	_	NN	NN	_	2	PMOD	_	_
4	by	_	IN	IN	_	1	NMOD	_	_
5	antisense	_	JJ	JJ	_	6	NMOD	_	_
6	oligonucleotides	_	NNS	NNS	_	4	PMOD	_	_
7	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	cell	_	NN	NN	_	9	NMOD	_	_
9	adhesion	_	NN	NN	_	7	OBJ	_	_
10	but	_	CC	CC	_	9	CC	_	_
11	not	_	RB	RB	_	10	COORD	_	_
12	respiratory	_	JJ	JJ	_	13	NMOD	_	_
13	burst	_	NN	NN	_	9	COORD	_	_
14	during	_	IN	IN	_	7	TMP	_	_
15	phorbol	_	NN	NN	_	17	NMOD	_	_
16	ester-induced	_	JJ	JJ	_	15	AMOD	_	_
17	differentiation	_	NN	NN	_	14	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	U937	_	NN	NN	_	22	NMOD	_	_
20	human	_	JJ	JJ	_	22	NMOD	_	_
21	monoblastic	_	JJ	JJ	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	18	PMOD	_	_
23	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	studied	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	role	_	NN	NN	_	2	IOBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	immediate	_	JJ	JJ	_	10	NMOD	_	_
8	early	_	JJ	JJ	_	10	NMOD	_	_
9	gene	_	NN	NN	_	10	NMOD	_	_
10	c-jun	_	NN	NN	_	5	PMOD	_	_
11	in	_	IN	IN	_	4	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	proliferation	_	NN	NN	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	phorbol	_	NN	NN	_	19	AMOD	_	_
16	12-myristate	_	NN	NN	_	19	AMOD	_	_
17	13-acetate	_	NN	NN	_	19	AMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	PMA	_	NN	NN	_	22	NMOD	_	_
20	)	_	)	)	_	19	P	_	_
21	-induced	_	JJ	JJ	_	19	AMOD	_	_
22	differentiation	_	NN	NN	_	13	COORD	_	_
23	in	_	IN	IN	_	13	NMOD	_	_
24	U937	_	NN	NN	_	27	NMOD	_	_
25	human	_	JJ	JJ	_	27	NMOD	_	_
26	monoblastic	_	JJ	JJ	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	23	PMOD	_	_
28	,	_	,	,	_	2	P	_	_
29	using	_	VBG	VBG	_	2	OBJ	_	_
30	c-jun-specific	_	JJ	JJ	_	36	NMOD	_	_
31	antisense	_	JJ	JJ	_	36	NMOD	_	_
32	(	_	(	(	_	33	P	_	_
33	AS	_	JJ	JJ	_	31	PRN	_	_
34	)	_	)	)	_	33	P	_	_
35	phosphorothioate	_	NN	NN	_	36	NMOD	_	_
36	oligonucleotides	_	NNS	NNS	_	29	OBJ	_	_
37	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	selecting	_	VBG	VBG	_	1	PMOD	_	_
3	the	_	DT	DT	_	9	NMOD	_	_
4	most	_	RBS	RBS	_	5	AMOD	_	_
5	specific	_	JJ	JJ	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	potent	_	JJ	JJ	_	5	COORD	_	_
8	oligonucleotide	_	JJ	JJ	_	9	NMOD	_	_
9	sequence	_	NN	NN	_	2	OBJ	_	_
10	,	_	,	,	_	12	P	_	_
11	we	_	PRP	PRP	_	12	SBJ	_	_
12	performed	_	VBD	VBD	_	0	ROOT-S	_	_
13	extensive	_	JJ	JJ	_	14	NMOD	_	_
14	analyses	_	NNS	NNS	_	12	IOBJ	_	_
15	for	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	binding	_	NN	NN	_	18	NMOD	_	_
18	specificity	_	NN	NN	_	15	PMOD	_	_
19	between	_	IN	IN	_	18	NMOD	_	_
20	all	_	DT	DT	_	21	NMOD	_	_
21	candidates	_	NNS	NNS	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	c-jun	_	NN	NN	_	25	NMOD	_	_
24	AS	_	JJ	JJ	_	25	NMOD	_	_
25	oligonucleotides	_	NNS	NNS	_	22	PMOD	_	_
26	and	_	CC	CC	_	21	CC	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	whole	_	JJ	JJ	_	29	NMOD	_	_
29	sequences	_	NNS	NNS	_	21	COORD	_	_
30	in	_	IN	IN	_	29	NMOD	_	_
31	GenBank	_	NN	NN	_	32	NMOD	_	_
32	database	_	NN	NN	_	30	PMOD	_	_
33	,	_	,	,	_	12	P	_	_
34	using	_	VBG	VBG	_	12	OBJ	_	_
35	a	_	DT	DT	_	37	NMOD	_	_
36	computer	_	NN	NN	_	37	NMOD	_	_
37	program	_	NN	NN	_	34	OBJ	_	_
38	.	_	.	.	_	12	P	_	_

1	Among	_	IN	IN	_	17	ADV	_	_
2	the	_	DT	DT	_	5	NMOD	_	_
3	20	_	CD	CD	_	5	NMOD	_	_
4	selected	_	VBN	VBN	_	5	NMOD	_	_
5	oligonucleotides	_	NNS	NNS	_	1	PMOD	_	_
6	,	_	,	,	_	17	P	_	_
7	two	_	CD	CD	_	11	NMOD	_	_
8	potent	_	JJ	JJ	_	11	NMOD	_	_
9	15-mer	_	JJ	JJ	_	11	NMOD	_	_
10	AS	_	JJ	JJ	_	11	NMOD	_	_
11	oligonucleotides	_	NNS	NNS	_	17	SBJ	_	_
12	(	_	(	(	_	15	P	_	_
13	C-JUN	_	NN	NN	_	15	NMOD	_	_
14	AS	_	JJ	JJ	_	15	NMOD	_	_
15	oligonucleotides	_	NNS	NNS	_	11	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	exhibited	_	VBD	VBD	_	0	ROOT-S	_	_
18	significant	_	JJ	JJ	_	19	NMOD	_	_
19	inhibition	_	NN	NN	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	cell	_	NN	NN	_	22	NMOD	_	_
22	growth	_	NN	NN	_	20	PMOD	_	_
23	in	_	IN	IN	_	17	ADV	_	_
24	a	_	DT	DT	_	26	NMOD	_	_
25	dose-dependent	_	JJ	JJ	_	26	NMOD	_	_
26	manner	_	NN	NN	_	23	PMOD	_	_
27	between	_	IN	IN	_	28	DEP	_	_
28	2	_	CD	CD	_	31	NMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	10	_	CD	CD	_	28	COORD	_	_
31	microM	_	NN	NN	_	26	NMOD	_	_
32	.	_	.	.	_	17	P	_	_

1	Reverse	_	JJ	JJ	_	2	NMOD	_	_
2	transcription-PCR	_	NN	NN	_	7	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	Western	_	NN	NN	_	6	NMOD	_	_
5	blot	_	NN	NN	_	6	NMOD	_	_
6	analysis	_	NN	NN	_	2	COORD	_	_
7	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	10	_	CD	CD	_	10	NMOD	_	_
10	microM	_	NN	NN	_	15	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	C-JUN	_	NN	NN	_	14	NMOD	_	_
13	AS	_	JJ	JJ	_	14	NMOD	_	_
14	oligonucleotides	_	NNS	NNS	_	11	PMOD	_	_
15	reduced	_	VBD	VBD	_	8	VMOD	_	_
16	c-jun	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	15	OBJ	_	_
18	at	_	IN	IN	_	15	ADV	_	_
19	both	_	CC	CC	_	24	CC	_	_
20	the	_	DT	DT	_	24	NMOD	_	_
21	mRNA	_	NN	NN	_	24	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	protein	_	NN	NN	_	21	COORD	_	_
24	levels	_	NNS	NNS	_	18	PMOD	_	_
25	.	_	.	.	_	7	P	_	_

1	More	_	RBR	RBR	_	2	AMOD	_	_
2	importantly	_	RB	RB	_	7	ADV	_	_
3	,	_	,	,	_	7	P	_	_
4	C-JUN	_	NN	NN	_	6	NMOD	_	_
5	AS	_	JJ	JJ	_	6	NMOD	_	_
6	oligonucleotides	_	NNS	NNS	_	7	SBJ	_	_
7	showed	_	VBD	VBD	_	0	ROOT-S	_	_
8	distinct	_	JJ	JJ	_	9	NMOD	_	_
9	effects	_	NNS	NNS	_	7	OBJ	_	_
10	on	_	IN	IN	_	9	NMOD	_	_
11	two	_	CD	CD	_	12	NMOD	_	_
12	markers	_	NNS	NNS	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	PMA-induced	_	JJ	JJ	_	15	NMOD	_	_
15	differentiation	_	NN	NN	_	13	PMOD	_	_
16	;	_	:	:	_	7	P	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	C-JUN	_	NN	NN	_	20	NMOD	_	_
19	AS	_	JJ	JJ	_	20	NMOD	_	_
20	oligonucleotides	_	NNS	NNS	_	21	SBJ	_	_
21	inhibited	_	VBD	VBD	_	7	VMOD	_	_
22	cell	_	NN	NN	_	23	NMOD	_	_
23	adhesion	_	NN	NN	_	21	OBJ	_	_
24	,	_	,	,	_	21	P	_	_
25	whereas	_	IN	IN	_	21	COORD	_	_
26	they	_	PRP	PRP	_	27	SBJ	_	_
27	did	_	VBD	VBD	_	21	COORD	_	_
28	not	_	RB	RB	_	27	VMOD	_	_
29	affect	_	VB	VB	_	27	VC	_	_
30	another	_	DT	DT	_	31	NMOD	_	_
31	marker	_	NN	NN	_	29	OBJ	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	differentiation	_	NN	NN	_	32	PMOD	_	_
34	,	_	,	,	_	31	P	_	_
35	respiratory	_	JJ	JJ	_	36	NMOD	_	_
36	burst	_	NN	NN	_	31	NMOD	_	_
37	(	_	(	(	_	31	P	_	_
38	measured	_	VBN	VBN	_	31	NMOD	_	_
39	by	_	IN	IN	_	38	ADV	_	_
40	nitro	_	NN	NN	_	44	NMOD	_	_
41	blue	_	JJ	JJ	_	44	NMOD	_	_
42	tetrazolium	_	NN	NN	_	44	NMOD	_	_
43	reduction	_	NN	NN	_	44	NMOD	_	_
44	assay	_	NN	NN	_	39	PMOD	_	_
45	)	_	)	)	_	31	P	_	_
46	.	_	.	.	_	21	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	critical	_	JJ	JJ	_	6	NMOD	_	_
6	role	_	NN	NN	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	c-jun	_	NN	NN	_	7	PMOD	_	_
9	in	_	IN	IN	_	6	NMOD	_	_
10	both	_	CC	CC	_	12	CC	_	_
11	cell	_	NN	NN	_	12	NMOD	_	_
12	proliferation	_	NN	NN	_	9	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	PMA-induced	_	JJ	JJ	_	16	NMOD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	adhesion	_	NN	NN	_	12	COORD	_	_
17	but	_	CC	CC	_	9	CC	_	_
18	not	_	RB	RB	_	19	DEP	_	_
19	in	_	IN	IN	_	9	COORD	_	_
20	PMA-induced	_	JJ	JJ	_	22	NMOD	_	_
21	respiratory	_	JJ	JJ	_	22	NMOD	_	_
22	burst	_	NN	NN	_	19	PMOD	_	_
23	in	_	IN	IN	_	22	NMOD	_	_
24	U937	_	NN	NN	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	23	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	Uneven	_	JJ	JJ	_	3	NMOD	_	_
2	X	_	NN	NN	_	3	NMOD	_	_
3	inactivation	_	NN	NN	_	0	ROOT-FRAG	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	a	_	DT	DT	_	9	NMOD	_	_
6	female	_	JJ	JJ	_	9	NMOD	_	_
7	monozygotic	_	JJ	JJ	_	9	NMOD	_	_
8	twin	_	JJ	JJ	_	9	NMOD	_	_
9	pair	_	NN	NN	_	4	PMOD	_	_
10	with	_	IN	IN	_	9	NMOD	_	_
11	Fabry	_	NN	NN	_	12	NMOD	_	_
12	disease	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	3	CC	_	_
14	discordant	_	JJ	JJ	_	15	NMOD	_	_
15	expression	_	NN	NN	_	3	COORD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	novel	_	JJ	JJ	_	19	NMOD	_	_
19	mutation	_	NN	NN	_	16	PMOD	_	_
20	in	_	IN	IN	_	15	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	alpha-galactosidase	_	NN	NN	_	24	NMOD	_	_
23	A	_	NN	NN	_	24	NMOD	_	_
24	gene	_	NN	NN	_	20	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	describe	_	VBP	VBP	_	0	ROOT-S	_	_
3	two	_	CD	CD	_	9	NMOD	_	_
4	female	_	JJ	JJ	_	9	NMOD	_	_
5	monozygotic	_	JJ	JJ	_	9	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	MZ	_	JJ	JJ	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	twins	_	NNS	NNS	_	2	OBJ	_	_
10	heterozygous	_	JJ	JJ	_	9	NMOD	_	_
11	for	_	IN	IN	_	10	AMOD	_	_
12	Fabry	_	NN	NN	_	13	NMOD	_	_
13	disease	_	NN	NN	_	11	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	an	_	DT	DT	_	18	NMOD	_	_
16	X	_	NN	NN	_	18	NMOD	_	_
17	linked	_	VBN	VBN	_	16	AMOD	_	_
18	disorder	_	NN	NN	_	13	NMOD	_	_
19	resulting	_	VBG	VBG	_	18	NMOD	_	_
20	from	_	IN	IN	_	19	ADV	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	deficient	_	JJ	JJ	_	23	NMOD	_	_
23	activity	_	NN	NN	_	20	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	alpha-galactosidase	_	NN	NN	_	26	NMOD	_	_
26	A	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	While	_	IN	IN	_	12	ADV	_	_
2	one	_	CD	CD	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	twins	_	NNS	NNS	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	1	VMOD	_	_
7	clinically	_	RB	RB	_	6	ADV	_	_
8	affected	_	VBN	VBN	_	6	PRD	_	_
9	,	_	,	,	_	12	P	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	other	_	JJ	JJ	_	12	SBJ	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	asymptomatic	_	JJ	JJ	_	12	PRD	_	_
14	.	_	.	.	_	12	P	_	_

1	Enzymatic	_	JJ	JJ	_	2	NMOD	_	_
2	assay	_	NN	NN	_	28	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	alpha-galactosidase	_	NN	NN	_	3	PMOD	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	blood	_	NN	NN	_	7	NMOD	_	_
7	leucocytes	_	NNS	NNS	_	5	PMOD	_	_
8	,	_	,	,	_	7	P	_	_
9	skin	_	NN	NN	_	10	NMOD	_	_
10	fibroblasts	_	NNS	NNS	_	7	COORD	_	_
11	,	_	,	,	_	7	P	_	_
12	Epstein-Barr	_	JJ	JJ	_	13	NMOD	_	_
13	virus	_	NN	NN	_	17	NMOD	_	_
14	transformed	_	VBD	VBD	_	13	AMOD	_	_
15	lymphoid	_	JJ	JJ	_	17	NMOD	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	lines	_	NNS	NNS	_	7	COORD	_	_
18	,	_	,	,	_	7	P	_	_
19	and	_	CC	CC	_	7	CC	_	_
20	hair	_	NN	NN	_	21	NMOD	_	_
21	follicles	_	NNS	NNS	_	7	COORD	_	_
22	of	_	IN	IN	_	7	NMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	twins	_	NNS	NNS	_	22	PMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	their	_	PRP$	PRP$	_	27	NMOD	_	_
27	parents	_	NNS	NNS	_	24	COORD	_	_
28	confirmed	_	VBD	VBD	_	0	ROOT-S	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	heterozygous	_	JJ	JJ	_	31	NMOD	_	_
31	status	_	NN	NN	_	28	OBJ	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	the	_	DT	DT	_	34	NMOD	_	_
34	twins	_	NNS	NNS	_	32	PMOD	_	_
35	and	_	CC	CC	_	28	CC	_	_
36	indicated	_	VBD	VBD	_	28	COORD	_	_
37	that	_	IN	IN	_	36	OBJ	_	_
38	Fabry	_	NN	NN	_	39	NMOD	_	_
39	disease	_	NN	NN	_	40	SBJ	_	_
40	had	_	VBD	VBD	_	37	VMOD	_	_
41	occurred	_	VBN	VBN	_	40	VC	_	_
42	as	_	IN	IN	_	41	ADV	_	_
43	a	_	DT	DT	_	44	NMOD	_	_
44	result	_	NN	NN	_	42	PMOD	_	_
45	of	_	IN	IN	_	44	NMOD	_	_
46	a	_	DT	DT	_	49	NMOD	_	_
47	de	_	FW	FW	_	48	AMOD	_	_
48	novo	_	FW	FW	_	49	NMOD	_	_
49	mutation	_	NN	NN	_	45	PMOD	_	_
50	.	_	.	.	_	28	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	son	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	unaffected	_	JJ	JJ	_	7	NMOD	_	_
6	twin	_	NN	NN	_	7	NMOD	_	_
7	sister	_	NN	NN	_	3	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	shown	_	VBN	VBN	_	8	VC	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	be	_	VB	VB	_	9	OBJ	_	_
12	hemizygous	_	JJ	JJ	_	11	PRD	_	_
13	.	_	.	.	_	8	P	_	_

1	Molecular	_	JJ	JJ	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	alpha-galactosidase	_	NN	NN	_	7	NMOD	_	_
6	A	_	NN	NN	_	7	NMOD	_	_
7	gene	_	NN	NN	_	3	PMOD	_	_
8	permitted	_	VBD	VBD	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	identification	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	an	_	DT	DT	_	17	NMOD	_	_
13	as	_	RB	RB	_	17	NMOD	_	_
14	yet	_	RB	RB	_	13	AMOD	_	_
15	undescribed	_	JJ	JJ	_	13	AMOD	_	_
16	point	_	NN	NN	_	17	NMOD	_	_
17	mutation	_	NN	NN	_	11	PMOD	_	_
18	at	_	IN	IN	_	17	NMOD	_	_
19	position	_	NN	NN	_	18	PMOD	_	_
20	10182	_	CD	CD	_	19	NMOD	_	_
21	of	_	IN	IN	_	19	NMOD	_	_
22	exon	_	NN	NN	_	21	PMOD	_	_
23	5	_	CD	CD	_	22	NMOD	_	_
24	which	_	WDT	WDT	_	25	SBJ	_	_
25	causes	_	VBZ	VBZ	_	17	NMOD	_	_
26	an	_	DT	DT	_	30	NMOD	_	_
27	Asp	_	NN	NN	_	30	NMOD	_	_
28	to	_	TO	TO	_	27	NMOD	_	_
29	Asn	_	NN	NN	_	27	NMOD	_	_
30	substitution	_	NN	NN	_	25	OBJ	_	_
31	at	_	IN	IN	_	30	NMOD	_	_
32	codon	_	NN	NN	_	31	PMOD	_	_
33	231	_	CD	CD	_	32	NMOD	_	_
34	.	_	.	.	_	8	P	_	_

1	Single	_	JJ	JJ	_	4	NMOD	_	_
2	strand	_	NN	NN	_	4	NMOD	_	_
3	conformation	_	NN	NN	_	4	NMOD	_	_
4	polymorphism	_	NN	NN	_	8	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	SSCP	_	NN	NN	_	8	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	analysis	_	NN	NN	_	10	SBJ	_	_
9	again	_	RB	RB	_	10	TMP	_	_
10	showed	_	VBD	VBD	_	0	ROOT-S	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	heterozygous	_	JJ	JJ	_	13	NMOD	_	_
13	status	_	NN	NN	_	10	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	twins	_	NNS	NNS	_	14	PMOD	_	_
17	and	_	CC	CC	_	13	CC	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	normal	_	JJ	JJ	_	20	NMOD	_	_
20	pattern	_	NN	NN	_	13	COORD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	their	_	PRP$	PRP$	_	23	NMOD	_	_
23	parents	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	basis	_	NN	NN	_	15	SBJ	_	_
3	for	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	discordant	_	JJ	JJ	_	6	NMOD	_	_
6	expression	_	NN	NN	_	3	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	this	_	DT	DT	_	11	NMOD	_	_
9	d	_	FW	FW	_	10	AMOD	_	_
10	novo	_	FW	FW	_	11	NMOD	_	_
11	mutation	_	NN	NN	_	7	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	twins	_	NNS	NNS	_	12	PMOD	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	investigated	_	VBN	VBN	_	15	VC	_	_
17	by	_	IN	IN	_	16	ADV	_	_
18	studying	_	VBG	VBG	_	17	PMOD	_	_
19	their	_	PRP$	PRP$	_	22	NMOD	_	_
20	X	_	NN	NN	_	22	NMOD	_	_
21	inactivation	_	NN	NN	_	22	NMOD	_	_
22	status	_	NN	NN	_	18	OBJ	_	_
23	.	_	.	.	_	15	P	_	_

1	Analysis	_	NN	NN	_	13	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	inactive	_	JJ	JJ	_	5	NMOD	_	_
5	X	_	NN	NN	_	6	AMOD	_	_
6	specific	_	JJ	JJ	_	7	NMOD	_	_
7	methylation	_	NN	NN	_	2	PMOD	_	_
8	at	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	androgen	_	NN	NN	_	12	NMOD	_	_
11	receptor	_	NN	NN	_	12	NMOD	_	_
12	gene	_	NN	NN	_	8	PMOD	_	_
13	showed	_	VBD	VBD	_	0	ROOT-S	_	_
14	unbalanced	_	JJ	JJ	_	15	NMOD	_	_
15	inactivation	_	NN	NN	_	13	OBJ	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	twins	_	NNS	NNS	_	20	NMOD	_	_
19	'	_	POS	POS	_	18	NMOD	_	_
20	fibroblasts	_	NNS	NNS	_	16	PMOD	_	_
21	and	_	CC	CC	_	16	CC	_	_
22	in	_	IN	IN	_	16	COORD	_	_
23	opposite	_	JJ	JJ	_	24	NMOD	_	_
24	directions	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	13	P	_	_

1	While	_	IN	IN	_	19	ADV	_	_
2	the	_	DT	DT	_	6	NMOD	_	_
3	maternally	_	RB	RB	_	4	AMOD	_	_
4	derived	_	VBN	VBN	_	6	NMOD	_	_
5	X	_	NN	NN	_	6	NMOD	_	_
6	chromosome	_	NN	NN	_	7	SBJ	_	_
7	was	_	VBD	VBD	_	1	VMOD	_	_
8	preferentially	_	RB	RB	_	9	AMOD	_	_
9	active	_	JJ	JJ	_	7	PRD	_	_
10	in	_	IN	IN	_	7	ADV	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	asymptomatic	_	JJ	JJ	_	13	NMOD	_	_
13	twin	_	NN	NN	_	10	PMOD	_	_
14	,	_	,	,	_	19	P	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	paternal	_	JJ	JJ	_	18	NMOD	_	_
17	X	_	NN	NN	_	18	NMOD	_	_
18	chromosome	_	NN	NN	_	19	SBJ	_	_
19	was	_	VBD	VBD	_	0	ROOT-S	_	_
20	active	_	JJ	JJ	_	19	PRD	_	_
21	in	_	IN	IN	_	19	ADV	_	_
22	the	_	DT	DT	_	26	NMOD	_	_
23	other	_	JJ	JJ	_	26	NMOD	_	_
24	,	_	,	,	_	23	P	_	_
25	affected	_	VBN	VBN	_	23	COORD	_	_
26	twin	_	NN	NN	_	21	PMOD	_	_
27	and	_	CC	CC	_	19	CC	_	_
28	was	_	VBD	VBD	_	19	COORD	_	_
29	found	_	VBN	VBN	_	28	VC	_	_
30	in	_	IN	IN	_	29	ADV	_	_
31	her	_	PRP$	PRP$	_	33	NMOD	_	_
32	hemizygotic	_	JJ	JJ	_	33	NMOD	_	_
33	nephew	_	NN	NN	_	30	PMOD	_	_
34	.	_	.	.	_	19	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	paternal	_	JJ	JJ	_	8	NMOD	_	_
7	X	_	NN	NN	_	8	NMOD	_	_
8	chromosome	_	NN	NN	_	9	SBJ	_	_
9	carries	_	VBZ	VBZ	_	4	VMOD	_	_
10	the	_	DT	DT	_	15	NMOD	_	_
11	de	_	FW	FW	_	12	AMOD	_	_
12	novo	_	FW	FW	_	15	NMOD	_	_
13	alpha-galactosidase	_	NN	NN	_	15	NMOD	_	_
14	A	_	NN	NN	_	15	NMOD	_	_
15	mutation	_	NN	NN	_	9	OBJ	_	_
16	and	_	CC	CC	_	4	CC	_	_
17	that	_	IN	IN	_	4	COORD	_	_
18	uneven	_	JJ	JJ	_	20	NMOD	_	_
19	X	_	NN	NN	_	20	NMOD	_	_
20	inactivation	_	NN	NN	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	17	VMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	underlying	_	VBG	VBG	_	24	NMOD	_	_
24	mechanism	_	NN	NN	_	21	PRD	_	_
25	for	_	IN	IN	_	24	NMOD	_	_
26	disease	_	NN	NN	_	27	NMOD	_	_
27	expression	_	NN	NN	_	25	PMOD	_	_
28	in	_	IN	IN	_	27	NMOD	_	_
29	this	_	DT	DT	_	34	NMOD	_	_
30	novel	_	JJ	JJ	_	34	NMOD	_	_
31	female	_	NN	NN	_	34	NMOD	_	_
32	MZ	_	JJ	JJ	_	34	NMOD	_	_
33	twin	_	NN	NN	_	34	NMOD	_	_
34	pair	_	NN	NN	_	28	PMOD	_	_
35	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	first	_	JJ	JJ	_	6	NMOD	_	_
5	documented	_	VBN	VBN	_	6	NMOD	_	_
6	case	_	NN	NN	_	2	PRD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	female	_	JJ	JJ	_	9	NMOD	_	_
9	twins	_	NNS	NNS	_	7	PMOD	_	_
10	discordant	_	JJ	JJ	_	9	NMOD	_	_
11	for	_	IN	IN	_	10	AMOD	_	_
12	Fabry	_	NN	NN	_	13	NMOD	_	_
13	disease	_	NN	NN	_	11	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	Signaling	_	NN	NN	_	0	ROOT-FRAG	_	_
2	by	_	IN	IN	_	1	NMOD	_	_
3	IL-2	_	NN	NN	_	2	PMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	related	_	JJ	JJ	_	6	NMOD	_	_
6	cytokines	_	NNS	NNS	_	3	COORD	_	_
7	:	_	:	:	_	1	P	_	_
8	JAKs	_	NNS	NNS	_	1	NMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	STATs	_	NNS	NNS	_	8	COORD	_	_
11	,	_	,	,	_	8	P	_	_
12	and	_	CC	CC	_	8	CC	_	_
13	relationship	_	NN	NN	_	8	COORD	_	_
14	to	_	TO	TO	_	13	NMOD	_	_
15	immunodeficiency	_	NN	NN	_	14	PMOD	_	_
16	.	_	.	.	_	8	P	_	_

1	Cytokines	_	NNS	NNS	_	31	SBJ	_	_
2	that	_	WDT	WDT	_	3	SBJ	_	_
3	bind	_	VBP	VBP	_	1	NMOD	_	_
4	to	_	TO	TO	_	3	ADV	_	_
5	the	_	DT	DT	_	10	NMOD	_	_
6	interleukin-2	_	NN	NN	_	10	NMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	IL-2	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	receptor	_	NN	NN	_	4	PMOD	_	_
11	common	_	JJ	JJ	_	10	NMOD	_	_
12	gamma	_	NN	NN	_	13	NMOD	_	_
13	chain	_	NN	NN	_	10	NMOD	_	_
14	(	_	(	(	_	16	P	_	_
15	gamma	_	NN	NN	_	16	NMOD	_	_
16	c	_	NN	NN	_	13	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	,	_	,	,	_	10	P	_	_
19	including	_	VBG	VBG	_	10	NMOD	_	_
20	IL-2	_	NN	NN	_	19	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	IL-4	_	NN	NN	_	20	COORD	_	_
23	,	_	,	,	_	20	P	_	_
24	IL-7	_	NN	NN	_	20	COORD	_	_
25	,	_	,	,	_	20	P	_	_
26	IL-9	_	NN	NN	_	20	COORD	_	_
27	,	_	,	,	_	20	P	_	_
28	and	_	CC	CC	_	20	CC	_	_
29	IL-15	_	NN	NN	_	20	COORD	_	_
30	,	_	,	,	_	10	P	_	_
31	are	_	VBP	VBP	_	0	ROOT-S	_	_
32	important	_	JJ	JJ	_	31	PRD	_	_
33	for	_	IN	IN	_	32	AMOD	_	_
34	the	_	DT	DT	_	35	NMOD	_	_
35	growth	_	NN	NN	_	33	PMOD	_	_
36	and	_	CC	CC	_	35	CC	_	_
37	differentiation	_	NN	NN	_	35	COORD	_	_
38	of	_	IN	IN	_	35	NMOD	_	_
39	T	_	NN	NN	_	42	NMOD	_	_
40	and	_	CC	CC	_	39	CC	_	_
41	B	_	NN	NN	_	39	COORD	_	_
42	lymphocytes	_	NNS	NNS	_	38	PMOD	_	_
43	,	_	,	,	_	42	P	_	_
44	natural	_	JJ	JJ	_	46	NMOD	_	_
45	killer	_	NN	NN	_	46	NMOD	_	_
46	cells	_	NNS	NNS	_	42	COORD	_	_
47	,	_	,	,	_	42	P	_	_
48	macrophages	_	NNS	NNS	_	42	COORD	_	_
49	,	_	,	,	_	42	P	_	_
50	and	_	CC	CC	_	42	CC	_	_
51	monoctyes	_	NNS	NNS	_	42	COORD	_	_
52	.	_	.	.	_	31	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	cytokines	_	NNS	NNS	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	overlapping	_	VBG	VBG	_	6	NMOD	_	_
5	biological	_	JJ	JJ	_	6	NMOD	_	_
6	effects	_	NNS	NNS	_	3	OBJ	_	_
7	that	_	WDT	WDT	_	10	SBJ	_	_
8	in	_	IN	IN	_	10	ADV	_	_
9	part	_	NN	NN	_	8	PMOD	_	_
10	result	_	VBP	VBP	_	6	NMOD	_	_
11	from	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	use	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	20	NMOD	_	_
16	shared	_	VBN	VBN	_	20	NMOD	_	_
17	receptor	_	NN	NN	_	20	NMOD	_	_
18	subunit	_	NN	NN	_	20	NMOD	_	_
19	gamma	_	NN	NN	_	20	NMOD	_	_
20	c	_	NN	NN	_	14	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	Recently	_	RB	RB	_	3	TMP	_	_
2	it	_	PRP	PRP	_	3	SBJ	_	_
3	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	become	_	VBN	VBN	_	3	VC	_	_
5	clear	_	JJ	JJ	_	4	PRD	_	_
6	that	_	IN	IN	_	4	EXP	_	_
7	these	_	DT	DT	_	8	NMOD	_	_
8	cytokines	_	NNS	NNS	_	9	SBJ	_	_
9	activate	_	VBP	VBP	_	6	VMOD	_	_
10	a	_	DT	DT	_	11	NMOD	_	_
11	number	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	important	_	JJ	JJ	_	16	NMOD	_	_
14	intracellular	_	JJ	JJ	_	16	NMOD	_	_
15	signaling	_	VBG	VBG	_	16	NMOD	_	_
16	molecules	_	NNS	NNS	_	12	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	including	_	VBG	VBG	_	16	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	Janus	_	NN	NN	_	21	NMOD	_	_
21	kinases	_	NNS	NNS	_	18	PMOD	_	_
22	JAK1	_	NN	NN	_	21	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	JAK3	_	NN	NN	_	22	COORD	_	_
25	and	_	CC	CC	_	21	CC	_	_
26	members	_	NNS	NNS	_	21	COORD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	31	NMOD	_	_
29	transcription	_	NN	NN	_	31	NMOD	_	_
30	factor	_	NN	NN	_	31	NMOD	_	_
31	family	_	NN	NN	_	27	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	signal	_	NN	NN	_	32	PMOD	_	_
34	transducers	_	NNS	NNS	_	33	NMOD	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	activators	_	NNS	NNS	_	34	COORD	_	_
37	of	_	IN	IN	_	33	NMOD	_	_
38	transcription	_	NN	NN	_	37	PMOD	_	_
39	(	_	(	(	_	40	P	_	_
40	STATs	_	NNS	NNS	_	33	PRN	_	_
41	)	_	)	)	_	40	P	_	_
42	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	discovery	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	these	_	DT	DT	_	6	NMOD	_	_
5	signaling	_	NN	NN	_	6	NMOD	_	_
6	pathways	_	NNS	NNS	_	3	PMOD	_	_
7	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	led	_	VBN	VBN	_	7	VC	_	_
9	to	_	TO	TO	_	8	ADV	_	_
10	important	_	JJ	JJ	_	12	NMOD	_	_
11	new	_	JJ	JJ	_	12	NMOD	_	_
12	insights	_	NNS	NNS	_	9	PMOD	_	_
13	into	_	IN	IN	_	12	NMOD	_	_
14	their	_	PRP$	PRP$	_	15	NMOD	_	_
15	role	_	NN	NN	_	13	PMOD	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	lymphocyte	_	NN	NN	_	18	NMOD	_	_
18	maturation	_	NN	NN	_	16	PMOD	_	_
19	,	_	,	,	_	8	P	_	_
20	as	_	IN	IN	_	8	ADV	_	_
21	it	_	PRP	PRP	_	22	SBJ	_	_
22	has	_	VBZ	VBZ	_	20	VMOD	_	_
23	emerged	_	VBN	VBN	_	22	VC	_	_
24	that	_	IN	IN	_	23	EXP	_	_
25	mutations	_	NNS	NNS	_	35	SBJ	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	genes	_	NNS	NNS	_	26	PMOD	_	_
29	encoding	_	VBG	VBG	_	28	NMOD	_	_
30	both	_	CC	CC	_	32	CC	_	_
31	gamma	_	NN	NN	_	32	NMOD	_	_
32	c	_	NN	NN	_	29	OBJ	_	_
33	and	_	CC	CC	_	32	CC	_	_
34	JAK3	_	NN	NN	_	32	COORD	_	_
35	result	_	VBP	VBP	_	24	VMOD	_	_
36	in	_	IN	IN	_	35	ADV	_	_
37	similar	_	JJ	JJ	_	38	NMOD	_	_
38	forms	_	NNS	NNS	_	36	PMOD	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	severe	_	JJ	JJ	_	42	NMOD	_	_
41	combined	_	JJ	JJ	_	42	NMOD	_	_
42	immunodeficiency	_	NN	NN	_	39	PMOD	_	_
43	(	_	(	(	_	44	P	_	_
44	SCID	_	NN	NN	_	42	PRN	_	_
45	)	_	)	)	_	44	P	_	_
46	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	review	_	NN	NN	_	1	PMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	examine	_	VBP	VBP	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	structure	_	NN	NN	_	5	OBJ	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	function	_	NN	NN	_	7	COORD	_	_
10	of	_	IN	IN	_	7	NMOD	_	_
11	cytokine	_	NN	NN	_	12	NMOD	_	_
12	receptors	_	NNS	NNS	_	10	PMOD	_	_
13	and	_	CC	CC	_	7	CC	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	signaling	_	NN	NN	_	16	NMOD	_	_
16	pathways	_	NNS	NNS	_	7	COORD	_	_
17	involved	_	VBN	VBN	_	16	NMOD	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	their	_	PRP$	PRP$	_	20	NMOD	_	_
20	regulation	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	gene	_	NN	NN	_	23	NMOD	_	_
23	expression	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	5	P	_	_

1	Furthermore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	discuss	_	VBP	VBP	_	0	ROOT-S	_	_
5	recent	_	JJ	JJ	_	6	NMOD	_	_
6	advances	_	NNS	NNS	_	4	OBJ	_	_
7	that	_	WDT	WDT	_	8	SBJ	_	_
8	have	_	VBP	VBP	_	6	NMOD	_	_
9	led	_	VBN	VBN	_	8	VC	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	better	_	JJR	JJR	_	13	NMOD	_	_
13	understanding	_	NN	NN	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	how	_	WRB	WRB	_	17	ADV	_	_
16	cytokines	_	NNS	NNS	_	17	SBJ	_	_
17	elicit	_	VBP	VBP	_	14	PMOD	_	_
18	intracellular	_	JJ	JJ	_	19	NMOD	_	_
19	responses	_	NNS	NNS	_	17	OBJ	_	_
20	,	_	,	,	_	17	P	_	_
21	as	_	RB	RB	_	23	DEP	_	_
22	well	_	RB	RB	_	23	DEP	_	_
23	as	_	IN	IN	_	17	ADV	_	_
24	their	_	PRP$	PRP$	_	25	NMOD	_	_
25	role	_	NN	NN	_	23	PMOD	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	normal	_	JJ	JJ	_	29	NMOD	_	_
28	lymphoid	_	JJ	JJ	_	29	NMOD	_	_
29	development	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	suppression	_	NN	NN	_	14	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	T	_	NN	NN	_	6	NMOD	_	_
5	cell	_	NN	NN	_	6	NMOD	_	_
6	function	_	NN	NN	_	3	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	NF-LRB-kappa-RRB-B	_	NN	NN	_	9	NMOD	_	_
9	expression	_	NN	NN	_	6	COORD	_	_
10	by	_	IN	IN	_	2	NMOD	_	_
11	serine	_	NN	NN	_	13	NMOD	_	_
12	protease	_	NN	NN	_	13	NMOD	_	_
13	inhibitors	_	NNS	NNS	_	10	PMOD	_	_
14	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	blocked	_	VBN	VBN	_	14	VC	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	N-acetylcysteine	_	NN	NN	_	16	PMOD	_	_
18	.	_	.	.	_	14	P	_	_

1	Direct	_	JJ	JJ	_	2	NMOD	_	_
2	evidence	_	NN	NN	_	22	SBJ	_	_
3	that	_	IN	IN	_	2	NMOD	_	_
4	N-acetylcysteine	_	NN	NN	_	8	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	NAC	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	enhances	_	VBZ	VBZ	_	3	VMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	immune	_	JJ	JJ	_	11	NMOD	_	_
11	response	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	peripheral	_	JJ	JJ	_	16	NMOD	_	_
14	blood	_	NN	NN	_	16	NMOD	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	12	PMOD	_	_
17	at	_	IN	IN	_	11	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	level	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	NF-LRB-kappa-RRB-B	_	NN	NN	_	20	PMOD	_	_
22	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
23	presented	_	VBN	VBN	_	22	VC	_	_
24	.	_	.	.	_	22	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	NAC	_	NN	NN	_	5	SBJ	_	_
5	blocks	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	suppression	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	T	_	NN	NN	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	mitogenesis	_	NN	NN	_	8	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	cytokine	_	NN	NN	_	14	NMOD	_	_
14	production	_	NN	NN	_	11	COORD	_	_
15	by	_	IN	IN	_	5	ADV	_	_
16	protease	_	NN	NN	_	17	NMOD	_	_
17	inhibitors	_	NNS	NNS	_	15	PMOD	_	_
18	such	_	JJ	JJ	_	19	DEP	_	_
19	as	_	IN	IN	_	17	NMOD	_	_
20	N-tosylphenylalanine	_	NN	NN	_	22	NMOD	_	_
21	chloromethyl	_	NN	NN	_	22	NMOD	_	_
22	ketone	_	NN	NN	_	19	PMOD	_	_
23	(	_	(	(	_	24	P	_	_
24	TPCK	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	proliferative	_	JJ	JJ	_	3	NMOD	_	_
3	responses	_	NNS	NNS	_	11	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	purified	_	VBN	VBN	_	10	NMOD	_	_
6	CD4+	_	JJ	JJ	_	10	NMOD	_	_
7	or	_	CC	CC	_	6	CC	_	_
8	CD8+	_	JJ	JJ	_	6	COORD	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	4	PMOD	_	_
11	are	_	VBP	VBP	_	0	ROOT-S	_	_
12	suppressed	_	VBN	VBN	_	11	VC	_	_
13	more	_	RBR	RBR	_	14	AMOD	_	_
14	strongly	_	RB	RB	_	12	ADV	_	_
15	by	_	IN	IN	_	12	LGS	_	_
16	TPCK	_	NN	NN	_	15	PMOD	_	_
17	when	_	WRB	WRB	_	26	ADV	_	_
18	anti-CD28	_	NN	NN	_	25	SBJ	_	_
19	rather	_	RB	RB	_	18	CC	_	_
20	than	_	IN	IN	_	19	DEP	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	phorbol	_	NN	NN	_	24	NMOD	_	_
23	ester	_	NN	NN	_	24	NMOD	_	_
24	PMA	_	NN	NN	_	18	COORD	_	_
25	is	_	VBZ	VBZ	_	12	TMP	_	_
26	used	_	VBN	VBN	_	25	VC	_	_
27	as	_	IN	IN	_	26	ADV	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	mitogenic	_	JJ	JJ	_	30	NMOD	_	_
30	coactivator	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	11	P	_	_

1	Cytokine	_	NN	NN	_	9	NMOD	_	_
2	(	_	(	(	_	3	P	_	_
3	IL-2	_	NN	NN	_	1	PRN	_	_
4	,	_	,	,	_	3	P	_	_
5	IL-6	_	NN	NN	_	3	NMOD	_	_
6	,	_	,	,	_	3	P	_	_
7	INF-gamma	_	NN	NN	_	3	NMOD	_	_
8	)	_	)	)	_	3	P	_	_
9	production	_	NN	NN	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	inhibited	_	VBN	VBN	_	10	VC	_	_
12	95-100	_	CD	CD	_	13	NMOD	_	_
13	%	_	NN	NN	_	11	OBJ	_	_
14	by	_	IN	IN	_	11	LGS	_	_
15	concentrations	_	NNS	NNS	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	TPCK	_	NN	NN	_	16	PMOD	_	_
18	that	_	WDT	WDT	_	20	SBJ	_	_
19	totally	_	RB	RB	_	20	ADV	_	_
20	suppress	_	VB	VB	_	17	NMOD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	mitogenesis	_	NN	NN	_	20	OBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	CD4+	_	JJ	JJ	_	27	NMOD	_	_
25	or	_	CC	CC	_	24	CC	_	_
26	CD8+	_	JJ	JJ	_	24	COORD	_	_
27	cells	_	NNS	NNS	_	23	PMOD	_	_
28	.	_	.	.	_	10	P	_	_

1	Using	_	VBG	VBG	_	8	VMOD	_	_
2	electrophoretic	_	JJ	JJ	_	5	NMOD	_	_
3	mobility	_	NN	NN	_	5	NMOD	_	_
4	shift	_	NN	NN	_	5	NMOD	_	_
5	assays	_	NNS	NNS	_	1	OBJ	_	_
6	,	_	,	,	_	8	P	_	_
7	we	_	PRP	PRP	_	8	SBJ	_	_
8	find	_	VBP	VBP	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	TPCK	_	NN	NN	_	12	SBJ	_	_
11	virtually	_	RB	RB	_	12	ADV	_	_
12	abolishes	_	VBZ	VBZ	_	9	VMOD	_	_
13	(	_	(	(	_	12	P	_	_
14	to	_	TO	TO	_	12	ADV	_	_
15	less	_	JJR	JJR	_	17	DEP	_	_
16	than	_	IN	IN	_	17	DEP	_	_
17	1	_	CD	CD	_	18	NMOD	_	_
18	%	_	NN	NN	_	14	PMOD	_	_
19	)	_	)	)	_	12	P	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	levels	_	NNS	NNS	_	12	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	NF-LRB-kappa-RRB-B	_	NN	NN	_	22	PMOD	_	_
24	(	_	(	(	_	23	P	_	_
25	but	_	CC	CC	_	23	CC	_	_
26	not	_	RB	RB	_	25	COORD	_	_
27	Oct-1	_	NN	NN	_	23	COORD	_	_
28	)	_	)	)	_	23	P	_	_
29	found	_	VBN	VBN	_	23	NMOD	_	_
30	in	_	IN	IN	_	29	ADV	_	_
31	nuclear	_	JJ	JJ	_	35	NMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	whole	_	JJ	JJ	_	34	NMOD	_	_
34	cell	_	NN	NN	_	31	COORD	_	_
35	extracts	_	NNS	NNS	_	30	PMOD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	activated	_	VBN	VBN	_	39	NMOD	_	_
38	T	_	NN	NN	_	39	NMOD	_	_
39	cells	_	NNS	NNS	_	36	PMOD	_	_
40	.	_	.	.	_	8	P	_	_

1	Strikingly	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	immunosuppressive	_	JJ	JJ	_	5	NMOD	_	_
5	effects	_	NNS	NNS	_	8	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	TPCK	_	NN	NN	_	6	PMOD	_	_
8	are	_	VBP	VBP	_	0	ROOT-S	_	_
9	blocked	_	VBN	VBN	_	8	VC	_	_
10	when	_	WRB	WRB	_	14	ADV	_	_
11	T	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	13	SBJ	_	_
13	are	_	VBP	VBP	_	9	TMP	_	_
14	pretreated	_	VBN	VBN	_	13	VC	_	_
15	for	_	IN	IN	_	14	TMP	_	_
16	15	_	CD	CD	_	17	NMOD	_	_
17	min	_	NN	NN	_	15	PMOD	_	_
18	with	_	IN	IN	_	14	ADV	_	_
19	5	_	CD	CD	_	20	AMOD	_	_
20	mM	_	NN	NN	_	21	NMOD	_	_
21	NAC	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	8	P	_	_

1	NAC	_	NN	NN	_	4	SBJ	_	_
2	not	_	RB	RB	_	4	CC	_	_
3	only	_	RB	RB	_	2	DEP	_	_
4	blocks	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	effect	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	TPCK	_	NN	NN	_	7	PMOD	_	_
9	but	_	CC	CC	_	4	CC	_	_
10	enhances	_	VBZ	VBZ	_	4	COORD	_	_
11	mitogenesis	_	NN	NN	_	10	OBJ	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	cytokine	_	NN	NN	_	14	NMOD	_	_
14	production	_	NN	NN	_	11	COORD	_	_
15	(	_	(	(	_	10	PRN	_	_
16	&gt;	_	JJR	JJR	_	17	AMOD	_	_
17	2.5-fold	_	RB	RB	_	18	ADV	_	_
18	in	_	IN	IN	_	15	DEP	_	_
19	some	_	DT	DT	_	20	NMOD	_	_
20	cases	_	NNS	NNS	_	18	PMOD	_	_
21	)	_	)	)	_	15	P	_	_
22	upon	_	IN	IN	_	10	TMP	_	_
23	activation	_	NN	NN	_	22	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	unsuppressed	_	JJ	JJ	_	27	NMOD	_	_
26	T	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	24	PMOD	_	_
28	.	_	.	.	_	4	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	support	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	notion	_	NN	NN	_	3	OBJ	_	_
6	that	_	IN	IN	_	5	NMOD	_	_
7	NF	_	NN	NN	_	11	SBJ	_	_
8	(	_	(	(	_	7	P	_	_
9	kappa	_	NN	NN	_	7	NMOD	_	_
10	)	_	)	)	_	7	P	_	_
11	B	_	NN	NN	_	6	VMOD	_	_
12	and	_	CC	CC	_	13	CC	_	_
13	I	_	NN	NN	_	11	OBJ	_	_
14	(	_	(	(	_	11	ADV	_	_
15	kappa	_	NN	NN	_	17	NMOD	_	_
16	)	_	)	)	_	17	P	_	_
17	B	_	NN	NN	_	18	NMOD	_	_
18	proteases	_	NNS	NNS	_	14	PMOD	_	_
19	play	_	VBP	VBP	_	18	NMOD	_	_
20	obligate	_	JJ	JJ	_	11	VMOD	_	_
21	roles	_	NNS	NNS	_	11	OBJ	_	_
22	in	_	IN	IN	_	24	SBJ	_	_
23	T	_	NN	NN	_	24	VMOD	_	_
24	cell	_	NN	NN	_	21	NMOD	_	_
25	activation	_	NN	NN	_	24	ADV	_	_
26	and	_	CC	CC	_	24	LGS	_	_
27	mitogenesis	_	NN	NN	_	26	COORD	_	_
28	,	_	,	,	_	3	P	_	_

1	IL-12-induced	_	JJ	JJ	_	2	NMOD	_	_
2	activation	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NK	_	NN	NN	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	T	_	NN	NN	_	4	COORD	_	_
7	cells	_	NNS	NNS	_	3	PMOD	_	_
8	occurs	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	9	DEP	_	_
11	absence	_	NN	NN	_	9	DEP	_	_
12	of	_	IN	IN	_	9	DEP	_	_
13	immediate-early	_	JJ	JJ	_	16	NMOD	_	_
14	activation	_	NN	NN	_	16	NMOD	_	_
15	gene	_	NN	NN	_	16	NMOD	_	_
16	expression	_	NN	NN	_	9	PMOD	_	_
17	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	responses	_	NNS	NNS	_	19	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	lymphocytes	_	NNS	NNS	_	3	PMOD	_	_
5	to	_	TO	TO	_	2	NMOD	_	_
6	IL-2	_	NN	NN	_	5	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	IL-12	_	NN	NN	_	6	COORD	_	_
9	,	_	,	,	_	2	P	_	_
10	involving	_	VBG	VBG	_	2	NMOD	_	_
11	proliferation	_	NN	NN	_	10	OBJ	_	_
12	,	_	,	,	_	11	P	_	_
13	differentiation	_	NN	NN	_	11	COORD	_	_
14	,	_	,	,	_	11	P	_	_
15	and	_	CC	CC	_	11	CC	_	_
16	cytokine	_	NN	NN	_	17	NMOD	_	_
17	production	_	NN	NN	_	11	COORD	_	_
18	,	_	,	,	_	2	P	_	_
19	are	_	VBP	VBP	_	0	ROOT-S	_	_
20	only	_	RB	RB	_	19	ADV	_	_
21	partially	_	RB	RB	_	20	AMOD	_	_
22	overlapping	_	VBG	VBG	_	19	VC	_	_
23	,	_	,	,	_	19	P	_	_
24	and	_	CC	CC	_	19	CC	_	_
25	may	_	MD	MD	_	19	COORD	_	_
26	depend	_	VB	VB	_	25	VC	_	_
27	on	_	IN	IN	_	26	ADV	_	_
28	induced	_	VBN	VBN	_	30	NMOD	_	_
29	differential	_	JJ	JJ	_	30	NMOD	_	_
30	expression	_	NN	NN	_	27	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	specific	_	JJ	JJ	_	33	NMOD	_	_
33	sets	_	NNS	NNS	_	31	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	genes	_	NNS	NNS	_	34	PMOD	_	_
36	.	_	.	.	_	19	P	_	_

1	Using	_	VBG	VBG	_	8	VMOD	_	_
2	reverse-transcription	_	JJ	JJ	_	5	NMOD	_	_
3	PCR	_	NN	NN	_	5	NMOD	_	_
4	differential	_	JJ	JJ	_	5	NMOD	_	_
5	display	_	NN	NN	_	1	OBJ	_	_
6	,	_	,	,	_	8	P	_	_
7	we	_	PRP	PRP	_	8	SBJ	_	_
8	isolated	_	VBD	VBD	_	0	ROOT-S	_	_
9	an	_	DT	DT	_	11	NMOD	_	_
10	mRNA	_	NN	NN	_	11	NMOD	_	_
11	species	_	NNS	NNS	_	8	OBJ	_	_
12	expressed	_	VBN	VBN	_	11	NMOD	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	IL-2-	_	NN	NN	_	19	NMOD	_	_
15	but	_	CC	CC	_	14	CC	_	_
16	not	_	RB	RB	_	17	AMOD	_	_
17	IL-12-stimulated	_	JJ	JJ	_	14	COORD	_	_
18	NK	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	13	PMOD	_	_
20	.	_	.	.	_	8	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	identified	_	VBN	VBN	_	2	VC	_	_
4	as	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	mRNA	_	NN	NN	_	4	PMOD	_	_
7	encoding	_	VBG	VBG	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	transcription	_	NN	NN	_	11	NMOD	_	_
10	factor	_	NN	NN	_	11	NMOD	_	_
11	egr-1	_	NN	NN	_	7	OBJ	_	_
12	,	_	,	,	_	6	P	_	_
13	which	_	WDT	WDT	_	14	SBJ	_	_
14	is	_	VBZ	VBZ	_	6	NMOD	_	_
15	expressed	_	VBN	VBN	_	14	VC	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	fast	_	JJ	JJ	_	18	NMOD	_	_
18	kinetics	_	NNS	NNS	_	16	PMOD	_	_
19	in	_	IN	IN	_	15	ADV	_	_
20	T	_	NN	NN	_	23	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	NK	_	NN	NN	_	20	COORD	_	_
23	cells	_	NNS	NNS	_	19	PMOD	_	_
24	upon	_	IN	IN	_	15	TMP	_	_
25	IL-2	_	NN	NN	_	31	NMOD	_	_
26	,	_	,	,	_	25	P	_	_
27	but	_	CC	CC	_	25	CC	_	_
28	not	_	RB	RB	_	27	COORD	_	_
29	IL-12	_	NN	NN	_	25	COORD	_	_
30	,	_	,	,	_	25	P	_	_
31	stimulation	_	NN	NN	_	24	PMOD	_	_
32	.	_	.	.	_	2	P	_	_

1	Analysis	_	NN	NN	_	14	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	accumulation	_	NN	NN	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	mRNA-encoding	_	JJ	JJ	_	7	NMOD	_	_
7	members	_	NNS	NNS	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	AP-1	_	NN	NN	_	13	NMOD	_	_
11	transcription	_	NN	NN	_	13	NMOD	_	_
12	factor	_	NN	NN	_	13	NMOD	_	_
13	family	_	NN	NN	_	8	PMOD	_	_
14	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
15	that	_	IN	IN	_	14	OBJ	_	_
16	c-fos	_	NN	NN	_	19	SBJ	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	junB	_	NN	NN	_	16	COORD	_	_
19	are	_	VBP	VBP	_	15	VMOD	_	_
20	also	_	RB	RB	_	19	ADV	_	_
21	expressed	_	VBN	VBN	_	19	VC	_	_
22	upon	_	IN	IN	_	21	TMP	_	_
23	stimulation	_	NN	NN	_	22	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	NK	_	NN	NN	_	28	NMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	T	_	NN	NN	_	25	COORD	_	_
28	cells	_	NNS	NNS	_	24	PMOD	_	_
29	with	_	IN	IN	_	23	NMOD	_	_
30	IL-2	_	NN	NN	_	29	PMOD	_	_
31	,	_	,	,	_	30	P	_	_
32	but	_	CC	CC	_	30	CC	_	_
33	not	_	RB	RB	_	32	COORD	_	_
34	IL-12	_	NN	NN	_	30	COORD	_	_
35	,	_	,	,	_	19	P	_	_
36	whereas	_	IN	IN	_	19	COORD	_	_
37	expression	_	NN	NN	_	42	SBJ	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	c-jun	_	NN	NN	_	38	PMOD	_	_
40	and	_	CC	CC	_	39	CC	_	_
41	junD	_	NN	NN	_	39	COORD	_	_
42	is	_	VBZ	VBZ	_	19	COORD	_	_
43	not	_	RB	RB	_	42	VMOD	_	_
44	modified	_	VBN	VBN	_	42	VC	_	_
45	by	_	IN	IN	_	44	LGS	_	_
46	either	_	DT	DT	_	47	NMOD	_	_
47	cytokine	_	NN	NN	_	45	PMOD	_	_
48	.	_	.	.	_	14	P	_	_

1	Accordingly	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	increased	_	VBN	VBN	_	6	NMOD	_	_
4	AP-1	_	NN	NN	_	6	NMOD	_	_
5	DNA-binding	_	JJ	JJ	_	6	NMOD	_	_
6	activity	_	NN	NN	_	11	SBJ	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	AP-1-dependent	_	JJ	JJ	_	10	NMOD	_	_
9	transcriptional	_	JJ	JJ	_	10	NMOD	_	_
10	activity	_	NN	NN	_	6	COORD	_	_
11	were	_	VBD	VBD	_	0	ROOT-S	_	_
12	detected	_	VBN	VBN	_	11	VC	_	_
13	exclusively	_	RB	RB	_	12	ADV	_	_
14	in	_	IN	IN	_	12	ADV	_	_
15	IL-2-stimulated	_	JJ	JJ	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	.	_	.	.	_	11	P	_	_

1	Analysis	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	expression	_	NN	NN	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	genes	_	NNS	NNS	_	5	PMOD	_	_
7	reported	_	VBN	VBN	_	6	NMOD	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	regulate	_	VB	VB	_	7	OBJ	_	_
10	cytokine-induced	_	JJ	JJ	_	11	NMOD	_	_
11	proliferation	_	NN	NN	_	9	OBJ	_	_
12	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
13	that	_	IN	IN	_	12	OBJ	_	_
14	both	_	CC	CC	_	15	CC	_	_
15	IL-2	_	NN	NN	_	18	SBJ	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	IL-12	_	NN	NN	_	15	COORD	_	_
18	induce	_	VBP	VBP	_	13	VMOD	_	_
19	c-myc	_	NN	NN	_	21	NMOD	_	_
20	mRNA	_	NN	NN	_	21	NMOD	_	_
21	accumulation	_	NN	NN	_	18	OBJ	_	_
22	in	_	IN	IN	_	18	ADV	_	_
23	NK	_	NN	NN	_	26	NMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	T	_	NN	NN	_	23	COORD	_	_
26	cells	_	NNS	NNS	_	22	PMOD	_	_
27	,	_	,	,	_	18	P	_	_
28	whereas	_	IN	IN	_	18	COORD	_	_
29	only	_	RB	RB	_	30	NMOD	_	_
30	IL-2	_	NN	NN	_	31	SBJ	_	_
31	induces	_	VBZ	VBZ	_	18	COORD	_	_
32	bcl-2	_	NN	NN	_	33	NMOD	_	_
33	expression	_	NN	NN	_	31	OBJ	_	_
34	.	_	.	.	_	12	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	provide	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	first	_	JJ	JJ	_	6	NMOD	_	_
6	demonstration	_	NN	NN	_	3	OBJ	_	_
7	that	_	IN	IN	_	6	NMOD	_	_
8	IL-12-mediated	_	JJ	JJ	_	9	NMOD	_	_
9	activation	_	NN	NN	_	15	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	T	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	NK	_	NN	NN	_	11	COORD	_	_
14	cells	_	NNS	NNS	_	10	PMOD	_	_
15	does	_	VBZ	VBZ	_	7	VMOD	_	_
16	not	_	RB	RB	_	15	VMOD	_	_
17	involve	_	VB	VB	_	15	VC	_	_
18	expression	_	NN	NN	_	17	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	members	_	NNS	NNS	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	26	NMOD	_	_
23	immediate-early	_	JJ	JJ	_	26	NMOD	_	_
24	activation	_	NN	NN	_	26	NMOD	_	_
25	genes	_	NNS	NNS	_	26	NMOD	_	_
26	family	_	NN	NN	_	21	PMOD	_	_
27	(	_	(	(	_	28	P	_	_
28	egr-1	_	NN	NN	_	26	PRN	_	_
29	,	_	,	,	_	28	P	_	_
30	c-fos	_	NN	NN	_	28	COORD	_	_
31	,	_	,	,	_	28	P	_	_
32	and	_	CC	CC	_	28	CC	_	_
33	junB	_	NN	NN	_	28	COORD	_	_
34	)	_	)	)	_	28	P	_	_
35	,	_	,	,	_	18	P	_	_
36	AP-1	_	NN	NN	_	38	NMOD	_	_
37	transcriptional	_	JJ	JJ	_	38	NMOD	_	_
38	activity	_	NN	NN	_	18	COORD	_	_
39	,	_	,	,	_	18	P	_	_
40	or	_	CC	CC	_	18	CC	_	_
41	bcl-2	_	NN	NN	_	42	NMOD	_	_
42	expression	_	NN	NN	_	18	COORD	_	_
43	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	indicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	functional	_	JJ	JJ	_	5	NMOD	_	_
5	differences	_	NNS	NNS	_	12	SBJ	_	_
6	observed	_	VBN	VBN	_	5	NMOD	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	IL-2-	_	NN	NN	_	11	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	IL-12-stimulated	_	JJ	JJ	_	8	COORD	_	_
11	cells	_	NNS	NNS	_	7	PMOD	_	_
12	may	_	MD	MD	_	3	VMOD	_	_
13	depend	_	VB	VB	_	12	VC	_	_
14	,	_	,	,	_	15	P	_	_
15	at	_	IN	IN	_	13	ADV	_	_
16	least	_	JJS	JJS	_	15	PMOD	_	_
17	in	_	IN	IN	_	15	PMOD	_	_
18	part	_	NN	NN	_	13	VMOD	_	_
19	,	_	,	,	_	13	ADV	_	_
20	on	_	IN	IN	_	22	NMOD	_	_
21	differential	_	JJ	JJ	_	22	NMOD	_	_
22	gene	_	NN	NN	_	19	COORD	_	_
23	regulation	_	NN	NN	_	2	VMOD	_	_

1	Soluble	_	JJ	JJ	_	2	NMOD	_	_
2	factors	_	NNS	NNS	_	7	SBJ	_	_
3	secreted	_	VBN	VBN	_	2	NMOD	_	_
4	by	_	IN	IN	_	3	LGS	_	_
5	activated	_	VBN	VBN	_	6	NMOD	_	_
6	T-lymphocytes	_	NNS	NNS	_	4	PMOD	_	_
7	modulate	_	VBP	VBP	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	transcription	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	immunosuppressive	_	JJ	JJ	_	14	NMOD	_	_
13	cytokine	_	NN	NN	_	14	NMOD	_	_
14	TGF-beta	_	NN	NN	_	10	PMOD	_	_
15	2	_	CD	CD	_	14	NMOD	_	_
16	in	_	IN	IN	_	14	NMOD	_	_
17	glial	_	JJ	JJ	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	16	PMOD	_	_
19	.	_	.	.	_	7	P	_	_

1	Coordination	_	NN	NN	_	13	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	immune	_	JJ	JJ	_	5	NMOD	_	_
5	response	_	NN	NN	_	2	PMOD	_	_
6	to	_	TO	TO	_	5	NMOD	_	_
7	injury	_	NN	NN	_	6	PMOD	_	_
8	or	_	CC	CC	_	7	CC	_	_
9	disease	_	NN	NN	_	7	COORD	_	_
10	in	_	IN	IN	_	7	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	brain	_	NN	NN	_	10	PMOD	_	_
13	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	postulated	_	VBN	VBN	_	13	VC	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	involve	_	VB	VB	_	14	OBJ	_	_
17	bi-directional	_	JJ	JJ	_	18	NMOD	_	_
18	discourse	_	NN	NN	_	16	OBJ	_	_
19	between	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	immune	_	JJ	JJ	_	22	NMOD	_	_
22	system	_	NN	NN	_	19	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	central	_	JJ	JJ	_	27	NMOD	_	_
26	nervous	_	JJ	JJ	_	27	NMOD	_	_
27	system	_	NN	NN	_	22	COORD	_	_
28	.	_	.	.	_	13	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	cross	_	JJ	JJ	_	3	NMOD	_	_
3	communication	_	NN	NN	_	4	SBJ	_	_
4	involves	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	soluble	_	JJ	JJ	_	6	NMOD	_	_
6	mediators	_	NNS	NNS	_	4	OBJ	_	_
7	,	_	,	,	_	6	P	_	_
8	including	_	VBG	VBG	_	6	NMOD	_	_
9	various	_	JJ	JJ	_	11	NMOD	_	_
10	growth	_	NN	NN	_	11	NMOD	_	_
11	factors	_	NNS	NNS	_	8	PMOD	_	_
12	,	_	,	,	_	6	P	_	_
13	cytokines	_	NNS	NNS	_	6	COORD	_	_
14	,	_	,	,	_	6	P	_	_
15	and	_	CC	CC	_	6	CC	_	_
16	neuropeptides	_	NNS	NNS	_	6	COORD	_	_
17	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	supernatant	_	NN	NN	_	13	SBJ	_	_
10	from	_	IN	IN	_	9	NMOD	_	_
11	activated	_	VBN	VBN	_	12	NMOD	_	_
12	T-lymphocytes	_	NNS	NNS	_	10	PMOD	_	_
13	is	_	VBZ	VBZ	_	7	VMOD	_	_
14	able	_	JJ	JJ	_	13	PRD	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	induce	_	VB	VB	_	14	AMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	transcription	_	NN	NN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	potent	_	JJ	JJ	_	22	NMOD	_	_
22	cytokine	_	NN	NN	_	19	PMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	TGF-beta	_	NN	NN	_	22	NMOD	_	_
25	2	_	CD	CD	_	24	NMOD	_	_
26	in	_	IN	IN	_	22	NMOD	_	_
27	glial	_	JJ	JJ	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	26	PMOD	_	_
29	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	activating	_	VBG	VBG	_	3	NMOD	_	_
3	stimulus	_	NN	NN	_	4	SBJ	_	_
4	invokes	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	signaling	_	NN	NN	_	6	NMOD	_	_
6	mechanisms	_	NNS	NNS	_	4	OBJ	_	_
7	distinct	_	JJ	JJ	_	6	NMOD	_	_
8	from	_	IN	IN	_	7	AMOD	_	_
9	known	_	JJ	JJ	_	13	NMOD	_	_
10	kinase	_	NN	NN	_	13	NMOD	_	_
11	or	_	CC	CC	_	10	CC	_	_
12	protease	_	NN	NN	_	10	COORD	_	_
13	pathways	_	NNS	NNS	_	8	PMOD	_	_
14	.	_	.	.	_	4	P	_	_

1	Activation	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	TGF-beta	_	NN	NN	_	5	NMOD	_	_
4	2	_	CD	CD	_	5	NMOD	_	_
5	transcription	_	NN	NN	_	2	PMOD	_	_
6	correlates	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	with	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	loss	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	binding	_	NN	NN	_	12	NMOD	_	_
12	activity	_	NN	NN	_	10	PMOD	_	_
13	for	_	IN	IN	_	12	NMOD	_	_
14	an	_	DT	DT	_	20	NMOD	_	_
15	80	_	CD	CD	_	20	NMOD	_	_
16	kDA	_	NN	NN	_	20	NMOD	_	_
17	glial	_	JJ	JJ	_	20	NMOD	_	_
18	labile	_	NN	NN	_	20	NMOD	_	_
19	repressor	_	NN	NN	_	20	NMOD	_	_
20	protein	_	NN	NN	_	13	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	GLRP	_	NN	NN	_	20	NMOD	_	_
23	,	_	,	,	_	20	P	_	_
24	to	_	TO	TO	_	12	NMOD	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	responsive	_	JJ	JJ	_	27	NMOD	_	_
27	region	_	NN	NN	_	24	PMOD	_	_
28	within	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	32	NMOD	_	_
30	TFG-beta	_	NN	NN	_	32	NMOD	_	_
31	2	_	CD	CD	_	32	NMOD	_	_
32	promoter	_	NN	NN	_	28	PMOD	_	_
33	.	_	.	.	_	6	P	_	_

1	Although	_	IN	IN	_	14	ADV	_	_
2	GLRP	_	NN	NN	_	3	SBJ	_	_
3	shares	_	VBZ	VBZ	_	1	VMOD	_	_
4	some	_	DT	DT	_	5	NMOD	_	_
5	characteristics	_	NNS	NNS	_	3	OBJ	_	_
6	with	_	IN	IN	_	3	ADV	_	_
7	the	_	DT	DT	_	11	NMOD	_	_
8	inducible	_	JJ	JJ	_	11	NMOD	_	_
9	transcription	_	NN	NN	_	11	NMOD	_	_
10	factor	_	NN	NN	_	11	NMOD	_	_
11	AP-1	_	NN	NN	_	6	PMOD	_	_
12	,	_	,	,	_	14	P	_	_
13	it	_	PRP	PRP	_	14	SBJ	_	_
14	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	be	_	VB	VB	_	14	OBJ	_	_
17	distinct	_	JJ	JJ	_	16	PRD	_	_
18	from	_	IN	IN	_	17	AMOD	_	_
19	known	_	JJ	JJ	_	22	NMOD	_	_
20	AP-1	_	NN	NN	_	22	NMOD	_	_
21	family	_	NN	NN	_	22	NMOD	_	_
22	members	_	NNS	NNS	_	18	PMOD	_	_
23	.	_	.	.	_	14	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	16	SBJ	_	_
3	along	_	IN	IN	_	2	NMOD	_	_
4	with	_	IN	IN	_	3	DEP	_	_
5	previous	_	JJ	JJ	_	6	NMOD	_	_
6	observations	_	NNS	NNS	_	3	PMOD	_	_
7	demonstrating	_	VBG	VBG	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	potent	_	JJ	JJ	_	11	NMOD	_	_
10	immunosuppressive	_	JJ	JJ	_	11	NMOD	_	_
11	activity	_	NN	NN	_	7	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	TGF-beta	_	NN	NN	_	12	PMOD	_	_
14	2	_	CD	CD	_	13	NMOD	_	_
15	,	_	,	,	_	16	P	_	_
16	support	_	VBP	VBP	_	0	ROOT-S	_	_
17	a	_	DT	DT	_	18	NMOD	_	_
18	model	_	NN	NN	_	16	OBJ	_	_
19	for	_	IN	IN	_	18	NMOD	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	feedback	_	NN	NN	_	22	NMOD	_	_
22	mechanism	_	NN	NN	_	19	PMOD	_	_
23	between	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	activated	_	VBN	VBN	_	26	NMOD	_	_
26	T-lymphocytes	_	NNS	NNS	_	23	PMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	astrocytes	_	NNS	NNS	_	26	COORD	_	_
29	via	_	IN	IN	_	22	NMOD	_	_
30	TGF-beta	_	NN	NN	_	29	PMOD	_	_
31	2	_	CD	CD	_	30	NMOD	_	_
32	to	_	TO	TO	_	33	VMOD	_	_
33	regulate	_	VB	VB	_	22	NMOD	_	_
34	the	_	DT	DT	_	36	NMOD	_	_
35	immune	_	JJ	JJ	_	36	NMOD	_	_
36	response	_	NN	NN	_	33	OBJ	_	_
37	.	_	.	.	_	16	P	_	_

1	Inorganic	_	JJ	JJ	_	2	NMOD	_	_
2	lead	_	NN	NN	_	3	SBJ	_	_
3	activates	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	NF-kappa	_	NN	NN	_	5	NMOD	_	_
5	B	_	NN	NN	_	3	OBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	primary	_	JJ	JJ	_	11	NMOD	_	_
8	human	_	JJ	JJ	_	11	NMOD	_	_
9	CD4+	_	JJ	JJ	_	11	NMOD	_	_
10	T	_	NN	NN	_	11	NMOD	_	_
11	lymphocytes	_	NNS	NNS	_	6	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	Inorganic	_	JJ	JJ	_	2	NMOD	_	_
2	lead	_	NN	NN	_	6	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	Pb	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	10	NMOD	_	_
8	ubiquitous	_	JJ	JJ	_	10	NMOD	_	_
9	environmental	_	JJ	JJ	_	10	NMOD	_	_
10	contaminant	_	NN	NN	_	6	PRD	_	_
11	that	_	WDT	WDT	_	12	SBJ	_	_
12	produces	_	VBZ	VBZ	_	10	NMOD	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	variety	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	effects	_	NNS	NNS	_	15	PMOD	_	_
17	on	_	IN	IN	_	16	NMOD	_	_
18	humoral	_	JJ	JJ	_	23	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	cell	_	NN	NN	_	18	COORD	_	_
21	mediated	_	JJ	JJ	_	20	AMOD	_	_
22	immune	_	JJ	JJ	_	23	NMOD	_	_
23	responses	_	NNS	NNS	_	17	PMOD	_	_
24	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	underlying	_	VBG	VBG	_	4	NMOD	_	_
3	molecular	_	JJ	JJ	_	4	NMOD	_	_
4	mechanism	_	NN	NN	_	14	SBJ	_	_
5	for	_	IN	IN	_	4	NMOD	_	_
6	Pb	_	NN	NN	_	9	NMOD	_	_
7	's	_	POS	POS	_	6	NMOD	_	_
8	complex	_	JJ	JJ	_	9	NMOD	_	_
9	effects	_	NNS	NNS	_	5	PMOD	_	_
10	on	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	immune	_	JJ	JJ	_	13	NMOD	_	_
13	system	_	NN	NN	_	10	PMOD	_	_
14	remain	_	VBP	VBP	_	0	ROOT-S	_	_
15	obscure	_	JJ	JJ	_	14	PRD	_	_
16	.	_	.	.	_	14	P	_	_

1	Many	_	JJ	JJ	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	Pb	_	NN	NN	_	5	NMOD	_	_
4	's	_	POS	POS	_	3	NMOD	_	_
5	effects	_	NNS	NNS	_	2	PMOD	_	_
6	on	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	immune	_	JJ	JJ	_	9	NMOD	_	_
9	system	_	NN	NN	_	6	PMOD	_	_
10	could	_	MD	MD	_	0	ROOT-S	_	_
11	be	_	VB	VB	_	10	VC	_	_
12	explained	_	VBN	VBN	_	11	VC	_	_
13	through	_	IN	IN	_	12	ADV	_	_
14	activation	_	NN	NN	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	transcription	_	NN	NN	_	18	NMOD	_	_
18	factor	_	NN	NN	_	15	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	NF-kappa	_	NN	NN	_	21	NMOD	_	_
21	B	_	NN	NN	_	18	NMOD	_	_
22	.	_	.	.	_	10	P	_	_

1	NF-kappa	_	NN	NN	_	2	NMOD	_	_
2	B	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	critical	_	JJ	JJ	_	3	PRD	_	_
5	for	_	IN	IN	_	4	AMOD	_	_
6	T	_	NN	NN	_	8	NMOD	_	_
7	lymphocyte	_	NN	NN	_	8	NMOD	_	_
8	function	_	NN	NN	_	5	PMOD	_	_
9	and	_	CC	CC	_	3	CC	_	_
10	is	_	VBZ	VBZ	_	3	COORD	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	strong	_	JJ	JJ	_	13	NMOD	_	_
13	inducer	_	NN	NN	_	10	PRD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	HIV-LTR	_	NN	NN	_	16	NMOD	_	_
16	activation	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	Pb	_	NN	NN	_	9	SBJ	_	_
5	at	_	IN	IN	_	4	NMOD	_	_
6	physiologically	_	RB	RB	_	7	AMOD	_	_
7	relevant	_	JJ	JJ	_	8	NMOD	_	_
8	concentrations	_	NNS	NNS	_	5	PMOD	_	_
9	activates	_	VBZ	VBZ	_	3	VMOD	_	_
10	NF-kappa	_	NN	NN	_	11	NMOD	_	_
11	B	_	NN	NN	_	9	OBJ	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	primary	_	JJ	JJ	_	17	NMOD	_	_
14	human	_	JJ	JJ	_	17	NMOD	_	_
15	CD4+	_	JJ	JJ	_	17	NMOD	_	_
16	T	_	NN	NN	_	17	NMOD	_	_
17	lymphocytes	_	NNS	NNS	_	12	PMOD	_	_
18	.	_	.	.	_	2	P	_	_

1	Pb-induced	_	JJ	JJ	_	2	NMOD	_	_
2	activation	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NF-kappa	_	NN	NN	_	5	NMOD	_	_
5	B	_	NN	NN	_	3	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	blocked	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	antibodies	_	NNS	NNS	_	8	PMOD	_	_
10	for	_	IN	IN	_	9	NMOD	_	_
11	p65	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	p50	_	NN	NN	_	11	COORD	_	_
14	subunits	_	NNS	NNS	_	10	PMOD	_	_
15	but	_	CC	CC	_	14	CC	_	_
16	not	_	RB	RB	_	15	COORD	_	_
17	cRel	_	NN	NN	_	14	COORD	_	_
18	,	_	,	,	_	7	P	_	_
19	indicating	_	VBG	VBG	_	7	OBJ	_	_
20	that	_	IN	IN	_	19	OBJ	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	p65:p50	_	NN	NN	_	23	NMOD	_	_
23	heterodimer	_	NN	NN	_	28	SBJ	_	_
24	(	_	(	(	_	26	P	_	_
25	NF-kappa	_	NN	NN	_	26	NMOD	_	_
26	B	_	NN	NN	_	23	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	is	_	VBZ	VBZ	_	20	VMOD	_	_
29	involved	_	VBN	VBN	_	28	VC	_	_
30	.	_	.	.	_	6	P	_	_

1	Functional	_	JJ	JJ	_	2	NMOD	_	_
2	activation	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	gene	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	3	PMOD	_	_
6	by	_	IN	IN	_	2	NMOD	_	_
7	Pb	_	NN	NN	_	6	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	confirmed	_	VBN	VBN	_	8	VC	_	_
10	using	_	VBG	VBG	_	9	OBJ	_	_
11	primary	_	JJ	JJ	_	14	NMOD	_	_
12	CD4+	_	JJ	JJ	_	14	NMOD	_	_
13	T	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	10	OBJ	_	_
15	transfected	_	VBN	VBN	_	14	NMOD	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	an	_	DT	DT	_	23	NMOD	_	_
18	NF-kappa	_	NN	NN	_	19	NMOD	_	_
19	B	_	NN	NN	_	20	AMOD	_	_
20	dependent	_	JJ	JJ	_	23	NMOD	_	_
21	reporter	_	NN	NN	_	23	NMOD	_	_
22	gene	_	NN	NN	_	23	NMOD	_	_
23	construct	_	NN	NN	_	16	PMOD	_	_
24	.	_	.	.	_	8	P	_	_

1	Pb	_	NN	NN	_	2	SBJ	_	_
2	did	_	VBD	VBD	_	0	ROOT-S	_	_
3	not	_	RB	RB	_	2	VMOD	_	_
4	activate	_	VB	VB	_	2	VC	_	_
5	NF-kappa	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	4	IOBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	4	_	CD	CD	_	12	NMOD	_	_
9	different	_	JJ	JJ	_	12	NMOD	_	_
10	T	_	NN	NN	_	12	NMOD	_	_
11	cell	_	NN	NN	_	12	NMOD	_	_
12	lines	_	NNS	NNS	_	7	PMOD	_	_
13	,	_	,	,	_	4	P	_	_
14	suggesting	_	VBG	VBG	_	4	OBJ	_	_
15	that	_	IN	IN	_	14	OBJ	_	_
16	lymphoid	_	JJ	JJ	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	lines	_	NNS	NNS	_	19	SBJ	_	_
19	may	_	MD	MD	_	15	VMOD	_	_
20	not	_	RB	RB	_	19	VMOD	_	_
21	be	_	VB	VB	_	19	VC	_	_
22	reliable	_	JJ	JJ	_	23	NMOD	_	_
23	surrogates	_	NNS	NNS	_	21	PRD	_	_
24	for	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	study	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	transcriptional	_	JJ	JJ	_	29	NMOD	_	_
29	activation	_	NN	NN	_	27	PMOD	_	_
30	in	_	IN	IN	_	29	NMOD	_	_
31	human	_	JJ	JJ	_	33	NMOD	_	_
32	T	_	NN	NN	_	33	NMOD	_	_
33	cells	_	NNS	NNS	_	30	PMOD	_	_
34	.	_	.	.	_	2	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	NF-kappa	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	7	SBJ	_	_
7	may	_	MD	MD	_	4	VMOD	_	_
8	be	_	VB	VB	_	7	VC	_	_
9	an	_	DT	DT	_	12	NMOD	_	_
10	important	_	JJ	JJ	_	12	NMOD	_	_
11	molecular	_	JJ	JJ	_	12	NMOD	_	_
12	mediator	_	NN	NN	_	8	PRD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	Pb-induced	_	JJ	JJ	_	15	NMOD	_	_
15	immunotoxicity	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	Calcium-dependent	_	JJ	JJ	_	4	NMOD	_	_
2	immediate-early	_	JJ	JJ	_	4	NMOD	_	_
3	gene	_	NN	NN	_	4	NMOD	_	_
4	induction	_	NN	NN	_	7	SBJ	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	lymphocytes	_	NNS	NNS	_	5	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	negatively	_	RB	RB	_	9	ADV	_	_
9	regulated	_	VBN	VBN	_	7	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	p21Ha-ras	_	NN	NN	_	10	PMOD	_	_
12	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	induction	_	NN	NN	_	20	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	immediate-early	_	JJ	JJ	_	9	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	IE	_	JJ	JJ	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	response	_	NN	NN	_	9	NMOD	_	_
9	genes	_	NNS	NNS	_	3	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	such	_	JJ	JJ	_	12	DEP	_	_
12	as	_	IN	IN	_	9	NMOD	_	_
13	egr-1	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	c-fos	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	13	P	_	_
17	and	_	CC	CC	_	13	CC	_	_
18	c-jun	_	NN	NN	_	13	COORD	_	_
19	,	_	,	,	_	9	P	_	_
20	occurs	_	VBZ	VBZ	_	0	ROOT-S	_	_
21	rapidly	_	RB	RB	_	20	TMP	_	_
22	after	_	IN	IN	_	20	TMP	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	activation	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	T	_	NN	NN	_	27	NMOD	_	_
27	lymphocytes	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	20	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	process	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	activation	_	NN	NN	_	3	PMOD	_	_
5	involves	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	calcium	_	NN	NN	_	7	NMOD	_	_
7	mobilization	_	NN	NN	_	5	OBJ	_	_
8	,	_	,	,	_	7	P	_	_
9	activation	_	NN	NN	_	7	COORD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	protein	_	NN	NN	_	13	NMOD	_	_
12	kinase	_	NN	NN	_	13	NMOD	_	_
13	C	_	NN	NN	_	10	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	PKC	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	,	_	,	,	_	7	P	_	_
18	and	_	CC	CC	_	7	CC	_	_
19	phosphorylation	_	NN	NN	_	7	COORD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	tyrosine	_	NN	NN	_	22	NMOD	_	_
22	kinases	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	5	P	_	_

1	p21-LRB-ras-RRB-	_	NN	NN	_	9	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	a	_	DT	DT	_	7	NMOD	_	_
4	guanine	_	NN	NN	_	7	NMOD	_	_
5	nucleotide	_	NN	NN	_	7	NMOD	_	_
6	binding	_	NN	NN	_	7	NMOD	_	_
7	factor	_	NN	NN	_	1	NMOD	_	_
8	,	_	,	,	_	1	P	_	_
9	mediates	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	T-cell	_	NN	NN	_	12	NMOD	_	_
11	signal	_	NN	NN	_	12	NMOD	_	_
12	transduction	_	NN	NN	_	9	OBJ	_	_
13	through	_	IN	IN	_	9	ADV	_	_
14	PKC-dependent	_	JJ	JJ	_	17	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	PKC-independent	_	JJ	JJ	_	14	COORD	_	_
17	pathways	_	NNS	NNS	_	13	PMOD	_	_
18	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	involvement	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	p21-LRB-ras-RRB-	_	NN	NN	_	3	PMOD	_	_
5	in	_	IN	IN	_	2	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	regulation	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	calcium-dependent	_	JJ	JJ	_	10	NMOD	_	_
10	signals	_	NNS	NNS	_	8	PMOD	_	_
11	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	been	_	VBN	VBN	_	11	VC	_	_
13	suggested	_	VBN	VBN	_	12	VC	_	_
14	through	_	IN	IN	_	13	ADV	_	_
15	analysis	_	NN	NN	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	its	_	PRP$	PRP$	_	18	NMOD	_	_
18	role	_	NN	NN	_	16	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	activation	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	NF-AT	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	11	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	investigated	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	inductions	_	NNS	NNS	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	IE	_	JJ	JJ	_	9	NMOD	_	_
9	genes	_	NNS	NNS	_	6	PMOD	_	_
10	in	_	IN	IN	_	5	NMOD	_	_
11	response	_	NN	NN	_	10	DEP	_	_
12	to	_	TO	TO	_	10	DEP	_	_
13	calcium	_	NN	NN	_	14	NMOD	_	_
14	signals	_	NNS	NNS	_	10	PMOD	_	_
15	in	_	IN	IN	_	5	NMOD	_	_
16	Jurkat	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	15	PMOD	_	_
18	(	_	(	(	_	5	P	_	_
19	in	_	IN	IN	_	5	NMOD	_	_
20	the	_	DT	DT	_	19	DEP	_	_
21	presence	_	NN	NN	_	19	DEP	_	_
22	of	_	IN	IN	_	19	DEP	_	_
23	activated	_	VBN	VBN	_	24	NMOD	_	_
24	p21-LRB-ras-RRB-	_	NN	NN	_	19	PMOD	_	_
25	)	_	)	)	_	5	P	_	_
26	and	_	CC	CC	_	5	CC	_	_
27	their	_	PRP$	PRP$	_	29	NMOD	_	_
28	correlated	_	VBN	VBN	_	29	NMOD	_	_
29	consequences	_	NNS	NNS	_	5	COORD	_	_
30	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	expression	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	activated	_	VBN	VBN	_	5	NMOD	_	_
5	p21-LRB-ras-RRB-	_	NN	NN	_	3	PMOD	_	_
6	negatively	_	RB	RB	_	7	ADV	_	_
7	regulated	_	VBD	VBD	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	induction	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	IE	_	JJ	JJ	_	12	NMOD	_	_
12	genes	_	NNS	NNS	_	10	PMOD	_	_
13	by	_	IN	IN	_	9	NMOD	_	_
14	calcium	_	NN	NN	_	15	NMOD	_	_
15	ionophore	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	7	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	inhibition	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	calcium-activated	_	JJ	JJ	_	7	NMOD	_	_
5	IE	_	JJ	JJ	_	7	NMOD	_	_
6	gene	_	NN	NN	_	7	NMOD	_	_
7	induction	_	NN	NN	_	3	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	reversed	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	treatment	_	NN	NN	_	10	PMOD	_	_
12	with	_	IN	IN	_	11	NMOD	_	_
13	cyclosporin	_	NN	NN	_	14	NMOD	_	_
14	A	_	NN	NN	_	12	PMOD	_	_
15	,	_	,	,	_	8	P	_	_
16	suggesting	_	VBG	VBG	_	8	VC	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	involvement	_	NN	NN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	calcineurin	_	NN	NN	_	19	PMOD	_	_
21	in	_	IN	IN	_	18	NMOD	_	_
22	this	_	DT	DT	_	23	NMOD	_	_
23	regulation	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	8	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	later	_	JJ	JJ	_	3	NMOD	_	_
3	result	_	NN	NN	_	12	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	inhibition	_	NN	NN	_	4	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	this	_	DT	DT	_	9	NMOD	_	_
8	activation	_	NN	NN	_	9	NMOD	_	_
9	pathway	_	NN	NN	_	6	PMOD	_	_
10	by	_	IN	IN	_	5	NMOD	_	_
11	p21-LRB-ras-RRB-	_	NN	NN	_	10	PMOD	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	down-regulation	_	NN	NN	_	12	PRD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	activity	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	transcription	_	NN	NN	_	21	NMOD	_	_
20	factor	_	NN	NN	_	21	NMOD	_	_
21	AP-1	_	NN	NN	_	17	PMOD	_	_
22	and	_	CC	CC	_	13	CC	_	_
23	subsequent	_	JJ	JJ	_	25	NMOD	_	_
24	coordinate	_	JJ	JJ	_	25	NMOD	_	_
25	reductions	_	NNS	NNS	_	13	COORD	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	IL-2	_	NN	NN	_	29	NMOD	_	_
28	gene	_	NN	NN	_	29	NMOD	_	_
29	expression	_	NN	NN	_	26	PMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	protein	_	NN	NN	_	32	NMOD	_	_
32	production	_	NN	NN	_	29	COORD	_	_
33	.	_	.	.	_	12	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	p2l-LRB-ras-RRB-	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	4	VMOD	_	_
7	an	_	DT	DT	_	9	NMOD	_	_
8	essential	_	JJ	JJ	_	9	NMOD	_	_
9	mediator	_	NN	NN	_	6	PRD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	generating	_	VBG	VBG	_	10	PMOD	_	_
12	not	_	RB	RB	_	14	CC	_	_
13	only	_	RB	RB	_	12	DEP	_	_
14	positive	_	JJ	JJ	_	19	NMOD	_	_
15	but	_	CC	CC	_	14	CC	_	_
16	also	_	RB	RB	_	15	COORD	_	_
17	negative	_	JJ	JJ	_	14	COORD	_	_
18	modulatory	_	JJ	JJ	_	19	NMOD	_	_
19	mechanisms	_	NNS	NNS	_	11	OBJ	_	_
20	controlling	_	VBG	VBG	_	19	NMOD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	competence	_	NN	NN	_	20	OBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	T	_	NN	NN	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	23	PMOD	_	_
26	in	_	IN	IN	_	20	ADV	_	_
27	response	_	NN	NN	_	26	DEP	_	_
28	to	_	TO	TO	_	26	DEP	_	_
29	inductive	_	JJ	JJ	_	30	NMOD	_	_
30	stimulations	_	NNS	NNS	_	26	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	CD14-mediated	_	JJ	JJ	_	3	NMOD	_	_
2	signal	_	NN	NN	_	3	NMOD	_	_
3	pathway	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	Porphyromonas	_	NN	NN	_	7	NMOD	_	_
6	gingivalis	_	NN	NN	_	7	NMOD	_	_
7	lipopolysaccharide	_	NN	NN	_	4	PMOD	_	_
8	in	_	IN	IN	_	3	NMOD	_	_
9	human	_	JJ	JJ	_	11	NMOD	_	_
10	gingival	_	JJ	JJ	_	11	NMOD	_	_
11	fibroblasts	_	NNS	NNS	_	8	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	Lipopolysaccharide	_	NN	NN	_	5	SBJ	_	_
2	(	_	(	(	_	3	P	_	_
3	LPS	_	NN	NN	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	expression	_	NN	NN	_	5	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	inflammatory	_	JJ	JJ	_	9	NMOD	_	_
9	cytokines	_	NNS	NNS	_	7	PMOD	_	_
10	in	_	IN	IN	_	6	NMOD	_	_
11	monocytes\/macrophages	_	NNS	NNS	_	10	PMOD	_	_
12	via	_	IN	IN	_	5	ADV	_	_
13	CD14	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	one	_	CD	CD	_	13	NMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	LPS	_	NN	NN	_	19	NMOD	_	_
19	receptors	_	NNS	NNS	_	16	PMOD	_	_
20	,	_	,	,	_	13	P	_	_
21	which	_	WDT	WDT	_	22	SBJ	_	_
22	is	_	VBZ	VBZ	_	13	NMOD	_	_
23	expressed	_	VBN	VBN	_	22	VC	_	_
24	predominantly	_	RB	RB	_	23	ADV	_	_
25	in	_	IN	IN	_	23	ADV	_	_
26	these	_	DT	DT	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	5	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	been	_	VBN	VBN	_	2	VC	_	_
4	demonstrated	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	Porphyromonas	_	NN	NN	_	8	NMOD	_	_
7	gingivalis	_	NN	NN	_	8	NMOD	_	_
8	LPS	_	NN	NN	_	13	SBJ	_	_
9	(	_	(	(	_	10	P	_	_
10	P-LPS	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	also	_	RB	RB	_	13	ADV	_	_
13	is	_	VBZ	VBZ	_	5	VMOD	_	_
14	able	_	JJ	JJ	_	13	PRD	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	induce	_	VB	VB	_	14	AMOD	_	_
17	inflammatory	_	JJ	JJ	_	18	NMOD	_	_
18	cytokines	_	NNS	NNS	_	16	OBJ	_	_
19	in	_	IN	IN	_	16	ADV	_	_
20	human	_	JJ	JJ	_	22	NMOD	_	_
21	gingival	_	JJ	JJ	_	22	NMOD	_	_
22	fibroblasts	_	NNS	NNS	_	19	PMOD	_	_
23	.	_	.	.	_	2	P	_	_

1	Therefore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	it	_	PRP	PRP	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	important	_	JJ	JJ	_	4	PRD	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	determine	_	VB	VB	_	4	EXP	_	_
8	whether	_	IN	IN	_	7	OBJ	_	_
9	CD14	_	NN	NN	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	8	VMOD	_	_
11	expressed	_	VBN	VBN	_	10	VC	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	gingival	_	JJ	JJ	_	14	NMOD	_	_
14	fibroblasts	_	NNS	NNS	_	12	PMOD	_	_
15	and	_	CC	CC	_	7	CC	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	define	_	VB	VB	_	7	COORD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	P-LPS-mediated	_	JJ	JJ	_	21	NMOD	_	_
20	signal-transducing	_	JJ	JJ	_	21	NMOD	_	_
21	mechanism	_	NN	NN	_	17	OBJ	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	observed	_	VBD	VBD	_	0	ROOT-S	_	_
7	unexpectedly	_	RB	RB	_	6	ADV	_	_
8	by	_	IN	IN	_	6	ADV	_	_
9	immunohistochemical	_	JJ	JJ	_	23	NMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	Western	_	JJ	JJ	_	12	NMOD	_	_
12	blotting	_	NN	NN	_	9	COORD	_	_
13	(	_	(	(	_	14	P	_	_
14	immunoblotting	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	,	_	,	,	_	9	P	_	_
17	and	_	CC	CC	_	9	CC	_	_
18	Northern	_	NN	NN	_	22	NMOD	_	_
19	(	_	(	(	_	22	P	_	_
20	RNA	_	NN	NN	_	22	NMOD	_	_
21	)	_	)	)	_	22	P	_	_
22	blotting	_	NN	NN	_	9	COORD	_	_
23	assays	_	NNS	NNS	_	8	PMOD	_	_
24	that	_	IN	IN	_	6	OBJ	_	_
25	CD14	_	NN	NN	_	26	SBJ	_	_
26	is	_	VBZ	VBZ	_	24	VMOD	_	_
27	expressed	_	VBN	VBN	_	26	VC	_	_
28	at	_	IN	IN	_	27	ADV	_	_
29	high	_	JJ	JJ	_	30	NMOD	_	_
30	density	_	NN	NN	_	28	PMOD	_	_
31	in	_	IN	IN	_	27	ADV	_	_
32	human	_	JJ	JJ	_	34	NMOD	_	_
33	gingival	_	JJ	JJ	_	34	NMOD	_	_
34	fibroblasts	_	NNS	NNS	_	31	PMOD	_	_
35	.	_	.	.	_	6	P	_	_

1	P-LPS-induced	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	16	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	12	NMOD	_	_
5	monocyte	_	NN	NN	_	7	NMOD	_	_
6	chemoattractant	_	NN	NN	_	7	NMOD	_	_
7	protein	_	NN	NN	_	12	NMOD	_	_
8	1	_	CD	CD	_	7	NMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	MCP-1	_	NN	NN	_	7	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	gene	_	NN	NN	_	3	PMOD	_	_
13	in	_	IN	IN	_	2	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	13	PMOD	_	_
16	was	_	VBD	VBD	_	0	ROOT-S	_	_
17	inhibited	_	VBN	VBN	_	16	VC	_	_
18	markedly	_	RB	RB	_	17	ADV	_	_
19	by	_	IN	IN	_	17	LGS	_	_
20	treatment	_	NN	NN	_	19	PMOD	_	_
21	with	_	IN	IN	_	20	NMOD	_	_
22	anti-human	_	JJ	JJ	_	24	NMOD	_	_
23	CD14	_	NN	NN	_	24	NMOD	_	_
24	antibody	_	NN	NN	_	21	PMOD	_	_
25	and	_	CC	CC	_	16	CC	_	_
26	was	_	VBD	VBD	_	16	COORD	_	_
27	completely	_	RB	RB	_	28	ADV	_	_
28	inhibited	_	VBN	VBN	_	26	VC	_	_
29	by	_	IN	IN	_	28	LGS	_	_
30	herbimycin	_	NN	NN	_	31	NMOD	_	_
31	A	_	NN	NN	_	29	PMOD	_	_
32	,	_	,	,	_	31	P	_	_
33	a	_	DT	DT	_	35	NMOD	_	_
34	potent	_	JJ	JJ	_	35	NMOD	_	_
35	inhibitor	_	NN	NN	_	31	NMOD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	tyrosine	_	NN	NN	_	38	NMOD	_	_
38	kinase	_	NN	NN	_	36	PMOD	_	_
39	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	inhibitor	_	NN	NN	_	5	SBJ	_	_
3	also	_	RB	RB	_	5	ADV	_	_
4	dramatically	_	RB	RB	_	5	ADV	_	_
5	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
6	monocyte	_	NN	NN	_	8	NMOD	_	_
7	chemotactic	_	JJ	JJ	_	8	NMOD	_	_
8	activity	_	NN	NN	_	5	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	and	_	CC	CC	_	8	CC	_	_
11	MCP-1	_	NN	NN	_	12	NMOD	_	_
12	production	_	NN	NN	_	8	COORD	_	_
13	by	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	9	PMOD	_	_
16	.	_	.	.	_	5	P	_	_

1	Furthermore	_	RB	RB	_	13	ADV	_	_
2	,	_	,	,	_	13	P	_	_
3	P-LPS-induced	_	JJ	JJ	_	4	NMOD	_	_
4	expression	_	NN	NN	_	13	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	MCP-1	_	JJ	JJ	_	8	NMOD	_	_
8	gene	_	NN	NN	_	5	PMOD	_	_
9	in	_	IN	IN	_	4	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	also	_	RB	RB	_	13	ADV	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	blocked	_	VBN	VBN	_	13	VC	_	_
15	by	_	IN	IN	_	14	LGS	_	_
16	inhibitors	_	NNS	NNS	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	two	_	CD	CD	_	20	NMOD	_	_
19	transcription	_	NN	NN	_	20	NMOD	_	_
20	factors	_	NNS	NNS	_	17	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	i.e.	_	FW	FW	_	24	NMOD	_	_
23	,	_	,	,	_	24	P	_	_
24	curcumin	_	NN	NN	_	20	NMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	an	_	DT	DT	_	27	NMOD	_	_
27	inhibitor	_	NN	NN	_	24	NMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	AP-1	_	NN	NN	_	28	PMOD	_	_
30	,	_	,	,	_	24	P	_	_
31	and	_	CC	CC	_	24	CC	_	_
32	pyrolidine	_	NN	NN	_	33	NMOD	_	_
33	dithiocarbamate	_	NN	NN	_	24	COORD	_	_
34	,	_	,	,	_	33	P	_	_
35	an	_	DT	DT	_	36	NMOD	_	_
36	inhibitor	_	NN	NN	_	33	NMOD	_	_
37	of	_	IN	IN	_	36	NMOD	_	_
38	NF-kappaB	_	NN	NN	_	37	PMOD	_	_
39	.	_	.	.	_	13	P	_	_

1	Both	_	DT	DT	_	2	NMOD	_	_
2	inhibitors	_	NNS	NNS	_	3	SBJ	_	_
3	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
4	monocyte	_	NN	NN	_	6	NMOD	_	_
5	chemotactic	_	JJ	JJ	_	6	NMOD	_	_
6	activity	_	NN	NN	_	3	OBJ	_	_
7	in	_	IN	IN	_	3	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	culture	_	NN	NN	_	7	PMOD	_	_
10	supernatant	_	JJ	JJ	_	9	NMOD	_	_
11	of	_	IN	IN	_	9	NMOD	_	_
12	P-LPS-treated	_	JJ	JJ	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	.	_	.	.	_	3	P	_	_

1	Gel	_	NN	NN	_	4	NMOD	_	_
2	shift	_	NN	NN	_	4	NMOD	_	_
3	mobility	_	NN	NN	_	4	NMOD	_	_
4	assay	_	NN	NN	_	5	SBJ	_	_
5	showed	_	VBD	VBD	_	0	ROOT-S	_	_
6	stimulation	_	NN	NN	_	5	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	AP-1	_	NN	NN	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	NF-kappaB	_	NN	NN	_	9	COORD	_	_
12	contents	_	NNS	NNS	_	7	PMOD	_	_
13	in	_	IN	IN	_	6	NMOD	_	_
14	P-LPS-treated	_	JJ	JJ	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	13	PMOD	_	_
16	.	_	.	.	_	5	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	study	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	first	_	JJ	JJ	_	3	PRD	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	demonstrate	_	VB	VB	_	5	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	expression	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	CD14	_	NN	NN	_	10	PMOD	_	_
12	in	_	IN	IN	_	9	NMOD	_	_
13	human	_	JJ	JJ	_	15	NMOD	_	_
14	gingival	_	JJ	JJ	_	15	NMOD	_	_
15	fibroblasts	_	NNS	NNS	_	12	PMOD	_	_
16	and	_	CC	CC	_	7	CC	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	show	_	VB	VB	_	7	COORD	_	_
19	that	_	IN	IN	_	18	OBJ	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	signal-transducing	_	JJ	JJ	_	22	NMOD	_	_
22	pathway	_	NN	NN	_	28	SBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	P-LPS	_	NN	NN	_	23	PMOD	_	_
25	in	_	IN	IN	_	22	NMOD	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	is	_	VBZ	VBZ	_	19	VMOD	_	_
29	mediated	_	VBN	VBN	_	28	VC	_	_
30	by	_	IN	IN	_	29	LGS	_	_
31	CD14	_	NN	NN	_	30	PMOD	_	_
32	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	catalytic	_	JJ	JJ	_	3	NMOD	_	_
3	domain	_	NN	NN	_	13	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	pp56-LRB-lck-RRB-	_	NN	NN	_	4	PMOD	_	_
6	,	_	,	,	_	3	P	_	_
7	but	_	CC	CC	_	3	CC	_	_
8	not	_	RB	RB	_	7	COORD	_	_
9	its	_	PRP$	PRP$	_	11	NMOD	_	_
10	regulatory	_	JJ	JJ	_	11	NMOD	_	_
11	domain	_	NN	NN	_	3	COORD	_	_
12	,	_	,	,	_	3	P	_	_
13	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	sufficient	_	JJ	JJ	_	13	PRD	_	_
15	for	_	IN	IN	_	14	AMOD	_	_
16	inducing	_	VBG	VBG	_	15	PMOD	_	_
17	IL-2	_	NN	NN	_	18	NMOD	_	_
18	production	_	NN	NN	_	16	OBJ	_	_
19	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	lymphoid	_	JJ	JJ	_	5	NMOD	_	_
3	src	_	NN	NN	_	5	NMOD	_	_
4	kinase	_	NN	NN	_	5	NMOD	_	_
5	pp56-LRB-lck-RRB-	_	NN	NN	_	6	SBJ	_	_
6	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	been	_	VBN	VBN	_	6	VC	_	_
8	shown	_	VBN	VBN	_	7	VC	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	be	_	VB	VB	_	8	OBJ	_	_
11	essential	_	JJ	JJ	_	10	PRD	_	_
12	for	_	IN	IN	_	11	AMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	induction	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	different	_	JJ	JJ	_	19	NMOD	_	_
17	T	_	NN	NN	_	19	NMOD	_	_
18	lymphocyte	_	NN	NN	_	19	NMOD	_	_
19	responses	_	NNS	NNS	_	15	PMOD	_	_
20	,	_	,	,	_	19	P	_	_
21	including	_	VBG	VBG	_	19	NMOD	_	_
22	CD4-mediated	_	JJ	JJ	_	23	NMOD	_	_
23	enhancement	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	Ag-induced	_	JJ	JJ	_	28	NMOD	_	_
26	T	_	NN	NN	_	28	NMOD	_	_
27	cell	_	NN	NN	_	28	NMOD	_	_
28	activation	_	NN	NN	_	24	PMOD	_	_
29	,	_	,	,	_	23	P	_	_
30	early	_	JJ	JJ	_	33	NMOD	_	_
31	T	_	NN	NN	_	33	NMOD	_	_
32	cell	_	NN	NN	_	33	NMOD	_	_
33	differentiation	_	NN	NN	_	23	COORD	_	_
34	,	_	,	,	_	23	P	_	_
35	induction	_	NN	NN	_	23	COORD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	IL-2	_	NN	NN	_	38	NMOD	_	_
38	production	_	NN	NN	_	36	PMOD	_	_
39	,	_	,	,	_	23	P	_	_
40	and	_	CC	CC	_	23	CC	_	_
41	cytotoxicity	_	NN	NN	_	23	COORD	_	_
42	.	_	.	.	_	6	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	assumed	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	pp56-LRB-lck-RRB-	_	NN	NN	_	6	SBJ	_	_
6	acts	_	VBZ	VBZ	_	4	VMOD	_	_
7	on	_	IN	IN	_	6	ADV	_	_
8	these	_	DT	DT	_	9	NMOD	_	_
9	processes	_	NNS	NNS	_	7	PMOD	_	_
10	by	_	IN	IN	_	6	ADV	_	_
11	phosphorylating	_	VBG	VBG	_	10	PMOD	_	_
12	substrates	_	NNS	NNS	_	11	OBJ	_	_
13	.	_	.	.	_	2	P	_	_

1	However	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	it	_	PRP	PRP	_	4	SBJ	_	_
4	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	been	_	VBN	VBN	_	4	VC	_	_
6	recently	_	RB	RB	_	5	TMP	_	_
7	reported	_	VBN	VBN	_	5	VC	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	NH2	_	NN	NN	_	12	NMOD	_	_
11	regulatory	_	JJ	JJ	_	12	NMOD	_	_
12	domain	_	NN	NN	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	8	VMOD	_	_
14	sufficient	_	JJ	JJ	_	13	PRD	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	mediate	_	VB	VB	_	14	AMOD	_	_
17	CD4	_	NN	NN	_	19	NMOD	_	_
18	accessory	_	JJ	JJ	_	19	NMOD	_	_
19	function	_	NN	NN	_	16	OBJ	_	_
20	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	address	_	VBP	VBP	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	contribution	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	regulatory	_	JJ	JJ	_	13	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	catalytic	_	JJ	JJ	_	10	COORD	_	_
13	domains	_	NNS	NNS	_	8	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	pp56-LRB-lck-RRB-	_	NN	NN	_	14	PMOD	_	_
16	to	_	TO	TO	_	7	NMOD	_	_
17	another	_	DT	DT	_	18	NMOD	_	_
18	function	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	this	_	DT	DT	_	21	NMOD	_	_
21	enzyme	_	NN	NN	_	19	PMOD	_	_
22	independent	_	JJ	JJ	_	18	NMOD	_	_
23	of	_	IN	IN	_	22	AMOD	_	_
24	CD4	_	NN	NN	_	23	PMOD	_	_
25	:	_	:	:	_	7	P	_	_
26	TCR-induced	_	JJ	JJ	_	28	NMOD	_	_
27	IL-2	_	NN	NN	_	28	NMOD	_	_
28	production	_	NN	NN	_	7	NMOD	_	_
29	.	_	.	.	_	5	P	_	_

1	Two	_	CD	CD	_	3	NMOD	_	_
2	pp56-LRB-lck-RRB-	_	NN	NN	_	3	NMOD	_	_
3	mutants	_	NNS	NNS	_	16	SBJ	_	_
4	lacking	_	VBG	VBG	_	3	NMOD	_	_
5	either	_	CC	CC	_	9	CC	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	entire	_	JJ	JJ	_	9	NMOD	_	_
8	catalytic	_	JJ	JJ	_	9	NMOD	_	_
9	domain	_	NN	NN	_	4	OBJ	_	_
10	or	_	CC	CC	_	9	CC	_	_
11	the	_	DT	DT	_	15	NMOD	_	_
12	entire	_	JJ	JJ	_	15	NMOD	_	_
13	NH2	_	NN	NN	_	15	NMOD	_	_
14	regulatory	_	JJ	JJ	_	15	NMOD	_	_
15	domain	_	NN	NN	_	9	COORD	_	_
16	were	_	VBD	VBD	_	0	ROOT-S	_	_
17	generated	_	VBN	VBN	_	16	VC	_	_
18	,	_	,	,	_	16	P	_	_
19	and	_	CC	CC	_	16	CC	_	_
20	their	_	PRP$	PRP$	_	21	NMOD	_	_
21	abilities	_	NNS	NNS	_	42	SBJ	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	trigger	_	VB	VB	_	21	NMOD	_	_
24	transactivation	_	NN	NN	_	23	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	37	NMOD	_	_
27	TCR-regulated	_	JJ	JJ	_	37	NMOD	_	_
28	nuclear	_	JJ	JJ	_	29	NMOD	_	_
29	factor	_	NN	NN	_	37	NMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	activated	_	VBN	VBN	_	33	NMOD	_	_
32	T	_	NN	NN	_	33	NMOD	_	_
33	cells	_	NNS	NNS	_	30	PMOD	_	_
34	(	_	(	(	_	35	P	_	_
35	NF-AT	_	NN	NN	_	29	PRN	_	_
36	)	_	)	)	_	35	P	_	_
37	region	_	NN	NN	_	25	PMOD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	the	_	DT	DT	_	41	NMOD	_	_
40	IL-2	_	NN	NN	_	41	NMOD	_	_
41	promoter	_	NN	NN	_	38	PMOD	_	_
42	were	_	VBD	VBD	_	16	COORD	_	_
43	compared	_	VBN	VBN	_	42	VC	_	_
44	.	_	.	.	_	16	P	_	_

1	Only	_	RB	RB	_	11	NMOD	_	_
2	the	_	DT	DT	_	11	NMOD	_	_
3	catalytic	_	JJ	JJ	_	11	NMOD	_	_
4	,	_	,	,	_	11	P	_	_
5	but	_	CC	CC	_	11	CC	_	_
6	not	_	RB	RB	_	5	COORD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	NH2	_	NN	NN	_	11	COORD	_	_
9	regulatory	_	JJ	JJ	_	8	NMOD	_	_
10	,	_	,	,	_	11	P	_	_
11	domain	_	NN	NN	_	14	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	pp56-LRB-lck-RRB-	_	NN	NN	_	12	PMOD	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	able	_	JJ	JJ	_	14	PRD	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	induce	_	VB	VB	_	15	AMOD	_	_
18	NF-AT	_	NN	NN	_	20	NMOD	_	_
19	region	_	NN	NN	_	20	NMOD	_	_
20	transactivation	_	NN	NN	_	17	OBJ	_	_
21	on	_	IN	IN	_	17	ADV	_	_
22	its	_	PRP$	PRP$	_	23	NMOD	_	_
23	own	_	JJ	JJ	_	21	PMOD	_	_
24	and	_	CC	CC	_	17	CC	_	_
25	to	_	TO	TO	_	26	VMOD	_	_
26	cooperate	_	VB	VB	_	17	COORD	_	_
27	with	_	IN	IN	_	26	ADV	_	_
28	other	_	JJ	JJ	_	30	NMOD	_	_
29	intracellular	_	JJ	JJ	_	30	NMOD	_	_
30	signals	_	NNS	NNS	_	27	PMOD	_	_
31	to	_	TO	TO	_	32	VMOD	_	_
32	trigger	_	VB	VB	_	26	OBJ	_	_
33	this	_	DT	DT	_	34	NMOD	_	_
34	response	_	NN	NN	_	32	OBJ	_	_
35	.	_	.	.	_	14	P	_	_

1	Moreover	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	catalytic	_	JJ	JJ	_	5	NMOD	_	_
5	domain	_	NN	NN	_	8	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	pp56-LRB-lck-RRB-	_	NN	NN	_	6	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	able	_	JJ	JJ	_	8	PRD	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	induce	_	VB	VB	_	9	AMOD	_	_
12	IL-2	_	NN	NN	_	14	NMOD	_	_
13	cytokine	_	NN	NN	_	14	NMOD	_	_
14	production	_	NN	NN	_	11	OBJ	_	_
15	to	_	TO	TO	_	11	ADV	_	_
16	an	_	DT	DT	_	17	NMOD	_	_
17	extent	_	NN	NN	_	15	PMOD	_	_
18	similar	_	JJ	JJ	_	17	NMOD	_	_
19	to	_	TO	TO	_	18	AMOD	_	_
20	that	_	DT	DT	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	wild-type	_	JJ	JJ	_	23	NMOD	_	_
23	pp56-LRB-lck-RRB-	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	8	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	conclude	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	different	_	JJ	JJ	_	5	NMOD	_	_
5	domains	_	NNS	NNS	_	10	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	pp56-LRB-lck-RRB-	_	NN	NN	_	9	NMOD	_	_
9	molecule	_	NN	NN	_	6	PMOD	_	_
10	contribute	_	VBP	VBP	_	3	VMOD	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	regulate	_	VB	VB	_	10	OBJ	_	_
13	distinct	_	JJ	JJ	_	15	NMOD	_	_
14	biologic	_	JJ	JJ	_	15	NMOD	_	_
15	functions	_	NNS	NNS	_	12	OBJ	_	_
16	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	18	ADV	_	_
2	fact	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	18	P	_	_
4	while	_	IN	IN	_	18	ADV	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	NH2	_	NN	NN	_	8	NMOD	_	_
7	regulatory	_	JJ	JJ	_	8	NMOD	_	_
8	domain	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	4	VMOD	_	_
10	sufficient	_	JJ	JJ	_	9	PRD	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	mediate	_	VB	VB	_	10	AMOD	_	_
13	CD4	_	NN	NN	_	15	NMOD	_	_
14	accessory	_	JJ	JJ	_	15	NMOD	_	_
15	function	_	NN	NN	_	12	OBJ	_	_
16	,	_	,	,	_	18	P	_	_
17	we	_	PRP	PRP	_	18	SBJ	_	_
18	show	_	VBP	VBP	_	0	ROOT-S	_	_
19	here	_	RB	RB	_	18	ADV	_	_
20	that	_	IN	IN	_	18	OBJ	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	catalytic	_	JJ	JJ	_	23	NMOD	_	_
23	domain	_	NN	NN	_	26	SBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	pp56-LRB-lck-RRB-	_	NN	NN	_	24	PMOD	_	_
26	is	_	VBZ	VBZ	_	20	VMOD	_	_
27	sufficient	_	JJ	JJ	_	26	PRD	_	_
28	for	_	IN	IN	_	27	AMOD	_	_
29	induction	_	NN	NN	_	28	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	IL-2	_	NN	NN	_	32	NMOD	_	_
32	production	_	NN	NN	_	30	PMOD	_	_
33	,	_	,	,	_	26	P	_	_
34	mimicking	_	VBG	VBG	_	26	VC	_	_
35	TCR	_	NN	NN	_	36	NMOD	_	_
36	ligation	_	NN	NN	_	34	OBJ	_	_
37	.	_	.	.	_	18	P	_	_

1	Isolation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	characterization	_	NN	NN	_	1	COORD	_	_
4	of	_	IN	IN	_	1	NMOD	_	_
5	murine	_	JJ	JJ	_	6	NMOD	_	_
6	fra-1	_	NN	NN	_	4	PMOD	_	_
7	:	_	:	:	_	1	P	_	_
8	induction	_	NN	NN	_	15	SBJ	_	_
9	mediated	_	VBN	VBN	_	8	NMOD	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	CD40	_	NN	NN	_	10	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	surface	_	NN	NN	_	14	NMOD	_	_
14	Ig	_	NN	NN	_	11	COORD	_	_
15	is	_	VBZ	VBZ	_	1	NMOD	_	_
16	protein	_	NN	NN	_	18	NMOD	_	_
17	kinase	_	NN	NN	_	18	NMOD	_	_
18	C	_	NN	NN	_	19	AMOD	_	_
19	dependent	_	JJ	JJ	_	15	PRD	_	_
20	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	murine	_	JJ	JJ	_	4	NMOD	_	_
3	fra-1	_	NN	NN	_	4	NMOD	_	_
4	gene	_	NN	NN	_	11	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	encoding	_	VBG	VBG	_	4	NMOD	_	_
7	Fos-related	_	JJ	JJ	_	8	NMOD	_	_
8	Ag	_	NN	NN	_	6	OBJ	_	_
9	1	_	CD	CD	_	8	NMOD	_	_
10	,	_	,	,	_	4	P	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	isolated	_	VBN	VBN	_	11	VC	_	_
13	from	_	IN	IN	_	12	ADV	_	_
14	a	_	DT	DT	_	17	NMOD	_	_
15	splenic	_	JJ	JJ	_	17	NMOD	_	_
16	cDNA	_	NN	NN	_	17	NMOD	_	_
17	library	_	NN	NN	_	13	PMOD	_	_
18	and	_	CC	CC	_	12	CC	_	_
19	sequenced	_	VBN	VBN	_	12	COORD	_	_
20	.	_	.	.	_	11	P	_	_

1	Murine	_	JJ	JJ	_	2	NMOD	_	_
2	fra-1	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	highly	_	RB	RB	_	5	AMOD	_	_
5	homologous	_	JJ	JJ	_	3	PRD	_	_
6	to	_	TO	TO	_	5	AMOD	_	_
7	rat	_	NN	NN	_	10	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	human	_	JJ	JJ	_	7	COORD	_	_
10	fra-1	_	NN	NN	_	6	PMOD	_	_
11	.	_	.	.	_	3	P	_	_

1	Oligonucleotide	_	NN	NN	_	2	NMOD	_	_
2	primers	_	NNS	NNS	_	8	SBJ	_	_
3	based	_	VBN	VBN	_	2	NMOD	_	_
4	on	_	IN	IN	_	3	PMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	murine	_	JJ	JJ	_	7	NMOD	_	_
7	sequence	_	NN	NN	_	4	PMOD	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	used	_	VBN	VBN	_	8	VC	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	construct	_	VB	VB	_	9	OBJ	_	_
12	a	_	DT	DT	_	16	NMOD	_	_
13	quantitative	_	JJ	JJ	_	16	NMOD	_	_
14	reverse	_	NN	NN	_	16	NMOD	_	_
15	transcription-PCR	_	NN	NN	_	16	NMOD	_	_
16	assay	_	NN	NN	_	11	OBJ	_	_
17	for	_	IN	IN	_	16	NMOD	_	_
18	gene	_	NN	NN	_	19	NMOD	_	_
19	expression	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	8	P	_	_

1	B	_	NN	NN	_	3	NMOD	_	_
2	lymphocyte	_	NN	NN	_	3	NMOD	_	_
3	stimulation	_	NN	NN	_	15	SBJ	_	_
4	via	_	IN	IN	_	3	NMOD	_	_
5	both	_	CC	CC	_	6	CC	_	_
6	CD40	_	NN	NN	_	13	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	surface	_	NN	NN	_	9	NMOD	_	_
9	Ig	_	NN	NN	_	6	COORD	_	_
10	(	_	(	(	_	11	P	_	_
11	sIg	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	receptors	_	NNS	NNS	_	4	PMOD	_	_
14	substantially	_	RB	RB	_	15	ADV	_	_
15	induced	_	VBD	VBD	_	0	ROOT-S	_	_
16	fra-1	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	15	OBJ	_	_
18	,	_	,	,	_	15	P	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	for	_	IN	IN	_	25	ADV	_	_
21	both	_	DT	DT	_	22	NMOD	_	_
22	receptors	_	NNS	NNS	_	20	PMOD	_	_
23	,	_	,	,	_	25	P	_	_
24	induction	_	NN	NN	_	25	SBJ	_	_
25	was	_	VBD	VBD	_	15	COORD	_	_
26	protein	_	NN	NN	_	28	NMOD	_	_
27	kinase	_	NN	NN	_	28	NMOD	_	_
28	C	_	NN	NN	_	32	AMOD	_	_
29	(	_	(	(	_	30	P	_	_
30	PKC	_	NN	NN	_	28	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	dependent	_	JJ	JJ	_	25	PRD	_	_
33	.	_	.	.	_	15	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	contrasts	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	with	_	IN	IN	_	2	ADV	_	_
4	induction	_	NN	NN	_	3	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	c-fos	_	NN	NN	_	5	PMOD	_	_
7	by	_	IN	IN	_	4	NMOD	_	_
8	both	_	CC	CC	_	9	CC	_	_
9	CD40	_	NN	NN	_	7	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	sIg	_	NN	NN	_	9	COORD	_	_
12	,	_	,	,	_	4	P	_	_
13	which	_	WDT	WDT	_	14	SBJ	_	_
14	is	_	VBZ	VBZ	_	4	NMOD	_	_
15	PKC	_	NN	NN	_	14	PRD	_	_
16	independent	_	JJ	JJ	_	15	AMOD	_	_
17	and	_	CC	CC	_	14	CC	_	_
18	indicates	_	VBZ	VBZ	_	14	COORD	_	_
19	that	_	IN	IN	_	18	OBJ	_	_
20	CD40	_	NN	NN	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	19	VMOD	_	_
22	capable	_	JJ	JJ	_	21	PRD	_	_
23	of	_	IN	IN	_	22	AMOD	_	_
24	signaling	_	VBG	VBG	_	23	PMOD	_	_
25	through	_	IN	IN	_	24	ADV	_	_
26	PKC	_	NN	NN	_	25	PMOD	_	_
27	or	_	CC	CC	_	26	CC	_	_
28	a	_	DT	DT	_	31	NMOD	_	_
29	closely	_	RB	RB	_	30	AMOD	_	_
30	related	_	JJ	JJ	_	31	NMOD	_	_
31	kinase	_	NN	NN	_	26	COORD	_	_
32	.	_	.	.	_	2	P	_	_

1	Induction	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	fra-1	_	NN	NN	_	2	PMOD	_	_
4	following	_	VBG	VBG	_	1	TMP	_	_
5	engagement	_	NN	NN	_	4	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	CD40	_	NN	NN	_	6	PMOD	_	_
8	did	_	VBD	VBD	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	require	_	VB	VB	_	8	VC	_	_
11	protein	_	NN	NN	_	12	NMOD	_	_
12	synthesis	_	NN	NN	_	10	IOBJ	_	_
13	,	_	,	,	_	10	P	_	_
14	suggesting	_	VBG	VBG	_	10	OBJ	_	_
15	that	_	IN	IN	_	14	OBJ	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	PKC-dependent	_	JJ	JJ	_	18	NMOD	_	_
18	linkage	_	NN	NN	_	23	SBJ	_	_
19	between	_	IN	IN	_	18	NMOD	_	_
20	CD40	_	NN	NN	_	19	PMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	fra-1	_	NN	NN	_	20	COORD	_	_
23	is	_	VBZ	VBZ	_	15	VMOD	_	_
24	direct	_	JJ	JJ	_	23	PRD	_	_
25	.	_	.	.	_	8	P	_	_

1	CD40-mediated	_	JJ	JJ	_	3	NMOD	_	_
2	fra-1	_	NN	NN	_	3	NMOD	_	_
3	induction	_	NN	NN	_	4	SBJ	_	_
4	did	_	VBD	VBD	_	0	ROOT-S	_	_
5	require	_	VB	VB	_	4	VC	_	_
6	tyrosine	_	NN	NN	_	8	NMOD	_	_
7	kinase	_	NN	NN	_	8	NMOD	_	_
8	activity	_	NN	NN	_	5	OBJ	_	_
9	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	CD40	_	NN	NN	_	10	SBJ	_	_
6	,	_	,	,	_	10	P	_	_
7	like	_	IN	IN	_	10	ADV	_	_
8	sIg	_	NN	NN	_	7	PMOD	_	_
9	,	_	,	,	_	10	P	_	_
10	may	_	MD	MD	_	4	VMOD	_	_
11	employ	_	VB	VB	_	10	VC	_	_
12	PKC	_	NN	NN	_	11	OBJ	_	_
13	in	_	IN	IN	_	11	ADV	_	_
14	producing	_	VBG	VBG	_	13	PMOD	_	_
15	select	_	JJ	JJ	_	16	NMOD	_	_
16	outcomes	_	NNS	NNS	_	14	OBJ	_	_
17	,	_	,	,	_	4	P	_	_
18	that	_	IN	IN	_	4	COORD	_	_
19	individual	_	JJ	JJ	_	22	NMOD	_	_
20	B	_	NN	NN	_	22	NMOD	_	_
21	cell	_	NN	NN	_	22	NMOD	_	_
22	receptors	_	NNS	NNS	_	23	SBJ	_	_
23	may	_	MD	MD	_	18	VMOD	_	_
24	signal	_	VB	VB	_	23	VC	_	_
25	downstream	_	JJ	JJ	_	26	NMOD	_	_
26	events	_	NNS	NNS	_	24	OBJ	_	_
27	via	_	IN	IN	_	24	ADV	_	_
28	both	_	CC	CC	_	29	CC	_	_
29	PKC-dependent	_	JJ	JJ	_	32	NMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	PKC-independent	_	JJ	JJ	_	29	COORD	_	_
32	pathways	_	NNS	NNS	_	27	PMOD	_	_
33	,	_	,	,	_	4	P	_	_
34	and	_	CC	CC	_	4	CC	_	_
35	that	_	IN	IN	_	4	COORD	_	_
36	multiple	_	JJ	JJ	_	39	NMOD	_	_
37	signal	_	NN	NN	_	39	NMOD	_	_
38	transduction	_	NN	NN	_	39	NMOD	_	_
39	pathways	_	NNS	NNS	_	40	SBJ	_	_
40	may	_	MD	MD	_	35	VMOD	_	_
41	be	_	VB	VB	_	40	VC	_	_
42	used	_	VBN	VBN	_	41	VC	_	_
43	to	_	TO	TO	_	44	VMOD	_	_
44	activate	_	VB	VB	_	42	OBJ	_	_
45	the	_	DT	DT	_	46	NMOD	_	_
46	expression	_	NN	NN	_	44	OBJ	_	_
47	of	_	IN	IN	_	46	NMOD	_	_
48	closely	_	RB	RB	_	49	AMOD	_	_
49	related	_	JJ	JJ	_	50	NMOD	_	_
50	genes	_	NNS	NNS	_	47	PMOD	_	_
51	.	_	.	.	_	3	P	_	_

1	Comparative	_	JJ	JJ	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	3	SBJ	_	_
3	identifies	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	conserved	_	VBN	VBN	_	12	NMOD	_	_
5	tumor	_	NN	NN	_	7	AMOD	_	_
6	necrosis	_	NN	NN	_	7	AMOD	_	_
7	factor	_	NN	NN	_	12	NMOD	_	_
8	receptor-associated	_	JJ	JJ	_	7	AMOD	_	_
9	factor	_	NN	NN	_	12	NMOD	_	_
10	3	_	CD	CD	_	12	NMOD	_	_
11	binding	_	NN	NN	_	12	NMOD	_	_
12	sites	_	NNS	NNS	_	3	OBJ	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	21	NMOD	_	_
15	human	_	JJ	JJ	_	21	NMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	simian	_	JJ	JJ	_	15	COORD	_	_
18	Epstein-Barr	_	JJ	JJ	_	21	NMOD	_	_
19	virus	_	NN	NN	_	21	NMOD	_	_
20	oncogene	_	NN	NN	_	21	NMOD	_	_
21	LMP1	_	NN	NN	_	13	PMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	Nonhuman	_	JJ	JJ	_	2	NMOD	_	_
2	primates	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	naturally	_	RB	RB	_	5	ADV	_	_
5	infected	_	VBN	VBN	_	3	VC	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	B-lymphotropic	_	JJ	JJ	_	9	NMOD	_	_
9	herpesvirus	_	NN	NN	_	6	PMOD	_	_
10	closely	_	RB	RB	_	9	NMOD	_	_
11	related	_	JJ	JJ	_	10	AMOD	_	_
12	to	_	TO	TO	_	10	AMOD	_	_
13	Epstein-Barr	_	JJ	JJ	_	14	NMOD	_	_
14	virus	_	NN	NN	_	12	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	EBV	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	3	NMOD	_	_
2	simian	_	JJ	JJ	_	3	NMOD	_	_
3	EBV	_	NNS	NNS	_	4	SBJ	_	_
4	share	_	VBP	VBP	_	0	ROOT-S	_	_
5	considerable	_	JJ	JJ	_	12	NMOD	_	_
6	genetic	_	JJ	JJ	_	12	NMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	biologic	_	JJ	JJ	_	6	COORD	_	_
9	,	_	,	,	_	6	P	_	_
10	and	_	CC	CC	_	6	CC	_	_
11	epidemiologic	_	JJ	JJ	_	6	COORD	_	_
12	features	_	NNS	NNS	_	4	OBJ	_	_
13	with	_	IN	IN	_	4	ADV	_	_
14	human	_	JJ	JJ	_	15	NMOD	_	_
15	EBV	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	4	P	_	_
17	including	_	VBG	VBG	_	4	ADV	_	_
18	virus-induced	_	JJ	JJ	_	19	NMOD	_	_
19	tumorigenesis	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	4	P	_	_

1	However	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	latent	_	JJ	JJ	_	7	NMOD	_	_
4	,	_	,	,	_	3	P	_	_
5	transformation-associated	_	JJ	JJ	_	3	COORD	_	_
6	viral	_	JJ	JJ	_	7	NMOD	_	_
7	genes	_	NNS	NNS	_	8	SBJ	_	_
8	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
9	marked	_	JJ	JJ	_	11	NMOD	_	_
10	sequence	_	NN	NN	_	11	NMOD	_	_
11	divergence	_	NN	NN	_	8	OBJ	_	_
12	among	_	IN	IN	_	11	NMOD	_	_
13	species	_	NNS	NNS	_	12	PMOD	_	_
14	despite	_	IN	IN	_	8	ADV	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	conserved	_	VBN	VBN	_	17	NMOD	_	_
17	functions	_	NNS	NNS	_	14	PMOD	_	_
18	.	_	.	.	_	8	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	cloned	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	12	NMOD	_	_
5	latent	_	JJ	JJ	_	7	NMOD	_	_
6	membrane	_	NN	NN	_	7	NMOD	_	_
7	protein	_	NN	NN	_	12	NMOD	_	_
8	1	_	CD	CD	_	7	NMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	LMP1	_	NN	NN	_	7	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	homologs	_	NNS	NNS	_	3	OBJ	_	_
13	from	_	IN	IN	_	3	ADV	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	simian	_	JJ	JJ	_	16	NMOD	_	_
16	EBV	_	NN	NN	_	13	PMOD	_	_
17	naturally	_	RB	RB	_	18	ADV	_	_
18	infecting	_	VBG	VBG	_	16	NMOD	_	_
19	baboons	_	NNS	NNS	_	18	OBJ	_	_
20	(	_	(	(	_	22	P	_	_
21	cercopithicine	_	NN	NN	_	22	NMOD	_	_
22	herpesvirus	_	NN	NN	_	16	PRN	_	_
23	12	_	CD	CD	_	22	NMOD	_	_
24	,	_	,	,	_	22	P	_	_
25	herpesvirus	_	NN	NN	_	26	NMOD	_	_
26	papio	_	NN	NN	_	22	NMOD	_	_
27	)	_	)	)	_	22	P	_	_
28	and	_	CC	CC	_	16	CC	_	_
29	rhesus	_	NN	NN	_	30	NMOD	_	_
30	monkeys	_	NNS	NNS	_	19	GAP	_	_
31	(	_	(	(	_	33	P	_	_
32	cercopithicine	_	NN	NN	_	33	NMOD	_	_
33	herpesvirus	_	NN	NN	_	22	GAP	_	_
34	15	_	CD	CD	_	33	NMOD	_	_
35	)	_	)	)	_	33	P	_	_
36	for	_	IN	IN	_	3	ADV	_	_
37	a	_	DT	DT	_	39	NMOD	_	_
38	comparative	_	JJ	JJ	_	39	NMOD	_	_
39	study	_	NN	NN	_	36	PMOD	_	_
40	with	_	IN	IN	_	39	NMOD	_	_
41	the	_	DT	DT	_	44	NMOD	_	_
42	human	_	JJ	JJ	_	44	NMOD	_	_
43	EBV	_	NN	NN	_	44	NMOD	_	_
44	oncogene	_	NN	NN	_	40	PMOD	_	_
45	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	transmembrane	_	NN	NN	_	3	NMOD	_	_
3	domains	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	well	_	RB	RB	_	6	ADV	_	_
6	conserved	_	VBN	VBN	_	4	VC	_	_
7	,	_	,	,	_	4	P	_	_
8	but	_	CC	CC	_	4	CC	_	_
9	there	_	EX	EX	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	4	COORD	_	_
11	striking	_	JJ	JJ	_	13	NMOD	_	_
12	sequence	_	NN	NN	_	13	NMOD	_	_
13	divergence	_	NN	NN	_	10	PRD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	carboxy-terminal	_	JJ	JJ	_	18	NMOD	_	_
17	cytoplasmic	_	JJ	JJ	_	18	NMOD	_	_
18	domain	_	NN	NN	_	14	PMOD	_	_
19	essential	_	JJ	JJ	_	18	NMOD	_	_
20	for	_	IN	IN	_	19	AMOD	_	_
21	B-cell	_	NN	NN	_	22	NMOD	_	_
22	immortalization	_	NN	NN	_	20	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	interaction	_	NN	NN	_	22	COORD	_	_
25	with	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	32	NMOD	_	_
27	tumor	_	NN	NN	_	32	NMOD	_	_
28	necrosis	_	NN	NN	_	32	NMOD	_	_
29	factor	_	NN	NN	_	32	NMOD	_	_
30	receptor	_	NN	NN	_	32	NMOD	_	_
31	signaling	_	NN	NN	_	32	NMOD	_	_
32	pathway	_	NN	NN	_	25	PMOD	_	_
33	.	_	.	.	_	4	P	_	_

1	Nevertheless	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	simian	_	JJ	JJ	_	6	NMOD	_	_
5	EBV	_	NN	NN	_	6	NMOD	_	_
6	LMP1s	_	NNS	NNS	_	7	SBJ	_	_
7	retain	_	VBP	VBP	_	0	ROOT-S	_	_
8	most	_	JJS	JJS	_	9	NMOD	_	_
9	functions	_	NNS	NNS	_	7	OBJ	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	common	_	NN	NN	_	10	DEP	_	_
12	with	_	IN	IN	_	10	DEP	_	_
13	EBV	_	NN	NN	_	14	NMOD	_	_
14	LMP1	_	NN	NN	_	10	PMOD	_	_
15	,	_	,	,	_	9	P	_	_
16	including	_	VBG	VBG	_	9	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	ability	_	NN	NN	_	16	PMOD	_	_
19	to	_	TO	TO	_	20	VMOD	_	_
20	induce	_	VB	VB	_	18	NMOD	_	_
21	NF--LRB-kappa-RRB-B	_	NN	NN	_	22	NMOD	_	_
22	activity	_	NN	NN	_	20	OBJ	_	_
23	in	_	IN	IN	_	20	ADV	_	_
24	human	_	JJ	JJ	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	23	PMOD	_	_
26	,	_	,	,	_	20	P	_	_
27	to	_	TO	TO	_	28	VMOD	_	_
28	bind	_	VB	VB	_	20	COORD	_	_
29	the	_	DT	DT	_	33	NMOD	_	_
30	tumor	_	NN	NN	_	31	AMOD	_	_
31	necrosis	_	NN	NN	_	33	NMOD	_	_
32	factor-associated	_	JJ	JJ	_	31	AMOD	_	_
33	factor	_	NN	NN	_	28	OBJ	_	_
34	3	_	CD	CD	_	33	NMOD	_	_
35	(	_	(	(	_	36	P	_	_
36	TRAF3	_	NN	NN	_	33	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	in	_	FW	FW	_	28	ADV	_	_
39	vitro	_	FW	FW	_	38	AMOD	_	_
40	,	_	,	,	_	20	P	_	_
41	and	_	CC	CC	_	20	CC	_	_
42	to	_	TO	TO	_	43	VMOD	_	_
43	induce	_	VB	VB	_	20	COORD	_	_
44	expression	_	NN	NN	_	43	OBJ	_	_
45	of	_	IN	IN	_	44	NMOD	_	_
46	tumor	_	NN	NN	_	47	AMOD	_	_
47	necrosis	_	NN	NN	_	49	NMOD	_	_
48	factor-responsive	_	JJ	JJ	_	47	AMOD	_	_
49	genes	_	NNS	NNS	_	45	PMOD	_	_
50	,	_	,	,	_	49	P	_	_
51	such	_	JJ	JJ	_	52	DEP	_	_
52	as	_	IN	IN	_	49	NMOD	_	_
53	ICAM1	_	NN	NN	_	52	PMOD	_	_
54	,	_	,	,	_	49	P	_	_
55	in	_	IN	IN	_	43	ADV	_	_
56	human	_	JJ	JJ	_	58	NMOD	_	_
57	B	_	NN	NN	_	58	NMOD	_	_
58	lymphocytes	_	NNS	NNS	_	55	PMOD	_	_
59	.	_	.	.	_	7	P	_	_

1	Multiple	_	JJ	JJ	_	4	NMOD	_	_
2	TRAF3	_	NN	NN	_	4	NMOD	_	_
3	binding	_	NN	NN	_	4	NMOD	_	_
4	sites	_	NNS	NNS	_	10	SBJ	_	_
5	containing	_	VBG	VBG	_	4	NMOD	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	PXQXT\/S	_	NN	NN	_	9	NMOD	_	_
8	core	_	NN	NN	_	9	NMOD	_	_
9	sequence	_	NN	NN	_	5	OBJ	_	_
10	can	_	MD	MD	_	0	ROOT-S	_	_
11	be	_	VB	VB	_	10	VC	_	_
12	identified	_	VBN	VBN	_	11	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	simian	_	JJ	JJ	_	17	NMOD	_	_
16	EBV	_	NN	NN	_	17	NMOD	_	_
17	LMP1s	_	NNS	NNS	_	13	PMOD	_	_
18	by	_	IN	IN	_	12	LGS	_	_
19	an	_	DT	DT	_	23	NMOD	_	_
20	in	_	FW	FW	_	21	AMOD	_	_
21	vitro	_	FW	FW	_	23	NMOD	_	_
22	binding	_	NN	NN	_	23	NMOD	_	_
23	assay	_	NN	NN	_	18	PMOD	_	_
24	.	_	.	.	_	10	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	PXQXT\/S-containing	_	JJ	JJ	_	3	NMOD	_	_
3	sequence	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	also	_	RB	RB	_	4	ADV	_	_
6	present	_	JJ	JJ	_	4	PRD	_	_
7	in	_	IN	IN	_	6	AMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	cytoplasmic	_	JJ	JJ	_	10	NMOD	_	_
10	domain	_	NN	NN	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	16	NMOD	_	_
13	Hodgkin	_	NN	NN	_	16	NMOD	_	_
14	's	_	POS	POS	_	13	NMOD	_	_
15	disease	_	NN	NN	_	16	NMOD	_	_
16	marker	_	NN	NN	_	11	PMOD	_	_
17	,	_	,	,	_	10	P	_	_
18	CD30	_	NN	NN	_	10	NMOD	_	_
19	,	_	,	,	_	10	P	_	_
20	and	_	CC	CC	_	4	CC	_	_
21	binds	_	VBZ	VBZ	_	4	COORD	_	_
22	TRAF3	_	NN	NN	_	21	OBJ	_	_
23	in	_	FW	FW	_	21	ADV	_	_
24	vitro	_	FW	FW	_	23	AMOD	_	_
25	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	last	_	JJ	JJ	_	5	NMOD	_	_
3	13	_	CD	CD	_	5	NMOD	_	_
4	amino	_	NN	NN	_	5	NMOD	_	_
5	acids	_	NNS	NNS	_	10	SBJ	_	_
6	containing	_	VBG	VBG	_	5	NMOD	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	PXQXT\/S	_	NN	NN	_	9	NMOD	_	_
9	sequence	_	NN	NN	_	6	OBJ	_	_
10	are	_	VBP	VBP	_	0	ROOT-S	_	_
11	highly	_	RB	RB	_	12	ADV	_	_
12	conserved	_	VBN	VBN	_	10	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	human	_	JJ	JJ	_	18	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	simian	_	JJ	JJ	_	14	COORD	_	_
17	EBV	_	NN	NN	_	18	NMOD	_	_
18	LMP1	_	NN	NN	_	13	PMOD	_	_
19	but	_	CC	CC	_	10	CC	_	_
20	do	_	VBP	VBP	_	10	COORD	_	_
21	not	_	RB	RB	_	20	VMOD	_	_
22	bind	_	VB	VB	_	20	VC	_	_
23	TRAF3	_	NN	NN	_	22	OBJ	_	_
24	,	_	,	,	_	10	P	_	_
25	suggesting	_	VBG	VBG	_	10	VC	_	_
26	a	_	DT	DT	_	28	NMOD	_	_
27	distinct	_	JJ	JJ	_	28	NMOD	_	_
28	role	_	NN	NN	_	25	OBJ	_	_
29	for	_	IN	IN	_	28	NMOD	_	_
30	this	_	DT	DT	_	32	NMOD	_	_
31	conserved	_	VBN	VBN	_	32	NMOD	_	_
32	region	_	NN	NN	_	29	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	LMP1	_	NN	NN	_	33	PMOD	_	_
35	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	conserved	_	VBN	VBN	_	5	NMOD	_	_
3	TRAF3	_	NN	NN	_	5	NMOD	_	_
4	binding	_	NN	NN	_	5	NMOD	_	_
5	sites	_	NNS	NNS	_	15	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	LMP1	_	NN	NN	_	6	PMOD	_	_
8	and	_	CC	CC	_	5	CC	_	_
9	the	_	DT	DT	_	14	NMOD	_	_
10	CD30	_	NN	NN	_	14	NMOD	_	_
11	Hodgkin	_	NN	NN	_	14	NMOD	_	_
12	's	_	POS	POS	_	11	NMOD	_	_
13	disease	_	NN	NN	_	14	NMOD	_	_
14	marker	_	NN	NN	_	5	COORD	_	_
15	provides	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	further	_	JJ	JJ	_	17	NMOD	_	_
17	evidence	_	NN	NN	_	15	OBJ	_	_
18	that	_	IN	IN	_	17	NMOD	_	_
19	a	_	DT	DT	_	23	NMOD	_	_
20	TRAF3-mediated	_	JJ	JJ	_	23	NMOD	_	_
21	signal	_	NN	NN	_	23	NMOD	_	_
22	transduction	_	NN	NN	_	23	NMOD	_	_
23	pathway	_	NN	NN	_	24	SBJ	_	_
24	may	_	MD	MD	_	18	VMOD	_	_
25	be	_	VB	VB	_	24	VC	_	_
26	important	_	JJ	JJ	_	25	PRD	_	_
27	in	_	IN	IN	_	26	AMOD	_	_
28	malignant	_	JJ	JJ	_	29	NMOD	_	_
29	transformation	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	15	P	_	_

1	Rapid	_	JJ	JJ	_	2	NMOD	_	_
2	shuttling	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NF-AT	_	NN	NN	_	3	PMOD	_	_
5	in	_	IN	IN	_	2	NMOD	_	_
6	discrimination	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	Ca2+	_	NN	NN	_	9	NMOD	_	_
9	signals	_	NNS	NNS	_	7	PMOD	_	_
10	and	_	CC	CC	_	6	CC	_	_
11	immunosuppression	_	NN	NN	_	6	COORD	_	_
12	.	_	.	.	_	2	P	_	_

1	Cells	_	NNS	NNS	_	2	SBJ	_	_
2	need	_	VBP	VBP	_	0	ROOT-S	_	_
3	to	_	TO	TO	_	4	VMOD	_	_
4	distinguish	_	VB	VB	_	2	OBJ	_	_
5	between	_	IN	IN	_	4	ADV	_	_
6	transient	_	JJ	JJ	_	8	NMOD	_	_
7	Ca2+	_	NN	NN	_	8	NMOD	_	_
8	signals	_	NNS	NNS	_	5	PMOD	_	_
9	that	_	WDT	WDT	_	10	SBJ	_	_
10	induce	_	VBP	VBP	_	8	NMOD	_	_
11	events	_	NNS	NNS	_	10	OBJ	_	_
12	such	_	JJ	JJ	_	13	DEP	_	_
13	as	_	IN	IN	_	11	NMOD	_	_
14	muscle	_	NN	NN	_	15	NMOD	_	_
15	contraction	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	secretion	_	NN	NN	_	15	COORD	_	_
18	,	_	,	,	_	15	P	_	_
19	adhesion	_	NN	NN	_	15	COORD	_	_
20	and	_	CC	CC	_	15	CC	_	_
21	synaptic	_	JJ	JJ	_	22	NMOD	_	_
22	transmission	_	NN	NN	_	15	COORD	_	_
23	,	_	,	,	_	8	P	_	_
24	and	_	CC	CC	_	8	CC	_	_
25	sustained	_	JJ	JJ	_	27	NMOD	_	_
26	Ca2+	_	NN	NN	_	27	NMOD	_	_
27	signals	_	NNS	NNS	_	8	COORD	_	_
28	that	_	WDT	WDT	_	29	SBJ	_	_
29	are	_	VBP	VBP	_	27	NMOD	_	_
30	involved	_	VBN	VBN	_	29	VC	_	_
31	in	_	IN	IN	_	30	ADV	_	_
32	cell	_	NN	NN	_	31	PMOD	_	_
33	proliferation	_	NN	NN	_	32	NMOD	_	_
34	and	_	CC	CC	_	33	CC	_	_
35	differentiation	_	NN	NN	_	33	COORD	_	_
36	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	latter	_	JJ	JJ	_	3	NMOD	_	_
3	class	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	events	_	NNS	NNS	_	4	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	blocked	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	lymphocytes	_	NNS	NNS	_	8	PMOD	_	_
10	by	_	IN	IN	_	7	LGS	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	immunosuppressive	_	JJ	JJ	_	13	NMOD	_	_
13	drugs	_	NNS	NNS	_	10	PMOD	_	_
14	cyclosporin	_	NN	NN	_	15	NMOD	_	_
15	A	_	NN	NN	_	13	NMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	FK506	_	NN	NN	_	15	COORD	_	_
18	,	_	,	,	_	13	P	_	_
19	which	_	WDT	WDT	_	20	SBJ	_	_
20	inhibit	_	VBP	VBP	_	13	NMOD	_	_
21	calcineurin	_	NN	NN	_	20	OBJ	_	_
22	,	_	,	,	_	21	P	_	_
23	a	_	DT	DT	_	26	NMOD	_	_
24	Ca2+-activated	_	JJ	JJ	_	26	NMOD	_	_
25	serine\/threonine	_	NN	NN	_	26	NMOD	_	_
26	phosphatase	_	NN	NN	_	21	NMOD	_	_
27	necessary	_	JJ	JJ	_	26	NMOD	_	_
28	for	_	IN	IN	_	27	AMOD	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	nuclear	_	JJ	JJ	_	31	NMOD	_	_
31	import	_	NN	NN	_	28	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	NF-AT	_	NN	NN	_	35	NMOD	_	_
34	transcription	_	NN	NN	_	35	NMOD	_	_
35	factors	_	NNS	NNS	_	32	PMOD	_	_
36	.	_	.	.	_	6	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	report	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	sustained	_	JJ	JJ	_	7	NMOD	_	_
6	high	_	JJ	JJ	_	7	NMOD	_	_
7	concentrations	_	NNS	NNS	_	16	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	Ca2+	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	7	P	_	_
11	but	_	CC	CC	_	7	CC	_	_
12	not	_	RB	RB	_	11	COORD	_	_
13	transient	_	JJ	JJ	_	14	NMOD	_	_
14	pulses	_	NNS	NNS	_	7	COORD	_	_
15	,	_	,	,	_	7	P	_	_
16	are	_	VBP	VBP	_	4	VMOD	_	_
17	required	_	VBN	VBN	_	16	VC	_	_
18	to	_	TO	TO	_	19	VMOD	_	_
19	maintain	_	VB	VB	_	17	OBJ	_	_
20	NF-AT	_	NN	NN	_	22	NMOD	_	_
21	transcription	_	NN	NN	_	22	NMOD	_	_
22	factors	_	NNS	NNS	_	19	OBJ	_	_
23	in	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	nucleus	_	NN	NN	_	23	PMOD	_	_
26	,	_	,	,	_	25	P	_	_
27	where	_	WRB	WRB	_	29	ADV	_	_
28	they	_	PRP	PRP	_	29	SBJ	_	_
29	participate	_	VBP	VBP	_	25	NMOD	_	_
30	in	_	IN	IN	_	29	ADV	_	_
31	Ca2+-dependent	_	JJ	JJ	_	32	NMOD	_	_
32	induction	_	NN	NN	_	30	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	genes	_	NNS	NNS	_	33	PMOD	_	_
35	required	_	VBN	VBN	_	34	NMOD	_	_
36	for	_	IN	IN	_	35	ADV	_	_
37	lymphocyte	_	NN	NN	_	36	PMOD	_	_
38	activation	_	NN	NN	_	37	NMOD	_	_
39	and	_	CC	CC	_	38	CC	_	_
40	proliferation	_	NN	NN	_	38	COORD	_	_
41	.	_	.	.	_	3	P	_	_

1	Furthermore	_	RB	RB	_	25	ADV	_	_
2	,	_	,	,	_	25	P	_	_
3	overexpression	_	NN	NN	_	25	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	constitutive	_	JJ	JJ	_	7	NMOD	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	localization	_	NN	NN	_	3	COORD	_	_
8	of	_	IN	IN	_	3	NMOD	_	_
9	NF-AT	_	NN	NN	_	23	NMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	but	_	CC	CC	_	9	CC	_	_
12	not	_	RB	RB	_	11	COORD	_	_
13	Jun	_	NN	NN	_	9	COORD	_	_
14	,	_	,	,	_	13	P	_	_
15	Fos	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	13	P	_	_
17	NF-kappaB	_	NN	NN	_	13	COORD	_	_
18	,	_	,	,	_	13	P	_	_
19	Oct	_	NN	NN	_	13	COORD	_	_
20	or	_	CC	CC	_	13	CC	_	_
21	Ets	_	NN	NN	_	13	COORD	_	_
22	family	_	NN	NN	_	23	NMOD	_	_
23	members	_	NNS	NNS	_	8	PMOD	_	_
24	,	_	,	,	_	3	P	_	_
25	renders	_	VBZ	VBZ	_	0	ROOT-S	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	interleukin-2	_	NN	NN	_	28	NMOD	_	_
28	enhancer	_	NN	NN	_	33	SBJ	_	_
29	in	_	IN	IN	_	28	NMOD	_	_
30	Jurkat	_	NN	NN	_	32	NMOD	_	_
31	T	_	NN	NN	_	32	NMOD	_	_
32	lymphocytes	_	NNS	NNS	_	29	PMOD	_	_
33	resistant	_	JJ	JJ	_	25	OBJ	_	_
34	to	_	TO	TO	_	33	AMOD	_	_
35	FK506	_	NN	NN	_	34	PMOD	_	_
36	and	_	CC	CC	_	35	CC	_	_
37	cyclosporin	_	NN	NN	_	38	NMOD	_	_
38	A	_	NN	NN	_	35	COORD	_	_
39	.	_	.	.	_	25	P	_	_

1	Thus	_	RB	RB	_	9	ADV	_	_
2	a	_	DT	DT	_	4	NMOD	_	_
3	primary	_	JJ	JJ	_	4	NMOD	_	_
4	effect	_	NN	NN	_	9	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	these	_	DT	DT	_	8	NMOD	_	_
7	immunosuppressive	_	JJ	JJ	_	8	NMOD	_	_
8	reagents	_	NNS	NNS	_	5	PMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	control	_	VB	VB	_	9	PRD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	subcellular	_	JJ	JJ	_	14	NMOD	_	_
14	localization	_	NN	NN	_	11	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	NF-AT	_	NN	NN	_	18	NMOD	_	_
18	family	_	NN	NN	_	15	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	transcription	_	NN	NN	_	21	NMOD	_	_
21	factors	_	NNS	NNS	_	19	PMOD	_	_
22	.	_	.	.	_	9	P	_	_

1	Interferons	_	NNS	NNS	_	2	SBJ	_	_
2	induce	_	VBP	VBP	_	0	ROOT-S	_	_
3	normal	_	JJ	JJ	_	9	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	aberrant	_	JJ	JJ	_	3	COORD	_	_
6	retinoic-acid	_	NN	NN	_	9	NMOD	_	_
7	receptors	_	NNS	NNS	_	9	NMOD	_	_
8	type	_	NN	NN	_	9	NMOD	_	_
9	alpha	_	NN	NN	_	2	OBJ	_	_
10	in	_	IN	IN	_	2	ADV	_	_
11	acute	_	JJ	JJ	_	14	NMOD	_	_
12	promyelocytic	_	JJ	JJ	_	14	NMOD	_	_
13	leukemia	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	10	PMOD	_	_
15	:	_	:	:	_	2	P	_	_
16	potentiation	_	NN	NN	_	2	VMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	induction	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	retinoid-dependent	_	JJ	JJ	_	23	NMOD	_	_
22	differentiation	_	NN	NN	_	23	NMOD	_	_
23	markers	_	NNS	NNS	_	20	PMOD	_	_
24	.	_	.	.	_	16	P	_	_

1	Treatment	_	NN	NN	_	26	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	11	NMOD	_	_
4	acute	_	JJ	JJ	_	5	AMOD	_	_
5	promyelocytic	_	JJ	JJ	_	11	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	APL	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	cell	_	NN	NN	_	11	NMOD	_	_
10	line	_	NN	NN	_	11	NMOD	_	_
11	NB4	_	NN	NN	_	2	PMOD	_	_
12	with	_	IN	IN	_	1	NMOD	_	_
13	interferon	_	NN	NN	_	14	NMOD	_	_
14	alpha	_	NN	NN	_	12	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	IFN-LRB-alpha-RRB-	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	,	_	,	,	_	14	P	_	_
19	as	_	RB	RB	_	14	CC	_	_
20	well	_	RB	RB	_	19	DEP	_	_
21	as	_	IN	IN	_	19	DEP	_	_
22	IFN-LRB-beta-RRB-	_	NN	NN	_	14	COORD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	gamma	_	NN	NN	_	22	COORD	_	_
25	,	_	,	,	_	14	P	_	_
26	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
27	in	_	IN	IN	_	26	ADV	_	_
28	an	_	DT	DT	_	30	NMOD	_	_
29	increased	_	VBN	VBN	_	30	NMOD	_	_
30	expression	_	NN	NN	_	27	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	transcripts	_	NNS	NNS	_	31	PMOD	_	_
34	coding	_	VBG	VBG	_	33	NMOD	_	_
35	for	_	IN	IN	_	34	ADV	_	_
36	retinoic-acid	_	JJ	JJ	_	39	NMOD	_	_
37	receptor	_	NN	NN	_	39	NMOD	_	_
38	type	_	NN	NN	_	39	NMOD	_	_
39	alpha	_	NN	NN	_	35	PMOD	_	_
40	(	_	(	(	_	41	P	_	_
41	RAR-LRB-alpha-RRB-	_	NN	NN	_	39	PRN	_	_
42	)	_	)	)	_	41	P	_	_
43	and	_	CC	CC	_	39	CC	_	_
44	the	_	DT	DT	_	49	NMOD	_	_
45	leukemia-specific	_	JJ	JJ	_	49	NMOD	_	_
46	retinoic	_	JJ	JJ	_	49	NMOD	_	_
47	acid	_	NN	NN	_	49	NMOD	_	_
48	receptor	_	NN	NN	_	49	NMOD	_	_
49	PML-RAR	_	NN	NN	_	39	COORD	_	_
50	.	_	.	.	_	26	P	_	_

1	Transcriptional	_	JJ	JJ	_	2	NMOD	_	_
2	induction	_	NN	NN	_	3	SBJ	_	_
3	of	_	IN	IN	_	9	SBJ	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	RAR-LRB-alpha-RRB-	_	NN	NN	_	8	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	PML-RAR	_	NN	NN	_	5	COORD	_	_
8	mRNAs	_	NNS	NNS	_	3	PMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	rapid	_	JJ	JJ	_	9	PRD	_	_
11	and	_	CC	CC	_	9	CC	_	_
12	it	_	PRP	PRP	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	9	COORD	_	_
14	parallelled	_	VBN	VBN	_	13	VC	_	_
15	by	_	IN	IN	_	14	LGS	_	_
16	an	_	DT	DT	_	17	NMOD	_	_
17	increase	_	NN	NN	_	15	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	corresponding	_	JJ	JJ	_	21	NMOD	_	_
21	proteins	_	NNS	NNS	_	18	PMOD	_	_
22	.	_	.	.	_	9	P	_	_

1	Up-regulation	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	RAR-LRB-alpha-RRB-	_	NN	NN	_	7	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	PML-RAR	_	NN	NN	_	3	COORD	_	_
6	gene	_	NN	NN	_	7	NMOD	_	_
7	expression	_	NN	NN	_	2	PMOD	_	_
8	by	_	IN	IN	_	1	NMOD	_	_
9	IFN-LRB-alpha-RRB-	_	NN	NN	_	8	PMOD	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	accompanied	_	VBN	VBN	_	10	VC	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	strong	_	JJ	JJ	_	15	NMOD	_	_
15	potentiation	_	NN	NN	_	12	PMOD	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	induction	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	2	_	CD	CD	_	23	NMOD	_	_
21	retinoid-dependent	_	JJ	JJ	_	23	NMOD	_	_
22	granulocytic	_	JJ	JJ	_	23	NMOD	_	_
23	markers	_	NNS	NNS	_	19	PMOD	_	_
24	,	_	,	,	_	23	P	_	_
25	i.e.	_	FW	FW	_	23	NMOD	_	_
26	,	_	,	,	_	23	P	_	_
27	granulocyte-colony-stimulating	_	JJ	JJ	_	30	NMOD	_	_
28	factor	_	NN	NN	_	30	NMOD	_	_
29	receptor	_	NN	NN	_	30	NMOD	_	_
30	mRNA	_	NN	NN	_	23	NMOD	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	leukocyte	_	NN	NN	_	34	NMOD	_	_
33	alkaline	_	NN	NN	_	34	NMOD	_	_
34	phosphatase	_	NN	NN	_	30	COORD	_	_
35	.	_	.	.	_	10	P	_	_

1	However	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	IFN-LRB-alpha-RRB-	_	NN	NN	_	4	SBJ	_	_
4	does	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	have	_	VB	VB	_	4	VC	_	_
7	any	_	DT	DT	_	8	NMOD	_	_
8	effects	_	NNS	NNS	_	6	OBJ	_	_
9	on	_	IN	IN	_	6	ADV	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	retinoid-dependent	_	JJ	JJ	_	12	NMOD	_	_
12	regulation	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	myeloid	_	JJ	JJ	_	17	NMOD	_	_
16	surface	_	NN	NN	_	17	NMOD	_	_
17	markers	_	NNS	NNS	_	13	PMOD	_	_
18	CD11b	_	NN	NN	_	17	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	CD33	_	NN	NN	_	18	COORD	_	_
21	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	IFN-dependent	_	JJ	JJ	_	3	NMOD	_	_
3	increase	_	NN	NN	_	19	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	RAR-LRB-alpha-RRB-	_	NN	NN	_	6	NMOD	_	_
6	levels	_	NNS	NNS	_	4	PMOD	_	_
7	and	_	CC	CC	_	3	CC	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	enhancing	_	JJ	JJ	_	10	NMOD	_	_
10	effect	_	NN	NN	_	3	COORD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	cytokine	_	NN	NN	_	11	PMOD	_	_
14	on	_	IN	IN	_	10	NMOD	_	_
15	retinoid-dependent	_	JJ	JJ	_	18	NMOD	_	_
16	granulocytic	_	JJ	JJ	_	18	NMOD	_	_
17	markers	_	NNS	NNS	_	18	NMOD	_	_
18	expression	_	NN	NN	_	14	PMOD	_	_
19	may	_	MD	MD	_	0	ROOT-S	_	_
20	be	_	VB	VB	_	19	VC	_	_
21	a	_	DT	DT	_	22	NMOD	_	_
22	characteristic	_	NN	NN	_	20	PRD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	PML-RAR	_	NN	NN	_	26	NMOD	_	_
25	positive	_	JJ	JJ	_	24	AMOD	_	_
26	cells	_	NNS	NNS	_	23	PMOD	_	_
27	,	_	,	,	_	20	P	_	_
28	since	_	IN	IN	_	20	ADV	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	phenomena	_	NNS	NNS	_	31	SBJ	_	_
31	are	_	VBP	VBP	_	28	VMOD	_	_
32	not	_	RB	RB	_	31	VMOD	_	_
33	observed	_	VBN	VBN	_	31	VC	_	_
34	in	_	IN	IN	_	33	ADV	_	_
35	HL-60	_	NN	NN	_	36	NMOD	_	_
36	promyelocytes	_	NNS	NNS	_	34	PMOD	_	_
37	.	_	.	.	_	19	P	_	_

1	Interferons	_	NNS	NNS	_	6	SBJ	_	_
2	as	_	RB	RB	_	1	CC	_	_
3	well	_	RB	RB	_	2	DEP	_	_
4	as	_	IN	IN	_	2	DEP	_	_
5	retinoids	_	NNS	NNS	_	1	COORD	_	_
6	inhibit	_	VBP	VBP	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	growth	_	NN	NN	_	6	IOBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	NB4	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	,	_	,	,	_	6	P	_	_
13	although	_	IN	IN	_	6	OBJ	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	2	_	CD	CD	_	16	NMOD	_	_
16	classes	_	NNS	NNS	_	19	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	compounds	_	NNS	NNS	_	17	PMOD	_	_
19	do	_	VBP	VBP	_	13	VMOD	_	_
20	not	_	RB	RB	_	19	VMOD	_	_
21	significantly	_	RB	RB	_	19	ADV	_	_
22	interact	_	VBP	VBP	_	19	VC	_	_
23	in	_	IN	IN	_	22	ADV	_	_
24	terms	_	NNS	NNS	_	23	DEP	_	_
25	of	_	IN	IN	_	23	DEP	_	_
26	anti-proliferative	_	JJ	JJ	_	27	NMOD	_	_
27	activity	_	NN	NN	_	23	PMOD	_	_
28	.	_	.	.	_	6	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	possible	_	JJ	JJ	_	6	NMOD	_	_
6	use	_	NN	NN	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	combinations	_	NNS	NNS	_	7	PMOD	_	_
9	between	_	IN	IN	_	8	NMOD	_	_
10	IFNs	_	NNS	NNS	_	9	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	retinoic	_	JJ	JJ	_	13	NMOD	_	_
13	acid	_	NN	NN	_	10	COORD	_	_
14	in	_	IN	IN	_	6	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	cyto-differentiating	_	JJ	JJ	_	17	NMOD	_	_
17	treatment	_	NN	NN	_	14	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	APL	_	NN	NN	_	20	NMOD	_	_
20	patients	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	An	_	DT	DT	_	4	NMOD	_	_
2	IL-2	_	NN	NN	_	4	NMOD	_	_
3	response	_	NN	NN	_	4	NMOD	_	_
4	element	_	NN	NN	_	13	SBJ	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	12	NMOD	_	_
7	human	_	JJ	JJ	_	12	NMOD	_	_
8	IL-2	_	NN	NN	_	12	NMOD	_	_
9	receptor	_	NN	NN	_	12	NMOD	_	_
10	alpha	_	NN	NN	_	12	NMOD	_	_
11	chain	_	NN	NN	_	12	NMOD	_	_
12	promoter	_	NN	NN	_	5	PMOD	_	_
13	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	composite	_	JJ	JJ	_	16	NMOD	_	_
16	element	_	NN	NN	_	13	PRD	_	_
17	that	_	WDT	WDT	_	18	SBJ	_	_
18	binds	_	VBZ	VBZ	_	16	NMOD	_	_
19	Stat5	_	NN	NN	_	18	OBJ	_	_
20	,	_	,	,	_	19	P	_	_
21	Elf-1	_	NN	NN	_	19	COORD	_	_
22	,	_	,	,	_	19	P	_	_
23	HMG-I-LRB-Y-RRB-	_	NN	NN	_	19	COORD	_	_
24	and	_	CC	CC	_	19	CC	_	_
25	a	_	DT	DT	_	28	NMOD	_	_
26	GATA	_	NN	NN	_	28	NMOD	_	_
27	family	_	NN	NN	_	28	NMOD	_	_
28	protein	_	NN	NN	_	19	COORD	_	_
29	.	_	.	.	_	13	P	_	_

1	Expression	_	NN	NN	_	13	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	12	NMOD	_	_
4	human	_	JJ	JJ	_	12	NMOD	_	_
5	interleukin-2	_	NN	NN	_	12	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	IL-2	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	receptor	_	NN	NN	_	12	NMOD	_	_
10	alpha	_	NN	NN	_	12	NMOD	_	_
11	chain	_	NN	NN	_	12	NMOD	_	_
12	gene	_	NN	NN	_	2	PMOD	_	_
13	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	potently	_	RB	RB	_	13	ADV	_	_
15	upregulated	_	VBN	VBN	_	13	VC	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	its	_	PRP$	PRP$	_	19	NMOD	_	_
18	own	_	JJ	JJ	_	19	NMOD	_	_
19	ligand	_	NN	NN	_	16	PMOD	_	_
20	,	_	,	,	_	19	P	_	_
21	IL-2	_	NN	NN	_	19	NMOD	_	_
22	.	_	.	.	_	13	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	characterize	_	VBP	VBP	_	0	ROOT-S	_	_
7	an	_	DT	DT	_	12	NMOD	_	_
8	essential	_	JJ	JJ	_	12	NMOD	_	_
9	upstream	_	JJ	JJ	_	12	NMOD	_	_
10	IL-2	_	NN	NN	_	12	NMOD	_	_
11	response	_	NN	NN	_	12	NMOD	_	_
12	element	_	NN	NN	_	6	OBJ	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	contains	_	VBZ	VBZ	_	12	NMOD	_	_
15	both	_	CC	CC	_	20	NMOD	_	_
16	consensus	_	NN	NN	_	15	COORD	_	_
17	and	_	CC	CC	_	15	CC	_	_
18	non-consensus	_	JJ	JJ	_	15	COORD	_	_
19	GAS	_	NN	NN	_	20	NMOD	_	_
20	motifs	_	NNS	NNS	_	14	OBJ	_	_
21	,	_	,	,	_	12	P	_	_
22	two	_	CD	CD	_	26	NMOD	_	_
23	putative	_	JJ	JJ	_	26	NMOD	_	_
24	Ets	_	NN	NN	_	26	NMOD	_	_
25	binding	_	NN	NN	_	26	NMOD	_	_
26	sites	_	NNS	NNS	_	12	COORD	_	_
27	(	_	(	(	_	28	P	_	_
28	EBS	_	NN	NN	_	26	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	,	_	,	,	_	26	P	_	_
31	one	_	CD	CD	_	32	NMOD	_	_
32	of	_	IN	IN	_	34	SBJ	_	_
33	which	_	WDT	WDT	_	32	PMOD	_	_
34	overlaps	_	VBZ	VBZ	_	26	NMOD	_	_
35	the	_	DT	DT	_	38	NMOD	_	_
36	consensus	_	NN	NN	_	38	NMOD	_	_
37	GAS	_	NN	NN	_	38	NMOD	_	_
38	motif	_	NN	NN	_	34	OBJ	_	_
39	,	_	,	,	_	12	P	_	_
40	and	_	CC	CC	_	12	CC	_	_
41	a	_	DT	DT	_	43	NMOD	_	_
42	GATA	_	NN	NN	_	43	NMOD	_	_
43	motif	_	NN	NN	_	12	COORD	_	_
44	,	_	,	,	_	43	P	_	_
45	which	_	WDT	WDT	_	46	SBJ	_	_
46	overlaps	_	VBZ	VBZ	_	43	NMOD	_	_
47	the	_	DT	DT	_	50	NMOD	_	_
48	non-consensus	_	JJ	JJ	_	50	NMOD	_	_
49	GAS	_	NN	NN	_	50	NMOD	_	_
50	motif	_	NN	NN	_	46	OBJ	_	_
51	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	although	_	IN	IN	_	19	ADV	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	individual	_	JJ	JJ	_	7	NMOD	_	_
7	components	_	NNS	NNS	_	11	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	this	_	DT	DT	_	10	NMOD	_	_
10	element	_	NN	NN	_	8	PMOD	_	_
11	do	_	VBP	VBP	_	4	VMOD	_	_
12	not	_	RB	RB	_	11	VMOD	_	_
13	respond	_	VB	VB	_	11	VC	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	IL-2	_	NN	NN	_	14	PMOD	_	_
16	,	_	,	,	_	19	P	_	_
17	together	_	RB	RB	_	19	ADV	_	_
18	they	_	PRP	PRP	_	19	SBJ	_	_
19	form	_	VBP	VBP	_	3	VMOD	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	composite	_	JJ	JJ	_	22	NMOD	_	_
22	element	_	NN	NN	_	19	OBJ	_	_
23	capable	_	JJ	JJ	_	22	NMOD	_	_
24	of	_	IN	IN	_	23	AMOD	_	_
25	conferring	_	VBG	VBG	_	24	PMOD	_	_
26	IL-2	_	NN	NN	_	27	NMOD	_	_
27	responsiveness	_	NN	NN	_	25	OBJ	_	_
28	to	_	TO	TO	_	27	NMOD	_	_
29	a	_	DT	DT	_	31	NMOD	_	_
30	heterologous	_	JJ	JJ	_	31	NMOD	_	_
31	promoter	_	NN	NN	_	28	PMOD	_	_
32	.	_	.	.	_	2	P	_	_

1	Multiple	_	JJ	JJ	_	2	NMOD	_	_
2	factors	_	NNS	NNS	_	13	SBJ	_	_
3	including	_	VBG	VBG	_	2	NMOD	_	_
4	Stat5	_	NN	NN	_	3	PMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	Elf-1	_	NN	NN	_	4	COORD	_	_
7	,	_	,	,	_	4	P	_	_
8	HMG-I-LRB-Y-RRB-	_	NN	NN	_	4	COORD	_	_
9	and	_	CC	CC	_	4	CC	_	_
10	GATA	_	NN	NN	_	12	NMOD	_	_
11	family	_	NN	NN	_	12	NMOD	_	_
12	proteins	_	NNS	NNS	_	4	COORD	_	_
13	bind	_	VBP	VBP	_	0	ROOT-S	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	IL-2	_	NN	NN	_	18	NMOD	_	_
17	response	_	NN	NN	_	18	NMOD	_	_
18	element	_	NN	NN	_	14	PMOD	_	_
19	and	_	CC	CC	_	13	CC	_	_
20	mutation	_	NN	NN	_	28	SBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	any	_	DT	DT	_	23	NMOD	_	_
23	one	_	CD	CD	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	these	_	DT	DT	_	27	NMOD	_	_
26	binding	_	VBG	VBG	_	27	NMOD	_	_
27	sites	_	NNS	NNS	_	24	PMOD	_	_
28	diminishes	_	VBZ	VBZ	_	13	COORD	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	activity	_	NN	NN	_	28	OBJ	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	this	_	DT	DT	_	33	NMOD	_	_
33	element	_	NN	NN	_	31	PMOD	_	_
34	.	_	.	.	_	13	P	_	_

1	An	_	DT	DT	_	5	NMOD	_	_
2	unidentified	_	JJ	JJ	_	5	NMOD	_	_
3	Ets	_	NN	NN	_	5	NMOD	_	_
4	family	_	NN	NN	_	5	NMOD	_	_
5	protein	_	NN	NN	_	6	SBJ	_	_
6	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	to	_	TO	TO	_	6	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	EBS	_	NN	NN	_	7	PMOD	_	_
10	overlapping	_	VBG	VBG	_	9	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	consensus	_	NN	NN	_	14	NMOD	_	_
13	GAS	_	NN	NN	_	14	NMOD	_	_
14	motif	_	NN	NN	_	10	OBJ	_	_
15	and	_	CC	CC	_	6	CC	_	_
16	appears	_	VBZ	VBZ	_	6	COORD	_	_
17	to	_	TO	TO	_	19	VMOD	_	_
18	negatively	_	RB	RB	_	19	ADV	_	_
19	regulate	_	VB	VB	_	16	OBJ	_	_
20	the	_	DT	DT	_	24	NMOD	_	_
21	human	_	JJ	JJ	_	24	NMOD	_	_
22	IL-2R	_	NN	NN	_	24	NMOD	_	_
23	alpha	_	NN	NN	_	24	NMOD	_	_
24	promoter	_	NN	NN	_	19	OBJ	_	_
25	.	_	.	.	_	6	P	_	_

1	Thus	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	IL-2-induced	_	JJ	JJ	_	7	NMOD	_	_
4	IL-2R	_	NN	NN	_	7	NMOD	_	_
5	alpha	_	NN	NN	_	7	NMOD	_	_
6	promoter	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	8	SBJ	_	_
8	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	complex	_	JJ	JJ	_	12	NMOD	_	_
11	upstream	_	JJ	JJ	_	12	NMOD	_	_
12	element	_	NN	NN	_	8	OBJ	_	_
13	,	_	,	,	_	12	P	_	_
14	which	_	WDT	WDT	_	15	SBJ	_	_
15	appears	_	VBZ	VBZ	_	12	NMOD	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	contain	_	VB	VB	_	15	OBJ	_	_
18	binding	_	VBG	VBG	_	19	NMOD	_	_
19	sites	_	NNS	NNS	_	17	OBJ	_	_
20	for	_	IN	IN	_	19	NMOD	_	_
21	both	_	CC	CC	_	22	CC	_	_
22	positive	_	JJ	JJ	_	26	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	negative	_	JJ	JJ	_	22	COORD	_	_
25	regulatory	_	JJ	JJ	_	26	NMOD	_	_
26	factors	_	NNS	NNS	_	20	PMOD	_	_
27	.	_	.	.	_	8	P	_	_

1	Tyrosine	_	NN	NN	_	2	NMOD	_	_
2	kinase	_	NN	NN	_	7	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	cAMP-dependent	_	JJ	JJ	_	6	NMOD	_	_
5	protein	_	NN	NN	_	6	NMOD	_	_
6	kinase	_	NN	NN	_	2	COORD	_	_
7	activities	_	NNS	NNS	_	0	ROOT-FRAG	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	CD40-activated	_	JJ	JJ	_	12	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	B	_	NN	NN	_	12	NMOD	_	_
12	lymphocytes	_	NNS	NNS	_	8	PMOD	_	_
13	.	_	.	.	_	7	P	_	_

1	In	_	FW	FW	_	7	ADV	_	_
2	vitro	_	FW	FW	_	1	AMOD	_	_
3	,	_	,	,	_	7	P	_	_
4	human	_	JJ	JJ	_	6	NMOD	_	_
5	B	_	NN	NN	_	6	NMOD	_	_
6	lymphocytes	_	NNS	NNS	_	7	SBJ	_	_
7	undergo	_	VBP	VBP	_	0	ROOT-S	_	_
8	long-term	_	JJ	JJ	_	9	NMOD	_	_
9	proliferation	_	NN	NN	_	7	OBJ	_	_
10	when	_	WRB	WRB	_	11	ADV	_	_
11	activated	_	VBN	VBN	_	7	TMP	_	_
12	through	_	IN	IN	_	11	ADV	_	_
13	CD40	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	protein	_	NN	NN	_	13	NMOD	_	_
17	expressed	_	VBN	VBN	_	16	NMOD	_	_
18	on	_	IN	IN	_	17	ADV	_	_
19	their	_	PRP$	PRP$	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	surface	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	nature	_	NN	NN	_	14	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	CD40-dependent	_	JJ	JJ	_	5	NMOD	_	_
5	signals	_	NNS	NNS	_	3	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	proliferating	_	VBG	VBG	_	13	NMOD	_	_
8	fresh	_	JJ	JJ	_	13	NMOD	_	_
9	human	_	JJ	JJ	_	13	NMOD	_	_
10	Epstein-Barr	_	JJ	JJ	_	11	AMOD	_	_
11	virus-negative	_	JJ	JJ	_	13	NMOD	_	_
12	B	_	NN	NN	_	13	NMOD	_	_
13	lymphocytes	_	NNS	NNS	_	6	PMOD	_	_
14	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	currently	_	RB	RB	_	14	TMP	_	_
16	unknown	_	JJ	JJ	_	14	PRD	_	_
17	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	11	P	_	_
5	a	_	DT	DT	_	10	NMOD	_	_
6	CD40-dependent	_	JJ	JJ	_	10	NMOD	_	_
7	B	_	NN	NN	_	10	NMOD	_	_
8	cell	_	NN	NN	_	10	NMOD	_	_
9	culture	_	NN	NN	_	10	NMOD	_	_
10	system	_	NN	NN	_	11	SBJ	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	used	_	VBN	VBN	_	11	VC	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	examine	_	VB	VB	_	12	OBJ	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	role	_	NN	NN	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	different	_	JJ	JJ	_	21	NMOD	_	_
19	signal	_	NN	NN	_	21	NMOD	_	_
20	transduction	_	NN	NN	_	21	NMOD	_	_
21	elements	_	NNS	NNS	_	17	PMOD	_	_
22	.	_	.	.	_	11	P	_	_

1	Protein	_	NN	NN	_	3	NMOD	_	_
2	kinase	_	NN	NN	_	3	NMOD	_	_
3	C	_	NN	NN	_	7	NMOD	_	_
4	(	_	(	(	_	5	P	_	_
5	PKC	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	depletion	_	NN	NN	_	17	SBJ	_	_
8	generated	_	VBN	VBN	_	7	NMOD	_	_
9	by	_	IN	IN	_	8	ADV	_	_
10	a	_	DT	DT	_	16	NMOD	_	_
11	long-term	_	JJ	JJ	_	16	NMOD	_	_
12	phorbol	_	NN	NN	_	16	NMOD	_	_
13	12	_	CD	CD	_	16	NMOD	_	_
14	myristate	_	NN	NN	_	16	NMOD	_	_
15	13-acetate	_	NN	NN	_	16	NMOD	_	_
16	treatment	_	NN	NN	_	9	PMOD	_	_
17	had	_	VBD	VBD	_	0	ROOT-S	_	_
18	weak	_	JJ	JJ	_	19	NMOD	_	_
19	effects	_	NNS	NNS	_	17	OBJ	_	_
20	on	_	IN	IN	_	17	ADV	_	_
21	proliferation	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	17	P	_	_

1	Rather	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	tyrosine	_	NN	NN	_	4	NMOD	_	_
4	phosphorylation	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	shown	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	be	_	VB	VB	_	6	OBJ	_	_
9	directly	_	RB	RB	_	10	ADV	_	_
10	involved	_	VBN	VBN	_	8	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	mediating	_	VBG	VBG	_	11	PMOD	_	_
13	CD40-dependent	_	JJ	JJ	_	14	NMOD	_	_
14	signals	_	NNS	NNS	_	12	OBJ	_	_
15	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	12	P	_	_
4	the	_	DT	DT	_	10	NMOD	_	_
5	cAMP-dependent	_	JJ	JJ	_	7	NMOD	_	_
6	protein	_	NN	NN	_	7	NMOD	_	_
7	kinase	_	NN	NN	_	8	AMOD	_	_
8	specific	_	JJ	JJ	_	10	NMOD	_	_
9	inhibitor	_	NN	NN	_	10	NMOD	_	_
10	H-89	_	NN	NN	_	12	SBJ	_	_
11	totally	_	RB	RB	_	12	ADV	_	_
12	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
13	HIV-1	_	NN	NN	_	15	NMOD	_	_
14	LTR	_	NN	NN	_	15	NMOD	_	_
15	activity	_	NN	NN	_	12	OBJ	_	_
16	at	_	IN	IN	_	12	ADV	_	_
17	a	_	DT	DT	_	18	NMOD	_	_
18	concentration	_	NN	NN	_	16	PMOD	_	_
19	as	_	RB	RB	_	20	DEP	_	_
20	low	_	JJ	JJ	_	23	NMOD	_	_
21	as	_	IN	IN	_	20	DEP	_	_
22	100	_	CD	CD	_	20	DEP	_	_
23	nM	_	NN	NN	_	18	NMOD	_	_
24	without	_	IN	IN	_	12	ADV	_	_
25	affecting	_	VBG	VBG	_	24	PMOD	_	_
26	cellular	_	JJ	JJ	_	27	NMOD	_	_
27	proliferation	_	NN	NN	_	25	OBJ	_	_
28	.	_	.	.	_	12	P	_	_

1	Electrophoretic	_	JJ	JJ	_	4	NMOD	_	_
2	mobility	_	NN	NN	_	4	NMOD	_	_
3	shift	_	NN	NN	_	4	NMOD	_	_
4	assay	_	NN	NN	_	26	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	EMSA	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	and	_	CC	CC	_	4	CC	_	_
9	supershift	_	NN	NN	_	10	NMOD	_	_
10	assay	_	NN	NN	_	4	COORD	_	_
11	using	_	VBG	VBG	_	4	NMOD	_	_
12	an	_	DT	DT	_	16	NMOD	_	_
13	NF-kappa	_	NN	NN	_	16	NMOD	_	_
14	B	_	NN	NN	_	16	NMOD	_	_
15	binding	_	NN	NN	_	16	NMOD	_	_
16	sequence	_	NN	NN	_	11	OBJ	_	_
17	from	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	kappa	_	NN	NN	_	21	NMOD	_	_
20	light	_	JJ	JJ	_	21	NMOD	_	_
21	chain	_	NN	NN	_	17	PMOD	_	_
22	as	_	IN	IN	_	11	ADV	_	_
23	a	_	DT	DT	_	24	NMOD	_	_
24	probe	_	NN	NN	_	22	PMOD	_	_
25	,	_	,	,	_	26	P	_	_
26	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
27	that	_	IN	IN	_	26	OBJ	_	_
28	both	_	CC	CC	_	29	CC	_	_
29	p65	_	NNS	NNS	_	35	SBJ	_	_
30	(	_	(	(	_	31	P	_	_
31	RelA	_	NN	NN	_	29	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	and	_	CC	CC	_	29	CC	_	_
34	c-Rel	_	NN	NN	_	29	COORD	_	_
35	were	_	VBD	VBD	_	27	VMOD	_	_
36	present	_	JJ	JJ	_	35	PRD	_	_
37	in	_	IN	IN	_	36	AMOD	_	_
38	CD40-stimulated	_	JJ	JJ	_	40	NMOD	_	_
39	B	_	NN	NN	_	40	NMOD	_	_
40	cells	_	NNS	NNS	_	37	PMOD	_	_
41	.	_	.	.	_	26	P	_	_

1	While	_	IN	IN	_	21	ADV	_	_
2	PKC	_	NN	NN	_	3	NMOD	_	_
3	depletion	_	NN	NN	_	4	SBJ	_	_
4	did	_	VBD	VBD	_	1	VMOD	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	alter	_	VB	VB	_	4	VC	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	NF-kappa	_	NN	NN	_	10	NMOD	_	_
9	B	_	NN	NN	_	10	NMOD	_	_
10	level	_	NN	NN	_	6	OBJ	_	_
11	,	_	,	,	_	21	P	_	_
12	treatment	_	NN	NN	_	21	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	B	_	NN	NN	_	15	NMOD	_	_
15	lymphocytes	_	NNS	NNS	_	13	PMOD	_	_
16	with	_	IN	IN	_	12	NMOD	_	_
17	H-89	_	NN	NN	_	16	PMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	herbimycin	_	NN	NN	_	20	NMOD	_	_
20	A	_	NN	NN	_	17	COORD	_	_
21	provoked	_	VBD	VBD	_	0	ROOT-S	_	_
22	a	_	DT	DT	_	23	NMOD	_	_
23	decrease	_	NN	NN	_	21	OBJ	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	28	NMOD	_	_
26	NF-kappa	_	NN	NN	_	28	NMOD	_	_
27	B	_	NN	NN	_	28	NMOD	_	_
28	level	_	NN	NN	_	24	PMOD	_	_
29	.	_	.	.	_	21	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	observations	_	NNS	NNS	_	3	SBJ	_	_
3	establish	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	importance	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	different	_	JJ	JJ	_	10	NMOD	_	_
8	signal	_	NN	NN	_	10	NMOD	_	_
9	transducing	_	NN	NN	_	10	NMOD	_	_
10	pathways	_	NNS	NNS	_	6	PMOD	_	_
11	leading	_	VBG	VBG	_	10	NMOD	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	CD40	_	NN	NN	_	14	NMOD	_	_
14	activation	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	B	_	NN	NN	_	17	NMOD	_	_
17	lymphocytes	_	NNS	NNS	_	15	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	Chromosome	_	NN	NN	_	3	NMOD	_	_
2	1	_	CD	CD	_	3	NMOD	_	_
3	aneusomy	_	NN	NN	_	7	SBJ	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	1p36	_	NN	NN	_	6	NMOD	_	_
6	under-representation	_	NN	NN	_	4	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	related	_	JJ	JJ	_	7	PRD	_	_
9	to	_	TO	TO	_	8	AMOD	_	_
10	histologic	_	JJ	JJ	_	11	NMOD	_	_
11	grade	_	NN	NN	_	9	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	DNA	_	NN	NN	_	14	NMOD	_	_
14	aneuploidy	_	NN	NN	_	11	COORD	_	_
15	,	_	,	,	_	11	P	_	_
16	high	_	JJ	JJ	_	18	NMOD	_	_
17	c-erb	_	NN	NN	_	18	NMOD	_	_
18	B-2	_	NN	NN	_	11	COORD	_	_
19	and	_	CC	CC	_	11	CC	_	_
20	loss	_	NN	NN	_	11	COORD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	bcl-2	_	NN	NN	_	23	NMOD	_	_
23	expression	_	NN	NN	_	21	PMOD	_	_
24	in	_	IN	IN	_	11	NMOD	_	_
25	ductal	_	JJ	JJ	_	27	NMOD	_	_
26	breast	_	NN	NN	_	27	NMOD	_	_
27	carcinoma	_	NN	NN	_	24	PMOD	_	_
28	.	_	.	.	_	7	P	_	_

1	Chromosome	_	NN	NN	_	3	NMOD	_	_
2	1	_	CD	CD	_	3	NMOD	_	_
3	abnormalities	_	NNS	NNS	_	8	SBJ	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	loss	_	NN	NN	_	4	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	1p36	_	NN	NN	_	6	PMOD	_	_
8	have	_	VBP	VBP	_	0	ROOT-S	_	_
9	been	_	VBN	VBN	_	8	VC	_	_
10	investigated	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	95	_	CD	CD	_	14	NMOD	_	_
13	breast-cancer	_	NN	NN	_	14	NMOD	_	_
14	samples	_	NNS	NNS	_	11	PMOD	_	_
15	by	_	IN	IN	_	10	ADV	_	_
16	means	_	NNS	NNS	_	15	DEP	_	_
17	of	_	IN	IN	_	15	DEP	_	_
18	a	_	DT	DT	_	26	NMOD	_	_
19	dual-target	_	JJ	JJ	_	26	NMOD	_	_
20	fluorescence	_	NN	NN	_	22	NMOD	_	_
21	in-situ	_	FW	FW	_	22	NMOD	_	_
22	hybridization	_	NN	NN	_	26	NMOD	_	_
23	(	_	(	(	_	24	P	_	_
24	FISH	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	technique	_	NN	NN	_	15	PMOD	_	_
27	using	_	VBG	VBG	_	26	NMOD	_	_
28	the	_	DT	DT	_	33	NMOD	_	_
29	pUC	_	NN	NN	_	33	NMOD	_	_
30	1.77	_	CD	CD	_	29	NMOD	_	_
31	and	_	CC	CC	_	29	CC	_	_
32	p1-79	_	NN	NN	_	29	COORD	_	_
33	probes	_	NNS	NNS	_	27	OBJ	_	_
34	,	_	,	,	_	33	P	_	_
35	specific	_	JJ	JJ	_	43	AMOD	_	_
36	for	_	IN	IN	_	43	AMOD	_	_
37	the	_	DT	DT	_	41	NMOD	_	_
38	1q12	_	NN	NN	_	41	NMOD	_	_
39	and	_	CC	CC	_	38	CC	_	_
40	1p36	_	NN	NN	_	38	COORD	_	_
41	regions	_	NNS	NNS	_	36	PMOD	_	_
42	,	_	,	,	_	43	P	_	_
43	respectively	_	RB	RB	_	33	NMOD	_	_
44	.	_	.	.	_	8	P	_	_

1	Abnormalities	_	NNS	NNS	_	7	SBJ	_	_
2	for	_	IN	IN	_	1	NMOD	_	_
3	one	_	CD	CD	_	2	PMOD	_	_
4	or	_	CC	CC	_	3	CC	_	_
5	both	_	DT	DT	_	6	NMOD	_	_
6	probes	_	NNS	NNS	_	3	COORD	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	detected	_	VBN	VBN	_	7	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	83\/95	_	CD	CD	_	11	NMOD	_	_
11	samples	_	NNS	NNS	_	9	PMOD	_	_
12	.	_	.	.	_	7	P	_	_

1	Relative	_	JJ	JJ	_	3	NMOD	_	_
2	1p36	_	NN	NN	_	3	NMOD	_	_
3	under-representation	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	found	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	79\/95	_	CD	CD	_	6	PMOD	_	_
8	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	clinical	_	JJ	JJ	_	3	NMOD	_	_
3	relevance	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	these	_	DT	DT	_	6	NMOD	_	_
6	alterations	_	NNS	NNS	_	4	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	studied	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	ADV	_	_
10	comparing	_	VBG	VBG	_	9	PMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	FISH	_	NN	NN	_	13	NMOD	_	_
13	results	_	NNS	NNS	_	10	OBJ	_	_
14	with	_	IN	IN	_	10	ADV	_	_
15	several	_	JJ	JJ	_	16	NMOD	_	_
16	parameters	_	NNS	NNS	_	14	PMOD	_	_
17	currently	_	RB	RB	_	18	TMP	_	_
18	used	_	VBN	VBN	_	16	NMOD	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	breast-cancer	_	JJ	JJ	_	21	NMOD	_	_
21	pathology	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	Distinct	_	JJ	JJ	_	2	NMOD	_	_
2	patterns	_	NNS	NNS	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	chromosome	_	NN	NN	_	6	NMOD	_	_
5	1	_	CD	CD	_	6	NMOD	_	_
6	abnormalities	_	NNS	NNS	_	3	PMOD	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	found	_	VBN	VBN	_	7	VC	_	_
9	among	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	histologic	_	JJ	JJ	_	12	NMOD	_	_
12	types	_	NNS	NNS	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	breast	_	NN	NN	_	15	NMOD	_	_
15	carcinoma	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	7	P	_	_

1	Lobular	_	JJ	JJ	_	4	NMOD	_	_
2	or	_	CC	CC	_	1	CC	_	_
3	mucinous	_	JJ	JJ	_	1	COORD	_	_
4	samples	_	NNS	NNS	_	5	SBJ	_	_
5	showed	_	VBD	VBD	_	0	ROOT-S	_	_
6	few	_	JJ	JJ	_	9	NMOD	_	_
7	or	_	CC	CC	_	6	CC	_	_
8	no	_	DT	DT	_	6	COORD	_	_
9	alterations	_	NNS	NNS	_	5	OBJ	_	_
10	,	_	,	,	_	5	P	_	_
11	whereas	_	IN	IN	_	5	COORD	_	_
12	most	_	JJS	JJS	_	14	NMOD	_	_
13	ductal	_	JJ	JJ	_	14	NMOD	_	_
14	samples	_	NNS	NNS	_	15	SBJ	_	_
15	had	_	VBD	VBD	_	5	COORD	_	_
16	high	_	JJ	JJ	_	19	NMOD	_	_
17	chromosome	_	NN	NN	_	19	NMOD	_	_
18	1	_	CD	CD	_	19	NMOD	_	_
19	polysomy	_	NN	NN	_	15	OBJ	_	_
20	with	_	IN	IN	_	19	NMOD	_	_
21	under-representation	_	NN	NN	_	20	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	1p36	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	ductal	_	JJ	JJ	_	3	NMOD	_	_
3	carcinomas	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	8	P	_	_
5	chromosome	_	NN	NN	_	7	NMOD	_	_
6	1	_	CD	CD	_	7	NMOD	_	_
7	alterations	_	NNS	NNS	_	8	SBJ	_	_
8	increased	_	VBD	VBD	_	0	ROOT-S	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	histologic	_	JJ	JJ	_	11	NMOD	_	_
11	grade	_	NN	NN	_	9	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	DNA	_	NN	NN	_	14	NMOD	_	_
14	aneuploidy	_	NN	NN	_	11	COORD	_	_
15	,	_	,	,	_	11	P	_	_
16	loss	_	NN	NN	_	11	COORD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	bcl-2	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	11	CC	_	_
20	high	_	JJ	JJ	_	23	NMOD	_	_
21	c-erb	_	NN	NN	_	23	NMOD	_	_
22	B-2	_	NN	NN	_	23	NMOD	_	_
23	expression	_	NN	NN	_	11	COORD	_	_
24	.	_	.	.	_	8	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	associations	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	found	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	be	_	VB	VB	_	4	OBJ	_	_
7	statistically	_	RB	RB	_	6	ADV	_	_
8	significant	_	JJ	JJ	_	6	PRD	_	_
9	.	_	.	.	_	3	P	_	_

1	No	_	DT	DT	_	2	NMOD	_	_
2	correlation	_	NN	NN	_	28	SBJ	_	_
3	between	_	IN	IN	_	2	NMOD	_	_
4	chromosome	_	NN	NN	_	6	NMOD	_	_
5	1	_	CD	CD	_	6	NMOD	_	_
6	alterations	_	NNS	NNS	_	3	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	grade	_	NN	NN	_	6	COORD	_	_
10	,	_	,	,	_	9	P	_	_
11	age	_	NN	NN	_	9	NMOD	_	_
12	,	_	,	,	_	9	P	_	_
13	size	_	NN	NN	_	9	NMOD	_	_
14	,	_	,	,	_	9	P	_	_
15	lymph-node	_	JJ	JJ	_	16	NMOD	_	_
16	involvement	_	NN	NN	_	9	COORD	_	_
17	,	_	,	,	_	9	P	_	_
18	hormonal	_	JJ	JJ	_	20	NMOD	_	_
19	receptor	_	NN	NN	_	20	NMOD	_	_
20	presence	_	NN	NN	_	9	COORD	_	_
21	,	_	,	,	_	9	P	_	_
22	proliferation	_	NN	NN	_	23	NMOD	_	_
23	activity	_	NN	NN	_	9	COORD	_	_
24	or	_	CC	CC	_	9	CC	_	_
25	p53	_	NN	NN	_	27	NMOD	_	_
26	protein	_	NN	NN	_	27	NMOD	_	_
27	expression	_	NN	NN	_	9	COORD	_	_
28	was	_	VBD	VBD	_	0	ROOT-S	_	_
29	detected	_	VBN	VBN	_	28	VC	_	_
30	.	_	.	.	_	28	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	utility	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	this	_	DT	DT	_	9	NMOD	_	_
8	FISH	_	NN	NN	_	9	NMOD	_	_
9	technique	_	NN	NN	_	6	PMOD	_	_
10	for	_	IN	IN	_	5	NMOD	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	better	_	JJR	JJR	_	13	NMOD	_	_
13	definition	_	NN	NN	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	biological	_	JJ	JJ	_	17	NMOD	_	_
17	characteristics	_	NNS	NNS	_	14	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	ductal	_	JJ	JJ	_	20	NMOD	_	_
20	carcinomas	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	Silencing	_	NN	NN	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	human	_	JJ	JJ	_	6	NMOD	_	_
4	fetal	_	JJ	JJ	_	6	NMOD	_	_
5	globin	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	2	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	impaired	_	JJ	JJ	_	7	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	9	DEP	_	_
11	absence	_	NN	NN	_	9	DEP	_	_
12	of	_	IN	IN	_	9	DEP	_	_
13	the	_	DT	DT	_	19	NMOD	_	_
14	adult	_	JJ	JJ	_	19	NMOD	_	_
15	beta-globin	_	IN	IN	_	19	NMOD	_	_
16	gene	_	NN	NN	_	19	NMOD	_	_
17	activator	_	NN	NN	_	19	NMOD	_	_
18	protein	_	NN	NN	_	19	NMOD	_	_
19	EKLF	_	NN	NN	_	9	PMOD	_	_
20	.	_	.	.	_	7	P	_	_

1	Globin	_	NN	NN	_	2	NMOD	_	_
2	genes	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	subject	_	JJ	JJ	_	3	PRD	_	_
5	to	_	TO	TO	_	4	AMOD	_	_
6	tissue-specific	_	JJ	JJ	_	10	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	developmental	_	JJ	JJ	_	9	AMOD	_	_
9	stage-specific	_	JJ	JJ	_	6	COORD	_	_
10	regulation	_	NN	NN	_	5	PMOD	_	_
11	.	_	.	.	_	3	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	switch	_	NN	NN	_	16	SBJ	_	_
3	from	_	IN	IN	_	2	NMOD	_	_
4	human	_	JJ	JJ	_	15	NMOD	_	_
5	fetal	_	JJ	JJ	_	15	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	gamma	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	-to	_	TO	TO	_	2	NMOD	_	_
10	adult	_	JJ	JJ	_	9	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	beta	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	-globin	_	NN	NN	_	15	NMOD	_	_
15	expression	_	NN	NN	_	3	PMOD	_	_
16	occurs	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	within	_	IN	IN	_	16	ADV	_	_
18	erythroid	_	JJ	JJ	_	20	NMOD	_	_
19	precursor	_	JJ	JJ	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	17	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	adult	_	JJ	JJ	_	24	NMOD	_	_
24	lineage	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	16	P	_	_

1	Previously	_	RB	RB	_	5	TMP	_	_
2	we	_	PRP	PRP	_	5	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	others	_	NNS	NNS	_	2	COORD	_	_
5	showed	_	VBD	VBD	_	0	ROOT-S	_	_
6	by	_	IN	IN	_	5	ADV	_	_
7	targeted	_	VBN	VBN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	disruption	_	NN	NN	_	6	PMOD	_	_
10	that	_	IN	IN	_	5	OBJ	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	zinc	_	NN	NN	_	14	NMOD	_	_
13	finger	_	NN	NN	_	14	NMOD	_	_
14	gene	_	NN	NN	_	23	SBJ	_	_
15	,	_	,	,	_	14	P	_	_
16	erythroid	_	JJ	JJ	_	18	NMOD	_	_
17	Kruppel-like	_	JJ	JJ	_	18	NMOD	_	_
18	factor	_	NN	NN	_	14	NMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	EKLF	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	,	_	,	,	_	14	P	_	_
23	is	_	VBZ	VBZ	_	10	VMOD	_	_
24	required	_	VBN	VBN	_	23	VC	_	_
25	for	_	IN	IN	_	24	ADV	_	_
26	expression	_	NN	NN	_	25	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	beta-globin	_	NN	NN	_	30	NMOD	_	_
30	gene	_	NN	NN	_	27	PMOD	_	_
31	in	_	IN	IN	_	26	NMOD	_	_
32	mice	_	NNS	NNS	_	31	PMOD	_	_
33	,	_	,	,	_	24	P	_	_
34	presumably	_	RB	RB	_	35	DEP	_	_
35	through	_	IN	IN	_	24	ADV	_	_
36	interaction	_	NN	NN	_	35	PMOD	_	_
37	with	_	IN	IN	_	36	NMOD	_	_
38	a	_	DT	DT	_	41	NMOD	_	_
39	high-affinity	_	JJ	JJ	_	41	NMOD	_	_
40	binding	_	VBG	VBG	_	41	NMOD	_	_
41	site	_	NN	NN	_	37	PMOD	_	_
42	in	_	IN	IN	_	41	NMOD	_	_
43	the	_	DT	DT	_	45	NMOD	_	_
44	proximal	_	JJ	JJ	_	45	NMOD	_	_
45	promoter	_	NN	NN	_	42	PMOD	_	_
46	.	_	.	.	_	5	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	examine	_	VB	VB	_	17	VMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	role	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	EKLF	_	NN	NN	_	5	PMOD	_	_
7	in	_	IN	IN	_	4	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	developmental	_	JJ	JJ	_	10	NMOD	_	_
10	regulation	_	NN	NN	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	human	_	JJ	JJ	_	15	NMOD	_	_
14	gamma-globin	_	NN	NN	_	15	NMOD	_	_
15	gene	_	NN	NN	_	11	PMOD	_	_
16	we	_	PRP	PRP	_	17	SBJ	_	_
17	interbred	_	VBD	VBD	_	0	ROOT-S	_	_
18	EKLF	_	NN	NN	_	19	NMOD	_	_
19	heterozygotes	_	NNS	NNS	_	17	OBJ	_	_
20	(	_	(	(	_	19	P	_	_
21	+\/-	_	CC	CC	_	19	CC	_	_
22	)	_	)	)	_	19	P	_	_
23	with	_	IN	IN	_	17	ADV	_	_
24	mice	_	NNS	NNS	_	23	PMOD	_	_
25	harboring	_	VBG	VBG	_	24	NMOD	_	_
26	a	_	DT	DT	_	32	NMOD	_	_
27	human	_	JJ	JJ	_	32	NMOD	_	_
28	beta-globin	_	NN	NN	_	32	NMOD	_	_
29	yeast	_	NN	NN	_	32	NMOD	_	_
30	artificial	_	JJ	JJ	_	32	NMOD	_	_
31	chromosome	_	NN	NN	_	32	NMOD	_	_
32	transgene	_	NN	NN	_	25	OBJ	_	_
33	.	_	.	.	_	17	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	find	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	in	_	IN	IN	_	20	ADV	_	_
5	the	_	DT	DT	_	4	DEP	_	_
6	absence	_	NN	NN	_	4	DEP	_	_
7	of	_	IN	IN	_	4	DEP	_	_
8	EKLF	_	NN	NN	_	4	PMOD	_	_
9	,	_	,	,	_	20	P	_	_
10	while	_	IN	IN	_	20	ADV	_	_
11	human	_	JJ	JJ	_	13	NMOD	_	_
12	beta-globin	_	NN	NN	_	13	NMOD	_	_
13	expression	_	NN	NN	_	14	SBJ	_	_
14	is	_	VBZ	VBZ	_	10	VMOD	_	_
15	dramatically	_	RB	RB	_	14	ADV	_	_
16	reduced	_	VBN	VBN	_	14	VC	_	_
17	,	_	,	,	_	20	P	_	_
18	gamma-globin	_	NN	NN	_	19	NMOD	_	_
19	transcripts	_	NNS	NNS	_	20	SBJ	_	_
20	are	_	VBP	VBP	_	3	VMOD	_	_
21	elevated	_	JJ	JJ	_	20	VC	_	_
22	approximately	_	RB	RB	_	21	ADV	_	_
23	5-fold	_	RB	RB	_	22	AMOD	_	_
24	.	_	.	.	_	2	P	_	_

1	Impaired	_	JJ	JJ	_	2	NMOD	_	_
2	silencing	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	gamma-globin	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	3	PMOD	_	_
6	identifies	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	EKLF	_	NN	NN	_	6	OBJ	_	_
8	as	_	IN	IN	_	6	ADV	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	first	_	JJ	JJ	_	12	NMOD	_	_
11	transcription	_	NN	NN	_	12	NMOD	_	_
12	factor	_	NN	NN	_	8	PMOD	_	_
13	participating	_	VBG	VBG	_	12	NMOD	_	_
14	quantitatively	_	RB	RB	_	13	ADV	_	_
15	in	_	IN	IN	_	13	ADV	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	gamma-globin	_	NN	NN	_	20	NMOD	_	_
18	to	_	TO	TO	_	17	NMOD	_	_
19	beta-globin	_	NN	NN	_	17	NMOD	_	_
20	switch	_	NN	NN	_	15	PMOD	_	_
21	.	_	.	.	_	6	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	compatible	_	JJ	JJ	_	3	PRD	_	_
5	with	_	IN	IN	_	4	AMOD	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	competitive	_	JJ	JJ	_	8	NMOD	_	_
8	model	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	switching	_	NN	NN	_	9	PMOD	_	_
11	in	_	IN	IN	_	14	ADV	_	_
12	which	_	WDT	WDT	_	11	PMOD	_	_
13	EKLF	_	NN	NN	_	14	SBJ	_	_
14	mediates	_	VBZ	VBZ	_	8	NMOD	_	_
15	an	_	DT	DT	_	18	NMOD	_	_
16	adult	_	JJ	JJ	_	18	NMOD	_	_
17	stage-specific	_	JJ	JJ	_	18	NMOD	_	_
18	interaction	_	NN	NN	_	14	OBJ	_	_
19	between	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	beta-globin	_	NN	NN	_	23	NMOD	_	_
22	gene	_	NN	NN	_	23	NMOD	_	_
23	promoter	_	NN	NN	_	19	PMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	the	_	DT	DT	_	28	NMOD	_	_
26	locus	_	NN	NN	_	28	NMOD	_	_
27	control	_	NN	NN	_	28	NMOD	_	_
28	region	_	NN	NN	_	23	COORD	_	_
29	that	_	WDT	WDT	_	30	SBJ	_	_
30	excludes	_	VBZ	VBZ	_	28	NMOD	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	gamma-globin	_	NN	NN	_	33	NMOD	_	_
33	gene	_	NN	NN	_	30	OBJ	_	_
34	.	_	.	.	_	3	P	_	_

1	Modulatory	_	JJ	JJ	_	2	NMOD	_	_
2	effects	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	glucocorticoids	_	NNS	NNS	_	3	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	catecholamines	_	NNS	NNS	_	4	COORD	_	_
7	on	_	IN	IN	_	2	NMOD	_	_
8	human	_	JJ	JJ	_	12	NMOD	_	_
9	interleukin-12	_	NN	NN	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	interleukin-10	_	NN	NN	_	9	COORD	_	_
12	production	_	NN	NN	_	7	PMOD	_	_
13	:	_	:	:	_	2	P	_	_
14	clinical	_	JJ	JJ	_	15	NMOD	_	_
15	implications	_	NNS	NNS	_	2	NMOD	_	_
16	.	_	.	.	_	2	P	_	_

1	Interleukin-12	_	NN	NN	_	5	SBJ	_	_
2	(	_	(	(	_	3	P	_	_
3	IL-12	_	NN	NN	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	key	_	JJ	JJ	_	8	NMOD	_	_
8	inducer	_	NN	NN	_	5	PRD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	differentiation	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	uncommitted	_	JJ	JJ	_	18	NMOD	_	_
13	T	_	NN	NN	_	14	NMOD	_	_
14	helper	_	NN	NN	_	18	NMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	TH	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	cells	_	NNS	NNS	_	11	PMOD	_	_
19	toward	_	IN	IN	_	10	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	TH1	_	NN	NN	_	22	NMOD	_	_
22	phenotype	_	NN	NN	_	19	PMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	which	_	WDT	WDT	_	25	SBJ	_	_
25	regulates	_	VBZ	VBZ	_	22	NMOD	_	_
26	cellular	_	JJ	JJ	_	27	NMOD	_	_
27	immunity	_	NN	NN	_	25	OBJ	_	_
28	,	_	,	,	_	5	P	_	_
29	whereas	_	IN	IN	_	5	COORD	_	_
30	IL-10	_	NN	NN	_	31	SBJ	_	_
31	inhibits	_	VBZ	VBZ	_	5	COORD	_	_
32	TH1	_	NN	NN	_	33	NMOD	_	_
33	functions	_	NNS	NNS	_	31	OBJ	_	_
34	and	_	CC	CC	_	31	CC	_	_
35	potentiates	_	VBZ	VBZ	_	31	COORD	_	_
36	TH2-regulated	_	JJ	JJ	_	37	NMOD	_	_
37	responses	_	NNS	NNS	_	35	OBJ	_	_
38	(	_	(	(	_	42	P	_	_
39	i.e.	_	FW	FW	_	42	NMOD	_	_
40	,	_	,	,	_	42	P	_	_
41	humoral	_	JJ	JJ	_	42	NMOD	_	_
42	immunity	_	NN	NN	_	37	PRN	_	_
43	)	_	)	)	_	42	P	_	_
44	.	_	.	.	_	5	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	examine	_	VB	VB	_	13	VMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	potential	_	JJ	JJ	_	5	NMOD	_	_
5	effects	_	NNS	NNS	_	2	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	stress	_	NN	NN	_	6	PMOD	_	_
8	on	_	IN	IN	_	5	NMOD	_	_
9	TH1\/TH2	_	NN	NN	_	10	NMOD	_	_
10	balance	_	NN	NN	_	8	PMOD	_	_
11	,	_	,	,	_	13	P	_	_
12	we	_	PRP	PRP	_	13	SBJ	_	_
13	studied	_	VBD	VBD	_	0	ROOT-S	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	ability	_	NN	NN	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	three	_	CD	CD	_	20	NMOD	_	_
18	prototype	_	NN	NN	_	20	NMOD	_	_
19	stress	_	NN	NN	_	20	NMOD	_	_
20	hormones	_	NNS	NNS	_	16	PMOD	_	_
21	-	_	:	:	_	20	P	_	_
22	dexamethasone	_	NN	NN	_	20	NMOD	_	_
23	(	_	(	(	_	26	P	_	_
24	a	_	DT	DT	_	26	NMOD	_	_
25	synthetic	_	JJ	JJ	_	26	NMOD	_	_
26	glucocorticoid	_	NN	NN	_	22	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	and	_	CC	CC	_	22	CC	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	catecholamines	_	NNS	NNS	_	22	COORD	_	_
31	norepinephrine	_	NN	NN	_	30	NMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	epinephrine	_	NN	NN	_	31	COORD	_	_
34	-	_	:	:	_	20	P	_	_
35	to	_	TO	TO	_	36	VMOD	_	_
36	alter	_	VB	VB	_	15	NMOD	_	_
37	the	_	DT	DT	_	38	NMOD	_	_
38	production	_	NN	NN	_	36	OBJ	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	IL-12	_	NN	NN	_	39	PMOD	_	_
41	(	_	(	(	_	42	P	_	_
42	p70	_	NN	NN	_	40	PRN	_	_
43	)	_	)	)	_	42	P	_	_
44	and	_	CC	CC	_	40	CC	_	_
45	IL-10	_	NN	NN	_	40	COORD	_	_
46	induced	_	VBN	VBN	_	38	NMOD	_	_
47	by	_	IN	IN	_	46	LGS	_	_
48	bacterial	_	JJ	JJ	_	49	NMOD	_	_
49	lipopolysaccharide	_	NN	NN	_	47	PMOD	_	_
50	(	_	(	(	_	51	P	_	_
51	LPS	_	NN	NN	_	49	PRN	_	_
52	)	_	)	)	_	51	P	_	_
53	in	_	IN	IN	_	49	NMOD	_	_
54	human	_	JJ	JJ	_	56	NMOD	_	_
55	whole	_	JJ	JJ	_	56	NMOD	_	_
56	blood	_	NN	NN	_	53	PMOD	_	_
57	.	_	.	.	_	13	P	_	_

1	Dexamethasone	_	NN	NN	_	2	SBJ	_	_
2	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
3	LPS-induced	_	JJ	JJ	_	6	NMOD	_	_
4	bioactive	_	JJ	JJ	_	6	NMOD	_	_
5	IL-12	_	NN	NN	_	6	NMOD	_	_
6	production	_	NN	NN	_	2	OBJ	_	_
7	in	_	IN	IN	_	2	ADV	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	dose-dependent	_	JJ	JJ	_	10	NMOD	_	_
10	fashion	_	NN	NN	_	7	PMOD	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	at	_	IN	IN	_	7	COORD	_	_
13	physiologically	_	RB	RB	_	14	AMOD	_	_
14	relevant	_	JJ	JJ	_	15	NMOD	_	_
15	concentrations	_	NNS	NNS	_	12	PMOD	_	_
16	;	_	:	:	_	2	P	_	_

1	Lack	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	IL-12	_	NN	NN	_	4	NMOD	_	_
4	signaling	_	NN	NN	_	2	PMOD	_	_
5	in	_	IN	IN	_	1	NMOD	_	_
6	human	_	JJ	JJ	_	9	NMOD	_	_
7	allergen-specific	_	JJ	JJ	_	9	NMOD	_	_
8	Th2	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	5	PMOD	_	_
10	.	_	.	.	_	1	P	_	_

1	IL-12	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	powerful	_	JJ	JJ	_	5	NMOD	_	_
5	skewer	_	NN	NN	_	2	PRD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	CD4+	_	JJ	JJ	_	10	NMOD	_	_
8	T	_	NN	NN	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	responses	_	NNS	NNS	_	6	PMOD	_	_
11	toward	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	Th1	_	NN	NN	_	14	NMOD	_	_
14	phenotype	_	NN	NN	_	11	PMOD	_	_
15	by	_	IN	IN	_	2	ADV	_	_
16	inducing	_	VBG	VBG	_	15	PMOD	_	_
17	IFN-gamma	_	NN	NN	_	18	NMOD	_	_
18	production	_	NN	NN	_	16	OBJ	_	_
19	in	_	IN	IN	_	16	ADV	_	_
20	naive	_	JJ	JJ	_	22	NMOD	_	_
21	Th	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	19	PMOD	_	_
23	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	present	_	JJ	JJ	_	4	NMOD	_	_
4	study	_	NN	NN	_	1	PMOD	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	addressed	_	VBD	VBD	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	question	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	whether	_	IN	IN	_	9	PMOD	_	_
11	IL-12	_	NN	NN	_	12	SBJ	_	_
12	can	_	MD	MD	_	10	VMOD	_	_
13	reverse	_	VB	VB	_	12	VC	_	_
14	established	_	JJ	JJ	_	16	NMOD	_	_
15	Th2	_	NN	NN	_	16	NMOD	_	_
16	responses	_	NNS	NNS	_	13	OBJ	_	_
17	into	_	IN	IN	_	13	ADV	_	_
18	Th1\/Th0	_	NN	NN	_	19	NMOD	_	_
19	responses	_	NNS	NNS	_	17	PMOD	_	_
20	by	_	IN	IN	_	13	ADV	_	_
21	inducing	_	VBG	VBG	_	20	PMOD	_	_
22	IFN-gamma	_	NN	NN	_	23	NMOD	_	_
23	production	_	NN	NN	_	21	OBJ	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	memory	_	NN	NN	_	27	NMOD	_	_
26	Th2	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	24	PMOD	_	_
28	.	_	.	.	_	6	P	_	_

1	To	_	TO	TO	_	13	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	aim	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	13	P	_	_
5	allergen-specific	_	JJ	JJ	_	9	NMOD	_	_
6	CD4+	_	JJ	JJ	_	9	NMOD	_	_
7	T	_	NN	NN	_	9	NMOD	_	_
8	cell	_	NN	NN	_	9	NMOD	_	_
9	clones	_	NNS	NNS	_	13	SBJ	_	_
10	(	_	(	(	_	11	P	_	_
11	TCC	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	were	_	VBD	VBD	_	0	ROOT-S	_	_
14	generated	_	VBN	VBN	_	13	VC	_	_
15	from	_	IN	IN	_	14	ADV	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	peripheral	_	JJ	JJ	_	18	NMOD	_	_
18	blood	_	NN	NN	_	15	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	three	_	CD	CD	_	22	NMOD	_	_
21	atopic	_	JJ	JJ	_	22	NMOD	_	_
22	patients	_	NNS	NNS	_	19	PMOD	_	_
23	,	_	,	,	_	13	P	_	_
24	and	_	CC	CC	_	13	CC	_	_
25	their	_	PRP$	PRP$	_	27	NMOD	_	_
26	cytokine	_	NN	NN	_	27	NMOD	_	_
27	profiles	_	NNS	NNS	_	28	SBJ	_	_
28	were	_	VBD	VBD	_	13	COORD	_	_
29	analyzed	_	VBN	VBN	_	28	VC	_	_
30	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	majority	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	these	_	DT	DT	_	5	NMOD	_	_
5	TCC	_	NN	NN	_	3	PMOD	_	_
6	exhibited	_	VBD	VBD	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	12	NMOD	_	_
8	strongly	_	RB	RB	_	9	AMOD	_	_
9	polarized	_	VBN	VBN	_	12	NMOD	_	_
10	Th2	_	NN	NN	_	12	NMOD	_	_
11	cytokine	_	NN	NN	_	12	NMOD	_	_
12	profile	_	NN	NN	_	6	OBJ	_	_
13	,	_	,	,	_	6	P	_	_
14	and	_	CC	CC	_	6	CC	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	production	_	NN	NN	_	19	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	IFN-gamma	_	NN	NN	_	17	PMOD	_	_
19	could	_	MD	MD	_	6	COORD	_	_
20	not	_	RB	RB	_	19	VMOD	_	_
21	be	_	VB	VB	_	19	VC	_	_
22	induced	_	VBN	VBN	_	21	VC	_	_
23	by	_	IN	IN	_	22	LGS	_	_
24	exogenous	_	JJ	JJ	_	25	NMOD	_	_
25	IL-12	_	NN	NN	_	23	PMOD	_	_
26	.	_	.	.	_	6	P	_	_

1	Only	_	RB	RB	_	3	NMOD	_	_
2	those	_	DT	DT	_	3	NMOD	_	_
3	TCC	_	NN	NN	_	13	SBJ	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	low	_	JJ	JJ	_	7	NMOD	_	_
6	IFN-gamma	_	NN	NN	_	7	NMOD	_	_
7	levels	_	NNS	NNS	_	4	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	8	DEP	_	_
10	absence	_	NN	NN	_	8	DEP	_	_
11	of	_	IN	IN	_	8	DEP	_	_
12	IL-12	_	NN	NN	_	8	PMOD	_	_
13	responded	_	VBD	VBD	_	0	ROOT-S	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	IL-12	_	NN	NN	_	14	PMOD	_	_
16	by	_	IN	IN	_	13	ADV	_	_
17	additional	_	JJ	JJ	_	18	NMOD	_	_
18	enhancement	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	IFN-gamma	_	NN	NN	_	21	NMOD	_	_
21	production	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	IL-12	_	NN	NN	_	3	NMOD	_	_
3	nonresponsiveness	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	Th2	_	NN	NN	_	7	NMOD	_	_
7	clones	_	NNS	NNS	_	4	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	further	_	RBR	RBR	_	10	AMOD	_	_
10	evident	_	JJ	JJ	_	8	PRD	_	_
11	by	_	IN	IN	_	8	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	total	_	JJ	JJ	_	14	NMOD	_	_
14	lack	_	NN	NN	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	IL-12-induced	_	JJ	JJ	_	17	NMOD	_	_
17	phosphorylation	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	STAT4	_	NN	NN	_	18	PMOD	_	_
20	(	_	(	(	_	22	P	_	_
21	signal	_	NN	NN	_	22	NMOD	_	_
22	transducer	_	NN	NN	_	19	PRN	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	activator	_	NN	NN	_	22	COORD	_	_
25	of	_	IN	IN	_	22	NMOD	_	_
26	transcription-4	_	NN	NN	_	25	PMOD	_	_
27	)	_	)	)	_	22	P	_	_
28	,	_	,	,	_	19	P	_	_
29	a	_	DT	DT	_	31	NMOD	_	_
30	transcription	_	NN	NN	_	31	NMOD	_	_
31	factor	_	NN	NN	_	19	NMOD	_	_
32	that	_	WDT	WDT	_	33	SBJ	_	_
33	is	_	VBZ	VBZ	_	31	NMOD	_	_
34	typically	_	RB	RB	_	35	ADV	_	_
35	involved	_	VBN	VBN	_	33	VC	_	_
36	in	_	IN	IN	_	35	ADV	_	_
37	IL-12	_	NN	NN	_	38	NMOD	_	_
38	signaling	_	NN	NN	_	36	PMOD	_	_
39	.	_	.	.	_	8	P	_	_

1	Consequently	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	IL-12	_	NN	NN	_	5	SBJ	_	_
4	also	_	RB	RB	_	5	ADV	_	_
5	failed	_	VBD	VBD	_	0	ROOT-S	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	induce	_	VB	VB	_	5	OBJ	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	DNA-binding	_	JJ	JJ	_	10	NMOD	_	_
10	activity	_	NN	NN	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	STAT4-containing	_	JJ	JJ	_	13	NMOD	_	_
13	complexes	_	NNS	NNS	_	11	PMOD	_	_
14	in	_	IN	IN	_	10	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	nuclei	_	NNS	NNS	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	these	_	DT	DT	_	20	NMOD	_	_
19	Th2	_	NN	NN	_	20	NMOD	_	_
20	clones	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	5	P	_	_

1	All	_	DT	DT	_	2	NMOD	_	_
2	TCC	_	NN	NN	_	3	SBJ	_	_
3	expressed	_	VBD	VBD	_	0	ROOT-S	_	_
4	equal	_	JJ	JJ	_	5	NMOD	_	_
5	levels	_	NNS	NNS	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	11	NMOD	_	_
8	low-affinity	_	JJ	JJ	_	11	NMOD	_	_
9	IL-12R	_	NN	NN	_	11	NMOD	_	_
10	beta1	_	NN	NN	_	11	NMOD	_	_
11	subunit	_	NN	NN	_	6	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	human	_	JJ	JJ	_	8	NMOD	_	_
6	allergen-specific	_	JJ	JJ	_	8	NMOD	_	_
7	Th	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	15	SBJ	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	strongly	_	RB	RB	_	11	AMOD	_	_
11	polarized	_	VBN	VBN	_	14	NMOD	_	_
12	Th2	_	NN	NN	_	14	NMOD	_	_
13	cytokine	_	NN	NN	_	14	NMOD	_	_
14	profiles	_	NNS	NNS	_	9	PMOD	_	_
15	do	_	VBP	VBP	_	4	VMOD	_	_
16	not	_	RB	RB	_	15	VMOD	_	_
17	respond	_	VB	VB	_	15	VC	_	_
18	to	_	TO	TO	_	17	ADV	_	_
19	IL-12	_	NN	NN	_	18	PMOD	_	_
20	and	_	CC	CC	_	15	CC	_	_
21	,	_	,	,	_	15	P	_	_
22	therefore	_	RB	RB	_	15	COORD	_	_
23	,	_	,	,	_	15	P	_	_
24	can	_	MD	MD	_	15	COORD	_	_
25	not	_	RB	RB	_	24	VMOD	_	_
26	be	_	VB	VB	_	24	VC	_	_
27	induced	_	VBN	VBN	_	26	VC	_	_
28	to	_	TO	TO	_	29	VMOD	_	_
29	produce	_	VB	VB	_	27	OBJ	_	_
30	IFN-gamma	_	NN	NN	_	29	OBJ	_	_
31	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	apparent	_	JJ	JJ	_	4	NMOD	_	_
3	high	_	JJ	JJ	_	4	NMOD	_	_
4	frequency	_	NN	NN	_	16	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	IL-12-nonresponsive	_	JJ	JJ	_	8	NMOD	_	_
7	Th	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	5	PMOD	_	_
9	within	_	IN	IN	_	4	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	allergen-specific	_	JJ	JJ	_	12	NMOD	_	_
12	populations	_	NNS	NNS	_	9	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	atopic	_	JJ	JJ	_	15	NMOD	_	_
15	patients	_	NNS	NNS	_	13	PMOD	_	_
16	predicts	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	a	_	DT	DT	_	20	NMOD	_	_
18	limited	_	JJ	JJ	_	20	NMOD	_	_
19	skewing	_	JJ	JJ	_	20	NMOD	_	_
20	potential	_	NN	NN	_	16	IOBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	IL-12	_	NN	NN	_	21	PMOD	_	_
23	in	_	IN	IN	_	20	NMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	case	_	NN	NN	_	23	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	established	_	JJ	JJ	_	29	NMOD	_	_
28	Th2	_	NN	NN	_	29	NMOD	_	_
29	responses	_	NNS	NNS	_	26	PMOD	_	_
30	,	_	,	,	_	16	P	_	_
31	but	_	CC	CC	_	16	CC	_	_
32	only	_	RB	RB	_	33	ADV	_	_
33	affecting	_	VBG	VBG	_	16	OBJ	_	_
34	newly	_	RB	RB	_	35	AMOD	_	_
35	recruited	_	VBN	VBN	_	38	NMOD	_	_
36	naive	_	JJ	JJ	_	38	NMOD	_	_
37	Th	_	NN	NN	_	38	NMOD	_	_
38	cells	_	NNS	NNS	_	33	OBJ	_	_
39	.	_	.	.	_	16	P	_	_

1	Characterization	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	CD43\/leukosialin-mediated	_	JJ	JJ	_	5	NMOD	_	_
5	pathway	_	NN	NN	_	2	PMOD	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	inducing	_	VBG	VBG	_	6	PMOD	_	_
8	apoptosis	_	NN	NN	_	7	OBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	T-lymphoblastoid	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	PMOD	_	_
13	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	7	NMOD	_	_
2	monoclonal	_	JJ	JJ	_	3	NMOD	_	_
3	antibody	_	NN	NN	_	7	NMOD	_	_
4	(	_	(	(	_	5	P	_	_
5	mAb	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	J393	_	NN	NN	_	8	SBJ	_	_
8	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	apoptosis	_	NN	NN	_	8	OBJ	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	Jurkat	_	NN	NN	_	12	NMOD	_	_
12	T-cells	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	8	P	_	_

1	NH2-terminal	_	JJ	JJ	_	5	NMOD	_	_
2	amino	_	NN	NN	_	5	NMOD	_	_
3	acid	_	NN	NN	_	5	NMOD	_	_
4	sequence	_	NN	NN	_	5	NMOD	_	_
5	analysis	_	NN	NN	_	6	SBJ	_	_
6	identified	_	VBD	VBD	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	140-kDa	_	JJ	JJ	_	10	NMOD	_	_
9	surface	_	NN	NN	_	10	NMOD	_	_
10	antigen	_	NN	NN	_	6	OBJ	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	mAb	_	NN	NN	_	13	NMOD	_	_
13	J393	_	NN	NN	_	11	PMOD	_	_
14	as	_	IN	IN	_	6	ADV	_	_
15	CD43\/leukosialin	_	NN	NN	_	14	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	major	_	JJ	JJ	_	19	NMOD	_	_
19	sialoglycoprotein	_	NN	NN	_	15	NMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	leukocytes	_	NNS	NNS	_	20	PMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	While	_	IN	IN	_	24	ADV	_	_
2	Jurkat	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	4	SBJ	_	_
4	co-expressed	_	VBD	VBD	_	1	VMOD	_	_
5	two	_	CD	CD	_	8	NMOD	_	_
6	discrete	_	JJ	JJ	_	8	NMOD	_	_
7	cell-surface	_	JJ	JJ	_	8	NMOD	_	_
8	isoforms	_	NNS	NNS	_	4	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	CD43	_	NN	NN	_	9	PMOD	_	_
11	,	_	,	,	_	8	P	_	_
12	recognized	_	VBN	VBN	_	8	NMOD	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	mAb	_	NN	NN	_	15	NMOD	_	_
15	J393	_	NN	NN	_	13	PMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	mAb	_	NN	NN	_	18	NMOD	_	_
18	G10-2	_	NN	NN	_	15	COORD	_	_
19	,	_	,	,	_	15	P	_	_
20	respectively	_	RB	RB	_	15	NMOD	_	_
21	,	_	,	,	_	24	P	_	_
22	only	_	RB	RB	_	23	NMOD	_	_
23	J393\/CD43	_	NN	NN	_	24	SBJ	_	_
24	signaled	_	VBD	VBD	_	0	ROOT-S	_	_
25	apoptosis	_	NN	NN	_	24	OBJ	_	_
26	.	_	.	.	_	24	P	_	_

1	J393\/CD43	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	to	_	TO	TO	_	5	VMOD	_	_
5	be	_	VB	VB	_	3	OBJ	_	_
6	hyposialylated	_	VBN	VBN	_	5	VC	_	_
7	,	_	,	,	_	6	P	_	_
8	bearing	_	VBG	VBG	_	6	OBJ	_	_
9	predominantly	_	RB	RB	_	10	AMOD	_	_
10	O-linked	_	JJ	JJ	_	12	NMOD	_	_
11	monosaccharide	_	NN	NN	_	12	NMOD	_	_
12	glycans	_	NNS	NNS	_	8	OBJ	_	_
13	,	_	,	,	_	2	P	_	_
14	whereas	_	IN	IN	_	2	COORD	_	_
15	G10-2\/CD43	_	NN	NN	_	16	SBJ	_	_
16	bore	_	VBD	VBD	_	2	COORD	_	_
17	complex	_	JJ	JJ	_	22	NMOD	_	_
18	sialylated	_	VBN	VBN	_	17	AMOD	_	_
19	tetra-	_	JJ	JJ	_	22	NMOD	_	_
20	and	_	CC	CC	_	22	CC	_	_
21	hexasaccharide	_	NN	NN	_	22	COORD	_	_
22	chains	_	NNS	NNS	_	16	OBJ	_	_
23	.	_	.	.	_	2	P	_	_

1	Treatment	_	NN	NN	_	8	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	soluble	_	JJ	JJ	_	7	NMOD	_	_
4	,	_	,	,	_	3	P	_	_
5	bivalent	_	JJ	JJ	_	3	COORD	_	_
6	mAb	_	NN	NN	_	7	NMOD	_	_
7	J393	_	NN	NN	_	2	PMOD	_	_
8	killed	_	VBD	VBD	_	0	ROOT-S	_	_
9	25-50	_	CD	CD	_	10	NMOD	_	_
10	%	_	NN	NN	_	8	IOBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	population	_	NN	NN	_	11	PMOD	_	_
15	,	_	,	,	_	8	P	_	_
16	while	_	IN	IN	_	8	OBJ	_	_
17	concomitant	_	JJ	JJ	_	18	NMOD	_	_
18	engagement	_	NN	NN	_	31	SBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	either	_	CC	CC	_	23	CC	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	CD3.TcR	_	NN	NN	_	23	NMOD	_	_
23	complex	_	NN	NN	_	19	PMOD	_	_
24	or	_	CC	CC	_	23	CC	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	integrins	_	NNS	NNS	_	23	COORD	_	_
27	CD18	_	NN	NN	_	26	NMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	CD29	_	NN	NN	_	27	COORD	_	_
30	significantly	_	RB	RB	_	31	ADV	_	_
31	potentiated	_	VBD	VBD	_	16	VMOD	_	_
32	this	_	DT	DT	_	33	NMOD	_	_
33	effect	_	NN	NN	_	31	OBJ	_	_
34	.	_	.	.	_	8	P	_	_

1	Treatment	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	Jurkat	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	mAb	_	NN	NN	_	7	NMOD	_	_
7	J393	_	NN	NN	_	5	PMOD	_	_
8	induced	_	VBD	VBD	_	0	ROOT-S	_	_
9	tyrosine	_	NN	NN	_	10	NMOD	_	_
10	phosphorylation	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	specific	_	JJ	JJ	_	14	NMOD	_	_
13	protein	_	NN	NN	_	14	NMOD	_	_
14	substrates	_	NNS	NNS	_	11	PMOD	_	_
15	that	_	WDT	WDT	_	16	SBJ	_	_
16	underwent	_	VBD	VBD	_	14	NMOD	_	_
17	hyperphosphorylation	_	NN	NN	_	16	OBJ	_	_
18	upon	_	IN	IN	_	16	TMP	_	_
19	antigen	_	NN	NN	_	21	NMOD	_	_
20	receptor	_	NN	NN	_	21	NMOD	_	_
21	costimulation	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	8	P	_	_

1	Tyrosine	_	NN	NN	_	3	NMOD	_	_
2	kinase	_	NN	NN	_	3	NMOD	_	_
3	inhibition	_	NN	NN	_	7	SBJ	_	_
4	by	_	IN	IN	_	3	NMOD	_	_
5	herbimycin	_	NN	NN	_	6	NMOD	_	_
6	A	_	NN	NN	_	4	PMOD	_	_
7	diminished	_	VBD	VBD	_	0	ROOT-S	_	_
8	J393\/CD43-mediated	_	JJ	JJ	_	9	NMOD	_	_
9	apoptosis	_	NN	NN	_	7	OBJ	_	_
10	,	_	,	,	_	7	P	_	_
11	whereas	_	IN	IN	_	7	COORD	_	_
12	inhibition	_	NN	NN	_	19	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	phosphotyrosine	_	NN	NN	_	16	NMOD	_	_
15	phosphatase	_	NN	NN	_	16	NMOD	_	_
16	activity	_	NN	NN	_	13	PMOD	_	_
17	by	_	IN	IN	_	12	NMOD	_	_
18	bis-LRB-maltolato-RRB-oxovanadium-IV	_	NN	NN	_	17	PMOD	_	_
19	enhanced	_	VBD	VBD	_	7	COORD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	death	_	NN	NN	_	19	OBJ	_	_
22	.	_	.	.	_	7	P	_	_

1	Signal	_	NN	NN	_	2	NMOD	_	_
2	transduction	_	NN	NN	_	7	SBJ	_	_
3	through	_	IN	IN	_	2	NMOD	_	_
4	tyrosine	_	NN	NN	_	6	NMOD	_	_
5	kinase	_	NN	NN	_	6	NMOD	_	_
6	activation	_	NN	NN	_	3	PMOD	_	_
7	may	_	MD	MD	_	0	ROOT-S	_	_
8	lead	_	VB	VB	_	7	VC	_	_
9	to	_	TO	TO	_	8	ADV	_	_
10	altered	_	JJ	JJ	_	12	NMOD	_	_
11	gene	_	NN	NN	_	12	NMOD	_	_
12	expression	_	NN	NN	_	9	PMOD	_	_
13	,	_	,	,	_	7	P	_	_
14	as	_	IN	IN	_	7	ADV	_	_
15	J393\/CD43	_	NN	NN	_	16	NMOD	_	_
16	ligation	_	NN	NN	_	17	SBJ	_	_
17	prompted	_	VBD	VBD	_	14	VMOD	_	_
18	decreases	_	NNS	NNS	_	17	OBJ	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	nuclear	_	JJ	JJ	_	22	NMOD	_	_
22	localization	_	NN	NN	_	19	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	28	NMOD	_	_
25	transcriptional	_	JJ	JJ	_	28	NMOD	_	_
26	regulatory	_	JJ	JJ	_	28	NMOD	_	_
27	protein	_	NN	NN	_	28	NMOD	_	_
28	NF-kappaB	_	NN	NN	_	23	PMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	proteins	_	NNS	NNS	_	28	COORD	_	_
31	binding	_	VBG	VBG	_	30	NMOD	_	_
32	the	_	DT	DT	_	35	NMOD	_	_
33	interferon-inducible	_	JJ	JJ	_	35	NMOD	_	_
34	regulatory	_	JJ	JJ	_	35	NMOD	_	_
35	element	_	NN	NN	_	31	OBJ	_	_
36	.	_	.	.	_	7	P	_	_

1	Since	_	IN	IN	_	14	ADV	_	_
2	peripheral	_	JJ	JJ	_	4	NMOD	_	_
3	blood	_	NN	NN	_	4	NMOD	_	_
4	T-lymphocytes	_	NNS	NNS	_	5	SBJ	_	_
5	express	_	VBP	VBP	_	1	VMOD	_	_
6	cryptic	_	JJ	JJ	_	7	NMOD	_	_
7	epitopes	_	NNS	NNS	_	5	OBJ	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	mAb	_	NN	NN	_	10	NMOD	_	_
10	J393	_	NN	NN	_	8	PMOD	_	_
11	,	_	,	,	_	14	P	_	_
12	these	_	DT	DT	_	13	NMOD	_	_
13	findings	_	NNS	NNS	_	14	SBJ	_	_
14	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	existence	_	NN	NN	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	a	_	DT	DT	_	22	NMOD	_	_
19	tightly	_	RB	RB	_	20	AMOD	_	_
20	regulated	_	VBN	VBN	_	22	NMOD	_	_
21	CD43-mediated	_	JJ	JJ	_	22	NMOD	_	_
22	pathway	_	NN	NN	_	17	PMOD	_	_
23	for	_	IN	IN	_	22	NMOD	_	_
24	inducing	_	VBG	VBG	_	23	PMOD	_	_
25	apoptosis	_	NN	NN	_	24	OBJ	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	human	_	JJ	JJ	_	29	NMOD	_	_
28	T-cell	_	NN	NN	_	29	NMOD	_	_
29	lineages	_	NNS	NNS	_	26	PMOD	_	_
30	.	_	.	.	_	14	P	_	_

1	Identification	_	NN	NN	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	characterization	_	NN	NN	_	1	COORD	_	_
4	of	_	IN	IN	_	1	NMOD	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	leukocyte-specific	_	JJ	JJ	_	7	NMOD	_	_
7	component	_	NN	NN	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	nuclear	_	JJ	JJ	_	11	NMOD	_	_
11	body	_	NN	NN	_	8	PMOD	_	_
12	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	nuclear	_	JJ	JJ	_	3	NMOD	_	_
3	body	_	NN	NN	_	7	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	NB	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	cellular	_	JJ	JJ	_	10	NMOD	_	_
10	organelle	_	NN	NN	_	7	PRD	_	_
11	that	_	WDT	WDT	_	12	SBJ	_	_
12	is	_	VBZ	VBZ	_	10	NMOD	_	_
13	involved	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	pathogenesis	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	acute	_	JJ	JJ	_	20	NMOD	_	_
19	promyelocytic	_	JJ	JJ	_	20	NMOD	_	_
20	leukemia	_	NN	NN	_	17	PMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	viral	_	JJ	JJ	_	23	NMOD	_	_
23	infection	_	NN	NN	_	20	COORD	_	_
24	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	NB	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	also	_	RB	RB	_	3	ADV	_	_
5	a	_	DT	DT	_	6	NMOD	_	_
6	target	_	NN	NN	_	3	PRD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	antibodies	_	NNS	NNS	_	7	PMOD	_	_
9	in	_	IN	IN	_	6	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	serum	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	patients	_	NNS	NNS	_	12	PMOD	_	_
14	with	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	20	NMOD	_	_
16	autoimmune	_	JJ	JJ	_	20	NMOD	_	_
17	disease	_	NN	NN	_	20	NMOD	_	_
18	primary	_	JJ	JJ	_	20	NMOD	_	_
19	biliary	_	JJ	JJ	_	20	NMOD	_	_
20	cirrhosis	_	NN	NN	_	14	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	13	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	13	P	_	_
5	serum	_	NN	NN	_	13	SBJ	_	_
6	from	_	IN	IN	_	5	NMOD	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	patient	_	NN	NN	_	6	PMOD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	primary	_	JJ	JJ	_	12	NMOD	_	_
11	biliary	_	JJ	JJ	_	12	NMOD	_	_
12	cirrhosis	_	NN	NN	_	9	PMOD	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	used	_	VBN	VBN	_	13	VC	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	identify	_	VB	VB	_	14	OBJ	_	_
17	a	_	DT	DT	_	18	NMOD	_	_
18	cDNA	_	NN	NN	_	16	OBJ	_	_
19	encoding	_	VBG	VBG	_	18	NMOD	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	novel	_	JJ	JJ	_	22	NMOD	_	_
22	component	_	NN	NN	_	19	OBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	NB	_	NN	NN	_	23	PMOD	_	_
26	,	_	,	,	_	22	P	_	_
27	a	_	DT	DT	_	29	NMOD	_	_
28	140-kDa	_	JJ	JJ	_	29	NMOD	_	_
29	protein	_	NN	NN	_	22	NMOD	_	_
30	designated	_	VBN	VBN	_	29	NMOD	_	_
31	Sp140	_	NN	NN	_	30	OBJ	_	_
32	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	predicted	_	VBN	VBN	_	5	NMOD	_	_
3	amino	_	NN	NN	_	5	NMOD	_	_
4	acid	_	NN	NN	_	5	NMOD	_	_
5	sequence	_	NN	NN	_	12	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	amino-terminal	_	JJ	JJ	_	9	NMOD	_	_
9	portion	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	Sp140	_	NN	NN	_	10	PMOD	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	similar	_	JJ	JJ	_	12	PRD	_	_
14	to	_	TO	TO	_	13	AMOD	_	_
15	Sp100	_	NN	NN	_	14	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	a	_	DT	DT	_	21	NMOD	_	_
18	previously	_	RB	RB	_	19	AMOD	_	_
19	identified	_	VBN	VBN	_	21	NMOD	_	_
20	NB	_	NN	NN	_	21	NMOD	_	_
21	protein	_	NN	NN	_	15	NMOD	_	_
22	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	carboxyl	_	JJ	JJ	_	3	NMOD	_	_
3	portion	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	Sp140	_	NN	NN	_	4	PMOD	_	_
6	contained	_	VBD	VBD	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	zinc-finger	_	JJ	JJ	_	9	NMOD	_	_
9	domain	_	NN	NN	_	6	OBJ	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	bromodomain	_	NN	NN	_	9	COORD	_	_
13	,	_	,	,	_	9	P	_	_
14	motifs	_	NNS	NNS	_	9	NMOD	_	_
15	that	_	WDT	WDT	_	16	SBJ	_	_
16	are	_	VBP	VBP	_	14	NMOD	_	_
17	present	_	JJ	JJ	_	16	PRD	_	_
18	in	_	IN	IN	_	17	AMOD	_	_
19	proteins	_	NNS	NNS	_	18	PMOD	_	_
20	regulating	_	VBG	VBG	_	19	NMOD	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	transcription	_	NN	NN	_	20	OBJ	_	_
23	.	_	.	.	_	6	P	_	_

1	High	_	JJ	JJ	_	2	NMOD	_	_
2	levels	_	NNS	NNS	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	Sp140	_	NN	NN	_	5	NMOD	_	_
5	mRNA	_	NN	NN	_	3	PMOD	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	detected	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	human	_	JJ	JJ	_	14	NMOD	_	_
10	spleen	_	NN	NN	_	14	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	peripheral	_	JJ	JJ	_	13	NMOD	_	_
13	blood	_	NN	NN	_	10	COORD	_	_
14	leukocytes	_	NNS	NNS	_	8	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	but	_	CC	CC	_	14	CC	_	_
17	not	_	RB	RB	_	16	COORD	_	_
18	other	_	JJ	JJ	_	20	NMOD	_	_
19	human	_	JJ	JJ	_	20	NMOD	_	_
20	tissues	_	NNS	NNS	_	14	COORD	_	_
21	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	level	_	NN	NN	_	15	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	SP140	_	NN	NN	_	5	NMOD	_	_
5	mRNA	_	NN	NN	_	3	PMOD	_	_
6	in	_	IN	IN	_	2	NMOD	_	_
7	myeloid	_	JJ	JJ	_	10	NMOD	_	_
8	precursor	_	NN	NN	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	lines	_	NNS	NNS	_	6	PMOD	_	_
11	HL60	_	NN	NN	_	10	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	NB4	_	NN	NN	_	11	COORD	_	_
14	markedly	_	RB	RB	_	15	ADV	_	_
15	increased	_	VBD	VBD	_	0	ROOT-S	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	response	_	NN	NN	_	16	DEP	_	_
18	to	_	TO	TO	_	16	DEP	_	_
19	chemically	_	RB	RB	_	20	AMOD	_	_
20	induced	_	VBN	VBN	_	22	NMOD	_	_
21	cellular	_	JJ	JJ	_	22	NMOD	_	_
22	differentiation	_	NN	NN	_	16	PMOD	_	_
23	.	_	.	.	_	15	P	_	_

1	Immunohistochemical	_	JJ	JJ	_	2	NMOD	_	_
2	techniques	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	used	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	demonstrate	_	VB	VB	_	4	OBJ	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	SP140	_	NN	NN	_	9	SBJ	_	_
9	localized	_	VBD	VBD	_	7	VMOD	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	NB	_	NN	NN	_	10	PMOD	_	_
13	in	_	IN	IN	_	9	ADV	_	_
14	differentiated	_	VBN	VBN	_	18	NMOD	_	_
15	HL60	_	NN	NN	_	18	NMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	NB4	_	NN	NN	_	15	COORD	_	_
18	cells	_	NNS	NNS	_	13	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	location	_	NN	NN	_	21	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	Sp140	_	NN	NN	_	3	PMOD	_	_
5	in	_	IN	IN	_	2	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	NB	_	NN	NN	_	5	PMOD	_	_
8	,	_	,	,	_	2	P	_	_
9	and	_	CC	CC	_	2	CC	_	_
10	expression	_	NN	NN	_	2	COORD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	this	_	DT	DT	_	13	NMOD	_	_
13	gene	_	NN	NN	_	11	PMOD	_	_
14	in	_	IN	IN	_	10	NMOD	_	_
15	cells	_	NNS	NNS	_	14	PMOD	_	_
16	involved	_	VBN	VBN	_	15	NMOD	_	_
17	in	_	IN	IN	_	16	ADV	_	_
18	host	_	NN	NN	_	19	NMOD	_	_
19	defense	_	NN	NN	_	17	PMOD	_	_
20	,	_	,	,	_	2	P	_	_
21	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	Sp140	_	NN	NN	_	24	SBJ	_	_
24	may	_	MD	MD	_	22	VMOD	_	_
25	be	_	VB	VB	_	24	VC	_	_
26	involved	_	VBN	VBN	_	25	VC	_	_
27	in	_	IN	IN	_	26	ADV	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	pathogenesis	_	NN	NN	_	27	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	acute	_	JJ	JJ	_	33	NMOD	_	_
32	promyelocytic	_	JJ	JJ	_	33	NMOD	_	_
33	leukemia	_	NN	NN	_	30	PMOD	_	_
34	and	_	CC	CC	_	33	CC	_	_
35	viral	_	JJ	JJ	_	36	NMOD	_	_
36	infection	_	NN	NN	_	33	COORD	_	_
37	.	_	.	.	_	21	P	_	_

1	T-cell-directed	_	JJ	JJ	_	3	NMOD	_	_
2	TAL-1	_	NN	NN	_	3	NMOD	_	_
3	expression	_	NN	NN	_	4	SBJ	_	_
4	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	T-cell	_	NN	NN	_	6	NMOD	_	_
6	malignancies	_	NNS	NNS	_	4	OBJ	_	_
7	in	_	IN	IN	_	4	ADV	_	_
8	transgenic	_	JJ	JJ	_	9	NMOD	_	_
9	mice	_	NNS	NNS	_	7	PMOD	_	_
10	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	TAL-1	_	NN	NN	_	3	NMOD	_	_
3	gene	_	NN	NN	_	4	SBJ	_	_
4	specifies	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	for	_	IN	IN	_	4	ADV	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	basic	_	JJ	JJ	_	9	NMOD	_	_
8	domain-helix-loop-helix	_	JJ	JJ	_	9	NMOD	_	_
9	protein	_	NN	NN	_	5	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	is	_	VBZ	VBZ	_	9	NMOD	_	_
13	involved	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	control	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	normal	_	JJ	JJ	_	19	NMOD	_	_
19	hematopoiesis	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	human	_	JJ	JJ	_	3	NMOD	_	_
3	pathology	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	9	P	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	TAL-1	_	NN	NN	_	8	NMOD	_	_
7	gene	_	NN	NN	_	8	NMOD	_	_
8	product	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	expressed	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	high	_	JJ	JJ	_	14	NMOD	_	_
14	percentage	_	NN	NN	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	T-cell	_	NN	NN	_	19	NMOD	_	_
17	acute	_	JJ	JJ	_	19	NMOD	_	_
18	lymphoblastic	_	JJ	JJ	_	19	NMOD	_	_
19	leukemias	_	NNS	NNS	_	15	PMOD	_	_
20	in	_	IN	IN	_	10	ADV	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	pediatric	_	JJ	JJ	_	24	NMOD	_	_
23	age	_	NN	NN	_	24	NMOD	_	_
24	range	_	NN	NN	_	20	PMOD	_	_
25	;	_	:	:	_	9	P	_	_
26	however	_	RB	RB	_	29	ADV	_	_
27	,	_	,	,	_	29	P	_	_
28	it	_	PRP	PRP	_	29	SBJ	_	_
29	has	_	VBZ	VBZ	_	9	VC	_	_
30	not	_	RB	RB	_	29	VMOD	_	_
31	been	_	VBN	VBN	_	29	VC	_	_
32	established	_	VBN	VBN	_	31	VC	_	_
33	whether	_	IN	IN	_	32	OBJ	_	_
34	the	_	DT	DT	_	35	NMOD	_	_
35	expression	_	NN	NN	_	36	SBJ	_	_
36	has	_	VBZ	VBZ	_	33	VMOD	_	_
37	a	_	DT	DT	_	39	NMOD	_	_
38	causal	_	JJ	JJ	_	39	NMOD	_	_
39	role	_	NN	NN	_	36	OBJ	_	_
40	in	_	IN	IN	_	36	ADV	_	_
41	oncogenesis	_	NN	NN	_	40	PMOD	_	_
42	.	_	.	.	_	29	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	describe	_	VBP	VBP	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	phenotype	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	mouse	_	NN	NN	_	12	NMOD	_	_
11	transgenic	_	JJ	JJ	_	12	NMOD	_	_
12	lines	_	NNS	NNS	_	9	PMOD	_	_
13	obtained	_	VBN	VBN	_	8	NMOD	_	_
14	by	_	IN	IN	_	13	ADV	_	_
15	inducing	_	VBG	VBG	_	14	PMOD	_	_
16	tal-1	_	NN	NN	_	18	NMOD	_	_
17	protein	_	NN	NN	_	18	NMOD	_	_
18	expression	_	NN	NN	_	15	IOBJ	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	lymphoid	_	JJ	JJ	_	21	NMOD	_	_
21	tissues	_	NNS	NNS	_	19	PMOD	_	_
22	using	_	VBG	VBG	_	15	OBJ	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	LCK	_	NN	NN	_	25	NMOD	_	_
25	promoter	_	NN	NN	_	22	OBJ	_	_
26	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	survival	_	NN	NN	_	3	NMOD	_	_
3	rate	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	tal-1	_	NN	NN	_	7	NMOD	_	_
6	transgenic	_	JJ	JJ	_	7	NMOD	_	_
7	animals	_	NNS	NNS	_	4	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	much	_	RB	RB	_	10	AMOD	_	_
10	lower	_	JJR	JJR	_	8	PRD	_	_
11	as	_	IN	IN	_	8	ADV	_	_
12	compared	_	VBN	VBN	_	11	VMOD	_	_
13	with	_	IN	IN	_	12	ADV	_	_
14	control	_	NN	NN	_	15	NMOD	_	_
15	mice	_	NNS	NNS	_	13	PMOD	_	_
16	.	_	.	.	_	8	P	_	_

1	Histopathological	_	JJ	JJ	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	3	SBJ	_	_
3	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
4	lymphomas	_	NNS	NNS	_	3	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	T-cell	_	NN	NN	_	7	NMOD	_	_
7	type	_	NN	NN	_	5	PMOD	_	_
8	,	_	,	,	_	4	P	_	_
9	often	_	RB	RB	_	10	TMP	_	_
10	comprising	_	VBG	VBG	_	4	NMOD	_	_
11	a	_	DT	DT	_	14	NMOD	_	_
12	minor	_	JJ	JJ	_	14	NMOD	_	_
13	B-cell	_	NN	NN	_	14	NMOD	_	_
14	component	_	NN	NN	_	10	OBJ	_	_
15	.	_	.	.	_	3	P	_	_

1	Some	_	DT	DT	_	2	NMOD	_	_
2	mice	_	NNS	NNS	_	3	SBJ	_	_
3	showed	_	VBD	VBD	_	0	ROOT-S	_	_
4	marked	_	JJ	JJ	_	7	NMOD	_	_
5	splenic	_	JJ	JJ	_	7	NMOD	_	_
6	lymphocyte	_	NN	NN	_	7	NMOD	_	_
7	depletion	_	NN	NN	_	3	OBJ	_	_
8	.	_	.	.	_	3	P	_	_

1	Primary	_	JJ	JJ	_	3	NMOD	_	_
2	lymphocyte	_	NN	NN	_	3	NMOD	_	_
3	cultures	_	NNS	NNS	_	4	SBJ	_	_
4	showed	_	VBD	VBD	_	0	ROOT-S	_	_
5	partial	_	JJ	JJ	_	6	NMOD	_	_
6	independence	_	NN	NN	_	4	OBJ	_	_
7	from	_	IN	IN	_	6	NMOD	_	_
8	exogenous	_	JJ	JJ	_	10	NMOD	_	_
9	growth	_	NN	NN	_	10	NMOD	_	_
10	stimuli	_	NNS	NNS	_	7	PMOD	_	_
11	and	_	CC	CC	_	4	CC	_	_
12	increased	_	VBD	VBD	_	4	COORD	_	_
13	resistance	_	NN	NN	_	12	OBJ	_	_
14	to	_	TO	TO	_	13	NMOD	_	_
15	low-serum	_	JJ	JJ	_	16	NMOD	_	_
16	apoptosis	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	4	P	_	_

1	To	_	TO	TO	_	3	VMOD	_	_
2	further	_	RB	RB	_	3	ADV	_	_
3	unravel	_	VB	VB	_	15	VC	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	tal-1	_	NN	NN	_	7	NMOD	_	_
6	oncogenic	_	JJ	JJ	_	7	NMOD	_	_
7	potential	_	NN	NN	_	3	OBJ	_	_
8	,	_	,	,	_	15	P	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	strain	_	NN	NN	_	15	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	tal-1	_	NN	NN	_	14	NMOD	_	_
13	transgenic	_	JJ	JJ	_	14	NMOD	_	_
14	mice	_	NNS	NNS	_	11	PMOD	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	crossbred	_	VBN	VBN	_	15	VC	_	_
17	with	_	IN	IN	_	16	ADV	_	_
18	p53-\/-	_	JJ	JJ	_	19	NMOD	_	_
19	mice	_	NNS	NNS	_	17	PMOD	_	_
20	;	_	:	:	_	15	P	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	survival	_	NN	NN	_	23	NMOD	_	_
23	rate	_	NN	NN	_	27	SBJ	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	these	_	DT	DT	_	26	NMOD	_	_
26	animals	_	NNS	NNS	_	24	PMOD	_	_
27	was	_	VBD	VBD	_	15	VC	_	_
28	reduced	_	VBN	VBN	_	27	VC	_	_
29	by	_	IN	IN	_	28	ADV	_	_
30	more	_	JJR	JJR	_	32	DEP	_	_
31	than	_	IN	IN	_	32	DEP	_	_
32	one-half	_	NN	NN	_	29	PMOD	_	_
33	when	_	WRB	WRB	_	34	ADV	_	_
34	compared	_	VBN	VBN	_	28	TMP	_	_
35	with	_	IN	IN	_	34	ADV	_	_
36	that	_	DT	DT	_	35	PMOD	_	_
37	of	_	IN	IN	_	36	NMOD	_	_
38	tal-1	_	NN	NN	_	39	NMOD	_	_
39	mice	_	NNS	NNS	_	37	PMOD	_	_
40	,	_	,	,	_	27	P	_	_
41	and	_	CC	CC	_	27	CC	_	_
42	histopathological	_	JJ	JJ	_	43	NMOD	_	_
43	analysis	_	NN	NN	_	44	SBJ	_	_
44	revealed	_	VBD	VBD	_	27	COORD	_	_
45	exclusively	_	RB	RB	_	44	ADV	_	_
46	T-cell	_	NN	NN	_	47	NMOD	_	_
47	lymphomas	_	NNS	NNS	_	44	OBJ	_	_
48	.	_	.	.	_	27	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	TAL-1	_	NN	NN	_	12	SBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	expressed	_	VBN	VBN	_	5	NMOD	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	,	_	,	,	_	5	P	_	_
12	is	_	VBZ	VBZ	_	4	VMOD	_	_
13	per	_	FW	FW	_	12	ADV	_	_
14	se	_	FW	FW	_	13	AMOD	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	potent	_	JJ	JJ	_	17	NMOD	_	_
17	oncogene	_	NN	NN	_	12	PRD	_	_
18	,	_	,	,	_	17	P	_	_
19	which	_	WDT	WDT	_	20	SBJ	_	_
20	may	_	MD	MD	_	17	NMOD	_	_
21	exert	_	VB	VB	_	20	VC	_	_
22	a	_	DT	DT	_	25	NMOD	_	_
23	key	_	JJ	JJ	_	25	NMOD	_	_
24	leukemogenetic	_	JJ	JJ	_	25	NMOD	_	_
25	role	_	NN	NN	_	21	OBJ	_	_
26	in	_	IN	IN	_	21	ADV	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	majority	_	NN	NN	_	26	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	T-cell	_	NN	NN	_	33	NMOD	_	_
31	acute	_	JJ	JJ	_	33	NMOD	_	_
32	lymphoblastic	_	JJ	JJ	_	33	NMOD	_	_
33	leukemias	_	NNS	NNS	_	29	PMOD	_	_
34	.	_	.	.	_	3	P	_	_

1	Naive	_	JJ	JJ	_	6	NMOD	_	_
2	(	_	(	(	_	6	P	_	_
3	CD45RA+	_	JJ	JJ	_	6	NMOD	_	_
4	)	_	)	)	_	6	P	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	lymphocytes	_	NNS	NNS	_	7	SBJ	_	_
7	are	_	VBP	VBP	_	0	ROOT-S	_	_
8	more	_	RBR	RBR	_	9	AMOD	_	_
9	sensitive	_	JJ	JJ	_	7	PRD	_	_
10	to	_	TO	TO	_	9	AMOD	_	_
11	oxidative	_	JJ	JJ	_	12	AMOD	_	_
12	stress-induced	_	JJ	JJ	_	13	NMOD	_	_
13	signals	_	NNS	NNS	_	10	PMOD	_	_
14	than	_	IN	IN	_	9	AMOD	_	_
15	memory	_	NN	NN	_	19	NMOD	_	_
16	(	_	(	(	_	19	P	_	_
17	CD45RO+	_	JJ	JJ	_	19	NMOD	_	_
18	)	_	)	)	_	19	P	_	_
19	cells	_	NNS	NNS	_	14	PMOD	_	_
20	.	_	.	.	_	7	P	_	_

1	Formation	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	reactive	_	JJ	JJ	_	5	NMOD	_	_
4	oxygen	_	NN	NN	_	5	NMOD	_	_
5	intermediates	_	NNS	NNS	_	2	PMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	ROI	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	after	_	IN	IN	_	1	TMP	_	_
10	oxidative	_	JJ	JJ	_	11	NMOD	_	_
11	stress	_	NN	NN	_	9	PMOD	_	_
12	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	been	_	VBN	VBN	_	12	VC	_	_
14	shown	_	VBN	VBN	_	13	VC	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	be	_	VB	VB	_	14	OBJ	_	_
17	an	_	DT	DT	_	19	NMOD	_	_
18	activation	_	NN	NN	_	19	NMOD	_	_
19	signal	_	NN	NN	_	16	PRD	_	_
20	for	_	IN	IN	_	19	NMOD	_	_
21	T	_	NN	NN	_	22	NMOD	_	_
22	lymphocytes	_	NNS	NNS	_	20	PMOD	_	_
23	,	_	,	,	_	16	P	_	_
24	e.g.	_	FW	FW	_	32	ADV	_	_
25	,	_	,	,	_	32	P	_	_
26	expression	_	NN	NN	_	32	SBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	IL-2	_	NN	NN	_	27	PMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	its	_	PRP$	PRP$	_	31	NMOD	_	_
31	receptor	_	NN	NN	_	28	COORD	_	_
32	are	_	VBP	VBP	_	16	COORD	_	_
33	induced	_	VBN	VBN	_	32	VC	_	_
34	.	_	.	.	_	12	P	_	_

1	These	_	DT	DT	_	3	NMOD	_	_
2	ROI-induced	_	JJ	JJ	_	3	NMOD	_	_
3	effects	_	NNS	NNS	_	4	SBJ	_	_
4	can	_	MD	MD	_	0	ROOT-S	_	_
5	,	_	,	,	_	4	P	_	_
6	to	_	TO	TO	_	4	ADV	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	large	_	JJ	JJ	_	9	NMOD	_	_
9	extent	_	NN	NN	_	6	PMOD	_	_
10	,	_	,	,	_	4	P	_	_
11	be	_	VB	VB	_	4	VC	_	_
12	attributed	_	VBN	VBN	_	11	VC	_	_
13	to	_	TO	TO	_	12	ADV	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	activation	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	transcription	_	NN	NN	_	20	NMOD	_	_
19	factor	_	NN	NN	_	20	NMOD	_	_
20	NF-kappaB	_	NN	NN	_	16	PMOD	_	_
21	.	_	.	.	_	4	P	_	_

1	Now	_	RB	RB	_	3	TMP	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	examined	_	VBN	VBN	_	3	VC	_	_
5	whether	_	IN	IN	_	4	OBJ	_	_
6	naive	_	JJ	JJ	_	10	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	memory	_	NN	NN	_	6	COORD	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	lymphocytes	_	NNS	NNS	_	11	SBJ	_	_
11	differ	_	VBP	VBP	_	5	VMOD	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	their	_	PRP$	PRP$	_	14	NMOD	_	_
14	sensitivity	_	NN	NN	_	12	PMOD	_	_
15	to	_	TO	TO	_	14	NMOD	_	_
16	ROI-mediated	_	JJ	JJ	_	17	NMOD	_	_
17	signals	_	NNS	NNS	_	15	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	When	_	WRB	WRB	_	15	ADV	_	_
2	CD45RA+	_	JJ	JJ	_	12	NMOD	_	_
3	(	_	(	(	_	4	P	_	_
4	naive	_	JJ	JJ	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	and	_	CC	CC	_	2	CC	_	_
7	CD45RO+	_	JJ	JJ	_	2	COORD	_	_
8	(	_	(	(	_	9	P	_	_
9	memory	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	T	_	NN	NN	_	12	NMOD	_	_
12	lymphocytes	_	NNS	NNS	_	13	SBJ	_	_
13	were	_	VBD	VBD	_	22	TMP	_	_
14	directly	_	RB	RB	_	15	ADV	_	_
15	stimulated	_	VBN	VBN	_	13	VC	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	H2O2	_	NN	NN	_	16	PMOD	_	_
18	,	_	,	,	_	22	P	_	_
19	NF-kappaB	_	NN	NN	_	21	NMOD	_	_
20	nuclear	_	JJ	JJ	_	21	NMOD	_	_
21	translocation	_	NN	NN	_	22	SBJ	_	_
22	was	_	VBD	VBD	_	0	ROOT-S	_	_
23	stronger	_	JJR	JJR	_	22	PRD	_	_
24	in	_	IN	IN	_	22	ADV	_	_
25	naive	_	JJ	JJ	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	24	PMOD	_	_
27	than	_	IN	IN	_	23	AMOD	_	_
28	in	_	IN	IN	_	27	PMOD	_	_
29	memory	_	NN	NN	_	30	NMOD	_	_
30	cells	_	NNS	NNS	_	28	PMOD	_	_
31	and	_	CC	CC	_	22	CC	_	_
32	it	_	PRP	PRP	_	33	SBJ	_	_
33	could	_	MD	MD	_	22	COORD	_	_
34	be	_	VB	VB	_	33	VC	_	_
35	induced	_	VBN	VBN	_	34	VC	_	_
36	with	_	IN	IN	_	35	ADV	_	_
37	lower	_	JJR	JJR	_	38	NMOD	_	_
38	doses	_	NNS	NNS	_	36	PMOD	_	_
39	.	_	.	.	_	22	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	composition	_	NN	NN	_	16	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	induced	_	VBN	VBN	_	7	NMOD	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	NF-kappaB	_	NN	NN	_	3	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	levels	_	NNS	NNS	_	2	PRN	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	p50	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	RelA	_	NN	NN	_	11	COORD	_	_
14	proteins	_	NNS	NNS	_	10	PMOD	_	_
15	)	_	)	)	_	9	P	_	_
16	was	_	VBD	VBD	_	0	ROOT-S	_	_
17	similar	_	JJ	JJ	_	16	PRD	_	_
18	in	_	IN	IN	_	16	ADV	_	_
19	these	_	DT	DT	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	types	_	NNS	NNS	_	18	PMOD	_	_
22	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	magnitude	_	NN	NN	_	8	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	kinetics	_	NNS	NNS	_	2	COORD	_	_
5	of	_	IN	IN	_	2	NMOD	_	_
6	intracellular	_	JJ	JJ	_	7	NMOD	_	_
7	ROI	_	NN	NN	_	5	PMOD	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	similar	_	JJ	JJ	_	8	PRD	_	_
10	,	_	,	,	_	8	P	_	_
11	suggesting	_	VBG	VBG	_	8	VC	_	_
12	that	_	IN	IN	_	11	OBJ	_	_
13	there	_	EX	EX	_	14	SBJ	_	_
14	were	_	VBD	VBD	_	12	VMOD	_	_
15	no	_	DT	DT	_	16	NMOD	_	_
16	differences	_	NNS	NNS	_	14	PRD	_	_
17	in	_	IN	IN	_	14	ADV	_	_
18	ROI-forming	_	JJ	JJ	_	19	NMOD	_	_
19	mechanisms	_	NNS	NNS	_	17	PMOD	_	_
20	or	_	CC	CC	_	19	CC	_	_
21	antioxidative	_	JJ	JJ	_	22	NMOD	_	_
22	capacities	_	NNS	NNS	_	19	COORD	_	_
23	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	probable	_	JJ	JJ	_	4	NMOD	_	_
3	regulatory	_	JJ	JJ	_	4	NMOD	_	_
4	point	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	cytoplasmic	_	JJ	JJ	_	9	NMOD	_	_
8	IkappaB	_	NN	NN	_	9	NMOD	_	_
9	inhibitor	_	NN	NN	_	5	PRD	_	_
10	:	_	:	:	_	5	P	_	_
11	in	_	IN	IN	_	16	ADV	_	_
12	CD45RA+	_	JJ	JJ	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	,	_	,	,	_	16	P	_	_
15	H2O2	_	NN	NN	_	16	SBJ	_	_
16	caused	_	VBD	VBD	_	5	VC	_	_
17	a	_	DT	DT	_	20	NMOD	_	_
18	more	_	RBR	RBR	_	19	AMOD	_	_
19	profound	_	JJ	JJ	_	20	NMOD	_	_
20	depression	_	NN	NN	_	16	OBJ	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	levels	_	NNS	NNS	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	IkappaB	_	NN	NN	_	26	NMOD	_	_
26	alpha	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	16	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	13	SBJ	_	_
7	representing	_	VBG	VBG	_	6	NMOD	_	_
8	different	_	JJ	JJ	_	12	NMOD	_	_
9	activation	_	NN	NN	_	12	NMOD	_	_
10	and\/or	_	CC	CC	_	9	CC	_	_
11	differentiation	_	NN	NN	_	9	COORD	_	_
12	stages	_	NNS	NNS	_	7	OBJ	_	_
13	can	_	MD	MD	_	4	VMOD	_	_
14	be	_	VB	VB	_	13	VC	_	_
15	differentially	_	RB	RB	_	16	AMOD	_	_
16	responsive	_	JJ	JJ	_	14	PRD	_	_
17	to	_	TO	TO	_	16	AMOD	_	_
18	ROI-mediated	_	JJ	JJ	_	19	NMOD	_	_
19	signals	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Interferon	_	NN	NN	_	2	SBJ	_	_
2	augments	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	PML	_	NN	NN	_	7	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	PML\/RAR	_	NN	NN	_	6	NMOD	_	_
6	alpha	_	NN	NN	_	3	COORD	_	_
7	expression	_	NN	NN	_	2	OBJ	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	normal	_	JJ	JJ	_	10	AMOD	_	_
10	myeloid	_	JJ	JJ	_	14	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	acute	_	JJ	JJ	_	13	AMOD	_	_
13	promyelocytic	_	JJ	JJ	_	10	COORD	_	_
14	cells	_	NNS	NNS	_	8	PMOD	_	_
15	and	_	CC	CC	_	2	CC	_	_
16	cooperates	_	VBZ	VBZ	_	2	COORD	_	_
17	with	_	IN	IN	_	16	ADV	_	_
18	all-trans	_	JJ	JJ	_	20	NMOD	_	_
19	retinoic	_	JJ	JJ	_	20	NMOD	_	_
20	acid	_	NN	NN	_	17	PMOD	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	induce	_	VB	VB	_	16	OBJ	_	_
23	maturation	_	NN	NN	_	22	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	a	_	DT	DT	_	29	NMOD	_	_
26	retinoid-resistant	_	JJ	JJ	_	29	NMOD	_	_
27	promyelocytic	_	JJ	JJ	_	29	NMOD	_	_
28	cell	_	NN	NN	_	29	NMOD	_	_
29	line	_	NN	NN	_	24	PMOD	_	_
30	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	PML	_	NN	NN	_	3	NMOD	_	_
3	gene	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	fused	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	the	_	DT	DT	_	12	NMOD	_	_
8	retinoic	_	JJ	JJ	_	12	NMOD	_	_
9	acid	_	NN	NN	_	12	NMOD	_	_
10	receptor	_	NN	NN	_	12	NMOD	_	_
11	alpha	_	NN	NN	_	12	NMOD	_	_
12	gene	_	NN	NN	_	6	PMOD	_	_
13	(	_	(	(	_	15	P	_	_
14	RAR	_	NN	NN	_	15	NMOD	_	_
15	alpha	_	NN	NN	_	12	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	in	_	IN	IN	_	5	ADV	_	_
18	the	_	DT	DT	_	28	NMOD	_	_
19	acute	_	JJ	JJ	_	21	NMOD	_	_
20	promyelocytic	_	JJ	JJ	_	21	NMOD	_	_
21	leukemia	_	NN	NN	_	28	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	APL	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	15	_	CD	CD	_	28	NMOD	_	_
26	;	_	:	:	_	28	P	_	_
27	17	_	CD	CD	_	28	NMOD	_	_
28	translocation	_	NN	NN	_	17	PMOD	_	_
29	.	_	.	.	_	4	P	_	_

1	PML	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	expressed	_	VBN	VBN	_	2	VC	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	diverse	_	JJ	JJ	_	6	NMOD	_	_
6	tissues	_	NNS	NNS	_	4	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	cell	_	NN	NN	_	9	NMOD	_	_
9	lines	_	NNS	NNS	_	6	COORD	_	_
10	and	_	CC	CC	_	3	CC	_	_
11	localized	_	JJ	JJ	_	3	COORD	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	nucleus	_	NN	NN	_	12	PMOD	_	_
15	with	_	IN	IN	_	11	ADV	_	_
16	a	_	DT	DT	_	19	NMOD	_	_
17	typical	_	JJ	JJ	_	19	NMOD	_	_
18	speckled	_	JJ	JJ	_	19	NMOD	_	_
19	pattern	_	NN	NN	_	15	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	bone	_	NN	NN	_	4	NMOD	_	_
4	marrow	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	it	_	PRP	PRP	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	preferentially	_	RB	RB	_	9	ADV	_	_
9	expressed	_	VBN	VBN	_	7	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	myeloid	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	7	P	_	_

1	PML	_	NN	NN	_	2	SBJ	_	_
2	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	to	_	TO	TO	_	4	VMOD	_	_
4	be	_	VB	VB	_	2	OBJ	_	_
5	transcriptionally	_	RB	RB	_	6	ADV	_	_
6	regulated	_	VBN	VBN	_	4	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	class	_	NN	NN	_	12	NMOD	_	_
9	I	_	CD	CD	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	II	_	CD	CD	_	9	COORD	_	_
12	interferons	_	NNS	NNS	_	7	PMOD	_	_
13	,	_	,	,	_	6	P	_	_
14	which	_	WDT	WDT	_	15	SBJ	_	_
15	raises	_	VBZ	VBZ	_	6	OBJ	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	possibility	_	NN	NN	_	15	OBJ	_	_
18	that	_	IN	IN	_	17	NMOD	_	_
19	interferons	_	NNS	NNS	_	20	SBJ	_	_
20	modulate	_	VBP	VBP	_	18	VMOD	_	_
21	the	_	DT	DT	_	27	NMOD	_	_
22	function	_	NN	NN	_	27	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	growth	_	NN	NN	_	22	COORD	_	_
25	and	_	CC	CC	_	22	CC	_	_
26	differentiation	_	NN	NN	_	22	COORD	_	_
27	potential	_	NN	NN	_	20	OBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	normal	_	JJ	JJ	_	31	NMOD	_	_
30	myeloid	_	JJ	JJ	_	31	NMOD	_	_
31	cells	_	NNS	NNS	_	28	PMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	precursors	_	NNS	NNS	_	31	COORD	_	_
34	by	_	IN	IN	_	20	ADV	_	_
35	activating	_	VBG	VBG	_	34	PMOD	_	_
36	PML-dependent	_	JJ	JJ	_	37	NMOD	_	_
37	pathways	_	NNS	NNS	_	35	OBJ	_	_
38	.	_	.	.	_	2	P	_	_

1	Similarly	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	interferons	_	NNS	NNS	_	4	SBJ	_	_
4	could	_	MD	MD	_	0	ROOT-S	_	_
5	act	_	VB	VB	_	4	VC	_	_
6	on	_	IN	IN	_	5	ADV	_	_
7	APL	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	,	_	,	,	_	5	P	_	_
10	alone	_	RB	RB	_	5	VMOD	_	_
11	or	_	CC	CC	_	10	CC	_	_
12	in	_	IN	IN	_	10	COORD	_	_
13	combination	_	NN	NN	_	12	PMOD	_	_
14	with	_	IN	IN	_	13	NMOD	_	_
15	all-trans	_	JJ	JJ	_	17	NMOD	_	_
16	retinoic	_	JJ	JJ	_	17	NMOD	_	_
17	acid	_	NN	NN	_	14	PMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	RA	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	,	_	,	,	_	5	P	_	_
22	especially	_	RB	RB	_	23	VMOD	_	_
23	if	_	IN	IN	_	5	OBJ	_	_
24	the	_	DT	DT	_	28	NMOD	_	_
25	PML\/RAR	_	NN	NN	_	28	NMOD	_	_
26	alpha	_	NN	NN	_	28	NMOD	_	_
27	fusion	_	NN	NN	_	28	NMOD	_	_
28	transcript	_	NN	NN	_	34	SBJ	_	_
29	that	_	WDT	WDT	_	30	SBJ	_	_
30	results	_	VBZ	VBZ	_	28	NMOD	_	_
31	from	_	IN	IN	_	30	ADV	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	t-LRB-15;17-RRB-	_	NN	NN	_	31	PMOD	_	_
34	is	_	VBZ	VBZ	_	23	VMOD	_	_
35	induced	_	VBN	VBN	_	34	VC	_	_
36	by	_	IN	IN	_	35	LGS	_	_
37	interferon	_	NN	NN	_	36	PMOD	_	_
38	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	that	_	IN	IN	_	2	OBJ	_	_
5	PML	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	4	VMOD	_	_
7	expressed	_	VBN	VBN	_	6	VC	_	_
8	at	_	IN	IN	_	7	ADV	_	_
9	low	_	JJ	JJ	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	8	PMOD	_	_
11	or	_	CC	CC	_	7	CC	_	_
12	not	_	RB	RB	_	13	VMOD	_	_
13	expressed	_	VBN	VBN	_	7	COORD	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	normal	_	JJ	JJ	_	18	NMOD	_	_
16	circulating	_	VBG	VBG	_	18	NMOD	_	_
17	human	_	JJ	JJ	_	18	NMOD	_	_
18	monocytes	_	NNS	NNS	_	14	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	lymphocytes	_	NNS	NNS	_	18	COORD	_	_
21	,	_	,	,	_	18	P	_	_
22	and	_	CC	CC	_	18	CC	_	_
23	polymorphonucleate	_	JJ	JJ	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	18	COORD	_	_
25	,	_	,	,	_	6	P	_	_
26	but	_	CC	CC	_	6	CC	_	_
27	is	_	VBZ	VBZ	_	6	COORD	_	_
28	markedly	_	RB	RB	_	29	ADV	_	_
29	induced	_	VBN	VBN	_	27	VC	_	_
30	by	_	IN	IN	_	29	LGS	_	_
31	interferon	_	NN	NN	_	30	PMOD	_	_
32	;	_	:	:	_	4	P	_	_
33	that	_	IN	IN	_	4	COORD	_	_
34	PML	_	NN	NN	_	38	NMOD	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	PML\/RAR	_	NN	NN	_	37	NMOD	_	_
37	alpha	_	NN	NN	_	34	COORD	_	_
38	expression	_	NN	NN	_	39	SBJ	_	_
39	is	_	VBZ	VBZ	_	33	VMOD	_	_
40	augmented	_	VBN	VBN	_	39	VC	_	_
41	by	_	IN	IN	_	40	LGS	_	_
42	interferon	_	NN	NN	_	41	PMOD	_	_
43	in	_	IN	IN	_	40	ADV	_	_
44	the	_	DT	DT	_	48	NMOD	_	_
45	NB4	_	NN	NN	_	48	NMOD	_	_
46	APL	_	NN	NN	_	48	NMOD	_	_
47	cell	_	NN	NN	_	48	NMOD	_	_
48	line	_	NN	NN	_	43	PMOD	_	_
49	,	_	,	,	_	48	P	_	_
50	which	_	WDT	WDT	_	51	SBJ	_	_
51	carries	_	VBZ	VBZ	_	48	NMOD	_	_
52	the	_	DT	DT	_	53	NMOD	_	_
53	t-LRB-15;17-RRB-	_	NN	NN	_	51	OBJ	_	_
54	,	_	,	,	_	48	P	_	_
55	and	_	CC	CC	_	43	CC	_	_
56	in	_	IN	IN	_	43	COORD	_	_
57	APL	_	NN	NN	_	58	NMOD	_	_
58	blasts	_	NNS	NNS	_	56	PMOD	_	_
59	from	_	IN	IN	_	58	NMOD	_	_
60	patients	_	NNS	NNS	_	59	PMOD	_	_
61	;	_	:	:	_	4	P	_	_
62	that	_	IN	IN	_	4	COORD	_	_
63	interferon	_	NN	NN	_	64	SBJ	_	_
64	inhibits	_	VBZ	VBZ	_	62	VMOD	_	_
65	growth	_	NN	NN	_	64	OBJ	_	_
66	and	_	CC	CC	_	65	CC	_	_
67	survival	_	NN	NN	_	65	COORD	_	_
68	of	_	IN	IN	_	65	NMOD	_	_
69	NB4	_	NN	NN	_	71	NMOD	_	_
70	APL	_	NN	NN	_	71	NMOD	_	_
71	cells	_	NNS	NNS	_	68	PMOD	_	_
72	in	_	IN	IN	_	64	ADV	_	_
73	cooperation	_	NN	NN	_	72	DEP	_	_
74	with	_	IN	IN	_	72	DEP	_	_
75	RA	_	NN	NN	_	72	PMOD	_	_
76	;	_	:	:	_	4	P	_	_
77	that	_	IN	IN	_	4	COORD	_	_
78	interferons	_	NNS	NNS	_	80	SBJ	_	_
79	alone	_	RB	RB	_	78	NMOD	_	_
80	have	_	VBP	VBP	_	77	VMOD	_	_
81	minimal	_	JJ	JJ	_	83	NMOD	_	_
82	maturation	_	NN	NN	_	83	NMOD	_	_
83	effect	_	NN	NN	_	80	OBJ	_	_
84	on	_	IN	IN	_	80	ADV	_	_
85	NB4	_	NN	NN	_	86	NMOD	_	_
86	cells	_	NNS	NNS	_	84	PMOD	_	_
87	;	_	:	:	_	4	P	_	_
88	and	_	CC	CC	_	4	CC	_	_
89	,	_	,	,	_	4	P	_	_
90	finally	_	RB	RB	_	92	TMP	_	_
91	,	_	,	,	_	92	P	_	_
92	that	_	IN	IN	_	4	COORD	_	_
93	interferon	_	NN	NN	_	102	SBJ	_	_
94	gamma	_	NN	NN	_	93	NMOD	_	_
95	,	_	,	,	_	94	P	_	_
96	but	_	CC	CC	_	94	CC	_	_
97	not	_	RB	RB	_	96	COORD	_	_
98	alpha	_	NN	NN	_	94	COORD	_	_
99	or	_	CC	CC	_	98	CC	_	_
100	beta	_	NN	NN	_	98	COORD	_	_
101	,	_	,	,	_	94	P	_	_
102	induces	_	VBZ	VBZ	_	92	VMOD	_	_
103	maturation	_	NN	NN	_	102	OBJ	_	_
104	and	_	CC	CC	_	103	CC	_	_
105	growth	_	NN	NN	_	106	NMOD	_	_
106	suppression	_	NN	NN	_	103	COORD	_	_
107	of	_	IN	IN	_	103	NMOD	_	_
108	NB4	_	NN	NN	_	109	NMOD	_	_
109	cells	_	NNS	NNS	_	107	PMOD	_	_
110	with	_	IN	IN	_	109	NMOD	_	_
111	de	_	FW	FW	_	112	AMOD	_	_
112	novo	_	FW	FW	_	114	NMOD	_	_
113	retinoid	_	NN	NN	_	114	NMOD	_	_
114	resistance	_	NN	NN	_	110	PMOD	_	_
115	,	_	,	,	_	102	P	_	_
116	and	_	CC	CC	_	102	CC	_	_
117	partially	_	RB	RB	_	118	ADV	_	_
118	restores	_	VBZ	VBZ	_	102	COORD	_	_
119	RA	_	NN	NN	_	120	NMOD	_	_
120	response	_	NN	NN	_	118	OBJ	_	_
121	.	_	.	.	_	2	P	_	_

1	Generation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	CD1+RelB+	_	JJ	JJ	_	5	NMOD	_	_
4	dendritic	_	JJ	JJ	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	2	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	tartrate-resistant	_	JJ	JJ	_	8	AMOD	_	_
8	acid	_	NN	NN	_	13	NMOD	_	_
9	phosphatase-positive	_	JJ	JJ	_	8	AMOD	_	_
10	osteoclast-like	_	JJ	JJ	_	13	NMOD	_	_
11	multinucleated	_	JJ	JJ	_	13	NMOD	_	_
12	giant	_	JJ	JJ	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	5	COORD	_	_
14	from	_	IN	IN	_	1	NMOD	_	_
15	human	_	JJ	JJ	_	16	NMOD	_	_
16	monocytes	_	NNS	NNS	_	14	PMOD	_	_
17	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	previously	_	RB	RB	_	3	TMP	_	_
3	showed	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	granulocyte-macrophage	_	JJ	JJ	_	7	NMOD	_	_
6	colony-stimulating	_	JJ	JJ	_	7	NMOD	_	_
7	factor	_	NN	NN	_	18	SBJ	_	_
8	(	_	(	(	_	9	P	_	_
9	GM-CSF	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	macrophage	_	NN	NN	_	14	NMOD	_	_
13	colony-stimulating	_	JJ	JJ	_	14	NMOD	_	_
14	factor	_	NN	NN	_	7	COORD	_	_
15	(	_	(	(	_	16	P	_	_
16	M-CSF	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	stimulate	_	VBP	VBP	_	4	VMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	differentiation	_	NN	NN	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	human	_	JJ	JJ	_	23	NMOD	_	_
23	monocytes	_	NNS	NNS	_	21	PMOD	_	_
24	into	_	IN	IN	_	20	NMOD	_	_
25	two	_	CD	CD	_	28	NMOD	_	_
26	phenotypically	_	RB	RB	_	27	AMOD	_	_
27	distinct	_	JJ	JJ	_	28	NMOD	_	_
28	types	_	NNS	NNS	_	24	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	macrophages	_	NNS	NNS	_	29	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	14	ADV	_	_
2	,	_	,	,	_	14	P	_	_
3	in	_	FW	FW	_	14	ADV	_	_
4	vivo	_	FW	FW	_	3	AMOD	_	_
5	,	_	,	,	_	14	P	_	_
6	not	_	RB	RB	_	8	CC	_	_
7	only	_	RB	RB	_	6	DEP	_	_
8	CSF	_	NN	NN	_	14	SBJ	_	_
9	but	_	CC	CC	_	8	CC	_	_
10	also	_	RB	RB	_	9	COORD	_	_
11	many	_	JJ	JJ	_	13	NMOD	_	_
12	other	_	JJ	JJ	_	13	NMOD	_	_
13	cytokines	_	NNS	NNS	_	8	COORD	_	_
14	are	_	VBP	VBP	_	0	ROOT-S	_	_
15	produced	_	VBN	VBN	_	14	VC	_	_
16	under	_	IN	IN	_	15	ADV	_	_
17	various	_	JJ	JJ	_	18	NMOD	_	_
18	conditions	_	NNS	NNS	_	16	PMOD	_	_
19	.	_	.	.	_	14	P	_	_

1	Those	_	DT	DT	_	2	NMOD	_	_
2	cytokines	_	NNS	NNS	_	3	SBJ	_	_
3	may	_	MD	MD	_	0	ROOT-S	_	_
4	modulate	_	VB	VB	_	3	VC	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	differentiation	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	monocytes	_	NNS	NNS	_	7	PMOD	_	_
9	by	_	IN	IN	_	6	NMOD	_	_
10	CSFs	_	NNS	NNS	_	9	PMOD	_	_
11	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	present	_	JJ	JJ	_	4	NMOD	_	_
4	study	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	we	_	PRP	PRP	_	7	SBJ	_	_
7	showed	_	VBD	VBD	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	CD14+	_	JJ	JJ	_	12	NMOD	_	_
10	adherent	_	JJ	JJ	_	12	NMOD	_	_
11	human	_	JJ	JJ	_	12	NMOD	_	_
12	monocytes	_	NNS	NNS	_	13	SBJ	_	_
13	can	_	MD	MD	_	8	VMOD	_	_
14	differentiate	_	VB	VB	_	13	VC	_	_
15	into	_	IN	IN	_	14	ADV	_	_
16	CD1+relB+	_	JJ	JJ	_	18	NMOD	_	_
17	dendritic	_	JJ	JJ	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	15	PMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	DC	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	by	_	IN	IN	_	14	ADV	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	combination	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	GM-CSF	_	NN	NN	_	25	PMOD	_	_
27	plus	_	CC	CC	_	26	CC	_	_
28	interleukin-4	_	NN	NN	_	26	COORD	_	_
29	(	_	(	(	_	30	P	_	_
30	IL-4	_	NN	NN	_	28	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	and	_	CC	CC	_	8	CC	_	_
33	that	_	IN	IN	_	8	COORD	_	_
34	they	_	PRP	PRP	_	35	SBJ	_	_
35	differentiate	_	VBP	VBP	_	33	VMOD	_	_
36	into	_	IN	IN	_	35	ADV	_	_
37	tartrate-resistant	_	JJ	JJ	_	41	AMOD	_	_
38	acid	_	NN	NN	_	41	AMOD	_	_
39	phosphatase	_	NN	NN	_	41	AMOD	_	_
40	(	_	(	(	_	41	P	_	_
41	TRAP	_	NN	NN	_	47	NMOD	_	_
42	)	_	)	)	_	41	P	_	_
43	-positive	_	JJ	JJ	_	41	AMOD	_	_
44	osteoclast-like	_	JJ	JJ	_	47	NMOD	_	_
45	multinucleated	_	JJ	JJ	_	47	NMOD	_	_
46	giant	_	JJ	JJ	_	47	NMOD	_	_
47	cells	_	NNS	NNS	_	36	PMOD	_	_
48	(	_	(	(	_	49	P	_	_
49	MGC	_	NN	NN	_	47	PRN	_	_
50	)	_	)	)	_	49	P	_	_
51	by	_	IN	IN	_	35	ADV	_	_
52	the	_	DT	DT	_	53	NMOD	_	_
53	combination	_	NN	NN	_	51	PMOD	_	_
54	of	_	IN	IN	_	53	NMOD	_	_
55	M-CSF	_	NN	NN	_	54	PMOD	_	_
56	plus	_	CC	CC	_	55	CC	_	_
57	IL-4	_	NN	NN	_	55	COORD	_	_
58	.	_	.	.	_	7	P	_	_

1	However	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	monocyte-derived	_	JJ	JJ	_	5	NMOD	_	_
5	DC	_	NN	NN	_	6	SBJ	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	not	_	RB	RB	_	6	VMOD	_	_
8	terminally	_	RB	RB	_	9	AMOD	_	_
9	differentiated	_	VBN	VBN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	6	PRD	_	_
11	;	_	:	:	_	6	P	_	_
12	they	_	PRP	PRP	_	13	SBJ	_	_
13	could	_	MD	MD	_	6	VC	_	_
14	still	_	RB	RB	_	15	ADV	_	_
15	convert	_	VB	VB	_	13	VC	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	macrophages	_	NNS	NNS	_	16	PMOD	_	_
18	in	_	IN	IN	_	15	ADV	_	_
19	response	_	NN	NN	_	18	DEP	_	_
20	to	_	TO	TO	_	18	DEP	_	_
21	M-CSF	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	13	P	_	_

1	Tumor	_	NN	NN	_	3	NMOD	_	_
2	necrosis	_	NN	NN	_	3	NMOD	_	_
3	factor-alpha	_	NN	NN	_	7	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	TNF-alpha	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	stimulated	_	VBD	VBD	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	terminal	_	JJ	JJ	_	10	NMOD	_	_
10	differentiation	_	NN	NN	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	DC	_	NN	NN	_	11	PMOD	_	_
14	by	_	IN	IN	_	7	ADV	_	_
15	downregulating	_	VBG	VBG	_	14	PMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	expression	_	NN	NN	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	M-CSF	_	NN	NN	_	21	NMOD	_	_
21	receptor	_	NN	NN	_	18	PMOD	_	_
22	,	_	,	,	_	21	P	_	_
23	cfms	_	NN	NN	_	24	NMOD	_	_
24	mRNA	_	NN	NN	_	21	NMOD	_	_
25	,	_	,	,	_	15	P	_	_
26	and	_	CC	CC	_	15	CC	_	_
27	aborting	_	VBG	VBG	_	15	COORD	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	potential	_	NN	NN	_	27	OBJ	_	_
30	to	_	TO	TO	_	31	VMOD	_	_
31	convert	_	VB	VB	_	29	NMOD	_	_
32	to	_	TO	TO	_	31	ADV	_	_
33	macrophages	_	NNS	NNS	_	32	PMOD	_	_
34	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	contrast	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	IL-4	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	10	P	_	_
6	interferon-gamma	_	NN	NN	_	10	SBJ	_	_
7	(	_	(	(	_	8	P	_	_
8	IFN-gamma	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	had	_	VBD	VBD	_	0	ROOT-S	_	_
11	no	_	DT	DT	_	13	NMOD	_	_
12	demonstrable	_	JJ	JJ	_	13	NMOD	_	_
13	effect	_	NN	NN	_	10	OBJ	_	_
14	on	_	IN	IN	_	10	ADV	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	differentiation	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	monocytes	_	NNS	NNS	_	17	PMOD	_	_
19	.	_	.	.	_	10	P	_	_

1	Rather	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	IFN-gamma	_	NN	NN	_	4	SBJ	_	_
4	antagonized	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	effect	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	IL-4	_	NN	NN	_	7	PMOD	_	_
9	and	_	CC	CC	_	4	CC	_	_
10	suppressed	_	VBD	VBD	_	4	COORD	_	_
11	the	_	DT	DT	_	15	NMOD	_	_
12	DC	_	NN	NN	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	MGC	_	NN	NN	_	12	COORD	_	_
15	formation	_	NN	NN	_	10	OBJ	_	_
16	induced	_	VBN	VBN	_	15	NMOD	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	GM-CSF	_	NN	NN	_	17	PMOD	_	_
19	+	_	CC	CC	_	18	CC	_	_
20	IL-4	_	NN	NN	_	18	COORD	_	_
21	and	_	CC	CC	_	18	CC	_	_
22	M-CSF	_	NN	NN	_	18	COORD	_	_
23	+	_	CC	CC	_	22	CC	_	_
24	IL-4	_	NN	NN	_	22	COORD	_	_
25	,	_	,	,	_	18	P	_	_
26	respectively	_	RB	RB	_	18	NMOD	_	_
27	.	_	.	.	_	4	P	_	_

1	Taken	_	VBN	VBN	_	6	VMOD	_	_
2	together	_	RB	RB	_	1	ADV	_	_
3	,	_	,	,	_	6	P	_	_
4	these	_	DT	DT	_	5	NMOD	_	_
5	results	_	NNS	NNS	_	6	SBJ	_	_
6	provide	_	VBP	VBP	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	new	_	JJ	JJ	_	9	NMOD	_	_
9	aspect	_	NN	NN	_	6	OBJ	_	_
10	to	_	TO	TO	_	6	DTV	_	_
11	our	_	PRP$	PRP$	_	12	NMOD	_	_
12	knowledge	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	monocyte	_	NN	NN	_	15	NMOD	_	_
15	differentiation	_	NN	NN	_	13	PMOD	_	_
16	and	_	CC	CC	_	6	CC	_	_
17	provide	_	VBP	VBP	_	6	COORD	_	_
18	evidence	_	NN	NN	_	17	OBJ	_	_
19	that	_	IN	IN	_	18	NMOD	_	_
20	human	_	JJ	JJ	_	21	NMOD	_	_
21	monocytes	_	NNS	NNS	_	22	SBJ	_	_
22	are	_	VBP	VBP	_	19	VMOD	_	_
23	flexible	_	JJ	JJ	_	22	PRD	_	_
24	in	_	IN	IN	_	22	ADV	_	_
25	their	_	PRP$	PRP$	_	27	NMOD	_	_
26	differentiation	_	NN	NN	_	27	NMOD	_	_
27	potential	_	NN	NN	_	24	PMOD	_	_
28	and	_	CC	CC	_	22	CC	_	_
29	are	_	VBP	VBP	_	22	COORD	_	_
30	precursors	_	NNS	NNS	_	29	PRD	_	_
31	not	_	RB	RB	_	30	NMOD	_	_
32	only	_	RB	RB	_	31	DEP	_	_
33	of	_	IN	IN	_	31	COORD	_	_
34	macrophages	_	NNS	NNS	_	33	PMOD	_	_
35	but	_	CC	CC	_	31	CC	_	_
36	also	_	RB	RB	_	35	COORD	_	_
37	of	_	IN	IN	_	31	COORD	_	_
38	CD1+relB+DC	_	NN	NN	_	37	PMOD	_	_
39	and	_	CC	CC	_	38	CC	_	_
40	TRAP-positive	_	JJ	JJ	_	41	NMOD	_	_
41	MGC	_	NN	NN	_	38	COORD	_	_
42	.	_	.	.	_	6	P	_	_

1	Such	_	PDT	PDT	_	4	NMOD	_	_
2	a	_	DT	DT	_	4	NMOD	_	_
3	diverse	_	JJ	JJ	_	4	NMOD	_	_
4	pathway	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	monocyte	_	NN	NN	_	7	NMOD	_	_
7	differentiation	_	NN	NN	_	5	PMOD	_	_
8	may	_	MD	MD	_	0	ROOT-S	_	_
9	constitute	_	VB	VB	_	8	VC	_	_
10	one	_	CD	CD	_	9	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	basic	_	JJ	JJ	_	14	NMOD	_	_
14	mechanisms	_	NNS	NNS	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	immune	_	JJ	JJ	_	17	NMOD	_	_
17	regulation	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	8	P	_	_

1	Differential	_	JJ	JJ	_	3	NMOD	_	_
2	nuclear	_	JJ	JJ	_	3	NMOD	_	_
3	localization	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	p50	_	NN	NN	_	11	NMOD	_	_
6	,	_	,	,	_	5	P	_	_
7	p52	_	NN	NN	_	5	COORD	_	_
8	,	_	,	,	_	5	P	_	_
9	and	_	CC	CC	_	5	CC	_	_
10	RelB	_	NN	NN	_	5	COORD	_	_
11	proteins	_	NNS	NNS	_	4	PMOD	_	_
12	in	_	IN	IN	_	3	NMOD	_	_
13	human	_	JJ	JJ	_	15	NMOD	_	_
14	accessory	_	JJ	JJ	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	12	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	immune	_	JJ	JJ	_	19	NMOD	_	_
19	response	_	NN	NN	_	16	PMOD	_	_
20	in	_	FW	FW	_	19	NMOD	_	_
21	situ	_	FW	FW	_	20	AMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	Rel\/NF-kappa	_	NN	NN	_	4	NMOD	_	_
3	B	_	NN	NN	_	4	NMOD	_	_
4	proteins	_	NNS	NNS	_	17	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	p50	_	NN	NN	_	4	NMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	p52	_	NN	NN	_	6	COORD	_	_
9	,	_	,	,	_	6	P	_	_
10	p65	_	NN	NN	_	6	COORD	_	_
11	,	_	,	,	_	6	P	_	_
12	c-Rel	_	NN	NN	_	6	COORD	_	_
13	,	_	,	,	_	6	P	_	_
14	and	_	CC	CC	_	6	CC	_	_
15	RelB	_	NN	NN	_	6	COORD	_	_
16	,	_	,	,	_	4	P	_	_
17	constitute	_	VBP	VBP	_	0	ROOT-S	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	family	_	NN	NN	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	transcription	_	NN	NN	_	22	NMOD	_	_
22	factors	_	NNS	NNS	_	20	PMOD	_	_
23	involved	_	VBN	VBN	_	19	NMOD	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	positive	_	JJ	JJ	_	27	NMOD	_	_
27	regulation	_	NN	NN	_	24	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	a	_	DT	DT	_	30	NMOD	_	_
30	variety	_	NN	NN	_	28	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	genes	_	NNS	NNS	_	31	PMOD	_	_
33	during	_	IN	IN	_	27	TMP	_	_
34	the	_	DT	DT	_	36	NMOD	_	_
35	immune	_	JJ	JJ	_	36	NMOD	_	_
36	response	_	NN	NN	_	33	PMOD	_	_
37	.	_	.	.	_	17	P	_	_

1	Recently	_	RB	RB	_	4	TMP	_	_
2	,	_	,	,	_	4	P	_	_
3	it	_	PRP	PRP	_	4	SBJ	_	_
4	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	been	_	VBN	VBN	_	4	VC	_	_
6	shown	_	VBN	VBN	_	5	VC	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	RelB	_	NN	NN	_	10	NMOD	_	_
9	knockout	_	JJ	JJ	_	10	NMOD	_	_
10	mice	_	NNS	NNS	_	11	SBJ	_	_
11	have	_	VBP	VBP	_	7	VMOD	_	_
12	no	_	DT	DT	_	14	NMOD	_	_
13	dendritic	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	11	OBJ	_	_
15	(	_	(	(	_	16	P	_	_
16	DC	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	.	_	.	.	_	4	P	_	_

1	An	_	DT	DT	_	2	NMOD	_	_
2	overexpression	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	p50	_	NN	NN	_	3	PMOD	_	_
5	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	been	_	VBN	VBN	_	5	VC	_	_
7	described	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	follicular	_	JJ	JJ	_	11	NMOD	_	_
10	dendritic	_	JJ	JJ	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	8	PMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	FDC	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	.	_	.	.	_	5	P	_	_

1	A	_	DT	DT	_	5	NMOD	_	_
2	constitutive	_	JJ	JJ	_	5	NMOD	_	_
3	NF-kappa	_	NN	NN	_	5	NMOD	_	_
4	B	_	NN	NN	_	5	NMOD	_	_
5	activity	_	NN	NN	_	6	SBJ	_	_
6	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	been	_	VBN	VBN	_	6	VC	_	_
8	reported	_	VBN	VBN	_	7	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	mature	_	JJ	JJ	_	11	NMOD	_	_
11	macrophages	_	NNS	NNS	_	9	PMOD	_	_
12	.	_	.	.	_	6	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	led	_	VBD	VBD	_	0	ROOT-S	_	_
3	to	_	TO	TO	_	2	ADV	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	hypothesis	_	NN	NN	_	3	PMOD	_	_
6	that	_	IN	IN	_	5	NMOD	_	_
7	some	_	DT	DT	_	13	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	Rel\/NF-kappa	_	NN	NN	_	12	NMOD	_	_
11	B	_	NN	NN	_	12	NMOD	_	_
12	proteins	_	NNS	NNS	_	8	PMOD	_	_
13	were	_	VBD	VBD	_	6	VMOD	_	_
14	key	_	JJ	JJ	_	16	NMOD	_	_
15	nuclear	_	JJ	JJ	_	16	NMOD	_	_
16	factors	_	NNS	NNS	_	13	PRD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	functions	_	NNS	NNS	_	17	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	accessory	_	JJ	JJ	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	immune	_	JJ	JJ	_	25	NMOD	_	_
25	response	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	2	P	_	_

1	Therefore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	investigated	_	VBD	VBD	_	0	ROOT-S	_	_
5	in	_	FW	FW	_	4	ADV	_	_
6	situ	_	FW	FW	_	5	AMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	localization	_	NN	NN	_	4	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	Rel\/NF-kappa	_	NN	NN	_	13	NMOD	_	_
12	B	_	NN	NN	_	13	NMOD	_	_
13	proteins	_	NNS	NNS	_	10	PMOD	_	_
14	in	_	IN	IN	_	9	NMOD	_	_
15	accessory	_	JJ	JJ	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	immune	_	JJ	JJ	_	20	NMOD	_	_
20	system	_	NN	NN	_	17	PMOD	_	_
21	by	_	IN	IN	_	4	ADV	_	_
22	immunohistochemistry	_	NN	NN	_	21	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	double	_	JJ	JJ	_	25	NMOD	_	_
25	labeling	_	NN	NN	_	22	COORD	_	_
26	by	_	IN	IN	_	25	NMOD	_	_
27	immunofluorescence	_	NN	NN	_	26	PMOD	_	_
28	from	_	IN	IN	_	16	NMOD	_	_
29	five	_	CD	CD	_	32	NMOD	_	_
30	normal	_	JJ	JJ	_	32	NMOD	_	_
31	human	_	JJ	JJ	_	32	NMOD	_	_
32	tonsils	_	NNS	NNS	_	28	PMOD	_	_
33	and	_	CC	CC	_	32	CC	_	_
34	five	_	CD	CD	_	36	NMOD	_	_
35	lymph	_	NN	NN	_	36	NMOD	_	_
36	nodes	_	NNS	NNS	_	32	COORD	_	_
37	with	_	IN	IN	_	36	NMOD	_	_
38	follicular	_	JJ	JJ	_	39	NMOD	_	_
39	hyperplasia	_	NN	NN	_	37	PMOD	_	_
40	.	_	.	.	_	4	P	_	_

1	Nuclear	_	JJ	JJ	_	5	NMOD	_	_
2	p65	_	NN	NN	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	c-Rel	_	NN	NN	_	2	COORD	_	_
5	proteins	_	NNS	NNS	_	6	SBJ	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	found	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	all	_	DT	DT	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	types	_	NNS	NNS	_	8	PMOD	_	_
12	including	_	VBG	VBG	_	11	NMOD	_	_
13	lymphocytes	_	NNS	NNS	_	12	PMOD	_	_
14	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	germinal	_	JJ	JJ	_	4	NMOD	_	_
3	centers	_	NNS	NNS	_	4	NMOD	_	_
4	GC	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	12	P	_	_
6	p50	_	NN	NN	_	12	SBJ	_	_
7	,	_	,	,	_	6	P	_	_
8	p52	_	NN	NN	_	6	COORD	_	_
9	,	_	,	,	_	6	P	_	_
10	and	_	CC	CC	_	6	CC	_	_
11	RelB	_	NN	NN	_	6	COORD	_	_
12	were	_	VBD	VBD	_	0	ROOT-S	_	_
13	found	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	nuclei	_	NNS	NNS	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	FDC	_	NN	NN	_	17	PMOD	_	_
19	only	_	RB	RB	_	16	NMOD	_	_
20	and	_	CC	CC	_	12	CC	_	_
21	were	_	VBD	VBD	_	12	COORD	_	_
22	not	_	RB	RB	_	21	VMOD	_	_
23	detected	_	VBN	VBN	_	21	VC	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	nuclei	_	NNS	NNS	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	CD68+	_	JJ	JJ	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	27	PMOD	_	_
30	.	_	.	.	_	12	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	T	_	NN	NN	_	4	NMOD	_	_
3	cell	_	NN	NN	_	4	NMOD	_	_
4	areas	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	12	P	_	_
6	p50	_	NN	NN	_	12	SBJ	_	_
7	,	_	,	,	_	6	P	_	_
8	p52	_	NN	NN	_	6	COORD	_	_
9	,	_	,	,	_	6	P	_	_
10	and	_	CC	CC	_	6	CC	_	_
11	RelB	_	NN	NN	_	6	COORD	_	_
12	were	_	VBD	VBD	_	0	ROOT-S	_	_
13	found	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	nuclei	_	NNS	NNS	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	HLA-DR+	_	JJ	JJ	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	17	PMOD	_	_
20	with	_	IN	IN	_	19	NMOD	_	_
21	an	_	DT	DT	_	27	NMOD	_	_
22	antigen-presenting	_	JJ	JJ	_	23	NMOD	_	_
23	cell	_	NN	NN	_	27	NMOD	_	_
24	(	_	(	(	_	25	P	_	_
25	APC	_	NN	NN	_	23	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	morphology	_	NN	NN	_	20	PMOD	_	_
28	.	_	.	.	_	12	P	_	_

1	p52	_	NN	NN	_	4	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	RelB	_	NN	NN	_	1	COORD	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	detected	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	nuclei	_	NNS	NNS	_	6	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	both	_	CC	CC	_	11	CC	_	_
11	CD1a+	_	JJ	JJ	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	CD68+	_	JJ	JJ	_	11	COORD	_	_
14	cells	_	NNS	NNS	_	9	PMOD	_	_
15	from	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	T	_	NN	NN	_	19	NMOD	_	_
18	cell	_	NN	NN	_	19	NMOD	_	_
19	area	_	NN	NN	_	15	PMOD	_	_
20	,	_	,	,	_	4	P	_	_
21	whereas	_	IN	IN	_	4	COORD	_	_
22	p50	_	NN	NN	_	23	SBJ	_	_
23	was	_	VBD	VBD	_	4	COORD	_	_
24	found	_	VBN	VBN	_	23	VC	_	_
25	only	_	RB	RB	_	26	DEP	_	_
26	in	_	IN	IN	_	24	ADV	_	_
27	CD68-	_	JJ	JJ	_	30	NMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	CD1a-	_	JJ	JJ	_	27	COORD	_	_
30	cells	_	NNS	NNS	_	26	PMOD	_	_
31	.	_	.	.	_	4	P	_	_

1	Cells	_	NNS	NNS	_	5	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	nuclear	_	JJ	JJ	_	4	NMOD	_	_
4	p50	_	NN	NN	_	2	PMOD	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	negative	_	JJ	JJ	_	5	PRD	_	_
7	for	_	IN	IN	_	5	ADV	_	_
8	the	_	DT	DT	_	14	NMOD	_	_
9	CD38	_	NN	NN	_	14	NMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	CD20	_	NN	NN	_	9	COORD	_	_
12	and	_	CC	CC	_	9	CC	_	_
13	CD2	_	NN	NN	_	9	COORD	_	_
14	markers	_	NNS	NNS	_	7	PMOD	_	_
15	.	_	.	.	_	5	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	physiologically	_	RB	RB	_	18	ADV	_	_
7	,	_	,	,	_	18	P	_	_
8	high	_	JJ	JJ	_	9	NMOD	_	_
9	levels	_	NNS	NNS	_	18	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	nuclear	_	JJ	JJ	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	p50	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	p52	_	NN	NN	_	13	COORD	_	_
16	and	_	CC	CC	_	13	CC	_	_
17	RelB	_	NN	NN	_	13	COORD	_	_
18	are	_	VBP	VBP	_	4	VMOD	_	_
19	restricted	_	JJ	JJ	_	18	VC	_	_
20	to	_	TO	TO	_	19	ADV	_	_
21	accessory	_	JJ	JJ	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	immune	_	JJ	JJ	_	26	NMOD	_	_
26	system	_	NN	NN	_	23	PMOD	_	_
27	,	_	,	,	_	22	P	_	_
28	which	_	WDT	WDT	_	29	SBJ	_	_
29	include	_	VBP	VBP	_	22	NMOD	_	_
30	FDC	_	NN	NN	_	29	OBJ	_	_
31	in	_	IN	IN	_	30	NMOD	_	_
32	GC	_	NN	NN	_	31	PMOD	_	_
33	,	_	,	,	_	22	P	_	_
34	and	_	CC	CC	_	22	CC	_	_
35	DC	_	NN	NN	_	22	COORD	_	_
36	and	_	CC	CC	_	35	CC	_	_
37	macrophages	_	NNS	NNS	_	35	COORD	_	_
38	in	_	IN	IN	_	35	NMOD	_	_
39	the	_	DT	DT	_	42	NMOD	_	_
40	T	_	NN	NN	_	42	NMOD	_	_
41	cell	_	NN	NN	_	42	NMOD	_	_
42	zone	_	NN	NN	_	38	PMOD	_	_
43	,	_	,	,	_	4	P	_	_
44	that	_	IN	IN	_	4	COORD	_	_
45	specialized	_	VBN	VBN	_	47	NMOD	_	_
46	scavenger	_	NN	NN	_	47	NMOD	_	_
47	macrophages	_	NNS	NNS	_	50	SBJ	_	_
48	from	_	IN	IN	_	47	NMOD	_	_
49	GC	_	NN	NN	_	48	PMOD	_	_
50	do	_	VBP	VBP	_	44	VMOD	_	_
51	not	_	RB	RB	_	50	VMOD	_	_
52	have	_	VB	VB	_	50	VC	_	_
53	detectable	_	JJ	JJ	_	54	NMOD	_	_
54	levels	_	NNS	NNS	_	52	OBJ	_	_
55	of	_	IN	IN	_	54	NMOD	_	_
56	p52	_	NN	NN	_	55	PMOD	_	_
57	and	_	CC	CC	_	56	CC	_	_
58	RelB	_	NN	NN	_	56	COORD	_	_
59	,	_	,	,	_	50	P	_	_
60	whereas	_	IN	IN	_	50	COORD	_	_
61	macrophages	_	NNS	NNS	_	77	SBJ	_	_
62	from	_	IN	IN	_	61	NMOD	_	_
63	the	_	DT	DT	_	66	NMOD	_	_
64	T	_	NN	NN	_	66	NMOD	_	_
65	cell	_	NN	NN	_	66	NMOD	_	_
66	area	_	NN	NN	_	62	PMOD	_	_
67	,	_	,	,	_	61	P	_	_
68	known	_	VBN	VBN	_	61	NMOD	_	_
69	to	_	TO	TO	_	70	VMOD	_	_
70	present	_	VB	VB	_	68	OBJ	_	_
71	the	_	DT	DT	_	72	NMOD	_	_
72	antigen	_	NN	NN	_	70	OBJ	_	_
73	to	_	TO	TO	_	70	DTV	_	_
74	T	_	NN	NN	_	75	NMOD	_	_
75	cells	_	NNS	NNS	_	73	PMOD	_	_
76	,	_	,	,	_	61	P	_	_
77	do	_	VBP	VBP	_	50	COORD	_	_
78	have	_	VB	VB	_	77	VC	_	_
79	both	_	CC	CC	_	81	CC	_	_
80	nuclear	_	JJ	JJ	_	81	NMOD	_	_
81	p52	_	NN	NN	_	78	OBJ	_	_
82	and	_	CC	CC	_	81	CC	_	_
83	RelB	_	NN	NN	_	81	COORD	_	_
84	,	_	,	,	_	4	P	_	_
85	and	_	CC	CC	_	4	CC	_	_
86	that	_	IN	IN	_	4	COORD	_	_
87	in	_	IN	IN	_	96	ADV	_	_
88	the	_	DT	DT	_	91	NMOD	_	_
89	T	_	NN	NN	_	91	NMOD	_	_
90	cell	_	NN	NN	_	91	NMOD	_	_
91	zone	_	NN	NN	_	87	PMOD	_	_
92	,	_	,	,	_	96	P	_	_
93	p52	_	NN	NN	_	96	SBJ	_	_
94	and	_	CC	CC	_	93	CC	_	_
95	RelB	_	NN	NN	_	93	COORD	_	_
96	are	_	VBP	VBP	_	86	VMOD	_	_
97	located	_	JJ	JJ	_	96	PRD	_	_
98	in	_	IN	IN	_	97	AMOD	_	_
99	nuclei	_	NNS	NNS	_	98	PMOD	_	_
100	of	_	IN	IN	_	99	NMOD	_	_
101	both	_	DT	DT	_	102	AMOD	_	_
102	CD1a+	_	JJ	JJ	_	109	NMOD	_	_
103	,	_	,	,	_	102	P	_	_
104	CD68+	_	JJ	JJ	_	102	COORD	_	_
105	or	_	CC	CC	_	102	CC	_	_
106	both	_	DT	DT	_	102	COORD	_	_
107	,	_	,	,	_	102	P	_	_
108	cells	_	NNS	NNS	_	109	NMOD	_	_
109	APC	_	NN	NN	_	100	PMOD	_	_
110	,	_	,	,	_	96	P	_	_
111	whereas	_	IN	IN	_	96	COORD	_	_
112	p50	_	NN	NN	_	113	SBJ	_	_
113	is	_	VBZ	VBZ	_	96	COORD	_	_
114	restricted	_	JJ	JJ	_	113	VC	_	_
115	to	_	TO	TO	_	114	ADV	_	_
116	CD1a-	_	NN	NN	_	119	NMOD	_	_
117	and	_	CC	CC	_	116	CC	_	_
118	CD68-	_	JJ	JJ	_	116	COORD	_	_
119	APC	_	NN	NN	_	115	PMOD	_	_
120	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	different	_	JJ	JJ	_	3	NMOD	_	_
3	patterns	_	NNS	NNS	_	13	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	p50	_	NN	NN	_	12	NMOD	_	_
6	,	_	,	,	_	5	P	_	_
7	p52	_	NN	NN	_	5	COORD	_	_
8	and	_	CC	CC	_	5	CC	_	_
9	RelB	_	NN	NN	_	5	COORD	_	_
10	protein	_	NN	NN	_	12	NMOD	_	_
11	nuclear	_	JJ	JJ	_	12	NMOD	_	_
12	localization	_	NN	NN	_	4	PMOD	_	_
13	may	_	MD	MD	_	0	ROOT-S	_	_
14	provide	_	VB	VB	_	13	VC	_	_
15	insight	_	NN	NN	_	14	OBJ	_	_
16	into	_	IN	IN	_	15	NMOD	_	_
17	their	_	PRP$	PRP$	_	19	NMOD	_	_
18	different	_	JJ	JJ	_	19	NMOD	_	_
19	roles	_	NNS	NNS	_	16	PMOD	_	_
20	during	_	IN	IN	_	19	TMP	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	immune	_	JJ	JJ	_	23	NMOD	_	_
23	response	_	NN	NN	_	20	PMOD	_	_
24	in	_	FW	FW	_	23	NMOD	_	_
25	vivo	_	FW	FW	_	24	AMOD	_	_
26	.	_	.	.	_	13	P	_	_

1	Signal	_	NN	NN	_	2	NMOD	_	_
2	transduction	_	NN	NN	_	0	ROOT-FRAG	_	_
3	by	_	IN	IN	_	2	NMOD	_	_
4	DR3	_	NN	NN	_	3	PMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	death	_	NN	NN	_	9	NMOD	_	_
8	domain-containing	_	JJ	JJ	_	7	AMOD	_	_
9	receptor	_	NN	NN	_	4	NMOD	_	_
10	related	_	JJ	JJ	_	9	NMOD	_	_
11	to	_	TO	TO	_	10	AMOD	_	_
12	TNFR-1	_	NN	NN	_	11	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	CD95	_	NN	NN	_	12	COORD	_	_
15	.	_	.	.	_	2	P	_	_

1	Tumor	_	NN	NN	_	4	NMOD	_	_
2	necrosis	_	NN	NN	_	4	NMOD	_	_
3	factor	_	NN	NN	_	4	NMOD	_	_
4	receptor-1	_	NN	NN	_	17	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	TNFR-1	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	and	_	CC	CC	_	4	CC	_	_
9	CD95	_	NN	NN	_	4	COORD	_	_
10	(	_	(	(	_	9	P	_	_
11	also	_	RB	RB	_	12	ADV	_	_
12	called	_	VBN	VBN	_	9	NMOD	_	_
13	Fas	_	NN	NN	_	12	OBJ	_	_
14	or	_	CC	CC	_	13	CC	_	_
15	APO-1	_	NN	NN	_	13	COORD	_	_
16	)	_	)	)	_	9	P	_	_
17	are	_	VBP	VBP	_	0	ROOT-S	_	_
18	cytokine	_	NN	NN	_	19	NMOD	_	_
19	receptors	_	NNS	NNS	_	17	PRD	_	_
20	that	_	WDT	WDT	_	21	SBJ	_	_
21	engage	_	VBP	VBP	_	19	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	apoptosis	_	NN	NN	_	24	NMOD	_	_
24	pathway	_	NN	NN	_	21	OBJ	_	_
25	through	_	IN	IN	_	24	NMOD	_	_
26	a	_	DT	DT	_	27	NMOD	_	_
27	region	_	NN	NN	_	25	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	intracellular	_	JJ	JJ	_	30	NMOD	_	_
30	homology	_	NN	NN	_	28	PMOD	_	_
31	,	_	,	,	_	24	P	_	_
32	designated	_	VBD	VBD	_	24	NMOD	_	_
33	the	_	DT	DT	_	36	NMOD	_	_
34	"	_	``	``	_	36	P	_	_
35	death	_	NN	NN	_	36	NMOD	_	_
36	domain	_	NN	NN	_	32	OBJ	_	_
37	.	_	.	.	_	17	P	_	_
38	"	_	''	''	_	17	P	_	_

1	Another	_	DT	DT	_	4	NMOD	_	_
2	death	_	NN	NN	_	3	AMOD	_	_
3	domain-containing	_	NN	NN	_	4	NMOD	_	_
4	member	_	NN	NN	_	17	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	TNFR	_	NN	NN	_	8	NMOD	_	_
8	family	_	NN	NN	_	5	PMOD	_	_
9	,	_	,	,	_	4	P	_	_
10	death	_	NN	NN	_	11	NMOD	_	_
11	receptor	_	NN	NN	_	4	NMOD	_	_
12	3	_	CD	CD	_	11	NMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	DR3	_	NN	NN	_	11	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	,	_	,	,	_	4	P	_	_
17	was	_	VBD	VBD	_	0	ROOT-S	_	_
18	identified	_	VBN	VBN	_	17	VC	_	_
19	and	_	CC	CC	_	17	CC	_	_
20	was	_	VBD	VBD	_	17	COORD	_	_
21	shown	_	VBN	VBN	_	20	VC	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	induce	_	VB	VB	_	21	OBJ	_	_
24	both	_	CC	CC	_	25	CC	_	_
25	apoptosis	_	NNS	NNS	_	23	OBJ	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	activation	_	NN	NN	_	25	COORD	_	_
28	of	_	IN	IN	_	25	NMOD	_	_
29	nuclear	_	JJ	JJ	_	31	NMOD	_	_
30	factor	_	NN	NN	_	31	NMOD	_	_
31	kappaB	_	NN	NN	_	28	PMOD	_	_
32	.	_	.	.	_	17	P	_	_

1	Expression	_	NN	NN	_	4	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	DR3	_	NN	NN	_	2	PMOD	_	_
4	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	be	_	VB	VB	_	4	OBJ	_	_
7	restricted	_	JJ	JJ	_	6	VC	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	tissues	_	NNS	NNS	_	8	PMOD	_	_
10	enriched	_	VBN	VBN	_	9	NMOD	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	lymphocytes	_	NNS	NNS	_	11	PMOD	_	_
13	.	_	.	.	_	4	P	_	_

1	DR3	_	NN	NN	_	3	NMOD	_	_
2	signal	_	NN	NN	_	3	NMOD	_	_
3	transduction	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	mediated	_	VBN	VBN	_	4	VC	_	_
6	by	_	IN	IN	_	5	LGS	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	complex	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	intracellular	_	JJ	JJ	_	12	NMOD	_	_
11	signaling	_	VBG	VBG	_	12	NMOD	_	_
12	molecules	_	NNS	NNS	_	9	PMOD	_	_
13	including	_	VBG	VBG	_	12	NMOD	_	_
14	TRADD	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	TRAF2	_	NN	NN	_	14	COORD	_	_
17	,	_	,	,	_	14	P	_	_
18	FADD	_	NN	NN	_	14	COORD	_	_
19	,	_	,	,	_	14	P	_	_
20	and	_	CC	CC	_	14	CC	_	_
21	FLICE	_	NN	NN	_	14	COORD	_	_
22	.	_	.	.	_	4	P	_	_

1	Thus	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	DR3	_	NN	NN	_	5	SBJ	_	_
4	likely	_	RB	RB	_	5	ADV	_	_
5	plays	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	role	_	NN	NN	_	5	OBJ	_	_
8	in	_	IN	IN	_	5	ADV	_	_
9	regulating	_	VBG	VBG	_	8	PMOD	_	_
10	lymphocyte	_	NN	NN	_	11	NMOD	_	_
11	homeostasis	_	NN	NN	_	9	OBJ	_	_
12	.	_	.	.	_	5	P	_	_

1	Cloning	_	NN	NN	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	expression	_	NN	NN	_	1	COORD	_	_
4	of	_	IN	IN	_	1	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	Epstein-Barr	_	JJ	JJ	_	7	AMOD	_	_
7	virus-encoded	_	JJ	JJ	_	8	NMOD	_	_
8	dUTPase	_	NN	NN	_	4	PMOD	_	_
9	:	_	:	:	_	1	P	_	_
10	patients	_	NNS	NNS	_	19	SBJ	_	_
11	with	_	IN	IN	_	10	NMOD	_	_
12	acute	_	JJ	JJ	_	18	NMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	reactivated	_	VBN	VBN	_	12	COORD	_	_
15	or	_	CC	CC	_	12	CC	_	_
16	chronic	_	JJ	JJ	_	12	COORD	_	_
17	virus	_	NN	NN	_	18	NMOD	_	_
18	infection	_	NN	NN	_	11	PMOD	_	_
19	develop	_	VBP	VBP	_	1	NMOD	_	_
20	antibodies	_	NNS	NNS	_	19	OBJ	_	_
21	against	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	enzyme	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	19	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	gene	_	NN	NN	_	12	SBJ	_	_
3	encoding	_	VBG	VBG	_	2	NMOD	_	_
4	the	_	DT	DT	_	11	NMOD	_	_
5	Epstein-Barr	_	JJ	JJ	_	6	NMOD	_	_
6	virus	_	NN	NN	_	8	AMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	EBV	_	NN	NN	_	11	NMOD	_	_
9	)	_	)	)	_	8	P	_	_
10	-specific	_	JJ	JJ	_	8	AMOD	_	_
11	dUTPase	_	NN	NN	_	3	OBJ	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	amplified	_	VBN	VBN	_	12	VC	_	_
14	from	_	IN	IN	_	13	ADV	_	_
15	virus	_	NN	NN	_	16	NMOD	_	_
16	DNA	_	NN	NN	_	14	PMOD	_	_
17	by	_	IN	IN	_	13	LGS	_	_
18	PCR	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	active	_	JJ	JJ	_	3	NMOD	_	_
3	enzyme	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	expressed	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	Escherichia	_	FW	FW	_	8	NMOD	_	_
8	coli	_	FW	FW	_	6	PMOD	_	_
9	and	_	CC	CC	_	6	CC	_	_
10	in	_	IN	IN	_	6	COORD	_	_
11	insect	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	as	_	IN	IN	_	5	ADV	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	non-fusion	_	JJ	JJ	_	16	NMOD	_	_
16	protein	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	protein	_	NN	NN	_	7	SBJ	_	_
3	from	_	IN	IN	_	2	NMOD	_	_
4	E.	_	FW	FW	_	5	NMOD	_	_
5	coli	_	FW	FW	_	3	PMOD	_	_
6	specifically	_	RB	RB	_	7	ADV	_	_
7	converted	_	VBD	VBD	_	0	ROOT-S	_	_
8	dUTP	_	NN	NN	_	7	OBJ	_	_
9	to	_	TO	TO	_	7	ADV	_	_
10	dUMP	_	NN	NN	_	9	PMOD	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	did	_	VBD	VBD	_	7	COORD	_	_
13	not	_	RB	RB	_	12	VMOD	_	_
14	react	_	VB	VB	_	12	VC	_	_
15	with	_	IN	IN	_	14	ADV	_	_
16	other	_	JJ	JJ	_	17	NMOD	_	_
17	dNTPs	_	NNS	NNS	_	15	PMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	NTPs	_	NNS	NNS	_	17	COORD	_	_
20	.	_	.	.	_	7	P	_	_

1	Preliminary	_	JJ	JJ	_	2	NMOD	_	_
2	experiments	_	NNS	NNS	_	3	SBJ	_	_
3	yielded	_	VBD	VBD	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	Km	_	NN	NN	_	6	NMOD	_	_
6	value	_	NN	NN	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	about	_	RB	RB	_	10	NMOD	_	_
9	0.8	_	CD	CD	_	8	DEP	_	_
10	microM	_	NN	NN	_	7	PMOD	_	_
11	for	_	IN	IN	_	3	ADV	_	_
12	dUTP	_	NN	NN	_	11	PMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	MAbs	_	NNS	NNS	_	5	SBJ	_	_
2	against	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	dUTPase	_	NN	NN	_	2	PMOD	_	_
5	reacted	_	VBD	VBD	_	0	ROOT-S	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	protein	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	approximately	_	RB	RB	_	12	NMOD	_	_
11	31	_	CD	CD	_	10	DEP	_	_
12	kDa	_	NN	NN	_	9	PMOD	_	_
13	in	_	IN	IN	_	8	NMOD	_	_
14	12-O-tetradecanoyl-phorbol-13-acetate	_	NN	NN	_	16	AMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	TPA	_	NN	NN	_	20	NMOD	_	_
17	)	_	)	)	_	16	P	_	_
18	-stimulated	_	JJ	JJ	_	16	AMOD	_	_
19	B	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	13	PMOD	_	_
21	harbouring	_	VBG	VBG	_	20	NMOD	_	_
22	either	_	CC	CC	_	23	CC	_	_
23	type	_	NN	NN	_	28	NMOD	_	_
24	1	_	CD	CD	_	23	NMOD	_	_
25	or	_	CC	CC	_	23	CC	_	_
26	type	_	NN	NN	_	23	COORD	_	_
27	2	_	CD	CD	_	26	NMOD	_	_
28	EBV	_	NN	NN	_	21	OBJ	_	_
29	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	protein	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	found	_	VBN	VBN	_	3	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	untreated	_	JJ	JJ	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	5	PMOD	_	_
8	at	_	IN	IN	_	4	ADV	_	_
9	low	_	JJ	JJ	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	8	PMOD	_	_
11	,	_	,	,	_	3	P	_	_
12	whereas	_	IN	IN	_	3	COORD	_	_
13	induction	_	NN	NN	_	32	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	lytic	_	JJ	JJ	_	18	NMOD	_	_
17	replication	_	NN	NN	_	18	NMOD	_	_
18	cycle	_	NN	NN	_	14	PMOD	_	_
19	by	_	IN	IN	_	13	NMOD	_	_
20	TPA	_	NN	NN	_	21	NMOD	_	_
21	treatment	_	NN	NN	_	19	PMOD	_	_
22	or	_	CC	CC	_	19	CC	_	_
23	by	_	IN	IN	_	19	COORD	_	_
24	providing	_	VBG	VBG	_	23	PMOD	_	_
25	the	_	DT	DT	_	29	NMOD	_	_
26	immediate	_	JJ	JJ	_	29	NMOD	_	_
27	early	_	JJ	JJ	_	29	NMOD	_	_
28	transactivator	_	NN	NN	_	29	NMOD	_	_
29	BZLF1	_	NN	NN	_	24	OBJ	_	_
30	in	_	IN	IN	_	13	NMOD	_	_
31	trans	_	NN	NN	_	30	PMOD	_	_
32	resulted	_	VBD	VBD	_	3	COORD	_	_
33	in	_	IN	IN	_	32	ADV	_	_
34	increased	_	VBN	VBN	_	35	NMOD	_	_
35	expression	_	NN	NN	_	33	PMOD	_	_
36	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	virus	_	NN	NN	_	6	NMOD	_	_
6	dUTPase	_	NN	NN	_	11	SBJ	_	_
7	isolated	_	VBN	VBN	_	6	NMOD	_	_
8	from	_	IN	IN	_	7	ADV	_	_
9	EBV-infected	_	JJ	JJ	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	is	_	VBZ	VBZ	_	3	VMOD	_	_
12	a	_	DT	DT	_	13	NMOD	_	_
13	phosphoprotein	_	NN	NN	_	11	PRD	_	_
14	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	protein	_	NN	NN	_	7	SBJ	_	_
3	expressed	_	VBN	VBN	_	2	NMOD	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	insect	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	used	_	VBN	VBN	_	7	VC	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	test	_	VB	VB	_	8	OBJ	_	_
11	for	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	presence	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	specific	_	JJ	JJ	_	16	NMOD	_	_
16	antibodies	_	NNS	NNS	_	14	PMOD	_	_
17	in	_	IN	IN	_	13	NMOD	_	_
18	sera	_	NN	NN	_	17	PMOD	_	_
19	from	_	IN	IN	_	18	NMOD	_	_
20	normal	_	JJ	JJ	_	23	NMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	healthy	_	JJ	JJ	_	20	COORD	_	_
23	carriers	_	NNS	NNS	_	19	PMOD	_	_
24	and	_	CC	CC	_	19	CC	_	_
25	from	_	IN	IN	_	19	COORD	_	_
26	patients	_	NNS	NNS	_	25	PMOD	_	_
27	with	_	IN	IN	_	26	NMOD	_	_
28	various	_	JJ	JJ	_	29	NMOD	_	_
29	diseases	_	NNS	NNS	_	27	PMOD	_	_
30	.	_	.	.	_	7	P	_	_

1	While	_	IN	IN	_	51	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	sera	_	NN	NN	_	16	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	EBV-negative	_	JJ	JJ	_	6	NMOD	_	_
6	individuals	_	NNS	NNS	_	4	PMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	0\/3	_	CD	CD	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	or	_	CC	CC	_	6	CC	_	_
11	healthy	_	JJ	JJ	_	12	NMOD	_	_
12	carriers	_	NNS	NNS	_	6	COORD	_	_
13	(	_	(	(	_	14	P	_	_
14	0\/33	_	CD	CD	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	did	_	VBD	VBD	_	1	VMOD	_	_
17	not	_	RB	RB	_	16	VMOD	_	_
18	contain	_	VB	VB	_	16	VC	_	_
19	detectable	_	JJ	JJ	_	20	NMOD	_	_
20	levels	_	NNS	NNS	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	antibodies	_	NNS	NNS	_	21	PMOD	_	_
23	,	_	,	,	_	51	P	_	_
24	patients	_	NNS	NNS	_	51	SBJ	_	_
25	with	_	IN	IN	_	24	NMOD	_	_
26	mononucleosis	_	NN	NN	_	25	PMOD	_	_
27	(	_	(	(	_	28	P	_	_
28	5\/18	_	CD	CD	_	26	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	,	_	,	,	_	26	P	_	_
31	chronic	_	JJ	JJ	_	33	NMOD	_	_
32	EBV	_	NN	NN	_	33	NMOD	_	_
33	infection	_	NN	NN	_	26	COORD	_	_
34	(	_	(	(	_	35	P	_	_
35	2\/7	_	CD	CD	_	33	PRN	_	_
36	)	_	)	)	_	35	P	_	_
37	,	_	,	,	_	26	P	_	_
38	EBV	_	NN	NN	_	39	NMOD	_	_
39	reactivation	_	NN	NN	_	26	COORD	_	_
40	(	_	(	(	_	41	P	_	_
41	7\/20	_	CD	CD	_	39	PRN	_	_
42	)	_	)	)	_	41	P	_	_
43	and	_	CC	CC	_	26	CC	_	_
44	human	_	JJ	JJ	_	47	NMOD	_	_
45	immunodeficiency	_	NN	NN	_	47	NMOD	_	_
46	virus	_	NN	NN	_	47	NMOD	_	_
47	infection	_	NN	NN	_	26	COORD	_	_
48	(	_	(	(	_	49	P	_	_
49	5\/24	_	CD	CD	_	47	PRN	_	_
50	)	_	)	)	_	49	P	_	_
51	showed	_	VBD	VBD	_	0	ROOT-S	_	_
52	elevated	_	JJ	JJ	_	54	NMOD	_	_
53	antibody	_	NN	NN	_	54	NMOD	_	_
54	titres	_	NNS	NNS	_	51	OBJ	_	_
55	against	_	IN	IN	_	54	NMOD	_	_
56	the	_	DT	DT	_	57	NMOD	_	_
57	enzyme	_	NN	NN	_	55	PMOD	_	_
58	.	_	.	.	_	51	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	dUTPase	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	3	VMOD	_	_
7	expressed	_	VBN	VBN	_	6	VC	_	_
8	during	_	IN	IN	_	7	TMP	_	_
9	EBV	_	NN	NN	_	8	PMOD	_	_
10	replication	_	NN	NN	_	9	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	reactivation	_	NN	NN	_	10	COORD	_	_
13	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	enzyme	_	NN	NN	_	3	SBJ	_	_
3	might	_	MD	MD	_	0	ROOT-S	_	_
4	therefore	_	RB	RB	_	3	ADV	_	_
5	be	_	VB	VB	_	3	VC	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	potential	_	JJ	JJ	_	8	NMOD	_	_
8	target	_	NN	NN	_	5	PRD	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	drug	_	NN	NN	_	11	NMOD	_	_
11	therapy	_	NN	NN	_	9	PMOD	_	_
12	under	_	IN	IN	_	5	ADV	_	_
13	conditions	_	NNS	NNS	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	active	_	JJ	JJ	_	17	NMOD	_	_
16	DNA	_	NN	NN	_	17	NMOD	_	_
17	replication	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	Regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	cytokine	_	NN	NN	_	7	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	cytokine	_	NN	NN	_	6	NMOD	_	_
6	receptor	_	NN	NN	_	3	COORD	_	_
7	expression	_	NN	NN	_	2	PMOD	_	_
8	by	_	IN	IN	_	1	NMOD	_	_
9	glucocorticoids	_	NNS	NNS	_	8	PMOD	_	_
10	.	_	.	.	_	1	P	_	_

1	Glucocorticoids	_	NNS	NNS	_	6	SBJ	_	_
2	(	_	(	(	_	3	P	_	_
3	GCS	_	NNS	NNS	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	profoundly	_	RB	RB	_	6	ADV	_	_
6	inhibit	_	VBP	VBP	_	0	ROOT-S	_	_
7	several	_	JJ	JJ	_	8	NMOD	_	_
8	aspects	_	NNS	NNS	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	T	_	NN	NN	_	12	NMOD	_	_
11	cell	_	NN	NN	_	12	NMOD	_	_
12	immunity	_	NN	NN	_	9	PMOD	_	_
13	largely	_	RB	RB	_	14	DEP	_	_
14	through	_	IN	IN	_	6	ADV	_	_
15	inhibition	_	NN	NN	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	cytokine	_	NN	NN	_	18	NMOD	_	_
18	expression	_	NN	NN	_	16	PMOD	_	_
19	at	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	24	NMOD	_	_
21	transcriptional	_	JJ	JJ	_	24	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	posttranscriptional	_	JJ	JJ	_	21	COORD	_	_
24	levels	_	NNS	NNS	_	19	PMOD	_	_
25	.	_	.	.	_	6	P	_	_

1	GCS	_	NNS	NNS	_	2	SBJ	_	_
2	were	_	VBD	VBD	_	0	ROOT-S	_	_
3	also	_	RB	RB	_	4	ADV	_	_
4	reported	_	VBN	VBN	_	2	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	act	_	VB	VB	_	4	OBJ	_	_
7	indirectly	_	RB	RB	_	6	ADV	_	_
8	by	_	IN	IN	_	6	ADV	_	_
9	inducing	_	VBG	VBG	_	8	PMOD	_	_
10	transforming	_	VBG	VBG	_	13	NMOD	_	_
11	growth	_	NN	NN	_	13	NMOD	_	_
12	factor-beta	_	NN	NN	_	13	NMOD	_	_
13	expression	_	NN	NN	_	9	OBJ	_	_
14	,	_	,	,	_	13	P	_	_
15	which	_	WDT	WDT	_	18	SBJ	_	_
16	in	_	IN	IN	_	18	ADV	_	_
17	turn	_	NN	NN	_	16	PMOD	_	_
18	blocks	_	VBZ	VBZ	_	13	NMOD	_	_
19	T	_	NN	NN	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	immunity	_	NN	NN	_	18	OBJ	_	_
22	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	exerting	_	VBG	VBG	_	1	PMOD	_	_
3	their	_	PRP$	PRP$	_	5	NMOD	_	_
4	antiproliferative	_	JJ	JJ	_	5	NMOD	_	_
5	effects	_	NNS	NNS	_	2	OBJ	_	_
6	,	_	,	,	_	8	P	_	_
7	GCS	_	NNS	NNS	_	8	SBJ	_	_
8	diffuse	_	VBP	VBP	_	0	ROOT-S	_	_
9	into	_	IN	IN	_	8	ADV	_	_
10	target	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	where	_	WRB	WRB	_	14	ADV	_	_
13	they	_	PRP	PRP	_	14	SBJ	_	_
14	bind	_	VBP	VBP	_	11	NMOD	_	_
15	their	_	PRP$	PRP$	_	17	NMOD	_	_
16	cytoplasmic	_	JJ	JJ	_	17	NMOD	_	_
17	receptor	_	NN	NN	_	14	OBJ	_	_
18	,	_	,	,	_	17	P	_	_
19	which	_	WDT	WDT	_	22	SBJ	_	_
20	in	_	IN	IN	_	22	ADV	_	_
21	turn	_	NN	NN	_	20	PMOD	_	_
22	translocates	_	VBZ	VBZ	_	17	NMOD	_	_
23	to	_	TO	TO	_	22	ADV	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	nucleus	_	NN	NN	_	23	PMOD	_	_
26	where	_	WRB	WRB	_	28	ADV	_	_
27	it	_	PRP	PRP	_	28	SBJ	_	_
28	inhibits	_	VBZ	VBZ	_	25	NMOD	_	_
29	transcription	_	NN	NN	_	28	OBJ	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	cytokine	_	NN	NN	_	32	NMOD	_	_
32	genes	_	NNS	NNS	_	30	PMOD	_	_
33	through	_	IN	IN	_	28	ADV	_	_
34	direct	_	JJ	JJ	_	35	NMOD	_	_
35	binding	_	NN	NN	_	33	PMOD	_	_
36	to	_	TO	TO	_	35	NMOD	_	_
37	the	_	DT	DT	_	40	NMOD	_	_
38	glucocorticoid	_	NN	NN	_	40	NMOD	_	_
39	response	_	NN	NN	_	40	NMOD	_	_
40	elements	_	NNS	NNS	_	36	PMOD	_	_
41	(	_	(	(	_	42	P	_	_
42	GRE	_	NN	NN	_	40	PRN	_	_
43	)	_	)	)	_	42	P	_	_
44	,	_	,	,	_	40	P	_	_
45	which	_	WDT	WDT	_	46	SBJ	_	_
46	are	_	VBP	VBP	_	40	NMOD	_	_
47	located	_	JJ	JJ	_	46	PRD	_	_
48	in	_	IN	IN	_	47	AMOD	_	_
49	the	_	DT	DT	_	51	NMOD	_	_
50	promoter	_	NN	NN	_	51	NMOD	_	_
51	region	_	NN	NN	_	48	PMOD	_	_
52	of	_	IN	IN	_	51	NMOD	_	_
53	cytokine	_	NN	NN	_	54	NMOD	_	_
54	genes	_	NNS	NNS	_	52	PMOD	_	_
55	or	_	CC	CC	_	33	CC	_	_
56	,	_	,	,	_	33	P	_	_
57	alternatively	_	RB	RB	_	59	PMOD	_	_
58	,	_	,	,	_	59	P	_	_
59	through	_	IN	IN	_	33	COORD	_	_
60	antagonism	_	NN	NN	_	59	PMOD	_	_
61	of	_	IN	IN	_	60	NMOD	_	_
62	the	_	DT	DT	_	63	NMOD	_	_
63	action	_	NN	NN	_	61	PMOD	_	_
64	of	_	IN	IN	_	63	NMOD	_	_
65	transcription	_	NN	NN	_	66	NMOD	_	_
66	factors	_	NNS	NNS	_	64	PMOD	_	_
67	required	_	VBN	VBN	_	66	NMOD	_	_
68	for	_	IN	IN	_	67	ADV	_	_
69	optimal	_	JJ	JJ	_	71	NMOD	_	_
70	transcriptional	_	JJ	JJ	_	71	NMOD	_	_
71	activation	_	NN	NN	_	68	PMOD	_	_
72	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	contrast	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	their	_	PRP$	PRP$	_	6	NMOD	_	_
5	inhibitory	_	JJ	JJ	_	6	NMOD	_	_
6	effects	_	NNS	NNS	_	1	PMOD	_	_
7	on	_	IN	IN	_	6	NMOD	_	_
8	cytokine	_	NN	NN	_	9	NMOD	_	_
9	expression	_	NN	NN	_	7	PMOD	_	_
10	,	_	,	,	_	12	P	_	_
11	GCS	_	NNS	NNS	_	12	SBJ	_	_
12	up-regulate	_	VBP	VBP	_	0	ROOT-S	_	_
13	cytokine	_	NN	NN	_	15	NMOD	_	_
14	receptor	_	NN	NN	_	15	NMOD	_	_
15	expression	_	NN	NN	_	12	OBJ	_	_
16	that	_	WDT	WDT	_	17	SBJ	_	_
17	correlates	_	VBZ	VBZ	_	15	NMOD	_	_
18	with	_	IN	IN	_	17	ADV	_	_
19	enhanced	_	VBN	VBN	_	21	NMOD	_	_
20	cytokine	_	NN	NN	_	21	NMOD	_	_
21	effects	_	NNS	NNS	_	18	PMOD	_	_
22	on	_	IN	IN	_	21	NMOD	_	_
23	target	_	NN	NN	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	12	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	review	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	summarize	_	VBP	VBP	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	current	_	JJ	JJ	_	9	NMOD	_	_
9	state	_	NN	NN	_	6	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	knowledge	_	NN	NN	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	mechanism	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	action	_	NN	NN	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	GCS	_	NNS	NNS	_	17	PMOD	_	_
19	,	_	,	,	_	16	P	_	_
20	including	_	VBG	VBG	_	16	NMOD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	phenomenon	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	steroid-induced	_	JJ	JJ	_	25	NMOD	_	_
25	rebound	_	NN	NN	_	23	PMOD	_	_
26	,	_	,	,	_	16	P	_	_
27	which	_	WDT	WDT	_	28	SBJ	_	_
28	ensues	_	VBZ	VBZ	_	16	NMOD	_	_
29	upon	_	IN	IN	_	28	TMP	_	_
30	GCS	_	NNS	NNS	_	31	NMOD	_	_
31	withdrawal	_	NN	NN	_	29	PMOD	_	_
32	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	Oct-2	_	NN	NN	_	4	NMOD	_	_
3	transcription	_	NN	NN	_	4	NMOD	_	_
4	factor	_	NN	NN	_	0	ROOT-FRAG	_	_
5	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	Oct-2	_	NN	NN	_	4	NMOD	_	_
3	transcription	_	NN	NN	_	4	NMOD	_	_
4	factor	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	member	_	NN	NN	_	5	PRD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	14	NMOD	_	_
10	POU	_	NN	NN	_	14	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	Pit-Oct-Unc	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	family	_	NN	NN	_	8	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	transcription	_	NN	NN	_	17	NMOD	_	_
17	factors	_	NNS	NNS	_	15	PMOD	_	_
18	and	_	CC	CC	_	5	CC	_	_
19	is	_	VBZ	VBZ	_	5	COORD	_	_
20	expressed	_	VBN	VBN	_	19	VC	_	_
21	only	_	RB	RB	_	20	ADV	_	_
22	in	_	IN	IN	_	21	PMOD	_	_
23	B	_	NN	NN	_	24	NMOD	_	_
24	lymphocytes	_	NNS	NNS	_	22	PMOD	_	_
25	and	_	CC	CC	_	22	CC	_	_
26	in	_	IN	IN	_	22	COORD	_	_
27	neuronal	_	JJ	JJ	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	26	PMOD	_	_
29	but	_	CC	CC	_	21	CC	_	_
30	not	_	RB	RB	_	31	DEP	_	_
31	in	_	IN	IN	_	21	COORD	_	_
32	other	_	JJ	JJ	_	34	NMOD	_	_
33	cell	_	NN	NN	_	34	NMOD	_	_
34	types	_	NNS	NNS	_	31	PMOD	_	_
35	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	primary	_	JJ	JJ	_	4	NMOD	_	_
3	RNA	_	NN	NN	_	4	NMOD	_	_
4	transcript	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	gene	_	NN	NN	_	5	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	subject	_	JJ	JJ	_	8	PRD	_	_
10	to	_	TO	TO	_	9	AMOD	_	_
11	alternative	_	JJ	JJ	_	12	NMOD	_	_
12	splicing	_	NN	NN	_	10	PMOD	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	yield	_	VB	VB	_	8	VC	_	_
15	different	_	JJ	JJ	_	16	NMOD	_	_
16	variants	_	NNS	NNS	_	14	OBJ	_	_
17	which	_	WDT	WDT	_	18	SBJ	_	_
18	can	_	MD	MD	_	16	NMOD	_	_
19	either	_	CC	CC	_	20	CC	_	_
20	activate	_	VBP	VBP	_	18	VC	_	_
21	or	_	CC	CC	_	20	CC	_	_
22	repress	_	VBP	VBP	_	20	COORD	_	_
23	gene	_	NN	NN	_	24	NMOD	_	_
24	expression	_	NN	NN	_	20	OBJ	_	_
25	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	forms	_	NNS	NNS	_	7	SBJ	_	_
3	produced	_	VBN	VBN	_	2	NMOD	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	B	_	NN	NN	_	6	NMOD	_	_
6	lymphocytes	_	NNS	NNS	_	4	PMOD	_	_
7	have	_	VBP	VBP	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	11	NMOD	_	_
9	predominantly	_	RB	RB	_	10	AMOD	_	_
10	activating	_	JJ	JJ	_	11	NMOD	_	_
11	effect	_	NN	NN	_	7	OBJ	_	_
12	on	_	IN	IN	_	7	ADV	_	_
13	gene	_	NN	NN	_	14	NMOD	_	_
14	expression	_	NN	NN	_	12	PMOD	_	_
15	whereas	_	IN	IN	_	7	VMOD	_	_
16	those	_	DT	DT	_	21	SBJ	_	_
17	produced	_	VBN	VBN	_	16	NMOD	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	neuronal	_	JJ	JJ	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	18	PMOD	_	_
21	have	_	VBP	VBP	_	7	VMOD	_	_
22	a	_	DT	DT	_	25	NMOD	_	_
23	predominantly	_	RB	RB	_	24	AMOD	_	_
24	inhibitory	_	JJ	JJ	_	25	NMOD	_	_
25	effect	_	NN	NN	_	21	OBJ	_	_
26	and	_	CC	CC	_	21	CC	_	_
27	can	_	MD	MD	_	21	COORD	_	_
28	repress	_	VB	VB	_	27	VC	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	expression	_	NN	NN	_	28	OBJ	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	both	_	CC	CC	_	38	CC	_	_
33	the	_	DT	DT	_	38	NMOD	_	_
34	herpes	_	NN	NN	_	38	NMOD	_	_
35	simplex	_	NN	NN	_	38	NMOD	_	_
36	virus	_	NN	NN	_	38	NMOD	_	_
37	immediate-early	_	JJ	JJ	_	38	NMOD	_	_
38	genes	_	NNS	NNS	_	31	PMOD	_	_
39	and	_	CC	CC	_	38	CC	_	_
40	the	_	DT	DT	_	44	NMOD	_	_
41	cellular	_	JJ	JJ	_	44	NMOD	_	_
42	tyrosine	_	NN	NN	_	44	NMOD	_	_
43	hydroxylase	_	NN	NN	_	44	NMOD	_	_
44	gene	_	NN	NN	_	38	COORD	_	_
45	.	_	.	.	_	7	P	_	_

1	Thus	_	RB	RB	_	3	ADV	_	_
2	Oct-2	_	NN	NN	_	3	SBJ	_	_
3	plays	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	an	_	DT	DT	_	6	NMOD	_	_
5	important	_	JJ	JJ	_	6	NMOD	_	_
6	role	_	NN	NN	_	3	OBJ	_	_
7	in	_	IN	IN	_	3	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	regulation	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	cellular	_	JJ	JJ	_	13	NMOD	_	_
12	gene	_	NN	NN	_	13	NMOD	_	_
13	expression	_	NN	NN	_	10	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	both	_	CC	CC	_	17	CC	_	_
16	B	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	14	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	neuronal	_	JJ	JJ	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	17	COORD	_	_
21	as	_	RB	RB	_	7	CC	_	_
22	well	_	RB	RB	_	21	DEP	_	_
23	as	_	IN	IN	_	21	DEP	_	_
24	in	_	IN	IN	_	7	COORD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	control	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	viral	_	JJ	JJ	_	29	NMOD	_	_
29	latency	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	Cell	_	NN	NN	_	3	NMOD	_	_
2	specific	_	JJ	JJ	_	3	NMOD	_	_
3	expression	_	NN	NN	_	15	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	human	_	JJ	JJ	_	11	NMOD	_	_
6	Bruton	_	NN	NN	_	11	NMOD	_	_
7	's	_	POS	POS	_	6	NMOD	_	_
8	agammaglobulinemia	_	NN	NN	_	11	NMOD	_	_
9	tyrosine	_	NN	NN	_	11	NMOD	_	_
10	kinase	_	NN	NN	_	11	NMOD	_	_
11	gene	_	NN	NN	_	4	PMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	Btk	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	regulated	_	VBN	VBN	_	15	VC	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	Sp1-	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	Spi-1\/PU.1-family	_	NN	NN	_	21	NMOD	_	_
21	members	_	NNS	NNS	_	18	COORD	_	_
22	.	_	.	.	_	15	P	_	_

1	Bruton	_	NN	NN	_	5	NMOD	_	_
2	's	_	POS	POS	_	1	NMOD	_	_
3	agammaglobulinemia	_	NN	NN	_	5	NMOD	_	_
4	tyrosine	_	NN	NN	_	5	NMOD	_	_
5	kinase	_	NN	NN	_	9	SBJ	_	_
6	(	_	(	(	_	7	P	_	_
7	Btk	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	a	_	DT	DT	_	13	NMOD	_	_
11	cytoplasmic	_	JJ	JJ	_	13	NMOD	_	_
12	tyrosine	_	NN	NN	_	13	NMOD	_	_
13	kinase	_	NN	NN	_	9	PRD	_	_
14	involved	_	VBN	VBN	_	13	NMOD	_	_
15	in	_	IN	IN	_	14	ADV	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	human	_	JJ	JJ	_	18	NMOD	_	_
18	disease	_	NN	NN	_	15	PMOD	_	_
19	X-linked	_	JJ	JJ	_	20	NMOD	_	_
20	agammaglobulinemia	_	NN	NN	_	18	NMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	XLA	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	gene	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	expressed	_	VBN	VBN	_	3	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	all	_	DT	DT	_	8	NMOD	_	_
7	hematopoietic	_	JJ	JJ	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	5	PMOD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	exception	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	T-cells	_	NNS	NNS	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	plasma	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	13	COORD	_	_
17	.	_	.	.	_	3	P	_	_

1	For	_	IN	IN	_	16	ADV	_	_
2	this	_	DT	DT	_	4	NMOD	_	_
3	expression	_	NN	NN	_	4	NMOD	_	_
4	pattern	_	NN	NN	_	1	PMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	first	_	JJ	JJ	_	8	NMOD	_	_
7	280	_	CD	CD	_	8	NMOD	_	_
8	bp	_	NN	NN	_	16	SBJ	_	_
9	upstream	_	JJ	JJ	_	8	NMOD	_	_
10	of	_	IN	IN	_	9	AMOD	_	_
11	the	_	DT	DT	_	15	NMOD	_	_
12	major	_	JJ	JJ	_	15	NMOD	_	_
13	transcriptional	_	JJ	JJ	_	15	NMOD	_	_
14	start	_	NN	NN	_	15	NMOD	_	_
15	site	_	NN	NN	_	10	PMOD	_	_
16	seems	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	be	_	VB	VB	_	16	OBJ	_	_
19	sufficient	_	JJ	JJ	_	18	PRD	_	_
20	.	_	.	.	_	16	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	vitro	_	FW	FW	_	4	NMOD	_	_
3	footprinting	_	NN	NN	_	4	NMOD	_	_
4	analysis	_	NN	NN	_	11	SBJ	_	_
5	within	_	IN	IN	_	4	NMOD	_	_
6	this	_	DT	DT	_	7	NMOD	_	_
7	part	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	promoter	_	NN	NN	_	8	PMOD	_	_
11	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
12	two	_	CD	CD	_	15	NMOD	_	_
13	Sp1	_	NN	NN	_	15	NMOD	_	_
14	binding	_	NN	NN	_	15	NMOD	_	_
15	sites	_	NNS	NNS	_	11	OBJ	_	_
16	as	_	RB	RB	_	15	CC	_	_
17	well	_	RB	RB	_	16	DEP	_	_
18	as	_	IN	IN	_	16	DEP	_	_
19	a	_	DT	DT	_	20	NMOD	_	_
20	PU-box	_	NN	NN	_	15	COORD	_	_
21	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	transcription	_	NN	NN	_	4	NMOD	_	_
3	factor	_	NN	NN	_	4	NMOD	_	_
4	Spi-1\/PU.1	_	NN	NN	_	13	SBJ	_	_
5	as	_	RB	RB	_	4	CC	_	_
6	well	_	RB	RB	_	5	DEP	_	_
7	as	_	IN	IN	_	5	DEP	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	closely	_	RB	RB	_	10	AMOD	_	_
10	related	_	JJ	JJ	_	12	NMOD	_	_
11	factor	_	NN	NN	_	12	NMOD	_	_
12	Spi-B	_	NN	NN	_	4	COORD	_	_
13	bound	_	VBD	VBD	_	0	ROOT-S	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	PU-box	_	NN	NN	_	14	PMOD	_	_
17	in	_	IN	IN	_	13	ADV	_	_
18	B-cells	_	NNS	NNS	_	17	PMOD	_	_
19	.	_	.	.	_	13	P	_	_

1	In	_	IN	IN	_	17	ADV	_	_
2	the	_	DT	DT	_	6	NMOD	_	_
3	erythroleukemia	_	NN	NN	_	6	NMOD	_	_
4	cell	_	NN	NN	_	6	NMOD	_	_
5	line	_	NN	NN	_	6	NMOD	_	_
6	K562	_	NN	NN	_	1	PMOD	_	_
7	,	_	,	,	_	17	P	_	_
8	due	_	IN	IN	_	17	ADV	_	_
9	to	_	TO	TO	_	8	DEP	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	absence	_	NN	NN	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	Spi-B	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	17	P	_	_
15	only	_	RB	RB	_	16	NMOD	_	_
16	PU.1	_	NN	NN	_	17	SBJ	_	_
17	bound	_	VBD	VBD	_	0	ROOT-S	_	_
18	to	_	TO	TO	_	17	ADV	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	Btk	_	NN	NN	_	21	NMOD	_	_
21	promoter	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	17	P	_	_

1	Mutation	_	NN	NN	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	either	_	DT	DT	_	4	NMOD	_	_
4	site	_	NN	NN	_	2	PMOD	_	_
5	reduced	_	VBD	VBD	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	expression	_	NN	NN	_	5	OBJ	_	_
8	in	_	IN	IN	_	5	ADV	_	_
9	transient	_	JJ	JJ	_	11	NMOD	_	_
10	transfection	_	NN	NN	_	11	NMOD	_	_
11	experiments	_	NNS	NNS	_	8	PMOD	_	_
12	.	_	.	.	_	5	P	_	_

1	However	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	mutation	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	PU	_	NN	NN	_	7	NMOD	_	_
7	box	_	NN	NN	_	4	PMOD	_	_
8	had	_	VBD	VBD	_	0	ROOT-S	_	_
9	no	_	DT	DT	_	10	NMOD	_	_
10	effect	_	NN	NN	_	8	OBJ	_	_
11	in	_	IN	IN	_	8	ADV	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	T-cell	_	NN	NN	_	15	NMOD	_	_
14	line	_	NN	NN	_	15	NMOD	_	_
15	Jurkat	_	NN	NN	_	11	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	where	_	WRB	WRB	_	25	ADV	_	_
18	none	_	NN	NN	_	24	SBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	Spi-1	_	NN	NN	_	23	NMOD	_	_
22	family	_	NN	NN	_	23	NMOD	_	_
23	members	_	NNS	NNS	_	19	PMOD	_	_
24	is	_	VBZ	VBZ	_	15	NMOD	_	_
25	expressed	_	VBN	VBN	_	24	VC	_	_
26	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	Spi-B	_	NN	NN	_	8	SBJ	_	_
4	as	_	RB	RB	_	3	CC	_	_
5	well	_	RB	RB	_	4	DEP	_	_
6	as	_	IN	IN	_	4	DEP	_	_
7	PU.1	_	NN	NN	_	3	COORD	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	able	_	JJ	JJ	_	8	PRD	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	transactivate	_	VB	VB	_	9	AMOD	_	_
12	Btk	_	NN	NN	_	13	NMOD	_	_
13	expression	_	NN	NN	_	11	OBJ	_	_
14	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	18	ADV	_	_
2	fetal	_	JJ	JJ	_	3	NMOD	_	_
3	liver	_	NN	NN	_	1	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	PU.1-\/-	_	JJ	JJ	_	6	NMOD	_	_
6	mice	_	NNS	NNS	_	4	PMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	which	_	WDT	WDT	_	9	SBJ	_	_
9	lack	_	VBP	VBP	_	6	NMOD	_	_
10	lymphoid	_	JJ	JJ	_	13	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	myeloid	_	JJ	JJ	_	10	COORD	_	_
13	cells	_	NNS	NNS	_	9	OBJ	_	_
14	,	_	,	,	_	18	P	_	_
15	expression	_	NN	NN	_	18	SBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	Btk	_	NN	NN	_	16	PMOD	_	_
18	was	_	VBD	VBD	_	0	ROOT-S	_	_
19	reduced	_	VBN	VBN	_	18	VC	_	_
20	two-	_	CD	CD	_	19	ADV	_	_
21	to	_	TO	TO	_	20	AMOD	_	_
22	threefold	_	RB	RB	_	20	AMOD	_	_
23	but	_	CC	CC	_	19	CC	_	_
24	not	_	RB	RB	_	25	VMOD	_	_
25	abolished	_	VBN	VBN	_	19	COORD	_	_
26	.	_	.	.	_	18	P	_	_

1	Collectively	_	RB	RB	_	4	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	4	SBJ	_	_
4	shows	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	expression	_	NN	NN	_	11	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	Btk	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	7	PMOD	_	_
11	is	_	VBZ	VBZ	_	5	VMOD	_	_
12	regulated	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	combined	_	JJ	JJ	_	16	NMOD	_	_
16	action	_	NN	NN	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	Sp1-	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	PU.1-family	_	NN	NN	_	21	NMOD	_	_
21	members	_	NNS	NNS	_	18	COORD	_	_
22	.	_	.	.	_	4	P	_	_

1	Elf-1	_	NN	NN	_	4	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	Stat5	_	NN	NN	_	1	COORD	_	_
4	bind	_	VBP	VBP	_	0	ROOT-S	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	critical	_	JJ	JJ	_	8	NMOD	_	_
8	element	_	NN	NN	_	5	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	new	_	JJ	JJ	_	12	NMOD	_	_
12	enhancer	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	19	NMOD	_	_
15	human	_	JJ	JJ	_	19	NMOD	_	_
16	interleukin-2	_	NN	NN	_	19	NMOD	_	_
17	receptor	_	NN	NN	_	19	NMOD	_	_
18	alpha	_	NN	NN	_	19	NMOD	_	_
19	gene	_	NN	NN	_	13	PMOD	_	_
20	{	_	(	(	_	23	P	_	_
21	published	_	VBN	VBN	_	22	NMOD	_	_
22	erratum	_	NN	NN	_	23	SBJ	_	_
23	appears	_	VBZ	VBZ	_	4	PRN	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	Mol	_	NNP	NNP	_	27	NMOD	_	_
26	Cell	_	NNP	NNP	_	27	NMOD	_	_
27	Biol	_	NNP	NNP	_	24	PMOD	_	_
28	1997	_	CD	CD	_	29	NMOD	_	_
29	Apr	_	NNP	NNP	_	27	TMP	_	_
30	;	_	:	:	_	27	P	_	_
31	17	_	CD	CD	_	33	NMOD	_	_
32	(	_	(	(	_	33	P	_	_
33	4	_	CD	CD	_	27	NMOD	_	_
34	)	_	)	)	_	33	P	_	_
35	:	_	:	:	_	27	P	_	_
36	2351	_	CD	CD	_	27	NMOD	_	_
37	}	_	)	)	_	23	P	_	_

1	The	_	DT	DT	_	10	NMOD	_	_
2	interleukin	_	NN	NN	_	5	NMOD	_	_
3	2	_	CD	CD	_	5	NMOD	_	_
4	receptor	_	NN	NN	_	5	NMOD	_	_
5	alpha-chain	_	NN	NN	_	10	NMOD	_	_
6	(	_	(	(	_	8	P	_	_
7	IL-2R	_	NN	NN	_	8	NMOD	_	_
8	alpha	_	NN	NN	_	5	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	gene	_	NN	NN	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	key	_	JJ	JJ	_	14	NMOD	_	_
14	regulator	_	NN	NN	_	11	PRD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	lymphocyte	_	NN	NN	_	17	NMOD	_	_
17	proliferation	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	11	P	_	_

1	IL-2R	_	NN	NN	_	2	NMOD	_	_
2	alpha	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	rapidly	_	RB	RB	_	7	ADV	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	potently	_	RB	RB	_	4	COORD	_	_
7	induced	_	VBN	VBN	_	3	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	in	_	IN	IN	_	7	ADV	_	_
12	response	_	NN	NN	_	11	DEP	_	_
13	to	_	TO	TO	_	11	DEP	_	_
14	mitogenic	_	JJ	JJ	_	15	NMOD	_	_
15	stimuli	_	NNS	NNS	_	11	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	Interleukin	_	NN	NN	_	6	SBJ	_	_
2	2	_	CD	CD	_	1	NMOD	_	_
3	(	_	(	(	_	4	P	_	_
4	IL-2	_	NN	NN	_	1	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	stimulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	IL-2R	_	NN	NN	_	9	NMOD	_	_
8	alpha.	_	NN	NN	_	9	NMOD	_	_
9	transcription	_	NN	NN	_	6	IOBJ	_	_
10	,	_	,	,	_	6	P	_	_
11	thereby	_	RB	RB	_	12	ADV	_	_
12	amplifying	_	VBG	VBG	_	6	OBJ	_	_
13	expression	_	NN	NN	_	12	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	its	_	PRP$	PRP$	_	18	NMOD	_	_
16	own	_	JJ	JJ	_	18	NMOD	_	_
17	high-affinity	_	NN	NN	_	18	NMOD	_	_
18	receptor	_	NN	NN	_	14	PMOD	_	_
19	.	_	.	.	_	6	P	_	_

1	IL-2R	_	NN	NN	_	3	NMOD	_	_
2	alpha	_	NN	NN	_	3	NMOD	_	_
3	transcription	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	at	_	IN	IN	_	7	PMOD	_	_
6	least	_	JJS	JJS	_	5	AMOD	_	_
7	in	_	IN	IN	_	4	ADV	_	_
8	part	_	NN	NN	_	7	PMOD	_	_
9	controlled	_	VBN	VBN	_	4	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	two	_	CD	CD	_	14	NMOD	_	_
12	positive	_	JJ	JJ	_	14	NMOD	_	_
13	regulatory	_	JJ	JJ	_	14	NMOD	_	_
14	regions	_	NNS	NNS	_	10	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	PRRI	_	NN	NN	_	14	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	PRRII	_	NN	NN	_	16	COORD	_	_
19	.	_	.	.	_	4	P	_	_

1	PRRI	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	an	_	DT	DT	_	6	NMOD	_	_
4	inducible	_	JJ	JJ	_	6	NMOD	_	_
5	proximal	_	JJ	JJ	_	6	NMOD	_	_
6	enhancer	_	NN	NN	_	2	PRD	_	_
7	,	_	,	,	_	6	P	_	_
8	located	_	JJ	JJ	_	6	NMOD	_	_
9	between	_	IN	IN	_	8	AMOD	_	_
10	nucleotides	_	NNS	NNS	_	9	PMOD	_	_
11	-276	_	CD	CD	_	10	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	-244	_	CD	CD	_	11	COORD	_	_
14	,	_	,	,	_	6	P	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	contains	_	VBZ	VBZ	_	6	NMOD	_	_
17	NF-kappaB	_	NN	NN	_	20	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	SRE\/CArG	_	NN	NN	_	17	COORD	_	_
20	motifs	_	NNS	NNS	_	16	OBJ	_	_
21	.	_	.	.	_	2	P	_	_

1	PRRII	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	T-cell-specific	_	JJ	JJ	_	5	NMOD	_	_
5	enhancer	_	NN	NN	_	2	PRD	_	_
6	,	_	,	,	_	5	P	_	_
7	located	_	JJ	JJ	_	5	NMOD	_	_
8	between	_	IN	IN	_	7	AMOD	_	_
9	nucleotides	_	NNS	NNS	_	8	PMOD	_	_
10	-137	_	CD	CD	_	9	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	-64	_	CD	CD	_	10	COORD	_	_
13	,	_	,	,	_	5	P	_	_
14	which	_	WDT	WDT	_	15	SBJ	_	_
15	binds	_	VBZ	VBZ	_	5	NMOD	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	T-cell-specific	_	JJ	JJ	_	20	NMOD	_	_
18	Ets	_	NN	NN	_	20	NMOD	_	_
19	protein	_	NN	NN	_	20	NMOD	_	_
20	Elf-1	_	NN	NN	_	15	OBJ	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	HMG-I-LRB-Y-RRB-	_	NN	NN	_	23	NMOD	_	_
23	proteins	_	NNS	NNS	_	20	COORD	_	_
24	.	_	.	.	_	2	P	_	_

1	However	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	none	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	these	_	DT	DT	_	7	NMOD	_	_
6	proximal	_	JJ	JJ	_	7	NMOD	_	_
7	regions	_	NNS	NNS	_	4	PMOD	_	_
8	account	_	VBP	VBP	_	0	ROOT-S	_	_
9	for	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	induction	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	IL-2R	_	NN	NN	_	15	NMOD	_	_
14	alpha	_	NN	NN	_	15	NMOD	_	_
15	transcription	_	NN	NN	_	12	PMOD	_	_
16	by	_	IN	IN	_	11	NMOD	_	_
17	IL-2	_	NN	NN	_	16	PMOD	_	_
18	.	_	.	.	_	8	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	find	_	VB	VB	_	25	VMOD	_	_
3	new	_	JJ	JJ	_	5	NMOD	_	_
4	regulatory	_	JJ	JJ	_	5	NMOD	_	_
5	regions	_	NNS	NNS	_	2	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	IL-2R	_	NN	NN	_	10	NMOD	_	_
9	alpha	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	6	PMOD	_	_
11	,	_	,	,	_	25	P	_	_
12	8.5	_	CD	CD	_	13	NMOD	_	_
13	kb	_	NN	NN	_	25	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	5'	_	JJ	JJ	_	19	NMOD	_	_
17	end	_	NN	NN	_	19	NMOD	_	_
18	noncoding	_	JJ	JJ	_	19	NMOD	_	_
19	sequence	_	NN	NN	_	14	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	IL-2R	_	NN	NN	_	24	NMOD	_	_
23	alpha	_	NN	NN	_	24	NMOD	_	_
24	gene	_	NN	NN	_	20	PMOD	_	_
25	have	_	VBP	VBP	_	0	ROOT-S	_	_
26	been	_	VBN	VBN	_	25	VC	_	_
27	sequenced	_	VBN	VBN	_	26	VC	_	_
28	.	_	.	.	_	25	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	identified	_	VBD	VBD	_	0	ROOT-S	_	_
3	an	_	DT	DT	_	5	NMOD	_	_
4	86-nucleotide	_	JJ	JJ	_	5	NMOD	_	_
5	fragment	_	NN	NN	_	2	OBJ	_	_
6	that	_	WDT	WDT	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	5	NMOD	_	_
8	90	_	CD	CD	_	9	NMOD	_	_
9	%	_	NN	NN	_	10	AMOD	_	_
10	identical	_	JJ	JJ	_	7	PRD	_	_
11	to	_	TO	TO	_	10	AMOD	_	_
12	the	_	DT	DT	_	17	NMOD	_	_
13	recently	_	RB	RB	_	14	AMOD	_	_
14	characterized	_	VBN	VBN	_	17	NMOD	_	_
15	murine	_	JJ	JJ	_	17	NMOD	_	_
16	IL-2-responsive	_	JJ	JJ	_	17	NMOD	_	_
17	element	_	NN	NN	_	11	PMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	mIL-2rE	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	4	NMOD	_	_
2	putative	_	JJ	JJ	_	4	NMOD	_	_
3	human	_	JJ	JJ	_	4	NMOD	_	_
4	IL-2rE	_	NN	NN	_	9	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	designated	_	VBN	VBN	_	4	NMOD	_	_
7	PRRIII	_	NN	NN	_	6	OBJ	_	_
8	,	_	,	,	_	4	P	_	_
9	confers	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	IL-2	_	NN	NN	_	11	NMOD	_	_
11	responsiveness	_	NN	NN	_	9	OBJ	_	_
12	on	_	IN	IN	_	9	ADV	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	heterologous	_	JJ	JJ	_	15	NMOD	_	_
15	promoter	_	NN	NN	_	12	PMOD	_	_
16	.	_	.	.	_	9	P	_	_

1	PRRIII	_	NN	NN	_	2	SBJ	_	_
2	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	7	NMOD	_	_
4	Stat	_	NN	NN	_	7	NMOD	_	_
5	protein	_	NN	NN	_	7	NMOD	_	_
6	binding	_	NN	NN	_	7	NMOD	_	_
7	site	_	NN	NN	_	2	OBJ	_	_
8	that	_	WDT	WDT	_	9	SBJ	_	_
9	overlaps	_	VBZ	VBZ	_	7	NMOD	_	_
10	with	_	IN	IN	_	9	ADV	_	_
11	an	_	DT	DT	_	13	NMOD	_	_
12	EBS	_	NN	NN	_	13	NMOD	_	_
13	motif	_	NN	NN	_	10	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	GASd\/EBSd	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	.	_	.	.	_	2	P	_	_

1	These	_	DT	DT	_	2	SBJ	_	_
2	are	_	VBP	VBP	_	0	ROOT-S	_	_
3	essential	_	JJ	JJ	_	2	PRD	_	_
4	for	_	IN	IN	_	3	AMOD	_	_
5	IL-2	_	NN	NN	_	6	NMOD	_	_
6	inducibility	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	PRRIII\/CAT	_	NN	NN	_	10	NMOD	_	_
9	reporter	_	NN	NN	_	10	NMOD	_	_
10	constructs	_	NNS	NNS	_	7	PMOD	_	_
11	.	_	.	.	_	2	P	_	_

1	IL-2	_	NN	NN	_	2	SBJ	_	_
2	induced	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	binding	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	Stat5a	_	NN	NN	_	9	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	b	_	NN	NN	_	6	COORD	_	_
9	proteins	_	NNS	NNS	_	5	PMOD	_	_
10	to	_	TO	TO	_	4	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	human	_	JJ	JJ	_	14	NMOD	_	_
13	GASd	_	NN	NN	_	14	NMOD	_	_
14	element	_	NN	NN	_	10	PMOD	_	_
15	.	_	.	.	_	2	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	confirm	_	VB	VB	_	11	VMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	physiological	_	JJ	JJ	_	5	NMOD	_	_
5	relevance	_	NN	NN	_	2	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	these	_	DT	DT	_	8	NMOD	_	_
8	findings	_	NNS	NNS	_	6	PMOD	_	_
9	,	_	,	,	_	11	P	_	_
10	we	_	PRP	PRP	_	11	SBJ	_	_
11	carried	_	VBD	VBD	_	0	ROOT-S	_	_
12	out	_	RP	RP	_	11	PRT	_	_
13	in	_	FW	FW	_	14	AMOD	_	_
14	vivo	_	FW	FW	_	16	NMOD	_	_
15	footprinting	_	NN	NN	_	16	NMOD	_	_
16	experiments	_	NNS	NNS	_	11	OBJ	_	_
17	which	_	WDT	WDT	_	18	SBJ	_	_
18	showed	_	VBD	VBD	_	16	NMOD	_	_
19	that	_	IN	IN	_	18	OBJ	_	_
20	stimulation	_	NN	NN	_	25	SBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	IL-2R	_	NN	NN	_	24	NMOD	_	_
23	alpha	_	NN	NN	_	24	NMOD	_	_
24	expression	_	NN	NN	_	21	PMOD	_	_
25	correlated	_	VBD	VBD	_	19	VMOD	_	_
26	with	_	IN	IN	_	25	ADV	_	_
27	occupancy	_	NN	NN	_	26	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	GASd	_	NN	NN	_	31	NMOD	_	_
31	element	_	NN	NN	_	28	PMOD	_	_
32	.	_	.	.	_	11	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	major	_	JJ	JJ	_	6	NMOD	_	_
6	role	_	NN	NN	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	GASd\/EBSd	_	NN	NN	_	10	NMOD	_	_
10	element	_	NN	NN	_	7	PMOD	_	_
11	in	_	IN	IN	_	6	NMOD	_	_
12	IL-2R	_	NN	NN	_	14	NMOD	_	_
13	alpha	_	NN	NN	_	14	NMOD	_	_
14	regulation	_	NN	NN	_	11	PMOD	_	_
15	and	_	CC	CC	_	3	CC	_	_
16	suggest	_	VBP	VBP	_	3	COORD	_	_
17	that	_	IN	IN	_	16	OBJ	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	T-cell-specific	_	JJ	JJ	_	21	NMOD	_	_
20	Elf-1	_	NN	NN	_	21	NMOD	_	_
21	factor	_	NN	NN	_	22	SBJ	_	_
22	can	_	MD	MD	_	17	VMOD	_	_
23	serve	_	VB	VB	_	22	VC	_	_
24	as	_	IN	IN	_	23	ADV	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	transcriptional	_	JJ	JJ	_	27	NMOD	_	_
27	repressor	_	NN	NN	_	24	PMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	Association	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	TRAF1	_	NN	NN	_	2	PMOD	_	_
4	,	_	,	,	_	3	P	_	_
5	TRAF2	_	NN	NN	_	3	COORD	_	_
6	,	_	,	,	_	3	P	_	_
7	and	_	CC	CC	_	3	CC	_	_
8	TRAF3	_	NN	NN	_	3	COORD	_	_
9	with	_	IN	IN	_	1	NMOD	_	_
10	an	_	DT	DT	_	14	NMOD	_	_
11	Epstein-Barr	_	JJ	JJ	_	14	NMOD	_	_
12	virus	_	NN	NN	_	14	NMOD	_	_
13	LMP1	_	NN	NN	_	14	NMOD	_	_
14	domain	_	NN	NN	_	9	PMOD	_	_
15	important	_	JJ	JJ	_	14	NMOD	_	_
16	for	_	IN	IN	_	15	AMOD	_	_
17	B-lymphocyte	_	NN	NN	_	18	NMOD	_	_
18	transformation	_	NN	NN	_	16	PMOD	_	_
19	:	_	:	:	_	1	P	_	_
20	role	_	NN	NN	_	1	NMOD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	NF-kappaB	_	NN	NN	_	23	NMOD	_	_
23	activation	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	Epstein-Barr	_	JJ	JJ	_	3	NMOD	_	_
3	virus	_	NN	NN	_	9	NMOD	_	_
4	(	_	(	(	_	5	P	_	_
5	EBV	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	transforming	_	VBG	VBG	_	9	NMOD	_	_
8	protein	_	NN	NN	_	9	NMOD	_	_
9	LMP1	_	NN	NN	_	10	SBJ	_	_
10	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	be	_	VB	VB	_	10	OBJ	_	_
13	a	_	DT	DT	_	19	NMOD	_	_
14	constitutively	_	RB	RB	_	15	AMOD	_	_
15	activated	_	VBN	VBN	_	19	NMOD	_	_
16	tumor	_	NN	NN	_	19	NMOD	_	_
17	necrosis	_	NN	NN	_	19	NMOD	_	_
18	factor	_	NN	NN	_	19	NMOD	_	_
19	receptor	_	NN	NN	_	12	PRD	_	_
20	(	_	(	(	_	21	P	_	_
21	TNFR	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	on	_	IN	IN	_	12	ADV	_	_
24	the	_	DT	DT	_	23	DEP	_	_
25	basis	_	NN	NN	_	23	DEP	_	_
26	of	_	IN	IN	_	23	DEP	_	_
27	an	_	DT	DT	_	29	NMOD	_	_
28	intrinsic	_	JJ	JJ	_	29	NMOD	_	_
29	ability	_	NN	NN	_	23	PMOD	_	_
30	to	_	TO	TO	_	31	VMOD	_	_
31	aggregate	_	VB	VB	_	29	NMOD	_	_
32	in	_	IN	IN	_	31	ADV	_	_
33	the	_	DT	DT	_	35	NMOD	_	_
34	plasma	_	NN	NN	_	35	NMOD	_	_
35	membrane	_	NN	NN	_	32	PMOD	_	_
36	and	_	CC	CC	_	29	CC	_	_
37	an	_	DT	DT	_	38	NMOD	_	_
38	association	_	NN	NN	_	29	COORD	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	its	_	PRP$	PRP$	_	43	NMOD	_	_
41	cytoplasmic	_	JJ	JJ	_	43	NMOD	_	_
42	carboxyl	_	NN	NN	_	43	NMOD	_	_
43	terminus	_	NN	NN	_	39	PMOD	_	_
44	(	_	(	(	_	45	P	_	_
45	CT	_	NN	NN	_	43	PRN	_	_
46	)	_	)	)	_	45	P	_	_
47	with	_	IN	IN	_	38	NMOD	_	_
48	TNFR-associated	_	JJ	JJ	_	49	NMOD	_	_
49	factors	_	NNS	NNS	_	47	PMOD	_	_
50	(	_	(	(	_	51	P	_	_
51	TRAFs	_	NNS	NNS	_	49	PRN	_	_
52	)	_	)	)	_	51	P	_	_
53	.	_	.	.	_	10	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	now	_	RB	RB	_	3	TMP	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	in	_	IN	IN	_	19	ADV	_	_
6	EBV-transformed	_	JJ	JJ	_	8	NMOD	_	_
7	B	_	NN	NN	_	8	NMOD	_	_
8	lymphocytes	_	NNS	NNS	_	5	PMOD	_	_
9	most	_	JJS	JJS	_	19	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	TRAF1	_	NN	NN	_	10	PMOD	_	_
12	or	_	CC	CC	_	11	CC	_	_
13	TRAF3	_	NN	NN	_	11	COORD	_	_
14	and	_	CC	CC	_	9	CC	_	_
15	5	_	CD	CD	_	16	NMOD	_	_
16	%	_	NN	NN	_	9	COORD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	TRAF2	_	NN	NN	_	17	PMOD	_	_
19	are	_	VBP	VBP	_	4	VMOD	_	_
20	associated	_	VBN	VBN	_	19	VC	_	_
21	with	_	IN	IN	_	20	ADV	_	_
22	LMP1	_	NN	NN	_	21	PMOD	_	_
23	and	_	CC	CC	_	4	CC	_	_
24	that	_	IN	IN	_	4	COORD	_	_
25	most	_	JJS	JJS	_	28	SBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	LMP1	_	NN	NN	_	26	PMOD	_	_
28	is	_	VBZ	VBZ	_	24	VMOD	_	_
29	associated	_	VBN	VBN	_	28	VC	_	_
30	with	_	IN	IN	_	29	ADV	_	_
31	TRAF1	_	NN	NN	_	30	PMOD	_	_
32	or	_	CC	CC	_	31	CC	_	_
33	TRAF3	_	NN	NN	_	31	COORD	_	_
34	.	_	.	.	_	3	P	_	_

1	TRAF1	_	NN	NN	_	7	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	TRAF2	_	NN	NN	_	1	COORD	_	_
4	,	_	,	,	_	1	P	_	_
5	and	_	CC	CC	_	1	CC	_	_
6	TRAF3	_	NN	NN	_	1	COORD	_	_
7	bind	_	VBP	VBP	_	0	ROOT-S	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	single	_	JJ	JJ	_	11	NMOD	_	_
11	site	_	NN	NN	_	8	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	LMP1	_	NN	NN	_	15	NMOD	_	_
15	CT	_	NN	NN	_	12	PMOD	_	_
16	corresponding	_	VBG	VBG	_	15	NMOD	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	amino	_	NN	NN	_	19	NMOD	_	_
19	acids	_	NNS	NNS	_	17	PMOD	_	_
20	(	_	(	(	_	21	P	_	_
21	aa	_	NNS	NNS	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	199	_	CD	CD	_	19	NMOD	_	_
24	to	_	TO	TO	_	23	NMOD	_	_
25	214	_	CD	CD	_	23	NMOD	_	_
26	,	_	,	,	_	11	P	_	_
27	within	_	IN	IN	_	11	NMOD	_	_
28	a	_	DT	DT	_	29	NMOD	_	_
29	domain	_	NN	NN	_	27	PMOD	_	_
30	which	_	WDT	WDT	_	31	SBJ	_	_
31	is	_	VBZ	VBZ	_	29	NMOD	_	_
32	important	_	JJ	JJ	_	31	PRD	_	_
33	for	_	IN	IN	_	32	AMOD	_	_
34	B-lymphocyte	_	NN	NN	_	36	NMOD	_	_
35	growth	_	NN	NN	_	36	NMOD	_	_
36	transformation	_	NN	NN	_	33	PMOD	_	_
37	(	_	(	(	_	38	P	_	_
38	aa	_	NNS	NNS	_	27	PRN	_	_
39	187	_	CD	CD	_	38	NMOD	_	_
40	to	_	TO	TO	_	39	NMOD	_	_
41	231	_	CD	CD	_	39	NMOD	_	_
42	)	_	)	)	_	38	P	_	_
43	.	_	.	.	_	7	P	_	_

1	Further	_	JJ	JJ	_	6	NMOD	_	_
2	deletional	_	JJ	JJ	_	6	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	alanine	_	NN	NN	_	5	NMOD	_	_
5	mutagenesis	_	NN	NN	_	2	COORD	_	_
6	analyses	_	NNS	NNS	_	26	SBJ	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	comparison	_	NN	NN	_	6	COORD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	TRAF	_	NN	NN	_	12	NMOD	_	_
11	binding	_	NN	NN	_	12	NMOD	_	_
12	sequences	_	NNS	NNS	_	9	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	CD40	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	13	P	_	_
16	in	_	IN	IN	_	13	COORD	_	_
17	CD30	_	NN	NN	_	16	PMOD	_	_
18	,	_	,	,	_	13	P	_	_
19	and	_	CC	CC	_	13	CC	_	_
20	in	_	IN	IN	_	13	COORD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	LMP1	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	other	_	JJ	JJ	_	25	NMOD	_	_
25	lymphycryptoviruses	_	NNS	NNS	_	23	PMOD	_	_
26	provide	_	VBP	VBP	_	0	ROOT-S	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	first	_	JJ	JJ	_	29	NMOD	_	_
29	evidence	_	NN	NN	_	26	OBJ	_	_
30	that	_	IN	IN	_	29	NMOD	_	_
31	PXQXT\/S	_	NN	NN	_	32	SBJ	_	_
32	is	_	VBZ	VBZ	_	30	VMOD	_	_
33	a	_	DT	DT	_	37	NMOD	_	_
34	core	_	NN	NN	_	37	NMOD	_	_
35	TRAF	_	NN	NN	_	37	NMOD	_	_
36	binding	_	NN	NN	_	37	NMOD	_	_
37	motif	_	NN	NN	_	32	PRD	_	_
38	.	_	.	.	_	26	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	negative	_	JJ	JJ	_	3	NMOD	_	_
3	effects	_	NNS	NNS	_	21	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	point	_	NN	NN	_	6	NMOD	_	_
6	mutations	_	NNS	NNS	_	4	PMOD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	13	NMOD	_	_
9	LMP1-LRB-1-231-RRB-	_	NN	NN	_	13	NMOD	_	_
10	core	_	NN	NN	_	13	NMOD	_	_
11	TRAF	_	NN	NN	_	13	NMOD	_	_
12	binding	_	NN	NN	_	13	NMOD	_	_
13	motif	_	NN	NN	_	7	PMOD	_	_
14	on	_	IN	IN	_	3	NMOD	_	_
15	TRAF	_	NN	NN	_	16	NMOD	_	_
16	binding	_	NN	NN	_	14	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	NF-kappaB	_	NN	NN	_	19	NMOD	_	_
19	activation	_	NN	NN	_	16	COORD	_	_
20	genetically	_	RB	RB	_	21	ADV	_	_
21	link	_	VBP	VBP	_	0	ROOT-S	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	TRAFs	_	NNS	NNS	_	21	OBJ	_	_
24	to	_	TO	TO	_	21	ADV	_	_
25	LMP1-LRB-1-231-RRB--mediated	_	JJ	JJ	_	27	NMOD	_	_
26	NF-kappaB	_	NN	NN	_	27	NMOD	_	_
27	activation	_	NN	NN	_	24	PMOD	_	_
28	.	_	.	.	_	21	P	_	_

1	NF-kappaB	_	NN	NN	_	2	NMOD	_	_
2	activation	_	NN	NN	_	5	SBJ	_	_
3	by	_	IN	IN	_	2	NMOD	_	_
4	LMP1-LRB-1-231-RRB-	_	NN	NN	_	3	PMOD	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	likely	_	JJ	JJ	_	5	PRD	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	be	_	VB	VB	_	6	AMOD	_	_
9	mediated	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	TRAF1\/TRAF2	_	NN	NN	_	12	NMOD	_	_
12	heteroaggregates	_	NNS	NNS	_	10	PMOD	_	_
13	since	_	IN	IN	_	9	ADV	_	_
14	TRAF1	_	NN	NN	_	15	SBJ	_	_
15	is	_	VBZ	VBZ	_	13	VMOD	_	_
16	unique	_	JJ	JJ	_	15	PRD	_	_
17	among	_	IN	IN	_	15	ADV	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	TRAFs	_	NNS	NNS	_	17	PMOD	_	_
20	in	_	IN	IN	_	15	ADV	_	_
21	coactivating	_	VBG	VBG	_	20	PMOD	_	_
22	NF-kappaB	_	NN	NN	_	21	OBJ	_	_
23	with	_	IN	IN	_	21	ADV	_	_
24	LMP1-LRB-1-231-RRB-	_	NN	NN	_	23	PMOD	_	_
25	,	_	,	,	_	5	P	_	_
26	a	_	DT	DT	_	29	NMOD	_	_
27	TRAF2	_	NN	NN	_	29	NMOD	_	_
28	dominant-negative	_	JJ	JJ	_	29	NMOD	_	_
29	mutant	_	NN	NN	_	30	SBJ	_	_
30	can	_	MD	MD	_	5	COORD	_	_
31	block	_	VB	VB	_	30	VC	_	_
32	LMP1-LRB-1-231-RRB--mediated	_	JJ	JJ	_	34	NMOD	_	_
33	NF-kappaB	_	NN	NN	_	34	NMOD	_	_
34	activation	_	NN	NN	_	31	OBJ	_	_
35	as	_	RB	RB	_	34	CC	_	_
36	well	_	RB	RB	_	35	DEP	_	_
37	as	_	IN	IN	_	35	DEP	_	_
38	TRAF1	_	NN	NN	_	39	NMOD	_	_
39	coactivation	_	NN	NN	_	34	COORD	_	_
40	,	_	,	,	_	5	P	_	_
41	and	_	CC	CC	_	5	CC	_	_
42	30	_	CD	CD	_	43	NMOD	_	_
43	%	_	NN	NN	_	46	SBJ	_	_
44	of	_	IN	IN	_	43	NMOD	_	_
45	TRAF2	_	NN	NN	_	44	PMOD	_	_
46	is	_	VBZ	VBZ	_	5	COORD	_	_
47	associated	_	VBN	VBN	_	46	VC	_	_
48	with	_	IN	IN	_	47	ADV	_	_
49	TRAF1	_	NN	NN	_	48	PMOD	_	_
50	in	_	IN	IN	_	47	ADV	_	_
51	EBV-transformed	_	JJ	JJ	_	53	NMOD	_	_
52	B	_	NN	NN	_	53	NMOD	_	_
53	cells	_	NNS	NNS	_	50	PMOD	_	_
54	.	_	.	.	_	5	P	_	_

1	TRAF3	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	negative	_	JJ	JJ	_	5	NMOD	_	_
5	modulator	_	NN	NN	_	2	PRD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	LMP1-LRB-1-231-RRB--mediated	_	JJ	JJ	_	9	NMOD	_	_
8	NF-kappaB	_	NN	NN	_	9	NMOD	_	_
9	activation	_	NN	NN	_	6	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	Surprisingly	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	TRAF1	_	NN	NN	_	9	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	-2	_	CD	CD	_	3	NMOD	_	_
6	,	_	,	,	_	3	P	_	_
7	or	_	CC	CC	_	3	CC	_	_
8	-3	_	CD	CD	_	3	NMOD	_	_
9	does	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	not	_	RB	RB	_	9	VMOD	_	_
11	interact	_	VB	VB	_	9	VC	_	_
12	with	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	terminal	_	JJ	JJ	_	17	NMOD	_	_
15	LMP1	_	NN	NN	_	17	NMOD	_	_
16	CT	_	NN	NN	_	17	NMOD	_	_
17	aa	_	NNS	NNS	_	12	PMOD	_	_
18	333	_	CD	CD	_	17	NMOD	_	_
19	to	_	TO	TO	_	18	NMOD	_	_
20	386	_	CD	CD	_	18	NMOD	_	_
21	which	_	WDT	WDT	_	22	SBJ	_	_
22	can	_	MD	MD	_	17	NMOD	_	_
23	independently	_	RB	RB	_	22	ADV	_	_
24	mediate	_	VBP	VBP	_	22	VC	_	_
25	NF-kappaB	_	NN	NN	_	26	NMOD	_	_
26	activation	_	NN	NN	_	24	OBJ	_	_
27	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	constitutive	_	JJ	JJ	_	3	NMOD	_	_
3	association	_	NN	NN	_	26	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	TRAFs	_	NNS	NNS	_	4	PMOD	_	_
6	with	_	IN	IN	_	3	NMOD	_	_
7	LMP1	_	NN	NN	_	6	PMOD	_	_
8	through	_	IN	IN	_	3	NMOD	_	_
9	the	_	DT	DT	_	14	NMOD	_	_
10	aa	_	NNS	NNS	_	14	NMOD	_	_
11	187	_	CD	CD	_	14	NMOD	_	_
12	to	_	TO	TO	_	11	NMOD	_	_
13	231	_	CD	CD	_	11	NMOD	_	_
14	domain	_	NN	NN	_	8	PMOD	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	is	_	VBZ	VBZ	_	14	NMOD	_	_
17	important	_	JJ	JJ	_	16	PRD	_	_
18	in	_	IN	IN	_	16	ADV	_	_
19	NF-kappaB	_	NN	NN	_	20	NMOD	_	_
20	activation	_	NN	NN	_	18	PMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	primary	_	JJ	JJ	_	25	NMOD	_	_
23	B-lymphocyte	_	NN	NN	_	25	NMOD	_	_
24	growth	_	NN	NN	_	25	NMOD	_	_
25	transformation	_	NN	NN	_	20	COORD	_	_
26	implicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
27	TRAF	_	NN	NN	_	28	NMOD	_	_
28	aggregation	_	NN	NN	_	26	OBJ	_	_
29	in	_	IN	IN	_	28	NMOD	_	_
30	LMP1	_	NN	NN	_	31	NMOD	_	_
31	signaling	_	NN	NN	_	29	PMOD	_	_
32	.	_	.	.	_	26	P	_	_

1	Sterol	_	NN	NN	_	5	NMOD	_	_
2	dependent	_	JJ	JJ	_	1	AMOD	_	_
3	LDL-receptor	_	NN	NN	_	5	NMOD	_	_
4	gene	_	NN	NN	_	5	NMOD	_	_
5	transcription	_	NN	NN	_	0	ROOT-FRAG	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	lymphocytes	_	NNS	NNS	_	6	PMOD	_	_
8	from	_	IN	IN	_	7	NMOD	_	_
9	normal	_	JJ	JJ	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	CML	_	NN	NN	_	9	COORD	_	_
12	patients	_	NNS	NNS	_	8	PMOD	_	_
13	.	_	.	.	_	5	P	_	_

1	Sterol	_	NN	NN	_	3	NMOD	_	_
2	regulatory	_	JJ	JJ	_	3	NMOD	_	_
3	element	_	NN	NN	_	7	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	SRE	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	been	_	VBN	VBN	_	7	VC	_	_
9	recognized	_	VBN	VBN	_	8	VC	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	regulate	_	VB	VB	_	9	OBJ	_	_
12	various	_	JJ	JJ	_	14	NMOD	_	_
13	key	_	JJ	JJ	_	14	NMOD	_	_
14	genes	_	NNS	NNS	_	11	OBJ	_	_
15	coding	_	VBG	VBG	_	14	NMOD	_	_
16	for	_	IN	IN	_	15	ADV	_	_
17	especially	_	RB	RB	_	18	AMOD	_	_
18	low	_	JJ	JJ	_	24	NMOD	_	_
19	density	_	NN	NN	_	24	NMOD	_	_
20	lipoprotein	_	NN	NN	_	24	NMOD	_	_
21	(	_	(	(	_	24	P	_	_
22	LDL	_	NN	NN	_	24	NMOD	_	_
23	)	_	)	)	_	24	P	_	_
24	-receptor	_	NN	NN	_	16	PMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	3-hydroxy-3-methylglutaryl	_	NN	NN	_	28	NMOD	_	_
27	coenzyme	_	NN	NN	_	28	NMOD	_	_
28	A	_	NN	NN	_	32	NMOD	_	_
29	(	_	(	(	_	30	P	_	_
30	HMG-CoA	_	NN	NN	_	32	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	reductase	_	NN	NN	_	24	COORD	_	_
33	and	_	CC	CC	_	24	CC	_	_
34	HMG-CoA	_	NN	NN	_	35	NMOD	_	_
35	synthase	_	NN	NN	_	24	COORD	_	_
36	known	_	VBN	VBN	_	24	NMOD	_	_
37	to	_	TO	TO	_	38	VMOD	_	_
38	play	_	VB	VB	_	36	OBJ	_	_
39	a	_	DT	DT	_	41	NMOD	_	_
40	crucial	_	JJ	JJ	_	41	NMOD	_	_
41	role	_	NN	NN	_	38	OBJ	_	_
42	in	_	IN	IN	_	38	ADV	_	_
43	the	_	DT	DT	_	46	NMOD	_	_
44	cholesterol	_	NN	NN	_	46	NMOD	_	_
45	feedback	_	NN	NN	_	46	NMOD	_	_
46	mechanism	_	NN	NN	_	42	PMOD	_	_
47	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	deranged	_	JJ	JJ	_	5	NMOD	_	_
3	cholesterol	_	NN	NN	_	5	NMOD	_	_
4	feedback	_	NN	NN	_	5	NMOD	_	_
5	mechanism	_	NN	NN	_	6	SBJ	_	_
6	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	been	_	VBN	VBN	_	6	VC	_	_
8	widely	_	RB	RB	_	9	ADV	_	_
9	recognised	_	VBN	VBN	_	7	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	initiation	_	NN	NN	_	10	PMOD	_	_
12	as	_	RB	RB	_	11	CC	_	_
13	well	_	RB	RB	_	12	DEP	_	_
14	as	_	IN	IN	_	12	DEP	_	_
15	progression	_	NN	NN	_	11	COORD	_	_
16	of	_	IN	IN	_	11	NMOD	_	_
17	various	_	JJ	JJ	_	18	NMOD	_	_
18	types	_	NNS	NNS	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	cancers	_	NNS	NNS	_	19	PMOD	_	_
21	including	_	VBG	VBG	_	18	NMOD	_	_
22	chronic	_	JJ	JJ	_	24	NMOD	_	_
23	myeloid	_	JJ	JJ	_	24	NMOD	_	_
24	leukaemia	_	NN	NN	_	21	PMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	CML	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	.	_	.	.	_	6	P	_	_

1	Consequently	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	present	_	JJ	JJ	_	5	NMOD	_	_
5	study	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	addressed	_	VBN	VBN	_	6	VC	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	understand	_	VB	VB	_	7	OBJ	_	_
10	this	_	DT	DT	_	11	NMOD	_	_
11	phenomenon	_	NN	NN	_	9	OBJ	_	_
12	and	_	CC	CC	_	6	CC	_	_
13	revealed	_	VBD	VBD	_	6	COORD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	existence	_	NN	NN	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	a	_	DT	DT	_	22	NMOD	_	_
18	unique	_	JJ	JJ	_	22	NMOD	_	_
19	47	_	CD	CD	_	20	AMOD	_	_
20	kDa	_	NN	NN	_	22	NMOD	_	_
21	protein	_	NN	NN	_	22	NMOD	_	_
22	factor	_	NN	NN	_	16	PMOD	_	_
23	having	_	VBG	VBG	_	22	NMOD	_	_
24	affinity	_	NN	NN	_	23	OBJ	_	_
25	for	_	IN	IN	_	24	NMOD	_	_
26	this	_	DT	DT	_	28	NMOD	_	_
27	SRE	_	NN	NN	_	28	NMOD	_	_
28	sequence	_	NN	NN	_	25	PMOD	_	_
29	in	_	IN	IN	_	15	NMOD	_	_
30	lymphocytes	_	NNS	NNS	_	29	PMOD	_	_
31	from	_	IN	IN	_	30	NMOD	_	_
32	normal	_	JJ	JJ	_	33	NMOD	_	_
33	subjects	_	NNS	NNS	_	31	PMOD	_	_
34	as	_	RB	RB	_	15	CC	_	_
35	well	_	RB	RB	_	34	DEP	_	_
36	as	_	IN	IN	_	34	DEP	_	_
37	its	_	PRP$	PRP$	_	38	NMOD	_	_
38	absence	_	NN	NN	_	15	COORD	_	_
39	in	_	IN	IN	_	38	NMOD	_	_
40	lymphocytes	_	NNS	NNS	_	39	PMOD	_	_
41	from	_	IN	IN	_	40	NMOD	_	_
42	untreated	_	JJ	JJ	_	44	NMOD	_	_
43	CML	_	NN	NN	_	44	NMOD	_	_
44	patients	_	NNS	NNS	_	41	PMOD	_	_
45	.	_	.	.	_	6	P	_	_

1	However	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	factor	_	NN	NN	_	5	SBJ	_	_
5	appeared	_	VBD	VBD	_	0	ROOT-S	_	_
6	when	_	WRB	WRB	_	10	ADV	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	CML	_	NN	NN	_	9	NMOD	_	_
9	patients	_	NNS	NNS	_	10	SBJ	_	_
10	achieved	_	VBD	VBD	_	5	TMP	_	_
11	complete	_	JJ	JJ	_	13	NMOD	_	_
12	haematological	_	JJ	JJ	_	13	NMOD	_	_
13	remission	_	NN	NN	_	10	OBJ	_	_
14	(	_	(	(	_	15	P	_	_
15	CHR	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	through	_	IN	IN	_	10	ADV	_	_
18	alpha-interferon	_	NN	NN	_	19	NMOD	_	_
19	therapy	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	Further	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	an	_	DT	DT	_	5	NMOD	_	_
4	inverse	_	NN	NN	_	5	NMOD	_	_
5	relationship	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	also	_	RB	RB	_	8	ADV	_	_
8	observed	_	VBN	VBN	_	6	VC	_	_
9	between	_	IN	IN	_	8	ADV	_	_
10	sterol	_	NN	NN	_	14	NMOD	_	_
11	modulated	_	JJ	JJ	_	10	AMOD	_	_
12	LDL-receptor	_	NN	NN	_	14	NMOD	_	_
13	gene	_	NN	NN	_	14	NMOD	_	_
14	transcription	_	NN	NN	_	9	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	binding	_	NN	NN	_	18	NMOD	_	_
18	affinity	_	NN	NN	_	14	COORD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	this	_	DT	DT	_	23	NMOD	_	_
21	47	_	CD	CD	_	22	AMOD	_	_
22	kDa	_	NN	NN	_	23	NMOD	_	_
23	factor	_	NN	NN	_	19	PMOD	_	_
24	to	_	TO	TO	_	18	NMOD	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	SRE	_	NN	NN	_	27	NMOD	_	_
27	sequence	_	NN	NN	_	24	PMOD	_	_
28	.	_	.	.	_	6	P	_	_

1	Based	_	VBN	VBN	_	6	ADV	_	_
2	upon	_	IN	IN	_	1	PMOD	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	results	_	NNS	NNS	_	2	PMOD	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	propose	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	alpha-interferon	_	NN	NN	_	12	SBJ	_	_
9	through	_	IN	IN	_	12	ADV	_	_
10	its	_	PRP$	PRP$	_	11	NMOD	_	_
11	receptor	_	NN	NN	_	9	PMOD	_	_
12	initiates	_	VBZ	VBZ	_	7	VMOD	_	_
13	phosphatidic	_	JJ	JJ	_	14	NMOD	_	_
14	acid	_	NN	NN	_	15	AMOD	_	_
15	dependent	_	JJ	JJ	_	16	NMOD	_	_
16	signalling	_	NN	NN	_	12	OBJ	_	_
17	which	_	WDT	WDT	_	20	SBJ	_	_
18	in	_	IN	IN	_	20	ADV	_	_
19	turn	_	NN	NN	_	18	PMOD	_	_
20	regulates	_	VBZ	VBZ	_	16	NMOD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	affinity	_	NN	NN	_	20	OBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	47	_	CD	CD	_	25	AMOD	_	_
25	kDa	_	NN	NN	_	30	NMOD	_	_
26	sterol	_	NN	NN	_	30	NMOD	_	_
27	regulatory	_	JJ	JJ	_	30	NMOD	_	_
28	element	_	NN	NN	_	30	NMOD	_	_
29	binding	_	NN	NN	_	30	NMOD	_	_
30	factor	_	NN	NN	_	23	PMOD	_	_
31	as	_	RB	RB	_	22	CC	_	_
32	well	_	RB	RB	_	31	DEP	_	_
33	as	_	IN	IN	_	31	DEP	_	_
34	LDL-receptor	_	NN	NN	_	36	NMOD	_	_
35	gene	_	NN	NN	_	36	NMOD	_	_
36	transcription	_	NN	NN	_	22	COORD	_	_
37	in	_	IN	IN	_	16	NMOD	_	_
38	lymphocytes	_	NNS	NNS	_	37	PMOD	_	_
39	from	_	IN	IN	_	38	NMOD	_	_
40	CML	_	NN	NN	_	41	NMOD	_	_
41	patients	_	NNS	NNS	_	39	PMOD	_	_
42	.	_	.	.	_	6	P	_	_

1	Effects	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	Ara-C	_	NN	NN	_	2	PMOD	_	_
4	on	_	IN	IN	_	3	NMOD	_	_
5	neutral	_	JJ	JJ	_	6	NMOD	_	_
6	sphingomyelinase	_	NN	NN	_	4	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	mitogen-	_	NN	NN	_	12	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	stress-activated	_	JJ	JJ	_	8	COORD	_	_
11	protein	_	NN	NN	_	12	NMOD	_	_
12	kinases	_	NNS	NNS	_	6	COORD	_	_
13	in	_	IN	IN	_	6	NMOD	_	_
14	T-lymphocyte	_	NN	NN	_	16	NMOD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	lines	_	NNS	NNS	_	13	PMOD	_	_
17	.	_	.	.	_	1	P	_	_

1	Neutral	_	JJ	JJ	_	2	NMOD	_	_
2	sphingomyelinase	_	NN	NN	_	6	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	SMase	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	can	_	MD	MD	_	0	ROOT-S	_	_
7	be	_	VB	VB	_	6	VC	_	_
8	activated	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	extracellular	_	JJ	JJ	_	11	NMOD	_	_
11	signals	_	NNS	NNS	_	9	PMOD	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	produce	_	VB	VB	_	8	OBJ	_	_
14	ceramide	_	NN	NN	_	13	OBJ	_	_
15	,	_	,	,	_	14	P	_	_
16	which	_	WDT	WDT	_	17	SBJ	_	_
17	may	_	MD	MD	_	14	NMOD	_	_
18	affect	_	VB	VB	_	17	VC	_	_
19	mitogen-activated	_	JJ	JJ	_	21	NMOD	_	_
20	protein	_	NN	NN	_	21	NMOD	_	_
21	kinase	_	NN	NN	_	25	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	MAPK	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	activities	_	NNS	NNS	_	18	OBJ	_	_
26	.	_	.	.	_	6	P	_	_

1	Neutral	_	JJ	JJ	_	3	NMOD	_	_
2	SMase	_	NN	NN	_	3	NMOD	_	_
3	activity	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	assessed	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	membranes	_	NNS	NNS	_	6	PMOD	_	_
8	from	_	IN	IN	_	7	NMOD	_	_
9	Jurkat	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	a	_	DT	DT	_	14	NMOD	_	_
12	human	_	JJ	JJ	_	14	NMOD	_	_
13	T-cell	_	NN	NN	_	14	NMOD	_	_
14	line	_	NN	NN	_	9	NMOD	_	_
15	,	_	,	,	_	9	P	_	_
16	and	_	CC	CC	_	9	CC	_	_
17	EL4	_	NN	NN	_	9	COORD	_	_
18	,	_	,	,	_	17	P	_	_
19	a	_	DT	DT	_	22	NMOD	_	_
20	murine	_	JJ	JJ	_	22	NMOD	_	_
21	T-cell	_	NN	NN	_	22	NMOD	_	_
22	line	_	NN	NN	_	17	NMOD	_	_
23	.	_	.	.	_	4	P	_	_

1	Ara-C	_	NN	NN	_	2	SBJ	_	_
2	activated	_	VBD	VBD	_	0	ROOT-S	_	_
3	SMase	_	NN	NN	_	2	IOBJ	_	_
4	with	_	IN	IN	_	2	TMP	_	_
5	10	_	CD	CD	_	6	NMOD	_	_
6	minutes	_	NNS	NNS	_	4	PMOD	_	_
7	in	_	IN	IN	_	2	ADV	_	_
8	both	_	CC	CC	_	9	CC	_	_
9	Jurkat	_	NN	NN	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	EL4	_	NN	NN	_	9	COORD	_	_
12	cells	_	NNS	NNS	_	7	PMOD	_	_
13	,	_	,	,	_	2	P	_	_
14	while	_	IN	IN	_	2	OBJ	_	_
15	phorbol	_	NN	NN	_	16	NMOD	_	_
16	ester	_	NN	NN	_	20	SBJ	_	_
17	(	_	(	(	_	18	P	_	_
18	PMA	_	NN	NN	_	16	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	had	_	VBD	VBD	_	14	VMOD	_	_
21	no	_	DT	DT	_	22	NMOD	_	_
22	effect	_	NN	NN	_	20	OBJ	_	_
23	.	_	.	.	_	2	P	_	_

1	PMA	_	NN	NN	_	9	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	but	_	CC	CC	_	1	CC	_	_
4	not	_	RB	RB	_	3	COORD	_	_
5	Ara-C	_	NN	NN	_	1	COORD	_	_
6	or	_	CC	CC	_	5	CC	_	_
7	ceramides	_	NNS	NNS	_	5	COORD	_	_
8	,	_	,	,	_	1	P	_	_
9	activated	_	VBD	VBD	_	0	ROOT-S	_	_
10	ERK	_	NN	NN	_	11	NMOD	_	_
11	MAPKS	_	NNS	NNS	_	9	OBJ	_	_
12	,	_	,	,	_	9	P	_	_
13	in	_	IN	IN	_	9	ADV	_	_
14	Jurkat	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	EL4	_	NN	NN	_	14	COORD	_	_
17	.	_	.	.	_	9	P	_	_

1	PMA	_	NN	NN	_	2	SBJ	_	_
2	acted	_	VBD	VBD	_	0	ROOT-S	_	_
3	synergistically	_	RB	RB	_	2	ADV	_	_
4	with	_	IN	IN	_	2	ADV	_	_
5	ionomycin	_	NN	NN	_	4	PMOD	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	activate	_	VB	VB	_	2	OBJ	_	_
8	JNK	_	NN	NN	_	9	NMOD	_	_
9	MAPKs	_	NNS	NNS	_	7	OBJ	_	_
10	in	_	IN	IN	_	7	ADV	_	_
11	Jurkat	_	NN	NN	_	10	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	EL4	_	NN	NN	_	11	COORD	_	_
14	within	_	IN	IN	_	7	TMP	_	_
15	10	_	CD	CD	_	16	NMOD	_	_
16	minutes	_	NNS	NNS	_	14	PMOD	_	_
17	.	_	.	.	_	2	P	_	_

1	Ara-C	_	NN	NN	_	2	SBJ	_	_
2	activated	_	VBD	VBD	_	0	ROOT-S	_	_
3	JNKs	_	NNS	NNS	_	2	OBJ	_	_
4	only	_	RB	RB	_	5	DEP	_	_
5	after	_	IN	IN	_	2	TMP	_	_
6	prolonged	_	JJ	JJ	_	7	NMOD	_	_
7	incubation	_	NN	NN	_	5	PMOD	_	_
8	(	_	(	(	_	10	P	_	_
9	90-120	_	CD	CD	_	10	NMOD	_	_
10	minutes	_	NNS	NNS	_	7	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	.	_	.	.	_	2	P	_	_

1	Thus	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	ceramide	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	positive	_	JJ	JJ	_	8	NMOD	_	_
8	signal	_	NN	NN	_	4	PRD	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	ERK	_	NN	NN	_	11	NMOD	_	_
11	activation	_	NN	NN	_	9	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	T-cell	_	NN	NN	_	14	NMOD	_	_
14	lines	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effects	_	NNS	NNS	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	Ara-C	_	NN	NN	_	3	PMOD	_	_
5	on	_	IN	IN	_	2	NMOD	_	_
6	JNK	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	5	PMOD	_	_
8	may	_	MD	MD	_	0	ROOT-S	_	_
9	be	_	VB	VB	_	8	VC	_	_
10	mediated	_	VBN	VBN	_	9	VC	_	_
11	through	_	IN	IN	_	10	ADV	_	_
12	secondary	_	JJ	JJ	_	14	NMOD	_	_
13	response	_	NN	NN	_	14	NMOD	_	_
14	pathways	_	NNS	NNS	_	11	PMOD	_	_
15	.	_	.	.	_	8	P	_	_

1	Expression	_	NN	NN	_	4	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	Egr-1	_	NN	NN	_	2	PMOD	_	_
4	correlates	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	transformed	_	VBN	VBN	_	8	NMOD	_	_
8	phenotype	_	NN	NN	_	5	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	type	_	NN	NN	_	8	COORD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	viral	_	JJ	JJ	_	14	NMOD	_	_
14	latency	_	NN	NN	_	12	PMOD	_	_
15	in	_	IN	IN	_	8	NMOD	_	_
16	EBV	_	NN	NN	_	17	NMOD	_	_
17	genome	_	NN	NN	_	18	AMOD	_	_
18	positive	_	JJ	JJ	_	21	NMOD	_	_
19	lymphoid	_	JJ	JJ	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	lines	_	NNS	NNS	_	15	PMOD	_	_
22	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	paper	_	NN	NN	_	1	PMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	have	_	VBP	VBP	_	0	ROOT-S	_	_
6	investigated	_	VBN	VBN	_	5	VC	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	role	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	Egr-1	_	NN	NN	_	9	PMOD	_	_
11	in	_	IN	IN	_	8	NMOD	_	_
12	B	_	NN	NN	_	15	NMOD	_	_
13	cell	_	NN	NN	_	15	NMOD	_	_
14	growth	_	NN	NN	_	15	NMOD	_	_
15	regulation	_	NN	NN	_	11	PMOD	_	_
16	by	_	IN	IN	_	6	ADV	_	_
17	examining	_	VBG	VBG	_	16	PMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	gene	_	NN	NN	_	20	NMOD	_	_
20	expression	_	NN	NN	_	17	OBJ	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	a	_	DT	DT	_	23	NMOD	_	_
23	panel	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	B	_	NN	NN	_	27	NMOD	_	_
26	cell	_	NN	NN	_	27	NMOD	_	_
27	lines	_	NNS	NNS	_	24	PMOD	_	_
28	,	_	,	,	_	27	P	_	_
29	including	_	VBG	VBG	_	27	NMOD	_	_
30	both	_	CC	CC	_	33	CC	_	_
31	EBV	_	NN	NN	_	32	NMOD	_	_
32	genome	_	NN	NN	_	33	AMOD	_	_
33	negative	_	JJ	JJ	_	38	NMOD	_	_
34	and	_	CC	CC	_	33	CC	_	_
35	EBV	_	NN	NN	_	33	COORD	_	_
36	carrying	_	VBG	VBG	_	35	AMOD	_	_
37	cell	_	NN	NN	_	38	NMOD	_	_
38	lines	_	NNS	NNS	_	29	PMOD	_	_
39	.	_	.	.	_	5	P	_	_

1	Egr-1	_	NN	NN	_	2	NMOD	_	_
2	expression	_	NN	NN	_	3	SBJ	_	_
3	correlates	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	with	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	cellular	_	JJ	JJ	_	7	NMOD	_	_
7	phenotype	_	NN	NN	_	4	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	specific	_	JJ	JJ	_	11	NMOD	_	_
11	pattern	_	NN	NN	_	7	COORD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	viral	_	JJ	JJ	_	14	NMOD	_	_
14	latency	_	NN	NN	_	12	PMOD	_	_
15	established	_	VBN	VBN	_	7	NMOD	_	_
16	within	_	IN	IN	_	15	ADV	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	individual	_	JJ	JJ	_	20	NMOD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	lines	_	NNS	NNS	_	16	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	Thus	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	constitutive	_	JJ	JJ	_	4	NMOD	_	_
4	activation	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	Egr-1	_	NN	NN	_	7	NMOD	_	_
7	gene	_	NN	NN	_	5	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	invariably	_	RB	RB	_	10	ADV	_	_
10	associated	_	VBN	VBN	_	8	VC	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	unrestricted	_	JJ	JJ	_	13	NMOD	_	_
13	expression	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	viral	_	JJ	JJ	_	17	NMOD	_	_
16	latent	_	JJ	JJ	_	17	NMOD	_	_
17	genes	_	NNS	NNS	_	14	PMOD	_	_
18	in	_	IN	IN	_	13	NMOD	_	_
19	all	_	DT	DT	_	26	NMOD	_	_
20	group	_	NN	NN	_	26	NMOD	_	_
21	III	_	CD	CD	_	26	NMOD	_	_
22	EBV	_	NN	NN	_	23	NMOD	_	_
23	genome	_	NN	NN	_	24	AMOD	_	_
24	carrying	_	VBG	VBG	_	26	NMOD	_	_
25	cell	_	NN	NN	_	26	NMOD	_	_
26	lines	_	NNS	NNS	_	18	PMOD	_	_
27	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	6	P	_	_
4	Egr-1	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	abrogated	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	group	_	NN	NN	_	13	NMOD	_	_
10	I	_	NN	NN	_	13	NMOD	_	_
11	Burkitt	_	NN	NN	_	13	NMOD	_	_
12	tumor	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	8	PMOD	_	_
14	,	_	,	,	_	7	P	_	_
15	irrespective	_	JJ	JJ	_	7	ADV	_	_
16	of	_	IN	IN	_	15	AMOD	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	EBV	_	NN	NN	_	21	NMOD	_	_
19	genome	_	NN	NN	_	21	NMOD	_	_
20	carrying	_	NN	NN	_	21	NMOD	_	_
21	status	_	NN	NN	_	16	PMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	Activated	_	VBN	VBN	_	4	NMOD	_	_
2	viral	_	JJ	JJ	_	4	NMOD	_	_
3	gene	_	NN	NN	_	4	NMOD	_	_
4	expression	_	NN	NN	_	20	SBJ	_	_
5	associated	_	VBN	VBN	_	4	NMOD	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	phenotypic	_	JJ	JJ	_	8	NMOD	_	_
8	conversion	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	group	_	NN	NN	_	13	NMOD	_	_
11	I	_	NN	NN	_	13	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	lines	_	NNS	NNS	_	9	PMOD	_	_
14	in	_	IN	IN	_	8	NMOD	_	_
15	to	_	TO	TO	_	14	DEP	_	_
16	group	_	NN	NN	_	14	PMOD	_	_
17	II	_	CD	CD	_	16	NMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	III	_	CD	CD	_	17	COORD	_	_
20	restores	_	VBZ	VBZ	_	0	ROOT-S	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	Egr-1	_	NN	NN	_	24	NMOD	_	_
23	gene	_	NN	NN	_	24	NMOD	_	_
24	expression	_	NN	NN	_	20	OBJ	_	_
25	.	_	.	.	_	20	P	_	_

1	Several	_	JJ	JJ	_	2	NMOD	_	_
2	forms	_	NNS	NNS	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	EGR-1	_	JJ	JJ	_	5	NMOD	_	_
5	protein	_	NN	NN	_	3	PMOD	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	found	_	VBN	VBN	_	6	VC	_	_
8	within	_	IN	IN	_	7	ADV	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	different	_	JJ	JJ	_	11	NMOD	_	_
11	groups	_	NNS	NNS	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	lines	_	NNS	NNS	_	12	PMOD	_	_
15	,	_	,	,	_	6	P	_	_
16	and	_	CC	CC	_	6	CC	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	binding	_	NN	NN	_	19	NMOD	_	_
19	activity	_	NN	NN	_	24	SBJ	_	_
20	to	_	TO	TO	_	19	NMOD	_	_
21	DNA	_	NN	NN	_	23	NMOD	_	_
22	consensus	_	NN	NN	_	23	NMOD	_	_
23	sequences	_	NNS	NNS	_	20	PMOD	_	_
24	was	_	VBD	VBD	_	6	COORD	_	_
25	investigated	_	VBN	VBN	_	24	VC	_	_
26	.	_	.	.	_	6	P	_	_

1	Finally	_	RB	RB	_	18	ADV	_	_
2	,	_	,	,	_	18	P	_	_
3	time	_	NN	NN	_	5	NMOD	_	_
4	course	_	NN	NN	_	5	NMOD	_	_
5	analysis	_	NN	NN	_	18	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	Egr-1	_	NN	NN	_	8	NMOD	_	_
8	expression	_	NN	NN	_	6	PMOD	_	_
9	during	_	IN	IN	_	8	TMP	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	early	_	JJ	JJ	_	12	NMOD	_	_
12	steps	_	NNS	NNS	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	EBV	_	NN	NN	_	15	NMOD	_	_
15	infection	_	NN	NN	_	13	PMOD	_	_
16	in	_	FW	FW	_	15	NMOD	_	_
17	vitro	_	FW	FW	_	16	AMOD	_	_
18	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
19	that	_	IN	IN	_	18	OBJ	_	_
20	Egr-1	_	NN	NN	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	19	VMOD	_	_
22	upregulated	_	VBN	VBN	_	21	VC	_	_
23	within	_	IN	IN	_	22	TMP	_	_
24	minutes	_	NNS	NNS	_	23	PMOD	_	_
25	from	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	initial	_	JJ	JJ	_	28	NMOD	_	_
28	interaction	_	NN	NN	_	25	PMOD	_	_
29	with	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	B	_	NN	NN	_	32	NMOD	_	_
32	lymphocyte	_	NN	NN	_	29	PMOD	_	_
33	.	_	.	.	_	18	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	proximal	_	JJ	JJ	_	4	NMOD	_	_
3	regulatory	_	JJ	JJ	_	4	NMOD	_	_
4	element	_	NN	NN	_	9	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	interferon-gamma	_	NN	NN	_	8	NMOD	_	_
8	promoter	_	NN	NN	_	5	PMOD	_	_
9	mediates	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	selective	_	JJ	JJ	_	11	NMOD	_	_
11	expression	_	NN	NN	_	9	OBJ	_	_
12	in	_	IN	IN	_	9	ADV	_	_
13	T	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	9	P	_	_

1	Interferon-gamma	_	NN	NN	_	5	SBJ	_	_
2	(	_	(	(	_	3	P	_	_
3	IFN-gamma	_	NN	NN	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	produced	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	natural	_	JJ	JJ	_	10	NMOD	_	_
9	killer	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	7	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	certain	_	JJ	JJ	_	13	NMOD	_	_
13	subsets	_	NNS	NNS	_	10	COORD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	,	_	,	,	_	5	P	_	_
18	but	_	CC	CC	_	5	CC	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	basis	_	NN	NN	_	25	SBJ	_	_
21	for	_	IN	IN	_	20	NMOD	_	_
22	its	_	PRP$	PRP$	_	24	NMOD	_	_
23	selective	_	JJ	JJ	_	24	NMOD	_	_
24	expression	_	NN	NN	_	21	PMOD	_	_
25	is	_	VBZ	VBZ	_	5	COORD	_	_
26	unknown	_	JJ	JJ	_	25	PRD	_	_
27	.	_	.	.	_	5	P	_	_

1	Within	_	IN	IN	_	14	PRD	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	region	_	NN	NN	_	1	PMOD	_	_
4	between	_	IN	IN	_	3	NMOD	_	_
5	-108	_	CD	CD	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	-40	_	CD	CD	_	5	COORD	_	_
8	base	_	NN	NN	_	9	NMOD	_	_
9	pairs	_	NNS	NNS	_	4	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	IFN-gamma	_	NN	NN	_	13	NMOD	_	_
13	promoter	_	NN	NN	_	10	PMOD	_	_
14	are	_	VBP	VBP	_	0	ROOT-S	_	_
15	two	_	CD	CD	_	20	NMOD	_	_
16	conserved	_	VBN	VBN	_	20	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	essential	_	JJ	JJ	_	16	COORD	_	_
19	regulatory	_	JJ	JJ	_	20	NMOD	_	_
20	elements	_	NNS	NNS	_	14	SBJ	_	_
21	,	_	,	,	_	20	P	_	_
22	which	_	WDT	WDT	_	23	SBJ	_	_
23	confer	_	VBP	VBP	_	20	NMOD	_	_
24	activation-specific	_	JJ	JJ	_	25	NMOD	_	_
25	expression	_	NN	NN	_	23	OBJ	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	T	_	NN	NN	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	26	PMOD	_	_
29	.	_	.	.	_	14	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	report	_	NN	NN	_	3	SBJ	_	_
3	describes	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	studies	_	NNS	NNS	_	3	OBJ	_	_
5	indicating	_	VBG	VBG	_	4	NMOD	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	most	_	RBS	RBS	_	9	AMOD	_	_
9	proximal	_	JJ	JJ	_	15	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	these	_	DT	DT	_	14	NMOD	_	_
12	two	_	CD	CD	_	14	NMOD	_	_
13	regulatory	_	JJ	JJ	_	14	NMOD	_	_
14	elements	_	NNS	NNS	_	10	PMOD	_	_
15	is	_	VBZ	VBZ	_	6	VMOD	_	_
16	an	_	DT	DT	_	18	NMOD	_	_
17	important	_	JJ	JJ	_	18	NMOD	_	_
18	determinant	_	NN	NN	_	15	PRD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	its	_	PRP$	PRP$	_	22	NMOD	_	_
21	restricted	_	JJ	JJ	_	22	NMOD	_	_
22	expression	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	proximal	_	JJ	JJ	_	3	NMOD	_	_
3	element	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	composite	_	JJ	JJ	_	7	NMOD	_	_
7	site	_	NN	NN	_	4	VMOD	_	_
8	that	_	WDT	WDT	_	9	SBJ	_	_
9	binds	_	VBZ	VBZ	_	7	NMOD	_	_
10	members	_	NNS	NNS	_	9	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	19	NMOD	_	_
13	CREB\/ATF	_	NN	NN	_	19	NMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	AP-1	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	13	P	_	_
17	and	_	CC	CC	_	13	CC	_	_
18	octamer	_	NN	NN	_	13	COORD	_	_
19	families	_	NNS	NNS	_	11	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	transcription	_	NN	NN	_	22	NMOD	_	_
22	factors	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	4	P	_	_

1	Jun	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	essential	_	JJ	JJ	_	2	PRD	_	_
4	for	_	IN	IN	_	3	AMOD	_	_
5	activation-induced	_	JJ	JJ	_	6	NMOD	_	_
6	transcription	_	NN	NN	_	4	PMOD	_	_
7	and	_	CC	CC	_	2	CC	_	_
8	binds	_	VBZ	VBZ	_	2	COORD	_	_
9	preferably	_	RB	RB	_	8	ADV	_	_
10	as	_	IN	IN	_	8	ADV	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	heterodimer	_	NN	NN	_	10	PMOD	_	_
13	with	_	IN	IN	_	8	ADV	_	_
14	ATF-2	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	CREB	_	NN	NN	_	5	SBJ	_	_
5	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	dampen	_	VB	VB	_	5	OBJ	_	_
8	transcription	_	NN	NN	_	7	OBJ	_	_
9	from	_	IN	IN	_	8	NMOD	_	_
10	this	_	DT	DT	_	11	NMOD	_	_
11	element	_	NN	NN	_	9	PMOD	_	_
12	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	CpG	_	NN	NN	_	3	NMOD	_	_
3	dinucleotide	_	NN	NN	_	7	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	this	_	DT	DT	_	6	NMOD	_	_
6	element	_	NN	NN	_	4	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	selectively	_	RB	RB	_	9	ADV	_	_
9	methylated	_	VBN	VBN	_	7	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	Th2	_	NN	NN	_	13	NMOD	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	10	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	other	_	JJ	JJ	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	13	COORD	_	_
17	that	_	WDT	WDT	_	18	SBJ	_	_
18	do	_	VBP	VBP	_	16	NMOD	_	_
19	not	_	RB	RB	_	18	VMOD	_	_
20	express	_	VB	VB	_	18	VC	_	_
21	IFN-gamma	_	NN	NN	_	20	OBJ	_	_
22	,	_	,	,	_	7	P	_	_
23	and	_	CC	CC	_	7	CC	_	_
24	methylation	_	NN	NN	_	26	SBJ	_	_
25	markedly	_	RB	RB	_	26	ADV	_	_
26	reduces	_	VBZ	VBZ	_	7	COORD	_	_
27	transcription	_	NN	NN	_	29	NMOD	_	_
28	factor	_	NN	NN	_	29	NMOD	_	_
29	binding	_	NN	NN	_	26	OBJ	_	_
30	.	_	.	.	_	7	P	_	_

1	As	_	IN	IN	_	21	ADV	_	_
2	a	_	DT	DT	_	3	NMOD	_	_
3	target	_	NN	NN	_	1	PMOD	_	_
4	for	_	IN	IN	_	3	NMOD	_	_
5	DNA	_	NN	NN	_	6	NMOD	_	_
6	methylation	_	NN	NN	_	4	PMOD	_	_
7	and	_	CC	CC	_	4	CC	_	_
8	for	_	IN	IN	_	4	COORD	_	_
9	binding	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	transcription	_	NN	NN	_	12	NMOD	_	_
12	factors	_	NNS	NNS	_	10	PMOD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	mediate	_	VBP	VBP	_	12	NMOD	_	_
15	or	_	CC	CC	_	14	CC	_	_
16	impede	_	VBP	VBP	_	14	COORD	_	_
17	transcription	_	NN	NN	_	14	OBJ	_	_
18	,	_	,	,	_	21	P	_	_
19	this	_	DT	DT	_	20	NMOD	_	_
20	element	_	NN	NN	_	21	SBJ	_	_
21	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	play	_	VB	VB	_	21	OBJ	_	_
24	a	_	DT	DT	_	26	NMOD	_	_
25	central	_	JJ	JJ	_	26	NMOD	_	_
26	role	_	NN	NN	_	23	OBJ	_	_
27	in	_	IN	IN	_	23	ADV	_	_
28	controlling	_	VBG	VBG	_	27	PMOD	_	_
29	IFN-gamma	_	NN	NN	_	30	NMOD	_	_
30	expression	_	NN	NN	_	28	OBJ	_	_
31	.	_	.	.	_	21	P	_	_

1	Activation	_	NN	NN	_	9	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	nuclear	_	JJ	JJ	_	4	NMOD	_	_
4	factor-kappaB	_	NN	NN	_	2	PMOD	_	_
5	via	_	IN	IN	_	1	NMOD	_	_
6	T	_	NN	NN	_	8	NMOD	_	_
7	cell	_	NN	NN	_	8	NMOD	_	_
8	receptor	_	NN	NN	_	5	PMOD	_	_
9	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	a	_	DT	DT	_	15	NMOD	_	_
11	Raf	_	NN	NN	_	12	NMOD	_	_
12	kinase	_	NN	NN	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	Ca2+	_	NN	NN	_	12	COORD	_	_
15	influx	_	NN	NN	_	9	OBJ	_	_
16	.	_	.	.	_	9	P	_	_

1	Functional	_	JJ	JJ	_	2	NMOD	_	_
2	synergy	_	NN	NN	_	0	ROOT-FRAG	_	_
3	between	_	IN	IN	_	2	NMOD	_	_
4	Raf	_	NN	NN	_	3	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	calcineurin	_	NN	NN	_	4	COORD	_	_
7	.	_	.	.	_	2	P	_	_

1	Signals	_	NNS	NNS	_	6	SBJ	_	_
2	transduced	_	VBN	VBN	_	1	NMOD	_	_
3	via	_	IN	IN	_	2	ADV	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	TCR	_	NN	NN	_	3	PMOD	_	_
6	activate	_	VBP	VBP	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	transcription	_	NN	NN	_	9	NMOD	_	_
9	factor	_	NN	NN	_	6	OBJ	_	_
10	nuclear	_	JJ	JJ	_	11	NMOD	_	_
11	factor-kappaB	_	NN	NN	_	9	NMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	NF-kappaB	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	,	_	,	,	_	9	P	_	_
16	which	_	WDT	WDT	_	21	SBJ	_	_
17	,	_	,	,	_	21	P	_	_
18	in	_	IN	IN	_	21	ADV	_	_
19	turn	_	NN	NN	_	18	PMOD	_	_
20	,	_	,	,	_	21	P	_	_
21	is	_	VBZ	VBZ	_	9	NMOD	_	_
22	critical	_	JJ	JJ	_	21	PRD	_	_
23	to	_	TO	TO	_	22	AMOD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	transcriptional	_	JJ	JJ	_	26	NMOD	_	_
26	induction	_	NN	NN	_	23	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	many	_	JJ	JJ	_	29	NMOD	_	_
29	genes	_	NNS	NNS	_	27	PMOD	_	_
30	important	_	JJ	JJ	_	29	NMOD	_	_
31	for	_	IN	IN	_	30	AMOD	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	proliferation	_	NN	NN	_	31	PMOD	_	_
34	and	_	CC	CC	_	33	CC	_	_
35	expression	_	NN	NN	_	33	COORD	_	_
36	of	_	IN	IN	_	33	NMOD	_	_
37	a	_	DT	DT	_	39	NMOD	_	_
38	differentiated	_	VBN	VBN	_	39	NMOD	_	_
39	phenotype	_	NN	NN	_	36	PMOD	_	_
40	.	_	.	.	_	6	P	_	_

1	Treatment	_	NN	NN	_	17	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	T	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	the	_	DT	DT	_	11	NMOD	_	_
7	protein	_	NN	NN	_	11	NMOD	_	_
8	kinase	_	NN	NN	_	11	NMOD	_	_
9	C	_	NN	NN	_	11	NMOD	_	_
10	activator	_	NN	NN	_	11	NMOD	_	_
11	PMA	_	NN	NN	_	5	PMOD	_	_
12	in	_	IN	IN	_	1	NMOD	_	_
13	combination	_	NN	NN	_	12	PMOD	_	_
14	with	_	IN	IN	_	13	NMOD	_	_
15	Ca2+	_	NN	NN	_	16	NMOD	_	_
16	ionophores	_	NNS	NNS	_	14	PMOD	_	_
17	mimics	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	this	_	DT	DT	_	19	NMOD	_	_
19	process	_	NN	NN	_	17	OBJ	_	_
20	,	_	,	,	_	17	P	_	_
21	and	_	CC	CC	_	17	CC	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	two	_	CD	CD	_	24	NMOD	_	_
24	agents	_	NNS	NNS	_	25	SBJ	_	_
25	are	_	VBP	VBP	_	17	COORD	_	_
26	often	_	RB	RB	_	27	TMP	_	_
27	substituted	_	VBN	VBN	_	25	VC	_	_
28	for	_	IN	IN	_	27	ADV	_	_
29	TCR	_	NN	NN	_	30	NMOD	_	_
30	stimulation	_	NN	NN	_	28	PMOD	_	_
31	,	_	,	,	_	25	P	_	_
32	bypassing	_	VBG	VBG	_	25	VC	_	_
33	the	_	DT	DT	_	34	NMOD	_	_
34	TCR	_	NN	NN	_	32	OBJ	_	_
35	.	_	.	.	_	17	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	identify	_	VBP	VBP	_	0	ROOT-S	_	_
4	intracellular	_	JJ	JJ	_	6	NMOD	_	_
5	signaling	_	VBG	VBG	_	6	NMOD	_	_
6	components	_	NNS	NNS	_	3	OBJ	_	_
7	involved	_	VBN	VBN	_	6	NMOD	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	activation	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	NF-kappaB	_	NN	NN	_	10	PMOD	_	_
12	following	_	VBG	VBG	_	9	TMP	_	_
13	TCR	_	NN	NN	_	14	NMOD	_	_
14	stimulation	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	TCR	_	NN	NN	_	2	NMOD	_	_
2	signaling	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	triggered	_	VBN	VBN	_	3	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	treating	_	VBG	VBG	_	5	PMOD	_	_
7	Jurkat	_	NN	NN	_	9	NMOD	_	_
8	T	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	6	OBJ	_	_
10	with	_	IN	IN	_	6	ADV	_	_
11	PHA	_	NN	NN	_	14	NMOD	_	_
12	or	_	CC	CC	_	11	CC	_	_
13	anti-CD3	_	JJ	JJ	_	11	COORD	_	_
14	Abs	_	NNS	NNS	_	10	PMOD	_	_
15	,	_	,	,	_	3	P	_	_
16	and	_	CC	CC	_	3	CC	_	_
17	NF-kappaB	_	NN	NN	_	18	NMOD	_	_
18	activation	_	NN	NN	_	19	SBJ	_	_
19	was	_	VBD	VBD	_	3	COORD	_	_
20	monitored	_	VBN	VBN	_	19	VC	_	_
21	by	_	IN	IN	_	20	ADV	_	_
22	electrophoretic	_	JJ	JJ	_	25	NMOD	_	_
23	mobility	_	NN	NN	_	25	NMOD	_	_
24	shift	_	NN	NN	_	25	NMOD	_	_
25	assays	_	NNS	NNS	_	21	PMOD	_	_
26	and\/or	_	CC	CC	_	21	CC	_	_
27	by	_	IN	IN	_	21	COORD	_	_
28	kappaB-dependent	_	JJ	JJ	_	30	NMOD	_	_
29	reporter	_	NN	NN	_	30	NMOD	_	_
30	assays	_	NNS	NNS	_	27	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	Contrary	_	JJ	JJ	_	2	DEP	_	_
2	to	_	TO	TO	_	21	ADV	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	idea	_	NN	NN	_	2	PMOD	_	_
5	that	_	IN	IN	_	4	NMOD	_	_
6	protein	_	NN	NN	_	8	NMOD	_	_
7	kinase	_	NN	NN	_	8	NMOD	_	_
8	C	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	5	VMOD	_	_
10	involved	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	TCR-mediated	_	JJ	JJ	_	13	NMOD	_	_
13	activation	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	NF-kappaB	_	NN	NN	_	14	PMOD	_	_
16	,	_	,	,	_	21	P	_	_
17	high	_	JJ	JJ	_	18	NMOD	_	_
18	doses	_	NNS	NNS	_	21	SBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	staurosporine	_	NN	NN	_	19	PMOD	_	_
21	did	_	VBD	VBD	_	0	ROOT-S	_	_
22	not	_	RB	RB	_	21	VMOD	_	_
23	interfere	_	VB	VB	_	21	VC	_	_
24	with	_	IN	IN	_	23	ADV	_	_
25	activation	_	NN	NN	_	24	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	NF-kappaB	_	NN	NN	_	26	PMOD	_	_
28	by	_	IN	IN	_	25	NMOD	_	_
29	PHA	_	NN	NN	_	28	PMOD	_	_
30	,	_	,	,	_	23	P	_	_
31	while	_	IN	IN	_	23	OBJ	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	same	_	JJ	JJ	_	34	NMOD	_	_
34	dose	_	NN	NN	_	38	SBJ	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	staurosporine	_	NN	NN	_	35	PMOD	_	_
37	completely	_	RB	RB	_	38	ADV	_	_
38	blocked	_	VBD	VBD	_	31	VMOD	_	_
39	activation	_	NN	NN	_	38	OBJ	_	_
40	by	_	IN	IN	_	39	NMOD	_	_
41	PMA	_	NN	NN	_	40	PMOD	_	_
42	.	_	.	.	_	21	P	_	_

1	PHA-induced	_	JJ	JJ	_	4	NMOD	_	_
2	kappaB-dependent	_	JJ	JJ	_	4	NMOD	_	_
3	reporter	_	NN	NN	_	4	NMOD	_	_
4	activity	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	,	_	,	,	_	5	P	_	_
7	however	_	RB	RB	_	5	ADV	_	_
8	,	_	,	,	_	5	P	_	_
9	effectively	_	RB	RB	_	10	ADV	_	_
10	blocked	_	VBN	VBN	_	5	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	a	_	DT	DT	_	15	NMOD	_	_
13	dominant	_	JJ	JJ	_	15	NMOD	_	_
14	negative	_	JJ	JJ	_	15	NMOD	_	_
15	form	_	NN	NN	_	11	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	Raf-1	_	NN	NN	_	16	PMOD	_	_
18	,	_	,	,	_	10	P	_	_
19	suggesting	_	VBG	VBG	_	10	OBJ	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	critical	_	JJ	JJ	_	22	NMOD	_	_
22	role	_	NN	NN	_	19	OBJ	_	_
23	for	_	IN	IN	_	22	NMOD	_	_
24	a	_	DT	DT	_	26	NMOD	_	_
25	Raf	_	NN	NN	_	26	NMOD	_	_
26	kinase	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	TCR-mediated	_	JJ	JJ	_	3	NMOD	_	_
3	activation	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	NF-kappaB	_	NN	NN	_	4	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	also	_	RB	RB	_	6	ADV	_	_
8	dependent	_	JJ	JJ	_	6	PRD	_	_
9	on	_	IN	IN	_	8	AMOD	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	Ca2+	_	NN	NN	_	12	NMOD	_	_
12	influx	_	NN	NN	_	9	PMOD	_	_
13	,	_	,	,	_	6	P	_	_
14	because	_	IN	IN	_	6	ADV	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	Ca2+	_	NN	NN	_	18	NMOD	_	_
17	channel	_	NN	NN	_	18	NMOD	_	_
18	blocker	_	NN	NN	_	34	SBJ	_	_
19	,	_	,	,	_	18	P	_	_
20	SK&amp;F	_	NN	NN	_	18	NMOD	_	_
21	96365	_	CD	CD	_	20	NMOD	_	_
22	,	_	,	,	_	18	P	_	_
23	as	_	RB	RB	_	18	CC	_	_
24	well	_	RB	RB	_	23	DEP	_	_
25	as	_	IN	IN	_	23	DEP	_	_
26	other	_	JJ	JJ	_	27	NMOD	_	_
27	agents	_	NNS	NNS	_	18	COORD	_	_
28	that	_	WDT	WDT	_	29	SBJ	_	_
29	prevented	_	VBD	VBD	_	27	NMOD	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	Ca2+	_	NN	NN	_	32	NMOD	_	_
32	influx	_	NN	NN	_	29	OBJ	_	_
33	,	_	,	,	_	18	P	_	_
34	inhibited	_	VBD	VBD	_	14	VMOD	_	_
35	NF-kappaB	_	NN	NN	_	36	NMOD	_	_
36	activation	_	NN	NN	_	34	OBJ	_	_
37	.	_	.	.	_	6	P	_	_

1	Cotransfection	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	constitutively	_	RB	RB	_	5	AMOD	_	_
5	active	_	JJ	JJ	_	6	NMOD	_	_
6	form	_	NN	NN	_	2	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	calcineurin	_	NN	NN	_	7	PMOD	_	_
9	largely	_	RB	RB	_	10	ADV	_	_
10	substituted	_	VBD	VBD	_	0	ROOT-S	_	_
11	for	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	Ca2+	_	NN	NN	_	14	NMOD	_	_
14	requirement	_	NN	NN	_	11	PMOD	_	_
15	and	_	CC	CC	_	10	CC	_	_
16	reversed	_	VBD	VBD	_	10	COORD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	blockade	_	NN	NN	_	16	OBJ	_	_
19	by	_	IN	IN	_	18	NMOD	_	_
20	SK&amp;F	_	NN	NN	_	19	PMOD	_	_
21	96365	_	CD	CD	_	20	NMOD	_	_
22	.	_	.	.	_	10	P	_	_

1	Consistent	_	JJ	JJ	_	16	VMOD	_	_
2	with	_	IN	IN	_	1	AMOD	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	observations	_	NNS	NNS	_	2	PMOD	_	_
5	,	_	,	,	_	16	P	_	_
6	coexpression	_	NN	NN	_	16	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	constitutively	_	RB	RB	_	9	AMOD	_	_
9	active	_	JJ	JJ	_	10	NMOD	_	_
10	forms	_	NNS	NNS	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	Raf-1	_	NN	NN	_	11	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	calcineurin	_	NN	NN	_	12	COORD	_	_
15	synergistically	_	RB	RB	_	16	ADV	_	_
16	induced	_	VBD	VBD	_	0	ROOT-S	_	_
17	kappaB-dependent	_	JJ	JJ	_	19	NMOD	_	_
18	reporter	_	NN	NN	_	19	NMOD	_	_
19	activity	_	NN	NN	_	16	IOBJ	_	_
20	,	_	,	,	_	16	P	_	_
21	suggesting	_	VBG	VBG	_	16	OBJ	_	_
22	a	_	DT	DT	_	26	NMOD	_	_
23	physiologically	_	RB	RB	_	24	AMOD	_	_
24	relevant	_	JJ	JJ	_	26	NMOD	_	_
25	functional	_	JJ	JJ	_	26	NMOD	_	_
26	interaction	_	NN	NN	_	21	OBJ	_	_
27	between	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	kinase	_	NN	NN	_	27	PMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	the	_	DT	DT	_	32	NMOD	_	_
32	phosphatase	_	NN	NN	_	29	COORD	_	_
33	.	_	.	.	_	16	P	_	_

1	HIV-1	_	NN	NN	_	3	NMOD	_	_
2	LTR	_	NN	NN	_	3	NMOD	_	_
3	activity	_	NN	NN	_	9	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	human	_	JJ	JJ	_	8	NMOD	_	_
6	CD40-activated	_	JJ	JJ	_	8	NMOD	_	_
7	B	_	NN	NN	_	8	NMOD	_	_
8	lymphocytes	_	NNS	NNS	_	4	PMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	dependent	_	JJ	JJ	_	9	PRD	_	_
11	on	_	IN	IN	_	10	AMOD	_	_
12	NF-kappaB	_	NN	NN	_	11	PMOD	_	_
13	.	_	.	.	_	9	P	_	_

1	CD40-stimulated	_	JJ	JJ	_	4	NMOD	_	_
2	human	_	JJ	JJ	_	4	NMOD	_	_
3	B	_	NN	NN	_	4	NMOD	_	_
4	lymphocytes	_	NNS	NNS	_	5	SBJ	_	_
5	are	_	VBP	VBP	_	0	ROOT-S	_	_
6	highly	_	RB	RB	_	7	AMOD	_	_
7	permissive	_	JJ	JJ	_	5	PRD	_	_
8	to	_	TO	TO	_	7	AMOD	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	productive	_	JJ	JJ	_	11	NMOD	_	_
11	infection	_	NN	NN	_	8	PMOD	_	_
12	by	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	human	_	JJ	JJ	_	17	NMOD	_	_
15	immunodeficiency	_	NN	NN	_	17	NMOD	_	_
16	virus	_	NN	NN	_	17	NMOD	_	_
17	type	_	NN	NN	_	12	PMOD	_	_
18	1	_	CD	CD	_	17	NMOD	_	_
19	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	25	ADV	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	25	P	_	_
5	nuclear	_	JJ	JJ	_	6	NMOD	_	_
6	factors	_	NNS	NNS	_	25	SBJ	_	_
7	involved	_	VBN	VBN	_	6	NMOD	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	activation	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	HIV-1	_	NN	NN	_	13	NMOD	_	_
13	LTR	_	NN	NN	_	10	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	contains	_	VBZ	VBZ	_	13	NMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	transcriptional	_	JJ	JJ	_	20	NMOD	_	_
19	control	_	NN	NN	_	20	NMOD	_	_
20	elements	_	NNS	NNS	_	16	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	virus	_	NN	NN	_	21	PMOD	_	_
24	,	_	,	,	_	13	P	_	_
25	are	_	VBP	VBP	_	0	ROOT-S	_	_
26	unknown	_	JJ	JJ	_	25	PRD	_	_
27	.	_	.	.	_	25	P	_	_

1	Transient	_	JJ	JJ	_	3	NMOD	_	_
2	expression	_	NN	NN	_	3	NMOD	_	_
3	assays	_	NNS	NNS	_	18	SBJ	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	plasmids	_	NNS	NNS	_	4	PMOD	_	_
6	containing	_	VBG	VBG	_	5	NMOD	_	_
7	deleted	_	VBN	VBN	_	8	NMOD	_	_
8	parts	_	NNS	NNS	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	LTR	_	NN	NN	_	12	NMOD	_	_
12	region	_	NN	NN	_	9	PMOD	_	_
13	linked	_	VBN	VBN	_	12	NMOD	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	reporter	_	NN	NN	_	17	NMOD	_	_
17	gene	_	NN	NN	_	14	PMOD	_	_
18	showed	_	VBD	VBD	_	0	ROOT-S	_	_
19	that	_	IN	IN	_	18	OBJ	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	NF-kappaB	_	NN	NN	_	23	NMOD	_	_
22	binding	_	NN	NN	_	23	NMOD	_	_
23	site	_	NN	NN	_	24	SBJ	_	_
24	was	_	VBD	VBD	_	19	VMOD	_	_
25	essential	_	JJ	JJ	_	24	PRD	_	_
26	for	_	IN	IN	_	25	AMOD	_	_
27	HIV-1	_	NN	NN	_	29	NMOD	_	_
28	LTR	_	NN	NN	_	29	NMOD	_	_
29	activity	_	NN	NN	_	26	PMOD	_	_
30	in	_	IN	IN	_	29	NMOD	_	_
31	CD40-stimulated	_	JJ	JJ	_	33	NMOD	_	_
32	B	_	NN	NN	_	33	NMOD	_	_
33	lymphocytes	_	NNS	NNS	_	30	PMOD	_	_
34	.	_	.	.	_	18	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	10	P	_	_
4	electrophoretic	_	JJ	JJ	_	6	NMOD	_	_
5	mobility	_	NN	NN	_	6	NMOD	_	_
6	shift	_	NN	NN	_	9	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	supershift	_	NN	NN	_	6	COORD	_	_
9	assays	_	NNS	NNS	_	10	SBJ	_	_
10	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
11	that	_	IN	IN	_	10	OBJ	_	_
12	important	_	JJ	JJ	_	15	NMOD	_	_
13	NF-kappaB	_	NN	NN	_	15	NMOD	_	_
14	binding	_	NN	NN	_	15	NMOD	_	_
15	activity	_	NN	NN	_	28	SBJ	_	_
16	composed	_	VBN	VBN	_	15	NMOD	_	_
17	of	_	IN	IN	_	16	ADV	_	_
18	at	_	IN	IN	_	27	NMOD	_	_
19	least	_	JJS	JJS	_	18	AMOD	_	_
20	p50	_	NN	NN	_	27	NMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	p65	_	NN	NN	_	20	COORD	_	_
23	,	_	,	,	_	20	P	_	_
24	and	_	CC	CC	_	20	CC	_	_
25	c-Rel	_	NN	NN	_	26	NMOD	_	_
26	NF-kappaB	_	NN	NN	_	20	COORD	_	_
27	subunits	_	NNS	NNS	_	17	PMOD	_	_
28	was	_	VBD	VBD	_	11	VMOD	_	_
29	present	_	JJ	JJ	_	28	PRD	_	_
30	in	_	IN	IN	_	29	AMOD	_	_
31	nuclei	_	NNS	NNS	_	30	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	CD40-stimulated	_	JJ	JJ	_	35	NMOD	_	_
34	B	_	NN	NN	_	35	NMOD	_	_
35	cells	_	NNS	NNS	_	32	PMOD	_	_
36	.	_	.	.	_	10	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	confirm	_	VBP	VBP	_	0	ROOT-S	_	_
4	at	_	IN	IN	_	3	ADV	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	molecular	_	JJ	JJ	_	7	NMOD	_	_
7	level	_	NN	NN	_	4	PMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	ability	_	NN	NN	_	3	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	HIV-1	_	NN	NN	_	10	PMOD	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	replicate	_	VB	VB	_	9	NMOD	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	B	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	and	_	CC	CC	_	3	CC	_	_
18	that	_	IN	IN	_	9	GAP	_	_
19	this	_	DT	DT	_	20	NMOD	_	_
20	activity	_	NN	NN	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	18	VMOD	_	_
22	strongly	_	RB	RB	_	23	ADV	_	_
23	associated	_	VBN	VBN	_	21	VC	_	_
24	with	_	IN	IN	_	23	ADV	_	_
25	NF-kappaB	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	Mutation	_	NN	NN	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	tyrosines	_	NNS	NNS	_	2	PMOD	_	_
4	492\/493	_	CD	CD	_	3	NMOD	_	_
5	in	_	IN	IN	_	1	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	kinase	_	NN	NN	_	8	NMOD	_	_
8	domain	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	ZAP-70	_	NN	NN	_	9	PMOD	_	_
11	affects	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	multiple	_	JJ	JJ	_	16	NMOD	_	_
13	T-cell	_	NN	NN	_	16	NMOD	_	_
14	receptor	_	NN	NN	_	16	NMOD	_	_
15	signaling	_	NN	NN	_	16	NMOD	_	_
16	pathways	_	NNS	NNS	_	11	OBJ	_	_
17	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	protein-tyrosine	_	JJ	JJ	_	4	NMOD	_	_
3	kinase	_	NN	NN	_	4	NMOD	_	_
4	ZAP-70	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	implicated	_	VBN	VBN	_	5	VC	_	_
7	,	_	,	,	_	6	P	_	_
8	together	_	RB	RB	_	9	DEP	_	_
9	with	_	IN	IN	_	6	ADV	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	Src	_	NN	NN	_	13	NMOD	_	_
12	kinase	_	NN	NN	_	13	NMOD	_	_
13	p56-LRB-lck-RRB-	_	NN	NN	_	9	PMOD	_	_
14	,	_	,	,	_	6	P	_	_
15	in	_	IN	IN	_	6	ADV	_	_
16	controlling	_	VBG	VBG	_	15	PMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	early	_	JJ	JJ	_	19	NMOD	_	_
19	steps	_	NNS	NNS	_	16	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	29	NMOD	_	_
22	T-cell	_	NN	NN	_	24	NMOD	_	_
23	antigen	_	NN	NN	_	24	NMOD	_	_
24	receptor	_	NN	NN	_	29	NMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	TCR	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	signaling	_	NN	NN	_	29	NMOD	_	_
29	cascade	_	NN	NN	_	20	PMOD	_	_
30	.	_	.	.	_	5	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	help	_	VB	VB	_	16	VMOD	_	_
3	elucidate	_	VB	VB	_	2	OBJ	_	_
4	further	_	RBR	RBR	_	3	ADV	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	mechanism	_	NN	NN	_	3	OBJ	_	_
7	by	_	IN	IN	_	10	ADV	_	_
8	which	_	WDT	WDT	_	7	PMOD	_	_
9	ZAP-70	_	NN	NN	_	10	SBJ	_	_
10	regulates	_	VBZ	VBZ	_	6	NMOD	_	_
11	these	_	DT	DT	_	13	NMOD	_	_
12	initial	_	JJ	JJ	_	13	NMOD	_	_
13	events	_	NNS	NNS	_	10	OBJ	_	_
14	,	_	,	,	_	16	P	_	_
15	we	_	PRP	PRP	_	16	SBJ	_	_
16	used	_	VBD	VBD	_	0	ROOT-S	_	_
17	a	_	DT	DT	_	20	NMOD	_	_
18	dominant-negative	_	JJ	JJ	_	20	NMOD	_	_
19	mutant	_	NN	NN	_	20	NMOD	_	_
20	approach	_	NN	NN	_	16	OBJ	_	_
21	.	_	.	.	_	16	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	overexpressed	_	VBD	VBD	_	0	ROOT-S	_	_
3	in	_	IN	IN	_	2	ADV	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	Jurkat	_	NN	NN	_	7	NMOD	_	_
6	T-cell	_	NN	NN	_	7	NMOD	_	_
7	line	_	NN	NN	_	3	PMOD	_	_
8	ZAP-70	_	NN	NN	_	2	OBJ	_	_
9	mutated	_	VBN	VBN	_	8	NMOD	_	_
10	on	_	IN	IN	_	9	ADV	_	_
11	Tyr-492	_	NN	NN	_	10	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	Tyr-493	_	NN	NN	_	11	COORD	_	_
14	in	_	IN	IN	_	11	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	putative	_	JJ	JJ	_	18	NMOD	_	_
17	regulatory	_	JJ	JJ	_	18	NMOD	_	_
18	loop	_	NN	NN	_	14	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	its	_	PRP$	PRP$	_	22	NMOD	_	_
21	kinase	_	NN	NN	_	22	NMOD	_	_
22	domain	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	mutant	_	NN	NN	_	3	SBJ	_	_
3	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
4	TCR-induced	_	JJ	JJ	_	5	NMOD	_	_
5	activation	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	nuclear	_	JJ	JJ	_	8	NMOD	_	_
8	factor	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	activated	_	VBN	VBN	_	12	NMOD	_	_
11	T	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	PMOD	_	_
13	by	_	IN	IN	_	3	ADV	_	_
14	interfering	_	VBG	VBG	_	13	PMOD	_	_
15	with	_	IN	IN	_	14	ADV	_	_
16	both	_	CC	CC	_	19	CC	_	_
17	intracellular	_	JJ	JJ	_	19	NMOD	_	_
18	calcium	_	NN	NN	_	19	NMOD	_	_
19	increase	_	NN	NN	_	15	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	Ras-regulated	_	JJ	JJ	_	22	NMOD	_	_
22	activation	_	NN	NN	_	19	COORD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	extracellular	_	JJ	JJ	_	26	NMOD	_	_
25	signal-regulated	_	JJ	JJ	_	26	NMOD	_	_
26	kinases	_	NNS	NNS	_	23	PMOD	_	_
27	.	_	.	.	_	3	P	_	_

1	Moreover	_	RB	RB	_	18	ADV	_	_
2	,	_	,	,	_	18	P	_	_
3	TCR-induced	_	JJ	JJ	_	4	NMOD	_	_
4	phosphorylation	_	NN	NN	_	18	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	pp36-38	_	NN	NN	_	5	PMOD	_	_
7	,	_	,	,	_	4	P	_	_
8	thought	_	VBN	VBN	_	4	NMOD	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	play	_	VB	VB	_	8	OBJ	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	role	_	NN	NN	_	10	OBJ	_	_
13	upstream	_	RB	RB	_	10	ADV	_	_
14	of	_	IN	IN	_	13	AMOD	_	_
15	these	_	DT	DT	_	16	NMOD	_	_
16	pathways	_	NNS	NNS	_	14	PMOD	_	_
17	,	_	,	,	_	4	P	_	_
18	was	_	VBD	VBD	_	0	ROOT-S	_	_
19	found	_	VBN	VBN	_	18	VC	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	be	_	VB	VB	_	19	OBJ	_	_
22	reduced	_	VBN	VBN	_	21	VC	_	_
23	.	_	.	.	_	18	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	8	P	_	_
4	overexpression	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	wild-type	_	JJ	JJ	_	7	NMOD	_	_
7	ZAP-70	_	NN	NN	_	5	PMOD	_	_
8	induced	_	VBD	VBD	_	0	ROOT-S	_	_
9	constitutive	_	JJ	JJ	_	10	NMOD	_	_
10	activation	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	nuclear	_	JJ	JJ	_	13	NMOD	_	_
13	factor	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	activated	_	VBN	VBN	_	17	NMOD	_	_
16	T	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	14	PMOD	_	_
18	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	ZAP-70	_	NN	NN	_	3	NMOD	_	_
3	mutant	_	NN	NN	_	6	SBJ	_	_
4	studied	_	VBN	VBN	_	3	NMOD	_	_
5	here	_	RB	RB	_	4	ADV	_	_
6	could	_	MD	MD	_	0	ROOT-S	_	_
7	be	_	VB	VB	_	6	VC	_	_
8	phosphorylated	_	VBN	VBN	_	7	VC	_	_
9	on	_	IN	IN	_	8	ADV	_	_
10	tyrosine	_	NN	NN	_	9	PMOD	_	_
11	when	_	WRB	WRB	_	12	ADV	_	_
12	associated	_	VBN	VBN	_	8	TMP	_	_
13	to	_	TO	TO	_	12	ADV	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	TCR	_	NN	NN	_	17	NMOD	_	_
16	zeta	_	NN	NN	_	17	NMOD	_	_
17	chain	_	NN	NN	_	13	PMOD	_	_
18	and	_	CC	CC	_	6	CC	_	_
19	was	_	VBD	VBD	_	6	COORD	_	_
20	able	_	JJ	JJ	_	19	PRD	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	bind	_	VB	VB	_	20	AMOD	_	_
23	p56-LRB-lck-RRB-	_	NN	NN	_	22	OBJ	_	_
24	.	_	.	.	_	6	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	result	_	NN	NN	_	3	SBJ	_	_
3	demonstrates	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	Tyr-492	_	NN	NN	_	8	SBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	Tyr-493	_	NN	NN	_	5	COORD	_	_
8	are	_	VBP	VBP	_	4	VMOD	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	responsible	_	JJ	JJ	_	8	PRD	_	_
11	for	_	IN	IN	_	10	AMOD	_	_
12	the	_	DT	DT	_	17	NMOD	_	_
13	Src	_	NN	NN	_	15	AMOD	_	_
14	homology	_	NN	NN	_	15	AMOD	_	_
15	domain	_	NN	NN	_	17	NMOD	_	_
16	2-mediated	_	JJ	JJ	_	15	AMOD	_	_
17	association	_	NN	NN	_	11	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	p56-LRB-lck-RRB-	_	NN	NN	_	18	PMOD	_	_
20	with	_	IN	IN	_	17	NMOD	_	_
21	ZAP-70	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	most	_	RBS	RBS	_	5	AMOD	_	_
5	consistent	_	JJ	JJ	_	3	PRD	_	_
6	with	_	IN	IN	_	5	AMOD	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	model	_	NN	NN	_	6	PMOD	_	_
9	in	_	IN	IN	_	15	ADV	_	_
10	which	_	WDT	WDT	_	9	PMOD	_	_
11	recruitment	_	NN	NN	_	15	SBJ	_	_
12	to	_	TO	TO	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	TCR	_	NN	NN	_	12	PMOD	_	_
15	allows	_	VBZ	VBZ	_	8	NMOD	_	_
16	ZAP-70	_	NN	NN	_	15	OBJ	_	_
17	autophosphorylation	_	NN	NN	_	16	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	binding	_	NN	NN	_	17	COORD	_	_
20	to	_	TO	TO	_	19	NMOD	_	_
21	p56-LRB-lck-RRB-	_	NN	NN	_	20	PMOD	_	_
22	,	_	,	,	_	16	P	_	_
23	which	_	WDT	WDT	_	26	SBJ	_	_
24	in	_	IN	IN	_	26	ADV	_	_
25	turn	_	NN	NN	_	24	PMOD	_	_
26	phosphorylates	_	VBZ	VBZ	_	16	NMOD	_	_
27	Tyr-492	_	NN	NN	_	26	OBJ	_	_
28	and\/or	_	CC	CC	_	27	CC	_	_
29	Tyr-493	_	NN	NN	_	27	COORD	_	_
30	with	_	IN	IN	_	26	ADV	_	_
31	consequent	_	JJ	JJ	_	32	NMOD	_	_
32	up-regulation	_	NN	NN	_	30	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	the	_	DT	DT	_	37	NMOD	_	_
35	ZAP-70	_	NN	NN	_	37	NMOD	_	_
36	kinase	_	NN	NN	_	37	NMOD	_	_
37	activity	_	NN	NN	_	33	PMOD	_	_
38	.	_	.	.	_	3	P	_	_

1	ZAP-70	_	NN	NN	_	2	SBJ	_	_
2	will	_	MD	MD	_	0	ROOT-S	_	_
3	then	_	RB	RB	_	2	TMP	_	_
4	be	_	VB	VB	_	2	VC	_	_
5	able	_	JJ	JJ	_	4	PRD	_	_
6	to	_	TO	TO	_	8	VMOD	_	_
7	effectively	_	RB	RB	_	8	ADV	_	_
8	control	_	VB	VB	_	5	AMOD	_	_
9	phosphorylation	_	NN	NN	_	8	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	its	_	PRP$	PRP$	_	12	NMOD	_	_
12	substrates	_	NNS	NNS	_	10	PMOD	_	_
13	and	_	CC	CC	_	8	CC	_	_
14	lead	_	VB	VB	_	8	COORD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	gene	_	NN	NN	_	17	NMOD	_	_
17	activation	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	2	P	_	_

1	Lymphocytes	_	NNS	NNS	_	5	SBJ	_	_
2	from	_	IN	IN	_	1	NMOD	_	_
3	CML	_	NN	NN	_	4	NMOD	_	_
4	patients	_	NNS	NNS	_	2	PMOD	_	_
5	lack	_	VBP	VBP	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	47	_	CD	CD	_	8	AMOD	_	_
8	kDa	_	NN	NN	_	9	NMOD	_	_
9	factor	_	NN	NN	_	5	OBJ	_	_
10	having	_	VBG	VBG	_	9	NMOD	_	_
11	affinity	_	NN	NN	_	10	OBJ	_	_
12	for	_	IN	IN	_	11	NMOD	_	_
13	a	_	DT	DT	_	17	NMOD	_	_
14	genomic	_	JJ	JJ	_	17	NMOD	_	_
15	sterol	_	NN	NN	_	17	NMOD	_	_
16	regulatory	_	JJ	JJ	_	17	NMOD	_	_
17	sequence	_	NN	NN	_	12	PMOD	_	_
18	.	_	.	.	_	5	P	_	_

1	Deranged	_	VBN	VBN	_	4	NMOD	_	_
2	cellular	_	JJ	JJ	_	4	NMOD	_	_
3	cholesterol	_	NN	NN	_	4	NMOD	_	_
4	homeostasis	_	NN	NN	_	5	SBJ	_	_
5	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	been	_	VBN	VBN	_	5	VC	_	_
7	widely	_	RB	RB	_	6	ADV	_	_
8	recognized	_	VBN	VBN	_	6	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	initiation	_	NN	NN	_	9	PMOD	_	_
12	as	_	RB	RB	_	11	CC	_	_
13	well	_	RB	RB	_	12	DEP	_	_
14	as	_	IN	IN	_	12	DEP	_	_
15	progression	_	NN	NN	_	11	COORD	_	_
16	of	_	IN	IN	_	11	NMOD	_	_
17	various	_	JJ	JJ	_	18	NMOD	_	_
18	types	_	NNS	NNS	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	cancers	_	NNS	NNS	_	19	PMOD	_	_
21	including	_	VBG	VBG	_	18	NMOD	_	_
22	chronic	_	JJ	JJ	_	24	NMOD	_	_
23	myeloid	_	JJ	JJ	_	24	NMOD	_	_
24	leukaemia	_	NN	NN	_	21	PMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	CML	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	.	_	.	.	_	5	P	_	_

1	Since	_	IN	IN	_	27	ADV	_	_
2	the	_	DT	DT	_	7	NMOD	_	_
3	human	_	JJ	JJ	_	7	NMOD	_	_
4	genomic	_	JJ	JJ	_	7	NMOD	_	_
5	sterol	_	NN	NN	_	7	NMOD	_	_
6	regulatory	_	JJ	JJ	_	7	NMOD	_	_
7	element	_	NN	NN	_	11	SBJ	_	_
8	(	_	(	(	_	9	P	_	_
9	SRE	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	has	_	VBZ	VBZ	_	1	VMOD	_	_
12	been	_	VBN	VBN	_	11	VC	_	_
13	shown	_	VBN	VBN	_	12	VC	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	regulate	_	VB	VB	_	13	OBJ	_	_
16	various	_	JJ	JJ	_	18	NMOD	_	_
17	key	_	JJ	JJ	_	18	NMOD	_	_
18	genes	_	NNS	NNS	_	15	OBJ	_	_
19	involved	_	VBN	VBN	_	18	NMOD	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	this	_	DT	DT	_	22	NMOD	_	_
22	phenomenon	_	NN	NN	_	20	PMOD	_	_
23	,	_	,	,	_	27	P	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	present	_	JJ	JJ	_	26	NMOD	_	_
26	study	_	NN	NN	_	27	SBJ	_	_
27	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	existence	_	NN	NN	_	27	OBJ	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	a	_	DT	DT	_	36	NMOD	_	_
32	unique	_	JJ	JJ	_	36	NMOD	_	_
33	47	_	CD	CD	_	34	AMOD	_	_
34	kDa	_	NN	NN	_	36	NMOD	_	_
35	protein	_	NN	NN	_	36	NMOD	_	_
36	factor	_	NN	NN	_	30	PMOD	_	_
37	having	_	VBG	VBG	_	36	NMOD	_	_
38	affinity	_	NN	NN	_	37	OBJ	_	_
39	for	_	IN	IN	_	38	NMOD	_	_
40	this	_	DT	DT	_	42	NMOD	_	_
41	SRE	_	JJ	JJ	_	42	NMOD	_	_
42	sequence	_	NN	NN	_	39	PMOD	_	_
43	in	_	IN	IN	_	29	NMOD	_	_
44	lymphocytes	_	NNS	NNS	_	43	PMOD	_	_
45	from	_	IN	IN	_	44	NMOD	_	_
46	normal	_	JJ	JJ	_	47	NMOD	_	_
47	subjects	_	NNS	NNS	_	45	PMOD	_	_
48	,	_	,	,	_	29	P	_	_
49	as	_	RB	RB	_	29	CC	_	_
50	well	_	RB	RB	_	49	DEP	_	_
51	as	_	IN	IN	_	49	DEP	_	_
52	its	_	PRP$	PRP$	_	53	NMOD	_	_
53	absence	_	NN	NN	_	29	COORD	_	_
54	in	_	IN	IN	_	53	NMOD	_	_
55	lymphocytes	_	NNS	NNS	_	54	PMOD	_	_
56	from	_	IN	IN	_	55	NMOD	_	_
57	untreated	_	JJ	JJ	_	59	NMOD	_	_
58	CML	_	NN	NN	_	59	NMOD	_	_
59	patients	_	NNS	NNS	_	56	PMOD	_	_
60	.	_	.	.	_	27	P	_	_

1	However	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	factor	_	NN	NN	_	5	SBJ	_	_
5	appeared	_	VBD	VBD	_	0	ROOT-S	_	_
6	when	_	WRB	WRB	_	10	ADV	_	_
7	these	_	DT	DT	_	9	NMOD	_	_
8	CML	_	NN	NN	_	9	NMOD	_	_
9	patients	_	NNS	NNS	_	10	SBJ	_	_
10	achieved	_	VBD	VBD	_	5	TMP	_	_
11	complete	_	JJ	JJ	_	13	NMOD	_	_
12	haematological	_	JJ	JJ	_	13	NMOD	_	_
13	remission	_	NN	NN	_	10	OBJ	_	_
14	(	_	(	(	_	15	P	_	_
15	CHR	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	through	_	IN	IN	_	10	ADV	_	_
18	alpha-interferon	_	NN	NN	_	19	NMOD	_	_
19	therapy	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	Furthermore	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	an	_	DT	DT	_	5	NMOD	_	_
4	inverse	_	JJ	JJ	_	5	NMOD	_	_
5	relationship	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	also	_	RB	RB	_	6	ADV	_	_
8	observed	_	VBN	VBN	_	6	VC	_	_
9	between	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	LDL	_	NN	NN	_	14	NMOD	_	_
12	receptor	_	NN	NN	_	14	NMOD	_	_
13	gene	_	NN	NN	_	14	NMOD	_	_
14	expression	_	NN	NN	_	9	PMOD	_	_
15	at	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	transcriptional	_	JJ	JJ	_	18	NMOD	_	_
18	level	_	NN	NN	_	15	PMOD	_	_
19	and	_	CC	CC	_	14	CC	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	binding	_	NN	NN	_	22	NMOD	_	_
22	affinity	_	NN	NN	_	14	COORD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	this	_	DT	DT	_	28	NMOD	_	_
25	47	_	CD	CD	_	26	AMOD	_	_
26	kDa	_	NN	NN	_	28	NMOD	_	_
27	protein	_	NN	NN	_	28	NMOD	_	_
28	factor	_	NN	NN	_	23	PMOD	_	_
29	to	_	TO	TO	_	22	NMOD	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	SRE	_	NN	NN	_	32	NMOD	_	_
32	sequence	_	NN	NN	_	29	PMOD	_	_
33	.	_	.	.	_	6	P	_	_

1	Based	_	VBN	VBN	_	6	ADV	_	_
2	upon	_	IN	IN	_	1	PMOD	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	results	_	NNS	NNS	_	2	PMOD	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	propose	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	this	_	DT	DT	_	9	NMOD	_	_
9	factor	_	NN	NN	_	10	SBJ	_	_
10	may	_	MD	MD	_	7	VMOD	_	_
11	have	_	VB	VB	_	10	VC	_	_
12	a	_	DT	DT	_	13	NMOD	_	_
13	role	_	NN	NN	_	11	OBJ	_	_
14	in	_	IN	IN	_	11	ADV	_	_
15	pathophysiology	_	NN	NN	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	chronic	_	JJ	JJ	_	19	NMOD	_	_
18	myeloid	_	JJ	JJ	_	19	NMOD	_	_
19	leukaemia	_	NN	NN	_	16	PMOD	_	_
20	.	_	.	.	_	6	P	_	_

1	Synergistic	_	JJ	JJ	_	2	NMOD	_	_
2	interactions	_	NNS	NNS	_	15	SBJ	_	_
3	between	_	IN	IN	_	2	NMOD	_	_
4	overlapping	_	VBG	VBG	_	6	NMOD	_	_
5	binding	_	VBG	VBG	_	6	NMOD	_	_
6	sites	_	NNS	NNS	_	3	PMOD	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	serum	_	NN	NN	_	11	NMOD	_	_
10	response	_	NN	NN	_	11	NMOD	_	_
11	factor	_	NN	NN	_	7	PMOD	_	_
12	and	_	CC	CC	_	6	CC	_	_
13	ELK-1	_	NN	NN	_	14	NMOD	_	_
14	proteins	_	NNS	NNS	_	6	COORD	_	_
15	mediate	_	VBP	VBP	_	0	ROOT-S	_	_
16	both	_	CC	CC	_	18	CC	_	_
17	basal	_	JJ	JJ	_	18	NMOD	_	_
18	enhancement	_	NN	NN	_	15	OBJ	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	phorbol	_	NN	NN	_	22	NMOD	_	_
21	ester	_	NN	NN	_	22	NMOD	_	_
22	responsiveness	_	NN	NN	_	18	COORD	_	_
23	of	_	IN	IN	_	18	NMOD	_	_
24	primate	_	JJ	JJ	_	28	NMOD	_	_
25	cytomegalovirus	_	NN	NN	_	28	NMOD	_	_
26	major	_	JJ	JJ	_	28	NMOD	_	_
27	immediate-early	_	JJ	JJ	_	28	NMOD	_	_
28	promoters	_	NNS	NNS	_	23	PMOD	_	_
29	in	_	IN	IN	_	15	ADV	_	_
30	monocyte	_	NN	NN	_	34	NMOD	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	T-lymphocyte	_	NN	NN	_	30	COORD	_	_
33	cell	_	NN	NN	_	34	NMOD	_	_
34	types	_	NNS	NNS	_	29	PMOD	_	_
35	.	_	.	.	_	15	P	_	_

1	Cytomegalovirus	_	NN	NN	_	5	NMOD	_	_
2	(	_	(	(	_	3	P	_	_
3	CMV	_	NN	NN	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	infection	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	nonpermissive	_	JJ	JJ	_	6	PRD	_	_
8	or	_	CC	CC	_	7	CC	_	_
9	persistent	_	JJ	JJ	_	7	COORD	_	_
10	in	_	IN	IN	_	6	ADV	_	_
11	many	_	JJ	JJ	_	16	NMOD	_	_
12	lymphoid	_	JJ	JJ	_	16	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	myeloid	_	JJ	JJ	_	12	COORD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	types	_	NNS	NNS	_	10	PMOD	_	_
17	but	_	CC	CC	_	6	CC	_	_
18	can	_	MD	MD	_	6	COORD	_	_
19	be	_	VB	VB	_	18	VC	_	_
20	activated	_	VBN	VBN	_	19	VC	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	differentiated	_	VBN	VBN	_	23	NMOD	_	_
23	macrophages	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	shown	_	VBN	VBN	_	2	VC	_	_
4	elsewhere	_	RB	RB	_	3	ADV	_	_
5	that	_	IN	IN	_	3	OBJ	_	_
6	both	_	CC	CC	_	20	CC	_	_
7	the	_	DT	DT	_	20	NMOD	_	_
8	major	_	JJ	JJ	_	10	NMOD	_	_
9	immediate-early	_	JJ	JJ	_	10	NMOD	_	_
10	gene	_	NN	NN	_	20	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	MIE	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	and	_	CC	CC	_	10	CC	_	_
15	lytic	_	JJ	JJ	_	19	NMOD	_	_
16	cycle	_	NN	NN	_	19	NMOD	_	_
17	infectious	_	JJ	JJ	_	19	NMOD	_	_
18	progeny	_	NN	NN	_	19	NMOD	_	_
19	virus	_	NN	NN	_	10	COORD	_	_
20	expression	_	NN	NN	_	21	SBJ	_	_
21	can	_	MD	MD	_	5	VMOD	_	_
22	be	_	VB	VB	_	21	VC	_	_
23	induced	_	VBN	VBN	_	22	VC	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	otherwise	_	JJ	JJ	_	30	NMOD	_	_
26	nonpermissive	_	JJ	JJ	_	25	AMOD	_	_
27	monocyte-like	_	JJ	JJ	_	30	NMOD	_	_
28	U-937	_	NN	NN	_	30	NMOD	_	_
29	cell	_	NN	NN	_	30	NMOD	_	_
30	cultures	_	NNS	NNS	_	24	PMOD	_	_
31	infected	_	VBN	VBN	_	30	NMOD	_	_
32	with	_	IN	IN	_	31	ADV	_	_
33	either	_	CC	CC	_	35	CC	_	_
34	human	_	JJ	JJ	_	35	NMOD	_	_
35	CMV	_	NN	NN	_	32	PMOD	_	_
36	(	_	(	(	_	37	P	_	_
37	HCMV	_	NN	NN	_	35	PRN	_	_
38	)	_	)	)	_	37	P	_	_
39	or	_	CC	CC	_	35	CC	_	_
40	simian	_	JJ	JJ	_	41	NMOD	_	_
41	CMV	_	NN	NN	_	35	COORD	_	_
42	(	_	(	(	_	43	P	_	_
43	SCMV	_	NN	NN	_	41	PRN	_	_
44	)	_	)	)	_	43	P	_	_
45	by	_	IN	IN	_	23	LGS	_	_
46	treatment	_	NN	NN	_	45	PMOD	_	_
47	with	_	IN	IN	_	46	NMOD	_	_
48	the	_	DT	DT	_	51	NMOD	_	_
49	phorbol	_	NN	NN	_	51	NMOD	_	_
50	ester	_	NN	NN	_	51	NMOD	_	_
51	12-O-tetradecanoylphorbol-13-acetate	_	NN	NN	_	47	PMOD	_	_
52	(	_	(	(	_	53	P	_	_
53	TPA	_	NN	NN	_	51	PRN	_	_
54	)	_	)	)	_	53	P	_	_
55	.	_	.	.	_	2	P	_	_

1	Two	_	CD	CD	_	5	NMOD	_	_
2	multicopy	_	JJ	JJ	_	5	NMOD	_	_
3	basal	_	JJ	JJ	_	5	NMOD	_	_
4	enhancer	_	NN	NN	_	5	NMOD	_	_
5	motifs	_	NNS	NNS	_	62	SBJ	_	_
6	within	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	SCMV	_	NN	NN	_	10	NMOD	_	_
9	MIE	_	NN	NN	_	10	NMOD	_	_
10	enhancer	_	NN	NN	_	6	PMOD	_	_
11	,	_	,	,	_	5	P	_	_
12	namely	_	RB	RB	_	5	NMOD	_	_
13	,	_	,	,	_	5	P	_	_
14	11	_	CD	CD	_	15	NMOD	_	_
15	copies	_	NNS	NNS	_	5	NMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	22	NMOD	_	_
18	16-bp	_	JJ	JJ	_	22	NMOD	_	_
19	cyclic	_	JJ	JJ	_	22	NMOD	_	_
20	AMP	_	NN	NN	_	22	NMOD	_	_
21	response	_	NN	NN	_	22	NMOD	_	_
22	element	_	NN	NN	_	16	PMOD	_	_
23	(	_	(	(	_	24	P	_	_
24	CRE	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	and	_	CC	CC	_	15	CC	_	_
27	3	_	CD	CD	_	28	NMOD	_	_
28	copies	_	NNS	NNS	_	15	COORD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	novel	_	JJ	JJ	_	39	NMOD	_	_
31	17-bp	_	JJ	JJ	_	39	NMOD	_	_
32	serum	_	NN	NN	_	34	NMOD	_	_
33	response	_	NN	NN	_	34	NMOD	_	_
34	factor	_	NN	NN	_	39	NMOD	_	_
35	(	_	(	(	_	36	P	_	_
36	SRF	_	NN	NN	_	34	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	binding	_	NN	NN	_	39	NMOD	_	_
39	sites	_	NNS	NNS	_	29	PMOD	_	_
40	referred	_	VBN	VBN	_	15	NMOD	_	_
41	to	_	TO	TO	_	40	ADV	_	_
42	as	_	IN	IN	_	40	ADV	_	_
43	the	_	DT	DT	_	44	NMOD	_	_
44	SNE	_	NN	NN	_	42	PMOD	_	_
45	(	_	(	(	_	47	P	_	_
46	SRF\/NFkappaB-like	_	JJ	JJ	_	47	NMOD	_	_
47	element	_	NN	NN	_	44	PRN	_	_
48	)	_	)	)	_	47	P	_	_
49	,	_	,	,	_	44	P	_	_
50	as	_	RB	RB	_	44	CC	_	_
51	well	_	RB	RB	_	50	DEP	_	_
52	as	_	IN	IN	_	50	DEP	_	_
53	four	_	CD	CD	_	56	NMOD	_	_
54	classical	_	JJ	JJ	_	56	NMOD	_	_
55	NFkappaB	_	NN	NN	_	56	NMOD	_	_
56	sites	_	NNS	NNS	_	44	COORD	_	_
57	within	_	IN	IN	_	56	NMOD	_	_
58	the	_	DT	DT	_	60	NMOD	_	_
59	HCMV	_	NN	NN	_	60	NMOD	_	_
60	version	_	NN	NN	_	57	PMOD	_	_
61	,	_	,	,	_	44	P	_	_
62	contribute	_	VBP	VBP	_	0	ROOT-S	_	_
63	to	_	TO	TO	_	62	ADV	_	_
64	TPA	_	NN	NN	_	65	NMOD	_	_
65	responsiveness	_	NN	NN	_	63	PMOD	_	_
66	in	_	IN	IN	_	65	NMOD	_	_
67	transient	_	JJ	JJ	_	68	NMOD	_	_
68	assays	_	NNS	NNS	_	66	PMOD	_	_
69	in	_	IN	IN	_	65	NMOD	_	_
70	monocyte	_	NN	NN	_	73	NMOD	_	_
71	and	_	CC	CC	_	70	CC	_	_
72	T-cell	_	NN	NN	_	70	COORD	_	_
73	types	_	NNS	NNS	_	69	PMOD	_	_
74	.	_	.	.	_	62	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	SCMV	_	NN	NN	_	4	NMOD	_	_
3	SNE	_	NN	NN	_	4	NMOD	_	_
4	sites	_	NNS	NNS	_	5	SBJ	_	_
5	contain	_	VBP	VBP	_	0	ROOT-S	_	_
6	potential	_	JJ	JJ	_	11	NMOD	_	_
7	overlapping	_	VBG	VBG	_	11	NMOD	_	_
8	core	_	NN	NN	_	11	NMOD	_	_
9	recognition	_	NN	NN	_	11	NMOD	_	_
10	binding	_	NN	NN	_	11	NMOD	_	_
11	motifs	_	NNS	NNS	_	5	OBJ	_	_
12	for	_	IN	IN	_	11	NMOD	_	_
13	SRF	_	NN	NN	_	23	NMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	Rel\/NFkappaB	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	13	P	_	_
17	ETS	_	NN	NN	_	13	COORD	_	_
18	,	_	,	,	_	13	P	_	_
19	and	_	CC	CC	_	13	CC	_	_
20	YY1	_	NN	NN	_	13	COORD	_	_
21	class	_	NN	NN	_	23	NMOD	_	_
22	transcription	_	NN	NN	_	23	NMOD	_	_
23	factors	_	NNS	NNS	_	12	PMOD	_	_
24	but	_	CC	CC	_	5	CC	_	_
25	fail	_	VBP	VBP	_	5	COORD	_	_
26	to	_	TO	TO	_	27	VMOD	_	_
27	respond	_	VB	VB	_	25	OBJ	_	_
28	to	_	TO	TO	_	27	ADV	_	_
29	either	_	CC	CC	_	30	CC	_	_
30	serum	_	NN	NN	_	28	PMOD	_	_
31	or	_	CC	CC	_	30	CC	_	_
32	tumor	_	NN	NN	_	35	NMOD	_	_
33	necrosis	_	NN	NN	_	35	NMOD	_	_
34	factor	_	NN	NN	_	35	NMOD	_	_
35	alpha	_	NN	NN	_	30	COORD	_	_
36	.	_	.	.	_	5	P	_	_

1	Therefore	_	RB	RB	_	36	ADV	_	_
2	,	_	,	,	_	36	P	_	_
3	to	_	TO	TO	_	4	VMOD	_	_
4	evaluate	_	VB	VB	_	36	VMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	mechanism	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	TPA	_	NN	NN	_	9	NMOD	_	_
9	responsiveness	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	SNE	_	NN	NN	_	13	NMOD	_	_
13	motifs	_	NNS	NNS	_	10	PMOD	_	_
14	and	_	CC	CC	_	10	CC	_	_
15	of	_	IN	IN	_	10	COORD	_	_
16	a	_	DT	DT	_	24	NMOD	_	_
17	related	_	JJ	JJ	_	24	NMOD	_	_
18	16-bp	_	JJ	JJ	_	24	NMOD	_	_
19	SEE	_	NN	NN	_	24	NMOD	_	_
20	(	_	(	(	_	22	P	_	_
21	SRF\/ETS	_	NN	NN	_	22	NMOD	_	_
22	element	_	NN	NN	_	19	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	motif	_	NN	NN	_	15	PMOD	_	_
25	found	_	VBN	VBN	_	24	NMOD	_	_
26	in	_	IN	IN	_	25	ADV	_	_
27	the	_	DT	DT	_	33	NMOD	_	_
28	HCMV	_	NN	NN	_	33	NMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	chimpanzee	_	NN	NN	_	31	NMOD	_	_
31	CMV	_	NN	NN	_	28	COORD	_	_
32	MIE	_	NN	NN	_	33	NMOD	_	_
33	enhancers	_	NNS	NNS	_	26	PMOD	_	_
34	,	_	,	,	_	36	P	_	_
35	we	_	PRP	PRP	_	36	SBJ	_	_
36	have	_	VBP	VBP	_	0	ROOT-S	_	_
37	examined	_	VBN	VBN	_	36	VC	_	_
38	the	_	DT	DT	_	40	NMOD	_	_
39	functional	_	JJ	JJ	_	40	NMOD	_	_
40	responses	_	NNS	NNS	_	37	OBJ	_	_
41	and	_	CC	CC	_	40	CC	_	_
42	protein	_	NN	NN	_	44	NMOD	_	_
43	binding	_	NN	NN	_	44	NMOD	_	_
44	properties	_	NNS	NNS	_	40	COORD	_	_
45	of	_	IN	IN	_	40	NMOD	_	_
46	multimerized	_	JJ	JJ	_	50	NMOD	_	_
47	wild-type	_	JJ	JJ	_	50	NMOD	_	_
48	and	_	CC	CC	_	47	CC	_	_
49	mutant	_	JJ	JJ	_	47	COORD	_	_
50	elements	_	NNS	NNS	_	45	PMOD	_	_
51	added	_	VBN	VBN	_	50	NMOD	_	_
52	upstream	_	RB	RB	_	53	PMOD	_	_
53	to	_	TO	TO	_	51	ADV	_	_
54	the	_	DT	DT	_	63	NMOD	_	_
55	SCMV	_	NN	NN	_	56	NMOD	_	_
56	MIE	_	NN	NN	_	63	NMOD	_	_
57	or	_	CC	CC	_	56	CC	_	_
58	simian	_	JJ	JJ	_	59	NMOD	_	_
59	virus	_	NN	NN	_	56	COORD	_	_
60	40	_	CD	CD	_	63	NMOD	_	_
61	minimal	_	JJ	JJ	_	63	NMOD	_	_
62	promoter	_	NN	NN	_	63	NMOD	_	_
63	regions	_	NNS	NNS	_	53	PMOD	_	_
64	in	_	IN	IN	_	63	NMOD	_	_
65	the	_	DT	DT	_	77	NMOD	_	_
66	U-937	_	NN	NN	_	77	NMOD	_	_
67	,	_	,	,	_	66	P	_	_
68	K-562	_	NN	NN	_	66	COORD	_	_
69	,	_	,	,	_	66	P	_	_
70	HL-60	_	NN	NN	_	66	COORD	_	_
71	,	_	,	,	_	66	P	_	_
72	THP-1	_	NN	NN	_	66	COORD	_	_
73	,	_	,	,	_	66	P	_	_
74	and	_	CC	CC	_	66	CC	_	_
75	Jurkat	_	NN	NN	_	66	COORD	_	_
76	cell	_	NN	NN	_	77	NMOD	_	_
77	lines	_	NNS	NNS	_	64	PMOD	_	_
78	.	_	.	.	_	36	P	_	_

1	Unlike	_	IN	IN	_	13	ADV	_	_
2	classical	_	JJ	JJ	_	4	NMOD	_	_
3	NFkappaB	_	NN	NN	_	4	NMOD	_	_
4	sites	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	13	P	_	_
6	neither	_	CC	CC	_	8	CC	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	SNE	_	NN	NN	_	12	NMOD	_	_
9	nor	_	CC	CC	_	8	CC	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	SEE	_	NN	NN	_	8	COORD	_	_
12	motif	_	NN	NN	_	13	SBJ	_	_
13	responded	_	VBD	VBD	_	0	ROOT-S	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	phosphatase	_	NN	NN	_	16	NMOD	_	_
16	inhibition	_	NN	NN	_	14	PMOD	_	_
17	by	_	IN	IN	_	16	NMOD	_	_
18	okadaic	_	JJ	JJ	_	19	NMOD	_	_
19	acid	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	13	P	_	_

1	However	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	TPA	_	NN	NN	_	5	NMOD	_	_
5	responsiveness	_	NN	NN	_	10	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	both	_	DT	DT	_	9	NMOD	_	_
8	CMV	_	NN	NN	_	9	NMOD	_	_
9	elements	_	NNS	NNS	_	6	PMOD	_	_
10	proved	_	VBD	VBD	_	0	ROOT-S	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	involve	_	VB	VB	_	10	OBJ	_	_
13	synergistic	_	JJ	JJ	_	14	NMOD	_	_
14	interactions	_	NNS	NNS	_	12	OBJ	_	_
15	between	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	core	_	NN	NN	_	20	NMOD	_	_
18	SRF	_	NN	NN	_	20	NMOD	_	_
19	binding	_	NN	NN	_	20	NMOD	_	_
20	site	_	NN	NN	_	15	PMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	CCATATATGG	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	and	_	CC	CC	_	20	CC	_	_
25	the	_	DT	DT	_	30	NMOD	_	_
26	adjacent	_	JJ	JJ	_	30	NMOD	_	_
27	inverted	_	VBN	VBN	_	30	NMOD	_	_
28	ETS	_	NN	NN	_	30	NMOD	_	_
29	binding	_	NN	NN	_	30	NMOD	_	_
30	motifs	_	NNS	NNS	_	20	COORD	_	_
31	(	_	(	(	_	32	P	_	_
32	TTCC	_	NN	NN	_	30	PRN	_	_
33	)	_	)	)	_	32	P	_	_
34	,	_	,	,	_	14	P	_	_
35	which	_	WDT	WDT	_	36	SBJ	_	_
36	correlated	_	VBD	VBD	_	14	NMOD	_	_
37	directly	_	RB	RB	_	36	ADV	_	_
38	with	_	IN	IN	_	36	ADV	_	_
39	formation	_	NN	NN	_	38	PMOD	_	_
40	of	_	IN	IN	_	39	NMOD	_	_
41	a	_	DT	DT	_	44	NMOD	_	_
42	bound	_	VBN	VBN	_	44	NMOD	_	_
43	tripartite	_	JJ	JJ	_	44	NMOD	_	_
44	complex	_	NN	NN	_	40	PMOD	_	_
45	containing	_	VBG	VBG	_	44	NMOD	_	_
46	both	_	CC	CC	_	49	CC	_	_
47	the	_	DT	DT	_	49	NMOD	_	_
48	cellular	_	JJ	JJ	_	49	NMOD	_	_
49	SRF	_	NN	NN	_	45	OBJ	_	_
50	and	_	CC	CC	_	49	CC	_	_
51	ELK-1	_	NN	NN	_	52	NMOD	_	_
52	proteins	_	NNS	NNS	_	49	COORD	_	_
53	.	_	.	.	_	10	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	protein	_	NN	NN	_	3	NMOD	_	_
3	complex	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	more	_	RBR	RBR	_	6	AMOD	_	_
6	abundant	_	JJ	JJ	_	4	PRD	_	_
7	in	_	IN	IN	_	4	ADV	_	_
8	U-937	_	NN	NN	_	15	NMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	K-562	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	8	P	_	_
12	and	_	CC	CC	_	8	CC	_	_
13	HeLa	_	NN	NN	_	8	COORD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	extracts	_	NNS	NNS	_	7	PMOD	_	_
16	than	_	IN	IN	_	6	AMOD	_	_
17	in	_	IN	IN	_	16	PMOD	_	_
18	Raji	_	NN	NN	_	27	NMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	HF	_	NN	NN	_	18	COORD	_	_
21	,	_	,	,	_	18	P	_	_
22	BALB\/c	_	NN	NN	_	23	NMOD	_	_
23	3T3	_	NN	NN	_	18	COORD	_	_
24	,	_	,	,	_	18	P	_	_
25	or	_	CC	CC	_	18	CC	_	_
26	HL-60	_	NN	NN	_	18	COORD	_	_
27	cells	_	NNS	NNS	_	17	PMOD	_	_
28	,	_	,	,	_	4	P	_	_
29	but	_	CC	CC	_	4	CC	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	binding	_	NN	NN	_	32	NMOD	_	_
32	activity	_	NN	NN	_	33	SBJ	_	_
33	was	_	VBD	VBD	_	4	COORD	_	_
34	altered	_	VBN	VBN	_	33	VC	_	_
35	only	_	RB	RB	_	34	ADV	_	_
36	twofold	_	RB	RB	_	35	AMOD	_	_
37	after	_	IN	IN	_	34	TMP	_	_
38	TPA	_	NN	NN	_	39	NMOD	_	_
39	treatment	_	NN	NN	_	37	PMOD	_	_
40	.	_	.	.	_	4	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	40-fold	_	JJ	JJ	_	3	NMOD	_	_
3	stimulation	_	NN	NN	_	16	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	chloramphenicol	_	JJ	JJ	_	7	NMOD	_	_
6	acetyltransferase	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	4	PMOD	_	_
8	mediated	_	VBN	VBN	_	3	NMOD	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	four	_	CD	CD	_	12	NMOD	_	_
11	tandem	_	JJ	JJ	_	12	NMOD	_	_
12	repeats	_	NNS	NNS	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	SNE	_	NN	NN	_	13	PMOD	_	_
16	could	_	MD	MD	_	0	ROOT-S	_	_
17	be	_	VB	VB	_	16	VC	_	_
18	induced	_	VBN	VBN	_	17	VC	_	_
19	within	_	IN	IN	_	18	TMP	_	_
20	2	_	CD	CD	_	21	NMOD	_	_
21	h	_	NN	NN	_	19	PMOD	_	_
22	(	_	(	(	_	18	P	_	_
23	and	_	CC	CC	_	18	CC	_	_
24	up	_	RB	RB	_	27	ADV	_	_
25	to	_	TO	TO	_	24	AMOD	_	_
26	250-fold	_	JJ	JJ	_	24	AMOD	_	_
27	within	_	IN	IN	_	19	GAP	_	_
28	6	_	CD	CD	_	29	NMOD	_	_
29	h	_	NN	NN	_	27	PMOD	_	_
30	)	_	)	)	_	18	P	_	_
31	after	_	IN	IN	_	18	TMP	_	_
32	addition	_	NN	NN	_	31	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	TPA	_	NN	NN	_	33	PMOD	_	_
35	in	_	IN	IN	_	32	NMOD	_	_
36	DNA-transfected	_	JJ	JJ	_	38	NMOD	_	_
37	U-937	_	NN	NN	_	38	NMOD	_	_
38	cells	_	NNS	NNS	_	35	PMOD	_	_
39	,	_	,	,	_	18	P	_	_
40	indicating	_	VBG	VBG	_	18	OBJ	_	_
41	that	_	IN	IN	_	40	OBJ	_	_
42	the	_	DT	DT	_	43	NMOD	_	_
43	stimulation	_	NN	NN	_	44	SBJ	_	_
44	appeared	_	VBD	VBD	_	41	VMOD	_	_
45	likely	_	JJ	JJ	_	44	PRD	_	_
46	to	_	TO	TO	_	47	VMOD	_	_
47	be	_	VB	VB	_	45	AMOD	_	_
48	a	_	DT	DT	_	55	NMOD	_	_
49	true	_	JJ	JJ	_	55	NMOD	_	_
50	protein	_	NN	NN	_	51	AMOD	_	_
51	kinase	_	NN	NN	_	55	NMOD	_	_
52	C-mediated	_	JJ	JJ	_	51	AMOD	_	_
53	signal	_	NN	NN	_	55	NMOD	_	_
54	transduction	_	NN	NN	_	55	NMOD	_	_
55	event	_	NN	NN	_	47	PRD	_	_
56	rather	_	RB	RB	_	55	CC	_	_
57	than	_	IN	IN	_	56	DEP	_	_
58	a	_	DT	DT	_	60	NMOD	_	_
59	differentiation	_	NN	NN	_	60	NMOD	_	_
60	response	_	NN	NN	_	55	COORD	_	_
61	.	_	.	.	_	16	P	_	_

1	Slight	_	JJ	JJ	_	2	NMOD	_	_
2	differences	_	NNS	NNS	_	37	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	sequence	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	11	NMOD	_	_
8	core	_	NN	NN	_	11	NMOD	_	_
9	SRF	_	NN	NN	_	11	NMOD	_	_
10	binding	_	NN	NN	_	11	NMOD	_	_
11	site	_	NN	NN	_	6	PMOD	_	_
12	compared	_	VBN	VBN	_	2	NMOD	_	_
13	with	_	IN	IN	_	12	PMOD	_	_
14	that	_	DT	DT	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	22	NMOD	_	_
17	classical	_	JJ	JJ	_	22	NMOD	_	_
18	c-Fos	_	NN	NN	_	22	NMOD	_	_
19	promoter	_	NN	NN	_	22	NMOD	_	_
20	serum	_	NN	NN	_	22	NMOD	_	_
21	response	_	NN	NN	_	22	NMOD	_	_
22	element	_	NN	NN	_	15	PMOD	_	_
23	,	_	,	,	_	2	P	_	_
24	together	_	RB	RB	_	25	DEP	_	_
25	with	_	IN	IN	_	2	NMOD	_	_
26	differences	_	NNS	NNS	_	25	PMOD	_	_
27	in	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	spacing	_	NN	NN	_	27	PMOD	_	_
30	between	_	IN	IN	_	26	NMOD	_	_
31	the	_	DT	DT	_	35	NMOD	_	_
32	SRF	_	NN	NN	_	35	NMOD	_	_
33	and	_	CC	CC	_	32	CC	_	_
34	ETS	_	NN	NN	_	32	COORD	_	_
35	motifs	_	NNS	NNS	_	30	PMOD	_	_
36	,	_	,	,	_	2	P	_	_
37	appear	_	VBP	VBP	_	0	ROOT-S	_	_
38	to	_	TO	TO	_	39	VMOD	_	_
39	account	_	VB	VB	_	37	OBJ	_	_
40	for	_	IN	IN	_	39	ADV	_	_
41	the	_	DT	DT	_	42	NMOD	_	_
42	inability	_	NN	NN	_	40	PMOD	_	_
43	of	_	IN	IN	_	42	NMOD	_	_
44	the	_	DT	DT	_	46	NMOD	_	_
45	SCMV	_	NN	NN	_	46	NMOD	_	_
46	SNEs	_	NNS	NNS	_	43	PMOD	_	_
47	to	_	TO	TO	_	48	VMOD	_	_
48	respond	_	VB	VB	_	42	NMOD	_	_
49	to	_	TO	TO	_	48	ADV	_	_
50	serum	_	NN	NN	_	51	NMOD	_	_
51	induction	_	NN	NN	_	49	PMOD	_	_
52	.	_	.	.	_	37	P	_	_

1	Acetylsalicylic	_	JJ	JJ	_	2	NMOD	_	_
2	acid	_	NN	NN	_	6	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	sodium	_	NN	NN	_	5	NMOD	_	_
5	salicylate	_	NN	NN	_	2	COORD	_	_
6	inhibit	_	VBP	VBP	_	0	ROOT-S	_	_
7	LPS-induced	_	JJ	JJ	_	11	NMOD	_	_
8	NF-kappa	_	NN	NN	_	11	NMOD	_	_
9	B\/c-Rel	_	NN	NN	_	11	NMOD	_	_
10	nuclear	_	JJ	JJ	_	11	NMOD	_	_
11	translocation	_	NN	NN	_	6	OBJ	_	_
12	,	_	,	,	_	11	P	_	_
13	and	_	CC	CC	_	11	CC	_	_
14	synthesis	_	NN	NN	_	11	COORD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	tissue	_	NN	NN	_	17	NMOD	_	_
17	factor	_	NN	NN	_	15	PMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	TF	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	and	_	CC	CC	_	17	CC	_	_
22	tumor	_	NN	NN	_	25	NMOD	_	_
23	necrosis	_	NN	NN	_	25	NMOD	_	_
24	factor	_	NN	NN	_	25	NMOD	_	_
25	alfa	_	NN	NN	_	17	COORD	_	_
26	(	_	(	(	_	27	P	_	_
27	TNF-alpha	_	NN	NN	_	25	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	in	_	IN	IN	_	11	NMOD	_	_
30	human	_	JJ	JJ	_	31	NMOD	_	_
31	monocytes	_	NNS	NNS	_	29	PMOD	_	_
32	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	investigated	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	effects	_	NNS	NNS	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	acetylsalicylic	_	JJ	JJ	_	8	NMOD	_	_
8	acid	_	NN	NN	_	6	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	sodium	_	NN	NN	_	11	NMOD	_	_
11	salicylate	_	NN	NN	_	8	COORD	_	_
12	on	_	IN	IN	_	5	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	LPS-induced	_	JJ	JJ	_	15	NMOD	_	_
15	synthesis	_	NN	NN	_	12	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	pro-coagulant	_	JJ	JJ	_	19	NMOD	_	_
19	protein	_	NN	NN	_	16	PMOD	_	_
20	tissue	_	NN	NN	_	21	NMOD	_	_
21	factor	_	NN	NN	_	19	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	TF	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	and	_	CC	CC	_	19	CC	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	pro-inflammatory	_	JJ	JJ	_	28	NMOD	_	_
28	protein	_	NN	NN	_	19	COORD	_	_
29	tumor	_	NN	NN	_	31	NMOD	_	_
30	necrosis	_	NN	NN	_	31	NMOD	_	_
31	factor-alpha	_	NN	NN	_	28	NMOD	_	_
32	(	_	(	(	_	33	P	_	_
33	TNF-alpha	_	NN	NN	_	31	PRN	_	_
34	)	_	)	)	_	33	P	_	_
35	,	_	,	,	_	15	P	_	_
36	as	_	RB	RB	_	15	CC	_	_
37	well	_	RB	RB	_	36	DEP	_	_
38	as	_	IN	IN	_	36	DEP	_	_
39	the	_	DT	DT	_	41	NMOD	_	_
40	prostaglandin	_	NN	NN	_	41	NMOD	_	_
41	PGE2	_	NN	NN	_	15	COORD	_	_
42	in	_	IN	IN	_	15	NMOD	_	_
43	human	_	JJ	JJ	_	44	NMOD	_	_
44	monocytes	_	NNS	NNS	_	42	PMOD	_	_
45	.	_	.	.	_	2	P	_	_

1	Both	_	DT	DT	_	2	NMOD	_	_
2	drugs	_	NNS	NNS	_	4	SBJ	_	_
3	dose-dependently	_	RB	RB	_	4	ADV	_	_
4	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
5	LPS-induced	_	JJ	JJ	_	9	NMOD	_	_
6	TF	_	NN	NN	_	9	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	TNF-alpha	_	NN	NN	_	6	COORD	_	_
9	synthesis	_	NN	NN	_	4	OBJ	_	_
10	at	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	mRNA	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	protein	_	NN	NN	_	12	COORD	_	_
16	level	_	NN	NN	_	12	NMOD	_	_
17	,	_	,	,	_	4	P	_	_
18	and	_	CC	CC	_	4	CC	_	_
19	reduced	_	VBD	VBD	_	4	COORD	_	_
20	PGE2	_	NN	NN	_	21	NMOD	_	_
21	production	_	NN	NN	_	19	OBJ	_	_
22	.	_	.	.	_	4	P	_	_

1	As	_	IN	IN	_	24	ADV	_	_
2	evidenced	_	VBN	VBN	_	1	VMOD	_	_
3	by	_	IN	IN	_	2	LGS	_	_
4	electro	_	NN	NN	_	7	NMOD	_	_
5	mobility	_	NN	NN	_	7	NMOD	_	_
6	shift	_	NN	NN	_	7	NMOD	_	_
7	assay	_	NN	NN	_	3	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	EMSA	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	use	_	NN	NN	_	7	COORD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	a	_	DT	DT	_	19	NMOD	_	_
16	NF-kappa	_	NN	NN	_	19	NMOD	_	_
17	B	_	NN	NN	_	19	NMOD	_	_
18	prototypic	_	JJ	JJ	_	19	NMOD	_	_
19	probe	_	NN	NN	_	14	PMOD	_	_
20	,	_	,	,	_	24	P	_	_
21	these	_	DT	DT	_	22	NMOD	_	_
22	drugs	_	NNS	NNS	_	24	SBJ	_	_
23	probably	_	RB	RB	_	24	ADV	_	_
24	exert	_	VBP	VBP	_	0	ROOT-S	_	_
25	their	_	PRP$	PRP$	_	27	NMOD	_	_
26	inhibitory	_	JJ	JJ	_	27	NMOD	_	_
27	effects	_	NNS	NNS	_	24	OBJ	_	_
28	by	_	IN	IN	_	24	ADV	_	_
29	interference	_	NN	NN	_	28	PMOD	_	_
30	with	_	IN	IN	_	29	NMOD	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	nuclear	_	JJ	JJ	_	33	NMOD	_	_
33	translocation	_	NN	NN	_	30	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	NF-kappa	_	NN	NN	_	37	NMOD	_	_
36	B\/c-Rel	_	NN	NN	_	37	NMOD	_	_
37	proteins	_	NNS	NNS	_	34	PMOD	_	_
38	.	_	.	.	_	24	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	may	_	MD	MD	_	0	ROOT-S	_	_
4	expand	_	VB	VB	_	3	VC	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	understanding	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	anti-thrombotic	_	JJ	JJ	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	anti-inflammatory	_	JJ	JJ	_	9	COORD	_	_
12	effects	_	NNS	NNS	_	7	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	these	_	DT	DT	_	15	NMOD	_	_
15	drugs	_	NNS	NNS	_	13	PMOD	_	_
16	when	_	WRB	WRB	_	20	ADV	_	_
17	activation	_	NN	NN	_	20	SBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	monocytes	_	NNS	NNS	_	18	PMOD	_	_
20	occurs	_	VBZ	VBZ	_	12	TMP	_	_
21	.	_	.	.	_	3	P	_	_

1	Characterization	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	9	NMOD	_	_
4	murine	_	JJ	JJ	_	9	NMOD	_	_
5	cyclin-dependent	_	JJ	JJ	_	9	NMOD	_	_
6	kinase	_	NN	NN	_	9	NMOD	_	_
7	inhibitor	_	NN	NN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	p27Kip1	_	NN	NN	_	2	PMOD	_	_
10	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	cyclin-dependent	_	JJ	JJ	_	5	NMOD	_	_
3	kinase	_	NN	NN	_	5	NMOD	_	_
4	inhibitor	_	NN	NN	_	5	NMOD	_	_
5	p27Kip1	_	NN	NN	_	6	SBJ	_	_
6	plays	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	an	_	DT	DT	_	9	NMOD	_	_
8	important	_	JJ	JJ	_	9	NMOD	_	_
9	role	_	NN	NN	_	6	OBJ	_	_
10	in	_	IN	IN	_	6	ADV	_	_
11	regulating	_	VBG	VBG	_	10	PMOD	_	_
12	cell-cycle	_	JJ	JJ	_	13	NMOD	_	_
13	progression	_	NN	NN	_	11	OBJ	_	_
14	.	_	.	.	_	6	P	_	_

1	p27Kip1	_	NN	NN	_	3	SBJ	_	_
2	directly	_	RB	RB	_	3	ADV	_	_
3	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	catalytic	_	JJ	JJ	_	6	NMOD	_	_
6	activity	_	NN	NN	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	cyclin\/cdks	_	NNS	NNS	_	13	NMOD	_	_
9	(	_	(	(	_	11	P	_	_
10	cyclin-dependent	_	JJ	JJ	_	11	NMOD	_	_
11	kinase	_	NN	NN	_	13	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	complexes	_	NNS	NNS	_	7	PMOD	_	_
14	and\/or	_	CC	CC	_	3	CC	_	_
15	interferes	_	VBZ	VBZ	_	3	COORD	_	_
16	physically	_	RB	RB	_	15	ADV	_	_
17	with	_	IN	IN	_	15	ADV	_	_
18	cyclin\/cdks	_	NN	NN	_	19	NMOD	_	_
19	activation	_	NN	NN	_	17	PMOD	_	_
20	by	_	IN	IN	_	19	NMOD	_	_
21	CAK	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	Interestingly	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	expression	_	NN	NN	_	5	NMOD	_	_
5	level	_	NN	NN	_	9	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	p27Kip1	_	NN	NN	_	8	NMOD	_	_
8	mRNA	_	NN	NN	_	6	PMOD	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	maximal	_	JJ	JJ	_	9	PRD	_	_
11	in	_	IN	IN	_	9	ADV	_	_
12	resting	_	VBG	VBG	_	14	NMOD	_	_
13	Go	_	NN	NN	_	14	NMOD	_	_
14	T-cells	_	NNS	NNS	_	11	PMOD	_	_
15	and	_	CC	CC	_	9	CC	_	_
16	rapidly	_	RB	RB	_	17	TMP	_	_
17	declined	_	VBD	VBD	_	9	COORD	_	_
18	following	_	VBG	VBG	_	17	TMP	_	_
19	anti-CD3	_	JJ	JJ	_	20	NMOD	_	_
20	activation	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	cloning	_	NN	NN	_	2	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	p27Kip1	_	NN	NN	_	8	NMOD	_	_
8	gene	_	NN	NN	_	6	PMOD	_	_
9	from	_	IN	IN	_	5	NMOD	_	_
10	murine	_	JJ	JJ	_	12	NMOD	_	_
11	genomic	_	JJ	JJ	_	12	NMOD	_	_
12	DNA	_	NN	NN	_	9	PMOD	_	_
13	and	_	CC	CC	_	5	CC	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	functional	_	JJ	JJ	_	16	NMOD	_	_
16	analysis	_	NN	NN	_	5	COORD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	promoter	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	p27Kip1	_	NN	NN	_	23	NMOD	_	_
23	gene	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	gene	_	NN	NN	_	3	SBJ	_	_
3	consists	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	of	_	IN	IN	_	3	ADV	_	_
5	at	_	IN	IN	_	7	DEP	_	_
6	least	_	JJS	JJS	_	7	DEP	_	_
7	three	_	CD	CD	_	8	NMOD	_	_
8	exons	_	NNS	NNS	_	4	PMOD	_	_
9	and	_	CC	CC	_	3	CC	_	_
10	spans	_	NNS	NNS	_	3	COORD	_	_
11	more	_	RBR	RBR	_	13	DEP	_	_
12	than	_	IN	IN	_	13	DEP	_	_
13	5.6	_	CD	CD	_	14	NMOD	_	_
14	kb	_	NN	NN	_	10	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	DNA	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	Primer	_	NN	NN	_	2	NMOD	_	_
2	extension	_	NN	NN	_	7	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	nuclease	_	NN	NN	_	6	NMOD	_	_
5	S1	_	NN	NN	_	6	NMOD	_	_
6	protection	_	NN	NN	_	2	COORD	_	_
7	analysis	_	NN	NN	_	8	SBJ	_	_
8	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
9	two	_	CD	CD	_	13	NMOD	_	_
10	major	_	JJ	JJ	_	13	NMOD	_	_
11	transcription	_	NN	NN	_	13	NMOD	_	_
12	initiation	_	NN	NN	_	13	NMOD	_	_
13	sites	_	NNS	NNS	_	8	OBJ	_	_
14	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	promoter	_	NN	NN	_	3	NMOD	_	_
3	region	_	NN	NN	_	4	SBJ	_	_
4	lacked	_	VBD	VBD	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	TATA	_	NN	NN	_	7	NMOD	_	_
7	box	_	NN	NN	_	4	OBJ	_	_
8	but	_	CC	CC	_	4	CC	_	_
9	contained	_	VBD	VBD	_	4	COORD	_	_
10	potential	_	JJ	JJ	_	12	NMOD	_	_
11	binding	_	VBG	VBG	_	12	NMOD	_	_
12	sites	_	NNS	NNS	_	9	OBJ	_	_
13	for	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	transcriptional	_	JJ	JJ	_	16	NMOD	_	_
16	factors	_	NNS	NNS	_	13	PMOD	_	_
17	including	_	VBG	VBG	_	16	NMOD	_	_
18	two	_	CD	CD	_	19	NMOD	_	_
19	Sp1	_	NN	NN	_	17	PMOD	_	_
20	,	_	,	,	_	19	P	_	_
21	CRE	_	NN	NN	_	19	COORD	_	_
22	,	_	,	,	_	19	P	_	_
23	Myb	_	NN	NN	_	19	COORD	_	_
24	and	_	CC	CC	_	19	CC	_	_
25	NFkB	_	NN	NN	_	19	COORD	_	_
26	located	_	JJ	JJ	_	12	NMOD	_	_
27	at	_	IN	IN	_	26	AMOD	_	_
28	positions	_	NNS	NNS	_	27	PMOD	_	_
29	-153	_	CD	CD	_	28	NMOD	_	_
30	,	_	,	,	_	29	P	_	_
31	-178	_	CD	CD	_	29	COORD	_	_
32	,	_	,	,	_	29	P	_	_
33	-286	_	CD	CD	_	29	COORD	_	_
34	,	_	,	,	_	29	P	_	_
35	-875	_	CD	CD	_	29	COORD	_	_
36	,	_	,	,	_	29	P	_	_
37	and	_	CC	CC	_	29	CC	_	_
38	-1011	_	CD	CD	_	29	COORD	_	_
39	,	_	,	,	_	28	P	_	_
40	respectively	_	RB	RB	_	28	NMOD	_	_
41	.	_	.	.	_	4	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	analyze	_	VB	VB	_	12	VMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	regulatory	_	JJ	JJ	_	5	NMOD	_	_
5	mechanisms	_	NNS	NNS	_	2	OBJ	_	_
6	controlling	_	VBG	VBG	_	5	NMOD	_	_
7	p27Kip1	_	NN	NN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	expression	_	NN	NN	_	6	OBJ	_	_
10	,	_	,	,	_	12	P	_	_
11	we	_	PRP	PRP	_	12	SBJ	_	_
12	characterized	_	VBD	VBD	_	0	ROOT-S	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	5'-flanking	_	JJ	JJ	_	15	NMOD	_	_
15	region	_	NN	NN	_	12	OBJ	_	_
16	from	_	IN	IN	_	15	NMOD	_	_
17	nt	_	NN	NN	_	16	PMOD	_	_
18	-1609	_	CD	CD	_	17	NMOD	_	_
19	to	_	TO	TO	_	16	PMOD	_	_
20	+178	_	CD	CD	_	19	PMOD	_	_
21	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	-326	_	CD	CD	_	4	DEP	_	_
3	to	_	TO	TO	_	4	DEP	_	_
4	-615	_	CD	CD	_	5	NMOD	_	_
5	region	_	NN	NN	_	6	SBJ	_	_
6	contained	_	VBD	VBD	_	0	ROOT-S	_	_
7	positive	_	JJ	JJ	_	9	NMOD	_	_
8	regulatory	_	JJ	JJ	_	9	NMOD	_	_
9	elements	_	NNS	NNS	_	6	OBJ	_	_
10	.	_	.	.	_	6	P	_	_

1	Glucocorticoid-mediated	_	JJ	JJ	_	2	NMOD	_	_
2	inhibition	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	RANTES	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	3	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	human	_	JJ	JJ	_	9	NMOD	_	_
8	T	_	NN	NN	_	9	NMOD	_	_
9	lymphocytes	_	NNS	NNS	_	6	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	chemokine	_	NN	NN	_	3	NMOD	_	_
3	RANTES	_	NN	NN	_	4	SBJ	_	_
4	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	been	_	VBN	VBN	_	4	VC	_	_
6	implicated	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	pathogenesis	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	allergic	_	JJ	JJ	_	13	NMOD	_	_
12	inflammatory	_	JJ	JJ	_	13	NMOD	_	_
13	diseases	_	NNS	NNS	_	10	PMOD	_	_
14	including	_	VBG	VBG	_	13	NMOD	_	_
15	asthma	_	NN	NN	_	14	PMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	rhinitis	_	NN	NN	_	15	COORD	_	_
18	which	_	WDT	WDT	_	19	SBJ	_	_
19	are	_	VBP	VBP	_	15	NMOD	_	_
20	frequently	_	RB	RB	_	21	TMP	_	_
21	treated	_	VBN	VBN	_	19	VC	_	_
22	with	_	IN	IN	_	21	ADV	_	_
23	glucocorticoids	_	NNS	NNS	_	22	PMOD	_	_
24	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	observed	_	VBD	VBD	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	dexamethasone	_	NN	NN	_	6	SBJ	_	_
5	dramatically	_	RB	RB	_	6	ADV	_	_
6	inhibited	_	VBD	VBD	_	3	VMOD	_	_
7	RANTES	_	NN	NN	_	9	NMOD	_	_
8	mRNA	_	NN	NN	_	9	NMOD	_	_
9	expression	_	NN	NN	_	6	OBJ	_	_
10	dose	_	NN	NN	_	11	AMOD	_	_
11	dependently	_	RB	RB	_	6	ADV	_	_
12	in	_	IN	IN	_	6	ADV	_	_
13	anti-CD3	_	NN	NN	_	17	NMOD	_	_
14	activated	_	JJ	JJ	_	13	AMOD	_	_
15	Hut-78	_	NN	NN	_	17	NMOD	_	_
16	T	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	12	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	human	_	JJ	JJ	_	20	NMOD	_	_
20	PBMCs	_	NNS	NNS	_	17	COORD	_	_
21	.	_	.	.	_	2	P	_	_

1	Inhibition	_	NN	NN	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	RANTES	_	NNS	NNS	_	4	NMOD	_	_
4	expression	_	NN	NN	_	2	PMOD	_	_
5	did	_	VBD	VBD	_	0	ROOT-S	_	_
6	not	_	RB	RB	_	5	VMOD	_	_
7	appear	_	VB	VB	_	5	VC	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	be	_	VB	VB	_	7	OBJ	_	_
10	secondary	_	JJ	JJ	_	9	PRD	_	_
11	to	_	TO	TO	_	10	AMOD	_	_
12	IL-2	_	NN	NN	_	13	NMOD	_	_
13	inhibition	_	NN	NN	_	11	PMOD	_	_
14	and	_	CC	CC	_	5	CC	_	_
15	required	_	VBD	VBD	_	5	COORD	_	_
16	binding	_	VBG	VBG	_	15	OBJ	_	_
17	to	_	TO	TO	_	16	NMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	intracellular	_	JJ	JJ	_	21	NMOD	_	_
20	glucocorticoid	_	NN	NN	_	21	NMOD	_	_
21	receptor	_	NN	NN	_	17	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	down-regulation	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	RANTES	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	3	PMOD	_	_
6	by	_	IN	IN	_	2	NMOD	_	_
7	glucocorticoids	_	NNS	NNS	_	6	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	may	_	MD	MD	_	0	ROOT-S	_	_
12	directly	_	RB	RB	_	13	ADV	_	_
13	contribute	_	VB	VB	_	11	VC	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	efficacy	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	these	_	DT	DT	_	19	NMOD	_	_
19	agents	_	NNS	NNS	_	17	PMOD	_	_
20	in	_	IN	IN	_	16	NMOD	_	_
21	suppressing	_	VBG	VBG	_	20	PMOD	_	_
22	cellular	_	JJ	JJ	_	23	NMOD	_	_
23	infiltration	_	NN	NN	_	21	OBJ	_	_
24	and	_	CC	CC	_	14	CC	_	_
25	to	_	TO	TO	_	14	COORD	_	_
26	their	_	PRP$	PRP$	_	28	NMOD	_	_
27	anti-inflammatory	_	JJ	JJ	_	28	NMOD	_	_
28	properties	_	NNS	NNS	_	25	PMOD	_	_
29	.	_	.	.	_	11	P	_	_

1	Effects	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	glucocorticoids	_	NNS	NNS	_	2	PMOD	_	_
4	on	_	IN	IN	_	1	NMOD	_	_
5	lymphocyte	_	NN	NN	_	6	NMOD	_	_
6	activation	_	NN	NN	_	4	PMOD	_	_
7	in	_	IN	IN	_	1	NMOD	_	_
8	patients	_	NNS	NNS	_	7	PMOD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	steroid-sensitive	_	JJ	JJ	_	13	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	steroid-resistant	_	JJ	JJ	_	10	COORD	_	_
13	asthma	_	NN	NN	_	9	PMOD	_	_
14	.	_	.	.	_	1	P	_	_

1	BACKGROUND	_	NN	NN	_	4	VMOD	_	_
2	:	_	:	:	_	1	P	_	_
3	Glucocorticoids	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	important	_	JJ	JJ	_	6	NMOD	_	_
6	medications	_	NNS	NNS	_	4	PRD	_	_
7	used	_	VBN	VBN	_	6	NMOD	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	control	_	VB	VB	_	7	OBJ	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	airway	_	NN	NN	_	12	NMOD	_	_
12	inflammation	_	NN	NN	_	9	OBJ	_	_
13	associated	_	VBN	VBN	_	12	NMOD	_	_
14	with	_	IN	IN	_	13	ADV	_	_
15	asthma	_	NN	NN	_	14	PMOD	_	_
16	.	_	.	.	_	4	P	_	_

1	Synthetic	_	JJ	JJ	_	2	NMOD	_	_
2	glucocorticoids	_	NNS	NNS	_	3	SBJ	_	_
3	vary	_	VBP	VBP	_	0	ROOT-S	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	their	_	PRP$	PRP$	_	7	NMOD	_	_
6	binding	_	NN	NN	_	7	NMOD	_	_
7	affinity	_	NN	NN	_	4	PMOD	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	glucocorticoid	_	NN	NN	_	11	NMOD	_	_
11	receptor	_	NN	NN	_	8	PMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	GCR	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	.	_	.	.	_	3	P	_	_

1	METHODS	_	NNS	NNS	_	4	VMOD	_	_
2	:	_	:	:	_	1	P	_	_
3	We	_	PRP	PRP	_	4	SBJ	_	_
4	compared	_	VBD	VBD	_	0	ROOT-S	_	_
5	hydrocortisone	_	NN	NN	_	4	OBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	beclomethasone	_	NN	NN	_	8	NMOD	_	_
8	dipropionate	_	NN	NN	_	5	COORD	_	_
9	,	_	,	,	_	5	P	_	_
10	triamcinolone	_	NN	NN	_	11	NMOD	_	_
11	acetonide	_	NN	NN	_	5	COORD	_	_
12	,	_	,	,	_	5	P	_	_
13	flunisolide	_	NN	NN	_	5	COORD	_	_
14	,	_	,	,	_	5	P	_	_
15	and	_	CC	CC	_	5	CC	_	_
16	budesonide	_	NN	NN	_	5	COORD	_	_
17	with	_	IN	IN	_	4	ADV	_	_
18	regard	_	NN	NN	_	17	PMOD	_	_
19	to	_	TO	TO	_	18	NMOD	_	_
20	their	_	PRP$	PRP$	_	21	NMOD	_	_
21	capacity	_	NN	NN	_	19	PMOD	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	inhibit	_	VB	VB	_	21	NMOD	_	_
24	phytohemagglutinin-induced	_	JJ	JJ	_	29	NMOD	_	_
25	peripheral	_	JJ	JJ	_	29	NMOD	_	_
26	blood	_	NN	NN	_	29	NMOD	_	_
27	mononuclear	_	JJ	JJ	_	29	NMOD	_	_
28	cell	_	NN	NN	_	29	NMOD	_	_
29	proliferation	_	NN	NN	_	23	OBJ	_	_
30	from	_	IN	IN	_	5	NMOD	_	_
31	six	_	CD	CD	_	32	NMOD	_	_
32	patients	_	NNS	NNS	_	30	PMOD	_	_
33	with	_	IN	IN	_	32	NMOD	_	_
34	steroid-sensitive	_	JJ	JJ	_	35	NMOD	_	_
35	asthma	_	NN	NN	_	33	PMOD	_	_
36	and	_	CC	CC	_	32	CC	_	_
37	seven	_	CD	CD	_	38	NMOD	_	_
38	patients	_	NNS	NNS	_	32	COORD	_	_
39	with	_	IN	IN	_	38	NMOD	_	_
40	steroid-resistant	_	JJ	JJ	_	41	NMOD	_	_
41	asthma	_	NN	NN	_	39	PMOD	_	_
42	.	_	.	.	_	4	P	_	_

1	Peripheral	_	JJ	JJ	_	7	NMOD	_	_
2	blood	_	NN	NN	_	7	NMOD	_	_
3	mononuclear	_	JJ	JJ	_	7	NMOD	_	_
4	cell	_	NN	NN	_	7	NMOD	_	_
5	GCR	_	NN	NN	_	7	NMOD	_	_
6	binding	_	NN	NN	_	7	NMOD	_	_
7	affinities	_	NNS	NNS	_	12	SBJ	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	dexamethasone	_	NN	NN	_	8	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	budesonide	_	NN	NN	_	9	COORD	_	_
12	were	_	VBD	VBD	_	0	ROOT-S	_	_
13	also	_	RB	RB	_	14	ADV	_	_
14	determined	_	VBN	VBN	_	12	VC	_	_
15	for	_	IN	IN	_	14	ADV	_	_
16	both	_	DT	DT	_	18	NMOD	_	_
17	patient	_	NN	NN	_	18	NMOD	_	_
18	groups	_	NNS	NNS	_	15	PMOD	_	_
19	by	_	IN	IN	_	14	ADV	_	_
20	using	_	VBG	VBG	_	19	PMOD	_	_
21	a	_	DT	DT	_	24	NMOD	_	_
22	radioligand	_	NN	NN	_	24	NMOD	_	_
23	binding	_	NN	NN	_	24	NMOD	_	_
24	assay	_	NN	NN	_	20	OBJ	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	Scatchard	_	NN	NN	_	27	NMOD	_	_
27	analysis	_	NN	NN	_	24	COORD	_	_
28	.	_	.	.	_	12	P	_	_

1	RESULTS	_	NNS	NNS	_	5	VMOD	_	_
2	:	_	:	:	_	1	P	_	_
3	Dose-dependent	_	JJ	JJ	_	4	NMOD	_	_
4	inhibition	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	demonstrated	_	VBN	VBN	_	5	VC	_	_
7	for	_	IN	IN	_	6	ADV	_	_
8	all	_	DT	DT	_	9	NMOD	_	_
9	glucocorticoids	_	NNS	NNS	_	7	PMOD	_	_
10	in	_	IN	IN	_	6	ADV	_	_
11	both	_	DT	DT	_	13	NMOD	_	_
12	patient	_	NN	NN	_	13	NMOD	_	_
13	groups	_	NNS	NNS	_	10	PMOD	_	_
14	,	_	,	,	_	6	P	_	_
15	with	_	IN	IN	_	6	ADV	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	steroid-resistant	_	JJ	JJ	_	18	NMOD	_	_
18	group	_	NN	NN	_	19	SBJ	_	_
19	requiring	_	VBG	VBG	_	15	PMOD	_	_
20	approximately	_	RB	RB	_	22	DEP	_	_
21	2	_	CD	CD	_	22	DEP	_	_
22	log-fold	_	JJ	JJ	_	24	NMOD	_	_
23	more	_	JJR	JJR	_	22	DEP	_	_
24	glucocorticoids	_	NNS	NNS	_	19	OBJ	_	_
25	for	_	IN	IN	_	19	ADV	_	_
26	an	_	DT	DT	_	28	NMOD	_	_
27	equivalent	_	JJ	JJ	_	28	NMOD	_	_
28	degree	_	NN	NN	_	25	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	inhibition	_	NN	NN	_	29	PMOD	_	_
31	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	mean	_	NN	NN	_	3	NMOD	_	_
3	concentrations	_	NNS	NNS	_	20	SBJ	_	_
4	necessary	_	JJ	JJ	_	3	NMOD	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	cause	_	VB	VB	_	4	AMOD	_	_
7	50	_	CD	CD	_	9	NMOD	_	_
8	%	_	NN	NN	_	9	NMOD	_	_
9	inhibition	_	NN	NN	_	6	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	lymphocyte	_	NN	NN	_	12	NMOD	_	_
12	proliferation	_	NN	NN	_	10	PMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	IC50s	_	NNS	NNS	_	9	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	for	_	IN	IN	_	6	ADV	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	steroid-sensitive	_	JJ	JJ	_	19	NMOD	_	_
19	group	_	NN	NN	_	16	PMOD	_	_
20	ranged	_	VBD	VBD	_	0	ROOT-S	_	_
21	from	_	IN	IN	_	20	ADV	_	_
22	2	_	CD	CD	_	25	NMOD	_	_
23	x	_	CC	CC	_	22	CC	_	_
24	10-LRB--10-RRB-	_	CD	CD	_	22	COORD	_	_
25	mol\/L	_	NN	NN	_	21	PMOD	_	_
26	for	_	IN	IN	_	25	NMOD	_	_
27	budesonide	_	NN	NN	_	26	PMOD	_	_
28	to	_	TO	TO	_	21	PMOD	_	_
29	7	_	CD	CD	_	32	NMOD	_	_
30	x	_	CC	CC	_	29	CC	_	_
31	10-LRB--8-RRB-	_	CD	CD	_	29	COORD	_	_
32	mol\/L	_	NN	NN	_	28	PMOD	_	_
33	for	_	IN	IN	_	32	NMOD	_	_
34	hydrocortisone	_	NN	NN	_	33	PMOD	_	_
35	,	_	,	,	_	20	P	_	_
36	whereas	_	IN	IN	_	20	COORD	_	_
37	the	_	DT	DT	_	39	NMOD	_	_
38	mean	_	NN	NN	_	39	NMOD	_	_
39	IC50s	_	NNS	NNS	_	44	SBJ	_	_
40	for	_	IN	IN	_	39	NMOD	_	_
41	the	_	DT	DT	_	43	NMOD	_	_
42	steroid-resistant	_	JJ	JJ	_	43	NMOD	_	_
43	group	_	NN	NN	_	40	PMOD	_	_
44	ranged	_	VBD	VBD	_	20	COORD	_	_
45	from	_	IN	IN	_	44	ADV	_	_
46	approximately	_	RB	RB	_	50	NMOD	_	_
47	2	_	CD	CD	_	46	COORD	_	_
48	x	_	CC	CC	_	46	CC	_	_
49	10-LRB--8-RRB-	_	CD	CD	_	46	COORD	_	_
50	mol\/L	_	NN	NN	_	45	PMOD	_	_
51	for	_	IN	IN	_	50	NMOD	_	_
52	budesonide	_	NN	NN	_	51	PMOD	_	_
53	to	_	TO	TO	_	45	PMOD	_	_
54	greater	_	JJR	JJR	_	56	DEP	_	_
55	than	_	IN	IN	_	56	DEP	_	_
56	10-LRB--6-RRB-	_	CD	CD	_	57	NMOD	_	_
57	mol\/L	_	NN	NN	_	53	PMOD	_	_
58	for	_	IN	IN	_	57	NMOD	_	_
59	hydrocortisone	_	NN	NN	_	58	PMOD	_	_
60	.	_	.	.	_	20	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	7	P	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	significant	_	JJ	JJ	_	6	NMOD	_	_
6	correlation	_	NN	NN	_	7	SBJ	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	noted	_	VBN	VBN	_	7	VC	_	_
9	between	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	degree	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	inhibition	_	NN	NN	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	lymphocyte	_	NN	NN	_	16	NMOD	_	_
16	proliferation	_	NN	NN	_	14	PMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	IC50	_	NN	NN	_	13	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	and	_	CC	CC	_	11	CC	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	binding	_	NN	NN	_	23	NMOD	_	_
23	affinity	_	NN	NN	_	11	COORD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	dexamethasone	_	NN	NN	_	24	PMOD	_	_
26	to	_	TO	TO	_	23	NMOD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	GCR	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	7	P	_	_

1	Patients	_	NNS	NNS	_	5	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	steroid-resistant	_	JJ	JJ	_	4	NMOD	_	_
4	asthma	_	NN	NN	_	2	PMOD	_	_
5	have	_	VBP	VBP	_	0	ROOT-S	_	_
6	been	_	VBN	VBN	_	5	VC	_	_
7	shown	_	VBN	VBN	_	6	VC	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	have	_	VB	VB	_	7	OBJ	_	_
10	a	_	DT	DT	_	14	NMOD	_	_
11	reduced	_	VBN	VBN	_	14	NMOD	_	_
12	GCR	_	NN	NN	_	14	NMOD	_	_
13	binding	_	NN	NN	_	14	NMOD	_	_
14	affinity	_	NN	NN	_	9	OBJ	_	_
15	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	GCR	_	NN	NN	_	4	NMOD	_	_
3	binding	_	NN	NN	_	4	NMOD	_	_
4	affinity	_	NN	NN	_	7	SBJ	_	_
5	for	_	IN	IN	_	4	NMOD	_	_
6	budesonide	_	NN	NN	_	5	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	significantly	_	RB	RB	_	9	AMOD	_	_
9	higher	_	JJR	JJR	_	7	PRD	_	_
10	in	_	IN	IN	_	7	ADV	_	_
11	both	_	DT	DT	_	12	NMOD	_	_
12	groups	_	NNS	NNS	_	10	PMOD	_	_
13	(	_	(	(	_	18	P	_	_
14	i.e.	_	FW	FW	_	18	NMOD	_	_
15	,	_	,	,	_	18	P	_	_
16	lower	_	JJR	JJR	_	18	NMOD	_	_
17	dissociation	_	NN	NN	_	18	NMOD	_	_
18	constant	_	NN	NN	_	7	VMOD	_	_
19	)	_	)	)	_	18	P	_	_
20	than	_	IN	IN	_	9	AMOD	_	_
21	that	_	DT	DT	_	20	PMOD	_	_
22	obtained	_	VBN	VBN	_	21	NMOD	_	_
23	for	_	IN	IN	_	22	ADV	_	_
24	dexamethasone	_	NN	NN	_	23	PMOD	_	_
25	.	_	.	.	_	7	P	_	_

1	CONCLUSION	_	NN	NN	_	5	VMOD	_	_
2	:	_	:	:	_	1	P	_	_
3	These	_	DT	DT	_	4	NMOD	_	_
4	data	_	NNS	NNS	_	5	SBJ	_	_
5	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	glucocorticoids	_	NNS	NNS	_	28	SBJ	_	_
8	such	_	JJ	JJ	_	9	DEP	_	_
9	as	_	IN	IN	_	7	NMOD	_	_
10	budesonide	_	NN	NN	_	9	PMOD	_	_
11	,	_	,	,	_	28	P	_	_
12	by	_	IN	IN	_	28	ADV	_	_
13	virtue	_	NN	NN	_	12	DEP	_	_
14	of	_	IN	IN	_	12	DEP	_	_
15	their	_	PRP$	PRP$	_	19	NMOD	_	_
16	high	_	JJ	JJ	_	19	NMOD	_	_
17	GCR	_	NN	NN	_	19	NMOD	_	_
18	binding	_	NN	NN	_	19	NMOD	_	_
19	affinities	_	NNS	NNS	_	12	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	greater	_	JJR	JJR	_	22	NMOD	_	_
22	ability	_	NN	NN	_	19	COORD	_	_
23	to	_	TO	TO	_	24	VMOD	_	_
24	suppress	_	VB	VB	_	22	NMOD	_	_
25	lymphocyte	_	NN	NN	_	26	NMOD	_	_
26	proliferation	_	NN	NN	_	24	OBJ	_	_
27	,	_	,	,	_	28	P	_	_
28	may	_	MD	MD	_	6	VMOD	_	_
29	therefore	_	RB	RB	_	28	ADV	_	_
30	be	_	VB	VB	_	28	VC	_	_
31	beneficial	_	JJ	JJ	_	30	PRD	_	_
32	in	_	IN	IN	_	30	ADV	_	_
33	the	_	DT	DT	_	34	NMOD	_	_
34	management	_	NN	NN	_	32	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	difficult-to-control	_	JJ	JJ	_	37	NMOD	_	_
37	asthma	_	NN	NN	_	35	PMOD	_	_
38	.	_	.	.	_	5	P	_	_

1	Involvement	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	nuclear	_	JJ	JJ	_	6	NMOD	_	_
4	factor-kappa	_	NN	NN	_	6	NMOD	_	_
5	B	_	NN	NN	_	6	NMOD	_	_
6	activation	_	NN	NN	_	2	PMOD	_	_
7	in	_	IN	IN	_	1	NMOD	_	_
8	IgE	_	NN	NN	_	9	NMOD	_	_
9	synthesis	_	NN	NN	_	7	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	human	_	JJ	JJ	_	13	NMOD	_	_
12	B	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	10	PMOD	_	_
14	.	_	.	.	_	1	P	_	_

1	Nuclear	_	JJ	JJ	_	3	NMOD	_	_
2	factor-kappa	_	NN	NN	_	3	NMOD	_	_
3	B	_	NN	NN	_	8	SBJ	_	_
4	(	_	(	(	_	6	P	_	_
5	NF-kappa	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	3	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	transcription	_	NN	NN	_	11	NMOD	_	_
11	factor	_	NN	NN	_	8	PRD	_	_
12	that	_	WDT	WDT	_	13	SBJ	_	_
13	binds	_	VBZ	VBZ	_	11	NMOD	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	consensus	_	NN	NN	_	18	NMOD	_	_
17	DNA	_	NN	NN	_	18	NMOD	_	_
18	sequence	_	NN	NN	_	14	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	cis-acting	_	JJ	JJ	_	22	NMOD	_	_
22	elements	_	NNS	NNS	_	19	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	various	_	JJ	JJ	_	25	NMOD	_	_
25	genes	_	NNS	NNS	_	23	PMOD	_	_
26	.	_	.	.	_	8	P	_	_

1	Although	_	IN	IN	_	18	ADV	_	_
2	NF-kappa	_	NN	NN	_	3	NMOD	_	_
3	B	_	NN	NN	_	4	SBJ	_	_
4	activates	_	VBZ	VBZ	_	1	VMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	expression	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	many	_	JJ	JJ	_	9	NMOD	_	_
9	genes	_	NNS	NNS	_	7	PMOD	_	_
10	involved	_	VBN	VBN	_	9	NMOD	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	immune	_	JJ	JJ	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	inflammatory	_	JJ	JJ	_	12	COORD	_	_
15	responses	_	NNS	NNS	_	11	PMOD	_	_
16	,	_	,	,	_	18	P	_	_
17	little	_	JJ	JJ	_	18	SBJ	_	_
18	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
19	known	_	VBN	VBN	_	18	VC	_	_
20	about	_	IN	IN	_	19	ADV	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	role	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	NF-kappa	_	NN	NN	_	26	NMOD	_	_
25	B	_	NN	NN	_	26	NMOD	_	_
26	activation	_	NN	NN	_	23	PMOD	_	_
27	in	_	IN	IN	_	22	NMOD	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	induction	_	NN	NN	_	27	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	IgE	_	NN	NN	_	32	NMOD	_	_
32	synthesis	_	NN	NN	_	30	PMOD	_	_
33	in	_	IN	IN	_	29	NMOD	_	_
34	human	_	JJ	JJ	_	36	NMOD	_	_
35	B	_	NN	NN	_	36	NMOD	_	_
36	cells	_	NNS	NNS	_	33	PMOD	_	_
37	.	_	.	.	_	18	P	_	_

1	Therefore	_	RB	RB	_	4	ADV	_	_
2	we	_	PRP	PRP	_	4	SBJ	_	_
3	first	_	RB	RB	_	4	TMP	_	_
4	examined	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	participation	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	NF-kappa	_	NN	NN	_	9	NMOD	_	_
9	B	_	NN	NN	_	7	PMOD	_	_
10	in	_	IN	IN	_	6	NMOD	_	_
11	germline	_	NN	NN	_	14	NMOD	_	_
12	C	_	NN	NN	_	14	NMOD	_	_
13	epsilon	_	NN	NN	_	14	NMOD	_	_
14	transcription	_	NN	NN	_	10	PMOD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	a	_	DT	DT	_	22	NMOD	_	_
17	human	_	JJ	JJ	_	22	NMOD	_	_
18	Burkitt	_	NN	NN	_	22	NMOD	_	_
19	lymphoma	_	NN	NN	_	22	NMOD	_	_
20	B	_	NN	NN	_	22	NMOD	_	_
21	cell	_	NN	NN	_	22	NMOD	_	_
22	line	_	NN	NN	_	15	PMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	DND39	_	NN	NN	_	22	NMOD	_	_
25	.	_	.	.	_	4	P	_	_

1	Stimulation	_	NN	NN	_	14	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	DND39	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	IL-4	_	NN	NN	_	5	PMOD	_	_
7	or	_	CC	CC	_	6	CC	_	_
8	anti-CD40	_	JJ	JJ	_	10	NMOD	_	_
9	monoclonal	_	JJ	JJ	_	10	NMOD	_	_
10	antibody	_	NN	NN	_	6	COORD	_	_
11	(	_	(	(	_	12	P	_	_
12	mAb	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	activated	_	VBD	VBD	_	0	ROOT-S	_	_
15	phosphatidylinositol	_	NN	NN	_	16	NMOD	_	_
16	3-kinase	_	NN	NN	_	14	OBJ	_	_
17	and	_	CC	CC	_	14	CC	_	_
18	subsequently	_	RB	RB	_	19	ADV	_	_
19	induced	_	VBD	VBD	_	14	COORD	_	_
20	nuclear	_	JJ	JJ	_	21	NMOD	_	_
21	expression	_	NN	NN	_	19	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	NF-kappa	_	NN	NN	_	24	NMOD	_	_
24	B	_	NN	NN	_	22	PMOD	_	_
25	,	_	,	,	_	21	P	_	_
26	which	_	WDT	WDT	_	27	SBJ	_	_
27	was	_	VBD	VBD	_	21	NMOD	_	_
28	identified	_	VBN	VBN	_	27	VC	_	_
29	by	_	IN	IN	_	28	LGS	_	_
30	electrophoretic	_	JJ	JJ	_	33	NMOD	_	_
31	mobility	_	NN	NN	_	33	NMOD	_	_
32	shift	_	NN	NN	_	33	NMOD	_	_
33	assays	_	NNS	NNS	_	29	PMOD	_	_
34	.	_	.	.	_	14	P	_	_

1	n-Acetyl-L-cysteine	_	NN	NN	_	10	SBJ	_	_
2	(	_	(	(	_	3	P	_	_
3	NAC	_	NN	NN	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	,	_	,	,	_	1	P	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	potent	_	JJ	JJ	_	8	NMOD	_	_
8	antioxidant	_	NN	NN	_	1	NMOD	_	_
9	,	_	,	,	_	1	P	_	_
10	blocked	_	VBD	VBD	_	0	ROOT-S	_	_
11	NF-kappa	_	NN	NN	_	13	NMOD	_	_
12	B	_	NN	NN	_	13	NMOD	_	_
13	activation	_	NN	NN	_	10	OBJ	_	_
14	caused	_	VBN	VBN	_	13	NMOD	_	_
15	by	_	IN	IN	_	14	ADV	_	_
16	IL-4	_	NN	NN	_	15	PMOD	_	_
17	and	_	CC	CC	_	15	CC	_	_
18	by	_	IN	IN	_	15	LGS	_	_
19	anti-CD40	_	JJ	JJ	_	20	NMOD	_	_
20	mAb	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	10	P	_	_

1	Although	_	IN	IN	_	18	ADV	_	_
2	inhibition	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	IL-4-driven	_	JJ	JJ	_	8	NMOD	_	_
5	germline	_	NN	NN	_	8	NMOD	_	_
6	C	_	NN	NN	_	8	NMOD	_	_
7	epsilon	_	NN	NN	_	8	NMOD	_	_
8	transcription	_	NN	NN	_	3	PMOD	_	_
9	by	_	IN	IN	_	2	NMOD	_	_
10	NAC	_	NN	NN	_	9	PMOD	_	_
11	was	_	VBD	VBD	_	1	VMOD	_	_
12	not	_	RB	RB	_	11	VMOD	_	_
13	sufficient	_	JJ	JJ	_	11	PRD	_	_
14	,	_	,	,	_	18	P	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	agent	_	NN	NN	_	18	SBJ	_	_
17	remarkably	_	RB	RB	_	18	ADV	_	_
18	diminished	_	VBD	VBD	_	0	ROOT-S	_	_
19	anti-CD40	_	JJ	JJ	_	20	AMOD	_	_
20	mAb-mediated	_	JJ	JJ	_	21	NMOD	_	_
21	up-regulation	_	NN	NN	_	18	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	germline	_	NN	NN	_	26	NMOD	_	_
24	C	_	NN	NN	_	26	NMOD	_	_
25	epsilon	_	NN	NN	_	26	NMOD	_	_
26	transcription	_	NN	NN	_	22	PMOD	_	_
27	.	_	.	.	_	18	P	_	_

1	Second	_	RB	RB	_	4	TMP	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	studied	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	effect	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	NAC	_	NN	NN	_	7	PMOD	_	_
9	on	_	IN	IN	_	6	NMOD	_	_
10	IgE	_	NN	NN	_	11	NMOD	_	_
11	synthesis	_	NN	NN	_	9	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	human	_	JJ	JJ	_	16	NMOD	_	_
14	normal	_	JJ	JJ	_	16	NMOD	_	_
15	B	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	12	PMOD	_	_
17	costimulated	_	VBN	VBN	_	16	NMOD	_	_
18	with	_	IN	IN	_	17	ADV	_	_
19	IL-4	_	NN	NN	_	18	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	anti-CD40	_	JJ	JJ	_	22	NMOD	_	_
22	mAb	_	NN	NN	_	19	COORD	_	_
23	.	_	.	.	_	4	P	_	_

1	NAC	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	effective	_	JJ	JJ	_	2	PRD	_	_
4	in	_	IN	IN	_	2	ADV	_	_
5	inhibiting	_	VBG	VBG	_	4	PMOD	_	_
6	mature	_	JJ	JJ	_	9	NMOD	_	_
7	C	_	NN	NN	_	9	NMOD	_	_
8	epsilon	_	NN	NN	_	9	NMOD	_	_
9	transcription	_	NN	NN	_	5	OBJ	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	IgE	_	NN	NN	_	12	NMOD	_	_
12	synthesis	_	NN	NN	_	9	COORD	_	_
13	in	_	IN	IN	_	9	NMOD	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	T	_	NN	NN	_	18	NMOD	_	_
16	cell-independent	_	JJ	JJ	_	15	AMOD	_	_
17	culture	_	NN	NN	_	18	NMOD	_	_
18	system	_	NN	NN	_	13	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	However	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	NAC	_	NN	NN	_	4	SBJ	_	_
4	did	_	VBD	VBD	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	significantly	_	RB	RB	_	4	ADV	_	_
7	affect	_	VB	VB	_	4	VC	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	spontaneous	_	JJ	JJ	_	10	NMOD	_	_
10	production	_	NN	NN	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	IgE	_	NN	NN	_	11	PMOD	_	_
13	by	_	IN	IN	_	10	NMOD	_	_
14	atopic	_	JJ	JJ	_	16	NMOD	_	_
15	B	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	13	PMOD	_	_
17	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	NF-kappa	_	NN	NN	_	7	NMOD	_	_
6	B	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	8	SBJ	_	_
8	is	_	VBZ	VBZ	_	4	VMOD	_	_
9	commonly	_	RB	RB	_	8	ADV	_	_
10	inducible	_	JJ	JJ	_	8	PRD	_	_
11	in	_	IN	IN	_	8	ADV	_	_
12	DND39	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	by	_	IN	IN	_	10	AMOD	_	_
15	IL-4	_	NN	NN	_	14	PMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	anti-CD40	_	JJ	JJ	_	18	NMOD	_	_
18	mAb	_	NN	NN	_	15	COORD	_	_
19	and	_	CC	CC	_	3	CC	_	_
20	suggest	_	VBP	VBP	_	3	COORD	_	_
21	that	_	IN	IN	_	20	OBJ	_	_
22	NF-kappa	_	NN	NN	_	23	NMOD	_	_
23	B	_	NN	NN	_	27	SBJ	_	_
24	sensitive	_	JJ	JJ	_	23	NMOD	_	_
25	to	_	TO	TO	_	24	AMOD	_	_
26	NAC	_	NN	NN	_	25	PMOD	_	_
27	may	_	MD	MD	_	21	VMOD	_	_
28	play	_	VB	VB	_	27	VC	_	_
29	a	_	DT	DT	_	30	NMOD	_	_
30	role	_	NN	NN	_	28	OBJ	_	_
31	in	_	IN	IN	_	28	ADV	_	_
32	regulating	_	VBG	VBG	_	31	PMOD	_	_
33	IgE	_	NN	NN	_	34	NMOD	_	_
34	synthesis	_	NN	NN	_	32	OBJ	_	_
35	in	_	IN	IN	_	34	NMOD	_	_
36	B	_	NN	NN	_	37	NMOD	_	_
37	cells	_	NNS	NNS	_	35	PMOD	_	_
38	.	_	.	.	_	3	P	_	_

1	{	_	(	(	_	3	P	_	_
2	Molecular	_	JJ	JJ	_	3	NMOD	_	_
3	mechanisms	_	NNS	NNS	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	age-related	_	JJ	JJ	_	7	NMOD	_	_
6	lymphocyte	_	NN	NN	_	7	NMOD	_	_
7	dysfunction	_	NN	NN	_	4	PMOD	_	_
8	}	_	)	)	_	3	P	_	_

1	Aging	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	classically	_	RB	RB	_	2	ADV	_	_
4	accompanied	_	VBN	VBN	_	2	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	dysregulation	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	immunologic	_	JJ	JJ	_	11	NMOD	_	_
11	machinery	_	NN	NN	_	8	PMOD	_	_
12	.	_	.	.	_	2	P	_	_

1	As	_	IN	IN	_	12	ADV	_	_
2	a	_	DT	DT	_	3	NMOD	_	_
3	consequence	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	12	P	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	immune	_	JJ	JJ	_	7	NMOD	_	_
7	response	_	NN	NN	_	12	SBJ	_	_
8	developed	_	VBN	VBN	_	7	NMOD	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	senescent	_	JJ	JJ	_	11	NMOD	_	_
11	organisms	_	NNS	NNS	_	9	PMOD	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	usually	_	RB	RB	_	12	TMP	_	_
14	inappropriate	_	JJ	JJ	_	12	PRD	_	_
15	,	_	,	,	_	12	P	_	_
16	often	_	RB	RB	_	13	GAP	_	_
17	inefficient	_	JJ	JJ	_	14	GAP	_	_
18	,	_	,	,	_	12	P	_	_
19	sometimes	_	RB	RB	_	13	GAP	_	_
20	aberrant	_	JJ	JJ	_	14	GAP	_	_
21	,	_	,	,	_	12	P	_	_
22	and	_	CC	CC	_	12	CC	_	_
23	potentially	_	RB	RB	_	13	GAP	_	_
24	detrimental	_	JJ	JJ	_	14	GAP	_	_
25	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	age-associated	_	JJ	JJ	_	4	NMOD	_	_
3	immune	_	JJ	JJ	_	4	NMOD	_	_
4	dysfunction	_	NN	NN	_	5	SBJ	_	_
5	may	_	MD	MD	_	0	ROOT-S	_	_
6	be	_	VB	VB	_	5	VC	_	_
7	implicated	_	VBN	VBN	_	6	VC	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	some	_	DT	DT	_	10	NMOD	_	_
10	degree	_	NN	NN	_	8	PMOD	_	_
11	in	_	IN	IN	_	7	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	extreme	_	JJ	JJ	_	14	NMOD	_	_
14	susceptibility	_	NN	NN	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	elderly	_	JJ	JJ	_	15	PMOD	_	_
18	to	_	TO	TO	_	14	NMOD	_	_
19	infection	_	NN	NN	_	18	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	neoplasia	_	NN	NN	_	19	COORD	_	_
22	and	_	CC	CC	_	5	CC	_	_
23	may	_	MD	MD	_	5	COORD	_	_
24	even	_	RB	RB	_	23	ADV	_	_
25	participate	_	VB	VB	_	23	VC	_	_
26	in	_	IN	IN	_	25	ADV	_	_
27	various	_	JJ	JJ	_	28	NMOD	_	_
28	aspects	_	NNS	NNS	_	26	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	senescence	_	NN	NN	_	29	PMOD	_	_
31	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	current	_	JJ	JJ	_	3	NMOD	_	_
3	understanding	_	NN	NN	_	10	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	molecular	_	JJ	JJ	_	7	NMOD	_	_
7	mechanisms	_	NNS	NNS	_	4	PMOD	_	_
8	underlying	_	VBG	VBG	_	7	NMOD	_	_
9	immunosenescence	_	NN	NN	_	8	OBJ	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	still	_	RB	RB	_	10	ADV	_	_
12	fragmentary	_	JJ	JJ	_	10	PRD	_	_
13	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	most	_	RBS	RBS	_	3	AMOD	_	_
3	extensively	_	RB	RB	_	5	NMOD	_	_
4	studied	_	VBN	VBN	_	3	AMOD	_	_
5	phenomenon	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	progressive	_	JJ	JJ	_	9	NMOD	_	_
9	decline	_	NN	NN	_	6	PRD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	proliferative	_	JJ	JJ	_	13	NMOD	_	_
13	capacities	_	NNS	NNS	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	lymphocytes	_	NNS	NNS	_	14	PMOD	_	_
17	with	_	IN	IN	_	9	NMOD	_	_
18	aging	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	loss	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	proliferative	_	JJ	JJ	_	5	NMOD	_	_
5	potential	_	NN	NN	_	3	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	response	_	NN	NN	_	6	DEP	_	_
8	to	_	TO	TO	_	6	DEP	_	_
9	antigenic	_	JJ	JJ	_	10	NMOD	_	_
10	challenge	_	NN	NN	_	6	PMOD	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	characteristic	_	JJ	JJ	_	14	NMOD	_	_
14	feature	_	NN	NN	_	11	PRD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	immune	_	JJ	JJ	_	17	NMOD	_	_
17	senescence	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	11	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	directly	_	RB	RB	_	2	ADV	_	_
4	implicated	_	VBN	VBN	_	2	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	emergence	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	age-related	_	JJ	JJ	_	12	NMOD	_	_
11	immune	_	JJ	JJ	_	12	NMOD	_	_
12	deficiency	_	NN	NN	_	8	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	purpose	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	this	_	DT	DT	_	5	NMOD	_	_
5	review	_	NN	NN	_	3	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	show	_	VB	VB	_	6	PRD	_	_
9	how	_	WRB	WRB	_	19	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	accumulation	_	NN	NN	_	19	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	various	_	JJ	JJ	_	15	NMOD	_	_
14	biochemical	_	JJ	JJ	_	15	NMOD	_	_
15	lesions	_	NNS	NNS	_	12	PMOD	_	_
16	with	_	IN	IN	_	11	NMOD	_	_
17	advancing	_	VBG	VBG	_	18	NMOD	_	_
18	age	_	NN	NN	_	16	PMOD	_	_
19	leads	_	VBZ	VBZ	_	8	OBJ	_	_
20	to	_	TO	TO	_	19	ADV	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	failure	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	a	_	DT	DT	_	27	NMOD	_	_
25	critical	_	JJ	JJ	_	27	NMOD	_	_
26	cell	_	NN	NN	_	27	NMOD	_	_
27	function	_	NN	NN	_	23	PMOD	_	_
28	,	_	,	,	_	27	P	_	_
29	namely	_	RB	RB	_	27	NMOD	_	_
30	the	_	DT	DT	_	33	NMOD	_	_
31	activation-induced	_	JJ	JJ	_	33	NMOD	_	_
32	lymphocyte	_	NN	NN	_	33	NMOD	_	_
33	proliferation	_	NN	NN	_	27	NMOD	_	_
34	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	biochemical	_	JJ	JJ	_	3	NMOD	_	_
3	modifications	_	NNS	NNS	_	16	SBJ	_	_
4	responsible	_	JJ	JJ	_	3	NMOD	_	_
5	for	_	IN	IN	_	4	AMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	defect	_	NN	NN	_	5	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	transduction	_	NN	NN	_	8	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	execution	_	NN	NN	_	9	COORD	_	_
12	of	_	IN	IN	_	9	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	proliferative	_	JJ	JJ	_	15	NMOD	_	_
15	signal	_	NN	NN	_	12	PMOD	_	_
16	are	_	VBP	VBP	_	0	ROOT-S	_	_
17	analyzed	_	VBN	VBN	_	16	VC	_	_
18	as	_	IN	IN	_	17	ADV	_	_
19	a	_	DT	DT	_	20	NMOD	_	_
20	function	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	age	_	NN	NN	_	21	PMOD	_	_
23	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	multiple	_	JJ	JJ	_	3	NMOD	_	_
3	alterations	_	NNS	NNS	_	10	SBJ	_	_
4	observed	_	VBN	VBN	_	3	NMOD	_	_
5	on	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	various	_	JJ	JJ	_	9	NMOD	_	_
8	biochemical	_	JJ	JJ	_	9	NMOD	_	_
9	pathways	_	NNS	NNS	_	5	PMOD	_	_
10	may	_	MD	MD	_	0	ROOT-S	_	_
11	appear	_	VB	VB	_	10	VC	_	_
12	as	_	IN	IN	_	11	ADV	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	consequence	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	a	_	DT	DT	_	19	NMOD	_	_
17	unique	_	JJ	JJ	_	19	NMOD	_	_
18	deleterious	_	JJ	JJ	_	19	NMOD	_	_
19	mechanism	_	NN	NN	_	15	PMOD	_	_
20	more	_	RBR	RBR	_	21	AMOD	_	_
21	fundamentally	_	RB	RB	_	19	NMOD	_	_
22	related	_	JJ	JJ	_	21	AMOD	_	_
23	to	_	TO	TO	_	21	AMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	process	_	NN	NN	_	23	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	senescence	_	NN	NN	_	26	PMOD	_	_
28	such	_	JJ	JJ	_	29	DEP	_	_
29	as	_	IN	IN	_	27	NMOD	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	inability	_	NN	NN	_	29	PMOD	_	_
32	to	_	TO	TO	_	33	VMOD	_	_
33	cope	_	VB	VB	_	31	NMOD	_	_
34	with	_	IN	IN	_	33	ADV	_	_
35	oxidative	_	JJ	JJ	_	36	NMOD	_	_
36	stress	_	NN	NN	_	34	PMOD	_	_
37	.	_	.	.	_	10	P	_	_

1	Sequence	_	NN	NN	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	0	ROOT-FRAG	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	expression	_	NN	NN	_	2	COORD	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	cultured	_	VBN	VBN	_	7	NMOD	_	_
7	lymphocytes	_	NNS	NNS	_	5	PMOD	_	_
8	of	_	IN	IN	_	2	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	FOSB	_	NN	NN	_	12	NMOD	_	_
12	gene	_	NN	NN	_	8	PMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	G0S3	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	.	_	.	.	_	2	P	_	_

1	G0S3	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	member	_	NN	NN	_	2	PRD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	set	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	putative	_	JJ	JJ	_	13	NMOD	_	_
10	G0\/G1	_	NN	NN	_	13	NMOD	_	_
11	switch	_	NN	NN	_	13	NMOD	_	_
12	regulatory	_	JJ	JJ	_	13	NMOD	_	_
13	genes	_	NNS	NNS	_	8	PMOD	_	_
14	(	_	(	(	_	16	P	_	_
15	G0S	_	NN	NN	_	16	NMOD	_	_
16	genes	_	NNS	NNS	_	13	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	selected	_	VBN	VBN	_	13	NMOD	_	_
19	by	_	IN	IN	_	18	ADV	_	_
20	screening	_	VBG	VBG	_	19	PMOD	_	_
21	cDNA	_	NN	NN	_	22	NMOD	_	_
22	libraries	_	NNS	NNS	_	20	OBJ	_	_
23	prepared	_	VBN	VBN	_	22	NMOD	_	_
24	from	_	IN	IN	_	23	ADV	_	_
25	human	_	JJ	JJ	_	28	NMOD	_	_
26	blood	_	NN	NN	_	28	NMOD	_	_
27	mononuclear	_	JJ	JJ	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	24	PMOD	_	_
29	cultured	_	VBN	VBN	_	28	NMOD	_	_
30	for	_	IN	IN	_	29	TMP	_	_
31	2	_	CD	CD	_	32	NMOD	_	_
32	hr	_	NN	NN	_	30	PMOD	_	_
33	with	_	IN	IN	_	29	ADV	_	_
34	lectin	_	NN	NN	_	33	PMOD	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	cycloheximide	_	NN	NN	_	34	COORD	_	_
37	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	sequence	_	NN	NN	_	3	SBJ	_	_
3	shows	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	high	_	JJ	JJ	_	5	NMOD	_	_
5	homology	_	NN	NN	_	3	OBJ	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	murine	_	JJ	JJ	_	10	NMOD	_	_
9	FOSB	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	6	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	which	_	WDT	WDT	_	13	SBJ	_	_
13	encodes	_	VBZ	VBZ	_	10	NMOD	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	component	_	NN	NN	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	AP1	_	NN	NN	_	20	NMOD	_	_
19	transcriptional	_	JJ	JJ	_	20	NMOD	_	_
20	regulator	_	NN	NN	_	16	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	Comparison	_	NN	NN	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	cDNA	_	NN	NN	_	2	PMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	genomic	_	JJ	JJ	_	6	NMOD	_	_
6	sequences	_	NNS	NNS	_	3	COORD	_	_
7	reveals	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	4-exon	_	JJ	JJ	_	10	NMOD	_	_
10	structure	_	NN	NN	_	7	OBJ	_	_
11	characteristic	_	JJ	JJ	_	10	NMOD	_	_
12	of	_	IN	IN	_	10	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	FOS	_	NN	NN	_	15	NMOD	_	_
15	family	_	NN	NN	_	12	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	genes	_	NNS	NNS	_	16	PMOD	_	_
18	.	_	.	.	_	7	P	_	_

1	Freshly	_	RB	RB	_	2	AMOD	_	_
2	isolated	_	VBN	VBN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	4	SBJ	_	_
4	show	_	VBP	VBP	_	0	ROOT-S	_	_
5	high	_	JJ	JJ	_	6	NMOD	_	_
6	levels	_	NNS	NNS	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	FOSB\/G0S3	_	NN	NN	_	11	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	FOS\/G0S7	_	NN	NN	_	8	COORD	_	_
11	mRNAs	_	NNS	NNS	_	7	PMOD	_	_
12	,	_	,	,	_	6	P	_	_
13	which	_	WDT	WDT	_	14	SBJ	_	_
14	decline	_	VBP	VBP	_	6	NMOD	_	_
15	rapidly	_	RB	RB	_	14	TMP	_	_
16	during	_	IN	IN	_	14	TMP	_	_
17	incubation	_	NN	NN	_	16	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	culture	_	NN	NN	_	20	NMOD	_	_
20	medium	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	kinetics	_	NNS	NNS	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	expression	_	NN	NN	_	3	PMOD	_	_
5	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	high	_	JJ	JJ	_	10	NMOD	_	_
9	initial	_	JJ	JJ	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	11	SBJ	_	_
11	are	_	VBP	VBP	_	6	VMOD	_	_
12	caused	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	isolation	_	NN	NN	_	16	NMOD	_	_
16	procedure	_	NN	NN	_	13	PMOD	_	_
17	,	_	,	,	_	5	P	_	_
18	and	_	CC	CC	_	5	CC	_	_
19	do	_	VBP	VBP	_	5	COORD	_	_
20	not	_	RB	RB	_	19	VMOD	_	_
21	reflect	_	VB	VB	_	19	VC	_	_
22	constitutive	_	JJ	JJ	_	23	NMOD	_	_
23	expression	_	NN	NN	_	21	OBJ	_	_
24	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	cells	_	NNS	NNS	_	1	PMOD	_	_
3	preincubated	_	VBN	VBN	_	2	NMOD	_	_
4	for	_	IN	IN	_	3	TMP	_	_
5	a	_	DT	DT	_	6	NMOD	_	_
6	day	_	NN	NN	_	4	PMOD	_	_
7	,	_	,	,	_	12	P	_	_
8	levels	_	NNS	NNS	_	12	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	FOS	_	NN	NN	_	11	NMOD	_	_
11	mRNA	_	NN	NN	_	9	PMOD	_	_
12	reach	_	VBP	VBP	_	0	ROOT-S	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	maximum	_	NN	NN	_	12	OBJ	_	_
15	20	_	CD	CD	_	16	NMOD	_	_
16	min	_	NN	NN	_	17	PMOD	_	_
17	after	_	IN	IN	_	12	TMP	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	addition	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	lectin	_	NN	NN	_	20	PMOD	_	_
22	and	_	CC	CC	_	12	CC	_	_
23	decline	_	VBP	VBP	_	12	COORD	_	_
24	to	_	TO	TO	_	23	ADV	_	_
25	control	_	NN	NN	_	26	NMOD	_	_
26	levels	_	NNS	NNS	_	24	PMOD	_	_
27	over	_	IN	IN	_	23	TMP	_	_
28	the	_	DT	DT	_	31	NMOD	_	_
29	next	_	JJ	JJ	_	31	NMOD	_	_
30	3	_	CD	CD	_	31	NMOD	_	_
31	hr	_	NN	NN	_	27	PMOD	_	_
32	.	_	.	.	_	12	P	_	_

1	Levels	_	NNS	NNS	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	FOSB	_	NN	NN	_	4	NMOD	_	_
4	mRNA	_	NN	NN	_	2	PMOD	_	_
5	reach	_	VBP	VBP	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	maximum	_	JJ	JJ	_	5	OBJ	_	_
8	40	_	CD	CD	_	9	NMOD	_	_
9	min	_	NN	NN	_	10	PMOD	_	_
10	after	_	IN	IN	_	5	TMP	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	addition	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	lectin	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	5	CC	_	_
16	decline	_	VBP	VBP	_	5	COORD	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	control	_	NN	NN	_	19	NMOD	_	_
19	levels	_	NNS	NNS	_	17	PMOD	_	_
20	over	_	IN	IN	_	16	TMP	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	next	_	JJ	JJ	_	24	NMOD	_	_
23	6	_	CD	CD	_	24	NMOD	_	_
24	hr	_	NN	NN	_	20	PMOD	_	_
25	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	freshly	_	RB	RB	_	3	AMOD	_	_
3	isolated	_	VBN	VBN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	11	P	_	_
6	both	_	CC	CC	_	7	CC	_	_
7	FOS	_	NNS	NNS	_	10	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	FOSB	_	NN	NN	_	7	COORD	_	_
10	mRNAs	_	NNS	NNS	_	11	SBJ	_	_
11	increase	_	VBP	VBP	_	0	ROOT-S	_	_
12	dramatically	_	RB	RB	_	11	ADV	_	_
13	in	_	IN	IN	_	11	ADV	_	_
14	response	_	NN	NN	_	13	DEP	_	_
15	to	_	TO	TO	_	13	DEP	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	protein	_	NN	NN	_	20	NMOD	_	_
18	synthesis	_	NN	NN	_	20	NMOD	_	_
19	inhibitor	_	NN	NN	_	20	NMOD	_	_
20	cycloheximide	_	NN	NN	_	13	PMOD	_	_
21	.	_	.	.	_	11	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	preincubated	_	JJ	JJ	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	8	P	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	cycloheximide	_	NN	NN	_	7	NMOD	_	_
7	response	_	NN	NN	_	8	SBJ	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	decreased	_	VBN	VBN	_	8	VC	_	_
10	,	_	,	,	_	9	P	_	_
11	especially	_	RB	RB	_	12	DEP	_	_
12	in	_	IN	IN	_	9	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	case	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	FOSB	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	8	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	differences	_	NNS	NNS	_	9	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	expression	_	NN	NN	_	3	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	FOS	_	NN	NN	_	5	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	FOSB	_	NN	NN	_	6	COORD	_	_
9	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
10	different	_	JJ	JJ	_	11	NMOD	_	_
11	roles	_	NNS	NNS	_	9	OBJ	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	regulation	_	NN	NN	_	11	COORD	_	_
14	.	_	.	.	_	9	P	_	_

1	Regions	_	NNS	NNS	_	14	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	low	_	JJ	JJ	_	7	NMOD	_	_
4	base	_	NN	NN	_	7	NMOD	_	_
5	order-dependent	_	JJ	JJ	_	4	AMOD	_	_
6	stem-loop	_	JJ	JJ	_	7	NMOD	_	_
7	potential	_	NN	NN	_	2	PMOD	_	_
8	in	_	IN	IN	_	1	NMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	region	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	gene	_	NN	NN	_	11	PMOD	_	_
14	are	_	VBP	VBP	_	0	ROOT-S	_	_
15	defined	_	VBN	VBN	_	14	VC	_	_
16	.	_	.	.	_	14	P	_	_

1	These	_	DT	DT	_	2	SBJ	_	_
2	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
3	where	_	WRB	WRB	_	8	ADV	_	_
4	base	_	NN	NN	_	5	NMOD	_	_
5	order	_	NN	NN	_	6	SBJ	_	_
6	has	_	VBZ	VBZ	_	2	OBJ	_	_
7	been	_	VBN	VBN	_	6	VC	_	_
8	adapted	_	VBN	VBN	_	7	VC	_	_
9	for	_	IN	IN	_	8	ADV	_	_
10	purposes	_	NNS	NNS	_	9	PMOD	_	_
11	other	_	JJ	JJ	_	12	DEP	_	_
12	than	_	IN	IN	_	10	NMOD	_	_
13	stem-loop	_	JJ	JJ	_	14	NMOD	_	_
14	stability	_	NN	NN	_	12	PMOD	_	_
15	(	_	(	(	_	10	PRN	_	_
16	e.g.	_	FW	FW	_	15	DEP	_	_
17	,	_	,	,	_	16	P	_	_
18	encoding	_	VBG	VBG	_	16	COORD	_	_
19	proteins	_	NNS	NNS	_	18	OBJ	_	_
20	or	_	CC	CC	_	18	CC	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	regulation	_	NN	NN	_	18	COORD	_	_
23	)	_	)	)	_	15	P	_	_
24	.	_	.	.	_	2	P	_	_

1	Regions	_	NNS	NNS	_	14	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	low	_	JJ	JJ	_	4	NMOD	_	_
4	potential	_	NN	NN	_	2	PMOD	_	_
5	in	_	IN	IN	_	1	NMOD	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	68.5-kb	_	JJ	JJ	_	9	NMOD	_	_
8	genomic	_	JJ	JJ	_	9	NMOD	_	_
9	segment	_	NN	NN	_	5	PMOD	_	_
10	containing	_	VBG	VBG	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	FOSB	_	NN	NN	_	13	NMOD	_	_
13	gene	_	NN	NN	_	10	OBJ	_	_
14	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
15	that	_	IN	IN	_	14	OBJ	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	potential	_	NN	NN	_	18	SBJ	_	_
18	may	_	MD	MD	_	15	VMOD	_	_
19	help	_	VB	VB	_	18	VC	_	_
20	locate	_	VB	VB	_	19	OBJ	_	_
21	genes	_	NNS	NNS	_	20	OBJ	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	uncharted	_	JJ	JJ	_	25	NMOD	_	_
24	DNA	_	NN	NN	_	25	NMOD	_	_
25	sequences	_	NNS	NNS	_	22	PMOD	_	_
26	.	_	.	.	_	14	P	_	_

1	Pancreatic	_	JJ	JJ	_	2	NMOD	_	_
2	development	_	NN	NN	_	0	ROOT-FRAG	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	maturation	_	NN	NN	_	2	COORD	_	_
5	of	_	IN	IN	_	2	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	islet	_	NN	NN	_	9	NMOD	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	cell	_	NN	NN	_	5	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	Studies	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	pluripotent	_	JJ	JJ	_	5	NMOD	_	_
4	islet	_	NN	NN	_	5	NMOD	_	_
5	cultures	_	NNS	NNS	_	2	PMOD	_	_
6	.	_	.	.	_	1	P	_	_

1	Pancreas	_	NN	NN	_	2	NMOD	_	_
2	organogenesis	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	highly	_	RB	RB	_	6	AMOD	_	_
6	regulated	_	VBN	VBN	_	7	NMOD	_	_
7	process	_	NN	NN	_	3	PRD	_	_
8	,	_	,	,	_	7	P	_	_
9	in	_	IN	IN	_	13	ADV	_	_
10	which	_	WDT	WDT	_	9	PMOD	_	_
11	two	_	CD	CD	_	12	NMOD	_	_
12	anlage	_	NNS	NNS	_	13	SBJ	_	_
13	evaginate	_	VBP	VBP	_	7	NMOD	_	_
14	from	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	primitive	_	JJ	JJ	_	17	NMOD	_	_
17	gut	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	They	_	PRP	PRP	_	3	SBJ	_	_
2	later	_	RB	RB	_	3	TMP	_	_
3	fuse	_	VBP	VBP	_	0	ROOT-S	_	_
4	,	_	,	,	_	3	P	_	_
5	and	_	CC	CC	_	3	CC	_	_
6	,	_	,	,	_	3	P	_	_
7	under	_	IN	IN	_	18	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	influence	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	surrounding	_	VBG	VBG	_	13	NMOD	_	_
13	mesenchyme	_	NN	NN	_	10	PMOD	_	_
14	,	_	,	,	_	18	P	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	mature	_	JJ	JJ	_	17	NMOD	_	_
17	organ	_	NN	NN	_	18	SBJ	_	_
18	develops	_	VBZ	VBZ	_	3	COORD	_	_
19	,	_	,	,	_	18	P	_	_
20	being	_	VBG	VBG	_	18	OBJ	_	_
21	mainly	_	RB	RB	_	22	ADV	_	_
22	composed	_	VBN	VBN	_	20	VC	_	_
23	of	_	IN	IN	_	22	ADV	_	_
24	ductal	_	JJ	JJ	_	29	NMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	exocrine	_	JJ	JJ	_	24	COORD	_	_
27	and	_	CC	CC	_	24	CC	_	_
28	endocrine	_	JJ	JJ	_	24	COORD	_	_
29	compartments	_	NNS	NNS	_	23	PMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	Early	_	JJ	JJ	_	2	NMOD	_	_
2	buds	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	characterized	_	VBN	VBN	_	3	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	branching	_	VBG	VBG	_	8	NMOD	_	_
8	morphogenesis	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	ductal	_	JJ	JJ	_	12	NMOD	_	_
12	epithelium	_	NN	NN	_	9	PMOD	_	_
13	from	_	IN	IN	_	20	ADV	_	_
14	which	_	WDT	WDT	_	13	PMOD	_	_
15	endocrine	_	JJ	JJ	_	19	NMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	exocrine	_	JJ	JJ	_	15	COORD	_	_
18	precursor	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	20	SBJ	_	_
20	bud	_	VBP	VBP	_	12	NMOD	_	_
21	to	_	TO	TO	_	23	VMOD	_	_
22	eventually	_	RB	RB	_	23	TMP	_	_
23	form	_	VB	VB	_	20	OBJ	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	two	_	CD	CD	_	27	NMOD	_	_
26	other	_	JJ	JJ	_	27	NMOD	_	_
27	compartments	_	NNS	NNS	_	23	OBJ	_	_
28	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	three	_	CD	CD	_	3	NMOD	_	_
3	compartments	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	thought	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	be	_	VB	VB	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	PRD	_	_
9	common	_	JJ	JJ	_	11	NMOD	_	_
10	endodermal	_	JJ	JJ	_	11	NMOD	_	_
11	origin	_	NN	NN	_	8	PMOD	_	_
12	;	_	:	:	_	7	P	_	_
13	in	_	IN	IN	_	7	ADV	_	_
14	contrast	_	NN	NN	_	13	DEP	_	_
15	to	_	TO	TO	_	13	DEP	_	_
16	earlier	_	JJR	JJR	_	17	NMOD	_	_
17	hypotheses	_	NNS	NNS	_	13	PMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	which	_	WDT	WDT	_	20	SBJ	_	_
20	suggested	_	VBD	VBD	_	17	NMOD	_	_
21	that	_	IN	IN	_	20	OBJ	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	endocrine	_	JJ	JJ	_	24	NMOD	_	_
24	compartment	_	NN	NN	_	25	SBJ	_	_
25	was	_	VBD	VBD	_	21	VMOD	_	_
26	of	_	IN	IN	_	25	PRD	_	_
27	neuroectodermal	_	JJ	JJ	_	28	NMOD	_	_
28	origin	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	4	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	thus	_	RB	RB	_	2	ADV	_	_
4	generally	_	RB	RB	_	5	ADV	_	_
5	believed	_	VBN	VBN	_	2	VC	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	pancreatic	_	JJ	JJ	_	9	NMOD	_	_
9	endocrine-lineage	_	NN	NN	_	10	SBJ	_	_
10	possesses	_	VBZ	VBZ	_	6	VMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	ability	_	NN	NN	_	10	OBJ	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	mature	_	VB	VB	_	12	NMOD	_	_
15	along	_	IN	IN	_	14	ADV	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	differentiation	_	NN	NN	_	18	NMOD	_	_
18	pathway	_	NN	NN	_	15	PMOD	_	_
19	that	_	WDT	WDT	_	20	SBJ	_	_
20	shares	_	VBZ	VBZ	_	18	NMOD	_	_
21	many	_	JJ	JJ	_	22	NMOD	_	_
22	characteristics	_	NNS	NNS	_	20	OBJ	_	_
23	with	_	IN	IN	_	20	ADV	_	_
24	those	_	DT	DT	_	23	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	neuronal	_	JJ	JJ	_	27	NMOD	_	_
27	differentiation	_	NN	NN	_	25	PMOD	_	_
28	.	_	.	.	_	2	P	_	_

1	During	_	IN	IN	_	21	TMP	_	_
2	recent	_	JJ	JJ	_	3	NMOD	_	_
3	years	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	21	P	_	_
5	studies	_	NNS	NNS	_	21	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	insulin-gene	_	JJ	JJ	_	8	NMOD	_	_
8	regulation	_	NN	NN	_	6	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	,	_	,	,	_	8	P	_	_
11	in	_	IN	IN	_	17	NMOD	_	_
12	particular	_	JJ	JJ	_	11	PMOD	_	_
13	,	_	,	,	_	17	P	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	tissue-specific	_	JJ	JJ	_	17	NMOD	_	_
16	transcriptional	_	JJ	JJ	_	17	NMOD	_	_
17	control	_	NN	NN	_	8	COORD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	insulin-gene	_	JJ	JJ	_	20	NMOD	_	_
20	activity	_	NN	NN	_	18	PMOD	_	_
21	have	_	VBP	VBP	_	0	ROOT-S	_	_
22	provided	_	VBN	VBN	_	21	VC	_	_
23	information	_	NN	NN	_	22	OBJ	_	_
24	on	_	IN	IN	_	23	NMOD	_	_
25	pancreas	_	NN	NN	_	26	NMOD	_	_
26	development	_	NN	NN	_	24	PMOD	_	_
27	in	_	IN	IN	_	23	NMOD	_	_
28	general	_	JJ	JJ	_	27	PMOD	_	_
29	.	_	.	.	_	21	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	present	_	JJ	JJ	_	3	NMOD	_	_
3	review	_	NN	NN	_	4	SBJ	_	_
4	summarizes	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	these	_	DT	DT	_	6	NMOD	_	_
6	findings	_	NNS	NNS	_	4	OBJ	_	_
7	,	_	,	,	_	4	P	_	_
8	with	_	IN	IN	_	4	ADV	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	special	_	JJ	JJ	_	11	NMOD	_	_
11	focus	_	NN	NN	_	8	PMOD	_	_
12	on	_	IN	IN	_	11	NMOD	_	_
13	our	_	PRP$	PRP$	_	15	NMOD	_	_
14	own	_	JJ	JJ	_	15	NMOD	_	_
15	studies	_	NNS	NNS	_	12	PMOD	_	_
16	on	_	IN	IN	_	15	NMOD	_	_
17	pluripotent	_	JJ	JJ	_	19	NMOD	_	_
18	endocrine	_	JJ	JJ	_	19	NMOD	_	_
19	cultures	_	NNS	NNS	_	16	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	rat	_	NN	NN	_	22	NMOD	_	_
22	pancreas	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	4	P	_	_

1	Induction	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	vascular	_	JJ	JJ	_	6	NMOD	_	_
4	cell	_	NN	NN	_	6	NMOD	_	_
5	adhesion	_	NN	NN	_	6	NMOD	_	_
6	molecule-1	_	NN	NN	_	2	PMOD	_	_
7	by	_	IN	IN	_	1	NMOD	_	_
8	low-density	_	JJ	JJ	_	9	NMOD	_	_
9	lipoprotein	_	NN	NN	_	7	PMOD	_	_
10	.	_	.	.	_	1	P	_	_

1	Low-density	_	JJ	JJ	_	2	NMOD	_	_
2	lipoprotein	_	NN	NN	_	6	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	LDL	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	10	NMOD	_	_
8	well-established	_	JJ	JJ	_	10	NMOD	_	_
9	risk	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	6	PRD	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	atherosclerosis	_	NN	NN	_	11	PMOD	_	_
13	.	_	.	.	_	6	P	_	_

1	When	_	WRB	WRB	_	5	ADV	_	_
2	endothelial	_	JJ	JJ	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	15	TMP	_	_
5	incubated	_	VBN	VBN	_	4	VC	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	this	_	DT	DT	_	8	NMOD	_	_
8	lipoprotein	_	NN	NN	_	6	PMOD	_	_
9	in	_	IN	IN	_	5	ADV	_	_
10	pathophysiologic	_	JJ	JJ	_	11	NMOD	_	_
11	amounts	_	NNS	NNS	_	9	PMOD	_	_
12	,	_	,	,	_	15	P	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	15	SBJ	_	_
15	are	_	VBP	VBP	_	0	ROOT-S	_	_
16	activated	_	VBN	VBN	_	15	VC	_	_
17	.	_	.	.	_	15	P	_	_

1	Among	_	IN	IN	_	8	PRD	_	_
2	the	_	DT	DT	_	5	NMOD	_	_
3	documented	_	VBN	VBN	_	5	NMOD	_	_
4	cellular	_	JJ	JJ	_	5	NMOD	_	_
5	responses	_	NNS	NNS	_	1	PMOD	_	_
6	to	_	TO	TO	_	5	NMOD	_	_
7	LDL	_	NN	NN	_	6	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	increased	_	VBN	VBN	_	10	NMOD	_	_
10	recruitment	_	NN	NN	_	8	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	monocytes	_	NNS	NNS	_	11	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	which	_	WDT	WDT	_	15	SBJ	_	_
15	are	_	VBP	VBP	_	12	NMOD	_	_
16	believed	_	VBN	VBN	_	15	VC	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	play	_	VB	VB	_	16	OBJ	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	major	_	JJ	JJ	_	21	NMOD	_	_
21	role	_	NN	NN	_	18	OBJ	_	_
22	in	_	IN	IN	_	18	ADV	_	_
23	promoting	_	VBG	VBG	_	22	PMOD	_	_
24	intimal	_	JJ	JJ	_	26	NMOD	_	_
25	plaque	_	NN	NN	_	26	NMOD	_	_
26	formation	_	NN	NN	_	23	OBJ	_	_
27	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	5	SBJ	_	_
3	presented	_	VBN	VBN	_	2	NMOD	_	_
4	here	_	RB	RB	_	3	ADV	_	_
5	link	_	VB	VB	_	0	ROOT-S	_	_
6	an	_	DT	DT	_	8	NMOD	_	_
7	atheogenic	_	JJ	JJ	_	8	NMOD	_	_
8	lipoprotein	_	NN	NN	_	5	OBJ	_	_
9	,	_	,	,	_	8	P	_	_
10	LDL	_	NN	NN	_	8	NMOD	_	_
11	,	_	,	,	_	8	P	_	_
12	with	_	IN	IN	_	5	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	induction	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	an	_	DT	DT	_	18	NMOD	_	_
17	adhesion	_	NN	NN	_	18	NMOD	_	_
18	molecule	_	NN	NN	_	15	PMOD	_	_
19	important	_	JJ	JJ	_	18	NMOD	_	_
20	in	_	IN	IN	_	19	AMOD	_	_
21	atherogenesis	_	NN	NN	_	20	PMOD	_	_

1	Human	_	JJ	JJ	_	2	NMOD	_	_
2	LDL	_	NN	NN	_	3	SBJ	_	_
3	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	vascular	_	JJ	JJ	_	8	NMOD	_	_
6	cell	_	NN	NN	_	8	NMOD	_	_
7	adhesion	_	NN	NN	_	8	NMOD	_	_
8	molecule-1	_	NN	NN	_	3	OBJ	_	_
9	(	_	(	(	_	10	P	_	_
10	VCAM-1	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	transcriptionally	_	RB	RB	_	3	ADV	_	_
13	with	_	IN	IN	_	3	ADV	_	_
14	an	_	DT	DT	_	15	NMOD	_	_
15	increase	_	NN	NN	_	13	PMOD	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	mRNA	_	NN	NN	_	18	NMOD	_	_
18	levels	_	NNS	NNS	_	16	PMOD	_	_
19	through	_	IN	IN	_	3	ADV	_	_
20	activation	_	NN	NN	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	VCAM	_	NN	NN	_	24	NMOD	_	_
24	promoter	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	blocked	_	VBN	VBN	_	3	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	anti-VCAM	_	JJ	JJ	_	7	NMOD	_	_
7	antibodies	_	NNS	NNS	_	5	PMOD	_	_
8	.	_	.	.	_	3	P	_	_

1	After	_	IN	IN	_	27	TMP	_	_
2	a	_	DT	DT	_	4	NMOD	_	_
3	2-day	_	JJ	JJ	_	4	NMOD	_	_
4	incubation	_	NN	NN	_	1	PMOD	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	LDL	_	NN	NN	_	5	PMOD	_	_
7	,	_	,	,	_	27	P	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	binding	_	NN	NN	_	27	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	NF-kappa	_	NN	NN	_	12	NMOD	_	_
12	B	_	NN	NN	_	10	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	which	_	WDT	WDT	_	15	SBJ	_	_
15	is	_	VBZ	VBZ	_	12	NMOD	_	_
16	believed	_	VBN	VBN	_	15	VC	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	be	_	VB	VB	_	16	OBJ	_	_
19	a	_	DT	DT	_	22	NMOD	_	_
20	key	_	JJ	JJ	_	22	NMOD	_	_
21	oxidative-stress	_	JJ	JJ	_	22	NMOD	_	_
22	sensor	_	NN	NN	_	18	PRD	_	_
23	for	_	IN	IN	_	22	NMOD	_	_
24	VCAM	_	NN	NN	_	25	NMOD	_	_
25	regulation	_	NN	NN	_	23	PMOD	_	_
26	,	_	,	,	_	12	P	_	_
27	remains	_	VBZ	VBZ	_	0	ROOT-S	_	_
28	at	_	IN	IN	_	27	ADV	_	_
29	basal	_	JJ	JJ	_	30	NMOD	_	_
30	level	_	NN	NN	_	28	PMOD	_	_
31	.	_	.	.	_	27	P	_	_

1	In	_	IN	IN	_	17	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	17	P	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	binding	_	NN	NN	_	6	NMOD	_	_
6	activities	_	NNS	NNS	_	17	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	AP-1	_	NN	NN	_	7	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	GATA	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	17	P	_	_
12	on	_	IN	IN	_	17	ADV	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	other	_	JJ	JJ	_	15	NMOD	_	_
15	hand	_	NN	NN	_	12	PMOD	_	_
16	,	_	,	,	_	17	P	_	_
17	are	_	VBP	VBP	_	0	ROOT-S	_	_
18	increased	_	VBN	VBN	_	17	VC	_	_
19	by	_	IN	IN	_	18	LGS	_	_
20	LDL	_	NN	NN	_	19	PMOD	_	_
21	.	_	.	.	_	17	P	_	_

1	Thus	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	component	_	NN	NN	_	11	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	LDL-enhanced	_	JJ	JJ	_	8	NMOD	_	_
7	endothelial	_	JJ	JJ	_	8	NMOD	_	_
8	recruitment	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	monocytes	_	NNS	NNS	_	9	PMOD	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	attributed	_	VBN	VBN	_	11	VC	_	_
13	to	_	TO	TO	_	12	ADV	_	_
14	VCAM-1	_	JJ	JJ	_	15	NMOD	_	_
15	expression	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	which	_	WDT	WDT	_	18	SBJ	_	_
18	appears	_	VBZ	VBZ	_	15	NMOD	_	_
19	to	_	TO	TO	_	20	VMOD	_	_
20	be	_	VB	VB	_	18	OBJ	_	_
21	mediated	_	VBN	VBN	_	20	VC	_	_
22	through	_	IN	IN	_	21	ADV	_	_
23	AP-1	_	NN	NN	_	22	PMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	GATA	_	NN	NN	_	23	COORD	_	_
26	.	_	.	.	_	11	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	identify	_	VBP	VBP	_	0	ROOT-S	_	_
4	LDL	_	NN	NN	_	3	OBJ	_	_
5	as	_	IN	IN	_	3	ADV	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	VCAM-inducer	_	NN	NN	_	5	PMOD	_	_
8	possibly	_	RB	RB	_	7	NMOD	_	_
9	distinct	_	JJ	JJ	_	8	AMOD	_	_
10	from	_	IN	IN	_	8	AMOD	_	_
11	cytokines	_	NNS	NNS	_	10	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	endotoxin	_	NN	NN	_	11	COORD	_	_
14	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	NF-kappa	_	NN	NN	_	4	NMOD	_	_
3	B	_	NN	NN	_	4	NMOD	_	_
4	inhibitor	_	NN	NN	_	8	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	tepoxalin	_	NN	NN	_	4	NMOD	_	_
7	,	_	,	,	_	4	P	_	_
8	suppresses	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	surface	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	cell	_	NN	NN	_	15	NMOD	_	_
14	adhesion	_	NN	NN	_	15	NMOD	_	_
15	molecules	_	NNS	NNS	_	11	PMOD	_	_
16	CD62E	_	NN	NN	_	15	NMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	CD11b\/CD18	_	NN	NN	_	16	COORD	_	_
19	and	_	CC	CC	_	16	CC	_	_
20	CD106	_	NN	NN	_	16	COORD	_	_
21	.	_	.	.	_	8	P	_	_

1	Tepoxalin	_	NN	NN	_	11	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	dual	_	JJ	JJ	_	6	NMOD	_	_
5	enzyme	_	NN	NN	_	6	NMOD	_	_
6	inhibitor	_	NN	NN	_	1	NMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	cyclooxygenase	_	NN	NN	_	7	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	5-lipoxygenase	_	NN	NN	_	8	COORD	_	_
11	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	been	_	VBN	VBN	_	11	VC	_	_
13	shown	_	VBN	VBN	_	12	VC	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	inhibit	_	VB	VB	_	13	OBJ	_	_
16	T-cell	_	NN	NN	_	17	NMOD	_	_
17	activation	_	NN	NN	_	15	OBJ	_	_
18	.	_	.	.	_	11	P	_	_

1	Its	_	PRP$	PRP$	_	3	NMOD	_	_
2	immunosuppressive	_	JJ	JJ	_	3	NMOD	_	_
3	property	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	distinct	_	JJ	JJ	_	4	PRD	_	_
6	from	_	IN	IN	_	5	AMOD	_	_
7	cyclosporin	_	NN	NN	_	6	PMOD	_	_
8	because	_	IN	IN	_	4	ADV	_	_
9	only	_	RB	RB	_	10	NMOD	_	_
10	tepoxalin	_	NN	NN	_	16	SBJ	_	_
11	,	_	,	,	_	10	P	_	_
12	but	_	CC	CC	_	10	CC	_	_
13	not	_	RB	RB	_	12	COORD	_	_
14	cyclosporin	_	NN	NN	_	10	COORD	_	_
15	,	_	,	,	_	10	P	_	_
16	suppresses	_	VBZ	VBZ	_	8	VMOD	_	_
17	NF-kappa	_	NN	NN	_	19	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	activation	_	NN	NN	_	16	OBJ	_	_
20	.	_	.	.	_	4	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	report	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	tepoxalin	_	NN	NN	_	7	SBJ	_	_
6	selectively	_	RB	RB	_	7	ADV	_	_
7	inhibits	_	VBZ	VBZ	_	4	VMOD	_	_
8	intercellular	_	JJ	JJ	_	18	NMOD	_	_
9	adhesion	_	NN	NN	_	18	NMOD	_	_
10	molecule-1	_	NN	NN	_	18	NMOD	_	_
11	(	_	(	(	_	18	P	_	_
12	ICAM-1	_	NN	NN	_	18	NMOD	_	_
13	,	_	,	,	_	18	P	_	_
14	CD54	_	NN	NN	_	18	NMOD	_	_
15	)	_	)	)	_	18	P	_	_
16	\/MAC-1	_	NN	NN	_	18	NMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	CD11b\/CD18	_	NN	NN	_	20	AMOD	_	_
19	)	_	)	)	_	18	P	_	_
20	dependent	_	JJ	JJ	_	21	NMOD	_	_
21	adhesion	_	NN	NN	_	7	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	polymorphonuclear	_	JJ	JJ	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	to	_	TO	TO	_	21	NMOD	_	_
26	IL-1	_	NN	NN	_	32	NMOD	_	_
27	activated	_	JJ	JJ	_	26	AMOD	_	_
28	human	_	JJ	JJ	_	32	NMOD	_	_
29	umbilical	_	JJ	JJ	_	32	NMOD	_	_
30	vein	_	NN	NN	_	32	NMOD	_	_
31	endothelial	_	JJ	JJ	_	32	NMOD	_	_
32	cells	_	NNS	NNS	_	25	PMOD	_	_
33	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	mechanism	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	inhibition	_	NN	NN	_	3	PMOD	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	related	_	JJ	JJ	_	5	PRD	_	_
7	to	_	TO	TO	_	6	AMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	surface	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	several	_	JJ	JJ	_	15	NMOD	_	_
13	cell	_	NN	NN	_	15	NMOD	_	_
14	adhesion	_	NN	NN	_	15	NMOD	_	_
15	molecules	_	NNS	NNS	_	11	PMOD	_	_
16	.	_	.	.	_	5	P	_	_

1	Flow	_	NN	NN	_	3	NMOD	_	_
2	cytometry	_	NN	NN	_	3	NMOD	_	_
3	analyses	_	NNS	NNS	_	29	SBJ	_	_
4	on	_	IN	IN	_	3	NMOD	_	_
5	cultured	_	VBN	VBN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	that	_	WDT	WDT	_	8	SBJ	_	_
8	were	_	VBD	VBD	_	6	NMOD	_	_
9	treated	_	VBN	VBN	_	8	VC	_	_
10	with	_	IN	IN	_	9	ADV	_	_
11	tepoxalin	_	NN	NN	_	10	PMOD	_	_
12	or	_	CC	CC	_	11	CC	_	_
13	antisense	_	JJ	JJ	_	14	NMOD	_	_
14	oligonucleotides	_	NNS	NNS	_	11	COORD	_	_
15	to	_	TO	TO	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	P65\/p50	_	NN	NN	_	18	NMOD	_	_
18	subunit	_	NN	NN	_	15	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	NF-kappa	_	NN	NN	_	21	NMOD	_	_
21	B	_	NN	NN	_	19	PMOD	_	_
22	,	_	,	,	_	9	P	_	_
23	and	_	CC	CC	_	9	CC	_	_
24	then	_	RB	RB	_	9	COORD	_	_
25	stimulated	_	VBN	VBN	_	9	COORD	_	_
26	with	_	IN	IN	_	25	ADV	_	_
27	PMA	_	NN	NN	_	26	PMOD	_	_
28	,	_	,	,	_	9	P	_	_
29	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
30	a	_	DT	DT	_	32	NMOD	_	_
31	reduced	_	VBN	VBN	_	32	NMOD	_	_
32	expression	_	NN	NN	_	29	OBJ	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	CD11b\/CD18	_	NN	NN	_	33	PMOD	_	_
35	on	_	IN	IN	_	32	NMOD	_	_
36	monocytic	_	JJ	JJ	_	38	NMOD	_	_
37	HL60	_	NN	NN	_	38	NMOD	_	_
38	cells	_	NNS	NNS	_	35	PMOD	_	_
39	,	_	,	,	_	32	P	_	_
40	and	_	CC	CC	_	32	CC	_	_
41	endothelial	_	JJ	JJ	_	43	NMOD	_	_
42	adhesion	_	NN	NN	_	43	NMOD	_	_
43	molecule-1	_	NN	NN	_	34	GAP	_	_
44	(	_	(	(	_	45	P	_	_
45	CD62E	_	NN	NN	_	43	PRN	_	_
46	)	_	)	)	_	45	P	_	_
47	and	_	CC	CC	_	43	CC	_	_
48	vascular	_	JJ	JJ	_	50	NMOD	_	_
49	adhesion	_	NN	NN	_	50	NMOD	_	_
50	molecule-1	_	NN	NN	_	43	COORD	_	_
51	(	_	(	(	_	52	P	_	_
52	CD106	_	NN	NN	_	50	PRN	_	_
53	)	_	)	)	_	52	P	_	_
54	on	_	IN	IN	_	35	GAP	_	_
55	human	_	JJ	JJ	_	59	NMOD	_	_
56	umbilical	_	JJ	JJ	_	59	NMOD	_	_
57	vein	_	NN	NN	_	59	NMOD	_	_
58	endothelial	_	JJ	JJ	_	59	NMOD	_	_
59	cells	_	NNS	NNS	_	54	PMOD	_	_
60	.	_	.	.	_	29	P	_	_

1	Expression	_	NN	NN	_	16	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	other	_	JJ	JJ	_	5	NMOD	_	_
4	adhesion	_	NN	NN	_	5	NMOD	_	_
5	molecules	_	NNS	NNS	_	2	PMOD	_	_
6	such	_	JJ	JJ	_	7	DEP	_	_
7	as	_	IN	IN	_	5	NMOD	_	_
8	lymphocyte	_	NN	NN	_	10	NMOD	_	_
9	function	_	NN	NN	_	10	NMOD	_	_
10	associated-antigen-1	_	NN	NN	_	7	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	CD11a\/CD18	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	and	_	CC	CC	_	10	CC	_	_
15	CD54	_	NN	NN	_	10	COORD	_	_
16	were	_	VBD	VBD	_	0	ROOT-S	_	_
17	unaffected	_	JJ	JJ	_	16	PRD	_	_
18	.	_	.	.	_	16	P	_	_

1	Tepoxalin	_	NN	NN	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	secretion	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	a	_	DT	DT	_	11	NMOD	_	_
8	NF-kappa	_	NN	NN	_	9	NMOD	_	_
9	B	_	NN	NN	_	10	AMOD	_	_
10	regulated	_	JJ	JJ	_	11	NMOD	_	_
11	chemokine	_	NN	NN	_	6	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	IL-8	_	NN	NN	_	11	NMOD	_	_
14	,	_	,	,	_	11	P	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	known	_	JJ	JJ	_	17	NMOD	_	_
17	inducer	_	NN	NN	_	11	NMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	CD11b\/CD18	_	NN	NN	_	20	NMOD	_	_
20	expression	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	Thus	_	RB	RB	_	9	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	suppression	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	CD11b\/CD18	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	4	PMOD	_	_
7	by	_	IN	IN	_	3	NMOD	_	_
8	tepoxalin	_	NN	NN	_	7	PMOD	_	_
9	may	_	MD	MD	_	0	ROOT-S	_	_
10	involve	_	VB	VB	_	9	VC	_	_
11	IL-8	_	NN	NN	_	10	OBJ	_	_
12	.	_	.	.	_	9	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	by	_	IN	IN	_	17	LGS	_	_
6	inhibiting	_	VBG	VBG	_	5	PMOD	_	_
7	NF-kappa	_	NN	NN	_	9	NMOD	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	activation	_	NN	NN	_	6	OBJ	_	_
10	,	_	,	,	_	17	P	_	_
11	surface	_	NN	NN	_	12	NMOD	_	_
12	expression	_	NN	NN	_	17	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	several	_	JJ	JJ	_	16	NMOD	_	_
15	adhesion	_	NN	NN	_	16	NMOD	_	_
16	molecules	_	NNS	NNS	_	13	PMOD	_	_
17	can	_	MD	MD	_	4	VMOD	_	_
18	be	_	VB	VB	_	17	VC	_	_
19	modulated	_	VBN	VBN	_	18	VC	_	_
20	and	_	CC	CC	_	4	CC	_	_
21	that	_	IN	IN	_	4	COORD	_	_
22	tepoxalin	_	NN	NN	_	23	SBJ	_	_
23	may	_	MD	MD	_	21	VMOD	_	_
24	be	_	VB	VB	_	23	VC	_	_
25	useful	_	JJ	JJ	_	24	PRD	_	_
26	in	_	IN	IN	_	24	ADV	_	_
27	treating	_	VBG	VBG	_	26	PMOD	_	_
28	selected	_	VBN	VBN	_	31	NMOD	_	_
29	adhesion	_	NN	NN	_	31	NMOD	_	_
30	mediated	_	JJ	JJ	_	29	AMOD	_	_
31	events	_	NNS	NNS	_	27	OBJ	_	_
32	such	_	JJ	JJ	_	33	DEP	_	_
33	as	_	IN	IN	_	31	NMOD	_	_
34	leukocyte	_	NN	NN	_	35	NMOD	_	_
35	migration	_	NN	NN	_	33	PMOD	_	_
36	or	_	CC	CC	_	35	CC	_	_
37	atherosclerotic	_	JJ	JJ	_	39	NMOD	_	_
38	plaque	_	NN	NN	_	39	NMOD	_	_
39	formation	_	NN	NN	_	35	COORD	_	_
40	.	_	.	.	_	3	P	_	_

1	Nuclear	_	JJ	JJ	_	2	NMOD	_	_
2	NF-ATp	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	hallmark	_	NN	NN	_	3	PRD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	unstimulated	_	JJ	JJ	_	9	NMOD	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	6	PMOD	_	_
10	from	_	IN	IN	_	9	NMOD	_	_
11	B-CLL	_	NN	NN	_	12	NMOD	_	_
12	patients	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	B	_	NN	NN	_	2	NMOD	_	_
2	lymphocytes	_	NNS	NNS	_	16	SBJ	_	_
3	from	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	peripheral	_	JJ	JJ	_	6	NMOD	_	_
6	blood	_	NN	NN	_	3	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	patients	_	NNS	NNS	_	7	PMOD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	chronic	_	JJ	JJ	_	12	NMOD	_	_
11	lymphocytic	_	JJ	JJ	_	12	NMOD	_	_
12	leukaemia	_	NN	NN	_	9	PMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	CLL	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	were	_	VBD	VBD	_	0	ROOT-S	_	_
17	analysed	_	VBN	VBN	_	16	VC	_	_
18	for	_	IN	IN	_	17	ADV	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	nuclear	_	JJ	JJ	_	21	NMOD	_	_
21	presence	_	NN	NN	_	18	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	DNA	_	NN	NN	_	24	NMOD	_	_
24	binding	_	NN	NN	_	21	COORD	_	_
25	of	_	IN	IN	_	21	NMOD	_	_
26	a	_	DT	DT	_	27	NMOD	_	_
27	panel	_	NN	NN	_	25	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	transcription	_	NN	NN	_	30	NMOD	_	_
30	factors	_	NNS	NNS	_	28	PMOD	_	_
31	which	_	WDT	WDT	_	32	SBJ	_	_
32	are	_	VBP	VBP	_	30	NMOD	_	_
33	involved	_	VBN	VBN	_	32	VC	_	_
34	in	_	IN	IN	_	33	ADV	_	_
35	the	_	DT	DT	_	37	NMOD	_	_
36	gene	_	NN	NN	_	37	NMOD	_	_
37	control	_	NN	NN	_	34	PMOD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	lymphoid	_	JJ	JJ	_	40	NMOD	_	_
40	cells	_	NNS	NNS	_	38	PMOD	_	_
41	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	following	_	JJ	JJ	_	4	NMOD	_	_
3	transcription	_	NN	NN	_	4	NMOD	_	_
4	factors	_	NNS	NNS	_	5	SBJ	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	studied	_	VBN	VBN	_	5	VC	_	_
7	:	_	:	:	_	6	P	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	Octamer	_	NN	NN	_	10	NMOD	_	_
10	factors	_	NNS	NNS	_	4	NMOD	_	_
11	Oct-1	_	NN	NN	_	10	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	Oct-2	_	NN	NN	_	11	COORD	_	_
14	,	_	,	,	_	10	P	_	_
15	members	_	NNS	NNS	_	10	COORD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	AP-1	_	NN	NN	_	20	NMOD	_	_
19	factor	_	NN	NN	_	20	NMOD	_	_
20	family	_	NN	NN	_	16	PMOD	_	_
21	,	_	,	,	_	10	P	_	_
22	NF-AT	_	NN	NN	_	23	NMOD	_	_
23	factors	_	NNS	NNS	_	10	COORD	_	_
24	,	_	,	,	_	23	P	_	_
25	in	_	IN	IN	_	27	NMOD	_	_
26	particular	_	JJ	JJ	_	25	PMOD	_	_
27	NF-ATp	_	NN	NN	_	23	NMOD	_	_
28	,	_	,	,	_	10	P	_	_
29	and	_	CC	CC	_	10	CC	_	_
30	members	_	NNS	NNS	_	10	COORD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	Rel\/NF-kB	_	NN	NN	_	34	NMOD	_	_
34	family	_	NN	NN	_	31	PMOD	_	_
35	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	constitutive	_	JJ	JJ	_	7	NMOD	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	translocation	_	NN	NN	_	21	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	NF-ATp	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	member	_	NN	NN	_	9	NMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	growing	_	VBG	VBG	_	16	NMOD	_	_
16	family	_	NN	NN	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	NF-AT	_	NN	NN	_	19	NMOD	_	_
19	factors	_	NNS	NNS	_	17	PMOD	_	_
20	,	_	,	,	_	9	P	_	_
21	is	_	VBZ	VBZ	_	3	VMOD	_	_
22	a	_	DT	DT	_	23	NMOD	_	_
23	hallmark	_	NN	NN	_	21	PRD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	nonstimulated	_	JJ	JJ	_	27	NMOD	_	_
26	B	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	24	PMOD	_	_
28	from	_	IN	IN	_	27	NMOD	_	_
29	CLL	_	NN	NN	_	30	NMOD	_	_
30	patients	_	NNS	NNS	_	28	PMOD	_	_
31	that	_	WDT	WDT	_	32	SBJ	_	_
32	distinguishes	_	VBZ	VBZ	_	23	NMOD	_	_
33	B-CLL	_	NN	NN	_	34	NMOD	_	_
34	cells	_	NNS	NNS	_	32	OBJ	_	_
35	from	_	IN	IN	_	32	ADV	_	_
36	'	_	``	``	_	40	P	_	_
37	normal	_	JJ	JJ	_	40	NMOD	_	_
38	'	_	''	''	_	40	P	_	_
39	B	_	NN	NN	_	40	NMOD	_	_
40	lymphocytes	_	NNS	NNS	_	35	PMOD	_	_
41	.	_	.	.	_	2	P	_	_

1	Constitutive	_	JJ	JJ	_	3	NMOD	_	_
2	nuclear	_	JJ	JJ	_	3	NMOD	_	_
3	appearance	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	also	_	RB	RB	_	4	ADV	_	_
6	observed	_	VBN	VBN	_	4	VC	_	_
7	for	_	IN	IN	_	6	ADV	_	_
8	NF-kB2\/p52	_	NN	NN	_	7	PMOD	_	_
9	.	_	.	.	_	4	P	_	_

1	Constitutive	_	JJ	JJ	_	2	NMOD	_	_
2	binding	_	NN	NN	_	18	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	further	_	JJ	JJ	_	6	NMOD	_	_
5	factor	_	NN	NN	_	6	NMOD	_	_
6	proteins	_	NNS	NNS	_	3	PMOD	_	_
7	to	_	TO	TO	_	2	NMOD	_	_
8	DNA	_	NN	NN	_	7	PMOD	_	_
9	,	_	,	,	_	2	P	_	_
10	such	_	JJ	JJ	_	11	DEP	_	_
11	as	_	IN	IN	_	6	NMOD	_	_
12	JunD	_	NN	NN	_	11	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	c-Fos	_	NN	NN	_	12	COORD	_	_
15	and	_	CC	CC	_	12	CC	_	_
16	FosB	_	NN	NN	_	12	COORD	_	_
17	,	_	,	,	_	2	P	_	_
18	was	_	VBD	VBD	_	0	ROOT-S	_	_
19	detected	_	VBN	VBN	_	18	VC	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	several	_	JJ	JJ	_	22	NMOD	_	_
22	patients	_	NNS	NNS	_	20	PMOD	_	_
23	whereas	_	IN	IN	_	19	OBJ	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	localisation	_	NN	NN	_	39	SBJ	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	DNA	_	NN	NN	_	28	NMOD	_	_
28	binding	_	NN	NN	_	25	COORD	_	_
29	of	_	IN	IN	_	25	NMOD	_	_
30	other	_	JJ	JJ	_	31	NMOD	_	_
31	factors	_	NNS	NNS	_	29	PMOD	_	_
32	such	_	JJ	JJ	_	33	DEP	_	_
33	as	_	IN	IN	_	31	NMOD	_	_
34	c-Jun	_	NN	NN	_	33	PMOD	_	_
35	,	_	,	,	_	34	P	_	_
36	RelA\/p65	_	NN	NN	_	34	COORD	_	_
37	and	_	CC	CC	_	34	CC	_	_
38	c-Rel	_	NN	NN	_	34	COORD	_	_
39	was	_	VBD	VBD	_	23	VMOD	_	_
40	unaltered	_	JJ	JJ	_	39	PRD	_	_
41	.	_	.	.	_	18	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	remarkable	_	JJ	JJ	_	2	PRD	_	_
4	that	_	IN	IN	_	2	EXP	_	_
5	in	_	IN	IN	_	18	ADV	_	_
6	B-CLL	_	JJ	JJ	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	5	PMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	nuclear	_	JJ	JJ	_	10	NMOD	_	_
10	appearance	_	NN	NN	_	18	SBJ	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	DNA	_	NN	NN	_	13	NMOD	_	_
13	binding	_	NN	NN	_	10	COORD	_	_
14	of	_	IN	IN	_	10	NMOD	_	_
15	specific	_	JJ	JJ	_	17	NMOD	_	_
16	transcription	_	NN	NN	_	17	NMOD	_	_
17	factors	_	NNS	NNS	_	14	PMOD	_	_
18	is	_	VBZ	VBZ	_	4	VMOD	_	_
19	dramatically	_	RB	RB	_	18	ADV	_	_
20	affected	_	JJ	JJ	_	18	VC	_	_
21	whereas	_	IN	IN	_	20	OBJ	_	_
22	other	_	JJ	JJ	_	23	NMOD	_	_
23	members	_	NNS	NNS	_	29	SBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	28	NMOD	_	_
26	same	_	JJ	JJ	_	28	NMOD	_	_
27	factor	_	NN	NN	_	28	NMOD	_	_
28	family	_	NN	NN	_	24	PMOD	_	_
29	remained	_	VBD	VBD	_	21	VMOD	_	_
30	unaltered	_	JJ	JJ	_	29	PRD	_	_
31	in	_	IN	IN	_	29	ADV	_	_
32	these	_	DT	DT	_	34	NMOD	_	_
33	leukemic	_	JJ	JJ	_	34	NMOD	_	_
34	cells	_	NNS	NNS	_	31	PMOD	_	_
35	.	_	.	.	_	2	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	remains	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	to	_	TO	TO	_	4	VMOD	_	_
4	be	_	VB	VB	_	2	OBJ	_	_
5	shown	_	VBN	VBN	_	4	VC	_	_
6	which	_	WDT	WDT	_	8	NMOD	_	_
7	molecular	_	JJ	JJ	_	8	NMOD	_	_
8	events	_	NNS	NNS	_	9	SBJ	_	_
9	lead	_	VBP	VBP	_	5	OBJ	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	specific	_	JJ	JJ	_	14	NMOD	_	_
13	'	_	``	``	_	14	P	_	_
14	pre-activation	_	NN	NN	_	10	PMOD	_	_
15	'	_	''	''	_	14	P	_	_
16	,	_	,	,	_	14	P	_	_
17	i.e.	_	FW	FW	_	20	NMOD	_	_
18	constitutive	_	JJ	JJ	_	20	NMOD	_	_
19	nuclear	_	JJ	JJ	_	20	NMOD	_	_
20	translocation	_	NN	NN	_	14	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	DNA	_	NN	NN	_	23	NMOD	_	_
23	binding	_	NN	NN	_	20	COORD	_	_
24	,	_	,	,	_	14	P	_	_
25	of	_	IN	IN	_	14	NMOD	_	_
26	these	_	DT	DT	_	27	NMOD	_	_
27	members	_	NNS	NNS	_	25	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	NF-AT	_	NN	NN	_	35	NMOD	_	_
30	,	_	,	,	_	29	P	_	_
31	NF-kB	_	NN	NN	_	29	COORD	_	_
32	and	_	CC	CC	_	29	CC	_	_
33	AP-1	_	NN	NN	_	29	COORD	_	_
34	factor	_	NN	NN	_	35	NMOD	_	_
35	families	_	NNS	NNS	_	28	PMOD	_	_
36	.	_	.	.	_	2	P	_	_

1	{	_	(	(	_	3	P	_	_
2	The	_	DT	DT	_	3	NMOD	_	_
3	value	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	clinical	_	JJ	JJ	_	7	NMOD	_	_
7	test	_	NN	NN	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	glucocorticoid	_	NN	NN	_	10	NMOD	_	_
10	receptors	_	NNS	NNS	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	peripheral	_	JJ	JJ	_	14	NMOD	_	_
13	blood	_	NN	NN	_	14	NMOD	_	_
14	leukocytes	_	NNS	NNS	_	11	PMOD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	patients	_	NNS	NNS	_	15	PMOD	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	chronic	_	JJ	JJ	_	21	NMOD	_	_
19	pulmonary	_	JJ	JJ	_	21	NMOD	_	_
20	heart	_	NN	NN	_	21	NMOD	_	_
21	disease	_	NN	NN	_	17	PMOD	_	_
22	}	_	)	)	_	3	P	_	_

1	In	_	IN	IN	_	38	ADV	_	_
2	order	_	NN	NN	_	1	VMOD	_	_
3	to	_	TO	TO	_	1	VMOD	_	_
4	inquire	_	VB	VB	_	1	VMOD	_	_
5	into	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	functional	_	JJ	JJ	_	8	NMOD	_	_
8	state	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	adrenal	_	JJ	JJ	_	11	NMOD	_	_
11	cortex	_	NN	NN	_	9	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	patients	_	NNS	NNS	_	12	PMOD	_	_
14	with	_	IN	IN	_	13	NMOD	_	_
15	pulmonary	_	JJ	JJ	_	17	NMOD	_	_
16	heart	_	NN	NN	_	17	NMOD	_	_
17	disease	_	NN	NN	_	14	PMOD	_	_
18	,	_	,	,	_	38	P	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	number	_	NN	NN	_	38	SBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	glucocorticoid	_	NN	NN	_	23	NMOD	_	_
23	receptors	_	NNS	NNS	_	21	PMOD	_	_
24	(	_	(	(	_	25	P	_	_
25	GCR	_	NN	NN	_	23	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	of	_	IN	IN	_	23	NMOD	_	_
28	peripheral	_	JJ	JJ	_	30	NMOD	_	_
29	blood	_	NN	NN	_	30	NMOD	_	_
30	leukocytes	_	NNS	NNS	_	27	PMOD	_	_
31	in	_	IN	IN	_	30	NMOD	_	_
32	patients	_	NNS	NNS	_	31	PMOD	_	_
33	with	_	IN	IN	_	32	NMOD	_	_
34	chronic	_	JJ	JJ	_	37	NMOD	_	_
35	pulmonary	_	JJ	JJ	_	37	NMOD	_	_
36	heart	_	NN	NN	_	37	NMOD	_	_
37	disease	_	NN	NN	_	33	PMOD	_	_
38	was	_	VBD	VBD	_	0	ROOT-S	_	_
39	determined	_	VBN	VBN	_	38	VC	_	_
40	with	_	IN	IN	_	39	ADV	_	_
41	radioligand-binding	_	JJ	JJ	_	42	NMOD	_	_
42	assay	_	NN	NN	_	40	PMOD	_	_
43	and	_	CC	CC	_	38	CC	_	_
44	the	_	DT	DT	_	48	NMOD	_	_
45	corresponding	_	JJ	JJ	_	48	NMOD	_	_
46	plasma	_	NN	NN	_	48	NMOD	_	_
47	cortisol	_	NN	NN	_	48	NMOD	_	_
48	levels	_	NNS	NNS	_	49	SBJ	_	_
49	were	_	VBD	VBD	_	38	COORD	_	_
50	assessed	_	VBN	VBN	_	49	VC	_	_
51	with	_	IN	IN	_	50	ADV	_	_
52	radioimmune	_	JJ	JJ	_	53	NMOD	_	_
53	assays	_	NNS	NNS	_	51	PMOD	_	_
54	.	_	.	.	_	38	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	showed	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	number	_	NN	NN	_	12	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	GCR	_	NN	NN	_	7	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	patients	_	NNS	NNS	_	9	PMOD	_	_
12	was	_	VBD	VBD	_	4	VMOD	_	_
13	significantly	_	RB	RB	_	12	ADV	_	_
14	reduced	_	VBN	VBN	_	12	VC	_	_
15	(	_	(	(	_	18	P	_	_
16	P	_	NN	NN	_	18	SBJ	_	_
17	&lt;	_	JJR	JJR	_	18	DEP	_	_
18	0.01	_	CD	CD	_	14	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	and	_	CC	CC	_	12	CC	_	_
21	it	_	PRP	PRP	_	22	SBJ	_	_
22	was	_	VBD	VBD	_	12	COORD	_	_
23	increased	_	VBN	VBN	_	22	VC	_	_
24	when	_	WRB	WRB	_	29	ADV	_	_
25	their	_	PRP$	PRP$	_	27	NMOD	_	_
26	health	_	NN	NN	_	27	NMOD	_	_
27	state	_	NN	NN	_	28	SBJ	_	_
28	was	_	VBD	VBD	_	23	TMP	_	_
29	improved	_	VBN	VBN	_	28	VC	_	_
30	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	it	_	PRP	PRP	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	still	_	RB	RB	_	4	ADV	_	_
6	lower	_	JJR	JJR	_	4	PRD	_	_
7	than	_	IN	IN	_	6	AMOD	_	_
8	that	_	DT	DT	_	7	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	healthy	_	JJ	JJ	_	11	NMOD	_	_
11	subjects	_	NNS	NNS	_	9	PMOD	_	_
12	(	_	(	(	_	15	P	_	_
13	P	_	NN	NN	_	15	SBJ	_	_
14	&lt;	_	JJR	JJR	_	15	DEP	_	_
15	0.01	_	CD	CD	_	4	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	number	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	GCR	_	NN	NN	_	3	PMOD	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	patients	_	NNS	NNS	_	5	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	greatly	_	RB	RB	_	8	ADV	_	_
10	increased	_	VBN	VBN	_	8	VC	_	_
11	when	_	WRB	WRB	_	15	ADV	_	_
12	these	_	DT	DT	_	13	NMOD	_	_
13	patients	_	NNS	NNS	_	14	SBJ	_	_
14	were	_	VBD	VBD	_	10	TMP	_	_
15	treated	_	VBN	VBN	_	14	VC	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	oxygen	_	NN	NN	_	16	PMOD	_	_
18	(	_	(	(	_	21	P	_	_
19	P	_	NN	NN	_	21	SBJ	_	_
20	&lt;	_	JJR	JJR	_	21	DEP	_	_
21	0.01	_	CD	CD	_	10	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	.	_	.	.	_	8	P	_	_

1	No	_	DT	DT	_	2	NMOD	_	_
2	difference	_	NN	NN	_	6	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	plasma	_	NN	NN	_	5	NMOD	_	_
5	cortisol	_	NN	NN	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	found	_	VBN	VBN	_	6	VC	_	_
8	between	_	IN	IN	_	7	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	patients	_	NNS	NNS	_	8	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	healthy	_	JJ	JJ	_	14	NMOD	_	_
14	subjects	_	NNS	NNS	_	10	COORD	_	_
15	(	_	(	(	_	18	P	_	_
16	P	_	NN	NN	_	18	SBJ	_	_
17	&gt;	_	JJR	JJR	_	18	DEP	_	_
18	0.05	_	CD	CD	_	7	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	.	_	.	.	_	6	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	function	_	NN	NN	_	10	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	adrenal	_	JJ	JJ	_	9	NMOD	_	_
9	cortex	_	NN	NN	_	7	PMOD	_	_
10	may	_	MD	MD	_	4	VMOD	_	_
11	be	_	VB	VB	_	10	VC	_	_
12	improved	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	compensation	_	NN	NN	_	16	NMOD	_	_
16	mechanism	_	NN	NN	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	patients	_	NNS	NNS	_	17	PMOD	_	_
20	,	_	,	,	_	10	P	_	_
21	but	_	CC	CC	_	10	CC	_	_
22	the	_	DT	DT	_	25	NMOD	_	_
23	lower	_	JJR	JJR	_	25	NMOD	_	_
24	GCR	_	NN	NN	_	25	NMOD	_	_
25	number	_	NN	NN	_	26	SBJ	_	_
26	was	_	VBD	VBD	_	10	COORD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	result	_	NN	NN	_	26	PRD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	lacking	_	NN	NN	_	29	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	oxygen	_	NN	NN	_	31	PMOD	_	_
33	in	_	IN	IN	_	30	NMOD	_	_
34	the	_	DT	DT	_	35	NMOD	_	_
35	patients	_	NNS	NNS	_	33	PMOD	_	_
36	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	number	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	GCR	_	NN	NN	_	3	PMOD	_	_
5	may	_	MD	MD	_	0	ROOT-S	_	_
6	be	_	VB	VB	_	5	VC	_	_
7	improved	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	inhalation	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	oxygen	_	NN	NN	_	10	PMOD	_	_
12	.	_	.	.	_	5	P	_	_

1	Therefore	_	RB	RB	_	4	ADV	_	_
2	oxygen	_	NN	NN	_	3	NMOD	_	_
3	therapy	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	helpful	_	JJ	JJ	_	4	PRD	_	_
6	in	_	IN	IN	_	4	ADV	_	_
7	raising	_	VBG	VBG	_	6	PMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	activity	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	glucocorticoid	_	NN	NN	_	12	NMOD	_	_
12	receptors	_	NNS	NNS	_	10	PMOD	_	_
13	and	_	CC	CC	_	7	CC	_	_
14	controlling	_	VBG	VBG	_	7	COORD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	development	_	NN	NN	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	disease	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	4	P	_	_

1	Lack	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	T-cell-mediated	_	JJ	JJ	_	4	NMOD	_	_
4	recognition	_	NN	NN	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	fusion	_	NN	NN	_	8	NMOD	_	_
8	region	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	pml\/RAR-alpha	_	NN	NN	_	13	NMOD	_	_
12	hybrid	_	NN	NN	_	13	NMOD	_	_
13	protein	_	NN	NN	_	9	PMOD	_	_
14	by	_	IN	IN	_	4	NMOD	_	_
15	lymphocytes	_	NNS	NNS	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	acute	_	JJ	JJ	_	20	NMOD	_	_
18	promyelocytic	_	JJ	JJ	_	20	NMOD	_	_
19	leukemia	_	NN	NN	_	20	NMOD	_	_
20	patients	_	NNS	NNS	_	16	PMOD	_	_
21	.	_	.	.	_	1	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	previous	_	JJ	JJ	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	it	_	PRP	PRP	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	shown	_	VBN	VBN	_	6	VC	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	fusion	_	NN	NN	_	11	NMOD	_	_
11	region	_	NN	NN	_	27	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	pml\/RAR-alpha	_	NN	NN	_	15	NMOD	_	_
15	protein	_	NN	NN	_	12	PMOD	_	_
16	,	_	,	,	_	11	P	_	_
17	expressed	_	VBN	VBN	_	11	NMOD	_	_
18	by	_	IN	IN	_	17	LGS	_	_
19	acute	_	JJ	JJ	_	21	NMOD	_	_
20	promyelocytic	_	JJ	JJ	_	21	NMOD	_	_
21	leukemia	_	NN	NN	_	25	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	APL	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	cells	_	NNS	NNS	_	18	PMOD	_	_
26	,	_	,	,	_	11	P	_	_
27	can	_	MD	MD	_	8	VMOD	_	_
28	be	_	VB	VB	_	27	VC	_	_
29	specifically	_	RB	RB	_	30	ADV	_	_
30	recognized	_	VBN	VBN	_	28	VC	_	_
31	in	_	FW	FW	_	30	ADV	_	_
32	vitro	_	FW	FW	_	31	AMOD	_	_
33	by	_	IN	IN	_	30	LGS	_	_
34	donor	_	NN	NN	_	41	NMOD	_	_
35	(	_	(	(	_	37	P	_	_
36	D.	_	NNP	NNP	_	37	NMOD	_	_
37	E.	_	NNP	NNP	_	34	PRN	_	_
38	)	_	)	)	_	37	P	_	_
39	CD4	_	NN	NN	_	41	NMOD	_	_
40	T	_	NN	NN	_	41	NMOD	_	_
41	cells	_	NNS	NNS	_	33	PMOD	_	_
42	in	_	IN	IN	_	30	ADV	_	_
43	a	_	DT	DT	_	48	NMOD	_	_
44	HLA	_	NN	NN	_	45	AMOD	_	_
45	class	_	NN	NN	_	48	NMOD	_	_
46	II	_	CD	CD	_	45	AMOD	_	_
47	DR11-restricted	_	JJ	JJ	_	45	AMOD	_	_
48	fashion	_	NN	NN	_	42	PMOD	_	_
49	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	present	_	VBP	VBP	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	results	_	NNS	NNS	_	2	OBJ	_	_
6	on	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	recognition	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	several	_	JJ	JJ	_	12	NMOD	_	_
11	pml\/RAR-alpha	_	NN	NN	_	12	NMOD	_	_
12	peptides	_	NNS	NNS	_	9	PMOD	_	_
13	by	_	IN	IN	_	8	NMOD	_	_
14	APL	_	NN	NN	_	15	NMOD	_	_
15	patients	_	NNS	NNS	_	13	PMOD	_	_
16	expressing	_	VBG	VBG	_	15	NMOD	_	_
17	HLA	_	NN	NN	_	18	NMOD	_	_
18	DR11	_	NN	NN	_	16	OBJ	_	_
19	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	in	_	FW	FW	_	3	AMOD	_	_
3	vitro	_	FW	FW	_	4	NMOD	_	_
4	immunization	_	NN	NN	_	31	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	peripheral	_	JJ	JJ	_	8	NMOD	_	_
7	blood	_	NN	NN	_	8	NMOD	_	_
8	lymphocytes	_	NNS	NNS	_	5	PMOD	_	_
9	from	_	IN	IN	_	8	NMOD	_	_
10	four	_	CD	CD	_	11	NMOD	_	_
11	patients	_	NNS	NNS	_	9	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	remission	_	NN	NN	_	12	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	S.R.	_	NNP	NNP	_	11	PRN	_	_
16	,	_	,	,	_	15	P	_	_
17	F.R.	_	NNP	NNP	_	15	NMOD	_	_
18	,	_	,	,	_	15	P	_	_
19	M.M.	_	NNP	NNP	_	15	NMOD	_	_
20	,	_	,	,	_	15	P	_	_
21	P.	_	NNP	NNP	_	22	NMOD	_	_
22	G.	_	NNP	NNP	_	15	NMOD	_	_
23	)	_	)	)	_	15	P	_	_
24	with	_	IN	IN	_	4	NMOD	_	_
25	BCR1\/25	_	NN	NN	_	24	PMOD	_	_
26	,	_	,	,	_	25	P	_	_
27	a	_	DT	DT	_	29	NMOD	_	_
28	25-mer	_	NN	NN	_	29	NMOD	_	_
29	pml\/RAR-alpha	_	NN	NN	_	25	NMOD	_	_
30	,	_	,	,	_	25	P	_	_
31	did	_	VBD	VBD	_	0	ROOT-S	_	_
32	not	_	RB	RB	_	31	VMOD	_	_
33	elicit	_	VB	VB	_	31	VC	_	_
34	either	_	CC	CC	_	41	CC	_	_
35	a	_	DT	DT	_	41	NMOD	_	_
36	polyclonal	_	JJ	JJ	_	41	NMOD	_	_
37	or	_	CC	CC	_	41	CC	_	_
38	a	_	DT	DT	_	41	NMOD	_	_
39	clonal	_	JJ	JJ	_	41	NMOD	_	_
40	immune	_	JJ	JJ	_	41	NMOD	_	_
41	response	_	NN	NN	_	33	OBJ	_	_
42	specific	_	JJ	JJ	_	41	NMOD	_	_
43	to	_	TO	TO	_	42	AMOD	_	_
44	the	_	DT	DT	_	45	NMOD	_	_
45	peptide	_	NN	NN	_	43	PMOD	_	_
46	.	_	.	.	_	31	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	then	_	RB	RB	_	3	TMP	_	_
3	generated	_	VBD	VBD	_	0	ROOT-S	_	_
4	new	_	JJ	JJ	_	9	NMOD	_	_
5	donor	_	NN	NN	_	9	NMOD	_	_
6	anti-pml\/RAR-alpha	_	JJ	JJ	_	9	NMOD	_	_
7	CD4-LRB-+-RRB-	_	JJ	JJ	_	9	NMOD	_	_
8	T-cell	_	NN	NN	_	9	NMOD	_	_
9	clones	_	NNS	NNS	_	3	OBJ	_	_
10	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	clones	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	tested	_	VBN	VBN	_	3	VC	_	_
5	for	_	IN	IN	_	4	ADV	_	_
6	their	_	PRP$	PRP$	_	7	NMOD	_	_
7	recognition	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	BCR1\/25	_	NN	NN	_	8	PMOD	_	_
10	.	_	.	.	_	3	P	_	_

1	One	_	CD	CD	_	2	NMOD	_	_
2	clone	_	NN	NN	_	12	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	C3\/5	_	NN	NN	_	2	PRN	_	_
5	,	_	,	,	_	4	P	_	_
6	CD3-LRB-+-RRB-	_	JJ	JJ	_	4	NMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	CD4-LRB-+-RRB-	_	JJ	JJ	_	6	COORD	_	_
9	,	_	,	,	_	6	P	_	_
10	CD8-LRB---RRB-	_	JJ	JJ	_	6	COORD	_	_
11	)	_	)	)	_	4	P	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	selected	_	VBN	VBN	_	12	VC	_	_
14	for	_	IN	IN	_	13	ADV	_	_
15	further	_	JJ	JJ	_	16	NMOD	_	_
16	analysis	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	12	P	_	_

1	Clone	_	NN	NN	_	2	NMOD	_	_
2	C3\/5	_	NN	NN	_	3	SBJ	_	_
3	showed	_	VBD	VBD	_	0	ROOT-S	_	_
4	specific	_	JJ	JJ	_	5	NMOD	_	_
5	proliferation	_	NN	NN	_	3	OBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	cytotoxicity	_	NN	NN	_	5	COORD	_	_
8	,	_	,	,	_	5	P	_	_
9	and	_	CC	CC	_	5	CC	_	_
10	cytokine	_	NN	NN	_	21	NMOD	_	_
11	(	_	(	(	_	19	P	_	_
12	tumor	_	NN	NN	_	15	NMOD	_	_
13	necrosis	_	NN	NN	_	15	NMOD	_	_
14	factor	_	NN	NN	_	15	NMOD	_	_
15	alpha	_	NN	NN	_	19	NMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	granulocyte-macrophage	_	JJ	JJ	_	18	AMOD	_	_
18	colony-stimulating	_	JJ	JJ	_	15	COORD	_	_
19	factor	_	NN	NN	_	10	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	production	_	NN	NN	_	5	COORD	_	_
22	when	_	WRB	WRB	_	23	ADV	_	_
23	challenged	_	VBN	VBN	_	3	TMP	_	_
24	with	_	IN	IN	_	23	ADV	_	_
25	autologous	_	JJ	JJ	_	28	NMOD	_	_
26	lymphoblastic	_	JJ	JJ	_	28	NMOD	_	_
27	cell	_	NN	NN	_	28	NMOD	_	_
28	lines	_	NNS	NNS	_	24	PMOD	_	_
29	pulsed	_	VBN	VBN	_	28	NMOD	_	_
30	with	_	IN	IN	_	29	ADV	_	_
31	peptide	_	NN	NN	_	32	NMOD	_	_
32	BCR1\/25	_	NN	NN	_	30	PMOD	_	_
33	.	_	.	.	_	3	P	_	_

1	C3\/5	_	NN	NN	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	3	SBJ	_	_
3	developed	_	VBD	VBD	_	0	ROOT-S	_	_
4	specific	_	JJ	JJ	_	5	NMOD	_	_
5	proliferation	_	NN	NN	_	3	OBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	cytotoxicity	_	NN	NN	_	5	COORD	_	_
8	when	_	WRB	WRB	_	9	ADV	_	_
9	challenged	_	VBN	VBN	_	3	TMP	_	_
10	with	_	IN	IN	_	9	ADV	_	_
11	peptide-pulsed	_	JJ	JJ	_	14	NMOD	_	_
12	lymphoblastic	_	JJ	JJ	_	14	NMOD	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	lines	_	NNS	NNS	_	10	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	peripheral	_	JJ	JJ	_	18	NMOD	_	_
17	blood	_	NN	NN	_	18	NMOD	_	_
18	lymphocytes	_	NNS	NNS	_	14	COORD	_	_
19	from	_	IN	IN	_	14	NMOD	_	_
20	the	_	DT	DT	_	24	NMOD	_	_
21	four	_	CD	CD	_	24	NMOD	_	_
22	DR11-LRB-+-RRB-	_	JJ	JJ	_	24	NMOD	_	_
23	APL	_	NN	NN	_	24	NMOD	_	_
24	patients	_	NNS	NNS	_	19	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	APL	_	NN	NN	_	2	NMOD	_	_
2	blasts	_	NNS	NNS	_	12	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	available	_	JJ	JJ	_	2	NMOD	_	_
5	only	_	RB	RB	_	6	DEP	_	_
6	from	_	IN	IN	_	4	AMOD	_	_
7	patients	_	NNS	NNS	_	6	PMOD	_	_
8	F.R.	_	NNP	NNP	_	7	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	P.G.	_	NNP	NNP	_	8	COORD	_	_
11	,	_	,	,	_	2	P	_	_
12	were	_	VBD	VBD	_	0	ROOT-S	_	_
13	not	_	RB	RB	_	12	VMOD	_	_
14	lysed	_	VBN	VBN	_	12	VC	_	_
15	by	_	IN	IN	_	14	LGS	_	_
16	C3\/5	_	NN	NN	_	15	PMOD	_	_
17	and	_	CC	CC	_	12	CC	_	_
18	were	_	VBD	VBD	_	12	COORD	_	_
19	unable	_	JJ	JJ	_	18	PRD	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	present	_	VB	VB	_	19	AMOD	_	_
22	peptide	_	NN	NN	_	23	NMOD	_	_
23	BCR1\/25	_	NN	NN	_	21	OBJ	_	_
24	.	_	.	.	_	12	P	_	_

1	Incubation	_	NN	NN	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	APL	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	IFN-gamma	_	NN	NN	_	5	PMOD	_	_
7	failed	_	VBD	VBD	_	0	ROOT-S	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	induce	_	VB	VB	_	7	OBJ	_	_
10	HLA	_	NN	NN	_	13	NMOD	_	_
11	class	_	NN	NN	_	13	NMOD	_	_
12	II	_	CD	CD	_	13	NMOD	_	_
13	molecules	_	NNS	NNS	_	9	OBJ	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	recognition	_	NN	NN	_	13	COORD	_	_
16	by	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	C3\/5	_	NN	NN	_	19	NMOD	_	_
19	clone	_	NN	NN	_	16	PMOD	_	_
20	.	_	.	.	_	7	P	_	_

1	Since	_	IN	IN	_	13	ADV	_	_
2	APL	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	4	SBJ	_	_
4	do	_	VBP	VBP	_	1	VMOD	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	express	_	VB	VB	_	4	VC	_	_
7	HLA	_	NN	NN	_	10	NMOD	_	_
8	class	_	NN	NN	_	10	NMOD	_	_
9	II	_	CD	CD	_	10	NMOD	_	_
10	molecules	_	NNS	NNS	_	6	OBJ	_	_
11	,	_	,	,	_	13	P	_	_
12	we	_	PRP	PRP	_	13	SBJ	_	_
13	tested	_	VBD	VBD	_	0	ROOT-S	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	two	_	CD	CD	_	16	NMOD	_	_
16	donors	_	NNS	NNS	_	14	PMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	D.E.	_	NNP	NNP	_	16	PRN	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	C.H.R.	_	NNP	NNP	_	18	COORD	_	_
21	)	_	)	)	_	18	P	_	_
22	and	_	CC	CC	_	14	CC	_	_
23	in	_	IN	IN	_	14	COORD	_	_
24	patients	_	NNS	NNS	_	23	PMOD	_	_
25	S.R.	_	NN	NN	_	24	NMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	P.G.	_	NN	NN	_	25	COORD	_	_
28	whether	_	CC	CC	_	37	CC	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	use	_	NN	NN	_	37	SBJ	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	9-mer	_	NN	NN	_	33	NMOD	_	_
33	peptides	_	NNS	NNS	_	31	PMOD	_	_
34	(	_	(	(	_	35	P	_	_
35	BCR1\/9	_	NN	NN	_	33	PRN	_	_
36	)	_	)	)	_	35	P	_	_
37	would	_	MD	MD	_	13	OBJ	_	_
38	generate	_	VB	VB	_	37	VC	_	_
39	a	_	DT	DT	_	43	NMOD	_	_
40	CD8\/HLA	_	NN	NN	_	41	AMOD	_	_
41	class	_	NN	NN	_	43	NMOD	_	_
42	I-restricted	_	JJ	JJ	_	41	AMOD	_	_
43	response	_	NN	NN	_	38	OBJ	_	_
44	.	_	.	.	_	13	P	_	_

1	No	_	DT	DT	_	3	NMOD	_	_
2	peptide-specific	_	JJ	JJ	_	3	NMOD	_	_
3	T-cell	_	NN	NN	_	7	SBJ	_	_
4	line	_	NN	NN	_	3	NMOD	_	_
5	or	_	CC	CC	_	4	CC	_	_
6	clone	_	NN	NN	_	4	COORD	_	_
7	could	_	MD	MD	_	0	ROOT-S	_	_
8	be	_	VB	VB	_	7	VC	_	_
9	generated	_	VBN	VBN	_	8	VC	_	_
10	from	_	IN	IN	_	9	ADV	_	_
11	both	_	CC	CC	_	12	CC	_	_
12	donors	_	NNS	NNS	_	10	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	patients	_	NNS	NNS	_	12	COORD	_	_
15	.	_	.	.	_	7	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	discussed	_	VBN	VBN	_	3	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	relation	_	NN	NN	_	5	DEP	_	_
7	to	_	TO	TO	_	5	DEP	_	_
8	possible	_	JJ	JJ	_	10	NMOD	_	_
9	therapeutic	_	JJ	JJ	_	10	NMOD	_	_
10	approaches	_	NNS	NNS	_	5	PMOD	_	_
11	to	_	TO	TO	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	immunotherapy	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	APL	_	NN	NN	_	14	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	Induction	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	NF-KB	_	NN	NN	_	2	PMOD	_	_
4	during	_	IN	IN	_	1	TMP	_	_
5	monocyte	_	NN	NN	_	6	NMOD	_	_
6	differentiation	_	NN	NN	_	4	PMOD	_	_
7	by	_	IN	IN	_	1	NMOD	_	_
8	HIV	_	NN	NN	_	11	NMOD	_	_
9	type	_	NN	NN	_	11	NMOD	_	_
10	1	_	CD	CD	_	11	NMOD	_	_
11	infection	_	NN	NN	_	7	PMOD	_	_
12	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	production	_	NN	NN	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	human	_	JJ	JJ	_	7	NMOD	_	_
5	immunodeficiency	_	NN	NN	_	7	NMOD	_	_
6	virus	_	NN	NN	_	7	NMOD	_	_
7	type	_	NN	NN	_	12	NMOD	_	_
8	1	_	CD	CD	_	7	NMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	HIV-1	_	NN	NN	_	7	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	progeny	_	NN	NN	_	3	PMOD	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	followed	_	VBN	VBN	_	13	VC	_	_
15	in	_	IN	IN	_	14	VMOD	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	U937	_	NN	NN	_	20	NMOD	_	_
18	promonocytic	_	JJ	JJ	_	20	NMOD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	line	_	NN	NN	_	15	PMOD	_	_
21	after	_	IN	IN	_	14	TMP	_	_
22	stimulation	_	NN	NN	_	21	PMOD	_	_
23	either	_	CC	CC	_	24	CC	_	_
24	with	_	IN	IN	_	22	NMOD	_	_
25	retinoic	_	JJ	JJ	_	26	NMOD	_	_
26	acid	_	NN	NN	_	24	PMOD	_	_
27	or	_	CC	CC	_	26	CC	_	_
28	PMA	_	NN	NN	_	26	COORD	_	_
29	,	_	,	,	_	14	P	_	_
30	and	_	CC	CC	_	14	CC	_	_
31	in	_	IN	IN	_	15	GAP	_	_
32	purified	_	VBN	VBN	_	34	NMOD	_	_
33	human	_	JJ	JJ	_	34	NMOD	_	_
34	monocytes	_	NNS	NNS	_	31	PMOD	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	macrophages	_	NNS	NNS	_	34	COORD	_	_
37	.	_	.	.	_	13	P	_	_

1	Electrophoretic	_	JJ	JJ	_	4	NMOD	_	_
2	mobility	_	NN	NN	_	4	NMOD	_	_
3	shift	_	NN	NN	_	4	NMOD	_	_
4	assays	_	NNS	NNS	_	9	SBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	Southwestern	_	NN	NN	_	8	NMOD	_	_
7	blotting	_	NN	NN	_	8	NMOD	_	_
8	experiments	_	NNS	NNS	_	4	COORD	_	_
9	were	_	VBD	VBD	_	0	ROOT-S	_	_
10	used	_	VBN	VBN	_	9	VC	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	detect	_	VB	VB	_	10	OBJ	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	binding	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	cellular	_	JJ	JJ	_	19	NMOD	_	_
17	transactivation	_	NN	NN	_	19	NMOD	_	_
18	factor	_	NN	NN	_	19	NMOD	_	_
19	NF-KB	_	NN	NN	_	15	PMOD	_	_
20	to	_	TO	TO	_	14	NMOD	_	_
21	the	_	DT	DT	_	25	NMOD	_	_
22	double	_	JJ	JJ	_	25	NMOD	_	_
23	repeat-KB	_	JJ	JJ	_	25	NMOD	_	_
24	enhancer	_	NN	NN	_	25	NMOD	_	_
25	sequence	_	NN	NN	_	20	PMOD	_	_
26	located	_	JJ	JJ	_	25	NMOD	_	_
27	in	_	IN	IN	_	26	AMOD	_	_
28	the	_	DT	DT	_	31	NMOD	_	_
29	long	_	JJ	JJ	_	31	NMOD	_	_
30	terminal	_	JJ	JJ	_	31	NMOD	_	_
31	repeat	_	NN	NN	_	27	PMOD	_	_
32	.	_	.	.	_	9	P	_	_

1	PMA	_	NN	NN	_	2	NMOD	_	_
2	treatment	_	NN	NN	_	13	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	and	_	CC	CC	_	2	CC	_	_
5	not	_	RB	RB	_	4	COORD	_	_
6	retinoic	_	JJ	JJ	_	8	NMOD	_	_
7	acid	_	NN	NN	_	8	NMOD	_	_
8	treatment	_	NN	NN	_	2	COORD	_	_
9	of	_	IN	IN	_	2	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	U937	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	PMOD	_	_
13	acts	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	inducing	_	VBG	VBG	_	14	PMOD	_	_
16	NF-KB	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	15	OBJ	_	_
18	in	_	IN	IN	_	15	ADV	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	nuclei	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	13	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	nuclear	_	JJ	JJ	_	3	NMOD	_	_
3	extracts	_	NNS	NNS	_	1	PMOD	_	_
4	from	_	IN	IN	_	3	NMOD	_	_
5	monocytes	_	NNS	NNS	_	4	PMOD	_	_
6	or	_	CC	CC	_	5	CC	_	_
7	macrophages	_	NNS	NNS	_	5	COORD	_	_
8	,	_	,	,	_	12	P	_	_
9	induction	_	NN	NN	_	12	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	NF-KB	_	NN	NN	_	10	PMOD	_	_
12	occurred	_	VBD	VBD	_	0	ROOT-S	_	_
13	only	_	RB	RB	_	14	VMOD	_	_
14	if	_	IN	IN	_	12	OBJ	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	17	SBJ	_	_
17	were	_	VBD	VBD	_	14	VMOD	_	_
18	previously	_	RB	RB	_	17	TMP	_	_
19	infected	_	VBN	VBN	_	17	VC	_	_
20	with	_	IN	IN	_	19	ADV	_	_
21	HIV-1	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	12	P	_	_

1	When	_	WRB	WRB	_	5	ADV	_	_
2	U937	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	14	TMP	_	_
5	infected	_	VBN	VBN	_	4	VC	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	HIV-1	_	NN	NN	_	6	PMOD	_	_
8	,	_	,	,	_	14	P	_	_
9	no	_	DT	DT	_	10	NMOD	_	_
10	induction	_	NN	NN	_	14	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	NF-KB	_	NN	NN	_	13	NMOD	_	_
13	factor	_	NN	NN	_	11	PMOD	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	detected	_	VBN	VBN	_	14	VC	_	_
16	,	_	,	,	_	14	P	_	_
17	whereas	_	IN	IN	_	14	COORD	_	_
18	high	_	JJ	JJ	_	19	NMOD	_	_
19	level	_	NN	NN	_	23	SBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	progeny	_	NN	NN	_	22	NMOD	_	_
22	virions	_	NNS	NNS	_	20	PMOD	_	_
23	was	_	VBD	VBD	_	14	COORD	_	_
24	produced	_	VBN	VBN	_	23	VC	_	_
25	,	_	,	,	_	24	P	_	_
26	suggesting	_	VBG	VBG	_	24	OBJ	_	_
27	that	_	IN	IN	_	26	OBJ	_	_
28	this	_	DT	DT	_	29	NMOD	_	_
29	factor	_	NN	NN	_	30	SBJ	_	_
30	was	_	VBD	VBD	_	27	VMOD	_	_
31	not	_	RB	RB	_	30	VMOD	_	_
32	required	_	VBN	VBN	_	30	VC	_	_
33	for	_	IN	IN	_	32	ADV	_	_
34	viral	_	JJ	JJ	_	35	NMOD	_	_
35	replication	_	NN	NN	_	33	PMOD	_	_
36	.	_	.	.	_	14	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	in	_	IN	IN	_	11	ADV	_	_
6	monocytic	_	JJ	JJ	_	8	NMOD	_	_
7	cell	_	NN	NN	_	8	NMOD	_	_
8	lineage	_	NN	NN	_	5	PMOD	_	_
9	,	_	,	,	_	11	P	_	_
10	HIV-1	_	NN	NN	_	11	SBJ	_	_
11	could	_	MD	MD	_	4	VMOD	_	_
12	mimic	_	VB	VB	_	11	VC	_	_
13	some	_	DT	DT	_	15	NMOD	_	_
14	differentiation\/activation	_	JJ	JJ	_	15	NMOD	_	_
15	stimuli	_	NNS	NNS	_	12	OBJ	_	_
16	allowing	_	VBG	VBG	_	15	NMOD	_	_
17	nuclear	_	JJ	JJ	_	19	NMOD	_	_
18	NF-KB	_	NN	NN	_	19	NMOD	_	_
19	expression	_	NN	NN	_	16	OBJ	_	_
20	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	7	NMOD	_	_
2	NF	_	NN	NN	_	7	NMOD	_	_
3	kappa	_	NN	NN	_	7	NMOD	_	_
4	B	_	NN	NN	_	7	NMOD	_	_
5	independent	_	JJ	JJ	_	7	NMOD	_	_
6	cis-acting	_	JJ	JJ	_	7	NMOD	_	_
7	sequences	_	NNS	NNS	_	0	ROOT-FRAG	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	HIV-1	_	NN	NN	_	10	NMOD	_	_
10	LTR	_	NN	NN	_	8	PMOD	_	_
11	responsive	_	NN	NN	_	10	NMOD	_	_
12	to	_	TO	TO	_	11	AMOD	_	_
13	T-cell	_	NN	NN	_	14	NMOD	_	_
14	activation	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	rate	_	NN	NN	_	17	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	transcription	_	NN	NN	_	5	NMOD	_	_
5	initiation	_	NN	NN	_	3	PMOD	_	_
6	directed	_	VBN	VBN	_	5	NMOD	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	long	_	JJ	JJ	_	11	NMOD	_	_
10	terminal	_	JJ	JJ	_	11	NMOD	_	_
11	repeat	_	NN	NN	_	7	PMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	LTR	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	of	_	IN	IN	_	11	NMOD	_	_
16	HIV-1	_	NN	NN	_	15	PMOD	_	_
17	increases	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	response	_	NN	NN	_	18	DEP	_	_
20	to	_	TO	TO	_	18	DEP	_	_
21	mitogenic	_	JJ	JJ	_	22	NMOD	_	_
22	stimuli	_	NNS	NNS	_	18	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	T	_	NN	NN	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	23	PMOD	_	_
26	.	_	.	.	_	17	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	response	_	NN	NN	_	11	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	HIV-1	_	NN	NN	_	10	NMOD	_	_
10	LTR	_	NN	NN	_	7	PMOD	_	_
11	may	_	MD	MD	_	4	VMOD	_	_
12	be	_	VB	VB	_	11	VC	_	_
13	governed	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	two	_	CD	CD	_	17	NMOD	_	_
16	independent	_	JJ	JJ	_	17	NMOD	_	_
17	sequences	_	NNS	NNS	_	14	PMOD	_	_
18	located	_	JJ	JJ	_	17	NMOD	_	_
19	5'	_	JJ	JJ	_	20	PMOD	_	_
20	to	_	TO	TO	_	18	AMOD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	site	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	transcription	_	NN	NN	_	26	NMOD	_	_
25	initiation	_	NN	NN	_	26	NMOD	_	_
26	sequences	_	NNS	NNS	_	23	PMOD	_	_
27	that	_	WDT	WDT	_	28	SBJ	_	_
28	bind	_	VBP	VBP	_	26	NMOD	_	_
29	either	_	CC	CC	_	30	CC	_	_
30	NFAT-1	_	NN	NN	_	28	OBJ	_	_
31	or	_	CC	CC	_	30	CC	_	_
32	NF	_	NN	NN	_	34	NMOD	_	_
33	kappa	_	NN	NN	_	34	NMOD	_	_
34	B	_	NN	NN	_	30	COORD	_	_
35	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	rate	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	LTR-directed	_	JJ	JJ	_	6	NMOD	_	_
5	gene	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	3	PMOD	_	_
7	increased	_	VBD	VBD	_	0	ROOT-S	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	response	_	NN	NN	_	8	DEP	_	_
10	to	_	TO	TO	_	8	DEP	_	_
11	treatment	_	NN	NN	_	8	PMOD	_	_
12	with	_	IN	IN	_	11	NMOD	_	_
13	either	_	CC	CC	_	16	CC	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	phorbol	_	NN	NN	_	16	NMOD	_	_
16	ester	_	NN	NN	_	12	PMOD	_	_
17	or	_	CC	CC	_	16	CC	_	_
18	tumor	_	NN	NN	_	21	NMOD	_	_
19	necrosis	_	NN	NN	_	21	NMOD	_	_
20	factor	_	NN	NN	_	21	NMOD	_	_
21	alpha	_	NN	NN	_	16	COORD	_	_
22	if	_	IN	IN	_	7	OBJ	_	_
23	either	_	CC	CC	_	31	CC	_	_
24	the	_	DT	DT	_	31	NMOD	_	_
25	NFAT-1	_	NN	NN	_	31	NMOD	_	_
26	or	_	CC	CC	_	25	CC	_	_
27	NF	_	NN	NN	_	29	NMOD	_	_
28	kappa	_	NN	NN	_	29	NMOD	_	_
29	B	_	NN	NN	_	25	COORD	_	_
30	binding	_	NN	NN	_	31	NMOD	_	_
31	sites	_	NNS	NNS	_	32	SBJ	_	_
32	were	_	VBD	VBD	_	22	VMOD	_	_
33	deleted	_	VBN	VBN	_	32	VC	_	_
34	,	_	,	,	_	7	P	_	_
35	but	_	CC	CC	_	7	CC	_	_
36	failed	_	VBD	VBD	_	7	COORD	_	_
37	to	_	TO	TO	_	38	VMOD	_	_
38	respond	_	VB	VB	_	36	OBJ	_	_
39	to	_	TO	TO	_	38	ADV	_	_
40	these	_	DT	DT	_	42	NMOD	_	_
41	mitogenic	_	JJ	JJ	_	42	NMOD	_	_
42	stimuli	_	NNS	NNS	_	39	PMOD	_	_
43	if	_	IN	IN	_	38	OBJ	_	_
44	both	_	DT	DT	_	45	NMOD	_	_
45	sequences	_	NNS	NNS	_	46	SBJ	_	_
46	were	_	VBD	VBD	_	43	VMOD	_	_
47	absent	_	JJ	JJ	_	46	PRD	_	_
48	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	HIV-1	_	NN	NN	_	4	NMOD	_	_
3	mutant	_	JJ	JJ	_	4	NMOD	_	_
4	virus	_	NN	NN	_	13	SBJ	_	_
5	containing	_	VBG	VBG	_	4	NMOD	_	_
6	both	_	CC	CC	_	9	CC	_	_
7	NF	_	NN	NN	_	9	NMOD	_	_
8	kappa	_	NN	NN	_	9	NMOD	_	_
9	B	_	NN	NN	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	NFAT-1	_	NN	NN	_	9	COORD	_	_
12	deletion	_	NN	NN	_	5	OBJ	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	able	_	JJ	JJ	_	13	PRD	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	replicate	_	VB	VB	_	14	AMOD	_	_
17	although	_	IN	IN	_	16	OBJ	_	_
18	at	_	IN	IN	_	17	VMOD	_	_
19	a	_	DT	DT	_	23	NMOD	_	_
20	much	_	JJ	JJ	_	23	NMOD	_	_
21	decreased	_	VBN	VBN	_	20	AMOD	_	_
22	growth	_	NN	NN	_	23	NMOD	_	_
23	rate	_	NN	NN	_	18	PMOD	_	_
24	,	_	,	,	_	13	P	_	_
25	while	_	IN	IN	_	13	ADV	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	deletion	_	NN	NN	_	31	SBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	NFAT-1	_	NN	NN	_	28	PMOD	_	_
30	alone	_	RB	RB	_	27	NMOD	_	_
31	increased	_	VBD	VBD	_	25	VMOD	_	_
32	the	_	DT	DT	_	35	NMOD	_	_
33	viral	_	JJ	JJ	_	35	NMOD	_	_
34	growth	_	NN	NN	_	35	NMOD	_	_
35	rate	_	NN	NN	_	31	OBJ	_	_
36	in	_	IN	IN	_	35	NMOD	_	_
37	Jurkat	_	NN	NN	_	38	NMOD	_	_
38	cells	_	NNS	NNS	_	36	PMOD	_	_
39	.	_	.	.	_	13	P	_	_

1	Neither	_	CC	CC	_	2	CC	_	_
2	deletion	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NF	_	NN	NN	_	6	NMOD	_	_
5	kappa	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	3	PMOD	_	_
7	nor	_	CC	CC	_	2	CC	_	_
8	deletion	_	NN	NN	_	2	COORD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	NFAT-1	_	NN	NN	_	9	PMOD	_	_
11	decreased	_	VBD	VBD	_	0	ROOT-S	_	_
12	activation	_	NN	NN	_	11	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	viral	_	JJ	JJ	_	15	NMOD	_	_
15	replication	_	NN	NN	_	13	PMOD	_	_
16	by	_	IN	IN	_	12	NMOD	_	_
17	phorbol	_	NN	NN	_	18	NMOD	_	_
18	ester	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	11	P	_	_

1	Nuclear	_	JJ	JJ	_	4	NMOD	_	_
2	factor	_	NN	NN	_	4	NMOD	_	_
3	kappa	_	NN	NN	_	4	NMOD	_	_
4	B	_	NN	NN	_	5	SBJ	_	_
5	activates	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	proenkephalin	_	NN	NN	_	7	NMOD	_	_
7	transcription	_	NN	NN	_	5	OBJ	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	lymphocytes	_	NNS	NNS	_	8	PMOD	_	_
11	.	_	.	.	_	5	P	_	_

1	Upon	_	IN	IN	_	6	TMP	_	_
2	activation	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	6	P	_	_
4	T	_	NN	NN	_	5	NMOD	_	_
5	lymphocytes	_	NNS	NNS	_	6	SBJ	_	_
6	accumulate	_	VBP	VBP	_	0	ROOT-S	_	_
7	high	_	JJ	JJ	_	8	NMOD	_	_
8	levels	_	NNS	NNS	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	neuropeptide	_	NN	NN	_	12	NMOD	_	_
12	enkephalin	_	NN	NN	_	9	PMOD	_	_
13	which	_	WDT	WDT	_	14	SBJ	_	_
14	correlate	_	VBP	VBP	_	8	NMOD	_	_
15	with	_	IN	IN	_	14	ADV	_	_
16	high	_	JJ	JJ	_	17	NMOD	_	_
17	levels	_	NNS	NNS	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	proenkephalin	_	NN	NN	_	20	NMOD	_	_
20	mRNA	_	NN	NN	_	18	PMOD	_	_
21	in	_	IN	IN	_	17	NMOD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	6	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	investigated	_	VBD	VBD	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	transcriptional	_	JJ	JJ	_	6	NMOD	_	_
6	basis	_	NN	NN	_	3	OBJ	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	these	_	DT	DT	_	9	NMOD	_	_
9	changes	_	NNS	NNS	_	7	PMOD	_	_
10	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	proenkephalin	_	NN	NN	_	3	NMOD	_	_
3	promoter	_	NN	NN	_	4	SBJ	_	_
4	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	sequence	_	NN	NN	_	7	NMOD	_	_
7	GGGGACGTCCCC	_	NN	NN	_	4	OBJ	_	_
8	,	_	,	,	_	7	P	_	_
9	named	_	VBN	VBN	_	7	NMOD	_	_
10	B2	_	NN	NN	_	9	OBJ	_	_
11	,	_	,	,	_	7	P	_	_
12	which	_	WDT	WDT	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	7	NMOD	_	_
14	similar	_	JJ	JJ	_	13	PRD	_	_
15	to	_	TO	TO	_	14	AMOD	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	kappa	_	NN	NN	_	20	NMOD	_	_
18	B	_	NN	NN	_	20	NMOD	_	_
19	sequence	_	NN	NN	_	20	NMOD	_	_
20	GGGGACTTTCC	_	NN	NN	_	15	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	binding	_	VBG	VBG	_	24	NMOD	_	_
24	site	_	NN	NN	_	20	NMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	transcription	_	NN	NN	_	28	NMOD	_	_
28	factor	_	NN	NN	_	25	PMOD	_	_
29	nuclear	_	JJ	JJ	_	30	NMOD	_	_
30	factor	_	NN	NN	_	35	NMOD	_	_
31	(	_	(	(	_	32	P	_	_
32	NF	_	NN	NN	_	35	PRN	_	_
33	)	_	)	)	_	32	P	_	_
34	-kappa	_	NN	NN	_	35	NMOD	_	_
35	B	_	NN	NN	_	28	NMOD	_	_
36	.	_	.	.	_	4	P	_	_

1	Activation	_	NN	NN	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	T	_	NN	NN	_	4	NMOD	_	_
4	lymphocytes	_	NNS	NNS	_	2	PMOD	_	_
5	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	an	_	DT	DT	_	10	NMOD	_	_
7	NF-kappa	_	NN	NN	_	10	NMOD	_	_
8	B-like	_	JJ	JJ	_	7	AMOD	_	_
9	binding	_	NN	NN	_	10	NMOD	_	_
10	activity	_	NN	NN	_	5	IOBJ	_	_
11	to	_	TO	TO	_	5	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	B2	_	NN	NN	_	14	NMOD	_	_
14	site	_	NN	NN	_	11	PMOD	_	_
15	,	_	,	,	_	5	P	_	_
16	concomitant	_	JJ	JJ	_	5	OBJ	_	_
17	with	_	IN	IN	_	16	AMOD	_	_
18	activation	_	NN	NN	_	17	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	proenkephalin	_	NN	NN	_	22	NMOD	_	_
22	promoter	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	5	P	_	_

1	Mutations	_	NNS	NNS	_	6	SBJ	_	_
2	at	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	B2	_	NN	NN	_	5	NMOD	_	_
5	site	_	NN	NN	_	2	PMOD	_	_
6	abolish	_	VBP	VBP	_	0	ROOT-S	_	_
7	this	_	DT	DT	_	9	NMOD	_	_
8	transcriptional	_	JJ	JJ	_	9	NMOD	_	_
9	activation	_	NN	NN	_	6	OBJ	_	_
10	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	purified	_	VBN	VBN	_	3	NMOD	_	_
3	homodimer	_	NN	NN	_	15	SBJ	_	_
4	(	_	(	(	_	6	P	_	_
5	two	_	CD	CD	_	6	NMOD	_	_
6	p50s	_	NNS	NNS	_	3	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	of	_	IN	IN	_	3	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	DNA-binding	_	JJ	JJ	_	11	NMOD	_	_
11	subunit	_	NN	NN	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	NF-kappa	_	NN	NN	_	14	NMOD	_	_
14	B	_	NN	NN	_	12	PMOD	_	_
15	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	B2	_	NN	NN	_	18	NMOD	_	_
18	site	_	NN	NN	_	15	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	proenkephalin	_	NN	NN	_	19	PMOD	_	_
21	relatively	_	RB	RB	_	15	ADV	_	_
22	better	_	JJR	JJR	_	21	AMOD	_	_
23	than	_	IN	IN	_	21	AMOD	_	_
24	does	_	VBZ	VBZ	_	23	VMOD	_	_
25	the	_	DT	DT	_	34	NMOD	_	_
26	heterotetramer	_	NN	NN	_	34	NMOD	_	_
27	(	_	(	(	_	29	P	_	_
28	two	_	CD	CD	_	29	NMOD	_	_
29	p65s	_	NNS	NNS	_	26	PRN	_	_
30	plus	_	CC	CC	_	29	CC	_	_
31	two	_	CD	CD	_	32	NMOD	_	_
32	p50s	_	NNS	NNS	_	29	COORD	_	_
33	)	_	)	)	_	29	P	_	_
34	form	_	NN	NN	_	24	SBJ	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	the	_	DT	DT	_	37	NMOD	_	_
37	factor	_	NN	NN	_	35	PMOD	_	_
38	.	_	.	.	_	15	P	_	_

1	Thus	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	it	_	PRP	PRP	_	4	SBJ	_	_
4	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	T-cell-specific	_	JJ	JJ	_	8	NMOD	_	_
8	activation	_	NN	NN	_	13	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	proenkephalin	_	NN	NN	_	12	NMOD	_	_
12	promoter	_	NN	NN	_	9	PMOD	_	_
13	is	_	VBZ	VBZ	_	5	VMOD	_	_
14	mediated	_	VBN	VBN	_	13	VC	_	_
15	by	_	IN	IN	_	14	LGS	_	_
16	NF-kappa	_	NN	NN	_	17	NMOD	_	_
17	B	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	4	P	_	_

1	However	_	RB	RB	_	30	ADV	_	_
2	,	_	,	,	_	30	P	_	_
3	as	_	IN	IN	_	30	ADV	_	_
4	NF-kappa	_	NN	NN	_	5	NMOD	_	_
5	B	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	3	VMOD	_	_
7	ubiquitous	_	JJ	JJ	_	6	PRD	_	_
8	and	_	CC	CC	_	6	CC	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	transcriptional	_	JJ	JJ	_	11	NMOD	_	_
11	activation	_	NN	NN	_	16	SBJ	_	_
12	through	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	B2	_	NN	NN	_	15	NMOD	_	_
15	site	_	NN	NN	_	12	PMOD	_	_
16	is	_	VBZ	VBZ	_	6	COORD	_	_
17	T	_	NN	NN	_	18	NMOD	_	_
18	cell	_	NN	NN	_	19	AMOD	_	_
19	specific	_	JJ	JJ	_	16	PRD	_	_
20	,	_	,	,	_	30	P	_	_
21	yet	_	RB	RB	_	24	NMOD	_	_
22	another	_	DT	DT	_	24	NMOD	_	_
23	T-cell-specific	_	JJ	JJ	_	24	NMOD	_	_
24	factor	_	NN	NN	_	30	SBJ	_	_
25	which	_	WDT	WDT	_	26	SBJ	_	_
26	synergizes	_	VBZ	VBZ	_	24	NMOD	_	_
27	with	_	IN	IN	_	26	ADV	_	_
28	NF-kappa	_	NN	NN	_	29	NMOD	_	_
29	B	_	NN	NN	_	27	PMOD	_	_
30	should	_	MD	MD	_	0	ROOT-S	_	_
31	be	_	VB	VB	_	30	VC	_	_
32	considered	_	VBN	VBN	_	31	VC	_	_
33	.	_	.	.	_	30	P	_	_

1	1,25-Dihydroxyvitamin	_	NN	NN	_	4	NMOD	_	_
2	D3	_	NN	NN	_	4	NMOD	_	_
3	receptor	_	NN	NN	_	4	NMOD	_	_
4	RNA	_	NN	NN	_	0	ROOT-FRAG	_	_
5	:	_	:	:	_	4	P	_	_
6	expression	_	NN	NN	_	4	NMOD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	hematopoietic	_	JJ	JJ	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	7	PMOD	_	_
10	.	_	.	.	_	6	P	_	_

1	1,25-Dihydroxyvitamin	_	NN	NN	_	2	NMOD	_	_
2	D3	_	NN	NN	_	6	SBJ	_	_
3	{	_	(	(	_	4	P	_	_
4	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	2	PRN	_	_
5	}	_	)	)	_	4	P	_	_
6	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	differentiation	_	NN	NN	_	6	OBJ	_	_
8	and	_	CC	CC	_	6	CC	_	_
9	inhibits	_	VBZ	VBZ	_	6	COORD	_	_
10	proliferation	_	NN	NN	_	9	OBJ	_	_
11	of	_	IN	IN	_	7	NMOD	_	_
12	myeloid	_	JJ	JJ	_	14	NMOD	_	_
13	leukemic	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	11	PMOD	_	_
15	from	_	IN	IN	_	14	NMOD	_	_
16	various	_	JJ	JJ	_	17	NMOD	_	_
17	lines	_	NNS	NNS	_	15	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	patients	_	NNS	NNS	_	17	COORD	_	_
20	;	_	:	:	_	6	P	_	_
21	these	_	DT	DT	_	22	NMOD	_	_
22	effects	_	NNS	NNS	_	23	SBJ	_	_
23	are	_	VBP	VBP	_	6	VMOD	_	_
24	probably	_	RB	RB	_	23	ADV	_	_
25	mediated	_	VBN	VBN	_	23	VC	_	_
26	through	_	IN	IN	_	25	ADV	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	29	NMOD	_	_
29	receptor	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	23	P	_	_

1	Little	_	JJ	JJ	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	known	_	VBN	VBN	_	2	VC	_	_
4	of	_	IN	IN	_	1	NMOD	_	_
5	expression	_	NN	NN	_	4	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	9	NMOD	_	_
8	receptor	_	NN	NN	_	9	NMOD	_	_
9	RNA	_	NN	NN	_	6	PMOD	_	_
10	in	_	IN	IN	_	5	NMOD	_	_
11	hematopoietic	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	examined	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	expression	_	NN	NN	_	2	OBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	modulation	_	NN	NN	_	4	COORD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	expression	_	NN	NN	_	7	PMOD	_	_
9	of	_	IN	IN	_	4	NMOD	_	_
10	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	12	NMOD	_	_
11	receptor	_	NN	NN	_	12	NMOD	_	_
12	RNA	_	NN	NN	_	9	PMOD	_	_
13	in	_	IN	IN	_	4	NMOD	_	_
14	various	_	JJ	JJ	_	19	NMOD	_	_
15	proliferating	_	VBG	VBG	_	19	NMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	nonproliferating	_	JJ	JJ	_	15	COORD	_	_
18	hematopoietic	_	JJ	JJ	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	13	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	Constitutive	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	6	NMOD	_	_
5	receptor	_	NN	NN	_	6	NMOD	_	_
6	RNA	_	NN	NN	_	3	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	detected	_	VBN	VBN	_	7	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	various	_	JJ	JJ	_	11	NMOD	_	_
11	kinds	_	NNS	NNS	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	hematopoietic	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	including	_	VBG	VBG	_	14	NMOD	_	_
17	macrophages	_	NNS	NNS	_	16	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	activated	_	VBN	VBN	_	21	NMOD	_	_
20	T	_	NN	NN	_	21	NMOD	_	_
21	lymphocytes	_	NNS	NNS	_	17	COORD	_	_
22	,	_	,	,	_	14	P	_	_
23	as	_	RB	RB	_	9	CC	_	_
24	well	_	RB	RB	_	23	DEP	_	_
25	as	_	IN	IN	_	23	DEP	_	_
26	in	_	IN	IN	_	9	COORD	_	_
27	cell	_	NN	NN	_	28	NMOD	_	_
28	lines	_	NNS	NNS	_	26	PMOD	_	_
29	KG-1	_	NN	NN	_	28	NMOD	_	_
30	(	_	(	(	_	31	P	_	_
31	myeloblasts	_	NNS	NNS	_	29	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	,	_	,	,	_	29	P	_	_
34	HL-60	_	NN	NN	_	29	COORD	_	_
35	(	_	(	(	_	36	P	_	_
36	promyelocytes	_	NNS	NNS	_	34	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	,	_	,	,	_	29	P	_	_
39	ML-3	_	NN	NN	_	29	COORD	_	_
40	(	_	(	(	_	41	P	_	_
41	myelomonoblasts	_	NNS	NNS	_	39	PRN	_	_
42	)	_	)	)	_	41	P	_	_
43	,	_	,	,	_	29	P	_	_
44	U937	_	NN	NN	_	29	COORD	_	_
45	,	_	,	,	_	29	P	_	_
46	THP-1	_	NN	NN	_	29	COORD	_	_
47	(	_	(	(	_	48	P	_	_
48	monoblasts	_	NNS	NNS	_	46	PRN	_	_
49	)	_	)	)	_	48	P	_	_
50	,	_	,	,	_	29	P	_	_
51	K562	_	NN	NN	_	29	COORD	_	_
52	(	_	(	(	_	53	P	_	_
53	erythroblasts	_	NNS	NNS	_	51	PRN	_	_
54	)	_	)	)	_	53	P	_	_
55	,	_	,	,	_	29	P	_	_
56	and	_	CC	CC	_	29	CC	_	_
57	S-LB1	_	NN	NN	_	29	COORD	_	_
58	(	_	(	(	_	61	P	_	_
59	HTLV-1-transfected	_	JJ	JJ	_	61	NMOD	_	_
60	T	_	NN	NN	_	61	NMOD	_	_
61	lymphocytes	_	NNS	NNS	_	57	PRN	_	_
62	)	_	)	)	_	61	P	_	_
63	.	_	.	.	_	7	P	_	_

1	Receptor	_	NN	NN	_	2	NMOD	_	_
2	transcripts	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	4.6	_	CD	CD	_	5	NMOD	_	_
5	kilobases	_	NNS	NNS	_	3	PRD	_	_
6	(	_	(	(	_	7	P	_	_
7	kb	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	,	_	,	,	_	3	P	_	_
10	and	_	CC	CC	_	3	CC	_	_
11	no	_	DT	DT	_	13	NMOD	_	_
12	variant	_	JJ	JJ	_	13	NMOD	_	_
13	sizes	_	NNS	NNS	_	14	SBJ	_	_
14	were	_	VBD	VBD	_	3	COORD	_	_
15	observed	_	VBN	VBN	_	14	VC	_	_
16	.	_	.	.	_	3	P	_	_

1	All	_	DT	DT	_	3	NMOD	_	_
2	cell	_	NN	NN	_	3	NMOD	_	_
3	lines	_	NNS	NNS	_	9	SBJ	_	_
4	examined	_	VBN	VBN	_	3	NMOD	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	this	_	DT	DT	_	7	NMOD	_	_
7	group	_	NN	NN	_	5	PMOD	_	_
8	also	_	RB	RB	_	9	ADV	_	_
9	expressed	_	VBD	VBD	_	0	ROOT-S	_	_
10	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	11	NMOD	_	_
11	receptors	_	NNS	NNS	_	9	OBJ	_	_
12	.	_	.	.	_	9	P	_	_

1	Most	_	JJS	JJS	_	4	NMOD	_	_
2	B	_	NN	NN	_	4	NMOD	_	_
3	lymphocyte	_	NN	NN	_	4	NMOD	_	_
4	lines	_	NNS	NNS	_	5	SBJ	_	_
5	expressed	_	VBD	VBD	_	0	ROOT-S	_	_
6	negligible	_	JJ	JJ	_	7	NMOD	_	_
7	levels	_	NNS	NNS	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	11	NMOD	_	_
10	receptor	_	NN	NN	_	11	NMOD	_	_
11	RNA	_	NN	NN	_	8	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	protein	_	NN	NN	_	11	COORD	_	_
14	;	_	:	:	_	5	P	_	_
15	however	_	RB	RB	_	5	COORD	_	_
16	;	_	:	:	_	5	P	_	_
17	analysis	_	NN	NN	_	23	SBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	a	_	DT	DT	_	22	NMOD	_	_
20	lymphoid\/myeloid	_	JJ	JJ	_	22	NMOD	_	_
21	somatic	_	JJ	JJ	_	22	NMOD	_	_
22	hybrid	_	NN	NN	_	18	PMOD	_	_
23	suggested	_	VBD	VBD	_	5	COORD	_	_
24	that	_	IN	IN	_	23	OBJ	_	_
25	suppression	_	NN	NN	_	35	SBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	expression	_	NN	NN	_	26	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	31	NMOD	_	_
30	receptor	_	NN	NN	_	31	NMOD	_	_
31	RNA	_	NN	NN	_	28	PMOD	_	_
32	in	_	IN	IN	_	25	NMOD	_	_
33	B	_	NN	NN	_	34	NMOD	_	_
34	lymphocytes	_	NNS	NNS	_	32	PMOD	_	_
35	may	_	MD	MD	_	24	VMOD	_	_
36	be	_	VB	VB	_	35	VC	_	_
37	a	_	DT	DT	_	39	NMOD	_	_
38	dominant	_	JJ	JJ	_	39	NMOD	_	_
39	characteristic	_	NN	NN	_	36	PRD	_	_
40	.	_	.	.	_	5	P	_	_

1	HL-60	_	NN	NN	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	cultured	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	10-LRB--7-RRB-	_	CD	CD	_	7	NMOD	_	_
7	mol\/L	_	NN	NN	_	5	PMOD	_	_
8	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	7	NMOD	_	_
9	for	_	IN	IN	_	4	TMP	_	_
10	24	_	CD	CD	_	12	DEP	_	_
11	to	_	TO	TO	_	12	DEP	_	_
12	72	_	CD	CD	_	13	NMOD	_	_
13	hours	_	NNS	NNS	_	9	PMOD	_	_
14	,	_	,	,	_	3	P	_	_
15	and	_	CC	CC	_	3	CC	_	_
16	levels	_	NNS	NNS	_	25	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	expression	_	NN	NN	_	17	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	21	NMOD	_	_
21	receptor	_	NN	NN	_	19	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	its	_	PRP$	PRP$	_	24	NMOD	_	_
24	RNA	_	NN	NN	_	21	COORD	_	_
25	were	_	VBD	VBD	_	3	COORD	_	_
26	examined	_	VBN	VBN	_	25	VC	_	_
27	.	_	.	.	_	3	P	_	_

1	Levels	_	NNS	NNS	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	RNA	_	NN	NN	_	2	PMOD	_	_
4	coding	_	NN	NN	_	3	NMOD	_	_
5	for	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	receptor	_	NN	NN	_	5	PMOD	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	modulated	_	VBN	VBN	_	8	VC	_	_
11	by	_	IN	IN	_	10	ADV	_	_
12	exposure	_	NN	NN	_	11	PMOD	_	_
13	to	_	TO	TO	_	12	NMOD	_	_
14	high	_	JJ	JJ	_	15	NMOD	_	_
15	levels	_	NNS	NNS	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	ligand	_	NN	NN	_	16	PMOD	_	_
18	.	_	.	.	_	8	P	_	_

1	Levels	_	NNS	NNS	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	occupied	_	VBN	VBN	_	6	NMOD	_	_
4	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	6	NMOD	_	_
5	receptor	_	NN	NN	_	6	NMOD	_	_
6	protein	_	NN	NN	_	2	PMOD	_	_
7	increased	_	VBD	VBD	_	0	ROOT-S	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	these	_	DT	DT	_	11	NMOD	_	_
10	HL-60	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	8	PMOD	_	_
12	;	_	:	:	_	7	P	_	_
13	but	_	CC	CC	_	7	CC	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	total	_	JJ	JJ	_	16	NMOD	_	_
16	number	_	NN	NN	_	20	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	19	NMOD	_	_
19	receptors	_	NNS	NNS	_	17	PMOD	_	_
20	decreased	_	VBD	VBD	_	7	COORD	_	_
21	about	_	RB	RB	_	23	NMOD	_	_
22	50	_	CD	CD	_	21	DEP	_	_
23	%	_	NN	NN	_	20	OBJ	_	_
24	at	_	IN	IN	_	20	TMP	_	_
25	24	_	CD	CD	_	26	NMOD	_	_
26	hours	_	NNS	NNS	_	24	PMOD	_	_
27	and	_	CC	CC	_	20	CC	_	_
28	returned	_	VBD	VBD	_	20	COORD	_	_
29	toward	_	IN	IN	_	28	ADV	_	_
30	normal	_	JJ	JJ	_	29	PMOD	_	_
31	at	_	IN	IN	_	28	TMP	_	_
32	72	_	CD	CD	_	33	NMOD	_	_
33	hours	_	NNS	NNS	_	31	PMOD	_	_
34	.	_	.	.	_	7	P	_	_

1	Steady-state	_	JJ	JJ	_	2	NMOD	_	_
2	levels	_	NNS	NNS	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	6	NMOD	_	_
5	receptor	_	NN	NN	_	6	NMOD	_	_
6	RNA	_	NN	NN	_	3	PMOD	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	not	_	RB	RB	_	7	VMOD	_	_
9	affected	_	VBN	VBN	_	7	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	terminal	_	JJ	JJ	_	12	NMOD	_	_
12	differentiation	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	HL-60	_	NN	NN	_	13	PMOD	_	_
15	toward	_	IN	IN	_	12	NMOD	_	_
16	either	_	CC	CC	_	17	CC	_	_
17	granulocytes	_	NNS	NNS	_	15	PMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	macrophages	_	NNS	NNS	_	17	COORD	_	_
20	.	_	.	.	_	7	P	_	_

1	Nondividing	_	JJ	JJ	_	2	NMOD	_	_
2	macrophages	_	NNS	NNS	_	7	SBJ	_	_
3	from	_	IN	IN	_	2	NMOD	_	_
4	normal	_	JJ	JJ	_	5	NMOD	_	_
5	individuals	_	NNS	NNS	_	3	PMOD	_	_
6	also	_	RB	RB	_	7	ADV	_	_
7	expressed	_	VBD	VBD	_	0	ROOT-S	_	_
8	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	10	NMOD	_	_
9	receptor	_	NN	NN	_	10	NMOD	_	_
10	RNA	_	NN	NN	_	7	OBJ	_	_
11	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	11	P	_	_
4	nondividing	_	JJ	JJ	_	7	NMOD	_	_
5	peripheral	_	JJ	JJ	_	7	NMOD	_	_
6	blood	_	NN	NN	_	7	NMOD	_	_
7	lymphocytes	_	NNS	NNS	_	11	SBJ	_	_
8	from	_	IN	IN	_	7	NMOD	_	_
9	normal	_	JJ	JJ	_	10	NMOD	_	_
10	individuals	_	NNS	NNS	_	8	PMOD	_	_
11	did	_	VBD	VBD	_	0	ROOT-S	_	_
12	not	_	RB	RB	_	11	VMOD	_	_
13	express	_	VB	VB	_	11	VC	_	_
14	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	16	NMOD	_	_
15	receptor	_	NN	NN	_	16	NMOD	_	_
16	RNA	_	NN	NN	_	13	OBJ	_	_
17	;	_	:	:	_	11	P	_	_
18	with	_	IN	IN	_	31	ADV	_	_
19	stimulation	_	NN	NN	_	18	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	proliferation	_	NN	NN	_	20	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	these	_	DT	DT	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	,	_	,	,	_	31	P	_	_
26	accumulation	_	NN	NN	_	31	SBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	30	NMOD	_	_
29	receptor	_	NN	NN	_	30	NMOD	_	_
30	RNA	_	NN	NN	_	27	PMOD	_	_
31	increased	_	VBD	VBD	_	11	VMOD	_	_
32	markedly	_	RB	RB	_	31	ADV	_	_
33	.	_	.	.	_	31	P	_	_

1	Half-life	_	NN	NN	_	12	SBJ	_	_
2	(	_	(	(	_	3	P	_	_
3	t1\/2	_	NN	NN	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	of	_	IN	IN	_	1	NMOD	_	_
6	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	8	NMOD	_	_
7	receptor	_	NN	NN	_	8	NMOD	_	_
8	RNA	_	NN	NN	_	5	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	T	_	NN	NN	_	11	NMOD	_	_
11	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	short	_	JJ	JJ	_	12	PRD	_	_
14	(	_	(	(	_	16	P	_	_
15	1	_	CD	CD	_	16	NMOD	_	_
16	hour	_	NN	NN	_	13	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	as	_	IN	IN	_	12	ADV	_	_
19	determined	_	VBN	VBN	_	18	VMOD	_	_
20	by	_	IN	IN	_	19	ADV	_	_
21	measuring	_	VBG	VBG	_	20	PMOD	_	_
22	decay	_	NN	NN	_	21	OBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	message	_	NN	NN	_	23	PMOD	_	_
26	after	_	IN	IN	_	22	TMP	_	_
27	addition	_	NN	NN	_	26	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	actinomycin	_	NN	NN	_	30	NMOD	_	_
30	D	_	NN	NN	_	28	PMOD	_	_
31	.	_	.	.	_	12	P	_	_

1	Consistent	_	JJ	JJ	_	12	ADV	_	_
2	with	_	IN	IN	_	1	AMOD	_	_
3	this	_	DT	DT	_	5	NMOD	_	_
4	short	_	JJ	JJ	_	5	NMOD	_	_
5	t1\/2	_	NN	NN	_	2	PMOD	_	_
6	,	_	,	,	_	12	P	_	_
7	accumulation	_	NN	NN	_	12	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	11	NMOD	_	_
10	receptor	_	NN	NN	_	11	NMOD	_	_
11	RNA	_	NN	NN	_	8	PMOD	_	_
12	increased	_	VBD	VBD	_	0	ROOT-S	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	cells	_	NNS	NNS	_	13	PMOD	_	_
15	as	_	IN	IN	_	12	ADV	_	_
16	their	_	PRP$	PRP$	_	18	NMOD	_	_
17	protein	_	NN	NN	_	18	NMOD	_	_
18	synthesis	_	NN	NN	_	19	SBJ	_	_
19	was	_	VBD	VBD	_	15	VMOD	_	_
20	inhibited	_	VBN	VBN	_	19	VC	_	_
21	.	_	.	.	_	12	P	_	_

1	Comparison	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	constitutive	_	JJ	JJ	_	7	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	inducible	_	JJ	JJ	_	3	COORD	_	_
6	transcriptional	_	JJ	JJ	_	7	NMOD	_	_
7	enhancement	_	NN	NN	_	2	PMOD	_	_
8	mediated	_	VBN	VBN	_	7	NMOD	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	kappa	_	NN	NN	_	12	NMOD	_	_
11	B-related	_	JJ	JJ	_	10	AMOD	_	_
12	sequences	_	NNS	NNS	_	9	PMOD	_	_
13	:	_	:	:	_	1	P	_	_
14	modulation	_	NN	NN	_	1	NMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	activity	_	NN	NN	_	15	PMOD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	17	PMOD	_	_
20	by	_	IN	IN	_	14	NMOD	_	_
21	human	_	JJ	JJ	_	28	NMOD	_	_
22	T-cell	_	NN	NN	_	28	NMOD	_	_
23	leukemia	_	NN	NN	_	28	NMOD	_	_
24	virus	_	NN	NN	_	28	NMOD	_	_
25	type	_	NN	NN	_	28	NMOD	_	_
26	I	_	CD	CD	_	28	NMOD	_	_
27	tax	_	NN	NN	_	28	NMOD	_	_
28	gene	_	NN	NN	_	20	PMOD	_	_
29	.	_	.	.	_	14	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	kappa	_	NN	NN	_	4	NMOD	_	_
3	B	_	NN	NN	_	4	NMOD	_	_
4	sequence	_	NN	NN	_	8	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	GGGACTTTCC	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	factor	_	NN	NN	_	8	OBJ	_	_
11	,	_	,	,	_	10	P	_	_
12	NF-kappa	_	NN	NN	_	13	NMOD	_	_
13	B	_	NN	NN	_	10	NMOD	_	_
14	,	_	,	,	_	10	P	_	_
15	that	_	WDT	WDT	_	16	SBJ	_	_
16	is	_	VBZ	VBZ	_	10	NMOD	_	_
17	constitutively	_	RB	RB	_	16	ADV	_	_
18	found	_	VBN	VBN	_	16	VC	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	its	_	PRP$	PRP$	_	25	NMOD	_	_
21	functional	_	JJ	JJ	_	25	NMOD	_	_
22	,	_	,	,	_	21	P	_	_
23	DNA	_	NN	NN	_	24	AMOD	_	_
24	binding	_	NN	NN	_	21	COORD	_	_
25	form	_	NN	NN	_	19	PMOD	_	_
26	only	_	RB	RB	_	27	DEP	_	_
27	in	_	IN	IN	_	18	ADV	_	_
28	B	_	NN	NN	_	29	NMOD	_	_
29	lymphocytes	_	NNS	NNS	_	27	PMOD	_	_
30	.	_	.	.	_	8	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	factor	_	NN	NN	_	8	SBJ	_	_
3	with	_	IN	IN	_	2	NMOD	_	_
4	apparently	_	RB	RB	_	5	AMOD	_	_
5	indistinguishable	_	JJ	JJ	_	7	NMOD	_	_
6	sequence	_	NN	NN	_	7	NMOD	_	_
7	specificity	_	NN	NN	_	3	PMOD	_	_
8	can	_	MD	MD	_	0	ROOT-S	_	_
9	be	_	VB	VB	_	8	VC	_	_
10	induced	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	many	_	JJ	JJ	_	15	NMOD	_	_
13	other	_	JJ	JJ	_	15	NMOD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	types	_	NNS	NNS	_	11	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	where	_	WRB	WRB	_	19	VMOD	_	_
18	it	_	PRP	PRP	_	19	SBJ	_	_
19	is	_	VBZ	VBZ	_	15	NMOD	_	_
20	used	_	VBN	VBN	_	19	VC	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	regulate	_	VB	VB	_	20	OBJ	_	_
23	inducible	_	JJ	JJ	_	25	NMOD	_	_
24	gene	_	NN	NN	_	25	NMOD	_	_
25	expression	_	NN	NN	_	22	OBJ	_	_
26	.	_	.	.	_	8	P	_	_

1	For	_	IN	IN	_	7	ADV	_	_
2	example	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	7	P	_	_
4	kappa	_	NN	NN	_	6	NMOD	_	_
5	B-related	_	JJ	JJ	_	4	AMOD	_	_
6	sequences	_	NNS	NNS	_	7	SBJ	_	_
7	have	_	VBP	VBP	_	0	ROOT-S	_	_
8	been	_	VBN	VBN	_	7	VC	_	_
9	shown	_	VBN	VBN	_	8	VC	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	be	_	VB	VB	_	9	OBJ	_	_
12	important	_	JJ	JJ	_	11	PRD	_	_
13	for	_	IN	IN	_	12	AMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	transcription	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	a	_	DT	DT	_	18	DEP	_	_
18	few	_	JJ	JJ	_	20	NMOD	_	_
19	inducible	_	JJ	JJ	_	20	NMOD	_	_
20	genes	_	NNS	NNS	_	16	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	such	_	JJ	JJ	_	23	DEP	_	_
23	as	_	IN	IN	_	20	NMOD	_	_
24	the	_	DT	DT	_	29	NMOD	_	_
25	interleukin	_	NN	NN	_	29	NMOD	_	_
26	2	_	CD	CD	_	29	NMOD	_	_
27	receptor	_	NN	NN	_	29	NMOD	_	_
28	alpha-chain	_	NN	NN	_	29	NMOD	_	_
29	gene	_	NN	NN	_	23	PMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	beta-interferon	_	NN	NN	_	33	NMOD	_	_
33	gene	_	NN	NN	_	29	COORD	_	_
34	.	_	.	.	_	7	P	_	_

1	However	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	genes	_	NNS	NNS	_	5	SBJ	_	_
5	are	_	VBP	VBP	_	0	ROOT-S	_	_
6	not	_	RB	RB	_	5	VMOD	_	_
7	constitutively	_	RB	RB	_	8	AMOD	_	_
8	active	_	JJ	JJ	_	5	PRD	_	_
9	in	_	IN	IN	_	8	AMOD	_	_
10	B	_	NN	NN	_	11	NMOD	_	_
11	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
12	,	_	,	,	_	5	P	_	_
13	suggesting	_	VBG	VBG	_	5	VC	_	_
14	that	_	IN	IN	_	13	OBJ	_	_
15	other	_	JJ	JJ	_	17	NMOD	_	_
16	regulatory	_	JJ	JJ	_	17	NMOD	_	_
17	mechanisms	_	NNS	NNS	_	18	SBJ	_	_
18	must	_	MD	MD	_	14	VMOD	_	_
19	play	_	VB	VB	_	18	VC	_	_
20	a	_	DT	DT	_	21	NMOD	_	_
21	role	_	NN	NN	_	19	OBJ	_	_
22	in	_	IN	IN	_	19	ADV	_	_
23	determining	_	VBG	VBG	_	22	PMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	patterns	_	NNS	NNS	_	23	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	expression	_	NN	NN	_	26	PMOD	_	_
28	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	investigated	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	9	NMOD	_	_
5	constitutive	_	JJ	JJ	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	inducible	_	JJ	JJ	_	5	COORD	_	_
8	transcriptional	_	JJ	JJ	_	9	NMOD	_	_
9	activity	_	NN	NN	_	3	OBJ	_	_
10	mediated	_	VBN	VBN	_	9	NMOD	_	_
11	by	_	IN	IN	_	10	ADV	_	_
12	five	_	CD	CD	_	16	NMOD	_	_
13	kappa	_	NN	NN	_	16	NMOD	_	_
14	B-related	_	JJ	JJ	_	13	AMOD	_	_
15	sequence	_	NN	NN	_	16	NMOD	_	_
16	elements	_	NNS	NNS	_	11	PMOD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	two	_	CD	CD	_	21	NMOD	_	_
19	different	_	JJ	JJ	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	types	_	NNS	NNS	_	17	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	in	_	IN	IN	_	13	ADV	_	_
5	S194	_	NN	NN	_	7	NMOD	_	_
6	plasma	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	4	PMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	activity	_	NN	NN	_	13	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	each	_	DT	DT	_	12	NMOD	_	_
12	element	_	NN	NN	_	10	PMOD	_	_
13	correlates	_	VBZ	VBZ	_	3	VMOD	_	_
14	well	_	RB	RB	_	13	ADV	_	_
15	with	_	IN	IN	_	13	ADV	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	relative	_	JJ	JJ	_	18	NMOD	_	_
18	affinity	_	NN	NN	_	15	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	B-cell-derived	_	JJ	JJ	_	22	NMOD	_	_
21	NF-kappa	_	NN	NN	_	22	NMOD	_	_
22	B	_	NN	NN	_	19	PMOD	_	_
23	for	_	IN	IN	_	18	NMOD	_	_
24	that	_	DT	DT	_	25	NMOD	_	_
25	element	_	NN	NN	_	23	PMOD	_	_
26	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	leads	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	to	_	TO	TO	_	2	ADV	_	_
4	significantly	_	RB	RB	_	5	AMOD	_	_
5	lower	_	RBR	RBR	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	enhancement	_	NN	NN	_	3	PMOD	_	_
8	by	_	IN	IN	_	7	NMOD	_	_
9	sites	_	NNS	NNS	_	8	PMOD	_	_
10	derived	_	VBN	VBN	_	9	NMOD	_	_
11	from	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	19	NMOD	_	_
13	interleukin	_	NN	NN	_	15	NMOD	_	_
14	2	_	CD	CD	_	15	NMOD	_	_
15	receptor	_	NN	NN	_	19	NMOD	_	_
16	or	_	CC	CC	_	15	CC	_	_
17	T-cell	_	NN	NN	_	18	NMOD	_	_
18	receptor	_	NN	NN	_	15	COORD	_	_
19	genes	_	NNS	NNS	_	11	PMOD	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	S194	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	2	P	_	_

1	However	_	RB	RB	_	17	ADV	_	_
2	,	_	,	,	_	17	P	_	_
3	in	_	IN	IN	_	17	ADV	_	_
4	either	_	CC	CC	_	9	CC	_	_
5	EL-4	_	NN	NN	_	9	NMOD	_	_
6	(	_	(	(	_	9	P	_	_
7	T	_	NN	NN	_	9	NMOD	_	_
8	)	_	)	)	_	9	P	_	_
9	cells	_	NNS	NNS	_	3	PMOD	_	_
10	or	_	CC	CC	_	9	CC	_	_
11	S194	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	COORD	_	_
13	,	_	,	,	_	17	P	_	_
14	both	_	DT	DT	_	16	NMOD	_	_
15	lower-affinity	_	JJ	JJ	_	16	NMOD	_	_
16	sites	_	NNS	NNS	_	17	SBJ	_	_
17	can	_	MD	MD	_	0	ROOT-S	_	_
18	be	_	VB	VB	_	17	VC	_	_
19	significantly	_	RB	RB	_	18	ADV	_	_
20	induced	_	VBN	VBN	_	18	VC	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	the	_	DT	DT	_	25	NMOD	_	_
23	tax	_	NN	NN	_	25	NMOD	_	_
24	gene	_	NN	NN	_	25	NMOD	_	_
25	product	_	NN	NN	_	21	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	human	_	JJ	JJ	_	31	NMOD	_	_
28	T-cell	_	NN	NN	_	31	NMOD	_	_
29	leukemia	_	NN	NN	_	31	NMOD	_	_
30	virus	_	NN	NN	_	31	NMOD	_	_
31	type	_	NN	NN	_	26	PMOD	_	_
32	I	_	CD	CD	_	31	NMOD	_	_
33	,	_	,	,	_	20	P	_	_
34	showing	_	VBG	VBG	_	20	ADV	_	_
35	that	_	IN	IN	_	34	OBJ	_	_
36	NF-kappa	_	NN	NN	_	38	NMOD	_	_
37	B	_	NN	NN	_	38	NMOD	_	_
38	activity	_	NN	NN	_	39	SBJ	_	_
39	can	_	MD	MD	_	35	VMOD	_	_
40	be	_	VB	VB	_	39	VC	_	_
41	modulated	_	VBN	VBN	_	40	VC	_	_
42	even	_	RB	RB	_	43	DEP	_	_
43	in	_	IN	IN	_	41	ADV	_	_
44	a	_	DT	DT	_	46	NMOD	_	_
45	B-cell	_	NN	NN	_	46	NMOD	_	_
46	line	_	NN	NN	_	43	PMOD	_	_
47	that	_	WDT	WDT	_	49	SBJ	_	_
48	constitutively	_	RB	RB	_	49	ADV	_	_
49	expresses	_	VBZ	VBZ	_	46	NMOD	_	_
50	this	_	DT	DT	_	51	NMOD	_	_
51	factor	_	NN	NN	_	49	OBJ	_	_
52	.	_	.	.	_	17	P	_	_

1	Immune	_	JJ	JJ	_	2	NMOD	_	_
2	response	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	peripheral	_	JJ	JJ	_	7	NMOD	_	_
5	blood	_	NN	NN	_	7	NMOD	_	_
6	mononuclear	_	JJ	JJ	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	3	PMOD	_	_
8	to	_	TO	TO	_	2	NMOD	_	_
9	HBx-antigen	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	hepatitis	_	NN	NN	_	13	NMOD	_	_
12	B	_	NN	NN	_	13	NMOD	_	_
13	virus	_	NN	NN	_	10	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	hepatitis	_	NN	NN	_	5	NMOD	_	_
3	B	_	NN	NN	_	5	NMOD	_	_
4	virus	_	NN	NN	_	5	NMOD	_	_
5	genome	_	NN	NN	_	6	SBJ	_	_
6	encodes	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	10	NMOD	_	_
8	transcriptional	_	JJ	JJ	_	10	NMOD	_	_
9	transactivator	_	NN	NN	_	10	NMOD	_	_
10	protein	_	NN	NN	_	6	OBJ	_	_
11	designated	_	VBN	VBN	_	10	NMOD	_	_
12	HBxAg	_	NN	NN	_	11	OBJ	_	_
13	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	investigated	_	VBN	VBN	_	2	VC	_	_
4	whether	_	IN	IN	_	3	OBJ	_	_
5	this	_	DT	DT	_	6	NMOD	_	_
6	antigen	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	4	VMOD	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	target	_	NN	NN	_	10	NMOD	_	_
10	structure	_	NN	NN	_	7	PRD	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	human	_	JJ	JJ	_	13	NMOD	_	_
13	T-lymphocytes	_	NNS	NNS	_	11	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	Using	_	VBG	VBG	_	7	ADV	_	_
2	recombinant	_	JJ	JJ	_	4	NMOD	_	_
3	HBxAg	_	NN	NN	_	4	NMOD	_	_
4	protein	_	NN	NN	_	1	OBJ	_	_
5	,	_	,	,	_	7	P	_	_
6	we	_	PRP	PRP	_	7	SBJ	_	_
7	found	_	VBD	VBD	_	0	ROOT-S	_	_
8	HBxAg-specific	_	JJ	JJ	_	9	NMOD	_	_
9	stimulation	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	peripheral	_	JJ	JJ	_	14	NMOD	_	_
12	blood	_	NN	NN	_	14	NMOD	_	_
13	mononuclear	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	10	PMOD	_	_
15	in	_	IN	IN	_	7	ADV	_	_
16	patients	_	NNS	NNS	_	15	PMOD	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	acute	_	JJ	JJ	_	22	NMOD	_	_
19	hepatitis	_	NN	NN	_	22	NMOD	_	_
20	B	_	NN	NN	_	22	NMOD	_	_
21	virus	_	NN	NN	_	22	NMOD	_	_
22	infection	_	NN	NN	_	17	PMOD	_	_
23	(	_	(	(	_	24	P	_	_
24	6	_	CD	CD	_	22	PRN	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	6	_	CD	CD	_	25	PMOD	_	_
27	)	_	)	)	_	24	P	_	_
28	and	_	CC	CC	_	22	CC	_	_
29	chronic	_	JJ	JJ	_	33	NMOD	_	_
30	hepatitis	_	NN	NN	_	33	NMOD	_	_
31	B	_	NN	NN	_	33	NMOD	_	_
32	virus	_	NN	NN	_	33	NMOD	_	_
33	infection	_	NN	NN	_	22	COORD	_	_
34	(	_	(	(	_	35	P	_	_
35	6	_	CD	CD	_	33	PRN	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	17	_	CD	CD	_	36	PMOD	_	_
38	)	_	)	)	_	35	P	_	_
39	but	_	CC	CC	_	15	CC	_	_
40	not	_	RB	RB	_	41	DEP	_	_
41	in	_	IN	IN	_	15	COORD	_	_
42	healthy	_	JJ	JJ	_	43	NMOD	_	_
43	individuals	_	NNS	NNS	_	41	PMOD	_	_
44	.	_	.	.	_	7	P	_	_

1	With	_	IN	IN	_	9	ADV	_	_
2	HBxAg-specific	_	JJ	JJ	_	4	NMOD	_	_
3	synthetic	_	JJ	JJ	_	4	NMOD	_	_
4	polypeptides	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	9	P	_	_
6	several	_	JJ	JJ	_	8	NMOD	_	_
7	T-cell	_	NN	NN	_	8	NMOD	_	_
8	epitopes	_	NNS	NNS	_	9	SBJ	_	_
9	were	_	VBD	VBD	_	0	ROOT-S	_	_
10	identified	_	VBN	VBN	_	9	VC	_	_
11	.	_	.	.	_	9	P	_	_

1	Most	_	JJS	JJS	_	2	SBJ	_	_
2	were	_	VBD	VBD	_	0	ROOT-S	_	_
3	located	_	JJ	JJ	_	2	VC	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	carboxyterminal	_	JJ	JJ	_	7	NMOD	_	_
7	half	_	NN	NN	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	HBxAg	_	NN	NN	_	11	NMOD	_	_
11	protein	_	NN	NN	_	8	PMOD	_	_
12	.	_	.	.	_	2	P	_	_

1	Five	_	CD	CD	_	3	NMOD	_	_
2	T-cell	_	NN	NN	_	3	NMOD	_	_
3	clones	_	NNS	NNS	_	16	SBJ	_	_
4	specific	_	JJ	JJ	_	3	NMOD	_	_
5	for	_	IN	IN	_	4	AMOD	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	T-cell	_	NN	NN	_	8	NMOD	_	_
8	epitope	_	NN	NN	_	5	PMOD	_	_
9	located	_	JJ	JJ	_	5	PMOD	_	_
10	at	_	IN	IN	_	9	AMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	carboxyterminal	_	JJ	JJ	_	13	NMOD	_	_
13	region	_	NN	NN	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	HBxAg	_	NN	NN	_	14	PMOD	_	_
16	were	_	VBD	VBD	_	0	ROOT-S	_	_
17	established	_	VBN	VBN	_	16	VC	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	found	_	VBN	VBN	_	17	COORD	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	belong	_	VB	VB	_	19	OBJ	_	_
22	to	_	TO	TO	_	21	ADV	_	_
23	the	_	DT	DT	_	27	NMOD	_	_
24	CD2\/CD4-positive	_	JJ	JJ	_	27	NMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	CD8-negative	_	JJ	JJ	_	24	COORD	_	_
27	subtype	_	NN	NN	_	22	PMOD	_	_
28	.	_	.	.	_	16	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	establish	_	VBP	VBP	_	0	ROOT-S	_	_
4	for	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	first	_	JJ	JJ	_	7	NMOD	_	_
7	time	_	NN	NN	_	4	PMOD	_	_
8	HBxAg	_	NN	NN	_	3	OBJ	_	_
9	as	_	IN	IN	_	3	ADV	_	_
10	an	_	DT	DT	_	11	NMOD	_	_
11	antigen	_	NN	NN	_	9	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	cellular	_	JJ	JJ	_	16	NMOD	_	_
15	immune	_	JJ	JJ	_	16	NMOD	_	_
16	response	_	NN	NN	_	12	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	Murine	_	JJ	JJ	_	6	NMOD	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	human	_	JJ	JJ	_	1	COORD	_	_
4	T-lymphocyte	_	NN	NN	_	6	NMOD	_	_
5	GATA-3	_	NN	NN	_	6	NMOD	_	_
6	factors	_	NNS	NNS	_	7	SBJ	_	_
7	mediate	_	VBP	VBP	_	0	ROOT-S	_	_
8	transcription	_	NN	NN	_	7	OBJ	_	_
9	through	_	IN	IN	_	7	ADV	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	cis-regulatory	_	JJ	JJ	_	12	NMOD	_	_
12	element	_	NN	NN	_	9	PMOD	_	_
13	within	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	20	NMOD	_	_
15	human	_	JJ	JJ	_	20	NMOD	_	_
16	T-cell	_	NN	NN	_	20	NMOD	_	_
17	receptor	_	NN	NN	_	20	NMOD	_	_
18	delta	_	NN	NN	_	20	NMOD	_	_
19	gene	_	NN	NN	_	20	NMOD	_	_
20	enhancer	_	NN	NN	_	13	PMOD	_	_
21	.	_	.	.	_	7	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	family	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	transcriptional	_	JJ	JJ	_	5	NMOD	_	_
5	activators	_	NNS	NNS	_	3	PMOD	_	_
6	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	recently	_	RB	RB	_	6	ADV	_	_
8	been	_	VBN	VBN	_	6	VC	_	_
9	identified	_	VBN	VBN	_	8	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	chickens	_	NNS	NNS	_	10	PMOD	_	_
12	;	_	:	:	_	6	P	_	_
13	these	_	DT	DT	_	15	NMOD	_	_
14	transcriptional	_	JJ	JJ	_	15	NMOD	_	_
15	activators	_	NNS	NNS	_	16	SBJ	_	_
16	recognize	_	VBP	VBP	_	6	VMOD	_	_
17	a	_	DT	DT	_	20	NMOD	_	_
18	common	_	JJ	JJ	_	20	NMOD	_	_
19	consensus	_	NN	NN	_	20	NMOD	_	_
20	motif	_	NN	NN	_	16	OBJ	_	_
21	(	_	(	(	_	22	P	_	_
22	WGATAR	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	through	_	IN	IN	_	16	ADV	_	_
25	a	_	DT	DT	_	31	NMOD	_	_
26	conserved	_	VBN	VBN	_	31	NMOD	_	_
27	C4	_	NN	NN	_	31	NMOD	_	_
28	zinc	_	NN	NN	_	31	NMOD	_	_
29	finger	_	NN	NN	_	31	NMOD	_	_
30	DNA-binding	_	JJ	JJ	_	31	NMOD	_	_
31	domain	_	NN	NN	_	24	PMOD	_	_
32	.	_	.	.	_	16	P	_	_

1	One	_	CD	CD	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	members	_	NNS	NNS	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	this	_	DT	DT	_	8	NMOD	_	_
7	multigene	_	JJ	JJ	_	8	NMOD	_	_
8	family	_	NN	NN	_	5	PMOD	_	_
9	,	_	,	,	_	1	P	_	_
10	cGATA-3	_	NN	NN	_	1	NMOD	_	_
11	,	_	,	,	_	1	P	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	most	_	RBS	RBS	_	14	AMOD	_	_
14	abundantly	_	RB	RB	_	12	ADV	_	_
15	expressed	_	VBN	VBN	_	12	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	T-lymphocyte	_	NN	NN	_	20	NMOD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	lineage	_	NN	NN	_	16	PMOD	_	_
21	.	_	.	.	_	12	P	_	_

1	Analysis	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	human	_	JJ	JJ	_	7	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	murine	_	JJ	JJ	_	3	COORD	_	_
6	GATA-3	_	NN	NN	_	7	NMOD	_	_
7	factors	_	NNS	NNS	_	2	PMOD	_	_
8	shows	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	striking	_	JJ	JJ	_	11	NMOD	_	_
11	degree	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	amino	_	NN	NN	_	16	NMOD	_	_
14	acid	_	NN	NN	_	16	NMOD	_	_
15	sequence	_	NN	NN	_	16	NMOD	_	_
16	identity	_	NN	NN	_	12	PMOD	_	_
17	and	_	CC	CC	_	11	CC	_	_
18	similar	_	JJ	JJ	_	19	NMOD	_	_
19	patterns	_	NNS	NNS	_	11	COORD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	tissue	_	NN	NN	_	22	NMOD	_	_
22	specificity	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	expression	_	NN	NN	_	23	PMOD	_	_
25	in	_	IN	IN	_	11	NMOD	_	_
26	these	_	DT	DT	_	28	NMOD	_	_
27	three	_	CD	CD	_	28	NMOD	_	_
28	organisms	_	NNS	NNS	_	25	PMOD	_	_
29	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	murine	_	JJ	JJ	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	human	_	JJ	JJ	_	2	COORD	_	_
5	factors	_	NNS	NNS	_	6	SBJ	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	abundantly	_	RB	RB	_	6	ADV	_	_
8	expressed	_	VBN	VBN	_	6	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	a	_	DT	DT	_	11	NMOD	_	_
11	variety	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	human	_	JJ	JJ	_	17	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	murine	_	JJ	JJ	_	13	COORD	_	_
16	T-cell	_	NN	NN	_	17	NMOD	_	_
17	lines	_	NNS	NNS	_	12	PMOD	_	_
18	and	_	CC	CC	_	6	CC	_	_
19	can	_	MD	MD	_	6	COORD	_	_
20	activate	_	VB	VB	_	19	VC	_	_
21	transcription	_	NN	NN	_	20	OBJ	_	_
22	through	_	IN	IN	_	20	ADV	_	_
23	a	_	DT	DT	_	26	NMOD	_	_
24	tissue-specific	_	JJ	JJ	_	26	NMOD	_	_
25	GATA-binding	_	JJ	JJ	_	26	NMOD	_	_
26	site	_	NN	NN	_	22	PMOD	_	_
27	identified	_	VBN	VBN	_	26	NMOD	_	_
28	within	_	IN	IN	_	27	ADV	_	_
29	the	_	DT	DT	_	35	NMOD	_	_
30	human	_	JJ	JJ	_	35	NMOD	_	_
31	T-cell	_	NN	NN	_	35	NMOD	_	_
32	receptor	_	NN	NN	_	35	NMOD	_	_
33	delta	_	NN	NN	_	35	NMOD	_	_
34	gene	_	NN	NN	_	35	NMOD	_	_
35	enhancer	_	NN	NN	_	28	PMOD	_	_
36	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	infer	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	9	NMOD	_	_
5	murine	_	JJ	JJ	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	human	_	JJ	JJ	_	5	COORD	_	_
8	GATA-3	_	NN	NN	_	9	NMOD	_	_
9	proteins	_	NNS	NNS	_	10	SBJ	_	_
10	play	_	VBP	VBP	_	3	VMOD	_	_
11	a	_	DT	DT	_	16	NMOD	_	_
12	central	_	JJ	JJ	_	16	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	highly	_	RB	RB	_	15	AMOD	_	_
15	conserved	_	VBN	VBN	_	12	COORD	_	_
16	role	_	NN	NN	_	10	OBJ	_	_
17	in	_	IN	IN	_	10	ADV	_	_
18	vertebrate	_	NN	NN	_	21	NMOD	_	_
19	T-cell-specific	_	JJ	JJ	_	21	NMOD	_	_
20	transcriptional	_	JJ	JJ	_	21	NMOD	_	_
21	regulation	_	NN	NN	_	17	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	HIV	_	NN	NN	_	3	NMOD	_	_
2	enhancer	_	NN	NN	_	3	NMOD	_	_
3	activity	_	NN	NN	_	0	ROOT-FRAG	_	_
4	perpetuated	_	VBN	VBN	_	3	NMOD	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	NF-kappa	_	NN	NN	_	8	NMOD	_	_
7	B	_	NN	NN	_	8	NMOD	_	_
8	induction	_	NN	NN	_	5	PMOD	_	_
9	on	_	IN	IN	_	8	NMOD	_	_
10	infection	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	monocytes	_	NNS	NNS	_	11	PMOD	_	_
13	{	_	(	(	_	14	P	_	_
14	see	_	VB	VB	_	3	NMOD	_	_
15	comments	_	NNS	NNS	_	14	OBJ	_	_
16	}	_	)	)	_	14	P	_	_

1	Permissiveness	_	NN	NN	_	11	SBJ	_	_
2	to	_	TO	TO	_	1	NMOD	_	_
3	replication	_	NN	NN	_	2	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	human	_	JJ	JJ	_	7	NMOD	_	_
6	immunodeficiency	_	NN	NN	_	7	NMOD	_	_
7	virus	_	NN	NN	_	4	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	HIV	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	differs	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	T	_	NN	NN	_	14	NMOD	_	_
14	lymphocytes	_	NNS	NNS	_	12	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	macrophages	_	NNS	NNS	_	14	COORD	_	_
17	.	_	.	.	_	11	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	T	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	7	P	_	_
5	HIV	_	NN	NN	_	6	NMOD	_	_
6	transcription	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	poorly	_	RB	RB	_	7	ADV	_	_
9	detected	_	VBN	VBN	_	7	VC	_	_
10	in	_	FW	FW	_	9	ADV	_	_
11	vivo	_	FW	FW	_	10	AMOD	_	_
12	.	_	.	.	_	7	P	_	_

1	Cloned	_	VBN	VBN	_	5	NMOD	_	_
2	,	_	,	,	_	1	P	_	_
3	normal	_	JJ	JJ	_	1	COORD	_	_
4	T	_	NN	NN	_	5	NMOD	_	_
5	lymphocytes	_	NNS	NNS	_	6	SBJ	_	_
6	show	_	VBP	VBP	_	0	ROOT-S	_	_
7	very	_	RB	RB	_	8	AMOD	_	_
8	little	_	JJ	JJ	_	14	NMOD	_	_
9	,	_	,	,	_	10	P	_	_
10	if	_	IN	IN	_	14	PRN	_	_
11	any	_	DT	DT	_	10	VMOD	_	_
12	,	_	,	,	_	10	P	_	_
13	basal	_	JJ	JJ	_	14	NMOD	_	_
14	activity	_	NN	NN	_	6	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	HIV	_	NN	NN	_	18	NMOD	_	_
18	enhancer	_	NN	NN	_	15	PMOD	_	_
19	and	_	CC	CC	_	14	CC	_	_
20	low	_	JJ	JJ	_	22	NMOD	_	_
21	nuclear	_	JJ	JJ	_	22	NMOD	_	_
22	expression	_	NN	NN	_	14	COORD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	NF-kappa	_	NN	NN	_	25	NMOD	_	_
25	B	_	NN	NN	_	23	PMOD	_	_
26	,	_	,	,	_	25	P	_	_
27	a	_	DT	DT	_	30	NMOD	_	_
28	potent	_	JJ	JJ	_	30	NMOD	_	_
29	transcriptional	_	JJ	JJ	_	30	NMOD	_	_
30	activator	_	NN	NN	_	25	NMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	HIV	_	NN	NN	_	34	NMOD	_	_
34	enhancer	_	NN	NN	_	31	PMOD	_	_
35	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	7	P	_	_
4	fixed	_	JJ	JJ	_	6	NMOD	_	_
5	tissue	_	NN	NN	_	6	NMOD	_	_
6	macrophages	_	NNS	NNS	_	7	SBJ	_	_
7	express	_	VBP	VBP	_	0	ROOT-S	_	_
8	detectable	_	JJ	JJ	_	10	NMOD	_	_
9	HIV	_	NN	NN	_	10	NMOD	_	_
10	proteins	_	NNS	NNS	_	7	IOBJ	_	_
11	,	_	,	,	_	7	P	_	_
12	indicating	_	VBG	VBG	_	7	OBJ	_	_
13	permanent	_	JJ	JJ	_	15	NMOD	_	_
14	virus	_	NN	NN	_	15	NMOD	_	_
15	transcription	_	NN	NN	_	12	OBJ	_	_
16	.	_	.	.	_	7	P	_	_

1	One	_	CD	CD	_	2	NMOD	_	_
2	explanation	_	NN	NN	_	11	SBJ	_	_
3	for	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	perpetuation	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	virus	_	NN	NN	_	8	NMOD	_	_
8	infection	_	NN	NN	_	6	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	macrophages	_	NNS	NNS	_	9	PMOD	_	_
11	could	_	MD	MD	_	0	ROOT-S	_	_
12	be	_	VB	VB	_	11	VC	_	_
13	sustained	_	JJ	JJ	_	17	NMOD	_	_
14	nuclear	_	JJ	JJ	_	17	NMOD	_	_
15	NF-kappa	_	NN	NN	_	17	NMOD	_	_
16	B	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	12	PRD	_	_
18	.	_	.	.	_	11	P	_	_

1	However	_	RB	RB	_	17	ADV	_	_
2	,	_	,	,	_	17	P	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	U937	_	NN	NN	_	7	NMOD	_	_
5	monocytic	_	JJ	JJ	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	line	_	NN	NN	_	17	SBJ	_	_
8	,	_	,	,	_	7	P	_	_
9	which	_	WDT	WDT	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	7	NMOD	_	_
11	fully	_	RB	RB	_	12	AMOD	_	_
12	permissive	_	JJ	JJ	_	10	PRD	_	_
13	to	_	TO	TO	_	12	AMOD	_	_
14	HIV	_	NN	NN	_	15	NMOD	_	_
15	replication	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	7	P	_	_
17	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	known	_	VBN	VBN	_	17	VC	_	_
19	to	_	TO	TO	_	20	VMOD	_	_
20	express	_	VB	VB	_	18	OBJ	_	_
21	only	_	RB	RB	_	22	AMOD	_	_
22	low	_	JJ	JJ	_	23	NMOD	_	_
23	levels	_	NNS	NNS	_	20	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	nuclear	_	JJ	JJ	_	27	NMOD	_	_
26	NF-kappa	_	NN	NN	_	27	NMOD	_	_
27	B	_	NN	NN	_	24	PMOD	_	_
28	.	_	.	.	_	17	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	that	_	IN	IN	_	2	OBJ	_	_
5	chronic	_	JJ	JJ	_	7	NMOD	_	_
6	HIV	_	VBP	VBP	_	7	NMOD	_	_
7	infection	_	NN	NN	_	8	SBJ	_	_
8	results	_	VBZ	VBZ	_	4	VMOD	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	both	_	CC	CC	_	11	CC	_	_
11	induction	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	nuclear	_	JJ	JJ	_	15	NMOD	_	_
15	factor	_	NN	NN	_	12	PMOD	_	_
16	with	_	IN	IN	_	15	NMOD	_	_
17	antigenic	_	JJ	JJ	_	18	NMOD	_	_
18	properties	_	NNS	NNS	_	16	PMOD	_	_
19	indistinguishable	_	JJ	JJ	_	18	NMOD	_	_
20	from	_	IN	IN	_	19	AMOD	_	_
21	those	_	DT	DT	_	22	NMOD	_	_
22	of	_	IN	IN	_	20	PMOD	_	_
23	NF-kappa	_	NN	NN	_	24	NMOD	_	_
24	B	_	NN	NN	_	22	PMOD	_	_
25	and	_	CC	CC	_	11	CC	_	_
26	permanently	_	RB	RB	_	27	AMOD	_	_
27	increased	_	VBN	VBN	_	30	NMOD	_	_
28	HIV	_	NN	NN	_	30	NMOD	_	_
29	enhancer	_	NN	NN	_	30	NMOD	_	_
30	activity	_	NN	NN	_	11	COORD	_	_
31	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	phenomenon	_	NN	NN	_	12	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	which	_	WDT	WDT	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	2	NMOD	_	_
6	independent	_	JJ	JJ	_	5	PRD	_	_
7	of	_	IN	IN	_	6	AMOD	_	_
8	tumour	_	NN	NN	_	10	NMOD	_	_
9	necrosis	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	7	PMOD	_	_
11	,	_	,	,	_	2	P	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	associated	_	VBN	VBN	_	12	VC	_	_
14	with	_	IN	IN	_	13	ADV	_	_
15	HIV	_	NN	NN	_	16	NMOD	_	_
16	replication	_	NN	NN	_	14	PMOD	_	_
17	,	_	,	,	_	12	P	_	_
18	and	_	CC	CC	_	12	CC	_	_
19	is	_	VBZ	VBZ	_	12	COORD	_	_
20	thus	_	RB	RB	_	19	VMOD	_	_
21	likely	_	JJ	JJ	_	19	PRD	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	explain	_	VB	VB	_	21	AMOD	_	_
24	at	_	IN	IN	_	26	PMOD	_	_
25	least	_	JJS	JJS	_	24	AMOD	_	_
26	in	_	IN	IN	_	23	ADV	_	_
27	part	_	NN	NN	_	26	PMOD	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	perpetuation	_	NN	NN	_	23	OBJ	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	HIV	_	NN	NN	_	32	NMOD	_	_
32	infection	_	NN	NN	_	30	PMOD	_	_
33	in	_	IN	IN	_	32	NMOD	_	_
34	monocytes	_	NNS	NNS	_	33	PMOD	_	_
35	.	_	.	.	_	12	P	_	_

1	Role	_	NN	NN	_	0	ROOT-FRAG	_	_
2	for	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	Epstein-Barr	_	JJ	JJ	_	7	NMOD	_	_
5	virus	_	NN	NN	_	7	NMOD	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	antigen	_	NN	NN	_	2	PMOD	_	_
8	2	_	CD	CD	_	7	NMOD	_	_
9	in	_	IN	IN	_	1	NMOD	_	_
10	viral	_	JJ	JJ	_	11	NMOD	_	_
11	promoter	_	NN	NN	_	9	PMOD	_	_
12	switching	_	VBG	VBG	_	11	NMOD	_	_
13	during	_	IN	IN	_	11	TMP	_	_
14	initial	_	JJ	JJ	_	15	NMOD	_	_
15	stages	_	NNS	NNS	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	infection	_	NN	NN	_	16	PMOD	_	_
18	.	_	.	.	_	1	P	_	_

1	During	_	IN	IN	_	21	TMP	_	_
2	latent	_	JJ	JJ	_	8	NMOD	_	_
3	Epstein-Barr	_	JJ	JJ	_	4	NMOD	_	_
4	virus	_	NN	NN	_	8	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	EBV	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	infection	_	NN	NN	_	1	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	B	_	NN	NN	_	12	NMOD	_	_
12	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
13	,	_	,	,	_	21	P	_	_
14	six	_	CD	CD	_	17	NMOD	_	_
15	viral	_	JJ	JJ	_	17	NMOD	_	_
16	nuclear	_	JJ	JJ	_	17	NMOD	_	_
17	antigen	_	NN	NN	_	21	SBJ	_	_
18	(	_	(	(	_	19	P	_	_
19	EBNAs	_	NNS	NNS	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	are	_	VBP	VBP	_	0	ROOT-S	_	_
22	expressed	_	VBN	VBN	_	21	VC	_	_
23	from	_	IN	IN	_	22	ADV	_	_
24	long	_	JJ	JJ	_	26	NMOD	_	_
25	primary	_	JJ	JJ	_	26	NMOD	_	_
26	transcripts	_	NNS	NNS	_	23	PMOD	_	_
27	by	_	IN	IN	_	22	ADV	_	_
28	means	_	NNS	NNS	_	27	DEP	_	_
29	of	_	IN	IN	_	27	DEP	_	_
30	alternative	_	JJ	JJ	_	31	NMOD	_	_
31	splicing	_	NN	NN	_	27	PMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	alternative	_	JJ	JJ	_	35	NMOD	_	_
34	polyadenylylation	_	NN	NN	_	35	NMOD	_	_
35	sites	_	NNS	NNS	_	31	COORD	_	_
36	.	_	.	.	_	21	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	transcripts	_	NNS	NNS	_	3	SBJ	_	_
3	initiate	_	VBP	VBP	_	0	ROOT-S	_	_
4	from	_	IN	IN	_	3	ADV	_	_
5	one	_	CD	CD	_	4	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	two	_	CD	CD	_	8	NMOD	_	_
8	promoters	_	NNS	NNS	_	6	PMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	Cp	_	NN	NN	_	8	NMOD	_	_
11	or	_	CC	CC	_	10	CC	_	_
12	Wp	_	NN	NN	_	10	COORD	_	_
13	,	_	,	,	_	8	P	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	function	_	VBP	VBP	_	8	NMOD	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	a	_	DT	DT	_	20	NMOD	_	_
18	mutually	_	RB	RB	_	19	AMOD	_	_
19	exclusive	_	JJ	JJ	_	20	NMOD	_	_
20	fashion	_	NN	NN	_	16	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	Wp	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	exclusively	_	RB	RB	_	2	ADV	_	_
4	utilized	_	VBN	VBN	_	2	VC	_	_
5	during	_	IN	IN	_	4	TMP	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	initial	_	JJ	JJ	_	8	NMOD	_	_
8	stages	_	NNS	NNS	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	infection	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	primary	_	JJ	JJ	_	14	NMOD	_	_
13	B	_	NN	NN	_	14	NMOD	_	_
14	lymphocytes	_	NNS	NNS	_	11	PMOD	_	_
15	,	_	,	,	_	4	P	_	_
16	followed	_	VBN	VBN	_	4	OBJ	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	switch	_	NN	NN	_	17	PMOD	_	_
20	to	_	TO	TO	_	19	NMOD	_	_
21	Cp	_	NN	NN	_	22	NMOD	_	_
22	usage	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	2	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	been	_	VBN	VBN	_	3	VC	_	_
5	extended	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	show	_	VB	VB	_	5	OBJ	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	(	_	(	(	_	10	P	_	_
10	i	_	LS	LS	_	22	VMOD	_	_
11	)	_	)	)	_	10	P	_	_
12	a	_	DT	DT	_	15	NMOD	_	_
13	mutant	_	JJ	JJ	_	15	NMOD	_	_
14	EBV	_	NN	NN	_	15	NMOD	_	_
15	strain	_	NN	NN	_	22	SBJ	_	_
16	lacking	_	VBG	VBG	_	15	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	gene	_	NN	NN	_	16	OBJ	_	_
19	encoding	_	VBG	VBG	_	18	NMOD	_	_
20	EBNA	_	NN	NN	_	19	OBJ	_	_
21	2	_	CD	CD	_	20	NMOD	_	_
22	fails	_	VBZ	VBZ	_	8	VMOD	_	_
23	to	_	TO	TO	_	24	VMOD	_	_
24	switch	_	VB	VB	_	22	OBJ	_	_
25	from	_	IN	IN	_	24	ADV	_	_
26	Wp	_	NN	NN	_	25	PMOD	_	_
27	to	_	TO	TO	_	25	PMOD	_	_
28	Cp	_	NN	NN	_	27	PMOD	_	_
29	usage	_	NN	NN	_	26	NMOD	_	_
30	in	_	IN	IN	_	24	ADV	_	_
31	primary	_	JJ	JJ	_	33	NMOD	_	_
32	B	_	NN	NN	_	33	NMOD	_	_
33	lymphocytes	_	NNS	NNS	_	30	PMOD	_	_
34	,	_	,	,	_	24	P	_	_
35	although	_	IN	IN	_	24	OBJ	_	_
36	the	_	DT	DT	_	37	NMOD	_	_
37	virus	_	NN	NN	_	38	SBJ	_	_
38	contains	_	VBZ	VBZ	_	35	VMOD	_	_
39	a	_	DT	DT	_	41	NMOD	_	_
40	functional	_	JJ	JJ	_	41	NMOD	_	_
41	Cp	_	NN	NN	_	38	OBJ	_	_
42	;	_	:	:	_	22	P	_	_
43	(	_	(	(	_	44	P	_	_
44	ii	_	LS	LS	_	57	VMOD	_	_
45	)	_	)	)	_	44	P	_	_
46	a	_	DT	DT	_	47	NMOD	_	_
47	region	_	NN	NN	_	57	SBJ	_	_
48	from	_	IN	IN	_	51	DEP	_	_
49	-429	_	CD	CD	_	51	DEP	_	_
50	to	_	TO	TO	_	51	DEP	_	_
51	-245	_	CD	CD	_	53	NMOD	_	_
52	base	_	NN	NN	_	53	NMOD	_	_
53	pairs	_	NNS	NNS	_	47	NMOD	_	_
54	upstream	_	JJ	JJ	_	47	NMOD	_	_
55	of	_	IN	IN	_	54	AMOD	_	_
56	Cp	_	NN	NN	_	55	PMOD	_	_
57	is	_	VBZ	VBZ	_	22	COORD	_	_
58	essential	_	JJ	JJ	_	57	PRD	_	_
59	for	_	IN	IN	_	58	COORD	_	_
60	Cp	_	NN	NN	_	61	NMOD	_	_
61	activity	_	NN	NN	_	59	PMOD	_	_
62	in	_	IN	IN	_	61	NMOD	_	_
63	B	_	NN	NN	_	64	NMOD	_	_
64	lymphocytes	_	NNS	NNS	_	62	PMOD	_	_
65	,	_	,	,	_	58	P	_	_
66	but	_	CC	CC	_	58	CC	_	_
67	only	_	RB	RB	_	68	DEP	_	_
68	in	_	IN	IN	_	58	COORD	_	_
69	the	_	DT	DT	_	70	NMOD	_	_
70	context	_	NN	NN	_	68	PMOD	_	_
71	of	_	IN	IN	_	70	NMOD	_	_
72	upstream	_	JJ	JJ	_	75	NMOD	_	_
73	and	_	CC	CC	_	72	CC	_	_
74	downstream	_	JJ	JJ	_	72	COORD	_	_
75	sequences	_	NNS	NNS	_	71	PMOD	_	_
76	;	_	:	:	_	22	P	_	_
77	(	_	(	(	_	78	P	_	_
78	iii	_	LS	LS	_	82	VMOD	_	_
79	)	_	)	)	_	78	P	_	_
80	this	_	DT	DT	_	81	NMOD	_	_
81	region	_	NN	NN	_	82	SBJ	_	_
82	contains	_	VBZ	VBZ	_	22	COORD	_	_
83	an	_	DT	DT	_	86	NMOD	_	_
84	EBNA	_	NN	NN	_	86	NMOD	_	_
85	2-dependent	_	JJ	JJ	_	86	NMOD	_	_
86	enhancer	_	NN	NN	_	82	OBJ	_	_
87	;	_	:	:	_	22	P	_	_
88	and	_	CC	CC	_	22	CC	_	_
89	(	_	(	(	_	90	P	_	_
90	iv	_	LS	LS	_	103	VMOD	_	_
91	)	_	)	)	_	90	P	_	_
92	DNase	_	NN	NN	_	94	NMOD	_	_
93	I	_	CD	CD	_	94	NMOD	_	_
94	protection	_	NN	NN	_	103	SBJ	_	_
95	employing	_	VBG	VBG	_	94	NMOD	_	_
96	nuclear	_	JJ	JJ	_	97	NMOD	_	_
97	extracts	_	NNS	NNS	_	95	OBJ	_	_
98	from	_	IN	IN	_	97	NMOD	_	_
99	B	_	NN	NN	_	102	NMOD	_	_
100	and	_	CC	CC	_	99	CC	_	_
101	T	_	NN	NN	_	99	COORD	_	_
102	lymphocytes	_	NNS	NNS	_	98	PMOD	_	_
103	revealed	_	VBD	VBD	_	22	COORD	_	_
104	a	_	DT	DT	_	106	NMOD	_	_
105	B-cell-specific	_	JJ	JJ	_	106	NMOD	_	_
106	footprint	_	NN	NN	_	103	OBJ	_	_
107	in	_	IN	IN	_	106	NMOD	_	_
108	the	_	DT	DT	_	109	NMOD	_	_
109	region	_	NN	NN	_	107	PMOD	_	_
110	of	_	IN	IN	_	109	NMOD	_	_
111	the	_	DT	DT	_	114	NMOD	_	_
112	EBNA	_	NN	NN	_	114	NMOD	_	_
113	2-dependent	_	JJ	JJ	_	112	AMOD	_	_
114	enhancer	_	NN	NN	_	110	PMOD	_	_
115	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	support	_	VBP	VBP	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	model	_	NN	NN	_	3	OBJ	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	viral	_	JJ	JJ	_	9	NMOD	_	_
8	promoter	_	NN	NN	_	9	NMOD	_	_
9	switching	_	NN	NN	_	6	PMOD	_	_
10	during	_	IN	IN	_	9	TMP	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	initial	_	JJ	JJ	_	13	NMOD	_	_
13	stages	_	NNS	NNS	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	infection	_	NN	NN	_	14	PMOD	_	_
16	in	_	IN	IN	_	20	ADV	_	_
17	which	_	WDT	WDT	_	16	PMOD	_	_
18	Wp	_	NN	NN	_	19	NMOD	_	_
19	activity	_	NN	NN	_	20	SBJ	_	_
20	leads	_	VBZ	VBZ	_	10	PMOD	_	_
21	to	_	TO	TO	_	20	ADV	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	expression	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	EBNA	_	NN	NN	_	24	PMOD	_	_
26	2	_	CD	CD	_	25	NMOD	_	_
27	,	_	,	,	_	20	P	_	_
28	followed	_	VBN	VBN	_	20	ADV	_	_
29	by	_	IN	IN	_	28	LGS	_	_
30	activation	_	NN	NN	_	29	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	Cp	_	NN	NN	_	31	PMOD	_	_
33	through	_	IN	IN	_	30	NMOD	_	_
34	the	_	DT	DT	_	37	NMOD	_	_
35	EBNA	_	NN	NN	_	37	NMOD	_	_
36	2-dependent	_	JJ	JJ	_	35	AMOD	_	_
37	enhancer	_	NN	NN	_	33	PMOD	_	_
38	.	_	.	.	_	3	P	_	_

1	Inhibition	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	protein	_	NN	NN	_	4	NMOD	_	_
4	phosphatases	_	NNS	NNS	_	2	PMOD	_	_
5	by	_	IN	IN	_	1	NMOD	_	_
6	okadaic	_	JJ	JJ	_	7	NMOD	_	_
7	acid	_	NN	NN	_	5	PMOD	_	_
8	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	AP1	_	NN	NN	_	8	OBJ	_	_
10	in	_	IN	IN	_	8	ADV	_	_
11	human	_	JJ	JJ	_	13	NMOD	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	10	PMOD	_	_
14	.	_	.	.	_	8	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	examine	_	VB	VB	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	role	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	protein	_	NN	NN	_	7	NMOD	_	_
7	phosphatases	_	NNS	NNS	_	5	PMOD	_	_
8	in	_	IN	IN	_	4	NMOD	_	_
9	T	_	NN	NN	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	activation	_	NN	NN	_	8	PMOD	_	_
12	,	_	,	,	_	2	P	_	_
13	Jurkat	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	15	SBJ	_	_
15	were	_	VBD	VBD	_	2	COORD	_	_
16	treated	_	VBN	VBN	_	15	VC	_	_
17	with	_	IN	IN	_	16	ADV	_	_
18	okadaic	_	JJ	JJ	_	19	NMOD	_	_
19	acid	_	NN	NN	_	17	PMOD	_	_
20	,	_	,	,	_	19	P	_	_
21	an	_	DT	DT	_	22	NMOD	_	_
22	inhibitor	_	NN	NN	_	19	NMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	type	_	NN	NN	_	28	NMOD	_	_
25	1	_	CD	CD	_	28	COORD	_	_
26	and	_	CC	CC	_	28	CC	_	_
27	2A	_	NN	NN	_	28	COORD	_	_
28	phosphatases	_	NNS	NNS	_	23	PMOD	_	_
29	,	_	,	,	_	19	P	_	_
30	and	_	CC	CC	_	15	CC	_	_
31	nuclear	_	JJ	JJ	_	32	NMOD	_	_
32	extracts	_	NNS	NNS	_	33	SBJ	_	_
33	were	_	VBD	VBD	_	15	COORD	_	_
34	examined	_	VBN	VBN	_	33	VC	_	_
35	for	_	IN	IN	_	34	ADV	_	_
36	the	_	DT	DT	_	37	NMOD	_	_
37	presence	_	NN	NN	_	35	PMOD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	AP1	_	NN	NN	_	38	PMOD	_	_
40	as	_	IN	IN	_	34	ADV	_	_
41	a	_	DT	DT	_	42	NMOD	_	_
42	measure	_	NN	NN	_	40	PMOD	_	_
43	of	_	IN	IN	_	42	NMOD	_	_
44	early	_	JJ	JJ	_	47	NMOD	_	_
45	T	_	NN	NN	_	47	NMOD	_	_
46	cell	_	NN	NN	_	47	NMOD	_	_
47	activation	_	NN	NN	_	43	PMOD	_	_
48	.	_	.	.	_	2	P	_	_

1	Okadaic	_	JJ	JJ	_	2	NMOD	_	_
2	acid	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	found	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	be	_	VB	VB	_	4	OBJ	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	potent	_	JJ	JJ	_	9	NMOD	_	_
9	inducer	_	NN	NN	_	6	PRD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	AP1	_	NN	NN	_	10	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	22	ADV	_	_
2	contrast	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	phorbol	_	NN	NN	_	5	NMOD	_	_
5	esters	_	NNS	NNS	_	1	PMOD	_	_
6	such	_	JJ	JJ	_	7	DEP	_	_
7	as	_	IN	IN	_	5	NMOD	_	_
8	phorbol	_	NN	NN	_	10	NMOD	_	_
9	myristate	_	NN	NN	_	10	NMOD	_	_
10	acetate	_	NN	NN	_	7	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	PMA	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	,	_	,	,	_	22	P	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	induction	_	NN	NN	_	22	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	AP1	_	NN	NN	_	17	PMOD	_	_
19	by	_	IN	IN	_	16	NMOD	_	_
20	okadaic	_	JJ	JJ	_	21	NMOD	_	_
21	acid	_	NN	NN	_	19	PMOD	_	_
22	occurs	_	VBZ	VBZ	_	0	ROOT-S	_	_
23	predominantly	_	RB	RB	_	24	DEP	_	_
24	by	_	IN	IN	_	22	ADV	_	_
25	transcriptional	_	JJ	JJ	_	26	NMOD	_	_
26	activation	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	32	NMOD	_	_
29	jun	_	NN	NN	_	32	NMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	fos	_	NN	NN	_	29	COORD	_	_
32	family	_	NN	NN	_	27	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	proto-oncogenes	_	NNS	NNS	_	33	PMOD	_	_
35	.	_	.	.	_	22	P	_	_

1	Surprisingly	_	RB	RB	_	19	ADV	_	_
2	,	_	,	,	_	19	P	_	_
3	while	_	IN	IN	_	19	ADV	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	addition	_	NN	NN	_	9	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	phytohemagglutinin	_	NN	NN	_	6	PMOD	_	_
8	further	_	RB	RB	_	9	ADV	_	_
9	enhanced	_	VBD	VBD	_	3	VMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	induction	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	AP1	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	19	P	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	addition	_	NN	NN	_	19	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	PMA	_	NN	NN	_	17	PMOD	_	_
19	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
20	it	_	PRP	PRP	_	19	OBJ	_	_
21	.	_	.	.	_	19	P	_	_

1	Okadaic	_	JJ	JJ	_	3	NMOD	_	_
2	acid	_	NN	NN	_	3	NMOD	_	_
3	treatment	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	found	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	8	VMOD	_	_
7	dramatically	_	RB	RB	_	8	ADV	_	_
8	increase	_	VB	VB	_	5	OBJ	_	_
9	mRNA	_	NN	NN	_	10	NMOD	_	_
10	transcripts	_	NNS	NNS	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	jun	_	NN	NN	_	14	NMOD	_	_
14	family	_	NN	NN	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	proto-oncogenes	_	NNS	NNS	_	15	PMOD	_	_
17	including	_	VBG	VBG	_	14	NMOD	_	_
18	c-jun	_	NN	NN	_	17	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	junD	_	NN	NN	_	18	COORD	_	_
21	,	_	,	,	_	18	P	_	_
22	and	_	CC	CC	_	18	CC	_	_
23	junB	_	NN	NN	_	18	COORD	_	_
24	and	_	CC	CC	_	8	CC	_	_
25	to	_	TO	TO	_	31	ADV	_	_
26	a	_	DT	DT	_	28	NMOD	_	_
27	lesser	_	JJR	JJR	_	28	NMOD	_	_
28	extent	_	NN	NN	_	25	PMOD	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	fos	_	NN	NN	_	31	NMOD	_	_
31	family	_	NN	NN	_	14	GAP	_	_
32	including	_	VBG	VBG	_	31	NMOD	_	_
33	c-fos	_	NN	NN	_	32	PMOD	_	_
34	and	_	CC	CC	_	33	CC	_	_
35	fra-1	_	NN	NN	_	33	COORD	_	_
36	.	_	.	.	_	4	P	_	_

1	By	_	IN	IN	_	5	ADV	_	_
2	comparison	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	PMA	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	very	_	RB	RB	_	8	AMOD	_	_
8	inefficient	_	JJ	JJ	_	9	NMOD	_	_
9	inducer	_	NN	NN	_	5	PRD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	jun	_	NN	NN	_	14	NMOD	_	_
13	gene	_	NN	NN	_	14	NMOD	_	_
14	family	_	NN	NN	_	10	PMOD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	Jurkat	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	15	PMOD	_	_
18	.	_	.	.	_	5	P	_	_

1	Similar	_	JJ	JJ	_	15	ADV	_	_
2	to	_	TO	TO	_	1	AMOD	_	_
3	its	_	PRP$	PRP$	_	4	NMOD	_	_
4	effect	_	NN	NN	_	2	PMOD	_	_
5	on	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	induction	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	AP1	_	NN	NN	_	8	PMOD	_	_
10	by	_	IN	IN	_	7	NMOD	_	_
11	okadaic	_	JJ	JJ	_	12	NMOD	_	_
12	acid	_	NN	NN	_	10	PMOD	_	_
13	,	_	,	,	_	15	P	_	_
14	PMA	_	NN	NN	_	15	SBJ	_	_
15	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	induction	_	NN	NN	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	c-jun	_	NN	NN	_	20	NMOD	_	_
20	mRNA	_	NN	NN	_	18	PMOD	_	_
21	by	_	IN	IN	_	17	NMOD	_	_
22	okadaic	_	JJ	JJ	_	23	NMOD	_	_
23	acid	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	15	P	_	_

1	Transfection	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	c-jun	_	NN	NN	_	5	NMOD	_	_
4	promoter	_	NN	NN	_	5	NMOD	_	_
5	constructs	_	NNS	NNS	_	2	PMOD	_	_
6	confirmed	_	VBD	VBD	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	marked	_	JJ	JJ	_	9	NMOD	_	_
9	difference	_	NN	NN	_	6	OBJ	_	_
10	between	_	IN	IN	_	9	NMOD	_	_
11	PMA	_	NN	NN	_	10	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	okadaic	_	JJ	JJ	_	14	NMOD	_	_
14	acid	_	NN	NN	_	11	COORD	_	_
15	in	_	IN	IN	_	9	NMOD	_	_
16	inducing	_	VBG	VBG	_	15	PMOD	_	_
17	c-jun	_	NN	NN	_	18	NMOD	_	_
18	transcription	_	NN	NN	_	16	OBJ	_	_
19	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	induction	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	AP1	_	NN	NN	_	3	PMOD	_	_
5	by	_	IN	IN	_	2	NMOD	_	_
6	okadaic	_	JJ	JJ	_	7	NMOD	_	_
7	acid	_	NN	NN	_	5	PMOD	_	_
8	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	protein	_	NN	NN	_	11	NMOD	_	_
11	phosphatases	_	NNS	NNS	_	20	SBJ	_	_
12	1	_	CD	CD	_	11	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	2A	_	NN	NN	_	12	COORD	_	_
15	(	_	(	(	_	16	P	_	_
16	PP1	_	NN	NN	_	11	PRN	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	PP2A	_	NN	NN	_	16	COORD	_	_
19	)	_	)	)	_	16	P	_	_
20	may	_	MD	MD	_	9	VMOD	_	_
21	be	_	VB	VB	_	20	VC	_	_
22	involved	_	VBN	VBN	_	21	VC	_	_
23	in	_	IN	IN	_	22	ADV	_	_
24	T	_	NN	NN	_	26	NMOD	_	_
25	cell	_	NN	NN	_	26	NMOD	_	_
26	activation	_	NN	NN	_	23	PMOD	_	_
27	as	_	IN	IN	_	22	ADV	_	_
28	important	_	JJ	JJ	_	30	NMOD	_	_
29	negative	_	JJ	JJ	_	30	NMOD	_	_
30	regulators	_	NNS	NNS	_	27	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	35	NMOD	_	_
33	transcription	_	NN	NN	_	35	NMOD	_	_
34	factor	_	NN	NN	_	35	NMOD	_	_
35	AP1	_	NN	NN	_	31	PMOD	_	_
36	.	_	.	.	_	8	P	_	_

1	Transactivation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	human	_	JJ	JJ	_	7	NMOD	_	_
5	immunodeficiency	_	NN	NN	_	7	NMOD	_	_
6	virus	_	NN	NN	_	7	NMOD	_	_
7	promoter	_	NN	NN	_	2	PMOD	_	_
8	by	_	IN	IN	_	1	NMOD	_	_
9	human	_	JJ	JJ	_	10	NMOD	_	_
10	herpesvirus	_	NN	NN	_	8	PMOD	_	_
11	6	_	CD	CD	_	10	NMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	HHV-6	_	NN	NN	_	10	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	strains	_	VBZ	VBZ	_	10	NMOD	_	_
16	GS	_	NN	NN	_	10	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	Z-29	_	NN	NN	_	16	COORD	_	_
19	in	_	IN	IN	_	1	NMOD	_	_
20	primary	_	JJ	JJ	_	23	NMOD	_	_
21	human	_	JJ	JJ	_	23	NMOD	_	_
22	T	_	NN	NN	_	23	NMOD	_	_
23	lymphocytes	_	NNS	NNS	_	19	PMOD	_	_
24	and	_	CC	CC	_	1	CC	_	_
25	identification	_	NN	NN	_	1	COORD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	transactivating	_	VBG	VBG	_	33	NMOD	_	_
28	HHV-6	_	NN	NN	_	33	NMOD	_	_
29	(	_	(	(	_	33	P	_	_
30	GS	_	NN	NN	_	33	NMOD	_	_
31	)	_	)	)	_	33	P	_	_
32	gene	_	NN	NN	_	33	NMOD	_	_
33	fragments	_	NNS	NNS	_	26	PMOD	_	_
34	.	_	.	.	_	1	P	_	_

1	Human	_	JJ	JJ	_	2	NMOD	_	_
2	herpesvirus	_	NN	NN	_	7	SBJ	_	_
3	6	_	CD	CD	_	2	NMOD	_	_
4	(	_	(	(	_	5	P	_	_
5	HHV-6	_	NN	NN	_	2	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	can	_	MD	MD	_	0	ROOT-S	_	_
8	activate	_	VB	VB	_	7	VC	_	_
9	the	_	DT	DT	_	16	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	immunodeficiency	_	NN	NN	_	12	NMOD	_	_
12	virus	_	NN	NN	_	16	NMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	HIV	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	promoter	_	NN	NN	_	8	OBJ	_	_
17	and	_	CC	CC	_	8	CC	_	_
18	accelerate	_	VB	VB	_	8	COORD	_	_
19	cytopathic	_	JJ	JJ	_	20	NMOD	_	_
20	effects	_	NNS	NNS	_	18	OBJ	_	_
21	in	_	IN	IN	_	8	ADV	_	_
22	HIV-infected	_	JJ	JJ	_	25	NMOD	_	_
23	human	_	JJ	JJ	_	25	NMOD	_	_
24	T	_	NN	NN	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	21	PMOD	_	_
26	.	_	.	.	_	7	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	study	_	NN	NN	_	3	SBJ	_	_
3	examines	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	regions	_	NNS	NNS	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	HIV	_	NN	NN	_	9	NMOD	_	_
9	promoter	_	NN	NN	_	6	PMOD	_	_
10	required	_	VBN	VBN	_	5	NMOD	_	_
11	for	_	IN	IN	_	10	ADV	_	_
12	HHV-6	_	NN	NN	_	13	NMOD	_	_
13	transactivation	_	NN	NN	_	11	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	heterogeneous	_	JJ	JJ	_	17	NMOD	_	_
17	population	_	NN	NN	_	14	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	primary	_	JJ	JJ	_	22	NMOD	_	_
20	human	_	JJ	JJ	_	22	NMOD	_	_
21	T	_	NN	NN	_	22	NMOD	_	_
22	lymphocytes	_	NNS	NNS	_	18	PMOD	_	_
23	with	_	IN	IN	_	13	NMOD	_	_
24	or	_	CC	CC	_	23	CC	_	_
25	without	_	IN	IN	_	23	COORD	_	_
26	antigenic	_	JJ	JJ	_	27	NMOD	_	_
27	stimulation	_	NN	NN	_	23	PMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	Two	_	CD	CD	_	3	NMOD	_	_
2	different	_	JJ	JJ	_	3	NMOD	_	_
3	strains	_	NNS	NNS	_	11	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	HHV-6	_	NN	NN	_	4	PMOD	_	_
6	,	_	,	,	_	3	P	_	_
7	GS	_	NN	NN	_	3	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	Z29	_	NN	NN	_	7	COORD	_	_
10	,	_	,	,	_	3	P	_	_
11	transactivated	_	VBD	VBD	_	0	ROOT-S	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	HIV	_	NN	NN	_	14	NMOD	_	_
14	promoter	_	NN	NN	_	11	OBJ	_	_
15	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	GS	_	NN	NN	_	3	NMOD	_	_
3	strain	_	NN	NN	_	4	SBJ	_	_
4	transactivated	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	promoter	_	NN	NN	_	4	IOBJ	_	_
7	in	_	IN	IN	_	4	ADV	_	_
8	both	_	CC	CC	_	9	CC	_	_
9	stimulated	_	VBN	VBN	_	13	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	resting	_	VBG	VBG	_	9	COORD	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	7	PMOD	_	_
14	,	_	,	,	_	4	P	_	_
15	while	_	IN	IN	_	4	OBJ	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	Z29	_	NN	NN	_	18	NMOD	_	_
18	strain	_	NN	NN	_	19	SBJ	_	_
19	increased	_	VBD	VBD	_	15	VMOD	_	_
20	HIV	_	NN	NN	_	22	NMOD	_	_
21	promoter	_	NN	NN	_	22	NMOD	_	_
22	activity	_	NN	NN	_	19	OBJ	_	_
23	only	_	RB	RB	_	24	DEP	_	_
24	in	_	IN	IN	_	19	ADV	_	_
25	stimulated	_	VBN	VBN	_	27	NMOD	_	_
26	T	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	24	PMOD	_	_
28	.	_	.	.	_	4	P	_	_

1	Three	_	CD	CD	_	3	NMOD	_	_
2	DNA	_	NN	NN	_	3	NMOD	_	_
3	clones	_	NNS	NNS	_	11	SBJ	_	_
4	containing	_	VBG	VBG	_	3	NMOD	_	_
5	HHV-6	_	NN	NN	_	10	NMOD	_	_
6	(	_	(	(	_	10	P	_	_
7	GS	_	NN	NN	_	10	NMOD	_	_
8	)	_	)	)	_	10	P	_	_
9	genomic	_	JJ	JJ	_	10	NMOD	_	_
10	fragments	_	NNS	NNS	_	4	OBJ	_	_
11	transactivated	_	VBD	VBD	_	0	ROOT-S	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	HIV	_	NN	NN	_	14	NMOD	_	_
14	promoter	_	NN	NN	_	11	OBJ	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	cotransfected	_	VBN	VBN	_	18	NMOD	_	_
17	T	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	11	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	21.4-kb	_	JJ	JJ	_	4	NMOD	_	_
3	DNA	_	NN	NN	_	4	NMOD	_	_
4	clone	_	NN	NN	_	8	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	pZVB70	_	NN	NN	_	4	NMOD	_	_
7	,	_	,	,	_	4	P	_	_
8	showed	_	VBD	VBD	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	highest	_	JJS	JJS	_	12	NMOD	_	_
11	transactivating	_	NN	NN	_	12	NMOD	_	_
12	ability	_	NN	NN	_	8	IOBJ	_	_
13	,	_	,	,	_	8	P	_	_
14	while	_	IN	IN	_	8	OBJ	_	_
15	two	_	CD	CD	_	18	NMOD	_	_
16	other	_	JJ	JJ	_	18	NMOD	_	_
17	DNA	_	NN	NN	_	18	NMOD	_	_
18	fragments	_	NNS	NNS	_	32	SBJ	_	_
19	,	_	,	,	_	18	P	_	_
20	pZVB10	_	NN	NN	_	18	NMOD	_	_
21	(	_	(	(	_	23	P	_	_
22	6.2	_	CD	CD	_	23	NMOD	_	_
23	kb	_	NN	NN	_	20	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	and	_	CC	CC	_	20	CC	_	_
26	pZVH14	_	NN	NN	_	20	COORD	_	_
27	(	_	(	(	_	29	P	_	_
28	8.7	_	CD	CD	_	29	NMOD	_	_
29	kb	_	NN	NN	_	26	PRN	_	_
30	)	_	)	)	_	29	P	_	_
31	,	_	,	,	_	18	P	_	_
32	showed	_	VBD	VBD	_	14	VMOD	_	_
33	lower	_	JJR	JJR	_	34	NMOD	_	_
34	activity	_	NN	NN	_	32	OBJ	_	_
35	.	_	.	.	_	8	P	_	_

1	One	_	CD	CD	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	clones	_	NNS	NNS	_	2	PMOD	_	_
5	,	_	,	,	_	1	P	_	_
6	pZVH14	_	NN	NN	_	1	NMOD	_	_
7	,	_	,	,	_	1	P	_	_
8	activated	_	VBD	VBD	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	HIV	_	NN	NN	_	12	NMOD	_	_
11	promoter	_	NN	NN	_	12	NMOD	_	_
12	construct	_	NN	NN	_	8	OBJ	_	_
13	containing	_	VBG	VBG	_	12	NMOD	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	mutation	_	NN	NN	_	13	OBJ	_	_
16	in	_	IN	IN	_	13	ADV	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	NF	_	NN	NN	_	21	NMOD	_	_
19	kappa	_	NN	NN	_	21	NMOD	_	_
20	B	_	NN	NN	_	21	NMOD	_	_
21	site	_	NN	NN	_	16	PMOD	_	_
22	.	_	.	.	_	8	P	_	_

1	However	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	this	_	DT	DT	_	8	NMOD	_	_
4	mutated	_	VBN	VBN	_	8	NMOD	_	_
5	NF	_	NN	NN	_	8	NMOD	_	_
6	kappa	_	NN	NN	_	8	NMOD	_	_
7	B	_	NN	NN	_	8	NMOD	_	_
8	promoter	_	NN	NN	_	9	SBJ	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	not	_	RB	RB	_	9	VMOD	_	_
11	transactivated	_	VBN	VBN	_	9	VC	_	_
12	during	_	IN	IN	_	11	TMP	_	_
13	HHV-6	_	NN	NN	_	17	NMOD	_	_
14	(	_	(	(	_	17	P	_	_
15	GS	_	NN	NN	_	17	NMOD	_	_
16	)	_	)	)	_	17	P	_	_
17	infection	_	NN	NN	_	12	PMOD	_	_
18	or	_	CC	CC	_	12	CC	_	_
19	after	_	IN	IN	_	12	COORD	_	_
20	cotransfection	_	NN	NN	_	19	PMOD	_	_
21	with	_	IN	IN	_	20	NMOD	_	_
22	pZVB70	_	NN	NN	_	21	PMOD	_	_
23	or	_	CC	CC	_	22	CC	_	_
24	pZVB10	_	NN	NN	_	22	COORD	_	_
25	.	_	.	.	_	9	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	NF	_	NN	NN	_	9	NMOD	_	_
7	kappa	_	NN	NN	_	9	NMOD	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	sites	_	NNS	NNS	_	14	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	HIV	_	NN	NN	_	13	NMOD	_	_
13	promoter	_	NN	NN	_	10	PMOD	_	_
14	are	_	VBP	VBP	_	4	VMOD	_	_
15	essential	_	JJ	JJ	_	14	PRD	_	_
16	for	_	IN	IN	_	15	AMOD	_	_
17	its	_	PRP$	PRP$	_	18	NMOD	_	_
18	transactivation	_	NN	NN	_	16	PMOD	_	_
19	during	_	IN	IN	_	18	TMP	_	_
20	HHV-6	_	NN	NN	_	24	NMOD	_	_
21	(	_	(	(	_	24	P	_	_
22	GS	_	NN	NN	_	24	NMOD	_	_
23	)	_	)	)	_	24	P	_	_
24	infection	_	NN	NN	_	19	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	By	_	IN	IN	_	12	ADV	_	_
2	increasing	_	VBG	VBG	_	1	PMOD	_	_
3	HIV	_	NN	NN	_	5	NMOD	_	_
4	promoter	_	NN	NN	_	5	NMOD	_	_
5	activity	_	NN	NN	_	2	OBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	primary	_	JJ	JJ	_	9	NMOD	_	_
8	T	_	NN	NN	_	9	NMOD	_	_
9	lymphocytes	_	NNS	NNS	_	6	PMOD	_	_
10	,	_	,	,	_	12	P	_	_
11	HHV-6	_	NN	NN	_	12	SBJ	_	_
12	may	_	MD	MD	_	0	ROOT-S	_	_
13	consequently	_	RB	RB	_	12	ADV	_	_
14	increase	_	VB	VB	_	12	VC	_	_
15	HIV	_	NN	NN	_	16	NMOD	_	_
16	replication	_	NN	NN	_	14	IOBJ	_	_
17	,	_	,	,	_	14	P	_	_
18	leading	_	VBG	VBG	_	14	OBJ	_	_
19	to	_	TO	TO	_	18	ADV	_	_
20	an	_	DT	DT	_	21	NMOD	_	_
21	increase	_	NN	NN	_	19	PMOD	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	cytopathic	_	JJ	JJ	_	25	NMOD	_	_
25	effect	_	NN	NN	_	22	PMOD	_	_
26	on	_	IN	IN	_	25	NMOD	_	_
27	coinfected	_	VBN	VBN	_	30	NMOD	_	_
28	human	_	JJ	JJ	_	30	NMOD	_	_
29	T	_	NN	NN	_	30	NMOD	_	_
30	cells	_	NNS	NNS	_	26	PMOD	_	_
31	.	_	.	.	_	12	P	_	_

1	Cortivazol	_	NN	NN	_	3	NMOD	_	_
2	mediated	_	VBD	VBD	_	3	NMOD	_	_
3	induction	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	glucocorticoid	_	NN	NN	_	9	NMOD	_	_
6	receptor	_	NN	NN	_	9	NMOD	_	_
7	messenger	_	NN	NN	_	9	NMOD	_	_
8	ribonucleic	_	JJ	JJ	_	9	NMOD	_	_
9	acid	_	NN	NN	_	4	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	wild-type	_	JJ	JJ	_	19	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	dexamethasone-resistant	_	JJ	JJ	_	11	COORD	_	_
14	human	_	JJ	JJ	_	19	NMOD	_	_
15	leukemic	_	NN	NN	_	19	NMOD	_	_
16	(	_	(	(	_	19	P	_	_
17	CEM	_	NN	NN	_	19	NMOD	_	_
18	)	_	)	)	_	19	P	_	_
19	cells	_	NNS	NNS	_	10	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Cortivazol	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	phenylpyrazolo	_	JJ	JJ	_	5	NMOD	_	_
5	glucocorticoid	_	NN	NN	_	2	PRD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	high	_	JJ	JJ	_	8	NMOD	_	_
8	potency	_	NN	NN	_	6	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	unusual	_	JJ	JJ	_	11	NMOD	_	_
11	structure	_	NN	NN	_	8	COORD	_	_
12	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	23	ADV	_	_
2	both	_	CC	CC	_	3	CC	_	_
3	wild-type	_	JJ	JJ	_	11	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	highly	_	RB	RB	_	10	AMOD	_	_
6	dexamethasone	_	NN	NN	_	10	AMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	dex	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	-resistant	_	JJ	JJ	_	3	COORD	_	_
11	clones	_	NNS	NNS	_	1	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	18	NMOD	_	_
14	human	_	JJ	JJ	_	18	NMOD	_	_
15	leukemic	_	JJ	JJ	_	18	NMOD	_	_
16	cell	_	NN	NN	_	18	NMOD	_	_
17	line	_	NN	NN	_	18	NMOD	_	_
18	CEM	_	NN	NN	_	12	PMOD	_	_
19	,	_	,	,	_	23	P	_	_
20	exposure	_	NN	NN	_	23	SBJ	_	_
21	to	_	TO	TO	_	20	NMOD	_	_
22	cortivazol	_	NN	NN	_	21	PMOD	_	_
23	leads	_	VBZ	VBZ	_	0	ROOT-S	_	_
24	to	_	TO	TO	_	23	ADV	_	_
25	cell	_	NN	NN	_	26	NMOD	_	_
26	death	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	23	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	been	_	VBN	VBN	_	2	VC	_	_
4	shown	_	VBN	VBN	_	3	VC	_	_
5	recently	_	RB	RB	_	4	TMP	_	_
6	that	_	IN	IN	_	4	OBJ	_	_
7	in	_	IN	IN	_	28	ADV	_	_
8	wild-type	_	JJ	JJ	_	10	NMOD	_	_
9	CEM	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	7	PMOD	_	_
11	but	_	CC	CC	_	7	CC	_	_
12	not	_	RB	RB	_	13	DEP	_	_
13	in	_	IN	IN	_	7	COORD	_	_
14	a	_	DT	DT	_	25	NMOD	_	_
15	dex-resistant	_	JJ	JJ	_	25	NMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	glucocorticoid	_	NN	NN	_	20	AMOD	_	_
18	receptor	_	NN	NN	_	20	AMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	GR	_	NN	NN	_	15	COORD	_	_
21	)	_	)	)	_	20	P	_	_
22	-defective	_	JJ	JJ	_	20	AMOD	_	_
23	clone	_	NN	NN	_	25	NMOD	_	_
24	ICR-27	_	NN	NN	_	25	NMOD	_	_
25	TK-3	_	NN	NN	_	13	PMOD	_	_
26	,	_	,	,	_	28	P	_	_
27	dex	_	NN	NN	_	28	SBJ	_	_
28	induces	_	VBZ	VBZ	_	6	VMOD	_	_
29	GR	_	NN	NN	_	30	NMOD	_	_
30	mRNA	_	NN	NN	_	28	OBJ	_	_
31	.	_	.	.	_	2	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	test	_	VB	VB	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	hypothesis	_	NN	NN	_	2	OBJ	_	_
5	that	_	IN	IN	_	4	NMOD	_	_
6	cortivazol	_	NN	NN	_	7	SBJ	_	_
7	acts	_	VBZ	VBZ	_	5	VMOD	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	dex-resistant	_	JJ	JJ	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	by	_	IN	IN	_	7	ADV	_	_
12	making	_	VBG	VBG	_	11	PMOD	_	_
13	use	_	NN	NN	_	12	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	residual	_	JJ	JJ	_	17	NMOD	_	_
17	GR	_	NN	NN	_	14	PMOD	_	_
18	found	_	VBN	VBN	_	17	NMOD	_	_
19	there	_	RB	RB	_	18	ADV	_	_
20	,	_	,	,	_	2	P	_	_
21	wild-type	_	JJ	JJ	_	24	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	dex-resistant	_	JJ	JJ	_	21	COORD	_	_
24	clones	_	NNS	NNS	_	25	SBJ	_	_
25	were	_	VBD	VBD	_	2	COORD	_	_
26	treated	_	VBN	VBN	_	25	VC	_	_
27	with	_	IN	IN	_	26	ADV	_	_
28	various	_	JJ	JJ	_	29	NMOD	_	_
29	concentrations	_	NNS	NNS	_	27	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	cortivazol	_	NN	NN	_	30	PMOD	_	_
32	and	_	CC	CC	_	25	CC	_	_
33	induction	_	NN	NN	_	37	SBJ	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	GR	_	NN	NN	_	36	NMOD	_	_
36	mRNA	_	NN	NN	_	34	PMOD	_	_
37	was	_	VBD	VBD	_	25	COORD	_	_
38	studied	_	VBN	VBN	_	37	VC	_	_
39	.	_	.	.	_	2	P	_	_

1	Cortivazol	_	NN	NN	_	3	SBJ	_	_
2	significantly	_	RB	RB	_	3	ADV	_	_
3	induced	_	VBD	VBD	_	0	ROOT-S	_	_
4	GR	_	NN	NN	_	5	NMOD	_	_
5	mRNA	_	NN	NN	_	3	IOBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	normal	_	JJ	JJ	_	9	NMOD	_	_
9	CEM-C7	_	NN	NN	_	6	PMOD	_	_
10	as	_	RB	RB	_	6	CC	_	_
11	well	_	RB	RB	_	10	DEP	_	_
12	as	_	IN	IN	_	10	DEP	_	_
13	in	_	IN	IN	_	6	COORD	_	_
14	two	_	CD	CD	_	15	NMOD	_	_
15	classes	_	NNS	NNS	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	dex-resistant	_	JJ	JJ	_	18	NMOD	_	_
18	clones	_	NNS	NNS	_	16	PMOD	_	_
19	,	_	,	,	_	3	P	_	_
20	although	_	IN	IN	_	3	OBJ	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	dex-resistant	_	JJ	JJ	_	23	NMOD	_	_
23	clones	_	NNS	NNS	_	24	SBJ	_	_
24	needed	_	VBD	VBD	_	20	VMOD	_	_
25	at	_	IN	IN	_	28	DEP	_	_
26	least	_	JJS	JJS	_	28	DEP	_	_
27	10	_	CD	CD	_	28	DEP	_	_
28	times	_	NNS	NNS	_	30	NMOD	_	_
29	more	_	JJR	JJR	_	28	AMOD	_	_
30	cortivazol	_	NN	NN	_	24	OBJ	_	_
31	than	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	normal	_	JJ	JJ	_	34	NMOD	_	_
34	cells	_	NNS	NNS	_	31	PMOD	_	_
35	for	_	IN	IN	_	24	ADV	_	_
36	significant	_	JJ	JJ	_	39	NMOD	_	_
37	GR	_	NN	NN	_	39	NMOD	_	_
38	mRNA	_	NN	NN	_	39	NMOD	_	_
39	induction	_	NN	NN	_	35	PMOD	_	_
40	.	_	.	.	_	3	P	_	_

1	Increased	_	VBN	VBN	_	2	NMOD	_	_
2	levels	_	NNS	NNS	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	GR	_	NN	NN	_	5	NMOD	_	_
5	mRNA	_	NN	NN	_	3	PMOD	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	noticed	_	VBN	VBN	_	6	VC	_	_
8	as	_	RB	RB	_	7	TMP	_	_
9	early	_	RB	RB	_	8	AMOD	_	_
10	as	_	IN	IN	_	8	AMOD	_	_
11	3	_	CD	CD	_	12	NMOD	_	_
12	h	_	NN	NN	_	13	PMOD	_	_
13	after	_	IN	IN	_	10	TMP	_	_
14	treatment	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	6	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	general	_	JJ	JJ	_	3	NMOD	_	_
3	correlation	_	NN	NN	_	17	SBJ	_	_
4	between	_	IN	IN	_	3	NMOD	_	_
5	induction	_	NN	NN	_	4	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	GR	_	NN	NN	_	8	NMOD	_	_
8	mRNA	_	NN	NN	_	6	PMOD	_	_
9	and	_	CC	CC	_	5	CC	_	_
10	lysis	_	NN	NN	_	5	COORD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	16	NMOD	_	_
13	normal	_	JJ	JJ	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	dex-resistant	_	JJ	JJ	_	13	COORD	_	_
16	cells	_	NNS	NNS	_	11	PMOD	_	_
17	was	_	VBD	VBD	_	0	ROOT-S	_	_
18	found	_	VBN	VBN	_	17	VC	_	_
19	.	_	.	.	_	17	P	_	_

1	Positive	_	JJ	JJ	_	2	NMOD	_	_
2	induction	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	GR	_	NN	NN	_	5	NMOD	_	_
5	mRNA	_	NN	NN	_	3	PMOD	_	_
6	might	_	MD	MD	_	0	ROOT-S	_	_
7	be	_	VB	VB	_	6	VC	_	_
8	one	_	CD	CD	_	7	PRD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	earliest	_	JJS	JJS	_	13	NMOD	_	_
12	crucial	_	JJ	JJ	_	13	NMOD	_	_
13	steps	_	NNS	NNS	_	9	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	lysis	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	normal	_	JJ	JJ	_	22	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	dex-resistant	_	JJ	JJ	_	18	COORD	_	_
21	CEM	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	17	PMOD	_	_
23	,	_	,	,	_	6	P	_	_
24	or	_	CC	CC	_	6	CC	_	_
25	might	_	MD	MD	_	6	COORD	_	_
26	serve	_	VB	VB	_	25	VC	_	_
27	as	_	IN	IN	_	26	ADV	_	_
28	a	_	DT	DT	_	29	NMOD	_	_
29	marker	_	NN	NN	_	27	PMOD	_	_
30	for	_	IN	IN	_	29	NMOD	_	_
31	the	_	DT	DT	_	32	NMOD	_	_
32	process	_	NN	NN	_	30	PMOD	_	_
33	.	_	.	.	_	6	P	_	_

1	However	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	lysis	_	NN	NN	_	5	NMOD	_	_
5	pathway	_	NN	NN	_	10	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	dex-resistant	_	JJ	JJ	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	6	PMOD	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	defective	_	JJ	JJ	_	10	PRD	_	_
12	in	_	IN	IN	_	10	ADV	_	_
13	that	_	IN	IN	_	12	PMOD	_	_
14	dex-resistant	_	JJ	JJ	_	15	NMOD	_	_
15	clones	_	NNS	NNS	_	16	SBJ	_	_
16	needed	_	VBD	VBD	_	13	VMOD	_	_
17	significantly	_	RB	RB	_	18	AMOD	_	_
18	more	_	JJR	JJR	_	19	NMOD	_	_
19	cortivazol	_	NN	NN	_	16	OBJ	_	_
20	than	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	normal	_	JJ	JJ	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	20	PMOD	_	_
24	for	_	IN	IN	_	16	ADV	_	_
25	lysis	_	NN	NN	_	24	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	26	PMOD	_	_
29	.	_	.	.	_	10	P	_	_

1	Human	_	JJ	JJ	_	7	NMOD	_	_
2	tumor	_	NN	NN	_	7	NMOD	_	_
3	necrosis	_	NN	NN	_	7	NMOD	_	_
4	factor	_	NN	NN	_	7	NMOD	_	_
5	alpha	_	NN	NN	_	7	NMOD	_	_
6	gene	_	NN	NN	_	7	NMOD	_	_
7	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	phorbol	_	NN	NN	_	10	AMOD	_	_
10	ester	_	NN	NN	_	16	NMOD	_	_
11	stimulated	_	VBD	VBD	_	10	AMOD	_	_
12	T	_	NN	NN	_	16	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	B	_	NN	NN	_	12	COORD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	lines	_	NNS	NNS	_	8	PMOD	_	_
17	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	minimal	_	JJ	JJ	_	3	NMOD	_	_
3	region	_	NN	NN	_	35	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	15	NMOD	_	_
6	human	_	JJ	JJ	_	15	NMOD	_	_
7	tumor	_	NN	NN	_	15	NMOD	_	_
8	necrosis	_	NN	NN	_	15	NMOD	_	_
9	factor	_	NN	NN	_	15	NMOD	_	_
10	alpha	_	NN	NN	_	15	NMOD	_	_
11	(	_	(	(	_	15	P	_	_
12	TNF-alpha	_	NN	NN	_	15	NMOD	_	_
13	)	_	)	)	_	15	P	_	_
14	gene	_	NN	NN	_	15	NMOD	_	_
15	promoter	_	NN	NN	_	4	PMOD	_	_
16	necessary	_	JJ	JJ	_	15	NMOD	_	_
17	for	_	IN	IN	_	16	AMOD	_	_
18	its	_	PRP$	PRP$	_	20	NMOD	_	_
19	transcriptional	_	JJ	JJ	_	20	NMOD	_	_
20	induction	_	NN	NN	_	17	PMOD	_	_
21	by	_	IN	IN	_	20	NMOD	_	_
22	phorbol	_	NN	NN	_	23	NMOD	_	_
23	esters	_	NNS	NNS	_	21	PMOD	_	_
24	(	_	(	(	_	25	P	_	_
25	PMA	_	NN	NN	_	23	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	in	_	IN	IN	_	20	NMOD	_	_
28	human	_	JJ	JJ	_	34	NMOD	_	_
29	T	_	NN	NN	_	34	NMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	B	_	NN	NN	_	29	COORD	_	_
32	lymphocyte	_	NN	NN	_	34	NMOD	_	_
33	cell	_	NN	NN	_	34	NMOD	_	_
34	lines	_	NNS	NNS	_	27	PMOD	_	_
35	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
36	been	_	VBN	VBN	_	35	VC	_	_
37	localized	_	JJ	JJ	_	36	VC	_	_
38	between	_	IN	IN	_	37	ADV	_	_
39	-52	_	CD	CD	_	38	PMOD	_	_
40	and	_	CC	CC	_	39	CC	_	_
41	+89	_	CD	CD	_	39	COORD	_	_
42	nucleotides	_	NNS	NNS	_	39	NMOD	_	_
43	(	_	(	(	_	44	P	_	_
44	nt	_	NN	NN	_	42	PRN	_	_
45	)	_	)	)	_	44	P	_	_
46	relative	_	JJ	JJ	_	37	ADV	_	_
47	to	_	TO	TO	_	46	AMOD	_	_
48	the	_	DT	DT	_	49	NMOD	_	_
49	gene	_	NN	NN	_	53	NMOD	_	_
50	's	_	POS	POS	_	49	NMOD	_	_
51	transcriptional	_	JJ	JJ	_	53	NMOD	_	_
52	start	_	NN	NN	_	53	NMOD	_	_
53	site	_	NN	NN	_	47	PMOD	_	_
54	.	_	.	.	_	35	P	_	_

1	Comparison	_	NN	NN	_	20	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	sequences	_	NNS	NNS	_	2	PMOD	_	_
5	to	_	TO	TO	_	1	NMOD	_	_
6	those	_	DT	DT	_	5	PMOD	_	_
7	required	_	VBN	VBN	_	6	NMOD	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	mediate	_	VB	VB	_	7	OBJ	_	_
10	virus	_	NN	NN	_	16	NMOD	_	_
11	or	_	CC	CC	_	10	CC	_	_
12	lipopolysaccharide	_	NN	NN	_	10	COORD	_	_
13	(	_	(	(	_	14	P	_	_
14	LPS	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	induction	_	NN	NN	_	9	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	gene	_	NN	NN	_	17	PMOD	_	_
20	reveal	_	VB	VB	_	0	ROOT-S	_	_
21	significant	_	JJ	JJ	_	22	NMOD	_	_
22	differences	_	NNS	NNS	_	20	OBJ	_	_
23	,	_	,	,	_	20	P	_	_
24	and	_	CC	CC	_	20	CC	_	_
25	thus	_	RB	RB	_	20	COORD	_	_
26	,	_	,	,	_	20	P	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	sequence	_	NN	NN	_	29	NMOD	_	_
29	requirements	_	NNS	NNS	_	33	SBJ	_	_
30	for	_	IN	IN	_	29	NMOD	_	_
31	PMA	_	NN	NN	_	32	NMOD	_	_
32	induction	_	NN	NN	_	30	PMOD	_	_
33	are	_	VBP	VBP	_	20	COORD	_	_
34	distinct	_	JJ	JJ	_	33	PRD	_	_
35	from	_	IN	IN	_	34	AMOD	_	_
36	those	_	DT	DT	_	35	PMOD	_	_
37	that	_	WDT	WDT	_	38	SBJ	_	_
38	mediate	_	VBP	VBP	_	36	NMOD	_	_
39	induction	_	NN	NN	_	38	OBJ	_	_
40	by	_	IN	IN	_	39	NMOD	_	_
41	virus	_	NN	NN	_	40	PMOD	_	_
42	or	_	CC	CC	_	41	CC	_	_
43	LPS	_	NN	NN	_	41	COORD	_	_
44	.	_	.	.	_	20	P	_	_

1	Although	_	IN	IN	_	36	ADV	_	_
2	three	_	CD	CD	_	3	NMOD	_	_
3	sites	_	NNS	NNS	_	20	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	TNF-alpha	_	NN	NN	_	7	NMOD	_	_
7	promoter	_	NN	NN	_	4	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	kappa	_	NN	NN	_	3	PRN	_	_
10	1	_	CD	CD	_	9	NMOD	_	_
11	,	_	,	,	_	9	P	_	_
12	kappa	_	NN	NN	_	9	COORD	_	_
13	2	_	CD	CD	_	12	NMOD	_	_
14	,	_	,	,	_	9	P	_	_
15	and	_	CC	CC	_	9	CC	_	_
16	kappa	_	NN	NN	_	9	COORD	_	_
17	3	_	CD	CD	_	16	NMOD	_	_
18	)	_	)	)	_	9	P	_	_
19	specifically	_	RB	RB	_	20	ADV	_	_
20	bind	_	VBP	VBP	_	1	VMOD	_	_
21	the	_	DT	DT	_	25	NMOD	_	_
22	transcription	_	NN	NN	_	25	NMOD	_	_
23	factor	_	NN	NN	_	25	NMOD	_	_
24	NF-kappa	_	NN	NN	_	25	NMOD	_	_
25	B	_	NN	NN	_	20	OBJ	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	lymphoid	_	JJ	JJ	_	29	NMOD	_	_
28	nuclear	_	JJ	JJ	_	29	NMOD	_	_
29	extracts	_	NNS	NNS	_	26	PMOD	_	_
30	,	_	,	,	_	36	P	_	_
31	TNF-alpha	_	NN	NN	_	33	NMOD	_	_
32	mRNA	_	NN	NN	_	33	NMOD	_	_
33	induction	_	NN	NN	_	36	SBJ	_	_
34	by	_	IN	IN	_	33	NMOD	_	_
35	PMA	_	NN	NN	_	34	PMOD	_	_
36	does	_	VBZ	VBZ	_	0	ROOT-S	_	_
37	not	_	RB	RB	_	36	VMOD	_	_
38	correlate	_	VB	VB	_	36	VC	_	_
39	with	_	IN	IN	_	38	ADV	_	_
40	NF-kappa	_	NN	NN	_	43	NMOD	_	_
41	B	_	NN	NN	_	43	NMOD	_	_
42	binding	_	NN	NN	_	43	NMOD	_	_
43	activities	_	NNS	NNS	_	39	PMOD	_	_
44	displayed	_	VBN	VBN	_	43	NMOD	_	_
45	by	_	IN	IN	_	44	ADV	_	_
46	different	_	JJ	JJ	_	51	NMOD	_	_
47	T	_	NN	NN	_	51	NMOD	_	_
48	and	_	CC	CC	_	47	CC	_	_
49	B	_	NN	NN	_	47	COORD	_	_
50	cell	_	NN	NN	_	51	NMOD	_	_
51	lines	_	NNS	NNS	_	45	PMOD	_	_
52	.	_	.	.	_	36	P	_	_

1	Moreover	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	kappa	_	NN	NN	_	8	SBJ	_	_
4	1	_	CD	CD	_	3	NMOD	_	_
5	-	_	:	:	_	3	P	_	_
6	kappa	_	NN	NN	_	3	NMOD	_	_
7	3	_	CD	CD	_	6	NMOD	_	_
8	can	_	MD	MD	_	0	ROOT-S	_	_
9	each	_	DT	DT	_	8	VMOD	_	_
10	be	_	VB	VB	_	8	VC	_	_
11	deleted	_	VBN	VBN	_	10	VC	_	_
12	from	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	TNF-alpha	_	NN	NN	_	15	NMOD	_	_
15	promoter	_	NN	NN	_	12	PMOD	_	_
16	with	_	IN	IN	_	11	ADV	_	_
17	little	_	JJ	JJ	_	18	NMOD	_	_
18	effect	_	NN	NN	_	16	PMOD	_	_
19	on	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	gene	_	NN	NN	_	23	NMOD	_	_
22	's	_	POS	POS	_	21	NMOD	_	_
23	inducibility	_	NN	NN	_	19	PMOD	_	_
24	by	_	IN	IN	_	23	NMOD	_	_
25	PMA	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	8	P	_	_

1	Therefore	_	RB	RB	_	17	ADV	_	_
2	,	_	,	,	_	17	P	_	_
3	TNF-alpha	_	NN	NN	_	5	NMOD	_	_
4	mRNA	_	NN	NN	_	5	NMOD	_	_
5	induction	_	NN	NN	_	17	SBJ	_	_
6	by	_	IN	IN	_	5	NMOD	_	_
7	PMA	_	NN	NN	_	6	PMOD	_	_
8	,	_	,	,	_	17	P	_	_
9	like	_	IN	IN	_	17	ADV	_	_
10	its	_	PRP$	PRP$	_	11	NMOD	_	_
11	induction	_	NN	NN	_	9	PMOD	_	_
12	by	_	IN	IN	_	11	NMOD	_	_
13	virus	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	LPS	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	17	P	_	_
17	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	not	_	RB	RB	_	17	VMOD	_	_
19	primarily	_	RB	RB	_	17	ADV	_	_
20	mediated	_	VBN	VBN	_	17	VC	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	NF-kappa	_	NN	NN	_	23	NMOD	_	_
23	B	_	NN	NN	_	21	PMOD	_	_
24	,	_	,	,	_	17	P	_	_
25	but	_	CC	CC	_	17	CC	_	_
26	rather	_	RB	RB	_	25	COORD	_	_
27	is	_	VBZ	VBZ	_	17	COORD	_	_
28	mediated	_	VBN	VBN	_	27	VC	_	_
29	through	_	IN	IN	_	28	ADV	_	_
30	other	_	JJ	JJ	_	31	NMOD	_	_
31	sequences	_	NNS	NNS	_	29	PMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	protein	_	NN	NN	_	34	NMOD	_	_
34	factors	_	NNS	NNS	_	31	COORD	_	_
35	.	_	.	.	_	17	P	_	_

1	Surprisingly	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	multimers	_	NNS	NNS	_	10	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	kappa	_	NN	NN	_	4	PMOD	_	_
6	1	_	CD	CD	_	5	NMOD	_	_
7	-	_	:	:	_	5	P	_	_
8	kappa	_	NN	NN	_	5	NMOD	_	_
9	3	_	CD	CD	_	8	NMOD	_	_
10	can	_	MD	MD	_	0	ROOT-S	_	_
11	confer	_	VB	VB	_	10	VC	_	_
12	PMA	_	NN	NN	_	13	NMOD	_	_
13	inducibility	_	NN	NN	_	11	OBJ	_	_
14	on	_	IN	IN	_	11	ADV	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	heterologous	_	JJ	JJ	_	17	NMOD	_	_
17	promoter	_	NN	NN	_	14	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	a	_	DT	DT	_	20	NMOD	_	_
20	B	_	NN	NN	_	18	PMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	Raji	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	,	_	,	,	_	20	P	_	_
25	but	_	CC	CC	_	20	CC	_	_
26	not	_	RB	RB	_	25	COORD	_	_
27	a	_	DT	DT	_	28	NMOD	_	_
28	T	_	NN	NN	_	20	COORD	_	_
29	(	_	(	(	_	30	P	_	_
30	HUT78	_	NN	NN	_	28	PRN	_	_
31	)	_	)	)	_	30	P	_	_
32	cell	_	NN	NN	_	33	NMOD	_	_
33	line	_	NN	NN	_	20	NMOD	_	_
34	.	_	.	.	_	10	P	_	_

1	However	_	WRB	WRB	_	3	ADV	_	_
2	they	_	PRP	PRP	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	functional	_	JJ	JJ	_	3	PRD	_	_
6	on	_	IN	IN	_	3	ADV	_	_
7	a	_	DT	DT	_	10	NMOD	_	_
8	truncated	_	VBN	VBN	_	10	NMOD	_	_
9	TNF-alpha	_	NN	NN	_	10	NMOD	_	_
10	promoter	_	NN	NN	_	6	PMOD	_	_
11	,	_	,	,	_	3	P	_	_
12	indicating	_	VBG	VBG	_	3	VC	_	_
13	that	_	IN	IN	_	12	OBJ	_	_
14	promoter	_	NN	NN	_	15	NMOD	_	_
15	context	_	NN	NN	_	20	SBJ	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	cell	_	NN	NN	_	19	NMOD	_	_
18	type	_	NN	NN	_	19	NMOD	_	_
19	specificity	_	NN	NN	_	15	COORD	_	_
20	influence	_	VBP	VBP	_	13	VMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	PMA	_	NN	NN	_	24	NMOD	_	_
23	inducible	_	JJ	JJ	_	24	NMOD	_	_
24	function	_	NN	NN	_	20	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	these	_	DT	DT	_	30	NMOD	_	_
27	NF-kappa	_	NN	NN	_	30	NMOD	_	_
28	B	_	NN	NN	_	30	NMOD	_	_
29	binding	_	NN	NN	_	30	NMOD	_	_
30	sites	_	NNS	NNS	_	25	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	Cloning	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	human	_	JJ	JJ	_	6	NMOD	_	_
5	homeobox	_	NN	NN	_	6	NMOD	_	_
6	gene	_	NN	NN	_	2	PMOD	_	_
7	that	_	WDT	WDT	_	8	SBJ	_	_
8	resembles	_	VBZ	VBZ	_	6	NMOD	_	_
9	a	_	DT	DT	_	13	NMOD	_	_
10	diverged	_	JJ	JJ	_	13	NMOD	_	_
11	Drosophila	_	NN	NN	_	13	NMOD	_	_
12	homeobox	_	NN	NN	_	13	NMOD	_	_
13	gene	_	NN	NN	_	8	OBJ	_	_
14	and	_	CC	CC	_	8	CC	_	_
15	is	_	VBZ	VBZ	_	8	COORD	_	_
16	expressed	_	VBN	VBN	_	15	VC	_	_
17	in	_	IN	IN	_	16	ADV	_	_
18	activated	_	VBN	VBN	_	19	NMOD	_	_
19	lymphocytes	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	1	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	new	_	JJ	JJ	_	4	NMOD	_	_
3	homeobox	_	NN	NN	_	4	NMOD	_	_
4	gene	_	NN	NN	_	8	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	HB24	_	NN	NN	_	4	NMOD	_	_
7	,	_	,	,	_	4	P	_	_
8	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	been	_	VBN	VBN	_	8	VC	_	_
10	isolated	_	VBN	VBN	_	9	VC	_	_
11	from	_	IN	IN	_	10	ADV	_	_
12	a	_	DT	DT	_	16	NMOD	_	_
13	human	_	JJ	JJ	_	16	NMOD	_	_
14	B-lymphocyte	_	NN	NN	_	16	NMOD	_	_
15	cDNA	_	NN	NN	_	16	NMOD	_	_
16	library	_	NN	NN	_	11	PMOD	_	_
17	.	_	.	.	_	8	P	_	_

1	Northern	_	JJ	JJ	_	3	NMOD	_	_
2	blot	_	NN	NN	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	13	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	polyadenylated	_	JJ	JJ	_	6	NMOD	_	_
6	RNA	_	NN	NN	_	4	PMOD	_	_
7	purified	_	VBN	VBN	_	6	NMOD	_	_
8	from	_	IN	IN	_	7	ADV	_	_
9	activated	_	VBN	VBN	_	12	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	B	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	8	PMOD	_	_
13	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
14	a	_	DT	DT	_	17	NMOD	_	_
15	single	_	JJ	JJ	_	17	NMOD	_	_
16	mRNA	_	NN	NN	_	17	NMOD	_	_
17	transcript	_	NN	NN	_	13	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	approximately	_	RB	RB	_	21	NMOD	_	_
20	2.3	_	CD	CD	_	19	DEP	_	_
21	kb	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	13	P	_	_

1	Two	_	CD	CD	_	3	NMOD	_	_
2	cDNA	_	NN	NN	_	3	NMOD	_	_
3	clones	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	sequenced	_	VBN	VBN	_	4	VC	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	provided	_	VBN	VBN	_	5	COORD	_	_
8	2,250	_	CD	CD	_	9	NMOD	_	_
9	nucleotides	_	NNS	NNS	_	7	OBJ	_	_
10	(	_	(	(	_	11	P	_	_
11	nt	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	of	_	IN	IN	_	9	NMOD	_	_
14	DNA	_	NN	NN	_	16	NMOD	_	_
15	sequence	_	NN	NN	_	16	NMOD	_	_
16	information	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	4	P	_	_

1	There	_	EX	EX	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	9	NMOD	_	_
4	single	_	JJ	JJ	_	9	NMOD	_	_
5	methionine	_	NN	NN	_	9	NMOD	_	_
6	codon-initiated	_	JJ	JJ	_	5	AMOD	_	_
7	open	_	JJ	JJ	_	9	NMOD	_	_
8	reading	_	NN	NN	_	9	NMOD	_	_
9	frame	_	NN	NN	_	2	PRD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	1,458	_	CD	CD	_	12	NMOD	_	_
12	nt	_	NN	NN	_	10	PMOD	_	_
13	in	_	IN	IN	_	2	ADV	_	_
14	frame	_	NN	NN	_	13	PMOD	_	_
15	with	_	IN	IN	_	14	NMOD	_	_
16	a	_	DT	DT	_	17	NMOD	_	_
17	homeobox	_	NN	NN	_	15	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	CAX	_	NN	NN	_	21	NMOD	_	_
21	repeat	_	NN	NN	_	17	COORD	_	_
22	,	_	,	,	_	2	P	_	_
23	and	_	CC	CC	_	2	CC	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	open	_	JJ	JJ	_	27	NMOD	_	_
26	reading	_	NN	NN	_	27	NMOD	_	_
27	frame	_	NN	NN	_	28	SBJ	_	_
28	is	_	VBZ	VBZ	_	2	COORD	_	_
29	predicted	_	VBN	VBN	_	28	VC	_	_
30	to	_	TO	TO	_	31	VMOD	_	_
31	encode	_	VB	VB	_	29	OBJ	_	_
32	a	_	DT	DT	_	33	NMOD	_	_
33	protein	_	NN	NN	_	31	OBJ	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	51,659	_	CD	CD	_	36	NMOD	_	_
36	daltons	_	NNS	NNS	_	34	PMOD	_	_
37	.	_	.	.	_	2	P	_	_

1	When	_	WRB	WRB	_	7	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	homeodomain	_	NN	NN	_	6	SBJ	_	_
4	from	_	IN	IN	_	3	NMOD	_	_
5	HB24	_	NN	NN	_	4	PMOD	_	_
6	was	_	VBD	VBD	_	15	TMP	_	_
7	compared	_	VBN	VBN	_	6	VC	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	known	_	JJ	JJ	_	13	NMOD	_	_
10	mammalian	_	JJ	JJ	_	13	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	Drosophila	_	NN	NN	_	10	COORD	_	_
13	homeodomains	_	NNS	NNS	_	8	PMOD	_	_
14	it	_	PRP	PRP	_	15	SBJ	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	found	_	VBN	VBN	_	15	VC	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	be	_	VB	VB	_	16	OBJ	_	_
19	only	_	RB	RB	_	18	PRD	_	_
20	moderately	_	RB	RB	_	19	AMOD	_	_
21	conserved	_	VBN	VBN	_	19	AMOD	_	_
22	,	_	,	,	_	15	P	_	_
23	but	_	CC	CC	_	15	CC	_	_
24	when	_	WRB	WRB	_	27	ADV	_	_
25	it	_	PRP	PRP	_	26	SBJ	_	_
26	was	_	VBD	VBD	_	38	TMP	_	_
27	compared	_	VBN	VBN	_	26	VC	_	_
28	to	_	TO	TO	_	27	ADV	_	_
29	a	_	DT	DT	_	33	NMOD	_	_
30	highly	_	RB	RB	_	31	AMOD	_	_
31	diverged	_	JJ	JJ	_	33	NMOD	_	_
32	Drosophila	_	FW	FW	_	33	NMOD	_	_
33	homeodomain	_	NN	NN	_	28	PMOD	_	_
34	,	_	,	,	_	33	P	_	_
35	H2.0	_	NN	NN	_	33	NMOD	_	_
36	,	_	,	,	_	33	P	_	_
37	it	_	PRP	PRP	_	38	SBJ	_	_
38	was	_	VBD	VBD	_	15	COORD	_	_
39	found	_	VBN	VBN	_	38	VC	_	_
40	to	_	TO	TO	_	41	VMOD	_	_
41	be	_	VB	VB	_	39	OBJ	_	_
42	80	_	CD	CD	_	43	NMOD	_	_
43	%	_	NN	NN	_	44	AMOD	_	_
44	identical	_	JJ	JJ	_	41	PRD	_	_
45	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	HB24	_	NN	NN	_	3	NMOD	_	_
3	mRNA	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	absent	_	JJ	JJ	_	4	PRD	_	_
6	or	_	CC	CC	_	5	CC	_	_
7	present	_	JJ	JJ	_	5	COORD	_	_
8	at	_	IN	IN	_	4	ADV	_	_
9	low	_	JJ	JJ	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	8	PMOD	_	_
11	in	_	IN	IN	_	4	ADV	_	_
12	normal	_	JJ	JJ	_	16	NMOD	_	_
13	B	_	NN	NN	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	T	_	NN	NN	_	13	COORD	_	_
16	lymphocytes	_	NNS	NNS	_	11	PMOD	_	_
17	;	_	:	:	_	4	P	_	_
18	however	_	RB	RB	_	27	ADV	_	_
19	,	_	,	,	_	27	P	_	_
20	with	_	IN	IN	_	27	ADV	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	appropriate	_	JJ	JJ	_	24	NMOD	_	_
23	activation	_	NN	NN	_	24	NMOD	_	_
24	signal	_	NN	NN	_	20	PMOD	_	_
25	HB24	_	NN	NN	_	26	NMOD	_	_
26	mRNA	_	NN	NN	_	27	SBJ	_	_
27	was	_	VBD	VBD	_	4	VC	_	_
28	induced	_	VBN	VBN	_	27	VC	_	_
29	within	_	IN	IN	_	28	TMP	_	_
30	several	_	JJ	JJ	_	31	NMOD	_	_
31	hours	_	NNS	NNS	_	29	PMOD	_	_
32	even	_	RB	RB	_	33	DEP	_	_
33	in	_	IN	IN	_	28	ADV	_	_
34	the	_	DT	DT	_	33	DEP	_	_
35	presence	_	NN	NN	_	33	DEP	_	_
36	of	_	IN	IN	_	33	DEP	_	_
37	cycloheximide	_	NN	NN	_	33	PMOD	_	_
38	.	_	.	.	_	27	P	_	_

1	Characterization	_	NN	NN	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	HB24	_	NN	NN	_	4	NMOD	_	_
4	expression	_	NN	NN	_	2	PMOD	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	lymphoid	_	JJ	JJ	_	5	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	select	_	JJ	JJ	_	10	NMOD	_	_
9	developing	_	VBG	VBG	_	10	NMOD	_	_
10	tissues	_	NNS	NNS	_	6	COORD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	performed	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	ADV	_	_
14	in	_	FW	FW	_	15	AMOD	_	_
15	situ	_	FW	FW	_	16	NMOD	_	_
16	hybridization	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	11	P	_	_

1	Positive	_	JJ	JJ	_	2	NMOD	_	_
2	hybridization	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	found	_	VBN	VBN	_	3	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	thymus	_	NN	NN	_	5	PMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	tonsil	_	NN	NN	_	6	NMOD	_	_
9	,	_	,	,	_	6	P	_	_
10	bone	_	NN	NN	_	11	NMOD	_	_
11	marrow	_	NN	NN	_	6	NMOD	_	_
12	,	_	,	,	_	6	P	_	_
13	developing	_	VBG	VBG	_	14	NMOD	_	_
14	vessels	_	NNS	NNS	_	6	NMOD	_	_
15	,	_	,	,	_	5	P	_	_
16	and	_	CC	CC	_	5	CC	_	_
17	in	_	IN	IN	_	5	COORD	_	_
18	fetal	_	JJ	JJ	_	19	NMOD	_	_
19	brain	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	HB24	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	likely	_	JJ	JJ	_	2	PRD	_	_
4	to	_	TO	TO	_	5	VMOD	_	_
5	have	_	VB	VB	_	3	AMOD	_	_
6	an	_	DT	DT	_	8	NMOD	_	_
7	important	_	JJ	JJ	_	8	NMOD	_	_
8	role	_	NN	NN	_	5	OBJ	_	_
9	in	_	IN	IN	_	5	ADV	_	_
10	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
11	as	_	RB	RB	_	9	CC	_	_
12	well	_	RB	RB	_	11	DEP	_	_
13	as	_	IN	IN	_	11	DEP	_	_
14	in	_	IN	IN	_	9	COORD	_	_
15	certain	_	JJ	JJ	_	17	NMOD	_	_
16	developing	_	VBG	VBG	_	17	NMOD	_	_
17	tissues	_	NNS	NNS	_	14	PMOD	_	_
18	.	_	.	.	_	2	P	_	_

1	HTLV-1	_	NN	NN	_	2	NMOD	_	_
2	Tax	_	NN	NN	_	3	SBJ	_	_
3	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	expression	_	NN	NN	_	3	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	various	_	JJ	JJ	_	11	NMOD	_	_
7	immediate	_	JJ	JJ	_	11	NMOD	_	_
8	early	_	JJ	JJ	_	11	NMOD	_	_
9	serum	_	NN	NN	_	11	NMOD	_	_
10	responsive	_	JJ	JJ	_	11	NMOD	_	_
11	genes	_	NNS	NNS	_	5	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	Human	_	JJ	JJ	_	5	NMOD	_	_
2	T-cell	_	NN	NN	_	5	NMOD	_	_
3	leukemia	_	NN	NN	_	5	NMOD	_	_
4	virus	_	NN	NN	_	5	NMOD	_	_
5	type	_	NN	NN	_	10	SBJ	_	_
6	1	_	CD	CD	_	5	NMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	HTLV-1	_	NN	NN	_	5	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	an	_	DT	DT	_	13	NMOD	_	_
12	etiological	_	JJ	JJ	_	13	NMOD	_	_
13	agent	_	NN	NN	_	10	PRD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	adult	_	JJ	JJ	_	17	NMOD	_	_
16	T-cell	_	NN	NN	_	17	NMOD	_	_
17	leukemia	_	NN	NN	_	14	PMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	ATL	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	.	_	.	.	_	10	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	showed	_	VBD	VBD	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	by	_	IN	IN	_	2	ADV	_	_
5	mobility-shift	_	NN	NN	_	6	NMOD	_	_
6	assay	_	NN	NN	_	4	PMOD	_	_
7	that	_	IN	IN	_	2	OBJ	_	_
8	T-cell	_	NN	NN	_	9	NMOD	_	_
9	lines	_	NNS	NNS	_	14	SBJ	_	_
10	transformed	_	VBN	VBN	_	9	NMOD	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	virus	_	NN	NN	_	11	PMOD	_	_
14	contained	_	VBD	VBD	_	7	VMOD	_	_
15	high	_	JJ	JJ	_	16	NMOD	_	_
16	levels	_	NNS	NNS	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	AP-1	_	NN	NN	_	19	NMOD	_	_
19	activities	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	Consistent	_	JJ	JJ	_	9	ADV	_	_
2	with	_	IN	IN	_	1	AMOD	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	result	_	NN	NN	_	2	PMOD	_	_
5	,	_	,	,	_	9	P	_	_
6	these	_	DT	DT	_	8	NMOD	_	_
7	cell	_	NN	NN	_	8	NMOD	_	_
8	lines	_	NNS	NNS	_	9	SBJ	_	_
9	expressed	_	VBD	VBD	_	0	ROOT-S	_	_
10	increased	_	VBN	VBN	_	11	NMOD	_	_
11	levels	_	NNS	NNS	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	mRNAs	_	NNS	NNS	_	12	PMOD	_	_
14	encoding	_	VBG	VBG	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	AP-1	_	NN	NN	_	17	NMOD	_	_
17	proteins	_	NNS	NNS	_	14	OBJ	_	_
18	,	_	,	,	_	17	P	_	_
19	c-Fos	_	NN	NN	_	17	NMOD	_	_
20	,	_	,	,	_	19	P	_	_
21	Fra-1	_	NN	NN	_	19	COORD	_	_
22	,	_	,	,	_	19	P	_	_
23	c-Jun	_	NN	NN	_	19	COORD	_	_
24	,	_	,	,	_	19	P	_	_
25	JunB	_	NN	NN	_	19	COORD	_	_
26	,	_	,	,	_	19	P	_	_
27	and	_	CC	CC	_	19	CC	_	_
28	JunD	_	NN	NN	_	19	COORD	_	_
29	.	_	.	.	_	9	P	_	_

1	Previously	_	RB	RB	_	8	TMP	_	_
2	,	_	,	,	_	8	P	_	_
3	transcription	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	c-fos	_	NN	NN	_	7	NMOD	_	_
7	gene	_	NN	NN	_	4	PMOD	_	_
8	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	been	_	VBN	VBN	_	8	VC	_	_
10	reported	_	VBN	VBN	_	9	VC	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	be	_	VB	VB	_	10	OBJ	_	_
13	transactivated	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	viral	_	JJ	JJ	_	18	NMOD	_	_
17	transcription	_	NN	NN	_	18	NMOD	_	_
18	factor	_	NN	NN	_	14	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	Tax1	_	NN	NN	_	18	NMOD	_	_
21	.	_	.	.	_	8	P	_	_

1	By	_	IN	IN	_	21	ADV	_	_
2	using	_	VBG	VBG	_	1	PMOD	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	human	_	JJ	JJ	_	6	NMOD	_	_
5	T-cell	_	NN	NN	_	6	NMOD	_	_
6	line	_	NN	NN	_	2	OBJ	_	_
7	(	_	(	(	_	8	P	_	_
8	JPX-9	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	,	_	,	,	_	6	P	_	_
11	in	_	IN	IN	_	17	ADV	_	_
12	which	_	WDT	WDT	_	11	PMOD	_	_
13	expression	_	NN	NN	_	17	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	Tax1	_	NN	NN	_	14	PMOD	_	_
17	is	_	VBZ	VBZ	_	6	NMOD	_	_
18	inducible	_	JJ	JJ	_	17	PRD	_	_
19	,	_	,	,	_	21	P	_	_
20	we	_	PRP	PRP	_	21	SBJ	_	_
21	showed	_	VBD	VBD	_	0	ROOT-S	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	expression	_	NN	NN	_	33	SBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	mRNAs	_	NNS	NNS	_	24	PMOD	_	_
26	for	_	IN	IN	_	25	NMOD	_	_
27	Fra-1	_	NN	NN	_	26	PMOD	_	_
28	,	_	,	,	_	27	P	_	_
29	c-Jun	_	NN	NN	_	27	COORD	_	_
30	,	_	,	,	_	27	P	_	_
31	and	_	CC	CC	_	27	CC	_	_
32	JunD	_	NN	NN	_	27	COORD	_	_
33	was	_	VBD	VBD	_	22	VMOD	_	_
34	also	_	RB	RB	_	33	ADV	_	_
35	transactivated	_	VBN	VBN	_	33	VC	_	_
36	by	_	IN	IN	_	35	LGS	_	_
37	Tax1	_	NN	NN	_	36	PMOD	_	_
38	.	_	.	.	_	21	P	_	_

1	Moreover	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	Tax1	_	NN	NN	_	4	SBJ	_	_
4	activated	_	VBD	VBD	_	0	ROOT-S	_	_
5	expression	_	NN	NN	_	4	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	two	_	CD	CD	_	10	NMOD	_	_
8	other	_	JJ	JJ	_	10	NMOD	_	_
9	transcription	_	NN	NN	_	10	NMOD	_	_
10	factors	_	NNS	NNS	_	6	PMOD	_	_
11	having	_	VBG	VBG	_	10	NMOD	_	_
12	zinc	_	NN	NN	_	14	NMOD	_	_
13	finger	_	NN	NN	_	14	NMOD	_	_
14	motifs	_	NNS	NNS	_	11	OBJ	_	_
15	,	_	,	,	_	10	P	_	_
16	Egr-1	_	NN	NN	_	10	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	Egr-2	_	NN	NN	_	16	COORD	_	_
19	,	_	,	,	_	10	P	_	_
20	in	_	IN	IN	_	10	NMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	same	_	JJ	JJ	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	20	PMOD	_	_
24	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	Tax1-inducible	_	JJ	JJ	_	4	NMOD	_	_
3	transcription	_	NN	NN	_	4	NMOD	_	_
4	factors	_	NNS	NNS	_	7	SBJ	_	_
5	identified	_	VBN	VBN	_	4	NMOD	_	_
6	here	_	RB	RB	_	5	ADV	_	_
7	are	_	VBP	VBP	_	0	ROOT-S	_	_
8	encoded	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	members	_	NNS	NNS	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	immediate	_	JJ	JJ	_	15	NMOD	_	_
14	early	_	JJ	JJ	_	15	NMOD	_	_
15	genes	_	NNS	NNS	_	12	PMOD	_	_
16	under	_	IN	IN	_	8	ADV	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	control	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	growth	_	NN	NN	_	21	NMOD	_	_
21	signals	_	NNS	NNS	_	19	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	Thus	_	RB	RB	_	4	VMOD	_	_
2	,	_	,	,	_	4	P	_	_
3	Tax1	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	suggested	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	replace	_	VB	VB	_	5	OBJ	_	_
8	growth	_	NN	NN	_	9	NMOD	_	_
9	signals	_	NNS	NNS	_	7	OBJ	_	_
10	,	_	,	,	_	7	P	_	_
11	at	_	IN	IN	_	13	PMOD	_	_
12	least	_	JJS	JJS	_	11	AMOD	_	_
13	in	_	IN	IN	_	7	ADV	_	_
14	part	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	7	P	_	_
16	by	_	IN	IN	_	7	ADV	_	_
17	this	_	DT	DT	_	18	NMOD	_	_
18	mechanism	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	4	P	_	_

1	Inhibition	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	HIV-1	_	NN	NN	_	4	NMOD	_	_
4	replication	_	NN	NN	_	2	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	NF-kappa	_	NN	NN	_	8	NMOD	_	_
7	B	_	NN	NN	_	8	NMOD	_	_
8	activity	_	NN	NN	_	4	COORD	_	_
9	by	_	IN	IN	_	1	NMOD	_	_
10	cysteine	_	NN	NN	_	9	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	cysteine	_	NN	NN	_	13	NMOD	_	_
13	derivatives	_	NNS	NNS	_	10	COORD	_	_
14	.	_	.	.	_	1	P	_	_

1	HIV-1	_	NN	NN	_	3	NMOD	_	_
2	proviral	_	JJ	JJ	_	3	NMOD	_	_
3	DNA	_	NN	NN	_	4	SBJ	_	_
4	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	two	_	CD	CD	_	7	NMOD	_	_
6	binding	_	VBG	VBG	_	7	NMOD	_	_
7	sites	_	NNS	NNS	_	4	OBJ	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	transcription	_	NN	NN	_	13	NMOD	_	_
11	factor	_	NN	NN	_	13	NMOD	_	_
12	NF-kappa	_	NN	NN	_	13	NMOD	_	_
13	B	_	NN	NN	_	8	PMOD	_	_
14	.	_	.	.	_	4	P	_	_

1	HIV-1-infected	_	JJ	JJ	_	2	NMOD	_	_
2	individuals	_	NNS	NNS	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	,	_	,	,	_	3	P	_	_
5	on	_	IN	IN	_	3	ADV	_	_
6	average	_	NN	NN	_	5	PMOD	_	_
7	,	_	,	,	_	3	P	_	_
8	abnormally	_	RB	RB	_	9	AMOD	_	_
9	high	_	JJ	JJ	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	3	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	tumour	_	NN	NN	_	15	NMOD	_	_
13	necrosis	_	NN	NN	_	15	NMOD	_	_
14	factor	_	NN	NN	_	15	NMOD	_	_
15	alpha	_	NN	NN	_	11	PMOD	_	_
16	(	_	(	(	_	18	P	_	_
17	TNF	_	NN	NN	_	18	NMOD	_	_
18	alpha	_	NN	NN	_	15	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	and	_	CC	CC	_	10	CC	_	_
21	abnormally	_	RB	RB	_	22	AMOD	_	_
22	low	_	JJ	JJ	_	25	NMOD	_	_
23	plasma	_	NN	NN	_	25	NMOD	_	_
24	cysteine	_	NN	NN	_	25	NMOD	_	_
25	levels	_	NNS	NNS	_	10	COORD	_	_
26	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	therefore	_	RB	RB	_	3	ADV	_	_
3	investigated	_	VBD	VBD	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	effects	_	NNS	NNS	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	cysteine	_	NN	NN	_	6	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	related	_	JJ	JJ	_	10	NMOD	_	_
10	thiols	_	NNS	NNS	_	7	COORD	_	_
11	on	_	IN	IN	_	5	NMOD	_	_
12	HIV-1	_	NN	NN	_	13	NMOD	_	_
13	replication	_	NN	NN	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	NF-kappa	_	NN	NN	_	17	NMOD	_	_
16	B	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	13	COORD	_	_
18	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	experiments	_	NNS	NNS	_	6	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	this	_	DT	DT	_	5	NMOD	_	_
5	report	_	NN	NN	_	3	PMOD	_	_
6	show	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	cysteine	_	NN	NN	_	14	SBJ	_	_
9	or	_	CC	CC	_	8	CC	_	_
10	N-acetylcysteine	_	NN	NN	_	8	COORD	_	_
11	(	_	(	(	_	12	P	_	_
12	NP	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	raise	_	VBP	VBP	_	7	VMOD	_	_
15	the	_	DT	DT	_	21	NMOD	_	_
16	intracellular	_	JJ	JJ	_	21	NMOD	_	_
17	glutathione	_	NN	NN	_	21	NMOD	_	_
18	(	_	(	(	_	21	P	_	_
19	GSH	_	NN	NN	_	21	NMOD	_	_
20	)	_	)	)	_	21	P	_	_
21	level	_	NN	NN	_	14	OBJ	_	_
22	and	_	CC	CC	_	14	CC	_	_
23	inhibit	_	VBP	VBP	_	14	COORD	_	_
24	HIV-1	_	NN	NN	_	25	NMOD	_	_
25	replication	_	NN	NN	_	23	OBJ	_	_
26	in	_	IN	IN	_	21	NMOD	_	_
27	persistently	_	RB	RB	_	28	AMOD	_	_
28	infected	_	JJ	JJ	_	32	NMOD	_	_
29	Molt-4	_	NN	NN	_	32	NMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	U937	_	NN	NN	_	29	COORD	_	_
32	cells	_	NNS	NNS	_	26	PMOD	_	_
33	.	_	.	.	_	6	P	_	_

1	However	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	inhibition	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	HIV-1	_	NN	NN	_	6	NMOD	_	_
6	replication	_	NN	NN	_	4	PMOD	_	_
7	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	not	_	RB	RB	_	10	VMOD	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	be	_	VB	VB	_	7	VC	_	_
11	directly	_	RB	RB	_	10	ADV	_	_
12	correlated	_	VBN	VBN	_	10	VC	_	_
13	with	_	IN	IN	_	12	ADV	_	_
14	GSH	_	NN	NN	_	15	NMOD	_	_
15	levels	_	NNS	NNS	_	13	PMOD	_	_
16	.	_	.	.	_	7	P	_	_

1	Cysteine	_	NN	NN	_	5	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	NP	_	NN	NN	_	1	COORD	_	_
4	also	_	RB	RB	_	5	ADV	_	_
5	inhibit	_	VBP	VBP	_	0	ROOT-S	_	_
6	NF-kappa	_	NN	NN	_	8	NMOD	_	_
7	B	_	NN	NN	_	8	NMOD	_	_
8	activity	_	NN	NN	_	5	OBJ	_	_
9	as	_	IN	IN	_	8	NMOD	_	_
10	determined	_	VBN	VBN	_	9	VMOD	_	_
11	by	_	IN	IN	_	10	ADV	_	_
12	electrophoretic	_	JJ	JJ	_	15	NMOD	_	_
13	mobility	_	NN	NN	_	15	NMOD	_	_
14	shift	_	NN	NN	_	15	NMOD	_	_
15	assays	_	NNS	NNS	_	11	PMOD	_	_
16	and	_	CC	CC	_	8	CC	_	_
17	chloramphenicol	_	NN	NN	_	18	NMOD	_	_
18	acetyl-transferase	_	NN	NN	_	23	NMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	CAT	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	gene	_	NN	NN	_	23	NMOD	_	_
23	expression	_	NN	NN	_	8	COORD	_	_
24	under	_	IN	IN	_	23	NMOD	_	_
25	control	_	NN	NN	_	24	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	NF-kappa	_	NN	NN	_	30	NMOD	_	_
28	B	_	NN	NN	_	30	NMOD	_	_
29	binding	_	NN	NN	_	30	NMOD	_	_
30	sites	_	NNS	NNS	_	26	PMOD	_	_
31	in	_	IN	IN	_	30	NMOD	_	_
32	uninfected	_	JJ	JJ	_	33	NMOD	_	_
33	cells	_	NNS	NNS	_	31	PMOD	_	_
34	.	_	.	.	_	5	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	cysteine	_	NN	NN	_	6	NMOD	_	_
6	deficiency	_	NN	NN	_	10	SBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	HIV-1-infected	_	JJ	JJ	_	9	NMOD	_	_
9	individuals	_	NNS	NNS	_	7	PMOD	_	_
10	may	_	MD	MD	_	3	VMOD	_	_
11	cause	_	VB	VB	_	10	VC	_	_
12	an	_	DT	DT	_	13	NMOD	_	_
13	over-expression	_	NN	NN	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	NF-kappa	_	NN	NN	_	17	NMOD	_	_
16	B-dependent	_	JJ	JJ	_	15	AMOD	_	_
17	genes	_	NNS	NNS	_	14	PMOD	_	_
18	and	_	CC	CC	_	11	CC	_	_
19	enhance	_	VB	VB	_	11	COORD	_	_
20	HIV-1	_	NN	NN	_	21	NMOD	_	_
21	replication	_	NN	NN	_	19	OBJ	_	_
22	.	_	.	.	_	2	P	_	_

1	NP	_	NN	NN	_	2	SBJ	_	_
2	may	_	MD	MD	_	0	ROOT-S	_	_
3	be	_	VB	VB	_	2	VC	_	_
4	considered	_	VBN	VBN	_	3	VC	_	_
5	for	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	treatment	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	HIV-1-infected	_	JJ	JJ	_	10	NMOD	_	_
10	individuals	_	NNS	NNS	_	8	PMOD	_	_
11	.	_	.	.	_	2	P	_	_

1	Lymphocyte	_	NN	NN	_	4	NMOD	_	_
2	glucocorticoid	_	NN	NN	_	4	NMOD	_	_
3	receptor	_	NN	NN	_	4	NMOD	_	_
4	binding	_	NN	NN	_	0	ROOT-FRAG	_	_
5	during	_	IN	IN	_	4	TMP	_	_
6	depression	_	NN	NN	_	5	PMOD	_	_
7	and	_	CC	CC	_	5	CC	_	_
8	after	_	IN	IN	_	5	COORD	_	_
9	clinical	_	JJ	JJ	_	10	NMOD	_	_
10	recovery	_	NN	NN	_	8	PMOD	_	_
11	.	_	.	.	_	4	P	_	_

1	Lymphocyte	_	NN	NN	_	5	NMOD	_	_
2	glucocorticoid	_	NN	NN	_	5	NMOD	_	_
3	receptor	_	NN	NN	_	5	NMOD	_	_
4	binding	_	NN	NN	_	5	NMOD	_	_
5	parameters	_	NNS	NNS	_	6	SBJ	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	studied	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	VMOD	_	_
9	15	_	CD	CD	_	12	NMOD	_	_
10	severely	_	RB	RB	_	11	AMOD	_	_
11	depressed	_	JJ	JJ	_	12	NMOD	_	_
12	patients	_	NNS	NNS	_	8	PMOD	_	_
13	during	_	IN	IN	_	7	TMP	_	_
14	depression	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	13	CC	_	_
16	after	_	IN	IN	_	13	COORD	_	_
17	clinical	_	JJ	JJ	_	18	NMOD	_	_
18	recovery	_	NN	NN	_	16	PMOD	_	_
19	,	_	,	,	_	7	P	_	_
20	and	_	CC	CC	_	7	CC	_	_
21	in	_	IN	IN	_	8	GAP	_	_
22	15	_	CD	CD	_	24	NMOD	_	_
23	healthy	_	JJ	JJ	_	24	NMOD	_	_
24	controls	_	NNS	NNS	_	21	PMOD	_	_
25	.	_	.	.	_	6	P	_	_

1	There	_	EX	EX	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	no	_	DT	DT	_	4	NMOD	_	_
4	difference	_	NN	NN	_	2	PRD	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	glucocorticoid	_	NN	NN	_	7	NMOD	_	_
7	receptor	_	NN	NN	_	5	PMOD	_	_
8	number	_	NN	NN	_	7	NMOD	_	_
9	or	_	CC	CC	_	8	CC	_	_
10	affinity	_	NN	NN	_	8	COORD	_	_
11	between	_	IN	IN	_	4	NMOD	_	_
12	depressed	_	JJ	JJ	_	13	NMOD	_	_
13	patients	_	NNS	NNS	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	recovered	_	JJ	JJ	_	18	NMOD	_	_
16	or	_	CC	CC	_	15	CC	_	_
17	control	_	NN	NN	_	15	COORD	_	_
18	subjects	_	NNS	NNS	_	13	COORD	_	_
19	.	_	.	.	_	2	P	_	_

1	Afternoon	_	NN	NN	_	5	NMOD	_	_
2	ACTH	_	NN	NN	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	cortisol	_	NN	NN	_	2	COORD	_	_
5	concentrations	_	NNS	NNS	_	6	SBJ	_	_
6	did	_	VBD	VBD	_	0	ROOT-S	_	_
7	not	_	RB	RB	_	6	VMOD	_	_
8	differ	_	VB	VB	_	6	VC	_	_
9	significantly	_	RB	RB	_	8	ADV	_	_
10	between	_	IN	IN	_	8	ADV	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	three	_	CD	CD	_	13	NMOD	_	_
13	groups	_	NNS	NNS	_	10	PMOD	_	_
14	.	_	.	.	_	6	P	_	_

1	No	_	DT	DT	_	2	NMOD	_	_
2	relationship	_	NN	NN	_	3	SBJ	_	_
3	could	_	MD	MD	_	0	ROOT-S	_	_
4	be	_	VB	VB	_	3	VC	_	_
5	established	_	VBN	VBN	_	4	VC	_	_
6	between	_	IN	IN	_	5	ADV	_	_
7	glucocorticoid	_	NN	NN	_	9	NMOD	_	_
8	receptor	_	NN	NN	_	9	NMOD	_	_
9	binding	_	NN	NN	_	6	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	antidepressant	_	JJ	JJ	_	12	NMOD	_	_
12	medication	_	NN	NN	_	9	COORD	_	_
13	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	support	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	view	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	an	_	DT	DT	_	10	NMOD	_	_
8	impaired	_	JJ	JJ	_	9	AMOD	_	_
9	ligand-induced	_	JJ	JJ	_	10	NMOD	_	_
10	plasticity	_	NN	NN	_	6	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	glucocorticoid	_	NN	NN	_	14	NMOD	_	_
13	receptor	_	NN	NN	_	14	NMOD	_	_
14	regulation	_	NN	NN	_	11	PMOD	_	_
15	rather	_	RB	RB	_	5	CC	_	_
16	than	_	IN	IN	_	15	DEP	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	hypothesis	_	NN	NN	_	5	COORD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	decreased	_	VBN	VBN	_	23	NMOD	_	_
21	glucocorticoid	_	NN	NN	_	23	NMOD	_	_
22	receptor	_	NN	NN	_	23	NMOD	_	_
23	numbers	_	NNS	NNS	_	19	PMOD	_	_
24	during	_	IN	IN	_	23	TMP	_	_
25	depression	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	NF-kappa	_	NN	NN	_	3	NMOD	_	_
2	B	_	NN	NN	_	3	NMOD	_	_
3	activation	_	NN	NN	_	15	SBJ	_	_
4	by	_	IN	IN	_	3	NMOD	_	_
5	tumor	_	NN	NN	_	8	NMOD	_	_
6	necrosis	_	NN	NN	_	8	NMOD	_	_
7	factor	_	NN	NN	_	8	NMOD	_	_
8	alpha	_	NN	NN	_	4	PMOD	_	_
9	in	_	IN	IN	_	3	NMOD	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	Jurkat	_	NN	NN	_	14	NMOD	_	_
12	T	_	NN	NN	_	14	NMOD	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	line	_	NN	NN	_	9	PMOD	_	_
15	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	independent	_	JJ	JJ	_	15	PRD	_	_
17	of	_	IN	IN	_	16	AMOD	_	_
18	protein	_	NN	NN	_	20	NMOD	_	_
19	kinase	_	NN	NN	_	20	NMOD	_	_
20	A	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	protein	_	NN	NN	_	24	NMOD	_	_
23	kinase	_	NN	NN	_	24	NMOD	_	_
24	C	_	NN	NN	_	20	COORD	_	_
25	,	_	,	,	_	20	P	_	_
26	and	_	CC	CC	_	20	CC	_	_
27	Ca-LRB-2+-RRB--regulated	_	JJ	JJ	_	28	NMOD	_	_
28	kinases	_	NNS	NNS	_	20	COORD	_	_
29	.	_	.	.	_	15	P	_	_

1	NF-kappa	_	NN	NN	_	2	NMOD	_	_
2	B	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	DNA-binding	_	JJ	JJ	_	7	NMOD	_	_
6	regulatory	_	JJ	JJ	_	7	NMOD	_	_
7	factor	_	NN	NN	_	3	PRD	_	_
8	able	_	JJ	JJ	_	7	NMOD	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	control	_	VB	VB	_	8	AMOD	_	_
11	transcription	_	NN	NN	_	10	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	number	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	genes	_	NNS	NNS	_	15	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	including	_	VBG	VBG	_	16	NMOD	_	_
19	human	_	JJ	JJ	_	21	NMOD	_	_
20	immunodeficiency	_	NN	NN	_	21	NMOD	_	_
21	virus	_	NN	NN	_	25	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	HIV	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	genes	_	NNS	NNS	_	18	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	T	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	7	P	_	_
5	NF-kappa	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	activated	_	VBN	VBN	_	7	VC	_	_
9	upon	_	IN	IN	_	8	TMP	_	_
10	cellular	_	JJ	JJ	_	11	NMOD	_	_
11	treatment	_	NN	NN	_	9	PMOD	_	_
12	by	_	IN	IN	_	11	NMOD	_	_
13	phorbol	_	NN	NN	_	14	NMOD	_	_
14	esters	_	NNS	NNS	_	12	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	cytokine	_	NN	NN	_	14	COORD	_	_
18	tumor	_	NN	NN	_	21	NMOD	_	_
19	necrosis	_	NN	NN	_	21	NMOD	_	_
20	factor	_	NN	NN	_	21	NMOD	_	_
21	alpha	_	NN	NN	_	17	NMOD	_	_
22	(	_	(	(	_	24	P	_	_
23	TNF	_	NN	NN	_	24	NMOD	_	_
24	alpha	_	NN	NN	_	21	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	present	_	JJ	JJ	_	4	NMOD	_	_
4	work	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	we	_	PRP	PRP	_	7	SBJ	_	_
7	investigated	_	VBD	VBD	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	molecular	_	JJ	JJ	_	10	NMOD	_	_
10	events	_	NNS	NNS	_	7	OBJ	_	_
11	leading	_	VBG	VBG	_	10	NMOD	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	NF-kappa	_	NN	NN	_	15	NMOD	_	_
14	B	_	NN	NN	_	15	NMOD	_	_
15	activation	_	NN	NN	_	12	PMOD	_	_
16	by	_	IN	IN	_	15	NMOD	_	_
17	TNF	_	NN	NN	_	18	NMOD	_	_
18	alpha	_	NN	NN	_	16	PMOD	_	_
19	in	_	IN	IN	_	15	NMOD	_	_
20	a	_	DT	DT	_	24	NMOD	_	_
21	human	_	JJ	JJ	_	24	NMOD	_	_
22	T	_	NN	NN	_	24	NMOD	_	_
23	cell	_	NN	NN	_	24	NMOD	_	_
24	line	_	NN	NN	_	19	PMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	Jurkat	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	and	_	CC	CC	_	24	CC	_	_
29	its	_	PRP$	PRP$	_	31	NMOD	_	_
30	subclone	_	JJ	JJ	_	31	NMOD	_	_
31	JCT6	_	NN	NN	_	24	COORD	_	_
32	,	_	,	,	_	31	P	_	_
33	which	_	WDT	WDT	_	34	SBJ	_	_
34	presents	_	VBZ	VBZ	_	31	NMOD	_	_
35	a	_	DT	DT	_	36	NMOD	_	_
36	deficiency	_	NN	NN	_	34	OBJ	_	_
37	in	_	IN	IN	_	36	NMOD	_	_
38	the	_	DT	DT	_	41	NMOD	_	_
39	PKA	_	NN	NN	_	41	NMOD	_	_
40	transduction	_	NN	NN	_	41	NMOD	_	_
41	pathway	_	NN	NN	_	37	PMOD	_	_
42	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	found	_	VBD	VBD	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	in	_	IN	IN	_	15	ADV	_	_
5	both	_	DT	DT	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	lines	_	NNS	NNS	_	4	PMOD	_	_
8	,	_	,	,	_	15	P	_	_
9	both	_	CC	CC	_	11	CC	_	_
10	phorbol	_	NN	NN	_	11	NMOD	_	_
11	ester	_	NN	NN	_	15	SBJ	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	TNF	_	NN	NN	_	14	NMOD	_	_
14	alpha	_	NN	NN	_	11	COORD	_	_
15	were	_	VBD	VBD	_	3	VMOD	_	_
16	able	_	JJ	JJ	_	15	PRD	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	activate	_	VB	VB	_	16	AMOD	_	_
19	NF-kappa	_	NN	NN	_	20	NMOD	_	_
20	B	_	NN	NN	_	18	OBJ	_	_
21	.	_	.	.	_	2	P	_	_

1	Phorbol	_	NN	NN	_	2	NMOD	_	_
2	activation	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	positively	_	RB	RB	_	3	ADV	_	_
5	modulated	_	VBN	VBN	_	3	VC	_	_
6	by	_	IN	IN	_	5	LGS	_	_
7	Ca2+	_	NN	NN	_	8	NMOD	_	_
8	influx	_	NN	NN	_	6	PMOD	_	_
9	while	_	IN	IN	_	5	OBJ	_	_
10	TNF	_	NN	NN	_	12	NMOD	_	_
11	alpha	_	NN	NN	_	12	NMOD	_	_
12	activation	_	NN	NN	_	13	SBJ	_	_
13	was	_	VBD	VBD	_	9	VMOD	_	_
14	not	_	RB	RB	_	13	VMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	Furthermore	_	RB	RB	_	18	ADV	_	_
2	,	_	,	,	_	18	P	_	_
3	while	_	IN	IN	_	18	ADV	_	_
4	PMA	_	NN	NN	_	5	NMOD	_	_
5	activation	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	3	VMOD	_	_
7	inhibited	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	PKC	_	NN	NN	_	12	NMOD	_	_
11	inhibitor	_	NN	NN	_	12	NMOD	_	_
12	staurosporin	_	NN	NN	_	8	PMOD	_	_
13	,	_	,	,	_	18	P	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	TNF	_	NN	NN	_	17	NMOD	_	_
16	alpha	_	NN	NN	_	17	NMOD	_	_
17	effect	_	NN	NN	_	18	SBJ	_	_
18	was	_	VBD	VBD	_	0	ROOT-S	_	_
19	unchanged	_	JJ	JJ	_	18	PRD	_	_
20	.	_	.	.	_	18	P	_	_

1	TNF	_	NN	NN	_	2	NMOD	_	_
2	alpha	_	NN	NN	_	3	SBJ	_	_
3	did	_	VBD	VBD	_	0	ROOT-S	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	activate	_	VB	VB	_	3	VC	_	_
6	cAMP	_	NN	NN	_	7	NMOD	_	_
7	production	_	NN	NN	_	5	OBJ	_	_
8	and	_	CC	CC	_	3	CC	_	_
9	its	_	PRP$	PRP$	_	10	NMOD	_	_
10	signal	_	NN	NN	_	11	SBJ	_	_
11	was	_	VBD	VBD	_	3	COORD	_	_
12	not	_	RB	RB	_	11	VMOD	_	_
13	modulated	_	VBN	VBN	_	11	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	cAMP	_	NN	NN	_	16	NMOD	_	_
16	activators	_	NNS	NNS	_	14	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	Moreover	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	cAMP	_	NN	NN	_	4	NMOD	_	_
4	activators	_	NNS	NNS	_	5	SBJ	_	_
5	did	_	VBD	VBD	_	0	ROOT-S	_	_
6	not	_	RB	RB	_	5	VMOD	_	_
7	activate	_	VB	VB	_	5	VC	_	_
8	NF-kappa	_	NN	NN	_	9	NMOD	_	_
9	B	_	NN	NN	_	7	OBJ	_	_
10	in	_	IN	IN	_	7	ADV	_	_
11	Jurkat	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	5	P	_	_

1	Thus	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	TNF	_	NN	NN	_	7	NMOD	_	_
4	alpha-induced	_	JJ	JJ	_	3	AMOD	_	_
5	NF-kappa	_	NN	NN	_	7	NMOD	_	_
6	B	_	NN	NN	_	7	NMOD	_	_
7	activation	_	NN	NN	_	8	SBJ	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	found	_	VBN	VBN	_	8	VC	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	be	_	VB	VB	_	9	OBJ	_	_
12	mediated	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	none	_	NN	NN	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	major	_	JJ	JJ	_	19	NMOD	_	_
18	signal-mediating	_	JJ	JJ	_	19	NMOD	_	_
19	kinases	_	NNS	NNS	_	15	PMOD	_	_
20	such	_	JJ	JJ	_	21	DEP	_	_
21	as	_	IN	IN	_	19	NMOD	_	_
22	protein	_	NN	NN	_	24	NMOD	_	_
23	kinase	_	NN	NN	_	24	NMOD	_	_
24	C	_	NN	NN	_	21	PMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	PKC	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	,	_	,	,	_	24	P	_	_
29	protein	_	NN	NN	_	31	NMOD	_	_
30	kinase	_	NN	NN	_	31	NMOD	_	_
31	A	_	NN	NN	_	24	COORD	_	_
32	,	_	,	,	_	24	P	_	_
33	or	_	CC	CC	_	24	CC	_	_
34	Ca-LRB-2+-RRB--regulated	_	JJ	JJ	_	35	NMOD	_	_
35	kinases	_	NNS	NNS	_	24	COORD	_	_
36	.	_	.	.	_	8	P	_	_

1	Furthermore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	found	_	VBD	VBD	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	cytoplasmic	_	JJ	JJ	_	7	NMOD	_	_
7	acidification	_	NN	NN	_	8	SBJ	_	_
8	facilitated	_	VBD	VBD	_	5	VMOD	_	_
9	NF-kappa	_	NN	NN	_	11	NMOD	_	_
10	B	_	NN	NN	_	11	NMOD	_	_
11	activation	_	NN	NN	_	8	OBJ	_	_
12	by	_	IN	IN	_	11	NMOD	_	_
13	both	_	CC	CC	_	15	CC	_	_
14	TNF	_	NN	NN	_	15	NMOD	_	_
15	alpha	_	NN	NN	_	12	PMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	PKC	_	NN	NN	_	15	COORD	_	_
18	,	_	,	,	_	8	P	_	_
19	by	_	IN	IN	_	8	ADV	_	_
20	a	_	DT	DT	_	21	NMOD	_	_
21	mechanism	_	NN	NN	_	19	PMOD	_	_
22	that	_	WDT	WDT	_	23	SBJ	_	_
23	increases	_	VBZ	VBZ	_	21	NMOD	_	_
24	NF-kappa	_	NN	NN	_	28	NMOD	_	_
25	B\/I	_	NN	NN	_	28	NMOD	_	_
26	kappa	_	NN	NN	_	28	NMOD	_	_
27	B	_	NN	NN	_	28	NMOD	_	_
28	dissociation	_	NN	NN	_	23	OBJ	_	_
29	without	_	IN	IN	_	23	ADV	_	_
30	affecting	_	VBG	VBG	_	29	PMOD	_	_
31	the	_	DT	DT	_	35	NMOD	_	_
32	NF-kappa	_	NN	NN	_	35	NMOD	_	_
33	B	_	NN	NN	_	35	NMOD	_	_
34	translocation	_	NN	NN	_	35	NMOD	_	_
35	step	_	NN	NN	_	30	OBJ	_	_
36	.	_	.	.	_	4	P	_	_

1	Tumor	_	NN	NN	_	5	NMOD	_	_
2	necrosis	_	NN	NN	_	5	NMOD	_	_
3	factor-alpha	_	NN	NN	_	5	NMOD	_	_
4	mRNA	_	NN	NN	_	5	NMOD	_	_
5	accumulation	_	NN	NN	_	0	ROOT-FRAG	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	human	_	JJ	JJ	_	10	NMOD	_	_
8	myelomonocytic	_	JJ	JJ	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	lines	_	NNS	NNS	_	6	PMOD	_	_
11	.	_	.	.	_	5	P	_	_

1	Role	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	transcriptional	_	JJ	JJ	_	4	NMOD	_	_
4	regulation	_	NN	NN	_	2	PMOD	_	_
5	by	_	IN	IN	_	4	NMOD	_	_
6	DNA	_	NN	NN	_	8	NMOD	_	_
7	sequence	_	NN	NN	_	8	NMOD	_	_
8	motifs	_	NNS	NNS	_	5	PMOD	_	_
9	and	_	CC	CC	_	1	CC	_	_
10	mRNA	_	NN	NN	_	11	NMOD	_	_
11	stabilization	_	NN	NN	_	1	COORD	_	_
12	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	cytokine	_	NN	NN	_	3	NMOD	_	_
3	TNF	_	NN	NN	_	4	SBJ	_	_
4	mediates	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	many	_	JJ	JJ	_	4	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	pathologic	_	JJ	JJ	_	9	NMOD	_	_
9	signs	_	NNS	NNS	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	cachexia	_	NN	NN	_	10	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	inflammation	_	NN	NN	_	11	COORD	_	_
14	,	_	,	,	_	11	P	_	_
15	and	_	CC	CC	_	11	CC	_	_
16	sepsis	_	NN	NN	_	11	COORD	_	_
17	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	current	_	JJ	JJ	_	3	NMOD	_	_
3	work	_	NN	NN	_	4	SBJ	_	_
4	describes	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	regulation	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	TNF	_	NN	NN	_	7	PMOD	_	_
9	in	_	IN	IN	_	6	NMOD	_	_
10	human	_	JJ	JJ	_	13	NMOD	_	_
11	myelomonocytic	_	JJ	JJ	_	13	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	lines	_	NNS	NNS	_	9	PMOD	_	_
14	after	_	IN	IN	_	6	TMP	_	_
15	PMA	_	NN	NN	_	16	NMOD	_	_
16	stimulation	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	cell	_	NN	NN	_	3	NMOD	_	_
3	lines	_	NNS	NNS	_	4	SBJ	_	_
4	exhibit	_	VBP	VBP	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	low	_	JJ	JJ	_	7	NMOD	_	_
7	level	_	NN	NN	_	4	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	constitutive	_	JJ	JJ	_	12	NMOD	_	_
10	TNF	_	NN	NN	_	12	NMOD	_	_
11	mRNA	_	NN	NN	_	12	NMOD	_	_
12	expression	_	NN	NN	_	8	PMOD	_	_
13	.	_	.	.	_	4	P	_	_

1	Within	_	IN	IN	_	16	TMP	_	_
2	2	_	CD	CD	_	4	DEP	_	_
3	to	_	TO	TO	_	4	DEP	_	_
4	4	_	CD	CD	_	5	NMOD	_	_
5	h	_	NN	NN	_	1	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	PMA	_	NN	NN	_	8	NMOD	_	_
8	exposure	_	NN	NN	_	6	PMOD	_	_
9	,	_	,	,	_	16	P	_	_
10	steady	_	JJ	JJ	_	12	NMOD	_	_
11	state	_	NN	NN	_	12	NMOD	_	_
12	levels	_	NNS	NNS	_	16	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	TNF	_	NN	NN	_	15	NMOD	_	_
15	mRNA	_	NN	NN	_	13	PMOD	_	_
16	are	_	VBP	VBP	_	0	ROOT-S	_	_
17	markedly	_	RB	RB	_	16	ADV	_	_
18	elevated	_	JJ	JJ	_	16	VC	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	all	_	DT	DT	_	23	NMOD	_	_
21	myelomonocytic	_	JJ	JJ	_	23	NMOD	_	_
22	cell	_	NN	NN	_	23	NMOD	_	_
23	lines	_	NNS	NNS	_	19	PMOD	_	_
24	studied	_	VBN	VBN	_	23	NMOD	_	_
25	.	_	.	.	_	16	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	rise	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	due	_	JJ	JJ	_	3	PRD	_	_
5	to	_	TO	TO	_	4	PMOD	_	_
6	increased	_	VBN	VBN	_	8	NMOD	_	_
7	mRNA	_	NN	NN	_	8	NMOD	_	_
8	stability	_	NN	NN	_	5	PMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	which	_	WDT	WDT	_	11	SBJ	_	_
11	increased	_	VBD	VBD	_	8	NMOD	_	_
12	by	_	IN	IN	_	11	ADV	_	_
13	almost	_	RB	RB	_	14	NMOD	_	_
14	twofold	_	RB	RB	_	12	PMOD	_	_
15	,	_	,	,	_	5	P	_	_
16	and	_	CC	CC	_	5	CC	_	_
17	to	_	TO	TO	_	5	COORD	_	_
18	an	_	DT	DT	_	20	NMOD	_	_
19	overall	_	JJ	JJ	_	20	NMOD	_	_
20	increase	_	NN	NN	_	17	PMOD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	transcription	_	NN	NN	_	21	PMOD	_	_
23	,	_	,	,	_	20	P	_	_
24	which	_	WDT	WDT	_	25	SBJ	_	_
25	rises	_	VBZ	VBZ	_	20	NMOD	_	_
26	by	_	IN	IN	_	25	ADV	_	_
27	more	_	JJR	JJR	_	26	PMOD	_	_
28	than	_	IN	IN	_	27	NMOD	_	_
29	sixfold	_	RB	RB	_	27	NMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	At	_	IN	IN	_	15	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	level	_	NN	NN	_	1	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	genomic	_	JJ	JJ	_	8	NMOD	_	_
7	TNF	_	NN	NN	_	8	NMOD	_	_
8	gene	_	NN	NN	_	4	PMOD	_	_
9	,	_	,	,	_	15	P	_	_
10	a	_	DT	DT	_	14	NMOD	_	_
11	DNase	_	NN	NN	_	14	NMOD	_	_
12	I	_	CD	CD	_	14	NMOD	_	_
13	hypersensitive	_	JJ	JJ	_	14	NMOD	_	_
14	site	_	NN	NN	_	15	SBJ	_	_
15	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	detected	_	VBN	VBN	_	15	VC	_	_
17	within	_	IN	IN	_	16	ADV	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	TNF	_	NN	NN	_	20	NMOD	_	_
20	promoter	_	NN	NN	_	17	PMOD	_	_
21	between	_	IN	IN	_	20	NMOD	_	_
22	-200	_	CD	CD	_	24	DEP	_	_
23	to	_	TO	TO	_	24	DEP	_	_
24	-100	_	CD	CD	_	25	NMOD	_	_
25	bp	_	NN	NN	_	21	PMOD	_	_
26	relative	_	JJ	JJ	_	27	DEP	_	_
27	to	_	TO	TO	_	16	ADV	_	_
28	the	_	DT	DT	_	31	NMOD	_	_
29	transcription	_	NN	NN	_	31	NMOD	_	_
30	initiation	_	NN	NN	_	31	NMOD	_	_
31	site	_	NN	NN	_	27	PMOD	_	_
32	.	_	.	.	_	15	P	_	_

1	Although	_	IN	IN	_	13	ADV	_	_
2	absent	_	JJ	JJ	_	1	VMOD	_	_
3	in	_	IN	IN	_	2	AMOD	_	_
4	nonexpressing	_	VBG	VBG	_	7	NMOD	_	_
5	erythroleukemia	_	NN	NN	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	lines	_	NNS	NNS	_	3	PMOD	_	_
8	,	_	,	,	_	13	P	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	DNase	_	NN	NN	_	12	NMOD	_	_
11	I	_	CD	CD	_	12	NMOD	_	_
12	site	_	NN	NN	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	present	_	JJ	JJ	_	13	PRD	_	_
15	in	_	IN	IN	_	14	AMOD	_	_
16	uninduced	_	JJ	JJ	_	19	NMOD	_	_
17	myelomonocytic	_	JJ	JJ	_	19	NMOD	_	_
18	cell	_	NN	NN	_	19	NMOD	_	_
19	lines	_	NNS	NNS	_	15	PMOD	_	_
20	and	_	CC	CC	_	13	CC	_	_
21	is	_	VBZ	VBZ	_	13	COORD	_	_
22	not	_	RB	RB	_	21	VMOD	_	_
23	changed	_	VBN	VBN	_	21	VC	_	_
24	after	_	IN	IN	_	23	TMP	_	_
25	PMA	_	NN	NN	_	26	NMOD	_	_
26	induction	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	PMA	_	NN	NN	_	3	NMOD	_	_
3	induction	_	NN	NN	_	7	VMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	c-fos	_	NN	NN	_	6	NMOD	_	_
6	mRNA	_	NN	NN	_	4	PMOD	_	_
7	correlated	_	VBD	VBD	_	0	ROOT-S	_	_
8	well	_	RB	RB	_	7	ADV	_	_
9	with	_	IN	IN	_	7	ADV	_	_
10	TNF	_	NN	NN	_	12	NMOD	_	_
11	gene	_	NN	NN	_	12	NMOD	_	_
12	induction	_	NN	NN	_	9	PMOD	_	_
13	;	_	:	:	_	7	P	_	_
14	expression	_	NN	NN	_	29	SBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	genes	_	NNS	NNS	_	15	PMOD	_	_
17	encoding	_	VBG	VBG	_	16	NMOD	_	_
18	other	_	JJ	JJ	_	19	NMOD	_	_
19	proteins	_	NNS	NNS	_	17	OBJ	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	AP-1	_	NN	NN	_	23	NMOD	_	_
23	complex	_	NN	NN	_	20	PMOD	_	_
24	(	_	(	(	_	25	P	_	_
25	junB	_	NN	NN	_	23	PRN	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	junD	_	NN	NN	_	25	COORD	_	_
28	)	_	)	)	_	25	P	_	_
29	were	_	VBD	VBD	_	7	VMOD	_	_
30	also	_	RB	RB	_	29	ADV	_	_
31	induced	_	VBN	VBN	_	29	VC	_	_
32	by	_	IN	IN	_	31	LGS	_	_
33	PMA	_	NN	NN	_	32	PMOD	_	_
34	.	_	.	.	_	29	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	nuclear	_	JJ	JJ	_	3	NMOD	_	_
3	extracts	_	NNS	NNS	_	10	SBJ	_	_
4	from	_	IN	IN	_	3	NMOD	_	_
5	resting	_	VBG	VBG	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	induced	_	VBN	VBN	_	5	COORD	_	_
8	ML-1	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	4	PMOD	_	_
10	contain	_	VBP	VBP	_	0	ROOT-S	_	_
11	proteins	_	NNS	NNS	_	10	OBJ	_	_
12	binding	_	VBG	VBG	_	11	NMOD	_	_
13	specifically	_	RB	RB	_	12	ADV	_	_
14	to	_	TO	TO	_	12	ADV	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	AP-1	_	NN	NN	_	14	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	AP-2	_	NN	NN	_	16	COORD	_	_
19	,	_	,	,	_	16	P	_	_
20	and	_	CC	CC	_	16	CC	_	_
21	NF	_	NN	NN	_	24	NMOD	_	_
22	kappa	_	NN	NN	_	24	NMOD	_	_
23	B	_	NN	NN	_	24	NMOD	_	_
24	sequence	_	NN	NN	_	16	COORD	_	_
25	located	_	JJ	JJ	_	16	NMOD	_	_
26	within	_	IN	IN	_	25	AMOD	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	TNF	_	NN	NN	_	29	NMOD	_	_
29	promoter	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	10	P	_	_

1	PMA	_	NN	NN	_	2	NMOD	_	_
2	induction	_	NN	NN	_	3	SBJ	_	_
3	increases	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	level	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	number	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	specific	_	JJ	JJ	_	12	NMOD	_	_
11	binding	_	VBG	VBG	_	12	NMOD	_	_
12	complexes	_	NNS	NNS	_	9	PMOD	_	_
13	relative	_	JJ	JJ	_	14	DEP	_	_
14	to	_	TO	TO	_	3	ADV	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	resting	_	VBG	VBG	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	14	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	regulatory	_	JJ	JJ	_	3	NMOD	_	_
3	mechanisms	_	NNS	NNS	_	11	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	10	NMOD	_	_
6	human	_	JJ	JJ	_	10	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	murine	_	JJ	JJ	_	6	COORD	_	_
9	TNF	_	NN	NN	_	10	NMOD	_	_
10	genes	_	NNS	NNS	_	4	PMOD	_	_
11	are	_	VBP	VBP	_	0	ROOT-S	_	_
12	discussed	_	VBN	VBN	_	11	VC	_	_
13	.	_	.	.	_	11	P	_	_

1	HIV1	_	NN	NN	_	2	NMOD	_	_
2	infection	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	human	_	JJ	JJ	_	5	NMOD	_	_
5	monocytes	_	NNS	NNS	_	3	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	macrophages	_	NNS	NNS	_	5	COORD	_	_
8	promotes	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	induction	_	NN	NN	_	8	OBJ	_	_
10	or	_	CC	CC	_	9	CC	_	_
11	translocation	_	NN	NN	_	9	COORD	_	_
12	of	_	IN	IN	_	9	NMOD	_	_
13	NF-KB-related	_	JJ	JJ	_	14	NMOD	_	_
14	factors	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	5	TMP	_	_
2	1991	_	CD	CD	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
6	,	_	,	,	_	5	P	_	_
7	using	_	VBG	VBG	_	5	OBJ	_	_
8	electrophoretic	_	JJ	JJ	_	11	NMOD	_	_
9	mobility	_	NN	NN	_	11	NMOD	_	_
10	shift	_	NN	NN	_	11	NMOD	_	_
11	assays	_	NNS	NNS	_	7	OBJ	_	_
12	,	_	,	,	_	5	P	_	_
13	that	_	IN	IN	_	5	ADV	_	_
14	3	_	CD	CD	_	16	NMOD	_	_
15	different	_	JJ	JJ	_	16	NMOD	_	_
16	factors	_	NNS	NNS	_	32	SBJ	_	_
17	(	_	(	(	_	16	P	_	_
18	termed	_	VBN	VBN	_	16	NMOD	_	_
19	B1	_	NN	NN	_	18	OBJ	_	_
20	,	_	,	,	_	19	P	_	_
21	B2	_	NN	NN	_	19	COORD	_	_
22	and	_	CC	CC	_	19	CC	_	_
23	B3	_	NN	NN	_	19	COORD	_	_
24	)	_	)	)	_	16	P	_	_
25	with	_	IN	IN	_	16	NMOD	_	_
26	affinity	_	NN	NN	_	25	PMOD	_	_
27	for	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	31	NMOD	_	_
29	KB-enhancer	_	JJ	JJ	_	31	NMOD	_	_
30	target	_	NN	NN	_	31	NMOD	_	_
31	sequence	_	NN	NN	_	27	PMOD	_	_
32	were	_	VBD	VBD	_	13	VMOD	_	_
33	specifically	_	RB	RB	_	32	ADV	_	_
34	detected	_	VBN	VBN	_	32	VC	_	_
35	in	_	IN	IN	_	34	ADV	_	_
36	nuclear	_	JJ	JJ	_	37	NMOD	_	_
37	extracts	_	NNS	NNS	_	35	PMOD	_	_
38	from	_	IN	IN	_	37	NMOD	_	_
39	HIV1-infected	_	JJ	JJ	_	40	NMOD	_	_
40	monocytes	_	NNS	NNS	_	38	PMOD	_	_
41	and	_	CC	CC	_	40	CC	_	_
42	macrophages	_	NNS	NNS	_	40	COORD	_	_
43	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	B2	_	NN	NN	_	3	NMOD	_	_
3	factor	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	induced	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	nuclei	_	NNS	NNS	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	these	_	DT	DT	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	only	_	RB	RB	_	13	DEP	_	_
13	upon	_	IN	IN	_	5	TMP	_	_
14	HIV1	_	NN	NN	_	15	NMOD	_	_
15	infection	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	B3	_	NN	NN	_	3	NMOD	_	_
3	factor	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	only	_	RB	RB	_	4	PRD	_	_
6	slightly	_	RB	RB	_	5	AMOD	_	_
7	evident	_	JJ	JJ	_	5	AMOD	_	_
8	in	_	IN	IN	_	4	ADV	_	_
9	nuclei	_	NNS	NNS	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	uninfected	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	but	_	CC	CC	_	4	CC	_	_
14	was	_	VBD	VBD	_	4	COORD	_	_
15	readily	_	RB	RB	_	16	AMOD	_	_
16	detectable	_	JJ	JJ	_	14	PRD	_	_
17	in	_	IN	IN	_	14	ADV	_	_
18	nuclei	_	NNS	NNS	_	17	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	infected	_	JJ	JJ	_	21	NMOD	_	_
21	monocytes	_	NNS	NNS	_	19	PMOD	_	_
22	.	_	.	.	_	4	P	_	_

1	Its	_	PRP$	PRP$	_	2	NMOD	_	_
2	expression	_	NN	NN	_	3	SBJ	_	_
3	remained	_	VBD	VBD	_	0	ROOT-S	_	_
4	very	_	RB	RB	_	5	AMOD	_	_
5	low	_	JJ	JJ	_	3	PRD	_	_
6	in	_	IN	IN	_	5	AMOD	_	_
7	nuclei	_	NNS	NNS	_	6	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	HIV1-infected	_	JJ	JJ	_	10	NMOD	_	_
10	macrophages	_	NNS	NNS	_	8	PMOD	_	_
11	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	paper	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	B2	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	7	VMOD	_	_
12	expressed	_	VBN	VBN	_	11	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	cytosol	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	monocytes	_	NNS	NNS	_	16	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	macrophages	_	NNS	NNS	_	17	COORD	_	_
20	as	_	IN	IN	_	12	ADV	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	DNA-binding	_	JJ	JJ	_	23	NMOD	_	_
23	protein	_	NN	NN	_	20	PMOD	_	_
24	,	_	,	,	_	12	P	_	_
25	indicating	_	VBG	VBG	_	12	OBJ	_	_
26	that	_	IN	IN	_	25	OBJ	_	_
27	it	_	PRP	PRP	_	28	SBJ	_	_
28	is	_	VBZ	VBZ	_	26	VMOD	_	_
29	not	_	RB	RB	_	28	VMOD	_	_
30	associated	_	VBN	VBN	_	28	VC	_	_
31	with	_	IN	IN	_	30	ADV	_	_
32	an	_	DT	DT	_	33	NMOD	_	_
33	inhibitor	_	NN	NN	_	31	PMOD	_	_
34	(	_	(	(	_	35	P	_	_
35	IKB	_	NN	NN	_	33	PRN	_	_
36	)	_	)	)	_	35	P	_	_
37	.	_	.	.	_	6	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	factor	_	NN	NN	_	3	SBJ	_	_
3	remained	_	VBD	VBD	_	0	ROOT-S	_	_
4	clustered	_	VBN	VBN	_	3	PRD	_	_
5	in	_	IN	IN	_	4	AMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	cytosol	_	NN	NN	_	5	PMOD	_	_
8	and	_	CC	CC	_	3	CC	_	_
9	was	_	VBD	VBD	_	3	COORD	_	_
10	translocated	_	VBN	VBN	_	9	VC	_	_
11	to	_	TO	TO	_	10	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	nuclei	_	NNS	NNS	_	11	PMOD	_	_
14	only	_	RB	RB	_	15	DEP	_	_
15	after	_	IN	IN	_	10	TMP	_	_
16	HIV1	_	NN	NN	_	17	NMOD	_	_
17	infection	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	B3	_	NN	NN	_	3	NMOD	_	_
3	factor	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	detected	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	cytosol	_	NN	NN	_	6	PMOD	_	_
9	only	_	RB	RB	_	12	VMOD	_	_
10	when	_	WRB	WRB	_	12	ADV	_	_
11	cells	_	NNS	NNS	_	12	SBJ	_	_
12	are	_	VBP	VBP	_	5	TMP	_	_
13	HIV1-infected	_	JJ	JJ	_	12	PRD	_	_
14	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	role	_	NN	NN	_	15	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	HIV1	_	NN	NN	_	5	NMOD	_	_
5	infection	_	NN	NN	_	3	PMOD	_	_
6	in	_	IN	IN	_	2	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	expression	_	NN	NN	_	6	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	translocation	_	NN	NN	_	8	COORD	_	_
12	of	_	IN	IN	_	8	NMOD	_	_
13	these	_	DT	DT	_	14	NMOD	_	_
14	factors	_	NNS	NNS	_	12	PMOD	_	_
15	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	discussed	_	VBN	VBN	_	15	VC	_	_
17	.	_	.	.	_	15	P	_	_

1	Anti-CD2	_	JJ	JJ	_	3	NMOD	_	_
2	receptor	_	NN	NN	_	3	NMOD	_	_
3	antibodies	_	NNS	NNS	_	4	SBJ	_	_
4	activate	_	VBP	VBP	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	HIV	_	NN	NN	_	9	NMOD	_	_
7	long	_	JJ	JJ	_	9	NMOD	_	_
8	terminal	_	JJ	JJ	_	9	NMOD	_	_
9	repeat	_	NN	NN	_	4	OBJ	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	T	_	NN	NN	_	12	NMOD	_	_
12	lymphocytes	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	7	NMOD	_	_
2	CD2	_	NN	NN	_	7	NMOD	_	_
3	T	_	NN	NN	_	7	NMOD	_	_
4	lymphocyte	_	NN	NN	_	7	NMOD	_	_
5	glycoprotein	_	NN	NN	_	7	NMOD	_	_
6	surface	_	NN	NN	_	7	NMOD	_	_
7	molecule	_	NN	NN	_	8	SBJ	_	_
8	mediates	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	both	_	CC	CC	_	13	CC	_	_
10	cell	_	NN	NN	_	13	NMOD	_	_
11	to	_	TO	TO	_	13	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	adhesion	_	NN	NN	_	8	OBJ	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	T	_	NN	NN	_	17	NMOD	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	activation	_	NN	NN	_	13	COORD	_	_
18	,	_	,	,	_	13	P	_	_
19	two	_	CD	CD	_	20	NMOD	_	_
20	processes	_	NNS	NNS	_	13	NMOD	_	_
21	that	_	WDT	WDT	_	22	SBJ	_	_
22	are	_	VBP	VBP	_	20	NMOD	_	_
23	involved	_	VBN	VBN	_	22	VC	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	spread	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	HIV	_	NN	NN	_	29	NMOD	_	_
29	infection	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	8	P	_	_

1	Treatment	_	NN	NN	_	9	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	chronically	_	RB	RB	_	4	AMOD	_	_
4	HIV-infected	_	JJ	JJ	_	5	NMOD	_	_
5	PBMC	_	NN	NN	_	2	PMOD	_	_
6	with	_	IN	IN	_	1	NMOD	_	_
7	anti-CD2	_	JJ	JJ	_	8	NMOD	_	_
8	mAb	_	NN	NN	_	6	PMOD	_	_
9	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	been	_	VBN	VBN	_	9	VC	_	_
11	shown	_	VBN	VBN	_	10	VC	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	induce	_	VB	VB	_	11	OBJ	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	expression	_	NN	NN	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	infectious	_	JJ	JJ	_	18	NMOD	_	_
18	virus	_	NN	NN	_	16	PMOD	_	_
19	from	_	IN	IN	_	18	NMOD	_	_
20	these	_	DT	DT	_	21	NMOD	_	_
21	cultures	_	NNS	NNS	_	19	PMOD	_	_
22	.	_	.	.	_	9	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	investigated	_	VBD	VBD	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	mechanisms	_	NNS	NNS	_	5	OBJ	_	_
8	whereby	_	WRB	WRB	_	11	ADV	_	_
9	anti-CD2	_	JJ	JJ	_	10	NMOD	_	_
10	antibodies	_	NNS	NNS	_	11	SBJ	_	_
11	stimulate	_	VBP	VBP	_	7	NMOD	_	_
12	viral	_	JJ	JJ	_	13	NMOD	_	_
13	production	_	NN	NN	_	11	OBJ	_	_
14	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	treatment	_	NN	NN	_	13	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	transiently	_	RB	RB	_	7	AMOD	_	_
7	transfected	_	VBN	VBN	_	9	NMOD	_	_
8	T	_	NN	NN	_	9	NMOD	_	_
9	lymphocytes	_	NNS	NNS	_	5	PMOD	_	_
10	with	_	IN	IN	_	4	NMOD	_	_
11	anti-CD2	_	JJ	JJ	_	12	NMOD	_	_
12	antibodies	_	NNS	NNS	_	10	PMOD	_	_
13	results	_	VBZ	VBZ	_	3	VMOD	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	activation	_	NN	NN	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	HIV	_	NN	NN	_	21	NMOD	_	_
19	long	_	JJ	JJ	_	21	NMOD	_	_
20	terminal	_	JJ	JJ	_	21	NMOD	_	_
21	repeat	_	NN	NN	_	16	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	Furthermore	_	RB	RB	_	16	ADV	_	_
2	,	_	,	,	_	16	P	_	_
3	CAT	_	NN	NN	_	4	NMOD	_	_
4	assays	_	NNS	NNS	_	16	SBJ	_	_
5	using	_	VBG	VBG	_	4	NMOD	_	_
6	mutated	_	VBN	VBN	_	11	NMOD	_	_
7	HIV	_	NN	NN	_	11	NMOD	_	_
8	long	_	JJ	JJ	_	10	AMOD	_	_
9	terminal	_	JJ	JJ	_	10	AMOD	_	_
10	repeat-CAT	_	NN	NN	_	11	NMOD	_	_
11	constructs	_	NNS	NNS	_	5	OBJ	_	_
12	and	_	CC	CC	_	4	CC	_	_
13	gel	_	NN	NN	_	15	NMOD	_	_
14	shift	_	NN	NN	_	15	NMOD	_	_
15	assays	_	NNS	NNS	_	4	COORD	_	_
16	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
17	that	_	IN	IN	_	16	OBJ	_	_
18	this	_	DT	DT	_	19	NMOD	_	_
19	activation	_	NN	NN	_	20	SBJ	_	_
20	is	_	VBZ	VBZ	_	17	VMOD	_	_
21	dependent	_	JJ	JJ	_	20	PRD	_	_
22	on	_	IN	IN	_	21	AMOD	_	_
23	the	_	DT	DT	_	26	NMOD	_	_
24	NF-kappa	_	NN	NN	_	26	NMOD	_	_
25	B	_	NN	NN	_	26	NMOD	_	_
26	enhancer	_	NN	NN	_	22	PMOD	_	_
27	.	_	.	.	_	16	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	interaction	_	NN	NN	_	15	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	CD2	_	NN	NN	_	6	PMOD	_	_
8	with	_	IN	IN	_	5	NMOD	_	_
9	its	_	PRP$	PRP$	_	11	NMOD	_	_
10	natural	_	JJ	JJ	_	11	NMOD	_	_
11	ligand	_	NN	NN	_	8	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	LFA-3	_	NN	NN	_	11	NMOD	_	_
14	,	_	,	,	_	11	P	_	_
15	may	_	MD	MD	_	4	VMOD	_	_
16	play	_	VB	VB	_	15	VC	_	_
17	a	_	DT	DT	_	18	NMOD	_	_
18	role	_	NN	NN	_	16	OBJ	_	_
19	in	_	IN	IN	_	16	ADV	_	_
20	regulation	_	NN	NN	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	HIV	_	NN	NN	_	23	NMOD	_	_
23	expression	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	Demonstration	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	1,25-dihydroxyvitamin	_	NN	NN	_	6	NMOD	_	_
5	D3-responsive	_	JJ	JJ	_	4	AMOD	_	_
6	protein	_	NN	NN	_	2	PMOD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	human	_	JJ	JJ	_	9	NMOD	_	_
9	lymphocytes	_	NNS	NNS	_	7	PMOD	_	_
10	:	_	:	:	_	1	P	_	_
11	immunologic	_	JJ	JJ	_	12	NMOD	_	_
12	crossreactivity	_	NN	NN	_	1	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	inverse	_	JJ	JJ	_	15	NMOD	_	_
15	regulation	_	NN	NN	_	12	COORD	_	_
16	with	_	IN	IN	_	12	NMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	vitamin	_	NN	NN	_	20	NMOD	_	_
19	D	_	NN	NN	_	20	NMOD	_	_
20	receptor	_	NN	NN	_	16	PMOD	_	_
21	.	_	.	.	_	1	P	_	_

1	Using	_	VBG	VBG	_	24	ADV	_	_
2	Western	_	NN	NN	_	4	NMOD	_	_
3	blot	_	NN	NN	_	4	NMOD	_	_
4	analysis	_	NN	NN	_	1	OBJ	_	_
5	with	_	IN	IN	_	4	NMOD	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	monoclonal	_	JJ	JJ	_	8	NMOD	_	_
8	antibody	_	NN	NN	_	5	PMOD	_	_
9	recognizing	_	VBG	VBG	_	8	NMOD	_	_
10	a	_	DT	DT	_	13	NMOD	_	_
11	17-amino	_	NN	NN	_	13	NMOD	_	_
12	acid	_	NN	NN	_	13	NMOD	_	_
13	epitope	_	NN	NN	_	9	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	21	NMOD	_	_
16	1,25-dihydroxyvitamin	_	NN	NN	_	17	NMOD	_	_
17	D3	_	NN	NN	_	21	NMOD	_	_
18	{	_	(	(	_	19	P	_	_
19	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	17	PRN	_	_
20	}	_	)	)	_	19	P	_	_
21	receptor	_	NN	NN	_	14	PMOD	_	_
22	,	_	,	,	_	24	P	_	_
23	we	_	PRP	PRP	_	24	SBJ	_	_
24	have	_	VBP	VBP	_	0	ROOT-S	_	_
25	detected	_	VBN	VBN	_	24	VC	_	_
26	two	_	CD	CD	_	28	NMOD	_	_
27	crossreacting	_	VBG	VBG	_	28	NMOD	_	_
28	proteins	_	NNS	NNS	_	25	OBJ	_	_
29	in	_	IN	IN	_	25	ADV	_	_
30	activated	_	VBN	VBN	_	33	NMOD	_	_
31	normal	_	JJ	JJ	_	33	NMOD	_	_
32	human	_	JJ	JJ	_	33	NMOD	_	_
33	lymphocytes	_	NNS	NNS	_	29	PMOD	_	_
34	.	_	.	.	_	24	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	smaller	_	JJR	JJR	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	two	_	CD	CD	_	6	NMOD	_	_
6	proteins	_	NNS	NNS	_	3	PMOD	_	_
7	(	_	(	(	_	9	P	_	_
8	50	_	CD	CD	_	9	NMOD	_	_
9	kDa	_	NN	NN	_	2	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	indistinguishable	_	JJ	JJ	_	11	PRD	_	_
13	from	_	IN	IN	_	12	AMOD	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	classical	_	JJ	JJ	_	17	NMOD	_	_
16	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	17	NMOD	_	_
17	receptor	_	NN	NN	_	13	PMOD	_	_
18	and	_	CC	CC	_	11	CC	_	_
19	,	_	,	,	_	11	P	_	_
20	similar	_	JJ	JJ	_	27	ADV	_	_
21	to	_	TO	TO	_	20	AMOD	_	_
22	the	_	DT	DT	_	25	NMOD	_	_
23	classical	_	JJ	JJ	_	25	NMOD	_	_
24	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	25	NMOD	_	_
25	receptor	_	NN	NN	_	21	PMOD	_	_
26	,	_	,	,	_	20	P	_	_
27	was	_	VBD	VBD	_	11	COORD	_	_
28	upregulated	_	VBN	VBN	_	27	VC	_	_
29	in	_	IN	IN	_	28	ADV	_	_
30	a	_	DT	DT	_	32	NMOD	_	_
31	dose-dependent	_	JJ	JJ	_	32	NMOD	_	_
32	fashion	_	NN	NN	_	29	PMOD	_	_
33	by	_	IN	IN	_	28	LGS	_	_
34	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	33	PMOD	_	_
35	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	larger	_	JJR	JJR	_	4	NMOD	_	_
3	crossreacting	_	VBG	VBG	_	4	NMOD	_	_
4	protein	_	NN	NN	_	5	SBJ	_	_
5	exhibited	_	VBD	VBD	_	0	ROOT-S	_	_
6	an	_	DT	DT	_	8	NMOD	_	_
7	electrophoretic	_	JJ	JJ	_	8	NMOD	_	_
8	mobility	_	NN	NN	_	5	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	80	_	CD	CD	_	11	NMOD	_	_
11	kDa	_	NN	NN	_	9	PMOD	_	_
12	,	_	,	,	_	5	P	_	_
13	was	_	VBD	VBD	_	5	COORD	_	_
14	localized	_	JJ	JJ	_	13	VC	_	_
15	in	_	IN	IN	_	14	ADV	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	cytosol	_	NN	NN	_	15	PMOD	_	_
19	,	_	,	,	_	5	P	_	_
20	and	_	CC	CC	_	5	CC	_	_
21	appeared	_	VBD	VBD	_	5	COORD	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	be	_	VB	VB	_	21	OBJ	_	_
24	specific	_	JJ	JJ	_	23	PRD	_	_
25	for	_	IN	IN	_	24	AMOD	_	_
26	activated	_	VBN	VBN	_	27	NMOD	_	_
27	lymphocytes	_	NNS	NNS	_	25	PMOD	_	_
28	since	_	IN	IN	_	23	ADV	_	_
29	it	_	PRP	PRP	_	30	SBJ	_	_
30	was	_	VBD	VBD	_	28	VMOD	_	_
31	not	_	RB	RB	_	30	VMOD	_	_
32	detected	_	VBN	VBN	_	30	VC	_	_
33	in	_	IN	IN	_	32	ADV	_	_
34	several	_	JJ	JJ	_	37	NMOD	_	_
35	other	_	JJ	JJ	_	37	NMOD	_	_
36	human	_	JJ	JJ	_	37	NMOD	_	_
37	cells	_	NNS	NNS	_	33	PMOD	_	_
38	including	_	VBG	VBG	_	37	NMOD	_	_
39	monocytes	_	NNS	NNS	_	38	PMOD	_	_
40	.	_	.	.	_	5	P	_	_

1	More	_	RBR	RBR	_	2	AMOD	_	_
2	strikingly	_	RB	RB	_	7	ADV	_	_
3	,	_	,	,	_	7	P	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	80-kDa	_	JJ	JJ	_	6	NMOD	_	_
6	protein	_	NN	NN	_	7	SBJ	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	downregulated	_	VBN	VBN	_	7	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	dose-dependent	_	JJ	JJ	_	12	NMOD	_	_
12	fashion	_	NN	NN	_	9	PMOD	_	_
13	by	_	IN	IN	_	8	LGS	_	_
14	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	13	PMOD	_	_
15	;	_	:	:	_	7	P	_	_
16	this	_	DT	DT	_	17	NMOD	_	_
17	effect	_	NN	NN	_	18	SBJ	_	_
18	was	_	VBD	VBD	_	7	VC	_	_
19	independent	_	JJ	JJ	_	18	PRD	_	_
20	of	_	IN	IN	_	19	AMOD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	mode	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	lymphocyte	_	NN	NN	_	25	NMOD	_	_
25	activation	_	NN	NN	_	23	PMOD	_	_
26	and	_	CC	CC	_	19	CC	_	_
27	specific	_	JJ	JJ	_	19	COORD	_	_
28	for	_	IN	IN	_	27	AMOD	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	31	NMOD	_	_
31	metabolite	_	NN	NN	_	28	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	vitamin	_	NN	NN	_	34	NMOD	_	_
34	D3	_	NN	NN	_	32	PMOD	_	_
35	.	_	.	.	_	18	P	_	_

1	However	_	RB	RB	_	14	ADV	_	_
2	,	_	,	,	_	14	P	_	_
3	two	_	CD	CD	_	6	NMOD	_	_
4	potent	_	JJ	JJ	_	6	NMOD	_	_
5	immunosuppressive	_	JJ	JJ	_	6	NMOD	_	_
6	agents	_	NNS	NNS	_	14	SBJ	_	_
7	,	_	,	,	_	6	P	_	_
8	glucocorticoids	_	NNS	NNS	_	6	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	cyclosporin	_	NN	NN	_	8	COORD	_	_
11	A	_	DT	DT	_	10	NMOD	_	_
12	,	_	,	,	_	6	P	_	_
13	also	_	RB	RB	_	14	ADV	_	_
14	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	80-kDa	_	JJ	JJ	_	17	NMOD	_	_
17	protein	_	NN	NN	_	14	OBJ	_	_
18	.	_	.	.	_	14	P	_	_

1	v-erbA	_	NN	NN	_	2	NMOD	_	_
2	overexpression	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	required	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	extinguish	_	VB	VB	_	4	OBJ	_	_
7	c-erbA	_	NN	NN	_	8	NMOD	_	_
8	function	_	NN	NN	_	6	OBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	erythroid	_	JJ	JJ	_	12	NMOD	_	_
11	cell	_	NN	NN	_	12	NMOD	_	_
12	differentiation	_	NN	NN	_	9	PMOD	_	_
13	and	_	CC	CC	_	8	CC	_	_
14	regulation	_	NN	NN	_	8	COORD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	erbA	_	NN	NN	_	20	NMOD	_	_
18	target	_	NN	NN	_	20	NMOD	_	_
19	gene	_	NN	NN	_	20	NMOD	_	_
20	CAII	_	NN	NN	_	15	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	v-erbA	_	NN	NN	_	3	NMOD	_	_
3	oncoprotein	_	NN	NN	_	4	SBJ	_	_
4	represents	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	retrovirus-transduced	_	JJ	JJ	_	8	NMOD	_	_
7	oncogenic	_	JJ	JJ	_	8	NMOD	_	_
8	version	_	NN	NN	_	4	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	20	NMOD	_	_
11	thyroid	_	NN	NN	_	20	NMOD	_	_
12	hormone	_	NN	NN	_	20	NMOD	_	_
13	(	_	(	(	_	20	P	_	_
14	T3\/T4	_	NN	NN	_	20	NMOD	_	_
15	)	_	)	)	_	20	P	_	_
16	receptor	_	NN	NN	_	20	NMOD	_	_
17	c-erbA	_	NN	NN	_	20	NMOD	_	_
18	(	_	(	(	_	20	P	_	_
19	type	_	NN	NN	_	20	NMOD	_	_
20	alpha	_	NN	NN	_	9	PMOD	_	_
21	)	_	)	)	_	20	P	_	_
22	.	_	.	.	_	4	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	contributes	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	to	_	TO	TO	_	2	ADV	_	_
4	virus-induced	_	JJ	JJ	_	5	NMOD	_	_
5	erythroleukemia	_	NN	NN	_	3	PMOD	_	_
6	by	_	IN	IN	_	2	ADV	_	_
7	efficiently	_	RB	RB	_	8	ADV	_	_
8	arresting	_	VBG	VBG	_	6	PMOD	_	_
9	differentiation	_	NN	NN	_	8	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	red	_	JJ	JJ	_	13	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	progenitors	_	NNS	NNS	_	10	PMOD	_	_
14	and	_	CC	CC	_	6	CC	_	_
15	by	_	IN	IN	_	6	COORD	_	_
16	suppressing	_	VBG	VBG	_	15	PMOD	_	_
17	transcription	_	NN	NN	_	16	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	erythrocyte-specific	_	JJ	JJ	_	20	NMOD	_	_
20	genes	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	2	P	_	_

1	Here	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	show	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	v-erbA	_	NN	NN	_	9	SBJ	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	c-erbA	_	NN	NN	_	6	COORD	_	_
9	bind	_	VBP	VBP	_	5	VMOD	_	_
10	directly	_	RB	RB	_	9	ADV	_	_
11	to	_	TO	TO	_	9	ADV	_	_
12	sequences	_	NNS	NNS	_	11	PMOD	_	_
13	within	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	promoter	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	erythrocyte-specific	_	JJ	JJ	_	20	NMOD	_	_
19	carbonic	_	JJ	JJ	_	20	NMOD	_	_
20	anhydrase	_	NN	NN	_	16	PMOD	_	_
21	II	_	CD	CD	_	20	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	CAII	_	NN	NN	_	20	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	,	_	,	,	_	20	P	_	_
26	a	_	DT	DT	_	27	NMOD	_	_
27	gene	_	NN	NN	_	20	NMOD	_	_
28	whose	_	WP$	WP$	_	29	NMOD	_	_
29	transcription	_	NN	NN	_	30	SBJ	_	_
30	is	_	VBZ	VBZ	_	27	NMOD	_	_
31	efficiently	_	RB	RB	_	30	ADV	_	_
32	suppressed	_	VBN	VBN	_	30	VC	_	_
33	by	_	IN	IN	_	32	LGS	_	_
34	v-erbA	_	NN	NN	_	33	PMOD	_	_
35	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	erbA-binding	_	JJ	JJ	_	3	NMOD	_	_
3	site	_	NN	NN	_	4	SBJ	_	_
4	confers	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	thyroid	_	NN	NN	_	7	NMOD	_	_
6	hormone	_	NN	NN	_	7	NMOD	_	_
7	responsiveness	_	NN	NN	_	4	OBJ	_	_
8	to	_	TO	TO	_	7	NMOD	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	heterologous	_	JJ	JJ	_	11	NMOD	_	_
11	promoter	_	NN	NN	_	8	PMOD	_	_
12	in	_	IN	IN	_	7	NMOD	_	_
13	transient	_	JJ	JJ	_	15	NMOD	_	_
14	expression	_	NN	NN	_	15	NMOD	_	_
15	experiments	_	NNS	NNS	_	12	PMOD	_	_
16	and	_	CC	CC	_	4	CC	_	_
17	is	_	VBZ	VBZ	_	4	COORD	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	target	_	NN	NN	_	17	PRD	_	_
20	for	_	IN	IN	_	19	NMOD	_	_
21	efficient	_	JJ	JJ	_	22	NMOD	_	_
22	down-regulation	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	CAII	_	NN	NN	_	25	NMOD	_	_
25	transcription	_	NN	NN	_	23	PMOD	_	_
26	by	_	IN	IN	_	22	NMOD	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	v-erbA	_	NN	NN	_	29	NMOD	_	_
29	oncoprotein	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	21	ADV	_	_
2	stably	_	RB	RB	_	3	AMOD	_	_
3	transformed	_	VBN	VBN	_	4	NMOD	_	_
4	erythroblasts	_	NNS	NNS	_	1	PMOD	_	_
5	coexpressing	_	VBG	VBG	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	v-erbA	_	NN	NN	_	8	NMOD	_	_
8	oncoprotein	_	NN	NN	_	5	OBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	c-erbA\/T3	_	NN	NN	_	12	NMOD	_	_
12	receptor	_	NN	NN	_	8	COORD	_	_
13	at	_	IN	IN	_	5	ADV	_	_
14	an	_	DT	DT	_	17	NMOD	_	_
15	approximately	_	RB	RB	_	16	AMOD	_	_
16	equimolar	_	JJ	JJ	_	17	NMOD	_	_
17	ratio	_	NN	NN	_	13	PMOD	_	_
18	,	_	,	,	_	21	P	_	_
19	c-erbA	_	NN	NN	_	20	NMOD	_	_
20	activity	_	NN	NN	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
22	dominant	_	JJ	JJ	_	21	PRD	_	_
23	over	_	IN	IN	_	22	AMOD	_	_
24	v-erbA	_	NN	NN	_	23	PMOD	_	_
25	.	_	.	.	_	21	P	_	_

1	T3	_	NN	NN	_	3	SBJ	_	_
2	efficiently	_	RB	RB	_	3	ADV	_	_
3	induced	_	VBD	VBD	_	0	ROOT-S	_	_
4	erythroid	_	JJ	JJ	_	5	NMOD	_	_
5	differentiation	_	NN	NN	_	3	IOBJ	_	_
6	in	_	IN	IN	_	3	ADV	_	_
7	these	_	DT	DT	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	,	_	,	,	_	3	P	_	_
10	thus	_	RB	RB	_	3	VMOD	_	_
11	overcoming	_	VBG	VBG	_	3	OBJ	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	v-erbA-mediated	_	JJ	JJ	_	15	NMOD	_	_
14	differentiation	_	NN	NN	_	15	NMOD	_	_
15	arrest	_	NN	NN	_	11	OBJ	_	_
16	.	_	.	.	_	3	P	_	_

1	Likewise	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	T3	_	NN	NN	_	4	SBJ	_	_
4	activated	_	VBD	VBD	_	0	ROOT-S	_	_
5	CAII	_	NN	NN	_	6	NMOD	_	_
6	transcription	_	NN	NN	_	4	OBJ	_	_
7	as	_	RB	RB	_	6	CC	_	_
8	well	_	RB	RB	_	7	DEP	_	_
9	as	_	IN	IN	_	7	DEP	_	_
10	transient	_	JJ	JJ	_	11	NMOD	_	_
11	expression	_	NN	NN	_	6	COORD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	a	_	DT	DT	_	16	NMOD	_	_
14	T3-responsive	_	JJ	JJ	_	16	NMOD	_	_
15	reporter	_	NN	NN	_	16	NMOD	_	_
16	gene	_	NN	NN	_	12	PMOD	_	_
17	containing	_	VBG	VBG	_	16	NMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	CAII-specific	_	JJ	JJ	_	21	NMOD	_	_
20	erbA-binding	_	JJ	JJ	_	21	NMOD	_	_
21	site	_	NN	NN	_	17	OBJ	_	_
22	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	c-erbA-dependent	_	JJ	JJ	_	3	NMOD	_	_
3	activation	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	this	_	DT	DT	_	8	NMOD	_	_
6	CAII	_	NN	NN	_	8	NMOD	_	_
7	reporter	_	NN	NN	_	8	NMOD	_	_
8	construct	_	NN	NN	_	4	PMOD	_	_
9	could	_	MD	MD	_	0	ROOT-S	_	_
10	only	_	RB	RB	_	9	ADV	_	_
11	be	_	VB	VB	_	9	VC	_	_
12	suppressed	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	very	_	RB	RB	_	15	AMOD	_	_
15	high	_	JJ	JJ	_	16	NMOD	_	_
16	amounts	_	NNS	NNS	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	v-erbA	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	9	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	overexpression	_	NN	NN	_	8	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	v-erbA	_	NN	NN	_	6	PMOD	_	_
8	is	_	VBZ	VBZ	_	4	VMOD	_	_
9	required	_	VBN	VBN	_	8	VC	_	_
10	for	_	IN	IN	_	9	ADV	_	_
11	its	_	PRP$	PRP$	_	12	NMOD	_	_
12	function	_	NN	NN	_	10	PMOD	_	_
13	as	_	IN	IN	_	12	NMOD	_	_
14	an	_	DT	DT	_	15	NMOD	_	_
15	oncoprotein	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	Evaluation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	role	_	NN	NN	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	ligand	_	NN	NN	_	5	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	thermal	_	JJ	JJ	_	9	NMOD	_	_
9	activation	_	NN	NN	_	6	COORD	_	_
10	of	_	IN	IN	_	6	NMOD	_	_
11	specific	_	JJ	JJ	_	13	NMOD	_	_
12	DNA	_	NN	NN	_	13	NMOD	_	_
13	binding	_	NN	NN	_	10	PMOD	_	_
14	by	_	IN	IN	_	13	NMOD	_	_
15	in	_	FW	FW	_	20	NMOD	_	_
16	vitro	_	FW	FW	_	15	AMOD	_	_
17	synthesized	_	VBN	VBN	_	15	AMOD	_	_
18	human	_	JJ	JJ	_	20	NMOD	_	_
19	glucocorticoid	_	NN	NN	_	20	NMOD	_	_
20	receptor	_	NN	NN	_	14	PMOD	_	_
21	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	used	_	VBN	VBN	_	2	VC	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	DNA-binding\/immunoprecipitation	_	JJ	JJ	_	6	NMOD	_	_
6	assay	_	NN	NN	_	3	IOBJ	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	analyze	_	VB	VB	_	3	OBJ	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	capacity	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	human	_	JJ	JJ	_	14	NMOD	_	_
13	glucocorticoid	_	NN	NN	_	14	NMOD	_	_
14	receptor	_	NN	NN	_	11	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	hGR	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	,	_	,	,	_	14	P	_	_
19	generated	_	VBN	VBN	_	14	NMOD	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	rabbit	_	NN	NN	_	23	NMOD	_	_
22	reticulocyte	_	NN	NN	_	23	NMOD	_	_
23	lysates	_	NNS	NNS	_	20	PMOD	_	_
24	,	_	,	,	_	10	P	_	_
25	to	_	TO	TO	_	26	VMOD	_	_
26	bind	_	VB	VB	_	10	NMOD	_	_
27	DNA	_	NN	NN	_	26	OBJ	_	_
28	.	_	.	.	_	2	P	_	_

1	In	_	FW	FW	_	4	NMOD	_	_
2	vitro	_	FW	FW	_	1	AMOD	_	_
3	translated	_	VBN	VBN	_	1	AMOD	_	_
4	hGR	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	indistinguishable	_	JJ	JJ	_	5	PRD	_	_
7	from	_	IN	IN	_	6	AMOD	_	_
8	native	_	JJ	JJ	_	9	NMOD	_	_
9	hGR	_	NN	NN	_	7	PMOD	_	_
10	,	_	,	,	_	5	P	_	_
11	as	_	IN	IN	_	5	ADV	_	_
12	determined	_	VBN	VBN	_	11	VMOD	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	migration	_	NN	NN	_	13	PMOD	_	_
15	on	_	IN	IN	_	14	NMOD	_	_
16	sodium	_	NN	NN	_	17	AMOD	_	_
17	dodecyl	_	NN	NN	_	19	NMOD	_	_
18	sulfate-polyacrylamide	_	JJ	JJ	_	17	AMOD	_	_
19	gels	_	NNS	NNS	_	15	PMOD	_	_
20	,	_	,	,	_	14	P	_	_
21	sedimentation	_	NN	NN	_	14	COORD	_	_
22	on	_	IN	IN	_	21	NMOD	_	_
23	sucrose	_	NN	NN	_	25	NMOD	_	_
24	density	_	NN	NN	_	25	NMOD	_	_
25	gradients	_	NNS	NNS	_	22	PMOD	_	_
26	,	_	,	,	_	14	P	_	_
27	and	_	CC	CC	_	14	CC	_	_
28	reactivity	_	NN	NN	_	14	COORD	_	_
29	with	_	IN	IN	_	28	NMOD	_	_
30	antipeptide	_	JJ	JJ	_	31	NMOD	_	_
31	antibodies	_	NNS	NNS	_	29	PMOD	_	_
32	generated	_	VBN	VBN	_	31	NMOD	_	_
33	against	_	IN	IN	_	32	ADV	_	_
34	hGR	_	NN	NN	_	33	PMOD	_	_
35	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	7	P	_	_
4	cell-free	_	JJ	JJ	_	6	NMOD	_	_
5	synthesized	_	VBN	VBN	_	6	NMOD	_	_
6	hGR	_	NN	NN	_	7	SBJ	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	capable	_	JJ	JJ	_	7	PRD	_	_
9	of	_	IN	IN	_	8	AMOD	_	_
10	specific	_	JJ	JJ	_	11	NMOD	_	_
11	binding	_	NN	NN	_	9	PMOD	_	_
12	to	_	TO	TO	_	11	NMOD	_	_
13	glucocorticoid	_	NN	NN	_	17	AMOD	_	_
14	response	_	NN	NN	_	17	AMOD	_	_
15	element	_	NN	NN	_	17	AMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	GRE	_	NN	NN	_	21	NMOD	_	_
18	)	_	)	)	_	17	P	_	_
19	-containing	_	JJ	JJ	_	17	AMOD	_	_
20	DNA	_	NN	NN	_	21	NMOD	_	_
21	fragments	_	NNS	NNS	_	12	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	Using	_	VBG	VBG	_	7	ADV	_	_
2	this	_	DT	DT	_	4	NMOD	_	_
3	assay	_	NN	NN	_	4	NMOD	_	_
4	system	_	NN	NN	_	1	OBJ	_	_
5	,	_	,	,	_	7	P	_	_
6	we	_	PRP	PRP	_	7	SBJ	_	_
7	have	_	VBP	VBP	_	0	ROOT-S	_	_
8	evaluated	_	VBN	VBN	_	7	VC	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	contributions	_	NNS	NNS	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	ligand	_	NN	NN	_	13	NMOD	_	_
13	binding	_	NN	NN	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	heat	_	NN	NN	_	16	NMOD	_	_
16	activation	_	NN	NN	_	13	COORD	_	_
17	to	_	TO	TO	_	10	NMOD	_	_
18	DNA	_	NN	NN	_	19	NMOD	_	_
19	binding	_	NN	NN	_	17	PMOD	_	_
20	by	_	IN	IN	_	19	NMOD	_	_
21	these	_	DT	DT	_	23	NMOD	_	_
22	glucocorticoid	_	NN	NN	_	23	NMOD	_	_
23	receptors	_	NNS	NNS	_	20	PMOD	_	_
24	.	_	.	.	_	7	P	_	_

1	In	_	FW	FW	_	4	NMOD	_	_
2	vitro	_	FW	FW	_	1	AMOD	_	_
3	translated	_	VBN	VBN	_	1	AMOD	_	_
4	hGR	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	capable	_	JJ	JJ	_	5	PRD	_	_
7	of	_	IN	IN	_	6	AMOD	_	_
8	selective	_	JJ	JJ	_	10	NMOD	_	_
9	DNA	_	NN	NN	_	10	NMOD	_	_
10	binding	_	NN	NN	_	7	PMOD	_	_
11	even	_	RB	RB	_	12	DEP	_	_
12	in	_	IN	IN	_	6	AMOD	_	_
13	the	_	DT	DT	_	12	DEP	_	_
14	absence	_	NN	NN	_	12	DEP	_	_
15	of	_	IN	IN	_	12	DEP	_	_
16	glucocorticoid	_	NN	NN	_	12	PMOD	_	_
17	.	_	.	.	_	5	P	_	_

1	Treatment	_	NN	NN	_	8	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	dexamethasone	_	NN	NN	_	2	PMOD	_	_
4	or	_	CC	CC	_	3	CC	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	antiglucocorticoid	_	JJ	JJ	_	7	NMOD	_	_
7	RU486	_	NN	NN	_	3	COORD	_	_
8	had	_	VBD	VBD	_	0	ROOT-S	_	_
9	no	_	DT	DT	_	11	NMOD	_	_
10	additional	_	JJ	JJ	_	11	NMOD	_	_
11	effect	_	NN	NN	_	8	OBJ	_	_
12	on	_	IN	IN	_	8	ADV	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	DNA-binding	_	JJ	JJ	_	15	NMOD	_	_
15	capacity	_	NN	NN	_	12	PMOD	_	_
16	when	_	WRB	WRB	_	20	ADV	_	_
17	receptor	_	NN	NN	_	18	NMOD	_	_
18	preparations	_	NNS	NNS	_	19	SBJ	_	_
19	were	_	VBD	VBD	_	8	TMP	_	_
20	maintained	_	VBN	VBN	_	19	VC	_	_
21	at	_	IN	IN	_	20	ADV	_	_
22	0	_	CD	CD	_	23	NMOD	_	_
23	C	_	NN	NN	_	21	PMOD	_	_
24	(	_	(	(	_	26	P	_	_
25	no	_	DT	DT	_	26	NMOD	_	_
26	activation	_	NN	NN	_	23	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	17	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	17	P	_	_
4	addition	_	NN	NN	_	17	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	either	_	CC	CC	_	7	CC	_	_
7	ligand	_	NN	NN	_	5	PMOD	_	_
8	or	_	CC	CC	_	7	CC	_	_
9	antagonist	_	NN	NN	_	7	COORD	_	_
10	in	_	IN	IN	_	4	NMOD	_	_
11	combination	_	NN	NN	_	10	PMOD	_	_
12	with	_	IN	IN	_	11	NMOD	_	_
13	a	_	DT	DT	_	16	NMOD	_	_
14	heat	_	NN	NN	_	16	NMOD	_	_
15	activation	_	NN	NN	_	16	NMOD	_	_
16	step	_	NN	NN	_	12	PMOD	_	_
17	promoted	_	VBD	VBD	_	0	ROOT-S	_	_
18	DNA	_	NN	NN	_	19	NMOD	_	_
19	binding	_	NN	NN	_	17	OBJ	_	_
20	by	_	IN	IN	_	17	ADV	_	_
21	approximately	_	RB	RB	_	22	NMOD	_	_
22	3-fold	_	RB	RB	_	20	PMOD	_	_
23	over	_	IN	IN	_	22	NMOD	_	_
24	that	_	DT	DT	_	23	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	heat-activated	_	JJ	JJ	_	28	NMOD	_	_
27	unliganded	_	JJ	JJ	_	28	NMOD	_	_
28	receptors	_	NNS	NNS	_	25	PMOD	_	_
29	.	_	.	.	_	17	P	_	_

1	Agonist	_	NN	NN	_	5	SBJ	_	_
2	(	_	(	(	_	3	P	_	_
3	dexamethasone	_	NN	NN	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	slightly	_	RB	RB	_	5	PRD	_	_
7	more	_	JJR	JJR	_	6	AMOD	_	_
8	effective	_	JJ	JJ	_	6	AMOD	_	_
9	in	_	IN	IN	_	5	ADV	_	_
10	supporting	_	VBG	VBG	_	9	PMOD	_	_
11	specific	_	JJ	JJ	_	13	NMOD	_	_
12	DNA	_	NN	NN	_	13	NMOD	_	_
13	binding	_	NN	NN	_	10	OBJ	_	_
14	than	_	IN	IN	_	6	AMOD	_	_
15	antagonist	_	NN	NN	_	14	PMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	RU486	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	.	_	.	.	_	5	P	_	_

1	DNA	_	NN	NN	_	2	NMOD	_	_
2	binding	_	NN	NN	_	8	SBJ	_	_
3	by	_	IN	IN	_	2	NMOD	_	_
4	in	_	FW	FW	_	7	NMOD	_	_
5	vitro	_	FW	FW	_	4	AMOD	_	_
6	synthesized	_	VBN	VBN	_	4	AMOD	_	_
7	GR	_	NN	NN	_	3	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	blocked	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	addition	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	sodium	_	NN	NN	_	15	NMOD	_	_
15	molybdate	_	NN	NN	_	13	PMOD	_	_
16	to	_	TO	TO	_	12	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	receptor	_	NN	NN	_	19	NMOD	_	_
19	preparations	_	NNS	NNS	_	16	PMOD	_	_
20	before	_	IN	IN	_	12	TMP	_	_
21	steroid	_	NN	NN	_	22	NMOD	_	_
22	addition	_	NN	NN	_	20	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	thermal	_	JJ	JJ	_	25	NMOD	_	_
25	activation	_	NN	NN	_	22	COORD	_	_
26	.	_	.	.	_	8	P	_	_

1	Addition	_	NN	NN	_	4	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	KCl	_	NN	NN	_	2	PMOD	_	_
4	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	less	_	RBR	RBR	_	8	NMOD	_	_
7	DNA	_	NN	NN	_	8	NMOD	_	_
8	binding	_	NN	NN	_	5	PMOD	_	_
9	either	_	CC	CC	_	11	CC	_	_
10	due	_	JJ	JJ	_	11	DEP	_	_
11	to	_	TO	TO	_	4	ADV	_	_
12	blockage	_	NN	NN	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	DNA-receptor	_	JJ	JJ	_	16	NMOD	_	_
15	complex	_	NN	NN	_	16	NMOD	_	_
16	formation	_	NN	NN	_	13	PMOD	_	_
17	or	_	CC	CC	_	12	CC	_	_
18	disruption	_	NN	NN	_	12	COORD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	complexes	_	NNS	NNS	_	19	PMOD	_	_
22	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	specificity	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	DNA	_	NN	NN	_	5	NMOD	_	_
5	binding	_	NN	NN	_	3	PMOD	_	_
6	by	_	IN	IN	_	5	NMOD	_	_
7	cell-free	_	JJ	JJ	_	9	NMOD	_	_
8	synthesized	_	VBN	VBN	_	9	NMOD	_	_
9	hGR	_	NN	NN	_	6	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	analyzed	_	VBN	VBN	_	10	VC	_	_
12	further	_	RB	RB	_	11	ADV	_	_
13	by	_	IN	IN	_	11	ADV	_	_
14	examining	_	VBG	VBG	_	13	PMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	abilities	_	NNS	NNS	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	various	_	JJ	JJ	_	19	NMOD	_	_
19	DNAs	_	NNS	NNS	_	17	PMOD	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	compete	_	VB	VB	_	16	NMOD	_	_
22	for	_	IN	IN	_	21	ADV	_	_
23	binding	_	VBG	VBG	_	22	PMOD	_	_
24	to	_	TO	TO	_	23	ADV	_	_
25	a	_	DT	DT	_	28	NMOD	_	_
26	naturally	_	RB	RB	_	27	AMOD	_	_
27	occurring	_	VBG	VBG	_	28	NMOD	_	_
28	GRE	_	NN	NN	_	24	PMOD	_	_
29	found	_	VBD	VBD	_	28	NMOD	_	_
30	in	_	IN	IN	_	29	ADV	_	_
31	the	_	DT	DT	_	37	NMOD	_	_
32	mouse	_	NN	NN	_	34	AMOD	_	_
33	mammary	_	JJ	JJ	_	34	AMOD	_	_
34	tumor	_	NN	NN	_	37	NMOD	_	_
35	virus-long	_	JJ	JJ	_	34	AMOD	_	_
36	terminal	_	JJ	JJ	_	34	AMOD	_	_
37	repeat	_	NN	NN	_	30	PMOD	_	_
38	.	_	.	.	_	10	P	_	_

1	Oligonucleotides	_	NNS	NNS	_	6	SBJ	_	_
2	containing	_	VBG	VBG	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	consensus	_	NN	NN	_	5	NMOD	_	_
5	GRE	_	NN	NN	_	2	OBJ	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	most	_	RBS	RBS	_	9	AMOD	_	_
9	efficient	_	JJ	JJ	_	10	NMOD	_	_
10	competitors	_	NNS	NNS	_	6	PRD	_	_
11	,	_	,	,	_	6	P	_	_
12	and	_	CC	CC	_	6	CC	_	_
13	fragments	_	NNS	NNS	_	20	SBJ	_	_
14	containing	_	VBG	VBG	_	13	NMOD	_	_
15	regulatory	_	JJ	JJ	_	16	NMOD	_	_
16	sequences	_	NNS	NNS	_	14	OBJ	_	_
17	from	_	IN	IN	_	16	NMOD	_	_
18	glucocorticoid-repressible	_	JJ	JJ	_	19	NMOD	_	_
19	genes	_	NNS	NNS	_	17	PMOD	_	_
20	were	_	VBD	VBD	_	6	COORD	_	_
21	somewhat	_	RB	RB	_	22	AMOD	_	_
22	competitive	_	JJ	JJ	_	20	PRD	_	_
23	,	_	,	,	_	6	P	_	_
24	whereas	_	IN	IN	_	6	COORD	_	_
25	single	_	JJ	JJ	_	26	AMOD	_	_
26	stranded	_	JJ	JJ	_	27	NMOD	_	_
27	oligonucleotides	_	NNS	NNS	_	28	SBJ	_	_
28	were	_	VBD	VBD	_	6	COORD	_	_
29	unable	_	JJ	JJ	_	28	PRD	_	_
30	to	_	TO	TO	_	31	VMOD	_	_
31	compete	_	VB	VB	_	29	AMOD	_	_
32	for	_	IN	IN	_	31	ADV	_	_
33	mouse	_	NN	NN	_	38	AMOD	_	_
34	mammary	_	JJ	JJ	_	38	AMOD	_	_
35	tumor	_	NN	NN	_	38	AMOD	_	_
36	virus-long	_	JJ	JJ	_	38	AMOD	_	_
37	terminal	_	JJ	JJ	_	38	AMOD	_	_
38	repeat	_	NN	NN	_	40	NMOD	_	_
39	DNA	_	NN	NN	_	40	NMOD	_	_
40	binding	_	NN	NN	_	32	PMOD	_	_
41	,	_	,	,	_	28	P	_	_
42	except	_	IN	IN	_	28	ADV	_	_
43	when	_	WRB	WRB	_	45	ADV	_	_
44	competitor	_	NN	NN	_	45	SBJ	_	_
45	was	_	VBD	VBD	_	42	TMP	_	_
46	present	_	JJ	JJ	_	45	PRD	_	_
47	at	_	IN	IN	_	45	ADV	_	_
48	extremely	_	RB	RB	_	49	AMOD	_	_
49	high	_	JJ	JJ	_	50	NMOD	_	_
50	concentrations	_	NNS	NNS	_	47	PMOD	_	_
51	.	_	.	.	_	6	P	_	_

1	Together	_	RB	RB	_	4	ADV	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	4	SBJ	_	_
4	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	hGR	_	NN	NN	_	12	SBJ	_	_
7	synthesized	_	VBN	VBN	_	6	NMOD	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	rabbit	_	NN	NN	_	11	NMOD	_	_
10	reticulocyte	_	NN	NN	_	11	NMOD	_	_
11	lysates	_	NNS	NNS	_	8	PMOD	_	_
12	displays	_	VBZ	VBZ	_	5	VMOD	_	_
13	many	_	JJ	JJ	_	12	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	same	_	JJ	JJ	_	17	NMOD	_	_
17	properties	_	NNS	NNS	_	14	PMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	including	_	VBG	VBG	_	17	NMOD	_	_
20	GRE-specific	_	JJ	JJ	_	22	NMOD	_	_
21	DNA	_	NN	NN	_	22	NMOD	_	_
22	binding	_	NN	NN	_	19	PMOD	_	_
23	,	_	,	,	_	17	P	_	_
24	observed	_	VBN	VBN	_	17	NMOD	_	_
25	for	_	IN	IN	_	24	ADV	_	_
26	glucocorticoid	_	NN	NN	_	27	NMOD	_	_
27	receptor	_	NN	NN	_	25	PMOD	_	_
28	present	_	JJ	JJ	_	27	NMOD	_	_
29	in	_	IN	IN	_	28	AMOD	_	_
30	cytosolic	_	JJ	JJ	_	31	NMOD	_	_
31	extracts	_	NNS	NNS	_	29	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	mammalian	_	JJ	JJ	_	34	NMOD	_	_
34	cells	_	NNS	NNS	_	32	PMOD	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	tissues	_	NNS	NNS	_	34	COORD	_	_
37	.	_	.	.	_	4	P	_	_

1	Similarities	_	NNS	NNS	_	9	SBJ	_	_
2	between	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	effects	_	NNS	NNS	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	dexamethasone	_	NN	NN	_	5	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	RU486	_	NN	NN	_	6	COORD	_	_
9	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
10	that	_	IN	IN	_	9	OBJ	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	antiglucocorticoid	_	JJ	JJ	_	13	NMOD	_	_
13	properties	_	NNS	NNS	_	16	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	RU486	_	NN	NN	_	14	PMOD	_	_
16	do	_	VBP	VBP	_	10	VMOD	_	_
17	not	_	RB	RB	_	16	VMOD	_	_
18	occur	_	VB	VB	_	16	VC	_	_
19	at	_	IN	IN	_	18	ADV	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	level	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	specific	_	JJ	JJ	_	25	NMOD	_	_
24	DNA	_	NN	NN	_	25	NMOD	_	_
25	binding	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	9	P	_	_

1	Clone	_	NN	NN	_	2	NMOD	_	_
2	pAT	_	NN	NN	_	4	SBJ	_	_
3	133	_	CD	CD	_	2	NMOD	_	_
4	identifies	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	6	NMOD	_	_
6	gene	_	NN	NN	_	4	OBJ	_	_
7	that	_	WDT	WDT	_	8	SBJ	_	_
8	encodes	_	VBZ	VBZ	_	6	NMOD	_	_
9	another	_	DT	DT	_	11	NMOD	_	_
10	human	_	JJ	JJ	_	11	NMOD	_	_
11	member	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	class	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	growth	_	NN	NN	_	18	NMOD	_	_
17	factor-induced	_	JJ	JJ	_	16	AMOD	_	_
18	genes	_	NNS	NNS	_	15	PMOD	_	_
19	with	_	IN	IN	_	18	NMOD	_	_
20	almost	_	RB	RB	_	21	AMOD	_	_
21	identical	_	JJ	JJ	_	23	NMOD	_	_
22	zinc-finger	_	NN	NN	_	23	NMOD	_	_
23	domains	_	NNS	NNS	_	19	PMOD	_	_
24	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	structure	_	NN	NN	_	2	OBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	regulation	_	NN	NN	_	4	COORD	_	_
7	of	_	IN	IN	_	4	NMOD	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	gene	_	NN	NN	_	7	PMOD	_	_
10	represented	_	VBN	VBN	_	9	NMOD	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	clone	_	NN	NN	_	13	NMOD	_	_
13	pAT	_	NN	NN	_	11	PMOD	_	_
14	133	_	CD	CD	_	13	NMOD	_	_
15	,	_	,	,	_	13	P	_	_
16	which	_	WDT	WDT	_	17	SBJ	_	_
17	is	_	VBZ	VBZ	_	13	NMOD	_	_
18	induced	_	VBN	VBN	_	17	VC	_	_
19	upon	_	IN	IN	_	18	TMP	_	_
20	transition	_	NN	NN	_	19	PMOD	_	_
21	from	_	IN	IN	_	20	NMOD	_	_
22	a	_	DT	DT	_	24	NMOD	_	_
23	resting	_	JJ	JJ	_	24	NMOD	_	_
24	state	_	NN	NN	_	21	PMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	G0	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	through	_	IN	IN	_	20	NMOD	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	early	_	JJ	JJ	_	31	NMOD	_	_
31	phase	_	NN	NN	_	28	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	the	_	DT	DT	_	35	NMOD	_	_
34	cell	_	NN	NN	_	35	NMOD	_	_
35	cycle	_	NN	NN	_	32	PMOD	_	_
36	(	_	(	(	_	37	P	_	_
37	G1	_	NN	NN	_	31	PRN	_	_
38	)	_	)	)	_	37	P	_	_
39	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	pAT	_	NN	NN	_	4	NMOD	_	_
3	133	_	CD	CD	_	4	NMOD	_	_
4	gene	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	immediately	_	RB	RB	_	5	TMP	_	_
7	induced	_	VBN	VBN	_	5	VC	_	_
8	,	_	,	,	_	7	P	_	_
9	with	_	IN	IN	_	7	ADV	_	_
10	FOS-like	_	JJ	JJ	_	11	NMOD	_	_
11	kinetics	_	NNS	NNS	_	9	PMOD	_	_
12	,	_	,	,	_	7	P	_	_
13	in	_	IN	IN	_	7	ADV	_	_
14	human	_	JJ	JJ	_	16	NMOD	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	13	PMOD	_	_
17	and	_	CC	CC	_	13	CC	_	_
18	in	_	IN	IN	_	13	COORD	_	_
19	fibroblasts	_	NNS	NNS	_	18	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	Primary	_	JJ	JJ	_	3	NMOD	_	_
2	structure	_	NN	NN	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	4	SBJ	_	_
4	showed	_	VBD	VBD	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	encoded	_	VBN	VBN	_	8	NMOD	_	_
8	protein	_	NN	NN	_	9	SBJ	_	_
9	contains	_	VBZ	VBZ	_	5	VMOD	_	_
10	three	_	CD	CD	_	13	NMOD	_	_
11	tandem	_	JJ	JJ	_	13	NMOD	_	_
12	zinc-finger	_	NN	NN	_	13	NMOD	_	_
13	sequences	_	NNS	NNS	_	9	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	type	_	NN	NN	_	17	NMOD	_	_
17	Cys2-Xaa12-His2	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	zinc-finger	_	NN	NN	_	3	NMOD	_	_
3	region	_	NN	NN	_	16	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	which	_	WDT	WDT	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	3	NMOD	_	_
7	thought	_	VBN	VBN	_	6	VC	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	bind	_	VB	VB	_	7	OBJ	_	_
10	DNA	_	NN	NN	_	9	OBJ	_	_
11	in	_	IN	IN	_	9	ADV	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	sequence-specific	_	JJ	JJ	_	14	NMOD	_	_
14	manner	_	NN	NN	_	11	PMOD	_	_
15	,	_	,	,	_	3	P	_	_
16	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	similar	_	JJ	JJ	_	16	PRD	_	_
18	(	_	(	(	_	17	PRN	_	_
19	greater	_	JJR	JJR	_	21	DEP	_	_
20	than	_	IN	IN	_	21	DEP	_	_
21	80	_	CD	CD	_	22	NMOD	_	_
22	%	_	NN	NN	_	18	DEP	_	_
23	on	_	IN	IN	_	22	ADV	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	amino	_	NN	NN	_	27	NMOD	_	_
26	acid	_	NN	NN	_	27	NMOD	_	_
27	level	_	NN	NN	_	23	PMOD	_	_
28	)	_	)	)	_	18	P	_	_
29	to	_	TO	TO	_	17	AMOD	_	_
30	two	_	CD	CD	_	34	NMOD	_	_
31	previously	_	RB	RB	_	32	AMOD	_	_
32	described	_	VBN	VBN	_	34	NMOD	_	_
33	transcription	_	NN	NN	_	34	NMOD	_	_
34	factors	_	NNS	NNS	_	29	PMOD	_	_
35	pAT	_	NN	NN	_	36	NMOD	_	_
36	225\/EGR1	_	NN	NN	_	34	NMOD	_	_
37	and	_	CC	CC	_	36	CC	_	_
38	pAT	_	NN	NN	_	39	NMOD	_	_
39	591\/EGR2	_	NN	NN	_	36	COORD	_	_
40	.	_	.	.	_	16	P	_	_

1	Except	_	IN	IN	_	16	ADV	_	_
2	for	_	IN	IN	_	1	DEP	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	conserved	_	VBN	VBN	_	6	NMOD	_	_
5	zinc-finger	_	NN	NN	_	6	NMOD	_	_
6	domains	_	NNS	NNS	_	1	PMOD	_	_
7	,	_	,	,	_	16	P	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	amino	_	NN	NN	_	11	NMOD	_	_
10	acid	_	NN	NN	_	11	NMOD	_	_
11	sequences	_	NNS	NNS	_	16	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	three	_	CD	CD	_	15	NMOD	_	_
15	proteins	_	NNS	NNS	_	12	PMOD	_	_
16	are	_	VBP	VBP	_	0	ROOT-S	_	_
17	distinct	_	JJ	JJ	_	16	PRD	_	_
18	.	_	.	.	_	16	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	structural	_	JJ	JJ	_	3	NMOD	_	_
3	similarity	_	NN	NN	_	4	SBJ	_	_
4	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	pAT	_	NN	NN	_	9	NMOD	_	_
8	133	_	CD	CD	_	9	NMOD	_	_
9	gene	_	NN	NN	_	10	SBJ	_	_
10	encodes	_	VBZ	VBZ	_	5	VMOD	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	transcription	_	NN	NN	_	13	NMOD	_	_
13	factor	_	NN	NN	_	10	OBJ	_	_
14	with	_	IN	IN	_	13	NMOD	_	_
15	a	_	DT	DT	_	18	NMOD	_	_
16	specific	_	JJ	JJ	_	18	NMOD	_	_
17	biological	_	JJ	JJ	_	18	NMOD	_	_
18	function	_	NN	NN	_	14	PMOD	_	_
19	.	_	.	.	_	4	P	_	_

1	Comparing	_	VBG	VBG	_	9	SBJ	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	regulation	_	NN	NN	_	1	OBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	these	_	DT	DT	_	8	NMOD	_	_
6	related	_	JJ	JJ	_	8	NMOD	_	_
7	zinc-finger-encoding	_	JJ	JJ	_	8	NMOD	_	_
8	genes	_	NNS	NNS	_	4	PMOD	_	_
9	showed	_	VBD	VBD	_	0	ROOT-S	_	_
10	coordinate	_	JJ	JJ	_	11	NMOD	_	_
11	induction	_	NN	NN	_	9	OBJ	_	_
12	upon	_	IN	IN	_	11	TMP	_	_
13	mitogenic	_	JJ	JJ	_	14	NMOD	_	_
14	stimulation	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	resting	_	VBG	VBG	_	18	NMOD	_	_
17	T	_	NN	NN	_	18	NMOD	_	_
18	lymphocytes	_	NNS	NNS	_	15	PMOD	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	of	_	IN	IN	_	15	COORD	_	_
21	resting	_	VBG	VBG	_	22	NMOD	_	_
22	fibroblasts	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	9	P	_	_

1	However	_	RB	RB	_	22	ADV	_	_
2	,	_	,	,	_	22	P	_	_
3	upon	_	IN	IN	_	22	TMP	_	_
4	transition	_	NN	NN	_	3	PMOD	_	_
5	from	_	IN	IN	_	4	NMOD	_	_
6	a	_	DT	DT	_	14	NMOD	_	_
7	proliferating	_	JJ	JJ	_	14	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	G1	_	NN	NN	_	14	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	to	_	TO	TO	_	4	NMOD	_	_
12	a	_	DT	DT	_	11	NMOD	_	_
13	resting	_	JJ	JJ	_	11	NMOD	_	_
14	state	_	NN	NN	_	5	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	cycle	_	NN	NN	_	15	PMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	three	_	CD	CD	_	21	NMOD	_	_
21	genes	_	NNS	NNS	_	22	SBJ	_	_
22	were	_	VBD	VBD	_	0	ROOT-S	_	_
23	differently	_	RB	RB	_	22	ADV	_	_
24	regulated	_	VBN	VBN	_	22	VC	_	_
25	.	_	.	.	_	22	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	human	_	JJ	JJ	_	5	NMOD	_	_
3	histiocytic	_	JJ	JJ	_	5	NMOD	_	_
4	U937	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	1	PMOD	_	_
6	mRNA	_	NN	NN	_	11	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	clone	_	NN	NN	_	9	NMOD	_	_
9	pAT	_	NN	NN	_	7	PMOD	_	_
10	133	_	CD	CD	_	9	NMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	constitutively	_	RB	RB	_	11	ADV	_	_
13	expressed	_	VBN	VBN	_	11	VC	_	_
14	,	_	,	,	_	11	P	_	_
15	whereas	_	IN	IN	_	11	COORD	_	_
16	mRNA	_	NN	NN	_	20	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	pAT	_	NN	NN	_	19	NMOD	_	_
19	225\/EGR1	_	NN	NN	_	17	PMOD	_	_
20	was	_	VBD	VBD	_	11	COORD	_	_
21	induced	_	VBN	VBN	_	20	VC	_	_
22	upon	_	IN	IN	_	21	TMP	_	_
23	induction	_	NN	NN	_	22	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	terminal	_	JJ	JJ	_	26	NMOD	_	_
26	differentiation	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	11	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	mRNA	_	NN	NN	_	7	SBJ	_	_
4	representing	_	VBG	VBG	_	3	NMOD	_	_
5	pAT	_	NN	NN	_	6	NMOD	_	_
6	591\/EGR2	_	NN	NN	_	4	OBJ	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	not	_	RB	RB	_	7	VMOD	_	_
9	expressed	_	VBN	VBN	_	7	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	these	_	DT	DT	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	7	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	difference	_	NN	NN	_	6	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	gene	_	NN	NN	_	5	NMOD	_	_
5	regulation	_	NN	NN	_	3	PMOD	_	_
6	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	distinct	_	JJ	JJ	_	9	NMOD	_	_
8	biological	_	JJ	JJ	_	9	NMOD	_	_
9	roles	_	NNS	NNS	_	6	OBJ	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	control	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	proliferation	_	NN	NN	_	13	PMOD	_	_
16	for	_	IN	IN	_	9	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	respective	_	JJ	JJ	_	19	NMOD	_	_
19	proteins	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	6	P	_	_

1	Regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	interleukin-1	_	NN	NN	_	5	NMOD	_	_
4	beta	_	NN	NN	_	5	NMOD	_	_
5	production	_	NN	NN	_	2	PMOD	_	_
6	by	_	IN	IN	_	1	NMOD	_	_
7	glucocorticoids	_	NNS	NNS	_	6	PMOD	_	_
8	in	_	IN	IN	_	1	NMOD	_	_
9	human	_	JJ	JJ	_	10	NMOD	_	_
10	monocytes	_	NNS	NNS	_	8	PMOD	_	_
11	:	_	:	:	_	1	P	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	mechanism	_	NN	NN	_	16	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	action	_	NN	NN	_	14	PMOD	_	_
16	depends	_	VBZ	VBZ	_	1	NMOD	_	_
17	on	_	IN	IN	_	16	ADV	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	activation	_	NN	NN	_	20	NMOD	_	_
20	signal	_	NN	NN	_	17	PMOD	_	_
21	.	_	.	.	_	16	P	_	_

1	Glucocorticoids	_	NNS	NNS	_	2	SBJ	_	_
2	are	_	VBP	VBP	_	0	ROOT-S	_	_
3	known	_	VBN	VBN	_	2	VC	_	_
4	to	_	TO	TO	_	5	VMOD	_	_
5	downregulate	_	VB	VB	_	3	OBJ	_	_
6	interleukin-1	_	NN	NN	_	8	NMOD	_	_
7	beta	_	NN	NN	_	8	NMOD	_	_
8	production	_	NN	NN	_	5	OBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	monocytic	_	JJ	JJ	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	by	_	IN	IN	_	5	ADV	_	_
13	two	_	CD	CD	_	15	NMOD	_	_
14	different	_	JJ	JJ	_	15	NMOD	_	_
15	mechanims	_	NNS	NNS	_	12	PMOD	_	_
16	:	_	:	:	_	15	P	_	_
17	direct	_	JJ	JJ	_	18	NMOD	_	_
18	inhibition	_	NN	NN	_	15	NMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	transcription	_	NN	NN	_	19	PMOD	_	_
23	and	_	CC	CC	_	18	CC	_	_
24	destabilization	_	NN	NN	_	18	COORD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	30	NMOD	_	_
27	preformed	_	JJ	JJ	_	30	NMOD	_	_
28	interleukin-1	_	NN	NN	_	30	NMOD	_	_
29	beta	_	NN	NN	_	30	NMOD	_	_
30	mRNA	_	NN	NN	_	25	PMOD	_	_
31	.	_	.	.	_	2	P	_	_

1	Now	_	RB	RB	_	3	TMP	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	examined	_	VBN	VBN	_	3	VC	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	effect	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	nature	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	monocyte	_	NN	NN	_	14	NMOD	_	_
13	activating	_	NN	NN	_	14	NMOD	_	_
14	signal	_	NN	NN	_	10	PMOD	_	_
15	on	_	IN	IN	_	6	NMOD	_	_
16	these	_	DT	DT	_	19	NMOD	_	_
17	two	_	CD	CD	_	19	NMOD	_	_
18	inhibitory	_	JJ	JJ	_	19	NMOD	_	_
19	mechanims	_	NNS	NNS	_	15	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	When	_	WRB	WRB	_	5	ADV	_	_
2	human	_	JJ	JJ	_	3	NMOD	_	_
3	monocytes	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	23	TMP	_	_
5	preincubated	_	VBN	VBN	_	4	VC	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	dexamethasone	_	NN	NN	_	6	PMOD	_	_
8	for	_	IN	IN	_	5	TMP	_	_
9	1	_	CD	CD	_	10	NMOD	_	_
10	hour	_	NN	NN	_	8	PMOD	_	_
11	and	_	CC	CC	_	5	CC	_	_
12	then	_	RB	RB	_	5	COORD	_	_
13	stimulated	_	VBN	VBN	_	5	COORD	_	_
14	either	_	CC	CC	_	15	CC	_	_
15	with	_	IN	IN	_	13	ADV	_	_
16	bacterial	_	JJ	JJ	_	17	NMOD	_	_
17	lipopolysaccharide	_	NN	NN	_	15	PMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	phorbol	_	NN	NN	_	20	NMOD	_	_
20	myristate	_	NN	NN	_	17	COORD	_	_
21	,	_	,	,	_	23	P	_	_
22	it	_	PRP	PRP	_	23	SBJ	_	_
23	was	_	VBD	VBD	_	0	ROOT-S	_	_
24	found	_	VBN	VBN	_	23	VC	_	_
25	that	_	IN	IN	_	24	OBJ	_	_
26	dexamethasone	_	NN	NN	_	27	SBJ	_	_
27	inhibited	_	VBD	VBD	_	25	VMOD	_	_
28	the	_	DT	DT	_	33	NMOD	_	_
29	lipopolysaccharide-induced	_	JJ	JJ	_	33	NMOD	_	_
30	interleukin-1	_	NN	NN	_	33	NMOD	_	_
31	beta	_	NN	NN	_	33	NMOD	_	_
32	protein	_	NN	NN	_	33	NMOD	_	_
33	production	_	NN	NN	_	27	OBJ	_	_
34	,	_	,	,	_	27	P	_	_
35	but	_	CC	CC	_	27	CC	_	_
36	the	_	DT	DT	_	39	NMOD	_	_
37	phorbol	_	NN	NN	_	39	NMOD	_	_
38	myristate-induced	_	JJ	JJ	_	37	AMOD	_	_
39	production	_	NN	NN	_	40	SBJ	_	_
40	was	_	VBD	VBD	_	27	COORD	_	_
41	increased	_	VBN	VBN	_	40	VC	_	_
42	3-10	_	CD	CD	_	43	NMOD	_	_
43	fold	_	RB	RB	_	41	OBJ	_	_
44	.	_	.	.	_	23	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	difference	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	also	_	RB	RB	_	3	ADV	_	_
5	seen	_	VBN	VBN	_	3	VC	_	_
6	at	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	mRNA	_	NN	NN	_	9	NMOD	_	_
9	level	_	NN	NN	_	6	PMOD	_	_
10	.	_	.	.	_	3	P	_	_

1	When	_	WRB	WRB	_	4	ADV	_	_
2	dexamethasone	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	16	TMP	_	_
4	added	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	cultures	_	NNS	NNS	_	5	PMOD	_	_
8	3	_	CD	CD	_	9	NMOD	_	_
9	hours	_	NNS	NNS	_	10	PMOD	_	_
10	after	_	IN	IN	_	4	TMP	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	stimulators	_	NNS	NNS	_	10	PMOD	_	_
13	,	_	,	,	_	16	P	_	_
14	it	_	PRP	PRP	_	16	SBJ	_	_
15	clearly	_	RB	RB	_	16	ADV	_	_
16	decreased	_	VBD	VBD	_	0	ROOT-S	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	interleukin-1	_	NN	NN	_	21	NMOD	_	_
19	beta	_	NN	NN	_	21	NMOD	_	_
20	mRNA	_	NN	NN	_	21	NMOD	_	_
21	levels	_	NNS	NNS	_	16	IOBJ	_	_
22	regardless	_	RB	RB	_	16	ADV	_	_
23	of	_	IN	IN	_	22	AMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	stimulator	_	NN	NN	_	23	PMOD	_	_
26	used	_	VBN	VBN	_	25	NMOD	_	_
27	(	_	(	(	_	16	P	_	_
28	although	_	IN	IN	_	16	OBJ	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	effect	_	NN	NN	_	31	SBJ	_	_
31	was	_	VBD	VBD	_	28	VMOD	_	_
32	clearly	_	RB	RB	_	33	AMOD	_	_
33	weaker	_	JJR	JJR	_	31	PRD	_	_
34	on	_	IN	IN	_	31	ADV	_	_
35	the	_	DT	DT	_	37	NMOD	_	_
36	PMA-induced	_	JJ	JJ	_	37	NMOD	_	_
37	mRNA	_	NN	NN	_	34	PMOD	_	_
38	)	_	)	)	_	16	P	_	_
39	.	_	.	.	_	16	P	_	_

1	Thus	_	RB	RB	_	4	ADV	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	data	_	NNS	NNS	_	4	SBJ	_	_
4	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	phorbol	_	NN	NN	_	9	NMOD	_	_
8	myristate-induced	_	JJ	JJ	_	7	AMOD	_	_
9	signal	_	NN	NN	_	18	SBJ	_	_
10	(	_	(	(	_	9	PRN	_	_
11	prolonged	_	JJ	JJ	_	15	NMOD	_	_
12	protein	_	NN	NN	_	15	NMOD	_	_
13	kinase	_	NN	NN	_	15	NMOD	_	_
14	C	_	NN	NN	_	15	NMOD	_	_
15	activation	_	NN	NN	_	10	DEP	_	_
16	?	_	.	.	_	15	P	_	_
17	)	_	)	)	_	10	P	_	_
18	can	_	MD	MD	_	5	VMOD	_	_
19	not	_	RB	RB	_	18	VMOD	_	_
20	be	_	VB	VB	_	18	VC	_	_
21	inhibited	_	VBN	VBN	_	20	VC	_	_
22	by	_	IN	IN	_	21	LGS	_	_
23	prior	_	JJ	JJ	_	24	NMOD	_	_
24	incubation	_	NN	NN	_	22	PMOD	_	_
25	with	_	IN	IN	_	24	NMOD	_	_
26	dexamethasone	_	NN	NN	_	25	PMOD	_	_
27	and	_	CC	CC	_	18	CC	_	_
28	it	_	PRP	PRP	_	30	SBJ	_	_
29	also	_	RB	RB	_	30	ADV	_	_
30	protects	_	VBZ	VBZ	_	18	COORD	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	induced	_	VBN	VBN	_	33	NMOD	_	_
33	mRNA	_	NN	NN	_	30	OBJ	_	_
34	for	_	IN	IN	_	30	ADV	_	_
35	the	_	DT	DT	_	37	NMOD	_	_
36	degradative	_	JJ	JJ	_	37	NMOD	_	_
37	action	_	NN	NN	_	34	PMOD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	dexamethasone	_	NN	NN	_	38	PMOD	_	_
40	.	_	.	.	_	4	P	_	_

1	TCF-1	_	NN	NN	_	14	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	a	_	DT	DT	_	7	NMOD	_	_
4	T	_	NN	NN	_	7	NMOD	_	_
5	cell-specific	_	JJ	JJ	_	4	AMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factor	_	NN	NN	_	1	NMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	HMG	_	NN	NN	_	12	NMOD	_	_
11	box	_	NN	NN	_	12	NMOD	_	_
12	family	_	NN	NN	_	8	PMOD	_	_
13	,	_	,	,	_	1	P	_	_
14	interacts	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	with	_	IN	IN	_	14	ADV	_	_
16	sequence	_	NN	NN	_	17	NMOD	_	_
17	motifs	_	NNS	NNS	_	15	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	25	NMOD	_	_
20	TCR	_	NN	NN	_	21	NMOD	_	_
21	beta	_	NN	NN	_	25	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	TCR	_	NN	NN	_	24	NMOD	_	_
24	delta	_	NN	NN	_	21	COORD	_	_
25	enhancers	_	NNS	NNS	_	18	PMOD	_	_
26	.	_	.	.	_	14	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	recently	_	RB	RB	_	2	TMP	_	_
4	identified	_	VBN	VBN	_	2	VC	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	cloned	_	VBN	VBN	_	4	COORD	_	_
7	TCF-1	_	NN	NN	_	4	OBJ	_	_
8	,	_	,	,	_	7	P	_	_
9	a	_	DT	DT	_	13	NMOD	_	_
10	T	_	NN	NN	_	13	NMOD	_	_
11	cell-specific	_	JJ	JJ	_	10	AMOD	_	_
12	transcription	_	NN	NN	_	13	NMOD	_	_
13	factor	_	NN	NN	_	7	NMOD	_	_
14	with	_	IN	IN	_	13	NMOD	_	_
15	specificity	_	NN	NN	_	14	PMOD	_	_
16	for	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	AACAAAG	_	NN	NN	_	19	NMOD	_	_
19	motif	_	NN	NN	_	16	PMOD	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	CD3	_	NN	NN	_	24	NMOD	_	_
23	epsilon	_	NN	NN	_	24	NMOD	_	_
24	enhancer	_	NN	NN	_	20	PMOD	_	_
25	and	_	CC	CC	_	16	CC	_	_
26	for	_	IN	IN	_	16	COORD	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	TTCAAAG	_	NN	NN	_	29	NMOD	_	_
29	motif	_	NN	NN	_	26	PMOD	_	_
30	in	_	IN	IN	_	29	NMOD	_	_
31	the	_	DT	DT	_	34	NMOD	_	_
32	TCR	_	NN	NN	_	34	NMOD	_	_
33	alpha	_	NN	NN	_	34	NMOD	_	_
34	enhancer	_	NN	NN	_	30	PMOD	_	_
35	.	_	.	.	_	2	P	_	_

1	TCF-1	_	NN	NN	_	2	SBJ	_	_
2	belongs	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	to	_	TO	TO	_	2	ADV	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	family	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	transcription-regulating	_	JJ	JJ	_	8	NMOD	_	_
8	proteins	_	NNS	NNS	_	6	PMOD	_	_
9	which	_	WDT	WDT	_	10	SBJ	_	_
10	share	_	VBP	VBP	_	8	NMOD	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	region	_	NN	NN	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	homology	_	NN	NN	_	13	PMOD	_	_
15	termed	_	VBN	VBN	_	12	NMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	HMG-box	_	NN	NN	_	15	OBJ	_	_
18	.	_	.	.	_	2	P	_	_

1	Here	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	show	_	VBP	VBP	_	0	ROOT-S	_	_
5	by	_	IN	IN	_	4	ADV	_	_
6	gel	_	NN	NN	_	8	NMOD	_	_
7	retardation	_	NN	NN	_	8	NMOD	_	_
8	analysis	_	NN	NN	_	5	PMOD	_	_
9	that	_	IN	IN	_	4	OBJ	_	_
10	TCF-1	_	NN	NN	_	9	SBJ	_	_
11	specifically	_	RB	RB	_	9	VMOD	_	_
12	recognizes	_	VBZ	VBZ	_	9	VMOD	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	T	_	NN	NN	_	17	NMOD	_	_
15	beta	_	NN	NN	_	17	NMOD	_	_
16	5	_	CD	CD	_	17	NMOD	_	_
17	element	_	NN	NN	_	12	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	TCR	_	NN	NN	_	22	NMOD	_	_
21	beta	_	NN	NN	_	22	NMOD	_	_
22	enhancer	_	NN	NN	_	18	PMOD	_	_
23	and	_	CC	CC	_	17	CC	_	_
24	the	_	DT	DT	_	28	NMOD	_	_
25	T	_	NN	NN	_	28	NMOD	_	_
26	delta	_	NN	NN	_	28	NMOD	_	_
27	7	_	CD	CD	_	28	NMOD	_	_
28	element	_	NN	NN	_	17	COORD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	33	NMOD	_	_
31	TCR	_	NN	NN	_	33	NMOD	_	_
32	delta	_	NN	NN	_	33	NMOD	_	_
33	enhancer	_	NN	NN	_	29	PMOD	_	_
34	.	_	.	.	_	4	P	_	_

1	Comparison	_	NN	NN	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	sequences	_	NNS	NNS	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	all	_	DT	DT	_	7	NMOD	_	_
7	elements	_	NNS	NNS	_	5	PMOD	_	_
8	recognized	_	VBN	VBN	_	7	NMOD	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	TCF-1	_	NN	NN	_	9	PMOD	_	_
11	defines	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	a	_	DT	DT	_	21	NMOD	_	_
13	consensus	_	NN	NN	_	21	NMOD	_	_
14	motif	_	NN	NN	_	21	NMOD	_	_
15	A\/T	_	NN	NN	_	21	NMOD	_	_
16	A\/T	_	NN	NN	_	21	NMOD	_	_
17	C	_	NN	NN	_	21	NMOD	_	_
18	A	_	NN	NN	_	21	NMOD	_	_
19	A\/G	_	NN	NN	_	21	NMOD	_	_
20	A	_	NN	NN	_	21	NMOD	_	_
21	G	_	NN	NN	_	11	OBJ	_	_
22	.	_	.	.	_	11	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	observations	_	NNS	NNS	_	3	SBJ	_	_
3	imply	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	TCF-1	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	4	VMOD	_	_
7	involved	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	control	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	several	_	JJ	JJ	_	15	NMOD	_	_
13	T	_	NN	NN	_	15	NMOD	_	_
14	cell-specific	_	JJ	JJ	_	13	AMOD	_	_
15	genes	_	NNS	NNS	_	11	PMOD	_	_
16	and	_	CC	CC	_	6	CC	_	_
17	might	_	MD	MD	_	6	COORD	_	_
18	thus	_	RB	RB	_	17	ADV	_	_
19	play	_	VB	VB	_	17	VC	_	_
20	an	_	DT	DT	_	22	NMOD	_	_
21	important	_	JJ	JJ	_	22	NMOD	_	_
22	role	_	NN	NN	_	19	OBJ	_	_
23	in	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	establishment	_	NN	NN	_	23	PMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	maintenance	_	NN	NN	_	25	COORD	_	_
28	of	_	IN	IN	_	25	NMOD	_	_
29	the	_	DT	DT	_	33	NMOD	_	_
30	mature	_	JJ	JJ	_	33	NMOD	_	_
31	T	_	NN	NN	_	33	NMOD	_	_
32	cell	_	NN	NN	_	33	NMOD	_	_
33	phenotype	_	NN	NN	_	28	PMOD	_	_
34	.	_	.	.	_	3	P	_	_

1	Characterization	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	cofactor	_	NN	NN	_	2	PMOD	_	_
5	that	_	WDT	WDT	_	6	SBJ	_	_
6	regulates	_	VBZ	VBZ	_	4	NMOD	_	_
7	dimerization	_	NN	NN	_	6	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	mammalian	_	JJ	JJ	_	12	NMOD	_	_
11	homeodomain	_	NN	NN	_	12	NMOD	_	_
12	protein	_	NN	NN	_	8	PMOD	_	_
13	.	_	.	.	_	1	P	_	_

1	Dimerization	_	NN	NN	_	5	SBJ	_	_
2	among	_	IN	IN	_	1	NMOD	_	_
3	transcription	_	NN	NN	_	4	NMOD	_	_
4	factors	_	NNS	NNS	_	2	PMOD	_	_
5	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	become	_	VBN	VBN	_	5	VC	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	recurrent	_	JJ	JJ	_	9	NMOD	_	_
9	theme	_	NN	NN	_	6	PRD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	regulation	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	eukaryotic	_	JJ	JJ	_	16	NMOD	_	_
15	gene	_	NN	NN	_	16	NMOD	_	_
16	expression	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	5	P	_	_

1	Hepatocyte	_	NN	NN	_	4	NMOD	_	_
2	nuclear	_	JJ	JJ	_	4	NMOD	_	_
3	factor-1	_	NN	NN	_	4	NMOD	_	_
4	alpha	_	NN	NN	_	9	SBJ	_	_
5	(	_	(	(	_	7	P	_	_
6	HNF-1	_	NN	NN	_	7	NMOD	_	_
7	alpha	_	NN	NN	_	4	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	homeodomain-containing	_	JJ	JJ	_	12	NMOD	_	_
12	protein	_	NN	NN	_	9	PRD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	functions	_	VBZ	VBZ	_	12	NMOD	_	_
15	as	_	IN	IN	_	14	ADV	_	_
16	a	_	DT	DT	_	17	NMOD	_	_
17	dimer	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	9	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	dimerization	_	NN	NN	_	3	NMOD	_	_
3	cofactor	_	NN	NN	_	10	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	HNF-1	_	NN	NN	_	6	NMOD	_	_
6	alpha	_	NN	NN	_	4	PMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	DCoH	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	identified	_	VBN	VBN	_	10	VC	_	_
12	that	_	WDT	WDT	_	13	SBJ	_	_
13	displayed	_	VBD	VBD	_	3	NMOD	_	_
14	a	_	DT	DT	_	17	NMOD	_	_
15	restricted	_	JJ	JJ	_	17	NMOD	_	_
16	tissue	_	NN	NN	_	17	NMOD	_	_
17	distribution	_	NN	NN	_	13	OBJ	_	_
18	and	_	CC	CC	_	13	CC	_	_
19	did	_	VBD	VBD	_	13	COORD	_	_
20	not	_	RB	RB	_	19	VMOD	_	_
21	bind	_	VB	VB	_	19	VC	_	_
22	to	_	TO	TO	_	21	ADV	_	_
23	DNA	_	NN	NN	_	22	PMOD	_	_
24	,	_	,	,	_	13	P	_	_
25	but	_	CC	CC	_	13	CC	_	_
26	,	_	,	,	_	25	P	_	_
27	rather	_	RB	RB	_	25	COORD	_	_
28	,	_	,	,	_	13	P	_	_
29	selectively	_	RB	RB	_	30	ADV	_	_
30	stabilized	_	VBD	VBD	_	13	COORD	_	_
31	HNF-1	_	NN	NN	_	33	NMOD	_	_
32	alpha	_	NN	NN	_	33	NMOD	_	_
33	dimers	_	NNS	NNS	_	30	OBJ	_	_
34	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	formation	_	NN	NN	_	20	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	a	_	DT	DT	_	9	NMOD	_	_
5	stable	_	JJ	JJ	_	9	NMOD	_	_
6	tetrameric	_	JJ	JJ	_	9	NMOD	_	_
7	DCoH-HNF-1	_	NN	NN	_	9	NMOD	_	_
8	alpha	_	NN	NN	_	9	NMOD	_	_
9	complex	_	NN	NN	_	3	PMOD	_	_
10	,	_	,	,	_	2	P	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	required	_	VBD	VBD	_	2	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	dimerization	_	NN	NN	_	15	NMOD	_	_
15	domain	_	NN	NN	_	12	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	HNF-1	_	NN	NN	_	18	NMOD	_	_
18	alpha	_	NN	NN	_	16	PMOD	_	_
19	,	_	,	,	_	2	P	_	_
20	did	_	VBD	VBD	_	0	ROOT-S	_	_
21	not	_	RB	RB	_	20	VMOD	_	_
22	change	_	VB	VB	_	20	VC	_	_
23	the	_	DT	DT	_	26	NMOD	_	_
24	DNA	_	NN	NN	_	26	NMOD	_	_
25	binding	_	NN	NN	_	26	NMOD	_	_
26	characteristics	_	NNS	NNS	_	22	OBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	HNF-1	_	NN	NN	_	29	NMOD	_	_
29	alpha	_	NN	NN	_	27	PMOD	_	_
30	,	_	,	,	_	20	P	_	_
31	but	_	CC	CC	_	20	CC	_	_
32	enhanced	_	VBD	VBD	_	20	COORD	_	_
33	its	_	PRP$	PRP$	_	35	NMOD	_	_
34	transcriptional	_	JJ	JJ	_	35	NMOD	_	_
35	activity	_	NN	NN	_	32	OBJ	_	_
36	.	_	.	.	_	20	P	_	_

1	However	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	DCoH	_	NN	NN	_	4	SBJ	_	_
4	did	_	VBD	VBD	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	confer	_	VB	VB	_	4	VC	_	_
7	transcriptional	_	JJ	JJ	_	8	NMOD	_	_
8	activation	_	NN	NN	_	6	OBJ	_	_
9	to	_	TO	TO	_	6	ADV	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	GAL4	_	NN	NN	_	14	NMOD	_	_
12	DNA	_	NN	NN	_	14	NMOD	_	_
13	binding	_	NN	NN	_	14	NMOD	_	_
14	domain	_	NN	NN	_	9	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	DCoH	_	NN	NN	_	6	SBJ	_	_
6	regulates	_	VBZ	VBZ	_	4	VMOD	_	_
7	formation	_	NN	NN	_	6	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	transcriptionally	_	RB	RB	_	10	AMOD	_	_
10	active	_	JJ	JJ	_	12	NMOD	_	_
11	tetrameric	_	JJ	JJ	_	12	NMOD	_	_
12	complexes	_	NNS	NNS	_	8	PMOD	_	_
13	and	_	CC	CC	_	6	CC	_	_
14	may	_	MD	MD	_	6	COORD	_	_
15	contribute	_	VB	VB	_	14	VC	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	developmental	_	JJ	JJ	_	19	NMOD	_	_
19	specificity	_	NN	NN	_	16	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	complex	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	Kappa	_	NN	NN	_	5	NMOD	_	_
2	B-specific	_	JJ	JJ	_	1	AMOD	_	_
3	DNA	_	NN	NN	_	5	NMOD	_	_
4	binding	_	NN	NN	_	5	NMOD	_	_
5	proteins	_	NNS	NNS	_	6	SBJ	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	differentially	_	RB	RB	_	6	ADV	_	_
8	inhibited	_	VBN	VBN	_	6	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	enhancer	_	NN	NN	_	11	NMOD	_	_
11	mutations	_	NNS	NNS	_	9	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	biological	_	JJ	JJ	_	14	NMOD	_	_
14	oxidation	_	NN	NN	_	11	COORD	_	_
15	.	_	.	.	_	6	P	_	_

1	Kappa	_	NN	NN	_	2	NMOD	_	_
2	B	_	NN	NN	_	9	NMOD	_	_
3	(	_	(	(	_	5	P	_	_
4	kappa	_	NN	NN	_	5	NMOD	_	_
5	B	_	NN	NN	_	2	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	enhancer	_	NN	NN	_	9	NMOD	_	_
8	binding	_	NN	NN	_	9	NMOD	_	_
9	proteins	_	NNS	NNS	_	19	SBJ	_	_
10	isolated	_	VBN	VBN	_	9	NMOD	_	_
11	from	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	nuclei	_	NNS	NNS	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	activated	_	VBN	VBN	_	18	NMOD	_	_
16	human	_	JJ	JJ	_	18	NMOD	_	_
17	T	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	14	PMOD	_	_
19	produce	_	VBP	VBP	_	0	ROOT-S	_	_
20	two	_	CD	CD	_	23	NMOD	_	_
21	distinct	_	JJ	JJ	_	23	NMOD	_	_
22	nucleoprotein	_	NN	NN	_	23	NMOD	_	_
23	complexes	_	NNS	NNS	_	19	OBJ	_	_
24	when	_	WRB	WRB	_	25	ADV	_	_
25	incubated	_	VBN	VBN	_	19	TMP	_	_
26	with	_	IN	IN	_	25	ADV	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	kappa	_	NN	NN	_	30	NMOD	_	_
29	B	_	NN	NN	_	30	NMOD	_	_
30	element	_	NN	NN	_	26	PMOD	_	_
31	from	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	39	NMOD	_	_
33	interleukin-2	_	NN	NN	_	34	NMOD	_	_
34	receptor-alpha	_	NN	NN	_	39	NMOD	_	_
35	(	_	(	(	_	37	P	_	_
36	IL-2R	_	NN	NN	_	37	NMOD	_	_
37	alpha	_	NN	NN	_	34	PRN	_	_
38	)	_	)	)	_	37	P	_	_
39	gene	_	NN	NN	_	31	PMOD	_	_
40	.	_	.	.	_	19	P	_	_

1	These	_	DT	DT	_	4	NMOD	_	_
2	two	_	CD	CD	_	4	NMOD	_	_
3	DNA-protein	_	JJ	JJ	_	4	NMOD	_	_
4	complexes	_	NNS	NNS	_	5	SBJ	_	_
5	are	_	VBP	VBP	_	0	ROOT-S	_	_
6	composed	_	VBN	VBN	_	5	VC	_	_
7	of	_	IN	IN	_	6	ADV	_	_
8	at	_	IN	IN	_	10	DEP	_	_
9	least	_	JJS	JJS	_	10	DEP	_	_
10	four	_	CD	CD	_	12	NMOD	_	_
11	host	_	NN	NN	_	12	NMOD	_	_
12	proteins	_	NNS	NNS	_	7	PMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	p50	_	NN	NN	_	12	PRN	_	_
15	,	_	,	,	_	14	P	_	_
16	p55	_	NN	NN	_	14	NMOD	_	_
17	,	_	,	,	_	14	P	_	_
18	p75	_	NN	NN	_	14	NMOD	_	_
19	,	_	,	,	_	14	P	_	_
20	p85	_	NN	NN	_	14	NMOD	_	_
21	)	_	)	)	_	14	P	_	_
22	,	_	,	,	_	12	P	_	_
23	each	_	DT	DT	_	24	NMOD	_	_
24	of	_	IN	IN	_	26	SBJ	_	_
25	which	_	WDT	WDT	_	24	PMOD	_	_
26	shares	_	VBZ	VBZ	_	12	NMOD	_	_
27	structural	_	JJ	JJ	_	28	NMOD	_	_
28	similarity	_	NN	NN	_	26	OBJ	_	_
29	with	_	IN	IN	_	26	ADV	_	_
30	the	_	DT	DT	_	33	NMOD	_	_
31	v-rel	_	NN	NN	_	33	NMOD	_	_
32	oncogene	_	NN	NN	_	33	NMOD	_	_
33	product	_	NN	NN	_	29	PMOD	_	_
34	.	_	.	.	_	5	P	_	_

1	Nuclear	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	these	_	DT	DT	_	5	NMOD	_	_
5	proteins	_	NNS	NNS	_	3	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	induced	_	VBN	VBN	_	6	VC	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	distinctly	_	RB	RB	_	10	AMOD	_	_
10	biphasic	_	JJ	JJ	_	11	NMOD	_	_
11	kinetics	_	NNS	NNS	_	8	PMOD	_	_
12	following	_	VBG	VBG	_	7	TMP	_	_
13	phorbol	_	NN	NN	_	15	NMOD	_	_
14	ester	_	NN	NN	_	15	NMOD	_	_
15	activation	_	NN	NN	_	12	PMOD	_	_
16	of	_	IN	IN	_	12	PMOD	_	_
17	T	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	16	PMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	p55\/p75	_	NN	NN	_	18	PRN	_	_
21	early	_	JJ	JJ	_	20	NMOD	_	_
22	and	_	CC	CC	_	20	CC	_	_
23	p50\/p85	_	NN	NN	_	20	COORD	_	_
24	late	_	JJ	JJ	_	23	NMOD	_	_
25	)	_	)	)	_	20	P	_	_
26	.	_	.	.	_	6	P	_	_

1	DNA-protein	_	JJ	JJ	_	3	NMOD	_	_
2	crosslinking	_	NN	NN	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	4	SBJ	_	_
4	have	_	VBP	VBP	_	0	ROOT-S	_	_
5	revealed	_	VBN	VBN	_	4	VC	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	the	_	DT	DT	_	12	NMOD	_	_
8	more	_	RBR	RBR	_	9	AMOD	_	_
9	rapidly	_	RB	RB	_	12	NMOD	_	_
10	migrating	_	VBG	VBG	_	9	AMOD	_	_
11	B2	_	NN	NN	_	12	NMOD	_	_
12	complex	_	NN	NN	_	13	SBJ	_	_
13	contains	_	VBZ	VBZ	_	6	VMOD	_	_
14	both	_	CC	CC	_	15	CC	_	_
15	p50	_	NN	NN	_	13	IOBJ	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	p55	_	NN	NN	_	15	COORD	_	_
18	while	_	IN	IN	_	13	OBJ	_	_
19	the	_	DT	DT	_	24	NMOD	_	_
20	more	_	RBR	RBR	_	21	AMOD	_	_
21	slowly	_	RB	RB	_	24	NMOD	_	_
22	migrating	_	VBG	VBG	_	21	AMOD	_	_
23	B1	_	NN	NN	_	24	NMOD	_	_
24	complex	_	NN	NN	_	25	SBJ	_	_
25	is	_	VBZ	VBZ	_	18	VMOD	_	_
26	composed	_	VBN	VBN	_	25	VC	_	_
27	of	_	IN	IN	_	26	ADV	_	_
28	p50	_	NN	NN	_	27	PMOD	_	_
29	,	_	,	,	_	28	P	_	_
30	p55	_	NN	NN	_	28	COORD	_	_
31	,	_	,	,	_	28	P	_	_
32	p75	_	NN	NN	_	28	COORD	_	_
33	,	_	,	,	_	28	P	_	_
34	and	_	CC	CC	_	28	CC	_	_
35	p85	_	NN	NN	_	28	COORD	_	_
36	.	_	.	.	_	4	P	_	_

1	Site-directed	_	JJ	JJ	_	2	NMOD	_	_
2	mutagenesis	_	NN	NN	_	14	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	10	NMOD	_	_
5	wild-type	_	JJ	JJ	_	10	NMOD	_	_
6	IL-2R	_	NN	NN	_	10	NMOD	_	_
7	alpha	_	NN	NN	_	10	NMOD	_	_
8	kappa	_	NN	NN	_	10	NMOD	_	_
9	B	_	NN	NN	_	10	NMOD	_	_
10	enhancer	_	NN	NN	_	3	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	GGGGAATCTCCC	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	revealed	_	VBN	VBN	_	14	VC	_	_
16	that	_	IN	IN	_	15	OBJ	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	binding	_	NN	NN	_	27	SBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	p50	_	NN	NN	_	19	PMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	p55	_	NN	NN	_	20	COORD	_	_
23	(	_	(	(	_	25	P	_	_
24	B2	_	NN	NN	_	25	NMOD	_	_
25	complex	_	NN	NN	_	20	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	is	_	VBZ	VBZ	_	16	VMOD	_	_
28	particularly	_	RB	RB	_	29	AMOD	_	_
29	sensitive	_	JJ	JJ	_	27	PRD	_	_
30	to	_	TO	TO	_	29	AMOD	_	_
31	alteration	_	NN	NN	_	30	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	the	_	DT	DT	_	35	NMOD	_	_
34	5'	_	JJ	JJ	_	35	NMOD	_	_
35	triplet	_	NN	NN	_	32	PMOD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	deoxyguanosine	_	NN	NN	_	38	NMOD	_	_
38	residues	_	NNS	NNS	_	36	PMOD	_	_
39	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	19	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	19	P	_	_
4	formation	_	NN	NN	_	19	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	B1	_	NN	NN	_	8	NMOD	_	_
8	complex	_	NN	NN	_	5	PMOD	_	_
9	,	_	,	,	_	4	P	_	_
10	reflecting	_	VBG	VBG	_	4	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	binding	_	NN	NN	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	p75	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	p85	_	NN	NN	_	14	COORD	_	_
17	,	_	,	,	_	4	P	_	_
18	critically	_	RB	RB	_	19	ADV	_	_
19	depends	_	VBZ	VBZ	_	0	ROOT-S	_	_
20	upon	_	IN	IN	_	19	ADV	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	more	_	RBR	RBR	_	24	NMOD	_	_
23	3'	_	JJ	JJ	_	24	NMOD	_	_
24	sequences	_	NNS	NNS	_	20	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	this	_	DT	DT	_	28	NMOD	_	_
27	enhancer	_	NN	NN	_	28	NMOD	_	_
28	element	_	NN	NN	_	25	PMOD	_	_
29	.	_	.	.	_	19	P	_	_

1	DNA	_	NN	NN	_	2	NMOD	_	_
2	binding	_	NN	NN	_	10	SBJ	_	_
3	by	_	IN	IN	_	2	NMOD	_	_
4	all	_	DT	DT	_	5	NMOD	_	_
5	four	_	CD	CD	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	these	_	DT	DT	_	9	NMOD	_	_
8	Rel-related	_	JJ	JJ	_	9	NMOD	_	_
9	factors	_	NNS	NNS	_	6	PMOD	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	blocked	_	VBN	VBN	_	10	VC	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	selective	_	JJ	JJ	_	15	NMOD	_	_
14	chemical	_	JJ	JJ	_	15	NMOD	_	_
15	modification	_	NN	NN	_	12	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	lysine	_	NN	NN	_	20	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	arginine	_	NN	NN	_	17	COORD	_	_
20	residues	_	NNS	NNS	_	16	PMOD	_	_
21	,	_	,	,	_	11	P	_	_
22	suggesting	_	VBG	VBG	_	11	OBJ	_	_
23	that	_	IN	IN	_	22	OBJ	_	_
24	both	_	DT	DT	_	30	SBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	these	_	DT	DT	_	29	NMOD	_	_
27	basic	_	JJ	JJ	_	29	NMOD	_	_
28	amino	_	NN	NN	_	29	NMOD	_	_
29	acids	_	NNS	NNS	_	25	PMOD	_	_
30	are	_	VBP	VBP	_	23	VMOD	_	_
31	required	_	VBN	VBN	_	30	VC	_	_
32	for	_	IN	IN	_	31	ADV	_	_
33	binding	_	VBG	VBG	_	32	PMOD	_	_
34	to	_	TO	TO	_	33	ADV	_	_
35	the	_	DT	DT	_	38	NMOD	_	_
36	kappa	_	NN	NN	_	38	NMOD	_	_
37	B	_	NN	NN	_	38	NMOD	_	_
38	element	_	NN	NN	_	34	PMOD	_	_
39	.	_	.	.	_	10	P	_	_

1	Similarly	_	RB	RB	_	19	ADV	_	_
2	,	_	,	,	_	19	P	_	_
3	covalent	_	JJ	JJ	_	4	NMOD	_	_
4	modification	_	NN	NN	_	19	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	free	_	JJ	JJ	_	8	NMOD	_	_
7	sulfhydryl	_	NN	NN	_	8	NMOD	_	_
8	groups	_	NNS	NNS	_	5	PMOD	_	_
9	with	_	IN	IN	_	4	NMOD	_	_
10	diamide	_	NN	NN	_	9	PMOD	_	_
11	(	_	(	(	_	10	PRN	_	_
12	reversible	_	JJ	JJ	_	11	DEP	_	_
13	)	_	)	)	_	11	P	_	_
14	or	_	CC	CC	_	10	CC	_	_
15	N-ethylmaleimide	_	NN	NN	_	10	COORD	_	_
16	(	_	(	(	_	15	PRN	_	_
17	irreversible	_	JJ	JJ	_	16	DEP	_	_
18	)	_	)	)	_	16	P	_	_
19	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	complete	_	JJ	JJ	_	23	NMOD	_	_
23	loss	_	NN	NN	_	20	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	DNA	_	NN	NN	_	27	NMOD	_	_
26	binding	_	NN	NN	_	27	NMOD	_	_
27	activity	_	NN	NN	_	24	PMOD	_	_
28	.	_	.	.	_	19	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	10	P	_	_
4	mild	_	JJ	JJ	_	5	NMOD	_	_
5	oxidation	_	NN	NN	_	10	SBJ	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	glucose	_	NN	NN	_	8	NMOD	_	_
8	oxidase	_	NN	NN	_	6	PMOD	_	_
9	selectively	_	RB	RB	_	10	ADV	_	_
10	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	p75	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	p85	_	NN	NN	_	11	COORD	_	_
14	binding	_	NN	NN	_	10	IOBJ	_	_
15	while	_	IN	IN	_	10	OBJ	_	_
16	not	_	RB	RB	_	17	VMOD	_	_
17	blocking	_	VBG	VBG	_	15	VMOD	_	_
18	p50	_	NN	NN	_	21	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	p55	_	NN	NN	_	18	COORD	_	_
21	interactions	_	NNS	NNS	_	17	OBJ	_	_
22	.	_	.	.	_	10	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	reduced	_	VBN	VBN	_	7	NMOD	_	_
6	cysteine	_	NN	NN	_	7	NMOD	_	_
7	thiols	_	NNS	NNS	_	8	SBJ	_	_
8	play	_	VBP	VBP	_	4	VMOD	_	_
9	an	_	DT	DT	_	11	NMOD	_	_
10	important	_	JJ	JJ	_	11	NMOD	_	_
11	role	_	NN	NN	_	8	OBJ	_	_
12	in	_	IN	IN	_	8	ADV	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	DNA	_	NN	NN	_	16	NMOD	_	_
15	binding	_	NN	NN	_	16	NMOD	_	_
16	activity	_	NN	NN	_	12	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	this	_	DT	DT	_	19	NMOD	_	_
19	family	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	Rel-related	_	JJ	JJ	_	23	NMOD	_	_
22	transcription	_	NN	NN	_	23	NMOD	_	_
23	factors	_	NNS	NNS	_	20	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	A	_	DT	DT	_	5	NMOD	_	_
2	novel	_	JJ	JJ	_	5	NMOD	_	_
3	primer	_	NN	NN	_	5	NMOD	_	_
4	extension	_	NN	NN	_	5	NMOD	_	_
5	method	_	NN	NN	_	0	ROOT-FRAG	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	detect	_	VB	VB	_	5	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	number	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	CAG	_	NN	NN	_	12	NMOD	_	_
12	repeats	_	NNS	NNS	_	10	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	androgen	_	NN	NN	_	17	NMOD	_	_
16	receptor	_	NN	NN	_	17	NMOD	_	_
17	gene	_	NN	NN	_	13	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	families	_	NNS	NNS	_	18	PMOD	_	_
20	with	_	IN	IN	_	19	NMOD	_	_
21	X-linked	_	JJ	JJ	_	26	NMOD	_	_
22	spinal	_	JJ	JJ	_	26	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	bulbar	_	JJ	JJ	_	22	COORD	_	_
25	muscular	_	JJ	JJ	_	26	NMOD	_	_
26	atrophy	_	NN	NN	_	20	PMOD	_	_
27	.	_	.	.	_	5	P	_	_

1	X-linked	_	JJ	JJ	_	6	NMOD	_	_
2	spinal	_	JJ	JJ	_	6	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	bulbar	_	JJ	JJ	_	2	COORD	_	_
5	muscular	_	JJ	JJ	_	6	NMOD	_	_
6	atrophy	_	NN	NN	_	19	SBJ	_	_
7	(	_	(	(	_	8	P	_	_
8	SBMA	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	,	_	,	,	_	6	P	_	_
11	an	_	DT	DT	_	13	NMOD	_	_
12	adult-onset	_	JJ	JJ	_	13	NMOD	_	_
13	form	_	NN	NN	_	6	NMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	motor	_	NN	NN	_	17	NMOD	_	_
16	neuron	_	NN	NN	_	17	NMOD	_	_
17	disease	_	NN	NN	_	14	PMOD	_	_
18	,	_	,	,	_	6	P	_	_
19	was	_	VBD	VBD	_	0	ROOT-S	_	_
20	recently	_	RB	RB	_	19	TMP	_	_
21	reported	_	VBN	VBN	_	19	VC	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	be	_	VB	VB	_	21	OBJ	_	_
24	caused	_	VBN	VBN	_	23	VC	_	_
25	by	_	IN	IN	_	24	LGS	_	_
26	amplification	_	NN	NN	_	25	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	CAG	_	NN	NN	_	30	NMOD	_	_
30	repeats	_	NNS	NNS	_	27	PMOD	_	_
31	in	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	35	NMOD	_	_
33	androgen	_	NN	NN	_	35	NMOD	_	_
34	receptor	_	NN	NN	_	35	NMOD	_	_
35	gene	_	NN	NN	_	31	PMOD	_	_
36	.	_	.	.	_	19	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	a	_	DT	DT	_	8	NMOD	_	_
5	simple	_	JJ	JJ	_	8	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	rapid	_	JJ	JJ	_	5	COORD	_	_
8	strategy	_	NN	NN	_	2	OBJ	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	detect	_	VB	VB	_	8	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	precise	_	JJ	JJ	_	13	NMOD	_	_
13	number	_	NN	NN	_	10	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	CAGs	_	NNS	NNS	_	14	PMOD	_	_
17	.	_	.	.	_	2	P	_	_

1	After	_	IN	IN	_	20	TMP	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	DNA	_	NN	NN	_	4	NMOD	_	_
4	fragment	_	NN	NN	_	9	SBJ	_	_
5	containing	_	VBG	VBG	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	CAG	_	NN	NN	_	8	NMOD	_	_
8	repeats	_	NNS	NNS	_	5	OBJ	_	_
9	is	_	VBZ	VBZ	_	1	VMOD	_	_
10	amplified	_	VBN	VBN	_	9	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	polymerase	_	NN	NN	_	15	NMOD	_	_
14	chain	_	NN	NN	_	15	NMOD	_	_
15	reaction	_	NN	NN	_	11	PMOD	_	_
16	,	_	,	,	_	20	P	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	primer	_	NN	NN	_	19	NMOD	_	_
19	extension	_	NN	NN	_	20	SBJ	_	_
20	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
21	carried	_	VBN	VBN	_	20	VC	_	_
22	out	_	RP	RP	_	21	PRT	_	_
23	;	_	:	:	_	20	P	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	extension	_	NN	NN	_	38	SBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	end-labelled	_	JJ	JJ	_	30	NMOD	_	_
29	reverse	_	JJ	JJ	_	30	NMOD	_	_
30	primer	_	NN	NN	_	26	PMOD	_	_
31	adjacent	_	JJ	JJ	_	30	NMOD	_	_
32	to	_	TO	TO	_	31	AMOD	_	_
33	3'	_	JJ	JJ	_	34	NMOD	_	_
34	end	_	NN	NN	_	32	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	CAG	_	NN	NN	_	37	NMOD	_	_
37	repeats	_	NNS	NNS	_	35	PMOD	_	_
38	stops	_	VBZ	VBZ	_	20	VC	_	_
39	at	_	IN	IN	_	38	ADV	_	_
40	the	_	DT	DT	_	42	NMOD	_	_
41	first	_	JJ	JJ	_	42	NMOD	_	_
42	T	_	NN	NN	_	39	PMOD	_	_
43	after	_	IN	IN	_	42	TMP	_	_
44	CAG	_	NN	NN	_	45	NMOD	_	_
45	repeats	_	NNS	NNS	_	43	PMOD	_	_
46	with	_	IN	IN	_	38	ADV	_	_
47	the	_	DT	DT	_	48	NMOD	_	_
48	incorporation	_	NN	NN	_	46	PMOD	_	_
49	of	_	IN	IN	_	48	NMOD	_	_
50	dideoxy	_	JJ	JJ	_	51	NMOD	_	_
51	ATP	_	NN	NN	_	49	PMOD	_	_
52	in	_	IN	IN	_	48	NMOD	_	_
53	the	_	DT	DT	_	55	NMOD	_	_
54	reaction	_	NN	NN	_	55	NMOD	_	_
55	mixture	_	NN	NN	_	52	PMOD	_	_
56	.	_	.	.	_	38	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	resultant	_	JJ	JJ	_	4	NMOD	_	_
3	primer	_	NN	NN	_	4	NMOD	_	_
4	products	_	NNS	NNS	_	5	SBJ	_	_
5	are	_	VBP	VBP	_	0	ROOT-S	_	_
6	analysed	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	ADV	_	_
8	denaturing	_	VBG	VBG	_	7	PMOD	_	_
9	polyacrylamide	_	NN	NN	_	11	NMOD	_	_
10	gel	_	NN	NN	_	11	NMOD	_	_
11	electrophoresis	_	NN	NN	_	8	OBJ	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	autoradiography	_	NN	NN	_	11	COORD	_	_
14	.	_	.	.	_	5	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	method	_	NN	NN	_	3	SBJ	_	_
3	could	_	MD	MD	_	0	ROOT-S	_	_
4	be	_	VB	VB	_	3	VC	_	_
5	quite	_	RB	RB	_	6	AMOD	_	_
6	useful	_	JJ	JJ	_	4	PRD	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	detect	_	VB	VB	_	6	AMOD	_	_
9	not	_	RB	RB	_	12	CC	_	_
10	only	_	RB	RB	_	9	DEP	_	_
11	CAG	_	NN	NN	_	12	NMOD	_	_
12	repeats	_	NNS	NNS	_	8	OBJ	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	SBMA	_	NN	NN	_	13	PMOD	_	_
15	but	_	CC	CC	_	12	CC	_	_
16	also	_	RB	RB	_	15	COORD	_	_
17	other	_	JJ	JJ	_	22	NMOD	_	_
18	polymorphic	_	JJ	JJ	_	22	NMOD	_	_
19	dinucleotide	_	JJ	JJ	_	22	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	trinucleotide	_	JJ	JJ	_	19	COORD	_	_
22	repeats	_	NNS	NNS	_	12	COORD	_	_
23	.	_	.	.	_	3	P	_	_

1	Stimulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	interferon	_	NN	NN	_	6	NMOD	_	_
4	beta	_	NN	NN	_	6	NMOD	_	_
5	gene	_	NN	NN	_	6	NMOD	_	_
6	transcription	_	NN	NN	_	2	PMOD	_	_
7	in	_	FW	FW	_	6	NMOD	_	_
8	vitro	_	FW	FW	_	7	AMOD	_	_
9	by	_	IN	IN	_	1	NMOD	_	_
10	purified	_	VBN	VBN	_	12	NMOD	_	_
11	NF-kappa	_	NN	NN	_	12	NMOD	_	_
12	B	_	NN	NN	_	9	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	a	_	DT	DT	_	17	NMOD	_	_
15	novel	_	JJ	JJ	_	17	NMOD	_	_
16	TH	_	NN	NN	_	17	NMOD	_	_
17	protein	_	NN	NN	_	12	COORD	_	_
18	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	9	NMOD	_	_
2	human	_	JJ	JJ	_	9	NMOD	_	_
3	interferon	_	NN	NN	_	4	NMOD	_	_
4	beta	_	NN	NN	_	9	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	IFN-beta	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	regulatory	_	JJ	JJ	_	9	NMOD	_	_
9	element	_	NN	NN	_	10	SBJ	_	_
10	consists	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	of	_	IN	IN	_	10	ADV	_	_
12	multiple	_	JJ	JJ	_	14	NMOD	_	_
13	enhanson	_	NN	NN	_	14	NMOD	_	_
14	domains	_	NNS	NNS	_	11	PMOD	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	are	_	VBP	VBP	_	14	NMOD	_	_
17	targets	_	NNS	NNS	_	16	PRD	_	_
18	for	_	IN	IN	_	17	NMOD	_	_
19	transcription	_	NN	NN	_	20	NMOD	_	_
20	factors	_	NNS	NNS	_	18	PMOD	_	_
21	involved	_	VBN	VBN	_	20	NMOD	_	_
22	in	_	IN	IN	_	21	ADV	_	_
23	inducible	_	JJ	JJ	_	24	NMOD	_	_
24	expression	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	promoter	_	NN	NN	_	25	PMOD	_	_
28	.	_	.	.	_	10	P	_	_

1	To	_	TO	TO	_	3	VMOD	_	_
2	further	_	RB	RB	_	3	ADV	_	_
3	characterize	_	VB	VB	_	20	ADV	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	protein-DNA	_	JJ	JJ	_	6	NMOD	_	_
6	interactions	_	NNS	NNS	_	3	OBJ	_	_
7	mediating	_	VBG	VBG	_	6	NMOD	_	_
8	IFN-beta	_	NN	NN	_	9	NMOD	_	_
9	induction	_	NN	NN	_	7	OBJ	_	_
10	,	_	,	,	_	20	P	_	_
11	positive	_	JJ	JJ	_	13	NMOD	_	_
12	regulatory	_	JJ	JJ	_	13	NMOD	_	_
13	domain	_	NN	NN	_	19	NMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	PRD	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	II	_	CD	CD	_	19	NMOD	_	_
18	binding	_	NN	NN	_	19	NMOD	_	_
19	proteins	_	NNS	NNS	_	20	SBJ	_	_
20	were	_	VBD	VBD	_	0	ROOT-S	_	_
21	purified	_	VBN	VBN	_	20	VC	_	_
22	from	_	IN	IN	_	21	ADV	_	_
23	phorbol	_	NN	NN	_	24	NMOD	_	_
24	ester	_	NN	NN	_	25	AMOD	_	_
25	induced	_	JJ	JJ	_	27	NMOD	_	_
26	Jurkat	_	NN	NN	_	27	NMOD	_	_
27	T-cells	_	NNS	NNS	_	22	PMOD	_	_
28	and	_	CC	CC	_	22	CC	_	_
29	from	_	IN	IN	_	22	COORD	_	_
30	IFN	_	NN	NN	_	31	AMOD	_	_
31	primed	_	VBN	VBN	_	29	PMOD	_	_
32	,	_	,	,	_	31	P	_	_
33	cycloheximide\/polyinosinic-polycytidylic	_	JJ	JJ	_	34	NMOD	_	_
34	acid	_	NN	NN	_	35	AMOD	_	_
35	treated	_	VBN	VBN	_	31	COORD	_	_
36	HeLa	_	NN	NN	_	29	PMOD	_	_
37	S3	_	NN	NN	_	29	PMOD	_	_
38	cells	_	NNS	NNS	_	29	PMOD	_	_
39	.	_	.	.	_	20	P	_	_

1	From	_	IN	IN	_	16	ADV	_	_
2	HeLa	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	16	P	_	_
5	two	_	CD	CD	_	7	NMOD	_	_
6	major	_	JJ	JJ	_	7	NMOD	_	_
7	proteins	_	NNS	NNS	_	16	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	52	_	CD	CD	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	45	_	CD	CD	_	9	COORD	_	_
12	kilodaltons	_	NNS	NNS	_	8	PMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	kD	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	copurified	_	VBD	VBD	_	0	ROOT-S	_	_
17	with	_	IN	IN	_	16	ADV	_	_
18	DNA	_	NN	NN	_	20	NMOD	_	_
19	binding	_	NN	NN	_	20	NMOD	_	_
20	activity	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	16	P	_	_
22	whereas	_	IN	IN	_	16	COORD	_	_
23	from	_	IN	IN	_	48	ADV	_	_
24	T-cells	_	NNS	NNS	_	23	PMOD	_	_
25	,	_	,	,	_	48	P	_	_
26	four	_	CD	CD	_	27	NMOD	_	_
27	proteins	_	NNS	NNS	_	48	SBJ	_	_
28	--	_	:	:	_	27	P	_	_
29	a	_	DT	DT	_	31	NMOD	_	_
30	major	_	JJ	JJ	_	31	NMOD	_	_
31	protein	_	NN	NN	_	27	NMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	52	_	CD	CD	_	34	NMOD	_	_
34	kD	_	NN	NN	_	32	PMOD	_	_
35	and	_	CC	CC	_	31	CC	_	_
36	three	_	CD	CD	_	38	NMOD	_	_
37	minor	_	JJ	JJ	_	38	NMOD	_	_
38	proteins	_	NNS	NNS	_	31	COORD	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	82	_	CD	CD	_	46	NMOD	_	_
41	,	_	,	,	_	40	P	_	_
42	67	_	CD	CD	_	40	COORD	_	_
43	,	_	,	,	_	40	P	_	_
44	and	_	CC	CC	_	40	CC	_	_
45	43-47	_	CD	CD	_	40	COORD	_	_
46	kD	_	NN	NN	_	39	PMOD	_	_
47	--	_	:	:	_	27	P	_	_
48	were	_	VBD	VBD	_	16	COORD	_	_
49	purified	_	VBN	VBN	_	48	VC	_	_
50	.	_	.	.	_	16	P	_	_

1	Also	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	an	_	DT	DT	_	8	NMOD	_	_
4	induction	_	NN	NN	_	5	AMOD	_	_
5	specific	_	JJ	JJ	_	8	NMOD	_	_
6	DNA	_	NN	NN	_	8	NMOD	_	_
7	binding	_	NN	NN	_	8	NMOD	_	_
8	protein	_	NN	NN	_	9	SBJ	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	purified	_	VBN	VBN	_	9	VC	_	_
11	from	_	IN	IN	_	10	ADV	_	_
12	HeLa	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	interacted	_	VBD	VBD	_	13	NMOD	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	the	_	DT	DT	_	23	NMOD	_	_
18	(	_	(	(	_	23	P	_	_
19	AAGTGA	_	NN	NN	_	23	NMOD	_	_
20	)	_	)	)	_	23	P	_	_
21	4	_	CD	CD	_	23	NMOD	_	_
22	tetrahexamer	_	NN	NN	_	23	NMOD	_	_
23	sequence	_	NN	NN	_	16	PMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	PRDI	_	NN	NN	_	27	NMOD	_	_
27	domain	_	NN	NN	_	23	COORD	_	_
28	.	_	.	.	_	9	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	protein	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	immunologically	_	RB	RB	_	5	AMOD	_	_
5	distinct	_	JJ	JJ	_	3	PRD	_	_
6	from	_	IN	IN	_	5	AMOD	_	_
7	IRF-1\/ISGF2	_	NN	NN	_	6	PMOD	_	_
8	.	_	.	.	_	3	P	_	_

1	Uninduced	_	JJ	JJ	_	7	NMOD	_	_
2	or	_	CC	CC	_	1	CC	_	_
3	Sendai	_	NN	NN	_	4	NMOD	_	_
4	virus	_	NN	NN	_	5	AMOD	_	_
5	induced	_	JJ	JJ	_	1	COORD	_	_
6	HeLa	_	NN	NN	_	7	NMOD	_	_
7	extracts	_	NNS	NNS	_	8	SBJ	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	used	_	VBN	VBN	_	8	VC	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	examine	_	VB	VB	_	9	OBJ	_	_
12	transcription	_	NN	NN	_	11	IOBJ	_	_
13	in	_	FW	FW	_	11	ADV	_	_
14	vitro	_	FW	FW	_	13	AMOD	_	_
15	using	_	VBG	VBG	_	11	OBJ	_	_
16	a	_	DT	DT	_	17	NMOD	_	_
17	series	_	NN	NN	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	IFN	_	NN	NN	_	22	NMOD	_	_
20	beta	_	NN	NN	_	22	NMOD	_	_
21	promoter	_	NN	NN	_	22	NMOD	_	_
22	deletions	_	NNS	NNS	_	18	PMOD	_	_
23	.	_	.	.	_	8	P	_	_

1	Deletions	_	NNS	NNS	_	7	SBJ	_	_
2	upstream	_	JJ	JJ	_	1	NMOD	_	_
3	of	_	IN	IN	_	2	AMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	PRDII	_	NN	NN	_	6	NMOD	_	_
6	element	_	NN	NN	_	3	PMOD	_	_
7	increased	_	VBD	VBD	_	0	ROOT-S	_	_
8	transcription	_	NN	NN	_	7	IOBJ	_	_
9	in	_	IN	IN	_	7	ADV	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	uninduced	_	JJ	JJ	_	12	NMOD	_	_
12	extract	_	NN	NN	_	9	PMOD	_	_
13	,	_	,	,	_	7	P	_	_
14	indicating	_	VBG	VBG	_	7	OBJ	_	_
15	predominantly	_	RB	RB	_	16	AMOD	_	_
16	negative	_	JJ	JJ	_	17	NMOD	_	_
17	regulation	_	NN	NN	_	14	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	promoter	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	7	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	2-4-fold	_	JJ	JJ	_	3	NMOD	_	_
3	increase	_	NN	NN	_	8	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	IFN-beta	_	NN	NN	_	7	NMOD	_	_
6	promoter	_	NN	NN	_	7	NMOD	_	_
7	transcription	_	NN	NN	_	4	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	observed	_	VBN	VBN	_	8	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	Sendai	_	NN	NN	_	12	NMOD	_	_
12	virus	_	NN	NN	_	13	AMOD	_	_
13	induced	_	JJ	JJ	_	14	NMOD	_	_
14	extracts	_	NNS	NNS	_	10	PMOD	_	_
15	,	_	,	,	_	8	P	_	_
16	and	_	CC	CC	_	8	CC	_	_
17	deletion	_	NN	NN	_	23	SBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	PRDI	_	NN	NN	_	22	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	PRDII	_	NN	NN	_	19	COORD	_	_
22	elements	_	NNS	NNS	_	18	PMOD	_	_
23	decreased	_	VBD	VBD	_	8	COORD	_	_
24	this	_	DT	DT	_	26	NMOD	_	_
25	induced	_	VBN	VBN	_	26	NMOD	_	_
26	level	_	NN	NN	_	23	OBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	transcription	_	NN	NN	_	27	PMOD	_	_
29	.	_	.	.	_	8	P	_	_

1	When	_	WRB	WRB	_	9	ADV	_	_
2	purified	_	VBN	VBN	_	3	NMOD	_	_
3	PRDII	_	NN	NN	_	8	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	tetrahexamer	_	NN	NN	_	7	NMOD	_	_
6	binding	_	NN	NN	_	7	NMOD	_	_
7	proteins	_	NNS	NNS	_	3	COORD	_	_
8	were	_	VBD	VBD	_	20	TMP	_	_
9	added	_	VBN	VBN	_	8	VC	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	induced	_	VBN	VBN	_	13	NMOD	_	_
13	extract	_	NN	NN	_	10	PMOD	_	_
14	,	_	,	,	_	20	P	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	4-fold	_	JJ	JJ	_	17	NMOD	_	_
17	increase	_	NN	NN	_	20	SBJ	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	transcription	_	NN	NN	_	18	PMOD	_	_
20	was	_	VBD	VBD	_	0	ROOT-S	_	_
21	observed	_	VBN	VBN	_	20	VC	_	_
22	.	_	.	.	_	20	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	experiments	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	it	_	PRP	PRP	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	4	VMOD	_	_
7	possible	_	JJ	JJ	_	6	PRD	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	modulate	_	VB	VB	_	6	EXP	_	_
10	IFN-beta	_	NN	NN	_	11	NMOD	_	_
11	transcription	_	NN	NN	_	9	OBJ	_	_
12	in	_	FW	FW	_	9	ADV	_	_
13	vitro	_	FW	FW	_	12	AMOD	_	_
14	but	_	CC	CC	_	3	CC	_	_
15	indicate	_	VBP	VBP	_	3	COORD	_	_
16	that	_	IN	IN	_	15	OBJ	_	_
17	additional	_	JJ	JJ	_	18	NMOD	_	_
18	proteins	_	NNS	NNS	_	19	SBJ	_	_
19	may	_	MD	MD	_	16	VMOD	_	_
20	be	_	VB	VB	_	19	VC	_	_
21	required	_	VBN	VBN	_	20	VC	_	_
22	to	_	TO	TO	_	24	VMOD	_	_
23	fully	_	RB	RB	_	24	ADV	_	_
24	activate	_	VB	VB	_	21	OBJ	_	_
25	IFN-beta	_	NN	NN	_	26	NMOD	_	_
26	transcription	_	NN	NN	_	24	OBJ	_	_
27	.	_	.	.	_	3	P	_	_

1	Cortisol	_	NN	NN	_	2	NMOD	_	_
2	resistance	_	NN	NN	_	0	ROOT-FRAG	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	acquired	_	VBN	VBN	_	6	NMOD	_	_
5	immunodeficiency	_	NN	NN	_	6	NMOD	_	_
6	syndrome	_	NN	NN	_	3	PMOD	_	_
7	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	study	_	NN	NN	_	3	SBJ	_	_
3	concerns	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	9	_	CD	CD	_	7	NMOD	_	_
5	iv	_	NN	NN	_	7	NMOD	_	_
6	drug	_	NN	NN	_	7	NMOD	_	_
7	abusers	_	NNS	NNS	_	3	IOBJ	_	_
8	with	_	IN	IN	_	3	ADV	_	_
9	acquired	_	VBN	VBN	_	11	NMOD	_	_
10	immunodeficiency	_	NN	NN	_	11	NMOD	_	_
11	syndrome	_	NN	NN	_	8	PMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	AIDS	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	who	_	WP	WP	_	16	SBJ	_	_
16	developed	_	VBD	VBD	_	3	OBJ	_	_
17	hypercortisolism	_	NN	NN	_	16	OBJ	_	_
18	without	_	IN	IN	_	16	ADV	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	clinical	_	JJ	JJ	_	21	NMOD	_	_
21	signs	_	NNS	NNS	_	18	PMOD	_	_
22	or	_	CC	CC	_	21	CC	_	_
23	metabolic	_	JJ	JJ	_	24	NMOD	_	_
24	consequences	_	NNS	NNS	_	21	COORD	_	_
25	of	_	IN	IN	_	21	NMOD	_	_
26	hypercortisolism	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	3	P	_	_

1	All	_	DT	DT	_	2	NMOD	_	_
2	patients	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	characterized	_	VBN	VBN	_	3	VC	_	_
5	by	_	IN	IN	_	4	ADV	_	_
6	an	_	DT	DT	_	8	NMOD	_	_
7	Addisonian	_	JJ	JJ	_	8	NMOD	_	_
8	picture	_	NN	NN	_	5	PMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	weakness	_	NN	NN	_	8	PRN	_	_
11	,	_	,	,	_	10	P	_	_
12	weight	_	NN	NN	_	13	NMOD	_	_
13	loss	_	NN	NN	_	10	COORD	_	_
14	,	_	,	,	_	10	P	_	_
15	hypotension	_	NN	NN	_	10	COORD	_	_
16	,	_	,	,	_	10	P	_	_
17	hyponatremia	_	NN	NN	_	10	COORD	_	_
18	,	_	,	,	_	10	P	_	_
19	and	_	CC	CC	_	10	CC	_	_
20	intense	_	JJ	JJ	_	22	NMOD	_	_
21	mucocutaneous	_	JJ	JJ	_	22	NMOD	_	_
22	melanosis	_	NN	NN	_	10	COORD	_	_
23	)	_	)	)	_	10	P	_	_
24	.	_	.	.	_	3	P	_	_

1	An	_	DT	DT	_	3	NMOD	_	_
2	acquired	_	JJ	JJ	_	3	NMOD	_	_
3	form	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	peripheral	_	JJ	JJ	_	6	NMOD	_	_
6	resistance	_	NN	NN	_	4	PMOD	_	_
7	to	_	TO	TO	_	6	NMOD	_	_
8	glucocorticoids	_	NNS	NNS	_	7	PMOD	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	suspected	_	VBN	VBN	_	9	VC	_	_
11	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	5	SBJ	_	_
2	,	_	,	,	_	5	P	_	_
3	therefore	_	RB	RB	_	5	ADV	_	_
4	,	_	,	,	_	5	P	_	_
5	examined	_	VBD	VBD	_	0	ROOT-S	_	_
6	glucocorticoid	_	NN	NN	_	8	NMOD	_	_
7	receptor	_	NN	NN	_	8	NMOD	_	_
8	characteristics	_	NNS	NNS	_	5	OBJ	_	_
9	on	_	IN	IN	_	8	NMOD	_	_
10	mononuclear	_	JJ	JJ	_	11	NMOD	_	_
11	leukocytes	_	NNS	NNS	_	9	PMOD	_	_
12	by	_	IN	IN	_	5	ADV	_	_
13	measuring	_	VBG	VBG	_	12	PMOD	_	_
14	-LCB-3H-RCB-dexamethasone	_	NN	NN	_	15	NMOD	_	_
15	binding	_	NN	NN	_	13	OBJ	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	effect	_	NN	NN	_	15	COORD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	dexamethasone	_	NN	NN	_	19	PMOD	_	_
21	on	_	IN	IN	_	18	NMOD	_	_
22	-LCB-3H-RCB-thymidine	_	NN	NN	_	23	NMOD	_	_
23	incorporation	_	NN	NN	_	21	PMOD	_	_
24	,	_	,	,	_	23	P	_	_
25	which	_	WDT	WDT	_	26	SBJ	_	_
26	is	_	VBZ	VBZ	_	23	NMOD	_	_
27	one	_	CD	CD	_	26	PRD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	effects	_	NNS	NNS	_	28	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	glucocorticoid	_	NN	NN	_	34	NMOD	_	_
33	receptor	_	NN	NN	_	34	NMOD	_	_
34	activation	_	NN	NN	_	31	PMOD	_	_
35	.	_	.	.	_	5	P	_	_

1	Glucocorticoid	_	NN	NN	_	3	NMOD	_	_
2	receptor	_	NN	NN	_	3	NMOD	_	_
3	density	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	increased	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	AIDS	_	NN	NN	_	8	NMOD	_	_
8	patients	_	NNS	NNS	_	6	PMOD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	an	_	DT	DT	_	12	NMOD	_	_
11	Addisonian	_	JJ	JJ	_	12	NMOD	_	_
12	picture	_	NN	NN	_	9	PMOD	_	_
13	(	_	(	(	_	8	PRN	_	_
14	group	_	NN	NN	_	13	DEP	_	_
15	1	_	CD	CD	_	14	NMOD	_	_
16	;	_	:	:	_	14	P	_	_
17	16.2	_	CD	CD	_	21	NMOD	_	_
18	+\/-	_	CC	CC	_	17	CC	_	_
19	9.4	_	CD	CD	_	17	COORD	_	_
20	fmol\/million	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	14	NMOD	_	_
22	)	_	)	)	_	13	P	_	_
23	compared	_	VBN	VBN	_	5	OBJ	_	_
24	to	_	TO	TO	_	23	ADV	_	_
25	values	_	NNS	NNS	_	24	PMOD	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	12	_	CD	CD	_	29	NMOD	_	_
28	AIDS	_	NN	NN	_	29	NMOD	_	_
29	patients	_	NNS	NNS	_	26	PMOD	_	_
30	without	_	IN	IN	_	29	NMOD	_	_
31	an	_	DT	DT	_	33	NMOD	_	_
32	Addisonian	_	JJ	JJ	_	33	NMOD	_	_
33	picture	_	NN	NN	_	30	PMOD	_	_
34	(	_	(	(	_	47	P	_	_
35	group	_	NN	NN	_	47	DEP	_	_
36	2	_	CD	CD	_	35	NMOD	_	_
37	;	_	:	:	_	35	P	_	_
38	6.05	_	CD	CD	_	42	NMOD	_	_
39	+\/-	_	CC	CC	_	38	CC	_	_
40	2.6	_	CD	CD	_	38	COORD	_	_
41	fmol\/million	_	NN	NN	_	42	NMOD	_	_
42	cells	_	NNS	NNS	_	35	NMOD	_	_
43	;	_	:	:	_	47	P	_	_
44	P	_	NN	NN	_	47	SBJ	_	_
45	less	_	JJR	JJR	_	47	DEP	_	_
46	than	_	IN	IN	_	47	DEP	_	_
47	0.01	_	CD	CD	_	29	PRN	_	_
48	)	_	)	)	_	47	P	_	_
49	and	_	CC	CC	_	29	CC	_	_
50	sex-	_	NN	NN	_	53	NMOD	_	_
51	and	_	CC	CC	_	50	CC	_	_
52	age-matched	_	JJ	JJ	_	50	COORD	_	_
53	controls	_	NNS	NNS	_	29	COORD	_	_
54	(	_	(	(	_	64	P	_	_
55	3.15	_	CD	CD	_	59	NMOD	_	_
56	+\/-	_	CC	CC	_	55	CC	_	_
57	2.3	_	CD	CD	_	55	COORD	_	_
58	fmol\/million	_	NN	NN	_	59	NMOD	_	_
59	cells	_	NNS	NNS	_	64	DEP	_	_
60	;	_	:	:	_	64	P	_	_
61	P	_	NN	NN	_	64	SBJ	_	_
62	less	_	JJR	JJR	_	64	DEP	_	_
63	than	_	IN	IN	_	64	DEP	_	_
64	0.01	_	CD	CD	_	53	PRN	_	_
65	)	_	)	)	_	64	P	_	_
66	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	affinity	_	NN	NN	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	glucocorticoid	_	NN	NN	_	5	NMOD	_	_
5	receptors	_	NNS	NNS	_	3	PMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	Kd	_	NN	NN	_	2	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	strikingly	_	RB	RB	_	9	ADV	_	_
11	decreased	_	VBN	VBN	_	9	VC	_	_
12	(	_	(	(	_	39	P	_	_
13	9.36	_	CD	CD	_	16	NMOD	_	_
14	+\/-	_	CC	CC	_	13	CC	_	_
15	3.44	_	CD	CD	_	13	COORD	_	_
16	nM	_	NN	NN	_	39	DEP	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	group	_	NN	NN	_	17	PMOD	_	_
19	1	_	CD	CD	_	18	NMOD	_	_
20	;	_	:	:	_	16	P	_	_
21	3.2	_	CD	CD	_	24	NMOD	_	_
22	+\/-	_	CC	CC	_	21	CC	_	_
23	1.5	_	CD	CD	_	21	COORD	_	_
24	nM	_	NN	NN	_	16	NMOD	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	group	_	NN	NN	_	25	PMOD	_	_
27	2	_	CD	CD	_	26	NMOD	_	_
28	;	_	:	:	_	16	P	_	_
29	2.0	_	CD	CD	_	32	NMOD	_	_
30	+\/-	_	CC	CC	_	29	CC	_	_
31	0.8	_	CD	CD	_	29	COORD	_	_
32	nM	_	NN	NN	_	16	NMOD	_	_
33	in	_	IN	IN	_	32	NMOD	_	_
34	controls	_	NNS	NNS	_	33	PMOD	_	_
35	;	_	:	:	_	39	P	_	_
36	P	_	NN	NN	_	39	SBJ	_	_
37	less	_	JJR	JJR	_	39	DEP	_	_
38	than	_	IN	IN	_	39	DEP	_	_
39	0.01	_	CD	CD	_	11	PRN	_	_
40	)	_	)	)	_	39	P	_	_
41	.	_	.	.	_	9	P	_	_

1	-LCB-3H-RCB-Thymidine	_	NN	NN	_	2	NMOD	_	_
2	incorporation	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	decreased	_	VBN	VBN	_	3	VC	_	_
5	dose-dependently	_	RB	RB	_	4	ADV	_	_
6	by	_	IN	IN	_	4	LGS	_	_
7	dexamethasone	_	NN	NN	_	6	PMOD	_	_
8	in	_	IN	IN	_	4	ADV	_	_
9	controls	_	NNS	NNS	_	8	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	patients	_	NNS	NNS	_	9	COORD	_	_
12	;	_	:	:	_	3	P	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	effect	_	NN	NN	_	15	SBJ	_	_
15	was	_	VBD	VBD	_	3	VC	_	_
16	significantly	_	RB	RB	_	15	ADV	_	_
17	blunted	_	VBN	VBN	_	15	VC	_	_
18	(	_	(	(	_	22	P	_	_
19	P	_	NN	NN	_	22	SBJ	_	_
20	less	_	JJR	JJR	_	22	DEP	_	_
21	than	_	IN	IN	_	22	DEP	_	_
22	0.05	_	CD	CD	_	17	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	in	_	IN	IN	_	17	ADV	_	_
25	group	_	NN	NN	_	27	NMOD	_	_
26	1	_	CD	CD	_	27	NMOD	_	_
27	patients	_	NNS	NNS	_	24	PMOD	_	_
28	,	_	,	,	_	17	P	_	_
29	which	_	WDT	WDT	_	30	SBJ	_	_
30	suggests	_	VBZ	VBZ	_	17	OBJ	_	_
31	that	_	IN	IN	_	30	OBJ	_	_
32	activation	_	NN	NN	_	36	SBJ	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	glucocorticoid	_	NN	NN	_	35	NMOD	_	_
35	receptor	_	NN	NN	_	33	PMOD	_	_
36	is	_	VBZ	VBZ	_	31	VMOD	_	_
37	impaired	_	JJ	JJ	_	36	PRD	_	_
38	as	_	IN	IN	_	36	ADV	_	_
39	a	_	DT	DT	_	40	NMOD	_	_
40	result	_	NN	NN	_	38	PMOD	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	the	_	DT	DT	_	45	NMOD	_	_
43	glucocorticoid	_	NN	NN	_	45	NMOD	_	_
44	receptor	_	NN	NN	_	45	NMOD	_	_
45	abnormality	_	NN	NN	_	41	PMOD	_	_
46	.	_	.	.	_	15	P	_	_

1	In	_	IN	IN	_	16	ADV	_	_
2	conclusion	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	16	P	_	_
4	AIDS	_	NN	NN	_	5	NMOD	_	_
5	patients	_	NNS	NNS	_	16	SBJ	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	hypercortisolism	_	NN	NN	_	6	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	clinical	_	JJ	JJ	_	10	NMOD	_	_
10	features	_	NNS	NNS	_	7	COORD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	peripheral	_	JJ	JJ	_	13	NMOD	_	_
13	resistance	_	NN	NN	_	11	PMOD	_	_
14	to	_	TO	TO	_	13	NMOD	_	_
15	glucocorticoids	_	NNS	NNS	_	14	PMOD	_	_
16	are	_	VBP	VBP	_	0	ROOT-S	_	_
17	characterized	_	VBN	VBN	_	16	VC	_	_
18	by	_	IN	IN	_	17	LGS	_	_
19	abnormal	_	JJ	JJ	_	21	NMOD	_	_
20	glucocorticoid	_	NN	NN	_	21	NMOD	_	_
21	receptors	_	NNS	NNS	_	18	PMOD	_	_
22	on	_	IN	IN	_	21	NMOD	_	_
23	lymphocytes	_	NNS	NNS	_	22	PMOD	_	_
24	.	_	.	.	_	16	P	_	_

1	Resistance	_	NN	NN	_	4	SBJ	_	_
2	to	_	TO	TO	_	1	NMOD	_	_
3	glucocorticoids	_	NNS	NNS	_	2	PMOD	_	_
4	implies	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	complex	_	JJ	JJ	_	7	NMOD	_	_
7	change	_	NN	NN	_	4	OBJ	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	immune-endocrine	_	JJ	JJ	_	10	NMOD	_	_
10	function	_	NN	NN	_	8	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	which	_	WDT	WDT	_	13	SBJ	_	_
13	may	_	MD	MD	_	10	NMOD	_	_
14	be	_	VB	VB	_	13	VC	_	_
15	important	_	JJ	JJ	_	14	PRD	_	_
16	in	_	IN	IN	_	14	ADV	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	course	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	immunodeficiency	_	NN	NN	_	21	NMOD	_	_
21	syndrome	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	4	P	_	_

1	Binding	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	erythroid	_	JJ	JJ	_	7	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	non-erythroid	_	JJ	JJ	_	3	COORD	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	proteins	_	NNS	NNS	_	2	PMOD	_	_
8	to	_	TO	TO	_	1	NMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	silencer	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	human	_	JJ	JJ	_	15	NMOD	_	_
14	epsilon-globin-encoding	_	JJ	JJ	_	15	NMOD	_	_
15	gene	_	NN	NN	_	11	PMOD	_	_
16	.	_	.	.	_	1	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	clarify	_	VB	VB	_	15	ADV	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	molecular	_	JJ	JJ	_	5	NMOD	_	_
5	mechanisms	_	NNS	NNS	_	2	OBJ	_	_
6	involved	_	VBN	VBN	_	5	NMOD	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	developmental	_	JJ	JJ	_	10	NMOD	_	_
10	control	_	NN	NN	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	hemoglobin-encoding	_	JJ	JJ	_	13	NMOD	_	_
13	genes	_	NNS	NNS	_	11	PMOD	_	_
14	we	_	PRP	PRP	_	15	SBJ	_	_
15	have	_	VBP	VBP	_	0	ROOT-S	_	_
16	been	_	VBN	VBN	_	15	VC	_	_
17	studying	_	VBG	VBG	_	16	VC	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	expression	_	NN	NN	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	these	_	DT	DT	_	22	NMOD	_	_
22	genes	_	NNS	NNS	_	20	PMOD	_	_
23	in	_	IN	IN	_	19	NMOD	_	_
24	human	_	JJ	JJ	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	23	PMOD	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	continuous	_	JJ	JJ	_	28	NMOD	_	_
28	culture	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	15	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	previously	_	RB	RB	_	2	TMP	_	_
4	reported	_	VBN	VBN	_	2	VC	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	presence	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	11	NMOD	_	_
9	transcriptional	_	JJ	JJ	_	11	NMOD	_	_
10	control	_	NN	NN	_	11	NMOD	_	_
11	element	_	NN	NN	_	7	PMOD	_	_
12	with	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	properties	_	NNS	NNS	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	a	_	DT	DT	_	17	NMOD	_	_
17	silencer	_	NN	NN	_	15	PMOD	_	_
18	extending	_	VBG	VBG	_	17	NMOD	_	_
19	from	_	IN	IN	_	18	ADV	_	_
20	-392	_	CD	CD	_	23	NMOD	_	_
21	to	_	TO	TO	_	19	PMOD	_	_
22	-177	_	CD	CD	_	21	NMOD	_	_
23	bp	_	NN	NN	_	19	PMOD	_	_
24	relative	_	JJ	JJ	_	25	DEP	_	_
25	to	_	TO	TO	_	18	ADV	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	cap	_	NN	NN	_	28	NMOD	_	_
28	site	_	NN	NN	_	25	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	33	NMOD	_	_
31	human	_	JJ	JJ	_	33	NMOD	_	_
32	epsilon-globin-encoding	_	JJ	JJ	_	33	NMOD	_	_
33	gene	_	NN	NN	_	29	PMOD	_	_
34	{	_	(	(	_	4	PRN	_	_
35	Cao	_	NNP	NNP	_	34	DEP	_	_
36	et	_	FW	FW	_	35	NMOD	_	_
37	al.	_	FW	FW	_	35	NMOD	_	_
38	,	_	,	,	_	35	P	_	_
39	Proc.Natl.Acad.Sci.USA	_	NNP	NNP	_	35	COORD	_	_
40	86	_	CD	CD	_	39	NMOD	_	_
41	(	_	(	(	_	39	P	_	_
42	1989	_	CD	CD	_	39	NMOD	_	_
43	)	_	)	)	_	39	P	_	_
44	5306-5309	_	CD	CD	_	39	NMOD	_	_
45	}	_	)	)	_	34	P	_	_
46	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	showed	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	this	_	DT	DT	_	6	NMOD	_	_
6	silencer	_	NN	NN	_	7	SBJ	_	_
7	has	_	VBZ	VBZ	_	4	VMOD	_	_
8	stronger	_	JJR	JJR	_	10	NMOD	_	_
9	inhibitory	_	JJ	JJ	_	10	NMOD	_	_
10	activity	_	NN	NN	_	7	OBJ	_	_
11	in	_	IN	IN	_	7	ADV	_	_
12	HeLa	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	,	_	,	,	_	7	P	_	_
15	as	_	IN	IN	_	7	ADV	_	_
16	compared	_	VBN	VBN	_	15	VMOD	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	K562	_	NN	NN	_	21	NMOD	_	_
19	human	_	JJ	JJ	_	21	NMOD	_	_
20	erythroleukemia	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	17	PMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	Using	_	VBG	VBG	_	19	ADV	_	_
2	deletion	_	NN	NN	_	3	NMOD	_	_
3	mutants	_	NNS	NNS	_	1	OBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	cis-cloned	_	JJ	JJ	_	7	NMOD	_	_
6	synthetic	_	JJ	JJ	_	7	NMOD	_	_
7	oligodeoxyribonucleotides	_	NNS	NNS	_	3	COORD	_	_
8	in	_	IN	IN	_	1	ADV	_	_
9	transient	_	JJ	JJ	_	11	NMOD	_	_
10	expression	_	NN	NN	_	11	NMOD	_	_
11	assays	_	NNS	NNS	_	8	PMOD	_	_
12	,	_	,	,	_	19	P	_	_
13	nucleotide	_	NN	NN	_	14	NMOD	_	_
14	sequences	_	NNS	NNS	_	19	SBJ	_	_
15	responsible	_	JJ	JJ	_	14	NMOD	_	_
16	for	_	IN	IN	_	15	AMOD	_	_
17	this	_	DT	DT	_	18	NMOD	_	_
18	effect	_	NN	NN	_	16	PMOD	_	_
19	have	_	VBP	VBP	_	0	ROOT-S	_	_
20	now	_	RB	RB	_	19	TMP	_	_
21	been	_	VBN	VBN	_	19	VC	_	_
22	further	_	RBR	RBR	_	21	ADV	_	_
23	delimited	_	VBN	VBN	_	21	VC	_	_
24	to	_	TO	TO	_	23	ADV	_	_
25	44	_	CD	CD	_	26	NMOD	_	_
26	bp	_	NN	NN	_	24	PMOD	_	_
27	located	_	JJ	JJ	_	26	NMOD	_	_
28	from	_	IN	IN	_	27	AMOD	_	_
29	-294	_	CD	CD	_	32	NMOD	_	_
30	to	_	TO	TO	_	28	PMOD	_	_
31	-251	_	CD	CD	_	30	NMOD	_	_
32	bp	_	NN	NN	_	28	PMOD	_	_
33	.	_	.	.	_	19	P	_	_

1	Gel	_	NN	NN	_	5	NMOD	_	_
2	electrophoresis	_	NN	NN	_	5	NMOD	_	_
3	mobility	_	NN	NN	_	5	NMOD	_	_
4	shift	_	NN	NN	_	5	NMOD	_	_
5	assays	_	NNS	NNS	_	10	SBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	DNaseI	_	NN	NN	_	9	NMOD	_	_
8	footprinting	_	NN	NN	_	9	NMOD	_	_
9	assays	_	NNS	NNS	_	5	COORD	_	_
10	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
11	that	_	IN	IN	_	10	OBJ	_	_
12	these	_	DT	DT	_	15	NMOD	_	_
13	negative	_	JJ	JJ	_	15	NMOD	_	_
14	regulatory	_	JJ	JJ	_	15	NMOD	_	_
15	sequences	_	NNS	NNS	_	16	SBJ	_	_
16	are	_	VBP	VBP	_	11	VMOD	_	_
17	recognized	_	VBN	VBN	_	16	VC	_	_
18	differently	_	RB	RB	_	17	ADV	_	_
19	by	_	IN	IN	_	17	LGS	_	_
20	proteins	_	NNS	NNS	_	19	PMOD	_	_
21	present	_	JJ	JJ	_	20	NMOD	_	_
22	in	_	IN	IN	_	21	AMOD	_	_
23	nuclear	_	JJ	JJ	_	24	NMOD	_	_
24	extracts	_	NNS	NNS	_	22	PMOD	_	_
25	obtained	_	VBN	VBN	_	24	NMOD	_	_
26	from	_	IN	IN	_	25	ADV	_	_
27	HeLa	_	NN	NN	_	30	NMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	K562	_	NN	NN	_	27	COORD	_	_
30	cells	_	NNS	NNS	_	26	PMOD	_	_
31	.	_	.	.	_	10	P	_	_

1	Two	_	CD	CD	_	3	NMOD	_	_
2	binding	_	VBG	VBG	_	3	NMOD	_	_
3	proteins	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	detected	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	K562	_	NN	NN	_	9	NMOD	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	extracts	_	NNS	NNS	_	6	PMOD	_	_
10	,	_	,	,	_	5	P	_	_
11	while	_	IN	IN	_	5	OBJ	_	_
12	only	_	RB	RB	_	14	SBJ	_	_
13	one	_	CD	CD	_	12	DEP	_	_
14	is	_	VBZ	VBZ	_	11	VMOD	_	_
15	found	_	VBN	VBN	_	14	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	extracts	_	NNS	NNS	_	16	PMOD	_	_
18	from	_	IN	IN	_	17	NMOD	_	_
19	HeLa	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	4	P	_	_

1	Possible	_	JJ	JJ	_	2	NMOD	_	_
2	mechanisms	_	NNS	NNS	_	19	SBJ	_	_
3	by	_	IN	IN	_	8	ADV	_	_
4	which	_	WDT	WDT	_	3	PMOD	_	_
5	these	_	DT	DT	_	6	NMOD	_	_
6	proteins	_	NNS	NNS	_	7	SBJ	_	_
7	may	_	MD	MD	_	2	NMOD	_	_
8	regulate	_	VB	VB	_	7	VC	_	_
9	transcription	_	NN	NN	_	8	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	epsilon-globin-encoding	_	JJ	JJ	_	13	NMOD	_	_
13	gene	_	NN	NN	_	10	PMOD	_	_
14	in	_	IN	IN	_	9	NMOD	_	_
15	erythroid	_	JJ	JJ	_	18	NMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	non-erythroid	_	JJ	JJ	_	15	COORD	_	_
18	cells	_	NNS	NNS	_	14	PMOD	_	_
19	are	_	VBP	VBP	_	0	ROOT-S	_	_
20	discussed	_	VBN	VBN	_	19	VC	_	_
21	.	_	.	.	_	19	P	_	_

1	{	_	(	(	_	3	P	_	_
2	Regulatory	_	JJ	JJ	_	3	NMOD	_	_
3	effect	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	insulin	_	NN	NN	_	4	PMOD	_	_
6	on	_	IN	IN	_	3	NMOD	_	_
7	glucocorticoid	_	NN	NN	_	8	NMOD	_	_
8	receptor	_	NN	NN	_	6	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	peripheral	_	JJ	JJ	_	12	NMOD	_	_
12	leukocytes	_	NNS	NNS	_	9	PMOD	_	_
13	}	_	)	)	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	regulatory	_	JJ	JJ	_	3	NMOD	_	_
3	effect	_	NN	NN	_	20	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	insulin	_	NN	NN	_	4	PMOD	_	_
6	on	_	IN	IN	_	3	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	specific	_	JJ	JJ	_	10	NMOD	_	_
9	binding	_	VBG	VBG	_	10	NMOD	_	_
10	power	_	NN	NN	_	6	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	glucocorticoid	_	NN	NN	_	13	NMOD	_	_
13	receptor	_	NN	NN	_	11	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	GR	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	of	_	IN	IN	_	13	NMOD	_	_
18	human	_	JJ	JJ	_	19	NMOD	_	_
19	leukocytes	_	NNS	NNS	_	17	PMOD	_	_
20	was	_	VBD	VBD	_	0	ROOT-S	_	_
21	assessed	_	VBN	VBN	_	20	VC	_	_
22	by	_	IN	IN	_	21	ADV	_	_
23	the	_	DT	DT	_	26	NMOD	_	_
24	unoccupied	_	JJ	JJ	_	26	NMOD	_	_
25	receptor	_	NN	NN	_	26	NMOD	_	_
26	sites	_	NNS	NNS	_	22	PMOD	_	_
27	capable	_	JJ	JJ	_	26	NMOD	_	_
28	of	_	IN	IN	_	27	AMOD	_	_
29	combining	_	VBG	VBG	_	28	PMOD	_	_
30	with	_	IN	IN	_	29	ADV	_	_
31	-LCB-3H-RCB-	_	NN	NN	_	33	NMOD	_	_
32	labelled	_	JJ	JJ	_	33	NMOD	_	_
33	dexamethasone	_	NN	NN	_	30	PMOD	_	_
34	measured	_	VBN	VBN	_	33	NMOD	_	_
35	at	_	IN	IN	_	34	TMP	_	_
36	3	_	CD	CD	_	39	NMOD	_	_
37	and	_	CC	CC	_	36	CC	_	_
38	24	_	CD	CD	_	36	COORD	_	_
39	h	_	NN	NN	_	35	PMOD	_	_
40	after	_	IN	IN	_	39	TMP	_	_
41	incubation	_	NN	NN	_	40	PMOD	_	_
42	with	_	IN	IN	_	41	NMOD	_	_
43	various	_	JJ	JJ	_	44	NMOD	_	_
44	concentrations	_	NNS	NNS	_	42	PMOD	_	_
45	of	_	IN	IN	_	44	NMOD	_	_
46	insulin	_	NN	NN	_	45	PMOD	_	_
47	added	_	VBN	VBN	_	44	NMOD	_	_
48	to	_	TO	TO	_	47	ADV	_	_
49	the	_	DT	DT	_	50	NMOD	_	_
50	medium	_	NN	NN	_	48	PMOD	_	_
51	.	_	.	.	_	20	P	_	_

1	After	_	IN	IN	_	12	TMP	_	_
2	3	_	CD	CD	_	3	AMOD	_	_
3	h	_	NN	NN	_	4	NMOD	_	_
4	incubation	_	NN	NN	_	1	PMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	specific	_	JJ	JJ	_	8	NMOD	_	_
7	binding	_	VBG	VBG	_	8	NMOD	_	_
8	power	_	NN	NN	_	12	SBJ	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	-LCB-3H-RCB-	_	NN	NN	_	11	NMOD	_	_
11	Dex	_	NN	NN	_	9	PMOD	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	decreased	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	ADV	_	_
15	23.3	_	CD	CD	_	26	NMOD	_	_
16	+\/-	_	CC	CC	_	15	CC	_	_
17	10.0	_	CD	CD	_	15	COORD	_	_
18	,	_	,	,	_	26	P	_	_
19	32.2	_	CD	CD	_	26	NMOD	_	_
20	+\/-	_	CC	CC	_	19	CC	_	_
21	13.2	_	CD	CD	_	19	COORD	_	_
22	and	_	CC	CC	_	26	CC	_	_
23	54.3	_	CD	CD	_	26	NMOD	_	_
24	+\/-	_	CC	CC	_	23	CC	_	_
25	9.2	_	CD	CD	_	23	COORD	_	_
26	%	_	NN	NN	_	14	PMOD	_	_
27	(	_	(	(	_	28	P	_	_
28	P	_	NN	NN	_	26	PRN	_	_
29	greater	_	JJR	JJR	_	28	NMOD	_	_
30	than	_	IN	IN	_	29	AMOD	_	_
31	0.05	_	CD	CD	_	30	PMOD	_	_
32	,	_	,	,	_	28	P	_	_
33	P	_	NN	NN	_	28	COORD	_	_
34	greater	_	JJR	JJR	_	33	NMOD	_	_
35	than	_	IN	IN	_	34	AMOD	_	_
36	0.05	_	CD	CD	_	35	PMOD	_	_
37	and	_	CC	CC	_	28	CC	_	_
38	P	_	NN	NN	_	28	COORD	_	_
39	less	_	JJR	JJR	_	38	NMOD	_	_
40	than	_	IN	IN	_	39	AMOD	_	_
41	0.01	_	CD	CD	_	40	PMOD	_	_
42	as	_	IN	IN	_	28	NMOD	_	_
43	compared	_	VBN	VBN	_	42	VMOD	_	_
44	with	_	IN	IN	_	43	ADV	_	_
45	the	_	DT	DT	_	47	NMOD	_	_
46	control	_	NN	NN	_	47	NMOD	_	_
47	value	_	NN	NN	_	44	PMOD	_	_
48	of	_	IN	IN	_	47	NMOD	_	_
49	100	_	CD	CD	_	48	PMOD	_	_
50	in	_	IN	IN	_	47	NMOD	_	_
51	the	_	DT	DT	_	50	DEP	_	_
52	absence	_	NN	NN	_	50	DEP	_	_
53	of	_	IN	IN	_	50	DEP	_	_
54	insulin	_	NN	NN	_	50	PMOD	_	_
55	)	_	)	)	_	28	P	_	_
56	respectively	_	RB	RB	_	13	ADV	_	_
57	in	_	IN	IN	_	13	ADV	_	_
58	the	_	DT	DT	_	57	DEP	_	_
59	presence	_	NN	NN	_	57	DEP	_	_
60	of	_	IN	IN	_	57	DEP	_	_
61	20	_	CD	CD	_	62	NMOD	_	_
62	mU\/L	_	NN	NN	_	83	NMOD	_	_
63	(	_	(	(	_	66	P	_	_
64	physiological	_	JJ	JJ	_	66	NMOD	_	_
65	testing	_	NN	NN	_	66	NMOD	_	_
66	concentration	_	NN	NN	_	62	PRN	_	_
67	)	_	)	)	_	66	P	_	_
68	,	_	,	,	_	62	P	_	_
69	200	_	CD	CD	_	70	NMOD	_	_
70	mU\/L	_	NN	NN	_	62	COORD	_	_
71	(	_	(	(	_	74	P	_	_
72	physiological	_	JJ	JJ	_	74	NMOD	_	_
73	upper	_	JJ	JJ	_	74	NMOD	_	_
74	limit	_	NN	NN	_	70	PRN	_	_
75	)	_	)	)	_	74	P	_	_
76	and	_	CC	CC	_	62	CC	_	_
77	2,000	_	CD	CD	_	78	NMOD	_	_
78	mU\/L	_	NN	NN	_	62	COORD	_	_
79	(	_	(	(	_	81	P	_	_
80	pharmacological	_	JJ	JJ	_	81	NMOD	_	_
81	concentration	_	NN	NN	_	78	PRN	_	_
82	)	_	)	)	_	81	P	_	_
83	insulin	_	NN	NN	_	57	PMOD	_	_
84	in	_	IN	IN	_	83	NMOD	_	_
85	the	_	DT	DT	_	87	NMOD	_	_
86	incubation	_	NN	NN	_	87	NMOD	_	_
87	medium	_	NN	NN	_	84	PMOD	_	_
88	.	_	.	.	_	12	P	_	_

1	After	_	IN	IN	_	10	TMP	_	_
2	24	_	CD	CD	_	3	AMOD	_	_
3	h	_	NN	NN	_	4	NMOD	_	_
4	incubation	_	NN	NN	_	1	PMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	decrease	_	NN	NN	_	10	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	these	_	DT	DT	_	9	NMOD	_	_
9	values	_	NNS	NNS	_	7	PMOD	_	_
10	increased	_	VBD	VBD	_	0	ROOT-S	_	_
11	respectively	_	RB	RB	_	10	ADV	_	_
12	to	_	TO	TO	_	10	ADV	_	_
13	43.5	_	CD	CD	_	12	PMOD	_	_
14	+\/-	_	CC	CC	_	13	CC	_	_
15	19.0	_	CD	CD	_	13	COORD	_	_
16	,	_	,	,	_	13	P	_	_
17	56.1	_	CD	CD	_	13	COORD	_	_
18	+\/-	_	CC	CC	_	17	CC	_	_
19	20.7	_	CD	CD	_	17	COORD	_	_
20	and	_	CC	CC	_	13	CC	_	_
21	80.2	_	CD	CD	_	13	COORD	_	_
22	+\/-	_	CC	CC	_	21	CC	_	_
23	15.5	_	CD	CD	_	21	COORD	_	_
24	(	_	(	(	_	25	P	_	_
25	P	_	NN	NN	_	13	PRN	_	_
26	less	_	JJR	JJR	_	25	NMOD	_	_
27	than	_	IN	IN	_	26	AMOD	_	_
28	0.05	_	CD	CD	_	27	PMOD	_	_
29	,	_	,	,	_	25	P	_	_
30	P	_	NN	NN	_	25	COORD	_	_
31	less	_	JJR	JJR	_	30	NMOD	_	_
32	than	_	IN	IN	_	31	AMOD	_	_
33	0.01	_	CD	CD	_	32	PMOD	_	_
34	and	_	CC	CC	_	25	CC	_	_
35	P	_	NN	NN	_	25	COORD	_	_
36	less	_	JJR	JJR	_	35	NMOD	_	_
37	than	_	IN	IN	_	36	AMOD	_	_
38	0.01	_	CD	CD	_	37	PMOD	_	_
39	compared	_	VBN	VBN	_	25	NMOD	_	_
40	with	_	IN	IN	_	39	ADV	_	_
41	control	_	NN	NN	_	40	PMOD	_	_
42	)	_	)	)	_	25	P	_	_
43	.	_	.	.	_	10	P	_	_

1	Thus	_	RB	RB	_	12	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	inhibitory	_	JJ	JJ	_	4	NMOD	_	_
4	effect	_	NN	NN	_	12	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	insulin	_	NN	NN	_	5	PMOD	_	_
7	on	_	IN	IN	_	4	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	GR	_	NN	NN	_	11	NMOD	_	_
10	binding	_	NN	NN	_	11	NMOD	_	_
11	power	_	NN	NN	_	7	PMOD	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	both	_	CC	CC	_	14	CC	_	_
14	dose-	_	NN	NN	_	12	PRD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	time-dependent	_	JJ	JJ	_	14	COORD	_	_
17	,	_	,	,	_	12	P	_	_
18	which	_	WDT	WDT	_	20	SBJ	_	_
19	strongly	_	RB	RB	_	20	ADV	_	_
20	suggests	_	VBZ	VBZ	_	12	ADV	_	_
21	that	_	IN	IN	_	20	OBJ	_	_
22	GR	_	NN	NN	_	23	SBJ	_	_
23	is	_	VBZ	VBZ	_	21	VMOD	_	_
24	tonically	_	RB	RB	_	23	ADV	_	_
25	controlled	_	VBN	VBN	_	23	VC	_	_
26	by	_	IN	IN	_	25	LGS	_	_
27	insulin	_	NN	NN	_	29	NMOD	_	_
28	concentration	_	NN	NN	_	29	NMOD	_	_
29	change	_	NN	NN	_	26	PMOD	_	_
30	under	_	IN	IN	_	29	NMOD	_	_
31	physiological	_	JJ	JJ	_	32	NMOD	_	_
32	conditions	_	NNS	NNS	_	30	PMOD	_	_
33	.	_	.	.	_	12	P	_	_

1	Mineralocorticoid	_	NN	NN	_	3	NMOD	_	_
2	effector	_	NN	NN	_	3	NMOD	_	_
3	mechanism	_	NN	NN	_	0	ROOT-FRAG	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	preeclampsia	_	NN	NN	_	4	PMOD	_	_
6	.	_	.	.	_	3	P	_	_

1	Mineralocorticoid	_	NN	NN	_	3	NMOD	_	_
2	effector	_	NN	NN	_	3	NMOD	_	_
3	mechanisms	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	evaluated	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	29	_	CD	CD	_	8	NMOD	_	_
8	patients	_	NNS	NNS	_	6	PMOD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	preeclampsia	_	NN	NN	_	9	PMOD	_	_
11	and	_	CC	CC	_	6	CC	_	_
12	in	_	IN	IN	_	6	COORD	_	_
13	25	_	CD	CD	_	15	NMOD	_	_
14	uncomplicated	_	JJ	JJ	_	15	NMOD	_	_
15	pregnancies	_	NNS	NNS	_	12	PMOD	_	_
16	by	_	IN	IN	_	5	ADV	_	_
17	measurement	_	NN	NN	_	16	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	plasma	_	NN	NN	_	20	NMOD	_	_
20	aldosterone	_	NN	NN	_	18	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	levels	_	NNS	NNS	_	20	COORD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	mineralocorticoid	_	NN	NN	_	25	NMOD	_	_
25	receptor	_	NN	NN	_	23	PMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	MR	_	NN	NN	_	25	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	in	_	IN	IN	_	25	NMOD	_	_
30	mononuclear	_	JJ	JJ	_	31	NMOD	_	_
31	leucocytes	_	NNS	NNS	_	29	PMOD	_	_
32	,	_	,	,	_	20	P	_	_
33	and	_	CC	CC	_	20	CC	_	_
34	subtraction	_	NN	NN	_	36	NMOD	_	_
35	potential	_	NN	NN	_	36	NMOD	_	_
36	difference	_	NN	NN	_	20	COORD	_	_
37	(	_	(	(	_	38	P	_	_
38	SPD	_	NN	NN	_	36	PRN	_	_
39	;	_	:	:	_	38	P	_	_
40	rectal	_	JJ	JJ	_	43	NMOD	_	_
41	minus	_	CC	CC	_	40	CC	_	_
42	oral	_	JJ	JJ	_	40	COORD	_	_
43	values	_	NNS	NNS	_	38	COORD	_	_
44	)	_	)	)	_	38	P	_	_
45	.	_	.	.	_	4	P	_	_

1	Mean	_	NN	NN	_	2	NMOD	_	_
2	values	_	NNS	NNS	_	6	SBJ	_	_
3	for	_	IN	IN	_	2	NMOD	_	_
4	plasma	_	NN	NN	_	5	NMOD	_	_
5	aldosterone	_	NN	NN	_	3	PMOD	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	not	_	RB	RB	_	6	VMOD	_	_
8	different	_	JJ	JJ	_	6	PRD	_	_
9	between	_	IN	IN	_	6	ADV	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	two	_	CD	CD	_	12	NMOD	_	_
12	groups	_	NNS	NNS	_	9	PMOD	_	_
13	,	_	,	,	_	6	P	_	_
14	but	_	CC	CC	_	6	CC	_	_
15	significant	_	JJ	JJ	_	16	NMOD	_	_
16	differences	_	NNS	NNS	_	17	SBJ	_	_
17	were	_	VBD	VBD	_	6	COORD	_	_
18	observed	_	VBN	VBN	_	17	VC	_	_
19	for	_	IN	IN	_	18	ADV	_	_
20	MR	_	NN	NN	_	19	PMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	preeclampsia	_	NN	NN	_	20	PRN	_	_
23	,	_	,	,	_	22	P	_	_
24	81	_	CD	CD	_	27	NMOD	_	_
25	+\/-	_	CC	CC	_	24	CC	_	_
26	44	_	CD	CD	_	24	COORD	_	_
27	receptors\/cell	_	NNS	NNS	_	22	NMOD	_	_
28	;	_	:	:	_	22	P	_	_
29	controls	_	NNS	NNS	_	22	NMOD	_	_
30	,	_	,	,	_	29	P	_	_
31	306	_	CD	CD	_	29	NMOD	_	_
32	+\/-	_	CC	CC	_	31	CC	_	_
33	168	_	CD	CD	_	31	COORD	_	_
34	)	_	)	)	_	22	P	_	_
35	and	_	CC	CC	_	20	CC	_	_
36	SPD	_	NN	NN	_	20	COORD	_	_
37	(	_	(	(	_	38	P	_	_
38	preeclampsia	_	NN	NN	_	36	PRN	_	_
39	,	_	,	,	_	38	P	_	_
40	65	_	CD	CD	_	43	NMOD	_	_
41	+\/-	_	CC	CC	_	40	CC	_	_
42	7	_	CD	CD	_	40	COORD	_	_
43	mV	_	NN	NN	_	38	NMOD	_	_
44	;	_	:	:	_	38	P	_	_
45	controls	_	NNS	NNS	_	38	NMOD	_	_
46	,	_	,	,	_	45	P	_	_
47	12	_	CD	CD	_	50	NMOD	_	_
48	+\/-	_	CC	CC	_	47	CC	_	_
49	5	_	CD	CD	_	47	COORD	_	_
50	mV	_	NN	NN	_	45	NMOD	_	_
51	)	_	)	)	_	38	P	_	_
52	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	six	_	CD	CD	_	3	NMOD	_	_
3	cases	_	NNS	NNS	_	1	PMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	determined	_	VBD	VBD	_	0	ROOT-S	_	_
6	MR	_	NN	NN	_	5	OBJ	_	_
7	,	_	,	,	_	6	P	_	_
8	plasma	_	NN	NN	_	9	NMOD	_	_
9	aldosterone	_	NN	NN	_	6	COORD	_	_
10	,	_	,	,	_	6	P	_	_
11	and	_	CC	CC	_	6	CC	_	_
12	SPD	_	NN	NN	_	6	COORD	_	_
13	in	_	IN	IN	_	6	NMOD	_	_
14	patients	_	NNS	NNS	_	13	PMOD	_	_
15	with	_	IN	IN	_	14	NMOD	_	_
16	preeclampsia	_	NN	NN	_	15	PMOD	_	_
17	before	_	IN	IN	_	14	TMP	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	3	_	CD	CD	_	20	NMOD	_	_
20	months	_	NNS	NNS	_	21	PMOD	_	_
21	after	_	IN	IN	_	17	COORD	_	_
22	delivery	_	NN	NN	_	17	PMOD	_	_
23	.	_	.	.	_	5	P	_	_

1	MR	_	NNS	NNS	_	2	SBJ	_	_
2	were	_	VBD	VBD	_	0	ROOT-S	_	_
3	reduced	_	VBN	VBN	_	2	VC	_	_
4	before	_	IN	IN	_	3	TMP	_	_
5	delivery	_	NN	NN	_	4	PMOD	_	_
6	(	_	(	(	_	10	P	_	_
7	96	_	CD	CD	_	10	NMOD	_	_
8	+\/-	_	CC	CC	_	7	CC	_	_
9	27	_	CD	CD	_	7	COORD	_	_
10	receptors\/cell	_	NNS	NNS	_	3	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	,	_	,	,	_	2	P	_	_
13	and	_	CC	CC	_	2	CC	_	_
14	SPD	_	NN	NN	_	15	SBJ	_	_
15	increased	_	VBD	VBD	_	2	COORD	_	_
16	(	_	(	(	_	20	P	_	_
17	64	_	CD	CD	_	20	NMOD	_	_
18	+\/-	_	CC	CC	_	17	CC	_	_
19	8	_	CD	CD	_	17	COORD	_	_
20	mV	_	NN	NN	_	15	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	,	_	,	,	_	2	P	_	_
23	with	_	IN	IN	_	2	ADV	_	_
24	both	_	DT	DT	_	25	NMOD	_	_
25	parameters	_	NNS	NNS	_	26	SBJ	_	_
26	normalizing	_	VBG	VBG	_	23	PMOD	_	_
27	after	_	IN	IN	_	26	TMP	_	_
28	delivery	_	NN	NN	_	27	PMOD	_	_
29	(	_	(	(	_	30	P	_	_
30	MR	_	NN	NN	_	26	PRN	_	_
31	,	_	,	,	_	30	P	_	_
32	242	_	CD	CD	_	30	NMOD	_	_
33	+\/-	_	CC	CC	_	32	CC	_	_
34	79	_	CD	CD	_	32	COORD	_	_
35	;	_	:	:	_	30	P	_	_
36	SPD	_	NN	NN	_	30	NMOD	_	_
37	,	_	,	,	_	36	P	_	_
38	14.0	_	CD	CD	_	41	NMOD	_	_
39	+\/-	_	CC	CC	_	38	CC	_	_
40	4	_	CD	CD	_	38	COORD	_	_
41	mV	_	NN	NN	_	36	NMOD	_	_
42	)	_	)	)	_	30	P	_	_
43	.	_	.	.	_	2	P	_	_

1	Aldosterone	_	NN	NN	_	2	NMOD	_	_
2	levels	_	NNS	NNS	_	3	SBJ	_	_
3	returned	_	VBD	VBD	_	0	ROOT-S	_	_
4	to	_	TO	TO	_	3	ADV	_	_
5	normal	_	JJ	JJ	_	7	NMOD	_	_
6	nonpregnant	_	JJ	JJ	_	7	NMOD	_	_
7	values	_	NNS	NNS	_	4	PMOD	_	_
8	after	_	IN	IN	_	3	TMP	_	_
9	delivery	_	NN	NN	_	8	PMOD	_	_
10	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	an	_	DT	DT	_	6	NMOD	_	_
5	important	_	JJ	JJ	_	6	NMOD	_	_
6	role	_	NN	NN	_	3	OBJ	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	abnormalities	_	NNS	NNS	_	7	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	mineralocorticoid	_	NN	NN	_	12	NMOD	_	_
11	effector	_	NN	NN	_	12	NMOD	_	_
12	mechanisms	_	NNS	NNS	_	9	PMOD	_	_
13	in	_	IN	IN	_	6	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	etiology	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	preeclampsia	_	NN	NN	_	16	PMOD	_	_
18	and	_	CC	CC	_	3	CC	_	_
19	could	_	MD	MD	_	3	COORD	_	_
20	be	_	VB	VB	_	19	VC	_	_
21	an	_	DT	DT	_	23	NMOD	_	_
22	useful	_	JJ	JJ	_	23	NMOD	_	_
23	marker	_	NN	NN	_	20	PRD	_	_
24	for	_	IN	IN	_	23	NMOD	_	_
25	diagnosis	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	Leukotriene	_	NN	NN	_	2	NMOD	_	_
2	B4	_	NN	NN	_	3	SBJ	_	_
3	stimulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	c-fos	_	NN	NN	_	8	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	c-jun	_	NN	NN	_	4	COORD	_	_
7	gene	_	NN	NN	_	8	NMOD	_	_
8	transcription	_	NN	NN	_	3	OBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	AP-1	_	NN	NN	_	12	NMOD	_	_
11	binding	_	NN	NN	_	12	NMOD	_	_
12	activity	_	NN	NN	_	8	COORD	_	_
13	in	_	IN	IN	_	8	NMOD	_	_
14	human	_	JJ	JJ	_	15	NMOD	_	_
15	monocytes	_	NNS	NNS	_	13	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	examined	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	effect	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	leukotriene	_	NN	NN	_	8	NMOD	_	_
8	B4	_	NN	NN	_	6	PMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	LTB4	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	,	_	,	,	_	8	P	_	_
13	a	_	DT	DT	_	17	NMOD	_	_
14	potent	_	JJ	JJ	_	17	NMOD	_	_
15	lipid	_	NN	NN	_	17	NMOD	_	_
16	proinflammatory	_	JJ	JJ	_	17	NMOD	_	_
17	mediator	_	NN	NN	_	8	NMOD	_	_
18	,	_	,	,	_	8	P	_	_
19	on	_	IN	IN	_	5	NMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	expression	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	proto-oncogenes	_	NNS	NNS	_	22	PMOD	_	_
25	c-jun	_	NN	NN	_	24	NMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	c-fos	_	NN	NN	_	25	COORD	_	_
28	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	looked	_	VBD	VBD	_	0	ROOT-S	_	_
6	at	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	modulation	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	nuclear	_	JJ	JJ	_	11	NMOD	_	_
11	factors	_	NNS	NNS	_	9	PMOD	_	_
12	binding	_	VBG	VBG	_	11	NMOD	_	_
13	specifically	_	RB	RB	_	14	DEP	_	_
14	to	_	TO	TO	_	12	ADV	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	AP-1	_	NN	NN	_	17	NMOD	_	_
17	element	_	NN	NN	_	14	PMOD	_	_
18	after	_	IN	IN	_	12	TMP	_	_
19	LTB4	_	NN	NN	_	20	NMOD	_	_
20	stimulation	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	5	P	_	_

1	LTB4	_	NN	NN	_	2	SBJ	_	_
2	increased	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	expression	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	c-fos	_	NN	NN	_	8	NMOD	_	_
8	gene	_	NN	NN	_	5	PMOD	_	_
9	in	_	IN	IN	_	2	ADV	_	_
10	a	_	DT	DT	_	14	NMOD	_	_
11	time-	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	concentration-dependent	_	JJ	JJ	_	11	COORD	_	_
14	manner	_	NN	NN	_	9	PMOD	_	_
15	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	c-jun	_	NN	NN	_	3	NMOD	_	_
3	mRNA	_	NN	NN	_	18	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	which	_	WDT	WDT	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	3	NMOD	_	_
7	constitutively	_	RB	RB	_	6	ADV	_	_
8	expressed	_	VBN	VBN	_	6	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	peripheral-blood	_	NN	NN	_	12	NMOD	_	_
12	monocytes	_	NNS	NNS	_	9	PMOD	_	_
13	at	_	IN	IN	_	8	ADV	_	_
14	relatively	_	RB	RB	_	15	AMOD	_	_
15	high	_	JJ	JJ	_	16	NMOD	_	_
16	levels	_	NNS	NNS	_	13	PMOD	_	_
17	,	_	,	,	_	3	P	_	_
18	was	_	VBD	VBD	_	0	ROOT-S	_	_
19	also	_	RB	RB	_	18	ADV	_	_
20	slightly	_	RB	RB	_	18	ADV	_	_
21	augmented	_	JJ	JJ	_	18	VC	_	_
22	by	_	IN	IN	_	21	LGS	_	_
23	LTB4	_	NN	NN	_	22	PMOD	_	_
24	,	_	,	,	_	21	P	_	_
25	although	_	IN	IN	_	21	ADV	_	_
26	to	_	TO	TO	_	25	VMOD	_	_
27	a	_	DT	DT	_	30	NMOD	_	_
28	much	_	RB	RB	_	29	AMOD	_	_
29	lower	_	JJR	JJR	_	30	NMOD	_	_
30	extent	_	NN	NN	_	26	PMOD	_	_
31	than	_	IN	IN	_	30	NMOD	_	_
32	c-fos	_	NN	NN	_	31	PMOD	_	_
33	.	_	.	.	_	18	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	kinetics	_	NNS	NNS	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	expression	_	NN	NN	_	3	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	two	_	CD	CD	_	8	NMOD	_	_
8	genes	_	NNS	NNS	_	5	PMOD	_	_
9	were	_	VBD	VBD	_	0	ROOT-S	_	_
10	also	_	RB	RB	_	12	AMOD	_	_
11	slightly	_	RB	RB	_	12	AMOD	_	_
12	different	_	JJ	JJ	_	9	PRD	_	_
13	,	_	,	,	_	9	P	_	_
14	with	_	IN	IN	_	9	ADV	_	_
15	c-fos	_	NN	NN	_	16	NMOD	_	_
16	mRNA	_	NN	NN	_	17	SBJ	_	_
17	reaching	_	VBG	VBG	_	14	PMOD	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	peak	_	NN	NN	_	17	OBJ	_	_
20	at	_	IN	IN	_	17	TMP	_	_
21	15	_	CD	CD	_	22	NMOD	_	_
22	min	_	NN	NN	_	20	PMOD	_	_
23	after	_	IN	IN	_	22	TMP	_	_
24	stimulation	_	NN	NN	_	23	PMOD	_	_
25	and	_	CC	CC	_	17	CC	_	_
26	c-jun	_	NN	NN	_	16	GAP	_	_
27	at	_	IN	IN	_	20	GAP	_	_
28	30	_	CD	CD	_	29	NMOD	_	_
29	min	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	9	P	_	_

1	Both	_	DT	DT	_	2	NMOD	_	_
2	messages	_	NNS	NNS	_	4	SBJ	_	_
3	rapidly	_	RB	RB	_	4	TMP	_	_
4	declined	_	VBD	VBD	_	0	ROOT-S	_	_
5	thereafter	_	RB	RB	_	4	ADV	_	_
6	.	_	.	.	_	4	P	_	_

1	Stability	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	c-fos	_	NN	NN	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	c-jun	_	NN	NN	_	4	COORD	_	_
7	mRNA	_	NN	NN	_	2	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	affected	_	VBN	VBN	_	8	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	LTB4	_	NN	NN	_	11	PMOD	_	_
13	,	_	,	,	_	10	P	_	_
14	as	_	IN	IN	_	10	ADV	_	_
15	assessed	_	VBN	VBN	_	14	VMOD	_	_
16	after	_	IN	IN	_	15	TMP	_	_
17	actinomycin	_	NN	NN	_	19	NMOD	_	_
18	D	_	NN	NN	_	19	NMOD	_	_
19	treatment	_	NN	NN	_	16	PMOD	_	_
20	.	_	.	.	_	8	P	_	_

1	Nuclear	_	JJ	JJ	_	3	NMOD	_	_
2	transcription	_	NN	NN	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	6	SBJ	_	_
4	in	_	FW	FW	_	3	NMOD	_	_
5	vitro	_	FW	FW	_	4	AMOD	_	_
6	showed	_	VBD	VBD	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	LTB4	_	NN	NN	_	9	SBJ	_	_
9	increased	_	VBD	VBD	_	7	VMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	transcription	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	c-fos	_	NN	NN	_	15	NMOD	_	_
15	gene	_	NN	NN	_	12	PMOD	_	_
16	7-fold	_	RB	RB	_	9	VMOD	_	_
17	and	_	CC	CC	_	9	CC	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	c-jun	_	NN	NN	_	20	NMOD	_	_
20	gene	_	NN	NN	_	15	GAP	_	_
21	1.4-fold	_	RB	RB	_	16	GAP	_	_
22	.	_	.	.	_	6	P	_	_

1	Resting	_	VBG	VBG	_	2	NMOD	_	_
2	monocytes	_	NNS	NNS	_	3	SBJ	_	_
3	contained	_	VBD	VBD	_	0	ROOT-S	_	_
4	nuclear	_	JJ	JJ	_	5	NMOD	_	_
5	factors	_	NNS	NNS	_	3	OBJ	_	_
6	binding	_	VBG	VBG	_	5	NMOD	_	_
7	to	_	TO	TO	_	6	ADV	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	AP-1	_	NN	NN	_	10	NMOD	_	_
10	element	_	NN	NN	_	7	PMOD	_	_
11	,	_	,	,	_	3	P	_	_
12	but	_	CC	CC	_	3	CC	_	_
13	stimulation	_	NN	NN	_	18	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	monocytes	_	NNS	NNS	_	14	PMOD	_	_
16	with	_	IN	IN	_	13	NMOD	_	_
17	LTB4	_	NN	NN	_	16	PMOD	_	_
18	induced	_	VBD	VBD	_	3	COORD	_	_
19	greater	_	JJR	JJR	_	21	NMOD	_	_
20	AP-1-binding	_	JJ	JJ	_	21	NMOD	_	_
21	activity	_	NN	NN	_	18	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	nuclear	_	JJ	JJ	_	24	NMOD	_	_
24	proteins	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	LTB4	_	NN	NN	_	6	SBJ	_	_
6	may	_	MD	MD	_	4	VMOD	_	_
7	regulate	_	VB	VB	_	6	VC	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	production	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	different	_	JJ	JJ	_	12	NMOD	_	_
12	cytokines	_	NNS	NNS	_	10	PMOD	_	_
13	by	_	IN	IN	_	7	ADV	_	_
14	modulating	_	VBG	VBG	_	13	PMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	yield	_	NN	NN	_	14	OBJ	_	_
17	and\/or	_	CC	CC	_	16	CC	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	function	_	NN	NN	_	16	COORD	_	_
20	of	_	IN	IN	_	16	NMOD	_	_
21	transcription	_	NN	NN	_	22	NMOD	_	_
22	factors	_	NNS	NNS	_	20	PMOD	_	_
23	such	_	JJ	JJ	_	24	DEP	_	_
24	as	_	IN	IN	_	22	NMOD	_	_
25	AP-1-binding	_	JJ	JJ	_	27	NMOD	_	_
26	proto-oncogene	_	NN	NN	_	27	NMOD	_	_
27	products	_	NNS	NNS	_	24	PMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	B	_	NN	NN	_	6	NMOD	_	_
3	cell-specific	_	JJ	JJ	_	2	AMOD	_	_
4	nuclear	_	JJ	JJ	_	6	NMOD	_	_
5	factor	_	NN	NN	_	6	NMOD	_	_
6	OTF-2	_	NN	NN	_	8	SBJ	_	_
7	positively	_	RB	RB	_	8	ADV	_	_
8	regulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	transcription	_	NN	NN	_	8	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	16	NMOD	_	_
12	human	_	JJ	JJ	_	16	NMOD	_	_
13	class	_	NN	NN	_	16	NMOD	_	_
14	II	_	CD	CD	_	16	NMOD	_	_
15	transplantation	_	NN	NN	_	16	NMOD	_	_
16	gene	_	NN	NN	_	10	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	DRA	_	NN	NN	_	16	NMOD	_	_
19	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	promoter	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	10	NMOD	_	_
5	major	_	JJ	JJ	_	10	NMOD	_	_
6	histocompatibility	_	NN	NN	_	10	NMOD	_	_
7	class	_	NN	NN	_	10	NMOD	_	_
8	II	_	CD	CD	_	10	NMOD	_	_
9	gene	_	NN	NN	_	10	NMOD	_	_
10	DRA	_	NN	NN	_	3	PMOD	_	_
11	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	an	_	DT	DT	_	14	NMOD	_	_
13	octamer	_	NN	NN	_	14	NMOD	_	_
14	element	_	NN	NN	_	11	OBJ	_	_
15	(	_	(	(	_	16	P	_	_
16	ATTTGCAT	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	that	_	WDT	WDT	_	19	SBJ	_	_
19	is	_	VBZ	VBZ	_	14	NMOD	_	_
20	required	_	VBN	VBN	_	19	VC	_	_
21	for	_	IN	IN	_	20	ADV	_	_
22	efficient	_	JJ	JJ	_	24	NMOD	_	_
23	DRA	_	NN	NN	_	24	NMOD	_	_
24	expression	_	NN	NN	_	21	PMOD	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	B	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	11	P	_	_

1	Several	_	JJ	JJ	_	3	NMOD	_	_
2	DNA-binding	_	JJ	JJ	_	3	NMOD	_	_
3	proteins	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	known	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	bind	_	VB	VB	_	5	OBJ	_	_
8	this	_	DT	DT	_	9	NMOD	_	_
9	sequence	_	NN	NN	_	7	OBJ	_	_
10	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	AMOD	_	_
2	best	_	RBS	RBS	_	3	AMOD	_	_
3	characterized	_	VBN	VBN	_	4	PRD	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	B	_	NN	NN	_	8	NMOD	_	_
7	cell-specific	_	JJ	JJ	_	6	AMOD	_	_
8	OTF-2	_	NN	NN	_	4	SBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	ubiquitous	_	JJ	JJ	_	12	NMOD	_	_
12	OTF-1	_	NN	NN	_	8	COORD	_	_
13	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	report	_	NN	NN	_	4	SBJ	_	_
3	directly	_	RB	RB	_	4	ADV	_	_
4	demonstrates	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	OTF-2	_	NN	NN	_	10	SBJ	_	_
7	but	_	CC	CC	_	6	CC	_	_
8	not	_	RB	RB	_	7	COORD	_	_
9	OTF-1	_	NN	NN	_	6	COORD	_	_
10	regulates	_	VBZ	VBZ	_	5	VMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	DRA	_	NN	NN	_	13	NMOD	_	_
13	gene	_	NN	NN	_	10	OBJ	_	_
14	.	_	.	.	_	4	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	vitro	_	FW	FW	_	4	NMOD	_	_
3	transcription	_	NN	NN	_	4	NMOD	_	_
4	analysis	_	NN	NN	_	14	SBJ	_	_
5	using	_	VBG	VBG	_	4	NMOD	_	_
6	protein	_	NN	NN	_	7	NMOD	_	_
7	fractions	_	NNS	NNS	_	5	OBJ	_	_
8	enriched	_	VBN	VBN	_	7	NMOD	_	_
9	for	_	IN	IN	_	8	AMOD	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	octamer-binding	_	JJ	JJ	_	13	NMOD	_	_
12	protein	_	NN	NN	_	13	NMOD	_	_
13	OTF-2	_	NN	NN	_	9	PMOD	_	_
14	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
15	a	_	DT	DT	_	18	NMOD	_	_
16	positive	_	JJ	JJ	_	18	NMOD	_	_
17	functional	_	JJ	JJ	_	18	NMOD	_	_
18	role	_	NN	NN	_	14	OBJ	_	_
19	for	_	IN	IN	_	18	NMOD	_	_
20	OTF-2	_	NN	NN	_	19	PMOD	_	_
21	in	_	IN	IN	_	18	NMOD	_	_
22	DRA	_	NN	NN	_	24	NMOD	_	_
23	gene	_	NN	NN	_	24	NMOD	_	_
24	transcription	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	7	P	_	_
4	OTF-1-enriched	_	JJ	JJ	_	6	NMOD	_	_
5	protein	_	NN	NN	_	6	NMOD	_	_
6	fractions	_	NNS	NNS	_	7	SBJ	_	_
7	did	_	VBD	VBD	_	0	ROOT-S	_	_
8	not	_	RB	RB	_	7	VMOD	_	_
9	affect	_	VB	VB	_	7	VC	_	_
10	DRA	_	NN	NN	_	12	NMOD	_	_
11	gene	_	NN	NN	_	12	NMOD	_	_
12	transcription	_	NN	NN	_	9	IOBJ	_	_
13	although	_	IN	IN	_	9	OBJ	_	_
14	it	_	PRP	PRP	_	16	SBJ	_	_
15	functionally	_	RB	RB	_	16	ADV	_	_
16	enhanced	_	VBD	VBD	_	13	VMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	transcription	_	NN	NN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	another	_	DT	DT	_	21	NMOD	_	_
21	gene	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	Recombinant	_	JJ	JJ	_	3	NMOD	_	_
2	OTF-2	_	NN	NN	_	3	NMOD	_	_
3	protein	_	NN	NN	_	9	SBJ	_	_
4	produced	_	VBN	VBN	_	3	NMOD	_	_
5	by	_	IN	IN	_	4	ADV	_	_
6	in	_	FW	FW	_	7	AMOD	_	_
7	vitro	_	FW	FW	_	8	NMOD	_	_
8	transcription\/translation	_	NN	NN	_	5	PMOD	_	_
9	could	_	MD	MD	_	0	ROOT-S	_	_
10	also	_	RB	RB	_	9	ADV	_	_
11	enhance	_	VB	VB	_	9	VC	_	_
12	DRA	_	NN	NN	_	14	NMOD	_	_
13	gene	_	NN	NN	_	14	NMOD	_	_
14	transcription	_	NN	NN	_	11	OBJ	_	_
15	in	_	FW	FW	_	11	ADV	_	_
16	vitro	_	FW	FW	_	15	AMOD	_	_
17	.	_	.	.	_	9	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	vivo	_	FW	FW	_	5	NMOD	_	_
3	transient	_	JJ	JJ	_	5	NMOD	_	_
4	transfection	_	NN	NN	_	5	NMOD	_	_
5	studies	_	NNS	NNS	_	11	SBJ	_	_
6	utilizing	_	VBG	VBG	_	5	NMOD	_	_
7	an	_	DT	DT	_	10	NMOD	_	_
8	OTF-2	_	NN	NN	_	10	NMOD	_	_
9	expression	_	NN	NN	_	10	NMOD	_	_
10	vector	_	NN	NN	_	6	OBJ	_	_
11	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	similar	_	JJ	JJ	_	14	NMOD	_	_
14	findings	_	NNS	NNS	_	12	PMOD	_	_
15	:	_	:	:	_	14	P	_	_
16	that	_	IN	IN	_	14	NMOD	_	_
17	OTF-2	_	NN	NN	_	18	NMOD	_	_
18	protein	_	NN	NN	_	19	SBJ	_	_
19	enhanced	_	VBD	VBD	_	16	VMOD	_	_
20	DRA	_	NN	NN	_	22	NMOD	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	transcription	_	NN	NN	_	19	OBJ	_	_
23	,	_	,	,	_	16	P	_	_
24	and	_	CC	CC	_	16	CC	_	_
25	that	_	IN	IN	_	16	COORD	_	_
26	this	_	DT	DT	_	27	NMOD	_	_
27	effect	_	NN	NN	_	28	SBJ	_	_
28	requires	_	VBZ	VBZ	_	25	VMOD	_	_
29	an	_	DT	DT	_	32	NMOD	_	_
30	intact	_	JJ	JJ	_	32	NMOD	_	_
31	octamer	_	NN	NN	_	32	NMOD	_	_
32	element	_	NN	NN	_	28	OBJ	_	_
33	.	_	.	.	_	11	P	_	_

1	Together	_	RB	RB	_	4	ADV	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	results	_	NNS	NNS	_	4	SBJ	_	_
4	constitute	_	VBP	VBP	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	first	_	JJ	JJ	_	8	NMOD	_	_
7	direct	_	JJ	JJ	_	8	NMOD	_	_
8	evidence	_	NN	NN	_	4	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	positive	_	JJ	JJ	_	12	NMOD	_	_
12	role	_	NN	NN	_	9	PMOD	_	_
13	for	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	lymphoid-specific	_	JJ	JJ	_	17	NMOD	_	_
16	octamer-binding	_	JJ	JJ	_	17	NMOD	_	_
17	factor	_	NN	NN	_	13	PMOD	_	_
18	in	_	IN	IN	_	12	NMOD	_	_
19	DRA	_	NN	NN	_	21	NMOD	_	_
20	gene	_	NN	NN	_	21	NMOD	_	_
21	transcription	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	4	P	_	_

1	Corticosteroid	_	NN	NN	_	2	NMOD	_	_
2	receptors	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	lymphocyte	_	NN	NN	_	5	NMOD	_	_
5	subsets	_	NNS	NNS	_	2	COORD	_	_
6	in	_	IN	IN	_	2	NMOD	_	_
7	mononuclear	_	JJ	JJ	_	8	NMOD	_	_
8	leukocytes	_	NNS	NNS	_	6	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	aging	_	NN	NN	_	9	PMOD	_	_
11	.	_	.	.	_	2	P	_	_

1	Plasma	_	NN	NN	_	2	NMOD	_	_
2	cortisol	_	NN	NN	_	14	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	aldosterone	_	NN	NN	_	2	COORD	_	_
5	levels	_	NNS	NNS	_	4	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	number	_	NN	NN	_	5	COORD	_	_
8	of	_	IN	IN	_	4	NMOD	_	_
9	related	_	JJ	JJ	_	10	NMOD	_	_
10	receptors	_	NNS	NNS	_	8	PMOD	_	_
11	in	_	IN	IN	_	2	NMOD	_	_
12	mononuclear	_	JJ	JJ	_	13	NMOD	_	_
13	leukocytes	_	NNS	NNS	_	11	PMOD	_	_
14	were	_	VBD	VBD	_	0	ROOT-S	_	_
15	measured	_	VBN	VBN	_	14	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	49	_	CD	CD	_	20	NMOD	_	_
18	healthy	_	JJ	JJ	_	20	NMOD	_	_
19	aged	_	JJ	JJ	_	20	NMOD	_	_
20	subjects	_	NNS	NNS	_	16	PMOD	_	_
21	(	_	(	(	_	20	PRN	_	_
22	62-97	_	CD	CD	_	23	NMOD	_	_
23	yr	_	NN	NN	_	21	DEP	_	_
24	)	_	)	)	_	21	P	_	_
25	and	_	CC	CC	_	16	CC	_	_
26	in	_	IN	IN	_	16	COORD	_	_
27	21	_	CD	CD	_	29	NMOD	_	_
28	adult	_	JJ	JJ	_	29	NMOD	_	_
29	controls	_	NNS	NNS	_	26	PMOD	_	_
30	(	_	(	(	_	29	PRN	_	_
31	21-50	_	CD	CD	_	32	NMOD	_	_
32	yr	_	NN	NN	_	30	DEP	_	_
33	)	_	)	)	_	30	P	_	_
34	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	all	_	DT	DT	_	3	NMOD	_	_
3	subjects	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	10	P	_	_
5	in	_	IN	IN	_	10	ADV	_	_
6	addition	_	NN	NN	_	5	PMOD	_	_
7	,	_	,	,	_	10	P	_	_
8	lymphocyte	_	NN	NN	_	9	NMOD	_	_
9	subsets	_	NNS	NNS	_	10	SBJ	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	determined	_	VBN	VBN	_	10	VC	_	_
12	as	_	IN	IN	_	11	ADV	_	_
13	an	_	DT	DT	_	14	NMOD	_	_
14	index	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	corticosteroid	_	NN	NN	_	17	NMOD	_	_
17	action	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	mean	_	NN	NN	_	3	NMOD	_	_
3	number	_	NN	NN	_	11	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	type	_	NN	NN	_	10	NMOD	_	_
6	I	_	CD	CD	_	5	NMOD	_	_
7	and	_	CC	CC	_	5	CC	_	_
8	type	_	NN	NN	_	5	COORD	_	_
9	II	_	CD	CD	_	8	NMOD	_	_
10	receptors	_	NNS	NNS	_	4	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	significantly	_	RB	RB	_	13	AMOD	_	_
13	lower	_	JJR	JJR	_	11	PRD	_	_
14	in	_	IN	IN	_	11	ADV	_	_
15	aged	_	JJ	JJ	_	16	NMOD	_	_
16	subjects	_	NNS	NNS	_	14	PMOD	_	_
17	than	_	IN	IN	_	13	AMOD	_	_
18	in	_	IN	IN	_	17	PMOD	_	_
19	controls	_	NNS	NNS	_	18	PMOD	_	_
20	(	_	(	(	_	11	PRN	_	_
21	respectively	_	RB	RB	_	30	ADV	_	_
22	,	_	,	,	_	30	P	_	_
23	198	_	CD	CD	_	30	NMOD	_	_
24	+\/-	_	CC	CC	_	23	CC	_	_
25	96	_	CD	CD	_	23	COORD	_	_
26	and	_	CC	CC	_	23	CC	_	_
27	272	_	CD	CD	_	23	COORD	_	_
28	+\/-	_	CC	CC	_	23	CC	_	_
29	97	_	CD	CD	_	23	COORD	_	_
30	receptors\/cell	_	NNS	NNS	_	20	DEP	_	_
31	for	_	IN	IN	_	30	NMOD	_	_
32	type	_	NN	NN	_	31	PMOD	_	_
33	I	_	CD	CD	_	32	NMOD	_	_
34	,	_	,	,	_	30	P	_	_
35	and	_	CC	CC	_	30	CC	_	_
36	1,794	_	CD	CD	_	30	COORD	_	_
37	+\/-	_	CC	CC	_	36	CC	_	_
38	803	_	CD	CD	_	36	COORD	_	_
39	and	_	CC	CC	_	36	CC	_	_
40	3,339	_	CD	CD	_	36	COORD	_	_
41	+\/-	_	CC	CC	_	36	CC	_	_
42	918	_	CD	CD	_	36	COORD	_	_
43	for	_	IN	IN	_	36	NMOD	_	_
44	type	_	NN	NN	_	43	PMOD	_	_
45	II	_	CD	CD	_	44	NMOD	_	_
46	receptors	_	NNS	NNS	_	32	NMOD	_	_
47	)	_	)	)	_	20	P	_	_
48	.	_	.	.	_	11	P	_	_

1	Plasma	_	NN	NN	_	8	SBJ	_	_
2	aldosterone	_	NN	NN	_	1	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	cortisol	_	NN	NN	_	2	COORD	_	_
5	and	_	CC	CC	_	1	CC	_	_
6	lymphocyte	_	NN	NN	_	7	NMOD	_	_
7	subsets	_	NNS	NNS	_	1	COORD	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	different	_	JJ	JJ	_	8	PRD	_	_
11	in	_	IN	IN	_	8	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	two	_	CD	CD	_	14	NMOD	_	_
14	groups	_	NNS	NNS	_	11	PMOD	_	_
15	.	_	.	.	_	8	P	_	_

1	All	_	DT	DT	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	parameters	_	NNS	NNS	_	2	PMOD	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	also	_	RB	RB	_	5	ADV	_	_
7	tested	_	VBN	VBN	_	5	VC	_	_
8	for	_	IN	IN	_	7	ADV	_	_
9	correlation	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	5	P	_	_
11	and	_	CC	CC	_	5	CC	_	_
12	a	_	DT	DT	_	15	NMOD	_	_
13	significant	_	JJ	JJ	_	15	NMOD	_	_
14	inverse	_	JJ	JJ	_	15	NMOD	_	_
15	correlation	_	NN	NN	_	16	SBJ	_	_
16	was	_	VBD	VBD	_	5	COORD	_	_
17	found	_	VBN	VBN	_	16	VC	_	_
18	between	_	IN	IN	_	17	ADV	_	_
19	age	_	NN	NN	_	18	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	type	_	NN	NN	_	26	NMOD	_	_
22	I	_	CD	CD	_	21	NMOD	_	_
23	and	_	CC	CC	_	21	CC	_	_
24	type	_	NN	NN	_	21	COORD	_	_
25	II	_	CD	CD	_	24	NMOD	_	_
26	receptors	_	NNS	NNS	_	19	COORD	_	_
27	when	_	WRB	WRB	_	31	ADV	_	_
28	all	_	DT	DT	_	29	NMOD	_	_
29	subjects	_	NNS	NNS	_	30	SBJ	_	_
30	were	_	VBD	VBD	_	17	TMP	_	_
31	plotted	_	VBN	VBN	_	30	VC	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	between	_	IN	IN	_	31	ADV	_	_
34	aged	_	JJ	JJ	_	33	PMOD	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	CD4	_	NN	NN	_	34	COORD	_	_
37	and	_	CC	CC	_	34	CC	_	_
38	age	_	NN	NN	_	34	COORD	_	_
39	and	_	CC	CC	_	34	CC	_	_
40	CD4\/CD8	_	NN	NN	_	34	COORD	_	_
41	in	_	IN	IN	_	31	ADV	_	_
42	the	_	DT	DT	_	44	NMOD	_	_
43	aged	_	JJ	JJ	_	44	NMOD	_	_
44	group	_	NN	NN	_	41	PMOD	_	_
45	.	_	.	.	_	5	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	aged	_	JJ	JJ	_	6	NMOD	_	_
6	subjects	_	NNS	NNS	_	7	SBJ	_	_
7	have	_	VBP	VBP	_	4	VMOD	_	_
8	reductions	_	NNS	NNS	_	7	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	corticosteroid	_	NN	NN	_	11	NMOD	_	_
11	receptors	_	NNS	NNS	_	9	PMOD	_	_
12	that	_	WDT	WDT	_	13	SBJ	_	_
13	are	_	VBP	VBP	_	8	NMOD	_	_
14	not	_	RB	RB	_	13	VMOD	_	_
15	associated	_	VBN	VBN	_	13	VC	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	increase	_	NN	NN	_	16	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	related	_	JJ	JJ	_	20	NMOD	_	_
20	steroids	_	NNS	NNS	_	18	PMOD	_	_
21	and	_	CC	CC	_	4	CC	_	_
22	that	_	IN	IN	_	4	COORD	_	_
23	this	_	DT	DT	_	24	NMOD	_	_
24	situation	_	NN	NN	_	26	SBJ	_	_
25	probably	_	RB	RB	_	26	ADV	_	_
26	represents	_	VBZ	VBZ	_	22	VMOD	_	_
27	a	_	DT	DT	_	28	NMOD	_	_
28	concomitant	_	NN	NN	_	26	OBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	33	NMOD	_	_
31	normal	_	JJ	JJ	_	33	NMOD	_	_
32	aging	_	NN	NN	_	33	NMOD	_	_
33	process	_	NN	NN	_	29	PMOD	_	_
34	.	_	.	.	_	3	P	_	_

1	Interferon-gamma	_	NN	NN	_	2	SBJ	_	_
2	potentiates	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	antiviral	_	JJ	JJ	_	5	NMOD	_	_
5	activity	_	NN	NN	_	2	OBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	expression	_	NN	NN	_	5	COORD	_	_
9	of	_	IN	IN	_	5	NMOD	_	_
10	interferon-stimulated	_	JJ	JJ	_	11	NMOD	_	_
11	genes	_	NNS	NNS	_	9	PMOD	_	_
12	induced	_	VBN	VBN	_	5	NMOD	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	interferon-alpha	_	NN	NN	_	13	PMOD	_	_
15	in	_	IN	IN	_	12	ADV	_	_
16	U937	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	15	PMOD	_	_
18	.	_	.	.	_	2	P	_	_

1	Binding	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	type	_	NN	NN	_	5	NMOD	_	_
4	I	_	CD	CD	_	5	NMOD	_	_
5	interferon	_	NN	NN	_	2	PMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	IFN-alpha\/beta	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	to	_	TO	TO	_	1	NMOD	_	_
10	specific	_	JJ	JJ	_	11	NMOD	_	_
11	receptors	_	NNS	NNS	_	9	PMOD	_	_
12	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	rapid	_	JJ	JJ	_	17	NMOD	_	_
16	transcriptional	_	JJ	JJ	_	17	NMOD	_	_
17	activation	_	NN	NN	_	13	PMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	independent	_	JJ	JJ	_	17	NMOD	_	_
20	of	_	IN	IN	_	19	AMOD	_	_
21	protein	_	NN	NN	_	22	NMOD	_	_
22	synthesis	_	NN	NN	_	20	PMOD	_	_
23	,	_	,	,	_	17	P	_	_
24	of	_	IN	IN	_	17	NMOD	_	_
25	IFN-alpha-stimulated	_	JJ	JJ	_	26	NMOD	_	_
26	genes	_	NNS	NNS	_	24	PMOD	_	_
27	(	_	(	(	_	28	P	_	_
28	ISGs	_	NNS	NNS	_	26	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	in	_	IN	IN	_	26	NMOD	_	_
31	human	_	JJ	JJ	_	32	NMOD	_	_
32	fibroblasts	_	NNS	NNS	_	30	PMOD	_	_
33	and	_	CC	CC	_	32	CC	_	_
34	HeLa	_	NN	NN	_	38	NMOD	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	Daudi	_	NN	NN	_	34	COORD	_	_
37	cell	_	NN	NN	_	38	NMOD	_	_
38	lines	_	NNS	NNS	_	32	COORD	_	_
39	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	binding	_	NN	NN	_	20	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	ISGF3	_	NN	NN	_	3	PMOD	_	_
5	(	_	(	(	_	8	P	_	_
6	IFN-stimulated	_	JJ	JJ	_	8	NMOD	_	_
7	gene	_	NN	NN	_	8	NMOD	_	_
8	factor	_	NN	NN	_	4	PRN	_	_
9	3	_	CD	CD	_	8	NMOD	_	_
10	)	_	)	)	_	8	P	_	_
11	to	_	TO	TO	_	2	NMOD	_	_
12	the	_	DT	DT	_	16	NMOD	_	_
13	conserved	_	VBN	VBN	_	16	NMOD	_	_
14	IFN-stimulated	_	JJ	JJ	_	16	NMOD	_	_
15	response	_	NN	NN	_	16	NMOD	_	_
16	element	_	NN	NN	_	11	PMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	ISRE	_	NN	NN	_	16	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	transcriptional	_	JJ	JJ	_	23	NMOD	_	_
23	activation	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	20	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	factor	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	composed	_	VBN	VBN	_	3	VC	_	_
5	of	_	IN	IN	_	4	ADV	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	DNA-binding	_	JJ	JJ	_	8	NMOD	_	_
8	protein	_	NN	NN	_	5	PMOD	_	_
9	(	_	(	(	_	11	P	_	_
10	ISGF3	_	NN	NN	_	11	NMOD	_	_
11	gamma	_	NN	NN	_	8	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	,	_	,	,	_	8	P	_	_
14	which	_	WDT	WDT	_	16	SBJ	_	_
15	normally	_	RB	RB	_	16	ADV	_	_
16	is	_	VBZ	VBZ	_	8	NMOD	_	_
17	present	_	JJ	JJ	_	16	PRD	_	_
18	in	_	IN	IN	_	17	AMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	cytoplasm	_	NN	NN	_	18	PMOD	_	_
21	,	_	,	,	_	8	P	_	_
22	and	_	CC	CC	_	8	CC	_	_
23	other	_	JJ	JJ	_	25	NMOD	_	_
24	IFN-alpha-activated	_	JJ	JJ	_	25	NMOD	_	_
25	proteins	_	NNS	NNS	_	8	COORD	_	_
26	which	_	WDT	WDT	_	27	SBJ	_	_
27	preexist	_	VBP	VBP	_	25	NMOD	_	_
28	as	_	IN	IN	_	27	ADV	_	_
29	latent	_	JJ	JJ	_	31	NMOD	_	_
30	cytoplasmic	_	JJ	JJ	_	31	NMOD	_	_
31	precursors	_	NNS	NNS	_	28	PMOD	_	_
32	(	_	(	(	_	34	P	_	_
33	ISGF3	_	NN	NN	_	34	NMOD	_	_
34	alpha	_	NN	NN	_	31	PRN	_	_
35	)	_	)	)	_	34	P	_	_
36	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	ISG	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	13	SBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	monocytic	_	JJ	JJ	_	12	NMOD	_	_
10	U937	_	NN	NN	_	12	NMOD	_	_
11	cell	_	NN	NN	_	12	NMOD	_	_
12	line	_	NN	NN	_	7	PMOD	_	_
13	differs	_	VBZ	VBZ	_	4	VMOD	_	_
14	from	_	IN	IN	_	13	ADV	_	_
15	most	_	JJS	JJS	_	17	NMOD	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	lines	_	NNS	NNS	_	14	PMOD	_	_
18	previously	_	RB	RB	_	19	TMP	_	_
19	examined	_	VBN	VBN	_	17	NMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	U937	_	NN	NN	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	3	SBJ	_	_
3	express	_	VBP	VBP	_	0	ROOT-S	_	_
4	both	_	CC	CC	_	5	CC	_	_
5	type	_	NN	NN	_	11	NMOD	_	_
6	I	_	CD	CD	_	5	NMOD	_	_
7	and	_	CC	CC	_	5	CC	_	_
8	type	_	NN	NN	_	5	COORD	_	_
9	II	_	CD	CD	_	8	NMOD	_	_
10	IFN	_	NN	NN	_	11	NMOD	_	_
11	receptors	_	NNS	NNS	_	3	OBJ	_	_
12	,	_	,	,	_	3	P	_	_
13	but	_	CC	CC	_	3	CC	_	_
14	only	_	RB	RB	_	15	NMOD	_	_
15	IFN-alpha	_	NN	NN	_	16	SBJ	_	_
16	is	_	VBZ	VBZ	_	3	COORD	_	_
17	capable	_	JJ	JJ	_	16	PRD	_	_
18	of	_	IN	IN	_	17	AMOD	_	_
19	inducing	_	VBG	VBG	_	18	PMOD	_	_
20	antiviral	_	JJ	JJ	_	21	NMOD	_	_
21	protection	_	NN	NN	_	19	OBJ	_	_
22	in	_	IN	IN	_	19	ADV	_	_
23	these	_	DT	DT	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	Pretreatment	_	NN	NN	_	4	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	IFN-gamma	_	NN	NN	_	2	PMOD	_	_
4	potentiates	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	IFN-alpha-induced	_	JJ	JJ	_	7	NMOD	_	_
7	protection	_	NN	NN	_	4	OBJ	_	_
8	,	_	,	,	_	4	P	_	_
9	but	_	CC	CC	_	4	CC	_	_
10	IFN-gamma	_	NN	NN	_	12	SBJ	_	_
11	alone	_	RB	RB	_	10	NMOD	_	_
12	does	_	VBZ	VBZ	_	4	COORD	_	_
13	not	_	RB	RB	_	12	VMOD	_	_
14	have	_	VB	VB	_	12	VC	_	_
15	any	_	DT	DT	_	17	NMOD	_	_
16	antiviral	_	JJ	JJ	_	17	NMOD	_	_
17	activity	_	NN	NN	_	14	OBJ	_	_
18	.	_	.	.	_	4	P	_	_

1	ISG15	_	NN	NN	_	3	NMOD	_	_
2	mRNA	_	NN	NN	_	3	NMOD	_	_
3	accumulation	_	NN	NN	_	7	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	U937	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	not	_	RB	RB	_	7	VMOD	_	_
9	detectable	_	JJ	JJ	_	7	PRD	_	_
10	before	_	IN	IN	_	7	TMP	_	_
11	6	_	CD	CD	_	12	NMOD	_	_
12	h	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	IFN-alpha	_	NN	NN	_	15	NMOD	_	_
15	treatment	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	7	P	_	_
17	peaks	_	VBZ	VBZ	_	7	COORD	_	_
18	at	_	IN	IN	_	17	TMP	_	_
19	24	_	CD	CD	_	20	NMOD	_	_
20	h	_	NN	NN	_	18	PMOD	_	_
21	,	_	,	,	_	7	P	_	_
22	and	_	CC	CC	_	7	CC	_	_
23	requires	_	VBZ	VBZ	_	7	COORD	_	_
24	protein	_	NN	NN	_	25	NMOD	_	_
25	synthesis	_	NN	NN	_	23	OBJ	_	_
26	.	_	.	.	_	7	P	_	_

1	Although	_	IN	IN	_	13	ADV	_	_
2	IFN-gamma	_	NN	NN	_	4	SBJ	_	_
3	alone	_	RB	RB	_	2	NMOD	_	_
4	does	_	VBZ	VBZ	_	1	VMOD	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	induce	_	VB	VB	_	4	VC	_	_
7	ISG	_	NN	NN	_	8	NMOD	_	_
8	expression	_	NN	NN	_	6	OBJ	_	_
9	,	_	,	,	_	13	P	_	_
10	IFN-gamma	_	NN	NN	_	11	NMOD	_	_
11	pretreatment	_	NN	NN	_	13	SBJ	_	_
12	markedly	_	RB	RB	_	13	ADV	_	_
13	increases	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	hastens	_	VBZ	VBZ	_	13	COORD	_	_
16	ISG	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	13	OBJ	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	transcriptional	_	JJ	JJ	_	20	NMOD	_	_
20	induction	_	NN	NN	_	17	COORD	_	_
21	.	_	.	.	_	13	P	_	_

1	Nuclear	_	JJ	JJ	_	2	NMOD	_	_
2	extracts	_	NNS	NNS	_	16	SBJ	_	_
3	assayed	_	VBN	VBN	_	2	NMOD	_	_
4	for	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	presence	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	ISRE	_	NN	NN	_	10	NMOD	_	_
9	binding	_	NN	NN	_	10	NMOD	_	_
10	factors	_	NNS	NNS	_	7	PMOD	_	_
11	by	_	IN	IN	_	3	ADV	_	_
12	electrophoretic	_	JJ	JJ	_	15	NMOD	_	_
13	mobility	_	NN	NN	_	15	NMOD	_	_
14	shift	_	NN	NN	_	15	NMOD	_	_
15	assays	_	NNS	NNS	_	11	PMOD	_	_
16	show	_	VBP	VBP	_	0	ROOT-S	_	_
17	that	_	IN	IN	_	16	OBJ	_	_
18	ISGF3	_	NN	NN	_	19	SBJ	_	_
19	is	_	VBZ	VBZ	_	17	VMOD	_	_
20	induced	_	VBN	VBN	_	19	VC	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	IFN-alpha	_	NN	NN	_	21	PMOD	_	_
23	within	_	IN	IN	_	20	TMP	_	_
24	6	_	CD	CD	_	25	NMOD	_	_
25	h	_	NN	NN	_	23	PMOD	_	_
26	from	_	IN	IN	_	20	ADV	_	_
27	undetectable	_	JJ	JJ	_	29	NMOD	_	_
28	basal	_	JJ	JJ	_	29	NMOD	_	_
29	levels	_	NNS	NNS	_	26	PMOD	_	_
30	in	_	IN	IN	_	20	ADV	_	_
31	untreated	_	JJ	JJ	_	33	NMOD	_	_
32	U937	_	NN	NN	_	33	NMOD	_	_
33	cells	_	NNS	NNS	_	30	PMOD	_	_
34	.	_	.	.	_	16	P	_	_

1	Activation	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	ISGF3	_	NN	NN	_	4	NMOD	_	_
4	alpha	_	NN	NN	_	2	PMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	latent	_	JJ	JJ	_	8	NMOD	_	_
8	component	_	NN	NN	_	4	NMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	ISGF3	_	NN	NN	_	9	PMOD	_	_
11	,	_	,	,	_	4	P	_	_
12	occurs	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	rapidly	_	RB	RB	_	12	TMP	_	_
14	.	_	.	.	_	12	P	_	_

1	However	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	increase	_	NN	NN	_	9	SBJ	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	ISGF3	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	5	PMOD	_	_
8	ultimately	_	RB	RB	_	9	ADV	_	_
9	correlates	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	with	_	IN	IN	_	9	ADV	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	accumulation	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	ISGF3	_	NN	NN	_	15	NMOD	_	_
15	gamma	_	NN	NN	_	13	PMOD	_	_
16	induced	_	VBN	VBN	_	12	NMOD	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	IFN-alpha	_	NN	NN	_	17	PMOD	_	_
19	or	_	CC	CC	_	18	CC	_	_
20	IFN-gamma	_	NN	NN	_	18	COORD	_	_
21	.	_	.	.	_	9	P	_	_

1	(	_	(	(	_	3	P	_	_
2	ABSTRACT	_	NN	NN	_	3	SBJ	_	_
3	TRUNCATED	_	VBN	VBN	_	0	ROOT-S	_	_
4	AT	_	IN	IN	_	3	ADV	_	_
5	250	_	CD	CD	_	6	NMOD	_	_
6	WORDS	_	NNS	NNS	_	4	PMOD	_	_
7	)	_	)	)	_	3	P	_	_

1	Specific	_	JJ	JJ	_	4	NMOD	_	_
2	NF-kappa	_	NN	NN	_	4	NMOD	_	_
3	B	_	NN	NN	_	4	NMOD	_	_
4	subunits	_	NNS	NNS	_	5	SBJ	_	_
5	act	_	VBP	VBP	_	0	ROOT-S	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	concert	_	NN	NN	_	6	DEP	_	_
8	with	_	IN	IN	_	6	DEP	_	_
9	Tat	_	NN	NN	_	6	PMOD	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	stimulate	_	VB	VB	_	5	OBJ	_	_
12	human	_	JJ	JJ	_	17	NMOD	_	_
13	immunodeficiency	_	NN	NN	_	17	NMOD	_	_
14	virus	_	NN	NN	_	17	NMOD	_	_
15	type	_	NN	NN	_	17	NMOD	_	_
16	1	_	CD	CD	_	17	NMOD	_	_
17	transcription	_	NN	NN	_	11	OBJ	_	_
18	.	_	.	.	_	5	P	_	_

1	NF-kappa	_	NN	NN	_	2	NMOD	_	_
2	B	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	protein	_	NN	NN	_	6	NMOD	_	_
6	complex	_	NN	NN	_	3	PRD	_	_
7	which	_	WDT	WDT	_	8	SBJ	_	_
8	functions	_	VBZ	VBZ	_	6	NMOD	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	concert	_	NN	NN	_	9	DEP	_	_
11	with	_	IN	IN	_	9	DEP	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	tat-I	_	NN	NN	_	15	NMOD	_	_
14	gene	_	NN	NN	_	15	NMOD	_	_
15	product	_	NN	NN	_	9	PMOD	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	stimulate	_	VB	VB	_	8	OBJ	_	_
18	human	_	JJ	JJ	_	20	NMOD	_	_
19	immunodeficiency	_	NN	NN	_	20	NMOD	_	_
20	virus	_	NN	NN	_	24	NMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	HIV	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	transcription	_	NN	NN	_	17	OBJ	_	_
25	.	_	.	.	_	3	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	determine	_	VB	VB	_	17	ADV	_	_
3	whether	_	IN	IN	_	2	OBJ	_	_
4	specific	_	JJ	JJ	_	5	NMOD	_	_
5	members	_	NNS	NNS	_	11	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	NF-kappa	_	NN	NN	_	10	NMOD	_	_
9	B	_	NN	NN	_	10	NMOD	_	_
10	family	_	NN	NN	_	6	PMOD	_	_
11	contribute	_	VBP	VBP	_	3	VMOD	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	this	_	DT	DT	_	14	NMOD	_	_
14	effect	_	NN	NN	_	12	PMOD	_	_
15	,	_	,	,	_	17	P	_	_
16	we	_	PRP	PRP	_	17	SBJ	_	_
17	have	_	VBP	VBP	_	0	ROOT-S	_	_
18	examined	_	VBN	VBN	_	17	VC	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	abilities	_	NNS	NNS	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	different	_	JJ	JJ	_	25	NMOD	_	_
23	NF-kappa	_	NN	NN	_	25	NMOD	_	_
24	B	_	NN	NN	_	25	NMOD	_	_
25	subunits	_	NNS	NNS	_	21	PMOD	_	_
26	to	_	TO	TO	_	27	VMOD	_	_
27	act	_	VB	VB	_	20	NMOD	_	_
28	with	_	IN	IN	_	27	ADV	_	_
29	Tat-I	_	NN	NN	_	28	PMOD	_	_
30	to	_	TO	TO	_	31	VMOD	_	_
31	stimulate	_	VB	VB	_	27	OBJ	_	_
32	transcription	_	NN	NN	_	31	OBJ	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	HIV	_	NN	NN	_	33	PMOD	_	_
35	in	_	IN	IN	_	32	NMOD	_	_
36	Jurkat	_	NN	NN	_	38	NMOD	_	_
37	T-leukemia	_	NN	NN	_	38	NMOD	_	_
38	cells	_	NNS	NNS	_	35	PMOD	_	_
39	.	_	.	.	_	17	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	12	NMOD	_	_
6	p49	_	NN	NN	_	12	NMOD	_	_
7	(	_	(	(	_	12	P	_	_
8	100	_	CD	CD	_	12	NMOD	_	_
9	)	_	)	)	_	12	P	_	_
10	DNA	_	NN	NN	_	12	NMOD	_	_
11	binding	_	NN	NN	_	12	NMOD	_	_
12	subunit	_	NN	NN	_	18	SBJ	_	_
13	,	_	,	,	_	18	P	_	_
14	together	_	RB	RB	_	15	DEP	_	_
15	with	_	IN	IN	_	18	ADV	_	_
16	p65	_	NN	NN	_	15	PMOD	_	_
17	,	_	,	,	_	18	P	_	_
18	can	_	MD	MD	_	4	VMOD	_	_
19	act	_	VB	VB	_	18	VC	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	concert	_	NN	NN	_	20	DEP	_	_
22	with	_	IN	IN	_	20	DEP	_	_
23	Tat-I	_	NN	NN	_	20	PMOD	_	_
24	to	_	TO	TO	_	25	VMOD	_	_
25	stimulate	_	VB	VB	_	19	OBJ	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	expression	_	NN	NN	_	25	OBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	HIV-CAT	_	NN	NN	_	30	NMOD	_	_
30	plasmid	_	NN	NN	_	28	PMOD	_	_
31	.	_	.	.	_	2	P	_	_

1	Little	_	JJ	JJ	_	2	NMOD	_	_
2	effect	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	observed	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	50-kDa	_	JJ	JJ	_	7	NMOD	_	_
7	forms	_	NNS	NNS	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	p105	_	NN	NN	_	11	NMOD	_	_
10	NF-kappa	_	NN	NN	_	11	NMOD	_	_
11	B	_	NN	NN	_	8	PMOD	_	_
12	or	_	CC	CC	_	11	CC	_	_
13	rel	_	NN	NN	_	11	COORD	_	_
14	,	_	,	,	_	4	P	_	_
15	in	_	IN	IN	_	4	ADV	_	_
16	combination	_	NN	NN	_	15	PMOD	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	p65	_	NN	NN	_	17	PMOD	_	_
19	or	_	CC	CC	_	18	CC	_	_
20	full-length	_	JJ	JJ	_	21	NMOD	_	_
21	c-rel	_	NN	NN	_	18	COORD	_	_
22	,	_	,	,	_	18	P	_	_
23	which	_	WDT	WDT	_	24	SBJ	_	_
24	do	_	VBP	VBP	_	18	NMOD	_	_
25	not	_	RB	RB	_	24	VMOD	_	_
26	stimulate	_	VB	VB	_	24	VC	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	HIV	_	NN	NN	_	29	NMOD	_	_
29	enhancer	_	NN	NN	_	26	OBJ	_	_
30	in	_	IN	IN	_	29	NMOD	_	_
31	these	_	DT	DT	_	32	NMOD	_	_
32	cells	_	NNS	NNS	_	30	PMOD	_	_
33	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	combination	_	NN	NN	_	16	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	p49	_	NN	NN	_	7	PMOD	_	_
9	(	_	(	(	_	8	P	_	_
10	100	_	CD	CD	_	8	NMOD	_	_
11	)	_	)	)	_	8	P	_	_
12	and	_	CC	CC	_	8	CC	_	_
13	p65	_	NN	NN	_	15	NMOD	_	_
14	NF-kappa	_	NN	NN	_	15	NMOD	_	_
15	B	_	NN	NN	_	8	COORD	_	_
16	can	_	MD	MD	_	4	VMOD	_	_
17	act	_	VB	VB	_	16	VC	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	concert	_	NN	NN	_	18	DEP	_	_
20	with	_	IN	IN	_	18	DEP	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	tat-I	_	NN	NN	_	24	NMOD	_	_
23	gene	_	NN	NN	_	24	NMOD	_	_
24	product	_	NN	NN	_	18	PMOD	_	_
25	to	_	TO	TO	_	26	VMOD	_	_
26	stimulate	_	VB	VB	_	17	OBJ	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	synthesis	_	NN	NN	_	26	OBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	HIV	_	NN	NN	_	31	NMOD	_	_
31	RNA	_	NN	NN	_	29	PMOD	_	_
32	.	_	.	.	_	3	P	_	_

1	Reduced	_	VBN	VBN	_	2	NMOD	_	_
2	susceptibility	_	NN	NN	_	10	SBJ	_	_
3	to	_	TO	TO	_	2	NMOD	_	_
4	HIV-1	_	NN	NN	_	5	NMOD	_	_
5	infection	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	ethyl-methanesulfonate-treated	_	JJ	JJ	_	9	NMOD	_	_
8	CEM	_	NN	NN	_	9	NMOD	_	_
9	subclones	_	NNS	NNS	_	6	PMOD	_	_
10	correlates	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	a	_	DT	DT	_	13	NMOD	_	_
13	blockade	_	NN	NN	_	11	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	their	_	PRP$	PRP$	_	20	NMOD	_	_
16	protein	_	NN	NN	_	20	NMOD	_	_
17	kinase	_	NN	NN	_	20	NMOD	_	_
18	C	_	NN	NN	_	20	NMOD	_	_
19	signaling	_	NN	NN	_	20	NMOD	_	_
20	pathway	_	NN	NN	_	14	PMOD	_	_
21	.	_	.	.	_	10	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	described	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	isolation	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	chemically	_	RB	RB	_	8	AMOD	_	_
8	induced	_	VBN	VBN	_	10	NMOD	_	_
9	CEM	_	NN	NN	_	10	NMOD	_	_
10	subclones	_	NNS	NNS	_	6	PMOD	_	_
11	that	_	WDT	WDT	_	12	SBJ	_	_
12	express	_	VBP	VBP	_	10	NMOD	_	_
13	CD4	_	NN	NN	_	14	NMOD	_	_
14	receptors	_	NNS	NNS	_	12	OBJ	_	_
15	and	_	CC	CC	_	12	CC	_	_
16	bind	_	VBP	VBP	_	12	COORD	_	_
17	soluble	_	JJ	JJ	_	18	NMOD	_	_
18	gp120	_	NN	NN	_	16	OBJ	_	_
19	,	_	,	,	_	12	P	_	_
20	yet	_	RB	RB	_	12	COORD	_	_
21	show	_	VBP	VBP	_	12	COORD	_	_
22	a	_	DT	DT	_	25	NMOD	_	_
23	markedly	_	RB	RB	_	24	AMOD	_	_
24	reduced	_	VBN	VBN	_	25	NMOD	_	_
25	susceptibility	_	NN	NN	_	21	OBJ	_	_
26	to	_	TO	TO	_	25	NMOD	_	_
27	infection	_	NN	NN	_	26	PMOD	_	_
28	with	_	IN	IN	_	27	NMOD	_	_
29	HIV-1	_	NN	NN	_	28	PMOD	_	_
30	.	_	.	.	_	2	P	_	_

1	Two	_	CD	CD	_	2	NMOD	_	_
2	subclones	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	found	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	have	_	VB	VB	_	4	OBJ	_	_
7	an	_	DT	DT	_	9	NMOD	_	_
8	abnormal	_	JJ	JJ	_	9	NMOD	_	_
9	response	_	NN	NN	_	6	OBJ	_	_
10	to	_	TO	TO	_	9	NMOD	_	_
11	the	_	DT	DT	_	19	NMOD	_	_
12	protein	_	NN	NN	_	14	NMOD	_	_
13	kinase	_	NN	NN	_	14	NMOD	_	_
14	C	_	NN	NN	_	19	NMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	PKC	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	activator	_	NN	NN	_	19	NMOD	_	_
19	PMA	_	NN	NN	_	10	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	PMA	_	NN	NN	_	2	NMOD	_	_
2	treatment	_	NN	NN	_	3	SBJ	_	_
3	induced	_	VBD	VBD	_	0	ROOT-S	_	_
4	CD3	_	NN	NN	_	10	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	CD25	_	NN	NN	_	4	COORD	_	_
7	(	_	(	(	_	8	P	_	_
8	IL-2R	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	receptors	_	NNS	NNS	_	3	OBJ	_	_
11	on	_	IN	IN	_	3	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	parental	_	JJ	JJ	_	14	NMOD	_	_
14	line	_	NN	NN	_	11	PMOD	_	_
15	and	_	CC	CC	_	11	CC	_	_
16	on	_	IN	IN	_	11	COORD	_	_
17	other	_	JJ	JJ	_	19	NMOD	_	_
18	ethyl-methanesulfonate-derived	_	JJ	JJ	_	19	NMOD	_	_
19	subclones	_	NNS	NNS	_	16	PMOD	_	_
20	,	_	,	,	_	11	P	_	_
21	but	_	CC	CC	_	11	CC	_	_
22	not	_	RB	RB	_	23	DEP	_	_
23	on	_	IN	IN	_	11	COORD	_	_
24	these	_	DT	DT	_	26	NMOD	_	_
25	two	_	CD	CD	_	26	NMOD	_	_
26	mutants	_	NNS	NNS	_	23	PMOD	_	_
27	.	_	.	.	_	3	P	_	_

1	Direct	_	JJ	JJ	_	2	NMOD	_	_
2	assays	_	NNS	NNS	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	PKC	_	NN	NN	_	5	NMOD	_	_
5	activity	_	NN	NN	_	3	PMOD	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	conducted	_	VBN	VBN	_	6	VC	_	_
8	.	_	.	.	_	6	P	_	_

1	Total	_	JJ	JJ	_	5	NMOD	_	_
2	cellular	_	JJ	JJ	_	5	NMOD	_	_
3	PKC	_	NN	NN	_	5	NMOD	_	_
4	enzymatic	_	JJ	JJ	_	5	NMOD	_	_
5	activity	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	found	_	VBN	VBN	_	6	VC	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	be	_	VB	VB	_	7	OBJ	_	_
10	normal	_	JJ	JJ	_	9	PRD	_	_
11	in	_	IN	IN	_	9	ADV	_	_
12	these	_	DT	DT	_	13	NMOD	_	_
13	subclones	_	NNS	NNS	_	11	PMOD	_	_
14	.	_	.	.	_	6	P	_	_

1	PMA-induced	_	JJ	JJ	_	3	NMOD	_	_
2	CD4	_	NN	NN	_	3	NMOD	_	_
3	down-modulation	_	NN	NN	_	4	SBJ	_	_
4	occurred	_	VBD	VBD	_	0	ROOT-S	_	_
5	normally	_	RB	RB	_	4	ADV	_	_
6	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	8	P	_	_
4	activation	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	c-raf	_	NN	NN	_	7	NMOD	_	_
7	kinase	_	NN	NN	_	5	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	normal	_	JJ	JJ	_	8	PRD	_	_
10	.	_	.	.	_	8	P	_	_

1	Since	_	IN	IN	_	19	ADV	_	_
2	HIV-1	_	NN	NN	_	5	NMOD	_	_
3	long	_	JJ	JJ	_	5	NMOD	_	_
4	terminal	_	JJ	JJ	_	5	NMOD	_	_
5	repeat	_	NN	NN	_	6	SBJ	_	_
6	contains	_	VBZ	VBZ	_	1	VMOD	_	_
7	two	_	CD	CD	_	16	NMOD	_	_
8	functional	_	JJ	JJ	_	16	NMOD	_	_
9	nuclear	_	JJ	JJ	_	11	NMOD	_	_
10	factor	_	NN	NN	_	11	NMOD	_	_
11	kB	_	NN	NN	_	16	NMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	NF-kB	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	regulatory	_	JJ	JJ	_	16	NMOD	_	_
16	elements	_	NNS	NNS	_	6	OBJ	_	_
17	,	_	,	,	_	19	P	_	_
18	we	_	PRP	PRP	_	19	SBJ	_	_
19	studied	_	VBD	VBD	_	0	ROOT-S	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	ability	_	NN	NN	_	19	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	PMA	_	NN	NN	_	22	PMOD	_	_
24	to	_	TO	TO	_	25	VMOD	_	_
25	induce	_	VB	VB	_	21	NMOD	_	_
26	NF-kB	_	NN	NN	_	28	NMOD	_	_
27	binding	_	NN	NN	_	28	NMOD	_	_
28	activity	_	NN	NN	_	25	OBJ	_	_
29	by	_	IN	IN	_	25	ADV	_	_
30	different	_	JJ	JJ	_	31	NMOD	_	_
31	assays	_	NNS	NNS	_	29	PMOD	_	_
32	.	_	.	.	_	19	P	_	_

1	Chloramphenicol	_	NN	NN	_	3	NMOD	_	_
2	acetyl	_	NN	NN	_	3	NMOD	_	_
3	transferase	_	NN	NN	_	7	NMOD	_	_
4	(	_	(	(	_	5	P	_	_
5	CAT	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	assays	_	NNS	NNS	_	18	SBJ	_	_
8	using	_	VBG	VBG	_	7	NMOD	_	_
9	the	_	DT	DT	_	17	NMOD	_	_
10	HIV-1	_	NN	NN	_	17	NMOD	_	_
11	(	_	(	(	_	16	P	_	_
12	-139	_	CD	CD	_	16	AMOD	_	_
13	)	_	)	)	_	16	P	_	_
14	long	_	JJ	JJ	_	16	AMOD	_	_
15	terminal	_	JJ	JJ	_	16	AMOD	_	_
16	repeat-CAT	_	JJ	JJ	_	17	NMOD	_	_
17	construct	_	NN	NN	_	8	OBJ	_	_
18	showed	_	VBD	VBD	_	0	ROOT-S	_	_
19	no	_	DT	DT	_	21	NMOD	_	_
20	PMA	_	NN	NN	_	21	NMOD	_	_
21	induction	_	NN	NN	_	18	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	CAT	_	NN	NN	_	24	NMOD	_	_
24	activity	_	NN	NN	_	22	PMOD	_	_
25	in	_	IN	IN	_	18	ADV	_	_
26	these	_	DT	DT	_	27	NMOD	_	_
27	subclones	_	NNS	NNS	_	25	PMOD	_	_
28	(	_	(	(	_	18	P	_	_
29	unlike	_	IN	IN	_	18	ADV	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	parental	_	JJ	JJ	_	32	NMOD	_	_
32	line	_	NN	NN	_	29	PMOD	_	_
33	and	_	CC	CC	_	32	CC	_	_
34	other	_	JJ	JJ	_	35	NMOD	_	_
35	subclones	_	NNS	NNS	_	32	COORD	_	_
36	)	_	)	)	_	18	P	_	_
37	.	_	.	.	_	18	P	_	_

1	Okadaic	_	JJ	JJ	_	2	NMOD	_	_
2	acid	_	NN	NN	_	12	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	an	_	DT	DT	_	5	NMOD	_	_
5	inhibitor	_	NN	NN	_	2	NMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	phosphatases	_	NNS	NNS	_	6	PMOD	_	_
8	1	_	CD	CD	_	7	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	2A	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	2	P	_	_
12	did	_	VBD	VBD	_	0	ROOT-S	_	_
13	not	_	RB	RB	_	12	VMOD	_	_
14	overcome	_	VB	VB	_	12	VC	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	defect	_	NN	NN	_	14	OBJ	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	these	_	DT	DT	_	19	NMOD	_	_
19	subclones	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	12	P	_	_

1	Gel	_	NN	NN	_	3	NMOD	_	_
2	retardation	_	NN	NN	_	3	NMOD	_	_
3	assays	_	NNS	NNS	_	20	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	using	_	VBG	VBG	_	3	NMOD	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	32P-probe	_	NN	NN	_	5	OBJ	_	_
8	containing	_	VBG	VBG	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	HIV-1	_	NN	NN	_	12	NMOD	_	_
11	NF-kB	_	NN	NN	_	12	NMOD	_	_
12	probe	_	NN	NN	_	8	OBJ	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	nuclear	_	JJ	JJ	_	15	NMOD	_	_
15	extracts	_	NNS	NNS	_	12	COORD	_	_
16	from	_	IN	IN	_	15	NMOD	_	_
17	PMA-treated	_	JJ	JJ	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	16	PMOD	_	_
19	,	_	,	,	_	3	P	_	_
20	showed	_	VBD	VBD	_	0	ROOT-S	_	_
21	significantly	_	RB	RB	_	22	AMOD	_	_
22	reduced	_	VBN	VBN	_	23	NMOD	_	_
23	induction	_	NN	NN	_	20	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	nuclear	_	JJ	JJ	_	28	NMOD	_	_
26	NF-kB	_	NN	NN	_	28	NMOD	_	_
27	binding	_	NN	NN	_	28	NMOD	_	_
28	proteins	_	NNS	NNS	_	24	PMOD	_	_
29	in	_	IN	IN	_	20	ADV	_	_
30	these	_	DT	DT	_	32	NMOD	_	_
31	two	_	CD	CD	_	32	NMOD	_	_
32	subclones	_	NNS	NNS	_	29	PMOD	_	_
33	compared	_	VBN	VBN	_	20	ADV	_	_
34	with	_	IN	IN	_	33	PMOD	_	_
35	wild	_	JJ	JJ	_	37	NMOD	_	_
36	type	_	NN	NN	_	37	NMOD	_	_
37	CEM	_	NN	NN	_	34	PMOD	_	_
38	and	_	CC	CC	_	37	CC	_	_
39	a	_	DT	DT	_	41	NMOD	_	_
40	control	_	NN	NN	_	41	NMOD	_	_
41	subclone	_	NN	NN	_	37	COORD	_	_
42	.	_	.	.	_	20	P	_	_

1	Deoxycholate	_	JJ	JJ	_	2	NMOD	_	_
2	treatment	_	NN	NN	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	cytoplasmic	_	JJ	JJ	_	5	NMOD	_	_
5	extracts	_	NNS	NNS	_	3	PMOD	_	_
6	from	_	IN	IN	_	5	NMOD	_	_
7	these	_	DT	DT	_	8	NMOD	_	_
8	subclones	_	NNS	NNS	_	6	PMOD	_	_
9	released	_	VBD	VBD	_	0	ROOT-S	_	_
10	much	_	JJ	JJ	_	14	NMOD	_	_
11	reduced	_	VBN	VBN	_	10	AMOD	_	_
12	NF-kB	_	NN	NN	_	14	NMOD	_	_
13	binding	_	NN	NN	_	14	NMOD	_	_
14	proteins	_	NNS	NNS	_	9	OBJ	_	_
15	from	_	IN	IN	_	9	ADV	_	_
16	their	_	PRP$	PRP$	_	18	NMOD	_	_
17	cytoplasmic	_	JJ	JJ	_	18	NMOD	_	_
18	pools	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	9	P	_	_

1	Thus	_	RB	RB	_	15	ADV	_	_
2	,	_	,	,	_	15	P	_	_
3	reduced	_	JJ	JJ	_	4	NMOD	_	_
4	levels	_	NNS	NNS	_	15	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	PKC-induced	_	JJ	JJ	_	9	NMOD	_	_
7	nuclear	_	JJ	JJ	_	9	NMOD	_	_
8	NF-kB	_	NN	NN	_	9	NMOD	_	_
9	activity	_	NN	NN	_	5	PMOD	_	_
10	in	_	IN	IN	_	4	NMOD	_	_
11	two	_	CD	CD	_	14	NMOD	_	_
12	T	_	NN	NN	_	14	NMOD	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	subclones	_	NNS	NNS	_	10	PMOD	_	_
15	did	_	VBD	VBD	_	0	ROOT-S	_	_
16	not	_	RB	RB	_	15	VMOD	_	_
17	affect	_	VB	VB	_	15	VC	_	_
18	their	_	PRP$	PRP$	_	21	NMOD	_	_
19	normal	_	JJ	JJ	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	growth	_	NN	NN	_	17	OBJ	_	_
22	,	_	,	,	_	15	P	_	_
23	but	_	CC	CC	_	15	CC	_	_
24	correlated	_	VBD	VBD	_	15	COORD	_	_
25	with	_	IN	IN	_	24	ADV	_	_
26	a	_	DT	DT	_	28	NMOD	_	_
27	pronounced	_	JJ	JJ	_	28	NMOD	_	_
28	reduction	_	NN	NN	_	25	PMOD	_	_
29	in	_	IN	IN	_	28	NMOD	_	_
30	their	_	PRP$	PRP$	_	31	NMOD	_	_
31	susceptibility	_	NN	NN	_	29	PMOD	_	_
32	to	_	TO	TO	_	31	NMOD	_	_
33	HIV-1	_	NN	NN	_	34	NMOD	_	_
34	infection	_	NN	NN	_	32	PMOD	_	_
35	.	_	.	.	_	15	P	_	_

1	Cytoplasmic	_	JJ	JJ	_	3	NMOD	_	_
2	domain	_	NN	NN	_	3	NMOD	_	_
3	heterogeneity	_	NN	NN	_	0	ROOT-FRAG	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	functions	_	NNS	NNS	_	3	COORD	_	_
6	of	_	IN	IN	_	3	NMOD	_	_
7	IgG	_	NN	NN	_	9	NMOD	_	_
8	Fc	_	NN	NN	_	9	NMOD	_	_
9	receptors	_	NNS	NNS	_	6	PMOD	_	_
10	in	_	IN	IN	_	3	NMOD	_	_
11	B	_	NN	NN	_	12	NMOD	_	_
12	lymphocytes	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	B	_	NN	NN	_	2	NMOD	_	_
2	lymphocytes	_	NNS	NNS	_	5	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	macrophages	_	NNS	NNS	_	2	COORD	_	_
5	express	_	VBP	VBP	_	0	ROOT-S	_	_
6	closely	_	RB	RB	_	7	AMOD	_	_
7	related	_	JJ	JJ	_	9	NMOD	_	_
8	immunoglobulin	_	NN	NN	_	9	NMOD	_	_
9	G	_	NN	NN	_	5	OBJ	_	_
10	(	_	(	(	_	11	P	_	_
11	IgG	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	Fc	_	NN	NN	_	14	NMOD	_	_
14	receptors	_	NNS	NNS	_	9	NMOD	_	_
15	(	_	(	(	_	14	PRN	_	_
16	Fc	_	NN	NN	_	15	PRN	_	_
17	gamma	_	NN	NN	_	16	DEP	_	_
18	RII	_	NN	NN	_	16	DEP	_	_
19	)	_	)	)	_	15	P	_	_
20	that	_	WDT	WDT	_	21	SBJ	_	_
21	differ	_	VBP	VBP	_	9	NMOD	_	_
22	only	_	RB	RB	_	21	ADV	_	_
23	in	_	IN	IN	_	22	AMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	structures	_	NNS	NNS	_	22	AMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	their	_	PRP$	PRP$	_	29	NMOD	_	_
28	cytoplasmic	_	JJ	JJ	_	29	NMOD	_	_
29	domains	_	NNS	NNS	_	26	PMOD	_	_
30	.	_	.	.	_	5	P	_	_

1	Because	_	IN	IN	_	14	ADV	_	_
2	of	_	IN	IN	_	1	DEP	_	_
3	cell	_	NN	NN	_	8	NMOD	_	_
4	type-specific	_	JJ	JJ	_	3	AMOD	_	_
5	alternative	_	JJ	JJ	_	8	NMOD	_	_
6	messenger	_	NN	NN	_	8	NMOD	_	_
7	RNA	_	NN	NN	_	8	NMOD	_	_
8	splicing	_	NN	NN	_	1	PMOD	_	_
9	,	_	,	,	_	14	P	_	_
10	B-cell	_	NN	NN	_	13	NMOD	_	_
11	Fc	_	NN	NN	_	13	NMOD	_	_
12	gamma	_	NN	NN	_	13	NMOD	_	_
13	RII	_	NN	NN	_	14	SBJ	_	_
14	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	an	_	DT	DT	_	16	NMOD	_	_
16	insertion	_	NN	NN	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	47	_	CD	CD	_	20	NMOD	_	_
19	amino	_	NN	NN	_	20	NMOD	_	_
20	acids	_	NNS	NNS	_	17	PMOD	_	_
21	that	_	WDT	WDT	_	22	SBJ	_	_
22	participates	_	VBZ	VBZ	_	16	NMOD	_	_
23	in	_	IN	IN	_	22	ADV	_	_
24	determining	_	VBG	VBG	_	23	PMOD	_	_
25	receptor	_	NN	NN	_	26	NMOD	_	_
26	function	_	NN	NN	_	24	OBJ	_	_
27	in	_	IN	IN	_	26	NMOD	_	_
28	these	_	DT	DT	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	27	PMOD	_	_
30	.	_	.	.	_	14	P	_	_

1	Transfection	_	NN	NN	_	22	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	an	_	DT	DT	_	8	NMOD	_	_
4	Fc	_	NN	NN	_	5	AMOD	_	_
5	gamma	_	NN	NN	_	8	NMOD	_	_
6	RII-negative	_	JJ	JJ	_	5	AMOD	_	_
7	B-cell	_	NN	NN	_	8	NMOD	_	_
8	line	_	NN	NN	_	2	PMOD	_	_
9	with	_	IN	IN	_	1	NMOD	_	_
10	complementary	_	JJ	JJ	_	11	NMOD	_	_
11	DNA	_	NN	NN	_	13	SBJ	_	_
12	's	_	POS	POS	_	11	NMOD	_	_
13	encoding	_	VBG	VBG	_	9	PMOD	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	two	_	CD	CD	_	17	NMOD	_	_
16	splice	_	NN	NN	_	17	NMOD	_	_
17	products	_	NNS	NNS	_	13	OBJ	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	various	_	JJ	JJ	_	21	NMOD	_	_
20	receptor	_	NN	NN	_	21	NMOD	_	_
21	mutants	_	NNS	NNS	_	17	COORD	_	_
22	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
23	that	_	IN	IN	_	22	OBJ	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	insertion	_	NN	NN	_	26	SBJ	_	_
26	was	_	VBD	VBD	_	23	VMOD	_	_
27	responsible	_	JJ	JJ	_	26	PRD	_	_
28	for	_	IN	IN	_	27	AMOD	_	_
29	preventing	_	VBG	VBG	_	28	PMOD	_	_
30	both	_	CC	CC	_	34	CC	_	_
31	Fc	_	NN	NN	_	32	AMOD	_	_
32	gamma	_	NN	NN	_	34	NMOD	_	_
33	RII-mediated	_	JJ	JJ	_	32	AMOD	_	_
34	endocytosis	_	NN	NN	_	29	OBJ	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	Fc	_	NN	NN	_	37	AMOD	_	_
37	gamma	_	NN	NN	_	40	NMOD	_	_
38	RII-mediated	_	JJ	JJ	_	37	AMOD	_	_
39	antigen	_	NN	NN	_	40	NMOD	_	_
40	presentation	_	NN	NN	_	34	COORD	_	_
41	.	_	.	.	_	22	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	insertion	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	required	_	VBN	VBN	_	3	VC	_	_
6	for	_	IN	IN	_	5	ADV	_	_
7	Fc	_	NN	NN	_	9	NMOD	_	_
8	gamma	_	NN	NN	_	9	NMOD	_	_
9	RII	_	NN	NN	_	11	SBJ	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	modulate	_	VB	VB	_	6	PMOD	_	_
12	surface	_	NN	NN	_	15	NMOD	_	_
13	immunoglobulin-triggered	_	JJ	JJ	_	15	NMOD	_	_
14	B-cell	_	NN	NN	_	15	NMOD	_	_
15	activation	_	NN	NN	_	11	OBJ	_	_
16	.	_	.	.	_	3	P	_	_

1	Instead	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	regulation	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	activation	_	NN	NN	_	4	PMOD	_	_
6	involved	_	VBD	VBD	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	region	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	cytoplasmic	_	JJ	JJ	_	12	NMOD	_	_
12	domain	_	NN	NN	_	9	PMOD	_	_
13	common	_	JJ	JJ	_	8	NMOD	_	_
14	to	_	TO	TO	_	13	AMOD	_	_
15	both	_	CC	CC	_	21	CC	_	_
16	the	_	DT	DT	_	21	NMOD	_	_
17	lymphocyte	_	NN	NN	_	21	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	macrophage	_	NN	NN	_	17	COORD	_	_
20	receptor	_	NN	NN	_	21	NMOD	_	_
21	isoforms	_	NNS	NNS	_	14	PMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	6	P	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	insertion	_	NN	NN	_	6	SBJ	_	_
6	did	_	VBD	VBD	_	0	ROOT-S	_	_
7	contribute	_	VB	VB	_	6	VC	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	formation	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	caps	_	NNS	NNS	_	11	PMOD	_	_
13	in	_	IN	IN	_	7	ADV	_	_
14	response	_	NN	NN	_	13	DEP	_	_
15	to	_	TO	TO	_	13	DEP	_	_
16	receptor	_	NN	NN	_	17	NMOD	_	_
17	cross-linking	_	NN	NN	_	13	PMOD	_	_
18	,	_	,	,	_	7	P	_	_
19	consistent	_	JJ	JJ	_	7	OBJ	_	_
20	with	_	IN	IN	_	19	AMOD	_	_
21	suggestions	_	NNS	NNS	_	20	PMOD	_	_
22	that	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	28	NMOD	_	_
24	lymphocyte	_	NN	NN	_	28	NMOD	_	_
25	but	_	CC	CC	_	24	CC	_	_
26	not	_	RB	RB	_	25	COORD	_	_
27	macrophage	_	NN	NN	_	24	COORD	_	_
28	form	_	NN	NN	_	32	SBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	receptor	_	NN	NN	_	29	PMOD	_	_
32	can	_	MD	MD	_	22	VMOD	_	_
33	associate	_	VB	VB	_	32	VC	_	_
34	with	_	IN	IN	_	33	ADV	_	_
35	the	_	DT	DT	_	37	NMOD	_	_
36	detergent-insoluble	_	JJ	JJ	_	37	NMOD	_	_
37	cytoskeleton	_	NN	NN	_	34	PMOD	_	_
38	.	_	.	.	_	6	P	_	_

1	Induction	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	8	NMOD	_	_
4	POU	_	NN	NN	_	8	NMOD	_	_
5	domain	_	NN	NN	_	8	NMOD	_	_
6	transcription	_	NN	NN	_	8	NMOD	_	_
7	factor	_	NN	NN	_	8	NMOD	_	_
8	Oct-2	_	NN	NN	_	2	PMOD	_	_
9	during	_	IN	IN	_	1	TMP	_	_
10	T-cell	_	NN	NN	_	11	NMOD	_	_
11	activation	_	NN	NN	_	9	PMOD	_	_
12	by	_	IN	IN	_	1	NMOD	_	_
13	cognate	_	JJ	JJ	_	14	NMOD	_	_
14	antigen	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	1	P	_	_

1	Oct-2	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	transcription	_	NN	NN	_	5	NMOD	_	_
5	factor	_	NN	NN	_	2	PRD	_	_
6	that	_	WDT	WDT	_	7	SBJ	_	_
7	binds	_	VBZ	VBZ	_	5	NMOD	_	_
8	specifically	_	RB	RB	_	9	DEP	_	_
9	to	_	TO	TO	_	7	ADV	_	_
10	octamer	_	NN	NN	_	12	NMOD	_	_
11	DNA	_	NN	NN	_	12	NMOD	_	_
12	motifs	_	NNS	NNS	_	9	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	promoters	_	NNS	NNS	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	immunoglobulin	_	NN	NN	_	20	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	interleukin-2	_	NN	NN	_	17	COORD	_	_
20	genes	_	NNS	NNS	_	16	PMOD	_	_
21	.	_	.	.	_	2	P	_	_

1	All	_	DT	DT	_	4	NMOD	_	_
2	tumor	_	NN	NN	_	4	NMOD	_	_
3	cell	_	NN	NN	_	4	NMOD	_	_
4	lines	_	NNS	NNS	_	16	SBJ	_	_
5	from	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	B-cell	_	NN	NN	_	8	NMOD	_	_
8	lineage	_	NN	NN	_	5	PMOD	_	_
9	and	_	CC	CC	_	4	CC	_	_
10	a	_	DT	DT	_	11	NMOD	_	_
11	few	_	JJ	JJ	_	4	COORD	_	_
12	from	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	T-cell	_	NN	NN	_	15	NMOD	_	_
15	lineage	_	NN	NN	_	12	PMOD	_	_
16	express	_	VBP	VBP	_	0	ROOT-S	_	_
17	Oct-2	_	NN	NN	_	16	OBJ	_	_
18	.	_	.	.	_	16	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	address	_	VB	VB	_	13	ADV	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	role	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	Oct-2	_	NN	NN	_	5	PMOD	_	_
7	in	_	IN	IN	_	4	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	T-cell	_	NN	NN	_	10	NMOD	_	_
10	lineage	_	NN	NN	_	7	PMOD	_	_
11	,	_	,	,	_	13	P	_	_
12	we	_	PRP	PRP	_	13	SBJ	_	_
13	studied	_	VBD	VBD	_	0	ROOT-S	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	expression	_	NN	NN	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	Oct-2	_	NN	NN	_	18	NMOD	_	_
18	mRNA	_	NN	NN	_	16	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	protein	_	NN	NN	_	18	COORD	_	_
21	in	_	IN	IN	_	15	NMOD	_	_
22	nontransformed	_	JJ	JJ	_	27	NMOD	_	_
23	human	_	JJ	JJ	_	27	NMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	mouse	_	NN	NN	_	23	COORD	_	_
26	T	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	21	PMOD	_	_
28	.	_	.	.	_	13	P	_	_

1	Oct-2	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	CD4+	_	JJ	JJ	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	CD8+	_	JJ	JJ	_	5	COORD	_	_
8	T	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	4	PMOD	_	_
10	prepared	_	VBN	VBN	_	9	NMOD	_	_
11	from	_	IN	IN	_	10	ADV	_	_
12	human	_	JJ	JJ	_	14	NMOD	_	_
13	peripheral	_	JJ	JJ	_	14	NMOD	_	_
14	blood	_	NN	NN	_	11	PMOD	_	_
15	and	_	CC	CC	_	4	CC	_	_
16	in	_	IN	IN	_	4	COORD	_	_
17	mouse	_	NN	NN	_	21	NMOD	_	_
18	lymph	_	NN	NN	_	21	NMOD	_	_
19	node	_	NN	NN	_	21	NMOD	_	_
20	T	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	16	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	17	ADV	_	_
2	a	_	DT	DT	_	4	NMOD	_	_
3	T-cell	_	NN	NN	_	4	NMOD	_	_
4	clone	_	NN	NN	_	1	PMOD	_	_
5	specific	_	JJ	JJ	_	4	NMOD	_	_
6	for	_	IN	IN	_	5	AMOD	_	_
7	pigeon	_	NN	NN	_	9	NMOD	_	_
8	cytochrome	_	NN	NN	_	9	NMOD	_	_
9	c	_	NN	NN	_	6	PMOD	_	_
10	in	_	IN	IN	_	5	AMOD	_	_
11	the	_	DT	DT	_	10	DEP	_	_
12	context	_	NN	NN	_	10	DEP	_	_
13	of	_	IN	IN	_	10	DEP	_	_
14	I-Ek	_	NN	NN	_	10	PMOD	_	_
15	,	_	,	,	_	17	P	_	_
16	Oct-2	_	NN	NN	_	17	SBJ	_	_
17	was	_	VBD	VBD	_	0	ROOT-S	_	_
18	induced	_	VBN	VBN	_	17	VC	_	_
19	by	_	IN	IN	_	18	LGS	_	_
20	antigen	_	NN	NN	_	21	NMOD	_	_
21	stimulation	_	NN	NN	_	19	PMOD	_	_
22	,	_	,	,	_	18	P	_	_
23	with	_	IN	IN	_	18	ADV	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	increase	_	NN	NN	_	29	VMOD	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	Oct-2	_	NN	NN	_	28	NMOD	_	_
28	protein	_	NN	NN	_	26	PMOD	_	_
29	seen	_	VBN	VBN	_	23	VMOD	_	_
30	first	_	RB	RB	_	29	ADV	_	_
31	at	_	IN	IN	_	29	TMP	_	_
32	3	_	CD	CD	_	33	NMOD	_	_
33	h	_	NN	NN	_	31	PMOD	_	_
34	after	_	IN	IN	_	33	TMP	_	_
35	activation	_	NN	NN	_	34	PMOD	_	_
36	and	_	CC	CC	_	29	CC	_	_
37	continuing	_	VBG	VBG	_	29	COORD	_	_
38	for	_	IN	IN	_	37	TMP	_	_
39	at	_	IN	IN	_	41	DEP	_	_
40	least	_	JJS	JJS	_	41	DEP	_	_
41	24	_	CD	CD	_	42	NMOD	_	_
42	h	_	NN	NN	_	38	PMOD	_	_
43	.	_	.	.	_	17	P	_	_

1	Oct-2	_	NN	NN	_	3	NMOD	_	_
2	mRNA	_	NN	NN	_	3	NMOD	_	_
3	induction	_	NN	NN	_	8	SBJ	_	_
4	during	_	IN	IN	_	3	TMP	_	_
5	antigen-driven	_	JJ	JJ	_	7	NMOD	_	_
6	T-cell	_	NN	NN	_	7	NMOD	_	_
7	activation	_	NN	NN	_	4	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	blocked	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	ADV	_	_
11	cyclosporin	_	NN	NN	_	12	NMOD	_	_
12	A	_	NN	NN	_	10	PMOD	_	_
13	,	_	,	,	_	10	P	_	_
14	as	_	RB	RB	_	10	CC	_	_
15	well	_	RB	RB	_	14	DEP	_	_
16	as	_	IN	IN	_	14	DEP	_	_
17	by	_	IN	IN	_	10	LGS	_	_
18	protein	_	NN	NN	_	20	NMOD	_	_
19	synthesis	_	NN	NN	_	20	NMOD	_	_
20	inhibitors	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	8	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	Oct-2	_	NN	NN	_	6	SBJ	_	_
6	participates	_	VBZ	VBZ	_	4	VMOD	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	transcriptional	_	JJ	JJ	_	9	NMOD	_	_
9	regulation	_	NN	NN	_	7	PMOD	_	_
10	during	_	IN	IN	_	9	TMP	_	_
11	T-cell	_	NN	NN	_	12	NMOD	_	_
12	activation	_	NN	NN	_	10	PMOD	_	_
13	.	_	.	.	_	3	P	_	_
14	The	_	DT	DT	_	17	NMOD	_	_
15	relatively	_	RB	RB	_	16	AMOD	_	_
16	delayed	_	VBN	VBN	_	17	TMP	_	_
17	kinetics	_	NNS	NNS	_	21	SBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	Oct-2	_	NN	NN	_	20	NMOD	_	_
20	induction	_	NN	NN	_	18	PMOD	_	_
21	suggests	_	VBZ	VBZ	_	3	VMOD	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	Oct-2	_	NN	NN	_	24	SBJ	_	_
24	mediates	_	VBZ	VBZ	_	22	VMOD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	changes	_	NNS	NNS	_	24	OBJ	_	_
27	in	_	IN	IN	_	26	NMOD	_	_
28	gene	_	NN	NN	_	29	NMOD	_	_
29	expression	_	NN	NN	_	27	PMOD	_	_
30	which	_	WDT	WDT	_	31	SBJ	_	_
31	occur	_	VBP	VBP	_	26	NMOD	_	_
32	many	_	JJ	JJ	_	33	NMOD	_	_
33	hours	_	NNS	NNS	_	36	PMOD	_	_
34	or	_	CC	CC	_	33	CC	_	_
35	days	_	NNS	NNS	_	33	COORD	_	_
36	following	_	VBG	VBG	_	31	TMP	_	_
37	antigen	_	NN	NN	_	38	NMOD	_	_
38	stimulation	_	NN	NN	_	36	PMOD	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	T	_	NN	NN	_	41	NMOD	_	_
41	lymphocytes	_	NNS	NNS	_	39	PMOD	_	_
42	.	_	.	.	_	21	P	_	_

1	NF-kappa	_	NN	NN	_	3	NMOD	_	_
2	B-dependent	_	JJ	JJ	_	1	AMOD	_	_
3	induction	_	NN	NN	_	12	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	11	NMOD	_	_
6	NF-kappa	_	NN	NN	_	11	NMOD	_	_
7	B	_	NN	NN	_	11	NMOD	_	_
8	p50	_	NN	NN	_	11	NMOD	_	_
9	subunit	_	NN	NN	_	11	NMOD	_	_
10	gene	_	NN	NN	_	11	NMOD	_	_
11	promoter	_	NN	NN	_	4	PMOD	_	_
12	underlies	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	self-perpetuation	_	NN	NN	_	12	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	human	_	JJ	JJ	_	18	NMOD	_	_
16	immunodeficiency	_	NN	NN	_	18	NMOD	_	_
17	virus	_	NN	NN	_	18	NMOD	_	_
18	transcription	_	NN	NN	_	14	PMOD	_	_
19	in	_	IN	IN	_	13	NMOD	_	_
20	monocytic	_	JJ	JJ	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	19	PMOD	_	_
22	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	molecular	_	JJ	JJ	_	3	NMOD	_	_
3	mechanisms	_	NNS	NNS	_	26	SBJ	_	_
4	underlying	_	VBG	VBG	_	3	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	sustained	_	JJ	JJ	_	8	NMOD	_	_
7	nuclear	_	JJ	JJ	_	8	NMOD	_	_
8	translocation	_	NN	NN	_	4	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	NF-kappa	_	NN	NN	_	11	NMOD	_	_
11	B	_	NN	NN	_	9	PMOD	_	_
12	observed	_	VBN	VBN	_	8	NMOD	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	U937	_	NN	NN	_	16	NMOD	_	_
15	monocytic	_	JJ	JJ	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	13	PMOD	_	_
17	chronically	_	RB	RB	_	18	ADV	_	_
18	infected	_	VBN	VBN	_	16	NMOD	_	_
19	with	_	IN	IN	_	18	ADV	_	_
20	human	_	JJ	JJ	_	22	NMOD	_	_
21	immunodeficiency	_	NN	NN	_	22	NMOD	_	_
22	virus	_	NN	NN	_	19	PMOD	_	_
23	(	_	(	(	_	24	P	_	_
24	HIV	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	were	_	VBD	VBD	_	0	ROOT-S	_	_
27	studied	_	VBN	VBN	_	26	VC	_	_
28	.	_	.	.	_	26	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	activity	_	NN	NN	_	19	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	promoter	_	NN	NN	_	3	PMOD	_	_
6	regulating	_	VBG	VBG	_	2	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	synthesis	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	p105	_	NN	NN	_	12	NMOD	_	_
12	precursor	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	NF-kappa	_	NN	NN	_	18	NMOD	_	_
16	B	_	NN	NN	_	18	NMOD	_	_
17	p50	_	NN	NN	_	18	NMOD	_	_
18	subunit	_	NN	NN	_	13	PMOD	_	_
19	was	_	VBD	VBD	_	0	ROOT-S	_	_
20	enhanced	_	VBN	VBN	_	19	VC	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	these	_	DT	DT	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	19	P	_	_

1	Deletions	_	NNS	NNS	_	5	SBJ	_	_
2	in	_	IN	IN	_	1	NMOD	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	promoter	_	NN	NN	_	2	PMOD	_	_
5	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	this	_	DT	DT	_	8	NMOD	_	_
8	upregulation	_	NN	NN	_	9	SBJ	_	_
9	was	_	VBD	VBD	_	6	VMOD	_	_
10	mediated	_	VBN	VBN	_	9	VC	_	_
11	through	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	19	NMOD	_	_
13	NF-kappa	_	NN	NN	_	14	NMOD	_	_
14	B-	_	NN	NN	_	19	NMOD	_	_
15	but	_	CC	CC	_	19	CC	_	_
16	not	_	RB	RB	_	15	COORD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	AP-1-binding	_	JJ	JJ	_	19	NMOD	_	_
19	motif	_	NN	NN	_	11	PMOD	_	_
20	,	_	,	,	_	10	P	_	_
21	by	_	IN	IN	_	10	ADV	_	_
22	bona	_	FW	FW	_	23	AMOD	_	_
23	fide	_	FW	FW	_	25	NMOD	_	_
24	p50\/p65	_	NN	NN	_	25	NMOD	_	_
25	heterodimers	_	NNS	NNS	_	21	PMOD	_	_
26	.	_	.	.	_	5	P	_	_

1	Analysis	_	NN	NN	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	cytosolic	_	JJ	JJ	_	4	NMOD	_	_
4	extracts	_	NNS	NNS	_	2	PMOD	_	_
5	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	NF-kappa	_	NN	NN	_	9	NMOD	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	levels	_	NNS	NNS	_	10	SBJ	_	_
10	were	_	VBD	VBD	_	6	VMOD	_	_
11	increased	_	VBN	VBN	_	10	VC	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	HIV-infected	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	23	ADV	_	_
2	contrast	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	transient	_	JJ	JJ	_	8	NMOD	_	_
6	NF-kappa	_	NN	NN	_	8	NMOD	_	_
7	B	_	NN	NN	_	8	NMOD	_	_
8	activation	_	NN	NN	_	1	PMOD	_	_
9	induced	_	VBN	VBN	_	8	NMOD	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	phorbol	_	NN	NN	_	12	NMOD	_	_
12	ester	_	NN	NN	_	10	PMOD	_	_
13	,	_	,	,	_	23	P	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	permanent	_	JJ	JJ	_	18	NMOD	_	_
16	NF-kappa	_	NN	NN	_	18	NMOD	_	_
17	B	_	NN	NN	_	18	NMOD	_	_
18	translocation	_	NN	NN	_	23	SBJ	_	_
19	induced	_	VBN	VBN	_	18	NMOD	_	_
20	by	_	IN	IN	_	19	LGS	_	_
21	HIV	_	NN	NN	_	22	NMOD	_	_
22	infection	_	NN	NN	_	20	PMOD	_	_
23	was	_	VBD	VBD	_	0	ROOT-S	_	_
24	not	_	RB	RB	_	23	VMOD	_	_
25	dependent	_	JJ	JJ	_	23	PRD	_	_
26	on	_	IN	IN	_	25	AMOD	_	_
27	PKC	_	NN	NN	_	28	NMOD	_	_
28	isoenzymes	_	NNS	NNS	_	26	PMOD	_	_
29	alpha	_	NN	NN	_	28	NMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	beta	_	NN	NN	_	29	COORD	_	_
32	as	_	IN	IN	_	23	ADV	_	_
33	shown	_	VBN	VBN	_	32	VMOD	_	_
34	by	_	IN	IN	_	33	LGS	_	_
35	the	_	DT	DT	_	36	NMOD	_	_
36	use	_	NN	NN	_	34	PMOD	_	_
37	of	_	IN	IN	_	36	NMOD	_	_
38	a	_	DT	DT	_	40	NMOD	_	_
39	specific	_	JJ	JJ	_	40	NMOD	_	_
40	inhibitor	_	NN	NN	_	37	PMOD	_	_
41	(	_	(	(	_	43	P	_	_
42	GF	_	NN	NN	_	43	NMOD	_	_
43	109203X	_	NN	NN	_	40	PRN	_	_
44	)	_	)	)	_	43	P	_	_
45	.	_	.	.	_	23	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	observations	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	during	_	IN	IN	_	20	TMP	_	_
6	chronic	_	JJ	JJ	_	8	NMOD	_	_
7	HIV	_	NN	NN	_	8	NMOD	_	_
8	infection	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	U937	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	,	_	,	,	_	20	P	_	_
13	continuous	_	JJ	JJ	_	19	NMOD	_	_
14	NF-kappa	_	NN	NN	_	19	NMOD	_	_
15	B	_	NN	NN	_	19	NMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	p50\/p65	_	NN	NN	_	19	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	translocation	_	NN	NN	_	20	SBJ	_	_
20	results	_	VBZ	VBZ	_	4	VMOD	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	p105	_	NN	NN	_	24	NMOD	_	_
23	promoter	_	NN	NN	_	24	NMOD	_	_
24	upregulation	_	NN	NN	_	21	PMOD	_	_
25	with	_	IN	IN	_	24	NMOD	_	_
26	subsequent	_	JJ	JJ	_	30	NMOD	_	_
27	cytosolic	_	JJ	JJ	_	30	NMOD	_	_
28	NF-kappa	_	NN	NN	_	30	NMOD	_	_
29	B	_	NN	NN	_	30	NMOD	_	_
30	accumulation	_	NN	NN	_	25	PMOD	_	_
31	,	_	,	,	_	30	P	_	_
32	ready	_	JJ	JJ	_	30	NMOD	_	_
33	for	_	IN	IN	_	32	AMOD	_	_
34	further	_	JJ	JJ	_	35	NMOD	_	_
35	translocation	_	NN	NN	_	33	PMOD	_	_
36	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	HIV-mediated	_	JJ	JJ	_	3	NMOD	_	_
3	mechanism	_	NN	NN	_	4	SBJ	_	_
4	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	self-perpetuating	_	JJ	JJ	_	8	NMOD	_	_
8	loop	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	NF-kappa	_	NN	NN	_	12	NMOD	_	_
11	B	_	NN	NN	_	12	NMOD	_	_
12	production	_	NN	NN	_	9	PMOD	_	_
13	.	_	.	.	_	4	P	_	_

1	TAR-independent	_	JJ	JJ	_	2	NMOD	_	_
2	transactivation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	by	_	IN	IN	_	2	NMOD	_	_
4	Tat	_	NN	NN	_	3	PMOD	_	_
5	in	_	IN	IN	_	2	NMOD	_	_
6	cells	_	NNS	NNS	_	5	PMOD	_	_
7	derived	_	VBN	VBN	_	6	NMOD	_	_
8	from	_	IN	IN	_	7	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	CNS	_	NN	NN	_	8	PMOD	_	_
11	:	_	:	:	_	2	P	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	novel	_	JJ	JJ	_	14	NMOD	_	_
14	mechanism	_	NN	NN	_	2	NMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	HIV-1	_	NN	NN	_	18	NMOD	_	_
17	gene	_	NN	NN	_	18	NMOD	_	_
18	regulation	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	14	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	Tat	_	NN	NN	_	3	NMOD	_	_
3	protein	_	NN	NN	_	13	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	human	_	JJ	JJ	_	8	NMOD	_	_
6	immunodeficiency	_	NN	NN	_	8	NMOD	_	_
7	virus	_	NN	NN	_	8	NMOD	_	_
8	type	_	NN	NN	_	4	PMOD	_	_
9	1	_	CD	CD	_	8	NMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	HIV-1	_	NN	NN	_	8	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	essential	_	JJ	JJ	_	13	PRD	_	_
15	for	_	IN	IN	_	14	AMOD	_	_
16	productive	_	JJ	JJ	_	17	NMOD	_	_
17	infection	_	NN	NN	_	15	PMOD	_	_
18	and	_	CC	CC	_	13	CC	_	_
19	is	_	VBZ	VBZ	_	13	COORD	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	potential	_	JJ	JJ	_	22	NMOD	_	_
22	target	_	NN	NN	_	19	PRD	_	_
23	for	_	IN	IN	_	22	NMOD	_	_
24	antiviral	_	JJ	JJ	_	25	NMOD	_	_
25	therapy	_	NN	NN	_	23	PMOD	_	_
26	.	_	.	.	_	13	P	_	_

1	Tat	_	NN	NN	_	11	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	potent	_	JJ	JJ	_	5	NMOD	_	_
5	activator	_	NN	NN	_	1	NMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	HIV-1	_	NN	NN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	expression	_	NN	NN	_	6	PMOD	_	_
10	,	_	,	,	_	1	P	_	_
11	serves	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	to	_	TO	TO	_	14	VMOD	_	_
13	greatly	_	RB	RB	_	14	ADV	_	_
14	increase	_	VB	VB	_	11	OBJ	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	rate	_	NN	NN	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	transcription	_	NN	NN	_	17	PMOD	_	_
19	directed	_	VBN	VBN	_	18	NMOD	_	_
20	by	_	IN	IN	_	19	LGS	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	viral	_	JJ	JJ	_	23	NMOD	_	_
23	promoter	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	11	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	induction	_	NN	NN	_	23	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	which	_	WDT	WDT	_	5	SBJ	_	_
5	seems	_	VBZ	VBZ	_	2	NMOD	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	be	_	VB	VB	_	5	OBJ	_	_
8	an	_	DT	DT	_	10	NMOD	_	_
9	important	_	JJ	JJ	_	10	NMOD	_	_
10	component	_	NN	NN	_	7	PRD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	progression	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	acquired	_	VBN	VBN	_	18	NMOD	_	_
16	immune	_	JJ	JJ	_	18	NMOD	_	_
17	deficiency	_	NN	NN	_	18	NMOD	_	_
18	syndrome	_	NN	NN	_	14	PMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	AIDS	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	,	_	,	,	_	2	P	_	_
23	may	_	MD	MD	_	0	ROOT-S	_	_
24	be	_	VB	VB	_	23	VC	_	_
25	due	_	JJ	JJ	_	26	DEP	_	_
26	to	_	TO	TO	_	24	PRD	_	_
27	increased	_	VBN	VBN	_	29	NMOD	_	_
28	transcriptional	_	JJ	JJ	_	29	NMOD	_	_
29	initiation	_	NN	NN	_	26	PMOD	_	_
30	,	_	,	,	_	29	P	_	_
31	increased	_	VBN	VBN	_	33	NMOD	_	_
32	transcriptional	_	JJ	JJ	_	33	NMOD	_	_
33	elongation	_	NN	NN	_	29	COORD	_	_
34	,	_	,	,	_	29	P	_	_
35	or	_	CC	CC	_	29	CC	_	_
36	a	_	DT	DT	_	37	NMOD	_	_
37	combination	_	NN	NN	_	29	COORD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	these	_	DT	DT	_	40	NMOD	_	_
40	processes	_	NNS	NNS	_	38	PMOD	_	_
41	.	_	.	.	_	23	P	_	_

1	Much	_	JJ	JJ	_	2	NMOD	_	_
2	attention	_	NN	NN	_	3	SBJ	_	_
3	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	been	_	VBN	VBN	_	3	VC	_	_
5	focused	_	VBN	VBN	_	4	VC	_	_
6	on	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	interaction	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	Tat	_	NN	NN	_	9	PMOD	_	_
11	with	_	IN	IN	_	8	NMOD	_	_
12	a	_	DT	DT	_	15	NMOD	_	_
13	specific	_	JJ	JJ	_	15	NMOD	_	_
14	RNA	_	NN	NN	_	15	NMOD	_	_
15	target	_	NN	NN	_	11	PMOD	_	_
16	termed	_	VBN	VBN	_	15	NMOD	_	_
17	TAR	_	NN	NN	_	16	OBJ	_	_
18	(	_	(	(	_	20	P	_	_
19	transactivation	_	NN	NN	_	20	NMOD	_	_
20	responsive	_	NN	NN	_	17	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	which	_	WDT	WDT	_	23	SBJ	_	_
23	is	_	VBZ	VBZ	_	15	NMOD	_	_
24	present	_	JJ	JJ	_	23	PRD	_	_
25	in	_	IN	IN	_	24	AMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	leader	_	NN	NN	_	28	NMOD	_	_
28	sequence	_	NN	NN	_	25	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	all	_	DT	DT	_	32	NMOD	_	_
31	HIV-1	_	NN	NN	_	32	NMOD	_	_
32	mRNAs	_	NNS	NNS	_	29	PMOD	_	_
33	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	interaction	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	believed	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	be	_	VB	VB	_	4	OBJ	_	_
7	an	_	DT	DT	_	9	NMOD	_	_
8	important	_	JJ	JJ	_	9	NMOD	_	_
9	component	_	NN	NN	_	6	PRD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	mechanism	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	transactivation	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	in	_	IN	IN	_	12	ADV	_	_
8	certain	_	JJ	JJ	_	10	NMOD	_	_
9	CNS-derived	_	JJ	JJ	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	7	PMOD	_	_
11	Tat	_	NN	NN	_	12	SBJ	_	_
12	is	_	VBZ	VBZ	_	6	VMOD	_	_
13	capable	_	JJ	JJ	_	12	PRD	_	_
14	of	_	IN	IN	_	13	AMOD	_	_
15	activating	_	VBG	VBG	_	14	PMOD	_	_
16	HIV-1	_	NN	NN	_	15	OBJ	_	_
17	through	_	IN	IN	_	15	ADV	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	TAR-independent	_	JJ	JJ	_	20	NMOD	_	_
20	pathway	_	NN	NN	_	17	PMOD	_	_
21	.	_	.	.	_	5	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	Tat-responsive	_	JJ	JJ	_	3	NMOD	_	_
3	element	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	found	_	VBN	VBN	_	4	VC	_	_
6	upstream	_	RB	RB	_	5	OBJ	_	_
7	within	_	IN	IN	_	6	AMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	viral	_	JJ	JJ	_	10	NMOD	_	_
10	promoter	_	NN	NN	_	7	PMOD	_	_
11	that	_	WDT	WDT	_	16	SBJ	_	_
12	in	_	IN	IN	_	16	ADV	_	_
13	glial-derived	_	JJ	JJ	_	15	NMOD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	lines	_	NNS	NNS	_	12	PMOD	_	_
16	allows	_	VBZ	VBZ	_	10	NMOD	_	_
17	transactivation	_	NN	NN	_	16	OBJ	_	_
18	in	_	IN	IN	_	16	ADV	_	_
19	the	_	DT	DT	_	18	DEP	_	_
20	absence	_	NN	NN	_	18	DEP	_	_
21	of	_	IN	IN	_	18	DEP	_	_
22	TAR	_	NN	NN	_	18	PMOD	_	_
23	.	_	.	.	_	4	P	_	_

1	Deletion	_	NN	NN	_	2	NMOD	_	_
2	mapping	_	NN	NN	_	7	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	hybrid	_	NN	NN	_	6	NMOD	_	_
5	promoter	_	NN	NN	_	6	NMOD	_	_
6	constructs	_	NNS	NNS	_	2	COORD	_	_
7	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	newly	_	RB	RB	_	11	AMOD	_	_
11	identified	_	VBN	VBN	_	13	NMOD	_	_
12	Tat-responsive	_	JJ	JJ	_	13	NMOD	_	_
13	element	_	NN	NN	_	14	SBJ	_	_
14	corresponds	_	VBZ	VBZ	_	8	VMOD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	a	_	DT	DT	_	17	NMOD	_	_
17	sequence	_	NN	NN	_	15	PMOD	_	_
18	within	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	23	NMOD	_	_
20	viral	_	JJ	JJ	_	23	NMOD	_	_
21	long	_	JJ	JJ	_	23	NMOD	_	_
22	terminal	_	JJ	JJ	_	23	NMOD	_	_
23	repeat	_	NN	NN	_	18	PMOD	_	_
24	(	_	(	(	_	25	P	_	_
25	LTR	_	NN	NN	_	23	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	previously	_	RB	RB	_	28	TMP	_	_
28	identified	_	VBN	VBN	_	17	NMOD	_	_
29	as	_	IN	IN	_	28	ADV	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	HIV-1	_	NN	NN	_	32	NMOD	_	_
32	enhancer	_	NN	NN	_	29	PMOD	_	_
33	,	_	,	,	_	32	P	_	_
34	or	_	CC	CC	_	32	CC	_	_
35	NF-kappa	_	NN	NN	_	37	NMOD	_	_
36	B	_	NN	NN	_	37	NMOD	_	_
37	domain	_	NN	NN	_	32	COORD	_	_
38	.	_	.	.	_	7	P	_	_

1	DNA	_	NN	NN	_	3	NMOD	_	_
2	band-shift	_	JJ	JJ	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	4	SBJ	_	_
4	reveals	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	NF-kappa	_	NN	NN	_	8	NMOD	_	_
6	B	_	NN	NN	_	8	NMOD	_	_
7	binding	_	NN	NN	_	8	NMOD	_	_
8	activity	_	NN	NN	_	4	OBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	glial	_	JJ	JJ	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	that	_	WDT	WDT	_	13	SBJ	_	_
13	differs	_	VBZ	VBZ	_	8	NMOD	_	_
14	from	_	IN	IN	_	13	ADV	_	_
15	that	_	DT	DT	_	14	PMOD	_	_
16	present	_	JJ	JJ	_	15	NMOD	_	_
17	in	_	IN	IN	_	16	AMOD	_	_
18	T	_	NN	NN	_	20	NMOD	_	_
19	lymphoid	_	JJ	JJ	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	4	P	_	_

1	Further	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	observe	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	TAR-deleted	_	JJ	JJ	_	7	NMOD	_	_
7	mutants	_	NNS	NNS	_	10	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	HIV-1	_	NN	NN	_	8	PMOD	_	_
10	demonstrate	_	VBP	VBP	_	5	VMOD	_	_
11	normal	_	JJ	JJ	_	14	NMOD	_	_
12	late	_	JJ	JJ	_	14	NMOD	_	_
13	gene	_	NN	NN	_	14	NMOD	_	_
14	expression	_	NN	NN	_	10	OBJ	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	glial	_	JJ	JJ	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	15	PMOD	_	_
18	as	_	IN	IN	_	10	ADV	_	_
19	evidenced	_	VBN	VBN	_	18	VMOD	_	_
20	by	_	IN	IN	_	19	LGS	_	_
21	syncytia	_	NN	NN	_	20	PMOD	_	_
22	formation	_	NN	NN	_	21	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	production	_	NN	NN	_	22	COORD	_	_
25	of	_	IN	IN	_	21	NMOD	_	_
26	viral	_	JJ	JJ	_	28	NMOD	_	_
27	p24	_	NN	NN	_	28	NMOD	_	_
28	antigen	_	NN	NN	_	25	PMOD	_	_
29	.	_	.	.	_	4	P	_	_

1	(	_	(	(	_	3	P	_	_
2	ABSTRACT	_	NN	NN	_	3	SBJ	_	_
3	TRUNCATED	_	VBN	VBN	_	0	ROOT-S	_	_
4	AT	_	IN	IN	_	3	ADV	_	_
5	250	_	CD	CD	_	6	NMOD	_	_
6	WORDS	_	NNS	NNS	_	4	PMOD	_	_
7	)	_	)	)	_	3	P	_	_

1	Pax-5	_	NN	NN	_	2	SBJ	_	_
2	encodes	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	transcription	_	NN	NN	_	6	NMOD	_	_
5	factor	_	NN	NN	_	6	NMOD	_	_
6	BSAP	_	NN	NN	_	2	OBJ	_	_
7	and	_	CC	CC	_	2	CC	_	_
8	is	_	VBZ	VBZ	_	2	COORD	_	_
9	expressed	_	VBN	VBN	_	8	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	B	_	NN	NN	_	12	NMOD	_	_
12	lymphocytes	_	NNS	NNS	_	10	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	developing	_	VBG	VBG	_	16	NMOD	_	_
16	CNS	_	NNS	NNS	_	12	COORD	_	_
17	,	_	,	,	_	12	P	_	_
18	and	_	CC	CC	_	12	CC	_	_
19	adult	_	JJ	JJ	_	20	NMOD	_	_
20	testis	_	NN	NN	_	12	COORD	_	_
21	.	_	.	.	_	2	P	_	_

1	BSAP	_	NN	NN	_	2	SBJ	_	_
2	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	been	_	VBN	VBN	_	2	VC	_	_
4	identified	_	VBN	VBN	_	3	VC	_	_
5	previously	_	RB	RB	_	4	TMP	_	_
6	as	_	IN	IN	_	4	ADV	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	transcription	_	NN	NN	_	9	NMOD	_	_
9	factor	_	NN	NN	_	6	PMOD	_	_
10	that	_	WDT	WDT	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	9	NMOD	_	_
12	expressed	_	VBN	VBN	_	11	VC	_	_
13	at	_	IN	IN	_	12	TMP	_	_
14	early	_	JJ	JJ	_	20	NMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	but	_	CC	CC	_	14	CC	_	_
17	not	_	RB	RB	_	18	AMOD	_	_
18	late	_	JJ	JJ	_	14	COORD	_	_
19	,	_	,	,	_	14	P	_	_
20	stages	_	NNS	NNS	_	13	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	B-cell	_	NN	NN	_	23	NMOD	_	_
23	differentiation	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	2	P	_	_

1	Biochemical	_	JJ	JJ	_	2	NMOD	_	_
2	purification	_	NN	NN	_	6	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	cDNA	_	NN	NN	_	5	NMOD	_	_
5	cloning	_	NN	NN	_	2	COORD	_	_
6	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	now	_	RB	RB	_	6	TMP	_	_
8	revealed	_	VBN	VBN	_	6	VC	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	BSAP	_	NN	NN	_	11	SBJ	_	_
11	belongs	_	VBZ	VBZ	_	9	VMOD	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	family	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	paired	_	JJ	JJ	_	18	NMOD	_	_
17	domain	_	NN	NN	_	18	NMOD	_	_
18	proteins	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	6	P	_	_

1	BSAP	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	encoded	_	VBN	VBN	_	2	VC	_	_
4	by	_	IN	IN	_	3	LGS	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	Pax-5	_	NN	NN	_	7	NMOD	_	_
7	gene	_	NN	NN	_	4	PMOD	_	_
8	and	_	CC	CC	_	2	CC	_	_
9	has	_	VBZ	VBZ	_	2	COORD	_	_
10	been	_	VBN	VBN	_	9	VC	_	_
11	highly	_	RB	RB	_	10	ADV	_	_
12	conserved	_	VBN	VBN	_	10	VC	_	_
13	between	_	IN	IN	_	12	ADV	_	_
14	human	_	JJ	JJ	_	13	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	mouse	_	NN	NN	_	14	COORD	_	_
17	.	_	.	.	_	2	P	_	_

1	An	_	DT	DT	_	4	NMOD	_	_
2	intact	_	JJ	JJ	_	4	NMOD	_	_
3	paired	_	JJ	JJ	_	4	NMOD	_	_
4	domain	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	shown	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	be	_	VB	VB	_	6	OBJ	_	_
9	both	_	CC	CC	_	10	CC	_	_
10	necessary	_	JJ	JJ	_	8	PRD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	sufficient	_	JJ	JJ	_	10	COORD	_	_
13	for	_	IN	IN	_	10	AMOD	_	_
14	DNA	_	NN	NN	_	15	NMOD	_	_
15	binding	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	BSAP	_	NN	NN	_	16	PMOD	_	_
18	.	_	.	.	_	5	P	_	_

1	Binding	_	VBG	VBG	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	8	SBJ	_	_
3	with	_	IN	IN	_	2	NMOD	_	_
4	several	_	JJ	JJ	_	7	NMOD	_	_
5	BSAP	_	NN	NN	_	7	NMOD	_	_
6	recognition	_	NN	NN	_	7	NMOD	_	_
7	sequences	_	NNS	NNS	_	3	PMOD	_	_
8	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	sequence	_	NN	NN	_	12	NMOD	_	_
12	specificity	_	NN	NN	_	15	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	BSAP	_	NN	NN	_	13	PMOD	_	_
15	differs	_	VBZ	VBZ	_	9	VMOD	_	_
16	from	_	IN	IN	_	15	ADV	_	_
17	that	_	DT	DT	_	16	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	25	NMOD	_	_
20	distantly	_	RB	RB	_	21	AMOD	_	_
21	related	_	JJ	JJ	_	25	NMOD	_	_
22	paired	_	JJ	JJ	_	25	NMOD	_	_
23	domain	_	NN	NN	_	25	NMOD	_	_
24	protein	_	NN	NN	_	25	NMOD	_	_
25	Pax-1	_	NN	NN	_	18	PMOD	_	_
26	.	_	.	.	_	8	P	_	_

1	During	_	IN	IN	_	7	TMP	_	_
2	embryogenesis	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	7	P	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	BSAP	_	NN	NN	_	6	NMOD	_	_
6	gene	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	transiently	_	RB	RB	_	7	TMP	_	_
9	expressed	_	VBN	VBN	_	7	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	mesencephalon	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	spinal	_	JJ	JJ	_	15	NMOD	_	_
15	cord	_	NN	NN	_	12	COORD	_	_
16	with	_	IN	IN	_	9	ADV	_	_
17	a	_	DT	DT	_	22	NMOD	_	_
18	spatial	_	JJ	JJ	_	22	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	temporal	_	JJ	JJ	_	18	COORD	_	_
21	expression	_	NN	NN	_	22	NMOD	_	_
22	pattern	_	NN	NN	_	16	PMOD	_	_
23	that	_	WDT	WDT	_	24	SBJ	_	_
24	is	_	VBZ	VBZ	_	22	NMOD	_	_
25	distinct	_	JJ	JJ	_	24	PRD	_	_
26	from	_	IN	IN	_	25	AMOD	_	_
27	that	_	DT	DT	_	26	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	other	_	JJ	JJ	_	31	NMOD	_	_
30	Pax	_	NN	NN	_	31	NMOD	_	_
31	genes	_	NNS	NNS	_	28	PMOD	_	_
32	in	_	IN	IN	_	31	NMOD	_	_
33	the	_	DT	DT	_	37	NMOD	_	_
34	developing	_	VBG	VBG	_	37	NMOD	_	_
35	central	_	JJ	JJ	_	37	NMOD	_	_
36	nervous	_	JJ	JJ	_	37	NMOD	_	_
37	system	_	NN	NN	_	32	PMOD	_	_
38	(	_	(	(	_	39	P	_	_
39	CNS	_	NN	NN	_	37	PRN	_	_
40	)	_	)	)	_	39	P	_	_
41	.	_	.	.	_	7	P	_	_

1	Later	_	RB	RB	_	9	TMP	_	_
2	,	_	,	,	_	9	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	expression	_	NN	NN	_	9	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	BSAP	_	NN	NN	_	8	NMOD	_	_
8	gene	_	NN	NN	_	5	PMOD	_	_
9	shifts	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	fetal	_	JJ	JJ	_	13	NMOD	_	_
13	liver	_	NN	NN	_	10	PMOD	_	_
14	where	_	WRB	WRB	_	16	ADV	_	_
15	it	_	PRP	PRP	_	16	SBJ	_	_
16	correlates	_	VBZ	VBZ	_	13	NMOD	_	_
17	with	_	IN	IN	_	16	ADV	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	onset	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	B	_	NN	NN	_	22	NMOD	_	_
22	lymphopoiesis	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	9	P	_	_

1	BSAP	_	NN	NN	_	2	NMOD	_	_
2	expression	_	NN	NN	_	3	SBJ	_	_
3	persists	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	B	_	NN	NN	_	6	NMOD	_	_
6	lymphocytes	_	NNS	NNS	_	4	PMOD	_	_
7	and	_	CC	CC	_	3	CC	_	_
8	is	_	VBZ	VBZ	_	3	COORD	_	_
9	also	_	RB	RB	_	8	ADV	_	_
10	seen	_	VBN	VBN	_	8	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	testis	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	adult	_	JJ	JJ	_	17	NMOD	_	_
17	mouse	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	All	_	DT	DT	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	evidence	_	NN	NN	_	2	PMOD	_	_
5	indicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	transcription	_	NN	NN	_	10	NMOD	_	_
9	factor	_	NN	NN	_	10	NMOD	_	_
10	BSAP	_	NN	NN	_	11	SBJ	_	_
11	may	_	MD	MD	_	6	VMOD	_	_
12	not	_	RB	RB	_	14	CC	_	_
13	only	_	RB	RB	_	12	DEP	_	_
14	play	_	VB	VB	_	11	VC	_	_
15	an	_	DT	DT	_	17	NMOD	_	_
16	important	_	JJ	JJ	_	17	NMOD	_	_
17	role	_	NN	NN	_	14	OBJ	_	_
18	in	_	IN	IN	_	14	VMOD	_	_
19	B-cell	_	NN	NN	_	20	NMOD	_	_
20	differentiation	_	NN	NN	_	18	PMOD	_	_
21	but	_	CC	CC	_	14	CC	_	_
22	also	_	RB	RB	_	21	COORD	_	_
23	in	_	IN	IN	_	18	GAP	_	_
24	neural	_	JJ	JJ	_	25	NMOD	_	_
25	development	_	NN	NN	_	23	PMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	spermatogenesis	_	NN	NN	_	25	COORD	_	_
28	.	_	.	.	_	5	P	_	_

1	Human	_	JJ	JJ	_	7	NMOD	_	_
2	immunodeficiency	_	NN	NN	_	7	NMOD	_	_
3	virus	_	NN	NN	_	7	NMOD	_	_
4	type	_	NN	NN	_	7	NMOD	_	_
5	1	_	CD	CD	_	7	NMOD	_	_
6	Nef	_	NN	NN	_	7	NMOD	_	_
7	protein	_	NN	NN	_	8	SBJ	_	_
8	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	NF-kappa	_	NN	NN	_	11	NMOD	_	_
10	B	_	NN	NN	_	11	NMOD	_	_
11	induction	_	NN	NN	_	8	OBJ	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	human	_	JJ	JJ	_	15	NMOD	_	_
14	T	_	NN	NN	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	12	PMOD	_	_
16	.	_	.	.	_	8	P	_	_

1	Human	_	JJ	JJ	_	4	NMOD	_	_
2	immunodeficiency	_	NN	NN	_	4	NMOD	_	_
3	virus	_	NN	NN	_	4	NMOD	_	_
4	type	_	NN	NN	_	9	SBJ	_	_
5	1	_	CD	CD	_	4	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	HIV-1	_	NN	NN	_	4	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	can	_	MD	MD	_	0	ROOT-S	_	_
10	establish	_	VB	VB	_	9	VC	_	_
11	a	_	DT	DT	_	15	NMOD	_	_
12	persistent	_	JJ	JJ	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	latent	_	JJ	JJ	_	12	COORD	_	_
15	infection	_	NN	NN	_	10	OBJ	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	CD4+	_	JJ	JJ	_	19	NMOD	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	lymphocytes	_	NNS	NNS	_	16	PMOD	_	_
20	(	_	(	(	_	21	P	_	_
21	W.C.Greene	_	NNP	NNP	_	10	PRN	_	_
22	,	_	,	,	_	21	P	_	_
23	N.Engl.J.	_	NNP	NNP	_	24	NMOD	_	_
24	Med.324	_	NNP	NNP	_	21	NMOD	_	_
25	:	_	:	:	_	24	P	_	_
26	308-317	_	CD	CD	_	24	NMOD	_	_
27	,	_	,	,	_	21	P	_	_
28	1991	_	CD	CD	_	21	TMP	_	_
29	;	_	:	:	_	21	P	_	_
30	S.M.Schnittman	_	NNP	NNP	_	21	NMOD	_	_
31	,	_	,	,	_	30	P	_	_
32	M.C.Psallidopoulos	_	NNP	NNP	_	30	COORD	_	_
33	,	_	,	,	_	30	P	_	_
34	H.C.	_	NNP	NNP	_	35	NMOD	_	_
35	Lane	_	NNP	NNP	_	30	COORD	_	_
36	,	_	,	,	_	30	P	_	_
37	L.Thompson	_	NNP	NNP	_	30	COORD	_	_
38	,	_	,	,	_	30	P	_	_
39	M.Baseler	_	NNP	NNP	_	30	COORD	_	_
40	,	_	,	,	_	30	P	_	_
41	F.Massari	_	NNP	NNP	_	30	COORD	_	_
42	,	_	,	,	_	30	P	_	_
43	C.H.Fox	_	NNP	NNP	_	30	COORD	_	_
44	,	_	,	,	_	30	P	_	_
45	N.P.Salzman	_	NNP	NNP	_	30	COORD	_	_
46	,	_	,	,	_	30	P	_	_
47	and	_	CC	CC	_	30	CC	_	_
48	A.S.Fauci	_	NNP	NNP	_	30	COORD	_	_
49	,	_	,	,	_	30	P	_	_
50	Science	_	NNP	NNP	_	30	NMOD	_	_
51	245	_	CD	CD	_	50	NMOD	_	_
52	:	_	:	:	_	50	P	_	_
53	305-308	_	CD	CD	_	50	NMOD	_	_
54	,	_	,	,	_	30	P	_	_
55	1989	_	CD	CD	_	30	TMP	_	_
56	)	_	)	)	_	21	P	_	_
57	.	_	.	.	_	9	P	_	_

1	Production	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	HIV-1	_	NN	NN	_	2	PMOD	_	_
4	from	_	IN	IN	_	1	NMOD	_	_
5	latently	_	RB	RB	_	6	AMOD	_	_
6	infected	_	JJ	JJ	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	4	PMOD	_	_
8	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	host	_	NN	NN	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	activation	_	NN	NN	_	8	OBJ	_	_
12	by	_	IN	IN	_	11	NMOD	_	_
13	T-cell	_	NN	NN	_	14	NMOD	_	_
14	mitogens	_	NNS	NNS	_	12	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	T.Folks	_	NNP	NNP	_	8	PRN	_	_
17	,	_	,	,	_	16	P	_	_
18	D.M.Powell	_	NNP	NNP	_	16	COORD	_	_
19	,	_	,	,	_	16	P	_	_
20	M.M.Lightfoote	_	NNP	NNP	_	16	COORD	_	_
21	,	_	,	,	_	16	P	_	_
22	S.Benn	_	NNP	NNP	_	16	COORD	_	_
23	,	_	,	,	_	16	P	_	_
24	M.A.	_	NNP	NNP	_	25	NMOD	_	_
25	Martin	_	NNP	NNP	_	16	COORD	_	_
26	,	_	,	,	_	16	P	_	_
27	and	_	CC	CC	_	16	CC	_	_
28	A.S.Fauci	_	NNP	NNP	_	16	COORD	_	_
29	,	_	,	,	_	16	P	_	_
30	Science	_	NNP	NNP	_	16	NMOD	_	_
31	231	_	CD	CD	_	30	NMOD	_	_
32	:	_	:	:	_	30	P	_	_
33	600-602	_	CD	CD	_	30	NMOD	_	_
34	,	_	,	,	_	16	P	_	_
35	1986	_	CD	CD	_	16	TMP	_	_
36	;	_	:	:	_	16	P	_	_
37	D.Zagury	_	NNP	NNP	_	16	NMOD	_	_
38	,	_	,	,	_	37	P	_	_
39	J.	_	NNP	NNP	_	40	NMOD	_	_
40	Bernard	_	NNP	NNP	_	37	COORD	_	_
41	,	_	,	,	_	37	P	_	_
42	R.Leonard	_	NNP	NNP	_	37	COORD	_	_
43	,	_	,	,	_	37	P	_	_
44	R.Cheynier	_	NNP	NNP	_	37	COORD	_	_
45	,	_	,	,	_	37	P	_	_
46	M.Feldman	_	NNP	NNP	_	37	COORD	_	_
47	,	_	,	,	_	37	P	_	_
48	P.S.Sarin	_	NNP	NNP	_	37	COORD	_	_
49	,	_	,	,	_	37	P	_	_
50	and	_	CC	CC	_	37	CC	_	_
51	R.C.	_	NNP	NNP	_	52	NMOD	_	_
52	Gallo	_	NNP	NNP	_	37	COORD	_	_
53	,	_	,	,	_	37	P	_	_
54	Science	_	NNP	NNP	_	37	NMOD	_	_
55	231	_	CD	CD	_	54	NMOD	_	_
56	:	_	:	:	_	54	P	_	_
57	850-853	_	CD	CD	_	54	NMOD	_	_
58	,	_	,	,	_	37	P	_	_
59	1986	_	CD	CD	_	37	TMP	_	_
60	)	_	)	)	_	16	P	_	_
61	.	_	.	.	_	8	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	activation	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	mediated	_	VBN	VBN	_	3	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	the	_	DT	DT	_	11	NMOD	_	_
7	host	_	NN	NN	_	11	NMOD	_	_
8	transcription	_	NN	NN	_	11	NMOD	_	_
9	factor	_	NN	NN	_	11	NMOD	_	_
10	NF-kappa	_	NN	NN	_	11	NMOD	_	_
11	B	_	NN	NN	_	5	PMOD	_	_
12	{	_	(	(	_	13	P	_	_
13	G.Nabel	_	NNP	NNP	_	4	PRN	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	D.Baltimore	_	NNP	NNP	_	13	COORD	_	_
16	,	_	,	,	_	13	P	_	_
17	Nature	_	NNP	NNP	_	19	NMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	London	_	NNP	NNP	_	13	NMOD	_	_
20	)	_	)	)	_	19	P	_	_
21	326	_	CD	CD	_	19	NMOD	_	_
22	:	_	:	:	_	19	P	_	_
23	711-717	_	CD	CD	_	19	NMOD	_	_
24	,	_	,	,	_	13	P	_	_
25	1987	_	CD	CD	_	13	TMP	_	_
26	}	_	)	)	_	13	P	_	_
27	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	that	_	IN	IN	_	2	OBJ	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	HIV-1-encoded	_	JJ	JJ	_	8	NMOD	_	_
7	Nef	_	NN	NN	_	8	NMOD	_	_
8	protein	_	NN	NN	_	9	SBJ	_	_
9	inhibits	_	VBZ	VBZ	_	4	VMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	induction	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	NF-kappa	_	NN	NN	_	16	NMOD	_	_
14	B	_	NN	NN	_	16	NMOD	_	_
15	DNA-binding	_	JJ	JJ	_	16	NMOD	_	_
16	activity	_	NN	NN	_	12	PMOD	_	_
17	by	_	IN	IN	_	11	NMOD	_	_
18	T-cell	_	NN	NN	_	19	NMOD	_	_
19	mitogens	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	However	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	Nef	_	NN	NN	_	4	SBJ	_	_
4	does	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	affect	_	VB	VB	_	4	VC	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	DNA-binding	_	JJ	JJ	_	9	NMOD	_	_
9	activity	_	NN	NN	_	6	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	other	_	JJ	JJ	_	13	NMOD	_	_
12	transcription	_	NN	NN	_	13	NMOD	_	_
13	factors	_	NNS	NNS	_	10	PMOD	_	_
14	implicated	_	VBN	VBN	_	13	NMOD	_	_
15	in	_	IN	IN	_	14	ADV	_	_
16	HIV-1	_	NN	NN	_	17	NMOD	_	_
17	regulation	_	NN	NN	_	15	PMOD	_	_
18	,	_	,	,	_	13	P	_	_
19	including	_	VBG	VBG	_	13	NMOD	_	_
20	SP-1	_	NN	NN	_	19	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	USF	_	NN	NN	_	20	COORD	_	_
23	,	_	,	,	_	20	P	_	_
24	URS	_	NN	NN	_	20	COORD	_	_
25	,	_	,	,	_	20	P	_	_
26	and	_	CC	CC	_	20	CC	_	_
27	NF-AT	_	NN	NN	_	20	COORD	_	_
28	.	_	.	.	_	4	P	_	_

1	Additionally	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	Nef	_	NN	NN	_	4	SBJ	_	_
4	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	induction	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	HIV-1-	_	NN	NN	_	13	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	interleukin	_	NN	NN	_	8	COORD	_	_
11	2-directed	_	JJ	JJ	_	10	AMOD	_	_
12	gene	_	NN	NN	_	13	NMOD	_	_
13	expression	_	NN	NN	_	7	PMOD	_	_
14	,	_	,	,	_	4	P	_	_
15	and	_	CC	CC	_	4	CC	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	effect	_	NN	NN	_	21	SBJ	_	_
18	on	_	IN	IN	_	17	NMOD	_	_
19	HIV-1	_	NN	NN	_	20	NMOD	_	_
20	transcription	_	NN	NN	_	18	PMOD	_	_
21	depends	_	VBZ	VBZ	_	4	COORD	_	_
22	on	_	IN	IN	_	21	ADV	_	_
23	an	_	DT	DT	_	27	NMOD	_	_
24	intact	_	JJ	JJ	_	27	NMOD	_	_
25	NF-kappa	_	NN	NN	_	27	NMOD	_	_
26	B-binding	_	JJ	JJ	_	27	NMOD	_	_
27	site	_	NN	NN	_	22	PMOD	_	_
28	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	defective	_	JJ	JJ	_	6	NMOD	_	_
6	recruitment	_	NN	NN	_	10	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	NF-kappa	_	NN	NN	_	9	NMOD	_	_
9	B	_	NN	NN	_	7	PMOD	_	_
10	may	_	MD	MD	_	4	VMOD	_	_
11	underlie	_	VB	VB	_	10	VC	_	_
12	Nef	_	NN	NN	_	16	NMOD	_	_
13	's	_	POS	POS	_	12	NMOD	_	_
14	negative	_	JJ	JJ	_	16	NMOD	_	_
15	transcriptional	_	JJ	JJ	_	16	NMOD	_	_
16	effects	_	NNS	NNS	_	11	OBJ	_	_
17	on	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	23	NMOD	_	_
19	HIV-1	_	NN	NN	_	23	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	interleukin	_	NN	NN	_	19	COORD	_	_
22	2	_	CD	CD	_	21	NMOD	_	_
23	promoters	_	NNS	NNS	_	17	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	Further	_	JJ	JJ	_	2	NMOD	_	_
2	evidence	_	NN	NN	_	3	SBJ	_	_
3	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	Nef	_	NN	NN	_	6	SBJ	_	_
6	inhibits	_	VBZ	VBZ	_	4	VMOD	_	_
7	NF-kappa	_	NN	NN	_	9	NMOD	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	induction	_	NN	NN	_	6	OBJ	_	_
10	by	_	IN	IN	_	6	ADV	_	_
11	interfering	_	VBG	VBG	_	10	PMOD	_	_
12	with	_	IN	IN	_	11	ADV	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	signal	_	NN	NN	_	12	PMOD	_	_
15	derived	_	VBN	VBN	_	14	NMOD	_	_
16	from	_	IN	IN	_	15	ADV	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	T-cell	_	NN	NN	_	20	NMOD	_	_
19	receptor	_	NN	NN	_	20	NMOD	_	_
20	complex	_	NN	NN	_	16	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	{	_	(	(	_	2	P	_	_
2	Mechanism	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	action	_	NN	NN	_	3	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	steroid	_	NN	NN	_	11	NMOD	_	_
7	hormones	_	NNS	NNS	_	11	NMOD	_	_
8	.	_	.	.	_	11	P	_	_
9	I	_	LS	LS	_	11	NMOD	_	_
10	.	_	.	.	_	11	P	_	_
11	Estrogens	_	NNS	NNS	_	5	PMOD	_	_
12	}	_	)	)	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	steroid	_	NN	NN	_	3	NMOD	_	_
3	hormone	_	NN	NN	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	very	_	RB	RB	_	6	AMOD	_	_
6	versatile	_	JJ	JJ	_	7	NMOD	_	_
7	molecules	_	NNS	NNS	_	4	PRD	_	_
8	:	_	:	:	_	4	P	_	_
9	although	_	IN	IN	_	21	ADV	_	_
10	they	_	PRP	PRP	_	11	SBJ	_	_
11	are	_	VBP	VBP	_	9	VMOD	_	_
12	related	_	JJ	JJ	_	11	PRD	_	_
13	among	_	IN	IN	_	11	ADV	_	_
14	them	_	PRP	PRP	_	13	PMOD	_	_
15	by	_	IN	IN	_	11	ADV	_	_
16	their	_	PRP$	PRP$	_	18	NMOD	_	_
17	chemical	_	JJ	JJ	_	18	NMOD	_	_
18	structure	_	NN	NN	_	15	PRD	_	_
19	,	_	,	,	_	21	P	_	_
20	they	_	PRP	PRP	_	21	SBJ	_	_
21	have	_	VBP	VBP	_	4	VC	_	_
22	very	_	RB	RB	_	23	AMOD	_	_
23	diverse	_	JJ	JJ	_	24	NMOD	_	_
24	functions	_	NNS	NNS	_	21	OBJ	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	including	_	VBG	VBG	_	24	COORD	_	_
27	antagonic	_	JJ	JJ	_	26	PMOD	_	_
28	.	_	.	.	_	21	P	_	_

1	Their	_	PRP$	PRP$	_	3	NMOD	_	_
2	action	_	NN	NN	_	3	NMOD	_	_
3	mechanism	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	completely	_	RB	RB	_	4	ADV	_	_
7	cleared	_	VBN	VBN	_	4	VC	_	_
8	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	estrogens	_	NNS	NNS	_	3	SBJ	_	_
3	participate	_	VBP	VBP	_	0	ROOT-S	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	regulation	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	practically	_	RB	RB	_	14	NMOD	_	_
9	all	_	PDT	PDT	_	8	DEP	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	reproductive	_	JJ	JJ	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	sexual	_	JJ	JJ	_	11	COORD	_	_
14	events	_	NNS	NNS	_	7	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	female	_	NN	NN	_	15	PMOD	_	_
18	,	_	,	,	_	3	P	_	_
19	although	_	IN	IN	_	3	ADV	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	intracellular	_	JJ	JJ	_	22	NMOD	_	_
22	actions	_	NNS	NNS	_	28	SBJ	_	_
23	by	_	IN	IN	_	26	ADV	_	_
24	which	_	WDT	WDT	_	23	PMOD	_	_
25	they	_	PRP	PRP	_	26	SBJ	_	_
26	take	_	VBP	VBP	_	22	NMOD	_	_
27	place	_	NN	NN	_	26	OBJ	_	_
28	are	_	VBP	VBP	_	19	VMOD	_	_
29	not	_	RB	RB	_	28	VMOD	_	_
30	well	_	RB	RB	_	28	ADV	_	_
31	known	_	VBN	VBN	_	28	VC	_	_
32	and	_	CC	CC	_	28	CC	_	_
33	the	_	DT	DT	_	35	NMOD	_	_
34	proposed	_	JJ	JJ	_	35	NMOD	_	_
35	models	_	NNS	NNS	_	36	SBJ	_	_
36	do	_	VBP	VBP	_	28	COORD	_	_
37	not	_	RB	RB	_	36	VMOD	_	_
38	adequately	_	RB	RB	_	36	ADV	_	_
39	satisfy	_	VB	VB	_	36	VC	_	_
40	the	_	DT	DT	_	41	NMOD	_	_
41	questions	_	NNS	NNS	_	39	OBJ	_	_
42	.	_	.	.	_	3	P	_	_

1	Currently	_	RB	RB	_	3	TMP	_	_
2	it	_	PRP	PRP	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	accepted	_	VBN	VBN	_	3	VC	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	existence	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	12	NMOD	_	_
9	cytoplasmic	_	JJ	JJ	_	12	NMOD	_	_
10	and\/or	_	CC	CC	_	9	CC	_	_
11	nuclear	_	JJ	JJ	_	9	COORD	_	_
12	receptor	_	NN	NN	_	7	PMOD	_	_
13	,	_	,	,	_	4	P	_	_
14	without	_	IN	IN	_	4	ADV	_	_
15	explaining	_	VBG	VBG	_	14	PMOD	_	_
16	satisfactorily	_	RB	RB	_	15	ADV	_	_
17	how	_	WRB	WRB	_	20	ADV	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	hormones	_	NNS	NNS	_	20	SBJ	_	_
20	come	_	VBN	VBN	_	15	OBJ	_	_
21	to	_	TO	TO	_	20	ADV	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	nucleus	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	endocrine	_	JJ	JJ	_	3	NMOD	_	_
3	events	_	NNS	NNS	_	11	SBJ	_	_
4	that	_	WDT	WDT	_	5	SBJ	_	_
5	are	_	VBP	VBP	_	3	NMOD	_	_
6	rapidly	_	RB	RB	_	5	TMP	_	_
7	expressed	_	VBN	VBN	_	5	VC	_	_
8	(	_	(	(	_	9	P	_	_
9	seconds	_	NNS	NNS	_	6	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	are	_	VBP	VBP	_	0	ROOT-S	_	_
12	due	_	JJ	JJ	_	13	DEP	_	_
13	to	_	TO	TO	_	11	PRD	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	possible	_	JJ	JJ	_	16	NMOD	_	_
16	interaction	_	NN	NN	_	13	PMOD	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	cellular	_	JJ	JJ	_	19	NMOD	_	_
19	membrane	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	purpose	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	this	_	DT	DT	_	5	NMOD	_	_
5	review	_	NN	NN	_	3	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	analyze	_	VB	VB	_	6	PRD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	concilliate	_	VB	VB	_	8	COORD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	reported	_	VBN	VBN	_	13	NMOD	_	_
13	data	_	NNS	NNS	_	8	OBJ	_	_
14	on	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	mechanism	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	action	_	NN	NN	_	17	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	estrogens	_	NNS	NNS	_	19	PMOD	_	_
21	.	_	.	.	_	6	P	_	_

1	Selection	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	optimal	_	JJ	JJ	_	7	NMOD	_	_
4	kappa	_	NN	NN	_	5	AMOD	_	_
5	B\/Rel	_	NN	NN	_	7	NMOD	_	_
6	DNA-binding	_	JJ	JJ	_	7	NMOD	_	_
7	motifs	_	NNS	NNS	_	2	PMOD	_	_
8	:	_	:	:	_	1	P	_	_
9	interaction	_	NN	NN	_	18	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	both	_	DT	DT	_	12	NMOD	_	_
12	subunits	_	NNS	NNS	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	NF-kappa	_	NN	NN	_	15	NMOD	_	_
15	B	_	NN	NN	_	13	PMOD	_	_
16	with	_	IN	IN	_	9	NMOD	_	_
17	DNA	_	NN	NN	_	16	PMOD	_	_
18	is	_	VBZ	VBZ	_	1	NMOD	_	_
19	required	_	VBN	VBN	_	18	VC	_	_
20	for	_	IN	IN	_	19	ADV	_	_
21	transcriptional	_	JJ	JJ	_	22	NMOD	_	_
22	activation	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	18	P	_	_

1	Analysis	_	NN	NN	_	15	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	p50	_	NN	NN	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	p65	_	NN	NN	_	4	COORD	_	_
7	subunits	_	NNS	NNS	_	2	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	14	NMOD	_	_
10	NF-kappa	_	NN	NN	_	14	NMOD	_	_
11	B	_	NN	NN	_	14	NMOD	_	_
12	transcription	_	NN	NN	_	14	NMOD	_	_
13	factor	_	NN	NN	_	14	NMOD	_	_
14	complex	_	NN	NN	_	8	PMOD	_	_
15	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	revealed	_	VBN	VBN	_	15	VC	_	_
17	that	_	IN	IN	_	16	OBJ	_	_
18	both	_	DT	DT	_	19	NMOD	_	_
19	proteins	_	NNS	NNS	_	20	SBJ	_	_
20	can	_	MD	MD	_	17	VMOD	_	_
21	interact	_	VB	VB	_	20	VC	_	_
22	with	_	IN	IN	_	21	ADV	_	_
23	related	_	JJ	JJ	_	25	NMOD	_	_
24	DNA	_	NN	NN	_	25	NMOD	_	_
25	sequences	_	NNS	NNS	_	22	PMOD	_	_
26	through	_	IN	IN	_	21	ADV	_	_
27	either	_	CC	CC	_	31	CC	_	_
28	homo-	_	JJ	JJ	_	31	NMOD	_	_
29	or	_	CC	CC	_	31	CC	_	_
30	heterodimer	_	NN	NN	_	31	COORD	_	_
31	formation	_	NN	NN	_	26	PMOD	_	_
32	.	_	.	.	_	15	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	10	P	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	product	_	NN	NN	_	10	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	proto-oncogene	_	NN	NN	_	9	NMOD	_	_
9	c-rel	_	NN	NN	_	6	PMOD	_	_
10	can	_	MD	MD	_	0	ROOT-S	_	_
11	bind	_	VB	VB	_	10	VC	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	similar	_	JJ	JJ	_	15	NMOD	_	_
14	DNA	_	NN	NN	_	15	NMOD	_	_
15	motifs	_	NNS	NNS	_	12	PMOD	_	_
16	by	_	IN	IN	_	11	ADV	_	_
17	itself	_	PRP	PRP	_	16	PMOD	_	_
18	or	_	CC	CC	_	16	CC	_	_
19	as	_	IN	IN	_	16	COORD	_	_
20	a	_	DT	DT	_	21	NMOD	_	_
21	heterodimer	_	NN	NN	_	19	PMOD	_	_
22	with	_	IN	IN	_	21	NMOD	_	_
23	p50	_	NN	NN	_	22	PMOD	_	_
24	or	_	CC	CC	_	23	CC	_	_
25	p65	_	NN	NN	_	23	COORD	_	_
26	.	_	.	.	_	10	P	_	_

1	However	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	studies	_	NNS	NNS	_	5	SBJ	_	_
5	have	_	VBP	VBP	_	0	ROOT-S	_	_
6	used	_	VBN	VBN	_	5	VC	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	limited	_	JJ	JJ	_	9	NMOD	_	_
9	number	_	NN	NN	_	6	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	known	_	JJ	JJ	_	15	NMOD	_	_
12	kappa	_	NN	NN	_	15	NMOD	_	_
13	B	_	NN	NN	_	15	NMOD	_	_
14	DNA	_	NN	NN	_	15	NMOD	_	_
15	motifs	_	NNS	NNS	_	10	PMOD	_	_
16	,	_	,	,	_	5	P	_	_
17	and	_	CC	CC	_	5	CC	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	question	_	NN	NN	_	29	SBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	optimal	_	JJ	JJ	_	24	NMOD	_	_
23	DNA	_	NN	NN	_	24	NMOD	_	_
24	sequences	_	NNS	NNS	_	20	PMOD	_	_
25	preferred	_	VBN	VBN	_	24	NMOD	_	_
26	by	_	IN	IN	_	25	LGS	_	_
27	each	_	DT	DT	_	28	NMOD	_	_
28	homodimer	_	NN	NN	_	26	PMOD	_	_
29	has	_	VBZ	VBZ	_	5	COORD	_	_
30	not	_	RB	RB	_	29	VMOD	_	_
31	been	_	VBN	VBN	_	29	VC	_	_
32	addressed	_	VBN	VBN	_	31	VC	_	_
33	.	_	.	.	_	5	P	_	_

1	Using	_	VBG	VBG	_	15	ADV	_	_
2	purified	_	VBN	VBN	_	10	NMOD	_	_
3	recombinant	_	JJ	JJ	_	10	NMOD	_	_
4	p50	_	NN	NN	_	10	NMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	p65	_	NN	NN	_	4	COORD	_	_
7	,	_	,	,	_	4	P	_	_
8	and	_	CC	CC	_	4	CC	_	_
9	c-Rel	_	NN	NN	_	4	COORD	_	_
10	proteins	_	NNS	NNS	_	1	OBJ	_	_
11	,	_	,	,	_	15	P	_	_
12	optimal	_	JJ	JJ	_	14	NMOD	_	_
13	DNA-binding	_	JJ	JJ	_	14	NMOD	_	_
14	motifs	_	NNS	NNS	_	15	SBJ	_	_
15	were	_	VBD	VBD	_	0	ROOT-S	_	_
16	selected	_	VBN	VBN	_	15	VC	_	_
17	from	_	IN	IN	_	16	ADV	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	pool	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	random	_	JJ	JJ	_	22	NMOD	_	_
22	oligonucleotides	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	15	P	_	_

1	Alignment	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	selected	_	VBN	VBN	_	5	NMOD	_	_
5	sequences	_	NNS	NNS	_	2	PMOD	_	_
6	allowed	_	VBD	VBD	_	0	ROOT-S	_	_
7	us	_	PRP	PRP	_	9	SBJ	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	predict	_	VB	VB	_	6	OBJ	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	consensus	_	NN	NN	_	12	NMOD	_	_
12	sequence	_	NN	NN	_	9	OBJ	_	_
13	for	_	IN	IN	_	12	NMOD	_	_
14	binding	_	NN	NN	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	individual	_	JJ	JJ	_	20	NMOD	_	_
18	homodimeric	_	JJ	JJ	_	20	NMOD	_	_
19	Rel-related	_	JJ	JJ	_	20	NMOD	_	_
20	proteins	_	NNS	NNS	_	15	PMOD	_	_
21	,	_	,	,	_	6	P	_	_
22	and	_	CC	CC	_	6	CC	_	_
23	DNA-protein	_	NN	NN	_	25	NMOD	_	_
24	binding	_	NN	NN	_	25	NMOD	_	_
25	analysis	_	NN	NN	_	31	SBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	selected	_	VBN	VBN	_	29	NMOD	_	_
29	DNA	_	NN	NN	_	26	PMOD	_	_
30	sequences	_	VBZ	VBZ	_	29	NMOD	_	_
31	revealed	_	VBD	VBD	_	6	COORD	_	_
32	sequence	_	NN	NN	_	33	NMOD	_	_
33	specificity	_	NN	NN	_	31	OBJ	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	the	_	DT	DT	_	36	NMOD	_	_
36	proteins	_	NNS	NNS	_	34	PMOD	_	_
37	.	_	.	.	_	6	P	_	_

1	Contrary	_	JJ	JJ	_	2	DEP	_	_
2	to	_	TO	TO	_	7	ADV	_	_
3	previous	_	JJ	JJ	_	4	NMOD	_	_
4	assumptions	_	NNS	NNS	_	2	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	we	_	PRP	PRP	_	7	SBJ	_	_
7	observed	_	VBD	VBD	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	p65	_	NN	NN	_	10	NMOD	_	_
10	homodimers	_	NNS	NNS	_	11	SBJ	_	_
11	can	_	MD	MD	_	8	VMOD	_	_
12	interact	_	VB	VB	_	11	VC	_	_
13	with	_	IN	IN	_	12	ADV	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	subset	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	DNA	_	NN	NN	_	16	PMOD	_	_
18	sequences	_	VBZ	VBZ	_	17	NMOD	_	_
19	not	_	RB	RB	_	20	VMOD	_	_
20	recognized	_	VBN	VBN	_	17	NMOD	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	p50	_	NN	NN	_	23	NMOD	_	_
23	homodimers	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	7	P	_	_

1	Differential	_	JJ	JJ	_	3	NMOD	_	_
2	binding	_	NN	NN	_	3	NMOD	_	_
3	affinities	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	also	_	RB	RB	_	4	ADV	_	_
6	obtained	_	VBN	VBN	_	4	VC	_	_
7	with	_	IN	IN	_	6	ADV	_	_
8	p50-	_	NN	NN	_	11	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	c-Rel-selected	_	JJ	JJ	_	8	COORD	_	_
11	sequences	_	NNS	NNS	_	7	PMOD	_	_
12	.	_	.	.	_	4	P	_	_

1	Using	_	VBG	VBG	_	26	ADV	_	_
2	either	_	CC	CC	_	9	CC	_	_
3	a	_	DT	DT	_	9	NMOD	_	_
4	p50-	_	NN	NN	_	9	NMOD	_	_
5	or	_	CC	CC	_	4	CC	_	_
6	p65-selected	_	JJ	JJ	_	4	COORD	_	_
7	kappa	_	NN	NN	_	9	NMOD	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	motif	_	NN	NN	_	1	OBJ	_	_
10	,	_	,	,	_	9	P	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	displayed	_	VBD	VBD	_	9	NMOD	_	_
13	differential	_	JJ	JJ	_	14	NMOD	_	_
14	binding	_	NN	NN	_	12	OBJ	_	_
15	with	_	IN	IN	_	12	ADV	_	_
16	respect	_	NN	NN	_	15	DEP	_	_
17	to	_	TO	TO	_	15	DEP	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	other	_	JJ	JJ	_	20	NMOD	_	_
20	protein	_	NN	NN	_	15	PMOD	_	_
21	,	_	,	,	_	9	P	_	_
22	little	_	JJ	JJ	_	25	NMOD	_	_
23	to	_	TO	TO	_	22	DEP	_	_
24	no	_	DT	DT	_	22	DEP	_	_
25	binding	_	NN	NN	_	26	SBJ	_	_
26	was	_	VBD	VBD	_	0	ROOT-S	_	_
27	observed	_	VBN	VBN	_	26	VC	_	_
28	with	_	IN	IN	_	27	ADV	_	_
29	the	_	DT	DT	_	33	NMOD	_	_
30	heterodimeric	_	JJ	JJ	_	33	NMOD	_	_
31	NF-kappa	_	NN	NN	_	33	NMOD	_	_
32	B	_	NN	NN	_	33	NMOD	_	_
33	complex	_	NN	NN	_	28	PMOD	_	_
34	.	_	.	.	_	26	P	_	_

1	Similarly	_	RB	RB	_	32	ADV	_	_
2	,	_	,	,	_	32	P	_	_
3	in	_	IN	IN	_	32	ADV	_	_
4	transfection	_	NN	NN	_	5	NMOD	_	_
5	experiments	_	NNS	NNS	_	3	PMOD	_	_
6	in	_	IN	IN	_	15	ADV	_	_
7	which	_	WDT	WDT	_	6	PMOD	_	_
8	the	_	DT	DT	_	13	NMOD	_	_
9	selective	_	JJ	JJ	_	13	NMOD	_	_
10	kappa	_	NN	NN	_	13	NMOD	_	_
11	B	_	NN	NN	_	13	NMOD	_	_
12	binding	_	NN	NN	_	13	NMOD	_	_
13	sites	_	NNS	NNS	_	14	SBJ	_	_
14	were	_	VBD	VBD	_	5	NMOD	_	_
15	used	_	VBN	VBN	_	14	VC	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	drive	_	VB	VB	_	15	OBJ	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	expression	_	NN	NN	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	a	_	DT	DT	_	25	NMOD	_	_
22	chloramphenicol	_	NN	NN	_	25	NMOD	_	_
23	acetyltransferase	_	NN	NN	_	25	NMOD	_	_
24	reporter	_	NN	NN	_	25	NMOD	_	_
25	construct	_	NN	NN	_	20	PMOD	_	_
26	,	_	,	,	_	32	P	_	_
27	the	_	DT	DT	_	31	NMOD	_	_
28	p65-	_	NN	NN	_	31	NMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	p50-selected	_	JJ	JJ	_	28	COORD	_	_
31	motifs	_	NNS	NNS	_	32	SBJ	_	_
32	were	_	VBD	VBD	_	0	ROOT-S	_	_
33	activated	_	VBN	VBN	_	32	VC	_	_
34	only	_	RB	RB	_	35	DEP	_	_
35	in	_	IN	IN	_	33	ADV	_	_
36	the	_	DT	DT	_	35	DEP	_	_
37	presence	_	NN	NN	_	35	DEP	_	_
38	of	_	IN	IN	_	35	DEP	_	_
39	p65	_	NN	NN	_	58	NMOD	_	_
40	and	_	CC	CC	_	39	CC	_	_
41	p50\/65	_	NN	NN	_	39	COORD	_	_
42	(	_	(	(	_	45	P	_	_
43	a	_	DT	DT	_	45	NMOD	_	_
44	chimeric	_	JJ	JJ	_	45	NMOD	_	_
45	protein	_	NN	NN	_	41	PRN	_	_
46	with	_	IN	IN	_	45	NMOD	_	_
47	the	_	DT	DT	_	51	NMOD	_	_
48	p50	_	NN	NN	_	51	NMOD	_	_
49	DNA	_	NN	NN	_	51	NMOD	_	_
50	binding	_	NN	NN	_	51	NMOD	_	_
51	domain	_	NN	NN	_	46	PMOD	_	_
52	and	_	CC	CC	_	51	CC	_	_
53	p65	_	NN	NN	_	55	NMOD	_	_
54	activation	_	NN	NN	_	55	NMOD	_	_
55	domain	_	NN	NN	_	51	COORD	_	_
56	)	_	)	)	_	45	P	_	_
57	expression	_	NN	NN	_	58	NMOD	_	_
58	vectors	_	NNS	NNS	_	35	PMOD	_	_
59	,	_	,	,	_	33	P	_	_
60	respectively	_	RB	RB	_	33	ADV	_	_
61	,	_	,	,	_	32	P	_	_
62	and	_	CC	CC	_	32	CC	_	_
63	neither	_	DT	DT	_	64	SBJ	_	_
64	demonstrated	_	VBD	VBD	_	32	COORD	_	_
65	a	_	DT	DT	_	67	NMOD	_	_
66	significant	_	JJ	JJ	_	67	NMOD	_	_
67	response	_	NN	NN	_	64	OBJ	_	_
68	to	_	TO	TO	_	67	NMOD	_	_
69	stimuli	_	NNS	NNS	_	68	PMOD	_	_
70	that	_	WDT	WDT	_	71	SBJ	_	_
71	induce	_	VBP	VBP	_	69	NMOD	_	_
72	NF-kappa	_	NN	NN	_	74	NMOD	_	_
73	B	_	NN	NN	_	74	NMOD	_	_
74	activity	_	NN	NN	_	71	OBJ	_	_
75	.	_	.	.	_	32	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	interaction	_	NN	NN	_	17	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	both	_	DT	DT	_	8	NMOD	_	_
8	subunits	_	NNS	NNS	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	heterodimeric	_	JJ	JJ	_	14	NMOD	_	_
12	NF-kappa	_	NN	NN	_	14	NMOD	_	_
13	B	_	NN	NN	_	14	NMOD	_	_
14	complex	_	NN	NN	_	9	PMOD	_	_
15	with	_	IN	IN	_	5	NMOD	_	_
16	DNA	_	NN	NN	_	15	PMOD	_	_
17	is	_	VBZ	VBZ	_	4	VMOD	_	_
18	required	_	VBN	VBN	_	17	VC	_	_
19	for	_	IN	IN	_	18	ADV	_	_
20	DNA	_	NN	NN	_	21	NMOD	_	_
21	binding	_	NN	NN	_	19	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	transcriptional	_	JJ	JJ	_	24	NMOD	_	_
24	activation	_	NN	NN	_	21	COORD	_	_
25	and	_	CC	CC	_	3	CC	_	_
26	suggest	_	VBP	VBP	_	3	COORD	_	_
27	that	_	IN	IN	_	26	OBJ	_	_
28	transcriptional	_	JJ	JJ	_	29	NMOD	_	_
29	activation	_	NN	NN	_	36	SBJ	_	_
30	mediated	_	VBN	VBN	_	29	NMOD	_	_
31	by	_	IN	IN	_	30	ADV	_	_
32	the	_	DT	DT	_	35	NMOD	_	_
33	individual	_	JJ	JJ	_	35	NMOD	_	_
34	rel-related	_	JJ	JJ	_	35	NMOD	_	_
35	proteins	_	NNS	NNS	_	31	PMOD	_	_
36	will	_	MD	MD	_	27	VMOD	_	_
37	differ	_	VB	VB	_	36	VC	_	_
38	dramatically	_	RB	RB	_	37	ADV	_	_
39	,	_	,	,	_	37	P	_	_
40	depending	_	VBG	VBG	_	37	ADV	_	_
41	on	_	IN	IN	_	40	PMOD	_	_
42	the	_	DT	DT	_	46	NMOD	_	_
43	specific	_	JJ	JJ	_	46	NMOD	_	_
44	kappa	_	NN	NN	_	46	NMOD	_	_
45	B	_	NN	NN	_	46	NMOD	_	_
46	motifs	_	NNS	NNS	_	41	PMOD	_	_
47	present	_	JJ	JJ	_	46	NMOD	_	_
48	.	_	.	.	_	3	P	_	_

1	Regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	c-jun	_	NN	NN	_	4	NMOD	_	_
4	expression	_	NN	NN	_	2	PMOD	_	_
5	during	_	IN	IN	_	1	TMP	_	_
6	induction	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	monocytic	_	JJ	JJ	_	9	NMOD	_	_
9	differentiation	_	NN	NN	_	7	PMOD	_	_
10	by	_	IN	IN	_	1	NMOD	_	_
11	okadaic	_	JJ	JJ	_	12	NMOD	_	_
12	acid	_	NN	NN	_	10	PMOD	_	_
13	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	present	_	JJ	JJ	_	3	NMOD	_	_
3	work	_	NN	NN	_	4	SBJ	_	_
4	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	examined	_	VBN	VBN	_	4	VC	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	effects	_	NNS	NNS	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	okadaic	_	JJ	JJ	_	10	NMOD	_	_
10	acid	_	NN	NN	_	8	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	an	_	DT	DT	_	13	NMOD	_	_
13	inhibitor	_	NN	NN	_	10	NMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	type	_	NN	NN	_	20	NMOD	_	_
16	1	_	CD	CD	_	20	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	2A	_	NN	NN	_	16	COORD	_	_
19	protein	_	NN	NN	_	20	NMOD	_	_
20	phosphatases	_	NNS	NNS	_	14	PMOD	_	_
21	,	_	,	,	_	10	P	_	_
22	on	_	IN	IN	_	7	NMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	regulation	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	c-jun	_	NN	NN	_	27	NMOD	_	_
27	expression	_	NN	NN	_	25	PMOD	_	_
28	during	_	IN	IN	_	24	TMP	_	_
29	monocytic	_	JJ	JJ	_	30	NMOD	_	_
30	differentiation	_	NN	NN	_	28	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	U-937	_	NN	NN	_	34	NMOD	_	_
33	leukemia	_	NN	NN	_	34	NMOD	_	_
34	cells	_	NNS	NNS	_	31	PMOD	_	_
35	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	okadaic	_	JJ	JJ	_	7	NMOD	_	_
6	acid	_	NN	NN	_	7	NMOD	_	_
7	treatment	_	NN	NN	_	8	SBJ	_	_
8	is	_	VBZ	VBZ	_	4	VMOD	_	_
9	associated	_	VBN	VBN	_	8	VC	_	_
10	with	_	IN	IN	_	9	ADV	_	_
11	induction	_	NN	NN	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	a	_	DT	DT	_	16	NMOD	_	_
14	differentiated	_	VBN	VBN	_	16	NMOD	_	_
15	monocyte	_	NN	NN	_	16	NMOD	_	_
16	phenotype	_	NN	NN	_	12	PMOD	_	_
17	characterized	_	VBN	VBN	_	16	NMOD	_	_
18	by	_	IN	IN	_	17	LGS	_	_
19	:	_	:	:	_	18	P	_	_
20	(	_	(	(	_	21	P	_	_
21	a	_	LS	LS	_	24	NMOD	_	_
22	)	_	)	)	_	21	P	_	_
23	growth	_	NN	NN	_	24	NMOD	_	_
24	arrest	_	NN	NN	_	18	PMOD	_	_
25	;	_	:	:	_	24	P	_	_
26	(	_	(	(	_	27	P	_	_
27	b	_	LS	LS	_	29	NMOD	_	_
28	)	_	)	)	_	27	P	_	_
29	increases	_	NNS	NNS	_	24	COORD	_	_
30	in	_	IN	IN	_	29	NMOD	_	_
31	Mac-1	_	NN	NN	_	35	NMOD	_	_
32	cell	_	NN	NN	_	35	NMOD	_	_
33	surface	_	NN	NN	_	35	NMOD	_	_
34	antigen	_	NN	NN	_	35	NMOD	_	_
35	expression	_	NN	NN	_	30	PMOD	_	_
36	;	_	:	:	_	24	P	_	_
37	(	_	(	(	_	38	P	_	_
38	c	_	LS	LS	_	40	NMOD	_	_
39	)	_	)	)	_	38	P	_	_
40	down-regulation	_	NN	NN	_	24	COORD	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	c-myc	_	NN	NN	_	43	NMOD	_	_
43	transcripts	_	NNS	NNS	_	41	PMOD	_	_
44	;	_	:	:	_	24	P	_	_
45	and	_	CC	CC	_	24	CC	_	_
46	(	_	(	(	_	47	P	_	_
47	d	_	LS	LS	_	49	NMOD	_	_
48	)	_	)	)	_	47	P	_	_
49	induction	_	NN	NN	_	24	COORD	_	_
50	of	_	IN	IN	_	49	NMOD	_	_
51	tumor	_	NN	NN	_	55	NMOD	_	_
52	necrosis	_	NN	NN	_	55	NMOD	_	_
53	factor	_	NN	NN	_	55	NMOD	_	_
54	gene	_	NN	NN	_	55	NMOD	_	_
55	expression	_	NN	NN	_	50	PMOD	_	_
56	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	induction	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	monocytic	_	JJ	JJ	_	5	NMOD	_	_
5	differentiation	_	NN	NN	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	associated	_	VBN	VBN	_	6	VC	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	transient	_	JJ	JJ	_	10	NMOD	_	_
10	increases	_	NNS	NNS	_	8	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	c-jun	_	NN	NN	_	14	NMOD	_	_
13	mRNA	_	NN	NN	_	14	NMOD	_	_
14	levels	_	NNS	NNS	_	11	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	which	_	WDT	WDT	_	17	SBJ	_	_
17	were	_	VBD	VBD	_	14	NMOD	_	_
18	maximal	_	JJ	JJ	_	17	PRD	_	_
19	at	_	IN	IN	_	17	TMP	_	_
20	6	_	CD	CD	_	21	NMOD	_	_
21	h	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	Similar	_	JJ	JJ	_	2	NMOD	_	_
2	effects	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	obtained	_	VBN	VBN	_	3	VC	_	_
5	for	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	c-fos	_	NN	NN	_	8	NMOD	_	_
8	gene	_	NN	NN	_	5	PMOD	_	_
9	.	_	.	.	_	3	P	_	_

1	Run-on	_	JJ	JJ	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	3	SBJ	_	_
3	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
4	detectable	_	JJ	JJ	_	5	NMOD	_	_
5	levels	_	NNS	NNS	_	3	VMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	c-jun	_	NN	NN	_	8	NMOD	_	_
8	transcription	_	NN	NN	_	6	PMOD	_	_
9	in	_	IN	IN	_	5	NMOD	_	_
10	U-937	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	and	_	CC	CC	_	5	CC	_	_
13	that	_	IN	IN	_	5	COORD	_	_
14	this	_	DT	DT	_	15	NMOD	_	_
15	rate	_	NN	NN	_	16	SBJ	_	_
16	is	_	VBZ	VBZ	_	13	VMOD	_	_
17	increased	_	VBN	VBN	_	16	VC	_	_
18	approximately	_	RB	RB	_	17	ADV	_	_
19	40-fold	_	RB	RB	_	18	AMOD	_	_
20	following	_	VBG	VBG	_	17	TMP	_	_
21	okadaic	_	JJ	JJ	_	23	NMOD	_	_
22	acid	_	NN	NN	_	23	NMOD	_	_
23	exposure	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	c-jun	_	NN	NN	_	3	NMOD	_	_
2	mRNA	_	NN	NN	_	3	NMOD	_	_
3	levels	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	superinduced	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	cells	_	NNS	NNS	_	6	PMOD	_	_
8	treated	_	VBN	VBN	_	7	NMOD	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	both	_	CC	CC	_	12	CC	_	_
11	okadaic	_	JJ	JJ	_	12	NMOD	_	_
12	acid	_	NN	NN	_	9	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	cycloheximide	_	NN	NN	_	12	COORD	_	_
15	,	_	,	,	_	4	P	_	_
16	whereas	_	IN	IN	_	4	COORD	_	_
17	inhibition	_	NN	NN	_	21	SBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	protein	_	NN	NN	_	20	NMOD	_	_
20	synthesis	_	NN	NN	_	18	PMOD	_	_
21	had	_	VBD	VBD	_	4	COORD	_	_
22	little	_	JJ	JJ	_	27	NMOD	_	_
23	,	_	,	,	_	24	P	_	_
24	if	_	IN	IN	_	27	PRN	_	_
25	any	_	DT	DT	_	24	VMOD	_	_
26	,	_	,	,	_	24	P	_	_
27	effect	_	NN	NN	_	21	OBJ	_	_
28	on	_	IN	IN	_	27	NMOD	_	_
29	okadaic	_	JJ	JJ	_	30	AMOD	_	_
30	acid-induced	_	JJ	JJ	_	32	NMOD	_	_
31	c-jun	_	NN	NN	_	32	NMOD	_	_
32	transcription	_	NN	NN	_	28	PMOD	_	_
33	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	half-life	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	c-jun	_	NN	NN	_	5	NMOD	_	_
5	mRNA	_	NN	NN	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	similar	_	JJ	JJ	_	6	PRD	_	_
8	(	_	(	(	_	10	P	_	_
9	45-50	_	CD	CD	_	10	NMOD	_	_
10	min	_	NN	NN	_	7	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	in	_	IN	IN	_	6	ADV	_	_
13	both	_	CC	CC	_	14	CC	_	_
14	untreated	_	JJ	JJ	_	18	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	okadaic	_	JJ	JJ	_	17	AMOD	_	_
17	acid-induced	_	JJ	JJ	_	14	COORD	_	_
18	cells	_	NNS	NNS	_	12	PMOD	_	_
19	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	11	P	_	_
4	treatment	_	NN	NN	_	11	SBJ	_	_
5	with	_	IN	IN	_	4	NMOD	_	_
6	both	_	DT	DT	_	8	NMOD	_	_
7	okadaic	_	JJ	JJ	_	8	NMOD	_	_
8	acid	_	NN	NN	_	5	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	cycloheximide	_	NN	NN	_	8	COORD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	associated	_	VBN	VBN	_	11	VC	_	_
13	with	_	IN	IN	_	12	ADV	_	_
14	stabilization	_	NN	NN	_	13	PMOD	_	_
15	(	_	(	(	_	20	P	_	_
16	t	_	NN	NN	_	20	SBJ	_	_
17	1\/2	_	CD	CD	_	16	NMOD	_	_
18	=	_	JJ	JJ	_	20	VMOD	_	_
19	90	_	CD	CD	_	20	NMOD	_	_
20	min	_	NN	NN	_	14	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	of	_	IN	IN	_	14	NMOD	_	_
23	c-jun	_	NN	NN	_	24	NMOD	_	_
24	transcripts	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	11	P	_	_

1	Taken	_	VBN	VBN	_	6	ADV	_	_
2	together	_	RB	RB	_	1	ADV	_	_
3	,	_	,	,	_	6	P	_	_
4	these	_	DT	DT	_	5	NMOD	_	_
5	findings	_	NNS	NNS	_	6	SBJ	_	_
6	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	induction	_	NN	NN	_	16	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	c-jun	_	NN	NN	_	12	NMOD	_	_
12	transcription	_	NN	NN	_	10	PMOD	_	_
13	by	_	IN	IN	_	9	NMOD	_	_
14	okadaic	_	JJ	JJ	_	15	NMOD	_	_
15	acid	_	NN	NN	_	13	PMOD	_	_
16	is	_	VBZ	VBZ	_	7	VMOD	_	_
17	controlled	_	VBN	VBN	_	16	VC	_	_
18	primarily	_	RB	RB	_	17	ADV	_	_
19	by	_	IN	IN	_	17	LGS	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	transcriptional	_	JJ	JJ	_	22	NMOD	_	_
22	mechanism	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	6	P	_	_

1	Since	_	IN	IN	_	17	ADV	_	_
2	previous	_	JJ	JJ	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	4	SBJ	_	_
4	have	_	VBP	VBP	_	1	VMOD	_	_
5	demonstrated	_	VBN	VBN	_	4	VC	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	c-jun	_	NN	NN	_	9	NMOD	_	_
9	gene	_	NN	NN	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	6	VMOD	_	_
11	autoinduced	_	VBN	VBN	_	10	VC	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	Jun\/AP-1	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	17	P	_	_
15	we	_	PRP	PRP	_	17	SBJ	_	_
16	also	_	RB	RB	_	17	ADV	_	_
17	studied	_	VBD	VBD	_	0	ROOT-S	_	_
18	transcription	_	NN	NN	_	17	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	c-jun	_	NN	NN	_	28	NMOD	_	_
21	promoter	_	NN	NN	_	28	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	positions	_	NNS	NNS	_	28	PRN	_	_
24	-132\/+170	_	CD	CD	_	23	NMOD	_	_
25	)	_	)	)	_	23	P	_	_
26	-reporter	_	JJ	JJ	_	28	NMOD	_	_
27	gene	_	NN	NN	_	28	NMOD	_	_
28	constructs	_	NNS	NNS	_	19	PMOD	_	_
29	with	_	IN	IN	_	18	NMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	without	_	IN	IN	_	29	COORD	_	_
32	a	_	DT	DT	_	35	NMOD	_	_
33	mutated	_	VBN	VBN	_	35	NMOD	_	_
34	AP-1	_	NN	NN	_	35	NMOD	_	_
35	element	_	NN	NN	_	29	PMOD	_	_
36	.	_	.	.	_	17	P	_	_

1	(	_	(	(	_	3	P	_	_
2	ABSTRACT	_	NN	NN	_	3	SBJ	_	_
3	TRUNCATED	_	VBN	VBN	_	0	ROOT-S	_	_
4	AT	_	IN	IN	_	3	ADV	_	_
5	250	_	CD	CD	_	6	NMOD	_	_
6	WORDS	_	NNS	NNS	_	4	PMOD	_	_
7	)	_	)	)	_	3	P	_	_

1	A	_	DT	DT	_	5	NMOD	_	_
2	novel	_	JJ	JJ	_	5	NMOD	_	_
3	B	_	NN	NN	_	5	NMOD	_	_
4	cell-derived	_	JJ	JJ	_	3	AMOD	_	_
5	coactivator	_	NN	NN	_	6	SBJ	_	_
6	potentiates	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	activation	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	immunoglobulin	_	NN	NN	_	11	NMOD	_	_
11	promoters	_	NNS	NNS	_	9	PMOD	_	_
12	by	_	IN	IN	_	8	NMOD	_	_
13	octamer-binding	_	JJ	JJ	_	15	NMOD	_	_
14	transcription	_	NN	NN	_	15	NMOD	_	_
15	factors	_	NNS	NNS	_	12	PMOD	_	_
16	.	_	.	.	_	6	P	_	_

1	A	_	DT	DT	_	5	NMOD	_	_
2	novel	_	JJ	JJ	_	5	NMOD	_	_
3	B	_	NN	NN	_	5	NMOD	_	_
4	cell-restricted	_	JJ	JJ	_	3	AMOD	_	_
5	activity	_	NN	NN	_	24	SBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	required	_	VBN	VBN	_	5	NMOD	_	_
8	for	_	IN	IN	_	7	ADV	_	_
9	high	_	JJ	JJ	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	octamer\/Oct-dependent	_	JJ	JJ	_	13	NMOD	_	_
13	transcription	_	NN	NN	_	11	PMOD	_	_
14	from	_	IN	IN	_	10	NMOD	_	_
15	an	_	DT	DT	_	22	NMOD	_	_
16	immunoglobulin	_	NN	NN	_	18	NMOD	_	_
17	heavy	_	JJ	JJ	_	18	NMOD	_	_
18	chain	_	NN	NN	_	22	NMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	IgH	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	promoter	_	NN	NN	_	14	PMOD	_	_
23	,	_	,	,	_	5	P	_	_
24	was	_	VBD	VBD	_	0	ROOT-S	_	_
25	detected	_	VBN	VBN	_	24	VC	_	_
26	in	_	IN	IN	_	25	ADV	_	_
27	an	_	DT	DT	_	30	NMOD	_	_
28	in	_	FW	FW	_	29	AMOD	_	_
29	vitro	_	FW	FW	_	30	NMOD	_	_
30	system	_	NN	NN	_	26	PMOD	_	_
31	consisting	_	VBG	VBG	_	30	NMOD	_	_
32	of	_	IN	IN	_	31	ADV	_	_
33	HeLa	_	NN	NN	_	35	NMOD	_	_
34	cell-derived	_	JJ	JJ	_	33	AMOD	_	_
35	extracts	_	NNS	NNS	_	32	PMOD	_	_
36	complemented	_	VBN	VBN	_	35	NMOD	_	_
37	with	_	IN	IN	_	36	ADV	_	_
38	fractionated	_	VBN	VBN	_	42	NMOD	_	_
39	B	_	NN	NN	_	42	NMOD	_	_
40	cell	_	NN	NN	_	42	NMOD	_	_
41	nuclear	_	JJ	JJ	_	42	NMOD	_	_
42	proteins	_	NNS	NNS	_	37	PMOD	_	_
43	.	_	.	.	_	24	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	factor	_	NN	NN	_	7	SBJ	_	_
3	responsible	_	JJ	JJ	_	2	NMOD	_	_
4	for	_	IN	IN	_	3	AMOD	_	_
5	this	_	DT	DT	_	6	NMOD	_	_
6	activity	_	NN	NN	_	4	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	designated	_	VBN	VBN	_	7	VC	_	_
9	Oct	_	NN	NN	_	10	NMOD	_	_
10	coactivator	_	NN	NN	_	8	OBJ	_	_
11	from	_	IN	IN	_	10	NMOD	_	_
12	B	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	OCA-B	_	NN	NN	_	10	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	.	_	.	.	_	7	P	_	_

1	OCA-B	_	NN	NN	_	2	SBJ	_	_
2	stimulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	transcription	_	NN	NN	_	2	OBJ	_	_
5	from	_	IN	IN	_	4	NMOD	_	_
6	an	_	DT	DT	_	8	NMOD	_	_
7	IgH	_	NN	NN	_	8	NMOD	_	_
8	promoter	_	NN	NN	_	5	PMOD	_	_
9	in	_	IN	IN	_	2	ADV	_	_
10	conjunction	_	NN	NN	_	9	DEP	_	_
11	with	_	IN	IN	_	9	DEP	_	_
12	either	_	CC	CC	_	13	CC	_	_
13	Oct-1	_	NN	NN	_	9	PMOD	_	_
14	or	_	CC	CC	_	13	CC	_	_
15	Oct-2	_	NN	NN	_	13	COORD	_	_
16	but	_	CC	CC	_	2	CC	_	_
17	shows	_	VBZ	VBZ	_	2	COORD	_	_
18	no	_	DT	DT	_	20	NMOD	_	_
19	significant	_	JJ	JJ	_	20	NMOD	_	_
20	effect	_	NN	NN	_	17	OBJ	_	_
21	on	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	octamer\/Oct-dependent	_	JJ	JJ	_	24	NMOD	_	_
24	transcription	_	NN	NN	_	21	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	31	NMOD	_	_
27	ubiquitously	_	RB	RB	_	28	AMOD	_	_
28	expressed	_	VBN	VBN	_	31	NMOD	_	_
29	histone	_	NN	NN	_	31	NMOD	_	_
30	H2B	_	NN	NN	_	31	NMOD	_	_
31	promoter	_	NN	NN	_	25	PMOD	_	_
32	and	_	CC	CC	_	24	CC	_	_
33	the	_	DT	DT	_	34	NMOD	_	_
34	transcription	_	NN	NN	_	24	COORD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	USF-	_	NN	NN	_	39	NMOD	_	_
37	and	_	CC	CC	_	36	CC	_	_
38	Sp1-regulated	_	JJ	JJ	_	36	COORD	_	_
39	promoters	_	NNS	NNS	_	35	PMOD	_	_
40	.	_	.	.	_	2	P	_	_

1	Taken	_	VBN	VBN	_	6	ADV	_	_
2	together	_	RB	RB	_	1	ADV	_	_
3	,	_	,	,	_	6	P	_	_
4	our	_	PRP$	PRP$	_	5	NMOD	_	_
5	results	_	NNS	NNS	_	6	SBJ	_	_
6	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	OCA-B	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	7	VMOD	_	_
10	a	_	DT	DT	_	17	NMOD	_	_
11	tissue-	_	NN	NN	_	17	NMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	promoter-	_	NN	NN	_	11	COORD	_	_
14	,	_	,	,	_	11	P	_	_
15	and	_	CC	CC	_	11	CC	_	_
16	factor-specific	_	JJ	JJ	_	11	COORD	_	_
17	coactivator	_	NN	NN	_	9	PRD	_	_
18	and	_	CC	CC	_	7	CC	_	_
19	that	_	IN	IN	_	7	COORD	_	_
20	OCA-B	_	NN	NN	_	21	SBJ	_	_
21	may	_	MD	MD	_	19	VMOD	_	_
22	be	_	VB	VB	_	21	VC	_	_
23	a	_	DT	DT	_	25	NMOD	_	_
24	major	_	JJ	JJ	_	25	NMOD	_	_
25	determinant	_	NN	NN	_	22	PRD	_	_
26	for	_	IN	IN	_	25	NMOD	_	_
27	B	_	NN	NN	_	29	NMOD	_	_
28	cell-specific	_	JJ	JJ	_	27	AMOD	_	_
29	activation	_	NN	NN	_	26	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	immunoglobulin	_	NN	NN	_	32	NMOD	_	_
32	promoters	_	NNS	NNS	_	30	PMOD	_	_
33	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	18	ADV	_	_
2	light	_	NN	NN	_	1	DEP	_	_
3	of	_	IN	IN	_	1	DEP	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	evidence	_	NN	NN	_	1	PMOD	_	_
6	showing	_	VBG	VBG	_	5	NMOD	_	_
7	physical	_	JJ	JJ	_	10	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	functional	_	JJ	JJ	_	7	COORD	_	_
10	interactions	_	NNS	NNS	_	6	OBJ	_	_
11	between	_	IN	IN	_	10	NMOD	_	_
12	Oct	_	NN	NN	_	13	NMOD	_	_
13	factors	_	NNS	NNS	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	OCA-B	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	18	P	_	_
17	we	_	PRP	PRP	_	18	SBJ	_	_
18	propose	_	VBP	VBP	_	0	ROOT-S	_	_
19	a	_	DT	DT	_	20	NMOD	_	_
20	mechanism	_	NN	NN	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	action	_	NN	NN	_	21	PMOD	_	_
23	for	_	IN	IN	_	20	NMOD	_	_
24	OCA-B	_	NN	NN	_	23	PMOD	_	_
25	and	_	CC	CC	_	18	CC	_	_
26	discuss	_	VBP	VBP	_	18	COORD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	implications	_	NNS	NNS	_	26	OBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	OCA-B	_	NN	NN	_	29	PMOD	_	_
31	for	_	IN	IN	_	28	NMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	transcriptional	_	JJ	JJ	_	34	NMOD	_	_
34	regulation	_	NN	NN	_	31	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	other	_	JJ	JJ	_	38	NMOD	_	_
37	tissue-specific	_	JJ	JJ	_	38	NMOD	_	_
38	promoters	_	NNS	NNS	_	35	PMOD	_	_
39	.	_	.	.	_	18	P	_	_

1	Characterization	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	7	NMOD	_	_
4	novel	_	JJ	JJ	_	7	NMOD	_	_
5	T	_	NN	NN	_	7	NMOD	_	_
6	lymphocyte	_	NN	NN	_	7	NMOD	_	_
7	protein	_	NN	NN	_	2	PMOD	_	_
8	which	_	WDT	WDT	_	9	SBJ	_	_
9	binds	_	VBZ	VBZ	_	7	NMOD	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	site	_	NN	NN	_	10	PMOD	_	_
13	related	_	JJ	JJ	_	12	NMOD	_	_
14	to	_	TO	TO	_	13	AMOD	_	_
15	steroid\/thyroid	_	JJ	JJ	_	19	NMOD	_	_
16	hormone	_	NN	NN	_	19	NMOD	_	_
17	receptor	_	NN	NN	_	19	NMOD	_	_
18	response	_	NN	NN	_	19	NMOD	_	_
19	elements	_	NNS	NNS	_	14	PMOD	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	negative	_	JJ	JJ	_	24	NMOD	_	_
23	regulatory	_	JJ	JJ	_	24	NMOD	_	_
24	sequence	_	NN	NN	_	20	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	32	NMOD	_	_
27	human	_	JJ	JJ	_	32	NMOD	_	_
28	immunodeficiency	_	NN	NN	_	32	NMOD	_	_
29	virus	_	NN	NN	_	32	NMOD	_	_
30	long	_	JJ	JJ	_	32	NMOD	_	_
31	terminal	_	JJ	JJ	_	32	NMOD	_	_
32	repeat	_	NN	NN	_	25	PMOD	_	_
33	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	previously	_	RB	RB	_	2	TMP	_	_
4	identified	_	VBN	VBN	_	2	VC	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	T	_	NN	NN	_	8	NMOD	_	_
7	lymphocyte	_	NN	NN	_	8	NMOD	_	_
8	protein	_	NN	NN	_	4	OBJ	_	_
9	which	_	WDT	WDT	_	10	SBJ	_	_
10	binds	_	VBZ	VBZ	_	8	NMOD	_	_
11	to	_	TO	TO	_	10	ADV	_	_
12	a	_	DT	DT	_	13	NMOD	_	_
13	site	_	NN	NN	_	11	PMOD	_	_
14	within	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	LTR	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	22	NMOD	_	_
19	human	_	JJ	JJ	_	22	NMOD	_	_
20	immunodeficiency	_	NN	NN	_	22	NMOD	_	_
21	virus	_	NN	NN	_	22	NMOD	_	_
22	type	_	NN	NN	_	17	PMOD	_	_
23	1	_	CD	CD	_	22	NMOD	_	_
24	(	_	(	(	_	25	P	_	_
25	HIV-1	_	NN	NN	_	22	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	and	_	CC	CC	_	10	CC	_	_
28	exerts	_	VBZ	VBZ	_	10	COORD	_	_
29	an	_	DT	DT	_	31	NMOD	_	_
30	inhibitory	_	JJ	JJ	_	31	NMOD	_	_
31	effect	_	NN	NN	_	28	OBJ	_	_
32	on	_	IN	IN	_	28	ADV	_	_
33	virus	_	NN	NN	_	35	NMOD	_	_
34	gene	_	NN	NN	_	35	NMOD	_	_
35	expression	_	NN	NN	_	32	PMOD	_	_
36	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	palindromic	_	JJ	JJ	_	3	NMOD	_	_
3	site	_	NN	NN	_	12	SBJ	_	_
4	(	_	(	(	_	6	P	_	_
5	site	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	3	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	recognized	_	VBN	VBN	_	3	NMOD	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	this	_	DT	DT	_	11	NMOD	_	_
11	protein	_	NN	NN	_	9	PMOD	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	related	_	JJ	JJ	_	12	PRD	_	_
14	to	_	TO	TO	_	13	AMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	palindromic	_	JJ	JJ	_	18	NMOD	_	_
17	binding	_	VBG	VBG	_	18	NMOD	_	_
18	sites	_	NNS	NNS	_	14	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	members	_	NNS	NNS	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	26	NMOD	_	_
23	steroid\/thyroid	_	JJ	JJ	_	26	NMOD	_	_
24	hormone	_	NN	NN	_	26	NMOD	_	_
25	receptor	_	NN	NN	_	26	NMOD	_	_
26	family	_	NN	NN	_	21	PMOD	_	_
27	.	_	.	.	_	12	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	characterize	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	T	_	NN	NN	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	protein	_	NN	NN	_	3	OBJ	_	_
8	binding	_	VBG	VBG	_	7	NMOD	_	_
9	to	_	TO	TO	_	8	ADV	_	_
10	this	_	DT	DT	_	11	NMOD	_	_
11	site	_	NN	NN	_	9	PMOD	_	_
12	as	_	IN	IN	_	3	ADV	_	_
13	a	_	DT	DT	_	16	NMOD	_	_
14	100	_	CD	CD	_	15	AMOD	_	_
15	kD	_	NN	NN	_	16	NMOD	_	_
16	protein	_	NN	NN	_	12	PMOD	_	_
17	which	_	WDT	WDT	_	18	SBJ	_	_
18	is	_	VBZ	VBZ	_	16	NMOD	_	_
19	most	_	RBS	RBS	_	20	AMOD	_	_
20	abundant	_	JJ	JJ	_	18	PRD	_	_
21	in	_	IN	IN	_	20	AMOD	_	_
22	T	_	NN	NN	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	21	PMOD	_	_
24	and	_	CC	CC	_	18	CC	_	_
25	which	_	WDT	WDT	_	26	SBJ	_	_
26	binds	_	VBZ	VBZ	_	18	COORD	_	_
27	to	_	TO	TO	_	26	ADV	_	_
28	site	_	NN	NN	_	29	NMOD	_	_
29	B	_	NN	NN	_	27	PMOD	_	_
30	as	_	IN	IN	_	26	ADV	_	_
31	a	_	DT	DT	_	34	NMOD	_	_
32	200	_	CD	CD	_	33	AMOD	_	_
33	kD	_	NN	NN	_	34	NMOD	_	_
34	complex	_	NN	NN	_	30	PMOD	_	_
35	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	protein	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	distinct	_	JJ	JJ	_	3	PRD	_	_
5	from	_	IN	IN	_	4	AMOD	_	_
6	other	_	JJ	JJ	_	7	NMOD	_	_
7	members	_	NNS	NNS	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	steroid\/thyroid	_	JJ	JJ	_	13	NMOD	_	_
11	hormone	_	NN	NN	_	13	NMOD	_	_
12	receptor	_	NN	NN	_	13	NMOD	_	_
13	family	_	NN	NN	_	8	PMOD	_	_
14	including	_	VBG	VBG	_	7	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	COUP	_	NN	NN	_	17	NMOD	_	_
17	protein	_	NN	NN	_	14	PMOD	_	_
18	which	_	WDT	WDT	_	19	SBJ	_	_
19	has	_	VBZ	VBZ	_	17	NMOD	_	_
20	a	_	DT	DT	_	25	NMOD	_	_
21	closely	_	RB	RB	_	22	AMOD	_	_
22	related	_	JJ	JJ	_	25	NMOD	_	_
23	DNA	_	NN	NN	_	25	NMOD	_	_
24	binding	_	NN	NN	_	25	NMOD	_	_
25	specificity	_	NN	NN	_	19	OBJ	_	_
26	.	_	.	.	_	3	P	_	_

1	Reticuloendotheliosis	_	NN	NN	_	6	NMOD	_	_
2	virus	_	NN	NN	_	6	NMOD	_	_
3	long	_	JJ	JJ	_	6	NMOD	_	_
4	terminal	_	JJ	JJ	_	6	NMOD	_	_
5	repeat	_	NN	NN	_	6	NMOD	_	_
6	elements	_	NNS	NNS	_	7	SBJ	_	_
7	are	_	VBP	VBP	_	0	ROOT-S	_	_
8	efficient	_	JJ	JJ	_	9	NMOD	_	_
9	promoters	_	NNS	NNS	_	7	PRD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	cells	_	NNS	NNS	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	various	_	JJ	JJ	_	14	NMOD	_	_
14	species	_	NNS	NNS	_	17	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	tissue	_	NN	NN	_	14	COORD	_	_
17	origin	_	NN	NN	_	12	PMOD	_	_
18	,	_	,	,	_	11	P	_	_
19	including	_	VBG	VBG	_	11	NMOD	_	_
20	human	_	JJ	JJ	_	22	NMOD	_	_
21	lymphoid	_	JJ	JJ	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	19	PMOD	_	_
23	.	_	.	.	_	7	P	_	_

1	Promiscuous	_	JJ	JJ	_	3	NMOD	_	_
2	transcriptional	_	JJ	JJ	_	3	NMOD	_	_
3	activity	_	NN	NN	_	17	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	reticuloendotheliosis	_	NN	NN	_	7	NMOD	_	_
7	virus	_	NN	NN	_	4	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	REV	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	long	_	JJ	JJ	_	13	NMOD	_	_
12	terminal	_	JJ	JJ	_	13	NMOD	_	_
13	repeat	_	NN	NN	_	7	NMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	LTR	_	NN	NN	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	was	_	VBD	VBD	_	0	ROOT-S	_	_
18	detected	_	VBN	VBN	_	17	VC	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	transient	_	JJ	JJ	_	22	NMOD	_	_
21	expression	_	NN	NN	_	22	NMOD	_	_
22	assays	_	NNS	NNS	_	19	PMOD	_	_
23	using	_	VBG	VBG	_	18	OBJ	_	_
24	LTR-chloramphenicol	_	NN	NN	_	27	NMOD	_	_
25	acetyltransferase-encoding	_	JJ	JJ	_	27	NMOD	_	_
26	gene	_	NN	NN	_	27	NMOD	_	_
27	chimeras	_	NNS	NNS	_	23	OBJ	_	_
28	,	_	,	,	_	27	P	_	_
29	and	_	CC	CC	_	27	CC	_	_
30	cells	_	NNS	NNS	_	27	COORD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	diverse	_	JJ	JJ	_	33	NMOD	_	_
33	species	_	NNS	NNS	_	36	NMOD	_	_
34	and	_	CC	CC	_	33	CC	_	_
35	tissue	_	NN	NN	_	33	COORD	_	_
36	type	_	NN	NN	_	31	PMOD	_	_
37	;	_	:	:	_	17	P	_	_
38	levels	_	NNS	NNS	_	46	SBJ	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	expression	_	NN	NN	_	39	PMOD	_	_
41	from	_	IN	IN	_	40	NMOD	_	_
42	two	_	CD	CD	_	45	NMOD	_	_
43	different	_	JJ	JJ	_	45	NMOD	_	_
44	REV	_	NN	NN	_	45	NMOD	_	_
45	LTRs	_	NNS	NNS	_	41	PMOD	_	_
46	correlate	_	VBP	VBP	_	17	VC	_	_
47	with	_	IN	IN	_	46	ADV	_	_
48	reports	_	NNS	NNS	_	47	PMOD	_	_
49	of	_	IN	IN	_	48	NMOD	_	_
50	pathogenicity	_	NN	NN	_	49	PMOD	_	_
51	of	_	IN	IN	_	50	NMOD	_	_
52	the	_	DT	DT	_	54	NMOD	_	_
53	respective	_	JJ	JJ	_	54	NMOD	_	_
54	viruses	_	NNS	NNS	_	51	PMOD	_	_
55	in	_	FW	FW	_	50	NMOD	_	_
56	vivo	_	FW	FW	_	55	AMOD	_	_
57	.	_	.	.	_	46	P	_	_

1	REVs	_	NNS	NNS	_	2	SBJ	_	_
2	do	_	VBP	VBP	_	0	ROOT-S	_	_
3	not	_	RB	RB	_	2	VMOD	_	_
4	encode	_	VB	VB	_	2	VC	_	_
5	a	_	DT	DT	_	6	NMOD	_	_
6	transactivator	_	NN	NN	_	4	OBJ	_	_
7	targeted	_	VBN	VBN	_	6	NMOD	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	viral	_	JJ	JJ	_	11	NMOD	_	_
11	LTR	_	NN	NN	_	8	PMOD	_	_
12	,	_	,	,	_	2	P	_	_
13	and	_	CC	CC	_	2	CC	_	_
14	cells	_	NNS	NNS	_	30	SBJ	_	_
15	infected	_	VBN	VBN	_	14	NMOD	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	Marek	_	NN	NN	_	20	NMOD	_	_
18	's	_	POS	POS	_	17	NMOD	_	_
19	disease	_	NN	NN	_	20	NMOD	_	_
20	virus	_	NN	NN	_	16	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	a	_	DT	DT	_	23	NMOD	_	_
23	herpesvirus	_	NN	NN	_	20	NMOD	_	_
24	with	_	IN	IN	_	23	NMOD	_	_
25	an	_	DT	DT	_	28	NMOD	_	_
26	overlapping	_	VBG	VBG	_	28	NMOD	_	_
27	host	_	NN	NN	_	28	NMOD	_	_
28	range	_	NN	NN	_	24	PMOD	_	_
29	,	_	,	,	_	20	P	_	_
30	do	_	VBP	VBP	_	2	COORD	_	_
31	not	_	RB	RB	_	30	VMOD	_	_
32	express	_	VB	VB	_	30	VC	_	_
33	factors	_	NNS	NNS	_	32	OBJ	_	_
34	that	_	WDT	WDT	_	36	SBJ	_	_
35	preferentially	_	RB	RB	_	36	ADV	_	_
36	enhance	_	VBP	VBP	_	33	NMOD	_	_
37	expression	_	NN	NN	_	36	OBJ	_	_
38	from	_	IN	IN	_	37	NMOD	_	_
39	REV	_	NN	NN	_	38	PMOD	_	_
40	or	_	CC	CC	_	39	CC	_	_
41	avian	_	JJ	JJ	_	44	NMOD	_	_
42	sarcoma\/leukemia	_	NN	NN	_	44	NMOD	_	_
43	virus	_	NN	NN	_	44	NMOD	_	_
44	LTRs	_	NNS	NNS	_	39	COORD	_	_
45	.	_	.	.	_	2	P	_	_

1	REV	_	NN	NN	_	2	NMOD	_	_
2	LTRs	_	NNS	NNS	_	3	SBJ	_	_
3	work	_	VBP	VBP	_	0	ROOT-S	_	_
4	efficiently	_	RB	RB	_	3	ADV	_	_
5	in	_	IN	IN	_	3	ADV	_	_
6	human	_	JJ	JJ	_	8	NMOD	_	_
7	lymphoid	_	JJ	JJ	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	5	PMOD	_	_
9	,	_	,	,	_	3	P	_	_
10	and	_	CC	CC	_	3	CC	_	_
11	are	_	VBP	VBP	_	3	COORD	_	_
12	viable	_	JJ	JJ	_	13	NMOD	_	_
13	alternatives	_	NNS	NNS	_	11	PRD	_	_
14	to	_	TO	TO	_	13	NMOD	_	_
15	promoters	_	NNS	NNS	_	14	PMOD	_	_
16	commonly	_	RB	RB	_	17	ADV	_	_
17	used	_	VBN	VBN	_	15	NMOD	_	_
18	for	_	IN	IN	_	17	ADV	_	_
19	expression	_	NN	NN	_	18	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	cloned	_	VBN	VBN	_	22	NMOD	_	_
22	genes	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	They	_	PRP	PRP	_	2	SBJ	_	_
2	may	_	MD	MD	_	0	ROOT-S	_	_
3	also	_	RB	RB	_	2	ADV	_	_
4	prove	_	VB	VB	_	2	VC	_	_
5	useful	_	JJ	JJ	_	4	PRD	_	_
6	in	_	IN	IN	_	4	ADV	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	identification	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	new	_	JJ	JJ	_	15	NMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	ubiquitous	_	JJ	JJ	_	10	COORD	_	_
13	cellular	_	JJ	JJ	_	15	NMOD	_	_
14	transcription	_	NN	NN	_	15	NMOD	_	_
15	factors	_	NNS	NNS	_	9	PMOD	_	_
16	.	_	.	.	_	2	P	_	_

1	Phorbol	_	NN	NN	_	2	NMOD	_	_
2	ester	_	NN	NN	_	3	SBJ	_	_
3	reduces	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	constitutive	_	JJ	JJ	_	8	NMOD	_	_
5	nuclear	_	JJ	JJ	_	8	NMOD	_	_
6	NF	_	NN	NN	_	8	NMOD	_	_
7	kappa	_	NN	NN	_	8	NMOD	_	_
8	B	_	NN	NN	_	3	OBJ	_	_
9	and	_	CC	CC	_	3	CC	_	_
10	inhibits	_	VBZ	VBZ	_	3	COORD	_	_
11	HIV-1	_	NN	NN	_	12	NMOD	_	_
12	production	_	NN	NN	_	10	OBJ	_	_
13	in	_	IN	IN	_	3	ADV	_	_
14	mature	_	JJ	JJ	_	17	NMOD	_	_
15	human	_	JJ	JJ	_	17	NMOD	_	_
16	monocytic	_	JJ	JJ	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	13	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	NF	_	NN	NN	_	3	NMOD	_	_
2	kappa	_	NN	NN	_	3	NMOD	_	_
3	B	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	potent	_	JJ	JJ	_	7	NMOD	_	_
7	mediator	_	NN	NN	_	4	PRD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	specific	_	JJ	JJ	_	11	NMOD	_	_
10	gene	_	NN	NN	_	11	NMOD	_	_
11	expression	_	NN	NN	_	8	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	human	_	JJ	JJ	_	14	NMOD	_	_
14	monocytes	_	NNS	NNS	_	12	PMOD	_	_
15	and	_	CC	CC	_	4	CC	_	_
16	has	_	VBZ	VBZ	_	4	COORD	_	_
17	been	_	VBN	VBN	_	16	VC	_	_
18	shown	_	VBN	VBN	_	17	VC	_	_
19	to	_	TO	TO	_	20	VMOD	_	_
20	play	_	VB	VB	_	18	OBJ	_	_
21	a	_	DT	DT	_	22	NMOD	_	_
22	role	_	NN	NN	_	20	OBJ	_	_
23	in	_	IN	IN	_	20	ADV	_	_
24	transcription	_	NN	NN	_	23	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	HIV-1	_	NN	NN	_	28	NMOD	_	_
28	genome	_	NN	NN	_	25	PMOD	_	_
29	in	_	IN	IN	_	28	NMOD	_	_
30	promonocytic	_	JJ	JJ	_	31	NMOD	_	_
31	leukemias	_	NNS	NNS	_	29	PMOD	_	_
32	.	_	.	.	_	4	P	_	_

1	There	_	EX	EX	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	little	_	JJ	JJ	_	4	NMOD	_	_
4	information	_	NN	NN	_	2	PRD	_	_
5	available	_	JJ	JJ	_	4	NMOD	_	_
6	on	_	IN	IN	_	4	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	response	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	NF	_	NN	NN	_	12	NMOD	_	_
11	kappa	_	NN	NN	_	12	NMOD	_	_
12	B	_	NN	NN	_	9	PMOD	_	_
13	to	_	TO	TO	_	8	NMOD	_	_
14	cytokines	_	NNS	NNS	_	13	PMOD	_	_
15	in	_	IN	IN	_	8	NMOD	_	_
16	normal	_	JJ	JJ	_	18	NMOD	_	_
17	human	_	JJ	JJ	_	18	NMOD	_	_
18	monocytes	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	used	_	VBN	VBN	_	2	VC	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	32P-labeled	_	JJ	JJ	_	6	NMOD	_	_
6	oligonucleotide	_	NN	NN	_	3	OBJ	_	_
7	derived	_	VBN	VBN	_	6	NMOD	_	_
8	from	_	IN	IN	_	7	ADV	_	_
9	human	_	JJ	JJ	_	11	NMOD	_	_
10	immunodeficiency	_	NN	NN	_	11	NMOD	_	_
11	virus	_	NN	NN	_	17	NMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	HIV-1	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	long	_	JJ	JJ	_	17	NMOD	_	_
16	terminal	_	JJ	JJ	_	17	NMOD	_	_
17	repeat	_	NN	NN	_	8	PMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	which	_	WDT	WDT	_	20	SBJ	_	_
20	contains	_	VBZ	VBZ	_	17	NMOD	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	tandem	_	JJ	JJ	_	23	NMOD	_	_
23	repeat	_	NN	NN	_	20	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	30	NMOD	_	_
26	NF	_	NN	NN	_	30	NMOD	_	_
27	kappa	_	NN	NN	_	30	NMOD	_	_
28	B	_	NN	NN	_	30	NMOD	_	_
29	binding	_	NN	NN	_	30	NMOD	_	_
30	sequence	_	NN	NN	_	24	PMOD	_	_
31	,	_	,	,	_	17	P	_	_
32	as	_	IN	IN	_	3	ADV	_	_
33	a	_	DT	DT	_	34	NMOD	_	_
34	probe	_	NN	NN	_	32	PMOD	_	_
35	in	_	IN	IN	_	3	ADV	_	_
36	a	_	DT	DT	_	39	NMOD	_	_
37	gel	_	NN	NN	_	39	NMOD	_	_
38	retardation	_	NN	NN	_	39	NMOD	_	_
39	assay	_	NN	NN	_	35	PMOD	_	_
40	to	_	TO	TO	_	41	VMOD	_	_
41	study	_	VB	VB	_	2	OBJ	_	_
42	this	_	DT	DT	_	44	NMOD	_	_
43	transcription	_	NN	NN	_	44	NMOD	_	_
44	factor	_	NN	NN	_	41	OBJ	_	_
45	.	_	.	.	_	2	P	_	_

1	Using	_	VBG	VBG	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	assay	_	NN	NN	_	1	OBJ	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	have	_	VBP	VBP	_	0	ROOT-S	_	_
7	detected	_	VBN	VBN	_	6	VC	_	_
8	NF	_	NN	NN	_	10	NMOD	_	_
9	kappa	_	NN	NN	_	10	NMOD	_	_
10	B	_	NN	NN	_	7	OBJ	_	_
11	in	_	IN	IN	_	7	ADV	_	_
12	extracts	_	NNS	NNS	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	nuclei	_	NNS	NNS	_	13	PMOD	_	_
15	from	_	IN	IN	_	14	NMOD	_	_
16	normal	_	JJ	JJ	_	18	NMOD	_	_
17	human	_	JJ	JJ	_	18	NMOD	_	_
18	monocytes	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	6	P	_	_

1	Treatment	_	NN	NN	_	14	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	normal	_	JJ	JJ	_	4	NMOD	_	_
4	monocytes	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	12-0-tetradecanoyl	_	JJ	JJ	_	7	NMOD	_	_
7	phorbol-13-acetate	_	NN	NN	_	5	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	TPA	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	for	_	IN	IN	_	1	TMP	_	_
12	4-24	_	CD	CD	_	13	NMOD	_	_
13	h	_	NN	NN	_	11	PMOD	_	_
14	caused	_	VBD	VBD	_	0	ROOT-S	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	complete	_	JJ	JJ	_	17	NMOD	_	_
17	disappearance	_	NN	NN	_	14	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	NF	_	NN	NN	_	21	NMOD	_	_
20	kappa	_	NN	NN	_	21	NMOD	_	_
21	B	_	NN	NN	_	18	PMOD	_	_
22	from	_	IN	IN	_	17	NMOD	_	_
23	nuclear	_	JJ	JJ	_	24	NMOD	_	_
24	extracts	_	NNS	NNS	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	monocytes	_	NNS	NNS	_	25	PMOD	_	_
27	.	_	.	.	_	14	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	similar	_	JJ	JJ	_	3	NMOD	_	_
3	result	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	obtained	_	VBN	VBN	_	4	VC	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	13	NMOD	_	_
8	mature	_	JJ	JJ	_	13	NMOD	_	_
9	monocytic	_	JJ	JJ	_	13	NMOD	_	_
10	leukemia	_	NN	NN	_	13	NMOD	_	_
11	cell	_	NN	NN	_	13	NMOD	_	_
12	line	_	NN	NN	_	13	NMOD	_	_
13	THP-1	_	NN	NN	_	6	PMOD	_	_
14	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	constitutive	_	JJ	JJ	_	5	NMOD	_	_
3	transcription	_	NN	NN	_	5	NMOD	_	_
4	factor	_	NN	NN	_	5	NMOD	_	_
5	SP1	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	unaffected	_	JJ	JJ	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	addition	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	TPA	_	NN	NN	_	10	PMOD	_	_
12	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	disappearance	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NF	_	NN	NN	_	6	NMOD	_	_
5	kappa	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	3	PMOD	_	_
7	from	_	IN	IN	_	2	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	nucleus	_	NN	NN	_	7	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	concentration	_	NN	NN	_	12	AMOD	_	_
12	dependent	_	JJ	JJ	_	10	PRD	_	_
13	between	_	IN	IN	_	10	ADV	_	_
14	10	_	CD	CD	_	17	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	50	_	CD	CD	_	14	COORD	_	_
17	ng\/ml	_	NN	NN	_	13	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	phorbol	_	NN	NN	_	20	NMOD	_	_
20	ester	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	THP-1	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	7	P	_	_
5	TPA	_	NN	NN	_	7	SBJ	_	_
6	also	_	RB	RB	_	7	ADV	_	_
7	induced	_	VBD	VBD	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	15	NMOD	_	_
9	new	_	JJ	JJ	_	15	NMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	faster-migrating	_	JJ	JJ	_	9	COORD	_	_
12	NF	_	NN	NN	_	15	NMOD	_	_
13	kappa	_	NN	NN	_	15	NMOD	_	_
14	B	_	NN	NN	_	15	NMOD	_	_
15	species	_	NNS	NNS	_	7	OBJ	_	_
16	not	_	RB	RB	_	17	VMOD	_	_
17	induced	_	VBN	VBN	_	15	NMOD	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	monocytes	_	NNS	NNS	_	18	PMOD	_	_
20	.	_	.	.	_	7	P	_	_

1	Protein	_	NN	NN	_	5	NMOD	_	_
2	kinase	_	NN	NN	_	5	NMOD	_	_
3	C	_	NN	NN	_	5	NMOD	_	_
4	inhibitor	_	NN	NN	_	5	NMOD	_	_
5	staurosporine	_	NN	NN	_	18	SBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	but	_	CC	CC	_	5	CC	_	_
8	not	_	RB	RB	_	7	COORD	_	_
9	cyclic	_	JJ	JJ	_	10	AMOD	_	_
10	nucleotide-dependent	_	JJ	JJ	_	14	NMOD	_	_
11	protein	_	NN	NN	_	14	NMOD	_	_
12	kinase	_	NN	NN	_	14	NMOD	_	_
13	inhibitor	_	NN	NN	_	14	NMOD	_	_
14	HA-1004	_	NN	NN	_	5	COORD	_	_
15	,	_	,	,	_	5	P	_	_
16	also	_	RB	RB	_	18	ADV	_	_
17	dramatically	_	RB	RB	_	18	ADV	_	_
18	reduced	_	VBD	VBD	_	0	ROOT-S	_	_
19	constitutive	_	JJ	JJ	_	20	NMOD	_	_
20	levels	_	NNS	NNS	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	nuclear	_	JJ	JJ	_	25	NMOD	_	_
23	NF	_	NN	NN	_	25	NMOD	_	_
24	kappa	_	NN	NN	_	25	NMOD	_	_
25	B	_	NN	NN	_	21	PMOD	_	_
26	.	_	.	.	_	18	P	_	_

1	Finally	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	TPA	_	NN	NN	_	4	NMOD	_	_
4	addition	_	NN	NN	_	10	SBJ	_	_
5	to	_	TO	TO	_	4	NMOD	_	_
6	monocytes	_	NNS	NNS	_	5	PMOD	_	_
7	infected	_	VBN	VBN	_	6	NMOD	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	HIV-1	_	NN	NN	_	8	PMOD	_	_
10	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
11	HIV-1	_	NN	NN	_	12	NMOD	_	_
12	replication	_	NN	NN	_	10	OBJ	_	_
13	,	_	,	,	_	10	P	_	_
14	as	_	IN	IN	_	10	ADV	_	_
15	determined	_	VBN	VBN	_	14	VMOD	_	_
16	by	_	IN	IN	_	15	ADV	_	_
17	reverse	_	JJ	JJ	_	19	NMOD	_	_
18	transcriptase	_	NN	NN	_	19	NMOD	_	_
19	assays	_	NNS	NNS	_	16	PMOD	_	_
20	,	_	,	,	_	10	P	_	_
21	in	_	IN	IN	_	10	ADV	_	_
22	a	_	DT	DT	_	24	NMOD	_	_
23	concentration-dependent	_	JJ	JJ	_	24	NMOD	_	_
24	manner	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	10	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	striking	_	JJ	JJ	_	6	NMOD	_	_
6	contrast	_	NN	NN	_	4	PMOD	_	_
7	to	_	TO	TO	_	6	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	increase	_	NN	NN	_	7	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	nuclear	_	JJ	JJ	_	14	NMOD	_	_
12	NF	_	NN	NN	_	14	NMOD	_	_
13	kappa	_	NN	NN	_	14	NMOD	_	_
14	B	_	NN	NN	_	10	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	HIV-1	_	NN	NN	_	17	NMOD	_	_
17	replication	_	NN	NN	_	14	COORD	_	_
18	induced	_	VBN	VBN	_	14	NMOD	_	_
19	by	_	IN	IN	_	18	LGS	_	_
20	phorbol	_	NN	NN	_	21	NMOD	_	_
21	esters	_	NNS	NNS	_	19	PMOD	_	_
22	in	_	IN	IN	_	18	ADV	_	_
23	promonocytic	_	JJ	JJ	_	25	NMOD	_	_
24	leukemia	_	NN	NN	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	22	PMOD	_	_
26	U937	_	NN	NN	_	25	NMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	HL-60	_	NN	NN	_	26	COORD	_	_
29	,	_	,	,	_	3	P	_	_
30	and	_	CC	CC	_	3	CC	_	_
31	emphasize	_	VBP	VBP	_	3	COORD	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	importance	_	NN	NN	_	31	OBJ	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	studying	_	VBG	VBG	_	34	PMOD	_	_
36	cytokine	_	NN	NN	_	37	NMOD	_	_
37	regulation	_	NN	NN	_	35	OBJ	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	HIV-1	_	NN	NN	_	38	PMOD	_	_
40	in	_	IN	IN	_	37	NMOD	_	_
41	normal	_	JJ	JJ	_	42	NMOD	_	_
42	monocytes	_	NNS	NNS	_	40	PMOD	_	_
43	.	_	.	.	_	3	P	_	_

1	Targeted	_	VBN	VBN	_	2	NMOD	_	_
2	degradation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	c-Fos	_	NN	NN	_	3	PMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	but	_	CC	CC	_	4	CC	_	_
7	not	_	RB	RB	_	6	COORD	_	_
8	v-Fos	_	NN	NN	_	4	COORD	_	_
9	,	_	,	,	_	4	P	_	_
10	by	_	IN	IN	_	2	NMOD	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	phosphorylation-dependent	_	JJ	JJ	_	13	NMOD	_	_
13	signal	_	NN	NN	_	10	PMOD	_	_
14	on	_	IN	IN	_	13	NMOD	_	_
15	c-Jun	_	NN	NN	_	14	PMOD	_	_
16	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	proto-oncogene	_	NN	NN	_	3	NMOD	_	_
3	products	_	NNS	NNS	_	7	SBJ	_	_
4	c-Fos	_	NN	NN	_	3	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	c-Jun	_	NN	NN	_	4	COORD	_	_
7	heterodimerize	_	VBP	VBP	_	0	ROOT-S	_	_
8	through	_	IN	IN	_	7	ADV	_	_
9	their	_	PRP$	PRP$	_	11	NMOD	_	_
10	leucine	_	NN	NN	_	11	NMOD	_	_
11	zippers	_	NNS	NNS	_	8	PMOD	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	form	_	VB	VB	_	7	OBJ	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	AP-1	_	NN	NN	_	17	NMOD	_	_
16	transcription	_	NN	NN	_	17	NMOD	_	_
17	factor	_	NN	NN	_	13	OBJ	_	_
18	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	transcriptional	_	JJ	JJ	_	3	NMOD	_	_
3	activity	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	heterodimer	_	NN	NN	_	4	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	regulated	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	signal-dependent	_	JJ	JJ	_	14	NMOD	_	_
11	phosphorylation	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	dephosphorylation	_	NN	NN	_	11	COORD	_	_
14	events	_	NNS	NNS	_	9	PMOD	_	_
15	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	stability	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	c-Fos	_	NN	NN	_	3	PMOD	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	found	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	9	VMOD	_	_
8	also	_	RB	RB	_	9	ADV	_	_
9	be	_	VB	VB	_	6	OBJ	_	_
10	controlled	_	VBN	VBN	_	9	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	intracellular	_	JJ	JJ	_	14	NMOD	_	_
13	signal	_	NN	NN	_	14	NMOD	_	_
14	transduction	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	14	ADV	_	_
2	transient	_	JJ	JJ	_	3	NMOD	_	_
3	expression	_	NN	NN	_	8	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	in	_	FW	FW	_	6	AMOD	_	_
6	vitro	_	FW	FW	_	7	NMOD	_	_
7	degradation	_	NN	NN	_	3	COORD	_	_
8	experiments	_	NNS	NNS	_	1	PMOD	_	_
9	,	_	,	,	_	14	P	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	stability	_	NN	NN	_	14	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	c-Fos	_	NN	NN	_	12	PMOD	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	decreased	_	VBN	VBN	_	14	VC	_	_
16	when	_	WRB	WRB	_	20	ADV	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	protein	_	NN	NN	_	19	SBJ	_	_
19	was	_	VBD	VBD	_	15	TMP	_	_
20	dimerized	_	JJ	JJ	_	19	VC	_	_
21	with	_	IN	IN	_	20	ADV	_	_
22	phosphorylated	_	VBN	VBN	_	23	NMOD	_	_
23	c-Jun	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	14	P	_	_

1	c-Jun	_	NN	NN	_	2	NMOD	_	_
2	protein	_	NN	NN	_	8	SBJ	_	_
3	isolated	_	VBN	VBN	_	2	NMOD	_	_
4	from	_	IN	IN	_	3	ADV	_	_
5	phorbol	_	NN	NN	_	7	NMOD	_	_
6	ester-induced	_	JJ	JJ	_	5	AMOD	_	_
7	cells	_	NNS	NNS	_	4	PMOD	_	_
8	did	_	VBD	VBD	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	target	_	VB	VB	_	8	VC	_	_
11	c-Fos	_	NN	NN	_	10	OBJ	_	_
12	for	_	IN	IN	_	10	ADV	_	_
13	degradation	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	8	P	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	suggests	_	VBZ	VBZ	_	8	OBJ	_	_
17	that	_	IN	IN	_	16	OBJ	_	_
18	c-Fos	_	NN	NN	_	19	SBJ	_	_
19	is	_	VBZ	VBZ	_	17	VMOD	_	_
20	transiently	_	RB	RB	_	19	TMP	_	_
21	stabilized	_	VBN	VBN	_	19	VC	_	_
22	after	_	IN	IN	_	21	TMP	_	_
23	stimulation	_	NN	NN	_	22	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	cell	_	NN	NN	_	26	NMOD	_	_
26	growth	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	8	P	_	_

1	v-Fos	_	NN	NN	_	2	NMOD	_	_
2	protein	_	NN	NN	_	10	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	retroviral	_	JJ	JJ	_	6	NMOD	_	_
6	counterpart	_	NN	NN	_	2	NMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	c-Fos	_	NN	NN	_	7	PMOD	_	_
9	,	_	,	,	_	2	P	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	not	_	RB	RB	_	10	VMOD	_	_
12	susceptible	_	JJ	JJ	_	10	PRD	_	_
13	to	_	TO	TO	_	12	AMOD	_	_
14	degradation	_	NN	NN	_	13	PMOD	_	_
15	targeted	_	VBN	VBN	_	14	NMOD	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	c-Jun	_	NN	NN	_	16	PMOD	_	_
18	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	use	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	interferon-gamma-treated	_	JJ	JJ	_	6	NMOD	_	_
5	U937	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	3	PMOD	_	_
7	in	_	IN	IN	_	2	NMOD	_	_
8	chemiluminescence	_	NN	NN	_	9	NMOD	_	_
9	assays	_	NNS	NNS	_	7	PMOD	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	detect	_	VB	VB	_	2	NMOD	_	_
12	red	_	JJ	JJ	_	13	NMOD	_	_
13	cell	_	NN	NN	_	11	OBJ	_	_
14	,	_	,	,	_	13	P	_	_
15	platelet	_	NN	NN	_	13	COORD	_	_
16	and	_	CC	CC	_	13	CC	_	_
17	granulocyte	_	NN	NN	_	18	NMOD	_	_
18	antibodies	_	NNS	NNS	_	13	COORD	_	_
19	of	_	IN	IN	_	13	NMOD	_	_
20	potential	_	JJ	JJ	_	22	NMOD	_	_
21	clinical	_	JJ	JJ	_	22	NMOD	_	_
22	significance	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	chemiluminescent	_	JJ	JJ	_	6	NMOD	_	_
3	(	_	(	(	_	4	P	_	_
4	CL	_	JJ	JJ	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	response	_	NN	NN	_	18	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	interferon-gamma-treated	_	JJ	JJ	_	9	NMOD	_	_
9	U937	_	NN	NN	_	13	NMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	IFN-U937	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	cells	_	NNS	NNS	_	7	PMOD	_	_
14	to	_	TO	TO	_	6	NMOD	_	_
15	sensitized	_	VBN	VBN	_	17	NMOD	_	_
16	target	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	14	PMOD	_	_
18	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
19	been	_	VBN	VBN	_	18	VC	_	_
20	used	_	VBN	VBN	_	19	VC	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	detect	_	VB	VB	_	20	OBJ	_	_
23	red	_	JJ	JJ	_	24	NMOD	_	_
24	cell	_	NN	NN	_	22	OBJ	_	_
25	,	_	,	,	_	24	P	_	_
26	platelet	_	NN	NN	_	24	COORD	_	_
27	and	_	CC	CC	_	24	CC	_	_
28	granulocyte	_	NN	NN	_	29	NMOD	_	_
29	antibodies	_	NNS	NNS	_	24	COORD	_	_
30	.	_	.	.	_	18	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	clone	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	U937	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	selected	_	VBN	VBN	_	6	VC	_	_
8	which	_	WDT	WDT	_	9	SBJ	_	_
9	expressed	_	VBD	VBD	_	2	NMOD	_	_
10	Fc	_	NN	NN	_	12	NMOD	_	_
11	receptor	_	NN	NN	_	12	NMOD	_	_
12	I	_	NN	NN	_	9	OBJ	_	_
13	(	_	(	(	_	16	P	_	_
14	Fc	_	NN	NN	_	16	NMOD	_	_
15	gamma	_	NN	NN	_	16	NMOD	_	_
16	RI	_	NN	NN	_	12	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	and	_	CC	CC	_	9	CC	_	_
19	which	_	WDT	WDT	_	29	SBJ	_	_
20	,	_	,	,	_	29	P	_	_
21	after	_	IN	IN	_	29	TMP	_	_
22	incubation	_	NN	NN	_	21	PMOD	_	_
23	with	_	IN	IN	_	22	NMOD	_	_
24	IFN-gamma	_	NN	NN	_	23	PMOD	_	_
25	for	_	IN	IN	_	22	TMP	_	_
26	72	_	CD	CD	_	27	NMOD	_	_
27	h	_	NN	NN	_	25	PMOD	_	_
28	,	_	,	,	_	29	P	_	_
29	was	_	VBD	VBD	_	9	COORD	_	_
30	capable	_	JJ	JJ	_	29	PRD	_	_
31	of	_	IN	IN	_	30	AMOD	_	_
32	generating	_	VBG	VBG	_	31	PMOD	_	_
33	high	_	JJ	JJ	_	34	NMOD	_	_
34	levels	_	NNS	NNS	_	32	OBJ	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	lucigenin-enhanced	_	JJ	JJ	_	37	NMOD	_	_
37	CL	_	NN	NN	_	35	PMOD	_	_
38	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	CL	_	NN	NN	_	3	NMOD	_	_
3	responses	_	NNS	NNS	_	20	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	IFN-U937	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	peripheral	_	JJ	JJ	_	11	NMOD	_	_
9	blood	_	NN	NN	_	11	NMOD	_	_
10	human	_	JJ	JJ	_	11	NMOD	_	_
11	monocytes	_	NNS	NNS	_	6	COORD	_	_
12	to	_	TO	TO	_	3	NMOD	_	_
13	sensitized	_	VBN	VBN	_	15	NMOD	_	_
14	red	_	JJ	JJ	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	12	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	platelets	_	NNS	NNS	_	15	COORD	_	_
18	or	_	CC	CC	_	15	CC	_	_
19	granulocytes	_	NNS	NNS	_	15	COORD	_	_
20	were	_	VBD	VBD	_	0	ROOT-S	_	_
21	then	_	RB	RB	_	20	ADV	_	_
22	compared	_	VBN	VBN	_	20	VC	_	_
23	.	_	.	.	_	20	P	_	_

1	Assays	_	NNS	NNS	_	7	SBJ	_	_
2	using	_	VBG	VBG	_	1	NMOD	_	_
3	monocytes	_	NNS	NNS	_	2	OBJ	_	_
4	or	_	CC	CC	_	3	CC	_	_
5	IFN-U937	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	3	COORD	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	of	_	IN	IN	_	7	PRD	_	_
9	comparable	_	JJ	JJ	_	10	NMOD	_	_
10	sensitivity	_	NN	NN	_	8	PMOD	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	detection	_	NN	NN	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	antibodies	_	NNS	NNS	_	13	PMOD	_	_
15	against	_	IN	IN	_	14	NMOD	_	_
16	all	_	DT	DT	_	18	NMOD	_	_
17	three	_	CD	CD	_	18	NMOD	_	_
18	types	_	NNS	NNS	_	15	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	target	_	NN	NN	_	21	NMOD	_	_
21	cell	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	9	P	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	use	_	NN	NN	_	9	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	IFN-U937	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	reduced	_	VBD	VBD	_	0	ROOT-S	_	_
10	interassay	_	JJ	JJ	_	11	NMOD	_	_
11	variation	_	NN	NN	_	9	OBJ	_	_
12	and	_	CC	CC	_	9	CC	_	_
13	simplified	_	VBD	VBD	_	9	COORD	_	_
14	assay	_	NN	NN	_	15	NMOD	_	_
15	performance	_	NN	NN	_	13	OBJ	_	_
16	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	potential	_	JJ	JJ	_	4	NMOD	_	_
3	clinical	_	JJ	JJ	_	4	NMOD	_	_
4	usefulness	_	NN	NN	_	9	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	these	_	DT	DT	_	8	NMOD	_	_
7	CL	_	NN	NN	_	8	NMOD	_	_
8	assays	_	NNS	NNS	_	5	PMOD	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	suggested	_	VBN	VBN	_	9	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	ability	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	both	_	CC	CC	_	16	CC	_	_
16	monocytes	_	NNS	NNS	_	14	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	IFN-U937	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	COORD	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	respond	_	VB	VB	_	13	NMOD	_	_
22	to	_	TO	TO	_	21	ADV	_	_
23	red	_	JJ	JJ	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	platelets	_	NNS	NNS	_	24	COORD	_	_
27	or	_	CC	CC	_	24	CC	_	_
28	granulocytes	_	NNS	NNS	_	24	COORD	_	_
29	sensitized	_	VBN	VBN	_	24	NMOD	_	_
30	with	_	IN	IN	_	29	ADV	_	_
31	sera	_	NN	NN	_	30	PMOD	_	_
32	from	_	IN	IN	_	31	NMOD	_	_
33	pregnant	_	JJ	JJ	_	34	NMOD	_	_
34	women	_	NNS	NNS	_	32	PMOD	_	_
35	whose	_	WP$	WP$	_	36	NMOD	_	_
36	babies	_	NNS	NNS	_	37	SBJ	_	_
37	had	_	VBD	VBD	_	34	NMOD	_	_
38	either	_	CC	CC	_	40	CC	_	_
39	haemolytic	_	JJ	JJ	_	40	NMOD	_	_
40	disease	_	NN	NN	_	37	OBJ	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	the	_	DT	DT	_	40	NMOD	_	_
43	newborn	_	JJ	JJ	_	40	NMOD	_	_
44	(	_	(	(	_	45	P	_	_
45	HDN	_	NN	NN	_	40	PRN	_	_
46	)	_	)	)	_	45	P	_	_
47	,	_	,	,	_	40	P	_	_
48	alloimmune	_	JJ	JJ	_	49	NMOD	_	_
49	thrombocytopenia	_	NN	NN	_	40	COORD	_	_
50	or	_	CC	CC	_	40	CC	_	_
51	alloimmune	_	JJ	JJ	_	52	NMOD	_	_
52	neutropenia	_	NN	NN	_	40	COORD	_	_
53	respectively	_	RB	RB	_	37	ADV	_	_
54	.	_	.	.	_	9	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	9	P	_	_
4	monocytes	_	NNS	NNS	_	9	SBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	IFN-U937	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	4	COORD	_	_
8	both	_	DT	DT	_	4	NMOD	_	_
9	responded	_	VBD	VBD	_	0	ROOT-S	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	red	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	sensitized	_	VBN	VBN	_	12	NMOD	_	_
14	with	_	IN	IN	_	13	ADV	_	_
15	antibodies	_	NNS	NNS	_	14	PMOD	_	_
16	against	_	IN	IN	_	15	NMOD	_	_
17	a	_	DT	DT	_	18	NMOD	_	_
18	variety	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	specificities	_	NNS	NNS	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	assumed	_	VBN	VBN	_	26	AMOD	_	_
23	(	_	(	(	_	26	P	_	_
24	although	_	IN	IN	_	26	AMOD	_	_
25	not	_	RB	RB	_	26	AMOD	_	_
26	documented	_	VBN	VBN	_	29	NMOD	_	_
27	)	_	)	)	_	26	P	_	_
28	clinical	_	JJ	JJ	_	29	NMOD	_	_
29	significance	_	NN	NN	_	21	PMOD	_	_
30	for	_	IN	IN	_	29	NMOD	_	_
31	blood	_	NN	NN	_	33	NMOD	_	_
32	transfusion	_	NN	NN	_	33	NMOD	_	_
33	recipients	_	NNS	NNS	_	30	PMOD	_	_
34	.	_	.	.	_	9	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	8	P	_	_
4	monocytes	_	NNS	NNS	_	8	SBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	IFN-U937	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	4	COORD	_	_
8	responded	_	VBD	VBD	_	0	ROOT-S	_	_
9	only	_	RB	RB	_	8	ADV	_	_
10	weakly	_	RB	RB	_	9	AMOD	_	_
11	to	_	TO	TO	_	8	ADV	_	_
12	red	_	JJ	JJ	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	sensitized	_	VBN	VBN	_	13	NMOD	_	_
15	with	_	IN	IN	_	14	ADV	_	_
16	either	_	CC	CC	_	15	CC	_	_
17	anti-D	_	JJ	JJ	_	15	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	sera	_	NN	NN	_	18	PMOD	_	_
20	from	_	IN	IN	_	19	NMOD	_	_
21	mothers	_	NNS	NNS	_	20	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	babies	_	NNS	NNS	_	22	PMOD	_	_
24	unaffected	_	JJ	JJ	_	23	NMOD	_	_
25	by	_	IN	IN	_	24	LGS	_	_
26	HDN	_	NN	NN	_	25	PMOD	_	_
27	,	_	,	,	_	15	P	_	_
28	or	_	CC	CC	_	15	CC	_	_
29	with	_	IN	IN	_	15	COORD	_	_
30	antisera	_	NNS	NNS	_	29	PMOD	_	_
31	containing	_	VBG	VBG	_	30	NMOD	_	_
32	high	_	JJ	JJ	_	34	NMOD	_	_
33	titre	_	NN	NN	_	34	NMOD	_	_
34	antibodies	_	NNS	NNS	_	31	OBJ	_	_
35	with	_	IN	IN	_	34	NMOD	_	_
36	specificities	_	NNS	NNS	_	35	PMOD	_	_
37	not	_	RB	RB	_	39	VMOD	_	_
38	normally	_	RB	RB	_	39	ADV	_	_
39	associated	_	VBN	VBN	_	36	NMOD	_	_
40	with	_	IN	IN	_	39	ADV	_	_
41	significantly	_	RB	RB	_	42	AMOD	_	_
42	reduced	_	VBN	VBN	_	45	NMOD	_	_
43	red	_	JJ	JJ	_	45	NMOD	_	_
44	cell	_	NN	NN	_	45	NMOD	_	_
45	survival	_	NN	NN	_	40	PMOD	_	_
46	.	_	.	.	_	8	P	_	_

1	Tyrosine	_	NN	NN	_	2	NMOD	_	_
2	phosphorylation	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	mandatory	_	JJ	JJ	_	7	NMOD	_	_
6	proximal	_	JJ	JJ	_	7	NMOD	_	_
7	step	_	NN	NN	_	3	PRD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	radiation-induced	_	JJ	JJ	_	10	NMOD	_	_
10	activation	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	17	NMOD	_	_
13	protein	_	NN	NN	_	17	NMOD	_	_
14	kinase	_	NN	NN	_	17	NMOD	_	_
15	C	_	NN	NN	_	17	NMOD	_	_
16	signaling	_	NN	NN	_	17	NMOD	_	_
17	pathway	_	NN	NN	_	11	PMOD	_	_
18	in	_	IN	IN	_	10	NMOD	_	_
19	human	_	JJ	JJ	_	22	NMOD	_	_
20	B-	_	NN	NN	_	22	NMOD	_	_
21	lymphocyte	_	NN	NN	_	22	NMOD	_	_
22	precursors	_	NNS	NNS	_	18	PMOD	_	_
23	{	_	(	(	_	26	P	_	_
24	published	_	VBN	VBN	_	25	NMOD	_	_
25	erratum	_	NN	NN	_	26	SBJ	_	_
26	appears	_	VBZ	VBZ	_	3	PRN	_	_
27	in	_	IN	IN	_	26	ADV	_	_
28	Proc	_	NNP	NNP	_	34	NMOD	_	_
29	Natl	_	NNP	NNP	_	34	NMOD	_	_
30	Acad	_	NNP	NNP	_	34	NMOD	_	_
31	Sci	_	NNP	NNP	_	34	NMOD	_	_
32	U	_	NNP	NNP	_	34	NMOD	_	_
33	S	_	NNP	NNP	_	34	NMOD	_	_
34	A	_	NNP	NNP	_	27	PMOD	_	_
35	1993	_	CD	CD	_	36	NMOD	_	_
36	Apr	_	NNP	NNP	_	34	TMP	_	_
37	15	_	CD	CD	_	36	NMOD	_	_
38	;	_	:	:	_	34	P	_	_
39	90	_	CD	CD	_	44	NMOD	_	_
40	(	_	(	(	_	44	P	_	_
41	8	_	CD	CD	_	44	NMOD	_	_
42	)	_	)	)	_	44	P	_	_
43	:	_	:	:	_	44	P	_	_
44	3775	_	CD	CD	_	34	NMOD	_	_
45	}	_	)	)	_	26	P	_	_

1	Ionizing	_	VBG	VBG	_	2	NMOD	_	_
2	radiation	_	NN	NN	_	3	SBJ	_	_
3	triggers	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	signal	_	NN	NN	_	3	OBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	human	_	JJ	JJ	_	9	NMOD	_	_
8	B-lymphocyte	_	NN	NN	_	9	NMOD	_	_
9	precursors	_	NNS	NNS	_	6	PMOD	_	_
10	that	_	WDT	WDT	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	5	NMOD	_	_
12	intimately	_	RB	RB	_	13	ADV	_	_
13	linked	_	VBN	VBN	_	11	VC	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	an	_	DT	DT	_	20	NMOD	_	_
16	active	_	JJ	JJ	_	20	NMOD	_	_
17	protein-tyrosine	_	NN	NN	_	20	NMOD	_	_
18	kinase	_	NN	NN	_	20	NMOD	_	_
19	regulatory	_	JJ	JJ	_	20	NMOD	_	_
20	pathway	_	NN	NN	_	14	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	in	_	IN	IN	_	11	ADV	_	_
5	B-lymphocyte	_	NN	NN	_	6	NMOD	_	_
6	precursors	_	NNS	NNS	_	4	PMOD	_	_
7	,	_	,	,	_	11	P	_	_
8	irradiation	_	NN	NN	_	11	SBJ	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	gamma-rays	_	NNS	NNS	_	9	PMOD	_	_
11	leads	_	VBZ	VBZ	_	3	VMOD	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	(	_	(	(	_	14	P	_	_
14	i	_	LS	LS	_	16	NMOD	_	_
15	)	_	)	)	_	14	P	_	_
16	stimulation	_	NN	NN	_	12	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	phosphatidylinositol	_	NN	NN	_	19	NMOD	_	_
19	turnover	_	NN	NN	_	17	PMOD	_	_
20	;	_	:	:	_	16	P	_	_
21	(	_	(	(	_	22	P	_	_
22	ii	_	LS	LS	_	25	NMOD	_	_
23	)	_	)	)	_	22	P	_	_
24	downstream	_	JJ	JJ	_	25	NMOD	_	_
25	activation	_	NN	NN	_	16	COORD	_	_
26	by	_	IN	IN	_	25	NMOD	_	_
27	covalent	_	JJ	JJ	_	28	NMOD	_	_
28	modification	_	NN	NN	_	26	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	multiple	_	JJ	JJ	_	33	NMOD	_	_
31	serine-specific	_	JJ	JJ	_	33	NMOD	_	_
32	protein	_	NN	NN	_	33	NMOD	_	_
33	kinases	_	NNS	NNS	_	29	PMOD	_	_
34	,	_	,	,	_	33	P	_	_
35	including	_	VBG	VBG	_	33	NMOD	_	_
36	protein	_	NN	NN	_	38	NMOD	_	_
37	kinase	_	NN	NN	_	38	NMOD	_	_
38	C	_	NN	NN	_	35	PMOD	_	_
39	;	_	:	:	_	16	P	_	_
40	and	_	CC	CC	_	16	CC	_	_
41	(	_	(	(	_	42	P	_	_
42	iii	_	LS	LS	_	44	NMOD	_	_
43	)	_	)	)	_	42	P	_	_
44	activation	_	NN	NN	_	16	COORD	_	_
45	of	_	IN	IN	_	44	NMOD	_	_
46	nuclear	_	JJ	JJ	_	49	NMOD	_	_
47	factor	_	NN	NN	_	49	NMOD	_	_
48	kappa	_	NN	NN	_	49	NMOD	_	_
49	B	_	NN	NN	_	45	PMOD	_	_
50	.	_	.	.	_	2	P	_	_

1	All	_	DT	DT	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	radiation-induced	_	JJ	JJ	_	5	NMOD	_	_
5	signals	_	NNS	NNS	_	2	PMOD	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	effectively	_	RB	RB	_	8	ADV	_	_
8	prevented	_	VBN	VBN	_	6	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	protein-tyrosine	_	NN	NN	_	13	NMOD	_	_
12	kinase	_	NN	NN	_	13	NMOD	_	_
13	inhibitors	_	NNS	NNS	_	9	PMOD	_	_
14	genistein	_	NN	NN	_	13	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	herbimycin	_	NN	NN	_	17	NMOD	_	_
17	A	_	NN	NN	_	14	COORD	_	_
18	.	_	.	.	_	6	P	_	_

1	Thus	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	tyrosine	_	NN	NN	_	4	NMOD	_	_
4	phosphorylation	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	an	_	DT	DT	_	12	NMOD	_	_
7	important	_	JJ	JJ	_	12	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	perhaps	_	RB	RB	_	7	COORD	_	_
10	mandatory	_	JJ	JJ	_	9	AMOD	_	_
11	proximal	_	JJ	JJ	_	12	NMOD	_	_
12	step	_	NN	NN	_	5	PRD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	activation	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	22	NMOD	_	_
18	protein	_	NN	NN	_	22	NMOD	_	_
19	kinase	_	NN	NN	_	22	NMOD	_	_
20	C	_	NN	NN	_	22	NMOD	_	_
21	signaling	_	NN	NN	_	22	NMOD	_	_
22	cascade	_	NN	NN	_	16	PMOD	_	_
23	in	_	IN	IN	_	15	NMOD	_	_
24	human	_	JJ	JJ	_	26	NMOD	_	_
25	B-lymphocyte	_	NN	NN	_	26	NMOD	_	_
26	precursors	_	NNS	NNS	_	23	PMOD	_	_
27	.	_	.	.	_	5	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	report	_	VBP	VBP	_	3	SBJ	_	_
3	expands	_	NNS	NNS	_	0	ROOT-S	_	_
4	current	_	JJ	JJ	_	5	NMOD	_	_
5	knowledge	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	radiation-induced	_	JJ	JJ	_	10	NMOD	_	_
9	signaling	_	NN	NN	_	10	NMOD	_	_
10	cascade	_	NN	NN	_	6	PMOD	_	_
11	by	_	IN	IN	_	3	ADV	_	_
12	clarifying	_	VBG	VBG	_	11	PMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	chronological	_	JJ	JJ	_	15	NMOD	_	_
15	sequence	_	NN	NN	_	12	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	biochemical	_	JJ	JJ	_	18	NMOD	_	_
18	events	_	NNS	NNS	_	16	PMOD	_	_
19	that	_	WDT	WDT	_	20	SBJ	_	_
20	follow	_	VBP	VBP	_	18	NMOD	_	_
21	irradiation	_	NN	NN	_	20	OBJ	_	_
22	.	_	.	.	_	3	P	_	_

1	Interleukin-4	_	NN	NN	_	2	SBJ	_	_
2	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	lipopolysaccharide-induced	_	JJ	JJ	_	5	NMOD	_	_
5	expression	_	NN	NN	_	2	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	c-jun	_	NN	NN	_	11	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	c-fos	_	NN	NN	_	7	COORD	_	_
10	messenger	_	NN	NN	_	11	NMOD	_	_
11	RNA	_	NN	NN	_	6	PMOD	_	_
12	and	_	CC	CC	_	5	CC	_	_
13	activator	_	NN	NN	_	16	NMOD	_	_
14	protein-1	_	NN	NN	_	16	NMOD	_	_
15	binding	_	NN	NN	_	16	NMOD	_	_
16	activity	_	NN	NN	_	5	COORD	_	_
17	in	_	IN	IN	_	5	NMOD	_	_
18	human	_	JJ	JJ	_	19	NMOD	_	_
19	monocytes	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	studied	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	effect	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	interleukin-4	_	NN	NN	_	5	PMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	IL-4	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	on	_	IN	IN	_	4	NMOD	_	_
11	the	_	DT	DT	_	16	NMOD	_	_
12	lipopolysaccharide	_	NN	NN	_	16	NMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	LPS	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	induction	_	NN	NN	_	10	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	two	_	CD	CD	_	21	NMOD	_	_
19	immediate	_	JJ	JJ	_	21	NMOD	_	_
20	early	_	JJ	JJ	_	21	NMOD	_	_
21	genes	_	NNS	NNS	_	17	PMOD	_	_
22	c-fos	_	NN	NN	_	21	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	c-jun	_	NN	NN	_	22	COORD	_	_
25	.	_	.	.	_	2	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	genes	_	NNS	NNS	_	3	SBJ	_	_
3	encode	_	VBP	VBP	_	0	ROOT-S	_	_
4	proteins	_	NNS	NNS	_	3	OBJ	_	_
5	that	_	WDT	WDT	_	6	SBJ	_	_
6	form	_	VBP	VBP	_	4	NMOD	_	_
7	the	_	DT	DT	_	11	NMOD	_	_
8	dimeric	_	JJ	JJ	_	11	NMOD	_	_
9	complex	_	NN	NN	_	11	NMOD	_	_
10	activator	_	NN	NN	_	11	NMOD	_	_
11	protein-1	_	NN	NN	_	6	OBJ	_	_
12	(	_	(	(	_	13	P	_	_
13	AP-1	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	,	_	,	,	_	11	P	_	_
16	which	_	WDT	WDT	_	17	SBJ	_	_
17	is	_	VBZ	VBZ	_	11	NMOD	_	_
18	active	_	JJ	JJ	_	17	PRD	_	_
19	as	_	IN	IN	_	17	ADV	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	transcriptional	_	JJ	JJ	_	22	NMOD	_	_
22	factor	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	Maximal	_	JJ	JJ	_	2	NMOD	_	_
2	accumulation	_	NN	NN	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	either	_	CC	CC	_	5	CC	_	_
5	c-fos	_	NN	NN	_	3	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	c-jun	_	NN	NN	_	5	COORD	_	_
8	messenger	_	NN	NN	_	9	NMOD	_	_
9	RNA	_	NN	NN	_	5	NMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	mRNA	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	occurred	_	VBD	VBD	_	0	ROOT-S	_	_
14	30	_	CD	CD	_	15	NMOD	_	_
15	minutes	_	NNS	NNS	_	16	PMOD	_	_
16	after	_	IN	IN	_	13	TMP	_	_
17	LPS	_	NN	NN	_	18	NMOD	_	_
18	addition	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	13	P	_	_

1	When	_	WRB	WRB	_	4	ADV	_	_
2	cells	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	22	TMP	_	_
4	treated	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	IL-4	_	NN	NN	_	5	PMOD	_	_
7	for	_	IN	IN	_	4	TMP	_	_
8	5	_	CD	CD	_	9	NMOD	_	_
9	hours	_	NNS	NNS	_	7	PMOD	_	_
10	before	_	IN	IN	_	4	TMP	_	_
11	LPS	_	NN	NN	_	12	NMOD	_	_
12	activation	_	NN	NN	_	10	PMOD	_	_
13	,	_	,	,	_	22	P	_	_
14	both	_	CC	CC	_	16	CC	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	c-fos	_	NN	NN	_	22	SBJ	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	c-jun	_	NN	NN	_	16	COORD	_	_
20	mRNA	_	NN	NN	_	21	NMOD	_	_
21	expression	_	NN	NN	_	16	NMOD	_	_
22	was	_	VBD	VBD	_	0	ROOT-S	_	_
23	decreased	_	VBN	VBN	_	22	VC	_	_
24	.	_	.	.	_	22	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	inhibition	_	NN	NN	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	c-fos	_	NN	NN	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	c-jun	_	NN	NN	_	4	COORD	_	_
7	expression	_	NN	NN	_	3	PMOD	_	_
8	by	_	IN	IN	_	2	NMOD	_	_
9	IL-4	_	NN	NN	_	8	PMOD	_	_
10	in	_	IN	IN	_	2	NMOD	_	_
11	LPS-treated	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	shown	_	VBN	VBN	_	13	VC	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	be	_	VB	VB	_	14	OBJ	_	_
17	due	_	JJ	JJ	_	18	DEP	_	_
18	to	_	TO	TO	_	16	PRD	_	_
19	a	_	DT	DT	_	22	NMOD	_	_
20	lower	_	JJR	JJR	_	22	NMOD	_	_
21	transcription	_	NN	NN	_	22	NMOD	_	_
22	rate	_	NN	NN	_	18	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	28	NMOD	_	_
25	c-fos	_	NN	NN	_	28	NMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	c-jun	_	NN	NN	_	25	COORD	_	_
28	genes	_	NNS	NNS	_	23	PMOD	_	_
29	.	_	.	.	_	13	P	_	_

1	IL-4	_	NN	NN	_	2	SBJ	_	_
2	did	_	VBD	VBD	_	0	ROOT-S	_	_
3	not	_	RB	RB	_	2	VMOD	_	_
4	affect	_	VB	VB	_	2	VC	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	stability	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	c-fos	_	NN	NN	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	c-jun	_	NN	NN	_	9	COORD	_	_
12	transcripts	_	NNS	NNS	_	7	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	Finally	_	RB	RB	_	10	TMP	_	_
2	,	_	,	,	_	10	P	_	_
3	using	_	VBG	VBG	_	10	VC	_	_
4	electrophoretic	_	JJ	JJ	_	7	NMOD	_	_
5	mobility	_	NN	NN	_	7	NMOD	_	_
6	shift	_	NN	NN	_	7	NMOD	_	_
7	assays	_	NNS	NNS	_	3	OBJ	_	_
8	,	_	,	,	_	10	P	_	_
9	evidence	_	NN	NN	_	10	SBJ	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	obtained	_	VBN	VBN	_	10	VC	_	_
12	that	_	IN	IN	_	9	NMOD	_	_
13	IL-4	_	NN	NN	_	14	SBJ	_	_
14	inhibits	_	VBZ	VBZ	_	12	VMOD	_	_
15	LPS-induced	_	JJ	JJ	_	16	NMOD	_	_
16	expression	_	NN	NN	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	AP-1	_	NN	NN	_	19	NMOD	_	_
19	protein	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	10	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	IL-4	_	NN	NN	_	6	SBJ	_	_
6	suppresses	_	VBZ	VBZ	_	4	VMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	induction	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	transcription	_	NN	NN	_	11	NMOD	_	_
11	factors	_	NNS	NNS	_	9	PMOD	_	_
12	in	_	IN	IN	_	8	NMOD	_	_
13	human	_	JJ	JJ	_	15	NMOD	_	_
14	activated	_	VBN	VBN	_	15	NMOD	_	_
15	monocytes	_	NNS	NNS	_	12	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	zinc	_	NN	NN	_	6	NMOD	_	_
3	finger	_	NN	NN	_	6	NMOD	_	_
4	transcription	_	NN	NN	_	6	NMOD	_	_
5	factor	_	NN	NN	_	6	NMOD	_	_
6	Egr-1	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	essential	_	JJ	JJ	_	7	PRD	_	_
9	for	_	IN	IN	_	8	AMOD	_	_
10	and	_	CC	CC	_	7	CC	_	_
11	restricts	_	VBZ	VBZ	_	7	COORD	_	_
12	differentiation	_	NN	NN	_	9	PMOD	_	_
13	along	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	macrophage	_	NN	NN	_	16	NMOD	_	_
16	lineage	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	isolated	_	VBN	VBN	_	2	VC	_	_
4	cDNA	_	NN	NN	_	5	NMOD	_	_
5	clones	_	NNS	NNS	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	myeloid	_	JJ	JJ	_	10	NMOD	_	_
8	differentiation	_	NN	NN	_	10	NMOD	_	_
9	primary	_	JJ	JJ	_	10	NMOD	_	_
10	response	_	NN	NN	_	14	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	MyD	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	genes	_	NNS	NNS	_	6	PMOD	_	_
15	,	_	,	,	_	5	P	_	_
16	activated	_	VBN	VBN	_	5	NMOD	_	_
17	in	_	IN	IN	_	16	ADV	_	_
18	the	_	DT	DT	_	17	DEP	_	_
19	absence	_	NN	NN	_	17	DEP	_	_
20	of	_	IN	IN	_	17	DEP	_	_
21	de	_	FW	FW	_	22	AMOD	_	_
22	novo	_	FW	FW	_	24	NMOD	_	_
23	protein	_	NN	NN	_	24	NMOD	_	_
24	synthesis	_	NN	NN	_	17	PMOD	_	_
25	following	_	VBG	VBG	_	24	TMP	_	_
26	induction	_	NN	NN	_	25	PMOD	_	_
27	for	_	IN	IN	_	26	NMOD	_	_
28	differentiation	_	NN	NN	_	27	PMOD	_	_
29	along	_	IN	IN	_	28	NMOD	_	_
30	either	_	CC	CC	_	35	CC	_	_
31	the	_	DT	DT	_	35	NMOD	_	_
32	macrophage	_	NN	NN	_	35	NMOD	_	_
33	or	_	CC	CC	_	32	CC	_	_
34	granulocyte	_	NN	NN	_	32	COORD	_	_
35	lineage	_	NN	NN	_	29	PMOD	_	_
36	in	_	IN	IN	_	35	NMOD	_	_
37	human	_	JJ	JJ	_	41	NMOD	_	_
38	myeloblastic	_	JJ	JJ	_	41	NMOD	_	_
39	leukemia	_	NN	NN	_	41	NMOD	_	_
40	HL-60	_	NN	NN	_	41	NMOD	_	_
41	cells	_	NNS	NNS	_	36	PMOD	_	_
42	.	_	.	.	_	2	P	_	_

1	One	_	CD	CD	_	3	NMOD	_	_
2	cDNA	_	NN	NN	_	3	NMOD	_	_
3	clone	_	NN	NN	_	15	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	primary	_	JJ	JJ	_	8	NMOD	_	_
7	response	_	NN	NN	_	8	NMOD	_	_
8	gene	_	NN	NN	_	4	PMOD	_	_
9	,	_	,	,	_	3	P	_	_
10	expressed	_	VBN	VBN	_	3	NMOD	_	_
11	upon	_	IN	IN	_	10	TMP	_	_
12	macrophage	_	NN	NN	_	13	NMOD	_	_
13	differentiation	_	NN	NN	_	11	PMOD	_	_
14	,	_	,	,	_	3	P	_	_
15	encoded	_	VBD	VBD	_	0	ROOT-S	_	_
16	for	_	IN	IN	_	15	ADV	_	_
17	Egr-1	_	NN	NN	_	16	PMOD	_	_
18	,	_	,	,	_	17	P	_	_
19	a	_	DT	DT	_	23	NMOD	_	_
20	zinc	_	NN	NN	_	23	NMOD	_	_
21	finger	_	NN	NN	_	23	NMOD	_	_
22	transcription	_	NN	NN	_	23	NMOD	_	_
23	factor	_	NN	NN	_	17	NMOD	_	_
24	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	Egr-1	_	NN	NN	_	3	NMOD	_	_
3	gene	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	observed	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	be	_	VB	VB	_	5	OBJ	_	_
8	transcriptionally	_	RB	RB	_	7	ADV	_	_
9	silent	_	JJ	JJ	_	7	PRD	_	_
10	in	_	IN	IN	_	7	VMOD	_	_
11	HL-60	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	,	_	,	,	_	7	P	_	_
14	but	_	CC	CC	_	7	CC	_	_
15	active	_	JJ	JJ	_	9	GAP	_	_
16	in	_	IN	IN	_	10	GAP	_	_
17	U-937	_	NN	NN	_	20	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	M1	_	NN	NN	_	17	COORD	_	_
20	cells	_	NNS	NNS	_	16	PMOD	_	_
21	,	_	,	,	_	7	P	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	latter	_	JJ	JJ	_	24	NMOD	_	_
24	two	_	CD	CD	_	25	SBJ	_	_
25	being	_	VBG	VBG	_	7	VC	_	_
26	predetermined	_	VBN	VBN	_	25	PRD	_	_
27	for	_	IN	IN	_	25	ADV	_	_
28	macrophage	_	NN	NN	_	29	NMOD	_	_
29	differentiation	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	4	P	_	_

1	Egr-1	_	NN	NN	_	3	NMOD	_	_
2	antisense	_	JJ	JJ	_	3	NMOD	_	_
3	oligomers	_	NNS	NNS	_	8	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	culture	_	NN	NN	_	7	NMOD	_	_
7	media	_	NNS	NNS	_	4	PMOD	_	_
8	blocked	_	VBD	VBD	_	0	ROOT-S	_	_
9	macrophage	_	NN	NN	_	10	NMOD	_	_
10	differentiation	_	NN	NN	_	8	OBJ	_	_
11	in	_	IN	IN	_	8	ADV	_	_
12	both	_	DT	DT	_	16	NMOD	_	_
13	myeloid	_	JJ	JJ	_	16	NMOD	_	_
14	leukemia	_	NN	NN	_	16	NMOD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	lines	_	NNS	NNS	_	11	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	normal	_	JJ	JJ	_	19	NMOD	_	_
19	myeloblasts	_	NNS	NNS	_	16	COORD	_	_
20	.	_	.	.	_	8	P	_	_

1	HL-60	_	NN	NN	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	11	SBJ	_	_
3	constitutively	_	RB	RB	_	4	ADV	_	_
4	expressing	_	VBG	VBG	_	2	NMOD	_	_
5	an	_	DT	DT	_	7	NMOD	_	_
6	Egr-1	_	NN	NN	_	7	NMOD	_	_
7	transgene	_	NN	NN	_	4	OBJ	_	_
8	(	_	(	(	_	9	P	_	_
9	HL-60Egr-1	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	could	_	MD	MD	_	0	ROOT-S	_	_
12	be	_	VB	VB	_	11	VC	_	_
13	induced	_	VBN	VBN	_	12	VC	_	_
14	for	_	IN	IN	_	13	ADV	_	_
15	macrophage	_	NN	NN	_	21	NMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	but	_	CC	CC	_	15	CC	_	_
18	not	_	RB	RB	_	17	COORD	_	_
19	granulocyte	_	NN	NN	_	15	COORD	_	_
20	,	_	,	,	_	15	P	_	_
21	differentiation	_	NN	NN	_	14	PMOD	_	_
22	.	_	.	.	_	11	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	observations	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	expression	_	NN	NN	_	8	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	Egr-1	_	NN	NN	_	6	PMOD	_	_
8	is	_	VBZ	VBZ	_	4	VMOD	_	_
9	essential	_	JJ	JJ	_	8	PRD	_	_
10	for	_	IN	IN	_	9	AMOD	_	_
11	and	_	CC	CC	_	8	CC	_	_
12	restricts	_	VBZ	VBZ	_	8	COORD	_	_
13	differentiation	_	NN	NN	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	myeloblasts	_	NNS	NNS	_	14	PMOD	_	_
16	along	_	IN	IN	_	13	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	macrophage	_	NN	NN	_	19	NMOD	_	_
19	lineage	_	NN	NN	_	16	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Interleukin-3	_	NN	NN	_	2	NMOD	_	_
2	expression	_	NN	NN	_	7	SBJ	_	_
3	by	_	IN	IN	_	2	NMOD	_	_
4	activated	_	VBN	VBN	_	6	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	3	PMOD	_	_
7	involves	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	an	_	DT	DT	_	12	NMOD	_	_
9	inducible	_	JJ	JJ	_	12	NMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	T-cell-specific	_	JJ	JJ	_	9	COORD	_	_
12	factor	_	NN	NN	_	7	OBJ	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	an	_	DT	DT	_	17	NMOD	_	_
15	octamer	_	NN	NN	_	17	NMOD	_	_
16	binding	_	NN	NN	_	17	NMOD	_	_
17	protein	_	NN	NN	_	12	COORD	_	_
18	.	_	.	.	_	7	P	_	_

1	Interleukin-3	_	NN	NN	_	5	SBJ	_	_
2	(	_	(	(	_	3	P	_	_
3	IL-3	_	NN	NN	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	exclusively	_	RB	RB	_	7	ADV	_	_
7	expressed	_	VBN	VBN	_	5	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	activated	_	VBN	VBN	_	10	NMOD	_	_
10	T	_	NN	NN	_	8	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	natural	_	JJ	JJ	_	13	NMOD	_	_
13	killer	_	NN	NN	_	10	COORD	_	_
14	cells	_	NNS	NNS	_	10	NMOD	_	_
15	,	_	,	,	_	7	P	_	_
16	a	_	DT	DT	_	17	NMOD	_	_
17	function	_	NN	NN	_	7	OBJ	_	_
18	that	_	WDT	WDT	_	19	SBJ	_	_
19	is	_	VBZ	VBZ	_	17	NMOD	_	_
20	tightly	_	RB	RB	_	19	ADV	_	_
21	controlled	_	VBN	VBN	_	19	VC	_	_
22	both	_	CC	CC	_	21	ADV	_	_
23	in	_	IN	IN	_	22	COORD	_	_
24	a	_	DT	DT	_	30	NMOD	_	_
25	lineage-specific	_	JJ	JJ	_	30	NMOD	_	_
26	and	_	CC	CC	_	22	CC	_	_
27	in	_	IN	IN	_	22	COORD	_	_
28	a	_	DT	DT	_	27	NMOD	_	_
29	stimulation-dependent	_	JJ	JJ	_	27	NMOD	_	_
30	manner	_	NN	NN	_	23	PMOD	_	_
31	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	investigated	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	protein	_	NN	NN	_	7	NMOD	_	_
6	binding	_	NN	NN	_	7	NMOD	_	_
7	characteristics	_	NNS	NNS	_	3	OBJ	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	functional	_	JJ	JJ	_	10	NMOD	_	_
10	importance	_	NN	NN	_	7	COORD	_	_
11	of	_	IN	IN	_	7	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	ACT-1-activating	_	JJ	JJ	_	14	NMOD	_	_
14	region	_	NN	NN	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	IL-3	_	NN	NN	_	18	NMOD	_	_
18	promoter	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	region	_	NN	NN	_	3	SBJ	_	_
3	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	an	_	DT	DT	_	8	NMOD	_	_
5	inducible	_	JJ	JJ	_	8	NMOD	_	_
6	,	_	,	,	_	5	P	_	_
7	T-cell-specific	_	JJ	JJ	_	5	COORD	_	_
8	factor	_	NN	NN	_	3	OBJ	_	_
9	over	_	IN	IN	_	3	ADV	_	_
10	its	_	PRP$	PRP$	_	12	NMOD	_	_
11	5'	_	JJ	JJ	_	12	NMOD	_	_
12	end	_	NN	NN	_	9	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	site	_	NN	NN	_	12	NMOD	_	_
16	that	_	WDT	WDT	_	17	SBJ	_	_
17	is	_	VBZ	VBZ	_	15	NMOD	_	_
18	necessary	_	JJ	JJ	_	17	PRD	_	_
19	for	_	IN	IN	_	18	AMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	expression	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	IL-3	_	NN	NN	_	22	PMOD	_	_
24	in	_	IN	IN	_	17	ADV	_	_
25	the	_	DT	DT	_	24	DEP	_	_
26	absence	_	NN	NN	_	24	DEP	_	_
27	of	_	IN	IN	_	24	DEP	_	_
28	other	_	JJ	JJ	_	30	NMOD	_	_
29	upstream	_	JJ	JJ	_	30	NMOD	_	_
30	elements	_	NNS	NNS	_	24	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	Over	_	IN	IN	_	7	ADV	_	_
2	its	_	PRP$	PRP$	_	4	NMOD	_	_
3	3'	_	JJ	JJ	_	4	NMOD	_	_
4	end	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	it	_	PRP	PRP	_	7	SBJ	_	_
7	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	factor	_	NN	NN	_	7	OBJ	_	_
10	that	_	WDT	WDT	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	9	NMOD	_	_
12	ubiquitously	_	RB	RB	_	11	ADV	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	constitutively	_	RB	RB	_	12	COORD	_	_
15	expressed	_	VBN	VBN	_	11	VC	_	_
16	.	_	.	.	_	7	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	factor	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	Oct-1	_	NN	NN	_	3	PRD	_	_
5	or	_	CC	CC	_	4	CC	_	_
6	an	_	DT	DT	_	10	NMOD	_	_
7	immunologically	_	RB	RB	_	8	AMOD	_	_
8	related	_	JJ	JJ	_	10	NMOD	_	_
9	octamer-binding	_	JJ	JJ	_	10	NMOD	_	_
10	protein	_	NN	NN	_	4	LGS	_	_
11	,	_	,	,	_	3	P	_	_
12	and	_	CC	CC	_	3	CC	_	_
13	it	_	PRP	PRP	_	14	SBJ	_	_
14	plays	_	VBZ	VBZ	_	3	COORD	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	role	_	NN	NN	_	14	OBJ	_	_
17	in	_	IN	IN	_	14	ADV	_	_
18	coordinating	_	VBG	VBG	_	17	PMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	activity	_	NN	NN	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	several	_	JJ	JJ	_	24	NMOD	_	_
23	regulatory	_	JJ	JJ	_	24	NMOD	_	_
24	elements	_	NNS	NNS	_	21	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	characteristics	_	NNS	NNS	_	3	SBJ	_	_
3	make	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	ACT-1	_	NN	NN	_	6	NMOD	_	_
6	site	_	NN	NN	_	7	SBJ	_	_
7	analogous	_	JJ	JJ	_	3	OBJ	_	_
8	to	_	TO	TO	_	7	AMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	activating	_	VBG	VBG	_	12	NMOD	_	_
11	ARRE-1	_	NN	NN	_	12	NMOD	_	_
12	site	_	NN	NN	_	8	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	IL-2	_	NN	NN	_	16	NMOD	_	_
16	promoter	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	Furthermore	_	RB	RB	_	17	VMOD	_	_
2	,	_	,	,	_	1	P	_	_
3	and	_	CC	CC	_	1	CC	_	_
4	despite	_	IN	IN	_	1	COORD	_	_
5	a	_	DT	DT	_	6	NMOD	_	_
6	lack	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	sequence	_	NN	NN	_	9	NMOD	_	_
9	homology	_	NN	NN	_	7	PMOD	_	_
10	,	_	,	,	_	17	P	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	promoters	_	NNS	NNS	_	17	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	IL-3	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	IL-2	_	NN	NN	_	14	COORD	_	_
17	share	_	VBP	VBP	_	0	ROOT-S	_	_
18	an	_	DT	DT	_	20	NMOD	_	_
19	organizational	_	JJ	JJ	_	20	NMOD	_	_
20	pattern	_	NN	NN	_	17	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	regulatory	_	JJ	JJ	_	23	NMOD	_	_
23	elements	_	NNS	NNS	_	21	PMOD	_	_
24	that	_	WDT	WDT	_	25	SBJ	_	_
25	is	_	VBZ	VBZ	_	20	NMOD	_	_
26	likely	_	JJ	JJ	_	25	PRD	_	_
27	to	_	TO	TO	_	28	VMOD	_	_
28	be	_	VB	VB	_	26	AMOD	_	_
29	important	_	JJ	JJ	_	28	PRD	_	_
30	for	_	IN	IN	_	28	ADV	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	T-cell-specific	_	JJ	JJ	_	33	NMOD	_	_
33	expression	_	NN	NN	_	30	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	these	_	DT	DT	_	36	NMOD	_	_
36	genes	_	NNS	NNS	_	34	PMOD	_	_
37	.	_	.	.	_	17	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	Epstein-Barr	_	JJ	JJ	_	5	NMOD	_	_
3	virus	_	NN	NN	_	5	NMOD	_	_
4	nuclear	_	JJ	JJ	_	5	NMOD	_	_
5	antigen	_	NN	NN	_	7	SBJ	_	_
6	2	_	CD	CD	_	5	NMOD	_	_
7	interacts	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	an	_	DT	DT	_	12	NMOD	_	_
10	EBNA2	_	NN	NN	_	12	NMOD	_	_
11	responsive	_	JJ	JJ	_	10	AMOD	_	_
12	cis-element	_	NN	NN	_	8	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	19	NMOD	_	_
15	terminal	_	JJ	JJ	_	19	NMOD	_	_
16	protein	_	NN	NN	_	19	NMOD	_	_
17	1	_	CD	CD	_	19	NMOD	_	_
18	gene	_	NN	NN	_	19	NMOD	_	_
19	promoter	_	NN	NN	_	13	PMOD	_	_
20	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	Epstein-Barr	_	JJ	JJ	_	5	NMOD	_	_
3	virus	_	NN	NN	_	5	NMOD	_	_
4	protein	_	NN	NN	_	5	NMOD	_	_
5	EBNA2	_	NN	NN	_	6	SBJ	_	_
6	acts	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	as	_	IN	IN	_	6	ADV	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	transcriptional	_	JJ	JJ	_	10	NMOD	_	_
10	activator	_	NN	NN	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	cellular	_	JJ	JJ	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	viral	_	JJ	JJ	_	12	COORD	_	_
15	genes	_	NNS	NNS	_	11	PMOD	_	_
16	and	_	CC	CC	_	6	CC	_	_
17	plays	_	VBZ	VBZ	_	6	COORD	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	crucial	_	JJ	JJ	_	20	NMOD	_	_
20	role	_	NN	NN	_	17	OBJ	_	_
21	in	_	IN	IN	_	17	ADV	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	immortalization	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	human	_	JJ	JJ	_	27	NMOD	_	_
26	primary	_	JJ	JJ	_	27	NMOD	_	_
27	B-cells	_	NNS	NNS	_	24	PMOD	_	_
28	by	_	IN	IN	_	23	NMOD	_	_
29	EBV	_	NN	NN	_	28	PMOD	_	_
30	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	shown	_	VBN	VBN	_	2	VC	_	_
4	previously	_	RB	RB	_	3	TMP	_	_
5	that	_	IN	IN	_	3	OBJ	_	_
6	EBNA2	_	NN	NN	_	7	SBJ	_	_
7	transactivates	_	VBZ	VBZ	_	5	VMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	promoters	_	NNS	NNS	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	latent	_	JJ	JJ	_	14	NMOD	_	_
13	membrane	_	NN	NN	_	14	NMOD	_	_
14	antigens	_	NNS	NNS	_	10	PMOD	_	_
15	LMP	_	NN	NN	_	14	NMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	TP1	_	NN	NN	_	15	COORD	_	_
18	and	_	CC	CC	_	15	CC	_	_
19	TP2	_	NN	NN	_	15	COORD	_	_
20	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	promoter	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	TP1	_	NN	NN	_	6	NMOD	_	_
6	gene	_	NN	NN	_	3	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	chosen	_	VBN	VBN	_	7	VC	_	_
9	as	_	IN	IN	_	8	ADV	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	model	_	JJ	JJ	_	12	NMOD	_	_
12	system	_	NN	NN	_	9	PMOD	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	study	_	VB	VB	_	12	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	molecular	_	JJ	JJ	_	17	NMOD	_	_
17	mechanism	_	NN	NN	_	14	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	EBNA2	_	NN	NN	_	21	NMOD	_	_
20	mediated	_	JJ	JJ	_	19	AMOD	_	_
21	transactivation	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	identify	_	VB	VB	_	14	VC	_	_
3	an	_	DT	DT	_	7	NMOD	_	_
4	EBNA2	_	NN	NN	_	7	NMOD	_	_
5	dependent	_	JJ	JJ	_	4	AMOD	_	_
6	cis-acting	_	JJ	JJ	_	7	NMOD	_	_
7	element	_	NN	NN	_	2	OBJ	_	_
8	,	_	,	,	_	14	P	_	_
9	various	_	JJ	JJ	_	13	NMOD	_	_
10	TP1	_	NN	NN	_	13	NMOD	_	_
11	promoter-reporter	_	NN	NN	_	13	NMOD	_	_
12	gene	_	NN	NN	_	13	NMOD	_	_
13	constructs	_	NNS	NNS	_	14	SBJ	_	_
14	were	_	VBD	VBD	_	0	ROOT-S	_	_
15	transfected	_	VBN	VBN	_	14	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	absence	_	NN	NN	_	16	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	presence	_	NN	NN	_	18	COORD	_	_
21	of	_	IN	IN	_	18	NMOD	_	_
22	an	_	DT	DT	_	25	NMOD	_	_
23	EBNA2	_	NN	NN	_	25	NMOD	_	_
24	expression	_	NN	NN	_	25	NMOD	_	_
25	vector	_	NN	NN	_	21	PMOD	_	_
26	into	_	IN	IN	_	15	ADV	_	_
27	the	_	DT	DT	_	31	NMOD	_	_
28	established	_	JJ	JJ	_	31	NMOD	_	_
29	B-cell	_	NN	NN	_	31	NMOD	_	_
30	line	_	NN	NN	_	31	NMOD	_	_
31	BL41-P3HR1	_	NN	NN	_	26	PMOD	_	_
32	.	_	.	.	_	14	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	were	_	VBD	VBD	_	0	ROOT-S	_	_
3	able	_	JJ	JJ	_	2	PRD	_	_
4	to	_	TO	TO	_	5	VMOD	_	_
5	delineate	_	VB	VB	_	3	AMOD	_	_
6	an	_	DT	DT	_	11	NMOD	_	_
7	81	_	CD	CD	_	11	NMOD	_	_
8	bp	_	NN	NN	_	11	NMOD	_	_
9	EBNA2	_	NN	NN	_	11	NMOD	_	_
10	responsive	_	JJ	JJ	_	9	AMOD	_	_
11	region	_	NN	NN	_	5	OBJ	_	_
12	between	_	IN	IN	_	11	NMOD	_	_
13	-258	_	CD	CD	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	-177	_	CD	CD	_	13	COORD	_	_
16	relative	_	JJ	JJ	_	17	DEP	_	_
17	to	_	TO	TO	_	13	NMOD	_	_
18	the	_	DT	DT	_	22	NMOD	_	_
19	TP1	_	NN	NN	_	22	NMOD	_	_
20	RNA	_	NN	NN	_	22	NMOD	_	_
21	start	_	NN	NN	_	22	NMOD	_	_
22	site	_	NN	NN	_	17	PMOD	_	_
23	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	element	_	NN	NN	_	3	SBJ	_	_
3	worked	_	VBD	VBD	_	0	ROOT-S	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	either	_	DT	DT	_	6	NMOD	_	_
6	orientation	_	NN	NN	_	4	PMOD	_	_
7	and	_	CC	CC	_	3	CC	_	_
8	could	_	MD	MD	_	3	COORD	_	_
9	mediate	_	VB	VB	_	8	VC	_	_
10	EBNA2	_	NN	NN	_	12	NMOD	_	_
11	dependent	_	JJ	JJ	_	10	AMOD	_	_
12	transactivation	_	NN	NN	_	9	OBJ	_	_
13	on	_	IN	IN	_	12	NMOD	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	heterologous	_	JJ	JJ	_	16	NMOD	_	_
16	promoter	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	Electrophoretic	_	JJ	JJ	_	4	NMOD	_	_
2	mobility	_	NN	NN	_	4	NMOD	_	_
3	shift	_	NN	NN	_	4	NMOD	_	_
4	assays	_	NNS	NNS	_	5	SBJ	_	_
5	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
6	three	_	CD	CD	_	9	NMOD	_	_
7	specific	_	JJ	JJ	_	9	NMOD	_	_
8	protein-DNA	_	NN	NN	_	9	NMOD	_	_
9	complexes	_	NNS	NNS	_	5	OBJ	_	_
10	formed	_	VBN	VBN	_	9	NMOD	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	sequences	_	NNS	NNS	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	EBNA2	_	NN	NN	_	17	NMOD	_	_
16	responsive	_	JJ	JJ	_	15	AMOD	_	_
17	element	_	NN	NN	_	13	PMOD	_	_
18	.	_	.	.	_	5	P	_	_

1	Two	_	CD	CD	_	4	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	these	_	DT	DT	_	2	PMOD	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	type	_	NN	NN	_	8	AMOD	_	_
8	specific	_	JJ	JJ	_	4	PRD	_	_
9	,	_	,	,	_	4	P	_	_
10	but	_	CC	CC	_	4	CC	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	third	_	JJ	JJ	_	13	SBJ	_	_
13	was	_	VBD	VBD	_	4	COORD	_	_
14	detected	_	VBN	VBN	_	13	VC	_	_
15	only	_	RB	RB	_	16	DEP	_	_
16	in	_	IN	IN	_	14	ADV	_	_
17	EBNA2	_	NN	NN	_	20	NMOD	_	_
18	positive	_	JJ	JJ	_	17	AMOD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	extracts	_	NNS	NNS	_	16	PMOD	_	_
21	.	_	.	.	_	4	P	_	_

1	Gel-shift	_	JJ	JJ	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	11	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	3	DEP	_	_
5	presence	_	NN	NN	_	3	DEP	_	_
6	of	_	IN	IN	_	3	DEP	_	_
7	EBNA2	_	NN	NN	_	10	NMOD	_	_
8	specific	_	JJ	JJ	_	7	AMOD	_	_
9	monoclonal	_	JJ	JJ	_	10	NMOD	_	_
10	antibodies	_	NNS	NNS	_	3	PMOD	_	_
11	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
12	that	_	IN	IN	_	11	OBJ	_	_
13	EBNA2	_	NN	NN	_	14	SBJ	_	_
14	is	_	VBZ	VBZ	_	12	VMOD	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	component	_	NN	NN	_	14	PRD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	third	_	JJ	JJ	_	20	NMOD	_	_
20	complex	_	NN	NN	_	17	PMOD	_	_
21	.	_	.	.	_	11	P	_	_

1	Thus	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	experiments	_	NNS	NNS	_	5	SBJ	_	_
5	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	EBNA2	_	NN	NN	_	8	SBJ	_	_
8	interacts	_	VBZ	VBZ	_	6	VMOD	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	an	_	DT	DT	_	13	NMOD	_	_
11	EBNA2	_	NN	NN	_	13	NMOD	_	_
12	responsive	_	JJ	JJ	_	11	AMOD	_	_
13	cis-element	_	NN	NN	_	9	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	TP1	_	NN	NN	_	17	NMOD	_	_
17	promoter	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	5	P	_	_

1	Protease	_	NN	NN	_	2	NMOD	_	_
2	treatment	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	nuclear	_	JJ	JJ	_	5	NMOD	_	_
5	extracts	_	NNS	NNS	_	3	PMOD	_	_
6	distinguishes	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	between	_	IN	IN	_	6	ADV	_	_
8	class	_	NN	NN	_	14	NMOD	_	_
9	II	_	CD	CD	_	14	NMOD	_	_
10	MHC	_	NN	NN	_	14	NMOD	_	_
11	X1	_	NN	NN	_	14	NMOD	_	_
12	box	_	NN	NN	_	14	NMOD	_	_
13	DNA-binding	_	JJ	JJ	_	14	NMOD	_	_
14	proteins	_	NNS	NNS	_	7	PMOD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	wild-type	_	JJ	JJ	_	21	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	class	_	NN	NN	_	16	COORD	_	_
19	II-deficient	_	JJ	JJ	_	18	AMOD	_	_
20	B	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	15	PMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	X	_	NN	NN	_	4	NMOD	_	_
3	box	_	NN	NN	_	4	NMOD	_	_
4	region	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	critical	_	JJ	JJ	_	5	PRD	_	_
7	for	_	IN	IN	_	6	AMOD	_	_
8	directing	_	VBG	VBG	_	7	PMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	expression	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	class	_	NN	NN	_	17	NMOD	_	_
13	II	_	CD	CD	_	17	NMOD	_	_
14	major	_	JJ	JJ	_	17	NMOD	_	_
15	histocompatibility	_	NN	NN	_	17	NMOD	_	_
16	complex	_	NN	NN	_	17	NMOD	_	_
17	genes	_	NNS	NNS	_	11	PMOD	_	_
18	in	_	IN	IN	_	10	NMOD	_	_
19	B	_	NN	NN	_	20	NMOD	_	_
20	lymphocytes	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	5	P	_	_

1	Although	_	IN	IN	_	22	ADV	_	_
2	several	_	JJ	JJ	_	8	NMOD	_	_
3	class	_	NN	NN	_	8	NMOD	_	_
4	II	_	CD	CD	_	8	NMOD	_	_
5	promoter-specific	_	JJ	JJ	_	8	NMOD	_	_
6	DNA	_	NN	NN	_	8	NMOD	_	_
7	binding	_	NN	NN	_	8	NMOD	_	_
8	factors	_	NNS	NNS	_	9	SBJ	_	_
9	have	_	VBP	VBP	_	1	VMOD	_	_
10	been	_	VBN	VBN	_	9	VC	_	_
11	described	_	VBN	VBN	_	10	VC	_	_
12	,	_	,	,	_	22	P	_	_
13	only	_	RB	RB	_	18	NMOD	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	X	_	NN	NN	_	18	NMOD	_	_
16	box	_	NN	NN	_	18	NMOD	_	_
17	region	_	NN	NN	_	18	NMOD	_	_
18	factor	_	NN	NN	_	22	SBJ	_	_
19	,	_	,	,	_	18	P	_	_
20	RFX	_	NN	NN	_	18	NMOD	_	_
21	,	_	,	,	_	18	P	_	_
22	shows	_	VBZ	VBZ	_	0	ROOT-S	_	_
23	a	_	DT	DT	_	25	NMOD	_	_
24	genetic	_	JJ	JJ	_	25	NMOD	_	_
25	correlation	_	NN	NN	_	22	IOBJ	_	_
26	with	_	IN	IN	_	25	NMOD	_	_
27	class	_	NN	NN	_	29	NMOD	_	_
28	II	_	CD	CD	_	29	NMOD	_	_
29	expression	_	NN	NN	_	26	PMOD	_	_
30	,	_	,	,	_	22	P	_	_
31	being	_	VBG	VBG	_	22	OBJ	_	_
32	deficient	_	JJ	JJ	_	31	PRD	_	_
33	in	_	IN	IN	_	31	ADV	_	_
34	some	_	DT	DT	_	37	NMOD	_	_
35	B	_	NN	NN	_	37	NMOD	_	_
36	cell	_	NN	NN	_	37	NMOD	_	_
37	lines	_	NNS	NNS	_	33	PMOD	_	_
38	derived	_	VBN	VBN	_	37	NMOD	_	_
39	from	_	IN	IN	_	38	ADV	_	_
40	patients	_	NNS	NNS	_	39	PMOD	_	_
41	with	_	IN	IN	_	40	NMOD	_	_
42	class	_	NN	NN	_	45	NMOD	_	_
43	II-deficient	_	JJ	JJ	_	42	AMOD	_	_
44	congenital	_	JJ	JJ	_	45	NMOD	_	_
45	immunodeficiency	_	NN	NN	_	41	PMOD	_	_
46	.	_	.	.	_	22	P	_	_

1	To	_	TO	TO	_	3	VMOD	_	_
2	further	_	RB	RB	_	3	ADV	_	_
3	evaluate	_	VB	VB	_	24	VC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	role	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	X	_	NN	NN	_	10	NMOD	_	_
8	box	_	NN	NN	_	10	NMOD	_	_
9	DNA-binding	_	JJ	JJ	_	10	NMOD	_	_
10	proteins	_	NNS	NNS	_	6	PMOD	_	_
11	in	_	IN	IN	_	5	NMOD	_	_
12	class	_	NN	NN	_	15	NMOD	_	_
13	II	_	CD	CD	_	15	NMOD	_	_
14	gene	_	NN	NN	_	15	NMOD	_	_
15	expression	_	NN	NN	_	11	PMOD	_	_
16	,	_	,	,	_	24	P	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	role	_	NN	NN	_	24	SBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	X	_	NN	NN	_	23	NMOD	_	_
22	box	_	NN	NN	_	23	NMOD	_	_
23	region	_	NN	NN	_	19	PMOD	_	_
24	was	_	VBD	VBD	_	0	ROOT-S	_	_
25	examined	_	VBN	VBN	_	24	VC	_	_
26	in	_	IN	IN	_	25	ADV	_	_
27	both	_	DT	DT	_	28	AMOD	_	_
28	class	_	NN	NN	_	33	NMOD	_	_
29	II-positive	_	JJ	JJ	_	28	AMOD	_	_
30	and	_	CC	CC	_	28	CC	_	_
31	-negative	_	JJ	JJ	_	28	COORD	_	_
32	lymphoid	_	JJ	JJ	_	33	NMOD	_	_
33	cells	_	NNS	NNS	_	26	PMOD	_	_
34	.	_	.	.	_	24	P	_	_

1	In	_	IN	IN	_	34	ADV	_	_
2	addition	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	the	_	DT	DT	_	9	NMOD	_	_
5	wild-type	_	JJ	JJ	_	9	NMOD	_	_
6	B	_	NN	NN	_	9	NMOD	_	_
7	cell	_	NN	NN	_	9	NMOD	_	_
8	line	_	NN	NN	_	9	NMOD	_	_
9	Raji	_	NN	NN	_	1	PMOD	_	_
10	,	_	,	,	_	34	P	_	_
11	two	_	CD	CD	_	17	NMOD	_	_
12	class	_	NN	NN	_	17	NMOD	_	_
13	II	_	CD	CD	_	12	AMOD	_	_
14	transcriptional	_	JJ	JJ	_	12	AMOD	_	_
15	mutant	_	JJ	JJ	_	17	NMOD	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	lines	_	NNS	NNS	_	34	SBJ	_	_
18	,	_	,	,	_	17	P	_	_
19	SJO	_	NN	NN	_	17	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	RJ2.2.5	_	NN	NN	_	19	COORD	_	_
22	,	_	,	,	_	17	P	_	_
23	and	_	CC	CC	_	17	CC	_	_
24	Jurkat	_	NN	NN	_	17	COORD	_	_
25	,	_	,	,	_	24	P	_	_
26	a	_	DT	DT	_	32	NMOD	_	_
27	class	_	NN	NN	_	32	NMOD	_	_
28	II	_	CD	CD	_	27	AMOD	_	_
29	negative	_	JJ	JJ	_	27	AMOD	_	_
30	T	_	NN	NN	_	32	NMOD	_	_
31	cell	_	NN	NN	_	32	NMOD	_	_
32	line	_	NN	NN	_	24	NMOD	_	_
33	,	_	,	,	_	24	P	_	_
34	were	_	VBD	VBD	_	0	ROOT-S	_	_
35	examined	_	VBN	VBN	_	34	VC	_	_
36	.	_	.	.	_	34	P	_	_

1	In	_	IN	IN	_	16	ADV	_	_
2	contrast	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	wild-type	_	JJ	JJ	_	6	NMOD	_	_
5	B	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	1	PMOD	_	_
7	,	_	,	,	_	16	P	_	_
8	neither	_	DT	DT	_	16	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	15	NMOD	_	_
11	class	_	NN	NN	_	15	NMOD	_	_
12	II	_	CD	CD	_	15	NMOD	_	_
13	mutant	_	JJ	JJ	_	15	NMOD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	lines	_	NNS	NNS	_	9	PMOD	_	_
16	could	_	MD	MD	_	0	ROOT-S	_	_
17	use	_	VB	VB	_	16	VC	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	X	_	NN	NN	_	21	NMOD	_	_
20	box	_	NN	NN	_	21	NMOD	_	_
21	region	_	NN	NN	_	17	IOBJ	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	direct	_	VB	VB	_	17	OBJ	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	expression	_	NN	NN	_	23	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	a	_	DT	DT	_	31	NMOD	_	_
28	transiently	_	RB	RB	_	29	AMOD	_	_
29	transfected	_	VBN	VBN	_	31	NMOD	_	_
30	reporter	_	NN	NN	_	31	NMOD	_	_
31	gene	_	NN	NN	_	26	PMOD	_	_
32	,	_	,	,	_	17	P	_	_
33	indicating	_	VBG	VBG	_	17	OBJ	_	_
34	that	_	IN	IN	_	33	OBJ	_	_
35	the	_	DT	DT	_	39	NMOD	_	_
36	X	_	NN	NN	_	39	NMOD	_	_
37	box-dependent	_	JJ	JJ	_	36	AMOD	_	_
38	transcriptional	_	JJ	JJ	_	39	NMOD	_	_
39	pathway	_	NN	NN	_	40	SBJ	_	_
40	is	_	VBZ	VBZ	_	34	VMOD	_	_
41	defective	_	JJ	JJ	_	40	PRD	_	_
42	in	_	IN	IN	_	40	ADV	_	_
43	these	_	DT	DT	_	44	NMOD	_	_
44	cells	_	NNS	NNS	_	42	PMOD	_	_
45	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	binding	_	NN	NN	_	3	NMOD	_	_
3	activity	_	NN	NN	_	11	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	10	NMOD	_	_
6	X1	_	NN	NN	_	10	NMOD	_	_
7	box	_	NN	NN	_	10	NMOD	_	_
8	DNA-binding	_	JJ	JJ	_	10	NMOD	_	_
9	protein	_	NN	NN	_	10	NMOD	_	_
10	RFX	_	NN	NN	_	4	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	examined	_	VBN	VBN	_	11	VC	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	found	_	VBN	VBN	_	12	COORD	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	be	_	VB	VB	_	14	OBJ	_	_
17	present	_	JJ	JJ	_	16	PRD	_	_
18	in	_	IN	IN	_	17	AMOD	_	_
19	wild-type	_	JJ	JJ	_	21	NMOD	_	_
20	B	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	18	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	mutant	_	JJ	JJ	_	25	NMOD	_	_
25	RJ2.2.5	_	NN	NN	_	21	COORD	_	_
26	but	_	CC	CC	_	11	CC	_	_
27	was	_	VBD	VBD	_	11	COORD	_	_
28	absent	_	JJ	JJ	_	27	PRD	_	_
29	in	_	IN	IN	_	28	AMOD	_	_
30	SJO	_	NN	NN	_	29	PMOD	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	Jurkat	_	NN	NN	_	30	COORD	_	_
33	.	_	.	.	_	11	P	_	_

1	However	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	other	_	JJ	JJ	_	6	NMOD	_	_
4	X1	_	NN	NN	_	6	NMOD	_	_
5	box-specific	_	JJ	JJ	_	4	AMOD	_	_
6	activities	_	NNS	NNS	_	7	SBJ	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	detected	_	VBN	VBN	_	7	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	all	_	DT	DT	_	13	NMOD	_	_
11	these	_	DT	DT	_	13	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	lines	_	NNS	NNS	_	9	PMOD	_	_
14	.	_	.	.	_	7	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	determine	_	VB	VB	_	36	VC	_	_
3	whether	_	IN	IN	_	2	OBJ	_	_
4	these	_	DT	DT	_	8	NMOD	_	_
5	different	_	JJ	JJ	_	8	NMOD	_	_
6	X1	_	NN	NN	_	8	NMOD	_	_
7	box	_	NN	NN	_	8	NMOD	_	_
8	activities	_	NNS	NNS	_	9	SBJ	_	_
9	represented	_	VBD	VBD	_	3	VMOD	_	_
10	distinct	_	JJ	JJ	_	13	NMOD	_	_
11	DNA	_	NN	NN	_	13	NMOD	_	_
12	binding	_	NN	NN	_	13	NMOD	_	_
13	proteins	_	NNS	NNS	_	9	OBJ	_	_
14	or	_	CC	CC	_	13	CC	_	_
15	multimeric	_	JJ	JJ	_	16	NMOD	_	_
16	forms	_	NNS	NNS	_	13	COORD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	22	NMOD	_	_
19	same	_	JJ	JJ	_	22	NMOD	_	_
20	factor	_	NN	NN	_	22	NMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	s	_	NNS	NNS	_	17	PMOD	_	_
23	)	_	)	)	_	22	P	_	_
24	,	_	,	,	_	36	P	_	_
25	protease	_	NN	NN	_	26	NMOD	_	_
26	treatment	_	NN	NN	_	36	SBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	31	NMOD	_	_
29	crude	_	JJ	JJ	_	31	NMOD	_	_
30	nuclear	_	JJ	JJ	_	31	NMOD	_	_
31	extracts	_	NNS	NNS	_	27	PMOD	_	_
32	followed	_	VBN	VBN	_	26	NMOD	_	_
33	by	_	IN	IN	_	32	ADV	_	_
34	DNA-binding	_	JJ	JJ	_	35	NMOD	_	_
35	assays	_	NNS	NNS	_	33	PMOD	_	_
36	were	_	VBD	VBD	_	0	ROOT-S	_	_
37	carried	_	VBN	VBN	_	36	VC	_	_
38	out	_	RP	RP	_	37	PRT	_	_
39	and	_	CC	CC	_	36	CC	_	_
40	demonstrated	_	VBD	VBD	_	36	COORD	_	_
41	that	_	IN	IN	_	40	OBJ	_	_
42	B	_	NN	NN	_	44	NMOD	_	_
43	cell	_	NN	NN	_	44	NMOD	_	_
44	extracts	_	NNS	NNS	_	45	SBJ	_	_
45	contain	_	VBP	VBP	_	41	VMOD	_	_
46	at	_	IN	IN	_	48	DEP	_	_
47	least	_	JJS	JJS	_	48	DEP	_	_
48	two	_	CD	CD	_	50	NMOD	_	_
49	X1-specific	_	JJ	JJ	_	50	NMOD	_	_
50	factors	_	NNS	NNS	_	45	OBJ	_	_
51	.	_	.	.	_	36	P	_	_

1	One	_	CD	CD	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	these	_	DT	DT	_	5	NMOD	_	_
4	cleaved	_	VBN	VBN	_	5	NMOD	_	_
5	products	_	NNS	NNS	_	2	PMOD	_	_
6	(	_	(	(	_	9	P	_	_
7	band	_	NN	NN	_	9	NMOD	_	_
8	1	_	CD	CD	_	9	NMOD	_	_
9	pk	_	NN	NN	_	1	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	correlates	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	with	_	IN	IN	_	11	ADV	_	_
13	RFX	_	NN	NN	_	14	NMOD	_	_
14	activity	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	11	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	similar	_	JJ	JJ	_	3	NMOD	_	_
3	comparison	_	NN	NN	_	11	SBJ	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	protease-treated	_	JJ	JJ	_	6	NMOD	_	_
6	extracts	_	NNS	NNS	_	4	PMOD	_	_
7	prepared	_	VBN	VBN	_	6	NMOD	_	_
8	from	_	IN	IN	_	7	ADV	_	_
9	Jurkat	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	presence	_	NN	NN	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	band	_	NN	NN	_	18	NMOD	_	_
17	1pk	_	NN	NN	_	18	NMOD	_	_
18	activity	_	NN	NN	_	14	PMOD	_	_
19	despite	_	IN	IN	_	11	ADV	_	_
20	an	_	DT	DT	_	21	NMOD	_	_
21	absence	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	26	NMOD	_	_
24	native	_	JJ	JJ	_	26	NMOD	_	_
25	RFX	_	NN	NN	_	26	NMOD	_	_
26	activity	_	NN	NN	_	22	PMOD	_	_
27	.	_	.	.	_	11	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	11	P	_	_
4	protease	_	NN	NN	_	11	SBJ	_	_
5	treatment	_	NN	NN	_	4	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	analysis	_	NN	NN	_	5	COORD	_	_
8	of	_	IN	IN	_	4	NMOD	_	_
9	SJO	_	NN	NN	_	10	NMOD	_	_
10	extracts	_	NNS	NNS	_	8	PMOD	_	_
11	showed	_	VBD	VBD	_	0	ROOT-S	_	_
12	no	_	DT	DT	_	14	NMOD	_	_
13	detectable	_	JJ	JJ	_	14	NMOD	_	_
14	levels	_	NNS	NNS	_	11	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	band	_	NN	NN	_	19	NMOD	_	_
18	1pk	_	NN	NN	_	19	NMOD	_	_
19	activity	_	NN	NN	_	15	PMOD	_	_
20	.	_	.	.	_	11	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	multiple	_	JJ	JJ	_	9	NMOD	_	_
6	X1	_	NN	NN	_	9	NMOD	_	_
7	box-specific	_	JJ	JJ	_	6	AMOD	_	_
8	DNA-binding	_	JJ	JJ	_	9	NMOD	_	_
9	activities	_	NNS	NNS	_	10	SBJ	_	_
10	exist	_	VBP	VBP	_	4	VMOD	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	all	_	DT	DT	_	14	NMOD	_	_
13	lymphoid	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	11	PMOD	_	_
15	,	_	,	,	_	3	P	_	_
16	but	_	CC	CC	_	3	CC	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	presence	_	NN	NN	_	25	SBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	an	_	DT	DT	_	24	NMOD	_	_
21	actively	_	RB	RB	_	22	AMOD	_	_
22	binding	_	NN	NN	_	24	NMOD	_	_
23	RFX	_	NN	NN	_	24	NMOD	_	_
24	species	_	NNS	NNS	_	19	PMOD	_	_
25	correlates	_	VBZ	VBZ	_	3	COORD	_	_
26	with	_	IN	IN	_	25	ADV	_	_
27	class	_	NN	NN	_	29	NMOD	_	_
28	II	_	CD	CD	_	29	NMOD	_	_
29	transcription	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	human	_	JJ	JJ	_	6	NMOD	_	_
3	prointerleukin	_	NN	NN	_	6	NMOD	_	_
4	1	_	CD	CD	_	6	NMOD	_	_
5	beta	_	NN	NN	_	6	NMOD	_	_
6	gene	_	NN	NN	_	7	SBJ	_	_
7	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	DNA	_	NN	NN	_	9	NMOD	_	_
9	sequences	_	NNS	NNS	_	7	OBJ	_	_
10	both	_	CC	CC	_	11	CC	_	_
11	proximal	_	JJ	JJ	_	9	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	distal	_	JJ	JJ	_	11	COORD	_	_
14	to	_	TO	TO	_	11	AMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	transcription	_	NN	NN	_	18	NMOD	_	_
17	start	_	NN	NN	_	18	NMOD	_	_
18	site	_	NN	NN	_	14	PMOD	_	_
19	for	_	IN	IN	_	7	ADV	_	_
20	tissue-specific	_	JJ	JJ	_	21	NMOD	_	_
21	induction	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	have	_	VBP	VBP	_	0	ROOT-S	_	_
7	identified	_	VBN	VBN	_	6	VC	_	_
8	DNA	_	NN	NN	_	9	NMOD	_	_
9	sequences	_	NNS	NNS	_	7	OBJ	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	specific	_	JJ	JJ	_	13	NMOD	_	_
12	protein	_	NN	NN	_	13	NMOD	_	_
13	interactions	_	NNS	NNS	_	9	COORD	_	_
14	necessary	_	JJ	JJ	_	9	NMOD	_	_
15	for	_	IN	IN	_	14	AMOD	_	_
16	transcriptional	_	JJ	JJ	_	17	NMOD	_	_
17	regulation	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	28	NMOD	_	_
20	human	_	JJ	JJ	_	28	NMOD	_	_
21	prointerleukin	_	NN	NN	_	23	NMOD	_	_
22	1	_	CD	CD	_	23	NMOD	_	_
23	beta	_	NN	NN	_	28	NMOD	_	_
24	(	_	(	(	_	26	P	_	_
25	proIL-1	_	NN	NN	_	26	NMOD	_	_
26	beta	_	NN	NN	_	23	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	gene	_	NN	NN	_	18	PMOD	_	_
29	.	_	.	.	_	6	P	_	_

1	A	_	DT	DT	_	9	NMOD	_	_
2	cell-type-independent	_	JJ	JJ	_	9	NMOD	_	_
3	lipopolysaccharide	_	NN	NN	_	5	AMOD	_	_
4	(	_	(	(	_	5	P	_	_
5	LPS	_	NN	NN	_	9	NMOD	_	_
6	)	_	)	)	_	5	P	_	_
7	-responsive	_	JJ	JJ	_	5	AMOD	_	_
8	enhancer	_	NN	NN	_	9	NMOD	_	_
9	element	_	NN	NN	_	26	SBJ	_	_
10	located	_	JJ	JJ	_	16	AMOD	_	_
11	between	_	IN	IN	_	16	AMOD	_	_
12	-3757	_	CD	CD	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	-2729	_	CD	CD	_	12	COORD	_	_
15	bp	_	NN	NN	_	11	PMOD	_	_
16	upstream	_	RB	RB	_	9	NMOD	_	_
17	from	_	IN	IN	_	16	AMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	transcription	_	NN	NN	_	21	NMOD	_	_
20	start	_	NN	NN	_	21	NMOD	_	_
21	site	_	NN	NN	_	17	PMOD	_	_
22	(	_	(	(	_	24	P	_	_
23	cap	_	NN	NN	_	24	NMOD	_	_
24	site	_	NN	NN	_	21	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	consisted	_	VBD	VBD	_	0	ROOT-S	_	_
27	of	_	IN	IN	_	26	ADV	_	_
28	at	_	IN	IN	_	30	DEP	_	_
29	least	_	JJS	JJS	_	30	DEP	_	_
30	six	_	CD	CD	_	32	NMOD	_	_
31	discrete	_	JJ	JJ	_	32	NMOD	_	_
32	subregions	_	NNS	NNS	_	27	PMOD	_	_
33	which	_	WDT	WDT	_	34	SBJ	_	_
34	were	_	VBD	VBD	_	32	NMOD	_	_
35	essential	_	JJ	JJ	_	34	PRD	_	_
36	to	_	TO	TO	_	35	AMOD	_	_
37	the	_	DT	DT	_	39	NMOD	_	_
38	maximal	_	JJ	JJ	_	39	NMOD	_	_
39	induction	_	NN	NN	_	36	PMOD	_	_
40	by	_	IN	IN	_	39	NMOD	_	_
41	LPS	_	NN	NN	_	40	PMOD	_	_
42	in	_	IN	IN	_	39	NMOD	_	_
43	transfected	_	VBN	VBN	_	44	NMOD	_	_
44	monocytes	_	NNS	NNS	_	42	PMOD	_	_
45	.	_	.	.	_	26	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	enhancer	_	NN	NN	_	4	SBJ	_	_
3	also	_	RB	RB	_	4	ADV	_	_
4	appeared	_	VBD	VBD	_	0	ROOT-S	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	mediate	_	VB	VB	_	4	OBJ	_	_
7	phorbol	_	NN	NN	_	10	NMOD	_	_
8	myristate	_	NN	NN	_	10	NMOD	_	_
9	acetate	_	NN	NN	_	10	NMOD	_	_
10	induction	_	NN	NN	_	6	OBJ	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	monocytes	_	NNS	NNS	_	11	PMOD	_	_
13	and	_	CC	CC	_	10	CC	_	_
14	IL-1	_	NN	NN	_	15	NMOD	_	_
15	responsiveness	_	NN	NN	_	10	COORD	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	fibroblasts	_	NNS	NNS	_	16	PMOD	_	_
18	.	_	.	.	_	4	P	_	_

1	Deletion	_	NN	NN	_	11	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	base	_	NN	NN	_	5	NMOD	_	_
4	substitution	_	NN	NN	_	5	NMOD	_	_
5	mutations	_	NNS	NNS	_	1	COORD	_	_
6	along	_	IN	IN	_	1	CC	_	_
7	with	_	IN	IN	_	6	DEP	_	_
8	DNA	_	NN	NN	_	10	NMOD	_	_
9	binding	_	NN	NN	_	10	NMOD	_	_
10	studies	_	NNS	NNS	_	1	COORD	_	_
11	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
12	that	_	IN	IN	_	11	OBJ	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	enhancer	_	NN	NN	_	15	SBJ	_	_
15	contained	_	VBD	VBD	_	12	VMOD	_	_
16	a	_	DT	DT	_	17	NMOD	_	_
17	minimum	_	NN	NN	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	three	_	CD	CD	_	23	NMOD	_	_
20	functional	_	JJ	JJ	_	23	NMOD	_	_
21	protein	_	NN	NN	_	23	NMOD	_	_
22	binding	_	NN	NN	_	23	NMOD	_	_
23	sequences	_	NNS	NNS	_	18	PMOD	_	_
24	,	_	,	,	_	23	P	_	_
25	two	_	CD	CD	_	26	NMOD	_	_
26	of	_	IN	IN	_	28	SBJ	_	_
27	which	_	WDT	WDT	_	26	PMOD	_	_
28	appeared	_	VBD	VBD	_	23	NMOD	_	_
29	to	_	TO	TO	_	30	VMOD	_	_
30	be	_	VB	VB	_	28	OBJ	_	_
31	important	_	JJ	JJ	_	30	PRD	_	_
32	for	_	IN	IN	_	31	AMOD	_	_
33	gene	_	NN	NN	_	34	NMOD	_	_
34	induction	_	NN	NN	_	32	PMOD	_	_
35	.	_	.	.	_	11	P	_	_

1	One	_	CD	CD	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	essential	_	JJ	JJ	_	5	NMOD	_	_
5	proteins	_	NNS	NNS	_	2	PMOD	_	_
6	which	_	WDT	WDT	_	7	SBJ	_	_
7	bound	_	VBD	VBD	_	5	NMOD	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	enhancer	_	NN	NN	_	8	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	similar	_	JJ	JJ	_	11	PRD	_	_
13	or	_	CC	CC	_	12	CC	_	_
14	identical	_	JJ	JJ	_	12	COORD	_	_
15	to	_	TO	TO	_	12	AMOD	_	_
16	members	_	NNS	NNS	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	C\/EBP	_	NN	NN	_	20	NMOD	_	_
20	family	_	NN	NN	_	17	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	transcription	_	NN	NN	_	23	NMOD	_	_
23	factors	_	NNS	NNS	_	21	PMOD	_	_
24	required	_	VBN	VBN	_	23	NMOD	_	_
25	for	_	IN	IN	_	24	ADV	_	_
26	both	_	CC	CC	_	27	CC	_	_
27	IL-1-	_	NN	NN	_	30	NMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	LPS-specific	_	JJ	JJ	_	27	COORD	_	_
30	induction	_	NN	NN	_	25	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	IL-6	_	NN	NN	_	34	NMOD	_	_
34	gene	_	NN	NN	_	31	PMOD	_	_
35	(	_	(	(	_	40	P	_	_
36	i.e.	_	FW	FW	_	40	NMOD	_	_
37	,	_	,	,	_	40	P	_	_
38	the	_	DT	DT	_	40	NMOD	_	_
39	NF-IL6	_	NN	NN	_	40	NMOD	_	_
40	proteins	_	NNS	NNS	_	34	PRN	_	_
41	)	_	)	)	_	40	P	_	_
42	.	_	.	.	_	11	P	_	_

1	When	_	WRB	WRB	_	2	ADV	_	_
2	ligated	_	VBN	VBN	_	29	TMP	_	_
3	to	_	TO	TO	_	2	ADV	_	_
4	the	_	DT	DT	_	9	NMOD	_	_
5	proIL-1	_	NN	NN	_	9	NMOD	_	_
6	beta	_	NN	NN	_	9	NMOD	_	_
7	cap	_	NN	NN	_	9	NMOD	_	_
8	site-proximal	_	JJ	JJ	_	7	AMOD	_	_
9	region	_	NN	NN	_	3	PMOD	_	_
10	(	_	(	(	_	9	P	_	_
11	located	_	JJ	JJ	_	9	NMOD	_	_
12	between	_	IN	IN	_	11	AMOD	_	_
13	-131	_	CD	CD	_	12	PMOD	_	_
14	to	_	TO	TO	_	13	NMOD	_	_
15	+12	_	CD	CD	_	13	NMOD	_	_
16	)	_	)	)	_	9	P	_	_
17	,	_	,	,	_	29	P	_	_
18	both	_	CC	CC	_	21	CC	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	proIL-1	_	NN	NN	_	21	NMOD	_	_
21	beta	_	NN	NN	_	29	SBJ	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	the	_	DT	DT	_	28	NMOD	_	_
24	simian	_	JJ	JJ	_	28	NMOD	_	_
25	virus	_	NN	NN	_	28	NMOD	_	_
26	40	_	CD	CD	_	28	NMOD	_	_
27	enhancer	_	NN	NN	_	28	NMOD	_	_
28	elements	_	NNS	NNS	_	21	COORD	_	_
29	functioned	_	VBD	VBD	_	0	ROOT-S	_	_
30	more	_	RBR	RBR	_	31	AMOD	_	_
31	efficiently	_	RB	RB	_	29	ADV	_	_
32	in	_	IN	IN	_	29	ADV	_	_
33	monocytes	_	NNS	NNS	_	32	PMOD	_	_
34	than	_	IN	IN	_	31	AMOD	_	_
35	in	_	IN	IN	_	34	PMOD	_	_
36	HeLa	_	NN	NN	_	37	NMOD	_	_
37	cells	_	NNS	NNS	_	35	PMOD	_	_
38	,	_	,	,	_	37	P	_	_
39	which	_	WDT	WDT	_	40	SBJ	_	_
40	are	_	VBP	VBP	_	37	NMOD	_	_
41	not	_	RB	RB	_	40	VMOD	_	_
42	normally	_	RB	RB	_	40	ADV	_	_
43	competent	_	JJ	JJ	_	40	PRD	_	_
44	for	_	IN	IN	_	43	AMOD	_	_
45	IL-1	_	NN	NN	_	47	NMOD	_	_
46	beta	_	NN	NN	_	47	NMOD	_	_
47	expression	_	NN	NN	_	44	PMOD	_	_
48	.	_	.	.	_	29	P	_	_

1	When	_	WRB	WRB	_	2	ADV	_	_
2	ligated	_	VBN	VBN	_	15	TMP	_	_
3	to	_	TO	TO	_	2	ADV	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	murine	_	JJ	JJ	_	7	NMOD	_	_
6	c-fos	_	NN	NN	_	7	NMOD	_	_
7	promoter	_	NN	NN	_	3	PMOD	_	_
8	,	_	,	,	_	15	P	_	_
9	however	_	RB	RB	_	15	ADV	_	_
10	,	_	,	,	_	15	P	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	proIL-1	_	NN	NN	_	14	NMOD	_	_
13	beta	_	NN	NN	_	14	NMOD	_	_
14	enhancer	_	NN	NN	_	15	SBJ	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	inducible	_	JJ	JJ	_	15	PRD	_	_
17	in	_	IN	IN	_	15	ADV	_	_
18	phorbol	_	NN	NN	_	19	AMOD	_	_
19	myristate	_	NN	NN	_	22	NMOD	_	_
20	acetate-stimulated	_	JJ	JJ	_	19	AMOD	_	_
21	HeLa	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	17	PMOD	_	_
23	,	_	,	,	_	15	P	_	_
24	suggesting	_	VBG	VBG	_	15	VC	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	existence	_	NN	NN	_	24	OBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	a	_	DT	DT	_	32	NMOD	_	_
29	proIL-1	_	NN	NN	_	30	AMOD	_	_
30	beta	_	NN	NN	_	32	NMOD	_	_
31	promoter-proximal	_	JJ	JJ	_	30	AMOD	_	_
32	requirement	_	NN	NN	_	27	PMOD	_	_
33	for	_	IN	IN	_	32	NMOD	_	_
34	tissue	_	NN	NN	_	35	NMOD	_	_
35	specificity	_	NN	NN	_	33	PMOD	_	_
36	.	_	.	.	_	15	P	_	_

1	Suppression	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	cellular	_	JJ	JJ	_	6	NMOD	_	_
5	differentiation	_	NN	NN	_	6	NMOD	_	_
6	program	_	NN	NN	_	2	PMOD	_	_
7	by	_	IN	IN	_	1	NMOD	_	_
8	phorbol	_	NN	NN	_	9	NMOD	_	_
9	esters	_	NNS	NNS	_	7	PMOD	_	_
10	coincides	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	inhibition	_	NN	NN	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	binding	_	NN	NN	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	a	_	DT	DT	_	19	NMOD	_	_
17	cell-specific	_	JJ	JJ	_	19	NMOD	_	_
18	transcription	_	NN	NN	_	19	NMOD	_	_
19	factor	_	NN	NN	_	15	PMOD	_	_
20	(	_	(	(	_	21	P	_	_
21	NF-E2	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	to	_	TO	TO	_	14	NMOD	_	_
24	an	_	DT	DT	_	26	NMOD	_	_
25	enhancer	_	NN	NN	_	26	NMOD	_	_
26	element	_	NN	NN	_	23	PMOD	_	_
27	required	_	VBN	VBN	_	26	NMOD	_	_
28	for	_	IN	IN	_	27	ADV	_	_
29	expression	_	NN	NN	_	28	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	an	_	DT	DT	_	33	NMOD	_	_
32	erythroid-specific	_	JJ	JJ	_	33	NMOD	_	_
33	gene	_	NN	NN	_	30	PMOD	_	_
34	.	_	.	.	_	10	P	_	_

1	Induction	_	NN	NN	_	4	SBJ	_	_
2	by	_	IN	IN	_	1	NMOD	_	_
3	hemin	_	NN	NN	_	2	PMOD	_	_
4	increases	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	,	_	,	,	_	4	P	_	_
6	while	_	IN	IN	_	4	OBJ	_	_
7	induction	_	NN	NN	_	13	SBJ	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	12-O-tetradecanoylphorbol-13-acetate	_	NN	NN	_	8	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	TPA	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	represses	_	VBZ	VBZ	_	6	VMOD	_	_
14	,	_	,	,	_	4	P	_	_
15	erythroid-specific	_	JJ	JJ	_	17	NMOD	_	_
16	gene	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	4	IOBJ	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	23	NMOD	_	_
20	human	_	JJ	JJ	_	23	NMOD	_	_
21	cell	_	NN	NN	_	23	NMOD	_	_
22	line	_	NN	NN	_	23	NMOD	_	_
23	K562	_	NN	NN	_	18	PMOD	_	_
24	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	analyzed	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	effects	_	NNS	NNS	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	hemin	_	NN	NN	_	9	NMOD	_	_
7	or	_	CC	CC	_	6	CC	_	_
8	TPA	_	NN	NN	_	6	COORD	_	_
9	induction	_	NN	NN	_	5	PMOD	_	_
10	on	_	IN	IN	_	4	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	binding	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	activity	_	NN	NN	_	12	COORD	_	_
15	of	_	IN	IN	_	12	NMOD	_	_
16	transcription	_	NN	NN	_	17	NMOD	_	_
17	factors	_	NNS	NNS	_	15	PMOD	_	_
18	at	_	IN	IN	_	12	NMOD	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	regulatory	_	JJ	JJ	_	21	NMOD	_	_
21	element	_	NN	NN	_	18	PMOD	_	_
22	found	_	VBN	VBN	_	21	NMOD	_	_
23	within	_	IN	IN	_	22	ADV	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	transcriptional	_	JJ	JJ	_	26	AMOD	_	_
26	regulatory	_	JJ	JJ	_	27	NMOD	_	_
27	sequences	_	NNS	NNS	_	23	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	many	_	JJ	JJ	_	31	NMOD	_	_
30	erythroid-specific	_	JJ	JJ	_	31	NMOD	_	_
31	genes	_	NNS	NNS	_	28	PMOD	_	_
32	.	_	.	.	_	2	P	_	_

1	TPA	_	NN	NN	_	2	NMOD	_	_
2	induction	_	NN	NN	_	3	SBJ	_	_
3	increases	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	binding	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	ubiquitous	_	JJ	JJ	_	9	NMOD	_	_
8	AP-1	_	NN	NN	_	9	NMOD	_	_
9	factors	_	NNS	NNS	_	6	PMOD	_	_
10	to	_	TO	TO	_	5	NMOD	_	_
11	this	_	DT	DT	_	12	NMOD	_	_
12	element	_	NN	NN	_	10	PMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	TPA	_	NN	NN	_	2	NMOD	_	_
2	induction	_	NN	NN	_	3	SBJ	_	_
3	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	binding	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	12	NMOD	_	_
8	lineage	_	NN	NN	_	12	NMOD	_	_
9	limited	_	JJ	JJ	_	8	AMOD	_	_
10	transcription	_	NN	NN	_	12	NMOD	_	_
11	factor	_	NN	NN	_	12	NMOD	_	_
12	NF-E2	_	NN	NN	_	6	PMOD	_	_
13	to	_	TO	TO	_	5	NMOD	_	_
14	this	_	DT	DT	_	17	NMOD	_	_
15	transcriptional	_	JJ	JJ	_	17	NMOD	_	_
16	control	_	NN	NN	_	17	NMOD	_	_
17	element	_	NN	NN	_	13	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	Hemin	_	NN	NN	_	2	NMOD	_	_
2	induction	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	K562	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	3	PMOD	_	_
6	does	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	not	_	RB	RB	_	6	VMOD	_	_
8	facilitate	_	VB	VB	_	6	VC	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	binding	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	NF-E2	_	NN	NN	_	11	PMOD	_	_
13	to	_	TO	TO	_	10	NMOD	_	_
14	its	_	PRP$	PRP$	_	16	NMOD	_	_
15	recognition	_	NN	NN	_	16	NMOD	_	_
16	site	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	6	P	_	_

1	Hemin	_	NN	NN	_	2	NMOD	_	_
2	induction	_	NN	NN	_	3	SBJ	_	_
3	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	to	_	TO	TO	_	6	VMOD	_	_
5	nonspecifically	_	RB	RB	_	6	ADV	_	_
6	increase	_	VB	VB	_	3	OBJ	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	expression	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	transiently	_	RB	RB	_	11	AMOD	_	_
11	transfected	_	VBN	VBN	_	12	NMOD	_	_
12	genes	_	NNS	NNS	_	9	PMOD	_	_
13	in	_	IN	IN	_	8	NMOD	_	_
14	K562	_	NN	NN	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	13	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	Beyond	_	IN	IN	_	11	ADV	_	_
2	this	_	DT	DT	_	4	NMOD	_	_
3	nonspecific	_	JJ	JJ	_	4	NMOD	_	_
4	increase	_	NN	NN	_	1	PMOD	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	gene	_	NN	NN	_	7	NMOD	_	_
7	expression	_	NN	NN	_	5	PMOD	_	_
8	,	_	,	,	_	11	P	_	_
9	hemin	_	NN	NN	_	10	NMOD	_	_
10	induction	_	NN	NN	_	11	SBJ	_	_
11	acts	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	increase	_	VB	VB	_	11	OBJ	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	activity	_	NN	NN	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	22	NMOD	_	_
18	lineage	_	NN	NN	_	22	NMOD	_	_
19	limited	_	JJ	JJ	_	18	AMOD	_	_
20	transcription	_	NN	NN	_	22	NMOD	_	_
21	factor	_	NN	NN	_	22	NMOD	_	_
22	NF-E2	_	NN	NN	_	16	PMOD	_	_
23	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	divergent	_	JJ	JJ	_	3	NMOD	_	_
3	effects	_	NNS	NNS	_	14	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	hemin	_	NN	NN	_	4	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	TPA	_	NN	NN	_	5	COORD	_	_
8	on	_	IN	IN	_	3	NMOD	_	_
9	gene	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	8	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	K562	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	are	_	VBP	VBP	_	0	ROOT-S	_	_
15	mediated	_	VBN	VBN	_	14	VC	_	_
16	,	_	,	,	_	20	P	_	_
17	in	_	IN	IN	_	20	PMOD	_	_
18	part	_	NN	NN	_	17	PMOD	_	_
19	,	_	,	,	_	20	P	_	_
20	by	_	IN	IN	_	15	LGS	_	_
21	their	_	PRP$	PRP$	_	23	NMOD	_	_
22	contrasting	_	JJ	JJ	_	23	NMOD	_	_
23	effects	_	NNS	NNS	_	20	PMOD	_	_
24	on	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	28	NMOD	_	_
26	transcription	_	NN	NN	_	28	NMOD	_	_
27	factor	_	NN	NN	_	28	NMOD	_	_
28	NF-E2	_	NN	NN	_	24	PMOD	_	_
29	.	_	.	.	_	14	P	_	_

1	Transcriptional	_	JJ	JJ	_	2	NMOD	_	_
2	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	pyruvate	_	NN	NN	_	8	NMOD	_	_
6	kinase	_	NN	NN	_	8	NMOD	_	_
7	erythroid-specific	_	JJ	JJ	_	8	NMOD	_	_
8	promoter	_	NN	NN	_	3	PMOD	_	_
9	.	_	.	.	_	2	P	_	_

1	Mammal	_	JJ	JJ	_	3	NMOD	_	_
2	pyruvate	_	NN	NN	_	3	NMOD	_	_
3	kinases	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	encoded	_	VBN	VBN	_	4	VC	_	_
6	by	_	IN	IN	_	5	LGS	_	_
7	two	_	CD	CD	_	8	NMOD	_	_
8	genes	_	NNS	NNS	_	6	PMOD	_	_
9	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	L	_	NN	NN	_	3	NMOD	_	_
3	gene	_	NN	NN	_	4	SBJ	_	_
4	produces	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	16	NMOD	_	_
6	erythroid	_	JJ	JJ	_	16	NMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	R-PK	_	NN	NN	_	16	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	or	_	CC	CC	_	16	CC	_	_
11	the	_	DT	DT	_	16	NMOD	_	_
12	hepatic	_	JJ	JJ	_	16	NMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	L-PK	_	JJ	JJ	_	16	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	isozymes	_	NNS	NNS	_	4	OBJ	_	_
17	by	_	IN	IN	_	4	ADV	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	alternative	_	JJ	JJ	_	20	NMOD	_	_
20	use	_	NN	NN	_	17	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	two	_	CD	CD	_	23	NMOD	_	_
23	promoters	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	characterization	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	cis-	_	JJ	JJ	_	10	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	trans-acting	_	JJ	JJ	_	7	COORD	_	_
10	elements	_	NNS	NNS	_	5	PMOD	_	_
11	involved	_	VBN	VBN	_	10	NMOD	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	tissue-specific	_	JJ	JJ	_	15	NMOD	_	_
15	activity	_	NN	NN	_	12	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	L	_	NN	NN	_	21	NMOD	_	_
19	gene	_	NN	NN	_	21	NMOD	_	_
20	erythroid	_	JJ	JJ	_	21	NMOD	_	_
21	promoter	_	NN	NN	_	16	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	R-PK	_	NN	NN	_	4	NMOD	_	_
3	DNA	_	NN	NN	_	4	NMOD	_	_
4	fragment	_	NN	NN	_	15	SBJ	_	_
5	extending	_	VBG	VBG	_	4	NMOD	_	_
6	from	_	IN	IN	_	5	ADV	_	_
7	-870	_	CD	CD	_	6	PMOD	_	_
8	to	_	TO	TO	_	6	PMOD	_	_
9	+54	_	CD	CD	_	8	PMOD	_	_
10	relative	_	JJ	JJ	_	11	DEP	_	_
11	to	_	TO	TO	_	5	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	cap	_	NN	NN	_	14	NMOD	_	_
14	site	_	NN	NN	_	11	PMOD	_	_
15	confers	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	erythroid	_	JJ	JJ	_	17	NMOD	_	_
17	specificity	_	NN	NN	_	15	OBJ	_	_
18	to	_	TO	TO	_	15	ADV	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	reporter	_	NN	NN	_	21	NMOD	_	_
21	gene	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	15	P	_	_

1	Within	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	region	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	define	_	VBP	VBP	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	minimal	_	JJ	JJ	_	9	NMOD	_	_
9	promoter	_	NN	NN	_	6	OBJ	_	_
10	(	_	(	(	_	11	P	_	_
11	-62	_	CD	CD	_	9	PRN	_	_
12	to	_	TO	TO	_	11	NMOD	_	_
13	+54	_	CD	CD	_	11	NMOD	_	_
14	)	_	)	)	_	11	P	_	_
15	that	_	WDT	WDT	_	16	SBJ	_	_
16	displays	_	VBZ	VBZ	_	9	NMOD	_	_
17	erythroid-specific	_	JJ	JJ	_	18	NMOD	_	_
18	activity	_	NN	NN	_	16	OBJ	_	_
19	and	_	CC	CC	_	16	CC	_	_
20	contains	_	VBZ	VBZ	_	16	COORD	_	_
21	two	_	CD	CD	_	24	NMOD	_	_
22	DNA	_	NN	NN	_	24	NMOD	_	_
23	binding	_	NN	NN	_	24	NMOD	_	_
24	sites	_	NNS	NNS	_	20	OBJ	_	_
25	.	_	.	.	_	6	P	_	_

1	One	_	CD	CD	_	7	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	located	_	JJ	JJ	_	1	NMOD	_	_
4	at	_	IN	IN	_	3	AMOD	_	_
5	-50	_	CD	CD	_	4	PMOD	_	_
6	,	_	,	,	_	1	P	_	_
7	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	members	_	NNS	NNS	_	7	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	CCACC\/Sp1	_	NN	NN	_	12	NMOD	_	_
12	family	_	NN	NN	_	9	PMOD	_	_
13	and	_	CC	CC	_	7	CC	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	other	_	JJ	JJ	_	21	SBJ	_	_
16	,	_	,	,	_	15	P	_	_
17	located	_	JJ	JJ	_	15	NMOD	_	_
18	at	_	IN	IN	_	17	AMOD	_	_
19	-20	_	CD	CD	_	18	PMOD	_	_
20	,	_	,	,	_	15	P	_	_
21	binds	_	VBZ	VBZ	_	7	COORD	_	_
22	the	_	DT	DT	_	25	NMOD	_	_
23	erythroid	_	JJ	JJ	_	25	NMOD	_	_
24	factor	_	NN	NN	_	25	NMOD	_	_
25	GATA-1	_	NN	NN	_	21	OBJ	_	_
26	.	_	.	.	_	7	P	_	_

1	Although	_	IN	IN	_	19	ADV	_	_
2	the	_	DT	DT	_	6	NMOD	_	_
3	-20	_	CD	CD	_	6	NMOD	_	_
4	GATA	_	NN	NN	_	6	NMOD	_	_
5	binding	_	NN	NN	_	6	NMOD	_	_
6	site	_	NN	NN	_	10	SBJ	_	_
7	(	_	(	(	_	8	P	_	_
8	AGATAA	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	is	_	VBZ	VBZ	_	1	VMOD	_	_
11	also	_	RB	RB	_	10	ADV	_	_
12	a	_	DT	DT	_	16	NMOD	_	_
13	potential	_	JJ	JJ	_	16	NMOD	_	_
14	TFIID	_	NN	NN	_	16	NMOD	_	_
15	binding	_	NN	NN	_	16	NMOD	_	_
16	site	_	NN	NN	_	10	PRD	_	_
17	,	_	,	,	_	19	P	_	_
18	it	_	PRP	PRP	_	19	SBJ	_	_
19	does	_	VBZ	VBZ	_	0	ROOT-S	_	_
20	not	_	RB	RB	_	19	VMOD	_	_
21	bind	_	VB	VB	_	19	VC	_	_
22	TFIID	_	NN	NN	_	21	OBJ	_	_
23	.	_	.	.	_	19	P	_	_

1	Furthermore	_	RB	RB	_	16	ADV	_	_
2	,	_	,	,	_	16	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	substitution	_	NN	NN	_	16	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	this	_	DT	DT	_	9	NMOD	_	_
7	GATA	_	NN	NN	_	9	NMOD	_	_
8	binding	_	NN	NN	_	9	NMOD	_	_
9	site	_	NN	NN	_	5	PMOD	_	_
10	by	_	IN	IN	_	4	NMOD	_	_
11	a	_	DT	DT	_	15	NMOD	_	_
12	canonical	_	JJ	JJ	_	15	NMOD	_	_
13	TFIID	_	NN	NN	_	15	NMOD	_	_
14	binding	_	NN	NN	_	15	NMOD	_	_
15	site	_	NN	NN	_	10	PMOD	_	_
16	suppresses	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	promoter	_	NN	NN	_	19	NMOD	_	_
19	activity	_	NN	NN	_	16	OBJ	_	_
20	.	_	.	.	_	16	P	_	_

1	Mutations	_	NNS	NNS	_	7	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	deletions	_	NNS	NNS	_	1	COORD	_	_
4	of	_	IN	IN	_	1	NMOD	_	_
5	both	_	DT	DT	_	6	NMOD	_	_
6	sites	_	NNS	NNS	_	4	PMOD	_	_
7	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	only	_	RB	RB	_	11	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	association	_	NN	NN	_	18	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	CCACC\/Sp1	_	NN	NN	_	17	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	GATA	_	NN	NN	_	13	COORD	_	_
16	binding	_	NN	NN	_	17	NMOD	_	_
17	sites	_	NNS	NNS	_	12	PMOD	_	_
18	can	_	MD	MD	_	8	VMOD	_	_
19	drive	_	VB	VB	_	18	VC	_	_
20	efficient	_	JJ	JJ	_	23	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	tissue-specific	_	JJ	JJ	_	20	COORD	_	_
23	expression	_	NN	NN	_	19	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	this	_	DT	DT	_	28	NMOD	_	_
26	R-PK	_	NN	NN	_	28	NMOD	_	_
27	minimal	_	JJ	JJ	_	28	NMOD	_	_
28	promoter	_	NN	NN	_	24	PMOD	_	_
29	.	_	.	.	_	7	P	_	_

1	Finally	_	RB	RB	_	8	TMP	_	_
2	,	_	,	,	_	8	P	_	_
3	by	_	IN	IN	_	8	ADV	_	_
4	co-transfection	_	NN	NN	_	5	NMOD	_	_
5	experiments	_	NNS	NNS	_	3	PMOD	_	_
6	,	_	,	,	_	8	P	_	_
7	we	_	PRP	PRP	_	8	SBJ	_	_
8	study	_	VBD	VBD	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	elements	_	NNS	NNS	_	8	OBJ	_	_
11	involved	_	VBN	VBN	_	10	NMOD	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	hGATA-1	_	NN	NN	_	15	NMOD	_	_
15	transactivation	_	NN	NN	_	12	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	R-PK	_	NN	NN	_	19	NMOD	_	_
19	promoter	_	NN	NN	_	16	PMOD	_	_
20	in	_	IN	IN	_	15	NMOD	_	_
21	HeLa	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	8	P	_	_

1	Transcriptional	_	JJ	JJ	_	2	NMOD	_	_
2	activation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	human	_	JJ	JJ	_	8	NMOD	_	_
5	zeta	_	NN	NN	_	8	NMOD	_	_
6	2	_	CD	CD	_	8	NMOD	_	_
7	globin	_	NN	NN	_	8	NMOD	_	_
8	promoter	_	NN	NN	_	3	PMOD	_	_
9	by	_	IN	IN	_	2	NMOD	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	alpha	_	NN	NN	_	14	NMOD	_	_
12	globin	_	NN	NN	_	14	NMOD	_	_
13	regulatory	_	JJ	JJ	_	14	NMOD	_	_
14	element	_	NN	NN	_	9	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	HS-40	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	:	_	:	:	_	2	P	_	_
19	functional	_	JJ	JJ	_	20	NMOD	_	_
20	role	_	NN	NN	_	2	NMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	specific	_	JJ	JJ	_	24	AMOD	_	_
23	nuclear	_	JJ	JJ	_	24	AMOD	_	_
24	factor-DNA	_	JJ	JJ	_	25	NMOD	_	_
25	complexes	_	NNS	NNS	_	21	PMOD	_	_
26	.	_	.	.	_	20	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	studied	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	functional	_	JJ	JJ	_	5	NMOD	_	_
5	interaction	_	NN	NN	_	2	OBJ	_	_
6	between	_	IN	IN	_	5	NMOD	_	_
7	human	_	JJ	JJ	_	12	NMOD	_	_
8	embryonic	_	JJ	JJ	_	12	NMOD	_	_
9	zeta	_	NN	NN	_	12	NMOD	_	_
10	2	_	CD	CD	_	12	NMOD	_	_
11	globin	_	NN	NN	_	12	NMOD	_	_
12	promoter	_	NN	NN	_	6	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	alpha	_	NN	NN	_	18	NMOD	_	_
16	globin	_	NN	NN	_	18	NMOD	_	_
17	regulatory	_	JJ	JJ	_	18	NMOD	_	_
18	element	_	NN	NN	_	12	COORD	_	_
19	(	_	(	(	_	20	P	_	_
20	HS-40	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	located	_	JJ	JJ	_	25	AMOD	_	_
23	40	_	CD	CD	_	24	NMOD	_	_
24	kb	_	NN	NN	_	25	AMOD	_	_
25	upstream	_	RB	RB	_	18	NMOD	_	_
26	of	_	IN	IN	_	25	AMOD	_	_
27	the	_	DT	DT	_	31	NMOD	_	_
28	zeta	_	NN	NN	_	31	NMOD	_	_
29	2	_	CD	CD	_	31	NMOD	_	_
30	globin	_	NN	NN	_	31	NMOD	_	_
31	gene	_	NN	NN	_	26	PMOD	_	_
32	.	_	.	.	_	2	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	shown	_	VBN	VBN	_	2	VC	_	_
4	by	_	IN	IN	_	3	LGS	_	_
5	transient	_	JJ	JJ	_	7	NMOD	_	_
6	expression	_	NN	NN	_	7	NMOD	_	_
7	assay	_	NN	NN	_	4	PMOD	_	_
8	that	_	IN	IN	_	3	OBJ	_	_
9	HS-40	_	NN	NN	_	10	SBJ	_	_
10	behaved	_	VBD	VBD	_	8	VMOD	_	_
11	as	_	IN	IN	_	10	ADV	_	_
12	an	_	DT	DT	_	14	NMOD	_	_
13	authentic	_	JJ	JJ	_	14	NMOD	_	_
14	enhancer	_	NN	NN	_	11	PMOD	_	_
15	for	_	IN	IN	_	14	NMOD	_	_
16	high-level	_	JJ	JJ	_	21	NMOD	_	_
17	zeta	_	NN	NN	_	21	NMOD	_	_
18	2	_	CD	CD	_	21	NMOD	_	_
19	globin	_	NN	NN	_	21	NMOD	_	_
20	promoter	_	NN	NN	_	21	NMOD	_	_
21	activity	_	NN	NN	_	15	PMOD	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	K562	_	NN	NN	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	,	_	,	,	_	14	P	_	_
26	an	_	DT	DT	_	29	NMOD	_	_
27	erythroid	_	JJ	JJ	_	29	NMOD	_	_
28	cell	_	NN	NN	_	29	NMOD	_	_
29	line	_	NN	NN	_	14	NMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	embryonic	_	JJ	JJ	_	34	NMOD	_	_
32	and\/or	_	CC	CC	_	31	CC	_	_
33	fetal	_	JJ	JJ	_	31	COORD	_	_
34	origin	_	NN	NN	_	30	PMOD	_	_
35	.	_	.	.	_	2	P	_	_

1	Although	_	IN	IN	_	24	ADV	_	_
2	sequences	_	NNS	NNS	_	14	SBJ	_	_
3	located	_	JJ	JJ	_	2	NMOD	_	_
4	between	_	IN	IN	_	3	AMOD	_	_
5	-559	_	CD	CD	_	4	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	-88	_	CD	CD	_	5	COORD	_	_
8	of	_	IN	IN	_	5	NMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	zeta	_	NN	NN	_	13	NMOD	_	_
11	2	_	CD	CD	_	13	NMOD	_	_
12	globin	_	NN	NN	_	13	NMOD	_	_
13	gene	_	NN	NN	_	8	PMOD	_	_
14	were	_	VBD	VBD	_	1	VMOD	_	_
15	dispensable	_	JJ	JJ	_	14	PRD	_	_
16	for	_	IN	IN	_	15	AMOD	_	_
17	its	_	PRP$	PRP$	_	18	NMOD	_	_
18	expression	_	NN	NN	_	16	PMOD	_	_
19	on	_	IN	IN	_	18	NMOD	_	_
20	enhancerless	_	NN	NN	_	21	NMOD	_	_
21	plasmids	_	NNS	NNS	_	19	PMOD	_	_
22	,	_	,	,	_	24	P	_	_
23	they	_	PRP	PRP	_	24	SBJ	_	_
24	were	_	VBD	VBD	_	0	ROOT-S	_	_
25	required	_	VBN	VBN	_	24	VC	_	_
26	for	_	IN	IN	_	25	ADV	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	HS-40	_	NN	NN	_	30	NMOD	_	_
29	enhancer-mediated	_	JJ	JJ	_	28	AMOD	_	_
30	activity	_	NN	NN	_	26	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	36	NMOD	_	_
33	zeta	_	NN	NN	_	36	NMOD	_	_
34	2	_	CD	CD	_	36	NMOD	_	_
35	globin	_	NN	NN	_	36	NMOD	_	_
36	promoter	_	NN	NN	_	31	PMOD	_	_
37	.	_	.	.	_	24	P	_	_

1	Site-directed	_	JJ	JJ	_	2	NMOD	_	_
2	mutagenesis	_	NN	NN	_	3	SBJ	_	_
3	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	this	_	DT	DT	_	11	NMOD	_	_
6	HS-40	_	NN	NN	_	10	AMOD	_	_
7	enhancer-zeta	_	NN	NN	_	10	AMOD	_	_
8	2	_	CD	CD	_	10	AMOD	_	_
9	globin	_	NN	NN	_	10	AMOD	_	_
10	promoter	_	NN	NN	_	11	NMOD	_	_
11	interaction	_	NN	NN	_	12	SBJ	_	_
12	is	_	VBZ	VBZ	_	4	VMOD	_	_
13	mediated	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	the	_	DT	DT	_	20	NMOD	_	_
16	two	_	CD	CD	_	20	NMOD	_	_
17	GATA-1	_	NN	NN	_	20	NMOD	_	_
18	factor	_	NN	NN	_	20	NMOD	_	_
19	binding	_	NN	NN	_	20	NMOD	_	_
20	motifs	_	NNS	NNS	_	14	PMOD	_	_
21	located	_	JJ	JJ	_	20	NMOD	_	_
22	at	_	IN	IN	_	21	AMOD	_	_
23	-230	_	CD	CD	_	22	PMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	-104	_	CD	CD	_	23	COORD	_	_
26	,	_	,	,	_	23	P	_	_
27	respectively	_	RB	RB	_	23	NMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	functional	_	JJ	JJ	_	3	NMOD	_	_
3	domains	_	NNS	NNS	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	HS-40	_	NN	NN	_	4	PMOD	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	also	_	RB	RB	_	8	ADV	_	_
8	mapped	_	VBN	VBN	_	6	VC	_	_
9	.	_	.	.	_	6	P	_	_

1	Bal	_	NN	NN	_	5	NMOD	_	_
2	31	_	CD	CD	_	5	NMOD	_	_
3	deletion	_	NN	NN	_	5	NMOD	_	_
4	mapping	_	VBG	VBG	_	5	NMOD	_	_
5	data	_	NNS	NNS	_	6	SBJ	_	_
6	suggested	_	VBD	VBD	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	one	_	CD	CD	_	10	NMOD	_	_
9	GATA-1	_	NN	NN	_	10	NMOD	_	_
10	motif	_	NN	NN	_	21	SBJ	_	_
11	,	_	,	,	_	10	P	_	_
12	one	_	CD	CD	_	14	NMOD	_	_
13	GT	_	NN	NN	_	14	NMOD	_	_
14	motif	_	NN	NN	_	10	COORD	_	_
15	,	_	,	,	_	10	P	_	_
16	and	_	CC	CC	_	10	CC	_	_
17	two	_	CD	CD	_	19	NMOD	_	_
18	NF-E2\/AP1	_	NN	NN	_	19	NMOD	_	_
19	motifs	_	NNS	NNS	_	10	COORD	_	_
20	together	_	RB	RB	_	10	NMOD	_	_
21	formed	_	VBD	VBD	_	7	VMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	functional	_	JJ	JJ	_	24	NMOD	_	_
24	core	_	NN	NN	_	21	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	HS-40	_	NN	NN	_	25	PMOD	_	_
27	in	_	IN	IN	_	21	ADV	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	erythroid-specific	_	JJ	JJ	_	30	NMOD	_	_
30	activation	_	NN	NN	_	27	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	36	NMOD	_	_
33	zeta	_	NN	NN	_	36	NMOD	_	_
34	2	_	CD	CD	_	36	NMOD	_	_
35	globin	_	NN	NN	_	36	NMOD	_	_
36	promoter	_	NN	NN	_	31	PMOD	_	_
37	.	_	.	.	_	6	P	_	_

1	Site-directed	_	JJ	JJ	_	2	NMOD	_	_
2	mutagenesis	_	NN	NN	_	4	SBJ	_	_
3	further	_	RBR	RBR	_	4	ADV	_	_
4	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	enhancer	_	NN	NN	_	8	NMOD	_	_
8	function	_	NN	NN	_	18	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	one	_	CD	CD	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	two	_	CD	CD	_	15	NMOD	_	_
14	NF-E2\/AP1	_	NN	NN	_	15	NMOD	_	_
15	motifs	_	NNS	NNS	_	11	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	HS-40	_	NN	NN	_	16	PMOD	_	_
18	is	_	VBZ	VBZ	_	5	VMOD	_	_
19	mediated	_	VBN	VBN	_	18	VC	_	_
20	through	_	IN	IN	_	19	ADV	_	_
21	its	_	PRP$	PRP$	_	22	NMOD	_	_
22	binding	_	NN	NN	_	20	PMOD	_	_
23	to	_	TO	TO	_	22	NMOD	_	_
24	NF-E2	_	NN	NN	_	23	PMOD	_	_
25	but	_	CC	CC	_	24	CC	_	_
26	not	_	RB	RB	_	25	COORD	_	_
27	AP1	_	NN	NN	_	29	NMOD	_	_
28	transcription	_	NN	NN	_	29	NMOD	_	_
29	factor	_	NN	NN	_	24	COORD	_	_
30	.	_	.	.	_	4	P	_	_

1	Finally	_	RB	RB	_	4	TMP	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	did	_	VBD	VBD	_	0	ROOT-S	_	_
5	genomic	_	JJ	JJ	_	6	NMOD	_	_
6	footprinting	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	HS-40	_	NN	NN	_	11	NMOD	_	_
10	enhancer	_	NN	NN	_	11	NMOD	_	_
11	region	_	NN	NN	_	7	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	K562	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	adult	_	JJ	JJ	_	18	NMOD	_	_
17	nucleated	_	JJ	JJ	_	18	NMOD	_	_
18	erythroblasts	_	NNS	NNS	_	14	COORD	_	_
19	,	_	,	,	_	14	P	_	_
20	and	_	CC	CC	_	14	CC	_	_
21	different	_	JJ	JJ	_	23	NMOD	_	_
22	nonerythroid	_	JJ	JJ	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	14	COORD	_	_
24	.	_	.	.	_	4	P	_	_

1	All	_	DT	DT	_	3	NMOD	_	_
2	sequence	_	NN	NN	_	3	NMOD	_	_
3	motifs	_	NNS	NNS	_	18	SBJ	_	_
4	within	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	functional	_	JJ	JJ	_	7	NMOD	_	_
7	core	_	NN	NN	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	HS-40	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	3	P	_	_
11	as	_	IN	IN	_	3	NMOD	_	_
12	mapped	_	VBN	VBN	_	11	VMOD	_	_
13	by	_	IN	IN	_	12	ADV	_	_
14	transient	_	JJ	JJ	_	16	NMOD	_	_
15	expression	_	NN	NN	_	16	NMOD	_	_
16	analysis	_	NN	NN	_	13	PMOD	_	_
17	,	_	,	,	_	3	P	_	_
18	appeared	_	VBD	VBD	_	0	ROOT-S	_	_
19	to	_	TO	TO	_	20	VMOD	_	_
20	bind	_	VB	VB	_	18	OBJ	_	_
21	a	_	DT	DT	_	25	NMOD	_	_
22	nuclear	_	JJ	JJ	_	25	NMOD	_	_
23	factor	_	NN	NN	_	25	NMOD	_	_
24	(	_	(	(	_	25	P	_	_
25	s	_	NNS	NNS	_	20	OBJ	_	_
26	)	_	)	)	_	25	P	_	_
27	in	_	IN	IN	_	25	NMOD	_	_
28	living	_	VBG	VBG	_	30	NMOD	_	_
29	K562	_	NN	NN	_	30	NMOD	_	_
30	cells	_	NNS	NNS	_	27	PMOD	_	_
31	but	_	CC	CC	_	27	CC	_	_
32	not	_	RB	RB	_	33	DEP	_	_
33	in	_	IN	IN	_	27	COORD	_	_
34	nonerythroid	_	JJ	JJ	_	35	NMOD	_	_
35	cells	_	NNS	NNS	_	33	PMOD	_	_
36	.	_	.	.	_	18	P	_	_

1	On	_	IN	IN	_	14	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	other	_	JJ	JJ	_	4	NMOD	_	_
4	hand	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	14	P	_	_
6	only	_	RB	RB	_	14	SBJ	_	_
7	one	_	CD	CD	_	6	DEP	_	_
8	of	_	IN	IN	_	6	NMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	apparently	_	RB	RB	_	11	AMOD	_	_
11	nonfunctional	_	JJ	JJ	_	13	NMOD	_	_
12	sequence	_	NN	NN	_	13	NMOD	_	_
13	motifs	_	NNS	NNS	_	8	PMOD	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	bound	_	VBN	VBN	_	14	VC	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	factors	_	NNS	NNS	_	16	PMOD	_	_
18	in	_	FW	FW	_	15	ADV	_	_
19	vivo	_	FW	FW	_	18	AMOD	_	_
20	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	13	ADV	_	_
2	comparison	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	K562	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	13	P	_	_
6	nucleated	_	JJ	JJ	_	7	NMOD	_	_
7	erythroblasts	_	NNS	NNS	_	13	SBJ	_	_
8	from	_	IN	IN	_	7	NMOD	_	_
9	adult	_	JJ	JJ	_	12	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	bone	_	NN	NN	_	12	NMOD	_	_
12	marrow	_	NN	NN	_	8	PMOD	_	_
13	exhibited	_	VBD	VBD	_	0	ROOT-S	_	_
14	a	_	DT	DT	_	18	NMOD	_	_
15	similar	_	JJ	JJ	_	18	NMOD	_	_
16	but	_	CC	CC	_	15	CC	_	_
17	nonidentical	_	JJ	JJ	_	15	COORD	_	_
18	pattern	_	NN	NN	_	13	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	nuclear	_	JJ	JJ	_	22	NMOD	_	_
21	factor	_	NN	NN	_	22	NMOD	_	_
22	binding	_	NN	NN	_	19	PMOD	_	_
23	in	_	FW	FW	_	22	NMOD	_	_
24	vivo	_	FW	FW	_	23	AMOD	_	_
25	at	_	IN	IN	_	13	ADV	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	HS-40	_	NN	NN	_	28	NMOD	_	_
28	region	_	NN	NN	_	25	PMOD	_	_
29	.	_	.	.	_	13	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	transcriptional	_	JJ	JJ	_	6	NMOD	_	_
6	activation	_	NN	NN	_	20	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	human	_	JJ	JJ	_	13	NMOD	_	_
9	embryonic	_	JJ	JJ	_	13	NMOD	_	_
10	zeta	_	NN	NN	_	13	NMOD	_	_
11	2	_	CD	CD	_	13	NMOD	_	_
12	globin	_	NN	NN	_	13	NMOD	_	_
13	gene	_	NN	NN	_	7	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	fetal\/adult	_	JJ	JJ	_	19	NMOD	_	_
17	alpha	_	NN	NN	_	19	NMOD	_	_
18	globin	_	NN	NN	_	19	NMOD	_	_
19	genes	_	NNS	NNS	_	13	COORD	_	_
20	is	_	VBZ	VBZ	_	4	VMOD	_	_
21	mediated	_	VBN	VBN	_	20	VC	_	_
22	by	_	IN	IN	_	21	LGS	_	_
23	erythroid	_	JJ	JJ	_	24	AMOD	_	_
24	cell-specific	_	JJ	JJ	_	29	AMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	developmental	_	JJ	JJ	_	27	AMOD	_	_
27	stage-specific	_	JJ	JJ	_	24	COORD	_	_
28	nuclear	_	JJ	JJ	_	29	AMOD	_	_
29	factor-DNA	_	NN	NN	_	30	NMOD	_	_
30	complexes	_	NNS	NNS	_	22	PMOD	_	_
31	which	_	WDT	WDT	_	32	SBJ	_	_
32	form	_	VBP	VBP	_	30	NMOD	_	_
33	at	_	IN	IN	_	32	ADV	_	_
34	the	_	DT	DT	_	35	NMOD	_	_
35	enhancer	_	NN	NN	_	33	PMOD	_	_
36	(	_	(	(	_	37	P	_	_
37	HS-40	_	NN	NN	_	35	PRN	_	_
38	)	_	)	)	_	37	P	_	_
39	and	_	CC	CC	_	35	CC	_	_
40	the	_	DT	DT	_	42	NMOD	_	_
41	globin	_	NN	NN	_	42	NMOD	_	_
42	promoters	_	NNS	NNS	_	35	COORD	_	_
43	.	_	.	.	_	3	P	_	_

1	NF-kappa	_	NN	NN	_	2	NMOD	_	_
2	B	_	NN	NN	_	3	SBJ	_	_
3	controls	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	expression	_	NN	NN	_	3	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	inhibitor	_	NN	NN	_	10	NMOD	_	_
7	I	_	NN	NN	_	10	NMOD	_	_
8	kappa	_	NN	NN	_	10	NMOD	_	_
9	B	_	NN	NN	_	10	NMOD	_	_
10	alpha	_	NN	NN	_	5	PMOD	_	_
11	:	_	:	:	_	3	P	_	_
12	evidence	_	NN	NN	_	3	VMOD	_	_
13	for	_	IN	IN	_	12	NMOD	_	_
14	an	_	DT	DT	_	17	NMOD	_	_
15	inducible	_	JJ	JJ	_	17	NMOD	_	_
16	autoregulatory	_	JJ	JJ	_	17	NMOD	_	_
17	pathway	_	NN	NN	_	13	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	eukaryotic	_	JJ	JJ	_	4	NMOD	_	_
3	transcription	_	NN	NN	_	4	NMOD	_	_
4	factor	_	NN	NN	_	12	SBJ	_	_
5	nuclear	_	JJ	JJ	_	7	NMOD	_	_
6	factor-kappa	_	NN	NN	_	7	NMOD	_	_
7	B	_	NN	NN	_	4	NMOD	_	_
8	(	_	(	(	_	10	P	_	_
9	NF-kappa	_	NN	NN	_	10	NMOD	_	_
10	B	_	NN	NN	_	7	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	participates	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	many	_	JJ	JJ	_	15	NMOD	_	_
15	parts	_	NNS	NNS	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	genetic	_	JJ	JJ	_	19	NMOD	_	_
19	program	_	NN	NN	_	16	PMOD	_	_
20	mediating	_	VBG	VBG	_	19	NMOD	_	_
21	T	_	NN	NN	_	22	NMOD	_	_
22	lymphocyte	_	NN	NN	_	20	OBJ	_	_
23	activation	_	NN	NN	_	22	NMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	growth	_	NN	NN	_	23	COORD	_	_
26	.	_	.	.	_	12	P	_	_

1	Nuclear	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NF-kappa	_	NN	NN	_	5	NMOD	_	_
5	B	_	NN	NN	_	3	PMOD	_	_
6	occurs	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	after	_	IN	IN	_	6	TMP	_	_
8	its	_	PRP$	PRP$	_	10	NMOD	_	_
9	induced	_	VBN	VBN	_	10	NMOD	_	_
10	dissociation	_	NN	NN	_	7	PMOD	_	_
11	from	_	IN	IN	_	10	NMOD	_	_
12	its	_	PRP$	PRP$	_	18	NMOD	_	_
13	cytoplasmic	_	JJ	JJ	_	18	NMOD	_	_
14	inhibitor	_	NN	NN	_	18	NMOD	_	_
15	I	_	NN	NN	_	18	NMOD	_	_
16	kappa	_	NN	NN	_	18	NMOD	_	_
17	B	_	NN	NN	_	18	NMOD	_	_
18	alpha	_	NN	NN	_	11	PMOD	_	_
19	.	_	.	.	_	6	P	_	_

1	Phorbol	_	NN	NN	_	2	NMOD	_	_
2	ester	_	NN	NN	_	7	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	tumor	_	NN	NN	_	6	NMOD	_	_
5	necrosis	_	NN	NN	_	6	NMOD	_	_
6	factor-alpha	_	NN	NN	_	2	COORD	_	_
7	induction	_	NN	NN	_	12	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	nuclear	_	JJ	JJ	_	11	NMOD	_	_
10	NF-kappa	_	NN	NN	_	11	NMOD	_	_
11	B	_	NN	NN	_	8	PMOD	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	associated	_	VBN	VBN	_	12	VC	_	_
14	with	_	IN	IN	_	13	ADV	_	_
15	both	_	CC	CC	_	17	CC	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	degradation	_	NN	NN	_	14	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	performed	_	VBN	VBN	_	23	NMOD	_	_
20	I	_	NN	NN	_	23	NMOD	_	_
21	kappa	_	NN	NN	_	23	NMOD	_	_
22	B	_	NN	NN	_	23	NMOD	_	_
23	alpha	_	NN	NN	_	18	PMOD	_	_
24	and	_	CC	CC	_	17	CC	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	activation	_	NN	NN	_	17	COORD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	I	_	NN	NN	_	33	NMOD	_	_
29	kappa	_	NN	NN	_	33	NMOD	_	_
30	B	_	NN	NN	_	33	NMOD	_	_
31	alpha	_	NN	NN	_	33	NMOD	_	_
32	gene	_	NN	NN	_	33	NMOD	_	_
33	expression	_	NN	NN	_	27	PMOD	_	_
34	.	_	.	.	_	12	P	_	_

1	Transfection	_	NN	NN	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	10	NMOD	_	_
6	I	_	NN	NN	_	10	NMOD	_	_
7	kappa	_	NN	NN	_	10	NMOD	_	_
8	B	_	NN	NN	_	10	NMOD	_	_
9	alpha	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	4	VMOD	_	_
12	specifically	_	RB	RB	_	11	ADV	_	_
13	induced	_	VBN	VBN	_	11	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	65-kilodalton	_	JJ	JJ	_	18	NMOD	_	_
17	transactivating	_	VBG	VBG	_	18	NMOD	_	_
18	subunit	_	NN	NN	_	14	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	NF-kappa	_	NN	NN	_	21	NMOD	_	_
21	B	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	Association	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	9	NMOD	_	_
4	newly	_	RB	RB	_	5	AMOD	_	_
5	synthesized	_	VBN	VBN	_	9	NMOD	_	_
6	I	_	NN	NN	_	9	NMOD	_	_
7	kappa	_	NN	NN	_	9	NMOD	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	alpha	_	NN	NN	_	2	PMOD	_	_
10	with	_	IN	IN	_	1	NMOD	_	_
11	p65	_	NN	NN	_	10	PMOD	_	_
12	restores	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	intracellular	_	JJ	JJ	_	14	NMOD	_	_
14	inhibition	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	NF-kappa	_	NN	NN	_	20	NMOD	_	_
17	B	_	NN	NN	_	20	NMOD	_	_
18	DNA	_	NN	NN	_	20	NMOD	_	_
19	binding	_	NN	NN	_	20	NMOD	_	_
20	activity	_	NN	NN	_	15	PMOD	_	_
21	and	_	CC	CC	_	12	CC	_	_
22	prolongs	_	VBZ	VBZ	_	12	COORD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	survival	_	NN	NN	_	22	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	this	_	DT	DT	_	28	NMOD	_	_
27	labile	_	JJ	JJ	_	28	NMOD	_	_
28	inhibitor	_	NN	NN	_	25	PMOD	_	_
29	.	_	.	.	_	12	P	_	_

1	Together	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	results	_	NNS	NNS	_	5	SBJ	_	_
5	show	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	NF-kappa	_	NN	NN	_	8	NMOD	_	_
8	B	_	NN	NN	_	9	SBJ	_	_
9	controls	_	VBZ	VBZ	_	6	VMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	expression	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	I	_	NN	NN	_	16	NMOD	_	_
14	kappa	_	NN	NN	_	16	NMOD	_	_
15	B	_	NN	NN	_	16	NMOD	_	_
16	alpha	_	NN	NN	_	12	PMOD	_	_
17	by	_	IN	IN	_	9	ADV	_	_
18	means	_	NNS	NNS	_	17	DEP	_	_
19	of	_	IN	IN	_	17	DEP	_	_
20	an	_	DT	DT	_	23	NMOD	_	_
21	inducible	_	JJ	JJ	_	23	NMOD	_	_
22	autoregulatory	_	JJ	JJ	_	23	NMOD	_	_
23	pathway	_	NN	NN	_	17	PMOD	_	_
24	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	Sp1	_	NN	NN	_	4	NMOD	_	_
3	transcription	_	NN	NN	_	4	NMOD	_	_
4	factor	_	NN	NN	_	5	SBJ	_	_
5	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	CD11b	_	NN	NN	_	8	NMOD	_	_
8	promoter	_	NN	NN	_	5	OBJ	_	_
9	specifically	_	RB	RB	_	10	DEP	_	_
10	in	_	IN	IN	_	5	ADV	_	_
11	myeloid	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	in	_	FW	FW	_	5	ADV	_	_
14	vivo	_	FW	FW	_	13	AMOD	_	_
15	and	_	CC	CC	_	5	CC	_	_
16	is	_	VBZ	VBZ	_	5	COORD	_	_
17	essential	_	JJ	JJ	_	16	PRD	_	_
18	for	_	IN	IN	_	17	AMOD	_	_
19	myeloid-specific	_	JJ	JJ	_	21	NMOD	_	_
20	promoter	_	NN	NN	_	21	NMOD	_	_
21	activity	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	myeloid	_	JJ	JJ	_	4	NMOD	_	_
3	integrin	_	NN	NN	_	4	NMOD	_	_
4	CD11b	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	expressed	_	VBN	VBN	_	5	VC	_	_
7	selectively	_	RB	RB	_	6	ADV	_	_
8	on	_	IN	IN	_	6	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	surface	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	mature	_	JJ	JJ	_	13	NMOD	_	_
13	macrophages	_	NNS	NNS	_	11	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	monocytes	_	NNS	NNS	_	13	COORD	_	_
16	,	_	,	,	_	13	P	_	_
17	neutrophils	_	NNS	NNS	_	13	COORD	_	_
18	,	_	,	,	_	13	P	_	_
19	and	_	CC	CC	_	13	CC	_	_
20	natural	_	JJ	JJ	_	22	NMOD	_	_
21	killer	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	13	COORD	_	_
23	.	_	.	.	_	5	P	_	_

1	Lineage-specific	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	controlled	_	VBN	VBN	_	3	VC	_	_
5	at	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	level	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	mRNA	_	NN	NN	_	10	NMOD	_	_
10	transcription	_	NN	NN	_	8	PMOD	_	_
11	.	_	.	.	_	3	P	_	_

1	Recent	_	JJ	JJ	_	2	NMOD	_	_
2	isolation	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	CD11b	_	NN	NN	_	6	NMOD	_	_
6	promoter	_	NN	NN	_	3	PMOD	_	_
7	shows	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	92	_	CD	CD	_	11	NMOD	_	_
10	base	_	NN	NN	_	11	NMOD	_	_
11	pairs	_	NNS	NNS	_	18	SBJ	_	_
12	(	_	(	(	_	13	P	_	_
13	bp	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	of	_	IN	IN	_	11	NMOD	_	_
16	5'-flanking	_	JJ	JJ	_	17	NMOD	_	_
17	DNA	_	NN	NN	_	15	PMOD	_	_
18	are	_	VBP	VBP	_	8	VMOD	_	_
19	sufficient	_	JJ	JJ	_	18	PRD	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	direct	_	VB	VB	_	19	AMOD	_	_
22	myeloid-specific	_	JJ	JJ	_	23	NMOD	_	_
23	expression	_	NN	NN	_	21	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	reporter	_	NN	NN	_	27	NMOD	_	_
27	gene	_	NN	NN	_	24	PMOD	_	_
28	.	_	.	.	_	7	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	characterize	_	VB	VB	_	11	VMOD	_	_
3	regulatory	_	JJ	JJ	_	4	NMOD	_	_
4	sequences	_	NNS	NNS	_	2	OBJ	_	_
5	important	_	JJ	JJ	_	4	NMOD	_	_
6	for	_	IN	IN	_	5	AMOD	_	_
7	promoter	_	NN	NN	_	8	NMOD	_	_
8	activity	_	NN	NN	_	6	PMOD	_	_
9	,	_	,	,	_	11	P	_	_
10	we	_	PRP	PRP	_	11	SBJ	_	_
11	performed	_	VBD	VBD	_	0	ROOT-S	_	_
12	linker	_	NN	NN	_	14	NMOD	_	_
13	scanning	_	NN	NN	_	14	NMOD	_	_
14	analysis	_	NN	NN	_	11	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	92-bp	_	JJ	JJ	_	19	NMOD	_	_
18	CD11b	_	NN	NN	_	19	NMOD	_	_
19	promoter	_	NN	NN	_	15	PMOD	_	_
20	and	_	CC	CC	_	11	CC	_	_
21	demonstrate	_	VB	VB	_	11	COORD	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	a	_	DT	DT	_	24	NMOD	_	_
24	sequence	_	NN	NN	_	28	SBJ	_	_
25	at	_	IN	IN	_	24	NMOD	_	_
26	bp	_	NN	NN	_	25	PMOD	_	_
27	-60	_	CD	CD	_	26	NMOD	_	_
28	is	_	VBZ	VBZ	_	22	VMOD	_	_
29	essential	_	JJ	JJ	_	28	PRD	_	_
30	for	_	IN	IN	_	29	AMOD	_	_
31	CD11b	_	NN	NN	_	33	NMOD	_	_
32	promoter	_	NN	NN	_	33	NMOD	_	_
33	activity	_	NN	NN	_	30	PMOD	_	_
34	.	_	.	.	_	11	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	this	_	DT	DT	_	5	NMOD	_	_
5	sequence	_	NN	NN	_	6	SBJ	_	_
6	binds	_	VBZ	VBZ	_	3	VMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	transcription	_	NN	NN	_	10	NMOD	_	_
9	factor	_	NN	NN	_	10	NMOD	_	_
10	Sp1	_	NN	NN	_	6	OBJ	_	_
11	in	_	FW	FW	_	6	ADV	_	_
12	vitro	_	FW	FW	_	11	AMOD	_	_
13	and	_	CC	CC	_	11	CC	_	_
14	in	_	FW	FW	_	11	COORD	_	_
15	vivo	_	FW	FW	_	14	AMOD	_	_
16	.	_	.	.	_	2	P	_	_

1	In	_	FW	FW	_	6	ADV	_	_
2	vivo	_	FW	FW	_	1	AMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	Sp1	_	NN	NN	_	5	NMOD	_	_
5	site	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	bound	_	VBN	VBN	_	6	VC	_	_
8	only	_	RB	RB	_	9	DEP	_	_
9	in	_	IN	IN	_	7	ADV	_	_
10	myeloid	_	JJ	JJ	_	14	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	U937	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	cells	_	NNS	NNS	_	9	PMOD	_	_
15	,	_	,	,	_	9	P	_	_
16	not	_	RB	RB	_	17	DEP	_	_
17	in	_	IN	IN	_	9	COORD	_	_
18	cervical	_	JJ	JJ	_	19	NMOD	_	_
19	carcinoma	_	NN	NN	_	23	NMOD	_	_
20	(	_	(	(	_	21	P	_	_
21	HeLa	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	cells	_	NNS	NNS	_	17	PMOD	_	_
24	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	9	P	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	macrophage	_	NN	NN	_	8	NMOD	_	_
6	transcription	_	NN	NN	_	8	NMOD	_	_
7	factor	_	NN	NN	_	8	NMOD	_	_
8	PU.1	_	NN	NN	_	9	SBJ	_	_
9	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	CD11b	_	NN	NN	_	12	NMOD	_	_
12	promoter	_	NN	NN	_	9	OBJ	_	_
13	in	_	FW	FW	_	9	ADV	_	_
14	vitro	_	FW	FW	_	13	AMOD	_	_
15	and	_	CC	CC	_	13	CC	_	_
16	in	_	FW	FW	_	13	COORD	_	_
17	vivo	_	FW	FW	_	16	AMOD	_	_
18	close	_	RB	RB	_	9	ADV	_	_
19	to	_	TO	TO	_	18	AMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	Sp1	_	NN	NN	_	22	NMOD	_	_
22	site	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	propose	_	VBP	VBP	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	model	_	NN	NN	_	2	OBJ	_	_
5	in	_	IN	IN	_	15	ADV	_	_
6	which	_	WDT	WDT	_	5	PMOD	_	_
7	binding	_	NN	NN	_	15	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	myeloid-specific	_	JJ	JJ	_	11	NMOD	_	_
11	factor	_	NN	NN	_	8	PMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	PU.1	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	allows	_	VBZ	VBZ	_	4	NMOD	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	general	_	JJ	JJ	_	18	NMOD	_	_
18	factor	_	NN	NN	_	23	SBJ	_	_
19	(	_	(	(	_	20	P	_	_
20	Sp1	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	bind	_	VB	VB	_	15	OBJ	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	tissue-specific	_	JJ	JJ	_	27	NMOD	_	_
27	fashion	_	NN	NN	_	24	PMOD	_	_
28	thereby	_	RB	RB	_	29	ADV	_	_
29	contributing	_	VBG	VBG	_	15	ADV	_	_
30	to	_	TO	TO	_	29	ADV	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	myeloid-specific	_	JJ	JJ	_	33	NMOD	_	_
33	expression	_	NN	NN	_	30	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	CD11b	_	NN	NN	_	34	PMOD	_	_
36	.	_	.	.	_	2	P	_	_

1	Functional	_	JJ	JJ	_	2	NMOD	_	_
2	antagonism	_	NN	NN	_	0	ROOT-FRAG	_	_
3	between	_	IN	IN	_	2	NMOD	_	_
4	vitamin	_	NN	NN	_	5	NMOD	_	_
5	D3	_	NN	NN	_	3	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	retinoic	_	JJ	JJ	_	8	NMOD	_	_
8	acid	_	NN	NN	_	5	COORD	_	_
9	in	_	IN	IN	_	2	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	regulation	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	CD14	_	NN	NN	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	CD23	_	NN	NN	_	13	COORD	_	_
16	expression	_	NN	NN	_	12	PMOD	_	_
17	during	_	IN	IN	_	11	TMP	_	_
18	monocytic	_	JJ	JJ	_	19	NMOD	_	_
19	differentiation	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	U-937	_	NN	NN	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	2	P	_	_

1	1,25	_	CD	CD	_	2	NMOD	_	_
2	alpha-Dihydroxicholecalciferol	_	NN	NN	_	12	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	VitD3	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	and	_	CC	CC	_	2	CC	_	_
7	retinoic	_	JJ	JJ	_	8	NMOD	_	_
8	acid	_	NN	NN	_	2	COORD	_	_
9	(	_	(	(	_	10	P	_	_
10	RA	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	are	_	VBP	VBP	_	0	ROOT-S	_	_
13	important	_	JJ	JJ	_	14	NMOD	_	_
14	regulators	_	NNS	NNS	_	12	PRD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	proliferation	_	NN	NN	_	15	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	differentiation	_	NN	NN	_	17	COORD	_	_
20	of	_	IN	IN	_	17	NMOD	_	_
21	several	_	JJ	JJ	_	23	NMOD	_	_
22	cell	_	NN	NN	_	23	NMOD	_	_
23	types	_	NNS	NNS	_	20	PMOD	_	_
24	.	_	.	.	_	12	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	paper	_	NN	NN	_	3	SBJ	_	_
3	describes	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	how	_	WRB	WRB	_	27	ADV	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	expression	_	NN	NN	_	25	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	monocyte-macrophage	_	JJ	JJ	_	10	NMOD	_	_
10	Ag	_	NN	NN	_	7	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	CD14	_	NN	NN	_	10	NMOD	_	_
13	,	_	,	,	_	10	P	_	_
14	and	_	CC	CC	_	6	CC	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	low	_	JJ	JJ	_	19	NMOD	_	_
17	affinity	_	NN	NN	_	19	NMOD	_	_
18	Fc	_	NN	NN	_	19	NMOD	_	_
19	receptor	_	NN	NN	_	6	COORD	_	_
20	for	_	IN	IN	_	19	NMOD	_	_
21	IgE	_	NN	NN	_	20	PMOD	_	_
22	,	_	,	,	_	19	P	_	_
23	CD23	_	NN	NN	_	19	NMOD	_	_
24	,	_	,	,	_	19	P	_	_
25	were	_	VBD	VBD	_	3	OBJ	_	_
26	inversely	_	RB	RB	_	27	ADV	_	_
27	regulated	_	VBN	VBN	_	25	VC	_	_
28	during	_	IN	IN	_	27	TMP	_	_
29	VitD3-	_	NN	NN	_	33	NMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	RA-induced	_	JJ	JJ	_	29	COORD	_	_
32	monocytic	_	JJ	JJ	_	33	NMOD	_	_
33	differentiation	_	NN	NN	_	28	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	human	_	JJ	JJ	_	37	NMOD	_	_
36	U-937	_	NN	NN	_	37	NMOD	_	_
37	monoblasts	_	NNS	NNS	_	34	PMOD	_	_
38	.	_	.	.	_	3	P	_	_

1	PMA	_	NN	NN	_	2	SBJ	_	_
2	induced	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	expression	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	both	_	CC	CC	_	7	CC	_	_
7	CD14	_	NN	NN	_	5	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	CD23	_	NN	NN	_	7	COORD	_	_
10	mRNA	_	NN	NN	_	7	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	protein	_	NN	NN	_	10	COORD	_	_
13	.	_	.	.	_	2	P	_	_

1	Exposure	_	NN	NN	_	5	SBJ	_	_
2	to	_	TO	TO	_	1	NMOD	_	_
3	VitD3	_	NN	NN	_	2	PMOD	_	_
4	rapidly	_	RB	RB	_	5	TMP	_	_
5	induced	_	VBD	VBD	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	de	_	FW	FW	_	8	AMOD	_	_
8	novo	_	FW	FW	_	9	NMOD	_	_
9	expression	_	NN	NN	_	5	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	CD14	_	NN	NN	_	10	PMOD	_	_
12	mRNA	_	NN	NN	_	11	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	protein	_	NN	NN	_	12	COORD	_	_
15	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	addition	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	cycloheximide	_	NN	NN	_	3	PMOD	_	_
5	completely	_	RB	RB	_	6	ADV	_	_
6	blocked	_	VBD	VBD	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	VitD3	_	NN	NN	_	9	NMOD	_	_
9	induction	_	NN	NN	_	6	IOBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	CD14	_	NN	NN	_	13	NMOD	_	_
12	mRNA	_	NN	NN	_	13	NMOD	_	_
13	expression	_	NN	NN	_	10	PMOD	_	_
14	,	_	,	,	_	6	P	_	_
15	indicating	_	VBG	VBG	_	6	OBJ	_	_
16	that	_	IN	IN	_	15	OBJ	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	induction	_	NN	NN	_	19	SBJ	_	_
19	was	_	VBD	VBD	_	16	VMOD	_	_
20	dependent	_	JJ	JJ	_	19	PRD	_	_
21	on	_	IN	IN	_	20	AMOD	_	_
22	ongoing	_	JJ	JJ	_	24	NMOD	_	_
23	protein	_	NN	NN	_	24	NMOD	_	_
24	synthesis	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	6	P	_	_

1	While	_	IN	IN	_	8	ADV	_	_
2	inducing	_	VBG	VBG	_	1	VMOD	_	_
3	CD14	_	NN	NN	_	4	NMOD	_	_
4	expression	_	NN	NN	_	2	OBJ	_	_
5	,	_	,	,	_	8	P	_	_
6	VitD3	_	NN	NN	_	8	SBJ	_	_
7	concomitantly	_	RB	RB	_	8	TMP	_	_
8	suppressed	_	VBD	VBD	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	17	NMOD	_	_
10	basal	_	JJ	JJ	_	17	NMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	PMA-	_	NN	NN	_	10	COORD	_	_
13	,	_	,	,	_	10	P	_	_
14	and	_	CC	CC	_	10	CC	_	_
15	RA-inducible	_	JJ	JJ	_	10	COORD	_	_
16	CD23	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	8	OBJ	_	_
18	in	_	IN	IN	_	8	ADV	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	dose-dependent	_	JJ	JJ	_	21	NMOD	_	_
21	manner	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	10	P	_	_
4	U-937	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	10	SBJ	_	_
6	induced	_	VBN	VBN	_	5	NMOD	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	RA	_	NN	NN	_	7	PMOD	_	_
9	strongly	_	RB	RB	_	10	ADV	_	_
10	increased	_	VBD	VBD	_	0	ROOT-S	_	_
11	their	_	PRP$	PRP$	_	12	NMOD	_	_
12	expression	_	NN	NN	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	CD23	_	NN	NN	_	13	PMOD	_	_
15	mRNA	_	NN	NN	_	14	NMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	protein	_	NN	NN	_	15	COORD	_	_
18	,	_	,	,	_	10	P	_	_
19	whereas	_	IN	IN	_	10	COORD	_	_
20	they	_	PRP	PRP	_	22	SBJ	_	_
21	completely	_	RB	RB	_	22	ADV	_	_
22	lacked	_	VBD	VBD	_	10	COORD	_	_
23	detectable	_	JJ	JJ	_	29	NMOD	_	_
24	CD14	_	NN	NN	_	29	NMOD	_	_
25	cell	_	NN	NN	_	26	NMOD	_	_
26	surface	_	NN	NN	_	29	NMOD	_	_
27	or	_	CC	CC	_	26	CC	_	_
28	mRNA	_	NN	NN	_	26	COORD	_	_
29	expression	_	NN	NN	_	22	OBJ	_	_
30	.	_	.	.	_	10	P	_	_

1	Furthermore	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	the	_	DT	DT	_	9	NMOD	_	_
4	VitD3-	_	NN	NN	_	9	NMOD	_	_
5	and	_	CC	CC	_	9	CC	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	PMA-induced	_	JJ	JJ	_	9	NMOD	_	_
8	CD14	_	NN	NN	_	9	NMOD	_	_
9	expression	_	NN	NN	_	10	SBJ	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	inhibited	_	VBN	VBN	_	10	VC	_	_
12	as	_	IN	IN	_	11	ADV	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	temporal	_	JJ	JJ	_	15	NMOD	_	_
15	consequence	_	NN	NN	_	12	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	RA-induced	_	JJ	JJ	_	19	NMOD	_	_
19	differentiation	_	NN	NN	_	16	PMOD	_	_
20	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	there	_	EX	EX	_	6	SBJ	_	_
6	exists	_	VBZ	VBZ	_	4	VMOD	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	functional	_	JJ	JJ	_	9	NMOD	_	_
9	antagonism	_	NN	NN	_	6	PRD	_	_
10	between	_	IN	IN	_	9	NMOD	_	_
11	VitD3	_	NN	NN	_	10	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	RA	_	NN	NN	_	11	COORD	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	may	_	MD	MD	_	9	NMOD	_	_
16	have	_	VB	VB	_	15	VC	_	_
17	important	_	JJ	JJ	_	18	NMOD	_	_
18	implications	_	NNS	NNS	_	16	OBJ	_	_
19	for	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	regulation	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	certain	_	JJ	JJ	_	27	NMOD	_	_
24	immune	_	JJ	JJ	_	27	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	inflammatory	_	JJ	JJ	_	24	COORD	_	_
27	responses	_	NNS	NNS	_	22	PMOD	_	_
28	through	_	IN	IN	_	16	ADV	_	_
29	their	_	PRP$	PRP$	_	31	NMOD	_	_
30	inverse	_	JJ	JJ	_	31	NMOD	_	_
31	effects	_	NNS	NNS	_	28	PMOD	_	_
32	on	_	IN	IN	_	31	NMOD	_	_
33	CD14	_	NN	NN	_	37	NMOD	_	_
34	and	_	CC	CC	_	33	CC	_	_
35	CD23	_	NN	NN	_	33	COORD	_	_
36	gene	_	NN	NN	_	37	NMOD	_	_
37	expression	_	NN	NN	_	32	PMOD	_	_
38	.	_	.	.	_	3	P	_	_

1	Lymphocytes	_	NNS	NNS	_	7	SBJ	_	_
2	from	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	site	_	NN	NN	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	disease	_	NN	NN	_	5	PMOD	_	_
7	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
8	adenovirus	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	7	OBJ	_	_
10	one	_	CD	CD	_	11	NMOD	_	_
11	cause	_	NN	NN	_	9	PRD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	persistent	_	JJ	JJ	_	17	NMOD	_	_
14	or	_	CC	CC	_	13	CC	_	_
15	recurrent	_	JJ	JJ	_	13	COORD	_	_
16	inflammatory	_	JJ	JJ	_	17	NMOD	_	_
17	arthritis	_	NN	NN	_	12	PMOD	_	_
18	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	assessment	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	synovial	_	JJ	JJ	_	6	NMOD	_	_
5	lymphocyte	_	NN	NN	_	6	NMOD	_	_
6	reactivity	_	NN	NN	_	3	PMOD	_	_
7	to	_	TO	TO	_	6	NMOD	_	_
8	adenovirus	_	NN	NN	_	10	NMOD	_	_
9	antigen	_	NN	NN	_	10	NMOD	_	_
10	stimulation	_	NN	NN	_	7	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	undertaken	_	VBN	VBN	_	11	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	patients	_	NNS	NNS	_	13	PMOD	_	_
15	with	_	IN	IN	_	14	NMOD	_	_
16	persistent	_	JJ	JJ	_	20	NMOD	_	_
17	or	_	CC	CC	_	16	CC	_	_
18	recurrent	_	JJ	JJ	_	16	COORD	_	_
19	inflammatory	_	JJ	JJ	_	20	NMOD	_	_
20	arthritis	_	NN	NN	_	15	PMOD	_	_
21	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	3H-thymidine	_	JJ	JJ	_	4	NMOD	_	_
3	uptake	_	NN	NN	_	4	NMOD	_	_
4	procedure	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	employed	_	VBN	VBN	_	5	VC	_	_
7	,	_	,	,	_	6	P	_	_
8	incorporating	_	VBG	VBG	_	6	OBJ	_	_
9	multiple	_	JJ	JJ	_	11	NMOD	_	_
10	microbiological	_	JJ	JJ	_	11	NMOD	_	_
11	antigens	_	NNS	NNS	_	8	OBJ	_	_
12	.	_	.	.	_	5	P	_	_

1	Five	_	CD	CD	_	2	NMOD	_	_
2	patients	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	found	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	OBJ	_	_
6	repeated	_	VBN	VBN	_	8	NMOD	_	_
7	maximal	_	JJ	JJ	_	8	NMOD	_	_
8	responses	_	NNS	NNS	_	5	PMOD	_	_
9	to	_	TO	TO	_	8	NMOD	_	_
10	adenovirus	_	NN	NN	_	11	NMOD	_	_
11	antigen	_	NN	NN	_	9	PMOD	_	_
12	;	_	:	:	_	3	P	_	_
13	in	_	IN	IN	_	20	ADV	_	_
14	one	_	CD	CD	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	these	_	DT	DT	_	15	PMOD	_	_
17	adenovirus	_	NN	NN	_	19	NMOD	_	_
18	nucleotide	_	NN	NN	_	19	NMOD	_	_
19	sequences	_	NNS	NNS	_	20	SBJ	_	_
20	were	_	VBD	VBD	_	3	COORD	_	_
21	present	_	JJ	JJ	_	20	PRD	_	_
22	in	_	IN	IN	_	21	AMOD	_	_
23	a	_	DT	DT	_	26	NMOD	_	_
24	synovial	_	JJ	JJ	_	26	NMOD	_	_
25	biopsy	_	NN	NN	_	26	NMOD	_	_
26	specimen	_	NN	NN	_	22	PMOD	_	_
27	.	_	.	.	_	3	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	concluded	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	adenovirus	_	NN	NN	_	6	SBJ	_	_
6	may	_	MD	MD	_	4	VMOD	_	_
7	be	_	VB	VB	_	6	VC	_	_
8	one	_	CD	CD	_	9	NMOD	_	_
9	cause	_	NN	NN	_	7	PRD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	persistent	_	JJ	JJ	_	15	NMOD	_	_
12	or	_	CC	CC	_	11	CC	_	_
13	recurrent	_	JJ	JJ	_	11	COORD	_	_
14	inflammatory	_	JJ	JJ	_	15	NMOD	_	_
15	arthritis	_	NN	NN	_	10	PMOD	_	_
16	.	_	.	.	_	2	P	_	_

1	HIV-1	_	NN	NN	_	3	NMOD	_	_
2	Nef	_	NN	NN	_	3	NMOD	_	_
3	protein	_	NN	NN	_	4	SBJ	_	_
4	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	recruitment	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	AP-1	_	NN	NN	_	10	NMOD	_	_
9	DNA-binding	_	JJ	JJ	_	10	NMOD	_	_
10	activity	_	NN	NN	_	7	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	human	_	JJ	JJ	_	13	NMOD	_	_
13	T-cells	_	NNS	NNS	_	11	PMOD	_	_
14	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	9	NMOD	_	_
2	human	_	JJ	JJ	_	9	NMOD	_	_
3	immunodeficiency	_	NN	NN	_	9	NMOD	_	_
4	virus	_	NN	NN	_	9	NMOD	_	_
5	type	_	NN	NN	_	9	NMOD	_	_
6	1	_	CD	CD	_	9	NMOD	_	_
7	long	_	JJ	JJ	_	9	NMOD	_	_
8	terminal	_	JJ	JJ	_	9	NMOD	_	_
9	repeat	_	NN	NN	_	13	SBJ	_	_
10	,	_	,	,	_	9	P	_	_
11	HIV-1-LTR	_	NN	NN	_	9	NMOD	_	_
12	,	_	,	,	_	9	P	_	_
13	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	binding	_	VBG	VBG	_	15	NMOD	_	_
15	sites	_	NNS	NNS	_	13	OBJ	_	_
16	for	_	IN	IN	_	15	NMOD	_	_
17	several	_	JJ	JJ	_	20	NMOD	_	_
18	cellular	_	JJ	JJ	_	20	NMOD	_	_
19	transcription	_	NN	NN	_	20	NMOD	_	_
20	factors	_	NNS	NNS	_	16	PMOD	_	_
21	which	_	WDT	WDT	_	22	SBJ	_	_
22	contribute	_	VBP	VBP	_	20	NMOD	_	_
23	to	_	TO	TO	_	22	ADV	_	_
24	HIV-1	_	NN	NN	_	26	NMOD	_	_
25	gene	_	NN	NN	_	26	NMOD	_	_
26	expression	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	13	P	_	_

1	Our	_	PRP$	PRP$	_	3	NMOD	_	_
2	previous	_	JJ	JJ	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	12	SBJ	_	_
4	on	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	function	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	HIV-1-encoded	_	JJ	JJ	_	11	NMOD	_	_
10	Nef	_	NN	NN	_	11	NMOD	_	_
11	protein	_	NN	NN	_	7	PMOD	_	_
12	suggested	_	VBD	VBD	_	0	ROOT-S	_	_
13	that	_	IN	IN	_	12	OBJ	_	_
14	Nef	_	NN	NN	_	15	SBJ	_	_
15	may	_	MD	MD	_	13	VMOD	_	_
16	be	_	VB	VB	_	15	VC	_	_
17	an	_	DT	DT	_	20	NMOD	_	_
18	inhibitor	_	NN	NN	_	20	NMOD	_	_
19	HIV-1	_	NN	NN	_	20	NMOD	_	_
20	transcription	_	NN	NN	_	16	PRD	_	_
21	.	_	.	.	_	12	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	determine	_	VB	VB	_	23	VC	_	_
3	whether	_	IN	IN	_	2	OBJ	_	_
4	Nef	_	NN	NN	_	5	SBJ	_	_
5	affects	_	VBZ	VBZ	_	3	VMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	binding	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	cellular	_	JJ	JJ	_	10	NMOD	_	_
10	factors	_	NNS	NNS	_	8	PMOD	_	_
11	implicated	_	VBN	VBN	_	7	NMOD	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	HIV-1	_	NN	NN	_	14	NMOD	_	_
14	regulation	_	NN	NN	_	12	PMOD	_	_
15	,	_	,	,	_	23	P	_	_
16	32P-labeled	_	JJ	JJ	_	17	NMOD	_	_
17	oligonucleotides	_	NNS	NNS	_	23	SBJ	_	_
18	corresponding	_	VBG	VBG	_	17	NMOD	_	_
19	to	_	TO	TO	_	18	ADV	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	binding	_	VBG	VBG	_	22	NMOD	_	_
22	sites	_	NNS	NNS	_	19	PMOD	_	_
23	were	_	VBD	VBD	_	0	ROOT-S	_	_
24	incubated	_	VBN	VBN	_	23	VC	_	_
25	with	_	IN	IN	_	24	ADV	_	_
26	nuclear	_	JJ	JJ	_	27	NMOD	_	_
27	extracts	_	NNS	NNS	_	25	PMOD	_	_
28	prepared	_	VBN	VBN	_	27	NMOD	_	_
29	from	_	IN	IN	_	28	ADV	_	_
30	Nef-expressing	_	JJ	JJ	_	32	NMOD	_	_
31	T-cell	_	NN	NN	_	32	NMOD	_	_
32	lines	_	NNS	NNS	_	29	PMOD	_	_
33	that	_	WDT	WDT	_	34	SBJ	_	_
34	were	_	VBD	VBD	_	32	NMOD	_	_
35	not	_	RB	RB	_	34	VMOD	_	_
36	stimulated	_	VBN	VBN	_	34	VC	_	_
37	or	_	CC	CC	_	34	CC	_	_
38	were	_	VBD	VBD	_	34	COORD	_	_
39	stimulated	_	VBN	VBN	_	38	VC	_	_
40	with	_	IN	IN	_	34	ADV	_	_
41	T-cell	_	NN	NN	_	42	NMOD	_	_
42	mitogens	_	NNS	NNS	_	40	PMOD	_	_
43	.	_	.	.	_	23	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	found	_	VBD	VBD	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	Nef	_	NN	NN	_	5	SBJ	_	_
5	inhibited	_	VBD	VBD	_	3	VMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	recruitment	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	AP-1	_	NN	NN	_	11	NMOD	_	_
10	DNA-binding	_	JJ	JJ	_	11	NMOD	_	_
11	activity	_	NN	NN	_	8	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	mitogen-stimulated	_	JJ	JJ	_	15	NMOD	_	_
14	human	_	JJ	JJ	_	15	NMOD	_	_
15	T-cells	_	NNS	NNS	_	12	PMOD	_	_
16	.	_	.	.	_	2	P	_	_

1	Additionally	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	Nef	_	NN	NN	_	5	NMOD	_	_
4	expressing	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	6	SBJ	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	transiently	_	RB	RB	_	8	TMP	_	_
8	transfected	_	VBN	VBN	_	6	VC	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	a	_	DT	DT	_	11	NMOD	_	_
11	plasmid	_	NN	NN	_	9	PMOD	_	_
12	in	_	IN	IN	_	20	ADV	_	_
13	which	_	WDT	WDT	_	12	PMOD	_	_
14	HIV-1	_	NN	NN	_	18	NMOD	_	_
15	AP-1	_	NN	NN	_	18	NMOD	_	_
16	DNA	_	NN	NN	_	18	NMOD	_	_
17	recognition	_	NN	NN	_	18	NMOD	_	_
18	sequences	_	NNS	NNS	_	19	SBJ	_	_
19	were	_	VBD	VBD	_	11	NMOD	_	_
20	cloned	_	VBN	VBN	_	19	VC	_	_
21	downstream	_	RB	RB	_	20	ADV	_	_
22	of	_	IN	IN	_	21	AMOD	_	_
23	the	_	DT	DT	_	29	NMOD	_	_
24	chloramphenicol	_	NN	NN	_	25	NMOD	_	_
25	acetyltransferase	_	NN	NN	_	29	NMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	CAT	_	NN	NN	_	25	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	gene	_	NN	NN	_	22	PMOD	_	_
30	.	_	.	.	_	6	P	_	_

1	Mitogen-mediated	_	JJ	JJ	_	3	NMOD	_	_
2	transcriptional	_	JJ	JJ	_	3	NMOD	_	_
3	activation	_	NN	NN	_	11	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	CAT	_	NN	NN	_	7	NMOD	_	_
7	gene	_	NN	NN	_	4	PMOD	_	_
8	in	_	IN	IN	_	3	NMOD	_	_
9	this	_	DT	DT	_	10	NMOD	_	_
10	construct	_	NN	NN	_	8	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	inhibited	_	VBN	VBN	_	11	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	Nef-expressing	_	JJ	JJ	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	13	PMOD	_	_
16	but	_	CC	CC	_	13	CC	_	_
17	not	_	RB	RB	_	18	DEP	_	_
18	in	_	IN	IN	_	13	COORD	_	_
19	control	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	11	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	,	_	,	,	_	12	ADV	_	_
6	by	_	IN	IN	_	8	VMOD	_	_
7	inhibiting	_	VBG	VBG	_	8	NMOD	_	_
8	AP-1	_	NN	NN	_	5	COORD	_	_
9	activation	_	NN	NN	_	12	VMOD	_	_
10	,	_	,	,	_	12	SBJ	_	_
11	Nef	_	NN	NN	_	12	VMOD	_	_
12	may	_	MD	MD	_	4	VMOD	_	_
13	play	_	VB	VB	_	14	NMOD	_	_
14	a	_	DT	DT	_	12	OBJ	_	_
15	role	_	NN	NN	_	12	ADV	_	_
16	in	_	IN	IN	_	19	VMOD	_	_
17	regulating	_	VBG	VBG	_	19	NMOD	_	_
18	HIV-1	_	NN	NN	_	19	NMOD	_	_
19	gene	_	NN	NN	_	15	PMOD	_	_
20	expression	_	NN	NN	_	19	NMOD	_	_
21	in	_	IN	IN	_	22	NMOD	_	_
22	infected	_	JJ	JJ	_	20	PMOD	_	_
23	T-cells	_	NNS	NNS	_	3	VMOD	_	_

1	A	_	DT	DT	_	9	NMOD	_	_
2	chimeric	_	JJ	JJ	_	9	NMOD	_	_
3	type	_	NN	NN	_	9	NMOD	_	_
4	II	_	CD	CD	_	9	NMOD	_	_
5	\/	_	:	:	_	9	P	_	_
6	type	_	NN	NN	_	9	NMOD	_	_
7	I	_	CD	CD	_	9	NMOD	_	_
8	interleukin-1	_	NN	NN	_	9	NMOD	_	_
9	receptor	_	NN	NN	_	10	SBJ	_	_
10	can	_	MD	MD	_	0	ROOT-S	_	_
11	mediate	_	VB	VB	_	10	VC	_	_
12	interleukin-1	_	NN	NN	_	13	NMOD	_	_
13	induction	_	NN	NN	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	gene	_	NN	NN	_	16	NMOD	_	_
16	expression	_	NN	NN	_	14	PMOD	_	_
17	in	_	IN	IN	_	13	NMOD	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	type	_	NN	NN	_	9	SBJ	_	_
3	I	_	CD	CD	_	2	NMOD	_	_
4	interleukin-1	_	NN	NN	_	5	NMOD	_	_
5	receptor	_	NN	NN	_	2	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	IL-1R	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	capable	_	JJ	JJ	_	9	PRD	_	_
11	of	_	IN	IN	_	10	AMOD	_	_
12	transducing	_	VBG	VBG	_	11	PMOD	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	signal	_	NN	NN	_	12	OBJ	_	_
15	resulting	_	VBG	VBG	_	14	NMOD	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	promoter	_	NN	NN	_	18	NMOD	_	_
18	activation	_	NN	NN	_	16	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	T	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	19	PMOD	_	_
22	.	_	.	.	_	9	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	signal	_	NN	NN	_	3	NMOD	_	_
3	transduction	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	dependent	_	JJ	JJ	_	4	PRD	_	_
6	on	_	IN	IN	_	5	AMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	cytoplasmic	_	JJ	JJ	_	9	NMOD	_	_
9	domain	_	NN	NN	_	6	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	consists	_	VBZ	VBZ	_	9	NMOD	_	_
13	of	_	IN	IN	_	12	ADV	_	_
14	213	_	CD	CD	_	16	NMOD	_	_
15	amino	_	NN	NN	_	16	NMOD	_	_
16	acids	_	NNS	NNS	_	13	PMOD	_	_
17	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	13	ADV	_	_
2	contrast	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	type	_	NN	NN	_	7	NMOD	_	_
6	I	_	CD	CD	_	7	NMOD	_	_
7	receptor	_	NN	NN	_	1	PMOD	_	_
8	,	_	,	,	_	13	P	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	type	_	NN	NN	_	12	NMOD	_	_
11	II	_	CD	CD	_	12	NMOD	_	_
12	IL-1R	_	NN	NN	_	13	SBJ	_	_
13	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	a	_	DT	DT	_	17	NMOD	_	_
15	small	_	JJ	JJ	_	17	NMOD	_	_
16	cytoplasmic	_	JJ	JJ	_	17	NMOD	_	_
17	tail	_	NN	NN	_	13	OBJ	_	_
18	,	_	,	,	_	13	P	_	_
19	and	_	CC	CC	_	13	CC	_	_
20	it	_	PRP	PRP	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	13	COORD	_	_
22	not	_	RB	RB	_	21	VMOD	_	_
23	clear	_	JJ	JJ	_	21	PRD	_	_
24	whether	_	IN	IN	_	21	EXP	_	_
25	this	_	DT	DT	_	26	NMOD	_	_
26	receptor	_	NN	NN	_	27	SBJ	_	_
27	is	_	VBZ	VBZ	_	24	VMOD	_	_
28	a	_	DT	DT	_	33	NMOD	_	_
29	signal-transducing	_	JJ	JJ	_	33	NMOD	_	_
30	or	_	CC	CC	_	33	CC	_	_
31	a	_	DT	DT	_	33	NMOD	_	_
32	regulatory	_	JJ	JJ	_	33	NMOD	_	_
33	molecule	_	NN	NN	_	27	PRD	_	_
34	.	_	.	.	_	13	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	report	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	type	_	NN	NN	_	8	NMOD	_	_
7	II	_	CD	CD	_	8	NMOD	_	_
8	IL-1R	_	NN	NN	_	9	SBJ	_	_
9	does	_	VBZ	VBZ	_	4	VMOD	_	_
10	not	_	RB	RB	_	9	VMOD	_	_
11	mediate	_	VB	VB	_	9	VC	_	_
12	gene	_	NN	NN	_	13	NMOD	_	_
13	activation	_	NN	NN	_	11	OBJ	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	Jurkat	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	30	ADV	_	_
2	,	_	,	,	_	30	P	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	hybrid	_	NN	NN	_	5	NMOD	_	_
5	receptor	_	NN	NN	_	30	SBJ	_	_
6	composed	_	VBN	VBN	_	5	NMOD	_	_
7	of	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	extracellular	_	JJ	JJ	_	12	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	transmembrane	_	NN	NN	_	9	COORD	_	_
12	regions	_	NNS	NNS	_	7	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	human	_	JJ	JJ	_	18	NMOD	_	_
16	type	_	NN	NN	_	18	NMOD	_	_
17	II	_	CD	CD	_	18	NMOD	_	_
18	interleukin-1	_	NN	NN	_	13	PMOD	_	_
19	fused	_	VBN	VBN	_	18	NMOD	_	_
20	to	_	TO	TO	_	19	ADV	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	cytoplasmic	_	JJ	JJ	_	23	NMOD	_	_
23	domain	_	NN	NN	_	20	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	29	NMOD	_	_
26	human	_	JJ	JJ	_	29	NMOD	_	_
27	type	_	NN	NN	_	29	NMOD	_	_
28	I	_	CD	CD	_	29	NMOD	_	_
29	IL-1R	_	NN	NN	_	24	PMOD	_	_
30	was	_	VBD	VBD	_	0	ROOT-S	_	_
31	capable	_	JJ	JJ	_	30	PRD	_	_
32	of	_	IN	IN	_	31	AMOD	_	_
33	transducing	_	VBG	VBG	_	32	PMOD	_	_
34	a	_	DT	DT	_	35	NMOD	_	_
35	signal	_	NN	NN	_	33	OBJ	_	_
36	across	_	IN	IN	_	33	ADV	_	_
37	the	_	DT	DT	_	38	NMOD	_	_
38	membrane	_	NN	NN	_	36	PMOD	_	_
39	resulting	_	VBG	VBG	_	35	NMOD	_	_
40	in	_	IN	IN	_	39	ADV	_	_
41	a	_	DT	DT	_	42	NMOD	_	_
42	pattern	_	NN	NN	_	40	PMOD	_	_
43	of	_	IN	IN	_	42	NMOD	_	_
44	gene	_	NN	NN	_	45	NMOD	_	_
45	activation	_	NN	NN	_	43	PMOD	_	_
46	identical	_	JJ	JJ	_	45	NMOD	_	_
47	to	_	TO	TO	_	46	AMOD	_	_
48	that	_	DT	DT	_	47	PMOD	_	_
49	mediated	_	VBN	VBN	_	48	NMOD	_	_
50	by	_	IN	IN	_	49	LGS	_	_
51	the	_	DT	DT	_	54	NMOD	_	_
52	type	_	NN	NN	_	54	NMOD	_	_
53	I	_	CD	CD	_	54	NMOD	_	_
54	IL-1R	_	NN	NN	_	50	PMOD	_	_
55	.	_	.	.	_	30	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	extracellular	_	JJ	JJ	_	7	NMOD	_	_
7	domain	_	NN	NN	_	13	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	type	_	NN	NN	_	12	NMOD	_	_
11	II	_	CD	CD	_	12	NMOD	_	_
12	IL-1R	_	NN	NN	_	8	PMOD	_	_
13	was	_	VBD	VBD	_	4	VMOD	_	_
14	capable	_	JJ	JJ	_	13	PRD	_	_
15	of	_	IN	IN	_	14	AMOD	_	_
16	functionally	_	RB	RB	_	17	ADV	_	_
17	interacting	_	VBG	VBG	_	15	PMOD	_	_
18	with	_	IN	IN	_	17	ADV	_	_
19	interleukin-1	_	NN	NN	_	18	PMOD	_	_
20	and	_	CC	CC	_	17	CC	_	_
21	transmitting	_	VBG	VBG	_	17	COORD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	resulting	_	VBG	VBG	_	24	NMOD	_	_
24	signal	_	NN	NN	_	21	OBJ	_	_
25	to	_	TO	TO	_	21	ADV	_	_
26	a	_	DT	DT	_	29	NMOD	_	_
27	heterologous	_	JJ	JJ	_	29	NMOD	_	_
28	cytoplasmic	_	JJ	JJ	_	29	NMOD	_	_
29	domain	_	NN	NN	_	25	PMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	Cloning	_	NN	NN	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	functional	_	JJ	JJ	_	4	NMOD	_	_
4	characterization	_	NN	NN	_	1	COORD	_	_
5	of	_	IN	IN	_	1	NMOD	_	_
6	early	_	JJ	JJ	_	8	NMOD	_	_
7	B-cell	_	NN	NN	_	8	NMOD	_	_
8	factor	_	NN	NN	_	5	PMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	a	_	DT	DT	_	11	NMOD	_	_
11	regulator	_	NN	NN	_	8	NMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	lymphocyte-specific	_	JJ	JJ	_	15	NMOD	_	_
14	gene	_	NN	NN	_	15	NMOD	_	_
15	expression	_	NN	NN	_	12	PMOD	_	_
16	.	_	.	.	_	1	P	_	_

1	Early	_	JJ	JJ	_	3	NMOD	_	_
2	B-cell	_	NN	NN	_	3	NMOD	_	_
3	factor	_	NN	NN	_	7	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	EBF	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	identified	_	VBN	VBN	_	7	VC	_	_
9	previously	_	RB	RB	_	8	TMP	_	_
10	as	_	IN	IN	_	8	ADV	_	_
11	a	_	DT	DT	_	17	NMOD	_	_
12	tissue-specific	_	JJ	JJ	_	17	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	differentiation	_	NN	NN	_	12	COORD	_	_
15	stage-specific	_	JJ	JJ	_	14	AMOD	_	_
16	DNA-binding	_	JJ	JJ	_	17	NMOD	_	_
17	protein	_	NN	NN	_	10	PMOD	_	_
18	that	_	WDT	WDT	_	19	SBJ	_	_
19	participates	_	VBZ	VBZ	_	17	NMOD	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	regulation	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	30	NMOD	_	_
25	pre-B	_	JJ	JJ	_	28	AMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	B	_	NN	NN	_	25	COORD	_	_
28	lymphocyte-specific	_	JJ	JJ	_	30	NMOD	_	_
29	mb-1	_	NN	NN	_	30	NMOD	_	_
30	gene	_	NN	NN	_	23	PMOD	_	_
31	.	_	.	.	_	7	P	_	_

1	Partial	_	JJ	JJ	_	4	NMOD	_	_
2	amino	_	NN	NN	_	4	NMOD	_	_
3	acid	_	NN	NN	_	4	NMOD	_	_
4	sequences	_	NNS	NNS	_	9	SBJ	_	_
5	obtained	_	VBN	VBN	_	4	NMOD	_	_
6	from	_	IN	IN	_	5	ADV	_	_
7	purified	_	VBN	VBN	_	8	NMOD	_	_
8	EBF	_	NN	NN	_	6	PMOD	_	_
9	were	_	VBD	VBD	_	0	ROOT-S	_	_
10	used	_	VBN	VBN	_	9	VC	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	isolate	_	VB	VB	_	10	OBJ	_	_
13	cDNA	_	NN	NN	_	14	NMOD	_	_
14	clones	_	NNS	NNS	_	12	OBJ	_	_
15	,	_	,	,	_	14	P	_	_
16	which	_	WDT	WDT	_	20	SBJ	_	_
17	by	_	IN	IN	_	20	ADV	_	_
18	multiple	_	JJ	JJ	_	19	NMOD	_	_
19	criteria	_	NNS	NNS	_	17	PMOD	_	_
20	encode	_	VB	VB	_	14	NMOD	_	_
21	EBF	_	NN	NN	_	20	OBJ	_	_
22	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	recombinant	_	JJ	JJ	_	3	NMOD	_	_
3	polypeptide	_	NN	NN	_	4	SBJ	_	_
4	formed	_	VBD	VBD	_	0	ROOT-S	_	_
5	sequence-specific	_	JJ	JJ	_	6	NMOD	_	_
6	complexes	_	NNS	NNS	_	4	OBJ	_	_
7	with	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	EBF-binding	_	NN	NN	_	10	NMOD	_	_
10	site	_	NN	NN	_	7	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	mb-1	_	NN	NN	_	14	NMOD	_	_
14	promoter	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	cDNA	_	NN	NN	_	3	SBJ	_	_
3	hybridized	_	VBD	VBD	_	0	ROOT-S	_	_
4	to	_	TO	TO	_	3	ADV	_	_
5	multiple	_	JJ	JJ	_	6	NMOD	_	_
6	transcripts	_	NNS	NNS	_	4	PMOD	_	_
7	in	_	IN	IN	_	3	ADV	_	_
8	pre-B	_	JJ	JJ	_	11	NMOD	_	_
9	and	_	CC	CC	_	11	CC	_	_
10	B-cell	_	NN	NN	_	11	COORD	_	_
11	lines	_	NNS	NNS	_	7	PMOD	_	_
12	,	_	,	,	_	3	P	_	_
13	but	_	CC	CC	_	3	CC	_	_
14	transcripts	_	NNS	NNS	_	15	SBJ	_	_
15	were	_	VBD	VBD	_	3	COORD	_	_
16	not	_	RB	RB	_	15	VMOD	_	_
17	detected	_	VBN	VBN	_	15	VC	_	_
18	at	_	IN	IN	_	17	ADV	_	_
19	significant	_	JJ	JJ	_	20	NMOD	_	_
20	levels	_	NNS	NNS	_	18	PMOD	_	_
21	in	_	IN	IN	_	17	ADV	_	_
22	plasmacytoma	_	NN	NN	_	29	NMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	T-cell	_	NN	NN	_	22	COORD	_	_
25	,	_	,	,	_	22	P	_	_
26	and	_	CC	CC	_	22	CC	_	_
27	nonlymphoid	_	JJ	JJ	_	22	COORD	_	_
28	cell	_	NN	NN	_	29	NMOD	_	_
29	lines	_	NNS	NNS	_	21	PMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	Expression	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	recombinant	_	JJ	JJ	_	4	NMOD	_	_
4	EBF	_	NN	NN	_	2	PMOD	_	_
5	in	_	IN	IN	_	1	NMOD	_	_
6	transfected	_	VBN	VBN	_	8	NMOD	_	_
7	nonlymphoid	_	JJ	JJ	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	5	PMOD	_	_
9	strongly	_	RB	RB	_	10	ADV	_	_
10	activated	_	VBD	VBD	_	0	ROOT-S	_	_
11	transcription	_	NN	NN	_	10	OBJ	_	_
12	from	_	IN	IN	_	11	NMOD	_	_
13	reporter	_	NN	NN	_	14	NMOD	_	_
14	plasmids	_	NNS	NNS	_	12	PMOD	_	_
15	containing	_	VBG	VBG	_	14	NMOD	_	_
16	functional	_	JJ	JJ	_	18	NMOD	_	_
17	EBF-binding	_	JJ	JJ	_	18	NMOD	_	_
18	sites	_	NNS	NNS	_	15	OBJ	_	_
19	.	_	.	.	_	10	P	_	_

1	Analysis	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	DNA	_	NN	NN	_	4	NMOD	_	_
4	binding	_	NN	NN	_	2	PMOD	_	_
5	by	_	IN	IN	_	4	NMOD	_	_
6	deletion	_	NN	NN	_	7	NMOD	_	_
7	mutants	_	NNS	NNS	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	EBF	_	NN	NN	_	8	PMOD	_	_
10	identified	_	VBD	VBD	_	0	ROOT-S	_	_
11	an	_	DT	DT	_	15	NMOD	_	_
12	amino-terminal	_	JJ	JJ	_	15	NMOD	_	_
13	cysteine-rich	_	JJ	JJ	_	15	NMOD	_	_
14	DNA-binding	_	JJ	JJ	_	15	NMOD	_	_
15	domain	_	NN	NN	_	10	OBJ	_	_
16	lacking	_	VBG	VBG	_	15	NMOD	_	_
17	obvious	_	JJ	JJ	_	19	NMOD	_	_
18	sequence	_	NN	NN	_	19	NMOD	_	_
19	similarity	_	NN	NN	_	16	OBJ	_	_
20	to	_	TO	TO	_	19	NMOD	_	_
21	known	_	JJ	JJ	_	23	NMOD	_	_
22	transcription	_	NN	NN	_	23	NMOD	_	_
23	factors	_	NNS	NNS	_	20	PMOD	_	_
24	.	_	.	.	_	10	P	_	_

1	DNA-binding	_	JJ	JJ	_	2	NMOD	_	_
2	assays	_	NNS	NNS	_	11	SBJ	_	_
3	with	_	IN	IN	_	2	NMOD	_	_
4	cotranslated	_	VBN	VBN	_	8	NMOD	_	_
5	wild-type	_	JJ	JJ	_	8	NMOD	_	_
6	and	_	CC	CC	_	8	CC	_	_
7	truncated	_	JJ	JJ	_	8	NMOD	_	_
8	forms	_	NNS	NNS	_	3	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	EBF	_	NN	NN	_	9	PMOD	_	_
11	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
12	that	_	IN	IN	_	11	OBJ	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	protein	_	NN	NN	_	15	SBJ	_	_
15	interacts	_	VBZ	VBZ	_	12	VMOD	_	_
16	with	_	IN	IN	_	15	ADV	_	_
17	its	_	PRP$	PRP$	_	18	NMOD	_	_
18	site	_	NN	NN	_	16	PMOD	_	_
19	as	_	IN	IN	_	15	ADV	_	_
20	a	_	DT	DT	_	21	NMOD	_	_
21	homodimer	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	11	P	_	_

1	Deletions	_	NNS	NNS	_	2	SBJ	_	_
2	delineated	_	VBD	VBD	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	carboxy-terminal	_	JJ	JJ	_	6	NMOD	_	_
5	dimerization	_	NN	NN	_	6	NMOD	_	_
6	region	_	NN	NN	_	2	OBJ	_	_
7	containing	_	VBG	VBG	_	6	NMOD	_	_
8	two	_	CD	CD	_	9	NMOD	_	_
9	repeats	_	NNS	NNS	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	15	_	CD	CD	_	13	NMOD	_	_
12	amino	_	NN	NN	_	13	NMOD	_	_
13	acids	_	NNS	NNS	_	10	PMOD	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	show	_	VBP	VBP	_	9	NMOD	_	_
16	similarity	_	NN	NN	_	15	OBJ	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	dimerization	_	NN	NN	_	20	NMOD	_	_
20	domains	_	NNS	NNS	_	17	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	basic-helix-loop-helix	_	JJ	JJ	_	23	NMOD	_	_
23	proteins	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	2	P	_	_

1	Together	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	data	_	NNS	NNS	_	5	SBJ	_	_
5	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	EBF	_	NN	NN	_	8	SBJ	_	_
8	represents	_	VBZ	VBZ	_	6	VMOD	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	novel	_	JJ	JJ	_	11	NMOD	_	_
11	regulator	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	B	_	NN	NN	_	16	NMOD	_	_
14	lymphocyte-specific	_	JJ	JJ	_	13	AMOD	_	_
15	gene	_	NN	NN	_	16	NMOD	_	_
16	expression	_	NN	NN	_	12	PMOD	_	_
17	.	_	.	.	_	5	P	_	_

1	Oxidoreductive	_	JJ	JJ	_	2	NMOD	_	_
2	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	nuclear	_	JJ	JJ	_	7	NMOD	_	_
5	factor	_	NN	NN	_	7	NMOD	_	_
6	kappa	_	NN	NN	_	7	NMOD	_	_
7	B	_	NN	NN	_	3	PMOD	_	_
8	.	_	.	.	_	2	P	_	_

1	Involvement	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	7	NMOD	_	_
4	cellular	_	JJ	JJ	_	7	NMOD	_	_
5	reducing	_	NN	NN	_	7	NMOD	_	_
6	catalyst	_	NN	NN	_	7	NMOD	_	_
7	thioredoxin	_	NN	NN	_	2	PMOD	_	_
8	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	investigated	_	VBN	VBN	_	2	VC	_	_
4	an	_	DT	DT	_	7	NMOD	_	_
5	oxidoreductive	_	JJ	JJ	_	7	NMOD	_	_
6	regulatory	_	JJ	JJ	_	7	NMOD	_	_
7	pathway	_	NN	NN	_	3	OBJ	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	DNA	_	NN	NN	_	12	NMOD	_	_
11	binding	_	NN	NN	_	12	NMOD	_	_
12	activity	_	NN	NN	_	8	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	a	_	DT	DT	_	18	NMOD	_	_
15	pleiotropic	_	JJ	JJ	_	18	NMOD	_	_
16	cellular	_	JJ	JJ	_	18	NMOD	_	_
17	transcription	_	NN	NN	_	18	NMOD	_	_
18	factor	_	NN	NN	_	13	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	nuclear	_	JJ	JJ	_	23	NMOD	_	_
21	factor	_	NN	NN	_	23	NMOD	_	_
22	kappa	_	NN	NN	_	23	NMOD	_	_
23	B	_	NN	NN	_	18	NMOD	_	_
24	(	_	(	(	_	27	P	_	_
25	NF	_	NN	NN	_	27	NMOD	_	_
26	kappa	_	NN	NN	_	27	NMOD	_	_
27	B	_	NN	NN	_	23	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	,	_	,	,	_	18	P	_	_
30	has	_	VBZ	VBZ	_	3	VMOD	_	_
31	been	_	VBN	VBN	_	3	VMOD	_	_
32	investigated	_	VBN	VBN	_	3	VMOD	_	_
33	by	_	IN	IN	_	3	ADV	_	_
34	using	_	VBG	VBG	_	33	PMOD	_	_
35	NF	_	NN	NN	_	37	NMOD	_	_
36	kappa	_	NN	NN	_	37	NMOD	_	_
37	B	_	NN	NN	_	34	OBJ	_	_
38	prepared	_	VBN	VBN	_	37	NMOD	_	_
39	from	_	IN	IN	_	38	ADV	_	_
40	the	_	DT	DT	_	41	NMOD	_	_
41	nucleus	_	NN	NN	_	39	PMOD	_	_
42	and	_	CC	CC	_	41	CC	_	_
43	the	_	DT	DT	_	44	NMOD	_	_
44	cytosol	_	NN	NN	_	41	COORD	_	_
45	of	_	IN	IN	_	41	NMOD	_	_
46	the	_	DT	DT	_	50	NMOD	_	_
47	primary	_	JJ	JJ	_	50	NMOD	_	_
48	human	_	JJ	JJ	_	50	NMOD	_	_
49	T	_	NN	NN	_	50	NMOD	_	_
50	lymphocytes	_	NNS	NNS	_	45	PMOD	_	_
51	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	cellular	_	JJ	JJ	_	7	NMOD	_	_
6	reducing	_	NN	NN	_	7	NMOD	_	_
7	catalyst	_	NN	NN	_	12	SBJ	_	_
8	thioredoxin	_	NN	NN	_	7	NMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	Trx	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	plays	_	VBZ	VBZ	_	3	VMOD	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	major	_	JJ	JJ	_	15	NMOD	_	_
15	role	_	NN	NN	_	12	OBJ	_	_
16	in	_	IN	IN	_	12	ADV	_	_
17	activation	_	NN	NN	_	16	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	DNA	_	NN	NN	_	21	NMOD	_	_
21	binding	_	NN	NN	_	18	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	NF	_	NN	NN	_	25	NMOD	_	_
24	kappa	_	NN	NN	_	25	NMOD	_	_
25	B	_	NN	NN	_	22	PMOD	_	_
26	in	_	FW	FW	_	21	NMOD	_	_
27	vitro	_	FW	FW	_	26	AMOD	_	_
28	and	_	CC	CC	_	17	CC	_	_
29	stimulation	_	NN	NN	_	17	COORD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	transcription	_	NN	NN	_	30	PMOD	_	_
32	from	_	IN	IN	_	31	NMOD	_	_
33	the	_	DT	DT	_	38	NMOD	_	_
34	NF	_	NN	NN	_	35	AMOD	_	_
35	kappa	_	NN	NN	_	38	NMOD	_	_
36	B-dependent	_	JJ	JJ	_	35	AMOD	_	_
37	gene	_	NN	NN	_	38	NMOD	_	_
38	expression	_	NN	NN	_	32	PMOD	_	_
39	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
3	evidence	_	NN	NN	_	2	OBJ	_	_
4	suggesting	_	VBG	VBG	_	3	NMOD	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	redox	_	NN	NN	_	7	NMOD	_	_
7	regulation	_	NN	NN	_	14	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	NF	_	NN	NN	_	11	NMOD	_	_
10	kappa	_	NN	NN	_	11	NMOD	_	_
11	B	_	NN	NN	_	8	PMOD	_	_
12	by	_	IN	IN	_	7	NMOD	_	_
13	Trx	_	NN	NN	_	12	PMOD	_	_
14	might	_	MD	MD	_	5	VMOD	_	_
15	be	_	VB	VB	_	14	VC	_	_
16	exerted	_	VBN	VBN	_	15	VC	_	_
17	at	_	IN	IN	_	16	TMP	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	step	_	NN	NN	_	17	PMOD	_	_
20	after	_	IN	IN	_	19	TMP	_	_
21	dissociation	_	NN	NN	_	20	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	28	NMOD	_	_
24	inhibitory	_	JJ	JJ	_	28	NMOD	_	_
25	molecule	_	NN	NN	_	28	NMOD	_	_
26	I	_	NN	NN	_	28	NMOD	_	_
27	kappa	_	NN	NN	_	28	NMOD	_	_
28	B	_	NN	NN	_	22	PMOD	_	_
29	,	_	,	,	_	28	P	_	_
30	a	_	DT	DT	_	32	NMOD	_	_
31	cytosolic-anchoring	_	JJ	JJ	_	32	NMOD	_	_
32	protein	_	NN	NN	_	28	NMOD	_	_
33	for	_	IN	IN	_	32	NMOD	_	_
34	NF	_	NN	NN	_	36	NMOD	_	_
35	kappa	_	NN	NN	_	36	NMOD	_	_
36	B	_	NN	NN	_	33	PMOD	_	_
37	.	_	.	.	_	2	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	examine	_	VB	VB	_	12	VMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	effect	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	Trx	_	NN	NN	_	5	PMOD	_	_
7	in	_	IN	IN	_	4	NMOD	_	_
8	intact	_	JJ	JJ	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	7	PMOD	_	_
10	,	_	,	,	_	12	P	_	_
11	we	_	PRP	PRP	_	12	SBJ	_	_
12	performed	_	VBD	VBD	_	0	ROOT-S	_	_
13	transient	_	JJ	JJ	_	14	NMOD	_	_
14	assay	_	NN	NN	_	12	OBJ	_	_
15	with	_	IN	IN	_	12	ADV	_	_
16	a	_	DT	DT	_	19	NMOD	_	_
17	chloramphenicol	_	NN	NN	_	19	NMOD	_	_
18	acetyltransferase-expressing	_	JJ	JJ	_	17	AMOD	_	_
19	plasmid	_	NN	NN	_	15	PMOD	_	_
20	under	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	control	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	human	_	JJ	JJ	_	26	NMOD	_	_
25	immunodeficiency	_	NN	NN	_	26	NMOD	_	_
26	virus	_	NN	NN	_	32	NMOD	_	_
27	(	_	(	(	_	28	P	_	_
28	HIV	_	NN	NN	_	26	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	long	_	JJ	JJ	_	32	NMOD	_	_
31	terminal	_	JJ	JJ	_	32	NMOD	_	_
32	repeat	_	NN	NN	_	23	PMOD	_	_
33	and	_	CC	CC	_	19	CC	_	_
34	an	_	DT	DT	_	36	NMOD	_	_
35	effector	_	NN	NN	_	36	NMOD	_	_
36	plasmid	_	NN	NN	_	19	COORD	_	_
37	expressing	_	VBG	VBG	_	36	NMOD	_	_
38	human	_	JJ	JJ	_	39	NMOD	_	_
39	Trx	_	NN	NN	_	37	OBJ	_	_
40	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	promoter	_	NN	NN	_	3	NMOD	_	_
3	activity	_	NN	NN	_	9	SBJ	_	_
4	from	_	IN	IN	_	3	NMOD	_	_
5	HIV	_	NN	NN	_	8	NMOD	_	_
6	long	_	JJ	JJ	_	8	NMOD	_	_
7	terminal	_	JJ	JJ	_	8	NMOD	_	_
8	repeat	_	NN	NN	_	4	PMOD	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	greatly	_	RB	RB	_	11	ADV	_	_
11	augmented	_	VBN	VBN	_	9	VC	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	co-transfecting	_	VBG	VBG	_	12	PMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	Trx-expressing	_	NN	NN	_	16	NMOD	_	_
16	plasmid	_	NN	NN	_	13	OBJ	_	_
17	,	_	,	,	_	16	P	_	_
18	whose	_	WP$	WP$	_	19	NMOD	_	_
19	effect	_	NN	NN	_	20	SBJ	_	_
20	was	_	VBD	VBD	_	16	NMOD	_	_
21	dependent	_	JJ	JJ	_	20	PRD	_	_
22	on	_	IN	IN	_	21	AMOD	_	_
23	the	_	DT	DT	_	27	NMOD	_	_
24	NF	_	NN	NN	_	26	AMOD	_	_
25	kappa	_	NN	NN	_	26	AMOD	_	_
26	B-binding	_	NN	NN	_	27	NMOD	_	_
27	sites	_	NNS	NNS	_	22	PMOD	_	_
28	.	_	.	.	_	9	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	suggested	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	cysteine	_	NN	NN	_	9	NMOD	_	_
7	residue	_	NN	NN	_	9	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	s	_	NNS	NNS	_	15	SBJ	_	_
10	)	_	)	)	_	9	P	_	_
11	of	_	IN	IN	_	9	NMOD	_	_
12	NF	_	NN	NN	_	14	NMOD	_	_
13	kappa	_	NN	NN	_	14	NMOD	_	_
14	B	_	NN	NN	_	11	PMOD	_	_
15	might	_	MD	MD	_	5	VMOD	_	_
16	be	_	VB	VB	_	15	VC	_	_
17	involved	_	VBN	VBN	_	16	VC	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	DNA-recognition	_	NN	NN	_	18	PMOD	_	_
21	by	_	IN	IN	_	20	NMOD	_	_
22	NF	_	NN	NN	_	24	NMOD	_	_
23	kappa	_	NN	NN	_	24	NMOD	_	_
24	B	_	NN	NN	_	21	PMOD	_	_
25	and	_	CC	CC	_	5	CC	_	_
26	that	_	IN	IN	_	5	COORD	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	redox	_	NN	NN	_	30	NMOD	_	_
29	control	_	NN	NN	_	30	NMOD	_	_
30	mechanism	_	NN	NN	_	34	SBJ	_	_
31	mediated	_	VBN	VBN	_	30	NMOD	_	_
32	by	_	IN	IN	_	31	LGS	_	_
33	Trx	_	NN	NN	_	32	PMOD	_	_
34	might	_	MD	MD	_	26	VMOD	_	_
35	have	_	VB	VB	_	34	VC	_	_
36	a	_	DT	DT	_	38	NMOD	_	_
37	regulatory	_	JJ	JJ	_	38	NMOD	_	_
38	role	_	NN	NN	_	35	OBJ	_	_
39	in	_	IN	IN	_	35	ADV	_	_
40	the	_	DT	DT	_	45	NMOD	_	_
41	NF	_	NN	NN	_	42	AMOD	_	_
42	kappa	_	NN	NN	_	45	NMOD	_	_
43	B-mediated	_	JJ	JJ	_	42	AMOD	_	_
44	gene	_	NN	NN	_	45	NMOD	_	_
45	expression	_	NN	NN	_	39	PMOD	_	_
46	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	may	_	MD	MD	_	0	ROOT-S	_	_
4	also	_	RB	RB	_	3	ADV	_	_
5	provide	_	VB	VB	_	3	VC	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	clue	_	NN	NN	_	5	OBJ	_	_
8	to	_	TO	TO	_	7	NMOD	_	_
9	understanding	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	molecular	_	JJ	JJ	_	13	NMOD	_	_
13	process	_	NN	NN	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	AIDS	_	NN	NN	_	16	NMOD	_	_
16	pathogenesis	_	NN	NN	_	14	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	its	_	PRP$	PRP$	_	21	NMOD	_	_
19	possible	_	JJ	JJ	_	21	NMOD	_	_
20	biochemical	_	JJ	JJ	_	21	NMOD	_	_
21	intervention	_	NN	NN	_	16	COORD	_	_
22	.	_	.	.	_	3	P	_	_

1	Synergism	_	NN	NN	_	0	ROOT-FRAG	_	_
2	between	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	9	NMOD	_	_
4	CD3	_	NN	NN	_	5	NMOD	_	_
5	antigen-	_	NN	NN	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	CD2	_	NN	NN	_	5	COORD	_	_
8	antigen-derived	_	JJ	JJ	_	7	AMOD	_	_
9	signals	_	NNS	NNS	_	2	PMOD	_	_
10	.	_	.	.	_	1	P	_	_

1	Exploration	_	NN	NN	_	0	ROOT-FRAG	_	_
2	at	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	level	_	NN	NN	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	induction	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	DNA-binding	_	JJ	JJ	_	9	NMOD	_	_
9	proteins	_	NNS	NNS	_	7	PMOD	_	_
10	and	_	CC	CC	_	1	CC	_	_
11	characterization	_	NN	NN	_	1	COORD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	inhibitory	_	JJ	JJ	_	15	NMOD	_	_
15	activity	_	NN	NN	_	12	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	cyclosporine	_	NN	NN	_	16	PMOD	_	_
18	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	demonstrated	_	VBN	VBN	_	2	VC	_	_
4	earlier	_	RBR	RBR	_	3	TMP	_	_
5	that	_	IN	IN	_	3	OBJ	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	crosslinkage	_	NN	NN	_	16	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	CD3\/TCR	_	NN	NN	_	11	NMOD	_	_
11	complex	_	NN	NN	_	8	PMOD	_	_
12	with	_	IN	IN	_	7	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	CD2	_	NN	NN	_	15	NMOD	_	_
15	antigen	_	NN	NN	_	12	PMOD	_	_
16	results	_	VBZ	VBZ	_	5	VMOD	_	_
17	in	_	IN	IN	_	16	ADV	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	proliferation	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	normal	_	JJ	JJ	_	24	NMOD	_	_
22	human	_	JJ	JJ	_	24	NMOD	_	_
23	T	_	NN	NN	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	20	PMOD	_	_
25	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	this	_	DT	DT	_	5	NMOD	_	_
5	synergism	_	NN	NN	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	perceptible	_	JJ	JJ	_	6	PRD	_	_
8	at	_	IN	IN	_	6	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	level	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	induction	_	NN	NN	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	IL-2	_	NN	NN	_	16	NMOD	_	_
16	gene	_	NN	NN	_	13	PMOD	_	_
17	,	_	,	,	_	12	P	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	process	_	NN	NN	_	12	NMOD	_	_
20	critical	_	JJ	JJ	_	19	NMOD	_	_
21	for	_	IN	IN	_	20	AMOD	_	_
22	T	_	NN	NN	_	24	NMOD	_	_
23	cell	_	NN	NN	_	24	NMOD	_	_
24	growth	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	6	P	_	_

1	To	_	TO	TO	_	3	VMOD	_	_
2	further	_	RB	RB	_	3	ADV	_	_
3	understand	_	VB	VB	_	14	VMOD	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	molecular	_	JJ	JJ	_	8	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	nuclear	_	JJ	JJ	_	5	COORD	_	_
8	basis	_	NN	NN	_	3	OBJ	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	this	_	DT	DT	_	11	NMOD	_	_
11	synergism	_	NN	NN	_	9	PMOD	_	_
12	,	_	,	,	_	14	P	_	_
13	we	_	PRP	PRP	_	14	SBJ	_	_
14	have	_	VBP	VBP	_	0	ROOT-S	_	_
15	explored	_	VBN	VBN	_	14	VC	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	induction	_	NN	NN	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	DNA-binding	_	JJ	JJ	_	20	NMOD	_	_
20	proteins	_	NNS	NNS	_	18	PMOD	_	_
21	in	_	IN	IN	_	17	NMOD	_	_
22	highly	_	RB	RB	_	23	AMOD	_	_
23	purified	_	VBN	VBN	_	27	NMOD	_	_
24	normal	_	JJ	JJ	_	27	NMOD	_	_
25	human	_	JJ	JJ	_	27	NMOD	_	_
26	T	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	21	PMOD	_	_
28	signaled	_	VBN	VBN	_	27	NMOD	_	_
29	via	_	IN	IN	_	28	ADV	_	_
30	the	_	DT	DT	_	34	NMOD	_	_
31	CD3	_	NN	NN	_	34	NMOD	_	_
32	and\/or	_	CC	CC	_	31	CC	_	_
33	CD2	_	NN	NN	_	31	COORD	_	_
34	proteins	_	NNS	NNS	_	29	PMOD	_	_
35	.	_	.	.	_	14	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	17	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	transmembrane	_	NN	NN	_	5	NMOD	_	_
5	signaling	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	T	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	with	_	IN	IN	_	5	NMOD	_	_
10	ionomycin	_	NN	NN	_	9	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	and\/or	_	CC	CC	_	10	CC	_	_
13	sn-1,2	_	NN	NN	_	15	NMOD	_	_
14	dioctanoyl	_	NN	NN	_	15	NMOD	_	_
15	glycerol	_	NN	NN	_	10	COORD	_	_
16	,	_	,	,	_	10	P	_	_
17	was	_	VBD	VBD	_	0	ROOT-S	_	_
18	also	_	RB	RB	_	17	ADV	_	_
19	determined	_	VBN	VBN	_	17	VC	_	_
20	.	_	.	.	_	17	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	emergence	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	nuclear	_	JJ	JJ	_	6	NMOD	_	_
5	binding	_	NN	NN	_	6	NMOD	_	_
6	proteins	_	NNS	NNS	_	3	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	investigated	_	VBN	VBN	_	7	VC	_	_
9	using	_	VBG	VBG	_	8	OBJ	_	_
10	interleukin-2	_	NN	NN	_	11	AMOD	_	_
11	sequence	_	NN	NN	_	14	NMOD	_	_
12	specific	_	JJ	JJ	_	11	AMOD	_	_
13	oligonucleotide	_	NN	NN	_	14	NMOD	_	_
14	probes	_	NNS	NNS	_	9	OBJ	_	_
15	in	_	IN	IN	_	9	ADV	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	electrophoretic	_	JJ	JJ	_	20	NMOD	_	_
18	mobility	_	NN	NN	_	20	NMOD	_	_
19	shift	_	NN	NN	_	20	NMOD	_	_
20	assay	_	NN	NN	_	15	PMOD	_	_
21	.	_	.	.	_	7	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	for	_	IN	IN	_	3	TMP	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	first	_	JJ	JJ	_	7	NMOD	_	_
7	time	_	NN	NN	_	4	PMOD	_	_
8	that	_	IN	IN	_	3	OBJ	_	_
9	CD3	_	NN	NN	_	11	NMOD	_	_
10	antigen-derived	_	JJ	JJ	_	9	AMOD	_	_
11	signals	_	NNS	NNS	_	16	SBJ	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	CD2	_	NN	NN	_	15	NMOD	_	_
14	antigen-derived	_	JJ	JJ	_	13	AMOD	_	_
15	signals	_	NNS	NNS	_	11	COORD	_	_
16	are	_	VBP	VBP	_	8	VMOD	_	_
17	synergistic	_	JJ	JJ	_	16	PRD	_	_
18	in	_	IN	IN	_	16	ADV	_	_
19	inducing	_	VBG	VBG	_	18	PMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	emergence	_	NN	NN	_	19	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	transcription	_	NN	NN	_	24	NMOD	_	_
24	factors	_	NNS	NNS	_	22	PMOD	_	_
25	that	_	WDT	WDT	_	26	SBJ	_	_
26	bind	_	VBP	VBP	_	24	NMOD	_	_
27	to	_	TO	TO	_	26	ADV	_	_
28	the	_	DT	DT	_	35	NMOD	_	_
29	NF-AT1	_	NN	NN	_	35	NMOD	_	_
30	,	_	,	,	_	29	P	_	_
31	AP-1	_	NN	NN	_	29	COORD	_	_
32	,	_	,	,	_	29	P	_	_
33	and	_	CC	CC	_	29	CC	_	_
34	NF-kB	_	NN	NN	_	29	COORD	_	_
35	sites	_	NNS	NNS	_	27	PMOD	_	_
36	located	_	JJ	JJ	_	35	NMOD	_	_
37	in	_	IN	IN	_	36	AMOD	_	_
38	the	_	DT	DT	_	40	NMOD	_	_
39	promoter\/enhancer	_	NN	NN	_	40	NMOD	_	_
40	region	_	NN	NN	_	37	PMOD	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	the	_	DT	DT	_	44	NMOD	_	_
43	IL-2	_	NN	NN	_	44	NMOD	_	_
44	gene	_	NN	NN	_	41	PMOD	_	_
45	.	_	.	.	_	3	P	_	_

1	Moreover	_	RB	RB	_	13	ADV	_	_
2	,	_	,	,	_	13	P	_	_
3	cyclosporine	_	NN	NN	_	13	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	at	_	IN	IN	_	3	NMOD	_	_
6	concentrations	_	NNS	NNS	_	5	PMOD	_	_
7	readily	_	RB	RB	_	8	ADV	_	_
8	accomplished	_	VBN	VBN	_	6	NMOD	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	clinical	_	JJ	JJ	_	11	NMOD	_	_
11	practice	_	NN	NN	_	9	PMOD	_	_
12	,	_	,	,	_	3	P	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	found	_	VBN	VBN	_	13	VC	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	inhibit	_	VB	VB	_	14	OBJ	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	emergence	_	NN	NN	_	16	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	these	_	DT	DT	_	22	NMOD	_	_
21	DNA-binding	_	JJ	JJ	_	22	NMOD	_	_
22	proteins	_	NNS	NNS	_	19	PMOD	_	_
23	in	_	IN	IN	_	18	NMOD	_	_
24	normal	_	JJ	JJ	_	27	NMOD	_	_
25	human	_	JJ	JJ	_	27	NMOD	_	_
26	T	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	23	PMOD	_	_
28	signaled	_	VBN	VBN	_	27	NMOD	_	_
29	via	_	IN	IN	_	28	ADV	_	_
30	cell	_	NN	NN	_	32	NMOD	_	_
31	surface	_	NN	NN	_	32	NMOD	_	_
32	proteins	_	NNS	NNS	_	29	PMOD	_	_
33	implicated	_	VBN	VBN	_	32	NMOD	_	_
34	in	_	IN	IN	_	33	ADV	_	_
35	antigen-dependent	_	JJ	JJ	_	38	NMOD	_	_
36	T	_	NN	NN	_	38	NMOD	_	_
37	cell	_	NN	NN	_	38	NMOD	_	_
38	activation	_	NN	NN	_	34	PMOD	_	_
39	and	_	CC	CC	_	23	CC	_	_
40	in	_	IN	IN	_	23	COORD	_	_
41	T	_	NN	NN	_	42	NMOD	_	_
42	cells	_	NNS	NNS	_	40	PMOD	_	_
43	stimulated	_	VBN	VBN	_	42	NMOD	_	_
44	by	_	IN	IN	_	43	LGS	_	_
45	mobilization	_	NN	NN	_	44	PMOD	_	_
46	of	_	IN	IN	_	45	NMOD	_	_
47	cellular	_	JJ	JJ	_	48	NMOD	_	_
48	calcium	_	NN	NN	_	46	PMOD	_	_
49	and	_	CC	CC	_	45	CC	_	_
50	activation	_	NN	NN	_	45	COORD	_	_
51	of	_	IN	IN	_	50	NMOD	_	_
52	protein	_	NN	NN	_	54	NMOD	_	_
53	kinase	_	NN	NN	_	54	NMOD	_	_
54	C	_	NN	NN	_	51	PMOD	_	_
55	.	_	.	.	_	13	P	_	_

1	Regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	beta-globin	_	NN	NN	_	5	NMOD	_	_
5	locus	_	NN	NN	_	2	PMOD	_	_
6	.	_	.	.	_	1	P	_	_

1	Transcription	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	human	_	JJ	JJ	_	7	NMOD	_	_
5	beta-globin	_	NN	NN	_	7	NMOD	_	_
6	gene	_	NN	NN	_	7	NMOD	_	_
7	cluster	_	NN	NN	_	2	PMOD	_	_
8	depends	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	upon	_	IN	IN	_	8	ADV	_	_
10	upstream	_	JJ	JJ	_	12	NMOD	_	_
11	regulatory	_	JJ	JJ	_	12	NMOD	_	_
12	sequences	_	NNS	NNS	_	9	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	which	_	WDT	WDT	_	15	SBJ	_	_
15	are	_	VBP	VBP	_	12	NMOD	_	_
16	collectively	_	RB	RB	_	17	ADV	_	_
17	termed	_	VBN	VBN	_	15	VC	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	locus	_	NN	NN	_	21	NMOD	_	_
20	control	_	NN	NN	_	21	NMOD	_	_
21	region	_	NN	NN	_	17	OBJ	_	_
22	.	_	.	.	_	8	P	_	_

1	Recent	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	provided	_	VBN	VBN	_	3	VC	_	_
5	new	_	JJ	JJ	_	6	NMOD	_	_
6	insights	_	NNS	NNS	_	4	OBJ	_	_
7	into	_	IN	IN	_	6	NMOD	_	_
8	how	_	WRB	WRB	_	16	ADV	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	individual	_	JJ	JJ	_	11	NMOD	_	_
11	genes	_	NNS	NNS	_	15	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	cluster	_	NN	NN	_	12	PMOD	_	_
15	are	_	VBP	VBP	_	7	PMOD	_	_
16	regulated	_	VBN	VBN	_	15	VC	_	_
17	through	_	IN	IN	_	16	ADV	_	_
18	development	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	crux	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	transcriptional	_	JJ	JJ	_	5	NMOD	_	_
5	activation	_	NN	NN	_	3	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	how	_	WRB	WRB	_	12	ADV	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	locus	_	NN	NN	_	11	NMOD	_	_
10	control	_	NN	NN	_	11	NMOD	_	_
11	region	_	NN	NN	_	12	SBJ	_	_
12	communicates	_	VBZ	VBZ	_	6	PRD	_	_
13	with	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	gene-proximal	_	JJ	JJ	_	17	NMOD	_	_
16	regulatory	_	JJ	JJ	_	17	NMOD	_	_
17	elements	_	NNS	NNS	_	13	PMOD	_	_
18	.	_	.	.	_	6	P	_	_

1	Induction	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	CD8	_	NN	NN	_	7	NMOD	_	_
4	antigen	_	NN	NN	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	suppressor	_	NN	NN	_	4	COORD	_	_
7	activity	_	NN	NN	_	2	PMOD	_	_
8	by	_	IN	IN	_	1	NMOD	_	_
9	glucocorticoids	_	NNS	NNS	_	8	PMOD	_	_
10	in	_	IN	IN	_	1	NMOD	_	_
11	a	_	DT	DT	_	16	NMOD	_	_
12	CEM	_	NN	NN	_	16	NMOD	_	_
13	human	_	JJ	JJ	_	16	NMOD	_	_
14	leukemic	_	JJ	JJ	_	16	NMOD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	clone	_	NN	NN	_	10	PMOD	_	_
17	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	relationship	_	NN	NN	_	12	SBJ	_	_
3	between	_	IN	IN	_	2	NMOD	_	_
4	glucocorticoid	_	NN	NN	_	5	NMOD	_	_
5	effect	_	NN	NN	_	3	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	regulation	_	NN	NN	_	5	COORD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	cell	_	NN	NN	_	11	NMOD	_	_
10	surface	_	NN	NN	_	11	NMOD	_	_
11	antigens	_	NNS	NNS	_	8	PMOD	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	investigated	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	two	_	CD	CD	_	16	NMOD	_	_
16	models	_	NNS	NNS	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	leukemic	_	JJ	JJ	_	20	NMOD	_	_
19	cell	_	NN	NN	_	20	NMOD	_	_
20	lines	_	NNS	NNS	_	17	PMOD	_	_
21	,	_	,	,	_	16	P	_	_
22	CEM	_	NN	NN	_	23	NMOD	_	_
23	C7	_	NN	NN	_	16	NMOD	_	_
24	denoted	_	VBN	VBN	_	23	NMOD	_	_
25	(	_	(	(	_	23	P	_	_
26	r+	_	JJ	JJ	_	23	NMOD	_	_
27	,	_	,	,	_	26	P	_	_
28	ly+	_	JJ	JJ	_	26	COORD	_	_
29	)	_	)	)	_	23	P	_	_
30	and	_	CC	CC	_	23	CC	_	_
31	CEM	_	NN	NN	_	32	NMOD	_	_
32	C1	_	NN	NN	_	23	COORD	_	_
33	(	_	(	(	_	32	P	_	_
34	r+	_	JJ	JJ	_	32	NMOD	_	_
35	,	_	,	,	_	34	P	_	_
36	ly-	_	JJ	JJ	_	34	COORD	_	_
37	)	_	)	)	_	32	P	_	_
38	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	reactivity	_	NN	NN	_	16	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	murine	_	JJ	JJ	_	6	NMOD	_	_
5	monoclonal	_	JJ	JJ	_	6	NMOD	_	_
6	antibodies	_	NNS	NNS	_	3	PMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	anti-CD4-FITC	_	NN	NN	_	6	NMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	anti-CD8-FITC	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	8	P	_	_
12	anti-CD2-FITC	_	NN	NN	_	8	COORD	_	_
13	and	_	CC	CC	_	8	CC	_	_
14	anti-calla-FITC	_	NN	NN	_	8	COORD	_	_
15	,	_	,	,	_	6	P	_	_
16	were	_	VBD	VBD	_	0	ROOT-S	_	_
17	analyzed	_	VBN	VBN	_	16	VC	_	_
18	using	_	VBG	VBG	_	17	OBJ	_	_
19	flow	_	NN	NN	_	20	NMOD	_	_
20	cytometry	_	NN	NN	_	18	OBJ	_	_
21	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	suppressor	_	NN	NN	_	3	NMOD	_	_
3	function	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	determined	_	VBN	VBN	_	4	VC	_	_
6	using	_	VBG	VBG	_	5	OBJ	_	_
7	-LCB-3H-RCB-thymidine	_	NN	NN	_	8	NMOD	_	_
8	incorporation	_	NN	NN	_	6	OBJ	_	_
9	into	_	IN	IN	_	8	NMOD	_	_
10	phytohemagglutinin-activated	_	JJ	JJ	_	13	NMOD	_	_
11	peripheral	_	JJ	JJ	_	13	NMOD	_	_
12	blood	_	NN	NN	_	13	NMOD	_	_
13	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
14	.	_	.	.	_	4	P	_	_

1	Dexamethasone	_	NN	NN	_	2	NMOD	_	_
2	treatment	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	a	_	DT	DT	_	10	NMOD	_	_
5	human	_	JJ	JJ	_	10	NMOD	_	_
6	leukemic	_	JJ	JJ	_	10	NMOD	_	_
7	cell	_	NN	NN	_	10	NMOD	_	_
8	clone	_	NN	NN	_	10	NMOD	_	_
9	CEM	_	NN	NN	_	10	NMOD	_	_
10	C7	_	NN	NN	_	3	PMOD	_	_
11	caused	_	VBD	VBD	_	0	ROOT-S	_	_
12	an	_	DT	DT	_	13	NMOD	_	_
13	increase	_	NN	NN	_	11	OBJ	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	subset	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	cells	_	NNS	NNS	_	17	PMOD	_	_
19	expressing	_	VBG	VBG	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	surface	_	NN	NN	_	23	NMOD	_	_
22	antigen	_	NN	NN	_	23	NMOD	_	_
23	CD8	_	NN	NN	_	19	OBJ	_	_
24	,	_	,	,	_	23	P	_	_
25	which	_	WDT	WDT	_	26	SBJ	_	_
26	is	_	VBZ	VBZ	_	23	NMOD	_	_
27	present	_	JJ	JJ	_	26	PRD	_	_
28	on	_	IN	IN	_	27	AMOD	_	_
29	suppressor	_	NN	NN	_	32	NMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	cytotoxic	_	JJ	JJ	_	29	COORD	_	_
32	T-lymphocytes	_	NNS	NNS	_	28	PMOD	_	_
33	.	_	.	.	_	11	P	_	_

1	By	_	IN	IN	_	5	ADV	_	_
2	comparison	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	there	_	EX	EX	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	no	_	DT	DT	_	7	NMOD	_	_
7	modification	_	NN	NN	_	5	PRD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	expression	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	CD4	_	NN	NN	_	13	NMOD	_	_
13	antigen	_	NN	NN	_	11	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	is	_	VBZ	VBZ	_	13	NMOD	_	_
17	expressed	_	VBN	VBN	_	16	VC	_	_
18	at	_	IN	IN	_	17	ADV	_	_
19	high	_	JJ	JJ	_	20	NMOD	_	_
20	levels	_	NNS	NNS	_	18	PMOD	_	_
21	in	_	IN	IN	_	17	ADV	_	_
22	these	_	DT	DT	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	5	P	_	_

1	After	_	IN	IN	_	15	TMP	_	_
2	two	_	CD	CD	_	3	NMOD	_	_
3	days	_	NNS	NNS	_	1	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	treatment	_	NN	NN	_	4	PMOD	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	5	_	CD	CD	_	9	DEP	_	_
8	x	_	NN	NN	_	9	DEP	_	_
9	10-LRB--8-RRB--SP-M	_	NN	NN	_	6	PMOD	_	_
10	dexamethasone	_	NN	NN	_	9	AMOD	_	_
11	,	_	,	,	_	15	P	_	_
12	CEM	_	NN	NN	_	14	NMOD	_	_
13	C7	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	15	SBJ	_	_
15	showed	_	VBD	VBD	_	0	ROOT-S	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	two-fold	_	JJ	JJ	_	18	NMOD	_	_
18	increase	_	NN	NN	_	15	OBJ	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	suppressor	_	NN	NN	_	21	NMOD	_	_
21	activity	_	NN	NN	_	19	PMOD	_	_
22	compared	_	VBN	VBN	_	18	NMOD	_	_
23	to	_	TO	TO	_	22	PMOD	_	_
24	untreated	_	JJ	JJ	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	23	PMOD	_	_
26	.	_	.	.	_	15	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	there	_	EX	EX	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	no	_	DT	DT	_	7	NMOD	_	_
7	regulation	_	NN	NN	_	5	PRD	_	_
8	by	_	IN	IN	_	7	NMOD	_	_
9	glucocorticoids	_	NNS	NNS	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	either	_	CC	CC	_	16	CC	_	_
12	the	_	DT	DT	_	16	NMOD	_	_
13	CD8	_	NN	NN	_	16	NMOD	_	_
14	or	_	CC	CC	_	13	CC	_	_
15	CD4	_	NN	NN	_	13	COORD	_	_
16	antigens	_	NNS	NNS	_	10	PMOD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	22	NMOD	_	_
19	leukemic	_	JJ	JJ	_	22	NMOD	_	_
20	clone	_	NN	NN	_	22	NMOD	_	_
21	CEM	_	NN	NN	_	22	NMOD	_	_
22	C1	_	NN	NN	_	17	PMOD	_	_
23	.	_	.	.	_	5	P	_	_

1	Furthermore	_	RB	RB	_	15	ADV	_	_
2	,	_	,	,	_	15	P	_	_
3	no	_	DT	DT	_	4	NMOD	_	_
4	modification	_	NN	NN	_	15	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	suppressor	_	NN	NN	_	8	NMOD	_	_
8	function	_	NN	NN	_	5	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	CEM	_	NN	NN	_	12	NMOD	_	_
11	C1	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	PMOD	_	_
13	by	_	IN	IN	_	4	NMOD	_	_
14	dexamethasone	_	NN	NN	_	13	PMOD	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	observed	_	VBN	VBN	_	15	VC	_	_
17	.	_	.	.	_	15	P	_	_

1	In	_	IN	IN	_	20	ADV	_	_
2	the	_	DT	DT	_	5	NMOD	_	_
3	human	_	JJ	JJ	_	5	NMOD	_	_
4	leukemic	_	JJ	JJ	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	1	PMOD	_	_
6	studied	_	VBN	VBN	_	5	NMOD	_	_
7	here	_	RB	RB	_	6	ADV	_	_
8	,	_	,	,	_	20	P	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	ability	_	NN	NN	_	20	SBJ	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	induce	_	VB	VB	_	10	NMOD	_	_
13	CD8	_	NN	NN	_	15	NMOD	_	_
14	antigen	_	NN	NN	_	15	NMOD	_	_
15	expression	_	NN	NN	_	12	OBJ	_	_
16	in	_	IN	IN	_	12	ADV	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	CD4+	_	JJ	JJ	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	PMOD	_	_
20	correlates	_	VBZ	VBZ	_	0	ROOT-S	_	_
21	with	_	IN	IN	_	20	ADV	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	ability	_	NN	NN	_	21	PMOD	_	_
24	to	_	TO	TO	_	25	VMOD	_	_
25	induce	_	VB	VB	_	23	NMOD	_	_
26	cell	_	NN	NN	_	27	NMOD	_	_
27	lysis	_	NN	NN	_	25	OBJ	_	_
28	in	_	IN	IN	_	25	ADV	_	_
29	a	_	DT	DT	_	34	NMOD	_	_
30	glucocorticoid	_	NN	NN	_	34	NMOD	_	_
31	receptor	_	NN	NN	_	34	NMOD	_	_
32	positive	_	JJ	JJ	_	34	NMOD	_	_
33	cell	_	NN	NN	_	34	NMOD	_	_
34	population	_	NN	NN	_	28	PMOD	_	_
35	.	_	.	.	_	20	P	_	_

1	Defective	_	JJ	JJ	_	2	NMOD	_	_
2	translocation	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	protein	_	NN	NN	_	6	NMOD	_	_
5	kinase	_	NN	NN	_	6	NMOD	_	_
6	C	_	NN	NN	_	3	PMOD	_	_
7	in	_	IN	IN	_	2	NMOD	_	_
8	multidrug-resistant	_	JJ	JJ	_	10	NMOD	_	_
9	HL-60	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	7	PMOD	_	_
11	confers	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	reversible	_	JJ	JJ	_	14	NMOD	_	_
14	loss	_	NN	NN	_	11	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	phorbol	_	NN	NN	_	19	NMOD	_	_
17	ester-induced	_	JJ	JJ	_	16	AMOD	_	_
18	monocytic	_	JJ	JJ	_	19	NMOD	_	_
19	differentiation	_	NN	NN	_	15	PMOD	_	_
20	.	_	.	.	_	11	P	_	_

1	Previous	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	demonstrated	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	human	_	JJ	JJ	_	10	NMOD	_	_
7	HL-60	_	NN	NN	_	10	NMOD	_	_
8	myeloid	_	JJ	JJ	_	10	NMOD	_	_
9	leukemia	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	11	SBJ	_	_
11	differentiate	_	VBP	VBP	_	5	VMOD	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	response	_	NN	NN	_	12	DEP	_	_
14	to	_	TO	TO	_	12	DEP	_	_
15	phorbol	_	NN	NN	_	16	NMOD	_	_
16	esters	_	NNS	NNS	_	12	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	event	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	associated	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	induction	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	c-jun	_	NN	NN	_	12	NMOD	_	_
10	early	_	JJ	JJ	_	12	NMOD	_	_
11	response	_	NN	NN	_	12	NMOD	_	_
12	gene	_	NN	NN	_	7	PMOD	_	_
13	and	_	CC	CC	_	6	CC	_	_
14	appearance	_	NN	NN	_	6	COORD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	monocytic	_	JJ	JJ	_	18	NMOD	_	_
18	phenotype	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	present	_	JJ	JJ	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	4	SBJ	_	_
4	have	_	VBP	VBP	_	0	ROOT-S	_	_
5	examined	_	VBN	VBN	_	4	VC	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	effects	_	NNS	NNS	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	vincristine-selected	_	JJ	JJ	_	12	NMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	multidrug	_	JJ	JJ	_	9	COORD	_	_
12	resistance	_	NN	NN	_	8	PMOD	_	_
13	on	_	IN	IN	_	7	NMOD	_	_
14	12-O-tetradecanoylphorbol-13-acetate	_	NN	NN	_	16	AMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	TPA	_	NN	NN	_	21	NMOD	_	_
17	)	_	)	)	_	16	P	_	_
18	-induced	_	JJ	JJ	_	16	AMOD	_	_
19	HL-60	_	NN	NN	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	differentiation	_	NN	NN	_	13	PMOD	_	_
22	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	multidrug-resistant	_	JJ	JJ	_	7	NMOD	_	_
6	HL-60	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	12	SBJ	_	_
8	,	_	,	,	_	7	P	_	_
9	designated	_	VBN	VBN	_	7	NMOD	_	_
10	HL-60\/vinc	_	NN	NN	_	9	OBJ	_	_
11	,	_	,	,	_	7	P	_	_
12	fail	_	VBP	VBP	_	4	VMOD	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	respond	_	VB	VB	_	12	OBJ	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	TPA	_	NN	NN	_	15	PMOD	_	_
17	with	_	IN	IN	_	14	ADV	_	_
18	an	_	DT	DT	_	19	NMOD	_	_
19	increase	_	NN	NN	_	17	PMOD	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	c-jun	_	NN	NN	_	22	NMOD	_	_
22	transcripts	_	NNS	NNS	_	20	PMOD	_	_
23	or	_	CC	CC	_	22	CC	_	_
24	other	_	JJ	JJ	_	26	NMOD	_	_
25	phenotypic	_	JJ	JJ	_	26	NMOD	_	_
26	characteristics	_	NNS	NNS	_	22	COORD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	monocytic	_	JJ	JJ	_	29	NMOD	_	_
29	differentiation	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	By	_	IN	IN	_	19	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	19	P	_	_
4	treatment	_	NN	NN	_	19	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	HL-60\/vinc	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	5	PMOD	_	_
8	with	_	IN	IN	_	4	NMOD	_	_
9	okadaic	_	JJ	JJ	_	10	NMOD	_	_
10	acid	_	NN	NN	_	8	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	an	_	DT	DT	_	13	NMOD	_	_
13	inhibitor	_	NN	NN	_	10	NMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	serine\/threonine	_	NN	NN	_	17	NMOD	_	_
16	protein	_	NN	NN	_	17	NMOD	_	_
17	phosphatases	_	NNS	NNS	_	14	PMOD	_	_
18	,	_	,	,	_	10	P	_	_
19	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
20	c-jun	_	NN	NN	_	21	NMOD	_	_
21	transcription	_	NN	NN	_	19	OBJ	_	_
22	,	_	,	,	_	21	P	_	_
23	growth	_	NN	NN	_	24	NMOD	_	_
24	arrest	_	NN	NN	_	21	COORD	_	_
25	,	_	,	,	_	21	P	_	_
26	and	_	CC	CC	_	21	CC	_	_
27	expression	_	NN	NN	_	21	COORD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	c-fms	_	NN	NN	_	31	NMOD	_	_
31	gene	_	NN	NN	_	28	PMOD	_	_
32	.	_	.	.	_	19	P	_	_

1	Studies	_	NNS	NNS	_	2	SBJ	_	_
2	were	_	VBD	VBD	_	0	ROOT-S	_	_
3	also	_	RB	RB	_	4	ADV	_	_
4	performed	_	VBN	VBN	_	2	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	an	_	DT	DT	_	12	NMOD	_	_
7	HL-60\/vinc	_	NN	NN	_	8	AMOD	_	_
8	revertant	_	NN	NN	_	12	NMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	HL-60\/vinc/R	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	line	_	NN	NN	_	5	PMOD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	has	_	VBZ	VBZ	_	12	NMOD	_	_
15	regained	_	VBN	VBN	_	14	VC	_	_
16	partial	_	JJ	JJ	_	17	NMOD	_	_
17	sensitivity	_	NN	NN	_	15	OBJ	_	_
18	to	_	TO	TO	_	17	NMOD	_	_
19	vincristine	_	NN	NN	_	18	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	finding	_	NN	NN	_	21	SBJ	_	_
3	that	_	IN	IN	_	2	NMOD	_	_
4	HL-60\/vinc/R	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	6	SBJ	_	_
6	respond	_	VBP	VBP	_	3	VMOD	_	_
7	to	_	TO	TO	_	6	ADV	_	_
8	TPA	_	NN	NN	_	7	PMOD	_	_
9	with	_	IN	IN	_	6	ADV	_	_
10	induction	_	NN	NN	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	monocytic	_	JJ	JJ	_	14	NMOD	_	_
14	phenotype	_	NN	NN	_	11	PMOD	_	_
15	,	_	,	,	_	10	P	_	_
16	but	_	CC	CC	_	10	CC	_	_
17	not	_	RB	RB	_	16	COORD	_	_
18	c-jun	_	NN	NN	_	19	NMOD	_	_
19	expression	_	NN	NN	_	10	COORD	_	_
20	,	_	,	,	_	10	P	_	_
21	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
22	that	_	IN	IN	_	21	OBJ	_	_
23	c-jun	_	NN	NN	_	24	NMOD	_	_
24	induction	_	NN	NN	_	25	SBJ	_	_
25	is	_	VBZ	VBZ	_	22	VMOD	_	_
26	not	_	RB	RB	_	25	VMOD	_	_
27	obligatory	_	JJ	JJ	_	25	PRD	_	_
28	for	_	IN	IN	_	27	AMOD	_	_
29	monocytic	_	JJ	JJ	_	30	NMOD	_	_
30	differentiation	_	NN	NN	_	28	PMOD	_	_
31	.	_	.	.	_	21	P	_	_

1	Other	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	4	SBJ	_	_
3	further	_	RB	RB	_	4	ADV	_	_
4	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	jun-B	_	NN	NN	_	10	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	fra-1	_	NN	NN	_	7	COORD	_	_
10	genes	_	NNS	NNS	_	11	SBJ	_	_
11	are	_	VBP	VBP	_	5	VMOD	_	_
12	induced	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	TPA	_	NN	NN	_	13	PMOD	_	_
15	in	_	IN	IN	_	12	ADV	_	_
16	both	_	CC	CC	_	17	CC	_	_
17	HL-60\/vinc	_	NN	NN	_	20	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	HL-60\/vinc/R	_	NN	NN	_	17	COORD	_	_
20	cells	_	NNS	NNS	_	15	PMOD	_	_
21	,	_	,	,	_	4	P	_	_
22	whereas	_	IN	IN	_	4	COORD	_	_
23	c-fos	_	NN	NN	_	24	NMOD	_	_
24	expression	_	NN	NN	_	25	SBJ	_	_
25	is	_	VBZ	VBZ	_	4	COORD	_	_
26	attenuated	_	VBN	VBN	_	25	VC	_	_
27	in	_	IN	IN	_	26	ADV	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	HL-60\/vinc	_	NN	NN	_	30	NMOD	_	_
30	line	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	4	P	_	_

1	Since	_	IN	IN	_	12	ADV	_	_
2	TPA	_	NN	NN	_	3	SBJ	_	_
3	activates	_	VBZ	VBZ	_	1	VMOD	_	_
4	protein	_	NN	NN	_	6	NMOD	_	_
5	kinase	_	NN	NN	_	6	NMOD	_	_
6	C	_	NN	NN	_	3	OBJ	_	_
7	(	_	(	(	_	8	P	_	_
8	PKC	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	,	_	,	,	_	12	P	_	_
11	we	_	PRP	PRP	_	12	SBJ	_	_
12	examined	_	VBD	VBD	_	0	ROOT-S	_	_
13	translocation	_	NN	NN	_	12	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	PKC	_	NN	NN	_	14	PMOD	_	_
16	from	_	IN	IN	_	13	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	cytosol	_	NN	NN	_	16	PMOD	_	_
19	to	_	TO	TO	_	13	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	membrane	_	NN	NN	_	22	NMOD	_	_
22	fraction	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	12	P	_	_

1	Although	_	IN	IN	_	15	ADV	_	_
2	HL-60	_	NN	NN	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	HL-60\/vinc/R	_	NN	NN	_	2	COORD	_	_
5	cells	_	NNS	NNS	_	6	SBJ	_	_
6	demonstrated	_	VBD	VBD	_	1	VMOD	_	_
7	translocation	_	NN	NN	_	6	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	PKC	_	NN	NN	_	10	NMOD	_	_
10	activity	_	NN	NN	_	8	PMOD	_	_
11	,	_	,	,	_	15	P	_	_
12	this	_	DT	DT	_	14	NMOD	_	_
13	subcellular	_	JJ	JJ	_	14	NMOD	_	_
14	redistribution	_	NN	NN	_	15	SBJ	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	undetectable	_	JJ	JJ	_	15	PRD	_	_
17	in	_	IN	IN	_	15	ADV	_	_
18	HL-60\/vinc	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	15	P	_	_

1	Activity	_	NN	NN	_	14	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	mitogen-activated	_	JJ	JJ	_	7	NMOD	_	_
5	protein	_	NN	NN	_	7	NMOD	_	_
6	kinase	_	NN	NN	_	7	NMOD	_	_
7	family	_	NN	NN	_	2	PMOD	_	_
8	with	_	IN	IN	_	1	NMOD	_	_
9	associated	_	JJ	JJ	_	10	NMOD	_	_
10	phosphorylation	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	c-Jun	_	NN	NN	_	13	NMOD	_	_
13	Y-peptide	_	NN	NN	_	11	PMOD	_	_
14	was	_	VBD	VBD	_	0	ROOT-S	_	_
15	markedly	_	RB	RB	_	16	ADV	_	_
16	diminished	_	VBN	VBN	_	14	VC	_	_
17	in	_	IN	IN	_	16	ADV	_	_
18	TPA-treated	_	JJ	JJ	_	20	NMOD	_	_
19	HL-60\/vinc	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	17	PMOD	_	_
21	,	_	,	,	_	16	P	_	_
22	but	_	CC	CC	_	16	CC	_	_
23	not	_	RB	RB	_	24	DEP	_	_
24	in	_	IN	IN	_	16	ADV	_	_
25	response	_	NN	NN	_	24	DEP	_	_
26	to	_	TO	TO	_	24	DEP	_	_
27	okadaic	_	JJ	JJ	_	28	NMOD	_	_
28	acid	_	NN	NN	_	24	PMOD	_	_
29	.	_	.	.	_	14	P	_	_

1	Taken	_	VBN	VBN	_	6	VMOD	_	_
2	together	_	RB	RB	_	1	ADV	_	_
3	,	_	,	,	_	6	P	_	_
4	these	_	DT	DT	_	5	NMOD	_	_
5	findings	_	NNS	NNS	_	6	SBJ	_	_
6	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	vincristine	_	NN	NN	_	9	NMOD	_	_
9	resistance	_	NN	NN	_	10	SBJ	_	_
10	confers	_	VBZ	VBZ	_	7	VMOD	_	_
11	insensitivity	_	NN	NN	_	10	OBJ	_	_
12	to	_	TO	TO	_	11	NMOD	_	_
13	TPA-induced	_	JJ	JJ	_	14	NMOD	_	_
14	differentiation	_	NN	NN	_	12	PMOD	_	_
15	and	_	CC	CC	_	10	CC	_	_
16	can	_	MD	MD	_	10	COORD	_	_
17	include	_	VB	VB	_	16	VC	_	_
18	defects	_	NNS	NNS	_	17	OBJ	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	PKC-mediated	_	JJ	JJ	_	22	NMOD	_	_
21	signaling	_	NN	NN	_	22	NMOD	_	_
22	events	_	NNS	NNS	_	19	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	induction	_	NN	NN	_	22	COORD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	jun\/fos	_	NN	NN	_	30	NMOD	_	_
27	early	_	JJ	JJ	_	30	NMOD	_	_
28	response	_	NN	NN	_	30	NMOD	_	_
29	gene	_	NN	NN	_	30	NMOD	_	_
30	expression	_	NN	NN	_	25	PMOD	_	_
31	.	_	.	.	_	6	P	_	_

1	Regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	lymphoid-specific	_	JJ	JJ	_	9	NMOD	_	_
4	immunoglobulin	_	NN	NN	_	9	NMOD	_	_
5	mu	_	NN	NN	_	9	NMOD	_	_
6	heavy	_	NN	NN	_	9	NMOD	_	_
7	chain	_	NN	NN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	enhancer	_	NN	NN	_	2	PMOD	_	_
10	by	_	IN	IN	_	1	NMOD	_	_
11	ETS-domain	_	JJ	JJ	_	12	NMOD	_	_
12	proteins	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	enhancer	_	NN	NN	_	13	SBJ	_	_
3	for	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	9	NMOD	_	_
5	immunoglobulin	_	NN	NN	_	9	NMOD	_	_
6	mu	_	NN	NN	_	9	NMOD	_	_
7	heavy	_	NN	NN	_	9	NMOD	_	_
8	chain	_	NN	NN	_	9	NMOD	_	_
9	gene	_	NN	NN	_	3	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	IgH	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	activates	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	heterologous	_	JJ	JJ	_	16	NMOD	_	_
16	gene	_	NN	NN	_	13	OBJ	_	_
17	at	_	IN	IN	_	13	TMP	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	pre-B	_	JJ	JJ	_	20	AMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	stage	_	NN	NN	_	17	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	B	_	NN	NN	_	25	NMOD	_	_
24	lymphocyte	_	NN	NN	_	25	NMOD	_	_
25	differentiation	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	13	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	lymphoid-specific	_	JJ	JJ	_	3	NMOD	_	_
3	element	_	NN	NN	_	7	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	microB	_	NN	NN	_	3	NMOD	_	_
6	,	_	,	,	_	3	P	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	necessary	_	JJ	JJ	_	7	PRD	_	_
9	for	_	IN	IN	_	8	AMOD	_	_
10	enhancer	_	NN	NN	_	11	NMOD	_	_
11	function	_	NN	NN	_	9	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	pre-B	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	7	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	microB	_	NN	NN	_	4	NMOD	_	_
3	binding	_	NN	NN	_	4	NMOD	_	_
4	protein	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	encoded	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	PU.1\/Spi-1	_	NN	NN	_	10	NMOD	_	_
10	proto-oncogene	_	NN	NN	_	7	PMOD	_	_
11	.	_	.	.	_	5	P	_	_

1	Another	_	DT	DT	_	3	NMOD	_	_
2	sequence	_	NN	NN	_	3	NMOD	_	_
3	element	_	NN	NN	_	7	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	microA	_	NN	NN	_	3	NMOD	_	_
6	,	_	,	,	_	3	P	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	identified	_	VBN	VBN	_	7	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	mu	_	NN	NN	_	12	NMOD	_	_
12	enhancer	_	NN	NN	_	9	PMOD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	binds	_	VBZ	VBZ	_	12	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	product	_	NN	NN	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	ets-1	_	NN	NN	_	20	NMOD	_	_
20	proto-oncogene	_	NN	NN	_	17	PMOD	_	_
21	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	microA	_	NN	NN	_	3	NMOD	_	_
3	motif	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	required	_	VBN	VBN	_	4	VC	_	_
6	for	_	IN	IN	_	5	ADV	_	_
7	microB-dependent	_	JJ	JJ	_	9	NMOD	_	_
8	enhancer	_	NN	NN	_	9	NMOD	_	_
9	activity	_	NN	NN	_	6	PMOD	_	_
10	,	_	,	,	_	5	P	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	suggests	_	VBZ	VBZ	_	5	OBJ	_	_
13	that	_	IN	IN	_	12	OBJ	_	_
14	a	_	DT	DT	_	18	NMOD	_	_
15	minimal	_	JJ	JJ	_	18	NMOD	_	_
16	B	_	NN	NN	_	18	NMOD	_	_
17	cell-specific	_	JJ	JJ	_	16	AMOD	_	_
18	enhancer	_	NN	NN	_	19	SBJ	_	_
19	is	_	VBZ	VBZ	_	13	VMOD	_	_
20	composed	_	VBN	VBN	_	19	VC	_	_
21	of	_	IN	IN	_	20	ADV	_	_
22	both	_	CC	CC	_	28	CC	_	_
23	the	_	DT	DT	_	28	NMOD	_	_
24	PU.1	_	NN	NN	_	28	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	Ets-1	_	NN	NN	_	24	COORD	_	_
27	binding	_	NN	NN	_	28	NMOD	_	_
28	sites	_	NNS	NNS	_	21	PMOD	_	_
29	.	_	.	.	_	4	P	_	_

1	Co-expression	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	both	_	CC	CC	_	4	CC	_	_
4	PU.1	_	NN	NN	_	2	PMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	Ets-1	_	NN	NN	_	4	COORD	_	_
7	in	_	IN	IN	_	1	NMOD	_	_
8	nonlymphoid	_	JJ	JJ	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	7	PMOD	_	_
10	trans-activated	_	JJ	JJ	_	12	VMOD	_	_
11	reporter	_	NN	NN	_	12	NMOD	_	_
12	plasmids	_	NNS	NNS	_	0	ROOT-S	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	contained	_	VBD	VBD	_	12	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	minimal	_	JJ	JJ	_	18	NMOD	_	_
17	mu	_	NN	NN	_	18	NMOD	_	_
18	enhancer	_	NN	NN	_	14	OBJ	_	_
19	.	_	.	.	_	12	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	implicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	two	_	CD	CD	_	5	NMOD	_	_
5	members	_	NNS	NNS	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	Ets	_	NN	NN	_	9	NMOD	_	_
9	family	_	NN	NN	_	6	PMOD	_	_
10	in	_	IN	IN	_	3	ADV	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	activation	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	IgH	_	NN	NN	_	16	NMOD	_	_
15	gene	_	NN	NN	_	16	NMOD	_	_
16	expression	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	Cell	_	NN	NN	_	3	NMOD	_	_
2	cycle	_	NN	NN	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	11	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	E2F	_	NN	NN	_	4	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	primary	_	JJ	JJ	_	10	NMOD	_	_
8	human	_	JJ	JJ	_	10	NMOD	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	6	PMOD	_	_
11	reveals	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	novel	_	JJ	JJ	_	14	NMOD	_	_
13	E2F	_	NN	NN	_	14	NMOD	_	_
14	complexes	_	NNS	NNS	_	11	OBJ	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	biochemically	_	RB	RB	_	17	AMOD	_	_
17	distinct	_	JJ	JJ	_	18	NMOD	_	_
18	forms	_	NNS	NNS	_	14	COORD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	free	_	JJ	JJ	_	21	NMOD	_	_
21	E2F	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	transcription	_	NN	NN	_	4	NMOD	_	_
3	factor	_	NN	NN	_	4	NMOD	_	_
4	E2F	_	NN	NN	_	5	SBJ	_	_
5	activates	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	expression	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	multiple	_	JJ	JJ	_	10	NMOD	_	_
10	genes	_	NNS	NNS	_	8	PMOD	_	_
11	involved	_	VBN	VBN	_	10	NMOD	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	proliferation	_	NN	NN	_	12	PMOD	_	_
15	,	_	,	,	_	10	P	_	_
16	such	_	JJ	JJ	_	17	DEP	_	_
17	as	_	IN	IN	_	10	NMOD	_	_
18	c-myc	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	dihydrofolate	_	JJ	JJ	_	23	NMOD	_	_
22	reductase	_	NN	NN	_	23	NMOD	_	_
23	gene	_	NN	NN	_	18	COORD	_	_
24	.	_	.	.	_	5	P	_	_

1	Regulation	_	NN	NN	_	4	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	E2F	_	NN	NN	_	2	PMOD	_	_
4	involves	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	its	_	PRP$	PRP$	_	6	NMOD	_	_
6	interactions	_	NNS	NNS	_	4	OBJ	_	_
7	with	_	IN	IN	_	6	NMOD	_	_
8	other	_	JJ	JJ	_	10	NMOD	_	_
9	cellular	_	JJ	JJ	_	10	NMOD	_	_
10	proteins	_	NNS	NNS	_	7	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	including	_	VBG	VBG	_	10	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	retinoblastoma	_	NN	NN	_	15	NMOD	_	_
15	protein	_	NN	NN	_	12	PMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	Rb	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	,	_	,	,	_	15	P	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	Rb-related	_	JJ	JJ	_	23	NMOD	_	_
22	protein	_	NN	NN	_	23	NMOD	_	_
23	p107	_	NN	NN	_	15	COORD	_	_
24	,	_	,	,	_	15	P	_	_
25	cyclin	_	NN	NN	_	26	NMOD	_	_
26	A	_	NN	NN	_	15	COORD	_	_
27	,	_	,	,	_	15	P	_	_
28	and	_	CC	CC	_	15	CC	_	_
29	cdk2	_	NN	NN	_	15	COORD	_	_
30	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	undertook	_	VBD	VBD	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	detailed	_	JJ	JJ	_	5	NMOD	_	_
5	analysis	_	NN	NN	_	2	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	E2F	_	NN	NN	_	9	NMOD	_	_
8	DNA-binding	_	JJ	JJ	_	9	NMOD	_	_
9	activities	_	NNS	NNS	_	6	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	their	_	PRP$	PRP$	_	14	NMOD	_	_
12	cell	_	NN	NN	_	14	NMOD	_	_
13	cycle	_	NN	NN	_	14	NMOD	_	_
14	behavior	_	NN	NN	_	9	COORD	_	_
15	in	_	IN	IN	_	9	NMOD	_	_
16	primary	_	JJ	JJ	_	19	NMOD	_	_
17	human	_	JJ	JJ	_	19	NMOD	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	15	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	Three	_	CD	CD	_	4	NMOD	_	_
2	E2F	_	NN	NN	_	4	NMOD	_	_
3	DNA-binding	_	JJ	JJ	_	4	NMOD	_	_
4	activities	_	NNS	NNS	_	5	SBJ	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	identified	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	resting	_	VBG	VBG	_	13	NMOD	_	_
9	(	_	(	(	_	13	P	_	_
10	G0	_	NN	NN	_	13	NMOD	_	_
11	)	_	)	)	_	13	P	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	7	PMOD	_	_
14	with	_	IN	IN	_	6	OBJ	_	_
15	mobilities	_	NNS	NNS	_	14	PMOD	_	_
16	in	_	IN	IN	_	20	AMOD	_	_
17	gel	_	NN	NN	_	19	NMOD	_	_
18	shift	_	NN	NN	_	19	NMOD	_	_
19	assays	_	NNS	NNS	_	16	PMOD	_	_
20	distinct	_	JJ	JJ	_	15	NMOD	_	_
21	from	_	IN	IN	_	20	AMOD	_	_
22	those	_	DT	DT	_	21	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	previously	_	RB	RB	_	25	AMOD	_	_
25	defined	_	VBN	VBN	_	27	NMOD	_	_
26	E2F	_	NN	NN	_	27	NMOD	_	_
27	complexes	_	NNS	NNS	_	23	PMOD	_	_
28	.	_	.	.	_	5	P	_	_

1	One	_	CD	CD	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	activities	_	NNS	NNS	_	2	PMOD	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	found	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	be	_	VB	VB	_	6	OBJ	_	_
9	a	_	DT	DT	_	16	NMOD	_	_
10	novel	_	JJ	JJ	_	16	NMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	less	_	RBR	RBR	_	13	AMOD	_	_
13	abundant	_	JJ	JJ	_	10	COORD	_	_
14	,	_	,	,	_	10	P	_	_
15	Rb-E2F	_	NN	NN	_	10	COORD	_	_
16	complex	_	NN	NN	_	8	PRD	_	_
17	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	most	_	RBS	RBS	_	3	AMOD	_	_
3	prominent	_	JJ	JJ	_	5	NMOD	_	_
4	E2F	_	NN	NN	_	5	NMOD	_	_
5	activity	_	NN	NN	_	15	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	resting	_	VBG	VBG	_	9	NMOD	_	_
8	T	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	6	PMOD	_	_
10	(	_	(	(	_	5	P	_	_
11	termed	_	VBN	VBN	_	5	NMOD	_	_
12	complex	_	JJ	JJ	_	13	NMOD	_	_
13	X	_	NN	NN	_	11	OBJ	_	_
14	)	_	)	)	_	5	P	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	abundant	_	JJ	JJ	_	15	PRD	_	_
17	in	_	IN	IN	_	15	ADV	_	_
18	both	_	CC	CC	_	19	CC	_	_
19	G0	_	NN	NN	_	17	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	G1	_	NN	NN	_	19	COORD	_	_
22	but	_	CC	CC	_	15	CC	_	_
23	disappeared	_	VBD	VBD	_	15	COORD	_	_
24	as	_	IN	IN	_	23	TMP	_	_
25	cells	_	NNS	NNS	_	26	SBJ	_	_
26	entered	_	VBD	VBD	_	24	VMOD	_	_
27	S	_	NN	NN	_	28	NMOD	_	_
28	phase	_	NN	NN	_	26	OBJ	_	_
29	,	_	,	,	_	15	P	_	_
30	suggesting	_	VBG	VBG	_	15	VC	_	_
31	a	_	DT	DT	_	33	NMOD	_	_
32	possible	_	JJ	JJ	_	33	NMOD	_	_
33	role	_	NN	NN	_	30	OBJ	_	_
34	in	_	IN	IN	_	33	NMOD	_	_
35	negatively	_	RB	RB	_	36	AMOD	_	_
36	regulating	_	VBG	VBG	_	38	NMOD	_	_
37	E2F	_	NN	NN	_	38	NMOD	_	_
38	function	_	NN	NN	_	34	PMOD	_	_
39	.	_	.	.	_	15	P	_	_

1	Complex	_	NN	NN	_	2	NMOD	_	_
2	X	_	NN	NN	_	3	SBJ	_	_
3	could	_	MD	MD	_	0	ROOT-S	_	_
4	be	_	VB	VB	_	3	VC	_	_
5	dissociated	_	VBN	VBN	_	4	VC	_	_
6	by	_	IN	IN	_	5	LGS	_	_
7	adenovirus	_	NN	NN	_	8	NMOD	_	_
8	E1A	_	NN	NN	_	6	PMOD	_	_
9	with	_	IN	IN	_	5	ADV	_	_
10	a	_	DT	DT	_	11	NMOD	_	_
11	requirement	_	NN	NN	_	9	PMOD	_	_
12	for	_	IN	IN	_	11	NMOD	_	_
13	an	_	DT	DT	_	17	NMOD	_	_
14	intact	_	JJ	JJ	_	17	NMOD	_	_
15	E1A	_	NN	NN	_	17	NMOD	_	_
16	conserved	_	VBN	VBN	_	17	NMOD	_	_
17	region	_	NN	NN	_	12	PMOD	_	_
18	2	_	CD	CD	_	17	NMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	X	_	NN	NN	_	4	SBJ	_	_
4	failed	_	VBD	VBD	_	0	ROOT-S	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	react	_	VB	VB	_	4	OBJ	_	_
7	with	_	IN	IN	_	6	ADV	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	variety	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	antibodies	_	NNS	NNS	_	10	PMOD	_	_
12	against	_	IN	IN	_	11	NMOD	_	_
13	Rb	_	NN	NN	_	12	PMOD	_	_
14	or	_	CC	CC	_	13	CC	_	_
15	p107	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	4	P	_	_
17	implicating	_	VBG	VBG	_	4	ADV	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	involvement	_	NN	NN	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	an	_	DT	DT	_	23	NMOD	_	_
22	E1A-binding	_	JJ	JJ	_	23	NMOD	_	_
23	protein	_	NN	NN	_	20	PMOD	_	_
24	other	_	JJ	JJ	_	25	DEP	_	_
25	than	_	IN	IN	_	23	NMOD	_	_
26	Rb	_	NN	NN	_	25	PMOD	_	_
27	or	_	CC	CC	_	26	CC	_	_
28	p107	_	NN	NN	_	26	COORD	_	_
29	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	18	ADV	_	_
2	addition	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	these	_	DT	DT	_	7	NMOD	_	_
5	novel	_	JJ	JJ	_	7	NMOD	_	_
6	E2F	_	NN	NN	_	7	NMOD	_	_
7	complexes	_	NNS	NNS	_	1	PMOD	_	_
8	,	_	,	,	_	18	P	_	_
9	three	_	CD	CD	_	11	NMOD	_	_
10	distinct	_	JJ	JJ	_	11	NMOD	_	_
11	forms	_	NNS	NNS	_	18	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	unbound	_	JJ	JJ	_	17	NMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	free	_	JJ	JJ	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	E2F	_	NN	NN	_	12	PMOD	_	_
18	were	_	VBD	VBD	_	0	ROOT-S	_	_
19	resolved	_	VBN	VBN	_	18	VC	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	gel	_	NN	NN	_	23	NMOD	_	_
22	shift	_	NN	NN	_	23	NMOD	_	_
23	experiments	_	NNS	NNS	_	20	PMOD	_	_
24	.	_	.	.	_	18	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	species	_	NNS	NNS	_	3	SBJ	_	_
3	showed	_	VBD	VBD	_	0	ROOT-S	_	_
4	different	_	JJ	JJ	_	7	NMOD	_	_
5	cell	_	NN	NN	_	7	NMOD	_	_
6	cycle	_	NN	NN	_	7	NMOD	_	_
7	kinetics	_	NNS	NNS	_	3	OBJ	_	_
8	.	_	.	.	_	3	P	_	_

1	UV	_	NN	NN	_	3	NMOD	_	_
2	cross-linking	_	JJ	JJ	_	3	NMOD	_	_
3	experiments	_	NNS	NNS	_	4	SBJ	_	_
4	suggested	_	VBD	VBD	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	a	_	DT	DT	_	10	NMOD	_	_
7	distinct	_	JJ	JJ	_	10	NMOD	_	_
8	E2F	_	NN	NN	_	10	NMOD	_	_
9	DNA-binding	_	JJ	JJ	_	10	NMOD	_	_
10	protein	_	NN	NN	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	5	VMOD	_	_
12	uniquely	_	RB	RB	_	13	ADV	_	_
13	associated	_	VBN	VBN	_	11	VC	_	_
14	with	_	IN	IN	_	13	ADV	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	S-phase	_	NN	NN	_	18	NMOD	_	_
17	p107	_	NN	NN	_	18	NMOD	_	_
18	complex	_	NN	NN	_	14	PMOD	_	_
19	and	_	CC	CC	_	11	CC	_	_
20	is	_	VBZ	VBZ	_	11	COORD	_	_
21	not	_	RB	RB	_	20	VMOD	_	_
22	associated	_	VBN	VBN	_	20	VC	_	_
23	with	_	IN	IN	_	22	ADV	_	_
24	Rb	_	NN	NN	_	23	PMOD	_	_
25	.	_	.	.	_	4	P	_	_

1	Together	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	results	_	NNS	NNS	_	5	SBJ	_	_
5	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	E2F	_	NN	NN	_	8	SBJ	_	_
8	consists	_	VBZ	VBZ	_	6	VMOD	_	_
9	of	_	IN	IN	_	8	ADV	_	_
10	multiple	_	JJ	JJ	_	15	NMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	biochemically	_	RB	RB	_	13	AMOD	_	_
13	distinct	_	JJ	JJ	_	10	COORD	_	_
14	DNA-binding	_	JJ	JJ	_	15	NMOD	_	_
15	proteins	_	NNS	NNS	_	9	PMOD	_	_
16	which	_	WDT	WDT	_	17	SBJ	_	_
17	function	_	VBP	VBP	_	15	NMOD	_	_
18	at	_	IN	IN	_	17	TMP	_	_
19	different	_	JJ	JJ	_	20	NMOD	_	_
20	points	_	NNS	NNS	_	18	PMOD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	cell	_	NN	NN	_	24	NMOD	_	_
24	cycle	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	5	P	_	_

1	Antisense	_	JJ	JJ	_	2	NMOD	_	_
2	oligonucleotides	_	NNS	NNS	_	10	SBJ	_	_
3	to	_	TO	TO	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	p65	_	NN	NN	_	6	NMOD	_	_
6	subunit	_	NN	NN	_	3	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	NF-kappa	_	NN	NN	_	9	NMOD	_	_
9	B	_	NN	NN	_	7	PMOD	_	_
10	block	_	VBP	VBP	_	0	ROOT-S	_	_
11	CD11b	_	NN	NN	_	12	NMOD	_	_
12	expression	_	NN	NN	_	10	OBJ	_	_
13	and	_	CC	CC	_	10	CC	_	_
14	alter	_	VBP	VBP	_	10	COORD	_	_
15	adhesion	_	NN	NN	_	16	NMOD	_	_
16	properties	_	NNS	NNS	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	differentiated	_	VBN	VBN	_	20	NMOD	_	_
19	HL-60	_	NN	NN	_	20	NMOD	_	_
20	granulocytes	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	10	P	_	_

1	NF-kappa	_	NN	NN	_	2	NMOD	_	_
2	B	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	pleiotropic	_	JJ	JJ	_	6	NMOD	_	_
6	regulator	_	NN	NN	_	3	PRD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	variety	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	genes	_	NNS	NNS	_	10	PMOD	_	_
12	implicated	_	VBN	VBN	_	11	NMOD	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	cellular	_	JJ	JJ	_	16	NMOD	_	_
16	response	_	NN	NN	_	13	PMOD	_	_
17	to	_	TO	TO	_	16	NMOD	_	_
18	injury	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	function	_	NN	NN	_	3	SBJ	_	_
3	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	been	_	VBN	VBN	_	3	VC	_	_
5	attributed	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	coordinated	_	VBN	VBN	_	9	NMOD	_	_
9	binding	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	subunits	_	NNS	NNS	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	NF-kappa	_	NN	NN	_	14	NMOD	_	_
14	B	_	NN	NN	_	12	PMOD	_	_
15	to	_	TO	TO	_	9	NMOD	_	_
16	distinct	_	JJ	JJ	_	17	NMOD	_	_
17	regions	_	NNS	NNS	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	promoter	_	JJ	JJ	_	21	NMOD	_	_
21	elements	_	NNS	NNS	_	18	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	numerous	_	JJ	JJ	_	24	NMOD	_	_
24	genes	_	NNS	NNS	_	22	PMOD	_	_
25	,	_	,	,	_	21	P	_	_
26	including	_	VBG	VBG	_	21	NMOD	_	_
27	cytokines	_	NNS	NNS	_	26	PMOD	_	_
28	,	_	,	,	_	27	P	_	_
29	growth	_	NN	NN	_	31	NMOD	_	_
30	factor	_	NN	NN	_	31	NMOD	_	_
31	receptors	_	NNS	NNS	_	27	COORD	_	_
32	,	_	,	,	_	27	P	_	_
33	and	_	CC	CC	_	27	CC	_	_
34	adhesion	_	NN	NN	_	35	NMOD	_	_
35	molecules	_	NNS	NNS	_	27	COORD	_	_
36	.	_	.	.	_	3	P	_	_

1	Antisense	_	JJ	JJ	_	3	NMOD	_	_
2	phosphorothioate	_	JJ	JJ	_	3	NMOD	_	_
3	oligonucleotides	_	NNS	NNS	_	15	SBJ	_	_
4	to	_	TO	TO	_	3	NMOD	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	p50	_	NN	NN	_	9	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	p65	_	NN	NN	_	6	COORD	_	_
9	subunits	_	NNS	NNS	_	4	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	NF-kappa	_	NN	NN	_	14	NMOD	_	_
13	B	_	NN	NN	_	14	NMOD	_	_
14	complex	_	NN	NN	_	10	PMOD	_	_
15	were	_	VBD	VBD	_	0	ROOT-S	_	_
16	used	_	VBN	VBN	_	15	VC	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	define	_	VB	VB	_	16	OBJ	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	physiologic	_	JJ	JJ	_	21	NMOD	_	_
21	role	_	NN	NN	_	18	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	this	_	DT	DT	_	25	NMOD	_	_
24	transcription	_	NN	NN	_	25	NMOD	_	_
25	factor	_	NN	NN	_	22	PMOD	_	_
26	in	_	IN	IN	_	21	NMOD	_	_
27	resting	_	VBG	VBG	_	30	NMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	stimulated	_	VBN	VBN	_	27	COORD	_	_
30	granulocytes	_	NNS	NNS	_	26	PMOD	_	_
31	.	_	.	.	_	15	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	reduction	_	NN	NN	_	8	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	expression	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	p65	_	NN	NN	_	6	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	produced	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	ADV	_	_
11	treatment	_	NN	NN	_	10	PMOD	_	_
12	with	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	phosphorothioate	_	JJ	JJ	_	16	NMOD	_	_
15	antisense	_	JJ	JJ	_	16	NMOD	_	_
16	oligodeoxynucleotide	_	NN	NN	_	12	PMOD	_	_
17	.	_	.	.	_	8	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	reduction	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	accompanied	_	VBN	VBN	_	3	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	rapid	_	JJ	JJ	_	7	NMOD	_	_
7	changes	_	NNS	NNS	_	5	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	cellular	_	JJ	JJ	_	11	NMOD	_	_
11	adhesion	_	NN	NN	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	dimethyl	_	JJ	JJ	_	14	AMOD	_	_
14	sulfoxide-differentiated	_	JJ	JJ	_	17	NMOD	_	_
15	HL-60	_	NN	NN	_	17	NMOD	_	_
16	leukemia	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	12	PMOD	_	_
18	stimulated	_	VBN	VBN	_	17	NMOD	_	_
19	by	_	IN	IN	_	18	LGS	_	_
20	12-O-tetradecanoylphorbol	_	NN	NN	_	21	NMOD	_	_
21	13-acetate	_	NN	NN	_	19	PMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	TPA	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	effects	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	characterized	_	VBN	VBN	_	3	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	marked	_	JJ	JJ	_	8	NMOD	_	_
8	reduction	_	NN	NN	_	5	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	CD11b	_	NN	NN	_	12	NMOD	_	_
11	integrin	_	JJ	JJ	_	12	NMOD	_	_
12	expression	_	NN	NN	_	9	PMOD	_	_
13	on	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	surface	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	treated	_	VBN	VBN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	16	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	Furthermore	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	p65	_	NN	NN	_	6	NMOD	_	_
5	antisense	_	JJ	JJ	_	6	NMOD	_	_
6	oligomer	_	NN	NN	_	8	SBJ	_	_
7	effectively	_	RB	RB	_	8	ADV	_	_
8	abolished	_	VBD	VBD	_	0	ROOT-S	_	_
9	an	_	DT	DT	_	10	NMOD	_	_
10	upregulation	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	CD11b	_	NN	NN	_	11	PMOD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	was	_	VBD	VBD	_	12	NMOD	_	_
15	produced	_	VBN	VBN	_	14	VC	_	_
16	by	_	IN	IN	_	15	LGS	_	_
17	formyl-met-leu-phe	_	NN	NN	_	16	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	TPA	_	NN	NN	_	17	COORD	_	_
20	.	_	.	.	_	8	P	_	_

1	However	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	p65	_	NN	NN	_	7	NMOD	_	_
5	antisense	_	JJ	JJ	_	7	NMOD	_	_
6	phosphorothioate	_	JJ	JJ	_	7	NMOD	_	_
7	oligodeoxynucleotide	_	NN	NN	_	8	SBJ	_	_
8	had	_	VBD	VBD	_	0	ROOT-S	_	_
9	no	_	DT	DT	_	11	NMOD	_	_
10	significant	_	JJ	JJ	_	11	NMOD	_	_
11	effect	_	NN	NN	_	8	OBJ	_	_
12	on	_	IN	IN	_	8	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	production	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	reactive	_	JJ	JJ	_	18	NMOD	_	_
17	oxygen	_	NN	NN	_	18	NMOD	_	_
18	intermediates	_	NNS	NNS	_	15	PMOD	_	_
19	or	_	CC	CC	_	12	CC	_	_
20	on	_	IN	IN	_	12	COORD	_	_
21	phagocytosis	_	NNS	NNS	_	20	PMOD	_	_
22	by	_	IN	IN	_	21	NMOD	_	_
23	these	_	DT	DT	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	8	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	antisense	_	JJ	JJ	_	6	NMOD	_	_
6	oligomers	_	NNS	NNS	_	9	SBJ	_	_
7	to	_	TO	TO	_	6	NMOD	_	_
8	p65	_	NN	NN	_	7	PMOD	_	_
9	can	_	MD	MD	_	4	VMOD	_	_
10	be	_	VB	VB	_	9	VC	_	_
11	used	_	VBN	VBN	_	10	VC	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	define	_	VB	VB	_	11	OBJ	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	role	_	NN	NN	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	NF-kappa	_	NN	NN	_	18	NMOD	_	_
18	B	_	NN	NN	_	16	PMOD	_	_
19	in	_	IN	IN	_	15	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	activation	_	NN	NN	_	22	NMOD	_	_
22	pathways	_	NNS	NNS	_	19	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	neutrophils	_	NNS	NNS	_	23	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	Human	_	JJ	JJ	_	6	NMOD	_	_
2	T	_	NN	NN	_	6	NMOD	_	_
3	cell	_	NN	NN	_	6	NMOD	_	_
4	transcription	_	NN	NN	_	6	NMOD	_	_
5	factor	_	NN	NN	_	6	NMOD	_	_
6	GATA-3	_	NN	NN	_	7	SBJ	_	_
7	stimulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	HIV-1	_	NN	NN	_	9	NMOD	_	_
9	expression	_	NN	NN	_	7	OBJ	_	_
10	.	_	.	.	_	7	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	family	_	NN	NN	_	12	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	transcriptional	_	JJ	JJ	_	6	NMOD	_	_
5	activating	_	VBG	VBG	_	6	NMOD	_	_
6	proteins	_	NNS	NNS	_	3	PMOD	_	_
7	,	_	,	,	_	2	P	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	GATA	_	NN	NN	_	10	NMOD	_	_
10	factors	_	NNS	NNS	_	2	NMOD	_	_
11	,	_	,	,	_	2	P	_	_
12	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	been	_	VBN	VBN	_	12	VC	_	_
14	shown	_	VBN	VBN	_	13	VC	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	bind	_	VB	VB	_	14	OBJ	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	consensus	_	NN	NN	_	20	NMOD	_	_
20	motif	_	NN	NN	_	17	PMOD	_	_
21	through	_	IN	IN	_	16	ADV	_	_
22	a	_	DT	DT	_	30	NMOD	_	_
23	highly	_	RB	RB	_	24	AMOD	_	_
24	conserved	_	VBN	VBN	_	30	NMOD	_	_
25	C4	_	NN	NN	_	30	NMOD	_	_
26	zinc	_	NN	NN	_	30	NMOD	_	_
27	finger	_	NN	NN	_	30	NMOD	_	_
28	DNA	_	NN	NN	_	30	NMOD	_	_
29	binding	_	NN	NN	_	30	NMOD	_	_
30	domain	_	NN	NN	_	21	PMOD	_	_
31	.	_	.	.	_	12	P	_	_

1	One	_	CD	CD	_	2	NMOD	_	_
2	member	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	this	_	DT	DT	_	6	NMOD	_	_
5	multigene	_	JJ	JJ	_	6	NMOD	_	_
6	family	_	NN	NN	_	3	PMOD	_	_
7	,	_	,	,	_	2	P	_	_
8	GATA-3	_	NN	NN	_	2	NMOD	_	_
9	,	_	,	,	_	2	P	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	most	_	RBS	RBS	_	12	AMOD	_	_
12	abundantly	_	RB	RB	_	10	PRD	_	_
13	expressed	_	VBN	VBN	_	10	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	lymphocytes	_	NNS	NNS	_	14	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	cellular	_	JJ	JJ	_	20	NMOD	_	_
20	target	_	NN	NN	_	16	NMOD	_	_
21	for	_	IN	IN	_	20	NMOD	_	_
22	human	_	JJ	JJ	_	25	NMOD	_	_
23	immunodeficiency	_	NN	NN	_	25	NMOD	_	_
24	virus	_	NN	NN	_	25	NMOD	_	_
25	type	_	NN	NN	_	21	PMOD	_	_
26	1	_	CD	CD	_	25	NMOD	_	_
27	(	_	(	(	_	28	P	_	_
28	HIV-1	_	NN	NN	_	25	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	infection	_	NN	NN	_	25	NMOD	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	replication	_	NN	NN	_	30	COORD	_	_
33	.	_	.	.	_	10	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	vitro	_	FW	FW	_	6	NMOD	_	_
3	DNase	_	NN	NN	_	6	NMOD	_	_
4	I	_	CD	CD	_	6	NMOD	_	_
5	footprinting	_	NN	NN	_	6	NMOD	_	_
6	analysis	_	NN	NN	_	7	SBJ	_	_
7	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
8	six	_	CD	CD	_	11	NMOD	_	_
9	hGATA-3	_	NN	NN	_	11	NMOD	_	_
10	binding	_	NN	NN	_	11	NMOD	_	_
11	sites	_	NNS	NNS	_	7	OBJ	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	U3	_	NN	NN	_	15	NMOD	_	_
15	region	_	NN	NN	_	12	PMOD	_	_
16	(	_	(	(	_	20	P	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	transcriptional	_	JJ	JJ	_	19	AMOD	_	_
19	regulatory	_	JJ	JJ	_	20	NMOD	_	_
20	domain	_	NN	NN	_	15	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	of	_	IN	IN	_	15	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	HIV-1	_	NN	NN	_	25	NMOD	_	_
25	LTR	_	NN	NN	_	22	PMOD	_	_
26	.	_	.	.	_	7	P	_	_

1	Cotransfection	_	NN	NN	_	19	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	an	_	DT	DT	_	6	NMOD	_	_
4	hGATA-3	_	NN	NN	_	6	NMOD	_	_
5	expression	_	NN	NN	_	6	NMOD	_	_
6	plasmid	_	NN	NN	_	2	PMOD	_	_
7	with	_	IN	IN	_	1	NMOD	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	reporter	_	NN	NN	_	10	NMOD	_	_
10	plasmid	_	NN	NN	_	7	PMOD	_	_
11	whose	_	WP$	WP$	_	12	NMOD	_	_
12	transcription	_	NN	NN	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	10	NMOD	_	_
14	directed	_	VBN	VBN	_	13	VC	_	_
15	by	_	IN	IN	_	14	LGS	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	HIV-1	_	NN	NN	_	18	NMOD	_	_
18	LTR	_	NN	NN	_	15	PMOD	_	_
19	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	6-	_	CD	CD	_	23	DEP	_	_
22	to	_	TO	TO	_	23	DEP	_	_
23	10-fold	_	JJ	JJ	_	24	NMOD	_	_
24	stimulation	_	NN	NN	_	20	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	LTR-mediated	_	JJ	JJ	_	27	NMOD	_	_
27	transcription	_	NN	NN	_	25	PMOD	_	_
28	,	_	,	,	_	19	P	_	_
29	whereas	_	IN	IN	_	19	COORD	_	_
30	site	_	NN	NN	_	32	NMOD	_	_
31	specific	_	JJ	JJ	_	30	AMOD	_	_
32	mutation	_	NN	NN	_	37	SBJ	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	these	_	DT	DT	_	36	NMOD	_	_
35	GATA	_	NN	NN	_	36	NMOD	_	_
36	sites	_	NNS	NNS	_	33	PMOD	_	_
37	resulted	_	VBD	VBD	_	19	COORD	_	_
38	in	_	IN	IN	_	37	ADV	_	_
39	virtual	_	JJ	JJ	_	40	NMOD	_	_
40	abrogation	_	NN	NN	_	38	PMOD	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	the	_	DT	DT	_	43	NMOD	_	_
43	activation	_	NN	NN	_	41	PMOD	_	_
44	by	_	IN	IN	_	43	NMOD	_	_
45	hGATA-3	_	NN	NN	_	44	PMOD	_	_
46	.	_	.	.	_	19	P	_	_

1	Further	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	deletion	_	NN	NN	_	10	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	hGATA-3	_	NN	NN	_	9	NMOD	_	_
7	transcriptional	_	JJ	JJ	_	9	NMOD	_	_
8	activation	_	NN	NN	_	9	NMOD	_	_
9	domain	_	NN	NN	_	4	PMOD	_	_
10	abolished	_	VBD	VBD	_	0	ROOT-S	_	_
11	GATA-dependent	_	JJ	JJ	_	13	NMOD	_	_
12	HIV-1	_	NN	NN	_	13	NMOD	_	_
13	trans-activation	_	NN	NN	_	10	IOBJ	_	_
14	,	_	,	,	_	10	P	_	_
15	showing	_	VBG	VBG	_	10	OBJ	_	_
16	that	_	IN	IN	_	15	OBJ	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	stimulation	_	NN	NN	_	23	SBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	viral	_	JJ	JJ	_	21	NMOD	_	_
21	transcription	_	NN	NN	_	19	PMOD	_	_
22	observed	_	VBN	VBN	_	21	NMOD	_	_
23	is	_	VBZ	VBZ	_	16	VMOD	_	_
24	a	_	DT	DT	_	26	NMOD	_	_
25	direct	_	JJ	JJ	_	26	NMOD	_	_
26	effect	_	NN	NN	_	23	PRD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	cotransfected	_	VBN	VBN	_	29	NMOD	_	_
29	hGATA-3	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	10	P	_	_

1	Introduction	_	NN	NN	_	19	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	HIV-1	_	NN	NN	_	5	NMOD	_	_
5	plasmids	_	NNS	NNS	_	2	PMOD	_	_
6	in	_	IN	IN	_	13	ADV	_	_
7	which	_	WDT	WDT	_	6	PMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	GATA	_	NN	NN	_	10	NMOD	_	_
10	sites	_	NNS	NNS	_	11	SBJ	_	_
11	have	_	VBP	VBP	_	5	NMOD	_	_
12	been	_	VBN	VBN	_	11	VC	_	_
13	mutated	_	VBN	VBN	_	12	VC	_	_
14	into	_	IN	IN	_	13	ADV	_	_
15	human	_	JJ	JJ	_	17	NMOD	_	_
16	T	_	NN	NN	_	17	NMOD	_	_
17	lymphocytes	_	NNS	NNS	_	14	PMOD	_	_
18	also	_	RB	RB	_	19	ADV	_	_
19	caused	_	VBD	VBD	_	0	ROOT-S	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	significant	_	JJ	JJ	_	22	NMOD	_	_
22	reduction	_	NN	NN	_	19	OBJ	_	_
23	in	_	IN	IN	_	22	NMOD	_	_
24	LTR-mediated	_	JJ	JJ	_	25	NMOD	_	_
25	transcription	_	NN	NN	_	23	PMOD	_	_
26	at	_	IN	IN	_	19	ADV	_	_
27	both	_	CC	CC	_	30	CC	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	basal	_	JJ	JJ	_	30	NMOD	_	_
30	level	_	NN	NN	_	26	PMOD	_	_
31	and	_	CC	CC	_	26	CC	_	_
32	in	_	IN	IN	_	26	COORD	_	_
33	(	_	(	(	_	38	P	_	_
34	PHA-	_	NN	NN	_	38	AMOD	_	_
35	plus	_	CC	CC	_	34	CC	_	_
36	PMA-	_	NN	NN	_	34	COORD	_	_
37	)	_	)	)	_	38	P	_	_
38	stimulated	_	JJ	JJ	_	40	NMOD	_	_
39	T	_	NN	NN	_	40	NMOD	_	_
40	cells	_	NNS	NNS	_	32	PMOD	_	_
41	.	_	.	.	_	19	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	observations	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	in	_	IN	IN	_	18	ADV	_	_
6	addition	_	NN	NN	_	5	DEP	_	_
7	to	_	TO	TO	_	5	DEP	_	_
8	its	_	PRP$	PRP$	_	10	NMOD	_	_
9	normal	_	JJ	JJ	_	10	NMOD	_	_
10	role	_	NN	NN	_	5	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	T	_	NN	NN	_	15	NMOD	_	_
13	lymphocyte	_	NN	NN	_	15	NMOD	_	_
14	gene	_	NN	NN	_	15	NMOD	_	_
15	regulation	_	NN	NN	_	11	PMOD	_	_
16	,	_	,	,	_	18	P	_	_
17	hGATA-3	_	NN	NN	_	18	SBJ	_	_
18	may	_	MD	MD	_	4	VMOD	_	_
19	also	_	RB	RB	_	18	ADV	_	_
20	play	_	VB	VB	_	18	VC	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	significant	_	JJ	JJ	_	23	NMOD	_	_
23	role	_	NN	NN	_	20	OBJ	_	_
24	in	_	IN	IN	_	20	ADV	_	_
25	HIV-1	_	NN	NN	_	27	NMOD	_	_
26	transcriptional	_	JJ	JJ	_	27	NMOD	_	_
27	activation	_	NN	NN	_	24	PMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	Tumor	_	NN	NN	_	5	NMOD	_	_
2	necrosis	_	NN	NN	_	5	NMOD	_	_
3	factor	_	NN	NN	_	5	NMOD	_	_
4	receptor	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	0	ROOT-FRAG	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	signal	_	NN	NN	_	8	NMOD	_	_
8	transduction	_	NN	NN	_	5	COORD	_	_
9	in	_	IN	IN	_	5	NMOD	_	_
10	HIV-1-infected	_	JJ	JJ	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	.	_	.	.	_	5	P	_	_

1	OBJECTIVE	_	NN	NN	_	4	VMOD	_	_
2	:	_	:	:	_	1	P	_	_
3	To	_	TO	TO	_	4	VMOD	_	_
4	examine	_	VB	VB	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	inter-relationship	_	NN	NN	_	4	OBJ	_	_
7	between	_	IN	IN	_	6	NMOD	_	_
8	HIV-1	_	NN	NN	_	9	NMOD	_	_
9	infection	_	NN	NN	_	7	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	cell	_	NN	NN	_	14	NMOD	_	_
13	surface	_	NN	NN	_	14	NMOD	_	_
14	receptors	_	NNS	NNS	_	9	COORD	_	_
15	for	_	IN	IN	_	14	NMOD	_	_
16	tumor	_	NN	NN	_	22	NMOD	_	_
17	necrosis	_	NN	NN	_	22	NMOD	_	_
18	factor	_	NN	NN	_	22	NMOD	_	_
19	(	_	(	(	_	22	P	_	_
20	TNF	_	NN	NN	_	22	NMOD	_	_
21	)	_	)	)	_	22	P	_	_
22	-alpha	_	NN	NN	_	15	PMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	an	_	DT	DT	_	26	NMOD	_	_
25	immunoregulatory	_	JJ	JJ	_	26	NMOD	_	_
26	cytokine	_	NN	NN	_	22	NMOD	_	_
27	that	_	WDT	WDT	_	28	SBJ	_	_
28	can	_	MD	MD	_	26	NMOD	_	_
29	enhance	_	VB	VB	_	28	VC	_	_
30	HIV-1	_	NN	NN	_	31	NMOD	_	_
31	replication	_	NN	NN	_	29	OBJ	_	_
32	.	_	.	.	_	4	P	_	_

1	DESIGN	_	NN	NN	_	8	VMOD	_	_
2	:	_	:	:	_	1	P	_	_
3	Infected	_	JJ	JJ	_	7	NMOD	_	_
4	promyelocytic	_	JJ	JJ	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	promonocytic	_	JJ	JJ	_	4	COORD	_	_
7	cells	_	NNS	NNS	_	8	SBJ	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	examined	_	VBN	VBN	_	8	VC	_	_
10	because	_	IN	IN	_	9	ADV	_	_
11	they	_	PRP	PRP	_	13	SBJ	_	_
12	normally	_	RB	RB	_	13	ADV	_	_
13	express	_	VBP	VBP	_	10	VMOD	_	_
14	both	_	DT	DT	_	15	NMOD	_	_
15	types	_	NNS	NNS	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	TNF	_	NN	NN	_	18	NMOD	_	_
18	receptors	_	NNS	NNS	_	16	PMOD	_	_
19	.	_	.	.	_	8	P	_	_

1	METHODS	_	NNS	NNS	_	7	VMOD	_	_
2	:	_	:	:	_	1	P	_	_
3	TNF	_	NN	NN	_	6	NMOD	_	_
4	receptor	_	NN	NN	_	6	NMOD	_	_
5	surface	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	7	SBJ	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	determined	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	specific	_	JJ	JJ	_	13	NMOD	_	_
11	monoclonal	_	JJ	JJ	_	13	NMOD	_	_
12	antibody	_	NN	NN	_	13	NMOD	_	_
13	recognition	_	NN	NN	_	9	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	flow	_	NN	NN	_	16	NMOD	_	_
16	cytometry	_	NN	NN	_	13	COORD	_	_
17	,	_	,	,	_	7	P	_	_
18	and	_	CC	CC	_	7	CC	_	_
19	signal	_	NN	NN	_	20	NMOD	_	_
20	transduction	_	NN	NN	_	21	SBJ	_	_
21	was	_	VBD	VBD	_	7	COORD	_	_
22	detected	_	VBN	VBN	_	21	VC	_	_
23	by	_	IN	IN	_	22	LGS	_	_
24	gel	_	NN	NN	_	26	NMOD	_	_
25	shift	_	NN	NN	_	26	NMOD	_	_
26	analysis	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	7	P	_	_

1	HIV-1	_	NN	NN	_	5	SBJ	_	_
2	activation	_	NN	NN	_	1	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	expression	_	NN	NN	_	2	COORD	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	quantitated	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	reverse	_	JJ	JJ	_	10	NMOD	_	_
9	transcriptase	_	NN	NN	_	10	NMOD	_	_
10	assay	_	NN	NN	_	7	PMOD	_	_
11	.	_	.	.	_	5	P	_	_

1	RESULTS	_	NNS	NNS	_	16	VMOD	_	_
2	:	_	:	:	_	1	P	_	_
3	In	_	IN	IN	_	16	ADV	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	OM-10.1	_	NN	NN	_	7	NMOD	_	_
6	promyelocytic	_	JJ	JJ	_	7	NMOD	_	_
7	model	_	NN	NN	_	3	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	chronic	_	JJ	JJ	_	10	NMOD	_	_
10	infection	_	NN	NN	_	8	PMOD	_	_
11	,	_	,	,	_	16	P	_	_
12	TNF-alpha-induced	_	JJ	JJ	_	14	NMOD	_	_
13	HIV-1	_	NN	NN	_	14	NMOD	_	_
14	expression	_	NN	NN	_	16	SBJ	_	_
15	also	_	RB	RB	_	16	ADV	_	_
16	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
17	in	_	IN	IN	_	16	ADV	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	substantial	_	JJ	JJ	_	20	NMOD	_	_
20	increase	_	NN	NN	_	17	PMOD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	75	_	CD	CD	_	25	NMOD	_	_
23	kd	_	NN	NN	_	25	NMOD	_	_
24	TNF	_	NN	NN	_	25	NMOD	_	_
25	receptor	_	NN	NN	_	29	NMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	TR75	_	NN	NN	_	25	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	expression	_	NN	NN	_	21	PMOD	_	_
30	although	_	IN	IN	_	16	OBJ	_	_
31	55	_	CD	CD	_	34	NMOD	_	_
32	kD	_	NN	NN	_	34	NMOD	_	_
33	TNF	_	NN	NN	_	34	NMOD	_	_
34	receptor	_	NN	NN	_	38	NMOD	_	_
35	(	_	(	(	_	36	P	_	_
36	TR55	_	NN	NN	_	34	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	levels	_	NNS	NNS	_	39	SBJ	_	_
39	were	_	VBD	VBD	_	30	VMOD	_	_
40	not	_	RB	RB	_	39	VMOD	_	_
41	dramatically	_	RB	RB	_	39	ADV	_	_
42	altered	_	VBN	VBN	_	39	VC	_	_
43	.	_	.	.	_	16	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	series	_	NN	NN	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	uninfected	_	JJ	JJ	_	7	NMOD	_	_
5	parental	_	JJ	JJ	_	7	NMOD	_	_
6	HL-60	_	NN	NN	_	7	NMOD	_	_
7	subclones	_	NNS	NNS	_	3	PMOD	_	_
8	all	_	DT	DT	_	2	NMOD	_	_
9	reduced	_	VBD	VBD	_	0	ROOT-S	_	_
10	TR75	_	NN	NN	_	12	NMOD	_	_
11	surface	_	NN	NN	_	12	NMOD	_	_
12	expression	_	NN	NN	_	9	OBJ	_	_
13	in	_	IN	IN	_	9	ADV	_	_
14	response	_	NN	NN	_	13	DEP	_	_
15	to	_	TO	TO	_	13	DEP	_	_
16	TNF-alpha	_	NN	NN	_	17	NMOD	_	_
17	treatment	_	NN	NN	_	13	PMOD	_	_
18	.	_	.	.	_	9	P	_	_

1	Enhanced	_	VBN	VBN	_	3	NMOD	_	_
2	TR75	_	NN	NN	_	3	NMOD	_	_
3	expression	_	NN	NN	_	7	SBJ	_	_
4	on	_	IN	IN	_	3	NMOD	_	_
5	OM-10.1	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	followed	_	VBD	VBD	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	same	_	JJ	JJ	_	11	NMOD	_	_
10	TNF-alpha-dose	_	NN	NN	_	11	NMOD	_	_
11	dependency	_	NN	NN	_	7	OBJ	_	_
12	as	_	IN	IN	_	11	NMOD	_	_
13	that	_	WDT	WDT	_	12	PMOD	_	_
14	observed	_	VBN	VBN	_	13	NMOD	_	_
15	for	_	IN	IN	_	14	ADV	_	_
16	HIV-1	_	NN	NN	_	17	NMOD	_	_
17	production	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	7	P	_	_

1	An	_	DT	DT	_	2	NMOD	_	_
2	increase	_	NN	NN	_	6	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	TR75	_	NN	NN	_	5	NMOD	_	_
5	expression	_	NN	NN	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	also	_	RB	RB	_	6	ADV	_	_
8	evident	_	JJ	JJ	_	6	PRD	_	_
9	during	_	IN	IN	_	6	TMP	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	peak	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	an	_	DT	DT	_	16	NMOD	_	_
14	acute	_	JJ	JJ	_	16	NMOD	_	_
15	HIV-1	_	NN	NN	_	16	NMOD	_	_
16	infection	_	NN	NN	_	12	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	HL-60	_	NN	NN	_	19	NMOD	_	_
19	promyelocytes	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	6	P	_	_

1	Although	_	IN	IN	_	13	ADV	_	_
2	TR55	_	NN	NN	_	3	NMOD	_	_
3	expression	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	1	VMOD	_	_
5	unaltered	_	JJ	JJ	_	4	PRD	_	_
6	during	_	IN	IN	_	4	TMP	_	_
7	TNF-alpha-induced	_	JJ	JJ	_	9	NMOD	_	_
8	HIV	_	NN	NN	_	9	NMOD	_	_
9	activation	_	NN	NN	_	6	PMOD	_	_
10	,	_	,	,	_	13	P	_	_
11	this	_	DT	DT	_	12	NMOD	_	_
12	receptor	_	NN	NN	_	13	SBJ	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	still	_	RB	RB	_	13	ADV	_	_
15	involved	_	VBN	VBN	_	13	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	viral	_	JJ	JJ	_	20	NMOD	_	_
19	activation	_	NN	NN	_	20	NMOD	_	_
20	process	_	NN	NN	_	16	PMOD	_	_
21	.	_	.	.	_	13	P	_	_

1	Antibody	_	NN	NN	_	2	NMOD	_	_
2	cross-linking	_	NN	NN	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	TR55	_	NN	NN	_	3	PMOD	_	_
5	,	_	,	,	_	13	P	_	_
6	in	_	IN	IN	_	13	ADV	_	_
7	the	_	DT	DT	_	6	DEP	_	_
8	absence	_	NN	NN	_	6	DEP	_	_
9	of	_	IN	IN	_	6	DEP	_	_
10	exogenous	_	JJ	JJ	_	11	NMOD	_	_
11	TNF-alpha	_	NN	NN	_	6	PMOD	_	_
12	,	_	,	,	_	13	P	_	_
13	induced	_	VBN	VBN	_	0	ROOT-S	_	_
14	maximal	_	JJ	JJ	_	16	NMOD	_	_
15	HIV-1	_	NN	NN	_	16	NMOD	_	_
16	expression	_	NN	NN	_	13	OBJ	_	_
17	,	_	,	,	_	16	P	_	_
18	an	_	DT	DT	_	19	NMOD	_	_
19	up-modulation	_	NN	NN	_	16	COORD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	surface	_	NN	NN	_	22	NMOD	_	_
22	TR75	_	NN	NN	_	20	PMOD	_	_
23	,	_	,	,	_	16	P	_	_
24	and	_	CC	CC	_	16	CC	_	_
25	nuclear	_	JJ	JJ	_	28	NMOD	_	_
26	NF-kappa	_	NN	NN	_	28	NMOD	_	_
27	B	_	NN	NN	_	28	NMOD	_	_
28	activity	_	NN	NN	_	16	COORD	_	_
29	in	_	IN	IN	_	16	NMOD	_	_
30	OM-10.1	_	NN	NN	_	31	NMOD	_	_
31	cultures	_	NNS	NNS	_	29	PMOD	_	_
32	.	_	.	.	_	13	P	_	_

1	Surprisingly	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	this	_	DT	DT	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	case	_	NN	NN	_	4	PRD	_	_
7	even	_	RB	RB	_	8	AMOD	_	_
8	when	_	WRB	WRB	_	14	ADV	_	_
9	an	_	DT	DT	_	12	NMOD	_	_
10	antagonistic	_	JJ	JJ	_	12	NMOD	_	_
11	anti-TR55	_	JJ	JJ	_	12	NMOD	_	_
12	antibody	_	NN	NN	_	13	SBJ	_	_
13	was	_	VBD	VBD	_	4	TMP	_	_
14	used	_	VBN	VBN	_	13	VC	_	_
15	.	_	.	.	_	4	P	_	_

1	Anti-TR55	_	JJ	JJ	_	3	NMOD	_	_
2	antibody	_	NN	NN	_	3	NMOD	_	_
3	cross-linking	_	NN	NN	_	10	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	chronically	_	RB	RB	_	6	AMOD	_	_
6	infected	_	JJ	JJ	_	9	NMOD	_	_
7	U1	_	NN	NN	_	9	NMOD	_	_
8	promonocytic	_	JJ	JJ	_	9	NMOD	_	_
9	cultures	_	NNS	NNS	_	4	PMOD	_	_
10	could	_	MD	MD	_	0	ROOT-S	_	_
11	only	_	RB	RB	_	10	ADV	_	_
12	partially	_	RB	RB	_	11	AMOD	_	_
13	substitute	_	VB	VB	_	10	VC	_	_
14	for	_	IN	IN	_	13	ADV	_	_
15	TNF-alpha-induced	_	JJ	JJ	_	17	NMOD	_	_
16	HIV-1	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	10	P	_	_

1	CONCLUSIONS	_	NNS	NNS	_	5	VMOD	_	_
2	:	_	:	:	_	1	P	_	_
3	Our	_	PRP$	PRP$	_	4	NMOD	_	_
4	results	_	NNS	NNS	_	5	SBJ	_	_
5	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	HIV-1	_	NN	NN	_	8	NMOD	_	_
8	infection	_	NN	NN	_	9	SBJ	_	_
9	can	_	MD	MD	_	6	VMOD	_	_
10	selectively	_	RB	RB	_	9	ADV	_	_
11	influence	_	VB	VB	_	9	VC	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	surface	_	NN	NN	_	14	NMOD	_	_
14	expression	_	NN	NN	_	11	IOBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	TNF	_	NN	NN	_	17	NMOD	_	_
17	receptors	_	NNS	NNS	_	15	PMOD	_	_
18	,	_	,	,	_	11	P	_	_
19	potentially	_	RB	RB	_	20	ADV	_	_
20	influencing	_	VBG	VBG	_	11	OBJ	_	_
21	its	_	PRP$	PRP$	_	23	NMOD	_	_
22	own	_	JJ	JJ	_	23	NMOD	_	_
23	expression	_	NN	NN	_	20	OBJ	_	_
24	and	_	CC	CC	_	20	CC	_	_
25	altering	_	VBG	VBG	_	20	COORD	_	_
26	normal	_	JJ	JJ	_	29	NMOD	_	_
27	immunoregulatory	_	JJ	JJ	_	29	NMOD	_	_
28	signal	_	NN	NN	_	29	NMOD	_	_
29	transduction	_	NN	NN	_	25	OBJ	_	_
30	.	_	.	.	_	5	P	_	_

1	Inhibition	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	HIV-1	_	NN	NN	_	5	NMOD	_	_
4	latency	_	NN	NN	_	5	NMOD	_	_
5	reactivation	_	NN	NN	_	2	PMOD	_	_
6	by	_	IN	IN	_	1	NMOD	_	_
7	dehydroepiandrosterone	_	NN	NN	_	6	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	DHEA	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	an	_	DT	DT	_	13	NMOD	_	_
13	analog	_	NN	NN	_	7	COORD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	DHEA	_	NN	NN	_	14	PMOD	_	_
16	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	initial	_	JJ	JJ	_	3	NMOD	_	_
3	infection	_	NN	NN	_	17	SBJ	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	human	_	JJ	JJ	_	8	NMOD	_	_
6	immunodeficiency	_	NN	NN	_	8	NMOD	_	_
7	virus	_	NN	NN	_	8	NMOD	_	_
8	type	_	NN	NN	_	4	PMOD	_	_
9	1	_	CD	CD	_	8	NMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	HIV-1	_	NN	NN	_	8	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	in	_	IN	IN	_	3	NMOD	_	_
14	most	_	JJS	JJS	_	15	NMOD	_	_
15	individuals	_	NNS	NNS	_	13	PMOD	_	_
16	usually	_	RB	RB	_	17	TMP	_	_
17	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	establishment	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	a	_	DT	DT	_	26	NMOD	_	_
23	latent	_	JJ	JJ	_	26	NMOD	_	_
24	or	_	CC	CC	_	23	CC	_	_
25	chronic	_	JJ	JJ	_	23	COORD	_	_
26	infection	_	NN	NN	_	21	PMOD	_	_
27	before	_	IN	IN	_	20	TMP	_	_
28	eventual	_	JJ	JJ	_	29	NMOD	_	_
29	progression	_	NN	NN	_	27	PMOD	_	_
30	toward	_	IN	IN	_	29	NMOD	_	_
31	acquired	_	VBN	VBN	_	33	NMOD	_	_
32	immunodeficiency	_	NN	NN	_	33	NMOD	_	_
33	syndrome	_	NN	NN	_	30	PMOD	_	_
34	.	_	.	.	_	17	P	_	_

1	HIV-1	_	NN	NN	_	2	SBJ	_	_
2	can	_	MD	MD	_	0	ROOT-S	_	_
3	also	_	RB	RB	_	2	ADV	_	_
4	establish	_	VB	VB	_	2	VC	_	_
5	a	_	DT	DT	_	9	NMOD	_	_
6	latent	_	JJ	JJ	_	9	NMOD	_	_
7	or	_	CC	CC	_	6	CC	_	_
8	persistent	_	JJ	JJ	_	6	COORD	_	_
9	infection	_	NN	NN	_	4	OBJ	_	_
10	in	_	IN	IN	_	4	ADV	_	_
11	some	_	DT	DT	_	14	NMOD	_	_
12	T	_	NN	NN	_	14	NMOD	_	_
13	cell	_	NN	NN	_	14	NMOD	_	_
14	lines	_	NNS	NNS	_	10	PMOD	_	_
15	that	_	WDT	WDT	_	16	SBJ	_	_
16	show	_	VBP	VBP	_	14	NMOD	_	_
17	minimal	_	JJ	JJ	_	20	NMOD	_	_
18	constitutive	_	JJ	JJ	_	20	NMOD	_	_
19	virus	_	NN	NN	_	20	NMOD	_	_
20	expression	_	NN	NN	_	16	OBJ	_	_
21	.	_	.	.	_	2	P	_	_

1	However	_	RB	RB	_	14	ADV	_	_
2	,	_	,	,	_	14	P	_	_
3	activation	_	NN	NN	_	14	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	T	_	NN	NN	_	8	NMOD	_	_
7	cell	_	NN	NN	_	8	NMOD	_	_
8	lines	_	NNS	NNS	_	4	PMOD	_	_
9	leading	_	VBG	VBG	_	3	NMOD	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	enhanced	_	VBN	VBN	_	13	NMOD	_	_
12	HIV-1	_	NN	NN	_	13	NMOD	_	_
13	replication	_	NN	NN	_	10	PMOD	_	_
14	can	_	MD	MD	_	0	ROOT-S	_	_
15	be	_	VB	VB	_	14	VC	_	_
16	induced	_	VBN	VBN	_	15	VC	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	antigens	_	NNS	NNS	_	17	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	mitogens	_	NNS	NNS	_	18	COORD	_	_
21	,	_	,	,	_	18	P	_	_
22	and	_	CC	CC	_	18	CC	_	_
23	cytokines	_	NNS	NNS	_	18	COORD	_	_
24	(	_	(	(	_	28	P	_	_
25	tumor	_	NN	NN	_	28	NMOD	_	_
26	necrosis	_	NN	NN	_	28	NMOD	_	_
27	factor	_	NN	NN	_	28	NMOD	_	_
28	alpha	_	NN	NN	_	18	PRN	_	_
29	{	_	(	(	_	30	P	_	_
30	TNF-alpha	_	NN	NN	_	28	PRN	_	_
31	}	_	)	)	_	30	P	_	_
32	,	_	,	,	_	28	P	_	_
33	interleukin	_	NN	NN	_	28	COORD	_	_
34	1	_	CD	CD	_	33	NMOD	_	_
35	,	_	,	,	_	28	P	_	_
36	and	_	CC	CC	_	28	CC	_	_
37	interleukin-2	_	NN	NN	_	28	COORD	_	_
38	)	_	)	)	_	28	P	_	_
39	.	_	.	.	_	14	P	_	_

1	Various	_	JJ	JJ	_	3	NMOD	_	_
2	gene	_	NN	NN	_	3	NMOD	_	_
3	products	_	NNS	NNS	_	21	SBJ	_	_
4	from	_	IN	IN	_	3	NMOD	_	_
5	other	_	JJ	JJ	_	6	NMOD	_	_
6	viruses	_	NNS	NNS	_	4	PMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	HTLV-1	_	NN	NN	_	6	PRN	_	_
9	,	_	,	,	_	8	P	_	_
10	HSV	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	8	P	_	_
12	EBV	_	NN	NN	_	8	COORD	_	_
13	,	_	,	,	_	8	P	_	_
14	CMV	_	NN	NN	_	8	COORD	_	_
15	,	_	,	,	_	8	P	_	_
16	HBV	_	NN	NN	_	8	COORD	_	_
17	,	_	,	,	_	8	P	_	_
18	and	_	CC	CC	_	8	CC	_	_
19	HHV-6	_	NN	NN	_	8	COORD	_	_
20	)	_	)	)	_	8	P	_	_
21	can	_	MD	MD	_	0	ROOT-S	_	_
22	also	_	RB	RB	_	21	ADV	_	_
23	enhance	_	VB	VB	_	21	VC	_	_
24	HIV-1	_	NN	NN	_	34	NMOD	_	_
25	long	_	JJ	JJ	_	29	AMOD	_	_
26	terminal	_	JJ	JJ	_	29	AMOD	_	_
27	repeat	_	NN	NN	_	29	AMOD	_	_
28	(	_	(	(	_	29	P	_	_
29	LTR	_	NN	NN	_	34	NMOD	_	_
30	)	_	)	)	_	29	P	_	_
31	-driven	_	JJ	JJ	_	29	AMOD	_	_
32	reporter	_	NN	NN	_	34	NMOD	_	_
33	gene	_	NN	NN	_	34	NMOD	_	_
34	activity	_	NN	NN	_	23	OBJ	_	_
35	.	_	.	.	_	21	P	_	_

1	On	_	IN	IN	_	9	ADV	_	_
2	the	_	DT	DT	_	1	DEP	_	_
3	basis	_	NN	NN	_	1	DEP	_	_
4	of	_	IN	IN	_	1	DEP	_	_
5	these	_	DT	DT	_	6	NMOD	_	_
6	observations	_	NNS	NNS	_	1	PMOD	_	_
7	,	_	,	,	_	9	P	_	_
8	it	_	PRP	PRP	_	9	SBJ	_	_
9	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	been	_	VBN	VBN	_	9	VC	_	_
11	proposed	_	VBN	VBN	_	10	VC	_	_
12	that	_	IN	IN	_	11	OBJ	_	_
13	reactivation	_	NN	NN	_	28	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	latent	_	JJ	JJ	_	16	NMOD	_	_
16	HIV-1	_	NN	NN	_	14	PMOD	_	_
17	harbored	_	VBN	VBN	_	16	NMOD	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	chronically	_	RB	RB	_	20	AMOD	_	_
20	infected	_	JJ	JJ	_	22	NMOD	_	_
21	T	_	NN	NN	_	22	NMOD	_	_
22	lymphocytes	_	NNS	NNS	_	18	PMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	monocytes	_	NNS	NNS	_	22	COORD	_	_
25	,	_	,	,	_	22	P	_	_
26	or	_	CC	CC	_	22	CC	_	_
27	macrophages	_	NNS	NNS	_	22	COORD	_	_
28	plays	_	VBZ	VBZ	_	12	VMOD	_	_
29	an	_	DT	DT	_	31	NMOD	_	_
30	important	_	JJ	JJ	_	31	NMOD	_	_
31	role	_	NN	NN	_	28	OBJ	_	_
32	in	_	IN	IN	_	28	ADV	_	_
33	the	_	DT	DT	_	34	NMOD	_	_
34	pathogenesis	_	NN	NN	_	32	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	AIDS	_	NN	NN	_	35	PMOD	_	_
37	.	_	.	.	_	9	P	_	_

1	So	_	RB	RB	_	5	TMP	_	_
2	far	_	RB	RB	_	1	AMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	there	_	EX	EX	_	5	SBJ	_	_
5	are	_	VBP	VBP	_	0	ROOT-S	_	_
6	no	_	DT	DT	_	7	NMOD	_	_
7	drugs	_	NNS	NNS	_	5	PRD	_	_
8	or	_	CC	CC	_	7	CC	_	_
9	therapy	_	NN	NN	_	7	COORD	_	_
10	available	_	JJ	JJ	_	7	NMOD	_	_
11	that	_	WDT	WDT	_	12	SBJ	_	_
12	can	_	MD	MD	_	7	NMOD	_	_
13	provide	_	VB	VB	_	12	VC	_	_
14	protection	_	NN	NN	_	13	OBJ	_	_
15	against	_	IN	IN	_	14	NMOD	_	_
16	HIV-1	_	NN	NN	_	18	NMOD	_	_
17	latency	_	NN	NN	_	18	NMOD	_	_
18	reactivation	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	5	P	_	_

1	ACH-2	_	NN	NN	_	14	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	derived	_	VBN	VBN	_	1	NMOD	_	_
4	from	_	IN	IN	_	3	ADV	_	_
5	a	_	DT	DT	_	9	NMOD	_	_
6	human	_	JJ	JJ	_	9	NMOD	_	_
7	T	_	NN	NN	_	9	NMOD	_	_
8	cell	_	NN	NN	_	9	NMOD	_	_
9	line	_	NN	NN	_	4	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	CEM	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	,	_	,	,	_	1	P	_	_
14	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	chronically	_	RB	RB	_	16	AMOD	_	_
16	infected	_	VBN	VBN	_	14	PRD	_	_
17	with	_	IN	IN	_	16	AMOD	_	_
18	HIV-1	_	NN	NN	_	17	DEP	_	_
19	,	_	,	,	_	14	P	_	_
20	with	_	IN	IN	_	14	ADV	_	_
21	low	_	JJ	JJ	_	22	NMOD	_	_
22	levels	_	NNS	NNS	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	constitutive	_	JJ	JJ	_	26	NMOD	_	_
25	virus	_	NN	NN	_	26	NMOD	_	_
26	expression	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	14	P	_	_

1	ACH-2	_	NN	NN	_	2	SBJ	_	_
2	can	_	MD	MD	_	0	ROOT-S	_	_
3	be	_	VB	VB	_	2	VC	_	_
4	converted	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	productive	_	JJ	JJ	_	7	NMOD	_	_
7	infection	_	NN	NN	_	5	PMOD	_	_
8	by	_	IN	IN	_	7	NMOD	_	_
9	stimulation	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	with	_	IN	IN	_	9	NMOD	_	_
14	12-O-tetradecanoylphorbol-13-acetate	_	NN	NN	_	13	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	TPA	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	,	_	,	,	_	14	P	_	_
19	mitogen	_	NN	NN	_	14	COORD	_	_
20	or	_	CC	CC	_	14	CC	_	_
21	cytokines	_	NNS	NNS	_	14	COORD	_	_
22	(	_	(	(	_	23	P	_	_
23	TNF-alpha	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	,	_	,	,	_	7	P	_	_
26	or	_	CC	CC	_	7	CC	_	_
27	infection	_	NN	NN	_	7	COORD	_	_
28	with	_	IN	IN	_	27	NMOD	_	_
29	HSV	_	NN	NN	_	28	PMOD	_	_
30	.	_	.	.	_	2	P	_	_

1	Therefore	_	RB	RB	_	6	ADV	_	_
2	the	_	DT	DT	_	5	NMOD	_	_
3	ACH-2	_	NN	NN	_	5	NMOD	_	_
4	cell	_	NN	NN	_	5	NMOD	_	_
5	line	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	good	_	JJ	JJ	_	9	NMOD	_	_
9	candidate	_	NN	NN	_	6	PRD	_	_
10	for	_	IN	IN	_	9	NMOD	_	_
11	studying	_	VBG	VBG	_	10	PMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	effects	_	NNS	NNS	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	drugs	_	NNS	NNS	_	14	PMOD	_	_
16	on	_	IN	IN	_	13	NMOD	_	_
17	HIV-1	_	NN	NN	_	18	NMOD	_	_
18	activation	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	6	P	_	_

1	Previously	_	RB	RB	_	4	TMP	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	have	_	VBP	VBP	_	0	ROOT-S	_	_
5	reported	_	VBN	VBN	_	4	VC	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	DHEA	_	NN	NN	_	13	SBJ	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	synthetic	_	JJ	JJ	_	10	NMOD	_	_
10	analogs	_	NNS	NNS	_	7	COORD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	DHEA	_	NN	NN	_	11	PMOD	_	_
13	can	_	MD	MD	_	6	VMOD	_	_
14	be	_	VB	VB	_	13	VC	_	_
15	modest	_	JJ	JJ	_	16	NMOD	_	_
16	inhibitors	_	NNS	NNS	_	14	PRD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	HIV-1	_	NN	NN	_	20	NMOD	_	_
19	IIIB	_	NN	NN	_	20	NMOD	_	_
20	replication	_	NN	NN	_	17	PMOD	_	_
21	in	_	IN	IN	_	14	ADV	_	_
22	phytohemagglutinin-stimulated	_	JJ	JJ	_	26	NMOD	_	_
23	peripheral	_	JJ	JJ	_	26	NMOD	_	_
24	blood	_	NN	NN	_	26	NMOD	_	_
25	lymphocyte	_	NN	NN	_	26	NMOD	_	_
26	cultures	_	NNS	NNS	_	21	PMOD	_	_
27	.	_	.	.	_	4	P	_	_

1	(	_	(	(	_	3	P	_	_
2	ABSTRACT	_	NN	NN	_	3	SBJ	_	_
3	TRUNCATED	_	VBN	VBN	_	0	ROOT-S	_	_
4	AT	_	IN	IN	_	3	ADV	_	_
5	250	_	CD	CD	_	6	NMOD	_	_
6	WORDS	_	NNS	NNS	_	4	PMOD	_	_
7	)	_	)	)	_	3	P	_	_

1	Chlorinated	_	VBN	VBN	_	2	NMOD	_	_
2	dibenzo-p-dioxins	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	dibenzofurans	_	NNS	NNS	_	2	COORD	_	_
5	and	_	CC	CC	_	2	CC	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	human	_	JJ	JJ	_	9	NMOD	_	_
8	immune	_	JJ	JJ	_	9	NMOD	_	_
9	system	_	NN	NN	_	2	COORD	_	_
10	.	_	.	.	_	2	P	_	_

1	1	_	LS	LS	_	5	NMOD	_	_
2	.	_	.	.	_	1	P	_	_
3	Blood	_	NN	NN	_	5	NMOD	_	_
4	cell	_	NN	NN	_	5	NMOD	_	_
5	receptors	_	NNS	NNS	_	0	ROOT-FRAG	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	volunteers	_	NNS	NNS	_	6	PMOD	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	moderately	_	RB	RB	_	10	AMOD	_	_
10	increased	_	VBN	VBN	_	12	NMOD	_	_
11	body	_	NN	NN	_	12	NMOD	_	_
12	burdens	_	NNS	NNS	_	8	PMOD	_	_
13	.	_	.	.	_	5	P	_	_

1	Using	_	VBG	VBG	_	12	VMOD	_	_
2	monoclonal	_	JJ	JJ	_	3	NMOD	_	_
3	antibodies	_	NNS	NNS	_	1	OBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	mAbs	_	NNS	NNS	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	and	_	CC	CC	_	3	CC	_	_
8	flow	_	NN	NN	_	9	NMOD	_	_
9	cytometry	_	NN	NN	_	3	COORD	_	_
10	,	_	,	,	_	12	P	_	_
11	we	_	PRP	PRP	_	12	SBJ	_	_
12	studied	_	VBD	VBD	_	0	ROOT-S	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	variety	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	surface	_	NN	NN	_	17	NMOD	_	_
17	receptors	_	NNS	NNS	_	15	PMOD	_	_
18	on	_	IN	IN	_	12	ADV	_	_
19	lymphocyte	_	NN	NN	_	20	NMOD	_	_
20	subpopulations	_	NNS	NNS	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	workers	_	NNS	NNS	_	21	PMOD	_	_
23	with	_	IN	IN	_	22	NMOD	_	_
24	moderately	_	RB	RB	_	25	AMOD	_	_
25	increased	_	VBN	VBN	_	27	NMOD	_	_
26	body	_	NN	NN	_	27	NMOD	_	_
27	burdens	_	NNS	NNS	_	23	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	2,3,7,8-tetrachlorodibenzo-p-dioxin	_	NN	NN	_	28	PMOD	_	_
30	(	_	(	(	_	31	P	_	_
31	TCDD	_	NN	NN	_	29	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	and	_	CC	CC	_	28	CC	_	_
34	of	_	IN	IN	_	28	COORD	_	_
35	other	_	JJ	JJ	_	37	NMOD	_	_
36	polychlorinated	_	VBN	VBN	_	37	NMOD	_	_
37	dibenzo-p-dioxins	_	NNS	NNS	_	34	PMOD	_	_
38	and	_	CC	CC	_	37	CC	_	_
39	dibenzofurans	_	NNS	NNS	_	37	COORD	_	_
40	(	_	(	(	_	41	P	_	_
41	PCDD\/PCDF	_	NN	NN	_	37	PRN	_	_
42	)	_	)	)	_	41	P	_	_
43	,	_	,	,	_	27	P	_	_
44	expressed	_	VBN	VBN	_	27	NMOD	_	_
45	here	_	RB	RB	_	44	ADV	_	_
46	as	_	IN	IN	_	44	ADV	_	_
47	International-Toxicity	_	NN	NN	_	48	NMOD	_	_
48	Equivalencies	_	NN	NN	_	46	PMOD	_	_
49	(	_	(	(	_	50	P	_	_
50	I-TE	_	NN	NN	_	48	PRN	_	_
51	)	_	)	)	_	50	P	_	_
52	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	hypothesis	_	NN	NN	_	6	SBJ	_	_
3	to	_	TO	TO	_	4	VMOD	_	_
4	be	_	VB	VB	_	2	NMOD	_	_
5	tested	_	VBN	VBN	_	4	VC	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	whether	_	IN	IN	_	6	PRD	_	_
8	or	_	CC	CC	_	7	CC	_	_
9	not	_	RB	RB	_	7	COORD	_	_
10	humans	_	NNS	NNS	_	11	SBJ	_	_
11	exhibit	_	VBP	VBP	_	7	COORD	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	similar	_	JJ	JJ	_	14	NMOD	_	_
14	susceptibility	_	NN	NN	_	11	OBJ	_	_
15	to	_	TO	TO	_	14	NMOD	_	_
16	PCDDs\/PCDFs	_	NNS	NNS	_	15	PMOD	_	_
17	with	_	IN	IN	_	11	ADV	_	_
18	respect	_	NN	NN	_	17	DEP	_	_
19	to	_	TO	TO	_	17	DEP	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	surface	_	NN	NN	_	22	NMOD	_	_
22	receptors	_	NNS	NNS	_	17	PMOD	_	_
23	found	_	VBN	VBN	_	22	NMOD	_	_
24	previously	_	RB	RB	_	23	TMP	_	_
25	to	_	TO	TO	_	26	VMOD	_	_
26	respond	_	VB	VB	_	23	OBJ	_	_
27	to	_	TO	TO	_	26	ADV	_	_
28	small	_	JJ	JJ	_	29	NMOD	_	_
29	doses	_	NNS	NNS	_	27	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	2,3,7,8-tetrachlorodibenzo-p-dioxin	_	NN	NN	_	30	PMOD	_	_
32	(	_	(	(	_	33	P	_	_
33	TCDD	_	NN	NN	_	31	PRN	_	_
34	)	_	)	)	_	33	P	_	_
35	in	_	IN	IN	_	29	NMOD	_	_
36	Callithrix	_	FW	FW	_	37	NMOD	_	_
37	jacchus	_	FW	FW	_	35	PMOD	_	_
38	.	_	.	.	_	6	P	_	_

1	These	_	DT	DT	_	2	SBJ	_	_
2	are	_	VBP	VBP	_	0	ROOT-S	_	_
3	:	_	:	:	_	2	P	_	_
4	helper-inducer	_	JJ	JJ	_	9	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	memory	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	T	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	2	PRD	_	_
10	(	_	(	(	_	11	P	_	_
11	CD4+CD45R0+CD45RA-CD29highCD11a+	_	JJ	JJ	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	,	_	,	,	_	9	P	_	_
14	CD20+	_	JJ	JJ	_	16	NMOD	_	_
15	B	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	9	COORD	_	_
17	,	_	,	,	_	9	P	_	_
18	and	_	CC	CC	_	9	CC	_	_
19	cytotoxic	_	JJ	JJ	_	21	NMOD	_	_
20	T	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	9	COORD	_	_
22	(	_	(	(	_	23	P	_	_
23	CD8+CD56+\/CD57+	_	JJ	JJ	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	.	_	.	.	_	2	P	_	_

1	Furthermore	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	68	_	CD	CD	_	4	NMOD	_	_
4	triple-labellings	_	NNS	NNS	_	7	SBJ	_	_
5	with	_	IN	IN	_	4	NMOD	_	_
6	mAbs	_	NNS	NNS	_	5	PMOD	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	performed	_	VBN	VBN	_	7	VC	_	_
9	on	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	each	_	DT	DT	_	14	NMOD	_	_
14	volunteer	_	NN	NN	_	12	PMOD	_	_
15	to	_	TO	TO	_	17	VMOD	_	_
16	possibly	_	RB	RB	_	17	ADV	_	_
17	generate	_	VB	VB	_	8	OBJ	_	_
18	further	_	JJ	JJ	_	19	NMOD	_	_
19	hypotheses	_	NNS	NNS	_	17	OBJ	_	_
20	.	_	.	.	_	7	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	evaluated	_	VBN	VBN	_	2	VC	_	_
4	whether	_	IN	IN	_	3	OBJ	_	_
5	any	_	DT	DT	_	9	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	variables	_	NNS	NNS	_	6	PMOD	_	_
9	might	_	MD	MD	_	4	VMOD	_	_
10	be	_	VB	VB	_	9	VC	_	_
11	used	_	VBN	VBN	_	10	VC	_	_
12	as	_	IN	IN	_	11	ADV	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	biomarker	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	effects	_	NNS	NNS	_	15	PMOD	_	_
17	for	_	IN	IN	_	14	NMOD	_	_
18	this	_	DT	DT	_	19	NMOD	_	_
19	class	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	compounds	_	NNS	NNS	_	20	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	There	_	EX	EX	_	2	SBJ	_	_
2	were	_	VBD	VBD	_	0	ROOT-S	_	_
3	two	_	CD	CD	_	5	NMOD	_	_
4	main	_	JJ	JJ	_	5	NMOD	_	_
5	goals	_	NNS	NNS	_	2	PRD	_	_
6	:	_	:	:	_	5	P	_	_
7	(	_	(	(	_	8	P	_	_
8	1	_	LS	LS	_	11	VMOD	_	_
9	)	_	)	)	_	8	P	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	evaluate	_	VB	VB	_	5	NMOD	_	_
12	whether	_	IN	IN	_	11	OBJ	_	_
13	workers	_	NNS	NNS	_	32	SBJ	_	_
14	with	_	IN	IN	_	13	NMOD	_	_
15	a	_	DT	DT	_	19	NMOD	_	_
16	moderately	_	RB	RB	_	17	AMOD	_	_
17	increased	_	VBN	VBN	_	19	NMOD	_	_
18	PCDD\/PCDF-body	_	NN	NN	_	19	NMOD	_	_
19	burden	_	NN	NN	_	14	PMOD	_	_
20	{	_	(	(	_	23	P	_	_
21	25-140	_	CD	CD	_	23	NMOD	_	_
22	ppt	_	NN	NN	_	21	AMOD	_	_
23	TCDD	_	NN	NN	_	19	PRN	_	_
24	or	_	CC	CC	_	23	CC	_	_
25	104-522	_	CD	CD	_	27	NMOD	_	_
26	ppt	_	NN	NN	_	25	AMOD	_	_
27	I-TE	_	NN	NN	_	23	COORD	_	_
28	in	_	IN	IN	_	23	NMOD	_	_
29	blood	_	NN	NN	_	30	NMOD	_	_
30	fat	_	NN	NN	_	28	PMOD	_	_
31	}	_	)	)	_	23	P	_	_
32	exhibit	_	VBP	VBP	_	12	VMOD	_	_
33	changes	_	NNS	NNS	_	32	OBJ	_	_
34	in	_	IN	IN	_	32	ADV	_	_
35	the	_	DT	DT	_	37	NMOD	_	_
36	surface	_	NN	NN	_	37	NMOD	_	_
37	receptors	_	NNS	NNS	_	34	PMOD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	white	_	JJ	JJ	_	41	NMOD	_	_
40	blood	_	NN	NN	_	41	NMOD	_	_
41	cells	_	NNS	NNS	_	38	PMOD	_	_
42	,	_	,	,	_	32	P	_	_
43	as	_	IN	IN	_	32	ADV	_	_
44	observed	_	VBN	VBN	_	43	VMOD	_	_
45	in	_	IN	IN	_	44	ADV	_	_
46	previous	_	JJ	JJ	_	47	NMOD	_	_
47	studies	_	NNS	NNS	_	45	PMOD	_	_
48	in	_	IN	IN	_	47	NMOD	_	_
49	non-human	_	JJ	JJ	_	50	NMOD	_	_
50	primates	_	NNS	NNS	_	48	PMOD	_	_
51	,	_	,	,	_	11	P	_	_
52	and	_	CC	CC	_	11	CC	_	_
53	(	_	(	(	_	54	P	_	_
54	2	_	LS	LS	_	57	VMOD	_	_
55	)	_	)	)	_	54	P	_	_
56	to	_	TO	TO	_	57	VMOD	_	_
57	clarify	_	VB	VB	_	11	COORD	_	_
58	whether	_	IN	IN	_	57	OBJ	_	_
59	persons	_	NNS	NNS	_	88	SBJ	_	_
60	at	_	IN	IN	_	59	NMOD	_	_
61	the	_	DT	DT	_	63	NMOD	_	_
62	upper	_	JJ	JJ	_	63	NMOD	_	_
63	range	_	NN	NN	_	60	PMOD	_	_
64	{	_	(	(	_	67	P	_	_
65	10-23	_	CD	CD	_	67	NMOD	_	_
66	ppt	_	NN	NN	_	65	AMOD	_	_
67	TCDD	_	NN	NN	_	63	PRN	_	_
68	or	_	CC	CC	_	67	CC	_	_
69	30-90	_	CD	CD	_	71	NMOD	_	_
70	ppt	_	NN	NN	_	69	AMOD	_	_
71	I-TE	_	NN	NN	_	67	COORD	_	_
72	in	_	IN	IN	_	67	NMOD	_	_
73	blood	_	NN	NN	_	74	NMOD	_	_
74	fat	_	NN	NN	_	72	PMOD	_	_
75	}	_	)	)	_	67	P	_	_
76	of	_	IN	IN	_	63	NMOD	_	_
77	the	_	DT	DT	_	81	NMOD	_	_
78	body	_	NN	NN	_	81	NMOD	_	_
79	burden	_	NN	NN	_	81	NMOD	_	_
80	reference	_	NN	NN	_	81	NMOD	_	_
81	values	_	NNS	NNS	_	76	PMOD	_	_
82	of	_	IN	IN	_	63	NMOD	_	_
83	a	_	DT	DT	_	87	NMOD	_	_
84	not	_	RB	RB	_	87	NMOD	_	_
85	particularly	_	RB	RB	_	84	AMOD	_	_
86	exposed	_	VBN	VBN	_	84	AMOD	_	_
87	population	_	NN	NN	_	82	PMOD	_	_
88	show	_	VBP	VBP	_	58	VMOD	_	_
89	detectable	_	JJ	JJ	_	90	NMOD	_	_
90	deviations	_	NNS	NNS	_	88	OBJ	_	_
91	in	_	IN	IN	_	88	ADV	_	_
92	these	_	DT	DT	_	94	NMOD	_	_
93	immunological	_	JJ	JJ	_	94	NMOD	_	_
94	variables	_	NNS	NNS	_	91	PMOD	_	_
95	,	_	,	,	_	88	P	_	_
96	when	_	WRB	WRB	_	97	ADV	_	_
97	compared	_	VBN	VBN	_	88	TMP	_	_
98	with	_	IN	IN	_	97	ADV	_	_
99	persons	_	NNS	NNS	_	98	PMOD	_	_
100	at	_	IN	IN	_	99	NMOD	_	_
101	the	_	DT	DT	_	105	NMOD	_	_
102	lower	_	JJR	JJR	_	105	NMOD	_	_
103	and	_	CC	CC	_	102	CC	_	_
104	medium	_	NN	NN	_	102	COORD	_	_
105	range	_	NN	NN	_	100	PMOD	_	_
106	{	_	(	(	_	109	P	_	_
107	1-3	_	CD	CD	_	109	NMOD	_	_
108	ppt	_	NN	NN	_	107	AMOD	_	_
109	TCDD	_	NN	NN	_	105	PRN	_	_
110	or	_	CC	CC	_	109	CC	_	_
111	9-29	_	CD	CD	_	113	NMOD	_	_
112	ppt	_	NN	NN	_	111	AMOD	_	_
113	I-TE	_	NN	NN	_	109	COORD	_	_
114	}	_	)	)	_	109	P	_	_
115	of	_	IN	IN	_	105	NMOD	_	_
116	these	_	DT	DT	_	120	NMOD	_	_
117	body	_	NN	NN	_	120	NMOD	_	_
118	burden	_	NN	NN	_	120	NMOD	_	_
119	reference	_	NN	NN	_	120	NMOD	_	_
120	values	_	NNS	NNS	_	115	PMOD	_	_
121	.	_	.	.	_	2	P	_	_

1	Regression	_	NN	NN	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	our	_	PRP$	PRP$	_	5	NMOD	_	_
5	data	_	NNS	NNS	_	3	PMOD	_	_
6	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
7	slight	_	JJ	JJ	_	8	NMOD	_	_
8	trends	_	NNS	NNS	_	6	OBJ	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	some	_	DT	DT	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	biomarkers	_	NNS	NNS	_	11	PMOD	_	_
14	(	_	(	(	_	16	P	_	_
15	e.g.	_	FW	FW	_	16	NMOD	_	_
16	CD45R0+	_	JJ	JJ	_	10	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	.	_	.	.	_	6	P	_	_

1	With	_	IN	IN	_	6	ADV	_	_
2	one	_	CD	CD	_	3	NMOD	_	_
3	exception	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	these	_	DT	DT	_	6	SBJ	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	all	_	DT	DT	_	6	ADV	_	_
8	increases	_	NNS	NNS	_	6	PRD	_	_
9	.	_	.	.	_	6	P	_	_

1	None	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	alterations	_	NNS	NNS	_	2	PMOD	_	_
5	observed	_	VBN	VBN	_	4	NMOD	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	of	_	IN	IN	_	6	PRD	_	_
8	medical	_	JJ	JJ	_	9	NMOD	_	_
9	relevance	_	NN	NN	_	7	PMOD	_	_
10	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	slight	_	JJ	JJ	_	3	NMOD	_	_
3	increase	_	NN	NN	_	10	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	percentage	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	CD4+CD45R0+	_	JJ	JJ	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	7	PMOD	_	_
10	remained	_	VBD	VBD	_	0	ROOT-S	_	_
11	significant	_	JJ	JJ	_	10	PRD	_	_
12	even	_	RB	RB	_	13	DEP	_	_
13	after	_	IN	IN	_	10	TMP	_	_
14	covariant	_	JJ	JJ	_	15	NMOD	_	_
15	analysis	_	NN	NN	_	13	PMOD	_	_
16	taking	_	VBG	VBG	_	15	NMOD	_	_
17	age-related	_	JJ	JJ	_	18	NMOD	_	_
18	changes	_	NNS	NNS	_	16	OBJ	_	_
19	into	_	IN	IN	_	16	ADV	_	_
20	account	_	NN	NN	_	19	PMOD	_	_
21	.	_	.	.	_	10	P	_	_

1	Altogether	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	data	_	NNS	NNS	_	5	SBJ	_	_
5	do	_	VBP	VBP	_	0	ROOT-S	_	_
6	not	_	RB	RB	_	5	VMOD	_	_
7	provide	_	VB	VB	_	5	VC	_	_
8	any	_	DT	DT	_	9	NMOD	_	_
9	evidence	_	NN	NN	_	7	OBJ	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	support	_	VB	VB	_	9	NMOD	_	_
12	an	_	DT	DT	_	13	NMOD	_	_
13	assumption	_	NN	NN	_	11	OBJ	_	_
14	that	_	IN	IN	_	13	NMOD	_	_
15	moderately	_	RB	RB	_	16	AMOD	_	_
16	increased	_	VBN	VBN	_	18	NMOD	_	_
17	body	_	NN	NN	_	18	NMOD	_	_
18	burdens	_	NNS	NNS	_	23	SBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	PCDDs\/PCDFs	_	NNS	NNS	_	19	PMOD	_	_
21	in	_	IN	IN	_	18	NMOD	_	_
22	adults	_	NNS	NNS	_	21	PMOD	_	_
23	induce	_	VBP	VBP	_	14	VMOD	_	_
24	decreases	_	NNS	NNS	_	23	OBJ	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	cellular	_	JJ	JJ	_	28	NMOD	_	_
28	components	_	NNS	NNS	_	25	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	33	NMOD	_	_
31	human	_	JJ	JJ	_	33	NMOD	_	_
32	immune	_	JJ	JJ	_	33	NMOD	_	_
33	system	_	NN	NN	_	29	PMOD	_	_
34	.	_	.	.	_	5	P	_	_

1	Adult	_	JJ	JJ	_	2	NMOD	_	_
2	humans	_	NNS	NNS	_	4	SBJ	_	_
3	certainly	_	RB	RB	_	4	ADV	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	less	_	RBR	RBR	_	6	AMOD	_	_
6	susceptible	_	JJ	JJ	_	4	PRD	_	_
7	to	_	TO	TO	_	6	AMOD	_	_
8	this	_	DT	DT	_	9	NMOD	_	_
9	action	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	PCDDs\/PCDFs	_	NNS	NNS	_	10	PMOD	_	_
12	than	_	IN	IN	_	6	AMOD	_	_
13	adolescent	_	JJ	JJ	_	12	PMOD	_	_
14	Callithrix	_	FW	FW	_	13	NMOD	_	_
15	jacchus	_	FW	FW	_	13	NMOD	_	_
16	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	macrophage	_	NN	NN	_	5	NMOD	_	_
3	transcription	_	NN	NN	_	5	NMOD	_	_
4	factor	_	NN	NN	_	5	NMOD	_	_
5	PU.1	_	NN	NN	_	6	SBJ	_	_
6	directs	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	tissue-specific	_	JJ	JJ	_	8	NMOD	_	_
8	expression	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	macrophage	_	NN	NN	_	14	NMOD	_	_
12	colony-stimulating	_	JJ	JJ	_	14	NMOD	_	_
13	factor	_	NN	NN	_	14	NMOD	_	_
14	receptor	_	NN	NN	_	9	PMOD	_	_
15	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	8	NMOD	_	_
2	macrophage	_	NN	NN	_	4	NMOD	_	_
3	colony-stimulating	_	JJ	JJ	_	4	NMOD	_	_
4	factor	_	NN	NN	_	8	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	M-CSF	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	receptor	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	expressed	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	tissue-specific	_	JJ	JJ	_	14	NMOD	_	_
14	fashion	_	NN	NN	_	11	PMOD	_	_
15	from	_	IN	IN	_	10	ADV	_	_
16	two	_	CD	CD	_	18	NMOD	_	_
17	distinct	_	JJ	JJ	_	18	NMOD	_	_
18	promoters	_	NNS	NNS	_	15	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	monocytes\/macrophages	_	NNS	NNS	_	19	PMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	placenta	_	NN	NN	_	20	COORD	_	_
24	.	_	.	.	_	9	P	_	_

1	In	_	IN	IN	_	25	ADV	_	_
2	order	_	NN	NN	_	1	VMOD	_	_
3	to	_	TO	TO	_	1	VMOD	_	_
4	further	_	RB	RB	_	5	ADV	_	_
5	understand	_	VB	VB	_	1	VMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	transcription	_	NN	NN	_	8	NMOD	_	_
8	factors	_	NNS	NNS	_	5	OBJ	_	_
9	which	_	WDT	WDT	_	10	SBJ	_	_
10	play	_	VBP	VBP	_	8	NMOD	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	role	_	NN	NN	_	10	OBJ	_	_
13	in	_	IN	IN	_	10	ADV	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	commitment	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	multipotential	_	JJ	JJ	_	18	NMOD	_	_
18	progenitors	_	NNS	NNS	_	16	PMOD	_	_
19	to	_	TO	TO	_	15	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	monocyte\/macrophage	_	NN	NN	_	22	NMOD	_	_
22	lineage	_	NN	NN	_	19	PMOD	_	_
23	,	_	,	,	_	25	P	_	_
24	we	_	PRP	PRP	_	25	SBJ	_	_
25	have	_	VBP	VBP	_	0	ROOT-S	_	_
26	initiated	_	VBN	VBN	_	25	VC	_	_
27	an	_	DT	DT	_	28	NMOD	_	_
28	investigation	_	NN	NN	_	26	OBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	factors	_	NNS	NNS	_	29	PMOD	_	_
32	which	_	WDT	WDT	_	33	SBJ	_	_
33	activate	_	VBP	VBP	_	31	NMOD	_	_
34	the	_	DT	DT	_	36	NMOD	_	_
35	M-CSF	_	NN	NN	_	36	NMOD	_	_
36	receptor	_	NN	NN	_	33	OBJ	_	_
37	very	_	RB	RB	_	33	TMP	_	_
38	early	_	RB	RB	_	37	AMOD	_	_
39	during	_	IN	IN	_	33	TMP	_	_
40	the	_	DT	DT	_	43	NMOD	_	_
41	monocyte	_	NN	NN	_	43	NMOD	_	_
42	differentiation	_	NN	NN	_	43	NMOD	_	_
43	process	_	NN	NN	_	39	PMOD	_	_
44	.	_	.	.	_	25	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	10	NMOD	_	_
6	human	_	JJ	JJ	_	10	NMOD	_	_
7	monocytic	_	JJ	JJ	_	10	NMOD	_	_
8	M-CSF	_	NN	NN	_	10	NMOD	_	_
9	receptor	_	NN	NN	_	10	NMOD	_	_
10	promoter	_	NN	NN	_	11	SBJ	_	_
11	directs	_	VBZ	VBZ	_	4	VMOD	_	_
12	reporter	_	NN	NN	_	14	NMOD	_	_
13	gene	_	NN	NN	_	14	NMOD	_	_
14	activity	_	NN	NN	_	11	OBJ	_	_
15	in	_	IN	IN	_	11	ADV	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	tissue-specific	_	JJ	JJ	_	18	NMOD	_	_
18	fashion	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	Since	_	IN	IN	_	28	ADV	_	_
2	one	_	CD	CD	_	18	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	few	_	JJ	JJ	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factors	_	NNS	NNS	_	3	PMOD	_	_
8	which	_	WDT	WDT	_	9	SBJ	_	_
9	have	_	VBP	VBP	_	7	NMOD	_	_
10	been	_	VBN	VBN	_	9	VC	_	_
11	implicated	_	VBN	VBN	_	10	VC	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	regulation	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	monocyte	_	NN	NN	_	17	NMOD	_	_
17	genes	_	NNS	NNS	_	15	PMOD	_	_
18	is	_	VBZ	VBZ	_	1	VMOD	_	_
19	the	_	DT	DT	_	25	NMOD	_	_
20	macrophage-	_	NN	NN	_	25	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	B-cell-specific	_	JJ	JJ	_	20	COORD	_	_
23	PU.1	_	NN	NN	_	25	NMOD	_	_
24	transcription	_	NN	NN	_	25	NMOD	_	_
25	factor	_	NN	NN	_	18	PRD	_	_
26	,	_	,	,	_	28	P	_	_
27	we	_	PRP	PRP	_	28	SBJ	_	_
28	investigated	_	VBD	VBD	_	0	ROOT-S	_	_
29	whether	_	IN	IN	_	28	OBJ	_	_
30	PU.1	_	NN	NN	_	31	SBJ	_	_
31	binds	_	VBZ	VBZ	_	29	VMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	activates	_	VBZ	VBZ	_	31	COORD	_	_
34	the	_	DT	DT	_	37	NMOD	_	_
35	M-CSF	_	NN	NN	_	37	NMOD	_	_
36	receptor	_	NN	NN	_	37	NMOD	_	_
37	promoter	_	NN	NN	_	31	OBJ	_	_
38	.	_	.	.	_	28	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	both	_	CC	CC	_	8	CC	_	_
6	in	_	FW	FW	_	7	AMOD	_	_
7	vitro-translated	_	VBN	VBN	_	8	NMOD	_	_
8	PU.1	_	NN	NN	_	14	SBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	PU.1	_	NN	NN	_	8	COORD	_	_
11	from	_	IN	IN	_	10	NMOD	_	_
12	nuclear	_	JJ	JJ	_	13	NMOD	_	_
13	extracts	_	NNS	NNS	_	11	PMOD	_	_
14	bind	_	VBP	VBP	_	4	VMOD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	specific	_	JJ	JJ	_	18	NMOD	_	_
18	site	_	NN	NN	_	15	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	M-CSF	_	NN	NN	_	23	NMOD	_	_
22	receptor	_	NN	NN	_	23	NMOD	_	_
23	promoter	_	NN	NN	_	19	PMOD	_	_
24	just	_	RB	RB	_	18	NMOD	_	_
25	upstream	_	JJ	JJ	_	24	AMOD	_	_
26	from	_	IN	IN	_	24	AMOD	_	_
27	the	_	DT	DT	_	31	NMOD	_	_
28	major	_	JJ	JJ	_	31	NMOD	_	_
29	transcription	_	NN	NN	_	31	NMOD	_	_
30	initiation	_	NN	NN	_	31	NMOD	_	_
31	site	_	NN	NN	_	26	PMOD	_	_
32	.	_	.	.	_	3	P	_	_

1	Mutations	_	NNS	NNS	_	9	SBJ	_	_
2	in	_	IN	IN	_	1	NMOD	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	site	_	NN	NN	_	2	PMOD	_	_
5	which	_	WDT	WDT	_	6	SBJ	_	_
6	eliminate	_	VB	VB	_	1	NMOD	_	_
7	PU.1	_	NN	NN	_	8	NMOD	_	_
8	binding	_	NN	NN	_	6	OBJ	_	_
9	decrease	_	VBP	VBP	_	0	ROOT-S	_	_
10	M-CSF	_	NN	NN	_	13	NMOD	_	_
11	receptor	_	NN	NN	_	13	NMOD	_	_
12	promoter	_	NN	NN	_	13	NMOD	_	_
13	activity	_	NN	NN	_	9	OBJ	_	_
14	significantly	_	RB	RB	_	9	ADV	_	_
15	in	_	IN	IN	_	9	ADV	_	_
16	macrophage	_	JJ	JJ	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	lines	_	NNS	NNS	_	15	PMOD	_	_
19	only	_	RB	RB	_	18	NMOD	_	_
20	.	_	.	.	_	9	P	_	_

1	Furthermore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	PU.1	_	NN	NN	_	4	SBJ	_	_
4	transactivates	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	M-CSF	_	NN	NN	_	8	NMOD	_	_
7	receptor	_	NN	NN	_	8	NMOD	_	_
8	promoter	_	NN	NN	_	4	OBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	nonmacrophage	_	JJ	JJ	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	9	PMOD	_	_
12	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	PU.1	_	NN	NN	_	6	SBJ	_	_
6	plays	_	VBZ	VBZ	_	4	VMOD	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	major	_	JJ	JJ	_	9	NMOD	_	_
9	role	_	NN	NN	_	6	OBJ	_	_
10	in	_	IN	IN	_	6	ADV	_	_
11	macrophage	_	NN	NN	_	12	NMOD	_	_
12	gene	_	NN	NN	_	10	PMOD	_	_
13	regulation	_	NN	NN	_	12	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	development	_	NN	NN	_	13	COORD	_	_
16	by	_	IN	IN	_	6	ADV	_	_
17	directing	_	VBG	VBG	_	16	PMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	expression	_	NN	NN	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	a	_	DT	DT	_	22	NMOD	_	_
22	receptor	_	NN	NN	_	20	PMOD	_	_
23	for	_	IN	IN	_	22	NMOD	_	_
24	a	_	DT	DT	_	28	NMOD	_	_
25	key	_	JJ	JJ	_	28	NMOD	_	_
26	macrophage	_	NN	NN	_	28	NMOD	_	_
27	growth	_	NN	NN	_	28	NMOD	_	_
28	factor	_	NN	NN	_	23	PMOD	_	_
29	.	_	.	.	_	3	P	_	_

1	Rhabdomyosarcomas	_	NNS	NNS	_	2	SBJ	_	_
2	do	_	VBP	VBP	_	0	ROOT-S	_	_
3	not	_	RB	RB	_	2	VMOD	_	_
4	contain	_	VB	VB	_	2	VC	_	_
5	mutations	_	NNS	NNS	_	4	OBJ	_	_
6	in	_	IN	IN	_	4	ADV	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	DNA	_	NN	NN	_	10	NMOD	_	_
9	binding	_	NN	NN	_	10	NMOD	_	_
10	domains	_	NNS	NNS	_	6	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	myogenic	_	JJ	JJ	_	14	NMOD	_	_
13	transcription	_	NN	NN	_	14	NMOD	_	_
14	factors	_	NNS	NNS	_	11	PMOD	_	_
15	.	_	.	.	_	2	P	_	_

1	Skeletal	_	JJ	JJ	_	2	NMOD	_	_
2	myogenesis	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	regulated	_	VBN	VBN	_	3	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	group	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	transcription	_	NN	NN	_	10	NMOD	_	_
10	factors	_	NNS	NNS	_	8	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	MyoD	_	NN	NN	_	10	PRN	_	_
13	,	_	,	,	_	12	P	_	_
14	myogenin	_	NN	NN	_	12	COORD	_	_
15	,	_	,	,	_	12	P	_	_
16	myf5	_	NN	NN	_	12	COORD	_	_
17	,	_	,	,	_	12	P	_	_
18	and	_	CC	CC	_	12	CC	_	_
19	myf6	_	NN	NN	_	12	COORD	_	_
20	)	_	)	)	_	12	P	_	_
21	that	_	WDT	WDT	_	22	SBJ	_	_
22	are	_	VBP	VBP	_	10	NMOD	_	_
23	"	_	``	``	_	27	P	_	_
24	basic	_	JJ	JJ	_	27	NMOD	_	_
25	helix-loop-helix	_	JJ	JJ	_	27	NMOD	_	_
26	"	_	''	''	_	27	P	_	_
27	proteins	_	NNS	NNS	_	22	PRD	_	_
28	that	_	WDT	WDT	_	29	SBJ	_	_
29	bind	_	VBP	VBP	_	27	NMOD	_	_
30	to	_	TO	TO	_	29	ADV	_	_
31	the	_	DT	DT	_	32	NMOD	_	_
32	promoters	_	NNS	NNS	_	30	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	muscle-specific	_	JJ	JJ	_	35	NMOD	_	_
35	genes	_	NNS	NNS	_	33	PMOD	_	_
36	and	_	CC	CC	_	29	CC	_	_
37	promote	_	VBP	VBP	_	29	COORD	_	_
38	their	_	PRP$	PRP$	_	39	NMOD	_	_
39	expression	_	NN	NN	_	37	OBJ	_	_
40	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	previously	_	RB	RB	_	2	TMP	_	_
4	shown	_	VBN	VBN	_	2	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	after	_	IN	IN	_	20	TMP	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	mutation	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	Leu122	_	NN	NN	_	9	PMOD	_	_
11	to	_	TO	TO	_	8	NMOD	_	_
12	Arg	_	NN	NN	_	11	PMOD	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	DNA	_	NN	NN	_	17	NMOD	_	_
15	binding	_	NN	NN	_	17	NMOD	_	_
16	basic	_	JJ	JJ	_	17	NMOD	_	_
17	domain	_	NN	NN	_	20	SBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	MyoD	_	NN	NN	_	18	PMOD	_	_
20	confers	_	VBZ	VBZ	_	5	VMOD	_	_
21	c-myc-like	_	JJ	JJ	_	23	NMOD	_	_
22	functional	_	JJ	JJ	_	23	NMOD	_	_
23	characteristics	_	NNS	NNS	_	20	OBJ	_	_
24	to	_	TO	TO	_	20	ADV	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	protein	_	NN	NN	_	24	PMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	used	_	VBD	VBD	_	0	ROOT-S	_	_
6	single-strand	_	JJ	JJ	_	9	NMOD	_	_
7	conformation	_	NN	NN	_	9	NMOD	_	_
8	polymorphism	_	NN	NN	_	9	NMOD	_	_
9	analysis	_	NN	NN	_	5	IOBJ	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	determine	_	VB	VB	_	5	OBJ	_	_
12	whether	_	IN	IN	_	11	OBJ	_	_
13	such	_	JJ	JJ	_	14	NMOD	_	_
14	mutations	_	NNS	NNS	_	15	SBJ	_	_
15	occur	_	VBP	VBP	_	12	VMOD	_	_
16	naturally	_	RB	RB	_	15	ADV	_	_
17	in	_	IN	IN	_	15	ADV	_	_
18	rhabdomyosarcomas	_	NNS	NNS	_	17	PMOD	_	_
19	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	basic	_	JJ	JJ	_	7	NMOD	_	_
7	domains	_	NNS	NNS	_	13	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	all	_	PDT	PDT	_	12	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	myogenic	_	JJ	JJ	_	12	NMOD	_	_
12	factors	_	NNS	NNS	_	8	PMOD	_	_
13	remain	_	VBP	VBP	_	4	VMOD	_	_
14	unaltered	_	JJ	JJ	_	13	PRD	_	_
15	in	_	IN	IN	_	13	ADV	_	_
16	rhabdomyosarcomas	_	NNS	NNS	_	15	PMOD	_	_
17	.	_	.	.	_	2	P	_	_

1	Selection	_	NN	NN	_	5	SBJ	_	_
2	against	_	IN	IN	_	1	NMOD	_	_
3	such	_	JJ	JJ	_	4	NMOD	_	_
4	mutations	_	NNS	NNS	_	2	PMOD	_	_
5	may	_	MD	MD	_	0	ROOT-S	_	_
6	be	_	VB	VB	_	5	VC	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	result	_	NN	NN	_	6	PRD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	functional	_	JJ	JJ	_	11	NMOD	_	_
11	redundancy	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	these	_	DT	DT	_	16	NMOD	_	_
14	myogenic	_	JJ	JJ	_	16	NMOD	_	_
15	transcription	_	NN	NN	_	16	NMOD	_	_
16	factors	_	NNS	NNS	_	12	PMOD	_	_
17	.	_	.	.	_	5	P	_	_

1	Activation	_	NN	NN	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	granulocyte-macrophage	_	JJ	JJ	_	7	NMOD	_	_
5	colony-stimulating	_	JJ	JJ	_	7	NMOD	_	_
6	factor	_	NN	NN	_	7	NMOD	_	_
7	promoter	_	NN	NN	_	2	PMOD	_	_
8	in	_	IN	IN	_	1	NMOD	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	cooperative	_	JJ	JJ	_	13	NMOD	_	_
13	binding	_	NN	NN	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	Elf-1	_	NN	NN	_	19	NMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	AP-1	_	NN	NN	_	15	COORD	_	_
18	transcription	_	NN	NN	_	19	NMOD	_	_
19	factors	_	NNS	NNS	_	14	PMOD	_	_
20	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	8	NMOD	_	_
2	granulocyte-macrophage	_	JJ	JJ	_	4	NMOD	_	_
3	colony-stimulating	_	JJ	JJ	_	4	NMOD	_	_
4	factor	_	NN	NN	_	8	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	GM-CSF	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	gene	_	NN	NN	_	9	SBJ	_	_
9	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	been	_	VBN	VBN	_	9	VC	_	_
11	studied	_	VBN	VBN	_	10	VC	_	_
12	extensively	_	RB	RB	_	11	ADV	_	_
13	as	_	IN	IN	_	11	ADV	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	model	_	NN	NN	_	16	NMOD	_	_
16	system	_	NN	NN	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	transcriptional	_	JJ	JJ	_	19	NMOD	_	_
19	induction	_	NN	NN	_	17	PMOD	_	_
20	during	_	IN	IN	_	19	TMP	_	_
21	T-lymphocyte	_	NN	NN	_	22	NMOD	_	_
22	activation	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	GM-CSF	_	NN	NN	_	3	NMOD	_	_
3	gene	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	expressed	_	VBN	VBN	_	4	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	resting	_	VBG	VBG	_	12	NMOD	_	_
9	peripheral	_	JJ	JJ	_	12	NMOD	_	_
10	blood	_	NN	NN	_	12	NMOD	_	_
11	T	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	7	PMOD	_	_
13	but	_	CC	CC	_	4	CC	_	_
14	is	_	VBZ	VBZ	_	4	COORD	_	_
15	rapidly	_	RB	RB	_	16	TMP	_	_
16	induced	_	VBN	VBN	_	14	VC	_	_
17	at	_	IN	IN	_	16	ADV	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	transcriptional	_	JJ	JJ	_	20	NMOD	_	_
20	level	_	NN	NN	_	17	PMOD	_	_
21	following	_	VBG	VBG	_	16	TMP	_	_
22	activation	_	NN	NN	_	21	PMOD	_	_
23	through	_	IN	IN	_	16	ADV	_	_
24	the	_	DT	DT	_	28	NMOD	_	_
25	cell	_	NN	NN	_	28	NMOD	_	_
26	surface	_	NN	NN	_	28	NMOD	_	_
27	T-cell	_	NN	NN	_	28	NMOD	_	_
28	receptor	_	NN	NN	_	23	PMOD	_	_
29	.	_	.	.	_	4	P	_	_

1	A	_	DT	DT	_	5	NMOD	_	_
2	highly	_	RB	RB	_	3	AMOD	_	_
3	conserved	_	VBN	VBN	_	5	NMOD	_	_
4	19-bp	_	JJ	JJ	_	5	NMOD	_	_
5	element	_	NN	NN	_	31	SBJ	_	_
6	located	_	JJ	JJ	_	7	AMOD	_	_
7	immediately	_	RB	RB	_	5	NMOD	_	_
8	5'	_	JJ	JJ	_	7	AMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	human	_	JJ	JJ	_	14	NMOD	_	_
12	GM-CSF	_	NN	NN	_	14	NMOD	_	_
13	TATA	_	NN	NN	_	14	NMOD	_	_
14	box	_	NN	NN	_	9	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	bp	_	NN	NN	_	8	PRN	_	_
17	-34	_	CD	CD	_	18	PMOD	_	_
18	to	_	TO	TO	_	16	NMOD	_	_
19	-52	_	CD	CD	_	18	PMOD	_	_
20	)	_	)	)	_	16	P	_	_
21	,	_	,	,	_	5	P	_	_
22	herein	_	RB	RB	_	23	ADV	_	_
23	called	_	VBN	VBN	_	5	NMOD	_	_
24	purine	_	NN	NN	_	25	NMOD	_	_
25	box	_	NN	NN	_	23	OBJ	_	_
26	1	_	CD	CD	_	25	NMOD	_	_
27	(	_	(	(	_	28	P	_	_
28	PB1	_	NN	NN	_	25	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	,	_	,	,	_	5	P	_	_
31	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
32	been	_	VBN	VBN	_	31	VC	_	_
33	shown	_	VBN	VBN	_	32	VC	_	_
34	to	_	TO	TO	_	35	VMOD	_	_
35	bind	_	VB	VB	_	33	OBJ	_	_
36	a	_	DT	DT	_	40	NMOD	_	_
37	T-cell	_	NN	NN	_	40	NMOD	_	_
38	nuclear	_	JJ	JJ	_	40	NMOD	_	_
39	protein	_	NN	NN	_	40	NMOD	_	_
40	complex	_	NN	NN	_	35	OBJ	_	_
41	and	_	CC	CC	_	35	CC	_	_
42	to	_	TO	TO	_	43	VMOD	_	_
43	be	_	VB	VB	_	35	COORD	_	_
44	required	_	VBN	VBN	_	43	VC	_	_
45	for	_	IN	IN	_	44	ADV	_	_
46	transcriptional	_	JJ	JJ	_	47	NMOD	_	_
47	induction	_	NN	NN	_	45	PMOD	_	_
48	of	_	IN	IN	_	47	NMOD	_	_
49	the	_	DT	DT	_	51	NMOD	_	_
50	GM-CSF	_	NN	NN	_	51	NMOD	_	_
51	gene	_	NN	NN	_	48	PMOD	_	_
52	following	_	VBG	VBG	_	47	TMP	_	_
53	T-cell	_	NN	NN	_	54	NMOD	_	_
54	activation	_	NN	NN	_	52	PMOD	_	_
55	.	_	.	.	_	31	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	PB1	_	NN	NN	_	4	NMOD	_	_
3	sequence	_	NN	NN	_	4	NMOD	_	_
4	motif	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	highly	_	RB	RB	_	7	AMOD	_	_
7	conserved	_	VBN	VBN	_	5	PRD	_	_
8	in	_	IN	IN	_	5	ADV	_	_
9	both	_	CC	CC	_	10	CC	_	_
10	human	_	JJ	JJ	_	14	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	murine	_	JJ	JJ	_	10	COORD	_	_
13	GM-CSF	_	NN	NN	_	14	NMOD	_	_
14	genes	_	NNS	NNS	_	8	PMOD	_	_
15	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	PB1	_	NN	NN	_	10	NMOD	_	_
10	element	_	NN	NN	_	12	SBJ	_	_
11	alone	_	RB	RB	_	10	NMOD	_	_
12	confers	_	VBZ	VBZ	_	7	VMOD	_	_
13	inducibility	_	NN	NN	_	12	OBJ	_	_
14	on	_	IN	IN	_	12	ADV	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	heterologous	_	JJ	JJ	_	17	NMOD	_	_
17	promoter	_	NN	NN	_	14	PMOD	_	_
18	following	_	VBG	VBG	_	12	TMP	_	_
19	transfection	_	NN	NN	_	18	PMOD	_	_
20	into	_	IN	IN	_	19	NMOD	_	_
21	human	_	JJ	JJ	_	24	NMOD	_	_
22	Jurkat	_	NN	NN	_	24	NMOD	_	_
23	T	_	NN	NN	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	20	PMOD	_	_
25	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	identify	_	VBP	VBP	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	11	NMOD	_	_
7	major	_	JJ	JJ	_	11	NMOD	_	_
8	PB1	_	NN	NN	_	11	NMOD	_	_
9	nuclear	_	JJ	JJ	_	11	NMOD	_	_
10	protein-binding	_	JJ	JJ	_	11	NMOD	_	_
11	complex	_	NN	NN	_	5	OBJ	_	_
12	that	_	WDT	WDT	_	13	SBJ	_	_
13	is	_	VBZ	VBZ	_	11	NMOD	_	_
14	not	_	RB	RB	_	13	VMOD	_	_
15	present	_	JJ	JJ	_	13	PRD	_	_
16	in	_	IN	IN	_	15	AMOD	_	_
17	resting	_	VBG	VBG	_	21	NMOD	_	_
18	peripheral	_	JJ	JJ	_	21	NMOD	_	_
19	blood	_	NN	NN	_	21	NMOD	_	_
20	T	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	16	PMOD	_	_
22	but	_	CC	CC	_	13	CC	_	_
23	is	_	VBZ	VBZ	_	13	COORD	_	_
24	rapidly	_	RB	RB	_	25	TMP	_	_
25	induced	_	VBN	VBN	_	23	VC	_	_
26	following	_	VBG	VBG	_	25	TMP	_	_
27	T-cell	_	NN	NN	_	28	NMOD	_	_
28	activation	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	5	P	_	_

1	Sequence	_	NN	NN	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	3	SBJ	_	_
3	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	PB1	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	4	VMOD	_	_
7	composed	_	VBN	VBN	_	6	VC	_	_
8	of	_	IN	IN	_	7	ADV	_	_
9	adjacent	_	JJ	JJ	_	11	NMOD	_	_
10	binding	_	VBG	VBG	_	11	NMOD	_	_
11	sites	_	NNS	NNS	_	8	PMOD	_	_
12	for	_	IN	IN	_	11	NMOD	_	_
13	Ets	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	AP-1	_	NN	NN	_	17	NMOD	_	_
16	transcription	_	NN	NN	_	17	NMOD	_	_
17	factors	_	NNS	NNS	_	13	COORD	_	_
18	.	_	.	.	_	3	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	vitro	_	FW	FW	_	4	NMOD	_	_
3	mutagenesis	_	NN	NN	_	4	NMOD	_	_
4	experiments	_	NNS	NNS	_	5	SBJ	_	_
5	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	both	_	CC	CC	_	9	CC	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	Ets	_	NNS	NNS	_	13	SBJ	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	AP-1	_	NN	NN	_	12	NMOD	_	_
12	sites	_	NNS	NNS	_	9	COORD	_	_
13	are	_	VBP	VBP	_	6	VMOD	_	_
14	required	_	VBN	VBN	_	13	VC	_	_
15	for	_	IN	IN	_	14	ADV	_	_
16	binding	_	NN	NN	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	23	NMOD	_	_
19	inducible	_	JJ	JJ	_	23	NMOD	_	_
20	PB1	_	NN	NN	_	23	NMOD	_	_
21	nuclear	_	JJ	JJ	_	23	NMOD	_	_
22	protein	_	NN	NN	_	23	NMOD	_	_
23	complex	_	NN	NN	_	17	PMOD	_	_
24	and	_	CC	CC	_	15	CC	_	_
25	for	_	IN	IN	_	15	COORD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	transcriptional	_	JJ	JJ	_	28	NMOD	_	_
28	activity	_	NN	NN	_	25	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	this	_	DT	DT	_	31	NMOD	_	_
31	element	_	NN	NN	_	29	PMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	the	_	DT	DT	_	35	NMOD	_	_
34	GM-CSF	_	NN	NN	_	35	NMOD	_	_
35	promoter	_	NN	NN	_	31	COORD	_	_
36	in	_	IN	IN	_	16	NMOD	_	_
37	activated	_	VBN	VBN	_	39	NMOD	_	_
38	T	_	NN	NN	_	39	NMOD	_	_
39	cells	_	NNS	NNS	_	36	PMOD	_	_
40	.	_	.	.	_	5	P	_	_

1	(	_	(	(	_	3	P	_	_
2	ABSTRACT	_	NN	NN	_	3	SBJ	_	_
3	TRUNCATED	_	VBN	VBN	_	0	ROOT-S	_	_
4	AT	_	IN	IN	_	3	ADV	_	_
5	250	_	CD	CD	_	6	NMOD	_	_
6	WORDS	_	NNS	NNS	_	4	PMOD	_	_
7	)	_	)	)	_	3	P	_	_

1	Effects	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	CD45	_	NN	NN	_	2	PMOD	_	_
4	on	_	IN	IN	_	1	NMOD	_	_
5	NF-kappa	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	4	PMOD	_	_
7	.	_	.	.	_	1	P	_	_

1	Implications	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	for	_	IN	IN	_	1	NMOD	_	_
3	replication	_	NN	NN	_	2	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	HIV-1	_	NN	NN	_	4	PMOD	_	_
6	.	_	.	.	_	1	P	_	_

1	Increased	_	VBN	VBN	_	2	NMOD	_	_
2	levels	_	NNS	NNS	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	replication	_	NN	NN	_	3	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	HIV	_	NN	NN	_	8	NMOD	_	_
8	type	_	NN	NN	_	5	PMOD	_	_
9	1	_	CD	CD	_	8	NMOD	_	_
10	are	_	VBP	VBP	_	0	ROOT-S	_	_
11	observed	_	VBN	VBN	_	10	VC	_	_
12	after	_	IN	IN	_	11	TMP	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	activation	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	infected	_	JJ	JJ	_	18	NMOD	_	_
17	T	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	15	PMOD	_	_
19	through	_	IN	IN	_	14	NMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	TCR	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	10	P	_	_

1	However	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	anti-CD45	_	JJ	JJ	_	4	NMOD	_	_
4	antibodies	_	NNS	NNS	_	5	SBJ	_	_
5	inhibit	_	VBP	VBP	_	0	ROOT-S	_	_
6	these	_	DT	DT	_	7	NMOD	_	_
7	effects	_	NNS	NNS	_	5	OBJ	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	cells	_	NNS	NNS	_	8	PMOD	_	_
10	from	_	IN	IN	_	9	NMOD	_	_
11	infected	_	JJ	JJ	_	12	NMOD	_	_
12	individuals	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	examined	_	VBD	VBD	_	0	ROOT-S	_	_
7	interrelationships	_	NNS	NNS	_	6	OBJ	_	_
8	between	_	IN	IN	_	7	NMOD	_	_
9	CD45	_	NN	NN	_	8	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	HIV-1	_	NN	NN	_	9	COORD	_	_
12	further	_	RB	RB	_	6	ADV	_	_
13	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	measured	_	VBD	VBD	_	0	ROOT-S	_	_
3	effects	_	NNS	NNS	_	2	OBJ	_	_
4	on	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	HIV-1	_	NN	NN	_	7	NMOD	_	_
7	LTR	_	NN	NN	_	4	PMOD	_	_
8	in	_	IN	IN	_	3	NMOD	_	_
9	T	_	NN	NN	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	lines	_	NNS	NNS	_	8	PMOD	_	_
12	that	_	WDT	WDT	_	13	SBJ	_	_
13	were	_	VBD	VBD	_	11	NMOD	_	_
14	stimulated	_	VBN	VBN	_	13	VC	_	_
15	with	_	IN	IN	_	14	ADV	_	_
16	antibodies	_	NNS	NNS	_	15	PMOD	_	_
17	against	_	IN	IN	_	16	NMOD	_	_
18	CD45	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	8	CC	_	_
20	in	_	IN	IN	_	8	COORD	_	_
21	those	_	DT	DT	_	20	PMOD	_	_
22	that	_	WDT	WDT	_	23	SBJ	_	_
23	lacked	_	VBD	VBD	_	21	NMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	expression	_	NN	NN	_	23	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	CD45	_	NN	NN	_	26	PMOD	_	_
28	on	_	IN	IN	_	25	NMOD	_	_
29	their	_	PRP$	PRP$	_	30	NMOD	_	_
30	surfaces	_	NNS	NNS	_	28	PMOD	_	_
31	.	_	.	.	_	2	P	_	_

1	First	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	anti-CD45	_	JJ	JJ	_	4	NMOD	_	_
4	antibodies	_	NNS	NNS	_	5	SBJ	_	_
5	did	_	VBD	VBD	_	0	ROOT-S	_	_
6	not	_	RB	RB	_	5	VMOD	_	_
7	affect	_	VB	VB	_	5	VC	_	_
8	basal	_	JJ	JJ	_	12	NMOD	_	_
9	but	_	CC	CC	_	5	CC	_	_
10	decreased	_	VBD	VBD	_	5	COORD	_	_
11	activated	_	JJ	JJ	_	10	NMOD	_	_
12	levels	_	NNS	NNS	_	7	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	expression	_	NN	NN	_	13	PMOD	_	_
15	from	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	HIV-1	_	NN	NN	_	18	NMOD	_	_
18	LTR	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	5	P	_	_

1	Second	_	RB	RB	_	17	ADV	_	_
2	,	_	,	,	_	17	P	_	_
3	T	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	17	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	which	_	WDT	WDT	_	7	SBJ	_	_
7	lack	_	VBP	VBP	_	4	NMOD	_	_
8	CD45	_	NN	NN	_	7	OBJ	_	_
9	and	_	CC	CC	_	7	CC	_	_
10	can	_	MD	MD	_	7	COORD	_	_
11	not	_	RB	RB	_	10	VMOD	_	_
12	signal	_	VB	VB	_	10	VC	_	_
13	via	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	TCR	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	4	P	_	_
17	supported	_	VBD	VBD	_	0	ROOT-S	_	_
18	higher	_	JJR	JJR	_	19	NMOD	_	_
19	levels	_	NNS	NNS	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	viral	_	JJ	JJ	_	22	NMOD	_	_
22	replication	_	NN	NN	_	20	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	gene	_	NN	NN	_	25	NMOD	_	_
25	expression	_	NN	NN	_	22	COORD	_	_
26	.	_	.	.	_	17	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	due	_	JJ	JJ	_	4	DEP	_	_
4	to	_	TO	TO	_	2	PRD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	presence	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	active	_	JJ	JJ	_	11	NMOD	_	_
9	NF-kappa	_	NN	NN	_	11	NMOD	_	_
10	B	_	NN	NN	_	11	NMOD	_	_
11	complexes	_	NNS	NNS	_	7	PMOD	_	_
12	in	_	IN	IN	_	6	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	nucleus	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	CD45-	_	JJ	JJ	_	18	NMOD	_	_
17	T	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	Additionally	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	infected	_	JJ	JJ	_	5	NMOD	_	_
4	T	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	6	SBJ	_	_
6	displayed	_	VBD	VBD	_	0	ROOT-S	_	_
7	lower	_	JJR	JJR	_	8	NMOD	_	_
8	levels	_	NNS	NNS	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	CD45	_	NN	NN	_	9	PMOD	_	_
11	on	_	IN	IN	_	6	ADV	_	_
12	their	_	PRP$	PRP$	_	13	NMOD	_	_
13	surfaces	_	NNS	NNS	_	11	PMOD	_	_
14	.	_	.	.	_	6	P	_	_

1	Thus	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	CD45	_	NN	NN	_	4	SBJ	_	_
4	plays	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	an	_	DT	DT	_	7	NMOD	_	_
6	active	_	JJ	JJ	_	7	NMOD	_	_
7	role	_	NN	NN	_	4	OBJ	_	_
8	in	_	IN	IN	_	4	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	physiology	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	and	_	CC	CC	_	8	CC	_	_
15	in	_	IN	IN	_	8	COORD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	replication	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	HIV-1	_	NN	NN	_	18	PMOD	_	_
20	.	_	.	.	_	4	P	_	_

1	Human	_	JJ	JJ	_	6	NMOD	_	_
2	interferon	_	NN	NN	_	6	NMOD	_	_
3	regulatory	_	JJ	JJ	_	6	NMOD	_	_
4	factor	_	NN	NN	_	6	NMOD	_	_
5	2	_	CD	CD	_	6	NMOD	_	_
6	gene	_	NN	NN	_	0	ROOT-FRAG	_	_
7	.	_	.	.	_	6	P	_	_

1	Intron-exon	_	JJ	JJ	_	2	NMOD	_	_
2	organization	_	NN	NN	_	0	ROOT-FRAG	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	functional	_	JJ	JJ	_	5	NMOD	_	_
5	analysis	_	NN	NN	_	2	COORD	_	_
6	of	_	IN	IN	_	2	NMOD	_	_
7	5'-flanking	_	JJ	JJ	_	8	NMOD	_	_
8	region	_	NN	NN	_	6	PMOD	_	_
9	.	_	.	.	_	2	P	_	_

1	Interferon	_	NN	NN	_	3	NMOD	_	_
2	regulatory	_	JJ	JJ	_	3	NMOD	_	_
3	factor	_	NN	NN	_	8	SBJ	_	_
4	2	_	CD	CD	_	3	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	IRF-2	_	NN	NN	_	3	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	transcriptional	_	JJ	JJ	_	12	NMOD	_	_
11	regulatory	_	JJ	JJ	_	12	NMOD	_	_
12	protein	_	NN	NN	_	8	PRD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	terminates	_	VBZ	VBZ	_	12	NMOD	_	_
15	interferon	_	NN	NN	_	17	NMOD	_	_
16	beta	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	14	OBJ	_	_
18	initiated	_	VBN	VBN	_	17	NMOD	_	_
19	by	_	IN	IN	_	18	LGS	_	_
20	interferon	_	NN	NN	_	22	NMOD	_	_
21	regulatory	_	JJ	JJ	_	22	NMOD	_	_
22	factor	_	NN	NN	_	19	PMOD	_	_
23	1	_	CD	CD	_	22	NMOD	_	_
24	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	isolated	_	VBD	VBD	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	genomic	_	JJ	JJ	_	9	NMOD	_	_
9	DNA	_	NN	NN	_	6	OBJ	_	_
10	for	_	IN	IN	_	9	NMOD	_	_
11	human	_	JJ	JJ	_	13	NMOD	_	_
12	IRF-2	_	NN	NN	_	13	NMOD	_	_
13	gene	_	NN	NN	_	10	PMOD	_	_
14	,	_	,	,	_	6	P	_	_
15	determined	_	VBD	VBD	_	6	COORD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	intron-exon	_	JJ	JJ	_	18	NMOD	_	_
18	structure	_	NN	NN	_	15	OBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	human	_	JJ	JJ	_	23	NMOD	_	_
22	IRF-2	_	NN	NN	_	23	NMOD	_	_
23	gene	_	NN	NN	_	19	PMOD	_	_
24	,	_	,	,	_	6	P	_	_
25	mapped	_	VBD	VBD	_	6	COORD	_	_
26	the	_	DT	DT	_	30	NMOD	_	_
27	major	_	JJ	JJ	_	30	NMOD	_	_
28	transcription	_	NN	NN	_	30	NMOD	_	_
29	initiation	_	NN	NN	_	30	NMOD	_	_
30	site	_	NN	NN	_	25	OBJ	_	_
31	,	_	,	,	_	6	P	_	_
32	identified	_	VBD	VBD	_	6	COORD	_	_
33	a	_	DT	DT	_	34	NMOD	_	_
34	number	_	NN	NN	_	32	OBJ	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	potential	_	JJ	JJ	_	38	NMOD	_	_
37	regulatory	_	JJ	JJ	_	38	NMOD	_	_
38	elements	_	NNS	NNS	_	35	PMOD	_	_
39	in	_	IN	IN	_	38	NMOD	_	_
40	the	_	DT	DT	_	42	NMOD	_	_
41	5'-flanking	_	JJ	JJ	_	42	NMOD	_	_
42	region	_	NN	NN	_	39	PMOD	_	_
43	,	_	,	,	_	6	P	_	_
44	and	_	CC	CC	_	6	CC	_	_
45	localized	_	VBD	VBD	_	6	COORD	_	_
46	the	_	DT	DT	_	48	NMOD	_	_
47	IRF-2	_	NN	NN	_	48	NMOD	_	_
48	gene	_	NN	NN	_	45	OBJ	_	_
49	on	_	IN	IN	_	48	NMOD	_	_
50	human	_	JJ	JJ	_	51	NMOD	_	_
51	chromosome	_	NN	NN	_	49	PMOD	_	_
52	4	_	CD	CD	_	51	NMOD	_	_
53	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	IRF-2	_	NN	NN	_	4	NMOD	_	_
3	promoter	_	NN	NN	_	4	NMOD	_	_
4	region	_	NN	NN	_	5	SBJ	_	_
5	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	CpG	_	NN	NN	_	8	NMOD	_	_
8	island	_	NN	NN	_	5	OBJ	_	_
9	,	_	,	,	_	8	P	_	_
10	with	_	IN	IN	_	8	NMOD	_	_
11	several	_	JJ	JJ	_	13	NMOD	_	_
12	GC	_	NN	NN	_	13	NMOD	_	_
13	boxes	_	NNS	NNS	_	10	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	a	_	DT	DT	_	19	NMOD	_	_
16	putative	_	JJ	JJ	_	19	NMOD	_	_
17	NF-kappa	_	NN	NN	_	19	NMOD	_	_
18	B-binding	_	JJ	JJ	_	17	AMOD	_	_
19	site	_	NN	NN	_	13	COORD	_	_
20	,	_	,	,	_	13	P	_	_
21	and	_	CC	CC	_	13	CC	_	_
22	a	_	DT	DT	_	24	NMOD	_	_
23	CAAT	_	NN	NN	_	24	NMOD	_	_
24	box	_	NN	NN	_	13	COORD	_	_
25	,	_	,	,	_	13	P	_	_
26	but	_	CC	CC	_	13	CC	_	_
27	no	_	DT	DT	_	29	NMOD	_	_
28	TATA	_	NN	NN	_	29	NMOD	_	_
29	box	_	NN	NN	_	13	COORD	_	_
30	.	_	.	.	_	5	P	_	_

1	When	_	WRB	WRB	_	6	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	promoter	_	NN	NN	_	4	NMOD	_	_
4	region	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	14	TMP	_	_
6	linked	_	VBN	VBN	_	5	VC	_	_
7	with	_	IN	IN	_	6	ADV	_	_
8	a	_	DT	DT	_	11	NMOD	_	_
9	heterologous	_	JJ	JJ	_	11	NMOD	_	_
10	reporter	_	NN	NN	_	11	NMOD	_	_
11	gene	_	NN	NN	_	7	PMOD	_	_
12	,	_	,	,	_	14	P	_	_
13	we	_	PRP	PRP	_	14	SBJ	_	_
14	found	_	VBD	VBD	_	0	ROOT-S	_	_
15	that	_	IN	IN	_	14	OBJ	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	promoter	_	NN	NN	_	18	NMOD	_	_
18	region	_	NN	NN	_	19	SBJ	_	_
19	is	_	VBZ	VBZ	_	15	VMOD	_	_
20	inducible	_	JJ	JJ	_	19	PRD	_	_
21	by	_	IN	IN	_	20	AMOD	_	_
22	both	_	CC	CC	_	23	CC	_	_
23	interferons	_	NNS	NNS	_	21	PMOD	_	_
24	(	_	(	(	_	25	P	_	_
25	interferon-alpha	_	NN	NN	_	23	PRN	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	-gamma	_	NN	NN	_	25	COORD	_	_
28	)	_	)	)	_	25	P	_	_
29	and	_	CC	CC	_	23	CC	_	_
30	interferon	_	NN	NN	_	32	NMOD	_	_
31	regulatory	_	JJ	JJ	_	32	NMOD	_	_
32	factor	_	NN	NN	_	23	COORD	_	_
33	1	_	CD	CD	_	32	NMOD	_	_
34	.	_	.	.	_	14	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	region	_	NN	NN	_	7	SBJ	_	_
3	which	_	WDT	WDT	_	4	SBJ	_	_
4	induced	_	VBD	VBD	_	2	NMOD	_	_
5	these	_	DT	DT	_	6	NMOD	_	_
6	inductions	_	NNS	NNS	_	4	OBJ	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	identified	_	VBN	VBN	_	7	VC	_	_
9	as	_	IN	IN	_	8	ADV	_	_
10	being	_	VBG	VBG	_	9	PMOD	_	_
11	confined	_	VBN	VBN	_	10	VC	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	40	_	CD	CD	_	14	NMOD	_	_
14	nucleotides	_	NNS	NNS	_	12	PMOD	_	_
15	5'	_	JJ	JJ	_	16	PMOD	_	_
16	to	_	TO	TO	_	12	PMOD	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	major	_	JJ	JJ	_	21	NMOD	_	_
19	transcriptional	_	JJ	JJ	_	21	NMOD	_	_
20	initiation	_	NN	NN	_	21	NMOD	_	_
21	site	_	NN	NN	_	16	PMOD	_	_
22	by	_	IN	IN	_	8	LGS	_	_
23	testing	_	VBG	VBG	_	22	PMOD	_	_
24	a	_	DT	DT	_	25	NMOD	_	_
25	series	_	NN	NN	_	23	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	clones	_	NNS	NNS	_	26	PMOD	_	_
28	with	_	IN	IN	_	23	ADV	_	_
29	truncated	_	VBN	VBN	_	30	NMOD	_	_
30	promoter	_	NN	NN	_	28	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	IRF-2	_	NN	NN	_	31	PMOD	_	_
33	.	_	.	.	_	7	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	region	_	NN	NN	_	3	SBJ	_	_
3	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	elements	_	NNS	NNS	_	3	OBJ	_	_
5	which	_	WDT	WDT	_	6	SBJ	_	_
6	are	_	VBP	VBP	_	4	NMOD	_	_
7	shared	_	VBN	VBN	_	6	VC	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	transcriptional	_	JJ	JJ	_	11	NMOD	_	_
11	enhancers	_	NNS	NNS	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	other	_	JJ	JJ	_	14	NMOD	_	_
14	genes	_	NNS	NNS	_	12	PMOD	_	_
15	including	_	VBG	VBG	_	11	NMOD	_	_
16	interferon	_	NN	NN	_	18	NMOD	_	_
17	regulatory	_	JJ	JJ	_	18	NMOD	_	_
18	factor	_	NN	NN	_	15	PMOD	_	_
19	1	_	CD	CD	_	18	NMOD	_	_
20	,	_	,	,	_	18	P	_	_
21	interferon	_	NN	NN	_	22	NMOD	_	_
22	beta	_	NN	NN	_	18	COORD	_	_
23	,	_	,	,	_	18	P	_	_
24	and	_	CC	CC	_	18	CC	_	_
25	interferon-inducible	_	JJ	JJ	_	26	NMOD	_	_
26	genes	_	NNS	NNS	_	18	COORD	_	_
27	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	interferon	_	NN	NN	_	7	NMOD	_	_
6	regulatory	_	JJ	JJ	_	7	NMOD	_	_
7	factor	_	NN	NN	_	11	SBJ	_	_
8	1	_	CD	CD	_	7	NMOD	_	_
9	not	_	RB	RB	_	11	CC	_	_
10	only	_	RB	RB	_	9	DEP	_	_
11	triggers	_	VBZ	VBZ	_	4	VMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	activation	_	NN	NN	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	interferon	_	NN	NN	_	19	NMOD	_	_
17	signal	_	NN	NN	_	19	NMOD	_	_
18	transduction	_	NN	NN	_	19	NMOD	_	_
19	pathway	_	NN	NN	_	14	PMOD	_	_
20	,	_	,	,	_	11	P	_	_
21	but	_	CC	CC	_	11	CC	_	_
22	also	_	RB	RB	_	21	COORD	_	_
23	may	_	MD	MD	_	11	COORD	_	_
24	play	_	VB	VB	_	23	VC	_	_
25	a	_	DT	DT	_	26	NMOD	_	_
26	role	_	NN	NN	_	24	OBJ	_	_
27	in	_	IN	IN	_	24	ADV	_	_
28	limiting	_	VBG	VBG	_	27	PMOD	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	duration	_	NN	NN	_	28	OBJ	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	this	_	DT	DT	_	33	NMOD	_	_
33	response	_	NN	NN	_	31	PMOD	_	_
34	by	_	IN	IN	_	28	ADV	_	_
35	activating	_	VBG	VBG	_	34	PMOD	_	_
36	the	_	DT	DT	_	37	NMOD	_	_
37	transcription	_	NN	NN	_	35	OBJ	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	IRF-2	_	NN	NN	_	38	PMOD	_	_
40	.	_	.	.	_	3	P	_	_

1	Direct	_	JJ	JJ	_	2	NMOD	_	_
2	exposure	_	NN	NN	_	8	SBJ	_	_
3	to	_	TO	TO	_	2	NMOD	_	_
4	2,3,7,8-tetrachlorodibenzo-p-dioxin	_	NN	NN	_	3	PMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	TCDD	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	increases	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	infectivity	_	NN	NN	_	8	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	human	_	JJ	JJ	_	12	NMOD	_	_
12	erythrocytes	_	NNS	NNS	_	10	PMOD	_	_
13	to	_	TO	TO	_	9	NMOD	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	malarial	_	JJ	JJ	_	16	NMOD	_	_
16	parasite	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	8	P	_	_

1	Direct	_	JJ	JJ	_	2	NMOD	_	_
2	exposure	_	NN	NN	_	7	SBJ	_	_
3	to	_	TO	TO	_	2	NMOD	_	_
4	10	_	CD	CD	_	5	AMOD	_	_
5	nM	_	NN	NN	_	6	NMOD	_	_
6	2,3,7,8-TCDD	_	NN	NN	_	3	PMOD	_	_
7	caused	_	VBD	VBD	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	11	NMOD	_	_
9	75	_	CD	CD	_	11	NMOD	_	_
10	%	_	NN	NN	_	11	NMOD	_	_
11	increase	_	NN	NN	_	7	OBJ	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	2-fold	_	JJ	JJ	_	15	NMOD	_	_
15	increase	_	NN	NN	_	11	COORD	_	_
16	in	_	IN	IN	_	11	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	infectivity	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	isolated	_	VBN	VBN	_	22	NMOD	_	_
21	human	_	JJ	JJ	_	22	NMOD	_	_
22	erythrocytes	_	NNS	NNS	_	19	PMOD	_	_
23	to	_	TO	TO	_	18	NMOD	_	_
24	P.	_	FW	FW	_	25	NMOD	_	_
25	falciparum	_	FW	FW	_	23	PMOD	_	_
26	after	_	IN	IN	_	7	TMP	_	_
27	48	_	CD	CD	_	28	NMOD	_	_
28	hours	_	NNS	NNS	_	26	PMOD	_	_
29	when	_	WRB	WRB	_	32	ADV	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	parasites	_	NNS	NNS	_	32	SBJ	_	_
32	were	_	VBD	VBD	_	28	NMOD	_	_
33	in	_	IN	IN	_	32	PRD	_	_
34	an	_	DT	DT	_	38	NMOD	_	_
35	unsynchronized	_	JJ	JJ	_	38	NMOD	_	_
36	or	_	CC	CC	_	35	CC	_	_
37	synchronized	_	JJ	JJ	_	35	COORD	_	_
38	state	_	NN	NN	_	33	PMOD	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	growth	_	NN	NN	_	39	PMOD	_	_
41	,	_	,	,	_	32	P	_	_
42	respectively	_	RB	RB	_	32	ADV	_	_
43	.	_	.	.	_	7	P	_	_

1	Treatment	_	NN	NN	_	24	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	human	_	JJ	JJ	_	4	NMOD	_	_
4	erythrocytes	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	10	_	CD	CD	_	7	AMOD	_	_
7	microM	_	NN	NN	_	9	NMOD	_	_
8	sodium	_	NN	NN	_	9	NMOD	_	_
9	orthovanadate	_	NN	NN	_	5	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	NaOV	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	,	_	,	,	_	9	P	_	_
14	an	_	DT	DT	_	15	NMOD	_	_
15	inhibitor	_	NN	NN	_	9	NMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	plasma	_	NN	NN	_	19	NMOD	_	_
18	membrane	_	NN	NN	_	19	NMOD	_	_
19	Ca-ATPase	_	NN	NN	_	16	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	phosphotyrosine	_	NN	NN	_	22	NMOD	_	_
22	phosphatase	_	NN	NN	_	19	COORD	_	_
23	,	_	,	,	_	9	P	_	_
24	decreased	_	VBD	VBD	_	0	ROOT-S	_	_
25	parasitemia	_	NN	NN	_	24	OBJ	_	_
26	by	_	IN	IN	_	24	ADV	_	_
27	30	_	CD	CD	_	28	NMOD	_	_
28	%	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	24	P	_	_

1	Co-treatment	_	NN	NN	_	9	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	RBCs	_	NNS	NNS	_	2	PMOD	_	_
4	with	_	IN	IN	_	1	NMOD	_	_
5	TCDD	_	NN	NN	_	4	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	NaOV	_	NN	NN	_	5	COORD	_	_
8	completely	_	RB	RB	_	9	ADV	_	_
9	blocked	_	VBD	VBD	_	0	ROOT-S	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	TCDD-induced	_	JJ	JJ	_	12	NMOD	_	_
12	increase	_	NN	NN	_	9	OBJ	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	parasitemia	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	9	P	_	_

1	Because	_	IN	IN	_	8	ADV	_	_
2	erythrocytes	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	1	VMOD	_	_
4	anucleated	_	JJ	JJ	_	3	VC	_	_
5	,	_	,	,	_	8	P	_	_
6	these	_	DT	DT	_	7	NMOD	_	_
7	results	_	NNS	NNS	_	8	SBJ	_	_
8	are	_	VBP	VBP	_	0	ROOT-S	_	_
9	discussed	_	VBN	VBN	_	8	VC	_	_
10	as	_	IN	IN	_	9	ADV	_	_
11	evidence	_	NN	NN	_	10	PMOD	_	_
12	for	_	IN	IN	_	11	NMOD	_	_
13	biochemical	_	JJ	JJ	_	14	NMOD	_	_
14	changes	_	NNS	NNS	_	12	PMOD	_	_
15	by	_	IN	IN	_	14	NMOD	_	_
16	TCDD	_	NN	NN	_	15	PMOD	_	_
17	without	_	IN	IN	_	14	NMOD	_	_
18	requiring	_	VBG	VBG	_	17	PMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	activation	_	NN	NN	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	gene	_	NN	NN	_	23	NMOD	_	_
23	products	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	8	P	_	_

1	Novel	_	JJ	JJ	_	3	NMOD	_	_
2	aldosterone	_	NN	NN	_	3	NMOD	_	_
3	receptors	_	NNS	NNS	_	0	ROOT-FRAG	_	_
4	:	_	:	:	_	3	P	_	_
5	specificity-conferring	_	JJ	JJ	_	6	NMOD	_	_
6	mechanism	_	NN	NN	_	3	NMOD	_	_
7	at	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	level	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	membrane	_	NN	NN	_	10	PMOD	_	_
14	.	_	.	.	_	6	P	_	_

1	Functional	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	19	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	extra-renal	_	JJ	JJ	_	7	NMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	nonepithelial	_	JJ	JJ	_	4	COORD	_	_
7	cells	_	NNS	NNS	_	3	PMOD	_	_
8	such	_	JJ	JJ	_	9	DEP	_	_
9	as	_	IN	IN	_	7	NMOD	_	_
10	smooth	_	JJ	JJ	_	12	NMOD	_	_
11	muscle	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	more	_	RBR	RBR	_	15	AMOD	_	_
15	recently	_	RB	RB	_	18	TMP	_	_
16	circulating	_	VBG	VBG	_	18	NMOD	_	_
17	human	_	JJ	JJ	_	18	NMOD	_	_
18	lymphocytes	_	NNS	NNS	_	12	COORD	_	_
19	have	_	VBP	VBP	_	0	ROOT-S	_	_
20	provided	_	VBN	VBN	_	19	VC	_	_
21	increasing	_	VBG	VBG	_	22	NMOD	_	_
22	evidence	_	NN	NN	_	20	OBJ	_	_
23	that	_	IN	IN	_	22	NMOD	_	_
24	aldosterone	_	NN	NN	_	25	SBJ	_	_
25	produces	_	VBZ	VBZ	_	23	VMOD	_	_
26	not	_	RB	RB	_	30	CC	_	_
27	only	_	RB	RB	_	26	DEP	_	_
28	classical	_	JJ	JJ	_	30	NMOD	_	_
29	genomic	_	JJ	JJ	_	30	NMOD	_	_
30	effects	_	NNS	NNS	_	25	OBJ	_	_
31	,	_	,	,	_	30	P	_	_
32	but	_	CC	CC	_	30	CC	_	_
33	also	_	RB	RB	_	32	COORD	_	_
34	rapid	_	JJ	JJ	_	36	NMOD	_	_
35	non-genomic	_	JJ	JJ	_	36	NMOD	_	_
36	effects	_	NNS	NNS	_	30	COORD	_	_
37	on	_	IN	IN	_	30	NMOD	_	_
38	transmembrane	_	NN	NN	_	40	NMOD	_	_
39	electrolyte	_	NN	NN	_	40	NMOD	_	_
40	movements	_	NNS	NNS	_	37	PMOD	_	_
41	.	_	.	.	_	19	P	_	_

1	These	_	DT	DT	_	2	SBJ	_	_
2	involve	_	VBP	VBP	_	0	ROOT-S	_	_
3	activation	_	NN	NN	_	2	OBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	sodium\/proton-exchanger	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	membrane	_	NN	NN	_	7	PMOD	_	_
11	at	_	IN	IN	_	3	NMOD	_	_
12	very	_	RB	RB	_	13	AMOD	_	_
13	low	_	JJ	JJ	_	16	NMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	physiological	_	JJ	JJ	_	13	COORD	_	_
16	concentrations	_	NNS	NNS	_	11	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	aldosterone	_	NN	NN	_	17	PMOD	_	_
19	with	_	IN	IN	_	3	NMOD	_	_
20	an	_	DT	DT	_	22	NMOD	_	_
21	acute	_	JJ	JJ	_	22	NMOD	_	_
22	onset	_	NN	NN	_	19	PMOD	_	_
23	within	_	IN	IN	_	22	TMP	_	_
24	1-2	_	CD	CD	_	25	NMOD	_	_
25	minutes	_	NNS	NNS	_	23	PMOD	_	_
26	.	_	.	.	_	2	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	second	_	JJ	JJ	_	4	NMOD	_	_
3	messenger	_	NN	NN	_	4	NMOD	_	_
4	cascade	_	NN	NN	_	6	SBJ	_	_
5	involved	_	VBN	VBN	_	4	NMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	inositol-1,4,5-trisphosphate\/calcium	_	NN	NN	_	9	NMOD	_	_
9	pathway	_	NN	NN	_	6	PRD	_	_
10	which	_	WDT	WDT	_	11	SBJ	_	_
11	responds	_	VBZ	VBZ	_	9	NMOD	_	_
12	over	_	IN	IN	_	11	TMP	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	same	_	JJ	JJ	_	17	NMOD	_	_
15	rapid	_	JJ	JJ	_	17	NMOD	_	_
16	time	_	NN	NN	_	17	NMOD	_	_
17	course	_	NN	NN	_	12	PMOD	_	_
18	.	_	.	.	_	6	P	_	_

1	Such	_	JJ	JJ	_	2	NMOD	_	_
2	changes	_	NNS	NNS	_	4	SBJ	_	_
3	clearly	_	RB	RB	_	4	ADV	_	_
4	can	_	MD	MD	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	be	_	VB	VB	_	4	VC	_	_
7	explained	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	genomic	_	JJ	JJ	_	10	NMOD	_	_
10	mechanisms	_	NNS	NNS	_	8	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	which	_	WDT	WDT	_	13	SBJ	_	_
13	are	_	VBP	VBP	_	10	NMOD	_	_
14	responsible	_	JJ	JJ	_	13	PRD	_	_
15	for	_	IN	IN	_	14	AMOD	_	_
16	later	_	JJ	JJ	_	17	NMOD	_	_
17	effects	_	NNS	NNS	_	15	PMOD	_	_
18	than	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	membrane-related	_	JJ	JJ	_	22	NMOD	_	_
21	rapid	_	JJ	JJ	_	22	NMOD	_	_
22	responses	_	NNS	NNS	_	18	PMOD	_	_
23	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	18	ADV	_	_
2	addition	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	its	_	PRP$	PRP$	_	7	NMOD	_	_
5	rapid	_	JJ	JJ	_	7	NMOD	_	_
6	time	_	NN	NN	_	7	NMOD	_	_
7	course	_	NN	NN	_	1	PMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	unique	_	JJ	JJ	_	10	NMOD	_	_
10	characteristics	_	NNS	NNS	_	18	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	this	_	DT	DT	_	14	NMOD	_	_
13	new	_	JJ	JJ	_	14	NMOD	_	_
14	pathway	_	NN	NN	_	11	PMOD	_	_
15	for	_	IN	IN	_	14	NMOD	_	_
16	steroid	_	NN	NN	_	17	NMOD	_	_
17	action	_	NN	NN	_	15	PMOD	_	_
18	include	_	VBP	VBP	_	0	ROOT-S	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	10000-fold	_	JJ	JJ	_	21	NMOD	_	_
21	selectivity	_	NN	NN	_	18	OBJ	_	_
22	for	_	IN	IN	_	21	NMOD	_	_
23	aldosterone	_	NN	NN	_	22	PMOD	_	_
24	over	_	IN	IN	_	21	NMOD	_	_
25	cortisol	_	NN	NN	_	24	PMOD	_	_
26	and	_	CC	CC	_	21	CC	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	ineffectiveness	_	NN	NN	_	21	COORD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	spironolactones	_	NNS	NNS	_	29	PMOD	_	_
31	,	_	,	,	_	30	P	_	_
32	classical	_	JJ	JJ	_	34	NMOD	_	_
33	mineralocorticoid	_	NN	NN	_	34	NMOD	_	_
34	antagonists	_	NNS	NNS	_	30	NMOD	_	_
35	,	_	,	,	_	30	P	_	_
36	as	_	IN	IN	_	28	NMOD	_	_
37	antagonists	_	NNS	NNS	_	36	PMOD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	the	_	DT	DT	_	40	NMOD	_	_
40	response	_	NN	NN	_	38	PMOD	_	_
41	.	_	.	.	_	18	P	_	_

1	Subsequently	_	RB	RB	_	2	AMOD	_	_
2	binding	_	VBG	VBG	_	3	NMOD	_	_
3	sites	_	NNS	NNS	_	4	SBJ	_	_
4	have	_	VBP	VBP	_	0	ROOT-S	_	_
5	been	_	VBN	VBN	_	4	VC	_	_
6	demonstrated	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	plasma	_	NN	NN	_	10	NMOD	_	_
10	membrane	_	NN	NN	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	human	_	JJ	JJ	_	13	NMOD	_	_
13	lymphocytes	_	NNS	NNS	_	11	PMOD	_	_
14	which	_	WDT	WDT	_	15	SBJ	_	_
15	show	_	VBP	VBP	_	3	NMOD	_	_
16	pharmacological	_	JJ	JJ	_	27	NMOD	_	_
17	(	_	(	(	_	19	P	_	_
18	aldosterone	_	NN	NN	_	19	NMOD	_	_
19	specificity	_	NN	NN	_	27	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	and	_	CC	CC	_	27	CC	_	_
22	kinetic	_	JJ	JJ	_	27	NMOD	_	_
23	(	_	(	(	_	25	P	_	_
24	high	_	JJ	JJ	_	25	NMOD	_	_
25	turnover	_	NN	NN	_	27	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	properties	_	NNS	NNS	_	15	OBJ	_	_
28	identical	_	JJ	JJ	_	27	NMOD	_	_
29	with	_	IN	IN	_	28	AMOD	_	_
30	those	_	DT	DT	_	29	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	35	NMOD	_	_
33	rapid	_	JJ	JJ	_	35	NMOD	_	_
34	aldosterone	_	NN	NN	_	35	NMOD	_	_
35	effects	_	NNS	NNS	_	31	PMOD	_	_
36	in	_	IN	IN	_	35	NMOD	_	_
37	the	_	DT	DT	_	39	NMOD	_	_
38	same	_	JJ	JJ	_	39	NMOD	_	_
39	cells	_	NNS	NNS	_	36	PMOD	_	_
40	.	_	.	.	_	4	P	_	_

1	SDS-PAGE	_	NN	NN	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	receptor	_	NN	NN	_	6	NMOD	_	_
6	protein	_	NN	NN	_	3	PMOD	_	_
7	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	shown	_	VBN	VBN	_	7	VC	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	molecular	_	JJ	JJ	_	11	NMOD	_	_
11	weight	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	approximately	_	RB	RB	_	15	NMOD	_	_
14	50	_	CD	CD	_	13	DEP	_	_
15	kD	_	NN	NN	_	12	PMOD	_	_
16	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	present	_	JJ	JJ	_	3	NMOD	_	_
3	paper	_	NN	NN	_	4	SBJ	_	_
4	reviews	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	data	_	NNS	NNS	_	4	OBJ	_	_
7	supporting	_	VBG	VBG	_	6	NMOD	_	_
8	a	_	DT	DT	_	12	NMOD	_	_
9	new	_	JJ	JJ	_	12	NMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	two-step	_	JJ	JJ	_	9	COORD	_	_
12	model	_	NN	NN	_	7	OBJ	_	_
13	for	_	IN	IN	_	12	NMOD	_	_
14	non-genomic	_	JJ	JJ	_	18	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	genomic	_	JJ	JJ	_	14	COORD	_	_
17	aldosterone	_	NN	NN	_	18	NMOD	_	_
18	effects	_	NNS	NNS	_	13	PMOD	_	_
19	.	_	.	.	_	4	P	_	_

1	It	_	PRP	PRP	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	novel	_	JJ	JJ	_	7	NMOD	_	_
6	specificity-conferring	_	JJ	JJ	_	7	NMOD	_	_
7	mechanism	_	NN	NN	_	3	OBJ	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	mineralocorticoid	_	NN	NN	_	10	NMOD	_	_
10	action	_	NN	NN	_	8	PMOD	_	_
11	at	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	membrane	_	NN	NN	_	14	NMOD	_	_
14	level	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	Pentoxifylline	_	NN	NN	_	0	ROOT-FRAG	_	_
2	for	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	treatment	_	NN	NN	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	infection	_	NN	NN	_	5	PMOD	_	_
7	with	_	IN	IN	_	6	NMOD	_	_
8	human	_	JJ	JJ	_	10	NMOD	_	_
9	immunodeficiency	_	NN	NN	_	10	NMOD	_	_
10	virus	_	NN	NN	_	7	PMOD	_	_
11	.	_	.	.	_	1	P	_	_

1	Cytokine	_	NN	NN	_	2	NMOD	_	_
2	dysregulation	_	NN	NN	_	13	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	human	_	JJ	JJ	_	7	NMOD	_	_
5	immunodeficiency	_	NN	NN	_	7	NMOD	_	_
6	virus	_	NN	NN	_	7	NMOD	_	_
7	type	_	NN	NN	_	12	NMOD	_	_
8	1	_	CD	CD	_	7	NMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	HIV-1	_	NN	NN	_	7	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	infection	_	NN	NN	_	3	PMOD	_	_
13	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	been	_	VBN	VBN	_	13	VC	_	_
15	documented	_	VBN	VBN	_	14	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	numerous	_	JJ	JJ	_	18	NMOD	_	_
18	studies	_	NNS	NNS	_	16	PMOD	_	_
19	and	_	CC	CC	_	13	CC	_	_
20	has	_	VBZ	VBZ	_	13	COORD	_	_
21	been	_	VBN	VBN	_	20	VC	_	_
22	cited	_	VBN	VBN	_	21	VC	_	_
23	as	_	IN	IN	_	22	ADV	_	_
24	an	_	DT	DT	_	26	NMOD	_	_
25	important	_	JJ	JJ	_	26	NMOD	_	_
26	component	_	NN	NN	_	23	PMOD	_	_
27	in	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	pathogenesis	_	NN	NN	_	27	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	this	_	DT	DT	_	33	NMOD	_	_
32	retroviral	_	JJ	JJ	_	33	NMOD	_	_
33	infection	_	NN	NN	_	30	PMOD	_	_
34	.	_	.	.	_	13	P	_	_

1	Pharmacological	_	JJ	JJ	_	2	NMOD	_	_
2	modification	_	NN	NN	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	cytokine	_	NN	NN	_	5	NMOD	_	_
5	dysregulation	_	NN	NN	_	3	PMOD	_	_
6	,	_	,	,	_	9	P	_	_
7	therefore	_	RB	RB	_	9	ADV	_	_
8	,	_	,	,	_	9	P	_	_
9	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	been	_	VBN	VBN	_	9	VC	_	_
11	suggested	_	VBN	VBN	_	10	VC	_	_
12	as	_	IN	IN	_	11	ADV	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	therapeutic	_	JJ	JJ	_	15	NMOD	_	_
15	modality	_	NN	NN	_	12	PMOD	_	_
16	for	_	IN	IN	_	15	NMOD	_	_
17	HIV-1	_	NN	NN	_	18	NMOD	_	_
18	infection	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	9	P	_	_

1	Dr.	_	NNP	NNP	_	2	NMOD	_	_
2	Dezube	_	NNP	NNP	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	Beth	_	NNP	NNP	_	6	NMOD	_	_
5	Israel	_	NNP	NNP	_	6	NMOD	_	_
6	Hospital	_	NNP	NNP	_	3	PMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	Boston	_	NNP	NNP	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	concisely	_	RB	RB	_	11	ADV	_	_
11	reviews	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	state	_	NN	NN	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	our	_	PRP$	PRP$	_	16	NMOD	_	_
16	knowledge	_	NN	NN	_	14	PMOD	_	_
17	regarding	_	VBG	VBG	_	16	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	effects	_	NNS	NNS	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	pentoxifylline	_	NN	NN	_	20	PMOD	_	_
22	on	_	IN	IN	_	19	NMOD	_	_
23	expression	_	NN	NN	_	22	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	tumor	_	NN	NN	_	27	NMOD	_	_
26	necrosis	_	NN	NN	_	27	NMOD	_	_
27	factor-alpha	_	NN	NN	_	24	PMOD	_	_
28	,	_	,	,	_	27	P	_	_
29	a	_	DT	DT	_	30	NMOD	_	_
30	cytokine	_	NN	NN	_	27	NMOD	_	_
31	known	_	VBN	VBN	_	30	NMOD	_	_
32	to	_	TO	TO	_	33	VMOD	_	_
33	influence	_	VB	VB	_	31	OBJ	_	_
34	HIV-1	_	NN	NN	_	35	NMOD	_	_
35	replication	_	NN	NN	_	33	OBJ	_	_
36	and	_	CC	CC	_	33	CC	_	_
37	to	_	TO	TO	_	38	VMOD	_	_
38	play	_	VB	VB	_	33	COORD	_	_
39	a	_	DT	DT	_	41	NMOD	_	_
40	possible	_	JJ	JJ	_	41	NMOD	_	_
41	role	_	NN	NN	_	38	OBJ	_	_
42	in	_	IN	IN	_	38	ADV	_	_
43	the	_	DT	DT	_	45	NMOD	_	_
44	clinical	_	JJ	JJ	_	45	NMOD	_	_
45	manifestations	_	NNS	NNS	_	42	PMOD	_	_
46	of	_	IN	IN	_	45	NMOD	_	_
47	advanced	_	JJ	JJ	_	48	NMOD	_	_
48	infection	_	NN	NN	_	46	PMOD	_	_
49	with	_	IN	IN	_	48	NMOD	_	_
50	this	_	DT	DT	_	51	NMOD	_	_
51	virus	_	NN	NN	_	49	PMOD	_	_
52	.	_	.	.	_	11	P	_	_

1	Pentoxifylline	_	NN	NN	_	8	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	trisubstituted	_	JJ	JJ	_	6	NMOD	_	_
5	xanthine	_	NN	NN	_	6	NMOD	_	_
6	derivative	_	NN	NN	_	1	NMOD	_	_
7	,	_	,	,	_	1	P	_	_
8	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	been	_	VBN	VBN	_	8	VC	_	_
10	used	_	VBN	VBN	_	9	VC	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	decrease	_	VB	VB	_	10	OBJ	_	_
13	blood	_	NN	NN	_	14	NMOD	_	_
14	viscosity	_	NN	NN	_	12	OBJ	_	_
15	and	_	CC	CC	_	8	CC	_	_
16	is	_	VBZ	VBZ	_	8	COORD	_	_
17	reasonably	_	RB	RB	_	19	ADV	_	_
18	well	_	RB	RB	_	17	AMOD	_	_
19	tolerated	_	VBN	VBN	_	16	VC	_	_
20	by	_	IN	IN	_	19	LGS	_	_
21	most	_	JJS	JJS	_	22	NMOD	_	_
22	recipients	_	NNS	NNS	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	drug	_	NN	NN	_	23	PMOD	_	_
26	.	_	.	.	_	8	P	_	_

1	Results	_	NNS	NNS	_	14	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	preliminary	_	JJ	JJ	_	4	NMOD	_	_
4	studies	_	NNS	NNS	_	13	NMOD	_	_
5	,	_	,	,	_	13	P	_	_
6	many	_	JJ	JJ	_	7	NMOD	_	_
7	of	_	IN	IN	_	9	SBJ	_	_
8	which	_	WDT	WDT	_	7	PMOD	_	_
9	were	_	VBD	VBD	_	13	NMOD	_	_
10	conducted	_	VBN	VBN	_	9	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	Dr.	_	NNP	NNP	_	11	PMOD	_	_
13	Dezube	_	NNP	NNP	_	2	PMOD	_	_
14	,	_	,	,	_	0	ROOT-S	_	_
15	suggest	_	VBP	VBP	_	26	VMOD	_	_
16	that	_	IN	IN	_	26	SBJ	_	_
17	use	_	NN	NN	_	16	NMOD	_	_
18	of	_	IN	IN	_	19	NMOD	_	_
19	this	_	DT	DT	_	17	PMOD	_	_
20	agent	_	NN	NN	_	16	NMOD	_	_
21	in	_	IN	IN	_	20	PMOD	_	_
22	combination	_	NN	NN	_	21	NMOD	_	_
23	with	_	IN	IN	_	24	NMOD	_	_
24	antiretroviral	_	JJ	JJ	_	22	PMOD	_	_
25	compounds	_	NNS	NNS	_	26	VMOD	_	_
26	may	_	MD	MD	_	14	OBJ	_	_
27	prove	_	VB	VB	_	28	AMOD	_	_
28	useful	_	JJ	JJ	_	26	PRD	_	_
29	in	_	IN	IN	_	30	NMOD	_	_
30	the	_	DT	DT	_	28	PMOD	_	_
31	treatment	_	NN	NN	_	30	NMOD	_	_
32	of	_	IN	IN	_	31	PMOD	_	_
33	patients	_	NNS	NNS	_	32	NMOD	_	_
34	with	_	IN	IN	_	35	NMOD	_	_
35	HIV-1	_	NN	NN	_	33	PMOD	_	_
36	infection	_	NN	NN	_	14	VMOD	_	_

1	Evidence	_	NN	NN	_	0	ROOT-FRAG	_	_
2	for	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	trans-acting	_	JJ	JJ	_	6	NMOD	_	_
5	activator	_	NN	NN	_	6	NMOD	_	_
6	function	_	NN	NN	_	2	PMOD	_	_
7	regulating	_	VBG	VBG	_	6	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	expression	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	human	_	JJ	JJ	_	14	NMOD	_	_
13	CD5	_	NN	NN	_	14	NMOD	_	_
14	antigen	_	NN	NN	_	10	PMOD	_	_
15	.	_	.	.	_	1	P	_	_

1	Interspecies	_	JJ	JJ	_	4	NMOD	_	_
2	somatic	_	JJ	JJ	_	4	NMOD	_	_
3	cell	_	NN	NN	_	4	NMOD	_	_
4	hybrids	_	NNS	NNS	_	5	SBJ	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	generated	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	ADV	_	_
8	fusing	_	VBG	VBG	_	7	PMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	mouse	_	NN	NN	_	13	NMOD	_	_
11	T-lymphoma	_	NN	NN	_	13	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	line	_	NN	NN	_	8	OBJ	_	_
14	,	_	,	,	_	13	P	_	_
15	BW5147	_	NN	NN	_	13	NMOD	_	_
16	,	_	,	,	_	13	P	_	_
17	with	_	IN	IN	_	8	ADV	_	_
18	normal	_	JJ	JJ	_	21	NMOD	_	_
19	human	_	JJ	JJ	_	21	NMOD	_	_
20	T	_	NN	NN	_	21	NMOD	_	_
21	lymphocytes	_	NNS	NNS	_	17	PMOD	_	_
22	at	_	IN	IN	_	8	ADV	_	_
23	different	_	JJ	JJ	_	24	NMOD	_	_
24	stages	_	NNS	NNS	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	differentiation	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	5	P	_	_

1	Thymocytes	_	NNS	NNS	_	13	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	activated	_	VBN	VBN	_	6	NMOD	_	_
4	peripheral	_	JJ	JJ	_	6	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	lymphocytes	_	NNS	NNS	_	1	COORD	_	_
7	,	_	,	,	_	1	P	_	_
8	or	_	CC	CC	_	1	CC	_	_
9	an	_	DT	DT	_	12	NMOD	_	_
10	activated	_	VBN	VBN	_	12	NMOD	_	_
11	T-cell	_	NN	NN	_	12	NMOD	_	_
12	clone	_	NN	NN	_	1	COORD	_	_
13	were	_	VBD	VBD	_	0	ROOT-S	_	_
14	used	_	VBN	VBN	_	13	VC	_	_
15	as	_	IN	IN	_	14	ADV	_	_
16	human	_	JJ	JJ	_	17	NMOD	_	_
17	partners	_	NNS	NNS	_	15	PMOD	_	_
18	,	_	,	,	_	14	P	_	_
19	respectively	_	RB	RB	_	14	ADV	_	_
20	,	_	,	,	_	14	P	_	_
21	in	_	IN	IN	_	14	ADV	_	_
22	three	_	CD	CD	_	24	NMOD	_	_
23	independent	_	JJ	JJ	_	24	NMOD	_	_
24	fusions	_	NNS	NNS	_	21	PMOD	_	_
25	.	_	.	.	_	13	P	_	_

1	Irrespective	_	JJ	JJ	_	2	DEP	_	_
2	of	_	IN	IN	_	16	ADV	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	human	_	JJ	JJ	_	6	NMOD	_	_
5	cell	_	NN	NN	_	6	NMOD	_	_
6	partner	_	NN	NN	_	2	PMOD	_	_
7	used	_	VBN	VBN	_	6	NMOD	_	_
8	for	_	IN	IN	_	7	ADV	_	_
9	fusion	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	16	P	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	certain	_	JJ	JJ	_	13	NMOD	_	_
13	number	_	NN	NN	_	16	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	hybrids	_	NNS	NNS	_	14	PMOD	_	_
16	lost	_	VBD	VBD	_	0	ROOT-S	_	_
17	CD5	_	NN	NN	_	19	NMOD	_	_
18	surface	_	NN	NN	_	19	NMOD	_	_
19	expression	_	NN	NN	_	16	OBJ	_	_
20	over	_	IN	IN	_	16	TMP	_	_
21	a	_	DT	DT	_	22	NMOD	_	_
22	period	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	time	_	NN	NN	_	23	PMOD	_	_
25	in	_	IN	IN	_	22	NMOD	_	_
26	culture	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	16	P	_	_

1	Analysis	_	NN	NN	_	8	SBJ	_	_
2	at	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	phenotype	_	NN	NN	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	genetic	_	JJ	JJ	_	4	COORD	_	_
7	level	_	NN	NN	_	2	PMOD	_	_
8	showed	_	VBD	VBD	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	lack	_	NN	NN	_	14	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	CD5	_	NN	NN	_	13	NMOD	_	_
13	expression	_	NN	NN	_	11	PMOD	_	_
14	was	_	VBD	VBD	_	9	VMOD	_	_
15	due	_	JJ	JJ	_	14	PRD	_	_
16	neither	_	CC	CC	_	15	PMOD	_	_
17	to	_	TO	TO	_	16	COORD	_	_
18	segregation	_	NN	NN	_	17	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	human	_	JJ	JJ	_	21	NMOD	_	_
21	autosome	_	NN	NN	_	19	PMOD	_	_
22	11	_	CD	CD	_	21	NMOD	_	_
23	,	_	,	,	_	21	P	_	_
24	on	_	IN	IN	_	31	ADV	_	_
25	which	_	WDT	WDT	_	24	PMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	CD5	_	NN	NN	_	28	NMOD	_	_
28	gene	_	NN	NN	_	29	SBJ	_	_
29	has	_	VBZ	VBZ	_	21	NMOD	_	_
30	been	_	VBN	VBN	_	29	VC	_	_
31	mapped	_	VBN	VBN	_	30	VC	_	_
32	,	_	,	,	_	21	P	_	_
33	nor	_	CC	CC	_	16	CC	_	_
34	to	_	TO	TO	_	16	COORD	_	_
35	deletion	_	NN	NN	_	34	PMOD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	the	_	DT	DT	_	40	NMOD	_	_
38	CD5	_	NN	NN	_	40	NMOD	_	_
39	structural	_	JJ	JJ	_	40	NMOD	_	_
40	gene	_	NN	NN	_	36	PMOD	_	_
41	.	_	.	.	_	8	P	_	_

1	Furthermore	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	loss	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	CD5	_	NN	NN	_	7	NMOD	_	_
6	surface	_	NN	NN	_	7	NMOD	_	_
7	expression	_	NN	NN	_	4	PMOD	_	_
8	correlated	_	VBD	VBD	_	0	ROOT-S	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	absence	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	specific	_	JJ	JJ	_	14	NMOD	_	_
14	mRNA	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	8	P	_	_

1	Since	_	IN	IN	_	11	ADV	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	hybrids	_	NNS	NNS	_	5	SBJ	_	_
4	preferentially	_	RB	RB	_	5	ADV	_	_
5	segregate	_	VBP	VBP	_	1	VMOD	_	_
6	human	_	JJ	JJ	_	7	NMOD	_	_
7	chromosomes	_	NNS	NNS	_	5	OBJ	_	_
8	,	_	,	,	_	11	P	_	_
9	these	_	DT	DT	_	10	NMOD	_	_
10	results	_	NNS	NNS	_	11	SBJ	_	_
11	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	existence	_	NN	NN	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	a	_	DT	DT	_	18	NMOD	_	_
16	non-syntenic	_	JJ	JJ	_	18	NMOD	_	_
17	trans-active	_	JJ	JJ	_	18	NMOD	_	_
18	locus	_	NN	NN	_	14	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	or	_	CC	CC	_	18	CC	_	_
21	loci	_	NNS	NNS	_	18	COORD	_	_
22	,	_	,	,	_	18	P	_	_
23	positively	_	RB	RB	_	24	ADV	_	_
24	controlling	_	VBG	VBG	_	18	NMOD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	expression	_	NN	NN	_	24	OBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	31	NMOD	_	_
29	human	_	JJ	JJ	_	31	NMOD	_	_
30	CD5	_	NN	NN	_	31	NMOD	_	_
31	gene	_	NN	NN	_	27	PMOD	_	_
32	.	_	.	.	_	11	P	_	_

1	Alternate	_	JJ	JJ	_	3	NMOD	_	_
2	immune	_	JJ	JJ	_	3	NMOD	_	_
3	system	_	NN	NN	_	0	ROOT-FRAG	_	_
4	targets	_	VBZ	VBZ	_	3	NMOD	_	_
5	for	_	IN	IN	_	3	NMOD	_	_
6	TCDD	_	NN	NN	_	5	PMOD	_	_
7	:	_	:	:	_	3	P	_	_
8	lymphocyte	_	NN	NN	_	10	NMOD	_	_
9	stem	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	3	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	extrathymic	_	JJ	JJ	_	14	NMOD	_	_
13	T-cell	_	NN	NN	_	14	NMOD	_	_
14	development	_	NN	NN	_	10	COORD	_	_
15	.	_	.	.	_	10	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	here	_	RB	RB	_	3	ADV	_	_
3	summarize	_	VBP	VBP	_	0	ROOT-S	_	_
4	evidence	_	NN	NN	_	3	OBJ	_	_
5	that	_	IN	IN	_	4	NMOD	_	_
6	thymic	_	JJ	JJ	_	7	NMOD	_	_
7	atrophy	_	NN	NN	_	14	SBJ	_	_
8	induced	_	VBN	VBN	_	7	NMOD	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	2,3,7,8-tetrachlorodibenzo-p-dioxin	_	NN	NN	_	9	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	TCDD	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	can	_	MD	MD	_	5	VMOD	_	_
15	be	_	VB	VB	_	14	VC	_	_
16	mediated	_	VBN	VBN	_	15	VC	_	_
17	,	_	,	,	_	16	P	_	_
18	at	_	IN	IN	_	20	PMOD	_	_
19	least	_	JJS	JJS	_	18	AMOD	_	_
20	in	_	IN	IN	_	16	ADV	_	_
21	part	_	NN	NN	_	20	PMOD	_	_
22	,	_	,	,	_	16	P	_	_
23	by	_	IN	IN	_	16	LGS	_	_
24	damage	_	NN	NN	_	23	PMOD	_	_
25	to	_	TO	TO	_	24	NMOD	_	_
26	extrathymic	_	JJ	JJ	_	28	NMOD	_	_
27	T-cell	_	NN	NN	_	28	NMOD	_	_
28	precursors	_	NNS	NNS	_	25	PMOD	_	_
29	in	_	IN	IN	_	28	NMOD	_	_
30	bone	_	NN	NN	_	31	NMOD	_	_
31	marrow	_	NN	NN	_	29	PMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	fetal	_	JJ	JJ	_	34	NMOD	_	_
34	liver	_	NN	NN	_	31	COORD	_	_
35	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	atrophy	_	NN	NN	_	3	NMOD	_	_
3	induction	_	NN	NN	_	4	SBJ	_	_
4	does	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	involve	_	VB	VB	_	4	VC	_	_
7	apoptotic	_	JJ	JJ	_	8	NMOD	_	_
8	mechanisms	_	NNS	NNS	_	6	OBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	thymocytes	_	NNS	NNS	_	9	PMOD	_	_
11	affected	_	VBN	VBN	_	10	NMOD	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	bcl-2	_	NN	NN	_	15	NMOD	_	_
15	proto-oncogene	_	NN	NN	_	12	PMOD	_	_
16	.	_	.	.	_	4	P	_	_

1	TCDD	_	NN	NN	_	2	SBJ	_	_
2	mediates	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	atrophy	_	NN	NN	_	4	NMOD	_	_
4	induction	_	NN	NN	_	2	OBJ	_	_
5	through	_	IN	IN	_	2	ADV	_	_
6	its	_	PRP$	PRP$	_	8	NMOD	_	_
7	specific	_	JJ	JJ	_	8	NMOD	_	_
8	receptor	_	NN	NN	_	5	PMOD	_	_
9	(	_	(	(	_	11	P	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	AhR	_	NN	NN	_	8	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	and	_	CC	CC	_	5	CC	_	_
14	not	_	RB	RB	_	15	DEP	_	_
15	through	_	IN	IN	_	5	COORD	_	_
16	effects	_	NNS	NNS	_	15	PMOD	_	_
17	on	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	estrogen	_	NN	NN	_	20	NMOD	_	_
20	receptor	_	NN	NN	_	17	PMOD	_	_
21	.	_	.	.	_	2	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	TCDD	_	NN	NN	_	5	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	estradiol	_	NN	NN	_	2	COORD	_	_
5	induce	_	VBP	VBP	_	0	ROOT-S	_	_
6	extrathymic	_	JJ	JJ	_	8	NMOD	_	_
7	T-cell	_	NN	NN	_	8	NMOD	_	_
8	differentiation	_	NN	NN	_	5	OBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	liver	_	NN	NN	_	9	PMOD	_	_
12	.	_	.	.	_	5	P	_	_

1	These	_	DT	DT	_	4	NMOD	_	_
2	extrathymic	_	JJ	JJ	_	4	NMOD	_	_
3	T-cell	_	NN	NN	_	4	NMOD	_	_
4	populations	_	NNS	NNS	_	5	SBJ	_	_
5	include	_	VBP	VBP	_	0	ROOT-S	_	_
6	cells	_	NNS	NNS	_	5	OBJ	_	_
7	expressing	_	VBG	VBG	_	6	NMOD	_	_
8	elevated	_	JJ	JJ	_	9	NMOD	_	_
9	levels	_	NNS	NNS	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	V	_	NN	NN	_	14	NMOD	_	_
12	beta	_	NN	NN	_	14	NMOD	_	_
13	T-cell	_	NN	NN	_	14	NMOD	_	_
14	receptors	_	NNS	NNS	_	10	PMOD	_	_
15	that	_	WDT	WDT	_	16	SBJ	_	_
16	are	_	VBP	VBP	_	14	NMOD	_	_
17	normally	_	RB	RB	_	18	ADV	_	_
18	deleted	_	VBN	VBN	_	16	VC	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	thymic	_	JJ	JJ	_	21	NMOD	_	_
21	development	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	BCL-6	_	NN	NN	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	molecular	_	JJ	JJ	_	5	NMOD	_	_
5	pathogenesis	_	NN	NN	_	1	COORD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	B-cell	_	NN	NN	_	8	NMOD	_	_
8	lymphoma	_	NN	NN	_	6	PMOD	_	_
9	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	4	SBJ	_	_
3	presented	_	VBN	VBN	_	2	NMOD	_	_
4	identify	_	VBP	VBP	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	first	_	JJ	JJ	_	8	NMOD	_	_
7	genetic	_	JJ	JJ	_	8	NMOD	_	_
8	lesion	_	NN	NN	_	4	OBJ	_	_
9	associated	_	VBN	VBN	_	8	NMOD	_	_
10	with	_	IN	IN	_	9	ADV	_	_
11	DLCL	_	NN	NN	_	10	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	most	_	RBS	RBS	_	16	AMOD	_	_
15	clinically	_	RB	RB	_	16	AMOD	_	_
16	relevant	_	JJ	JJ	_	17	NMOD	_	_
17	form	_	NN	NN	_	11	NMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	NHL	_	NN	NN	_	18	PMOD	_	_
20	.	_	.	.	_	4	P	_	_

1	Although	_	IN	IN	_	43	ADV	_	_
2	no	_	DT	DT	_	3	NMOD	_	_
3	proof	_	NN	NN	_	5	SBJ	_	_
4	yet	_	RB	RB	_	5	TMP	_	_
5	exists	_	VBZ	VBZ	_	1	VMOD	_	_
6	of	_	IN	IN	_	3	NMOD	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	role	_	NN	NN	_	6	PMOD	_	_
9	for	_	IN	IN	_	8	NMOD	_	_
10	these	_	DT	DT	_	11	NMOD	_	_
11	lesions	_	NNS	NNS	_	9	PMOD	_	_
12	in	_	IN	IN	_	8	NMOD	_	_
13	DLCL	_	NN	NN	_	14	NMOD	_	_
14	pathogenesis	_	NN	NN	_	12	PMOD	_	_
15	,	_	,	,	_	43	P	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	feature	_	NN	NN	_	43	SBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	BCL-6	_	NN	NN	_	22	NMOD	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	product	_	NN	NN	_	18	PMOD	_	_
23	,	_	,	,	_	17	P	_	_
24	its	_	PRP$	PRP$	_	26	NMOD	_	_
25	specific	_	JJ	JJ	_	26	NMOD	_	_
26	pattern	_	NN	NN	_	17	COORD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	expression	_	NN	NN	_	27	PMOD	_	_
29	in	_	IN	IN	_	26	NMOD	_	_
30	B	_	NN	NN	_	31	NMOD	_	_
31	cells	_	NNS	NNS	_	29	PMOD	_	_
32	,	_	,	,	_	17	P	_	_
33	and	_	CC	CC	_	17	CC	_	_
34	the	_	DT	DT	_	35	NMOD	_	_
35	clustering	_	NN	NN	_	17	COORD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	lesions	_	NNS	NNS	_	36	PMOD	_	_
38	disrupting	_	VBG	VBG	_	35	NMOD	_	_
39	its	_	PRP$	PRP$	_	41	NMOD	_	_
40	regulatory	_	JJ	JJ	_	41	NMOD	_	_
41	domain	_	NN	NN	_	38	OBJ	_	_
42	strongly	_	RB	RB	_	43	ADV	_	_
43	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
44	that	_	IN	IN	_	43	OBJ	_	_
45	deregulation	_	NN	NN	_	49	SBJ	_	_
46	of	_	IN	IN	_	45	NMOD	_	_
47	BCL-6	_	NN	NN	_	48	NMOD	_	_
48	expression	_	NN	NN	_	46	PMOD	_	_
49	may	_	MD	MD	_	44	VMOD	_	_
50	contribute	_	VB	VB	_	49	VC	_	_
51	to	_	TO	TO	_	50	ADV	_	_
52	DLCL	_	NN	NN	_	53	NMOD	_	_
53	development	_	NN	NN	_	51	PMOD	_	_
54	.	_	.	.	_	43	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	more	_	RBR	RBR	_	3	AMOD	_	_
3	precise	_	JJ	JJ	_	4	NMOD	_	_
4	definition	_	NN	NN	_	16	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	role	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	BCL-6	_	NN	NN	_	8	PMOD	_	_
10	in	_	IN	IN	_	7	NMOD	_	_
11	normal	_	JJ	JJ	_	15	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	neoplastic	_	JJ	JJ	_	11	COORD	_	_
14	B-cell	_	NN	NN	_	15	NMOD	_	_
15	development	_	NN	NN	_	10	PMOD	_	_
16	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	goal	_	NN	NN	_	16	PRD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	ongoing	_	JJ	JJ	_	21	NMOD	_	_
21	study	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	transgenic	_	JJ	JJ	_	24	NMOD	_	_
24	mice	_	NNS	NNS	_	22	PMOD	_	_
25	engineered	_	VBN	VBN	_	24	NMOD	_	_
26	either	_	CC	CC	_	28	CC	_	_
27	to	_	TO	TO	_	28	VMOD	_	_
28	express	_	VB	VB	_	25	OBJ	_	_
29	BCL-6	_	NN	NN	_	28	OBJ	_	_
30	under	_	IN	IN	_	28	ADV	_	_
31	heterologous	_	JJ	JJ	_	32	NMOD	_	_
32	promoters	_	NNS	NNS	_	30	PMOD	_	_
33	or	_	CC	CC	_	28	CC	_	_
34	lacking	_	VBG	VBG	_	28	COORD	_	_
35	BCL-6	_	NN	NN	_	36	NMOD	_	_
36	function	_	NN	NN	_	34	OBJ	_	_
37	due	_	JJ	JJ	_	38	DEP	_	_
38	to	_	TO	TO	_	34	ADV	_	_
39	targeted	_	VBN	VBN	_	40	NMOD	_	_
40	deletions	_	NNS	NNS	_	38	PMOD	_	_
41	.	_	.	.	_	16	P	_	_

1	In	_	IN	IN	_	17	ADV	_	_
2	addition	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	contributing	_	VBG	VBG	_	1	PMOD	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	understanding	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	DLCL	_	NN	NN	_	10	NMOD	_	_
10	pathogenesis	_	NN	NN	_	8	PMOD	_	_
11	,	_	,	,	_	17	P	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	identification	_	NN	NN	_	17	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	BCL-6	_	NN	NN	_	16	NMOD	_	_
16	lesions	_	NNS	NNS	_	14	PMOD	_	_
17	may	_	MD	MD	_	0	ROOT-S	_	_
18	have	_	VB	VB	_	17	VC	_	_
19	relevant	_	JJ	JJ	_	21	NMOD	_	_
20	clinical	_	JJ	JJ	_	21	NMOD	_	_
21	implications	_	NNS	NNS	_	18	OBJ	_	_
22	.	_	.	.	_	17	P	_	_

1	DLCL	_	NN	NN	_	2	SBJ	_	_
2	represent	_	VBP	VBP	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	heterogeneous	_	JJ	JJ	_	5	NMOD	_	_
5	group	_	NN	NN	_	2	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	neoplasms	_	NNS	NNS	_	6	PMOD	_	_
8	which	_	WDT	WDT	_	9	SBJ	_	_
9	are	_	VBP	VBP	_	7	NMOD	_	_
10	treated	_	VBN	VBN	_	9	VC	_	_
11	homogeneously	_	RB	RB	_	10	ADV	_	_
12	despite	_	IN	IN	_	10	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	fact	_	NN	NN	_	12	PMOD	_	_
15	that	_	IN	IN	_	14	NMOD	_	_
16	only	_	RB	RB	_	18	NMOD	_	_
17	50	_	CD	CD	_	16	DEP	_	_
18	%	_	NN	NN	_	21	SBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	patients	_	NNS	NNS	_	19	PMOD	_	_
21	experience	_	VBP	VBP	_	15	VMOD	_	_
22	long-term	_	JJ	JJ	_	24	NMOD	_	_
23	disease-free	_	JJ	JJ	_	24	NMOD	_	_
24	survival	_	NN	NN	_	21	OBJ	_	_
25	(	_	(	(	_	26	P	_	_
26	Schneider	_	NNP	NNP	_	2	PRN	_	_
27	et	_	FW	FW	_	26	NMOD	_	_
28	al.	_	FW	FW	_	27	AMOD	_	_
29	1990	_	CD	CD	_	26	TMP	_	_
30	)	_	)	)	_	26	P	_	_
31	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	fact	_	NN	NN	_	14	SBJ	_	_
3	that	_	IN	IN	_	2	NMOD	_	_
4	BCL-6	_	NN	NN	_	5	NMOD	_	_
5	rearrangements	_	NNS	NNS	_	6	SBJ	_	_
6	identify	_	VBP	VBP	_	3	VMOD	_	_
7	biologically	_	RB	RB	_	11	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	clinically	_	RB	RB	_	7	COORD	_	_
10	distinct	_	JJ	JJ	_	7	AMOD	_	_
11	subsets	_	NNS	NNS	_	6	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	DLCL	_	NN	NN	_	12	PMOD	_	_
14	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	that	_	IN	IN	_	14	OBJ	_	_
16	these	_	DT	DT	_	17	NMOD	_	_
17	lesions	_	NNS	NNS	_	18	SBJ	_	_
18	may	_	MD	MD	_	15	VMOD	_	_
19	be	_	VB	VB	_	18	VC	_	_
20	useful	_	JJ	JJ	_	19	PRD	_	_
21	as	_	IN	IN	_	19	ADV	_	_
22	markers	_	NNS	NNS	_	21	PMOD	_	_
23	in	_	IN	IN	_	19	ADV	_	_
24	selection	_	NN	NN	_	23	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	differential	_	JJ	JJ	_	28	NMOD	_	_
27	therapeutic	_	JJ	JJ	_	28	NMOD	_	_
28	strategies	_	NNS	NNS	_	25	PMOD	_	_
29	based	_	VBN	VBN	_	24	NMOD	_	_
30	on	_	IN	IN	_	29	PMOD	_	_
31	different	_	JJ	JJ	_	33	NMOD	_	_
32	risk	_	NN	NN	_	33	NMOD	_	_
33	groups	_	NNS	NNS	_	30	PMOD	_	_
34	.	_	.	.	_	14	P	_	_

1	Furthermore	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	BCL-6	_	NN	NN	_	5	NMOD	_	_
5	rearrangements	_	NNS	NNS	_	6	SBJ	_	_
6	can	_	MD	MD	_	0	ROOT-S	_	_
7	be	_	VB	VB	_	6	VC	_	_
8	used	_	VBN	VBN	_	7	VC	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	identify	_	VB	VB	_	8	OBJ	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	monitor	_	VB	VB	_	10	COORD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	malignant	_	JJ	JJ	_	15	NMOD	_	_
15	clone	_	NN	NN	_	10	OBJ	_	_
16	with	_	IN	IN	_	10	ADV	_	_
17	sensitive	_	JJ	JJ	_	19	NMOD	_	_
18	PCR-based	_	JJ	JJ	_	19	NMOD	_	_
19	techniques	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	6	P	_	_

1	Since	_	IN	IN	_	17	ADV	_	_
2	clinical	_	JJ	JJ	_	3	NMOD	_	_
3	remission	_	NN	NN	_	4	SBJ	_	_
4	has	_	VBZ	VBZ	_	1	VMOD	_	_
5	been	_	VBN	VBN	_	4	VC	_	_
6	observed	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	significant	_	JJ	JJ	_	10	NMOD	_	_
10	fraction	_	NN	NN	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	DLCL	_	NN	NN	_	13	NMOD	_	_
13	cases	_	NNS	NNS	_	11	PMOD	_	_
14	,	_	,	,	_	17	P	_	_
15	these	_	DT	DT	_	16	NMOD	_	_
16	markers	_	NNS	NNS	_	17	SBJ	_	_
17	may	_	MD	MD	_	0	ROOT-S	_	_
18	serve	_	VB	VB	_	17	VC	_	_
19	as	_	IN	IN	_	18	ADV	_	_
20	critical	_	JJ	JJ	_	21	NMOD	_	_
21	tools	_	NNS	NNS	_	19	PMOD	_	_
22	for	_	IN	IN	_	21	NMOD	_	_
23	sensitive	_	JJ	JJ	_	24	NMOD	_	_
24	monitoring	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	minimal	_	JJ	JJ	_	28	NMOD	_	_
27	residual	_	JJ	JJ	_	28	NMOD	_	_
28	disease	_	NN	NN	_	25	PMOD	_	_
29	and	_	CC	CC	_	24	CC	_	_
30	early	_	JJ	JJ	_	31	NMOD	_	_
31	diagnosis	_	NN	NN	_	24	COORD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	relapse	_	NN	NN	_	32	PMOD	_	_
34	(	_	(	(	_	35	P	_	_
35	Gribben	_	NNP	NNP	_	18	PRN	_	_
36	et	_	FW	FW	_	35	NMOD	_	_
37	al.	_	FW	FW	_	36	AMOD	_	_
38	1993	_	CD	CD	_	35	TMP	_	_
39	)	_	)	)	_	35	P	_	_
40	.	_	.	.	_	17	P	_	_

1	Differential	_	JJ	JJ	_	2	NMOD	_	_
2	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	IL-6	_	NN	NN	_	5	NMOD	_	_
5	gene	_	NN	NN	_	3	PMOD	_	_
6	transcription	_	NN	NN	_	5	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	expression	_	NN	NN	_	6	COORD	_	_
9	by	_	IN	IN	_	2	NMOD	_	_
10	IL-4	_	NN	NN	_	9	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	IL-10	_	NN	NN	_	10	COORD	_	_
13	in	_	IN	IN	_	2	NMOD	_	_
14	human	_	JJ	JJ	_	17	NMOD	_	_
15	monocytic	_	JJ	JJ	_	17	NMOD	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	lines	_	NNS	NNS	_	13	PMOD	_	_
18	.	_	.	.	_	2	P	_	_

1	IL-4	_	NN	NN	_	4	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	IL-10	_	NN	NN	_	1	COORD	_	_
4	inhibit	_	VBP	VBP	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	cytokine	_	NN	NN	_	7	NMOD	_	_
7	production	_	NN	NN	_	4	OBJ	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	mRNA	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	7	COORD	_	_
11	by	_	IN	IN	_	7	NMOD	_	_
12	monocytes\/macrophages	_	NNS	NNS	_	11	PMOD	_	_
13	.	_	.	.	_	4	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	investigate	_	VB	VB	_	25	VMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	molecular	_	JJ	JJ	_	5	NMOD	_	_
5	mechanism	_	NN	NN	_	2	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	inhibitory	_	JJ	JJ	_	9	NMOD	_	_
9	effect	_	NN	NN	_	6	PMOD	_	_
10	on	_	IN	IN	_	9	NMOD	_	_
11	transcriptional	_	JJ	JJ	_	14	NMOD	_	_
12	or	_	CC	CC	_	11	CC	_	_
13	post-transcriptional	_	JJ	JJ	_	11	COORD	_	_
14	regulation	_	NN	NN	_	10	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	IL-6	_	NN	NN	_	18	NMOD	_	_
17	gene	_	NN	NN	_	18	NMOD	_	_
18	expression	_	NN	NN	_	15	PMOD	_	_
19	by	_	IN	IN	_	9	NMOD	_	_
20	IL-4	_	NN	NN	_	19	PMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	IL-10	_	NN	NN	_	20	COORD	_	_
23	,	_	,	,	_	25	P	_	_
24	we	_	PRP	PRP	_	25	SBJ	_	_
25	studied	_	VBD	VBD	_	0	ROOT-S	_	_
26	IL-6	_	NN	NN	_	27	NMOD	_	_
27	production	_	NN	NN	_	25	OBJ	_	_
28	,	_	,	,	_	27	P	_	_
29	expression	_	NN	NN	_	30	NMOD	_	_
30	level	_	NN	NN	_	27	COORD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	IL-6	_	NN	NN	_	33	NMOD	_	_
33	mRNA	_	NN	NN	_	31	PMOD	_	_
34	,	_	,	,	_	27	P	_	_
35	IL-6	_	NN	NN	_	37	NMOD	_	_
36	promoter	_	NN	NN	_	37	NMOD	_	_
37	activity	_	NN	NN	_	27	COORD	_	_
38	,	_	,	,	_	27	P	_	_
39	transcriptional	_	JJ	JJ	_	40	NMOD	_	_
40	activity	_	NN	NN	_	27	COORD	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	NF-kappaB	_	NN	NN	_	41	PMOD	_	_
43	and	_	CC	CC	_	42	CC	_	_
44	NF-IL-6	_	NN	NN	_	42	COORD	_	_
45	,	_	,	,	_	27	P	_	_
46	and	_	CC	CC	_	27	CC	_	_
47	IL-6	_	NN	NN	_	49	NMOD	_	_
48	mRNA	_	NN	NN	_	49	NMOD	_	_
49	stability	_	NN	NN	_	27	COORD	_	_
50	in	_	IN	IN	_	27	NMOD	_	_
51	human	_	JJ	JJ	_	54	NMOD	_	_
52	monocytic	_	JJ	JJ	_	54	NMOD	_	_
53	cell	_	NN	NN	_	54	NMOD	_	_
54	lines	_	NNS	NNS	_	50	PMOD	_	_
55	,	_	,	,	_	54	P	_	_
56	THP-1	_	NN	NN	_	54	NMOD	_	_
57	and	_	CC	CC	_	56	CC	_	_
58	U937	_	NN	NN	_	56	COORD	_	_
59	,	_	,	,	_	54	P	_	_
60	stimulated	_	VBN	VBN	_	54	NMOD	_	_
61	by	_	IN	IN	_	60	LGS	_	_
62	PMA	_	NN	NN	_	61	PMOD	_	_
63	and	_	CC	CC	_	62	CC	_	_
64	LPS	_	NN	NN	_	62	COORD	_	_
65	in	_	IN	IN	_	60	ADV	_	_
66	the	_	DT	DT	_	67	NMOD	_	_
67	absence	_	NN	NN	_	65	PMOD	_	_
68	or	_	CC	CC	_	67	CC	_	_
69	the	_	DT	DT	_	70	NMOD	_	_
70	presence	_	NN	NN	_	67	COORD	_	_
71	of	_	IN	IN	_	67	NMOD	_	_
72	IL-4	_	NN	NN	_	71	PMOD	_	_
73	or	_	CC	CC	_	72	CC	_	_
74	IL-10	_	NN	NN	_	72	COORD	_	_
75	.	_	.	.	_	25	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	IL-4	_	NN	NN	_	5	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	IL-10	_	NN	NN	_	2	COORD	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	seen	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	inhibit	_	VB	VB	_	6	OBJ	_	_
9	IL-6	_	NN	NN	_	10	NMOD	_	_
10	production	_	NN	NN	_	8	OBJ	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	expression	_	NN	NN	_	10	COORD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	IL-6	_	NN	NN	_	16	NMOD	_	_
16	mRNA	_	NN	NN	_	14	PMOD	_	_
17	in	_	IN	IN	_	8	ADV	_	_
18	both	_	DT	DT	_	21	NMOD	_	_
19	monocytic	_	JJ	JJ	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	lines	_	NNS	NNS	_	17	PMOD	_	_
22	studied	_	VBN	VBN	_	21	NMOD	_	_
23	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	28	ADV	_	_
2	chloramphenicol	_	NN	NN	_	4	NMOD	_	_
3	acetyltransferase	_	NN	NN	_	4	NMOD	_	_
4	assays	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	28	P	_	_
6	utilizing	_	VBG	VBG	_	28	VMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	transient	_	JJ	JJ	_	9	NMOD	_	_
9	transfection	_	NN	NN	_	6	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	a	_	DT	DT	_	15	NMOD	_	_
12	chloramphenicol	_	NN	NN	_	15	NMOD	_	_
13	acetyltransferase	_	NN	NN	_	15	NMOD	_	_
14	reporter	_	NN	NN	_	15	NMOD	_	_
15	plasmid	_	NN	NN	_	10	PMOD	_	_
16	containing	_	VBG	VBG	_	15	NMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	IL-6	_	NN	NN	_	20	NMOD	_	_
19	gene	_	NN	NN	_	20	NMOD	_	_
20	promoter	_	NN	NN	_	16	OBJ	_	_
21	,	_	,	,	_	28	P	_	_
22	IL-4	_	NN	NN	_	28	SBJ	_	_
23	,	_	,	,	_	22	P	_	_
24	but	_	CC	CC	_	22	CC	_	_
25	not	_	RB	RB	_	24	COORD	_	_
26	IL-10	_	NN	NN	_	22	COORD	_	_
27	,	_	,	,	_	22	P	_	_
28	suppressed	_	VBD	VBD	_	0	ROOT-S	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	transcriptional	_	JJ	JJ	_	31	NMOD	_	_
31	activity	_	NN	NN	_	28	OBJ	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	the	_	DT	DT	_	36	NMOD	_	_
34	IL-6	_	NN	NN	_	36	NMOD	_	_
35	gene	_	NN	NN	_	36	NMOD	_	_
36	promoter	_	NN	NN	_	32	PMOD	_	_
37	stimulated	_	VBN	VBN	_	36	NMOD	_	_
38	by	_	IN	IN	_	37	LGS	_	_
39	PMA	_	NN	NN	_	38	PMOD	_	_
40	and	_	CC	CC	_	39	CC	_	_
41	LPS	_	NN	NN	_	39	COORD	_	_
42	.	_	.	.	_	28	P	_	_

1	Electrophoretic	_	JJ	JJ	_	4	NMOD	_	_
2	mobility	_	NN	NN	_	4	NMOD	_	_
3	shift	_	NN	NN	_	4	NMOD	_	_
4	assays	_	NNS	NNS	_	5	SBJ	_	_
5	showed	_	VBD	VBD	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	IL-4	_	NN	NN	_	13	SBJ	_	_
8	,	_	,	,	_	7	P	_	_
9	but	_	CC	CC	_	7	CC	_	_
10	not	_	RB	RB	_	9	COORD	_	_
11	IL-10	_	NN	NN	_	7	COORD	_	_
12	,	_	,	,	_	7	P	_	_
13	inhibited	_	VBD	VBD	_	6	VMOD	_	_
14	nuclear	_	JJ	JJ	_	16	NMOD	_	_
15	NF-kappaB	_	NN	NN	_	16	NMOD	_	_
16	activity	_	NN	NN	_	13	OBJ	_	_
17	,	_	,	,	_	6	P	_	_
18	and	_	CC	CC	_	6	CC	_	_
19	that	_	IN	IN	_	6	COORD	_	_
20	IL-4	_	NN	NN	_	23	SBJ	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	IL-10	_	NN	NN	_	20	COORD	_	_
23	did	_	VBD	VBD	_	19	VMOD	_	_
24	not	_	RB	RB	_	23	VMOD	_	_
25	affect	_	VB	VB	_	23	VC	_	_
26	NF-IL-6	_	NN	NN	_	27	NMOD	_	_
27	activity	_	NN	NN	_	25	OBJ	_	_
28	.	_	.	.	_	5	P	_	_

1	On	_	IN	IN	_	7	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	other	_	JJ	JJ	_	4	NMOD	_	_
4	hand	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	IL-10	_	NN	NN	_	7	SBJ	_	_
7	enhanced	_	VBD	VBD	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	degradation	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	IL-6	_	NN	NN	_	12	NMOD	_	_
12	mRNA	_	NN	NN	_	10	PMOD	_	_
13	in	_	IN	IN	_	7	ADV	_	_
14	a	_	DT	DT	_	17	NMOD	_	_
15	mRNA	_	NN	NN	_	17	NMOD	_	_
16	stability	_	NN	NN	_	17	NMOD	_	_
17	assay	_	NN	NN	_	13	PMOD	_	_
18	.	_	.	.	_	7	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	IL-4	_	NN	NN	_	6	SBJ	_	_
6	may	_	MD	MD	_	4	VMOD	_	_
7	inhibit	_	VB	VB	_	6	VC	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	transcription	_	NN	NN	_	7	IOBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	IL-6	_	NN	NN	_	13	NMOD	_	_
13	gene	_	NN	NN	_	10	PMOD	_	_
14	by	_	IN	IN	_	7	ADV	_	_
15	affecting	_	VBG	VBG	_	14	PMOD	_	_
16	NF-kappaB	_	NN	NN	_	18	NMOD	_	_
17	binding	_	NN	NN	_	18	NMOD	_	_
18	activity	_	NN	NN	_	15	OBJ	_	_
19	,	_	,	,	_	7	P	_	_
20	while	_	IN	IN	_	7	OBJ	_	_
21	IL-10	_	NN	NN	_	22	SBJ	_	_
22	may	_	MD	MD	_	20	VMOD	_	_
23	inhibit	_	VB	VB	_	22	VC	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	IL-6	_	NN	NN	_	27	NMOD	_	_
26	mRNA	_	NN	NN	_	27	NMOD	_	_
27	levels	_	NNS	NNS	_	23	OBJ	_	_
28	post-transcriptionally	_	RB	RB	_	23	TMP	_	_
29	,	_	,	,	_	23	P	_	_
30	without	_	IN	IN	_	23	ADV	_	_
31	suppressing	_	VBG	VBG	_	30	PMOD	_	_
32	promoter	_	NN	NN	_	33	NMOD	_	_
33	activity	_	NN	NN	_	31	OBJ	_	_
34	.	_	.	.	_	3	P	_	_

1	Therefore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	conclude	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	IL-4	_	NN	NN	_	9	SBJ	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	IL-10	_	NN	NN	_	6	COORD	_	_
9	inhibit	_	VBP	VBP	_	5	VMOD	_	_
10	IL-6	_	NN	NN	_	11	NMOD	_	_
11	production	_	NN	NN	_	9	OBJ	_	_
12	by	_	IN	IN	_	9	ADV	_	_
13	different	_	JJ	JJ	_	14	NMOD	_	_
14	mechanisms	_	NNS	NNS	_	12	PMOD	_	_
15	in	_	IN	IN	_	9	ADV	_	_
16	human	_	JJ	JJ	_	19	NMOD	_	_
17	monocytic	_	JJ	JJ	_	19	NMOD	_	_
18	cell	_	NN	NN	_	19	NMOD	_	_
19	lines	_	NNS	NNS	_	15	PMOD	_	_
20	.	_	.	.	_	4	P	_	_

1	Age-related	_	JJ	JJ	_	2	NMOD	_	_
2	decreases	_	NNS	NNS	_	10	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	IL-2	_	NN	NN	_	5	NMOD	_	_
5	production	_	NN	NN	_	3	PMOD	_	_
6	by	_	IN	IN	_	5	NMOD	_	_
7	human	_	JJ	JJ	_	9	NMOD	_	_
8	T	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	6	PMOD	_	_
10	are	_	VBP	VBP	_	0	ROOT-S	_	_
11	associated	_	VBN	VBN	_	10	VC	_	_
12	with	_	IN	IN	_	11	ADV	_	_
13	impaired	_	JJ	JJ	_	14	NMOD	_	_
14	activation	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	nuclear	_	JJ	JJ	_	18	NMOD	_	_
17	transcriptional	_	JJ	JJ	_	18	NMOD	_	_
18	factors	_	NNS	NNS	_	15	PMOD	_	_
19	AP-1	_	NN	NN	_	18	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	NF-AT	_	NN	NN	_	19	COORD	_	_
22	.	_	.	.	_	10	P	_	_

1	Although	_	IN	IN	_	25	ADV	_	_
2	transcriptional	_	JJ	JJ	_	4	NMOD	_	_
3	factors	_	NNS	NNS	_	4	NMOD	_	_
4	AP-1	_	NN	NN	_	15	SBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	nuclear	_	JJ	JJ	_	7	NMOD	_	_
7	factor	_	NN	NN	_	4	COORD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	activated	_	VBN	VBN	_	11	NMOD	_	_
10	T	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	8	PMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	NF-AT	_	NN	NN	_	7	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	are	_	VBP	VBP	_	1	VMOD	_	_
16	important	_	JJ	JJ	_	15	PRD	_	_
17	for	_	IN	IN	_	15	ADV	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	normal	_	JJ	JJ	_	20	NMOD	_	_
20	induction	_	NN	NN	_	17	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	IL-2	_	NN	NN	_	21	PMOD	_	_
23	,	_	,	,	_	25	P	_	_
24	it	_	PRP	PRP	_	25	SBJ	_	_
25	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
26	unknown	_	JJ	JJ	_	25	PRD	_	_
27	if	_	IN	IN	_	25	EXP	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	age-related	_	JJ	JJ	_	30	NMOD	_	_
30	decline	_	NN	NN	_	39	SBJ	_	_
31	in	_	IN	IN	_	30	NMOD	_	_
32	IL-2	_	NN	NN	_	33	NMOD	_	_
33	production	_	NN	NN	_	31	PMOD	_	_
34	by	_	IN	IN	_	33	NMOD	_	_
35	activated	_	VBN	VBN	_	38	NMOD	_	_
36	human	_	JJ	JJ	_	38	NMOD	_	_
37	T	_	NN	NN	_	38	NMOD	_	_
38	cells	_	NNS	NNS	_	34	PMOD	_	_
39	may	_	MD	MD	_	27	VMOD	_	_
40	be	_	VB	VB	_	39	VC	_	_
41	associated	_	VBN	VBN	_	40	VC	_	_
42	with	_	IN	IN	_	41	ADV	_	_
43	aberrancies	_	NNS	NNS	_	42	PMOD	_	_
44	in	_	IN	IN	_	43	NMOD	_	_
45	transcriptional	_	JJ	JJ	_	47	NMOD	_	_
46	regulatory	_	JJ	JJ	_	47	NMOD	_	_
47	proteins	_	NNS	NNS	_	44	PMOD	_	_
48	.	_	.	.	_	25	P	_	_

1	In	_	IN	IN	_	26	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	current	_	JJ	JJ	_	4	NMOD	_	_
4	studies	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	26	P	_	_
6	IL-2	_	NN	NN	_	7	NMOD	_	_
7	production	_	NN	NN	_	26	SBJ	_	_
8	by	_	IN	IN	_	7	NMOD	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	from	_	IN	IN	_	10	NMOD	_	_
12	elderly	_	JJ	JJ	_	25	NMOD	_	_
13	(	_	(	(	_	16	P	_	_
14	mean	_	NN	NN	_	16	SBJ	_	_
15	78	_	CD	CD	_	16	NMOD	_	_
16	years	_	NNS	NNS	_	12	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	and	_	CC	CC	_	12	CC	_	_
19	young	_	JJ	JJ	_	12	COORD	_	_
20	(	_	(	(	_	23	P	_	_
21	mean	_	NN	NN	_	23	SBJ	_	_
22	37	_	CD	CD	_	23	NMOD	_	_
23	years	_	NNS	NNS	_	19	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	humans	_	NNS	NNS	_	11	PMOD	_	_
26	was	_	VBD	VBD	_	0	ROOT-S	_	_
27	measured	_	VBN	VBN	_	26	VC	_	_
28	in	_	IN	IN	_	27	ADV	_	_
29	cultures	_	NNS	NNS	_	28	PMOD	_	_
30	stimulated	_	VBN	VBN	_	29	NMOD	_	_
31	with	_	IN	IN	_	30	ADV	_	_
32	PHA	_	NN	NN	_	31	PMOD	_	_
33	,	_	,	,	_	32	P	_	_
34	PHA	_	NN	NN	_	32	COORD	_	_
35	plus	_	CC	CC	_	34	CC	_	_
36	PMA	_	NN	NN	_	34	COORD	_	_
37	,	_	,	,	_	32	P	_	_
38	crosslinked	_	VBN	VBN	_	41	NMOD	_	_
39	anti-CD3	_	JJ	JJ	_	41	NMOD	_	_
40	mAB	_	NN	NN	_	41	NMOD	_	_
41	OKT3	_	NN	NN	_	32	COORD	_	_
42	plus	_	CC	CC	_	41	CC	_	_
43	PMA	_	NN	NN	_	41	COORD	_	_
44	,	_	,	,	_	32	P	_	_
45	or	_	CC	CC	_	32	CC	_	_
46	PMA	_	NN	NN	_	32	COORD	_	_
47	plus	_	CC	CC	_	46	CC	_	_
48	ionomycin	_	NN	NN	_	46	COORD	_	_
49	.	_	.	.	_	26	P	_	_

1	Substantial	_	JJ	JJ	_	2	NMOD	_	_
2	decreases	_	NNS	NNS	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	IL-2	_	NN	NN	_	5	NMOD	_	_
5	production	_	NN	NN	_	3	PMOD	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	observed	_	VBN	VBN	_	6	VC	_	_
8	for	_	IN	IN	_	7	ADV	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	cultures	_	NNS	NNS	_	8	PMOD	_	_
11	from	_	IN	IN	_	10	NMOD	_	_
12	7	_	CD	CD	_	14	DEP	_	_
13	of	_	IN	IN	_	14	DEP	_	_
14	12	_	CD	CD	_	16	NMOD	_	_
15	elderly	_	JJ	JJ	_	16	NMOD	_	_
16	individuals	_	NNS	NNS	_	11	PMOD	_	_
17	in	_	IN	IN	_	7	ADV	_	_
18	response	_	NN	NN	_	17	DEP	_	_
19	to	_	TO	TO	_	17	DEP	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	different	_	JJ	JJ	_	22	NMOD	_	_
22	stimuli	_	NNS	NNS	_	17	PMOD	_	_
23	,	_	,	,	_	6	P	_	_
24	whereas	_	IN	IN	_	6	COORD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	levels	_	NNS	NNS	_	38	SBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	IL-2	_	NN	NN	_	27	PMOD	_	_
29	produced	_	VBN	VBN	_	28	NMOD	_	_
30	by	_	IN	IN	_	29	LGS	_	_
31	stimulated	_	VBN	VBN	_	33	NMOD	_	_
32	T	_	NN	NN	_	33	NMOD	_	_
33	cells	_	NNS	NNS	_	30	PMOD	_	_
34	from	_	IN	IN	_	33	NMOD	_	_
35	other	_	JJ	JJ	_	37	NMOD	_	_
36	elderly	_	JJ	JJ	_	37	NMOD	_	_
37	individuals	_	NNS	NNS	_	34	PMOD	_	_
38	were	_	VBD	VBD	_	6	COORD	_	_
39	equivalent	_	JJ	JJ	_	38	PRD	_	_
40	to	_	TO	TO	_	39	AMOD	_	_
41	those	_	DT	DT	_	40	PMOD	_	_
42	observed	_	VBN	VBN	_	41	NMOD	_	_
43	for	_	IN	IN	_	42	ADV	_	_
44	stimulated	_	VBN	VBN	_	46	NMOD	_	_
45	T	_	NN	NN	_	46	NMOD	_	_
46	cells	_	NNS	NNS	_	43	PMOD	_	_
47	of	_	IN	IN	_	46	NMOD	_	_
48	young	_	JJ	JJ	_	49	NMOD	_	_
49	subjects	_	NNS	NNS	_	47	PMOD	_	_
50	.	_	.	.	_	6	P	_	_

1	Analyses	_	NNS	NNS	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	nuclear	_	JJ	JJ	_	4	NMOD	_	_
4	extracts	_	NNS	NNS	_	2	PMOD	_	_
5	by	_	IN	IN	_	1	NMOD	_	_
6	electrophoretic	_	JJ	JJ	_	10	NMOD	_	_
7	DNA	_	NN	NN	_	10	NMOD	_	_
8	mobility	_	NN	NN	_	10	NMOD	_	_
9	shift	_	NN	NN	_	10	NMOD	_	_
10	assays	_	NNS	NNS	_	5	PMOD	_	_
11	showed	_	VBD	VBD	_	0	ROOT-S	_	_
12	that	_	IN	IN	_	11	OBJ	_	_
13	decreased	_	VBN	VBN	_	15	NMOD	_	_
14	IL-2	_	NN	NN	_	15	NMOD	_	_
15	production	_	NN	NN	_	23	SBJ	_	_
16	by	_	IN	IN	_	15	NMOD	_	_
17	stimulated	_	VBN	VBN	_	19	NMOD	_	_
18	T	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	elderly	_	JJ	JJ	_	22	NMOD	_	_
22	individuals	_	NNS	NNS	_	20	PMOD	_	_
23	was	_	VBD	VBD	_	12	VMOD	_	_
24	closely	_	RB	RB	_	23	ADV	_	_
25	associated	_	VBN	VBN	_	23	VC	_	_
26	with	_	IN	IN	_	25	ADV	_	_
27	impairments	_	NNS	NNS	_	26	PMOD	_	_
28	in	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	activation	_	NN	NN	_	28	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	both	_	CC	CC	_	33	CC	_	_
33	AP-1	_	NN	NN	_	31	PMOD	_	_
34	and	_	CC	CC	_	33	CC	_	_
35	NF-AT	_	NN	NN	_	33	COORD	_	_
36	.	_	.	.	_	11	P	_	_

1	By	_	IN	IN	_	15	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	15	P	_	_
4	T	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	15	SBJ	_	_
6	from	_	IN	IN	_	5	NMOD	_	_
7	elderly	_	JJ	JJ	_	8	NMOD	_	_
8	subjects	_	NNS	NNS	_	6	PMOD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	normal	_	JJ	JJ	_	11	NMOD	_	_
11	levels	_	NNS	NNS	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	IL-2	_	NN	NN	_	14	NMOD	_	_
14	production	_	NN	NN	_	12	PMOD	_	_
15	exhibited	_	VBD	VBD	_	0	ROOT-S	_	_
16	normal	_	JJ	JJ	_	17	NMOD	_	_
17	activation	_	NN	NN	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	AP-1	_	NN	NN	_	18	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	NF-AT	_	NN	NN	_	19	COORD	_	_
22	.	_	.	.	_	15	P	_	_

1	In	_	IN	IN	_	15	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	15	P	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	results	_	NNS	NNS	_	15	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	competition	_	NN	NN	_	8	NMOD	_	_
8	experiments	_	NNS	NNS	_	6	PMOD	_	_
9	analyzing	_	VBG	VBG	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	normal	_	JJ	JJ	_	12	NMOD	_	_
12	components	_	NNS	NNS	_	9	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	NF-AT	_	NN	NN	_	13	PMOD	_	_
15	showed	_	VBD	VBD	_	0	ROOT-S	_	_
16	that	_	IN	IN	_	15	OBJ	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	age-related	_	JJ	JJ	_	19	NMOD	_	_
19	reductions	_	NNS	NNS	_	24	SBJ	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	stimulus-dependent	_	JJ	JJ	_	23	NMOD	_	_
22	NF-AT	_	NN	NN	_	23	NMOD	_	_
23	complexes	_	NNS	NNS	_	20	PMOD	_	_
24	corresponded	_	VBD	VBD	_	16	VMOD	_	_
25	to	_	TO	TO	_	24	ADV	_	_
26	the	_	DT	DT	_	29	NMOD	_	_
27	slow	_	JJ	JJ	_	29	NMOD	_	_
28	migrating	_	VBG	VBG	_	27	AMOD	_	_
29	complexes	_	NNS	NNS	_	25	PMOD	_	_
30	that	_	WDT	WDT	_	31	SBJ	_	_
31	were	_	VBD	VBD	_	29	NMOD	_	_
32	composed	_	VBN	VBN	_	31	VC	_	_
33	of	_	IN	IN	_	32	ADV	_	_
34	c-Fos\/c-Jun	_	NN	NN	_	35	NMOD	_	_
35	AP-1	_	NN	NN	_	33	PMOD	_	_
36	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	resting	_	JJ	JJ	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	stimulated	_	JJ	JJ	_	2	COORD	_	_
5	levels	_	NNS	NNS	_	10	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	NF	_	NN	NN	_	9	NMOD	_	_
8	kappa	_	NN	NN	_	9	NMOD	_	_
9	B	_	NN	NN	_	6	PMOD	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	reduced	_	VBN	VBN	_	10	VC	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	T	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	from	_	IN	IN	_	14	NMOD	_	_
16	certain	_	JJ	JJ	_	18	NMOD	_	_
17	elderly	_	JJ	JJ	_	18	NMOD	_	_
18	individuals	_	NNS	NNS	_	15	PMOD	_	_
19	;	_	:	:	_	10	P	_	_
20	however	_	RB	RB	_	27	ADV	_	_
21	,	_	,	,	_	27	P	_	_
22	alterations	_	NNS	NNS	_	27	SBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	NF	_	NN	NN	_	26	NMOD	_	_
25	kappa	_	NN	NN	_	26	NMOD	_	_
26	B	_	NN	NN	_	23	PMOD	_	_
27	did	_	VBD	VBD	_	10	VC	_	_
28	not	_	RB	RB	_	27	VMOD	_	_
29	correlate	_	VB	VB	_	27	VC	_	_
30	with	_	IN	IN	_	29	ADV	_	_
31	changes	_	NNS	NNS	_	30	PMOD	_	_
32	in	_	IN	IN	_	31	NMOD	_	_
33	IL-2	_	NN	NN	_	34	NMOD	_	_
34	expression	_	NN	NN	_	32	PMOD	_	_
35	.	_	.	.	_	27	P	_	_

1	Thus	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	results	_	NNS	NNS	_	5	SBJ	_	_
5	show	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	age-related	_	JJ	JJ	_	8	NMOD	_	_
8	impairments	_	NNS	NNS	_	16	SBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	activation	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	AP-1	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	NF-AT	_	NN	NN	_	13	COORD	_	_
16	are	_	VBP	VBP	_	6	VMOD	_	_
17	closely	_	RB	RB	_	16	ADV	_	_
18	associated	_	VBN	VBN	_	16	VC	_	_
19	with	_	IN	IN	_	18	ADV	_	_
20	decreased	_	VBN	VBN	_	21	NMOD	_	_
21	expression	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	IL-2	_	NN	NN	_	22	PMOD	_	_
24	and	_	CC	CC	_	5	CC	_	_
25	further	_	RB	RB	_	26	ADV	_	_
26	suggest	_	VBP	VBP	_	5	COORD	_	_
27	that	_	IN	IN	_	26	OBJ	_	_
28	aberrancies	_	NNS	NNS	_	42	SBJ	_	_
29	in	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	signaling	_	NN	NN	_	32	NMOD	_	_
32	pathways	_	NNS	NNS	_	29	PMOD	_	_
33	important	_	JJ	JJ	_	28	NMOD	_	_
34	for	_	IN	IN	_	33	AMOD	_	_
35	the	_	DT	DT	_	36	NMOD	_	_
36	induction	_	NN	NN	_	34	PMOD	_	_
37	of	_	IN	IN	_	36	NMOD	_	_
38	transcriptionally	_	RB	RB	_	39	AMOD	_	_
39	active	_	JJ	JJ	_	41	NMOD	_	_
40	c-Fos\/c-Jun	_	NN	NN	_	41	NMOD	_	_
41	AP-1	_	NN	NN	_	37	PMOD	_	_
42	may	_	MD	MD	_	27	VMOD	_	_
43	contribute	_	VB	VB	_	42	VC	_	_
44	to	_	TO	TO	_	43	ADV	_	_
45	the	_	DT	DT	_	47	NMOD	_	_
46	impaired	_	JJ	JJ	_	47	NMOD	_	_
47	activation	_	NN	NN	_	44	PMOD	_	_
48	of	_	IN	IN	_	47	NMOD	_	_
49	NF-AT	_	NN	NN	_	48	PMOD	_	_
50	.	_	.	.	_	5	P	_	_

1	Recombinant	_	JJ	JJ	_	2	NMOD	_	_
2	NFAT1	_	NN	NN	_	6	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	NFATp	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	regulated	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	calcineurin	_	NN	NN	_	8	PMOD	_	_
10	in	_	IN	IN	_	7	ADV	_	_
11	T	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	and	_	CC	CC	_	6	CC	_	_
14	mediates	_	VBZ	VBZ	_	6	COORD	_	_
15	transcription	_	NN	NN	_	14	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	several	_	JJ	JJ	_	19	NMOD	_	_
18	cytokine	_	NN	NN	_	19	NMOD	_	_
19	genes	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	6	P	_	_

1	Transcription	_	NN	NN	_	2	NMOD	_	_
2	factors	_	NNS	NNS	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	NFAT	_	NN	NN	_	6	NMOD	_	_
6	family	_	NN	NN	_	3	PMOD	_	_
7	play	_	VBP	VBP	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	key	_	JJ	JJ	_	10	NMOD	_	_
10	role	_	NN	NN	_	7	OBJ	_	_
11	in	_	IN	IN	_	7	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	transcription	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	cytokine	_	NN	NN	_	16	NMOD	_	_
16	genes	_	NNS	NNS	_	14	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	other	_	JJ	JJ	_	19	NMOD	_	_
19	genes	_	NNS	NNS	_	16	COORD	_	_
20	during	_	IN	IN	_	7	TMP	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	immune	_	JJ	JJ	_	23	NMOD	_	_
23	response	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	identified	_	VBN	VBN	_	2	VC	_	_
4	two	_	CD	CD	_	6	NMOD	_	_
5	new	_	JJ	JJ	_	6	NMOD	_	_
6	isoforms	_	NNS	NNS	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	transcription	_	NN	NN	_	11	NMOD	_	_
10	factor	_	NN	NN	_	11	NMOD	_	_
11	NFAT1	_	NN	NN	_	7	PMOD	_	_
12	(	_	(	(	_	11	P	_	_
13	previously	_	RB	RB	_	14	TMP	_	_
14	termed	_	VBN	VBN	_	11	NMOD	_	_
15	NFATp	_	NN	NN	_	14	OBJ	_	_
16	)	_	)	)	_	11	P	_	_
17	that	_	WDT	WDT	_	18	SBJ	_	_
18	are	_	VBP	VBP	_	6	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	predominant	_	JJ	JJ	_	21	NMOD	_	_
21	isoforms	_	NNS	NNS	_	18	PRD	_	_
22	expressed	_	VBN	VBN	_	21	NMOD	_	_
23	in	_	IN	IN	_	22	ADV	_	_
24	murine	_	JJ	JJ	_	28	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	human	_	JJ	JJ	_	24	COORD	_	_
27	T	_	NN	NN	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	23	PMOD	_	_
29	.	_	.	.	_	2	P	_	_

1	When	_	WRB	WRB	_	2	ADV	_	_
2	expressed	_	VBN	VBN	_	10	TMP	_	_
3	in	_	IN	IN	_	2	ADV	_	_
4	Jurkat	_	NN	NN	_	6	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	3	PMOD	_	_
7	,	_	,	,	_	10	P	_	_
8	recombinant	_	JJ	JJ	_	9	NMOD	_	_
9	NFAT1	_	NN	NN	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	regulated	_	VBN	VBN	_	10	VC	_	_
12	,	_	,	,	_	11	P	_	_
13	as	_	IN	IN	_	11	ADV	_	_
14	expected	_	VBN	VBN	_	13	VMOD	_	_
15	,	_	,	,	_	11	P	_	_
16	by	_	IN	IN	_	11	LGS	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	calmodulin-dependent	_	JJ	JJ	_	20	NMOD	_	_
19	phosphatase	_	NN	NN	_	20	NMOD	_	_
20	calcineurin	_	NN	NN	_	16	PMOD	_	_
21	,	_	,	,	_	10	P	_	_
22	and	_	CC	CC	_	10	CC	_	_
23	its	_	PRP$	PRP$	_	24	NMOD	_	_
24	function	_	NN	NN	_	25	SBJ	_	_
25	is	_	VBZ	VBZ	_	10	COORD	_	_
26	inhibited	_	VBN	VBN	_	25	VC	_	_
27	by	_	IN	IN	_	26	LGS	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	immunosuppressive	_	JJ	JJ	_	30	NMOD	_	_
30	agent	_	NN	NN	_	27	PMOD	_	_
31	cyclosporin	_	NN	NN	_	32	NMOD	_	_
32	A	_	NN	NN	_	30	NMOD	_	_
33	(	_	(	(	_	34	P	_	_
34	CsA	_	NN	NN	_	32	PRN	_	_
35	)	_	)	)	_	34	P	_	_
36	.	_	.	.	_	10	P	_	_

1	Transactivation	_	NN	NN	_	9	SBJ	_	_
2	by	_	IN	IN	_	1	NMOD	_	_
3	recombinant	_	JJ	JJ	_	4	NMOD	_	_
4	NFAT1	_	NN	NN	_	2	PMOD	_	_
5	in	_	IN	IN	_	1	NMOD	_	_
6	Jurkat	_	NN	NN	_	8	NMOD	_	_
7	T	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	5	PMOD	_	_
9	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	dual	_	JJ	JJ	_	11	NMOD	_	_
11	stimulation	_	NN	NN	_	9	OBJ	_	_
12	with	_	IN	IN	_	11	NMOD	_	_
13	ionomycin	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	phorbol	_	NN	NN	_	17	NMOD	_	_
16	12-myristate	_	NN	NN	_	17	NMOD	_	_
17	13-acetate	_	NN	NN	_	13	COORD	_	_
18	;	_	:	:	_	9	P	_	_
19	this	_	DT	DT	_	20	NMOD	_	_
20	activity	_	NN	NN	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	9	VMOD	_	_
22	potentiated	_	VBN	VBN	_	21	VC	_	_
23	by	_	IN	IN	_	22	LGS	_	_
24	coexpression	_	NN	NN	_	23	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	constitutively	_	RB	RB	_	27	AMOD	_	_
27	active	_	JJ	JJ	_	28	NMOD	_	_
28	calcineurin	_	NN	NN	_	25	PMOD	_	_
29	and	_	CC	CC	_	21	CC	_	_
30	is	_	VBZ	VBZ	_	21	COORD	_	_
31	inhibited	_	VBN	VBN	_	30	VC	_	_
32	by	_	IN	IN	_	31	LGS	_	_
33	CsA	_	NN	NN	_	32	PMOD	_	_
34	.	_	.	.	_	21	P	_	_

1	Immunocytochemical	_	JJ	JJ	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	3	SBJ	_	_
3	indicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	recombinant	_	JJ	JJ	_	6	NMOD	_	_
6	NFAT1	_	NN	NN	_	7	SBJ	_	_
7	localizes	_	VBZ	VBZ	_	4	VMOD	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	cytoplasm	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	transiently	_	RB	RB	_	13	AMOD	_	_
13	transfected	_	VBN	VBN	_	15	NMOD	_	_
14	T	_	NN	NN	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	11	PMOD	_	_
16	and	_	CC	CC	_	7	CC	_	_
17	translocates	_	VBZ	VBZ	_	7	COORD	_	_
18	into	_	IN	IN	_	17	ADV	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	nucleus	_	NN	NN	_	18	PMOD	_	_
21	in	_	IN	IN	_	17	ADV	_	_
22	a	_	DT	DT	_	24	NMOD	_	_
23	CsA-sensitive	_	JJ	JJ	_	24	NMOD	_	_
24	manner	_	NN	NN	_	21	PMOD	_	_
25	following	_	VBG	VBG	_	17	TMP	_	_
26	ionomycin	_	NN	NN	_	27	NMOD	_	_
27	stimulation	_	NN	NN	_	25	PMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	When	_	WRB	WRB	_	2	ADV	_	_
2	expressed	_	VBN	VBN	_	10	TMP	_	_
3	in	_	IN	IN	_	2	ADV	_	_
4	COS	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	3	PMOD	_	_
6	,	_	,	,	_	10	P	_	_
7	however	_	RB	RB	_	10	ADV	_	_
8	,	_	,	,	_	10	P	_	_
9	NFAT1	_	NN	NN	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	capable	_	JJ	JJ	_	10	PRD	_	_
12	of	_	IN	IN	_	11	AMOD	_	_
13	transactivation	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	10	P	_	_
15	but	_	CC	CC	_	10	CC	_	_
16	it	_	PRP	PRP	_	17	SBJ	_	_
17	is	_	VBZ	VBZ	_	10	COORD	_	_
18	not	_	RB	RB	_	17	VMOD	_	_
19	regulated	_	VBN	VBN	_	17	VC	_	_
20	correctly	_	RB	RB	_	19	ADV	_	_
21	:	_	:	:	_	10	P	_	_
22	its	_	PRP$	PRP$	_	24	NMOD	_	_
23	subcellular	_	JJ	JJ	_	24	NMOD	_	_
24	localization	_	NN	NN	_	28	SBJ	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	transcriptional	_	JJ	JJ	_	27	NMOD	_	_
27	function	_	NN	NN	_	24	COORD	_	_
28	are	_	VBP	VBP	_	10	VC	_	_
29	not	_	RB	RB	_	28	VMOD	_	_
30	affected	_	VBN	VBN	_	28	VC	_	_
31	by	_	IN	IN	_	30	LGS	_	_
32	stimulation	_	NN	NN	_	31	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	the	_	DT	DT	_	36	NMOD	_	_
35	COS	_	NN	NN	_	36	NMOD	_	_
36	cells	_	NNS	NNS	_	33	PMOD	_	_
37	with	_	IN	IN	_	32	NMOD	_	_
38	ionomycin	_	NN	NN	_	37	PMOD	_	_
39	and	_	CC	CC	_	38	CC	_	_
40	phorbol	_	NN	NN	_	42	NMOD	_	_
41	12-myristate	_	NN	NN	_	42	NMOD	_	_
42	13-acetate	_	NN	NN	_	38	COORD	_	_
43	.	_	.	.	_	28	P	_	_

1	Recombinant	_	JJ	JJ	_	2	NMOD	_	_
2	NFAT1	_	NN	NN	_	3	SBJ	_	_
3	can	_	MD	MD	_	0	ROOT-S	_	_
4	mediate	_	VB	VB	_	3	VC	_	_
5	transcription	_	NN	NN	_	4	IOBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	21	NMOD	_	_
8	interleukin-2	_	NN	NN	_	21	NMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	interleukin-4	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	8	P	_	_
12	tumor	_	NN	NN	_	15	NMOD	_	_
13	necrosis	_	NN	NN	_	15	NMOD	_	_
14	factor	_	NN	NN	_	15	NMOD	_	_
15	alpha	_	NN	NN	_	8	COORD	_	_
16	,	_	,	,	_	8	P	_	_
17	and	_	CC	CC	_	8	CC	_	_
18	granulocyte-macrophage	_	JJ	JJ	_	20	NMOD	_	_
19	colony-stimulating	_	JJ	JJ	_	20	NMOD	_	_
20	factor	_	NN	NN	_	8	COORD	_	_
21	promoters	_	NNS	NNS	_	6	PMOD	_	_
22	in	_	IN	IN	_	5	NMOD	_	_
23	T	_	NN	NN	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	,	_	,	,	_	4	P	_	_
26	suggesting	_	VBG	VBG	_	4	OBJ	_	_
27	that	_	IN	IN	_	26	OBJ	_	_
28	NFAT1	_	NN	NN	_	29	SBJ	_	_
29	contributes	_	VBZ	VBZ	_	27	VMOD	_	_
30	to	_	TO	TO	_	29	ADV	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	CsA-sensitive	_	JJ	JJ	_	33	NMOD	_	_
33	transcription	_	NN	NN	_	30	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	these	_	DT	DT	_	36	NMOD	_	_
36	genes	_	NNS	NNS	_	34	PMOD	_	_
37	during	_	IN	IN	_	33	TMP	_	_
38	the	_	DT	DT	_	40	NMOD	_	_
39	immune	_	JJ	JJ	_	40	NMOD	_	_
40	response	_	NN	NN	_	37	PMOD	_	_
41	.	_	.	.	_	3	P	_	_

1	Glucocorticoids	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	interferon-alpha	_	NN	NN	_	1	COORD	_	_
4	in	_	IN	IN	_	1	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	acquired	_	VBN	VBN	_	8	NMOD	_	_
7	immunodeficiency	_	NN	NN	_	8	NMOD	_	_
8	syndrome	_	NN	NN	_	4	PMOD	_	_
9	.	_	.	.	_	1	P	_	_

1	Some	_	DT	DT	_	2	NMOD	_	_
2	patients	_	NNS	NNS	_	10	SBJ	_	_
3	with	_	IN	IN	_	2	NMOD	_	_
4	acquired	_	VBN	VBN	_	6	NMOD	_	_
5	immunodeficiency	_	NN	NN	_	6	NMOD	_	_
6	syndrome	_	NN	NN	_	3	PMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	AIDS	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	develop	_	VBP	VBP	_	0	ROOT-S	_	_
11	glucocorticoid	_	NN	NN	_	12	NMOD	_	_
12	resistance	_	NN	NN	_	10	OBJ	_	_
13	characterized	_	VBN	VBN	_	12	NMOD	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	low	_	JJ	JJ	_	17	NMOD	_	_
16	receptor	_	NN	NN	_	17	NMOD	_	_
17	affinity	_	NN	NN	_	14	PMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	Kd	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	for	_	IN	IN	_	17	NMOD	_	_
22	glucocorticoids	_	NNS	NNS	_	21	PMOD	_	_
23	in	_	IN	IN	_	17	NMOD	_	_
24	mononuclear	_	JJ	JJ	_	26	NMOD	_	_
25	,	_	,	,	_	26	P	_	_
26	cells	_	NNS	NNS	_	23	PMOD	_	_
27	and	_	CC	CC	_	17	CC	_	_
28	high	_	JJ	JJ	_	29	NMOD	_	_
29	values	_	NNS	NNS	_	17	COORD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	ACTH	_	NN	NN	_	30	PMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	cortisol	_	NN	NN	_	31	COORD	_	_
34	.	_	.	.	_	10	P	_	_

1	As	_	IN	IN	_	12	ADV	_	_
2	glucocorticoids	_	NNS	NNS	_	3	SBJ	_	_
3	regulate	_	VBP	VBP	_	1	VMOD	_	_
4	interferon-alpha	_	NN	NN	_	9	NMOD	_	_
5	(	_	(	(	_	7	P	_	_
6	IFN	_	NN	NN	_	7	NMOD	_	_
7	alpha	_	NN	NN	_	4	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	production	_	NN	NN	_	3	OBJ	_	_
10	,	_	,	,	_	12	P	_	_
11	we	_	PRP	PRP	_	12	SBJ	_	_
12	hypothesized	_	VBD	VBD	_	0	ROOT-S	_	_
13	that	_	IN	IN	_	12	OBJ	_	_
14	IFN	_	NN	NN	_	15	NMOD	_	_
15	alpha	_	NN	NN	_	26	SBJ	_	_
16	,	_	,	,	_	15	P	_	_
17	a	_	DT	DT	_	18	NMOD	_	_
18	cytokine	_	NN	NN	_	15	NMOD	_	_
19	produced	_	VBN	VBN	_	18	NMOD	_	_
20	predominantly	_	RB	RB	_	21	DEP	_	_
21	by	_	IN	IN	_	19	LGS	_	_
22	monocytes	_	NNS	NNS	_	21	PMOD	_	_
23	in	_	IN	IN	_	19	ADV	_	_
24	AIDS	_	NN	NN	_	23	PMOD	_	_
25	,	_	,	,	_	15	P	_	_
26	should	_	MD	MD	_	13	VMOD	_	_
27	be	_	VB	VB	_	26	VC	_	_
28	increased	_	VBN	VBN	_	27	VC	_	_
29	in	_	IN	IN	_	28	ADV	_	_
30	cortisol-resistant	_	JJ	JJ	_	31	NMOD	_	_
31	AIDS	_	NN	NN	_	29	PMOD	_	_
32	,	_	,	,	_	12	P	_	_
33	attributing	_	VBG	VBG	_	12	ADV	_	_
34	the	_	DT	DT	_	35	NMOD	_	_
35	lack	_	NN	NN	_	33	OBJ	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	cortisol	_	NN	NN	_	38	NMOD	_	_
38	inhibition	_	NN	NN	_	36	PMOD	_	_
39	to	_	TO	TO	_	33	ADV	_	_
40	IFN	_	NN	NN	_	42	NMOD	_	_
41	alpha	_	NN	NN	_	42	NMOD	_	_
42	production	_	NN	NN	_	39	PMOD	_	_
43	.	_	.	.	_	12	P	_	_

1	Therefore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	examined	_	VBD	VBD	_	0	ROOT-S	_	_
5	glucocorticoid	_	NN	NN	_	7	NMOD	_	_
6	receptor	_	NN	NN	_	7	NMOD	_	_
7	characteristics	_	NNS	NNS	_	4	OBJ	_	_
8	on	_	IN	IN	_	7	NMOD	_	_
9	monocytes	_	NNS	NNS	_	8	PMOD	_	_
10	by	_	IN	IN	_	4	ADV	_	_
11	-LCB-3H-RCB-dexamethasone	_	NN	NN	_	12	NMOD	_	_
12	binding	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	4	CC	_	_
14	measured	_	VBD	VBD	_	4	COORD	_	_
15	IFN	_	NN	NN	_	16	NMOD	_	_
16	alpha	_	NN	NN	_	14	OBJ	_	_
17	,	_	,	,	_	16	P	_	_
18	cortisol	_	NN	NN	_	16	COORD	_	_
19	,	_	,	,	_	16	P	_	_
20	and	_	CC	CC	_	16	CC	_	_
21	ACTH	_	NN	NN	_	16	COORD	_	_
22	in	_	IN	IN	_	16	NMOD	_	_
23	AIDS	_	NN	NN	_	24	NMOD	_	_
24	patients	_	NNS	NNS	_	22	PMOD	_	_
25	with	_	IN	IN	_	24	NMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	AIDS-GR	_	NN	NN	_	24	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	or	_	CC	CC	_	24	CC	_	_
30	without	_	IN	IN	_	25	GAP	_	_
31	glucocorticoid	_	NN	NN	_	32	NMOD	_	_
32	resistance	_	NN	NN	_	25	PMOD	_	_
33	(	_	(	(	_	34	P	_	_
34	AIDS-C	_	NN	NN	_	27	GAP	_	_
35	)	_	)	)	_	34	P	_	_
36	and	_	CC	CC	_	24	CC	_	_
37	controls	_	NNS	NNS	_	24	COORD	_	_
38	(	_	(	(	_	39	P	_	_
39	C	_	NN	NN	_	37	PRN	_	_
40	)	_	)	)	_	39	P	_	_
41	.	_	.	.	_	4	P	_	_

1	Monocytes	_	NNS	NNS	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	AIDS-GR	_	NN	NN	_	4	NMOD	_	_
4	patients	_	NNS	NNS	_	2	PMOD	_	_
5	had	_	VBD	VBD	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	receptor	_	NN	NN	_	8	NMOD	_	_
8	Kd	_	NN	NN	_	5	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	10.5	_	CD	CD	_	13	NMOD	_	_
11	+\/-	_	CC	CC	_	10	CC	_	_
12	4.2	_	CD	CD	_	10	COORD	_	_
13	nmol\/L	_	NN	NN	_	9	PMOD	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	was	_	VBD	VBD	_	8	NMOD	_	_
16	higher	_	JJR	JJR	_	15	PRD	_	_
17	than	_	IN	IN	_	16	AMOD	_	_
18	that	_	DT	DT	_	17	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	AIDS-C	_	NN	NN	_	22	NMOD	_	_
22	group	_	NN	NN	_	19	PMOD	_	_
23	(	_	(	(	_	18	P	_	_
24	2.9	_	CD	CD	_	27	NMOD	_	_
25	+\/-	_	CC	CC	_	24	CC	_	_
26	0.8	_	CD	CD	_	24	COORD	_	_
27	nmol\/L	_	NN	NN	_	18	NMOD	_	_
28	)	_	)	)	_	18	P	_	_
29	and	_	CC	CC	_	18	CC	_	_
30	normal	_	JJ	JJ	_	31	NMOD	_	_
31	subjects	_	NNS	NNS	_	22	GAP	_	_
32	(	_	(	(	_	31	P	_	_
33	2.0	_	CD	CD	_	36	NMOD	_	_
34	+\/-	_	CC	CC	_	33	CC	_	_
35	0.8	_	CD	CD	_	33	COORD	_	_
36	nmol\/L	_	NN	NN	_	27	GAP	_	_
37	;	_	:	:	_	18	P	_	_
38	P	_	NN	NN	_	39	SBJ	_	_
39	&lt;	_	JJR	JJR	_	18	PRN	_	_
40	0.01	_	CD	CD	_	39	AMOD	_	_
41	)	_	)	)	_	18	P	_	_
42	.	_	.	.	_	5	P	_	_

1	IFN	_	NN	NN	_	3	NMOD	_	_
2	alpha	_	NN	NN	_	3	NMOD	_	_
3	levels	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	increased	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	AIDS-GR	_	NN	NN	_	9	NMOD	_	_
9	group	_	NN	NN	_	6	PMOD	_	_
10	(	_	(	(	_	34	P	_	_
11	17	_	CD	CD	_	34	DEP	_	_
12	+\/-	_	CC	CC	_	11	CC	_	_
13	6	_	CD	CD	_	11	COORD	_	_
14	vs.	_	CC	CC	_	11	CC	_	_
15	4	_	CD	CD	_	18	NMOD	_	_
16	+\/-	_	CC	CC	_	15	CC	_	_
17	1	_	CD	CD	_	15	COORD	_	_
18	U\/mL	_	NN	NN	_	11	COORD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	AIDS-C	_	NN	NN	_	22	NMOD	_	_
22	group	_	NN	NN	_	19	PMOD	_	_
23	and	_	CC	CC	_	18	CC	_	_
24	2	_	CD	CD	_	27	NMOD	_	_
25	+\/-	_	CC	CC	_	24	CC	_	_
26	0.5	_	CD	CD	_	24	COORD	_	_
27	U\/mL	_	NN	NN	_	18	COORD	_	_
28	in	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	C	_	NN	NN	_	31	NMOD	_	_
31	group	_	NN	NN	_	28	PMOD	_	_
32	;	_	:	:	_	34	P	_	_
33	P	_	NN	NN	_	34	SBJ	_	_
34	&lt;	_	JJR	JJR	_	5	PRN	_	_
35	0.01	_	CD	CD	_	34	AMOD	_	_
36	)	_	)	)	_	34	P	_	_
37	.	_	.	.	_	4	P	_	_

1	Correlations	_	NNS	NNS	_	2	SBJ	_	_
2	were	_	VBD	VBD	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	between	_	IN	IN	_	3	ADV	_	_
5	plasma	_	NN	NN	_	7	NMOD	_	_
6	IFN	_	NN	NN	_	7	NMOD	_	_
7	alpha	_	NN	NN	_	4	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	receptor	_	NN	NN	_	10	NMOD	_	_
10	Kd	_	NN	NN	_	7	COORD	_	_
11	on	_	IN	IN	_	7	NMOD	_	_
12	monocytes	_	NNS	NNS	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	AIDS-GR	_	NN	NN	_	13	PMOD	_	_
15	(	_	(	(	_	18	P	_	_
16	r	_	NN	NN	_	18	SBJ	_	_
17	=	_	JJ	JJ	_	18	VMOD	_	_
18	0.77	_	CD	CD	_	7	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	and	_	CC	CC	_	4	CC	_	_
21	between	_	IN	IN	_	4	COORD	_	_
22	IFN	_	NN	NN	_	23	NMOD	_	_
23	alpha	_	NN	NN	_	21	PMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	plasma	_	NN	NN	_	26	NMOD	_	_
26	cortisol	_	NN	NN	_	23	COORD	_	_
27	in	_	IN	IN	_	23	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	same	_	JJ	JJ	_	30	NMOD	_	_
30	group	_	NN	NN	_	27	PMOD	_	_
31	(	_	(	(	_	34	P	_	_
32	r	_	NN	NN	_	34	SBJ	_	_
33	=	_	JJ	JJ	_	34	VMOD	_	_
34	0.74	_	CD	CD	_	23	PRN	_	_
35	)	_	)	)	_	34	P	_	_
36	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	poly-LRB-I-RRB--poly-LRB-C-RRB--induced	_	JJ	JJ	_	5	NMOD	_	_
3	IFN	_	NN	NN	_	5	NMOD	_	_
4	alpha	_	NN	NN	_	5	NMOD	_	_
5	production	_	NN	NN	_	8	SBJ	_	_
6	by	_	IN	IN	_	5	NMOD	_	_
7	monocytes	_	NNS	NNS	_	6	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	inhibited	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	glucocorticoids	_	NNS	NNS	_	10	PMOD	_	_
12	in	_	IN	IN	_	9	ADV	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	C	_	NN	NN	_	17	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	AIDS-C	_	NN	NN	_	14	COORD	_	_
17	groups	_	NNS	NNS	_	12	PMOD	_	_
18	(	_	(	(	_	9	P	_	_
19	approximately	_	RB	RB	_	21	NMOD	_	_
20	80	_	CD	CD	_	19	DEP	_	_
21	%	_	NN	NN	_	9	OBJ	_	_
22	inhibition	_	NN	NN	_	21	NMOD	_	_
23	in	_	IN	IN	_	21	NMOD	_	_
24	both	_	DT	DT	_	25	NMOD	_	_
25	groups	_	NNS	NNS	_	23	PMOD	_	_
26	)	_	)	)	_	9	P	_	_
27	;	_	:	:	_	8	P	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	effect	_	NN	NN	_	30	SBJ	_	_
30	was	_	VBD	VBD	_	8	VC	_	_
31	reversed	_	VBN	VBN	_	30	VC	_	_
32	by	_	IN	IN	_	31	LGS	_	_
33	the	_	DT	DT	_	36	NMOD	_	_
34	receptor	_	NN	NN	_	36	NMOD	_	_
35	antagonist	_	NN	NN	_	36	NMOD	_	_
36	RU-38486	_	NN	NN	_	32	PMOD	_	_
37	.	_	.	.	_	30	P	_	_

1	By	_	IN	IN	_	5	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	glucocorticoids	_	NNS	NNS	_	5	SBJ	_	_
5	failed	_	VBD	VBD	_	0	ROOT-S	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	inhibit	_	VB	VB	_	5	OBJ	_	_
8	IFNalpha	_	NN	NN	_	9	NMOD	_	_
9	production	_	NN	NN	_	7	OBJ	_	_
10	from	_	IN	IN	_	9	NMOD	_	_
11	AIDS-GR	_	NN	NN	_	12	NMOD	_	_
12	monocytes	_	NNS	NNS	_	10	PMOD	_	_
13	(	_	(	(	_	7	P	_	_
14	approximately	_	RB	RB	_	16	NMOD	_	_
15	20	_	CD	CD	_	14	DEP	_	_
16	%	_	NN	NN	_	7	OBJ	_	_
17	inhibition	_	NN	NN	_	16	NMOD	_	_
18	)	_	)	)	_	7	P	_	_
19	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	conclusion	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	10	P	_	_
4	elevated	_	JJ	JJ	_	7	NMOD	_	_
5	IFN	_	NN	NN	_	7	NMOD	_	_
6	alpha	_	NN	NN	_	7	NMOD	_	_
7	levels	_	NNS	NNS	_	10	SBJ	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	AIDS-GR	_	NN	NN	_	8	PMOD	_	_
10	may	_	MD	MD	_	0	ROOT-S	_	_
11	be	_	VB	VB	_	10	VC	_	_
12	due	_	JJ	JJ	_	13	DEP	_	_
13	to	_	TO	TO	_	11	PRD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	lack	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	inhibitory	_	JJ	JJ	_	18	NMOD	_	_
18	effect	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	cortisol	_	NN	NN	_	19	PMOD	_	_
21	on	_	IN	IN	_	18	NMOD	_	_
22	IFN	_	NN	NN	_	24	NMOD	_	_
23	alpha	_	NN	NN	_	24	NMOD	_	_
24	production	_	NN	NN	_	21	PMOD	_	_
25	due	_	IN	IN	_	15	NMOD	_	_
26	to	_	TO	TO	_	25	DEP	_	_
27	cortisol	_	JJ	JJ	_	28	NMOD	_	_
28	resistance	_	NN	NN	_	25	PMOD	_	_
29	in	_	IN	IN	_	28	NMOD	_	_
30	monocytes	_	NNS	NNS	_	29	PMOD	_	_
31	.	_	.	.	_	10	P	_	_

1	Signals	_	NNS	NNS	_	11	SBJ	_	_
2	leading	_	VBG	VBG	_	1	NMOD	_	_
3	to	_	TO	TO	_	2	ADV	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	activation	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	NF-kappa	_	NN	NN	_	10	NMOD	_	_
8	B	_	NN	NN	_	10	NMOD	_	_
9	transcription	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	6	PMOD	_	_
11	are	_	VBP	VBP	_	0	ROOT-S	_	_
12	stronger	_	JJR	JJR	_	11	PRD	_	_
13	in	_	IN	IN	_	11	ADV	_	_
14	neonatal	_	JJ	JJ	_	13	NMOD	_	_
15	than	_	IN	IN	_	12	AMOD	_	_
16	adult	_	JJ	JJ	_	18	NMOD	_	_
17	T	_	NN	NN	_	18	NMOD	_	_
18	lymphocytes	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	molecular	_	JJ	JJ	_	3	NMOD	_	_
3	background	_	NN	NN	_	14	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	defects	_	NNS	NNS	_	4	PMOD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	immune	_	JJ	JJ	_	10	NMOD	_	_
10	reactivity	_	NN	NN	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	human	_	JJ	JJ	_	13	NMOD	_	_
13	neonates	_	NNS	NNS	_	11	PMOD	_	_
14	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	not	_	RB	RB	_	14	VMOD	_	_
16	been	_	VBN	VBN	_	14	VC	_	_
17	fully	_	RB	RB	_	16	ADV	_	_
18	elucidated	_	VBN	VBN	_	16	VC	_	_
19	.	_	.	.	_	14	P	_	_

1	As	_	IN	IN	_	28	ADV	_	_
2	the	_	DT	DT	_	6	NMOD	_	_
3	NF-kappa	_	NN	NN	_	6	NMOD	_	_
4	B	_	NN	NN	_	6	NMOD	_	_
5	transcription	_	NN	NN	_	6	NMOD	_	_
6	factor	_	NN	NN	_	7	SBJ	_	_
7	has	_	VBZ	VBZ	_	1	VMOD	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	central	_	JJ	JJ	_	10	NMOD	_	_
10	role	_	NN	NN	_	7	OBJ	_	_
11	in	_	IN	IN	_	7	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	control	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	transcription	_	NN	NN	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	several	_	JJ	JJ	_	18	NMOD	_	_
18	genes	_	NNS	NNS	_	16	PMOD	_	_
19	involved	_	VBN	VBN	_	18	NMOD	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	immune	_	JJ	JJ	_	24	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	inflammatory	_	JJ	JJ	_	21	COORD	_	_
24	responses	_	NNS	NNS	_	20	PMOD	_	_
25	,	_	,	,	_	28	P	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	authors	_	NNS	NNS	_	28	SBJ	_	_
28	have	_	VBP	VBP	_	0	ROOT-S	_	_
29	analysed	_	VBN	VBN	_	28	VC	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	activation	_	NN	NN	_	29	OBJ	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	NF-kappa	_	NN	NN	_	34	NMOD	_	_
34	B	_	NN	NN	_	32	PMOD	_	_
35	in	_	IN	IN	_	31	NMOD	_	_
36	human	_	JJ	JJ	_	40	NMOD	_	_
37	umbilical	_	JJ	JJ	_	40	NMOD	_	_
38	cord	_	NN	NN	_	40	NMOD	_	_
39	T	_	NN	NN	_	40	NMOD	_	_
40	lymphocytes	_	NNS	NNS	_	35	PMOD	_	_
41	.	_	.	.	_	28	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	activity	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	tested	_	VBN	VBN	_	3	VC	_	_
5	by	_	IN	IN	_	4	ADV	_	_
6	quantitating	_	VBG	VBG	_	5	PMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	proteins	_	NNS	NNS	_	6	OBJ	_	_
10	binding	_	VBG	VBG	_	9	NMOD	_	_
11	to	_	TO	TO	_	10	ADV	_	_
12	an	_	DT	DT	_	13	NMOD	_	_
13	oligonucleotide	_	NN	NN	_	11	PMOD	_	_
14	containing	_	VBG	VBG	_	13	NMOD	_	_
15	the	_	DT	DT	_	20	NMOD	_	_
16	consensus	_	NN	NN	_	20	NMOD	_	_
17	kappa	_	NN	NN	_	20	NMOD	_	_
18	B	_	NN	NN	_	20	NMOD	_	_
19	binding	_	NN	NN	_	20	NMOD	_	_
20	sequence	_	NN	NN	_	14	OBJ	_	_
21	(	_	(	(	_	25	P	_	_
22	electrophoretic	_	JJ	JJ	_	25	NMOD	_	_
23	mobility	_	NN	NN	_	25	NMOD	_	_
24	shift	_	NN	NN	_	25	NMOD	_	_
25	assay	_	NN	NN	_	6	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	4	SBJ	_	_
3	obtained	_	VBN	VBN	_	2	NMOD	_	_
4	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	phorbol	_	NN	NN	_	9	NMOD	_	_
7	dibutyrate\/calcium	_	NN	NN	_	9	NMOD	_	_
8	ionophore	_	NN	NN	_	9	NMOD	_	_
9	A23187	_	NN	NN	_	13	NMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	PDBu\/iono	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	combination	_	NN	NN	_	14	SBJ	_	_
14	induced	_	VBD	VBD	_	5	VMOD	_	_
15	a	_	DT	DT	_	19	NMOD	_	_
16	clearly	_	RB	RB	_	17	AMOD	_	_
17	higher	_	JJR	JJR	_	19	NMOD	_	_
18	nuclear	_	JJ	JJ	_	19	NMOD	_	_
19	translocation	_	NN	NN	_	14	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	NF-kappa	_	NN	NN	_	22	NMOD	_	_
22	B	_	NN	NN	_	20	PMOD	_	_
23	in	_	IN	IN	_	19	NMOD	_	_
24	neonatal	_	JJ	JJ	_	23	NMOD	_	_
25	than	_	IN	IN	_	19	NMOD	_	_
26	adult	_	JJ	JJ	_	28	NMOD	_	_
27	T	_	NN	NN	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	25	PMOD	_	_
29	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	5	NMOD	_	_
2	higher	_	JJR	JJR	_	5	NMOD	_	_
3	NF-kappa	_	NN	NN	_	5	NMOD	_	_
4	B	_	NN	NN	_	5	NMOD	_	_
5	activity	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	restricted	_	JJ	JJ	_	6	VC	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	CD4+	_	JJ	JJ	_	12	NMOD	_	_
11	T-cell	_	NN	NN	_	12	NMOD	_	_
12	subset	_	NN	NN	_	8	PMOD	_	_
13	.	_	.	.	_	6	P	_	_

1	Analysis	_	NN	NN	_	25	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	nuclear	_	JJ	JJ	_	5	NMOD	_	_
5	extracts	_	NNS	NNS	_	2	PMOD	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	antibodies	_	NNS	NNS	_	6	PMOD	_	_
8	directed	_	VBN	VBN	_	7	NMOD	_	_
9	against	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	major	_	JJ	JJ	_	12	NMOD	_	_
12	components	_	NNS	NNS	_	23	NMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	NF-kappa	_	NN	NN	_	15	NMOD	_	_
15	B	_	NN	NN	_	13	PMOD	_	_
16	the	_	DT	DT	_	23	NMOD	_	_
17	p50	_	NN	NN	_	23	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	RelA	_	NN	NN	_	17	COORD	_	_
20	(	_	(	(	_	21	P	_	_
21	p65	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	proteins	_	NNS	NNS	_	9	PMOD	_	_
24	,	_	,	,	_	23	P	_	_
25	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
26	that	_	IN	IN	_	25	OBJ	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	composition	_	NN	NN	_	32	SBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	NF-kappa	_	NN	NN	_	31	NMOD	_	_
31	B	_	NN	NN	_	29	PMOD	_	_
32	was	_	VBD	VBD	_	26	VMOD	_	_
33	similar	_	JJ	JJ	_	32	PRD	_	_
34	in	_	IN	IN	_	32	ADV	_	_
35	neonatal	_	JJ	JJ	_	38	NMOD	_	_
36	and	_	CC	CC	_	35	CC	_	_
37	adult	_	JJ	JJ	_	35	COORD	_	_
38	cells	_	NNS	NNS	_	34	PMOD	_	_
39	.	_	.	.	_	25	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	neonatal	_	JJ	JJ	_	7	NMOD	_	_
6	T	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	8	SBJ	_	_
8	are	_	VBP	VBP	_	4	VMOD	_	_
9	exposed	_	VBN	VBN	_	8	VC	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	oxidative	_	JJ	JJ	_	12	AMOD	_	_
12	stress-inducing	_	JJ	JJ	_	13	NMOD	_	_
13	signals	_	NNS	NNS	_	10	PMOD	_	_
14	during	_	IN	IN	_	9	TMP	_	_
15	delivery	_	NN	NN	_	14	PMOD	_	_
16	and\/or	_	CC	CC	_	8	CC	_	_
17	are	_	VBP	VBP	_	8	COORD	_	_
18	inherently	_	RB	RB	_	17	ADV	_	_
19	more	_	RBR	RBR	_	20	AMOD	_	_
20	sensitive	_	JJ	JJ	_	17	PRD	_	_
21	to	_	TO	TO	_	20	AMOD	_	_
22	NF-kappa	_	NN	NN	_	25	NMOD	_	_
23	B	_	NN	NN	_	25	NMOD	_	_
24	activating	_	NN	NN	_	25	NMOD	_	_
25	signals	_	NNS	NNS	_	21	PMOD	_	_
26	than	_	IN	IN	_	20	AMOD	_	_
27	adult	_	JJ	JJ	_	29	NMOD	_	_
28	T	_	NN	NN	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	26	PMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	BCL-6	_	NN	NN	_	7	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	POZ\/zinc-finger	_	NN	NN	_	5	NMOD	_	_
5	protein	_	NN	NN	_	1	NMOD	_	_
6	,	_	,	,	_	1	P	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	11	NMOD	_	_
9	sequence-specific	_	JJ	JJ	_	11	NMOD	_	_
10	transcriptional	_	JJ	JJ	_	11	NMOD	_	_
11	repressor	_	NN	NN	_	7	PRD	_	_
12	.	_	.	.	_	7	P	_	_

1	Approximately	_	RB	RB	_	3	NMOD	_	_
2	40	_	CD	CD	_	1	DEP	_	_
3	%	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	diffuse	_	JJ	JJ	_	8	NMOD	_	_
6	large	_	JJ	JJ	_	8	NMOD	_	_
7	cell	_	NN	NN	_	8	NMOD	_	_
8	lymphoma	_	NN	NN	_	4	PMOD	_	_
9	are	_	VBP	VBP	_	0	ROOT-S	_	_
10	associated	_	VBN	VBN	_	9	VC	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	chromosomal	_	JJ	JJ	_	13	NMOD	_	_
13	translocations	_	NNS	NNS	_	11	PMOD	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	deregulate	_	VBP	VBP	_	13	NMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	expression	_	NN	NN	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	BCL6	_	NN	NN	_	21	NMOD	_	_
21	gene	_	NN	NN	_	18	PMOD	_	_
22	by	_	IN	IN	_	15	ADV	_	_
23	juxtaposing	_	VBG	VBG	_	22	PMOD	_	_
24	heterologous	_	JJ	JJ	_	25	NMOD	_	_
25	promoters	_	NNS	NNS	_	23	OBJ	_	_
26	to	_	TO	TO	_	23	ADV	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	BCL-6	_	NN	NN	_	30	NMOD	_	_
29	coding	_	NN	NN	_	30	NMOD	_	_
30	domain	_	NN	NN	_	26	PMOD	_	_
31	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	BCL6	_	NN	NN	_	3	NMOD	_	_
3	gene	_	NN	NN	_	4	SBJ	_	_
4	encodes	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	95-kDa	_	JJ	JJ	_	7	NMOD	_	_
7	protein	_	NN	NN	_	4	IOBJ	_	_
8	containing	_	VBG	VBG	_	7	NMOD	_	_
9	six	_	CD	CD	_	12	NMOD	_	_
10	C-terminal	_	JJ	JJ	_	12	NMOD	_	_
11	zinc-finger	_	NN	NN	_	12	NMOD	_	_
12	motifs	_	NNS	NNS	_	8	OBJ	_	_
13	and	_	CC	CC	_	7	CC	_	_
14	an	_	DT	DT	_	17	NMOD	_	_
15	N-terminal	_	JJ	JJ	_	17	NMOD	_	_
16	POZ	_	NN	NN	_	17	NMOD	_	_
17	domain	_	NN	NN	_	7	COORD	_	_
18	,	_	,	,	_	4	P	_	_
19	suggesting	_	VBG	VBG	_	4	OBJ	_	_
20	that	_	IN	IN	_	19	OBJ	_	_
21	it	_	PRP	PRP	_	22	SBJ	_	_
22	may	_	MD	MD	_	20	VMOD	_	_
23	function	_	VB	VB	_	22	VC	_	_
24	as	_	IN	IN	_	23	ADV	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	transcription	_	NN	NN	_	27	NMOD	_	_
27	factor	_	NN	NN	_	24	PMOD	_	_
28	.	_	.	.	_	4	P	_	_

1	By	_	IN	IN	_	18	ADV	_	_
2	using	_	VBG	VBG	_	1	PMOD	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	DNA	_	NN	NN	_	5	NMOD	_	_
5	sequence	_	NN	NN	_	2	OBJ	_	_
6	selected	_	VBN	VBN	_	5	NMOD	_	_
7	for	_	IN	IN	_	6	ADV	_	_
8	its	_	PRP$	PRP$	_	9	NMOD	_	_
9	ability	_	NN	NN	_	7	PMOD	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	bind	_	VB	VB	_	9	NMOD	_	_
12	recombinant	_	JJ	JJ	_	13	NMOD	_	_
13	BCL-6	_	NN	NN	_	11	OBJ	_	_
14	in	_	FW	FW	_	11	ADV	_	_
15	vitro	_	FW	FW	_	14	AMOD	_	_
16	,	_	,	,	_	18	P	_	_
17	we	_	PRP	PRP	_	18	SBJ	_	_
18	show	_	VBP	VBP	_	0	ROOT-S	_	_
19	here	_	RB	RB	_	18	ADV	_	_
20	that	_	IN	IN	_	18	OBJ	_	_
21	BCL-6	_	NN	NN	_	22	SBJ	_	_
22	is	_	VBZ	VBZ	_	20	VMOD	_	_
23	present	_	JJ	JJ	_	22	PRD	_	_
24	in	_	IN	IN	_	23	AMOD	_	_
25	DNA-binding	_	JJ	JJ	_	26	NMOD	_	_
26	complexes	_	NNS	NNS	_	24	PMOD	_	_
27	in	_	IN	IN	_	26	NMOD	_	_
28	nuclear	_	JJ	JJ	_	29	NMOD	_	_
29	extracts	_	NNS	NNS	_	27	PMOD	_	_
30	from	_	IN	IN	_	29	NMOD	_	_
31	various	_	JJ	JJ	_	33	NMOD	_	_
32	B-cell	_	NN	NN	_	33	NMOD	_	_
33	lines	_	NNS	NNS	_	30	PMOD	_	_
34	.	_	.	.	_	18	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	transient	_	JJ	JJ	_	4	NMOD	_	_
3	transfectin	_	NN	NN	_	4	NMOD	_	_
4	experiments	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	BCL6	_	NN	NN	_	7	SBJ	_	_
7	can	_	MD	MD	_	0	ROOT-S	_	_
8	repress	_	VB	VB	_	7	VC	_	_
9	transcription	_	NN	NN	_	8	OBJ	_	_
10	from	_	IN	IN	_	9	NMOD	_	_
11	promoters	_	NNS	NNS	_	10	PMOD	_	_
12	linked	_	VBN	VBN	_	11	NMOD	_	_
13	to	_	TO	TO	_	12	ADV	_	_
14	its	_	PRP$	PRP$	_	17	NMOD	_	_
15	DNA	_	NN	NN	_	17	NMOD	_	_
16	target	_	NN	NN	_	17	NMOD	_	_
17	sequence	_	NN	NN	_	13	PMOD	_	_
18	and	_	CC	CC	_	7	CC	_	_
19	this	_	DT	DT	_	20	NMOD	_	_
20	activity	_	NN	NN	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	7	COORD	_	_
22	dependent	_	JJ	JJ	_	21	PRD	_	_
23	upon	_	IN	IN	_	22	AMOD	_	_
24	specific	_	JJ	JJ	_	25	NMOD	_	_
25	DNA-binding	_	NN	NN	_	23	PMOD	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	presence	_	NN	NN	_	25	COORD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	an	_	DT	DT	_	33	NMOD	_	_
31	intact	_	JJ	JJ	_	33	NMOD	_	_
32	N-terminal	_	JJ	JJ	_	33	NMOD	_	_
33	half	_	NN	NN	_	29	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	the	_	DT	DT	_	36	NMOD	_	_
36	protein	_	NN	NN	_	34	PMOD	_	_
37	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	this	_	DT	DT	_	5	NMOD	_	_
5	part	_	NN	NN	_	10	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	BCL6	_	NN	NN	_	9	NMOD	_	_
9	molecule	_	NN	NN	_	6	PMOD	_	_
10	contains	_	VBZ	VBZ	_	3	VMOD	_	_
11	an	_	DT	DT	_	14	NMOD	_	_
12	autonomous	_	JJ	JJ	_	14	NMOD	_	_
13	transrepressor	_	NN	NN	_	14	NMOD	_	_
14	domain	_	NN	NN	_	10	OBJ	_	_
15	and	_	CC	CC	_	3	CC	_	_
16	that	_	IN	IN	_	3	COORD	_	_
17	two	_	CD	CD	_	19	NMOD	_	_
18	noncontiguous	_	JJ	JJ	_	19	NMOD	_	_
19	regions	_	NNS	NNS	_	26	SBJ	_	_
20	,	_	,	,	_	19	P	_	_
21	including	_	VBG	VBG	_	19	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	POZ	_	NN	NN	_	24	NMOD	_	_
24	motif	_	NN	NN	_	21	PMOD	_	_
25	,	_	,	,	_	19	P	_	_
26	mediate	_	VBP	VBP	_	16	VMOD	_	_
27	maximum	_	JJ	JJ	_	29	NMOD	_	_
28	transrepressive	_	JJ	JJ	_	29	NMOD	_	_
29	activity	_	NN	NN	_	26	OBJ	_	_
30	.	_	.	.	_	2	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	BCL-6	_	NN	NN	_	7	NMOD	_	_
7	protein	_	NN	NN	_	8	SBJ	_	_
8	can	_	MD	MD	_	4	VMOD	_	_
9	function	_	VB	VB	_	8	VC	_	_
10	as	_	IN	IN	_	9	ADV	_	_
11	a	_	DT	DT	_	14	NMOD	_	_
12	sequence-specific	_	JJ	JJ	_	14	NMOD	_	_
13	transcriptional	_	JJ	JJ	_	14	NMOD	_	_
14	repressor	_	NN	NN	_	10	PMOD	_	_
15	and	_	CC	CC	_	3	CC	_	_
16	have	_	VBP	VBP	_	3	COORD	_	_
17	implications	_	NNS	NNS	_	16	OBJ	_	_
18	for	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	role	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	BCL6	_	NN	NN	_	21	PMOD	_	_
23	in	_	IN	IN	_	20	NMOD	_	_
24	normal	_	JJ	JJ	_	26	NMOD	_	_
25	lymphoid	_	JJ	JJ	_	26	NMOD	_	_
26	development	_	NN	NN	_	23	PMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	lymphomagenesis	_	NN	NN	_	26	COORD	_	_
29	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	Ets	_	NN	NN	_	4	NMOD	_	_
3	protein	_	NN	NN	_	4	NMOD	_	_
4	Spi-B	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	expressed	_	VBN	VBN	_	5	VC	_	_
7	exclusively	_	RB	RB	_	8	DEP	_	_
8	in	_	IN	IN	_	6	ADV	_	_
9	B	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	10	COORD	_	_
14	during	_	IN	IN	_	6	TMP	_	_
15	development	_	NN	NN	_	14	PMOD	_	_
16	.	_	.	.	_	5	P	_	_

1	Spi-B	_	NN	NN	_	4	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	PU.1	_	NN	NN	_	1	COORD	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	hematopoietic-specific	_	JJ	JJ	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factors	_	NNS	NNS	_	4	PRD	_	_
8	that	_	WDT	WDT	_	9	SBJ	_	_
9	constitute	_	VBP	VBP	_	7	NMOD	_	_
10	a	_	DT	DT	_	11	NMOD	_	_
11	subfamily	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	Ets	_	NN	NN	_	15	NMOD	_	_
15	family	_	NN	NN	_	12	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	DNA-binding	_	JJ	JJ	_	18	NMOD	_	_
18	proteins	_	NNS	NNS	_	16	PMOD	_	_
19	.	_	.	.	_	4	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	contrary	_	JJ	JJ	_	6	DEP	_	_
6	to	_	TO	TO	_	13	ADV	_	_
7	previous	_	JJ	JJ	_	8	NMOD	_	_
8	reports	_	NNS	NNS	_	6	PMOD	_	_
9	,	_	,	,	_	13	P	_	_
10	PU.1	_	NN	NN	_	13	SBJ	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	Spi-B	_	NN	NN	_	10	COORD	_	_
13	have	_	VBP	VBP	_	4	VMOD	_	_
14	very	_	RB	RB	_	15	AMOD	_	_
15	different	_	JJ	JJ	_	17	NMOD	_	_
16	expression	_	NN	NN	_	17	NMOD	_	_
17	patterns	_	NNS	NNS	_	13	OBJ	_	_
18	.	_	.	.	_	3	P	_	_

1	PU.1	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	expressed	_	VBN	VBN	_	2	VC	_	_
4	at	_	IN	IN	_	3	VMOD	_	_
5	high	_	JJ	JJ	_	6	NMOD	_	_
6	levels	_	NNS	NNS	_	4	PMOD	_	_
7	in	_	IN	IN	_	3	VMOD	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	7	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	mast	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	COORD	_	_
13	,	_	,	,	_	9	P	_	_
14	megakaryocytes	_	NNS	NNS	_	9	COORD	_	_
15	,	_	,	,	_	9	P	_	_
16	macrophages	_	NNS	NNS	_	9	COORD	_	_
17	,	_	,	,	_	9	P	_	_
18	neutrophils	_	NNS	NNS	_	9	COORD	_	_
19	,	_	,	,	_	9	P	_	_
20	and	_	CC	CC	_	9	CC	_	_
21	immature	_	JJ	JJ	_	23	NMOD	_	_
22	erythroid	_	JJ	JJ	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	9	COORD	_	_
24	and	_	CC	CC	_	3	CC	_	_
25	at	_	IN	IN	_	4	GAP	_	_
26	lower	_	JJR	JJR	_	27	NMOD	_	_
27	levels	_	NNS	NNS	_	25	PMOD	_	_
28	in	_	IN	IN	_	7	GAP	_	_
29	mature	_	JJ	JJ	_	30	NMOD	_	_
30	erythrocytes	_	NNS	NNS	_	28	PMOD	_	_
31	.	_	.	.	_	2	P	_	_

1	PU.1	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	completely	_	RB	RB	_	4	AMOD	_	_
4	absent	_	JJ	JJ	_	2	PRD	_	_
5	from	_	IN	IN	_	4	AMOD	_	_
6	peripheral	_	JJ	JJ	_	8	NMOD	_	_
7	T	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	5	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	most	_	JJS	JJS	_	13	NMOD	_	_
11	T	_	JJ	JJ	_	13	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	lines	_	NNS	NNS	_	8	COORD	_	_
14	based	_	VBN	VBN	_	2	ADV	_	_
15	on	_	IN	IN	_	14	PMOD	_	_
16	sensitive	_	JJ	JJ	_	18	NMOD	_	_
17	RT-PCR	_	NN	NN	_	18	NMOD	_	_
18	assays	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	Spi-B	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	expressed	_	VBN	VBN	_	5	VC	_	_
7	exclusively	_	RB	RB	_	6	ADV	_	_
8	in	_	IN	IN	_	6	ADV	_	_
9	lymphoid	_	JJ	JJ	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	and	_	CC	CC	_	5	CC	_	_
12	can	_	MD	MD	_	5	COORD	_	_
13	be	_	VB	VB	_	12	VC	_	_
14	detected	_	VBN	VBN	_	13	VC	_	_
15	in	_	IN	IN	_	14	ADV	_	_
16	early	_	JJ	JJ	_	18	NMOD	_	_
17	fetal	_	JJ	JJ	_	18	NMOD	_	_
18	thymus	_	NN	NN	_	15	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	spleen	_	NN	NN	_	18	COORD	_	_
21	.	_	.	.	_	5	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	situ	_	FW	FW	_	3	NMOD	_	_
3	hybridizations	_	NNS	NNS	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	adult	_	JJ	JJ	_	7	NMOD	_	_
6	murine	_	JJ	JJ	_	7	NMOD	_	_
7	tissues	_	NNS	NNS	_	4	PMOD	_	_
8	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
9	Spi-B	_	NN	NN	_	10	NMOD	_	_
10	mRNA	_	NN	NN	_	8	OBJ	_	_
11	in	_	IN	IN	_	8	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	medulla	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	thymus	_	NN	NN	_	14	PMOD	_	_
17	,	_	,	,	_	13	P	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	white	_	JJ	JJ	_	20	NMOD	_	_
20	pulp	_	NN	NN	_	13	COORD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	spleen	_	NN	NN	_	21	PMOD	_	_
24	,	_	,	,	_	13	P	_	_
25	and	_	CC	CC	_	13	CC	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	germinal	_	JJ	JJ	_	28	NMOD	_	_
28	centers	_	NNS	NNS	_	13	COORD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	lymph	_	NN	NN	_	31	NMOD	_	_
31	nodes	_	NNS	NNS	_	29	PMOD	_	_
32	.	_	.	.	_	8	P	_	_

1	Spi-B	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	very	_	RB	RB	_	5	AMOD	_	_
5	abundant	_	JJ	JJ	_	3	PRD	_	_
6	in	_	IN	IN	_	3	ADV	_	_
7	B	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	and	_	CC	CC	_	3	CC	_	_
10	both	_	CC	CC	_	11	CC	_	_
11	Spi-B	_	NN	NN	_	15	SBJ	_	_
12	mRNA	_	NN	NN	_	11	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	protein	_	NN	NN	_	12	COORD	_	_
15	are	_	VBP	VBP	_	3	COORD	_	_
16	detected	_	VBN	VBN	_	15	VC	_	_
17	in	_	IN	IN	_	16	ADV	_	_
18	some	_	DT	DT	_	20	NMOD	_	_
19	T	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	situ	_	FW	FW	_	3	NMOD	_	_
3	hybridization	_	NN	NN	_	8	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	Northern	_	NN	NN	_	7	NMOD	_	_
6	blot	_	NN	NN	_	7	NMOD	_	_
7	analysis	_	NN	NN	_	3	COORD	_	_
8	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	Spi-B	_	NN	NN	_	12	NMOD	_	_
11	gene	_	NN	NN	_	12	NMOD	_	_
12	expression	_	NN	NN	_	13	SBJ	_	_
13	increases	_	VBZ	VBZ	_	9	VMOD	_	_
14	during	_	IN	IN	_	13	TMP	_	_
15	B	_	NN	NN	_	17	NMOD	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	maturation	_	NN	NN	_	14	PMOD	_	_
18	and	_	CC	CC	_	13	CC	_	_
19	decreases	_	VBZ	VBZ	_	13	COORD	_	_
20	during	_	IN	IN	_	19	TMP	_	_
21	T	_	NN	NN	_	23	NMOD	_	_
22	cell	_	NN	NN	_	23	NMOD	_	_
23	maturation	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	8	P	_	_

1	Gel-retardation	_	JJ	JJ	_	2	NMOD	_	_
2	experiments	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	Spi-B	_	NN	NN	_	6	SBJ	_	_
6	can	_	MD	MD	_	4	VMOD	_	_
7	bind	_	VB	VB	_	6	VC	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	all	_	DT	DT	_	13	NMOD	_	_
10	putative	_	JJ	JJ	_	13	NMOD	_	_
11	PU.1	_	NN	NN	_	13	NMOD	_	_
12	binding	_	NN	NN	_	13	NMOD	_	_
13	sites	_	NNS	NNS	_	8	PMOD	_	_
14	,	_	,	,	_	3	P	_	_
15	but	_	CC	CC	_	3	CC	_	_
16	do	_	VBP	VBP	_	3	COORD	_	_
17	not	_	RB	RB	_	16	VMOD	_	_
18	reveal	_	VB	VB	_	16	VC	_	_
19	any	_	DT	DT	_	23	NMOD	_	_
20	preferred	_	JJ	JJ	_	23	NMOD	_	_
21	Spi-B	_	NN	NN	_	23	NMOD	_	_
22	binding	_	NN	NN	_	23	NMOD	_	_
23	site	_	NN	NN	_	18	OBJ	_	_
24	.	_	.	.	_	3	P	_	_

1	Finally	_	RB	RB	_	7	TMP	_	_
2	,	_	,	,	_	7	P	_	_
3	both	_	CC	CC	_	4	CC	_	_
4	PU.1	_	NN	NN	_	7	SBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	Spi-B	_	NN	NN	_	4	COORD	_	_
7	function	_	VBP	VBP	_	0	ROOT-S	_	_
8	as	_	IN	IN	_	7	ADV	_	_
9	transcriptional	_	JJ	JJ	_	10	NMOD	_	_
10	activators	_	NNS	NNS	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	17	NMOD	_	_
13	immunoglobulin	_	JJ	JJ	_	17	NMOD	_	_
14	light-chain	_	NN	NN	_	17	NMOD	_	_
15	enhancer	_	NN	NN	_	17	NMOD	_	_
16	E	_	NN	NN	_	17	NMOD	_	_
17	lambda	_	NN	NN	_	11	PMOD	_	_
18	2.4	_	CD	CD	_	17	NMOD	_	_
19	when	_	WRB	WRB	_	20	ADV	_	_
20	coexpressed	_	VBN	VBN	_	7	TMP	_	_
21	with	_	IN	IN	_	20	ADV	_	_
22	Pip	_	NN	NN	_	21	PMOD	_	_
23	(	_	(	(	_	25	P	_	_
24	PU.1-interaction	_	JJ	JJ	_	25	NMOD	_	_
25	partner	_	NN	NN	_	22	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	in	_	IN	IN	_	20	ADV	_	_
28	NIH-3T3	_	NN	NN	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	27	PMOD	_	_
30	.	_	.	.	_	7	P	_	_

1	Taken	_	VBN	VBN	_	6	VMOD	_	_
2	together	_	RB	RB	_	1	ADV	_	_
3	,	_	,	,	_	6	P	_	_
4	these	_	DT	DT	_	5	NMOD	_	_
5	data	_	NNS	NNS	_	6	SBJ	_	_
6	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	differences	_	NNS	NNS	_	17	SBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	patterns	_	NNS	NNS	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	expression	_	NN	NN	_	11	PMOD	_	_
13	between	_	IN	IN	_	8	NMOD	_	_
14	Spi-B	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	PU.1	_	NN	NN	_	14	COORD	_	_
17	distinguish	_	VBP	VBP	_	7	VMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	function	_	NN	NN	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	each	_	DT	DT	_	22	NMOD	_	_
22	protein	_	NN	NN	_	20	PMOD	_	_
23	during	_	IN	IN	_	19	TMP	_	_
24	development	_	NN	NN	_	23	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	immune	_	JJ	JJ	_	28	NMOD	_	_
28	system	_	NN	NN	_	25	PMOD	_	_
29	.	_	.	.	_	6	P	_	_

1	Effects	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	IL-10	_	NN	NN	_	2	PMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	IL-4	_	NN	NN	_	3	COORD	_	_
6	on	_	IN	IN	_	1	NMOD	_	_
7	LPS-induced	_	JJ	JJ	_	9	NMOD	_	_
8	transcription	_	NN	NN	_	9	NMOD	_	_
9	factors	_	NNS	NNS	_	6	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	AP-1	_	NN	NN	_	9	PRN	_	_
12	,	_	,	,	_	11	P	_	_
13	NF-IL6	_	NN	NN	_	11	COORD	_	_
14	and	_	CC	CC	_	11	CC	_	_
15	NF-kappa	_	NN	NN	_	16	NMOD	_	_
16	B	_	NN	NN	_	11	COORD	_	_
17	)	_	)	)	_	11	P	_	_
18	which	_	WDT	WDT	_	19	SBJ	_	_
19	are	_	VBP	VBP	_	9	NMOD	_	_
20	involved	_	VBN	VBN	_	19	VC	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	IL-6	_	NN	NN	_	23	NMOD	_	_
23	regulation	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	1	P	_	_

1	Interleukin-10	_	NN	NN	_	9	SBJ	_	_
2	(	_	(	(	_	3	P	_	_
3	IL-10	_	NN	NN	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	,	_	,	,	_	9	P	_	_
6	like	_	IN	IN	_	12	ADV	_	_
7	IL-4	_	NN	NN	_	6	PMOD	_	_
8	,	_	,	,	_	9	P	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	known	_	VBN	VBN	_	9	VC	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	inhibit	_	VB	VB	_	10	OBJ	_	_
13	cytokine	_	NN	NN	_	14	NMOD	_	_
14	expression	_	NN	NN	_	12	OBJ	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	activated	_	VBN	VBN	_	18	NMOD	_	_
17	human	_	JJ	JJ	_	18	NMOD	_	_
18	monocytes	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	showed	_	VBD	VBD	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	both	_	CC	CC	_	5	CC	_	_
5	IL-10	_	NN	NN	_	8	SBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	IL-4	_	NN	NN	_	5	COORD	_	_
8	inhibit	_	VBP	VBP	_	3	VMOD	_	_
9	LPS-induced	_	JJ	JJ	_	14	NMOD	_	_
10	IL-6	_	NN	NN	_	14	NMOD	_	_
11	mRNA	_	NN	NN	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	protein	_	NN	NN	_	11	COORD	_	_
14	expression	_	NN	NN	_	8	OBJ	_	_
15	by	_	IN	IN	_	8	ADV	_	_
16	inhibiting	_	VBG	VBG	_	15	PMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	transcription	_	NN	NN	_	19	NMOD	_	_
19	rate	_	NN	NN	_	16	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	IL-6	_	NN	NN	_	23	NMOD	_	_
23	gene	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	strong	_	JJ	JJ	_	3	NMOD	_	_
3	inhibition	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	IL-6	_	NN	NN	_	8	NMOD	_	_
7	transcription	_	NN	NN	_	8	NMOD	_	_
8	rate	_	NN	NN	_	4	PMOD	_	_
9	prompted	_	VBD	VBD	_	0	ROOT-S	_	_
10	us	_	PRP	PRP	_	12	SBJ	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	study	_	VB	VB	_	9	OBJ	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	effect	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	IL-10	_	NN	NN	_	15	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	IL-4	_	NN	NN	_	16	COORD	_	_
19	on	_	IN	IN	_	14	NMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	expression	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	transcription	_	NN	NN	_	24	NMOD	_	_
24	factors	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	questioned	_	VBD	VBD	_	0	ROOT-S	_	_
3	whether	_	IN	IN	_	2	OBJ	_	_
4	or	_	CC	CC	_	3	CC	_	_
5	not	_	RB	RB	_	3	COORD	_	_
6	IL-10	_	NN	NN	_	9	SBJ	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	IL-4	_	NN	NN	_	6	COORD	_	_
9	affected	_	VBD	VBD	_	3	COORD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	expression	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	transcription	_	NN	NN	_	14	NMOD	_	_
14	factors	_	NNS	NNS	_	12	PMOD	_	_
15	that	_	WDT	WDT	_	16	SBJ	_	_
16	are	_	VBP	VBP	_	14	NMOD	_	_
17	known	_	VBN	VBN	_	16	VC	_	_
18	to	_	TO	TO	_	19	VMOD	_	_
19	be	_	VB	VB	_	17	OBJ	_	_
20	involved	_	VBN	VBN	_	19	VC	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	control	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	28	NMOD	_	_
26	IL-6	_	NN	NN	_	28	NMOD	_	_
27	transcription	_	NN	NN	_	28	NMOD	_	_
28	rate	_	NN	NN	_	24	PMOD	_	_
29	,	_	,	,	_	14	P	_	_
30	namely	_	RB	RB	_	14	NMOD	_	_
31	activator	_	NN	NN	_	32	NMOD	_	_
32	protein-1	_	NN	NN	_	14	NMOD	_	_
33	(	_	(	(	_	34	P	_	_
34	AP-1	_	NN	NN	_	32	PRN	_	_
35	)	_	)	)	_	34	P	_	_
36	,	_	,	,	_	32	P	_	_
37	nuclear	_	JJ	JJ	_	39	NMOD	_	_
38	factor	_	NN	NN	_	39	NMOD	_	_
39	IL-6	_	NN	NN	_	32	COORD	_	_
40	(	_	(	(	_	41	P	_	_
41	NF-IL6	_	NN	NN	_	39	PRN	_	_
42	)	_	)	)	_	41	P	_	_
43	,	_	,	,	_	32	P	_	_
44	and	_	CC	CC	_	32	CC	_	_
45	nuclear	_	JJ	JJ	_	48	NMOD	_	_
46	factor	_	NN	NN	_	48	NMOD	_	_
47	kappa	_	NN	NN	_	48	NMOD	_	_
48	B	_	NN	NN	_	32	COORD	_	_
49	(	_	(	(	_	50	P	_	_
50	NF-kappaB	_	NN	NN	_	48	PRN	_	_
51	)	_	)	)	_	50	P	_	_
52	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	electrophoretic	_	JJ	JJ	_	5	NMOD	_	_
3	mobility	_	NN	NN	_	5	NMOD	_	_
4	shift	_	NN	NN	_	5	NMOD	_	_
5	assays	_	NNS	NNS	_	1	PMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	EMSAs	_	NNS	NNS	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	we	_	PRP	PRP	_	10	SBJ	_	_
10	showed	_	VBD	VBD	_	0	ROOT-S	_	_
11	that	_	IN	IN	_	10	OBJ	_	_
12	IL-10	_	NN	NN	_	15	SBJ	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	IL-4	_	NN	NN	_	12	COORD	_	_
15	inhibited	_	VBD	VBD	_	11	VMOD	_	_
16	LPS-induced	_	JJ	JJ	_	19	NMOD	_	_
17	AP-1	_	NN	NN	_	19	NMOD	_	_
18	binding	_	NN	NN	_	19	NMOD	_	_
19	activity	_	NN	NN	_	15	OBJ	_	_
20	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	inhibiting	_	JJ	JJ	_	3	NMOD	_	_
3	effect	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	IL-4	_	NN	NN	_	4	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	slightly	_	RB	RB	_	6	PRD	_	_
8	more	_	RBR	RBR	_	7	AMOD	_	_
9	pronounced	_	JJ	JJ	_	7	AMOD	_	_
10	than	_	IN	IN	_	7	AMOD	_	_
11	that	_	DT	DT	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	IL-10	_	NN	NN	_	12	PMOD	_	_
14	.	_	.	.	_	6	P	_	_

1	Downregulation	_	NN	NN	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	LPS-induced	_	JJ	JJ	_	4	NMOD	_	_
4	AP-1	_	NN	NN	_	2	PMOD	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	accompanied	_	VBN	VBN	_	5	VC	_	_
7	,	_	,	,	_	6	P	_	_
8	and	_	CC	CC	_	6	CC	_	_
9	thus	_	RB	RB	_	6	COORD	_	_
10	possibly	_	RB	RB	_	11	ADV	_	_
11	explained	_	VBN	VBN	_	6	COORD	_	_
12	,	_	,	,	_	6	P	_	_
13	by	_	IN	IN	_	6	ADV	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	reduced	_	VBN	VBN	_	16	NMOD	_	_
16	expression	_	NN	NN	_	13	PMOD	_	_
17	at	_	IN	IN	_	16	NMOD	_	_
18	mRNA	_	NN	NN	_	19	NMOD	_	_
19	level	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	16	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	two	_	CD	CD	_	24	NMOD	_	_
23	major	_	JJ	JJ	_	24	NMOD	_	_
24	components	_	NNS	NNS	_	20	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	AP-1	_	NN	NN	_	28	NMOD	_	_
28	complex	_	NN	NN	_	25	PMOD	_	_
29	,	_	,	,	_	24	P	_	_
30	namely	_	RB	RB	_	24	NMOD	_	_
31	c-fos	_	NN	NN	_	24	NMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	c-jun	_	NN	NN	_	31	COORD	_	_
34	as	_	IN	IN	_	31	NMOD	_	_
35	determined	_	VBN	VBN	_	34	VMOD	_	_
36	by	_	IN	IN	_	35	ADV	_	_
37	Northern	_	NN	NN	_	38	NMOD	_	_
38	experiments	_	NNS	NNS	_	36	PMOD	_	_
39	.	_	.	.	_	5	P	_	_

1	Binding	_	NN	NN	_	2	NMOD	_	_
2	activity	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NF-IL6	_	NN	NN	_	3	PMOD	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	also	_	RB	RB	_	5	ADV	_	_
7	strongly	_	RB	RB	_	8	ADV	_	_
8	inhibited	_	VBN	VBN	_	5	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	IL-4	_	NN	NN	_	9	PMOD	_	_
11	whereas	_	IN	IN	_	5	VMOD	_	_
12	IL-10	_	NN	NN	_	13	SBJ	_	_
13	showed	_	VBD	VBD	_	5	VC	_	_
14	no	_	DT	DT	_	15	NMOD	_	_
15	effect	_	NN	NN	_	13	OBJ	_	_
16	.	_	.	.	_	5	P	_	_

1	NF-IL6	_	NN	NN	_	3	NMOD	_	_
2	mRNA	_	NN	NN	_	3	NMOD	_	_
3	levels	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	affected	_	VBN	VBN	_	4	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	IL-10	_	NN	NN	_	7	PMOD	_	_
9	or	_	CC	CC	_	8	CC	_	_
10	IL-4	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	6	P	_	_
12	suggesting	_	VBG	VBG	_	6	OBJ	_	_
13	that	_	IN	IN	_	12	OBJ	_	_
14	IL-4	_	NN	NN	_	15	SBJ	_	_
15	affects	_	VBZ	VBZ	_	13	VMOD	_	_
16	binding	_	NN	NN	_	17	NMOD	_	_
17	activity	_	NN	NN	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	preexisting	_	VBG	VBG	_	20	NMOD	_	_
20	NF-IL6	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	4	P	_	_

1	Neither	_	CC	CC	_	2	CC	_	_
2	IL-10	_	NN	NN	_	5	SBJ	_	_
3	nor	_	CC	CC	_	2	CC	_	_
4	IL-4	_	NN	NN	_	2	COORD	_	_
5	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
6	LPS-induced	_	JJ	JJ	_	10	NMOD	_	_
7	NF-kappa	_	NN	NN	_	10	NMOD	_	_
8	B	_	NN	NN	_	10	NMOD	_	_
9	binding	_	NN	NN	_	10	NMOD	_	_
10	activity	_	NN	NN	_	5	OBJ	_	_
11	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	18	ADV	_	_
2	agreement	_	NN	NN	_	1	DEP	_	_
3	with	_	IN	IN	_	1	DEP	_	_
4	this	_	DT	DT	_	5	NMOD	_	_
5	finding	_	NN	NN	_	1	PMOD	_	_
6	,	_	,	,	_	18	P	_	_
7	Northern	_	NN	NN	_	8	NMOD	_	_
8	experiments	_	NNS	NNS	_	18	SBJ	_	_
9	where	_	WRB	WRB	_	16	ADV	_	_
10	p65	_	NN	NN	_	14	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	p105	_	NN	NN	_	10	COORD	_	_
13	mRNA	_	NN	NN	_	14	NMOD	_	_
14	levels	_	NNS	NNS	_	15	SBJ	_	_
15	were	_	VBD	VBD	_	8	NMOD	_	_
16	determined	_	VBN	VBN	_	15	VC	_	_
17	,	_	,	,	_	18	P	_	_
18	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
19	that	_	IN	IN	_	18	OBJ	_	_
20	expression	_	NN	NN	_	30	SBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	these	_	DT	DT	_	23	NMOD	_	_
23	components	_	NNS	NNS	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	29	NMOD	_	_
26	NF-kappa	_	NN	NN	_	29	NMOD	_	_
27	B	_	NN	NN	_	29	NMOD	_	_
28	transcription	_	NN	NN	_	29	NMOD	_	_
29	factor	_	NN	NN	_	24	PMOD	_	_
30	were	_	VBD	VBD	_	19	VMOD	_	_
31	not	_	RB	RB	_	30	VMOD	_	_
32	affected	_	VBN	VBN	_	30	VC	_	_
33	by	_	IN	IN	_	32	LGS	_	_
34	IL-10	_	NN	NN	_	33	PMOD	_	_
35	or	_	CC	CC	_	34	CC	_	_
36	IL-4	_	NN	NN	_	34	COORD	_	_
37	.	_	.	.	_	18	P	_	_

1	Furthermore	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	neither	_	CC	CC	_	4	CC	_	_
4	IL-10	_	NN	NN	_	7	SBJ	_	_
5	nor	_	CC	CC	_	4	CC	_	_
6	IL-4	_	NN	NN	_	4	COORD	_	_
7	showed	_	VBD	VBD	_	0	ROOT-S	_	_
8	any	_	DT	DT	_	9	NMOD	_	_
9	effect	_	NN	NN	_	7	OBJ	_	_
10	on	_	IN	IN	_	9	NMOD	_	_
11	I-kappa	_	NN	NN	_	14	NMOD	_	_
12	B	_	NN	NN	_	14	NMOD	_	_
13	mRNA	_	NN	NN	_	14	NMOD	_	_
14	expression	_	NN	NN	_	10	PMOD	_	_
15	as	_	IN	IN	_	7	ADV	_	_
16	determined	_	VBN	VBN	_	15	VMOD	_	_
17	by	_	IN	IN	_	16	ADV	_	_
18	Northern	_	NN	NN	_	19	NMOD	_	_
19	experiments	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	7	P	_	_

1	Thus	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	IL-10	_	NN	NN	_	7	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	IL-4	_	NN	NN	_	3	COORD	_	_
6	similarly	_	RB	RB	_	7	ADV	_	_
7	affect	_	VBP	VBP	_	0	ROOT-S	_	_
8	IL-6	_	NN	NN	_	9	NMOD	_	_
9	expression	_	NN	NN	_	7	OBJ	_	_
10	.	_	.	.	_	7	P	_	_

1	However	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	for	_	IN	IN	_	6	ADV	_	_
4	IL-4	_	NN	NN	_	3	PMOD	_	_
5	this	_	DT	DT	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	accompanied	_	VBN	VBN	_	6	VC	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	reduction	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	AP-1	_	NN	NN	_	16	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	NF-IL6	_	NN	NN	_	12	COORD	_	_
15	binding	_	NN	NN	_	16	NMOD	_	_
16	activity	_	NN	NN	_	11	PMOD	_	_
17	whereas	_	IN	IN	_	7	OBJ	_	_
18	IL-10	_	NN	NN	_	20	SBJ	_	_
19	only	_	RB	RB	_	20	ADV	_	_
20	inhibited	_	VBD	VBD	_	17	VMOD	_	_
21	AP-1	_	NN	NN	_	23	NMOD	_	_
22	binding	_	NN	NN	_	23	NMOD	_	_
23	activity	_	NN	NN	_	20	OBJ	_	_
24	.	_	.	.	_	6	P	_	_

1	Various	_	JJ	JJ	_	2	NMOD	_	_
2	modes	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	basic	_	JJ	JJ	_	6	AMOD	_	_
5	helix-loop-helix	_	JJ	JJ	_	6	AMOD	_	_
6	protein-mediated	_	JJ	JJ	_	7	NMOD	_	_
7	regulation	_	NN	NN	_	3	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	murine	_	JJ	JJ	_	12	NMOD	_	_
10	leukemia	_	NN	NN	_	12	NMOD	_	_
11	virus	_	NN	NN	_	12	NMOD	_	_
12	transcription	_	NN	NN	_	8	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	lymphoid	_	JJ	JJ	_	16	NMOD	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	lines	_	NNS	NNS	_	13	PMOD	_	_
17	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	transcriptionally	_	RB	RB	_	3	AMOD	_	_
3	regulatory	_	JJ	JJ	_	4	NMOD	_	_
4	regions	_	NNS	NNS	_	17	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	lymphomagenic	_	JJ	JJ	_	8	NMOD	_	_
8	Akv	_	NN	NN	_	5	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	SL3-3	_	NN	NN	_	8	COORD	_	_
11	murine	_	JJ	JJ	_	13	NMOD	_	_
12	leukemia	_	NN	NN	_	13	NMOD	_	_
13	retroviruses	_	NNS	NNS	_	8	NMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	MLVs	_	NNS	NNS	_	13	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	contain	_	VBP	VBP	_	0	ROOT-S	_	_
18	two	_	CD	CD	_	19	NMOD	_	_
19	types	_	NNS	NNS	_	17	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	E-box	_	NN	NN	_	23	NMOD	_	_
22	consensus	_	NN	NN	_	23	NMOD	_	_
23	motifs	_	NNS	NNS	_	20	PMOD	_	_
24	,	_	,	,	_	19	P	_	_
25	CAGATG	_	NN	NN	_	19	NMOD	_	_
26	.	_	.	.	_	17	P	_	_

1	One	_	CD	CD	_	2	NMOD	_	_
2	type	_	NN	NN	_	6	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	EA\/S	_	NN	NN	_	2	NMOD	_	_
5	,	_	,	,	_	2	P	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	located	_	JJ	JJ	_	6	PRD	_	_
8	in	_	IN	IN	_	7	AMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	upstream	_	JJ	JJ	_	12	NMOD	_	_
11	promoter	_	NN	NN	_	12	NMOD	_	_
12	region	_	NN	NN	_	8	PMOD	_	_
13	,	_	,	,	_	6	P	_	_
14	and	_	CC	CC	_	6	CC	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	other	_	JJ	JJ	_	20	SBJ	_	_
17	,	_	,	,	_	16	P	_	_
18	E-LRB-gre-RRB-	_	NN	NN	_	16	NMOD	_	_
19	,	_	,	,	_	16	P	_	_
20	is	_	VBZ	VBZ	_	6	COORD	_	_
21	located	_	JJ	JJ	_	20	PRD	_	_
22	in	_	IN	IN	_	21	AMOD	_	_
23	a	_	DT	DT	_	25	NMOD	_	_
24	tandem	_	JJ	JJ	_	25	NMOD	_	_
25	repeat	_	NN	NN	_	22	PMOD	_	_
26	with	_	IN	IN	_	25	NMOD	_	_
27	enhancer	_	NN	NN	_	28	NMOD	_	_
28	properties	_	NNS	NNS	_	26	PMOD	_	_
29	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	examined	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	requirements	_	NNS	NNS	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	individual	_	JJ	JJ	_	9	NMOD	_	_
9	E-boxes	_	NNS	NNS	_	6	PMOD	_	_
10	in	_	IN	IN	_	5	NMOD	_	_
11	MLV	_	NN	NN	_	13	NMOD	_	_
12	transcriptional	_	JJ	JJ	_	13	NMOD	_	_
13	regulation	_	NN	NN	_	10	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	lymphoid	_	JJ	JJ	_	4	NMOD	_	_
3	cell	_	NN	NN	_	4	NMOD	_	_
4	lines	_	NNS	NNS	_	1	PMOD	_	_
5	only	_	RB	RB	_	4	NMOD	_	_
6	,	_	,	,	_	11	P	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	E-LRB-gre-RRB--binding	_	JJ	JJ	_	10	NMOD	_	_
9	protein	_	NN	NN	_	10	NMOD	_	_
10	complexes	_	NNS	NNS	_	11	SBJ	_	_
11	included	_	VBD	VBD	_	0	ROOT-S	_	_
12	ALF1	_	NN	NN	_	19	NMOD	_	_
13	or	_	CC	CC	_	12	CC	_	_
14	HEB	_	NN	NN	_	12	COORD	_	_
15	and	_	CC	CC	_	12	CC	_	_
16	E2A	_	NN	NN	_	12	COORD	_	_
17	basic	_	JJ	JJ	_	19	NMOD	_	_
18	helix-loop-helix	_	JJ	JJ	_	19	NMOD	_	_
19	proteins	_	NNS	NNS	_	11	OBJ	_	_
20	.	_	.	.	_	11	P	_	_

1	Ectopic	_	JJ	JJ	_	5	NMOD	_	_
2	ALF1	_	NN	NN	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	E2A	_	NN	NN	_	2	COORD	_	_
5	proteins	_	NNS	NNS	_	6	SBJ	_	_
6	required	_	VBD	VBD	_	0	ROOT-S	_	_
7	intact	_	JJ	JJ	_	9	NMOD	_	_
8	E-LRB-gre-RRB-	_	NN	NN	_	9	NMOD	_	_
9	motifs	_	NNS	NNS	_	6	OBJ	_	_
10	for	_	IN	IN	_	6	ADV	_	_
11	mediating	_	VBG	VBG	_	10	PMOD	_	_
12	transcriptional	_	JJ	JJ	_	13	NMOD	_	_
13	activation	_	NN	NN	_	11	OBJ	_	_
14	.	_	.	.	_	6	P	_	_

1	ALF1	_	NNP	NNP	_	2	SBJ	_	_
2	transactivated	_	VBD	VBD	_	0	ROOT-S	_	_
3	transcription	_	NN	NN	_	2	OBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	Akv	_	NN	NN	_	6	NMOD	_	_
6	MLV	_	NN	NN	_	4	PMOD	_	_
7	through	_	IN	IN	_	2	ADV	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	two	_	CD	CD	_	11	NMOD	_	_
10	E-LRB-gre-RRB-	_	NN	NN	_	11	NMOD	_	_
11	motifs	_	NNS	NNS	_	7	PMOD	_	_
12	equally	_	RB	RB	_	2	ADV	_	_
13	,	_	,	,	_	2	P	_	_
14	whereas	_	IN	IN	_	2	COORD	_	_
15	E2A	_	NN	NN	_	16	NMOD	_	_
16	protein	_	NN	NN	_	17	SBJ	_	_
17	required	_	VBD	VBD	_	2	COORD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	promoter-proximal	_	JJ	JJ	_	21	NMOD	_	_
20	E-LRB-gre-RRB-	_	NN	NN	_	21	NMOD	_	_
21	motif	_	NN	NN	_	17	OBJ	_	_
22	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	T-	_	NN	NN	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	B-cell	_	NN	NN	_	2	COORD	_	_
5	lines	_	NNS	NNS	_	1	PMOD	_	_
6	,	_	,	,	_	10	P	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	E-LRB-gre-RRB-	_	NN	NN	_	9	NMOD	_	_
9	motifs	_	NNS	NNS	_	10	SBJ	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	of	_	IN	IN	_	10	PRD	_	_
12	major	_	JJ	JJ	_	13	NMOD	_	_
13	importance	_	NN	NN	_	11	PMOD	_	_
14	for	_	IN	IN	_	10	ADV	_	_
15	Akv	_	NN	NN	_	18	NMOD	_	_
16	MLV	_	NN	NN	_	18	NMOD	_	_
17	transcriptional	_	JJ	JJ	_	18	NMOD	_	_
18	activity	_	NN	NN	_	14	PMOD	_	_
19	,	_	,	,	_	10	P	_	_
20	while	_	IN	IN	_	10	ADV	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	EA\/S	_	NN	NN	_	23	NMOD	_	_
23	motif	_	NN	NN	_	24	SBJ	_	_
24	had	_	VBD	VBD	_	20	VMOD	_	_
25	some	_	DT	DT	_	26	NMOD	_	_
26	effect	_	NN	NN	_	24	OBJ	_	_
27	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	9	P	_	_
4	neither	_	CC	CC	_	5	CC	_	_
5	E-LRB-gre-RRB-	_	NN	NN	_	8	NMOD	_	_
6	nor	_	CC	CC	_	5	CC	_	_
7	EA\/S	_	NN	NN	_	5	COORD	_	_
8	motifs	_	NNS	NNS	_	9	SBJ	_	_
9	contributed	_	VBD	VBD	_	0	ROOT-S	_	_
10	pronouncedly	_	RB	RB	_	9	ADV	_	_
11	to	_	TO	TO	_	9	ADV	_	_
12	Akv	_	NN	NN	_	14	NMOD	_	_
13	MLV	_	NN	NN	_	14	NMOD	_	_
14	transcription	_	NN	NN	_	11	PMOD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	NIH	_	NN	NN	_	18	NMOD	_	_
17	3T3	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	15	PMOD	_	_
19	lacking	_	VBG	VBG	_	18	NMOD	_	_
20	DNA-binding	_	JJ	JJ	_	26	NMOD	_	_
21	ALF1	_	NN	NN	_	26	NMOD	_	_
22	or	_	CC	CC	_	21	CC	_	_
23	HEB	_	NN	NN	_	21	COORD	_	_
24	and	_	CC	CC	_	21	CC	_	_
25	E2A	_	NN	NN	_	21	COORD	_	_
26	proteins	_	NNS	NNS	_	19	OBJ	_	_
27	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	Id1	_	NN	NN	_	3	NMOD	_	_
3	protein	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	found	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	repress	_	VB	VB	_	5	OBJ	_	_
8	ALF1	_	NN	NN	_	9	NMOD	_	_
9	activity	_	NN	NN	_	7	OBJ	_	_
10	in	_	FW	FW	_	7	ADV	_	_
11	vitro	_	FW	FW	_	10	AMOD	_	_
12	and	_	CC	CC	_	10	CC	_	_
13	in	_	FW	FW	_	10	COORD	_	_
14	vivo	_	FW	FW	_	13	AMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	Moreover	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	ectopic	_	JJ	JJ	_	4	NMOD	_	_
4	Id1	_	NN	NN	_	5	SBJ	_	_
5	repressed	_	VBD	VBD	_	0	ROOT-S	_	_
6	E-LRB-gre-RRB--directed	_	JJ	JJ	_	11	NMOD	_	_
7	but	_	CC	CC	_	6	CC	_	_
8	not	_	RB	RB	_	7	COORD	_	_
9	EA\/S-directed	_	JJ	JJ	_	6	COORD	_	_
10	MLV	_	NN	NN	_	11	NMOD	_	_
11	transcription	_	NN	NN	_	5	OBJ	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	lymphoid	_	JJ	JJ	_	15	NMOD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	lines	_	NNS	NNS	_	12	PMOD	_	_
16	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	conclusion	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	11	P	_	_
4	E-LRB-gre-RRB-	_	NN	NN	_	5	NMOD	_	_
5	motifs	_	NNS	NNS	_	11	SBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	interacting	_	VBG	VBG	_	10	NMOD	_	_
8	basic	_	JJ	JJ	_	10	NMOD	_	_
9	helix-loop-helix	_	JJ	JJ	_	10	NMOD	_	_
10	proteins	_	NNS	NNS	_	5	COORD	_	_
11	are	_	VBP	VBP	_	0	ROOT-S	_	_
12	important	_	JJ	JJ	_	13	NMOD	_	_
13	determinants	_	NNS	NNS	_	11	PRD	_	_
14	for	_	IN	IN	_	13	NMOD	_	_
15	MLV	_	NN	NN	_	17	NMOD	_	_
16	transcriptional	_	JJ	JJ	_	17	NMOD	_	_
17	activity	_	NN	NN	_	14	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	lymphocytic	_	JJ	JJ	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	lines	_	NNS	NNS	_	18	PMOD	_	_
22	.	_	.	.	_	11	P	_	_

1	Granulocyte-macrophage	_	JJ	JJ	_	3	NMOD	_	_
2	colony-stimulating	_	JJ	JJ	_	3	NMOD	_	_
3	factor	_	NN	NN	_	5	SBJ	_	_
4	preferentially	_	RB	RB	_	5	ADV	_	_
5	activates	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	94-kD	_	JJ	JJ	_	8	NMOD	_	_
8	STAT5A	_	NN	NN	_	5	OBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	an	_	DT	DT	_	13	NMOD	_	_
11	80-kD	_	JJ	JJ	_	13	NMOD	_	_
12	STAT5A	_	NN	NN	_	13	NMOD	_	_
13	isoform	_	NN	NN	_	8	COORD	_	_
14	in	_	IN	IN	_	8	NMOD	_	_
15	human	_	JJ	JJ	_	18	NMOD	_	_
16	peripheral	_	JJ	JJ	_	18	NMOD	_	_
17	blood	_	NN	NN	_	18	NMOD	_	_
18	monocytes	_	NNS	NNS	_	14	PMOD	_	_
19	.	_	.	.	_	5	P	_	_

1	Granulocyte-macrophage	_	JJ	JJ	_	3	NMOD	_	_
2	colony-stimulating	_	JJ	JJ	_	3	NMOD	_	_
3	factor	_	NN	NN	_	7	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	GM-CSF	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	immediate	_	JJ	JJ	_	9	NMOD	_	_
9	effects	_	NNS	NNS	_	7	OBJ	_	_
10	in	_	IN	IN	_	7	ADV	_	_
11	monocytes	_	NNS	NNS	_	10	PMOD	_	_
12	by	_	IN	IN	_	7	ADV	_	_
13	activation	_	NN	NN	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	28	NMOD	_	_
16	Janus	_	NN	NN	_	17	NMOD	_	_
17	kinase	_	NN	NN	_	28	NMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	JAK2	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	and	_	CC	CC	_	17	CC	_	_
22	STAT	_	NN	NN	_	24	NMOD	_	_
23	transcription	_	NN	NN	_	24	NMOD	_	_
24	factor	_	NN	NN	_	17	COORD	_	_
25	(	_	(	(	_	26	P	_	_
26	STAT5	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	pathway	_	NN	NN	_	14	PMOD	_	_
29	.	_	.	.	_	7	P	_	_

1	Recent	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	identified	_	VBN	VBN	_	3	VC	_	_
5	homologues	_	NNS	NNS	_	4	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	STAT5	_	NN	NN	_	6	PMOD	_	_
8	,	_	,	,	_	7	P	_	_
9	STAT5A	_	NN	NN	_	7	COORD	_	_
10	,	_	,	,	_	7	P	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	STAT5B	_	NN	NN	_	7	COORD	_	_
13	,	_	,	,	_	5	P	_	_
14	as	_	RB	RB	_	5	CC	_	_
15	well	_	RB	RB	_	14	DEP	_	_
16	as	_	IN	IN	_	14	DEP	_	_
17	lower	_	JJR	JJR	_	20	NMOD	_	_
18	molecular	_	JJ	JJ	_	20	NMOD	_	_
19	weight	_	NN	NN	_	20	NMOD	_	_
20	variants	_	NNS	NNS	_	5	COORD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	STAT5	_	NN	NN	_	21	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	define	_	VB	VB	_	31	VMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	activation	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	STAT5	_	NN	NN	_	5	PMOD	_	_
8	homologues	_	NNS	NNS	_	7	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	lower	_	JJR	JJR	_	13	NMOD	_	_
11	molecular	_	JJ	JJ	_	13	NMOD	_	_
12	weight	_	NN	NN	_	13	NMOD	_	_
13	variant	_	NN	NN	_	8	COORD	_	_
14	in	_	IN	IN	_	4	NMOD	_	_
15	human	_	JJ	JJ	_	16	NMOD	_	_
16	monocytes	_	NNS	NNS	_	14	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	monocytes	_	NNS	NNS	_	16	COORD	_	_
19	differentiated	_	VBN	VBN	_	18	NMOD	_	_
20	into	_	IN	IN	_	19	ADV	_	_
21	macrophages	_	NNS	NNS	_	20	PMOD	_	_
22	by	_	IN	IN	_	19	LGS	_	_
23	culture	_	NN	NN	_	22	PMOD	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	macrophage-CSF	_	NN	NN	_	24	PMOD	_	_
26	(	_	(	(	_	27	P	_	_
27	M-CSF	_	NN	NN	_	25	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	,	_	,	,	_	31	P	_	_
30	we	_	PRP	PRP	_	31	SBJ	_	_
31	measured	_	VBD	VBD	_	0	ROOT-S	_	_
32	the	_	DT	DT	_	36	NMOD	_	_
33	GM-CSF	_	NN	NN	_	36	NMOD	_	_
34	induced	_	JJ	JJ	_	33	AMOD	_	_
35	tyrosine	_	NN	NN	_	36	NMOD	_	_
36	phosphorylation	_	NN	NN	_	31	OBJ	_	_
37	of	_	IN	IN	_	36	NMOD	_	_
38	STAT5A	_	NN	NN	_	37	PMOD	_	_
39	,	_	,	,	_	38	P	_	_
40	STAT5B	_	NN	NN	_	38	COORD	_	_
41	,	_	,	,	_	38	P	_	_
42	and	_	CC	CC	_	38	CC	_	_
43	any	_	DT	DT	_	48	NMOD	_	_
44	lower	_	JJR	JJR	_	48	NMOD	_	_
45	molecular	_	JJ	JJ	_	48	NMOD	_	_
46	weight	_	NN	NN	_	48	NMOD	_	_
47	STAT5	_	NN	NN	_	48	NMOD	_	_
48	isoforms	_	NNS	NNS	_	38	COORD	_	_
49	.	_	.	.	_	31	P	_	_

1	Freshly	_	RB	RB	_	2	AMOD	_	_
2	isolated	_	VBN	VBN	_	3	NMOD	_	_
3	monocytes	_	NNS	NNS	_	4	SBJ	_	_
4	expressed	_	VBD	VBD	_	0	ROOT-S	_	_
5	94-kD	_	JJ	JJ	_	6	NMOD	_	_
6	STAT5A	_	NN	NN	_	4	OBJ	_	_
7	,	_	,	,	_	6	P	_	_
8	92-kD	_	JJ	JJ	_	9	NMOD	_	_
9	STAT5B	_	NN	NN	_	6	COORD	_	_
10	,	_	,	,	_	6	P	_	_
11	and	_	CC	CC	_	6	CC	_	_
12	an	_	DT	DT	_	15	NMOD	_	_
13	80-kD	_	JJ	JJ	_	15	NMOD	_	_
14	STAT5A	_	NN	NN	_	15	NMOD	_	_
15	molecule	_	NN	NN	_	6	COORD	_	_
16	.	_	.	.	_	4	P	_	_

1	Whereas	_	IN	IN	_	32	ADV	_	_
2	94-kD	_	JJ	JJ	_	3	NMOD	_	_
3	STAT5A	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	1	VMOD	_	_
5	clearly	_	RB	RB	_	4	ADV	_	_
6	tyrosine	_	NN	NN	_	4	VC	_	_
7	phosphorylated	_	JJ	JJ	_	6	VMOD	_	_
8	and	_	CC	CC	_	6	CC	_	_
9	bound	_	VBD	VBD	_	6	COORD	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	enhancer	_	NN	NN	_	13	NMOD	_	_
13	element	_	NN	NN	_	10	PMOD	_	_
14	,	_	,	,	_	32	P	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	gamma	_	NN	NN	_	18	NMOD	_	_
17	response	_	NN	NN	_	18	NMOD	_	_
18	region	_	NN	NN	_	32	SBJ	_	_
19	(	_	(	(	_	20	P	_	_
20	GRR	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	,	_	,	,	_	18	P	_	_
23	of	_	IN	IN	_	18	NMOD	_	_
24	the	_	DT	DT	_	28	NMOD	_	_
25	Fc	_	NN	NN	_	28	NMOD	_	_
26	gamma	_	NN	NN	_	28	NMOD	_	_
27	RI	_	NN	NN	_	28	NMOD	_	_
28	gene	_	NN	NN	_	23	PMOD	_	_
29	,	_	,	,	_	18	P	_	_
30	substantially	_	RB	RB	_	32	ADV	_	_
31	less	_	JJR	JJR	_	30	AMOD	_	_
32	tyrosine	_	NN	NN	_	0	ROOT-S	_	_
33	phosphorylated	_	JJ	JJ	_	32	VMOD	_	_
34	STAT5B	_	NN	NN	_	32	OBJ	_	_
35	bound	_	VBD	VBD	_	34	NMOD	_	_
36	to	_	TO	TO	_	35	ADV	_	_
37	the	_	DT	DT	_	40	NMOD	_	_
38	immobilized	_	JJ	JJ	_	40	NMOD	_	_
39	GRR	_	NN	NN	_	40	NMOD	_	_
40	element	_	NN	NN	_	36	PMOD	_	_
41	.	_	.	.	_	32	P	_	_

1	Macrophages	_	NNS	NNS	_	2	SBJ	_	_
2	lost	_	VBD	VBD	_	0	ROOT-S	_	_
3	their	_	PRP$	PRP$	_	4	NMOD	_	_
4	ability	_	NN	NN	_	2	OBJ	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	express	_	VB	VB	_	4	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	80-kD	_	JJ	JJ	_	10	NMOD	_	_
9	STAT5A	_	NN	NN	_	10	NMOD	_	_
10	protein	_	NN	NN	_	6	OBJ	_	_
11	,	_	,	,	_	2	P	_	_
12	but	_	CC	CC	_	2	CC	_	_
13	retained	_	VBD	VBD	_	2	COORD	_	_
14	their	_	PRP$	PRP$	_	15	NMOD	_	_
15	ability	_	NN	NN	_	13	OBJ	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	activate	_	VB	VB	_	15	NMOD	_	_
18	STAT5A	_	NN	NN	_	17	OBJ	_	_
19	.	_	.	.	_	2	P	_	_

1	STAT5A-STAT5A	_	JJ	JJ	_	2	NMOD	_	_
2	homodimers	_	NNS	NNS	_	6	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	STAT5A-STAT5B	_	NN	NN	_	5	NMOD	_	_
5	heterodimers	_	NNS	NNS	_	2	COORD	_	_
6	formed	_	VBD	VBD	_	0	ROOT-S	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	response	_	NN	NN	_	7	DEP	_	_
9	to	_	TO	TO	_	7	DEP	_	_
10	GM-CSF	_	NN	NN	_	7	PMOD	_	_
11	.	_	.	.	_	6	P	_	_

1	Therefore	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	activation	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	STAT5A	_	NN	NN	_	4	PMOD	_	_
6	predominates	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	compared	_	VBN	VBN	_	6	ADV	_	_
8	to	_	TO	TO	_	7	PMOD	_	_
9	STAT5B	_	NN	NN	_	8	PMOD	_	_
10	when	_	WRB	WRB	_	11	ADV	_	_
11	assayed	_	VBN	VBN	_	6	TMP	_	_
12	by	_	IN	IN	_	11	ADV	_	_
13	direct	_	JJ	JJ	_	14	NMOD	_	_
14	immunoprecipitation	_	NN	NN	_	12	PMOD	_	_
15	and	_	CC	CC	_	12	CC	_	_
16	by	_	IN	IN	_	12	COORD	_	_
17	evaluation	_	NN	NN	_	16	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	bound	_	VBN	VBN	_	20	NMOD	_	_
20	STATs	_	NNS	NNS	_	18	PMOD	_	_
21	to	_	TO	TO	_	20	NMOD	_	_
22	immobilized	_	JJ	JJ	_	23	NMOD	_	_
23	GRR	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	6	P	_	_

1	Selective	_	JJ	JJ	_	2	NMOD	_	_
2	activation	_	NN	NN	_	14	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	STAT5	_	NN	NN	_	5	NMOD	_	_
5	homologues	_	NNS	NNS	_	3	PMOD	_	_
6	in	_	IN	IN	_	2	CC	_	_
7	addition	_	NN	NN	_	6	DEP	_	_
8	to	_	TO	TO	_	6	DEP	_	_
9	generation	_	NN	NN	_	2	COORD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	lower	_	JJR	JJR	_	13	NMOD	_	_
12	molecular	_	JJ	JJ	_	13	NMOD	_	_
13	isoforms	_	NNS	NNS	_	10	PMOD	_	_
14	may	_	MD	MD	_	0	ROOT-S	_	_
15	provide	_	VB	VB	_	14	VC	_	_
16	specificity	_	NN	NN	_	15	OBJ	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	control	_	NN	NN	_	16	COORD	_	_
19	to	_	TO	TO	_	15	DTV	_	_
20	genes	_	NNS	NNS	_	19	PMOD	_	_
21	expressed	_	VBN	VBN	_	20	NMOD	_	_
22	in	_	IN	IN	_	21	ADV	_	_
23	response	_	NN	NN	_	22	DEP	_	_
24	to	_	TO	TO	_	22	DEP	_	_
25	cytokines	_	NNS	NNS	_	22	PMOD	_	_
26	such	_	JJ	JJ	_	27	DEP	_	_
27	as	_	IN	IN	_	25	NMOD	_	_
28	GM-CSF	_	NN	NN	_	27	PMOD	_	_
29	.	_	.	.	_	14	P	_	_

1	CTL	_	NN	NN	_	2	NMOD	_	_
2	recognition	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	an	_	DT	DT	_	6	NMOD	_	_
5	altered	_	JJ	JJ	_	6	NMOD	_	_
6	peptide	_	NN	NN	_	3	PMOD	_	_
7	associated	_	VBN	VBN	_	2	NMOD	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	asparagine	_	NN	NN	_	11	NMOD	_	_
10	bond	_	NN	NN	_	11	NMOD	_	_
11	rearrangement	_	NN	NN	_	8	PMOD	_	_
12	.	_	.	.	_	2	P	_	_

1	Implications	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	for	_	IN	IN	_	1	NMOD	_	_
3	immunity	_	NN	NN	_	2	PMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	vaccine	_	NN	NN	_	6	NMOD	_	_
6	design	_	NN	NN	_	3	COORD	_	_
7	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	extent	_	NN	NN	_	20	SBJ	_	_
3	to	_	TO	TO	_	16	ADV	_	_
4	which	_	WDT	WDT	_	3	PMOD	_	_
5	peptides	_	NNS	NNS	_	15	SBJ	_	_
6	containing	_	VBG	VBG	_	5	NMOD	_	_
7	chemically	_	RB	RB	_	14	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	post-translationally	_	RB	RB	_	7	TMP	_	_
10	modified	_	VBN	VBN	_	7	AMOD	_	_
11	amino	_	NN	NN	_	14	NMOD	_	_
12	acid	_	NN	NN	_	14	NMOD	_	_
13	side	_	JJ	JJ	_	14	NMOD	_	_
14	chains	_	NNS	NNS	_	6	OBJ	_	_
15	are	_	VBP	VBP	_	2	NMOD	_	_
16	recognized	_	VBN	VBN	_	15	VC	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	primed	_	JJ	JJ	_	19	NMOD	_	_
19	CTL	_	NN	NN	_	17	PMOD	_	_
20	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
21	not	_	RB	RB	_	20	VMOD	_	_
22	been	_	VBN	VBN	_	20	VC	_	_
23	clearly	_	RB	RB	_	22	ADV	_	_
24	defined	_	VBN	VBN	_	22	VC	_	_
25	.	_	.	.	_	20	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	on	_	IN	IN	_	2	ADV	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	CTL	_	NN	NN	_	6	NMOD	_	_
6	recognition	_	NN	NN	_	3	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	12	NMOD	_	_
9	MHC	_	NN	NN	_	10	AMOD	_	_
10	class	_	NN	NN	_	12	NMOD	_	_
11	I-restricted	_	JJ	JJ	_	10	AMOD	_	_
12	peptide	_	NN	NN	_	7	PMOD	_	_
13	containing	_	VBG	VBG	_	12	NMOD	_	_
14	a	_	DT	DT	_	20	NMOD	_	_
15	cyclized	_	JJ	JJ	_	16	NMOD	_	_
16	asparagine	_	NN	NN	_	20	NMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	succinimide	_	NN	NN	_	16	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	residue	_	NN	NN	_	13	OBJ	_	_
21	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	modification	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	asparagine	_	NN	NN	_	7	NMOD	_	_
6	side	_	JJ	JJ	_	7	NMOD	_	_
7	chain	_	NN	NN	_	3	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	common	_	JJ	JJ	_	12	NMOD	_	_
11	intermediate	_	JJ	JJ	_	12	NMOD	_	_
12	structure	_	NN	NN	_	8	PRD	_	_
13	during	_	IN	IN	_	12	TMP	_	_
14	deamidation	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	isomerization	_	NN	NN	_	14	COORD	_	_
17	,	_	,	,	_	14	P	_	_
18	and	_	CC	CC	_	14	CC	_	_
19	bond	_	NN	NN	_	20	NMOD	_	_
20	rearrangements	_	NNS	NNS	_	14	COORD	_	_
21	of	_	IN	IN	_	14	NMOD	_	_
22	amide-containing	_	JJ	JJ	_	24	NMOD	_	_
23	amino	_	NN	NN	_	24	NMOD	_	_
24	acids	_	NNS	NNS	_	21	PMOD	_	_
25	and	_	CC	CC	_	8	CC	_	_
26	also	_	RB	RB	_	8	COORD	_	_
27	occurs	_	VBZ	VBZ	_	8	COORD	_	_
28	as	_	IN	IN	_	27	ADV	_	_
29	a	_	DT	DT	_	31	NMOD	_	_
30	side	_	JJ	JJ	_	31	NMOD	_	_
31	reaction	_	NN	NN	_	28	PMOD	_	_
32	in	_	IN	IN	_	31	NMOD	_	_
33	peptide	_	NN	NN	_	34	NMOD	_	_
34	synthesis	_	NN	NN	_	32	PMOD	_	_
35	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	CTL	_	NN	NN	_	4	SBJ	_	_
3	specifically	_	RB	RB	_	4	ADV	_	_
4	recognized	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	succinimide-containing	_	JJ	JJ	_	7	NMOD	_	_
7	peptide	_	NN	NN	_	4	OBJ	_	_
8	showing	_	VBG	VBG	_	7	NMOD	_	_
9	only	_	RB	RB	_	10	AMOD	_	_
10	weak	_	JJ	JJ	_	11	NMOD	_	_
11	cross-reactivity	_	NN	NN	_	8	OBJ	_	_
12	at	_	IN	IN	_	8	ADV	_	_
13	high	_	JJ	JJ	_	14	NMOD	_	_
14	concentrations	_	NNS	NNS	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	parent	_	NN	NN	_	18	NMOD	_	_
18	peptide	_	NN	NN	_	15	PMOD	_	_
19	containing	_	VBG	VBG	_	18	NMOD	_	_
20	unmodified	_	JJ	JJ	_	21	NMOD	_	_
21	asparagine	_	NN	NN	_	19	OBJ	_	_
22	.	_	.	.	_	4	P	_	_

1	Similarly	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	CTL	_	NN	NN	_	9	SBJ	_	_
4	raised	_	VBN	VBN	_	3	NMOD	_	_
5	against	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	parent	_	NN	NN	_	8	NMOD	_	_
8	peptide	_	NN	NN	_	5	PMOD	_	_
9	did	_	VBD	VBD	_	0	ROOT-S	_	_
10	not	_	RB	RB	_	9	VMOD	_	_
11	recognize	_	VB	VB	_	9	VC	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	succinimide	_	JJ	JJ	_	14	NMOD	_	_
14	derivative	_	NN	NN	_	11	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	this	_	DT	DT	_	17	NMOD	_	_
17	peptide	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	9	P	_	_

1	Naturally	_	RB	RB	_	2	AMOD	_	_
2	processed	_	VBN	VBN	_	3	NMOD	_	_
3	forms	_	NNS	NNS	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	these	_	DT	DT	_	6	NMOD	_	_
6	structures	_	NNS	NNS	_	4	PMOD	_	_
7	are	_	VBP	VBP	_	0	ROOT-S	_	_
8	likely	_	JJ	JJ	_	7	PRD	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	occur	_	VB	VB	_	8	AMOD	_	_
11	given	_	VBN	VBN	_	7	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	importance	_	NN	NN	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	frequency	_	NN	NN	_	13	COORD	_	_
16	of	_	IN	IN	_	13	NMOD	_	_
17	deamidation	_	NN	NN	_	16	PMOD	_	_
18	both	_	CC	CC	_	19	CC	_	_
19	in	_	FW	FW	_	13	NMOD	_	_
20	vitro	_	FW	FW	_	19	AMOD	_	_
21	and	_	CC	CC	_	19	CC	_	_
22	in	_	FW	FW	_	19	COORD	_	_
23	vivo	_	FW	FW	_	22	AMOD	_	_
24	.	_	.	.	_	7	P	_	_

1	Moreover	_	RB	RB	_	17	ADV	_	_
2	,	_	,	,	_	17	P	_	_
3	since	_	IN	IN	_	17	ADV	_	_
4	succinimide	_	NN	NN	_	5	NMOD	_	_
5	intermediates	_	NNS	NNS	_	9	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	deamidated	_	VBN	VBN	_	8	NMOD	_	_
8	peptides	_	NNS	NNS	_	6	PMOD	_	_
9	can	_	MD	MD	_	3	VMOD	_	_
10	occasionally	_	RB	RB	_	9	TMP	_	_
11	be	_	VB	VB	_	9	VC	_	_
12	very	_	RB	RB	_	13	AMOD	_	_
13	stable	_	JJ	JJ	_	11	PRD	_	_
14	,	_	,	,	_	17	P	_	_
15	these	_	DT	DT	_	16	NMOD	_	_
16	peptides	_	NNS	NNS	_	17	SBJ	_	_
17	have	_	VBP	VBP	_	0	ROOT-S	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	potential	_	NN	NN	_	17	OBJ	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	act	_	VB	VB	_	19	NMOD	_	_
22	as	_	IN	IN	_	21	ADV	_	_
23	altered	_	JJ	JJ	_	24	NMOD	_	_
24	self-Ags	_	NNS	NNS	_	22	PMOD	_	_
25	with	_	IN	IN	_	24	NMOD	_	_
26	significant	_	JJ	JJ	_	27	NMOD	_	_
27	implications	_	NNS	NNS	_	25	PMOD	_	_
28	for	_	IN	IN	_	27	NMOD	_	_
29	autoimmunity	_	NN	NN	_	28	PMOD	_	_
30	.	_	.	.	_	17	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	9	P	_	_
4	unwanted	_	JJ	JJ	_	8	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	potentially	_	RB	RB	_	7	AMOD	_	_
7	hazardous	_	JJ	JJ	_	4	COORD	_	_
8	specificities	_	NNS	NNS	_	9	SBJ	_	_
9	may	_	MD	MD	_	0	ROOT-S	_	_
10	be	_	VB	VB	_	9	VC	_	_
11	elicited	_	VBN	VBN	_	10	VC	_	_
12	when	_	WRB	WRB	_	13	ADV	_	_
13	using	_	VBG	VBG	_	11	TMP	_	_
14	synthetic	_	JJ	JJ	_	15	NMOD	_	_
15	peptides	_	NNS	NNS	_	13	OBJ	_	_
16	in	_	IN	IN	_	13	ADV	_	_
17	subunit	_	NN	NN	_	18	NMOD	_	_
18	vaccines	_	NNS	NNS	_	16	PMOD	_	_
19	in	_	IN	IN	_	24	ADV	_	_
20	which	_	WDT	WDT	_	19	PMOD	_	_
21	succinimide	_	NN	NN	_	22	NMOD	_	_
22	residues	_	NNS	NNS	_	23	SBJ	_	_
23	may	_	MD	MD	_	18	NMOD	_	_
24	form	_	VB	VB	_	23	VC	_	_
25	spontaneously	_	RB	RB	_	24	ADV	_	_
26	during	_	IN	IN	_	24	TMP	_	_
27	storage	_	NN	NN	_	26	PMOD	_	_
28	or	_	CC	CC	_	27	CC	_	_
29	chemical	_	JJ	JJ	_	30	NMOD	_	_
30	synthesis	_	NN	NN	_	27	COORD	_	_
31	.	_	.	.	_	9	P	_	_

1	Transgenic	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	PML\/RARalpha	_	NN	NN	_	3	PMOD	_	_
5	impairs	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	myelopoiesis	_	NN	NN	_	5	OBJ	_	_
7	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	translocation	_	NN	NN	_	8	SBJ	_	_
3	found	_	VBN	VBN	_	2	NMOD	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	acute	_	JJ	JJ	_	7	NMOD	_	_
6	promyelocytic	_	JJ	JJ	_	7	NMOD	_	_
7	leukemia	_	NN	NN	_	4	PMOD	_	_
8	rearranges	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	promyelocytic	_	JJ	JJ	_	12	NMOD	_	_
11	leukemia	_	NN	NN	_	12	NMOD	_	_
12	gene	_	NN	NN	_	8	OBJ	_	_
13	(	_	(	(	_	14	P	_	_
14	PML	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	on	_	IN	IN	_	12	NMOD	_	_
17	chromosome	_	NN	NN	_	16	PMOD	_	_
18	15	_	CD	CD	_	17	NMOD	_	_
19	with	_	IN	IN	_	8	ADV	_	_
20	the	_	DT	DT	_	24	NMOD	_	_
21	retinoic	_	JJ	JJ	_	24	NMOD	_	_
22	acid	_	NN	NN	_	24	NMOD	_	_
23	receptor	_	NN	NN	_	24	NMOD	_	_
24	alpha	_	NN	NN	_	19	PMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	RARalpha	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	on	_	IN	IN	_	24	NMOD	_	_
29	chromosome	_	NN	NN	_	28	PMOD	_	_
30	17	_	CD	CD	_	29	NMOD	_	_
31	.	_	.	.	_	8	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	yields	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	fusion	_	NN	NN	_	5	NMOD	_	_
5	transcript	_	NN	NN	_	2	OBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	PML\/RARalpha	_	NN	NN	_	5	NMOD	_	_
8	,	_	,	,	_	5	P	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	transcription	_	NN	NN	_	11	NMOD	_	_
11	factor	_	NN	NN	_	5	NMOD	_	_
12	with	_	IN	IN	_	11	NMOD	_	_
13	reported	_	VBN	VBN	_	16	NMOD	_	_
14	dominant	_	JJ	JJ	_	16	NMOD	_	_
15	negative	_	JJ	JJ	_	16	NMOD	_	_
16	functions	_	NNS	NNS	_	12	PMOD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	17	DEP	_	_
19	absence	_	NN	NN	_	17	DEP	_	_
20	of	_	IN	IN	_	17	DEP	_	_
21	hormone	_	NN	NN	_	17	PMOD	_	_
22	.	_	.	.	_	2	P	_	_

1	Clinical	_	JJ	JJ	_	2	NMOD	_	_
2	remissions	_	NNS	NNS	_	16	SBJ	_	_
3	induced	_	VBN	VBN	_	2	NMOD	_	_
4	with	_	IN	IN	_	3	ADV	_	_
5	all-trans	_	JJ	JJ	_	11	NMOD	_	_
6	retinoic	_	JJ	JJ	_	7	NMOD	_	_
7	acid	_	NN	NN	_	11	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	RA	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	treatment	_	NN	NN	_	4	PMOD	_	_
12	in	_	IN	IN	_	3	ADV	_	_
13	acute	_	JJ	JJ	_	15	NMOD	_	_
14	promyelocytic	_	JJ	JJ	_	15	NMOD	_	_
15	leukemia	_	NN	NN	_	12	PMOD	_	_
16	are	_	VBP	VBP	_	0	ROOT-S	_	_
17	linked	_	VBN	VBN	_	16	VC	_	_
18	to	_	TO	TO	_	17	ADV	_	_
19	PML\/RARalpha	_	NN	NN	_	20	NMOD	_	_
20	expression	_	NN	NN	_	18	PMOD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	leukemic	_	JJ	JJ	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	16	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	evaluate	_	VB	VB	_	13	VC	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	PML\/RARalpha	_	NN	NN	_	5	NMOD	_	_
5	role	_	NN	NN	_	2	OBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	myelopoiesis	_	NN	NN	_	6	PMOD	_	_
8	,	_	,	,	_	13	P	_	_
9	transgenic	_	JJ	JJ	_	10	NMOD	_	_
10	mice	_	NNS	NNS	_	13	SBJ	_	_
11	expressing	_	VBG	VBG	_	10	NMOD	_	_
12	PML\/RARalpha	_	NN	NN	_	11	OBJ	_	_
13	were	_	VBD	VBD	_	0	ROOT-S	_	_
14	engineered	_	VBN	VBN	_	13	VC	_	_
15	.	_	.	.	_	13	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	full-length	_	JJ	JJ	_	4	NMOD	_	_
3	PML\/RARalpha	_	NN	NN	_	4	NMOD	_	_
4	cDNA	_	NN	NN	_	10	SBJ	_	_
5	driven	_	VBN	VBN	_	4	NMOD	_	_
6	by	_	IN	IN	_	5	LGS	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	CD11b	_	NN	NN	_	9	NMOD	_	_
9	promoter	_	NN	NN	_	6	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	expressed	_	VBN	VBN	_	10	VC	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	transgenic	_	JJ	JJ	_	14	NMOD	_	_
14	mice	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	10	P	_	_

1	Expression	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	confirmed	_	VBN	VBN	_	2	VC	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	bone	_	NN	NN	_	7	NMOD	_	_
7	marrow	_	NN	NN	_	4	PMOD	_	_
8	with	_	IN	IN	_	3	ADV	_	_
9	a	_	DT	DT	_	13	NMOD	_	_
10	reverse	_	JJ	JJ	_	13	NMOD	_	_
11	transcription	_	NN	NN	_	13	NMOD	_	_
12	PCR	_	NN	NN	_	13	NMOD	_	_
13	assay	_	NN	NN	_	8	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	Basal	_	JJ	JJ	_	8	NMOD	_	_
2	total	_	JJ	JJ	_	8	NMOD	_	_
3	white	_	JJ	JJ	_	5	NMOD	_	_
4	blood	_	NN	NN	_	5	NMOD	_	_
5	cell	_	NN	NN	_	8	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	granulocyte	_	NN	NN	_	5	COORD	_	_
8	counts	_	NNS	NNS	_	9	SBJ	_	_
9	did	_	VBD	VBD	_	0	ROOT-S	_	_
10	not	_	RB	RB	_	9	VMOD	_	_
11	appreciably	_	RB	RB	_	9	ADV	_	_
12	differ	_	VB	VB	_	9	VC	_	_
13	between	_	IN	IN	_	12	ADV	_	_
14	PML\/RARalpha	_	NN	NN	_	18	NMOD	_	_
15	transgenic	_	JJ	JJ	_	14	AMOD	_	_
16	and	_	CC	CC	_	14	CC	_	_
17	control	_	NN	NN	_	14	COORD	_	_
18	mice	_	NNS	NNS	_	13	PMOD	_	_
19	.	_	.	.	_	9	P	_	_

1	Cell	_	NN	NN	_	3	NMOD	_	_
2	sorter	_	NN	NN	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	CD11b+	_	JJ	JJ	_	8	NMOD	_	_
6	bone	_	NN	NN	_	8	NMOD	_	_
7	marrow	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	4	PMOD	_	_
9	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
10	similar	_	JJ	JJ	_	12	NMOD	_	_
11	CD11b+	_	JJ	JJ	_	12	NMOD	_	_
12	populations	_	NNS	NNS	_	9	OBJ	_	_
13	in	_	IN	IN	_	9	ADV	_	_
14	transgenic	_	JJ	JJ	_	17	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	control	_	NN	NN	_	14	COORD	_	_
17	mice	_	NNS	NNS	_	13	PMOD	_	_
18	.	_	.	.	_	9	P	_	_

1	However	_	RB	RB	_	17	ADV	_	_
2	,	_	,	,	_	17	P	_	_
3	in	_	FW	FW	_	4	AMOD	_	_
4	vitro	_	FW	FW	_	7	NMOD	_	_
5	clonal	_	JJ	JJ	_	7	NMOD	_	_
6	growth	_	NN	NN	_	7	NMOD	_	_
7	assays	_	NNS	NNS	_	17	SBJ	_	_
8	performed	_	VBN	VBN	_	7	NMOD	_	_
9	on	_	IN	IN	_	8	ADV	_	_
10	peripheral	_	JJ	JJ	_	11	NMOD	_	_
11	blood	_	NN	NN	_	9	PMOD	_	_
12	from	_	IN	IN	_	11	NMOD	_	_
13	transgenic	_	JJ	JJ	_	16	NMOD	_	_
14	versus	_	CC	CC	_	13	CC	_	_
15	control	_	NN	NN	_	13	COORD	_	_
16	mice	_	NNS	NNS	_	12	PMOD	_	_
17	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	marked	_	JJ	JJ	_	20	NMOD	_	_
20	reduction	_	NN	NN	_	17	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	myeloid	_	JJ	JJ	_	23	NMOD	_	_
23	progenitors	_	NNS	NNS	_	21	PMOD	_	_
24	,	_	,	,	_	20	P	_	_
25	especially	_	RB	RB	_	26	DEP	_	_
26	in	_	IN	IN	_	20	NMOD	_	_
27	those	_	DT	DT	_	26	PMOD	_	_
28	responding	_	VBG	VBG	_	27	NMOD	_	_
29	to	_	TO	TO	_	28	ADV	_	_
30	granulocyte\/	_	NN	NN	_	33	NMOD	_	_
31	macrophage	_	NN	NN	_	33	NMOD	_	_
32	colony-stimulating	_	JJ	JJ	_	33	NMOD	_	_
33	factor	_	NN	NN	_	29	PMOD	_	_
34	.	_	.	.	_	17	P	_	_

1	Granulocyte\/macrophage	_	NN	NN	_	3	NMOD	_	_
2	colony-stimulating	_	JJ	JJ	_	3	NMOD	_	_
3	factor	_	NN	NN	_	8	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	kit	_	NN	NN	_	7	NMOD	_	_
6	ligand	_	NN	NN	_	7	NMOD	_	_
7	cotreatment	_	NN	NN	_	3	COORD	_	_
8	did	_	VBD	VBD	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	overcome	_	VB	VB	_	8	VC	_	_
11	this	_	DT	DT	_	12	NMOD	_	_
12	inhibition	_	NN	NN	_	10	OBJ	_	_
13	.	_	.	.	_	8	P	_	_

1	Impaired	_	JJ	JJ	_	2	NMOD	_	_
2	myelopoiesis	_	NN	NN	_	5	SBJ	_	_
3	in	_	FW	FW	_	2	NMOD	_	_
4	vivo	_	FW	FW	_	3	AMOD	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	shown	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	ADV	_	_
8	stressing	_	VBG	VBG	_	7	PMOD	_	_
9	these	_	DT	DT	_	10	NMOD	_	_
10	mice	_	NNS	NNS	_	8	OBJ	_	_
11	with	_	IN	IN	_	8	ADV	_	_
12	sublethal	_	JJ	JJ	_	13	NMOD	_	_
13	irradiation	_	NN	NN	_	11	PMOD	_	_
14	.	_	.	.	_	5	P	_	_

1	Following	_	VBG	VBG	_	15	TMP	_	_
2	irradiation	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	15	P	_	_
4	PML\/RARalpha	_	NN	NN	_	6	NMOD	_	_
5	transgenic	_	JJ	JJ	_	4	AMOD	_	_
6	mice	_	NNS	NNS	_	15	SBJ	_	_
7	,	_	,	,	_	15	P	_	_
8	as	_	IN	IN	_	15	ADV	_	_
9	compared	_	VBN	VBN	_	8	VMOD	_	_
10	with	_	IN	IN	_	9	ADV	_	_
11	controls	_	NNS	NNS	_	10	PMOD	_	_
12	,	_	,	,	_	15	P	_	_
13	more	_	RBR	RBR	_	14	AMOD	_	_
14	rapidly	_	RB	RB	_	15	TMP	_	_
15	depressed	_	VBD	VBD	_	0	ROOT-S	_	_
16	peripheral	_	JJ	JJ	_	19	NMOD	_	_
17	white	_	JJ	JJ	_	19	NMOD	_	_
18	blood	_	NN	NN	_	19	NMOD	_	_
19	cell	_	NN	NN	_	22	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	granulocyte	_	NN	NN	_	19	COORD	_	_
22	counts	_	NNS	NNS	_	15	OBJ	_	_
23	.	_	.	.	_	15	P	_	_

1	As	_	IN	IN	_	12	ADV	_	_
2	expected	_	VBN	VBN	_	1	VMOD	_	_
3	,	_	,	,	_	12	P	_	_
4	nearly	_	RB	RB	_	7	NMOD	_	_
5	all	_	DT	DT	_	4	DEP	_	_
6	control	_	NN	NN	_	7	NMOD	_	_
7	mice	_	NNS	NNS	_	12	SBJ	_	_
8	(	_	(	(	_	10	P	_	_
9	94.4	_	CD	CD	_	10	NMOD	_	_
10	%	_	NN	NN	_	7	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	survived	_	VBD	VBD	_	0	ROOT-S	_	_
13	irradiation	_	NN	NN	_	12	OBJ	_	_
14	,	_	,	,	_	12	P	_	_
15	yet	_	CC	CC	_	12	CC	_	_
16	this	_	DT	DT	_	17	NMOD	_	_
17	irradiation	_	NN	NN	_	18	SBJ	_	_
18	was	_	VBD	VBD	_	12	COORD	_	_
19	lethal	_	JJ	JJ	_	18	PRD	_	_
20	to	_	TO	TO	_	19	AMOD	_	_
21	45.8	_	CD	CD	_	22	NMOD	_	_
22	%	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	PML\/RARalpha	_	NN	NN	_	26	NMOD	_	_
25	transgenic	_	JJ	JJ	_	24	AMOD	_	_
26	mice	_	NNS	NNS	_	23	PMOD	_	_
27	.	_	.	.	_	12	P	_	_

1	Lethality	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	associated	_	VBN	VBN	_	2	VC	_	_
4	with	_	IN	IN	_	3	ADV	_	_
5	more	_	RBR	RBR	_	6	AMOD	_	_
6	severe	_	JJ	JJ	_	7	NMOD	_	_
7	leukopenia	_	NN	NN	_	4	PMOD	_	_
8	in	_	IN	IN	_	3	ADV	_	_
9	transgenic	_	JJ	JJ	_	12	NMOD	_	_
10	versus	_	CC	CC	_	9	CC	_	_
11	control	_	NN	NN	_	9	COORD	_	_
12	mice	_	NNS	NNS	_	8	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	Retinoic	_	JJ	JJ	_	3	NMOD	_	_
2	acid	_	NN	NN	_	3	NMOD	_	_
3	treatment	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	irradiated	_	JJ	JJ	_	7	NMOD	_	_
6	PML\/RARalpha	_	NN	NN	_	7	NMOD	_	_
7	mice	_	NNS	NNS	_	4	PMOD	_	_
8	enhanced	_	VBD	VBD	_	0	ROOT-S	_	_
9	granulocyte	_	NN	NN	_	10	NMOD	_	_
10	recovery	_	NN	NN	_	8	OBJ	_	_
11	.	_	.	.	_	8	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	abnormal	_	JJ	JJ	_	6	NMOD	_	_
6	myelopoiesis	_	NN	NN	_	11	SBJ	_	_
7	due	_	IN	IN	_	6	NMOD	_	_
8	to	_	TO	TO	_	7	DEP	_	_
9	PML\/RARalpha	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	7	PMOD	_	_
11	is	_	VBZ	VBZ	_	4	VMOD	_	_
12	an	_	DT	DT	_	14	NMOD	_	_
13	early	_	JJ	JJ	_	14	NMOD	_	_
14	event	_	NN	NN	_	11	PRD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	oncogenic	_	JJ	JJ	_	17	NMOD	_	_
17	transformation	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	3	P	_	_

1	Characterization	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	new	_	JJ	JJ	_	5	NMOD	_	_
5	isoform	_	NN	NN	_	20	NMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	19	NMOD	_	_
8	NFAT	_	NN	NN	_	19	NMOD	_	_
9	(	_	(	(	_	11	P	_	_
10	nuclear	_	JJ	JJ	_	11	NMOD	_	_
11	factor	_	NN	NN	_	8	PRN	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	activated	_	VBN	VBN	_	15	NMOD	_	_
14	T	_	NN	NN	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	12	PMOD	_	_
16	)	_	)	)	_	11	P	_	_
17	gene	_	NN	NN	_	19	NMOD	_	_
18	family	_	NN	NN	_	19	NMOD	_	_
19	member	_	NN	NN	_	6	PMOD	_	_
20	NFATc	_	NN	NN	_	2	PMOD	_	_
21	{	_	(	(	_	24	P	_	_
22	published	_	VBN	VBN	_	23	NMOD	_	_
23	erratum	_	NN	NN	_	24	SBJ	_	_
24	appears	_	VBZ	VBZ	_	1	PRN	_	_
25	in	_	IN	IN	_	24	ADV	_	_
26	J	_	NNP	NNP	_	28	NMOD	_	_
27	Biol	_	NNP	NNP	_	28	NMOD	_	_
28	Chem	_	NNP	NNP	_	25	PMOD	_	_
29	1996	_	CD	CD	_	30	NMOD	_	_
30	Dec	_	NNP	NNP	_	28	TMP	_	_
31	27	_	CD	CD	_	30	NMOD	_	_
32	;	_	:	:	_	28	P	_	_
33	271	_	CD	CD	_	35	NMOD	_	_
34	(	_	(	(	_	35	P	_	_
35	52	_	CD	CD	_	28	NMOD	_	_
36	)	_	)	)	_	35	P	_	_
37	:	_	:	:	_	28	P	_	_
38	33705	_	CD	CD	_	28	NMOD	_	_
39	}	_	)	)	_	24	P	_	_

1	The	_	DT	DT	_	9	NMOD	_	_
2	cyclosporin	_	NN	NN	_	5	AMOD	_	_
3	A	_	NN	NN	_	5	AMOD	_	_
4	(	_	(	(	_	5	P	_	_
5	CsA	_	NN	NN	_	9	NMOD	_	_
6	)	_	)	)	_	5	P	_	_
7	\/FK506-sensitive	_	JJ	JJ	_	5	AMOD	_	_
8	nuclear	_	JJ	JJ	_	9	NMOD	_	_
9	factor	_	NN	NN	_	17	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	activated	_	VBN	VBN	_	13	NMOD	_	_
12	T	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	10	PMOD	_	_
14	(	_	(	(	_	15	P	_	_
15	NFAT	_	NN	NN	_	9	PRN	_	_
16	)	_	)	)	_	15	P	_	_
17	plays	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	key	_	JJ	JJ	_	20	NMOD	_	_
20	role	_	NN	NN	_	17	OBJ	_	_
21	in	_	IN	IN	_	17	ADV	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	inducible	_	JJ	JJ	_	24	NMOD	_	_
24	expression	_	NN	NN	_	21	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	cytokine	_	NN	NN	_	27	NMOD	_	_
27	genes	_	NNS	NNS	_	25	PMOD	_	_
28	in	_	IN	IN	_	24	NMOD	_	_
29	T	_	NN	NN	_	30	NMOD	_	_
30	cells	_	NNS	NNS	_	28	PMOD	_	_
31	.	_	.	.	_	17	P	_	_

1	Although	_	IN	IN	_	24	ADV	_	_
2	NFAT	_	NN	NN	_	3	SBJ	_	_
3	has	_	VBZ	VBZ	_	1	VMOD	_	_
4	been	_	VBN	VBN	_	3	VC	_	_
5	recently	_	RB	RB	_	4	TMP	_	_
6	shown	_	VBN	VBN	_	4	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	be	_	VB	VB	_	6	OBJ	_	_
9	inducible	_	JJ	JJ	_	8	PRD	_	_
10	in	_	IN	IN	_	8	ADV	_	_
11	several	_	JJ	JJ	_	14	NMOD	_	_
12	non-T	_	JJ	JJ	_	13	AMOD	_	_
13	immune	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	10	PMOD	_	_
15	,	_	,	,	_	24	P	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	NFAT	_	NN	NN	_	20	NMOD	_	_
18	gene	_	NN	NN	_	20	NMOD	_	_
19	family	_	NN	NN	_	20	NMOD	_	_
20	members	_	NNS	NNS	_	24	SBJ	_	_
21	characterized	_	VBN	VBN	_	20	NMOD	_	_
22	to	_	TO	TO	_	21	TMP	_	_
23	date	_	NN	NN	_	22	PMOD	_	_
24	have	_	VBP	VBP	_	0	ROOT-S	_	_
25	been	_	VBN	VBN	_	24	VC	_	_
26	isolated	_	VBN	VBN	_	25	VC	_	_
27	only	_	RB	RB	_	28	DEP	_	_
28	from	_	IN	IN	_	26	ADV	_	_
29	T	_	NN	NN	_	30	NMOD	_	_
30	cells	_	NNS	NNS	_	28	PMOD	_	_
31	.	_	.	.	_	24	P	_	_

1	To	_	TO	TO	_	3	VMOD	_	_
2	further	_	RBR	RBR	_	3	ADV	_	_
3	characterize	_	VB	VB	_	21	VMOD	_	_
4	NFAT	_	NN	NN	_	5	NMOD	_	_
5	function	_	NN	NN	_	3	OBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	human	_	JJ	JJ	_	9	NMOD	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	6	PMOD	_	_
10	and	_	CC	CC	_	3	CC	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	demonstrate	_	VB	VB	_	3	COORD	_	_
13	cytokine	_	NN	NN	_	15	NMOD	_	_
14	gene	_	NN	NN	_	15	NMOD	_	_
15	specificity	_	NN	NN	_	12	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	NFAT	_	NN	NN	_	18	NMOD	_	_
18	proteins	_	NNS	NNS	_	16	PMOD	_	_
19	,	_	,	,	_	21	P	_	_
20	we	_	PRP	PRP	_	21	SBJ	_	_
21	report	_	VBP	VBP	_	0	ROOT-S	_	_
22	here	_	RB	RB	_	21	ADV	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	isolation	_	NN	NN	_	21	OBJ	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	characterization	_	NN	NN	_	24	COORD	_	_
27	of	_	IN	IN	_	24	NMOD	_	_
28	a	_	DT	DT	_	30	NMOD	_	_
29	cDNA	_	NN	NN	_	30	NMOD	_	_
30	clone	_	NN	NN	_	27	PMOD	_	_
31	from	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	36	NMOD	_	_
33	Raji	_	NN	NN	_	36	NMOD	_	_
34	B	_	NN	NN	_	36	NMOD	_	_
35	cell	_	NN	NN	_	36	NMOD	_	_
36	line	_	NN	NN	_	31	PMOD	_	_
37	.	_	.	.	_	21	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	cDNA	_	NN	NN	_	3	NMOD	_	_
3	clone	_	NN	NN	_	4	SBJ	_	_
4	encodes	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	new	_	JJ	JJ	_	7	NMOD	_	_
7	isoform	_	NN	NN	_	4	OBJ	_	_
8	,	_	,	,	_	7	P	_	_
9	NFATc.beta	_	NN	NN	_	7	NMOD	_	_
10	,	_	,	,	_	7	P	_	_
11	of	_	IN	IN	_	7	NMOD	_	_
12	the	_	DT	DT	_	17	NMOD	_	_
13	NFAT	_	NN	NN	_	17	NMOD	_	_
14	gene	_	NN	NN	_	17	NMOD	_	_
15	family	_	NN	NN	_	17	NMOD	_	_
16	member	_	NN	NN	_	17	NMOD	_	_
17	NFATc	_	NN	NN	_	11	PMOD	_	_
18	(	_	(	(	_	17	P	_	_
19	designated	_	VBN	VBN	_	17	NMOD	_	_
20	here	_	RB	RB	_	19	ADV	_	_
21	NFATc.alpha	_	NN	NN	_	19	OBJ	_	_
22	)	_	)	)	_	17	P	_	_
23	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	amino	_	NN	NN	_	4	NMOD	_	_
3	acid	_	NN	NN	_	4	NMOD	_	_
4	sequence	_	NN	NN	_	7	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	NFATc.beta	_	NN	NN	_	5	PMOD	_	_
7	differs	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	from	_	IN	IN	_	7	ADV	_	_
9	that	_	DT	DT	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	NFATc.alpha	_	NN	NN	_	10	PMOD	_	_
12	in	_	IN	IN	_	9	NMOD	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	first	_	JJ	JJ	_	17	NMOD	_	_
15	NH2-terminal	_	JJ	JJ	_	17	NMOD	_	_
16	29	_	CD	CD	_	17	NMOD	_	_
17	residues	_	NNS	NNS	_	12	PMOD	_	_
18	and	_	CC	CC	_	7	CC	_	_
19	contains	_	VBZ	VBZ	_	7	COORD	_	_
20	an	_	DT	DT	_	22	NMOD	_	_
21	additional	_	JJ	JJ	_	22	NMOD	_	_
22	region	_	NN	NN	_	19	OBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	142	_	CD	CD	_	25	NMOD	_	_
25	residues	_	NNS	NNS	_	23	PMOD	_	_
26	at	_	IN	IN	_	19	ADV	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	COOH	_	NN	NN	_	29	NMOD	_	_
29	terminus	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	7	P	_	_

1	Northern	_	NN	NN	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	13	SBJ	_	_
3	using	_	VBG	VBG	_	2	NMOD	_	_
4	a	_	VBG	VBG	_	5	NMOD	_	_
5	probe	_	NN	NN	_	3	OBJ	_	_
6	encompassing	_	VBG	VBG	_	5	NMOD	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	common	_	JJ	JJ	_	9	NMOD	_	_
9	region	_	NN	NN	_	6	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	both	_	DT	DT	_	12	NMOD	_	_
12	isoforms	_	NNS	NNS	_	10	PMOD	_	_
13	showed	_	VBD	VBD	_	0	ROOT-S	_	_
14	two	_	CD	CD	_	16	NMOD	_	_
15	mRNA	_	NN	NN	_	16	NMOD	_	_
16	species	_	NNS	NNS	_	13	IOBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	2.7	_	CD	CD	_	22	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	4.5	_	CD	CD	_	18	COORD	_	_
21	kilobase	_	NN	NN	_	18	AMOD	_	_
22	pairs	_	NNS	NNS	_	17	PMOD	_	_
23	,	_	,	,	_	13	P	_	_
24	while	_	IN	IN	_	13	OBJ	_	_
25	an	_	DT	DT	_	27	NMOD	_	_
26	NFATc.beta-specific	_	JJ	JJ	_	27	NMOD	_	_
27	probe	_	NN	NN	_	28	SBJ	_	_
28	detected	_	VBD	VBD	_	24	VMOD	_	_
29	only	_	RB	RB	_	33	NMOD	_	_
30	the	_	DT	DT	_	33	NMOD	_	_
31	4.5-kilobase	_	NN	NN	_	33	NMOD	_	_
32	pair	_	NN	NN	_	33	NMOD	_	_
33	mRNA	_	NN	NN	_	28	OBJ	_	_
34	which	_	WDT	WDT	_	35	SBJ	_	_
35	was	_	VBD	VBD	_	33	NMOD	_	_
36	preferentially	_	RB	RB	_	35	ADV	_	_
37	expressed	_	VBN	VBN	_	35	VC	_	_
38	in	_	IN	IN	_	37	ADV	_	_
39	the	_	DT	DT	_	40	NMOD	_	_
40	spleen	_	NN	NN	_	38	PMOD	_	_
41	.	_	.	.	_	13	P	_	_

1	Transient	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	NFATc.beta	_	NN	NN	_	3	PMOD	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	capable	_	JJ	JJ	_	5	PRD	_	_
7	of	_	IN	IN	_	6	AMOD	_	_
8	activating	_	VBG	VBG	_	7	PMOD	_	_
9	an	_	DT	DT	_	13	NMOD	_	_
10	interleukin-2	_	NN	NN	_	13	NMOD	_	_
11	NFAT-driven	_	JJ	JJ	_	13	NMOD	_	_
12	reporter	_	NN	NN	_	13	NMOD	_	_
13	gene	_	NN	NN	_	8	OBJ	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	stimulated	_	VBN	VBN	_	17	NMOD	_	_
16	Jurkat	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	14	PMOD	_	_
18	in	_	IN	IN	_	8	ADV	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	CsA-sensitive	_	JJ	JJ	_	21	NMOD	_	_
21	manner	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	5	P	_	_

1	However	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	NFATc.beta	_	NN	NN	_	5	SBJ	_	_
4	neither	_	CC	CC	_	5	CC	_	_
5	bound	_	VBD	VBD	_	0	ROOT-S	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	kappa3	_	NN	NN	_	9	NMOD	_	_
9	element	_	NN	NN	_	6	PMOD	_	_
10	(	_	(	(	_	13	P	_	_
11	an	_	DT	DT	_	13	NMOD	_	_
12	NFAT-binding	_	JJ	JJ	_	13	NMOD	_	_
13	site	_	NN	NN	_	9	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	in	_	IN	IN	_	9	NMOD	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	tumor	_	NN	NN	_	20	NMOD	_	_
18	necrosis	_	NN	NN	_	20	NMOD	_	_
19	factor-alpha	_	NN	NN	_	20	NMOD	_	_
20	promoter	_	NN	NN	_	15	PMOD	_	_
21	nor	_	CC	CC	_	5	CC	_	_
22	activated	_	VBD	VBD	_	5	COORD	_	_
23	the	_	DT	DT	_	27	NMOD	_	_
24	tumor	_	NN	NN	_	27	NMOD	_	_
25	necrosis	_	NN	NN	_	27	NMOD	_	_
26	factor-alpha	_	NN	NN	_	27	NMOD	_	_
27	promoter	_	NN	NN	_	22	OBJ	_	_
28	in	_	IN	IN	_	5	ADV	_	_
29	cotransfection	_	NN	NN	_	30	NMOD	_	_
30	assays	_	NN	NN	_	28	PMOD	_	_
31	.	_	.	.	_	5	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	different	_	JJ	JJ	_	6	NMOD	_	_
6	members	_	NNS	NNS	_	13	SBJ	_	_
7	or	_	CC	CC	_	6	CC	_	_
8	isoforms	_	NNS	NNS	_	6	COORD	_	_
9	of	_	IN	IN	_	6	NMOD	_	_
10	NFAT	_	NN	NN	_	12	NMOD	_	_
11	gene	_	NN	NN	_	12	NMOD	_	_
12	family	_	NN	NN	_	9	PMOD	_	_
13	may	_	MD	MD	_	4	VMOD	_	_
14	regulate	_	VB	VB	_	13	VC	_	_
15	inducible	_	JJ	JJ	_	16	NMOD	_	_
16	expression	_	NN	NN	_	14	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	different	_	JJ	JJ	_	20	NMOD	_	_
19	cytokine	_	NN	NN	_	20	NMOD	_	_
20	genes	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	Sequence-specific	_	JJ	JJ	_	3	NMOD	_	_
2	DNA	_	NN	NN	_	3	NMOD	_	_
3	binding	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	B-cell-specific	_	JJ	JJ	_	8	NMOD	_	_
7	coactivator	_	NN	NN	_	8	NMOD	_	_
8	OCA-B	_	NN	NN	_	4	PMOD	_	_
9	.	_	.	.	_	3	P	_	_

1	B-cell-specific	_	JJ	JJ	_	2	NMOD	_	_
2	transcription	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	immunoglobulin	_	NN	NN	_	5	NMOD	_	_
5	genes	_	NNS	NNS	_	3	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	mediated	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	interaction	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	POU	_	NN	NN	_	14	NMOD	_	_
14	domain	_	NN	NN	_	11	PMOD	_	_
15	containing	_	VBG	VBG	_	14	NMOD	_	_
16	transcription	_	NN	NN	_	17	NMOD	_	_
17	factor	_	NN	NN	_	15	OBJ	_	_
18	Oct-1	_	NN	NN	_	17	NMOD	_	_
19	or	_	CC	CC	_	18	CC	_	_
20	Oct-2	_	NN	NN	_	18	COORD	_	_
21	,	_	,	,	_	10	P	_	_
22	with	_	IN	IN	_	10	NMOD	_	_
23	the	_	DT	DT	_	26	NMOD	_	_
24	B-cell-specific	_	JJ	JJ	_	26	NMOD	_	_
25	coactivator	_	NN	NN	_	26	NMOD	_	_
26	OCA-B	_	NN	NN	_	22	PMOD	_	_
27	(	_	(	(	_	28	P	_	_
28	Bob-1	_	NN	NN	_	26	PRN	_	_
29	,	_	,	,	_	28	P	_	_
30	OBF-1	_	NN	NN	_	28	NMOD	_	_
31	)	_	)	)	_	28	P	_	_
32	and	_	CC	CC	_	26	CC	_	_
33	a	_	DT	DT	_	36	NMOD	_	_
34	prototype	_	NN	NN	_	36	NMOD	_	_
35	octamer	_	NN	NN	_	36	NMOD	_	_
36	element	_	NN	NN	_	26	COORD	_	_
37	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	find	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	OCA-B	_	NN	NN	_	5	SBJ	_	_
5	binds	_	VBZ	VBZ	_	3	VMOD	_	_
6	DNA	_	NN	NN	_	5	IOBJ	_	_
7	directly	_	RB	RB	_	5	ADV	_	_
8	in	_	IN	IN	_	5	ADV	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	major	_	JJ	JJ	_	11	NMOD	_	_
11	groove	_	NN	NN	_	8	PMOD	_	_
12	between	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	two	_	CD	CD	_	15	NMOD	_	_
15	subdomains	_	NNS	NNS	_	12	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	POU	_	NN	NN	_	19	NMOD	_	_
19	domain	_	NN	NN	_	16	PMOD	_	_
20	,	_	,	,	_	5	P	_	_
21	requiring	_	VBG	VBG	_	5	OBJ	_	_
22	both	_	CC	CC	_	24	CC	_	_
23	an	_	DT	DT	_	24	NMOD	_	_
24	A	_	NN	NN	_	21	OBJ	_	_
25	at	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	fifth	_	JJ	JJ	_	28	NMOD	_	_
28	position	_	NN	NN	_	25	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	octamer	_	NN	NN	_	32	NMOD	_	_
32	element	_	NN	NN	_	29	PMOD	_	_
33	and	_	CC	CC	_	24	CC	_	_
34	contact	_	NN	NN	_	24	COORD	_	_
35	with	_	IN	IN	_	34	NMOD	_	_
36	the	_	DT	DT	_	38	NMOD	_	_
37	POU	_	NN	NN	_	38	NMOD	_	_
38	domain	_	NN	NN	_	35	PMOD	_	_
39	.	_	.	.	_	2	P	_	_

1	An	_	DT	DT	_	3	NMOD	_	_
2	amino-terminal	_	JJ	JJ	_	3	NMOD	_	_
3	fragment	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	OCA-B	_	NN	NN	_	4	PMOD	_	_
6	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	octamer	_	NN	NN	_	9	NMOD	_	_
9	site	_	NN	NN	_	6	OBJ	_	_
10	in	_	IN	IN	_	6	ADV	_	_
11	the	_	DT	DT	_	10	DEP	_	_
12	absence	_	NN	NN	_	10	DEP	_	_
13	of	_	IN	IN	_	10	DEP	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	POU	_	NN	NN	_	16	NMOD	_	_
16	domain	_	NN	NN	_	10	PMOD	_	_
17	with	_	IN	IN	_	6	ADV	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	same	_	JJ	JJ	_	21	NMOD	_	_
20	sequence	_	NN	NN	_	21	NMOD	_	_
21	specificity	_	NN	NN	_	17	PMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	Coactivator	_	NN	NN	_	2	NMOD	_	_
2	OCA-B	_	NN	NN	_	3	SBJ	_	_
3	may	_	MD	MD	_	0	ROOT-S	_	_
4	undergo	_	VB	VB	_	3	VC	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	POU-dependent	_	JJ	JJ	_	8	NMOD	_	_
7	conformational	_	JJ	JJ	_	8	NMOD	_	_
8	change	_	NN	NN	_	4	IOBJ	_	_
9	that	_	WDT	WDT	_	10	SBJ	_	_
10	exposes	_	VBZ	VBZ	_	8	NMOD	_	_
11	its	_	PRP$	PRP$	_	13	NMOD	_	_
12	amino	_	NN	NN	_	13	NMOD	_	_
13	terminus	_	NN	NN	_	10	OBJ	_	_
14	,	_	,	,	_	4	P	_	_
15	allowing	_	VBG	VBG	_	4	OBJ	_	_
16	it	_	PRP	PRP	_	18	SBJ	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	recognize	_	VB	VB	_	15	OBJ	_	_
19	specific	_	JJ	JJ	_	21	NMOD	_	_
20	DNA	_	NN	NN	_	21	NMOD	_	_
21	sequences	_	NNS	NNS	_	18	OBJ	_	_
22	in	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	major	_	JJ	JJ	_	25	NMOD	_	_
25	groove	_	NN	NN	_	22	PMOD	_	_
26	within	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	binding	_	VBG	VBG	_	29	NMOD	_	_
29	site	_	NN	NN	_	26	PMOD	_	_
30	for	_	IN	IN	_	29	NMOD	_	_
31	Oct-1	_	NN	NN	_	30	PMOD	_	_
32	or	_	CC	CC	_	31	CC	_	_
33	Oct-2	_	NN	NN	_	31	COORD	_	_
34	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	recognition	_	NN	NN	_	14	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	both	_	CC	CC	_	7	CC	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	POU	_	NN	NN	_	7	NMOD	_	_
7	domain	_	NN	NN	_	3	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	octamer	_	NN	NN	_	11	NMOD	_	_
11	sequence	_	NN	NN	_	7	COORD	_	_
12	by	_	IN	IN	_	2	NMOD	_	_
13	OCA-B	_	NN	NN	_	12	PMOD	_	_
14	provides	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	mechanism	_	NN	NN	_	14	OBJ	_	_
17	for	_	IN	IN	_	16	NMOD	_	_
18	differential	_	JJ	JJ	_	19	NMOD	_	_
19	regulation	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	octamer	_	NN	NN	_	22	NMOD	_	_
22	sites	_	NNS	NNS	_	20	PMOD	_	_
23	containing	_	VBG	VBG	_	22	NMOD	_	_
24	genes	_	NNS	NNS	_	23	OBJ	_	_
25	by	_	IN	IN	_	19	NMOD	_	_
26	the	_	DT	DT	_	29	NMOD	_	_
27	ubiquitous	_	JJ	JJ	_	29	NMOD	_	_
28	factor	_	NN	NN	_	29	NMOD	_	_
29	Oct-1	_	NN	NN	_	25	PMOD	_	_
30	.	_	.	.	_	14	P	_	_

1	Cross	_	NN	NN	_	2	NMOD	_	_
2	talk	_	NN	NN	_	0	ROOT-FRAG	_	_
3	between	_	IN	IN	_	2	NMOD	_	_
4	cell	_	NN	NN	_	5	NMOD	_	_
5	death	_	NN	NN	_	3	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	cell	_	NN	NN	_	9	NMOD	_	_
8	cycle	_	NN	NN	_	9	NMOD	_	_
9	progression	_	NN	NN	_	5	COORD	_	_
10	:	_	:	:	_	2	P	_	_
11	BCL-2	_	NN	NN	_	12	SBJ	_	_
12	regulates	_	VBZ	VBZ	_	2	NMOD	_	_
13	NFAT-mediated	_	JJ	JJ	_	14	NMOD	_	_
14	activation	_	NN	NN	_	12	OBJ	_	_
15	.	_	.	.	_	12	P	_	_

1	BCL-2-deficient	_	JJ	JJ	_	3	NMOD	_	_
2	T	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	4	SBJ	_	_
4	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
5	accelerated	_	VBN	VBN	_	8	NMOD	_	_
6	cell	_	NN	NN	_	8	NMOD	_	_
7	cycle	_	NN	NN	_	8	NMOD	_	_
8	progression	_	NN	NN	_	4	OBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	increased	_	VBN	VBN	_	11	NMOD	_	_
11	apoptosis	_	NN	NN	_	8	COORD	_	_
12	following	_	VBG	VBG	_	11	TMP	_	_
13	activation	_	NN	NN	_	12	PMOD	_	_
14	.	_	.	.	_	4	P	_	_

1	Increasing	_	VBG	VBG	_	6	SBJ	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	levels	_	NNS	NNS	_	1	OBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	BCL-2	_	NN	NN	_	4	PMOD	_	_
6	retarded	_	VBD	VBD	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	11	NMOD	_	_
8	G0	_	NN	NN	_	10	AMOD	_	_
9	--&gt;	_	TO	TO	_	10	AMOD	_	_
10	S	_	NN	NN	_	11	NMOD	_	_
11	transition	_	NN	NN	_	6	OBJ	_	_
12	,	_	,	,	_	6	P	_	_
13	sustained	_	VBD	VBD	_	6	COORD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	levels	_	NNS	NNS	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	cyclin-dependent	_	JJ	JJ	_	20	NMOD	_	_
18	kinase	_	NN	NN	_	20	NMOD	_	_
19	inhibitor	_	NN	NN	_	20	NMOD	_	_
20	p27Kip1	_	NN	NN	_	16	PMOD	_	_
21	,	_	,	,	_	6	P	_	_
22	and	_	CC	CC	_	6	CC	_	_
23	repressed	_	VBD	VBD	_	6	COORD	_	_
24	postactivation	_	NN	NN	_	25	NMOD	_	_
25	death	_	NN	NN	_	23	OBJ	_	_
26	.	_	.	.	_	6	P	_	_

1	Proximal	_	JJ	JJ	_	4	NMOD	_	_
2	signal	_	NN	NN	_	4	NMOD	_	_
3	transduction	_	NN	NN	_	4	NMOD	_	_
4	events	_	NNS	NNS	_	10	SBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	immediate	_	JJ	JJ	_	9	NMOD	_	_
7	early	_	JJ	JJ	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	transcription	_	NN	NN	_	4	COORD	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	unaffected	_	JJ	JJ	_	10	PRD	_	_
12	.	_	.	.	_	10	P	_	_

1	However	_	RB	RB	_	15	ADV	_	_
2	,	_	,	,	_	15	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	transcription	_	NN	NN	_	15	SBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	synthesis	_	NN	NN	_	4	COORD	_	_
7	of	_	IN	IN	_	4	NMOD	_	_
8	interleukin	_	NN	NN	_	7	PMOD	_	_
9	2	_	CD	CD	_	8	NMOD	_	_
10	and	_	CC	CC	_	8	CC	_	_
11	other	_	JJ	JJ	_	14	NMOD	_	_
12	delayed	_	VBN	VBN	_	14	NMOD	_	_
13	early	_	JJ	JJ	_	14	NMOD	_	_
14	cytokines	_	NNS	NNS	_	8	COORD	_	_
15	were	_	VBD	VBD	_	0	ROOT-S	_	_
16	markedly	_	RB	RB	_	17	ADV	_	_
17	attenuated	_	VBN	VBN	_	15	VC	_	_
18	by	_	IN	IN	_	17	LGS	_	_
19	BCL-2	_	NN	NN	_	18	PMOD	_	_
20	.	_	.	.	_	15	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	12	P	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	cysteine	_	NN	NN	_	7	NMOD	_	_
6	protease	_	NN	NN	_	7	NMOD	_	_
7	inhibitor	_	NN	NN	_	12	SBJ	_	_
8	that	_	WDT	WDT	_	10	SBJ	_	_
9	also	_	RB	RB	_	10	ADV	_	_
10	blocks	_	VBZ	VBZ	_	7	NMOD	_	_
11	apoptosis	_	NN	NN	_	10	OBJ	_	_
12	had	_	VBD	VBD	_	0	ROOT-S	_	_
13	no	_	DT	DT	_	15	NMOD	_	_
14	substantial	_	JJ	JJ	_	15	NMOD	_	_
15	affect	_	NN	NN	_	12	OBJ	_	_
16	upon	_	IN	IN	_	12	ADV	_	_
17	cytokine	_	NN	NN	_	18	NMOD	_	_
18	production	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	12	P	_	_

1	InterleUkin	_	NN	NN	_	3	NMOD	_	_
2	2	_	CD	CD	_	3	NMOD	_	_
3	expression	_	NN	NN	_	4	SBJ	_	_
4	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	several	_	JJ	JJ	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factors	_	NNS	NNS	_	4	OBJ	_	_
8	of	_	IN	IN	_	11	NMOD	_	_
9	which	_	WDT	WDT	_	8	PMOD	_	_
10	nuclear	_	JJ	JJ	_	11	NMOD	_	_
11	translocation	_	NN	NN	_	25	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	NFAT	_	NN	NN	_	12	PMOD	_	_
14	(	_	(	(	_	16	P	_	_
15	nuclear	_	JJ	JJ	_	16	NMOD	_	_
16	factor	_	NN	NN	_	13	PRN	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	activated	_	VBN	VBN	_	20	NMOD	_	_
19	T	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	17	PMOD	_	_
21	)	_	)	)	_	16	P	_	_
22	and	_	CC	CC	_	11	CC	_	_
23	NFAT-mediated	_	JJ	JJ	_	24	NMOD	_	_
24	transactivation	_	NN	NN	_	11	COORD	_	_
25	were	_	VBD	VBD	_	7	NMOD	_	_
26	impaired	_	VBN	VBN	_	25	VC	_	_
27	by	_	IN	IN	_	26	LGS	_	_
28	BCL-2	_	NN	NN	_	27	PMOD	_	_
29	.	_	.	.	_	4	P	_	_

1	Thus	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	select	_	JJ	JJ	_	5	NMOD	_	_
4	genetic	_	JJ	JJ	_	5	NMOD	_	_
5	aberrations	_	NNS	NNS	_	10	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	apoptotic	_	JJ	JJ	_	9	NMOD	_	_
9	pathway	_	NN	NN	_	6	PMOD	_	_
10	reveal	_	VBP	VBP	_	0	ROOT-S	_	_
11	a	_	DT	DT	_	14	NMOD	_	_
12	cell	_	NN	NN	_	14	NMOD	_	_
13	autonomous	_	JJ	JJ	_	14	NMOD	_	_
14	coregulation	_	NN	NN	_	10	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	activation	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	10	P	_	_

1	Epstein-Barr	_	JJ	JJ	_	3	NMOD	_	_
2	viral	_	JJ	JJ	_	3	NMOD	_	_
3	latency	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	disrupted	_	VBN	VBN	_	4	VC	_	_
6	by	_	IN	IN	_	5	LGS	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	immediate-early	_	JJ	JJ	_	10	NMOD	_	_
9	BRLF1	_	NN	NN	_	10	NMOD	_	_
10	protein	_	NN	NN	_	6	PMOD	_	_
11	through	_	IN	IN	_	5	ADV	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	cell-specific	_	JJ	JJ	_	14	NMOD	_	_
14	mechanism	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	Epstein-Barr	_	JJ	JJ	_	2	NMOD	_	_
2	virus	_	NN	NN	_	14	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	EBV	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	,	_	,	,	_	2	P	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	causative	_	JJ	JJ	_	9	NMOD	_	_
9	agent	_	NN	NN	_	2	NMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	infectious	_	JJ	JJ	_	12	NMOD	_	_
12	mononucleosis	_	NN	NN	_	10	PMOD	_	_
13	,	_	,	,	_	2	P	_	_
14	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	human	_	JJ	JJ	_	17	NMOD	_	_
17	herpesvirus	_	NN	NN	_	14	PRD	_	_
18	associated	_	VBN	VBN	_	17	NMOD	_	_
19	with	_	IN	IN	_	18	ADV	_	_
20	epithelial	_	JJ	JJ	_	22	NMOD	_	_
21	cell	_	NN	NN	_	22	NMOD	_	_
22	malignancies	_	NNS	NNS	_	19	PMOD	_	_
23	(	_	(	(	_	25	P	_	_
24	nasopharyngeal	_	JJ	JJ	_	25	NMOD	_	_
25	carcinoma	_	NN	NN	_	22	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	as	_	RB	RB	_	22	CC	_	_
28	well	_	RB	RB	_	27	DEP	_	_
29	as	_	IN	IN	_	27	DEP	_	_
30	B-cell	_	NN	NN	_	31	NMOD	_	_
31	malignancies	_	NNS	NNS	_	22	COORD	_	_
32	.	_	.	.	_	14	P	_	_

1	Understanding	_	VBG	VBG	_	7	SBJ	_	_
2	how	_	WRB	WRB	_	6	ADV	_	_
3	viral	_	JJ	JJ	_	4	NMOD	_	_
4	latency	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	1	OBJ	_	_
6	disrupted	_	VBN	VBN	_	5	VC	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	central	_	JJ	JJ	_	10	NMOD	_	_
10	issue	_	NN	NN	_	7	PRD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	herpesvirus	_	JJ	JJ	_	13	NMOD	_	_
13	biology	_	NN	NN	_	11	PMOD	_	_
14	.	_	.	.	_	7	P	_	_

1	Epithelial	_	JJ	JJ	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	major	_	JJ	JJ	_	6	NMOD	_	_
6	site	_	NN	NN	_	3	PRD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	lytic	_	JJ	JJ	_	10	NMOD	_	_
9	EBV	_	NN	NN	_	10	NMOD	_	_
10	replication	_	NN	NN	_	7	PMOD	_	_
11	within	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	human	_	JJ	JJ	_	14	NMOD	_	_
14	host	_	NN	NN	_	11	PMOD	_	_
15	,	_	,	,	_	3	P	_	_
16	and	_	CC	CC	_	3	CC	_	_
17	viral	_	JJ	JJ	_	18	NMOD	_	_
18	reactivation	_	NN	NN	_	19	SBJ	_	_
19	occurs	_	VBZ	VBZ	_	3	COORD	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	EBV-associated	_	JJ	JJ	_	23	NMOD	_	_
22	nasopharyngeal	_	JJ	JJ	_	23	NMOD	_	_
23	carcinomas	_	NNS	NNS	_	20	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	known	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	expression	_	NN	NN	_	15	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	a	_	DT	DT	_	11	NMOD	_	_
8	single	_	JJ	JJ	_	11	NMOD	_	_
9	viral	_	JJ	JJ	_	11	NMOD	_	_
10	immediate-early	_	JJ	JJ	_	11	NMOD	_	_
11	protein	_	NN	NN	_	6	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	BZLF1	_	NN	NN	_	11	NMOD	_	_
14	,	_	,	,	_	11	P	_	_
15	is	_	VBZ	VBZ	_	4	VMOD	_	_
16	sufficient	_	JJ	JJ	_	15	PRD	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	initiate	_	VB	VB	_	16	AMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	switch	_	NN	NN	_	18	OBJ	_	_
21	from	_	IN	IN	_	20	NMOD	_	_
22	latent	_	JJ	JJ	_	25	NMOD	_	_
23	to	_	TO	TO	_	20	NMOD	_	_
24	lytic	_	JJ	JJ	_	23	NMOD	_	_
25	infection	_	NN	NN	_	21	PMOD	_	_
26	in	_	IN	IN	_	20	NMOD	_	_
27	B	_	NN	NN	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	26	PMOD	_	_
29	.	_	.	.	_	2	P	_	_

1	Cellular	_	JJ	JJ	_	2	NMOD	_	_
2	regulation	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	BZLF1	_	NN	NN	_	5	NMOD	_	_
5	transcription	_	NN	NN	_	3	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	therefore	_	RB	RB	_	6	ADV	_	_
8	thought	_	VBN	VBN	_	6	VC	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	play	_	VB	VB	_	8	OBJ	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	key	_	JJ	JJ	_	13	NMOD	_	_
13	role	_	NN	NN	_	10	OBJ	_	_
14	in	_	IN	IN	_	10	ADV	_	_
15	regulating	_	VBG	VBG	_	14	PMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	stringency	_	NN	NN	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	viral	_	JJ	JJ	_	20	NMOD	_	_
20	latency	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	6	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	unexpectedly	_	RB	RB	_	17	ADV	_	_
7	,	_	,	,	_	17	P	_	_
8	expression	_	NN	NN	_	17	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	another	_	DT	DT	_	13	NMOD	_	_
11	viral	_	JJ	JJ	_	13	NMOD	_	_
12	immediate-early	_	JJ	JJ	_	13	NMOD	_	_
13	protein	_	NN	NN	_	9	PMOD	_	_
14	,	_	,	,	_	13	P	_	_
15	BRLF1	_	NN	NN	_	13	NMOD	_	_
16	,	_	,	,	_	13	P	_	_
17	can	_	MD	MD	_	4	VMOD	_	_
18	disrupt	_	VB	VB	_	17	VC	_	_
19	viral	_	JJ	JJ	_	20	NMOD	_	_
20	latency	_	NN	NN	_	18	OBJ	_	_
21	in	_	IN	IN	_	18	ADV	_	_
22	an	_	DT	DT	_	25	NMOD	_	_
23	epithelial	_	JJ	JJ	_	24	AMOD	_	_
24	cell-specific	_	JJ	JJ	_	25	NMOD	_	_
25	fashion	_	NN	NN	_	21	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	Therefore	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	mechanisms	_	NNS	NNS	_	11	SBJ	_	_
5	leading	_	VBG	VBG	_	4	NMOD	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	disruption	_	NN	NN	_	6	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	EBV	_	NN	NN	_	10	NMOD	_	_
10	latency	_	NN	NN	_	8	PMOD	_	_
11	appear	_	VBP	VBP	_	0	ROOT-S	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	be	_	VB	VB	_	11	OBJ	_	_
14	cell-type	_	NN	NN	_	13	PRD	_	_
15	specific	_	JJ	JJ	_	14	AMOD	_	_
16	.	_	.	.	_	11	P	_	_

1	Multifactor	_	JJ	JJ	_	4	NMOD	_	_
2	cis-dominant	_	JJ	JJ	_	4	NMOD	_	_
3	negative	_	JJ	JJ	_	4	NMOD	_	_
4	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	IL-2	_	NN	NN	_	8	NMOD	_	_
7	gene	_	NN	NN	_	8	NMOD	_	_
8	expression	_	NN	NN	_	5	PMOD	_	_
9	in	_	IN	IN	_	4	NMOD	_	_
10	anergized	_	VBN	VBN	_	12	NMOD	_	_
11	T	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	PMOD	_	_
13	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	molecular	_	JJ	JJ	_	3	NMOD	_	_
3	mechanism	_	NN	NN	_	13	SBJ	_	_
4	underlying	_	VBG	VBG	_	3	NMOD	_	_
5	IL-2	_	NN	NN	_	7	NMOD	_	_
6	transcriptional	_	JJ	JJ	_	7	NMOD	_	_
7	blockade	_	NN	NN	_	4	OBJ	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	anergic	_	JJ	JJ	_	12	NMOD	_	_
10	T	_	NN	NN	_	12	NMOD	_	_
11	cell	_	NN	NN	_	12	NMOD	_	_
12	clones	_	NNS	NNS	_	8	PMOD	_	_
13	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	not	_	RB	RB	_	13	VMOD	_	_
15	fully	_	RB	RB	_	13	ADV	_	_
16	understood	_	VBN	VBN	_	13	VC	_	_
17	.	_	.	.	_	13	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	examine	_	VB	VB	_	12	VMOD	_	_
3	whether	_	IN	IN	_	2	OBJ	_	_
4	an	_	DT	DT	_	8	NMOD	_	_
5	active	_	JJ	JJ	_	8	NMOD	_	_
6	negative	_	JJ	JJ	_	7	AMOD	_	_
7	regulatory	_	JJ	JJ	_	8	NMOD	_	_
8	process	_	NN	NN	_	9	SBJ	_	_
9	occurs	_	VBZ	VBZ	_	3	VMOD	_	_
10	,	_	,	,	_	12	P	_	_
11	we	_	PRP	PRP	_	12	SBJ	_	_
12	created	_	VBD	VBD	_	0	ROOT-S	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	reporter	_	NN	NN	_	15	NMOD	_	_
15	construct	_	NN	NN	_	12	OBJ	_	_
16	containing	_	VBG	VBG	_	15	NMOD	_	_
17	as	_	IN	IN	_	16	ADV	_	_
18	an	_	DT	DT	_	19	NMOD	_	_
19	enhancer	_	NN	NN	_	17	PMOD	_	_
20	four	_	CD	CD	_	21	NMOD	_	_
21	copies	_	NNS	NNS	_	16	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	NF-AT	_	NN	NN	_	25	NMOD	_	_
25	site	_	NN	NN	_	22	PMOD	_	_
26	and	_	CC	CC	_	21	CC	_	_
27	one	_	CD	CD	_	28	NMOD	_	_
28	copy	_	NN	NN	_	21	COORD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	octamer	_	NN	NN	_	32	NMOD	_	_
32	site	_	NN	NN	_	29	PMOD	_	_
33	(	_	(	(	_	35	P	_	_
34	4X	_	NN	NN	_	35	NMOD	_	_
35	NF-AT-Oct	_	NN	NN	_	21	PRN	_	_
36	)	_	)	)	_	35	P	_	_
37	.	_	.	.	_	12	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	construct	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	only	_	RB	RB	_	3	ADV	_	_
5	slightly	_	RB	RB	_	4	AMOD	_	_
6	reduced	_	VBN	VBN	_	3	VC	_	_
7	(	_	(	(	_	8	P	_	_
8	1.3-fold	_	RB	RB	_	4	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	in	_	IN	IN	_	6	ADV	_	_
11	its	_	PRP$	PRP$	_	12	NMOD	_	_
12	expression	_	NN	NN	_	10	PMOD	_	_
13	when	_	WRB	WRB	_	14	ADV	_	_
14	stimulated	_	VBN	VBN	_	6	TMP	_	_
15	under	_	IN	IN	_	14	ADV	_	_
16	anergic	_	JJ	JJ	_	17	NMOD	_	_
17	conditions	_	NNS	NNS	_	15	PMOD	_	_
18	,	_	,	,	_	6	P	_	_
19	while	_	IN	IN	_	6	OBJ	_	_
20	a	_	DT	DT	_	25	NMOD	_	_
21	whole	_	JJ	JJ	_	25	NMOD	_	_
22	mouse	_	NN	NN	_	25	NMOD	_	_
23	IL-2	_	NN	NN	_	25	NMOD	_	_
24	enhancer	_	NN	NN	_	25	NMOD	_	_
25	construct	_	NN	NN	_	26	SBJ	_	_
26	showed	_	VBD	VBD	_	19	VMOD	_	_
27	a	_	DT	DT	_	28	NMOD	_	_
28	reduction	_	NN	NN	_	26	OBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	4.3-fold	_	JJ	JJ	_	29	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	Addition	_	NN	NN	_	13	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	-176	_	CD	CD	_	7	NMOD	_	_
5	to	_	TO	TO	_	4	NMOD	_	_
6	-96	_	CD	CD	_	4	NMOD	_	_
7	sequence	_	NN	NN	_	2	PMOD	_	_
8	to	_	TO	TO	_	1	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	4X	_	NN	NN	_	12	NMOD	_	_
11	NF-AT-Oct	_	NN	NN	_	12	NMOD	_	_
12	construct	_	NN	NN	_	8	PMOD	_	_
13	did	_	VBD	VBD	_	0	ROOT-S	_	_
14	not	_	RB	RB	_	13	VMOD	_	_
15	impart	_	VB	VB	_	13	VC	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	ability	_	NN	NN	_	15	OBJ	_	_
18	to	_	TO	TO	_	19	VMOD	_	_
19	be	_	VB	VB	_	17	NMOD	_	_
20	affected	_	VBN	VBN	_	19	VC	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	anergy	_	NN	NN	_	21	PMOD	_	_
23	,	_	,	,	_	13	P	_	_
24	but	_	CC	CC	_	13	CC	_	_
25	addition	_	NN	NN	_	32	SBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	31	NMOD	_	_
28	-236	_	CD	CD	_	31	NMOD	_	_
29	to	_	TO	TO	_	28	NMOD	_	_
30	-96	_	CD	CD	_	28	NMOD	_	_
31	sequence	_	NN	NN	_	26	PMOD	_	_
32	did	_	VBD	VBD	_	13	COORD	_	_
33	,	_	,	,	_	13	P	_	_
34	demonstrating	_	VBG	VBG	_	13	COORD	_	_
35	that	_	IN	IN	_	34	OBJ	_	_
36	anergy	_	NN	NN	_	37	SBJ	_	_
37	is	_	VBZ	VBZ	_	35	VMOD	_	_
38	an	_	DT	DT	_	41	NMOD	_	_
39	active	_	JJ	JJ	_	41	NMOD	_	_
40	inhibitory	_	JJ	JJ	_	41	NMOD	_	_
41	process	_	NN	NN	_	37	PRD	_	_
42	and	_	CC	CC	_	35	CC	_	_
43	that	_	IN	IN	_	35	COORD	_	_
44	more	_	JJR	JJR	_	59	SBJ	_	_
45	than	_	IN	IN	_	44	NMOD	_	_
46	the	_	DT	DT	_	47	NMOD	_	_
47	presence	_	NN	NN	_	45	PMOD	_	_
48	of	_	IN	IN	_	47	NMOD	_	_
49	the	_	DT	DT	_	53	NMOD	_	_
50	-150	_	CD	CD	_	53	NMOD	_	_
51	AP-1	_	NN	NN	_	53	NMOD	_	_
52	binding	_	NN	NN	_	53	NMOD	_	_
53	site	_	NN	NN	_	48	PMOD	_	_
54	(	_	(	(	_	55	P	_	_
55	-152	_	CD	CD	_	53	PRN	_	_
56	to	_	TO	TO	_	55	NMOD	_	_
57	-147	_	CD	CD	_	55	NMOD	_	_
58	)	_	)	)	_	55	P	_	_
59	is	_	VBZ	VBZ	_	43	VMOD	_	_
60	required	_	VBN	VBN	_	59	VC	_	_
61	to	_	TO	TO	_	62	VMOD	_	_
62	mediate	_	VB	VB	_	60	OBJ	_	_
63	the	_	DT	DT	_	64	NMOD	_	_
64	effect	_	NN	NN	_	62	OBJ	_	_
65	.	_	.	.	_	13	P	_	_

1	Mutational	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	-236	_	CD	CD	_	8	NMOD	_	_
6	to	_	TO	TO	_	5	NMOD	_	_
7	-96	_	CD	CD	_	5	NMOD	_	_
8	sequence	_	NN	NN	_	3	PMOD	_	_
9	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
10	that	_	IN	IN	_	9	OBJ	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	presence	_	NN	NN	_	30	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	both	_	CC	CC	_	18	CC	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	-130	_	CD	CD	_	18	NMOD	_	_
17	AP-1-like	_	JJ	JJ	_	18	NMOD	_	_
18	site	_	NN	NN	_	13	PMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	-187	_	CD	CD	_	18	PRN	_	_
21	to	_	TO	TO	_	20	NMOD	_	_
22	-181	_	CD	CD	_	20	NMOD	_	_
23	)	_	)	)	_	20	P	_	_
24	and	_	CC	CC	_	18	CC	_	_
25	the	_	DT	DT	_	29	NMOD	_	_
26	-150	_	CD	CD	_	29	NMOD	_	_
27	proximal	_	JJ	JJ	_	29	NMOD	_	_
28	AP-1	_	NN	NN	_	29	NMOD	_	_
29	site	_	NN	NN	_	18	COORD	_	_
30	were	_	VBD	VBD	_	10	VMOD	_	_
31	necessary	_	JJ	JJ	_	30	PRD	_	_
32	to	_	TO	TO	_	33	VMOD	_	_
33	observe	_	VB	VB	_	31	AMOD	_	_
34	anergy	_	NN	NN	_	33	OBJ	_	_
35	.	_	.	.	_	9	P	_	_

1	Because	_	IN	IN	_	12	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	-180	_	CD	CD	_	4	NMOD	_	_
4	site	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	1	VMOD	_	_
6	not	_	RB	RB	_	5	VMOD	_	_
7	required	_	VBN	VBN	_	5	VC	_	_
8	for	_	IN	IN	_	7	ADV	_	_
9	trans-activation	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	12	P	_	_
11	it	_	PRP	PRP	_	12	SBJ	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	possible	_	JJ	JJ	_	12	PRD	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	confirm	_	VB	VB	_	12	EXP	_	_
16	by	_	IN	IN	_	15	ADV	_	_
17	mutation	_	NN	NN	_	16	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	23	NMOD	_	_
20	normal	_	JJ	JJ	_	23	NMOD	_	_
21	mouse	_	NN	NN	_	23	NMOD	_	_
22	IL-2	_	NN	NN	_	23	NMOD	_	_
23	enhancer	_	NN	NN	_	18	PMOD	_	_
24	that	_	IN	IN	_	15	OBJ	_	_
25	this	_	DT	DT	_	26	NMOD	_	_
26	site	_	NN	NN	_	27	SBJ	_	_
27	is	_	VBZ	VBZ	_	24	VMOD	_	_
28	absolutely	_	RB	RB	_	29	AMOD	_	_
29	essential	_	JJ	JJ	_	27	PRD	_	_
30	for	_	IN	IN	_	29	AMOD	_	_
31	anergy	_	NN	NN	_	32	NMOD	_	_
32	induction	_	NN	NN	_	30	PMOD	_	_
33	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	simplest	_	JJS	JJS	_	3	NMOD	_	_
3	model	_	NN	NN	_	8	SBJ	_	_
4	to	_	TO	TO	_	5	VMOD	_	_
5	explain	_	VB	VB	_	3	NMOD	_	_
6	these	_	DT	DT	_	7	NMOD	_	_
7	results	_	NNS	NNS	_	5	OBJ	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	PRD	_	_
10	anergy	_	NN	NN	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	9	VMOD	_	_
12	mediated	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	complex	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	multiple	_	JJ	JJ	_	19	NMOD	_	_
18	transcription	_	NN	NN	_	19	NMOD	_	_
19	factors	_	NNS	NNS	_	16	PMOD	_	_
20	that	_	WDT	WDT	_	21	SBJ	_	_
21	exert	_	VBP	VBP	_	19	NMOD	_	_
22	a	_	DT	DT	_	27	NMOD	_	_
23	cis-acting	_	JJ	JJ	_	27	NMOD	_	_
24	dominant	_	JJ	JJ	_	27	NMOD	_	_
25	negative	_	JJ	JJ	_	27	NMOD	_	_
26	regulatory	_	JJ	JJ	_	27	NMOD	_	_
27	effect	_	NN	NN	_	21	OBJ	_	_
28	on	_	IN	IN	_	21	ADV	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	trans-activation	_	NN	NN	_	28	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	IL-2	_	NN	NN	_	34	NMOD	_	_
34	gene	_	NN	NN	_	31	PMOD	_	_
35	.	_	.	.	_	8	P	_	_

1	Abnormality	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	Oct-1	_	NN	NN	_	5	NMOD	_	_
4	DNA	_	NN	NN	_	5	NMOD	_	_
5	binding	_	NN	NN	_	2	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	T	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	6	PMOD	_	_
9	from	_	IN	IN	_	8	NMOD	_	_
10	Sjogren	_	NN	NN	_	13	NMOD	_	_
11	's	_	POS	POS	_	10	NMOD	_	_
12	syndrome	_	NN	NN	_	13	NMOD	_	_
13	patients	_	NNS	NNS	_	9	PMOD	_	_
14	.	_	.	.	_	1	P	_	_

1	Primary	_	JJ	JJ	_	4	NMOD	_	_
2	Sjogren	_	NN	NN	_	4	NMOD	_	_
3	's	_	POS	POS	_	2	NMOD	_	_
4	syndrome	_	NN	NN	_	8	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	SS	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	an	_	DT	DT	_	12	NMOD	_	_
10	autoimmune	_	JJ	JJ	_	12	NMOD	_	_
11	rheumatic	_	JJ	JJ	_	12	NMOD	_	_
12	disease	_	NN	NN	_	8	PRD	_	_
13	characterized	_	VBN	VBN	_	12	NMOD	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	T	_	NN	NN	_	17	NMOD	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	hypoactivity	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	8	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	understand	_	VB	VB	_	13	VMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	diminished	_	VBN	VBN	_	7	NMOD	_	_
5	T	_	NN	NN	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	response	_	NN	NN	_	2	OBJ	_	_
8	to	_	TO	TO	_	7	NMOD	_	_
9	activation	_	NN	NN	_	10	NMOD	_	_
10	signals	_	NNS	NNS	_	8	PMOD	_	_
11	,	_	,	,	_	13	P	_	_
12	we	_	PRP	PRP	_	13	SBJ	_	_
13	measured	_	VBD	VBD	_	0	ROOT-S	_	_
14	nucleoprotein	_	NN	NN	_	16	NMOD	_	_
15	DNA-binding	_	JJ	JJ	_	16	NMOD	_	_
16	activities	_	NNS	NNS	_	13	IOBJ	_	_
17	regulating	_	VBG	VBG	_	16	NMOD	_	_
18	gene	_	NN	NN	_	19	NMOD	_	_
19	expression	_	NN	NN	_	17	OBJ	_	_
20	during	_	IN	IN	_	17	TMP	_	_
21	T	_	NN	NN	_	23	NMOD	_	_
22	cell	_	NN	NN	_	23	NMOD	_	_
23	activation	_	NN	NN	_	20	PMOD	_	_
24	using	_	VBG	VBG	_	13	OBJ	_	_
25	the	_	DT	DT	_	29	NMOD	_	_
26	electrophoretic	_	JJ	JJ	_	29	NMOD	_	_
27	mobility	_	NN	NN	_	29	NMOD	_	_
28	shift	_	NN	NN	_	29	NMOD	_	_
29	assay	_	NN	NN	_	24	OBJ	_	_
30	.	_	.	.	_	13	P	_	_

1	Peripheral	_	JJ	JJ	_	3	NMOD	_	_
2	blood	_	NN	NN	_	3	NMOD	_	_
3	lymphocytes	_	NNS	NNS	_	8	SBJ	_	_
4	from	_	IN	IN	_	3	NMOD	_	_
5	9\/19	_	CD	CD	_	7	NMOD	_	_
6	SS	_	NN	NN	_	7	NMOD	_	_
7	patients	_	NNS	NNS	_	4	PMOD	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	found	_	VBN	VBN	_	8	VC	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	be	_	VB	VB	_	9	OBJ	_	_
12	defective	_	JJ	JJ	_	11	PRD	_	_
13	in	_	IN	IN	_	11	ADV	_	_
14	their	_	PRP$	PRP$	_	15	NMOD	_	_
15	ability	_	NN	NN	_	13	PMOD	_	_
16	to	_	TO	TO	_	17	VMOD	_	_
17	bind	_	VB	VB	_	15	NMOD	_	_
18	an	_	DT	DT	_	20	NMOD	_	_
19	october	_	NN	NN	_	20	NMOD	_	_
20	sequence	_	NN	NN	_	17	OBJ	_	_
21	(	_	(	(	_	22	P	_	_
22	Oct-1	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	.	_	.	.	_	8	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	Oct-1-binding	_	JJ	JJ	_	3	NMOD	_	_
3	phenotype	_	NN	NN	_	4	SBJ	_	_
4	remained	_	VBD	VBD	_	0	ROOT-S	_	_
5	stable	_	JJ	JJ	_	4	PRD	_	_
6	in	_	IN	IN	_	4	ADV	_	_
7	culture	_	NN	NN	_	6	PMOD	_	_
8	for	_	IN	IN	_	4	TMP	_	_
9	up	_	IN	IN	_	11	DEP	_	_
10	to	_	TO	TO	_	11	DEP	_	_
11	3	_	CD	CD	_	12	NMOD	_	_
12	days	_	NNS	NNS	_	8	PMOD	_	_
13	prior	_	RB	RB	_	14	DEP	_	_
14	to	_	TO	TO	_	12	TMP	_	_
15	activation	_	NN	NN	_	14	PMOD	_	_
16	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	abnormality	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	seen	_	VBN	VBN	_	3	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	resting	_	VBG	VBG	_	9	NMOD	_	_
8	T	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	6	PMOD	_	_
10	nor	_	CC	CC	_	9	CC	_	_
11	T	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	9	COORD	_	_
13	from	_	IN	IN	_	9	NMOD	_	_
14	patients	_	NNS	NNS	_	13	PMOD	_	_
15	with	_	IN	IN	_	14	NMOD	_	_
16	systemic	_	JJ	JJ	_	18	NMOD	_	_
17	lupus	_	NN	NN	_	18	NMOD	_	_
18	erythematosus	_	NN	NN	_	15	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	rheumatoid	_	JJ	JJ	_	21	NMOD	_	_
21	arthritis	_	NN	NN	_	18	COORD	_	_
22	(	_	(	(	_	23	P	_	_
23	RA	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	,	_	,	,	_	18	P	_	_
26	or	_	CC	CC	_	18	CC	_	_
27	SS	_	NN	NN	_	18	COORD	_	_
28	accompanied	_	VBN	VBN	_	27	NMOD	_	_
29	by	_	IN	IN	_	28	LGS	_	_
30	RA	_	NN	NN	_	29	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	SS	_	NN	NN	_	5	NMOD	_	_
3	Oct-1	_	NN	NN	_	5	NMOD	_	_
4	DNA-binding	_	JJ	JJ	_	5	NMOD	_	_
5	abnormality	_	NN	NN	_	6	SBJ	_	_
6	correlated	_	VBD	VBD	_	0	ROOT-S	_	_
7	significantly	_	RB	RB	_	6	ADV	_	_
8	with	_	IN	IN	_	6	ADV	_	_
9	an	_	DT	DT	_	10	NMOD	_	_
10	inability	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	cells	_	NNS	NNS	_	11	PMOD	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	exit	_	VB	VB	_	10	NMOD	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	Gzero\/G1	_	NN	NN	_	19	NMOD	_	_
17	cell	_	NN	NN	_	19	NMOD	_	_
18	cycle	_	NN	NN	_	19	NMOD	_	_
19	phase	_	NN	NN	_	14	OBJ	_	_
20	when	_	WRB	WRB	_	21	ADV	_	_
21	stimulated	_	VBN	VBN	_	14	TMP	_	_
22	in	_	FW	FW	_	21	ADV	_	_
23	vitro	_	FW	FW	_	22	AMOD	_	_
24	.	_	.	.	_	6	P	_	_

1	Importantly	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	nucleoprotein	_	NN	NN	_	4	NMOD	_	_
4	extracts	_	NNS	NNS	_	9	SBJ	_	_
5	showing	_	VBG	VBG	_	4	NMOD	_	_
6	decreased	_	VBN	VBN	_	8	NMOD	_	_
7	DNA-binding	_	JJ	JJ	_	8	NMOD	_	_
8	activity	_	NN	NN	_	5	OBJ	_	_
9	had	_	VBD	VBD	_	0	ROOT-S	_	_
10	normal	_	JJ	JJ	_	11	NMOD	_	_
11	amounts	_	NNS	NNS	_	9	IOBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	Oct-1	_	NN	NN	_	14	NMOD	_	_
14	proteins	_	NNS	NNS	_	12	PMOD	_	_
15	as	_	IN	IN	_	11	NMOD	_	_
16	determined	_	VBN	VBN	_	15	VMOD	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	immunoprecipitation	_	NN	NN	_	17	PMOD	_	_
19	,	_	,	,	_	9	P	_	_
20	implying	_	VBG	VBG	_	9	OBJ	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	functional	_	JJ	JJ	_	23	NMOD	_	_
23	defect	_	NN	NN	_	20	OBJ	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	Oct-1	_	NN	NN	_	27	NMOD	_	_
27	protein	_	NN	NN	_	24	PMOD	_	_
28	.	_	.	.	_	9	P	_	_

1	Moreover	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	defective	_	JJ	JJ	_	5	NMOD	_	_
4	DNA	_	NN	NN	_	5	NMOD	_	_
5	binding	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	corrected	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	treatment	_	NN	NN	_	8	PMOD	_	_
10	with	_	IN	IN	_	9	NMOD	_	_
11	acid	_	NN	NN	_	12	NMOD	_	_
12	phosphatase	_	NN	NN	_	10	PMOD	_	_
13	.	_	.	.	_	6	P	_	_

1	Cell-type-specific	_	JJ	JJ	_	2	NMOD	_	_
2	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	10	NMOD	_	_
5	human	_	JJ	JJ	_	10	NMOD	_	_
6	tumor	_	NN	NN	_	10	NMOD	_	_
7	necrosis	_	NN	NN	_	10	NMOD	_	_
8	factor	_	NN	NN	_	10	NMOD	_	_
9	alpha	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	3	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	B	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	13	COORD	_	_
17	by	_	IN	IN	_	2	NMOD	_	_
18	NFATp	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	ATF-2\/JUN	_	NN	NN	_	18	COORD	_	_
21	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	10	NMOD	_	_
2	human	_	JJ	JJ	_	10	NMOD	_	_
3	tumor	_	NN	NN	_	6	NMOD	_	_
4	necrosis	_	NN	NN	_	6	NMOD	_	_
5	factor	_	NN	NN	_	6	NMOD	_	_
6	alpha	_	NN	NN	_	10	NMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	TNF-alpha	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	gene	_	NN	NN	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	one	_	CD	CD	_	11	PRD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	earliest	_	JJS	JJS	_	16	NMOD	_	_
16	genes	_	NNS	NNS	_	13	PMOD	_	_
17	transcribed	_	VBN	VBN	_	16	NMOD	_	_
18	after	_	IN	IN	_	17	TMP	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	stimulation	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	a	_	DT	DT	_	24	NMOD	_	_
23	B	_	NN	NN	_	24	NMOD	_	_
24	cell	_	NN	NN	_	21	PMOD	_	_
25	through	_	IN	IN	_	20	NMOD	_	_
26	its	_	PRP$	PRP$	_	28	NMOD	_	_
27	antigen	_	NN	NN	_	28	NMOD	_	_
28	receptor	_	NN	NN	_	25	PMOD	_	_
29	or	_	CC	CC	_	25	CC	_	_
30	via	_	IN	IN	_	25	COORD	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	CD-40	_	NN	NN	_	33	NMOD	_	_
33	pathway	_	NN	NN	_	30	PMOD	_	_
34	.	_	.	.	_	11	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	both	_	DT	DT	_	3	NMOD	_	_
3	cases	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	10	P	_	_
5	induction	_	NN	NN	_	10	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	TNF-alpha	_	NN	NN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	transcription	_	NN	NN	_	6	PMOD	_	_
10	can	_	MD	MD	_	0	ROOT-S	_	_
11	be	_	VB	VB	_	10	VC	_	_
12	blocked	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	immunosuppressants	_	NNS	NNS	_	13	PMOD	_	_
16	cyclosporin	_	NN	NN	_	17	NMOD	_	_
17	A	_	NN	NN	_	15	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	FK506	_	NN	NN	_	17	COORD	_	_
20	,	_	,	,	_	12	P	_	_
21	which	_	WDT	WDT	_	22	SBJ	_	_
22	suggested	_	VBD	VBD	_	12	OBJ	_	_
23	a	_	DT	DT	_	24	NMOD	_	_
24	role	_	NN	NN	_	22	OBJ	_	_
25	for	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	NFAT	_	NN	NN	_	28	NMOD	_	_
28	family	_	NN	NN	_	25	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	proteins	_	NNS	NNS	_	29	PMOD	_	_
31	in	_	IN	IN	_	24	NMOD	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	regulation	_	NN	NN	_	31	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	the	_	DT	DT	_	36	NMOD	_	_
36	gene	_	NN	NN	_	34	PMOD	_	_
37	in	_	IN	IN	_	33	NMOD	_	_
38	B	_	NN	NN	_	39	NMOD	_	_
39	cells	_	NNS	NNS	_	37	PMOD	_	_
40	.	_	.	.	_	10	P	_	_

1	Furthermore	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	in	_	IN	IN	_	11	ADV	_	_
4	T	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	3	PMOD	_	_
6	,	_	,	,	_	11	P	_	_
7	two	_	CD	CD	_	8	NMOD	_	_
8	molecules	_	NNS	NNS	_	11	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	NFATp	_	NN	NN	_	9	PMOD	_	_
11	bind	_	VBP	VBP	_	0	ROOT-S	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	TNF-alpha	_	NN	NN	_	17	NMOD	_	_
15	promoter	_	NN	NN	_	17	NMOD	_	_
16	element	_	NN	NN	_	17	NMOD	_	_
17	kappa	_	NN	NN	_	12	PMOD	_	_
18	3	_	CD	CD	_	17	NMOD	_	_
19	in	_	NN	NN	_	11	ADV	_	_
20	association	_	NN	NN	_	19	PMOD	_	_
21	with	_	IN	IN	_	20	NMOD	_	_
22	ATF-2	_	NN	NN	_	25	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	Jun	_	NN	NN	_	22	COORD	_	_
25	proteins	_	NNS	NNS	_	21	PMOD	_	_
26	bound	_	VBN	VBN	_	25	NMOD	_	_
27	to	_	TO	TO	_	26	ADV	_	_
28	an	_	DT	DT	_	38	NMOD	_	_
29	immediately	_	RB	RB	_	30	AMOD	_	_
30	adjacent	_	JJ	JJ	_	38	NMOD	_	_
31	cyclic	_	JJ	JJ	_	34	NMOD	_	_
32	AMP	_	NN	NN	_	34	NMOD	_	_
33	response	_	NN	NN	_	34	NMOD	_	_
34	element	_	NN	NN	_	38	NMOD	_	_
35	(	_	(	(	_	36	P	_	_
36	CRE	_	NN	NN	_	34	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	site	_	NN	NN	_	27	PMOD	_	_
39	.	_	.	.	_	11	P	_	_

1	Here	_	RB	RB	_	13	ADV	_	_
2	,	_	,	,	_	13	P	_	_
3	using	_	VBG	VBG	_	13	VMOD	_	_
4	the	_	DT	DT	_	10	NMOD	_	_
5	murine	_	JJ	JJ	_	10	NMOD	_	_
6	B-cell	_	NN	NN	_	10	NMOD	_	_
7	lymphoma	_	NN	NN	_	10	NMOD	_	_
8	cell	_	NN	NN	_	10	NMOD	_	_
9	line	_	NN	NN	_	10	NMOD	_	_
10	A20	_	NN	NN	_	3	OBJ	_	_
11	,	_	,	,	_	13	P	_	_
12	we	_	PRP	PRP	_	13	SBJ	_	_
13	show	_	VBP	VBP	_	0	ROOT-S	_	_
14	that	_	IN	IN	_	13	OBJ	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	TNF-alpha	_	NN	NN	_	17	NMOD	_	_
17	gene	_	NN	NN	_	18	SBJ	_	_
18	is	_	VBZ	VBZ	_	14	VMOD	_	_
19	regulated	_	VBN	VBN	_	18	VC	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	cell-type-specific	_	JJ	JJ	_	23	NMOD	_	_
23	manner	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	13	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	A20	_	NN	NN	_	4	NMOD	_	_
3	B	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	9	P	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	TNF-alpha	_	NN	NN	_	8	NMOD	_	_
8	gene	_	NN	NN	_	9	SBJ	_	_
9	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	not	_	RB	RB	_	9	VMOD	_	_
11	regulated	_	VBN	VBN	_	9	VC	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	NFATp	_	NN	NN	_	12	PMOD	_	_
14	bound	_	VBN	VBN	_	13	NMOD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	kappa	_	NN	NN	_	19	NMOD	_	_
18	3	_	CD	CD	_	19	NMOD	_	_
19	element	_	NN	NN	_	15	PMOD	_	_
20	.	_	.	.	_	9	P	_	_

1	Instead	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	ATF-2	_	NN	NN	_	6	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	Jun	_	NN	NN	_	3	COORD	_	_
6	proteins	_	NNS	NNS	_	7	SBJ	_	_
7	bind	_	VBP	VBP	_	0	ROOT-S	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	composite	_	JJ	JJ	_	13	NMOD	_	_
11	kappa	_	NN	NN	_	13	NMOD	_	_
12	3\/CRE	_	NN	NN	_	13	NMOD	_	_
13	site	_	NN	NN	_	8	PMOD	_	_
14	and	_	CC	CC	_	7	CC	_	_
15	NFATp	_	NN	NN	_	16	SBJ	_	_
16	binds	_	VBZ	VBZ	_	7	COORD	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	a	_	DT	DT	_	23	NMOD	_	_
19	newly	_	RB	RB	_	20	AMOD	_	_
20	identified	_	VBN	VBN	_	23	NMOD	_	_
21	second	_	JJ	JJ	_	23	NMOD	_	_
22	NFAT	_	NN	NN	_	23	NMOD	_	_
23	site	_	NN	NN	_	17	PMOD	_	_
24	centered	_	JJ	JJ	_	23	NMOD	_	_
25	at	_	IN	IN	_	24	ADV	_	_
26	-76	_	CD	CD	_	27	NMOD	_	_
27	nucleotides	_	NNS	NNS	_	25	PMOD	_	_
28	relative	_	JJ	JJ	_	29	DEP	_	_
29	to	_	TO	TO	_	24	ADV	_	_
30	the	_	DT	DT	_	34	NMOD	_	_
31	TNF-alpha	_	NN	NN	_	34	NMOD	_	_
32	transcription	_	NN	NN	_	34	NMOD	_	_
33	start	_	NN	NN	_	34	NMOD	_	_
34	site	_	NN	NN	_	29	PMOD	_	_
35	.	_	.	.	_	7	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	new	_	JJ	JJ	_	3	NMOD	_	_
3	site	_	NN	NN	_	4	SBJ	_	_
4	plays	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	critical	_	JJ	JJ	_	7	NMOD	_	_
7	role	_	NN	NN	_	4	OBJ	_	_
8	in	_	IN	IN	_	4	ADV	_	_
9	the	_	DT	DT	_	14	NMOD	_	_
10	calcium-mediated	_	JJ	JJ	_	14	NMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	cyclosporin	_	NN	NN	_	10	COORD	_	_
13	A-sensitive	_	JJ	JJ	_	12	AMOD	_	_
14	induction	_	NN	NN	_	8	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	TNF-alpha	_	NN	NN	_	15	PMOD	_	_
17	in	_	IN	IN	_	14	NMOD	_	_
18	both	_	CC	CC	_	21	CC	_	_
19	A20	_	NN	NN	_	21	NMOD	_	_
20	B	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	17	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	Ar-5	_	NN	NN	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	21	COORD	_	_
25	.	_	.	.	_	4	P	_	_

1	Consistent	_	JJ	JJ	_	19	VMOD	_	_
2	with	_	IN	IN	_	1	AMOD	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	results	_	NNS	NNS	_	2	PMOD	_	_
5	,	_	,	,	_	19	P	_	_
6	quantitative	_	JJ	JJ	_	8	NMOD	_	_
7	DNase	_	NN	NN	_	8	NMOD	_	_
8	footprinting	_	NN	NN	_	19	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	TNF-alpha	_	NN	NN	_	12	NMOD	_	_
12	promoter	_	NN	NN	_	9	PMOD	_	_
13	using	_	VBG	VBG	_	8	NMOD	_	_
14	increasing	_	VBG	VBG	_	15	NMOD	_	_
15	amounts	_	NNS	NNS	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	recombinant	_	JJ	JJ	_	18	NMOD	_	_
18	NFATp	_	NN	NN	_	16	PMOD	_	_
19	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
20	that	_	IN	IN	_	19	OBJ	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	-76	_	CD	CD	_	23	NMOD	_	_
23	site	_	NN	NN	_	24	SBJ	_	_
24	binds	_	VBZ	VBZ	_	20	VMOD	_	_
25	to	_	TO	TO	_	24	ADV	_	_
26	NFATp	_	NN	NN	_	25	PMOD	_	_
27	with	_	IN	IN	_	24	ADV	_	_
28	a	_	DT	DT	_	30	NMOD	_	_
29	higher	_	JJR	JJR	_	30	NMOD	_	_
30	affinity	_	NN	NN	_	27	PMOD	_	_
31	than	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	35	NMOD	_	_
33	kappa	_	NN	NN	_	35	NMOD	_	_
34	3	_	CD	CD	_	35	NMOD	_	_
35	site	_	NN	NN	_	31	PMOD	_	_
36	.	_	.	.	_	19	P	_	_

1	Two	_	CD	CD	_	6	NMOD	_	_
2	other	_	JJ	JJ	_	6	NMOD	_	_
3	previously	_	RB	RB	_	4	AMOD	_	_
4	unrecognized	_	JJ	JJ	_	6	NMOD	_	_
5	NFATp-binding	_	JJ	JJ	_	6	NMOD	_	_
6	sites	_	NNS	NNS	_	12	SBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	proximal	_	JJ	JJ	_	11	NMOD	_	_
10	TNF-alpha	_	NN	NN	_	11	NMOD	_	_
11	promoter	_	NN	NN	_	7	PMOD	_	_
12	were	_	VBD	VBD	_	0	ROOT-S	_	_
13	also	_	RB	RB	_	12	ADV	_	_
14	identified	_	VBN	VBN	_	12	VC	_	_
15	by	_	IN	IN	_	14	LGS	_	_
16	this	_	DT	DT	_	17	NMOD	_	_
17	analysis	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	12	P	_	_

1	Thus	_	RB	RB	_	22	ADV	_	_
2	,	_	,	,	_	22	P	_	_
3	through	_	IN	IN	_	22	ADV	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	differential	_	JJ	JJ	_	6	NMOD	_	_
6	use	_	NN	NN	_	3	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	same	_	JJ	JJ	_	11	NMOD	_	_
10	promoter	_	NN	NN	_	11	NMOD	_	_
11	element	_	NN	NN	_	7	PMOD	_	_
12	,	_	,	,	_	11	P	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	composite	_	JJ	JJ	_	17	NMOD	_	_
15	kappa	_	NN	NN	_	17	NMOD	_	_
16	3\/CRE	_	NN	NN	_	17	NMOD	_	_
17	site	_	NN	NN	_	11	NMOD	_	_
18	,	_	,	,	_	22	P	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	TNF-alpha	_	NN	NN	_	21	NMOD	_	_
21	gene	_	NN	NN	_	22	SBJ	_	_
22	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
23	regulated	_	VBN	VBN	_	22	VC	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	cell-type-specific	_	JJ	JJ	_	27	NMOD	_	_
27	manner	_	NN	NN	_	24	PMOD	_	_
28	in	_	IN	IN	_	23	ADV	_	_
29	response	_	NN	NN	_	28	DEP	_	_
30	to	_	TO	TO	_	28	DEP	_	_
31	the	_	DT	DT	_	34	NMOD	_	_
32	same	_	JJ	JJ	_	34	NMOD	_	_
33	extracellular	_	JJ	JJ	_	34	NMOD	_	_
34	signal	_	NN	NN	_	28	PMOD	_	_
35	.	_	.	.	_	22	P	_	_

1	Interleukin-6	_	NN	NN	_	2	SBJ	_	_
2	promotes	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	multiple	_	JJ	JJ	_	6	NMOD	_	_
4	myeloma	_	NN	NN	_	6	NMOD	_	_
5	cell	_	NN	NN	_	6	NMOD	_	_
6	growth	_	NN	NN	_	2	OBJ	_	_
7	via	_	IN	IN	_	2	ADV	_	_
8	phosphorylation	_	NN	NN	_	7	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	retinoblastoma	_	NN	NN	_	11	NMOD	_	_
11	protein	_	NN	NN	_	9	PMOD	_	_
12	.	_	.	.	_	2	P	_	_

1	Interleukin-6	_	NN	NN	_	5	SBJ	_	_
2	(	_	(	(	_	3	P	_	_
3	IL-6	_	NN	NN	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	mediates	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	autocrine	_	NN	NN	_	9	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	paracrine	_	NN	NN	_	6	COORD	_	_
9	growth	_	NN	NN	_	5	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	multiple	_	JJ	JJ	_	12	NMOD	_	_
12	myeloma	_	NN	NN	_	16	NMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	MM	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	cells	_	NNS	NNS	_	10	PMOD	_	_
17	and	_	CC	CC	_	5	CC	_	_
18	inhibits	_	VBZ	VBZ	_	5	COORD	_	_
19	tumor	_	NN	NN	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	apoptosis	_	NN	NN	_	18	OBJ	_	_
22	.	_	.	.	_	5	P	_	_

1	Abnormalities	_	NNS	NNS	_	13	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	retinoblastoma	_	NN	NN	_	4	NMOD	_	_
4	protein	_	NN	NN	_	2	PMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	pRB	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	and	_	CC	CC	_	1	CC	_	_
9	mutations	_	NNS	NNS	_	1	COORD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	RB	_	NN	NN	_	12	NMOD	_	_
12	gene	_	NN	NN	_	10	PMOD	_	_
13	have	_	VBP	VBP	_	0	ROOT-S	_	_
14	been	_	VBN	VBN	_	13	VC	_	_
15	reported	_	VBN	VBN	_	14	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	up	_	IN	IN	_	19	DEP	_	_
18	to	_	TO	TO	_	19	DEP	_	_
19	70	_	CD	CD	_	20	NMOD	_	_
20	%	_	NN	NN	_	16	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	MM	_	NN	NN	_	23	NMOD	_	_
23	patients	_	NNS	NNS	_	21	PMOD	_	_
24	and	_	CC	CC	_	20	CC	_	_
25	80	_	CD	CD	_	26	NMOD	_	_
26	%	_	NN	NN	_	20	COORD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	MM-derived	_	JJ	JJ	_	30	NMOD	_	_
29	cell	_	NN	NN	_	30	NMOD	_	_
30	lines	_	NNS	NNS	_	27	PMOD	_	_
31	.	_	.	.	_	13	P	_	_

1	Because	_	IN	IN	_	30	ADV	_	_
2	dephosphorylated	_	VBN	VBN	_	6	NMOD	_	_
3	(	_	(	(	_	4	P	_	_
4	activated	_	VBN	VBN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	pRB	_	NN	NN	_	7	SBJ	_	_
7	blocks	_	VBZ	VBZ	_	1	VMOD	_	_
8	transition	_	NN	NN	_	7	OBJ	_	_
9	from	_	IN	IN	_	8	NMOD	_	_
10	G1	_	NN	NN	_	9	PMOD	_	_
11	to	_	TO	TO	_	8	NMOD	_	_
12	S	_	NN	NN	_	11	PMOD	_	_
13	phase	_	NN	NN	_	10	NMOD	_	_
14	of	_	IN	IN	_	10	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	cycle	_	NN	NN	_	14	PMOD	_	_
18	whereas	_	IN	IN	_	7	VMOD	_	_
19	phosphorylated	_	VBN	VBN	_	23	NMOD	_	_
20	(	_	(	(	_	21	P	_	_
21	inactivated	_	VBN	VBN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	pRB	_	NN	NN	_	24	SBJ	_	_
24	releases	_	VBZ	VBZ	_	7	VMOD	_	_
25	this	_	DT	DT	_	27	NMOD	_	_
26	growth	_	NN	NN	_	27	NMOD	_	_
27	arrest	_	NN	NN	_	24	OBJ	_	_
28	,	_	,	,	_	30	P	_	_
29	we	_	PRP	PRP	_	30	SBJ	_	_
30	characterized	_	VBD	VBD	_	0	ROOT-S	_	_
31	the	_	DT	DT	_	32	NMOD	_	_
32	role	_	NN	NN	_	30	OBJ	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	pRB	_	NN	NN	_	33	PMOD	_	_
35	in	_	IN	IN	_	32	NMOD	_	_
36	IL-6-mediated	_	JJ	JJ	_	39	NMOD	_	_
37	MM	_	NN	NN	_	39	NMOD	_	_
38	cell	_	NN	NN	_	39	NMOD	_	_
39	growth	_	NN	NN	_	35	PMOD	_	_
40	.	_	.	.	_	30	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	phosphorylated	_	VBN	VBN	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	dephosphorylated	_	VBN	VBN	_	2	COORD	_	_
5	pRB	_	NN	NN	_	6	SBJ	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	expressed	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	all	_	DT	DT	_	13	NMOD	_	_
10	serum-starved	_	JJ	JJ	_	13	NMOD	_	_
11	MM	_	NN	NN	_	13	NMOD	_	_
12	patient	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	8	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	MM-derived	_	JJ	JJ	_	17	NMOD	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	lines	_	NNS	NNS	_	13	COORD	_	_
18	,	_	,	,	_	6	P	_	_
19	but	_	CC	CC	_	6	CC	_	_
20	pRB	_	NN	NN	_	21	SBJ	_	_
21	was	_	VBD	VBD	_	6	COORD	_	_
22	predominantly	_	RB	RB	_	21	ADV	_	_
23	in	_	IN	IN	_	21	PRD	_	_
24	its	_	PRP$	PRP$	_	26	NMOD	_	_
25	phosphorylated	_	JJ	JJ	_	26	NMOD	_	_
26	form	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	13	ADV	_	_
2	MM	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	that	_	WDT	WDT	_	5	SBJ	_	_
5	proliferated	_	VBD	VBD	_	3	NMOD	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	response	_	NN	NN	_	6	DEP	_	_
8	to	_	TO	TO	_	6	DEP	_	_
9	IL-6	_	NN	NN	_	6	PMOD	_	_
10	,	_	,	,	_	13	P	_	_
11	exogenous	_	JJ	JJ	_	12	NMOD	_	_
12	IL-6	_	NN	NN	_	13	SBJ	_	_
13	downregulated	_	VBD	VBD	_	0	ROOT-S	_	_
14	dephosphorylated	_	VBN	VBN	_	15	NMOD	_	_
15	pRB	_	NN	NN	_	13	OBJ	_	_
16	and	_	CC	CC	_	13	CC	_	_
17	decreased	_	VBD	VBD	_	13	COORD	_	_
18	dephosphorylated	_	VBN	VBN	_	20	NMOD	_	_
19	pRB-E2F	_	NN	NN	_	20	NMOD	_	_
20	complexes	_	NNS	NNS	_	17	OBJ	_	_
21	.	_	.	.	_	13	P	_	_

1	Importantly	_	RB	RB	_	20	ADV	_	_
2	,	_	,	,	_	20	P	_	_
3	culture	_	NN	NN	_	20	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	MM	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	with	_	IN	IN	_	6	NMOD	_	_
8	RB	_	NN	NN	_	16	NMOD	_	_
9	antisense	_	JJ	JJ	_	8	AMOD	_	_
10	,	_	,	,	_	8	P	_	_
11	but	_	CC	CC	_	8	CC	_	_
12	not	_	RB	RB	_	14	AMOD	_	_
13	RB	_	NN	NN	_	14	AMOD	_	_
14	sense	_	NN	NN	_	8	COORD	_	_
15	,	_	,	,	_	8	P	_	_
16	oligonucleotide	_	NN	NN	_	7	PMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	ODN	_	NN	NN	_	16	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	triggered	_	VBD	VBD	_	0	ROOT-S	_	_
21	IL-6	_	NN	NN	_	20	OBJ	_	_
22	secretion	_	NN	NN	_	21	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	proliferation	_	NN	NN	_	22	COORD	_	_
25	in	_	IN	IN	_	21	NMOD	_	_
26	MM	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	;	_	:	:	_	20	P	_	_
29	however	_	RB	RB	_	32	ADV	_	_
30	,	_	,	,	_	32	P	_	_
31	proliferation	_	NN	NN	_	32	SBJ	_	_
32	was	_	VBD	VBD	_	20	VMOD	_	_
33	only	_	RB	RB	_	32	ADV	_	_
34	partially	_	RB	RB	_	33	AMOD	_	_
35	inhibited	_	VBN	VBN	_	32	VC	_	_
36	by	_	IN	IN	_	35	LGS	_	_
37	neutralizing	_	VBG	VBG	_	36	PMOD	_	_
38	anti-IL-6	_	JJ	JJ	_	40	NMOD	_	_
39	monoclonal	_	JJ	JJ	_	40	NMOD	_	_
40	antibody	_	NN	NN	_	37	OBJ	_	_
41	(	_	(	(	_	42	P	_	_
42	MoAb	_	NN	NN	_	40	PRN	_	_
43	)	_	)	)	_	42	P	_	_
44	.	_	.	.	_	32	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	contrast	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	MM	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	1	PMOD	_	_
6	,	_	,	,	_	11	P	_	_
7	normal	_	JJ	JJ	_	10	NMOD	_	_
8	splenic	_	JJ	JJ	_	10	NMOD	_	_
9	B	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	11	SBJ	_	_
11	express	_	VBP	VBP	_	0	ROOT-S	_	_
12	dephosphorylated	_	VBN	VBN	_	13	NMOD	_	_
13	pRB	_	NN	NN	_	11	OBJ	_	_
14	.	_	.	.	_	11	P	_	_

1	Although	_	IN	IN	_	30	ADV	_	_
2	CD40	_	NN	NN	_	3	NMOD	_	_
3	ligand	_	NN	NN	_	7	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	CD40L	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	triggers	_	VBZ	VBZ	_	1	VMOD	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	shift	_	NN	NN	_	7	OBJ	_	_
10	from	_	IN	IN	_	9	NMOD	_	_
11	dephosphorylated	_	VBN	VBN	_	14	NMOD	_	_
12	to	_	TO	TO	_	9	NMOD	_	_
13	phosphorylated	_	VBN	VBN	_	12	NMOD	_	_
14	pRB	_	NN	NN	_	10	PMOD	_	_
15	and	_	CC	CC	_	9	CC	_	_
16	proliferation	_	NN	NN	_	9	COORD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	17	PMOD	_	_
20	,	_	,	,	_	30	P	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	addition	_	NN	NN	_	30	SBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	exogenous	_	JJ	JJ	_	25	NMOD	_	_
25	IL-6	_	NN	NN	_	23	PMOD	_	_
26	to	_	TO	TO	_	22	NMOD	_	_
27	CD40L-treated	_	JJ	JJ	_	29	NMOD	_	_
28	B	_	NN	NN	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	26	PMOD	_	_
30	does	_	VBZ	VBZ	_	0	ROOT-S	_	_
31	not	_	RB	RB	_	30	VMOD	_	_
32	alter	_	VB	VB	_	30	VC	_	_
33	either	_	CC	CC	_	34	CC	_	_
34	pRB	_	NN	NN	_	32	OBJ	_	_
35	or	_	CC	CC	_	34	CC	_	_
36	proliferation	_	NN	NN	_	34	COORD	_	_
37	,	_	,	,	_	32	P	_	_
38	as	_	IN	IN	_	32	ADV	_	_
39	observed	_	VBN	VBN	_	38	VMOD	_	_
40	in	_	IN	IN	_	39	ADV	_	_
41	MM	_	NN	NN	_	42	NMOD	_	_
42	cells	_	NNS	NNS	_	40	PMOD	_	_
43	.	_	.	.	_	30	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	phosphorylated	_	VBN	VBN	_	6	NMOD	_	_
6	pRB	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	4	VMOD	_	_
8	constitutively	_	RB	RB	_	7	ADV	_	_
9	expressed	_	VBN	VBN	_	7	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	MM	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	and	_	CC	CC	_	4	CC	_	_
14	that	_	IN	IN	_	4	COORD	_	_
15	IL-6	_	NN	NN	_	17	SBJ	_	_
16	further	_	RB	RB	_	17	ADV	_	_
17	shifts	_	VBZ	VBZ	_	14	VMOD	_	_
18	pRB	_	NN	NN	_	17	IOBJ	_	_
19	from	_	IN	IN	_	17	ADV	_	_
20	its	_	PRP$	PRP$	_	25	NMOD	_	_
21	dephosphorylated	_	JJ	JJ	_	25	NMOD	_	_
22	to	_	TO	TO	_	17	ADV	_	_
23	its	_	PRP$	PRP$	_	22	NMOD	_	_
24	phosphorylated	_	JJ	JJ	_	22	NMOD	_	_
25	form	_	NN	NN	_	19	PMOD	_	_
26	,	_	,	,	_	17	P	_	_
27	thereby	_	RB	RB	_	28	ADV	_	_
28	promoting	_	VBG	VBG	_	17	OBJ	_	_
29	MM	_	NN	NN	_	31	NMOD	_	_
30	cell	_	NN	NN	_	31	NMOD	_	_
31	growth	_	NN	NN	_	28	OBJ	_	_
32	via	_	IN	IN	_	28	ADV	_	_
33	two	_	CD	CD	_	34	NMOD	_	_
34	mechanisms	_	NNS	NNS	_	32	PMOD	_	_
35	;	_	:	:	_	34	P	_	_
36	by	_	IN	IN	_	34	NMOD	_	_
37	decreasing	_	VBG	VBG	_	36	PMOD	_	_
38	the	_	DT	DT	_	39	NMOD	_	_
39	amount	_	NN	NN	_	37	IOBJ	_	_
40	of	_	IN	IN	_	39	NMOD	_	_
41	E2F	_	NN	NN	_	40	PMOD	_	_
42	bound	_	VBN	VBN	_	41	NMOD	_	_
43	by	_	IN	IN	_	42	LGS	_	_
44	dephosphorylated	_	VBN	VBN	_	45	NMOD	_	_
45	pRB	_	NN	NN	_	43	PMOD	_	_
46	due	_	IN	IN	_	37	ADV	_	_
47	to	_	TO	TO	_	46	DEP	_	_
48	reduced	_	VBN	VBN	_	50	NMOD	_	_
49	dephosphorylated	_	VBN	VBN	_	50	NMOD	_	_
50	pRB	_	NN	NN	_	46	PMOD	_	_
51	,	_	,	,	_	37	P	_	_
52	thereby	_	RB	RB	_	53	ADV	_	_
53	releasing	_	VBG	VBG	_	37	OBJ	_	_
54	growth	_	NN	NN	_	55	NMOD	_	_
55	arrest	_	NN	NN	_	53	OBJ	_	_
56	;	_	:	:	_	36	P	_	_
57	and	_	CC	CC	_	36	CC	_	_
58	by	_	IN	IN	_	36	COORD	_	_
59	upregulating	_	VBG	VBG	_	58	PMOD	_	_
60	IL-6	_	NN	NN	_	61	NMOD	_	_
61	secretion	_	NN	NN	_	59	OBJ	_	_
62	by	_	IN	IN	_	61	NMOD	_	_
63	MM	_	NN	NN	_	64	NMOD	_	_
64	cells	_	NNS	NNS	_	62	PMOD	_	_
65	and	_	CC	CC	_	61	CC	_	_
66	related	_	JJ	JJ	_	71	NMOD	_	_
67	IL-6-mediated	_	JJ	JJ	_	71	NMOD	_	_
68	autocrine	_	JJ	JJ	_	71	NMOD	_	_
69	tumor	_	NN	NN	_	71	NMOD	_	_
70	cell	_	NN	NN	_	71	NMOD	_	_
71	growth	_	NN	NN	_	61	COORD	_	_
72	.	_	.	.	_	3	P	_	_

1	E3	_	NN	NN	_	0	ROOT-FRAG	_	_
2	,	_	,	,	_	1	P	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	hematopoietic-specific	_	JJ	JJ	_	5	NMOD	_	_
5	transcript	_	NN	NN	_	1	NMOD	_	_
6	directly	_	RB	RB	_	7	ADV	_	_
7	regulated	_	VBN	VBN	_	5	NMOD	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	retinoic	_	JJ	JJ	_	13	NMOD	_	_
11	acid	_	NN	NN	_	13	NMOD	_	_
12	receptor	_	NN	NN	_	13	NMOD	_	_
13	alpha	_	NN	NN	_	8	PMOD	_	_
14	.	_	.	.	_	1	P	_	_

1	Retinoic	_	JJ	JJ	_	4	AMOD	_	_
2	acid	_	NN	NN	_	4	AMOD	_	_
3	(	_	(	(	_	4	P	_	_
4	RA	_	NN	NN	_	7	NMOD	_	_
5	)	_	)	)	_	4	P	_	_
6	-induced	_	JJ	JJ	_	4	AMOD	_	_
7	maturation	_	NN	NN	_	19	SBJ	_	_
8	mediated	_	VBN	VBN	_	7	NMOD	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	retinoic	_	JJ	JJ	_	14	NMOD	_	_
12	acid	_	NN	NN	_	14	NMOD	_	_
13	receptor	_	NN	NN	_	14	NMOD	_	_
14	alpha	_	NN	NN	_	9	PMOD	_	_
15	(	_	(	(	_	17	P	_	_
16	RAR	_	NN	NN	_	17	NMOD	_	_
17	alpha	_	NN	NN	_	14	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
20	been	_	VBN	VBN	_	19	VC	_	_
21	implicated	_	VBN	VBN	_	20	VC	_	_
22	in	_	IN	IN	_	21	ADV	_	_
23	myeloid	_	JJ	JJ	_	24	NMOD	_	_
24	development	_	NN	NN	_	22	PMOD	_	_
25	.	_	.	.	_	19	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	used	_	VBN	VBN	_	2	VC	_	_
4	differential	_	JJ	JJ	_	6	NMOD	_	_
5	hybridization	_	NN	NN	_	6	NMOD	_	_
6	analysis	_	NN	NN	_	3	IOBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	cDNA	_	NN	NN	_	10	NMOD	_	_
10	library	_	NN	NN	_	7	PMOD	_	_
11	constructed	_	VBN	VBN	_	10	NMOD	_	_
12	from	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	19	NMOD	_	_
14	murine	_	JJ	JJ	_	19	NMOD	_	_
15	RA-inducible	_	JJ	JJ	_	19	NMOD	_	_
16	MPRO	_	NN	NN	_	19	NMOD	_	_
17	promyelocyte	_	NN	NN	_	19	NMOD	_	_
18	cell	_	NN	NN	_	19	NMOD	_	_
19	line	_	NN	NN	_	12	PMOD	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	identify	_	VB	VB	_	3	OBJ	_	_
22	immediate-early	_	JJ	JJ	_	23	NMOD	_	_
23	genes	_	NNS	NNS	_	21	OBJ	_	_
24	induced	_	VBN	VBN	_	23	NMOD	_	_
25	by	_	IN	IN	_	24	LGS	_	_
26	RA	_	NN	NN	_	25	PMOD	_	_
27	during	_	IN	IN	_	24	TMP	_	_
28	granulocytic	_	JJ	JJ	_	29	NMOD	_	_
29	differentiation	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	2	P	_	_

1	E3	_	NN	NN	_	9	SBJ	_	_
2	,	_	,	,	_	1	P	_	_
3	one	_	CD	CD	_	1	NMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	nine	_	CD	CD	_	6	NMOD	_	_
6	sequences	_	NNS	NNS	_	4	PMOD	_	_
7	identified	_	VBN	VBN	_	6	NMOD	_	_
8	,	_	,	,	_	1	P	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	upregulated	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	an	_	DT	DT	_	14	NMOD	_	_
13	immediate-early	_	JJ	JJ	_	14	NMOD	_	_
14	manner	_	NN	NN	_	11	PMOD	_	_
15	,	_	,	,	_	10	P	_	_
16	with	_	IN	IN	_	10	ADV	_	_
17	transcript	_	NN	NN	_	18	NMOD	_	_
18	levels	_	NNS	NNS	_	19	SBJ	_	_
19	peaking	_	VBG	VBG	_	16	PMOD	_	_
20	after	_	IN	IN	_	19	TMP	_	_
21	60	_	CD	CD	_	22	NMOD	_	_
22	minutes	_	NNS	NNS	_	20	PMOD	_	_
23	exposure	_	NN	NN	_	22	NMOD	_	_
24	to	_	TO	TO	_	22	NMOD	_	_
25	RA	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	9	P	_	_

1	E3	_	NN	NN	_	2	NMOD	_	_
2	transcripts	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	RA-inducible	_	JJ	JJ	_	3	PRD	_	_
5	in	_	IN	IN	_	3	VMOD	_	_
6	HL60	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	5	PMOD	_	_
8	,	_	,	,	_	3	P	_	_
9	but	_	CC	CC	_	3	CC	_	_
10	not	_	RB	RB	_	11	DEP	_	_
11	in	_	IN	IN	_	5	GAP	_	_
12	an	_	DT	DT	_	14	NMOD	_	_
13	RA-resistant	_	JJ	JJ	_	14	NMOD	_	_
14	subclone	_	NN	NN	_	11	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	HL60R	_	NN	NN	_	14	NMOD	_	_
17	,	_	,	,	_	14	P	_	_
18	that	_	WDT	WDT	_	19	SBJ	_	_
19	harbors	_	VBZ	VBZ	_	14	NMOD	_	_
20	a	_	DT	DT	_	24	NMOD	_	_
21	mutated	_	VBN	VBN	_	24	NMOD	_	_
22	RAR	_	NN	NN	_	24	NMOD	_	_
23	alpha	_	NN	NN	_	24	NMOD	_	_
24	gene	_	NN	NN	_	19	OBJ	_	_
25	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	19	ADV	_	_
2	,	_	,	,	_	19	P	_	_
3	when	_	WRB	WRB	_	7	ADV	_	_
4	HL60R	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	6	SBJ	_	_
6	were	_	VBD	VBD	_	19	TMP	_	_
7	transduced	_	VBN	VBN	_	6	VC	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	functional	_	JJ	JJ	_	11	NMOD	_	_
11	copy	_	NN	NN	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	RAR	_	NN	NN	_	16	NMOD	_	_
15	alpha	_	NN	NN	_	16	NMOD	_	_
16	gene	_	NN	NN	_	12	PMOD	_	_
17	,	_	,	,	_	19	P	_	_
18	RA	_	NN	NN	_	19	SBJ	_	_
19	induced	_	VBD	VBD	_	0	ROOT-S	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	10-fold	_	JJ	JJ	_	22	NMOD	_	_
22	increase	_	NN	NN	_	19	OBJ	_	_
23	in	_	IN	IN	_	22	NMOD	_	_
24	E3	_	NN	NN	_	26	NMOD	_	_
25	mRNA	_	NN	NN	_	26	NMOD	_	_
26	levels	_	NNS	NNS	_	23	PMOD	_	_
27	.	_	.	.	_	19	P	_	_

1	E3	_	NN	NN	_	2	NMOD	_	_
2	transcripts	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	present	_	JJ	JJ	_	3	PRD	_	_
5	in	_	IN	IN	_	4	AMOD	_	_
6	the	_	DT	DT	_	13	NMOD	_	_
7	myeloid	_	JJ	JJ	_	13	NMOD	_	_
8	,	_	,	,	_	7	P	_	_
9	B-lymphoid	_	JJ	JJ	_	7	COORD	_	_
10	,	_	,	,	_	7	P	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	erythroid	_	JJ	JJ	_	7	COORD	_	_
13	lineages	_	NNS	NNS	_	5	PMOD	_	_
14	,	_	,	,	_	4	P	_	_
15	absent	_	JJ	JJ	_	4	COORD	_	_
16	in	_	IN	IN	_	15	AMOD	_	_
17	nonhematopoietic	_	JJ	JJ	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	16	PMOD	_	_
19	,	_	,	,	_	3	P	_	_
20	and	_	CC	CC	_	3	CC	_	_
21	encode	_	VBP	VBP	_	3	COORD	_	_
22	a	_	DT	DT	_	28	NMOD	_	_
23	highly	_	RB	RB	_	24	AMOD	_	_
24	hydrophobic	_	JJ	JJ	_	28	NMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	potentially	_	RB	RB	_	27	AMOD	_	_
27	phosphorylated	_	VBN	VBN	_	24	COORD	_	_
28	polypeptide	_	NN	NN	_	21	OBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	unknown	_	JJ	JJ	_	31	NMOD	_	_
31	function	_	NN	NN	_	29	PMOD	_	_
32	with	_	IN	IN	_	28	NMOD	_	_
33	significant	_	JJ	JJ	_	34	NMOD	_	_
34	homology	_	NN	NN	_	32	PMOD	_	_
35	to	_	TO	TO	_	34	NMOD	_	_
36	a	_	DT	DT	_	38	NMOD	_	_
37	putative	_	JJ	JJ	_	38	NMOD	_	_
38	protein	_	NN	NN	_	35	PMOD	_	_
39	expressed	_	VBN	VBN	_	38	NMOD	_	_
40	in	_	IN	IN	_	39	ADV	_	_
41	myeloid	_	JJ	JJ	_	42	NMOD	_	_
42	cells	_	NNS	NNS	_	40	PMOD	_	_
43	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	murine	_	JJ	JJ	_	4	NMOD	_	_
3	E3	_	NN	NN	_	4	NMOD	_	_
4	promoter	_	NN	NN	_	5	SBJ	_	_
5	harbors	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	12	NMOD	_	_
7	single	_	JJ	JJ	_	12	NMOD	_	_
8	bipartite	_	JJ	JJ	_	12	NMOD	_	_
9	retinoic	_	JJ	JJ	_	12	NMOD	_	_
10	acid	_	NN	NN	_	12	NMOD	_	_
11	response	_	NN	NN	_	12	NMOD	_	_
12	element	_	NN	NN	_	5	OBJ	_	_
13	which	_	WDT	WDT	_	18	SBJ	_	_
14	in	_	IN	IN	_	18	ADV	_	_
15	transient	_	NN	NN	_	17	NMOD	_	_
16	transfection	_	NN	NN	_	17	NMOD	_	_
17	assays	_	NNS	NNS	_	14	PMOD	_	_
18	conferred	_	VBD	VBD	_	12	NMOD	_	_
19	RA	_	NN	NN	_	20	NMOD	_	_
20	sensitivity	_	NN	NN	_	18	OBJ	_	_
21	.	_	.	.	_	5	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	E3	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	4	VMOD	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	hematopoietic-specific	_	JJ	JJ	_	9	NMOD	_	_
9	gene	_	NN	NN	_	6	PRD	_	_
10	that	_	WDT	WDT	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	9	NMOD	_	_
12	an	_	DT	DT	_	14	NMOD	_	_
13	immediate	_	JJ	JJ	_	14	NMOD	_	_
14	target	_	NN	NN	_	11	PRD	_	_
15	for	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	activated	_	VBN	VBN	_	19	NMOD	_	_
18	RAR	_	NN	NN	_	19	NMOD	_	_
19	alpha	_	NN	NN	_	15	PMOD	_	_
20	during	_	IN	IN	_	14	TMP	_	_
21	myelopoiesis	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	Human	_	JJ	JJ	_	2	NMOD	_	_
2	TAFII	_	NN	NN	_	4	SBJ	_	_
3	105	_	CD	CD	_	2	NMOD	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	9	NMOD	_	_
6	cell	_	NN	NN	_	9	NMOD	_	_
7	type-specific	_	JJ	JJ	_	6	AMOD	_	_
8	TFIID	_	NN	NN	_	9	NMOD	_	_
9	subunit	_	NN	NN	_	4	PRD	_	_
10	related	_	JJ	JJ	_	9	NMOD	_	_
11	to	_	TO	TO	_	10	AMOD	_	_
12	hTAFII130	_	NN	NN	_	11	PMOD	_	_
13	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	previously	_	RB	RB	_	3	TMP	_	_
3	characterized	_	VBD	VBD	_	0	ROOT-S	_	_
4	Drosophila	_	NN	NN	_	8	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	human	_	JJ	JJ	_	7	NMOD	_	_
7	TAF	_	NN	NN	_	4	COORD	_	_
8	subunits	_	NNS	NNS	_	3	OBJ	_	_
9	that	_	WDT	WDT	_	10	SBJ	_	_
10	make	_	VBP	VBP	_	8	NMOD	_	_
11	up	_	RP	RP	_	10	PRT	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	core	_	NN	NN	_	15	NMOD	_	_
14	TFIID	_	NN	NN	_	15	NMOD	_	_
15	complex	_	NN	NN	_	10	OBJ	_	_
16	found	_	VBN	VBN	_	15	NMOD	_	_
17	in	_	IN	IN	_	16	ADV	_	_
18	all	_	DT	DT	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Here	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	report	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	differentiated	_	VBN	VBN	_	8	NMOD	_	_
7	B	_	NN	NN	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	9	SBJ	_	_
9	contain	_	VBP	VBP	_	5	VMOD	_	_
10	a	_	DT	DT	_	13	NMOD	_	_
11	novel	_	JJ	JJ	_	13	NMOD	_	_
12	substoichiometric	_	JJ	JJ	_	13	NMOD	_	_
13	TAF	_	NN	NN	_	9	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	105	_	CD	CD	_	16	NMOD	_	_
16	kDa	_	NN	NN	_	14	PMOD	_	_
17	not	_	RB	RB	_	18	VMOD	_	_
18	found	_	VBN	VBN	_	13	NMOD	_	_
19	associated	_	VBN	VBN	_	18	OBJ	_	_
20	with	_	IN	IN	_	19	ADV	_	_
21	TFIID	_	NN	NN	_	20	PMOD	_	_
22	isolated	_	VBN	VBN	_	21	NMOD	_	_
23	from	_	IN	IN	_	22	ADV	_	_
24	other	_	JJ	JJ	_	26	NMOD	_	_
25	cell	_	NN	NN	_	26	NMOD	_	_
26	types	_	NNS	NNS	_	23	PMOD	_	_
27	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	cDNA	_	NN	NN	_	4	NMOD	_	_
3	encoding	_	NN	NN	_	4	NMOD	_	_
4	hTAFII105	_	NN	NN	_	5	SBJ	_	_
5	reveals	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	10	NMOD	_	_
7	highly	_	RB	RB	_	8	AMOD	_	_
8	conserved	_	VBN	VBN	_	10	NMOD	_	_
9	C-terminal	_	JJ	JJ	_	10	NMOD	_	_
10	domain	_	NN	NN	_	5	IOBJ	_	_
11	shared	_	VBN	VBN	_	10	NMOD	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	hTAFII130	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	oTAFII110	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	5	P	_	_
17	while	_	IN	IN	_	5	OBJ	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	N-terminal	_	JJ	JJ	_	21	NMOD	_	_
20	coactivator	_	NN	NN	_	21	NMOD	_	_
21	domain	_	NN	NN	_	22	SBJ	_	_
22	has	_	VBZ	VBZ	_	17	VMOD	_	_
23	diverged	_	VBN	VBN	_	22	VC	_	_
24	significantly	_	RB	RB	_	23	ADV	_	_
25	.	_	.	.	_	5	P	_	_

1	All	_	DT	DT	_	2	NMOD	_	_
2	cells	_	NNS	NNS	_	4	SBJ	_	_
3	tested	_	VBN	VBN	_	2	NMOD	_	_
4	express	_	VBP	VBP	_	0	ROOT-S	_	_
5	TAFII105	_	NN	NN	_	6	NMOD	_	_
6	mRNA	_	NN	NN	_	4	OBJ	_	_
7	,	_	,	,	_	4	P	_	_
8	but	_	CC	CC	_	4	CC	_	_
9	only	_	RB	RB	_	11	NMOD	_	_
10	B	_	NN	NN	_	11	NMOD	_	_
11	cells	_	NNS	NNS	_	12	SBJ	_	_
12	contain	_	VBP	VBP	_	4	COORD	_	_
13	significant	_	JJ	JJ	_	14	NMOD	_	_
14	levels	_	NNS	NNS	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	protein	_	NN	NN	_	15	PMOD	_	_
17	associated	_	VBN	VBN	_	16	NMOD	_	_
18	with	_	IN	IN	_	17	ADV	_	_
19	TFIID	_	NN	NN	_	18	PMOD	_	_
20	.	_	.	.	_	4	P	_	_

1	Transient	_	JJ	JJ	_	2	NMOD	_	_
2	overexpression	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	hTAFII105	_	NN	NN	_	3	PMOD	_	_
5	selectively	_	RB	RB	_	6	ADV	_	_
6	squelches	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	transcription	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	some	_	DT	DT	_	11	NMOD	_	_
11	genes	_	NNS	NNS	_	9	PMOD	_	_
12	in	_	IN	IN	_	8	NMOD	_	_
13	B	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	6	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	properties	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	TAFII105	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	4	VMOD	_	_
7	a	_	DT	DT	_	10	NMOD	_	_
8	cell	_	NN	NN	_	10	NMOD	_	_
9	type-specific	_	JJ	JJ	_	8	AMOD	_	_
10	subunit	_	NN	NN	_	6	PRD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	TFIID	_	NN	NN	_	11	PMOD	_	_
13	that	_	WDT	WDT	_	14	SBJ	_	_
14	may	_	MD	MD	_	10	NMOD	_	_
15	be	_	VB	VB	_	14	VC	_	_
16	responsible	_	JJ	JJ	_	15	PRD	_	_
17	for	_	IN	IN	_	16	AMOD	_	_
18	mediating	_	VBG	VBG	_	17	PMOD	_	_
19	transcription	_	NN	NN	_	18	OBJ	_	_
20	by	_	IN	IN	_	18	ADV	_	_
21	a	_	DT	DT	_	22	NMOD	_	_
22	subset	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	activators	_	NNS	NNS	_	23	PMOD	_	_
25	in	_	IN	IN	_	22	NMOD	_	_
26	B	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	Eosinophil	_	NN	NN	_	2	NMOD	_	_
2	priming	_	NN	NN	_	0	ROOT-FRAG	_	_
3	by	_	IN	IN	_	2	NMOD	_	_
4	cytokines	_	NNS	NNS	_	3	PMOD	_	_
5	:	_	:	:	_	2	P	_	_
6	from	_	IN	IN	_	2	NMOD	_	_
7	cellular	_	JJ	JJ	_	8	NMOD	_	_
8	signal	_	NN	NN	_	6	PMOD	_	_
9	to	_	TO	TO	_	6	PMOD	_	_
10	in	_	FW	FW	_	11	AMOD	_	_
11	vivo	_	FW	FW	_	12	NMOD	_	_
12	modulation	_	NN	NN	_	9	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	Eosinophils	_	NNS	NNS	_	2	SBJ	_	_
2	play	_	VBP	VBP	_	0	ROOT-S	_	_
3	an	_	DT	DT	_	5	NMOD	_	_
4	important	_	JJ	JJ	_	5	NMOD	_	_
5	role	_	NN	NN	_	2	OBJ	_	_
6	in	_	IN	IN	_	2	ADV	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	effector	_	NN	NN	_	9	NMOD	_	_
9	phase	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	allergic	_	JJ	JJ	_	12	NMOD	_	_
12	inflammation	_	NN	NN	_	10	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	review	_	NN	NN	_	3	SBJ	_	_
3	will	_	MD	MD	_	0	ROOT-S	_	_
4	focus	_	VB	VB	_	3	VC	_	_
5	on	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	conversion	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	unprimed	_	JJ	JJ	_	12	NMOD	_	_
11	eosinophil	_	NN	NN	_	12	NMOD	_	_
12	phenotype	_	NN	NN	_	8	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	peripheral	_	JJ	JJ	_	16	NMOD	_	_
16	blood	_	NN	NN	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	normal	_	JJ	JJ	_	19	NMOD	_	_
19	individuals	_	NNS	NNS	_	17	PMOD	_	_
20	to	_	TO	TO	_	7	NMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	primed	_	JJ	JJ	_	23	NMOD	_	_
23	phenotype	_	NN	NN	_	20	PMOD	_	_
24	found	_	VBN	VBN	_	23	NMOD	_	_
25	in	_	IN	IN	_	24	ADV	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	peripheral	_	JJ	JJ	_	28	NMOD	_	_
28	blood	_	NN	NN	_	25	PMOD	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	tissues	_	NNS	NNS	_	28	COORD	_	_
31	of	_	IN	IN	_	28	NMOD	_	_
32	allergic	_	JJ	JJ	_	33	NMOD	_	_
33	patients	_	NNS	NNS	_	31	PMOD	_	_
34	,	_	,	,	_	7	P	_	_
35	a	_	DT	DT	_	36	NMOD	_	_
36	phenomenon	_	NN	NN	_	7	NMOD	_	_
37	called	_	VBN	VBN	_	36	NMOD	_	_
38	priming	_	NN	NN	_	37	OBJ	_	_
39	.	_	.	.	_	3	P	_	_

1	Recent	_	JJ	JJ	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	13	SBJ	_	_
3	on	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	signals	_	NNS	NNS	_	3	PMOD	_	_
6	initiated	_	VBN	VBN	_	5	NMOD	_	_
7	after	_	IN	IN	_	6	TMP	_	_
8	cytokine	_	NN	NN	_	10	NMOD	_	_
9	receptor	_	NN	NN	_	10	NMOD	_	_
10	activation	_	NN	NN	_	7	PMOD	_	_
11	on	_	IN	IN	_	10	NMOD	_	_
12	eosinophils	_	NNS	NNS	_	11	PMOD	_	_
13	will	_	MD	MD	_	0	ROOT-S	_	_
14	be	_	VB	VB	_	13	VC	_	_
15	reviewed	_	VBN	VBN	_	14	VC	_	_
16	.	_	.	.	_	13	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	critical	_	JJ	JJ	_	3	NMOD	_	_
3	role	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	Sp1-	_	NN	NN	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	Ets-related	_	JJ	JJ	_	5	COORD	_	_
8	transcription	_	NN	NN	_	9	NMOD	_	_
9	factors	_	NNS	NNS	_	4	PMOD	_	_
10	in	_	IN	IN	_	3	NMOD	_	_
11	maintaining	_	VBG	VBG	_	10	PMOD	_	_
12	CTL-specific	_	JJ	JJ	_	13	NMOD	_	_
13	expression	_	NN	NN	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	mouse	_	NN	NN	_	18	NMOD	_	_
17	perforin	_	NN	NN	_	18	NMOD	_	_
18	gene	_	NN	NN	_	14	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	study	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	designed	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	determine	_	VB	VB	_	4	OBJ	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	potential	_	JJ	JJ	_	9	NMOD	_	_
9	cis-elements	_	NNS	NNS	_	6	OBJ	_	_
10	involved	_	VBN	VBN	_	9	NMOD	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	transcriptional	_	JJ	JJ	_	13	NMOD	_	_
13	regulation	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	mouse	_	NN	NN	_	18	NMOD	_	_
17	perforin	_	NN	NN	_	18	NMOD	_	_
18	gene	_	NN	NN	_	14	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	DNase	_	NN	NN	_	4	NMOD	_	_
2	I	_	CD	CD	_	4	NMOD	_	_
3	hypersensitive	_	JJ	JJ	_	4	NMOD	_	_
4	site	_	NN	NN	_	8	NMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	DHS	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	mapping	_	NN	NN	_	9	SBJ	_	_
9	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
10	that	_	IN	IN	_	9	OBJ	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	perforin	_	NN	NN	_	13	NMOD	_	_
13	locus	_	NN	NN	_	14	SBJ	_	_
14	contained	_	VBD	VBD	_	10	VMOD	_	_
15	six	_	CD	CD	_	16	NMOD	_	_
16	DHS	_	NN	NN	_	14	OBJ	_	_
17	within	_	IN	IN	_	14	VMOD	_	_
18	7.0	_	CD	CD	_	19	NMOD	_	_
19	kb	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	5'	_	JJ	JJ	_	23	AMOD	_	_
23	upstream	_	JJ	JJ	_	24	NMOD	_	_
24	sequence	_	NN	NN	_	20	PMOD	_	_
25	(	_	(	(	_	27	P	_	_
26	-7.0	_	CD	CD	_	27	NMOD	_	_
27	kb	_	NN	NN	_	24	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	and	_	CC	CC	_	14	CC	_	_
30	two	_	CD	CD	_	31	NMOD	_	_
31	DHS	_	NN	NN	_	16	GAP	_	_
32	in	_	IN	IN	_	17	GAP	_	_
33	intron	_	NN	NN	_	32	PMOD	_	_
34	2	_	CD	CD	_	33	NMOD	_	_
35	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	8	NMOD	_	_
2	six	_	CD	CD	_	8	NMOD	_	_
3	5'	_	JJ	JJ	_	4	AMOD	_	_
4	upstream	_	JJ	JJ	_	8	NMOD	_	_
5	and	_	CC	CC	_	8	CC	_	_
6	one	_	CD	CD	_	8	NMOD	_	_
7	intronic	_	JJ	JJ	_	8	NMOD	_	_
8	DHS	_	NN	NN	_	9	SBJ	_	_
9	were	_	VBD	VBD	_	0	ROOT-S	_	_
10	detected	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	only	_	RB	RB	_	14	NMOD	_	_
13	perforin-expressing	_	JJ	JJ	_	14	NMOD	_	_
14	lymphocytes	_	NNS	NNS	_	11	PMOD	_	_
15	.	_	.	.	_	9	P	_	_

1	Chloramphenicol	_	NN	NN	_	2	NMOD	_	_
2	acetyltransferase	_	NN	NN	_	6	NMOD	_	_
3	(	_	(	(	_	4	P	_	_
4	CAT	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	activities	_	NNS	NNS	_	12	SBJ	_	_
7	directed	_	VBN	VBN	_	6	NMOD	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	5'	_	JJ	JJ	_	10	AMOD	_	_
10	upstream	_	JJ	JJ	_	11	NMOD	_	_
11	promoter	_	NN	NN	_	8	PMOD	_	_
12	were	_	VBD	VBD	_	0	ROOT-S	_	_
13	detected	_	VBN	VBN	_	12	VC	_	_
14	preferentially	_	RB	RB	_	13	ADV	_	_
15	in	_	IN	IN	_	13	ADV	_	_
16	perforin-expressing	_	JJ	JJ	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	lines	_	NNS	NNS	_	15	PMOD	_	_
19	.	_	.	.	_	12	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	construct	_	NN	NN	_	8	SBJ	_	_
3	termed	_	VBN	VBN	_	2	NMOD	_	_
4	PFP5a	_	NN	NN	_	3	OBJ	_	_
5	containing	_	VBG	VBG	_	2	NMOD	_	_
6	-795	_	CD	CD	_	7	NMOD	_	_
7	bp	_	NN	NN	_	5	OBJ	_	_
8	exhibited	_	VBD	VBD	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	highest	_	JJS	JJS	_	12	NMOD	_	_
11	CAT	_	NN	NN	_	12	NMOD	_	_
12	activity	_	NN	NN	_	8	OBJ	_	_
13	,	_	,	,	_	8	P	_	_
14	and	_	CC	CC	_	8	CC	_	_
15	PFP9a20	_	NN	NN	_	21	SBJ	_	_
16	containing	_	VBG	VBG	_	15	NMOD	_	_
17	only	_	RB	RB	_	19	NMOD	_	_
18	-73	_	CD	CD	_	19	NMOD	_	_
19	bp	_	NN	NN	_	16	OBJ	_	_
20	also	_	RB	RB	_	21	ADV	_	_
21	produced	_	VBD	VBD	_	8	COORD	_	_
22	significantly	_	RB	RB	_	23	AMOD	_	_
23	high	_	JJ	JJ	_	25	NMOD	_	_
24	CAT	_	NN	NN	_	25	NMOD	_	_
25	activity	_	NN	NN	_	21	OBJ	_	_
26	in	_	IN	IN	_	21	ADV	_	_
27	CTLL-R8	_	NN	NN	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	26	PMOD	_	_
29	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	proximal	_	JJ	JJ	_	3	NMOD	_	_
3	region	_	NN	NN	_	6	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	PFP9a20	_	NN	NN	_	4	PMOD	_	_
6	contained	_	VBD	VBD	_	0	ROOT-S	_	_
7	two	_	CD	CD	_	11	NMOD	_	_
8	potential	_	JJ	JJ	_	11	NMOD	_	_
9	Sp1	_	NN	NN	_	11	NMOD	_	_
10	binding	_	NN	NN	_	11	NMOD	_	_
11	sites	_	NNS	NNS	_	6	OBJ	_	_
12	(	_	(	(	_	14	P	_	_
13	GC	_	NN	NN	_	14	NMOD	_	_
14	box	_	NN	NN	_	11	PRN	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	GT	_	NN	NN	_	17	NMOD	_	_
17	box	_	NN	NN	_	14	COORD	_	_
18	)	_	)	)	_	14	P	_	_
19	and	_	CC	CC	_	11	CC	_	_
20	one	_	CD	CD	_	23	NMOD	_	_
21	Ets	_	NN	NN	_	23	NMOD	_	_
22	binding	_	NN	NN	_	23	NMOD	_	_
23	site	_	NN	NN	_	11	COORD	_	_
24	(	_	(	(	_	25	P	_	_
25	EBS	_	NN	NN	_	23	PRN	_	_
26	)	_	)	)	_	25	P	_	_
27	.	_	.	.	_	6	P	_	_

1	Electrophoretic	_	JJ	JJ	_	4	NMOD	_	_
2	mobility	_	NN	NN	_	4	NMOD	_	_
3	shift	_	NN	NN	_	4	NMOD	_	_
4	assay	_	NN	NN	_	5	SBJ	_	_
5	showed	_	VBD	VBD	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	each	_	DT	DT	_	11	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	cis-elements	_	NNS	NNS	_	8	PMOD	_	_
11	bound	_	VBD	VBD	_	6	VMOD	_	_
12	specific	_	JJ	JJ	_	14	NMOD	_	_
13	protein	_	NN	NN	_	14	NMOD	_	_
14	factors	_	NNS	NNS	_	11	OBJ	_	_
15	.	_	.	.	_	5	P	_	_

1	When	_	WRB	WRB	_	5	ADV	_	_
2	single-point	_	JJ	JJ	_	3	NMOD	_	_
3	mutation	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	25	TMP	_	_
5	introduced	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	each	_	DT	DT	_	9	NMOD	_	_
8	GC	_	NN	NN	_	9	NMOD	_	_
9	box	_	NN	NN	_	6	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	EBS	_	NN	NN	_	9	COORD	_	_
12	,	_	,	,	_	9	P	_	_
13	and	_	CC	CC	_	9	CC	_	_
14	GT	_	NN	NN	_	15	NMOD	_	_
15	box	_	NN	NN	_	9	COORD	_	_
16	in	_	IN	IN	_	9	NMOD	_	_
17	PFP9a20	_	NN	NN	_	16	PMOD	_	_
18	,	_	,	,	_	25	P	_	_
19	at	_	IN	IN	_	21	DEP	_	_
20	least	_	JJS	JJS	_	21	DEP	_	_
21	3-fold	_	RB	RB	_	24	NMOD	_	_
22	less	_	JJR	JJR	_	21	AMOD	_	_
23	CAT	_	NN	NN	_	24	NMOD	_	_
24	activity	_	NN	NN	_	25	SBJ	_	_
25	was	_	VBD	VBD	_	0	ROOT-S	_	_
26	observed	_	VBN	VBN	_	25	VC	_	_
27	in	_	IN	IN	_	26	ADV	_	_
28	CTLL-R8	_	NN	NN	_	29	NMOD	_	_
29	cells	_	NNS	NNS	_	27	PMOD	_	_
30	.	_	.	.	_	25	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	confirm	_	VB	VB	_	18	VC	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	importance	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	three	_	CD	CD	_	9	NMOD	_	_
8	cis-acting	_	JJ	JJ	_	9	NMOD	_	_
9	elements	_	NNS	NNS	_	5	PMOD	_	_
10	in	_	IN	IN	_	4	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	perforin	_	NN	NN	_	14	NMOD	_	_
13	gene	_	NN	NN	_	14	NMOD	_	_
14	expression	_	NN	NN	_	10	PMOD	_	_
15	,	_	,	,	_	18	P	_	_
16	point	_	NN	NN	_	17	NMOD	_	_
17	mutation	_	NN	NN	_	18	SBJ	_	_
18	was	_	VBD	VBD	_	0	ROOT-S	_	_
19	introduced	_	VBN	VBN	_	18	VC	_	_
20	again	_	RB	RB	_	19	TMP	_	_
21	to	_	TO	TO	_	19	ADV	_	_
22	each	_	DT	DT	_	25	NMOD	_	_
23	proximal	_	JJ	JJ	_	25	NMOD	_	_
24	GC	_	NN	NN	_	25	NMOD	_	_
25	box	_	NN	NN	_	21	PMOD	_	_
26	,	_	,	,	_	25	P	_	_
27	EBS	_	NN	NN	_	25	COORD	_	_
28	,	_	,	,	_	25	P	_	_
29	and	_	CC	CC	_	25	CC	_	_
30	GT	_	NN	NN	_	31	NMOD	_	_
31	box	_	NN	NN	_	25	COORD	_	_
32	of	_	IN	IN	_	25	NMOD	_	_
33	PFP5a	_	NN	NN	_	32	PMOD	_	_
34	.	_	.	.	_	18	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	point	_	NN	NN	_	3	NMOD	_	_
3	mutations	_	NNS	NNS	_	4	SBJ	_	_
4	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	a	_	DT	DT	_	10	NMOD	_	_
7	2.5-	_	CD	CD	_	9	DEP	_	_
8	to	_	TO	TO	_	9	DEP	_	_
9	3-fold	_	JJ	JJ	_	10	NMOD	_	_
10	reduction	_	NN	NN	_	5	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	CAT	_	NN	NN	_	13	NMOD	_	_
13	activity	_	NN	NN	_	11	PMOD	_	_
14	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	a	_	DT	DT	_	6	NMOD	_	_
6	combination	_	NN	NN	_	13	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	three	_	CD	CD	_	12	NMOD	_	_
10	proximal	_	JJ	JJ	_	12	NMOD	_	_
11	cis-acting	_	JJ	JJ	_	12	NMOD	_	_
12	elements	_	NNS	NNS	_	7	PMOD	_	_
13	may	_	MD	MD	_	4	VMOD	_	_
14	constitute	_	VB	VB	_	13	VC	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	minimal	_	JJ	JJ	_	17	NMOD	_	_
17	region	_	NN	NN	_	14	OBJ	_	_
18	responsible	_	JJ	JJ	_	17	NMOD	_	_
19	for	_	IN	IN	_	18	AMOD	_	_
20	CTL-specific	_	JJ	JJ	_	21	NMOD	_	_
21	expression	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	perforin	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	Vitamin	_	NN	NN	_	2	NMOD	_	_
2	D3-	_	NN	NN	_	7	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	retinoic	_	JJ	JJ	_	5	AMOD	_	_
5	acid-induced	_	JJ	JJ	_	2	COORD	_	_
6	monocytic	_	JJ	JJ	_	7	NMOD	_	_
7	differentiation	_	NN	NN	_	0	ROOT-FRAG	_	_
8	:	_	:	:	_	7	P	_	_
9	interactions	_	NNS	NNS	_	7	NMOD	_	_
10	between	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	15	NMOD	_	_
12	endogenous	_	JJ	JJ	_	15	NMOD	_	_
13	vitamin	_	NN	NN	_	15	NMOD	_	_
14	D3	_	NN	NN	_	15	NMOD	_	_
15	receptor	_	NN	NN	_	10	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	retinoic	_	JJ	JJ	_	19	NMOD	_	_
18	acid	_	NN	NN	_	19	NMOD	_	_
19	receptors	_	NNS	NNS	_	15	COORD	_	_
20	,	_	,	,	_	15	P	_	_
21	and	_	CC	CC	_	15	CC	_	_
22	retinoid	_	NN	NN	_	24	NMOD	_	_
23	X	_	NN	NN	_	24	NMOD	_	_
24	receptors	_	NNS	NNS	_	15	COORD	_	_
25	in	_	IN	IN	_	15	NMOD	_	_
26	U-937	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	9	P	_	_

1	Retinoic	_	JJ	JJ	_	2	NMOD	_	_
2	acid	_	NN	NN	_	12	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	RA	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	and	_	CC	CC	_	2	CC	_	_
7	1,25	_	CD	CD	_	8	NMOD	_	_
8	alpha-dihydroxycholecalciferol	_	NN	NN	_	2	COORD	_	_
9	(	_	(	(	_	10	P	_	_
10	VitD3	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	are	_	VBP	VBP	_	0	ROOT-S	_	_
13	potent	_	JJ	JJ	_	14	NMOD	_	_
14	regulators	_	NNS	NNS	_	12	PRD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	hematopoletic	_	JJ	JJ	_	17	NMOD	_	_
17	differentiation	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	12	P	_	_

1	Yet	_	RB	RB	_	4	VMOD	_	_
2	,	_	,	,	_	4	P	_	_
3	little	_	JJ	JJ	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	known	_	VBN	VBN	_	4	VC	_	_
6	as	_	IN	IN	_	5	ADV	_	_
7	to	_	TO	TO	_	6	DEP	_	_
8	how	_	WRB	WRB	_	15	ADV	_	_
9	the	_	DT	DT	_	14	NMOD	_	_
10	RA	_	NN	NN	_	14	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	VitD3	_	NN	NN	_	10	COORD	_	_
13	receptor	_	NN	NN	_	14	NMOD	_	_
14	network	_	NN	NN	_	15	SBJ	_	_
15	operates	_	VBZ	VBZ	_	6	PMOD	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	hematopoietic	_	JJ	JJ	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	16	PMOD	_	_
19	,	_	,	,	_	15	P	_	_
20	and	_	CC	CC	_	15	CC	_	_
21	whether	_	IN	IN	_	15	COORD	_	_
22	receptor	_	NN	NN	_	23	NMOD	_	_
23	interactions	_	NNS	NNS	_	24	SBJ	_	_
24	can	_	MD	MD	_	21	VMOD	_	_
25	explain	_	VB	VB	_	24	VC	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	interplay	_	NN	NN	_	25	OBJ	_	_
28	between	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	33	NMOD	_	_
30	RA-	_	NN	NN	_	33	NMOD	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	VitD3-signaling	_	JJ	JJ	_	30	COORD	_	_
33	pathways	_	NNS	NNS	_	28	PMOD	_	_
34	during	_	IN	IN	_	27	TMP	_	_
35	differentiation	_	NN	NN	_	34	PMOD	_	_
36	.	_	.	.	_	4	P	_	_

1	Therefore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	analyzed	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	expression	_	NN	NN	_	4	OBJ	_	_
7	,	_	,	,	_	6	P	_	_
8	DNA	_	NN	NN	_	9	NMOD	_	_
9	binding	_	NN	NN	_	6	COORD	_	_
10	,	_	,	,	_	6	P	_	_
11	and	_	CC	CC	_	6	CC	_	_
12	transcriptional	_	JJ	JJ	_	13	NMOD	_	_
13	activity	_	NN	NN	_	6	COORD	_	_
14	of	_	IN	IN	_	6	NMOD	_	_
15	the	_	DT	DT	_	20	NMOD	_	_
16	endogenous	_	JJ	JJ	_	20	NMOD	_	_
17	RA	_	NN	NN	_	20	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	VitD3	_	NN	NN	_	17	COORD	_	_
20	receptors	_	NNS	NNS	_	14	PMOD	_	_
21	{	_	(	(	_	24	P	_	_
22	retinoic	_	JJ	JJ	_	24	NMOD	_	_
23	acid	_	NN	NN	_	24	NMOD	_	_
24	receptors	_	NNS	NNS	_	20	PRN	_	_
25	(	_	(	(	_	26	P	_	_
26	RARs	_	NNS	NNS	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	,	_	,	,	_	24	P	_	_
29	retinoid	_	NN	NN	_	31	NMOD	_	_
30	X	_	NN	NN	_	31	NMOD	_	_
31	receptors	_	NNS	NNS	_	24	COORD	_	_
32	(	_	(	(	_	33	P	_	_
33	RXRs	_	NNS	NNS	_	31	PRN	_	_
34	)	_	)	)	_	33	P	_	_
35	,	_	,	,	_	24	P	_	_
36	and	_	CC	CC	_	24	CC	_	_
37	VitD3	_	NN	NN	_	38	NMOD	_	_
38	receptor	_	NN	NN	_	24	COORD	_	_
39	(	_	(	(	_	40	P	_	_
40	VDR	_	NN	NN	_	38	PRN	_	_
41	)	_	)	)	_	40	P	_	_
42	}	_	)	)	_	24	P	_	_
43	in	_	IN	IN	_	6	NMOD	_	_
44	the	_	DT	DT	_	47	NMOD	_	_
45	U-937	_	NN	NN	_	47	NMOD	_	_
46	cell	_	NN	NN	_	47	NMOD	_	_
47	line	_	NN	NN	_	43	PMOD	_	_
48	,	_	,	,	_	47	P	_	_
49	in	_	IN	IN	_	54	ADV	_	_
50	which	_	WDT	WDT	_	49	PMOD	_	_
51	RA	_	NN	NN	_	54	SBJ	_	_
52	and	_	CC	CC	_	51	CC	_	_
53	VitD3	_	NN	NN	_	51	COORD	_	_
54	induce	_	VBP	VBP	_	47	NMOD	_	_
55	distinct	_	JJ	JJ	_	58	NMOD	_	_
56	monocytic	_	JJ	JJ	_	58	NMOD	_	_
57	differentiation	_	NN	NN	_	58	NMOD	_	_
58	pathways	_	NNS	NNS	_	54	OBJ	_	_
59	.	_	.	.	_	4	P	_	_

1	VitD3	_	NN	NN	_	2	NMOD	_	_
2	induction	_	NN	NN	_	3	SBJ	_	_
3	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
4	in	_	IN	IN	_	3	ADV	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	formation	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	VDR\/RXR	_	NN	NN	_	10	NMOD	_	_
9	DNA-binding	_	JJ	JJ	_	10	NMOD	_	_
10	complexes	_	NNS	NNS	_	7	PMOD	_	_
11	on	_	IN	IN	_	6	NMOD	_	_
12	both	_	CC	CC	_	15	CC	_	_
13	VitD3	_	NN	NN	_	15	NMOD	_	_
14	response	_	NN	NN	_	15	NMOD	_	_
15	elements	_	NNS	NNS	_	11	PMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	RA	_	NN	NN	_	19	NMOD	_	_
18	response	_	NN	NN	_	19	NMOD	_	_
19	elements	_	NNS	NNS	_	15	COORD	_	_
20	(	_	(	(	_	21	P	_	_
21	RAREs	_	NNS	NNS	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	transcriptional	_	JJ	JJ	_	4	NMOD	_	_
4	activation	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	only	_	RB	RB	_	7	ADV	_	_
7	observed	_	VBN	VBN	_	5	VC	_	_
8	from	_	IN	IN	_	7	ADV	_	_
9	a	_	DT	DT	_	14	NMOD	_	_
10	VitD3	_	NN	NN	_	11	AMOD	_	_
11	response	_	NN	NN	_	14	NMOD	_	_
12	element-driven	_	JJ	JJ	_	11	AMOD	_	_
13	reporter	_	NN	NN	_	14	NMOD	_	_
14	construct	_	NN	NN	_	8	PMOD	_	_
15	.	_	.	.	_	5	P	_	_

1	Several	_	JJ	JJ	_	3	NMOD	_	_
2	DNA-binding	_	JJ	JJ	_	3	NMOD	_	_
3	complexes	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	detected	_	VBN	VBN	_	4	VC	_	_
6	on	_	IN	IN	_	5	ADV	_	_
7	RAREs	_	NNS	NNS	_	6	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	undifferentiated	_	JJ	JJ	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	.	_	.	.	_	4	P	_	_

1	Stimulation	_	NN	NN	_	4	SBJ	_	_
2	by	_	IN	IN	_	1	NMOD	_	_
3	RA	_	NN	NN	_	2	PMOD	_	_
4	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	increased	_	VBN	VBN	_	10	NMOD	_	_
7	RAR	_	NN	NN	_	8	AMOD	_	_
8	beta\/RXR	_	NN	NN	_	10	NMOD	_	_
9	DNA	_	NN	NN	_	10	NMOD	_	_
10	binding	_	NN	NN	_	5	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	activated	_	VBN	VBN	_	14	NMOD	_	_
13	RARE-dependent	_	JJ	JJ	_	14	NMOD	_	_
14	transcription	_	NN	NN	_	10	COORD	_	_
15	,	_	,	,	_	10	P	_	_
16	and	_	CC	CC	_	10	CC	_	_
17	increased	_	VBN	VBN	_	18	NMOD	_	_
18	expression	_	NN	NN	_	10	COORD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	RAR-beta	_	NN	NN	_	19	PMOD	_	_
21	.	_	.	.	_	4	P	_	_

1	Concomitant	_	JJ	JJ	_	2	NMOD	_	_
2	stimulation	_	NN	NN	_	5	SBJ	_	_
3	by	_	IN	IN	_	2	NMOD	_	_
4	VitD3	_	NN	NN	_	3	PMOD	_	_
5	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	RA-stimulated	_	JJ	JJ	_	8	NMOD	_	_
8	formation	_	NN	NN	_	5	IOBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	RAR	_	NN	NN	_	11	AMOD	_	_
11	beta\/RXR	_	NN	NN	_	12	NMOD	_	_
12	heterodimers	_	NNS	NNS	_	9	PMOD	_	_
13	,	_	,	,	_	5	P	_	_
14	favoring	_	VBG	VBG	_	5	OBJ	_	_
15	VDR\/RXR	_	NN	NN	_	16	NMOD	_	_
16	binding	_	NN	NN	_	14	OBJ	_	_
17	to	_	TO	TO	_	16	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	RARE	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	Also	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	VitD3	_	NN	NN	_	4	SBJ	_	_
4	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	expression	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	CD23	_	NN	NN	_	7	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	CD49f	_	NN	NN	_	8	COORD	_	_
11	,	_	,	,	_	8	P	_	_
12	characteristic	_	JJ	JJ	_	13	NMOD	_	_
13	markers	_	NNS	NNS	_	8	NMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	retinoid-induced	_	JJ	JJ	_	18	NMOD	_	_
16	U-937	_	NN	NN	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	differentiation	_	NN	NN	_	14	PMOD	_	_
19	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	15	VMOD	_	_
2	contrast	_	NN	NN	_	15	VMOD	_	_
3	,	_	,	,	_	15	P	_	_
4	neither	_	CC	CC	_	9	CC	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	RA-stimulated	_	JJ	JJ	_	9	NMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	RARE-mediated	_	JJ	JJ	_	6	COORD	_	_
9	transcription	_	NN	NN	_	15	SBJ	_	_
10	nor	_	CC	CC	_	9	CC	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	induced	_	VBN	VBN	_	14	NMOD	_	_
13	RAR-beta	_	NN	NN	_	14	NMOD	_	_
14	expression	_	NN	NN	_	9	COORD	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	suppressed	_	VBN	VBN	_	15	VC	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	VitD3	_	NN	NN	_	17	PMOD	_	_
19	,	_	,	,	_	16	P	_	_
20	suggesting	_	VBG	VBG	_	16	OBJ	_	_
21	that	_	IN	IN	_	20	OBJ	_	_
22	VitD3	_	NN	NN	_	24	SBJ	_	_
23	selectively	_	RB	RB	_	24	ADV	_	_
24	inhibited	_	VBD	VBD	_	21	VMOD	_	_
25	the	_	DT	DT	_	28	NMOD	_	_
26	retinoid-induced	_	JJ	JJ	_	28	NMOD	_	_
27	differentiation	_	NN	NN	_	28	NMOD	_	_
28	program	_	NN	NN	_	24	OBJ	_	_
29	but	_	CC	CC	_	28	CC	_	_
30	not	_	RB	RB	_	29	COORD	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	RARE-mediated	_	JJ	JJ	_	33	NMOD	_	_
33	signal	_	NN	NN	_	28	COORD	_	_
34	.	_	.	.	_	15	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	complex	_	JJ	JJ	_	6	NMOD	_	_
6	role	_	NN	NN	_	3	OBJ	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	VitD3	_	NN	NN	_	7	PMOD	_	_
9	in	_	IN	IN	_	6	NMOD	_	_
10	modifying	_	VBG	VBG	_	9	PMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	retinoid	_	NN	NN	_	14	NMOD	_	_
13	differentiation	_	NN	NN	_	14	NMOD	_	_
14	pathway	_	NN	NN	_	10	OBJ	_	_
15	and	_	CC	CC	_	3	CC	_	_
16	may	_	MD	MD	_	3	COORD	_	_
17	have	_	VB	VB	_	16	VC	_	_
18	implications	_	NNS	NNS	_	17	OBJ	_	_
19	for	_	IN	IN	_	18	NMOD	_	_
20	differentiation-inducing	_	JJ	JJ	_	21	NMOD	_	_
21	therapy	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	hematopoietic	_	JJ	JJ	_	24	NMOD	_	_
24	tumors	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	Tyrosines	_	NNS	NNS	_	10	SBJ	_	_
2	113	_	CD	CD	_	1	NMOD	_	_
3	,	_	,	,	_	2	P	_	_
4	128	_	CD	CD	_	2	COORD	_	_
5	,	_	,	,	_	2	P	_	_
6	and	_	CC	CC	_	2	CC	_	_
7	145	_	CD	CD	_	2	COORD	_	_
8	of	_	IN	IN	_	1	NMOD	_	_
9	SLP-76	_	NN	NN	_	8	PMOD	_	_
10	are	_	VBP	VBP	_	0	ROOT-S	_	_
11	required	_	VBN	VBN	_	10	VC	_	_
12	for	_	IN	IN	_	11	ADV	_	_
13	optimal	_	JJ	JJ	_	14	NMOD	_	_
14	augmentation	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	NFAT	_	NN	NN	_	18	NMOD	_	_
17	promoter	_	NN	NN	_	18	NMOD	_	_
18	activity	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	10	P	_	_

1	SLP-76	_	NN	NN	_	11	SBJ	_	_
2	(	_	(	(	_	6	P	_	_
3	SH2	_	NN	NN	_	6	NMOD	_	_
4	domain	_	NN	NN	_	6	NMOD	_	_
5	leukocyte	_	NN	NN	_	6	NMOD	_	_
6	protein	_	NN	NN	_	1	PRN	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	76	_	CD	CD	_	9	NMOD	_	_
9	kDa	_	NN	NN	_	7	PMOD	_	_
10	)	_	)	)	_	6	P	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	a	_	DT	DT	_	15	NMOD	_	_
13	recently	_	RB	RB	_	14	AMOD	_	_
14	identified	_	VBN	VBN	_	15	NMOD	_	_
15	substrate	_	NN	NN	_	11	PRD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	TCR-stimulated	_	JJ	JJ	_	21	NMOD	_	_
19	protein	_	NN	NN	_	21	NMOD	_	_
20	tyrosine	_	NN	NN	_	21	NMOD	_	_
21	kinases	_	NNS	NNS	_	16	PMOD	_	_
22	that	_	WDT	WDT	_	23	SBJ	_	_
23	functions	_	VBZ	VBZ	_	15	NMOD	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	the	_	DT	DT	_	28	NMOD	_	_
26	signal	_	NN	NN	_	28	NMOD	_	_
27	transduction	_	NN	NN	_	28	NMOD	_	_
28	cascade	_	NN	NN	_	24	PMOD	_	_
29	linking	_	VBG	VBG	_	28	NMOD	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	TCR	_	NN	NN	_	29	OBJ	_	_
32	with	_	IN	IN	_	29	ADV	_	_
33	IL-2	_	NN	NN	_	35	NMOD	_	_
34	gene	_	NN	NN	_	35	NMOD	_	_
35	expression	_	NN	NN	_	32	PMOD	_	_
36	.	_	.	.	_	11	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	engagement	_	NN	NN	_	12	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	TCR	_	NN	NN	_	9	PMOD	_	_
12	results	_	VBZ	VBZ	_	7	VMOD	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	tyrosine	_	NN	NN	_	15	NMOD	_	_
15	phosphorylation	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	SLP-76	_	NN	NN	_	16	PMOD	_	_
18	in	_	IN	IN	_	15	NMOD	_	_
19	its	_	PRP$	PRP$	_	22	NMOD	_	_
20	amino-terminal	_	JJ	JJ	_	22	NMOD	_	_
21	acidic	_	JJ	JJ	_	22	NMOD	_	_
22	region	_	NN	NN	_	18	PMOD	_	_
23	.	_	.	.	_	6	P	_	_

1	Two	_	CD	CD	_	2	NMOD	_	_
2	tyrosines	_	NNS	NNS	_	8	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	Y113	_	NN	NN	_	2	PRN	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	Y128	_	NN	NN	_	4	COORD	_	_
7	)	_	)	)	_	4	P	_	_
8	fall	_	VBP	VBP	_	0	ROOT-S	_	_
9	within	_	IN	IN	_	8	ADV	_	_
10	an	_	DT	DT	_	14	NMOD	_	_
11	identical	_	JJ	JJ	_	14	NMOD	_	_
12	five	_	CD	CD	_	14	NMOD	_	_
13	amino-acid	_	JJ	JJ	_	14	NMOD	_	_
14	motif	_	NN	NN	_	9	PMOD	_	_
15	and	_	CC	CC	_	8	CC	_	_
16	are	_	VBP	VBP	_	8	COORD	_	_
17	shown	_	VBN	VBN	_	16	VC	_	_
18	to	_	TO	TO	_	19	VMOD	_	_
19	be	_	VB	VB	_	17	VC	_	_
20	phosphorylated	_	VBN	VBN	_	19	VC	_	_
21	upon	_	IN	IN	_	20	TMP	_	_
22	TCR	_	NN	NN	_	23	NMOD	_	_
23	ligation	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	8	P	_	_

1	Although	_	IN	IN	_	20	ADV	_	_
2	mutation	_	NN	NN	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	either	_	CC	CC	_	5	CC	_	_
5	Y113	_	NN	NN	_	3	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	Y128	_	NN	NN	_	5	COORD	_	_
8	has	_	VBZ	VBZ	_	1	VMOD	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	minimal	_	JJ	JJ	_	11	NMOD	_	_
11	effect	_	NN	NN	_	8	OBJ	_	_
12	on	_	IN	IN	_	8	ADV	_	_
13	SLP-76	_	NN	NN	_	14	NMOD	_	_
14	function	_	NN	NN	_	12	PMOD	_	_
15	,	_	,	,	_	20	P	_	_
16	mutation	_	NN	NN	_	20	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	both	_	DT	DT	_	19	NMOD	_	_
19	residues	_	NNS	NNS	_	17	PMOD	_	_
20	decreases	_	VBZ	VBZ	_	0	ROOT-S	_	_
21	significantly	_	RB	RB	_	20	ADV	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	ability	_	NN	NN	_	20	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	SLP-76	_	NN	NN	_	24	PMOD	_	_
26	to	_	TO	TO	_	27	VMOD	_	_
27	promote	_	VB	VB	_	23	NMOD	_	_
28	T	_	NN	NN	_	30	NMOD	_	_
29	cell	_	NN	NN	_	30	NMOD	_	_
30	activation	_	NN	NN	_	27	OBJ	_	_
31	.	_	.	.	_	20	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	third	_	JJ	JJ	_	3	NMOD	_	_
3	tyrosine	_	NN	NN	_	11	SBJ	_	_
4	within	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	amino-terminal	_	JJ	JJ	_	7	NMOD	_	_
7	region	_	NN	NN	_	4	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	Y145	_	NN	NN	_	3	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	be	_	VB	VB	_	11	OBJ	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	most	_	RBS	RBS	_	16	AMOD	_	_
16	important	_	JJ	JJ	_	13	PRD	_	_
17	for	_	IN	IN	_	13	ADV	_	_
18	optimal	_	JJ	JJ	_	20	NMOD	_	_
19	SLP-76	_	NN	NN	_	20	NMOD	_	_
20	function	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	13	P	_	_
22	as	_	IN	IN	_	13	ADV	_	_
23	altering	_	VBG	VBG	_	28	SBJ	_	_
24	it	_	PRP	PRP	_	23	OBJ	_	_
25	alone	_	RB	RB	_	24	NMOD	_	_
26	to	_	TO	TO	_	23	ADV	_	_
27	phenylalanine	_	NN	NN	_	26	PMOD	_	_
28	has	_	VBZ	VBZ	_	22	VMOD	_	_
29	a	_	DT	DT	_	31	NMOD	_	_
30	potent	_	JJ	JJ	_	31	NMOD	_	_
31	impact	_	NN	NN	_	28	OBJ	_	_
32	on	_	IN	IN	_	28	ADV	_	_
33	SLP-76	_	NN	NN	_	34	NMOD	_	_
34	augmentation	_	NN	NN	_	32	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	NFAT	_	NN	NN	_	38	NMOD	_	_
37	promoter	_	NN	NN	_	38	NMOD	_	_
38	activity	_	NN	NN	_	35	PMOD	_	_
39	.	_	.	.	_	11	P	_	_

1	Apoptosis	_	NN	NN	_	3	NMOD	_	_
2	signaling	_	NN	NN	_	3	NMOD	_	_
3	pathways	_	NNS	NNS	_	0	ROOT-FRAG	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	normal	_	JJ	JJ	_	7	NMOD	_	_
6	T	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	4	PMOD	_	_
8	:	_	:	:	_	3	P	_	_
9	differential	_	JJ	JJ	_	10	NMOD	_	_
10	activity	_	NN	NN	_	3	NMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	Bcl-2	_	NN	NN	_	11	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	IL-1beta-converting	_	JJ	JJ	_	18	NMOD	_	_
15	enzyme	_	NN	NN	_	18	NMOD	_	_
16	family	_	NN	NN	_	18	NMOD	_	_
17	protease	_	NN	NN	_	18	NMOD	_	_
18	inhibitors	_	NNS	NNS	_	12	COORD	_	_
19	on	_	IN	IN	_	10	NMOD	_	_
20	glucocorticoid-	_	NN	NN	_	23	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	Fas-mediated	_	JJ	JJ	_	20	COORD	_	_
23	cytotoxicity	_	NN	NN	_	19	PMOD	_	_
24	.	_	.	.	_	10	P	_	_

1	Fas-mediated	_	JJ	JJ	_	2	NMOD	_	_
2	apoptosis	_	NN	NN	_	3	SBJ	_	_
3	plays	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	an	_	DT	DT	_	6	NMOD	_	_
5	important	_	JJ	JJ	_	6	NMOD	_	_
6	role	_	NN	NN	_	3	OBJ	_	_
7	in	_	IN	IN	_	3	ADV	_	_
8	regulating	_	VBG	VBG	_	7	PMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	immune	_	JJ	JJ	_	11	NMOD	_	_
11	response	_	NN	NN	_	8	OBJ	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	peripheral	_	JJ	JJ	_	15	NMOD	_	_
14	T	_	NN	NN	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	12	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	Restimulation	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	T	_	NN	NN	_	5	NMOD	_	_
4	cell	_	NN	NN	_	5	NMOD	_	_
5	blasts	_	NNS	NNS	_	2	PMOD	_	_
6	up-regulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	Fas	_	NN	NN	_	6	OBJ	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	Fas	_	NN	NN	_	11	NMOD	_	_
10	ligand	_	NN	NN	_	11	NMOD	_	_
11	expression	_	NN	NN	_	7	COORD	_	_
12	,	_	,	,	_	6	P	_	_
13	with	_	IN	IN	_	6	ADV	_	_
14	subsequent	_	JJ	JJ	_	15	NMOD	_	_
15	interaction	_	NN	NN	_	16	SBJ	_	_
16	leading	_	VBG	VBG	_	13	PMOD	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	cell	_	NN	NN	_	19	NMOD	_	_
19	death	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	6	P	_	_

1	Overexpression	_	NN	NN	_	7	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	Bcl-2	_	NN	NN	_	2	PMOD	_	_
4	in	_	IN	IN	_	1	NMOD	_	_
5	tumor	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	blocks	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	apoptosis	_	NN	NN	_	7	OBJ	_	_
9	induced	_	VBN	VBN	_	8	NMOD	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	many	_	JJ	JJ	_	12	NMOD	_	_
12	stimuli	_	NNS	NNS	_	10	PMOD	_	_
13	,	_	,	,	_	7	P	_	_
14	but	_	CC	CC	_	7	CC	_	_
15	inhibition	_	NN	NN	_	19	SBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	Fas-mediated	_	JJ	JJ	_	18	NMOD	_	_
18	killing	_	NN	NN	_	16	PMOD	_	_
19	has	_	VBZ	VBZ	_	7	COORD	_	_
20	not	_	RB	RB	_	19	VMOD	_	_
21	been	_	VBN	VBN	_	19	VC	_	_
22	consistently	_	RB	RB	_	23	TMP	_	_
23	observed	_	VBN	VBN	_	21	VC	_	_
24	.	_	.	.	_	7	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	examine	_	VB	VB	_	14	VC	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	behavior	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	Bcl-2	_	NN	NN	_	5	PMOD	_	_
7	in	_	IN	IN	_	4	NMOD	_	_
8	normal	_	JJ	JJ	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	7	PMOD	_	_
10	,	_	,	,	_	14	P	_	_
11	T	_	NN	NN	_	13	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	blasts	_	NNS	NNS	_	14	SBJ	_	_
14	were	_	VBD	VBD	_	0	ROOT-S	_	_
15	transiently	_	RB	RB	_	16	TMP	_	_
16	transfected	_	VBN	VBN	_	14	VC	_	_
17	with	_	IN	IN	_	16	ADV	_	_
18	Bcl-2	_	NN	NN	_	17	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	related	_	JJ	JJ	_	22	NMOD	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	products	_	NNS	NNS	_	18	COORD	_	_
23	to	_	TO	TO	_	24	VMOD	_	_
24	determine	_	VB	VB	_	16	OBJ	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	effect	_	NN	NN	_	24	OBJ	_	_
27	on	_	IN	IN	_	26	NMOD	_	_
28	apoptotic	_	JJ	JJ	_	29	NMOD	_	_
29	signaling	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	14	P	_	_

1	Transient	_	JJ	JJ	_	2	NMOD	_	_
2	overexpression	_	NN	NN	_	12	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	Bcl-2	_	NN	NN	_	3	PMOD	_	_
5	in	_	IN	IN	_	2	NMOD	_	_
6	mouse	_	NN	NN	_	11	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	human	_	JJ	JJ	_	6	COORD	_	_
9	T	_	NN	NN	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	blasts	_	NNS	NNS	_	5	PMOD	_	_
12	did	_	VBD	VBD	_	0	ROOT-S	_	_
13	not	_	RB	RB	_	12	VMOD	_	_
14	block	_	VB	VB	_	12	VC	_	_
15	Fas-mediated	_	JJ	JJ	_	16	NMOD	_	_
16	apoptosis	_	NN	NN	_	14	OBJ	_	_
17	,	_	,	,	_	12	P	_	_
18	whereas	_	IN	IN	_	12	COORD	_	_
19	etoposide-	_	NN	NN	_	22	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	glucocorticoid-induced	_	JJ	JJ	_	19	COORD	_	_
22	cytotoxicity	_	NN	NN	_	23	SBJ	_	_
23	was	_	VBD	VBD	_	12	COORD	_	_
24	potently	_	RB	RB	_	25	ADV	_	_
25	inhibited	_	VBN	VBN	_	23	VC	_	_
26	.	_	.	.	_	12	P	_	_

1	Expression	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	Bcl-xL	_	NN	NN	_	2	PMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	adenovirus	_	NN	NN	_	7	NMOD	_	_
6	E1B	_	NN	NN	_	7	NMOD	_	_
7	19K	_	NN	NN	_	3	COORD	_	_
8	did	_	VBD	VBD	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	interfere	_	VB	VB	_	8	VC	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	anti-Fas	_	JJ	JJ	_	13	NMOD	_	_
13	killing	_	NN	NN	_	11	PMOD	_	_
14	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	12	P	_	_
4	interleukin-1beta-converting	_	JJ	JJ	_	8	NMOD	_	_
5	enzyme	_	NN	NN	_	8	NMOD	_	_
6	family	_	NN	NN	_	8	NMOD	_	_
7	protease	_	NN	NN	_	8	NMOD	_	_
8	inhibitors	_	NNS	NNS	_	12	SBJ	_	_
9	Ac-DEVD-CHO	_	NN	NN	_	8	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	CrmA	_	NN	NN	_	9	COORD	_	_
12	blocked	_	VBD	VBD	_	0	ROOT-S	_	_
13	Fas-mediated	_	JJ	JJ	_	14	NMOD	_	_
14	apoptosis	_	NN	NN	_	12	OBJ	_	_
15	.	_	.	.	_	12	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	peripheral	_	JJ	JJ	_	7	NMOD	_	_
6	T	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	8	SBJ	_	_
8	use	_	VBP	VBP	_	4	VMOD	_	_
9	distinct	_	JJ	JJ	_	12	NMOD	_	_
10	apoptosis	_	NN	NN	_	12	NMOD	_	_
11	signaling	_	NN	NN	_	12	NMOD	_	_
12	pathways	_	NNS	NNS	_	8	OBJ	_	_
13	with	_	IN	IN	_	12	NMOD	_	_
14	differential	_	JJ	JJ	_	15	NMOD	_	_
15	sensitivity	_	NN	NN	_	13	PMOD	_	_
16	to	_	TO	TO	_	15	NMOD	_	_
17	Bcl-2	_	NN	NN	_	16	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	interleukin-1beta-converting	_	JJ	JJ	_	23	NMOD	_	_
20	enzyme	_	NN	NN	_	23	NMOD	_	_
21	family	_	NN	NN	_	23	NMOD	_	_
22	protease	_	NN	NN	_	23	NMOD	_	_
23	inhibitors	_	NNS	NNS	_	17	COORD	_	_
24	.	_	.	.	_	3	P	_	_

1	Since	_	IN	IN	_	18	ADV	_	_
2	T	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	5	SBJ	_	_
4	normally	_	RB	RB	_	5	ADV	_	_
5	express	_	VBP	VBP	_	1	VMOD	_	_
6	Bcl-2	_	NN	NN	_	5	OBJ	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	Bcl-xL	_	NN	NN	_	6	COORD	_	_
9	following	_	VBG	VBG	_	5	TMP	_	_
10	activation	_	NN	NN	_	9	PMOD	_	_
11	,	_	,	,	_	18	P	_	_
12	their	_	PRP$	PRP$	_	13	NMOD	_	_
13	inability	_	NN	NN	_	18	SBJ	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	block	_	VB	VB	_	13	NMOD	_	_
16	Fas-mediated	_	JJ	JJ	_	17	NMOD	_	_
17	apoptosis	_	NN	NN	_	15	OBJ	_	_
18	may	_	MD	MD	_	0	ROOT-S	_	_
19	allow	_	VB	VB	_	18	VC	_	_
20	for	_	IN	IN	_	19	ADV	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	elimination	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	self-reactive	_	JJ	JJ	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	23	PMOD	_	_
26	and	_	CC	CC	_	22	CC	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	appropriate	_	JJ	JJ	_	29	NMOD	_	_
29	regulation	_	NN	NN	_	22	COORD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	immune	_	JJ	JJ	_	32	NMOD	_	_
32	responses	_	NNS	NNS	_	30	PMOD	_	_
33	.	_	.	.	_	18	P	_	_

1	Susceptibility	_	NN	NN	_	19	SBJ	_	_
2	to	_	TO	TO	_	1	NMOD	_	_
3	natural	_	JJ	JJ	_	5	NMOD	_	_
4	killer	_	NN	NN	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	2	PMOD	_	_
6	and	_	CC	CC	_	1	CC	_	_
7	down	_	JJ	JJ	_	8	NMOD	_	_
8	regulation	_	NN	NN	_	1	COORD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	MHC	_	NN	NN	_	13	NMOD	_	_
11	class	_	NN	NN	_	13	NMOD	_	_
12	I	_	CD	CD	_	13	NMOD	_	_
13	expression	_	NN	NN	_	9	PMOD	_	_
14	in	_	IN	IN	_	1	NMOD	_	_
15	adenovirus	_	NN	NN	_	18	NMOD	_	_
16	12	_	CD	CD	_	18	NMOD	_	_
17	transformed	_	VBN	VBN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	14	PMOD	_	_
19	are	_	VBP	VBP	_	0	ROOT-S	_	_
20	regulated	_	VBN	VBN	_	19	VC	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	different	_	JJ	JJ	_	24	NMOD	_	_
23	E1A	_	NN	NN	_	24	NMOD	_	_
24	domains	_	NNS	NNS	_	21	PMOD	_	_
25	.	_	.	.	_	19	P	_	_

1	All	_	DT	DT	_	3	NMOD	_	_
2	human	_	JJ	JJ	_	3	NMOD	_	_
3	adenoviruses	_	NNS	NNS	_	4	SBJ	_	_
4	transform	_	VBP	VBP	_	0	ROOT-S	_	_
5	rodent	_	JJ	JJ	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	OBJ	_	_
7	in	_	FW	FW	_	4	ADV	_	_
8	vitro	_	FW	FW	_	7	AMOD	_	_
9	,	_	,	,	_	4	P	_	_
10	but	_	CC	CC	_	4	CC	_	_
11	only	_	RB	RB	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	28	SBJ	_	_
13	transformed	_	VBN	VBN	_	12	NMOD	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	serotypes	_	NNS	NNS	_	14	PMOD	_	_
16	belonging	_	VBG	VBG	_	15	NMOD	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	subgroups	_	NNS	NNS	_	17	PMOD	_	_
19	A	_	NN	NN	_	18	NMOD	_	_
20	(	_	(	(	_	21	P	_	_
21	Ad12	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	and	_	CC	CC	_	19	CC	_	_
24	B	_	NN	NN	_	19	COORD	_	_
25	(	_	(	(	_	26	P	_	_
26	Ad3	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	are	_	VBP	VBP	_	4	COORD	_	_
29	tumorigenic	_	JJ	JJ	_	28	PRD	_	_
30	for	_	IN	IN	_	28	ADV	_	_
31	immunocompetent	_	JJ	JJ	_	32	NMOD	_	_
32	animals	_	NNS	NNS	_	30	PMOD	_	_
33	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	11	P	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	expression	_	NN	NN	_	11	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	MHC-class	_	NN	NN	_	10	NMOD	_	_
9	I	_	CD	CD	_	10	NMOD	_	_
10	antigens	_	NNS	NNS	_	7	PMOD	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	repressed	_	VBN	VBN	_	11	VC	_	_
13	and	_	CC	CC	_	11	CC	_	_
14	might	_	MD	MD	_	11	COORD	_	_
15	allow	_	VB	VB	_	14	VC	_	_
16	them	_	PRP	PRP	_	18	SBJ	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	escape	_	VB	VB	_	15	OBJ	_	_
19	from	_	IN	IN	_	18	ADV	_	_
20	recognition	_	NN	NN	_	19	PMOD	_	_
21	by	_	IN	IN	_	20	NMOD	_	_
22	cytotoxic	_	JJ	JJ	_	24	NMOD	_	_
23	T	_	NN	NN	_	24	NMOD	_	_
24	lymphocytes	_	NNS	NNS	_	21	PMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	CTL	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	and	_	CC	CC	_	18	CC	_	_
29	to	_	TO	TO	_	30	VMOD	_	_
30	develop	_	VB	VB	_	18	COORD	_	_
31	in	_	IN	IN	_	30	ADV	_	_
32	tumor	_	NN	NN	_	31	PMOD	_	_
33	.	_	.	.	_	11	P	_	_

1	Furthermore	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	these	_	DT	DT	_	5	NMOD	_	_
4	cell	_	NN	NN	_	5	NMOD	_	_
5	lines	_	NNS	NNS	_	6	SBJ	_	_
6	appear	_	VBP	VBP	_	0	ROOT-S	_	_
7	resistant	_	JJ	JJ	_	6	PRD	_	_
8	to	_	TO	TO	_	7	AMOD	_	_
9	lysis	_	NN	NN	_	8	PMOD	_	_
10	by	_	IN	IN	_	9	NMOD	_	_
11	natural	_	JJ	JJ	_	12	NMOD	_	_
12	killer	_	NN	NN	_	16	NMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	NK	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	cells	_	NNS	NNS	_	10	PMOD	_	_
17	.	_	.	.	_	6	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	determine	_	VB	VB	_	16	VC	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	E1A	_	NN	NN	_	7	NMOD	_	_
5	domain	_	NN	NN	_	7	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	s	_	NNS	NNS	_	2	OBJ	_	_
8	)	_	)	)	_	7	P	_	_
9	responsible	_	JJ	JJ	_	7	NMOD	_	_
10	for	_	IN	IN	_	9	AMOD	_	_
11	these	_	DT	DT	_	12	NMOD	_	_
12	properties	_	NNS	NNS	_	10	PMOD	_	_
13	several	_	JJ	JJ	_	15	NMOD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	lines	_	NNS	NNS	_	16	SBJ	_	_
16	were	_	VBD	VBD	_	0	ROOT-S	_	_
17	created	_	VBN	VBN	_	16	VC	_	_
18	by	_	IN	IN	_	17	ADV	_	_
19	transforming	_	VBG	VBG	_	26	NMOD	_	_
20	baby	_	NN	NN	_	22	NMOD	_	_
21	rat	_	NN	NN	_	22	NMOD	_	_
22	kidney	_	NN	NN	_	26	NMOD	_	_
23	(	_	(	(	_	24	P	_	_
24	BRK	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	cells	_	NNS	NNS	_	18	PMOD	_	_
27	with	_	IN	IN	_	26	NMOD	_	_
28	a	_	DT	DT	_	29	NMOD	_	_
29	set	_	NN	NN	_	27	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	plasmids	_	NNS	NNS	_	30	PMOD	_	_
32	expressing	_	VBG	VBG	_	31	NMOD	_	_
33	different	_	JJ	JJ	_	38	NMOD	_	_
34	Ad2\/Ad12	_	NN	NN	_	38	NMOD	_	_
35	hybrid	_	NN	NN	_	38	NMOD	_	_
36	E1A	_	NN	NN	_	38	NMOD	_	_
37	gene	_	NN	NN	_	38	NMOD	_	_
38	products	_	NNS	NNS	_	32	OBJ	_	_
39	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	MHC	_	NN	NN	_	6	NMOD	_	_
3	class	_	NN	NN	_	6	NMOD	_	_
4	1	_	CD	CD	_	6	NMOD	_	_
5	gene	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	7	SBJ	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	inhibited	_	VBN	VBN	_	7	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	cells	_	NNS	NNS	_	9	PMOD	_	_
11	expressing	_	VBG	VBG	_	10	NMOD	_	_
12	the	_	DT	DT	_	16	NMOD	_	_
13	Ad12	_	NN	NN	_	16	NMOD	_	_
14	13S	_	NN	NN	_	16	NMOD	_	_
15	mRNA	_	NN	NN	_	16	NMOD	_	_
16	product	_	NN	NN	_	11	OBJ	_	_
17	and	_	CC	CC	_	9	CC	_	_
18	in	_	IN	IN	_	9	COORD	_	_
19	cells	_	NNS	NNS	_	18	PMOD	_	_
20	transformed	_	VBN	VBN	_	19	NMOD	_	_
21	with	_	IN	IN	_	20	ADV	_	_
22	Ad2\/Ad12	_	NN	NN	_	26	NMOD	_	_
23	hybrid	_	NN	NN	_	26	NMOD	_	_
24	E1A	_	NN	NN	_	26	NMOD	_	_
25	gene	_	NN	NN	_	26	NMOD	_	_
26	product	_	NN	NN	_	21	PMOD	_	_
27	harboring	_	VBG	VBG	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	C-terminal	_	JJ	JJ	_	30	NMOD	_	_
30	part	_	NN	NN	_	27	OBJ	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	conserved	_	VBN	VBN	_	34	NMOD	_	_
34	region	_	NN	NN	_	31	PMOD	_	_
35	(	_	(	(	_	36	P	_	_
36	CR	_	NN	NN	_	34	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	3	_	CD	CD	_	34	NMOD	_	_
39	of	_	IN	IN	_	34	NMOD	_	_
40	Ad12	_	NN	NN	_	39	PMOD	_	_
41	.	_	.	.	_	7	P	_	_

1	Susceptibility	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	these	_	DT	DT	_	6	NMOD	_	_
4	transformed	_	VBN	VBN	_	6	NMOD	_	_
5	cell	_	NN	NN	_	6	NMOD	_	_
6	lines	_	NNS	NNS	_	2	PMOD	_	_
7	to	_	TO	TO	_	1	NMOD	_	_
8	NK	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	7	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	determined	_	VBN	VBN	_	10	VC	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	cytolytic	_	JJ	JJ	_	14	NMOD	_	_
14	assays	_	NNS	NNS	_	12	PMOD	_	_
15	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	4	SBJ	_	_
3	obtained	_	VBD	VBD	_	2	NMOD	_	_
4	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	two	_	CD	CD	_	9	NMOD	_	_
7	Ad12	_	NN	NN	_	9	NMOD	_	_
8	E1A	_	NN	NN	_	9	NMOD	_	_
9	domains	_	NNS	NNS	_	10	SBJ	_	_
10	are	_	VBP	VBP	_	5	VMOD	_	_
11	required	_	VBN	VBN	_	10	VC	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	induce	_	VB	VB	_	11	OBJ	_	_
14	resistance	_	NN	NN	_	13	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	lines	_	NNS	NNS	_	15	PMOD	_	_
19	to	_	TO	TO	_	14	NMOD	_	_
20	NK	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	19	PMOD	_	_
22	.	_	.	.	_	4	P	_	_

1	Active	_	JJ	JJ	_	2	NMOD	_	_
2	suppression	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	9	NMOD	_	_
5	class	_	NN	NN	_	9	NMOD	_	_
6	II	_	CD	CD	_	9	NMOD	_	_
7	transactivator-encoding	_	JJ	JJ	_	9	NMOD	_	_
8	AIR-1	_	NN	NN	_	9	NMOD	_	_
9	locus	_	NN	NN	_	3	PMOD	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	responsible	_	JJ	JJ	_	10	PRD	_	_
12	for	_	IN	IN	_	11	AMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	lack	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	major	_	JJ	JJ	_	22	NMOD	_	_
17	histocompatibility	_	NN	NN	_	22	NMOD	_	_
18	complex	_	NN	NN	_	22	NMOD	_	_
19	class	_	NN	NN	_	22	NMOD	_	_
20	II	_	CD	CD	_	22	NMOD	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	expression	_	NN	NN	_	15	PMOD	_	_
23	observed	_	VBN	VBN	_	22	NMOD	_	_
24	during	_	IN	IN	_	23	TMP	_	_
25	differentiation	_	NN	NN	_	24	PMOD	_	_
26	from	_	IN	IN	_	25	NMOD	_	_
27	B	_	NN	NN	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	26	PMOD	_	_
29	to	_	TO	TO	_	25	NMOD	_	_
30	plasma	_	NN	NN	_	31	NMOD	_	_
31	cells	_	NNS	NNS	_	29	PMOD	_	_
32	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	27	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	genetic	_	JJ	JJ	_	6	NMOD	_	_
6	control	_	NN	NN	_	27	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	major	_	JJ	JJ	_	10	NMOD	_	_
9	histocompatibility	_	NN	NN	_	10	NMOD	_	_
10	complex	_	NN	NN	_	17	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	MHC	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	class	_	NN	NN	_	17	NMOD	_	_
15	II	_	CD	CD	_	17	NMOD	_	_
16	gene	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	7	PMOD	_	_
18	during	_	IN	IN	_	17	TMP	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	transition	_	NN	NN	_	18	PMOD	_	_
21	from	_	IN	IN	_	20	NMOD	_	_
22	B	_	NN	NN	_	23	NMOD	_	_
23	cell	_	NN	NN	_	21	PMOD	_	_
24	to	_	TO	TO	_	20	NMOD	_	_
25	plasma	_	NN	NN	_	26	NMOD	_	_
26	cell	_	NN	NN	_	24	PMOD	_	_
27	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
28	been	_	VBN	VBN	_	27	VC	_	_
29	analyzed	_	VBN	VBN	_	28	VC	_	_
30	.	_	.	.	_	27	P	_	_

1	Class	_	NN	NN	_	3	NMOD	_	_
2	II	_	CD	CD	_	3	NMOD	_	_
3	molecules	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	expressed	_	VBN	VBN	_	4	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	plasma	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	7	PMOD	_	_
10	because	_	IN	IN	_	6	ADV	_	_
11	of	_	IN	IN	_	10	DEP	_	_
12	an	_	DT	DT	_	14	NMOD	_	_
13	active	_	JJ	JJ	_	14	NMOD	_	_
14	suppression	_	NN	NN	_	10	PMOD	_	_
15	resulting	_	VBG	VBG	_	14	NMOD	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	abrogation	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	class	_	NN	NN	_	23	NMOD	_	_
21	II	_	CD	CD	_	23	NMOD	_	_
22	gene	_	NN	NN	_	23	NMOD	_	_
23	transcription	_	NN	NN	_	19	PMOD	_	_
24	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	that	_	IN	IN	_	2	OBJ	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	plasma	_	NN	NN	_	9	NMOD	_	_
7	cell-specific	_	JJ	JJ	_	6	AMOD	_	_
8	repressor	_	NN	NN	_	9	NMOD	_	_
9	function	_	NN	NN	_	21	SBJ	_	_
10	,	_	,	,	_	9	P	_	_
11	designated	_	VBN	VBN	_	9	NMOD	_	_
12	SIR	_	NN	NN	_	11	OBJ	_	_
13	(	_	(	(	_	14	P	_	_
14	suppressor	_	NN	NN	_	12	PRN	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	immune	_	JJ	JJ	_	18	NMOD	_	_
17	response	_	NN	NN	_	18	NMOD	_	_
18	genes	_	NNS	NNS	_	15	PMOD	_	_
19	)	_	)	)	_	14	P	_	_
20	,	_	,	,	_	9	P	_	_
21	does	_	VBZ	VBZ	_	4	VMOD	_	_
22	not	_	RB	RB	_	21	VMOD	_	_
23	act	_	VB	VB	_	21	VC	_	_
24	directly	_	RB	RB	_	23	ADV	_	_
25	on	_	IN	IN	_	23	ADV	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	transcription	_	NN	NN	_	25	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	class	_	NN	NN	_	31	NMOD	_	_
30	II	_	CD	CD	_	31	NMOD	_	_
31	genes	_	NNS	NNS	_	28	PMOD	_	_
32	,	_	,	,	_	25	P	_	_
33	but	_	CC	CC	_	25	CC	_	_
34	instead	_	RB	RB	_	25	COORD	_	_
35	on	_	IN	IN	_	25	COORD	_	_
36	the	_	DT	DT	_	37	NMOD	_	_
37	transcription	_	NN	NN	_	35	PMOD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	the	_	DT	DT	_	41	NMOD	_	_
40	AIR-1	_	NN	NN	_	41	NMOD	_	_
41	gene	_	NN	NN	_	38	PMOD	_	_
42	,	_	,	,	_	41	P	_	_
43	whose	_	WP$	WP$	_	44	NMOD	_	_
44	product	_	NN	NN	_	54	SBJ	_	_
45	,	_	,	,	_	44	P	_	_
46	the	_	DT	DT	_	49	NMOD	_	_
47	class	_	NN	NN	_	49	NMOD	_	_
48	II	_	CD	CD	_	49	NMOD	_	_
49	transactivator	_	NN	NN	_	44	NMOD	_	_
50	(	_	(	(	_	51	P	_	_
51	CIITA	_	NN	NN	_	49	PRN	_	_
52	)	_	)	)	_	51	P	_	_
53	,	_	,	,	_	44	P	_	_
54	is	_	VBZ	VBZ	_	41	NMOD	_	_
55	fundamental	_	JJ	JJ	_	54	PRD	_	_
56	for	_	IN	IN	_	54	ADV	_	_
57	the	_	DT	DT	_	58	NMOD	_	_
58	regulation	_	NN	NN	_	56	PMOD	_	_
59	of	_	IN	IN	_	58	NMOD	_	_
60	the	_	DT	DT	_	64	NMOD	_	_
61	constitutive	_	JJ	JJ	_	64	NMOD	_	_
62	and	_	CC	CC	_	61	CC	_	_
63	inducible	_	JJ	JJ	_	61	COORD	_	_
64	expression	_	NN	NN	_	59	PMOD	_	_
65	of	_	IN	IN	_	64	NMOD	_	_
66	MHC	_	NN	NN	_	69	NMOD	_	_
67	class	_	NN	NN	_	69	NMOD	_	_
68	II	_	CD	CD	_	69	NMOD	_	_
69	genes	_	NNS	NNS	_	65	PMOD	_	_
70	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	unambiguously	_	RB	RB	_	2	ADV	_	_
4	demonstrated	_	VBN	VBN	_	2	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	fact	_	NN	NN	_	5	PMOD	_	_
8	that	_	IN	IN	_	7	NMOD	_	_
9	plasmacytoma	_	NN	NN	_	10	NMOD	_	_
10	x	_	NN	NN	_	13	NMOD	_	_
11	B	_	NN	NN	_	12	NMOD	_	_
12	cell	_	NN	NN	_	10	NMOD	_	_
13	hybrids	_	NNS	NNS	_	22	SBJ	_	_
14	carrying	_	VBG	VBG	_	13	NMOD	_	_
15	an	_	DT	DT	_	17	NMOD	_	_
16	AIR-1	_	NN	NN	_	17	NMOD	_	_
17	locus	_	NN	NN	_	14	OBJ	_	_
18	derived	_	VBN	VBN	_	17	NMOD	_	_
19	from	_	IN	IN	_	18	ADV	_	_
20	CIITA-expressing	_	JJ	JJ	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	19	PMOD	_	_
22	do	_	VBP	VBP	_	8	VMOD	_	_
23	not	_	RB	RB	_	22	VMOD	_	_
24	express	_	VB	VB	_	22	VC	_	_
25	CIITA-specific	_	JJ	JJ	_	26	NMOD	_	_
26	transcripts	_	NNS	NNS	_	24	OBJ	_	_
27	.	_	.	.	_	2	P	_	_

1	Transfection	_	NN	NN	_	18	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	cDNA	_	NN	NN	_	2	PMOD	_	_
5	containing	_	VBG	VBG	_	4	NMOD	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	human	_	JJ	JJ	_	10	NMOD	_	_
8	CIITA	_	NN	NN	_	10	NMOD	_	_
9	coding	_	NN	NN	_	10	NMOD	_	_
10	sequence	_	NN	NN	_	5	OBJ	_	_
11	under	_	IN	IN	_	1	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	control	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	an	_	DT	DT	_	17	NMOD	_	_
16	heterologous	_	JJ	JJ	_	17	NMOD	_	_
17	promoter	_	NN	NN	_	14	PMOD	_	_
18	restores	_	VBZ	VBZ	_	0	ROOT-S	_	_
19	expression	_	NN	NN	_	18	OBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	human	_	JJ	JJ	_	25	NMOD	_	_
22	MHC	_	NN	NN	_	25	NMOD	_	_
23	class	_	NN	NN	_	25	NMOD	_	_
24	II	_	CD	CD	_	25	NMOD	_	_
25	genes	_	NNS	NNS	_	20	PMOD	_	_
26	in	_	IN	IN	_	19	NMOD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	hybrids	_	NNS	NNS	_	26	PMOD	_	_
29	and	_	CC	CC	_	18	CC	_	_
30	is	_	VBZ	VBZ	_	18	COORD	_	_
31	responsible	_	JJ	JJ	_	30	PRD	_	_
32	for	_	IN	IN	_	31	AMOD	_	_
33	de	_	FW	FW	_	34	AMOD	_	_
34	novo	_	FW	FW	_	35	NMOD	_	_
35	expression	_	NN	NN	_	32	PMOD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	mouse	_	NN	NN	_	41	NMOD	_	_
38	MHC	_	NN	NN	_	41	NMOD	_	_
39	class	_	NN	NN	_	41	NMOD	_	_
40	II	_	CD	CD	_	41	NMOD	_	_
41	genes	_	NNS	NNS	_	36	PMOD	_	_
42	in	_	IN	IN	_	35	NMOD	_	_
43	both	_	CC	CC	_	48	CC	_	_
44	the	_	DT	DT	_	48	NMOD	_	_
45	mouse	_	NN	NN	_	48	NMOD	_	_
46	plasmacytoma	_	NN	NN	_	48	NMOD	_	_
47	cell	_	NN	NN	_	48	NMOD	_	_
48	line	_	NN	NN	_	42	PMOD	_	_
49	and	_	CC	CC	_	48	CC	_	_
50	the	_	DT	DT	_	51	NMOD	_	_
51	hybrids	_	NNS	NNS	_	48	COORD	_	_
52	.	_	.	.	_	18	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	confirm	_	VBP	VBP	_	0	ROOT-S	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	extend	_	VBP	VBP	_	3	COORD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	notion	_	NN	NN	_	3	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	functional	_	JJ	JJ	_	11	NMOD	_	_
11	conservation	_	NN	NN	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	AIR-1	_	JJ	JJ	_	16	NMOD	_	_
15	gene	_	NN	NN	_	16	NMOD	_	_
16	product	_	NN	NN	_	12	PMOD	_	_
17	across	_	IN	IN	_	11	NMOD	_	_
18	species	_	NNS	NNS	_	19	NMOD	_	_
19	barriers	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Interestingly	_	RB	RB	_	16	ADV	_	_
2	,	_	,	,	_	16	P	_	_
3	in	_	IN	IN	_	16	ADV	_	_
4	CIITA-transfected	_	JJ	JJ	_	6	NMOD	_	_
5	cell	_	NN	NN	_	6	NMOD	_	_
6	hybrids	_	NNS	NNS	_	3	PMOD	_	_
7	,	_	,	,	_	16	P	_	_
8	cell	_	NN	NN	_	10	NMOD	_	_
9	surface	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	16	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	human	_	JJ	JJ	_	15	NMOD	_	_
14	HLA-DQ	_	NN	NN	_	15	NMOD	_	_
15	heterodimer	_	NN	NN	_	11	PMOD	_	_
16	was	_	VBD	VBD	_	0	ROOT-S	_	_
17	not	_	RB	RB	_	16	VMOD	_	_
18	observed	_	VBN	VBN	_	16	VC	_	_
19	.	_	.	.	_	16	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	result	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	attributable	_	JJ	JJ	_	3	PRD	_	_
6	to	_	TO	TO	_	5	AMOD	_	_
7	lack	_	NN	NN	_	6	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	HLA-DQ	_	NN	NN	_	10	NMOD	_	_
10	alpha	_	NN	NN	_	14	NMOD	_	_
11	or	_	CC	CC	_	10	CC	_	_
12	-DQ	_	NN	NN	_	13	NMOD	_	_
13	beta	_	NN	NN	_	10	COORD	_	_
14	transcription	_	NN	NN	_	8	PMOD	_	_
15	,	_	,	,	_	3	P	_	_
16	because	_	IN	IN	_	3	ADV	_	_
17	both	_	DT	DT	_	18	NMOD	_	_
18	transcripts	_	NNS	NNS	_	19	SBJ	_	_
19	were	_	VBD	VBD	_	16	VMOD	_	_
20	present	_	JJ	JJ	_	19	PRD	_	_
21	in	_	IN	IN	_	20	AMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	CIITA-transfected	_	JJ	JJ	_	24	NMOD	_	_
24	hybrids	_	NNS	NNS	_	21	PMOD	_	_
25	,	_	,	,	_	19	P	_	_
26	although	_	IN	IN	_	19	ADV	_	_
27	at	_	IN	IN	_	26	VMOD	_	_
28	reduced	_	VBN	VBN	_	29	NMOD	_	_
29	levels	_	NNS	NNS	_	27	PMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	4	SBJ	_	_
3	further	_	RB	RB	_	4	ADV	_	_
4	support	_	VBP	VBP	_	0	ROOT-S	_	_
5	our	_	PRP$	PRP$	_	7	NMOD	_	_
6	previous	_	JJ	JJ	_	7	NMOD	_	_
7	observations	_	NNS	NNS	_	4	OBJ	_	_
8	on	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	distinct	_	JJ	JJ	_	11	NMOD	_	_
11	regulation	_	NN	NN	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	expression	_	NN	NN	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	20	NMOD	_	_
16	human	_	JJ	JJ	_	20	NMOD	_	_
17	HLA-DQ	_	NN	NN	_	20	NMOD	_	_
18	class	_	NN	NN	_	20	NMOD	_	_
19	II	_	CD	CD	_	20	NMOD	_	_
20	subset	_	NN	NN	_	14	PMOD	_	_
21	,	_	,	,	_	13	P	_	_
22	which	_	WDT	WDT	_	23	SBJ	_	_
23	may	_	MD	MD	_	13	NMOD	_	_
24	be	_	VB	VB	_	23	VC	_	_
25	thus	_	RB	RB	_	26	ADV	_	_
26	controlled	_	VBN	VBN	_	24	VC	_	_
27	at	_	IN	IN	_	26	TMP	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	posttranscriptional	_	JJ	JJ	_	30	NMOD	_	_
30	level	_	NN	NN	_	27	PMOD	_	_
31	by	_	IN	IN	_	26	LGS	_	_
32	a	_	DT	DT	_	34	NMOD	_	_
33	CIITA-independent	_	JJ	JJ	_	34	NMOD	_	_
34	mechanism	_	NN	NN	_	31	PMOD	_	_
35	.	_	.	.	_	4	P	_	_

1	Nasal	_	JJ	JJ	_	5	NMOD	_	_
2	NK-	_	NN	NN	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	T-cell	_	NN	NN	_	2	COORD	_	_
5	lymphomas	_	NNS	NNS	_	6	SBJ	_	_
6	share	_	VBP	VBP	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	same	_	JJ	JJ	_	9	NMOD	_	_
9	type	_	NN	NN	_	6	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	Epstein-Barr	_	JJ	JJ	_	13	NMOD	_	_
12	virus	_	NN	NN	_	13	NMOD	_	_
13	latency	_	NN	NN	_	10	PMOD	_	_
14	as	_	IN	IN	_	9	NMOD	_	_
15	nasopharyngeal	_	JJ	JJ	_	16	NMOD	_	_
16	carcinoma	_	NN	NN	_	14	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	Hodgkin	_	NN	NN	_	20	NMOD	_	_
19	's	_	POS	POS	_	18	NMOD	_	_
20	disease	_	NN	NN	_	16	COORD	_	_
21	.	_	.	.	_	6	P	_	_

1	Nasal	_	JJ	JJ	_	3	NMOD	_	_
2	T\/NK-cell	_	JJ	JJ	_	3	NMOD	_	_
3	lymphomas	_	NNS	NNS	_	4	SBJ	_	_
4	can	_	MD	MD	_	0	ROOT-S	_	_
5	be	_	VB	VB	_	4	VC	_	_
6	further	_	RBR	RBR	_	7	ADV	_	_
7	separated	_	VBN	VBN	_	5	VC	_	_
8	into	_	IN	IN	_	7	ADV	_	_
9	those	_	DT	DT	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	natural	_	JJ	JJ	_	12	NMOD	_	_
12	killer	_	NN	NN	_	17	NMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	NK	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	lineage	_	NN	NN	_	10	PMOD	_	_
18	or	_	CC	CC	_	10	CC	_	_
19	of	_	IN	IN	_	10	COORD	_	_
20	T-cell	_	NN	NN	_	21	NMOD	_	_
21	lineage	_	NN	NN	_	19	PMOD	_	_
22	,	_	,	,	_	9	P	_	_
23	with	_	IN	IN	_	9	NMOD	_	_
24	differences	_	NNS	NNS	_	23	PMOD	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	cellular	_	JJ	JJ	_	27	NMOD	_	_
27	phenotype	_	NN	NN	_	25	PMOD	_	_
28	,	_	,	,	_	27	P	_	_
29	T-cell	_	NN	NN	_	30	NMOD	_	_
30	receptor	_	NN	NN	_	35	NMOD	_	_
31	(	_	(	(	_	32	P	_	_
32	TcR	_	NN	NN	_	30	PRN	_	_
33	)	_	)	)	_	32	P	_	_
34	gene	_	NN	NN	_	35	NMOD	_	_
35	rearrangement	_	NN	NN	_	27	COORD	_	_
36	and	_	CC	CC	_	27	CC	_	_
37	TcR	_	NN	NN	_	39	NMOD	_	_
38	transcript	_	NN	NN	_	39	NMOD	_	_
39	expression	_	NN	NN	_	27	COORD	_	_
40	.	_	.	.	_	4	P	_	_

1	Both	_	CC	CC	_	2	CC	_	_
2	NK-	_	NN	NN	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	T-cell	_	NN	NN	_	2	COORD	_	_
5	subtypes	_	NNS	NNS	_	6	SBJ	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	closely	_	RB	RB	_	8	ADV	_	_
8	associated	_	VBN	VBN	_	6	VC	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	Epstein-Barr	_	JJ	JJ	_	11	NMOD	_	_
11	virus	_	NN	NN	_	9	PMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	EBV	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	8	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	8	P	_	_
5	EBV	_	NN	NN	_	7	NMOD	_	_
6	gene	_	NN	NN	_	7	NMOD	_	_
7	expression	_	NN	NN	_	8	SBJ	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	determined	_	VBN	VBN	_	8	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	23	_	CD	CD	_	12	NMOD	_	_
12	cases	_	NNS	NNS	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	nasal	_	JJ	JJ	_	15	NMOD	_	_
15	lymphoma	_	NN	NN	_	13	PMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	NL	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	by	_	IN	IN	_	9	LGS	_	_
20	in	_	FW	FW	_	21	AMOD	_	_
21	situ	_	FW	FW	_	22	NMOD	_	_
22	hybridisation	_	NN	NN	_	19	PMOD	_	_
23	(	_	(	(	_	24	P	_	_
24	ISH	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	,	_	,	,	_	22	P	_	_
27	reverse	_	JJ	JJ	_	30	NMOD	_	_
28	transcriptase-polymerase	_	NN	NN	_	30	NMOD	_	_
29	chain	_	NN	NN	_	30	NMOD	_	_
30	reaction	_	NN	NN	_	22	COORD	_	_
31	(	_	(	(	_	32	P	_	_
32	RT-PCR	_	NN	NN	_	30	PRN	_	_
33	)	_	)	)	_	32	P	_	_
34	and	_	CC	CC	_	22	CC	_	_
35	immunohistochemistry	_	NN	NN	_	22	COORD	_	_
36	(	_	(	(	_	37	P	_	_
37	IH	_	NN	NN	_	35	PRN	_	_
38	)	_	)	)	_	37	P	_	_
39	.	_	.	.	_	8	P	_	_

1	Of	_	IN	IN	_	6	NMOD	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	23	_	CD	CD	_	4	NMOD	_	_
4	cases	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	19	_	CD	CD	_	7	SBJ	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	classified	_	VBN	VBN	_	7	VC	_	_
9	as	_	IN	IN	_	8	VMOD	_	_
10	NK-cell	_	NN	NN	_	9	DEP	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	4	_	CD	CD	_	6	GAP	_	_
13	as	_	IN	IN	_	9	GAP	_	_
14	T-cell	_	NN	NN	_	15	NMOD	_	_
15	tumours	_	NNS	NNS	_	13	PMOD	_	_
16	.	_	.	.	_	7	P	_	_

1	ISH	_	NN	NN	_	7	SBJ	_	_
2	for	_	IN	IN	_	1	NMOD	_	_
3	EBV-encoded	_	JJ	JJ	_	6	NMOD	_	_
4	small	_	JJ	JJ	_	6	NMOD	_	_
5	non-polyadenylated	_	JJ	JJ	_	6	NMOD	_	_
6	RNAs	_	NNS	NNS	_	2	PMOD	_	_
7	showed	_	VBD	VBD	_	0	ROOT-S	_	_
8	that	_	IN	IN	_	7	OBJ	_	_
9	all	_	DT	DT	_	10	NMOD	_	_
10	cases	_	NNS	NNS	_	17	SBJ	_	_
11	,	_	,	,	_	17	P	_	_
12	whether	_	IN	IN	_	17	ADV	_	_
13	NK	_	NN	NN	_	12	VMOD	_	_
14	or	_	CC	CC	_	13	CC	_	_
15	T	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	17	P	_	_
17	harboured	_	VBD	VBD	_	8	VMOD	_	_
18	EBV	_	NN	NN	_	17	OBJ	_	_
19	in	_	IN	IN	_	17	ADV	_	_
20	virtually	_	RB	RB	_	21	AMOD	_	_
21	all	_	DT	DT	_	23	NMOD	_	_
22	tumour	_	NN	NN	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	19	PMOD	_	_
24	.	_	.	.	_	7	P	_	_

1	RT-PCR	_	NN	NN	_	2	SBJ	_	_
2	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	NL	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	both	_	DT	DT	_	7	NMOD	_	_
7	subtypes	_	NNS	NNS	_	5	PMOD	_	_
8	expressed	_	VBD	VBD	_	3	VMOD	_	_
9	EBNAI	_	NN	NN	_	8	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	QUK	_	NN	NN	_	14	NMOD	_	_
13	splice	_	NN	NN	_	14	NMOD	_	_
14	pattern	_	NN	NN	_	10	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	latent	_	JJ	JJ	_	19	NMOD	_	_
18	membrane	_	NN	NN	_	19	NMOD	_	_
19	proteins	_	NNS	NNS	_	14	COORD	_	_
20	,	_	,	,	_	19	P	_	_
21	LMP1	_	NN	NN	_	19	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	2	_	CD	CD	_	21	COORD	_	_
24	and	_	CC	CC	_	14	CC	_	_
25	the	_	DT	DT	_	29	NMOD	_	_
26	BamHI	_	NN	NN	_	29	NMOD	_	_
27	A	_	NN	NN	_	29	NMOD	_	_
28	rightward	_	JJ	JJ	_	29	NMOD	_	_
29	transcripts	_	NNS	NNS	_	14	COORD	_	_
30	in	_	IN	IN	_	8	ADV	_	_
31	the	_	DT	DT	_	30	DEP	_	_
32	absence	_	NN	NN	_	30	DEP	_	_
33	of	_	IN	IN	_	30	DEP	_	_
34	EBNA2	_	NN	NN	_	35	NMOD	_	_
35	mRNAs	_	NNS	NNS	_	30	PMOD	_	_
36	,	_	,	,	_	8	P	_	_
37	compatible	_	JJ	JJ	_	8	VMOD	_	_
38	with	_	IN	IN	_	37	AMOD	_	_
39	the	_	DT	DT	_	43	NMOD	_	_
40	latency	_	NN	NN	_	43	NMOD	_	_
41	type	_	NN	NN	_	43	NMOD	_	_
42	II	_	CD	CD	_	43	NMOD	_	_
43	pattern	_	NN	NN	_	38	PMOD	_	_
44	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	11	P	_	_
4	analysis	_	NN	NN	_	11	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	EBV	_	NN	NN	_	8	NMOD	_	_
7	protein	_	NN	NN	_	8	NMOD	_	_
8	expression	_	NN	NN	_	5	PMOD	_	_
9	by	_	IN	IN	_	8	NMOD	_	_
10	IH	_	NN	NN	_	9	PMOD	_	_
11	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	heterogeneous	_	JJ	JJ	_	14	NMOD	_	_
14	pattern	_	NN	NN	_	11	IOBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	EBV	_	NN	NN	_	18	NMOD	_	_
17	gene	_	NN	NN	_	18	NMOD	_	_
18	expression	_	NN	NN	_	15	PMOD	_	_
19	at	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	single-cell	_	NN	NN	_	22	NMOD	_	_
22	level	_	NN	NN	_	19	PMOD	_	_
23	consisting	_	VBG	VBG	_	22	NMOD	_	_
24	of	_	IN	IN	_	23	ADV	_	_
25	both	_	CC	CC	_	26	CC	_	_
26	LMP1+	_	JJ	JJ	_	30	NMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	LMP1-	_	JJ	JJ	_	26	COORD	_	_
29	tumour	_	NN	NN	_	30	NMOD	_	_
30	cells	_	NNS	NNS	_	24	PMOD	_	_
31	,	_	,	,	_	11	P	_	_
32	suggesting	_	VBG	VBG	_	11	OBJ	_	_
33	a	_	DT	DT	_	34	NMOD	_	_
34	mixture	_	NN	NN	_	32	OBJ	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	latency	_	NN	NN	_	35	PMOD	_	_
37	I	_	CD	CD	_	36	NMOD	_	_
38	and	_	CC	CC	_	37	CC	_	_
39	II	_	CD	CD	_	37	COORD	_	_
40	.	_	.	.	_	11	P	_	_

1	Although	_	IN	IN	_	30	ADV	_	_
2	2	_	CD	CD	_	5	NMOD	_	_
3	early	_	JJ	JJ	_	5	NMOD	_	_
4	lytic	_	JJ	JJ	_	5	NMOD	_	_
5	transcripts	_	NNS	NNS	_	11	SBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	BZLF1	_	NN	NN	_	5	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	BHRF1	_	NN	NN	_	7	COORD	_	_
10	,	_	,	,	_	5	P	_	_
11	were	_	VBD	VBD	_	1	VMOD	_	_
12	also	_	RB	RB	_	13	ADV	_	_
13	detected	_	VBN	VBN	_	11	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	13	_	CD	CD	_	18	NMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	10	_	CD	CD	_	15	COORD	_	_
18	cases	_	NNS	NNS	_	14	PMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	respectively	_	RB	RB	_	18	NMOD	_	_
21	,	_	,	,	_	30	P	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	lack	_	NN	NN	_	30	SBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	ZEBRA	_	NN	NN	_	26	NMOD	_	_
26	staining	_	NN	NN	_	24	PMOD	_	_
27	in	_	IN	IN	_	23	NMOD	_	_
28	any	_	DT	DT	_	29	NMOD	_	_
29	case	_	NN	NN	_	27	PMOD	_	_
30	indicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
31	that	_	IN	IN	_	30	OBJ	_	_
32	these	_	DT	DT	_	34	NMOD	_	_
33	lytic	_	JJ	JJ	_	34	NMOD	_	_
34	transcripts	_	NNS	NNS	_	35	SBJ	_	_
35	are	_	VBP	VBP	_	31	VMOD	_	_
36	most	_	RBS	RBS	_	37	AMOD	_	_
37	likely	_	RB	RB	_	38	ADV	_	_
38	expressed	_	VBN	VBN	_	35	VC	_	_
39	by	_	IN	IN	_	38	LGS	_	_
40	rare	_	JJ	JJ	_	41	NMOD	_	_
41	cells	_	NNS	NNS	_	39	PMOD	_	_
42	in	_	IN	IN	_	41	NMOD	_	_
43	the	_	DT	DT	_	44	NMOD	_	_
44	biopsies	_	NNS	NNS	_	42	PMOD	_	_
45	entering	_	VBG	VBG	_	44	NMOD	_	_
46	lytic	_	JJ	JJ	_	47	NMOD	_	_
47	cycle	_	NN	NN	_	45	OBJ	_	_
48	.	_	.	.	_	30	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	viral	_	JJ	JJ	_	4	NMOD	_	_
3	transcriptional	_	JJ	JJ	_	4	NMOD	_	_
4	pattern	_	NN	NN	_	15	SBJ	_	_
5	similar	_	JJ	JJ	_	4	NMOD	_	_
6	to	_	TO	TO	_	5	AMOD	_	_
7	that	_	DT	DT	_	6	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	nasopharyngeal	_	JJ	JJ	_	10	NMOD	_	_
10	carcinoma	_	NN	NN	_	8	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	Hodgkin	_	NN	NN	_	14	NMOD	_	_
13	's	_	POS	POS	_	12	NMOD	_	_
14	disease	_	NN	NN	_	10	COORD	_	_
15	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	that	_	IN	IN	_	15	OBJ	_	_
17	EBV	_	NN	NN	_	18	SBJ	_	_
18	can	_	MD	MD	_	16	VMOD	_	_
19	exploit	_	VB	VB	_	18	VC	_	_
20	common	_	JJ	JJ	_	22	NMOD	_	_
21	regulatory	_	JJ	JJ	_	22	NMOD	_	_
22	mechanisms	_	NNS	NNS	_	19	OBJ	_	_
23	for	_	IN	IN	_	22	NMOD	_	_
24	gene	_	NN	NN	_	25	NMOD	_	_
25	transcription	_	NN	NN	_	23	PMOD	_	_
26	in	_	IN	IN	_	22	NMOD	_	_
27	diverse	_	JJ	JJ	_	30	NMOD	_	_
28	host	_	NN	NN	_	30	NMOD	_	_
29	cell	_	NN	NN	_	30	NMOD	_	_
30	types	_	NNS	NNS	_	26	PMOD	_	_
31	.	_	.	.	_	15	P	_	_

1	Down-regulation	_	NN	NN	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	immunogenic	_	JJ	JJ	_	4	NMOD	_	_
4	proteins	_	NNS	NNS	_	2	PMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	EBNA2-EBNA6	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	in	_	IN	IN	_	1	NMOD	_	_
9	nasal	_	JJ	JJ	_	10	NMOD	_	_
10	lymphoma	_	NN	NN	_	8	PMOD	_	_
11	may	_	MD	MD	_	0	ROOT-S	_	_
12	enable	_	VB	VB	_	11	VC	_	_
13	tumour	_	NN	NN	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	16	SBJ	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	evade	_	VB	VB	_	12	OBJ	_	_
17	host	_	NN	NN	_	20	NMOD	_	_
18	cytotoxic	_	JJ	JJ	_	20	NMOD	_	_
19	T-cell	_	NN	NN	_	20	NMOD	_	_
20	surveillance	_	NN	NN	_	16	OBJ	_	_
21	.	_	.	.	_	11	P	_	_

1	Stat3	_	NN	NN	_	2	NMOD	_	_
2	recruitment	_	NN	NN	_	0	ROOT-FRAG	_	_
3	by	_	IN	IN	_	2	NMOD	_	_
4	two	_	CD	CD	_	10	NMOD	_	_
5	distinct	_	JJ	JJ	_	10	NMOD	_	_
6	ligand-induced	_	JJ	JJ	_	10	NMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	tyrosine-phosphorylated	_	JJ	JJ	_	6	COORD	_	_
9	docking	_	NN	NN	_	10	NMOD	_	_
10	sites	_	NNS	NNS	_	3	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	16	NMOD	_	_
13	interleukin-10	_	NN	NN	_	16	NMOD	_	_
14	receptor	_	NN	NN	_	16	NMOD	_	_
15	intracellular	_	JJ	JJ	_	16	NMOD	_	_
16	domain	_	NN	NN	_	11	PMOD	_	_
17	.	_	.	.	_	2	P	_	_

1	Recent	_	JJ	JJ	_	2	NMOD	_	_
2	work	_	NN	NN	_	3	SBJ	_	_
3	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	shown	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	IL-10	_	NN	NN	_	7	SBJ	_	_
7	induces	_	VBZ	VBZ	_	5	VMOD	_	_
8	activation	_	NN	NN	_	7	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	JAK-STAT	_	NN	NN	_	13	NMOD	_	_
12	signaling	_	NN	NN	_	13	NMOD	_	_
13	pathway	_	NN	NN	_	9	PMOD	_	_
14	.	_	.	.	_	3	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	define	_	VB	VB	_	36	VC	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	mechanism	_	NN	NN	_	2	OBJ	_	_
5	underlying	_	VBG	VBG	_	4	NMOD	_	_
6	signal	_	NN	NN	_	7	NMOD	_	_
7	transducer	_	NN	NN	_	16	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	activator	_	NN	NN	_	7	COORD	_	_
10	of	_	IN	IN	_	7	NMOD	_	_
11	transcription	_	NN	NN	_	10	PMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	STAT	_	NN	NN	_	7	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	protein	_	NN	NN	_	16	NMOD	_	_
16	recruitment	_	NN	NN	_	5	OBJ	_	_
17	to	_	TO	TO	_	16	NMOD	_	_
18	the	_	DT	DT	_	24	NMOD	_	_
19	interleukin	_	NN	NN	_	24	NMOD	_	_
20	10	_	CD	CD	_	19	NMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	IL-10	_	NN	NN	_	19	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	receptor	_	NN	NN	_	17	PMOD	_	_
25	,	_	,	,	_	36	P	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	STAT	_	NN	NN	_	28	NMOD	_	_
28	proteins	_	NNS	NNS	_	36	SBJ	_	_
29	activated	_	VBN	VBN	_	28	NMOD	_	_
30	by	_	IN	IN	_	29	LGS	_	_
31	IL-10	_	NN	NN	_	30	PMOD	_	_
32	in	_	IN	IN	_	29	ADV	_	_
33	different	_	JJ	JJ	_	35	NMOD	_	_
34	cell	_	NN	NN	_	35	NMOD	_	_
35	populations	_	NNS	NNS	_	32	PMOD	_	_
36	were	_	VBD	VBD	_	0	ROOT-S	_	_
37	first	_	RB	RB	_	36	TMP	_	_
38	defined	_	VBN	VBN	_	36	VC	_	_
39	using	_	VBG	VBG	_	38	OBJ	_	_
40	electrophoretic	_	JJ	JJ	_	43	NMOD	_	_
41	mobility	_	NN	NN	_	43	NMOD	_	_
42	shift	_	NN	NN	_	43	NMOD	_	_
43	assays	_	NNS	NNS	_	39	OBJ	_	_
44	.	_	.	.	_	36	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	all	_	DT	DT	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	tested	_	VBN	VBN	_	3	NMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	IL-10	_	NN	NN	_	7	SBJ	_	_
7	activated	_	VBD	VBD	_	0	ROOT-S	_	_
8	Stat1	_	NN	NN	_	7	OBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	Stat3	_	NN	NN	_	8	COORD	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	induced	_	VBD	VBD	_	7	COORD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	formation	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	three	_	CD	CD	_	20	NMOD	_	_
17	distinct	_	JJ	JJ	_	20	NMOD	_	_
18	DNA	_	NN	NN	_	20	NMOD	_	_
19	binding	_	NN	NN	_	20	NMOD	_	_
20	complexes	_	NNS	NNS	_	15	PMOD	_	_
21	that	_	WDT	WDT	_	22	SBJ	_	_
22	contained	_	VBD	VBD	_	20	NMOD	_	_
23	different	_	JJ	JJ	_	24	NMOD	_	_
24	combinations	_	NNS	NNS	_	22	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	these	_	DT	DT	_	29	NMOD	_	_
27	two	_	CD	CD	_	29	NMOD	_	_
28	transcription	_	NN	NN	_	29	NMOD	_	_
29	factors	_	NNS	NNS	_	25	PMOD	_	_
30	.	_	.	.	_	7	P	_	_

1	IL-10	_	NN	NN	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	activated	_	VBD	VBD	_	0	ROOT-S	_	_
4	Stat5	_	NN	NN	_	3	OBJ	_	_
5	in	_	IN	IN	_	3	ADV	_	_
6	Ba\/F3	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	5	PMOD	_	_
8	that	_	IN	IN	_	10	SBJ	_	_
9	stably	_	RB	RB	_	10	ADV	_	_
10	expressed	_	VBD	VBD	_	7	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	murine	_	JJ	JJ	_	14	NMOD	_	_
13	IL-10	_	NN	NN	_	14	NMOD	_	_
14	receptor	_	NN	NN	_	10	OBJ	_	_
15	.	_	.	.	_	3	P	_	_

1	Using	_	VBG	VBG	_	24	VC	_	_
2	a	_	DT	DT	_	5	NMOD	_	_
3	structure-function	_	JJ	JJ	_	5	NMOD	_	_
4	mutagenesis	_	NN	NN	_	5	NMOD	_	_
5	approach	_	NN	NN	_	1	OBJ	_	_
6	,	_	,	,	_	24	P	_	_
7	two	_	CD	CD	_	9	NMOD	_	_
8	tyrosine	_	NN	NN	_	9	NMOD	_	_
9	residues	_	NNS	NNS	_	24	SBJ	_	_
10	(	_	(	(	_	11	P	_	_
11	Tyr427	_	NN	NN	_	9	PRN	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	Tyr477	_	NN	NN	_	11	COORD	_	_
14	)	_	)	)	_	11	P	_	_
15	in	_	IN	IN	_	9	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	intracellular	_	JJ	JJ	_	18	NMOD	_	_
18	domain	_	NN	NN	_	15	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	murine	_	JJ	JJ	_	23	NMOD	_	_
22	IL-10	_	NN	NN	_	23	NMOD	_	_
23	receptor	_	NN	NN	_	19	PMOD	_	_
24	were	_	VBD	VBD	_	0	ROOT-S	_	_
25	found	_	VBN	VBN	_	24	VC	_	_
26	to	_	TO	TO	_	27	VMOD	_	_
27	be	_	VB	VB	_	25	OBJ	_	_
28	redundantly	_	RB	RB	_	29	ADV	_	_
29	required	_	VBN	VBN	_	27	VC	_	_
30	for	_	IN	IN	_	29	ADV	_	_
31	receptor	_	NN	NN	_	32	NMOD	_	_
32	function	_	NN	NN	_	30	PMOD	_	_
33	and	_	CC	CC	_	30	CC	_	_
34	for	_	IN	IN	_	30	COORD	_	_
35	activation	_	NN	NN	_	34	PMOD	_	_
36	of	_	IN	IN	_	35	NMOD	_	_
37	Stat3	_	NN	NN	_	36	PMOD	_	_
38	but	_	CC	CC	_	36	CC	_	_
39	not	_	RB	RB	_	40	DEP	_	_
40	for	_	IN	IN	_	36	COORD	_	_
41	Stat1	_	NN	NN	_	40	PMOD	_	_
42	or	_	CC	CC	_	41	CC	_	_
43	Stat5	_	NN	NN	_	41	COORD	_	_
44	.	_	.	.	_	24	P	_	_

1	Twelve	_	CD	CD	_	4	NMOD	_	_
2	amino	_	NN	NN	_	4	NMOD	_	_
3	acid	_	NN	NN	_	4	NMOD	_	_
4	peptides	_	NNS	NNS	_	15	SBJ	_	_
5	encompassing	_	VBG	VBG	_	4	NMOD	_	_
6	either	_	DT	DT	_	5	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	these	_	DT	DT	_	11	NMOD	_	_
9	two	_	CD	CD	_	11	NMOD	_	_
10	tyrosine	_	NN	NN	_	11	NMOD	_	_
11	residues	_	NNS	NNS	_	7	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	phosphorylated	_	JJ	JJ	_	14	NMOD	_	_
14	form	_	NN	NN	_	12	PMOD	_	_
15	coprecipitated	_	VBD	VBD	_	0	ROOT-S	_	_
16	Stat3	_	NN	NN	_	15	OBJ	_	_
17	but	_	CC	CC	_	16	CC	_	_
18	not	_	RB	RB	_	17	COORD	_	_
19	Stat1	_	NN	NN	_	16	COORD	_	_
20	and	_	CC	CC	_	15	CC	_	_
21	blocked	_	VBD	VBD	_	15	COORD	_	_
22	IL-10-induced	_	JJ	JJ	_	24	NMOD	_	_
23	Stat3	_	NN	NN	_	24	NMOD	_	_
24	phosphorylation	_	NN	NN	_	21	OBJ	_	_
25	in	_	IN	IN	_	21	ADV	_	_
26	a	_	DT	DT	_	28	NMOD	_	_
27	cell-free	_	JJ	JJ	_	28	NMOD	_	_
28	system	_	NN	NN	_	25	PMOD	_	_
29	.	_	.	.	_	15	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	10	P	_	_
4	tyrosine-phosphorylated	_	JJ	JJ	_	5	NMOD	_	_
5	peptides	_	NNS	NNS	_	10	SBJ	_	_
6	containing	_	VBG	VBG	_	5	NMOD	_	_
7	Tyr374	_	NN	NN	_	6	OBJ	_	_
8	or	_	CC	CC	_	7	CC	_	_
9	Tyr396	_	NN	NN	_	7	COORD	_	_
10	did	_	VBD	VBD	_	0	ROOT-S	_	_
11	not	_	RB	RB	_	10	VMOD	_	_
12	interact	_	VB	VB	_	10	VC	_	_
13	with	_	IN	IN	_	12	ADV	_	_
14	Stat3	_	NN	NN	_	13	PMOD	_	_
15	or	_	CC	CC	_	12	CC	_	_
16	block	_	VB	VB	_	12	COORD	_	_
17	Stat3	_	NN	NN	_	18	NMOD	_	_
18	activation	_	NN	NN	_	16	OBJ	_	_
19	.	_	.	.	_	10	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	Stat3	_	NN	NN	_	11	SBJ	_	_
6	but	_	CC	CC	_	7	CC	_	_
7	not	_	RB	RB	_	5	NMOD	_	_
8	Stat1	_	NN	NN	_	5	NMOD	_	_
9	or	_	CC	CC	_	8	CC	_	_
10	Stat5	_	NN	NN	_	8	COORD	_	_
11	is	_	VBZ	VBZ	_	4	VMOD	_	_
12	directly	_	RB	RB	_	13	ADV	_	_
13	recruited	_	VBN	VBN	_	11	VC	_	_
14	to	_	TO	TO	_	13	ADV	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	ligand-activated	_	JJ	JJ	_	18	NMOD	_	_
17	IL-10	_	NN	NN	_	18	NMOD	_	_
18	receptor	_	NN	NN	_	14	PMOD	_	_
19	by	_	IN	IN	_	13	ADV	_	_
20	binding	_	VBG	VBG	_	19	PMOD	_	_
21	to	_	TO	TO	_	20	ADV	_	_
22	specific	_	JJ	JJ	_	28	NMOD	_	_
23	but	_	CC	CC	_	22	CC	_	_
24	redundant	_	JJ	JJ	_	22	COORD	_	_
25	receptor	_	NN	NN	_	28	NMOD	_	_
26	intracellular	_	JJ	JJ	_	28	NMOD	_	_
27	domain	_	NN	NN	_	28	NMOD	_	_
28	sequences	_	NNS	NNS	_	21	PMOD	_	_
29	containing	_	VBG	VBG	_	28	NMOD	_	_
30	phosphotyrosine	_	NN	NN	_	29	OBJ	_	_
31	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	study	_	NN	NN	_	4	SBJ	_	_
3	thus	_	RB	RB	_	4	ADV	_	_
4	supports	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	concept	_	NN	NN	_	4	OBJ	_	_
7	that	_	IN	IN	_	6	NMOD	_	_
8	utilization	_	NN	NN	_	17	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	distinct	_	JJ	JJ	_	12	NMOD	_	_
11	STAT	_	NN	NN	_	12	NMOD	_	_
12	proteins	_	NNS	NNS	_	9	PMOD	_	_
13	by	_	IN	IN	_	8	NMOD	_	_
14	different	_	JJ	JJ	_	16	NMOD	_	_
15	cytokine	_	NN	NN	_	16	NMOD	_	_
16	receptors	_	NNS	NNS	_	13	PMOD	_	_
17	is	_	VBZ	VBZ	_	7	VMOD	_	_
18	dependent	_	JJ	JJ	_	17	PRD	_	_
19	on	_	IN	IN	_	18	AMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	expression	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	particular	_	JJ	JJ	_	29	NMOD	_	_
24	ligand-activatable	_	JJ	JJ	_	29	NMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	tyrosine-containing	_	JJ	JJ	_	24	COORD	_	_
27	STAT	_	NN	NN	_	29	NMOD	_	_
28	docking	_	NN	NN	_	29	NMOD	_	_
29	sites	_	NNS	NNS	_	22	PMOD	_	_
30	in	_	IN	IN	_	29	NMOD	_	_
31	receptor	_	NN	NN	_	33	NMOD	_	_
32	intracellular	_	JJ	JJ	_	33	NMOD	_	_
33	domains	_	NNS	NNS	_	30	PMOD	_	_
34	.	_	.	.	_	4	P	_	_

1	Potent	_	JJ	JJ	_	6	NMOD	_	_
2	gene	_	NN	NN	_	6	NMOD	_	_
3	regulatory	_	JJ	JJ	_	6	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	antiproliferative	_	JJ	JJ	_	3	COORD	_	_
6	activities	_	NNS	NNS	_	0	ROOT-FRAG	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	20-methyl	_	JJ	JJ	_	9	NMOD	_	_
9	analogues	_	NNS	NNS	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	1,25	_	CD	CD	_	13	NMOD	_	_
12	dihydroxyvitamin	_	NN	NN	_	13	NMOD	_	_
13	D3	_	NN	NN	_	10	PMOD	_	_
14	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	biological	_	JJ	JJ	_	4	NMOD	_	_
3	active	_	JJ	JJ	_	4	NMOD	_	_
4	form	_	NN	NN	_	15	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	vitamin	_	NN	NN	_	7	NMOD	_	_
7	D3	_	NN	NN	_	5	PMOD	_	_
8	,	_	,	,	_	4	P	_	_
9	1,25-dihydroxyvitamin	_	NN	NN	_	10	NMOD	_	_
10	D3	_	NN	NN	_	4	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	VD	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	,	_	,	,	_	4	P	_	_
15	regulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	cellular	_	JJ	JJ	_	17	NMOD	_	_
17	growth	_	NN	NN	_	15	OBJ	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	differentiation	_	NN	NN	_	17	COORD	_	_
20	.	_	.	.	_	15	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	provides	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	hormone	_	NN	NN	_	2	OBJ	_	_
5	with	_	IN	IN	_	2	ADV	_	_
6	an	_	DT	DT	_	9	NMOD	_	_
7	interesting	_	JJ	JJ	_	9	NMOD	_	_
8	therapeutic	_	JJ	JJ	_	9	NMOD	_	_
9	potential	_	NN	NN	_	5	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	However	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	hypercalcemia	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	side	_	JJ	JJ	_	7	NMOD	_	_
7	effect	_	NN	NN	_	4	PRD	_	_
8	,	_	,	,	_	7	P	_	_
9	which	_	WDT	WDT	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	7	NMOD	_	_
11	caused	_	VBN	VBN	_	10	VC	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	VD	_	NN	NN	_	16	NMOD	_	_
14	's	_	POS	POS	_	13	NMOD	_	_
15	classical	_	JJ	JJ	_	16	NMOD	_	_
16	action	_	NN	NN	_	12	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	regulation	_	NN	NN	_	16	NMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	calcium	_	NN	NN	_	22	NMOD	_	_
22	homeostasis	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	made	_	VBD	VBD	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	need	_	NN	NN	_	2	OBJ	_	_
5	for	_	IN	IN	_	4	NMOD	_	_
6	VD	_	NN	NN	_	7	NMOD	_	_
7	analogues	_	NNS	NNS	_	5	PMOD	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	selectively	_	RB	RB	_	10	AMOD	_	_
10	increased	_	VBN	VBN	_	13	NMOD	_	_
11	cell	_	NN	NN	_	13	NMOD	_	_
12	regulatory	_	JJ	JJ	_	13	NMOD	_	_
13	properties	_	NNS	NNS	_	8	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	Studies	_	NNS	NNS	_	5	SBJ	_	_
2	with	_	IN	IN	_	1	NMOD	_	_
3	20-epi	_	JJ	JJ	_	4	NMOD	_	_
4	analogues	_	NNS	NNS	_	2	PMOD	_	_
5	pointed	_	VBD	VBD	_	0	ROOT-S	_	_
6	out	_	RP	RP	_	5	PRT	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	importance	_	NN	NN	_	5	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	carbon-20	_	NN	NN	_	12	NMOD	_	_
12	position	_	NN	NN	_	9	PMOD	_	_
13	and	_	CC	CC	_	5	CC	_	_
14	led	_	VBD	VBD	_	5	COORD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	development	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	20-methyl	_	NN	NN	_	20	NMOD	_	_
20	derivatives	_	NNS	NNS	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	VD	_	NN	NN	_	21	PMOD	_	_
23	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	22	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	biological	_	JJ	JJ	_	6	NMOD	_	_
6	properties	_	NNS	NNS	_	22	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	compounds	_	NNS	NNS	_	7	PMOD	_	_
10	ZK161422	_	NN	NN	_	9	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	ZK157202	_	NN	NN	_	10	COORD	_	_
13	,	_	,	,	_	9	P	_	_
14	which	_	WDT	WDT	_	15	SBJ	_	_
15	are	_	VBP	VBP	_	9	NMOD	_	_
16	20-methyl-	_	NN	NN	_	15	PRD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	20-methyl-23-eneanalogues	_	NN	NN	_	16	COORD	_	_
19	,	_	,	,	_	16	P	_	_
20	respectively	_	RB	RB	_	16	NMOD	_	_
21	,	_	,	,	_	9	P	_	_
22	have	_	VBP	VBP	_	0	ROOT-S	_	_
23	been	_	VBN	VBN	_	22	VC	_	_
24	analyzed	_	VBN	VBN	_	23	VC	_	_
25	in	_	IN	IN	_	24	ADV	_	_
26	comparison	_	NN	NN	_	25	DEP	_	_
27	with	_	IN	IN	_	25	DEP	_	_
28	VD	_	NN	NN	_	25	PMOD	_	_
29	.	_	.	.	_	22	P	_	_

1	Both	_	DT	DT	_	2	NMOD	_	_
2	compounds	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	about	_	IN	IN	_	5	AMOD	_	_
5	2-fold	_	RB	RB	_	7	NMOD	_	_
6	lower	_	JJR	JJR	_	5	AMOD	_	_
7	affinity	_	NN	NN	_	3	OBJ	_	_
8	to	_	TO	TO	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	VD	_	NN	NN	_	11	NMOD	_	_
11	receptor	_	NN	NN	_	8	PMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	VDR	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	than	_	IN	IN	_	7	NMOD	_	_
16	VD	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	compared	_	VBN	VBN	_	10	VC	_	_
4	to	_	TO	TO	_	3	ADV	_	_
5	VD	_	NN	NN	_	4	PMOD	_	_
6	,	_	,	,	_	10	P	_	_
7	their	_	PRP$	PRP$	_	9	NMOD	_	_
8	antiproliferative	_	JJ	JJ	_	9	NMOD	_	_
9	effect	_	NN	NN	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	up	_	RB	RB	_	13	DEP	_	_
12	to	_	TO	TO	_	13	DEP	_	_
13	30-fold	_	RB	RB	_	10	PRD	_	_
14	higher	_	JJR	JJR	_	13	AMOD	_	_
15	on	_	IN	IN	_	10	VMOD	_	_
16	human	_	JJ	JJ	_	20	NMOD	_	_
17	peripheral	_	JJ	JJ	_	20	NMOD	_	_
18	blood	_	NN	NN	_	20	NMOD	_	_
19	mononuclear	_	JJ	JJ	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	15	PMOD	_	_
21	and	_	CC	CC	_	10	CC	_	_
22	even	_	RB	RB	_	23	AMOD	_	_
23	up	_	RB	RB	_	13	GAP	_	_
24	to	_	TO	TO	_	23	AMOD	_	_
25	300-fold	_	RB	RB	_	23	AMOD	_	_
26	higher	_	JJR	JJR	_	23	AMOD	_	_
27	on	_	IN	IN	_	15	GAP	_	_
28	human	_	JJ	JJ	_	32	NMOD	_	_
29	breast	_	NN	NN	_	32	NMOD	_	_
30	cancer	_	NN	NN	_	32	NMOD	_	_
31	MCF-7	_	NN	NN	_	32	NMOD	_	_
32	cells	_	NNS	NNS	_	27	PMOD	_	_
33	.	_	.	.	_	10	P	_	_

1	Whereas	_	IN	IN	_	13	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	hypercalcemic	_	JJ	JJ	_	4	NMOD	_	_
4	effect	_	NN	NN	_	7	SBJ	_	_
5	for	_	IN	IN	_	4	NMOD	_	_
6	ZK157202	_	NN	NN	_	5	PMOD	_	_
7	is	_	VBZ	VBZ	_	1	VMOD	_	_
8	also	_	RB	RB	_	7	ADV	_	_
9	increased	_	VBN	VBN	_	7	VC	_	_
10	10-fold	_	RB	RB	_	9	ADV	_	_
11	,	_	,	,	_	13	P	_	_
12	ZK161422	_	NN	NN	_	13	SBJ	_	_
13	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	same	_	JJ	JJ	_	17	NMOD	_	_
16	calcium-mobilizing	_	JJ	JJ	_	17	NMOD	_	_
17	potency	_	NN	NN	_	13	OBJ	_	_
18	as	_	IN	IN	_	17	NMOD	_	_
19	VD	_	NN	NN	_	18	PMOD	_	_
20	.	_	.	.	_	13	P	_	_

1	Moreover	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	ZK161422	_	NN	NN	_	9	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	but	_	CC	CC	_	3	CC	_	_
6	not	_	RB	RB	_	5	COORD	_	_
7	ZK157202	_	NN	NN	_	3	COORD	_	_
8	,	_	,	,	_	3	P	_	_
9	showed	_	VBD	VBD	_	0	ROOT-S	_	_
10	preference	_	NN	NN	_	9	OBJ	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	gene	_	NN	NN	_	13	NMOD	_	_
13	activation	_	NN	NN	_	11	PMOD	_	_
14	from	_	IN	IN	_	13	NMOD	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	promoter	_	NN	NN	_	14	PMOD	_	_
17	carrying	_	VBG	VBG	_	16	NMOD	_	_
18	a	_	DT	DT	_	21	NMOD	_	_
19	VD	_	NN	NN	_	21	NMOD	_	_
20	response	_	NN	NN	_	21	NMOD	_	_
21	element	_	NN	NN	_	17	OBJ	_	_
22	with	_	IN	IN	_	21	NMOD	_	_
23	a	_	DT	DT	_	25	NMOD	_	_
24	palindromic	_	JJ	JJ	_	25	NMOD	_	_
25	arrangement	_	NN	NN	_	22	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	two	_	CD	CD	_	31	NMOD	_	_
28	hexameric	_	JJ	JJ	_	31	NMOD	_	_
29	receptor	_	NN	NN	_	31	NMOD	_	_
30	binding	_	NN	NN	_	31	NMOD	_	_
31	sites	_	NNS	NNS	_	26	PMOD	_	_
32	spaced	_	VBN	VBN	_	31	NMOD	_	_
33	by	_	IN	IN	_	32	LGS	_	_
34	9	_	CD	CD	_	35	NMOD	_	_
35	nucleotides	_	NNS	NNS	_	33	PMOD	_	_
36	(	_	(	(	_	37	P	_	_
37	IP9	_	NN	NN	_	35	PRN	_	_
38	)	_	)	)	_	37	P	_	_
39	rather	_	RB	RB	_	11	CC	_	_
40	than	_	IN	IN	_	39	DEP	_	_
41	for	_	IN	IN	_	11	COORD	_	_
42	activation	_	NN	NN	_	41	PMOD	_	_
43	from	_	IN	IN	_	42	NMOD	_	_
44	a	_	DT	DT	_	46	NMOD	_	_
45	response	_	NN	NN	_	46	NMOD	_	_
46	element	_	NN	NN	_	43	PMOD	_	_
47	formed	_	VBN	VBN	_	46	NMOD	_	_
48	by	_	IN	IN	_	47	LGS	_	_
49	a	_	DT	DT	_	51	NMOD	_	_
50	direct	_	JJ	JJ	_	51	NMOD	_	_
51	repeat	_	NN	NN	_	48	PMOD	_	_
52	spaced	_	VBN	VBN	_	51	NMOD	_	_
53	by	_	IN	IN	_	52	LGS	_	_
54	3	_	CD	CD	_	55	NMOD	_	_
55	nucleotides	_	NNS	NNS	_	53	PMOD	_	_
56	(	_	(	(	_	57	P	_	_
57	DR3	_	NN	NN	_	51	PRN	_	_
58	)	_	)	)	_	57	P	_	_
59	.	_	.	.	_	9	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	observation	_	NN	NN	_	3	SBJ	_	_
3	supports	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	model	_	NN	NN	_	3	OBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	in	_	IN	IN	_	11	ADV	_	_
8	which	_	WDT	WDT	_	7	PMOD	_	_
9	promoter	_	NN	NN	_	10	NMOD	_	_
10	selectivity	_	NN	NN	_	11	SBJ	_	_
11	reflects	_	VBZ	VBZ	_	5	NMOD	_	_
12	the	_	DT	DT	_	16	NMOD	_	_
13	selectively	_	RB	RB	_	14	AMOD	_	_
14	increased	_	VBN	VBN	_	16	NMOD	_	_
15	antiproliferative	_	JJ	JJ	_	16	NMOD	_	_
16	effect	_	NN	NN	_	11	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	VD	_	NN	NN	_	19	NMOD	_	_
19	analogues	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	T	_	NN	NN	_	3	NMOD	_	_
2	cell	_	NN	NN	_	3	NMOD	_	_
3	response	_	NN	NN	_	0	ROOT-FRAG	_	_
4	to	_	TO	TO	_	3	NMOD	_	_
5	Epstein-Barr	_	JJ	JJ	_	7	NMOD	_	_
6	virus	_	NN	NN	_	7	NMOD	_	_
7	transactivators	_	NNS	NNS	_	4	PMOD	_	_
8	in	_	IN	IN	_	3	NMOD	_	_
9	chronic	_	JJ	JJ	_	11	NMOD	_	_
10	rheumatoid	_	JJ	JJ	_	11	NMOD	_	_
11	arthritis	_	NN	NN	_	8	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	Rheumatoid	_	JJ	JJ	_	2	NMOD	_	_
2	arthritis	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	multistep	_	JJ	JJ	_	6	NMOD	_	_
6	disorder	_	NN	NN	_	3	PRD	_	_
7	associated	_	VBN	VBN	_	6	NMOD	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	autoimmune	_	JJ	JJ	_	10	NMOD	_	_
10	features	_	NNS	NNS	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	yet	_	RB	RB	_	13	AMOD	_	_
13	unknown	_	JJ	JJ	_	14	NMOD	_	_
14	etiology	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	3	P	_	_

1	Implication	_	NN	NN	_	15	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	viruses	_	NNS	NNS	_	2	PMOD	_	_
4	such	_	JJ	JJ	_	5	DEP	_	_
5	as	_	IN	IN	_	3	NMOD	_	_
6	Epstein-Barr	_	JJ	JJ	_	7	NMOD	_	_
7	virus	_	NN	NN	_	5	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	EBV	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	in	_	IN	IN	_	1	NMOD	_	_
12	rheumatoid	_	JJ	JJ	_	14	NMOD	_	_
13	arthritis	_	NN	NN	_	14	NMOD	_	_
14	pathogenesis	_	NN	NN	_	11	PMOD	_	_
15	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	been	_	VBN	VBN	_	15	VC	_	_
17	suspected	_	VBN	VBN	_	16	VC	_	_
18	on	_	IN	IN	_	17	ADV	_	_
19	the	_	DT	DT	_	18	DEP	_	_
20	basis	_	NN	NN	_	18	DEP	_	_
21	of	_	IN	IN	_	18	DEP	_	_
22	several	_	JJ	JJ	_	24	NMOD	_	_
23	indirect	_	JJ	JJ	_	24	NMOD	_	_
24	observations	_	NNS	NNS	_	18	PMOD	_	_
25	,	_	,	,	_	15	P	_	_
26	but	_	CC	CC	_	15	CC	_	_
27	thus	_	RB	RB	_	38	TMP	_	_
28	far	_	RB	RB	_	27	AMOD	_	_
29	,	_	,	,	_	38	P	_	_
30	a	_	DT	DT	_	32	NMOD	_	_
31	direct	_	JJ	JJ	_	32	NMOD	_	_
32	link	_	NN	NN	_	38	SBJ	_	_
33	between	_	IN	IN	_	32	NMOD	_	_
34	EBV	_	NN	NN	_	33	PMOD	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	rheumatoid	_	JJ	JJ	_	37	NMOD	_	_
37	arthritis	_	NN	NN	_	34	COORD	_	_
38	has	_	VBZ	VBZ	_	15	COORD	_	_
39	not	_	RB	RB	_	38	VMOD	_	_
40	been	_	VBN	VBN	_	38	VC	_	_
41	provided	_	VBN	VBN	_	40	VC	_	_
42	.	_	.	.	_	15	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	large	_	JJ	JJ	_	7	NMOD	_	_
7	fraction	_	NN	NN	_	21	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	infiltrating	_	VBG	VBG	_	7	NMOD	_	_
12	affected	_	VBN	VBN	_	13	NMOD	_	_
13	joints	_	NNS	NNS	_	11	OBJ	_	_
14	from	_	IN	IN	_	13	NMOD	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	patient	_	NN	NN	_	14	PMOD	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	chronic	_	JJ	JJ	_	20	NMOD	_	_
19	rheumatoid	_	JJ	JJ	_	20	NMOD	_	_
20	arthritis	_	NN	NN	_	17	PMOD	_	_
21	recognizes	_	VBZ	VBZ	_	4	VMOD	_	_
22	two	_	CD	CD	_	24	NMOD	_	_
23	EBV	_	NN	NN	_	24	NMOD	_	_
24	transactivators	_	NNS	NNS	_	21	OBJ	_	_
25	(	_	(	(	_	26	P	_	_
26	BZLF1	_	NN	NN	_	24	PRN	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	BMLF1	_	NN	NN	_	26	COORD	_	_
29	)	_	)	)	_	26	P	_	_
30	in	_	IN	IN	_	21	ADV	_	_
31	a	_	DT	DT	_	35	NMOD	_	_
32	major	_	JJ	JJ	_	33	AMOD	_	_
33	histocompatibility	_	NN	NN	_	35	NMOD	_	_
34	complex-restricted	_	JJ	JJ	_	33	AMOD	_	_
35	fashion	_	NN	NN	_	30	PMOD	_	_
36	.	_	.	.	_	3	P	_	_

1	Responses	_	NNS	NNS	_	16	SBJ	_	_
2	to	_	TO	TO	_	1	NMOD	_	_
3	these	_	DT	DT	_	5	NMOD	_	_
4	EBV	_	NN	NN	_	5	NMOD	_	_
5	antigens	_	NNS	NNS	_	2	PMOD	_	_
6	by	_	IN	IN	_	1	NMOD	_	_
7	synovial	_	JJ	JJ	_	8	NMOD	_	_
8	lymphocytes	_	NNS	NNS	_	6	PMOD	_	_
9	from	_	IN	IN	_	8	NMOD	_	_
10	several	_	JJ	JJ	_	15	NMOD	_	_
11	other	_	JJ	JJ	_	15	NMOD	_	_
12	chronic	_	JJ	JJ	_	15	NMOD	_	_
13	rheumatoid	_	JJ	JJ	_	15	NMOD	_	_
14	arthritis	_	NN	NN	_	15	NMOD	_	_
15	patients	_	NNS	NNS	_	9	PMOD	_	_
16	were	_	VBD	VBD	_	0	ROOT-S	_	_
17	readily	_	RB	RB	_	18	AMOD	_	_
18	detectable	_	JJ	JJ	_	16	PRD	_	_
19	.	_	.	.	_	16	P	_	_

1	Thus	_	RB	RB	_	4	ADV	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	results	_	NNS	NNS	_	4	SBJ	_	_
4	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	direct	_	JJ	JJ	_	7	NMOD	_	_
7	contribution	_	NN	NN	_	4	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	EBV	_	NN	NN	_	8	PMOD	_	_
10	to	_	TO	TO	_	7	NMOD	_	_
11	chronic	_	JJ	JJ	_	14	NMOD	_	_
12	rheumatoid	_	JJ	JJ	_	14	NMOD	_	_
13	arthritis	_	NN	NN	_	14	NMOD	_	_
14	pathogenesis	_	NN	NN	_	10	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	They	_	PRP	PRP	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	for	_	IN	IN	_	3	TMP	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	first	_	JJ	JJ	_	7	NMOD	_	_
7	time	_	NN	NN	_	4	PMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	occurrence	_	NN	NN	_	3	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	T	_	NN	NN	_	13	NMOD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	responses	_	NNS	NNS	_	10	PMOD	_	_
14	against	_	IN	IN	_	13	NMOD	_	_
15	EBV	_	NN	NN	_	17	NMOD	_	_
16	transactivating	_	VBG	VBG	_	17	NMOD	_	_
17	factors	_	NNS	NNS	_	14	PMOD	_	_
18	,	_	,	,	_	9	P	_	_
19	which	_	WDT	WDT	_	20	SBJ	_	_
20	might	_	MD	MD	_	9	NMOD	_	_
21	be	_	VB	VB	_	20	VC	_	_
22	central	_	JJ	JJ	_	21	PRD	_	_
23	in	_	IN	IN	_	21	ADV	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	control	_	NN	NN	_	23	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	virus	_	NN	NN	_	28	NMOD	_	_
28	reactivation	_	NN	NN	_	26	PMOD	_	_
29	.	_	.	.	_	3	P	_	_

1	Prostaglandin	_	NN	NN	_	3	NMOD	_	_
2	E2	_	NN	NN	_	3	NMOD	_	_
3	induction	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	binding	_	NN	NN	_	6	NMOD	_	_
6	activity	_	NN	NN	_	4	PMOD	_	_
7	to	_	TO	TO	_	6	NMOD	_	_
8	CRE	_	NN	NN	_	11	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	AP-2	_	NN	NN	_	8	COORD	_	_
11	elements	_	NNS	NNS	_	7	PMOD	_	_
12	in	_	IN	IN	_	3	NMOD	_	_
13	human	_	JJ	JJ	_	15	NMOD	_	_
14	T	_	NN	NN	_	15	NMOD	_	_
15	lymphocytes	_	NNS	NNS	_	12	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	Prostaglandins	_	NNP	NNP	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	E	_	NN	NN	_	5	NMOD	_	_
5	series	_	NNS	NNS	_	2	PMOD	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	immunomodulatory	_	JJ	JJ	_	8	NMOD	_	_
8	agents	_	NNS	NNS	_	6	PRD	_	_
9	which	_	WDT	WDT	_	10	SBJ	_	_
10	exert	_	VBP	VBP	_	8	NMOD	_	_
11	inhibitory	_	JJ	JJ	_	16	NMOD	_	_
12	as	_	RB	RB	_	11	CC	_	_
13	well	_	RB	RB	_	12	DEP	_	_
14	as	_	IN	IN	_	12	DEP	_	_
15	stimulatory	_	JJ	JJ	_	11	COORD	_	_
16	effects	_	NNS	NNS	_	10	OBJ	_	_
17	on	_	IN	IN	_	10	ADV	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	variety	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	immune	_	JJ	JJ	_	22	NMOD	_	_
22	responses	_	NNS	NNS	_	20	PMOD	_	_
23	.	_	.	.	_	6	P	_	_

1	Since	_	IN	IN	_	15	ADV	_	_
2	it	_	PRP	PRP	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	1	VMOD	_	_
4	known	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	PGE2	_	NN	NN	_	7	SBJ	_	_
7	is	_	VBZ	VBZ	_	5	VMOD	_	_
8	able	_	JJ	JJ	_	7	PRD	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	increase	_	VB	VB	_	8	AMOD	_	_
11	cAMP	_	NN	NN	_	12	NMOD	_	_
12	levels	_	NNS	NNS	_	10	OBJ	_	_
13	,	_	,	,	_	15	P	_	_
14	we	_	PRP	PRP	_	15	SBJ	_	_
15	investigated	_	VBD	VBD	_	0	ROOT-S	_	_
16	whether	_	IN	IN	_	15	OBJ	_	_
17	it	_	PRP	PRP	_	18	SBJ	_	_
18	can	_	MD	MD	_	16	VMOD	_	_
19	affect	_	VB	VB	_	18	VC	_	_
20	gene	_	NN	NN	_	21	NMOD	_	_
21	expression	_	NN	NN	_	19	OBJ	_	_
22	through	_	IN	IN	_	19	ADV	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	activation	_	NN	NN	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	transcription	_	NN	NN	_	28	NMOD	_	_
28	factors	_	NNS	NNS	_	25	PMOD	_	_
29	which	_	WDT	WDT	_	30	SBJ	_	_
30	bind	_	VBP	VBP	_	28	NMOD	_	_
31	enhancer	_	NN	NN	_	32	NMOD	_	_
32	elements	_	NNS	NNS	_	30	OBJ	_	_
33	in	_	IN	IN	_	32	NMOD	_	_
34	the	_	DT	DT	_	36	NMOD	_	_
35	promoter	_	NN	NN	_	36	NMOD	_	_
36	regions	_	NNS	NNS	_	33	PMOD	_	_
37	of	_	IN	IN	_	36	NMOD	_	_
38	cAMP-regulated	_	JJ	JJ	_	39	NMOD	_	_
39	genes	_	NNS	NNS	_	37	PMOD	_	_
40	.	_	.	.	_	15	P	_	_

1	Using	_	VBG	VBG	_	8	VMOD	_	_
2	electrophoretic	_	JJ	JJ	_	5	NMOD	_	_
3	mobility	_	NN	NN	_	5	NMOD	_	_
4	shift	_	NN	NN	_	5	NMOD	_	_
5	assay	_	NN	NN	_	1	OBJ	_	_
6	,	_	,	,	_	8	P	_	_
7	we	_	PRP	PRP	_	8	SBJ	_	_
8	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	short	_	JJ	JJ	_	12	NMOD	_	_
12	treatment	_	NN	NN	_	19	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	human	_	JJ	JJ	_	16	NMOD	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	lymphocytes	_	NNS	NNS	_	13	PMOD	_	_
17	with	_	IN	IN	_	12	NMOD	_	_
18	PGE2	_	NN	NN	_	17	PMOD	_	_
19	induces	_	VBZ	VBZ	_	9	VMOD	_	_
20	specific	_	JJ	JJ	_	22	NMOD	_	_
21	binding	_	NN	NN	_	22	NMOD	_	_
22	activity	_	NN	NN	_	19	OBJ	_	_
23	to	_	TO	TO	_	22	NMOD	_	_
24	CRE	_	NN	NN	_	33	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	AP-2	_	NN	NN	_	24	COORD	_	_
27	,	_	,	,	_	26	P	_	_
28	but	_	CC	CC	_	29	CC	_	_
29	not	_	RB	RB	_	26	NMOD	_	_
30	AP-1	_	NN	NN	_	26	NMOD	_	_
31	,	_	,	,	_	26	P	_	_
32	DNA	_	NN	NN	_	33	NMOD	_	_
33	elements	_	NNS	NNS	_	23	PMOD	_	_
34	.	_	.	.	_	8	P	_	_

1	Since	_	IN	IN	_	22	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	okadaic	_	JJ	JJ	_	4	NMOD	_	_
4	acid	_	NN	NN	_	12	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	a	_	DT	DT	_	10	NMOD	_	_
7	potent	_	JJ	JJ	_	10	NMOD	_	_
8	protein	_	NN	NN	_	10	NMOD	_	_
9	phosphatase	_	NN	NN	_	10	NMOD	_	_
10	inhibitor	_	NN	NN	_	4	NMOD	_	_
11	,	_	,	,	_	4	P	_	_
12	prolongs	_	VBZ	VBZ	_	1	VMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	induction	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	binding	_	NN	NN	_	18	NMOD	_	_
18	activity	_	NN	NN	_	15	PMOD	_	_
19	,	_	,	,	_	22	P	_	_
20	phosphorylation	_	NN	NN	_	21	NMOD	_	_
21	events	_	NNS	NNS	_	22	SBJ	_	_
22	are	_	VBP	VBP	_	0	ROOT-S	_	_
23	likely	_	JJ	JJ	_	22	PRD	_	_
24	to	_	TO	TO	_	25	VMOD	_	_
25	occur	_	VB	VB	_	23	AMOD	_	_
26	.	_	.	.	_	22	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	activity	_	NN	NN	_	3	SBJ	_	_
3	seems	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	to	_	TO	TO	_	5	VMOD	_	_
5	be	_	VB	VB	_	3	OBJ	_	_
6	due	_	JJ	JJ	_	7	DEP	_	_
7	to	_	TO	TO	_	5	PRD	_	_
8	increased	_	VBN	VBN	_	10	NMOD	_	_
9	cAMP	_	NN	NN	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	7	PMOD	_	_
11	because	_	IN	IN	_	5	ADV	_	_
12	forskolin	_	NN	NN	_	15	SBJ	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	IBMX	_	NN	NN	_	12	COORD	_	_
15	mimic	_	VBP	VBP	_	11	VMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	effects	_	NNS	NNS	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	PGE2	_	NN	NN	_	18	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	More	_	RBR	RBR	_	2	AMOD	_	_
2	interestingly	_	RB	RB	_	9	ADV	_	_
3	,	_	,	,	_	9	P	_	_
4	transfection	_	NN	NN	_	5	NMOD	_	_
5	experiments	_	NNS	NNS	_	9	SBJ	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	CRE-CAT	_	NN	NN	_	8	NMOD	_	_
8	plasmide	_	NN	NN	_	6	PMOD	_	_
9	show	_	VBP	VBP	_	0	ROOT-S	_	_
10	that	_	IN	IN	_	9	OBJ	_	_
11	PGE2	_	NN	NN	_	12	SBJ	_	_
12	activates	_	VBZ	VBZ	_	10	VMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	transcription	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	CRE-containing	_	NN	NN	_	18	NMOD	_	_
18	promoter	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	9	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	support	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	positive	_	JJ	JJ	_	6	NMOD	_	_
6	role	_	NN	NN	_	3	OBJ	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	PGE2	_	NN	NN	_	7	PMOD	_	_
9	on	_	IN	IN	_	6	NMOD	_	_
10	some	_	DT	DT	_	12	NMOD	_	_
11	immune	_	JJ	JJ	_	12	NMOD	_	_
12	functions	_	NNS	NNS	_	9	PMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	Tissue	_	NN	NN	_	4	AMOD	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	cell-type	_	JJ	JJ	_	1	COORD	_	_
4	specific	_	JJ	JJ	_	5	NMOD	_	_
5	expression	_	NN	NN	_	0	ROOT-FRAG	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	tuberous	_	JJ	JJ	_	10	NMOD	_	_
9	sclerosis	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	6	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	TSC2	_	NN	NN	_	10	NMOD	_	_
13	,	_	,	,	_	10	P	_	_
14	in	_	IN	IN	_	5	NMOD	_	_
15	human	_	JJ	JJ	_	16	NMOD	_	_
16	tissues	_	NNS	NNS	_	14	PMOD	_	_
17	.	_	.	.	_	5	P	_	_

1	TSC2	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	gene	_	NN	NN	_	2	PRD	_	_
5	on	_	IN	IN	_	4	NMOD	_	_
6	chromosome	_	NN	NN	_	7	NMOD	_	_
7	16p13.3	_	NN	NN	_	5	PMOD	_	_
8	associated	_	VBN	VBN	_	4	NMOD	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	autosomal	_	JJ	JJ	_	14	NMOD	_	_
12	dominant	_	JJ	JJ	_	14	NMOD	_	_
13	neurocutaneous	_	JJ	JJ	_	14	NMOD	_	_
14	disorder	_	NN	NN	_	9	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	tuberous	_	JJ	JJ	_	18	NMOD	_	_
17	sclerosis	_	NN	NN	_	18	NMOD	_	_
18	complex	_	NN	NN	_	14	NMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	TSC	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	.	_	.	.	_	2	P	_	_

1	By	_	IN	IN	_	18	ADV	_	_
2	using	_	VBG	VBG	_	1	PMOD	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	partial	_	JJ	JJ	_	6	NMOD	_	_
5	nucleotide	_	JJ	JJ	_	6	NMOD	_	_
6	sequence	_	NN	NN	_	2	OBJ	_	_
7	from	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	cloned	_	VBN	VBN	_	10	NMOD	_	_
10	TSC2	_	NN	NN	_	7	PMOD	_	_
11	and	_	CC	CC	_	6	CC	_	_
12	polymerase	_	NN	NN	_	15	NMOD	_	_
13	chain	_	NN	NN	_	15	NMOD	_	_
14	reaction	_	NN	NN	_	15	NMOD	_	_
15	methodology	_	NN	NN	_	6	COORD	_	_
16	,	_	,	,	_	18	P	_	_
17	we	_	PRP	PRP	_	18	SBJ	_	_
18	constructed	_	VBD	VBD	_	0	ROOT-S	_	_
19	a	_	DT	DT	_	23	NMOD	_	_
20	digoxigenin-labeled	_	JJ	JJ	_	23	NMOD	_	_
21	complementary	_	JJ	JJ	_	23	NMOD	_	_
22	DNA	_	NN	NN	_	23	NMOD	_	_
23	probe	_	NN	NN	_	18	IOBJ	_	_
24	to	_	TO	TO	_	25	VMOD	_	_
25	examine	_	VB	VB	_	18	OBJ	_	_
26	TSC2	_	NN	NN	_	28	NMOD	_	_
27	gene	_	NN	NN	_	28	NMOD	_	_
28	expression	_	NN	NN	_	25	OBJ	_	_
29	in	_	IN	IN	_	28	NMOD	_	_
30	autopsy-	_	NN	NN	_	34	NMOD	_	_
31	or	_	CC	CC	_	30	CC	_	_
32	biopsy-derived	_	JJ	JJ	_	30	COORD	_	_
33	human	_	JJ	JJ	_	34	NMOD	_	_
34	tissues	_	NNS	NNS	_	29	PMOD	_	_
35	by	_	IN	IN	_	25	ADV	_	_
36	in	_	FW	FW	_	37	AMOD	_	_
37	situ	_	FW	FW	_	38	NMOD	_	_
38	hybridization	_	NN	NN	_	35	PMOD	_	_
39	.	_	.	.	_	18	P	_	_

1	TSC2	_	NN	NN	_	3	NMOD	_	_
2	messenger	_	NN	NN	_	3	NMOD	_	_
3	RNA	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	widely	_	RB	RB	_	6	ADV	_	_
6	expressed	_	VBN	VBN	_	4	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	various	_	JJ	JJ	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	types	_	NNS	NNS	_	7	PMOD	_	_
11	throughout	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	body	_	NN	NN	_	11	PMOD	_	_
14	,	_	,	,	_	10	P	_	_
15	including	_	VBG	VBG	_	10	NMOD	_	_
16	epithelia	_	NN	NN	_	15	PMOD	_	_
17	,	_	,	,	_	16	P	_	_
18	lymphocytes	_	NNS	NNS	_	16	COORD	_	_
19	,	_	,	,	_	16	P	_	_
20	and	_	CC	CC	_	16	CC	_	_
21	cells	_	NNS	NNS	_	16	COORD	_	_
22	with	_	IN	IN	_	21	NMOD	_	_
23	endocrine	_	JJ	JJ	_	24	NMOD	_	_
24	functions	_	NNS	NNS	_	22	PMOD	_	_
25	,	_	,	,	_	21	P	_	_
26	e.g.	_	FW	FW	_	29	NMOD	_	_
27	,	_	,	,	_	29	P	_	_
28	adrenal	_	JJ	JJ	_	29	NMOD	_	_
29	cortex	_	NN	NN	_	21	NMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	anterior	_	JJ	JJ	_	32	NMOD	_	_
32	pituitary	_	NN	NN	_	29	COORD	_	_
33	.	_	.	.	_	4	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	prominently	_	RB	RB	_	13	ADV	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	selectively	_	RB	RB	_	3	COORD	_	_
6	(	_	(	(	_	13	P	_	_
7	within	_	IN	IN	_	13	ADV	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	central	_	JJ	JJ	_	11	NMOD	_	_
10	nervous	_	JJ	JJ	_	11	NMOD	_	_
11	system	_	NN	NN	_	7	PMOD	_	_
12	)	_	)	)	_	13	P	_	_
13	expressed	_	VBN	VBN	_	2	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	pyramidal	_	JJ	JJ	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	cerebral	_	JJ	JJ	_	20	NMOD	_	_
20	cortex	_	NN	NN	_	17	PMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	other	_	JJ	JJ	_	24	NMOD	_	_
23	motor	_	NN	NN	_	24	NMOD	_	_
24	neurons	_	NNS	NNS	_	20	COORD	_	_
25	,	_	,	,	_	14	P	_	_
26	e.g.	_	FW	FW	_	28	PMOD	_	_
27	,	_	,	,	_	28	P	_	_
28	in	_	IN	IN	_	14	COORD	_	_
29	spinal	_	JJ	JJ	_	30	NMOD	_	_
30	cord	_	NN	NN	_	28	PMOD	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	brainstem	_	NN	NN	_	33	NMOD	_	_
33	nuclei	_	NNS	NNS	_	30	COORD	_	_
34	.	_	.	.	_	2	P	_	_

1	Visceral	_	JJ	JJ	_	3	NMOD	_	_
2	TSC2	_	NN	NN	_	3	NMOD	_	_
3	expression	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	comparable	_	JJ	JJ	_	4	PRD	_	_
6	in	_	IN	IN	_	4	ADV	_	_
7	autopsy	_	NN	NN	_	8	NMOD	_	_
8	tissues	_	NNS	NNS	_	6	PMOD	_	_
9	from	_	IN	IN	_	8	NMOD	_	_
10	patients	_	NNS	NNS	_	9	PMOD	_	_
11	with	_	IN	IN	_	10	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	without	_	IN	IN	_	11	COORD	_	_
14	TSC	_	NN	NN	_	11	PMOD	_	_
15	;	_	:	:	_	4	P	_	_
16	TSC2	_	NN	NN	_	19	NMOD	_	_
17	messenger	_	NN	NN	_	19	NMOD	_	_
18	RNA	_	NN	NN	_	19	NMOD	_	_
19	expression	_	NN	NN	_	20	SBJ	_	_
20	was	_	VBD	VBD	_	4	VC	_	_
21	most	_	RBS	RBS	_	22	AMOD	_	_
22	prominent	_	JJ	JJ	_	20	PRD	_	_
23	in	_	IN	IN	_	20	ADV	_	_
24	cells	_	NNS	NNS	_	23	PMOD	_	_
25	with	_	IN	IN	_	24	NMOD	_	_
26	a	_	DT	DT	_	29	NMOD	_	_
27	rapid	_	JJ	JJ	_	29	NMOD	_	_
28	mitotic	_	JJ	JJ	_	29	NMOD	_	_
29	rate	_	NN	NN	_	25	PMOD	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	turnover	_	NN	NN	_	29	COORD	_	_
32	,	_	,	,	_	24	P	_	_
33	e.g.	_	FW	FW	_	35	NMOD	_	_
34	,	_	,	,	_	35	P	_	_
35	epithelia	_	NN	NN	_	24	NMOD	_	_
36	and	_	CC	CC	_	35	CC	_	_
37	lymphocytes	_	NNS	NNS	_	35	COORD	_	_
38	,	_	,	,	_	24	P	_	_
39	with	_	IN	IN	_	24	NMOD	_	_
40	central	_	JJ	JJ	_	42	NMOD	_	_
41	nervous	_	JJ	JJ	_	42	NMOD	_	_
42	system	_	NN	NN	_	48	SBJ	_	_
43	pyramidal	_	JJ	JJ	_	44	NMOD	_	_
44	cells	_	NNS	NNS	_	42	NMOD	_	_
45	and	_	CC	CC	_	44	CC	_	_
46	other	_	JJ	JJ	_	47	NMOD	_	_
47	neurons	_	NNS	NNS	_	44	COORD	_	_
48	being	_	VBG	VBG	_	39	PMOD	_	_
49	an	_	DT	DT	_	51	NMOD	_	_
50	obvious	_	JJ	JJ	_	51	NMOD	_	_
51	exception	_	NN	NN	_	48	PRD	_	_
52	,	_	,	,	_	23	P	_	_
53	and\/or	_	CC	CC	_	23	CC	_	_
54	in	_	IN	IN	_	23	COORD	_	_
55	cells	_	NNS	NNS	_	54	PMOD	_	_
56	with	_	IN	IN	_	55	NMOD	_	_
57	important	_	JJ	JJ	_	59	NMOD	_	_
58	secretory\/transport	_	NN	NN	_	59	NMOD	_	_
59	functions	_	NNS	NNS	_	56	PMOD	_	_
60	.	_	.	.	_	20	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	widespread	_	JJ	JJ	_	3	NMOD	_	_
3	expression	_	NN	NN	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	TSC2	_	NN	NN	_	7	NMOD	_	_
7	gene	_	NN	NN	_	4	PMOD	_	_
8	supports	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	view	_	NN	NN	_	8	OBJ	_	_
11	that	_	IN	IN	_	10	NMOD	_	_
12	it	_	PRP	PRP	_	13	SBJ	_	_
13	encodes	_	VBZ	VBZ	_	11	VMOD	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	protein	_	NN	NN	_	13	OBJ	_	_
16	vital	_	JJ	JJ	_	15	NMOD	_	_
17	to	_	TO	TO	_	16	AMOD	_	_
18	cell	_	NN	NN	_	17	PMOD	_	_
19	growth	_	NN	NN	_	18	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	metabolism	_	NN	NN	_	19	COORD	_	_
22	or	_	CC	CC	_	15	CC	_	_
23	one	_	CD	CD	_	15	COORD	_	_
24	that	_	WDT	WDT	_	25	SBJ	_	_
25	functions	_	VBZ	VBZ	_	23	NMOD	_	_
26	as	_	IN	IN	_	25	ADV	_	_
27	a	_	DT	DT	_	29	NMOD	_	_
28	tumor\/growth	_	NN	NN	_	29	NMOD	_	_
29	suppressor	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	8	P	_	_

1	CD40	_	NN	NN	_	8	NMOD	_	_
2	,	_	,	,	_	1	P	_	_
3	but	_	CC	CC	_	1	CC	_	_
4	not	_	RB	RB	_	3	COORD	_	_
5	lipopolysaccharide	_	NN	NN	_	1	COORD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	anti-IgM	_	JJ	JJ	_	5	COORD	_	_
8	stimulation	_	NN	NN	_	14	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	primary	_	JJ	JJ	_	12	NMOD	_	_
11	B	_	NN	NN	_	12	NMOD	_	_
12	lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
13	,	_	,	,	_	8	P	_	_
14	leads	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	a	_	DT	DT	_	19	NMOD	_	_
17	persistent	_	JJ	JJ	_	19	NMOD	_	_
18	nuclear	_	JJ	JJ	_	19	NMOD	_	_
19	accumulation	_	NN	NN	_	15	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	RelB	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	analyzed	_	VBD	VBD	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	effect	_	NN	NN	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	CD40	_	NN	NN	_	10	NMOD	_	_
10	stimulation	_	NN	NN	_	8	PMOD	_	_
11	on	_	IN	IN	_	7	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	activity	_	NN	NN	_	11	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	nuclear	_	JJ	JJ	_	16	NMOD	_	_
16	appearance	_	NN	NN	_	13	COORD	_	_
17	of	_	IN	IN	_	13	NMOD	_	_
18	Rel\/nuclear	_	NN	NN	_	20	NMOD	_	_
19	factor	_	NN	NN	_	20	NMOD	_	_
20	kappaB	_	NN	NN	_	24	NMOD	_	_
21	(	_	(	(	_	22	P	_	_
22	NF-kappaB	_	NN	NN	_	20	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	factors	_	NNS	NNS	_	17	PMOD	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	primary	_	JJ	JJ	_	29	NMOD	_	_
27	murine	_	JJ	JJ	_	29	NMOD	_	_
28	B	_	NN	NN	_	29	NMOD	_	_
29	lymphocytes	_	NNS	NNS	_	25	PMOD	_	_
30	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	triggering	_	NN	NN	_	19	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	CD40	_	NN	NN	_	10	NMOD	_	_
7	signaling	_	NN	NN	_	10	NMOD	_	_
8	pathway	_	NN	NN	_	10	NMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	s	_	NNS	NNS	_	5	PMOD	_	_
11	)	_	)	)	_	10	P	_	_
12	by	_	IN	IN	_	4	NMOD	_	_
13	CD40	_	NN	NN	_	14	NMOD	_	_
14	ligands	_	NNS	NNS	_	12	PMOD	_	_
15	expressed	_	VBN	VBN	_	14	NMOD	_	_
16	on	_	IN	IN	_	15	ADV	_	_
17	L	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	16	PMOD	_	_
19	led	_	VBD	VBD	_	3	VMOD	_	_
20	to	_	TO	TO	_	19	ADV	_	_
21	strong	_	JJ	JJ	_	22	NMOD	_	_
22	activation	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	an	_	DT	DT	_	28	NMOD	_	_
25	NF-kappaB-controlled	_	JJ	JJ	_	28	NMOD	_	_
26	beta-globin	_	NN	NN	_	28	NMOD	_	_
27	reporter	_	NN	NN	_	28	NMOD	_	_
28	gene	_	NN	NN	_	23	PMOD	_	_
29	in	_	IN	IN	_	28	NMOD	_	_
30	primary	_	JJ	JJ	_	32	NMOD	_	_
31	B	_	NN	NN	_	32	NMOD	_	_
32	lymphocytes	_	NNS	NNS	_	29	PMOD	_	_
33	from	_	IN	IN	_	32	NMOD	_	_
34	transgenic	_	JJ	JJ	_	35	NMOD	_	_
35	mice	_	NNS	NNS	_	33	PMOD	_	_
36	.	_	.	.	_	2	P	_	_

1	Analyses	_	NNS	NNS	_	18	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	nuclear	_	JJ	JJ	_	4	NMOD	_	_
4	translocation	_	NN	NN	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	individual	_	JJ	JJ	_	7	NMOD	_	_
7	members	_	NNS	NNS	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	Rel	_	NN	NN	_	10	NMOD	_	_
10	proteins	_	NNS	NNS	_	8	PMOD	_	_
11	after	_	IN	IN	_	4	TMP	_	_
12	CD40	_	NN	NN	_	13	NMOD	_	_
13	induction	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	primary	_	JJ	JJ	_	17	NMOD	_	_
16	B	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	14	PMOD	_	_
18	showed	_	VBD	VBD	_	0	ROOT-S	_	_
19	a	_	DT	DT	_	23	NMOD	_	_
20	strong	_	JJ	JJ	_	23	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	long-lasting	_	JJ	JJ	_	20	COORD	_	_
23	accumulation	_	NN	NN	_	18	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	RelB	_	NN	NN	_	24	PMOD	_	_
26	and	_	CC	CC	_	23	CC	_	_
27	,	_	,	,	_	29	P	_	_
28	less	_	RBR	RBR	_	29	AMOD	_	_
29	pronounced	_	JJ	JJ	_	20	GAP	_	_
30	,	_	,	,	_	29	P	_	_
31	of	_	IN	IN	_	24	GAP	_	_
32	c-Rel	_	NN	NN	_	31	PMOD	_	_
33	.	_	.	.	_	18	P	_	_

1	LPS	_	NN	NN	_	2	NMOD	_	_
2	stimulation	_	NN	NN	_	3	SBJ	_	_
3	did	_	VBD	VBD	_	0	ROOT-S	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	give	_	VB	VB	_	3	VC	_	_
6	rise	_	NN	NN	_	5	OBJ	_	_
7	to	_	TO	TO	_	5	DTV	_	_
8	a	_	DT	DT	_	11	NMOD	_	_
9	persistent	_	JJ	JJ	_	11	NMOD	_	_
10	nuclear	_	JJ	JJ	_	11	NMOD	_	_
11	accumulation	_	NN	NN	_	7	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	RelB	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	c-Rel	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	3	P	_	_
17	whereas	_	IN	IN	_	3	COORD	_	_
18	nuclear	_	JJ	JJ	_	19	NMOD	_	_
19	c-Rel	_	NN	NN	_	25	SBJ	_	_
20	,	_	,	,	_	19	P	_	_
21	but	_	CC	CC	_	19	CC	_	_
22	not	_	RB	RB	_	21	COORD	_	_
23	RelB	_	NN	NN	_	19	COORD	_	_
24	,	_	,	,	_	19	P	_	_
25	accumulated	_	VBD	VBD	_	3	COORD	_	_
26	after	_	IN	IN	_	25	TMP	_	_
27	B	_	NN	NN	_	30	NMOD	_	_
28	cell	_	NN	NN	_	30	NMOD	_	_
29	receptor	_	NN	NN	_	30	NMOD	_	_
30	stimulation	_	NN	NN	_	26	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	CD40	_	NN	NN	_	2	SBJ	_	_
2	induced	_	VBD	VBD	_	0	ROOT-S	_	_
3	not	_	RB	RB	_	6	CC	_	_
4	only	_	RB	RB	_	3	DEP	_	_
5	nuclear	_	JJ	JJ	_	6	NMOD	_	_
6	translocation	_	NN	NN	_	2	OBJ	_	_
7	but	_	CC	CC	_	6	CC	_	_
8	also	_	RB	RB	_	7	COORD	_	_
9	de	_	FW	FW	_	10	AMOD	_	_
10	novo	_	FW	FW	_	11	NMOD	_	_
11	synthesis	_	NN	NN	_	6	COORD	_	_
12	of	_	IN	IN	_	6	NMOD	_	_
13	RelB	_	NN	NN	_	12	PMOD	_	_
14	RNA	_	NN	NN	_	13	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	protein	_	NN	NN	_	14	COORD	_	_
17	.	_	.	.	_	2	P	_	_

1	S107	_	NN	NN	_	3	NMOD	_	_
2	plasmacytoma	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	18	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	which	_	WDT	WDT	_	6	SBJ	_	_
6	express	_	VBP	VBP	_	3	NMOD	_	_
7	CD40	_	NN	NN	_	6	OBJ	_	_
8	but	_	CC	CC	_	6	CC	_	_
9	are	_	VBP	VBP	_	6	COORD	_	_
10	defective	_	JJ	JJ	_	9	PRD	_	_
11	for	_	IN	IN	_	10	AMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	nuclear	_	JJ	JJ	_	14	NMOD	_	_
14	appearance	_	NN	NN	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	p50\/p65-NF-kappaB	_	NN	NN	_	15	PMOD	_	_
17	,	_	,	,	_	3	P	_	_
18	do	_	VBP	VBP	_	0	ROOT-S	_	_
19	not	_	RB	RB	_	18	VMOD	_	_
20	express	_	VB	VB	_	18	VC	_	_
21	RelB	_	NN	NN	_	20	OBJ	_	_
22	after	_	IN	IN	_	20	TMP	_	_
23	CD40	_	NN	NN	_	24	NMOD	_	_
24	stimulation	_	NN	NN	_	22	PMOD	_	_
25	.	_	.	.	_	18	P	_	_

1	In	_	IN	IN	_	17	ADV	_	_
2	S107	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	stably	_	RB	RB	_	5	ADV	_	_
5	transfected	_	VBN	VBN	_	3	NMOD	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	relB	_	NN	NN	_	8	NMOD	_	_
8	genes	_	NNS	NNS	_	6	PMOD	_	_
9	,	_	,	,	_	17	P	_	_
10	stimulation	_	NN	NN	_	17	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	nuclear	_	JJ	JJ	_	14	NMOD	_	_
13	RelB	_	NN	NN	_	14	NMOD	_	_
14	translocation	_	NN	NN	_	11	PMOD	_	_
15	by	_	IN	IN	_	10	NMOD	_	_
16	CD40	_	NN	NN	_	15	PMOD	_	_
17	was	_	VBD	VBD	_	0	ROOT-S	_	_
18	observed	_	VBN	VBN	_	17	VC	_	_
19	.	_	.	.	_	17	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	stimulation	_	NN	NN	_	10	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	CD40	_	NN	NN	_	9	NMOD	_	_
8	signaling	_	NN	NN	_	9	NMOD	_	_
9	pathways	_	NNS	NNS	_	6	PMOD	_	_
10	exerts	_	VBZ	VBZ	_	4	VMOD	_	_
11	a	_	DT	DT	_	14	NMOD	_	_
12	long-lasting	_	JJ	JJ	_	14	NMOD	_	_
13	stimulatory	_	JJ	JJ	_	14	NMOD	_	_
14	effect	_	NN	NN	_	10	OBJ	_	_
15	on	_	IN	IN	_	10	ADV	_	_
16	both	_	CC	CC	_	18	CC	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	transcription	_	NN	NN	_	15	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	nuclear	_	JJ	JJ	_	21	NMOD	_	_
21	translocation	_	NN	NN	_	18	COORD	_	_
22	of	_	IN	IN	_	18	NMOD	_	_
23	RelB	_	NN	NN	_	22	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	Since	_	IN	IN	_	12	ADV	_	_
2	LPS	_	NN	NN	_	5	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	anti-IgM	_	NN	NN	_	2	COORD	_	_
5	were	_	VBD	VBD	_	1	VMOD	_	_
6	unable	_	JJ	JJ	_	5	PRD	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	activate	_	VB	VB	_	6	AMOD	_	_
9	RelB	_	NN	NN	_	8	OBJ	_	_
10	,	_	,	,	_	12	P	_	_
11	CD40	_	NN	NN	_	12	SBJ	_	_
12	appears	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	trigger	_	VB	VB	_	12	OBJ	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	special	_	JJ	JJ	_	17	NMOD	_	_
17	program	_	NN	NN	_	14	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	gene	_	NN	NN	_	20	NMOD	_	_
20	expression	_	NN	NN	_	18	PMOD	_	_
21	involved	_	VBN	VBN	_	17	NMOD	_	_
22	in	_	IN	IN	_	21	ADV	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	proliferation	_	NN	NN	_	22	PMOD	_	_
25	and\/or	_	CC	CC	_	24	CC	_	_
26	differentiation	_	NN	NN	_	24	COORD	_	_
27	of	_	IN	IN	_	24	NMOD	_	_
28	B	_	NN	NN	_	29	NMOD	_	_
29	lymphocytes	_	NNS	NNS	_	27	PMOD	_	_
30	.	_	.	.	_	12	P	_	_

1	{	_	(	(	_	4	P	_	_
2	Cortisone-resistant	_	JJ	JJ	_	4	NMOD	_	_
3	bronchial	_	JJ	JJ	_	4	NMOD	_	_
4	asthma	_	NN	NN	_	0	ROOT-FRAG	_	_
5	}	_	)	)	_	4	P	_	_

1	There	_	EX	EX	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	general	_	JJ	JJ	_	4	NMOD	_	_
4	agreement	_	NN	NN	_	2	PRD	_	_
5	on	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	inflammatory	_	JJ	JJ	_	8	NMOD	_	_
8	pathogenesis	_	NN	NN	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	bronchial	_	JJ	JJ	_	11	NMOD	_	_
11	asthma	_	NN	NN	_	9	PMOD	_	_
12	:	_	:	:	_	2	P	_	_
13	an	_	DT	DT	_	14	NMOD	_	_
14	accumulation	_	NN	NN	_	32	SBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	activated	_	VBN	VBN	_	17	NMOD	_	_
17	eosinophils	_	NNS	NNS	_	15	PMOD	_	_
18	,	_	,	,	_	14	P	_	_
19	degranulated	_	VBN	VBN	_	21	NMOD	_	_
20	mast	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	17	GAP	_	_
22	,	_	,	,	_	14	P	_	_
23	T	_	NN	NN	_	24	NMOD	_	_
24	lymphocytes	_	NNS	NNS	_	17	GAP	_	_
25	and	_	CC	CC	_	14	CC	_	_
26	in	_	IN	IN	_	31	NMOD	_	_
27	very	_	RB	RB	_	28	AMOD	_	_
28	severe	_	JJ	JJ	_	29	NMOD	_	_
29	forms	_	NNS	NNS	_	26	PMOD	_	_
30	,	_	,	,	_	31	P	_	_
31	granulocytes	_	NNS	NNS	_	17	GAP	_	_
32	has	_	VBZ	VBZ	_	2	VC	_	_
33	constantly	_	RB	RB	_	32	TMP	_	_
34	been	_	VBN	VBN	_	32	VC	_	_
35	found	_	VBN	VBN	_	34	VC	_	_
36	in	_	IN	IN	_	35	ADV	_	_
37	the	_	DT	DT	_	39	NMOD	_	_
38	bronchial	_	JJ	JJ	_	39	NMOD	_	_
39	mucosa	_	NN	NN	_	36	PMOD	_	_
40	.	_	.	.	_	32	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	allergic	_	JJ	JJ	_	4	NMOD	_	_
3	bronchial	_	JJ	JJ	_	4	NMOD	_	_
4	asthma	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	inflammation	_	NN	NN	_	7	SBJ	_	_
7	seems	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	be	_	VB	VB	_	7	OBJ	_	_
10	orchestrated	_	VBN	VBN	_	9	VC	_	_
11	predominantly	_	RB	RB	_	12	PMOD	_	_
12	by	_	IN	IN	_	10	LGS	_	_
13	a	_	DT	DT	_	14	NMOD	_	_
14	subset	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	T	_	NN	NN	_	17	NMOD	_	_
17	lymphocytes	_	NNS	NNS	_	15	PMOD	_	_
18	,	_	,	,	_	14	P	_	_
19	with	_	IN	IN	_	14	NMOD	_	_
20	a	_	DT	DT	_	21	NMOD	_	_
21	phenotype	_	NN	NN	_	19	PMOD	_	_
22	similar	_	JJ	JJ	_	21	NMOD	_	_
23	to	_	TO	TO	_	22	AMOD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	Th2	_	NN	NN	_	26	NMOD	_	_
26	subset	_	NN	NN	_	23	PMOD	_	_
27	able	_	JJ	JJ	_	26	NMOD	_	_
28	to	_	TO	TO	_	29	VMOD	_	_
29	produce	_	VB	VB	_	27	AMOD	_	_
30	IL-4	_	NN	NN	_	29	OBJ	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	IL-5	_	NN	NN	_	30	COORD	_	_
33	.	_	.	.	_	7	P	_	_

1	Although	_	IN	IN	_	17	ADV	_	_
2	corticosteroids	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	1	VMOD	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	most	_	RBS	RBS	_	6	AMOD	_	_
6	potent	_	JJ	JJ	_	8	NMOD	_	_
7	therapeutic	_	JJ	JJ	_	8	NMOD	_	_
8	agents	_	NNS	NNS	_	3	PRD	_	_
9	used	_	VBN	VBN	_	8	NMOD	_	_
10	for	_	IN	IN	_	9	ADV	_	_
11	this	_	DT	DT	_	12	NMOD	_	_
12	disease	_	NN	NN	_	10	PMOD	_	_
13	,	_	,	,	_	17	P	_	_
14	their	_	PRP$	PRP$	_	16	NMOD	_	_
15	anti-inflammatory	_	JJ	JJ	_	16	NMOD	_	_
16	effect	_	NN	NN	_	17	SBJ	_	_
17	differs	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	from	_	IN	IN	_	17	ADV	_	_
19	patient	_	NN	NN	_	18	PMOD	_	_
20	to	_	TO	TO	_	18	PMOD	_	_
21	patient	_	NN	NN	_	20	PMOD	_	_
22	.	_	.	.	_	17	P	_	_

1	Some	_	DT	DT	_	2	NMOD	_	_
2	criteria	_	NNS	NNS	_	12	SBJ	_	_
3	which	_	WDT	WDT	_	4	SBJ	_	_
4	can	_	MD	MD	_	2	NMOD	_	_
5	be	_	VB	VB	_	4	VC	_	_
6	used	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	define	_	VB	VB	_	6	OBJ	_	_
9	steroid-resistant	_	JJ	JJ	_	11	NMOD	_	_
10	bronchial	_	JJ	JJ	_	11	NMOD	_	_
11	asthma	_	NN	NN	_	8	OBJ	_	_
12	are	_	VBP	VBP	_	0	ROOT-S	_	_
13	listed	_	VBN	VBN	_	12	VC	_	_
14	here	_	RB	RB	_	13	ADV	_	_
15	.	_	.	.	_	12	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	review	_	NN	NN	_	3	SBJ	_	_
3	analyzes	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	various	_	JJ	JJ	_	6	NMOD	_	_
5	molecular	_	JJ	JJ	_	6	NMOD	_	_
6	alterations	_	NNS	NNS	_	3	OBJ	_	_
7	responsible	_	JJ	JJ	_	6	NMOD	_	_
8	for	_	IN	IN	_	7	AMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	deficient	_	JJ	JJ	_	11	NMOD	_	_
11	response	_	NN	NN	_	8	PMOD	_	_
12	to	_	TO	TO	_	11	NMOD	_	_
13	corticosteroid	_	NN	NN	_	14	NMOD	_	_
14	treatment	_	NN	NN	_	12	PMOD	_	_
15	observed	_	VBN	VBN	_	11	NMOD	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	steroid-resistant	_	JJ	JJ	_	19	AMOD	_	_
18	bronchial	_	JJ	JJ	_	19	AMOD	_	_
19	asthmatic	_	JJ	JJ	_	20	NMOD	_	_
20	subjects	_	NNS	NNS	_	16	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	New	_	JJ	JJ	_	2	NMOD	_	_
2	knowledge	_	NN	NN	_	9	SBJ	_	_
3	on	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	mechanism	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	steroid	_	NN	NN	_	8	NMOD	_	_
8	resistance	_	NN	NN	_	6	PMOD	_	_
9	may	_	MD	MD	_	0	ROOT-S	_	_
10	have	_	VB	VB	_	9	VC	_	_
11	important	_	JJ	JJ	_	12	NMOD	_	_
12	implications	_	NNS	NNS	_	10	OBJ	_	_
13	for	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	treatment	_	NN	NN	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	chronic	_	JJ	JJ	_	18	NMOD	_	_
18	asthma	_	NN	NN	_	16	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	other	_	JJ	JJ	_	21	NMOD	_	_
21	diseases	_	NNS	NNS	_	18	COORD	_	_
22	.	_	.	.	_	9	P	_	_

1	Induction	_	NN	NN	_	14	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	CD11b	_	NN	NN	_	5	NMOD	_	_
5	gene	_	NN	NN	_	2	PMOD	_	_
6	during	_	IN	IN	_	1	TMP	_	_
7	activation	_	NN	NN	_	6	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	monocytic	_	JJ	JJ	_	13	NMOD	_	_
11	cell	_	NN	NN	_	13	NMOD	_	_
12	line	_	NN	NN	_	13	NMOD	_	_
13	U937	_	NN	NN	_	8	PMOD	_	_
14	requires	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	a	_	DT	DT	_	19	NMOD	_	_
16	novel	_	JJ	JJ	_	19	NMOD	_	_
17	nuclear	_	JJ	JJ	_	19	NMOD	_	_
18	factor	_	NN	NN	_	19	NMOD	_	_
19	MS-2	_	NN	NN	_	14	OBJ	_	_
20	{	_	(	(	_	23	P	_	_
21	published	_	VBN	VBN	_	22	NMOD	_	_
22	erratum	_	NN	NN	_	23	SBJ	_	_
23	appears	_	VBZ	VBZ	_	14	PRN	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	J	_	NNP	NNP	_	26	NMOD	_	_
26	Immunol	_	NNP	NNP	_	24	PMOD	_	_
27	1999	_	CD	CD	_	28	NMOD	_	_
28	Jul	_	NNP	NNP	_	26	TMP	_	_
29	15	_	CD	CD	_	28	NMOD	_	_
30	;	_	:	:	_	26	P	_	_
31	163	_	CD	CD	_	33	NMOD	_	_
32	(	_	(	(	_	33	P	_	_
33	2	_	CD	CD	_	26	NMOD	_	_
34	)	_	)	)	_	33	P	_	_
35	:	_	:	:	_	26	P	_	_
36	1091	_	CD	CD	_	26	NMOD	_	_
37	}	_	)	)	_	23	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	differentiation	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	myeloid	_	JJ	JJ	_	5	NMOD	_	_
5	precursors	_	NNS	NNS	_	3	PMOD	_	_
6	into	_	IN	IN	_	2	NMOD	_	_
7	mature	_	JJ	JJ	_	9	NMOD	_	_
8	myelomonocytic	_	JJ	JJ	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	6	PMOD	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	characterized	_	VBN	VBN	_	10	VC	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	induction	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	gene	_	NN	NN	_	15	PMOD	_	_
18	encoding	_	VBG	VBG	_	17	NMOD	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	beta2	_	NN	NN	_	22	NMOD	_	_
21	integrin	_	NN	NN	_	22	NMOD	_	_
22	CD11b	_	NN	NN	_	18	OBJ	_	_
23	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	transcription	_	NN	NN	_	3	NMOD	_	_
3	factors	_	NNS	NNS	_	7	SBJ	_	_
4	Sp1	_	NN	NN	_	3	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	PU.1	_	NN	NN	_	4	COORD	_	_
7	prime	_	VBP	VBP	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	CD11b	_	NN	NN	_	10	NMOD	_	_
10	promoter	_	NN	NN	_	7	OBJ	_	_
11	,	_	,	,	_	7	P	_	_
12	but	_	CC	CC	_	7	CC	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	nature	_	NN	NN	_	23	SBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	factors	_	NNS	NNS	_	15	PMOD	_	_
18	responsible	_	JJ	JJ	_	17	NMOD	_	_
19	for	_	IN	IN	_	18	AMOD	_	_
20	its	_	PRP$	PRP$	_	22	NMOD	_	_
21	inducible	_	JJ	JJ	_	22	NMOD	_	_
22	expression	_	NN	NN	_	19	PMOD	_	_
23	are	_	VBP	VBP	_	7	COORD	_	_
24	unknown	_	JJ	JJ	_	23	PRD	_	_
25	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	16	ADV	_	_
2	addition	_	NN	NN	_	1	DEP	_	_
3	to	_	TO	TO	_	1	DEP	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	CD11b	_	NN	NN	_	6	NMOD	_	_
6	gene	_	NN	NN	_	1	PMOD	_	_
7	,	_	,	,	_	16	P	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	homologous	_	JJ	JJ	_	10	NMOD	_	_
10	genes	_	NNS	NNS	_	16	SBJ	_	_
11	encoding	_	VBG	VBG	_	10	NMOD	_	_
12	CD11a	_	NN	NN	_	11	OBJ	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	CD11c	_	NN	NN	_	12	COORD	_	_
15	also	_	RB	RB	_	16	ADV	_	_
16	exhibit	_	VBP	VBP	_	0	ROOT-S	_	_
17	inducible	_	JJ	JJ	_	18	NMOD	_	_
18	expression	_	NN	NN	_	16	OBJ	_	_
19	during	_	IN	IN	_	16	TMP	_	_
20	myeloid	_	JJ	JJ	_	21	NMOD	_	_
21	differentiation	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	16	P	_	_

1	Therefore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	compared	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	nucleotide	_	JJ	JJ	_	7	NMOD	_	_
7	sequences	_	NNS	NNS	_	4	IOBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	17	NMOD	_	_
10	CD11a	_	NN	NN	_	17	NMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	CD11b	_	NN	NN	_	10	COORD	_	_
13	,	_	,	,	_	10	P	_	_
14	and	_	CC	CC	_	10	CC	_	_
15	CD11c	_	NN	NN	_	10	COORD	_	_
16	gene	_	NN	NN	_	17	NMOD	_	_
17	promoters	_	NNS	NNS	_	8	PMOD	_	_
18	to	_	TO	TO	_	19	VMOD	_	_
19	identify	_	VB	VB	_	4	OBJ	_	_
20	common	_	JJ	JJ	_	21	NMOD	_	_
21	elements	_	NNS	NNS	_	19	OBJ	_	_
22	that	_	WDT	WDT	_	23	SBJ	_	_
23	might	_	MD	MD	_	21	NMOD	_	_
24	contribute	_	VB	VB	_	23	VC	_	_
25	to	_	TO	TO	_	24	ADV	_	_
26	inducible	_	JJ	JJ	_	27	NMOD	_	_
27	expression	_	NN	NN	_	25	PMOD	_	_
28	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	3	SBJ	_	_
3	identified	_	VBD	VBD	_	0	ROOT-S	_	_
4	one	_	CD	CD	_	6	NMOD	_	_
5	such	_	JJ	JJ	_	6	NMOD	_	_
6	element	_	NN	NN	_	3	OBJ	_	_
7	repeated	_	VBN	VBN	_	6	NMOD	_	_
8	four	_	CD	CD	_	9	NMOD	_	_
9	times	_	NNS	NNS	_	7	OBJ	_	_
10	within	_	IN	IN	_	7	ADV	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	CD11b	_	NN	NN	_	13	NMOD	_	_
13	promoter	_	NN	NN	_	10	PMOD	_	_
14	.	_	.	.	_	3	P	_	_

1	Mutation	_	NN	NN	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	elements	_	NNS	NNS	_	2	PMOD	_	_
5	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	two	_	CD	CD	_	13	SBJ	_	_
8	,	_	,	,	_	7	P	_	_
9	MS-2beta	_	NN	NN	_	7	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	MS-2gamma	_	NN	NN	_	9	COORD	_	_
12	,	_	,	,	_	7	P	_	_
13	are	_	VBP	VBP	_	6	VMOD	_	_
14	critical	_	JJ	JJ	_	13	PRD	_	_
15	to	_	TO	TO	_	14	AMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	induction	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	CD11b	_	NN	NN	_	21	NMOD	_	_
21	gene	_	NN	NN	_	18	PMOD	_	_
22	during	_	IN	IN	_	17	TMP	_	_
23	differentiation	_	NN	NN	_	22	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	29	NMOD	_	_
26	pro-monocytic	_	JJ	JJ	_	29	NMOD	_	_
27	cell	_	NN	NN	_	29	NMOD	_	_
28	line	_	NN	NN	_	29	NMOD	_	_
29	U937	_	NN	NN	_	24	PMOD	_	_
30	.	_	.	.	_	5	P	_	_

1	Electrophoretic	_	JJ	JJ	_	4	NMOD	_	_
2	mobility	_	NN	NN	_	4	NMOD	_	_
3	shift	_	NN	NN	_	4	NMOD	_	_
4	assays	_	NNS	NNS	_	5	SBJ	_	_
5	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	MS-2beta	_	NN	NN	_	10	SBJ	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	MS-2gamma	_	NN	NN	_	7	COORD	_	_
10	interact	_	VBP	VBP	_	6	VMOD	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	nuclear	_	JJ	JJ	_	13	NMOD	_	_
13	factors	_	NNS	NNS	_	11	PMOD	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	are	_	VBP	VBP	_	13	NMOD	_	_
16	induced	_	VBN	VBN	_	15	VC	_	_
17	during	_	IN	IN	_	16	TMP	_	_
18	U937	_	NN	NN	_	19	NMOD	_	_
19	differentiation	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	factors	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	detected	_	VBN	VBN	_	3	VC	_	_
5	at	_	IN	IN	_	4	TMP	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	time	_	NN	NN	_	5	PMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	CD11b	_	NN	NN	_	10	NMOD	_	_
10	promoter	_	NN	NN	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	7	NMOD	_	_
12	activated	_	VBN	VBN	_	11	VC	_	_
13	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	molecular	_	JJ	JJ	_	3	NMOD	_	_
3	mass	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	these	_	DT	DT	_	6	NMOD	_	_
6	factors	_	NNS	NNS	_	4	PMOD	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	approximately	_	RB	RB	_	10	NMOD	_	_
9	28	_	CD	CD	_	8	DEP	_	_
10	kDa	_	NN	NN	_	7	PRD	_	_
11	,	_	,	,	_	7	P	_	_
12	and	_	CC	CC	_	7	CC	_	_
13	their	_	PRP$	PRP$	_	16	NMOD	_	_
14	DNA	_	NN	NN	_	16	NMOD	_	_
15	binding	_	NN	NN	_	16	NMOD	_	_
16	characteristics	_	NNS	NNS	_	17	SBJ	_	_
17	are	_	VBP	VBP	_	7	COORD	_	_
18	indistinguishable	_	JJ	JJ	_	17	PRD	_	_
19	from	_	IN	IN	_	18	AMOD	_	_
20	those	_	DT	DT	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	26	NMOD	_	_
23	novel	_	JJ	JJ	_	26	NMOD	_	_
24	nuclear	_	JJ	JJ	_	26	NMOD	_	_
25	factor	_	NN	NN	_	26	NMOD	_	_
26	MS-2	_	NN	NN	_	21	PMOD	_	_
27	.	_	.	.	_	7	P	_	_

1	Taken	_	VBN	VBN	_	6	VMOD	_	_
2	together	_	RB	RB	_	1	ADV	_	_
3	,	_	,	,	_	6	P	_	_
4	our	_	PRP$	PRP$	_	5	NMOD	_	_
5	data	_	NNS	NNS	_	6	SBJ	_	_
6	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	MS-2	_	NN	NN	_	9	SBJ	_	_
9	mediates	_	VBZ	VBZ	_	7	VMOD	_	_
10	induction	_	NN	NN	_	9	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	CD11b	_	NN	NN	_	14	NMOD	_	_
14	gene	_	NN	NN	_	11	PMOD	_	_
15	as	_	IN	IN	_	9	ADV	_	_
16	cells	_	NNS	NNS	_	21	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	monocytic	_	JJ	JJ	_	20	NMOD	_	_
20	lineage	_	NN	NN	_	17	PMOD	_	_
21	mature	_	VBP	VBP	_	15	VMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	presence	_	NN	NN	_	25	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	multiple	_	JJ	JJ	_	7	NMOD	_	_
5	potential	_	JJ	JJ	_	7	NMOD	_	_
6	binding	_	VBG	VBG	_	7	NMOD	_	_
7	sites	_	NNS	NNS	_	3	PMOD	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	MS-2	_	NN	NN	_	8	PMOD	_	_
10	in	_	IN	IN	_	2	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	promoter	_	NN	NN	_	13	NMOD	_	_
13	regions	_	NNS	NNS	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	wide	_	JJ	JJ	_	17	NMOD	_	_
17	range	_	NN	NN	_	14	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	genes	_	NNS	NNS	_	18	PMOD	_	_
20	expressed	_	VBN	VBN	_	19	NMOD	_	_
21	in	_	IN	IN	_	20	ADV	_	_
22	mature	_	JJ	JJ	_	24	NMOD	_	_
23	myeloid	_	JJ	JJ	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	21	PMOD	_	_
25	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
26	this	_	DT	DT	_	27	NMOD	_	_
27	factor	_	NN	NN	_	28	SBJ	_	_
28	plays	_	VBZ	VBZ	_	25	OBJ	_	_
29	a	_	DT	DT	_	31	NMOD	_	_
30	general	_	JJ	JJ	_	31	NMOD	_	_
31	role	_	NN	NN	_	28	OBJ	_	_
32	in	_	IN	IN	_	28	ADV	_	_
33	myeloid	_	JJ	JJ	_	34	NMOD	_	_
34	differentiation	_	NN	NN	_	32	PMOD	_	_
35	.	_	.	.	_	25	P	_	_

1	Dexamethasone	_	NN	NN	_	3	NMOD	_	_
2	suppression	_	NN	NN	_	3	NMOD	_	_
3	test	_	NN	NN	_	0	ROOT-FRAG	_	_
4	:	_	:	:	_	3	P	_	_
5	corticosteroid	_	NN	NN	_	7	NMOD	_	_
6	receptors	_	NNS	NNS	_	7	NMOD	_	_
7	regulation	_	NN	NN	_	3	NMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	mononuclear	_	JJ	JJ	_	10	NMOD	_	_
10	leukocytes	_	NNS	NNS	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	young	_	JJ	JJ	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	aged	_	JJ	JJ	_	12	COORD	_	_
15	subjects	_	NNS	NNS	_	11	PMOD	_	_
16	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	dexamethasone	_	NN	NN	_	4	NMOD	_	_
3	suppression	_	NN	NN	_	4	NMOD	_	_
4	test	_	NN	NN	_	8	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	DST	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	considered	_	VBN	VBN	_	8	VC	_	_
10	an	_	DT	DT	_	11	NMOD	_	_
11	indicator	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	function	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	adrenal	_	JJ	JJ	_	19	NMOD	_	_
18	pituitary	_	JJ	JJ	_	19	NMOD	_	_
19	axis	_	NN	NN	_	15	PMOD	_	_
20	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	steroid	_	NN	NN	_	3	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	mediated	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	its	_	PRP$	PRP$	_	10	NMOD	_	_
10	binding	_	NN	NN	_	8	PMOD	_	_
11	to	_	TO	TO	_	10	NMOD	_	_
12	corticosteroid	_	NN	NN	_	13	NMOD	_	_
13	receptors	_	NNS	NNS	_	11	PMOD	_	_
14	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	previously	_	RB	RB	_	3	TMP	_	_
3	suggested	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	measurement	_	NN	NN	_	12	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	corticosteroid	_	NN	NN	_	9	NMOD	_	_
9	receptors	_	NNS	NNS	_	7	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	lymphocytes	_	NNS	NNS	_	10	PMOD	_	_
12	is	_	VBZ	VBZ	_	4	VMOD	_	_
13	an	_	DT	DT	_	14	NMOD	_	_
14	index	_	NN	NN	_	12	PRD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	an	_	DT	DT	_	18	NMOD	_	_
17	analogous	_	JJ	JJ	_	18	NMOD	_	_
18	pattern	_	NN	NN	_	15	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	brain	_	NN	NN	_	19	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	16	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	present	_	JJ	JJ	_	4	NMOD	_	_
4	study	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	16	P	_	_
6	corticosteroid	_	NN	NN	_	12	NMOD	_	_
7	Type	_	NN	NN	_	12	NMOD	_	_
8	I	_	CD	CD	_	7	NMOD	_	_
9	and	_	CC	CC	_	7	CC	_	_
10	Type	_	NN	NN	_	7	COORD	_	_
11	II	_	CD	CD	_	10	NMOD	_	_
12	receptors	_	NNS	NNS	_	16	SBJ	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	mononuclear	_	JJ	JJ	_	15	NMOD	_	_
15	leukocytes	_	NNS	NNS	_	13	PMOD	_	_
16	were	_	VBD	VBD	_	0	ROOT-S	_	_
17	measured	_	VBN	VBN	_	16	VC	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	10	_	CD	CD	_	21	NMOD	_	_
20	elderly	_	JJ	JJ	_	21	NMOD	_	_
21	subjects	_	NNS	NNS	_	18	PMOD	_	_
22	and	_	CC	CC	_	18	CC	_	_
23	in	_	IN	IN	_	18	COORD	_	_
24	9	_	CD	CD	_	26	NMOD	_	_
25	young	_	JJ	JJ	_	26	NMOD	_	_
26	adults	_	NNS	NNS	_	23	PMOD	_	_
27	,	_	,	,	_	17	P	_	_
28	before	_	IN	IN	_	17	TMP	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	after	_	IN	IN	_	28	COORD	_	_
31	overnight	_	JJ	JJ	_	32	NMOD	_	_
32	DST	_	NN	NN	_	28	PMOD	_	_
33	(	_	(	(	_	35	P	_	_
34	1	_	CD	CD	_	35	NMOD	_	_
35	mg	_	NN	NN	_	32	PRN	_	_
36	)	_	)	)	_	35	P	_	_
37	.	_	.	.	_	16	P	_	_

1	Receptors	_	NNS	NNS	_	2	SBJ	_	_
2	were	_	VBD	VBD	_	0	ROOT-S	_	_
3	measured	_	VBN	VBN	_	2	VC	_	_
4	by	_	IN	IN	_	3	ADV	_	_
5	radioreceptor	_	NN	NN	_	6	NMOD	_	_
6	assay	_	NN	NN	_	4	PMOD	_	_
7	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	all	_	PDT	PDT	_	4	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	subjects	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	dexamethasone	_	NN	NN	_	7	SBJ	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	able	_	JJ	JJ	_	7	PRD	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	suppress	_	VB	VB	_	8	AMOD	_	_
11	plasma	_	NN	NN	_	12	NMOD	_	_
12	cortisol	_	NN	NN	_	10	OBJ	_	_
13	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	number	_	NN	NN	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	Type	_	NN	NN	_	9	NMOD	_	_
5	I	_	CD	CD	_	4	NMOD	_	_
6	and	_	CC	CC	_	4	CC	_	_
7	Type	_	NN	NN	_	4	COORD	_	_
8	II	_	CD	CD	_	7	NMOD	_	_
9	receptors	_	NNS	NNS	_	3	PMOD	_	_
10	before	_	IN	IN	_	2	TMP	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	test	_	NN	NN	_	10	PMOD	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	lower	_	JJR	JJR	_	13	PRD	_	_
15	in	_	IN	IN	_	13	ADV	_	_
16	elderly	_	JJ	JJ	_	17	NMOD	_	_
17	subjects	_	NNS	NNS	_	15	PMOD	_	_
18	than	_	IN	IN	_	14	AMOD	_	_
19	in	_	IN	IN	_	18	PMOD	_	_
20	adults	_	NNS	NNS	_	19	PMOD	_	_
21	.	_	.	.	_	13	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	control	_	NN	NN	_	4	NMOD	_	_
4	group	_	NN	NN	_	1	PMOD	_	_
5	,	_	,	,	_	7	P	_	_
6	dexamethasone	_	NN	NN	_	7	SBJ	_	_
7	produced	_	VBD	VBD	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	significant	_	JJ	JJ	_	10	NMOD	_	_
10	depression	_	NN	NN	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	Type	_	NN	NN	_	14	NMOD	_	_
13	I	_	CD	CD	_	14	NMOD	_	_
14	receptors	_	NNS	NNS	_	11	PMOD	_	_
15	(	_	(	(	_	10	P	_	_
16	from	_	IN	IN	_	10	NMOD	_	_
17	267	_	CD	CD	_	24	NMOD	_	_
18	+\/-	_	CC	CC	_	17	CC	_	_
19	72	_	CD	CD	_	17	COORD	_	_
20	to	_	TO	TO	_	10	NMOD	_	_
21	169	_	CD	CD	_	20	NMOD	_	_
22	+\/-	_	CC	CC	_	21	CC	_	_
23	71	_	CD	CD	_	21	COORD	_	_
24	receptors	_	NNS	NNS	_	16	PMOD	_	_
25	per	_	IN	IN	_	24	NMOD	_	_
26	cell	_	NN	NN	_	25	PMOD	_	_
27	)	_	)	)	_	10	P	_	_
28	,	_	,	,	_	10	P	_	_
29	which	_	WDT	WDT	_	30	SBJ	_	_
30	can	_	MD	MD	_	10	NMOD	_	_
31	be	_	VB	VB	_	30	VC	_	_
32	interpreted	_	VBN	VBN	_	31	VC	_	_
33	as	_	IN	IN	_	32	ADV	_	_
34	a	_	DT	DT	_	36	NMOD	_	_
35	primary	_	JJ	JJ	_	36	NMOD	_	_
36	involvement	_	NN	NN	_	33	PMOD	_	_
37	of	_	IN	IN	_	36	NMOD	_	_
38	Type	_	NN	NN	_	40	NMOD	_	_
39	I	_	CD	CD	_	40	NMOD	_	_
40	receptors	_	NNS	NNS	_	37	PMOD	_	_
41	in	_	IN	IN	_	36	NMOD	_	_
42	the	_	DT	DT	_	43	NMOD	_	_
43	response	_	NN	NN	_	41	PMOD	_	_
44	to	_	TO	TO	_	43	NMOD	_	_
45	dexamethasone	_	NN	NN	_	44	PMOD	_	_
46	;	_	:	:	_	7	P	_	_
47	Type	_	NN	NN	_	49	NMOD	_	_
48	II	_	CD	CD	_	49	NMOD	_	_
49	receptors	_	NNS	NNS	_	50	SBJ	_	_
50	decreased	_	VBD	VBD	_	7	VMOD	_	_
51	in	_	IN	IN	_	50	ADV	_	_
52	half	_	PDT	PDT	_	54	NMOD	_	_
53	the	_	DT	DT	_	54	NMOD	_	_
54	subjects	_	NNS	NNS	_	51	PMOD	_	_
55	(	_	(	(	_	50	P	_	_
56	from	_	IN	IN	_	50	ADV	_	_
57	2849	_	CD	CD	_	64	NMOD	_	_
58	+\/-	_	CC	CC	_	57	CC	_	_
59	703	_	CD	CD	_	57	COORD	_	_
60	to	_	TO	TO	_	50	ADV	_	_
61	2345	_	CD	CD	_	60	NMOD	_	_
62	+\/-	_	CC	CC	_	61	CC	_	_
63	569	_	CD	CD	_	61	COORD	_	_
64	receptors	_	NNS	NNS	_	56	PMOD	_	_
65	per	_	IN	IN	_	64	NMOD	_	_
66	cell	_	NN	NN	_	65	PMOD	_	_
67	)	_	)	)	_	50	P	_	_
68	.	_	.	.	_	50	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	elderly	_	JJ	JJ	_	4	NMOD	_	_
3	healthy	_	JJ	JJ	_	4	NMOD	_	_
4	subjects	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	9	P	_	_
6	Type	_	NN	NN	_	8	NMOD	_	_
7	II	_	CD	CD	_	8	NMOD	_	_
8	receptors	_	NNS	NNS	_	9	SBJ	_	_
9	were	_	VBD	VBD	_	0	ROOT-S	_	_
10	also	_	RB	RB	_	9	ADV	_	_
11	significantly	_	RB	RB	_	12	ADV	_	_
12	decreased	_	VBN	VBN	_	9	VC	_	_
13	(	_	(	(	_	12	P	_	_
14	from	_	IN	IN	_	12	ADV	_	_
15	1796	_	CD	CD	_	14	PMOD	_	_
16	+\/-	_	CC	CC	_	15	CC	_	_
17	671	_	CD	CD	_	15	COORD	_	_
18	to	_	TO	TO	_	12	ADV	_	_
19	720	_	CD	CD	_	18	PMOD	_	_
20	+\/-	_	CC	CC	_	19	CC	_	_
21	345	_	CD	CD	_	19	COORD	_	_
22	)	_	)	)	_	12	P	_	_
23	.	_	.	.	_	9	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	in	_	IN	IN	_	10	ADV	_	_
5	young	_	JJ	JJ	_	6	NMOD	_	_
6	subjects	_	NNS	NNS	_	4	PMOD	_	_
7	Type	_	NN	NN	_	9	NMOD	_	_
8	II	_	CD	CD	_	9	NMOD	_	_
9	receptors	_	NNS	NNS	_	10	SBJ	_	_
10	are	_	VBP	VBP	_	3	VMOD	_	_
11	initially	_	RB	RB	_	12	TMP	_	_
12	up-regulated	_	VBN	VBN	_	10	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	dexamethasone	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	12	P	_	_
16	and	_	CC	CC	_	12	CC	_	_
17	then	_	RB	RB	_	18	TMP	_	_
18	down-regulated	_	VBN	VBN	_	12	COORD	_	_
19	,	_	,	,	_	10	P	_	_
20	while	_	IN	IN	_	10	ADV	_	_
21	in	_	RB	RB	_	26	ADV	_	_
22	aged	_	JJ	JJ	_	23	NMOD	_	_
23	subjects	_	NNS	NNS	_	21	PMOD	_	_
24	an	_	DT	DT	_	25	NMOD	_	_
25	up-regulation	_	NN	NN	_	26	SBJ	_	_
26	can	_	MD	MD	_	20	VMOD	_	_
27	not	_	RB	RB	_	29	VMOD	_	_
28	be	_	VB	VB	_	29	VMOD	_	_
29	achieved	_	VBN	VBN	_	26	VC	_	_
30	,	_	,	,	_	31	P	_	_
31	as	_	IN	IN	_	29	OBJ	_	_
32	suggested	_	VBN	VBN	_	31	LGS	_	_
33	by	_	IN	IN	_	35	NMOD	_	_
34	the	_	DT	DT	_	35	NMOD	_	_
35	higher	_	JJR	JJR	_	32	PMOD	_	_
36	values	_	NNS	NNS	_	35	NMOD	_	_
37	of	_	IN	IN	_	38	NMOD	_	_
38	plasma	_	NN	NN	_	36	PMOD	_	_
39	cortisol	_	NN	NN	_	35	NMOD	_	_
40	usually	_	RB	RB	_	39	VMOD	_	_
41	found	_	VBN	VBN	_	39	ADV	_	_
42	in	_	IN	IN	_	43	NMOD	_	_
43	aging	_	VBG	VBG	_	41	PMOD	_	_
44	subjects	_	NNS	NNS	_	2	VMOD	_	_

1	Octamer	_	NN	NN	_	3	NMOD	_	_
2	independent	_	JJ	JJ	_	1	AMOD	_	_
3	activation	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	transcription	_	NN	NN	_	4	PMOD	_	_
6	from	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	11	NMOD	_	_
8	kappa	_	NN	NN	_	11	NMOD	_	_
9	immunoglobulin	_	NN	NN	_	11	NMOD	_	_
10	germline	_	NN	NN	_	11	NMOD	_	_
11	promoter	_	NN	NN	_	6	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	Previous	_	JJ	JJ	_	2	NMOD	_	_
2	analyses	_	NNS	NNS	_	8	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	immunoglobulin	_	NN	NN	_	7	NMOD	_	_
5	V	_	JJ	JJ	_	7	NMOD	_	_
6	region	_	NN	NN	_	7	NMOD	_	_
7	promoters	_	NNS	NNS	_	3	PMOD	_	_
8	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	led	_	VBN	VBN	_	8	VC	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	discovery	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	a	_	DT	DT	_	17	NMOD	_	_
15	common	_	JJ	JJ	_	17	NMOD	_	_
16	octamer	_	NN	NN	_	17	NMOD	_	_
17	motif	_	NN	NN	_	13	PMOD	_	_
18	which	_	WDT	WDT	_	19	SBJ	_	_
19	is	_	VBZ	VBZ	_	17	NMOD	_	_
20	functionally	_	RB	RB	_	19	ADV	_	_
21	important	_	JJ	JJ	_	19	PRD	_	_
22	in	_	IN	IN	_	19	ADV	_	_
23	the	_	DT	DT	_	29	NMOD	_	_
24	tissue-specific	_	JJ	JJ	_	29	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	developmentally	_	RB	RB	_	27	AMOD	_	_
27	regulated	_	VBN	VBN	_	24	COORD	_	_
28	transcriptional	_	JJ	JJ	_	29	NMOD	_	_
29	activation	_	NN	NN	_	22	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	immunoglobulin	_	NN	NN	_	32	NMOD	_	_
32	genes	_	NNS	NNS	_	30	PMOD	_	_
33	.	_	.	.	_	8	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	germline	_	NN	NN	_	3	NMOD	_	_
3	promoters	_	NNS	NNS	_	20	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	Ko	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	located	_	JJ	JJ	_	8	AMOD	_	_
8	upstream	_	RB	RB	_	3	NMOD	_	_
9	of	_	IN	IN	_	8	AMOD	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	J	_	JJ	JJ	_	14	NMOD	_	_
12	region	_	NN	NN	_	14	NMOD	_	_
13	gene	_	NN	NN	_	14	NMOD	_	_
14	segments	_	NNS	NNS	_	9	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	kappa	_	NN	NN	_	18	NMOD	_	_
18	locus	_	NN	NN	_	15	PMOD	_	_
19	also	_	RB	RB	_	20	ADV	_	_
20	contain	_	VBP	VBP	_	0	ROOT-S	_	_
21	an	_	DT	DT	_	23	NMOD	_	_
22	octamer	_	NN	NN	_	23	NMOD	_	_
23	motif	_	NN	NN	_	20	OBJ	_	_
24	(	_	(	(	_	23	P	_	_
25	containing	_	VBG	VBG	_	23	NMOD	_	_
26	a	_	DT	DT	_	30	NMOD	_	_
27	single	_	JJ	JJ	_	30	NMOD	_	_
28	base	_	NN	NN	_	30	NMOD	_	_
29	pair	_	NN	NN	_	30	NMOD	_	_
30	mutation	_	NN	NN	_	25	OBJ	_	_
31	and	_	CC	CC	_	25	CC	_	_
32	referred	_	VBN	VBN	_	25	COORD	_	_
33	to	_	TO	TO	_	32	ADV	_	_
34	as	_	IN	IN	_	32	ADV	_	_
35	the	_	DT	DT	_	37	NMOD	_	_
36	variant	_	JJ	JJ	_	37	NMOD	_	_
37	octamer	_	NN	NN	_	34	PMOD	_	_
38	)	_	)	)	_	23	P	_	_
39	which	_	WDT	WDT	_	40	SBJ	_	_
40	has	_	VBZ	VBZ	_	23	NMOD	_	_
41	been	_	VBN	VBN	_	40	VC	_	_
42	shown	_	VBN	VBN	_	41	VC	_	_
43	previously	_	RB	RB	_	42	TMP	_	_
44	to	_	TO	TO	_	45	VMOD	_	_
45	bind	_	VB	VB	_	42	OBJ	_	_
46	Oct-1	_	NN	NN	_	50	NMOD	_	_
47	and	_	CC	CC	_	46	CC	_	_
48	Oct-2	_	NN	NN	_	46	COORD	_	_
49	transcription	_	NN	NN	_	50	NMOD	_	_
50	factors	_	NNS	NNS	_	45	OBJ	_	_
51	in	_	FW	FW	_	45	ADV	_	_
52	vitro	_	FW	FW	_	51	AMOD	_	_
53	.	_	.	.	_	20	P	_	_

1	To	_	TO	TO	_	3	VMOD	_	_
2	further	_	RB	RB	_	3	ADV	_	_
3	elucidate	_	VB	VB	_	24	VMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	role	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	this	_	DT	DT	_	10	NMOD	_	_
8	variant	_	JJ	JJ	_	10	NMOD	_	_
9	octamer	_	NN	NN	_	10	NMOD	_	_
10	motif	_	NN	NN	_	6	PMOD	_	_
11	in	_	IN	IN	_	5	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	regulation	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	germline	_	NN	NN	_	16	NMOD	_	_
16	transcription	_	NN	NN	_	14	PMOD	_	_
17	from	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	21	NMOD	_	_
19	unrearranged	_	JJ	JJ	_	21	NMOD	_	_
20	kappa	_	NN	NN	_	21	NMOD	_	_
21	locus	_	NN	NN	_	17	PMOD	_	_
22	,	_	,	,	_	24	P	_	_
23	we	_	PRP	PRP	_	24	SBJ	_	_
24	have	_	VBP	VBP	_	0	ROOT-S	_	_
25	quantitated	_	VBN	VBN	_	24	VC	_	_
26	the	_	DT	DT	_	29	NMOD	_	_
27	relative	_	JJ	JJ	_	29	NMOD	_	_
28	binding	_	NN	NN	_	29	NMOD	_	_
29	affinity	_	NN	NN	_	25	OBJ	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	Oct-1	_	NN	NN	_	30	PMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	Oct-2	_	NN	NN	_	31	COORD	_	_
34	for	_	IN	IN	_	29	NMOD	_	_
35	the	_	DT	DT	_	38	NMOD	_	_
36	variant	_	JJ	JJ	_	38	NMOD	_	_
37	octamer	_	NN	NN	_	38	NMOD	_	_
38	motif	_	NN	NN	_	34	PMOD	_	_
39	and	_	CC	CC	_	25	CC	_	_
40	determined	_	VBD	VBD	_	25	COORD	_	_
41	the	_	DT	DT	_	43	NMOD	_	_
42	functional	_	JJ	JJ	_	43	NMOD	_	_
43	role	_	NN	NN	_	40	OBJ	_	_
44	of	_	IN	IN	_	43	NMOD	_	_
45	this	_	DT	DT	_	47	NMOD	_	_
46	octamer	_	NN	NN	_	47	NMOD	_	_
47	motif	_	NN	NN	_	44	PMOD	_	_
48	in	_	IN	IN	_	43	NMOD	_	_
49	transcriptional	_	JJ	JJ	_	50	NMOD	_	_
50	activation	_	NN	NN	_	48	PMOD	_	_
51	.	_	.	.	_	24	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	find	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	although	_	IN	IN	_	40	ADV	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	variant	_	JJ	JJ	_	9	NMOD	_	_
8	octamer	_	NN	NN	_	9	NMOD	_	_
9	motif	_	NN	NN	_	10	SBJ	_	_
10	binds	_	VBZ	VBZ	_	5	VMOD	_	_
11	Oct-1	_	NN	NN	_	10	OBJ	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	Oct-2	_	NN	NN	_	11	COORD	_	_
14	in	_	FW	FW	_	10	ADV	_	_
15	vitro	_	FW	FW	_	14	AMOD	_	_
16	with	_	IN	IN	_	10	ADV	_	_
17	5-fold	_	JJ	JJ	_	19	NMOD	_	_
18	lower	_	JJR	JJR	_	17	AMOD	_	_
19	affinity	_	NN	NN	_	16	PMOD	_	_
20	than	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	consensus	_	NN	NN	_	24	NMOD	_	_
23	octamer	_	NN	NN	_	24	NMOD	_	_
24	motif	_	NN	NN	_	20	PMOD	_	_
25	,	_	,	,	_	40	P	_	_
26	mutation	_	NN	NN	_	40	SBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	31	NMOD	_	_
29	variant	_	JJ	JJ	_	31	NMOD	_	_
30	octamer	_	NN	NN	_	31	NMOD	_	_
31	motif	_	NN	NN	_	27	PMOD	_	_
32	to	_	TO	TO	_	26	NMOD	_	_
33	either	_	CC	CC	_	39	CC	_	_
34	a	_	DT	DT	_	39	NMOD	_	_
35	consensus	_	NN	NN	_	36	NMOD	_	_
36	octamer	_	NN	NN	_	39	NMOD	_	_
37	or	_	CC	CC	_	36	CC	_	_
38	non-octamer	_	JJ	JJ	_	36	COORD	_	_
39	motif	_	NN	NN	_	32	PMOD	_	_
40	has	_	VBZ	VBZ	_	3	VMOD	_	_
41	no	_	DT	DT	_	42	NMOD	_	_
42	effect	_	NN	NN	_	40	OBJ	_	_
43	on	_	IN	IN	_	40	ADV	_	_
44	transcriptional	_	JJ	JJ	_	45	NMOD	_	_
45	activation	_	NN	NN	_	43	PMOD	_	_
46	from	_	IN	IN	_	45	NMOD	_	_
47	the	_	DT	DT	_	49	NMOD	_	_
48	germline	_	NN	NN	_	49	NMOD	_	_
49	promoter	_	NN	NN	_	46	PMOD	_	_
50	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	find	_	VBP	VBP	_	0	ROOT-S	_	_
4	significant	_	JJ	JJ	_	5	NMOD	_	_
5	differences	_	NNS	NNS	_	3	OBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	activation	_	NN	NN	_	6	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	germline	_	NN	NN	_	13	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	V	_	JJ	JJ	_	12	NMOD	_	_
12	region	_	NN	NN	_	9	COORD	_	_
13	promoters	_	NNS	NNS	_	8	PMOD	_	_
14	by	_	IN	IN	_	7	NMOD	_	_
15	kappa	_	NN	NN	_	16	NMOD	_	_
16	enhancers	_	NNS	NNS	_	14	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	germline	_	NN	NN	_	7	NMOD	_	_
7	promoters	_	NNS	NNS	_	12	SBJ	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	V	_	JJ	JJ	_	11	NMOD	_	_
10	region	_	NN	NN	_	11	NMOD	_	_
11	promoters	_	NNS	NNS	_	7	COORD	_	_
12	differ	_	VBP	VBP	_	4	VMOD	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	their	_	PRP$	PRP$	_	15	NMOD	_	_
15	dependence	_	NN	NN	_	13	PMOD	_	_
16	on	_	IN	IN	_	15	NMOD	_	_
17	octamer	_	NN	NN	_	16	PMOD	_	_
18	for	_	IN	IN	_	15	NMOD	_	_
19	activation	_	NN	NN	_	18	PMOD	_	_
20	and	_	CC	CC	_	12	CC	_	_
21	respond	_	VBP	VBP	_	12	COORD	_	_
22	differently	_	RB	RB	_	21	ADV	_	_
23	to	_	TO	TO	_	21	ADV	_	_
24	enhancer	_	NN	NN	_	25	NMOD	_	_
25	activation	_	NN	NN	_	23	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	important	_	JJ	JJ	_	5	NMOD	_	_
5	implications	_	NNS	NNS	_	3	OBJ	_	_
6	in	_	IN	IN	_	3	ADV	_	_
7	regulation	_	NN	NN	_	6	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	germline	_	NN	NN	_	10	NMOD	_	_
10	transcription	_	NN	NN	_	8	PMOD	_	_
11	as	_	RB	RB	_	7	CC	_	_
12	well	_	RB	RB	_	11	DEP	_	_
13	as	_	IN	IN	_	11	DEP	_	_
14	concomitant	_	JJ	JJ	_	15	NMOD	_	_
15	activation	_	NN	NN	_	7	COORD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	V-J	_	JJ	JJ	_	19	NMOD	_	_
19	recombination	_	NN	NN	_	16	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	25	NMOD	_	_
22	kappa	_	NN	NN	_	25	NMOD	_	_
23	light	_	JJ	JJ	_	25	NMOD	_	_
24	chain	_	NN	NN	_	25	NMOD	_	_
25	locus	_	NN	NN	_	20	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	novel	_	JJ	JJ	_	4	NMOD	_	_
3	SP-1	_	NN	NN	_	4	NMOD	_	_
4	site	_	NN	NN	_	11	SBJ	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	human	_	JJ	JJ	_	10	NMOD	_	_
8	interleukin-1	_	NN	NN	_	10	NMOD	_	_
9	beta	_	NN	NN	_	10	NMOD	_	_
10	promoter	_	NN	NN	_	5	PMOD	_	_
11	confers	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	preferential	_	JJ	JJ	_	14	NMOD	_	_
13	transcriptional	_	JJ	JJ	_	14	NMOD	_	_
14	activity	_	NN	NN	_	11	OBJ	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	keratinocytes	_	NNS	NNS	_	15	PMOD	_	_
17	.	_	.	.	_	11	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	investigate	_	VB	VB	_	18	VMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	mechanisms	_	NNS	NNS	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	transcriptional	_	JJ	JJ	_	7	NMOD	_	_
7	activation	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	interleukin-1beta	_	NN	NN	_	8	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	IL-1beta	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	in	_	IN	IN	_	7	NMOD	_	_
14	non-monocytic	_	JJ	JJ	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	13	PMOD	_	_
16	,	_	,	,	_	18	P	_	_
17	we	_	PRP	PRP	_	18	SBJ	_	_
18	constructed	_	VBD	VBD	_	0	ROOT-S	_	_
19	a	_	DT	DT	_	20	NMOD	_	_
20	series	_	NN	NN	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	reporter	_	NN	NN	_	23	NMOD	_	_
23	plasmids	_	NNS	NNS	_	21	PMOD	_	_
24	with	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	29	NMOD	_	_
26	bacterial	_	JJ	JJ	_	29	NMOD	_	_
27	chloramphenicol	_	NN	NN	_	29	NMOD	_	_
28	acetyltransferase	_	NN	NN	_	29	NMOD	_	_
29	gene	_	NN	NN	_	24	PMOD	_	_
30	linked	_	VBN	VBN	_	29	NMOD	_	_
31	to	_	TO	TO	_	30	ADV	_	_
32	various	_	JJ	JJ	_	33	NMOD	_	_
33	parts	_	NNS	NNS	_	31	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	the	_	DT	DT	_	38	NMOD	_	_
36	human	_	JJ	JJ	_	38	NMOD	_	_
37	IL-1beta	_	NN	NN	_	38	NMOD	_	_
38	promoter	_	NN	NN	_	34	PMOD	_	_
39	and	_	CC	CC	_	18	CC	_	_
40	performed	_	VBD	VBD	_	18	COORD	_	_
41	transient	_	JJ	JJ	_	43	NMOD	_	_
42	transfection	_	NN	NN	_	43	NMOD	_	_
43	experiments	_	NNS	NNS	_	40	OBJ	_	_
44	.	_	.	.	_	18	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	identified	_	VBD	VBD	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	promoter	_	NN	NN	_	5	NMOD	_	_
5	segment	_	NN	NN	_	2	OBJ	_	_
6	that	_	WDT	WDT	_	7	SBJ	_	_
7	activates	_	VBZ	VBZ	_	5	NMOD	_	_
8	transcription	_	NN	NN	_	7	OBJ	_	_
9	most	_	RBS	RBS	_	10	AMOD	_	_
10	efficiently	_	RB	RB	_	7	ADV	_	_
11	in	_	IN	IN	_	7	ADV	_	_
12	keratinocytes	_	NNS	NNS	_	11	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	Electrophoretic	_	JJ	JJ	_	4	NMOD	_	_
2	mobility	_	NN	NN	_	4	NMOD	_	_
3	shift	_	NN	NN	_	4	NMOD	_	_
4	assays	_	NNS	NNS	_	19	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	EMSA	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	with	_	IN	IN	_	4	NMOD	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	43-mer	_	NN	NN	_	11	NMOD	_	_
11	oligonucleotide	_	NN	NN	_	8	PMOD	_	_
12	derived	_	VBN	VBN	_	11	NMOD	_	_
13	from	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	functionally	_	RB	RB	_	16	AMOD	_	_
16	identified	_	VBN	VBN	_	18	NMOD	_	_
17	cis-acting	_	JJ	JJ	_	18	NMOD	_	_
18	element	_	NN	NN	_	13	PMOD	_	_
19	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
20	specific	_	JJ	JJ	_	21	NMOD	_	_
21	complexes	_	NNS	NNS	_	19	OBJ	_	_
22	.	_	.	.	_	19	P	_	_

1	By	_	IN	IN	_	22	ADV	_	_
2	competition	_	NN	NN	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	1	PMOD	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	transcription	_	NN	NN	_	9	NMOD	_	_
6	factor	_	NN	NN	_	9	NMOD	_	_
7	consensus	_	NN	NN	_	9	NMOD	_	_
8	sequence	_	NN	NN	_	9	NMOD	_	_
9	oligonucleotides	_	NNS	NNS	_	4	PMOD	_	_
10	and	_	CC	CC	_	1	CC	_	_
11	by	_	IN	IN	_	1	LGS	_	_
12	immunosupershift	_	NN	NN	_	11	PMOD	_	_
13	,	_	,	,	_	22	P	_	_
14	transcription	_	NN	NN	_	16	NMOD	_	_
15	factor	_	NN	NN	_	16	NMOD	_	_
16	SP-1	_	NN	NN	_	22	SBJ	_	_
17	or	_	CC	CC	_	16	CC	_	_
18	a	_	DT	DT	_	21	NMOD	_	_
19	closely	_	RB	RB	_	20	AMOD	_	_
20	related	_	JJ	JJ	_	21	NMOD	_	_
21	protein	_	NN	NN	_	16	COORD	_	_
22	was	_	VBD	VBD	_	0	ROOT-S	_	_
23	shown	_	VBN	VBN	_	22	VC	_	_
24	to	_	TO	TO	_	25	VMOD	_	_
25	bind	_	VBP	VBP	_	23	OBJ	_	_
26	to	_	TO	TO	_	25	ADV	_	_
27	this	_	DT	DT	_	29	NMOD	_	_
28	regulatory	_	JJ	JJ	_	29	NMOD	_	_
29	element	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	22	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	closest	_	JJS	JJS	_	3	NMOD	_	_
3	match	_	NN	NN	_	14	SBJ	_	_
4	to	_	TO	TO	_	3	NMOD	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	known	_	VBN	VBN	_	9	NMOD	_	_
7	SP-1	_	NN	NN	_	9	NMOD	_	_
8	consensus	_	NN	NN	_	9	NMOD	_	_
9	sequence	_	NN	NN	_	4	PMOD	_	_
10	within	_	IN	IN	_	3	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	respective	_	JJ	JJ	_	13	NMOD	_	_
13	region	_	NN	NN	_	10	PMOD	_	_
14	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	TCCCCTCCCCT	_	NN	NN	_	17	NMOD	_	_
17	motif	_	NN	NN	_	14	PRD	_	_
18	.	_	.	.	_	14	P	_	_

1	Mutation	_	NN	NN	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	this	_	DT	DT	_	4	NMOD	_	_
4	motif	_	NN	NN	_	2	PMOD	_	_
5	almost	_	RB	RB	_	11	ADV	_	_
6	completely	_	RB	RB	_	5	AMOD	_	_
7	,	_	,	,	_	5	P	_	_
8	and	_	CC	CC	_	5	CC	_	_
9	specifically	_	RB	RB	_	5	COORD	_	_
10	,	_	,	,	_	5	P	_	_
11	abolished	_	VBD	VBD	_	0	ROOT-S	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	binding	_	NN	NN	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	two	_	CD	CD	_	17	NMOD	_	_
16	low-mobility	_	JJ	JJ	_	17	NMOD	_	_
17	complexes	_	NNS	NNS	_	14	PMOD	_	_
18	and	_	CC	CC	_	11	CC	_	_
19	led	_	VBD	VBD	_	11	COORD	_	_
20	to	_	TO	TO	_	19	ADV	_	_
21	a	_	DT	DT	_	24	NMOD	_	_
22	95	_	CD	CD	_	24	NMOD	_	_
23	%	_	NN	NN	_	24	NMOD	_	_
24	decrease	_	NN	NN	_	20	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	constitutive	_	JJ	JJ	_	28	NMOD	_	_
27	transcriptional	_	JJ	JJ	_	28	NMOD	_	_
28	activation	_	NN	NN	_	25	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	a	_	DT	DT	_	33	NMOD	_	_
31	reporter	_	NN	NN	_	33	NMOD	_	_
32	construct	_	NN	NN	_	33	NMOD	_	_
33	IL-1beta	_	NN	NN	_	29	PMOD	_	_
34	(	_	(	(	_	35	P	_	_
35	-170\/+108	_	CD	CD	_	33	PRN	_	_
36	)	_	)	)	_	35	P	_	_
37	.	_	.	.	_	11	P	_	_

1	Likewise	_	RB	RB	_	12	ADV	_	_
2	,	_	,	,	_	12	P	_	_
3	activation	_	NN	NN	_	12	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	this	_	DT	DT	_	7	NMOD	_	_
6	reporter	_	NN	NN	_	7	NMOD	_	_
7	construct	_	NN	NN	_	4	PMOD	_	_
8	by	_	IN	IN	_	3	NMOD	_	_
9	tumor	_	NN	NN	_	11	NMOD	_	_
10	necrosis	_	NN	NN	_	11	NMOD	_	_
11	factor-alpha	_	NN	NN	_	8	PMOD	_	_
12	depended	_	VBD	VBD	_	0	ROOT-S	_	_
13	on	_	IN	IN	_	12	ADV	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	SP-1	_	NN	NN	_	16	NMOD	_	_
16	site	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	12	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	observations	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	a	_	DT	DT	_	8	NMOD	_	_
6	so-far-unrecognized	_	JJ	JJ	_	8	NMOD	_	_
7	SP-1	_	NN	NN	_	8	NMOD	_	_
8	site	_	NN	NN	_	14	SBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	human	_	JJ	JJ	_	13	NMOD	_	_
12	IL-1beta	_	NN	NN	_	13	NMOD	_	_
13	promoter	_	NN	NN	_	9	PMOD	_	_
14	may	_	MD	MD	_	4	VMOD	_	_
15	participate	_	VB	VB	_	14	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	transcriptional	_	JJ	JJ	_	19	NMOD	_	_
19	regulation	_	NN	NN	_	16	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	this	_	DT	DT	_	22	NMOD	_	_
22	gene	_	NN	NN	_	20	PMOD	_	_
23	in	_	IN	IN	_	19	NMOD	_	_
24	keratinocytes	_	NNS	NNS	_	23	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	Stimulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	human	_	JJ	JJ	_	7	NMOD	_	_
4	peripheral	_	JJ	JJ	_	7	NMOD	_	_
5	blood	_	NN	NN	_	7	NMOD	_	_
6	mononuclear	_	JJ	JJ	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	2	PMOD	_	_
8	by	_	IN	IN	_	1	NMOD	_	_
9	zinc	_	NN	NN	_	8	PMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	related	_	JJ	JJ	_	12	NMOD	_	_
12	cations	_	NNS	NNS	_	9	COORD	_	_
13	.	_	.	.	_	1	P	_	_

1	Zinc	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	an	_	DT	DT	_	6	NMOD	_	_
4	important	_	JJ	JJ	_	6	NMOD	_	_
5	trace	_	NN	NN	_	6	NMOD	_	_
6	element	_	NN	NN	_	2	PRD	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	immune	_	JJ	JJ	_	9	NMOD	_	_
9	function	_	NN	NN	_	7	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	Here	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	show	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	zinc	_	NN	NN	_	7	NMOD	_	_
7	addition	_	NN	NN	_	16	SBJ	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	a	_	DT	DT	_	15	NMOD	_	_
10	serum-	_	NN	NN	_	15	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	lipopolysaccharide-free	_	JJ	JJ	_	10	COORD	_	_
13	cell	_	NN	NN	_	15	NMOD	_	_
14	culture	_	NN	NN	_	15	NMOD	_	_
15	system	_	NN	NN	_	8	PMOD	_	_
16	leads	_	VBZ	VBZ	_	5	VMOD	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	significantly	_	RB	RB	_	19	AMOD	_	_
19	enhanced	_	JJ	JJ	_	20	NMOD	_	_
20	levels	_	NNS	NNS	_	17	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	interleukin	_	NN	NN	_	24	NMOD	_	_
23	1	_	CD	CD	_	24	NMOD	_	_
24	beta	_	NN	NN	_	21	PMOD	_	_
25	(	_	(	(	_	27	P	_	_
26	IL-1	_	NN	NN	_	27	NMOD	_	_
27	beta	_	NN	NN	_	24	PRN	_	_
28	)	_	)	)	_	27	P	_	_
29	and	_	CC	CC	_	24	CC	_	_
30	tumour	_	NN	NN	_	33	NMOD	_	_
31	necrosis	_	NN	NN	_	33	NMOD	_	_
32	factor	_	NN	NN	_	33	NMOD	_	_
33	alpha	_	NN	NN	_	24	COORD	_	_
34	(	_	(	(	_	35	P	_	_
35	TNF-alpha	_	NN	NN	_	33	PRN	_	_
36	)	_	)	)	_	35	P	_	_
37	and	_	CC	CC	_	17	CC	_	_
38	to	_	TO	TO	_	17	COORD	_	_
39	expression	_	NN	NN	_	38	PMOD	_	_
40	of	_	IN	IN	_	39	NMOD	_	_
41	the	_	DT	DT	_	43	NMOD	_	_
42	corresponding	_	JJ	JJ	_	43	NMOD	_	_
43	mRNA	_	NN	NN	_	40	PMOD	_	_
44	in	_	IN	IN	_	43	NMOD	_	_
45	human	_	JJ	JJ	_	49	NMOD	_	_
46	peripheral	_	JJ	JJ	_	49	NMOD	_	_
47	blood	_	NN	NN	_	49	NMOD	_	_
48	mononuclear	_	JJ	JJ	_	49	NMOD	_	_
49	cells	_	NNS	NNS	_	44	PMOD	_	_
50	(	_	(	(	_	51	P	_	_
51	PBMC	_	NN	NN	_	49	PRN	_	_
52	)	_	)	)	_	51	P	_	_
53	.	_	.	.	_	4	P	_	_

1	Structurally	_	RB	RB	_	2	AMOD	_	_
2	related	_	JJ	JJ	_	4	NMOD	_	_
3	divalent	_	JJ	JJ	_	4	NMOD	_	_
4	cations	_	NNS	NNS	_	14	SBJ	_	_
5	like	_	IN	IN	_	4	NMOD	_	_
6	cobalt	_	NN	NN	_	5	PMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	nickel	_	NN	NN	_	6	COORD	_	_
9	,	_	,	,	_	6	P	_	_
10	and	_	CC	CC	_	6	CC	_	_
11	mercury	_	NN	NN	_	6	COORD	_	_
12	also	_	RB	RB	_	14	ADV	_	_
13	partially	_	RB	RB	_	14	ADV	_	_
14	increase	_	VBP	VBP	_	0	ROOT-S	_	_
15	monokine	_	NN	NN	_	16	NMOD	_	_
16	secretion	_	NN	NN	_	14	OBJ	_	_
17	but	_	CC	CC	_	14	CC	_	_
18	to	_	TO	TO	_	14	ADV	_	_
19	a	_	DT	DT	_	25	NMOD	_	_
20	much	_	RB	RB	_	21	AMOD	_	_
21	lower	_	JJR	JJR	_	25	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	thus	_	RB	RB	_	21	COORD	_	_
24	insignificant	_	JJ	JJ	_	21	COORD	_	_
25	extent	_	NN	NN	_	18	PMOD	_	_
26	.	_	.	.	_	14	P	_	_

1	They	_	PRP	PRP	_	2	SBJ	_	_
2	fail	_	VBP	VBP	_	0	ROOT-S	_	_
3	to	_	TO	TO	_	4	VMOD	_	_
4	induce	_	VB	VB	_	2	OBJ	_	_
5	mRNA	_	NN	NN	_	4	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	TNF-alpha	_	NN	NN	_	6	PMOD	_	_
8	after	_	IN	IN	_	4	TMP	_	_
9	3	_	CD	CD	_	10	NMOD	_	_
10	h	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	culture	_	NN	NN	_	11	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	Therefore	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	monokine	_	NN	NN	_	4	NMOD	_	_
4	induction	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	zinc-specific	_	JJ	JJ	_	8	NMOD	_	_
8	effect	_	NN	NN	_	5	PRD	_	_
9	influenced	_	VBN	VBN	_	8	NMOD	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	physicochemical	_	JJ	JJ	_	13	NMOD	_	_
13	properties	_	NNS	NNS	_	10	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	ion	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	5	P	_	_

1	Confirmation	_	NN	NN	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	unique	_	JJ	JJ	_	5	NMOD	_	_
5	significance	_	NN	NN	_	2	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	zinc	_	NN	NN	_	6	PMOD	_	_
8	for	_	IN	IN	_	5	NMOD	_	_
9	immune	_	JJ	JJ	_	10	NMOD	_	_
10	function	_	NN	NN	_	8	PMOD	_	_
11	provides	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	better	_	JJR	JJR	_	14	NMOD	_	_
14	understanding	_	NN	NN	_	11	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	mechanisms	_	NNS	NNS	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	specific	_	JJ	JJ	_	22	NMOD	_	_
20	zinc-mediated	_	JJ	JJ	_	22	NMOD	_	_
21	immune	_	JJ	JJ	_	22	NMOD	_	_
22	modulation	_	NN	NN	_	18	PMOD	_	_
23	.	_	.	.	_	11	P	_	_

1	Identification	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	Bcd	_	NN	NN	_	2	PMOD	_	_
4	,	_	,	,	_	3	P	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	novel	_	JJ	JJ	_	7	NMOD	_	_
7	proto-oncogene	_	NN	NN	_	3	NMOD	_	_
8	expressed	_	VBN	VBN	_	7	NMOD	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	B-cells	_	NNS	NNS	_	9	PMOD	_	_
11	.	_	.	.	_	1	P	_	_

1	A	_	DT	DT	_	8	NMOD	_	_
2	novel	_	JJ	JJ	_	8	NMOD	_	_
3	B-cell	_	NN	NN	_	8	NMOD	_	_
4	derived	_	JJ	JJ	_	3	AMOD	_	_
5	(	_	(	(	_	6	P	_	_
6	Bcd	_	NN	NN	_	3	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	oncogene	_	NN	NN	_	9	SBJ	_	_
9	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	been	_	VBN	VBN	_	9	VC	_	_
11	isolated	_	VBN	VBN	_	10	VC	_	_
12	from	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	peripheral	_	JJ	JJ	_	16	NMOD	_	_
15	blood	_	NN	NN	_	16	NMOD	_	_
16	lymphocytes	_	NNS	NNS	_	12	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	one	_	CD	CD	_	26	NMOD	_	_
19	B-cell	_	NN	NN	_	22	NMOD	_	_
20	chronic	_	JJ	JJ	_	22	NMOD	_	_
21	lymphocytic	_	JJ	JJ	_	22	NMOD	_	_
22	leukemia	_	NN	NN	_	26	NMOD	_	_
23	(	_	(	(	_	24	P	_	_
24	B-CLL	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	patient	_	NN	NN	_	17	PMOD	_	_
27	using	_	VBG	VBG	_	11	OBJ	_	_
28	DNA	_	NN	NN	_	29	NMOD	_	_
29	transfer	_	NN	NN	_	27	OBJ	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	a	_	DT	DT	_	34	NMOD	_	_
32	mouse	_	NN	NN	_	34	NMOD	_	_
33	tumorigenicity	_	NN	NN	_	34	NMOD	_	_
34	assay	_	NN	NN	_	29	COORD	_	_
35	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	Bcd	_	NN	NN	_	3	NMOD	_	_
3	proto-oncogene	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	activated	_	VBN	VBN	_	4	VC	_	_
6	by	_	IN	IN	_	5	LGS	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	truncation	_	NN	NN	_	6	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	5'	_	JJ	JJ	_	12	NMOD	_	_
12	UTR	_	NN	NN	_	9	PMOD	_	_
13	.	_	.	.	_	4	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	predicts	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	for	_	IN	IN	_	2	ADV	_	_
4	two	_	CD	CD	_	7	NMOD	_	_
5	open	_	JJ	JJ	_	7	NMOD	_	_
6	reading	_	NN	NN	_	7	NMOD	_	_
7	frames	_	NNS	NNS	_	3	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	ORFs	_	NNS	NNS	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	.	_	.	.	_	2	P	_	_

1	ORF1	_	NN	NN	_	2	SBJ	_	_
2	consists	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	of	_	IN	IN	_	2	ADV	_	_
4	240	_	CD	CD	_	5	NMOD	_	_
5	bp	_	NN	NN	_	3	PMOD	_	_
6	that	_	WDT	WDT	_	7	SBJ	_	_
7	would	_	MD	MD	_	5	NMOD	_	_
8	encode	_	VB	VB	_	7	VC	_	_
9	80	_	CD	CD	_	11	NMOD	_	_
10	amino	_	NN	NN	_	11	NMOD	_	_
11	acids	_	NNS	NNS	_	8	OBJ	_	_
12	,	_	,	,	_	2	P	_	_
13	while	_	IN	IN	_	2	OBJ	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	major	_	JJ	JJ	_	16	NMOD	_	_
16	ORF2	_	NN	NN	_	17	SBJ	_	_
17	consists	_	VBZ	VBZ	_	13	VMOD	_	_
18	of	_	IN	IN	_	17	ADV	_	_
19	648	_	CD	CD	_	20	NMOD	_	_
20	bp	_	NN	NN	_	18	PMOD	_	_
21	capable	_	JJ	JJ	_	20	NMOD	_	_
22	of	_	IN	IN	_	21	AMOD	_	_
23	coding	_	VBG	VBG	_	22	PMOD	_	_
24	for	_	IN	IN	_	23	ADV	_	_
25	216	_	CD	CD	_	27	NMOD	_	_
26	amino	_	NN	NN	_	27	NMOD	_	_
27	acids	_	NNS	NNS	_	24	PMOD	_	_
28	.	_	.	.	_	2	P	_	_

1	Predicted	_	VBN	VBN	_	3	NMOD	_	_
2	peptide	_	NN	NN	_	3	NMOD	_	_
3	sequence	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	ORF2	_	NN	NN	_	4	PMOD	_	_
6	contained	_	VBD	VBD	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	10	NMOD	_	_
8	zinc	_	NN	NN	_	10	NMOD	_	_
9	finger	_	NN	NN	_	10	NMOD	_	_
10	domain	_	NN	NN	_	6	OBJ	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	showed	_	VBD	VBD	_	10	NMOD	_	_
13	significant	_	JJ	JJ	_	14	NMOD	_	_
14	homology	_	NN	NN	_	12	OBJ	_	_
15	to	_	TO	TO	_	14	NMOD	_	_
16	GC	_	NN	NN	_	19	NMOD	_	_
17	box	_	NN	NN	_	19	NMOD	_	_
18	binding	_	NN	NN	_	19	NMOD	_	_
19	proteins	_	NNS	NNS	_	15	PMOD	_	_
20	BTEB2	_	NN	NN	_	19	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	SP1	_	NN	NN	_	20	COORD	_	_
23	.	_	.	.	_	6	P	_	_

1	Transfection	_	NN	NN	_	13	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	an	_	DT	DT	_	5	NMOD	_	_
4	expression	_	NN	NN	_	5	NMOD	_	_
5	vector	_	NN	NN	_	2	PMOD	_	_
6	containing	_	VBG	VBG	_	5	NMOD	_	_
7	ORF2	_	NN	NN	_	6	OBJ	_	_
8	but	_	CC	CC	_	7	CC	_	_
9	not	_	RB	RB	_	8	COORD	_	_
10	full	_	JJ	JJ	_	12	NMOD	_	_
11	length	_	NN	NN	_	12	NMOD	_	_
12	cDNA	_	NN	NN	_	7	COORD	_	_
13	was	_	VBD	VBD	_	0	ROOT-S	_	_
14	able	_	JJ	JJ	_	13	PRD	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	transform	_	VB	VB	_	14	AMOD	_	_
17	NIH3T3	_	NN	NN	_	18	NMOD	_	_
18	cells	_	NNS	NNS	_	16	OBJ	_	_
19	and	_	CC	CC	_	16	CC	_	_
20	induce	_	VB	VB	_	16	COORD	_	_
21	tumors	_	NNS	NNS	_	20	OBJ	_	_
22	in	_	IN	IN	_	20	ADV	_	_
23	nude	_	JJ	JJ	_	24	NMOD	_	_
24	mice	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	13	P	_	_

1	Bcd	_	NN	NN	_	3	NMOD	_	_
2	mRNA	_	NN	NN	_	3	NMOD	_	_
3	transcripts	_	NNS	NNS	_	10	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	&lt;	_	JJR	JJR	_	9	NMOD	_	_
6	or	_	CC	CC	_	5	CC	_	_
7	=	_	JJ	JJ	_	5	COORD	_	_
8	2.6	_	CD	CD	_	9	NMOD	_	_
9	kb	_	NN	NN	_	4	PMOD	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	selectively	_	RB	RB	_	12	ADV	_	_
12	expressed	_	VBN	VBN	_	10	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	PBL	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	testis	_	NN	NN	_	14	COORD	_	_
17	of	_	IN	IN	_	14	NMOD	_	_
18	healthy	_	JJ	JJ	_	19	NMOD	_	_
19	individuals	_	NNS	NNS	_	17	PMOD	_	_
20	.	_	.	.	_	10	P	_	_

1	Within	_	IN	IN	_	8	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	PBL	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	8	P	_	_
5	Bcd	_	NN	NN	_	7	NMOD	_	_
6	gene	_	NN	NN	_	7	NMOD	_	_
7	expression	_	NN	NN	_	8	SBJ	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	restricted	_	JJ	JJ	_	8	PRD	_	_
10	to	_	TO	TO	_	9	AMOD	_	_
11	CD19+	_	JJ	JJ	_	12	NMOD	_	_
12	B-cells	_	NNS	NNS	_	10	PMOD	_	_
13	and	_	CC	CC	_	9	CC	_	_
14	absent	_	JJ	JJ	_	9	COORD	_	_
15	from	_	IN	IN	_	14	AMOD	_	_
16	CD14+	_	JJ	JJ	_	17	NMOD	_	_
17	monocytes	_	NNS	NNS	_	15	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	T-cells	_	NNS	NNS	_	17	COORD	_	_
20	.	_	.	.	_	8	P	_	_

1	Bcd	_	NN	NN	_	2	NMOD	_	_
2	transcripts	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	detected	_	VBN	VBN	_	3	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	all	_	DT	DT	_	9	NMOD	_	_
7	normal	_	JJ	JJ	_	9	NMOD	_	_
8	PBL	_	NN	NN	_	9	NMOD	_	_
9	samples	_	NNS	NNS	_	5	PMOD	_	_
10	tested	_	VBN	VBN	_	9	NMOD	_	_
11	but	_	CC	CC	_	5	CC	_	_
12	not	_	RB	RB	_	13	DEP	_	_
13	in	_	IN	IN	_	5	COORD	_	_
14	several	_	JJ	JJ	_	18	NMOD	_	_
15	malignant	_	JJ	JJ	_	18	NMOD	_	_
16	human	_	JJ	JJ	_	18	NMOD	_	_
17	B-cell	_	NN	NN	_	18	NMOD	_	_
18	lines	_	NNS	NNS	_	13	PMOD	_	_
19	and	_	CC	CC	_	5	CC	_	_
20	not	_	RB	RB	_	21	DEP	_	_
21	in	_	IN	IN	_	5	COORD	_	_
22	50	_	CD	CD	_	23	NMOD	_	_
23	%	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	B-cells	_	NNS	NNS	_	24	PMOD	_	_
26	from	_	IN	IN	_	25	NMOD	_	_
27	B-CLL	_	NN	NN	_	28	NMOD	_	_
28	patients	_	NNS	NNS	_	26	PMOD	_	_
29	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	17	ADV	_	_
2	,	_	,	,	_	17	P	_	_
3	stimulation	_	NN	NN	_	17	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	B-cells	_	NNS	NNS	_	4	PMOD	_	_
6	from	_	IN	IN	_	5	NMOD	_	_
7	B-CLL	_	NN	NN	_	8	NMOD	_	_
8	patients	_	NNS	NNS	_	6	PMOD	_	_
9	under	_	IN	IN	_	3	NMOD	_	_
10	conditions	_	NNS	NNS	_	9	PMOD	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	induced	_	VBD	VBD	_	10	NMOD	_	_
13	differentiation	_	NN	NN	_	12	OBJ	_	_
14	into	_	IN	IN	_	13	NMOD	_	_
15	plasma	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	was	_	VBD	VBD	_	0	ROOT-S	_	_
18	associated	_	VBN	VBN	_	17	VC	_	_
19	with	_	IN	IN	_	18	ADV	_	_
20	induction	_	NN	NN	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	Bcd	_	NN	NN	_	24	NMOD	_	_
23	gene	_	NN	NN	_	24	NMOD	_	_
24	expression	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	17	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	Bcd	_	NN	NN	_	3	NMOD	_	_
3	gene	_	NN	NN	_	4	SBJ	_	_
4	may	_	MD	MD	_	0	ROOT-S	_	_
5	therefore	_	RB	RB	_	4	ADV	_	_
6	play	_	VB	VB	_	4	VC	_	_
7	an	_	DT	DT	_	9	NMOD	_	_
8	important	_	JJ	JJ	_	9	NMOD	_	_
9	role	_	NN	NN	_	6	OBJ	_	_
10	in	_	IN	IN	_	6	ADV	_	_
11	B-cell	_	NN	NN	_	10	PMOD	_	_
12	growth	_	NN	NN	_	11	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	development	_	NN	NN	_	12	COORD	_	_
15	.	_	.	.	_	4	P	_	_

1	Expression	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	erythroid-specific	_	JJ	JJ	_	4	NMOD	_	_
4	genes	_	NNS	NNS	_	2	PMOD	_	_
5	in	_	IN	IN	_	1	NMOD	_	_
6	megakaryoblastic	_	JJ	JJ	_	7	NMOD	_	_
7	disorders	_	NNS	NNS	_	5	PMOD	_	_
8	.	_	.	.	_	1	P	_	_

1	Currently	_	RB	RB	_	2	AMOD	_	_
2	available	_	JJ	JJ	_	3	NMOD	_	_
3	data	_	NNS	NNS	_	4	SBJ	_	_
4	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	erythroid	_	JJ	JJ	_	10	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	megakaryocytic	_	JJ	JJ	_	6	COORD	_	_
9	differentiation	_	NN	NN	_	10	NMOD	_	_
10	pathways	_	NNS	NNS	_	11	SBJ	_	_
11	are	_	VBP	VBP	_	5	VMOD	_	_
12	closely	_	RB	RB	_	13	AMOD	_	_
13	related	_	JJ	JJ	_	11	PRD	_	_
14	to	_	TO	TO	_	13	AMOD	_	_
15	each	_	DT	DT	_	16	NMOD	_	_
16	other	_	JJ	JJ	_	14	PMOD	_	_
17	,	_	,	,	_	11	P	_	_
18	and	_	CC	CC	_	11	CC	_	_
19	there	_	EX	EX	_	20	SBJ	_	_
20	may	_	MD	MD	_	11	COORD	_	_
21	exist	_	VB	VB	_	20	VC	_	_
22	progenitor	_	NN	NN	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	21	PRD	_	_
24	common	_	JJ	JJ	_	23	NMOD	_	_
25	to	_	TO	TO	_	24	AMOD	_	_
26	those	_	DT	DT	_	28	NMOD	_	_
27	two	_	CD	CD	_	28	NMOD	_	_
28	lineages	_	NNS	NNS	_	25	PMOD	_	_
29	may	_	MD	MD	_	20	VMOD	_	_
30	exist	_	VB	VB	_	20	VMOD	_	_
31	.	_	.	.	_	4	P	_	_

1	Acute	_	JJ	JJ	_	3	NMOD	_	_
2	megakaryoblastic	_	JJ	JJ	_	3	NMOD	_	_
3	leukemia	_	NN	NN	_	18	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	AML-M7	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	and	_	CC	CC	_	3	CC	_	_
8	transient	_	JJ	JJ	_	10	NMOD	_	_
9	myeloproliferative	_	JJ	JJ	_	10	NMOD	_	_
10	disorder	_	NN	NN	_	3	COORD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	Down	_	NN	NN	_	14	NMOD	_	_
13	's	_	POS	POS	_	12	NMOD	_	_
14	syndrome	_	NN	NN	_	11	PMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	TMD	_	NN	NN	_	10	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	are	_	VBP	VBP	_	0	ROOT-S	_	_
19	characterized	_	VBN	VBN	_	18	VC	_	_
20	by	_	IN	IN	_	19	LGS	_	_
21	rapid	_	JJ	JJ	_	22	NMOD	_	_
22	growth	_	NN	NN	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	abnormal	_	JJ	JJ	_	26	NMOD	_	_
25	blast	_	NN	NN	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	23	PMOD	_	_
27	which	_	WDT	WDT	_	28	SBJ	_	_
28	express	_	VBP	VBP	_	26	NMOD	_	_
29	megakaryocytic	_	JJ	JJ	_	30	NMOD	_	_
30	markers	_	NNS	NNS	_	28	OBJ	_	_
31	.	_	.	.	_	18	P	_	_

1	These	_	DT	DT	_	3	NMOD	_	_
2	blast	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	4	SBJ	_	_
4	express	_	VBP	VBP	_	0	ROOT-S	_	_
5	lineage-specific	_	JJ	JJ	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factors	_	NNS	NNS	_	4	OBJ	_	_
8	such	_	JJ	JJ	_	9	DEP	_	_
9	as	_	IN	IN	_	7	NMOD	_	_
10	GATA-1	_	NN	NN	_	9	PMOD	_	_
11	common	_	JJ	JJ	_	10	NMOD	_	_
12	to	_	TO	TO	_	11	AMOD	_	_
13	these	_	DT	DT	_	14	NMOD	_	_
14	lineages	_	NNS	NNS	_	12	PMOD	_	_
15	and	_	CC	CC	_	4	CC	_	_
16	frequently	_	RB	RB	_	17	TMP	_	_
17	express	_	VBP	VBP	_	4	COORD	_	_
18	erythroid-specific	_	JJ	JJ	_	19	NMOD	_	_
19	mRNAs	_	NNS	NNS	_	17	OBJ	_	_
20	such	_	JJ	JJ	_	21	DEP	_	_
21	as	_	IN	IN	_	19	NMOD	_	_
22	gamma-globin	_	NN	NN	_	21	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	erythroid	_	JJ	JJ	_	26	NMOD	_	_
25	delta-aminolevulinate	_	NN	NN	_	26	NMOD	_	_
26	synthase	_	NN	NN	_	22	COORD	_	_
27	(	_	(	(	_	28	P	_	_
28	ALAS-E	_	NN	NN	_	26	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	,	_	,	,	_	4	P	_	_
31	indicating	_	VBG	VBG	_	4	OBJ	_	_
32	that	_	IN	IN	_	31	OBJ	_	_
33	most	_	JJS	JJS	_	42	SBJ	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	the	_	DT	DT	_	36	NMOD	_	_
36	blasts	_	NNS	NNS	_	34	PMOD	_	_
37	in	_	IN	IN	_	36	NMOD	_	_
38	M7	_	NN	NN	_	41	NMOD	_	_
39	and	_	CC	CC	_	38	CC	_	_
40	TMD	_	NN	NN	_	38	COORD	_	_
41	cases	_	NNS	NNS	_	37	PMOD	_	_
42	have	_	VBP	VBP	_	32	VMOD	_	_
43	erythroid	_	JJ	JJ	_	46	NMOD	_	_
44	and	_	CC	CC	_	43	CC	_	_
45	megakaryocytic	_	JJ	JJ	_	43	COORD	_	_
46	phenotypes	_	NNS	NNS	_	42	OBJ	_	_
47	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	blasts	_	NNS	NNS	_	10	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	M7	_	NN	NN	_	6	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	TMD	_	NN	NN	_	7	COORD	_	_
10	may	_	MD	MD	_	4	VMOD	_	_
11	correspond	_	VB	VB	_	10	VC	_	_
12	to	_	TO	TO	_	11	ADV	_	_
13	progenitors	_	NNS	NNS	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	both	_	CC	CC	_	16	CC	_	_
16	erythroid	_	JJ	JJ	_	19	NMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	megakaryocytic	_	JJ	JJ	_	16	COORD	_	_
19	lineages	_	NNS	NNS	_	14	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Specific	_	JJ	JJ	_	2	NMOD	_	_
2	depletion	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	B-cell	_	NN	NN	_	6	NMOD	_	_
6	population	_	NN	NN	_	3	PMOD	_	_
7	induced	_	VBN	VBN	_	2	NMOD	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	aberrant	_	JJ	JJ	_	10	NMOD	_	_
10	expression	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	human	_	JJ	JJ	_	17	NMOD	_	_
13	interferon	_	NN	NN	_	17	NMOD	_	_
14	regulatory	_	JJ	JJ	_	17	NMOD	_	_
15	factor	_	NN	NN	_	17	NMOD	_	_
16	1	_	CD	CD	_	17	NMOD	_	_
17	gene	_	NN	NN	_	11	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	transgenic	_	JJ	JJ	_	20	NMOD	_	_
20	mice	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	2	P	_	_

1	Interferons	_	NNS	NNS	_	5	SBJ	_	_
2	(	_	(	(	_	3	P	_	_
3	IFNs	_	NNS	NNS	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	are	_	VBP	VBP	_	0	ROOT-S	_	_
6	well	_	RB	RB	_	5	ADV	_	_
7	known	_	VBN	VBN	_	5	VC	_	_
8	both	_	CC	CC	_	7	ADV	_	_
9	as	_	IN	IN	_	8	COORD	_	_
10	antiviral	_	JJ	JJ	_	11	NMOD	_	_
11	proteins	_	NNS	NNS	_	9	PMOD	_	_
12	and	_	CC	CC	_	8	CC	_	_
13	as	_	IN	IN	_	8	COORD	_	_
14	potent	_	JJ	JJ	_	15	NMOD	_	_
15	regulators	_	NNS	NNS	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	cell	_	NN	NN	_	16	PMOD	_	_
18	growth	_	NN	NN	_	17	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	differentiation	_	NN	NN	_	18	COORD	_	_
21	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	fact	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	IFNs	_	NNS	NNS	_	5	SBJ	_	_
5	inhibit	_	VBP	VBP	_	0	ROOT-S	_	_
6	growth	_	NN	NN	_	5	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	various	_	JJ	JJ	_	13	NMOD	_	_
9	normal	_	JJ	JJ	_	13	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	transformed	_	VBN	VBN	_	9	COORD	_	_
12	cell	_	NN	NN	_	13	NMOD	_	_
13	types	_	NNS	NNS	_	7	PMOD	_	_
14	.	_	.	.	_	5	P	_	_

1	Previously	_	RB	RB	_	27	TMP	_	_
2	,	_	,	,	_	27	P	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	nuclear	_	JJ	JJ	_	5	NMOD	_	_
5	factor	_	NN	NN	_	27	SBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	IRF-1	_	NN	NN	_	5	NMOD	_	_
8	(	_	(	(	_	11	P	_	_
9	interferon	_	NN	NN	_	11	NMOD	_	_
10	regulatory	_	JJ	JJ	_	11	NMOD	_	_
11	factor	_	NN	NN	_	7	PRN	_	_
12	1	_	CD	CD	_	11	NMOD	_	_
13	)	_	)	)	_	11	P	_	_
14	,	_	,	,	_	5	P	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	binds	_	VBZ	VBZ	_	5	NMOD	_	_
17	to	_	TO	TO	_	16	ADV	_	_
18	type	_	NN	NN	_	20	NMOD	_	_
19	I	_	CD	CD	_	20	NMOD	_	_
20	IFN	_	NN	NN	_	17	PMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	some	_	DT	DT	_	25	NMOD	_	_
23	IFN-inducible	_	JJ	JJ	_	25	NMOD	_	_
24	gene	_	NN	NN	_	25	NMOD	_	_
25	promoters	_	NNS	NNS	_	20	COORD	_	_
26	,	_	,	,	_	27	P	_	_
27	was	_	VBD	VBD	_	0	ROOT-S	_	_
28	identified	_	VBN	VBN	_	27	VC	_	_
29	and	_	CC	CC	_	28	CC	_	_
30	cloned	_	VBN	VBN	_	28	COORD	_	_
31	.	_	.	.	_	27	P	_	_

1	Since	_	IN	IN	_	15	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	IRF-1	_	NN	NN	_	4	NMOD	_	_
4	gene	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	1	VMOD	_	_
6	both	_	CC	CC	_	7	CC	_	_
7	virus	_	NN	NN	_	10	AMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	IFN	_	NN	NN	_	7	COORD	_	_
10	inducible	_	JJ	JJ	_	5	PRD	_	_
11	,	_	,	,	_	15	P	_	_
12	an	_	DT	DT	_	14	NMOD	_	_
13	intriguing	_	JJ	JJ	_	14	NMOD	_	_
14	issue	_	NN	NN	_	15	SBJ	_	_
15	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	raised	_	VBN	VBN	_	15	VC	_	_
17	as	_	IN	IN	_	16	ADV	_	_
18	to	_	TO	TO	_	17	DEP	_	_
19	whether	_	IN	IN	_	17	PMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	IRF-1	_	NN	NN	_	22	NMOD	_	_
22	gene	_	NN	NN	_	23	SBJ	_	_
23	is	_	VBZ	VBZ	_	19	VMOD	_	_
24	functioning	_	VBG	VBG	_	23	VC	_	_
25	in	_	IN	IN	_	24	ADV	_	_
26	IFN-mediated	_	JJ	JJ	_	27	NMOD	_	_
27	regulation	_	NN	NN	_	25	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	cell	_	NN	NN	_	28	PMOD	_	_
30	growth	_	NN	NN	_	29	NMOD	_	_
31	and	_	CC	CC	_	30	CC	_	_
32	differentiation	_	NN	NN	_	30	COORD	_	_
33	.	_	.	.	_	15	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	generated	_	VBD	VBD	_	0	ROOT-S	_	_
7	transgenic	_	JJ	JJ	_	8	NMOD	_	_
8	mice	_	NNS	NNS	_	6	OBJ	_	_
9	carrying	_	VBG	VBG	_	8	NMOD	_	_
10	the	_	DT	DT	_	13	NMOD	_	_
11	human	_	JJ	JJ	_	13	NMOD	_	_
12	IRF-1	_	NN	NN	_	13	NMOD	_	_
13	gene	_	NN	NN	_	9	OBJ	_	_
14	linked	_	VBN	VBN	_	13	NMOD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	human	_	JJ	JJ	_	20	NMOD	_	_
18	immunoglobulin	_	NN	NN	_	20	NMOD	_	_
19	heavy-chain	_	JJ	JJ	_	20	NMOD	_	_
20	enhancer	_	NN	NN	_	15	PMOD	_	_
21	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	transgenic	_	JJ	JJ	_	4	NMOD	_	_
4	mice	_	NNS	NNS	_	1	PMOD	_	_
5	,	_	,	,	_	11	P	_	_
6	all	_	PDT	PDT	_	9	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	lymphoid	_	JJ	JJ	_	9	NMOD	_	_
9	tissues	_	NNS	NNS	_	11	SBJ	_	_
10	examined	_	VBN	VBN	_	9	NMOD	_	_
11	showed	_	VBD	VBD	_	0	ROOT-S	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	dramatic	_	JJ	JJ	_	14	NMOD	_	_
14	reduction	_	NN	NN	_	11	OBJ	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	number	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	B	_	NN	NN	_	20	NMOD	_	_
20	lymphocytes	_	NNS	NNS	_	18	PMOD	_	_
21	(	_	(	(	_	23	P	_	_
22	B	_	NN	NN	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	20	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	.	_	.	.	_	11	P	_	_

1	Preparation	_	NN	NN	_	12	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	analysis	_	NN	NN	_	1	COORD	_	_
4	of	_	IN	IN	_	1	NMOD	_	_
5	bone	_	NN	NN	_	7	NMOD	_	_
6	marrow	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	4	PMOD	_	_
8	from	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	chimeric	_	JJ	JJ	_	11	NMOD	_	_
11	mice	_	NNS	NNS	_	8	PMOD	_	_
12	indicated	_	VBD	VBD	_	0	ROOT-S	_	_
13	that	_	IN	IN	_	12	OBJ	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	bone	_	NN	NN	_	16	NMOD	_	_
16	marrow	_	NN	NN	_	17	SBJ	_	_
17	is	_	VBZ	VBZ	_	13	VMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	effective	_	JJ	JJ	_	20	NMOD	_	_
20	site	_	NN	NN	_	17	PRD	_	_
21	for	_	IN	IN	_	20	NMOD	_	_
22	specific	_	JJ	JJ	_	23	NMOD	_	_
23	depletion	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	B-cell	_	NN	NN	_	27	NMOD	_	_
27	population	_	NN	NN	_	24	PMOD	_	_
28	.	_	.	.	_	12	P	_	_

1	In	_	IN	IN	_	16	ADV	_	_
2	fact	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	16	P	_	_
4	transgenic	_	JJ	JJ	_	7	NMOD	_	_
5	bone	_	NN	NN	_	7	NMOD	_	_
6	marrow	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	16	SBJ	_	_
8	cocultured	_	VBN	VBN	_	7	NMOD	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	a	_	DT	DT	_	15	NMOD	_	_
11	bone	_	NN	NN	_	15	NMOD	_	_
12	marrow-derived	_	JJ	JJ	_	11	AMOD	_	_
13	stromal	_	JJ	JJ	_	15	NMOD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	line	_	NN	NN	_	9	PMOD	_	_
16	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
17	an	_	DT	DT	_	21	NMOD	_	_
18	altered	_	JJ	JJ	_	21	NMOD	_	_
19	B-cell	_	NN	NN	_	21	NMOD	_	_
20	maturation	_	NN	NN	_	21	NMOD	_	_
21	pattern	_	NN	NN	_	16	OBJ	_	_
22	.	_	.	.	_	16	P	_	_

1	Identification	_	NN	NN	_	0	ROOT-FRAG	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	cloning	_	NN	NN	_	1	COORD	_	_
4	of	_	IN	IN	_	1	NMOD	_	_
5	TCF-1	_	NN	NN	_	4	PMOD	_	_
6	,	_	,	,	_	5	P	_	_
7	a	_	DT	DT	_	11	NMOD	_	_
8	T	_	NN	NN	_	11	NMOD	_	_
9	lymphocyte-specific	_	JJ	JJ	_	8	AMOD	_	_
10	transcription	_	NN	NN	_	11	NMOD	_	_
11	factor	_	NN	NN	_	5	NMOD	_	_
12	containing	_	VBG	VBG	_	11	NMOD	_	_
13	a	_	DT	DT	_	16	NMOD	_	_
14	sequence-specific	_	JJ	JJ	_	16	NMOD	_	_
15	HMG	_	NN	NN	_	16	NMOD	_	_
16	box	_	NN	NN	_	12	OBJ	_	_
17	.	_	.	.	_	1	P	_	_

1	CD3-epsilon	_	NN	NN	_	2	NMOD	_	_
2	expression	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	controlled	_	VBN	VBN	_	3	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	a	_	DT	DT	_	11	NMOD	_	_
7	downstream	_	JJ	JJ	_	11	NMOD	_	_
8	T	_	NN	NN	_	11	NMOD	_	_
9	lymphocyte-specific	_	JJ	JJ	_	8	AMOD	_	_
10	enhancer	_	NN	NN	_	11	NMOD	_	_
11	element	_	NN	NN	_	5	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	identification	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	a	_	DT	DT	_	10	NMOD	_	_
7	T	_	NN	NN	_	10	NMOD	_	_
8	cell-specific	_	JJ	JJ	_	7	AMOD	_	_
9	transcription	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	5	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	TCF-1	_	NN	NN	_	10	NMOD	_	_
13	,	_	,	,	_	10	P	_	_
14	binding	_	VBG	VBG	_	10	NMOD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	this	_	DT	DT	_	17	NMOD	_	_
17	element	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	multimerized	_	JJ	JJ	_	4	NMOD	_	_
3	recognition	_	NN	NN	_	4	NMOD	_	_
4	motif	_	NN	NN	_	7	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	TCF-1	_	NN	NN	_	5	PMOD	_	_
7	constituted	_	VBD	VBD	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	11	NMOD	_	_
9	T	_	NN	NN	_	11	NMOD	_	_
10	cell-specific	_	JJ	JJ	_	9	AMOD	_	_
11	enhancer	_	NN	NN	_	7	OBJ	_	_
12	.	_	.	.	_	7	P	_	_

1	Subsequent	_	JJ	JJ	_	2	NMOD	_	_
2	cloning	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	TCF-1	_	NN	NN	_	3	PMOD	_	_
5	identified	_	VBD	VBD	_	0	ROOT-S	_	_
6	three	_	CD	CD	_	8	NMOD	_	_
7	splice	_	NN	NN	_	8	NMOD	_	_
8	alternatives	_	NNS	NNS	_	5	OBJ	_	_
9	.	_	.	.	_	5	P	_	_

1	TCF-1	_	NN	NN	_	2	SBJ	_	_
2	contained	_	VBD	VBD	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	7	NMOD	_	_
4	single	_	JJ	JJ	_	7	NMOD	_	_
5	DNA-binding	_	JJ	JJ	_	7	NMOD	_	_
6	HMG	_	NN	NN	_	7	NMOD	_	_
7	box	_	NN	NN	_	2	OBJ	_	_
8	most	_	RBS	RBS	_	9	AMOD	_	_
9	closely	_	RB	RB	_	7	NMOD	_	_
10	related	_	JJ	JJ	_	9	AMOD	_	_
11	to	_	TO	TO	_	9	AMOD	_	_
12	similar	_	JJ	JJ	_	13	NMOD	_	_
13	boxes	_	NNS	NNS	_	11	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	20	NMOD	_	_
16	putative	_	JJ	JJ	_	20	NMOD	_	_
17	mammalian	_	JJ	JJ	_	20	NMOD	_	_
18	sex-determining	_	JJ	JJ	_	20	NMOD	_	_
19	gene	_	NN	NN	_	20	NMOD	_	_
20	SRY	_	NN	NN	_	14	PMOD	_	_
21	and	_	CC	CC	_	14	CC	_	_
22	in	_	IN	IN	_	14	COORD	_	_
23	the	_	DT	DT	_	29	NMOD	_	_
24	Schizosaccharomyces	_	FW	FW	_	29	NMOD	_	_
25	pombe	_	FW	FW	_	29	NMOD	_	_
26	Mc	_	NN	NN	_	29	NMOD	_	_
27	mating	_	NN	NN	_	29	NMOD	_	_
28	type	_	NN	NN	_	29	NMOD	_	_
29	gene	_	NN	NN	_	22	PMOD	_	_
30	.	_	.	.	_	2	P	_	_

1	TCF-1	_	NN	NN	_	3	SBJ	_	_
2	mRNA	_	NN	NN	_	1	AMOD	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	expressed	_	VBN	VBN	_	3	VC	_	_
5	uniquely	_	RB	RB	_	4	ADV	_	_
6	in	_	IN	IN	_	4	ADV	_	_
7	T	_	NN	NN	_	8	NMOD	_	_
8	lymphocytes	_	NNS	NNS	_	6	PMOD	_	_
9	.	_	.	.	_	3	P	_	_

1	Upon	_	IN	IN	_	8	TMP	_	_
2	cotransfection	_	NN	NN	_	1	PMOD	_	_
3	into	_	IN	IN	_	2	NMOD	_	_
4	non-T	_	JJ	JJ	_	5	NMOD	_	_
5	cells	_	NNS	NNS	_	3	PMOD	_	_
6	,	_	,	,	_	8	P	_	_
7	TCF-1	_	NN	NN	_	8	SBJ	_	_
8	could	_	MD	MD	_	0	ROOT-S	_	_
9	transactivate	_	VB	VB	_	8	VC	_	_
10	through	_	IN	IN	_	9	ADV	_	_
11	its	_	PRP$	PRP$	_	13	NMOD	_	_
12	cognate	_	JJ	JJ	_	13	NMOD	_	_
13	motif	_	NN	NN	_	10	PMOD	_	_
14	.	_	.	.	_	8	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	identify	_	VBP	VBP	_	0	ROOT-S	_	_
4	TCF-1	_	NN	NN	_	3	OBJ	_	_
5	as	_	IN	IN	_	3	ADV	_	_
6	a	_	DT	DT	_	10	NMOD	_	_
7	T	_	NN	NN	_	10	NMOD	_	_
8	cell-specific	_	JJ	JJ	_	7	AMOD	_	_
9	transcription	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	5	PMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	which	_	WDT	WDT	_	13	SBJ	_	_
13	might	_	MD	MD	_	10	NMOD	_	_
14	play	_	VB	VB	_	13	VC	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	role	_	NN	NN	_	14	OBJ	_	_
17	in	_	IN	IN	_	14	ADV	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	establishment	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	25	NMOD	_	_
22	mature	_	JJ	JJ	_	25	NMOD	_	_
23	T	_	NN	NN	_	25	NMOD	_	_
24	cell	_	NN	NN	_	25	NMOD	_	_
25	phenotype	_	NN	NN	_	20	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	Expression	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	c-jun	_	NN	NN	_	10	NMOD	_	_
4	,	_	,	,	_	3	P	_	_
5	jun	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	3	COORD	_	_
7	and	_	CC	CC	_	3	CC	_	_
8	jun	_	NN	NN	_	9	NMOD	_	_
9	D	_	NN	NN	_	3	COORD	_	_
10	proto-oncogenes	_	NNS	NNS	_	2	PMOD	_	_
11	in	_	IN	IN	_	1	NMOD	_	_
12	human	_	JJ	JJ	_	14	NMOD	_	_
13	peripheral-blood	_	JJ	JJ	_	14	NMOD	_	_
14	granulocytes	_	NNS	NNS	_	11	PMOD	_	_
15	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	purified	_	VBN	VBN	_	8	NMOD	_	_
6	human	_	JJ	JJ	_	8	NMOD	_	_
7	peripheral-blood	_	JJ	JJ	_	8	NMOD	_	_
8	granulocytes	_	NNS	NNS	_	9	SBJ	_	_
9	express	_	VBP	VBP	_	4	VMOD	_	_
10	constitutively	_	RB	RB	_	11	AMOD	_	_
11	significant	_	JJ	JJ	_	12	NMOD	_	_
12	levels	_	NNS	NNS	_	9	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	proto-oncogenes	_	NNS	NNS	_	22	NMOD	_	_
15	c-jun	_	NN	NN	_	14	NMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	jun	_	NN	NN	_	18	NMOD	_	_
18	B	_	NN	NN	_	15	COORD	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	jun	_	NN	NN	_	21	NMOD	_	_
21	D	_	NN	NN	_	15	COORD	_	_
22	mRNA	_	NN	NN	_	13	PMOD	_	_
23	.	_	.	.	_	2	P	_	_

1	Upon	_	IN	IN	_	26	ADV	_	_
2	functional	_	JJ	JJ	_	3	NMOD	_	_
3	activation	_	NN	NN	_	1	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	granulocytes	_	NNS	NNS	_	4	PMOD	_	_
6	by	_	IN	IN	_	3	NMOD	_	_
7	4	_	CD	CD	_	10	NMOD	_	_
8	beta-phorbol	_	NN	NN	_	10	NMOD	_	_
9	12-myristate	_	NN	NN	_	10	NMOD	_	_
10	13-acetate	_	NN	NN	_	6	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	PMA	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	,	_	,	,	_	26	P	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	levels	_	NNS	NNS	_	26	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	c-jun	_	NN	NN	_	25	NMOD	_	_
19	,	_	,	,	_	18	P	_	_
20	jun	_	NN	NN	_	21	NMOD	_	_
21	B	_	NN	NN	_	18	COORD	_	_
22	and	_	CC	CC	_	18	CC	_	_
23	jun	_	NN	NN	_	24	NMOD	_	_
24	D	_	NN	NN	_	18	COORD	_	_
25	transcripts	_	NNS	NNS	_	17	PMOD	_	_
26	were	_	VBD	VBD	_	0	ROOT-S	_	_
27	increased	_	VBN	VBN	_	26	VC	_	_
28	.	_	.	.	_	26	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	three	_	CD	CD	_	4	NMOD	_	_
3	jun	_	NN	NN	_	4	NMOD	_	_
4	genes	_	NNS	NNS	_	5	SBJ	_	_
5	showed	_	VBD	VBD	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	similar	_	JJ	JJ	_	9	NMOD	_	_
8	time	_	NN	NN	_	9	NMOD	_	_
9	course	_	NN	NN	_	5	IOBJ	_	_
10	in	_	IN	IN	_	5	ADV	_	_
11	their	_	PRP$	PRP$	_	12	NMOD	_	_
12	induction	_	NN	NN	_	10	PMOD	_	_
13	by	_	IN	IN	_	12	NMOD	_	_
14	PMA	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	5	P	_	_
16	maximal	_	JJ	JJ	_	18	NMOD	_	_
17	mRNA	_	NN	NN	_	18	NMOD	_	_
18	levels	_	NNS	NNS	_	19	SBJ	_	_
19	being	_	VBG	VBG	_	5	OBJ	_	_
20	reached	_	VBN	VBN	_	19	VC	_	_
21	after	_	IN	IN	_	20	TMP	_	_
22	60	_	CD	CD	_	23	NMOD	_	_
23	min	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	induction	_	NN	NN	_	24	PMOD	_	_
26	.	_	.	.	_	5	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	expression	_	NN	NN	_	15	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	c-jun	_	NN	NN	_	14	NMOD	_	_
8	,	_	,	,	_	7	P	_	_
9	jun	_	NN	NN	_	10	NMOD	_	_
10	B	_	NN	NN	_	7	COORD	_	_
11	and	_	CC	CC	_	7	CC	_	_
12	jun	_	NN	NN	_	13	NMOD	_	_
13	D	_	NN	NN	_	7	COORD	_	_
14	genes	_	NNS	NNS	_	6	PMOD	_	_
15	might	_	MD	MD	_	4	VMOD	_	_
16	be	_	VB	VB	_	15	VC	_	_
17	involved	_	VBN	VBN	_	16	VC	_	_
18	in	_	IN	IN	_	17	ADV	_	_
19	terminal	_	JJ	JJ	_	21	NMOD	_	_
20	granulocyte	_	NN	NN	_	21	NMOD	_	_
21	differentiation	_	NN	NN	_	18	PMOD	_	_
22	or	_	CC	CC	_	18	CC	_	_
23	in	_	IN	IN	_	18	COORD	_	_
24	regulating	_	VBG	VBG	_	23	PMOD	_	_
25	granulocyte	_	NN	NN	_	26	NMOD	_	_
26	functionality	_	NN	NN	_	24	OBJ	_	_
27	.	_	.	.	_	3	P	_	_

1	Platelet-activating	_	JJ	JJ	_	2	NMOD	_	_
2	factor	_	NN	NN	_	3	SBJ	_	_
3	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	phospholipid	_	JJ	JJ	_	5	NMOD	_	_
5	turnover	_	NN	NN	_	3	OBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	calcium	_	NN	NN	_	8	NMOD	_	_
8	flux	_	NN	NN	_	5	COORD	_	_
9	,	_	,	,	_	5	P	_	_
10	arachidonic	_	JJ	JJ	_	12	NMOD	_	_
11	acid	_	NN	NN	_	12	NMOD	_	_
12	liberation	_	NN	NN	_	5	COORD	_	_
13	,	_	,	,	_	5	P	_	_
14	eicosanoid	_	NN	NN	_	15	NMOD	_	_
15	generation	_	NN	NN	_	5	COORD	_	_
16	,	_	,	,	_	5	P	_	_
17	and	_	CC	CC	_	5	CC	_	_
18	oncogene	_	JJ	JJ	_	19	NMOD	_	_
19	expression	_	NN	NN	_	5	COORD	_	_
20	in	_	IN	IN	_	5	NMOD	_	_
21	a	_	DT	DT	_	25	NMOD	_	_
22	human	_	JJ	JJ	_	25	NMOD	_	_
23	B	_	NN	NN	_	25	NMOD	_	_
24	cell	_	NN	NN	_	25	NMOD	_	_
25	line	_	NN	NN	_	20	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	Platelet-activating	_	JJ	JJ	_	2	NMOD	_	_
2	factor	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	potent	_	JJ	JJ	_	6	NMOD	_	_
6	mediator	_	NN	NN	_	3	PRD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	inflammatory	_	JJ	JJ	_	10	NMOD	_	_
10	response	_	NN	NN	_	7	PMOD	_	_
11	.	_	.	.	_	3	P	_	_

1	Studies	_	NNS	NNS	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	actions	_	NNS	NNS	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	platelet-activating	_	JJ	JJ	_	7	NMOD	_	_
7	factor	_	NN	NN	_	5	PMOD	_	_
8	have	_	VBP	VBP	_	0	ROOT-S	_	_
9	centered	_	VBN	VBN	_	8	VC	_	_
10	mainly	_	RB	RB	_	11	DEP	_	_
11	around	_	IN	IN	_	9	ADV	_	_
12	neutrophils	_	NNS	NNS	_	11	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	monocytes	_	NNS	NNS	_	12	COORD	_	_
15	,	_	,	,	_	12	P	_	_
16	and	_	CC	CC	_	12	CC	_	_
17	platelets	_	NNS	NNS	_	12	COORD	_	_
18	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	report	_	NN	NN	_	1	PMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	begin	_	VBP	VBP	_	0	ROOT-S	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	uncover	_	VB	VB	_	5	OBJ	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	influence	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	platelet-activating	_	NN	NN	_	12	NMOD	_	_
12	factor	_	NN	NN	_	10	PMOD	_	_
13	on	_	IN	IN	_	9	NMOD	_	_
14	B	_	NN	NN	_	15	NMOD	_	_
15	lymphocytes	_	NNS	NNS	_	13	PMOD	_	_
16	.	_	.	.	_	5	P	_	_

1	Employing	_	VBG	VBG	_	11	ADV	_	_
2	the	_	DT	DT	_	8	NMOD	_	_
3	EBV-transformed	_	JJ	JJ	_	8	NMOD	_	_
4	human	_	JJ	JJ	_	8	NMOD	_	_
5	B	_	NN	NN	_	8	NMOD	_	_
6	cell	_	NN	NN	_	8	NMOD	_	_
7	line	_	NN	NN	_	8	NMOD	_	_
8	SKW6.4	_	NN	NN	_	1	OBJ	_	_
9	,	_	,	,	_	11	P	_	_
10	we	_	PRP	PRP	_	11	SBJ	_	_
11	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
12	that	_	IN	IN	_	11	OBJ	_	_
13	platelet-activating	_	JJ	JJ	_	14	NMOD	_	_
14	factor	_	NN	NN	_	16	SBJ	_	_
15	significantly	_	RB	RB	_	16	ADV	_	_
16	alters	_	VBZ	VBZ	_	12	VMOD	_	_
17	membrane	_	NN	NN	_	19	NMOD	_	_
18	phospholipid	_	JJ	JJ	_	19	NMOD	_	_
19	metabolism	_	NN	NN	_	16	OBJ	_	_
20	indicated	_	VBN	VBN	_	19	NMOD	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	incorporation	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	32P	_	NN	NN	_	24	PMOD	_	_
26	into	_	IN	IN	_	23	NMOD	_	_
27	phosphatidylcholine	_	NN	NN	_	26	PMOD	_	_
28	,	_	,	,	_	27	P	_	_
29	phosphatidylinositol	_	NN	NN	_	27	COORD	_	_
30	,	_	,	,	_	27	P	_	_
31	and	_	CC	CC	_	27	CC	_	_
32	phosphatidic	_	JJ	JJ	_	33	NMOD	_	_
33	acid	_	NN	NN	_	27	COORD	_	_
34	but	_	CC	CC	_	26	CC	_	_
35	not	_	RB	RB	_	37	PMOD	_	_
36	significantly	_	RB	RB	_	35	AMOD	_	_
37	into	_	IN	IN	_	26	COORD	_	_
38	phosphatidylethanolamine	_	NN	NN	_	37	PMOD	_	_
39	at	_	IN	IN	_	23	NMOD	_	_
40	concentrations	_	NNS	NNS	_	39	PMOD	_	_
41	ranging	_	VBG	VBG	_	40	NMOD	_	_
42	from	_	IN	IN	_	41	ADV	_	_
43	10-LRB--9-RRB-	_	CD	CD	_	46	NMOD	_	_
44	to	_	TO	TO	_	42	PMOD	_	_
45	10-LRB--6-RRB-	_	CD	CD	_	44	NMOD	_	_
46	M	_	NN	NN	_	42	PMOD	_	_
47	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	inactive	_	JJ	JJ	_	3	NMOD	_	_
3	precursor	_	NN	NN	_	16	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	lyso-platelet-activating	_	JJ	JJ	_	6	NMOD	_	_
6	factor	_	NN	NN	_	3	NMOD	_	_
7	,	_	,	,	_	3	P	_	_
8	at	_	IN	IN	_	3	NMOD	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	concentration	_	NN	NN	_	8	PMOD	_	_
11	as	_	RB	RB	_	12	AMOD	_	_
12	high	_	JJ	JJ	_	10	NMOD	_	_
13	as	_	IN	IN	_	12	AMOD	_	_
14	10-LRB--7-RRB-	_	CD	CD	_	15	NMOD	_	_
15	M	_	NN	NN	_	13	PMOD	_	_
16	had	_	VBD	VBD	_	0	ROOT-S	_	_
17	no	_	DT	DT	_	18	NMOD	_	_
18	effect	_	NN	NN	_	16	OBJ	_	_
19	on	_	IN	IN	_	16	ADV	_	_
20	any	_	DT	DT	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	membrane	_	NN	NN	_	24	NMOD	_	_
24	phospholipids	_	NNS	NNS	_	21	PMOD	_	_
25	.	_	.	.	_	16	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	platelet-activating	_	JJ	JJ	_	6	NMOD	_	_
6	factor	_	NN	NN	_	12	SBJ	_	_
7	from	_	IN	IN	_	6	NMOD	_	_
8	10-LRB--12-RRB-	_	CD	CD	_	10	DEP	_	_
9	to	_	TO	TO	_	10	DEP	_	_
10	10-LRB--6-RRB-	_	CD	CD	_	11	NMOD	_	_
11	M	_	NN	NN	_	7	PMOD	_	_
12	induced	_	VBD	VBD	_	4	VMOD	_	_
13	rapid	_	JJ	JJ	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	significant	_	JJ	JJ	_	13	COORD	_	_
16	elevation	_	NN	NN	_	12	OBJ	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	intracellular	_	JJ	JJ	_	20	NMOD	_	_
19	calcium	_	NN	NN	_	20	NMOD	_	_
20	levels	_	NNS	NNS	_	17	PMOD	_	_
21	,	_	,	,	_	12	P	_	_
22	whereas	_	IN	IN	_	12	COORD	_	_
23	lyso-platelet-activating	_	JJ	JJ	_	24	NMOD	_	_
24	factor	_	NN	NN	_	25	SBJ	_	_
25	was	_	VBD	VBD	_	12	COORD	_	_
26	again	_	RB	RB	_	25	ADV	_	_
27	ineffective	_	JJ	JJ	_	25	PRD	_	_
28	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	further	_	RB	RB	_	3	ADV	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	impact	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	platelet-activating	_	JJ	JJ	_	8	NMOD	_	_
8	factor	_	NN	NN	_	6	PMOD	_	_
9	binding	_	VBG	VBG	_	8	NMOD	_	_
10	to	_	TO	TO	_	9	ADV	_	_
11	B	_	NN	NN	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	by	_	IN	IN	_	3	ADV	_	_
14	measuring	_	VBG	VBG	_	13	PMOD	_	_
15	platelet-activating	_	JJ	JJ	_	16	NMOD	_	_
16	factor	_	NN	NN	_	17	AMOD	_	_
17	induced	_	JJ	JJ	_	20	NMOD	_	_
18	arachidonic	_	JJ	JJ	_	20	NMOD	_	_
19	acid	_	NN	NN	_	20	NMOD	_	_
20	release	_	NN	NN	_	14	OBJ	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	5-hydroxyeicosatetraenoic	_	JJ	JJ	_	24	NMOD	_	_
23	acid	_	NN	NN	_	24	NMOD	_	_
24	production	_	NN	NN	_	20	COORD	_	_
25	.	_	.	.	_	3	P	_	_

1	Moreover	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	platelet-activating	_	JJ	JJ	_	4	NMOD	_	_
4	factor	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	capable	_	JJ	JJ	_	5	PRD	_	_
7	of	_	IN	IN	_	6	AMOD	_	_
8	inducing	_	VBG	VBG	_	7	PMOD	_	_
9	transcription	_	NN	NN	_	8	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	nuclear	_	JJ	JJ	_	13	NMOD	_	_
13	proto-oncogenes	_	NNS	NNS	_	10	PMOD	_	_
14	c-fos	_	NN	NN	_	13	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	c-jun	_	NN	NN	_	14	COORD	_	_
17	.	_	.	.	_	5	P	_	_

1	Finally	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	explored	_	VBD	VBD	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	possible	_	JJ	JJ	_	6	NMOD	_	_
6	role	_	NN	NN	_	3	IOBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	5-hydroxyeicosatetraenoic	_	JJ	JJ	_	9	NMOD	_	_
9	acid	_	NN	NN	_	7	PMOD	_	_
10	as	_	IN	IN	_	6	NMOD	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	regulator	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	arachidonic	_	JJ	JJ	_	16	NMOD	_	_
15	acid	_	NN	NN	_	16	NMOD	_	_
16	liberation	_	NN	NN	_	13	PMOD	_	_
17	demonstrating	_	VBG	VBG	_	3	OBJ	_	_
18	that	_	IN	IN	_	17	OBJ	_	_
19	endogenous	_	JJ	JJ	_	21	NMOD	_	_
20	5-lipoxygenase	_	NN	NN	_	21	NMOD	_	_
21	activity	_	NN	NN	_	22	SBJ	_	_
22	modulates	_	VBZ	VBZ	_	18	VMOD	_	_
23	platelet-activating	_	JJ	JJ	_	24	NMOD	_	_
24	factor	_	NN	NN	_	25	AMOD	_	_
25	induced	_	JJ	JJ	_	28	NMOD	_	_
26	arachidonic	_	JJ	JJ	_	28	NMOD	_	_
27	acid	_	NN	NN	_	28	NMOD	_	_
28	release	_	NN	NN	_	22	IOBJ	_	_
29	perhaps	_	RB	RB	_	30	ADV	_	_
30	acting	_	VBG	VBG	_	22	OBJ	_	_
31	at	_	IN	IN	_	30	ADV	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	level	_	NN	NN	_	31	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	phospholipase	_	NN	NN	_	36	NMOD	_	_
36	A2	_	NN	NN	_	34	PMOD	_	_
37	.	_	.	.	_	3	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	summary	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	6	P	_	_
4	platelet-activating	_	JJ	JJ	_	5	NMOD	_	_
5	factor	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	shown	_	VBN	VBN	_	6	VC	_	_
8	here	_	RB	RB	_	7	ADV	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	have	_	VB	VB	_	7	OBJ	_	_
11	a	_	DT	DT	_	15	NMOD	_	_
12	direct	_	JJ	JJ	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	profound	_	JJ	JJ	_	12	COORD	_	_
15	effect	_	NN	NN	_	10	OBJ	_	_
16	on	_	IN	IN	_	10	ADV	_	_
17	a	_	DT	DT	_	21	NMOD	_	_
18	pure	_	JJ	JJ	_	21	NMOD	_	_
19	B	_	NN	NN	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	line	_	NN	NN	_	16	PMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	novel	_	JJ	JJ	_	3	NMOD	_	_
3	HIV-1	_	NN	NN	_	0	ROOT-FRAG	_	_
4	isolate	_	JJ	JJ	_	3	NMOD	_	_
5	containing	_	VBG	VBG	_	3	NMOD	_	_
6	alterations	_	NNS	NNS	_	5	OBJ	_	_
7	affecting	_	VBG	VBG	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	NF-kappa	_	NN	NN	_	11	NMOD	_	_
10	B	_	NN	NN	_	11	NMOD	_	_
11	element	_	NN	NN	_	7	OBJ	_	_
12	.	_	.	.	_	3	P	_	_

1	Three	_	CD	CD	_	3	NMOD	_	_
2	molecular	_	JJ	JJ	_	3	NMOD	_	_
3	clones	_	NNS	NNS	_	16	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	HIV-1	_	NN	NN	_	4	PMOD	_	_
6	,	_	,	,	_	3	P	_	_
7	derived	_	VBN	VBN	_	3	NMOD	_	_
8	from	_	IN	IN	_	7	ADV	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	single	_	JJ	JJ	_	11	NMOD	_	_
11	isolate	_	NN	NN	_	8	PMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	AL1	_	NN	NN	_	11	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	,	_	,	,	_	3	P	_	_
16	exhibited	_	VBD	VBD	_	0	ROOT-S	_	_
17	distinct	_	JJ	JJ	_	21	NMOD	_	_
18	replicative	_	JJ	JJ	_	21	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	cytopathic	_	JJ	JJ	_	18	COORD	_	_
21	properties	_	NNS	NNS	_	16	OBJ	_	_
22	during	_	IN	IN	_	16	TMP	_	_
23	propagation	_	NN	NN	_	22	PMOD	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	a	_	DT	DT	_	29	NMOD	_	_
26	human	_	JJ	JJ	_	29	NMOD	_	_
27	T	_	NN	NN	_	29	NMOD	_	_
28	cell	_	NN	NN	_	29	NMOD	_	_
29	line	_	NN	NN	_	24	PMOD	_	_
30	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	phenotypic	_	JJ	JJ	_	3	NMOD	_	_
3	differences	_	NNS	NNS	_	5	SBJ	_	_
4	observed	_	VBN	VBN	_	3	NMOD	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	attributable	_	JJ	JJ	_	5	PRD	_	_
7	,	_	,	,	_	5	P	_	_
8	in	_	IN	IN	_	5	ADV	_	_
9	large	_	JJ	JJ	_	10	NMOD	_	_
10	part	_	NN	NN	_	8	PMOD	_	_
11	,	_	,	,	_	5	P	_	_
12	to	_	TO	TO	_	6	AMOD	_	_
13	changes	_	NNS	NNS	_	12	PMOD	_	_
14	affecting	_	VBG	VBG	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	viral	_	JJ	JJ	_	17	NMOD	_	_
17	LTR	_	NN	NN	_	14	OBJ	_	_
18	.	_	.	.	_	5	P	_	_

1	Nucleotide	_	NN	NN	_	2	NMOD	_	_
2	sequence	_	NN	NN	_	6	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	PCR	_	NN	NN	_	5	NMOD	_	_
5	analyses	_	NNS	NNS	_	2	COORD	_	_
6	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	presence	_	NN	NN	_	6	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	novel	_	JJ	JJ	_	11	NMOD	_	_
11	duplications	_	NNS	NNS	_	9	PMOD	_	_
12	or	_	CC	CC	_	11	CC	_	_
13	deletions	_	NNS	NNS	_	11	COORD	_	_
14	involving	_	VBG	VBG	_	11	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	NF-kappa	_	NN	NN	_	18	NMOD	_	_
17	B	_	NN	NN	_	18	NMOD	_	_
18	motif	_	NN	NN	_	14	OBJ	_	_
19	.	_	.	.	_	6	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	changes	_	NNS	NNS	_	7	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	enhancer	_	NN	NN	_	6	NMOD	_	_
6	element	_	NN	NN	_	3	PMOD	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	identified	_	VBN	VBN	_	7	VC	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	14	NMOD	_	_
11	original	_	JJ	JJ	_	14	NMOD	_	_
12	AL1	_	NN	NN	_	14	NMOD	_	_
13	virus	_	NN	NN	_	14	NMOD	_	_
14	stock	_	NN	NN	_	9	PMOD	_	_
15	.	_	.	.	_	7	P	_	_

1	Subcloning	_	NN	NN	_	13	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	variant	_	JJ	JJ	_	7	NMOD	_	_
5	NF-kappa	_	NN	NN	_	7	NMOD	_	_
6	B	_	NN	NN	_	7	NMOD	_	_
7	segments	_	NNS	NNS	_	2	PMOD	_	_
8	into	_	IN	IN	_	1	NMOD	_	_
9	LTR-driven	_	JJ	JJ	_	12	NMOD	_	_
10	CAT	_	NN	NN	_	12	NMOD	_	_
11	expression	_	NN	NN	_	12	NMOD	_	_
12	vectors	_	NNS	NNS	_	8	PMOD	_	_
13	confirmed	_	VBD	VBD	_	0	ROOT-S	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	correlation	_	NN	NN	_	13	OBJ	_	_
16	between	_	IN	IN	_	15	NMOD	_	_
17	promoter	_	JJ	JJ	_	18	NMOD	_	_
18	activity	_	NN	NN	_	16	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	replicative\/cytopathic	_	JJ	JJ	_	21	NMOD	_	_
21	capacity	_	NN	NN	_	18	COORD	_	_
22	.	_	.	.	_	13	P	_	_

1	Kappa	_	NN	NN	_	4	NMOD	_	_
2	B	_	NN	NN	_	4	NMOD	_	_
3	binding	_	NN	NN	_	4	NMOD	_	_
4	proteins	_	NNS	NNS	_	5	SBJ	_	_
5	are	_	VBP	VBP	_	0	ROOT-S	_	_
6	constitutively	_	RB	RB	_	5	ADV	_	_
7	expressed	_	VBN	VBN	_	5	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	an	_	DT	DT	_	15	NMOD	_	_
10	IL-2	_	NN	NN	_	15	NMOD	_	_
11	autocrine	_	NN	NN	_	15	NMOD	_	_
12	human	_	JJ	JJ	_	15	NMOD	_	_
13	T	_	NN	NN	_	15	NMOD	_	_
14	cell	_	NN	NN	_	15	NMOD	_	_
15	line	_	NN	NN	_	8	PMOD	_	_
16	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	IL-2	_	NN	NN	_	7	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	IL-2-R	_	NN	NN	_	6	NMOD	_	_
6	alpha	_	NN	NN	_	2	COORD	_	_
7	genes	_	NNS	NNS	_	8	SBJ	_	_
8	are	_	VBP	VBP	_	0	ROOT-S	_	_
9	both	_	DT	DT	_	10	VMOD	_	_
10	expressed	_	VBN	VBN	_	8	VC	_	_
11	transiently	_	RB	RB	_	10	ADV	_	_
12	in	_	IN	IN	_	10	ADV	_	_
13	normal	_	JJ	JJ	_	15	NMOD	_	_
14	T	_	NN	NN	_	15	NMOD	_	_
15	lymphocytes	_	NNS	NNS	_	12	PMOD	_	_
16	after	_	IN	IN	_	10	TMP	_	_
17	Ag	_	NN	NN	_	20	NMOD	_	_
18	or	_	CC	CC	_	17	CC	_	_
19	mitogen	_	NN	NN	_	17	COORD	_	_
20	activation	_	NN	NN	_	16	PMOD	_	_
21	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	13	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	13	P	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	human	_	JJ	JJ	_	8	NMOD	_	_
6	T	_	NN	NN	_	8	NMOD	_	_
7	cell	_	NN	NN	_	8	NMOD	_	_
8	line	_	NN	NN	_	13	SBJ	_	_
9	,	_	,	,	_	8	P	_	_
10	IARC	_	NN	NN	_	8	NMOD	_	_
11	301	_	CD	CD	_	10	NMOD	_	_
12	,	_	,	,	_	8	P	_	_
13	expresses	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	these	_	DT	DT	_	16	NMOD	_	_
15	two	_	CD	CD	_	16	NMOD	_	_
16	genes	_	NNS	NNS	_	13	OBJ	_	_
17	constitutively	_	RB	RB	_	13	ADV	_	_
18	and	_	CC	CC	_	13	CC	_	_
19	we	_	PRP	PRP	_	20	SBJ	_	_
20	have	_	VBP	VBP	_	13	COORD	_	_
21	previously	_	RB	RB	_	20	TMP	_	_
22	demonstrated	_	VBN	VBN	_	20	VC	_	_
23	that	_	IN	IN	_	22	OBJ	_	_
24	its	_	PRP$	PRP$	_	25	NMOD	_	_
25	growth	_	NN	NN	_	26	SBJ	_	_
26	depends	_	VBZ	VBZ	_	23	VMOD	_	_
27	on	_	IN	IN	_	26	ADV	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	autocrine	_	JJ	JJ	_	30	NMOD	_	_
30	production	_	NN	NN	_	27	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	this	_	DT	DT	_	36	NMOD	_	_
33	T	_	NN	NN	_	36	NMOD	_	_
34	cell	_	NN	NN	_	36	NMOD	_	_
35	growth	_	NN	NN	_	36	NMOD	_	_
36	factor	_	NN	NN	_	31	PMOD	_	_
37	and	_	CC	CC	_	36	CC	_	_
38	high	_	JJ	JJ	_	40	NMOD	_	_
39	affinity	_	NN	NN	_	40	NMOD	_	_
40	IL-2R	_	NN	NN	_	36	COORD	_	_
41	.	_	.	.	_	13	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	dissect	_	VB	VB	_	26	ADV	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	molecular	_	JJ	JJ	_	5	NMOD	_	_
5	basis	_	NN	NN	_	2	OBJ	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	unusual	_	JJ	JJ	_	10	NMOD	_	_
9	persistent	_	JJ	JJ	_	10	NMOD	_	_
10	expression	_	NN	NN	_	6	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	17	NMOD	_	_
13	IL-2	_	NN	NN	_	17	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	IL-2-R	_	NN	NN	_	16	NMOD	_	_
16	alpha	_	NN	NN	_	13	COORD	_	_
17	genes	_	NNS	NNS	_	11	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	these	_	DT	DT	_	23	NMOD	_	_
20	IARC	_	NN	NN	_	23	NMOD	_	_
21	301	_	CD	CD	_	23	NMOD	_	_
22	T	_	NN	NN	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	18	PMOD	_	_
24	,	_	,	,	_	26	P	_	_
25	we	_	PRP	PRP	_	26	SBJ	_	_
26	have	_	VBP	VBP	_	0	ROOT-S	_	_
27	analyzed	_	VBN	VBN	_	26	VC	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	interactions	_	NNS	NNS	_	27	IOBJ	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	constitutively	_	RB	RB	_	32	AMOD	_	_
32	expressed	_	VBN	VBN	_	34	NMOD	_	_
33	nuclear	_	JJ	JJ	_	34	NMOD	_	_
34	proteins	_	NNS	NNS	_	30	PMOD	_	_
35	with	_	IN	IN	_	29	NMOD	_	_
36	the	_	DT	DT	_	39	NMOD	_	_
37	5'	_	JJ	JJ	_	39	NMOD	_	_
38	flanking	_	JJ	JJ	_	39	NMOD	_	_
39	regions	_	NNS	NNS	_	35	PMOD	_	_
40	of	_	IN	IN	_	39	NMOD	_	_
41	the	_	DT	DT	_	46	NMOD	_	_
42	IL-2	_	NN	NN	_	46	NMOD	_	_
43	and	_	CC	CC	_	42	CC	_	_
44	IL-2-R	_	NN	NN	_	45	NMOD	_	_
45	alpha	_	NN	NN	_	42	COORD	_	_
46	genes	_	NNS	NNS	_	40	PMOD	_	_
47	using	_	VBG	VBG	_	27	OBJ	_	_
48	both	_	DT	DT	_	51	NMOD	_	_
49	DNase	_	NN	NN	_	51	NMOD	_	_
50	I	_	CD	CD	_	51	NMOD	_	_
51	footprinting	_	NN	NN	_	55	NMOD	_	_
52	and	_	CC	CC	_	51	CC	_	_
53	gel	_	NN	NN	_	54	NMOD	_	_
54	retardation	_	NN	NN	_	51	COORD	_	_
55	techniques	_	NNS	NNS	_	47	OBJ	_	_
56	.	_	.	.	_	26	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	a	_	DT	DT	_	6	NMOD	_	_
6	region	_	NN	NN	_	34	SBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	both	_	DT	DT	_	9	NMOD	_	_
9	genes	_	NNS	NNS	_	7	PMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	-276	_	CD	CD	_	6	PRN	_	_
12	to	_	TO	TO	_	11	NMOD	_	_
13	-250	_	CD	CD	_	11	NMOD	_	_
14	for	_	IN	IN	_	11	NMOD	_	_
15	IL-2-R	_	NN	NN	_	16	NMOD	_	_
16	alpha	_	NN	NN	_	14	PMOD	_	_
17	and	_	CC	CC	_	11	CC	_	_
18	-203	_	CD	CD	_	11	COORD	_	_
19	to	_	TO	TO	_	18	NMOD	_	_
20	-183	_	CD	CD	_	18	NMOD	_	_
21	for	_	IN	IN	_	18	NMOD	_	_
22	IL-2	_	NN	NN	_	21	PMOD	_	_
23	)	_	)	)	_	11	P	_	_
24	,	_	,	,	_	6	P	_	_
25	which	_	WDT	WDT	_	26	SBJ	_	_
26	corresponds	_	VBZ	VBZ	_	6	NMOD	_	_
27	to	_	TO	TO	_	26	ADV	_	_
28	a	_	DT	DT	_	32	NMOD	_	_
29	kappa	_	NN	NN	_	32	NMOD	_	_
30	B	_	NN	NN	_	32	NMOD	_	_
31	enhancer	_	NN	NN	_	32	NMOD	_	_
32	element	_	NN	NN	_	27	PMOD	_	_
33	,	_	,	,	_	6	P	_	_
34	is	_	VBZ	VBZ	_	4	VMOD	_	_
35	specifically	_	RB	RB	_	34	ADV	_	_
36	protected	_	VBN	VBN	_	34	VC	_	_
37	by	_	IN	IN	_	36	LGS	_	_
38	nuclear	_	JJ	JJ	_	39	NMOD	_	_
39	proteins	_	NNS	NNS	_	37	PMOD	_	_
40	from	_	IN	IN	_	39	NMOD	_	_
41	IARC	_	NN	NN	_	40	PMOD	_	_
42	301	_	CD	CD	_	41	NMOD	_	_
43	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	14	ADV	_	_
2	agreement	_	NN	NN	_	1	DEP	_	_
3	with	_	IN	IN	_	1	DEP	_	_
4	this	_	DT	DT	_	5	NMOD	_	_
5	finding	_	NN	NN	_	1	PMOD	_	_
6	,	_	,	,	_	14	P	_	_
7	both	_	CC	CC	_	13	CC	_	_
8	the	_	DT	DT	_	13	NMOD	_	_
9	IL-2	_	NN	NN	_	13	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	IL-2-R	_	NN	NN	_	12	NMOD	_	_
12	alpha	_	NN	NN	_	9	COORD	_	_
13	promoters	_	NNS	NNS	_	14	SBJ	_	_
14	are	_	VBP	VBP	_	0	ROOT-S	_	_
15	active	_	JJ	JJ	_	14	PRD	_	_
16	in	_	IN	IN	_	14	ADV	_	_
17	transient	_	JJ	JJ	_	19	NMOD	_	_
18	transfection	_	NN	NN	_	19	NMOD	_	_
19	assays	_	NNS	NNS	_	16	PMOD	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	IARC	_	NN	NN	_	23	NMOD	_	_
22	301	_	CD	CD	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	20	PMOD	_	_
24	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	10	P	_	_
4	mutation	_	NN	NN	_	10	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	kappa	_	NN	NN	_	9	NMOD	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	enhancer	_	NN	NN	_	5	PMOD	_	_
10	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	markedly	_	RB	RB	_	13	AMOD	_	_
13	attenuated	_	VBN	VBN	_	14	NMOD	_	_
14	activities	_	NNS	NNS	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	both	_	DT	DT	_	17	NMOD	_	_
17	promoters	_	NNS	NNS	_	15	PMOD	_	_
18	.	_	.	.	_	10	P	_	_

1	Two	_	CD	CD	_	2	NMOD	_	_
2	proteins	_	NNS	NNS	_	14	SBJ	_	_
3	binding	_	VBG	VBG	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	kappa	_	NN	NN	_	7	NMOD	_	_
6	B	_	NN	NN	_	7	NMOD	_	_
7	sequence	_	NN	NN	_	3	OBJ	_	_
8	,	_	,	,	_	2	P	_	_
9	NF-kappa	_	NN	NN	_	10	NMOD	_	_
10	B	_	NN	NN	_	2	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	KBF1	_	NN	NN	_	10	COORD	_	_
13	,	_	,	,	_	2	P	_	_
14	are	_	VBP	VBP	_	0	ROOT-S	_	_
15	constitutively	_	RB	RB	_	14	ADV	_	_
16	expressed	_	VBN	VBN	_	14	VC	_	_
17	in	_	IN	IN	_	16	ADV	_	_
18	IARC	_	NN	NN	_	20	NMOD	_	_
19	301	_	CD	CD	_	20	NMOD	_	_
20	nuclei	_	NNS	NNS	_	17	PMOD	_	_
21	and	_	CC	CC	_	16	CC	_	_
22	induced	_	VBN	VBN	_	16	COORD	_	_
23	by	_	IN	IN	_	22	LGS	_	_
24	PMA	_	NN	NN	_	23	PMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	PHA	_	NN	NN	_	24	COORD	_	_
27	in	_	IN	IN	_	22	ADV	_	_
28	Jurkat	_	NN	NN	_	27	PMOD	_	_
29	.	_	.	.	_	14	P	_	_

1	They	_	PRP	PRP	_	2	SBJ	_	_
2	bind	_	VBP	VBP	_	0	ROOT-S	_	_
3	to	_	TO	TO	_	2	ADV	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	kappa	_	NN	NN	_	7	NMOD	_	_
6	B	_	NN	NN	_	7	NMOD	_	_
7	motifs	_	NNS	NNS	_	3	PMOD	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	different	_	JJ	JJ	_	11	NMOD	_	_
10	relative	_	JJ	JJ	_	11	NMOD	_	_
11	affinities	_	NNS	NNS	_	8	PMOD	_	_
12	that	_	WDT	WDT	_	13	SBJ	_	_
13	may	_	MD	MD	_	7	NMOD	_	_
14	reflect	_	VB	VB	_	13	VC	_	_
15	their	_	PRP$	PRP$	_	17	NMOD	_	_
16	different	_	JJ	JJ	_	17	NMOD	_	_
17	contribution	_	NN	NN	_	14	OBJ	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	expression	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	various	_	JJ	JJ	_	23	NMOD	_	_
23	promoters	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	functional	_	JJ	JJ	_	3	NMOD	_	_
3	domains	_	NNS	NNS	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	murine	_	JJ	JJ	_	9	NMOD	_	_
7	Thy-1	_	NN	NN	_	9	NMOD	_	_
8	gene	_	NN	NN	_	9	NMOD	_	_
9	promoter	_	NN	NN	_	4	PMOD	_	_
10	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	Thy-1	_	NN	NN	_	4	NMOD	_	_
3	gene	_	NN	NN	_	4	NMOD	_	_
4	promoter	_	NN	NN	_	5	SBJ	_	_
5	resembles	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	10	NMOD	_	_
7	"	_	``	``	_	10	P	_	_
8	housekeeping	_	JJ	JJ	_	10	NMOD	_	_
9	"	_	''	''	_	10	P	_	_
10	promoter	_	NN	NN	_	5	OBJ	_	_
11	in	_	IN	IN	_	5	ADV	_	_
12	that	_	IN	IN	_	11	PMOD	_	_
13	it	_	PRP	PRP	_	14	SBJ	_	_
14	is	_	VBZ	VBZ	_	12	VMOD	_	_
15	located	_	JJ	JJ	_	14	PRD	_	_
16	within	_	IN	IN	_	15	AMOD	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	methylation-free	_	JJ	JJ	_	19	NMOD	_	_
19	island	_	NN	NN	_	16	PMOD	_	_
20	,	_	,	,	_	14	P	_	_
21	lacks	_	VBZ	VBZ	_	14	COORD	_	_
22	a	_	DT	DT	_	25	NMOD	_	_
23	canonical	_	JJ	JJ	_	25	NMOD	_	_
24	TATA	_	NN	NN	_	25	NMOD	_	_
25	box	_	NN	NN	_	21	OBJ	_	_
26	,	_	,	,	_	14	P	_	_
27	and	_	CC	CC	_	14	CC	_	_
28	displays	_	VBZ	VBZ	_	14	COORD	_	_
29	heterogeneity	_	NN	NN	_	28	OBJ	_	_
30	in	_	IN	IN	_	28	ADV	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	5'-end	_	JJ	JJ	_	33	NMOD	_	_
33	termini	_	NNS	NNS	_	30	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	the	_	DT	DT	_	36	NMOD	_	_
36	mRNA	_	NN	NN	_	34	PMOD	_	_
37	.	_	.	.	_	5	P	_	_

1	Using	_	VBG	VBG	_	6	ADV	_	_
2	transgenic	_	JJ	JJ	_	3	NMOD	_	_
3	mice	_	NNS	NNS	_	1	OBJ	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	show	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	this	_	DT	DT	_	9	NMOD	_	_
9	promoter	_	NN	NN	_	10	SBJ	_	_
10	does	_	VBZ	VBZ	_	7	VMOD	_	_
11	not	_	RB	RB	_	10	VMOD	_	_
12	confer	_	VB	VB	_	10	VC	_	_
13	any	_	DT	DT	_	15	NMOD	_	_
14	tissue	_	NN	NN	_	15	NMOD	_	_
15	specificity	_	NN	NN	_	12	OBJ	_	_
16	and	_	CC	CC	_	10	CC	_	_
17	is	_	VBZ	VBZ	_	10	COORD	_	_
18	active	_	JJ	JJ	_	17	PRD	_	_
19	only	_	RB	RB	_	20	DEP	_	_
20	in	_	IN	IN	_	17	ADV	_	_
21	a	_	DT	DT	_	23	NMOD	_	_
22	position-dependent	_	JJ	JJ	_	23	NMOD	_	_
23	manner	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	6	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	can	_	MD	MD	_	0	ROOT-S	_	_
3	only	_	RB	RB	_	2	ADV	_	_
4	be	_	VB	VB	_	2	VC	_	_
5	activated	_	VBN	VBN	_	4	VC	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	tissue-specific	_	JJ	JJ	_	9	NMOD	_	_
9	manner	_	NN	NN	_	6	PMOD	_	_
10	by	_	IN	IN	_	5	LGS	_	_
11	elements	_	NNS	NNS	_	10	PMOD	_	_
12	that	_	WDT	WDT	_	13	SBJ	_	_
13	lie	_	VBP	VBP	_	11	NMOD	_	_
14	downstream	_	RB	RB	_	13	VMOD	_	_
15	of	_	IN	IN	_	14	AMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	initiation	_	NN	NN	_	18	NMOD	_	_
18	site	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	analyzed	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	functional	_	JJ	JJ	_	6	NMOD	_	_
6	domains	_	NNS	NNS	_	3	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	minimal	_	JJ	JJ	_	11	NMOD	_	_
10	Thy-1	_	NN	NN	_	11	NMOD	_	_
11	promoter	_	NN	NN	_	7	PMOD	_	_
12	and	_	CC	CC	_	2	CC	_	_
13	show	_	VB	VB	_	2	COORD	_	_
14	that	_	IN	IN	_	13	OBJ	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	dominant	_	JJ	JJ	_	18	NMOD	_	_
17	promoter	_	NN	NN	_	18	NMOD	_	_
18	elements	_	NNS	NNS	_	19	SBJ	_	_
19	consist	_	VBP	VBP	_	14	VMOD	_	_
20	of	_	IN	IN	_	19	ADV	_	_
21	multiple	_	JJ	JJ	_	23	NMOD	_	_
22	binding	_	VBG	VBG	_	23	NMOD	_	_
23	sites	_	NNS	NNS	_	20	PMOD	_	_
24	for	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	28	NMOD	_	_
26	transcription	_	NN	NN	_	28	NMOD	_	_
27	factor	_	NN	NN	_	28	NMOD	_	_
28	Sp1	_	NN	NN	_	24	PMOD	_	_
29	,	_	,	,	_	28	P	_	_
30	an	_	DT	DT	_	33	NMOD	_	_
31	inverted	_	JJ	JJ	_	33	NMOD	_	_
32	CCAAT	_	NN	NN	_	33	NMOD	_	_
33	box	_	NN	NN	_	28	COORD	_	_
34	,	_	,	,	_	28	P	_	_
35	and	_	CC	CC	_	28	CC	_	_
36	sequences	_	VBZ	VBZ	_	28	COORD	_	_
37	proximal	_	JJ	JJ	_	36	NMOD	_	_
38	to	_	TO	TO	_	37	AMOD	_	_
39	the	_	DT	DT	_	42	NMOD	_	_
40	transcription	_	NN	NN	_	42	NMOD	_	_
41	start	_	NN	NN	_	42	NMOD	_	_
42	site	_	NN	NN	_	38	PMOD	_	_
43	.	_	.	.	_	2	P	_	_

1	DNase	_	NN	NN	_	7	NMOD	_	_
2	I	_	CD	CD	_	7	COORD	_	_
3	and	_	CC	CC	_	7	CC	_	_
4	gel	_	NN	NN	_	7	COORD	_	_
5	mobility	_	NN	NN	_	7	COORD	_	_
6	shift	_	NN	NN	_	7	COORD	_	_
7	assays	_	NNS	NNS	_	8	SBJ	_	_
8	show	_	VBP	VBP	_	0	ROOT-S	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	binding	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	a	_	DT	DT	_	13	NMOD	_	_
13	number	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	nuclear	_	JJ	JJ	_	16	NMOD	_	_
16	factors	_	NNS	NNS	_	14	PMOD	_	_
17	to	_	TO	TO	_	10	NMOD	_	_
18	these	_	DT	DT	_	19	NMOD	_	_
19	elements	_	NNS	NNS	_	17	PMOD	_	_
20	,	_	,	,	_	19	P	_	_
21	including	_	VBG	VBG	_	19	NMOD	_	_
22	Sp1	_	NN	NN	_	21	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	CP1	_	NN	NN	_	22	COORD	_	_
25	.	_	.	.	_	8	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	show	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	structure	_	NN	NN	_	11	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	this	_	DT	DT	_	9	NMOD	_	_
9	promoter	_	NN	NN	_	7	PMOD	_	_
10	only	_	RB	RB	_	11	ADV	_	_
11	permits	_	VBZ	VBZ	_	4	VMOD	_	_
12	productive	_	JJ	JJ	_	13	NMOD	_	_
13	interactions	_	NNS	NNS	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	two	_	CD	CD	_	18	NMOD	_	_
17	transcription	_	NN	NN	_	18	NMOD	_	_
18	factors	_	NNS	NNS	_	14	PMOD	_	_
19	Sp1	_	NN	NN	_	18	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	CP1	_	NN	NN	_	19	COORD	_	_
22	with	_	IN	IN	_	13	NMOD	_	_
23	the	_	DT	DT	_	26	NMOD	_	_
24	basal	_	JJ	JJ	_	26	NMOD	_	_
25	transcription	_	NN	NN	_	26	NMOD	_	_
26	machinery	_	NN	NN	_	22	PMOD	_	_
27	in	_	IN	IN	_	11	ADV	_	_
28	the	_	DT	DT	_	27	DEP	_	_
29	presence	_	NN	NN	_	27	DEP	_	_
30	of	_	IN	IN	_	27	DEP	_	_
31	enhancer	_	NN	NN	_	32	NMOD	_	_
32	sequences	_	NNS	NNS	_	27	PMOD	_	_
33	.	_	.	.	_	3	P	_	_

1	Isolation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	rel-related	_	JJ	JJ	_	6	NMOD	_	_
5	human	_	JJ	JJ	_	6	NMOD	_	_
6	cDNA	_	NN	NN	_	2	PMOD	_	_
7	that	_	WDT	WDT	_	9	SBJ	_	_
8	potentially	_	RB	RB	_	9	ADV	_	_
9	encodes	_	VBZ	VBZ	_	6	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	65-kD	_	JJ	JJ	_	12	NMOD	_	_
12	subunit	_	NN	NN	_	9	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	NF-kappa	_	NN	NN	_	15	NMOD	_	_
15	B	_	NN	NN	_	13	PMOD	_	_
16	{	_	(	(	_	19	P	_	_
17	published	_	VBN	VBN	_	18	NMOD	_	_
18	erratum	_	NN	NN	_	19	SBJ	_	_
19	appears	_	VBZ	VBZ	_	1	NMOD	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	Science	_	NNP	NNP	_	20	PMOD	_	_
22	1991	_	CD	CD	_	21	NMOD	_	_
23	Oct	_	NNP	NNP	_	21	TMP	_	_
24	4	_	CD	CD	_	23	NMOD	_	_
25	;	_	:	:	_	21	P	_	_
26	254	_	CD	CD	_	21	NMOD	_	_
27	(	_	(	(	_	21	P	_	_
28	5028	_	CD	CD	_	21	NMOD	_	_
29	)	_	)	)	_	21	P	_	_
30	:	_	:	:	_	21	P	_	_
31	11	_	CD	CD	_	21	NMOD	_	_
32	}	_	)	)	_	19	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	DNA	_	NN	NN	_	3	NMOD	_	_
3	probe	_	NN	NN	_	28	SBJ	_	_
4	that	_	WDT	WDT	_	5	SBJ	_	_
5	spanned	_	VBD	VBD	_	3	NMOD	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	domain	_	NN	NN	_	5	OBJ	_	_
8	conserved	_	VBN	VBN	_	7	NMOD	_	_
9	among	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	proto-oncogene	_	NN	NN	_	12	NMOD	_	_
12	c-rel	_	NN	NN	_	9	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	Drosophila	_	NN	NN	_	17	NMOD	_	_
16	morphogen	_	NN	NN	_	17	NMOD	_	_
17	dorsal	_	NN	NN	_	12	COORD	_	_
18	,	_	,	,	_	12	P	_	_
19	and	_	CC	CC	_	12	CC	_	_
20	the	_	DT	DT	_	24	NMOD	_	_
21	p50	_	NN	NN	_	24	NMOD	_	_
22	DNA	_	NN	NN	_	24	NMOD	_	_
23	binding	_	NN	NN	_	24	NMOD	_	_
24	subunit	_	NN	NN	_	12	COORD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	NF-kappa	_	NN	NN	_	27	NMOD	_	_
27	B	_	NN	NN	_	25	PMOD	_	_
28	was	_	VBD	VBD	_	0	ROOT-S	_	_
29	generated	_	VBN	VBN	_	28	VC	_	_
30	from	_	IN	IN	_	29	ADV	_	_
31	Jurkat	_	NN	NN	_	35	NMOD	_	_
32	T	_	NN	NN	_	35	NMOD	_	_
33	cell	_	NN	NN	_	35	NMOD	_	_
34	complementary	_	JJ	JJ	_	35	NMOD	_	_
35	DNA	_	NN	NN	_	30	PMOD	_	_
36	with	_	IN	IN	_	35	NMOD	_	_
37	the	_	DT	DT	_	40	NMOD	_	_
38	polymerase	_	NN	NN	_	40	NMOD	_	_
39	chain	_	NN	NN	_	40	NMOD	_	_
40	reaction	_	NN	NN	_	36	PMOD	_	_
41	(	_	(	(	_	42	P	_	_
42	PCR	_	NN	NN	_	40	PRN	_	_
43	)	_	)	)	_	42	P	_	_
44	and	_	CC	CC	_	40	CC	_	_
45	degenerate	_	JJ	JJ	_	46	NMOD	_	_
46	oligonucleotides	_	NNS	NNS	_	40	COORD	_	_
47	.	_	.	.	_	28	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	probe	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	used	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	6	VMOD	_	_
6	identify	_	VB	VB	_	4	OBJ	_	_
7	a	_	DT	DT	_	10	NMOD	_	_
8	rel-related	_	JJ	JJ	_	10	NMOD	_	_
9	complementary	_	JJ	JJ	_	10	NMOD	_	_
10	DNA	_	NN	NN	_	6	OBJ	_	_
11	that	_	WDT	WDT	_	12	SBJ	_	_
12	hybridized	_	VBD	VBD	_	10	NMOD	_	_
13	to	_	TO	TO	_	12	ADV	_	_
14	a	_	DT	DT	_	17	NMOD	_	_
15	2.6-kilobase	_	JJ	JJ	_	17	NMOD	_	_
16	messenger	_	NN	NN	_	17	NMOD	_	_
17	RNA	_	NN	NN	_	13	PMOD	_	_
18	present	_	JJ	JJ	_	17	NMOD	_	_
19	in	_	IN	IN	_	18	AMOD	_	_
20	human	_	JJ	JJ	_	24	NMOD	_	_
21	T	_	NN	NN	_	24	NMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	B	_	NN	NN	_	21	COORD	_	_
24	lymphocytes	_	NNS	NNS	_	19	PMOD	_	_
25	.	_	.	.	_	3	P	_	_

1	In	_	FW	FW	_	2	AMOD	_	_
2	vitro	_	FW	FW	_	3	NMOD	_	_
3	transcription	_	NN	NN	_	10	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	translation	_	NN	NN	_	3	COORD	_	_
6	of	_	IN	IN	_	3	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	complementary	_	JJ	JJ	_	9	NMOD	_	_
9	DNA	_	NN	NN	_	6	PMOD	_	_
10	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	synthesis	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	a	_	DT	DT	_	16	NMOD	_	_
16	protein	_	NN	NN	_	14	PMOD	_	_
17	with	_	IN	IN	_	16	NMOD	_	_
18	an	_	DT	DT	_	21	NMOD	_	_
19	apparent	_	JJ	JJ	_	21	NMOD	_	_
20	molecular	_	JJ	JJ	_	21	NMOD	_	_
21	size	_	NN	NN	_	17	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	65	_	CD	CD	_	24	NMOD	_	_
24	kilodaltons	_	NNS	NNS	_	22	PMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	kD	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	translated	_	VBN	VBN	_	3	NMOD	_	_
3	protein	_	NN	NN	_	4	SBJ	_	_
4	showed	_	VBD	VBD	_	0	ROOT-S	_	_
5	weak	_	JJ	JJ	_	7	NMOD	_	_
6	DNA	_	NN	NN	_	7	NMOD	_	_
7	binding	_	NN	NN	_	4	OBJ	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	specificity	_	NN	NN	_	8	PMOD	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	16	NMOD	_	_
13	kappa	_	NN	NN	_	16	NMOD	_	_
14	B	_	NN	NN	_	16	NMOD	_	_
15	binding	_	VBG	VBG	_	16	NMOD	_	_
16	motif	_	NN	NN	_	11	PMOD	_	_
17	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	3	NMOD	_	_
2	protein-DNA	_	JJ	JJ	_	3	NMOD	_	_
3	complex	_	JJ	JJ	_	4	SBJ	_	_
4	comigrated	_	VBN	VBN	_	0	ROOT-S	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	complex	_	NN	NN	_	5	PMOD	_	_
8	obtained	_	VBN	VBN	_	7	NMOD	_	_
9	with	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	16	NMOD	_	_
11	purified	_	VBN	VBN	_	16	NMOD	_	_
12	human	_	JJ	JJ	_	16	NMOD	_	_
13	p65	_	NN	NN	_	16	NMOD	_	_
14	NF-kappa	_	NN	NN	_	16	NMOD	_	_
15	B	_	NN	NN	_	16	NMOD	_	_
16	subunit	_	NN	NN	_	9	PMOD	_	_
17	and	_	CC	CC	_	4	CC	_	_
18	binding	_	NN	NN	_	19	SBJ	_	_
19	was	_	VBD	VBD	_	4	COORD	_	_
20	inhibited	_	VBN	VBN	_	19	VC	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	I	_	NN	NN	_	24	NMOD	_	_
23	kappa	_	NN	NN	_	24	NMOD	_	_
24	B-alpha	_	NN	NN	_	27	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	-beta	_	NN	NN	_	24	COORD	_	_
27	proteins	_	NNS	NNS	_	21	PMOD	_	_
28	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	7	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	7	P	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	65-kD	_	JJ	JJ	_	6	NMOD	_	_
6	protein	_	NN	NN	_	7	SBJ	_	_
7	associated	_	VBN	VBN	_	0	ROOT-S	_	_
8	with	_	IN	IN	_	7	ADV	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	p50	_	NN	NN	_	11	NMOD	_	_
11	subunit	_	NN	NN	_	8	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	NF-kappa	_	NN	NN	_	14	NMOD	_	_
14	B	_	NN	NN	_	12	PMOD	_	_
15	and	_	CC	CC	_	11	CC	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	kappa	_	NN	NN	_	19	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	probe	_	NN	NN	_	11	COORD	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	form	_	VB	VB	_	7	OBJ	_	_
22	a	_	DT	DT	_	23	NMOD	_	_
23	complex	_	NN	NN	_	21	OBJ	_	_
24	with	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	28	NMOD	_	_
26	same	_	JJ	JJ	_	28	NMOD	_	_
27	electrophoretic	_	JJ	JJ	_	28	NMOD	_	_
28	mobility	_	NN	NN	_	24	PMOD	_	_
29	as	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	33	NMOD	_	_
31	NF-kappa	_	NN	NN	_	33	NMOD	_	_
32	B-DNA	_	JJ	JJ	_	31	AMOD	_	_
33	complex	_	NN	NN	_	29	PMOD	_	_
34	.	_	.	.	_	7	P	_	_

1	Therefore	_	RB	RB	_	6	ADV	_	_
2	the	_	DT	DT	_	5	NMOD	_	_
3	rel-related	_	JJ	JJ	_	5	NMOD	_	_
4	65-kD	_	JJ	JJ	_	5	NMOD	_	_
5	protein	_	NN	NN	_	6	SBJ	_	_
6	may	_	MD	MD	_	0	ROOT-S	_	_
7	represent	_	VB	VB	_	6	VC	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	p65	_	NN	NN	_	10	NMOD	_	_
10	subunit	_	NN	NN	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	18	NMOD	_	_
13	active	_	JJ	JJ	_	18	NMOD	_	_
14	NF-kappa	_	NN	NN	_	18	NMOD	_	_
15	B	_	NN	NN	_	18	NMOD	_	_
16	transcription	_	NN	NN	_	18	NMOD	_	_
17	factor	_	NN	NN	_	18	NMOD	_	_
18	complex	_	NN	NN	_	11	PMOD	_	_
19	.	_	.	.	_	6	P	_	_

1	Lymphocyte	_	NN	NN	_	4	NMOD	_	_
2	glucocorticoid	_	NN	NN	_	4	NMOD	_	_
3	receptor	_	NN	NN	_	4	NMOD	_	_
4	number	_	NN	NN	_	0	ROOT-FRAG	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	posttraumatic	_	JJ	JJ	_	8	NMOD	_	_
7	stress	_	NN	NN	_	8	NMOD	_	_
8	disorder	_	NN	NN	_	5	PMOD	_	_
9	.	_	.	.	_	4	P	_	_

1	OBJECTIVE	_	NN	NN	_	0	ROOT-FRAG	_	_
2	:	_	:	:	_	1	P	_	_
3	The	_	DT	DT	_	4	NMOD	_	_
4	authors	_	NNS	NNS	_	6	NMOD	_	_
5	'	_	POS	POS	_	4	NMOD	_	_
6	objective	_	NN	NN	_	7	SBJ	_	_
7	was	_	VBD	VBD	_	1	NMOD	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	investigate	_	VB	VB	_	7	PRD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	possibility	_	NN	NN	_	9	OBJ	_	_
12	that	_	IN	IN	_	11	NMOD	_	_
13	glucocorticoid	_	NN	NN	_	15	NMOD	_	_
14	receptor	_	NN	NN	_	15	NMOD	_	_
15	changes	_	NNS	NNS	_	16	SBJ	_	_
16	may	_	MD	MD	_	12	VMOD	_	_
17	be	_	VB	VB	_	16	VC	_	_
18	involved	_	VBN	VBN	_	17	VC	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	dysregulation	_	NN	NN	_	19	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	28	NMOD	_	_
24	hypothalamic-pituitary-adrenal	_	JJ	JJ	_	28	NMOD	_	_
25	(	_	(	(	_	26	P	_	_
26	HPA	_	JJ	JJ	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	axis	_	NN	NN	_	22	PMOD	_	_
29	in	_	IN	IN	_	21	NMOD	_	_
30	posttraumatic	_	JJ	JJ	_	32	NMOD	_	_
31	stress	_	NN	NN	_	32	NMOD	_	_
32	disorder	_	NN	NN	_	29	PMOD	_	_
33	(	_	(	(	_	34	P	_	_
34	PTSD	_	NN	NN	_	32	PRN	_	_
35	)	_	)	)	_	34	P	_	_
36	.	_	.	.	_	7	P	_	_

1	METHOD	_	NN	NN	_	0	ROOT-FRAG	_	_
2	:	_	:	:	_	1	P	_	_
3	They	_	PRP	PRP	_	4	SBJ	_	_
4	measured	_	VBD	VBD	_	1	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	number	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	lymphocyte	_	NN	NN	_	11	NMOD	_	_
9	cytosolic	_	JJ	JJ	_	11	NMOD	_	_
10	glucocorticoid	_	NN	NN	_	11	NMOD	_	_
11	receptors	_	NNS	NNS	_	7	PMOD	_	_
12	and	_	CC	CC	_	6	CC	_	_
13	plasma	_	NN	NN	_	15	NMOD	_	_
14	cortisol	_	NN	NN	_	15	NMOD	_	_
15	concentrations	_	NNS	NNS	_	6	COORD	_	_
16	in	_	IN	IN	_	6	NMOD	_	_
17	15	_	CD	CD	_	23	NMOD	_	_
18	consecutively	_	RB	RB	_	19	AMOD	_	_
19	admitted	_	VBN	VBN	_	23	NMOD	_	_
20	male	_	JJ	JJ	_	23	NMOD	_	_
21	combat	_	NN	NN	_	23	NMOD	_	_
22	Vietnam	_	NN	NN	_	23	NMOD	_	_
23	veterans	_	NNS	NNS	_	16	COORD	_	_
24	with	_	IN	IN	_	23	NMOD	_	_
25	PTSD	_	NN	NN	_	24	PMOD	_	_
26	and	_	CC	CC	_	16	CC	_	_
27	in	_	IN	IN	_	16	COORD	_	_
28	a	_	DT	DT	_	31	NMOD	_	_
29	normal	_	JJ	JJ	_	31	NMOD	_	_
30	comparison	_	NN	NN	_	31	NMOD	_	_
31	group	_	NN	NN	_	27	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	11	_	CD	CD	_	34	NMOD	_	_
34	subjects	_	NNS	NNS	_	32	PMOD	_	_
35	.	_	.	.	_	4	P	_	_

1	RESULTS	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	:	_	:	:	_	1	P	_	_
3	Both	_	CC	CC	_	5	CC	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	patients	_	NNS	NNS	_	11	SBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	normal	_	JJ	JJ	_	10	NMOD	_	_
9	comparison	_	NN	NN	_	10	NMOD	_	_
10	subjects	_	NNS	NNS	_	5	COORD	_	_
11	showed	_	VBD	VBD	_	1	NMOD	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	morning-to-afternoon	_	JJ	JJ	_	14	NMOD	_	_
14	decline	_	NN	NN	_	11	OBJ	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	glucocorticoid	_	NN	NN	_	18	NMOD	_	_
17	receptor	_	NN	NN	_	18	NMOD	_	_
18	concentrations	_	NNS	NNS	_	15	PMOD	_	_
19	,	_	,	,	_	14	P	_	_
20	paralleling	_	VBG	VBG	_	14	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	normal	_	JJ	JJ	_	24	NMOD	_	_
23	diurnal	_	JJ	JJ	_	24	NMOD	_	_
24	decline	_	NN	NN	_	20	OBJ	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	cortisol	_	NN	NN	_	27	NMOD	_	_
27	levels	_	NNS	NNS	_	25	PMOD	_	_
28	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	number	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	glucocorticoid	_	NN	NN	_	5	NMOD	_	_
5	receptors	_	NNS	NNS	_	3	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	63	_	CD	CD	_	8	NMOD	_	_
8	%	_	NN	NN	_	9	AMOD	_	_
9	greater	_	JJR	JJR	_	6	PRD	_	_
10	in	_	IN	IN	_	9	TMP	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	morning	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	9	CC	_	_
14	26	_	CD	CD	_	15	NMOD	_	_
15	%	_	NN	NN	_	16	AMOD	_	_
16	greater	_	JJR	JJR	_	9	COORD	_	_
17	in	_	IN	IN	_	16	TMP	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	afternoon	_	NN	NN	_	17	PMOD	_	_
20	in	_	IN	IN	_	9	AMOD	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	patients	_	NNS	NNS	_	20	PMOD	_	_
23	with	_	IN	IN	_	22	NMOD	_	_
24	PTSD	_	NN	NN	_	23	PMOD	_	_
25	than	_	IN	IN	_	9	AMOD	_	_
26	in	_	IN	IN	_	25	PMOD	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	normal	_	JJ	JJ	_	29	NMOD	_	_
29	subjects	_	NNS	NNS	_	26	PMOD	_	_
30	.	_	.	.	_	6	P	_	_

1	No	_	DT	DT	_	3	NMOD	_	_
2	group	_	NN	NN	_	3	NMOD	_	_
3	differences	_	NNS	NNS	_	7	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	cortisol	_	NN	NN	_	6	NMOD	_	_
6	levels	_	NNS	NNS	_	4	PMOD	_	_
7	were	_	VBD	VBD	_	0	ROOT-S	_	_
8	observed	_	VBN	VBN	_	7	VC	_	_
9	,	_	,	,	_	7	P	_	_
10	nor	_	CC	CC	_	7	CC	_	_
11	were	_	VBD	VBD	_	7	COORD	_	_
12	glucocorticoid	_	NN	NN	_	14	NMOD	_	_
13	receptor	_	NN	NN	_	14	NMOD	_	_
14	number	_	NN	NN	_	11	SBJ	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	cortisol	_	NN	NN	_	17	NMOD	_	_
17	levels	_	NNS	NNS	_	14	COORD	_	_
18	correlated	_	VBD	VBD	_	11	PRD	_	_
19	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	number	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	morning	_	NN	NN	_	6	NMOD	_	_
5	glucocorticoid	_	NN	NN	_	6	NMOD	_	_
6	receptors	_	NNS	NNS	_	3	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	positively	_	RB	RB	_	9	AMOD	_	_
9	correlated	_	VBN	VBN	_	7	PRD	_	_
10	with	_	IN	IN	_	9	AMOD	_	_
11	symptoms	_	NNS	NNS	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	PTSD	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	anxiety	_	NN	NN	_	13	COORD	_	_
16	.	_	.	.	_	7	P	_	_

1	CONCLUSIONS	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	:	_	:	:	_	1	P	_	_
3	These	_	DT	DT	_	4	NMOD	_	_
4	results	_	NNS	NNS	_	5	SBJ	_	_
5	provide	_	VBP	VBP	_	1	NMOD	_	_
6	further	_	JJ	JJ	_	7	NMOD	_	_
7	evidence	_	NN	NN	_	5	OBJ	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	dysregulation	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	HPA	_	JJ	JJ	_	14	NMOD	_	_
14	axis	_	NN	NN	_	11	PMOD	_	_
15	in	_	IN	IN	_	10	NMOD	_	_
16	PTSD	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	finding	_	NN	NN	_	20	SBJ	_	_
3	that	_	IN	IN	_	2	NMOD	_	_
4	patients	_	NNS	NNS	_	7	SBJ	_	_
5	with	_	IN	IN	_	4	NMOD	_	_
6	PTSD	_	NN	NN	_	5	PMOD	_	_
7	had	_	VBD	VBD	_	3	VMOD	_	_
8	a	_	DT	DT	_	11	NMOD	_	_
9	substantially	_	RB	RB	_	10	AMOD	_	_
10	greater	_	JJR	JJR	_	11	NMOD	_	_
11	number	_	NN	NN	_	7	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	lymphocyte	_	NN	NN	_	15	NMOD	_	_
14	glucocorticoid	_	NN	NN	_	15	NMOD	_	_
15	receptors	_	NNS	NNS	_	12	PMOD	_	_
16	than	_	IN	IN	_	11	NMOD	_	_
17	normal	_	JJ	JJ	_	19	NMOD	_	_
18	comparison	_	NN	NN	_	19	NMOD	_	_
19	subjects	_	NNS	NNS	_	16	PMOD	_	_
20	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
21	consistent	_	JJ	JJ	_	20	PRD	_	_
22	with	_	IN	IN	_	21	AMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	authors	_	NNS	NNS	_	27	NMOD	_	_
25	'	_	POS	POS	_	24	NMOD	_	_
26	previous	_	JJ	JJ	_	27	NMOD	_	_
27	observations	_	NNS	NNS	_	22	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	low	_	JJ	JJ	_	33	NMOD	_	_
30	24-hour	_	JJ	JJ	_	33	NMOD	_	_
31	urinary	_	JJ	JJ	_	33	NMOD	_	_
32	cortisol	_	NN	NN	_	33	NMOD	_	_
33	excretion	_	NN	NN	_	28	PMOD	_	_
34	in	_	IN	IN	_	33	NMOD	_	_
35	subjects	_	NNS	NNS	_	34	PMOD	_	_
36	with	_	IN	IN	_	35	NMOD	_	_
37	PTSD	_	NN	NN	_	36	PMOD	_	_
38	.	_	.	.	_	20	P	_	_

1	Furthermore	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	receptor	_	NN	NN	_	5	NMOD	_	_
5	changes	_	NNS	NNS	_	7	SBJ	_	_
6	observed	_	VBN	VBN	_	5	NMOD	_	_
7	are	_	VBP	VBP	_	0	ROOT-S	_	_
8	opposite	_	JJ	JJ	_	7	PRD	_	_
9	of	_	IN	IN	_	8	AMOD	_	_
10	those	_	DT	DT	_	9	PMOD	_	_
11	reported	_	VBN	VBN	_	10	NMOD	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	major	_	JJ	JJ	_	15	NMOD	_	_
14	depressive	_	JJ	JJ	_	15	NMOD	_	_
15	disorder	_	NN	NN	_	12	PMOD	_	_
16	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	present	_	JJ	JJ	_	3	NMOD	_	_
3	data	_	NNS	NNS	_	15	SBJ	_	_
4	,	_	,	,	_	15	P	_	_
5	along	_	IN	IN	_	15	ADV	_	_
6	with	_	IN	IN	_	5	DEP	_	_
7	other	_	JJ	JJ	_	8	NMOD	_	_
8	findings	_	NNS	NNS	_	5	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	HPA	_	JJ	JJ	_	11	NMOD	_	_
11	abnormalities	_	NNS	NNS	_	9	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	PTSD	_	NN	NN	_	12	PMOD	_	_
14	,	_	,	,	_	15	P	_	_
15	support	_	VBP	VBP	_	0	ROOT-S	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	possibility	_	NN	NN	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	a	_	DT	DT	_	23	NMOD	_	_
20	greater	_	JJR	JJR	_	23	NMOD	_	_
21	negative	_	JJ	JJ	_	23	NMOD	_	_
22	feedback	_	NN	NN	_	23	NMOD	_	_
23	sensitivity	_	NN	NN	_	18	PMOD	_	_
24	at	_	IN	IN	_	23	NMOD	_	_
25	one	_	CD	CD	_	28	NMOD	_	_
26	or	_	CC	CC	_	25	CC	_	_
27	more	_	JJR	JJR	_	25	COORD	_	_
28	levels	_	NNS	NNS	_	24	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	HPA	_	JJ	JJ	_	32	NMOD	_	_
32	axis	_	NN	NN	_	29	PMOD	_	_
33	.	_	.	.	_	15	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	thymus-specific	_	JJ	JJ	_	3	NMOD	_	_
3	member	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	HMG	_	NN	NN	_	8	NMOD	_	_
7	protein	_	NN	NN	_	8	NMOD	_	_
8	family	_	NN	NN	_	4	PMOD	_	_
9	regulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	the	_	DT	DT	_	17	NMOD	_	_
11	human	_	JJ	JJ	_	17	NMOD	_	_
12	T	_	NN	NN	_	17	NMOD	_	_
13	cell	_	NN	NN	_	17	NMOD	_	_
14	receptor	_	NN	NN	_	17	NMOD	_	_
15	C	_	NN	NN	_	17	NMOD	_	_
16	alpha	_	NN	NN	_	17	NMOD	_	_
17	enhancer	_	NN	NN	_	9	OBJ	_	_
18	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	human	_	JJ	JJ	_	3	AMOD	_	_
3	T	_	NN	NN	_	6	NMOD	_	_
4	cell-specific	_	JJ	JJ	_	3	AMOD	_	_
5	transcription	_	NN	NN	_	6	NMOD	_	_
6	factor	_	NN	NN	_	9	SBJ	_	_
7	TCF-1	_	NN	NN	_	8	NMOD	_	_
8	alpha	_	NN	NN	_	6	NMOD	_	_
9	plays	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	key	_	JJ	JJ	_	12	NMOD	_	_
12	role	_	NN	NN	_	9	OBJ	_	_
13	in	_	IN	IN	_	9	ADV	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	tissue-specific	_	JJ	JJ	_	16	NMOD	_	_
16	activation	_	NN	NN	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	27	NMOD	_	_
19	T	_	NN	NN	_	27	NMOD	_	_
20	cell	_	NN	NN	_	27	NMOD	_	_
21	receptor	_	NN	NN	_	27	NMOD	_	_
22	(	_	(	(	_	27	P	_	_
23	TCR	_	NN	NN	_	27	NMOD	_	_
24	)	_	)	)	_	27	P	_	_
25	C	_	NN	NN	_	27	NMOD	_	_
26	alpha	_	NN	NN	_	27	NMOD	_	_
27	enhancer	_	NN	NN	_	17	PMOD	_	_
28	and	_	CC	CC	_	9	CC	_	_
29	binds	_	VBZ	VBZ	_	9	COORD	_	_
30	to	_	TO	TO	_	29	ADV	_	_
31	pyrimidine-rich	_	JJ	JJ	_	32	NMOD	_	_
32	elements	_	NNS	NNS	_	30	PMOD	_	_
33	(	_	(	(	_	34	P	_	_
34	5'-PyCTTTG-3'	_	NN	NN	_	32	PRN	_	_
35	)	_	)	)	_	34	P	_	_
36	present	_	JJ	JJ	_	32	NMOD	_	_
37	in	_	IN	IN	_	36	AMOD	_	_
38	a	_	DT	DT	_	39	NMOD	_	_
39	variety	_	NN	NN	_	37	PMOD	_	_
40	of	_	IN	IN	_	39	NMOD	_	_
41	other	_	JJ	JJ	_	45	NMOD	_	_
42	T	_	NN	NN	_	45	NMOD	_	_
43	cell-specific	_	JJ	JJ	_	42	AMOD	_	_
44	control	_	NN	NN	_	45	NMOD	_	_
45	regions	_	NNS	NNS	_	40	PMOD	_	_
46	.	_	.	.	_	9	P	_	_

1	Using	_	VBG	VBG	_	14	ADV	_	_
2	amino	_	NN	NN	_	5	NMOD	_	_
3	acid	_	NN	NN	_	5	NMOD	_	_
4	sequence	_	NN	NN	_	5	NMOD	_	_
5	information	_	NN	NN	_	1	OBJ	_	_
6	derived	_	VBN	VBN	_	5	NMOD	_	_
7	from	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	DNA	_	NN	NN	_	11	NMOD	_	_
10	affinity-purified	_	JJ	JJ	_	11	NMOD	_	_
11	protein	_	NN	NN	_	7	PMOD	_	_
12	,	_	,	,	_	14	P	_	_
13	we	_	PRP	PRP	_	14	SBJ	_	_
14	have	_	VBP	VBP	_	0	ROOT-S	_	_
15	now	_	RB	RB	_	14	TMP	_	_
16	isolated	_	VBN	VBN	_	14	VC	_	_
17	cDNA	_	NN	NN	_	18	NMOD	_	_
18	clones	_	NNS	NNS	_	16	OBJ	_	_
19	encoding	_	VBG	VBG	_	18	NMOD	_	_
20	TCF-1	_	NN	NN	_	21	NMOD	_	_
21	alpha	_	NN	NN	_	19	OBJ	_	_
22	.	_	.	.	_	14	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	TCF-1	_	NN	NN	_	4	NMOD	_	_
3	alpha	_	NN	NN	_	4	NMOD	_	_
4	cDNA	_	NN	NN	_	5	SBJ	_	_
5	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	single	_	JJ	JJ	_	9	NMOD	_	_
8	68-amino-acid	_	JJ	JJ	_	9	NMOD	_	_
9	domain	_	NN	NN	_	5	OBJ	_	_
10	that	_	WDT	WDT	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	9	NMOD	_	_
12	homologous	_	JJ	JJ	_	11	PRD	_	_
13	to	_	TO	TO	_	12	AMOD	_	_
14	a	_	DT	DT	_	15	NMOD	_	_
15	region	_	NN	NN	_	13	PMOD	_	_
16	conserved	_	VBN	VBN	_	15	NMOD	_	_
17	among	_	IN	IN	_	16	ADV	_	_
18	high-mobility	_	JJ	JJ	_	19	NMOD	_	_
19	group	_	NN	NN	_	17	PMOD	_	_
20	(	_	(	(	_	21	P	_	_
21	HMG	_	NN	NN	_	19	PRN	_	_
22	)	_	)	)	_	21	P	_	_
23	and	_	CC	CC	_	19	CC	_	_
24	nonhistone	_	JJ	JJ	_	26	NMOD	_	_
25	chromosomal	_	JJ	JJ	_	26	NMOD	_	_
26	proteins	_	NNS	NNS	_	19	COORD	_	_
27	.	_	.	.	_	5	P	_	_

1	Expression	_	NN	NN	_	10	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	full-length	_	JJ	JJ	_	7	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	mutant	_	JJ	JJ	_	3	COORD	_	_
6	cDNA	_	NN	NN	_	7	NMOD	_	_
7	clones	_	NNS	NNS	_	2	PMOD	_	_
8	in	_	IN	IN	_	1	NMOD	_	_
9	bacteria	_	NNS	NNS	_	8	PMOD	_	_
10	reveal	_	VBP	VBP	_	0	ROOT-S	_	_
11	that	_	IN	IN	_	10	OBJ	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	single	_	JJ	JJ	_	15	NMOD	_	_
14	HMG	_	NN	NN	_	15	NMOD	_	_
15	motif	_	NN	NN	_	27	SBJ	_	_
16	,	_	,	,	_	15	P	_	_
17	which	_	WDT	WDT	_	18	SBJ	_	_
18	is	_	VBZ	VBZ	_	15	NMOD	_	_
19	predicted	_	VBN	VBN	_	18	VC	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	contain	_	VB	VB	_	19	OBJ	_	_
22	two	_	CD	CD	_	25	NMOD	_	_
23	extended	_	VBN	VBN	_	25	NMOD	_	_
24	alpha-helical	_	JJ	JJ	_	25	NMOD	_	_
25	segments	_	NNS	NNS	_	21	OBJ	_	_
26	,	_	,	,	_	15	P	_	_
27	is	_	VBZ	VBZ	_	11	VMOD	_	_
28	sufficient	_	JJ	JJ	_	27	PRD	_	_
29	to	_	TO	TO	_	30	VMOD	_	_
30	direct	_	VB	VB	_	28	AMOD	_	_
31	the	_	DT	DT	_	33	NMOD	_	_
32	sequence-specific	_	JJ	JJ	_	33	NMOD	_	_
33	binding	_	NN	NN	_	30	OBJ	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	TCF-1	_	NN	NN	_	36	NMOD	_	_
36	alpha	_	NN	NN	_	34	PMOD	_	_
37	to	_	TO	TO	_	33	NMOD	_	_
38	DNA	_	NN	NN	_	37	PMOD	_	_
39	.	_	.	.	_	10	P	_	_

1	Northern	_	NN	NN	_	3	NMOD	_	_
2	blot	_	NN	NN	_	3	NMOD	_	_
3	experiments	_	NNS	NNS	_	4	SBJ	_	_
4	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
5	further	_	RBR	RBR	_	4	ADV	_	_
6	that	_	IN	IN	_	4	OBJ	_	_
7	TCF-1	_	NN	NN	_	9	NMOD	_	_
8	alpha	_	NN	NN	_	9	NMOD	_	_
9	mRNA	_	NN	NN	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	6	VMOD	_	_
11	highly	_	RB	RB	_	12	AMOD	_	_
12	tissue	_	NN	NN	_	10	PRD	_	_
13	specific	_	JJ	JJ	_	12	AMOD	_	_
14	,	_	,	,	_	12	P	_	_
15	found	_	VBN	VBN	_	12	COORD	_	_
16	primarily	_	RB	RB	_	15	ADV	_	_
17	in	_	IN	IN	_	15	ADV	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	thymus	_	NN	NN	_	17	PMOD	_	_
20	or	_	CC	CC	_	19	CC	_	_
21	T	_	NN	NN	_	23	NMOD	_	_
22	cell	_	NN	NN	_	23	NMOD	_	_
23	lines	_	NNS	NNS	_	19	COORD	_	_
24	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	immature	_	JJ	JJ	_	6	NMOD	_	_
3	CEM	_	NN	NN	_	6	NMOD	_	_
4	T	_	NN	NN	_	6	NMOD	_	_
5	cell	_	NN	NN	_	6	NMOD	_	_
6	line	_	NN	NN	_	7	SBJ	_	_
7	expresses	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	relatively	_	RB	RB	_	9	AMOD	_	_
9	low	_	JJ	JJ	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	TCF-1	_	NN	NN	_	14	NMOD	_	_
13	alpha	_	NN	NN	_	14	NMOD	_	_
14	mRNA	_	NN	NN	_	11	PMOD	_	_
15	,	_	,	,	_	10	P	_	_
16	which	_	WDT	WDT	_	17	SBJ	_	_
17	are	_	VBP	VBP	_	10	NMOD	_	_
18	increased	_	VBN	VBN	_	17	VC	_	_
19	upon	_	IN	IN	_	18	TMP	_	_
20	activation	_	NN	NN	_	19	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	these	_	DT	DT	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	21	PMOD	_	_
24	by	_	IN	IN	_	20	NMOD	_	_
25	phorbol	_	NN	NN	_	26	NMOD	_	_
26	esters	_	NNS	NNS	_	24	PMOD	_	_
27	.	_	.	.	_	7	P	_	_

1	Interestingly	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	cloned	_	VBN	VBN	_	7	NMOD	_	_
5	TCF-1	_	NN	NN	_	7	NMOD	_	_
6	alpha	_	NN	NN	_	7	NMOD	_	_
7	protein	_	NN	NN	_	8	SBJ	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	potent	_	JJ	JJ	_	12	NMOD	_	_
11	transcriptional	_	JJ	JJ	_	12	NMOD	_	_
12	activator	_	NN	NN	_	8	PRD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	18	NMOD	_	_
15	human	_	JJ	JJ	_	18	NMOD	_	_
16	TCR	_	NN	NN	_	18	NMOD	_	_
17	alpha	_	NN	NN	_	18	NMOD	_	_
18	enhancer	_	NN	NN	_	13	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	nonlymphoid	_	JJ	JJ	_	22	NMOD	_	_
21	cell	_	NN	NN	_	22	NMOD	_	_
22	lines	_	NNS	NNS	_	19	PMOD	_	_
23	,	_	,	,	_	8	P	_	_
24	whereas	_	IN	IN	_	8	COORD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	activity	_	NN	NN	_	35	SBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	endogenous	_	JJ	JJ	_	30	NMOD	_	_
30	protein	_	NN	NN	_	27	PMOD	_	_
31	in	_	IN	IN	_	30	NMOD	_	_
32	T	_	NN	NN	_	34	NMOD	_	_
33	cell	_	NN	NN	_	34	NMOD	_	_
34	lines	_	NNS	NNS	_	31	PMOD	_	_
35	is	_	VBZ	VBZ	_	8	COORD	_	_
36	strongly	_	RB	RB	_	37	AMOD	_	_
37	dependent	_	JJ	JJ	_	35	PRD	_	_
38	on	_	IN	IN	_	37	AMOD	_	_
39	an	_	DT	DT	_	43	NMOD	_	_
40	additional	_	JJ	JJ	_	43	NMOD	_	_
41	T	_	NN	NN	_	43	NMOD	_	_
42	cell-specific	_	JJ	JJ	_	41	AMOD	_	_
43	protein	_	NN	NN	_	38	PMOD	_	_
44	that	_	WDT	WDT	_	45	SBJ	_	_
45	interacts	_	VBZ	VBZ	_	43	NMOD	_	_
46	with	_	IN	IN	_	45	ADV	_	_
47	the	_	DT	DT	_	49	NMOD	_	_
48	core	_	NN	NN	_	49	NMOD	_	_
49	enhancer	_	NN	NN	_	46	PMOD	_	_
50	.	_	.	.	_	8	P	_	_

1	TCF-1	_	NN	NN	_	2	NMOD	_	_
2	alpha	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	currently	_	RB	RB	_	5	AMOD	_	_
5	unique	_	JJ	JJ	_	3	PRD	_	_
6	among	_	IN	IN	_	3	ADV	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	newly	_	RB	RB	_	9	AMOD	_	_
9	emerging	_	VBG	VBG	_	10	NMOD	_	_
10	family	_	NN	NN	_	6	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	DNA-binding	_	JJ	JJ	_	14	NMOD	_	_
13	regulatory	_	JJ	JJ	_	14	NMOD	_	_
14	proteins	_	NNS	NNS	_	11	PMOD	_	_
15	that	_	WDT	WDT	_	16	SBJ	_	_
16	share	_	VBP	VBP	_	14	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	HMG	_	NN	NN	_	19	NMOD	_	_
19	motif	_	NN	NN	_	16	OBJ	_	_
20	in	_	IN	IN	_	23	ADV	_	_
21	that	_	IN	IN	_	20	PMOD	_	_
22	it	_	PRP	PRP	_	23	SBJ	_	_
23	is	_	VBZ	VBZ	_	19	NMOD	_	_
24	a	_	DT	DT	_	31	NMOD	_	_
25	highly	_	RB	RB	_	26	AMOD	_	_
26	tissue-specific	_	JJ	JJ	_	31	NMOD	_	_
27	RNA	_	NN	NN	_	31	NMOD	_	_
28	polymerase	_	NN	NN	_	31	NMOD	_	_
29	II	_	CD	CD	_	31	NMOD	_	_
30	transcription	_	NN	NN	_	31	NMOD	_	_
31	factor	_	NN	NN	_	23	PRD	_	_
32	.	_	.	.	_	3	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	study	_	NN	NN	_	0	ROOT-FRAG	_	_
3	on	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	circadian	_	JJ	JJ	_	6	NMOD	_	_
6	rhythm	_	NN	NN	_	3	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	glucocorticoid	_	NN	NN	_	9	NMOD	_	_
9	receptor	_	NN	NN	_	7	PMOD	_	_
10	.	_	.	.	_	2	P	_	_

1	Circadian	_	JJ	JJ	_	2	NMOD	_	_
2	rhythm	_	NN	NN	_	9	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	glucocorticoid	_	NN	NN	_	5	NMOD	_	_
5	receptor	_	NN	NN	_	3	PMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	GR	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	studied	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	18	NMOD	_	_
13	rat	_	NN	NN	_	14	NMOD	_	_
14	liver	_	NN	NN	_	18	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	human	_	JJ	JJ	_	17	AMOD	_	_
17	peripheral	_	JJ	JJ	_	14	COORD	_	_
18	leukocytes	_	NNS	NNS	_	11	PMOD	_	_
19	.	_	.	.	_	9	P	_	_

1	For	_	IN	IN	_	24	ADV	_	_
2	rats	_	NNS	NNS	_	1	PMOD	_	_
3	exposed	_	VBN	VBN	_	2	NMOD	_	_
4	to	_	TO	TO	_	3	ADV	_	_
5	a	_	DT	DT	_	9	NMOD	_	_
6	natural	_	JJ	JJ	_	7	AMOD	_	_
7	environmental	_	JJ	JJ	_	9	NMOD	_	_
8	photic	_	JJ	JJ	_	9	NMOD	_	_
9	cycle	_	NN	NN	_	4	PMOD	_	_
10	or	_	CC	CC	_	9	CC	_	_
11	a	_	DT	DT	_	17	NMOD	_	_
12	12L	_	NN	NN	_	17	NMOD	_	_
13	:	_	:	:	_	17	P	_	_
14	12D	_	NN	NN	_	17	NMOD	_	_
15	artificial	_	JJ	JJ	_	17	NMOD	_	_
16	light	_	NN	NN	_	17	NMOD	_	_
17	regime	_	NN	NN	_	9	COORD	_	_
18	,	_	,	,	_	24	P	_	_
19	peak	_	JJ	JJ	_	20	NMOD	_	_
20	values	_	NNS	NNS	_	24	SBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	hepatic	_	JJ	JJ	_	23	NMOD	_	_
23	GR	_	NN	NN	_	21	PMOD	_	_
24	were	_	VBD	VBD	_	0	ROOT-S	_	_
25	detected	_	VBN	VBN	_	24	VC	_	_
26	between	_	IN	IN	_	25	TMP	_	_
27	23:00	_	CD	CD	_	30	NMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	02:00	_	CD	CD	_	27	COORD	_	_
30	h	_	NN	NN	_	26	PMOD	_	_
31	.	_	.	.	_	24	P	_	_

1	Except	_	IN	IN	_	17	ADV	_	_
2	for	_	IN	IN	_	1	DEP	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	4-hour	_	JJ	JJ	_	5	NMOD	_	_
5	advancement	_	NN	NN	_	1	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	peak	_	NN	NN	_	6	PMOD	_	_
9	,	_	,	,	_	17	P	_	_
10	a	_	DT	DT	_	13	NMOD	_	_
11	similar	_	JJ	JJ	_	13	NMOD	_	_
12	circadian	_	JJ	JJ	_	13	NMOD	_	_
13	rhythm	_	NN	NN	_	17	SBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	hepatic	_	JJ	JJ	_	16	NMOD	_	_
16	GR	_	NN	NN	_	14	PMOD	_	_
17	was	_	VBD	VBD	_	0	ROOT-S	_	_
18	detected	_	VBN	VBN	_	17	VC	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	rats	_	NNS	NNS	_	19	PMOD	_	_
21	reared	_	VBN	VBN	_	20	NMOD	_	_
22	under	_	IN	IN	_	21	ADV	_	_
23	a	_	DT	DT	_	26	NMOD	_	_
24	reversed	_	VBN	VBN	_	26	NMOD	_	_
25	lighting	_	NN	NN	_	26	NMOD	_	_
26	regimen	_	NNS	NNS	_	22	PMOD	_	_
27	(	_	(	(	_	33	P	_	_
28	12D	_	NN	NN	_	30	NMOD	_	_
29	:	_	:	:	_	30	P	_	_
30	12L	_	NN	NN	_	33	DEP	_	_
31	;	_	:	:	_	33	P	_	_
32	lights	_	NNS	NNS	_	33	SBJ	_	_
33	on	_	IN	IN	_	26	PRN	_	_
34	between	_	IN	IN	_	33	TMP	_	_
35	18:30	_	CD	CD	_	38	NMOD	_	_
36	and	_	CC	CC	_	35	CC	_	_
37	06:30	_	CD	CD	_	35	COORD	_	_
38	h	_	NN	NN	_	34	PMOD	_	_
39	)	_	)	)	_	33	P	_	_
40	.	_	.	.	_	17	P	_	_

1	In	_	IN	IN	_	10	ADV	_	_
2	human	_	JJ	JJ	_	3	NMOD	_	_
3	leukocytes	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	10	P	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	peak	_	JJ	JJ	_	7	NMOD	_	_
7	value	_	NN	NN	_	10	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	GR	_	NN	NN	_	8	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	found	_	VBN	VBN	_	10	VC	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	parallel	_	VB	VB	_	11	OBJ	_	_
14	that	_	DT	DT	_	13	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	plasma	_	NN	NN	_	17	NMOD	_	_
17	cortisol	_	NN	NN	_	15	PMOD	_	_
18	with	_	IN	IN	_	17	NMOD	_	_
19	high	_	JJ	JJ	_	22	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	low	_	JJ	JJ	_	19	COORD	_	_
22	values	_	NNS	NNS	_	18	PMOD	_	_
23	detected	_	VBN	VBN	_	22	NMOD	_	_
24	at	_	IN	IN	_	23	TMP	_	_
25	04:00-08:00	_	CD	CD	_	26	NMOD	_	_
26	h	_	NN	NN	_	24	PMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	23:00-24:00	_	CD	CD	_	29	NMOD	_	_
29	h	_	NN	NN	_	26	COORD	_	_
30	,	_	,	,	_	23	P	_	_
31	respectively	_	RB	RB	_	23	ADV	_	_
32	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	16	ADV	_	_
2	patients	_	NNS	NNS	_	1	PMOD	_	_
3	suffering	_	VBG	VBG	_	2	NMOD	_	_
4	from	_	IN	IN	_	3	ADV	_	_
5	Cushing	_	NN	NN	_	7	NMOD	_	_
6	's	_	POS	POS	_	5	NMOD	_	_
7	syndrome	_	NN	NN	_	4	PMOD	_	_
8	,	_	,	,	_	16	P	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	circadian	_	JJ	JJ	_	11	NMOD	_	_
11	rhythm	_	NN	NN	_	16	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	plasma	_	NN	NN	_	14	NMOD	_	_
14	cortisol	_	NN	NN	_	12	PMOD	_	_
15	either	_	CC	CC	_	16	CC	_	_
16	disappeared	_	VBD	VBD	_	0	ROOT-S	_	_
17	or	_	CC	CC	_	16	CC	_	_
18	was	_	VBD	VBD	_	16	COORD	_	_
19	inverted	_	VBN	VBN	_	18	VC	_	_
20	while	_	IN	IN	_	16	OBJ	_	_
21	that	_	DT	DT	_	24	SBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	GR	_	NN	NN	_	22	PMOD	_	_
24	did	_	VBD	VBD	_	20	VMOD	_	_
25	not	_	RB	RB	_	24	VMOD	_	_
26	significantly	_	RB	RB	_	24	ADV	_	_
27	deviate	_	VB	VB	_	24	VC	_	_
28	from	_	IN	IN	_	27	ADV	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	normal	_	JJ	JJ	_	31	NMOD	_	_
31	subjects	_	NNS	NNS	_	28	PMOD	_	_
32	.	_	.	.	_	16	P	_	_

1	For	_	IN	IN	_	24	ADV	_	_
2	apoplexic	_	JJ	JJ	_	3	NMOD	_	_
3	patients	_	NNS	NNS	_	1	PMOD	_	_
4	with	_	IN	IN	_	3	NMOD	_	_
5	lesions	_	NNS	NNS	_	4	PMOD	_	_
6	localized	_	JJ	JJ	_	5	NMOD	_	_
7	to	_	TO	TO	_	6	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	base	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	brain	_	NN	NN	_	10	PMOD	_	_
13	as	_	IN	IN	_	6	ADV	_	_
14	indicated	_	VBN	VBN	_	13	VMOD	_	_
15	by	_	IN	IN	_	14	LGS	_	_
16	computerized	_	VBN	VBN	_	17	NMOD	_	_
17	tomography	_	NN	NN	_	15	PMOD	_	_
18	,	_	,	,	_	24	P	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	diurnal	_	JJ	JJ	_	21	NMOD	_	_
21	variation	_	NN	NN	_	24	SBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	GR	_	NN	NN	_	22	PMOD	_	_
24	was	_	VBD	VBD	_	0	ROOT-S	_	_
25	abolished	_	VBN	VBN	_	24	VC	_	_
26	.	_	.	.	_	24	P	_	_

1	Conversely	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	diurnal	_	JJ	JJ	_	4	NMOD	_	_
4	rhythmicity	_	NN	NN	_	5	SBJ	_	_
5	persisted	_	VBD	VBD	_	0	ROOT-S	_	_
6	in	_	IN	IN	_	5	ADV	_	_
7	apoplexy	_	NN	NN	_	8	NMOD	_	_
8	patients	_	NNS	NNS	_	6	PMOD	_	_
9	whose	_	WP$	WP$	_	10	NMOD	_	_
10	lesions	_	NNS	NNS	_	11	SBJ	_	_
11	were	_	VBD	VBD	_	8	NMOD	_	_
12	in	_	IN	IN	_	11	PRD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	cerebral	_	JJ	JJ	_	15	NMOD	_	_
15	cortex	_	NN	NN	_	12	PMOD	_	_
16	.	_	.	.	_	5	P	_	_

1	Thus	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	postulated	_	VBD	VBD	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	circadian	_	JJ	JJ	_	8	NMOD	_	_
8	modification	_	NN	NN	_	11	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	GR	_	NN	NN	_	9	PMOD	_	_
11	was	_	VBD	VBD	_	5	VMOD	_	_
12	independent	_	JJ	JJ	_	11	PRD	_	_
13	of	_	IN	IN	_	12	AMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	diurnal	_	JJ	JJ	_	16	NMOD	_	_
16	fluctuations	_	NNS	NNS	_	13	PMOD	_	_
17	in	_	IN	IN	_	16	NMOD	_	_
18	plasma	_	NN	NN	_	20	NMOD	_	_
19	cortisol	_	NN	NN	_	20	NMOD	_	_
20	level	_	NN	NN	_	17	PMOD	_	_
21	or	_	CC	CC	_	16	CC	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	circadian	_	JJ	JJ	_	24	NMOD	_	_
24	variations	_	NNS	NNS	_	16	COORD	_	_
25	in	_	IN	IN	_	24	NMOD	_	_
26	environmental	_	JJ	JJ	_	27	NMOD	_	_
27	lighting	_	NN	NN	_	25	PMOD	_	_
28	and	_	CC	CC	_	5	CC	_	_
29	that	_	IN	IN	_	5	COORD	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	rhythmicity	_	NN	NN	_	32	SBJ	_	_
32	might	_	MD	MD	_	29	VMOD	_	_
33	be	_	VB	VB	_	32	VC	_	_
34	regulated	_	VBN	VBN	_	33	VC	_	_
35	by	_	IN	IN	_	34	LGS	_	_
36	the	_	DT	DT	_	39	NMOD	_	_
37	'	_	``	``	_	39	P	_	_
38	circadian	_	JJ	JJ	_	39	NMOD	_	_
39	pacemaker	_	NN	NN	_	35	PMOD	_	_
40	'	_	''	''	_	39	P	_	_
41	located	_	JJ	JJ	_	39	NMOD	_	_
42	in	_	IN	IN	_	41	AMOD	_	_
43	the	_	DT	DT	_	46	NMOD	_	_
44	human	_	JJ	JJ	_	46	NMOD	_	_
45	basal	_	JJ	JJ	_	46	NMOD	_	_
46	brain	_	NN	NN	_	42	PMOD	_	_
47	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	3	NMOD	_	_
2	diurnal	_	JJ	JJ	_	3	NMOD	_	_
3	variations	_	NNS	NNS	_	6	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	GR	_	NN	NN	_	4	PMOD	_	_
6	might	_	MD	MD	_	0	ROOT-S	_	_
7	serve	_	VB	VB	_	6	VC	_	_
8	to	_	TO	TO	_	9	VMOD	_	_
9	coordinate	_	VB	VB	_	7	OBJ	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	reactivity	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	target	_	NN	NN	_	15	NMOD	_	_
15	cells	_	NNS	NNS	_	12	PMOD	_	_
16	to	_	TO	TO	_	11	NMOD	_	_
17	cortisol	_	NN	NN	_	16	PMOD	_	_
18	because	_	IN	IN	_	9	ADV	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	diurnal	_	JJ	JJ	_	21	NMOD	_	_
21	rhythms	_	NNS	NNS	_	40	SBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	a	_	DT	DT	_	25	NMOD	_	_
24	GR-mediated	_	JJ	JJ	_	25	NMOD	_	_
25	response	_	NN	NN	_	22	PMOD	_	_
26	,	_	,	,	_	21	P	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	fractional	_	JJ	JJ	_	29	NMOD	_	_
29	inhibition	_	NN	NN	_	21	NMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	chemotactic	_	JJ	JJ	_	33	NMOD	_	_
32	migration	_	NN	NN	_	33	NMOD	_	_
33	rate	_	NN	NN	_	30	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	polymorphonuclear	_	JJ	JJ	_	36	NMOD	_	_
36	leukocytes	_	NNS	NNS	_	34	PMOD	_	_
37	by	_	IN	IN	_	29	NMOD	_	_
38	cortisol	_	NN	NN	_	37	PMOD	_	_
39	,	_	,	,	_	21	P	_	_
40	were	_	VBD	VBD	_	18	VMOD	_	_
41	found	_	VBN	VBN	_	40	VC	_	_
42	to	_	TO	TO	_	43	VMOD	_	_
43	be	_	VB	VB	_	41	OBJ	_	_
44	synchronous	_	JJ	JJ	_	43	PRD	_	_
45	with	_	IN	IN	_	44	AMOD	_	_
46	those	_	DT	DT	_	47	NMOD	_	_
47	of	_	IN	IN	_	45	PMOD	_	_
48	GR	_	NN	NN	_	47	PMOD	_	_
49	.	_	.	.	_	6	P	_	_

1	Multiple	_	JJ	JJ	_	3	NMOD	_	_
2	Oct2	_	NN	NN	_	3	NMOD	_	_
3	isoforms	_	NNS	NNS	_	4	SBJ	_	_
4	are	_	VBP	VBP	_	0	ROOT-S	_	_
5	generated	_	VBN	VBN	_	4	VC	_	_
6	by	_	IN	IN	_	5	ADV	_	_
7	alternative	_	JJ	JJ	_	8	NMOD	_	_
8	splicing	_	NN	NN	_	6	PMOD	_	_
9	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	interaction	_	NN	NN	_	14	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	Oct2	_	NN	NN	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factor	_	NN	NN	_	3	PMOD	_	_
8	with	_	IN	IN	_	2	NMOD	_	_
9	the	_	DT	DT	_	13	NMOD	_	_
10	cognate	_	JJ	JJ	_	13	NMOD	_	_
11	octamer	_	NN	NN	_	13	NMOD	_	_
12	motif	_	NN	NN	_	13	NMOD	_	_
13	ATGCAAAT	_	NN	NN	_	8	PMOD	_	_
14	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	critical	_	JJ	JJ	_	17	NMOD	_	_
17	determinant	_	NN	NN	_	14	PRD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	lymphoid-specific	_	JJ	JJ	_	21	NMOD	_	_
21	expression	_	NN	NN	_	18	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	immunoglobulin	_	NN	NN	_	24	NMOD	_	_
24	genes	_	NNS	NNS	_	22	PMOD	_	_
25	.	_	.	.	_	14	P	_	_

1	Ectopic	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	cloned	_	VBN	VBN	_	6	NMOD	_	_
5	Oct2	_	NN	NN	_	6	NMOD	_	_
6	cDNA	_	NN	NN	_	3	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	shown	_	VBN	VBN	_	7	VC	_	_
9	to	_	TO	TO	_	10	VMOD	_	_
10	be	_	VB	VB	_	8	OBJ	_	_
11	sufficient	_	JJ	JJ	_	10	PRD	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	reconstitute	_	VB	VB	_	11	AMOD	_	_
14	at	_	IN	IN	_	16	DEP	_	_
15	least	_	JJS	JJS	_	16	DEP	_	_
16	some	_	DT	DT	_	17	NMOD	_	_
17	aspects	_	NNS	NNS	_	13	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	this	_	DT	DT	_	20	NMOD	_	_
20	regulation	_	NN	NN	_	18	PMOD	_	_
21	in	_	IN	IN	_	17	NMOD	_	_
22	non-lymphoid	_	JJ	JJ	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	describe	_	VBP	VBP	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	isolation	_	NN	NN	_	2	OBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	characterization	_	NN	NN	_	4	COORD	_	_
7	of	_	IN	IN	_	4	NMOD	_	_
8	multiple	_	JJ	JJ	_	9	NMOD	_	_
9	cDNAs	_	NNS	NNS	_	7	PMOD	_	_
10	encoding	_	VBG	VBG	_	9	NMOD	_	_
11	mouse	_	NN	NN	_	12	NMOD	_	_
12	Oct2	_	NN	NN	_	10	OBJ	_	_
13	from	_	IN	IN	_	12	NMOD	_	_
14	a	_	DT	DT	_	17	NMOD	_	_
15	mature	_	JJ	JJ	_	17	NMOD	_	_
16	B-cell	_	NN	NN	_	17	NMOD	_	_
17	line	_	NN	NN	_	13	PMOD	_	_
18	and	_	CC	CC	_	2	CC	_	_
19	we	_	PRP	PRP	_	20	SBJ	_	_
20	show	_	VBP	VBP	_	2	COORD	_	_
21	that	_	IN	IN	_	20	OBJ	_	_
22	a	_	DT	DT	_	23	NMOD	_	_
23	variety	_	NN	NN	_	30	SBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	isoforms	_	NNS	NNS	_	24	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	this	_	DT	DT	_	29	NMOD	_	_
28	transcription	_	NN	NN	_	29	NMOD	_	_
29	factor	_	NN	NN	_	26	PMOD	_	_
30	is	_	VBZ	VBZ	_	21	VMOD	_	_
31	generated	_	VBN	VBN	_	30	VC	_	_
32	from	_	IN	IN	_	31	ADV	_	_
33	a	_	DT	DT	_	35	NMOD	_	_
34	single	_	JJ	JJ	_	35	NMOD	_	_
35	gene	_	NN	NN	_	32	PMOD	_	_
36	by	_	IN	IN	_	31	ADV	_	_
37	an	_	DT	DT	_	40	NMOD	_	_
38	alternative	_	JJ	JJ	_	40	NMOD	_	_
39	splicing	_	NN	NN	_	40	NMOD	_	_
40	mechanism	_	NN	NN	_	36	PMOD	_	_
41	.	_	.	.	_	2	P	_	_

1	All	_	PDT	PDT	_	3	NMOD	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	isoforms	_	NNS	NNS	_	4	SBJ	_	_
4	retain	_	VBP	VBP	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	previously	_	RB	RB	_	7	AMOD	_	_
7	characterized	_	VBN	VBN	_	8	NMOD	_	_
8	POU-domain	_	NN	NN	_	4	OBJ	_	_
9	and	_	CC	CC	_	4	CC	_	_
10	are	_	VBP	VBP	_	4	COORD	_	_
11	therefore	_	RB	RB	_	10	ADV	_	_
12	able	_	JJ	JJ	_	10	PRD	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	bind	_	VB	VB	_	12	AMOD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	octamer	_	NN	NN	_	18	NMOD	_	_
18	motif	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	4	P	_	_

1	Different	_	JJ	JJ	_	2	NMOD	_	_
2	amounts	_	NNS	NNS	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	various	_	JJ	JJ	_	6	NMOD	_	_
6	isoforms	_	NNS	NNS	_	3	PMOD	_	_
7	are	_	VBP	VBP	_	0	ROOT-S	_	_
8	present	_	JJ	JJ	_	7	PRD	_	_
9	within	_	IN	IN	_	8	AMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	same	_	JJ	JJ	_	12	NMOD	_	_
12	B-cell	_	NN	NN	_	9	PMOD	_	_
13	regardless	_	RB	RB	_	7	ADV	_	_
14	of	_	IN	IN	_	13	AMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	developmental	_	JJ	JJ	_	17	NMOD	_	_
17	stage	_	NN	NN	_	14	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	B-cell	_	NN	NN	_	20	NMOD	_	_
20	differentiation	_	NN	NN	_	18	PMOD	_	_
21	and	_	CC	CC	_	7	CC	_	_
22	at	_	IN	IN	_	28	SBJ	_	_
23	least	_	JJS	JJS	_	22	AMOD	_	_
24	some	_	DT	DT	_	22	NMOD	_	_
25	of	_	IN	IN	_	22	NMOD	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	isoforms	_	NNS	NNS	_	25	PMOD	_	_
28	are	_	VBP	VBP	_	7	COORD	_	_
29	conserved	_	VBN	VBN	_	28	VC	_	_
30	between	_	IN	IN	_	29	ADV	_	_
31	mouse	_	NN	NN	_	30	PMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	humans	_	NNS	NNS	_	31	COORD	_	_
34	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	cotransfection	_	NN	NN	_	3	NMOD	_	_
3	experiments	_	NNS	NNS	_	1	PMOD	_	_
4	we	_	PRP	PRP	_	5	SBJ	_	_
5	show	_	VBP	VBP	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	all	_	PDT	PDT	_	9	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	isoforms	_	NNS	NNS	_	10	SBJ	_	_
10	are	_	VBP	VBP	_	6	VMOD	_	_
11	able	_	JJ	JJ	_	10	PRD	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	activate	_	VB	VB	_	11	AMOD	_	_
14	an	_	DT	DT	_	15	NMOD	_	_
15	octamer	_	NN	NN	_	13	IOBJ	_	_
16	containing	_	VBG	VBG	_	15	NMOD	_	_
17	promoter	_	NN	NN	_	18	NMOD	_	_
18	element	_	NN	NN	_	16	OBJ	_	_
19	in	_	IN	IN	_	16	ADV	_	_
20	fibroblasts	_	NNS	NNS	_	19	PMOD	_	_
21	revealing	_	VBG	VBG	_	13	OBJ	_	_
22	an	_	DT	DT	_	25	NMOD	_	_
23	unexpected	_	JJ	JJ	_	25	NMOD	_	_
24	functional	_	JJ	JJ	_	25	NMOD	_	_
25	redundancy	_	NN	NN	_	21	OBJ	_	_
26	.	_	.	.	_	5	P	_	_

1	Finally	_	RB	RB	_	4	TMP	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	show	_	VBP	VBP	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	one	_	CD	CD	_	10	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	isoforms	_	NNS	NNS	_	7	PMOD	_	_
10	encodes	_	VBZ	VBZ	_	5	VMOD	_	_
11	the	_	DT	DT	_	16	NMOD	_	_
12	previously	_	RB	RB	_	13	AMOD	_	_
13	described	_	VBN	VBN	_	16	NMOD	_	_
14	lymphoid-specific	_	JJ	JJ	_	16	NMOD	_	_
15	Oct2B	_	NN	NN	_	16	NMOD	_	_
16	protein	_	NN	NN	_	10	OBJ	_	_
17	which	_	WDT	WDT	_	18	SBJ	_	_
18	has	_	VBZ	VBZ	_	16	NMOD	_	_
19	been	_	VBN	VBN	_	18	VC	_	_
20	suggested	_	VBN	VBN	_	19	VC	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	be	_	VB	VB	_	20	OBJ	_	_
23	involved	_	VBN	VBN	_	22	VC	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	function	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	octamer	_	NN	NN	_	30	NMOD	_	_
30	motif	_	NN	NN	_	27	PMOD	_	_
31	in	_	IN	IN	_	23	ADV	_	_
32	the	_	DT	DT	_	31	DEP	_	_
33	context	_	NN	NN	_	31	DEP	_	_
34	of	_	IN	IN	_	31	DEP	_	_
35	the	_	DT	DT	_	41	NMOD	_	_
36	immunoglobulin	_	NN	NN	_	37	NMOD	_	_
37	heavy-chain	_	NN	NN	_	41	NMOD	_	_
38	(	_	(	(	_	39	P	_	_
39	IgH	_	NN	NN	_	37	PRN	_	_
40	)	_	)	)	_	39	P	_	_
41	enhancer	_	NN	NN	_	31	PMOD	_	_
42	.	_	.	.	_	4	P	_	_

1	Processing	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	precursor	_	NN	NN	_	2	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	NF-kappa	_	NN	NN	_	7	NMOD	_	_
7	B	_	NN	NN	_	5	PMOD	_	_
8	by	_	IN	IN	_	1	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	HIV-1	_	NN	NN	_	11	NMOD	_	_
11	protease	_	NN	NN	_	8	PMOD	_	_
12	during	_	IN	IN	_	1	TMP	_	_
13	acute	_	JJ	JJ	_	14	NMOD	_	_
14	infection	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	1	P	_	_

1	Transcription	_	NN	NN	_	12	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	7	NMOD	_	_
4	human	_	JJ	JJ	_	7	NMOD	_	_
5	immunodeficiency	_	NN	NN	_	7	NMOD	_	_
6	virus	_	NN	NN	_	7	NMOD	_	_
7	type-1	_	NN	NN	_	11	NMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	HIV-1	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	genome	_	NN	NN	_	2	PMOD	_	_
12	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	regulated	_	VBN	VBN	_	12	VC	_	_
14	in	_	IN	IN	_	16	PMOD	_	_
15	part	_	NN	NN	_	14	PMOD	_	_
16	by	_	IN	IN	_	13	LGS	_	_
17	cellular	_	JJ	JJ	_	18	NMOD	_	_
18	factors	_	NNS	NNS	_	16	PMOD	_	_
19	and	_	CC	CC	_	12	CC	_	_
20	is	_	VBZ	VBZ	_	12	COORD	_	_
21	stimulated	_	VBN	VBN	_	20	VC	_	_
22	by	_	IN	IN	_	21	LGS	_	_
23	activation	_	NN	NN	_	22	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	latently	_	RB	RB	_	26	AMOD	_	_
26	infected	_	JJ	JJ	_	28	NMOD	_	_
27	T	_	NN	NN	_	28	NMOD	_	_
28	cells	_	NNS	NNS	_	24	PMOD	_	_
29	.	_	.	.	_	12	P	_	_

1	T-cell	_	NN	NN	_	2	NMOD	_	_
2	activation	_	NN	NN	_	4	SBJ	_	_
3	also	_	RB	RB	_	4	ADV	_	_
4	correlates	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	induction	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	factor	_	NN	NN	_	12	NMOD	_	_
11	NF-kappa	_	NN	NN	_	12	NMOD	_	_
12	B	_	NN	NN	_	8	PMOD	_	_
13	which	_	WDT	WDT	_	14	SBJ	_	_
14	binds	_	VBZ	VBZ	_	12	NMOD	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	two	_	CD	CD	_	18	NMOD	_	_
17	adjacent	_	JJ	JJ	_	18	NMOD	_	_
18	sites	_	NNS	NNS	_	15	PMOD	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	24	NMOD	_	_
21	HIV-1	_	NN	NN	_	24	NMOD	_	_
22	long	_	JJ	JJ	_	24	NMOD	_	_
23	terminal	_	JJ	JJ	_	24	NMOD	_	_
24	repeat	_	NN	NN	_	19	PMOD	_	_
25	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	factor	_	NN	NN	_	3	SBJ	_	_
3	consists	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	of	_	IN	IN	_	3	ADV	_	_
5	two	_	CD	CD	_	7	NMOD	_	_
6	DNA-binding	_	JJ	JJ	_	7	NMOD	_	_
7	subunits	_	NNS	NNS	_	4	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	relative	_	JJ	JJ	_	11	NMOD	_	_
10	molecular	_	JJ	JJ	_	11	NMOD	_	_
11	mass	_	NN	NN	_	8	PMOD	_	_
12	50,000	_	CD	CD	_	11	NMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	50K	_	CD	CD	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	associated	_	VBN	VBN	_	7	NMOD	_	_
17	with	_	IN	IN	_	16	ADV	_	_
18	two	_	CD	CD	_	20	NMOD	_	_
19	65K	_	CD	CD	_	20	NMOD	_	_
20	subunits	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	located	_	JJ	JJ	_	2	PRD	_	_
4	in	_	IN	IN	_	3	AMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	nucleus	_	NN	NN	_	4	PMOD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	mature	_	JJ	JJ	_	10	NMOD	_	_
9	B	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	7	PMOD	_	_
11	,	_	,	,	_	2	P	_	_
12	but	_	CC	CC	_	2	CC	_	_
13	is	_	VBZ	VBZ	_	2	COORD	_	_
14	present	_	JJ	JJ	_	13	PRD	_	_
15	in	_	IN	IN	_	14	AMOD	_	_
16	other	_	JJ	JJ	_	18	NMOD	_	_
17	cell	_	NN	NN	_	18	NMOD	_	_
18	types	_	NNS	NNS	_	15	PMOD	_	_
19	as	_	IN	IN	_	14	AMOD	_	_
20	an	_	DT	DT	_	23	NMOD	_	_
21	inactive	_	JJ	JJ	_	23	NMOD	_	_
22	cytoplasmic	_	JJ	JJ	_	23	NMOD	_	_
23	complex	_	NN	NN	_	19	PMOD	_	_
24	.	_	.	.	_	2	P	_	_

1	External	_	JJ	JJ	_	2	NMOD	_	_
2	stimuli	_	NNS	NNS	_	11	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	including	_	VBG	VBG	_	2	NMOD	_	_
5	those	_	DT	DT	_	4	PMOD	_	_
6	that	_	WDT	WDT	_	7	SBJ	_	_
7	activate	_	VBP	VBP	_	5	NMOD	_	_
8	T	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	7	OBJ	_	_
10	,	_	,	,	_	2	P	_	_
11	result	_	VBP	VBP	_	0	ROOT-S	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	nuclear	_	JJ	JJ	_	14	NMOD	_	_
14	translocation	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	active	_	JJ	JJ	_	18	NMOD	_	_
17	NF-kappa	_	NN	NN	_	18	NMOD	_	_
18	B	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	cloning	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	complementary	_	JJ	JJ	_	6	NMOD	_	_
6	DNA	_	NN	NN	_	3	PMOD	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	50K	_	CD	CD	_	10	NMOD	_	_
10	subunit	_	NN	NN	_	7	PMOD	_	_
11	helped	_	VBD	VBD	_	0	ROOT-S	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	identify	_	VB	VB	_	11	OBJ	_	_
14	an	_	DT	DT	_	18	NMOD	_	_
15	exclusively	_	RB	RB	_	16	AMOD	_	_
16	cytoplasmic	_	JJ	JJ	_	18	NMOD	_	_
17	105K	_	CD	CD	_	18	NMOD	_	_
18	precursor	_	NN	NN	_	13	OBJ	_	_
19	(	_	(	(	_	20	P	_	_
20	p105	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	(	_	(	(	_	23	P	_	_
23	V.B.	_	NNP	NNP	_	13	PRN	_	_
24	,	_	,	,	_	23	P	_	_
25	P.K.	_	NNP	NNP	_	23	COORD	_	_
26	and	_	CC	CC	_	23	CC	_	_
27	A.I.	_	NNP	NNP	_	23	COORD	_	_
28	,	_	,	,	_	23	P	_	_
29	manuscript	_	NN	NN	_	23	DEP	_	_
30	submitted	_	VBN	VBN	_	29	NMOD	_	_
31	)	_	)	)	_	23	P	_	_
32	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	expression	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	active	_	JJ	JJ	_	6	NMOD	_	_
5	NF-kappa	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	3	PMOD	_	_
7	might	_	MD	MD	_	0	ROOT-S	_	_
8	therefore	_	RB	RB	_	7	ADV	_	_
9	also	_	RB	RB	_	7	ADV	_	_
10	be	_	VB	VB	_	7	VC	_	_
11	regulated	_	VBN	VBN	_	10	VC	_	_
12	by	_	IN	IN	_	11	LGS	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	extent	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	processing	_	NN	NN	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	p105	_	NN	NN	_	17	PMOD	_	_
19	.	_	.	.	_	7	P	_	_

1	Because	_	IN	IN	_	12	ADV	_	_
2	HIV-1	_	NN	NN	_	3	SBJ	_	_
3	requires	_	VBZ	VBZ	_	1	VMOD	_	_
4	active	_	JJ	JJ	_	6	NMOD	_	_
5	NF-kappa	_	NN	NN	_	6	NMOD	_	_
6	B	_	NN	NN	_	3	OBJ	_	_
7	for	_	IN	IN	_	3	ADV	_	_
8	efficient	_	JJ	JJ	_	9	NMOD	_	_
9	transcription	_	NN	NN	_	7	PMOD	_	_
10	,	_	,	,	_	12	P	_	_
11	we	_	PRP	PRP	_	12	SBJ	_	_
12	tested	_	VBD	VBD	_	0	ROOT-S	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	effect	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	HIV-1	_	NN	NN	_	17	NMOD	_	_
17	infection	_	NN	NN	_	15	PMOD	_	_
18	on	_	IN	IN	_	14	NMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	processing	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	25	NMOD	_	_
23	human	_	JJ	JJ	_	25	NMOD	_	_
24	105K	_	CD	CD	_	25	NMOD	_	_
25	precursor	_	NN	NN	_	21	PMOD	_	_
26	.	_	.	.	_	12	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	that	_	IN	IN	_	2	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	HIV-1	_	NN	NN	_	7	NMOD	_	_
7	protease	_	NN	NN	_	8	SBJ	_	_
8	can	_	MD	MD	_	4	VMOD	_	_
9	process	_	VB	VB	_	8	VC	_	_
10	p105	_	NN	NN	_	9	OBJ	_	_
11	and	_	CC	CC	_	8	CC	_	_
12	increases	_	VBZ	VBZ	_	8	COORD	_	_
13	levels	_	NNS	NNS	_	12	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	active	_	JJ	JJ	_	19	NMOD	_	_
16	nuclear	_	JJ	JJ	_	19	NMOD	_	_
17	NF-kappa	_	NN	NN	_	19	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	complex	_	NN	NN	_	14	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	Vitamin	_	NN	NN	_	4	NMOD	_	_
2	D	_	NN	NN	_	4	NMOD	_	_
3	receptor	_	NN	NN	_	4	NMOD	_	_
4	expression	_	NN	NN	_	0	ROOT-FRAG	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	human	_	JJ	JJ	_	7	NMOD	_	_
7	lymphocytes	_	NNS	NNS	_	5	PMOD	_	_
8	.	_	.	.	_	4	P	_	_

1	Signal	_	NN	NN	_	2	NMOD	_	_
2	requirements	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	characterization	_	NN	NN	_	2	COORD	_	_
5	by	_	IN	IN	_	2	NMOD	_	_
6	western	_	NN	NN	_	7	NMOD	_	_
7	blots	_	NNS	NNS	_	5	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	DNA	_	NN	NN	_	10	NMOD	_	_
10	sequencing	_	NN	NN	_	7	COORD	_	_
11	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	signals	_	NNS	NNS	_	30	SBJ	_	_
3	controlling	_	VBG	VBG	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	expression	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	receptor	_	NN	NN	_	9	NMOD	_	_
9	protein	_	NN	NN	_	6	PMOD	_	_
10	for	_	IN	IN	_	9	NMOD	_	_
11	1	_	CD	CD	_	13	NMOD	_	_
12	alpha,25-dihydroxyvitamin	_	NN	NN	_	13	NMOD	_	_
13	D3	_	NN	NN	_	10	PMOD	_	_
14	in	_	IN	IN	_	5	NMOD	_	_
15	normal	_	JJ	JJ	_	17	NMOD	_	_
16	human	_	JJ	JJ	_	17	NMOD	_	_
17	lymphocytes	_	NNS	NNS	_	14	PMOD	_	_
18	and	_	CC	CC	_	2	CC	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	relationship	_	NN	NN	_	2	COORD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	this	_	DT	DT	_	23	NMOD	_	_
23	protein	_	NN	NN	_	21	PMOD	_	_
24	to	_	TO	TO	_	20	NMOD	_	_
25	the	_	DT	DT	_	29	NMOD	_	_
26	classical	_	JJ	JJ	_	29	NMOD	_	_
27	vitamin	_	NN	NN	_	29	NMOD	_	_
28	D	_	NN	NN	_	29	NMOD	_	_
29	receptor	_	NN	NN	_	24	PMOD	_	_
30	were	_	VBD	VBD	_	0	ROOT-S	_	_
31	examined	_	VBN	VBN	_	30	VC	_	_
32	.	_	.	.	_	30	P	_	_

1	Lymphocytes	_	NNS	NNS	_	12	SBJ	_	_
2	activated	_	VBN	VBN	_	1	NMOD	_	_
3	with	_	IN	IN	_	2	ADV	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	OKT3	_	NN	NN	_	6	NMOD	_	_
6	antibody	_	NN	NN	_	3	PMOD	_	_
7	to	_	TO	TO	_	6	NMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	T-cell	_	NN	NN	_	11	NMOD	_	_
10	antigen	_	NN	NN	_	11	NMOD	_	_
11	receptor	_	NN	NN	_	7	PMOD	_	_
12	expressed	_	VBD	VBD	_	0	ROOT-S	_	_
13	fewer	_	JJR	JJR	_	15	NMOD	_	_
14	binding	_	VBG	VBG	_	15	NMOD	_	_
15	sites	_	NNS	NNS	_	12	OBJ	_	_
16	as	_	IN	IN	_	12	ADV	_	_
17	compared	_	VBN	VBN	_	16	VMOD	_	_
18	to	_	TO	TO	_	17	ADV	_	_
19	lymphocytes	_	NNS	NNS	_	18	PMOD	_	_
20	that	_	WDT	WDT	_	21	SBJ	_	_
21	were	_	VBD	VBD	_	19	NMOD	_	_
22	activated	_	VBN	VBN	_	21	VC	_	_
23	by	_	IN	IN	_	22	LGS	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	polyclonal	_	JJ	JJ	_	27	NMOD	_	_
26	activator	_	NN	NN	_	27	NMOD	_	_
27	phytohemagglutinin	_	NN	NN	_	23	PMOD	_	_
28	(	_	(	(	_	29	P	_	_
29	PHA	_	NN	NN	_	27	PRN	_	_
30	)	_	)	)	_	29	P	_	_
31	.	_	.	.	_	12	P	_	_

1	However	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	combination	_	NN	NN	_	10	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	OKT3	_	NN	NN	_	4	PMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	phorbol	_	NN	NN	_	9	NMOD	_	_
8	myristate	_	NN	NN	_	9	NMOD	_	_
9	acetate	_	NN	NN	_	5	COORD	_	_
10	produced	_	VBD	VBD	_	0	ROOT-S	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	concentration	_	NN	NN	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	binding	_	VBG	VBG	_	15	NMOD	_	_
15	sites	_	NNS	NNS	_	13	PMOD	_	_
16	similar	_	JJ	JJ	_	12	NMOD	_	_
17	to	_	TO	TO	_	16	AMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	PHA-activated	_	JJ	JJ	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	receptor	_	NN	NN	_	12	SBJ	_	_
3	from	_	IN	IN	_	2	NMOD	_	_
4	OKT3	_	NN	NN	_	11	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	OKT3	_	NN	NN	_	4	COORD	_	_
7	+	_	CC	CC	_	6	CC	_	_
8	phorbol	_	NN	NN	_	6	COORD	_	_
9	myristate	_	NN	NN	_	6	COORD	_	_
10	acetate-activated	_	JJ	JJ	_	6	COORD	_	_
11	lymphocytes	_	NNS	NNS	_	3	PMOD	_	_
12	exhibited	_	VBD	VBD	_	0	ROOT-S	_	_
13	decreased	_	VBN	VBN	_	14	NMOD	_	_
14	binding	_	NN	NN	_	12	IOBJ	_	_
15	to	_	TO	TO	_	14	NMOD	_	_
16	DNA-cellulose	_	NN	NN	_	15	PMOD	_	_
17	compared	_	VBN	VBN	_	12	OBJ	_	_
18	to	_	TO	TO	_	17	ADV	_	_
19	PHA-activated	_	JJ	JJ	_	20	NMOD	_	_
20	lymphocytes	_	NNS	NNS	_	18	PMOD	_	_
21	.	_	.	.	_	12	P	_	_

1	In	_	IN	IN	_	31	ADV	_	_
2	lymphocytes	_	NNS	NNS	_	1	PMOD	_	_
3	activated	_	VBN	VBN	_	2	NMOD	_	_
4	either	_	CC	CC	_	5	CC	_	_
5	by	_	IN	IN	_	3	LGS	_	_
6	PHA	_	NN	NN	_	5	PMOD	_	_
7	or	_	CC	CC	_	6	CC	_	_
8	OKT3	_	NN	NN	_	6	COORD	_	_
9	(	_	(	(	_	1	P	_	_
10	but	_	CC	CC	_	1	CC	_	_
11	not	_	RB	RB	_	12	DEP	_	_
12	in	_	IN	IN	_	1	COORD	_	_
13	resting	_	VBG	VBG	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	)	_	)	)	_	1	P	_	_
16	,	_	,	,	_	31	P	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	50-kDa	_	JJ	JJ	_	19	NMOD	_	_
19	species	_	NNS	NNS	_	31	SBJ	_	_
20	cross-reacting	_	VBG	VBG	_	19	NMOD	_	_
21	with	_	IN	IN	_	20	ADV	_	_
22	a	_	DT	DT	_	24	NMOD	_	_
23	monoclonal	_	JJ	JJ	_	24	NMOD	_	_
24	antibody	_	NN	NN	_	21	PMOD	_	_
25	against	_	IN	IN	_	24	NMOD	_	_
26	the	_	DT	DT	_	30	NMOD	_	_
27	intestinal	_	JJ	JJ	_	30	NMOD	_	_
28	vitamin	_	NN	NN	_	30	NMOD	_	_
29	D	_	NN	NN	_	30	NMOD	_	_
30	receptor	_	NN	NN	_	25	PMOD	_	_
31	was	_	VBD	VBD	_	0	ROOT-S	_	_
32	detected	_	VBN	VBN	_	31	VC	_	_
33	.	_	.	.	_	31	P	_	_

1	Finally	_	RB	RB	_	7	TMP	_	_
2	,	_	,	,	_	7	P	_	_
3	RNA	_	NN	NN	_	7	SBJ	_	_
4	from	_	IN	IN	_	3	NMOD	_	_
5	activated	_	VBN	VBN	_	6	NMOD	_	_
6	lymphocytes	_	NNS	NNS	_	4	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	amplified	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	ADV	_	_
10	polymerase	_	NN	NN	_	12	NMOD	_	_
11	chain	_	NN	NN	_	12	NMOD	_	_
12	reaction	_	NN	NN	_	9	PMOD	_	_
13	using	_	VBG	VBG	_	8	OBJ	_	_
14	oligonucleotide	_	NN	NN	_	15	NMOD	_	_
15	primers	_	NNS	NNS	_	13	OBJ	_	_
16	flanking	_	VBG	VBG	_	15	NMOD	_	_
17	the	_	DT	DT	_	22	NMOD	_	_
18	196	_	CD	CD	_	22	NMOD	_	_
19	base	_	NN	NN	_	22	NMOD	_	_
20	pair	_	NN	NN	_	22	NMOD	_	_
21	long	_	JJ	JJ	_	22	NMOD	_	_
22	region	_	NN	NN	_	16	OBJ	_	_
23	encoding	_	VBG	VBG	_	22	NMOD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	DNA-binding	_	JJ	JJ	_	26	NMOD	_	_
26	domain	_	NN	NN	_	23	OBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	31	NMOD	_	_
29	human	_	JJ	JJ	_	31	NMOD	_	_
30	intestinal	_	JJ	JJ	_	31	NMOD	_	_
31	receptor	_	NN	NN	_	27	PMOD	_	_
32	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	amplified	_	VBN	VBN	_	3	NMOD	_	_
3	product	_	NN	NN	_	4	SBJ	_	_
4	showed	_	VBD	VBD	_	0	ROOT-S	_	_
5	an	_	DT	DT	_	8	NMOD	_	_
6	identical	_	JJ	JJ	_	8	NMOD	_	_
7	nucleotide	_	NN	NN	_	8	NMOD	_	_
8	sequence	_	NN	NN	_	4	OBJ	_	_
9	to	_	TO	TO	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	DNA-binding	_	JJ	JJ	_	12	NMOD	_	_
12	domain	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	human	_	JJ	JJ	_	17	NMOD	_	_
16	intestinal	_	JJ	JJ	_	17	NMOD	_	_
17	receptor	_	NN	NN	_	13	PMOD	_	_
18	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	expression	_	NN	NN	_	12	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	1,25--LRB-OH-RRB-2D3	_	NN	NN	_	9	NMOD	_	_
9	receptor	_	NN	NN	_	6	PMOD	_	_
10	in	_	IN	IN	_	5	NMOD	_	_
11	lymphocytes	_	NNS	NNS	_	10	PMOD	_	_
12	is	_	VBZ	VBZ	_	4	VMOD	_	_
13	triggered	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	LGS	_	_
15	distinct	_	JJ	JJ	_	18	NMOD	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	contingent	_	JJ	JJ	_	15	COORD	_	_
18	signals	_	NNS	NNS	_	14	PMOD	_	_
19	,	_	,	,	_	4	P	_	_
20	and	_	CC	CC	_	4	CC	_	_
21	that	_	IN	IN	_	4	COORD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	protein	_	NN	NN	_	29	SBJ	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	mRNA	_	NN	NN	_	23	COORD	_	_
27	encoding	_	VBG	VBG	_	23	NMOD	_	_
28	it	_	PRP	PRP	_	27	OBJ	_	_
29	are	_	VBP	VBP	_	21	VMOD	_	_
30	identical	_	JJ	JJ	_	29	PRD	_	_
31	to	_	TO	TO	_	30	AMOD	_	_
32	the	_	DT	DT	_	36	NMOD	_	_
33	classical	_	JJ	JJ	_	36	NMOD	_	_
34	vitamin	_	NN	NN	_	36	NMOD	_	_
35	D	_	NN	NN	_	36	NMOD	_	_
36	receptor	_	NN	NN	_	31	PMOD	_	_
37	.	_	.	.	_	3	P	_	_

1	Cloning	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	murine	_	JJ	JJ	_	4	NMOD	_	_
4	TCF-1	_	NN	NN	_	2	PMOD	_	_
5	,	_	,	,	_	4	P	_	_
6	a	_	DT	DT	_	10	NMOD	_	_
7	T	_	NN	NN	_	10	NMOD	_	_
8	cell-specific	_	JJ	JJ	_	7	AMOD	_	_
9	transcription	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	4	NMOD	_	_
11	interacting	_	VBG	VBG	_	10	NMOD	_	_
12	with	_	IN	IN	_	11	ADV	_	_
13	functional	_	JJ	JJ	_	14	NMOD	_	_
14	motifs	_	NNS	NNS	_	12	PMOD	_	_
15	in	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	23	NMOD	_	_
17	CD3-epsilon	_	NN	NN	_	23	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	T	_	NN	NN	_	17	COORD	_	_
20	cell	_	NN	NN	_	23	NMOD	_	_
21	receptor	_	NN	NN	_	23	NMOD	_	_
22	alpha	_	NN	NN	_	23	NMOD	_	_
23	enhancers	_	NNS	NNS	_	15	PMOD	_	_
24	.	_	.	.	_	1	P	_	_

1	CD3-epsilon	_	NN	NN	_	3	NMOD	_	_
2	gene	_	NN	NN	_	3	NMOD	_	_
3	expression	_	NN	NN	_	4	SBJ	_	_
4	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	confined	_	VBN	VBN	_	4	VC	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	T	_	NN	NN	_	10	NMOD	_	_
9	cell	_	NN	NN	_	10	NMOD	_	_
10	lineage	_	NN	NN	_	6	PMOD	_	_
11	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	recently	_	RB	RB	_	4	TMP	_	_
4	identified	_	VBN	VBN	_	2	VC	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	cloned	_	VBN	VBN	_	4	COORD	_	_
7	a	_	DT	DT	_	10	NMOD	_	_
8	human	_	JJ	JJ	_	10	NMOD	_	_
9	transcription	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	4	OBJ	_	_
11	,	_	,	,	_	10	P	_	_
12	TCF-1	_	NN	NN	_	10	NMOD	_	_
13	,	_	,	,	_	10	P	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	binds	_	VBZ	VBZ	_	10	NMOD	_	_
16	to	_	TO	TO	_	15	ADV	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	functional	_	JJ	JJ	_	19	NMOD	_	_
19	element	_	NN	NN	_	16	PMOD	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	T	_	NN	NN	_	24	NMOD	_	_
23	lymphocyte-specific	_	JJ	JJ	_	22	AMOD	_	_
24	enhancer	_	NN	NN	_	20	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	CD3-epsilon	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	a	_	DT	DT	_	3	NMOD	_	_
3	panel	_	NN	NN	_	1	PMOD	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	human	_	JJ	JJ	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	lines	_	NNS	NNS	_	4	PMOD	_	_
8	,	_	,	,	_	11	P	_	_
9	TCF-1	_	NN	NN	_	10	NMOD	_	_
10	expression	_	NN	NN	_	11	SBJ	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	restricted	_	JJ	JJ	_	11	PRD	_	_
13	to	_	TO	TO	_	12	AMOD	_	_
14	T	_	NN	NN	_	16	NMOD	_	_
15	lineage	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	13	PMOD	_	_
17	.	_	.	.	_	11	P	_	_

1	TCF-1	_	NN	NN	_	2	SBJ	_	_
2	belonged	_	VBD	VBD	_	0	ROOT-S	_	_
3	to	_	TO	TO	_	2	ADV	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	novel	_	JJ	JJ	_	6	NMOD	_	_
6	family	_	NN	NN	_	3	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	genes	_	NNS	NNS	_	7	PMOD	_	_
9	that	_	WDT	WDT	_	10	SBJ	_	_
10	contain	_	VBP	VBP	_	8	NMOD	_	_
11	the	_	DT	DT	_	20	NMOD	_	_
12	so-called	_	JJ	JJ	_	20	NMOD	_	_
13	high	_	JJ	JJ	_	20	NMOD	_	_
14	mobility	_	NN	NN	_	20	NMOD	_	_
15	group	_	NN	NN	_	20	NMOD	_	_
16	1	_	CD	CD	_	20	NMOD	_	_
17	(	_	(	(	_	20	P	_	_
18	HMG	_	NN	NN	_	20	NMOD	_	_
19	)	_	)	)	_	20	P	_	_
20	box	_	NN	NN	_	10	OBJ	_	_
21	.	_	.	.	_	2	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	report	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	cloning	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	murine	_	JJ	JJ	_	8	NMOD	_	_
8	TCF-1	_	NN	NN	_	6	PMOD	_	_
9	.	_	.	.	_	3	P	_	_

1	Two	_	CD	CD	_	3	NMOD	_	_
2	splice	_	NN	NN	_	3	NMOD	_	_
3	alternatives	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	identified	_	VBN	VBN	_	4	VC	_	_
6	that	_	WDT	WDT	_	7	SBJ	_	_
7	were	_	VBD	VBD	_	3	NMOD	_	_
8	not	_	RB	RB	_	7	VMOD	_	_
9	previously	_	RB	RB	_	7	TMP	_	_
10	observed	_	VBN	VBN	_	7	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	human	_	JJ	JJ	_	13	NMOD	_	_
13	TCF-1	_	NN	NN	_	11	PMOD	_	_
14	.	_	.	.	_	4	P	_	_

1	Murine	_	JJ	JJ	_	4	NMOD	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	human	_	JJ	JJ	_	1	COORD	_	_
4	TCF-1	_	NN	NN	_	5	SBJ	_	_
5	displayed	_	VBD	VBD	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	12	NMOD	_	_
7	95.5	_	CD	CD	_	8	DEP	_	_
8	%	_	NN	NN	_	12	NMOD	_	_
9	overall	_	JJ	JJ	_	12	NMOD	_	_
10	amino	_	NN	NN	_	12	NMOD	_	_
11	acid	_	NN	NN	_	12	NMOD	_	_
12	homology	_	NN	NN	_	5	OBJ	_	_
13	.	_	.	.	_	5	P	_	_

1	Recombinant	_	JJ	JJ	_	5	NMOD	_	_
2	murine	_	JJ	JJ	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	human	_	JJ	JJ	_	2	COORD	_	_
5	TCF-1	_	NN	NN	_	6	SBJ	_	_
6	recognized	_	VBD	VBD	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	same	_	JJ	JJ	_	10	NMOD	_	_
9	sequence	_	NN	NN	_	10	NMOD	_	_
10	motif	_	NN	NN	_	6	OBJ	_	_
11	in	_	IN	IN	_	6	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	CD3-epsilon	_	NN	NN	_	14	NMOD	_	_
14	enhancer	_	NN	NN	_	11	PMOD	_	_
15	as	_	IN	IN	_	6	ADV	_	_
16	judged	_	VBN	VBN	_	15	VMOD	_	_
17	by	_	IN	IN	_	16	ADV	_	_
18	gel	_	NN	NN	_	19	NMOD	_	_
19	retardation	_	NN	NN	_	23	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	methylation	_	NN	NN	_	22	NMOD	_	_
22	interference	_	NN	NN	_	19	COORD	_	_
23	assays	_	NNS	NNS	_	17	PMOD	_	_
24	.	_	.	.	_	6	P	_	_

1	With	_	IN	IN	_	10	ADV	_	_
2	the	_	DT	DT	_	5	NMOD	_	_
3	murine	_	JJ	JJ	_	5	NMOD	_	_
4	cDNA	_	NN	NN	_	5	NMOD	_	_
5	clones	_	NNS	NNS	_	1	PMOD	_	_
6	several	_	JJ	JJ	_	7	NMOD	_	_
7	aspects	_	NNS	NNS	_	10	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	TCF-1	_	NN	NN	_	8	PMOD	_	_
10	were	_	VBD	VBD	_	0	ROOT-S	_	_
11	analyzed	_	VBN	VBN	_	10	VC	_	_
12	.	_	.	.	_	10	P	_	_

1	First	_	RB	RB	_	5	ADV	_	_
2	,	_	,	,	_	5	P	_	_
3	deletion	_	NN	NN	_	4	NMOD	_	_
4	analysis	_	NN	NN	_	5	SBJ	_	_
5	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	region	_	NN	NN	_	15	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	TCF-1	_	NN	NN	_	9	PMOD	_	_
11	containing	_	VBG	VBG	_	8	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	HMG	_	NN	NN	_	14	NMOD	_	_
14	box	_	NN	NN	_	11	OBJ	_	_
15	was	_	VBD	VBD	_	6	VMOD	_	_
16	sufficient	_	JJ	JJ	_	15	PRD	_	_
17	for	_	IN	IN	_	16	AMOD	_	_
18	sequence-specific	_	JJ	JJ	_	19	NMOD	_	_
19	binding	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	5	P	_	_

1	Second	_	RB	RB	_	15	ADV	_	_
2	,	_	,	,	_	15	P	_	_
3	by	_	IN	IN	_	15	ADV	_	_
4	high	_	JJ	JJ	_	7	NMOD	_	_
5	stringency	_	NN	NN	_	7	NMOD	_	_
6	Northern	_	NN	NN	_	7	NMOD	_	_
7	blotting	_	NN	NN	_	3	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	in	_	FW	FW	_	10	AMOD	_	_
10	situ	_	FW	FW	_	11	NMOD	_	_
11	hybridization	_	NN	NN	_	7	COORD	_	_
12	,	_	,	,	_	15	P	_	_
13	TCF-1	_	NN	NN	_	14	NMOD	_	_
14	expression	_	NN	NN	_	15	SBJ	_	_
15	was	_	VBD	VBD	_	0	ROOT-S	_	_
16	shown	_	VBN	VBN	_	15	VC	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	be	_	VB	VB	_	16	OBJ	_	_
19	confined	_	VBN	VBN	_	18	VC	_	_
20	to	_	TO	TO	_	19	ADV	_	_
21	the	_	DT	DT	_	22	NMOD	_	_
22	thymus	_	NN	NN	_	20	PMOD	_	_
23	and	_	CC	CC	_	20	CC	_	_
24	to	_	TO	TO	_	20	COORD	_	_
25	the	_	DT	DT	_	28	NMOD	_	_
26	T	_	NN	NN	_	28	NMOD	_	_
27	cell	_	NN	NN	_	28	NMOD	_	_
28	areas	_	NNS	NNS	_	24	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	spleen	_	NN	NN	_	29	PMOD	_	_
32	.	_	.	.	_	15	P	_	_

1	Third	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	TCF-1	_	NN	NN	_	4	SBJ	_	_
4	bound	_	VBD	VBD	_	0	ROOT-S	_	_
5	specifically	_	RB	RB	_	4	ADV	_	_
6	to	_	TO	TO	_	4	ADV	_	_
7	a	_	DT	DT	_	11	NMOD	_	_
8	functional	_	JJ	JJ	_	11	NMOD	_	_
9	T	_	NN	NN	_	11	NMOD	_	_
10	cell-specific	_	JJ	JJ	_	9	AMOD	_	_
11	element	_	NN	NN	_	6	PMOD	_	_
12	in	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	21	NMOD	_	_
14	T	_	NN	NN	_	17	NMOD	_	_
15	cell	_	NN	NN	_	17	NMOD	_	_
16	receptor	_	NN	NN	_	17	NMOD	_	_
17	alpha	_	NN	NN	_	21	NMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	TCR-alpha	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	enhancer	_	NN	NN	_	12	PMOD	_	_
22	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	T	_	NN	NN	_	4	NMOD	_	_
3	lineage-specific	_	JJ	JJ	_	2	AMOD	_	_
4	expression	_	NN	NN	_	17	SBJ	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	affinity	_	NN	NN	_	4	COORD	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	functional	_	JJ	JJ	_	10	NMOD	_	_
10	motifs	_	NNS	NNS	_	8	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	16	NMOD	_	_
13	TCR-alpha	_	NN	NN	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	CD3-epsilon	_	NN	NN	_	13	COORD	_	_
16	enhancers	_	NNS	NNS	_	11	PMOD	_	_
17	imply	_	VBP	VBP	_	0	ROOT-S	_	_
18	an	_	DT	DT	_	20	NMOD	_	_
19	important	_	JJ	JJ	_	20	NMOD	_	_
20	role	_	NN	NN	_	17	OBJ	_	_
21	for	_	IN	IN	_	20	NMOD	_	_
22	TCF-1	_	NN	NN	_	21	PMOD	_	_
23	in	_	IN	IN	_	20	NMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	establishment	_	NN	NN	_	23	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	31	NMOD	_	_
28	mature	_	JJ	JJ	_	31	NMOD	_	_
29	T	_	NN	NN	_	31	NMOD	_	_
30	cell	_	NN	NN	_	31	NMOD	_	_
31	phenotype	_	NN	NN	_	26	PMOD	_	_
32	.	_	.	.	_	17	P	_	_

1	Positive	_	JJ	JJ	_	4	NMOD	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	negative	_	JJ	JJ	_	1	COORD	_	_
4	regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	immunoglobulin	_	NN	NN	_	8	NMOD	_	_
7	gene	_	NN	NN	_	8	NMOD	_	_
8	expression	_	NN	NN	_	5	PMOD	_	_
9	by	_	IN	IN	_	4	NMOD	_	_
10	a	_	DT	DT	_	14	NMOD	_	_
11	novel	_	JJ	JJ	_	14	NMOD	_	_
12	B-cell-specific	_	JJ	JJ	_	14	NMOD	_	_
13	enhancer	_	NN	NN	_	14	NMOD	_	_
14	element	_	NN	NN	_	9	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	A	_	DT	DT	_	5	NMOD	_	_
2	new	_	JJ	JJ	_	5	NMOD	_	_
3	B-cell-specific	_	JJ	JJ	_	5	NMOD	_	_
4	enhancer	_	NN	NN	_	5	NMOD	_	_
5	element	_	NN	NN	_	6	SBJ	_	_
6	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	been	_	VBN	VBN	_	6	VC	_	_
8	identified	_	VBN	VBN	_	7	VC	_	_
9	3'	_	JJ	JJ	_	10	PMOD	_	_
10	of	_	IN	IN	_	8	ADV	_	_
11	E4	_	NN	NN	_	10	PMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	octamerlike	_	JJ	JJ	_	15	NMOD	_	_
15	motifs	_	NNS	NNS	_	11	COORD	_	_
16	in	_	IN	IN	_	11	NMOD	_	_
17	the	_	DT	DT	_	22	NMOD	_	_
18	human	_	JJ	JJ	_	22	NMOD	_	_
19	immunoglobulin	_	NN	NN	_	22	NMOD	_	_
20	heavy-chain	_	NN	NN	_	22	NMOD	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	enhancer	_	NN	NN	_	16	PMOD	_	_
23	.	_	.	.	_	6	P	_	_

1	Tandem	_	JJ	JJ	_	2	NMOD	_	_
2	copies	_	NNS	NNS	_	22	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	this	_	DT	DT	_	7	NMOD	_	_
5	67-bp	_	JJ	JJ	_	7	NMOD	_	_
6	MnlI-AluI	_	NN	NN	_	7	NMOD	_	_
7	fragment	_	NN	NN	_	3	PMOD	_	_
8	,	_	,	,	_	22	P	_	_
9	when	_	WRB	WRB	_	10	ADV	_	_
10	fused	_	VBN	VBN	_	22	TMP	_	_
11	to	_	TO	TO	_	10	ADV	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	chloramphenicol	_	JJ	JJ	_	15	NMOD	_	_
14	acetyltransferase	_	NN	NN	_	15	NMOD	_	_
15	gene	_	NN	NN	_	11	PMOD	_	_
16	driven	_	VBN	VBN	_	15	NMOD	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	conalbumin	_	JJ	JJ	_	20	NMOD	_	_
20	promoter	_	NN	NN	_	17	PMOD	_	_
21	,	_	,	,	_	22	P	_	_
22	stimulated	_	VBD	VBD	_	0	ROOT-S	_	_
23	transcription	_	NN	NN	_	22	OBJ	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	B	_	NN	NN	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	24	PMOD	_	_
27	but	_	CC	CC	_	24	CC	_	_
28	not	_	RB	RB	_	29	DEP	_	_
29	in	_	IN	IN	_	24	COORD	_	_
30	Jurkat	_	NN	NN	_	32	NMOD	_	_
31	T	_	NN	NN	_	32	NMOD	_	_
32	cells	_	NNS	NNS	_	29	PMOD	_	_
33	or	_	CC	CC	_	32	CC	_	_
34	HeLa	_	NN	NN	_	35	NMOD	_	_
35	cells	_	NNS	NNS	_	32	COORD	_	_
36	.	_	.	.	_	22	P	_	_

1	Footprinting	_	NN	NN	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	3	SBJ	_	_
3	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	identical	_	JJ	JJ	_	8	NMOD	_	_
7	sequence	_	NN	NN	_	8	NMOD	_	_
8	CCGAAACTGAAAAGG	_	NN	NN	_	13	SBJ	_	_
9	,	_	,	,	_	8	P	_	_
10	designated	_	VBN	VBN	_	8	NMOD	_	_
11	E6	_	NN	NN	_	10	OBJ	_	_
12	,	_	,	,	_	8	P	_	_
13	was	_	VBD	VBD	_	4	VMOD	_	_
14	protected	_	VBN	VBN	_	13	VC	_	_
15	by	_	IN	IN	_	14	LGS	_	_
16	nuclear	_	JJ	JJ	_	17	NMOD	_	_
17	extracts	_	NNS	NNS	_	15	PMOD	_	_
18	from	_	IN	IN	_	17	NMOD	_	_
19	B	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	18	PMOD	_	_
21	,	_	,	,	_	20	P	_	_
22	T	_	NN	NN	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	20	COORD	_	_
24	,	_	,	,	_	20	P	_	_
25	or	_	CC	CC	_	20	CC	_	_
26	HeLa	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	20	COORD	_	_
28	.	_	.	.	_	3	P	_	_

1	Gel	_	NN	NN	_	4	NMOD	_	_
2	mobility	_	NN	NN	_	4	NMOD	_	_
3	shift	_	NN	NN	_	4	NMOD	_	_
4	assays	_	NNS	NNS	_	10	SBJ	_	_
5	using	_	VBG	VBG	_	4	NMOD	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	synthetic	_	JJ	JJ	_	9	NMOD	_	_
8	E6	_	NN	NN	_	9	NMOD	_	_
9	motif	_	NN	NN	_	5	OBJ	_	_
10	detected	_	VBD	VBD	_	0	ROOT-S	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	B-cell-specific	_	JJ	JJ	_	13	NMOD	_	_
13	complex	_	NN	NN	_	10	OBJ	_	_
14	in	_	IN	IN	_	10	ADV	_	_
15	addition	_	NN	NN	_	14	DEP	_	_
16	to	_	TO	TO	_	14	DEP	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	ubiquitous	_	JJ	JJ	_	19	NMOD	_	_
19	band	_	NN	NN	_	14	PMOD	_	_
20	found	_	VBN	VBN	_	19	NMOD	_	_
21	also	_	RB	RB	_	22	DEP	_	_
22	in	_	IN	IN	_	20	ADV	_	_
23	T	_	NN	NN	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	22	PMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	HeLa	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	24	COORD	_	_
28	.	_	.	.	_	10	P	_	_

1	In	_	IN	IN	_	17	ADV	_	_
2	agreement	_	NN	NN	_	1	DEP	_	_
3	with	_	IN	IN	_	1	DEP	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	results	_	NNS	NNS	_	1	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	gel	_	NN	NN	_	9	NMOD	_	_
8	retardation	_	NN	NN	_	9	NMOD	_	_
9	assays	_	NNS	NNS	_	6	PMOD	_	_
10	,	_	,	,	_	17	P	_	_
11	tandem	_	JJ	JJ	_	12	NMOD	_	_
12	copies	_	NNS	NNS	_	17	SBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	E6	_	NN	NN	_	16	NMOD	_	_
16	motif	_	NN	NN	_	13	PMOD	_	_
17	stimulated	_	VBD	VBD	_	0	ROOT-S	_	_
18	transcription	_	NN	NN	_	17	OBJ	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	ARH77	_	NN	NN	_	23	NMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	Raji	_	NN	NN	_	20	COORD	_	_
23	cells	_	NNS	NNS	_	19	PMOD	_	_
24	but	_	CC	CC	_	19	CC	_	_
25	not	_	RB	RB	_	26	DEP	_	_
26	in	_	IN	IN	_	19	COORD	_	_
27	Jurkat	_	NN	NN	_	30	NMOD	_	_
28	or	_	CC	CC	_	27	CC	_	_
29	HeLa	_	NN	NN	_	27	COORD	_	_
30	cells	_	NNS	NNS	_	26	PMOD	_	_
31	.	_	.	.	_	17	P	_	_

1	Furthermore	_	RB	RB	_	7	ADV	_	_
2	,	_	,	,	_	7	P	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	mutant	_	JJ	JJ	_	6	NMOD	_	_
5	E6	_	NN	NN	_	6	NMOD	_	_
6	motif	_	NN	NN	_	7	SBJ	_	_
7	lost	_	VBD	VBD	_	0	ROOT-S	_	_
8	both	_	CC	CC	_	7	ADV	_	_
9	in	_	FW	FW	_	10	AMOD	_	_
10	vitro	_	FW	FW	_	12	NMOD	_	_
11	binding	_	NN	NN	_	12	NMOD	_	_
12	activity	_	NN	NN	_	8	COORD	_	_
13	and	_	CC	CC	_	8	CC	_	_
14	in	_	FW	FW	_	15	AMOD	_	_
15	vivo	_	FW	FW	_	17	NMOD	_	_
16	enhancer	_	NN	NN	_	17	NMOD	_	_
17	activity	_	NN	NN	_	8	COORD	_	_
18	.	_	.	.	_	7	P	_	_

1	In	_	IN	IN	_	26	ADV	_	_
2	striking	_	JJ	JJ	_	3	NMOD	_	_
3	contrast	_	NN	NN	_	1	PMOD	_	_
4	to	_	TO	TO	_	3	NMOD	_	_
5	the	_	DT	DT	_	9	NMOD	_	_
6	mouse	_	NN	NN	_	9	NMOD	_	_
7	Ig	_	NN	NN	_	9	NMOD	_	_
8	heavy-chain	_	JJ	JJ	_	9	NMOD	_	_
9	enhancer	_	NN	NN	_	4	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	in	_	IN	IN	_	16	ADV	_	_
12	which	_	WDT	WDT	_	11	PMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	octamer	_	NN	NN	_	15	NMOD	_	_
15	motif	_	NN	NN	_	16	SBJ	_	_
16	acts	_	VBZ	VBZ	_	9	NMOD	_	_
17	as	_	IN	IN	_	16	ADV	_	_
18	a	_	DT	DT	_	21	NMOD	_	_
19	B-cell-specific	_	JJ	JJ	_	21	NMOD	_	_
20	enhancer	_	NN	NN	_	21	NMOD	_	_
21	element	_	NN	NN	_	17	PMOD	_	_
22	,	_	,	,	_	9	P	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	human	_	JJ	JJ	_	25	NMOD	_	_
25	enhancer	_	NN	NN	_	26	SBJ	_	_
26	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
27	an	_	DT	DT	_	29	NMOD	_	_
28	octamerlike	_	JJ	JJ	_	29	NMOD	_	_
29	sequence	_	NN	NN	_	26	OBJ	_	_
30	with	_	IN	IN	_	29	NMOD	_	_
31	one	_	CD	CD	_	33	NMOD	_	_
32	base	_	NN	NN	_	33	NMOD	_	_
33	substitution	_	NN	NN	_	30	PMOD	_	_
34	which	_	WDT	WDT	_	35	SBJ	_	_
35	bound	_	VBD	VBD	_	29	NMOD	_	_
36	octamer-binding	_	JJ	JJ	_	37	NMOD	_	_
37	proteins	_	NNS	NNS	_	35	OBJ	_	_
38	with	_	IN	IN	_	37	NMOD	_	_
39	only	_	RB	RB	_	41	AMOD	_	_
40	very	_	RB	RB	_	41	AMOD	_	_
41	low	_	JJ	JJ	_	42	NMOD	_	_
42	affinity	_	NN	NN	_	38	PMOD	_	_
43	and	_	CC	CC	_	35	CC	_	_
44	showed	_	VBD	VBD	_	35	COORD	_	_
45	no	_	DT	DT	_	47	NMOD	_	_
46	enhancer	_	NN	NN	_	47	NMOD	_	_
47	activity	_	NN	NN	_	44	OBJ	_	_
48	of	_	IN	IN	_	47	NMOD	_	_
49	its	_	PRP$	PRP$	_	50	NMOD	_	_
50	own	_	JJ	JJ	_	48	PMOD	_	_
51	.	_	.	.	_	26	P	_	_

1	Interestingly	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	MnlI-AluI	_	NN	NN	_	5	NMOD	_	_
5	fragment	_	NN	NN	_	6	SBJ	_	_
6	could	_	MD	MD	_	0	ROOT-S	_	_
7	suppress	_	VB	VB	_	6	VC	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	basal-level	_	JJ	JJ	_	10	NMOD	_	_
10	activity	_	NN	NN	_	7	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	conalbumin	_	JJ	JJ	_	14	NMOD	_	_
14	promoter	_	NN	NN	_	11	PMOD	_	_
15	in	_	IN	IN	_	10	NMOD	_	_
16	both	_	CC	CC	_	17	CC	_	_
17	Jurkat	_	NN	NN	_	20	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	HeLa	_	NN	NN	_	17	COORD	_	_
20	cells	_	NNS	NNS	_	15	PMOD	_	_
21	.	_	.	.	_	6	P	_	_

1	Moreover	_	RB	RB	_	8	ADV	_	_
2	,	_	,	,	_	8	P	_	_
3	simian	_	JJ	JJ	_	7	NMOD	_	_
4	virus	_	NN	NN	_	7	NMOD	_	_
5	40	_	CD	CD	_	7	NMOD	_	_
6	enhancer	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	8	SBJ	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	blocked	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	LGS	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	MnlI-AluI	_	NN	NN	_	13	NMOD	_	_
13	fragment	_	NN	NN	_	10	PMOD	_	_
14	in	_	IN	IN	_	9	ADV	_	_
15	HeLa	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	14	PMOD	_	_
17	but	_	CC	CC	_	14	CC	_	_
18	not	_	RB	RB	_	19	DEP	_	_
19	in	_	IN	IN	_	14	COORD	_	_
20	B	_	NN	NN	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	19	PMOD	_	_
22	.	_	.	.	_	8	P	_	_

1	Thus	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	novel	_	JJ	JJ	_	6	NMOD	_	_
5	enhancer	_	NN	NN	_	6	NMOD	_	_
6	element	_	NN	NN	_	11	SBJ	_	_
7	identified	_	VBN	VBN	_	6	NMOD	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	this	_	DT	DT	_	10	NMOD	_	_
10	study	_	NN	NN	_	8	PMOD	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	probably	_	RB	RB	_	11	ADV	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	target	_	NN	NN	_	15	NMOD	_	_
15	site	_	NN	NN	_	11	PRD	_	_
16	for	_	IN	IN	_	15	NMOD	_	_
17	both	_	CC	CC	_	18	CC	_	_
18	positive	_	JJ	JJ	_	21	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	negative	_	JJ	JJ	_	18	COORD	_	_
21	factors	_	NNS	NNS	_	16	PMOD	_	_
22	.	_	.	.	_	11	P	_	_

1	Glucocorticoid	_	NN	NN	_	3	NMOD	_	_
2	receptor	_	NN	NN	_	3	NMOD	_	_
3	characteristics	_	NNS	NNS	_	0	ROOT-FRAG	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	monocytes	_	NNS	NNS	_	4	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	patients	_	NNS	NNS	_	6	PMOD	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	corticosteroid-resistant	_	JJ	JJ	_	11	NMOD	_	_
10	bronchial	_	JJ	JJ	_	11	NMOD	_	_
11	asthma	_	NN	NN	_	8	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	mechanism	_	NN	NN	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	corticosteroid	_	NN	NN	_	5	NMOD	_	_
5	resistance	_	NN	NN	_	3	PMOD	_	_
6	in	_	IN	IN	_	2	NMOD	_	_
7	bronchial	_	JJ	JJ	_	8	NMOD	_	_
8	asthma	_	NN	NN	_	6	PMOD	_	_
9	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	been	_	VBN	VBN	_	9	VC	_	_
11	studied	_	VBN	VBN	_	10	VC	_	_
12	by	_	IN	IN	_	11	ADV	_	_
13	determining	_	VBG	VBG	_	12	PMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	rank	_	NN	NN	_	16	NMOD	_	_
16	order	_	NN	NN	_	13	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	potency	_	NN	NN	_	17	PMOD	_	_
19	for	_	IN	IN	_	16	NMOD	_	_
20	different	_	JJ	JJ	_	21	NMOD	_	_
21	corticosteroids	_	NNS	NNS	_	19	PMOD	_	_
22	in	_	IN	IN	_	16	NMOD	_	_
23	inhibiting	_	VBG	VBG	_	22	PMOD	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	generation	_	NN	NN	_	23	OBJ	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	a	_	DT	DT	_	30	NMOD	_	_
28	3	_	CD	CD	_	29	AMOD	_	_
29	kD	_	NN	NN	_	30	NMOD	_	_
30	molecule	_	NN	NN	_	26	PMOD	_	_
31	from	_	IN	IN	_	25	NMOD	_	_
32	peripheral	_	JJ	JJ	_	34	NMOD	_	_
33	blood	_	NN	NN	_	34	NMOD	_	_
34	monocytes	_	NNS	NNS	_	31	PMOD	_	_
35	isolated	_	VBN	VBN	_	34	NMOD	_	_
36	from	_	IN	IN	_	35	ADV	_	_
37	corticosteroid-sensitive	_	JJ	JJ	_	47	NMOD	_	_
38	(	_	(	(	_	39	P	_	_
39	CS	_	JJ	JJ	_	37	PRN	_	_
40	)	_	)	)	_	39	P	_	_
41	and	_	CC	CC	_	37	CC	_	_
42	corticosteroid-resistant	_	JJ	JJ	_	37	COORD	_	_
43	(	_	(	(	_	44	P	_	_
44	CR	_	JJ	JJ	_	42	PRN	_	_
45	)	_	)	)	_	44	P	_	_
46	asthmatic	_	JJ	JJ	_	47	NMOD	_	_
47	subjects	_	NNS	NNS	_	36	PMOD	_	_
48	,	_	,	,	_	23	P	_	_
49	which	_	WDT	WDT	_	50	SBJ	_	_
50	augments	_	VBZ	VBZ	_	23	OBJ	_	_
51	leukotriene	_	NN	NN	_	52	NMOD	_	_
52	B4	_	NN	NN	_	56	NMOD	_	_
53	(	_	(	(	_	54	P	_	_
54	LTB4	_	NN	NN	_	52	PRN	_	_
55	)	_	)	)	_	54	P	_	_
56	generation	_	NN	NN	_	50	OBJ	_	_
57	by	_	IN	IN	_	56	NMOD	_	_
58	human	_	JJ	JJ	_	59	NMOD	_	_
59	neutrophils	_	NNS	NNS	_	57	PMOD	_	_
60	(	_	(	(	_	61	P	_	_
61	PMN	_	NN	NN	_	59	PRN	_	_
62	)	_	)	)	_	61	P	_	_
63	stimulated	_	VBN	VBN	_	59	NMOD	_	_
64	by	_	IN	IN	_	63	ADV	_	_
65	calcium	_	NN	NN	_	66	NMOD	_	_
66	ionophore	_	NN	NN	_	64	PMOD	_	_
67	.	_	.	.	_	9	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	11	P	_	_
4	binding	_	VBG	VBG	_	5	NMOD	_	_
5	studies	_	NNS	NNS	_	11	SBJ	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	(	_	(	(	_	10	P	_	_
8	3H	_	NN	NN	_	10	NMOD	_	_
9	)	_	)	)	_	10	P	_	_
10	dexamethasone	_	NN	NN	_	6	PMOD	_	_
11	have	_	VBP	VBP	_	0	ROOT-S	_	_
12	been	_	VBN	VBN	_	11	VC	_	_
13	performed	_	VBN	VBN	_	12	VC	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	determine	_	VB	VB	_	13	OBJ	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	dissociation	_	NN	NN	_	18	NMOD	_	_
18	constant	_	NN	NN	_	15	OBJ	_	_
19	(	_	(	(	_	20	P	_	_
20	Kd	_	NN	NN	_	18	PRN	_	_
21	)	_	)	)	_	20	P	_	_
22	and	_	CC	CC	_	18	CC	_	_
23	receptor	_	NN	NN	_	24	NMOD	_	_
24	numbers	_	NNS	NNS	_	18	COORD	_	_
25	(	_	(	(	_	26	P	_	_
26	Ro	_	NN	NN	_	24	PRN	_	_
27	)	_	)	)	_	26	P	_	_
28	in	_	IN	IN	_	18	NMOD	_	_
29	the	_	DT	DT	_	30	NMOD	_	_
30	monocytes	_	NNS	NNS	_	28	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	these	_	DT	DT	_	34	NMOD	_	_
33	two	_	CD	CD	_	34	NMOD	_	_
34	groups	_	NNS	NNS	_	31	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	subjects	_	NNS	NNS	_	35	PMOD	_	_
37	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	concentration	_	NN	NN	_	12	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	corticosteroid	_	NN	NN	_	3	PMOD	_	_
5	producing	_	VBG	VBG	_	4	NMOD	_	_
6	50	_	CD	CD	_	8	NMOD	_	_
7	%	_	NN	NN	_	8	NMOD	_	_
8	inhibition	_	NN	NN	_	5	OBJ	_	_
9	(	_	(	(	_	10	P	_	_
10	IC50	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	600	_	CD	CD	_	14	NMOD	_	_
14	nM	_	NN	NN	_	12	PRD	_	_
15	,	_	,	,	_	14	P	_	_
16	70	_	CD	CD	_	17	NMOD	_	_
17	nM	_	NN	NN	_	14	GAP	_	_
18	,	_	,	,	_	14	P	_	_
19	and	_	CC	CC	_	14	CC	_	_
20	0.5	_	CD	CD	_	21	NMOD	_	_
21	nM	_	NN	NN	_	14	GAP	_	_
22	for	_	IN	IN	_	14	NMOD	_	_
23	hydrocortisone	_	NN	NN	_	22	PMOD	_	_
24	,	_	,	,	_	12	P	_	_
25	methylprednisolone	_	NN	NN	_	23	GAP	_	_
26	,	_	,	,	_	12	P	_	_
27	and	_	CC	CC	_	12	CC	_	_
28	dexamethasone	_	NN	NN	_	23	GAP	_	_
29	,	_	,	,	_	12	P	_	_
30	respectively	_	RB	RB	_	12	ADV	_	_
31	,	_	,	,	_	12	P	_	_
32	in	_	IN	IN	_	12	ADV	_	_
33	monocytes	_	NNS	NNS	_	32	PMOD	_	_
34	from	_	IN	IN	_	33	NMOD	_	_
35	CS	_	JJ	JJ	_	36	NMOD	_	_
36	individuals	_	NNS	NNS	_	34	PMOD	_	_
37	.	_	.	.	_	12	P	_	_

1	There	_	EX	EX	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	only	_	RB	RB	_	4	AMOD	_	_
4	weak	_	JJ	JJ	_	5	NMOD	_	_
5	inhibition	_	NN	NN	_	2	PRD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	generation	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	enhancing	_	NN	NN	_	11	NMOD	_	_
11	activity	_	NN	NN	_	9	PMOD	_	_
12	by	_	IN	IN	_	5	NMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	corticosteroids	_	NNS	NNS	_	12	PMOD	_	_
15	in	_	IN	IN	_	2	ADV	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	CR	_	JJ	JJ	_	18	AMOD	_	_
18	asthmatic	_	JJ	JJ	_	19	NMOD	_	_
19	individuals	_	NNS	NNS	_	15	PMOD	_	_
20	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	dexamethasone	_	NN	NN	_	3	NMOD	_	_
3	Kd	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	2.45	_	CD	CD	_	8	NMOD	_	_
6	+\/-	_	CC	CC	_	5	CC	_	_
7	0.58	_	CD	CD	_	5	COORD	_	_
8	nM	_	NN	NN	_	4	PRD	_	_
9	(	_	(	(	_	16	P	_	_
10	mean	_	NN	NN	_	16	DEP	_	_
11	+\/-	_	CC	CC	_	10	CC	_	_
12	SEM	_	NN	NN	_	10	COORD	_	_
13	,	_	,	,	_	16	P	_	_
14	n	_	NN	NN	_	16	SBJ	_	_
15	=	_	JJ	JJ	_	16	VMOD	_	_
16	6	_	CD	CD	_	8	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	in	_	IN	IN	_	4	VMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	CS	_	JJ	JJ	_	21	NMOD	_	_
21	group	_	NN	NN	_	18	PMOD	_	_
22	and	_	CC	CC	_	4	CC	_	_
23	1.6	_	CD	CD	_	26	NMOD	_	_
24	+\/-	_	CC	CC	_	23	CC	_	_
25	0.35	_	CD	CD	_	23	COORD	_	_
26	nM	_	NN	NN	_	8	GAP	_	_
27	(	_	(	(	_	34	P	_	_
28	mean	_	NN	NN	_	34	DEP	_	_
29	+\/-	_	CC	CC	_	28	CC	_	_
30	SEM	_	NN	NN	_	28	COORD	_	_
31	,	_	,	,	_	34	P	_	_
32	n	_	NN	NN	_	34	SBJ	_	_
33	=	_	JJ	JJ	_	34	VMOD	_	_
34	6	_	CD	CD	_	26	PRN	_	_
35	)	_	)	)	_	34	P	_	_
36	in	_	IN	IN	_	18	GAP	_	_
37	the	_	DT	DT	_	39	NMOD	_	_
38	CR	_	JJ	JJ	_	39	NMOD	_	_
39	group	_	NN	NN	_	36	PMOD	_	_
40	of	_	IN	IN	_	36	PMOD	_	_
41	patients	_	NNS	NNS	_	40	PMOD	_	_
42	(	_	(	(	_	45	P	_	_
43	p	_	NN	NN	_	45	SBJ	_	_
44	=	_	JJ	JJ	_	45	VMOD	_	_
45	0.14	_	CD	CD	_	4	PRN	_	_
46	)	_	)	)	_	45	P	_	_
47	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	Ro	_	NN	NN	_	7	SBJ	_	_
3	in	_	IN	IN	_	7	VMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	CS	_	JJ	JJ	_	6	NMOD	_	_
6	group	_	NN	NN	_	3	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	3,605	_	CD	CD	_	12	NMOD	_	_
9	+\/-	_	CC	CC	_	8	CC	_	_
10	984	_	CD	CD	_	8	COORD	_	_
11	binding	_	VBG	VBG	_	12	NMOD	_	_
12	sites	_	NNS	NNS	_	7	PRD	_	_
13	per	_	IN	IN	_	7	VMOD	_	_
14	nucleus	_	NN	NN	_	13	PMOD	_	_
15	(	_	(	(	_	22	P	_	_
16	mean	_	NN	NN	_	22	DEP	_	_
17	+\/-	_	CC	CC	_	16	CC	_	_
18	SEM	_	NN	NN	_	16	COORD	_	_
19	,	_	,	,	_	22	P	_	_
20	n	_	NN	NN	_	22	SBJ	_	_
21	=	_	JJ	JJ	_	22	VMOD	_	_
22	6	_	CD	CD	_	7	PRN	_	_
23	)	_	)	)	_	22	P	_	_
24	and	_	CC	CC	_	7	CC	_	_
25	4,757	_	CD	CD	_	29	NMOD	_	_
26	+\/-	_	CC	CC	_	25	CC	_	_
27	692	_	CD	CD	_	25	COORD	_	_
28	binding	_	VBG	VBG	_	29	NMOD	_	_
29	sites	_	NNS	NNS	_	12	GAP	_	_
30	per	_	IN	IN	_	13	GAP	_	_
31	nucleus	_	NN	NN	_	30	PMOD	_	_
32	(	_	(	(	_	39	P	_	_
33	mean	_	NN	NN	_	39	DEP	_	_
34	+\/-	_	CC	CC	_	33	CC	_	_
35	SEM	_	NN	NN	_	33	COORD	_	_
36	,	_	,	,	_	39	P	_	_
37	n	_	NN	NN	_	39	SBJ	_	_
38	=	_	JJ	JJ	_	39	VMOD	_	_
39	6	_	CD	CD	_	22	GAP	_	_
40	)	_	)	)	_	39	P	_	_
41	in	_	IN	IN	_	3	GAP	_	_
42	the	_	DT	DT	_	44	NMOD	_	_
43	CR	_	JJ	JJ	_	44	NMOD	_	_
44	group	_	NN	NN	_	41	PMOD	_	_
45	(	_	(	(	_	48	P	_	_
46	p	_	NN	NN	_	48	SBJ	_	_
47	=	_	JJ	JJ	_	48	VMOD	_	_
48	0.23	_	CD	CD	_	7	PRN	_	_
49	)	_	)	)	_	48	P	_	_
50	.	_	.	.	_	7	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	corticosteroid	_	NN	NN	_	6	NMOD	_	_
6	resistance	_	NN	NN	_	10	SBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	bronchial	_	JJ	JJ	_	9	NMOD	_	_
9	asthma	_	NN	NN	_	7	PMOD	_	_
10	can	_	MD	MD	_	4	VMOD	_	_
11	not	_	RB	RB	_	10	VMOD	_	_
12	be	_	VB	VB	_	10	VC	_	_
13	explained	_	VBN	VBN	_	12	VC	_	_
14	by	_	IN	IN	_	13	ADV	_	_
15	abnormalities	_	NNS	NNS	_	14	PMOD	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	corticosteroid	_	NN	NN	_	18	NMOD	_	_
18	receptor	_	NN	NN	_	19	NMOD	_	_
19	characteristics	_	NNS	NNS	_	16	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Tissue-specific	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	platelet	_	NN	NN	_	7	NMOD	_	_
6	GPIIb	_	NN	NN	_	7	NMOD	_	_
7	gene	_	NN	NN	_	3	PMOD	_	_
8	.	_	.	.	_	2	P	_	_

1	One	_	CD	CD	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	major	_	JJ	JJ	_	5	NMOD	_	_
5	objectives	_	NNS	NNS	_	2	PMOD	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	study	_	NN	NN	_	6	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	thrombogenesis	_	NN	NN	_	9	PMOD	_	_
11	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
12	to	_	TO	TO	_	13	VMOD	_	_
13	determine	_	VB	VB	_	11	PRD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	mechanisms	_	NNS	NNS	_	13	OBJ	_	_
16	by	_	IN	IN	_	22	ADV	_	_
17	which	_	WDT	WDT	_	16	PMOD	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	hematopoietic	_	JJ	JJ	_	20	NMOD	_	_
20	progenitor	_	NN	NN	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	15	NMOD	_	_
22	activated	_	VBN	VBN	_	21	VC	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	committed	_	VBN	VBN	_	22	COORD	_	_
25	to	_	TO	TO	_	24	ADV	_	_
26	the	_	DT	DT	_	28	NMOD	_	_
27	megakaryocytic	_	JJ	JJ	_	28	NMOD	_	_
28	lineage	_	NN	NN	_	25	PMOD	_	_
29	.	_	.	.	_	11	P	_	_

1	Recent	_	JJ	JJ	_	2	NMOD	_	_
2	development	_	NN	NN	_	21	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	primary	_	JJ	JJ	_	5	NMOD	_	_
5	cultures	_	NNS	NNS	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	human	_	JJ	JJ	_	8	NMOD	_	_
8	megakaryocytes	_	NNS	NNS	_	6	PMOD	_	_
9	and	_	CC	CC	_	2	CC	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	molecular	_	JJ	JJ	_	12	NMOD	_	_
12	cloning	_	NN	NN	_	2	COORD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	genes	_	NNS	NNS	_	13	PMOD	_	_
15	that	_	WDT	WDT	_	16	SBJ	_	_
16	are	_	VBP	VBP	_	14	NMOD	_	_
17	specific	_	JJ	JJ	_	16	PRD	_	_
18	to	_	TO	TO	_	17	AMOD	_	_
19	this	_	DT	DT	_	20	NMOD	_	_
20	lineage	_	NN	NN	_	18	PMOD	_	_
21	offer	_	VBP	VBP	_	0	ROOT-S	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	possibility	_	NN	NN	_	21	OBJ	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	getting	_	VBG	VBG	_	24	PMOD	_	_
26	some	_	DT	DT	_	27	NMOD	_	_
27	insights	_	NNS	NNS	_	25	OBJ	_	_
28	into	_	IN	IN	_	27	NMOD	_	_
29	the	_	DT	DT	_	31	NMOD	_	_
30	genetic	_	JJ	JJ	_	31	NMOD	_	_
31	mechanisms	_	NNS	NNS	_	28	PMOD	_	_
32	that	_	WDT	WDT	_	33	SBJ	_	_
33	control	_	VBP	VBP	_	31	NMOD	_	_
34	megakaryocytopoiesis	_	NNS	NNS	_	33	OBJ	_	_
35	.	_	.	.	_	21	P	_	_

1	One	_	CD	CD	_	2	NMOD	_	_
2	gene	_	NN	NN	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	interest	_	NN	NN	_	3	PMOD	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	the	_	DT	DT	_	12	NMOD	_	_
7	glycoprotein	_	NN	NN	_	8	NMOD	_	_
8	IIb	_	NN	NN	_	12	NMOD	_	_
9	(	_	(	(	_	10	P	_	_
10	GPIIb	_	NN	NN	_	8	PRN	_	_
11	)	_	)	)	_	10	P	_	_
12	gene	_	NN	NN	_	5	PRD	_	_
13	;	_	:	:	_	5	P	_	_
14	GPIIb	_	NN	NN	_	25	SBJ	_	_
15	,	_	,	,	_	14	P	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	alpha	_	NN	NN	_	18	NMOD	_	_
18	subunit	_	NN	NN	_	14	NMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	23	NMOD	_	_
21	platelet	_	NN	NN	_	23	NMOD	_	_
22	cytoadhesin	_	NN	NN	_	23	NMOD	_	_
23	GPIIb-IIIa	_	NN	NN	_	19	PMOD	_	_
24	,	_	,	,	_	14	P	_	_
25	is	_	VBZ	VBZ	_	5	VC	_	_
26	produced	_	VBN	VBN	_	25	VC	_	_
27	in	_	IN	IN	_	26	ADV	_	_
28	megakaryocytes	_	NNS	NNS	_	27	PMOD	_	_
29	at	_	IN	IN	_	26	TMP	_	_
30	an	_	DT	DT	_	32	NMOD	_	_
31	early	_	JJ	JJ	_	32	NMOD	_	_
32	stage	_	NN	NN	_	29	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	the	_	DT	DT	_	35	NMOD	_	_
35	differentiation	_	NN	NN	_	33	PMOD	_	_
36	,	_	,	,	_	25	P	_	_
37	whereas	_	IN	IN	_	25	COORD	_	_
38	the	_	DT	DT	_	40	NMOD	_	_
39	other	_	JJ	JJ	_	40	NMOD	_	_
40	subunit	_	NN	NN	_	47	SBJ	_	_
41	of	_	IN	IN	_	40	NMOD	_	_
42	this	_	DT	DT	_	43	NMOD	_	_
43	complex	_	NN	NN	_	41	PMOD	_	_
44	,	_	,	,	_	40	P	_	_
45	GPIIIa	_	NN	NN	_	40	NMOD	_	_
46	,	_	,	,	_	40	P	_	_
47	is	_	VBZ	VBZ	_	25	COORD	_	_
48	expressed	_	VBN	VBN	_	47	VC	_	_
49	in	_	IN	IN	_	48	ADV	_	_
50	other	_	JJ	JJ	_	51	NMOD	_	_
51	cells	_	NNS	NNS	_	49	PMOD	_	_
52	.	_	.	.	_	25	P	_	_

1	For	_	IN	IN	_	12	ADV	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	reasons	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	12	P	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	5'-flanking	_	JJ	JJ	_	7	NMOD	_	_
7	region	_	NN	NN	_	12	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	GPIIb	_	NN	NN	_	11	NMOD	_	_
11	gene	_	NN	NN	_	8	PMOD	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	used	_	VBN	VBN	_	12	VC	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	identify	_	VB	VB	_	13	OBJ	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	regions	_	NNS	NNS	_	15	OBJ	_	_
18	that	_	WDT	WDT	_	19	SBJ	_	_
19	interact	_	VBP	VBP	_	17	NMOD	_	_
20	with	_	IN	IN	_	19	ADV	_	_
21	DNA-binding	_	JJ	JJ	_	23	NMOD	_	_
22	nuclear	_	JJ	JJ	_	23	NMOD	_	_
23	factors	_	NNS	NNS	_	20	PMOD	_	_
24	.	_	.	.	_	12	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	fragment	_	NN	NN	_	8	SBJ	_	_
3	extending	_	VBG	VBG	_	2	NMOD	_	_
4	from	_	IN	IN	_	3	ADV	_	_
5	-643	_	CD	CD	_	4	PMOD	_	_
6	to	_	TO	TO	_	4	PMOD	_	_
7	+33	_	CD	CD	_	6	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	capable	_	JJ	JJ	_	8	PRD	_	_
10	of	_	IN	IN	_	9	AMOD	_	_
11	controlling	_	VBG	VBG	_	10	PMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	tissue-specific	_	JJ	JJ	_	14	NMOD	_	_
14	expression	_	NN	NN	_	11	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	CAT	_	NN	NN	_	18	NMOD	_	_
18	gene	_	NN	NN	_	15	PMOD	_	_
19	in	_	IN	IN	_	11	ADV	_	_
20	transfection	_	NN	NN	_	21	NMOD	_	_
21	experiments	_	NNS	NNS	_	19	PMOD	_	_
22	.	_	.	.	_	8	P	_	_

1	Within	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	region	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	have	_	VBP	VBP	_	0	ROOT-S	_	_
7	identified	_	VBN	VBN	_	6	VC	_	_
8	several	_	JJ	JJ	_	9	NMOD	_	_
9	sequences	_	NNS	NNS	_	7	OBJ	_	_
10	that	_	WDT	WDT	_	11	SBJ	_	_
11	are	_	VBP	VBP	_	9	NMOD	_	_
12	implicated	_	VBN	VBN	_	11	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	DNA	_	NN	NN	_	16	NMOD	_	_
15	protein	_	NN	NN	_	16	NMOD	_	_
16	interactions	_	NNS	NNS	_	13	PMOD	_	_
17	as	_	IN	IN	_	12	ADV	_	_
18	shown	_	VBN	VBN	_	17	VMOD	_	_
19	in	_	IN	IN	_	18	ADV	_	_
20	DNAse	_	NN	NN	_	22	NMOD	_	_
21	I	_	NN	NN	_	22	NMOD	_	_
22	footprints	_	NNS	NNS	_	19	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	gel	_	NN	NN	_	27	NMOD	_	_
25	mobility	_	NN	NN	_	27	NMOD	_	_
26	shift	_	NN	NN	_	27	NMOD	_	_
27	assays	_	NNS	NNS	_	22	COORD	_	_
28	.	_	.	.	_	6	P	_	_

1	One	_	CD	CD	_	2	NMOD	_	_
2	region	_	NN	NN	_	8	SBJ	_	_
3	,	_	,	,	_	2	P	_	_
4	centered	_	VBN	VBN	_	2	NMOD	_	_
5	at	_	IN	IN	_	4	AMOD	_	_
6	-54	_	CD	CD	_	5	PMOD	_	_
7	,	_	,	,	_	2	P	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	similar	_	JJ	JJ	_	8	PRD	_	_
10	to	_	TO	TO	_	9	AMOD	_	_
11	a	_	DT	DT	_	15	NMOD	_	_
12	nuclear	_	JJ	JJ	_	13	AMOD	_	_
13	factor	_	NN	NN	_	15	NMOD	_	_
14	E1-binding	_	JJ	JJ	_	13	AMOD	_	_
15	site	_	NN	NN	_	10	PMOD	_	_
16	,	_	,	,	_	8	P	_	_
17	and	_	CC	CC	_	8	CC	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	region	_	NN	NN	_	24	SBJ	_	_
20	located	_	JJ	JJ	_	19	NMOD	_	_
21	at	_	IN	IN	_	20	AMOD	_	_
22	position	_	NN	NN	_	21	PMOD	_	_
23	-233	_	CD	CD	_	22	NMOD	_	_
24	contains	_	VBZ	VBZ	_	8	COORD	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	CCAAT	_	NN	NN	_	27	NMOD	_	_
27	motif	_	NN	NN	_	24	OBJ	_	_
28	.	_	.	.	_	8	P	_	_

1	Two	_	CD	CD	_	2	NMOD	_	_
2	domains	_	NNS	NNS	_	12	SBJ	_	_
3	centered	_	VBN	VBN	_	10	AMOD	_	_
4	at	_	IN	IN	_	10	AMOD	_	_
5	positions	_	NNS	NNS	_	4	PMOD	_	_
6	-345	_	CD	CD	_	5	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	-540	_	CD	CD	_	6	COORD	_	_
9	,	_	,	,	_	10	P	_	_
10	respectively	_	RB	RB	_	2	NMOD	_	_
11	,	_	,	,	_	10	P	_	_
12	bind	_	VBP	VBP	_	0	ROOT-S	_	_
13	proteins	_	NNS	NNS	_	12	OBJ	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	are	_	VBP	VBP	_	13	NMOD	_	_
16	present	_	JJ	JJ	_	15	PRD	_	_
17	in	_	IN	IN	_	16	AMOD	_	_
18	megakaryocytic	_	JJ	JJ	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	17	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	nonrelated	_	JJ	JJ	_	22	NMOD	_	_
22	cells	_	NNS	NNS	_	19	COORD	_	_
23	as	_	RB	RB	_	15	ADV	_	_
24	well	_	RB	RB	_	23	PMOD	_	_
25	.	_	.	.	_	12	P	_	_

1	Finally	_	RB	RB	_	14	ADV	_	_
2	,	_	,	,	_	14	P	_	_
3	two	_	CD	CD	_	5	NMOD	_	_
4	other	_	JJ	JJ	_	5	NMOD	_	_
5	domains	_	NNS	NNS	_	14	SBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	located	_	JJ	JJ	_	5	NMOD	_	_
8	at	_	IN	IN	_	7	AMOD	_	_
9	positions	_	NNS	NNS	_	8	PMOD	_	_
10	-460	_	CD	CD	_	9	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	-510	_	CD	CD	_	10	COORD	_	_
13	,	_	,	,	_	5	P	_	_
14	interact	_	VBP	VBP	_	0	ROOT-S	_	_
15	with	_	IN	IN	_	14	ADV	_	_
16	proteins	_	NNS	NNS	_	15	PMOD	_	_
17	that	_	WDT	WDT	_	18	SBJ	_	_
18	are	_	VBP	VBP	_	16	NMOD	_	_
19	only	_	RB	RB	_	20	AMOD	_	_
20	present	_	JJ	JJ	_	18	PRD	_	_
21	in	_	IN	IN	_	18	ADV	_	_
22	megakaryocytic	_	JJ	JJ	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	12	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	12	P	_	_
4	deletion	_	NN	NN	_	12	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	region	_	NN	NN	_	5	PMOD	_	_
8	containing	_	VBG	VBG	_	7	NMOD	_	_
9	these	_	DT	DT	_	11	NMOD	_	_
10	two	_	CD	CD	_	11	NMOD	_	_
11	domains	_	NNS	NNS	_	8	OBJ	_	_
12	results	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	significant	_	JJ	JJ	_	16	NMOD	_	_
16	decrease	_	NN	NN	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	promoter	_	NN	NN	_	20	NMOD	_	_
20	activity	_	NN	NN	_	17	PMOD	_	_
21	.	_	.	.	_	12	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	very	_	RB	RB	_	4	AMOD	_	_
4	likely	_	JJ	JJ	_	2	PRD	_	_
5	that	_	IN	IN	_	2	EXP	_	_
6	these	_	DT	DT	_	7	NMOD	_	_
7	domains	_	NNS	NNS	_	8	SBJ	_	_
8	bind	_	VBP	VBP	_	5	VMOD	_	_
9	megakaryocyte-specific	_	JJ	JJ	_	11	NMOD	_	_
10	nuclear	_	JJ	JJ	_	11	NMOD	_	_
11	proteins	_	NNS	NNS	_	8	OBJ	_	_
12	acting	_	VBG	VBG	_	11	NMOD	_	_
13	as	_	IN	IN	_	12	ADV	_	_
14	positive	_	JJ	JJ	_	16	NMOD	_	_
15	transcription	_	NN	NN	_	16	NMOD	_	_
16	factors	_	NNS	NNS	_	13	PMOD	_	_
17	.	_	.	.	_	2	P	_	_

1	Demonstration	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	estrogen	_	NN	NN	_	6	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	progesterone	_	NN	NN	_	3	COORD	_	_
6	receptors	_	NNS	NNS	_	2	PMOD	_	_
7	as	_	RB	RB	_	6	CC	_	_
8	well	_	RB	RB	_	7	DEP	_	_
9	as	_	IN	IN	_	7	DEP	_	_
10	Ki-67	_	NN	NN	_	13	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	p-145	_	NN	NN	_	10	COORD	_	_
13	antigens	_	NNS	NNS	_	6	COORD	_	_
14	in	_	IN	IN	_	6	NMOD	_	_
15	single	_	JJ	JJ	_	17	NMOD	_	_
16	tumor	_	NN	NN	_	17	NMOD	_	_
17	cells	_	NNS	NNS	_	14	PMOD	_	_
18	from	_	IN	IN	_	17	NMOD	_	_
19	blood	_	NN	NN	_	22	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	pleural	_	JJ	JJ	_	19	COORD	_	_
22	effusions	_	NNS	NNS	_	18	PMOD	_	_
23	using	_	VBG	VBG	_	1	NMOD	_	_
24	a	_	DT	DT	_	26	NMOD	_	_
25	slide	_	NN	NN	_	26	NMOD	_	_
26	assay	_	NN	NN	_	23	OBJ	_	_
27	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	describe	_	VBP	VBP	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	slide	_	NN	NN	_	5	NMOD	_	_
5	assay	_	NN	NN	_	2	OBJ	_	_
6	that	_	WDT	WDT	_	7	SBJ	_	_
7	allows	_	VBZ	VBZ	_	5	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	demonstration	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	antigens	_	NNS	NNS	_	10	PMOD	_	_
12	localized	_	JJ	JJ	_	11	NMOD	_	_
13	in	_	IN	IN	_	12	AMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	nucleus	_	NN	NN	_	13	PMOD	_	_
16	from	_	IN	IN	_	15	NMOD	_	_
17	isolated	_	VBN	VBN	_	20	NMOD	_	_
18	white	_	JJ	JJ	_	20	NMOD	_	_
19	blood	_	NN	NN	_	20	NMOD	_	_
20	cells	_	NNS	NNS	_	16	PMOD	_	_
21	as	_	RB	RB	_	16	CC	_	_
22	well	_	RB	RB	_	21	DEP	_	_
23	as	_	IN	IN	_	21	DEP	_	_
24	from	_	IN	IN	_	16	COORD	_	_
25	single	_	JJ	JJ	_	27	NMOD	_	_
26	tumor	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	24	PMOD	_	_
28	derived	_	VBN	VBN	_	27	NMOD	_	_
29	from	_	IN	IN	_	28	ADV	_	_
30	malignant	_	JJ	JJ	_	31	NMOD	_	_
31	effusions	_	NNS	NNS	_	29	PMOD	_	_
32	.	_	.	.	_	2	P	_	_

1	With	_	IN	IN	_	15	ADV	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	antibodies	_	NNS	NNS	_	1	PMOD	_	_
4	Ki-67	_	NN	NN	_	3	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	anti-p-145	_	NN	NN	_	4	COORD	_	_
7	an	_	DT	DT	_	9	NMOD	_	_
8	increased	_	VBN	VBN	_	9	NMOD	_	_
9	rate	_	NN	NN	_	15	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	nuclear	_	JJ	JJ	_	14	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	nucleolar	_	JJ	JJ	_	11	COORD	_	_
14	staining	_	NN	NN	_	10	PMOD	_	_
15	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	cells	_	NNS	NNS	_	16	PMOD	_	_
18	from	_	IN	IN	_	17	NMOD	_	_
19	highly	_	RB	RB	_	20	AMOD	_	_
20	malignant	_	JJ	JJ	_	21	NMOD	_	_
21	lymphomas	_	NNS	NNS	_	18	PMOD	_	_
22	.	_	.	.	_	15	P	_	_

1	An	_	DT	DT	_	4	NMOD	_	_
2	almost	_	RB	RB	_	3	AMOD	_	_
3	identical	_	JJ	JJ	_	4	NMOD	_	_
4	reaction	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	obtained	_	VBN	VBN	_	5	VC	_	_
7	when	_	WRB	WRB	_	14	ADV	_	_
8	tumor	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	13	SBJ	_	_
10	from	_	IN	IN	_	9	NMOD	_	_
11	malignant	_	JJ	JJ	_	12	NMOD	_	_
12	effusions	_	NNS	NNS	_	10	PMOD	_	_
13	were	_	VBD	VBD	_	6	TMP	_	_
14	tested	_	VBN	VBN	_	13	VC	_	_
15	.	_	.	.	_	5	P	_	_

1	Cells	_	NNS	NNS	_	16	SBJ	_	_
2	isolated	_	VBN	VBN	_	1	NMOD	_	_
3	from	_	IN	IN	_	2	ADV	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	blood	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	patients	_	NNS	NNS	_	6	PMOD	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	leukemic	_	JJ	JJ	_	10	NMOD	_	_
10	spread	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	lymphomas	_	NNS	NNS	_	11	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	low	_	JJ	JJ	_	15	NMOD	_	_
15	malignancy	_	NN	NN	_	13	PMOD	_	_
16	yielded	_	VBD	VBD	_	0	ROOT-S	_	_
17	a	_	DT	DT	_	19	NMOD	_	_
18	weak	_	JJ	JJ	_	19	NMOD	_	_
19	staining	_	NN	NN	_	16	OBJ	_	_
20	comparable	_	JJ	JJ	_	19	NMOD	_	_
21	to	_	TO	TO	_	20	AMOD	_	_
22	that	_	DT	DT	_	21	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	normal	_	JJ	JJ	_	26	NMOD	_	_
25	mesothelial	_	JJ	JJ	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	23	PMOD	_	_
27	from	_	IN	IN	_	26	NMOD	_	_
28	non-tumorous	_	JJ	JJ	_	30	NMOD	_	_
29	cavity	_	NN	NN	_	30	NMOD	_	_
30	fluids	_	NNS	NNS	_	27	PMOD	_	_
31	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	detection	_	NN	NN	_	18	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	estrogen	_	NN	NN	_	7	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	progesterone	_	NN	NN	_	4	COORD	_	_
7	receptors	_	NNS	NNS	_	3	PMOD	_	_
8	(	_	(	(	_	9	P	_	_
9	ER	_	NN	NN	_	7	PRN	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	PR	_	NN	NN	_	9	COORD	_	_
12	)	_	)	)	_	9	P	_	_
13	localized	_	JJ	JJ	_	7	NMOD	_	_
14	in	_	IN	IN	_	13	AMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	nucleus	_	NN	NN	_	14	PMOD	_	_
18	can	_	MD	MD	_	0	ROOT-S	_	_
19	be	_	VB	VB	_	18	VC	_	_
20	achieved	_	VBN	VBN	_	19	VC	_	_
21	by	_	IN	IN	_	20	ADV	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	same	_	JJ	JJ	_	24	NMOD	_	_
24	assay	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	18	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	reaction	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	enhanced	_	VBN	VBN	_	3	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	incubation	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	tumor	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	7	PMOD	_	_
11	for	_	IN	IN	_	6	TMP	_	_
12	30	_	CD	CD	_	13	NMOD	_	_
13	min	_	NN	NN	_	11	PMOD	_	_
14	at	_	IN	IN	_	6	NMOD	_	_
15	37	_	CD	CD	_	17	NMOD	_	_
16	degrees	_	NNS	NNS	_	17	NMOD	_	_
17	C	_	NN	NN	_	14	PMOD	_	_
18	prior	_	RB	RB	_	19	DEP	_	_
19	to	_	TO	TO	_	6	NMOD	_	_
20	fixation	_	NN	NN	_	19	PMOD	_	_
21	.	_	.	.	_	3	P	_	_

1	Pleural	_	JJ	JJ	_	2	NMOD	_	_
2	effusions	_	NNS	NNS	_	9	SBJ	_	_
3	from	_	IN	IN	_	2	NMOD	_	_
4	20	_	CD	CD	_	5	NMOD	_	_
5	patients	_	NNS	NNS	_	3	PMOD	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	breast	_	NN	NN	_	8	NMOD	_	_
8	cancer	_	NN	NN	_	6	PMOD	_	_
9	were	_	VBD	VBD	_	0	ROOT-S	_	_
10	tested	_	VBN	VBN	_	9	VC	_	_
11	.	_	.	.	_	9	P	_	_

1	ER	_	NN	NN	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	positive	_	JJ	JJ	_	2	PRD	_	_
4	in	_	IN	IN	_	2	ADV	_	_
5	13	_	CD	CD	_	4	PMOD	_	_
6	and	_	CC	CC	_	2	CC	_	_
7	PR	_	NN	NN	_	8	SBJ	_	_
8	was	_	VBD	VBD	_	2	COORD	_	_
9	positive	_	JJ	JJ	_	8	PRD	_	_
10	in	_	IN	IN	_	8	ADV	_	_
11	12	_	CD	CD	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	20	_	CD	CD	_	15	NMOD	_	_
15	samples	_	NNS	NNS	_	12	PMOD	_	_
16	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	5	_	CD	CD	_	3	NMOD	_	_
3	cases	_	NNS	NNS	_	1	PMOD	_	_
4	there	_	EX	EX	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	divergent	_	JJ	JJ	_	8	NMOD	_	_
8	reaction	_	NN	NN	_	5	PRD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	ER	_	NN	NN	_	13	NMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	PR	_	NN	NN	_	10	COORD	_	_
13	antibody	_	NN	NN	_	9	PMOD	_	_
14	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	hormone	_	NN	NN	_	3	NMOD	_	_
3	receptors	_	NNS	NNS	_	8	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	primary	_	JJ	JJ	_	7	NMOD	_	_
7	tumor	_	NN	NN	_	4	PMOD	_	_
8	were	_	VBD	VBD	_	0	ROOT-S	_	_
9	known	_	VBN	VBN	_	8	VC	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	15	_	CD	CD	_	20	NMOD	_	_
12	(	_	(	(	_	13	P	_	_
13	ER	_	NN	NN	_	20	PRN	_	_
14	)	_	)	)	_	13	P	_	_
15	and	_	CC	CC	_	20	CC	_	_
16	14	_	CD	CD	_	20	NMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	PR	_	NN	NN	_	20	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	patients	_	NNS	NNS	_	10	PMOD	_	_
21	,	_	,	,	_	9	P	_	_
22	respectively	_	RB	RB	_	9	ADV	_	_
23	.	_	.	.	_	8	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	each	_	DT	DT	_	3	NMOD	_	_
3	cohort	_	NN	NN	_	1	PMOD	_	_
4	there	_	EX	EX	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	only	_	RB	RB	_	8	NMOD	_	_
7	one	_	CD	CD	_	6	DEP	_	_
8	case	_	NN	NN	_	5	PRD	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	negative	_	JJ	JJ	_	12	NMOD	_	_
12	reaction	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	primary	_	JJ	JJ	_	16	NMOD	_	_
16	tumor	_	NN	NN	_	13	PMOD	_	_
17	and	_	CC	CC	_	12	CC	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	positive	_	JJ	JJ	_	20	NMOD	_	_
20	reaction	_	NN	NN	_	12	COORD	_	_
21	with	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	25	NMOD	_	_
23	isolated	_	VBN	VBN	_	25	NMOD	_	_
24	tumor	_	NN	NN	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	21	PMOD	_	_
26	from	_	IN	IN	_	25	NMOD	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	pleural	_	JJ	JJ	_	29	NMOD	_	_
29	effusions	_	NNS	NNS	_	26	PMOD	_	_
30	.	_	.	.	_	5	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	demonstration	_	NN	NN	_	16	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	hormone	_	NN	NN	_	10	NMOD	_	_
9	receptor	_	NN	NN	_	10	NMOD	_	_
10	proteins	_	NNS	NNS	_	7	PMOD	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	cells	_	NNS	NNS	_	11	PMOD	_	_
13	from	_	IN	IN	_	12	NMOD	_	_
14	malignant	_	JJ	JJ	_	15	NMOD	_	_
15	effusions	_	NNS	NNS	_	13	PMOD	_	_
16	is	_	VBZ	VBZ	_	4	VMOD	_	_
17	possible	_	JJ	JJ	_	16	PRD	_	_
18	and	_	CC	CC	_	4	CC	_	_
19	that	_	IN	IN	_	4	COORD	_	_
20	there	_	EX	EX	_	21	SBJ	_	_
21	is	_	VBZ	VBZ	_	19	VMOD	_	_
22	a	_	DT	DT	_	23	NMOD	_	_
23	correlation	_	NN	NN	_	21	PRD	_	_
24	with	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	status	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	30	NMOD	_	_
29	primary	_	JJ	JJ	_	30	NMOD	_	_
30	site	_	NN	NN	_	27	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	cancer	_	NN	NN	_	31	PMOD	_	_
33	.	_	.	.	_	3	P	_	_

1	Transforming	_	VBG	VBG	_	3	NMOD	_	_
2	growth	_	NN	NN	_	3	NMOD	_	_
3	factor-beta	_	NN	NN	_	4	SBJ	_	_
4	suppresses	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	human	_	JJ	JJ	_	9	NMOD	_	_
6	B	_	NN	NN	_	9	NMOD	_	_
7	lymphocyte	_	NN	NN	_	9	NMOD	_	_
8	Ig	_	NN	NN	_	9	NMOD	_	_
9	production	_	NN	NN	_	4	OBJ	_	_
10	by	_	IN	IN	_	4	ADV	_	_
11	inhibiting	_	VBG	VBG	_	10	PMOD	_	_
12	synthesis	_	NN	NN	_	11	OBJ	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	switch	_	NN	NN	_	12	COORD	_	_
16	from	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	membrane	_	NN	NN	_	19	NMOD	_	_
19	form	_	NN	NN	_	16	PMOD	_	_
20	to	_	TO	TO	_	15	NMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	secreted	_	JJ	JJ	_	23	NMOD	_	_
23	form	_	NN	NN	_	20	PMOD	_	_
24	of	_	IN	IN	_	19	NMOD	_	_
25	Ig	_	NN	NN	_	24	DEP	_	_
26	mRNA	_	NN	NN	_	24	DEP	_	_
27	.	_	.	.	_	4	P	_	_

1	Transforming	_	VBG	VBG	_	3	NMOD	_	_
2	growth	_	NN	NN	_	3	NMOD	_	_
3	factor-beta	_	NN	NN	_	7	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	TGF-beta	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	B	_	NN	NN	_	11	NMOD	_	_
9	cell	_	NN	NN	_	11	NMOD	_	_
10	Ig	_	NN	NN	_	11	NMOD	_	_
11	secretion	_	NN	NN	_	7	OBJ	_	_
12	and	_	CC	CC	_	7	CC	_	_
13	reduces	_	VBZ	VBZ	_	7	COORD	_	_
14	B	_	NN	NN	_	18	NMOD	_	_
15	cell	_	NN	NN	_	18	NMOD	_	_
16	membrane	_	NN	NN	_	18	NMOD	_	_
17	Ig	_	NN	NN	_	18	NMOD	_	_
18	expression	_	NN	NN	_	13	OBJ	_	_
19	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	addition	_	NN	NN	_	20	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	TGF-beta	_	NN	NN	_	3	PMOD	_	_
5	to	_	TO	TO	_	2	NMOD	_	_
6	human	_	JJ	JJ	_	9	NMOD	_	_
7	B	_	NN	NN	_	9	NMOD	_	_
8	lymphocyte	_	NN	NN	_	9	NMOD	_	_
9	cultures	_	NNS	NNS	_	5	PMOD	_	_
10	stimulated	_	VBN	VBN	_	9	NMOD	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	Staphylococcus	_	FW	FW	_	16	NMOD	_	_
13	aureus	_	FW	FW	_	16	NMOD	_	_
14	Cowan	_	NN	NN	_	16	NMOD	_	_
15	strain	_	NN	NN	_	16	NMOD	_	_
16	I	_	NN	NN	_	11	PMOD	_	_
17	and	_	CC	CC	_	16	CC	_	_
18	IL-2	_	NN	NN	_	16	COORD	_	_
19	completely	_	RB	RB	_	20	ADV	_	_
20	inhibited	_	VBD	VBD	_	0	ROOT-S	_	_
21	B	_	NN	NN	_	24	NMOD	_	_
22	cell	_	NN	NN	_	24	NMOD	_	_
23	Ig	_	NN	NN	_	24	NMOD	_	_
24	secretion	_	NN	NN	_	20	OBJ	_	_
25	(	_	(	(	_	20	PRN	_	_
26	greater	_	JJR	JJR	_	25	DEP	_	_
27	than	_	IN	IN	_	26	AMOD	_	_
28	90	_	CD	CD	_	29	NMOD	_	_
29	%	_	NN	NN	_	27	PMOD	_	_
30	)	_	)	)	_	25	P	_	_
31	and	_	CC	CC	_	20	CC	_	_
32	decreased	_	VBD	VBD	_	20	COORD	_	_
33	B	_	NN	NN	_	48	NMOD	_	_
34	cell	_	NN	NN	_	48	NMOD	_	_
35	surface	_	NN	NN	_	48	NMOD	_	_
36	IgM	_	NN	NN	_	48	NMOD	_	_
37	,	_	,	,	_	36	P	_	_
38	IgD	_	NN	NN	_	36	COORD	_	_
39	,	_	,	,	_	36	P	_	_
40	kappa	_	NN	NN	_	42	NMOD	_	_
41	L	_	NN	NN	_	42	NMOD	_	_
42	chain	_	NN	NN	_	36	COORD	_	_
43	,	_	,	,	_	36	P	_	_
44	and	_	CC	CC	_	36	CC	_	_
45	lambda	_	NN	NN	_	47	NMOD	_	_
46	L	_	NN	NN	_	47	NMOD	_	_
47	chain	_	NN	NN	_	36	COORD	_	_
48	expression	_	NN	NN	_	32	OBJ	_	_
49	.	_	.	.	_	20	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	TGF-beta	_	NN	NN	_	5	SBJ	_	_
5	had	_	VBD	VBD	_	0	ROOT-S	_	_
6	only	_	RB	RB	_	7	AMOD	_	_
7	minimal	_	JJ	JJ	_	8	NMOD	_	_
8	effects	_	NNS	NNS	_	5	OBJ	_	_
9	on	_	IN	IN	_	5	ADV	_	_
10	two	_	CD	CD	_	15	NMOD	_	_
11	other	_	JJ	JJ	_	15	NMOD	_	_
12	B	_	NN	NN	_	15	NMOD	_	_
13	cell	_	NN	NN	_	15	NMOD	_	_
14	membrane	_	NN	NN	_	15	NMOD	_	_
15	proteins	_	NNS	NNS	_	9	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	HLA-DR	_	NN	NN	_	15	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	CD20	_	NN	NN	_	17	COORD	_	_
20	.	_	.	.	_	5	P	_	_

1	Internal	_	JJ	JJ	_	2	NMOD	_	_
2	labeling	_	NN	NN	_	15	SBJ	_	_
3	with	_	IN	IN	_	2	NMOD	_	_
4	-LCB-35S-RCB-methionine	_	NN	NN	_	3	PMOD	_	_
5	and	_	CC	CC	_	2	CC	_	_
6	immunoprecipitation	_	NN	NN	_	2	COORD	_	_
7	with	_	IN	IN	_	6	NMOD	_	_
8	anti-IgM	_	JJ	JJ	_	14	NMOD	_	_
9	,	_	,	,	_	8	P	_	_
10	anti-kappa	_	JJ	JJ	_	8	COORD	_	_
11	,	_	,	,	_	8	P	_	_
12	and	_	CC	CC	_	8	CC	_	_
13	anti-lambda	_	JJ	JJ	_	8	COORD	_	_
14	antibodies	_	NNS	NNS	_	7	PMOD	_	_
15	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
16	a	_	DT	DT	_	18	NMOD	_	_
17	striking	_	JJ	JJ	_	18	NMOD	_	_
18	reduction	_	NN	NN	_	15	OBJ	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	kappa	_	NN	NN	_	22	NMOD	_	_
21	L	_	NN	NN	_	22	NMOD	_	_
22	chain	_	NN	NN	_	19	PMOD	_	_
23	in	_	IN	IN	_	18	NMOD	_	_
24	the	_	DT	DT	_	23	DEP	_	_
25	presence	_	NN	NN	_	23	DEP	_	_
26	of	_	IN	IN	_	23	DEP	_	_
27	TGF-beta	_	NN	NN	_	23	PMOD	_	_
28	.	_	.	.	_	15	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	less	_	RBR	RBR	_	3	AMOD	_	_
3	pronounced	_	JJ	JJ	_	4	NMOD	_	_
4	reduction	_	NN	NN	_	12	SBJ	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	lambda	_	NN	NN	_	8	NMOD	_	_
7	L	_	NN	NN	_	8	NMOD	_	_
8	chain	_	NN	NN	_	5	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	microH	_	NN	NN	_	11	NMOD	_	_
11	chain	_	NN	NN	_	8	COORD	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	also	_	RB	RB	_	12	ADV	_	_
14	noted	_	VBN	VBN	_	12	VC	_	_
15	.	_	.	.	_	12	P	_	_

1	Northern	_	NN	NN	_	3	NMOD	_	_
2	blot	_	NN	NN	_	3	NMOD	_	_
3	analysis	_	NN	NN	_	17	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	RNA	_	NN	NN	_	4	PMOD	_	_
6	purified	_	VBN	VBN	_	5	NMOD	_	_
7	from	_	IN	IN	_	6	ADV	_	_
8	B	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	7	PMOD	_	_
10	treated	_	VBN	VBN	_	9	NMOD	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	TGF-beta	_	NN	NN	_	11	PMOD	_	_
13	for	_	IN	IN	_	10	TMP	_	_
14	varying	_	VBG	VBG	_	16	NMOD	_	_
15	time	_	NN	NN	_	16	NMOD	_	_
16	intervals	_	NNS	NNS	_	13	PMOD	_	_
17	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
18	a	_	DT	DT	_	20	NMOD	_	_
19	significant	_	JJ	JJ	_	20	NMOD	_	_
20	decrease	_	NN	NN	_	17	OBJ	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	steady	_	JJ	JJ	_	30	NMOD	_	_
23	state	_	NN	NN	_	30	NMOD	_	_
24	kappa	_	NN	NN	_	30	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	lambda	_	NN	NN	_	24	COORD	_	_
27	L	_	NN	NN	_	30	NMOD	_	_
28	chain	_	NN	NN	_	30	NMOD	_	_
29	mRNA	_	NN	NN	_	30	NMOD	_	_
30	levels	_	NNS	NNS	_	21	PMOD	_	_
31	.	_	.	.	_	17	P	_	_

1	Furthermore	_	RB	RB	_	22	ADV	_	_
2	,	_	,	,	_	22	P	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	significant	_	JJ	JJ	_	5	NMOD	_	_
5	decrease	_	NN	NN	_	22	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	switch	_	NN	NN	_	6	PMOD	_	_
9	from	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	membrane	_	NN	NN	_	12	NMOD	_	_
12	forms	_	NNS	NNS	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	mu	_	NN	NN	_	13	PMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	gamma	_	NN	NN	_	14	COORD	_	_
17	to	_	TO	TO	_	8	NMOD	_	_
18	their	_	PRP$	PRP$	_	21	NMOD	_	_
19	respective	_	JJ	JJ	_	21	NMOD	_	_
20	secreted	_	JJ	JJ	_	21	NMOD	_	_
21	forms	_	NNS	NNS	_	17	PMOD	_	_
22	was	_	VBD	VBD	_	0	ROOT-S	_	_
23	noted	_	VBN	VBN	_	22	VC	_	_
24	in	_	IN	IN	_	23	ADV	_	_
25	the	_	DT	DT	_	24	DEP	_	_
26	presence	_	NN	NN	_	24	DEP	_	_
27	of	_	IN	IN	_	24	DEP	_	_
28	TGF-beta	_	NN	NN	_	24	PMOD	_	_
29	.	_	.	.	_	22	P	_	_

1	Nuclear	_	JJ	JJ	_	3	NMOD	_	_
2	run-on	_	JJ	JJ	_	3	NMOD	_	_
3	experiments	_	NNS	NNS	_	4	SBJ	_	_
4	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
5	decreased	_	VBN	VBN	_	6	NMOD	_	_
6	transcription	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	kappa	_	NN	NN	_	10	NMOD	_	_
9	L	_	NN	NN	_	10	NMOD	_	_
10	chain	_	NN	NN	_	7	PMOD	_	_
11	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effects	_	NNS	NNS	_	29	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	TGF-beta	_	NN	NN	_	3	PMOD	_	_
5	on	_	IN	IN	_	2	NMOD	_	_
6	two	_	CD	CD	_	9	NMOD	_	_
7	transcriptional	_	JJ	JJ	_	9	NMOD	_	_
8	regulatory	_	JJ	JJ	_	9	NMOD	_	_
9	factors	_	NNS	NNS	_	5	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	Oct-2	_	NN	NN	_	9	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	nuclear	_	JJ	JJ	_	14	NMOD	_	_
14	factor	_	NN	NN	_	19	NMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	NF	_	NN	NN	_	14	PRN	_	_
17	)	_	)	)	_	16	P	_	_
18	kappa	_	NN	NN	_	19	NMOD	_	_
19	B	_	NN	NN	_	11	COORD	_	_
20	,	_	,	,	_	9	P	_	_
21	known	_	VBN	VBN	_	9	NMOD	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	be	_	VB	VB	_	21	OBJ	_	_
24	important	_	JJ	JJ	_	23	PRD	_	_
25	in	_	IN	IN	_	24	AMOD	_	_
26	Ig	_	NN	NN	_	28	NMOD	_	_
27	gene	_	NN	NN	_	28	NMOD	_	_
28	transcription	_	NN	NN	_	25	PMOD	_	_
29	were	_	VBD	VBD	_	0	ROOT-S	_	_
30	examined	_	VBN	VBN	_	29	VC	_	_
31	.	_	.	.	_	29	P	_	_

1	Oct-2	_	NN	NN	_	3	NMOD	_	_
2	mRNA	_	NN	NN	_	3	NMOD	_	_
3	levels	_	NNS	NNS	_	14	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	both	_	DT	DT	_	6	NMOD	_	_
6	Oct-2	_	NN	NN	_	10	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	NF-kappa	_	NN	NN	_	9	NMOD	_	_
9	B	_	NN	NN	_	6	COORD	_	_
10	proteins	_	NNS	NNS	_	3	COORD	_	_
11	in	_	IN	IN	_	3	NMOD	_	_
12	nuclear	_	JJ	JJ	_	13	NMOD	_	_
13	extracts	_	NNS	NNS	_	11	PMOD	_	_
14	were	_	VBD	VBD	_	0	ROOT-S	_	_
15	not	_	RB	RB	_	14	VMOD	_	_
16	altered	_	VBN	VBN	_	14	VC	_	_
17	by	_	IN	IN	_	16	LGS	_	_
18	treatment	_	NN	NN	_	17	PMOD	_	_
19	with	_	IN	IN	_	18	NMOD	_	_
20	TGF-beta	_	NN	NN	_	19	PMOD	_	_
21	.	_	.	.	_	14	P	_	_

1	In	_	IN	IN	_	24	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	24	P	_	_
4	levels	_	NNS	NNS	_	24	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	transcriptional	_	JJ	JJ	_	9	NMOD	_	_
8	factor	_	NN	NN	_	9	NMOD	_	_
9	AP-1	_	NN	NN	_	5	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	is	_	VBZ	VBZ	_	9	NMOD	_	_
13	not	_	RB	RB	_	12	VMOD	_	_
14	known	_	VBN	VBN	_	12	VC	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	be	_	VB	VB	_	14	OBJ	_	_
17	important	_	JJ	JJ	_	16	PRD	_	_
18	in	_	IN	IN	_	17	AMOD	_	_
19	B	_	NN	NN	_	22	NMOD	_	_
20	cell	_	NN	NN	_	22	NMOD	_	_
21	Ig	_	NN	NN	_	22	NMOD	_	_
22	production	_	NN	NN	_	18	PMOD	_	_
23	,	_	,	,	_	9	P	_	_
24	were	_	VBD	VBD	_	0	ROOT-S	_	_
25	reduced	_	VBN	VBN	_	24	VC	_	_
26	by	_	IN	IN	_	25	LGS	_	_
27	TGF-beta	_	NN	NN	_	26	PMOD	_	_
28	.	_	.	.	_	24	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	TGF-beta	_	NN	NN	_	6	SBJ	_	_
6	decreases	_	VBZ	VBZ	_	4	VMOD	_	_
7	B	_	NN	NN	_	10	NMOD	_	_
8	lymphocyte	_	NN	NN	_	10	NMOD	_	_
9	Ig	_	NN	NN	_	10	NMOD	_	_
10	secretion	_	NN	NN	_	6	OBJ	_	_
11	by	_	IN	IN	_	6	ADV	_	_
12	inhibiting	_	VBG	VBG	_	11	PMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	synthesis	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	Ig	_	NN	NN	_	17	NMOD	_	_
17	mRNA	_	NN	NN	_	15	PMOD	_	_
18	and	_	CC	CC	_	12	CC	_	_
19	inhibiting	_	VBG	VBG	_	12	COORD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	switch	_	NN	NN	_	19	OBJ	_	_
22	from	_	IN	IN	_	21	NMOD	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	membrane	_	NN	NN	_	25	NMOD	_	_
25	form	_	NN	NN	_	22	PMOD	_	_
26	to	_	TO	TO	_	21	NMOD	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	secreted	_	JJ	JJ	_	29	NMOD	_	_
29	forms	_	NNS	NNS	_	26	PMOD	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	mu	_	NN	NN	_	34	NMOD	_	_
32	and	_	CC	CC	_	31	CC	_	_
33	gamma	_	NN	NN	_	31	COORD	_	_
34	mRNA	_	NN	NN	_	30	PMOD	_	_
35	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	mechanism	_	NN	NN	_	10	SBJ	_	_
3	by	_	IN	IN	_	6	ADV	_	_
4	which	_	WDT	WDT	_	3	PMOD	_	_
5	TGF-beta	_	NN	NN	_	6	SBJ	_	_
6	inhibits	_	VBZ	VBZ	_	2	NMOD	_	_
7	Ig	_	NN	NN	_	9	NMOD	_	_
8	chain	_	NN	NN	_	9	NMOD	_	_
9	synthesis	_	NN	NN	_	6	OBJ	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	unclear	_	JJ	JJ	_	10	PRD	_	_
12	although	_	IN	IN	_	10	ADV	_	_
13	it	_	PRP	PRP	_	14	SBJ	_	_
14	does	_	VBZ	VBZ	_	12	VMOD	_	_
15	not	_	RB	RB	_	14	VMOD	_	_
16	involve	_	VB	VB	_	14	VC	_	_
17	inhibition	_	NN	NN	_	16	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	binding	_	NN	NN	_	18	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	NF-kappa	_	NN	NN	_	23	NMOD	_	_
23	B	_	NN	NN	_	21	PMOD	_	_
24	or	_	CC	CC	_	23	CC	_	_
25	Oct-2	_	NN	NN	_	23	COORD	_	_
26	to	_	TO	TO	_	20	NMOD	_	_
27	their	_	PRP$	PRP$	_	30	NMOD	_	_
28	respective	_	JJ	JJ	_	30	NMOD	_	_
29	target	_	NN	NN	_	30	NMOD	_	_
30	sequences	_	NNS	NNS	_	26	PMOD	_	_
31	.	_	.	.	_	10	P	_	_

1	Differentiation-associated	_	JJ	JJ	_	2	NMOD	_	_
2	expression	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	9	NMOD	_	_
5	Epstein-Barr	_	JJ	JJ	_	9	NMOD	_	_
6	virus	_	NN	NN	_	9	NMOD	_	_
7	BZLF1	_	NN	NN	_	9	NMOD	_	_
8	transactivator	_	NN	NN	_	9	NMOD	_	_
9	protein	_	NN	NN	_	3	PMOD	_	_
10	in	_	IN	IN	_	2	NMOD	_	_
11	oral	_	JJ	JJ	_	13	NMOD	_	_
12	hairy	_	JJ	JJ	_	13	NMOD	_	_
13	leukoplakia	_	NN	NN	_	10	PMOD	_	_
14	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	BZLF1	_	NN	NN	_	3	NMOD	_	_
3	protein	_	NN	NN	_	10	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	Epstein-Barr	_	JJ	JJ	_	6	NMOD	_	_
6	virus	_	NN	NN	_	4	PMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	EBV	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
11	a	_	DT	DT	_	14	NMOD	_	_
12	key	_	JJ	JJ	_	14	NMOD	_	_
13	immediate-early	_	JJ	JJ	_	14	NMOD	_	_
14	protein	_	NN	NN	_	10	PRD	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	has	_	VBZ	VBZ	_	14	NMOD	_	_
17	been	_	VBN	VBN	_	16	VC	_	_
18	shown	_	VBN	VBN	_	17	VC	_	_
19	to	_	TO	TO	_	20	VMOD	_	_
20	disrupt	_	VB	VB	_	18	OBJ	_	_
21	virus	_	NN	NN	_	22	NMOD	_	_
22	latency	_	NN	NN	_	20	OBJ	_	_
23	in	_	IN	IN	_	22	NMOD	_	_
24	EBV-infected	_	JJ	JJ	_	26	NMOD	_	_
25	B	_	NN	NN	_	26	NMOD	_	_
26	cells	_	NNS	NNS	_	23	PMOD	_	_
27	.	_	.	.	_	10	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	generated	_	VBN	VBN	_	2	VC	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	monoclonal	_	JJ	JJ	_	6	NMOD	_	_
6	antibody	_	NN	NN	_	3	OBJ	_	_
7	,	_	,	,	_	6	P	_	_
8	BZ1	_	NN	NN	_	6	NMOD	_	_
9	,	_	,	,	_	6	P	_	_
10	to	_	TO	TO	_	6	NMOD	_	_
11	BZLF1	_	NN	NN	_	10	PMOD	_	_
12	which	_	WDT	WDT	_	13	SBJ	_	_
13	reacts	_	VBZ	VBZ	_	6	NMOD	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	immunohistology	_	NN	NN	_	14	PMOD	_	_
16	,	_	,	,	_	15	P	_	_
17	immunoblotting	_	NN	NN	_	15	COORD	_	_
18	,	_	,	,	_	15	P	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	immunoprecipitation	_	NN	NN	_	15	COORD	_	_
21	and	_	CC	CC	_	13	CC	_	_
22	which	_	WDT	WDT	_	23	SBJ	_	_
23	recognizes	_	VBZ	VBZ	_	13	COORD	_	_
24	both	_	CC	CC	_	29	CC	_	_
25	the	_	DT	DT	_	29	NMOD	_	_
26	active	_	JJ	JJ	_	29	NMOD	_	_
27	,	_	,	,	_	26	P	_	_
28	dimeric	_	JJ	JJ	_	26	COORD	_	_
29	form	_	NN	NN	_	23	OBJ	_	_
30	and	_	CC	CC	_	29	CC	_	_
31	the	_	DT	DT	_	35	NMOD	_	_
32	inactive	_	JJ	JJ	_	35	NMOD	_	_
33	,	_	,	,	_	32	P	_	_
34	monomeric	_	JJ	JJ	_	32	COORD	_	_
35	form	_	NN	NN	_	29	COORD	_	_
36	of	_	IN	IN	_	29	NMOD	_	_
37	the	_	DT	DT	_	38	NMOD	_	_
38	protein	_	NN	NN	_	36	PMOD	_	_
39	.	_	.	.	_	2	P	_	_

1	Biopsies	_	NNS	NNS	_	16	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	oral	_	JJ	JJ	_	5	NMOD	_	_
4	hairy	_	JJ	JJ	_	5	NMOD	_	_
5	leukoplakia	_	NN	NN	_	2	PMOD	_	_
6	,	_	,	,	_	5	P	_	_
7	an	_	DT	DT	_	9	NMOD	_	_
8	AIDS-associated	_	JJ	JJ	_	9	NMOD	_	_
9	lesion	_	NN	NN	_	5	NMOD	_	_
10	characterized	_	VBN	VBN	_	9	NMOD	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	high-level	_	JJ	JJ	_	14	NMOD	_	_
13	EBV	_	NN	NN	_	14	NMOD	_	_
14	replication	_	NN	NN	_	11	PMOD	_	_
15	,	_	,	,	_	5	P	_	_
16	were	_	VBD	VBD	_	0	ROOT-S	_	_
17	examined	_	VBN	VBN	_	16	VC	_	_
18	by	_	IN	IN	_	17	ADV	_	_
19	immunohistochemistry	_	NN	NN	_	18	PMOD	_	_
20	using	_	VBG	VBG	_	19	NMOD	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	BZ1	_	NN	NN	_	24	NMOD	_	_
23	monoclonal	_	JJ	JJ	_	24	NMOD	_	_
24	antibody	_	NN	NN	_	20	OBJ	_	_
25	.	_	.	.	_	16	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	differentiation-associated	_	JJ	JJ	_	3	NMOD	_	_
3	pattern	_	NN	NN	_	7	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	BZLF1	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	4	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	observed	_	VBN	VBN	_	7	VC	_	_
9	,	_	,	,	_	8	P	_	_
10	BZ1	_	NN	NN	_	11	SBJ	_	_
11	reacting	_	VBG	VBG	_	8	OBJ	_	_
12	with	_	IN	IN	_	11	ADV	_	_
13	nuclei	_	NNS	NNS	_	12	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	upper	_	JJ	JJ	_	18	NMOD	_	_
17	spinous	_	JJ	JJ	_	18	NMOD	_	_
18	layer	_	NN	NN	_	14	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	lesion	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	7	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	finding	_	NN	NN	_	3	SBJ	_	_
3	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	BZLF1	_	NN	NN	_	7	NMOD	_	_
7	promoter	_	NN	NN	_	8	SBJ	_	_
8	may	_	MD	MD	_	4	VMOD	_	_
9	be	_	VB	VB	_	8	VC	_	_
10	regulated	_	VBN	VBN	_	9	VC	_	_
11	by	_	IN	IN	_	10	LGS	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	degree	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	squamous	_	JJ	JJ	_	16	NMOD	_	_
16	differentiation	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	3	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	comparison	_	NN	NN	_	18	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	in	_	FW	FW	_	5	AMOD	_	_
5	situ	_	FW	FW	_	6	NMOD	_	_
6	hybridization	_	NN	NN	_	3	PMOD	_	_
7	to	_	TO	TO	_	6	NMOD	_	_
8	EBV	_	NN	NN	_	9	NMOD	_	_
9	DNA	_	NN	NN	_	7	PMOD	_	_
10	and	_	CC	CC	_	6	CC	_	_
11	viral	_	JJ	JJ	_	13	NMOD	_	_
12	capsid	_	NN	NN	_	13	NMOD	_	_
13	antigen	_	NN	NN	_	6	COORD	_	_
14	staining	_	VBG	VBG	_	13	NMOD	_	_
15	with	_	IN	IN	_	2	NMOD	_	_
16	BZ1	_	NN	NN	_	17	NMOD	_	_
17	reactivity	_	NN	NN	_	15	PMOD	_	_
18	suggested	_	VBD	VBD	_	0	ROOT-S	_	_
19	that	_	IN	IN	_	18	OBJ	_	_
20	BZLF1	_	NN	NN	_	21	NMOD	_	_
21	expression	_	NN	NN	_	22	SBJ	_	_
22	precedes	_	VBZ	VBZ	_	19	VMOD	_	_
23	rampant	_	JJ	JJ	_	25	NMOD	_	_
24	virus	_	NN	NN	_	25	NMOD	_	_
25	replication	_	NN	NN	_	22	OBJ	_	_
26	.	_	.	.	_	18	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	inability	_	NN	NN	_	15	SBJ	_	_
3	to	_	TO	TO	_	4	VMOD	_	_
4	detect	_	VB	VB	_	2	NMOD	_	_
5	EBV	_	NN	NN	_	4	OBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	lower	_	RBR	RBR	_	10	NMOD	_	_
9	epithelial	_	JJ	JJ	_	10	NMOD	_	_
10	layers	_	NNS	NNS	_	6	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	oral	_	JJ	JJ	_	14	NMOD	_	_
13	hairy	_	JJ	JJ	_	14	NMOD	_	_
14	leukoplakia	_	NN	NN	_	11	PMOD	_	_
15	raises	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	questions	_	NNS	NNS	_	15	OBJ	_	_
17	concerning	_	VBG	VBG	_	16	NMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	nature	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	EBV	_	NN	NN	_	20	PMOD	_	_
22	latency	_	NN	NN	_	21	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	persistence	_	NN	NN	_	22	COORD	_	_
25	in	_	IN	IN	_	21	NMOD	_	_
26	stratified	_	JJ	JJ	_	28	NMOD	_	_
27	squamous	_	JJ	JJ	_	28	NMOD	_	_
28	epithelium	_	NN	NN	_	25	PMOD	_	_
29	.	_	.	.	_	15	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	rhombotin	_	NN	NN	_	3	NMOD	_	_
3	family	_	NN	NN	_	0	ROOT-FRAG	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	cysteine-rich	_	JJ	JJ	_	7	NMOD	_	_
6	LIM-domain	_	JJ	JJ	_	7	NMOD	_	_
7	oncogenes	_	NNS	NNS	_	4	PMOD	_	_
8	:	_	:	:	_	3	P	_	_
9	distinct	_	JJ	JJ	_	10	NMOD	_	_
10	members	_	NNS	NNS	_	11	SBJ	_	_
11	are	_	VBP	VBP	_	3	NMOD	_	_
12	involved	_	VBN	VBN	_	11	VC	_	_
13	in	_	IN	IN	_	12	ADV	_	_
14	T-cell	_	NN	NN	_	15	NMOD	_	_
15	translocations	_	NNS	NNS	_	13	PMOD	_	_
16	to	_	TO	TO	_	15	NMOD	_	_
17	human	_	JJ	JJ	_	18	NMOD	_	_
18	chromosomes	_	NNS	NNS	_	16	PMOD	_	_
19	11p15	_	NN	NN	_	18	NMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	11p13	_	NN	NN	_	19	COORD	_	_
22	.	_	.	.	_	11	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	chromosomal	_	NN	NN	_	3	NMOD	_	_
3	translocation	_	NN	NN	_	19	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	T-cell	_	NN	NN	_	7	NMOD	_	_
7	leukemia	_	NN	NN	_	4	PMOD	_	_
8	involving	_	VBG	VBG	_	3	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	short	_	JJ	JJ	_	11	NMOD	_	_
11	arm	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	human	_	JJ	JJ	_	14	NMOD	_	_
14	chromosome	_	NN	NN	_	12	PMOD	_	_
15	11	_	CD	CD	_	14	NMOD	_	_
16	at	_	IN	IN	_	11	NMOD	_	_
17	band	_	NN	NN	_	18	NMOD	_	_
18	11p15	_	NN	NN	_	16	PMOD	_	_
19	disrupts	_	VBZ	VBZ	_	0	ROOT-S	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	rhombotin	_	NN	NN	_	22	NMOD	_	_
22	gene	_	NN	NN	_	19	OBJ	_	_
23	.	_	.	.	_	19	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	gene	_	NN	NN	_	3	SBJ	_	_
3	encodes	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	protein	_	NN	NN	_	3	OBJ	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	duplicated	_	JJ	JJ	_	9	NMOD	_	_
8	cysteine-rich	_	JJ	JJ	_	9	NMOD	_	_
9	regions	_	NNS	NNS	_	6	PMOD	_	_
10	called	_	VBN	VBN	_	9	NMOD	_	_
11	LIM	_	NN	NN	_	12	NMOD	_	_
12	domains	_	NNS	NNS	_	10	OBJ	_	_
13	,	_	,	,	_	9	P	_	_
14	which	_	WDT	WDT	_	15	SBJ	_	_
15	show	_	VBP	VBP	_	9	NMOD	_	_
16	homology	_	NN	NN	_	15	OBJ	_	_
17	to	_	TO	TO	_	16	NMOD	_	_
18	zinc-binding	_	JJ	JJ	_	19	NMOD	_	_
19	proteins	_	NNS	NNS	_	17	PMOD	_	_
20	and	_	CC	CC	_	17	CC	_	_
21	to	_	TO	TO	_	17	COORD	_	_
22	iron-sulfur	_	JJ	JJ	_	23	NMOD	_	_
23	centers	_	NNS	NNS	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	ferredoxins	_	NNS	NNS	_	24	PMOD	_	_
26	.	_	.	.	_	3	P	_	_

1	Two	_	CD	CD	_	2	NMOD	_	_
2	homologues	_	NNS	NNS	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	rhombotin	_	NN	NN	_	6	NMOD	_	_
6	gene	_	NN	NN	_	3	PMOD	_	_
7	have	_	VBP	VBP	_	0	ROOT-S	_	_
8	now	_	RB	RB	_	7	ADV	_	_
9	been	_	VBN	VBN	_	7	VC	_	_
10	isolated	_	VBN	VBN	_	9	VC	_	_
11	.	_	.	.	_	7	P	_	_

1	One	_	CD	CD	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	these	_	DT	DT	_	2	PMOD	_	_
4	,	_	,	,	_	1	P	_	_
5	designated	_	VBN	VBN	_	1	NMOD	_	_
6	Rhom-2	_	NN	NN	_	5	OBJ	_	_
7	,	_	,	,	_	1	P	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	located	_	JJ	JJ	_	8	PRD	_	_
10	on	_	IN	IN	_	9	AMOD	_	_
11	human	_	JJ	JJ	_	12	NMOD	_	_
12	chromosome	_	NN	NN	_	10	PMOD	_	_
13	11	_	CD	CD	_	12	NMOD	_	_
14	at	_	IN	IN	_	12	NMOD	_	_
15	band	_	NN	NN	_	16	NMOD	_	_
16	11p13	_	NN	NN	_	14	PMOD	_	_
17	,	_	,	,	_	12	P	_	_
18	where	_	WRB	WRB	_	25	ADV	_	_
19	a	_	DT	DT	_	20	NMOD	_	_
20	cluster	_	NN	NN	_	25	SBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	T-cell	_	NN	NN	_	24	NMOD	_	_
23	leukemia-specific	_	JJ	JJ	_	24	NMOD	_	_
24	translocations	_	NNS	NNS	_	21	PMOD	_	_
25	occur	_	VBP	VBP	_	12	NMOD	_	_
26	;	_	:	:	_	8	P	_	_
27	all	_	DT	DT	_	29	NMOD	_	_
28	translocation	_	NN	NN	_	29	NMOD	_	_
29	breakpoints	_	NNS	NNS	_	32	SBJ	_	_
30	at	_	IN	IN	_	29	NMOD	_	_
31	11p13	_	NN	NN	_	30	PMOD	_	_
32	are	_	VBP	VBP	_	8	VC	_	_
33	upstream	_	JJ	JJ	_	32	PRD	_	_
34	of	_	IN	IN	_	33	AMOD	_	_
35	the	_	DT	DT	_	37	NMOD	_	_
36	Rhom-2	_	NN	NN	_	37	NMOD	_	_
37	gene	_	NN	NN	_	34	PMOD	_	_
38	.	_	.	.	_	32	P	_	_

1	Human	_	JJ	JJ	_	4	NMOD	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	mouse	_	NN	NN	_	1	COORD	_	_
4	Rhom-2	_	NN	NN	_	5	SBJ	_	_
5	are	_	VBP	VBP	_	0	ROOT-S	_	_
6	highly	_	RB	RB	_	5	ADV	_	_
7	conserved	_	VBN	VBN	_	5	VC	_	_
8	and	_	CC	CC	_	5	CC	_	_
9	,	_	,	,	_	5	P	_	_
10	like	_	IN	IN	_	13	ADV	_	_
11	rhombotin	_	NN	NN	_	10	PMOD	_	_
12	,	_	,	,	_	13	P	_	_
13	encode	_	VBP	VBP	_	5	COORD	_	_
14	two	_	CD	CD	_	18	NMOD	_	_
15	tandem	_	JJ	JJ	_	18	NMOD	_	_
16	cysteine-rich	_	JJ	JJ	_	18	NMOD	_	_
17	LIM	_	NN	NN	_	18	NMOD	_	_
18	domains	_	NNS	NNS	_	13	OBJ	_	_
19	.	_	.	.	_	5	P	_	_

1	Rhom-2	_	NN	NN	_	2	NMOD	_	_
2	mRNA	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	expressed	_	VBN	VBN	_	3	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	early	_	JJ	JJ	_	8	NMOD	_	_
7	mouse	_	NN	NN	_	8	NMOD	_	_
8	development	_	NN	NN	_	5	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	central	_	JJ	JJ	_	12	NMOD	_	_
11	nervous	_	JJ	JJ	_	12	NMOD	_	_
12	system	_	NN	NN	_	9	PMOD	_	_
13	,	_	,	,	_	12	P	_	_
14	lung	_	NN	NN	_	12	COORD	_	_
15	,	_	,	,	_	12	P	_	_
16	kidney	_	NN	NN	_	12	COORD	_	_
17	,	_	,	,	_	12	P	_	_
18	liver	_	NN	NN	_	12	COORD	_	_
19	,	_	,	,	_	12	P	_	_
20	and	_	CC	CC	_	12	CC	_	_
21	spleen	_	NN	NN	_	12	COORD	_	_
22	but	_	CC	CC	_	3	CC	_	_
23	only	_	RB	RB	_	25	AMOD	_	_
24	very	_	RB	RB	_	25	AMOD	_	_
25	low	_	JJ	JJ	_	26	NMOD	_	_
26	levels	_	NNS	NNS	_	27	SBJ	_	_
27	occur	_	VBP	VBP	_	3	COORD	_	_
28	in	_	IN	IN	_	27	ADV	_	_
29	thymus	_	NN	NN	_	28	PMOD	_	_
30	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	other	_	JJ	JJ	_	3	NMOD	_	_
3	gene	_	NN	NN	_	8	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	designated	_	VBN	VBN	_	3	NMOD	_	_
6	Rhom-3	_	NN	NN	_	5	OBJ	_	_
7	,	_	,	,	_	3	P	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	on	_	IN	IN	_	8	PRD	_	_
11	chromosome	_	NN	NN	_	10	PMOD	_	_
12	11	_	CD	CD	_	11	NMOD	_	_
13	but	_	CC	CC	_	8	CC	_	_
14	also	_	RB	RB	_	13	COORD	_	_
15	retains	_	VBZ	VBZ	_	8	COORD	_	_
16	homology	_	NN	NN	_	15	OBJ	_	_
17	to	_	TO	TO	_	16	NMOD	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	LIM	_	NN	NN	_	20	NMOD	_	_
20	domain	_	NN	NN	_	17	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	rhombotin	_	NN	NN	_	21	PMOD	_	_
23	.	_	.	.	_	8	P	_	_

1	Since	_	IN	IN	_	25	ADV	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	Rhom-2	_	NN	NN	_	4	NMOD	_	_
4	gene	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	1	VMOD	_	_
6	such	_	JJ	JJ	_	9	NMOD	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	common	_	JJ	JJ	_	9	NMOD	_	_
9	site	_	NN	NN	_	5	PRD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	chromosomal	_	JJ	JJ	_	12	NMOD	_	_
12	damage	_	NN	NN	_	10	PMOD	_	_
13	in	_	IN	IN	_	9	NMOD	_	_
14	T-cell	_	NN	NN	_	15	NMOD	_	_
15	tumors	_	NNS	NNS	_	13	PMOD	_	_
16	,	_	,	,	_	25	P	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	consistency	_	NN	NN	_	25	SBJ	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	translocations	_	NNS	NNS	_	19	PMOD	_	_
21	near	_	IN	IN	_	20	NMOD	_	_
22	the	_	DT	DT	_	24	NMOD	_	_
23	rhombotin	_	NN	NN	_	24	NMOD	_	_
24	gene	_	NN	NN	_	21	PMOD	_	_
25	was	_	VBD	VBD	_	0	ROOT-S	_	_
26	further	_	RB	RB	_	25	ADV	_	_
27	examined	_	VBN	VBN	_	25	VC	_	_
28	.	_	.	.	_	25	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	second	_	JJ	JJ	_	3	NMOD	_	_
3	translocation	_	NN	NN	_	7	SBJ	_	_
4	adjacent	_	JJ	JJ	_	3	NMOD	_	_
5	to	_	TO	TO	_	4	AMOD	_	_
6	rhombotin	_	NN	NN	_	5	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	found	_	VBN	VBN	_	7	VMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	at	_	IN	IN	_	8	PRD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	same	_	JJ	JJ	_	13	NMOD	_	_
13	position	_	NN	NN	_	10	PMOD	_	_
14	as	_	IN	IN	_	13	NMOD	_	_
15	in	_	IN	IN	_	14	PMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	previous	_	JJ	JJ	_	18	NMOD	_	_
18	example	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	7	P	_	_

1	Therefore	_	RB	RB	_	14	ADV	_	_
2	,	_	,	,	_	14	P	_	_
3	chromosome	_	NN	NN	_	4	NMOD	_	_
4	bands	_	NNS	NNS	_	14	SBJ	_	_
5	11p15	_	NN	NN	_	4	NMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	rhombotin	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	and	_	CC	CC	_	5	CC	_	_
10	11p13	_	NN	NN	_	5	COORD	_	_
11	(	_	(	(	_	12	P	_	_
12	Rhom-2	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	are	_	VBP	VBP	_	0	ROOT-S	_	_
15	consistent	_	JJ	JJ	_	16	NMOD	_	_
16	sites	_	NNS	NNS	_	14	PRD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	chromosome	_	NN	NN	_	19	NMOD	_	_
19	translocation	_	NN	NN	_	17	PMOD	_	_
20	in	_	IN	IN	_	16	NMOD	_	_
21	T-cell	_	NN	NN	_	22	NMOD	_	_
22	leukemia	_	NN	NN	_	20	PMOD	_	_
23	,	_	,	,	_	14	P	_	_
24	with	_	IN	IN	_	14	ADV	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	11p15	_	NN	NN	_	27	NMOD	_	_
27	target	_	NN	NN	_	30	SBJ	_	_
28	more	_	RBR	RBR	_	29	AMOD	_	_
29	rarely	_	RB	RB	_	30	ADV	_	_
30	involved	_	VBN	VBN	_	24	VMOD	_	_
31	.	_	.	.	_	14	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	define	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	rhombotin	_	NN	NN	_	7	NMOD	_	_
6	gene	_	NN	NN	_	7	NMOD	_	_
7	family	_	NN	NN	_	3	OBJ	_	_
8	as	_	IN	IN	_	3	ADV	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	class	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	T-cell	_	NN	NN	_	13	NMOD	_	_
13	oncogenes	_	NNS	NNS	_	11	PMOD	_	_
14	with	_	IN	IN	_	10	NMOD	_	_
15	duplicated	_	JJ	JJ	_	18	NMOD	_	_
16	cysteine-rich	_	JJ	JJ	_	18	NMOD	_	_
17	LIM	_	NN	NN	_	18	NMOD	_	_
18	domains	_	NNS	NNS	_	14	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	6	NMOD	_	_
2	human	_	JJ	JJ	_	6	NMOD	_	_
3	myelomonocytic	_	JJ	JJ	_	6	NMOD	_	_
4	cell	_	NN	NN	_	6	NMOD	_	_
5	line	_	NN	NN	_	6	NMOD	_	_
6	U-937	_	NN	NN	_	0	ROOT-FRAG	_	_
7	as	_	IN	IN	_	6	NMOD	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	model	_	NN	NN	_	7	PMOD	_	_
10	for	_	IN	IN	_	9	NMOD	_	_
11	studying	_	VBG	VBG	_	10	PMOD	_	_
12	alterations	_	NNS	NNS	_	11	OBJ	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	steroid-induced	_	JJ	JJ	_	17	NMOD	_	_
15	monokine	_	NN	NN	_	17	NMOD	_	_
16	gene	_	NN	NN	_	17	NMOD	_	_
17	expression	_	NN	NN	_	13	PMOD	_	_
18	:	_	:	:	_	6	P	_	_
19	marked	_	JJ	JJ	_	20	NMOD	_	_
20	enhancement	_	NN	NN	_	6	NMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	lipopolysaccharide-stimulated	_	JJ	JJ	_	27	NMOD	_	_
23	interleukin-1	_	NN	NN	_	27	NMOD	_	_
24	beta	_	NN	NN	_	27	NMOD	_	_
25	messenger	_	NN	NN	_	27	NMOD	_	_
26	RNA	_	NN	NN	_	27	NMOD	_	_
27	levels	_	NNS	NNS	_	21	PMOD	_	_
28	by	_	IN	IN	_	20	NMOD	_	_
29	1,25-dihydroxyvitamin	_	NN	NN	_	30	NMOD	_	_
30	D3	_	NN	NN	_	28	PMOD	_	_
31	.	_	.	.	_	20	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	active	_	JJ	JJ	_	3	NMOD	_	_
3	metabolite	_	NN	NN	_	14	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	vitamin	_	NN	NN	_	6	NMOD	_	_
6	D	_	NN	NN	_	4	PMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	1,25-dihydroxyvitamin	_	NN	NN	_	9	NMOD	_	_
9	D3	_	NN	NN	_	6	NMOD	_	_
10	{	_	(	(	_	11	P	_	_
11	1,25--LRB-OH-RRB-2D3	_	NN	NN	_	9	PRN	_	_
12	}	_	)	)	_	11	P	_	_
13	,	_	,	,	_	14	P	_	_
14	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	potent	_	JJ	JJ	_	17	NMOD	_	_
17	regulator	_	NN	NN	_	14	PRD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	human	_	JJ	JJ	_	21	NMOD	_	_
20	monocyte\/macrophage	_	JJ	JJ	_	21	NMOD	_	_
21	function	_	NN	NN	_	18	PMOD	_	_
22	in	_	FW	FW	_	14	ADV	_	_
23	vitro	_	FW	FW	_	22	AMOD	_	_
24	.	_	.	.	_	14	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	establish	_	VB	VB	_	26	ADV	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	model	_	NN	NN	_	2	OBJ	_	_
5	for	_	IN	IN	_	4	NMOD	_	_
6	1,25--LRB-OH-RRB-2D3	_	NN	NN	_	7	NMOD	_	_
7	regulation	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	human	_	JJ	JJ	_	12	NMOD	_	_
10	monocyte	_	NN	NN	_	12	NMOD	_	_
11	monokine	_	NN	NN	_	12	NMOD	_	_
12	synthesis	_	NN	NN	_	8	PMOD	_	_
13	,	_	,	,	_	26	P	_	_
14	three	_	CD	CD	_	17	NMOD	_	_
15	human	_	JJ	JJ	_	17	NMOD	_	_
16	cell	_	NN	NN	_	17	NMOD	_	_
17	lines	_	NNS	NNS	_	26	SBJ	_	_
18	(	_	(	(	_	19	P	_	_
19	U-937	_	NN	NN	_	17	PRN	_	_
20	,	_	,	,	_	19	P	_	_
21	THP-1	_	NN	NN	_	19	COORD	_	_
22	,	_	,	,	_	19	P	_	_
23	and	_	CC	CC	_	19	CC	_	_
24	HL-60	_	NN	NN	_	19	COORD	_	_
25	)	_	)	)	_	19	P	_	_
26	were	_	VBD	VBD	_	0	ROOT-S	_	_
27	examined	_	VBN	VBN	_	26	VC	_	_
28	for	_	IN	IN	_	27	ADV	_	_
29	:	_	:	:	_	28	P	_	_
30	1	_	LS	LS	_	33	NMOD	_	_
31	)	_	)	)	_	30	P	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	presence	_	NN	NN	_	28	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	functional	_	JJ	JJ	_	37	NMOD	_	_
36	1,25--LRB-OH-RRB-2D3	_	NN	NN	_	37	NMOD	_	_
37	receptors	_	NNS	NNS	_	34	PMOD	_	_
38	;	_	:	:	_	33	P	_	_
39	2	_	LS	LS	_	42	NMOD	_	_
40	)	_	)	)	_	39	P	_	_
41	the	_	DT	DT	_	42	NMOD	_	_
42	accumulation	_	NN	NN	_	33	COORD	_	_
43	of	_	IN	IN	_	42	NMOD	_	_
44	interleukin-1	_	NN	NN	_	45	NMOD	_	_
45	beta	_	NN	NN	_	50	NMOD	_	_
46	(	_	(	(	_	48	P	_	_
47	IL-1	_	NN	NN	_	48	NMOD	_	_
48	beta	_	NN	NN	_	45	PRN	_	_
49	)	_	)	)	_	48	P	_	_
50	mRNA	_	NN	NN	_	43	PMOD	_	_
51	and	_	CC	CC	_	50	CC	_	_
52	IL-1	_	NN	NN	_	54	NMOD	_	_
53	beta	_	NN	NN	_	54	NMOD	_	_
54	protein	_	NN	NN	_	50	COORD	_	_
55	in	_	IN	IN	_	42	NMOD	_	_
56	response	_	NN	NN	_	55	DEP	_	_
57	to	_	TO	TO	_	55	DEP	_	_
58	lipopolysaccharide	_	NN	NN	_	55	PMOD	_	_
59	(	_	(	(	_	60	P	_	_
60	LPS	_	NN	NN	_	58	PRN	_	_
61	)	_	)	)	_	60	P	_	_
62	;	_	:	:	_	33	P	_	_
63	and	_	CC	CC	_	33	CC	_	_
64	3	_	LS	LS	_	67	NMOD	_	_
65	)	_	)	)	_	64	P	_	_
66	the	_	DT	DT	_	67	NMOD	_	_
67	regulation	_	NN	NN	_	33	COORD	_	_
68	of	_	IN	IN	_	67	NMOD	_	_
69	this	_	DT	DT	_	70	NMOD	_	_
70	response	_	NN	NN	_	68	PMOD	_	_
71	by	_	IN	IN	_	67	NMOD	_	_
72	1,25--LRB-OH-RRB-2D3	_	NN	NN	_	71	PMOD	_	_
73	.	_	.	.	_	26	P	_	_

1	All	_	DT	DT	_	4	NMOD	_	_
2	three	_	CD	CD	_	4	NMOD	_	_
3	cell	_	NN	NN	_	4	NMOD	_	_
4	lines	_	NNS	NNS	_	5	SBJ	_	_
5	expressed	_	VBD	VBD	_	0	ROOT-S	_	_
6	vitamin	_	NN	NN	_	8	NMOD	_	_
7	D	_	NN	NN	_	8	NMOD	_	_
8	receptor	_	NN	NN	_	5	OBJ	_	_
9	and	_	CC	CC	_	5	CC	_	_
10	had	_	VBD	VBD	_	5	COORD	_	_
11	increased	_	VBN	VBN	_	10	VC	_	_
12	levels	_	NNS	NNS	_	11	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	IL-1	_	NN	NN	_	16	NMOD	_	_
15	beta	_	NN	NN	_	16	NMOD	_	_
16	mRNA	_	NN	NN	_	13	PMOD	_	_
17	in	_	IN	IN	_	11	ADV	_	_
18	response	_	NN	NN	_	17	DEP	_	_
19	to	_	TO	TO	_	17	DEP	_	_
20	LPS	_	NN	NN	_	17	PMOD	_	_
21	.	_	.	.	_	5	P	_	_

1	Preincubation	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	cells	_	NNS	NNS	_	2	PMOD	_	_
4	with	_	IN	IN	_	1	NMOD	_	_
5	1,25--LRB-OH-RRB-2D3	_	NN	NN	_	4	PMOD	_	_
6	augmented	_	VBD	VBD	_	0	ROOT-S	_	_
7	IL-1	_	NN	NN	_	10	NMOD	_	_
8	beta	_	NN	NN	_	10	NMOD	_	_
9	mRNA	_	NN	NN	_	10	NMOD	_	_
10	levels	_	NNS	NNS	_	6	OBJ	_	_
11	only	_	RB	RB	_	12	DEP	_	_
12	in	_	IN	IN	_	6	ADV	_	_
13	U-937	_	NN	NN	_	16	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	HL-60	_	NN	NN	_	13	COORD	_	_
16	cells	_	NNS	NNS	_	12	PMOD	_	_
17	.	_	.	.	_	6	P	_	_

1	From	_	IN	IN	_	20	VMOD	_	_
2	these	_	DT	DT	_	3	NMOD	_	_
3	data	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	1	P	_	_
5	and	_	CC	CC	_	1	CC	_	_
6	taking	_	VBG	VBG	_	1	ADV	_	_
7	into	_	IN	IN	_	6	ADV	_	_
8	consideration	_	NN	NN	_	7	PMOD	_	_
9	their	_	PRP$	PRP$	_	10	NMOD	_	_
10	state	_	NN	NN	_	6	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	differentiation	_	NN	NN	_	11	PMOD	_	_
13	and	_	CC	CC	_	10	CC	_	_
14	relative	_	JJ	JJ	_	15	NMOD	_	_
15	ease	_	NN	NN	_	10	COORD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	culture	_	NN	NN	_	16	PMOD	_	_
18	,	_	,	,	_	20	P	_	_
19	U-937	_	NN	NN	_	20	SBJ	_	_
20	was	_	VBD	VBD	_	0	ROOT-S	_	_
21	chosen	_	VBN	VBN	_	20	VC	_	_
22	over	_	IN	IN	_	21	ADV	_	_
23	HL-60	_	NN	NN	_	22	PMOD	_	_
24	and	_	CC	CC	_	23	CC	_	_
25	THP-1	_	NN	NN	_	23	COORD	_	_
26	as	_	IN	IN	_	21	ADV	_	_
27	the	_	DT	DT	_	29	NMOD	_	_
28	cell	_	NN	NN	_	29	NMOD	_	_
29	line	_	NN	NN	_	26	PMOD	_	_
30	we	_	PRP	PRP	_	32	SBJ	_	_
31	further	_	RB	RB	_	32	ADV	_	_
32	characterized	_	VBD	VBD	_	29	NMOD	_	_
33	.	_	.	.	_	20	P	_	_

1	In	_	IN	IN	_	13	ADV	_	_
2	U-937	_	NN	NN	_	3	NMOD	_	_
3	cells	_	NNS	NNS	_	1	PMOD	_	_
4	,	_	,	,	_	13	P	_	_
5	optimum	_	JJ	JJ	_	6	NMOD	_	_
6	time	_	NN	NN	_	13	SBJ	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	dose	_	NN	NN	_	6	COORD	_	_
9	of	_	IN	IN	_	6	NMOD	_	_
10	pretreatment	_	NN	NN	_	9	PMOD	_	_
11	with	_	IN	IN	_	10	NMOD	_	_
12	1,25--LRB-OH-RRB-2D3	_	NN	NN	_	11	PMOD	_	_
13	were	_	VBD	VBD	_	0	ROOT-S	_	_
14	determined	_	VBN	VBN	_	13	VC	_	_
15	to	_	TO	TO	_	16	VMOD	_	_
16	be	_	VB	VB	_	14	OBJ	_	_
17	12-24	_	CD	CD	_	18	NMOD	_	_
18	h	_	NN	NN	_	16	PRD	_	_
19	at	_	IN	IN	_	16	ADV	_	_
20	a	_	DT	DT	_	23	NMOD	_	_
21	receptor	_	NN	NN	_	23	NMOD	_	_
22	saturating	_	JJ	JJ	_	23	NMOD	_	_
23	concentration	_	NN	NN	_	19	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	1,25--LRB-OH-RRB-2D3	_	NN	NN	_	24	PMOD	_	_
26	(	_	(	(	_	28	P	_	_
27	10	_	CD	CD	_	28	NMOD	_	_
28	nM	_	NN	NN	_	23	PRN	_	_
29	)	_	)	)	_	28	P	_	_
30	.	_	.	.	_	13	P	_	_

1	Preincubation	_	NN	NN	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	cells	_	NNS	NNS	_	2	PMOD	_	_
4	with	_	IN	IN	_	1	NMOD	_	_
5	1,25--LRB-OH-RRB-2D3	_	NN	NN	_	4	PMOD	_	_
6	had	_	VBD	VBD	_	0	ROOT-S	_	_
7	no	_	DT	DT	_	8	NMOD	_	_
8	effect	_	NN	NN	_	6	OBJ	_	_
9	on	_	IN	IN	_	6	ADV	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	time	_	NN	NN	_	12	NMOD	_	_
12	course	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	IL-1	_	NN	NN	_	17	NMOD	_	_
15	beta	_	NN	NN	_	17	NMOD	_	_
16	mRNA	_	NN	NN	_	17	NMOD	_	_
17	appearance	_	NN	NN	_	13	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	response	_	NN	NN	_	18	DEP	_	_
20	to	_	TO	TO	_	18	DEP	_	_
21	LPS	_	NN	NN	_	18	PMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	However	_	RB	RB	_	9	ADV	_	_
2	,	_	,	,	_	9	P	_	_
3	exposure	_	NN	NN	_	9	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	U-937	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	to	_	TO	TO	_	3	NMOD	_	_
8	1,25--LRB-OH-RRB-2D3	_	NN	NN	_	7	PMOD	_	_
9	increased	_	VBD	VBD	_	0	ROOT-S	_	_
10	by	_	IN	IN	_	9	ADV	_	_
11	200	_	CD	CD	_	12	NMOD	_	_
12	%	_	NN	NN	_	10	PMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	level	_	NN	NN	_	9	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	IL-1	_	NN	NN	_	18	NMOD	_	_
17	beta	_	NN	NN	_	18	NMOD	_	_
18	mRNA	_	NN	NN	_	15	PMOD	_	_
19	detected	_	VBD	VBD	_	18	NMOD	_	_
20	and	_	CC	CC	_	9	CC	_	_
21	decreased	_	VBD	VBD	_	9	COORD	_	_
22	by	_	IN	IN	_	21	ADV	_	_
23	three	_	CD	CD	_	24	NMOD	_	_
24	orders	_	NNS	NNS	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	magnitude	_	NN	NN	_	25	PMOD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	concentration	_	NN	NN	_	21	OBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	LPS	_	NN	NN	_	29	PMOD	_	_
31	required	_	VBN	VBN	_	28	NMOD	_	_
32	to	_	TO	TO	_	33	VMOD	_	_
33	achieve	_	VB	VB	_	31	OBJ	_	_
34	steady	_	JJ	JJ	_	37	NMOD	_	_
35	state	_	NN	NN	_	37	NMOD	_	_
36	mRNA	_	NN	NN	_	37	NMOD	_	_
37	levels	_	NNS	NNS	_	33	OBJ	_	_
38	equivalent	_	JJ	JJ	_	37	NMOD	_	_
39	to	_	TO	TO	_	38	AMOD	_	_
40	those	_	DT	DT	_	39	PMOD	_	_
41	observed	_	VBN	VBN	_	40	NMOD	_	_
42	in	_	IN	IN	_	41	ADV	_	_
43	U-937	_	NN	NN	_	44	NMOD	_	_
44	cells	_	NNS	NNS	_	42	PMOD	_	_
45	not	_	RB	RB	_	46	VMOD	_	_
46	preincubated	_	VBN	VBN	_	44	NMOD	_	_
47	with	_	IN	IN	_	46	ADV	_	_
48	the	_	DT	DT	_	49	NMOD	_	_
49	hormone.2+o	_	NN	NN	_	47	PMOD	_	_

1	Expression	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	4	NMOD	_	_
4	receptors	_	NNS	NNS	_	2	PMOD	_	_
5	on	_	IN	IN	_	1	NMOD	_	_
6	alveolar	_	JJ	JJ	_	7	NMOD	_	_
7	lymphocytes	_	NNS	NNS	_	5	PMOD	_	_
8	from	_	IN	IN	_	7	NMOD	_	_
9	patients	_	NNS	NNS	_	8	PMOD	_	_
10	with	_	IN	IN	_	9	NMOD	_	_
11	pulmonary	_	JJ	JJ	_	13	NMOD	_	_
12	granulomatous	_	JJ	JJ	_	13	NMOD	_	_
13	diseases	_	NNS	NNS	_	10	PMOD	_	_
14	.	_	.	.	_	1	P	_	_

1	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	known	_	VBN	VBN	_	2	VC	_	_
4	to	_	TO	TO	_	5	VMOD	_	_
5	be	_	VB	VB	_	3	OBJ	_	_
6	produced	_	VBN	VBN	_	5	VC	_	_
7	at	_	IN	IN	_	6	ADV	_	_
8	sites	_	NNS	NNS	_	7	PMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	granulomatous	_	JJ	JJ	_	11	NMOD	_	_
11	reactions	_	NNS	NNS	_	9	PMOD	_	_
12	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	17	ADV	_	_
2	order	_	NN	NN	_	1	VMOD	_	_
3	to	_	TO	TO	_	1	VMOD	_	_
4	characterize	_	VB	VB	_	1	VMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	types	_	NNS	NNS	_	4	OBJ	_	_
8	that	_	WDT	WDT	_	9	SBJ	_	_
9	are	_	VBP	VBP	_	7	NMOD	_	_
10	targets	_	NNS	NNS	_	9	PRD	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	this	_	DT	DT	_	14	NMOD	_	_
13	immunoregulatory	_	JJ	JJ	_	14	NMOD	_	_
14	hormone	_	NN	NN	_	11	PMOD	_	_
15	,	_	,	,	_	17	P	_	_
16	we	_	PRP	PRP	_	17	SBJ	_	_
17	have	_	VBP	VBP	_	0	ROOT-S	_	_
18	evaluated	_	VBN	VBN	_	17	VC	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	expression	_	NN	NN	_	18	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	23	NMOD	_	_
23	receptors	_	NNS	NNS	_	21	PMOD	_	_
24	on	_	IN	IN	_	20	NMOD	_	_
25	peripheral	_	JJ	JJ	_	27	NMOD	_	_
26	blood	_	NN	NN	_	27	NMOD	_	_
27	T-lymphocytes	_	NNS	NNS	_	24	PMOD	_	_
28	and	_	CC	CC	_	27	CC	_	_
29	those	_	DT	DT	_	27	COORD	_	_
30	recovered	_	VBN	VBN	_	29	NMOD	_	_
31	from	_	IN	IN	_	30	ADV	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	lung	_	NN	NN	_	31	PMOD	_	_
34	by	_	IN	IN	_	30	ADV	_	_
35	bronchoalveolar	_	JJ	JJ	_	36	NMOD	_	_
36	lavage	_	NN	NN	_	34	PMOD	_	_
37	from	_	IN	IN	_	36	NMOD	_	_
38	patients	_	NNS	NNS	_	37	PMOD	_	_
39	with	_	IN	IN	_	38	NMOD	_	_
40	pulmonary	_	JJ	JJ	_	42	NMOD	_	_
41	granulomatous	_	JJ	JJ	_	42	NMOD	_	_
42	diseases	_	NNS	NNS	_	39	PMOD	_	_
43	(	_	(	(	_	44	P	_	_
44	tuberculosis	_	NN	NN	_	42	PRN	_	_
45	and	_	CC	CC	_	44	CC	_	_
46	sarcoidosis	_	NN	NN	_	44	COORD	_	_
47	)	_	)	)	_	44	P	_	_
48	and	_	CC	CC	_	37	CC	_	_
49	from	_	IN	IN	_	37	COORD	_	_
50	normal	_	JJ	JJ	_	52	NMOD	_	_
51	control	_	NN	NN	_	52	NMOD	_	_
52	subjects	_	NNS	NNS	_	49	PMOD	_	_
53	using	_	VBG	VBG	_	30	OBJ	_	_
54	combined	_	JJ	JJ	_	58	NMOD	_	_
55	autoradiographic	_	JJ	JJ	_	58	NMOD	_	_
56	and	_	CC	CC	_	55	CC	_	_
57	immunohistochemical	_	JJ	JJ	_	55	COORD	_	_
58	techniques	_	NNS	NNS	_	53	OBJ	_	_
59	.	_	.	.	_	17	P	_	_

1	Lavage	_	NN	NN	_	2	NMOD	_	_
2	T-lymphocytes	_	NNS	NNS	_	19	SBJ	_	_
3	from	_	IN	IN	_	2	NMOD	_	_
4	patients	_	NNS	NNS	_	3	PMOD	_	_
5	with	_	IN	IN	_	4	NMOD	_	_
6	tuberculosis	_	NN	NN	_	5	PMOD	_	_
7	or	_	CC	CC	_	5	CC	_	_
8	with	_	IN	IN	_	5	COORD	_	_
9	sarcoidosis	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	2	P	_	_
11	but	_	CC	CC	_	2	CC	_	_
12	not	_	RB	RB	_	11	COORD	_	_
13	those	_	DT	DT	_	2	COORD	_	_
14	from	_	IN	IN	_	13	NMOD	_	_
15	normal	_	JJ	JJ	_	17	NMOD	_	_
16	control	_	NN	NN	_	17	NMOD	_	_
17	subjects	_	NNS	NNS	_	14	PMOD	_	_
18	,	_	,	,	_	2	P	_	_
19	expressed	_	VBD	VBD	_	0	ROOT-S	_	_
20	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	21	NMOD	_	_
21	receptors	_	NNS	NNS	_	19	OBJ	_	_
22	as	_	IN	IN	_	19	ADV	_	_
23	demonstrated	_	VBN	VBN	_	22	VMOD	_	_
24	by	_	IN	IN	_	23	LGS	_	_
25	binding	_	NN	NN	_	24	PMOD	_	_
26	of	_	IN	IN	_	25	NMOD	_	_
27	-LCB-3H-RCB-1,25-LRB-OH-RRB-2D3	_	NN	NN	_	26	PMOD	_	_
28	,	_	,	,	_	25	P	_	_
29	which	_	WDT	WDT	_	30	SBJ	_	_
30	was	_	VBD	VBD	_	25	NMOD	_	_
31	inhibited	_	VBN	VBN	_	30	VC	_	_
32	by	_	IN	IN	_	31	ADV	_	_
33	the	_	DT	DT	_	34	NMOD	_	_
34	presence	_	NN	NN	_	32	PMOD	_	_
35	of	_	IN	IN	_	34	NMOD	_	_
36	excess	_	JJ	JJ	_	38	NMOD	_	_
37	unlabeled	_	JJ	JJ	_	38	NMOD	_	_
38	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	35	PMOD	_	_
39	,	_	,	,	_	32	P	_	_
40	but	_	CC	CC	_	32	CC	_	_
41	not	_	RB	RB	_	42	DEP	_	_
42	by	_	IN	IN	_	32	LGS	_	_
43	the	_	DT	DT	_	44	NMOD	_	_
44	presence	_	NN	NN	_	42	PMOD	_	_
45	of	_	IN	IN	_	44	NMOD	_	_
46	unlabeled	_	JJ	JJ	_	47	NMOD	_	_
47	25-LRB-OH-RRB-D3	_	NN	NN	_	45	PMOD	_	_
48	(	_	(	(	_	50	P	_	_
49	receptor-positive	_	JJ	JJ	_	50	NMOD	_	_
50	lymphocytes	_	NNS	NNS	_	23	PRN	_	_
51	:	_	:	:	_	50	P	_	_
52	sarcoidosis	_	NN	NN	_	50	NMOD	_	_
53	,	_	,	,	_	52	P	_	_
54	20	_	CD	CD	_	57	NMOD	_	_
55	+\/-	_	CC	CC	_	54	CC	_	_
56	12	_	CD	CD	_	54	COORD	_	_
57	%	_	NN	NN	_	52	NMOD	_	_
58	;	_	:	:	_	52	P	_	_
59	tuberculosis	_	NN	NN	_	52	NMOD	_	_
60	,	_	,	,	_	59	P	_	_
61	31	_	CD	CD	_	64	NMOD	_	_
62	+\/-	_	CC	CC	_	61	CC	_	_
63	17	_	CD	CD	_	61	COORD	_	_
64	%	_	NN	NN	_	59	NMOD	_	_
65	)	_	)	)	_	50	P	_	_
66	.	_	.	.	_	19	P	_	_

1	In	_	IN	IN	_	11	ADV	_	_
2	contrast	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	11	P	_	_
4	blood	_	NN	NN	_	5	NMOD	_	_
5	lymphocytes	_	NNS	NNS	_	11	SBJ	_	_
6	from	_	IN	IN	_	5	NMOD	_	_
7	patients	_	NNS	NNS	_	6	PMOD	_	_
8	with	_	IN	IN	_	7	NMOD	_	_
9	granulomatous	_	JJ	JJ	_	10	NMOD	_	_
10	diseases	_	NNS	NNS	_	8	PMOD	_	_
11	did	_	VBD	VBD	_	0	ROOT-S	_	_
12	not	_	RB	RB	_	11	VMOD	_	_
13	express	_	VB	VB	_	11	VC	_	_
14	detectable	_	JJ	JJ	_	16	NMOD	_	_
15	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	16	NMOD	_	_
16	receptors	_	NNS	NNS	_	13	OBJ	_	_
17	.	_	.	.	_	11	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	percentage	_	NN	NN	_	9	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	lavage	_	NN	NN	_	5	NMOD	_	_
5	T-lymphocytes	_	NNS	NNS	_	3	PMOD	_	_
6	expressing	_	VBG	VBG	_	5	NMOD	_	_
7	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	8	NMOD	_	_
8	receptors	_	NNS	NNS	_	6	OBJ	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	significantly	_	RB	RB	_	11	AMOD	_	_
11	greater	_	JJR	JJR	_	9	PRD	_	_
12	for	_	IN	IN	_	9	ADV	_	_
13	patients	_	NNS	NNS	_	12	PMOD	_	_
14	with	_	IN	IN	_	13	NMOD	_	_
15	tuberculosis	_	NN	NN	_	14	PMOD	_	_
16	presenting	_	VBG	VBG	_	13	NMOD	_	_
17	with	_	IN	IN	_	16	ADV	_	_
18	isolated	_	VBN	VBN	_	20	NMOD	_	_
19	hilar	_	JJ	JJ	_	20	NMOD	_	_
20	adenopathy	_	JJ	JJ	_	17	PMOD	_	_
21	than	_	IN	IN	_	11	AMOD	_	_
22	for	_	IN	IN	_	21	PMOD	_	_
23	patients	_	NNS	NNS	_	22	PMOD	_	_
24	with	_	IN	IN	_	23	NMOD	_	_
25	pulmonary	_	JJ	JJ	_	26	NMOD	_	_
26	infiltrates	_	NNS	NNS	_	24	PMOD	_	_
27	and\/or	_	CC	CC	_	26	CC	_	_
28	cavities	_	NNS	NNS	_	26	COORD	_	_
29	.	_	.	.	_	9	P	_	_

1	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	2	NMOD	_	_
2	receptors	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	expressed	_	VBN	VBN	_	3	VC	_	_
5	to	_	TO	TO	_	4	ADV	_	_
6	a	_	DT	DT	_	8	NMOD	_	_
7	greater	_	JJR	JJR	_	8	NMOD	_	_
8	extent	_	NN	NN	_	5	PMOD	_	_
9	on	_	IN	IN	_	4	ADV	_	_
10	CD8+	_	JJ	JJ	_	11	NMOD	_	_
11	T-lymphocytes	_	NNS	NNS	_	9	PMOD	_	_
12	than	_	IN	IN	_	8	NMOD	_	_
13	on	_	IN	IN	_	12	PMOD	_	_
14	CD4+	_	JJ	JJ	_	15	NMOD	_	_
15	T-lymphocytes	_	NNS	NNS	_	13	PMOD	_	_
16	in	_	IN	IN	_	4	ADV	_	_
17	sarcoidosis	_	NN	NN	_	16	PMOD	_	_
18	,	_	,	,	_	3	P	_	_
19	whereas	_	IN	IN	_	3	COORD	_	_
20	a	_	DT	DT	_	22	NMOD	_	_
21	greater	_	JJR	JJR	_	22	NMOD	_	_
22	proportion	_	NN	NN	_	33	SBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	CD4+	_	JJ	JJ	_	28	NMOD	_	_
25	than	_	IN	IN	_	22	NMOD	_	_
26	of	_	IN	IN	_	25	PMOD	_	_
27	CD8+	_	JJ	JJ	_	26	NMOD	_	_
28	T-lymphocytes	_	NNS	NNS	_	23	PMOD	_	_
29	from	_	IN	IN	_	22	NMOD	_	_
30	patients	_	NNS	NNS	_	29	PMOD	_	_
31	with	_	IN	IN	_	30	NMOD	_	_
32	tuberculosis	_	NN	NN	_	31	PMOD	_	_
33	were	_	VBD	VBD	_	3	COORD	_	_
34	receptor-positive	_	JJ	JJ	_	33	PRD	_	_
35	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	findings	_	NNS	NNS	_	3	SBJ	_	_
3	support	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	conclusion	_	NN	NN	_	3	OBJ	_	_
6	that	_	IN	IN	_	5	NMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	interaction	_	NN	NN	_	16	SBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	9	PMOD	_	_
11	with	_	IN	IN	_	8	NMOD	_	_
12	its	_	PRP$	PRP$	_	13	NMOD	_	_
13	receptor	_	NN	NN	_	11	PMOD	_	_
14	on	_	IN	IN	_	13	NMOD	_	_
15	T-lymphocytes	_	NNS	NNS	_	14	PMOD	_	_
16	may	_	MD	MD	_	6	VMOD	_	_
17	play	_	VB	VB	_	16	VC	_	_
18	an	_	DT	DT	_	20	NMOD	_	_
19	important	_	JJ	JJ	_	20	NMOD	_	_
20	role	_	NN	NN	_	17	OBJ	_	_
21	in	_	IN	IN	_	17	ADV	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	regulation	_	NN	NN	_	21	PMOD	_	_
24	of	_	IN	IN	_	23	NMOD	_	_
25	granulomatous	_	JJ	JJ	_	26	NMOD	_	_
26	reactions	_	NNS	NNS	_	24	PMOD	_	_
27	,	_	,	,	_	3	P	_	_
28	but	_	CC	CC	_	3	CC	_	_
29	because	_	IN	IN	_	47	ADV	_	_
30	these	_	DT	DT	_	31	NMOD	_	_
31	receptors	_	NNS	NNS	_	32	SBJ	_	_
32	are	_	VBP	VBP	_	29	VMOD	_	_
33	expressed	_	VBN	VBN	_	32	VC	_	_
34	on	_	IN	IN	_	33	ADV	_	_
35	different	_	JJ	JJ	_	37	NMOD	_	_
36	lymphocyte	_	NN	NN	_	37	NMOD	_	_
37	populations	_	NNS	NNS	_	34	PMOD	_	_
38	,	_	,	,	_	47	P	_	_
39	the	_	DT	DT	_	41	NMOD	_	_
40	net	_	JJ	JJ	_	41	NMOD	_	_
41	effect	_	NN	NN	_	47	SBJ	_	_
42	of	_	IN	IN	_	41	NMOD	_	_
43	this	_	DT	DT	_	46	NMOD	_	_
44	potent	_	JJ	JJ	_	46	NMOD	_	_
45	immunoregulatory	_	JJ	JJ	_	46	NMOD	_	_
46	molecule	_	NN	NN	_	42	PMOD	_	_
47	is	_	VBZ	VBZ	_	3	COORD	_	_
48	likely	_	RB	RB	_	49	AMOD	_	_
49	different	_	JJ	JJ	_	47	PRD	_	_
50	in	_	IN	IN	_	47	ADV	_	_
51	sarcoidosis	_	NN	NN	_	50	PMOD	_	_
52	and	_	CC	CC	_	51	CC	_	_
53	tuberculosis	_	NN	NN	_	51	COORD	_	_
54	.	_	.	.	_	3	P	_	_

1	Inhibition	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	transcription	_	NN	NN	_	4	NMOD	_	_
4	factors	_	NNS	NNS	_	2	PMOD	_	_
5	belonging	_	VBG	VBG	_	4	NMOD	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	the	_	DT	DT	_	10	NMOD	_	_
8	rel\/NF-kappa	_	NN	NN	_	10	NMOD	_	_
9	B	_	NN	NN	_	10	NMOD	_	_
10	family	_	NN	NN	_	6	PMOD	_	_
11	by	_	IN	IN	_	1	NMOD	_	_
12	a	_	DT	DT	_	15	NMOD	_	_
13	transdominant	_	JJ	JJ	_	15	NMOD	_	_
14	negative	_	JJ	JJ	_	15	NMOD	_	_
15	mutant	_	NN	NN	_	11	PMOD	_	_
16	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	KBF1	_	NN	NN	_	3	NMOD	_	_
3	factor	_	NN	NN	_	24	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	which	_	WDT	WDT	_	6	SBJ	_	_
6	binds	_	VBZ	VBZ	_	3	NMOD	_	_
7	to	_	TO	TO	_	6	ADV	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	enhancer	_	NN	NN	_	10	NMOD	_	_
10	A	_	NN	NN	_	7	PMOD	_	_
11	located	_	JJ	JJ	_	10	NMOD	_	_
12	in	_	IN	IN	_	11	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	promoter	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	22	NMOD	_	_
17	mouse	_	NN	NN	_	22	NMOD	_	_
18	MHC	_	NN	NN	_	22	NMOD	_	_
19	class	_	NN	NN	_	22	NMOD	_	_
20	I	_	CD	CD	_	22	NMOD	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	H-2Kb	_	NN	NN	_	15	PMOD	_	_
23	,	_	,	,	_	3	P	_	_
24	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
25	indistinguishable	_	JJ	JJ	_	24	PRD	_	_
26	from	_	IN	IN	_	25	AMOD	_	_
27	the	_	DT	DT	_	31	NMOD	_	_
28	p50	_	NN	NN	_	31	NMOD	_	_
29	DNA	_	NN	NN	_	31	NMOD	_	_
30	binding	_	NN	NN	_	31	NMOD	_	_
31	subunit	_	NN	NN	_	26	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	the	_	DT	DT	_	37	NMOD	_	_
34	transcription	_	NN	NN	_	37	NMOD	_	_
35	factor	_	NN	NN	_	37	NMOD	_	_
36	NF-kappa	_	NN	NN	_	37	NMOD	_	_
37	B	_	NN	NN	_	32	PMOD	_	_
38	,	_	,	,	_	31	P	_	_
39	which	_	WDT	WDT	_	40	SBJ	_	_
40	regulates	_	VBZ	VBZ	_	31	NMOD	_	_
41	a	_	DT	DT	_	42	NMOD	_	_
42	series	_	NN	NN	_	40	OBJ	_	_
43	of	_	IN	IN	_	42	NMOD	_	_
44	genes	_	NNS	NNS	_	43	PMOD	_	_
45	involved	_	VBN	VBN	_	44	NMOD	_	_
46	in	_	IN	IN	_	45	ADV	_	_
47	immune	_	JJ	JJ	_	50	NMOD	_	_
48	and	_	CC	CC	_	47	CC	_	_
49	inflammatory	_	JJ	JJ	_	47	COORD	_	_
50	responses	_	NNS	NNS	_	46	PMOD	_	_
51	.	_	.	.	_	24	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	KBF1\/p50	_	NN	NN	_	3	NMOD	_	_
3	factor	_	NN	NN	_	4	SBJ	_	_
4	binds	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	as	_	IN	IN	_	4	ADV	_	_
6	a	_	DT	DT	_	7	NMOD	_	_
7	homodimer	_	NN	NN	_	5	PMOD	_	_
8	but	_	CC	CC	_	4	CC	_	_
9	can	_	MD	MD	_	4	COORD	_	_
10	also	_	RB	RB	_	9	ADV	_	_
11	form	_	VB	VB	_	9	VC	_	_
12	heterodimers	_	NNS	NNS	_	11	OBJ	_	_
13	with	_	IN	IN	_	11	ADV	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	products	_	NNS	NNS	_	13	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	other	_	JJ	JJ	_	18	NMOD	_	_
18	members	_	NNS	NNS	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	same	_	JJ	JJ	_	22	NMOD	_	_
22	family	_	NN	NN	_	19	PMOD	_	_
23	,	_	,	,	_	15	P	_	_
24	like	_	IN	IN	_	15	NMOD	_	_
25	the	_	DT	DT	_	32	NMOD	_	_
26	c-rel	_	NN	NN	_	32	NMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	v-rel	_	NN	NN	_	26	COORD	_	_
29	(	_	(	(	_	32	P	_	_
30	proto	_	NN	NN	_	32	NMOD	_	_
31	)	_	)	)	_	32	P	_	_
32	oncogenes	_	NNS	NNS	_	24	PMOD	_	_
33	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	dimerization	_	NN	NN	_	3	NMOD	_	_
3	domain	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	KBF1\/p50	_	NN	NN	_	4	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	contained	_	VBN	VBN	_	6	VC	_	_
8	between	_	IN	IN	_	7	ADV	_	_
9	amino	_	NN	NN	_	10	NMOD	_	_
10	acids	_	NNS	NNS	_	8	PMOD	_	_
11	201	_	CD	CD	_	10	NMOD	_	_
12	and	_	CC	CC	_	11	CC	_	_
13	367	_	CD	CD	_	11	COORD	_	_
14	.	_	.	.	_	6	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	mutant	_	NN	NN	_	23	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	KBF1\/p50	_	NN	NN	_	7	NMOD	_	_
5	(	_	(	(	_	7	P	_	_
6	delta	_	NN	NN	_	7	NMOD	_	_
7	SP	_	NN	NN	_	3	PMOD	_	_
8	)	_	)	)	_	7	P	_	_
9	,	_	,	,	_	2	P	_	_
10	unable	_	JJ	JJ	_	2	NMOD	_	_
11	to	_	TO	TO	_	12	VMOD	_	_
12	bind	_	VB	VB	_	10	AMOD	_	_
13	to	_	TO	TO	_	12	ADV	_	_
14	DNA	_	NN	NN	_	13	PMOD	_	_
15	but	_	CC	CC	_	10	CC	_	_
16	able	_	JJ	JJ	_	10	COORD	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	form	_	VB	VB	_	16	AMOD	_	_
19	homo-	_	JJ	JJ	_	18	NMOD	_	_
20	or	_	CC	CC	_	18	CC	_	_
21	heterodimers	_	NNS	NNS	_	18	COORD	_	_
22	,	_	,	,	_	2	P	_	_
23	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
24	been	_	VBN	VBN	_	23	VC	_	_
25	constructed	_	VBN	VBN	_	24	VC	_	_
26	.	_	.	.	_	23	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	protein	_	NN	NN	_	3	SBJ	_	_
3	reduces	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	or	_	CC	CC	_	3	CC	_	_
5	abolishes	_	VBZ	VBZ	_	3	COORD	_	_
6	in	_	FW	FW	_	3	ADV	_	_
7	vitro	_	FW	FW	_	6	AMOD	_	_
8	the	_	DT	DT	_	11	NMOD	_	_
9	DNA	_	NN	NN	_	11	NMOD	_	_
10	binding	_	NN	NN	_	11	NMOD	_	_
11	activity	_	NN	NN	_	3	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	wild-type	_	JJ	JJ	_	14	NMOD	_	_
14	proteins	_	NNS	NNS	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	same	_	JJ	JJ	_	18	NMOD	_	_
18	family	_	NN	NN	_	15	PMOD	_	_
19	(	_	(	(	_	20	P	_	_
20	KBF1\/p50	_	NN	NN	_	14	PRN	_	_
21	,	_	,	,	_	20	P	_	_
22	c-	_	NN	NN	_	20	NMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	v-rel	_	NN	NN	_	22	COORD	_	_
25	)	_	)	)	_	20	P	_	_
26	.	_	.	.	_	3	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	mutant	_	JJ	JJ	_	4	SBJ	_	_
3	also	_	RB	RB	_	4	ADV	_	_
4	functions	_	NNS	NNS	_	0	ROOT-S	_	_
5	in	_	FW	FW	_	4	ADV	_	_
6	vivo	_	FW	FW	_	5	AMOD	_	_
7	as	_	IN	IN	_	4	ADV	_	_
8	a	_	DT	DT	_	12	NMOD	_	_
9	trans-acting	_	JJ	JJ	_	12	NMOD	_	_
10	dominant	_	JJ	JJ	_	12	NMOD	_	_
11	negative	_	JJ	JJ	_	12	NMOD	_	_
12	regulator	_	NN	NN	_	7	PMOD	_	_
13	:	_	:	:	_	4	P	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	transcriptional	_	JJ	JJ	_	16	NMOD	_	_
16	inducibility	_	NN	NN	_	39	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	the	_	DT	DT	_	22	NMOD	_	_
19	HIV	_	NN	NN	_	22	NMOD	_	_
20	long	_	JJ	JJ	_	22	NMOD	_	_
21	terminal	_	JJ	JJ	_	22	NMOD	_	_
22	repeat	_	NN	NN	_	17	PMOD	_	_
23	(	_	(	(	_	22	P	_	_
24	which	_	WDT	WDT	_	25	SBJ	_	_
25	contains	_	VBZ	VBZ	_	22	NMOD	_	_
26	two	_	CD	CD	_	31	NMOD	_	_
27	potential	_	JJ	JJ	_	31	NMOD	_	_
28	NF-kappa	_	NN	NN	_	31	NMOD	_	_
29	B	_	NN	NN	_	31	NMOD	_	_
30	binding	_	NN	NN	_	31	NMOD	_	_
31	sites	_	NNS	NNS	_	25	OBJ	_	_
32	)	_	)	)	_	22	P	_	_
33	by	_	IN	IN	_	16	NMOD	_	_
34	phorbol	_	NN	NN	_	35	NMOD	_	_
35	ester	_	NN	NN	_	33	PMOD	_	_
36	(	_	(	(	_	37	P	_	_
37	PMA	_	NN	NN	_	35	PRN	_	_
38	)	_	)	)	_	37	P	_	_
39	is	_	VBZ	VBZ	_	4	VMOD	_	_
40	inhibited	_	VBN	VBN	_	39	VC	_	_
41	when	_	WRB	WRB	_	44	ADV	_	_
42	it	_	PRP	PRP	_	43	SBJ	_	_
43	is	_	VBZ	VBZ	_	40	TMP	_	_
44	co-transfected	_	VBN	VBN	_	43	VC	_	_
45	into	_	IN	IN	_	44	ADV	_	_
46	CD4+	_	JJ	JJ	_	48	NMOD	_	_
47	T	_	NN	NN	_	48	NMOD	_	_
48	cells	_	NNS	NNS	_	45	PMOD	_	_
49	with	_	IN	IN	_	44	ADV	_	_
50	the	_	DT	DT	_	53	NMOD	_	_
51	delta	_	NN	NN	_	53	NMOD	_	_
52	SP	_	NN	NN	_	53	NMOD	_	_
53	mutant	_	NN	NN	_	49	PMOD	_	_
54	.	_	.	.	_	39	P	_	_

1	Similarly	_	RB	RB	_	18	ADV	_	_
2	the	_	DT	DT	_	10	NMOD	_	_
3	basal	_	JJ	JJ	_	10	NMOD	_	_
4	as	_	RB	RB	_	3	CC	_	_
5	well	_	RB	RB	_	4	DEP	_	_
6	as	_	IN	IN	_	4	DEP	_	_
7	TNF	_	NN	NN	_	3	COORD	_	_
8	or	_	CC	CC	_	7	CC	_	_
9	IL1-induced	_	JJ	JJ	_	7	COORD	_	_
10	activity	_	NN	NN	_	18	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	17	NMOD	_	_
13	MHC	_	NN	NN	_	17	NMOD	_	_
14	class	_	NN	NN	_	17	NMOD	_	_
15	I	_	CD	CD	_	17	NMOD	_	_
16	H-2Kb	_	NN	NN	_	17	NMOD	_	_
17	promoter	_	NN	NN	_	11	PMOD	_	_
18	can	_	MD	MD	_	0	ROOT-S	_	_
19	be	_	VB	VB	_	18	VC	_	_
20	inhibited	_	VBN	VBN	_	19	VC	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	this	_	DT	DT	_	23	NMOD	_	_
23	mutant	_	NN	NN	_	21	PMOD	_	_
24	in	_	IN	IN	_	20	ADV	_	_
25	two	_	CD	CD	_	28	NMOD	_	_
26	different	_	JJ	JJ	_	28	NMOD	_	_
27	cell	_	NN	NN	_	28	NMOD	_	_
28	lines	_	NNS	NNS	_	24	PMOD	_	_
29	.	_	.	.	_	18	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	constitute	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	first	_	JJ	JJ	_	7	NMOD	_	_
6	formal	_	JJ	JJ	_	7	NMOD	_	_
7	demonstration	_	NN	NN	_	3	OBJ	_	_
8	that	_	IN	IN	_	7	NMOD	_	_
9	these	_	DT	DT	_	10	NMOD	_	_
10	genes	_	NNS	NNS	_	11	SBJ	_	_
11	are	_	VBP	VBP	_	8	VMOD	_	_
12	regulated	_	VBN	VBN	_	11	VC	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	members	_	NNS	NNS	_	13	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	rel\/NF-kappa	_	NN	NN	_	19	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	family	_	NN	NN	_	15	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Human	_	JJ	JJ	_	4	NMOD	_	_
2	erythroid	_	JJ	JJ	_	4	NMOD	_	_
3	5-aminolevulinate	_	NN	NN	_	4	NMOD	_	_
4	synthase	_	NN	NN	_	0	ROOT-FRAG	_	_
5	:	_	:	:	_	4	P	_	_
6	promoter	_	NN	NN	_	7	NMOD	_	_
7	analysis	_	NN	NN	_	4	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	identification	_	NN	NN	_	7	COORD	_	_
10	of	_	IN	IN	_	7	NMOD	_	_
11	an	_	DT	DT	_	13	NMOD	_	_
12	iron-responsive	_	JJ	JJ	_	13	NMOD	_	_
13	element	_	NN	NN	_	10	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	mRNA	_	NN	NN	_	14	PMOD	_	_
17	.	_	.	.	_	7	P	_	_

1	5-Aminolevulinate	_	NN	NN	_	2	NMOD	_	_
2	synthase	_	NN	NN	_	6	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	ALAS	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	catalyzes	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	first	_	JJ	JJ	_	9	NMOD	_	_
9	step	_	NN	NN	_	6	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	heme	_	NN	NN	_	14	NMOD	_	_
13	biosynthetic	_	JJ	JJ	_	14	NMOD	_	_
14	pathway	_	NN	NN	_	10	PMOD	_	_
15	.	_	.	.	_	6	P	_	_

1	cDNA	_	NN	NN	_	2	NMOD	_	_
2	clones	_	NNS	NNS	_	9	SBJ	_	_
3	for	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	8	NMOD	_	_
5	human	_	JJ	JJ	_	8	NMOD	_	_
6	erythroid	_	JJ	JJ	_	8	NMOD	_	_
7	ALAS	_	NN	NN	_	8	NMOD	_	_
8	isozyme	_	NN	NN	_	3	PMOD	_	_
9	were	_	VBD	VBD	_	0	ROOT-S	_	_
10	isolated	_	VBN	VBN	_	9	VC	_	_
11	from	_	IN	IN	_	10	ADV	_	_
12	a	_	DT	DT	_	15	NMOD	_	_
13	fetal	_	JJ	JJ	_	15	NMOD	_	_
14	liver	_	NN	NN	_	15	NMOD	_	_
15	library	_	NN	NN	_	11	PMOD	_	_
16	.	_	.	.	_	9	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	can	_	MD	MD	_	0	ROOT-S	_	_
3	be	_	VB	VB	_	2	VC	_	_
4	deduced	_	VBN	VBN	_	3	VC	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	erythroid	_	JJ	JJ	_	10	NMOD	_	_
8	ALAS	_	NN	NN	_	10	NMOD	_	_
9	precursor	_	NN	NN	_	10	NMOD	_	_
10	protein	_	NN	NN	_	11	SBJ	_	_
11	has	_	VBZ	VBZ	_	5	VMOD	_	_
12	a	_	DT	DT	_	14	NMOD	_	_
13	molecular	_	JJ	JJ	_	14	NMOD	_	_
14	weight	_	NN	NN	_	11	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	64.6	_	CD	CD	_	17	NMOD	_	_
17	kd	_	NN	NN	_	15	PMOD	_	_
18	,	_	,	,	_	11	P	_	_
19	and	_	CC	CC	_	11	CC	_	_
20	is	_	VBZ	VBZ	_	11	COORD	_	_
21	similar	_	JJ	JJ	_	20	PRD	_	_
22	in	_	IN	IN	_	21	AMOD	_	_
23	size	_	NN	NN	_	22	PMOD	_	_
24	to	_	TO	TO	_	21	AMOD	_	_
25	the	_	DT	DT	_	31	NMOD	_	_
26	previously	_	RB	RB	_	27	AMOD	_	_
27	isolated	_	VBN	VBN	_	31	NMOD	_	_
28	human	_	JJ	JJ	_	31	NMOD	_	_
29	housekeeping	_	JJ	JJ	_	31	NMOD	_	_
30	ALAS	_	NN	NN	_	31	NMOD	_	_
31	precursor	_	NN	NN	_	24	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	molecular	_	JJ	JJ	_	36	NMOD	_	_
34	weight	_	NN	NN	_	36	NMOD	_	_
35	70.6	_	CD	CD	_	36	NMOD	_	_
36	kd	_	NN	NN	_	32	PMOD	_	_
37	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	mature	_	JJ	JJ	_	4	NMOD	_	_
3	mitochondrial	_	JJ	JJ	_	4	NMOD	_	_
4	forms	_	NNS	NNS	_	12	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	11	NMOD	_	_
7	erythroid	_	JJ	JJ	_	11	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	housekeeping	_	JJ	JJ	_	7	COORD	_	_
10	ALAS	_	NN	NN	_	11	NMOD	_	_
11	isozymes	_	NNS	NNS	_	5	PMOD	_	_
12	are	_	VBP	VBP	_	0	ROOT-S	_	_
13	predicted	_	VBN	VBN	_	12	VC	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	have	_	VB	VB	_	13	OBJ	_	_
16	molecular	_	JJ	JJ	_	17	NMOD	_	_
17	weights	_	NNS	NNS	_	15	OBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	59.5	_	CD	CD	_	20	NMOD	_	_
20	kd	_	NN	NN	_	18	PMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	64.6	_	CD	CD	_	23	NMOD	_	_
23	kd	_	NN	NN	_	20	COORD	_	_
24	,	_	,	,	_	15	P	_	_
25	respectively	_	RB	RB	_	15	ADV	_	_
26	.	_	.	.	_	12	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	two	_	CD	CD	_	3	NMOD	_	_
3	isozymes	_	NNS	NNS	_	4	SBJ	_	_
4	show	_	VBP	VBP	_	0	ROOT-S	_	_
5	little	_	JJ	JJ	_	8	NMOD	_	_
6	amino	_	NN	NN	_	8	NMOD	_	_
7	acid	_	NN	NN	_	8	NMOD	_	_
8	identity	_	NN	NN	_	4	OBJ	_	_
9	in	_	IN	IN	_	4	ADV	_	_
10	their	_	PRP$	PRP$	_	13	NMOD	_	_
11	N-terminal	_	JJ	JJ	_	13	NMOD	_	_
12	signal	_	NN	NN	_	13	NMOD	_	_
13	sequences	_	NNS	NNS	_	9	PMOD	_	_
14	but	_	CC	CC	_	4	CC	_	_
15	have	_	VBP	VBP	_	4	COORD	_	_
16	considerable	_	JJ	JJ	_	18	NMOD	_	_
17	sequence	_	NN	NN	_	18	NMOD	_	_
18	identity	_	NN	NN	_	15	OBJ	_	_
19	in	_	IN	IN	_	15	ADV	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	C-terminal	_	JJ	JJ	_	22	NMOD	_	_
22	two-thirds	_	CD	CD	_	19	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	their	_	PRP$	PRP$	_	25	NMOD	_	_
25	proteins	_	NNS	NNS	_	23	PMOD	_	_
26	.	_	.	.	_	4	P	_	_

1	An	_	DT	DT	_	2	NMOD	_	_
2	analysis	_	NN	NN	_	13	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	immediate	_	JJ	JJ	_	6	NMOD	_	_
6	promoter	_	NN	NN	_	3	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	human	_	JJ	JJ	_	12	NMOD	_	_
10	erythroid	_	JJ	JJ	_	12	NMOD	_	_
11	ALAS	_	NN	NN	_	12	NMOD	_	_
12	gene	_	NN	NN	_	7	PMOD	_	_
13	revealed	_	VBD	VBD	_	0	ROOT-S	_	_
14	several	_	JJ	JJ	_	18	NMOD	_	_
15	putative	_	JJ	JJ	_	18	NMOD	_	_
16	erythroid-specific	_	JJ	JJ	_	18	NMOD	_	_
17	cis-acting	_	JJ	JJ	_	18	NMOD	_	_
18	elements	_	NNS	NNS	_	13	OBJ	_	_
19	including	_	VBG	VBG	_	18	NMOD	_	_
20	both	_	PDT	PDT	_	22	NMOD	_	_
21	a	_	DT	DT	_	22	NMOD	_	_
22	GATA-1	_	NN	NN	_	19	PMOD	_	_
23	and	_	CC	CC	_	22	CC	_	_
24	an	_	DT	DT	_	25	NMOD	_	_
25	NF-E2	_	NN	NN	_	22	COORD	_	_
26	binding	_	NN	NN	_	27	NMOD	_	_
27	site	_	NN	NN	_	22	NMOD	_	_
28	.	_	.	.	_	13	P	_	_

1	An	_	DT	DT	_	7	NMOD	_	_
2	iron-responsive	_	JJ	JJ	_	3	NMOD	_	_
3	element	_	NN	NN	_	7	NMOD	_	_
4	(	_	(	(	_	5	P	_	_
5	IRE	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	motif	_	NN	NN	_	8	SBJ	_	_
8	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	been	_	VBN	VBN	_	8	VC	_	_
10	identified	_	VBN	VBN	_	9	VC	_	_
11	in	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	5'-untranslated	_	JJ	JJ	_	14	NMOD	_	_
14	region	_	NN	NN	_	11	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	20	NMOD	_	_
17	human	_	JJ	JJ	_	20	NMOD	_	_
18	erythroid	_	JJ	JJ	_	20	NMOD	_	_
19	ALAS	_	NN	NN	_	20	NMOD	_	_
20	mRNA	_	NN	NN	_	15	PMOD	_	_
21	,	_	,	,	_	8	P	_	_
22	but	_	CC	CC	_	8	CC	_	_
23	is	_	VBZ	VBZ	_	8	COORD	_	_
24	not	_	RB	RB	_	23	VMOD	_	_
25	present	_	JJ	JJ	_	23	PRD	_	_
26	in	_	IN	IN	_	25	AMOD	_	_
27	the	_	DT	DT	_	30	NMOD	_	_
28	housekeeping	_	JJ	JJ	_	30	NMOD	_	_
29	ALAS	_	NN	NN	_	30	NMOD	_	_
30	mRNA	_	NN	NN	_	26	PMOD	_	_
31	.	_	.	.	_	8	P	_	_

1	Gel	_	NN	NN	_	3	NMOD	_	_
2	retardation	_	NN	NN	_	3	NMOD	_	_
3	experiments	_	NNS	NNS	_	4	SBJ	_	_
4	established	_	VBD	VBD	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	OBJ	_	_
6	this	_	DT	DT	_	8	NMOD	_	_
7	IRE	_	NN	NN	_	8	NMOD	_	_
8	motif	_	NN	NN	_	9	SBJ	_	_
9	formed	_	VBD	VBD	_	5	VMOD	_	_
10	a	_	DT	DT	_	12	NMOD	_	_
11	protein-RNA	_	JJ	JJ	_	12	NMOD	_	_
12	complex	_	NN	NN	_	9	OBJ	_	_
13	with	_	IN	IN	_	9	ADV	_	_
14	cytosolic	_	JJ	JJ	_	15	NMOD	_	_
15	extracts	_	NNS	NNS	_	13	PMOD	_	_
16	from	_	IN	IN	_	15	NMOD	_	_
17	human	_	JJ	JJ	_	19	NMOD	_	_
18	K562	_	NN	NN	_	19	NMOD	_	_
19	cells	_	NNS	NNS	_	16	PMOD	_	_
20	and	_	CC	CC	_	9	CC	_	_
21	this	_	DT	DT	_	22	NMOD	_	_
22	binding	_	NN	NN	_	23	SBJ	_	_
23	was	_	VBD	VBD	_	9	COORD	_	_
24	strongly	_	RB	RB	_	23	ADV	_	_
25	competed	_	VBN	VBN	_	23	VC	_	_
26	with	_	IN	IN	_	25	ADV	_	_
27	IRE	_	NN	NN	_	28	NMOD	_	_
28	transcripts	_	NNS	NNS	_	26	PMOD	_	_
29	from	_	IN	IN	_	28	NMOD	_	_
30	ferritin	_	NN	NN	_	33	NMOD	_	_
31	or	_	CC	CC	_	30	CC	_	_
32	transferrin	_	NN	NN	_	30	COORD	_	_
33	receptor	_	NN	NN	_	34	NMOD	_	_
34	mRNAs	_	NNS	NNS	_	29	PMOD	_	_
35	.	_	.	.	_	4	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	transcript	_	NN	NN	_	17	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	ALAS	_	NN	NN	_	6	NMOD	_	_
6	IRE	_	NN	NN	_	3	PMOD	_	_
7	,	_	,	,	_	2	P	_	_
8	mutated	_	VBN	VBN	_	2	NMOD	_	_
9	in	_	IN	IN	_	8	ADV	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	conserved	_	VBN	VBN	_	12	NMOD	_	_
12	loop	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	IRE	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	2	P	_	_
17	did	_	VBD	VBD	_	0	ROOT-S	_	_
18	not	_	RB	RB	_	17	VMOD	_	_
19	readily	_	RB	RB	_	17	ADV	_	_
20	form	_	VB	VB	_	17	VC	_	_
21	this	_	DT	DT	_	23	NMOD	_	_
22	protein-RNA	_	JJ	JJ	_	23	NMOD	_	_
23	complex	_	NN	NN	_	20	OBJ	_	_
24	.	_	.	.	_	17	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	IRE	_	NN	NN	_	7	NMOD	_	_
7	motif	_	NN	NN	_	12	SBJ	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	ALAS	_	NN	NN	_	11	NMOD	_	_
11	mRNA	_	NN	NN	_	8	PMOD	_	_
12	is	_	VBZ	VBZ	_	4	VMOD	_	_
13	functional	_	JJ	JJ	_	12	PRD	_	_
14	and	_	CC	CC	_	3	CC	_	_
15	imply	_	VBP	VBP	_	3	COORD	_	_
16	that	_	IN	IN	_	15	OBJ	_	_
17	translation	_	NN	NN	_	21	SBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	20	NMOD	_	_
20	mRNA	_	NN	NN	_	18	PMOD	_	_
21	is	_	VBZ	VBZ	_	16	VMOD	_	_
22	controlled	_	VBN	VBN	_	21	VC	_	_
23	by	_	IN	IN	_	22	LGS	_	_
24	cellular	_	JJ	JJ	_	26	NMOD	_	_
25	iron	_	NN	NN	_	26	NMOD	_	_
26	availability	_	NN	NN	_	23	PMOD	_	_
27	during	_	IN	IN	_	22	TMP	_	_
28	erythropoiesis	_	NN	NN	_	27	PMOD	_	_
29	.	_	.	.	_	3	P	_	_

1	Towards	_	IN	IN	_	0	ROOT-FRAG	_	_
2	a	_	DT	DT	_	4	NMOD	_	_
3	molecular	_	JJ	JJ	_	4	NMOD	_	_
4	understanding	_	NN	NN	_	1	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	T-cell	_	NN	NN	_	7	NMOD	_	_
7	differentiation	_	NN	NN	_	5	PMOD	_	_

1	Lymphoid	_	JJ	JJ	_	2	NMOD	_	_
2	differentiation	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	one	_	CD	CD	_	3	PRD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	best	_	RBS	RBS	_	8	AMOD	_	_
8	studied	_	VBN	VBN	_	9	NMOD	_	_
9	examples	_	NNS	NNS	_	5	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	mammalian	_	JJ	JJ	_	12	NMOD	_	_
12	development	_	NN	NN	_	10	PMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	Here	_	RB	RB	_	7	ADV	_	_
2	Hans	_	NNP	NNP	_	3	NMOD	_	_
3	Clevers	_	NNP	NNP	_	7	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	Michael	_	NNP	NNP	_	6	NMOD	_	_
6	Owen	_	NNP	NNP	_	3	COORD	_	_
7	describe	_	VBP	VBP	_	0	ROOT-S	_	_
8	how	_	WRB	WRB	_	19	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	cloning	_	NN	NN	_	19	SBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	genes	_	NNS	NNS	_	11	PMOD	_	_
14	that	_	WDT	WDT	_	15	SBJ	_	_
15	encode	_	VBP	VBP	_	13	NMOD	_	_
16	T-cell-specific	_	JJ	JJ	_	15	VMOD	_	_
17	membrane	_	NN	NN	_	15	VMOD	_	_
18	proteins	_	NNS	NNS	_	15	VMOD	_	_
19	allows	_	VBZ	VBZ	_	7	OBJ	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	identification	_	NN	NN	_	19	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	transcription	_	NN	NN	_	24	NMOD	_	_
24	factors	_	NNS	NNS	_	22	PMOD	_	_
25	that	_	WDT	WDT	_	26	SBJ	_	_
26	control	_	VBP	VBP	_	24	NMOD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	expression	_	NN	NN	_	26	OBJ	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	these	_	DT	DT	_	32	NMOD	_	_
31	T-cell	_	NN	NN	_	32	NMOD	_	_
32	genes	_	NNS	NNS	_	29	PMOD	_	_
33	.	_	.	.	_	7	P	_	_

1	Such	_	JJ	JJ	_	3	NMOD	_	_
2	transcription	_	NN	NN	_	3	NMOD	_	_
3	factors	_	NNS	NNS	_	4	SBJ	_	_
4	play	_	VBP	VBP	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	key	_	JJ	JJ	_	7	NMOD	_	_
7	role	_	NN	NN	_	4	OBJ	_	_
8	in	_	IN	IN	_	4	ADV	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	development	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	mature	_	JJ	JJ	_	15	NMOD	_	_
14	T-cell	_	NN	NN	_	15	NMOD	_	_
15	phenotype	_	NN	NN	_	11	PMOD	_	_
16	by	_	IN	IN	_	4	ADV	_	_
17	functioning	_	VBG	VBG	_	16	PMOD	_	_
18	as	_	IN	IN	_	17	ADV	_	_
19	'	_	``	``	_	18	P	_	_
20	master	_	JJ	JJ	_	21	NMOD	_	_
21	regulators	_	NNS	NNS	_	18	PMOD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	T-cell	_	NN	NN	_	24	NMOD	_	_
24	differentiation	_	NN	NN	_	22	PMOD	_	_
25	'	_	''	''	_	18	P	_	_
26	.	_	.	.	_	4	P	_	_

1	Regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	jun	_	NN	NN	_	7	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	fos	_	NN	NN	_	3	COORD	_	_
6	gene	_	NN	NN	_	7	NMOD	_	_
7	expression	_	NN	NN	_	2	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	human	_	JJ	JJ	_	10	NMOD	_	_
10	monocytes	_	NNS	NNS	_	8	PMOD	_	_
11	by	_	IN	IN	_	1	NMOD	_	_
12	the	_	DT	DT	_	15	NMOD	_	_
13	macrophage	_	NN	NN	_	15	NMOD	_	_
14	colony-stimulating	_	JJ	JJ	_	13	AMOD	_	_
15	factor	_	NN	NN	_	11	PMOD	_	_
16	.	_	.	.	_	1	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	macrophage	_	NN	NN	_	4	NMOD	_	_
3	colony-stimulating	_	JJ	JJ	_	2	AMOD	_	_
4	factor	_	NN	NN	_	8	SBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	M-CSF	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	required	_	VBN	VBN	_	8	VC	_	_
10	for	_	IN	IN	_	9	ADV	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	growth	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	differentiation	_	NN	NN	_	12	COORD	_	_
15	of	_	IN	IN	_	12	NMOD	_	_
16	mononuclear	_	JJ	JJ	_	17	NMOD	_	_
17	phagocytes	_	NNS	NNS	_	15	PMOD	_	_
18	.	_	.	.	_	8	P	_	_

1	However	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	signaling	_	NN	NN	_	5	NMOD	_	_
5	events	_	NNS	NNS	_	10	SBJ	_	_
6	responsible	_	JJ	JJ	_	5	NMOD	_	_
7	for	_	IN	IN	_	6	AMOD	_	_
8	these	_	DT	DT	_	9	NMOD	_	_
9	effects	_	NNS	NNS	_	7	PMOD	_	_
10	remain	_	VBP	VBP	_	0	ROOT-S	_	_
11	unclear	_	JJ	JJ	_	10	PRD	_	_
12	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	present	_	JJ	JJ	_	3	NMOD	_	_
3	studies	_	NNS	NNS	_	4	SBJ	_	_
4	have	_	VBP	VBP	_	0	ROOT-S	_	_
5	examined	_	VBN	VBN	_	4	VC	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	effects	_	NNS	NNS	_	5	OBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	M-CSF	_	NN	NN	_	8	PMOD	_	_
10	on	_	IN	IN	_	7	NMOD	_	_
11	potential	_	JJ	JJ	_	13	NMOD	_	_
12	signaling	_	NN	NN	_	13	NMOD	_	_
13	pathways	_	NNS	NNS	_	10	PMOD	_	_
14	involving	_	VBG	VBG	_	13	NMOD	_	_
15	expression	_	NN	NN	_	14	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	23	NMOD	_	_
18	jun	_	NN	NN	_	23	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	fos	_	NN	NN	_	18	COORD	_	_
21	early	_	JJ	JJ	_	23	NMOD	_	_
22	response	_	NN	NN	_	23	NMOD	_	_
23	genes	_	NNS	NNS	_	16	PMOD	_	_
24	.	_	.	.	_	4	P	_	_

1	Low	_	JJ	JJ	_	2	NMOD	_	_
2	levels	_	NNS	NNS	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	c-jun	_	NN	NN	_	5	NMOD	_	_
5	transcripts	_	NNS	NNS	_	3	PMOD	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	detectable	_	JJ	JJ	_	6	PRD	_	_
8	in	_	IN	IN	_	6	ADV	_	_
9	resting	_	VBG	VBG	_	13	NMOD	_	_
10	human	_	JJ	JJ	_	13	NMOD	_	_
11	peripheral	_	JJ	JJ	_	13	NMOD	_	_
12	blood	_	NN	NN	_	13	NMOD	_	_
13	monocytes	_	NNS	NNS	_	8	PMOD	_	_
14	.	_	.	.	_	6	P	_	_

1	Treatment	_	NN	NN	_	11	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	these	_	DT	DT	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	with	_	IN	IN	_	1	NMOD	_	_
6	10-LRB-3-RRB-	_	CD	CD	_	10	NMOD	_	_
7	units\/ml	_	NNS	NNS	_	10	NMOD	_	_
8	human	_	JJ	JJ	_	10	NMOD	_	_
9	recombinant	_	JJ	JJ	_	10	NMOD	_	_
10	M-CSF	_	NN	NN	_	5	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	associated	_	VBN	VBN	_	11	VC	_	_
13	with	_	IN	IN	_	12	ADV	_	_
14	rapid	_	JJ	JJ	_	17	NMOD	_	_
15	and	_	CC	CC	_	14	CC	_	_
16	transient	_	JJ	JJ	_	14	COORD	_	_
17	increases	_	NNS	NNS	_	13	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	c-jun	_	NN	NN	_	21	NMOD	_	_
20	mRNA	_	NN	NN	_	21	NMOD	_	_
21	levels	_	NNS	NNS	_	18	PMOD	_	_
22	.	_	.	.	_	11	P	_	_

1	Nuclear	_	JJ	JJ	_	3	NMOD	_	_
2	run-on	_	JJ	JJ	_	3	NMOD	_	_
3	assays	_	NNS	NNS	_	8	SBJ	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	mRNA	_	NN	NN	_	7	NMOD	_	_
6	stability	_	NN	NN	_	7	NMOD	_	_
7	studies	_	NNS	NNS	_	3	COORD	_	_
8	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
9	that	_	IN	IN	_	8	OBJ	_	_
10	M-CSF	_	NN	NN	_	11	SBJ	_	_
11	regulates	_	VBZ	VBZ	_	9	VMOD	_	_
12	c-jun	_	NN	NN	_	13	NMOD	_	_
13	expression	_	NN	NN	_	11	OBJ	_	_
14	by	_	IN	IN	_	11	ADV	_	_
15	both	_	CC	CC	_	17	CC	_	_
16	an	_	DT	DT	_	17	NMOD	_	_
17	increase	_	NN	NN	_	14	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	transcription	_	NN	NN	_	20	NMOD	_	_
20	rate	_	NN	NN	_	18	PMOD	_	_
21	and	_	CC	CC	_	17	CC	_	_
22	a	_	DT	DT	_	23	NMOD	_	_
23	prolongation	_	NN	NN	_	17	COORD	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	half-life	_	NN	NN	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	c-jun	_	NN	NN	_	29	NMOD	_	_
29	transcripts	_	NNS	NNS	_	27	PMOD	_	_
30	.	_	.	.	_	8	P	_	_

1	M-CSF	_	NN	NN	_	2	NMOD	_	_
2	treatment	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	also	_	RB	RB	_	3	ADV	_	_
5	associated	_	VBN	VBN	_	3	VC	_	_
6	with	_	IN	IN	_	5	ADV	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	rapid	_	JJ	JJ	_	9	NMOD	_	_
9	induction	_	NN	NN	_	6	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	jun-B	_	NN	NN	_	13	NMOD	_	_
13	gene	_	NN	NN	_	10	PMOD	_	_
14	,	_	,	,	_	5	P	_	_
15	although	_	IN	IN	_	5	OBJ	_	_
16	expression	_	NN	NN	_	20	SBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	this	_	DT	DT	_	19	NMOD	_	_
19	gene	_	NN	NN	_	17	PMOD	_	_
20	was	_	VBD	VBD	_	15	VMOD	_	_
21	prolonged	_	JJ	JJ	_	20	VC	_	_
22	compared	_	VBN	VBN	_	21	OBJ	_	_
23	to	_	TO	TO	_	22	ADV	_	_
24	that	_	DT	DT	_	23	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	c-jun	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	3	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	further	_	RB	RB	_	3	ADV	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	M-CSF	_	NN	NN	_	6	SBJ	_	_
6	increases	_	VBZ	VBZ	_	4	VMOD	_	_
7	c-fos	_	NN	NN	_	9	NMOD	_	_
8	mRNA	_	NN	NN	_	9	NMOD	_	_
9	levels	_	NNS	NNS	_	6	OBJ	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	human	_	JJ	JJ	_	12	NMOD	_	_
12	monocytes	_	NNS	NNS	_	10	PMOD	_	_
13	through	_	IN	IN	_	6	ADV	_	_
14	control	_	NN	NN	_	13	PMOD	_	_
15	at	_	IN	IN	_	14	NMOD	_	_
16	both	_	CC	CC	_	21	CC	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	transcriptional	_	JJ	JJ	_	21	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	posttranscriptional	_	JJ	JJ	_	18	COORD	_	_
21	levels	_	NNS	NNS	_	15	PMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	Maximal	_	JJ	JJ	_	2	NMOD	_	_
2	induction	_	NN	NN	_	7	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	c-fos	_	NN	NN	_	6	NMOD	_	_
6	gene	_	NN	NN	_	3	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	followed	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	that	_	DT	DT	_	9	PMOD	_	_
11	for	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	fos-B	_	NN	NN	_	14	NMOD	_	_
14	gene	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	7	P	_	_

1	Moreover	_	RB	RB	_	12	ADV	_	_
2	,	_	,	,	_	12	P	_	_
3	M-CSF-induced	_	JJ	JJ	_	4	NMOD	_	_
4	expression	_	NN	NN	_	12	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	fos-related	_	JJ	JJ	_	8	NMOD	_	_
8	gene	_	NN	NN	_	5	PMOD	_	_
9	,	_	,	,	_	4	P	_	_
10	fra-1	_	NN	NN	_	4	NMOD	_	_
11	,	_	,	,	_	4	P	_	_
12	was	_	VBD	VBD	_	0	ROOT-S	_	_
13	delayed	_	VBN	VBN	_	12	VC	_	_
14	compared	_	VBN	VBN	_	13	OBJ	_	_
15	to	_	TO	TO	_	14	ADV	_	_
16	that	_	DT	DT	_	15	PMOD	_	_
17	for	_	IN	IN	_	16	NMOD	_	_
18	both	_	DT	DT	_	19	NMOD	_	_
19	c-fos	_	NN	NN	_	17	PMOD	_	_
20	and	_	CC	CC	_	19	CC	_	_
21	fos-B	_	NN	NN	_	19	COORD	_	_
22	.	_	.	.	_	12	P	_	_

1	Taken	_	VBN	VBN	_	6	ADV	_	_
2	together	_	RB	RB	_	1	ADV	_	_
3	,	_	,	,	_	6	P	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	results	_	NNS	NNS	_	6	SBJ	_	_
6	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	M-CSF	_	NN	NN	_	9	NMOD	_	_
9	treatment	_	NN	NN	_	10	SBJ	_	_
10	is	_	VBZ	VBZ	_	7	VMOD	_	_
11	associated	_	VBN	VBN	_	10	VC	_	_
12	with	_	IN	IN	_	11	ADV	_	_
13	differential	_	JJ	JJ	_	14	NMOD	_	_
14	activation	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	multiple	_	JJ	JJ	_	17	NMOD	_	_
17	members	_	NNS	NNS	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	21	NMOD	_	_
20	jun\/fos	_	NN	NN	_	21	NMOD	_	_
21	family	_	NN	NN	_	18	PMOD	_	_
22	and	_	CC	CC	_	7	CC	_	_
23	that	_	IN	IN	_	7	COORD	_	_
24	expression	_	NN	NN	_	28	SBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	these	_	DT	DT	_	27	NMOD	_	_
27	genes	_	NNS	NNS	_	25	PMOD	_	_
28	could	_	MD	MD	_	23	VMOD	_	_
29	contribute	_	VB	VB	_	28	VC	_	_
30	to	_	TO	TO	_	29	ADV	_	_
31	nuclear	_	JJ	JJ	_	33	NMOD	_	_
32	signaling	_	NN	NN	_	33	NMOD	_	_
33	mechanisms	_	NNS	NNS	_	30	PMOD	_	_
34	that	_	WDT	WDT	_	35	SBJ	_	_
35	regulate	_	VBP	VBP	_	33	NMOD	_	_
36	a	_	DT	DT	_	38	NMOD	_	_
37	specific	_	JJ	JJ	_	38	NMOD	_	_
38	program	_	NN	NN	_	35	OBJ	_	_
39	of	_	IN	IN	_	38	NMOD	_	_
40	monocyte	_	NN	NN	_	41	NMOD	_	_
41	differentiation	_	NN	NN	_	39	PMOD	_	_
42	.	_	.	.	_	6	P	_	_

1	Severe	_	JJ	JJ	_	3	NMOD	_	_
2	5-fluorouracil	_	NN	NN	_	3	NMOD	_	_
3	toxicity	_	NN	NN	_	0	ROOT-FRAG	_	_
4	secondary	_	JJ	JJ	_	3	NMOD	_	_
5	to	_	TO	TO	_	4	AMOD	_	_
6	dihydropyrimidine	_	NN	NN	_	8	NMOD	_	_
7	dehydrogenase	_	NN	NN	_	8	NMOD	_	_
8	deficiency	_	NN	NN	_	5	PMOD	_	_
9	.	_	.	.	_	3	P	_	_

1	A	_	DT	DT	_	6	NMOD	_	_
2	potentially	_	RB	RB	_	4	AMOD	_	_
3	more	_	RBR	RBR	_	4	AMOD	_	_
4	common	_	JJ	JJ	_	6	NMOD	_	_
5	pharmacogenetic	_	JJ	JJ	_	6	NMOD	_	_
6	syndrome	_	NN	NN	_	0	ROOT-FRAG	_	_
7	.	_	.	.	_	6	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	study	_	NN	NN	_	3	SBJ	_	_
3	describes	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	inheritance	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	a	_	DT	DT	_	8	NMOD	_	_
8	defect	_	NN	NN	_	6	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	pyrimidine	_	NN	NN	_	11	NMOD	_	_
11	catabolism	_	NN	NN	_	9	PMOD	_	_
12	and	_	CC	CC	_	5	CC	_	_
13	its	_	PRP$	PRP$	_	14	NMOD	_	_
14	association	_	NN	NN	_	5	COORD	_	_
15	with	_	IN	IN	_	14	NMOD	_	_
16	drug-induced	_	JJ	JJ	_	17	NMOD	_	_
17	toxicity	_	NN	NN	_	15	PMOD	_	_
18	in	_	IN	IN	_	5	NMOD	_	_
19	a	_	DT	DT	_	20	NMOD	_	_
20	patient	_	NN	NN	_	18	PMOD	_	_
21	receiving	_	VBG	VBG	_	20	NMOD	_	_
22	5-fluorouracil	_	NN	NN	_	21	OBJ	_	_
23	(	_	(	(	_	24	P	_	_
24	FUra	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	as	_	IN	IN	_	21	ADV	_	_
27	adjuvant	_	JJ	JJ	_	28	NMOD	_	_
28	chemotherapy	_	NN	NN	_	26	PMOD	_	_
29	for	_	IN	IN	_	28	NMOD	_	_
30	breast	_	NN	NN	_	31	NMOD	_	_
31	carcinoma	_	NN	NN	_	29	PMOD	_	_
32	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	study	_	NN	NN	_	3	NMOD	_	_
3	population	_	NN	NN	_	4	SBJ	_	_
4	included	_	VBD	VBD	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	affected	_	VBN	VBN	_	7	NMOD	_	_
7	patient	_	NN	NN	_	4	OBJ	_	_
8	(	_	(	(	_	9	P	_	_
9	proband	_	NN	NN	_	7	PRN	_	_
10	)	_	)	)	_	9	P	_	_
11	,	_	,	,	_	7	P	_	_
12	nine	_	CD	CD	_	7	NMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	her	_	PRP$	PRP$	_	16	NMOD	_	_
15	blood	_	NN	NN	_	16	NMOD	_	_
16	relatives	_	NNS	NNS	_	13	PMOD	_	_
17	,	_	,	,	_	7	P	_	_
18	and	_	CC	CC	_	7	CC	_	_
19	seven	_	CD	CD	_	21	NMOD	_	_
20	healthy	_	JJ	JJ	_	21	NMOD	_	_
21	volunteers	_	NNS	NNS	_	7	COORD	_	_
22	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	activity	_	NN	NN	_	26	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	dihydropyrimidine	_	NN	NN	_	5	NMOD	_	_
5	dehydrogenase	_	NN	NN	_	3	PMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	DPD	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	,	_	,	,	_	5	P	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	initial	_	JJ	JJ	_	12	NMOD	_	_
12	enzyme	_	NN	NN	_	5	NMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	pyrimidine	_	NN	NN	_	19	NMOD	_	_
15	(	_	(	(	_	14	P	_	_
16	and	_	CC	CC	_	14	CC	_	_
17	FUra	_	NN	NN	_	14	COORD	_	_
18	)	_	)	)	_	14	P	_	_
19	catabolism	_	NN	NN	_	13	PMOD	_	_
20	,	_	,	,	_	5	P	_	_
21	in	_	IN	IN	_	5	NMOD	_	_
22	peripheral	_	JJ	JJ	_	25	NMOD	_	_
23	blood	_	NN	NN	_	25	NMOD	_	_
24	mononuclear	_	JJ	JJ	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	21	PMOD	_	_
26	was	_	VBD	VBD	_	0	ROOT-S	_	_
27	measured	_	VBN	VBN	_	26	VC	_	_
28	in	_	IN	IN	_	27	ADV	_	_
29	each	_	DT	DT	_	30	NMOD	_	_
30	subject	_	NN	NN	_	28	PMOD	_	_
31	by	_	IN	IN	_	27	ADV	_	_
32	a	_	DT	DT	_	35	NMOD	_	_
33	specific	_	JJ	JJ	_	35	NMOD	_	_
34	radiometric	_	JJ	JJ	_	35	NMOD	_	_
35	assay	_	NN	NN	_	31	PMOD	_	_
36	using	_	VBG	VBG	_	35	NMOD	_	_
37	FUra	_	NN	NN	_	36	OBJ	_	_
38	as	_	IN	IN	_	36	ADV	_	_
39	the	_	DT	DT	_	40	NMOD	_	_
40	substrate	_	NN	NN	_	38	PMOD	_	_
41	.	_	.	.	_	26	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	proband	_	NN	NN	_	3	SBJ	_	_
3	had	_	VBD	VBD	_	0	ROOT-S	_	_
4	no	_	DT	DT	_	7	NMOD	_	_
5	detectable	_	JJ	JJ	_	7	NMOD	_	_
6	DPD	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	3	OBJ	_	_
8	.	_	.	.	_	3	P	_	_

1	When	_	WRB	WRB	_	10	ADV	_	_
2	enzyme	_	NN	NN	_	3	NMOD	_	_
3	levels	_	NNS	NNS	_	9	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	proband	_	NN	NN	_	4	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	relatives	_	NNS	NNS	_	6	COORD	_	_
9	were	_	VBD	VBD	_	22	TMP	_	_
10	compared	_	VBN	VBN	_	9	VC	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	that	_	DT	DT	_	11	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	controls	_	NNS	NNS	_	13	PMOD	_	_
15	,	_	,	,	_	22	P	_	_
16	an	_	DT	DT	_	19	NMOD	_	_
17	autosomal	_	JJ	JJ	_	19	NMOD	_	_
18	recessive	_	JJ	JJ	_	19	NMOD	_	_
19	pattern	_	NN	NN	_	22	SBJ	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	inheritance	_	NN	NN	_	20	PMOD	_	_
22	was	_	VBD	VBD	_	0	ROOT-S	_	_
23	demonstrated	_	VBN	VBN	_	22	VC	_	_
24	.	_	.	.	_	22	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	third	_	JJ	JJ	_	5	NMOD	_	_
5	patient	_	NN	NN	_	2	PRD	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	severe	_	JJ	JJ	_	9	NMOD	_	_
8	FUra	_	NN	NN	_	9	NMOD	_	_
9	toxicity	_	NN	NN	_	6	PMOD	_	_
10	secondary	_	JJ	JJ	_	9	NMOD	_	_
11	to	_	TO	TO	_	10	AMOD	_	_
12	an	_	DT	DT	_	13	NMOD	_	_
13	alteration	_	NN	NN	_	11	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	pyrimidine	_	NN	NN	_	16	NMOD	_	_
16	catabolism	_	NN	NN	_	14	PMOD	_	_
17	and	_	CC	CC	_	5	CC	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	second	_	NN	NN	_	5	COORD	_	_
20	from	_	IN	IN	_	19	NMOD	_	_
21	our	_	PRP$	PRP$	_	23	NMOD	_	_
22	clinic	_	NN	NN	_	23	NMOD	_	_
23	population	_	NN	NN	_	20	PMOD	_	_
24	suggesting	_	VBG	VBG	_	2	VC	_	_
25	that	_	IN	IN	_	24	OBJ	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	frequency	_	NN	NN	_	32	SBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	this	_	DT	DT	_	31	NMOD	_	_
30	genetic	_	JJ	JJ	_	31	NMOD	_	_
31	defect	_	NN	NN	_	28	PMOD	_	_
32	may	_	MD	MD	_	25	VMOD	_	_
33	be	_	VB	VB	_	32	VC	_	_
34	greater	_	JJR	JJR	_	33	PRD	_	_
35	than	_	IN	IN	_	34	AMOD	_	_
36	previously	_	RB	RB	_	37	TMP	_	_
37	thought	_	VBN	VBN	_	35	VMOD	_	_
38	.	_	.	.	_	2	P	_	_

1	Monitoring	_	VBG	VBG	_	4	SBJ	_	_
2	DPD	_	NN	NN	_	3	NMOD	_	_
3	activity	_	NN	NN	_	1	OBJ	_	_
4	may	_	MD	MD	_	0	ROOT-S	_	_
5	be	_	VB	VB	_	4	VC	_	_
6	important	_	JJ	JJ	_	5	PRD	_	_
7	in	_	IN	IN	_	5	ADV	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	management	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	patients	_	NNS	NNS	_	10	PMOD	_	_
12	experiencing	_	VBG	VBG	_	11	NMOD	_	_
13	severe	_	JJ	JJ	_	14	NMOD	_	_
14	toxicity	_	NN	NN	_	12	OBJ	_	_
15	secondary	_	JJ	JJ	_	14	NMOD	_	_
16	to	_	TO	TO	_	15	AMOD	_	_
17	FUra	_	NN	NN	_	18	NMOD	_	_
18	chemotherapy	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	4	P	_	_

1	Characterization	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	an	_	DT	DT	_	5	NMOD	_	_
4	immediate-early	_	JJ	JJ	_	5	NMOD	_	_
5	gene	_	NN	NN	_	2	PMOD	_	_
6	induced	_	VBN	VBN	_	5	NMOD	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	adherent	_	JJ	JJ	_	9	NMOD	_	_
9	monocytes	_	NNS	NNS	_	7	PMOD	_	_
10	that	_	WDT	WDT	_	11	SBJ	_	_
11	encodes	_	VBZ	VBZ	_	5	NMOD	_	_
12	I	_	NN	NN	_	13	AMOD	_	_
13	kappa	_	NN	NN	_	15	NMOD	_	_
14	B-like	_	JJ	JJ	_	13	AMOD	_	_
15	activity	_	NN	NN	_	11	OBJ	_	_
16	.	_	.	.	_	1	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	cloned	_	VBN	VBN	_	2	VC	_	_
4	a	_	DT	DT	_	5	NMOD	_	_
5	group	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	cDNAs	_	NNS	NNS	_	6	PMOD	_	_
8	representing	_	VBG	VBG	_	7	NMOD	_	_
9	mRNAs	_	NNS	NNS	_	8	OBJ	_	_
10	that	_	WDT	WDT	_	11	SBJ	_	_
11	are	_	VBP	VBP	_	9	NMOD	_	_
12	rapidly	_	RB	RB	_	11	TMP	_	_
13	induced	_	VBN	VBN	_	11	VC	_	_
14	following	_	VBG	VBG	_	13	ADV	_	_
15	adherence	_	NN	NN	_	14	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	human	_	JJ	JJ	_	18	NMOD	_	_
18	monocytes	_	NNS	NNS	_	16	PMOD	_	_
19	.	_	.	.	_	2	P	_	_

1	One	_	CD	CD	_	9	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	induced	_	VBN	VBN	_	5	NMOD	_	_
5	transcripts	_	NNS	NNS	_	2	PMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	MAD-3	_	NN	NN	_	1	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	encodes	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	a	_	DT	DT	_	11	NMOD	_	_
11	protein	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	317	_	CD	CD	_	15	NMOD	_	_
14	amino	_	NN	NN	_	15	NMOD	_	_
15	acids	_	NNS	NNS	_	12	PMOD	_	_
16	with	_	IN	IN	_	11	NMOD	_	_
17	one	_	CD	CD	_	18	NMOD	_	_
18	domain	_	NN	NN	_	16	PMOD	_	_
19	containing	_	VBG	VBG	_	18	NMOD	_	_
20	five	_	CD	CD	_	22	NMOD	_	_
21	tandem	_	JJ	JJ	_	22	NMOD	_	_
22	repeats	_	NNS	NNS	_	19	OBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	26	NMOD	_	_
25	cdc10\/ankyrin	_	JJ	JJ	_	26	NMOD	_	_
26	motif	_	NN	NN	_	23	PMOD	_	_
27	,	_	,	,	_	11	P	_	_
28	which	_	WDT	WDT	_	29	SBJ	_	_
29	is	_	VBZ	VBZ	_	11	NMOD	_	_
30	60	_	CD	CD	_	31	NMOD	_	_
31	%	_	NN	NN	_	32	AMOD	_	_
32	similar	_	JJ	JJ	_	29	PRD	_	_
33	(	_	(	(	_	36	P	_	_
34	46	_	CD	CD	_	35	NMOD	_	_
35	%	_	NN	NN	_	36	AMOD	_	_
36	identical	_	JJ	JJ	_	32	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	to	_	TO	TO	_	32	AMOD	_	_
39	the	_	DT	DT	_	42	NMOD	_	_
40	ankyrin	_	NN	NN	_	42	NMOD	_	_
41	repeat	_	NN	NN	_	42	NMOD	_	_
42	region	_	NN	NN	_	38	PMOD	_	_
43	of	_	IN	IN	_	42	NMOD	_	_
44	the	_	DT	DT	_	45	NMOD	_	_
45	precursor	_	NN	NN	_	43	PMOD	_	_
46	of	_	IN	IN	_	45	NMOD	_	_
47	NF-kappa	_	NN	NN	_	49	NMOD	_	_
48	B\/KBF1	_	NN	NN	_	49	NMOD	_	_
49	p50	_	NN	NN	_	46	PMOD	_	_
50	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	C-terminus	_	NN	NN	_	3	SBJ	_	_
3	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	a	_	DT	DT	_	10	NMOD	_	_
5	putative	_	JJ	JJ	_	10	NMOD	_	_
6	protein	_	NN	NN	_	10	NMOD	_	_
7	kinase	_	NN	NN	_	10	NMOD	_	_
8	C	_	NN	NN	_	10	NMOD	_	_
9	phosphorylation	_	NN	NN	_	10	NMOD	_	_
10	site	_	NN	NN	_	3	OBJ	_	_
11	.	_	.	.	_	3	P	_	_

1	In	_	FW	FW	_	5	NMOD	_	_
2	vitro	_	FW	FW	_	1	AMOD	_	_
3	translated	_	VBN	VBN	_	1	AMOD	_	_
4	MAD-3	_	NN	NN	_	5	NMOD	_	_
5	protein	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	found	_	VBN	VBN	_	6	VC	_	_
8	to	_	TO	TO	_	10	VMOD	_	_
9	specifically	_	RB	RB	_	10	ADV	_	_
10	inhibit	_	VB	VB	_	7	OBJ	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	DNA-binding	_	JJ	JJ	_	13	NMOD	_	_
13	activity	_	NN	NN	_	10	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	19	NMOD	_	_
16	p50\/p65	_	NN	NN	_	19	NMOD	_	_
17	NF-kappa	_	NN	NN	_	19	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	complex	_	NN	NN	_	14	PMOD	_	_
20	but	_	CC	CC	_	13	CC	_	_
21	not	_	RB	RB	_	20	COORD	_	_
22	that	_	DT	DT	_	13	COORD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	the	_	DT	DT	_	27	NMOD	_	_
25	p50\/p50	_	NN	NN	_	27	NMOD	_	_
26	KBF1	_	NN	NN	_	27	NMOD	_	_
27	factor	_	NN	NN	_	23	PMOD	_	_
28	or	_	CC	CC	_	23	CC	_	_
29	of	_	IN	IN	_	23	COORD	_	_
30	other	_	JJ	JJ	_	32	NMOD	_	_
31	DNA-binding	_	JJ	JJ	_	32	NMOD	_	_
32	proteins	_	NNS	NNS	_	29	PMOD	_	_
33	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	MAD-3	_	NN	NN	_	3	NMOD	_	_
3	cDNA	_	NN	NN	_	4	SBJ	_	_
4	encodes	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	an	_	DT	DT	_	9	NMOD	_	_
6	I	_	NN	NN	_	7	AMOD	_	_
7	kappa	_	NN	NN	_	9	NMOD	_	_
8	B-like	_	JJ	JJ	_	7	AMOD	_	_
9	protein	_	NN	NN	_	4	OBJ	_	_
10	that	_	WDT	WDT	_	11	SBJ	_	_
11	is	_	VBZ	VBZ	_	9	NMOD	_	_
12	likely	_	JJ	JJ	_	11	PRD	_	_
13	to	_	TO	TO	_	14	VMOD	_	_
14	be	_	VB	VB	_	12	AMOD	_	_
15	involved	_	VBN	VBN	_	14	VC	_	_
16	in	_	IN	IN	_	15	ADV	_	_
17	regulation	_	NN	NN	_	16	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	transcriptional	_	JJ	JJ	_	20	NMOD	_	_
20	responses	_	NNS	NNS	_	18	PMOD	_	_
21	to	_	TO	TO	_	20	NMOD	_	_
22	NF-kappa	_	NN	NN	_	23	NMOD	_	_
23	B	_	NN	NN	_	21	PMOD	_	_
24	,	_	,	,	_	17	P	_	_
25	including	_	VBG	VBG	_	17	NMOD	_	_
26	adhesion-dependent	_	JJ	JJ	_	27	NMOD	_	_
27	pathways	_	NNS	NNS	_	25	PMOD	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	monocyte	_	NN	NN	_	30	NMOD	_	_
30	activation	_	NN	NN	_	28	PMOD	_	_
31	.	_	.	.	_	4	P	_	_

1	Reactive	_	JJ	JJ	_	3	NMOD	_	_
2	oxygen	_	NN	NN	_	3	NMOD	_	_
3	intermediates	_	NNS	NNS	_	0	ROOT-FRAG	_	_
4	as	_	IN	IN	_	3	NMOD	_	_
5	apparently	_	RB	RB	_	7	AMOD	_	_
6	widely	_	RB	RB	_	7	AMOD	_	_
7	used	_	VBN	VBN	_	4	PMOD	_	_
8	messengers	_	NNS	NNS	_	4	PMOD	_	_
9	in	_	IN	IN	_	3	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	activation	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	NF-kappa	_	NN	NN	_	17	NMOD	_	_
15	B	_	NN	NN	_	17	NMOD	_	_
16	transcription	_	NN	NN	_	17	NMOD	_	_
17	factor	_	NN	NN	_	12	PMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	HIV-1	_	NN	NN	_	17	COORD	_	_
20	.	_	.	.	_	3	P	_	_

1	Hydrogen	_	NN	NN	_	2	NMOD	_	_
2	peroxide	_	NN	NN	_	5	NMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	oxygen	_	NN	NN	_	2	COORD	_	_
5	radicals	_	NNS	NNS	_	6	SBJ	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	agents	_	NNS	NNS	_	6	PRD	_	_
8	commonly	_	RB	RB	_	9	ADV	_	_
9	produced	_	VBN	VBN	_	7	NMOD	_	_
10	during	_	IN	IN	_	9	TMP	_	_
11	inflammatory	_	JJ	JJ	_	12	NMOD	_	_
12	processes	_	NNS	NNS	_	10	PMOD	_	_
13	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	6	P	_	_
5	we	_	PRP	PRP	_	6	SBJ	_	_
6	show	_	VBP	VBP	_	0	ROOT-S	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	micromolar	_	JJ	JJ	_	9	NMOD	_	_
9	concentrations	_	NNS	NNS	_	12	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	H2O2	_	NN	NN	_	10	PMOD	_	_
12	can	_	MD	MD	_	7	VMOD	_	_
13	induce	_	VB	VB	_	12	VC	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	expression	_	NN	NN	_	13	OBJ	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	replication	_	NN	NN	_	15	COORD	_	_
18	of	_	IN	IN	_	15	NMOD	_	_
19	HIV-1	_	NN	NN	_	18	PMOD	_	_
20	in	_	IN	IN	_	15	NMOD	_	_
21	a	_	DT	DT	_	25	NMOD	_	_
22	human	_	JJ	JJ	_	25	NMOD	_	_
23	T	_	NN	NN	_	25	NMOD	_	_
24	cell	_	NN	NN	_	25	NMOD	_	_
25	line	_	NN	NN	_	20	PMOD	_	_
26	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	3	SBJ	_	_
3	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	mediated	_	VBN	VBN	_	3	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	the	_	DT	DT	_	10	NMOD	_	_
7	NF-kappa	_	NN	NN	_	10	NMOD	_	_
8	B	_	NN	NN	_	10	NMOD	_	_
9	transcription	_	NN	NN	_	10	NMOD	_	_
10	factor	_	NN	NN	_	5	PMOD	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	is	_	VBZ	VBZ	_	10	NMOD	_	_
13	potently	_	RB	RB	_	12	ADV	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	rapidly	_	RB	RB	_	13	TMP	_	_
16	activated	_	VBN	VBN	_	12	LGS	_	_
17	by	_	IN	IN	_	16	VMOD	_	_
18	an	_	DT	DT	_	20	NMOD	_	_
19	H2O2	_	NN	NN	_	20	NMOD	_	_
20	treatment	_	NN	NN	_	16	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	cells	_	NNS	NNS	_	21	PMOD	_	_
23	from	_	IN	IN	_	20	NMOD	_	_
24	its	_	PRP$	PRP$	_	27	NMOD	_	_
25	inactive	_	JJ	JJ	_	27	NMOD	_	_
26	cytoplasmic	_	JJ	JJ	_	27	NMOD	_	_
27	form	_	NN	NN	_	23	PMOD	_	_
28	.	_	.	.	_	3	P	_	_

1	N-acetyl-L-cysteine	_	NN	NN	_	25	SBJ	_	_
2	(	_	(	(	_	3	P	_	_
3	NP	_	NN	NN	_	1	PRN	_	_
4	)	_	)	)	_	3	P	_	_
5	,	_	,	,	_	1	P	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	well	_	RB	RB	_	8	AMOD	_	_
8	characterized	_	VBN	VBN	_	9	NMOD	_	_
9	antioxidant	_	NN	NN	_	1	NMOD	_	_
10	which	_	WDT	WDT	_	11	SBJ	_	_
11	counteracts	_	VBZ	VBZ	_	9	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	effects	_	NNS	NNS	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	reactive	_	JJ	JJ	_	17	NMOD	_	_
16	oxygen	_	NN	NN	_	17	NMOD	_	_
17	intermediates	_	NNS	NNS	_	14	PMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	ROI	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	in	_	IN	IN	_	13	NMOD	_	_
22	living	_	VBG	VBG	_	23	NMOD	_	_
23	cells	_	NNS	NNS	_	21	PMOD	_	_
24	,	_	,	,	_	1	P	_	_
25	prevented	_	VBD	VBD	_	0	ROOT-S	_	_
26	the	_	DT	DT	_	27	NMOD	_	_
27	activation	_	NN	NN	_	25	OBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	NF-kappa	_	NN	NN	_	30	NMOD	_	_
30	B	_	NN	NN	_	28	PMOD	_	_
31	by	_	IN	IN	_	27	NMOD	_	_
32	H2O2	_	NN	NN	_	31	PMOD	_	_
33	.	_	.	.	_	25	P	_	_

1	NP	_	NN	NN	_	7	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	other	_	JJ	JJ	_	5	NMOD	_	_
4	thiol	_	JJ	JJ	_	5	NMOD	_	_
5	compounds	_	NNS	NNS	_	1	COORD	_	_
6	also	_	RB	RB	_	7	ADV	_	_
7	blocked	_	VBD	VBD	_	0	ROOT-S	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	activation	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	NF-kappa	_	NN	NN	_	12	NMOD	_	_
12	B	_	NN	NN	_	10	PMOD	_	_
13	by	_	IN	IN	_	9	NMOD	_	_
14	cycloheximide	_	NN	NN	_	13	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	double-stranded	_	JJ	JJ	_	17	NMOD	_	_
17	RNA	_	NN	NN	_	14	COORD	_	_
18	,	_	,	,	_	14	P	_	_
19	calcium	_	NN	NN	_	20	NMOD	_	_
20	ionophore	_	NN	NN	_	14	COORD	_	_
21	,	_	,	,	_	14	P	_	_
22	TNF-alpha	_	NN	NN	_	14	COORD	_	_
23	,	_	,	,	_	14	P	_	_
24	active	_	JJ	JJ	_	26	NMOD	_	_
25	phorbol	_	NN	NN	_	26	NMOD	_	_
26	ester	_	NN	NN	_	14	COORD	_	_
27	,	_	,	,	_	14	P	_	_
28	interleukin-1	_	NN	NN	_	14	COORD	_	_
29	,	_	,	,	_	14	P	_	_
30	lipopolysaccharide	_	NN	NN	_	14	COORD	_	_
31	and	_	CC	CC	_	14	CC	_	_
32	lectin	_	NN	NN	_	14	COORD	_	_
33	.	_	.	.	_	7	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	diverse	_	JJ	JJ	_	5	NMOD	_	_
5	agents	_	NNS	NNS	_	15	SBJ	_	_
6	thought	_	VBN	VBN	_	5	NMOD	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	activate	_	VB	VB	_	6	OBJ	_	_
9	NF-kappa	_	NN	NN	_	10	NMOD	_	_
10	B	_	NN	NN	_	8	OBJ	_	_
11	by	_	IN	IN	_	8	ADV	_	_
12	distinct	_	JJ	JJ	_	14	NMOD	_	_
13	intracellular	_	JJ	JJ	_	14	NMOD	_	_
14	pathways	_	NNS	NNS	_	11	PMOD	_	_
15	might	_	MD	MD	_	3	VMOD	_	_
16	all	_	RB	RB	_	15	ADV	_	_
17	act	_	VB	VB	_	15	VC	_	_
18	through	_	IN	IN	_	17	ADV	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	common	_	JJ	JJ	_	21	NMOD	_	_
21	mechanism	_	NN	NN	_	18	PMOD	_	_
22	involving	_	VBG	VBG	_	21	NMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	synthesis	_	NN	NN	_	22	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	ROI	_	NN	NN	_	25	PMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	ROI	_	NN	NN	_	2	SBJ	_	_
2	appear	_	VBP	VBP	_	0	ROOT-S	_	_
3	to	_	TO	TO	_	4	VMOD	_	_
4	serve	_	VB	VB	_	2	OBJ	_	_
5	as	_	IN	IN	_	4	ADV	_	_
6	messengers	_	NNS	NNS	_	5	PMOD	_	_
7	mediating	_	VBG	VBG	_	6	NMOD	_	_
8	directly	_	RB	RB	_	7	ADV	_	_
9	or	_	CC	CC	_	8	CC	_	_
10	indirectly	_	RB	RB	_	8	COORD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	release	_	NN	NN	_	7	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	the	_	DT	DT	_	19	NMOD	_	_
15	inhibitory	_	JJ	JJ	_	19	NMOD	_	_
16	subunit	_	NN	NN	_	19	NMOD	_	_
17	I	_	NN	NN	_	19	NMOD	_	_
18	kappa	_	NN	NN	_	19	NMOD	_	_
19	B	_	NN	NN	_	13	PMOD	_	_
20	from	_	IN	IN	_	12	NMOD	_	_
21	NF-kappa	_	NN	NN	_	22	NMOD	_	_
22	B	_	NN	NN	_	20	PMOD	_	_
23	.	_	.	.	_	2	P	_	_

1	Contribution	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	NF-kappa	_	NN	NN	_	4	NMOD	_	_
4	B	_	NN	NN	_	8	NMOD	_	_
5	and	_	CC	CC	_	4	CC	_	_
6	Sp1	_	NN	NN	_	4	COORD	_	_
7	binding	_	NN	NN	_	8	NMOD	_	_
8	motifs	_	NNS	NNS	_	2	PMOD	_	_
9	to	_	TO	TO	_	1	NMOD	_	_
10	the	_	DT	DT	_	12	NMOD	_	_
11	replicative	_	JJ	JJ	_	12	NMOD	_	_
12	capacity	_	NN	NN	_	9	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	human	_	JJ	JJ	_	17	NMOD	_	_
15	immunodeficiency	_	NN	NN	_	17	NMOD	_	_
16	virus	_	NN	NN	_	17	NMOD	_	_
17	type	_	NN	NN	_	13	PMOD	_	_
18	1	_	CD	CD	_	17	NMOD	_	_
19	:	_	:	:	_	1	P	_	_
20	distinct	_	JJ	JJ	_	21	NMOD	_	_
21	patterns	_	NNS	NNS	_	25	SBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	viral	_	JJ	JJ	_	24	NMOD	_	_
24	growth	_	NN	NN	_	22	PMOD	_	_
25	are	_	VBP	VBP	_	1	NMOD	_	_
26	determined	_	VBN	VBN	_	25	VC	_	_
27	by	_	IN	IN	_	26	LGS	_	_
28	T-cell	_	NN	NN	_	29	NMOD	_	_
29	types	_	NNS	NNS	_	27	PMOD	_	_
30	.	_	.	.	_	25	P	_	_

1	Starting	_	VBG	VBG	_	48	ADV	_	_
2	with	_	IN	IN	_	1	ADV	_	_
3	a	_	DT	DT	_	6	NMOD	_	_
4	replication-incompetent	_	JJ	JJ	_	6	NMOD	_	_
5	molecular	_	JJ	JJ	_	6	NMOD	_	_
6	clone	_	NN	NN	_	2	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	human	_	JJ	JJ	_	11	NMOD	_	_
9	immunodeficiency	_	NN	NN	_	11	NMOD	_	_
10	virus	_	NN	NN	_	11	NMOD	_	_
11	type	_	NN	NN	_	7	PMOD	_	_
12	1	_	CD	CD	_	11	NMOD	_	_
13	,	_	,	,	_	6	P	_	_
14	lacking	_	VBG	VBG	_	6	NMOD	_	_
15	all	_	PDT	PDT	_	22	NMOD	_	_
16	the	_	DT	DT	_	22	NMOD	_	_
17	NF-kappa	_	NN	NN	_	18	NMOD	_	_
18	B	_	NN	NN	_	22	NMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	Sp1	_	NN	NN	_	18	COORD	_	_
21	binding	_	NN	NN	_	22	NMOD	_	_
22	sites	_	NNS	NNS	_	14	OBJ	_	_
23	present	_	JJ	JJ	_	22	NMOD	_	_
24	in	_	IN	IN	_	23	AMOD	_	_
25	the	_	DT	DT	_	29	NMOD	_	_
26	native	_	JJ	JJ	_	29	NMOD	_	_
27	long	_	JJ	JJ	_	29	NMOD	_	_
28	terminal	_	JJ	JJ	_	29	NMOD	_	_
29	repeat	_	NN	NN	_	24	PMOD	_	_
30	(	_	(	(	_	31	P	_	_
31	LTR	_	NN	NN	_	29	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	,	_	,	,	_	48	P	_	_
34	proviruses	_	NNS	NNS	_	48	SBJ	_	_
35	containing	_	VBG	VBG	_	34	NMOD	_	_
36	reconstructed	_	VBN	VBN	_	37	NMOD	_	_
37	LTRs	_	NNS	NNS	_	35	OBJ	_	_
38	with	_	IN	IN	_	37	NMOD	_	_
39	individual	_	JJ	JJ	_	47	NMOD	_	_
40	or	_	CC	CC	_	47	CC	_	_
41	combinations	_	NNS	NNS	_	47	COORD	_	_
42	of	_	IN	IN	_	41	NMOD	_	_
43	NF-kappa	_	NN	NN	_	44	NMOD	_	_
44	B	_	NN	NN	_	47	NMOD	_	_
45	and	_	CC	CC	_	44	CC	_	_
46	Sp1	_	NN	NN	_	44	COORD	_	_
47	elements	_	NNS	NNS	_	38	PMOD	_	_
48	were	_	VBD	VBD	_	0	ROOT-S	_	_
49	generated	_	VBN	VBN	_	48	VC	_	_
50	and	_	CC	CC	_	49	CC	_	_
51	evaluated	_	VBN	VBN	_	49	COORD	_	_
52	for	_	IN	IN	_	51	ADV	_	_
53	their	_	PRP$	PRP$	_	54	NMOD	_	_
54	capacity	_	NN	NN	_	52	PMOD	_	_
55	to	_	TO	TO	_	56	VMOD	_	_
56	produce	_	VB	VB	_	54	NMOD	_	_
57	virus	_	NN	NN	_	58	NMOD	_	_
58	progeny	_	NN	NN	_	56	OBJ	_	_
59	following	_	VBG	VBG	_	56	TMP	_	_
60	transfection-cocultivation	_	NN	NN	_	59	PMOD	_	_
61	.	_	.	.	_	48	P	_	_

1	Virus	_	NN	NN	_	2	NMOD	_	_
2	stocks	_	NNS	NNS	_	7	SBJ	_	_
3	obtained	_	VBN	VBN	_	2	NMOD	_	_
4	from	_	IN	IN	_	3	ADV	_	_
5	these	_	DT	DT	_	6	NMOD	_	_
6	experiments	_	NNS	NNS	_	4	PMOD	_	_
7	exhibited	_	VBD	VBD	_	0	ROOT-S	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	continuum	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	replicative	_	JJ	JJ	_	12	NMOD	_	_
12	capacities	_	NNS	NNS	_	10	PMOD	_	_
13	in	_	IN	IN	_	9	NMOD	_	_
14	different	_	JJ	JJ	_	17	NMOD	_	_
15	human	_	JJ	JJ	_	17	NMOD	_	_
16	T-cell	_	NN	NN	_	17	NMOD	_	_
17	types	_	NNS	NNS	_	13	PMOD	_	_
18	depending	_	VBG	VBG	_	7	ADV	_	_
19	on	_	IN	IN	_	18	PMOD	_	_
20	which	_	WDT	WDT	_	23	NMOD	_	_
21	element	_	NN	NN	_	23	NMOD	_	_
22	(	_	(	(	_	23	P	_	_
23	s	_	NNS	NNS	_	25	SBJ	_	_
24	)	_	)	)	_	23	P	_	_
25	was	_	VBD	VBD	_	19	PMOD	_	_
26	present	_	JJ	JJ	_	25	PRD	_	_
27	in	_	IN	IN	_	26	AMOD	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	LTR	_	NN	NN	_	27	PMOD	_	_
30	.	_	.	.	_	7	P	_	_

1	For	_	IN	IN	_	50	ADV	_	_
2	example	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	50	P	_	_
4	in	_	IN	IN	_	50	ADV	_	_
5	experiments	_	NNS	NNS	_	4	PMOD	_	_
6	involving	_	VBG	VBG	_	5	NMOD	_	_
7	proviral	_	JJ	JJ	_	8	NMOD	_	_
8	clones	_	NNS	NNS	_	6	OBJ	_	_
9	with	_	IN	IN	_	8	NMOD	_	_
10	LTRs	_	NNS	NNS	_	9	PMOD	_	_
11	containing	_	VBG	VBG	_	10	NMOD	_	_
12	one	_	CD	CD	_	17	NMOD	_	_
13	or	_	CC	CC	_	12	CC	_	_
14	two	_	CD	CD	_	12	COORD	_	_
15	NF-kappa	_	NN	NN	_	17	NMOD	_	_
16	B	_	NN	NN	_	17	NMOD	_	_
17	elements	_	NNS	NNS	_	11	OBJ	_	_
18	(	_	(	(	_	17	P	_	_
19	and	_	CC	CC	_	17	CC	_	_
20	no	_	DT	DT	_	23	NMOD	_	_
21	Sp1	_	NN	NN	_	23	NMOD	_	_
22	binding	_	NN	NN	_	23	NMOD	_	_
23	sites	_	NNS	NNS	_	17	COORD	_	_
24	)	_	)	)	_	17	P	_	_
25	,	_	,	,	_	50	P	_	_
26	a	_	DT	DT	_	27	NMOD	_	_
27	hierarchy	_	NN	NN	_	50	SBJ	_	_
28	of	_	IN	IN	_	27	NMOD	_	_
29	cellular	_	JJ	JJ	_	30	NMOD	_	_
30	permissivity	_	NN	NN	_	28	PMOD	_	_
31	to	_	TO	TO	_	30	NMOD	_	_
32	virus	_	NN	NN	_	33	NMOD	_	_
33	replication	_	NN	NN	_	31	PMOD	_	_
34	(	_	(	(	_	39	P	_	_
35	peripheral	_	JJ	JJ	_	37	NMOD	_	_
36	blood	_	NN	NN	_	37	NMOD	_	_
37	lymphocytes	_	NNS	NNS	_	39	SBJ	_	_
38	=	_	JJ	JJ	_	39	VMOD	_	_
39	MT4	_	NN	NN	_	27	PRN	_	_
40	greater	_	JJR	JJR	_	39	NMOD	_	_
41	than	_	IN	IN	_	40	AMOD	_	_
42	H9	_	NN	NN	_	41	PMOD	_	_
43	greater	_	JJR	JJR	_	42	NMOD	_	_
44	than	_	IN	IN	_	43	AMOD	_	_
45	CEM	_	NN	NN	_	44	PMOD	_	_
46	greater	_	JJR	JJR	_	45	NMOD	_	_
47	than	_	IN	IN	_	46	AMOD	_	_
48	Jurkat	_	NN	NN	_	47	PMOD	_	_
49	)	_	)	)	_	39	P	_	_
50	was	_	VBD	VBD	_	0	ROOT-S	_	_
51	observed	_	VBN	VBN	_	50	VC	_	_
52	.	_	.	.	_	50	P	_	_

1	Of	_	IN	IN	_	3	PRD	_	_
2	note	_	NN	NN	_	1	PMOD	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	associated	_	VBN	VBN	_	6	NMOD	_	_
6	emergence	_	NN	NN	_	3	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	second-site	_	JJ	JJ	_	10	NMOD	_	_
9	LTR	_	NN	NN	_	10	NMOD	_	_
10	revertants	_	NNS	NNS	_	7	PMOD	_	_
11	which	_	WDT	WDT	_	12	SBJ	_	_
12	involved	_	VBD	VBD	_	6	NMOD	_	_
13	an	_	DT	DT	_	14	NMOD	_	_
14	alteration	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	TATA	_	NN	NN	_	18	NMOD	_	_
18	box	_	NN	NN	_	15	PMOD	_	_
19	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	11	NMOD	_	_
6	human	_	JJ	JJ	_	11	NMOD	_	_
7	immunodeficiency	_	NN	NN	_	11	NMOD	_	_
8	virus	_	NN	NN	_	11	NMOD	_	_
9	type	_	NN	NN	_	11	NMOD	_	_
10	1	_	CD	CD	_	11	NMOD	_	_
11	LTR	_	NN	NN	_	12	SBJ	_	_
12	possesses	_	VBZ	VBZ	_	4	VMOD	_	_
13	functional	_	JJ	JJ	_	14	NMOD	_	_
14	redundancy	_	NN	NN	_	12	OBJ	_	_
15	which	_	WDT	WDT	_	16	SBJ	_	_
16	ensures	_	VBZ	VBZ	_	14	NMOD	_	_
17	virus	_	NN	NN	_	18	NMOD	_	_
18	replication	_	NN	NN	_	16	OBJ	_	_
19	in	_	IN	IN	_	18	NMOD	_	_
20	different	_	JJ	JJ	_	22	NMOD	_	_
21	T-cell	_	NN	NN	_	22	NMOD	_	_
22	types	_	NNS	NNS	_	19	PMOD	_	_
23	and	_	CC	CC	_	12	CC	_	_
24	is	_	VBZ	VBZ	_	12	COORD	_	_
25	capable	_	JJ	JJ	_	24	PRD	_	_
26	of	_	IN	IN	_	25	AMOD	_	_
27	changing	_	VBG	VBG	_	26	PMOD	_	_
28	depending	_	VBG	VBG	_	25	AMOD	_	_
29	on	_	IN	IN	_	28	PMOD	_	_
30	the	_	DT	DT	_	32	NMOD	_	_
31	particular	_	JJ	JJ	_	32	NMOD	_	_
32	combination	_	NN	NN	_	29	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	transcriptional	_	JJ	JJ	_	35	NMOD	_	_
35	factors	_	NNS	NNS	_	33	PMOD	_	_
36	present	_	JJ	JJ	_	35	NMOD	_	_
37	.	_	.	.	_	3	P	_	_

1	Enhancement	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	human	_	JJ	JJ	_	7	NMOD	_	_
4	immunodeficiency	_	NN	NN	_	7	NMOD	_	_
5	virus	_	NN	NN	_	7	NMOD	_	_
6	1	_	CD	CD	_	7	NMOD	_	_
7	replication	_	NN	NN	_	2	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	monocytes	_	NNS	NNS	_	8	PMOD	_	_
10	by	_	IN	IN	_	1	NMOD	_	_
11	1,25-dihydroxycholecalciferol	_	NN	NN	_	10	PMOD	_	_
12	.	_	.	.	_	1	P	_	_

1	Human	_	JJ	JJ	_	3	NMOD	_	_
2	immunodeficiency	_	NN	NN	_	3	NMOD	_	_
3	virus	_	NN	NN	_	10	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	HIV	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	expression	_	NN	NN	_	3	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	replication	_	NN	NN	_	7	COORD	_	_
10	are	_	VBP	VBP	_	0	ROOT-S	_	_
11	under	_	IN	IN	_	10	PRD	_	_
12	tight	_	JJ	JJ	_	14	NMOD	_	_
13	regulatory	_	JJ	JJ	_	14	NMOD	_	_
14	control	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	10	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	1,25-dihydroxycholecalciferol	_	NN	NN	_	8	SBJ	_	_
5	{	_	(	(	_	6	P	_	_
6	1,25--LRB-OH-RRB-2D3	_	NN	NN	_	4	PRN	_	_
7	}	_	)	)	_	6	P	_	_
8	enhances	_	VBZ	VBZ	_	3	VMOD	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	replication	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	monocyte-	_	NN	NN	_	15	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	lymphocyte-tropic	_	JJ	JJ	_	12	COORD	_	_
15	strains	_	NNS	NNS	_	11	PMOD	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	HIV-1	_	NN	NN	_	16	PMOD	_	_
18	up	_	IN	IN	_	8	ADV	_	_
19	to	_	TO	TO	_	18	DEP	_	_
20	10,000-fold	_	RB	RB	_	18	PMOD	_	_
21	in	_	IN	IN	_	8	ADV	_	_
22	monocyte	_	NN	NN	_	24	NMOD	_	_
23	cell	_	NN	NN	_	24	NMOD	_	_
24	lines	_	NNS	NNS	_	21	PMOD	_	_
25	,	_	,	,	_	24	P	_	_
26	peripheral	_	JJ	JJ	_	28	NMOD	_	_
27	blood	_	NN	NN	_	28	NMOD	_	_
28	monocytes	_	NNS	NNS	_	24	COORD	_	_
29	,	_	,	,	_	24	P	_	_
30	and	_	CC	CC	_	24	CC	_	_
31	unfractionated	_	JJ	JJ	_	35	NMOD	_	_
32	peripheral	_	JJ	JJ	_	35	NMOD	_	_
33	blood	_	NN	NN	_	35	NMOD	_	_
34	mononuclear	_	JJ	JJ	_	35	NMOD	_	_
35	cells	_	NNS	NNS	_	24	COORD	_	_
36	.	_	.	.	_	2	P	_	_

1	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	2	SBJ	_	_
2	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	therefore	_	RB	RB	_	2	ADV	_	_
4	one	_	CD	CD	_	2	PRD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	most	_	RBS	RBS	_	8	AMOD	_	_
8	potent	_	JJ	JJ	_	9	NMOD	_	_
9	regulators	_	NNS	NNS	_	5	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	HIV-1	_	NN	NN	_	12	NMOD	_	_
12	replication	_	NN	NN	_	10	PMOD	_	_
13	described	_	VBN	VBN	_	9	NMOD	_	_
14	to	_	TO	TO	_	13	TMP	_	_
15	date	_	NN	NN	_	14	PMOD	_	_
16	.	_	.	.	_	2	P	_	_

1	Precursors	_	NNS	NNS	_	4	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	2	PMOD	_	_
4	enhance	_	VBP	VBP	_	0	ROOT-S	_	_
5	HIV-1	_	NN	NN	_	6	NMOD	_	_
6	replication	_	NN	NN	_	4	IOBJ	_	_
7	in	_	IN	IN	_	4	ADV	_	_
8	proportion	_	NN	NN	_	7	DEP	_	_
9	to	_	TO	TO	_	7	DEP	_	_
10	their	_	PRP$	PRP$	_	11	NMOD	_	_
11	affinity	_	NN	NN	_	7	PMOD	_	_
12	for	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	16	NMOD	_	_
15	intracellular	_	JJ	JJ	_	16	NMOD	_	_
16	receptor	_	NN	NN	_	12	PMOD	_	_
17	,	_	,	,	_	4	P	_	_
18	suggesting	_	VBG	VBG	_	4	OBJ	_	_
19	that	_	IN	IN	_	18	OBJ	_	_
20	1,25-LRB-OH-RRB-2D3	_	NN	NN	_	21	SBJ	_	_
21	influences	_	VBZ	VBZ	_	19	VMOD	_	_
22	HIV-1	_	NN	NN	_	23	NMOD	_	_
23	replication	_	NN	NN	_	21	OBJ	_	_
24	by	_	IN	IN	_	21	ADV	_	_
25	mechanisms	_	NNS	NNS	_	24	PMOD	_	_
26	involving	_	VBG	VBG	_	25	NMOD	_	_
27	this	_	DT	DT	_	28	NMOD	_	_
28	receptor	_	NN	NN	_	26	OBJ	_	_
29	.	_	.	.	_	4	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	may	_	MD	MD	_	0	ROOT-S	_	_
4	have	_	VB	VB	_	3	VC	_	_
5	important	_	JJ	JJ	_	6	NMOD	_	_
6	implications	_	NNS	NNS	_	4	OBJ	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	design	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	effective	_	JJ	JJ	_	12	NMOD	_	_
12	therapy	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	HIV-1	_	NN	NN	_	15	NMOD	_	_
15	infection	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	3	P	_	_

1	Glucocorticoid	_	NN	NN	_	2	NMOD	_	_
2	receptors	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	systemic	_	JJ	JJ	_	6	NMOD	_	_
5	lupus	_	NN	NN	_	6	NMOD	_	_
6	erythematosus	_	NN	NN	_	3	PMOD	_	_
7	.	_	.	.	_	2	P	_	_

1	Glucocorticosteroids	_	NNS	NNS	_	2	SBJ	_	_
2	remain	_	VBP	VBP	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	6	NMOD	_	_
4	major	_	JJ	JJ	_	6	NMOD	_	_
5	treatment	_	NN	NN	_	6	NMOD	_	_
6	modality	_	NN	NN	_	2	PRD	_	_
7	for	_	IN	IN	_	6	NMOD	_	_
8	systemic	_	JJ	JJ	_	10	NMOD	_	_
9	lupus	_	NN	NN	_	10	NMOD	_	_
10	erythematosus	_	NN	NN	_	7	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	SLE	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	,	_	,	,	_	2	P	_	_
15	but	_	CC	CC	_	2	CC	_	_
16	their	_	PRP$	PRP$	_	17	NMOD	_	_
17	mechanism	_	NN	NN	_	20	SBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	action	_	NN	NN	_	18	PMOD	_	_
20	is	_	VBZ	VBZ	_	2	COORD	_	_
21	unclear	_	JJ	JJ	_	20	PRD	_	_
22	.	_	.	.	_	2	P	_	_

1	Over	_	IN	IN	_	6	TMP	_	_
2	the	_	DT	DT	_	4	NMOD	_	_
3	past	_	JJ	JJ	_	4	NMOD	_	_
4	decade	_	NN	NN	_	1	PMOD	_	_
5	it	_	PRP	PRP	_	6	SBJ	_	_
6	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	become	_	VBN	VBN	_	6	VC	_	_
8	clear	_	JJ	JJ	_	7	PRD	_	_
9	that	_	IN	IN	_	7	EXP	_	_
10	glucocorticosteroid	_	NN	NN	_	11	NMOD	_	_
11	receptors	_	NNS	NNS	_	12	SBJ	_	_
12	play	_	VBP	VBP	_	9	VMOD	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	significant	_	JJ	JJ	_	15	NMOD	_	_
15	role	_	NN	NN	_	12	OBJ	_	_
16	in	_	IN	IN	_	12	ADV	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	mechanism	_	NN	NN	_	16	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	glucocorticosteroid	_	NN	NN	_	21	NMOD	_	_
21	action	_	NN	NN	_	19	PMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	studied	_	VBD	VBD	_	0	ROOT-S	_	_
3	glucocorticosteroid	_	NN	NN	_	4	NMOD	_	_
4	receptor	_	NN	NN	_	2	OBJ	_	_
5	density	_	NN	NN	_	4	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	affinity	_	NN	NN	_	5	COORD	_	_
8	on	_	IN	IN	_	4	NMOD	_	_
9	peripheral	_	JJ	JJ	_	12	NMOD	_	_
10	blood	_	NN	NN	_	12	NMOD	_	_
11	mononuclear	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	8	PMOD	_	_
13	by	_	IN	IN	_	2	ADV	_	_
14	the	_	DT	DT	_	17	NMOD	_	_
15	glucocorticosteroid	_	NN	NN	_	17	NMOD	_	_
16	binding	_	NN	NN	_	17	NMOD	_	_
17	assay	_	NN	NN	_	13	PMOD	_	_
18	in	_	IN	IN	_	2	ADV	_	_
19	33	_	CD	CD	_	20	NMOD	_	_
20	patients	_	NNS	NNS	_	18	PMOD	_	_
21	with	_	IN	IN	_	20	NMOD	_	_
22	SLE	_	NN	NN	_	21	PMOD	_	_
23	who	_	WP	WP	_	24	SBJ	_	_
24	had	_	VBD	VBD	_	20	NMOD	_	_
25	taken	_	VBN	VBN	_	24	VC	_	_
26	no	_	DT	DT	_	27	NMOD	_	_
27	glucocorticosteroid	_	NN	NN	_	25	OBJ	_	_
28	for	_	IN	IN	_	25	TMP	_	_
29	the	_	DT	DT	_	32	NMOD	_	_
30	previous	_	JJ	JJ	_	32	NMOD	_	_
31	6	_	CD	CD	_	32	NMOD	_	_
32	months	_	NNS	NNS	_	28	PMOD	_	_
33	and	_	CC	CC	_	18	CC	_	_
34	in	_	IN	IN	_	18	COORD	_	_
35	32	_	CD	CD	_	37	NMOD	_	_
36	healthy	_	JJ	JJ	_	37	NMOD	_	_
37	controls	_	NNS	NNS	_	34	PMOD	_	_
38	.	_	.	.	_	2	P	_	_

1	Patients	_	NNS	NNS	_	4	NMOD	_	_
2	'	_	POS	POS	_	1	NMOD	_	_
3	disease	_	NN	NN	_	4	NMOD	_	_
4	activity	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	0	ROOT-S	_	_
6	measured	_	VBN	VBN	_	5	VC	_	_
7	by	_	IN	IN	_	6	LGS	_	_
8	the	_	DT	DT	_	12	NMOD	_	_
9	SLE	_	NN	NN	_	12	NMOD	_	_
10	Disease	_	NN	NN	_	12	NMOD	_	_
11	Activity	_	NN	NN	_	12	NMOD	_	_
12	Index	_	NN	NN	_	7	PMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	SLEDAI	_	NN	NN	_	12	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	.	_	.	.	_	5	P	_	_

1	Glucocorticosteroid	_	NN	NN	_	2	NMOD	_	_
2	receptors	_	NNS	NNS	_	9	SBJ	_	_
3	on	_	IN	IN	_	2	NMOD	_	_
4	leukocytes	_	NNS	NNS	_	3	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	patients	_	NNS	NNS	_	5	PMOD	_	_
7	with	_	IN	IN	_	6	NMOD	_	_
8	SLE	_	NN	NN	_	7	DEP	_	_
9	were	_	VBD	VBD	_	0	ROOT-S	_	_
10	significantly	_	RB	RB	_	11	AMOD	_	_
11	higher	_	JJR	JJR	_	9	PRD	_	_
12	than	_	IN	IN	_	11	AMOD	_	_
13	in	_	IN	IN	_	12	PMOD	_	_
14	healthy	_	JJ	JJ	_	15	NMOD	_	_
15	controls	_	NNS	NNS	_	13	PMOD	_	_
16	(	_	(	(	_	26	P	_	_
17	4419	_	CD	CD	_	26	DEP	_	_
18	+\/-	_	CC	CC	_	17	CC	_	_
19	306	_	CD	CD	_	17	COORD	_	_
20	vs	_	CC	CC	_	17	CC	_	_
21	3369	_	CD	CD	_	17	COORD	_	_
22	+\/-	_	CC	CC	_	21	CC	_	_
23	196	_	CD	CD	_	21	COORD	_	_
24	,	_	,	,	_	26	P	_	_
25	p	_	NN	NN	_	26	SBJ	_	_
26	less	_	JJR	JJR	_	11	PRN	_	_
27	than	_	IN	IN	_	26	AMOD	_	_
28	0.005	_	CD	CD	_	27	PMOD	_	_
29	)	_	)	)	_	26	P	_	_
30	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	binding	_	NN	NN	_	3	NMOD	_	_
3	affinity	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	different	_	JJ	JJ	_	4	PRD	_	_
7	between	_	IN	IN	_	4	ADV	_	_
8	patients	_	NNS	NNS	_	7	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	controls	_	NNS	NNS	_	8	COORD	_	_
11	.	_	.	.	_	4	P	_	_

1	There	_	EX	EX	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	no	_	DT	DT	_	4	NMOD	_	_
4	correlation	_	NN	NN	_	2	PRD	_	_
5	between	_	IN	IN	_	2	ADV	_	_
6	glucocorticosteroid	_	NN	NN	_	8	NMOD	_	_
7	receptor	_	NN	NN	_	8	NMOD	_	_
8	number	_	NN	NN	_	5	PMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	SLE	_	NN	NN	_	12	NMOD	_	_
11	disease	_	NN	NN	_	12	NMOD	_	_
12	activity	_	NN	NN	_	8	COORD	_	_
13	.	_	.	.	_	2	P	_	_

1	{	_	(	(	_	2	P	_	_
2	Changes	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	leucocytic	_	JJ	JJ	_	7	NMOD	_	_
5	estrogen	_	NN	NN	_	7	NMOD	_	_
6	receptor	_	NN	NN	_	7	NMOD	_	_
7	levels	_	NNS	NNS	_	3	PMOD	_	_
8	in	_	IN	IN	_	7	NMOD	_	_
9	patients	_	NNS	NNS	_	8	PMOD	_	_
10	with	_	IN	IN	_	9	NMOD	_	_
11	gynecomastia	_	NN	NN	_	10	PMOD	_	_
12	}	_	)	)	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	number	_	NN	NN	_	18	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	estrogen	_	NN	NN	_	5	NMOD	_	_
5	receptor	_	NN	NN	_	3	PMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	ER	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	in	_	IN	IN	_	5	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	peripheral	_	JJ	JJ	_	12	NMOD	_	_
12	leucocytes	_	NNS	NNS	_	9	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	13	_	CD	CD	_	15	NMOD	_	_
15	men	_	NNS	NNS	_	13	PMOD	_	_
16	with	_	IN	IN	_	15	NMOD	_	_
17	gynecomastia	_	NNS	NNS	_	16	PMOD	_	_
18	were	_	VBD	VBD	_	0	ROOT-S	_	_
19	measured	_	VBN	VBN	_	18	VC	_	_
20	by	_	IN	IN	_	19	LGS	_	_
21	radioligand	_	NN	NN	_	23	NMOD	_	_
22	binding	_	NN	NN	_	23	NMOD	_	_
23	method	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	18	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	compared	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	those	_	DT	DT	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	13	_	CD	CD	_	13	NMOD	_	_
9	sex-	_	NN	NN	_	13	NMOD	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	age-matched	_	JJ	JJ	_	9	COORD	_	_
12	healthy	_	JJ	JJ	_	13	NMOD	_	_
13	subjects	_	NNS	NNS	_	7	PMOD	_	_
14	.	_	.	.	_	3	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	number	_	NN	NN	_	11	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	ER	_	NN	NN	_	7	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	leucocytes	_	NNS	NNS	_	9	PMOD	_	_
11	was	_	VBD	VBD	_	4	VMOD	_	_
12	significantly	_	RB	RB	_	11	ADV	_	_
13	increased	_	VBN	VBN	_	11	VC	_	_
14	in	_	IN	IN	_	13	ADV	_	_
15	gynecomastia	_	NN	NN	_	14	PMOD	_	_
16	(	_	(	(	_	20	P	_	_
17	Rs	_	NN	NN	_	20	SBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	leucocytes	_	NNS	NNS	_	18	PMOD	_	_
20	were	_	VBD	VBD	_	13	PRN	_	_
21	1054	_	CD	CD	_	24	NMOD	_	_
22	+\/-	_	CC	CC	_	21	CC	_	_
23	254	_	CD	CD	_	21	COORD	_	_
24	sites\/cell	_	NN	NN	_	20	PRD	_	_
25	)	_	)	)	_	20	P	_	_
26	.	_	.	.	_	2	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	suggested	_	VBD	VBD	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	increase	_	NN	NN	_	8	SBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	ER	_	NN	NN	_	7	NMOD	_	_
7	levels	_	NNS	NNS	_	5	PMOD	_	_
8	play	_	VBP	VBP	_	3	VMOD	_	_
9	an	_	DT	DT	_	11	NMOD	_	_
10	important	_	JJ	JJ	_	11	NMOD	_	_
11	role	_	NN	NN	_	8	OBJ	_	_
12	in	_	IN	IN	_	8	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	pathogenesis	_	NN	NN	_	12	PMOD	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	gynecomastia	_	NN	NN	_	15	PMOD	_	_
17	.	_	.	.	_	2	P	_	_

1	{	_	(	(	_	2	P	_	_
2	Changes	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	levels	_	NNS	NNS	_	3	PMOD	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	leucocytic	_	JJ	JJ	_	8	NMOD	_	_
7	estrogen	_	NN	NN	_	8	NMOD	_	_
8	receptor	_	NN	NN	_	5	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	patients	_	NNS	NNS	_	9	PMOD	_	_
11	with	_	IN	IN	_	10	NMOD	_	_
12	menopausal	_	JJ	JJ	_	15	NMOD	_	_
13	type	_	NN	NN	_	15	NMOD	_	_
14	II	_	CD	CD	_	15	NMOD	_	_
15	diabetes	_	NNS	NNS	_	11	PMOD	_	_
16	and	_	CC	CC	_	2	CC	_	_
17	its	_	PRP$	PRP$	_	18	NMOD	_	_
18	significance	_	NN	NN	_	2	COORD	_	_
19	}	_	)	)	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	number	_	NN	NN	_	21	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	estrogen	_	NN	NN	_	5	NMOD	_	_
5	receptors	_	NNS	NNS	_	3	PMOD	_	_
6	(	_	(	(	_	7	P	_	_
7	ER	_	NN	NN	_	5	PRN	_	_
8	)	_	)	)	_	7	P	_	_
9	in	_	IN	IN	_	5	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	peripheral	_	JJ	JJ	_	12	NMOD	_	_
12	leucocytes	_	NNS	NNS	_	9	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	12	_	CD	CD	_	15	NMOD	_	_
15	women	_	NNS	NNS	_	13	PMOD	_	_
16	with	_	IN	IN	_	15	NMOD	_	_
17	menopausal	_	JJ	JJ	_	20	NMOD	_	_
18	type	_	NN	NN	_	20	NMOD	_	_
19	II	_	CD	CD	_	20	NMOD	_	_
20	diabetes	_	NNS	NNS	_	16	PMOD	_	_
21	was	_	VBD	VBD	_	0	ROOT-S	_	_
22	measured	_	VBN	VBN	_	21	VC	_	_
23	with	_	IN	IN	_	22	ADV	_	_
24	radio-ligand	_	JJ	JJ	_	26	NMOD	_	_
25	binding	_	NN	NN	_	26	NMOD	_	_
26	method	_	NN	NN	_	23	PMOD	_	_
27	.	_	.	.	_	21	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	compared	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	those	_	DT	DT	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	12	_	CD	CD	_	10	NMOD	_	_
9	menopausal	_	JJ	JJ	_	10	NMOD	_	_
10	women	_	NNS	NNS	_	7	PMOD	_	_
11	without	_	IN	IN	_	10	NMOD	_	_
12	diabetes	_	NNS	NNS	_	11	PMOD	_	_
13	and	_	CC	CC	_	10	CC	_	_
14	12	_	CD	CD	_	16	NMOD	_	_
15	normal	_	JJ	JJ	_	16	NMOD	_	_
16	women	_	NNS	NNS	_	10	COORD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	childbearing	_	JJ	JJ	_	19	NMOD	_	_
19	age	_	NN	NN	_	17	PMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	It	_	PRP	PRP	_	2	SBJ	_	_
2	was	_	VBD	VBD	_	0	ROOT-S	_	_
3	found	_	VBN	VBN	_	2	VC	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	number	_	NN	NN	_	12	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	ER	_	NN	NN	_	7	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	patients	_	NNS	NNS	_	9	PMOD	_	_
12	was	_	VBD	VBD	_	4	VMOD	_	_
13	significantly	_	RB	RB	_	12	ADV	_	_
14	decreased	_	VBN	VBN	_	12	VC	_	_
15	.	_	.	.	_	2	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	indicate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	decrease	_	NN	NN	_	11	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	ER	_	NN	NN	_	8	NMOD	_	_
8	level	_	NN	NN	_	6	PMOD	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	leukocytes	_	NNS	NNS	_	9	PMOD	_	_
11	may	_	MD	MD	_	4	VMOD	_	_
12	be	_	VB	VB	_	11	VC	_	_
13	related	_	JJ	JJ	_	12	PRD	_	_
14	to	_	TO	TO	_	13	AMOD	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	pathogenesis	_	NN	NN	_	14	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	type	_	NN	NN	_	20	NMOD	_	_
19	II	_	CD	CD	_	20	NMOD	_	_
20	diabetes	_	NNS	NNS	_	17	PMOD	_	_
21	in	_	IN	IN	_	16	NMOD	_	_
22	menopausal	_	JJ	JJ	_	23	NMOD	_	_
23	period	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	Nuclear	_	JJ	JJ	_	2	NMOD	_	_
2	association	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	T-cell	_	NN	NN	_	7	NMOD	_	_
6	transcription	_	NN	NN	_	7	NMOD	_	_
7	factor	_	NN	NN	_	3	PMOD	_	_
8	blocked	_	VBN	VBN	_	2	NMOD	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	FK-506	_	NN	NN	_	9	PMOD	_	_
11	and	_	CC	CC	_	10	CC	_	_
12	cyclosporin	_	NN	NN	_	13	NMOD	_	_
13	A	_	NN	NN	_	10	COORD	_	_
14	{	_	(	(	_	15	P	_	_
15	see	_	VB	VB	_	2	PRN	_	_
16	comments	_	NNS	NNS	_	15	OBJ	_	_
17	}	_	)	)	_	15	P	_	_

1	Cyclosporin	_	NN	NN	_	2	NMOD	_	_
2	A	_	NN	NN	_	5	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	FK506	_	NN	NN	_	2	COORD	_	_
5	inhibit	_	VBP	VBP	_	0	ROOT-S	_	_
6	T-	_	NN	NN	_	9	NMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	B-cell	_	NN	NN	_	6	COORD	_	_
9	activation	_	NN	NN	_	5	OBJ	_	_
10	and	_	CC	CC	_	9	CC	_	_
11	other	_	JJ	JJ	_	12	NMOD	_	_
12	processes	_	NNS	NNS	_	9	COORD	_	_
13	essential	_	JJ	JJ	_	9	NMOD	_	_
14	to	_	TO	TO	_	13	AMOD	_	_
15	an	_	DT	DT	_	18	NMOD	_	_
16	effective	_	JJ	JJ	_	18	NMOD	_	_
17	immune	_	JJ	JJ	_	18	NMOD	_	_
18	response	_	NN	NN	_	14	PMOD	_	_
19	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	6	ADV	_	_
2	T	_	NN	NN	_	3	NMOD	_	_
3	lymphocytes	_	NNS	NNS	_	1	PMOD	_	_
4	these	_	DT	DT	_	5	NMOD	_	_
5	drugs	_	NNS	NNS	_	6	SBJ	_	_
6	disrupt	_	VBP	VBP	_	0	ROOT-S	_	_
7	an	_	DT	DT	_	9	NMOD	_	_
8	unknown	_	JJ	JJ	_	9	NMOD	_	_
9	step	_	NN	NN	_	6	OBJ	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	transmission	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	signals	_	NNS	NNS	_	13	PMOD	_	_
15	from	_	IN	IN	_	12	NMOD	_	_
16	the	_	DT	DT	_	19	NMOD	_	_
17	T-cell	_	NN	NN	_	19	NMOD	_	_
18	antigen	_	NN	NN	_	19	NMOD	_	_
19	receptor	_	NN	NN	_	15	PMOD	_	_
20	to	_	TO	TO	_	12	NMOD	_	_
21	cytokine	_	NN	NN	_	22	NMOD	_	_
22	genes	_	NNS	NNS	_	20	PMOD	_	_
23	that	_	WDT	WDT	_	24	SBJ	_	_
24	coordinate	_	VBP	VBP	_	22	NMOD	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	immune	_	JJ	JJ	_	27	NMOD	_	_
27	response	_	NN	NN	_	24	OBJ	_	_
28	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	putative	_	JJ	JJ	_	4	NMOD	_	_
3	intracellular	_	JJ	JJ	_	4	NMOD	_	_
4	receptors	_	NNS	NNS	_	9	SBJ	_	_
5	for	_	IN	IN	_	4	NMOD	_	_
6	FK506	_	NN	NN	_	5	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	cyclosporin	_	NN	NN	_	6	COORD	_	_
9	are	_	VBP	VBP	_	0	ROOT-S	_	_
10	cis-trans	_	JJ	JJ	_	12	NMOD	_	_
11	prolyl	_	JJ	JJ	_	12	NMOD	_	_
12	isomerases	_	NNS	NNS	_	9	PRD	_	_
13	.	_	.	.	_	9	P	_	_

1	Binding	_	NN	NN	_	5	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	drug	_	NN	NN	_	2	PMOD	_	_
5	inhibits	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	isomerase	_	NN	NN	_	7	NMOD	_	_
7	activity	_	NN	NN	_	5	OBJ	_	_
8	,	_	,	,	_	5	P	_	_
9	but	_	CC	CC	_	5	CC	_	_
10	studies	_	NNS	NNS	_	23	SBJ	_	_
11	with	_	IN	IN	_	10	NMOD	_	_
12	other	_	JJ	JJ	_	15	NMOD	_	_
13	prolyl	_	JJ	JJ	_	15	NMOD	_	_
14	isomerase	_	NN	NN	_	15	NMOD	_	_
15	inhibitors	_	NNS	NNS	_	11	PMOD	_	_
16	and	_	CC	CC	_	10	CC	_	_
17	analysis	_	NN	NN	_	10	COORD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	cyclosporin-resistant	_	JJ	JJ	_	20	NMOD	_	_
20	mutants	_	NNS	NNS	_	18	PMOD	_	_
21	in	_	IN	IN	_	20	NMOD	_	_
22	yeast	_	NN	NN	_	21	PMOD	_	_
23	suggest	_	VBP	VBP	_	5	COORD	_	_
24	that	_	IN	IN	_	23	OBJ	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	effects	_	NNS	NNS	_	30	SBJ	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	drug	_	NN	NN	_	27	PMOD	_	_
30	result	_	VBP	VBP	_	24	VMOD	_	_
31	from	_	IN	IN	_	30	ADV	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	formation	_	NN	NN	_	31	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	an	_	DT	DT	_	37	NMOD	_	_
36	inhibitory	_	JJ	JJ	_	37	NMOD	_	_
37	complex	_	NN	NN	_	34	PMOD	_	_
38	between	_	IN	IN	_	33	NMOD	_	_
39	the	_	DT	DT	_	40	NMOD	_	_
40	drug	_	NN	NN	_	38	PMOD	_	_
41	and	_	CC	CC	_	40	CC	_	_
42	isomerase	_	NN	NN	_	40	COORD	_	_
43	,	_	,	,	_	31	P	_	_
44	and	_	CC	CC	_	31	CC	_	_
45	not	_	RB	RB	_	46	DEP	_	_
46	from	_	IN	IN	_	31	COORD	_	_
47	inhibition	_	NN	NN	_	46	PMOD	_	_
48	of	_	IN	IN	_	47	NMOD	_	_
49	isomerase	_	NN	NN	_	50	NMOD	_	_
50	activity	_	NN	NN	_	48	PMOD	_	_
51	.	_	.	.	_	5	P	_	_

1	A	_	DT	DT	_	3	NMOD	_	_
2	transcription	_	NN	NN	_	3	NMOD	_	_
3	factor	_	NN	NN	_	16	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	NF-AT	_	NN	NN	_	3	NMOD	_	_
6	,	_	,	,	_	3	P	_	_
7	which	_	WDT	WDT	_	8	SBJ	_	_
8	is	_	VBZ	VBZ	_	3	NMOD	_	_
9	essential	_	JJ	JJ	_	8	PRD	_	_
10	for	_	IN	IN	_	9	AMOD	_	_
11	early	_	JJ	JJ	_	14	NMOD	_	_
12	T-cell	_	NN	NN	_	14	NMOD	_	_
13	gene	_	NN	NN	_	14	NMOD	_	_
14	activation	_	NN	NN	_	10	PMOD	_	_
15	,	_	,	,	_	3	P	_	_
16	seems	_	VBZ	VBZ	_	0	ROOT-S	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	be	_	VB	VB	_	16	OBJ	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	specific	_	JJ	JJ	_	21	NMOD	_	_
21	target	_	NN	NN	_	18	PRD	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	cyclosporin	_	NN	NN	_	24	NMOD	_	_
24	A	_	NN	NN	_	27	NMOD	_	_
25	and	_	CC	CC	_	24	CC	_	_
26	FK506	_	NN	NN	_	24	COORD	_	_
27	action	_	NN	NN	_	22	PMOD	_	_
28	because	_	IN	IN	_	18	ADV	_	_
29	transcription	_	NN	NN	_	34	SBJ	_	_
30	directed	_	VBN	VBN	_	29	NMOD	_	_
31	by	_	IN	IN	_	30	LGS	_	_
32	this	_	DT	DT	_	33	NMOD	_	_
33	protein	_	NN	NN	_	31	PMOD	_	_
34	is	_	VBZ	VBZ	_	28	VMOD	_	_
35	blocked	_	VBN	VBN	_	34	VC	_	_
36	in	_	IN	IN	_	35	ADV	_	_
37	T	_	NN	NN	_	38	NMOD	_	_
38	cells	_	NNS	NNS	_	36	PMOD	_	_
39	treated	_	VBN	VBN	_	38	NMOD	_	_
40	with	_	IN	IN	_	39	ADV	_	_
41	these	_	DT	DT	_	42	NMOD	_	_
42	drugs	_	NNS	NNS	_	40	PMOD	_	_
43	,	_	,	,	_	35	P	_	_
44	with	_	IN	IN	_	35	ADV	_	_
45	little	_	JJ	JJ	_	48	NMOD	_	_
46	or	_	CC	CC	_	45	CC	_	_
47	no	_	DT	DT	_	45	COORD	_	_
48	effect	_	NN	NN	_	44	PMOD	_	_
49	on	_	IN	IN	_	48	NMOD	_	_
50	other	_	JJ	JJ	_	52	NMOD	_	_
51	transcription	_	NN	NN	_	52	NMOD	_	_
52	factors	_	NNS	NNS	_	49	PMOD	_	_
53	such	_	JJ	JJ	_	54	DEP	_	_
54	as	_	IN	IN	_	52	NMOD	_	_
55	AP-1	_	NN	NN	_	54	PMOD	_	_
56	and	_	CC	CC	_	55	CC	_	_
57	NF-kappa	_	NN	NN	_	58	NMOD	_	_
58	B	_	NN	NN	_	55	COORD	_	_
59	.	_	.	.	_	16	P	_	_

1	Here	_	RB	RB	_	3	ADV	_	_
2	we	_	PRP	PRP	_	3	SBJ	_	_
3	demonstrate	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	NF-AT	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	4	VMOD	_	_
7	formed	_	VBN	VBN	_	6	VC	_	_
8	when	_	WRB	WRB	_	15	ADV	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	signal	_	NN	NN	_	15	SBJ	_	_
11	from	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	antigen	_	NN	NN	_	14	NMOD	_	_
14	receptor	_	NN	NN	_	11	PMOD	_	_
15	induces	_	VBZ	VBZ	_	7	TMP	_	_
16	a	_	DT	DT	_	19	NMOD	_	_
17	pre-existing	_	JJ	JJ	_	19	NMOD	_	_
18	cytoplasmic	_	JJ	JJ	_	19	NMOD	_	_
19	subunit	_	NN	NN	_	15	IOBJ	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	translocate	_	VB	VB	_	15	OBJ	_	_
22	to	_	TO	TO	_	21	ADV	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	nucleus	_	NN	NN	_	22	PMOD	_	_
25	and	_	CC	CC	_	15	CC	_	_
26	combine	_	VB	VB	_	15	COORD	_	_
27	with	_	IN	IN	_	26	ADV	_	_
28	a	_	DT	DT	_	32	NMOD	_	_
29	newly	_	RB	RB	_	30	AMOD	_	_
30	synthesized	_	VBN	VBN	_	32	NMOD	_	_
31	nuclear	_	JJ	JJ	_	32	NMOD	_	_
32	subunit	_	NN	NN	_	27	PMOD	_	_
33	of	_	IN	IN	_	32	PMOD	_	_
34	NF-AT	_	NN	NN	_	33	PMOD	_	_
35	.	_	.	.	_	3	P	_	_

1	FK506	_	NN	NN	_	5	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	cyclosporin	_	NN	NN	_	4	NMOD	_	_
4	A	_	NN	NN	_	1	COORD	_	_
5	block	_	VBP	VBP	_	0	ROOT-S	_	_
6	translocation	_	NN	NN	_	5	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	cytoplasmic	_	JJ	JJ	_	10	NMOD	_	_
10	component	_	NN	NN	_	7	PMOD	_	_
11	without	_	IN	IN	_	5	ADV	_	_
12	affecting	_	VBG	VBG	_	11	PMOD	_	_
13	synthesis	_	NN	NN	_	12	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	17	NMOD	_	_
16	nuclear	_	JJ	JJ	_	17	NMOD	_	_
17	subunit	_	NN	NN	_	14	PMOD	_	_
18	.	_	.	.	_	5	P	_	_

1	Regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	M-CSF	_	NN	NN	_	4	NMOD	_	_
4	expression	_	NN	NN	_	2	PMOD	_	_
5	by	_	IN	IN	_	1	NMOD	_	_
6	M-CSF	_	NN	NN	_	5	PMOD	_	_
7	:	_	:	:	_	1	P	_	_
8	role	_	NN	NN	_	1	NMOD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	protein	_	NN	NN	_	12	NMOD	_	_
11	kinase	_	NN	NN	_	12	NMOD	_	_
12	C	_	NN	NN	_	9	PMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	transcription	_	NN	NN	_	18	NMOD	_	_
15	factor	_	NN	NN	_	18	NMOD	_	_
16	NF	_	NN	NN	_	18	NMOD	_	_
17	kappa	_	NN	NN	_	18	NMOD	_	_
18	B	_	NN	NN	_	12	COORD	_	_
19	.	_	.	.	_	8	P	_	_

1	Macrophage-colony-stimulating	_	JJ	JJ	_	2	NMOD	_	_
2	factor	_	NN	NN	_	13	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	M-CSF	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	,	_	,	,	_	2	P	_	_
7	also	_	RB	RB	_	8	ADV	_	_
8	referred	_	VBN	VBN	_	2	NMOD	_	_
9	to	_	TO	TO	_	8	ADV	_	_
10	as	_	IN	IN	_	8	ADV	_	_
11	CSF-1	_	NN	NN	_	10	PMOD	_	_
12	,	_	,	,	_	2	P	_	_
13	regulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	survival	_	NN	NN	_	13	OBJ	_	_
16	,	_	,	,	_	15	P	_	_
17	growth	_	NN	NN	_	15	COORD	_	_
18	,	_	,	,	_	15	P	_	_
19	differentiation	_	NN	NN	_	15	COORD	_	_
20	and	_	CC	CC	_	15	CC	_	_
21	functional	_	JJ	JJ	_	22	NMOD	_	_
22	activity	_	NN	NN	_	15	COORD	_	_
23	of	_	IN	IN	_	15	NMOD	_	_
24	monocytes	_	NNS	NNS	_	23	PMOD	_	_
25	by	_	IN	IN	_	13	ADV	_	_
26	binding	_	VBG	VBG	_	25	PMOD	_	_
27	to	_	TO	TO	_	26	ADV	_	_
28	a	_	DT	DT	_	30	NMOD	_	_
29	single	_	JJ	JJ	_	30	NMOD	_	_
30	class	_	NN	NN	_	27	PMOD	_	_
31	of	_	IN	IN	_	30	NMOD	_	_
32	high-affinity	_	JJ	JJ	_	35	NMOD	_	_
33	cell	_	NN	NN	_	35	NMOD	_	_
34	surface	_	NN	NN	_	35	NMOD	_	_
35	receptors	_	NNS	NNS	_	31	PMOD	_	_
36	,	_	,	,	_	30	P	_	_
37	known	_	VBN	VBN	_	30	NMOD	_	_
38	to	_	TO	TO	_	39	VMOD	_	_
39	be	_	VB	VB	_	37	OBJ	_	_
40	the	_	DT	DT	_	41	NMOD	_	_
41	product	_	NN	NN	_	39	PRD	_	_
42	of	_	IN	IN	_	41	NMOD	_	_
43	the	_	DT	DT	_	45	NMOD	_	_
44	c-fms	_	NN	NN	_	45	NMOD	_	_
45	protooncogene	_	NN	NN	_	42	PMOD	_	_
46	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	detection	_	NN	NN	_	15	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	both	_	CC	CC	_	5	CC	_	_
5	M-CSF	_	NN	NN	_	8	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	c-fms	_	NN	NN	_	5	COORD	_	_
8	expression	_	NN	NN	_	3	PMOD	_	_
9	by	_	IN	IN	_	8	NMOD	_	_
10	cells	_	NNS	NNS	_	9	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	monocyte	_	NN	NN	_	14	NMOD	_	_
14	lineage	_	NN	NN	_	11	PMOD	_	_
15	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
16	suggested	_	VBN	VBN	_	15	VC	_	_
17	that	_	IN	IN	_	16	OBJ	_	_
18	M-CSF	_	NN	NN	_	19	SBJ	_	_
19	may	_	MD	MD	_	17	VMOD	_	_
20	act	_	VB	VB	_	19	VC	_	_
21	by	_	IN	IN	_	20	ADV	_	_
22	an	_	DT	DT	_	24	NMOD	_	_
23	autocrine	_	JJ	JJ	_	24	NMOD	_	_
24	mechanism	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	15	P	_	_

1	Interestingly	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	it	_	PRP	PRP	_	4	SBJ	_	_
4	has	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	been	_	VBN	VBN	_	4	VC	_	_
6	shown	_	VBN	VBN	_	5	VC	_	_
7	that	_	IN	IN	_	6	OBJ	_	_
8	M-CSF	_	NN	NN	_	9	SBJ	_	_
9	can	_	MD	MD	_	7	VMOD	_	_
10	induce	_	VB	VB	_	9	VC	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	expression	_	NN	NN	_	10	OBJ	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	its	_	PRP$	PRP$	_	16	NMOD	_	_
15	own	_	JJ	JJ	_	16	NMOD	_	_
16	gene	_	NN	NN	_	13	PMOD	_	_
17	.	_	.	.	_	4	P	_	_

1	Although	_	IN	IN	_	18	ADV	_	_
2	sensitivity	_	NN	NN	_	5	SBJ	_	_
3	to	_	TO	TO	_	2	NMOD	_	_
4	M-CSF	_	NN	NN	_	3	PMOD	_	_
5	can	_	MD	MD	_	1	VMOD	_	_
6	be	_	VB	VB	_	5	VC	_	_
7	modulated	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	LGS	_	_
9	regulation	_	NN	NN	_	8	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	receptor	_	NN	NN	_	10	PMOD	_	_
12	expression	_	NN	NN	_	11	NMOD	_	_
13	and	_	CC	CC	_	12	CC	_	_
14	function	_	NN	NN	_	12	COORD	_	_
15	,	_	,	,	_	18	P	_	_
16	M-CSF	_	NN	NN	_	17	NMOD	_	_
17	responsiveness	_	NN	NN	_	18	SBJ	_	_
18	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
19	largely	_	RB	RB	_	18	ADV	_	_
20	determined	_	VBN	VBN	_	18	VC	_	_
21	at	_	IN	IN	_	20	ADV	_	_
22	a	_	DT	DT	_	24	NMOD	_	_
23	postreceptor	_	NN	NN	_	24	NMOD	_	_
24	level	_	NN	NN	_	21	PMOD	_	_
25	.	_	.	.	_	18	P	_	_

1	To	_	TO	TO	_	5	TMP	_	_
2	date	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	little	_	JJ	JJ	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	known	_	VBN	VBN	_	5	VC	_	_
7	about	_	IN	IN	_	6	ADV	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	intracellular	_	JJ	JJ	_	10	NMOD	_	_
10	pathway	_	NN	NN	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	M-CSF	_	NN	NN	_	14	NMOD	_	_
13	signal	_	NN	NN	_	14	NMOD	_	_
14	transduction	_	NN	NN	_	11	PMOD	_	_
15	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	therefore	_	RB	RB	_	2	ADV	_	_
4	investigated	_	VBN	VBN	_	2	VC	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	changes	_	NNS	NNS	_	4	OBJ	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	protein	_	NN	NN	_	10	NMOD	_	_
9	kinase	_	NN	NN	_	10	NMOD	_	_
10	C	_	NN	NN	_	14	NMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	PKC	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	activity	_	NN	NN	_	7	PMOD	_	_
15	upon	_	IN	IN	_	6	NMOD	_	_
16	exposure	_	NN	NN	_	15	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	monocytes	_	NNS	NNS	_	17	PMOD	_	_
19	to	_	TO	TO	_	16	NMOD	_	_
20	M-CSF	_	NN	NN	_	19	PMOD	_	_
21	.	_	.	.	_	2	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	show	_	VBP	VBP	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	M-CSF	_	NN	NN	_	5	SBJ	_	_
5	activates	_	VBZ	VBZ	_	3	VMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	translocates	_	VBZ	VBZ	_	5	COORD	_	_
8	PKC	_	NN	NN	_	5	OBJ	_	_
9	.	_	.	.	_	2	P	_	_

1	Inhibition	_	NN	NN	_	9	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	PKC	_	NN	NN	_	2	PMOD	_	_
4	by	_	IN	IN	_	1	NMOD	_	_
5	the	_	DT	DT	_	8	NMOD	_	_
6	isoquinoline	_	NN	NN	_	8	NMOD	_	_
7	derivative	_	JJ	JJ	_	8	NMOD	_	_
8	H7	_	NN	NN	_	4	PMOD	_	_
9	abolishes	_	VBZ	VBZ	_	0	ROOT-S	_	_
10	induction	_	NN	NN	_	9	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	M-CSF	_	NN	NN	_	11	PMOD	_	_
13	by	_	IN	IN	_	10	NMOD	_	_
14	M-CSF	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	9	P	_	_

1	Furthermore	_	RB	RB	_	6	ADV	_	_
2	,	_	,	,	_	6	P	_	_
3	activation	_	NN	NN	_	6	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	PKC	_	NN	NN	_	4	PMOD	_	_
6	was	_	VBD	VBD	_	0	ROOT-S	_	_
7	pertussis-toxin-sensitive	_	JJ	JJ	_	6	PRD	_	_
8	and	_	CC	CC	_	6	CC	_	_
9	was	_	VBD	VBD	_	6	COORD	_	_
10	associated	_	VBN	VBN	_	9	VC	_	_
11	with	_	IN	IN	_	10	ADV	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	detection	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	an	_	DT	DT	_	19	NMOD	_	_
16	NF	_	NN	NN	_	19	NMOD	_	_
17	kappa	_	NN	NN	_	19	NMOD	_	_
18	B	_	NN	NN	_	19	NMOD	_	_
19	protein	_	NN	NN	_	14	PMOD	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	nuclear	_	JJ	JJ	_	22	NMOD	_	_
22	extracts	_	NNS	NNS	_	20	PMOD	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	M-CSF-induced	_	JJ	JJ	_	26	NMOD	_	_
25	blood	_	NN	NN	_	26	NMOD	_	_
26	monocytes	_	NNS	NNS	_	23	PMOD	_	_
27	but	_	CC	CC	_	20	CC	_	_
28	not	_	RB	RB	_	29	DEP	_	_
29	in	_	IN	IN	_	20	COORD	_	_
30	monocytes	_	NNS	NNS	_	29	PMOD	_	_
31	exposed	_	VBN	VBN	_	30	NMOD	_	_
32	to	_	TO	TO	_	31	ADV	_	_
33	medium	_	NN	NN	_	34	NMOD	_	_
34	treatment	_	NN	NN	_	32	PMOD	_	_
35	only	_	RB	RB	_	34	NMOD	_	_
36	.	_	.	.	_	6	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	M-CSF	_	NN	NN	_	6	NMOD	_	_
6	induction	_	NN	NN	_	9	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	M-CSF	_	NN	NN	_	7	PMOD	_	_
9	involves	_	VBZ	VBZ	_	4	VMOD	_	_
10	G	_	NN	NN	_	11	NMOD	_	_
11	proteins	_	NNS	NNS	_	9	OBJ	_	_
12	,	_	,	,	_	11	P	_	_
13	PKC	_	NN	NN	_	11	NMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	NF	_	NN	NN	_	17	NMOD	_	_
16	kappa	_	NN	NN	_	17	NMOD	_	_
17	B	_	NN	NN	_	13	COORD	_	_
18	.	_	.	.	_	3	P	_	_

1	NF-kappa	_	NN	NN	_	3	NMOD	_	_
2	B	_	NN	NN	_	3	NMOD	_	_
3	activity	_	NN	NN	_	0	ROOT-FRAG	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	4	PMOD	_	_
7	stably	_	RB	RB	_	8	ADV	_	_
8	expressing	_	VBG	VBG	_	6	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	Tax	_	NN	NN	_	11	NMOD	_	_
11	protein	_	NN	NN	_	8	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	human	_	JJ	JJ	_	18	NMOD	_	_
14	T	_	NN	NN	_	18	NMOD	_	_
15	cell	_	NN	NN	_	18	NMOD	_	_
16	lymphotropic	_	JJ	JJ	_	18	NMOD	_	_
17	virus	_	NN	NN	_	18	NMOD	_	_
18	type	_	NN	NN	_	12	PMOD	_	_
19	I	_	CD	CD	_	18	NMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	23	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	constitutive	_	JJ	JJ	_	6	NMOD	_	_
5	Tax	_	NN	NN	_	6	NMOD	_	_
6	expression	_	NN	NN	_	3	PMOD	_	_
7	on	_	IN	IN	_	2	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	interaction	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	NF-kappa	_	NN	NN	_	12	NMOD	_	_
12	B	_	NN	NN	_	10	PMOD	_	_
13	with	_	IN	IN	_	9	NMOD	_	_
14	its	_	PRP$	PRP$	_	16	NMOD	_	_
15	recognition	_	NN	NN	_	16	NMOD	_	_
16	sequence	_	NN	NN	_	13	PMOD	_	_
17	and	_	CC	CC	_	7	CC	_	_
18	on	_	IN	IN	_	7	COORD	_	_
19	NF-kappa	_	NN	NN	_	22	NMOD	_	_
20	B-dependent	_	JJ	JJ	_	19	AMOD	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	expression	_	NN	NN	_	18	PMOD	_	_
23	was	_	VBD	VBD	_	0	ROOT-S	_	_
24	examined	_	VBN	VBN	_	23	VC	_	_
25	in	_	IN	IN	_	24	ADV	_	_
26	T	_	NN	NN	_	30	NMOD	_	_
27	lymphoid	_	JJ	JJ	_	30	NMOD	_	_
28	Jurkat	_	NN	NN	_	30	NMOD	_	_
29	cell	_	NN	NN	_	30	NMOD	_	_
30	lines	_	NNS	NNS	_	25	PMOD	_	_
31	(	_	(	(	_	32	P	_	_
32	19D	_	NN	NN	_	30	PRN	_	_
33	and	_	CC	CC	_	32	CC	_	_
34	9J	_	NN	NN	_	32	COORD	_	_
35	)	_	)	)	_	32	P	_	_
36	stably	_	RB	RB	_	37	ADV	_	_
37	transformed	_	VBN	VBN	_	30	NMOD	_	_
38	with	_	IN	IN	_	37	ADV	_	_
39	a	_	DT	DT	_	42	NMOD	_	_
40	Tax	_	NN	NN	_	42	NMOD	_	_
41	expression	_	NN	NN	_	42	NMOD	_	_
42	vector	_	NN	NN	_	38	PMOD	_	_
43	.	_	.	.	_	23	P	_	_

1	Tax	_	NN	NN	_	5	NMOD	_	_
2	expressing	_	NN	NN	_	5	NMOD	_	_
3	T	_	NN	NN	_	5	NMOD	_	_
4	cell	_	NN	NN	_	5	NMOD	_	_
5	lines	_	NNS	NNS	_	6	SBJ	_	_
6	contained	_	VBD	VBD	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	constitutive	_	JJ	JJ	_	9	NMOD	_	_
9	level	_	NN	NN	_	6	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	NF-kappa	_	NN	NN	_	14	NMOD	_	_
12	B	_	NN	NN	_	14	NMOD	_	_
13	binding	_	NN	NN	_	14	NMOD	_	_
14	activity	_	NN	NN	_	10	PMOD	_	_
15	,	_	,	,	_	14	P	_	_
16	detectable	_	JJ	JJ	_	14	NMOD	_	_
17	by	_	IN	IN	_	16	AMOD	_	_
18	mobility	_	NN	NN	_	20	NMOD	_	_
19	shift	_	NN	NN	_	20	NMOD	_	_
20	assay	_	NN	NN	_	17	PMOD	_	_
21	and	_	CC	CC	_	20	CC	_	_
22	uv	_	NN	NN	_	23	NMOD	_	_
23	cross-linking	_	NN	NN	_	20	COORD	_	_
24	using	_	VBG	VBG	_	20	NMOD	_	_
25	a	_	DT	DT	_	29	NMOD	_	_
26	palindromic	_	JJ	JJ	_	29	NMOD	_	_
27	NF-kappa	_	NN	NN	_	29	NMOD	_	_
28	B	_	NN	NN	_	29	NMOD	_	_
29	probe	_	NN	NN	_	24	OBJ	_	_
30	homologous	_	JJ	JJ	_	29	NMOD	_	_
31	to	_	TO	TO	_	30	AMOD	_	_
32	the	_	DT	DT	_	36	NMOD	_	_
33	interferon	_	NN	NN	_	36	NMOD	_	_
34	beta	_	NN	NN	_	36	NMOD	_	_
35	PRDII	_	NN	NN	_	36	NMOD	_	_
36	site	_	NN	NN	_	31	PMOD	_	_
37	.	_	.	.	_	6	P	_	_

1	In	_	IN	IN	_	9	ADV	_	_
2	Jurkat	_	NN	NN	_	1	PMOD	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	NC2.10	_	NN	NN	_	2	COORD	_	_
5	induction	_	NN	NN	_	9	SBJ	_	_
6	with	_	IN	IN	_	5	NMOD	_	_
7	phorbol	_	NN	NN	_	8	NMOD	_	_
8	esters	_	NNS	NNS	_	6	PMOD	_	_
9	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	appearance	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	new	_	JJ	JJ	_	17	NMOD	_	_
15	DNA	_	NN	NN	_	17	NMOD	_	_
16	binding	_	NN	NN	_	17	NMOD	_	_
17	proteins	_	NNS	NNS	_	13	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	85	_	CD	CD	_	25	NMOD	_	_
20	,	_	,	,	_	19	P	_	_
21	75	_	CD	CD	_	19	COORD	_	_
22	,	_	,	,	_	19	P	_	_
23	and	_	CC	CC	_	19	CC	_	_
24	54	_	CD	CD	_	19	COORD	_	_
25	kDa	_	NN	NN	_	18	PMOD	_	_
26	,	_	,	,	_	9	P	_	_
27	whereas	_	IN	IN	_	9	COORD	_	_
28	in	_	IN	IN	_	41	ADV	_	_
29	Tax	_	NN	NN	_	31	NMOD	_	_
30	expressing	_	NN	NN	_	31	NMOD	_	_
31	cells	_	NNS	NNS	_	28	PMOD	_	_
32	the	_	DT	DT	_	34	NMOD	_	_
33	85-kDa	_	JJ	JJ	_	34	NMOD	_	_
34	protein	_	NN	NN	_	41	SBJ	_	_
35	and	_	CC	CC	_	34	CC	_	_
36	a	_	DT	DT	_	40	NMOD	_	_
37	92-kDa	_	JJ	JJ	_	40	NMOD	_	_
38	DNA	_	NN	NN	_	40	NMOD	_	_
39	binding	_	NN	NN	_	40	NMOD	_	_
40	protein	_	NN	NN	_	34	COORD	_	_
41	were	_	VBD	VBD	_	9	COORD	_	_
42	constitutively	_	RB	RB	_	41	ADV	_	_
43	induced	_	VBN	VBN	_	41	VC	_	_
44	.	_	.	.	_	9	P	_	_

1	Expression	_	NN	NN	_	9	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	Tax	_	NN	NN	_	4	NMOD	_	_
4	protein	_	NN	NN	_	2	PMOD	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	19D	_	NN	NN	_	5	PMOD	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	9J	_	NN	NN	_	6	COORD	_	_
9	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
10	in	_	IN	IN	_	9	ADV	_	_
11	transcription	_	NN	NN	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	21	NMOD	_	_
14	endogenous	_	JJ	JJ	_	21	NMOD	_	_
15	NF-kappa	_	NN	NN	_	21	NMOD	_	_
16	B-dependent	_	JJ	JJ	_	15	AMOD	_	_
17	granulocyte-macrophage	_	JJ	JJ	_	21	NMOD	_	_
18	colony	_	NN	NN	_	21	NMOD	_	_
19	stimulating	_	NN	NN	_	21	NMOD	_	_
20	factor	_	NN	NN	_	21	NMOD	_	_
21	gene	_	NN	NN	_	12	PMOD	_	_
22	and	_	CC	CC	_	11	CC	_	_
23	increased	_	VBD	VBD	_	26	NMOD	_	_
24	basal	_	JJ	JJ	_	26	NMOD	_	_
25	level	_	NN	NN	_	26	NMOD	_	_
26	expression	_	NN	NN	_	11	COORD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	transfected	_	VBN	VBN	_	31	NMOD	_	_
29	NF-kappa	_	NN	NN	_	31	NMOD	_	_
30	B-regulated	_	JJ	JJ	_	29	AMOD	_	_
31	promoters	_	NNS	NNS	_	27	PMOD	_	_
32	.	_	.	.	_	9	P	_	_

1	Nonetheless	_	RB	RB	_	11	ADV	_	_
2	transcription	_	NN	NN	_	11	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	both	_	CC	CC	_	10	CC	_	_
5	the	_	DT	DT	_	10	NMOD	_	_
6	endogenous	_	JJ	JJ	_	10	NMOD	_	_
7	and	_	CC	CC	_	10	CC	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	transfected	_	VBN	VBN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	3	PMOD	_	_
11	was	_	VBD	VBD	_	0	ROOT-S	_	_
12	inducible	_	JJ	JJ	_	11	PRD	_	_
13	by	_	IN	IN	_	12	AMOD	_	_
14	PMA	_	NN	NN	_	15	NMOD	_	_
15	treatment	_	NN	NN	_	13	PMOD	_	_
16	.	_	.	.	_	11	P	_	_

1	Tax	_	NN	NN	_	2	NMOD	_	_
2	expression	_	NN	NN	_	7	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	Jurkat	_	NN	NN	_	6	NMOD	_	_
5	T	_	NN	NN	_	6	NMOD	_	_
6	cells	_	NNS	NNS	_	3	PMOD	_	_
7	may	_	MD	MD	_	0	ROOT-S	_	_
8	alter	_	VB	VB	_	7	VC	_	_
9	the	_	DT	DT	_	10	NMOD	_	_
10	stoichiometry	_	NN	NN	_	8	OBJ	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	NF-kappa	_	NN	NN	_	16	NMOD	_	_
13	B	_	NN	NN	_	16	NMOD	_	_
14	DNA	_	NN	NN	_	16	NMOD	_	_
15	binding	_	NN	NN	_	16	NMOD	_	_
16	proteins	_	NNS	NNS	_	11	PMOD	_	_
17	and	_	CC	CC	_	8	CC	_	_
18	thus	_	RB	RB	_	8	COORD	_	_
19	change	_	VB	VB	_	8	COORD	_	_
20	the	_	DT	DT	_	21	NMOD	_	_
21	expression	_	NN	NN	_	19	OBJ	_	_
22	of	_	IN	IN	_	21	NMOD	_	_
23	NF-kappa	_	NN	NN	_	25	NMOD	_	_
24	B-regulated	_	JJ	JJ	_	23	AMOD	_	_
25	promoters	_	NNS	NNS	_	22	PMOD	_	_
26	.	_	.	.	_	7	P	_	_

1	Regulation	_	NN	NN	_	0	ROOT-FRAG	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	glucocorticoid	_	NN	NN	_	4	NMOD	_	_
4	receptors	_	NNS	NNS	_	2	PMOD	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	human	_	JJ	JJ	_	8	NMOD	_	_
7	mononuclear	_	JJ	JJ	_	8	NMOD	_	_
8	cells	_	NNS	NNS	_	5	PMOD	_	_
9	:	_	:	:	_	1	P	_	_
10	effects	_	NNS	NNS	_	1	NMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	glucocorticoid	_	NN	NN	_	13	NMOD	_	_
13	treatment	_	NN	NN	_	11	PMOD	_	_
14	,	_	,	,	_	10	P	_	_
15	Cushing	_	NN	NN	_	17	NMOD	_	_
16	's	_	POS	POS	_	15	NMOD	_	_
17	disease	_	NN	NN	_	10	NMOD	_	_
18	and	_	CC	CC	_	17	CC	_	_
19	ketoconazole	_	NN	NN	_	17	COORD	_	_
20	.	_	.	.	_	10	P	_	_

1	Glucocorticoid	_	NN	NN	_	2	NMOD	_	_
2	receptors	_	NNS	NNS	_	6	SBJ	_	_
3	(	_	(	(	_	4	P	_	_
4	GcR	_	NN	NN	_	2	PRN	_	_
5	)	_	)	)	_	4	P	_	_
6	were	_	VBD	VBD	_	0	ROOT-S	_	_
7	determined	_	VBN	VBN	_	6	VC	_	_
8	by	_	IN	IN	_	7	ADV	_	_
9	a	_	DT	DT	_	12	NMOD	_	_
10	whole	_	JJ	JJ	_	12	NMOD	_	_
11	cell	_	NN	NN	_	12	NMOD	_	_
12	assay	_	NN	NN	_	8	PMOD	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	human	_	JJ	JJ	_	16	NMOD	_	_
15	mononulear	_	JJ	JJ	_	16	NMOD	_	_
16	leukocytes	_	NNS	NNS	_	13	PMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	hMNL	_	NN	NN	_	16	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	from	_	IN	IN	_	16	NMOD	_	_
21	control	_	NN	NN	_	22	NMOD	_	_
22	subjects	_	NNS	NNS	_	20	PMOD	_	_
23	,	_	,	,	_	22	P	_	_
24	patients	_	NNS	NNS	_	22	COORD	_	_
25	receiving	_	VBG	VBG	_	24	NMOD	_	_
26	glucocorticoid	_	NN	NN	_	27	NMOD	_	_
27	therapy	_	NN	NN	_	25	OBJ	_	_
28	for	_	IN	IN	_	27	NMOD	_	_
29	systemic	_	JJ	JJ	_	30	NMOD	_	_
30	diseases	_	NNS	NNS	_	28	PMOD	_	_
31	and	_	CC	CC	_	22	CC	_	_
32	Cushing	_	NN	NN	_	34	NMOD	_	_
33	's	_	POS	POS	_	32	NMOD	_	_
34	disease	_	NN	NN	_	35	NMOD	_	_
35	patients	_	NNS	NNS	_	22	COORD	_	_
36	with	_	IN	IN	_	35	NMOD	_	_
37	or	_	CC	CC	_	36	CC	_	_
38	without	_	IN	IN	_	36	COORD	_	_
39	ketoconazole	_	NN	NN	_	40	NMOD	_	_
40	therapy	_	NN	NN	_	36	PMOD	_	_
41	.	_	.	.	_	6	P	_	_

1	Prolonged	_	JJ	JJ	_	3	NMOD	_	_
2	corticosteroid	_	NN	NN	_	3	NMOD	_	_
3	treatment	_	NN	NN	_	4	SBJ	_	_
4	resulted	_	VBD	VBD	_	0	ROOT-S	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	down-regulation	_	NN	NN	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	GcR	_	NN	NN	_	7	PMOD	_	_
9	,	_	,	,	_	4	P	_	_
10	while	_	IN	IN	_	4	OBJ	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	mean	_	NN	NN	_	13	NMOD	_	_
13	level	_	NN	NN	_	20	VMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	GcR	_	NN	NN	_	14	PMOD	_	_
16	in	_	IN	IN	_	13	NMOD	_	_
17	Cushing	_	NN	NN	_	19	NMOD	_	_
18	's	_	POS	POS	_	17	NMOD	_	_
19	disease	_	NN	NN	_	16	PMOD	_	_
20	was	_	VBD	VBD	_	10	VMOD	_	_
21	normal	_	JJ	JJ	_	20	PRD	_	_
22	.	_	.	.	_	4	P	_	_

1	In	_	IN	IN	_	14	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	group	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	14	P	_	_
5	however	_	RB	RB	_	14	ADV	_	_
6	,	_	,	,	_	14	P	_	_
7	receptor	_	NN	NN	_	8	NMOD	_	_
8	levels	_	NNS	NNS	_	14	SBJ	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	morning	_	NN	NN	_	13	NMOD	_	_
11	plasma	_	NN	NN	_	13	NMOD	_	_
12	cortisol	_	NN	NN	_	13	NMOD	_	_
13	values	_	NNS	NNS	_	8	COORD	_	_
14	showed	_	VBD	VBD	_	0	ROOT-S	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	negative	_	JJ	JJ	_	17	NMOD	_	_
17	correlation	_	NN	NN	_	14	IOBJ	_	_
18	,	_	,	,	_	14	P	_	_
19	indicating	_	VBG	VBG	_	14	OBJ	_	_
20	a	_	DT	DT	_	23	NMOD	_	_
21	subtle	_	JJ	JJ	_	23	NMOD	_	_
22	down-regulatory	_	JJ	JJ	_	23	NMOD	_	_
23	effect	_	NN	NN	_	19	OBJ	_	_
24	.	_	.	.	_	14	P	_	_

1	Furthermore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	GcR	_	NN	NN	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	unaltered	_	JJ	JJ	_	4	PRD	_	_
6	after	_	IN	IN	_	4	TMP	_	_
7	these	_	DT	DT	_	8	NMOD	_	_
8	patients	_	NNS	NNS	_	9	SBJ	_	_
9	received	_	VBD	VBD	_	6	VMOD	_	_
10	ketoconazole	_	NN	NN	_	9	OBJ	_	_
11	,	_	,	,	_	4	P	_	_
12	in	_	IN	IN	_	4	ADV	_	_
13	spite	_	NN	NN	_	12	DEP	_	_
14	of	_	IN	IN	_	12	DEP	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	marked	_	JJ	JJ	_	17	NMOD	_	_
17	reduction	_	NN	NN	_	12	PMOD	_	_
18	in	_	IN	IN	_	17	NMOD	_	_
19	morning	_	NN	NN	_	21	NMOD	_	_
20	plasma	_	NN	NN	_	21	NMOD	_	_
21	cortisol	_	NN	NN	_	18	PMOD	_	_
22	and	_	CC	CC	_	21	CC	_	_
23	urinary	_	JJ	JJ	_	24	AMOD	_	_
24	free	_	JJ	JJ	_	25	NMOD	_	_
25	cortisol	_	NN	NN	_	21	COORD	_	_
26	.	_	.	.	_	4	P	_	_

1	We	_	PRP	PRP	_	3	SBJ	_	_
2	also	_	RB	RB	_	3	ADV	_	_
3	observed	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	ketoconazole	_	NN	NN	_	6	SBJ	_	_
6	was	_	VBD	VBD	_	4	VMOD	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	weak	_	JJ	JJ	_	9	NMOD	_	_
9	competitor	_	NN	NN	_	6	PRD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	GcR	_	NN	NN	_	10	PMOD	_	_
12	in	_	IN	IN	_	6	ADV	_	_
13	intact	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	,	_	,	,	_	6	P	_	_
16	although	_	IN	IN	_	6	ADV	_	_
17	it	_	PRP	PRP	_	19	SBJ	_	_
18	significantly	_	RB	RB	_	19	ADV	_	_
19	inhibited	_	VBD	VBD	_	16	VMOD	_	_
20	-LCB-3H-RCB-	_	NN	NN	_	22	NMOD	_	_
21	dexamethasone	_	NN	NN	_	22	NMOD	_	_
22	binding	_	NN	NN	_	19	OBJ	_	_
23	in	_	IN	IN	_	19	ADV	_	_
24	cytosolic	_	JJ	JJ	_	25	NMOD	_	_
25	preparations	_	NNS	NNS	_	23	PMOD	_	_
26	from	_	IN	IN	_	25	NMOD	_	_
27	rat	_	NN	NN	_	28	NMOD	_	_
28	tissues	_	NNS	NNS	_	26	PMOD	_	_
29	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggested	_	VBD	VBD	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	GcR	_	NN	NN	_	8	SBJ	_	_
6	in	_	IN	IN	_	5	NMOD	_	_
7	hMNL	_	NN	NN	_	6	PMOD	_	_
8	are	_	VBP	VBP	_	4	VMOD	_	_
9	down-regulated	_	VBN	VBN	_	8	VC	_	_
10	by	_	IN	IN	_	9	ADV	_	_
11	synthetic	_	JJ	JJ	_	12	NMOD	_	_
12	steroids	_	NNS	NNS	_	10	PMOD	_	_
13	given	_	VBN	VBN	_	12	NMOD	_	_
14	in	_	FW	FW	_	13	ADV	_	_
15	vivo	_	FW	FW	_	14	AMOD	_	_
16	,	_	,	,	_	8	P	_	_
17	but	_	CC	CC	_	8	CC	_	_
18	they	_	PRP	PRP	_	19	SBJ	_	_
19	showed	_	VBD	VBD	_	8	COORD	_	_
20	very	_	RB	RB	_	21	AMOD	_	_
21	mild	_	JJ	JJ	_	22	NMOD	_	_
22	down-regulation	_	NN	NN	_	19	OBJ	_	_
23	in	_	IN	IN	_	19	ADV	_	_
24	hypercortisolemic	_	JJ	JJ	_	25	NMOD	_	_
25	patients	_	NNS	NNS	_	23	PMOD	_	_
26	suffering	_	VBG	VBG	_	25	NMOD	_	_
27	from	_	IN	IN	_	26	ADV	_	_
28	Cushing	_	NN	NN	_	30	NMOD	_	_
29	's	_	POS	POS	_	28	NMOD	_	_
30	disease	_	NN	NN	_	27	PMOD	_	_
31	.	_	.	.	_	3	P	_	_

1	Finally	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	did	_	VBD	VBD	_	0	ROOT-S	_	_
5	not	_	RB	RB	_	4	VMOD	_	_
6	observed	_	VBN	VBN	_	4	VC	_	_
7	either	_	CC	CC	_	8	CC	_	_
8	up-regulation	_	NN	NN	_	6	OBJ	_	_
9	or	_	CC	CC	_	8	CC	_	_
10	antagonism	_	NN	NN	_	8	COORD	_	_
11	of	_	IN	IN	_	8	NMOD	_	_
12	GcR	_	NN	NN	_	11	PMOD	_	_
13	by	_	IN	IN	_	8	NMOD	_	_
14	ketoconazole	_	NN	NN	_	15	NMOD	_	_
15	treatment	_	NN	NN	_	13	PMOD	_	_
16	,	_	,	,	_	6	P	_	_
17	at	_	IN	IN	_	6	TMP	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	time	_	NN	NN	_	17	PMOD	_	_
20	that	_	IN	IN	_	30	ADV	_	_
21	cortisol	_	NN	NN	_	22	NMOD	_	_
22	levels	_	NNS	NNS	_	29	SBJ	_	_
23	of	_	IN	IN	_	22	NMOD	_	_
24	patients	_	NNS	NNS	_	23	PMOD	_	_
25	with	_	IN	IN	_	24	NMOD	_	_
26	Cushing	_	NN	NN	_	28	NMOD	_	_
27	's	_	POS	POS	_	26	NMOD	_	_
28	disease	_	NN	NN	_	25	PMOD	_	_
29	were	_	VBD	VBD	_	19	NMOD	_	_
30	reduced	_	VBN	VBN	_	29	VC	_	_
31	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	indicates	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	beneficial	_	JJ	JJ	_	6	NMOD	_	_
6	effects	_	NNS	NNS	_	13	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	ketoconazole	_	NN	NN	_	7	PMOD	_	_
9	in	_	IN	IN	_	6	NMOD	_	_
10	Cushing	_	NN	NN	_	12	NMOD	_	_
11	's	_	POS	POS	_	10	NMOD	_	_
12	disease	_	NN	NN	_	9	PMOD	_	_
13	are	_	VBP	VBP	_	3	VMOD	_	_
14	due	_	JJ	JJ	_	13	PRD	_	_
15	to	_	TO	TO	_	14	PMOD	_	_
16	adrenal	_	JJ	JJ	_	18	NMOD	_	_
17	cortisol	_	NN	NN	_	18	NMOD	_	_
18	suppression	_	NN	NN	_	15	PMOD	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	not	_	RB	RB	_	21	DEP	_	_
21	to	_	TO	TO	_	15	COORD	_	_
22	interaction	_	NN	NN	_	21	PMOD	_	_
23	with	_	IN	IN	_	22	NMOD	_	_
24	GcR	_	NN	NN	_	23	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	target	_	NN	NN	_	27	NMOD	_	_
27	cells	_	NNS	NNS	_	25	PMOD	_	_
28	,	_	,	,	_	3	P	_	_
29	and	_	CC	CC	_	3	CC	_	_
30	that	_	IN	IN	_	3	COORD	_	_
31	the	_	DT	DT	_	32	NMOD	_	_
32	process	_	NN	NN	_	38	SBJ	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	GcR	_	NN	NN	_	35	NMOD	_	_
35	regulation	_	NN	NN	_	33	PMOD	_	_
36	in	_	IN	IN	_	32	NMOD	_	_
37	hMNL	_	NN	NN	_	36	PMOD	_	_
38	is	_	VBZ	VBZ	_	30	VMOD	_	_
39	a	_	DT	DT	_	41	NMOD	_	_
40	complex	_	JJ	JJ	_	41	NMOD	_	_
41	phenomenon	_	NN	NN	_	38	PRD	_	_
42	awaiting	_	VBG	VBG	_	41	NMOD	_	_
43	further	_	RBR	RBR	_	44	NMOD	_	_
44	elucidation	_	NN	NN	_	42	OBJ	_	_
45	.	_	.	.	_	2	P	_	_

1	Glucocorticoid	_	NN	NN	_	2	NMOD	_	_
2	receptors	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	lymphocytes	_	NNS	NNS	_	3	PMOD	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	anorexia	_	NN	NN	_	7	NMOD	_	_
7	nervosa	_	NN	NN	_	5	PMOD	_	_
8	.	_	.	.	_	2	P	_	_

1	OBJECTIVE	_	NN	NN	_	0	ROOT-FRAG	_	_
2	:	_	:	:	_	1	P	_	_
3	The	_	DT	DT	_	4	NMOD	_	_
4	aim	_	NN	NN	_	5	SBJ	_	_
5	was	_	VBD	VBD	_	1	NMOD	_	_
6	to	_	TO	TO	_	7	VMOD	_	_
7	explore	_	VB	VB	_	5	PRD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	down-regulation	_	NN	NN	_	7	OBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	glucocorticoid	_	NN	NN	_	13	NMOD	_	_
13	receptors	_	NNS	NNS	_	10	PMOD	_	_
14	during	_	IN	IN	_	9	TMP	_	_
15	hypercortisolaemia	_	NN	NN	_	14	PMOD	_	_
16	in	_	IN	IN	_	9	NMOD	_	_
17	anorexia	_	NN	NN	_	18	NMOD	_	_
18	nervosa	_	NN	NN	_	16	PMOD	_	_
19	.	_	.	.	_	5	P	_	_

1	DESIGN	_	NN	NN	_	0	ROOT-FRAG	_	_
2	:	_	:	:	_	1	P	_	_
3	Urine	_	NN	NN	_	6	NMOD	_	_
4	and	_	CC	CC	_	3	CC	_	_
5	plasma	_	NN	NN	_	3	COORD	_	_
6	samples	_	NNS	NNS	_	7	SBJ	_	_
7	were	_	VBD	VBD	_	1	NMOD	_	_
8	obtained	_	VBN	VBN	_	7	VC	_	_
9	for	_	IN	IN	_	8	ADV	_	_
10	cortisol	_	NN	NN	_	11	NMOD	_	_
11	determination	_	NN	NN	_	9	PMOD	_	_
12	and	_	CC	CC	_	7	CC	_	_
13	blood	_	NN	NN	_	14	NMOD	_	_
14	lymphocytes	_	NNS	NNS	_	15	SBJ	_	_
15	were	_	VBD	VBD	_	7	COORD	_	_
16	isolated	_	VBN	VBN	_	15	VC	_	_
17	for	_	IN	IN	_	16	ADV	_	_
18	receptor	_	NN	NN	_	20	NMOD	_	_
19	binding	_	NN	NN	_	20	NMOD	_	_
20	studies	_	NNS	NNS	_	17	PMOD	_	_
21	.	_	.	.	_	7	P	_	_

1	PATIENTS	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	:	_	:	:	_	1	P	_	_
3	Sixteen	_	CD	CD	_	5	NMOD	_	_
4	anorexic	_	JJ	JJ	_	5	NMOD	_	_
5	patients	_	NNS	NNS	_	35	SBJ	_	_
6	,	_	,	,	_	5	P	_	_
7	aged	_	JJ	JJ	_	5	NMOD	_	_
8	16-27	_	CD	CD	_	9	NMOD	_	_
9	years	_	NNS	NNS	_	7	AMOD	_	_
10	,	_	,	,	_	5	P	_	_
11	with	_	IN	IN	_	5	NMOD	_	_
12	a	_	DT	DT	_	18	NMOD	_	_
13	mean	_	NN	NN	_	18	NMOD	_	_
14	+\/-	_	CC	CC	_	13	CC	_	_
15	SEM	_	NN	NN	_	13	COORD	_	_
16	body	_	NN	NN	_	18	NMOD	_	_
17	mass	_	NN	NN	_	18	NMOD	_	_
18	index	_	NN	NN	_	11	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	14.2	_	CD	CD	_	19	PMOD	_	_
21	+\/-	_	CC	CC	_	20	CC	_	_
22	2.0	_	CD	CD	_	20	COORD	_	_
23	(	_	(	(	_	18	P	_	_
24	ranging	_	VBG	VBG	_	18	NMOD	_	_
25	from	_	IN	IN	_	24	ADV	_	_
26	11.1	_	CD	CD	_	25	PMOD	_	_
27	to	_	TO	TO	_	25	PMOD	_	_
28	17.4	_	CD	CD	_	27	PMOD	_	_
29	)	_	)	)	_	18	P	_	_
30	,	_	,	,	_	5	P	_	_
31	and	_	CC	CC	_	5	CC	_	_
32	15	_	CD	CD	_	34	NMOD	_	_
33	normal	_	JJ	JJ	_	34	NMOD	_	_
34	women	_	NNS	NNS	_	5	COORD	_	_
35	were	_	VBD	VBD	_	1	NMOD	_	_
36	studied	_	VBN	VBN	_	35	VC	_	_
37	.	_	.	.	_	35	P	_	_

1	Six	_	CD	CD	_	2	NMOD	_	_
2	patients	_	NNS	NNS	_	3	SBJ	_	_
3	were	_	VBD	VBD	_	0	ROOT-S	_	_
4	reinvestigated	_	VBN	VBN	_	3	VC	_	_
5	after	_	IN	IN	_	4	TMP	_	_
6	a	_	DT	DT	_	9	NMOD	_	_
7	significant	_	JJ	JJ	_	9	NMOD	_	_
8	weight	_	NN	NN	_	9	NMOD	_	_
9	gain	_	NN	NN	_	5	PMOD	_	_
10	.	_	.	.	_	3	P	_	_

1	MEASUREMENTS	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	:	_	:	:	_	1	P	_	_
3	The	_	DT	DT	_	4	NMOD	_	_
4	binding	_	NN	NN	_	12	SBJ	_	_
5	capacity	_	NN	NN	_	4	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	affinity	_	NN	NN	_	5	COORD	_	_
8	of	_	IN	IN	_	4	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	glucocorticoid	_	NN	NN	_	11	NMOD	_	_
11	receptors	_	NNS	NNS	_	8	PMOD	_	_
12	were	_	VBD	VBD	_	1	NMOD	_	_
13	measured	_	VBN	VBN	_	12	VC	_	_
14	with	_	IN	IN	_	13	ADV	_	_
15	dexamethasone	_	NN	NN	_	14	PMOD	_	_
16	as	_	IN	IN	_	15	NMOD	_	_
17	ligand	_	NN	NN	_	16	PMOD	_	_
18	on	_	IN	IN	_	17	NMOD	_	_
19	lymphocytes	_	NNS	NNS	_	18	PMOD	_	_
20	.	_	.	.	_	12	P	_	_

1	RESULTS	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	:	_	:	:	_	1	P	_	_
3	In	_	IN	IN	_	13	ADV	_	_
4	patients	_	NNS	NNS	_	3	PMOD	_	_
5	,	_	,	,	_	13	P	_	_
6	both	_	DT	DT	_	7	AMOD	_	_
7	total	_	JJ	JJ	_	12	NMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	free	_	JJ	JJ	_	7	COORD	_	_
10	plasma	_	NN	NN	_	12	NMOD	_	_
11	cortisol	_	NN	NN	_	12	NMOD	_	_
12	concentrations	_	NNS	NNS	_	13	SBJ	_	_
13	were	_	VBD	VBD	_	1	NMOD	_	_
14	higher	_	JJR	JJR	_	13	PRD	_	_
15	than	_	IN	IN	_	14	AMOD	_	_
16	in	_	IN	IN	_	15	PMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	normal	_	JJ	JJ	_	19	NMOD	_	_
19	women	_	NNS	NNS	_	16	PMOD	_	_
20	,	_	,	,	_	13	P	_	_
21	as	_	IN	IN	_	13	ADV	_	_
22	was	_	VBD	VBD	_	21	VMOD	_	_
23	their	_	PRP$	PRP$	_	26	NMOD	_	_
24	urinary	_	JJ	JJ	_	26	NMOD	_	_
25	free	_	JJ	JJ	_	26	NMOD	_	_
26	cortisol	_	NN	NN	_	22	SBJ	_	_
27	;	_	:	:	_	13	P	_	_
28	the	_	DT	DT	_	29	NMOD	_	_
29	number	_	NN	NN	_	47	SBJ	_	_
30	of	_	IN	IN	_	29	NMOD	_	_
31	glucocorticoid	_	NN	NN	_	32	NMOD	_	_
32	receptors	_	NNS	NNS	_	30	PMOD	_	_
33	per	_	IN	IN	_	32	NMOD	_	_
34	cell	_	NN	NN	_	33	PMOD	_	_
35	(	_	(	(	_	36	P	_	_
36	Ro	_	NN	NN	_	32	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	and	_	CC	CC	_	29	CC	_	_
39	the	_	DT	DT	_	41	NMOD	_	_
40	binding	_	NN	NN	_	41	NMOD	_	_
41	affinity	_	NN	NN	_	29	COORD	_	_
42	(	_	(	(	_	43	P	_	_
43	Kd	_	NN	NN	_	41	PRN	_	_
44	)	_	)	)	_	43	P	_	_
45	for	_	IN	IN	_	41	NMOD	_	_
46	dexamethasone	_	NN	NN	_	45	PMOD	_	_
47	were	_	VBD	VBD	_	1	NMOD	_	_
48	,	_	,	,	_	47	P	_	_
49	however	_	RB	RB	_	47	ADV	_	_
50	,	_	,	,	_	47	P	_	_
51	not	_	RB	RB	_	47	PRD	_	_
52	significantly	_	RB	RB	_	51	AMOD	_	_
53	different	_	JJ	JJ	_	51	AMOD	_	_
54	(	_	(	(	_	55	P	_	_
55	Ro	_	NN	NN	_	51	PRN	_	_
56	:	_	:	:	_	55	P	_	_
57	7687	_	CD	CD	_	64	NMOD	_	_
58	+\/-	_	CC	CC	_	57	CC	_	_
59	1750	_	CD	CD	_	57	COORD	_	_
60	vs	_	CC	CC	_	57	CC	_	_
61	7347	_	CD	CD	_	57	COORD	_	_
62	+\/-	_	CC	CC	_	57	CC	_	_
63	1285	_	CD	CD	_	57	COORD	_	_
64	sites\/cell	_	NN	NN	_	55	NMOD	_	_
65	;	_	:	:	_	55	P	_	_
66	Kd	_	NN	NN	_	55	NMOD	_	_
67	:	_	:	:	_	66	P	_	_
68	7.7	_	CD	CD	_	75	NMOD	_	_
69	+\/-	_	CC	CC	_	68	CC	_	_
70	2.4	_	CD	CD	_	68	COORD	_	_
71	vs	_	CC	CC	_	68	CC	_	_
72	7.4	_	CD	CD	_	68	COORD	_	_
73	+\/-	_	CC	CC	_	68	CC	_	_
74	1.7	_	CD	CD	_	68	COORD	_	_
75	nM	_	NN	NN	_	66	NMOD	_	_
76	at	_	IN	IN	_	75	NMOD	_	_
77	24	_	CD	CD	_	79	NMOD	_	_
78	degrees	_	NNS	NNS	_	79	NMOD	_	_
79	C	_	NN	NN	_	76	PMOD	_	_
80	)	_	)	)	_	55	P	_	_
81	.	_	.	.	_	47	P	_	_

1	After	_	IN	IN	_	17	TMP	_	_
2	weight	_	NN	NN	_	3	NMOD	_	_
3	gain	_	NN	NN	_	1	PMOD	_	_
4	(	_	(	(	_	12	P	_	_
5	14	_	CD	CD	_	12	NMOD	_	_
6	+\/-	_	CC	CC	_	5	CC	_	_
7	2	_	CD	CD	_	5	COORD	_	_
8	to	_	TO	TO	_	5	COORD	_	_
9	16	_	CD	CD	_	5	COORD	_	_
10	+\/-	_	CC	CC	_	5	CC	_	_
11	2	_	CD	CD	_	5	COORD	_	_
12	kg\/m2	_	NN	NN	_	3	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	,	_	,	,	_	17	P	_	_
15	receptor	_	NN	NN	_	16	NMOD	_	_
16	numbers	_	NNS	NNS	_	17	SBJ	_	_
17	were	_	VBD	VBD	_	0	ROOT-S	_	_
18	8421	_	CD	CD	_	31	NMOD	_	_
19	+\/-	_	CC	CC	_	18	CC	_	_
20	2126	_	CD	CD	_	18	COORD	_	_
21	(	_	(	(	_	31	PRN	_	_
22	pre	_	JJ	JJ	_	21	DEP	_	_
23	)	_	)	)	_	21	P	_	_
24	and	_	CC	CC	_	31	CC	_	_
25	9011	_	CD	CD	_	31	NMOD	_	_
26	+\/-	_	CC	CC	_	25	CC	_	_
27	500	_	CD	CD	_	25	COORD	_	_
28	(	_	(	(	_	31	PRN	_	_
29	post	_	JJ	JJ	_	28	DEP	_	_
30	)	_	)	)	_	28	P	_	_
31	sites\/cell	_	NN	NN	_	17	PRD	_	_
32	,	_	,	,	_	31	P	_	_
33	which	_	WDT	WDT	_	34	SBJ	_	_
34	are	_	VBP	VBP	_	31	NMOD	_	_
35	not	_	RB	RB	_	34	VMOD	_	_
36	significantly	_	RB	RB	_	37	AMOD	_	_
37	different	_	JJ	JJ	_	34	PRD	_	_
38	(	_	(	(	_	40	P	_	_
39	P	_	NN	NN	_	40	SBJ	_	_
40	greater	_	JJR	JJR	_	37	PRN	_	_
41	than	_	IN	IN	_	40	AMOD	_	_
42	0.2	_	CD	CD	_	41	PMOD	_	_
43	)	_	)	)	_	40	P	_	_
44	;	_	:	:	_	17	P	_	_
45	the	_	DT	DT	_	46	NMOD	_	_
46	Kd	_	NN	NN	_	47	SBJ	_	_
47	was	_	VBD	VBD	_	17	VC	_	_
48	unchanged	_	JJ	JJ	_	47	PRD	_	_
49	(	_	(	(	_	57	P	_	_
50	9.3	_	CD	CD	_	57	NMOD	_	_
51	+\/-	_	CC	CC	_	50	CC	_	_
52	2.6	_	CD	CD	_	50	COORD	_	_
53	vs	_	CC	CC	_	50	CC	_	_
54	9.2	_	CD	CD	_	50	COORD	_	_
55	+\/-	_	CC	CC	_	50	CC	_	_
56	2.4	_	CD	CD	_	50	COORD	_	_
57	nM	_	NN	NN	_	48	PRN	_	_
58	)	_	)	)	_	57	P	_	_
59	.	_	.	.	_	47	P	_	_

1	CONCLUSIONS	_	NNS	NNS	_	0	ROOT-FRAG	_	_
2	Hypercortisolaemia	_	NN	NN	_	3	SBJ	_	_
3	does	_	VBZ	VBZ	_	1	NMOD	_	_
4	not	_	RB	RB	_	3	VMOD	_	_
5	down-regulate	_	VB	VB	_	3	VC	_	_
6	the	_	DT	DT	_	9	NMOD	_	_
7	lymphocyte	_	NN	NN	_	9	NMOD	_	_
8	glucocorticoid	_	NN	NN	_	9	NMOD	_	_
9	receptors	_	NNS	NNS	_	5	OBJ	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	anorexia	_	NN	NN	_	12	NMOD	_	_
12	nervosa	_	NN	NN	_	10	PMOD	_	_
13	and	_	CC	CC	_	3	CC	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	post-receptor	_	JJ	JJ	_	16	NMOD	_	_
16	defect	_	NN	NN	_	17	SBJ	_	_
17	might	_	MD	MD	_	3	COORD	_	_
18	be	_	VB	VB	_	17	VC	_	_
19	involved	_	VBN	VBN	_	18	VC	_	_
20	in	_	IN	IN	_	19	ADV	_	_
21	peripheral	_	JJ	JJ	_	23	NMOD	_	_
22	tissue	_	NN	NN	_	23	NMOD	_	_
23	resistance	_	NN	NN	_	20	PMOD	_	_
24	to	_	TO	TO	_	23	NMOD	_	_
25	the	_	DT	DT	_	26	NMOD	_	_
26	effects	_	NNS	NNS	_	24	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	glucocorticoid	_	NN	NN	_	29	NMOD	_	_
29	hormones	_	NNS	NNS	_	27	PMOD	_	_
30	in	_	IN	IN	_	29	NMOD	_	_
31	undernutrition	_	NN	NN	_	30	PMOD	_	_
32	.	_	.	.	_	3	P	_	_

1	USF-related	_	JJ	JJ	_	3	NMOD	_	_
2	transcription	_	NN	NN	_	3	NMOD	_	_
3	factor	_	NN	NN	_	7	SBJ	_	_
4	,	_	,	,	_	3	P	_	_
5	HIV-TF1	_	NN	NN	_	3	NMOD	_	_
6	,	_	,	,	_	3	P	_	_
7	stimulates	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	transcription	_	NN	NN	_	7	OBJ	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	human	_	JJ	JJ	_	12	NMOD	_	_
11	immunodeficiency	_	NN	NN	_	12	NMOD	_	_
12	virus-1	_	NN	NN	_	9	PMOD	_	_
13	.	_	.	.	_	7	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	transcription	_	NN	NN	_	4	NMOD	_	_
3	factor	_	NN	NN	_	4	NMOD	_	_
4	HIV-TF1	_	NN	NN	_	27	SBJ	_	_
5	,	_	,	,	_	4	P	_	_
6	which	_	WDT	WDT	_	7	SBJ	_	_
7	binds	_	VBZ	VBZ	_	4	NMOD	_	_
8	to	_	TO	TO	_	7	ADV	_	_
9	a	_	DT	DT	_	10	NMOD	_	_
10	region	_	NN	NN	_	8	PMOD	_	_
11	about	_	IN	IN	_	12	DEP	_	_
12	60	_	CD	CD	_	13	NMOD	_	_
13	bp	_	NN	NN	_	14	AMOD	_	_
14	upstream	_	JJ	JJ	_	10	NMOD	_	_
15	from	_	IN	IN	_	14	AMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	enhancer	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	the	_	DT	DT	_	22	NMOD	_	_
20	human	_	JJ	JJ	_	22	NMOD	_	_
21	immunodeficiency	_	NN	NN	_	22	NMOD	_	_
22	virus-1	_	NN	NN	_	18	PMOD	_	_
23	(	_	(	(	_	24	P	_	_
24	HIV-1	_	NN	NN	_	22	PRN	_	_
25	)	_	)	)	_	24	P	_	_
26	,	_	,	,	_	4	P	_	_
27	was	_	VBD	VBD	_	0	ROOT-S	_	_
28	purified	_	VBN	VBN	_	27	VC	_	_
29	from	_	IN	IN	_	28	ADV	_	_
30	human	_	JJ	JJ	_	32	NMOD	_	_
31	B	_	NN	NN	_	32	NMOD	_	_
32	cells	_	NNS	NNS	_	29	PMOD	_	_
33	.	_	.	.	_	27	P	_	_

1	HIV-TF1	_	NN	NN	_	2	SBJ	_	_
2	had	_	VBD	VBD	_	0	ROOT-S	_	_
3	a	_	DT	DT	_	5	NMOD	_	_
4	molecular	_	JJ	JJ	_	5	NMOD	_	_
5	weight	_	NN	NN	_	2	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	39,000	_	CD	CD	_	6	PMOD	_	_
8	.	_	.	.	_	2	P	_	_

1	Binding	_	NN	NN	_	13	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	HIV-TF1	_	NN	NN	_	2	PMOD	_	_
4	to	_	TO	TO	_	1	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	HIV	_	NN	NN	_	4	PMOD	_	_
7	long	_	JJ	JJ	_	9	NMOD	_	_
8	terminal	_	JJ	JJ	_	9	NMOD	_	_
9	repeat	_	NN	NN	_	6	NMOD	_	_
10	(	_	(	(	_	11	P	_	_
11	LTR	_	NN	NN	_	9	PRN	_	_
12	)	_	)	)	_	11	P	_	_
13	activated	_	VBD	VBD	_	0	ROOT-S	_	_
14	transcription	_	NN	NN	_	13	OBJ	_	_
15	from	_	IN	IN	_	14	NMOD	_	_
16	the	_	DT	DT	_	18	NMOD	_	_
17	HIV	_	NN	NN	_	18	NMOD	_	_
18	promoter	_	NN	NN	_	15	PMOD	_	_
19	in	_	FW	FW	_	13	ADV	_	_
20	vitro	_	FW	FW	_	19	AMOD	_	_
21	.	_	.	.	_	13	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	HIV-TF1-binding	_	JJ	JJ	_	3	NMOD	_	_
3	site	_	NN	NN	_	7	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	HIV	_	NN	NN	_	6	NMOD	_	_
6	LTR	_	NN	NN	_	4	PMOD	_	_
7	was	_	VBD	VBD	_	0	ROOT-S	_	_
8	similar	_	JJ	JJ	_	7	PRD	_	_
9	to	_	TO	TO	_	8	AMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	site	_	NN	NN	_	9	PMOD	_	_
12	recognized	_	VBN	VBN	_	11	NMOD	_	_
13	by	_	IN	IN	_	12	ADV	_	_
14	upstream	_	JJ	JJ	_	16	NMOD	_	_
15	stimulatory	_	JJ	JJ	_	16	NMOD	_	_
16	factor	_	NN	NN	_	13	PMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	USF	_	NN	NN	_	16	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	in	_	IN	IN	_	16	NMOD	_	_
21	the	_	DT	DT	_	25	NMOD	_	_
22	adenovirus	_	NN	NN	_	25	NMOD	_	_
23	major	_	JJ	JJ	_	25	NMOD	_	_
24	late	_	JJ	JJ	_	25	NMOD	_	_
25	promoter	_	NN	NN	_	20	PMOD	_	_
26	.	_	.	.	_	7	P	_	_

1	DNA-binding	_	JJ	JJ	_	2	NMOD	_	_
2	properties	_	NNS	NNS	_	5	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	HIV-TF1	_	NN	NN	_	3	PMOD	_	_
5	suggested	_	VBD	VBD	_	0	ROOT-S	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	HIV-TF1	_	NN	NN	_	8	SBJ	_	_
8	might	_	MD	MD	_	6	VMOD	_	_
9	be	_	VB	VB	_	8	VC	_	_
10	identical	_	JJ	JJ	_	9	PRD	_	_
11	or	_	CC	CC	_	10	CC	_	_
12	related	_	JJ	JJ	_	10	COORD	_	_
13	to	_	TO	TO	_	10	AMOD	_	_
14	USF	_	NN	NN	_	13	PMOD	_	_
15	.	_	.	.	_	5	P	_	_

1	Interestingly	_	RB	RB	_	10	ADV	_	_
2	,	_	,	,	_	10	P	_	_
3	treatment	_	NN	NN	_	10	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	purified	_	VBN	VBN	_	6	NMOD	_	_
6	HIV-TF1	_	NN	NN	_	4	PMOD	_	_
7	by	_	IN	IN	_	3	NMOD	_	_
8	phosphatase	_	NN	NN	_	7	PMOD	_	_
9	greatly	_	RB	RB	_	10	ADV	_	_
10	reduced	_	VBD	VBD	_	0	ROOT-S	_	_
11	its	_	PRP$	PRP$	_	13	NMOD	_	_
12	DNA-binding	_	JJ	JJ	_	13	NMOD	_	_
13	activity	_	NN	NN	_	10	IOBJ	_	_
14	,	_	,	,	_	10	P	_	_
15	suggesting	_	VBG	VBG	_	10	OBJ	_	_
16	that	_	IN	IN	_	15	OBJ	_	_
17	phosphorylation	_	NN	NN	_	20	SBJ	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	HIV-TF1	_	NN	NN	_	18	PMOD	_	_
20	was	_	VBD	VBD	_	16	VMOD	_	_
21	essential	_	JJ	JJ	_	20	PRD	_	_
22	for	_	IN	IN	_	21	AMOD	_	_
23	DNA	_	NN	NN	_	24	NMOD	_	_
24	binding	_	NN	NN	_	22	PMOD	_	_
25	.	_	.	.	_	10	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	disruption	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	HIV-TF1-binding	_	JJ	JJ	_	5	NMOD	_	_
5	site	_	NN	NN	_	3	PMOD	_	_
6	induced	_	VBD	VBD	_	0	ROOT-S	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	60	_	CD	CD	_	9	NMOD	_	_
9	%	_	NN	NN	_	6	OBJ	_	_
10	decrease	_	NN	NN	_	9	NMOD	_	_
11	in	_	IN	IN	_	9	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	level	_	NN	NN	_	11	PMOD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	transcription	_	NN	NN	_	14	PMOD	_	_
16	from	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	19	NMOD	_	_
18	HIV	_	NN	NN	_	19	NMOD	_	_
19	promoter	_	NN	NN	_	16	PMOD	_	_
20	in	_	FW	FW	_	6	ADV	_	_
21	vivo	_	FW	FW	_	20	AMOD	_	_
22	.	_	.	.	_	6	P	_	_

1	These	_	DT	DT	_	2	NMOD	_	_
2	results	_	NNS	NNS	_	3	SBJ	_	_
3	suggest	_	VBP	VBP	_	0	ROOT-S	_	_
4	that	_	IN	IN	_	3	OBJ	_	_
5	HIV-TF1	_	NN	NN	_	6	SBJ	_	_
6	is	_	VBZ	VBZ	_	4	VMOD	_	_
7	involved	_	VBN	VBN	_	6	VC	_	_
8	in	_	IN	IN	_	7	ADV	_	_
9	transcriptional	_	JJ	JJ	_	10	NMOD	_	_
10	regulation	_	NN	NN	_	8	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	HIV-1	_	NN	NN	_	11	PMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	effect	_	NN	NN	_	0	ROOT-FRAG	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	toremifene	_	NN	NN	_	5	NMOD	_	_
5	therapy	_	NN	NN	_	3	PMOD	_	_
6	on	_	IN	IN	_	2	NMOD	_	_
7	serum	_	NN	NN	_	9	NMOD	_	_
8	immunoglobulin	_	NN	NN	_	9	NMOD	_	_
9	levels	_	NNS	NNS	_	6	PMOD	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	breast	_	NN	NN	_	12	NMOD	_	_
12	cancer	_	NN	NN	_	10	PMOD	_	_
13	.	_	.	.	_	2	P	_	_

1	Estrogens	_	NNS	NNS	_	4	SBJ	_	_
2	and	_	CC	CC	_	1	CC	_	_
3	anti-estrogens	_	NNS	NNS	_	1	COORD	_	_
4	enhance	_	VBP	VBP	_	0	ROOT-S	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	number	_	NN	NN	_	4	OBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	immunoglobulin	_	NN	NN	_	12	AMOD	_	_
9	(	_	(	(	_	12	P	_	_
10	Ig	_	NN	NN	_	12	AMOD	_	_
11	)	_	)	)	_	12	P	_	_
12	-secreting	_	NN	NN	_	13	NMOD	_	_
13	cells	_	NNS	NNS	_	7	PMOD	_	_
14	in	_	IN	IN	_	4	ADV	_	_
15	pokeweed	_	NN	NN	_	18	AMOD	_	_
16	mitogen	_	NN	NN	_	18	AMOD	_	_
17	(	_	(	(	_	18	P	_	_
18	PWM	_	NN	NN	_	22	NMOD	_	_
19	)	_	)	)	_	18	P	_	_
20	-stimulated	_	JJ	JJ	_	18	AMOD	_	_
21	lymphocyte	_	NN	NN	_	22	NMOD	_	_
22	cultures	_	NNS	NNS	_	14	PMOD	_	_
23	.	_	.	.	_	4	P	_	_

1	Lymphocytes	_	NNS	NNS	_	9	SBJ	_	_
2	from	_	IN	IN	_	1	NMOD	_	_
3	patients	_	NNS	NNS	_	2	PMOD	_	_
4	who	_	WP	WP	_	5	SBJ	_	_
5	have	_	VBP	VBP	_	3	NMOD	_	_
6	received	_	VBN	VBN	_	5	VC	_	_
7	anti-estrogen	_	NN	NN	_	8	NMOD	_	_
8	therapy	_	NN	NN	_	6	OBJ	_	_
9	show	_	VBP	VBP	_	0	ROOT-S	_	_
10	similar	_	JJ	JJ	_	11	NMOD	_	_
11	enhancement	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	Ig-secreting	_	JJ	JJ	_	14	NMOD	_	_
14	cells	_	NNS	NNS	_	12	PMOD	_	_
15	after	_	IN	IN	_	9	TMP	_	_
16	PWM	_	NN	NN	_	17	NMOD	_	_
17	stimulation	_	NN	NN	_	15	PMOD	_	_
18	.	_	.	.	_	9	P	_	_

1	In	_	IN	IN	_	27	ADV	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	study	_	NN	NN	_	1	PMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	effect	_	NN	NN	_	27	SBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	anti-estrogen	_	NN	NN	_	11	NMOD	_	_
8	(	_	(	(	_	11	P	_	_
9	toremifene	_	NN	NN	_	11	NMOD	_	_
10	)	_	)	)	_	11	P	_	_
11	therapy	_	NN	NN	_	6	PMOD	_	_
12	on	_	IN	IN	_	5	NMOD	_	_
13	serum	_	NN	NN	_	14	NMOD	_	_
14	immunoglobulin	_	NN	NN	_	22	NMOD	_	_
15	(	_	(	(	_	16	P	_	_
16	IgA	_	NN	NN	_	14	PRN	_	_
17	,	_	,	,	_	16	P	_	_
18	IgM	_	NN	NN	_	16	NMOD	_	_
19	,	_	,	,	_	16	P	_	_
20	IgG	_	NN	NN	_	16	NMOD	_	_
21	)	_	)	)	_	16	P	_	_
22	levels	_	NNS	NNS	_	12	PMOD	_	_
23	in	_	IN	IN	_	22	NMOD	_	_
24	breast	_	NN	NN	_	26	NMOD	_	_
25	cancer	_	NN	NN	_	26	NMOD	_	_
26	patients	_	NNS	NNS	_	23	PMOD	_	_
27	was	_	VBD	VBD	_	0	ROOT-S	_	_
28	investigated	_	VBN	VBN	_	27	VC	_	_
29	.	_	.	.	_	27	P	_	_

1	Serum	_	NN	NN	_	3	NMOD	_	_
2	Ig	_	NN	NN	_	3	NMOD	_	_
3	levels	_	NNS	NNS	_	4	SBJ	_	_
4	were	_	VBD	VBD	_	0	ROOT-S	_	_
5	followed	_	VBN	VBN	_	4	VC	_	_
6	up	_	RB	RB	_	9	NMOD	_	_
7	to	_	TO	TO	_	6	DEP	_	_
8	two	_	CD	CD	_	6	DEP	_	_
9	years	_	NNS	NNS	_	5	TMP	_	_
10	after	_	IN	IN	_	5	TMP	_	_
11	or	_	CC	CC	_	10	CC	_	_
12	during	_	IN	IN	_	10	COORD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	therapy	_	NN	NN	_	10	PMOD	_	_
15	.	_	.	.	_	4	P	_	_

1	An	_	DT	DT	_	3	NMOD	_	_
2	unexpected	_	JJ	JJ	_	3	NMOD	_	_
3	finding	_	NN	NN	_	4	SBJ	_	_
4	was	_	VBD	VBD	_	0	ROOT-S	_	_
5	that	_	IN	IN	_	4	PRD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	Ig	_	NN	NN	_	8	NMOD	_	_
8	levels	_	NNS	NNS	_	9	SBJ	_	_
9	decreased	_	VBD	VBD	_	5	VMOD	_	_
10	during	_	IN	IN	_	9	TMP	_	_
11	the	_	DT	DT	_	13	NMOD	_	_
12	follow-up	_	JJ	JJ	_	13	NMOD	_	_
13	period	_	NN	NN	_	10	PMOD	_	_
14	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	decrease	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	seen	_	VBN	VBN	_	3	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	patients	_	NNS	NNS	_	5	PMOD	_	_
7	who	_	WP	WP	_	8	SBJ	_	_
8	responded	_	VBD	VBD	_	6	NMOD	_	_
9	to	_	TO	TO	_	8	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	therapy	_	NN	NN	_	9	PMOD	_	_
12	as	_	RB	RB	_	5	CC	_	_
13	well	_	RB	RB	_	12	DEP	_	_
14	as	_	IN	IN	_	12	DEP	_	_
15	in	_	IN	IN	_	5	COORD	_	_
16	those	_	DT	DT	_	15	PMOD	_	_
17	who	_	WP	WP	_	18	SBJ	_	_
18	did	_	VBD	VBD	_	16	NMOD	_	_
19	not	_	RB	RB	_	18	VMOD	_	_
20	.	_	.	.	_	3	P	_	_

1	Induction	_	NN	NN	_	8	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	NF-kappa	_	NN	NN	_	4	NMOD	_	_
4	B	_	NN	NN	_	2	PMOD	_	_
5	during	_	IN	IN	_	1	TMP	_	_
6	monocyte	_	NN	NN	_	7	NMOD	_	_
7	differentiation	_	NN	NN	_	5	PMOD	_	_
8	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
9	associated	_	VBN	VBN	_	8	VC	_	_
10	with	_	IN	IN	_	9	ADV	_	_
11	activation	_	NN	NN	_	10	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	HIV-gene	_	JJ	JJ	_	14	NMOD	_	_
14	expression	_	NN	NN	_	12	PMOD	_	_
15	.	_	.	.	_	8	P	_	_

1	Cells	_	NNS	NNS	_	6	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	monocyte-macrophage	_	JJ	JJ	_	5	NMOD	_	_
5	lineage	_	NN	NN	_	2	PMOD	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	important	_	JJ	JJ	_	8	NMOD	_	_
8	targets	_	NNS	NNS	_	6	PRD	_	_
9	of	_	IN	IN	_	8	NMOD	_	_
10	HIV	_	NN	NN	_	11	NMOD	_	_
11	infection	_	NN	NN	_	9	PMOD	_	_
12	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	here	_	RB	RB	_	2	ADV	_	_
4	that	_	IN	IN	_	2	OBJ	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	phenotypic	_	JJ	JJ	_	7	NMOD	_	_
7	differentiation	_	NN	NN	_	25	SBJ	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	monocyte	_	NN	NN	_	11	NMOD	_	_
10	cell	_	NN	NN	_	11	NMOD	_	_
11	lines	_	NNS	NNS	_	8	PMOD	_	_
12	induced	_	VBN	VBN	_	7	NMOD	_	_
13	by	_	IN	IN	_	12	LGS	_	_
14	phorbol	_	NN	NN	_	15	NMOD	_	_
15	esters	_	NNS	NNS	_	13	PMOD	_	_
16	or	_	CC	CC	_	15	CC	_	_
17	tumour	_	NN	NN	_	20	NMOD	_	_
18	necrosis	_	NN	NN	_	20	NMOD	_	_
19	factor	_	NN	NN	_	20	NMOD	_	_
20	alpha	_	NN	NN	_	15	COORD	_	_
21	(	_	(	(	_	23	P	_	_
22	TNF	_	NN	NN	_	23	NMOD	_	_
23	alpha	_	NN	NN	_	20	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	is	_	VBZ	VBZ	_	4	VMOD	_	_
26	associated	_	VBN	VBN	_	25	VC	_	_
27	with	_	IN	IN	_	26	ADV	_	_
28	expression	_	NN	NN	_	27	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	nuclear	_	JJ	JJ	_	33	NMOD	_	_
31	factor	_	NN	NN	_	33	NMOD	_	_
32	kappa	_	NN	NN	_	33	NMOD	_	_
33	B	_	NN	NN	_	29	PMOD	_	_
34	(	_	(	(	_	36	P	_	_
35	NF-kappa	_	NN	NN	_	36	NMOD	_	_
36	B	_	NN	NN	_	33	PRN	_	_
37	)	_	)	)	_	36	P	_	_
38	.	_	.	.	_	2	P	_	_

1	In	_	IN	IN	_	21	ADV	_	_
2	parallel	_	NN	NN	_	1	DEP	_	_
3	with	_	IN	IN	_	1	DEP	_	_
4	such	_	JJ	JJ	_	5	NMOD	_	_
5	differentiation	_	NN	NN	_	1	PMOD	_	_
6	,	_	,	,	_	21	P	_	_
7	HIV	_	NN	NN	_	8	NMOD	_	_
8	transcription	_	NN	NN	_	21	SBJ	_	_
9	,	_	,	,	_	8	P	_	_
10	monitored	_	VBN	VBN	_	8	NMOD	_	_
11	using	_	VBG	VBG	_	10	OBJ	_	_
12	an	_	DT	DT	_	19	NMOD	_	_
13	HIV	_	NN	NN	_	19	NMOD	_	_
14	long	_	JJ	JJ	_	19	NMOD	_	_
15	terminal	_	JJ	JJ	_	19	NMOD	_	_
16	repeat	_	NN	NN	_	19	NMOD	_	_
17	reporter	_	NN	NN	_	19	NMOD	_	_
18	gene	_	NN	NN	_	19	NMOD	_	_
19	construct	_	NN	NN	_	11	OBJ	_	_
20	,	_	,	,	_	8	P	_	_
21	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
22	activated	_	VBN	VBN	_	21	VC	_	_
23	in	_	IN	IN	_	22	ADV	_	_
24	such	_	JJ	JJ	_	25	NMOD	_	_
25	cells	_	NNS	NNS	_	23	PMOD	_	_
26	under	_	IN	IN	_	22	ADV	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	influence	_	NN	NN	_	26	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	enhanced	_	VBN	VBN	_	33	NMOD	_	_
31	NF-kappa	_	NN	NN	_	33	NMOD	_	_
32	B	_	NN	NN	_	33	NMOD	_	_
33	expression	_	NN	NN	_	29	PMOD	_	_
34	.	_	.	.	_	21	P	_	_

1	Also	_	RB	RB	_	19	ADV	_	_
2	,	_	,	,	_	19	P	_	_
3	in	_	IN	IN	_	19	ADV	_	_
4	a	_	DT	DT	_	7	NMOD	_	_
5	promonocyte	_	JJ	JJ	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	line	_	NN	NN	_	3	PMOD	_	_
8	chronically	_	RB	RB	_	9	AMOD	_	_
9	infected	_	VBN	VBN	_	7	NMOD	_	_
10	with	_	IN	IN	_	9	AMOD	_	_
11	HIV	_	NN	NN	_	10	PMOD	_	_
12	,	_	,	,	_	19	P	_	_
13	NF-kappa	_	NN	NN	_	15	NMOD	_	_
14	B	_	NN	NN	_	15	NMOD	_	_
15	expression	_	NN	NN	_	19	SBJ	_	_
16	and	_	CC	CC	_	15	CC	_	_
17	HIV	_	NN	NN	_	18	NMOD	_	_
18	transcription	_	NN	NN	_	15	COORD	_	_
19	were	_	VBD	VBD	_	0	ROOT-S	_	_
20	enhanced	_	VBN	VBN	_	19	VC	_	_
21	on	_	IN	IN	_	20	TMP	_	_
22	stimulation	_	NN	NN	_	21	PMOD	_	_
23	with	_	IN	IN	_	22	NMOD	_	_
24	phorbol	_	NN	NN	_	25	NMOD	_	_
25	ester	_	NN	NN	_	23	PMOD	_	_
26	or	_	CC	CC	_	25	CC	_	_
27	TNF	_	NN	NN	_	28	NMOD	_	_
28	alpha	_	NN	NN	_	25	COORD	_	_
29	.	_	.	.	_	19	P	_	_

1	Thus	_	RB	RB	_	14	ADV	_	_
2	,	_	,	,	_	14	P	_	_
3	stimulation	_	NN	NN	_	14	SBJ	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	monocyte	_	NN	NN	_	7	NMOD	_	_
6	cell	_	NN	NN	_	7	NMOD	_	_
7	lines	_	NNS	NNS	_	4	PMOD	_	_
8	by	_	IN	IN	_	3	NMOD	_	_
9	phorbol	_	NN	NN	_	10	NMOD	_	_
10	esters	_	NNS	NNS	_	8	PMOD	_	_
11	or	_	CC	CC	_	10	CC	_	_
12	TNF	_	NN	NN	_	13	NMOD	_	_
13	alpha	_	NN	NN	_	10	COORD	_	_
14	induces	_	VBZ	VBZ	_	0	ROOT-S	_	_
15	cell	_	NN	NN	_	16	NMOD	_	_
16	differentiation	_	NN	NN	_	14	OBJ	_	_
17	and	_	CC	CC	_	14	CC	_	_
18	activates	_	VBZ	VBZ	_	14	COORD	_	_
19	HIV	_	NN	NN	_	20	NMOD	_	_
20	transcription	_	NN	NN	_	18	OBJ	_	_
21	.	_	.	.	_	14	P	_	_

1	Such	_	PDT	PDT	_	3	NMOD	_	_
2	a	_	DT	DT	_	3	NMOD	_	_
3	process	_	NN	NN	_	4	SBJ	_	_
4	may	_	MD	MD	_	0	ROOT-S	_	_
5	have	_	VB	VB	_	4	VC	_	_
6	fundamental	_	JJ	JJ	_	7	NMOD	_	_
7	implications	_	NNS	NNS	_	5	OBJ	_	_
8	in	_	IN	IN	_	5	ADV	_	_
9	AIDS	_	NN	NN	_	10	NMOD	_	_
10	pathogenesis	_	NN	NN	_	8	PMOD	_	_
11	in	_	FW	FW	_	5	ADV	_	_
12	vivo	_	FW	FW	_	11	AMOD	_	_
13	and	_	CC	CC	_	4	CC	_	_
14	may	_	MD	MD	_	4	COORD	_	_
15	be	_	VB	VB	_	14	VC	_	_
16	important	_	JJ	JJ	_	15	PRD	_	_
17	in	_	IN	IN	_	16	AMOD	_	_
18	disease	_	NN	NN	_	19	NMOD	_	_
19	progression	_	NN	NN	_	17	PMOD	_	_
20	induced	_	VBN	VBN	_	19	NMOD	_	_
21	by	_	IN	IN	_	20	LGS	_	_
22	opportunistic	_	JJ	JJ	_	23	NMOD	_	_
23	infections	_	NNS	NNS	_	21	PMOD	_	_
24	directly	_	RB	RB	_	27	ADV	_	_
25	or	_	CC	CC	_	24	CC	_	_
26	indirectly	_	RB	RB	_	24	COORD	_	_
27	involving	_	VBG	VBG	_	23	NMOD	_	_
28	macrophages	_	NNS	NNS	_	27	OBJ	_	_
29	.	_	.	.	_	4	P	_	_

1	A	_	DT	DT	_	4	NMOD	_	_
2	nuclear	_	JJ	JJ	_	4	NMOD	_	_
3	factor	_	NN	NN	_	4	NMOD	_	_
4	NF-GM2	_	NN	NN	_	0	ROOT-FRAG	_	_
5	that	_	WDT	WDT	_	6	SBJ	_	_
6	interacts	_	VBZ	VBZ	_	4	NMOD	_	_
7	with	_	IN	IN	_	6	ADV	_	_
8	a	_	DT	DT	_	10	NMOD	_	_
9	regulatory	_	JJ	JJ	_	10	NMOD	_	_
10	region	_	NN	NN	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	GM-CSF	_	NN	NN	_	14	NMOD	_	_
14	gene	_	NN	NN	_	11	PMOD	_	_
15	essential	_	JJ	JJ	_	14	NMOD	_	_
16	for	_	IN	IN	_	15	AMOD	_	_
17	its	_	PRP$	PRP$	_	18	NMOD	_	_
18	induction	_	NN	NN	_	16	PMOD	_	_
19	in	_	IN	IN	_	15	AMOD	_	_
20	responses	_	NNS	NNS	_	19	DEP	_	_
21	to	_	TO	TO	_	19	DEP	_	_
22	T-cell	_	NN	NN	_	23	NMOD	_	_
23	activation	_	NN	NN	_	19	PMOD	_	_
24	:	_	:	:	_	4	P	_	_
25	purification	_	NN	NN	_	4	NMOD	_	_
26	from	_	IN	IN	_	25	NMOD	_	_
27	human	_	JJ	JJ	_	32	NMOD	_	_
28	T-cell	_	NN	NN	_	32	NMOD	_	_
29	leukemia	_	NN	NN	_	32	NMOD	_	_
30	line	_	NN	NN	_	32	NMOD	_	_
31	Jurkat	_	NN	NN	_	32	NMOD	_	_
32	cells	_	NNS	NNS	_	26	PMOD	_	_
33	and	_	CC	CC	_	25	CC	_	_
34	similarity	_	NN	NN	_	25	COORD	_	_
35	to	_	TO	TO	_	34	NMOD	_	_
36	NF-kappa	_	NN	NN	_	37	NMOD	_	_
37	B	_	NN	NN	_	35	PMOD	_	_
38	.	_	.	.	_	25	P	_	_

1	Activation	_	NN	NN	_	25	SBJ	_	_
2	of	_	IN	IN	_	1	NMOD	_	_
3	T	_	NN	NN	_	4	NMOD	_	_
4	cells	_	NNS	NNS	_	2	PMOD	_	_
5	by	_	IN	IN	_	1	NMOD	_	_
6	antigen	_	NN	NN	_	5	PMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	lectin	_	NN	NN	_	6	COORD	_	_
9	,	_	,	,	_	6	P	_	_
10	or	_	CC	CC	_	6	CC	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	combination	_	NN	NN	_	6	COORD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	phorbol-12-myristate	_	NN	NN	_	15	NMOD	_	_
15	acetate	_	NN	NN	_	13	PMOD	_	_
16	(	_	(	(	_	17	P	_	_
17	PMA	_	NN	NN	_	15	PRN	_	_
18	)	_	)	)	_	17	P	_	_
19	and	_	CC	CC	_	15	CC	_	_
20	calcium	_	NN	NN	_	21	NMOD	_	_
21	ionophore	_	NN	NN	_	15	COORD	_	_
22	(	_	(	(	_	23	P	_	_
23	A23187	_	NN	NN	_	21	PRN	_	_
24	)	_	)	)	_	23	P	_	_
25	leads	_	VBZ	VBZ	_	0	ROOT-S	_	_
26	to	_	TO	TO	_	25	ADV	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	induction	_	NN	NN	_	26	PMOD	_	_
29	of	_	IN	IN	_	28	NMOD	_	_
30	genes	_	NNS	NNS	_	29	PMOD	_	_
31	for	_	IN	IN	_	30	NMOD	_	_
32	a	_	DT	DT	_	33	NMOD	_	_
33	set	_	NN	NN	_	31	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	lymphokines	_	NNS	NNS	_	34	PMOD	_	_
36	,	_	,	,	_	35	P	_	_
37	including	_	VBG	VBG	_	35	NMOD	_	_
38	granulocyte-macrophage	_	JJ	JJ	_	39	AMOD	_	_
39	colony-stimulating	_	JJ	JJ	_	40	NMOD	_	_
40	factor	_	NN	NN	_	37	PMOD	_	_
41	(	_	(	(	_	42	P	_	_
42	GM-CSF	_	NN	NN	_	40	PRN	_	_
43	)	_	)	)	_	42	P	_	_
44	.	_	.	.	_	25	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	demonstrated	_	VBD	VBD	_	0	ROOT-S	_	_
3	in	_	IN	IN	_	2	ADV	_	_
4	earlier	_	JJR	JJR	_	5	NMOD	_	_
5	studies	_	NNS	NNS	_	3	PMOD	_	_
6	that	_	IN	IN	_	2	OBJ	_	_
7	the	_	DT	DT	_	9	NMOD	_	_
8	upstream	_	JJ	JJ	_	9	NMOD	_	_
9	region	_	NN	NN	_	21	SBJ	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	the	_	DT	DT	_	14	NMOD	_	_
12	mouse	_	NN	NN	_	14	NMOD	_	_
13	GM-CSF	_	NN	NN	_	14	NMOD	_	_
14	promoter	_	NN	NN	_	10	PMOD	_	_
15	at	_	IN	IN	_	9	NMOD	_	_
16	positions	_	NNS	NNS	_	15	PMOD	_	_
17	between	_	IN	IN	_	16	NMOD	_	_
18	-95	_	CD	CD	_	17	PMOD	_	_
19	and	_	CC	CC	_	18	CC	_	_
20	-73	_	CD	CD	_	18	COORD	_	_
21	is	_	VBZ	VBZ	_	6	VMOD	_	_
22	essential	_	JJ	JJ	_	21	PRD	_	_
23	for	_	IN	IN	_	22	AMOD	_	_
24	transcriptional	_	JJ	JJ	_	25	NMOD	_	_
25	activation	_	NN	NN	_	23	PMOD	_	_
26	in	_	IN	IN	_	25	NMOD	_	_
27	response	_	NN	NN	_	26	DEP	_	_
28	to	_	TO	TO	_	26	DEP	_	_
29	PMA\/A23187	_	NN	NN	_	26	PMOD	_	_
30	.	_	.	.	_	2	P	_	_

1	This	_	DT	DT	_	2	NMOD	_	_
2	region	_	NN	NN	_	3	SBJ	_	_
3	contains	_	VBZ	VBZ	_	0	ROOT-S	_	_
4	two	_	CD	CD	_	6	NMOD	_	_
5	DNA-binding	_	JJ	JJ	_	6	NMOD	_	_
6	motifs	_	NNS	NNS	_	3	OBJ	_	_
7	,	_	,	,	_	6	P	_	_
8	GM2	_	NN	NN	_	6	NMOD	_	_
9	and	_	CC	CC	_	8	CC	_	_
10	GC-box	_	NN	NN	_	8	COORD	_	_
11	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	GM2	_	NN	NN	_	3	NMOD	_	_
3	sequence	_	NN	NN	_	7	SBJ	_	_
4	(	_	(	(	_	5	P	_	_
5	GGTAGTTCCC	_	NN	NN	_	3	PRN	_	_
6	)	_	)	)	_	5	P	_	_
7	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
8	recognized	_	VBN	VBN	_	7	VC	_	_
9	by	_	IN	IN	_	8	LGS	_	_
10	an	_	DT	DT	_	13	NMOD	_	_
11	inducible	_	JJ	JJ	_	13	NMOD	_	_
12	factor	_	NN	NN	_	13	NMOD	_	_
13	NF-GM2	_	NN	NN	_	9	PMOD	_	_
14	;	_	:	:	_	7	P	_	_
15	the	_	DT	DT	_	16	NMOD	_	_
16	other	_	JJ	JJ	_	3	GAP	_	_
17	(	_	(	(	_	18	P	_	_
18	CCGCCC	_	NN	NN	_	16	PRN	_	_
19	)	_	)	)	_	18	P	_	_
20	by	_	IN	IN	_	9	GAP	_	_
21	constitutive	_	JJ	JJ	_	22	NMOD	_	_
22	factors	_	NNS	NNS	_	20	PMOD	_	_
23	A1	_	NN	NN	_	22	NMOD	_	_
24	,	_	,	,	_	23	P	_	_
25	A2	_	NN	NN	_	23	COORD	_	_
26	,	_	,	,	_	23	P	_	_
27	and	_	CC	CC	_	23	CC	_	_
28	B	_	NN	NN	_	23	COORD	_	_
29	.	_	.	.	_	7	P	_	_

1	To	_	TO	TO	_	2	VMOD	_	_
2	elucidate	_	VB	VB	_	0	ROOT-S	_	_
3	the	_	DT	DT	_	4	NMOD	_	_
4	mechanism	_	NN	NN	_	2	OBJ	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	GM-CSF	_	NN	NN	_	8	NMOD	_	_
7	gene	_	NN	NN	_	8	NMOD	_	_
8	activation	_	NN	NN	_	5	PMOD	_	_
9	,	_	,	,	_	2	P	_	_
10	we	_	PRP	PRP	_	11	SBJ	_	_
11	have	_	VBP	VBP	_	2	COORD	_	_
12	purified	_	VBN	VBN	_	11	VC	_	_
13	the	_	DT	DT	_	16	NMOD	_	_
14	inducible	_	JJ	JJ	_	16	NMOD	_	_
15	factor	_	NN	NN	_	16	NMOD	_	_
16	NF-GM2	_	NN	NN	_	12	OBJ	_	_
17	from	_	IN	IN	_	12	ADV	_	_
18	the	_	DT	DT	_	20	NMOD	_	_
19	nuclear	_	JJ	JJ	_	20	NMOD	_	_
20	extract	_	NN	NN	_	17	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	stimulated	_	VBN	VBN	_	24	NMOD	_	_
23	Jurkat	_	NN	NN	_	24	NMOD	_	_
24	cells	_	NNS	NNS	_	21	PMOD	_	_
25	on	_	IN	IN	_	12	ADV	_	_
26	the	_	DT	DT	_	25	DEP	_	_
27	basis	_	NN	NN	_	25	DEP	_	_
28	of	_	IN	IN	_	25	DEP	_	_
29	specific	_	JJ	JJ	_	31	NMOD	_	_
30	DNA-binding	_	JJ	JJ	_	31	NMOD	_	_
31	activity	_	NN	NN	_	25	PMOD	_	_
32	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	purified	_	VBN	VBN	_	3	NMOD	_	_
3	NF-GM2	_	NN	NN	_	4	SBJ	_	_
4	consists	_	VBZ	VBZ	_	0	ROOT-S	_	_
5	of	_	IN	IN	_	4	ADV	_	_
6	50	_	CD	CD	_	12	NMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	p50	_	NN	NN	_	6	PRN	_	_
9	)	_	)	)	_	8	P	_	_
10	and	_	CC	CC	_	6	CC	_	_
11	65	_	CD	CD	_	6	COORD	_	_
12	kDa	_	NN	NN	_	16	NMOD	_	_
13	(	_	(	(	_	14	P	_	_
14	p65	_	NN	NN	_	11	PRN	_	_
15	)	_	)	)	_	14	P	_	_
16	polypeptides	_	NNS	NNS	_	5	PMOD	_	_
17	and	_	CC	CC	_	4	CC	_	_
18	has	_	VBZ	VBZ	_	4	COORD	_	_
19	a	_	DT	DT	_	21	NMOD	_	_
20	binding	_	NN	NN	_	21	NMOD	_	_
21	activity	_	NN	NN	_	18	OBJ	_	_
22	specific	_	JJ	JJ	_	21	NMOD	_	_
23	for	_	IN	IN	_	22	AMOD	_	_
24	both	_	CC	CC	_	33	CC	_	_
25	the	_	DT	DT	_	33	NMOD	_	_
26	GM-CSF	_	NN	NN	_	33	NMOD	_	_
27	and	_	CC	CC	_	26	CC	_	_
28	immunoglobulin	_	NN	NN	_	29	NMOD	_	_
29	kappa	_	NN	NN	_	26	COORD	_	_
30	(	_	(	(	_	31	P	_	_
31	GGAAAGTCCC	_	NN	NN	_	29	PRN	_	_
32	)	_	)	)	_	31	P	_	_
33	enhancers	_	NNS	NNS	_	23	PMOD	_	_
34	.	_	.	.	_	4	P	_	_

1	Electrophoretically	_	RB	RB	_	2	AMOD	_	_
2	purified	_	VBN	VBN	_	3	NMOD	_	_
3	p50	_	NN	NN	_	5	SBJ	_	_
4	alone	_	RB	RB	_	3	NMOD	_	_
5	can	_	MD	MD	_	0	ROOT-S	_	_
6	form	_	VB	VB	_	5	VC	_	_
7	a	_	DT	DT	_	9	NMOD	_	_
8	protein-DNA	_	JJ	JJ	_	9	NMOD	_	_
9	complex	_	NN	NN	_	6	OBJ	_	_
10	,	_	,	,	_	5	P	_	_
11	but	_	CC	CC	_	5	CC	_	_
12	in	_	IN	IN	_	17	ADV	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	mixture	_	NN	NN	_	12	PMOD	_	_
15	,	_	,	,	_	17	P	_	_
16	p50	_	NN	NN	_	17	SBJ	_	_
17	associates	_	VBZ	VBZ	_	5	COORD	_	_
18	preferentially	_	RB	RB	_	17	ADV	_	_
19	with	_	IN	IN	_	17	ADV	_	_
20	p65	_	NN	NN	_	19	PMOD	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	form	_	VB	VB	_	17	OBJ	_	_
23	the	_	DT	DT	_	25	NMOD	_	_
24	NF-GM2	_	NN	NN	_	25	NMOD	_	_
25	complex	_	NN	NN	_	22	OBJ	_	_
26	.	_	.	.	_	5	P	_	_

1	In	_	IN	IN	_	5	ADV	_	_
2	addition	_	NN	NN	_	1	PMOD	_	_
3	,	_	,	,	_	5	P	_	_
4	p65	_	NN	NN	_	5	SBJ	_	_
5	gave	_	VBD	VBD	_	0	ROOT-S	_	_
6	per	_	FW	FW	_	5	ADV	_	_
7	se	_	FW	FW	_	6	AMOD	_	_
8	,	_	,	,	_	5	P	_	_
9	with	_	IN	IN	_	5	ADV	_	_
10	low	_	JJ	JJ	_	11	NMOD	_	_
11	affinity	_	NN	NN	_	9	PMOD	_	_
12	,	_	,	,	_	5	P	_	_
13	a	_	DT	DT	_	15	NMOD	_	_
14	protein-DNA	_	JJ	JJ	_	15	NMOD	_	_
15	complex	_	NN	NN	_	5	OBJ	_	_
16	that	_	WDT	WDT	_	17	SBJ	_	_
17	migrated	_	VBD	VBD	_	15	NMOD	_	_
18	more	_	RBR	RBR	_	19	AMOD	_	_
19	slowly	_	RB	RB	_	17	ADV	_	_
20	than	_	IN	IN	_	19	AMOD	_	_
21	native	_	JJ	JJ	_	23	NMOD	_	_
22	NF-GM2	_	NN	NN	_	23	NMOD	_	_
23	complex	_	NN	NN	_	20	PMOD	_	_
24	.	_	.	.	_	5	P	_	_

1	Furthermore	_	RB	RB	_	16	ADV	_	_
2	,	_	,	,	_	16	P	_	_
3	an	_	DT	DT	_	4	NMOD	_	_
4	antiserum	_	NN	NN	_	16	SBJ	_	_
5	against	_	IN	IN	_	4	NMOD	_	_
6	KBF1	_	NN	NN	_	5	PMOD	_	_
7	(	_	(	(	_	8	P	_	_
8	identical	_	JJ	JJ	_	6	PRN	_	_
9	to	_	TO	TO	_	8	AMOD	_	_
10	50	_	CD	CD	_	14	NMOD	_	_
11	kDa	_	NN	NN	_	14	NMOD	_	_
12	NF-kappa	_	NN	NN	_	14	NMOD	_	_
13	B	_	NN	NN	_	14	NMOD	_	_
14	protein	_	NN	NN	_	9	PMOD	_	_
15	)	_	)	)	_	8	P	_	_
16	reacted	_	VBD	VBD	_	0	ROOT-S	_	_
17	with	_	IN	IN	_	16	ADV	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	p50	_	NN	NN	_	17	PMOD	_	_
20	of	_	IN	IN	_	19	NMOD	_	_
21	NF-GM2	_	NN	NN	_	20	PMOD	_	_
22	,	_	,	,	_	16	P	_	_
23	indicating	_	VBG	VBG	_	16	OBJ	_	_
24	that	_	IN	IN	_	23	OBJ	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	NF-GM2	_	NN	NN	_	27	NMOD	_	_
27	polypeptide	_	NN	NN	_	28	SBJ	_	_
28	can	_	MD	MD	_	24	VMOD	_	_
29	not	_	RB	RB	_	28	VMOD	_	_
30	be	_	VB	VB	_	28	VC	_	_
31	immunologically	_	RB	RB	_	30	ADV	_	_
32	differentiated	_	VBN	VBN	_	30	VC	_	_
33	from	_	IN	IN	_	32	ADV	_	_
34	the	_	DT	DT	_	37	NMOD	_	_
35	50	_	CD	CD	_	37	NMOD	_	_
36	kDa	_	NN	NN	_	37	NMOD	_	_
37	subunit	_	NN	NN	_	33	PMOD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	NF-kappa	_	NN	NN	_	40	NMOD	_	_
40	B	_	NN	NN	_	38	PMOD	_	_
41	.	_	.	.	_	16	P	_	_

1	The	_	DT	DT	_	3	NMOD	_	_
2	purified	_	VBN	VBN	_	3	NMOD	_	_
3	NF-GM2	_	NN	NN	_	4	SBJ	_	_
4	activated	_	VBD	VBD	_	0	ROOT-S	_	_
5	in	_	FW	FW	_	6	AMOD	_	_
6	vitro	_	FW	FW	_	7	NMOD	_	_
7	transcription	_	NN	NN	_	4	IOBJ	_	_
8	from	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	12	NMOD	_	_
10	kappa	_	NN	NN	_	12	NMOD	_	_
11	B	_	NN	NN	_	12	NMOD	_	_
12	enhancer	_	NN	NN	_	8	PMOD	_	_
13	,	_	,	,	_	4	P	_	_
14	while	_	IN	IN	_	4	OBJ	_	_
15	it	_	PRP	PRP	_	16	SBJ	_	_
16	failed	_	VBD	VBD	_	14	VMOD	_	_
17	to	_	TO	TO	_	18	VMOD	_	_
18	stimulate	_	VB	VB	_	16	OBJ	_	_
19	transcription	_	NN	NN	_	18	OBJ	_	_
20	from	_	IN	IN	_	19	NMOD	_	_
21	the	_	DT	DT	_	23	NMOD	_	_
22	GM-CSF	_	NN	NN	_	23	NMOD	_	_
23	promoter	_	NN	NN	_	20	PMOD	_	_
24	harboring	_	VBG	VBG	_	23	NMOD	_	_
25	the	_	DT	DT	_	27	NMOD	_	_
26	GM2	_	NN	NN	_	27	NMOD	_	_
27	sequence	_	NN	NN	_	24	OBJ	_	_
28	.	_	.	.	_	4	P	_	_

1	This	_	DT	DT	_	2	SBJ	_	_
2	suggests	_	VBZ	VBZ	_	0	ROOT-S	_	_
3	that	_	IN	IN	_	2	OBJ	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	activation	_	NN	NN	_	6	NMOD	_	_
6	mechanism	_	NN	NN	_	15	SBJ	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	GM-CSF	_	NN	NN	_	10	NMOD	_	_
10	gene	_	NN	NN	_	7	PMOD	_	_
11	through	_	IN	IN	_	6	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	GM2\/GC-box	_	JJ	JJ	_	14	NMOD	_	_
14	sequence	_	NN	NN	_	11	PMOD	_	_
15	is	_	VBZ	VBZ	_	3	VMOD	_	_
16	different	_	JJ	JJ	_	15	PRD	_	_
17	from	_	IN	IN	_	16	AMOD	_	_
18	that	_	DT	DT	_	17	PMOD	_	_
19	of	_	IN	IN	_	18	NMOD	_	_
20	genes	_	NNS	NNS	_	19	PMOD	_	_
21	carrying	_	VBG	VBG	_	20	NMOD	_	_
22	the	_	DT	DT	_	25	NMOD	_	_
23	kappa	_	NN	NN	_	25	NMOD	_	_
24	B	_	NN	NN	_	25	NMOD	_	_
25	enhancer	_	NN	NN	_	21	OBJ	_	_
26	alone	_	RB	RB	_	25	NMOD	_	_
27	.	_	.	.	_	2	P	_	_

1	Glucocorticoid	_	NN	NN	_	2	NMOD	_	_
2	receptors	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	normal	_	JJ	JJ	_	5	NMOD	_	_
5	leukocytes	_	NNS	NNS	_	3	PMOD	_	_
6	:	_	:	:	_	2	P	_	_
7	effects	_	NNS	NNS	_	2	NMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	age	_	NN	NN	_	8	PMOD	_	_
10	,	_	,	,	_	9	P	_	_
11	gender	_	NN	NN	_	9	COORD	_	_
12	,	_	,	,	_	9	P	_	_
13	season	_	NN	NN	_	9	COORD	_	_
14	,	_	,	,	_	9	P	_	_
15	and	_	CC	CC	_	9	CC	_	_
16	plasma	_	NN	NN	_	18	NMOD	_	_
17	cortisol	_	NN	NN	_	18	NMOD	_	_
18	concentrations	_	NNS	NNS	_	9	COORD	_	_
19	.	_	.	.	_	7	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	measured	_	VBD	VBD	_	0	ROOT-S	_	_
3	glucocorticoid	_	NN	NN	_	4	NMOD	_	_
4	receptors	_	NNS	NNS	_	2	OBJ	_	_
5	(	_	(	(	_	6	P	_	_
6	GR	_	NN	NN	_	4	PRN	_	_
7	)	_	)	)	_	6	P	_	_
8	in	_	IN	IN	_	4	NMOD	_	_
9	mononuclear	_	JJ	JJ	_	10	NMOD	_	_
10	leukocytes	_	NNS	NNS	_	8	PMOD	_	_
11	(	_	(	(	_	12	P	_	_
12	MNL	_	NN	NN	_	10	PRN	_	_
13	)	_	)	)	_	12	P	_	_
14	isolated	_	VBN	VBN	_	10	NMOD	_	_
15	from	_	IN	IN	_	14	ADV	_	_
16	peripheral	_	JJ	JJ	_	17	NMOD	_	_
17	blood	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	145	_	CD	CD	_	22	NMOD	_	_
20	apparently	_	RB	RB	_	21	AMOD	_	_
21	healthy	_	JJ	JJ	_	22	NMOD	_	_
22	volunteers	_	NNS	NNS	_	18	PMOD	_	_
23	(	_	(	(	_	25	P	_	_
24	86	_	CD	CD	_	25	NMOD	_	_
25	men	_	NNS	NNS	_	22	PRN	_	_
26	and	_	CC	CC	_	25	CC	_	_
27	59	_	CD	CD	_	28	NMOD	_	_
28	women	_	NNS	NNS	_	25	COORD	_	_
29	)	_	)	)	_	25	P	_	_
30	.	_	.	.	_	2	P	_	_

1	An	_	DT	DT	_	3	NMOD	_	_
2	age-related	_	JJ	JJ	_	3	NMOD	_	_
3	decrease	_	NN	NN	_	9	SBJ	_	_
4	in	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	number	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	GR	_	NN	NN	_	7	PMOD	_	_
9	was	_	VBD	VBD	_	0	ROOT-S	_	_
10	suggested	_	VBN	VBN	_	9	VC	_	_
11	between	_	IN	IN	_	10	ADV	_	_
12	subjects	_	NNS	NNS	_	11	PMOD	_	_
13	younger	_	JJR	JJR	_	12	NMOD	_	_
14	than	_	IN	IN	_	13	AMOD	_	_
15	20	_	CD	CD	_	16	NMOD	_	_
16	years	_	NNS	NNS	_	14	PMOD	_	_
17	and	_	CC	CC	_	12	CC	_	_
18	elderly	_	JJ	JJ	_	19	NMOD	_	_
19	subjects	_	NNS	NNS	_	12	COORD	_	_
20	;	_	:	:	_	9	P	_	_
21	there	_	EX	EX	_	22	SBJ	_	_
22	was	_	VBD	VBD	_	9	VC	_	_
23	no	_	DT	DT	_	26	NMOD	_	_
24	apparent	_	JJ	JJ	_	26	NMOD	_	_
25	seasonal	_	JJ	JJ	_	26	NMOD	_	_
26	variation	_	NN	NN	_	22	PRD	_	_
27	in	_	IN	IN	_	26	NMOD	_	_
28	GR	_	NN	NN	_	27	PMOD	_	_
29	.	_	.	.	_	22	P	_	_

1	Gender	_	NN	NN	_	2	NMOD	_	_
2	difference	_	NN	NN	_	8	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	number	_	NN	NN	_	3	PMOD	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	GR	_	NN	NN	_	6	PMOD	_	_
8	was	_	VBD	VBD	_	0	ROOT-S	_	_
9	not	_	RB	RB	_	8	VMOD	_	_
10	significant	_	JJ	JJ	_	8	PRD	_	_
11	,	_	,	,	_	8	P	_	_
12	although	_	IN	IN	_	8	ADV	_	_
13	women	_	NNS	NNS	_	14	SBJ	_	_
14	showed	_	VBD	VBD	_	12	VMOD	_	_
15	slightly	_	RB	RB	_	16	AMOD	_	_
16	fewer	_	JJR	JJR	_	17	NMOD	_	_
17	GR	_	NN	NN	_	14	OBJ	_	_
18	.	_	.	.	_	8	P	_	_

1	Eight	_	CD	CD	_	2	NMOD	_	_
2	patients	_	NNS	NNS	_	5	SBJ	_	_
3	with	_	IN	IN	_	2	NMOD	_	_
4	dermatomyositis\/polymyositis	_	NN	NN	_	3	PMOD	_	_
5	were	_	VBD	VBD	_	0	ROOT-S	_	_
6	examined	_	VBN	VBN	_	5	VC	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	determine	_	VB	VB	_	6	OBJ	_	_
9	whether	_	IN	IN	_	8	OBJ	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	number	_	NN	NN	_	16	SBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	GR	_	NN	NN	_	12	PMOD	_	_
14	in	_	IN	IN	_	13	NMOD	_	_
15	MNL	_	NN	NN	_	14	PMOD	_	_
16	could	_	MD	MD	_	9	VMOD	_	_
17	be	_	VB	VB	_	16	VC	_	_
18	down-regulated	_	VBN	VBN	_	17	VC	_	_
19	by	_	IN	IN	_	18	LGS	_	_
20	their	_	PRP$	PRP$	_	22	NMOD	_	_
21	cognate	_	JJ	JJ	_	22	NMOD	_	_
22	ligands	_	NNS	NNS	_	19	PMOD	_	_
23	.	_	.	.	_	5	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	number	_	NN	NN	_	10	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	GR	_	NN	NN	_	3	PMOD	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	MNL	_	NN	NN	_	5	PMOD	_	_
7	from	_	IN	IN	_	6	NMOD	_	_
8	these	_	DT	DT	_	9	NMOD	_	_
9	patients	_	NNS	NNS	_	7	PMOD	_	_
10	was	_	VBD	VBD	_	0	ROOT-S	_	_
11	significantly	_	RB	RB	_	10	ADV	_	_
12	decreased	_	VBN	VBN	_	10	VC	_	_
13	one	_	CD	CD	_	14	NMOD	_	_
14	month	_	NN	NN	_	15	PMOD	_	_
15	after	_	IN	IN	_	12	TMP	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	initiation	_	NN	NN	_	15	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	prednisolone	_	NN	NN	_	20	NMOD	_	_
20	therapy	_	NN	NN	_	18	PMOD	_	_
21	.	_	.	.	_	10	P	_	_

1	However	_	RB	RB	_	11	ADV	_	_
2	,	_	,	,	_	11	P	_	_
3	in	_	IN	IN	_	11	ADV	_	_
4	normal	_	JJ	JJ	_	5	NMOD	_	_
5	subjects	_	NNS	NNS	_	3	PMOD	_	_
6	,	_	,	,	_	11	P	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	GR	_	NN	NN	_	11	SBJ	_	_
9	in	_	IN	IN	_	8	NMOD	_	_
10	MNL	_	NN	NN	_	9	PMOD	_	_
11	did	_	VBD	VBD	_	0	ROOT-S	_	_
12	not	_	RB	RB	_	11	VMOD	_	_
13	demonstrate	_	VB	VB	_	11	VC	_	_
14	circadian	_	JJ	JJ	_	15	NMOD	_	_
15	variation	_	NN	NN	_	13	OBJ	_	_
16	,	_	,	,	_	13	P	_	_
17	in	_	IN	IN	_	13	ADV	_	_
18	contrast	_	NN	NN	_	17	DEP	_	_
19	to	_	TO	TO	_	17	DEP	_	_
20	concentrations	_	NNS	NNS	_	17	PMOD	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	plasma	_	NN	NN	_	23	NMOD	_	_
23	cortisol	_	NN	NN	_	21	PMOD	_	_
24	.	_	.	.	_	11	P	_	_

1	Nuclear	_	JJ	JJ	_	3	NMOD	_	_
2	transcription	_	NN	NN	_	3	NMOD	_	_
3	factors	_	NNS	NNS	_	0	ROOT-FRAG	_	_
4	that	_	WDT	WDT	_	5	SBJ	_	_
5	bind	_	VBP	VBP	_	3	NMOD	_	_
6	to	_	TO	TO	_	5	ADV	_	_
7	elements	_	NNS	NNS	_	6	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	the	_	DT	DT	_	11	NMOD	_	_
10	IL-2	_	NN	NN	_	11	NMOD	_	_
11	promoter	_	NN	NN	_	8	PMOD	_	_
12	.	_	.	.	_	3	P	_	_

1	Induction	_	NN	NN	_	2	NMOD	_	_
2	requirements	_	NNS	NNS	_	0	ROOT-FRAG	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	primary	_	JJ	JJ	_	7	NMOD	_	_
5	human	_	JJ	JJ	_	7	NMOD	_	_
6	T	_	NN	NN	_	7	NMOD	_	_
7	cells	_	NNS	NNS	_	3	PMOD	_	_
8	.	_	.	.	_	2	P	_	_

1	Prior	_	JJ	JJ	_	2	NMOD	_	_
2	studies	_	NNS	NNS	_	3	SBJ	_	_
3	have	_	VBP	VBP	_	0	ROOT-S	_	_
4	identified	_	VBN	VBN	_	3	VC	_	_
5	several	_	JJ	JJ	_	6	NMOD	_	_
6	elements	_	NNS	NNS	_	4	OBJ	_	_
7	that	_	WDT	WDT	_	8	SBJ	_	_
8	contribute	_	VBP	VBP	_	6	NMOD	_	_
9	to	_	TO	TO	_	8	ADV	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	activity	_	NN	NN	_	9	PMOD	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	the	_	DT	DT	_	15	NMOD	_	_
14	IL-2	_	NN	NN	_	15	NMOD	_	_
15	promoter	_	NN	NN	_	12	PMOD	_	_
16	in	_	IN	IN	_	11	NMOD	_	_
17	the	_	DT	DT	_	21	NMOD	_	_
18	stimulated	_	VBN	VBN	_	21	NMOD	_	_
19	T	_	NN	NN	_	21	NMOD	_	_
20	cell	_	NN	NN	_	21	NMOD	_	_
21	line	_	NN	NN	_	16	PMOD	_	_
22	,	_	,	,	_	21	P	_	_
23	Jurkat	_	NN	NN	_	21	NMOD	_	_
24	.	_	.	.	_	3	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	sites	_	NNS	NNS	_	9	SBJ	_	_
3	and	_	CC	CC	_	2	CC	_	_
4	their	_	PRP$	PRP$	_	8	NMOD	_	_
5	corresponding	_	JJ	JJ	_	8	NMOD	_	_
6	nuclear	_	JJ	JJ	_	8	NMOD	_	_
7	binding	_	VBG	VBG	_	8	NMOD	_	_
8	factors	_	NNS	NNS	_	2	COORD	_	_
9	include	_	VBP	VBP	_	0	ROOT-S	_	_
10	:	_	:	:	_	9	P	_	_
11	NF-kappa	_	NN	NN	_	12	NMOD	_	_
12	B	_	NN	NN	_	9	OBJ	_	_
13	,	_	,	,	_	12	P	_	_
14	AP-1	_	NN	NN	_	12	COORD	_	_
15	,	_	,	,	_	12	P	_	_
16	AP-3	_	NN	NN	_	12	COORD	_	_
17	,	_	,	,	_	12	P	_	_
18	OCT-1	_	NN	NN	_	12	COORD	_	_
19	,	_	,	,	_	12	P	_	_
20	and	_	CC	CC	_	12	CC	_	_
21	NF-AT	_	NN	NN	_	12	COORD	_	_
22	.	_	.	.	_	9	P	_	_

1	The	_	DT	DT	_	5	NMOD	_	_
2	latter	_	JJ	JJ	_	5	NMOD	_	_
3	"	_	``	``	_	5	P	_	_
4	nuclear	_	JJ	JJ	_	5	NMOD	_	_
5	factor	_	NN	NN	_	12	SBJ	_	_
6	for	_	IN	IN	_	5	NMOD	_	_
7	activated	_	VBN	VBN	_	9	NMOD	_	_
8	T	_	NN	NN	_	9	NMOD	_	_
9	cells	_	NNS	NNS	_	6	PMOD	_	_
10	"	_	''	''	_	5	P	_	_
11	likely	_	RB	RB	_	12	ADV	_	_
12	contributes	_	VBZ	VBZ	_	0	ROOT-S	_	_
13	to	_	TO	TO	_	12	ADV	_	_
14	the	_	DT	DT	_	16	NMOD	_	_
15	tissue	_	NN	NN	_	16	NMOD	_	_
16	specificity	_	NN	NN	_	13	PMOD	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	IL-2	_	NN	NN	_	20	NMOD	_	_
19	gene	_	NN	NN	_	20	NMOD	_	_
20	expression	_	NN	NN	_	17	PMOD	_	_
21	.	_	.	.	_	12	P	_	_

1	Using	_	VBG	VBG	_	8	ADV	_	_
2	electrophoretic	_	JJ	JJ	_	5	NMOD	_	_
3	mobility	_	NN	NN	_	5	NMOD	_	_
4	shift	_	NN	NN	_	5	NMOD	_	_
5	assays	_	NNS	NNS	_	1	OBJ	_	_
6	,	_	,	,	_	8	P	_	_
7	we	_	PRP	PRP	_	8	SBJ	_	_
8	have	_	VBP	VBP	_	0	ROOT-S	_	_
9	studied	_	VBN	VBN	_	8	VC	_	_
10	these	_	DT	DT	_	12	NMOD	_	_
11	transcription	_	NN	NN	_	12	NMOD	_	_
12	factors	_	NNS	NNS	_	9	IOBJ	_	_
13	in	_	IN	IN	_	12	NMOD	_	_
14	primary	_	JJ	JJ	_	16	NMOD	_	_
15	T	_	NN	NN	_	16	NMOD	_	_
16	cells	_	NNS	NNS	_	13	PMOD	_	_
17	from	_	IN	IN	_	16	NMOD	_	_
18	human	_	JJ	JJ	_	19	NMOD	_	_
19	blood	_	NN	NN	_	17	PMOD	_	_
20	to	_	TO	TO	_	21	VMOD	_	_
21	verify	_	VB	VB	_	9	OBJ	_	_
22	their	_	PRP$	PRP$	_	23	NMOD	_	_
23	presence	_	NN	NN	_	21	OBJ	_	_
24	in	_	IN	IN	_	23	NMOD	_	_
25	a	_	DT	DT	_	27	NMOD	_	_
26	physiologic	_	JJ	JJ	_	27	NMOD	_	_
27	setting	_	NN	NN	_	24	PMOD	_	_
28	and	_	CC	CC	_	21	CC	_	_
29	to	_	TO	TO	_	30	VMOD	_	_
30	identify	_	VB	VB	_	21	COORD	_	_
31	the	_	DT	DT	_	32	NMOD	_	_
32	signals	_	NNS	NNS	_	30	OBJ	_	_
33	that	_	WDT	WDT	_	34	SBJ	_	_
34	stimulate	_	VBP	VBP	_	32	NMOD	_	_
35	factor	_	NN	NN	_	36	NMOD	_	_
36	activity	_	NN	NN	_	34	OBJ	_	_
37	.	_	.	.	_	8	P	_	_

1	All	_	DT	DT	_	2	NMOD	_	_
2	factors	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	induced	_	VBN	VBN	_	3	VC	_	_
5	in	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	nuclei	_	NNS	NNS	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	T	_	NN	NN	_	10	NMOD	_	_
10	cells	_	NNS	NNS	_	8	PMOD	_	_
11	upon	_	IN	IN	_	4	ADV	_	_
12	activation	_	NN	NN	_	11	PMOD	_	_
13	with	_	IN	IN	_	12	NMOD	_	_
14	mitogens	_	NNS	NNS	_	13	PMOD	_	_
15	but	_	CC	CC	_	13	CC	_	_
16	not	_	RB	RB	_	17	DEP	_	_
17	with	_	IN	IN	_	13	COORD	_	_
18	exogenous	_	JJ	JJ	_	21	NMOD	_	_
19	IL-2	_	NN	NN	_	21	NMOD	_	_
20	growth	_	NN	NN	_	21	NMOD	_	_
21	factor	_	NN	NN	_	17	PMOD	_	_
22	.	_	.	.	_	3	P	_	_

1	However	_	RB	RB	_	12	ADV	_	_
2	,	_	,	,	_	12	P	_	_
3	the	_	DT	DT	_	5	NMOD	_	_
4	signaling	_	NN	NN	_	5	NMOD	_	_
5	requirements	_	NNS	NNS	_	12	SBJ	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	sensitivity	_	NN	NN	_	5	COORD	_	_
8	to	_	TO	TO	_	7	NMOD	_	_
9	protein	_	NN	NN	_	11	NMOD	_	_
10	synthesis	_	NN	NN	_	11	NMOD	_	_
11	inhibitors	_	NNS	NNS	_	8	PMOD	_	_
12	differ	_	VBP	VBP	_	0	ROOT-S	_	_
13	considerably	_	RB	RB	_	12	ADV	_	_
14	.	_	.	.	_	12	P	_	_

1	Only	_	RB	RB	_	3	NMOD	_	_
2	the	_	DT	DT	_	3	NMOD	_	_
3	activities	_	NNS	NNS	_	9	SBJ	_	_
4	for	_	IN	IN	_	3	NMOD	_	_
5	NF-AT	_	NN	NN	_	8	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	AP-1	_	NN	NN	_	5	COORD	_	_
8	sites	_	NNS	NNS	_	4	PMOD	_	_
9	require	_	VBP	VBP	_	0	ROOT-S	_	_
10	two	_	CD	CD	_	11	NMOD	_	_
11	signals	_	NNS	NNS	_	9	OBJ	_	_
12	for	_	IN	IN	_	11	NMOD	_	_
13	optimal	_	JJ	JJ	_	14	NMOD	_	_
14	induction	_	NN	NN	_	12	PMOD	_	_
15	,	_	,	,	_	18	P	_	_
16	i.e.	_	FW	FW	_	18	NMOD	_	_
17	,	_	,	,	_	18	P	_	_
18	PMA	_	NN	NN	_	11	NMOD	_	_
19	plus	_	CC	CC	_	18	CC	_	_
20	either	_	CC	CC	_	21	CC	_	_
21	lectin	_	NN	NN	_	18	COORD	_	_
22	or	_	CC	CC	_	21	CC	_	_
23	antibody	_	NN	NN	_	21	COORD	_	_
24	to	_	TO	TO	_	23	NMOD	_	_
25	the	_	DT	DT	_	30	NMOD	_	_
26	CD3	_	NN	NN	_	30	NMOD	_	_
27	or	_	CC	CC	_	26	CC	_	_
28	CD28	_	NN	NN	_	26	COORD	_	_
29	surface	_	NN	NN	_	30	NMOD	_	_
30	molecules	_	NNS	NNS	_	24	PMOD	_	_
31	.	_	.	.	_	9	P	_	_

1	Other	_	JJ	JJ	_	2	NMOD	_	_
2	factors	_	NNS	NNS	_	3	SBJ	_	_
3	are	_	VBP	VBP	_	0	ROOT-S	_	_
4	induced	_	VBN	VBN	_	3	VC	_	_
5	by	_	IN	IN	_	4	LGS	_	_
6	lectin	_	NN	NN	_	5	PMOD	_	_
7	,	_	,	,	_	6	P	_	_
8	antibody	_	NN	NN	_	6	COORD	_	_
9	,	_	,	,	_	6	P	_	_
10	and\/or	_	CC	CC	_	6	CC	_	_
11	PMA	_	NN	NN	_	6	COORD	_	_
12	alone	_	RB	RB	_	11	NMOD	_	_
13	.	_	.	.	_	3	P	_	_

1	After	_	IN	IN	_	9	TMP	_	_
2	appropriate	_	JJ	JJ	_	3	NMOD	_	_
3	stimulation	_	NN	NN	_	1	PMOD	_	_
4	,	_	,	,	_	9	P	_	_
5	both	_	CC	CC	_	6	CC	_	_
6	NF-AT	_	NN	NN	_	9	SBJ	_	_
7	and	_	CC	CC	_	6	CC	_	_
8	AP-1	_	NN	NN	_	6	COORD	_	_
9	are	_	VBP	VBP	_	0	ROOT-S	_	_
10	peculiarly	_	RB	RB	_	11	AMOD	_	_
11	sensitive	_	JJ	JJ	_	9	PRD	_	_
12	to	_	TO	TO	_	11	AMOD	_	_
13	the	_	DT	DT	_	17	NMOD	_	_
14	protein	_	NN	NN	_	17	NMOD	_	_
15	synthesis	_	NN	NN	_	17	NMOD	_	_
16	inhibitor	_	NN	NN	_	17	NMOD	_	_
17	anisomycin	_	NN	NN	_	12	PMOD	_	_
18	.	_	.	.	_	9	P	_	_

1	Our	_	PRP$	PRP$	_	2	NMOD	_	_
2	data	_	NNS	NNS	_	3	SBJ	_	_
3	correlate	_	VBP	VBP	_	0	ROOT-S	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	activity	_	NN	NN	_	3	OBJ	_	_
6	of	_	IN	IN	_	5	NMOD	_	_
7	NF-AT	_	NN	NN	_	6	PMOD	_	_
8	and	_	CC	CC	_	7	CC	_	_
9	AP-1	_	NN	NN	_	7	COORD	_	_
10	in	_	IN	IN	_	5	NMOD	_	_
11	gel	_	NN	NN	_	13	NMOD	_	_
12	shift	_	NN	NN	_	13	NMOD	_	_
13	assays	_	NNS	NNS	_	10	PMOD	_	_
14	with	_	IN	IN	_	3	ADV	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	two	_	CD	CD	_	18	NMOD	_	_
17	signals	_	NNS	NNS	_	18	NMOD	_	_
18	requirements	_	NNS	NNS	_	14	PMOD	_	_
19	for	_	IN	IN	_	18	NMOD	_	_
20	IL-2	_	NN	NN	_	22	NMOD	_	_
21	gene	_	NN	NN	_	22	NMOD	_	_
22	expression	_	NN	NN	_	19	PMOD	_	_
23	.	_	.	.	_	3	P	_	_

1	An	_	DT	DT	_	4	NMOD	_	_
2	erythroid	_	JJ	JJ	_	3	AMOD	_	_
3	specific	_	JJ	JJ	_	4	NMOD	_	_
4	enhancer	_	NN	NN	_	0	ROOT-FRAG	_	_
5	upstream	_	JJ	JJ	_	4	NMOD	_	_
6	to	_	TO	TO	_	5	AMOD	_	_
7	the	_	DT	DT	_	8	NMOD	_	_
8	gene	_	NN	NN	_	6	PMOD	_	_
9	encoding	_	VBG	VBG	_	8	NMOD	_	_
10	the	_	DT	DT	_	15	NMOD	_	_
11	cell-type	_	JJ	JJ	_	12	AMOD	_	_
12	specific	_	JJ	JJ	_	15	NMOD	_	_
13	transcription	_	NN	NN	_	15	NMOD	_	_
14	factor	_	NN	NN	_	15	NMOD	_	_
15	GATA-1	_	NN	NN	_	9	OBJ	_	_
16	.	_	.	.	_	4	P	_	_

1	The	_	DT	DT	_	4	NMOD	_	_
2	transcription	_	NN	NN	_	4	NMOD	_	_
3	factor	_	NN	NN	_	4	NMOD	_	_
4	GATA-1	_	NN	NN	_	5	SBJ	_	_
5	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
6	expressed	_	VBN	VBN	_	5	VC	_	_
7	in	_	IN	IN	_	6	ADV	_	_
8	a	_	DT	DT	_	9	NMOD	_	_
9	subset	_	NN	NN	_	7	PMOD	_	_
10	of	_	IN	IN	_	9	NMOD	_	_
11	hemopoietic	_	JJ	JJ	_	12	NMOD	_	_
12	cells	_	NNS	NNS	_	10	PMOD	_	_
13	,	_	,	,	_	9	P	_	_
14	where	_	WRB	WRB	_	20	NMOD	_	_
15	it	_	PRP	PRP	_	16	SBJ	_	_
16	mediates	_	VBZ	VBZ	_	9	NMOD	_	_
17	the	_	DT	DT	_	20	NMOD	_	_
18	cell-type	_	JJ	JJ	_	19	AMOD	_	_
19	specific	_	JJ	JJ	_	20	NMOD	_	_
20	expression	_	NN	NN	_	16	OBJ	_	_
21	of	_	IN	IN	_	20	NMOD	_	_
22	several	_	JJ	JJ	_	23	NMOD	_	_
23	genes	_	NNS	NNS	_	21	PMOD	_	_
24	.	_	.	.	_	5	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	have	_	VBP	VBP	_	0	ROOT-S	_	_
3	cloned	_	VBN	VBN	_	2	VC	_	_
4	the	_	DT	DT	_	9	NMOD	_	_
5	mouse	_	NN	NN	_	9	NMOD	_	_
6	and	_	CC	CC	_	5	CC	_	_
7	human	_	JJ	JJ	_	5	COORD	_	_
8	GATA-1	_	NN	NN	_	9	NMOD	_	_
9	genes	_	NNS	NNS	_	3	OBJ	_	_
10	.	_	.	.	_	2	P	_	_

1	A	_	DT	DT	_	2	NMOD	_	_
2	region	_	NN	NN	_	17	SBJ	_	_
3	upstream	_	JJ	JJ	_	2	NMOD	_	_
4	to	_	TO	TO	_	3	AMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	first	_	JJ	JJ	_	7	NMOD	_	_
7	exon	_	NN	NN	_	4	PMOD	_	_
8	,	_	,	,	_	3	P	_	_
9	and	_	CC	CC	_	3	CC	_	_
10	highly	_	RB	RB	_	11	ADV	_	_
11	conserved	_	VBN	VBN	_	3	COORD	_	_
12	between	_	IN	IN	_	11	ADV	_	_
13	mouse	_	NN	NN	_	12	PMOD	_	_
14	and	_	CC	CC	_	13	CC	_	_
15	man	_	NN	NN	_	13	COORD	_	_
16	,	_	,	,	_	3	P	_	_
17	acts	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	as	_	IN	IN	_	17	ADV	_	_
19	an	_	DT	DT	_	22	NMOD	_	_
20	erythroid	_	JJ	JJ	_	21	AMOD	_	_
21	specific	_	JJ	JJ	_	22	NMOD	_	_
22	enhancer	_	NN	NN	_	18	PMOD	_	_
23	in	_	IN	IN	_	17	ADV	_	_
24	transient	_	JJ	JJ	_	25	NMOD	_	_
25	assays	_	NNS	NNS	_	23	PMOD	_	_
26	,	_	,	,	_	17	P	_	_
27	if	_	IN	IN	_	17	OBJ	_	_
28	linked	_	VBN	VBN	_	27	VMOD	_	_
29	to	_	TO	TO	_	28	ADV	_	_
30	the	_	DT	DT	_	31	NMOD	_	_
31	GATA-1	_	NN	NN	_	29	PMOD	_	_
32	or	_	CC	CC	_	29	CC	_	_
33	to	_	TO	TO	_	29	COORD	_	_
34	the	_	DT	DT	_	35	NMOD	_	_
35	SV40	_	NN	NN	_	33	PMOD	_	_
36	promoter	_	NN	NN	_	31	NMOD	_	_
37	.	_	.	.	_	17	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	activity	_	NN	NN	_	6	SBJ	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	5	NMOD	_	_
5	enhancer	_	NN	NN	_	3	PMOD	_	_
6	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
7	almost	_	RB	RB	_	6	PRD	_	_
8	completely	_	RB	RB	_	7	AMOD	_	_
9	dependent	_	JJ	JJ	_	7	AMOD	_	_
10	on	_	IN	IN	_	7	AMOD	_	_
11	the	_	DT	DT	_	12	NMOD	_	_
12	integrity	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	a	_	DT	DT	_	18	NMOD	_	_
15	dimeric	_	JJ	JJ	_	18	NMOD	_	_
16	GATA-1	_	NN	NN	_	18	NMOD	_	_
17	binding	_	NN	NN	_	18	NMOD	_	_
18	site	_	NN	NN	_	13	PMOD	_	_
19	.	_	.	.	_	6	P	_	_

1	T-helper-cell	_	JJ	JJ	_	2	NMOD	_	_
2	determinants	_	NNS	NNS	_	6	SBJ	_	_
3	in	_	IN	IN	_	2	NMOD	_	_
4	protein	_	NN	NN	_	5	NMOD	_	_
5	antigens	_	NNS	NNS	_	3	PMOD	_	_
6	are	_	VBP	VBP	_	0	ROOT-S	_	_
7	preferentially	_	RB	RB	_	6	PRD	_	_
8	located	_	JJ	JJ	_	7	AMOD	_	_
9	in	_	IN	IN	_	7	AMOD	_	_
10	cysteine-rich	_	JJ	JJ	_	12	NMOD	_	_
11	antigen	_	NN	NN	_	12	NMOD	_	_
12	segments	_	NNS	NNS	_	9	PMOD	_	_
13	resistant	_	JJ	JJ	_	12	NMOD	_	_
14	to	_	TO	TO	_	13	AMOD	_	_
15	proteolytic	_	JJ	JJ	_	16	NMOD	_	_
16	cleavage	_	NN	NN	_	14	PMOD	_	_
17	by	_	IN	IN	_	16	NMOD	_	_
18	cathepsin	_	NN	NN	_	17	PMOD	_	_
19	B	_	NN	NN	_	18	NMOD	_	_
20	,	_	,	,	_	19	P	_	_
21	L	_	NN	NN	_	19	COORD	_	_
22	,	_	,	,	_	19	P	_	_
23	and	_	CC	CC	_	19	CC	_	_
24	D	_	NN	NN	_	19	COORD	_	_
25	.	_	.	.	_	6	P	_	_

1	We	_	PRP	PRP	_	2	SBJ	_	_
2	report	_	VBP	VBP	_	0	ROOT-S	_	_
3	on	_	IN	IN	_	2	ADV	_	_
4	a	_	DT	DT	_	6	NMOD	_	_
5	computer	_	NN	NN	_	6	NMOD	_	_
6	algorithm	_	NN	NN	_	3	PMOD	_	_
7	capable	_	JJ	JJ	_	6	NMOD	_	_
8	of	_	IN	IN	_	7	AMOD	_	_
9	predicting	_	VBG	VBG	_	8	PMOD	_	_
10	the	_	DT	DT	_	11	NMOD	_	_
11	location	_	NN	NN	_	9	OBJ	_	_
12	of	_	IN	IN	_	11	NMOD	_	_
13	T-helper-cell	_	NN	NN	_	14	NMOD	_	_
14	epitopes	_	NNS	NNS	_	12	PMOD	_	_
15	in	_	IN	IN	_	11	NMOD	_	_
16	protein	_	NN	NN	_	15	PMOD	_	_
17	antigen	_	NN	NN	_	16	NMOD	_	_
18	(	_	(	(	_	19	P	_	_
19	Ag	_	NN	NN	_	17	PRN	_	_
20	)	_	)	)	_	19	P	_	_
21	by	_	IN	IN	_	9	ADV	_	_
22	analysing	_	VBG	VBG	_	21	PMOD	_	_
23	the	_	DT	DT	_	27	NMOD	_	_
24	Ag	_	NN	NN	_	27	NMOD	_	_
25	amino	_	NN	NN	_	27	NMOD	_	_
26	acid	_	NN	NN	_	27	NMOD	_	_
27	sequence	_	NN	NN	_	22	OBJ	_	_
28	.	_	.	.	_	2	P	_	_

1	The	_	DT	DT	_	2	NMOD	_	_
2	algorithm	_	NN	NN	_	3	SBJ	_	_
3	was	_	VBD	VBD	_	0	ROOT-S	_	_
4	constructed	_	VBN	VBN	_	3	VC	_	_
5	with	_	IN	IN	_	4	ADV	_	_
6	the	_	DT	DT	_	7	NMOD	_	_
7	aim	_	NN	NN	_	5	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	identifying	_	VBG	VBG	_	8	PMOD	_	_
10	segments	_	NNS	NNS	_	9	OBJ	_	_
11	in	_	IN	IN	_	10	NMOD	_	_
12	Ag	_	NN	NN	_	11	PMOD	_	_
13	which	_	WDT	WDT	_	14	SBJ	_	_
14	are	_	VBP	VBP	_	10	NMOD	_	_
15	resistant	_	JJ	JJ	_	14	PRD	_	_
16	to	_	TO	TO	_	15	AMOD	_	_
17	proteolytic	_	JJ	JJ	_	18	NMOD	_	_
18	degradation	_	NN	NN	_	16	PMOD	_	_
19	by	_	IN	IN	_	18	NMOD	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	enzymes	_	NNS	NNS	_	22	NMOD	_	_
22	cathepsin	_	NN	NN	_	19	PMOD	_	_
23	B	_	NN	NN	_	22	NMOD	_	_
24	,	_	,	,	_	23	P	_	_
25	L	_	NN	NN	_	23	COORD	_	_
26	,	_	,	,	_	23	P	_	_
27	and	_	CC	CC	_	23	CC	_	_
28	D	_	NN	NN	_	23	COORD	_	_
29	.	_	.	.	_	3	P	_	_

1	These	_	DT	DT	_	2	SBJ	_	_
2	are	_	VBP	VBP	_	0	ROOT-S	_	_
3	prominent	_	JJ	JJ	_	4	NMOD	_	_
4	enzymes	_	NNS	NNS	_	2	PRD	_	_
5	in	_	IN	IN	_	4	NMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	endocytic	_	JJ	JJ	_	8	NMOD	_	_
8	pathway	_	NN	NN	_	5	PMOD	_	_
9	through	_	IN	IN	_	14	ADV	_	_
10	which	_	WDT	WDT	_	9	PMOD	_	_
11	soluble	_	JJ	JJ	_	13	NMOD	_	_
12	protein	_	NN	NN	_	13	NMOD	_	_
13	Ag	_	NN	NN	_	14	SBJ	_	_
14	enter	_	VBP	VBP	_	8	NMOD	_	_
15	APC	_	NN	NN	_	14	OBJ	_	_
16	,	_	,	,	_	2	P	_	_
17	and	_	CC	CC	_	2	CC	_	_
18	resistant	_	JJ	JJ	_	19	NMOD	_	_
19	segments	_	NNS	NNS	_	22	SBJ	_	_
20	in	_	IN	IN	_	19	NMOD	_	_
21	Ag	_	NN	NN	_	20	PMOD	_	_
22	may	_	MD	MD	_	2	COORD	_	_
23	,	_	,	,	_	22	P	_	_
24	therefore	_	RB	RB	_	22	ADV	_	_
25	,	_	,	,	_	22	P	_	_
26	be	_	VB	VB	_	22	VC	_	_
27	expected	_	VBN	VBN	_	26	VC	_	_
28	to	_	TO	TO	_	29	VMOD	_	_
29	contain	_	VB	VB	_	27	OBJ	_	_
30	more	_	JJR	JJR	_	32	NMOD	_	_
31	T-cell	_	NN	NN	_	32	NMOD	_	_
32	determinants	_	NNS	NNS	_	29	OBJ	_	_
33	than	_	IN	IN	_	32	NMOD	_	_
34	susceptible	_	JJ	JJ	_	35	NMOD	_	_
35	segments	_	NNS	NNS	_	33	PMOD	_	_
36	.	_	.	.	_	2	P	_	_

1	From	_	IN	IN	_	17	ADV	_	_
2	information	_	NN	NN	_	1	PMOD	_	_
3	available	_	JJ	JJ	_	2	NMOD	_	_
4	in	_	IN	IN	_	3	AMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	literature	_	NN	NN	_	4	PMOD	_	_
7	on	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	10	NMOD	_	_
9	substrate	_	JJ	JJ	_	10	NMOD	_	_
10	specificity	_	NN	NN	_	7	PMOD	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	14	NMOD	_	_
13	three	_	CD	CD	_	14	NMOD	_	_
14	enzymes	_	NNS	NNS	_	11	PMOD	_	_
15	,	_	,	,	_	17	P	_	_
16	it	_	PRP	PRP	_	17	SBJ	_	_
17	is	_	VBZ	VBZ	_	0	ROOT-S	_	_
18	clear	_	JJ	JJ	_	17	PRD	_	_
19	that	_	IN	IN	_	17	EXP	_	_
20	a	_	DT	DT	_	21	NMOD	_	_
21	cysteine	_	NN	NN	_	22	SBJ	_	_
22	is	_	VBZ	VBZ	_	19	VMOD	_	_
23	not	_	RB	RB	_	22	VMOD	_	_
24	accepted	_	VBN	VBN	_	22	VC	_	_
25	in	_	IN	IN	_	24	ADV	_	_
26	any	_	DT	DT	_	25	PMOD	_	_
27	of	_	IN	IN	_	26	NMOD	_	_
28	the	_	DT	DT	_	37	NMOD	_	_
29	S2	_	NN	NN	_	37	NMOD	_	_
30	,	_	,	,	_	29	P	_	_
31	S1	_	NN	NN	_	29	COORD	_	_
32	,	_	,	,	_	29	P	_	_
33	S1'	_	NN	NN	_	29	COORD	_	_
34	,	_	,	,	_	29	P	_	_
35	and	_	CC	CC	_	29	CC	_	_
36	S2'	_	NN	NN	_	29	COORD	_	_
37	subsites	_	NNS	NNS	_	27	PMOD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	cathepsin	_	NN	NN	_	38	PMOD	_	_
40	B	_	NN	NN	_	39	NMOD	_	_
41	and	_	CC	CC	_	40	CC	_	_
42	L	_	NN	NN	_	40	COORD	_	_
43	,	_	,	,	_	25	P	_	_
44	and	_	CC	CC	_	25	CC	_	_
45	not	_	RB	RB	_	46	DEP	_	_
46	in	_	IN	IN	_	25	COORD	_	_
47	the	_	DT	DT	_	51	NMOD	_	_
48	S1	_	NN	NN	_	51	NMOD	_	_
49	and	_	CC	CC	_	48	CC	_	_
50	S1'	_	NN	NN	_	48	COORD	_	_
51	subsites	_	NNS	NNS	_	46	PMOD	_	_
52	of	_	IN	IN	_	51	NMOD	_	_
53	cathepsin	_	NN	NN	_	54	NMOD	_	_
54	D	_	NN	NN	_	52	PMOD	_	_
55	.	_	.	.	_	17	P	_	_

1	Moreover	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	have	_	VBP	VBP	_	0	ROOT-S	_	_
5	noticed	_	VBN	VBN	_	4	VC	_	_
6	that	_	IN	IN	_	5	OBJ	_	_
7	cysteine-containing	_	JJ	JJ	_	9	NMOD	_	_
8	T-cell	_	NN	NN	_	9	NMOD	_	_
9	determinants	_	NNS	NNS	_	16	SBJ	_	_
10	in	_	IN	IN	_	9	NMOD	_	_
11	a	_	DT	DT	_	12	NMOD	_	_
12	number	_	NN	NN	_	10	PMOD	_	_
13	of	_	IN	IN	_	12	NMOD	_	_
14	protein	_	NN	NN	_	15	NMOD	_	_
15	Ag	_	NN	NN	_	13	PMOD	_	_
16	are	_	VBP	VBP	_	6	VMOD	_	_
17	particularly	_	RB	RB	_	18	AMOD	_	_
18	rich	_	JJ	JJ	_	16	PRD	_	_
19	in	_	IN	IN	_	16	ADV	_	_
20	the	_	DT	DT	_	22	NMOD	_	_
21	amino	_	NN	NN	_	22	NMOD	_	_
22	acids	_	NNS	NNS	_	19	PMOD	_	_
23	alanine	_	NN	NN	_	22	NMOD	_	_
24	,	_	,	,	_	23	P	_	_
25	glycine	_	NN	NN	_	23	COORD	_	_
26	,	_	,	,	_	23	P	_	_
27	lysine	_	NN	NN	_	23	COORD	_	_
28	,	_	,	,	_	23	P	_	_
29	leucine	_	NN	NN	_	23	COORD	_	_
30	,	_	,	,	_	23	P	_	_
31	serine	_	NN	NN	_	23	COORD	_	_
32	,	_	,	,	_	23	P	_	_
33	threonine	_	NN	NN	_	23	COORD	_	_
34	,	_	,	,	_	23	P	_	_
35	and	_	CC	CC	_	23	CC	_	_
36	valine	_	NN	NN	_	23	COORD	_	_
37	.	_	.	.	_	4	P	_	_

1	By	_	IN	IN	_	20	ADV	_	_
2	searching	_	VBG	VBG	_	1	PMOD	_	_
3	protein	_	NN	NN	_	4	NMOD	_	_
4	Ag	_	NN	NN	_	2	OBJ	_	_
5	for	_	IN	IN	_	2	ADV	_	_
6	clusters	_	NNS	NNS	_	5	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	amino	_	NN	NN	_	9	NMOD	_	_
9	acids	_	NNS	NNS	_	7	PMOD	_	_
10	containing	_	VBG	VBG	_	9	NMOD	_	_
11	cysteine	_	NN	NN	_	10	OBJ	_	_
12	and	_	CC	CC	_	6	CC	_	_
13	two	_	CD	CD	_	6	COORD	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	the	_	DT	DT	_	18	NMOD	_	_
16	other	_	JJ	JJ	_	18	NMOD	_	_
17	amino	_	NN	NN	_	18	NMOD	_	_
18	acids	_	NNS	NNS	_	14	PMOD	_	_
19	we	_	PRP	PRP	_	20	SBJ	_	_
20	were	_	VBD	VBD	_	0	ROOT-S	_	_
21	able	_	JJ	JJ	_	20	PRD	_	_
22	to	_	TO	TO	_	23	VMOD	_	_
23	predict	_	VB	VB	_	21	AMOD	_	_
24	17	_	CD	CD	_	27	DEP	_	_
25	out	_	IN	IN	_	27	DEP	_	_
26	of	_	IN	IN	_	27	DEP	_	_
27	23	_	CD	CD	_	31	NMOD	_	_
28	empirically	_	RB	RB	_	29	AMOD	_	_
29	known	_	VBN	VBN	_	31	NMOD	_	_
30	T-cell	_	NN	NN	_	31	NMOD	_	_
31	determinants	_	NNS	NNS	_	23	OBJ	_	_
32	in	_	IN	IN	_	31	NMOD	_	_
33	the	_	DT	DT	_	34	NMOD	_	_
34	Ag	_	NN	NN	_	32	PMOD	_	_
35	with	_	IN	IN	_	23	ADV	_	_
36	a	_	DT	DT	_	39	NMOD	_	_
37	relatively	_	RB	RB	_	38	AMOD	_	_
38	low	_	JJ	JJ	_	39	NMOD	_	_
39	number	_	NN	NN	_	35	PMOD	_	_
40	of	_	IN	IN	_	39	NMOD	_	_
41	false	_	JJ	JJ	_	45	NMOD	_	_
42	(	_	(	(	_	43	P	_	_
43	positive	_	JJ	JJ	_	41	PRN	_	_
44	)	_	)	)	_	43	P	_	_
45	predictions	_	NNS	NNS	_	40	PMOD	_	_
46	.	_	.	.	_	20	P	_	_

1	Furthermore	_	RB	RB	_	4	ADV	_	_
2	,	_	,	,	_	4	P	_	_
3	we	_	PRP	PRP	_	4	SBJ	_	_
4	present	_	VBP	VBP	_	0	ROOT-S	_	_
5	a	_	DT	DT	_	7	NMOD	_	_
6	new	_	JJ	JJ	_	7	NMOD	_	_
7	principle	_	NN	NN	_	4	OBJ	_	_
8	for	_	IN	IN	_	7	NMOD	_	_
9	searching	_	VBG	VBG	_	8	PMOD	_	_
10	Ag	_	NN	NN	_	9	OBJ	_	_
11	for	_	IN	IN	_	9	ADV	_	_
12	potential	_	JJ	JJ	_	16	NMOD	_	_
13	amphipatic	_	JJ	JJ	_	16	NMOD	_	_
14	alpha-helical	_	JJ	JJ	_	16	NMOD	_	_
15	protein	_	NN	NN	_	16	NMOD	_	_
16	segments	_	NNS	NNS	_	11	PMOD	_	_
17	.	_	.	.	_	4	P	_	_

1	Such	_	JJ	JJ	_	2	NMOD	_	_
2	segments	_	NNS	NNS	_	3	SBJ	_	_
3	accord	_	VBP	VBP	_	0	ROOT-S	_	_
4	well	_	RB	RB	_	3	ADV	_	_
5	with	_	IN	IN	_	3	ADV	_	_
6	empirically	_	RB	RB	_	7	AMOD	_	_
7	known	_	JJ	JJ	_	9	NMOD	_	_
8	T-cell	_	NN	NN	_	9	NMOD	_	_
9	determinants	_	NNS	NNS	_	5	PMOD	_	_
10	and	_	CC	CC	_	3	CC	_	_
11	our	_	PRP$	PRP$	_	12	NMOD	_	_
12	algorithm	_	NN	NN	_	13	SBJ	_	_
13	produces	_	VBZ	VBZ	_	3	COORD	_	_
14	a	_	DT	DT	_	16	NMOD	_	_
15	lower	_	JJR	JJR	_	16	NMOD	_	_
16	number	_	NN	NN	_	13	OBJ	_	_
17	of	_	IN	IN	_	16	NMOD	_	_
18	false	_	JJ	JJ	_	20	NMOD	_	_
19	positive	_	JJ	JJ	_	20	NMOD	_	_
20	predictions	_	NNS	NNS	_	17	PMOD	_	_
21	than	_	IN	IN	_	16	NMOD	_	_
22	the	_	DT	DT	_	23	NMOD	_	_
23	principle	_	NN	NN	_	21	PMOD	_	_
24	based	_	VBN	VBN	_	23	NMOD	_	_
25	on	_	IN	IN	_	24	PMOD	_	_
26	discrete	_	JJ	JJ	_	28	NMOD	_	_
27	Fourier	_	NN	NN	_	28	NMOD	_	_
28	transformations	_	NNS	NNS	_	25	PMOD	_	_
29	previously	_	RB	RB	_	30	TMP	_	_
30	described	_	VBN	VBN	_	28	NMOD	_	_
31	.	_	.	.	_	3	P	_	_

